

APPROVED DRUG PRODUCTS

WITH

THERAPEUTIC EQUIVALENCE EVALUATIONS

39th EDITION

THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF GENERIC DRUGS
OFFICE OF GENERIC DRUG POLICY

2019

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

The products in this list have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act. This volume is current through December 31, 2018.

39th EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF GENERIC DRUGS
OFFICE OF GENERIC DRUG POLICY

2019

FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVED DRUG PRODUCTS
With
Therapeutic Equivalence Evaluations

CONTENTS

PAGE

PREFACE TO THIRTY-NINTH EDITION.....iv

1.0 INTRODUCTION vi
1.1 Content and Exclusion vi
1.2 Therapeutic Equivalence-Related Terms vii
1.3 Further Guidance on Bioequivalence ix
1.4 Reference Listed Drug and Reference Standard..... ix
1.5 General Policies and Legal Status x
1.6 Practitioner/User Responsibilities xi
1.7 Therapeutic Equivalence Evaluations Codes xiii
1.8 Description of Certain Special Situations xxi
1.9 Therapeutic Equivalence Code Change for a Drug Entity xxiii
1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product.....xxiv
1.11 Discontinued Section xxv
1.12 Changes to the Orange Book.....xxv
1.13 Availability of the Edition xxvi

2.0 HOW TO USE THE DRUG PRODUCTS LISTS 2-1
2.1 Key Sections for Using the Drug Product Lists 2-1
2.2 Drug Product Illustration 2-3
2.3 Therapeutic Equivalence Evaluations Illustration 2-4

DRUG PRODUCT LISTS
Prescription Drug Product List 3-1
OTC Drug Product List 4-1
Drug Products with Approval under Section 505 of the FD&C Act Administered by the Center for Biologics Evaluation and Research List 5-1
Discontinued Drug Product List 6-1
Orphan Products Designations and Approvals List 7-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution 8-1

APPENDICES
A. Product Name Index A-1
B. Product Name Index Listed by Applicant B-1
C. Uniform Terms C-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM AD1
A. Patent and Exclusivity Lists ADA1
B. Patent and Exclusivity Terms ADB1

FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVED DRUG PRODUCTS
With
Therapeutic Equivalence Evaluations

PREFACE TO THIRTY-NINTH EDITION

The publication, *Approved Drug Products With Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the FD&C Act). The main criterion for the inclusion of any product is that the product is the subject of an application with an approval that has not been withdrawn for safety or efficacy reasons. Inclusion of products in the Orange Book is independent of any current regulatory action being taken administratively or judicially against a drug product. In addition, the Orange Book contains therapeutic equivalence evaluations for approved multisource prescription drug products. These evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. Therapeutic equivalence evaluations in this publication are not official FDA actions affecting the legal status of products under the FD&C Act.

Background of the Publication. To contain drug costs, virtually every state has adopted laws and/or regulations that encourage the substitution of drug products. These state laws generally require either that substitution be limited to drugs on a specific list (the positive formulary approach) or that it be permitted for all drugs except those prohibited by a particular list (the negative formulary approach). Because of the number of requests in the late 1970s for FDA assistance in preparing both positive and negative formularies, it became apparent that FDA could not serve the needs of each state on an individual basis. The Agency also recognized that providing a single list based on common criteria would be preferable to evaluating drug products on the basis of differing definitions and criteria in various state laws. As a result, on May 31, 1978, the Commissioner of the Food and Drug Administration sent a letter to officials of each state announcing FDA's intent to provide a list of all prescription drug products that are approved by FDA for safety and effectiveness, along with therapeutic equivalence determinations for multisource prescription products.

The Orange Book was distributed as a proposal in January 1979. It included only currently marketed prescription drug products approved by FDA through new drug applications (NDAs) and abbreviated new drug applications (ANDAs) under the provisions of Section 505 of the FD&C Act and FDA regulations at that time.

The therapeutic equivalence evaluations in the Orange Book reflect FDA's application of specific criteria to the multisource prescription drug products listed in the Orange Book and approved under Section 505 of the FD&C Act. These evaluations are presented in the form of code letters that indicate the basis for the evaluation made. An explanation of the codes appears in the *Introduction*.

A complete discussion of the background and basis of FDA's therapeutic equivalence evaluation policy was published in the *Federal Register* on January 12, 1979 (44 FR 2932). The final rule, which includes FDA's responses to the public comments on the proposal, was published in the *Federal Register* on October 31, 1980 (45 FR 72582). The first publication of the Orange Book in October 1980, concurrent with finalization of the rule, incorporated appropriate corrections and additions. Each subsequent edition has included new approvals and made appropriate changes in data.

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments). The Hatch-Waxman Amendments require that FDA, among other things, make publicly available a list of approved drug products with monthly supplements. The Orange Book and its monthly Cumulative Supplements satisfy this requirement. The *Addendum* to this publication identifies drugs that qualify under the FD&C Act for periods of exclusivity and provides patent information concerning the approved drug products in the Orange Book. The *Addendum* also provides additional information that may be helpful to those submitting an NDA or ANDA to the Agency.

The Agency intends to use this publication to further its objective of obtaining input and comment on the publication itself and related Agency procedures. Therefore, if you have comments on how the publication can be improved, please send them to the Director, Division of Legal and Regulatory Support, Office of Generic Drug Policy, Office of Generic Drugs, Center for Drug Evaluation and Research, 7620 Standish Place, Rockville, MD 20855-2773. Comments received are publicly available to the extent allowable under the Freedom of Information Act and FDA regulations.

1.0 INTRODUCTION

1.1 Content and Exclusion

The Orange Book is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations; (2) approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; (3) drug products with approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research; and (4) a cumulative list of approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn from sale for safety or effectiveness reasons, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing.[1] This publication also includes indices of prescription and OTC drug products by trade name (proprietary name) or established name (if no trade name exists) and by applicant name (holder of the approved application), which have been abbreviated for this publication. Established names for active ingredients generally conform to official compendial names or *United States Adopted Names* (USAN) as described in 21 CFR 299.4(e). A list of uniform terms is provided in Appendix C.

The *Addendum* contains patent and exclusivity information for the Prescription, OTC, Discontinued Drug Product Lists, and for the Drug Products with Approval under Section 505 of the FD&C Act Administered by the Center for Biologics Evaluation and Research. The publication may include additional information that the Agency deems appropriate to disseminate.

Prior to the 6th Edition, the publication had excluded OTC drug products and drug products with approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research. The Hatch-Waxman Amendments required the Agency to begin publishing an up-to-date list of all marketed drug products, OTC as well as prescription, that have been approved for safety and efficacy and for which new drug applications are required.

Under the FD&C Act, some drug products are given tentative approvals. The Agency will not include drug products with tentative approvals in the Orange Book because a drug product that is granted tentative approval is not an approved drug product. Tentative approval lists by month are available on FDA's website Drugs@FDA. When the tentative approval becomes a final approval through a subsequent action letter to the applicant, the Agency will list the drug product and the date of approval in the appropriate approved drug product list. In addition, we note that Section 505(x) of the FD&C Act affects the date of approval for certain drug products subject to scheduling under the Controlled Substances Act. The Agency will list the drug product in the Orange Book and the date of approval as determined under Section 505(x).

The Orange Book identifies the application holder of a drug product and does not identify distributors or repackagers.

[1] Generally, newly approved products are added to the Active Section of the Orange Book (i.e., the Prescription Drug Product List or the Over-the-Counter Drug Product List), depending on the dispensing requirements (prescription or OTC) or approval authority, unless the Orange Book staff is otherwise notified before publication. See Section 1.12.

1.2 Therapeutic Equivalence-Related Terms

Pharmaceutical Equivalents. Pharmaceutical equivalents are drug products in identical dosage forms and route(s) of administration that contain identical amounts of the identical active drug ingredient, i.e., the same salt or ester of the same therapeutic moiety, or, in the case of modified-release dosage forms that require a reservoir or overage or such forms as prefilled syringes where the residual volume may vary, that deliver identical amounts of the active drug ingredient over the identical dosing period; do not necessarily contain the same inactive ingredients; and meet the identical compendial or other applicable standard of identity, strength, quality, and purity, including potency and, where applicable, content uniformity, disintegration times, and/or dissolution rates.[2] They may differ in characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, within certain limits, labeling.

Pharmaceutical Alternatives. Pharmaceutical alternatives are drug products that contain the identical therapeutic moiety, or its precursor, but not necessarily in the same amount or dosage form, or the same salt or ester (e.g., tetracycline hydrochloride, 250mg capsules vs. tetracycline phosphate complex, 250mg capsules; quinidine sulfate, 200mg tablets vs. quinidine sulfate, 200mg capsules).[3] Each such drug product individually meets either the identical or its own respective compendial or other applicable standard of identity, strength, quality, and purity, including potency and, where applicable, content uniformity, disintegration times, and/or dissolution rates. [4] Different dosage forms and strengths within a product line by a single manufacturer are pharmaceutical alternatives, as are extended-release products when compared with immediate-release or standard-release formulations of the same active ingredient.

Therapeutic Equivalents. Approved drug products are considered to be therapeutic equivalents only if they are pharmaceutical equivalents for which bioequivalence has been demonstrated, and they can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.[5]

FDA classifies as therapeutically equivalent those drug products that meet the following general criteria: (1) they are approved as safe and effective; (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the identical active drug ingredient in the identical dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; (3) they are bioequivalent in that (a) they do not present a known or potential bioequivalence problem, and they meet an acceptable *in vitro* standard, or (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standard; (4) they are adequately labeled; and (5) they are manufactured in compliance with Current Good Manufacturing Practice regulations. The concept of therapeutic equivalence applies only to drug products containing the identical active ingredient(s) and does not encompass a comparison of different therapeutic agents used for the same condition (e.g., meperidine hydrochloride vs. morphine sulfate for the treatment of pain). Any drug product in the Orange Book repackaged and/or distributed by other than the applicant is considered to be therapeutically

2 21 CFR 314.3(b).
3 See 21 CFR 314.3(b).
4 21 CFR 314.3(b).
5 21 CFR 314.3(b).

equivalent to the applicant's drug product even if the applicant's drug product is single source or coded as non-equivalent (e.g., **BN**). Distributors or repackagers of an applicant's drug product are not identified in the Orange Book.

FDA considers drug products to be therapeutically equivalent if they meet the criteria outlined above, even though they may differ in certain other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time and certain aspects of labeling (e.g., the presence of specific pharmacokinetic information), and storage conditions. When such differences are important in the care of a particular patient, it may be appropriate for the prescribing physician to require that a specific product be dispensed as a medical necessity. With this limitation, however, FDA believes that products classified as therapeutically equivalent can be substituted with the full expectation that the substituted product can be expected to have the same clinical effect and safety profile as the prescribed product when administered to patients under the conditions specified in the labeling.

Strength. Strength refers to the amount of drug substance contained in, delivered, or deliverable from a drug product, which includes: (1)(a) the total quantity of drug substance in mass or units of activity in a dosage unit or container closure (*e.g.*, weight/unit dose, weight/volume or weight/weight in a container closure, or units/volume or units/weight in a container closure); and/or, as applicable, (b) the concentration of the drug substance in mass or units of activity per unit volume or mass (*e.g.*, weight/weight, weight/volume, or units/volume); or (2) such other criteria the Agency establishes for determining the amount of drug substance contained in, delivered, or deliverable from a drug product if the weights and measures described in clause (1)(a) do not apply (*e.g.*, certain drug-device combination products for which the amount of drug substance is emitted per use or unit time).[6] Note that if the criteria the Agency establishes for determining and expressing the amount of drug substance in a product evolves over time, the Agency generally does not intend to revise the expressions of strength for drug products already included in the Orange Book, but rather intends to apply the criteria prospectively to drug products added to the Orange Book.

Although the strength of drug products in the Orange Book is generally expressed in terms of the amount of drug substance (active ingredient) in the drug product, it is sometimes expressed in terms of the amount of the active moiety. For example, certain drug products included in the Orange Book include a designation of "EQ" next to their expression of strength. This "EQ" designation generally is used in connection with salt drug products to indicate that the strength of such drug product is being expressed in terms of the equivalent strength of the active moiety (e.g., "EQ 200MG BASE"), rather than in terms of the strength of the active ingredient.

Bioavailability. Bioavailability is the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of drug action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by scientifically valid measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of drug action.[7]

6 See 21 CFR 314.3(b).
7 21 CFR 314.3(b).

Bioequivalence. Bioequivalence is the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study.[8] Section 505(j)(8)(B) of the FD&C Act describes certain conditions under which a test drug and reference listed drug (see Section 1.4) shall be considered bioequivalent:

> (i) the rate and extent of absorption of the [test] drug do not show a significant difference from the rate and extent of absorption of the [reference] listed drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses; or
>
> (ii) the extent of absorption of the [test] drug does not show a significant difference from the extent of absorption of the [reference] listed drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses and the difference from the [reference] listed drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug.

Where these above methods are not applicable (e.g., for drug products that are not intended to be absorbed into the bloodstream), other scientifically valid *in vivo* or *in vitro* test methods to demonstrate bioequivalence may be appropriate.

For example, bioequivalence may sometimes be demonstrated using an *in vitro* bioequivalence standard, especially when such an *in vitro* test has been correlated with human *in vivo* bioavailability data. In other situations, bioequivalence may sometimes be demonstrated through comparative clinical trials or pharmacodynamic studies.[9]

1.3 Further Guidance on Bioequivalence

FDA's regulations and guidance documents provide additional information regarding bioequivalence and bioavailability, including methodologies and statistical criteria used to establish the bioequivalence of drug products.[10]

1.4 Reference Listed Drug and Reference Standard

A reference listed drug is the listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA.[11] Generally, a reference listed drug is a drug product approved in a new drug application under Section 505(c) of the FD&C Act based on full reports of

---

8 21 CFR 314.3(b).

9 21 CFR 320.24

10 We note that prior editions of the Preface to the Orange Book included a section entitled "Statistical Criteria for Bioequivalence." Please see FDA's regulations and guidance documents for additional information regarding bioequivalence and bioavailability. See generally 21 CFR part 320. See FDA Drugs guidance Web page at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm; FDA Drugs guidance (Product-Specific Recommendations for Generic Drug Development) Web page at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075207.htm.

11 21 CFR 314.3(b).

investigations of safety and effectiveness. For an ANDA based on an approved suitability petition (a petitioned ANDA), the reference listed drug generally is the listed drug referenced in the approved suitability petition.[12]

A reference standard is the drug product selected by FDA that an applicant seeking approval of an ANDA must use in conducting an *in vivo* bioequivalence study required for approval.[13] FDA generally selects a single reference standard that ANDA applicants must use in *in vivo* bioequivalence testing. Ordinarily, FDA will select the reference listed drug as the reference standard. However, in some instances, the reference listed drug and the reference standard may be different. For example, where the reference listed drug has been withdrawn from sale and FDA has determined it was not withdrawn for reasons of safety or effectiveness, FDA may select an ANDA as the reference standard.

FDA identifies reference listed drugs in the Prescription Drug Product, OTC Drug Product, and Discontinued Drug Product Lists. Listed drugs identified as reference listed drugs represent drug products upon which an applicant can rely in seeking approval of an ANDA. FDA intends to update periodically the reference listed drugs identified in the Prescription Drug Product, OTC Drug Product, and Discontinued Drug Product Lists, as appropriate.

In some instances when FDA has not designated a listed drug as a reference listed drug, such listed drug may be shielded from generic competition. If FDA has not designated a reference listed drug for a drug product the applicant intends to duplicate, the potential applicant may submit a controlled correspondence to the Office of Generic Drugs to ask FDA to designate a reference listed drug for that drug product. Section 1.7, *Therapeutic Equivalence Evaluations Codes* (*products meeting necessary bioequivalence requirements*) explains the character coding system (e.g., **AB, AB1, AB2, AB3**...) for multisource drug products listed under the same heading with two or more reference listed drugs.

FDA also identifies reference standards in the Prescription Drug Product and OTC Drug Product Lists. Listed drugs identified as reference standards represent FDA's best judgment at this time as to the appropriate comparator for purposes of conducting any *in vivo* bioequivalence studies required for approval.

A potential applicant should consult Agency guidance related to referencing approved drug products in ANDA submissions for information on submitting a request for selection of a reference standard. FDA may, on its own initiative, select a new reference standard when doing so will help to ensure that applications for generic drugs may be submitted and evaluated, e.g., in the event that the listed drug currently selected as the reference standard has been withdrawn from sale for other than safety and efficacy reasons.

If an applicant has a question related to the appropriate reference standard, it is recommended that an applicant planning to conduct an *in vivo* bioequivalence study submit a controlled correspondence to the Office of Generic Drugs.

1.5 General Policies and Legal Status

12 21 CFR 314.94(a)(3)(i).
13 21 CFR 314.3(b).

The Orange Book contains public information and advice. It does not mandate the drug products that are purchased, prescribed, dispensed, or substituted for one another, nor does it, conversely, mandate the products that should be avoided. To the extent that the Orange Book sets forth FDA's evaluations of the therapeutic equivalence of drug products that have been approved, it contains FDA's advice to the public, to practitioners, and to the states regarding drug product selection. These evaluations do not constitute determinations that any product is in violation of the FD&C Act or that any product is preferable to any other. Therapeutic equivalence evaluations are a scientific judgment based upon evidence, while generic substitution may involve social and economic policy administered by the states, e.g., reducing the cost of drugs to consumers. To the extent that the Orange Book identifies drug products approved under Section 505 of the FD&C Act, it sets forth information that the Agency is required to publish and that the public is entitled to under the Freedom of Information Act. Exclusion of a drug product from the Orange Book does not necessarily mean that the drug product is in violation of Section 505 of the FD&C Act, that such a product is not safe or effective, or that such a product is not therapeutically equivalent to other drug products. Rather, the exclusion may be based on the fact that FDA has not evaluated the safety, effectiveness, and quality of the drug product.

1.6 Practitioner/User Responsibilities

Professional care and judgment should be exercised in using the Orange Book. Evaluations of therapeutic equivalence for prescription drugs are based on scientific and medical evaluations by FDA. Products evaluated as therapeutically equivalent can be expected, in the judgment of FDA, to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling. However, these products may differ in other characteristics that are not required by statute or regulation to be the same, such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, in some instances, labeling. If products with such differences are substituted for each other, there is a potential for patient confusion, e.g., due to differences in color or shape of tablets, inability to provide a given dose using a partial tablet if the proper scoring configuration is not available, or decreased patient acceptance of certain products because of flavor. There may also be patient-specific allergic reactions in rare cases due to a coloring or a preservative ingredient.

FDA evaluation of therapeutic equivalence in no way relieves practitioners of their professional responsibilities in prescribing and dispensing such products with due care and with appropriate information to individual patients. In those circumstances where the characteristics of a specific product, other than its active ingredient, are important in the therapy of a particular patient, the practitioner's prescribing of that product may be appropriate. Pharmacists must also be familiar with the different characteristics of therapeutically equivalent products, e.g., expiration dates/times and labeling directions for storage of the different products (particularly for reconstituted products), so they can properly advise patients when one product is substituted for another.

Multisource and single-source drug products. In the Orange Book, FDA has evaluated for therapeutic equivalence only multisource prescription drug products approved under Section 505 of the FD&C Act, which in most instances means those pharmaceutical equivalents available from more than one manufacturer. For such products, a therapeutic equivalence code is included

and product information is highlighted in bold face and underlined. Those products with approved applications that are single-source (i.e., there is only one approved product available for that active ingredient, dosage form, route of administration, and strength) are also included in the Orange Book, but no therapeutic equivalence code is included with such products. Any drug product in the Orange Book repackaged and/or distributed by the applicant or some other person authorized by the applicant (e.g., an authorized generic) is considered to be therapeutically equivalent to the applicant's drug product even if the applicant's drug product is single source or coded as non-equivalent (e.g., **BN**). Distributors or repackagers of an applicant's drug product are not identified in the Orange Book. The details of therapeutic equivalence codes and the policies underlying them are discussed in Section 1.7, *Therapeutic Equivalence Evaluations Codes*.

Products in the Orange Book are identified by the names of the holders of approved applications (applicants) who may not necessarily be the manufacturer of the product. There are numerous entities other than the applicant that may be involved in the development, manufacturing, and/or marketing of a product. The applicant may or may not be the manufacturer and may simply be distributing the product for which it has obtained approval. In many instances, however, the manufacturer of the product is also the applicant. The name of the manufacturer is permitted by regulation to appear on the label, even when the manufacturer is not the applicant or marketer.

Although the products in the Orange Book are identified by the names of the applicants, circumstances, such as changing corporate ownership, have sometimes made identification of the applicant difficult. The Agency believes, based on continuing document review and communication with firms, that the applicant designations in the Orange Book are, in most cases, correct.

To relate firm name information on a product label to that in the Orange Book, the following should be noted: the applicant's name always appears in the Orange Book. This applies whether the applicant (firm name on the Form FDA 356h in the application) is the manufacturer or marketer (firm name in largest letters on the label) or not. However, the applicant's name may not always appear on the label of the product.

If the applicant is the marketer, its name appears in the Orange Book and on the label; if the applicant is not the marketer, and the Agency is aware of a corporate relationship (e.g., parent and subsidiary) between the applicant and the marketer, the name of the applicant appears in the Orange Book and both firm names may appear on the label. Firms with known corporate relationships are displayed in Appendix B. If there is no known corporate relationship between the applicant and the marketer, the applicant's name appears in the Orange Book; however, unless the applicant is the manufacturer, packager, or distributor, the applicant's name may not appear on the label. In this case, the practitioner, from labeling alone, will not be able to relate the marketed product to an applicant cited in the Orange Book, and hence to a specific approved drug product. In such cases, to assure that the product in question is the subject of an approved application, the firm named on the label should be contacted.

To relate trade name (proprietary name) information on a product label to that in the Orange Book, the following should be noted: if the applicant is the marketer, the applicant's name appears in the Orange Book and on the label; if the Agency is aware of a corporate relationship between the applicant and the marketer, the trade name (proprietary name) of the drug product (established name of the active ingredient, if no trade name exists) appears in the Orange Book. If a corporate relationship exists between an applicant and a marketer and both firms are distributing the drug product,

the FDA reserves the right to select the trade name of either the marketer or the applicant to appear in the Orange Book. If there is no known corporate relationship between the applicant and the marketer, the established drug name (i.e., non-proprietary name) appears in the Orange Book.

Every product in the Orange Book is subject at all times to regulatory action. From time to time, approved products may be found in violation of one or more provisions of the FD&C Act. In such circumstances, the Agency may commence appropriate enforcement action to correct the violation, if necessary, by securing removal of the product from the market by voluntary recall, seizure, or other enforcement actions. Such regulatory actions are, however, independent of the inclusion of a product in the Orange Book. The main criterion for inclusion of a product is that it has an application that has been approved and that has not been withdrawn for safety or efficacy reasons. FDA believes that retention of a violative product in the Orange Book will not have any significant adverse health consequences, because other legal mechanisms are available to the Agency to prevent the product's actual marketing. FDA may, however, change a product's therapeutic equivalence rating if the circumstances giving rise to the violation change or otherwise call into question the Agency's assessment of whether a product meets the criteria for therapeutic equivalence.

1.7 Therapeutic Equivalence Evaluations Codes

Generally, drug products that the Agency considers multisource have been assigned a therapeutic equivalence code. The coding system for therapeutic equivalence evaluations is designed to allow users to determine quickly whether the Agency has evaluated a particular approved product (e.g., a particular strength of an approved drug) as therapeutically equivalent to other pharmaceutically equivalent products (first letter) and to provide additional information on the basis of FDA's evaluations (second letter). With some exceptions (e.g., therapeutic equivalence evaluations for certain 505(b)(2) applications), the therapeutic equivalence evaluation date is the same as the approval date.

The two basic categories into which multisource drugs have been placed are indicated by the first letter of the relevant therapeutic equivalence code as follows:

A Drug products that FDA considers to be <u>therapeutically equivalent</u> to other pharmaceutically equivalent products, i.e., drug products for which:

(1) there are no known or suspected bioequivalence problems. These are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form; or

(2) actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. These are designated **AB**.

B Drug products that FDA at this time, considers <u>not to be therapeutically equivalent</u> to other pharmaceutically equivalent products, i.e.,

drug products for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence. Often the problem is with specific dosage forms rather than with the active ingredients. These are designated **BC**, **BD**, **BE**, **BN**, **BP**, **BR**, **BS**, **BT**, **BX**, or **B***.

Individual drug products have been evaluated as therapeutically equivalent to the reference product in accordance with the definitions and policies outlined below:

"A" CODES

Drug products that are considered to be therapeutically equivalent to other pharmaceutically equivalent products.

"**A**" products are those for which there are no known or suspected bioequivalence problems or for which actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. Drug products designated with an "**A**" code fall under one of two main policies:

(1) for those active ingredients or dosage forms for which no *in vivo* bioequivalence issue is known or suspected, the information necessary to show bioequivalence between pharmaceutically equivalent products is either presumed and considered self-evident (based on other information in the application for some dosage forms (e.g., solutions)), or satisfied by a showing that an acceptable *in vitro* approach is met. A therapeutically equivalent rating is assigned such products so long as they are manufactured in accordance with Current Good Manufacturing Practice regulations and meet the other requirements of their approved applications (these are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form, as described below); or

(2) for those Drug Efficacy Study Implementation (DESI) drug products containing active ingredients or dosage forms that have been identified by FDA as having actual or potential bioequivalence problems, and for post-1962 drug products presenting a potential bioequivalence problem, an evaluation of therapeutic equivalence is assigned to pharmaceutical equivalents only if the approved application contains adequate scientific evidence establishing through *in vivo* and/or *in vitro* studies the bioequivalence of the product to a selected reference product (these products are designated as **AB**).

There are some general principles that may affect the substitution of pharmaceutically equivalent products in specific cases. Prescribers and dispensers of drugs should be alert to these principles so as to deal appropriately with situations that require professional judgment and discretion.

There may be labeling differences among pharmaceutically equivalent products that require attention on the part of the health professional (e.g., pharmaceutically equivalent powders to be reconstituted for administration as oral or injectable liquids may vary with respect to their expiration time or storage conditions after reconstitution). FDA’s determination that such products are therapeutically equivalent is applicable only when each product is reconstituted, stored, and used under the conditions specified in its labeling.

The Agency may use notes in this publication to point out special situations, such as potential differences between two drug products that have been evaluated as bioequivalent and otherwise therapeutically equivalent, when they should be brought to the attention of health professionals. These notes are contained in Section 1.8, *Description of Certain Special Situations*.

For example, in certain instances, there may be variations among therapeutically equivalent products in their use or in conditions of administration. Such differences may be due to patent or exclusivity rights associated with such use. When such variations may, in the Agency's opinion, affect prescribing or substitution decisions by health professionals, a note may be added to Section 1.8.

Also, occasionally a situation may arise in which changes in a listed drug product after its approval (for example, a change in dosing interval) may have an impact on the substitutability of already approved generic versions of that product that were rated by the Agency as therapeutically equivalent to the listed product. When such changes in the listed drug product are considered by the Agency to have a significant impact on therapeutic equivalence, the Agency will change the therapeutic equivalence ratings for other versions of the drug product unless the manufacturers of those other versions of the product provide additional information to assure equivalence under the changed conditions. Pending receipt of the additional data, the Agency may add a note to Section 1.8, or, in rare cases, may even change the therapeutic equivalence rating.

In some cases (e.g., Isolyte® S w/ Dextrose 5% in Plastic Container and Plasma-Lyte® 148 and Dextrose 5% in Plastic Container), closely related products are listed as containing the same active ingredients, but in somewhat different amounts. In determining which of these products are pharmaceutically equivalent, generally the Agency has considered products to be pharmaceutically equivalent with labeled strengths of an ingredient that do not vary by more than 1%.

Different salts, esters or other noncovalent derivatives (such as a complex, chelate, or clathrate) of the same active moiety are regarded as different active ingredients. For the purpose of this publication, products containing such different active ingredients are considered pharmaceutical alternatives and, thus, not therapeutically equivalent. Anhydrous and hydrated entities, as well as different polymorphs, are considered to be the same active ingredient and are expected to meet the same standards for identity to be considered pharmaceutical equivalents and therapeutic equivalents.

The codes in this book are not intended to preclude health care professionals from converting pharmaceutically different concentrations into pharmaceutical equivalents using accepted professional practice.

Where package size variations have therapeutic implications, products so packaged have not been considered pharmaceutically equivalent. For example, some oral contraceptives are supplied in 21-tablet and 28-tablet packets; the 28-tablet packets contain 7 placebo or iron tablets. These two packaging configurations are not regarded as pharmaceutically equivalent; thus, they are not designated as therapeutically equivalent.

Preservatives and other inactive ingredients may differ among some therapeutically equivalent drug products. These differences do not affect FDA's evaluation of therapeutic equivalence except in cases where these components may influence bioequivalence or routes of administration.

The specific sub-codes for those drugs evaluated as therapeutically equivalent and the policies underlying these sub-codes follow:

AA Products in conventional dosage forms not presenting bioequivalence problems

Multisource drug products coded as **AA** contain active ingredients and are in dosage forms that are not regarded as presenting either actual or

potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate *in vitro* bioequivalence standard that is acceptable to the Agency in order to be approved.

AB, AB1, AB2, AB3... Products meeting necessary bioequivalence requirements

Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Section 1.2, *Therapeutic Equivalence-Related Terms, Strength)* generally will be coded **AB** if data and information are submitted demonstrating bioequivalence.

In certain instances, a number is added to the end of the **AB** code to make a three character code (i.e., **AB1, AB2, AB3, etc.**). Three-character codes generally are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. If a study is submitted that demonstrates bioequivalence to a reference listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. For example, Adalat® CC and Procardia XL®, extended-release tablets, are listed under the active ingredient nifedipine. These drug products, listed under the same heading, are not bioequivalent to each other. Adalat® CC and Procardia XL® have been assigned ratings of **AB1** and **AB2**, respectively. Generic drug products deemed by FDA to be bioequivalent to Adalat® CC and Procardia XL® have been approved. As a result, the generic drug products bioequivalent to Adalat® CC have been assigned a rating of **AB1** and those bioequivalent to Procardia XL® have been assigned a rating of **AB2**. (The assignment of an **AB1** or **AB2** rating to a specific product does not imply product preference.) Even though drug products of distributors and/or repackagers are not included in the Orange Book, they are considered therapeutically equivalent to the applicant's drug product if the applicant's drug product is rated either with an **AB** or three-character code or is single source in the Orange Book. Drugs coded as **AB** under a heading are considered therapeutically equivalent only to other drugs coded as **AB** under that heading. Drugs coded with a three-character code under a heading are considered therapeutically equivalent only to other drugs coded with the same three-character code under that heading.

AN Solutions and powders for aerosolization

Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in general-use delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded **AN**. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded **BN**, unless they have met an appropriate bioequivalence standard and are otherwise determined to be therapeutically equivalent. Solutions or suspensions in a specific delivery system will be coded **AN** if the bioequivalence standard is based upon *in vitro* methodology, if bioequivalence needs to be demonstrated by *in vivo* methodology then the drug products will be coded **AB**.

AO Injectable oil solutions

The absorption of drugs in injectable (parenteral) oil solutions may vary substantially with the type of oil employed as a vehicle and the

concentration of the active ingredient. Injectable oil solutions are therefore considered to be pharmaceutically and therapeutically equivalent only when the active ingredient, its concentration, and the type of oil used as a vehicle are all identical.

AP Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions

It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, historically some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.

Certain commonly used large volume intravenous products in glass containers are not included in the Orange Book (e.g., dextrose injection 5%, dextrose injection 10%, sodium chloride injection 0.9%) since these products are on the market without FDA approval and FDA has not published conditions for marketing such parenteral products under approved NDAs. When packaged in plastic containers, however, FDA regulations require approved applications prior to marketing. Approval then depends on, among other things, the extent of the available safety data involving the specific plastic component of the product. All large volume parenteral products are manufactured under similar standards, regardless of whether they are packaged in glass or plastic. Thus, FDA has no reason to believe that the packaging container of large volume parenteral drug products that are pharmaceutically equivalent would have any effect on their therapeutic equivalence.

Consistent with the definition of strength included in Section 1.2, *Therapeutic Equivalence-Related Terms,* the strength of parenteral drug products generally is identified by both the total drug content and the concentration of drug substance in a container approved by FDA.[14] In the past, the strength of liquid parenteral drug products in the Orange Book has not been fully displayed. Rather, the strength of liquid parenteral drug products in the Orange Book has been displayed in terms of concentration, expressed as xmg/mL. Generally, the amount of dry powder or lyophilized powder in a container is identified as the strength, expressed as xmg/vial.

After the enactment of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA), which amended the FD&C Act, it became evident that the format of the Orange Book with respect to parenteral

14 The strengths of certain parenteral drug products, including contrast agents, may be expressed as a percentage.

solutions should be changed to reflect that each strength of a drug is considered to be a separate listed drug. The Orange Book now displays the strength of all new approvals of parenteral solutions. Previously, we would have displayed only the concentration of an approved parenteral solution, e.g. 50mg/mL. For example, if this application had a 20 mL and 60 mL container approved, we would now display two product strengths, listing both total drug content and concentration of drug substance in the relevant approved container, e.g. 1gm/20mL (50mg/mL) and 3gm/60mL (50mg/mL).

AT Topical products

There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays, and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of *in vivo* bioequivalence has been granted, or the application contains adequate scientific evidence establishing through an *in vitro* approach the bioequivalence of the product to a selected reference product, and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded **AT**. Pharmaceutically equivalent topical products that raise questions of bioequivalence and for which a waiver of *in vivo* bioequivalence has not been granted, including all post-1962 non-solution topical drug products, are coded **AB** when supported by adequate *in vivo* bioequivalence data, and **BT** in the absence of such data.

"B" CODES

Drug products that FDA, at this time, considers <u>not to be therapeutically equivalent</u> to other pharmaceutically equivalent products.

"**B**" products, for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence, often have a problem with specific dosage forms rather than with the active ingredients. Drug products designated with a "**B**" code fall under one of three main policies:

(1) the drug products contain active ingredients or are manufactured in dosage forms that have been identified by the Agency as having documented bioequivalence problems or a significant potential for such problems and for which no adequate studies demonstrating bioequivalence have been submitted to FDA; or

(2) the quality standards are inadequate or FDA has an insufficient basis to determine therapeutic equivalence; or

(3) the drug products are under regulatory review.

The specific coding definitions and policies for the "**B**" sub-codes are as follows:

B* Drug products requiring further FDA investigation and review to determine therapeutic equivalence

The code **B*** is assigned to products previously assigned an **A** or **B** code when FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through further Agency investigation and/or review of data and information submitted by the applicant. The **B*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

BC Extended-release dosage forms (capsules, injectables and tablets)

Extended-release tablets are formulated in such a manner as to make the contained drug substance available over an extended period of time following ingestion.

Although bioavailability studies have been conducted on these dosage forms, they may be subject to bioavailability differences, primarily because applicants developing extended-release products for the same active ingredient rarely employ the same formulation approach. FDA, therefore, does not consider different extended-release dosage forms containing the same active ingredient in equal strength to be therapeutically equivalent unless equivalence between individual products in both rate and extent has been specifically demonstrated through appropriate bioequivalence studies. Extended-release products for which such bioequivalence data have not been submitted are coded **BC**, while those for which such data are available have been coded **AB**.

BD Active ingredients and dosage forms with documented bioequivalence problems

The **BD** code denotes products containing active ingredients with known bioequivalence problems and for which adequate studies have not been submitted to FDA demonstrating bioequivalence. Where studies showing bioequivalence have been submitted, the product has been coded **AB**.

BE Delayed-release oral dosage forms

Where the drug may be destroyed or inactivated by the gastric juice or where it may irritate the gastric mucosa, the use of “enteric” coatings is indicated. Such coatings are intended to delay the release of the medication until the tablet has passed through the stomach. Drug products in delayed-release dosage forms containing the same active ingredients are subject to significant differences in absorption. Unless otherwise specifically noted, the Agency considers different delayed-release products containing the same active ingredients as presenting a potential bioequivalence problem and codes these products **BE** in the absence of *in vivo* studies showing bioequivalence. If adequate *in vivo* studies have demonstrated the bioequivalence of specific delayed-release products, such products are coded **AB**.

BN Products in aerosol-nebulizer drug delivery systems

This code applies to drug solutions or powders that are marketed only as a component of, or as compatible with, a specific drug delivery system. There may, for example, be significant differences in the dose of drug and particle size delivered by different products of this type. Therefore,

the Agency does not consider different metered aerosol dosage forms containing the same active ingredient(s) in equal strengths to be therapeutically equivalent unless the drug products meet an appropriate bioequivalence standard; such products are coded **AB**.

BP Active ingredients and dosage forms with potential bioequivalence problems

FDA's bioequivalence regulations (21 CFR 320.33) contain criteria and procedures for determining whether a specific active ingredient in a specific dosage form has a potential for causing a bioequivalence problem. It is FDA's policy to consider an ingredient meeting these criteria as having a potential bioequivalence problem even in the absence of positive data demonstrating inequivalence. Pharmaceutically equivalent products containing these ingredients in oral dosage forms are coded **BP** until adequate bioequivalence data are submitted, after which such products are coded **AB**. Injectable suspensions containing an active ingredient suspended in an aqueous or oleaginous vehicle have also been coded **BP**. Injectable suspensions are subject to bioequivalence problems because differences in particle size, polymorphic structure of the suspended active ingredient, or the suspension formulation can significantly affect the rate of release and absorption. FDA does not consider pharmaceutical equivalents of these products bioequivalent without adequate evidence of bioequivalence; such products would be coded **AB**.

BR Suppositories or enemas that deliver drugs for systemic absorption

The absorption of active ingredients from suppositories or enemas that are intended to have a systemic effect (as distinct from suppositories administered for local effect) can vary significantly from product to product. Therefore, FDA considers pharmaceutically equivalent systemic suppositories or enemas bioequivalent only if *in vivo* evidence of bioequivalence is available. In those cases where *in vivo* evidence is available, the products are coded **AB**. If such evidence is not available, the products are coded **BR**.

BS Products having drug standard deficiencies

If the drug standards for an active ingredient in a particular dosage form are found by FDA to be deficient so as to prevent an FDA evaluation of either pharmaceutical or therapeutic equivalence, all drug products containing that active ingredient in that dosage form are coded **BS**. For example, if the standards permit a wide variation in pharmacologically active components of the active ingredient such that pharmaceutical equivalence is in question, all products containing that active ingredient in that dosage form are coded **BS**.

BT Topical products with bioequivalence issues

This code applies mainly to post-1962 dermatologic, ophthalmic, otic, rectal, and vaginal products for topical administration, including creams, gels, lotions, oils, ointments, pastes, solutions, and sprays, as well as suppositories not intended for systemic drug absorption. Topical products evaluated as having acceptable clinical performance, but that are not bioequivalent to other pharmaceutically equivalent products or that lack sufficient evidence of bioequivalence, will be coded **BT**.

BX Drug products for which the data are insufficient to determine therapeutic equivalence

The code **BX** is assigned to specific drug products for which the data that have been reviewed by the Agency are insufficient to determine therapeutic equivalence under the policies stated in this document. In these situations, the drug products are presumed to be therapeutically inequivalent until the Agency has determined that there is adequate information to make a full evaluation of therapeutic equivalence.

1.8 Description of Certain Special Situations

Certain drugs listed in the Orange Book present special situations that merit further discussion. The following are descriptions of certain examples of those special situations:

Amino Acid and Protein Hydrolysate Injections. These products differ in the amount and kinds of amino acids they contain and, therefore, are not considered pharmaceutical equivalents. For this reason, these products are not considered therapeutically equivalent. At the same time, the Agency believes that it is appropriate to point out that where nitrogen balance is the sole therapeutic objective and individual amino acid content is not a consideration, pharmaceutical alternatives with the same total amount of nitrogen content may be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.

Gaviscon®. Gaviscon® is an OTC product that has been marketed since September 1970. The active ingredients in this product, aluminum hydroxide and magnesium trisilicate, were reviewed by the Agency's OTC Antacid Panel and were considered to be safe and effective ingredients (Category I) by that Panel. However, the tablet failed to pass the antacid test that is required of all antacid products. The Agency, therefore, placed the tablet in Category III for lack of effectiveness. A full NDA with clinical studies was submitted by Marion Laboratories, Inc., and approved by FDA on December 9, 1983. Gaviscon®'s activity in treating reflux acidity is made possible by the physical-chemical properties of the inactive ingredients, sodium bicarbonate and alginic acid. Therefore, *all ANDAs that cite Gaviscon® tablets as the reference listed drug must contain the inactive ingredients sodium bicarbonate and alginic acid.* A full NDA will be required to support the effectiveness of the drug product if different inactive ingredients are to be substituted for sodium bicarbonate or alginic acid or if different proportions of these ingredients are to be used.

Levothyroxine Sodium. Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium tablet drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Cediprof Inc NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Cediprof Inc NDA 021342), Euthyrox (Provell Pharma LLC NDA 021292), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to

corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Cediprof Inc NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Thyro-Tabs (Lloyd NDA 021116) tablets.[15]

The chart outlines TE codes for all 0.025 mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	CEDIPROF INC	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	CEDIPROF INC	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
EUTHYROX	PROVELL PHARM	0.025MG	AB2	021292	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	CEDIPROF INC	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
THYRO-TABS	LLOYD	0.025MG	N/A[16]	021116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

15 Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) is currently listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for the AB4 category. Mylan's levothyroxine product (ANDA 076187) has been selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

16 Id. Thyro-Tabs is in the Discontinued Drug Product List and therefore no longer is assigned a TE code.

Patent Certification(s) and Reference Standard for ANDAs Duplicating a Drug Product Approved in a Petitioned ANDA. To submit an ANDA for a generic drug that is not the same as its reference listed drug because it has one different active ingredient in a fixed-combination drug product, or has a different route of administration, dosage form, or strength than that of the reference listed drug, an applicant first must obtain permission from FDA through what is known as a suitability petition pursuant to Section 505(j)(2)(C) of the FD&C Act. A petitioned ANDA relies on the reference listed drug described in the suitability petition. An ANDA seeking approval of a drug that is the same as a drug product approved in a petitioned ANDA should use as its reference listed drug, the reference listed drug that served as the basis for the approved suitability petition, and use the drug product approved in the petitioned ANDA as its reference standard for conducting an *in vivo* bioequivalence study required for approval. However, the reference listed drug for any such ANDA is generally the listed drug referenced in the approved suitability petition. The ANDA must include appropriate patent certification(s) and an exclusivity statement with respect to the reference listed drug that served as the basis for the approved suitability petition.[17] (This concept also generally applies to an ANDA applicant that utilizes a reference standard that is not a reference listed drug, as such an application must include appropriate patent certification(s) and an exclusivity statement with respect to the reference listed drug.)

Waived exclusivity. If an NDA submitted under Section 505(b) of the FD&C Act qualifies for exclusivity under the FD&C Act, the exclusivity is generally listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received this exclusivity, FDA will not accept for review and/or will not approve a 505(b)(2) application or an ANDA under Section 505(j) of the FD&C Act, as applicable, in accordance with the relevant exclusivity.[18] If the listed drug is also protected by one or more patents, the approval date for the ANDA or 505(b)(2) application will be determined based on an analysis of the applicant's patent certification(s) or statement(s) for each relevant patent and the effect of relevant exclusivity listed in the Orange Book. However, the holder of the NDA may waive its exclusivity as to any or all ANDAs and 505(b)(2) applications that might otherwise be blocked by such exclusivity. If an NDA sponsor waives its exclusivity, qualified ANDAs or 505(b)(2) applications may be accepted for review and/or approved, as applicable. An NDA for which the holder has waived its exclusivity as to all ANDAs and 505(b)(2) applications will be coded with a "W" in the Patent and Exclusivity Section of the Orange Book. The applicant whose product might otherwise be blocked by this exclusivity should indicate in the exclusivity statement in its application that the holder of the listed drug has waived its exclusivity.

1.9 Therapeutic Equivalence Code Change for a Category of Multisource Drug Products

The Agency will use the following procedures when, in response to a petition or on its own initiative, it is considering a change in the therapeutic equivalence code for approved multisource drug products. Such changes will generally occur when the Agency becomes aware of new scientific information affecting the therapeutic equivalence of an entire category of

17 If after approval of a suitability petition and before approval of an ANDA submitted pursuant to the approved petition, a drug product is approved in an NDA for the change described in the petition, the suitability petition and the listed drug identified in the petition can no longer be the basis of submission for such ANDA. Under these circumstances, an applicant seeking approval for a drug product with the change approved in the suitability petition must submit a new ANDA that identifies the drug product approved under such NDA as the RLD and comply with applicable regulatory requirements. See 21 CFR 314.93(f)(2).

18 See Patent and Exclusivity Information Addendum in the Orange Book.

multisource drug products in the Orange Book (e.g., information concerning the active ingredient or the dosage form), rather than information concerning a single drug product within the category. These procedures will be used when a change in therapeutic equivalence code is under consideration for all drug products found in the Prescription Drug Product List under a specific active ingredient and dosage form. The change may be from the code signifying that the drug does not present a bioequivalence problem (e.g., **AA**) to a code signifying an actual or potential bioequivalence problem (e.g., **BP**), or vice versa. This procedure does not apply to a change of a particular product code (e.g., a change from **BP** to **AB** or from **AB** to **BX**).

Before making a change in a therapeutic equivalence code for an entire category of multisource drug products as described above, the Agency will announce in the *Introduction* to the Cumulative Supplement that it is considering the change and will invite comments. Comments, along with scientific data, may be sent to the Director, Office of Bioequivalence, Food and Drug Administration, Office of Generic Drugs,Central Document Room, 5901-B Ammendale Rd., Beltsville, MD 20705-1266.

The comment period will generally be 60 days in length, and the closing date for comments will be listed in the description of the proposed change for each drug entity.

The most useful type of scientific data submitted to support comments is an *in vivo* bioavailability/bioequivalence study conducted on batches of the subject drug products. Comments including scientific data from an *in vivo* bioavailability/bioequivalence study should present a full description of the analytical procedures and equipment used, a validation of the analytical methodology, including the standard curve, a description of the method of calculating results, and a description of the pharmacokinetic and statistical models used in analyzing the data. Anecdotal or testimonial information is the least useful to the Agency, and submission of comments based on such information is discouraged. However, when there is supporting published or unpublished scientific literature, copies should be submitted with comments.

1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product

The procedure described in Section 1.9 does not apply to a change in a single drug product code. For example, a change in a single drug product's code from **BP** to **AB** as a result of the submission of an acceptable bioequivalence study ordinarily will not be the subject of notice and comment in the Cumulative Supplement. Likewise, a change in a single drug product's code from **AB** to **BX** (e.g., as a result of new information raising a significant question as to bioequivalence) does not require notice and comment. The Agency's responsibility to provide the public with the Agency's most current information related to therapeutic equivalence may require a change in a drug product's code prior to any formal notice and opportunity for the applicant to be heard. The publication in the *Federal Register* of a proposal to withdraw approval of a drug product will ordinarily result in a change in a product's code from **AB** to **BX** if this action has not already been taken.

We recognize that certain drug products approved in 505(b)(2) applications may not have therapeutic equivalence codes, and that FDA may undertake therapeutic equivalence evaluations with respect to such drug products. A person seeking to have a therapeutic equivalence rating for a drug product approved in a 505(b)(2) application may petition the Agency through the citizen petition procedure (see 21 CFR 10.25(a) and 21 CFR 10.30).

1.11 Discontinued Section

Those drug products in the discontinued section of the Orange Book (Discontinued Drug Product List) for which a determination has been made that the products were not withdrawn for safety or effectiveness reasons have been annotated with a footnote following the product strength: "**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**". The determinations listed in the Orange Book are only reflective of determinations made since 1995 and published in the Federal Register. The identification of these drug products in the Discontinued Drug Product List should avoid the submission of multiple citizen petitions requesting a determination for the same drug product.

Generally, approved products are added to the Discontinued Drug Product List when the applicant notifies the Orange Book staff of the products' not-marketed status. Products may also be added to the Discontinued Drug Product List if annual reports or other submissions to the Agency indicate the product is not being marketed or as a result of other Agency administrative actions.[19] Changes to the Orange Book are not affected by the drug registration and listing requirements of Section 510 of the FD&C Act.

1.12 Changes to the Orange Book

Every effort is made to ensure the Annual Edition is current and accurate. Applicants are requested to inform the FDA Orange Book Staff of any changes or corrections, including any change in ownership or a product's marketing status that would result in the product being moved to the Discontinued Drug Product List. FDA notes that under Section 506I(a) of the FD&C Act, applicants must notify the Agency in writing 180 days prior to withdrawing a drug product from sale, or if 180 days is not practicable, not later than the date of withdrawal from sale. Furthermore, Section 506I(b) of the FD&C Act requires that applicants notify the Agency in writing within 180 days of approval of a drug product if such drug product will not be available for sale within 180 days of approval. A request to include a newly approved product in the Discontinued Drug Product List, rather than parts 1, 2 or 3 of the Orange Book (as discussed in Section 1.1), must be submitted to the Orange Book staff by the end of the month in which the product is approved to ensure that the product is not included in the "active" portions of the next published Orange Book update.

In addition, the FDA Orange Book Staff generally will act on requests to change a proprietary name for a listed drug only after approval of a supplement for the relevant change in proprietary name. To the extent that conventions for describing product identification information (i.e., active ingredients, dosage forms, routes of administration, product names, applicants, strengths) evolve over time, the Agency generally does not intend to revise such information for drug products already included in the Orange Book, but rather intends to apply the change prospectively to drug products added to the Orange Book.

You can contact the Orange Book Staff by email at orangebook@fda.hhs.gov.

19 See, e.g., Section 506I(d) of the FD&C Act.

1.13 Availability of the Edition

Commencing with the 25th edition, the Annual Edition and current monthly Cumulative Supplement are available in a Portable Document Format (PDF) at the Orange Book home page by clicking on Publications. The PDF annual format duplicates previous paper versions except for the Orphan Products Designations and Approvals List. An annual subscription of the PDF format may be obtained from the U.S. Government Publishing Office, https://www.gpo.gov/.

2.0 HOW TO USE THE DRUG PRODUCT LISTS

2.1 Key Sections for Using the Drug Product Lists

This publication contains illustrations, along with Drug Product Lists, indices, and lists of abbreviations and terms which facilitate their use.

Illustrations. The annotated *Drug Product Illustration*, see Section 2.2, and the *Therapeutic Equivalence Evaluations Illustration*, see Section 2.3, are offered to provide further clarification. These depict the format found in the Prescription Drug Product List (the only list in which therapeutic equivalence evaluation codes are displayed).

Drug Product Lists. The Prescription and OTC Drug Product Lists, arranged alphabetically by active ingredient(s), contain product identification information (active ingredients, dosage forms, routes of administration, product names, applicants, strengths) for single and multiple ingredient drug products. Also shown are the application number and drug product number (FDA internal computer data use only) and approval dates for those drug products approved on or after January 1, 1982. The application number preceded by “N” is a New Drug Application (NDA or commonly the innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or commonly the generic).

The Discontinued Drug Product List, arranged alphabetically by active ingredient(s), contains product identification information (dosage form, product name, strength, and application number).

If a prescription drug product is available from more than one source (multisource), a therapeutic equivalence code will appear in front of the applicant's name. If a product is therapeutically equivalent to one or more products or to an appropriate reference, it will be designated with a code beginning with "**A**" and the entry will be underlined and printed in bold font for emphasis.

Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For purposes of this publication, this alphabetical sort takes precedence over United States Pharmacopeia official monograph order (i.e., Reserpine, Hydralazine Hydrochloride, Hydrochlorothiazide). For example, product information labeled as Reserpine, Hydrochlorothiazide and Hydralazine Hydrochloride appears under the active ingredient heading *Hydralazine Hydrochloride; Hydrochlorothiazide; Reserpine*. A cross-reference to the product information (for prescription and OTC products) appears for each additional active ingredient in the product. For combination drug products, the ingredient strengths are separated by semicolons and appear in the same relative sequence as the ingredients in the heading. Available strengths of the dosage form from an applicant appear on separate lines.

To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if necessary. Then, find the ingredient in the applicable Drug Product List. Proceed to the dosage form and route of administration and compare products within that ingredient heading only. Therapeutic equivalence or inequivalence for prescription products is determined on the basis of the therapeutic equivalence codes provided within that specific dosage form and route heading. The OTC Drug Product List, Discontinued Drug Product List, and

Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List have their data arranged similarly.

The Discontinued Drug Product List contains approved products that have never been marketed, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, are for military use, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. All products having a "@" in the December Cumulative Supplement of the previous Edition List have been added to the Discontinued Drug Product List appearing in this Edition. In addition, approved drug products that are not in the commercial distribution channel e.g., approved drug products in applications for export only are also listed in the Discontinued Drug Product List.

Product Name Index *(Prescription and OTC Drug Product Lists)*. This is an index of drug products by trade name or established name of the active ingredient, if no trade name exists. The second term of each entry indicates the active ingredient name under which product information can be found in the appropriate Drug Product List. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. OTC products are so designated.

Product Name Index Listed by Applicant *(Prescription and OTC Drug Product Lists*). This is an index that cross-references applicants to drug products. The bolded and underlined entry represents the applicant name abbreviation used in this publication. Each complete applicant name that is represented by the abbreviated name is marked with an asterisk (*). Listed under each complete applicant name is the first alphabetically arranged ingredient under which product information can be found in the appropriate Drug Product List. OTC products are so designated. To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if appropriate.

Uniform Terms. To improve readability, uniform terms are used to designate dosage forms, routes of administration, and abbreviations used to express strengths. These terms are listed in Appendix C. In some cases, the terms used may differ from those used in product labels and other labeling.

2.2 DRUG PRODUCT ILLUSTRATION

SINGLE INGREDIENT



*NOTE: REFERENCE LISTED DRUG AND REFERENCE STANDARD ARE DISCUSSED IN THE PREFACE SECTION 1.4

MULTIPLE INGREDIENTS WITH PRODUCT INFORMATION



THIS EXAMPLE IS FOR PURPOSE OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

2.3 THERAPEUTIC EQUIVALENCE EVALUATIONS ILLUSTRATION

DRUG PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN **"A"**) UNDER AN INGREDIENT AND DOSAGE FORM HEADING ARE CONSIDERED THERAPEUTICALLY EQUIVALENT ONLY TO OTHER PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN **A")** AND **NOT** TO THOSE CODED **BP** (OR ANY CODE BEGINNING WITH **"B"**) AND ANY PRODUCTS NOT LISTED. DRUG PRODUCTS CODED **BP** (OR ANY CODE BEGINNING WITH A **"B"**) ARE **NOT** CONSIDERED THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCT. FOR A COMPLETE EXPLANATION OF THE **TE** CODES REFER TO SECTION 1.7 OF THE *INTRODUCTION.*



NOTE: BOLD FONT AND UNDERLINING DENOTES MULTISOURCE PRODUCTS WHICH ARE CONSIDERED THERAPEUTICALLY EQUIVALENT.

THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

ABACAVIR SULFATE

SOLUTION;ORAL

ABACAVIR SULFATE

AA		AUROBINDO PHARMA LTD	**EQ 20MG BASE/ML**	**A077950**	**001**	Mar 14, 2018
AA		HETERO LABS LTD III	**EQ 20MG BASE/ML**	**A201107**	**001**	Sep 26, 2016

ZIAGEN

AA	**+!**	VIIV HLTHCARE	**EQ 20MG BASE/ML**	**N020978**	**001**	Dec 17, 1998

TABLET;ORAL

ABACAVIR SULFATE

AB		APOTEX INC	**EQ 300MG BASE**	**A201570**	**001**	Dec 17, 2012
AB		AUROBINDO PHARMA LTD	**EQ 300MG BASE**	**A077844**	**001**	Dec 17, 2012
AB		CIPLA	**EQ 300MG BASE**	**A078119**	**001**	Nov 21, 2017
AB		HETERO LABS LTD III	**EQ 300MG BASE**	**A091560**	**001**	Sep 13, 2013
AB		MYLAN PHARMS INC	**EQ 300MG BASE**	**A091294**	**001**	Jun 18, 2012
AB		STRIDES PHARMA	**EQ 300MG BASE**	**A091050**	**001**	Oct 28, 2016

ZIAGEN

AB	**+!**	VIIV HLTHCARE	**EQ 300MG BASE**	**N020977**	**001**	Dec 17, 1998

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET;ORAL

TRIUMEQ

	+!	VIIV HLTHCARE	EQ 600MG BASE;EQ 50MG BASE;300MG	N205551	001	Aug 22, 2014

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

AB		AUROBINDO PHARMA LTD	**EQ 600MG BASE;300MG**	**A090159**	**001**	Nov 15, 2018
AB			**EQ 600MG BASE;300MG**	**A206151**	**001**	Mar 28, 2017
AB		CIPLA	**EQ 600MG BASE;300MG**	**A091144**	**001**	Mar 28, 2017
AB		LUPIN LTD	**EQ 600MG BASE;300MG**	**A204990**	**001**	Mar 28, 2017
AB		TEVA PHARMS USA	**EQ 600MG BASE;300MG**	**A079246**	**001**	Sep 29, 2016
AB		ZYDUS PHARMS USA INC	**EQ 600MG BASE;300MG**	**A208990**	**001**	Nov 15, 2018

EPZICOM

AB	**+!**	VIIV HLTHCARE	**EQ 600MG BASE;300MG**	**N021652**	**001**	Aug 02, 2004

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE

AB		LUPIN LTD	**EQ 300MG BASE;150MG;300MG**	**A202912**	**001**	Dec 05, 2013

TRIZIVIR

AB	**+!**	VIIV HLTHCARE	**EQ 300MG BASE;150MG;300MG**	**N021205**	**001**	Nov 14, 2000

ABALOPARATIDE

SOLUTION;SUBCUTANEOUS

TYMLOS

	+!	RADIUS HEALTH INC	3.12MG/1.56ML (2MG/ML)	N208743	001	Apr 28, 2017

ABEMACICLIB

TABLET;ORAL

VERZENIO

	+	ELI LILLY AND CO	50MG	N208716	001	Sep 28, 2017
	+		100MG	N208716	002	Sep 28, 2017
	+		150MG	N208716	003	Sep 28, 2017
	+!		200MG	N208716	004	Sep 28, 2017

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

AB		AMNEAL PHARMS	**250MG**	**A208327**	**001**	Jan 07, 2019
AB		APOTEX INC	**250MG**	**A208453**	**001**	Oct 31, 2018
AB		HIKMA PHARMS	**250MG**	**A208339**	**001**	Oct 31, 2018
AB		MYLAN PHARMS INC	**250MG**	**A208446**	**001**	Oct 31, 2018
AB		TEVA PHARMS USA	**250MG**	**A208432**	**001**	Oct 31, 2018

ZYTIGA

AB	**+**	JANSSEN BIOTECH	**250MG**	**N202379**	**001**	Apr 28, 2011

YONSA

	+!	SUN PHARMA GLOBAL	125MG	N210308	001	May 22, 2018

ZYTIGA

	+!	JANSSEN BIOTECH	500MG	N202379	002	Apr 14, 2017

ACALABRUTINIB

CAPSULE;ORAL

CALQUENCE

	+!	ASTRAZENECA	100MG	N210259	001	Oct 31, 2017

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM

AB		BARR LABS DIV TEVA	**333MG**	**A200143**	**001**	Nov 18, 2013
AB	!	GLENMARK GENERICS	**333MG**	**A202229**	**001**	Jul 16, 2013
AB		MYLAN PHARMS INC	**333MG**	**A200142**	**001**	Mar 11, 2014
AB		ZYDUS PHARMS USA INC	**333MG**	**A205995**	**001**	May 26, 2017

ACARBOSE

TABLET;ORAL

ACARBOSE

AB		EMCURE PHARMS LTD	**25MG**	**A202271**	**001**	Feb 07, 2012
AB			**50MG**	**A202271**	**002**	Feb 07, 2012
AB			**100MG**	**A202271**	**003**	Feb 07, 2012
AB		IMPAX LABS	**25MG**	**A078441**	**001**	May 14, 2009
AB			**50MG**	**A078441**	**002**	May 14, 2009
AB			**100MG**	**A078441**	**003**	May 14, 2009
AB		MYLAN	**25MG**	**A091053**	**001**	Jan 06, 2011
AB			**50MG**	**A091053**	**002**	Jan 06, 2011
AB			**100MG**	**A091053**	**003**	Jan 06, 2011
AB		STRIDES PHARMA	**25MG**	**A090912**	**001**	Jul 27, 2011
AB			**50MG**	**A090912**	**002**	Jul 27, 2011
AB			**100MG**	**A090912**	**003**	Jul 27, 2011
AB		VIRTUS PHARM	**25MG**	**A091343**	**001**	Oct 17, 2013
AB			**50MG**	**A091343**	**002**	Oct 17, 2013
AB			**100MG**	**A091343**	**003**	Oct 17, 2013
AB		WATSON LABS	**25MG**	**A077532**	**001**	May 07, 2008
AB			**50MG**	**A077532**	**002**	May 07, 2008
AB			**100MG**	**A077532**	**003**	May 07, 2008
AB		WEST-WARD PHARMS INT	**25MG**	**A078470**	**001**	May 07, 2008
AB			**50MG**	**A078470**	**002**	May 07, 2008
AB			**100MG**	**A078470**	**003**	May 07, 2008

PRECOSE

AB	**+!**	BAYER HLTHCARE	**25MG**	**N020482**	**004**	May 29, 1997
AB	**+**		**50MG**	**N020482**	**001**	Sep 06, 1995
AB	**+**		**100MG**	**N020482**	**002**	Sep 06, 1995

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL

ACEBUTOLOL HYDROCHLORIDE

AB	!	AMNEAL PHARM	**EQ 200MG BASE**	**A075047**	**001**	Dec 30, 1999
AB	!		**EQ 400MG BASE**	**A075047**	**002**	Dec 30, 1999
AB		MYLAN	**EQ 200MG BASE**	**A074288**	**001**	Apr 24, 1995
AB			**EQ 400MG BASE**	**A074288**	**002**	Apr 24, 1995

ACETAMINOPHEN

SOLUTION;INTRAVENOUS

ACETAMINOPHEN

AP		CUSTOPHARM INC	**1GM/100ML (10MG/ML)**	**A202605**	**001**	Jun 13, 2016
AP		SANDOZ INC	**1GM/100ML (10MG/ML)**	**A204052**	**001**	Mar 22, 2016

OFIRMEV

AP	**+!**	MALLINCKRODT HOSP	**1GM/100ML (10MG/ML)**	**N022450**	**001**	Nov 02, 2010

ACETAMINOPHEN

		FRESENIUS KABI USA	1GM/100ML (10MG/ML)	N204767	001	Oct 28, 2015

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET;ORAL

APADAZ

	+	KEMPHARM	325MG;EQ 6.12MG BASE	N208653	001	Feb 23, 2018

ACETAMINOPHEN; BUTALBITAL

CAPSULE;ORAL

BUTALBITAL AND ACETAMINOPHEN

	!	MAYNE PHARMA INC	300MG;50MG	A207313	001	Dec 27, 2017

TABLET;ORAL

BUTALBITAL AND ACETAMINOPHEN

AA		CNTY LINE PHARMS	**300MG;50MG**	**A207635**	**001**	Jun 05, 2017
AA			**325MG;50MG**	**A205120**	**001**	Oct 30, 2015
AA		LARKEN LABS INC	**325MG;50MG**	**A203484**	**002**	Dec 04, 2015

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

BUTALBITAL AND ACETAMINOPHEN

AA		MIKART	**300MG;50MG**	**A207386**	**001**	Nov 15, 2016
AA	**!**	NEXGEN PHARMA	**300MG;50MG**	**A090956**	**001**	Aug 23, 2011

BUTAPAP

AA	**!**	MIKART	**325MG;50MG**	**A089987**	**001**	Oct 26, 1992

ALLZITAL

		LARKEN LABS INC	325MG;25MG	A203484	001	Dec 04, 2015

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA		AUROLIFE PHARMA LLC	**325MG;50MG;40MG**	**A204733**	**001**	Sep 26, 2018
AA	**!**	MAYNE PHARMA INC	**325MG;50MG;40MG**	**A089007**	**001**	Mar 17, 1986
AA	**!**	NEXGEN PHARMA	**300MG;50MG;40MG**	**A040885**	**001**	Nov 16, 2009
AA		NUVO PHARMS INC	**300MG;50MG;40MG**	**A207118**	**001**	Oct 28, 2016
AA		WRASER PHARMS LLC	**300MG;50MG;40MG**	**A206615**	**001**	Aug 04, 2017

SOLUTION;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

	!	MIKART	325MG/15ML;50MG/15ML;40MG/15ML	A040387	001	Jan 31, 2003

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA		ABHAI LLC	**325MG;50MG;40MG**	**A211106**	**001**	Sep 26, 2018
AA		ACTAVIS LABS UT INC	**325MG;50MG;40MG**	**A088616**	**001**	Nov 09, 1984
AA		CNTY LINE PHARMS	**325MG;50MG;40MG**	**A204984**	**001**	Jan 10, 2017
AA		HIKMA PHARMS	**325MG;50MG;40MG**	**A089718**	**001**	Jun 12, 1995
AA		LANNETT CO INC	**325MG;50MG;40MG**	**A200243**	**001**	Sep 13, 2012
AA		MIKART	**325MG;50MG;40MG**	**A089175**	**001**	Jan 21, 1987
AA		NEXGEN PHARMA INC	**325MG;50MG;40MG**	**A209587**	**001**	Oct 31, 2018
AA		SPECGX LLC	**325MG;50MG;40MG**	**A087804**	**001**	Jan 24, 1985
AA	**!**	VINTAGE PHARMS	**325MG;50MG;40MG**	**A040511**	**001**	Aug 27, 2003

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

AB		NEXGEN PHARMA INC	**325MG;50MG;40MG;30MG**	**A076560**	**001**	Jun 10, 2004
AB		VINTAGE PHARMS	**325MG;50MG;40MG;30MG**	**A075929**	**001**	Apr 22, 2002

FIORICET W/ CODEINE

AB	**+!**	ACTAVIS LABS UT INC	**325MG;50MG;40MG;30MG**	**N020232**	**001**	Jul 30, 1992

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

		NEXGEN PHARMA INC	300MG;50MG;40MG;30MG	A076560	002	Jul 19, 2012

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL

TREZIX

		WRASER PHARMS LLC	320.5MG;30MG;16MG	A204785	001	Nov 26, 2014

TABLET;ORAL

ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE

		LARKEN LABS INC	325MG;30MG;16MG	A204209	001	Sep 30, 2016

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		HI TECH PHARMA	**120MG/5ML;12MG/5ML**	**A040119**	**001**	Apr 26, 1996
AA		LANNETT CO INC	**120MG/5ML;12MG/5ML**	**A091238**	**001**	Nov 10, 2011
AA		MIKART	**120MG/5ML;12MG/5ML**	**A089450**	**001**	Oct 27, 1992
AA	**!**	PHARM ASSOC	**120MG/5ML;12MG/5ML**	**A087508**	**001**	
AA		WOCKHARDT BIO AG	**120MG/5ML;12MG/5ML**	**A087006**	**001**	

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		AMNEAL PHARMS NY	**300MG;30MG**	**A040779**	**001**	May 29, 2008
AA		AUROLIFE PHARMA LLC	**300MG;15MG**	**A202800**	**001**	Apr 15, 2013
AA			**300MG;30MG**	**A202800**	**002**	Apr 15, 2013
AA			**300MG;60MG**	**A202800**	**003**	Apr 15, 2013
AA	**!**	SPECGX LLC	**300MG;15MG**	**A040419**	**001**	May 31, 2001
AA			**300MG;30MG**	**A040419**	**002**	May 31, 2001
AA			**300MG;60MG**	**A040419**	**003**	May 31, 2001
AA		SUN PHARM INDS LTD	**300MG;30MG**	**A085868**	**001**	
AA			**300MG;60MG**	**A087083**	**001**	
AA		TEVA	**300MG;15MG**	**A088627**	**001**	Mar 06, 1985
AA			**300MG;30MG**	**A088628**	**001**	Mar 06, 1985
AA	**!**		**300MG;60MG**	**A088629**	**001**	Mar 06, 1985
AA		VINTAGE	**300MG;15MG**	**A089990**	**001**	Sep 30, 1988

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA			**300MG;30MG**	**A089805**	**001**	Sep 30, 1988
AA		VINTAGE PHARMS	**300MG;60MG**	**A089828**	**001**	Sep 30, 1988

TYLENOL W/ CODEINE NO. 3

AA	**!**	JANSSEN PHARMS	**300MG;30MG**	**A085055**	**003**	

TYLENOL W/ CODEINE NO. 4

AA		JANSSEN PHARMS	**300MG;60MG**	**A085055**	**004**	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		GENUS LIFESCIENCES	**325MG/15ML;7.5MG/15ML**	**A040894**	**001**	Jul 19, 2011
AA	**!**	MIKART	**325MG/15ML;7.5MG/15ML**	**A040482**	**001**	Sep 25, 2003
AA		PHARM ASSOC	**325MG/15ML;7.5MG/15ML**	**A040838**	**001**	May 10, 2013
AA		VISTAPHARM	**325MG/15ML;7.5MG/15ML**	**A200343**	**001**	Jan 25, 2012
	!	MIKART	300MG/15ML;10MG/15ML	A040881	001	Feb 25, 2010
	!	PHARM ASSOC	325MG/15ML;10MG/15ML	A040834	001	Apr 18, 2008

TABLET;ORAL

ANEXSIA 5/325

AA		SPECGX LLC	**325MG;5MG**	**A040409**	**001**	Oct 20, 2000

ANEXSIA 7.5/325

AA		SPECGX LLC	**325MG;7.5MG**	**A040405**	**001**	Sep 08, 2000

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		ABHAI LLC	**300MG;5MG**	**A209036**	**001**	Jun 21, 2017
AA			**300MG;7.5MG**	**A209036**	**002**	Jun 21, 2017
AA			**300MG;10MG**	**A209036**	**003**	Jun 21, 2017
AA			**325MG;5MG**	**A209037**	**001**	Jun 21, 2017
AA			**325MG;7.5MG**	**A209037**	**002**	Jun 21, 2017
AA			**325MG;10MG**	**A209037**	**003**	Jun 21, 2017
AA		ACTAVIS LABS FL INC	**300MG;5MG**	**A206470**	**001**	Jun 02, 2016
AA			**300MG;7.5MG**	**A206470**	**002**	Jun 02, 2016
AA			**300MG;10MG**	**A206470**	**003**	Jun 02, 2016
AA		ALVOGEN PINE BROOK	**300MG;5MG**	**A208540**	**001**	Nov 08, 2018
AA			**300MG;7.5MG**	**A208540**	**002**	Nov 08, 2018
AA			**300MG;10MG**	**A208540**	**003**	Nov 08, 2018
AA			**325MG;2.5MG**	**A209958**	**001**	Oct 24, 2018
AA			**325MG;5MG**	**A209958**	**002**	Oct 24, 2018
AA			**325MG;7.5MG**	**A209958**	**003**	Oct 24, 2018
AA			**325MG;10MG**	**A209958**	**004**	Oct 24, 2018
AA		AMNEAL PHARMS	**300MG;10MG**	**A207137**	**001**	Nov 29, 2016
AA		AMNEAL PHARMS NY	**300MG;5MG**	**A206869**	**001**	Jun 23, 2017
AA			**325MG;5MG**	**A040736**	**001**	Aug 25, 2006
AA			**325MG;7.5MG**	**A040746**	**002**	May 10, 2016
AA			**325MG;10MG**	**A040746**	**001**	Aug 25, 2006
AA		ASCENT PHARMS INC	**325MG;2.5MG**	**A211487**	**001**	Nov 07, 2018
AA			**325MG;5MG**	**A211487**	**002**	Nov 07, 2018
AA			**325MG;7.5MG**	**A211487**	**003**	Nov 07, 2018
AA			**325MG;10MG**	**A211487**	**004**	Nov 07, 2018
AA		AUROLIFE PHARMA LLC	**300MG;5MG**	**A207709**	**001**	Sep 13, 2018
AA			**300MG;7.5MG**	**A207709**	**002**	Sep 13, 2018
AA			**300MG;10MG**	**A207709**	**003**	Sep 13, 2018
AA			**325MG;5MG**	**A201013**	**001**	Apr 11, 2012
AA			**325MG;7.5MG**	**A201013**	**002**	Apr 11, 2012
AA			**325MG;10MG**	**A201013**	**003**	Apr 11, 2012
AA		ELITE LABS INC	**325MG;2.5MG**	**A209924**	**001**	Nov 16, 2018
AA			**325MG;5MG**	**A209924**	**002**	Nov 16, 2018
AA			**325MG;7.5MG**	**A209924**	**003**	Nov 16, 2018
AA			**325MG;10MG**	**A209924**	**004**	Nov 16, 2018
AA		EPIC PHARMA LLC	**325MG;5MG**	**A203863**	**001**	Mar 30, 2018
AA			**325MG;7.5MG**	**A203863**	**002**	Mar 30, 2018
AA			**325MG;10MG**	**A203863**	**003**	Mar 30, 2018
AA		LANNETT CO INC	**300MG;5MG**	**A207171**	**001**	Jun 20, 2017
AA			**300MG;7.5MG**	**A207171**	**002**	Jun 20, 2017
AA			**300MG;10MG**	**A207171**	**003**	Jun 20, 2017
AA			**325MG;5MG**	**A207172**	**001**	Jun 22, 2017
AA			**325MG;7.5MG**	**A207172**	**002**	Jun 22, 2017
AA			**325MG;10MG**	**A207172**	**003**	Jun 22, 2017
AA	**!**	MIKART	**300MG;5MG**	**A040658**	**001**	Jan 19, 2006
AA	**!**		**300MG;7.5MG**	**A040658**	**002**	Mar 24, 2006
AA	**!**		**300MG;10MG**	**A040658**	**003**	Jun 23, 2004
AA	**!**		**325MG;2.5MG**	**A040846**	**001**	Jun 09, 2010

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA			**325MG;7.5MG**	**A040432**	**001**	Jan 22, 2003
AA		NOVEL LABS INC	**300MG;5MG**	**A206142**	**001**	Nov 14, 2016
AA			**300MG;7.5MG**	**A206142**	**002**	Nov 14, 2016
AA			**300MG;10MG**	**A206142**	**003**	Nov 14, 2016
AA			**325MG;5MG**	**A206245**	**001**	Dec 01, 2016
AA			**325MG;7.5MG**	**A206245**	**002**	Dec 01, 2016
AA			**325MG;10MG**	**A206245**	**003**	Dec 01, 2016
AA		PAR PHARM	**300MG;5MG**	**A205001**	**001**	Jul 05, 2016
AA			**300MG;7.5MG**	**A205001**	**002**	Jul 05, 2016
AA			**300MG;10MG**	**A205001**	**003**	Jul 05, 2016
AA			**325MG;5MG**	**A202935**	**002**	Jun 15, 2016
AA			**325MG;7.5MG**	**A202935**	**003**	Jun 15, 2016
AA			**325MG;10MG**	**A202935**	**004**	Jun 15, 2016
AA		RHODES PHARMS	**300MG;5MG**	**A207808**	**001**	Mar 30, 2018
AA			**300MG;7.5MG**	**A207808**	**002**	Mar 30, 2018
AA			**300MG;10MG**	**A207808**	**003**	Mar 30, 2018
AA			**325MG;5MG**	**A202991**	**001**	Apr 12, 2016
AA			**325MG;7.5MG**	**A202991**	**002**	Apr 12, 2016
AA			**325MG;10MG**	**A202991**	**003**	Apr 12, 2016
AA		SPECGX LLC	**300MG;5MG**	**A206718**	**001**	Mar 31, 2017
AA			**300MG;7.5MG**	**A206718**	**002**	Mar 31, 2017
AA			**300MG;10MG**	**A206718**	**003**	Mar 31, 2017
AA			**325MG;10MG**	**A040400**	**001**	Jul 26, 2000
AA		SUN PHARM INDS INC	**325MG;5MG**	**A090118**	**001**	Dec 23, 2008
AA			**325MG;7.5MG**	**A090118**	**002**	Dec 23, 2008
AA			**325MG;10MG**	**A090118**	**003**	Dec 23, 2008
AA		TRIS PHARMA INC	**300MG;5MG**	**A202214**	**004**	Mar 15, 2016
AA			**300MG;7.5MG**	**A202214**	**005**	Mar 15, 2016
AA			**300MG;10MG**	**A202214**	**006**	Mar 15, 2016
AA			**325MG;5MG**	**A202214**	**001**	Mar 27, 2013
AA			**325MG;7.5MG**	**A202214**	**002**	Mar 27, 2013
AA			**325MG;10MG**	**A202214**	**003**	Mar 27, 2013
AA		UPSHER SMITH LABS	**325MG;5MG**	**A206484**	**001**	Mar 24, 2017
AA			**325MG;7.5MG**	**A206484**	**002**	Mar 24, 2017
AA			**325MG;10MG**	**A206484**	**003**	Mar 24, 2017
AA		VINTAGE PHARMS	**300MG;5MG**	**A090415**	**001**	Jan 24, 2011
AA			**300MG;7.5MG**	**A090415**	**002**	Jan 24, 2011
AA			**300MG;10MG**	**A090415**	**003**	Jan 24, 2011
AA			**325MG;5MG**	**A040655**	**001**	Jan 19, 2006
AA			**325MG;7.5MG**	**A040656**	**001**	Jan 19, 2006
AA			**325MG;10MG**	**A040355**	**001**	May 31, 2000
AA		WES PHARMA INC	**300MG;5MG**	**A207509**	**001**	Oct 29, 2018
AA			**300MG;7.5MG**	**A207509**	**002**	Oct 29, 2018
AA			**300MG;10MG**	**A207509**	**003**	Oct 29, 2018
AA			**325MG;5MG**	**A210211**	**001**	Oct 30, 2017
AA			**325MG;7.5MG**	**A210211**	**002**	Oct 30, 2017
AA			**325MG;10MG**	**A210211**	**003**	Oct 30, 2017

NORCO

AA		APIL	**325MG;2.5MG**	**A040148**	**004**	Jul 07, 2014
AA	**!**		**325MG;5MG**	**A040099**	**001**	Jun 25, 1997
AA			**325MG;5MG**	**A040148**	**005**	Jul 07, 2014
AA	**!**		**325MG;7.5MG**	**A040148**	**003**	Sep 12, 2000
AA	**!**		**325MG;10MG**	**A040148**	**001**	Feb 14, 1997

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

	!	ABHAI LLC	325MG/5ML;5MG/5ML	A211499	001	Dec 31, 2018
		MIKART INC	300MG/5ML;10MG/5ML	A202142	001	Nov 27, 2018

TABLET;ORAL

OXYCET

AA		SPECGX LLC	**325MG;5MG**	**A087463**	**001**	Dec 07, 1983

OXYCODONE AND ACETAMINOPHEN

AA		ABHAI LLC	**325MG;2.5MG**	**A210644**	**001**	Feb 09, 2018
AA			**325MG;5MG**	**A210644**	**002**	Feb 09, 2018
AA			**325MG;7.5MG**	**A210644**	**003**	Feb 09, 2018
AA			**325MG;10MG**	**A210644**	**004**	Feb 09, 2018
AA		ACTAVIS ELIZABETH	**325MG;2.5MG**	**A201447**	**001**	Apr 12, 2013
AA			**325MG;5MG**	**A201447**	**002**	Apr 12, 2013
AA			**325MG;7.5MG**	**A201447**	**003**	Apr 12, 2013

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

AA			**325MG;10MG**	**A201447**	**004**	Apr 12, 2013
AA		ALVOGEN MALTA	**325MG;5MG**	**A202677**	**003**	Mar 08, 2016
AA			**325MG;7.5MG**	**A202677**	**001**	Jul 26, 2012
AA			**325MG;10MG**	**A202677**	**002**	Jul 26, 2012
AA		AMNEAL PHARMS	**325MG;5MG**	**A040777**	**001**	Nov 27, 2007
AA		AMNEAL PHARMS NY	**325MG;7.5MG**	**A040778**	**002**	Jun 27, 2014
AA			**325MG;10MG**	**A040778**	**001**	Nov 27, 2007
AA		ASCENT PHARMS INC	**325MG;2.5MG**	**A207419**	**001**	Mar 22, 2017
AA			**325MG;5MG**	**A207419**	**002**	Mar 22, 2017
AA			**325MG;7.5MG**	**A207419**	**003**	Mar 22, 2017
AA			**325MG;10MG**	**A207419**	**004**	Mar 22, 2017
AA		AUROLIFE PHARMA LLC	**325MG;2.5MG**	**A201972**	**001**	Jul 15, 2013
AA			**325MG;5MG**	**A201972**	**002**	Jul 15, 2013
AA			**325MG;7.5MG**	**A201972**	**003**	Jul 15, 2013
AA			**325MG;10MG**	**A201972**	**004**	Jul 15, 2013
AA		CHEMO RESEARCH SL	**325MG;5MG**	**A207574**	**001**	Dec 13, 2016
AA		ELITE LABS INC	**325MG;5MG**	**A209385**	**001**	Jul 02, 2018
AA			**325MG;7.5MG**	**A209385**	**002**	Jul 02, 2018
AA			**325MG;10MG**	**A209385**	**003**	Jul 02, 2018
AA		EPIC PHARMA LLC	**325MG;5MG**	**A203864**	**001**	Jul 02, 2018
AA			**325MG;7.5MG**	**A203864**	**002**	Jul 02, 2018
AA			**325MG;10MG**	**A203864**	**003**	Jul 02, 2018
AA		LANNETT CO INC	**325MG;5MG**	**A207333**	**001**	Sep 25, 2017
AA			**325MG;10MG**	**A207333**	**002**	Sep 25, 2017
AA		MAYNE PHARMA INC	**325MG;2.5MG**	**A090177**	**001**	Oct 20, 2008
AA			**325MG;5MG**	**A090177**	**002**	Oct 20, 2008
AA			**325MG;7.5MG**	**A090177**	**003**	Oct 20, 2008
AA			**325MG;10MG**	**A090177**	**004**	Oct 20, 2008
AA		NESHER PHARMS	**325MG;2.5MG**	**A210079**	**001**	Dec 28, 2017
AA			**325MG;5MG**	**A210079**	**002**	Dec 28, 2017
AA			**325MG;7.5MG**	**A210079**	**003**	Dec 28, 2017
AA			**325MG;10MG**	**A210079**	**004**	Dec 28, 2017
AA		NOVEL LABS INC	**325MG;2.5MG**	**A204407**	**001**	Feb 24, 2017
AA			**325MG;5MG**	**A204407**	**002**	Feb 24, 2017
AA			**325MG;7.5MG**	**A204407**	**003**	Feb 24, 2017
AA			**325MG;10MG**	**A204407**	**004**	Feb 24, 2017
AA		RHODES PHARMS	**325MG;5MG**	**A201278**	**001**	Aug 28, 2014
AA			**325MG;7.5MG**	**A201278**	**002**	Aug 28, 2014
AA			**325MG;10MG**	**A201278**	**003**	Aug 28, 2014
AA		SPECGX LLC	**325MG;7.5MG**	**A040545**	**001**	Jun 30, 2004
AA			**325MG;10MG**	**A040545**	**002**	Jun 30, 2004
AA		SUN PHARM INDS INC	**325MG;2.5MG**	**A090535**	**001**	Dec 26, 2013
AA			**325MG;5MG**	**A090535**	**002**	Dec 26, 2013
AA			**325MG;7.5MG**	**A090535**	**003**	Dec 26, 2013
AA			**325MG;10MG**	**A090535**	**004**	Dec 26, 2013
AA		VINTAGE PHARMS	**325MG;2.5MG**	**A090733**	**001**	Jul 11, 2013
AA			**325MG;5MG**	**A040105**	**001**	Jul 30, 1996
AA			**325MG;7.5MG**	**A090734**	**001**	Jul 11, 2013
AA			**325MG;10MG**	**A090734**	**002**	Jul 11, 2013
AA		WATSON LABS	**325MG;5MG**	**A040171**	**001**	Oct 30, 1997
AA			**325MG;7.5MG**	**A040535**	**001**	Sep 05, 2003
AA			**325MG;10MG**	**A040535**	**002**	Sep 05, 2003
AA		WES PHARMA INC	**325MG;5MG**	**A207510**	**001**	Mar 21, 2018
AA			**325MG;7.5MG**	**A207510**	**002**	Mar 21, 2018
AA			**325MG;10MG**	**A207510**	**003**	Mar 21, 2018

PERCOCET

AA	**!**	VINTAGE PHARMS LLC	**325MG;2.5MG**	**A040330**	**001**	Jun 25, 1999
AA	**!**		**325MG;5MG**	**A040330**	**002**	Jun 25, 1999
AA	**!**		**325MG;7.5MG**	**A040330**	**003**	Nov 23, 2001
AA	**!**		**325MG;10MG**	**A040330**	**004**	Nov 23, 2001

ROXICET

AA		WEST-WARD PHARMS INT	**325MG;5MG**	**A087003**	**001**	

OXYCODONE AND ACETAMINOPHEN

	!	MIKART	300MG;2.5MG	A040608	001	Dec 30, 2005
	!		300MG;5MG	A040608	002	Dec 30, 2005
	!		300MG;7.5MG	A040608	003	Dec 30, 2005
	!		300MG;10MG	A040608	004	Dec 30, 2005

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB		ALKEM LABS LTD	**325MG;37.5MG**	**A202076**	**001**	Mar 30, 2012
AB		AMNEAL PHARMS	**325MG;37.5MG**	**A090485**	**001**	Dec 09, 2009
AB		APOTEX INC	**325MG;37.5MG**	**A078778**	**001**	Apr 07, 2014
AB		AUROBINDO PHARMA LTD	**325MG;37.5MG**	**A207152**	**001**	Mar 22, 2017
AB		MACLEODS PHARMS LTD	**325MG;37.5MG**	**A206885**	**001**	May 02, 2017
AB		MICRO LABS LTD INDIA	**325MG;37.5MG**	**A201952**	**001**	Dec 14, 2012
AB		MYLAN	**325MG;37.5MG**	**A077858**	**001**	Sep 26, 2008
AB		PAR PHARM	**325MG;37.5MG**	**A076475**	**001**	Apr 21, 2005
AB		SUN PHARM INDS INC	**325MG;37.5MG**	**A077184**	**001**	Dec 16, 2005
AB		ZYDUS PHARMS USA INC	**325MG;37.5MG**	**A090460**	**001**	Sep 06, 2012

ULTRACET

AB	**+!**	JANSSEN PHARMS	**325MG;37.5MG**	**N021123**	**001**	Aug 15, 2001

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

AB		ACCORD HLTHCARE	**500MG**	**A207659**	**001**	Oct 18, 2018
AB		HERITAGE PHARMS INC	**500MG**	**A090779**	**001**	Jul 14, 2011
AB		NOSTRUM LABS INC	**500MG**	**A204691**	**001**	Mar 29, 2016
AB		NOVAST LABS	**500MG**	**A203434**	**001**	Sep 30, 2016
AB		XYLOPIA	**500MG**	**A205301**	**001**	Jan 16, 2019
AB		ZYDUS PHARMS USA INC	**500MG**	**A040904**	**001**	Dec 10, 2008

DIAMOX

AB	**+!**	TEVA BRANDED PHARM	**500MG**	**N012945**	**001**	

TABLET;ORAL

ACETAZOLAMIDE

AB		HERITAGE PHARMA	**125MG**	**A205530**	**001**	Oct 27, 2016
AB			**250MG**	**A205530**	**002**	Oct 27, 2016
AB		LANNETT	**250MG**	**A084840**	**001**	
AB		STRIDES PHARMA	**125MG**	**A209734**	**001**	Nov 20, 2017
AB			**250MG**	**A209734**	**002**	Nov 20, 2017
AB		SUN PHARM INDUSTRIES	**125MG**	**A089753**	**002**	Jun 22, 1988
AB		TARO	**125MG**	**A040195**	**001**	May 28, 1997
AB	**!**		**250MG**	**A040195**	**002**	May 28, 1997

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

AP		EMCURE PHARMS LTD	**EQ 500MG BASE/VIAL**	**A202693**	**001**	Dec 19, 2014
AP		MYLAN ASI	**EQ 500MG BASE/VIAL**	**A200880**	**001**	May 09, 2012
AP		PAR STERILE PRODUCTS	**EQ 500MG BASE/VIAL**	**A205358**	**001**	Jun 20, 2017
AP		WEST-WARD PHARMS INT	**EQ 500MG BASE/VIAL**	**A040089**	**001**	Feb 28, 1995
AP	**!**	X GEN PHARMS	**EQ 500MG BASE/VIAL**	**A040784**	**001**	Dec 10, 2008

ACETIC ACID, GLACIAL

SOLUTION;IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT		B BRAUN	**250MG/100ML**	**N018161**	**001**	
AT		BAXTER HLTHCARE	**250MG/100ML**	**N018523**	**001**	Feb 19, 1982
AT	**+!**	ICU MEDICAL INC	**250MG/100ML**	**N017656**	**001**	

SOLUTION/DROPS;OTIC

ACETIC ACID

AT		LANNETT CO INC	**2%**	**A040607**	**001**	Feb 24, 2005
AT		RISING PHARMS	**2%**	**A207280**	**001**	Mar 09, 2018
AT		TARO	**2%**	**A088638**	**001**	Sep 06, 1984
AT	**!**	WOCKHARDT BIO AG	**2%**	**A040166**	**001**	Jul 26, 1996

VOSOL

AT		HI TECH PHARMA	**2%**	**N012179**	**001**	

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC

ACETASOL HC

AT		ACTAVIS MID ATLANTIC	**2%;1%**	**A087143**	**001**	Jan 13, 1982

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC

HYDROCORTISONE AND ACETIC ACID

AT		TARO PHARM INDS LTD	**2%;1%**	**A088759**	**001**	Mar 04, 1985
AT		VINTAGE	**2%;1%**	**A040609**	**001**	Feb 06, 2006

VOSOL HC

AT	**+!**	HI TECH PHARMA	**2%;1%**	**N012770**	**001**	

ACETOHYDROXAMIC ACID

TABLET;ORAL

LITHOSTAT

	+!	MISSION PHARMA	250MG	N018749	001	May 31, 1983

ACETYLCHOLINE CHLORIDE

FOR SOLUTION;OPHTHALMIC

MIOCHOL-E

	+!	BAUSCH AND LOMB	20MG/VIAL	N020213	001	Sep 22, 1993

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETADOTE

AP	**+!**	CUMBERLAND PHARMS	**6GM/30ML (200MG/ML)**	**N021539**	**001**	Jan 23, 2004

ACETYLCYSTEINE

AP		AKORN INC	**6GM/30ML (200MG/ML)**	**A203173**	**001**	Mar 24, 2015
AP		AUROBINDO PHARMA LTD	**6GM/30ML (200MG/ML)**	**A207358**	**001**	Feb 29, 2016
AP		FRESENIUS KABI USA	**6GM/30ML (200MG/ML)**	**A200644**	**001**	Nov 07, 2012
AP		MYLAN INSTITUTIONAL	**6GM/30ML (200MG/ML)**	**A203624**	**001**	Jun 19, 2015
AP		SAGENT PHARMS	**6GM/30ML (200MG/ML)**	**A091684**	**001**	Oct 31, 2017
AP		ZYDUS PHARMS USA INC	**6GM/30ML (200MG/ML)**	**A208166**	**001**	Jul 20, 2018

SOLUTION;INHALATION, ORAL

ACETYLCYSTEINE

AN		ALVOGEN INC	**10%**	**A204674**	**001**	Feb 11, 2014
AN			**20%**	**A203853**	**001**	Jun 21, 2012
AN		HOSPIRA	**10%**	**A073664**	**001**	Aug 30, 1994
AN			**20%**	**A074037**	**001**	Aug 30, 1994
AN	**!**	LUITPOLD	**10%**	**A072489**	**001**	Jul 28, 1995
AN	**!**		**20%**	**A072547**	**001**	Jul 28, 1995

TABLET, EFFERVESCENT;ORAL

CETYLEV

	+	ARBOR PHARMS LLC	500MG	N207916	001	Jan 29, 2016
	+!		2.5GM	N207916	002	Jan 29, 2016

ACITRETIN

CAPSULE;ORAL

ACITRETIN

AB		BARR LABS INC	**10MG**	**A091455**	**001**	Apr 04, 2013
AB			**25MG**	**A091455**	**002**	Apr 04, 2013
AB		IMPAX LABS INC	**10MG**	**A202552**	**001**	Dec 23, 2015
AB			**17.5MG**	**A202552**	**002**	Dec 23, 2015
AB			**22.5MG**	**A202552**	**003**	Dec 23, 2015
AB			**25MG**	**A202552**	**004**	Dec 23, 2015
AB		MYLAN PHARMS INC	**10MG**	**A202148**	**001**	Sep 10, 2015
AB			**25MG**	**A202148**	**002**	Sep 10, 2015
AB		SIGMAPHARM LABS LLC	**10MG**	**A204633**	**001**	May 22, 2015
AB			**17.5MG**	**A204633**	**002**	May 22, 2015
AB			**22.5MG**	**A204633**	**003**	May 22, 2015
AB			**25MG**	**A204633**	**004**	May 22, 2015
AB		TEVA PHARMS USA	**17.5MG**	**A202897**	**001**	Apr 04, 2013
AB			**22.5MG**	**A202897**	**002**	Apr 04, 2013

SORIATANE

AB	**+**	STIEFEL LABS INC	**10MG**	**N019821**	**001**	Oct 28, 1996
AB	**+**		**17.5MG**	**N019821**	**003**	Aug 06, 2009
AB	**+**		**22.5MG**	**N019821**	**004**	Aug 06, 2009
AB	**+!**		**25MG**	**N019821**	**002**	Oct 28, 1996

ACLIDINIUM BROMIDE

POWDER, METERED;INHALATION

TUDORZA PRESSAIR

	+!	ASTRAZENECA PHARMS	0.4MG/INH	N202450	001	Jul 23, 2012

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL

SEMPREX-D

	+!	AUXILIUM PHARMS LLC	8MG;60MG	N019806	001	Mar 25, 1994

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

AB	!	APOTEX INC	**200MG**	**A075677**	**001**	Sep 28, 2005
AB		BOSCOGEN	**200MG**	**A075090**	**001**	Jan 26, 1999
AB		CADILA PHARMS LTD	**200MG**	**A201445**	**001**	Mar 06, 2014
AB		CARLSBAD TECHNOLOGY	**200MG**	**A206261**	**001**	Aug 16, 2017
AB		DAVA PHARMS INC	**200MG**	**A074833**	**001**	Apr 22, 1997
AB		HERITAGE PHARMS INC	**200MG**	**A074889**	**001**	Oct 31, 1997
AB		TEVA	**200MG**	**A074578**	**001**	Apr 22, 1997
AB		ZYDUS PHARMS USA INC	**200MG**	**A204313**	**001**	Mar 25, 2016

ZOVIRAX

AB	+	MYLAN PHARMS INC	**200MG**	**N018828**	**001**	Jan 25, 1985

CREAM;TOPICAL

ZOVIRAX

	+!	VIB	5%	N021478	001	Dec 30, 2002

OINTMENT;TOPICAL

ACYCLOVIR

AB		ALEMBIC PHARMS LTD	**5%**	**A209000**	**001**	Apr 06, 2018
AB		AMNEAL PHARMS	**5%**	**A204605**	**001**	Jun 18, 2014
AB		FOUGERA PHARMS INC	**5%**	**A206633**	**001**	May 11, 2016
AB		G AND W LABS INC	**5%**	**A205591**	**001**	Nov 13, 2017
AB		GLENMARK PHARMS LTD	**5%**	**A205510**	**001**	Jul 31, 2017
AB		MYLAN PHARMS INC	**5%**	**A202459**	**001**	Apr 03, 2013
AB		TARO	**5%**	**A205469**	**001**	Dec 21, 2016
AB		TOLMAR	**5%**	**A206437**	**001**	Jul 31, 2017
AB		TORRENT PHARMS LTD	**5%**	**A209971**	**001**	Jan 11, 2019

ZOVIRAX

AB	**+!**	VALEANT BERMUDA	**5%**	**N018604**	**001**	Mar 29, 1982

SUSPENSION;ORAL

ACYCLOVIR

AB		ACTAVIS MID ATLANTIC	**200MG/5ML**	**A074738**	**001**	Apr 28, 1997
AB		HI TECH PHARMA	**200MG/5ML**	**A077026**	**001**	Jun 07, 2005

ZOVIRAX

AB	**+!**	MYLAN PHARMS INC	**200MG/5ML**	**N019909**	**001**	Dec 22, 1989

TABLET;BUCCAL

SITAVIG

	+!	EPI HLTH	50MG	N203791	001	Apr 12, 2013

TABLET;ORAL

ACYCLOVIR

AB		APOTEX INC	**400MG**	**A077309**	**001**	Sep 29, 2005
AB			**800MG**	**A077309**	**002**	Sep 29, 2005
AB		CADILA PHARMS LTD	**400MG**	**A202168**	**001**	Nov 15, 2013
AB			**800MG**	**A202168**	**002**	Nov 15, 2013
AB		CARLSBAD	**400MG**	**A075382**	**001**	Apr 30, 1999
AB			**800MG**	**A075382**	**002**	Apr 30, 1999
AB		DAVA PHARMS INC	**400MG**	**A074946**	**001**	Nov 19, 1997
AB			**800MG**	**A074946**	**002**	Nov 19, 1997
AB		HERITAGE PHARMS INC	**400MG**	**A074891**	**001**	Oct 31, 1997
AB			**800MG**	**A074891**	**002**	Oct 31, 1997
AB		HETERO LABS LTD V	**400MG**	**A203834**	**001**	Oct 29, 2013
AB			**800MG**	**A203834**	**002**	Oct 29, 2013
AB		TEVA	**400MG**	**A074556**	**002**	Apr 22, 1997
AB			**800MG**	**A074556**	**003**	Apr 22, 1997
AB		YILING PHARM LTD	**400MG**	**A210401**	**001**	Mar 07, 2018
AB			**800MG**	**A210401**	**002**	Mar 07, 2018
AB		ZYDUS PHARMS USA INC	**400MG**	**A204314**	**001**	Aug 19, 2014
AB			**800MG**	**A204314**	**002**	Aug 19, 2014

ZOVIRAX

AB	+	MYLAN PHARMS INC	**400MG**	**N020089**	**001**	Apr 30, 1991
AB	**+!**		**800MG**	**N020089**	**002**	Apr 30, 1991

ACYCLOVIR SODIUM						
INJECTABLE;INJECTION						
ACYCLOVIR SODIUM						
AP		AUROBINDO PHARMA LTD	**EQ 50MG BASE/ML**	**A203701**	**001**	Oct 11, 2013
AP	**!**	FRESENIUS KABI USA	**EQ 50MG BASE/ML**	**A074930**	**001**	May 13, 1998
		ZYDUS PHARMS USA INC	EQ 500MG BASE/VIAL	A206535	001	Aug 31, 2018
			EQ 1GM BASE/VIAL	A206535	002	Aug 31, 2018
ACYCLOVIR; HYDROCORTISONE						
CREAM;TOPICAL						
XERESE						
	+!	VALEANT BERMUDA	5%;1%	N022436	001	Jul 31, 2009
ADAPALENE						
CREAM;TOPICAL						
ADAPALENE						
AB		FOUGERA PHARMS	**0.1%**	**A090824**	**001**	Jun 30, 2010
DIFFERIN						
AB	**+!**	GALDERMA LABS LP	**0.1%**	**N020748**	**001**	May 26, 2000
GEL;TOPICAL						
ADAPALENE						
AB		ACTAVIS MID ATLANTIC	**0.3%**	**A201000**	**001**	Oct 27, 2014
AB		GLENMARK GENERICS	**0.1%**	**A091314**	**001**	Jul 01, 2010
AB		PLIVA HRVATSKA DOO	**0.1%**	**A090962**	**001**	Jun 02, 2010
AB		TARO	**0.3%**	**A208322**	**001**	Jun 23, 2016
AB		TOLMAR	**0.3%**	**A200298**	**001**	Jun 14, 2012
DIFFERIN						
AB	**+!**	GALDERMA LABS LP	**0.3%**	**N021753**	**001**	Jun 19, 2007
LOTION;TOPICAL						
DIFFERIN						
	+!	GALDERMA LABS LP	0.1%	N022502	001	Mar 17, 2010
SOLUTION;TOPICAL						
ADAPALENE						
AB		CALL INC	**0.1%**	**A203981**	**001**	Sep 23, 2016
AB			**0.1%**	**A204593**	**001**	Jan 05, 2016
ADAPALENE; BENZOYL PEROXIDE						
GEL;TOPICAL						
ADAPALENE AND BENZOYL PEROXIDE						
AB		ACTAVIS MID ATLANTIC	**0.1%;2.5%**	**A203790**	**001**	Sep 30, 2015
AB		PERRIGO ISRAEL	**0.1%;2.5%**	**A205033**	**001**	Jan 23, 2018
AB		TARO	**0.1%;2.5%**	**A206959**	**001**	Jan 24, 2018
AB			**0.3%;2.5%**	**A209148**	**001**	Oct 17, 2018
AB		TOLMAR	**0.1%;2.5%**	**A206164**	**001**	May 23, 2018
EPIDUO						
AB	**+!**	GALDERMA LABS LP	**0.1%;2.5%**	**N022320**	**001**	Dec 08, 2008
EPIDUO FORTE						
AB	**+!**	GALDERMA LABS	**0.3%;2.5%**	**N207917**	**001**	Jul 15, 2015
ADEFOVIR DIPIVOXIL						
TABLET;ORAL						
ADEFOVIR DIPIVOXIL						
AB		APOTEX INC	**10MG**	**A205459**	**001**	Jul 06, 2018
AB		SIGMAPHARM LABS LLC	**10MG**	**A202051**	**001**	Aug 29, 2013
HEPSERA						
AB	**+!**	GILEAD	**10MG**	**N021449**	**001**	Sep 20, 2002
ADENOSINE						
INJECTABLE;INJECTION						
ADENOSINE						
AP	**!**	AKORN	**3MG/ML**	**A078076**	**001**	Oct 31, 2008
AP		FRESENIUS KABI USA	**3MG/ML**	**A077133**	**001**	Apr 27, 2005
AP			**3MG/ML**	**A205568**	**001**	Apr 16, 2018
AP		GLAND PHARMA LTD	**3MG/ML**	**A077283**	**001**	Jun 14, 2007
AP			**3MG/ML**	**A206778**	**001**	Feb 16, 2018
AP		LUITPOLD	**3MG/ML**	**A090010**	**001**	Apr 28, 2009
AP		MYLAN LABS LTD	**3MG/ML**	**A078640**	**001**	Mar 21, 2014
AP			**3MG/ML**	**A078686**	**001**	May 13, 2009
AP		WEST-WARD PHARMS INT	**3MG/ML**	**A076404**	**001**	Jun 16, 2004
AP			**3MG/ML**	**A076500**	**001**	Jun 16, 2004

ADENOSINE							
SOLUTION;INTRAVENOUS							
ADENOSINE							
AP		AKORN	**60MG/20ML (3MG/ML)**	**A090450**	**001**	Oct 02, 2014
AP			**90MG/30ML (3MG/ML)**	**A090450**	**002**	Oct 02, 2014
AP		AUROBINDO PHARMA LTD	**60MG/20ML (3MG/ML)**	**A205331**	**001**	Nov 02, 2017
AP			**90MG/30ML (3MG/ML)**	**A205331**	**002**	Nov 02, 2017
AP		EMCURE PHARMS LTD	**60MG/20ML (3MG/ML)**	**A202313**	**001**	Sep 15, 2014
AP			**90MG/30ML (3MG/ML)**	**A202313**	**002**	Sep 15, 2014
AP		FRESENIUS KABI USA	**60MG/20ML (3MG/ML)**	**A077897**	**001**	Nov 27, 2017
AP			**90MG/30ML (3MG/ML)**	**A077897**	**002**	Nov 27, 2017
AP		HOSPIRA INC	**60MG/20ML (3MG/ML)**	**A203883**	**001**	Mar 24, 2014
AP			**90MG/30ML (3MG/ML)**	**A203883**	**002**	Mar 24, 2014
AP		MYLAN ASI	**60MG/20ML (3MG/ML)**	**A090212**	**001**	Mar 28, 2014
AP			**90MG/30ML (3MG/ML)**	**A090212**	**002**	Mar 28, 2014
AP	**!**	TEVA PHARMS USA	**60MG/20ML (3MG/ML)**	**A077425**	**001**	Aug 29, 2013
AP	**!**		**90MG/30ML (3MG/ML)**	**A077425**	**002**	Aug 29, 2013
AFATINIB DIMALEATE							
TABLET;ORAL							
GILOTRIF							
	+	BOEHRINGER INGELHEIM	EQ 20MG BASE	N201292	001	Jul 12, 2013
	+		EQ 30MG BASE	N201292	002	Jul 12, 2013
	+!		EQ 40MG BASE	N201292	003	Jul 12, 2013
ALBENDAZOLE							
TABLET;ORAL							
ALBENDAZOLE							
AB		CIPLA LTD	**200MG**	**A210434**	**001**	Sep 21, 2018
AB		STRIDES VIVIMED	**200MG**	**A210011**	**001**	Dec 07, 2018
AB		ZYDUS PHARMS USA INC	**200MG**	**A208979**	**001**	Dec 14, 2018
ALBENZA							
AB	**+!**	IMPAX LABS INC	**200MG**	**N020666**	**001**	Jun 11, 1996
ALBUMIN HUMAN							
INJECTABLE;INJECTION							
OPTISON							
	+!	GE HEALTHCARE	10MG/ML	N020899	001	Dec 31, 1997
ALBUMIN IODINATED I-125 SERUM							
INJECTABLE;INJECTION							
JEANATOPE							
	+	ISO TEX	100uCi/10ML (10uCi/ML)	N017836	003	Jun 08, 2004
	+		500uCi/0.5ML	N017836	001	
	+!		1,000uCi/ML	N017836	002	
ALBUMIN IODINATED I-131 SERUM							
INJECTABLE;INJECTION							
MEGATOPE							
	+!	ISO TEX	0.5mCi/VIAL	N017837	001	
	+!		1mCi/VIAL	N017837	002	
ALBUTEROL SULFATE							
AEROSOL, METERED;INHALATION							
PROAIR HFA							
BX	+!	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N021457	001	Oct 29, 2004
PROVENTIL-HFA							
BX	+!	3M DRUG DELIVERY	EQ 0.09MG BASE/INH	N020503	001	Aug 15, 1996
VENTOLIN HFA							
BX	+!	GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N020983	001	Apr 19, 2001
POWDER, METERED;INHALATION							
PROAIR RESPICLICK							
	+!	TEVA BRANDED PHARM	EQ 0.090MG BASE/INH	N205636	001	Mar 31, 2015
SOLUTION;INHALATION							
ACCUNEB							
AN	**+!**	MYLAN SPECIALITY LP	**EQ 0.021% BASE**	**N020949**	**002**	Apr 30, 2001
AN	**+!**		**EQ 0.042% BASE**	**N020949**	**001**	Apr 30, 2001
ALBUTEROL SULFATE							
AN		AUROBINDO PHARMA LTD	**EQ 0.083% BASE**	**A206224**	**001**	Oct 17, 2017
AN	**!**	BAUSCH AND LOMB	**EQ 0.5% BASE**	**A075050**	**001**	Jun 18, 1998
AN		HI TECH PHARMA	**EQ 0.5% BASE**	**A074543**	**001**	Jan 15, 1998
AN		NEPHRON	**EQ 0.021% BASE**	**A076355**	**002**	Mar 31, 2010

ALBUTEROL SULFATE

SOLUTION;INHALATION

ALBUTEROL SULFATE

AN			**EQ 0.042% BASE**	**A076355**	**001**	Jun 28, 2004
AN	!		**EQ 0.083% BASE**	**A074880**	**001**	Sep 17, 1997
AN			**EQ 0.5% BASE**	**A075664**	**001**	Jun 26, 2001
AN		RITEDOSE CORP	**EQ 0.083% BASE**	**A077839**	**001**	Dec 16, 2008
AN		SUN PHARMA GLOBAL	**EQ 0.083% BASE**	**A207857**	**001**	Jul 21, 2017
AN		WATSON LABS	**EQ 0.021% BASE**	**A077772**	**001**	Sep 25, 2007
AN			**EQ 0.042% BASE**	**A077772**	**002**	Sep 25, 2007

SYRUP;ORAL

ALBUTEROL SULFATE

AA		AMNEAL PHARMS	**EQ 2MG BASE/5ML**	**A079241**	**001**	May 12, 2010
AA		G AND W LABS INC	**EQ 2MG BASE/5ML**	**A074454**	**001**	Sep 25, 1995
AA		HI TECH PHARMA	**EQ 2MG BASE/5ML**	**A074749**	**001**	Jan 30, 1998
AA		LANNETT CO INC	**EQ 2MG BASE/5ML**	**A078105**	**001**	Dec 27, 2006
AA	!	TEVA	**EQ 2MG BASE/5ML**	**A073419**	**001**	Mar 30, 1992
AA		VISTAPHARM	**EQ 2MG BASE/5ML**	**A077788**	**001**	Jun 26, 2007

TABLET;ORAL

ALBUTEROL SULFATE

AB		AMNEAL PHARMS CO	**EQ 2MG BASE**	**A208804**	**001**	May 21, 2018
AB			**EQ 4MG BASE**	**A208804**	**002**	May 21, 2018
AB		MYLAN	**EQ 2MG BASE**	**A072894**	**002**	Jan 17, 1991
AB	!		**EQ 4MG BASE**	**A072894**	**001**	Jan 17, 1991
AB		RISING PHARMS	**EQ 2MG BASE**	**A207046**	**001**	Jun 29, 2018
AB			**EQ 4MG BASE**	**A207046**	**002**	Jun 29, 2018
AB		SUN PHARM INDUSTRIES	**EQ 2MG BASE**	**A072637**	**002**	Dec 05, 1989
AB			**EQ 4MG BASE**	**A072637**	**001**	Dec 05, 1989
AB		VIRTUS PHARM	**EQ 2MG BASE**	**A211397**	**001**	Oct 26, 2018
AB			**EQ 4MG BASE**	**A211397**	**002**	Oct 26, 2018

TABLET, EXTENDED RELEASE;ORAL

ALBUTEROL SULFATE

AB		MYLAN	**EQ 4MG BASE**	**A078092**	**002**	Jan 29, 2007

VOSPIRE ER

AB		DAVA PHARMS INC	**EQ 4MG BASE**	**A076130**	**002**	Sep 26, 2002

ALBUTEROL SULFATE

	!	MYLAN	EQ 8MG BASE	A078092	001	Jan 29, 2007

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION;INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

AN		CIPLA	**EQ 0.083% BASE;0.017%**	**A077559**	**001**	Dec 31, 2007
AN		NEPHRON	**EQ 0.083% BASE;0.017%**	**A076749**	**001**	Dec 31, 2007
AN		RITEDOSE CORP	**EQ 0.083% BASE;0.017%**	**A202496**	**001**	Oct 01, 2012
AN		SUN PHARMA GLOBAL	**EQ 0.083% BASE;0.017%**	**A207875**	**001**	Aug 07, 2017
AN		WATSON LABS TEVA	**EQ 0.083% BASE;0.017%**	**A077063**	**001**	Dec 31, 2007

SPRAY, METERED;INHALATION

COMBIVENT RESPIMAT

	+!	BOEHRINGER INGELHEIM	EQ 0.1MG BASE/INH;0.02MG/INH	N021747	001	Oct 07, 2011

ALCAFTADINE

SOLUTION/DROPS;OPHTHALMIC

LASTACAFT

	+!	ALLERGAN	0.25%	N022134	001	Jul 28, 2010

ALCLOMETASONE DIPROPIONATE

CREAM;TOPICAL

ALCLOMETASONE DIPROPIONATE

AB	!	FOUGERA PHARMS	**0.05%**	**A076973**	**001**	Jul 12, 2005
AB		GLENMARK GENERICS	**0.05%**	**A079061**	**001**	Jun 23, 2009
AB		TARO	**0.05%**	**A076587**	**001**	Sep 15, 2005

OINTMENT;TOPICAL

ALCLOMETASONE DIPROPIONATE

AB	!	FOUGERA PHARMS	**0.05%**	**A076884**	**001**	Jul 18, 2005
AB		GLENMARK GENERICS	**0.05%**	**A079227**	**001**	Jul 30, 2009
AB		TARO	**0.05%**	**A076730**	**001**	Jul 29, 2004

ALCOHOL

SOLUTION;INTRA-ARTERIAL

ABLYSINOL

+	BELCHER PHARMS LLC	99% (1ML)	N207987	001	Jun 21, 2018
+!		99% (5ML)	N207987	002	Jun 21, 2018

ALECTINIB HYDROCHLORIDE

CAPSULE;ORAL

ALECENSA

+!	HOFFMANN-LA ROCHE	EQ 150MG BASE	N208434	001	Dec 11, 2015

ALENDRONATE SODIUM

SOLUTION;ORAL

ALENDRONATE SODIUM

!	WEST-WARD PHARMS INT	EQ 70MG BASE/75ML	A090520	001	Feb 25, 2013

TABLET;ORAL

ALENDRONATE SODIUM

AB	APOTEX	**EQ 5MG BASE**	**A077982**	**001**	Aug 04, 2008
AB		**EQ 10MG BASE**	**A077982**	**002**	Aug 04, 2008
AB		**EQ 35MG BASE**	**A077982**	**003**	Aug 04, 2008
AB		**EQ 70MG BASE**	**A077982**	**004**	Aug 04, 2008
AB	AUROBINDO PHARMA	**EQ 10MG BASE**	**A090124**	**001**	Aug 04, 2008
AB		**EQ 35MG BASE**	**A090124**	**002**	Aug 04, 2008
AB		**EQ 70MG BASE**	**A090124**	**003**	Aug 04, 2008
AB	CIPLA	**EQ 5MG BASE**	**A076768**	**001**	Aug 04, 2008
AB		**EQ 10MG BASE**	**A076768**	**002**	Aug 04, 2008
AB		**EQ 35MG BASE**	**A076768**	**003**	Aug 04, 2008
AB		**EQ 40MG BASE**	**A076768**	**004**	Aug 04, 2008
AB		**EQ 70MG BASE**	**A076768**	**005**	Aug 04, 2008
AB	HANGZHOU BINJIANG	**EQ 5MG BASE**	**A090258**	**001**	Sep 24, 2009
AB		**EQ 10MG BASE**	**A090258**	**002**	Sep 24, 2009
AB		**EQ 35MG BASE**	**A090258**	**003**	Sep 24, 2009
AB		**EQ 70MG BASE**	**A090258**	**004**	Sep 24, 2009
AB	IMPAX LABS INC	**EQ 5MG BASE**	**A075710**	**001**	Feb 06, 2008
AB		**EQ 10MG BASE**	**A075710**	**002**	Feb 06, 2008
AB		**EQ 35MG BASE**	**A075710**	**003**	Feb 06, 2008
AB		**EQ 40MG BASE**	**A075710**	**004**	Feb 06, 2008
AB		**EQ 70MG BASE**	**A075710**	**005**	Feb 06, 2008
AB	JUBILANT CADISTA	**EQ 5MG BASE**	**A090557**	**001**	Feb 18, 2010
AB		**EQ 10MG BASE**	**A090557**	**002**	Feb 18, 2010
AB		**EQ 35MG BASE**	**A090557**	**003**	Feb 18, 2010
AB		**EQ 70MG BASE**	**A090557**	**004**	Feb 18, 2010
AB	MYLAN	**EQ 5MG BASE**	**A076584**	**001**	Aug 04, 2008
AB		**EQ 10MG BASE**	**A076584**	**002**	Aug 04, 2008
AB	NEOPHARMA	**EQ 5MG BASE**	**A079049**	**003**	Aug 04, 2008
AB		**EQ 10MG BASE**	**A079049**	**004**	Aug 04, 2008
AB		**EQ 35MG BASE**	**A079049**	**001**	Aug 04, 2008
AB		**EQ 70MG BASE**	**A079049**	**002**	Aug 04, 2008
AB	SUN PHARMA GLOBAL	**EQ 5MG BASE**	**A090022**	**001**	Sep 10, 2008
AB		**EQ 10MG BASE**	**A090022**	**002**	Sep 10, 2008
AB		**EQ 35MG BASE**	**A090022**	**003**	Sep 10, 2008
AB		**EQ 70MG BASE**	**A090022**	**004**	Sep 10, 2008
AB	WATSON LABS	**EQ 35MG BASE**	**A076984**	**001**	Aug 04, 2008
AB		**EQ 40MG BASE**	**A076984**	**002**	Aug 04, 2008
AB		**EQ 70MG BASE**	**A076984**	**003**	Aug 04, 2008

FOSAMAX

AB **+!**	MERCK AND CO INC	**EQ 70MG BASE**	**N020560**	**005**	Oct 20, 2000

TABLET, EFFERVESCENT;ORAL

BINOSTO

+!	MISSION PHARMA	EQ 70MG BASE	N202344	001	Mar 12, 2012

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET;ORAL

FOSAMAX PLUS D

+	MERCK	EQ 70MG BASE;2,800 IU	N021762	001	Apr 07, 2005
+!		EQ 70MG BASE;5,600 IU	N021762	002	Apr 26, 2007

ALFENTANIL HYDROCHLORIDE

INJECTABLE;INJECTION

ALFENTA

AP **+!**	AKORN	**EQ 0.5MG BASE/ML**	**N019353**	**001**	Dec 29, 1986

ALFENTANIL

AP	HOSPIRA	**EQ 0.5MG BASE/ML**	**A075221**	**001**	Oct 28, 1999

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALFUZOSIN HYDROCHLORIDE

AB		APOTEX INC	**10MG**	**A079013**	**001**	Jul 18, 2011
AB		AUROBINDO PHARMA LTD	**10MG**	**A079060**	**001**	Aug 30, 2012
AB		INVAGEN PHARMS	**10MG**	**A090284**	**001**	Jan 17, 2012
AB		MYLAN	**10MG**	**A079014**	**001**	Jul 18, 2011
AB		SUN PHARMA GLOBAL	**10MG**	**A079057**	**001**	Jul 18, 2011
AB		TEVA PHARMS	**10MG**	**A079056**	**001**	Jul 18, 2011
AB		TORRENT PHARMS	**10MG**	**A079054**	**001**	Jul 18, 2011
AB		UNICHEM LABS LTD	**10MG**	**A203192**	**001**	Jan 28, 2016

UROXATRAL

AB	**+!**	CONCORDIA PHARMS INC	**10MG**	**N021287**	**001**	Jun 12, 2003

ALISKIREN HEMIFUMARATE

TABLET;ORAL

TEKTURNA

	+	NODEN PHARMA	EQ 150MG BASE	N021985	001 Mar 05, 2007
	+!		EQ 300MG BASE	N021985	002 Mar 05, 2007

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

TEKTURNA HCT

	+	NODEN PHARMA	EQ 150MG BASE;12.5MG	N022107	001 Jan 18, 2008
	+		EQ 150MG BASE;25MG	N022107	002 Jan 18, 2008
	+!		EQ 300MG BASE;12.5MG	N022107	003 Jan 18, 2008
	+!		EQ 300MG BASE;25MG	N022107	004 Jan 18, 2008

ALITRETINOIN

GEL;TOPICAL

PANRETIN

	+!	EISAI INC	EQ 0.1% BASE	N020886	001 Feb 02, 1999

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

AB		ACCORD HLTHCARE	**100MG**	**A203154**	**001**	May 06, 2013
AB			**300MG**	**A203154**	**002**	May 06, 2013
AB		APOTEX INC	**100MG**	**A077353**	**001**	Sep 08, 2005
AB			**300MG**	**A077353**	**002**	Sep 08, 2005
AB		INDOCO REMEDIES	**100MG**	**A204467**	**001**	Jul 28, 2016
AB			**300MG**	**A204467**	**002**	Jul 28, 2016
AB		IPCA LABS LTD	**100MG**	**A090637**	**001**	Mar 16, 2011
AB			**300MG**	**A090637**	**002**	Mar 16, 2011
AB		MYLAN	**100MG**	**A018659**	**001**	Oct 24, 1986
AB			**300MG**	**A018659**	**002**	Oct 24, 1986
AB		NORTHSTAR HLTHCARE	**100MG**	**A078253**	**001**	Sep 11, 2007
AB			**300MG**	**A078253**	**002**	Sep 11, 2007
AB		SUN PHARM INDS INC	**100MG**	**A078390**	**001**	Aug 30, 2007
AB			**300MG**	**A078390**	**002**	Aug 30, 2007
AB		SUN PHARM INDUSTRIES	**100MG**	**A071450**	**002**	Jan 09, 1987
AB			**300MG**	**A071450**	**001**	Jan 09, 1987
AB		VINTAGE PHARMS	**100MG**	**A075798**	**001**	Jun 27, 2003
AB			**300MG**	**A075798**	**002**	Jun 27, 2003
AB		WATSON LABS	**100MG**	**N018832**	**002**	Sep 28, 1984
AB			**300MG**	**N018877**	**001**	Sep 28, 1984
AB		ZYDUS PHARMS USA INC	**100MG**	**A210117**	**001**	Oct 12, 2017
AB			**300MG**	**A210117**	**002**	Oct 12, 2017

LOPURIN

AB		DR REDDYS LA	**100MG**	**A071586**	**001**	Apr 02, 1987
AB			**300MG**	**A071587**	**001**	Apr 02, 1987

ZYLOPRIM

AB	**+**	CASPER PHARMA LLC	**100MG**	**N016084**	**001**
AB	**+!**		**300MG**	**N016084**	**002**

ALLOPURINOL SODIUM

INJECTABLE;INJECTION

ALLOPURINOL SODIUM

AP		WEST-WARD PHARMS INT	**EQ 500MG BASE/VIAL**	**A076870**	**001**	Aug 26, 2004

ALLOPURINOL SODIUM

INJECTABLE;INJECTION

ALOPRIM

AP	**+!**	MYLAN INSTITUTIONAL	**EQ 500MG BASE/VIAL**	**N020298**	**001**	May 17, 1996

ALLOPURINOL; LESINURAD

TABLET;ORAL

DUZALLO

+	IRONWOOD PHARMS INC	200MG;200MG	N209203	001	Aug 18, 2017
+!		300MG;200MG	N209203	002	Aug 18, 2017

ALMOTRIPTAN MALATE

TABLET;ORAL

ALMOTRIPTAN MALATE

AB		AJANTA PHARMA LTD	**EQ 6.25MG BASE**	**A205523**	**001**	Mar 03, 2016
AB			**EQ 12.5MG BASE**	**A205523**	**002**	Mar 03, 2016
AB		MYLAN PHARMS INC	**EQ 6.25MG BASE**	**A205171**	**001**	Nov 09, 2015
AB			**EQ 12.5MG BASE**	**A205171**	**002**	Nov 09, 2015
AB		TEVA PHARMS USA	**EQ 6.25MG BASE**	**A078027**	**001**	Jul 07, 2015
AB			**EQ 12.5MG BASE**	**A078027**	**002**	Jul 07, 2015

AXERT

AB	**+**	JANSSEN PHARMS	**EQ 6.25MG BASE**	**N021001**	**001**	May 07, 2001
AB	**+!**		**EQ 12.5MG BASE**	**N021001**	**002**	May 07, 2001

ALOGLIPTIN BENZOATE

TABLET;ORAL

NESINA

+	TAKEDA PHARMS USA	EQ 6.25MG BASE	N022271	001	Jan 25, 2013
+		EQ 12.5MG BASE	N022271	002	Jan 25, 2013
+!		EQ 25MG BASE	N022271	003	Jan 25, 2013

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

KAZANO

+	TAKEDA PHARMS USA	EQ 12.5MG BASE;500MG	N203414	001	Jan 25, 2013
+!		EQ 12.5MG BASE;1GM	N203414	002	Jan 25, 2013

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

OSENI

+	TAKEDA PHARMS USA	EQ 12.5MG BASE;EQ 15MG BASE	N022426	004	Jan 25, 2013
+		EQ 12.5MG BASE;EQ 30MG BASE	N022426	005	Jan 25, 2013
+		EQ 12.5MG BASE;EQ 45MG BASE	N022426	006	Jan 25, 2013
+		EQ 25MG BASE;EQ 15MG BASE	N022426	001	Jan 25, 2013
+		EQ 25MG BASE;EQ 30MG BASE	N022426	002	Jan 25, 2013
+!		EQ 25MG BASE;EQ 45MG BASE	N022426	003	Jan 25, 2013

ALOSETRON HYDROCHLORIDE

TABLET;ORAL

ALOSETRON HYDROCHLORIDE

AB		AMNEAL PHARMS	**EQ 0.5MG BASE**	**A206647**	**001**	Dec 22, 2016
AB			**EQ 1MG BASE**	**A206647**	**002**	Dec 22, 2016
AB		CIPLA	**EQ 0.5MG BASE**	**A209180**	**001**	Jan 14, 2019
AB			**EQ 1MG BASE**	**A209180**	**002**	Jan 14, 2019
AB		PAR PHARM INC	**EQ 0.5MG BASE**	**A206113**	**001**	Feb 23, 2018
AB			**EQ 1MG BASE**	**A206113**	**002**	Feb 23, 2018
AB		WEST-WARD PHARMS INT	**EQ 0.5MG BASE**	**A200652**	**001**	May 04, 2015
AB			**EQ 1MG BASE**	**A200652**	**002**	May 04, 2015

LOTRONEX

AB	**+**	SEBELA IRELAND LTD	**EQ 0.5MG BASE**	**N021107**	**002**	Dec 23, 2003
AB	**+!**		**EQ 1MG BASE**	**N021107**	**001**	Feb 09, 2000

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SOLUTION;INTRAVENOUS

INFUVITE ADULT

+!	SANDOZ INC	2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;0.03MG/ML	N021163	001	May 18, 2000
+!		2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;30MCG/ML	N021559	001	Jun 16, 2003

ALPRAZOLAM

CONCENTRATE;ORAL

ALPRAZOLAM

	!	WEST-WARD PHARMS INT	1MG/ML	A074312	001	Oct 31, 1993

TABLET;ORAL

ALPRAZOLAM

AB		ACTAVIS ELIZABETH	**0.25MG**	**A074342**	**001**	Oct 31, 1993
AB			**0.5MG**	**A074342**	**002**	Oct 31, 1993
AB			**1MG**	**A074342**	**003**	Oct 31, 1993
AB			**2MG**	**A074342**	**004**	Oct 31, 1993
AB		APOTEX INC	**0.25MG**	**A077741**	**001**	Jan 19, 2007
AB			**0.5MG**	**A077741**	**002**	Jan 19, 2007
AB			**1MG**	**A077741**	**003**	Jan 19, 2007
AB			**2MG**	**A077741**	**004**	Jan 19, 2007
AB		AUROBINDO PHARMA LTD	**0.25MG**	**A203346**	**001**	Jul 31, 2015
AB			**0.5MG**	**A203346**	**002**	Jul 31, 2015
AB			**1MG**	**A203346**	**003**	Jul 31, 2015
AB			**2MG**	**A203346**	**004**	Jul 31, 2015
AB		BRECKENRIDGE PHARM	**0.25MG**	**A207507**	**001**	Jul 09, 2018
AB			**0.5MG**	**A207507**	**002**	Jul 09, 2018
AB			**1MG**	**A207507**	**003**	Jul 09, 2018
AB			**2MG**	**A207507**	**004**	Jul 09, 2018
AB		DAVA INTL INC	**0.25MG**	**A074174**	**001**	Oct 19, 1993
AB			**0.5MG**	**A074174**	**002**	Oct 19, 1993
AB			**1MG**	**A074174**	**003**	Oct 19, 1993
AB			**2MG**	**A074174**	**004**	Oct 19, 1993
AB		MYLAN	**0.25MG**	**A074215**	**001**	Jan 27, 1994
AB			**0.5MG**	**A074215**	**002**	Jan 27, 1994
AB			**1MG**	**A074215**	**003**	Jan 27, 1994
AB			**2MG**	**A074215**	**004**	Jan 27, 1994
AB		NATCO PHARMA LTD	**0.25MG**	**A200739**	**001**	Apr 15, 2015
AB			**0.5MG**	**A200739**	**002**	Apr 15, 2015
AB			**1MG**	**A200739**	**003**	Apr 15, 2015
AB			**2MG**	**A200739**	**004**	Apr 15, 2015
AB		OXFORD PHARMS	**0.25MG**	**A078491**	**001**	Sep 25, 2008
AB			**0.5MG**	**A078491**	**002**	Sep 25, 2008
AB			**1MG**	**A078491**	**003**	Sep 25, 2008
AB			**2MG**	**A078491**	**004**	Dec 12, 2008
AB		SANDOZ	**0.25MG**	**A074112**	**001**	Dec 29, 1995
AB			**0.5MG**	**A074112**	**002**	Dec 29, 1995
AB			**1MG**	**A074112**	**003**	Dec 29, 1995
AB			**2MG**	**A074909**	**001**	Mar 25, 1998
AB		SUN PHARMA GLOBAL	**0.25MG**	**A090082**	**001**	Jun 17, 2010
AB			**0.5MG**	**A090082**	**002**	Jun 17, 2010
AB			**1MG**	**A090082**	**003**	Jun 17, 2010
AB			**2MG**	**A090082**	**004**	Jun 17, 2010
AB		VINTAGE PHARMS	**0.25MG**	**A090248**	**001**	Sep 17, 2010
AB			**0.5MG**	**A090248**	**002**	Sep 17, 2010
AB			**1MG**	**A090248**	**003**	Sep 17, 2010
AB			**2MG**	**A090248**	**004**	Sep 17, 2010

XANAX

AB	+	PHARMACIA AND UPJOHN	**0.25MG**	**N018276**	**001**	
AB	+		**0.5MG**	**N018276**	**002**	
AB	+!		**1MG**	**N018276**	**003**	
AB	+		**2MG**	**N018276**	**004**	Nov 27, 1985

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

AB		ACTAVIS ELIZABETH	**0.5MG**	**A078056**	**001**	Feb 13, 2007
AB			**1MG**	**A078056**	**002**	Feb 13, 2007
AB			**2MG**	**A078056**	**003**	Feb 13, 2007
AB			**3MG**	**A078056**	**004**	Feb 13, 2007
AB		AMNEAL PHARMS NY	**0.5MG**	**A078387**	**001**	May 30, 2008
AB			**1MG**	**A078387**	**002**	May 30, 2008
AB			**2MG**	**A078387**	**003**	May 30, 2008
AB			**3MG**	**A078387**	**004**	May 30, 2008
AB		ANCHEN PHARMS	**0.5MG**	**A078469**	**001**	Sep 29, 2011
AB			**1MG**	**A078469**	**002**	Sep 29, 2011
AB			**2MG**	**A078469**	**003**	Sep 29, 2011
AB			**3MG**	**A078469**	**004**	Sep 29, 2011
AB		ANI PHARMS INC	**0.5MG**	**A077725**	**001**	Jul 31, 2006

ALPRAZOLAM

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

AB			**1MG**	**A077725**	**002**	Jul 31, 2006
AB			**2MG**	**A077725**	**004**	Jul 31, 2006
AB			**3MG**	**A077725**	**003**	Jul 31, 2006
AB		APOTEX INC	**0.5MG**	**A078449**	**001**	Nov 12, 2008
AB			**1MG**	**A078449**	**004**	Dec 23, 2015
AB			**2MG**	**A078449**	**002**	Nov 12, 2008
AB			**3MG**	**A078449**	**003**	Nov 12, 2008
AB		AUROBINDO PHARMA LTD	**0.5MG**	**A090871**	**001**	Jun 07, 2011
AB			**1MG**	**A090871**	**002**	Jun 07, 2011
AB			**2MG**	**A090871**	**003**	Jun 07, 2011
AB			**3MG**	**A090871**	**004**	Jun 07, 2011
AB		HERITAGE PHARMS INC	**0.5MG**	**A078489**	**001**	Oct 17, 2008
AB			**1MG**	**A078489**	**002**	Oct 17, 2008
AB			**2MG**	**A078489**	**003**	Oct 17, 2008
AB			**3MG**	**A078489**	**004**	Oct 17, 2008

XANAX XR

AB	**+**	PHARMACIA AND UPJOHN	**0.5MG**	**N021434**	**001**	Jan 17, 2003
AB	**+**		**1MG**	**N021434**	**002**	Jan 17, 2003
AB	**+**		**2MG**	**N021434**	**003**	Jan 17, 2003
AB	**+!**		**3MG**	**N021434**	**004**	Jan 17, 2003

TABLET, ORALLY DISINTEGRATING;ORAL

ALPRAZOLAM

AB		ACTAVIS ELIZABETH	**0.25MG**	**A078561**	**001**	Mar 16, 2010
AB			**0.5MG**	**A078561**	**002**	Mar 16, 2010
AB			**1MG**	**A078561**	**003**	Mar 16, 2010
AB			**2MG**	**A078561**	**004**	Mar 16, 2010
AB		PAR PHARM	**0.25MG**	**A078088**	**001**	Jan 09, 2009
AB			**0.5MG**	**A078088**	**002**	Jan 09, 2009
AB	**!**		**1MG**	**A078088**	**003**	Jan 09, 2009
AB			**2MG**	**A078088**	**004**	Jan 09, 2009

ALPROSTADIL

INJECTABLE;INJECTION

ALPROSTADIL

AP		TEVA PHARMS USA	**0.5MG/ML**	**A075196**	**001**	Apr 30, 1999
AP		WEST-WARD PHARMS INT	**0.5MG/ML**	**A074815**	**001**	Jan 20, 1998

CAVERJECT

AP	**+**	PHARMACIA AND UPJOHN	**0.01MG/VIAL**	**N020379**	**001**	Jul 06, 1995
AP	**+!**		**0.02MG/VIAL**	**N020379**	**002**	Jul 06, 1995
AP	**+!**		**0.04MG/VIAL**	**N020379**	**004**	May 19, 1997

EDEX

AP	**+**	AUXILIUM PHARMS LLC	**0.01MG/VIAL**	**N020649**	**002**	Jun 12, 1997
AP	**+**		**0.02MG/VIAL**	**N020649**	**003**	Jun 12, 1997
AP	**+!**		**0.04MG/VIAL**	**N020649**	**004**	Jun 12, 1997

PROSTIN VR PEDIATRIC

AP	**+!**	PHARMACIA AND UPJOHN	**0.5MG/ML**	**N018484**	**001**	

CAVERJECT IMPULSE

		PHARMACIA AND UPJOHN	0.01MG/VIAL	N021212	001	Jun 11, 2002
			0.02MG/VIAL	N021212	002	Jun 11, 2002

EDEX

	+!	AUXILIUM PHARMS LLC	0.01MG/VIAL	N020649	005	Jul 30, 1998
	+!		0.02MG/VIAL	N020649	006	Jul 30, 1998
	+!		0.04MG/VIAL	N020649	007	Jul 30, 1998

SUPPOSITORY;URETHRAL

MUSE

	+!	MYLAN SPECIALITY LP	0.125MG	N020700	001	Nov 19, 1996
	+!		0.25MG	N020700	002	Nov 19, 1996
	+!		0.5MG	N020700	003	Nov 19, 1996
	+!		1MG	N020700	004	Nov 19, 1996

ALTRETAMINE

CAPSULE;ORAL

HEXALEN

	+!	EISAI INC	50MG	N019926	001	Dec 26, 1990

ALVIMOPAN

CAPSULE;ORAL

ENTEREG

	+!	CUBIST PHARMS	12MG	N021775	001	May 20, 2008

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	**100MG**	**A208966**	**001**	Jun 21, 2017
AB		BIONPHARMA INC	**100MG**	**A078720**	**001**	May 29, 2008
AB		GRAVITI PHARMS	**100MG**	**A207570**	**001**	Sep 30, 2016
AB		HERITAGE PHARMA	**100MG**	**A209171**	**001**	Jun 12, 2017
AB	!	SANDOZ	**100MG**	**A071293**	**001**	Feb 18, 1987
AB		STRIDES PHARMA	**100MG**	**A209047**	**001**	Jun 07, 2017
AB		USL PHARMA	**100MG**	**A070589**	**001**	Aug 05, 1986
AB		WATSON LABS INC	**100MG**	**A208107**	**001**	Dec 06, 2016
AB		ZYDUS PHARMS USA INC	**100MG**	**A208278**	**001**	May 31, 2016

CAPSULE, EXTENDED RELEASE;ORAL

GOCOVRI

	+	ADAMAS PHARMA	EQ 68.5MG BASE	N208944	001	Aug 24, 2017
	+!		EQ 137MG BASE	N208944	002	Aug 24, 2017

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

AA	!	CMP PHARMA INC	**50MG/5ML**	**A075819**	**001**	Sep 11, 2002
AA	!	HI TECH PHARMA	**50MG/5ML**	**A074170**	**001**	Oct 28, 1994
AA	!	MIKART	**50MG/5ML**	**A074028**	**001**	Jun 28, 1993
AA	!	PHARM ASSOC	**50MG/5ML**	**A074509**	**001**	Jul 17, 1995
AA	!	WOCKHARDT BIO AG	**50MG/5ML**	**A075060**	**001**	Dec 24, 1998

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

AB		GRAVITI PHARMS	**100MG**	**A207571**	**001**	Jan 31, 2017
AB		JUBILANT GENERICS	**100MG**	**A210403**	**001**	Feb 07, 2018
AB		STRIDES PHARMA	**100MG**	**A209035**	**001**	Jun 09, 2017
AB	!	USL PHARMA	**100MG**	**A076186**	**001**	Dec 16, 2002
AB		WATSON LABS INC	**100MG**	**A208096**	**001**	Dec 15, 2016

TABLET, EXTENDED RELEASE;ORAL

OSMOLEX ER

	+	OSMOTICA PHARM	EQ 129MG BASE	N209410	001	Feb 16, 2018
	+		EQ 193MG BASE	N209410	002	Feb 16, 2018
	+!		EQ 258MG BASE	N209410	003	Feb 16, 2018

AMBRISENTAN

TABLET;ORAL

LETAIRIS

	+	GILEAD	5MG	N022081	001	Jun 15, 2007
	+!		10MG	N022081	002	Jun 15, 2007

AMCINONIDE

CREAM;TOPICAL

AMCINONIDE

AB	!	FOUGERA PHARMS	**0.1%**	**A076065**	**001**	May 15, 2003
AB		TARO PHARM INDS	**0.1%**	**A076229**	**001**	May 31, 2002

LOTION;TOPICAL

AMCINONIDE

	!	FOUGERA PHARMS	0.1%	A076329	001	Nov 06, 2002

OINTMENT;TOPICAL

AMCINONIDE

AB	!	FOUGERA PHARMS	**0.1%**	**A076096**	**001**	Nov 19, 2002
AB		TARO PHARM INDS	**0.1%**	**A076367**	**001**	Mar 19, 2003

AMIFAMPRIDINE PHOSPHATE

TABLET;ORAL

FIRDAPSE

	+!	CATALYST PHARMS	EQ 10MG BASE	N208078	001	Nov 28, 2018

AMIFOSTINE

INJECTABLE;INJECTION

AMIFOSTINE

AP		MYLAN LABS LTD	**500MG/VIAL**	**A204363**	**001**	Jul 17, 2017
AP		SUN PHARMA GLOBAL	**500MG/VIAL**	**A077126**	**001**	Mar 14, 2008

ETHYOL

AP	**+!**	CLINIGEN HLTHCARE	**500MG/VIAL**	**N020221**	**001**	Dec 08, 1995

AMIKACIN SULFATE

INJECTABLE;INJECTION

AMIKACIN SULFATE

AP	**!**	EMCURE PHARMS LTD	**EQ 250MG BASE/ML**	**A204040**	**001**	Dec 12, 2013
AP		FRESENIUS KABI USA	**EQ 50MG BASE/ML**	**A205605**	**001**	Dec 09, 2015
AP			**EQ 250MG BASE/ML**	**A205604**	**001**	Dec 09, 2015
AP		SAGENT PHARMS	**EQ 250MG BASE/ML**	**A203323**	**001**	May 12, 2016
AP		TEVA PHARMS USA	**EQ 250MG BASE/ML**	**A064045**	**002**	Sep 28, 1993
AP	**!**	WEST-WARD PHARMS INT	**EQ 50MG BASE/ML**	**A063313**	**001**	Apr 11, 1994
AP			**EQ 250MG BASE/ML**	**A063315**	**001**	Apr 11, 1994

SUSPENSION, LIPOSOMAL;INHALATION

ARIKAYCE KIT

	+!	INSMED INC	EQ 590MG BASE/8.4ML	N207356	001	Sep 28, 2018

AMILORIDE HYDROCHLORIDE

TABLET;ORAL

AMILORIDE HYDROCHLORIDE

AB	**!**	PAR PHARM	**5MG**	**A070346**	**001**	Jan 22, 1986
AB		SIGMAPHARM LABS LLC	**5MG**	**A079133**	**001**	Jan 30, 2009
AB		USPHARMA WINDLAS	**5MG**	**A204180**	**001**	Aug 07, 2015

MIDAMOR

AB	**+**	PADDOCK LLC	**5MG**	**N018200**	**001**	

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		BARR	**EQ 5MG ANHYDROUS;50MG**	**A071111**	**001**	May 10, 1988
AB	**!**	MYLAN	**EQ 5MG ANHYDROUS;50MG**	**A073209**	**001**	Oct 31, 1991

AMINO ACIDS

INJECTABLE;INJECTION

AMINO ACIDS

	B BRAUN	15%(150GM/1000ML)	A091112	001	Apr 13, 2012
		15%(300GM/2000ML)	A091112	002	Apr 13, 2012

AMINOSYN 10%

	ICU MEDICAL INC	10% (10GM/100ML)	N017673	003	

AMINOSYN 8.5%

	ICU MEDICAL INC	8.5% (8.5GM/100ML)	N017673	004	

AMINOSYN II 10% IN PLASTIC CONTAINER

	ICU MEDICAL INC	10% (10GM/100ML)	N020015	001	Dec 19, 1991

AMINOSYN II 15% IN PLASTIC CONTAINER

	ICU MEDICAL INC	15% (15GM/100ML)	N020041	001	Dec 19, 1991

AMINOSYN-PF 10%

	ICU MEDICAL INC	10% (10GM/100ML)	N019492	002	Oct 17, 1986

AMINOSYN-PF 7%

	ICU MEDICAL INC	7% (7GM/100ML)	N019398	001	Sep 06, 1985

CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER

	BAXTER HLTHCARE	15% (15GM/100ML)	A020512	001	Aug 30, 1996

FREAMINE HBC 6.9%

	B BRAUN	6.9% (6.9GM/100ML)	N016822	006	May 17, 1983

FREAMINE III 10%

	B BRAUN	10% (10GM/100ML)	N016822	005	

FREAMINE III 8.5%

	B BRAUN	8.5% (8.5GM/100ML)	N016822	004	

HEPATAMINE 8%

	B BRAUN	8% (8GM/100ML)	N018676	001	Aug 03, 1982

NEPHRAMINE 5.4%

	B BRAUN	5.4% (5.4GM/100ML)	N017766	001	

PREMASOL 10% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	10% (10GM/100ML)	A075880	002	Jun 19, 2003

PREMASOL 6% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	6% (6GM/100ML)	A075880	001	Jun 19, 2003

PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE	20% (20GM/100ML)	N020849	001	Aug 26, 1998

AMINO ACIDS

INJECTABLE;INJECTION

TRAVASOL 10% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	10% (10MG/100ML)	N018931	003	Aug 23, 1984

TRAVASOL 5.5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N018931	001	Aug 23, 1984

TRAVASOL 8.5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N018931	002	Aug 23, 1984

TROPHAMINE

+!	B BRAUN	6% (6GM/100ML)	N019018	001	Jul 20, 1984

TROPHAMINE 10%

+!	B BRAUN	10% (10GM/100ML)	N019018	003	Sep 07, 1988

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PROCALAMINE

	B BRAUN	3%;26MG/100ML;3GM/100ML;54MG/100ML;41MG/100ML;150MG/100ML;200MG/100ML;120MG/100ML	N018582	001	May 08, 1982

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	2.75%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	002	Mar 26, 1997

CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	2.75%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	005	Mar 26, 1997

CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	2.75%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	001	Mar 26, 1997

CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	009	Mar 26, 1997

CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	4.25%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	011	Mar 26, 1997

CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	4.25%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	012	Mar 26, 1997

CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	4.25%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	008	Mar 26, 1997

CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	5%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	016	Mar 26, 1997

CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	5%;33MG/100ML;15GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	017	Mar 26, 1997

CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	5%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	018	Mar 26, 1997

CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	5%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	019	Mar 26, 1997

CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	5%;33MG/100ML;35GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	021	Mar 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION;INTRAVENOUS

KABIVEN IN PLASTIC CONTAINER

+	FRESENIUS KABI USA	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (1026ML)	N200656	004	Aug 25, 2014
+		3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (1540ML)	N200656	005	Aug 25, 2014
+		3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (2053ML)	N200656	006	Aug 25, 2014
+!		3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (2566ML)	N200656	007	Aug 25, 2014

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION;INTRAVENOUS

PERIKABIVEN IN PLASTIC CONTAINER

+	FRESENIUS KABI USA	2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5 GM/100ML (1440ML)	N200656	001	Aug 25, 2014
+		2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5 GM/100ML (1920ML)	N200656	002	Aug 25, 2014
+		2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML ;105MG/100ML;3.5GM/100ML (2400ML)	N200656	003	Aug 25, 2014

AMINO ACIDS; DEXTROSE

INJECTABLE;INJECTION

CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;10GM/100ML	N020734	002	Sep 29, 1997

CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;25GM/100ML	N020734	005	Sep 29, 1997

CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;5GM/100ML	N020734	001	Sep 29, 1997

CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;10GM/100ML	N020734	008	Sep 29, 1997

CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;20GM/100ML	N020734	010	Sep 29, 1997

CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;25GM/100ML	N020734	011	Sep 29, 1997

CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;5GM/100ML	N020734	007	Sep 29, 1997

CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5%;10GM/100ML	N020734	014	Sep 29, 1997

CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5%;15GM/100ML	N020734	015	Sep 29, 1997

CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5%;20GM/100ML	N020734	016	Sep 29, 1997

CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5%;25GM/100ML	N020734	017	Sep 29, 1997

CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5%;35GM/100ML	N020734	018	Sep 29, 1997

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE;INJECTION

FREAMINE III 8.5% W/ ELECTROLYTES

B BRAUN	8.5%;110MG/100ML;230MG/100ML;10MG/100ML ;440MG/100ML;690MG/100ML	N016822	007	Jul 01, 1988

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN 3.5% M

ICU MEDICAL INC	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N017789	003	

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

FREAMINE III 3% W/ ELECTROLYTES

B BRAUN	3%;54MG/100ML;40MG/100ML;150MG/100ML;200MG/100ML;120MG/100ML	N016822	003	

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE;INJECTION

AMINOSYN 8.5% W/ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;487MG/100ML;28MG/100ML ;425MG/100ML	N017673	009	Oct 25, 2002

AMINOCAPROIC ACID

INJECTABLE;INJECTION

AMINOCAPROIC ACID

AP	LUITPOLD	**250MG/ML**	**A071192**	**001**	Dec 01, 1987

AMINOCAPROIC ACID IN PLASTIC CONTAINER

AP	**!** HOSPIRA	**250MG/ML**	**A070010**	**001**	Mar 09, 1987

SYRUP;ORAL

AMICAR

+!	CLOVER PHARMS	1.25GM/5ML	N015230	002	

AMINOCAPROIC ACID							
TABLET;ORAL							
AMICAR							
AB	**+**	CLOVER PHARMS	**500MG**	**N015197**	**001**		
AB	**+!**		**1GM**	**N015197**	**002**	Jun 24, 2004	
AMINOCAPROIC ACID							
AB		SUNNY PHARMTECH INC	**500MG**	**A209060**	**001**	Nov 27, 2018	
AB			**1GM**	**A209060**	**002**	Nov 27, 2018	
AMINOLEVULINIC ACID HYDROCHLORIDE							
FOR SOLUTION;ORAL							
GLEOLAN							
	+!	NXDC	1.5GM/VIAL	N208630	001	Jun 06, 2017	
GEL;TOPICAL							
AMELUZ							
	+!	BIOFRONTERA	10%	N208081	001	May 10, 2016	
SOLUTION;TOPICAL							
LEVULAN							
	+!	DUSA	20%	N020965	001	Dec 03, 1999	
AMINOPHYLLINE							
INJECTABLE;INJECTION							
AMINOPHYLLINE							
AP	**!**	HOSPIRA	**25MG/ML**	**A087242**	**001**	Oct 26, 1983	
AP		LUITPOLD	**25MG/ML**	**A087600**	**001**		
AMINOSALICYLIC ACID							
GRANULE, DELAYED RELEASE;ORAL							
PASER							
	!	JACOBUS	4GM/PACKET	A074346	001	Jun 30, 1994	
AMIODARONE HYDROCHLORIDE							
INJECTABLE;INJECTION							
AMIODARONE HYDROCHLORIDE							
AP		AUROBINDO PHARMA LTD	**50MG/ML**	**A204550**	**001**	Oct 25, 2017	
AP	**!**	FRESENIUS KABI USA	**50MG/ML**	**A075761**	**001**	Oct 15, 2002	
AP	**!**	GLAND PHARMA LTD	**50MG/ML**	**A077161**	**001**	Apr 20, 2005	
AP		HIKMA FARMACEUTICA	**50MG/ML**	**A077234**	**001**	Feb 25, 2008	
AP	**!**	HOSPIRA	**50MG/ML**	**A075955**	**001**	Oct 18, 2002	
AP		HOSPIRA INC	**50MG/ML**	**A203884**	**001**	Nov 25, 2013	
AP			**50MG/ML**	**A203885**	**001**	Nov 25, 2013	
AP	**!**	MYLAN INSTITUTIONAL	**50MG/ML**	**A076217**	**001**	Oct 15, 2002	
AP		WOCKHARDT	**50MG/ML**	**A077610**	**001**	Oct 30, 2008	
AP			**50MG/ML**	**A077834**	**001**	Oct 30, 2008	
NEXTERONE							
	+!	BAXTER HLTHCARE	150MG/100ML (1.5MG/ML)	N022325	002	Nov 16, 2010	
	+!		360MG/200ML (1.8MG/ML)	N022325	003	Nov 16, 2010	
TABLET;ORAL							
AMIODARONE HYDROCHLORIDE							
AB		APOTEX INC	**200MG**	**A078578**	**001**	Nov 06, 2008	
AB		AUROBINDO PHARMA LTD	**200MG**	**A204742**	**001**	Jun 03, 2016	
AB		MAYNE PHARMA INC	**100MG**	**A075389**	**002**	Dec 28, 2017	
AB			**200MG**	**A075389**	**001**	Jan 25, 2001	
AB			**400MG**	**A075389**	**003**	Dec 28, 2017	
AB		MURTY PHARMS	**100MG**	**A077069**	**003**	Oct 04, 2016	
AB			**200MG**	**A077069**	**001**	Apr 08, 2005	
AB			**400MG**	**A077069**	**002**	Apr 08, 2005	
AB	**!**	SANDOZ	**200MG**	**A075315**	**001**	Dec 23, 1998	
AB			**400MG**	**A075315**	**002**	Jun 30, 2000	
AB		TARO PHARM	**100MG**	**A075424**	**002**	Dec 18, 2002	
AB			**200MG**	**A075424**	**001**	Mar 30, 2001	
AB			**400MG**	**A076362**	**001**	Nov 29, 2002	
AB		TEVA PHARMS	**200MG**	**A074739**	**001**	Nov 30, 1998	
AB		ZYDUS PHARMS USA INC	**200MG**	**A079029**	**001**	Sep 16, 2008	
PACERONE							
AB		UPSHER SMITH LABS	**100MG**	**A075135**	**002**	Apr 12, 2005	
AB			**200MG**	**A075135**	**001**	Apr 30, 1998	
AMIODARONE HYDROCHLORIDE							
		TARO PHARM	300MG	A076362	002	Dec 02, 2003	

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	ACCORD HLTHCARE	**10MG**	**A202446**	**001**	Jun 04, 2014
AB		**25MG**	**A202446**	**002**	Jun 04, 2014
AB		**50MG**	**A202446**	**003**	Jun 04, 2014
AB		**75MG**	**A202446**	**004**	Jun 04, 2014
AB		**100MG**	**A202446**	**005**	Jun 04, 2014
AB		**150MG**	**A202446**	**006**	Jun 04, 2014
AB	MYLAN	**10MG**	**A086009**	**002**	
AB		**25MG**	**A086009**	**003**	
AB		**50MG**	**A086009**	**001**	
AB		**75MG**	**A086009**	**004**	
AB		**100MG**	**A086009**	**005**	
AB		**150MG**	**A086009**	**006**	
AB	SANDOZ	**10MG**	**A085969**	**001**	
AB !		**25MG**	**A085966**	**001**	
AB		**50MG**	**A085968**	**001**	
AB		**75MG**	**A085971**	**001**	
AB		**100MG**	**A085967**	**001**	
AB		**150MG**	**A085970**	**001**	
AB	SUN PHARM INDS INC	**10MG**	**A089399**	**002**	Jul 14, 1987
AB		**25MG**	**A089399**	**001**	Jul 14, 1987
AB		**50MG**	**A089399**	**003**	Jul 14, 1987
AB		**75MG**	**A089399**	**004**	Jul 14, 1987
AB		**100MG**	**A089399**	**005**	Jul 14, 1987
AB		**150MG**	**A089399**	**006**	Jul 14, 1987
AB	VINTAGE PHARMS	**10MG**	**A040218**	**001**	Sep 11, 1997
AB		**25MG**	**A040218**	**002**	Sep 11, 1997
AB		**50MG**	**A040218**	**003**	Sep 11, 1997
AB		**75MG**	**A040218**	**004**	Sep 11, 1997
AB		**100MG**	**A040218**	**005**	Sep 11, 1997
AB		**150MG**	**A040218**	**006**	Sep 11, 1997
AB	ZYDUS PHARMS USA INC	**10MG**	**A210086**	**001**	Oct 06, 2017
AB		**25MG**	**A210086**	**002**	Oct 06, 2017
AB		**50MG**	**A210086**	**003**	Oct 06, 2017
AB		**75MG**	**A210086**	**004**	Oct 06, 2017
AB		**100MG**	**A210086**	**005**	Oct 06, 2017
AB		**150MG**	**A210086**	**006**	Oct 06, 2017

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986
!		EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN	10MG;2MG	A071443	002	Nov 10, 1988
		10MG;4MG	A071443	003	Nov 10, 1988
!		25MG;2MG	A071443	004	Nov 10, 1988
!		25MG;4MG	A071443	005	Nov 10, 1988
!		50MG;4MG	A071443	001	Nov 10, 1988

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB	ACCORD HLTHCARE	**EQ 2.5MG BASE**	**A202553**	**001**	Apr 29, 2013
AB		**EQ 5MG BASE**	**A202553**	**002**	Apr 29, 2013
AB		**EQ 10MG BASE**	**A202553**	**003**	Apr 29, 2013
AB	ALKEM	**EQ 2.5MG BASE**	**A078925**	**001**	May 04, 2009
AB		**EQ 5MG BASE**	**A078925**	**002**	May 04, 2009
AB		**EQ 10MG BASE**	**A078925**	**003**	May 04, 2009
AB	APOTEX	**EQ 2.5MG BASE**	**A076719**	**001**	May 23, 2007
AB		**EQ 5MG BASE**	**A076719**	**002**	May 23, 2007
AB		**EQ 10MG BASE**	**A076719**	**003**	May 23, 2007
AB	AUROBINDO PHARMA	**EQ 2.5MG BASE**	**A078021**	**001**	Jul 17, 2007
AB		**EQ 5MG BASE**	**A078021**	**002**	Jul 17, 2007
AB		**EQ 10MG BASE**	**A078021**	**003**	Jul 17, 2007
AB	CHINA RESOURCES	**EQ 2.5MG BASE**	**A090752**	**003**	May 16, 2016
AB		**EQ 5MG BASE**	**A090752**	**001**	Apr 15, 2011
AB		**EQ 10MG BASE**	**A090752**	**002**	Apr 15, 2011

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB	CIPLA	**EQ 2.5MG BASE**	**A077073**	**001** Sep 26, 2007
AB		**EQ 5MG BASE**	**A077073**	**002** Sep 26, 2007
AB		**EQ 10MG BASE**	**A077073**	**003** Sep 26, 2007
AB	EPIC PHARMA LLC	**EQ 2.5MG BASE**	**A078552**	**001** Apr 08, 2009
AB		**EQ 5MG BASE**	**A078552**	**002** Apr 08, 2009
AB		**EQ 10MG BASE**	**A078552**	**003** Apr 08, 2009
AB	HEBEI CHANGSHAN	**EQ 2.5MG BASE**	**A076692**	**001** Jul 20, 2007
AB		**EQ 5MG BASE**	**A076692**	**002** Jul 20, 2007
AB		**EQ 10MG BASE**	**A076692**	**003** Jul 20, 2007
AB	HIKMA PHARMS	**EQ 2.5MG BASE**	**A077771**	**001** Apr 12, 2011
AB		**EQ 5MG BASE**	**A077771**	**002** Apr 12, 2011
AB		**EQ 10MG BASE**	**A077771**	**003** Apr 12, 2011
AB	INVAGEN PHARMS	**EQ 2.5MG BASE**	**A077955**	**001** Aug 28, 2007
AB		**EQ 2.5MG BASE**	**A206367**	**001** Dec 10, 2015
AB		**EQ 5MG BASE**	**A077955**	**002** Aug 28, 2007
AB		**EQ 5MG BASE**	**A206367**	**002** Dec 10, 2015
AB		**EQ 10MG BASE**	**A077955**	**003** Aug 28, 2007
AB		**EQ 10MG BASE**	**A206367**	**003** Dec 10, 2015
AB	LUPIN	**EQ 2.5MG BASE**	**A078043**	**001** Jul 12, 2007
AB		**EQ 5MG BASE**	**A078043**	**002** Jul 12, 2007
AB		**EQ 10MG BASE**	**A078043**	**003** Jul 12, 2007
AB	MACLEODS PHARMS LTD	**EQ 5MG BASE**	**A201380**	**001** Apr 13, 2012
AB		**EQ 10MG BASE**	**A201380**	**002** Apr 13, 2012
AB	MYLAN PHARMS INC	**EQ 2.5MG BASE**	**A076418**	**001** Oct 03, 2005
AB		**EQ 5MG BASE**	**A076418**	**002** Oct 03, 2005
AB		**EQ 10MG BASE**	**A076418**	**003** Oct 03, 2005
AB	ORCHID HLTHCARE	**EQ 2.5MG BASE**	**A078453**	**001** Jul 02, 2009
AB		**EQ 5MG BASE**	**A078453**	**002** Jul 02, 2009
AB		**EQ 10MG BASE**	**A078453**	**003** Jul 02, 2009
AB	OXFORD PHARMS	**EQ 2.5MG BASE**	**A078414**	**001** Apr 07, 2010
AB		**EQ 5MG BASE**	**A078414**	**002** Apr 07, 2010
AB		**EQ 10MG BASE**	**A078414**	**003** Apr 07, 2010
AB	POLYGEN PHARMS	**EQ 2.5MG BASE**	**A207821**	**001** Jul 11, 2016
AB		**EQ 5MG BASE**	**A207821**	**002** Jul 11, 2016
AB		**EQ 10MG BASE**	**A207821**	**003** Jul 11, 2016
AB	STRIDES VIVIMED	**EQ 2.5MG BASE**	**A077516**	**001** Jul 11, 2007
AB		**EQ 5MG BASE**	**A077516**	**002** Jul 11, 2007
AB		**EQ 10MG BASE**	**A077516**	**003** Jul 11, 2007
AB	SUN PHARM INDS INC	**EQ 2.5MG BASE**	**A078231**	**001** Nov 30, 2007
AB		**EQ 5MG BASE**	**A078231**	**002** Nov 30, 2007
AB		**EQ 10MG BASE**	**A078231**	**003** Nov 30, 2007
AB	SUN PHARM INDS LTD	**EQ 2.5MG BASE**	**A077974**	**001** Jul 09, 2007
AB		**EQ 5MG BASE**	**A077974**	**002** Jul 09, 2007
AB		**EQ 10MG BASE**	**A077974**	**003** Jul 09, 2007
AB	TEVA	**EQ 2.5MG BASE**	**A076846**	**001** Jun 28, 2007
AB		**EQ 5MG BASE**	**A076846**	**002** Jun 28, 2007
AB		**EQ 10MG BASE**	**A076846**	**003** Jun 28, 2007
AB	TORRENT PHARMS	**EQ 2.5MG BASE**	**A078573**	**001** Sep 22, 2008
AB		**EQ 5MG BASE**	**A078573**	**002** Sep 22, 2008
AB		**EQ 10MG BASE**	**A078573**	**003** Sep 22, 2008
AB	UNICHEM LABS LTD	**EQ 2.5MG BASE**	**A203245**	**001** Oct 21, 2013
AB		**EQ 5MG BASE**	**A203245**	**002** Oct 21, 2013
AB		**EQ 10MG BASE**	**A203245**	**003** Oct 21, 2013
AB	UPSHER SMITH LABS	**EQ 2.5MG BASE**	**A077759**	**001** Jul 09, 2007
AB		**EQ 5MG BASE**	**A077759**	**002** Jul 09, 2007
AB		**EQ 10MG BASE**	**A077759**	**003** Jul 09, 2007
AB	WATSON LABS	**EQ 2.5MG BASE**	**A077671**	**001** Jul 19, 2007
AB		**EQ 5MG BASE**	**A077671**	**002** Jul 19, 2007
AB		**EQ 10MG BASE**	**A077671**	**003** Jul 19, 2007
AB	WEST-WARD PHARMS INT	**EQ 2.5MG BASE**	**A077262**	**001** Jul 09, 2007
AB		**EQ 5MG BASE**	**A077262**	**002** Jul 09, 2007
AB		**EQ 10MG BASE**	**A077262**	**003** Jul 09, 2007
AB	WOCKHARDT	**EQ 2.5MG BASE**	**A078500**	**001** Sep 06, 2007
AB		**EQ 5MG BASE**	**A078500**	**002** Sep 06, 2007
AB		**EQ 10MG BASE**	**A078500**	**003** Sep 06, 2007
AB	ZYDUS PHARMS USA	**EQ 2.5MG BASE**	**A078226**	**001** Jul 09, 2007
AB		**EQ 5MG BASE**	**A078226**	**002** Jul 09, 2007
AB		**EQ 10MG BASE**	**A078226**	**003** Jul 09, 2007

AMLODIPINE BESYLATE

TABLET;ORAL

NORVASC

AB	+	PFIZER	EQ 2.5MG BASE	N019787	001	Jul 31, 1992
AB	+		EQ 5MG BASE	N019787	002	Jul 31, 1992
AB	+!		EQ 10MG BASE	N019787	003	Jul 31, 1992

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB		DR REDDYS LABS LTD	EQ 2.5MG BASE;EQ 10MG BASE	A203874	001	Mar 07, 2014
AB			EQ 2.5MG BASE;EQ 20MG BASE	A203874	002	Mar 07, 2014
AB			EQ 2.5MG BASE;EQ 40MG BASE	A203874	003	Mar 07, 2014
AB			EQ 5MG BASE;EQ 10MG BASE	A203874	004	Mar 07, 2014
AB			EQ 5MG BASE;EQ 20MG BASE	A203874	005	Mar 07, 2014
AB			EQ 5MG BASE;EQ 40MG BASE	A203874	006	Mar 07, 2014
AB			EQ 5MG BASE;EQ 80MG BASE	A203874	007	Mar 07, 2014
AB			EQ 10MG BASE;EQ 10MG BASE	A203874	008	Mar 07, 2014
AB			EQ 10MG BASE;EQ 20MG BASE	A203874	009	Mar 07, 2014
AB			EQ 10MG BASE;EQ 40MG BASE	A203874	010	Mar 07, 2014
AB			EQ 10MG BASE;EQ 80MG BASE	A203874	011	Mar 07, 2014
AB		MYLAN PHARMS INC	EQ 2.5MG BASE;EQ 10MG BASE	A200465	001	Nov 29, 2013
AB			EQ 2.5MG BASE;EQ 20MG BASE	A200465	002	Nov 29, 2013
AB			EQ 2.5MG BASE;EQ 40MG BASE	A200465	003	Nov 29, 2013
AB			EQ 5MG BASE;EQ 10MG BASE	A200465	004	Nov 29, 2013
AB			EQ 5MG BASE;EQ 20MG BASE	A200465	005	Nov 29, 2013
AB			EQ 5MG BASE;EQ 40MG BASE	A200465	006	Nov 29, 2013
AB			EQ 5MG BASE;EQ 80MG BASE	A200465	007	Nov 29, 2013
AB			EQ 10MG BASE;EQ 10MG BASE	A200465	008	Nov 29, 2013
AB			EQ 10MG BASE;EQ 20MG BASE	A200465	009	Nov 29, 2013
AB			EQ 10MG BASE;EQ 40MG BASE	A200465	010	Nov 29, 2013
AB			EQ 10MG BASE;EQ 80MG BASE	A200465	011	Nov 29, 2013
AB		ZYDUS PHARMS USA INC	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019
AB			EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019
AB			EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019
AB			EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019
AB			EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019
AB			EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019
AB			EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019
AB			EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019
AB			EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019
AB			EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019
AB			EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019

CADUET

AB	+	PFIZER	EQ 2.5MG BASE;EQ 10MG BASE	N021540	009	Jul 29, 2004
AB	+		EQ 2.5MG BASE;EQ 20MG BASE	N021540	010	Jul 29, 2004
AB	+		EQ 2.5MG BASE;EQ 40MG BASE	N021540	011	Jul 29, 2004
AB	+		EQ 5MG BASE;EQ 10MG BASE	N021540	001	Jan 30, 2004
AB	+		EQ 5MG BASE;EQ 20MG BASE	N021540	002	Jan 30, 2004
AB	+		EQ 5MG BASE;EQ 40MG BASE	N021540	003	Jan 30, 2004
AB	+		EQ 5MG BASE;EQ 80MG BASE	N021540	004	Jan 30, 2004
AB	+		EQ 10MG BASE;EQ 10MG BASE	N021540	005	Jan 30, 2004
AB	+		EQ 10MG BASE;EQ 20MG BASE	N021540	006	Jan 30, 2004
AB	+		EQ 10MG BASE;EQ 40MG BASE	N021540	007	Jan 30, 2004
AB	+!		EQ 10MG BASE;EQ 80MG BASE	N021540	008	Jan 30, 2004

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB		APOTEX INC	EQ 2.5MG BASE;10MG	A091431	001	Dec 30, 2013
AB			EQ 5MG BASE;10MG	A091431	002	Dec 30, 2013
AB			EQ 5MG BASE;20MG	A091431	003	Dec 30, 2013
AB			EQ 5MG BASE;40MG	A091431	004	Dec 30, 2013
AB			EQ 10MG BASE;20MG	A091431	005	Dec 30, 2013
AB			EQ 10MG BASE;40MG	A091431	006	Dec 30, 2013
AB		AUROBINDO PHARMA LTD	EQ 2.5MG BASE;10MG	A202239	001	Sep 05, 2012
AB			EQ 5MG BASE;10MG	A202239	002	Sep 05, 2012
AB			EQ 5MG BASE;20MG	A202239	003	Sep 05, 2012
AB			EQ 5MG BASE;40MG	A202239	004	Sep 05, 2012
AB			EQ 10MG BASE;20MG	A202239	005	Sep 05, 2012
AB			EQ 10MG BASE;40MG	A202239	006	Sep 05, 2012
AB		CIPLA	EQ 2.5MG BASE;10MG	A077215	001	Dec 07, 2018

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB		**EQ 5MG BASE;10MG**	**A077215**	**002**	Dec 07, 2018
AB		**EQ 5MG BASE;20MG**	**A077215**	**003**	Dec 07, 2018
AB		**EQ 10MG BASE;20MG**	**A077215**	**004**	Dec 07, 2018
AB	DR REDDYS LABS INC	**EQ 2.5MG BASE;10MG**	**A077183**	**001**	Apr 15, 2010
AB		**EQ 5MG BASE;10MG**	**A077183**	**002**	Apr 15, 2010
AB		**EQ 5MG BASE;20MG**	**A077183**	**003**	Apr 15, 2010
AB		**EQ 5MG BASE;40MG**	**A090149**	**001**	Jul 05, 2011
AB		**EQ 10MG BASE;20MG**	**A077183**	**004**	Apr 15, 2010
AB		**EQ 10MG BASE;40MG**	**A090149**	**002**	Jul 05, 2011
AB	LUPIN PHARMS	**EQ 2.5MG BASE;10MG**	**A078466**	**001**	Feb 05, 2010
AB		**EQ 5MG BASE;10MG**	**A078466**	**002**	Feb 05, 2010
AB		**EQ 5MG BASE;20MG**	**A078466**	**003**	Feb 05, 2010
AB		**EQ 5MG BASE;40MG**	**A078466**	**005**	Jul 05, 2011
AB		**EQ 10MG BASE;20MG**	**A078466**	**004**	Feb 05, 2010
AB		**EQ 10MG BASE;40MG**	**A078466**	**006**	Jul 05, 2011
AB	MYLAN	**EQ 2.5MG BASE;10MG**	**A077375**	**001**	May 21, 2010
AB		**EQ 5MG BASE;10MG**	**A077375**	**002**	May 21, 2010
AB		**EQ 5MG BASE;20MG**	**A077375**	**003**	May 21, 2010
AB		**EQ 5MG BASE;40MG**	**A079047**	**001**	Jul 05, 2011
AB		**EQ 10MG BASE;20MG**	**A077375**	**004**	May 21, 2010
AB		**EQ 10MG BASE;40MG**	**A079047**	**002**	Jul 05, 2011
AB	PAR PHARM	**EQ 2.5MG BASE;10MG**	**A078381**	**001**	Jul 29, 2010
AB		**EQ 5MG BASE;10MG**	**A078381**	**002**	Jul 29, 2010
AB		**EQ 5MG BASE;20MG**	**A078381**	**003**	Jul 29, 2010
AB		**EQ 5MG BASE;40MG**	**A078381**	**005**	Jul 29, 2010
AB		**EQ 10MG BASE;20MG**	**A078381**	**004**	Jul 29, 2010
AB		**EQ 10MG BASE;40MG**	**A078381**	**006**	Jul 29, 2010
AB	TEVA PHARMS	**EQ 2.5MG BASE;10MG**	**A077179**	**001**	May 18, 2007
AB		**EQ 5MG BASE;10MG**	**A077179**	**002**	May 18, 2007
AB		**EQ 5MG BASE;20MG**	**A077179**	**003**	May 18, 2007
AB		**EQ 5MG BASE;40MG**	**A077179**	**005**	Jul 05, 2011
AB		**EQ 10MG BASE;20MG**	**A077179**	**004**	May 18, 2007
AB		**EQ 10MG BASE;40MG**	**A077179**	**006**	Jul 05, 2011
AB	WATSON LABS	**EQ 2.5MG BASE;10MG**	**A077890**	**001**	Oct 14, 2010
AB		**EQ 5MG BASE;10MG**	**A077890**	**002**	Oct 14, 2010
AB		**EQ 5MG BASE;20MG**	**A077890**	**003**	Oct 14, 2010
AB		**EQ 10MG BASE;20MG**	**A077890**	**004**	Oct 14, 2010
AB	WATSON LABS INC	**EQ 5MG BASE;40MG**	**A090364**	**001**	Jul 05, 2011
AB		**EQ 10MG BASE;40MG**	**A090364**	**002**	Jul 05, 2011

LOTREL

AB	**+** NOVARTIS	**EQ 2.5MG BASE;10MG**	**N020364**	**002**	Mar 03, 1995
AB	**+**	**EQ 5MG BASE;10MG**	**N020364**	**003**	Mar 03, 1995
AB	**+**	**EQ 5MG BASE;20MG**	**N020364**	**004**	Mar 03, 1995
AB	**+**	**EQ 5MG BASE;40MG**	**N020364**	**007**	Apr 11, 2006
AB	**+**	**EQ 10MG BASE;20MG**	**N020364**	**005**	Jun 20, 2002
AB	**+!**	**EQ 10MG BASE;40MG**	**N020364**	**006**	Apr 11, 2006

AMLODIPINE BESYLATE; CELECOXIB

TABLET;ORAL

CONSENSI

	+ KITOV PHARMS LTD	EQ 2.5MG BASE;200MG	N210045	001	May 31, 2018
	+	EQ 5MG BASE;200MG	N210045	002	May 31, 2018
	+!	EQ 10MG BASE;200MG	N210045	003	May 31, 2018

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

AB	PAR PHARM INC	**EQ 5MG BASE;12.5MG;20MG**	**A206137**	**001**	Oct 26, 2016
AB		**EQ 5MG BASE;12.5MG;40MG**	**A206137**	**002**	Oct 26, 2016
AB		**EQ 5MG BASE;25MG;40MG**	**A206137**	**003**	Oct 26, 2016
AB		**EQ 10MG BASE;12.5MG;40MG**	**A206137**	**004**	Oct 26, 2016
AB		**EQ 10MG BASE;25MG;40MG**	**A206137**	**005**	Oct 26, 2016
AB	TEVA PHARMS USA	**EQ 5MG BASE;12.5MG;20MG**	**A202491**	**001**	Nov 03, 2016
AB		**EQ 5MG BASE;12.5MG;40MG**	**A202491**	**002**	Nov 03, 2016
AB		**EQ 5MG BASE;25MG;40MG**	**A202491**	**003**	Nov 03, 2016
AB		**EQ 10MG BASE;12.5MG;40MG**	**A202491**	**004**	Nov 03, 2016
AB		**EQ 10MG BASE;25MG;40MG**	**A202491**	**005**	Nov 03, 2016
AB	TORRENT PHARMS LTD	**EQ 5MG BASE;12.5MG;20MG**	**A203580**	**001**	Oct 26, 2016
AB		**EQ 5MG BASE;12.5MG;40MG**	**A203580**	**002**	Oct 26, 2016
AB		**EQ 5MG BASE;25MG;40MG**	**A203580**	**003**	Oct 26, 2016

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

AB			**EQ 10MG BASE;12.5MG;40MG**	**A203580**	**004**	Oct 26, 2016
AB			**EQ 10MG BASE;25MG;40MG**	**A203580**	**005**	Oct 26, 2016

TRIBENZOR

AB	+	DAIICHI SANKYO	**EQ 5MG BASE;12.5MG;20MG**	**N200175**	**001**	Jul 23, 2010
AB	+		**EQ 5MG BASE;12.5MG;40MG**	**N200175**	**002**	Jul 23, 2010
AB	+		**EQ 5MG BASE;25MG;40MG**	**N200175**	**003**	Jul 23, 2010
AB	+		**EQ 10MG BASE;12.5MG;40MG**	**N200175**	**004**	Jul 23, 2010
AB	+!		**EQ 10MG BASE;25MG;40MG**	**N200175**	**005**	Jul 23, 2010

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		AUROBINDO PHARMA LTD	**5MG;12.5MG;160MG**	**A206180**	**001**	Dec 19, 2017
AB			**5MG;25MG;160MG**	**A206180**	**002**	Dec 19, 2017
AB			**10MG;12.5MG;160MG**	**A206180**	**003**	Dec 19, 2017
AB			**10MG;25MG;160MG**	**A206180**	**004**	Dec 19, 2017
AB			**10MG;25MG;320MG**	**A206180**	**005**	Dec 19, 2017
AB		LUPIN LTD	**5MG;12.5MG;160MG**	**A200797**	**001**	Jun 03, 2015
AB			**5MG;25MG;160MG**	**A200797**	**002**	Jun 03, 2015
AB			**10MG;12.5MG;160MG**	**A200797**	**003**	Jun 03, 2015
AB			**10MG;25MG;160MG**	**A200797**	**004**	Jun 03, 2015
AB			**10MG;25MG;320MG**	**A200797**	**005**	Jun 03, 2015
AB		PAR PHARM	**5MG;12.5MG;160MG**	**A201087**	**001**	Jun 01, 2015
AB			**5MG;25MG;160MG**	**A201087**	**002**	Jun 01, 2015
AB			**10MG;12.5MG;160MG**	**A201087**	**003**	Jun 01, 2015
AB			**10MG;25MG;160MG**	**A201087**	**004**	Jun 01, 2015
AB			**10MG;25MG;320MG**	**A201087**	**005**	Jun 01, 2015
AB		TEVA PHARMS	**5MG;12.5MG;160MG**	**A200435**	**001**	Sep 25, 2012
AB			**5MG;25MG;160MG**	**A200435**	**002**	Sep 25, 2012
AB			**10MG;12.5MG;160MG**	**A200435**	**005**	Sep 25, 2012
AB			**10MG;25MG;160MG**	**A200435**	**003**	Sep 25, 2012
AB			**10MG;25MG;320MG**	**A200435**	**004**	Sep 25, 2012
AB		TORRENT PHARMS LTD	**5MG;12.5MG;160MG**	**A201593**	**001**	Jun 03, 2015
AB			**5MG;25MG;160MG**	**A201593**	**002**	Jun 03, 2015
AB			**10MG;12.5MG;160MG**	**A201593**	**003**	Jun 03, 2015
AB			**10MG;25MG;160MG**	**A201593**	**004**	Jun 03, 2015
AB			**10MG;25MG;320MG**	**A201593**	**005**	Jun 03, 2015

EXFORGE HCT

AB	+	NOVARTIS	**5MG;12.5MG;160MG**	**N022314**	**001**	Apr 30, 2009
AB	+		**5MG;25MG;160MG**	**N022314**	**002**	Apr 30, 2009
AB	+		**10MG;12.5MG;160MG**	**N022314**	**003**	Apr 30, 2009
AB	+		**10MG;25MG;160MG**	**N022314**	**004**	Apr 30, 2009
AB	+!		**10MG;25MG;320MG**	**N022314**	**005**	Apr 30, 2009

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB		ACCORD HLTHCARE INC	**EQ 5MG BASE;20MG**	**A209600**	**001**	Aug 30, 2018
AB			**EQ 5MG BASE;40MG**	**A209600**	**003**	Aug 30, 2018
AB			**EQ 10MG BASE;20MG**	**A209600**	**002**	Aug 30, 2018
AB			**EQ 10MG BASE;40MG**	**A209600**	**004**	Aug 30, 2018
AB		AJANTA PHARMA LTD	**EQ 5MG BASE;20MG**	**A207216**	**001**	Oct 28, 2016
AB			**EQ 5MG BASE;40MG**	**A207216**	**002**	Oct 28, 2016
AB			**EQ 10MG BASE;20MG**	**A207216**	**003**	Oct 28, 2016
AB			**EQ 10MG BASE;40MG**	**A207216**	**004**	Oct 28, 2016
AB		ALEMBIC PHARMS LTD	**EQ 5MG BASE;20MG**	**A207073**	**001**	Jul 17, 2017
AB			**EQ 5MG BASE;40MG**	**A207073**	**002**	Jul 17, 2017
AB			**EQ 10MG BASE;20MG**	**A207073**	**003**	Jul 17, 2017
AB			**EQ 10MG BASE;40MG**	**A207073**	**004**	Jul 17, 2017
AB		ALKEM LABS LTD	**EQ 5MG BASE;20MG**	**A209042**	**001**	Aug 14, 2017
AB			**EQ 5MG BASE;40MG**	**A209042**	**002**	Aug 14, 2017
AB			**EQ 10MG BASE;20MG**	**A209042**	**003**	Aug 14, 2017
AB			**EQ 10MG BASE;40MG**	**A209042**	**004**	Aug 14, 2017
AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE;20MG**	**A206906**	**001**	May 15, 2017
AB			**EQ 5MG BASE;40MG**	**A206906**	**002**	May 15, 2017
AB			**EQ 10MG BASE;20MG**	**A206906**	**003**	May 15, 2017
AB			**EQ 10MG BASE;40MG**	**A206906**	**004**	May 15, 2017
AB		GLENMARK PHARMS LTD	**EQ 5MG BASE;20MG**	**A207807**	**001**	Jul 05, 2017
AB			**EQ 5MG BASE;40MG**	**A207807**	**002**	Jul 05, 2017

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB			**EQ 10MG BASE;20MG**	**A207807**	**003**	Jul 05, 2017
AB			**EQ 10MG BASE;40MG**	**A207807**	**004**	Jul 05, 2017
AB		JUBILANT GENERICS	**EQ 5MG BASE;20MG**	**A207450**	**001**	May 15, 2017
AB			**EQ 5MG BASE;40MG**	**A207450**	**002**	May 15, 2017
AB			**EQ 10MG BASE;20MG**	**A207450**	**003**	May 15, 2017
AB			**EQ 10MG BASE;40MG**	**A207450**	**004**	May 15, 2017
AB		MACLEODS PHARMS LTD	**EQ 5MG BASE;20MG**	**A206884**	**001**	Oct 26, 2016
AB			**EQ 5MG BASE;40MG**	**A206884**	**003**	Oct 26, 2016
AB			**EQ 10MG BASE;20MG**	**A206884**	**002**	Oct 26, 2016
AB			**EQ 10MG BASE;40MG**	**A206884**	**004**	Oct 26, 2016
AB		MICRO LABS	**EQ 5MG BASE;20MG**	**A207435**	**001**	Nov 02, 2017
AB			**EQ 5MG BASE;40MG**	**A207435**	**002**	Nov 02, 2017
AB			**EQ 10MG BASE;20MG**	**A207435**	**003**	Nov 02, 2017
AB			**EQ 10MG BASE;40MG**	**A207435**	**004**	Nov 02, 2017
AB		SCIEGEN PHARMS INC	**EQ 5MG BASE;20MG**	**A209010**	**001**	Dec 03, 2018
AB			**EQ 5MG BASE;40MG**	**A209010**	**002**	Dec 03, 2018
AB			**EQ 10MG BASE;20MG**	**A209010**	**003**	Dec 03, 2018
AB			**EQ 10MG BASE;40MG**	**A209010**	**004**	Dec 03, 2018
AB		TEVA PHARMS USA	**EQ 5MG BASE;20MG**	**A091154**	**001**	Oct 26, 2016
AB			**EQ 5MG BASE;40MG**	**A091154**	**002**	Oct 26, 2016
AB			**EQ 10MG BASE;20MG**	**A091154**	**003**	Oct 26, 2016
AB			**EQ 10MG BASE;40MG**	**A091154**	**004**	Oct 26, 2016
AB		TORRENT PHARMS LTD	**EQ 5MG BASE;20MG**	**A202933**	**001**	Nov 25, 2016
AB			**EQ 5MG BASE;40MG**	**A202933**	**002**	Nov 25, 2016
AB			**EQ 10MG BASE;20MG**	**A202933**	**003**	Nov 25, 2016
AB			**EQ 10MG BASE;40MG**	**A202933**	**004**	Nov 25, 2016
AB		ZYDUS PHARMS USA INC	**EQ 5MG BASE;20MG**	**A207771**	**001**	Sep 22, 2017
AB			**EQ 5MG BASE;40MG**	**A207771**	**002**	Sep 22, 2017
AB			**EQ 10MG BASE;20MG**	**A207771**	**003**	Sep 22, 2017
AB			**EQ 10MG BASE;40MG**	**A207771**	**004**	Sep 22, 2017

AZOR

AB	**+**	DAIICHI SANKYO	**EQ 5MG BASE;20MG**	**N022100**	**001**	Sep 26, 2007
AB	**+**		**EQ 5MG BASE;40MG**	**N022100**	**002**	Sep 26, 2007
AB	**+**		**EQ 10MG BASE;20MG**	**N022100**	**003**	Sep 26, 2007
AB	**+!**		**EQ 10MG BASE;40MG**	**N022100**	**004**	Sep 26, 2007

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET;ORAL

PRESTALIA

	+	MARINA BIOTECH	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015
	+		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015
	+!		EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND AMLODIPINE

AB		ALEMBIC PHARMS LTD	**EQ 5MG BASE;40MG**	**A205234**	**001**	Nov 17, 2016
AB			**EQ 5MG BASE;80MG**	**A205234**	**003**	Nov 17, 2016
AB			**EQ 10MG BASE;40MG**	**A205234**	**002**	Nov 17, 2016
AB			**EQ 10MG BASE;80MG**	**A205234**	**004**	Nov 17, 2016
AB		LUPIN LTD	**EQ 5MG BASE;40MG**	**A201586**	**001**	Jan 08, 2014
AB			**EQ 5MG BASE;80MG**	**A201586**	**003**	Jan 08, 2014
AB			**EQ 10MG BASE;40MG**	**A201586**	**002**	Jan 08, 2014
AB			**EQ 10MG BASE;80MG**	**A201586**	**004**	Jan 08, 2014
AB		MYLAN PHARMS INC	**EQ 5MG BASE;40MG**	**A202516**	**001**	Aug 26, 2014
AB			**EQ 5MG BASE;80MG**	**A202516**	**003**	Aug 26, 2014
AB			**EQ 10MG BASE;40MG**	**A202516**	**002**	Aug 26, 2014
AB			**EQ 10MG BASE;80MG**	**A202516**	**004**	Aug 26, 2014
AB		TORRENT PHARMS LTD	**EQ 5MG BASE;40MG**	**A202517**	**001**	Jan 08, 2014
AB			**EQ 5MG BASE;80MG**	**A202517**	**003**	Jan 08, 2014
AB			**EQ 10MG BASE;40MG**	**A202517**	**002**	Jan 08, 2014
AB			**EQ 10MG BASE;80MG**	**A202517**	**004**	Jan 08, 2014

TWYNSTA

AB	**+**	BOEHRINGER INGELHEIM	**EQ 5MG BASE;40MG**	**N022401**	**001**	Oct 16, 2009
AB	**+**		**EQ 5MG BASE;80MG**	**N022401**	**003**	Oct 16, 2009
AB	**+**		**EQ 10MG BASE;40MG**	**N022401**	**002**	Oct 16, 2009
AB	**+!**		**EQ 10MG BASE;80MG**	**N022401**	**004**	Oct 16, 2009

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB		ALEMBIC PHARMS LTD	**EQ 5MG BASE;160MG**	**A202713**	**001**	Apr 03, 2015
AB			**EQ 5MG BASE;320MG**	**A202713**	**003**	Apr 03, 2015
AB			**EQ 10MG BASE;160MG**	**A202713**	**002**	Apr 03, 2015
AB			**EQ 10MG BASE;320MG**	**A202713**	**004**	Apr 03, 2015
AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE;160MG**	**A206512**	**001**	Apr 22, 2016
AB			**EQ 5MG BASE;320MG**	**A206512**	**002**	Apr 22, 2016
AB			**EQ 10MG BASE;160MG**	**A206512**	**003**	Apr 22, 2016
AB			**EQ 10MG BASE;320MG**	**A206512**	**004**	Apr 22, 2016
AB		INVAGEN PHARMS	**EQ 5MG BASE;160MG**	**A205137**	**001**	Sep 16, 2016
AB			**EQ 5MG BASE;320MG**	**A205137**	**003**	Sep 16, 2016
AB			**EQ 10MG BASE;160MG**	**A205137**	**002**	Sep 16, 2016
AB			**EQ 10MG BASE;320MG**	**A205137**	**004**	Sep 16, 2016
AB		LUPIN	**EQ 5MG BASE;160MG**	**A090245**	**001**	Mar 30, 2015
AB			**EQ 5MG BASE;320MG**	**A090245**	**003**	Mar 30, 2015
AB			**EQ 10MG BASE;160MG**	**A090245**	**002**	Mar 30, 2015
AB			**EQ 10MG BASE;320MG**	**A090245**	**004**	Mar 30, 2015
AB		MYLAN PHARMS INC	**EQ 5MG BASE;160MG**	**A090483**	**001**	Mar 30, 2015
AB			**EQ 5MG BASE;320MG**	**A090483**	**003**	Mar 30, 2015
AB			**EQ 10MG BASE;160MG**	**A090483**	**002**	Mar 30, 2015
AB			**EQ 10MG BASE;320MG**	**A090483**	**004**	Mar 30, 2015
AB		NOVEL LABS INC	**EQ 5MG BASE;160MG**	**A202829**	**001**	Mar 30, 2015
AB			**EQ 5MG BASE;320MG**	**A202829**	**003**	Mar 30, 2015
AB			**EQ 10MG BASE;160MG**	**A202829**	**002**	Mar 30, 2015
AB			**EQ 10MG BASE;320MG**	**A202829**	**004**	Mar 30, 2015
AB		PAR PHARM INC	**EQ 5MG BASE;160MG**	**A090011**	**001**	Mar 28, 2013
AB			**EQ 5MG BASE;320MG**	**A090011**	**003**	Mar 28, 2013
AB			**EQ 10MG BASE;160MG**	**A090011**	**002**	Mar 28, 2013
AB			**EQ 10MG BASE;320MG**	**A090011**	**004**	Mar 28, 2013
AB		TEVA PHARMS USA	**EQ 5MG BASE;160MG**	**A091235**	**001**	Mar 30, 2015
AB			**EQ 5MG BASE;320MG**	**A091235**	**003**	Mar 30, 2015
AB			**EQ 10MG BASE;160MG**	**A091235**	**002**	Mar 30, 2015
AB			**EQ 10MG BASE;320MG**	**A091235**	**004**	Mar 30, 2015
AB		TORRENT PHARMS LTD	**EQ 5MG BASE;160MG**	**A202377**	**001**	Mar 30, 2015
AB			**EQ 5MG BASE;320MG**	**A202377**	**002**	Mar 30, 2015
AB			**EQ 10MG BASE;160MG**	**A202377**	**003**	Mar 30, 2015
AB			**EQ 10MG BASE;320MG**	**A202377**	**004**	Mar 30, 2015

EXFORGE

AB	+	NOVARTIS	**EQ 5MG BASE;160MG**	**N021990**	**002**	Jun 20, 2007
AB	+		**EQ 5MG BASE;320MG**	**N021990**	**004**	Jun 20, 2007
AB	+!		**EQ 10MG BASE;160MG**	**N021990**	**003**	Jun 20, 2007
AB	+!		**EQ 10MG BASE;320MG**	**N021990**	**005**	Jun 20, 2007

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP		3D IMAGING DRUG	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203779**	**001**	Oct 19, 2015
AP		BIOMEDCL RES FDN	**48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)**	**A204352**	**001**	May 01, 2015
AP		BRIGHAM WOMENS HOSP	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203783**	**001**	Oct 30, 2014
AP		CARDINAL HEALTH 414	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203700**	**001**	Feb 25, 2013
AP	+!	FEINSTEIN	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**N022119**	**001**	Aug 23, 2007
AP		GEN HOSP	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A207025**	**001**	Feb 03, 2016
AP		GLOBAL ISOTOPES LLC	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204465**	**001**	Oct 23, 2014
AP		IONETIX	**22.5mCi-225mCi/6ML (3.75-37.5mCi/ML)**	**A210524**	**001**	Dec 21, 2018
AP		JOHNS HOPKINS UNIV	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204514**	**001**	Aug 19, 2014
AP		KREITCHMAN PET CTR	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203938**	**001**	Dec 09, 2013
AP		MCPRF	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203321**	**001**	Feb 25, 2013
AP		MIDWEST MEDCL	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204457**	**001**	Nov 18, 2015
AP		MIPS CRF	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204535**	**001**	Nov 20, 2014
AP		PETNET	**30mCi-300mCi (3.75-37.5mCi/ML)**	**A204510**	**001**	Nov 02, 2015
AP		SOFIE	**18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)**	**A204667**	**001**	Apr 22, 2015
AP		SPECTRON MRC LLC	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204455**	**001**	Apr 23, 2015
AP		UCLA BIOMEDICAL	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203812**	**001**	Jun 27, 2013
AP		UCSF RODIOPHARM	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204496**	**001**	Mar 28, 2014
AP		WA UNIV SCH MED	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204506**	**001**	Feb 07, 2014
		ESSENTIAL ISOTOPES	3.75-260mCi/ML	A205687	001	Dec 17, 2015
		HOUSTON CYCLOTRON	3.75-260mCi/ML	A203543	001	Dec 14, 2012
		NCM USA BRONX LLC	3.75-260mCi/mL	A204515	001	Feb 04, 2015
		PRECISION NUCLEAR	3.75-260mCi/ML	A204547	001	Aug 14, 2015

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

		SHERTECH LABS LLC	3.75-260mCi/ML	A204366 001	Sep 19, 2014
		WI MEDCL CYCLOTRON	3.75-260mCi/ML	A204356 001	Dec 18, 2014

AMMONIUM CHLORIDE

INJECTABLE;INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

	!	HOSPIRA	5MEQ/ML	A088366 001	Jun 13, 1984

AMMONIUM LACTATE

CREAM;TOPICAL

AMMONIUM LACTATE

AB	**!**	PERRIGO NEW YORK	**EQ 12% BASE**	**A075774 001**	May 01, 2002
AB		TARO	**EQ 12% BASE**	**A075883 001**	Apr 10, 2003
AB		WATSON LABS INC	**EQ 12% BASE**	**A076829 001**	Feb 07, 2006

LOTION;TOPICAL

AMMONIUM LACTATE

AB	**!**	PERRIGO NEW YORK	**EQ 12% BASE**	**A075570 001**	Jun 23, 2004
AB		TARO	**EQ 12% BASE**	**A076216 001**	May 28, 2004
AB		WATSON LABS INC	**EQ 12% BASE**	**A075575 001**	Jun 11, 2002

AMOXAPINE

TABLET;ORAL

AMOXAPINE

		WATSON LABS	25MG	A072691 002	Aug 28, 1992
			50MG	A072691 003	Aug 28, 1992
			100MG	A072691 004	Aug 28, 1992
	!		150MG	A072691 001	Aug 28, 1992

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

AB		AM ANTIBIOTICS	**250MG**	**A062058 001**	
AB			**500MG**	**A062058 002**	
AB		AUROBINDO	**250MG**	**A065271 001**	Nov 09, 2005
AB			**500MG**	**A065271 002**	Nov 09, 2005
AB		DAVA PHARMS INC	**250MG**	**A062884 001**	Feb 25, 1988
AB			**500MG**	**A062881 001**	Feb 25, 1988
AB		HIKMA PHARMS	**250MG**	**A065291 001**	Feb 05, 2007
AB			**500MG**	**A065291 002**	Feb 05, 2007
AB		SANDOZ	**250MG**	**A064076 001**	Sep 30, 1994
AB			**500MG**	**A064076 002**	Sep 30, 1994
AB		TEVA	**250MG**	**A061926 001**	
AB	**!**		**500MG**	**A061926 003**	

AMOXIL

AB		NEOPHARMA	**250MG**	**A062216 001**	
AB			**500MG**	**A062216 004**	

FOR SUSPENSION;ORAL

AMOXICILLIN

AB		AUROBINDO	**200MG/5ML**	**A065334 001**	Dec 28, 2006
AB			**400MG/5ML**	**A065334 002**	Dec 28, 2006
AB		AUROBINDO PHARMA LTD	**125MG/5ML**	**A204030 001**	Sep 15, 2014
AB			**250MG/5ML**	**A204030 002**	Sep 15, 2014
AB		DAVA PHARMS INC	**125MG/5ML**	**A062927 001**	Nov 25, 1988
AB			**250MG/5ML**	**A062927 002**	Nov 25, 1988
AB		HIKMA	**125MG/5ML**	**A065322 002**	Jun 19, 2006
AB			**200MG/5ML**	**A065325 002**	Jun 19, 2006
AB			**250MG/5ML**	**A065322 001**	Jun 19, 2006
AB			**400MG/5ML**	**A065325 001**	Jun 19, 2006
AB		SANDOZ	**125MG/5ML**	**A065387 001**	Mar 26, 2007
AB			**200MG/5ML**	**A065378 001**	Mar 26, 2007
AB			**250MG/5ML**	**A065387 002**	Mar 26, 2007
AB			**400MG/5ML**	**A065378 002**	Mar 26, 2007
AB		TEVA	**125MG/5ML**	**A061931 001**	
AB			**200MG/5ML**	**A065119 001**	Dec 04, 2002
AB	**!**		**250MG/5ML**	**A061931 002**	
AB	**!**		**400MG/5ML**	**A065119 002**	Dec 04, 2002
AB		WOCKHARDT BIO AG	**400MG/5ML**	**A065319 002**	Jun 18, 2007

AMOXICILLIN PEDIATRIC

AB		TEVA	**50MG/ML**	**A061931 003**	Dec 01, 1982

AMOXICILLIN						
FOR SUSPENSION;ORAL						
AMOXIL						
AB	NEOPHARMA	**50MG/ML**	**A062226**	**005**		
AB		**125MG/5ML**	**A062226**	**001**		
AB		**250MG/5ML**	**A062226**	**002**		
LAROTID						
AB	NEOPHARMA	**125MG/5ML**	**A062226**	**003**		
AB		**250MG/5ML**	**A062226**	**004**		
TABLET;ORAL						
AMOXICILLIN						
AB	AUROBINDO	**500MG**	**A065256**	**001**	Nov 09, 2005	
AB		**875MG**	**A065256**	**002**	Nov 09, 2005	
AB	HIKMA	**875MG**	**A065255**	**001**	Mar 29, 2006	
AB	SANDOZ	**500MG**	**A065228**	**001**	Jul 13, 2005	
AB		**875MG**	**A065228**	**002**	Jul 13, 2005	
AB	TEVA	**500MG**	**A065056**	**001**	Sep 18, 2000	
AB !		**875MG**	**A065056**	**002**	Sep 18, 2000	
TABLET, CHEWABLE;ORAL						
AMOXICILLIN						
	TEVA	125MG	A064013	002	Sep 11, 1995	
!		250MG	A064013	001	Dec 22, 1992	
AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE						
CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL						
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN						
AB !	RISING PHARMS	**500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG**	**A206006**	**001**	Oct 07, 2016	
AB	SANDOZ INC	**500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG**	**A202588**	**001**	Mar 04, 2014	
AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE						
CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL						
OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN						
+!	CUMBERLAND PHARMS	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824	001	Feb 08, 2011	
AMOXICILLIN; CLAVULANATE POTASSIUM						
FOR SUSPENSION;ORAL						
AMOXICILLIN AND CLAVULANATE POTASSIUM						
AB	AUROBINDO PHARMA LTD	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A201090**	**001**	Dec 20, 2011	
AB		**400MG/5ML;EQ 57MG BASE/5ML**	**A201090**	**002**	Dec 20, 2011	
AB		**600MG/5ML;EQ 42.9MG BASE/5ML**	**A201091**	**001**	Dec 20, 2011	
AB	HIKMA PHARMS	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A065191**	**002**	Jan 25, 2005	
AB		**400MG/5ML;EQ 57MG BASE/5ML**	**A065191**	**001**	Jan 25, 2005	
AB		**600MG/5ML;EQ 42.9MG BASE/5ML**	**A065373**	**001**	Nov 09, 2007	
AB	SANDOZ	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A065066**	**001**	Jun 05, 2002	
AB		**400MG/5ML;EQ 57MG BASE/5ML**	**A065066**	**002**	Jun 05, 2002	
AB	SANDOZ INC	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A065098**	**001**	Dec 16, 2002	
AB		**400MG/5ML;EQ 57MG BASE/5ML**	**A065098**	**002**	Dec 16, 2002	
AB		**600MG/5ML;EQ 42.9MG BASE/5ML**	**A065358**	**001**	Aug 13, 2007	
AB	TEVA	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A065089**	**001**	May 25, 2004	
AB !		**400MG/5ML;EQ 57MG BASE/5ML**	**A065089**	**002**	May 25, 2004	
AB !		**600MG/5ML;EQ 42.9MG BASE/5ML**	**A065162**	**001**	Mar 12, 2004	
AB	WOCKHARDT BIO AG	**250MG/5ML;EQ 62.5MG BASE/5ML**	**A065431**	**001**	Nov 25, 2008	
AB		**600MG/5ML;EQ 42.9MG BASE/5ML**	**A065420**	**001**	Dec 02, 2013	
AUGMENTIN '250'						
AB **+!**	NEOPHARMA	**250MG/5ML;EQ 62.5MG BASE/5ML**	**N050575**	**002**	Aug 06, 1984	
AUGMENTIN '125'						
+	NEOPHARMA	125MG/5ML;EQ 31.25MG BASE/5ML	N050575	001	Aug 06, 1984	
TABLET;ORAL						
AMOXICILLIN AND CLAVULANATE POTASSIUM						
AB	AUROBINDO PHARMA LTD	**250MG;EQ 125MG BASE**	**A091569**	**001**	Jan 20, 2012	
AB		**500MG;EQ 125MG BASE**	**A091569**	**002**	Jan 20, 2012	
AB		**875MG;EQ 125MG BASE**	**A091568**	**001**	Jan 20, 2012	
AB	HIKMA PHARMS	**875MG;EQ 125MG BASE**	**A203824**	**001**	Aug 23, 2016	
AB	MICRO LABS LTD INDIA	**250MG;EQ 125MG BASE**	**A205707**	**001**	Dec 30, 2016	
AB		**500MG;EQ 125MG BASE**	**A205707**	**002**	Dec 30, 2016	
AB		**875MG;EQ 125MG BASE**	**A204755**	**003**	Dec 30, 2016	
AB !	SANDOZ	**250MG;EQ 125MG BASE**	**A065189**	**001**	Aug 23, 2005	
AB		**500MG;EQ 125MG BASE**	**A065064**	**001**	Mar 15, 2002	
AB !		**875MG;EQ 125MG BASE**	**A065063**	**001**	Mar 14, 2002	

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	**!**	SANDOZ INC	**500MG;EQ 125MG BASE**	**A065117**	**001**	Nov 27, 2002
AB			**875MG;EQ 125MG BASE**	**A065093**	**001**	Nov 21, 2002
AB		TEVA	**500MG;EQ 125MG BASE**	**A065101**	**001**	Oct 30, 2002
AB		TEVA PHARMS USA	**875MG;EQ 125MG BASE**	**A065096**	**001**	Oct 29, 2002

AUGMENTIN '875'

AB	**+**	DR REDDYS LABS INC	**875MG;EQ 125MG BASE**	**N050720**	**001**	Feb 13, 1996

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

	TEVA	200MG;EQ 28.5MG BASE	A065205	001	Feb 09, 2005
!		400MG;EQ 57MG BASE	A065205	002	Feb 09, 2005

TABLET, EXTENDED RELEASE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		SANDOZ	**1GM;EQ 62.5MG BASE**	**A090227**	**001**	Apr 21, 2010

AUGMENTIN XR

AB	**+!**	NEOPHARMA	**1GM;EQ 62.5MG BASE**	**N050785**	**001**	Sep 25, 2002

AMPHETAMINE

SUSPENSION, EXTENDED RELEASE;ORAL

ADZENYS ER

+!	NEOS THERAPS INC	EQ 1.25MG BASE/ML	N204325	001	Sep 15, 2017

DYANAVEL XR

+!	TRIS PHARMA INC	EQ 2.5MG BASE/ML	N208147	001	Oct 19, 2015

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

ADZENYS XR-ODT

+	NEOS THERAPS	EQ 3.1MG BASE	N204326	001	Jan 27, 2016
+		EQ 6.3MG BASE	N204326	002	Jan 27, 2016
+		EQ 9.4MG BASE	N204326	003	Jan 27, 2016
+		EQ 12.5MG BASE	N204326	004	Jan 27, 2016
+		EQ 15.7MG BASE	N204326	005	Jan 27, 2016
+!		EQ 18.8MG BASE	N204326	006	Jan 27, 2016

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

ADDERALL XR 10

AB	**+**	SHIRE	**2.5MG;2.5MG;2.5MG;2.5MG**	**N021303**	**001**	Oct 11, 2001

ADDERALL XR 15

AB	**+**	SHIRE	**3.75MG;3.75MG;3.75MG;3.75MG**	**N021303**	**006**	May 22, 2002

ADDERALL XR 20

AB	**+**	SHIRE	**5MG;5MG;5MG;5MG**	**N021303**	**002**	Oct 11, 2001

ADDERALL XR 25

AB	**+**	SHIRE	**6.25MG;6.25MG;6.25MG;6.25MG**	**N021303**	**004**	May 22, 2002

ADDERALL XR 30

AB	**+!**	SHIRE	**7.5MG;7.5MG;7.5MG;7.5MG**	**N021303**	**003**	Oct 11, 2001

ADDERALL XR 5

AB	**+**	SHIRE	**1.25MG;1.25MG;1.25MG;1.25MG**	**N021303**	**005**	May 22, 2002

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	**1.25MG;1.25MG;1.25MG;1.25MG**	**A077302**	**001**	Jun 22, 2012
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A077302**	**002**	Jun 22, 2012
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A077302**	**003**	Jun 22, 2012
AB		**5MG;5MG;5MG;5MG**	**A077302**	**004**	Jun 22, 2012
AB		**6.25MG;6.25MG;6.25MG;6.25MG**	**A077302**	**005**	Jun 22, 2012
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A077302**	**006**	Jun 22, 2012
AB	IMPAX LABS	**1.25MG;1.25MG;1.25MG;1.25MG**	**A076852**	**001**	Feb 16, 2016
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A076852**	**002**	Feb 16, 2016
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A076852**	**003**	Feb 16, 2016
AB		**5MG;5MG;5MG;5MG**	**A076852**	**004**	Feb 16, 2016
AB		**6.25MG;6.25MG;6.25MG;6.25MG**	**A076852**	**005**	Feb 16, 2016
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A076852**	**006**	Feb 16, 2016
AB	TEVA	**1.25MG;1.25MG;1.25MG;1.25MG**	**A077488**	**001**	Apr 29, 2013
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A077488**	**002**	Apr 29, 2013
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A077488**	**003**	Apr 29, 2013
AB		**5MG;5MG;5MG;5MG**	**A077488**	**004**	Apr 29, 2013
AB		**6.25MG;6.25MG;6.25MG;6.25MG**	**A077488**	**005**	Apr 29, 2013
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A077488**	**006**	Apr 29, 2013

DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE

AB	BARR LABS INC	**1.25MG;1.25MG;1.25MG;1.25MG**	**A076536**	**001**	Feb 12, 2013
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A076536**	**002**	Feb 12, 2013
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A076536**	**003**	Feb 12, 2013
AB		**5MG;5MG;5MG;5MG**	**A076536**	**004**	Feb 12, 2013
AB		**6.25MG;6.25MG;6.25MG;6.25MG**	**A076536**	**005**	Feb 12, 2013

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE

AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A076536**	**006**	Feb 12, 2013

MYDAYIS

+	SHIRE DEV LLC	3.125MG;3.125MG;3.125MG;3.125MG	N022063	001	Jun 20, 2017
+		6.25MG;6.25MG;6.25MG;6.25MG	N022063	002	Jun 20, 2017
+		9.375MG;9.375MG;9.375MG;9.375MG	N022063	003	Jun 20, 2017
+!		12.5MG;12.5MG;12.5MG;12.5MG	N022063	004	Jun 20, 2017

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	**1.25MG;1.25MG;1.25MG;1.25MG**	**A206340**	**001**	Feb 05, 2016
AB		**1.875MG;1.875MG;1.875MG;1.875MG**	**A206340**	**002**	Feb 05, 2016
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A206340**	**003**	Feb 05, 2016
AB		**3.125MG;3.125MG;3.125MG;3.125MG**	**A206340**	**004**	Feb 05, 2016
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A206340**	**005**	Feb 05, 2016
AB		**5MG;5MG;5MG;5MG**	**A206340**	**006**	Feb 05, 2016
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A206340**	**007**	Feb 05, 2016
AB	ALVOGEN MALTA	**1.25MG;1.25MG;1.25MG;1.25MG**	**A207388**	**001**	Jul 28, 2017
AB		**1.875MG;1.875MG;1.875MG;1.875MG**	**A207388**	**002**	Jul 28, 2017
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A207388**	**003**	Jul 28, 2017
AB		**3.125MG;3.125MG;3.125MG;3.125MG**	**A207388**	**004**	Jul 28, 2017
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A207388**	**005**	Jul 28, 2017
AB		**5MG;5MG;5MG;5MG**	**A207388**	**006**	Jul 28, 2017
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A207388**	**007**	Jul 28, 2017
AB	AUROLIFE PHARMA LLC	**1.25MG;1.25MG;1.25MG;1.25MG**	**A202424**	**001**	Nov 27, 2013
AB		**1.875MG;1.875MG;1.875MG;1.875MG**	**A202424**	**002**	Nov 27, 2013
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A202424**	**003**	Nov 27, 2013
AB		**3.125MG;3.125MG;3.125MG;3.125MG**	**A202424**	**004**	Nov 27, 2013
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A202424**	**005**	Nov 27, 2013
AB		**5MG;5MG;5MG;5MG**	**A202424**	**006**	Nov 27, 2013
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A202424**	**007**	Nov 27, 2013
AB	BARR	**1.25MG;1.25MG;1.25MG;1.25MG**	**A040422**	**001**	Feb 11, 2002
AB		**1.875MG;1.875MG;1.875MG;1.875MG**	**A040422**	**005**	Mar 19, 2003
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A040422**	**002**	Feb 11, 2002
AB		**3.125MG;3.125MG;3.125MG;3.125MG**	**A040422**	**006**	Mar 19, 2003
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A040422**	**007**	Mar 19, 2003
AB		**5MG;5MG;5MG;5MG**	**A040422**	**003**	Feb 11, 2002
AB	!	**7.5MG;7.5MG;7.5MG;7.5MG**	**A040422**	**004**	Feb 11, 2002
AB	EPIC PHARMA LLC	**1.25MG;1.25MG;1.25MG;1.25MG**	**A040444**	**001**	Jun 19, 2002
AB		**1.875MG;1.875MG;1.875MG;1.875MG**	**A040444**	**005**	Nov 03, 2014
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A040444**	**002**	Jun 19, 2002
AB		**3.125MG;3.125MG;3.125MG;3.125MG**	**A040444**	**006**	Nov 03, 2014
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A040444**	**007**	Nov 03, 2014
AB		**5MG;5MG;5MG;5MG**	**A040444**	**003**	Jun 19, 2002
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A040444**	**004**	Jun 19, 2002
AB	MYLAN PHARMS INC	**1.25MG;1.25MG;1.25MG;1.25MG**	**A206721**	**001**	Nov 10, 2015
AB		**1.875MG;1.875MG;1.875MG;1.875MG**	**A206721**	**002**	Nov 10, 2015
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A206721**	**003**	Nov 10, 2015
AB		**3.125MG;3.125MG;3.125MG;3.125MG**	**A206721**	**004**	Nov 10, 2015
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A206721**	**005**	Nov 10, 2015
AB		**5MG;5MG;5MG;5MG**	**A206721**	**006**	Nov 10, 2015
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A206721**	**007**	Nov 10, 2015
AB	NESHER PHARMS	**1.25MG;1.25MG;1.25MG;1.25MG**	**A207340**	**001**	Oct 31, 2017
AB		**1.875MG;1.875MG;1.875MG;1.875MG**	**A207340**	**002**	Oct 31, 2017
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A207340**	**003**	Oct 31, 2017
AB		**3.125MG;3.125MG;3.125MG;3.125MG**	**A207340**	**004**	Oct 31, 2017
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A207340**	**005**	Oct 31, 2017
AB		**5MG;5MG;5MG;5MG**	**A207340**	**006**	Oct 31, 2017
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A207340**	**007**	Oct 31, 2017
AB	NUVO PHARM	**1.25MG;1.25MG;1.25MG;1.25MG**	**A209799**	**001**	Dec 28, 2017
AB		**1.875MG;1.875MG;1.875MG;1.875MG**	**A209799**	**002**	Dec 28, 2017
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A209799**	**003**	Dec 28, 2017
AB		**3.125MG;3.125MG;3.125MG;3.125MG**	**A209799**	**004**	Dec 28, 2017
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A209799**	**005**	Dec 28, 2017
AB		**5MG;5MG;5MG;5MG**	**A209799**	**006**	Dec 28, 2017
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A209799**	**007**	Dec 28, 2017
AB	SANDOZ	**1.25MG;1.25MG;1.25MG;1.25MG**	**A040439**	**004**	Sep 27, 2002
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A040439**	**001**	Jun 14, 2002
AB		**5MG;5MG;5MG;5MG**	**A040439**	**002**	Jun 14, 2002
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A040439**	**003**	Jun 14, 2002
AB	SPECGX LLC	**1.25MG;1.25MG;1.25MG;1.25MG**	**A040440**	**001**	Oct 07, 2003

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		**1.875MG;1.875MG;1.875MG;1.875MG**	**A040440**	**002**	Oct 07, 2003
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A040440**	**003**	Oct 07, 2003
AB		**3.125MG;3.125MG;3.125MG;3.125MG**	**A040440**	**004**	Oct 07, 2003
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A040440**	**005**	Oct 07, 2003
AB		**5MG;5MG;5MG;5MG**	**A040440**	**006**	Oct 07, 2003
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A040440**	**007**	Oct 07, 2003
AB	SUN PHARM INDUSTRIES	**1.25MG;1.25MG;1.25MG;1.25MG**	**A040480**	**001**	Sep 09, 2003
AB		**1.875MG;1.875MG;1.875MG;1.875MG**	**A040480**	**002**	Sep 09, 2003
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A040480**	**003**	Sep 09, 2003
AB		**3.125MG;3.125MG;3.125MG;3.125MG**	**A040480**	**004**	Sep 09, 2003
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A040480**	**005**	Sep 09, 2003
AB		**5MG;5MG;5MG;5MG**	**A040480**	**006**	Sep 09, 2003
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A040480**	**007**	Sep 09, 2003
AB	SUNGEN PHARMA	**1.25MG;1.25MG;1.25MG;1.25MG**	**A211352**	**001**	Dec 07, 2018
AB		**1.875MG;1.875MG;1.875MG;1.875MG**	**A211352**	**002**	Dec 07, 2018
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A211352**	**003**	Dec 07, 2018
AB		**3.125MG;3.125MG;3.125MG;3.125MG**	**A211352**	**004**	Dec 07, 2018
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A211352**	**005**	Dec 07, 2018
AB		**5MG;5MG;5MG;5MG**	**A211352**	**006**	Dec 07, 2018
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A211352**	**007**	Dec 07, 2018

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

AA	AMNEAL PHARMS	**5MG**	**A211139**	**001**	Sep 26, 2018
AA		**10MG**	**A211139**	**002**	Sep 26, 2018

EVEKEO

AA	ARBOR PHARMS LLC	**5MG**	**A200166**	**001**	Aug 09, 2012
AA !		**10MG**	**A200166**	**002**	Aug 09, 2012

AMPHOTERICIN B

INJECTABLE;INJECTION

AMPHOTERICIN B

!	X GEN PHARMS	50MG/VIAL	A063206	001	Apr 29, 1992

INJECTABLE, LIPID COMPLEX;INJECTION

ABELCET

+!	LEADIANT BIOSCI INC	5MG/ML	N050724	001	Nov 20, 1995

INJECTABLE, LIPOSOMAL;INJECTION

AMBISOME

+!	ASTELLAS	50MG/VIAL	N050740	001	Aug 11, 1997

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

AP	ACS DOBFAR SPA	**EQ 10GM BASE/VIAL**	**A090889**	**001**	Apr 03, 2013
AP	ANTIBIOTICE	**EQ 250MG BASE/VIAL**	**A090354**	**001**	Dec 28, 2009
AP		**EQ 500MG BASE/VIAL**	**A090354**	**002**	Dec 28, 2009
AP		**EQ 1GM BASE/VIAL**	**A090354**	**003**	Dec 28, 2009
AP		**EQ 2GM BASE/VIAL**	**A090354**	**004**	Dec 28, 2009
AP	AUROBINDO PHARMA	**EQ 250MG BASE/VIAL**	**A065499**	**002**	Aug 17, 2010
AP		**EQ 500MG BASE/VIAL**	**A065499**	**003**	Aug 17, 2010
AP		**EQ 1GM BASE/VIAL**	**A065499**	**004**	Aug 17, 2010
AP		**EQ 2GM BASE/VIAL**	**A065499**	**005**	Aug 17, 2010
AP		**EQ 10GM BASE/VIAL**	**A065493**	**001**	Aug 17, 2010
AP	HANFORD GC	**EQ 250MG BASE/VIAL**	**A062772**	**006**	Apr 15, 1993
AP		**EQ 500MG BASE/VIAL**	**A062772**	**007**	Apr 15, 1993
AP		**EQ 1GM BASE/VIAL**	**A062772**	**001**	Apr 15, 1993
AP		**EQ 2GM BASE/VIAL**	**A062772**	**003**	Apr 15, 1993
AP		**EQ 10GM BASE/VIAL**	**A063142**	**001**	Apr 15, 1993
AP	HOSPIRA INC	**EQ 250MG BASE/VIAL**	**A202864**	**001**	Sep 04, 2015
AP		**EQ 500MG BASE/VIAL**	**A202864**	**002**	Sep 04, 2015
AP		**EQ 1GM BASE/VIAL**	**A202864**	**003**	Sep 04, 2015
AP		**EQ 2GM BASE/VIAL**	**A202864**	**004**	Sep 04, 2015
AP		**EQ 10GM BASE/VIAL**	**A202865**	**001**	Sep 04, 2015
AP	ISTITUTO BIO ITA SPA	**EQ 10GM BASE/VIAL**	**A201404**	**001**	Dec 20, 2013
AP		**EQ 250MG BASE/VIAL**	**A062719**	**001**	May 12, 1987
AP		**EQ 500MG BASE/VIAL**	**A062719**	**003**	May 12, 1987
AP		**EQ 1GM BASE/VIAL**	**A062719**	**002**	May 12, 1987

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

AP			EQ 2GM BASE/VIAL	A062797	002	Jul 12, 1993
AP		MYLAN LABS LTD	EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014
AP			EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014
AP			EQ 1GM BASE/VIAL	A201025	003	Apr 09, 2014
AP			EQ 2GM BASE/VIAL	A201025	004	Apr 09, 2014
AP			EQ 10GM BASE/VIAL	A202198	001	Apr 07, 2014
AP		SAGENT PHARMS	EQ 125MG BASE/VIAL	A090583	001	Nov 27, 2015
AP			EQ 250MG BASE/VIAL	A090583	002	Nov 27, 2015
AP			EQ 500MG BASE/VIAL	A090583	003	Nov 27, 2015
AP			EQ 1GM BASE/VIAL	A090583	004	Nov 27, 2015
AP			EQ 2GM BASE/VIAL	A090583	005	Nov 27, 2015
AP			EQ 10GM BASE/VIAL	A090581	001	Oct 20, 2015
AP	!	SANDOZ	EQ 125MG BASE/VIAL	A061395	001	
AP	!		EQ 250MG BASE/VIAL	A061395	002	
AP	!		EQ 500MG BASE/VIAL	A061395	003	
AP	!		EQ 1GM BASE/VIAL	A061395	004	
AP	!		EQ 2GM BASE/VIAL	A061395	005	
AP	!		EQ 10GM BASE/VIAL	A061395	006	

POWDER;INTRAVENOUS

AMPICILLIN SODIUM

AP	!	SANDOZ	EQ 1GM BASE/VIAL	A062738	001	Feb 19, 1987
AP	!		EQ 2GM BASE/VIAL	A062738	002	Feb 19, 1987

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

AP		ACS DOBFAR	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065406	001	Dec 22, 2009
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065406	002	Dec 22, 2009
AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065403	001	Dec 23, 2009
AP		ANTIBIOTICE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A201406	001	Dec 07, 2015
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A201406	002	Dec 07, 2015
AP		ASTRAL	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090579	001	Jan 08, 2016
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090579	002	Jan 08, 2016
AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090578	001	Jan 11, 2016
AP		AUROBINDO PHARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090340	001	Sep 20, 2010
AP			EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090349	001	Sep 20, 2010
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090340	002	Sep 20, 2010
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090349	002	Sep 20, 2010
AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090339	001	Sep 20, 2010
AP		HANFORD GC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065176	001	Nov 30, 2005
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065176	002	Nov 30, 2005
AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065188	001	Nov 25, 2005
AP		HOSPIRA INC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090375	001	Dec 21, 2011
AP			EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090653	001	Dec 21, 2011
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090375	002	Dec 21, 2011
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090653	002	Dec 21, 2011
AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090646	001	Dec 21, 2011
AP		ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065222	001	Nov 29, 2005
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065222	002	Nov 29, 2005
AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065314	001	Nov 27, 2006
AP		MUSTAFA NEVZAT ILAC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007
AP		MYLAN LABS LTD	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A201024	001	Apr 07, 2014
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A201024	002	Apr 07, 2014
AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A202197	001	Apr 07, 2014
AP		SANDOZ	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065241	001	Jul 25, 2006
AP			EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065310	001	Jul 25, 2006
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065241	002	Jul 25, 2006
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065310	002	Jul 25, 2006
AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065240	001	Jul 25, 2006
AP		WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065074	001	Mar 19, 2002
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065074	002	Mar 19, 2002
AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065076	001	Mar 19, 2002

UNASYN

AP	!	PFIZER	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A062901	002	Feb 27, 1992
AP	!		EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A062901	001	Nov 23, 1988
AP	+!		EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	N050608	002	Dec 31, 1986
AP	+!		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	N050608	001	Dec 31, 1986

AMPICILLIN SODIUM; SULBACTAM SODIUM						
INJECTABLE;INJECTION						
UNASYN						
AP	**+!**		**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**N050608**	**005**	Dec 10, 1993
AMPICILLIN/AMPICILLIN TRIHYDRATE						
CAPSULE;ORAL						
AMPICILLIN TRIHYDRATE						
AB		DAVA PHARMS INC	**EQ 250MG BASE**	**A062883**	**001**	Feb 25, 1988
AB	**!**		**EQ 500MG BASE**	**A062882**	**001**	Feb 25, 1988
AB		SANDOZ	**EQ 250MG BASE**	**A064082**	**001**	Aug 29, 1995
AB			**EQ 500MG BASE**	**A064082**	**002**	Aug 29, 1995
FOR SUSPENSION;ORAL						
AMPICILLIN TRIHYDRATE						
		DAVA PHARMS INC	EQ 125MG BASE/5ML	A062982	001	Feb 10, 1989
	!		EQ 250MG BASE/5ML	A062982	002	Feb 10, 1989
ANAGRELIDE HYDROCHLORIDE						
CAPSULE;ORAL						
AGRYLIN						
AB		SHIRE LLC	**EQ 0.5MG BASE**	**N020333**	**001**	Mar 14, 1997
ANAGRELIDE HYDROCHLORIDE						
AB		BARR	**EQ 0.5MG BASE**	**A076530**	**001**	Apr 18, 2005
AB			**EQ 1MG BASE**	**A076530**	**002**	Apr 18, 2005
AB		IMPAX LABS	**EQ 0.5MG BASE**	**A076910**	**001**	Apr 18, 2005
AB			**EQ 1MG BASE**	**A076910**	**002**	Apr 18, 2005
AB		IVAX SUB TEVA PHARMS	**EQ 0.5MG BASE**	**A076468**	**001**	Apr 18, 2005
AB	**!**		**EQ 1MG BASE**	**A076468**	**002**	Apr 18, 2005
AB		TORRENT PHARMS LTD	**EQ 0.5MG BASE**	**A209151**	**001**	Jun 30, 2017
AB			**EQ 1MG BASE**	**A209151**	**002**	Jun 30, 2017
ANASTROZOLE						
TABLET;ORAL						
ANASTROZOLE						
AB		ACCORD HLTHCARE	**1MG**	**A090568**	**001**	Jun 28, 2010
AB		APOTEX INC	**1MG**	**A200654**	**001**	May 11, 2012
AB		BEIJING YILING	**1MG**	**A206037**	**001**	Nov 09, 2018
AB		BOSCOGEN	**1MG**	**A078944**	**001**	Jun 28, 2010
AB		CIPLA	**1MG**	**A091164**	**001**	Jun 28, 2010
AB		FRESENIUS KABI ONCOL	**1MG**	**A090088**	**001**	Jun 28, 2010
AB		MYLAN	**1MG**	**A091051**	**001**	Jun 28, 2010
AB		NATCO PHARMA LTD	**1MG**	**A079220**	**001**	Jun 28, 2010
AB		NEOPHARMA	**1MG**	**A090732**	**001**	Jun 28, 2010
AB		TEVA PHARMS	**1MG**	**A078058**	**001**	Jun 28, 2010
AB		WEST-WARD PHARMS INT	**1MG**	**A078485**	**001**	Jun 28, 2010
AB		ZYDUS PHARMS USA INC	**1MG**	**A078921**	**001**	Jun 28, 2010
ARIMIDEX						
AB	**+!**	ANI PHARMS INC	**1MG**	**N020541**	**001**	Dec 27, 1995
ANGIOTENSIN II ACETATE						
SOLUTION;INTRAVENOUS						
GIAPREZA						
	+!	LA JOLLA PHARMA	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360	001	Dec 21, 2017
ANIDULAFUNGIN						
POWDER;INTRAVENOUS						
ERAXIS						
	+!	VICURON	50MG/VIAL	N021632	001	Feb 17, 2006
	+!		100MG/VIAL	N021632	002	Nov 14, 2006
APALUTAMIDE						
TABLET;ORAL						
ERLEADA						
	+!	JANSSEN BIOTECH	60MG	N210951	001	Feb 14, 2018
APIXABAN						
TABLET;ORAL						
ELIQUIS						
	+	BRISTOL MYERS SQUIBB	2.5MG	N202155	001	Dec 28, 2012
	+!		5MG	N202155	002	Dec 28, 2012

APOMORPHINE HYDROCHLORIDE						
INJECTABLE;SUBCUTANEOUS						
APOKYN						
	+!	US WORLDMEDS	30MG/3ML (10MG/ML)	N021264	002	Apr 20, 2004
APRACLONIDINE HYDROCHLORIDE						
SOLUTION/DROPS;OPHTHALMIC						
APRACLONIDINE HYDROCHLORIDE						
AT		AKORN INC	**EQ 0.5% BASE**	**A077764**	**001**	Mar 12, 2009
IOPIDINE						
AT	**+!**	NOVARTIS PHARMS CORP	**EQ 0.5% BASE**	**N020258**	**001**	Jul 30, 1993
	+!		EQ 1% BASE	N019779	001	Dec 31, 1987
APREMILAST						
TABLET;ORAL						
OTEZLA						
	+	CELGENE CORP	10MG	N205437	001	Mar 21, 2014
	+		20MG	N205437	002	Mar 21, 2014
	+!		30MG	N205437	003	Mar 21, 2014
APREPITANT						
CAPSULE;ORAL						
APREPITANT						
AB		GLENMARK PHARMS SA	**40MG**	**A207777**	**001**	Oct 12, 2017
AB			**80MG**	**A207777**	**002**	Oct 12, 2017
AB			**125MG**	**A207777**	**003**	Oct 12, 2017
AB		SANDOZ	**40MG**	**A090999**	**001**	Sep 24, 2012
AB			**80MG**	**A090999**	**002**	Sep 24, 2012
AB			**125MG**	**A090999**	**003**	Sep 24, 2012
EMEND						
AB	**+**	MERCK	**40MG**	**N021549**	**003**	Jun 30, 2006
AB	**+**		**80MG**	**N021549**	**001**	Mar 26, 2003
AB	**+!**		**125MG**	**N021549**	**002**	Mar 26, 2003
EMULSION;INTRAVENOUS						
CINVANTI						
	+!	HERON THERAPS INC	130MG/18ML (7.2MG/ML)	N209296	001	Nov 09, 2017
FOR SUSPENSION;ORAL						
EMEND						
	+!	MSD MERCK CO	125MG/KIT	N207865	001	Dec 17, 2015
ARFORMOTEROL TARTRATE						
SOLUTION;INHALATION						
BROVANA						
	+!	SUNOVION	EQ 0.015MG BASE/2ML	N021912	001	Oct 06, 2006
ARGATROBAN						
INJECTABLE;INJECTION						
ARGATROBAN						
AP		AMNEAL PHARMS CO	**250MG/2.5ML (100MG/ML)**	**A206698**	**001**	Jan 26, 2018
AP		FRESENIUS KABI USA	**250MG/2.5ML (100MG/ML)**	**N201811**	**001**	Mar 23, 2015
AP		HIKMA PHARM CO LTD	**250MG/2.5ML (100MG/ML)**	**N203049**	**001**	Jan 05, 2012
AP		HOSPIRA INC	**250MG/2.5ML (100MG/ML)**	**A204120**	**001**	Sep 21, 2016
AP		MYLAN INSTITUTIONAL	**250MG/2.5ML (100MG/ML)**	**A202626**	**001**	Jun 30, 2014
AP	**+!**	NOVARTIS PHARMS CORP	**250MG/2.5ML (100MG/ML)**	**N020883**	**001**	Jun 30, 2000
AP		PAR STERILE PRODUCTS	**250MG/2.5ML (100MG/ML)**	**A091665**	**001**	Jun 30, 2014
	+!	HIKMA PHARM CO LTD	50MG/50ML (1MG/ML)	N203049	002	Sep 30, 2016
INJECTABLE;INTRAVENOUS						
ARGATROBAN IN SODIUM CHLORIDE						
AP		GLAND PHARMA LTD	**125MG/125ML (1MG/ML)**	**A205570**	**001**	May 22, 2017
AP	**+!**	SANDOZ	**125MG/125ML (1MG/ML)**	**N022485**	**001**	May 09, 2011
ARGATROBAN IN 0.9% SODIUM CHLORIDE						
		TEVA PHARMS USA	250MG/250ML (1MG/ML)	N206769	001	Dec 15, 2014
ARGATROBAN IN SODIUM CHLORIDE						
	+!	EAGLE PHARMS	50MG/50ML (1MG/ML)	N022434	001	Jun 29, 2011
SOLUTION;INTRAVENOUS						
ARGATROBAN IN SODIUM CHLORIDE						
		AUROBINDO PHARMA LTD	50MG/50ML (1MG/ML)	N209552	001	Nov 27, 2018

ARGININE HYDROCHLORIDE							
INJECTABLE;INJECTION							
R-GENE 10							
	+!	PHARMACIA AND UPJOHN	10GM/100ML	N016931	001		
ARIPIPRAZOLE							
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR							
ABILIFY MAINTENA KIT							
	+	OTSUKA PHARM CO LTD	300MG/VIAL	N202971	001	Feb 28, 2013	
	+		300MG	N202971	003	Sep 29, 2014	
	+!		400MG/VIAL	N202971	002	Feb 28, 2013	
	+		400MG	N202971	004	Sep 29, 2014	
SOLUTION;ORAL							
ARIPIPRAZOLE							
AA	**!**	AMNEAL PHARMS	**1MG/ML**	**A203906**	**001**	Aug 14, 2015	
AA		APOTEX INC	**1MG/ML**	**A204094**	**001**	Sep 30, 2015	
AA		LANNETT CO INC	**1MG/ML**	**A204171**	**001**	Aug 14, 2015	
TABLET;ORAL							
ABILIFY							
AB	**+**	OTSUKA	**2MG**	**N021436**	**006**	Nov 15, 2002	
AB	**+!**		**5MG**	**N021436**	**005**	Nov 15, 2002	
AB	**+!**		**10MG**	**N021436**	**001**	Nov 15, 2002	
AB	**+**		**15MG**	**N021436**	**002**	Nov 15, 2002	
AB	**+**		**20MG**	**N021436**	**003**	Nov 15, 2002	
AB	**+**		**30MG**	**N021436**	**004**	Nov 15, 2002	
ARIPIPRAZOLE							
AB		ACCORD HLTHCARE	**2MG**	**A206251**	**001**	Dec 07, 2016	
AB			**5MG**	**A206251**	**002**	Dec 07, 2016	
AB			**10MG**	**A206251**	**003**	Dec 07, 2016	
AB			**15MG**	**A206251**	**004**	Dec 07, 2016	
AB			**20MG**	**A206251**	**005**	Dec 07, 2016	
AB			**30MG**	**A206251**	**006**	Dec 07, 2016	
AB		AJANTA PHARMA LTD	**2MG**	**A206174**	**001**	Sep 12, 2016	
AB			**5MG**	**A206174**	**002**	Sep 12, 2016	
AB			**10MG**	**A206174**	**003**	Sep 12, 2016	
AB			**15MG**	**A206174**	**004**	Sep 12, 2016	
AB			**20MG**	**A206174**	**005**	Sep 12, 2016	
AB			**30MG**	**A206174**	**006**	Sep 12, 2016	
AB		ALEMBIC PHARMS LTD	**2MG**	**A202101**	**001**	Apr 28, 2015	
AB			**5MG**	**A202101**	**002**	Apr 28, 2015	
AB			**10MG**	**A202101**	**003**	Apr 28, 2015	
AB			**15MG**	**A202101**	**004**	Apr 28, 2015	
AB			**20MG**	**A202101**	**005**	Apr 28, 2015	
AB			**30MG**	**A202101**	**006**	Apr 28, 2015	
AB		AMNEAL PHARMS	**2MG**	**A204838**	**001**	Jun 17, 2016	
AB			**5MG**	**A204838**	**002**	Jun 17, 2016	
AB			**10MG**	**A204838**	**003**	Jun 17, 2016	
AB			**15MG**	**A204838**	**004**	Jun 17, 2016	
AB			**20MG**	**A204838**	**005**	Jun 17, 2016	
AB			**30MG**	**A204838**	**006**	Jun 17, 2016	
AB		APOTEX INC	**2MG**	**A078583**	**001**	Jul 24, 2015	
AB			**5MG**	**A078583**	**002**	Jul 24, 2015	
AB			**10MG**	**A078583**	**003**	Jul 24, 2015	
AB			**15MG**	**A078583**	**004**	Jul 24, 2015	
AB			**20MG**	**A078583**	**005**	Jul 24, 2015	
AB			**30MG**	**A078583**	**006**	Jul 24, 2015	
AB		AUROBINDO PHARMA LTD	**2MG**	**A203908**	**001**	Oct 08, 2015	
AB			**5MG**	**A203908**	**002**	Oct 08, 2015	
AB			**10MG**	**A203908**	**003**	Oct 08, 2015	
AB			**15MG**	**A203908**	**004**	Oct 08, 2015	
AB			**20MG**	**A203908**	**005**	Oct 08, 2015	
AB			**30MG**	**A203908**	**006**	Oct 08, 2015	
AB		BOSCOGEN	**2MG**	**A091279**	**001**	Jan 09, 2017	
AB			**5MG**	**A091279**	**002**	Jan 09, 2017	
AB			**10MG**	**A091279**	**003**	Jan 09, 2017	
AB			**15MG**	**A091279**	**004**	Jan 09, 2017	
AB			**20MG**	**A091279**	**005**	Jan 09, 2017	
AB			**30MG**	**A091279**	**006**	Jan 09, 2017	
AB		HETERO LABS LTD V	**2MG**	**A205064**	**001**	Apr 28, 2015	
AB			**5MG**	**A205064**	**002**	Apr 28, 2015	
AB			**10MG**	**A205064**	**003**	Apr 28, 2015	

ARIPIPRAZOLE

TABLET;ORAL

ARIPIPRAZOLE

AB			**15MG**	**A205064**	**004**	Apr 28, 2015
AB			**20MG**	**A205064**	**005**	Apr 28, 2015
AB			**30MG**	**A205064**	**006**	Apr 28, 2015
AB		MACLEODS PHARMS LTD	**2MG**	**A204111**	**001**	Oct 07, 2016
AB			**5MG**	**A204111**	**002**	Oct 07, 2016
AB			**10MG**	**A204111**	**003**	Oct 07, 2016
AB			**15MG**	**A204111**	**004**	Oct 07, 2016
AB			**20MG**	**A204111**	**005**	Oct 07, 2016
AB			**30MG**	**A204111**	**006**	Oct 07, 2016
AB		ORCHID HLTHCARE	**2MG**	**A202683**	**001**	May 23, 2017
AB			**5MG**	**A202683**	**002**	May 23, 2017
AB			**10MG**	**A202683**	**003**	May 23, 2017
AB			**15MG**	**A202683**	**004**	May 23, 2017
AB			**20MG**	**A202683**	**005**	May 23, 2017
AB			**30MG**	**A202683**	**006**	May 23, 2017
AB		PRINSTON INC	**2MG**	**A205363**	**001**	Dec 04, 2017
AB			**5MG**	**A205363**	**002**	Dec 04, 2017
AB			**10MG**	**A205363**	**003**	Dec 04, 2017
AB			**15MG**	**A205363**	**004**	Dec 04, 2017
AB			**20MG**	**A205363**	**005**	Dec 04, 2017
AB			**30MG**	**A205363**	**006**	Dec 04, 2017
AB		SCIEGEN PHARMS INC	**2MG**	**A206383**	**001**	Sep 29, 2016
AB			**5MG**	**A206383**	**002**	Sep 29, 2016
AB			**10MG**	**A206383**	**003**	Sep 29, 2016
AB			**15MG**	**A206383**	**004**	Sep 29, 2016
AB			**20MG**	**A206383**	**005**	Sep 29, 2016
AB			**30MG**	**A206383**	**006**	Sep 29, 2016
AB		TEVA PHARMS USA	**2MG**	**A078607**	**001**	Apr 28, 2015
AB			**5MG**	**A078607**	**002**	Apr 28, 2015
AB			**10MG**	**A078608**	**001**	Apr 28, 2015
AB			**15MG**	**A078708**	**001**	Apr 28, 2015
AB			**20MG**	**A078708**	**002**	Apr 28, 2015
AB			**30MG**	**A078708**	**003**	Apr 28, 2015
AB		TORRENT PHARMS LTD	**2MG**	**A201519**	**001**	Apr 28, 2015
AB			**10MG**	**A201519**	**003**	Apr 28, 2015
AB			**5MG**	**A201519**	**002**	Apr 28, 2015
AB			**15MG**	**A201519**	**004**	Apr 28, 2015
AB			**20MG**	**A201519**	**005**	Apr 28, 2015
AB			**30MG**	**A201519**	**006**	Apr 28, 2015
AB		ZYDUS PHARMS USA INC	**2MG**	**A090472**	**001**	Jan 07, 2019
AB			**5MG**	**A090472**	**002**	Jan 07, 2019
AB			**10MG**	**A090472**	**003**	Jan 07, 2019
AB			**15MG**	**A090472**	**004**	Jan 07, 2019
AB			**20MG**	**A090472**	**005**	Jan 07, 2019
AB			**30MG**	**A090472**	**006**	Jan 07, 2019

ABILIFY MYCITE KIT

+		OTSUKA PHARM CO LTD	2MG	N207202	001 Nov 13, 2017
+!			5MG	N207202	002 Nov 13, 2017
+			10MG	N207202	003 Nov 13, 2017
+			15MG	N207202	004 Nov 13, 2017
+			20MG	N207202	005 Nov 13, 2017
+			30MG	N207202	006 Nov 13, 2017

TABLET, ORALLY DISINTEGRATING;ORAL

ARIPIPRAZOLE

AB	**!**	ALEMBIC PHARMS LTD	**10MG**	**A202102**	**001**	Apr 28, 2015
AB			**15MG**	**A202102**	**002**	Apr 28, 2015
AB		ORCHID HLTHCARE	**10MG**	**A202547**	**001**	Dec 11, 2017
AB			**15MG**	**A202547**	**002**	Dec 11, 2017
AB		SCIEGEN PHARMS INC	**10MG**	**A207240**	**001**	Apr 18, 2018
AB			**15MG**	**A207240**	**002**	Apr 18, 2018
AB		ZYDUS PHARMS USA INC	**10MG**	**A090165**	**001**	Aug 28, 2018
AB			**15MG**	**A090165**	**002**	Aug 28, 2018
			20MG	A090165	003	Aug 28, 2018
			30MG	A090165	004	Aug 28, 2018

ARIPIPRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ARISTADA

	+	ALKERMES INC	441MG/1.6ML (275.63MG/ML)	N207533	001	Oct 05, 2015
	+		662MG/2.4ML (275.83MG/ML)	N207533	002	Oct 05, 2015
	+!		882MG/3.2ML (275.63MG/ML)	N207533	003	Oct 05, 2015
	+		1064MG/3.9ML (272.82MG/ML)	N207533	004	Jun 05, 2017

ARISTADA INITIO KIT

	+	ALKERMES INC	675MG/2.4ML	N209830	001	Jun 29, 2018

ARMODAFINIL

TABLET;ORAL

ARMODAFINIL

AB		AURO BINDO PHARMA LTD	**50MG**	**A206069**	**001**	Mar 06, 2018
AB			**150MG**	**A206069**	**002**	Mar 06, 2018
AB			**250MG**	**A206069**	**003**	Mar 06, 2018
AB		LUPIN LTD	**50MG**	**A200751**	**001**	Nov 28, 2016
AB			**150MG**	**A200751**	**003**	Nov 28, 2016
AB			**200MG**	**A200751**	**004**	Nov 28, 2016
AB			**250MG**	**A200751**	**005**	Nov 28, 2016
AB		MYLAN PHARMS INC	**50MG**	**A200043**	**001**	Jun 01, 2012
AB			**150MG**	**A200043**	**002**	Jun 01, 2012
AB			**250MG**	**A200043**	**003**	Jun 01, 2012
AB		NATCO PHARMA LTD	**50MG**	**A202768**	**001**	Nov 28, 2016
AB			**150MG**	**A202768**	**002**	Nov 28, 2016
AB			**200MG**	**A202768**	**005**	Sep 28, 2017
AB			**250MG**	**A202768**	**003**	Nov 28, 2016

NUVIGIL

AB	**+**	CEPHALON	**50MG**	**N021875**	**001**	Jun 15, 2007
AB	**+**		**150MG**	**N021875**	**003**	Jun 15, 2007
AB	**+**		**200MG**	**N021875**	**005**	Mar 26, 2009
AB	**+!**		**250MG**	**N021875**	**004**	Jun 15, 2007

ARMODAFINIL

		NATCO PHARMA LTD	100MG	A202768	004	Sep 28, 2017

ARSENIC TRIOXIDE

INJECTABLE;INJECTION

ARSENIC TRIOXIDE

AP		AMRING PHARMS	**1MG/ML**	**A210802**	**001**	Nov 13, 2018
AP		FRESENIUS KABI USA	**1MG/ML**	**A208231**	**001**	Aug 31, 2018
AP		INGENUS PHARMS LLC	**1MG/ML**	**A209315**	**001**	Nov 15, 2018
AP		NEXUS PHARMS	**1MG/ML**	**A209780**	**001**	Nov 15, 2018
AP		ZYDUS PHARMS USA INC	**1MG/ML**	**A206228**	**001**	Nov 13, 2018

TRISENOX

	+!	CEPHALON	2MG/ML	N021248	002	Oct 13, 2017

ARTEMETHER; LUMEFANTRINE

TABLET;ORAL

COARTEM

	+!	NOVARTIS	20MG;120MG	N022268	001	Apr 07, 2009

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

AP		HOSPIRA	**4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)**	**A079138**	**001**	Jun 18, 2010

SEPTOCAINE

AP	**+!**	DEPROCO	**4%;EQ 0.0085MG BASE/1.7ML (4%;EQ 0.005MG BASE/ML)**	**N022010**	**001**	Mar 30, 2006
AP	**+!**		**4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)**	**N020971**	**001**	Apr 03, 2000

ULTACAN

AP		HANSAMED INC	**4%;EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)**	**A201751**	**001**	Jul 11, 2017

ULTACAN FORTE

AP		HANSAMED INC	**4%;EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)**	**A201750**	**001**	Jul 11, 2017

ORABLOC

	+	PIERREL	4%;EQ 0.009MG BASE/1.8ML (EQ 0.005MG BASE/ML)	N022466	001	Feb 26, 2010
	+!		4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML)	N022466	002	Feb 26, 2010

ASCORBIC ACID

SOLUTION;INTRAVENOUS

ASCOR

+!	MCGUFF	25,000MG/50ML (500MG/ML)	N209112	001	Oct 02, 2017

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE;INTRAVENOUS

INFUVITE PEDIATRIC

+!	SANDOZ INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	001	Feb 21, 2001

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+!	SANDOZ INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021646	001	Jan 29, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION;INTRAVENOUS

M.V.I. PEDIATRIC

+!	HOSPIRA	80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL	N018920	001	Sep 21, 2000

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE;INTRAVENOUS

M.V.I. ADULT

+!	HOSPIRA	200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL	N021625	001	Jan 30, 2004

M.V.I. ADULT (PHARMACY BULK PACKAGE)

+!	HOSPIRA	200MG/5ML;0.06MG/5ML;0.005MG/5ML;15MG/5ML;0.005MG/5ML;0.6MG/5ML;40MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;1MG/5ML;10MG/5ML;0.15MG/5ML	N021643	001	Feb 18, 2004

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

MOVIPREP

+!	SALIX PHARMS	4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM	N021881	001	Aug 02, 2006

PLENVU

+!	SALIX PHARMS INC	7.54GM;140GM;2.2GM;48.11GM;5.2GM;9GM	N209381	001	May 04, 2018

ASENAPINE MALEATE

TABLET;SUBLINGUAL

ASENAPINE MALEATE

AB		SIGMAPHARM LABS LLC	**EQ 5MG BASE**	**A206107**	**001**	Jul 17, 2018
AB			**EQ 10MG BASE**	**A206107**	**002**	Jul 17, 2018

SAPHRIS

AB	+	FOREST LABS LLC	**EQ 5MG BASE**	**N022117**	**001**	Aug 13, 2009
AB	**+!**		**EQ 10MG BASE**	**N022117**	**002**	Aug 13, 2009
	+		EQ 2.5 BASE	N022117	003	Mar 12, 2015

ASPIRIN

CAPSULE, EXTENDED RELEASE;ORAL

DURLAZA

+!	ESPERO	162.5MG	N200671	001	Sep 04, 2015

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

FIORINAL

AA	**+!**	ALLERGAN SALES LLC	**325MG;50MG;40MG**	**N017534**	**005**	Apr 16, 1986

LANORINAL

AA		LANNETT	**325MG;50MG;40MG**	**A086996**	**002**	Oct 11, 1985

TABLET;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

AA	**!**	HIKMA INTL PHARMS	**325MG;50MG;40MG**	**A086162**	**002**	Feb 16, 1984
AA		PII	**325MG;50MG;40MG**	**A204195**	**001**	Sep 22, 2016

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

AB		MAYNE PHARMA INC	**325MG;50MG;40MG;30MG**	**A203335**	**001**	Oct 30, 2015
AB		NEXGEN PHARMA INC	**325MG;50MG;40MG;30MG**	**A075231**	**001**	Nov 30, 2001
AB		STEVENS J	**325MG;50MG;40MG;30MG**	**A074951**	**001**	Aug 31, 1998

FIORINAL W/CODEINE

AB	**+!**	ALLERGAN SALES LLC	**325MG;50MG;40MG;30MG**	**N019429**	**003**	Oct 26, 1990

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

		SANDOZ	385MG;30MG;25MG	A074654	001	Dec 31, 1996
	!		770MG;60MG;50MG	A074654	002	Dec 31, 1996

ASPIRIN; CARISOPRODOL

TABLET;ORAL

CARISOPRODOL AND ASPIRIN

AB	**!**	HERITAGE PHARMS INC	**325MG;200MG**	**A089594**	**001**	Mar 31, 1989
AB		NOVAST LABS	**325MG;200MG**	**A040832**	**001**	Jan 07, 2010
AB		SANDOZ	**325MG;200MG**	**A040116**	**001**	Apr 25, 1996

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB		INGENUS PHARMS NJ	**325MG;200MG;16MG**	**A040860**	**001**	Jan 07, 2010
AB	**!**	SANDOZ	**325MG;200MG;16MG**	**A040118**	**001**	Apr 16, 1996

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL

AGGRENOX

AB	**+!**	BOEHRINGER INGELHEIM	**25MG;200MG**	**N020884**	**001**	Nov 22, 1999

ASPIRIN AND DIPYRIDAMOLE

AB		AMNEAL PHARMS	**25MG;200MG**	**A206392**	**001**	Mar 08, 2016
AB		ANI PHARMS INC	**25MG;200MG**	**A206964**	**001**	Jan 18, 2017
AB		BARR	**25MG;200MG**	**A078804**	**001**	Aug 14, 2009
AB		DR REDDYS LABS LTD	**25MG;200MG**	**A209048**	**001**	Oct 10, 2018
AB		PAR PHARM INC	**25MG;200MG**	**A207944**	**001**	Jan 18, 2017
AB		SANDOZ INC	**25MG;200MG**	**A206739**	**001**	Jan 18, 2017
AB		SUN PHARMA GLOBAL	**25MG;200MG**	**A208572**	**001**	Aug 21, 2018
AB		ZYDUS PHARMS USA INC	**25MG;200MG**	**A206753**	**001**	Aug 29, 2017

ASPIRIN; METHOCARBAMOL

TABLET;ORAL

METHOCARBAMOL AND ASPIRIN

	!	STEVENS J	325MG;400MG	A081145	001	Jan 31, 1995

ASPIRIN; OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

YOSPRALA

	+	GENUS LIFESCIENCES	81MG;40MG	N205103	001	Sep 14, 2016
	+!		325MG;40MG	N205103	002	Sep 14, 2016

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

AA		ACTAVIS LABS FL INC	**325MG;4.8355MG**	**A090084**	**001**	Mar 22, 2011
AA		MAYNE PHARMA INC	**325MG;4.8355MG**	**A091670**	**001**	Mar 16, 2011

PERCODAN

AA	**+!**	ENDO PHARMS	**325MG;4.8355MG**	**N007337**	**007**	Aug 05, 2005

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

AB		AUROBINDO PHARMA LTD	**EQ 100MG BASE**	**A204806**	**001**	Jun 25, 2018
AB			**EQ 150MG BASE**	**A204806**	**002**	Jun 25, 2018
AB			**EQ 200MG BASE**	**A204806**	**003**	Jun 25, 2018
AB			**EQ 300MG BASE**	**A204806**	**004**	Jun 25, 2018
AB		CIPLA	**EQ 100MG BASE**	**A200626**	**001**	Aug 09, 2018
AB			**EQ 150MG BASE**	**A200626**	**002**	Aug 09, 2018
AB			**EQ 200MG BASE**	**A200626**	**003**	Aug 09, 2018
AB			**EQ 300MG BASE**	**A200626**	**004**	Aug 09, 2018
AB		MYLAN PHARMS INC	**EQ 150MG BASE**	**A208177**	**001**	Sep 24, 2018
AB			**EQ 200MG BASE**	**A208177**	**002**	Sep 24, 2018

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

AB			**EQ 300MG BASE**	**A208177**	**003**	Sep 24, 2018
AB		TEVA PHARMS USA	**EQ 100MG BASE**	**A091673**	**001**	Apr 22, 2014
AB			**EQ 150MG BASE**	**A091673**	**002**	Apr 22, 2014
AB			**EQ 200MG BASE**	**A091673**	**003**	Apr 22, 2014
AB			**EQ 300MG BASE**	**A091673**	**004**	Apr 22, 2014

REYATAZ

AB	**+**	BRISTOL MYERS SQUIBB	**EQ 150MG BASE**	**N021567**	**002**	Jun 20, 2003
AB	**+**		**EQ 200MG BASE**	**N021567**	**003**	Jun 20, 2003
AB	**+!**		**EQ 300MG BASE**	**N021567**	**004**	Oct 16, 2006

POWDER;ORAL

REYATAZ

	+!	BRISTOL MYERS SQUIBB	EQ 50MG BASE/PACKET	N206352	001	Jun 02, 2014

ATAZANAVIR SULFATE; COBICISTAT

TABLET;ORAL

EVOTAZ

	+!	BRISTOL-MYERS SQUIBB	EQ 300MG BASE;150MG	N206353	001	Jan 29, 2015

ATENOLOL

TABLET;ORAL

ATENOLOL

AB		ALVOGEN MALTA	**25MG**	**A072304**	**002**	Jul 31, 1992
AB			**50MG**	**A072304**	**003**	Jul 18, 1988
AB			**100MG**	**A072304**	**001**	Jul 15, 1988
AB		AUROBINDO PHARMA	**25MG**	**A078512**	**001**	Oct 31, 2007
AB			**50MG**	**A078512**	**002**	Oct 31, 2007
AB			**100MG**	**A078512**	**003**	Oct 31, 2007
AB		DAVA PHARMS INC	**50MG**	**A073542**	**001**	Dec 19, 1991
AB			**100MG**	**A073543**	**001**	Dec 19, 1991
AB		IPCA LABS LTD	**25MG**	**A077877**	**001**	Dec 27, 2006
AB			**50MG**	**A077877**	**002**	Dec 27, 2006
AB			**100MG**	**A077877**	**003**	Dec 27, 2006
AB		MYLAN	**25MG**	**A073457**	**002**	Apr 26, 1999
AB			**50MG**	**A073457**	**003**	Jan 24, 1992
AB			**100MG**	**A073457**	**001**	Jan 24, 1992
AB		SANDOZ	**25MG**	**A074052**	**001**	May 01, 1992
AB			**50MG**	**A073025**	**001**	Sep 17, 1991
AB			**100MG**	**A073026**	**001**	Sep 17, 1991
AB		SUN PHARM INDS INC	**25MG**	**A078210**	**001**	Jul 10, 2007
AB			**50MG**	**A078210**	**002**	Jul 10, 2007
AB			**100MG**	**A078210**	**003**	Jul 10, 2007
AB		SUN PHARM INDUSTRIES	**25MG**	**A074499**	**001**	Jul 30, 1997
AB			**50MG**	**A073475**	**001**	Mar 30, 1993
AB			**100MG**	**A073476**	**001**	Mar 30, 1993
AB		TEVA	**25MG**	**A074056**	**003**	Jul 19, 2004
AB			**50MG**	**A074056**	**001**	Jan 18, 1995
AB			**100MG**	**A074056**	**002**	Jan 18, 1995
AB		UNIQUE PHARM LABS	**25MG**	**A077443**	**001**	Sep 13, 2006
AB			**50MG**	**A077443**	**002**	Sep 13, 2006
AB			**100MG**	**A077443**	**003**	Sep 13, 2006
AB		ZYDUS PHARMS USA	**25MG**	**A076900**	**001**	Jan 28, 2005
AB			**50MG**	**A076900**	**002**	Jan 28, 2005
AB			**100MG**	**A076900**	**003**	Jan 28, 2005

TENORMIN

AB	**+**	ALVOGEN MALTA	**25MG**	**N018240**	**004**	Apr 09, 1990
AB	**+**		**50MG**	**N018240**	**001**	
AB	**+!**		**100MG**	**N018240**	**002**	

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AB		ALVOGEN MALTA	**50MG;25MG**	**A072302**	**002**	May 31, 1990
AB			**100MG;25MG**	**A072302**	**001**	May 31, 1990
AB		MYLAN	**50MG;25MG**	**A074203**	**001**	Oct 31, 1993
AB			**100MG;25MG**	**A074203**	**002**	Oct 31, 1993
AB		SUN PHARM INDUSTRIES	**50MG;25MG**	**A073582**	**002**	Apr 29, 1993
AB			**100MG;25MG**	**A073582**	**001**	Apr 29, 1993

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AB		WATSON LABS	50MG;25MG	A073665	001	Jul 02, 1992
AB			100MG;25MG	A073665	002	Jul 02, 1992

TENORETIC 100

AB	+!	ALVOGEN MALTA	100MG;25MG	N018760	001	Jun 08, 1984

TENORETIC 50

AB	+	ALVOGEN MALTA	50MG;25MG	N018760	002	Jun 08, 1984

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB		APOTEX INC	10MG	A078983	001	May 30, 2017
AB			18MG	A078983	002	May 30, 2017
AB			25MG	A078983	003	May 30, 2017
AB			40MG	A078983	004	May 30, 2017
AB			60MG	A078983	005	May 30, 2017
AB			80MG	A078983	006	May 30, 2017
AB			100MG	A078983	007	May 30, 2017
AB		AUROBINDO PHARMA LTD	10MG	A079016	001	May 30, 2017
AB			18MG	A079016	002	May 30, 2017
AB			25MG	A079016	003	May 30, 2017
AB			40MG	A079016	004	May 30, 2017
AB			60MG	A079016	005	May 30, 2017
AB			80MG	A079016	006	May 30, 2017
AB			100MG	A079016	007	May 30, 2017
AB		DR REDDYS LABS LTD	10MG	A090609	001	Feb 23, 2018
AB			18MG	A090609	002	Feb 23, 2018
AB			25MG	A090609	003	Feb 23, 2018
AB			40MG	A090609	004	Feb 23, 2018
AB			60MG	A090609	005	Feb 23, 2018
AB			80MG	A090609	006	Feb 23, 2018
AB			100MG	A090609	007	Feb 23, 2018
AB		GLENMARK PHARMS LTD	10MG	A079019	001	May 30, 2017
AB			18MG	A079019	002	May 30, 2017
AB			25MG	A079019	003	May 30, 2017
AB			40MG	A079019	004	May 30, 2017
AB			60MG	A079019	005	May 30, 2017
AB			80MG	A079019	006	May 30, 2017
AB			100MG	A079019	007	May 30, 2017
AB		TEVA PHARMS USA	10MG	A079022	001	May 30, 2017
AB			18MG	A079022	002	May 30, 2017
AB			25MG	A079022	003	May 30, 2017
AB			40MG	A079022	004	May 30, 2017
AB			60MG	A079022	005	May 30, 2017
AB			80MG	A079022	006	May 30, 2017
AB			100MG	A079022	007	May 30, 2017

STRATTERA

AB	+	LILLY	10MG	N021411	002	Nov 26, 2002
AB	+		18MG	N021411	003	Nov 26, 2002
AB	+		25MG	N021411	004	Nov 26, 2002
AB	+		40MG	N021411	005	Nov 26, 2002
AB	+!		60MG	N021411	006	Nov 26, 2002
AB	+		80MG	N021411	007	Feb 14, 2005
AB	+		100MG	N021411	008	Feb 14, 2005

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB		ACCORD HLTHCARE	EQ 10MG BASE	A207687	001	Mar 30, 2018
AB			EQ 20MG BASE	A207687	002	Mar 30, 2018
AB			EQ 40MG BASE	A207687	003	Mar 30, 2018
AB			EQ 80MG BASE	A207687	004	Mar 30, 2018
AB		APOTEX INC	EQ 10MG BASE	A090548	001	May 29, 2012
AB			EQ 20MG BASE	A090548	002	May 29, 2012
AB			EQ 40MG BASE	A090548	003	May 29, 2012
AB			EQ 80MG BASE	A090548	004	May 29, 2012
AB		DR REDDYS LABS LTD	EQ 10MG BASE	A091650	001	Jul 17, 2012
AB			EQ 20MG BASE	A091650	002	Jul 17, 2012
AB			EQ 40MG BASE	A091650	003	Jul 17, 2012
AB			EQ 80MG BASE	A202357	001	Jul 17, 2012
AB		GRAVITI PHARMS	EQ 10MG BASE	A209912	001	Jun 18, 2018

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB		**EQ 20MG BASE**	**A209912**	**002**	Jun 18, 2018
AB		**EQ 40MG BASE**	**A209912**	**003**	Jun 18, 2018
AB		**EQ 80MG BASE**	**A209912**	**004**	Jun 18, 2018
AB	INVAGEN PHARMS	**EQ 10MG BASE**	**A204846**	**001**	Jan 09, 2017
AB		**EQ 20MG BASE**	**A204846**	**002**	Jan 09, 2017
AB		**EQ 40MG BASE**	**A204846**	**003**	Jan 09, 2017
AB		**EQ 80MG BASE**	**A204846**	**004**	Jan 09, 2017
AB	LANNETT CO INC	**EQ 10MG BASE**	**A091624**	**001**	Apr 05, 2013
AB		**EQ 20MG BASE**	**A091624**	**002**	Apr 05, 2013
AB		**EQ 40MG BASE**	**A091624**	**003**	Apr 05, 2013
AB		**EQ 80MG BASE**	**A091624**	**004**	Apr 05, 2013
AB	MYLAN PHARMS INC	**EQ 10MG BASE**	**A091226**	**001**	May 29, 2012
AB		**EQ 20MG BASE**	**A091226**	**002**	May 29, 2012
AB		**EQ 40MG BASE**	**A091226**	**003**	May 29, 2012
AB		**EQ 80MG BASE**	**A091226**	**004**	May 29, 2012
AB	SANDOZ INC	**EQ 10MG BASE**	**A077575**	**001**	May 29, 2012
AB		**EQ 20MG BASE**	**A077575**	**002**	May 29, 2012
AB		**EQ 40MG BASE**	**A077575**	**003**	May 29, 2012
AB		**EQ 80MG BASE**	**A077575**	**004**	May 29, 2012
AB	SCIEGEN PHARMS INC	**EQ 10MG BASE**	**A205519**	**001**	May 19, 2016
AB		**EQ 20MG BASE**	**A205519**	**002**	May 19, 2016
AB		**EQ 40MG BASE**	**A205519**	**003**	May 19, 2016
AB		**EQ 80MG BASE**	**A205519**	**004**	May 19, 2016
AB	SUN PHARM INDS LTD	**EQ 10MG BASE**	**A076477**	**001**	Nov 30, 2011
AB		**EQ 20MG BASE**	**A076477**	**002**	Nov 30, 2011
AB		**EQ 40MG BASE**	**A076477**	**003**	Nov 30, 2011
AB		**EQ 80MG BASE**	**A076477**	**004**	Nov 30, 2011
AB	TEVA PHARMS USA	**EQ 10MG BASE**	**A205300**	**001**	Mar 27, 2017
AB		**EQ 20MG BASE**	**A205300**	**002**	Mar 27, 2017
AB		**EQ 40MG BASE**	**A205300**	**003**	Mar 27, 2017
AB		**EQ 80MG BASE**	**A205300**	**004**	Mar 27, 2017
AB	THEPHARMANETWORK LLC	**EQ 10MG BASE**	**A209288**	**001**	Dec 21, 2018
AB		**EQ 20MG BASE**	**A209288**	**002**	Dec 21, 2018
AB		**EQ 40MG BASE**	**A209288**	**003**	Dec 21, 2018
AB		**EQ 80MG BASE**	**A209288**	**004**	Dec 21, 2018
AB	ZYDUS PHARMS USA INC	**EQ 10MG BASE**	**A206536**	**001**	Nov 20, 2018
AB		**EQ 20MG BASE**	**A206536**	**002**	Nov 20, 2018
AB		**EQ 40MG BASE**	**A206536**	**003**	Nov 20, 2018
AB		**EQ 80MG BASE**	**A206536**	**004**	Nov 20, 2018

LIPITOR

AB	**+**	PFIZER	**EQ 10MG BASE**	**N020702**	**001**	Dec 17, 1996
AB	**+**		**EQ 20MG BASE**	**N020702**	**002**	Dec 17, 1996
AB	**+**		**EQ 40MG BASE**	**N020702**	**003**	Dec 17, 1996
AB	**+!**		**EQ 80MG BASE**	**N020702**	**004**	Apr 07, 2000

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

EZETIMIBE AND ATORVASTATIN CALCIUM

	WATSON LABS TEVA	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017
		EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017
		EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017
!		EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

AB		AMNEAL PHARMS	**750MG/5ML**	**A202960**	**001**	Mar 18, 2014
AB		APOTEX INC	**750MG/5ML**	**A209750**	**001**	Oct 11, 2017
AB		GLENMARK PHARMS	**750MG/5ML**	**A209685**	**001**	Nov 21, 2018
AB		HETERO LABS LTD III	**750MG/5ML**	**A210692**	**001**	Oct 11, 2018
AB		LUPIN LTD	**750MG/5ML**	**A209105**	**001**	Sep 11, 2018
AB		PADDOCK LLC	**750MG/5ML**	**A207833**	**001**	Apr 28, 2017

MEPRON

AB	**+!**	GLAXOSMITHKLINE LLC	**750MG/5ML**	**N020500**	**001**	Feb 08, 1995

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET;ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB		GLENMARK GENERICS	**62.5MG;25MG**	**A091211**	**002**	Apr 06, 2015
AB			**250MG;100MG**	**A091211**	**001**	Jan 12, 2011
AB		MYLAN PHARMS INC	**62.5MG;25MG**	**A202362**	**001**	May 27, 2014
AB			**250MG;100MG**	**A202362**	**002**	May 27, 2014

MALARONE

AB	**+!**	GLAXOSMITHKLINE	**250MG;100MG**	**N021078**	**001**	Jul 14, 2000

MALARONE PEDIATRIC

AB	**+**	GLAXOSMITHKLINE	**62.5MG;25MG**	**N021078**	**002**	Jul 14, 2000

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

AP		AUROBINDO PHARMA LTD	**10MG/ML**	**A206011**	**001**	Apr 08, 2015
AP		HOSPIRA INC	**10MG/ML**	**A090761**	**001**	Oct 18, 2012
AP		MYLAN LABS LTD	**10MG/ML**	**A206096**	**001**	Jun 22, 2017
AP		NANJING KING-FRIEND	**10MG/ML**	**A091489**	**001**	Feb 17, 2012
AP	**!**	WEST-WARD PHARMS INT	**10MG/ML**	**A074901**	**001**	Jul 18, 1997

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP		AUROBINDO PHARMA LTD	**10MG/ML**	**A206010**	**001**	Apr 08, 2015
AP		HOSPIRA INC	**10MG/ML**	**A090782**	**001**	Oct 18, 2012
AP		MYLAN LABS LTD	**10MG/ML**	**A206001**	**001**	Apr 07, 2017
AP		NANJING KING-FRIEND	**10MG/ML**	**A091488**	**001**	Feb 17, 2012
AP	**!**	WEST-WARD PHARMS INT	**10MG/ML**	**A074900**	**001**	Jul 18, 1997

ATROPINE SULFATE

SOLUTION;INTRAMUSCULAR

ATROPEN

+!	MERIDIAN MEDCL TECHN	0.25MG/0.3ML	N017106	004	Sep 17, 2004
+!		0.5MG/0.7ML	N017106	003	Jun 19, 2003
+!		1MG/0.7ML	N017106	002	Jun 19, 2003
+!		2MG/0.7ML	N017106	001	

SOLUTION;INTRAVENOUS

ATROPINE SULFATE LIFESHIELD ABBOJECT SYRINGE

+!	HOSPIRA	0.5MG/5ML (0.1MG/ML)	N021146	004	Aug 17, 2017
+!		1MG/10ML (0.1MG/ML)	N021146	005	Aug 17, 2017

SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, ENDOTRACHEAL

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

+!	HOSPIRA	0.25MG/5ML (0.05MG/ML)	N021146	002	Jul 09, 2001
+!		1MG/10ML (0.1MG/ML)	N021146	003	Jul 09, 2001

SOLUTION;IV (INFUSION), INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

ATROPINE SULFATE

+!	FRESENIUS KABI USA	8MG/20ML (0.4MG/ML)	N209260	001	Jan 26, 2018

SOLUTION/DROPS;OPHTHALMIC

ATROPINE SULFATE

+!	AKORN	1%	N206289	001	Jul 18, 2014

ISOPTO ATROPINE

	ALCON LABS INC	1%	N208151	001	Dec 01, 2016

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET;ORAL

MOTOFEN

+!	SEBELA IRELAND LTD	0.025MG;1MG	N017744	002

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

!	WEST-WARD PHARMS INT	0.025MG/5ML;2.5MG/5ML	A087708	001	May 03, 1982

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA		ANI PHARMS INC	**0.025MG;2.5MG**	**A086727**	**001**	
AA		BAYSHORE PHARMS LLC	**0.025MG;2.5MG**	**A210819**	**001**	Nov 13, 2018
AA		LANNETT	**0.025MG;2.5MG**	**A085372**	**001**	
AA		MYLAN	**0.025MG;2.5MG**	**A085762**	**001**	
AA		PAR PHARM	**0.025MG;2.5MG**	**A040357**	**001**	May 02, 2000
AA		UPSHER SMITH LABS	**0.025MG;2.5MG**	**A210571**	**001**	Aug 31, 2018

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE
TABLET;ORAL
LOMOTIL

AA	**+!**	GD SEARLE LLC	**0.025MG;2.5MG**	**N012462**	**001**	

ATROPINE; PRALIDOXIME CHLORIDE
INJECTABLE;INTRAMUSCULAR
DUODOTE

	+!	MERIDIAN MEDCL	2.1MG/0.7ML;600MG/2ML	N021983	001 Sep 28, 2006

AURANOFIN
CAPSULE;ORAL
RIDAURA

	+!	SEBELA IRELAND LTD	3MG	N018689	001 May 24, 1985

AVANAFIL
TABLET;ORAL
STENDRA

	+	METUCHEN PHARMS	50MG	N202276	001 Apr 27, 2012
	+		100MG	N202276	002 Apr 27, 2012
	+!		200MG	N202276	003 Apr 27, 2012

AVATROMBOPAG MALEATE
TABLET;ORAL
DOPTELET

	+!	AKARX INC	EQ 20MG BASE	N210238	001 May 21, 2018

AVIBACTAM SODIUM; CEFTAZIDIME
POWDER;IV (INFUSION)
AVYCAZ

	+!	ALLERGAN SALES LLC	EQ 0.5GM BASE;2GM/VIAL	N206494	001 Feb 25, 2015

AXITINIB
TABLET;ORAL
INLYTA

	+	PF PRISM CV	1MG	N202324	001 Jan 27, 2012
	+!		5MG	N202324	002 Jan 27, 2012

AZACITIDINE
POWDER;INTRAVENOUS, SUBCUTANEOUS
AZACITIDINE

AP		ACCORD HLTHCARE	**100MG/VIAL**	**A207475**	**001**	Jul 02, 2018
AP		ACTAVIS LLC	**100MG/VIAL**	**N208216**	**001**	Apr 29, 2016
AP		CIPLA	**100MG/VIAL**	**A209540**	**001**	May 04, 2018
AP		DR REDDYS LABS LTD	**100MG/VIAL**	**A201537**	**001**	Sep 16, 2013
AP		MYLAN INSTITUTIONAL	**100MG/VIAL**	**A204949**	**001**	Apr 28, 2016
AP		NATCO PHARMA LTD	**100MG/VIAL**	**A207234**	**001**	Jun 23, 2017
AP		SHILPA MEDICARE	**100MG/VIAL**	**A207518**	**001**	Sep 29, 2016

VIDAZA

AP	**+!**	CELGENE	**100MG/VIAL**	**N050794**	**001**	May 19, 2004

AZATHIOPRINE
TABLET;ORAL
AZASAN

AB		AAIPHARMA LLC	**25MG**	**A075252**	**002**	Feb 03, 2003
AB			**50MG**	**A075252**	**001**	Jun 07, 1999
AB			**75MG**	**A075252**	**003**	Feb 03, 2003
AB			**100MG**	**A075252**	**004**	Feb 03, 2003

AZATHIOPRINE

AB		AMNEAL PHARMS LLC	**50MG**	**A074069**	**001**	Feb 16, 1996
AB		MYLAN	**50MG**	**A075568**	**001**	Dec 13, 1999
AB		ZYDUS PHARMS USA	**25MG**	**A077621**	**002**	Sep 05, 2008
AB			**50MG**	**A077621**	**001**	Mar 15, 2007
AB			**75MG**	**A077621**	**003**	Sep 05, 2008
AB			**100MG**	**A077621**	**004**	Sep 05, 2008

IMURAN

AB	**+!**	SEBELA IRELAND LTD	**50MG**	**N016324**	**001**

AZATHIOPRINE SODIUM
INJECTABLE;INJECTION
AZATHIOPRINE SODIUM

	!	WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A074419	001 Mar 31, 1995

AZELAIC ACID							
AEROSOL, FOAM;TOPICAL							
FINACEA							
	+!	LEO PHARMA AS	15%		N207071	001	Jul 29, 2015
CREAM;TOPICAL							
AZELEX							
	+!	AQUA PHARMS LLC	20%		N020428	001	Sep 13, 1995
GEL;TOPICAL							
AZELAIC ACID							
AB		ACTAVIS LABS UT INC	**15%**		**A208011**	**001**	Nov 19, 2018
AB		GLENMARK PHARMS	**15%**		**A204637**	**001**	Nov 19, 2018
AB		TOLMAR	**15%**		**A208724**	**001**	Nov 19, 2018
FINACEA							
AB	**+!**	LEO PHARMA AS	**15%**		**N021470**	**001**	Dec 24, 2002
AZELASTINE HYDROCHLORIDE							
SOLUTION/DROPS;OPHTHALMIC							
AZELASTINE HYDROCHLORIDE							
AT		AKORN	**0.05%**		**A203660**	**001**	Nov 08, 2016
AT		APOTEX INC	**0.05%**		**A078621**	**001**	Aug 03, 2009
AT	**!**	SANDOZ INC	**0.05%**		**A202305**	**001**	May 31, 2012
AT		SUN PHARMA GLOBAL	**0.05%**		**A078738**	**001**	Jun 21, 2010
SPRAY, METERED;NASAL							
ASTELIN							
AB	**+!**	MYLAN SPECIALITY LP	**EQ 0.125MG BASE/SPRAY**		**N020114**	**001**	Nov 01, 1996
ASTEPRO							
AB	**+!**	MYLAN SPECIALITY LP	**EQ 0.1876MG BASE/SPRAY**		**N022203**	**002**	Aug 31, 2009
AZELASTINE HYDROCHLORIDE							
AB		ALKEM LABS LTD	**EQ 0.125MG BASE/SPRAY**		**A208156**	**001**	Aug 18, 2017
AB		AMNEAL PHARMS LLC	**EQ 0.125MG BASE/SPRAY**		**A204660**	**001**	Aug 28, 2017
AB			**EQ 0.1876MG BASE/SPRAY**		**A208199**	**001**	Dec 15, 2017
AB		APOTEX INC	**EQ 0.125MG BASE/SPRAY**		**A077954**	**001**	Apr 30, 2009
AB			**EQ 0.1876MG BASE/SPRAY**		**A201846**	**001**	Aug 31, 2012
AB		BRECKENRIDGE PHARM	**EQ 0.125MG BASE/SPRAY**		**A090176**	**001**	Jul 28, 2015
AB		PERRIGO ISRAEL	**EQ 0.1876MG BASE/SPRAY**		**A202743**	**001**	May 08, 2014
AB		SUN PHARMA GLOBAL	**EQ 0.125MG BASE/SPRAY**		**A090423**	**001**	May 23, 2012
AB		UPSHER SMITH LABS	**EQ 0.125MG BASE/SPRAY**		**A202609**	**001**	Mar 17, 2017
AB		WEST-WARD PHARMS INT	**EQ 0.125MG BASE/SPRAY**		**A091444**	**001**	Oct 24, 2014
AB			**EQ 0.1876MG BASE/SPRAY**		**A207243**	**001**	Sep 22, 2017
AB		ZYDUS PHARMS USA INC	**EQ 0.125MG BASE/SPRAY**		**A091409**	**001**	Aug 14, 2017
AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE							
SPRAY, METERED;NASAL							
DYMISTA							
	+!	MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY		N202236	001	May 01, 2012
AZILSARTAN KAMEDOXOMIL							
TABLET;ORAL							
EDARBI							
	+	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL		N200796	001	Feb 25, 2011
	+!		EQ 80MG MEDOXOMIL		N200796	002	Feb 25, 2011
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE							
TABLET;ORAL							
EDARBYCLOR							
	+	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL;12.5MG		N202331	001	Dec 20, 2011
	+!		EQ 40MG MEDOXOMIL;25MG		N202331	002	Dec 20, 2011
AZITHROMYCIN							
FOR SUSPENSION;ORAL							
AZITHROMYCIN							
AB		AMNEAL PHARMS LLC	**EQ 100MG BASE/5ML**		**A205666**	**001**	Jul 19, 2018
AB			**EQ 200MG BASE/5ML**		**A205666**	**002**	Jul 19, 2018
AB		AUROBINDO PHARMA LTD	**EQ 100MG BASE/5ML**		**A209201**	**001**	Oct 09, 2018
AB			**EQ 200MG BASE/5ML**		**A209201**	**002**	Oct 09, 2018
AB		EPIC PHARMA LLC	**EQ 100MG BASE/5ML**		**A207531**	**001**	Apr 09, 2018
AB			**EQ 200MG BASE/5ML**		**A207531**	**002**	Apr 09, 2018
AB		LUPIN LTD	**EQ 100MG BASE/5ML**		**A065488**	**001**	May 15, 2015
AB			**EQ 200MG BASE/5ML**		**A065488**	**002**	May 15, 2015
AB		PLIVA	**EQ 100MG BASE/5ML**		**A065246**	**002**	Jul 05, 2006
AB			**EQ 200MG BASE/5ML**		**A065246**	**001**	Jul 05, 2006
AB		TEVA PHARMS	**EQ 100MG BASE/5ML**		**A065419**	**001**	Jun 24, 2008

AZITHROMYCIN						
FOR SUSPENSION;ORAL						
AZITHROMYCIN						
AB			**EQ 200MG BASE/5ML**	**A065419**	**002**	Jun 24, 2008
AB		ZYDUS WORLDWIDE	**EQ 100MG BASE/5ML**	**A211147**	**001**	Jul 31, 2018
AB			**EQ 200MG BASE/5ML**	**A211147**	**002**	Jul 31, 2018
ZITHROMAX						
AB	**+**	PFIZER	**EQ 100MG BASE/5ML**	**N050710**	**001**	Oct 19, 1995
AB	**+!**		**EQ 200MG BASE/5ML**	**N050710**	**002**	Oct 19, 1995
	+!		EQ 1GM BASE/PACKET	N050693	001	Sep 28, 1994
INJECTABLE;INJECTION						
AZITHROMYCIN						
AP		AUROBINDO PHARMA LTD	**EQ 500MG BASE/VIAL**	**A203294**	**001**	Jun 19, 2015
AP		FRESENIUS KABI USA	**EQ 500MG BASE/VIAL**	**A065179**	**001**	Dec 13, 2005
AP		GLAND PHARMA LTD	**EQ 500MG BASE/VIAL**	**A065501**	**001**	Nov 09, 2009
AP		HAINAN POLY PHARM	**EQ 500MG BASE/VIAL**	**A203412**	**001**	Oct 09, 2018
AP		HOSPIRA	**EQ 500MG BASE/VIAL**	**A065500**	**001**	Jun 26, 2009
AP			**EQ 500MG BASE/VIAL**	**A065511**	**001**	Jun 26, 2009
AP		MYLAN ASI	**EQ 500MG BASE/VIAL**	**A065506**	**001**	Mar 24, 2009
AP		MYLAN LABS LTD	**EQ 500MG BASE/VIAL**	**A204732**	**001**	Jan 26, 2017
AP		SUN PHARM INDS LTD	**EQ 500MG BASE/VIAL**	**A090923**	**001**	Apr 02, 2013
ZITHROMAX						
AP	**+!**	PFIZER	**EQ 500MG BASE/VIAL**	**N050733**	**001**	Jan 30, 1997
SOLUTION/DROPS;OPHTHALMIC						
AZASITE						
	+!	OAK PHARMS INC	1%	N050810	001	Apr 27, 2007
TABLET;ORAL						
AZITHROMYCIN						
AB		AUROBINDO PHARMA LTD	**EQ 250MG BASE**	**A207370**	**001**	Jul 05, 2018
AB			**EQ 500MG BASE**	**A207398**	**001**	Jul 05, 2018
AB		BIONPHARMA INC	**EQ 600MG BASE**	**A209999**	**001**	Dec 26, 2018
AB		CSPC OUYI PHARM CO	**EQ 500MG BASE**	**A208249**	**001**	Oct 25, 2018
AB			**EQ 600MG BASE**	**A207566**	**001**	Sep 24, 2018
AB		LUPIN LTD	**EQ 250MG BASE**	**A065398**	**001**	May 15, 2015
AB			**EQ 500MG BASE**	**A065399**	**001**	May 15, 2015
AB			**EQ 600MG BASE**	**A065400**	**001**	May 15, 2015
AB		MYLAN	**EQ 600MG BASE**	**A065360**	**001**	Jan 08, 2007
AB		PLIVA	**EQ 250MG BASE**	**A065225**	**001**	Nov 14, 2005
AB			**EQ 500MG BASE**	**A065223**	**001**	Nov 14, 2005
AB			**EQ 600MG BASE**	**A065218**	**001**	Nov 14, 2005
AB		SANDOZ	**EQ 250MG BASE**	**A065211**	**001**	Nov 14, 2005
AB			**EQ 500MG BASE**	**A065212**	**001**	Nov 14, 2005
AB			**EQ 600MG BASE**	**A065209**	**001**	Nov 14, 2005
AB		SUNSHINE LAKE	**EQ 250MG BASE**	**A209045**	**001**	Dec 07, 2018
AB			**EQ 500MG BASE**	**A209044**	**001**	Dec 07, 2018
AB			**EQ 600MG BASE**	**A209043**	**001**	Dec 06, 2018
AB		TEVA	**EQ 250MG BASE**	**A065153**	**001**	Nov 14, 2005
AB			**EQ 500MG BASE**	**A065193**	**001**	Nov 14, 2005
AB			**EQ 600MG BASE**	**A065150**	**001**	Nov 14, 2005
AB		WOCKHARDT	**EQ 250MG BASE**	**A065404**	**001**	Feb 11, 2008
AB			**EQ 500MG BASE**	**A065405**	**001**	Feb 11, 2008
AB			**EQ 600MG BASE**	**A065302**	**003**	Feb 11, 2008
ZITHROMAX						
AB	**+**	PFIZER	**EQ 250MG BASE**	**N050711**	**001**	Jul 18, 1996
AB	**+**		**EQ 500MG BASE**	**N050784**	**001**	May 24, 2002
AB	**+!**		**EQ 600MG BASE**	**N050730**	**001**	Jun 12, 1996
AZTREONAM						
FOR SOLUTION;INHALATION						
CAYSTON						
	+!	GILEAD	75MG/VIAL	N050814	001	Feb 22, 2010
INJECTABLE;INJECTION						
AZACTAM						
AP	**+!**	BRISTOL MYERS SQUIBB	**1GM/VIAL**	**N050580**	**002**	Dec 31, 1986
AP	**+!**		**2GM/VIAL**	**N050580**	**003**	Dec 31, 1986
AZTREONAM						
AP		FRESENIUS KABI USA	**1GM/VIAL**	**A065439**	**002**	Jun 18, 2010
AP			**2GM/VIAL**	**A065439**	**003**	Jun 18, 2010
AZACTAM IN PLASTIC CONTAINER						
	+!	BRISTOL MYERS SQUIBB	20MG/ML	N050632	002	May 24, 1989

AZTREONAM							
INJECTABLE;INJECTION							
AZACTAM IN PLASTIC CONTAINER							
	+!		40MG/ML		N050632	001	May 24, 1989
AZTREONAM							
		FRESENIUS KABI USA	500MG/VIAL		A065439	001	Jun 18, 2010
BACITRACIN							
INJECTABLE;INJECTION							
BACIIM							
AP		X GEN PHARMS	**50,000 UNITS/VIAL**		**A064153**	**001**	May 09, 1997
BACITRACIN							
AP		AKORN	**50,000 UNITS/VIAL**		**A206719**	**001**	Oct 20, 2017
AP		FRESENIUS KABI USA	**50,000 UNITS/VIAL**		**A065116**	**001**	Dec 03, 2002
AP	**!**	PHARMACIA AND UPJOHN	**50,000 UNITS/VIAL**		**A060733**	**002**	
AP		XELLIA PHARMS APS	**50,000 UNITS/VIAL**		**A203177**	**001**	Aug 25, 2014
OINTMENT;OPHTHALMIC							
BACITRACIN							
	!	PERRIGO CO TENNESSEE	500 UNITS/GM		A061212	001	
BACITRACIN ZINC; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE							
OINTMENT;OPHTHALMIC							
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE							
	!	PERRIGO CO TENNESSEE	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM		A062166	002	
BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE							
OINTMENT;OPHTHALMIC							
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE							
AT		AKORN	**400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**		**A065213**	**001**	Jul 25, 2012
AT	**!**	BAUSCH AND LOMB	**400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**		**A064068**	**001**	Oct 30, 1995
OINTMENT;TOPICAL							
CORTISPORIN							
	+!	MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM		N050168	002	May 04, 1984
BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE							
OINTMENT;OPHTHALMIC							
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC							
AT		AKORN	**400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM**		**A065088**	**001**	Feb 06, 2004
AT	**!**	BAUSCH AND LOMB	**400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM**		**A064064**	**001**	Oct 30, 1995
AT		PERRIGO CO TENNESSEE	**400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM**		**A060764**	**002**	
NEOSPORIN							
AT	**+**	CASPER PHARMA LLC	**400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM**		**N050417**	**001**	
BACITRACIN ZINC; POLYMYXIN B SULFATE							
OINTMENT;OPHTHALMIC							
BACITRACIN ZINC AND POLYMYXIN B SULFATE							
AT		AKORN	**500 UNITS/GM;10,000 UNITS/GM**		**A064028**	**001**	Jan 30, 1995
AT	**!**	BAUSCH AND LOMB	**500 UNITS/GM;10,000 UNITS/GM**		**A064046**	**001**	Jan 26, 1995
AT		PERRIGO CO TENNESSEE	**500 UNITS/GM;10,000 UNITS/GM**		**A065022**	**001**	Feb 27, 2002
BACLOFEN							
INJECTABLE;INTRATHECAL							
BACLOFEN							
AP		EMERALD INTL LTD	**0.05MG/ML**		**A091193**	**001**	May 03, 2016
AP			**0.5MG/ML**		**A091193**	**002**	May 03, 2016
AP			**2MG/ML**		**A091193**	**003**	May 03, 2016
AP		MYLAN LABS LTD	**0.5MG/ML**		**A209592**	**001**	Mar 21, 2018
AP			**1MG/ML**		**A209594**	**001**	Mar 06, 2018
AP			**2MG/ML**		**A209592**	**002**	Mar 21, 2018
GABLOFEN							
AP		PIRAMAL CRITICAL	**0.05MG/ML**		**N022462**	**001**	Nov 19, 2010
AP			**0.5MG/ML**		**N022462**	**002**	Nov 19, 2010
AP	**+!**		**1MG/ML**		**N022462**	**004**	Jun 22, 2012
AP			**2MG/ML**		**N022462**	**003**	Nov 19, 2010
LIORESAL							
AP	**+!**	SAOL THERAPS RES LTD	**0.05MG/ML**		**N020075**	**003**	Nov 07, 1996

BACLOFEN

INJECTABLE;INTRATHECAL

LIORESAL

AP	**+!**		**0.5MG/ML**	**N020075**	**001**	Jun 17, 1992
AP	**+!**		**2MG/ML**	**N020075**	**002**	Jun 17, 1992

TABLET;ORAL

BACLOFEN

AB		IMPAX LABS	**10MG**	**A077971**	**001**	Oct 26, 2007
AB			**20MG**	**A077971**	**002**	Oct 26, 2007
AB		IVAX SUB TEVA PHARMS	**10MG**	**A072234**	**001**	Jul 21, 1988
AB	**!**		**20MG**	**A072235**	**001**	Jul 21, 1988
AB		LANNETT CO INC	**10MG**	**A077241**	**002**	Jul 06, 2007
AB			**20MG**	**A077241**	**001**	Dec 20, 2005
AB		MYLAN	**20MG**	**A077121**	**002**	Jul 29, 2005
AB		MYLAN PHARMS INC	**10MG**	**A090334**	**001**	Feb 18, 2010
AB			**20MG**	**A090334**	**002**	Feb 18, 2010
AB		NORTHSTAR HLTHCARE	**10MG**	**A078401**	**002**	Sep 18, 2009
AB			**20MG**	**A078401**	**001**	Sep 18, 2009
AB		OXFORD PHARMS	**10MG**	**A077088**	**002**	Oct 31, 2007
AB			**20MG**	**A077088**	**001**	Oct 31, 2007
AB		RUBICON RES PVT LTD	**10MG**	**A209102**	**002**	Nov 28, 2017
AB			**20MG**	**A209102**	**003**	Nov 28, 2017
AB		SUN PHARM INDS INC	**10MG**	**A077862**	**001**	Aug 14, 2006
AB			**20MG**	**A077862**	**002**	Aug 14, 2006
AB		USL PHARMA	**10MG**	**A074584**	**001**	Aug 19, 1996
AB			**20MG**	**A074584**	**002**	Aug 19, 1996
AB		VINTAGE PHARMS	**10MG**	**A077068**	**002**	Aug 30, 2005
AB			**20MG**	**A077068**	**001**	Aug 30, 2005
AB		ZYDUS WORLDWIDE	**10MG**	**A211659**	**001**	Nov 23, 2018
AB			**20MG**	**A211659**	**002**	Nov 23, 2018
		RUBICON RES PVT LTD	5MG	A209102	001	Nov 28, 2017

BALOXAVIR MARBOXIL

TABLET;ORAL

XOFLUZA

	+	GENENTECH INC	20MG	N210854	001	Oct 24, 2018
	+!		40MG	N210854	002	Oct 24, 2018

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

AB		APOTEX INC	**750MG**	**A077883**	**001**	Dec 28, 2007
AB		MYLAN	**750MG**	**A077807**	**001**	Dec 28, 2007
AB		WEST-WARD PHARMS INT	**750MG**	**A077806**	**001**	Dec 28, 2007

COLAZAL

AB	**+!**	VALEANT PHARMS INTL	**750MG**	**N020610**	**001**	Jul 18, 2000

TABLET;ORAL

BALSALAZIDE DISODIUM

AB		PAR PHARM INC	**1.1GM**	**A206336**	**001**	Sep 08, 2015

GIAZO

AB	**+!**	VALEANT PHARMS INTL	**1.1GM**	**N022205**	**001**	Feb 03, 2012

BARICITINIB

TABLET;ORAL

OLUMIANT

	+!	ELI LILLY AND CO	2MG	N207924	001	May 31, 2018

BARIUM SULFATE

FOR SUSPENSION;ORAL

E-Z-HD

	+!	BRACCO	98% (334GM/BOT)	N208036	001	Jan 11, 2016

E-Z-PAQUE

	+!	BRACCO	96% (169GM/BOT)	N208036	002	Apr 07, 2017

PASTE;ORAL

VARIBAR PUDDING

		BRACCO	40%	N208844	001	Oct 14, 2016

SUSPENSION;ORAL

LIQUID E-Z-PAQUE

	+!	BRACCO	60% (213GM/BOT)	N208143	003	Mar 01, 2017

READI-CAT 2

	+!	BRACCO	2% (9GM/BOT)	N208143	001	Jan 15, 2016

BARIUM SULFATE

SUSPENSION;ORAL

READI-CAT 2 SMOOTHIES

+!	BRACCO	2% (9GM/BOT)	N208143	002	Jan 15, 2016

TAGITOL V

+!	BRACCO	40% (8GM/BOT)	N208143	005	Aug 04, 2017

VARIBAR HONEY

+!	BRACCO	40% (100GM/250ML)	N208143	007	Mar 26, 2018

VARIBAR NECTAR

+!	BRACCO	40% (96GM/240ML)	N208143	004	Jul 07, 2017

VARIBAR THIN HONEY

+!	BRACCO	40% (100GM/250ML)	N208143	006	Jan 23, 2018

BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED

TABLET;ORAL

DUAVEE

+!	WYETH PHARMS	EQ 20MG BASE;0.45MG	N022247	001	Oct 03, 2013

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED;INHALATION

QVAR REDIHALER

+	NORTON WATERFORD	0.04MG/INH	N207921	001	Aug 03, 2017
+		0.08MG/INH	N207921	002	Aug 03, 2017

AEROSOL, METERED;NASAL

QNASL

+	TEVA BRANDED PHARM	0.04MG/ACTUATION	N202813	002	Dec 17, 2014
+!		0.08MG/ACTUATION	N202813	001	Mar 23, 2012

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED;NASAL

BECONASE AQ

+!	GLAXOSMITHKLINE	EQ 0.042MG DIPROP/SPRAY	N019389	001	Jul 27, 1987

BEDAQUILINE FUMARATE

TABLET;ORAL

SIRTURO

+!	JANSSEN THERAP	EQ 100MG BASE	N204384	001	Dec 28, 2012

BELINOSTAT

POWDER;INTRAVENOUS

BELEODAQ

+!	SPECTRUM PHARMS	500MG/VIAL	N206256	001	Jul 03, 2014

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

AB	AMNEAL PHARMS	**5MG**	**A076820**	**001**	Feb 03, 2006
AB		**10MG**	**A076820**	**002**	Feb 03, 2006
AB		**20MG**	**A076820**	**003**	Feb 03, 2006
AB		**40MG**	**A076820**	**004**	Feb 03, 2006
AB	APOTEX INC	**5MG**	**A077128**	**001**	Mar 08, 2006
AB		**10MG**	**A077128**	**002**	Mar 08, 2006
AB		**20MG**	**A077128**	**003**	Mar 08, 2006
AB		**40MG**	**A077128**	**004**	Mar 08, 2006
AB	AUROBINDO PHARMA	**10MG**	**A078212**	**001**	May 22, 2008
AB		**20MG**	**A078212**	**002**	May 22, 2008
AB		**40MG**	**A078212**	**003**	May 22, 2008
AB	CASI PHARMS INC	**5MG**	**A076402**	**001**	Feb 11, 2004
AB		**10MG**	**A076402**	**002**	Feb 11, 2004
AB		**20MG**	**A076402**	**003**	Feb 11, 2004
AB		**40MG**	**A076402**	**004**	Feb 11, 2004
AB	IVAX SUB TEVA PHARMS	**5MG**	**A076333**	**001**	Feb 11, 2004
AB		**10MG**	**A076333**	**002**	Feb 11, 2004
AB		**20MG**	**A076333**	**003**	Feb 11, 2004
AB		**40MG**	**A076333**	**004**	Feb 11, 2004
AB	MYLAN	**5MG**	**A076430**	**001**	Feb 11, 2004
AB		**10MG**	**A076430**	**002**	Feb 11, 2004
AB		**20MG**	**A076430**	**003**	Feb 11, 2004
AB		**40MG**	**A076430**	**004**	Feb 11, 2004
AB	PRINSTON INC	**5MG**	**A076118**	**001**	Feb 11, 2004
AB		**10MG**	**A076118**	**002**	Feb 11, 2004
AB		**20MG**	**A076118**	**003**	Feb 11, 2004
AB		**40MG**	**A076118**	**004**	Feb 11, 2004
AB	SUN PHARM INDS LTD	**5MG**	**A076344**	**001**	Feb 11, 2004
AB		**10MG**	**A076344**	**002**	Feb 11, 2004

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

AB			**20MG**	**A076344**	**003**	Feb 11, 2004
AB			**40MG**	**A076344**	**004**	Feb 11, 2004
AB		TEVA	**5MG**	**A076211**	**001**	Feb 11, 2004
AB			**10MG**	**A076211**	**002**	Feb 11, 2004
AB			**20MG**	**A076211**	**003**	Feb 11, 2004
AB			**40MG**	**A076211**	**004**	Feb 11, 2004
AB		ZYDUS PHARMS USA	**5MG**	**A078848**	**001**	May 23, 2008
AB			**10MG**	**A078848**	**002**	May 23, 2008
AB			**20MG**	**A078848**	**003**	May 23, 2008
AB			**40MG**	**A078848**	**004**	May 23, 2008

LOTENSIN

AB	**+**	US PHARMS HOLDINGS I	**5MG**	**N019851**	**001**	Jun 25, 1991
AB	**+**		**10MG**	**N019851**	**002**	Jun 25, 1991
AB	**+**		**20MG**	**N019851**	**003**	Jun 25, 1991
AB	**+!**		**40MG**	**N019851**	**004**	Jun 25, 1991

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		APOTEX INC	**5MG;6.25MG**	**A078794**	**001**	Aug 21, 2014
AB			**10MG;12.5MG**	**A078794**	**002**	Aug 21, 2014
AB			**20MG;12.5MG**	**A078794**	**003**	Aug 21, 2014
AB			**20MG;25MG**	**A078794**	**004**	Aug 21, 2014
AB		MYLAN	**5MG;6.25MG**	**A076688**	**001**	Feb 11, 2004
AB			**10MG;12.5MG**	**A076688**	**002**	Feb 11, 2004
AB			**20MG;12.5MG**	**A076688**	**003**	Feb 11, 2004
AB			**20MG;25MG**	**A076688**	**004**	Feb 11, 2004
AB		SANDOZ	**5MG;6.25MG**	**A076631**	**001**	Feb 11, 2004
AB			**10MG;12.5MG**	**A076631**	**002**	Feb 11, 2004
AB			**20MG;12.5MG**	**A076631**	**003**	Feb 11, 2004
AB			**20MG;25MG**	**A076631**	**004**	Feb 11, 2004

LOTENSIN HCT

AB	**+**	US PHARMS HOLDINGS I	**10MG;12.5MG**	**N020033**	**002**	May 19, 1992
AB	**+**		**20MG;12.5MG**	**N020033**	**004**	May 19, 1992
AB	**+!**		**20MG;25MG**	**N020033**	**003**	May 19, 1992

BENDAMUSTINE HYDROCHLORIDE

POWDER;IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

AP		ACCORD HLTHCARE	**25MG/VIAL**	**A205574**	**001**	May 19, 2016
AP			**100MG/VIAL**	**A205574**	**002**	May 19, 2016
AP		BRECKENRIDGE PHARM	**25MG/VIAL**	**A205447**	**001**	Dec 29, 2016
AP			**100MG/VIAL**	**A205447**	**002**	Dec 29, 2016
AP		GLENMARK PHARMS LTD	**25MG/VIAL**	**A204771**	**001**	Mar 24, 2016
AP			**100MG/VIAL**	**A204771**	**002**	Mar 24, 2016
AP		MYLAN LABS LTD	**25MG/VIAL**	**A204104**	**001**	Apr 26, 2018
AP			**100MG/VIAL**	**A204104**	**002**	Apr 26, 2018

TREANDA

AP	**+!**	CEPHALON	**25MG/VIAL**	**N022249**	**002**	May 01, 2009
AP	**+!**		**100MG/VIAL**	**N022249**	**001**	Mar 20, 2008

SOLUTION;IV (INFUSION)

BELRAPZO

	+!	EAGLE PHARMS	100MG/4ML (25MG/ML)	N205580	001	May 15, 2018

BENDEKA

	+!	EAGLE PHARMS	100MG/4ML (25MG/ML)	N208194	001	Dec 07, 2015

BENDROFLUMETHIAZIDE; NADOLOL

TABLET;ORAL

CORZIDE

AB	**+**	KING PHARMS LLC	**5MG;40MG**	**N018647**	**001**	May 25, 1983
AB	**+!**		**5MG;80MG**	**N018647**	**002**	May 25, 1983

NADOLOL AND BENDROFLUMETHIAZIDE

AB		IMPAX LABS	**5MG;40MG**	**A077833**	**001**	Mar 30, 2007
AB			**5MG;80MG**	**A077833**	**002**	Mar 30, 2007

BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

SOLUTION/DROPS;OPHTHALMIC

ALTAFLUOR BENOX

	+!	ALTAIRE PHARMS INC	0.4%;0.25%	N208582 001	Dec 14, 2017

BENZNIDAZOLE

TABLET;ORAL

BENZNIDAZOLE

	+	CHEMO RESEARCH SL	12.5MG	N209570 001	Aug 29, 2017
	+!		100MG	N209570 002	Aug 29, 2017

BENZONATATE

CAPSULE;ORAL

BENZONATATE

AA		AIPING PHARM INC	**100MG**	**A210562 001**	Nov 09, 2018
AA			**150MG**	**A210562 002**	Nov 09, 2018
AA			**200MG**	**A210562 003**	Nov 09, 2018
AA		APOTEX INC	**100MG**	**A091310 001**	Jan 16, 2015
AA			**200MG**	**A091310 002**	Jan 16, 2015
AA		BIONPHARMA INC	**100MG**	**A081297 001**	Jan 29, 1993
AA			**200MG**	**A081297 002**	Oct 30, 2007
AA		CSPC NBP PHARM CO	**100MG**	**A202765 002**	Aug 25, 2017
AA			**200MG**	**A202765 001**	Jul 31, 2015
AA		MIKART	**100MG**	**A040851 001**	Nov 09, 2009
AA			**150MG**	**A040851 002**	Nov 09, 2009
AA			**200MG**	**A040851 003**	Nov 09, 2009
AA		ORIT LABS LLC	**100MG**	**A040682 001**	Jul 30, 2007
AA			**200MG**	**A040682 002**	Jul 30, 2007
AA		PURACAP PHARM LLC	**100MG**	**A206948 001**	Dec 19, 2018
AA			**200MG**	**A206948 002**	Dec 19, 2018
AA		STRIDES PHARMA	**100MG**	**A091133 001**	Jul 30, 2015
AA			**200MG**	**A091133 002**	Jul 30, 2015
AA		SUN PHARM INDS INC	**100MG**	**A040587 001**	Mar 19, 2008
AA			**200MG**	**A040587 002**	Mar 19, 2008
AA	!	THEPHARMANETWORK LLC	**100MG**	**A040627 001**	Mar 30, 2007
AA	!		**150MG**	**A201209 001**	Sep 24, 2014
AA	!		**200MG**	**A040749 001**	Jul 25, 2007
AA		ZYDUS PHARMS USA	**100MG**	**A040597 001**	Jun 08, 2007
AA			**200MG**	**A040597 002**	Jun 08, 2007

TESSALON

AA	+	PFIZER	**100MG**	**N011210 001**	

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

ACANYA

AB	+!	DOW PHARM	**2.5%;EQ 1.2% BASE**	**N050819 001**	Oct 23, 2008

BENZACLIN

AB	+!	VALEANT BERMUDA	**5%;EQ 1% BASE**	**N050756 001**	Dec 21, 2000

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB		ACTAVIS LABS UT INC	**2.5%;EQ 1.2% BASE**	**A205128 001**	Jun 19, 2015
AB		MYLAN PHARMS INC	**5%;EQ 1% BASE**	**A065443 001**	Aug 11, 2009
AB		PERRIGO ISRAEL	**5%;EQ 1% BASE**	**A202440 001**	Sep 21, 2015
AB			**5%;1.2%**	**A090979 001**	Jun 26, 2012
AB		TARO	**3.75%;EQ 1.2% BASE**	**A208683 001**	Jun 05, 2018
AB			**5%;EQ 1% BASE**	**A208776 001**	May 25, 2018
AB		TARO PHARMS	**5%;1.2%**	**A206218 001**	Dec 15, 2017
AB		TOLMAR	**5%;EQ 1% BASE**	**A204087 001**	Jun 27, 2017
AB			**5%;1.2%**	**A203688 001**	Aug 25, 2016
AB		ZYDUS PHARMS USA INC	**5%;1.2%**	**A210794 001**	Dec 28, 2018

DUAC

AB	+!	STIEFEL	**5%;1.2%**	**N050741 001**	Aug 26, 2002

ONEXTON

AB	+!	DOW PHARM	**3.75%;EQ 1.2% BASE**	**N050819 002**	Nov 24, 2014

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL;TOPICAL

BENZAMYCIN

AB	+!	VALEANT INTL	**5%;3%**	**N050557 001**	Oct 26, 1984

ERYTHROMYCIN AND BENZOYL PEROXIDE

AB		LYNE	**5%;3%**	**A065385 001**	Sep 18, 2015
AB		TOLMAR	**5%;3%**	**A065112 001**	Mar 29, 2004

BENZOYL PEROXIDE; ERYTHROMYCIN
GEL;TOPICAL
AKTIPAK

	+!	CUTANEA	5%;3%	N050769	001	Nov 27, 2000

BENZPHETAMINE HYDROCHLORIDE
TABLET;ORAL
BENZPHETAMINE HYDROCHLORIDE

AA		EMCURE PHARMS LTD	**50MG**	**A202061**	**001**	Jan 27, 2012
AA		EPIC PHARMA LLC	**50MG**	**A090346**	**001**	Dec 15, 2015
AA	!	KVK TECH	**50MG**	**A090968**	**001**	Jul 20, 2010
AA		MIKART	**50MG**	**A090473**	**002**	Sep 15, 2010
AA		SPECGX LLC	**50MG**	**A040773**	**001**	Apr 25, 2007
AA		TWI PHARMS	**50MG**	**A040578**	**001**	Apr 17, 2006
		MIKART	25MG	A090473	001	Sep 15, 2010

BENZTROPINE MESYLATE
INJECTABLE;INJECTION
BENZTROPINE MESYLATE

AP		FRESENIUS KABI USA	**1MG/ML**	**A090233**	**001**	Jul 28, 2009
AP		HIKMA FARMACEUTICA	**1MG/ML**	**A090287**	**001**	Aug 31, 2009
AP		LUITPOLD	**1MG/ML**	**A091152**	**001**	Mar 29, 2010
AP		NAVINTA LLC	**1MG/ML**	**A091525**	**001**	Feb 05, 2013

COGENTIN

AP	**+!**	OAK PHARMS AKORN	**1MG/ML**	**N012015**	**001**	

TABLET;ORAL
BENZTROPINE MESYLATE

AA		ASPEN GLOBAL INC	**0.5MG**	**A204713**	**001**	Apr 14, 2015
AA			**1MG**	**A204713**	**002**	Apr 14, 2015
AA			**2MG**	**A204713**	**003**	Apr 14, 2015
AA		EPIC PHARMA LLC	**0.5MG**	**A072264**	**001**	Feb 27, 1989
AA			**1MG**	**A072265**	**001**	Feb 27, 1989
AA			**2MG**	**A072266**	**001**	Feb 27, 1989
AA		INVAGEN PHARMS	**0.5MG**	**A090294**	**001**	Mar 29, 2010
AA			**1MG**	**A090294**	**002**	Mar 29, 2010
AA			**2MG**	**A090294**	**003**	Mar 29, 2010
AA		LEADING PHARMA LLC	**0.5MG**	**A090168**	**001**	Nov 28, 2012
AA			**1MG**	**A090168**	**002**	Nov 28, 2012
AA			**2MG**	**A090168**	**003**	Nov 28, 2012
AA		PLIVA	**0.5MG**	**A089058**	**001**	Aug 10, 1988
AA			**1MG**	**A089059**	**001**	Aug 10, 1988
AA			**2MG**	**A089060**	**001**	Aug 10, 1988
AA	!	USL PHARMA	**0.5MG**	**A040103**	**001**	Dec 12, 1996
AA	!		**1MG**	**A040103**	**002**	Dec 12, 1996
AA	!		**2MG**	**A040103**	**003**	Dec 12, 1996
AA		VINTAGE	**0.5MG**	**A040715**	**001**	Aug 27, 2007
AA			**1MG**	**A040715**	**002**	Aug 27, 2007
AA			**2MG**	**A040715**	**003**	Aug 27, 2007
		OXFORD PHARMS	0.5MG	A040706	002	Feb 14, 2008
			1MG	A040706	003	Feb 14, 2008

BENZYL ALCOHOL
LOTION;TOPICAL
ULESFIA

	+!	SHIONOGI INC	5%	N022129	001	Apr 09, 2009

BENZYLPENICILLOYL POLYLYSINE
INJECTABLE;INJECTION
PRE-PEN

	+!	ALLERQUEST	60UMOLAR	N050114	001	

BEPOTASTINE BESILATE
SOLUTION/DROPS;OPHTHALMIC
BEPREVE

	+!	BAUSCH AND LOMB INC	1.5%	N022288	001	Sep 08, 2009

BERACTANT
SUSPENSION;INTRATRACHEAL
SURVANTA

	+!	ABBVIE	25MG/ML	N020032	001	Jul 01, 1991

BESIFLOXACIN HYDROCHLORIDE
SUSPENSION/DROPS;OPHTHALMIC
BESIVANCE
+! BAUSCH AND LOMB EQ 0.6% BASE N022308 001 May 28, 2009

BETAINE
FOR SOLUTION;ORAL
CYSTADANE
+! ORPHAN EUROPE 1GM/SCOOPFUL N020576 001 Oct 25, 1996

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE
INJECTABLE;INJECTION
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
AB LUITPOLD **3MG/ML;EQ 3MG BASE/ML** **A090747 001** Jul 31, 2009
CELESTONE SOLUSPAN
AB **+!** MERCK SHARP DOHME **3MG/ML;EQ 3MG BASE/ML** **N014602 001**

BETAMETHASONE DIPROPIONATE
CREAM;TOPICAL
BETAMETHASONE DIPROPIONATE
AB ACTAVIS MID ATLANTIC **EQ 0.05% BASE** **A070885 001** Feb 03, 1987
AB **+!** FOUGERA PHARMS **EQ 0.05% BASE** **N019137 001** Jun 26, 1984
AB G AND W LABS INC **EQ 0.05% BASE** **A210217 001** Oct 12, 2018
AB TARO **EQ 0.05% BASE** **A073552 001** Apr 30, 1992
AB ZYDUS PHARMS USA INC **EQ 0.05% BASE** **A208885 001** Jan 11, 2019
CREAM, AUGMENTED;TOPICAL
BETAMETHASONE DIPROPIONATE
AB ANDA REPOSITORY **EQ 0.05% BASE** **A076603 001** Jan 23, 2004
AB FOUGERA PHARMS **EQ 0.05% BASE** **A076215 001** Dec 09, 2003
AB GLENMARK GENERICS **EQ 0.05% BASE** **A078930 001** Sep 23, 2008
AB PERRIGO NEW YORK **EQ 0.05% BASE** **A076592 001** Dec 09, 2003
AB TARO **EQ 0.05% BASE** **A076543 001** Dec 09, 2003
DIPROLENE AF
AB **+!** MERCK SHARP DOHME **EQ 0.05% BASE** **N019555 001** Apr 27, 1987
GEL, AUGMENTED;TOPICAL
BETAMETHASONE DIPROPIONATE
AB **!** FOUGERA PHARMS **EQ 0.05% BASE** **A075276 001** May 13, 2003
AB TARO **EQ 0.05% BASE** **A076508 001** Dec 02, 2003
LOTION;TOPICAL
BETAMETHASONE DIPROPIONATE
AB ACTAVIS MID ATLANTIC **EQ 0.05% BASE** **A070281 001** Jul 31, 1985
AB **!** FOUGERA PHARMS INC **EQ 0.05% BASE** **A070275 001** Aug 12, 1985
AB G AND W LABS INC **EQ 0.05% BASE** **A071467 001** Aug 10, 1987
AB HI-TECH PHARMACAL **EQ 0.05% BASE** **A209896 001** Feb 06, 2018
AB PERRIGO NEW YORK **EQ 0.05% BASE** **A072538 001** Jan 31, 1990
LOTION, AUGMENTED;TOPICAL
BETAMETHASONE DIPROPIONATE
AB FOUGERA PHARMS **EQ 0.05% BASE** **A077111 001** May 21, 2007
AB **!** TARO **EQ 0.05% BASE** **A077477 001** May 21, 2007
AB TELIGENT PHARMA INC **EQ 0.05% BASE** **A206389 001** Feb 13, 2018
OINTMENT;TOPICAL
BETAMETHASONE DIPROPIONATE
AB ACTAVIS MID ATLANTIC **EQ 0.05% BASE** **A071012 001** Feb 03, 1987
AB **+!** FOUGERA PHARMS INC **EQ 0.05% BASE** **N019141 001** Sep 04, 1984
AB TARO **EQ 0.05% BASE** **A074271 001** Sep 15, 1994
OINTMENT, AUGMENTED;TOPICAL
BETAMETHASONE DIPROPIONATE
AB ACTAVIS MID ATLANTIC **EQ 0.05% BASE** **A074304 001** Aug 31, 1995
AB FOUGERA PHARMS **EQ 0.05% BASE** **A075373 001** Jun 22, 1999
AB TARO **EQ 0.05% BASE** **A076753 001** Oct 12, 2004
AB TELIGENT PHARMA INC **EQ 0.05% BASE** **A206118 001** Nov 09, 2017
DIPROLENE
AB **+!** MERCK SHARP DOHME **EQ 0.05% BASE** **N018741 001** Jul 27, 1983
SPRAY;TOPICAL
SERNIVO
+! PROMIUS PHARMA LLC EQ 0.05% BASE/SPRAY N208079 001 Feb 05, 2016

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

AEROSOL, FOAM;TOPICAL

ENSTILAR

	+!	LEO PHARMA AS	0.064%;0.005%	N207589 001	Oct 16, 2015

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB		PERRIGO ISRAEL	**0.064%;0.005%**	**A200174 001**	Dec 12, 2014
AB		TOLMAR	**0.064%;0.005%**	**A201615 001**	Jan 14, 2013

TACLONEX

AB	**+!**	LEO PHARMA AS	**0.064%;0.005%**	**N021852 001**	Jan 09, 2006

SUSPENSION;TOPICAL

TACLONEX

	+!	LEO PHARMA AS	0.064%;0.005%	N022185 001	May 09, 2008

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		ACTAVIS MID ATLANTIC	**EQ 0.05% BASE;1%**	**A076002 001**	Aug 02, 2002
AB		FOUGERA PHARMS	**EQ 0.05% BASE;1%**	**A075502 001**	Jun 05, 2001
AB		GLENMARK PHARMS	**EQ 0.05% BASE;1%**	**A202894 001**	Oct 30, 2015
AB		TARO	**EQ 0.05% BASE;1%**	**A075673 001**	May 29, 2001

LOTRISONE

AB	**+!**	MERCK SHARP DOHME	**EQ 0.05% BASE;1%**	**N018827 001**	Jul 10, 1984

LOTION;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	**EQ 0.05% BASE;1%**	**A076516 001**	Jun 16, 2005
AB		TARO	**EQ 0.05% BASE;1%**	**A076493 001**	Jul 28, 2004

LOTRISONE

AB	**+!**	MERCK SHARP DOHME	**EQ 0.05% BASE;1%**	**N020010 001**	Dec 08, 2000

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

BETAMETHASONE VALERATE

AB		PERRIGO UK FINCO	**0.12%**	**A078337 001**	Nov 26, 2012
AB		RICONPHARMA LLC	**0.12%**	**A207144 001**	May 24, 2017
AB		TARO PHARM	**0.12%**	**A208204 001**	May 24, 2017

LUXIQ

AB	**+!**	MYLAN PHARMS INC	**0.12%**	**N020934 001**	Feb 28, 1999

CREAM;TOPICAL

BETA-VAL

AB		G AND W LABS INC	**EQ 0.1% BASE**	**N018642 001**	Mar 24, 1983

BETAMETHASONE VALERATE

AB	**+!**	FOUGERA PHARMS INC	**EQ 0.1% BASE**	**N018861 001**	Aug 31, 1983

DERMABET

AB		TARO	**EQ 0.1% BASE**	**A072041 001**	Jan 06, 1988

VALNAC

AB		ACTAVIS MID ATLANTIC	**EQ 0.1% BASE**	**A070050 001**	Oct 10, 1984

LOTION;TOPICAL

BETAMETHASONE VALERATE

AB	**+!**	FOUGERA PHARMS INC	**EQ 0.1% BASE**	**N018866 001**	Aug 31, 1983
AB		STI PHARMA LLC	**EQ 0.1% BASE**	**A070052 001**	Jul 31, 1985

OINTMENT;TOPICAL

BETA-VAL

AB		G AND W LABS INC	**EQ 0.1% BASE**	**A070069 001**	Dec 19, 1985

BETAMETHASONE VALERATE

AB		ACTAVIS MID ATLANTIC	**EQ 0.1% BASE**	**A070051 001**	Oct 10, 1984
AB	**+!**	FOUGERA PHARMS INC	**EQ 0.1% BASE**	**N018865 001**	Aug 31, 1983

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT		AKORN	**EQ 0.5% BASE**	**A075386 001**	Jun 30, 2000
AT		MEDIMETRIKS PHARMS	**EQ 0.5% BASE**	**A075630 001**	Apr 12, 2001
AT		WOCKHARDT	**EQ 0.5% BASE**	**A078694 001**	Nov 16, 2009

BETOPTIC

AT	**+!**	SANDOZ INC	**EQ 0.5% BASE**	**N019270 001**	Aug 30, 1985

SUSPENSION/DROPS;OPHTHALMIC

BETOPTIC S

	+!	NOVARTIS PHARMS CORP	EQ 0.25% BASE	N019845 001	Dec 29, 1989

BETAXOLOL HYDROCHLORIDE

TABLET;ORAL

BETAXOLOL HYDROCHLORIDE

AB		EPIC PHARMA	**10MG**	**A075541**	**001**	Oct 22, 1999
AB	**!**		**20MG**	**A075541**	**002**	Oct 22, 1999
AB		KVK TECH	**10MG**	**A078962**	**001**	Jun 27, 2008
AB			**20MG**	**A078962**	**002**	Jun 27, 2008

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

AA		AMNEAL PHARM	**5MG**	**A040855**	**001**	Nov 21, 2007
AA			**10MG**	**A040855**	**002**	Nov 21, 2007
AA			**25MG**	**A040855**	**003**	Nov 21, 2007
AA			**50MG**	**A040855**	**004**	Nov 21, 2007
AA		ECI PHARMS LLC	**5MG**	**A040725**	**001**	Oct 26, 2007
AA			**10MG**	**A040726**	**001**	Oct 26, 2007
AA			**25MG**	**A040727**	**001**	Oct 26, 2007
AA			**50MG**	**A040728**	**001**	Oct 26, 2007
AA		HERITAGE PHARMA	**5MG**	**A091256**	**001**	May 04, 2010
AA			**10MG**	**A091256**	**002**	May 04, 2010
AA			**25MG**	**A091256**	**003**	May 04, 2010
AA			**50MG**	**A091256**	**004**	May 04, 2010
AA		LANNETT CO INC	**5MG**	**A040677**	**002**	Mar 27, 2008
AA			**10MG**	**A040677**	**003**	Mar 27, 2008
AA			**25MG**	**A040677**	**004**	Mar 27, 2008
AA			**50MG**	**A040677**	**001**	Mar 27, 2008
AA		UPSHER SMITH LABS	**5MG**	**A040633**	**001**	Jun 01, 2005
AA			**10MG**	**A040634**	**001**	Jun 01, 2005
AA			**25MG**	**A040635**	**001**	Jun 01, 2005
AA			**50MG**	**A040636**	**001**	Jun 01, 2005
AA		WOCKHARDT	**5MG**	**A040532**	**001**	Sep 29, 2003
AA			**10MG**	**A040533**	**001**	Sep 29, 2003
AA			**25MG**	**A040534**	**001**	Sep 29, 2003
AA			**50MG**	**A040518**	**001**	Sep 29, 2003

DUVOID

AA		BI-COASTAL PHARMA	**10MG**	**A086262**	**001**	
AA			**25MG**	**A086263**	**001**	
AA			**50MG**	**A085882**	**003**	

URECHOLINE

AA	**!**	ODYSSEY PHARMS	**5MG**	**A089095**	**001**	Dec 19, 1985
AA	**!**		**10MG**	**A088440**	**001**	May 29, 1984
AA	**!**		**25MG**	**A088441**	**001**	May 29, 1984
AA	**!**		**50MG**	**A089096**	**001**	Dec 19, 1985

BETRIXABAN

CAPSULE;ORAL

BEVYXXA

	+	PORTOLA PHARMS INC	40MG	N208383	001	Jun 23, 2017
	+!		80MG	N208383	002	Jun 23, 2017

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

AB		AMERIGEN PHARMS LTD	**75MG**	**A209861**	**001**	May 08, 2018
AB		AMNEAL PHARMS NY	**75MG**	**A210105**	**001**	Sep 04, 2018
AB		BIONPHARMA INC	**75MG**	**A203174**	**001**	Aug 12, 2014
AB		UPSHER SMITH LABS	**75MG**	**A209886**	**001**	Jul 25, 2018

TARGRETIN

AB	**+!**	VALEANT LUXEMBOURG	**75MG**	**N021055**	**001**	Dec 29, 1999

GEL;TOPICAL

TARGRETIN

	+!	VALEANT LUXEMBOURG	1%	N021056	001	Jun 28, 2000

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

AB		ACCORD HLTHCARE	**50MG**	**A078917**	**001**	Jul 06, 2009
AB		APOTEX INC	**50MG**	**A200274**	**001**	May 21, 2015
AB		BOSCOGEN	**50MG**	**A091011**	**001**	Jun 10, 2015
AB		FRESENIUS KABI ONCOL	**50MG**	**A079045**	**001**	May 13, 2010
AB		MYLAN	**50MG**	**A079185**	**001**	Jul 06, 2009
AB		SANDOZ	**50MG**	**A078575**	**001**	Jul 06, 2009
AB		SUN PHARMA GLOBAL	**50MG**	**A079110**	**001**	Jul 06, 2009

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

AB		TEVA	**50MG**	**A076932**	**001**	Jul 06, 2009
AB		WATSON LABS TEVA	**50MG**	**A078634**	**001**	Aug 28, 2009
AB		ZYDUS PHARMS USA INC	**50MG**	**A079089**	**001**	Jul 06, 2009

CASODEX

AB	**+!**	ANI PHARMS INC	**50MG**	**N020498**	**001**	Oct 04, 1995

BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

BIKTARVY

	+!	GILEAD SCIENCES INC	EQ 50MG BASE;200MG;EQ 25MG BASE	N210251	001	Feb 07, 2018

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

AT		APOTEX INC	**0.03%**	**A090449**	**001**	Jul 20, 2015
AT		HI-TECH PHARMA CO	**0.03%**	**A203299**	**001**	Nov 08, 2018
AT	**!**	LUPIN LTD	**0.03%**	**A203991**	**001**	Feb 20, 2015
AT		SANDOZ INC	**0.03%**	**A202565**	**001**	May 05, 2015

LUMIGAN

	+!	ALLERGAN	0.01%	N022184	001	Aug 31, 2010

SOLUTION/DROPS;TOPICAL

BIMATOPROST

AT		APOTEX INC	**0.03%**	**A201894**	**001**	Dec 01, 2014
AT		HI-TECH PHARMACAL	**0.03%**	**A203051**	**001**	Oct 09, 2018
AT		SANDOZ INC	**0.03%**	**A202719**	**001**	Apr 19, 2016

LATISSE

AT	**+!**	ALLERGAN	**0.03%**	**N022369**	**001**	Dec 24, 2008

BINIMETINIB

TABLET;ORAL

MEKTOVI

	+!	ARRAY BIOPHARMA INC	15MG	N210498	001	Jun 27, 2018

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE;ORAL

PYLERA

	+!	ALLERGAN SALES LLC	140MG;125MG;125MG	N050786	001	Sep 28, 2006

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL

BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

	!	AILEX PHARMS LLC	262.4MG, N/A, N/A;N/A, 250MG, N/A;N/A, N/A, 500MG	A202584	001	Nov 30, 2018

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

AB		AUROBINDO PHARMA	**5MG**	**A077910**	**001**	Dec 27, 2006
AB			**10MG**	**A077910**	**002**	Dec 27, 2006
AB		CASI PHARMS INC	**5MG**	**A075643**	**001**	Nov 16, 2000
AB			**10MG**	**A075643**	**002**	Nov 16, 2000
AB		MYLAN	**5MG**	**A075831**	**001**	Dec 14, 2005
AB	**!**		**10MG**	**A075831**	**002**	Dec 14, 2005
AB		ORIT LABS LLC	**5MG**	**A204891**	**001**	Jan 11, 2017
AB			**10MG**	**A204891**	**002**	Jan 11, 2017
AB		TEVA PHARMS	**5MG**	**A075644**	**001**	Jun 26, 2001
AB			**10MG**	**A075644**	**002**	Jun 26, 2001
AB		UNICHEM PHARMS (USA)	**5MG**	**A078635**	**001**	Aug 18, 2009
AB			**10MG**	**A078635**	**002**	Aug 18, 2009

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

AB		MYLAN	**2.5MG;6.25MG**	**A075768**	**001**	Sep 25, 2000
AB			**5MG;6.25MG**	**A075768**	**002**	Sep 25, 2000
AB			**10MG;6.25MG**	**A075768**	**003**	Sep 25, 2000
AB		SANDOZ	**2.5MG;6.25MG**	**A075579**	**001**	Sep 25, 2000
AB			**5MG;6.25MG**	**A075579**	**002**	Sep 25, 2000
AB			**10MG;6.25MG**	**A075579**	**003**	Sep 25, 2000
AB		UNICHEM	**2.5MG;6.25MG**	**A079106**	**001**	Jul 28, 2010
AB			**5MG;6.25MG**	**A079106**	**002**	Jul 28, 2010

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

AB			**10MG;6.25MG**	**A079106**	**003**	Jul 28, 2010

ZIAC

AB	**+**	TEVA BRANDED PHARM	**2.5MG;6.25MG**	**N020186**	**003**	Mar 26, 1993
AB	**+**		**5MG;6.25MG**	**N020186**	**001**	Mar 26, 1993
AB	**+!**		**10MG;6.25MG**	**N020186**	**002**	Mar 26, 1993

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

ANGIOMAX

AP	**+!**	SANDOZ INC	**250MG/VIAL**	**N020873**	**001**	Dec 15, 2000

BIVALIRUDIN

AP		ACCORD HLTHCARE	**250MG/VIAL**	**A206551**	**001**	Nov 22, 2017
AP		APOTEX INC	**250MG/VIAL**	**A204876**	**001**	Jul 06, 2017
AP		AUROBINDO PHARMA LTD	**250MG/VIAL**	**A205962**	**001**	Jul 27, 2018
AP		CIPLA	**250MG/VIAL**	**A091602**	**001**	Jul 16, 2018
AP		DR REDDYS LABS LTD	**250MG/VIAL**	**A201577**	**001**	May 26, 2017
AP		FRESENIUS KABI USA	**250MG/VIAL**	**A090189**	**001**	Oct 28, 2016
AP		HOSPIRA INC	**250MG/VIAL**	**A090811**	**001**	Jul 14, 2015
AP			**250MG/VIAL**	**A090816**	**001**	Jul 14, 2015
AP		MYLAN INSTITUTIONAL	**250MG/VIAL**	**A202471**	**001**	Jun 01, 2018

SOLUTION;INTRAVENOUS

BIVALIRUDIN IN 0.9% SODIUM CHLORIDE

+!	BAXTER HLTHCARE CORP	250MG/50ML (5MG/ML)	N208374	001	Dec 21, 2017
+!		500MG/100ML (5MG/ML)	N208374	002	Dec 21, 2017

BLEOMYCIN SULFATE

INJECTABLE;INJECTION

BLEOMYCIN SULFATE

AP	**!**	FRESENIUS KABI USA	**EQ 15 UNITS BASE/VIAL**	**A065185**	**001**	Jan 28, 2008
AP	**!**		**EQ 30 UNITS BASE/VIAL**	**A065185**	**002**	Jan 28, 2008
AP		HONG KONG	**EQ 15 UNITS BASE/VIAL**	**A205030**	**001**	Apr 20, 2018
AP			**EQ 30 UNITS BASE/VIAL**	**A205030**	**002**	Apr 20, 2018
AP		HOSPIRA	**EQ 15 UNITS BASE/VIAL**	**A065031**	**001**	Mar 10, 2000
AP			**EQ 30 UNITS BASE/VIAL**	**A065031**	**002**	Mar 10, 2000
AP		TEVA PHARMS USA	**EQ 15 UNITS BASE/VIAL**	**A065033**	**001**	Jun 27, 2000
AP			**EQ 30 UNITS BASE/VIAL**	**A065033**	**002**	Jun 27, 2000
AP		WEST-WARD PHARMS INT	**EQ 15 UNITS BASE/VIAL**	**A065042**	**002**	Oct 17, 2001
AP			**EQ 30 UNITS BASE/VIAL**	**A065042**	**001**	Oct 17, 2001

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

VELCADE

+!	MILLENNIUM PHARMS	3.5MG/VIAL	N021602	001	May 13, 2003

POWDER;INTRAVENOUS

BORTEZOMIB

	FRESENIUS KABI USA	3.5MG/VIAL	N205004	001	Nov 06, 2017

POWDER;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

+	HOSPIRA INC	1MG/VIAL	N209191	002	Dec 28, 2018

BOSENTAN

TABLET;ORAL

TRACLEER

+	ACTELION PHARMS LTD	62.5MG	N021290	001	Nov 20, 2001
+!		125MG	N021290	002	Nov 20, 2001

TABLET, FOR SUSPENSION;ORAL

TRACLEER

+!	ACTELION PHARMS	32MG	N209279	001	Sep 05, 2017

BOSUTINIB MONOHYDRATE

TABLET;ORAL

BOSULIF

+!	PF PRISM CV	EQ 100MG BASE	N203341	001	Sep 04, 2012
+		EQ 400MG BASE	N203341	003	Oct 27, 2017
+		EQ 500MG BASE	N203341	002	Sep 04, 2012

BRETYLIUM TOSYLATE
INJECTABLE;INJECTION
BRETYLIUM TOSYLATE

!	ACADEMIC PHARMS INC	50MG/ML	A204386	001	Dec 21, 2018

BREXPIPRAZOLE
TABLET;ORAL
REXULTI

+	OTSUKA PHARM CO LTD	0.25MG	N205422	001	Jul 10, 2015
+		0.5MG	N205422	002	Jul 10, 2015
+		1MG	N205422	003	Jul 10, 2015
+!		2MG	N205422	004	Jul 10, 2015
+		3MG	N205422	005	Jul 10, 2015
+		4MG	N205422	006	Jul 10, 2015

BRIGATINIB
TABLET;ORAL
ALUNBRIG

+	ARIAD	30MG	N208772	001	Apr 28, 2017
+		90MG	N208772	002	Apr 28, 2017
+!		180MG	N208772	003	Oct 02, 2017

BRIMONIDINE TARTRATE
GEL;TOPICAL
MIRVASO

+!	GALDERMA LABS LP	EQ 0.33% BASE	N204708	001	Aug 23, 2013

SOLUTION/DROPS;OPHTHALMIC
ALPHAGAN P

AT	**+!**	ALLERGAN	**0.15%**	**N021262**	**001**	Mar 16, 2001

BRIMONIDINE TARTRATE

AT		AKORN	**0.2%**	**A076439**	**001**	Mar 14, 2006
AT	**!**	BAUSCH AND LOMB	**0.2%**	**A076260**	**001**	May 28, 2003
AT		INDOCO REMEDIES	**0.2%**	**A091691**	**001**	Nov 18, 2014
AT		SANDOZ INC	**0.2%**	**A076254**	**001**	Sep 16, 2003
AT			**0.2%**	**A078075**	**001**	Jan 30, 2008

QOLIANA

AT		SANDOZ INC	**0.15%**	**N021764**	**001**	May 22, 2006

ALPHAGAN P

+!	ALLERGAN	0.1%	N021770	001	Aug 19, 2005

BRIMONIDINE TARTRATE; BRINZOLAMIDE
SUSPENSION/DROPS;OPHTHALMIC
SIMBRINZA

+!	NOVARTIS PHARMS CORP	0.2%;1%	N204251	001	Apr 19, 2013

BRIMONIDINE TARTRATE; TIMOLOL MALEATE
SOLUTION/DROPS;OPHTHALMIC
COMBIGAN

+!	ALLERGAN	0.2%;EQ 0.5% BASE	N021398	001	Oct 30, 2007

BRINZOLAMIDE
SUSPENSION/DROPS;OPHTHALMIC
AZOPT

+!	NOVARTIS PHARMS CORP	1%	N020816	001	Apr 01, 1998

BRIVARACETAM
SOLUTION;INTRAVENOUS
BRIVIACT

+!	UCB INC	50MG/5ML (10MG/ML)	N205837	001	May 12, 2016

SOLUTION;ORAL
BRIVIACT

+!	UCB INC	10MG/ML	N205838	001	May 12, 2016

TABLET;ORAL
BRIVIACT

+	UCB INC	10MG	N205836	001	May 12, 2016
+		25MG	N205836	002	May 12, 2016
+		50MG	N205836	003	May 12, 2016
+		75MG	N205836	004	May 12, 2016
+!		100MG	N205836	005	May 12, 2016

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMFENAC SODIUM

	!	HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014

BROMSITE

	+!	SUN PHARMA GLOBAL	EQ 0.075% ACID	N206911	001	Apr 08, 2016

PROLENSA

	+!	BAUSCH AND LOMB	EQ 0.07% ACID	N203168	001	Apr 05, 2013

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL

BROMOCRIPTINE MESYLATE

AB	**!**	MYLAN	**EQ 5MG BASE**	**A077226**	**001**	Apr 04, 2005
AB		ZYDUS PHARMS USA INC	**EQ 5MG BASE**	**A078899**	**001**	Jul 30, 2008

PARLODEL

AB	**+**	US PHARMS HOLDINGS I	**EQ 5MG BASE**	**N017962**	**002**	Mar 01, 1982

TABLET;ORAL

BROMOCRIPTINE MESYLATE

AB		MYLAN	**EQ 2.5MG BASE**	**A076962**	**001**	Sep 24, 2004
AB	**!**	PADDOCK LLC	**EQ 2.5MG BASE**	**A077646**	**001**	Oct 01, 2008
AB		SANDOZ INC	**EQ 2.5MG BASE**	**A074631**	**001**	Jan 13, 1998

PARLODEL

AB	**+**	US PHARMS HOLDINGS I	**EQ 2.5MG BASE**	**N017962**	**001**	

CYCLOSET

	+!	VEROSCIENCE	EQ 0.8MG BASE	N020866	001	May 05, 2009

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMFED-DM

AA	**!**	WOCKHARDT BIO AG	**2MG/5ML;10MG/5ML;30MG/5ML**	**A088811**	**001**	Jun 07, 1985

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		ACELLA PHARMS LLC	**2MG/5ML;10MG/5ML;30MG/5ML**	**A203375**	**001**	Sep 20, 2016
AA		MAYNE PHARMA INC	**2MG/5ML;10MG/5ML;30MG/5ML**	**A207676**	**001**	Dec 04, 2018
AA		PADDOCK LLC	**2MG/5ML;10MG/5ML;30MG/5ML**	**A205292**	**001**	Jul 15, 2014
AA		TARO PHARM	**2MG/5ML;10MG/5ML;30MG/5ML**	**A205112**	**001**	Feb 27, 2017
AA		VINTAGE PHARMS	**2MG/5ML;10MG/5ML;30MG/5ML**	**A202940**	**001**	Jul 21, 2014

BUDESONIDE

AEROSOL, FOAM;RECTAL

UCERIS

	+!	VALEANT PHARMS INTL	2MG/ACTUATION	N205613	001	Oct 07, 2014

CAPSULE;ORAL

BUDESONIDE

AB		ALVOGEN MALTA	**3MG**	**A206724**	**001**	Nov 23, 2016
AB		AMNEAL PHARMS	**3MG**	**A206200**	**001**	Jul 31, 2017
AB		BARR LABS DIV TEVA	**3MG**	**A090379**	**001**	Apr 02, 2014
AB		MAYNE PHARMA	**3MG**	**A206623**	**001**	Apr 08, 2016
AB		MYLAN	**3MG**	**A090410**	**001**	May 16, 2011
AB		RISING PHARMS	**3MG**	**A207367**	**001**	Apr 07, 2017
AB		SCIECURE PHARMA INC	**3MG**	**A209041**	**001**	Sep 28, 2017
AB		ZYDUS PHARMS USA INC	**3MG**	**A206134**	**001**	May 04, 2017

ENTOCORT EC

AB	**+!**	PERRIGO PHARMA INTL	**3MG**	**N021324**	**001**	Oct 02, 2001

POWDER, METERED;INHALATION

PULMICORT FLEXHALER

	+	ASTRAZENECA	0.08MG/INH	N021949	001	Jul 12, 2006
	+!		0.16MG/INH	N021949	002	Jul 12, 2006

SUSPENSION;INHALATION

BUDESONIDE

AN		APOTEX INC	**0.25MG/2ML**	**A078202**	**001**	Mar 30, 2009
AN			**0.5MG/2ML**	**A078202**	**002**	Mar 30, 2009
AN		CIPLA	**0.25MG/2ML**	**A205710**	**001**	Nov 16, 2017
AN			**0.5MG/2ML**	**A205710**	**002**	Nov 16, 2017
AN			**1MG/2ML**	**A205710**	**003**	Nov 16, 2017
AN		IMPAX LABS INC	**0.25MG/2ML**	**A078404**	**001**	Jul 31, 2012
AN			**0.5MG/2ML**	**A078404**	**002**	Jul 31, 2012
AN		LUPIN ATLANTIS	**0.5MG/2ML**	**A210897**	**001**	Nov 09, 2018
AN		SANDOZ INC	**0.25MG/2ML**	**A201966**	**003**	Sep 27, 2013
AN			**0.5MG/2ML**	**A201966**	**002**	Sep 27, 2013
AN			**1MG/2ML**	**A201966**	**001**	Sep 27, 2013
AN		TEVA PHARMS	**0.25MG/2ML**	**A077519**	**001**	Nov 18, 2008

BUDESONIDE

SUSPENSION;INHALATION

BUDESONIDE

AN			**0.5MG/2ML**	**A077519**	**002**	Nov 18, 2008
AN		TEVA PHARMS USA	**1MG/2ML**	**A204548**	**001**	Mar 08, 2016

PULMICORT RESPULES

AN	+	ASTRAZENECA PHARMS	**0.25MG/2ML**	**N020929**	**001**	Aug 08, 2000
AN	+		**0.5MG/2ML**	**N020929**	**002**	Aug 08, 2000
AN	+!		**1MG/2ML**	**N020929**	**003**	Aug 08, 2000

TABLET, EXTENDED RELEASE;ORAL

BUDESONIDE

AB		ACTAVIS LABS FL INC	**9MG**	**A205457**	**001**	Jul 03, 2018

UCERIS

AB	+!	VALEANT PHARMS INTL	**9MG**	**N203634**	**001**	Jan 14, 2013

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED;INHALATION

SYMBICORT

	+!	ASTRAZENECA	0.08MG/INH;0.0045MG/INH	N021929	001	Jul 21, 2006
	+!		0.16MG/INH;0.0045MG/INH	N021929	002	Jul 21, 2006

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

AP		HOSPIRA	**0.25MG/ML**	**A074332**	**001**	Oct 31, 1994
AP	!	WEST-WARD PHARMS INT	**0.25MG/ML**	**A079196**	**001**	Apr 30, 2008

TABLET;ORAL

BUMETANIDE

AB		AMNEAL PHARMS CO	**0.5MG**	**A209724**	**001**	Oct 18, 2017
AB			**1MG**	**A209724**	**002**	Oct 18, 2017
AB			**2MG**	**A209724**	**003**	Oct 18, 2017
AB		IVAX SUB TEVA PHARMS	**0.5MG**	**A074225**	**001**	Apr 24, 1995
AB			**1MG**	**A074225**	**002**	Apr 24, 1995
AB			**2MG**	**A074225**	**003**	Apr 24, 1995
AB		SANDOZ	**0.5MG**	**A074700**	**001**	Nov 21, 1996
AB			**1MG**	**A074700**	**002**	Nov 21, 1996
AB	!		**2MG**	**A074700**	**003**	Nov 21, 1996
AB		UPSHER SMITH LABS	**0.5MG**	**A209916**	**001**	Jan 23, 2018
AB			**1MG**	**A209916**	**002**	Jan 23, 2018
AB			**2MG**	**A209916**	**003**	Jan 23, 2018
AB		ZYDUS PHARMS USA INC	**0.5MG**	**A202900**	**001**	Apr 30, 2018
AB			**1MG**	**A202900**	**002**	Apr 30, 2018
AB			**2MG**	**A202900**	**003**	Apr 30, 2018

BUMEX

AB	+	VALIDUS PHARMS	**0.5MG**	**N018225**	**002**	Feb 28, 1983
AB	+		**1MG**	**N018225**	**001**	Feb 28, 1983
AB	+		**2MG**	**N018225**	**003**	Jun 14, 1985

BUPIVACAINE

INJECTABLE, LIPOSOMAL;INJECTION

EXPAREL

	+!	PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011
	+!		266MG/20ML (13.3MG/ML)	N022496	002	Oct 28, 2011

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE

AP		AUROBINDO PHARMA LTD	**0.25%**	**A207183**	**001**	May 13, 2016
AP			**0.5%**	**A207183**	**002**	May 13, 2016
AP		HOSPIRA	**0.25%**	**A070583**	**001**	Feb 17, 1987
AP			**0.25%**	**A070586**	**001**	Mar 03, 1987
AP			**0.25%**	**A070590**	**001**	Feb 17, 1987
AP			**0.25%**	**N018053**	**002**	
AP			**0.5%**	**A070584**	**001**	Feb 17, 1986
AP			**0.5%**	**A070597**	**001**	Mar 03, 1987
AP			**0.5%**	**A070609**	**001**	Mar 03, 1987
AP			**0.5%**	**N018053**	**001**	
AP			**0.75%**	**A070585**	**001**	Mar 03, 1987
AP			**0.75%**	**N018053**	**003**	
AP		MYLAN ASI	**0.25%**	**A091503**	**001**	Oct 18, 2011
AP			**0.5%**	**A091503**	**002**	Oct 18, 2011

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

AP		AUROBINDO PHARMA LTD	**0.25%**	**A203895**	**001**	Nov 05, 2013
AP			**0.5%**	**A203895**	**002**	Nov 05, 2013
AP			**0.75%**	**A203895**	**003**	Nov 05, 2013
AP		MYLAN ASI	**0.25%**	**A091487**	**002**	Oct 18, 2011
AP			**0.5%**	**A091487**	**001**	Oct 18, 2011
AP			**0.75%**	**A091487**	**003**	Oct 18, 2011

MARCAINE HYDROCHLORIDE

AP	**+!**	HOSPIRA	**0.25%**	**N016964**	**001**	
AP	**+!**		**0.5%**	**N016964**	**006**	

MARCAINE HYDROCHLORIDE PRESERVATIVE FREE

AP	**+!**	HOSPIRA	**0.25%**	**N016964**	**012**	
AP	**+!**		**0.5%**	**N016964**	**005**	
AP	**+!**		**0.75%**	**N016964**	**009**	

SENSORCAINE

AP		FRESENIUS KABI USA	**0.25%**	**A070552**	**001**	May 21, 1986
AP			**0.25%**	**N018304**	**001**	
AP			**0.5%**	**A070553**	**001**	May 21, 1986
AP			**0.5%**	**N018304**	**002**	
AP			**0.75%**	**A070554**	**001**	May 21, 1986
AP			**0.75%**	**N018304**	**003**	

INJECTABLE;SPINAL

BUPIVACAINE HYDROCHLORIDE

AP		BAXTER HLTHCARE CORP	**0.75%**	**A207266**	**001**	Jul 25, 2016
AP		HOSPIRA	**0.75%**	**A071810**	**001**	Dec 11, 1987

MARCAINE

AP	**+!**	HOSPIRA	**0.75%**	**N018692**	**001**	May 04, 1984

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

AP	**!**	HOSPIRA	**0.5%;0.005MG/ML**	**A071168**	**001**	Jun 16, 1988
AP			**0.5%;0.005MG/ML**	**A071170**	**001**	Jun 16, 1988
	!		0.25%;0.005MG/ML	A071165	001	Jun 16, 1988
			0.25%;0.005MG/ML	A071167	001	Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

AP		SEPTODONT	**0.5%;0.0091MG/ML**	**A077250**	**001**	Sep 27, 2006

BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE

AP	**+!**	HOSPIRA	**0.5%;0.0091MG/ML**	**N022046**	**001**	Jul 13, 1983

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE

AP	**+!**	HOSPIRA	**0.25%;0.0091MG/ML**	**N016964**	**004**	
AP	**+!**		**0.5%;0.0091MG/ML**	**N016964**	**008**	

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE

AP	**+!**	HOSPIRA	**0.25%;0.0091MG/ML**	**N016964**	**013**	
AP	**+!**		**0.5%;0.0091MG/ML**	**N016964**	**007**	
AP	**+!**		**0.75%;0.0091MG/ML**	**N016964**	**010**	

SENSORCAINE

AP		FRESENIUS KABI USA	**0.25%;0.0091MG/ML**	**A070966**	**001**	Oct 13, 1987
AP			**0.25%;0.0091MG/ML**	**A070967**	**001**	Oct 13, 1987
AP			**0.5%;0.0091MG/ML**	**A070968**	**001**	Oct 13, 1987
AP			**0.5%;0.0091MG/ML**	**N018304**	**004**	Sep 02, 1983
AP			**0.75%;0.0091MG/ML**	**N018304**	**005**	Sep 02, 1983

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL

BUPRENORPHINE

AB		WATSON LABS TEVA	**5MCG/HR**	**A204937**	**001**	Nov 20, 2018
AB			**10MCG/HR**	**A204937**	**002**	Nov 20, 2018
AB			**15MCG/HR**	**A204937**	**003**	Nov 20, 2018
AB			**20MCG/HR**	**A204937**	**004**	Nov 20, 2018

BUTRANS

AB	**+**	PURDUE PHARMA LP	**5MCG/HR**	**N021306**	**001**	Jun 30, 2010
AB	**+**		**10MCG/HR**	**N021306**	**002**	Jun 30, 2010
AB	**+**		**15MCG/HR**	**N021306**	**004**	Jul 25, 2013
AB	**+!**		**20MCG/HR**	**N021306**	**003**	Jun 30, 2010
	+		7.5MCG/HR	N021306	005	Jun 30, 2014

BUPRENORPHINE

SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

SUBLOCADE

	+	INDIVIOR INC	100MG/0.5ML (100MG/0.5ML)	N209819	001	Nov 30, 2017
	+!		300MG/1.5ML (200MG/ML)	N209819	002	Nov 30, 2017

BUPRENORPHINE HYDROCHLORIDE

FILM;BUCCAL

BELBUCA

	+	BDSI	EQ 0.075MG BASE	N207932	001	Oct 23, 2015
	+		EQ 0.15MG BASE	N207932	002	Oct 23, 2015
	+		EQ 0.3MG BASE	N207932	003	Oct 23, 2015
	+		EQ 0.45MG BASE	N207932	004	Oct 23, 2015
	+		EQ 0.6MG BASE	N207932	005	Oct 23, 2015
	+		EQ 0.75MG BASE	N207932	006	Oct 23, 2015
	+!		EQ 0.9MG BASE	N207932	007	Oct 23, 2015

IMPLANT;IMPLANTATION

PROBUPHINE

	+!	TITAN PHARMS	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016

INJECTABLE;INJECTION

BUPRENEX

AP	**+!**	INDIVIOR INC	**EQ 0.3MG BASE/ML**	**N018401**	**001**	

BUPRENORPHINE HYDROCHLORIDE

AP		HOSPIRA	**EQ 0.3MG BASE/ML**	**A074137**	**001**	Jun 03, 1996
AP		LUITPOLD	**EQ 0.3MG BASE/ML**	**A078331**	**001**	Mar 27, 2007
AP		PAR STERILE PRODUCTS	**EQ 0.3MG BASE/ML**	**A206586**	**001**	Jul 28, 2015
AP		WEST-WARD PHARMS INT	**EQ 0.3MG BASE/ML**	**A076931**	**001**	Mar 02, 2005

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**EQ 2MG BASE**	**A090819**	**001**	Feb 19, 2015
AB			**EQ 8MG BASE**	**A090819**	**002**	Feb 19, 2015
AB		BARR	**EQ 2MG BASE**	**A090360**	**001**	May 07, 2010
AB			**EQ 8MG BASE**	**A090360**	**002**	May 07, 2010
AB		CASI PHARMS INC	**EQ 2MG BASE**	**A090279**	**001**	Jun 10, 2015
AB			**EQ 8MG BASE**	**A090279**	**002**	Jun 10, 2015
AB		ETHYPHARM	**EQ 2MG BASE**	**A090622**	**001**	Sep 24, 2010
AB			**EQ 8MG BASE**	**A090622**	**002**	Sep 24, 2010
AB		MYLAN PHARMS INC	**EQ 2MG BASE**	**A201066**	**001**	Mar 06, 2015
AB			**EQ 8MG BASE**	**A201066**	**002**	Mar 06, 2015
AB		RHODES PHARMS	**EQ 2MG BASE**	**A207276**	**001**	Mar 27, 2017
AB			**EQ 8MG BASE**	**A207276**	**002**	Mar 27, 2017
AB		SUN PHARM INDS LTD	**EQ 2MG BASE**	**A201760**	**001**	Jan 29, 2016
AB			**EQ 8MG BASE**	**A201760**	**002**	Jan 29, 2016
AB		WEST-WARD PHARMS INT	**EQ 2MG BASE**	**A078633**	**001**	Oct 08, 2009
AB	**!**		**EQ 8MG BASE**	**A078633**	**002**	Oct 08, 2009

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL

BUNAVAIL

	+	BDSI	EQ 2.1MG BASE;EQ 0.3MG BASE	N205637	001	Jun 06, 2014
	+		EQ 4.2MG BASE;EQ 0.7MG BASE	N205637	002	Jun 06, 2014
	+!		EQ 6.3MG BASE;EQ 1MG BASE	N205637	003	Jun 06, 2014

FILM;BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		DR REDDYS LABS SA	**EQ 2MG BASE;EQ 0.5MG BASE**	**A205299**	**001**	Jun 14, 2018
AB			**EQ 4MG BASE;EQ 1MG BASE**	**A205806**	**001**	Jun 14, 2018
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A205299**	**002**	Jun 14, 2018
AB			**EQ 12MG BASE;EQ 3MG BASE**	**A205806**	**002**	Jun 14, 2018
AB		MYLAN TECHNOLOGIES	**EQ 8MG BASE;EQ 2MG BASE**	**A207607**	**001**	Jun 14, 2018
AB			**EQ 12MG BASE;EQ 3MG BASE**	**A207607**	**002**	Jun 14, 2018

SUBOXONE

AB	**+**	INDIVIOR INC	**EQ 2MG BASE;EQ 0.5MG BASE**	**N022410**	**001**	Aug 30, 2010
AB	**+**		**EQ 4MG BASE;EQ 1MG BASE**	**N022410**	**003**	Aug 10, 2012
AB	**+**		**EQ 8MG BASE;EQ 2MG BASE**	**N022410**	**002**	Aug 30, 2010
AB	**+!**		**EQ 12MG BASE;EQ 3MG BASE**	**N022410**	**004**	Aug 10, 2012

FILM;SUBLINGUAL

CASSIPA

	+!	TEVA PHARMS USA	EQ 16MG BASE;EQ 4MG BASE	N208042	001	Sep 07, 2018

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	**EQ 2MG BASE;EQ 0.5MG BASE**	**A091422**	**001**	Feb 22, 2013
AB !		**EQ 8MG BASE;EQ 2MG BASE**	**A091422**	**002**	Feb 22, 2013
AB	AMNEAL PHARMS	**EQ 2MG BASE;EQ 0.5MG BASE**	**A203136**	**001**	Feb 22, 2013
AB		**EQ 8MG BASE;EQ 2MG BASE**	**A203136**	**002**	Feb 22, 2013
AB	ETHYPHARM USA CORP	**EQ 2MG BASE;EQ 0.5MG BASE**	**A204431**	**001**	Oct 16, 2015
AB		**EQ 8MG BASE;EQ 2MG BASE**	**A204431**	**002**	Oct 16, 2015
AB	LANNETT CO INC	**EQ 2MG BASE;EQ 0.5MG BASE**	**A205022**	**001**	Sep 19, 2016
AB		**EQ 8MG BASE;EQ 2MG BASE**	**A205022**	**002**	Sep 19, 2016
AB	SPECGX LLC	**EQ 2MG BASE;EQ 0.5MG BASE**	**A207000**	**001**	Dec 13, 2017
AB		**EQ 8MG BASE;EQ 2MG BASE**	**A207000**	**002**	Dec 13, 2017
AB	SUN PHARM INDS LTD	**EQ 2MG BASE;EQ 0.5MG BASE**	**A201633**	**001**	Aug 05, 2016
AB		**EQ 8MG BASE;EQ 2MG BASE**	**A201633**	**002**	Aug 05, 2016
AB	TEVA PHARMS USA	**EQ 2MG BASE;EQ 0.5MG BASE**	**A091149**	**001**	Sep 08, 2014
AB		**EQ 8MG BASE;EQ 2MG BASE**	**A091149**	**002**	Sep 08, 2014
AB	WEST-WARD PHARMS INT	**EQ 2MG BASE;EQ 0.5MG BASE**	**A203326**	**001**	Jun 27, 2014
AB		**EQ 8MG BASE;EQ 2MG BASE**	**A203326**	**002**	Jun 27, 2014

ZUBSOLV

+	OREXO US INC	EQ 0.7MG BASE;EQ 0.18MG BASE	N204242	006	Oct 04, 2016
+		EQ 1.4MG BASE;EQ 0.36MG BASE	N204242	001	Jul 03, 2013
+		EQ 2.9MG BASE;EQ 0.71MG BASE	N204242	005	Jun 04, 2015
+		EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002	Jul 03, 2013
+		EQ 8.6MG BASE;EQ 2.1MG BASE	N204242	003	Dec 11, 2014
+!		EQ 11.4MG BASE;EQ 2.9MG BASE	N204242	004	Dec 11, 2014

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

+	VALEANT PHARMS NORTH	174MG	N022108	001	Apr 23, 2008
+		348MG	N022108	002	Apr 23, 2008
+!		522MG	N022108	003	Apr 23, 2008

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	**75MG**	**A203013**	**001**	Jun 08, 2018
AB		**100MG**	**A203013**	**002**	Jun 08, 2018
AB	APOTEX INC	**75MG**	**A076143**	**001**	Jan 17, 2006
AB !		**100MG**	**A076143**	**002**	Jan 17, 2006
AB	HERITAGE PHARMA	**75MG**	**A206975**	**001**	Aug 19, 2016
AB		**100MG**	**A206975**	**002**	Aug 19, 2016
AB	INVAGEN PHARMS	**75MG**	**A207389**	**001**	Sep 18, 2017
AB		**100MG**	**A207389**	**002**	Sep 18, 2017
AB	MYLAN	**75MG**	**A075491**	**001**	Apr 17, 2000
AB		**100MG**	**A075491**	**002**	Apr 17, 2000
AB	SANDOZ	**75MG**	**A075584**	**001**	Feb 07, 2000
AB		**100MG**	**A075584**	**002**	Feb 07, 2000

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1	ACTAVIS LABS FL INC	**100MG**	**A079095**	**001**	Mar 24, 2009
AB1		**150MG**	**A079095**	**002**	Mar 24, 2009
AB1		**200MG**	**A079095**	**003**	Mar 24, 2009
AB1	ANCHEN PHARMS	**100MG**	**A091459**	**001**	Jun 09, 2011
AB1		**150MG**	**A091459**	**002**	Jun 09, 2011
AB1		**200MG**	**A091459**	**003**	Jun 09, 2011
AB1	IMPAX LABS	**100MG**	**A075913**	**001**	Jan 28, 2004
AB1		**150MG**	**A075913**	**002**	Mar 22, 2004
AB1		**200MG**	**A076711**	**001**	Dec 03, 2004
AB1	INVAGEN PHARMS	**100MG**	**A206674**	**001**	Feb 09, 2016
AB1		**150MG**	**A206674**	**002**	Feb 09, 2016
AB1		**200MG**	**A206674**	**003**	Feb 09, 2016
AB1	JUBILANT GENERICS	**100MG**	**A202774**	**001**	Oct 11, 2013
AB1		**150MG**	**A202774**	**002**	Oct 11, 2013
AB1		**200MG**	**A202774**	**003**	Oct 11, 2013
AB1	MYLAN	**100MG**	**A090325**	**001**	Apr 08, 2010
AB1		**150MG**	**A090325**	**002**	Apr 08, 2010
AB1		**200MG**	**A090325**	**003**	Apr 08, 2010
AB1	PRINSTON INC	**100MG**	**A202304**	**001**	May 26, 2015
AB1		**150MG**	**A202304**	**002**	May 26, 2015
AB1		**200MG**	**A202304**	**003**	May 26, 2015

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE							
AB1		SANDOZ	**100MG**	**A075932**	**001**	Nov 25, 2003
AB1			**150MG**	**A075932**	**002**	Mar 22, 2004
AB1			**200MG**	**A075932**	**003**	Jun 22, 2005
AB1		SCIEGEN PHARMS INC	**100MG**	**A205794**	**001**	Mar 01, 2016
AB1			**150MG**	**A205794**	**002**	Mar 01, 2016
AB1			**200MG**	**A205794**	**003**	Mar 01, 2016
AB1		SUN PHARMA GLOBAL	**100MG**	**A078866**	**001**	Apr 06, 2010
AB1			**150MG**	**A078866**	**002**	Apr 06, 2010
AB1			**200MG**	**A078866**	**003**	Apr 06, 2010
AB1		TORRENT PHARMS LTD	**100MG**	**A203969**	**001**	Oct 31, 2014
AB1			**150MG**	**A203969**	**002**	Oct 31, 2014
AB1			**200MG**	**A203969**	**003**	Oct 31, 2014
AB1		WATSON LABS INC	**100MG**	**A077455**	**001**	Jul 19, 2010
AB1			**150MG**	**A077455**	**002**	Mar 12, 2008
AB1			**200MG**	**A077455**	**003**	Jul 19, 2010
AB1		YICHANG HUMANWELL	**100MG**	**A211347**	**001**	Oct 16, 2018
AB1			**150MG**	**A211347**	**002**	Oct 16, 2018
AB1			**200MG**	**A211347**	**003**	Oct 16, 2018
WELLBUTRIN SR							
AB1	**+**	GLAXOSMITHKLINE	**100MG**	**N020358**	**002**	Oct 04, 1996
AB1	**+**		**150MG**	**N020358**	**003**	Oct 04, 1996
AB1	**+!**		**200MG**	**N020358**	**004**	Jun 14, 2002
BUPROPION HYDROCHLORIDE							
AB2		ACTAVIS LABS FL INC	**150MG**	**A079094**	**001**	Mar 24, 2009
AB2		ANCHEN PHARMS	**150MG**	**A091520**	**001**	Jun 09, 2011
AB2		IMPAX LABS	**150MG**	**A075914**	**001**	May 27, 2004
AB2		JUBILANT GENERICS	**150MG**	**A202775**	**001**	Oct 11, 2013
AB2		MYLAN	**150MG**	**A090941**	**001**	May 03, 2010
AB2		SANDOZ INC	**150MG**	**A077475**	**001**	Mar 12, 2008
AB2		SCIEGEN PHARMS INC	**150MG**	**A206122**	**001**	Aug 17, 2016
ZYBAN							
AB2	**+!**	GLAXOSMITHKLINE	**150MG**	**N020711**	**003**	May 14, 1997
BUPROPION HYDROCHLORIDE							
AB3		ACCORD HLTHCARE	**150MG**	**A210497**	**001**	Oct 31, 2018
AB3			**300MG**	**A210497**	**002**	Oct 31, 2018
AB3		ACTAVIS LABS FL INC	**150MG**	**A077715**	**001**	Nov 26, 2008
AB3		ANBISON LAB	**150MG**	**A207224**	**001**	Jun 30, 2017
AB3			**300MG**	**A207224**	**002**	Jun 30, 2017
AB3		ANCHEN PHARMS	**150MG**	**A077284**	**001**	Dec 14, 2006
AB3			**300MG**	**A077284**	**002**	Dec 14, 2006
AB3		IMPAX LABS	**150MG**	**A077415**	**001**	Nov 26, 2008
AB3		INVAGEN PHARMS	**150MG**	**A206556**	**001**	Aug 26, 2016
AB3			**300MG**	**A206556**	**002**	Aug 26, 2016
AB3		JUBILANT GENERICS	**150MG**	**A207459**	**001**	Jun 30, 2017
AB3			**300MG**	**A207459**	**002**	Jun 30, 2017
AB3		LUPIN LTD	**150MG**	**A090693**	**001**	Apr 06, 2017
AB3			**300MG**	**A090693**	**002**	Apr 06, 2017
AB3		MYLAN	**150MG**	**A090942**	**001**	Jul 14, 2010
AB3			**300MG**	**A090942**	**002**	Jul 14, 2010
AB3		SCIEGEN PHARMS INC	**150MG**	**A207479**	**001**	Apr 12, 2017
AB3			**300MG**	**A207479**	**002**	Apr 12, 2017
AB3		SINOTHERAPEUTICS INC	**150MG**	**A208652**	**001**	Aug 21, 2017
AB3			**300MG**	**A208652**	**002**	Aug 21, 2017
AB3		SUN PHARMA GLOBAL	**150MG**	**A200695**	**001**	Dec 18, 2014
AB3		TWI PHARMS	**150MG**	**A210081**	**001**	Nov 03, 2017
AB3			**300MG**	**A210081**	**002**	Nov 03, 2017
AB3		WATSON LABS INC	**150MG**	**A077285**	**001**	Nov 26, 2008
AB3			**300MG**	**A077285**	**002**	Aug 15, 2008
AB3		WOCKHARDT LTD	**150MG**	**A202189**	**001**	Nov 21, 2012
AB3		YICHANG HUMANWELL	**150MG**	**A210015**	**001**	Jun 14, 2018
AB3			**300MG**	**A210015**	**002**	Jun 14, 2018
AB3		ZYDUS PHARMS USA INC	**150MG**	**A201567**	**002**	Jul 23, 2018
AB3			**300MG**	**A201567**	**001**	Jan 17, 2014
WELLBUTRIN XL							
AB3	**+**	VALEANT INTL	**150MG**	**N021515**	**001**	Aug 28, 2003
AB3	**+!**		**300MG**	**N021515**	**002**	Aug 28, 2003

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FORFIVO XL

+!	ALVOGEN	450MG	N022497	001	Nov 10, 2011

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CONTRAVE

+!	NALPROPION	90MG;8MG	N200063	001	Sep 10, 2014

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	**5MG**	**A202557**	**001**	Dec 30, 2014
AB		**7.5MG**	**A202557**	**002**	Dec 30, 2014
AB		**10MG**	**A202557**	**003**	Dec 30, 2014
AB		**15MG**	**A202557**	**004**	Dec 30, 2014
AB		**30MG**	**A202557**	**005**	Dec 30, 2014
AB	AMNEAL PHARMS CO	**5MG**	**A208829**	**001**	May 24, 2017
AB		**7.5MG**	**A208829**	**002**	May 24, 2017
AB		**10MG**	**A208829**	**003**	May 24, 2017
AB		**15MG**	**A208829**	**004**	May 24, 2017
AB		**30MG**	**A208829**	**005**	May 24, 2017
AB	AUROBINDO PHARMA LTD	**5MG**	**A078246**	**001**	Feb 27, 2009
AB		**10MG**	**A078246**	**002**	Feb 27, 2009
AB		**15MG**	**A078246**	**003**	Feb 27, 2009
AB		**30MG**	**A078246**	**004**	Feb 27, 2009
AB	HERITAGE PHARMA	**5MG**	**A204582**	**001**	Sep 18, 2015
AB		**10MG**	**A204582**	**002**	Sep 18, 2015
AB		**15MG**	**A204582**	**003**	Sep 18, 2015
AB		**30MG**	**A204582**	**004**	Sep 18, 2015
AB	IMPAX LABS INC	**5MG**	**A074253**	**001**	Mar 28, 2001
AB		**10MG**	**A074253**	**002**	Mar 28, 2001
AB		**15MG**	**A074253**	**003**	Mar 13, 2002
AB	INVENTIA HLTHCARE	**5MG**	**A209696**	**001**	May 03, 2018
AB		**7.5MG**	**A209696**	**002**	May 03, 2018
AB		**10MG**	**A209696**	**003**	May 03, 2018
AB		**15MG**	**A209696**	**004**	May 03, 2018
AB		**30MG**	**A209696**	**005**	May 03, 2018
AB	MYLAN	**5MG**	**A076008**	**003**	Mar 01, 2002
AB		**7.5MG**	**A075467**	**002**	Mar 28, 2001
AB		**7.5MG**	**A076008**	**002**	Jul 08, 2013
AB		**10MG**	**A076008**	**004**	Mar 01, 2002
AB		**15MG**	**A076008**	**005**	Mar 28, 2001
AB		**30MG**	**A076008**	**001**	Jun 28, 2001
AB	OXFORD PHARMS	**30MG**	**A078302**	**001**	Dec 17, 2007
AB	STRIDES PHARMA	**5MG**	**A202330**	**001**	Aug 25, 2014
AB		**7.5MG**	**A202330**	**005**	Feb 17, 2017
AB		**10MG**	**A202330**	**002**	Aug 25, 2014
AB		**15MG**	**A202330**	**003**	Aug 25, 2014
AB		**30MG**	**A202330**	**004**	Aug 25, 2014
AB	TEVA	**5MG**	**A075022**	**001**	Feb 28, 2002
AB		**10MG**	**A075022**	**002**	Feb 28, 2002
AB !		**15MG**	**A075022**	**003**	Feb 28, 2002
AB		**30MG**	**A075022**	**004**	Mar 25, 2004
AB	YILING PHARM LTD	**5MG**	**A202087**	**001**	Dec 16, 2015
AB		**10MG**	**A202087**	**002**	Dec 16, 2015
AB		**15MG**	**A202087**	**003**	Dec 16, 2015
AB		**30MG**	**A202087**	**004**	Dec 16, 2015
AB	ZYDUS PHARMS USA INC	**5MG**	**A078888**	**001**	Feb 07, 2014
AB		**10MG**	**A078888**	**002**	Feb 07, 2014
AB		**15MG**	**A078888**	**003**	Feb 07, 2014
AB		**30MG**	**A078888**	**004**	Feb 07, 2014

BUSULFAN

INJECTABLE;INJECTION

BUSULFAN

AP	ACTAVIS LLC	**6MG/ML**	**A205139**	**001**	Dec 08, 2017
AP	AMNEAL PHARMS CO	**6MG/ML**	**A209580**	**001**	Dec 18, 2017
AP	HOSPIRA INC	**6MG/ML**	**A205672**	**001**	Jul 31, 2018
AP	LUITPOLD	**6MG/ML**	**A202259**	**001**	Dec 22, 2015
AP	MYLAN LABS LTD	**6MG/ML**	**A205184**	**001**	Jul 13, 2018

BUSULFAN						
INJECTABLE;INJECTION						
BUSULFAN						
AP		NEXUS PHARMS	**6MG/ML**	**A207794**	**001**	Jan 14, 2019
AP		PHARMASCIENCE INC	**6MG/ML**	**A207050**	**001**	Mar 24, 2017
AP		SANDOZ INC	**6MG/ML**	**A205106**	**001**	Sep 21, 2018
BUSULFEX						
AP	**+!**	OTSUKA PHARM	**6MG/ML**	**N020954**	**001**	Feb 04, 1999
MYLERAN						
AP		ASPEN GLOBAL INC	**6MG/ML**	**A208536**	**001**	Nov 20, 2017
TABLET;ORAL						
MYLERAN						
	+!	ASPEN GLOBAL	2MG	N009386	001	
BUTABARBITAL SODIUM						
TABLET;ORAL						
BUTISOL SODIUM						
	+!	MYLAN SPECIALITY LP	30MG	N000793	004	
BUTENAFINE HYDROCHLORIDE						
CREAM;TOPICAL						
MENTAX						
	+!	MYLAN	1%	N020524	001	Oct 18, 1996
BUTOCONAZOLE NITRATE						
CREAM;VAGINAL						
GYNAZOLE-1						
	!	PERRIGO ISRAEL	2%	A200923	001	May 18, 2012
BUTORPHANOL TARTRATE						
INJECTABLE;INJECTION						
BUTORPHANOL TARTRATE						
AP		HIKMA FARMACEUTICA	**1MG/ML**	**A078400**	**001**	May 01, 2009
AP			**2MG/ML**	**A078400**	**002**	May 01, 2009
AP		WEST-WARD PHARMS INT	**2MG/ML**	**A075046**	**001**	Aug 12, 1998
BUTORPHANOL TARTRATE PRESERVATIVE FREE						
AP	**!**	HOSPIRA	**1MG/ML**	**A074626**	**001**	Jan 23, 1997
AP	**!**		**2MG/ML**	**A074626**	**002**	Jan 23, 1997
AP		WEST-WARD PHARMS INT	**1MG/ML**	**A075045**	**001**	Aug 12, 1998
AP			**2MG/ML**	**A075045**	**002**	Aug 12, 1998
SPRAY, METERED;NASAL						
BUTORPHANOL TARTRATE						
AB		APOTEX INC	**1MG/SPRAY**	**A075499**	**001**	Dec 04, 2002
AB	**!**	MYLAN	**1MG/SPRAY**	**A075759**	**001**	Aug 08, 2001
AB		WEST-WARD PHARMS INT	**1MG/SPRAY**	**A075824**	**001**	Mar 12, 2002
CABAZITAXEL						
SOLUTION;INTRAVENOUS						
JEVTANA KIT						
	+!	SANOFI AVENTIS US	60MG/1.5ML (40MG/ML)	N201023	001	Jun 17, 2010
CABERGOLINE						
TABLET;ORAL						
CABERGOLINE						
AB		ACTAVIS LABS FL INC	**0.5MG**	**A078035**	**001**	Apr 21, 2008
AB		INGENUS PHARMS LLC	**0.5MG**	**A204735**	**001**	Aug 01, 2018
AB		IVAX SUB TEVA PHARMS	**0.5MG**	**A077750**	**001**	Mar 07, 2007
AB		MYLAN PHARMS INC	**0.5MG**	**A202947**	**001**	Dec 02, 2013
AB	**!**	PAR PHARM	**0.5MG**	**A076310**	**001**	Dec 29, 2005
CABOZANTINIB S-MALATE						
CAPSULE;ORAL						
COMETRIQ						
	+!	EXELIXIS	EQ 20MG BASE	N203756	001	Nov 29, 2012
	+		EQ 80MG BASE	N203756	002	Nov 29, 2012
TABLET;ORAL						
CABOMETYX						
	+	EXELIXIS INC	EQ 20MG BASE	N208692	001	Apr 25, 2016
	+		EQ 40MG BASE	N208692	002	Apr 25, 2016
	+!		EQ 60MG BASE	N208692	003	Apr 25, 2016

CAFFEINE CITRATE

SOLUTION;INTRAVENOUS

CAFCIT

AP	**+!**	WEST-WARD PHARMS INT	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**N020793**	**001**	Sep 21, 1999

CAFFEINE CITRATE

AP		AUROBINDO PHARMA LTD	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A205013**	**001**	Sep 22, 2015
AP		EXELA PHARMA SCIENCE	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A077233**	**001**	Sep 21, 2006
AP		FRESENIUS KABI USA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A077997**	**001**	Jul 20, 2007
AP		LUITPOLD	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A077906**	**001**	May 15, 2007
AP		MICRO LABS	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A207400**	**001**	Dec 14, 2017
AP		SAGENT PHARMS	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A090827**	**001**	Aug 29, 2012
AP		SUN PHARMA GLOBAL	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A090077**	**001**	Sep 30, 2009

SOLUTION;ORAL

CAFCIT

AA	**+!**	WEST-WARD PHARMS INT	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**N020793**	**002**	Apr 12, 2000

CAFFEINE CITRATE

AA		EXELA PHARMA SCS LLC	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A077304**	**001**	Sep 21, 2006
AA		FRESENIUS KABI USA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A078002**	**001**	Jan 31, 2008
AA		LUITPOLD	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A090064**	**001**	Nov 20, 2009
AA		SAGENT PHARMS	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A091102**	**001**	Aug 29, 2012
AA		SUN PHARMA GLOBAL	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A090357**	**001**	Sep 30, 2009

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY;RECTAL

MIGERGOT

	!	HZNP	100MG;2MG	A086557	001	Oct 04, 1983

TABLET;ORAL

CAFERGOT

AA	**!**	SANDOZ	**100MG;1MG**	**A084294**	**001**	

ERGOTAMINE TARTRATE AND CAFFEINE

AA		HIKMA INTL PHARMS	**100MG;1MG**	**A040510**	**001**	Sep 17, 2004
AA		MIKART	**100MG;1MG**	**A040590**	**001**	Sep 16, 2005

CALCIFEDIOL

CAPSULE, EXTENDED RELEASE;ORAL

RAYALDEE

	+!	OPKO IRELAND GLOBAL	0.03MG	N208010	001	Jun 17, 2016

CALCIPOTRIENE

AEROSOL, FOAM;TOPICAL

SORILUX

	+!	MAYNE PHARMA	0.005%	N022563	001	Oct 06, 2010

CREAM;TOPICAL

CALCIPOTRIENE

AB		GLENMARK PHARMS	**0.005%**	**A205772**	**001**	Jun 09, 2015
AB		TOLMAR	**0.005%**	**A200935**	**001**	May 30, 2012

DOVONEX

AB	**+!**	LEO PHARMA AS	**0.005%**	**N020554**	**001**	Jul 22, 1996

OINTMENT;TOPICAL

CALCIPOTRIENE

	!	GLENMARK PHARMS INC	0.005%	A090633	001	Mar 24, 2010

SOLUTION;TOPICAL

CALCIPOTRIENE

AT		FOUGERA PHARMS	**0.005%**	**A078305**	**001**	May 06, 2008
AT		G AND W LABS INC	**0.005%**	**A078468**	**001**	Mar 24, 2011
AT		HI TECH PHARMA	**0.005%**	**A077579**	**001**	Nov 19, 2009
AT		NOVEL LABS INC	**0.005%**	**A207163**	**001**	Dec 26, 2017
AT	**!**	TOLMAR	**0.005%**	**A077029**	**001**	Nov 20, 2009

CALCITONIN SALMON

INJECTABLE;INJECTION

MIACALCIN

	+!	MYLAN IRELAND LTD	200 IU/ML	N017808	002	Mar 29, 1991

SPRAY, METERED;NASAL

CALCITONIN-SALMON

AB	**!**	APOTEX INC	**200 IU/SPRAY**	**A076396**	**001**	Nov 17, 2008
AB		PAR PHARM	**200 IU/SPRAY**	**A076979**	**001**	Jun 08, 2009

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

AB		AMNEAL PHARMS	**0.25MCG**	**A203289**	**002**	Jun 14, 2017
AB			**0.5MCG**	**A203289**	**001**	Jun 14, 2017
AB		BIONPHARMA INC	**0.25MCG**	**A091174**	**001**	May 24, 2013
AB			**0.5MCG**	**A091174**	**002**	May 24, 2013
AB		STRIDES PHARMA	**0.25MCG**	**A091356**	**001**	Dec 12, 2014
AB			**0.5MCG**	**A091356**	**002**	Dec 12, 2014
AB		TEVA	**0.25MCG**	**A075765**	**001**	Oct 12, 2001
AB			**0.5MCG**	**A075765**	**002**	Oct 12, 2001
AB		WEST-WARD PHARMS INT	**0.25MCG**	**A076917**	**001**	Mar 27, 2006

ROCALTROL

AB	**+**	VALIDUS PHARMS	**0.25MCG**	**N018044**	**001**	
AB	**+!**		**0.5MCG**	**N018044**	**002**	

INJECTABLE;INJECTION

CALCITRIOL

	!	AKORN	0.001MG/ML	A078066	001	Jan 29, 2008

OINTMENT;TOPICAL

VECTICAL

	+!	GALDERMA LABS LP	3MCG/GM	N022087	001	Jan 23, 2009

SOLUTION;ORAL

CALCITRIOL

AA		INVATECH PHARMA	**1MCG/ML**	**A209798**	**001**	Nov 21, 2018
AA		WEST-WARD PHARMS INT	**1MCG/ML**	**A076242**	**001**	Jul 18, 2003

ROCALTROL

AA	**+!**	VALIDUS PHARMS	**1MCG/ML**	**N021068**	**001**	Nov 20, 1998

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

AB		AMNEAL PHARMS	**667MG**	**A201658**	**001**	Oct 06, 2014
AB		CHARTWELL RX	**667MG**	**A091312**	**001**	Jun 01, 2012
AB		HERITAGE PHARMS INC	**667MG**	**A202315**	**001**	Jun 29, 2015
AB		INVAGEN PHARMS	**667MG**	**A203135**	**001**	Feb 07, 2013
AB		LOTUS PHARM CO LTD	**667MG**	**A203298**	**001**	Jul 26, 2016
AB		LUPIN LTD	**667MG**	**A202127**	**001**	Jul 09, 2015
AB		NOSTRUM LABS INC	**667MG**	**A203179**	**001**	Oct 26, 2015
AB		WEST-WARD PHARMS INT	**667MG**	**A077728**	**001**	Feb 26, 2008

PHOSLO GELCAPS

AB	**+!**	FRESENIUS MEDCL	**667MG**	**N021160**	**003**	Apr 02, 2001

SOLUTION;ORAL

PHOSLYRA

	+!	FRESENIUS MEDCL	667MG/5ML	N022581	001	Apr 18, 2011

TABLET;ORAL

CALCIUM ACETATE

AB		HERITAGE PHARMS INC	**667MG**	**A202885**	**001**	Jan 22, 2015
AB		INVAGEN PHARMS	**667MG**	**A202420**	**001**	Feb 05, 2013
AB	**!**	PADDOCK LLC	**667MG**	**A091561**	**001**	Apr 13, 2011

CALCIUM CHLORIDE

INJECTABLE;INJECTION

CALCIUM CHLORIDE 10%

AP		INTL MEDICATION SYS	**100MG/ML**	**A203477**	**001**	May 09, 2018
AP		LUITPOLD	**100MG/ML**	**A209088**	**001**	Jul 27, 2017

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

AP	**+!**	HOSPIRA	**100MG/ML**	**N021117**	**001**	Jan 28, 2000

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

BSS PLUS

	+!	ALCON	0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML	N018469	001	

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE CORP	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE CORP	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE CORP	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE CORP	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE CORP	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.44GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE CORP	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE CORP	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	**25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML**	**N018883**	**001**	Nov 30, 1984

DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	**25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N018883**	**004**	Nov 30, 1984

DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	**18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020171**	**001**	Aug 19, 1992

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	**25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML**	**N018883**	**002**	Nov 30, 1984

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	**25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N018883**	**005**	Nov 30, 1984

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	**18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020171**	**002**	Aug 19, 1992

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	**25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML**	**N018883**	**003**	Nov 30, 1984

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	**25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N018883**	**006**	Nov 30, 1984

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	**18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020171**	**003**	Aug 19, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	**18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020183**	**001**	Dec 04, 1992

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	**18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**004**	
AT		**25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020163**	**001**	Dec 04, 1992

DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	**25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**005**	
AT		**25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020163**	**002**	Dec 04, 1992

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	**25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**006**	
AT		**25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;**	**N020163**	**003**	Dec 04, 1992

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

			538MG/100ML;448MG/100ML			
		DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
		BAXTER HLTHCARE	18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	002	Dec 04, 1992
		DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER				
		BAXTER HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	003	Dec 04, 1992
		DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
		BAXTER HLTHCARE	18.3MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	004	Dec 04, 1992

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INTRATHECAL

ELLIOTTS B SOLUTION

	+!	LUKARE MEDICAL LLC	0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML;1.9MG/ML;7.3MG/ML;0.2MG/ML	N020577	001	Sep 27, 1996

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	**+**	ICU MEDICAL INC	**20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N017608**	**001**	

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

AP		B BRAUN	**20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N019634**	**003**	Feb 24, 1988

LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N016679**	**001**	

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**006**	Apr 05, 1985

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**004**	Apr 05, 1985
AP			**20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**005**	Apr 05, 1985
AP	**+**	ICU MEDICAL INC	**20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML**	**N019685**	**002**	Oct 17, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**007**	Apr 05, 1985

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**008**	Apr 05, 1985
		DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER				
		B BRAUN	10MG/100ML;2.5GM/100ML;15MG/100ML;300MG/100ML;160MG/100ML	N019634	001	Feb 24, 1988
		POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER				
		BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML;600MG/100ML;310MG/100ML	N019367	002	Apr 05, 1985
			20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N019367	003	Apr 05, 1985
		POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER				
		BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML;600MG/100ML;310MG/100ML	N019367	001	Apr 05, 1985

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

	+!	HOSPIRA	16.5MG/ML;25.4MG/ML;74.6MG/ML;121MG/ML;16.1MG/ML	N018895	001	Jul 20, 1984

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SOLUTION;IRRIGATION

BALANCED SALT

AT		AKORN	**0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML**	**A075503**	**001**	Sep 27, 2006
AT		B BRAUN	**0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML**	**A091387**	**001**	Feb 03, 2010

BSS

AT	**+!**	ALCON	**0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML**	**N020742**	**001**	Dec 10, 1997

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE CORP	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE CORP	3.68GM/1000ML;3.05GM/1000ML;0.314GM/100 0ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/10	N207026	001	Jan 13, 2015

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION;PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

AT		BAXTER HLTHCARE	**17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML**	**A075323**	**001**	Apr 21, 2000

PLEGISOL IN PLASTIC CONTAINER

AT	**+!**	HOSPIRA	**17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML**	**N018608**	**001**	Feb 26, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

RINGER'S IN PLASTIC CONTAINER

AP		B BRAUN	**33MG/100ML;30MG/100ML;860MG/100ML**	**N020002**	**001**	Apr 17, 1992
AP		BAXTER HLTHCARE	**33MG/100ML;30MG/100ML;860MG/100ML**	**N016693**	**001**	
AP		ICU MEDICAL INC	**33MG/100ML;30MG/100ML;860MG/100ML**	**N018251**	**001**	

SOLUTION;IRRIGATION

RINGER'S IN PLASTIC CONTAINER

AT		B BRAUN	**33MG/100ML;30MG/100ML;860MG/100ML**	**N018156**	**001**	
AT		BAXTER HLTHCARE	**33MG/100ML;30MG/100ML;860MG/100ML**	**N018495**	**001**	Feb 19, 1982
AT		ICU MEDICAL INC	**33MG/100ML;30MG/100ML;860MG/100ML**	**N017635**	**001**	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP		B BRAUN	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N019632**	**001**	Feb 29, 1988
AP	**+!**	BAXTER HLTHCARE	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N016682**	**001**	
AP		ICU MEDICAL INC	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N017641**	**001**	

SOLUTION;IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

AT	**+!**	B BRAUN	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N018681**	**001**	Dec 27, 1982
AT		BAXTER HLTHCARE	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N018494**	**001**	Feb 19, 1982
AT	**+!**		**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N018921**	**001**	Apr 03, 1984
AT	**+!**	ICU MEDICAL INC	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N019416**	**001**	Jan 17, 1986

CALCIUM GLUCONATE

SOLUTION;INTRAVENOUS

CALCIUM GLUCONATE

	+!	FRESENIUS KABI USA	1GM/10ML (100MG/ML)	N208418	001	Jun 15, 2017
	+!		5GM/50ML (100MG/ML)	N208418	002	Jun 15, 2017
	+!		10GM/100ML (100MG/ML)	N208418	003	Jun 15, 2017

CALCIUM GLUCONATE IN SODIUM CHLORIDE

	+!	HQ SPCLT PHARMA	1GM/50ML (20MG/ML)	N210906	001	Oct 29, 2018
	+!		2GM/100ML (20MG/ML)	N210906	002	Oct 29, 2018

CALFACTANT

SUSPENSION;INTRATRACHEAL

INFASURF PRESERVATIVE FREE

	+!	ONY	35MG/ML	N020521	001	Jul 01, 1998

CANAGLIFLOZIN

TABLET;ORAL

INVOKANA

	+	JANSSEN PHARMS	100MG	N204042	001	Mar 29, 2013
	+!		300MG	N204042	002	Mar 29, 2013

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

INVOKAMET

+	JANSSEN PHARMS	50MG;500MG	N204353	001	Aug 08, 2014
+		50MG;1GM	N204353	002	Aug 08, 2014
+		150MG;500MG	N204353	003	Aug 08, 2014
+!		150MG;1GM	N204353	004	Aug 08, 2014

TABLET, EXTENDED RELEASE;ORAL

INVOKAMET XR

+	JANSSEN PHARMS	50MG;500MG	N205879	001	Sep 20, 2016
+		50MG;1GM	N205879	002	Sep 20, 2016
+		150MG;500MG	N205879	003	Sep 20, 2016
+!		150MG;1GM	N205879	004	Sep 20, 2016

CANDESARTAN CILEXETIL

TABLET;ORAL

ATACAND

AB	**+**	ANI PHARMS INC	**4MG**	**N020838**	**001**	Jun 04, 1998
AB	**+**		**8MG**	**N020838**	**002**	Jun 04, 1998
AB	**+**		**16MG**	**N020838**	**003**	Jun 04, 1998
AB	**+!**		**32MG**	**N020838**	**004**	Jun 04, 1998

CANDESARTAN CILEXETIL

AB	ALEMBIC PHARMS LTD	**4MG**	**A210302**	**001**	Dec 04, 2018
AB		**8MG**	**A210302**	**002**	Dec 04, 2018
AB		**16MG**	**A210302**	**003**	Dec 04, 2018
AB		**32MG**	**A209119**	**001**	Jun 20, 2017
AB	MACLEODS PHARMS LTD	**4MG**	**A203813**	**001**	Dec 05, 2016
AB		**8MG**	**A203813**	**002**	Dec 05, 2016
AB		**16MG**	**A203813**	**003**	Dec 05, 2016
AB		**32MG**	**A203813**	**004**	Dec 05, 2016
AB	MYLAN PHARMS INC	**4MG**	**A078702**	**001**	May 03, 2013
AB		**8MG**	**A078702**	**002**	May 03, 2013
AB		**16MG**	**A078702**	**003**	May 03, 2013
AB		**32MG**	**A078702**	**004**	May 03, 2013
AB	ZYDUS PHARMS USA INC	**4MG**	**A091390**	**001**	Aug 23, 2017
AB		**8MG**	**A091390**	**002**	Aug 23, 2017
AB		**16MG**	**A091390**	**003**	Aug 23, 2017
AB		**32MG**	**A091390**	**004**	Aug 23, 2017

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ATACAND HCT

AB	**+**	ANI PHARMS INC	**16MG;12.5MG**	**N021093**	**001**	Sep 05, 2000
AB	**+**		**32MG;12.5MG**	**N021093**	**002**	Sep 05, 2000
AB	**+!**		**32MG;25MG**	**N021093**	**003**	May 16, 2008

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB	DR REDDYS LABS LTD	**16MG;12.5MG**	**A202965**	**001**	Jun 03, 2013
AB		**32MG;12.5MG**	**A202965**	**002**	Jun 03, 2013
AB		**32MG;25MG**	**A202965**	**003**	Jun 03, 2013
AB	MACLEODS PHARMS LTD	**16MG;12.5MG**	**A204100**	**001**	Feb 27, 2015
AB		**32MG;12.5MG**	**A204100**	**002**	Feb 27, 2015
AB		**32MG;25MG**	**A204100**	**003**	Feb 27, 2015
AB	MYLAN PHARMS INC	**16MG;12.5MG**	**A090704**	**001**	Dec 04, 2012
AB		**32MG;12.5MG**	**A090704**	**002**	Dec 04, 2012
AB		**32MG;25MG**	**A090704**	**003**	Dec 04, 2012
AB	PRINSTON INC	**16MG;12.5MG**	**A207455**	**001**	Apr 11, 2018
AB		**32MG;12.5MG**	**A207455**	**002**	Apr 11, 2018
AB		**32MG;25MG**	**A207455**	**003**	Apr 11, 2018
AB	ZYDUS PHARMS USA INC	**16MG;12.5MG**	**A203466**	**001**	Nov 27, 2017
AB		**32MG;12.5MG**	**A203466**	**002**	Nov 27, 2017
AB		**32MG;25MG**	**A203466**	**003**	Nov 27, 2017

CANGRELOR

POWDER;INTRAVENOUS

KENGREAL

+!	CHIESI USA INC	50MG/VIAL	N204958	001	Jun 22, 2015

CANNABIDIOL

SOLUTION;ORAL

EPIDIOLEX

	+!	GW RES LTD	100MG/ML	N210365	001	Sep 28, 2018

CAPECITABINE

TABLET;ORAL

CAPECITABINE

AB		ACCORD HLTHCARE	**150MG**	**A202593**	**001**	Apr 23, 2015
AB			**500MG**	**A202593**	**002**	Apr 23, 2015
AB		ALKEM LABS LTD	**150MG**	**A207652**	**001**	Nov 24, 2017
AB			**500MG**	**A207652**	**002**	Nov 24, 2017
AB		AMNEAL PHARMS	**150MG**	**A204741**	**001**	Feb 28, 2017
AB			**500MG**	**A204741**	**002**	Feb 28, 2017
AB		EUGIA PHARMA	**150MG**	**A210604**	**001**	Apr 17, 2018
AB			**500MG**	**A210604**	**002**	Apr 17, 2018
AB		MSN LABS PVT LTD	**150MG**	**A209365**	**001**	Jul 02, 2018
AB			**500MG**	**A209365**	**002**	Jul 02, 2018
AB		MYLAN PHARMS INC	**150MG**	**A090943**	**001**	Aug 08, 2014
AB			**500MG**	**A090943**	**002**	Aug 08, 2014
AB		SHILPA MEDICARE LTD	**150MG**	**A207456**	**001**	Dec 12, 2016
AB			**500MG**	**A207456**	**002**	Dec 12, 2016
AB		TEVA PHARMS USA	**150MG**	**A091649**	**001**	Sep 16, 2013
AB			**500MG**	**A091649**	**002**	Sep 16, 2013
AB		WEST-WARD PHARMS INT	**150MG**	**A200483**	**001**	Jul 14, 2016
AB			**500MG**	**A200483**	**002**	Jul 14, 2016

XELODA

AB	**+**	HOFFMANN LA ROCHE	**150MG**	**N020896**	**001**	Apr 30, 1998
AB	**+!**		**500MG**	**N020896**	**002**	Apr 30, 1998

CAPREOMYCIN SULFATE

INJECTABLE;INJECTION

CAPASTAT SULFATE

AP	**+!**	AKORN	**EQ 1GM BASE/VIAL**	**N050095**	**001**	

CAPREOMYCIN SULFATE

AP		HISUN PHARM HANGZHOU	**EQ 1GM BASE/VIAL**	**A204796**	**001**	Oct 18, 2018
AP		MYLAN LABS LTD	**EQ 1GM BASE/VIAL**	**A202634**	**001**	Nov 27, 2017

CAPSAICIN

PATCH;TOPICAL

QUTENZA

	+!	AVERITAS	8%	N022395	001	Nov 16, 2009

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

AB		HIKMA INTL PHARMS	**12.5MG**	**A074505**	**001**	Feb 13, 1996
AB			**25MG**	**A074505**	**002**	Feb 13, 1996
AB			**50MG**	**A074505**	**003**	Feb 13, 1996
AB			**100MG**	**A074505**	**004**	Feb 13, 1996
AB		MYLAN PHARMS INC	**12.5MG**	**A074434**	**001**	Feb 13, 1996
AB			**25MG**	**A074434**	**002**	Feb 13, 1996
AB			**50MG**	**A074434**	**003**	Feb 13, 1996
AB	**!**		**100MG**	**A074434**	**004**	Feb 13, 1996
AB		PRINSTON INC	**12.5MG**	**A074477**	**001**	Feb 13, 1996
AB			**25MG**	**A074477**	**002**	Feb 13, 1996
AB			**50MG**	**A074477**	**003**	Feb 13, 1996
AB			**100MG**	**A074477**	**004**	Feb 13, 1996
AB		TEVA	**12.5MG**	**A074322**	**001**	Feb 13, 1996
AB			**25MG**	**A074322**	**002**	Feb 13, 1996
AB			**50MG**	**A074322**	**003**	Feb 13, 1996
AB			**100MG**	**A074322**	**004**	Feb 13, 1996
AB		WATSON LABS	**12.5MG**	**A074386**	**001**	May 23, 1996
AB			**25MG**	**A074386**	**002**	May 23, 1996
AB			**50MG**	**A074386**	**003**	May 23, 1996
AB			**100MG**	**A074386**	**004**	May 23, 1996
AB		WOCKHARDT LTD	**12.5MG**	**A074532**	**001**	Mar 28, 1997
AB			**25MG**	**A074532**	**002**	Mar 28, 1997
AB			**50MG**	**A074532**	**003**	Mar 28, 1997
AB			**100MG**	**A074532**	**004**	Mar 28, 1997

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

	MYLAN	25MG;15MG	A074896	001	Dec 29, 1997
!		25MG;25MG	A074896	002	Dec 29, 1997
!		50MG;15MG	A074896	004	Dec 29, 1997
		50MG;25MG	A074896	003	Dec 29, 1997

CARBACHOL

SOLUTION;INTRAOCULAR

MIOSTAT

+!	ALCON	0.01%	N016968	001	

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB		APOTEX INC	**100MG**	**A078986**	**001**	Nov 25, 2011
AB			**200MG**	**A078986**	**002**	Nov 25, 2011
AB			**300MG**	**A078986**	**003**	Nov 25, 2011
AB		MYLAN IRELAND LTD	**100MG**	**A076697**	**001**	May 20, 2011
AB			**200MG**	**A076697**	**002**	May 20, 2011
AB			**300MG**	**A076697**	**003**	May 20, 2011
AB		TARO	**100MG**	**A201106**	**001**	Jun 21, 2013
AB			**200MG**	**A201106**	**002**	Jun 21, 2013
AB			**300MG**	**A201106**	**003**	Jun 21, 2013
AB		TEVA PHARMS	**100MG**	**A078592**	**001**	Sep 20, 2012
AB			**200MG**	**A078592**	**002**	Sep 20, 2012
AB			**300MG**	**A078592**	**003**	Sep 20, 2012

CARBATROL

AB	+	SHIRE	**100MG**	**N020712**	**003**	Sep 30, 1997
AB	+		**200MG**	**N020712**	**001**	Sep 30, 1997
AB	+!		**300MG**	**N020712**	**002**	Sep 30, 1997

EQUETRO

	+	VALIDUS PHARMS	100MG	N021710	001	Dec 10, 2004
	+		200MG	N021710	002	Dec 10, 2004
	+!		300MG	N021710	003	Dec 10, 2004

SUSPENSION;ORAL

CARBAMAZEPINE

AB		WOCKHARDT BIO AG	**100MG/5ML**	**A075714**	**001**	Jun 05, 2002

TEGRETOL

AB	+!	NOVARTIS	**100MG/5ML**	**N018927**	**001**	Dec 18, 1987

TERIL

AB		TARO PHARM	**100MG/5ML**	**A076729**	**001**	Sep 20, 2004

TABLET;ORAL

CARBAMAZEPINE

AB		APOTEX INC	**200MG**	**A075948**	**001**	Feb 27, 2002
AB		TARO	**200MG**	**A074649**	**001**	Oct 03, 1996
AB		TORRENT PHARMS	**200MG**	**A077272**	**002**	Dec 07, 2005

EPITOL

AB		TEVA	**200MG**	**A070541**	**001**	Sep 17, 1986

TEGRETOL

AB	+!	NOVARTIS	**200MG**	**N016608**	**001**

CARBAMAZEPINE

	TORRENT PHARMS	100MG	A077272	001	Dec 07, 2005
		300MG	A077272	003	Dec 07, 2005
		400MG	A077272	004	Dec 07, 2005

TABLET, CHEWABLE;ORAL

CARBAMAZEPINE

AB		TARO PHARM INDS	**100MG**	**A075687**	**001**	Oct 24, 2000
AB		TORRENT PHARMS	**100MG**	**A075712**	**001**	Jul 05, 2001

EPITOL

AB		TEVA	**100MG**	**A073524**	**001**	Jul 29, 1992

TEGRETOL

AB	+!	NOVARTIS	**100MG**	**N018281**	**001**

CARBAMAZEPINE

!		TARO PHARM INDS	200MG	A075687	002	Jul 29, 2002

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB		TARO	**100MG**	**A078115**	**001**	Mar 31, 2009
AB			**200MG**	**A078115**	**002**	Mar 31, 2009
AB			**400MG**	**A078115**	**003**	Mar 31, 2009

TEGRETOL-XR

AB	+	NOVARTIS	**100MG**	**N020234**	**001**	Mar 25, 1996

CARBAMAZEPINE

TABLET, EXTENDED RELEASE;ORAL

TEGRETOL-XR

AB	**+**		**200MG**	**N020234**	**002**	Mar 25, 1996
AB	**+!**		**400MG**	**N020234**	**003**	Mar 25, 1996

CARBIDOPA

TABLET;ORAL

CARBIDOPA

AB		ALVOGEN MALTA	**25MG**	**A204291**	**001**	Jan 08, 2016
AB		AMERIGEN PHARMS LTD	**25MG**	**A203261**	**001**	Mar 10, 2014
AB		EDENBRIDGE PHARMS	**25MG**	**A205304**	**001**	Feb 17, 2016
AB		NOVEL LABS INC	**25MG**	**A204763**	**001**	Oct 20, 2017
AB		ZYDUS PHARMS USA INC	**25MG**	**A209910**	**001**	May 07, 2018

LODOSYN

AB	**+!**	ATON	**25MG**	**N017830**	**001**	

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB		SUN PHARMA GLOBAL	**25MG;200MG;100MG**	**A079085**	**001**	May 10, 2012
AB			**37.5MG;200MG;150MG**	**A079085**	**002**	May 10, 2012
AB		WOCKHARDT LTD	**12.5MG;200MG;50MG**	**A090786**	**001**	Nov 20, 2012
AB			**18.75MG;200MG;75MG**	**A090833**	**001**	Nov 20, 2012
AB			**25MG;200MG;100MG**	**A090833**	**002**	Nov 20, 2012
AB			**31.25MG;200MG;125MG**	**A090833**	**003**	Nov 20, 2012
AB			**37.5MG;200MG;150MG**	**A090833**	**004**	Nov 20, 2012
AB			**50MG;200MG;200MG**	**A090833**	**005**	Nov 20, 2012

STALEVO 100

AB	**+**	ORION PHARMA	**25MG;200MG;100MG**	**N021485**	**002**	Jun 11, 2003

STALEVO 125

AB	**+**	ORION PHARMA	**31.25MG;200MG;125MG**	**N021485**	**006**	Aug 29, 2008

STALEVO 150

AB	**+**	ORION PHARMA	**37.5MG;200MG;150MG**	**N021485**	**003**	Jun 11, 2003

STALEVO 200

AB	**+!**	ORION PHARMA	**50MG;200MG;200MG**	**N021485**	**004**	Aug 02, 2007

STALEVO 50

AB	**+!**	ORION PHARMA	**12.5MG;200MG;50MG**	**N021485**	**001**	Jun 11, 2003

STALEVO 75

AB	**+**	ORION PHARMA	**18.75MG;200MG;75MG**	**N021485**	**005**	Aug 29, 2008

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE;ORAL

RYTARY

	+	IMPAX LABS INC	23.75MG;95MG	N203312	001	Jan 07, 2015
	+		36.25MG;145MG	N203312	002	Jan 07, 2015
	+		48.75MG;195MG	N203312	003	Jan 07, 2015
	+!		61.25MG;245MG	N203312	004	Jan 07, 2015

SUSPENSION;ENTERAL

DUOPA

	+!	ABBVIE INC	4.63MG/ML;20MG/ML	N203952	001	Jan 09, 2015

TABLET;ORAL

CARBIDOPA AND LEVODOPA

AB		ACTAVIS ELIZABETH	**10MG;100MG**	**A074260**	**001**	Sep 03, 1993
AB			**25MG;100MG**	**A074260**	**002**	Sep 03, 1993
AB			**25MG;250MG**	**A074260**	**003**	Sep 03, 1993
AB		APOTEX INC	**10MG;100MG**	**A077120**	**001**	Jun 02, 2008
AB			**25MG;100MG**	**A077120**	**002**	Jun 02, 2008
AB			**25MG;250MG**	**A077120**	**003**	Jun 02, 2008
AB		MAYNE PHARMA	**10MG;100MG**	**A073618**	**001**	Aug 28, 1992
AB			**25MG;100MG**	**A073589**	**001**	Aug 28, 1992
AB			**25MG;250MG**	**A073607**	**001**	Aug 28, 1992
AB		MYLAN	**10MG;100MG**	**A090324**	**001**	Sep 28, 2009
AB			**25MG;100MG**	**A090324**	**002**	Sep 28, 2009
AB			**25MG;250MG**	**A090324**	**003**	Sep 28, 2009
AB		SUN PHARM INDS	**10MG;100MG**	**A078536**	**001**	Oct 28, 2008
AB			**25MG;100MG**	**A078536**	**002**	Oct 28, 2008
AB			**25MG;250MG**	**A078536**	**003**	Oct 28, 2008

SINEMET

AB	**+**	MERCK SHARP DOHME	**10MG;100MG**	**N017555**	**001**	
AB	**+**		**25MG;100MG**	**N017555**	**003**	
AB	**+!**		**25MG;250MG**	**N017555**	**002**	

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE;ORAL

CARBIDOPA AND LEVODOPA

AB		ACCORD HLTHCARE	**25MG;100MG**	**A202323**	**001**	Feb 08, 2013
AB			**50MG;200MG**	**A202323**	**002**	Feb 08, 2013
AB		APOTEX	**25MG;100MG**	**A076212**	**001**	Jun 16, 2004
AB			**50MG;200MG**	**A076212**	**002**	Jun 16, 2004
AB		IMPAX LABS	**25MG;100MG**	**A076521**	**001**	May 14, 2004
AB			**50MG;200MG**	**A076521**	**002**	May 14, 2004
AB		MYLAN	**25MG;100MG**	**A075091**	**002**	Apr 21, 2000
AB			**50MG;200MG**	**A075091**	**001**	Sep 30, 1999
AB		SUN PHARM INDS	**25MG;100MG**	**A077828**	**001**	Aug 23, 2007
AB			**50MG;200MG**	**A077828**	**002**	Aug 23, 2007

SINEMET CR

AB	+	MERCK SHARP DOHME	**25MG;100MG**	**N019856**	**002**	Dec 24, 1992
AB	+!		**50MG;200MG**	**N019856**	**001**	May 30, 1991

TABLET, ORALLY DISINTEGRATING;ORAL

CARBIDOPA AND LEVODOPA

AB		MYLAN	**10MG;100MG**	**A078893**	**001**	Sep 18, 2008
AB			**25MG;100MG**	**A078893**	**002**	Sep 18, 2008
AB	!		**25MG;250MG**	**A078893**	**003**	Sep 18, 2008
AB		SUN PHARMA GLOBAL	**10MG;100MG**	**A078690**	**001**	Jul 31, 2009
AB			**25MG;100MG**	**A078690**	**002**	Jul 31, 2009
AB			**25MG;250MG**	**A078690**	**003**	Jul 31, 2009

CARBINOXAMINE MALEATE

SOLUTION;ORAL

CARBINOXAMINE MALEATE

AA	!	MIKART	**4MG/5ML**	**A040458**	**001**	Apr 25, 2003
AA		VINTAGE PHARMS	**4MG/5ML**	**A040814**	**001**	Feb 26, 2008

SUSPENSION, EXTENDED RELEASE;ORAL

KARBINAL ER

	+!	TRIS PHARMA INC	4MG/5ML	N022556	001	Mar 28, 2013

TABLET;ORAL

CARBINOXAMINE MALEATE

AA		INVAGEN PHARMS	**4MG**	**A090435**	**001**	Apr 15, 2010
AA	!	MIKART	**4MG**	**A040442**	**001**	Mar 19, 2003
AA		MISSION PHARMACAL CO	**4MG**	**A090756**	**001**	May 27, 2011
AA		VINTAGE PHARMS	**4MG**	**A040639**	**002**	May 30, 2008
		MIKART	6MG	A207484	001	May 31, 2016

CARBOPLATIN

INJECTABLE;IV (INFUSION)

CARBOPLATIN

AP		ACCORD HLTHCARE	**50MG/5ML (10MG/ML)**	**A206775**	**001**	Feb 09, 2017
AP			**150MG/15ML (10MG/ML)**	**A206775**	**002**	Feb 09, 2017
AP			**450MG/45ML (10MG/ML)**	**A206775**	**003**	Feb 09, 2017
AP			**600MG/60ML (10MG/ML)**	**A206775**	**004**	Feb 09, 2017
AP		AKORN	**50MG/5ML (10MG/ML)**	**A090475**	**001**	Jul 29, 2009
AP			**150MG/15ML (10MG/ML)**	**A090475**	**002**	Jul 29, 2009
AP			**450MG/45ML (10MG/ML)**	**A090475**	**003**	Jul 29, 2009
AP			**600MG/60ML (10MG/ML)**	**A091268**	**002**	Jul 28, 2010
AP		CIPLA LTD	**50MG/5ML (10MG/ML)**	**A077861**	**001**	Jan 18, 2007
AP			**150MG/15ML (10MG/ML)**	**A077861**	**002**	Jan 18, 2007
AP			**450MG/45ML (10MG/ML)**	**A077861**	**003**	Jan 18, 2007
AP			**600MG/60ML (10MG/ML)**	**A077861**	**004**	Jan 18, 2007
AP		EUGIA PHARMA	**50MG/5ML (10MG/ML)**	**A205487**	**001**	Mar 28, 2016
AP			**150MG/15ML (10MG/ML)**	**A205487**	**002**	Mar 28, 2016
AP			**450MG/45ML (10MG/ML)**	**A205487**	**003**	Mar 28, 2016
AP		FRESENIUS KABI USA	**50MG/5ML (10MG/ML)**	**A077432**	**001**	Sep 29, 2006
AP			**150MG/15ML (10MG/ML)**	**A077432**	**002**	Sep 29, 2006
AP			**450MG/45ML (10MG/ML)**	**A077432**	**003**	Sep 29, 2006
AP			**450MG/45ML (10MG/ML)**	**A077247**	**003**	Oct 21, 2004
AP			**450MG/45ML (10MG/ML)**	**A077266**	**003**	Feb 15, 2006
AP			**600MG/60ML (10MG/ML)**	**A077266**	**004**	Feb 15, 2006
AP		GLAND PHARMA LTD	**50MG/5ML (10MG/ML)**	**A207324**	**001**	Feb 15, 2017
AP			**150MG/15ML (10MG/ML)**	**A207324**	**002**	Feb 15, 2017
AP			**450MG/45ML (10MG/ML)**	**A207324**	**003**	Feb 15, 2017
AP			**600MG/60ML (10MG/ML)**	**A207324**	**004**	Feb 15, 2017
AP		HOSPIRA	**50MG/5ML (10MG/ML)**	**A076517**	**001**	Oct 14, 2004
AP			**150MG/15ML (10MG/ML)**	**A076517**	**002**	Oct 14, 2004
AP			**450MG/45ML (10MG/ML)**	**A076517**	**003**	Oct 14, 2004
AP			**600MG/60ML (10MG/ML)**	**A077059**	**001**	Nov 23, 2004

CARBOPLATIN

INJECTABLE;IV (INFUSION)

CARBOPLATIN

AP		INGENUS PHARMS LLC	**50MG/5ML (10MG/ML)**	**A208487**	**001**	Apr 26, 2017
AP			**150MG/15ML (10MG/ML)**	**A208487**	**002**	Apr 26, 2017
AP			**450MG/45ML (10MG/ML)**	**A208487**	**003**	Apr 26, 2017
AP			**600MG/60ML (10MG/ML)**	**A208487**	**004**	Apr 26, 2017
AP		MYLAN INSTITUTIONAL	**50MG/5ML (10MG/ML)**	**A077998**	**001**	Apr 24, 2007
AP			**150MG/15ML (10MG/ML)**	**A077998**	**002**	Apr 24, 2007
AP			**450MG/45ML (10MG/ML)**	**A077998**	**003**	Apr 24, 2007
AP		MYLAN LABS LTD	**50MG/5ML (10MG/ML)**	**A091063**	**001**	Nov 09, 2011
AP			**150MG/15ML (10MG/ML)**	**A091063**	**002**	Nov 09, 2011
AP			**450MG/45ML (10MG/ML)**	**A091063**	**003**	Nov 09, 2011
AP			**600MG/60ML (10MG/ML)**	**A091063**	**004**	Nov 09, 2011
AP		NANJING KING-FRIEND	**50MG/5ML (10MG/ML)**	**A077096**	**001**	Jun 14, 2005
AP			**150MG/15ML (10MG/ML)**	**A077096**	**002**	Jun 14, 2005
AP			**450MG/45ML (10MG/ML)**	**A077096**	**003**	Jun 14, 2005
AP			**600MG/60ML (10MG/ML)**	**A077096**	**004**	Jun 03, 2013
AP	!	PHARMACHEMIE BV	**50MG/5ML (10MG/ML)**	**A077269**	**001**	Oct 14, 2004
AP	!		**150MG/15ML (10MG/ML)**	**A077269**	**002**	Oct 14, 2004
AP	!		**450MG/45ML (10MG/ML)**	**A077269**	**003**	Oct 14, 2004
AP	!		**600MG/60ML (10MG/ML)**	**A077269**	**004**	Dec 28, 2007
AP		PLIVA LACHEMA	**50MG/5ML (10MG/ML)**	**A078631**	**001**	Dec 02, 2008
AP			**150MG/15ML (10MG/ML)**	**A078631**	**002**	Dec 02, 2008
AP			**450MG/45ML (10MG/ML)**	**A078631**	**003**	Dec 02, 2008
AP			**600MG/60ML (10MG/ML)**	**A078631**	**004**	Dec 02, 2008
AP		SANDOZ INC	**50MG/5ML (10MG/ML)**	**A078280**	**001**	May 08, 2008
AP			**150MG/15ML (10MG/ML)**	**A078280**	**002**	May 08, 2008
AP			**450MG/45ML (10MG/ML)**	**A078280**	**003**	May 08, 2008
AP		SUN PHARMA GLOBAL	**50MG/5ML (10MG/ML)**	**A077926**	**001**	Sep 19, 2008
AP			**150MG/15ML (10MG/ML)**	**A077926**	**002**	Sep 19, 2008
AP			**450MG/45ML (10MG/ML)**	**A077926**	**003**	Sep 19, 2008
AP	!	TEVA PHARMS USA	**50MG/5ML (10MG/ML)**	**A077139**	**001**	Sep 21, 2005
AP	!		**150MG/15ML (10MG/ML)**	**A077139**	**002**	Sep 21, 2005
AP	!		**450MG/45ML (10MG/ML)**	**A077139**	**003**	Sep 21, 2005
AP	!		**600MG/60ML (10MG/ML)**	**A077139**	**004**	Sep 21, 2005
AP		WEST-WARD PHARMS INT	**50MG/5ML (10MG/ML)**	**A077244**	**001**	Oct 15, 2004
AP			**150MG/15ML (10MG/ML)**	**A077244**	**002**	Oct 15, 2004
AP			**450MG/45ML (10MG/ML)**	**A077244**	**003**	Oct 15, 2004
AP			**600MG/60ML (10MG/ML)**	**A077244**	**004**	Jan 20, 2006

CARBOPROST TROMETHAMINE

INJECTABLE;INJECTION

HEMABATE

+!	PHARMACIA AND UPJOHN	EQ 0.25MG BASE/ML	N017989	001	

CARFILZOMIB

POWDER;INTRAVENOUS

KYPROLIS

+	ONYX THERAP	10MG/VIAL	N202714	003	Jun 07, 2018
+		30MG/VIAL	N202714	002	Jun 03, 2016
+!		60MG/VIAL	N202714	001	Jul 20, 2012

CARGLUMIC ACID

TABLET;ORAL

CARBAGLU

+!	ORPHAN EUROPE	200MG	N022562	001	Mar 18, 2010

CARIPRAZINE HYDROCHLORIDE

CAPSULE;ORAL

VRAYLAR

+	ALLERGAN SALES LLC	EQ 1.5MG BASE	N204370	001	Sep 17, 2015
+		EQ 3MG BASE	N204370	002	Sep 17, 2015
+		EQ 4.5MG BASE	N204370	003	Sep 17, 2015
+!		EQ 6MG BASE	N204370	004	Sep 17, 2015

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL

AA		ACCELRX LABS	**350MG**	**A040576**	**001**	Jun 07, 2005
AA		AUROBINDO PHARMA	**350MG**	**A040792**	**001**	Aug 06, 2009
AA		HIKMA INTL PHARMS	**350MG**	**A040124**	**001**	Jan 24, 1996
AA		NATCO PHARMA LTD	**350MG**	**A090988**	**001**	Oct 28, 2014

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL

AA		NOVAST LABS	**350MG**	**A040823**	**001**	Oct 22, 2008
AA		ORIENT PHARMA CO LTD	**350MG**	**A205085**	**001**	Oct 28, 2014
AA		SCIEGEN PHARMS INC	**350MG**	**A203374**	**001**	Jan 27, 2014
AA		STRIDES PHARMA	**350MG**	**A205513**	**002**	Nov 12, 2015
AA		SUN PHARM INDUSTRIES	**350MG**	**A089346**	**001**	Oct 17, 1991
AA		VINTAGE PHARMS	**350MG**	**A040245**	**001**	Sep 08, 1997
AA		WATSON LABS	**350MG**	**A087499**	**001**	Apr 20, 1982
AA		WILSHIRE PHARMS INC	**350MG**	**A205126**	**002**	Jul 08, 2015

SOMA

AA	**+**	MYLAN SPECIALITY LP	**350MG**	**N011792**	**001**	

CARISOPRODOL

AB		AUROBINDO PHARMA	**250MG**	**A040792**	**002**	Nov 08, 2016
AB		NOSTRUM LABS INC	**250MG**	**A207237**	**001**	May 11, 2017
AB		STRIDES PHARMA	**250MG**	**A205513**	**001**	Nov 12, 2015
AB		WILSHIRE PHARMS INC	**250MG**	**A205126**	**001**	Jul 08, 2015

SOMA

AB	**+!**	MYLAN SPECIALITY LP	**250MG**	**N011792**	**004**	Sep 13, 2007

CARMUSTINE

IMPLANT;INTRACRANIAL

GLIADEL

	+!	ARBOR PHARMS LLC	7.7MG	N020637	001	Sep 23, 1996

INJECTABLE;INJECTION

BICNU

AP	**+!**	EMCURE PHARMS LTD	**100MG/VIAL**	**N017422**	**001**	

CARMUSTINE

AP		AMNEAL PHARMS CO	**100MG/VIAL**	**A211229**	**001**	Oct 16, 2018
AP		NAVINTA LLC	**100MG/VIAL**	**A210179**	**001**	Sep 11, 2018

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

AT		BAUSCH AND LOMB	**1%**	**A075546**	**001**	Jan 20, 2000
AT	**!**	SANDOZ INC	**1%**	**A075476**	**001**	Jan 03, 2000

CARVEDILOL

TABLET;ORAL

CARVEDILOL

AB		APOTEX INC	**3.125MG**	**A078165**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078165**	**002**	Sep 05, 2007
AB			**12.5MG**	**A078165**	**003**	Sep 05, 2007
AB			**25MG**	**A078165**	**004**	Sep 05, 2007
AB		AUROBINDO PHARMA	**3.125MG**	**A078332**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078332**	**002**	Sep 05, 2007
AB			**12.5MG**	**A078332**	**003**	Sep 05, 2007
AB			**25MG**	**A078332**	**004**	Sep 05, 2007
AB		BEXIMCO USA	**3.125MG**	**A078384**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078384**	**002**	Sep 05, 2007
AB			**12.5MG**	**A078384**	**003**	Sep 05, 2007
AB			**25MG**	**A078384**	**004**	Sep 05, 2007
AB		CHARTWELL MOLECULAR	**3.125MG**	**A077474**	**001**	Sep 05, 2007
AB			**6.25MG**	**A077474**	**002**	Sep 05, 2007
AB			**12.5MG**	**A077474**	**003**	Sep 05, 2007
AB			**25MG**	**A077474**	**004**	Sep 05, 2007
AB		DR REDDYS LABS LTD	**3.125MG**	**A076649**	**001**	Sep 05, 2007
AB			**6.25MG**	**A076649**	**002**	Sep 05, 2007
AB			**12.5MG**	**A076649**	**003**	Sep 05, 2007
AB			**25MG**	**A076649**	**004**	Sep 05, 2007
AB		GLENMARK GENERICS	**3.125MG**	**A078251**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078251**	**002**	Sep 05, 2007
AB			**12.5MG**	**A078251**	**003**	Sep 05, 2007
AB			**25MG**	**A078251**	**004**	Sep 05, 2007
AB		LUPIN	**3.125MG**	**A078217**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078217**	**002**	Sep 05, 2007
AB			**12.5MG**	**A078217**	**003**	Sep 05, 2007
AB			**25MG**	**A078217**	**004**	Sep 05, 2007
AB		MYLAN	**3.125MG**	**A077316**	**001**	Sep 05, 2007
AB			**6.25MG**	**A077316**	**002**	Sep 05, 2007
AB			**12.5MG**	**A077316**	**003**	Sep 05, 2007

CARVEDILOL

TABLET;ORAL

CARVEDILOL

AB			**25MG**	**A077316**	**004**	Sep 05, 2007
AB		SANDOZ	**3.125MG**	**A078227**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078227**	**002**	Sep 05, 2007
AB			**12.5MG**	**A078227**	**003**	Sep 05, 2007
AB			**25MG**	**A078227**	**004**	Sep 05, 2007
AB		SUN PHARM INDS INC	**3.125MG**	**A077346**	**004**	Sep 05, 2007
AB			**6.25MG**	**A077346**	**001**	Sep 05, 2007
AB			**12.5MG**	**A077346**	**002**	Sep 05, 2007
AB			**25MG**	**A077346**	**003**	Sep 05, 2007
AB		SUN PHARM INDS LTD	**3.125MG**	**A076989**	**001**	Sep 05, 2007
AB			**6.25MG**	**A076989**	**002**	Sep 05, 2007
AB			**12.5MG**	**A076989**	**003**	Sep 05, 2007
AB			**25MG**	**A076989**	**004**	Sep 05, 2007
AB		TARO	**3.125MG**	**A077780**	**001**	Sep 05, 2007
AB			**6.25MG**	**A077780**	**002**	Sep 05, 2007
AB			**12.5MG**	**A077780**	**003**	Sep 05, 2007
AB			**25MG**	**A077780**	**004**	Sep 05, 2007
AB		TEVA	**3.125MG**	**A076373**	**001**	Sep 05, 2007
AB			**6.25MG**	**A076373**	**002**	Sep 05, 2007
AB			**12.5MG**	**A076373**	**003**	Sep 05, 2007
AB			**25MG**	**A076373**	**004**	Sep 05, 2007
AB		ZYDUS PHARMS USA INC	**3.125MG**	**A077614**	**004**	Sep 05, 2007
AB			**6.25MG**	**A077614**	**001**	Sep 05, 2007
AB			**12.5MG**	**A077614**	**002**	Sep 05, 2007
AB			**25MG**	**A077614**	**003**	Sep 05, 2007

COREG

AB	+	SMITHKLINE BEECHAM	**3.125MG**	**N020297**	**004**	May 29, 1997
AB	+		**6.25MG**	**N020297**	**003**	Sep 14, 1995
AB	+!		**12.5MG**	**N020297**	**002**	Sep 14, 1995
AB	+		**25MG**	**N020297**	**001**	Sep 14, 1995

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE;ORAL

CARVEDILOL PHOSPHATE

AB		IMPAX LABS INC	**10MG**	**A204717**	**001**	May 07, 2018
AB			**20MG**	**A204717**	**002**	May 07, 2018
AB			**40MG**	**A204717**	**003**	May 07, 2018
AB			**80MG**	**A204717**	**004**	May 07, 2018
AB		SUN PHARM INDUSTRIES	**10MG**	**A090132**	**001**	Oct 25, 2017
AB			**20MG**	**A090132**	**002**	Oct 25, 2017
AB			**40MG**	**A090132**	**003**	Oct 25, 2017
AB			**80MG**	**A090132**	**004**	Oct 25, 2017

COREG CR

AB	+	SMITHKLINE BEECHAM	**10MG**	**N022012**	**001**	Oct 20, 2006
AB	+		**20MG**	**N022012**	**002**	Oct 20, 2006
AB	+!		**40MG**	**N022012**	**003**	Oct 20, 2006
AB	+		**80MG**	**N022012**	**004**	Oct 20, 2006

CASPOFUNGIN ACETATE

POWDER;INTRAVENOUS

CANCIDAS

AP	+!	MERCK	**50MG/VIAL**	**N021227**	**001**	Jan 26, 2001
AP	+!		**70MG/VIAL**	**N021227**	**002**	Jan 26, 2001

CASPOFUNGIN ACETATE

AP		CIPLA	**50MG/VIAL**	**A209489**	**001**	Jul 12, 2018
AP			**70MG/VIAL**	**A209489**	**002**	Jul 12, 2018
AP		FRESENIUS KABI USA	**50MG/VIAL**	**N206110**	**001**	Dec 30, 2016
AP			**70MG/VIAL**	**N206110**	**002**	Dec 30, 2016
AP		GLAND PHARMA LTD	**50MG/VIAL**	**A207092**	**001**	Sep 29, 2017
AP			**70MG/VIAL**	**A207092**	**002**	Sep 29, 2017
AP		MYLAN LABS LTD	**50MG/VIAL**	**A207650**	**001**	Sep 29, 2017
AP			**70MG/VIAL**	**A207650**	**002**	Sep 29, 2017
AP		SANDOZ INC	**50MG/VIAL**	**A200833**	**001**	Jun 28, 2018
AP			**70MG/VIAL**	**A200833**	**002**	Jun 28, 2018
AP		XELLIA PHARMS APS	**50MG/VIAL**	**A205923**	**001**	Jul 02, 2018
AP			**70MG/VIAL**	**A205923**	**002**	Jul 02, 2018

CEFACLOR

CAPSULE;ORAL

CEFACLOR

AB		HIKMA	**EQ 250MG BASE**	**A065350**	**001**	Apr 03, 2007
AB	**!**		**EQ 500MG BASE**	**A065350**	**002**	Apr 03, 2007
AB		YUNG SHIN PHARM	**EQ 250MG BASE**	**A065146**	**001**	Jan 22, 2004
AB			**EQ 500MG BASE**	**A065146**	**002**	Jan 22, 2004

FOR SUSPENSION;ORAL

CEFACLOR

	YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065412	001	Feb 17, 2012
		EQ 187MG BASE/5ML	A065412	002	Feb 17, 2012
		EQ 250MG BASE/5ML	A065412	003	Feb 17, 2012
!		EQ 375MG BASE/5ML	A065412	004	Feb 17, 2012

TABLET, EXTENDED RELEASE;ORAL

CEFACLOR

	TEVA	EQ 375MG BASE	A065058	001	Sep 04, 2002
!		EQ 500MG BASE	A065058	002	Sep 04, 2002

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL

CEFADROXIL

AB		AUROBINDO PHARMA	**EQ 500MG BASE**	**A065352**	**001**	Jan 25, 2007
AB		HIKMA	**EQ 500MG BASE**	**A065311**	**001**	Feb 07, 2006
AB		LUPIN	**EQ 500MG BASE**	**A065392**	**001**	May 29, 2007
AB		ORCHID HLTHCARE	**EQ 500MG BASE**	**A065309**	**001**	Sep 18, 2006
AB	**!**	TEVA PHARMS	**EQ 500MG BASE**	**A065282**	**001**	Jan 20, 2006

FOR SUSPENSION;ORAL

CEFADROXIL

AB		AUROBINDO	**EQ 250MG BASE/5ML**	**A065349**	**001**	Apr 25, 2013
AB			**EQ 500MG BASE/5ML**	**A065349**	**002**	Apr 25, 2013
AB		HIKMA PHARMS	**EQ 250MG BASE/5ML**	**A091036**	**001**	Nov 28, 2012
AB			**EQ 500MG BASE/5ML**	**A091036**	**002**	Nov 28, 2012
AB		LUPIN	**EQ 250MG BASE/5ML**	**A065396**	**001**	Feb 21, 2008
AB	**!**		**EQ 500MG BASE/5ML**	**A065396**	**002**	Feb 21, 2008
AB		ORCHID HLTHCARE	**EQ 250MG BASE/5ML**	**A065307**	**002**	Oct 16, 2006
AB			**EQ 500MG BASE/5ML**	**A065307**	**003**	Oct 16, 2006

TABLET;ORAL

CEFADROXIL

AB		HIKMA	**EQ 1GM BASE**	**A065260**	**001**	Mar 30, 2006
AB		ORCHID HLTHCARE	**EQ 1GM BASE**	**A065301**	**001**	Sep 18, 2006
!		TEVA PHARMS	EQ 1GM BASE	A062774	001	Apr 08, 1987

CEFAZOLIN SODIUM

INJECTABLE;INJECTION

CEFAZOLIN SODIUM

AP		ACS DOBFAR	**EQ 500MG BASE/VIAL**	**A065303**	**001**	Oct 22, 2008
AP			**EQ 1GM BASE/VIAL**	**A065303**	**002**	Oct 22, 2008
AP			**EQ 10GM BASE/VIAL**	**A065306**	**001**	Oct 22, 2008
AP		HIKMA FARMACEUTICA	**EQ 500MG BASE/VIAL**	**A065047**	**001**	Sep 18, 2001
AP			**EQ 1GM BASE/VIAL**	**A065047**	**002**	Sep 18, 2001
AP			**EQ 10GM BASE/VIAL**	**A065143**	**001**	Oct 18, 2004
AP	**!**	HOSPIRA INC	**EQ 500MG BASE/VIAL**	**A065226**	**001**	Apr 21, 2005
AP	**!**		**EQ 1GM BASE/VIAL**	**A065226**	**002**	Apr 21, 2005
AP	**!**		**EQ 1GM BASE/VIAL**	**A065244**	**001**	Aug 12, 2005
AP			**EQ 1GM BASE/VIAL**	**A201654**	**001**	Feb 03, 2016
AP	**!**		**EQ 10GM BASE/VIAL**	**A065247**	**001**	Aug 12, 2005
AP		QILU PHARM CO LTD	**EQ 1GM BASE/VIAL**	**A203661**	**001**	Dec 28, 2015
AP			**EQ 10GM BASE/VIAL**	**A209217**	**001**	Oct 17, 2018
AP		SANDOZ	**EQ 500MG BASE/VIAL**	**A062831**	**001**	Dec 09, 1988
AP			**EQ 1GM BASE/VIAL**	**A062831**	**002**	Dec 09, 1988
AP			**EQ 1GM BASE/VIAL**	**A065345**	**001**	May 09, 2007
AP			**EQ 10GM BASE/VIAL**	**A062831**	**003**	Sep 25, 1992

ANCEF IN PLASTIC CONTAINER

!	BAXTER HLTHCARE	EQ 20MG BASE/ML	A063002	002	Mar 28, 1991

CEFAZOLIN AND DEXTROSE

+!	B BRAUN	EQ 1GM BASE/VIAL	N050779	002	Jul 27, 2000
+		EQ 2GM BASE/VIAL	N050779	003	Jan 13, 2012

CEFAZOLIN SODIUM

!	ACS DOBFAR	EQ 20GM BASE/VIAL	A065306	002	Aug 18, 2014
!	SAMSON MEDCL	EQ 100GM BASE/VIAL	A065141	001	Nov 29, 2006
!		EQ 300GM BASE/VIAL	A065141	002	Nov 29, 2006

CEFAZOLIN SODIUM

SOLUTION;INTRAVENOUS

CEFAZOLIN IN PLASTIC CONTAINER

		BAXTER HLTHCARE CORP	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131 001	Aug 07, 2015

CEFDINIR

CAPSULE;ORAL

CEFDINIR

AB		AUROBINDO PHARMA	**300MG**	**A065434**	**001**	Jan 07, 2008
AB		LUPIN	**300MG**	**A065264**	**001**	May 19, 2006
AB		ORCHID HLTHCARE	**300MG**	**A065418**	**001**	Jul 18, 2007
AB	**!**	SANDOZ	**300MG**	**A065330**	**001**	Apr 06, 2007
AB		TEVA PHARMS	**300MG**	**A065368**	**001**	May 09, 2007

FOR SUSPENSION;ORAL

CEFDINIR

AB		AUROBINDO PHARMA	**125MG/5ML**	**A065473**	**001**	Dec 14, 2007
AB			**250MG/5ML**	**A065473**	**002**	Dec 14, 2007
AB		LUPIN	**125MG/5ML**	**A065259**	**001**	May 31, 2006
AB			**250MG/5ML**	**A065259**	**002**	May 07, 2007
AB		ORCHID HLTHCARE	**125MG/5ML**	**A065429**	**001**	Jul 18, 2007
AB			**250MG/5ML**	**A065429**	**002**	Jul 18, 2007
AB		SANDOZ	**125MG/5ML**	**A065337**	**001**	Apr 06, 2007
AB	**!**		**250MG/5ML**	**A065337**	**002**	Apr 06, 2007
AB		TEVA PHARMS	**125MG/5ML**	**A065332**	**001**	May 04, 2007
AB			**250MG/5ML**	**A065332**	**002**	May 04, 2007

CEFEPIME HYDROCHLORIDE

INJECTABLE;INJECTION

CEFEPIME HYDROCHLORIDE

AP		ACS DOBFAR	**EQ 1GM BASE/VIAL**	**A065441**	**001**	Mar 20, 2008
AP			**EQ 2GM BASE/VIAL**	**A065441**	**002**	Mar 20, 2008
AP		HOSPIRA INC	**EQ 500MG BASE/VIAL**	**A065369**	**001**	Jun 18, 2007
AP			**EQ 1GM BASE/VIAL**	**A065369**	**002**	Jun 18, 2007
AP			**EQ 1GM BASE/VIAL**	**A202268**	**001**	Jul 30, 2012
AP			**EQ 2GM BASE/VIAL**	**A065369**	**003**	Jun 18, 2007
AP			**EQ 2GM BASE/VIAL**	**A202268**	**002**	Jul 30, 2012
AP		QILU PHARM CO LTD	**EQ 500MG BASE/VIAL**	**A203704**	**001**	Feb 01, 2016
AP			**EQ 1GM BASE/VIAL**	**A203704**	**002**	Feb 01, 2016
AP			**EQ 2GM BASE/VIAL**	**A203704**	**003**	Feb 01, 2016
AP		SAGENT PHARMS	**EQ 1GM BASE/VIAL**	**A091048**	**001**	Jan 04, 2017
AP			**EQ 2GM BASE/VIAL**	**A091048**	**002**	Jan 04, 2017

MAXIPIME

AP	**+!**	HOSPIRA INC	**EQ 500MG BASE/VIAL**	**N050679**	**001**	Jan 18, 1996
AP	**+!**		**EQ 1GM BASE/VIAL**	**N050679**	**002**	Jan 18, 1996
AP	**+!**		**EQ 2GM BASE/VIAL**	**N050679**	**003**	Jan 18, 1996

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

		B BRAUN	EQ 1GM BASE/VIAL	N050821 001	May 06, 2010
			EQ 2GM BASE/VIAL	N050821 002	May 06, 2010

CEFEPIME IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N050817 001	Aug 05, 2008
	+!		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N050817 002	Aug 05, 2008

POWDER;INTRAVENOUS

CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER

		SAMSON MEDCL	EQ 100GM BASE	A209408 001	Aug 21, 2018

CEFIXIME

CAPSULE;ORAL

CEFIXIME

AB		ALKEM LABS LTD	**400MG**	**A210574**	**001**	Oct 09, 2018

SUPRAX

AB	**+!**	LUPIN LTD	**400MG**	**N203195**	**001**	Jun 01, 2012

FOR SUSPENSION;ORAL

CEFIXIME

AB		AUROBINDO PHARMA LTD	**100MG/5ML**	**A204835**	**001**	Apr 14, 2015
AB			**200MG/5ML**	**A204835**	**002**	Apr 14, 2015
AB		BELCHER PHARMS LLC	**100MG/5ML**	**A206938**	**001**	Feb 06, 2017
AB			**200MG/5ML**	**A206938**	**002**	Feb 06, 2017
AB			**500MG/5ML**	**A206939**	**001**	Feb 06, 2017
AB		SANDOZ INC	**100MG/5ML**	**A206144**	**001**	Nov 17, 2017
AB			**200MG/5ML**	**A206144**	**002**	Nov 17, 2017

SUPRAX

AB	**+!**	LUPIN LTD	**500MG/5ML**	**N202091**	**001**	Feb 20, 2013

CEFIXIME						
FOR SUSPENSION;ORAL						
SUPRAX						
AB		LUPIN PHARMS	**100MG/5ML**	**A065129**	**001**	Feb 23, 2004
AB			**200MG/5ML**	**A065355**	**001**	Apr 10, 2007
TABLET;ORAL						
SUPRAX						
	!	LUPIN PHARMS	400MG	A065130	001	Feb 12, 2004
TABLET, CHEWABLE;ORAL						
SUPRAX						
		LUPIN LTD	100MG	A065380	001	Oct 25, 2010
			150MG	A065380	002	Oct 25, 2010
	!		200MG	A065380	003	Oct 25, 2010
CEFOTAXIME SODIUM						
INJECTABLE;INJECTION						
CEFOTAXIME						
AP	!	HIKMA	**EQ 500MG BASE/VIAL**	**A065072**	**001**	Nov 20, 2002
AP	!		**EQ 1GM BASE/VIAL**	**A065072**	**002**	Nov 20, 2002
AP	!		**EQ 2GM BASE/VIAL**	**A065072**	**003**	Nov 20, 2002
AP	!		**EQ 10GM BASE/VIAL**	**A065071**	**001**	Nov 20, 2002
AP		WOCKHARDT	**EQ 1GM BASE/VIAL**	**A065197**	**001**	Aug 29, 2006
CEFOTAXIME SODIUM						
AP		HOSPIRA INC	**EQ 500MG BASE/VIAL**	**A065290**	**001**	Aug 11, 2006
AP			**EQ 1GM BASE/VIAL**	**A065290**	**002**	Aug 11, 2006
AP			**EQ 1GM BASE/VIAL**	**A065293**	**001**	Aug 10, 2006
AP			**EQ 1GM BASE/VIAL**	**A203132**	**001**	Feb 19, 2016
AP			**EQ 2GM BASE/VIAL**	**A065290**	**003**	Aug 11, 2006
AP			**EQ 2GM BASE/VIAL**	**A065293**	**002**	Aug 10, 2006
AP			**EQ 2GM BASE/VIAL**	**A203132**	**002**	Feb 19, 2016
AP			**EQ 10GM BASE/VIAL**	**A065292**	**001**	Aug 10, 2006
AP		WOCKHARDT	**EQ 500MG BASE/VIAL**	**A065197**	**002**	Jun 20, 2008
AP			**EQ 2GM BASE/VIAL**	**A065197**	**003**	Jun 20, 2008
CEFOTETAN DISODIUM						
INJECTABLE;INJECTION						
CEFOTAN						
AP	+	TELIGENT	**EQ 1GM BASE/VIAL**	**N050588**	**001**	Dec 27, 1985
AP	+		**EQ 2GM BASE/VIAL**	**N050588**	**002**	Dec 27, 1985
CEFOTETAN						
AP	!	FRESENIUS KABI USA	**EQ 1GM BASE/VIAL**	**A065374**	**001**	Aug 09, 2007
AP	!		**EQ 2GM BASE/VIAL**	**A065374**	**002**	Aug 09, 2007
AP	!		**EQ 10GM BASE/VIAL**	**A065375**	**001**	Aug 09, 2007
AP		HIKMA FARMACEUTICA	**EQ 1GM BASE/VIAL**	**A091031**	**001**	Oct 26, 2011
AP			**EQ 2GM BASE/VIAL**	**A091031**	**002**	Oct 26, 2011
AP		WEST-WARD PHARM CORP	**EQ 10GM BASE/VIAL**	**A091030**	**001**	Oct 26, 2011
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER						
	+!	B BRAUN	EQ 1GM BASE/VIAL	N065430	001	Aug 09, 2007
	+!		EQ 2GM BASE/VIAL	N065430	002	Aug 09, 2007
CEFOXITIN SODIUM						
INJECTABLE;INJECTION						
CEFOXITIN						
AP	!	ACS DOBFAR	**EQ 1GM BASE/VIAL**	**A065414**	**001**	Jun 12, 2009
AP	!		**EQ 2GM BASE/VIAL**	**A065414**	**002**	Jun 12, 2009
AP	!		**EQ 10GM BASE/VIAL**	**A065415**	**001**	May 19, 2010
AP		HIKMA FARMACEUTICA	**EQ 1GM BASE/VIAL**	**A065238**	**001**	Mar 12, 2010
AP			**EQ 2GM BASE/VIAL**	**A065238**	**002**	Mar 12, 2010
AP			**EQ 10GM BASE/VIAL**	**A065239**	**001**	Mar 02, 2010
AP		HOSPIRA INC	**EQ 1GM BASE/VIAL**	**A065313**	**001**	Jan 23, 2006
AP			**EQ 2GM BASE/VIAL**	**A065313**	**002**	Jan 23, 2006
AP			**EQ 10GM BASE/VIAL**	**A065312**	**001**	Feb 13, 2006
AP		WEST-WARD PHARMS INT	**EQ 1GM BASE/VIAL**	**A065051**	**001**	Sep 11, 2000
AP			**EQ 2GM BASE/VIAL**	**A065051**	**002**	Sep 11, 2000
AP			**EQ 10GM BASE/VIAL**	**A065050**	**001**	Sep 11, 2000
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER						
AP	+!	B BRAUN	**EQ 1GM BASE/VIAL**	**N065214**	**001**	Mar 10, 2006
AP	+!		**EQ 2GM BASE/VIAL**	**N065214**	**002**	Mar 10, 2006
MEFOXIN IN PLASTIC CONTAINER						
	!	MYLAN INSTITUTIONAL	EQ 20MG BASE/ML	A063182	001	Jan 25, 1993
	!		EQ 40MG BASE/ML	A063182	002	Jan 25, 1993

CEFOXITIN SODIUM						
POWDER;INTRAVENOUS						
CEFOXITIN IN PLASTIC CONTAINER						
		SAMSON MEDCL	EQ 100GM BASE	A200938	001	Nov 16, 2015
CEFPODOXIME PROXETIL						
FOR SUSPENSION;ORAL						
CEFPODOXIME PROXETIL						
AB		AUROBINDO PHARMA LTD	**EQ 50MG BASE/5ML**	**A065409**	**001**	Jun 08, 2007
AB			**EQ 100MG BASE/5ML**	**A065409**	**002**	Jun 08, 2007
AB		SANDOZ	**EQ 50MG BASE/5ML**	**A090031**	**001**	Jan 14, 2009
AB	**!**		**EQ 100MG BASE/5ML**	**A090031**	**002**	Jan 14, 2009
TABLET;ORAL						
CEFPODOXIME PROXETIL						
AB		AUROBINDO PHARMA	**EQ 100MG BASE**	**A065370**	**001**	Jun 11, 2007
AB			**EQ 200MG BASE**	**A065370**	**002**	Jun 11, 2007
AB		ORCHID HLTHCARE	**EQ 100MG BASE**	**A065388**	**001**	Nov 14, 2007
AB			**EQ 200MG BASE**	**A065388**	**002**	Nov 14, 2007
AB		SANDOZ	**EQ 100MG BASE**	**A065462**	**001**	May 28, 2008
AB	**!**		**EQ 200MG BASE**	**A065462**	**002**	May 28, 2008
CEFPROZIL						
FOR SUSPENSION;ORAL						
CEFPROZIL						
AB		APOTEX INC	**125MG/5ML**	**A065351**	**001**	Feb 29, 2012
AB			**250MG/5ML**	**A065351**	**002**	Feb 29, 2012
AB		AUROBINDO PHARMA	**125MG/5ML**	**A065381**	**001**	Jan 30, 2007
AB			**250MG/5ML**	**A065381**	**002**	Jan 30, 2007
AB		LUPIN	**125MG/5ML**	**A065261**	**001**	Dec 19, 2005
AB	**!**		**250MG/5ML**	**A065261**	**002**	Dec 19, 2005
AB		ORCHID HLTHCARE	**125MG/5ML**	**A065284**	**002**	Dec 30, 2005
AB			**250MG/5ML**	**A065284**	**001**	Dec 30, 2005
AB		SANDOZ	**125MG/5ML**	**A065257**	**001**	Dec 08, 2005
AB			**250MG/5ML**	**A065257**	**002**	Dec 08, 2005
AB		TEVA PHARMS	**125MG/5ML**	**A065236**	**001**	Dec 08, 2005
AB			**250MG/5ML**	**A065236**	**002**	Dec 08, 2005
TABLET;ORAL						
CEFPROZIL						
AB		APOTEX INC	**250MG**	**A065327**	**001**	Mar 26, 2008
AB			**500MG**	**A065327**	**002**	Mar 26, 2008
AB		AUROBINDO PHARMA LTD	**250MG**	**A065340**	**001**	May 24, 2007
AB			**500MG**	**A065340**	**002**	May 24, 2007
AB		CASI PHARMS INC	**250MG**	**A065235**	**001**	Nov 14, 2005
AB			**500MG**	**A065235**	**002**	Nov 14, 2005
AB		LUPIN	**250MG**	**A065276**	**001**	Dec 08, 2005
AB	**!**		**500MG**	**A065276**	**002**	Dec 08, 2005
AB		ORCHID HLTHCARE	**250MG**	**A065267**	**001**	Dec 19, 2005
AB			**500MG**	**A065267**	**002**	Dec 19, 2005
AB		TEVA	**250MG**	**A065208**	**001**	Dec 06, 2005
AB			**500MG**	**A065208**	**002**	Dec 06, 2005
AB		WOCKHARDT	**250MG**	**A065428**	**001**	Jun 14, 2007
AB			**500MG**	**A065428**	**002**	Jun 14, 2007
CEFTAROLINE FOSAMIL						
POWDER;INTRAVENOUS						
TEFLARO						
	+	ALLERGAN SALES LLC	400MG/VIAL	N200327	001	Oct 29, 2010
	+!		600MG/VIAL	N200327	002	Oct 29, 2010
CEFTAZIDIME						
INJECTABLE;INJECTION						
CEFTAZIDIME						
AP		ACS DOBFAR	**1GM/VIAL**	**A062640**	**002**	Nov 20, 1985
AP			**2GM/VIAL**	**A062640**	**003**	Nov 20, 1985
AP			**6GM/VIAL**	**A062640**	**004**	Feb 03, 1992
AP		WOCKHARDT	**1GM/VIAL**	**A065196**	**001**	Oct 15, 2008
FORTAZ						
AP	**+!**	TELIGENT	**500MG/VIAL**	**N050578**	**001**	Jul 19, 1985
AP	**+!**		**1GM/VIAL**	**N050578**	**002**	Jul 19, 1985
AP	**+!**		**2GM/VIAL**	**N050578**	**003**	Jul 19, 1985
AP	**+!**		**6GM/VIAL**	**N050578**	**004**	Jul 19, 1985

CEFTAZIDIME

INJECTABLE;INJECTION

TAZICEF

AP		HOSPIRA	**500MG/VIAL**	**A062662**	**001**	Mar 06, 1986
AP			**1GM/VIAL**	**A062662**	**002**	Mar 06, 1986
AP			**1GM/VIAL**	**A064032**	**001**	Oct 31, 1993
AP			**2GM/VIAL**	**A062662**	**003**	Mar 06, 1986
AP			**2GM/VIAL**	**A064032**	**002**	Oct 31, 1993
AP			**6GM/VIAL**	**A062662**	**004**	Mar 06, 1986

CEFTAZIDIME IN DEXTROSE CONTAINER

	+	B BRAUN	EQ 1GM BASE	N050823	001	Jun 13, 2011
	+!		EQ 2GM BASE	N050823	002	Jun 13, 2011

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

POWDER;INTRAVENOUS

ZERBAXA

	+!	CUBIST PHARMS LLC	EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL	N206829	001	Dec 19, 2014

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION

CEFTRIAXONE

AP		ACS DOBFAR	**EQ 500MG BASE/VIAL**	**A065329**	**001**	Jul 24, 2008
AP			**EQ 1GM BASE/VIAL**	**A065329**	**002**	Jul 24, 2008
AP			**EQ 2GM BASE/VIAL**	**A065329**	**003**	Jul 24, 2008
AP			**EQ 10GM BASE/VIAL**	**A065328**	**001**	Jul 24, 2008
AP		HOSPIRA INC	**EQ 10GM BASE/VIAL**	**A065232**	**001**	Aug 02, 2005
AP		QILU PHARM CO LTD	**EQ 10GM BASE/VIAL**	**A209218**	**001**	Oct 17, 2018
AP	**!**	SANDOZ	**EQ 10GM BASE/VIAL**	**A065168**	**001**	May 17, 2005
AP	**!**	SANDOZ INC	**EQ 1GM BASE/VIAL**	**A065204**	**001**	May 03, 2005
AP	**!**		**EQ 2GM BASE/VIAL**	**A065204**	**002**	May 03, 2005
AP		WOCKHARDT	**EQ 1GM BASE/VIAL**	**A065180**	**001**	May 12, 2006

CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER

AP	**+!**	B BRAUN	**EQ 1GM BASE/VIAL**	**N050796**	**001**	Apr 20, 2005
AP	**+!**		**EQ 2GM BASE/VIAL**	**N050796**	**002**	Apr 20, 2005

CEFTRIAXONE SODIUM

AP		ASTRAL	**EQ 10GM BASE/VIAL**	**A091117**	**001**	Jan 20, 2017
AP		HIKMA FARMACEUTICA	**EQ 10GM BASE/VIAL**	**A090701**	**001**	Oct 04, 2017

CEFTRIAXONE

		SAMSON MEDCL	EQ 100GM BASE/VIAL	A090057	001	Apr 25, 2014

CEFTRIAXONE IN PLASTIC CONTAINER

	!	BAXTER HLTHCARE	EQ 20MG BASE/ML	A065224	001	Aug 23, 2005
	!		EQ 40MG BASE/ML	A065224	002	Aug 23, 2005

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

AP		AKORN INC	**EQ 250MG BASE/VIAL**	**A065305**	**001**	Jan 11, 2008
AP			**EQ 500MG BASE/VIAL**	**A065305**	**002**	Jan 11, 2008
AP			**EQ 1GM BASE/VIAL**	**A065305**	**003**	Jan 11, 2008
AP			**EQ 2GM BASE/VIAL**	**A065305**	**004**	Jan 11, 2008
AP		ASTRAL	**EQ 250MG BASE/VIAL**	**A091049**	**001**	Jun 11, 2018
AP			**EQ 500MG BASE/VIAL**	**A091049**	**002**	Jun 11, 2018
AP			**EQ 1GM BASE/VIAL**	**A091049**	**003**	Jun 11, 2018
AP			**EQ 2GM BASE/VIAL**	**A091049**	**004**	Jun 11, 2018
AP		HIKMA FARMACEUTICA	**EQ 250MG BASE/VIAL**	**A065342**	**001**	Jan 10, 2008
AP			**EQ 500MG BASE/VIAL**	**A065342**	**002**	Jan 10, 2008
AP			**EQ 1GM BASE/VIAL**	**A065342**	**003**	Jan 10, 2008
AP			**EQ 2GM BASE/VIAL**	**A065342**	**004**	Jan 10, 2008
AP		HOSPIRA INC	**EQ 250MG BASE/VIAL**	**A065230**	**001**	Aug 02, 2005
AP			**EQ 500MG BASE/VIAL**	**A065230**	**002**	Aug 02, 2005
AP			**EQ 1GM BASE/VIAL**	**A065230**	**003**	Aug 02, 2005
AP			**EQ 2GM BASE/VIAL**	**A065230**	**004**	Aug 02, 2005
AP		LUPIN	**EQ 250MG BASE/VIAL**	**A065125**	**001**	Sep 30, 2003
AP			**EQ 500MG BASE/VIAL**	**A065125**	**002**	Sep 30, 2003
AP			**EQ 1GM BASE/VIAL**	**A065125**	**003**	Sep 30, 2003
AP			**EQ 2GM BASE/VIAL**	**A065125**	**004**	Sep 30, 2003
AP		QILU PHARM CO LTD	**EQ 250MG BASE/VIAL**	**A203702**	**001**	Jun 29, 2016
AP			**EQ 500MG BASE/VIAL**	**A203702**	**002**	Jun 29, 2016
AP			**EQ 1GM BASE/VIAL**	**A203702**	**003**	Jun 29, 2016
AP			**EQ 2GM BASE/VIAL**	**A203702**	**004**	Jun 29, 2016
AP	**!**	SANDOZ	**EQ 250MG BASE/VIAL**	**A065169**	**001**	May 09, 2005
AP	**!**		**EQ 500MG BASE/VIAL**	**A065169**	**002**	May 09, 2005
AP	**!**		**EQ 1GM BASE/VIAL**	**A065169**	**003**	May 09, 2005
AP	**!**		**EQ 2GM BASE/VIAL**	**A065169**	**004**	May 09, 2005
AP		WOCKHARDT	**EQ 250MG BASE/VIAL**	**A065391**	**001**	Apr 12, 2007

CEFTRIAXONE SODIUM

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

AP			**EQ 500MG BASE/VIAL**	**A065391**	**002**	Apr 12, 2007
AP			**EQ 2GM BASE/VIAL**	**A065391**	**003**	Apr 12, 2007

CEFUROXIME AXETIL

TABLET;ORAL

CEFUROXIME AXETIL

AB		ALKEM LABS LTD	**EQ 250MG BASE**	**A065496**	**001**	Jun 07, 2010
AB			**EQ 500MG BASE**	**A065496**	**002**	Jun 07, 2010
AB		ANI PHARMS INC	**EQ 250MG BASE**	**A065190**	**001**	Oct 18, 2004
AB			**EQ 500MG BASE**	**A065190**	**002**	Oct 18, 2004
AB		APOTEX	**EQ 250MG BASE**	**A065069**	**001**	Oct 02, 2002
AB			**EQ 500MG BASE**	**A065069**	**002**	Oct 02, 2002
AB		AUROBINDO PHARMA LTD	**EQ 125MG BASE**	**A065308**	**001**	Mar 29, 2006
AB			**EQ 250MG BASE**	**A065308**	**002**	Mar 29, 2006
AB			**EQ 500MG BASE**	**A065308**	**003**	Mar 29, 2006
AB		LUPIN	**EQ 250MG BASE**	**A065135**	**001**	Jul 25, 2003
AB	**!**		**EQ 500MG BASE**	**A065135**	**002**	Jul 25, 2003
AB		ORCHID HLTHCARE	**EQ 125MG BASE**	**A065359**	**001**	Feb 15, 2008
AB			**EQ 250MG BASE**	**A065359**	**002**	Feb 15, 2008
AB			**EQ 500MG BASE**	**A065359**	**003**	Feb 15, 2008
AB		WOCKHARDT	**EQ 125MG BASE**	**A065166**	**001**	Jul 29, 2005
AB			**EQ 250MG BASE**	**A065166**	**002**	Jul 29, 2005
AB			**EQ 500MG BASE**	**A065166**	**003**	Jul 29, 2005

CEFUROXIME SODIUM

INJECTABLE;INJECTION

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

AP	**+!**	B BRAUN	**EQ 750MG BASE/VIAL**	**N050780**	**001**	Feb 21, 2001
AP	**+!**		**EQ 1.5GM BASE/VIAL**	**N050780**	**002**	Feb 21, 2001

CEFUROXIME SODIUM

AP		ACS DOBFAR SPA	**EQ 1.5GM BASE/VIAL**	**A064125**	**002**	May 30, 1997
AP			**EQ 7.5GM BASE/VIAL**	**A064124**	**001**	May 30, 1997
AP		HIKMA FARMACEUTICA	**EQ 1.5GM BASE/VIAL**	**A065048**	**002**	Jan 09, 2004
AP			**EQ 7.5GM BASE/VIAL**	**A065046**	**001**	Jan 09, 2004
AP		HOSPIRA INC	**EQ 1.5GM BASE/VIAL**	**A065483**	**002**	Oct 15, 2008
AP			**EQ 1.5GM BASE/VIAL**	**A065503**	**001**	Oct 15, 2008
AP			**EQ 7.5GM BASE/VIAL**	**A065484**	**001**	Oct 15, 2008

ZINACEF

AP	**+!**	TELIGENT	**EQ 1.5GM BASE/VIAL**	**N050558**	**003**	Oct 19, 1983
AP	**+!**		**EQ 7.5GM BASE/VIAL**	**N050558**	**004**	Oct 23, 1986

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

AB		ACS DOBFAR SPA	**EQ 750MG BASE/VIAL**	**A064125**	**001**	May 30, 1997
AB		HIKMA FARMACEUTICA	**EQ 750MG BASE/VIAL**	**A065048**	**001**	Jan 09, 2004

ZINACEF

AB	**+!**	TELIGENT	**EQ 750MG BASE/VIAL**	**N050558**	**002**	Oct 19, 1983

CEFUROXIME SODIUM

AP		HOSPIRA INC	**EQ 750MG BASE/VIAL**	**A065483**	**001**	Oct 15, 2008

CELECOXIB

CAPSULE;ORAL

CELEBREX

AB	**+**	GD SEARLE	**50MG**	**N020998**	**004**	Dec 15, 2006
AB	**+**		**100MG**	**N020998**	**001**	Dec 31, 1998
AB	**+**		**200MG**	**N020998**	**002**	Dec 31, 1998
AB	**+!**		**400MG**	**N020998**	**003**	Aug 29, 2002

CELECOXIB

AB		ALEMBIC PHARMS LTD	**50MG**	**A204519**	**001**	Aug 21, 2015
AB			**100MG**	**A204519**	**002**	Aug 21, 2015
AB			**200MG**	**A204519**	**003**	Aug 21, 2015
AB			**400MG**	**A204519**	**004**	Aug 21, 2015
AB		AMNEAL PHARMS	**50MG**	**A208833**	**001**	May 31, 2018
AB			**100MG**	**A208833**	**002**	May 31, 2018
AB			**200MG**	**A208833**	**003**	May 31, 2018
AB			**400MG**	**A208833**	**004**	May 31, 2018
AB		APOTEX INC	**50MG**	**A204197**	**001**	Jun 02, 2015
AB			**100MG**	**A204197**	**002**	Jun 02, 2015
AB			**200MG**	**A204197**	**003**	Jun 02, 2015
AB		AUROBINDO PHARMA LTD	**50MG**	**A206827**	**001**	Feb 01, 2016

CELECOXIB

CAPSULE;ORAL

CELECOXIB

AB		**100MG**	**A206827**	**002**	Feb 01, 2016
AB		**200MG**	**A206827**	**003**	Feb 01, 2016
AB		**400MG**	**A206827**	**004**	Feb 01, 2016
AB	CIPLA	**50MG**	**A207446**	**001**	Sep 23, 2015
AB		**100MG**	**A207446**	**002**	Sep 23, 2015
AB		**200MG**	**A207446**	**003**	Sep 23, 2015
AB		**400MG**	**A207446**	**004**	Sep 23, 2015
AB	CSPC OUYI PHARM CO	**50MG**	**A210071**	**001**	Jan 23, 2018
AB		**100MG**	**A210071**	**002**	Jan 23, 2018
AB		**200MG**	**A210071**	**003**	Jan 23, 2018
AB	JUBILANT GENERICS	**50MG**	**A207061**	**001**	Apr 04, 2017
AB		**100MG**	**A207061**	**002**	Apr 04, 2017
AB		**200MG**	**A207061**	**003**	Apr 04, 2017
AB		**400MG**	**A207061**	**004**	Apr 04, 2017
AB	LUPIN LTD	**50MG**	**A202240**	**001**	Oct 29, 2014
AB		**100MG**	**A202240**	**002**	Jun 09, 2015
AB		**200MG**	**A202240**	**003**	Jun 09, 2015
AB		**400MG**	**A202240**	**004**	Jun 09, 2015
AB	MACLEODS PHARMS LTD	**50MG**	**A204590**	**001**	Mar 16, 2016
AB		**100MG**	**A204590**	**002**	Mar 16, 2016
AB		**200MG**	**A204590**	**003**	Mar 16, 2016
AB		**400MG**	**A204590**	**004**	Mar 16, 2016
AB	MICRO LABS	**50MG**	**A204776**	**001**	Apr 30, 2018
AB		**100MG**	**A204776**	**002**	Apr 30, 2018
AB		**200MG**	**A204776**	**003**	Apr 30, 2018
AB		**400MG**	**A204776**	**004**	Apr 30, 2018
AB	MYLAN PHARMS INC	**50MG**	**A078857**	**001**	May 30, 2014
AB		**100MG**	**A078857**	**002**	Feb 11, 2015
AB		**200MG**	**A078857**	**003**	Feb 11, 2015
AB		**400MG**	**A078857**	**004**	Feb 11, 2015
AB	TEVA	**50MG**	**A076898**	**001**	May 30, 2014
AB		**100MG**	**A076898**	**002**	May 30, 2014
AB		**200MG**	**A076898**	**003**	May 30, 2014
AB		**400MG**	**A076898**	**004**	May 30, 2014
AB	TORRENT PHARMS LTD	**50MG**	**A207677**	**001**	Dec 23, 2015
AB		**100MG**	**A207677**	**002**	Dec 23, 2015
AB		**200MG**	**A207677**	**003**	Dec 23, 2015
AB		**400MG**	**A207677**	**004**	Dec 23, 2015
AB	WATSON LABS INC	**50MG**	**A200562**	**001**	Feb 11, 2015
AB		**100MG**	**A200562**	**002**	Feb 11, 2015
AB		**200MG**	**A200562**	**003**	Feb 11, 2015
AB		**400MG**	**A200562**	**004**	Feb 11, 2015

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

AB	ALKEM LABS LTD	**EQ 250MG BASE**	**A090836**	**001**	Dec 20, 2010
AB		**EQ 500MG BASE**	**A090836**	**002**	Dec 20, 2010
AB		**EQ 750MG BASE**	**A090836**	**004**	Mar 29, 2013
AB	AUROBINDO PHARMA LTD	**EQ 250MG BASE**	**A065253**	**001**	Nov 16, 2005
AB		**EQ 500MG BASE**	**A065253**	**002**	Nov 16, 2005
AB	BELCHER PHARMS	**EQ 250MG BASE**	**A062713**	**001**	Jul 15, 1988
AB		**EQ 500MG BASE**	**A062713**	**002**	Jul 15, 1988
AB	HIKMA	**EQ 250MG BASE**	**A065215**	**001**	Jan 24, 2006
AB		**EQ 500MG BASE**	**A065215**	**002**	Jan 24, 2006
AB	LUPIN	**EQ 250MG BASE**	**A065229**	**001**	Nov 25, 2005
AB		**EQ 500MG BASE**	**A065229**	**002**	Nov 25, 2005
AB	ORCHID HLTHCARE	**EQ 250MG BASE**	**A065248**	**001**	Jun 28, 2005
AB		**EQ 500MG BASE**	**A065248**	**002**	Jun 28, 2005
AB	SUN PHARM INDS (IN)	**EQ 250MG BASE**	**A062791**	**001**	Jun 11, 1987
AB		**EQ 500MG BASE**	**A062791**	**002**	Jun 11, 1987
AB	TEVA	**EQ 250MG BASE**	**A062702**	**001**	Feb 13, 1987
AB		**EQ 500MG BASE**	**A062702**	**002**	Feb 13, 1987
AB	YUNG SHIN PHARM	**EQ 250MG BASE**	**A065152**	**001**	Feb 24, 2005
AB		**EQ 500MG BASE**	**A065152**	**002**	Feb 24, 2005

KEFLEX

AB	+ PRAGMA	**EQ 250MG BASE**	**N050405**	**002**	
AB	+	**EQ 500MG BASE**	**N050405**	**003**	
AB	+!	**EQ 750MG BASE**	**N050405**	**005**	May 12, 2006

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

		ALKEM LABS LTD	EQ 333MG BASE	A090836	003	Mar 29, 2013

FOR SUSPENSION;ORAL

CEPHALEXIN

AB		LUPIN	**EQ 125MG BASE/5ML**	**A065234**	**001**	Aug 17, 2005
AB			**EQ 250MG BASE/5ML**	**A065234**	**002**	Aug 17, 2005
AB		ORCHID HLTHCARE	**EQ 125MG BASE/5ML**	**A065326**	**001**	Jul 10, 2006
AB			**EQ 250MG BASE/5ML**	**A065326**	**002**	Jul 10, 2006
AB		TEVA	**EQ 125MG BASE/5ML**	**A062703**	**001**	Feb 13, 1987
AB	**!**		**EQ 250MG BASE/5ML**	**A062703**	**002**	Feb 13, 1987
AB		YUNG SHIN PHARM	**EQ 125MG BASE/5ML**	**A065336**	**001**	Jul 25, 2007
AB			**EQ 250MG BASE/5ML**	**A065336**	**002**	Jul 25, 2007

TABLET;ORAL

CEPHALEXIN

		TEVA	EQ 250MG BASE	A063023	001	Jan 12, 1989
	!		EQ 500MG BASE	A063024	001	Jan 12, 1989

CERITINIB

CAPSULE;ORAL

ZYKADIA

	+!	NOVARTIS PHARMS CORP	150MG	N205755	001	Apr 29, 2014

CETIRIZINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

ZERVIATE

	+!	EYEVANCE PHARMS	EQ 0.24% BASE	N208694	001	May 30, 2017

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

AA		AMNEAL PHARMS	**5MG/5ML**	**A090766**	**001**	Oct 07, 2009
AA		ANDA REPOSITORY	**5MG/5ML**	**A090191**	**001**	Nov 12, 2009
AA		BIO PHARM INC	**5MG/5ML**	**A078870**	**001**	Apr 27, 2009
AA		BRECKENRIDGE PHARM	**5MG/5ML**	**A078488**	**001**	Oct 06, 2008
AA		LANNETT CO INC	**5MG/5ML**	**A078496**	**001**	Sep 25, 2009
AA			**5MG/5ML**	**A078876**	**001**	May 11, 2012
AA	**!**	PERRIGO R AND D	**5MG/5ML**	**A078398**	**001**	Jun 17, 2008
AA		TARO	**5MG/5ML**	**A076601**	**001**	Jun 20, 2008
AA		TEVA PHARMS	**5MG/5ML**	**A077279**	**001**	May 27, 2008

CETRORELIX

INJECTABLE;INJECTION

CETROTIDE

	+!	EMD SERONO INC	EQ 0.25MG BASE/ML	N021197	001	Aug 11, 2000

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE HYDROCHLORIDE

AB		NOVEL LABS INC	**30MG**	**A204746**	**001**	Dec 30, 2016
AB		RISING PHARMS	**30MG**	**A203775**	**001**	Jun 04, 2014
AB		WEST-WARD PHARMS INT	**30MG**	**A091591**	**001**	Jul 08, 2013

EVOXAC

AB	**+!**	DAIICHI SANKYO INC	**30MG**	**N020989**	**002**	Jan 11, 2000

CHENODIOL

TABLET;ORAL

CHENODIOL

	!	NEXGEN PHARMA	250MG	A091019	001	Oct 22, 2009

CHLORAMBUCIL

TABLET;ORAL

LEUKERAN

	+!	ASPEN GLOBAL INC	2MG	N010669	002	

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE;INJECTION

CHLORAMPHENICOL SODIUM SUCCINATE

	!	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A062365	001	Aug 25, 1982

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

AB		BARR	**5MG**	**A084768**	**001**	
AB			**10MG**	**A083116**	**001**	
AB			**25MG**	**A084769**	**001**	

LIBRIUM

AB		VALEANT PHARM INTL	**5MG**	**A085461**	**001**	
AB			**10MG**	**A085472**	**001**	
AB	!		**25MG**	**A085475**	**001**	

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL

LIBRAX

	+!	VALEANT PHARMS	5MG;2.5MG	N012750	001	

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

CHLORHEXIDINE GLUCONATE

AT		HI TECH PHARMA	**0.12%**	**A074356**	**001**	May 07, 1996
AT		LYNE	**0.12%**	**A074291**	**001**	Dec 28, 1995
AT		TEVA	**0.12%**	**A074522**	**001**	Dec 15, 1995
AT		WOCKHARDT BIO AG	**0.12%**	**A075006**	**001**	Mar 03, 2004
AT		XTTRIUM	**0.12%**	**A077789**	**001**	Jun 18, 2009

PAROEX

AT		SUNSTAR AMERICAS	**0.12%**	**A076434**	**001**	Nov 29, 2005

PERIDEX

AT	**+!**	3M	**0.12%**	**N019028**	**001**	Aug 13, 1986

PERIOGARD

AT		COLGATE PALMOLIVE CO	**0.12%**	**A073695**	**001**	Jan 14, 1994
AT		COLGATE-PALMOLIVE CO	**0.12%**	**A203212**	**001**	Jan 28, 2016

TABLET;DENTAL

PERIOCHIP

	+!	DEXCEL PHARMA	2.5MG	N020774	001	May 15, 1998

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

CHLOROPROCAINE HYDROCHLORIDE

AP		HOSPIRA	**2%**	**A087447**	**001**	Apr 16, 1982
AP			**3%**	**A087446**	**001**	Apr 16, 1982
AP		WEST-WARD PHARMS INT	**2%**	**A040273**	**001**	Sep 09, 1998
AP			**3%**	**A040273**	**002**	Sep 09, 1998

NESACAINE

AP	**+**	FRESENIUS KABI USA	**2%**	**N009435**	**002**	

NESACAINE-MPF

AP	**+!**	FRESENIUS KABI USA	**2%**	**N009435**	**006**	May 02, 1996
AP	**+!**		**3%**	**N009435**	**007**	May 02, 1996

NESACAINE

	+!	FRESENIUS KABI USA	1%	N009435	001	

SOLUTION;INTRATHECAL

CLOROTEKAL

	+	B BRAUN MEDICAL INC	50MG/5ML (10MG/ML)	N208791	001	Sep 26, 2017

CHLOROQUINE PHOSPHATE

TABLET;ORAL

CHLOROQUINE PHOSPHATE

AA	!	HIKMA PHARMS	**EQ 150MG BASE**	**A083082**	**001**	
AA			**EQ 300MG BASE**	**A083082**	**002**	Sep 17, 1999
AA		IPCA LABS LTD	**EQ 150MG BASE**	**A090610**	**001**	Dec 03, 2009
AA			**EQ 300MG BASE**	**A090249**	**001**	Dec 03, 2009
AA		NATCO PHARMA LTD	**EQ 150MG BASE**	**A091621**	**001**	Jan 21, 2011
AA	!		**EQ 300MG BASE**	**A090612**	**001**	Jan 21, 2011

CHLOROTHIAZIDE

SUSPENSION;ORAL

DIURIL

	+!	SALIX PHARMS	250MG/5ML	N011870	001	

TABLET;ORAL

CHLOROTHIAZIDE

	!	MYLAN	250MG	A084217	002	
			500MG	A084217	001	

CHLOROTHIAZIDE SODIUM

INJECTABLE;INJECTION

CHLOROTHIAZIDE SODIUM

AP		FRESENIUS KABI USA	**EQ 500MG BASE/VIAL**	**A090896**	**001**	Oct 16, 2009
AP		LUITPOLD	**EQ 500MG BASE/VIAL**	**A202561**	**001**	Apr 22, 2013
AP		MYLAN INSTITUTIONAL	**EQ 500MG BASE/VIAL**	**A202493**	**001**	Jun 18, 2014
AP		SAGENT PHARMS	**EQ 500MG BASE/VIAL**	**A202462**	**001**	May 29, 2015
AP		SUN PHARMA GLOBAL	**EQ 500MG BASE/VIAL**	**A091546**	**001**	Jul 26, 2011

DIURIL

AP	**+!**	OAK PHARMS AKORN	**EQ 500MG BASE/VIAL**	**N011145**	**005**	

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

TABLET, EXTENDED RELEASE;ORAL

TUXARIN ER

	MAINPOINTE	8MG;54.3MG	N206323	001	Jun 22, 2015

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

AA		ACELLA PHARMS LLC	**4MG/5ML;5MG/5ML**	**A206891**	**001**	Jun 09, 2017

VITUZ

AA	**+!**	CYPRESS PHARM	**4MG/5ML;5MG/5ML**	**N204307**	**001**	Feb 20, 2013

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA		MAYNE PHARMA INC	**4MG/5ML;5MG/5ML;60MG/5ML**	**A205657**	**001**	Aug 03, 2015
AA		PADDOCK LLC	**4MG/5ML;5MG/5ML;60MG/5ML**	**A204627**	**001**	Apr 29, 2014

ZUTRIPRO

AA	**+!**	CYPRESS PHARM	**4MG/5ML;5MG/5ML;60MG/5ML**	**N022439**	**001**	Jun 08, 2011

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

TUZISTRA XR

+!	AYTU	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE;ORAL

TUSSICAPS

	ECR PHARMA	EQ 4MG MALEATE;EQ 5MG BITARTRATE	A077273	002	Sep 24, 2007
!		EQ 8MG MALEATE;EQ 10MG BITARTRATE	A077273	001	Sep 24, 2007

SUSPENSION, EXTENDED RELEASE;ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX

AB		TRIS PHARMA INC	**EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML**	**A091632**	**001**	Oct 01, 2010

HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX

AB	**!**	NEOS THERAP INC	**EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML**	**A091671**	**001**	Jun 29, 2012

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

CHLORPROMAZINE HYDROCHLORIDE

!	WEST-WARD PHARMS INT	25MG/ML	A083329	001	

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB		AMNEAL PHARMS CO	**10MG**	**A209755**	**001**	Sep 10, 2018
AB			**25MG**	**A209755**	**002**	Sep 10, 2018
AB			**50MG**	**A209755**	**003**	Sep 10, 2018
AB			**100MG**	**A209755**	**004**	Sep 10, 2018
AB			**200MG**	**A209755**	**005**	Sep 10, 2018
AB		USL PHARMA	**10MG**	**A083386**	**001**	
AB	**!**		**25MG**	**A084112**	**001**	
AB			**50MG**	**A084113**	**001**	
AB	**!**		**100MG**	**A084114**	**001**	
AB			**200MG**	**A084115**	**001**	

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

	MYLAN	100MG	A088549	002	Jun 01, 1984
!		250MG	A088549	001	Jun 01, 1984

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

AB		APPCO PHARMA LLC	**25MG**	**A210742**	**001**	Oct 12, 2018
AB			**50MG**	**A210742**	**002**	Oct 12, 2018
AB		MYLAN	**25MG**	**A086831**	**002**	
AB	**!**		**50MG**	**A086831**	**001**	
AB		RICONPHARMA LLC	**25MG**	**A206904**	**001**	Mar 30, 2017
AB			**50MG**	**A206904**	**002**	Mar 30, 2017
AB		SUN PHARM INDUSTRIES	**25MG**	**A089286**	**002**	Jul 21, 1986
AB			**50MG**	**A089286**	**001**	Jul 21, 1986
AB		UMEDICA LABS PVT LTD	**25MG**	**A207222**	**001**	May 24, 2018
AB			**50MG**	**A207222**	**002**	May 24, 2018

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

	!	MIKART	250MG	A207483	001 Jun 24, 2016
			375MG	A040861	001 Jun 01, 2010
	!		750MG	A040861	002 Jun 01, 2010
	!	WATSON LABS	500MG	A089859	001 May 04, 1988

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE

AB		ANI PHARMS INC	**EQ 4GM RESIN/PACKET**	**A074554**	**001**	Oct 02, 1996
AB			**EQ 4GM RESIN/SCOOPFUL**	**A074554**	**002**	Oct 02, 1996
AB		PAR PHARM	**EQ 4GM RESIN/PACKET**	**A077204**	**001**	Aug 26, 2005
AB			**EQ 4GM RESIN/SCOOPFUL**	**A077204**	**002**	Aug 26, 2005
AB	**!**	SANDOZ	**EQ 4GM RESIN/PACKET**	**A074557**	**001**	Aug 15, 1996
AB			**EQ 4GM RESIN/SCOOPFUL**	**A074557**	**002**	Aug 15, 1996
AB		ZYDUS PHARMS USA INC	**EQ 4GM RESIN/SCOOPFUL**	**A202901**	**001**	Jul 02, 2018

CHOLESTYRAMINE LIGHT

AB		PAR PHARM	**EQ 4GM RESIN/PACKET**	**A077203**	**001**	Aug 26, 2005
AB			**EQ 4GM RESIN/SCOOPFUL**	**A077203**	**002**	Aug 26, 2005
AB	**!**	SANDOZ	**EQ 4GM RESIN/PACKET**	**A074558**	**001**	Aug 15, 1996
AB			**EQ 4GM RESIN/SCOOPFUL**	**A074558**	**002**	Aug 15, 1996
AB		ZYDUS PHARMS USA INC	**EQ 4GM RESIN/SCOOPFUL**	**A202902**	**001**	Apr 25, 2017

PREVALITE

AB		UPSHER SMITH LABS	**EQ 4GM RESIN/PACKET**	**A073263**	**001**	Feb 22, 1996
AB			**EQ 4GM RESIN/SCOOPFUL**	**A073263**	**002**	Oct 30, 1997

CHOLIC ACID

CAPSULE;ORAL

CHOLBAM

	+	RTRX	50MG	N205750	001 Mar 17, 2015
	+!		250MG	N205750	002 Mar 17, 2015

CHOLINE C-11

INJECTABLE;INTRAVENOUS

CHOLINE C-11

AP		GLOBAL ISOTOPES LLC	**4-33.1mCi/ML**	**A206319**	**001**	Nov 13, 2015
AP	**+!**	MCPRF	**4-33.1mCi/ML**	**N203155**	**001**	Sep 12, 2012
AP		UCSF RODIOPHARM	**4-33.1mCi/ML**	**A208444**	**001**	Nov 20, 2017
AP		WA UNIV SCH MED	**4-33.1mCi/ML**	**A208413**	**001**	Jan 10, 2017
		UNIV TX MD ANDERSON	4-100mCi/ML	A205690	001	Oct 29, 2015

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL

FENOFIBRIC ACID

AB		ACTAVIS ELIZABETH	**EQ 45MG FENOFIBRIC ACID**	**A200920**	**001**	Oct 07, 2015
AB			**EQ 135MG FENOFIBRIC ACID**	**A200920**	**002**	Oct 07, 2015
AB		ALEMBIC PHARMS LTD	**EQ 45MG FENOFIBRIC ACID**	**A208705**	**001**	May 12, 2017
AB			**EQ 135MG FENOFIBRIC ACID**	**A208705**	**002**	May 12, 2017
AB		ANCHEN PHARMS	**EQ 45MG FENOFIBRIC ACID**	**A201573**	**002**	Jul 18, 2013
AB			**EQ 135MG FENOFIBRIC ACID**	**A201573**	**001**	Jul 18, 2013
AB		IMPAX LABS INC	**EQ 45MG FENOFIBRIC ACID**	**A200264**	**001**	Sep 07, 2016
AB			**EQ 135MG FENOFIBRIC ACID**	**A200264**	**002**	Sep 07, 2016
AB		LUPIN LTD	**EQ 45MG FENOFIBRIC ACID**	**A200750**	**001**	Dec 04, 2013
AB			**EQ 135MG FENOFIBRIC ACID**	**A200750**	**002**	Dec 04, 2013
AB		MYLAN PHARMS INC	**EQ 45MG FENOFIBRIC ACID**	**A200913**	**001**	Mar 25, 2013
AB			**EQ 135MG FENOFIBRIC ACID**	**A200913**	**002**	Mar 25, 2013

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL

TRILIPIX

AB	**+**	ABBVIE	**EQ 45MG FENOFIBRIC ACID**	**N022224**	**001**	Dec 15, 2008
AB	**+!**		**EQ 135MG FENOFIBRIC ACID**	**N022224**	**002**	Dec 15, 2008

CHORIOGONADOTROPIN ALFA

INJECTABLE;SUBCUTANEOUS

OVIDREL

	+!	EMD SERONO	EQ 0.25MG /0.5ML	N021149	002	Oct 06, 2003

CHROMIC CHLORIDE

INJECTABLE;INJECTION

CHROMIC CHLORIDE IN PLASTIC CONTAINER

	+!	HOSPIRA	EQ 0.004MG CHROMIUM/ML	N018961	001	Jun 26, 1986

CICLESONIDE

AEROSOL, METERED;INHALATION

ALVESCO

	+!	ASTRAZENECA PHARMS	0.08MG/INH	N021658	002	Jan 10, 2008
	+!		0.16MG/INH	N021658	003	Jan 10, 2008

AEROSOL, METERED;NASAL

ZETONNA

	+!	ASTRAZENECA PHARMS	0.037MG/INH	N202129	001	Jan 20, 2012

SPRAY, METERED;NASAL

OMNARIS

	+!	ASTRAZENECA PHARMS	0.05MG/INH	N022004	001	Oct 20, 2006

CICLOPIROX

CREAM;TOPICAL

CICLOPIROX

AB		FOUGERA PHARMS	**0.77%**	**A076435**	**001**	Dec 29, 2004
AB		G AND W LABS INC	**0.77%**	**A078463**	**001**	Dec 20, 2010
AB		GLENMARK PHARMS	**0.77%**	**A090273**	**001**	Nov 10, 2009
AB		PERRIGO NEW YORK	**0.77%**	**A077364**	**001**	Mar 03, 2006
AB		TARO	**0.77%**	**A076790**	**001**	Apr 12, 2005

LOPROX

AB	**+!**	MEDIMETRIKS PHARMS	**0.77%**	**N018748**	**001**	Dec 30, 1982

GEL;TOPICAL

CICLOPIROX

AB	**+!**	CNTY LINE PHARMS	**0.77%**	**N020519**	**001**	Jul 21, 1997
AB		FOUGERA PHARMS	**0.77%**	**A077896**	**001**	Jun 10, 2008
AB		GLENMARK GENERICS	**0.77%**	**A091595**	**001**	Feb 29, 2012
AB		PADDOCK LLC	**0.77%**	**A078266**	**001**	Jan 07, 2009

SHAMPOO;TOPICAL

CICLOPIROX

AT		ACTAVIS MID ATLANTIC	**1%**	**A090490**	**001**	Nov 24, 2009
AT		FOUGERA PHARMS	**1%**	**A090146**	**001**	May 25, 2010
AT		PERRIGO CO	**1%**	**A078594**	**001**	Feb 16, 2010
AT		TARO	**1%**	**A090269**	**001**	Feb 23, 2011
AT		TELIGENT PHARMA INC	**1%**	**A209975**	**001**	Apr 05, 2018

LOPROX

AT	**+!**	MEDICIS	**1%**	**N021159**	**001**	Feb 28, 2003

SOLUTION;TOPICAL

CICLOPIROX

AT		ACTAVIS MID ATLANTIC	**8%**	**A078046**	**001**	Sep 18, 2007
AT		AKORN	**8%**	**A078975**	**001**	Feb 17, 2010
AT		APOTEX INC	**8%**	**A078172**	**001**	Sep 18, 2007
AT		G AND W LABS	**8%**	**A078233**	**001**	Sep 18, 2007
AT		HI TECH PHARMA	**8%**	**A078270**	**001**	Sep 18, 2007
AT		INGENUS PHARMS LLC	**8%**	**A078124**	**001**	Sep 18, 2007
AT		PERRIGO NEW YORK	**8%**	**A077623**	**001**	Sep 18, 2007
AT		TARO PHARM INDS	**8%**	**A078144**	**001**	Sep 18, 2007
AT		TOLMAR	**8%**	**A077687**	**001**	Sep 18, 2007

PENLAC

AT	**+!**	VALEANT BERMUDA	**8%**	**N021022**	**001**	Dec 17, 1999

SUSPENSION;TOPICAL

CICLOPIROX

AB		FOUGERA PHARMS	**0.77%**	**A076422**	**001**	Aug 06, 2004
AB		PERRIGO NEW YORK	**0.77%**	**A077676**	**001**	Dec 15, 2006
AB		TARO	**0.77%**	**A077092**	**001**	Aug 10, 2005

CICLOPIROX

SUSPENSION;TOPICAL

LOPROX

AB	**+!**	MEDIMETRIKS PHARMS	**0.77%**	**N019824**	**001**	Dec 30, 1988

CIDOFOVIR

INJECTABLE;INJECTION

CIDOFOVIR

AP		EMCURE PHARMS LTD	**EQ 75MG BASE/ML**	**A202501**	**001**	Jul 26, 2012
AP	**!**	MYLAN INSTITUTIONAL	**EQ 75MG BASE/ML**	**A201276**	**001**	Jun 27, 2012

CILASTATIN SODIUM; IMIPENEM

POWDER;INTRAVENOUS

IMIPENEM AND CILASTATIN

AP		ACS DOBFAR	**EQ 500MG BASE/VIAL;500MG/VIAL**	**A090577**	**002**	Dec 21, 2011
AP		HOSPIRA INC	**EQ 500MG BASE/VIAL;500MG/VIAL**	**A090825**	**002**	Nov 16, 2011
AP			**EQ 500MG BASE/VIAL;500MG/VIAL**	**A091007**	**001**	Nov 16, 2011

PRIMAXIN

AP	**+!**	MERCK	**EQ 500MG BASE/VIAL;500MG/VIAL**	**N050587**	**002**	Nov 26, 1985

IMIPENEM AND CILASTATIN

	!	ACS DOBFAR	EQ 250MG BASE/VIAL;250MG/VIAL	A090577	001	Dec 21, 2011

CILOSTAZOL

TABLET;ORAL

CILOSTAZOL

AB		APOTEX INC	**50MG**	**A077030**	**001**	Dec 10, 2004
AB			**100MG**	**A077030**	**002**	Dec 10, 2004
AB		BRECKENRIDGE PHARM	**50MG**	**A077708**	**001**	Sep 28, 2009
AB			**100MG**	**A077708**	**002**	Sep 28, 2009
AB		CASI PHARMS INC	**50MG**	**A077310**	**001**	Nov 08, 2005
AB			**100MG**	**A077021**	**001**	Nov 23, 2004
AB		CHARTWELL RX	**50MG**	**A077722**	**001**	Sep 24, 2012
AB			**100MG**	**A077831**	**001**	Sep 24, 2012
AB		FRONTIDA BIOPHARM	**50MG**	**A077208**	**002**	Mar 29, 2006
AB			**100MG**	**A077208**	**001**	Mar 29, 2006
AB	**!**	TEVA	**50MG**	**A077027**	**001**	Nov 24, 2004
AB	**!**		**100MG**	**A077027**	**002**	Nov 24, 2004
AB		WEST-WARD PHARMS INT	**50MG**	**A077024**	**001**	May 17, 2005
AB			**100MG**	**A077024**	**002**	May 17, 2005

CIMETIDINE

TABLET;ORAL

CIMETIDINE

AB		APOTEX	**200MG**	**A074890**	**001**	Dec 18, 1998
AB			**300MG**	**A074890**	**002**	Dec 18, 1998
AB			**400MG**	**A074890**	**003**	Dec 18, 1998
AB			**800MG**	**A074890**	**004**	Dec 18, 1998
AB		MYLAN	**200MG**	**A074246**	**001**	May 17, 1994
AB			**300MG**	**A074246**	**002**	May 17, 1994
AB			**400MG**	**A074246**	**003**	May 17, 1994
AB	**!**		**800MG**	**A074246**	**004**	May 17, 1994
AB		PLIVA	**800MG**	**A074566**	**001**	Feb 27, 1997
AB		TEVA	**200MG**	**A074151**	**001**	May 17, 1994
AB			**300MG**	**A074151**	**002**	May 17, 1994
AB			**400MG**	**A074151**	**003**	May 17, 1994
AB			**800MG**	**A074463**	**001**	May 17, 1994

CIMETIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CIMETIDINE HYDROCHLORIDE

		DAVA PHARMS INC	EQ 300MG BASE/2ML	A074428	001	Apr 25, 1996

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

AA		ANI PHARMS INC	**EQ 300MG BASE/5ML**	**A074610**	**001**	Sep 26, 1996
AA	**!**	HI TECH PHARMA	**EQ 300MG BASE/5ML**	**A074664**	**001**	Oct 28, 1997
AA		PHARM ASSOC	**EQ 300MG BASE/5ML**	**A074553**	**001**	Jan 27, 1997
AA		WOCKHARDT BIO AG	**EQ 300MG BASE/5ML**	**A074757**	**001**	Oct 17, 1997

CINACALCET HYDROCHLORIDE

TABLET;ORAL

CINACALCET HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**EQ 30MG BASE**	**A206125**	**001**	Mar 08, 2018
AB			**EQ 60MG BASE**	**A206125**	**002**	Mar 08, 2018
AB			**EQ 90MG BASE**	**A206125**	**003**	Mar 08, 2018

CINACALCET HYDROCHLORIDE

TABLET;ORAL

CINACALCET HYDROCHLORIDE

AB		CIPLA	**EQ 30MG BASE**	**A208915**	**001**	Mar 08, 2018
AB			**EQ 60MG BASE**	**A208915**	**002**	Mar 08, 2018
AB			**EQ 90MG BASE**	**A208915**	**003**	Mar 08, 2018
AB		MYLAN PHARMS INC	**EQ 30MG BASE**	**A203422**	**001**	Oct 16, 2018
AB			**EQ 60MG BASE**	**A203422**	**002**	Oct 16, 2018
AB			**EQ 90MG BASE**	**A203422**	**003**	Oct 16, 2018
AB		PIRAMAL HLTHCARE UK	**EQ 30MG BASE**	**A210207**	**001**	Aug 01, 2018
AB			**EQ 60MG BASE**	**A210207**	**002**	Aug 01, 2018
AB			**EQ 90MG BASE**	**A210207**	**003**	Aug 01, 2018
AB		STRIDES PHARMA	**EQ 30MG BASE**	**A209226**	**001**	Apr 30, 2018
AB			**EQ 60MG BASE**	**A209226**	**002**	Apr 30, 2018
AB			**EQ 90MG BASE**	**A209226**	**003**	Apr 30, 2018
AB		SUN PHARMA GLOBAL	**EQ 30MG BASE**	**A207008**	**001**	Oct 11, 2018
AB			**EQ 60MG BASE**	**A207008**	**002**	Oct 11, 2018
AB			**EQ 90MG BASE**	**A207008**	**003**	Oct 11, 2018
AB		WATSON LABS TEVA	**EQ 30MG BASE**	**A204377**	**001**	Dec 27, 2018
AB			**EQ 60MG BASE**	**A204377**	**002**	Dec 27, 2018
AB			**EQ 90MG BASE**	**A204377**	**003**	Dec 27, 2018

SENSIPAR

AB	**+**	AMGEN	**EQ 30MG BASE**	**N021688**	**001**	Mar 08, 2004
AB	**+**		**EQ 60MG BASE**	**N021688**	**002**	Mar 08, 2004
AB	**+!**		**EQ 90MG BASE**	**N021688**	**003**	Mar 08, 2004

CIPROFLOXACIN

FOR SUSPENSION;ORAL

CIPRO

AB	**+**	BAYER HLTHCARE	**250MG/5ML**	**N020780**	**001**	Sep 26, 1997
AB	**+!**		**500MG/5ML**	**N020780**	**002**	Sep 26, 1997

CIPROFLOXACIN

AB		LUPIN LTD	**250MG/5ML**	**A200563**	**001**	Mar 05, 2014
AB			**500MG/5ML**	**A200563**	**002**	Mar 05, 2014

INJECTABLE;INJECTION

CIPROFLOXACIN

AP	**!**	BAXTER HLTHCARE CORP	**200MG/20ML (10MG/ML)**	**A078062**	**001**	Apr 29, 2008
AP	**!**		**400MG/40ML (10MG/ML)**	**A078062**	**002**	Apr 29, 2008
AP		HIKMA FARMACEUTICA	**200MG/20ML (10MG/ML)**	**A076717**	**001**	Dec 22, 2009
AP			**400MG/40ML (10MG/ML)**	**A076717**	**002**	Dec 22, 2009
AP		HOSPIRA	**200MG/20ML (10MG/ML)**	**A077245**	**001**	Aug 28, 2006
AP			**400MG/40ML (10MG/ML)**	**A077245**	**002**	Aug 28, 2006

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE CORP	**200MG/100ML**	**A078024**	**001**	Mar 18, 2008
AP			**400MG/200ML**	**A078024**	**002**	Mar 18, 2008
AP		HIKMA FARMACEUTICA	**400MG/200ML**	**A078431**	**001**	Nov 18, 2009
AP	**!**	HOSPIRA	**200MG/100ML**	**A077753**	**001**	Mar 18, 2008
AP	**!**		**400MG/200ML**	**A077753**	**002**	Mar 18, 2008
AP		INFORLIFE	**200MG/100ML**	**A078252**	**001**	Mar 18, 2008
AP			**400MG/200ML**	**A078252**	**002**	Mar 18, 2008

INJECTABLE, SUSPENSION;OTIC

OTIPRIO

	+!	OTONOMY INC	6% (60MG/ML)	N207986	001	Dec 10, 2015

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT;OPHTHALMIC

CILOXAN

	+!	NOVARTIS PHARMS CORP	EQ 0.3% BASE	N020369	001	Mar 30, 1998

SOLUTION/DROPS;OPHTHALMIC

CILOXAN

AT	**+!**	NOVARTIS PHARMS CORP	**EQ 0.3% BASE**	**N019992**	**001**	Dec 31, 1990

CIPROFLOXACIN HYDROCHLORIDE

AT		AKORN INC	**EQ 0.3% BASE**	**A076555**	**001**	Dec 11, 2008
AT		ALTAIRE PHARMS INC	**EQ 0.3% BASE**	**A204613**	**001**	May 03, 2018
AT		FDC LTD	**EQ 0.3% BASE**	**A077568**	**001**	Jun 30, 2008
AT		RISING PHARMS	**EQ 0.3% BASE**	**A077689**	**001**	Dec 13, 2006
AT		TELIGENT	**EQ 0.3% BASE**	**A076754**	**001**	Jun 09, 2004
AT		WATSON LABS INC	**EQ 0.3% BASE**	**A076673**	**001**	Jan 21, 2005

CIPROFLOXACIN HYDROCHLORIDE							
SOLUTION/DROPS;OTIC							
CETRAXAL							
	+!	WRASER PHARMS	EQ 0.2% BASE		N021918	001	May 01, 2009
TABLET;ORAL							
CIPRO							
AB	**+**	BAYER HLTHCARE	**EQ 250MG BASE**		**N019537**	**002**	Oct 22, 1987
AB	**+!**		**EQ 500MG BASE**		**N019537**	**003**	Oct 22, 1987
CIPROFLOXACIN HYDROCHLORIDE							
AB		APOTEX	**EQ 250MG BASE**		**A076896**	**001**	Nov 04, 2004
AB			**EQ 500MG BASE**		**A076896**	**002**	Nov 04, 2004
AB			**EQ 750MG BASE**		**A076896**	**003**	Nov 04, 2004
AB		AUROBINDO PHARMA	**EQ 250MG BASE**		**A077859**	**001**	Apr 26, 2007
AB			**EQ 500MG BASE**		**A077859**	**002**	Apr 26, 2007
AB			**EQ 750MG BASE**		**A077859**	**003**	Apr 26, 2007
AB		CARLSBAD	**EQ 250MG BASE**		**A076126**	**002**	Jun 09, 2004
AB			**EQ 500MG BASE**		**A076126**	**003**	Jun 09, 2004
AB			**EQ 750MG BASE**		**A076126**	**004**	Jun 09, 2004
AB		DR REDDYS LABS LTD	**EQ 100MG BASE**		**A075593**	**002**	Jun 09, 2004
AB			**EQ 250MG BASE**		**A075593**	**003**	Jun 09, 2004
AB			**EQ 500MG BASE**		**A075593**	**004**	Jun 09, 2004
AB			**EQ 750MG BASE**		**A075593**	**001**	Jun 09, 2004
AB		HIKMA	**EQ 250MG BASE**		**A076558**	**002**	Jun 09, 2004
AB			**EQ 500MG BASE**		**A076558**	**003**	Jun 09, 2004
AB			**EQ 750MG BASE**		**A076558**	**004**	Jun 09, 2004
AB		IVAX SUB TEVA PHARMS	**EQ 250MG BASE**		**A076089**	**002**	Jun 09, 2004
AB			**EQ 500MG BASE**		**A076089**	**003**	Jun 09, 2004
AB			**EQ 750MG BASE**		**A076089**	**004**	Jun 09, 2004
AB		MYLAN	**EQ 500MG BASE**		**A075817**	**003**	Jun 09, 2004
AB		TARO PHARM	**EQ 100MG BASE**		**A076912**	**001**	Feb 18, 2005
AB			**EQ 250MG BASE**		**A076912**	**002**	Oct 06, 2004
AB			**EQ 500MG BASE**		**A076912**	**003**	Oct 06, 2004
AB			**EQ 750MG BASE**		**A076912**	**004**	Oct 06, 2004
AB		UNIQUE PHARM LABS	**EQ 250MG BASE**		**A076639**	**001**	Sep 10, 2004
AB			**EQ 500MG BASE**		**A076639**	**002**	Sep 10, 2004
AB			**EQ 750MG BASE**		**A076639**	**003**	Sep 10, 2004
AB		WATSON LABS	**EQ 100MG BASE**		**A076794**	**001**	Feb 10, 2005
AB			**EQ 250MG BASE**		**A076794**	**002**	Jun 09, 2004
AB			**EQ 500MG BASE**		**A076794**	**003**	Jun 09, 2004
AB			**EQ 750MG BASE**		**A076794**	**004**	Jun 09, 2004
AB		YILING PHARM LTD	**EQ 250MG BASE**		**A208921**	**001**	Jun 22, 2018
AB			**EQ 500MG BASE**		**A208921**	**002**	Jun 22, 2018
CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE							
SOLUTION/DROPS;OTIC							
OTOVEL							
	+!	LABORATORIOS SALVAT	EQ 0.3% BASE;0.025%		N208251	001	Apr 29, 2016
CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE							
SUSPENSION/DROPS;OTIC							
CIPRO HC							
	+!	NOVARTIS PHARMS CORP	EQ 0.2% BASE;1%		N020805	001	Feb 10, 1998
CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE							
TABLET, EXTENDED RELEASE;ORAL							
CIPROFLOXACIN EXTENDED RELEASE							
AB		ANCHEN PHARMS	**212.6MG;EQ 287.5MG BASE**		**A078166**	**002**	Nov 27, 2007
AB			**425.2MG;EQ 574.9MG BASE**		**A078166**	**001**	Nov 27, 2007
AB		DR REDDYS LABS LTD	**425.2MG;EQ 574.9MG BASE**		**A077701**	**001**	Mar 26, 2007
AB	**!**	MYLAN PHARMS INC	**212.6MG;EQ 287.5MG BASE**		**A078183**	**001**	Mar 22, 2007
AB	**!**		**425.2MG;EQ 574.9MG BASE**		**A078183**	**002**	Mar 22, 2007
CIPROFLOXACIN; DEXAMETHASONE							
SUSPENSION/DROPS;OTIC							
CIPRODEX							
	+!	NOVARTIS PHARMS CORP	0.3%;0.1%		N021537	001	Jul 18, 2003

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE						
AP		ACCORD HLTHCARE	**EQ 2MG BASE/ML**	**A205873**	**001**	Jun 16, 2017
AP		FRESENIUS KABI USA	**EQ 2MG BASE/ML**	**A203183**	**001**	Feb 26, 2015
AP		JIANGSU HENGRUI MED	**EQ 2MG BASE/ML**	**A209334**	**001**	Aug 30, 2017
AP		SANDOZ INC	**EQ 2MG BASE/ML**	**A200159**	**001**	Feb 03, 2012
CISATRACURIUM BESYLATE PRESERVATIVE FREE						
AP		ACCORD HLTHCARE	**EQ 2MG BASE/ML**	**A205872**	**001**	Jun 16, 2017
AP			**EQ 10MG BASE/ML**	**A205872**	**002**	Jun 16, 2017
AP		FRESENIUS KABI USA	**EQ 2MG BASE/ML**	**A203182**	**001**	Feb 26, 2015
AP			**EQ 10MG BASE/ML**	**A203182**	**002**	Feb 26, 2015
AP		JIANGSU HENGRUI MED	**EQ 2MG BASE/ML**	**A204960**	**001**	Jan 27, 2017
AP			**EQ 10MG BASE/ML**	**A204960**	**002**	Sep 19, 2017
AP		SANDOZ INC	**EQ 2MG BASE/ML**	**A200154**	**001**	Feb 03, 2012
AP			**EQ 10MG BASE/ML**	**A200154**	**002**	Feb 03, 2012
NIMBEX						
AP	**+!**	ABBVIE	**EQ 2MG BASE/ML**	**N020551**	**001**	Dec 15, 1995
NIMBEX PRESERVATIVE FREE						
AP	**+!**	ABBVIE	**EQ 2MG BASE/ML**	**N020551**	**003**	Dec 15, 1995
	+!		EQ 10MG BASE/ML	N020551	002	Dec 15, 1995

CISPLATIN

INJECTABLE;INJECTION

CISPLATIN						
AP		ACCORD HLTHCARE	**1MG/ML**	**A206774**	**001**	Aug 18, 2015
AP	**!**	FRESENIUS KABI USA	**1MG/ML**	**A074735**	**001**	Jul 16, 1999
AP		GLAND PHARMA LTD	**1MG/ML**	**A207323**	**001**	Mar 17, 2017
AP	**+**	HQ SPCLT PHARMA	**1MG/ML**	**N018057**	**004**	Nov 08, 1988
AP		MYLAN LABS LTD	**1MG/ML**	**A091062**	**001**	Apr 18, 2012
AP		PHARMACHEMIE BV	**1MG/ML**	**A074656**	**001**	May 16, 2000
AP		WEST-WARD PHARMS INT	**1MG/ML**	**A075036**	**001**	Nov 07, 2000

CITALOPRAM HYDROBROMIDE

SOLUTION;ORAL

CITALOPRAM HYDROBROMIDE						
AA		AUROBINDO PHARMA LTD	**EQ 10MG BASE/5ML**	**A077812**	**001**	Aug 28, 2006
AA		HETERO LABS LTD III	**EQ 10MG BASE/5ML**	**A201450**	**001**	Dec 15, 2015
AA		LANNETT CO INC	**EQ 10MG BASE/5ML**	**A077629**	**001**	Jun 15, 2006
AA	**!**	WEST-WARD PHARMS INT	**EQ 10MG BASE/5ML**	**A077043**	**001**	Dec 13, 2004

TABLET;ORAL

CELEXA						
AB	**+**	ALLERGAN SALES LLC	**EQ 10MG BASE**	**N020822**	**001**	Apr 27, 2000
AB	**+**		**EQ 20MG BASE**	**N020822**	**002**	Jul 17, 1998
AB	**+!**		**EQ 40MG BASE**	**N020822**	**003**	Jul 17, 1998
CITALOPRAM HYDROBROMIDE						
AB		AMNEAL PHARMS NY	**EQ 10MG BASE**	**A077289**	**001**	Nov 30, 2006
AB			**EQ 20MG BASE**	**A077289**	**002**	Nov 30, 2006
AB			**EQ 40MG BASE**	**A077289**	**003**	Nov 30, 2006
AB		APOTEX INC	**EQ 10MG BASE**	**A077046**	**001**	Nov 24, 2004
AB		AUROBINDO	**EQ 10MG BASE**	**A077031**	**001**	Oct 28, 2004
AB			**EQ 20MG BASE**	**A077031**	**002**	Oct 28, 2004
AB			**EQ 40MG BASE**	**A077031**	**003**	Oct 28, 2004
AB		CHARTWELL MOLECULAR	**EQ 10MG BASE**	**A077044**	**001**	Nov 05, 2004
AB			**EQ 20MG BASE**	**A077044**	**002**	Nov 05, 2004
AB			**EQ 40MG BASE**	**A077044**	**003**	Nov 05, 2004
AB		DR REDDYS LABS LTD	**EQ 10MG BASE**	**A077038**	**001**	Oct 28, 2004
AB			**EQ 20MG BASE**	**A077038**	**002**	Oct 28, 2004
AB			**EQ 40MG BASE**	**A077038**	**003**	Oct 28, 2004
AB		EPIC PHARMA	**EQ 10MG BASE**	**A077045**	**003**	Apr 29, 2005
AB			**EQ 20MG BASE**	**A077045**	**002**	Apr 29, 2005
AB			**EQ 40MG BASE**	**A077045**	**001**	Apr 29, 2005
AB		G AND W LABS INC	**EQ 10MG BASE**	**A077048**	**001**	Nov 16, 2004
AB			**EQ 20MG BASE**	**A077048**	**002**	Nov 16, 2004
AB			**EQ 40MG BASE**	**A077048**	**003**	Nov 16, 2004
AB		GLENMARK GENERICS	**EQ 10MG BASE**	**A077654**	**001**	Feb 27, 2009
AB			**EQ 20MG BASE**	**A077654**	**002**	Feb 27, 2009
AB			**EQ 40MG BASE**	**A077654**	**003**	Feb 27, 2009
AB		INVAGEN PHARMS	**EQ 10MG BASE**	**A077534**	**001**	Oct 03, 2006
AB			**EQ 20MG BASE**	**A077534**	**002**	Oct 03, 2006
AB			**EQ 40MG BASE**	**A077534**	**003**	Oct 03, 2006

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

AB		JUBILANT GENERICS	**EQ 10MG BASE**	**A205407**	**001**	Dec 23, 2015
AB			**EQ 20MG BASE**	**A205407**	**002**	Dec 23, 2015
AB			**EQ 40MG BASE**	**A205407**	**003**	Dec 23, 2015
AB		MYLAN	**EQ 10MG BASE**	**A077042**	**001**	Nov 05, 2004
AB			**EQ 20MG BASE**	**A077042**	**002**	Nov 05, 2004
AB			**EQ 40MG BASE**	**A077042**	**003**	Nov 05, 2004
AB		PLIVA	**EQ 10MG BASE**	**A077232**	**001**	Oct 31, 2005
AB			**EQ 20MG BASE**	**A077232**	**002**	Oct 31, 2005
AB			**EQ 40MG BASE**	**A077232**	**003**	Oct 31, 2005
AB		SUN PHARM INDS INC	**EQ 10MG BASE**	**A077032**	**001**	Nov 12, 2004
AB			**EQ 20MG BASE**	**A077032**	**002**	Nov 12, 2004
AB			**EQ 40MG BASE**	**A077032**	**003**	Nov 12, 2004
AB		TORPHARM	**EQ 20MG BASE**	**A077046**	**002**	Nov 24, 2004
AB			**EQ 40MG BASE**	**A077046**	**003**	Nov 24, 2004
AB		TORRENT PHARMS	**EQ 10MG BASE**	**A078216**	**001**	Mar 27, 2007
AB			**EQ 20MG BASE**	**A078216**	**002**	Mar 27, 2007
AB			**EQ 40MG BASE**	**A078216**	**003**	Mar 27, 2007

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION;IRRIGATION

RENACIDIN

+!	UNITED GUARDIAN	6.602GM/100ML;198MG/100ML;3.177GM/100ML	N019481	001	Oct 02, 1990

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION;ORAL

PREPOPIK

+!	FERRING PHARMS INC	12GM/PACKET;3.5GM/PACKET;10MG/PACKET	N202535	001	Jul 16, 2012

SOLUTION;ORAL

CLENPIQ

+!	FERRING PHARMS INC	12GM/BOT;3.5GM/BOT;10MG/BOT	N209589	001	Nov 28, 2017

CITRIC ACID; UREA C-13

FOR SOLUTION, TABLET, FOR SOLUTION;ORAL

IDKIT:HP

+!	EXALENZ BIOSCIENCE	N/A,4GM;75MG,N/A	N021314	001	Dec 17, 2002

CLADRIBINE

INJECTABLE;INJECTION

CLADRIBINE

AP	**!**	FRESENIUS KABI USA	**1MG/ML**	**A076571**	**001**	Apr 22, 2004
AP		MYLAN LABS LTD	**1MG/ML**	**A200510**	**001**	Oct 06, 2011
AP		WEST-WARD PHARMS INT	**1MG/ML**	**A075405**	**001**	Feb 28, 2000

CLARITHROMYCIN

FOR SUSPENSION;ORAL

CLARITHROMYCIN

AB		SANDOZ	**125MG/5ML**	**A065283**	**002**	Sep 04, 2007
AB	**!**		**250MG/5ML**	**A065283**	**003**	Sep 04, 2007

TABLET;ORAL

CLARITHROMYCIN

AB		ALLIED PHARMA INC	**250MG**	**A202710**	**001**	Jun 10, 2013
AB			**500MG**	**A202710**	**002**	Jun 10, 2013
AB		APOTEX CORP	**250MG**	**A065384**	**001**	Aug 20, 2007
AB			**500MG**	**A065384**	**002**	Aug 20, 2007
AB	**!**	AUROBINDO	**250MG**	**A065489**	**001**	Jul 25, 2012
AB	**!**		**500MG**	**A065489**	**002**	Jul 25, 2012
AB		HEC PHARM	**250MG**	**A203584**	**001**	Sep 28, 2015
AB			**500MG**	**A203584**	**002**	Sep 28, 2015
AB		SANDOZ	**250MG**	**A065144**	**001**	Oct 18, 2005
AB			**500MG**	**A065136**	**001**	Aug 25, 2005
AB		TEVA	**250MG**	**A065155**	**001**	May 31, 2005
AB			**500MG**	**A065155**	**002**	May 31, 2005
AB		WEST-WARD PHARMS INT	**250MG**	**A065178**	**002**	May 25, 2004
AB			**500MG**	**A065178**	**001**	May 25, 2004
AB		WOCKHARDT	**250MG**	**A065266**	**001**	May 31, 2006
AB			**500MG**	**A065266**	**002**	May 31, 2006

TABLET, EXTENDED RELEASE;ORAL

CLARITHROMYCIN

AB		ACTAVIS LABS FL INC	**500MG**	**A065145**	**001**	Jun 24, 2004
AB		ALLIED	**500MG**	**A203243**	**001**	Feb 29, 2016

CLARITHROMYCIN							
TABLET, EXTENDED RELEASE;ORAL							
CLARITHROMYCIN							
AB		LUPIN LTD	**500MG**	**A202532**	**001**	Sep 15, 2015
AB	!	MAYNE PHARMA	**500MG**	**A065154**	**001**	May 18, 2005
AB		SUNSHINE LAKE	**500MG**	**A208987**	**001**	Jul 09, 2018
CLEMASTINE FUMARATE							
SYRUP;ORAL							
CLEMASTINE FUMARATE							
	!	TEVA	EQ 0.5MG BASE/5ML	A073399	001	Jun 30, 1994
TABLET;ORAL							
CLEMASTINE FUMARATE							
	!	TEVA	2.68MG	A073283	001	Jan 31, 1992
CLEVIDIPINE							
EMULSION;INTRAVENOUS							
CLEVIPREX							
	+!	CHIESI USA INC	25MG/50ML (0.5MG/ML)	N022156	001	Aug 01, 2008
	+!		50MG/100ML (0.5MG/ML)	N022156	002	Aug 01, 2008
CLINDAMYCIN HYDROCHLORIDE							
CAPSULE;ORAL							
CLEOCIN HYDROCHLORIDE							
AB	+	PHARMACIA AND UPJOHN	**EQ 75MG BASE**	**N050162**	**001**	
AB	+		**EQ 150MG BASE**	**N050162**	**002**	
AB	+!		**EQ 300MG BASE**	**N050162**	**003**	Apr 14, 1988
CLINDAMYCIN HYDROCHLORIDE							
AB		AUROBINDO PHARMA	**EQ 150MG BASE**	**A065442**	**001**	Aug 26, 2009
AB			**EQ 300MG BASE**	**A065442**	**002**	Aug 26, 2009
AB		EPIC PHARMA LLC	**EQ 150MG BASE**	**A065194**	**001**	Mar 22, 2004
AB			**EQ 300MG BASE**	**A065194**	**002**	Mar 22, 2004
AB		G AND W LABS INC	**EQ 150MG BASE**	**A063029**	**001**	Sep 20, 1989
AB			**EQ 300MG BASE**	**A063029**	**002**	Aug 05, 2005
AB		LANNETT CO INC	**EQ 75MG BASE**	**A065243**	**002**	Aug 12, 2005
AB			**EQ 150MG BASE**	**A065243**	**003**	Aug 12, 2005
AB			**EQ 300MG BASE**	**A065243**	**001**	Aug 12, 2005
AB		MICRO LABS	**EQ 75MG BASE**	**A207402**	**001**	Nov 05, 2018
AB			**EQ 150MG BASE**	**A207402**	**002**	Nov 05, 2018
AB			**EQ 300MG BASE**	**A207402**	**003**	Nov 05, 2018
AB		SUN PHARM INDS LTD	**EQ 150MG BASE**	**A065061**	**001**	Feb 02, 2001
AB			**EQ 300MG BASE**	**A065061**	**002**	Feb 02, 2001
AB		WATSON LABS	**EQ 150MG BASE**	**A063083**	**001**	Jul 31, 1991
AB			**EQ 300MG BASE**	**A063083**	**002**	Mar 18, 2003
AB		ZYDUS PHARMS USA	**EQ 75MG BASE**	**A065217**	**001**	Jan 31, 2005
AB			**EQ 150MG BASE**	**A065217**	**002**	Jan 31, 2005
AB			**EQ 300MG BASE**	**A065217**	**003**	Jan 31, 2005
CLINDAMYCIN PALMITATE HYDROCHLORIDE							
FOR SOLUTION;ORAL							
CLEOCIN							
AA	!	PHARMACIA AND UPJOHN	**EQ 75MG BASE/5ML**	**A062644**	**001**	Apr 07, 1986
CLINDAMYCIN PALMITATE HYDROCHLORIDE							
AA		AMNEAL PHARMS	**EQ 75MG BASE/5ML**	**A203513**	**001**	Mar 13, 2014
AA		AUROBINDO PHARMA LTD	**EQ 75MG BASE/5ML**	**A202409**	**001**	Apr 30, 2013
AA		HERITAGE PHARMS INC	**EQ 75MG BASE/5ML**	**A207047**	**001**	May 11, 2018
AA		LYNE	**EQ 75MG BASE/5ML**	**A201821**	**001**	Aug 28, 2012
AA		MYLAN PHARMS INC	**EQ 75MG BASE/5ML**	**A203063**	**001**	May 25, 2016
AA		ORIT LABS LLC	**EQ 75MG BASE/5ML**	**A206958**	**001**	May 05, 2017
AA		PADDOCK LLC	**EQ 75MG BASE/5ML**	**A090902**	**001**	Jul 07, 2010
CLINDAMYCIN PHOSPHATE							
AEROSOL, FOAM;TOPICAL							
CLINDAMYCIN PHOSPHATE							
AT		PERRIGO UK FINCO	**1%**	**A090785**	**001**	Mar 31, 2010
EVOCLIN							
AT	+!	MYLAN PHARMS INC	**1%**	**N050801**	**001**	Oct 22, 2004
CREAM;VAGINAL							
CLEOCIN							
AB	+!	PHARMACIA AND UPJOHN	**EQ 2% BASE**	**N050680**	**002**	Mar 02, 1998

CLINDAMYCIN PHOSPHATE						
CREAM;VAGINAL						
CLINDAMYCIN PHOSPHATE						
AB		FOUGERA PHARMS	**EQ 2% BASE**	**A065139**	**001**	Dec 27, 2004
CLINDESSE						
	+!	PERRIGO PHARMA INTL	EQ 2% BASE	N050793	001	Nov 30, 2004
GEL;TOPICAL						
CLEOCIN T						
AB	**+!**	PHARMACIA AND UPJOHN	**EQ 1% BASE**	**N050615**	**001**	Jan 07, 1987
CLINDAMYCIN PHOSPHATE						
AB		FOUGERA PHARMS	**EQ 1% BASE**	**A064160**	**001**	Jan 28, 2000
CLINDAGEL						
BT	+!	PRECISION DERMAT	EQ 1% BASE	N050782	001	Nov 27, 2000
INJECTABLE;INJECTION						
CLEOCIN PHOSPHATE						
AP		PHARMACIA AND UPJOHN	**EQ 150MG BASE/ML**	**A062803**	**001**	Oct 16, 1987
AP	**+!**		**EQ 150MG BASE/ML**	**N050441**	**001**	
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	**+!**	PHARMACIA AND UPJOHN	**EQ 6MG BASE/ML**	**N050639**	**001**	Aug 30, 1989
AP	**+!**		**EQ 12MG BASE/ML**	**N050639**	**002**	Aug 30, 1989
AP	**+!**		**EQ 18MG BASE/ML**	**N050639**	**003**	Apr 10, 1991
CLINDAMYCIN PHOSPHATE						
AP		ALVOGEN INC	**EQ 150MG BASE/ML**	**A062800**	**001**	Jul 24, 1987
AP			**EQ 150MG BASE/ML**	**A062801**	**001**	Jul 24, 1987
AP			**EQ 150MG BASE/ML**	**A062943**	**001**	Sep 29, 1988
AP		FRESENIUS KABI USA	**EQ 150MG BASE/ML**	**A065346**	**001**	Mar 29, 2007
AP			**EQ 150MG BASE/ML**	**A065347**	**001**	May 09, 2007
AP		MYLAN LABS LTD	**EQ 150MG BASE/ML**	**A204748**	**001**	Oct 10, 2017
AP			**EQ 150MG BASE/ML**	**A204749**	**001**	Oct 10, 2017
AP		SAGENT PHARMS	**EQ 150MG BASE/ML**	**A090108**	**001**	Sep 30, 2011
AP			**EQ 150MG BASE/ML**	**A090109**	**001**	Sep 30, 2011
AP		WEST-WARD PHARMS INT	**EQ 150MG BASE/ML**	**A062889**	**001**	Apr 25, 1988
AP			**EQ 150MG BASE/ML**	**A065206**	**001**	Sep 24, 2004
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER						
AP		AKORN INC	**EQ 6MG BASE/ML**	**A203048**	**001**	Apr 04, 2013
AP			**EQ 12MG BASE/ML**	**A203048**	**002**	Apr 04, 2013
AP			**EQ 18MG BASE/ML**	**A203048**	**003**	Apr 04, 2013
AP		BAXTER HLTHCARE CORP	**EQ 6MG BASE/ML**	**A208084**	**001**	Jun 28, 2017
AP			**EQ 12MG BASE/ML**	**A208084**	**002**	Jun 28, 2017
AP			**EQ 18MG BASE/ML**	**A208084**	**003**	Jun 28, 2017
AP		SANDOZ INC	**EQ 6MG BASE/ML**	**A201692**	**001**	May 31, 2012
AP			**EQ 12MG BASE/ML**	**A201692**	**002**	May 31, 2012
AP			**EQ 18MG BASE/ML**	**A201692**	**003**	May 31, 2012
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%						
	+!	ABRAXIS PHARM	EQ 900MG BASE/100ML	N050635	001	Dec 22, 1989
LOTION;TOPICAL						
CLEOCIN T						
AB	**+!**	PHARMACIA AND UPJOHN	**EQ 1% BASE**	**N050600**	**001**	May 31, 1989
CLINDAMYCIN PHOSPHATE						
AB		FOUGERA PHARMS	**EQ 1% BASE**	**A065067**	**001**	Jan 31, 2002
SOLUTION;INTRAVENOUS						
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE						
	+!	BAXTER HLTHCARE CORP	EQ 300MG BASE/50ML (EQ 6MG BASE/ML)	N208083	001	Apr 20, 2017
	+!		EQ 600MG BASE/50ML (EQ 12MG BASE/ML)	N208083	002	Apr 20, 2017
	+!		EQ 900MG BASE/50ML (EQ 18MG BASE/ML)	N208083	003	Apr 20, 2017
SOLUTION;TOPICAL						
CLEOCIN T						
AT	**+!**	PHARMACIA AND UPJOHN	**EQ 1% BASE**	**N050537**	**001**	
CLINDA-DERM						
AT		PADDOCK LLC	**EQ 1% BASE**	**A063329**	**001**	Sep 30, 1992
CLINDAMYCIN PHOSPHATE						
AT		FOUGERA PHARMS	**EQ 1% BASE**	**A065254**	**001**	Feb 14, 2006
AT		FOUGERA PHARMS INC	**EQ 1% BASE**	**A064159**	**001**	Jun 05, 1997
AT		G AND W LABS INC	**EQ 1% BASE**	**A062811**	**001**	Sep 01, 1988
AT		GLASSHOUSE PHARMS	**EQ 1% BASE**	**A209846**	**001**	Feb 08, 2018
AT		PERRIGO NEW YORK	**EQ 1% BASE**	**A064050**	**001**	Nov 30, 1995

CLINDAMYCIN PHOSPHATE						
SOLUTION;TOPICAL						
CLINDAMYCIN PHOSPHATE						
AT		TARO PHARM INDS	**EQ 1% BASE**	**A065184**	**001**	Mar 31, 2004
AT		TELIGENT PHARMA INC	**EQ 1% BASE**	**A206945**	**001**	Dec 30, 2016
AT		VINTAGE PHARMS	**EQ 1% BASE**	**A203343**	**001**	May 29, 2015
AT		ZYDUS PHARMS USA INC	**EQ 1% BASE**	**A208767**	**001**	Jul 16, 2018
SUPPOSITORY;VAGINAL						
CLEOCIN						
	+!	PHARMACIA AND UPJOHN	100MG	N050767	001	Aug 13, 1999
SWAB;TOPICAL						
CLEOCIN						
AT	**+**	PHARMACIA AND UPJOHN	**EQ 1% BASE**	**N050537**	**002**	Feb 22, 1994
CLINDAMYCIN PHOSPHATE						
AT		AKORN	**EQ 1% BASE**	**A065513**	**001**	Jun 17, 2010
AT		PERRIGO NEW YORK	**EQ 1% BASE**	**A065049**	**001**	May 25, 2000
CLINDETS						
AT		PERRIGO CO	**EQ 1% BASE**	**A064136**	**001**	Sep 30, 1996
CLINDAMYCIN PHOSPHATE; TRETINOIN						
GEL;TOPICAL						
CLINDAMYCIN PHOSPHATE AND TRETINOIN						
AB		ACTAVIS MID ATLANTIC	**1.2%;0.025%**	**A202564**	**001**	Jun 12, 2015
ZIANA						
AB	**+!**	MEDICIS	**1.2%;0.025%**	**N050802**	**001**	Nov 07, 2006
VELTIN						
BX	+!	AQUA PHARMS LLC	1.2%;0.025%	N050803	001	Jul 16, 2010
CLOBAZAM						
FILM;ORAL						
SYMPAZAN						
	+	AQUESTIVE THERAP	5MG	N210833	001	Nov 01, 2018
	+		10MG	N210833	002	Nov 01, 2018
	+!		20MG	N210833	003	Nov 01, 2018
SUSPENSION;ORAL						
CLOBAZAM						
AB		AMNEAL PHARMS LLC	**2.5MG/ML**	**A210039**	**001**	Oct 22, 2018
AB		BIONPHARMA INC	**2.5MG/ML**	**A208819**	**001**	Oct 22, 2018
AB		LUPIN LTD	**2.5MG/ML**	**A210546**	**001**	Dec 28, 2018
AB		MYLAN PHARMS INC	**2.5MG/ML**	**A211259**	**001**	Oct 22, 2018
AB		UPSHER SMITH LABS	**2.5MG/ML**	**A210569**	**001**	Oct 22, 2018
AB		WEST-WARD PHARMS INT	**2.5MG/ML**	**A209715**	**001**	Oct 22, 2018
ONFI						
AB	**+!**	LUNDBECK PHARMS LLC	**2.5MG/ML**	**N203993**	**001**	Dec 14, 2012
TABLET;ORAL						
CLOBAZAM						
AB		AMNEAL PHARMS CO	**10MG**	**A209718**	**001**	Oct 22, 2018
AB			**20MG**	**A209718**	**002**	Oct 22, 2018
AB		BIONPHARMA INC	**10MG**	**A208825**	**001**	Oct 22, 2018
AB			**20MG**	**A208825**	**002**	Oct 22, 2018
AB		BRECKENRIDGE PHARM	**10MG**	**A209308**	**001**	Oct 22, 2018
AB			**20MG**	**A209308**	**002**	Oct 22, 2018
AB		HETERO LABS LTD III	**10MG**	**A209795**	**001**	Oct 22, 2018
AB			**20MG**	**A209795**	**002**	Oct 22, 2018
AB		LUPIN LTD	**10MG**	**A210545**	**001**	Dec 14, 2018
AB			**20MG**	**A210545**	**002**	Dec 14, 2018
AB		PIRAMAL HLTHCARE UK	**10MG**	**A209808**	**001**	Oct 22, 2018
AB			**20MG**	**A209808**	**002**	Oct 22, 2018
AB		TARO PHARM	**10MG**	**A209440**	**001**	Oct 22, 2018
AB			**20MG**	**A209440**	**002**	Oct 22, 2018
AB		UPSHER SMITH LABS	**10MG**	**A209687**	**001**	Oct 22, 2018
AB			**20MG**	**A209687**	**002**	Oct 22, 2018
AB		WEST-WARD PHARMS INT	**10MG**	**A208785**	**001**	Oct 22, 2018
AB			**20MG**	**A208785**	**002**	Oct 22, 2018
AB		ZYDUS PHARMS USA INC	**10MG**	**A211449**	**001**	Oct 22, 2018
AB			**20MG**	**A211449**	**002**	Oct 22, 2018

CLOBAZAM

TABLET;ORAL

ONFI

AB	**+**	LUNDBECK PHARMS LLC	**10MG**	**N202067**	**002**	Oct 21, 2011
AB	**+!**		**20MG**	**N202067**	**003**	Oct 21, 2011

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

AB1		INGENUS PHARMS LLC	**0.05%**	**A206805**	**001**	Jul 31, 2017
AB1		PERRIGO ISRAEL	**0.05%**	**A077763**	**001**	Mar 10, 2008
AB1		TARO PHARM	**0.05%**	**A208779**	**001**	Oct 04, 2018

OLUX

AB1	**+!**	MYLAN PHARMS INC	**0.05%**	**N021142**	**001**	May 26, 2000

CLOBETASOL PROPIONATE

AB2		PERRIGO ISRAEL	**0.05%**	**A201402**	**001**	Aug 14, 2012

OLUX E

AB2	**+!**	MYLAN PHARMS INC	**0.05%**	**N022013**	**001**	Jan 12, 2007

CREAM;TOPICAL

CLOBETASOL PROPIONATE

AB1		AMNEAL PHARMS LLC	**0.05%**	**A211256**	**001**	Dec 26, 2018
AB1		CHEMO RESEARCH SL	**0.05%**	**A210034**	**001**	Jun 15, 2018
AB1		FOUGERA PHARMS INC	**0.05%**	**A074392**	**001**	Sep 30, 1996
AB1		G AND W LABS INC	**0.05%**	**A074139**	**001**	Aug 03, 1994
AB1		GLENMARK PHARMS	**0.05%**	**A209095**	**001**	May 10, 2018
AB1		LUPIN LTD	**0.05%**	**A210208**	**001**	Jan 30, 2018
AB1		MYLAN PHARMS INC	**0.05%**	**A075338**	**001**	Feb 09, 2001
AB1		SOLARIS PHARMA CORP	**0.05%**	**A211401**	**001**	Jan 11, 2019
AB1		TARO	**0.05%**	**A074249**	**001**	Jul 08, 1996
AB1		TELIGENT PHARMA INC	**0.05%**	**A209974**	**001**	Apr 17, 2018
AB1		ZYDUS PHARMS USA INC	**0.05%**	**A211074**	**001**	Oct 15, 2018

CORMAX

AB1	**!**	HI TECH PHARMA	**0.05%**	**A074220**	**001**	May 16, 1997

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2	**!**	FOUGERA PHARMS	**0.05%**	**A075430**	**001**	May 26, 1999
AB2		TARO	**0.05%**	**A075633**	**001**	May 17, 2000
AB2		TELIGENT PHARMA INC	**0.05%**	**A209411**	**001**	Aug 21, 2017

EMBELINE E

AB2		HI TECH PHARMA	**0.05%**	**A075325**	**001**	Dec 24, 1998

IMPOYZ

	+!	ENCORE DERMAT	0.025%	N209483	001	Nov 28, 2017

GEL;TOPICAL

CLOBETASOL PROPIONATE

AB	**!**	FOUGERA PHARMS	**0.05%**	**A075368**	**001**	Feb 15, 2000
AB		PERRIGO CO	**0.05%**	**A075027**	**001**	Oct 31, 1997
AB		TARO	**0.05%**	**A075279**	**001**	May 28, 1999
AB		TELIGENT PHARMA INC	**0.05%**	**A208881**	**001**	Mar 06, 2017

EMBELINE

AB		HI TECH PHARMA	**0.05%**	**A076141**	**001**	Apr 12, 2002

LOTION;TOPICAL

CLOBETASOL PROPIONATE

AB		ACTAVIS MID ATLANTIC	**0.05%**	**A078223**	**001**	Dec 04, 2008
AB		HI-TECH PHARMACAL	**0.05%**	**A211348**	**001**	Oct 26, 2018
AB		LUPIN LTD	**0.05%**	**A209147**	**001**	Sep 22, 2017
AB		TARO	**0.05%**	**A200302**	**001**	Jul 02, 2012
AB		TELIGENT PHARMA INC	**0.05%**	**A208667**	**001**	Nov 29, 2016

CLOBEX

AB	**+!**	GALDERMA LABS LP	**0.05%**	**N021535**	**001**	Jul 24, 2003

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

AB		AMNEAL PHARMS LLC	**0.05%**	**A210551**	**001**	Aug 21, 2018
AB		CHEMO RESEARCH SL	**0.05%**	**A209701**	**001**	Apr 17, 2018
AB	**!**	FOUGERA PHARMS	**0.05%**	**A074407**	**001**	Feb 23, 1996
AB		G AND W LABS INC	**0.05%**	**A074089**	**001**	Feb 16, 1994
AB		GLENMARK PHARMS	**0.05%**	**A208933**	**001**	Mar 20, 2017
AB		MYLAN PHARMS INC	**0.05%**	**A075057**	**001**	Aug 12, 1998
AB		NOVEL LABS INC	**0.05%**	**A208841**	**001**	May 04, 2018
AB		TARO	**0.05%**	**A074248**	**001**	Jul 12, 1996
AB		ZYDUS PHARMS USA INC	**0.05%**	**A210199**	**001**	Oct 27, 2017

CLOBETASOL PROPIONATE

OINTMENT;TOPICAL

EMBELINE

AB		HI TECH PHARMA	**0.05%**	**A074221**	**001**	Mar 31, 1995

SHAMPOO;TOPICAL

CLOBETASOL PROPIONATE

AB		ACTAVIS MID ATLANTIC	**0.05%**	**A078854**	**001**	Jun 07, 2011
AB		HI-TECH PHARMACAL	**0.05%**	**A209871**	**001**	Oct 27, 2017
AB		PERRIGO ISRAEL	**0.05%**	**A090974**	**001**	Aug 09, 2012

CLOBEX

AB	**+!**	GALDERMA LABS	**0.05%**	**N021644**	**001**	Feb 05, 2004

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

AT		FOUGERA PHARMS	**0.05%**	**A075391**	**001**	Feb 08, 1999
AT		G AND W LABS INC	**0.05%**	**A074331**	**001**	Dec 15, 1995
AT		GLENMARK PHARMS LTD	**0.05%**	**A210190**	**001**	Apr 18, 2018
AT		MACLEODS PHARMS LTD	**0.05%**	**A209361**	**001**	Oct 25, 2017
AT		NOVEL LABS INC	**0.05%**	**A206075**	**001**	Nov 23, 2015
AT		TARO	**0.05%**	**A075224**	**001**	Nov 16, 1998
AT			**0.05%**	**A075363**	**001**	Dec 29, 2000
AT		TOLMAR	**0.05%**	**A076977**	**001**	Aug 05, 2005
AT		WOCKHARDT BIO AG	**0.05%**	**A075205**	**001**	Nov 13, 1998

EMBELINE

AT	**!**	HI TECH PHARMA	**0.05%**	**A074222**	**001**	Dec 06, 1995

SPRAY;TOPICAL

CLOBETASOL PROPIONATE

AT		AKORN	**0.05%**	**A207218**	**001**	Apr 28, 2017
AT		GLENMARK PHARMS	**0.05%**	**A209004**	**001**	Mar 26, 2018
AT		LUPIN LTD	**0.05%**	**A208125**	**001**	Mar 26, 2018
AT		PADDOCK LLC	**0.05%**	**A090898**	**001**	Jun 16, 2011
AT		TARO	**0.05%**	**A208842**	**001**	Mar 26, 2018
AT		ZYDUS PHARMS USA INC	**0.05%**	**A206378**	**001**	Feb 16, 2017

CLOBEX

AT	**+!**	GALDERMA LABS LP	**0.05%**	**N021835**	**001**	Oct 27, 2005

CLOCORTOLONE PIVALATE

CREAM;TOPICAL

CLODERM

	+!	EPI HLTH	0.1%	N017765	001	

CLOFARABINE

SOLUTION;INTRAVENOUS

CLOFARABINE

AP		ABON PHARMS LLC	**20MG/20ML (1MG/ML)**	**A204029**	**001**	May 09, 2017
AP		AMNEAL PHARMS CO	**20MG/20ML (1MG/ML)**	**A208857**	**001**	Nov 06, 2017
AP		DR REDDYS LABS LTD	**20MG/20ML (1MG/ML)**	**A205375**	**001**	Nov 06, 2017
AP		GLAND PHARMA LTD	**20MG/20ML (1MG/ML)**	**A207831**	**001**	Oct 31, 2018
AP		HOSPIRA INC	**20MG/20ML (1MG/ML)**	**A210283**	**001**	Dec 27, 2018
AP		INGENUS PHARMS LLC	**20MG/20ML (1MG/ML)**	**A210270**	**001**	Sep 14, 2018
AP		MSN LABS PVT LTD	**20MG/20ML (1MG/ML)**	**A209775**	**001**	Dec 06, 2017
AP		MYLAN LABS LTD	**20MG/20ML (1MG/ML)**	**A208860**	**001**	Nov 06, 2017

CLOLAR

AP	**+!**	GENZYME	**20MG/20ML (1MG/ML)**	**N021673**	**001**	Dec 28, 2004

CLOMIPHENE CITRATE

TABLET;ORAL

CLOMIPHENE CITRATE

	!	PAR PHARM	50MG	A075528	001	Aug 30, 1999

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

ANAFRANIL

AB	**+!**	SPECGX LLC	**25MG**	**N019906**	**001**	Dec 29, 1989
AB	**+**		**50MG**	**N019906**	**002**	Dec 29, 1989
AB	**+**		**75MG**	**N019906**	**003**	Dec 29, 1989

CLOMIPRAMINE HYDROCHLORIDE

AB		AMNEAL PHARMS CO	**25MG**	**A208632**	**001**	Oct 31, 2018
AB			**50MG**	**A208632**	**002**	Oct 31, 2018
AB			**75MG**	**A208632**	**003**	Oct 31, 2018
AB		LUPIN LTD	**25MG**	**A209294**	**001**	Nov 21, 2018
AB			**50MG**	**A209294**	**002**	Nov 21, 2018
AB			**75MG**	**A209294**	**003**	Nov 21, 2018
AB		MYLAN	**25MG**	**A074947**	**001**	Apr 30, 1998

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

AB		**50MG**	**A074947**	**002**	Apr 30, 1998
AB		**75MG**	**A074947**	**003**	Apr 30, 1998
AB	SANDOZ	**25MG**	**A074364**	**001**	Mar 29, 1996
AB		**25MG**	**A074953**	**001**	Jun 25, 1997
AB		**50MG**	**A074364**	**002**	Mar 29, 1996
AB		**50MG**	**A074953**	**002**	Jun 25, 1997
AB		**75MG**	**A074364**	**003**	Mar 29, 1996
AB		**75MG**	**A074953**	**003**	Jun 25, 1997
AB	TARO	**25MG**	**A074694**	**001**	Dec 31, 1996
AB		**50MG**	**A074694**	**002**	Dec 31, 1996
AB		**75MG**	**A074694**	**003**	Dec 31, 1996
AB	TEVA	**25MG**	**A074958**	**001**	Aug 26, 1997
AB		**50MG**	**A074958**	**002**	Aug 26, 1997
AB		**75MG**	**A074958**	**003**	Aug 26, 1997
AB	ZYDUS PHARMS USA INC	**25MG**	**A208961**	**001**	Dec 27, 2017
AB		**50MG**	**A208961**	**002**	Dec 27, 2017
AB		**75MG**	**A208961**	**003**	Dec 27, 2017

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

AB	ACCORD HLTHCARE	**0.5MG**	**A077147**	**001**	May 02, 2005
AB		**1MG**	**A077147**	**002**	May 02, 2005
AB		**2MG**	**A077147**	**003**	May 02, 2005
AB	ACTAVIS ELIZABETH	**0.5MG**	**A074869**	**001**	Oct 31, 1996
AB		**1MG**	**A074869**	**002**	Oct 31, 1996
AB		**2MG**	**A074869**	**003**	Oct 31, 1996
AB	MYLAN	**0.5MG**	**A075150**	**001**	Oct 05, 1998
AB		**1MG**	**A075150**	**002**	Oct 05, 1998
AB		**2MG**	**A075150**	**003**	Oct 05, 1998
AB	PRINSTON INC	**0.5MG**	**A077856**	**001**	Jun 28, 2006
AB		**1MG**	**A077856**	**002**	Jun 28, 2006
AB		**2MG**	**A077856**	**003**	Jun 28, 2006
AB	SANDOZ	**0.5MG**	**A074979**	**001**	Aug 29, 1997
AB		**1MG**	**A074979**	**002**	Aug 29, 1997
AB		**2MG**	**A074979**	**003**	Aug 29, 1997
AB	SUN PHARM INDS INC	**0.5MG**	**A075423**	**001**	Apr 27, 2001
AB		**1MG**	**A075423**	**002**	Apr 27, 2001
AB		**2MG**	**A075423**	**003**	Apr 27, 2001
AB	TEVA	**0.5MG**	**A074569**	**001**	Sep 10, 1996
AB		**1MG**	**A074569**	**002**	Sep 10, 1996
AB		**2MG**	**A074569**	**003**	Sep 10, 1996
AB	WATSON LABS	**0.5MG**	**A074964**	**001**	Dec 30, 1997
AB		**1MG**	**A074964**	**002**	Dec 30, 1997
AB		**2MG**	**A074964**	**003**	Dec 30, 1997

KLONOPIN

AB	**+** ROCHE	**0.5MG**	**N017533**	**001**	
AB	**+!**	**1MG**	**N017533**	**002**	
AB	**+**	**2MG**	**N017533**	**003**	

TABLET, ORALLY DISINTEGRATING;ORAL

CLONAZEPAM

AB	BARR	**0.125MG**	**A077194**	**001**	Aug 10, 2005
AB		**0.25MG**	**A077194**	**002**	Aug 10, 2005
AB		**0.5MG**	**A077194**	**003**	Aug 10, 2005
AB		**1MG**	**A077194**	**004**	Aug 10, 2005
AB		**2MG**	**A077194**	**005**	Aug 10, 2005
AB	PAR PHARM	**0.125MG**	**A077171**	**001**	Aug 03, 2005
AB		**0.25MG**	**A077171**	**002**	Aug 03, 2005
AB		**0.5MG**	**A077171**	**003**	Aug 03, 2005
AB	**!**	**1MG**	**A077171**	**004**	Aug 03, 2005
AB		**2MG**	**A077171**	**005**	Aug 03, 2005
AB	SUN PHARM INDS INC	**0.125MG**	**A078654**	**001**	Aug 27, 2014
AB		**0.25MG**	**A078654**	**002**	Aug 27, 2014
AB		**0.5MG**	**A078654**	**003**	Aug 27, 2014
AB		**1MG**	**A078654**	**004**	Aug 27, 2014
AB		**2MG**	**A078654**	**005**	Aug 27, 2014

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL

CATAPRES-TTS-1							
AB	+	BOEHRINGER INGELHEIM	**0.1MG/24HR**	**N018891**	**001**	Oct 10, 1984
CATAPRES-TTS-2							
AB	+	BOEHRINGER INGELHEIM	**0.2MG/24HR**	**N018891**	**002**	Oct 10, 1984
CATAPRES-TTS-3							
AB	+!	BOEHRINGER INGELHEIM	**0.3MG/24HR**	**N018891**	**003**	Oct 10, 1984
CLONIDINE							
AB		ACTAVIS LABS UT INC	**0.1MG/24HR**	**A090873**	**001**	May 06, 2014
AB			**0.2MG/24HR**	**A090873**	**002**	May 06, 2014
AB			**0.3MG/24HR**	**A090873**	**003**	May 06, 2014
AB		AVEVA	**0.1MG/24HR**	**A076157**	**001**	Aug 18, 2009
AB			**0.2MG/24HR**	**A076157**	**002**	Aug 18, 2009
AB			**0.3MG/24HR**	**A076157**	**003**	Aug 18, 2009
AB		MAYNE PHARMA	**0.1MG/24HR**	**A079090**	**001**	Aug 20, 2010
AB			**0.2MG/24HR**	**A079090**	**002**	Aug 20, 2010
AB			**0.3MG/24HR**	**A079090**	**003**	Aug 20, 2010
AB		MYLAN TECHNOLOGIES	**0.1MG/24HR**	**A076166**	**001**	Jul 16, 2010
AB			**0.2MG/24HR**	**A076166**	**002**	Jul 16, 2010
AB			**0.3MG/24HR**	**A076166**	**003**	Jul 16, 2010

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CLONIDINE HYDROCHLORIDE							
AP		FRESENIUS KABI USA	**1MG/10ML (0.1MG/ML)**	**A200673**	**001**	Jul 08, 2011
AP			**5MG/10ML (0.5MG/ML)**	**A200673**	**002**	Jul 08, 2011
AP		HIKMA FARMACEUTICA	**1MG/10ML (0.1MG/ML)**	**A200300**	**001**	Jan 26, 2011
AP			**5MG/10ML (0.5MG/ML)**	**A200300**	**002**	Jan 26, 2011
AP		LUITPOLD	**1MG/10ML (0.1MG/ML)**	**A091104**	**001**	Oct 08, 2009
AP			**5MG/10ML (0.5MG/ML)**	**A091104**	**002**	Oct 08, 2009
AP		X-GEN PHARMS INC	**1MG/10ML (0.1MG/ML)**	**A203167**	**001**	Oct 29, 2013
AP			**5MG/10ML (0.5MG/ML)**	**A203167**	**002**	Oct 29, 2013
AP		ZYDUS PHARMS USA INC	**1MG/10ML (0.1MG/ML)**	**A202601**	**001**	Feb 20, 2014
AP			**5MG/10ML (0.5MG/ML)**	**A202601**	**002**	Feb 20, 2014
DURACLON							
AP	+	MYLAN INSTITUTIONAL	**1MG/10ML (0.1MG/ML)**	**N020615**	**001**	Oct 02, 1996
AP	+!		**5MG/10ML (0.5MG/ML)**	**N020615**	**002**	Apr 27, 1999

TABLET;ORAL

CATAPRES							
AB	+	BOEHRINGER INGELHEIM	**0.1MG**	**N017407**	**001**		
AB	+		**0.2MG**	**N017407**	**002**		
AB	+!		**0.3MG**	**N017407**	**003**		
CLONIDINE HYDROCHLORIDE							
AB		ACTAVIS ELIZABETH	**0.1MG**	**A070974**	**001**	Dec 16, 1986
AB			**0.2MG**	**A070975**	**001**	Dec 16, 1986
AB			**0.3MG**	**A070976**	**001**	Dec 16, 1986
AB		ALEMBIC PHARMS LTD	**0.1MG**	**A091368**	**001**	Dec 06, 2011
AB			**0.2MG**	**A091368**	**002**	Dec 06, 2011
AB			**0.3MG**	**A091368**	**003**	Dec 06, 2011
AB		FRONTIDA BIOPHARM	**0.1MG**	**A070925**	**001**	Sep 04, 1987
AB			**0.2MG**	**A070924**	**001**	Sep 04, 1987
AB			**0.3MG**	**A070923**	**001**	Sep 04, 1987
AB		IMPAX LABS	**0.1MG**	**A078099**	**001**	Aug 27, 2009
AB			**0.2MG**	**A078099**	**002**	Aug 27, 2009
AB			**0.3MG**	**A078099**	**003**	Aug 27, 2009
AB		MYLAN	**0.1MG**	**A070317**	**002**	Jul 09, 1987
AB			**0.2MG**	**A070317**	**003**	Jun 09, 1987
AB			**0.3MG**	**A070317**	**001**	Jun 09, 1987
AB		PRINSTON INC	**0.1MG**	**A077901**	**001**	Mar 09, 2007
AB			**0.2MG**	**A077901**	**002**	Mar 09, 2007
AB			**0.3MG**	**A077901**	**003**	Mar 09, 2007
AB		SUN PHARM INDS INC	**0.1MG**	**A090329**	**001**	Jul 03, 2014
AB			**0.2MG**	**A090329**	**002**	Jul 03, 2014
AB			**0.3MG**	**A090329**	**003**	Jul 03, 2014
AB		UNICHEM	**0.1MG**	**A078895**	**001**	Aug 26, 2009
AB			**0.2MG**	**A078895**	**002**	Aug 26, 2009
AB			**0.3MG**	**A078895**	**003**	Aug 26, 2009
AB		YUNG SHIN PHARM	**0.1MG**	**A202297**	**001**	Jun 13, 2013

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

AB			**0.2MG**	**A202297**	**002**	Jun 13, 2013
AB			**0.3MG**	**A202297**	**003**	Jun 13, 2013

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB1		ACTAVIS ELIZABETH	**0.1MG**	**A203320**	**001**	May 15, 2015
AB1		AJANTA PHARMA LTD	**0.1MG**	**A209686**	**001**	Nov 20, 2017
AB1		AMNEAL PHARMS NY	**0.1MG**	**A210052**	**001**	Nov 20, 2017
AB1		ANCHEN PHARMS	**0.1MG**	**A202984**	**001**	Sep 30, 2013
AB1		JUBILANT GENERICS	**0.1MG**	**A210338**	**001**	Jan 29, 2018
AB1		LUPIN LTD	**0.1MG**	**A209285**	**001**	Oct 23, 2017
AB1		MAYNE PHARMA INC	**0.1MG**	**A210680**	**001**	Apr 30, 2018
AB1		UPSHER SMITH LABS	**0.1MG**	**A211433**	**001**	Oct 12, 2018
AB1		XIAMEN LP PHARM CO	**0.1MG**	**A209757**	**001**	Nov 20, 2017

KAPVAY

AB1	**+!**	CONCORDIA PHARMS INC	**0.1MG**	**N022331**	**003**	Sep 28, 2010

CLONIDINE HYDROCHLORIDE

AB2		ACTAVIS ELIZABETH	**0.1MG**	**A202792**	**001**	May 15, 2015

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB		ACCORD HLTHCARE	**EQ 75MG BASE**	**A202925**	**001**	Mar 27, 2013
AB			**EQ 300MG BASE**	**A202925**	**002**	Mar 27, 2013
AB		ACME LABS	**EQ 75MG BASE**	**A078004**	**001**	May 17, 2012
AB		AMNEAL PHARMS	**EQ 75MG BASE**	**A203751**	**001**	Apr 11, 2014
AB		APOTEX INC	**EQ 75MG BASE**	**A076274**	**001**	May 17, 2012
AB			**EQ 300MG BASE**	**A076274**	**002**	Mar 04, 2014
AB		AUROBINDO PHARMA LTD	**EQ 75MG BASE**	**A090540**	**001**	May 17, 2012
AB		CSPC OUYI PHARM CO	**EQ 75MG BASE**	**A204359**	**001**	Feb 02, 2017
AB		DR REDDYS LABS INC	**EQ 75MG BASE**	**A076273**	**001**	Jan 14, 2008
AB		DR REDDYS LABS LTD	**EQ 300MG BASE**	**A091023**	**001**	May 17, 2012
AB		GATE PHARMS	**EQ 300MG BASE**	**A091216**	**001**	May 17, 2012
AB		MACLEODS PHARMS LTD	**EQ 75MG BASE**	**A202928**	**001**	Feb 10, 2014
AB		MYLAN PHARMS INC	**EQ 75MG BASE**	**A077665**	**001**	May 17, 2012
AB			**EQ 300MG BASE**	**A077665**	**002**	May 17, 2012
AB		PRINSTON INC	**EQ 75MG BASE**	**A206376**	**001**	May 07, 2018
AB			**EQ 300MG BASE**	**A206376**	**002**	May 07, 2018
AB		SCIEGEN PHARMS INC	**EQ 75MG BASE**	**A204165**	**001**	Sep 15, 2014
AB			**EQ 300MG BASE**	**A204165**	**002**	Sep 15, 2014
AB		SUN PHARM INDUSTRIES	**EQ 75MG BASE**	**A078133**	**001**	Jun 10, 2013
AB		SUN PHARMA GLOBAL	**EQ 75MG BASE**	**A090494**	**001**	May 17, 2012
AB		TEVA	**EQ 75MG BASE**	**A076999**	**001**	May 17, 2012
AB		TEVA PHARMS	**EQ 300MG BASE**	**A090625**	**001**	May 17, 2012
AB		TORRENT PHARMS LTD	**EQ 75MG BASE**	**A090844**	**001**	May 17, 2012
AB		WOCKHARDT LTD	**EQ 75MG BASE**	**A202266**	**001**	Aug 14, 2012
AB			**EQ 300MG BASE**	**A202266**	**002**	Nov 20, 2012
AB		ZYDUS PHARMS USA INC	**EQ 75MG BASE**	**A201686**	**001**	Oct 10, 2012

PLAVIX

AB	**+**	SANOFI AVENTIS US	**EQ 75MG BASE**	**N020839**	**001**	Nov 17, 1997
AB	**+!**		**EQ 300MG BASE**	**N020839**	**002**	Sep 20, 2007

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

AB		MYLAN	**3.75MG**	**A071858**	**002**	Jul 17, 1987
AB			**7.5MG**	**A071858**	**003**	Jul 17, 1987
AB	**!**		**15MG**	**A071858**	**001**	Jul 17, 1987
AB		TARO PHARM	**3.75MG**	**A075731**	**003**	Apr 27, 2000
AB			**7.5MG**	**A075731**	**002**	Apr 27, 2000
AB			**15MG**	**A075731**	**001**	Apr 27, 2000

GEN-XENE

AB		ALRA	**3.75MG**	**A071787**	**001**	Apr 26, 1988
AB			**7.5MG**	**A071788**	**001**	Apr 26, 1988
AB			**15MG**	**A071789**	**001**	Apr 26, 1988

TRANXENE

AB	**+**	RECORDATI RARE	**7.5MG**	**N017105**	**007**	

CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE

AB		FOUGERA PHARMS	**1%**	**A078338**	**001**	Sep 02, 2008
AB		GLENMARK PHARMS	**1%**	**A090219**	**001**	Aug 03, 2010
AB	!	TARO	**1%**	**A072640**	**001**	Aug 31, 1993

SOLUTION;TOPICAL

CLOTRIMAZOLE

AT	!	TARO	**1%**	**A074580**	**001**	Jul 29, 1996
AT		TEVA	**1%**	**A073306**	**001**	Feb 28, 1995

TROCHE/LOZENGE;ORAL

CLOTRIMAZOLE

AB		PADDOCK LLC	**10MG**	**A076763**	**001**	Oct 28, 2005
AB	!	WEST-WARD PHARMS INT	**10MG**	**A076387**	**001**	Jul 29, 2004

CLOZAPINE

SUSPENSION;ORAL

VERSACLOZ

	+!	TASMAN PHARMA	50MG/ML	N203479	001	Feb 06, 2013

TABLET;ORAL

CLOZAPINE

AB		ACCORD HLTHCARE	**25MG**	**A202873**	**001**	Nov 25, 2015
AB			**100MG**	**A202873**	**002**	Nov 25, 2015
AB		AUROBINDO PHARMA LTD	**25MG**	**A206433**	**001**	Nov 29, 2016
AB			**50MG**	**A206433**	**002**	Nov 29, 2016
AB			**100MG**	**A206433**	**003**	Nov 29, 2016
AB			**200MG**	**A206433**	**004**	Nov 29, 2016
AB		IVAX SUB TEVA PHARMS	**25MG**	**A074949**	**001**	Nov 26, 1997
AB			**50MG**	**A074949**	**004**	Apr 25, 2005
AB			**50MG**	**A076809**	**003**	Dec 16, 2005
AB			**100MG**	**A074949**	**002**	Nov 26, 1997
AB			**100MG**	**A076809**	**002**	Dec 16, 2005
AB			**200MG**	**A076809**	**001**	Dec 16, 2005
AB		MAYNE PHARMA	**25MG**	**A203807**	**001**	Sep 17, 2015
AB			**50MG**	**A203807**	**003**	Aug 22, 2017
AB			**100MG**	**A203807**	**002**	Sep 17, 2015
AB			**200MG**	**A203807**	**004**	Aug 22, 2017
AB		MYLAN	**25MG**	**A075417**	**001**	May 27, 1999
AB			**50MG**	**A075417**	**004**	Apr 15, 2010
AB			**100MG**	**A075417**	**002**	May 27, 1999
AB			**200MG**	**A075417**	**005**	Apr 15, 2010
AB		SUN PHARM INDS INC	**25MG**	**A075713**	**001**	Nov 15, 2002
AB			**50MG**	**A075713**	**003**	Aug 19, 2005
AB			**100MG**	**A075713**	**002**	Nov 15, 2002
AB			**200MG**	**A075713**	**004**	Nov 07, 2017

CLOZARIL

AB	+	HERITAGE LIFE	**25MG**	**N019758**	**001**	Sep 26, 1989
AB	+!		**100MG**	**N019758**	**002**	Sep 26, 1989

CLOZAPINE

		IVAX SUB TEVA PHARMS	12.5MG	A074949	003	Jul 31, 2003

TABLET, ORALLY DISINTEGRATING;ORAL

CLOZAPINE

AB		BARR LABS INC	**12.5MG**	**A090308**	**003**	Apr 09, 2018
AB			**25MG**	**A090308**	**001**	Nov 25, 2015
AB			**100MG**	**A090308**	**002**	Nov 25, 2015
AB		MYLAN PHARMS INC	**25MG**	**A201824**	**002**	Sep 15, 2015
AB			**100MG**	**A201824**	**003**	Sep 15, 2015
AB		TEVA PHARMS USA	**150MG**	**A203039**	**001**	Nov 25, 2015
AB			**200MG**	**A203039**	**002**	Nov 25, 2015

FAZACLO ODT

AB	+	JAZZ PHARMS III	**12.5MG**	**N021590**	**004**	May 30, 2007
AB	+		**25MG**	**N021590**	**001**	Feb 10, 2004
AB	+!		**100MG**	**N021590**	**002**	Feb 10, 2004
AB	+		**150MG**	**N021590**	**005**	Jul 09, 2010
AB	+		**200MG**	**N021590**	**006**	Jul 09, 2010

COBICISTAT

TABLET;ORAL

TYBOST

	+!	GILEAD SCIENCES INC	150MG	N203094	001	Sep 24, 2014

COBICISTAT; DARUNAVIR ETHANOLATE

TABLET;ORAL

PREZCOBIX

	+!	JANSSEN PRODS	150MG;EQ 800MG BASE	N205395	001	Jan 29, 2015

COBICISTAT; DARUNAVIR ETHANOLATE; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

SYMTUZA

	+!	JANSSEN PRODS	150MG;EQ 800MG BASE;200MG;EQ 10MG BASE	N210455	001	Jul 17, 2018

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

GENVOYA

	+!	GILEAD SCIENCES INC	150MG;150MG;200MG;EQ 10MG BASE	N207561	001	Nov 05, 2015

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

STRIBILD

	+!	GILEAD SCIENCES INC	150MG;150MG;200MG;300MG	N203100	001	Aug 27, 2012

COBIMETINIB FUMARATE

TABLET;ORAL

COTELLIC

	+!	GENENTECH INC	EQ 20MG BASE	N206192	001	Nov 10, 2015

COCAINE HYDROCHLORIDE

SOLUTION;NASAL

GOPRELTO

	+!	GENUS LIFESCIENCES	4%	N209963	001	Dec 14, 2017

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA		VINTAGE	**10MG/5ML;5MG/5ML;6.25MG/5ML**	**A040660**	**001**	Dec 07, 2006

PROMETH VC W/ CODEINE

AA	**!**	ACTAVIS MID ATLANTIC	**10MG/5ML;5MG/5ML;6.25MG/5ML**	**A088764**	**001**	Oct 31, 1984

PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA		HI-TECH PHARMA CO	**10MG/5ML;5MG/5ML;6.25MG/5ML**	**A040674**	**001**	Dec 23, 2014

PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA		AMNEAL PHARMS	**10MG/5ML;5MG/5ML;6.25MG/5ML**	**A200963**	**001**	Aug 26, 2015

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA	**!**	ACTAVIS MID ATLANTIC	**10MG/5ML;6.25MG/5ML**	**A088763**	**001**	Oct 31, 1984
AA		AMNEAL PHARMS	**10MG/5ML;6.25MG/5ML**	**A200894**	**001**	Apr 24, 2013
AA		HI TECH PHARMA	**10MG/5ML;6.25MG/5ML**	**A040151**	**001**	Aug 26, 1997
AA		NOSTRUM LABS INC	**10MG/5ML;6.25MG/5ML**	**A090180**	**001**	Mar 17, 2010
AA		TRIS PHARMA INC	**10MG/5ML;6.25MG/5ML**	**A200386**	**001**	Jun 29, 2012
AA		WOCKHARDT BIO AG	**10MG/5ML;6.25MG/5ML**	**A088875**	**001**	Dec 17, 1984

PROMETHAZINE WITH CODEINE

AA		VINTAGE	**10MG/5ML;6.25MG/5ML**	**A040650**	**001**	Jan 31, 2006

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL

TRIACIN-C

	!	STI PHARMA LLC	10MG/5ML;30MG/5ML;1.25MG/5ML	A088704	001	Mar 22, 1985

CODEINE SULFATE

TABLET;ORAL

CODEINE SULFATE

AB		LANNETT CO INC	**15MG**	**A203046**	**001**	Jun 13, 2014
AB			**30MG**	**A203046**	**002**	Jun 13, 2014
AB			**60MG**	**A203046**	**003**	Jun 13, 2014
AB	**+**	WEST-WARD PHARMS INT	**15MG**	**N022402**	**001**	Jul 16, 2009
AB	**+**		**30MG**	**N022402**	**002**	Jul 16, 2009
AB	**+!**		**60MG**	**N022402**	**003**	Jul 16, 2009

COLCHICINE						
CAPSULE;ORAL						
COLCHICINE						
AB		PAR PHARM INC	**0.6MG**	**A208678**	**001**	Nov 29, 2018
MITIGARE						
AB	**+!**	HIKMA INTL PHARMS	**0.6MG**	**N204820**	**001**	Sep 26, 2014
TABLET;ORAL						
COLCRYS						
	+!	TAKEDA PHARMS USA	0.6MG	N022352	001	Jul 29, 2009
COLCHICINE; PROBENECID						
TABLET;ORAL						
COL-PROBENECID						
AB	**!**	WATSON LABS	**0.5MG;500MG**	**A084279**	**001**	
PROBENECID AND COLCHICINE						
AB		NOVAST LABS	**0.5MG;500MG**	**A040618**	**001**	May 13, 2008
COLESEVELAM HYDROCHLORIDE						
FOR SUSPENSION;ORAL						
COLESEVELAM HYDROCHLORIDE						
AB		GLENMARK PHARMS LTD	**1.875GM/PACKET**	**A202190**	**001**	Jul 16, 2018
AB			**3.75GM/PACKET**	**A202190**	**002**	Jul 16, 2018
WELCHOL						
AB	**+**	DAIICHI SANKYO	**1.875GM/PACKET**	**N022362**	**001**	Oct 02, 2009
AB	**+!**		**3.75GM/PACKET**	**N022362**	**002**	Oct 02, 2009
TABLET;ORAL						
COLESEVELAM HYDROCHLORIDE						
AB		ALKEM LABS LTD	**625MG**	**A209038**	**001**	Oct 05, 2018
AB		DR REDDYS LABS LTD	**625MG**	**A210889**	**001**	Oct 05, 2018
AB		GLENMARK PHARMS LTD	**625MG**	**A203480**	**001**	May 18, 2018
AB		IMPAX LABS INC	**625MG**	**A091600**	**001**	May 16, 2018
WELCHOL						
AB	**+!**	DAIICHI SANKYO	**625MG**	**N021176**	**001**	May 26, 2000
COLESTIPOL HYDROCHLORIDE						
GRANULE;ORAL						
COLESTID						
AB	**+**	PHARMACIA UPJOHN	**5GM/SCOOPFUL**	**N017563**	**003**	Sep 22, 1995
AB	**+!**		**5GM/PACKET**	**N017563**	**004**	Sep 22, 1995
COLESTIPOL HYDROCHLORIDE						
AB		IMPAX LABS	**5GM/SCOOPFUL**	**A077277**	**001**	May 02, 2006
AB			**5GM/PACKET**	**A077277**	**002**	May 02, 2006
FLAVORED COLESTID						
	+	PHARMACIA UPJOHN	5GM/PACKET	N017563	001	
	+		5GM/SCOOPFUL	N017563	002	
TABLET;ORAL						
COLESTID						
AB	**+!**	PHARMACIA UPJOHN	**1GM**	**N020222**	**001**	Jul 19, 1994
COLESTIPOL HYDROCHLORIDE						
AB		IMPAX LABS	**1GM**	**A077510**	**001**	Oct 24, 2006
COLISTIMETHATE SODIUM						
INJECTABLE;INJECTION						
COLISTIMETHATE SODIUM						
AP		EMCURE PHARMS LTD	**EQ 150MG BASE/VIAL**	**A202359**	**001**	Sep 28, 2012
AP		FRESENIUS KABI USA	**EQ 150MG BASE/VIAL**	**A065364**	**001**	Apr 17, 2008
AP		NEXUS PHARMS	**EQ 150MG BASE/VIAL**	**A065177**	**001**	Mar 19, 2004
AP		SAGENT PHARMS	**EQ 150MG BASE/VIAL**	**A201365**	**001**	Feb 19, 2014
AP		X GEN PHARMS	**EQ 150MG BASE/VIAL**	**A064216**	**001**	Feb 26, 1999
AP		XELLIA PHARMS APS	**EQ 150MG BASE/VIAL**	**A205356**	**001**	May 29, 2015
COLY-MYCIN M						
AP	**+!**	PAR STERILE PRODUCTS	**EQ 150MG BASE/VIAL**	**N050108**	**002**	
COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE						
SUSPENSION/DROPS;OTIC						
COLY-MYCIN S						
	+!	ENDO PHARMS INC	EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML	N050356	001	

CONIVAPTAN HYDROCHLORIDE
INJECTABLE;INTRAVENOUS
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

	+!	CUMBERLAND PHARMS	20MG/100ML (0.2MG/ML)	N021697	002	Oct 08, 2008

COPANLISIB DIHYDROCHLORIDE
POWDER;INTRAVENOUS
ALIQOPA

	+!	BAYER HEALTHCARE	60MG/VIAL	N209936	001	Sep 14, 2017

COPPER
INTRAUTERINE DEVICE;INTRAUTERINE
PARAGARD T 380A

	+!	COOPERSURGICAL	309MG/COPPER	N018680	001	Nov 15, 1984

CORTICORELIN OVINE TRIFLUTATE
INJECTABLE;INJECTION
ACTHREL

	+!	FERRING	EQ 0.1MG BASE/VIAL	N020162	001	May 23, 1996

CORTICOTROPIN
INJECTABLE;INJECTION
H.P. ACTHAR GEL

	+!	MALLINCKRODT ARD	80 UNITS/ML	N008372	008	

CORTISONE ACETATE
TABLET;ORAL
CORTISONE ACETATE

	!	HIKMA INTL PHARMS	25MG	A080776	002	

COSYNTROPIN
INJECTABLE;INJECTION

CORTROSYN						
AP	**+!**	AMPHASTAR PHARMS INC	**0.25MG/VIAL**	**N016750**	**001**	
COSYNTROPIN						
AP		MYLAN INSTITUTIONAL	**0.25MG/VIAL**	**A090574**	**001**	Dec 17, 2009
AP		SANDOZ	**0.25MG/VIAL**	**A202147**	**001**	Jun 29, 2012

CRISABOROLE
OINTMENT;TOPICAL
EUCRISA

	+!	ANACOR PHARMS INC	2%	N207695	001	Dec 14, 2016

CRIZOTINIB
CAPSULE;ORAL
XALKORI

	+	PF PRISM CV	200MG	N202570	001	Aug 26, 2011
	+!		250MG	N202570	002	Aug 26, 2011

CROFELEMER
TABLET, DELAYED RELEASE;ORAL
MYTESI

	+!	NAPO PHARMS INC	125MG	N202292	001	Dec 31, 2012

CROMOLYN SODIUM
CONCENTRATE;ORAL

CROMOLYN SODIUM						
AA		AILEX PHARMS LLC	**100MG/5ML**	**A209264**	**001**	Oct 16, 2017
AA		MICRO LABS LTD INDIA	**100MG/5ML**	**A202745**	**001**	Apr 04, 2013
AA		RISING PHARMS	**100MG/5ML**	**A202583**	**001**	Oct 27, 2011
GASTROCROM						
AA	**+!**	MYLAN SPECIALITY LP	**100MG/5ML**	**N020479**	**001**	Feb 29, 1996

SOLUTION;INHALATION

CROMOLYN SODIUM						
AN		AILEX PHARMS LLC	**10MG/ML**	**A209453**	**001**	Oct 16, 2017
AN		MYLAN SPECIALITY LP	**10MG/ML**	**A074209**	**001**	Apr 26, 1994
AN	**!**	TEVA PHARMS	**10MG/ML**	**A075271**	**001**	Jan 18, 2000
AN		WOCKHARDT BIO AG	**10MG/ML**	**A075346**	**001**	Oct 25, 1999

SOLUTION/DROPS;OPHTHALMIC

CROMOLYN SODIUM						
AT	**!**	AKORN	**4%**	**A074706**	**001**	Apr 29, 1998
AT		SANDOZ INC	**4%**	**A075282**	**001**	Jun 16, 1999

CROTAMITON							
CREAM;TOPICAL							
EURAX							
	+!	SUN PHARM INDS INC	10%		N006927	001	
LOTION;TOPICAL							
CROTAN							
AT		MARNEL PHARMS	**10%**		**A087204**	**001**	
EURAX							
AT	**+!**	SUN PHARM INDS INC	**10%**		**N009112**	**003**	
CUPRIC CHLORIDE							
INJECTABLE;INJECTION							
CUPRIC CHLORIDE IN PLASTIC CONTAINER							
	+!	HOSPIRA	EQ 0.4MG COPPER/ML		N018960	001	Jun 26, 1986
CYANOCOBALAMIN							
INJECTABLE;INJECTION							
CYANOCOBALAMIN							
AP	**+!**	LUITPOLD	**1MG/ML**		**A080737**	**001**	
AP		MYLAN LABS LTD	**1MG/ML**		**A204829**	**001**	Jun 05, 2017
AP		SOMERSET THERAPS LLC	**1MG/ML**		**A206503**	**001**	Dec 11, 2015
AP			**1MG/ML**		**A209429**	**001**	Dec 18, 2018
AP		VITRUVIAS THERAP	**1MG/ML**		**A209255**	**001**	Dec 18, 2018
AP		WEST-WARD PHARMS INT	**1MG/ML**		**A080515**	**002**	
VIBISONE							
AP	**!**	FRESENIUS KABI USA	**1MG/ML**		**A080557**	**003**	
SPRAY, METERED;NASAL							
NASCOBAL							
	+!	ENDO PHARMS INC	0.5MG/SPRAY		N021642	001	Jan 31, 2005
CYCLOBENZAPRINE HYDROCHLORIDE							
CAPSULE, EXTENDED RELEASE;ORAL							
AMRIX							
AB	**+**	TEVA PHARMS INTL	**15MG**		**N021777**	**001**	Feb 01, 2007
AB	**+!**		**30MG**		**N021777**	**002**	Feb 01, 2007
CYCLOBENZAPRINE HYDROCHLORIDE							
AB		APOTEX INC	**15MG**		**A206703**	**001**	Jul 24, 2018
AB			**30MG**		**A206703**	**002**	Jul 24, 2018
TABLET;ORAL							
CYCLOBENZAPRINE HYDROCHLORIDE							
AB		ACTAVIS LABS FL INC	**5MG**		**A071611**	**002**	Feb 03, 2006
AB			**7.5MG**		**A071611**	**003**	Feb 03, 2006
AB			**10MG**		**A071611**	**001**	May 03, 1989
AB		AUROBINDO PHARMA	**5MG**		**A078643**	**001**	Sep 26, 2008
AB			**10MG**		**A078643**	**002**	Sep 26, 2008
AB		FRONTIDA BIOPHARM	**5MG**		**A073541**	**002**	Apr 06, 2006
AB			**10MG**		**A073541**	**001**	May 23, 1995
AB		INVAGEN PHARMS	**5MG**		**A090478**	**001**	Jul 23, 2010
AB			**10MG**		**A090478**	**002**	Jul 23, 2010
AB		JUBILANT CADISTA	**5MG**		**A077563**	**001**	Apr 19, 2006
AB			**7.5MG**		**A077563**	**003**	Aug 25, 2017
AB			**10MG**		**A077563**	**002**	Apr 19, 2006
AB		KVK TECH	**5MG**		**A078048**	**001**	Feb 28, 2011
AB			**10MG**		**A078048**	**002**	Feb 28, 2011
AB		MYLAN PHARMS INC	**5MG**		**A073144**	**002**	Feb 03, 2006
AB			**7.5MG**		**A073144**	**003**	Mar 25, 2013
AB	**!**		**10MG**		**A073144**	**001**	May 30, 1991
AB		ORIT LABS LLC	**5MG**		**A078218**	**002**	Jun 19, 2015
AB			**10MG**		**A078218**	**001**	Apr 18, 2008
AB		OXFORD PHARMS	**5MG**		**A077209**	**002**	Feb 03, 2006
AB			**10MG**		**A077209**	**001**	Oct 04, 2005
AB		PLIVA	**10MG**		**A074421**	**001**	Sep 29, 1995
AB		PRINSTON INC	**5MG**		**A077797**	**001**	Feb 28, 2007
AB			**10MG**		**A077797**	**002**	Feb 28, 2007
AB		RUBICON RES PVT LTD	**5MG**		**A208170**	**001**	May 31, 2017
AB			**7.5MG**		**A208170**	**002**	May 31, 2017
AB			**10MG**		**A208170**	**003**	May 31, 2017
AB		SUN PHARM INDS LTD	**5MG**		**A078722**	**001**	May 12, 2008
AB			**7.5MG**		**A078722**	**002**	May 12, 2008
AB			**10MG**		**A078722**	**003**	May 12, 2008

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AKPENTOLATE						
AT		AKORN	**1%**	**A040164**	**001**	Jan 13, 1997
CYCLOGYL						
AT	**!**	ALCON LABS INC	**0.5%**	**A084109**	**001**	
AT	**!**		**1%**	**A084110**	**001**	
CYCLOPENTOLATE HYDROCHLORIDE						
AT		AKORN INC	**0.5%**	**A205937**	**001**	Dec 09, 2015
PENTOLAIR						
AT		BAUSCH AND LOMB	**1%**	**A040075**	**001**	Apr 29, 1994
CYCLOGYL						
	!	ALCON LABS INC	2%	A084108	001	

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYCLOMYDRIL						
	!	ALCON LABS INC	0.2%;1%	A084300	001	

CYCLOPHOSPHAMIDE

CAPSULE;ORAL

CYCLOPHOSPHAMIDE						
AB		AMERIGEN PHARMS LTD	**25MG**	**A207014**	**001**	Mar 19, 2018
AB			**50MG**	**A207014**	**002**	Mar 19, 2018
AB		STI PHARMA LLC	**25MG**	**A209872**	**001**	May 07, 2018
AB			**50MG**	**A209872**	**002**	May 07, 2018
AB	**+**	WEST-WARD PHARMS INT	**25MG**	**N203856**	**001**	Sep 16, 2013
AB	**+!**		**50MG**	**N203856**	**002**	Sep 16, 2013

INJECTABLE;INJECTION

CYCLOPHOSPHAMIDE						
AP		AMNEAL PHARMS CO	**500MG/VIAL**	**A210046**	**001**	May 25, 2018
AP			**1GM/VIAL**	**A210046**	**002**	May 25, 2018
AP			**2GM/VIAL**	**A210046**	**003**	May 25, 2018
AP	**!**	BAXTER HLTHCARE	**500MG/VIAL**	**A040745**	**001**	May 21, 2008
AP	**!**		**1GM/VIAL**	**A040745**	**002**	May 21, 2008
AP	**!**		**2GM/VIAL**	**A040745**	**003**	May 21, 2008
AP		JIANGSU HENGRUI MED	**500MG/VIAL**	**A204555**	**001**	Oct 31, 2014
AP			**1GM/VIAL**	**A204555**	**002**	Oct 31, 2014
AP			**2GM/VIAL**	**A204555**	**003**	Oct 31, 2014

CYCLOSERINE

CAPSULE;ORAL

SEROMYCIN						
	!	PURDUE GMP	250MG	A060593	001	

CYCLOSPORINE

CAPSULE;ORAL

CYCLOSPORINE						
AB1		IVAX SUB TEVA PHARMS	**25MG**	**A065110**	**003**	Mar 29, 2005
AB1			**100MG**	**A065110**	**002**	Mar 29, 2005
AB1		MAYNE PHARMA	**25MG**	**A065044**	**002**	Dec 20, 2000
AB1			**100MG**	**A065044**	**001**	Dec 20, 2000
AB1		SANDOZ	**25MG**	**A065017**	**002**	Jan 13, 2000
AB1			**100MG**	**A065017**	**001**	Jan 13, 2000
GENGRAF						
AB1		ABBVIE	**25MG**	**A065003**	**001**	May 12, 2000
AB1			**100MG**	**A065003**	**003**	May 12, 2000
NEORAL						
AB1	**+**	NOVARTIS	**25MG**	**N050715**	**001**	Jul 14, 1995
AB1	**+!**		**100MG**	**N050715**	**002**	Jul 14, 1995
CYCLOSPORINE						
AB2		APOTEX	**25MG**	**A065040**	**001**	May 09, 2002
AB2			**100MG**	**A065040**	**002**	May 09, 2002
SANDIMMUNE						
AB2	**+**	NOVARTIS	**25MG**	**N050625**	**001**	Mar 02, 1990
AB2	**+!**		**100MG**	**N050625**	**002**	Mar 02, 1990
BX	+		50MG	N050625	003	Nov 23, 1992
CYCLOSPORINE						
		IVAX SUB TEVA PHARMS	50MG	A065110	001	Mar 29, 2005

CYCLOSPORINE							
EMULSION;OPHTHALMIC							
RESTASIS							
	+!	ALLERGAN	0.05%	N050790	001	Dec 23, 2002
RESTASIS MULTIDOSE							
	+!	ALLERGAN	0.05%	N050790	002	Oct 27, 2016
INJECTABLE;INJECTION							
CYCLOSPORINE							
AP		LUITPOLD	**50MG/ML**	**A065151**	**001**	Oct 07, 2003
AP		WEST-WARD PHARMS INT	**50MG/ML**	**A065004**	**001**	Oct 29, 1999
SANDIMMUNE							
AP	**+!**	NOVARTIS	**50MG/ML**	**N050573**	**001**	Nov 14, 1983
SOLUTION;OPHTHALMIC							
CEQUA							
	+!	SUN PHARMA GLOBAL	0.09%	N210913	001	Aug 14, 2018
SOLUTION;ORAL							
CYCLOSPORINE							
AB1		ABBVIE	**100MG/ML**	**A065025**	**001**	Mar 03, 2000
AB1		IVAX SUB TEVA PHARMS	**100MG/ML**	**A065078**	**001**	Mar 25, 2005
AB1		MAYNE PHARMA	**100MG/ML**	**A065054**	**001**	Dec 18, 2001
NEORAL							
AB1	**+!**	NOVARTIS	**100MG/ML**	**N050716**	**001**	Jul 14, 1995
CYCLOSPORINE							
AB2		WOCKHARDT BIO AG	**100MG/ML**	**A065133**	**001**	Sep 17, 2004
SANDIMMUNE							
AB2	**+!**	NOVARTIS	**100MG/ML**	**N050574**	**001**	Nov 14, 1983
CYPROHEPTADINE HYDROCHLORIDE							
SYRUP;ORAL							
CYPROHEPTADINE HYDROCHLORIDE							
AA		BIO-PHARM INC	**2MG/5ML**	**A204823**	**001**	Dec 27, 2016
AA		INVATECH PHARMA	**2MG/5ML**	**A209108**	**001**	Oct 16, 2018
AA		LANNETT CO INC	**2MG/5ML**	**A203191**	**001**	Jul 13, 2017
AA	**!**	LYNE	**2MG/5ML**	**A040668**	**001**	Jun 28, 2006
AA		PHARM ASSOC	**2MG/5ML**	**A091295**	**001**	Mar 28, 2013
TABLET;ORAL							
CYPROHEPTADINE HYDROCHLORIDE							
AA		APEX PHARMS INC	**4MG**	**A207783**	**001**	Dec 29, 2016
AA		APNAR PHARMA LP	**4MG**	**A207555**	**001**	Jan 31, 2017
AA		BOSCOGEN	**4MG**	**A040644**	**001**	May 30, 2006
AA	**!**	IVAX SUB TEVA PHARMS	**4MG**	**A087056**	**001**	
AA		MOUNTAIN	**4MG**	**A040537**	**001**	Sep 30, 2003
AA		NOVAST LABS	**4MG**	**A205087**	**001**	Sep 23, 2015
AA		PAR PHARM	**4MG**	**A087129**	**001**	
AA		STRIDES PHARMA	**4MG**	**A209172**	**001**	Apr 11, 2018
AA		TWI PHARMS	**4MG**	**A206553**	**001**	Nov 29, 2016
AA		ZYDUS PHARMS USA INC	**4MG**	**A208938**	**001**	May 19, 2017
CYSTEAMINE BITARTRATE							
CAPSULE;ORAL							
CYSTAGON							
	+	MYLAN	EQ 50MG BASE	N020392	001	Aug 15, 1994
	+!		EQ 150MG BASE	N020392	002	Aug 15, 1994
CAPSULE, DELAYED RELEASE;ORAL							
PROCYSBI							
	+	HORIZON PHARMA USA	EQ 25MG BASE	N203389	001	Apr 30, 2013
	+!		EQ 75MG BASE	N203389	002	Apr 30, 2013
CYSTEAMINE HYDROCHLORIDE							
SOLUTION/DROPS;OPHTHALMIC							
CYSTARAN							
	+!	LEADIANT BIOSCI INC	EQ 0.44% BASE	N200740	001	Oct 02, 2012
CYTARABINE							
INJECTABLE;INJECTION							
CYTARABINE							
AP	**!**	FRESENIUS KABI USA	**100MG/ML**	**A076512**	**001**	Jan 15, 2004
AP		HONG KONG	**20MG/ML**	**A206190**	**001**	Nov 09, 2017
AP			**100MG/ML**	**A205696**	**001**	Jul 17, 2018
AP	**!**	HOSPIRA	**20MG/ML**	**A071868**	**001**	Jun 04, 1990
AP	**!**		**20MG/ML**	**A072168**	**001**	Aug 31, 1990

CYTARABINE

INJECTABLE;INJECTION

CYTARABINE

AP	**!**		**20MG/ML**	**A072945**	**001**	Feb 28, 1994
AP			**100MG/ML**	**A075383**	**001**	Nov 22, 1999
AP		MYLAN LABS LTD	**20MG/ML**	**A200914**	**001**	Dec 13, 2011
AP			**20MG/ML**	**A200915**	**001**	Dec 13, 2011
AP			**20MG/ML**	**A200916**	**001**	Dec 13, 2011
AP			**100MG/ML**	**A201784**	**001**	Jan 30, 2012
		WEST-WARD PHARMS INT	100MG/VIAL	A071471	001	Aug 02, 1989
	!		500MG/VIAL	A071472	001	Aug 02, 1989
	!		1GM/VIAL	A074245	001	Aug 31, 1994
	!		2GM/VIAL	A074245	002	Aug 31, 1994

CYTARABINE; DAUNORUBICIN

POWDER;INTRAVENOUS

VYXEOS

+!	CELATOR PHARMS	100MG;44MG	N209401	001	Aug 03, 2017

DABIGATRAN ETEXILATE MESYLATE

CAPSULE;ORAL

PRADAXA

+	BOEHRINGER INGELHEIM	EQ 75MG BASE	N022512	001	Oct 19, 2010
+		EQ 110MG BASE	N022512	003	Nov 20, 2015
+!		EQ 150MG BASE	N022512	002	Oct 19, 2010

DABRAFENIB MESYLATE

CAPSULE;ORAL

TAFINLAR

+	NOVARTIS PHARMS CORP	EQ 50MG BASE	N202806	001	May 29, 2013
+!		EQ 75MG BASE	N202806	002	May 29, 2013

DACARBAZINE

INJECTABLE;INJECTION

DACARBAZINE

AP	**!**	FRESENIUS KABI USA	**200MG/VIAL**	**A075371**	**002**	Aug 27, 1999
AP		HOSPIRA	**200MG/VIAL**	**A075940**	**001**	Oct 18, 2001
AP		TEVA PHARMS USA	**200MG/VIAL**	**A075259**	**002**	Aug 27, 1998
AP	**!**		**500MG/VIAL**	**A075259**	**001**	Sep 22, 2000
AP		WEST-WARD PHARMS INT	**200MG/VIAL**	**A075812**	**001**	Jun 15, 2001
AP			**500MG/VIAL**	**A075812**	**002**	Oct 31, 2002
	!	FRESENIUS KABI USA	100MG/VIAL	A075371	001	Aug 27, 1999

DACLATASVIR DIHYDROCHLORIDE

TABLET;ORAL

DAKLINZA

+	BRISTOL-MYERS SQUIBB	EQ 30MG BASE	N206843	001	Jul 24, 2015
+		EQ 60MG BASE	N206843	002	Jul 24, 2015
+!		EQ 90MG BASE	N206843	003	Apr 13, 2016

DACOMITINIB

TABLET;ORAL

VIZIMPRO

+	PFIZER INC	15MG	N211288	001	Sep 27, 2018
+		30MG	N211288	002	Sep 27, 2018
+!		45MG	N211288	003	Sep 27, 2018

DACTINOMYCIN

INJECTABLE;INJECTION

COSMEGEN

AP	**+!**	RECORDATI RARE	**0.5MG/VIAL**	**N050682**	**001**	

DACTINOMYCIN

AP		LUITPOLD	**0.5MG/VIAL**	**A202562**	**001**	Aug 23, 2013
AP		MYLAN LABS LTD	**0.5MG/VIAL**	**A203385**	**001**	Nov 09, 2017

DALBAVANCIN HYDROCHLORIDE

POWDER;INTRAVENOUS

DALVANCE

+!	ALLERGAN SALES LLC	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014

DALFAMPRIDINE

TABLET, EXTENDED RELEASE;ORAL

AMPYRA						
AB	**+!**	ACORDA	**10MG**	**N022250**	**001**	Jan 22, 2010
DALFAMPRIDINE						
AB		ACCORD HLTHCARE	**10MG**	**A206863**	**001**	Jul 11, 2018
AB		ACTAVIS LABS FL INC	**10MG**	**A206836**	**001**	Jan 23, 2017
AB		ALKEM LABS LTD	**10MG**	**A206765**	**001**	Jul 30, 2018
AB		AUROBINDO PHARMA LTD	**10MG**	**A206811**	**001**	Jan 23, 2017
AB		WEST-WARD PHARMS INT	**10MG**	**A206646**	**001**	Oct 24, 2018

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE;INTRAVENOUS

SYNERCID					
	+!	KING PHARMS	350MG/VIAL;150MG/VIAL	N050748	001 Sep 21, 1999

DALTEPARIN SODIUM

INJECTABLE;SUBCUTANEOUS

FRAGMIN					
	+	PFIZER INC	2,500IU/0.2ML (12,500IU/ML)	N020287	001 Dec 22, 1994
	+		5,000IU/0.2ML (25,000IU/ML)	N020287	003 Mar 18, 1996
	+		7,500IU/0.3ML (25,000IU/ML)	N020287	005 Apr 04, 2002
	+		10,000IU/ML (10,000IU/ML)	N020287	004 Jan 30, 1998
	+		12,500IU/0.5ML (25,000IU/ML)	N020287	009 May 01, 2007
	+		15,000IU/0.6ML (25,000IU/ML)	N020287	010 May 01, 2007
	+		18,000IU/0.72ML (25,000IU/ML)	N020287	011 May 01, 2007
	+!		95,000IU/3.8ML (25,000IU/ML)	N020287	006 Apr 04, 2002

DANAZOL

CAPSULE;ORAL

DANAZOL						
AB		BARR	**50MG**	**A074582**	**003**	May 29, 1998
AB			**100MG**	**A074582**	**002**	May 29, 1998
AB	**!**		**200MG**	**A074582**	**001**	Aug 09, 1996
AB		LANNETT CO INC	**50MG**	**A077246**	**002**	Apr 19, 2007
AB			**100MG**	**A077246**	**003**	Apr 19, 2007
AB			**200MG**	**A077246**	**001**	Sep 28, 2005

DANTROLENE SODIUM

CAPSULE;ORAL

DANTRIUM						
AB	**+**	PAR STERILE PRODUCTS	**25MG**	**N017443**	**001**	
AB	**+**		**50MG**	**N017443**	**003**	
AB	**+!**		**100MG**	**N017443**	**002**	
DANTROLENE SODIUM						
AB		ELITE LABS INC	**25MG**	**A076686**	**001**	Oct 24, 2005
AB			**50MG**	**A076686**	**002**	Oct 24, 2005
AB			**100MG**	**A076686**	**003**	Oct 24, 2005
AB		IMPAX LABS	**25MG**	**A076856**	**001**	Mar 01, 2005
AB			**50MG**	**A076856**	**002**	Mar 01, 2005
AB			**100MG**	**A076856**	**003**	Mar 01, 2005

FOR SUSPENSION;INTRAVENOUS

RYANODEX					
	+!	EAGLE PHARMS	250MG/VIAL	N205579	001 Jul 22, 2014

INJECTABLE;INJECTION

DANTRIUM						
AP	**+!**	PAR STERILE PRODUCTS	**20MG/VIAL**	**N018264**	**001**	
DANTROLENE SODIUM						
AP		HIKMA PHARMS	**20MG/VIAL**	**A204762**	**001**	Jun 19, 2017
AP		MYLAN INSTITUTIONAL	**20MG/VIAL**	**A205239**	**001**	Feb 18, 2016
REVONTO						
AP		US WORLDMEDS	**20MG/VIAL**	**A078378**	**001**	Jul 24, 2007

DAPAGLIFLOZIN

TABLET;ORAL

FARXIGA					
	+	ASTRAZENECA AB	5MG	N202293	001 Jan 08, 2014
	+!		10MG	N202293	002 Jan 08, 2014

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

XIGDUO XR

+	ASTRAZENECA AB	2.5MG;1GM	N205649	005	Jul 28, 2017
+		5MG;500MG	N205649	001	Oct 29, 2014
+		5MG;1GM	N205649	002	Oct 29, 2014
+		10MG;500MG	N205649	003	Oct 29, 2014
+!		10MG;1GM	N205649	004	Oct 29, 2014

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL

QTERN

+!	ASTRAZENECA AB	10MG;EQ 5MG BASE	N209091	001	Feb 27, 2017

DAPSONE

GEL;TOPICAL

ACZONE

AB	**+!**	ALLERGAN	**5%**	**N021794**	**001**	Jul 07, 2005

DAPSONE

AB		TARO	**5%**	**A209506**	**001**	Oct 16, 2017

ACZONE

+!	AQUA PHARMS LLC	7.5%	N207154	001	Feb 24, 2016

TABLET;ORAL

DAPSONE

AB		ACTAVIS LLC	**25MG**	**A204380**	**001**	Mar 23, 2017
AB			**100MG**	**A204380**	**002**	Mar 23, 2017
AB		ALVOGEN	**25MG**	**A205429**	**001**	Jan 07, 2016
AB			**100MG**	**A205429**	**002**	Jan 07, 2016
AB		JACOBUS	**25MG**	**A086841**	**001**	
AB	**!**		**100MG**	**A086842**	**001**	
AB		NOSTRUM LABS INC	**25MG**	**A203887**	**001**	May 06, 2016
AB			**100MG**	**A203887**	**002**	May 06, 2016
AB		NOVITIUM PHARMA	**25MG**	**A206505**	**001**	Dec 01, 2016
AB			**100MG**	**A206505**	**002**	Dec 01, 2016
AB		VIRTUS PHARMS	**25MG**	**A204074**	**001**	May 10, 2016
AB			**100MG**	**A204074**	**002**	May 10, 2016

DAPTOMYCIN

POWDER;INTRAVENOUS

CUBICIN

AP	**+!**	CUBIST PHARMS LLC	**500MG/VIAL**	**N021572**	**002**	Sep 12, 2003

DAPTOMYCIN

AP		CRANE PHARMS LLC	**500MG/VIAL**	**A206005**	**001**	Jun 15, 2016
AP		FRESENIUS KABI USA	**500MG/VIAL**	**A206077**	**001**	Apr 11, 2018
AP		HOSPIRA INC	**500MG/VIAL**	**A202857**	**001**	Sep 12, 2014
AP		MYLAN LABS LTD	**500MG/VIAL**	**A205037**	**001**	Jun 05, 2018
AP		TEVA PHARMS USA	**500MG/VIAL**	**A091039**	**001**	Mar 25, 2016

CUBICIN RF

+!	CUBIST PHARMS LLC	500MG/VIAL	N021572	003	Jul 06, 2016

POWDER;IV (INFUSION)

DAPTOMYCIN

+!	SAGENT PHARMS	350MG/VIAL	N208385	001	Sep 12, 2017
+!	XELLIA PHARMS APS	350MG/VIAL	N209949	001	Oct 20, 2017

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

DARIFENACIN

AB		MACLEODS PHARMS LTD	**EQ 7.5MG BASE**	**A207302**	**001**	Jul 28, 2017
AB			**EQ 15MG BASE**	**A207302**	**002**	Jul 28, 2017

DARIFENACIN HYDROBROMIDE

AB		ALEMBIC PHARMS LTD	**EQ 7.5MG BASE**	**A207681**	**001**	Dec 08, 2017
AB			**EQ 15MG BASE**	**A207681**	**002**	Dec 08, 2017
AB		ANCHEN PHARMS	**EQ 7.5MG BASE**	**A091190**	**001**	Mar 13, 2015
AB			**EQ 15MG BASE**	**A091190**	**002**	Mar 13, 2015
AB		AUROBINDO PHARMA LTD	**EQ 7.5MG BASE**	**A206743**	**001**	Sep 19, 2016
AB			**EQ 15MG BASE**	**A206743**	**002**	Sep 19, 2016
AB		CIPLA	**EQ 7.5MG BASE**	**A207664**	**001**	Sep 01, 2016
AB			**EQ 15MG BASE**	**A207664**	**002**	Sep 01, 2016
AB		JUBILANT GENERICS	**EQ 7.5MG BASE**	**A205550**	**001**	Oct 12, 2016
AB			**EQ 15MG BASE**	**A205550**	**002**	Oct 12, 2016
AB		TORRENT PHARMS LTD	**EQ 7.5MG BASE**	**A205209**	**001**	Nov 17, 2016
AB			**EQ 15MG BASE**	**A205209**	**002**	Nov 17, 2016

DARIFENACIN HYDROBROMIDE						
TABLET, EXTENDED RELEASE;ORAL						
ENABLEX						
AB	**+**	APIL	**EQ 7.5MG BASE**	**N021513**	**001**	Dec 22, 2004
AB	**+!**		**EQ 15MG BASE**	**N021513**	**002**	Dec 22, 2004
DARUNAVIR ETHANOLATE						
SUSPENSION;ORAL						
PREZISTA						
	+!	JANSSEN PRODS	EQ 100MG BASE/ML	N202895	001	Dec 16, 2011
TABLET;ORAL						
DARUNAVIR ETHANOLATE						
AB		TEVA PHARMS USA	**EQ 600MG BASE**	**A202118**	**001**	Nov 21, 2017
PREZISTA						
AB	**+**	JANSSEN PRODS	**EQ 600MG BASE**	**N021976**	**002**	Feb 25, 2008
	+		EQ 75MG BASE	N021976	004	Dec 18, 2008
	+		EQ 150MG BASE	N021976	005	Dec 18, 2008
	+!		EQ 800MG BASE	N021976	006	Nov 09, 2012
DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR						
TABLET, TABLET;ORAL						
VIEKIRA PAK (COPACKAGED)						
	+!	ABBVIE INC	EQ 250MG BASE,N/A,N/A,N/A; N/A,12.5MG,75MG,50MG	N206619	001	Dec 19, 2014
DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR						
TABLET, EXTENDED RELEASE;ORAL						
VIEKIRA XR						
	+!	ABBVIE INC	EQ 200MG BASE;8.33MG;50MG;33.33MG	N208624	001	Jul 22, 2016
DASATINIB						
TABLET;ORAL						
SPRYCEL						
	+	BRISTOL MYERS SQUIBB	20MG	N021986	001	Jun 28, 2006
	+		50MG	N021986	002	Jun 28, 2006
	+		70MG	N021986	003	Jun 28, 2006
	+		80MG	N021986	005	Oct 28, 2010
	+!		100MG	N021986	004	May 30, 2008
	+		140MG	N021986	006	Oct 28, 2010
DAUNORUBICIN HYDROCHLORIDE						
INJECTABLE;INJECTION						
CERUBIDINE						
AP	**!**	WEST-WARD PHARMS INT	**EQ 20MG BASE/VIAL**	**A064103**	**001**	Feb 03, 1995
DAUNORUBICIN HYDROCHLORIDE						
AP		FRESENIUS KABI USA	**EQ 20MG BASE/VIAL**	**A065000**	**001**	May 25, 1999
AP		TEVA PHARMS USA	**EQ 5MG BASE/ML**	**A065035**	**001**	Jan 24, 2000
AP	**+!**	WEST-WARD PHARMS INT	**EQ 5MG BASE/ML**	**N050731**	**001**	Jan 30, 1998
		FRESENIUS KABI USA	EQ 5MG BASE/VIAL	A065034	001	Nov 20, 2001
DECITABINE						
INJECTABLE;INTRAVENOUS						
DACOGEN						
AP	**+!**	OTSUKA PHARM CO LTD	**50MG/VIAL**	**N021790**	**001**	May 02, 2006
DECITABINE						
AP		ACCORD HLTHCARE	**50MG/VIAL**	**A203475**	**001**	Feb 27, 2017
AP		CHEMI SPA	**50MG/VIAL**	**A206033**	**001**	Sep 22, 2017
AP		CIPLA	**50MG/VIAL**	**A208601**	**001**	Nov 16, 2017
AP		DR REDDYS LABS LTD	**50MG/VIAL**	**A203131**	**001**	Jul 11, 2013
AP		LUPIN LTD	**50MG/VIAL**	**A210756**	**001**	Nov 09, 2018
AP		PHARMASCIENCE INC	**50MG/VIAL**	**A204607**	**001**	May 31, 2017
AP		SAGENT PHARMS	**50MG/VIAL**	**A207100**	**001**	Mar 16, 2018
AP		SANDOZ INC	**50MG/VIAL**	**A202969**	**001**	Aug 28, 2014
POWDER;INTRAVENOUS						
DECITABINE						
	+!	SUN PHARMA GLOBAL	50MG/VIAL	N205582	001	Jan 28, 2014
DEFERASIROX						
GRANULE;ORAL						
JADENU SPRINKLE						
	+	NOVARTIS PHARMS CORP	90MG	N207968	001	May 18, 2017
	+		180MG	N207968	002	May 18, 2017
	+!		360MG	N207968	003	May 18, 2017

DEFERASIROX						
TABLET;ORAL						
JADENU						
	+	NOVARTIS PHARMS CORP	90MG	N206910	001	Mar 30, 2015
	+		180MG	N206910	002	Mar 30, 2015
	+!		360MG	N206910	003	Mar 30, 2015
TABLET, FOR SUSPENSION;ORAL						
DEFERASIROX						
AB		ACTAVIS ELIZABETH	**125MG**	**A203560**	**001**	Jan 26, 2016
AB			**250MG**	**A203560**	**002**	Jan 26, 2016
AB			**500MG**	**A203560**	**003**	Jan 26, 2016
EXJADE						
AB	**+**	NOVARTIS	**125MG**	**N021882**	**001**	Nov 02, 2005
AB	**+**		**250MG**	**N021882**	**002**	Nov 02, 2005
AB	**+!**		**500MG**	**N021882**	**003**	Nov 02, 2005
DEFERIPRONE						
SOLUTION;ORAL						
FERRIPROX						
	+	APOPHARMA INC	80MG/ML	N208030	002	Apr 20, 2018
	+!		100MG/ML	N208030	001	Sep 09, 2015
TABLET;ORAL						
FERRIPROX						
	+!	APOPHARMA INC	500MG	N021825	001	Oct 14, 2011
DEFEROXAMINE MESYLATE						
INJECTABLE;INJECTION						
DEFEROXAMINE MESYLATE						
AP		FRESENIUS KABI USA	**500MG/VIAL**	**A078718**	**001**	Sep 15, 2009
AP			**2GM/VIAL**	**A078718**	**002**	Sep 15, 2009
AP		GLAND PHARMA LTD	**500MG/VIAL**	**A207384**	**001**	Sep 29, 2017
AP			**2GM/VIAL**	**A207384**	**002**	Sep 29, 2017
AP		HOSPIRA	**500MG/VIAL**	**A076019**	**001**	Mar 17, 2004
AP			**2GM/VIAL**	**A076019**	**002**	Mar 17, 2004
AP		WEST-WARD PHARMS INT	**500MG/VIAL**	**A078086**	**001**	May 30, 2007
AP			**2GM/VIAL**	**A078086**	**002**	May 30, 2007
DESFERAL						
AP	**+!**	NOVARTIS	**500MG/VIAL**	**N016267**	**001**	
AP	**+!**		**2GM/VIAL**	**N016267**	**002**	May 25, 2000
DEFIBROTIDE SODIUM						
SOLUTION;INTRAVENOUS						
DEFITELIO						
	+!	JAZZ PHARMS INC	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016
DEFLAZACORT						
SUSPENSION;ORAL						
EMFLAZA						
	+!	PTC THERAP	22.75MG/ML	N208685	001	Feb 09, 2017
TABLET;ORAL						
EMFLAZA						
	+	PTC THERAP	6MG	N208684	001	Feb 09, 2017
	+		18MG	N208684	002	Feb 09, 2017
	+		30MG	N208684	003	Feb 09, 2017
	+!		36MG	N208684	004	Feb 09, 2017
DEGARELIX ACETATE						
POWDER;SUBCUTANEOUS						
FIRMAGON						
	+	FERRING	EQ 80MG BASE/VIAL	N022201	001	Dec 24, 2008
	+!		EQ 120MG BASE/VIAL	N022201	002	Dec 24, 2008
DELAFLOXACIN MEGLUMINE						
POWDER;INTRAVENOUS						
BAXDELA						
	+!	MELINTA	EQ 300MG BASE/VIAL	N208611	001	Jun 19, 2017
TABLET;ORAL						
BAXDELA						
	+!	MELINTA	EQ 450MG BASE	N208610	001	Jun 19, 2017

DELAVIRDINE MESYLATE

TABLET;ORAL

RESCRIPTOR

+	VIIV HLTHCARE	100MG	N020705	001	Apr 04, 1997
+!		200MG	N020705	002	Jul 14, 1999

DEMECLOCYCLINE HYDROCHLORIDE

TABLET;ORAL

DEMECLOCYCLINE HYDROCHLORIDE

AB	AKORN	**150MG**	**A065389**	**001**	Dec 01, 2008
AB		**300MG**	**A065389**	**002**	Dec 01, 2008
AB	AMNEAL PHARM	**150MG**	**A065425**	**001**	Feb 27, 2008
AB **!**		**300MG**	**A065425**	**002**	Feb 27, 2008
AB	BARR	**150MG**	**A065171**	**001**	Dec 13, 2004
AB		**300MG**	**A065171**	**002**	Dec 13, 2004
AB	EPIC PHARMA LLC	**150MG**	**A065447**	**001**	Aug 18, 2015
AB		**300MG**	**A065447**	**002**	Aug 18, 2015

DEOXYCHOLIC ACID

SOLUTION;SUBCUTANEOUS

KYBELLA

+!	KYTHERA BIOPHARMS	20MG/2ML (10MG/ML)	N206333	001	Apr 29, 2015

DESFLURANE

LIQUID;INHALATION

DESFLURANE

AN	SHANGHAI HENGRUI	**100%**	**A208234**	**001**	Feb 26, 2018

SUPRANE

AN **+!**	BAXTER HLTHCARE	**100%**	**N020118**	**001**	Sep 18, 1992

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

AB	ACTAVIS TOTOWA	**10MG**	**A074430**	**001**	Feb 09, 1996
AB		**25MG**	**A071601**	**001**	Jun 05, 1987
AB		**50MG**	**A071588**	**001**	Jun 05, 1987
AB		**75MG**	**A071602**	**001**	Oct 05, 1987
AB		**100MG**	**A071766**	**001**	Oct 05, 1987
AB		**150MG**	**A074430**	**002**	Feb 09, 1996
AB	AMNEAL PHARMS CO	**10MG**	**A208105**	**001**	Mar 17, 2016
AB		**25MG**	**A208105**	**002**	Mar 17, 2016
AB		**50MG**	**A208105**	**003**	Mar 17, 2016
AB		**75MG**	**A208105**	**004**	Mar 17, 2016
AB		**100MG**	**A208105**	**005**	Mar 17, 2016
AB		**150MG**	**A208105**	**006**	Mar 17, 2016
AB	ANI PHARMS INC	**10MG**	**A205153**	**001**	Oct 28, 2016
AB		**25MG**	**A205153**	**002**	Oct 28, 2016
AB		**50MG**	**A205153**	**003**	Oct 28, 2016
AB		**75MG**	**A205153**	**004**	Oct 28, 2016
AB		**100MG**	**A205153**	**005**	Oct 28, 2016
AB		**150MG**	**A205153**	**006**	Oct 28, 2016
AB	HERITAGE PHARMS INC	**10MG**	**A207433**	**001**	May 05, 2016
AB		**25MG**	**A207433**	**002**	May 05, 2016
AB		**50MG**	**A207433**	**003**	May 05, 2016
AB		**75MG**	**A207433**	**004**	May 05, 2016
AB		**100MG**	**A207433**	**005**	May 05, 2016
AB		**150MG**	**A207433**	**006**	May 05, 2016
AB	INGENUS PHARMS LLC	**10MG**	**A204963**	**001**	Dec 26, 2017
AB		**25MG**	**A204963**	**002**	Dec 26, 2017
AB		**50MG**	**A204963**	**003**	Dec 26, 2017
AB		**75MG**	**A204963**	**004**	Dec 26, 2017
AB		**100MG**	**A204963**	**005**	Dec 26, 2017
AB		**150MG**	**A204963**	**006**	Dec 26, 2017
AB	SANDOZ	**10MG**	**A072099**	**001**	May 24, 1988
AB		**25MG**	**A072100**	**001**	May 24, 1988
AB		**50MG**	**A072101**	**001**	May 24, 1988
AB		**75MG**	**A072102**	**001**	Jun 20, 1988
AB		**100MG**	**A072103**	**001**	Jun 20, 1988
AB		**150MG**	**A072104**	**001**	Jun 20, 1988

NORPRAMIN

AB **+**	US PHARM HOLDINGS	**10MG**	**N014399**	**007**	Feb 11, 1982
AB **+**		**25MG**	**N014399**	**001**	
AB **+**		**50MG**	**N014399**	**003**	
AB **+**		**75MG**	**N014399**	**004**	

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

NORPRAMIN

AB	**+!**		**100MG**	**N014399**	**005**	
AB	**+**		**150MG**	**N014399**	**006**	

DESLORATADINE

SOLUTION;ORAL

CLARINEX

AA	**+!**	MERCK SHARP DOHME	**0.5MG/ML**	**N021300**	**001**	Sep 01, 2004

DESLORATADINE

AA		TARO PHARM	**0.5MG/ML**	**A202936**	**001**	May 26, 2016
AA		TARO PHARM INDS LTD	**0.5MG/ML**	**A202592**	**001**	Jun 30, 2015

TABLET;ORAL

CLARINEX

AB	**+!**	MERCK SHARP DOHME	**5MG**	**N021165**	**001**	Dec 21, 2001

DESLORATADINE

AB		BELCHER PHARMS	**5MG**	**A078355**	**001**	Apr 19, 2012
AB		DR REDDYS LABS LTD	**5MG**	**A078365**	**001**	Mar 08, 2011
AB		LUPIN PHARMS	**5MG**	**A078352**	**001**	Oct 25, 2010
AB		MYLAN PHARMS INC	**5MG**	**A078351**	**001**	Feb 10, 2012
AB		ORCHID HLTHCARE	**5MG**	**A078357**	**001**	Feb 19, 2010
AB		PERRIGO R AND D	**5MG**	**A078361**	**001**	Dec 22, 2011
AB		SANDOZ	**5MG**	**A078364**	**001**	Dec 03, 2010
AB		SUN PHARM INDS	**5MG**	**A078359**	**001**	Nov 16, 2010

TABLET, ORALLY DISINTEGRATING;ORAL

CLARINEX

AB	**+**	MERCK SHARP DOHME	**2.5MG**	**N021312**	**002**	Jul 14, 2005
AB	**+!**		**5MG**	**N021312**	**001**	Jun 26, 2002

DESLORATADINE

AB		REDDYS	**2.5MG**	**A078367**	**001**	Jul 12, 2010
AB			**5MG**	**A078367**	**002**	Jul 12, 2010

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CLARINEX D 24 HOUR

AB	**+!**	MERCK SHARP DOHME	**5MG;240MG**	**N021605**	**001**	Mar 03, 2005

DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR

AB		DR REDDYS LABS LTD	**5MG;240MG**	**A078366**	**001**	Apr 26, 2011

CLARINEX-D 12 HOUR

	+!	MERCK SHARP DOHME	2.5MG;120MG	N021313	001	Feb 01, 2006

DESMOPRESSIN ACETATE

INJECTABLE;INJECTION

DDAVP

AP	**+!**	FERRING PHARMS INC	**0.004MG/ML**	**N018938**	**001**	Mar 30, 1984

DESMOPRESSIN ACETATE

AP		SAGENT PHARMS	**0.004MG/ML**	**A204695**	**001**	Aug 22, 2017
AP			**0.004MG/ML**	**A204751**	**001**	Aug 22, 2017
AP		SUN PHARM INDS LTD	**0.004MG/ML**	**A091280**	**001**	Jan 25, 2013

SOLUTION;NASAL

DDAVP

AB	**+!**	FERRING PHARMS INC	**0.01%**	**N017922**	**001**	

DESMOPRESSIN ACETATE

AB		SUN PHARM INDS	**0.01%**	**A077212**	**001**	Apr 12, 2012

SPRAY, METERED;NASAL

DDAVP (NEEDS NO REFRIGERATION)

AB	**+!**	FERRING PHARMS INC	**0.01MG/SPRAY**	**N017922**	**003**	Aug 07, 1996

DESMOPRESSIN ACETATE

AB	**!**	BAUSCH AND LOMB	**0.01MG/SPRAY**	**A074830**	**001**	Jan 25, 1999

DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)

AB		APOTEX INC	**0.01MG/SPRAY**	**A076703**	**001**	Jan 27, 2005
AB		SUN PHARMA GLOBAL	**0.01MG/SPRAY**	**A078271**	**001**	Dec 23, 2013
AB		ZYDUS PHARMS USA INC	**0.01MG/SPRAY**	**A091345**	**001**	Oct 03, 2017

MINIRIN

AB	**+!**	FERRING	**0.01MG/SPRAY**	**N021333**	**001**	Sep 16, 2002

NOCTIVA

	+	AVADEL SPECLT	0.00083MG/SPRAY	N201656	001	Mar 03, 2017
	+!		0.00166MG/SPRAY	N201656	002	Mar 03, 2017

STIMATE (NEEDS NO REFRIGERATION)

	+!	FERRING PHARMS INC	0.15MG/SPRAY	N020355	002	Oct 24, 2007

DESMOPRESSIN ACETATE

TABLET;ORAL

DDAVP

AB	**+**	FERRING PHARMS INC	**0.1MG**	**N019955**	**001**	Sep 06, 1995
AB	**+!**		**0.2MG**	**N019955**	**002**	Sep 06, 1995

DESMOPRESSIN ACETATE

AB		ACTAVIS LABS FL INC	**0.1MG**	**A076470**	**001**	Jul 01, 2005
AB			**0.2MG**	**A076470**	**002**	Jul 01, 2005
AB		APOTEX INC	**0.1MG**	**A077414**	**001**	Mar 07, 2006
AB			**0.2MG**	**A077414**	**002**	Mar 07, 2006
AB		GLENMARK PHARMS LTD	**0.1MG**	**A201831**	**001**	May 28, 2015
AB			**0.2MG**	**A201831**	**002**	May 28, 2015
AB		HERITAGE PHARMA	**0.1MG**	**A207880**	**001**	May 26, 2017
AB			**0.2MG**	**A207880**	**002**	May 26, 2017
AB		IMPAX LABS INC	**0.1MG**	**A077122**	**001**	Jan 25, 2006
AB			**0.2MG**	**A077122**	**002**	Jan 25, 2006
AB		MYLAN PHARMS INC	**0.1MG**	**A200653**	**001**	Jun 27, 2014
AB			**0.2MG**	**A200653**	**002**	Jun 27, 2014

TABLET;SUBLINGUAL

NOCDURNA

	+	FERRING PHARMS INC	0.0277MG	N022517	001	Jun 21, 2018
	+!		0.0553MG	N022517	002	Jun 21, 2018

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

BEKYREE

AB		LUPIN LTD	**0.15MG,N/A;0.02MG,0.01MG**	**A202226**	**001**	Aug 12, 2015

CYCLESSA

AB	**+!**	ASPEN GLOBAL INC	**0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG**	**N021090**	**001**	Dec 20, 2000

DESOGEN

AB		ORGANON USA INC	**0.15MG;0.03MG**	**N020071**	**002**	Dec 10, 1992

DESOGESTREL AND ETHINYL ESTRADIOL

AB		ACCORD HLTHCARE	**0.15MG,N/A;0.02MG,0.01MG**	**A209170**	**001**	Jun 05, 2017
AB			**0.15MG;0.03MG**	**A207067**	**001**	Sep 13, 2018
AB		AUROBINDO PHARMA LTD	**0.15MG,N/A;0.02MG,0.01MG**	**A206853**	**001**	Mar 22, 2017
AB	**!**	DURAMED PHARMS BARR	**0.15MG;0.03MG**	**A075256**	**002**	Aug 12, 1999
AB		MAYNE PHARMA	**0.15MG,N/A;0.02MG,0.01MG**	**A076916**	**001**	Dec 29, 2008
AB			**0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG**	**A077182**	**001**	Jan 24, 2006
AB		MYLAN LABS LTD	**0.15MG,N/A;0.02MG,0.01MG**	**A202296**	**001**	Aug 30, 2013
AB			**0.15MG;0.03MG**	**A202085**	**001**	May 20, 2015
AB		NOVAST LABS	**0.15MG;0.03MG**	**A091234**	**001**	Jul 12, 2013
AB		WATSON LABS	**0.15MG;0.03MG**	**A076915**	**001**	Jul 29, 2005

EMOQUETTE

AB		VINTAGE PHARMS LLC	**0.15MG;0.03MG**	**A076675**	**001**	Feb 25, 2011

ENSKYCE

AB		LUPIN LTD	**0.15MG;0.03MG**	**A201887**	**001**	Mar 07, 2013

ISIBLOOM

AB		LABS LEON FARMA	**0.15MG;0.03MG**	**A202789**	**001**	Aug 12, 2015

KALLIGA

AB		AUROBINDO PHARMA LTD	**0.15MG;0.03MG**	**A207081**	**001**	May 17, 2017

KARIVA

AB	**!**	BARR	**0.15MG,N/A;0.02MG,0.01MG**	**A075863**	**001**	Apr 05, 2002

KIMIDESS

AB		VINTAGE PHARMS	**0.15MG,N/A;0.02MG,0.01MG**	**A076681**	**001**	Apr 30, 2015

PIMTREA

AB		NOVAST LABS	**0.15MG,N/A;0.02MG,0.01MG**	**A091247**	**001**	Aug 01, 2013

VELIVET

AB		DURAMED PHARMS BARR	**0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG**	**A076455**	**001**	Feb 24, 2004

VIORELE

AB		GLENMARK GENERICS	**0.15MG,N/A;0.02MG,0.01MG**	**A091346**	**001**	Apr 02, 2012

VOLNEA

AB		LABS LEON FARMA	**0.15MG,N/A;0.02MG,0.01MG**	**A202689**	**001**	Sep 09, 2016

DESONIDE

AEROSOL, FOAM;TOPICAL

VERDESO

	+!	AQUA PHARMS	0.05%	N021978	001	Sep 19, 2006

CREAM;TOPICAL

DESONIDE

AB		G AND W LABS INC	**0.05%**	**A074027**	**001**	Sep 28, 1992
AB		GLENMARK PHARMS	**0.05%**	**A209729**	**001**	Jul 24, 2017
AB	**+!**	PERRIGO NEW YORK	**0.05%**	**N017010**	**001**	
AB		TARO	**0.05%**	**A073548**	**001**	Jun 30, 1992

DESOWEN

AB		GALDERMA LABS LP	**0.05%**	**N019048**	**001**	Dec 14, 1984

GEL;TOPICAL

DESONATE

	+!	LEO PHARMA AS	0.05%	N021844	001	Oct 20, 2006

LOTION;TOPICAL

DESONIDE

AB		FOUGERA PHARMS	**0.05%**	**A075860**	**001**	Mar 19, 2002
AB		GLENMARK PHARMS	**0.05%**	**A209494**	**001**	Sep 26, 2017
AB		TARO PHARM	**0.05%**	**A202161**	**001**	Oct 31, 2014
AB		TELIGENT PHARMA INC	**0.05%**	**A207855**	**001**	Sep 28, 2017

DESOWEN

AB	**!**	GALDERMA LABS LP	**0.05%**	**A072354**	**001**	Jan 24, 1992

OINTMENT;TOPICAL

DESONIDE

AB		FOUGERA PHARMS	**0.05%**	**A075751**	**001**	Mar 12, 2001
AB		GLENMARK PHARMS LTD	**0.05%**	**A209996**	**001**	Sep 15, 2017
AB		HI-TECH PHARMACAL	**0.05%**	**A208836**	**001**	Mar 27, 2017
AB	**+!**	PERRIGO NEW YORK	**0.05%**	**N017426**	**001**	
AB		TARO	**0.05%**	**A074254**	**001**	Aug 03, 1994

DESOWEN

AB		GALDERMA LABS LP	**0.05%**	**A071425**	**001**	Jun 15, 1988

DESOXIMETASONE

CREAM;TOPICAL

DESOXIMETASONE

AB		ACTAVIS MID ATLANTIC	**0.25%**	**A205082**	**001**	Sep 04, 2015
AB		AKORN	**0.05%**	**A203787**	**001**	Jan 06, 2017
AB			**0.25%**	**A203234**	**001**	Jun 12, 2015
AB		FOUGERA PHARMS	**0.25%**	**A078369**	**001**	Jun 29, 2010
AB		LUPIN ATLANTIS	**0.05%**	**A208163**	**001**	Jan 10, 2017
AB			**0.25%**	**A208164**	**001**	Jan 09, 2017
AB		PERRIGO NEW YORK	**0.25%**	**A076510**	**001**	Jul 01, 2003
AB		RICONPHARMA LLC	**0.05%**	**A210980**	**001**	Dec 21, 2018
AB		RISING PHARMS	**0.25%**	**A205594**	**001**	Jul 02, 2018
AB		ZYDUS PHARMS USA INC	**0.25%**	**A205620**	**001**	Sep 28, 2018

TOPICORT

AB	**!**	TARO PHARM INDS LTD	**0.05%**	**A073210**	**001**	Nov 30, 1990
AB	**!**		**0.25%**	**A073193**	**001**	Nov 30, 1990

GEL;TOPICAL

DESOXIMETASONE

AB		AKORN	**0.05%**	**A090727**	**001**	Mar 10, 2011
AB		PERRIGO NEW YORK	**0.05%**	**A077552**	**001**	Jan 09, 2006
AB		RISING PHARMS	**0.05%**	**A204675**	**001**	Aug 12, 2016

TOPICORT

AB	**!**	TARO PHARM INDS LTD	**0.05%**	**A074904**	**001**	Jul 14, 1998

OINTMENT;TOPICAL

DESOXIMETASONE

AB		ACTAVIS MID ATLANTIC	**0.25%**	**A204965**	**001**	Nov 07, 2016
AB		AKORN	**0.25%**	**A201005**	**001**	Apr 24, 2014
AB		FOUGERA PHARMS	**0.25%**	**A078657**	**001**	Sep 28, 2012
AB		G AND W LABS INC	**0.25%**	**A206740**	**001**	Dec 23, 2016
AB		GLENMARK GENERICS	**0.25%**	**A202838**	**001**	Sep 20, 2013
AB		LUPIN ATLANTIS	**0.05%**	**A208044**	**001**	Dec 12, 2016
AB			**0.25%**	**A208104**	**001**	Dec 01, 2016
AB		NOVEL LABS INC	**0.25%**	**A206792**	**001**	May 10, 2016
AB		PERRIGO ISRAEL	**0.25%**	**A077770**	**001**	Apr 20, 2015
AB		RISING PHARMS	**0.25%**	**A204272**	**001**	Nov 30, 2016
AB		TELIGENT PHARMA INC	**0.05%**	**A209973**	**001**	Oct 23, 2018
AB			**0.25%**	**A208101**	**001**	Feb 25, 2016

DESOXIMETASONE

OINTMENT;TOPICAL

DESOXIMETASONE

AB		ZYDUS PHARMS USA INC	**0.25%**	**A205206**	**001**	Sep 19, 2017

TOPICORT

AB	**+!**	TARO PHARM INDS LTD	**0.05%**	**N018594**	**001**	Jan 17, 1985
AB	**!**		**0.25%**	**A074286**	**001**	Jun 07, 1996

SPRAY;TOPICAL

DESOXIMETASONE

AT		LUPIN ATLANTIS	**0.25%**	**A208124**	**001**	Mar 16, 2018
AT		PERRIGO ISRAEL	**0.25%**	**A206441**	**001**	Jan 20, 2017

TOPICORT

AT	**+!**	TARO PHARMS	**0.25%**	**N204141**	**001**	Apr 11, 2013

DESVENLAFAXINE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE

BC	+!	ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013
BC	+!		100MG	N204150	002	Mar 04, 2013

KHEDEZLA

BC		OSMOTICA PHARM CORP	50MG	N204683	001	Jul 10, 2013
BC			100MG	N204683	002	Jul 10, 2013

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

AB		ACTAVIS LABS FL	**EQ 25MG BASE**	**A204065**	**001**	Jul 29, 2016
AB			**EQ 50MG BASE**	**A204065**	**002**	Jul 29, 2016
AB			**EQ 100MG BASE**	**A204065**	**003**	Jul 29, 2016
AB		ALEMBIC PHARMS LTD	**EQ 25MG BASE**	**A204003**	**003**	Sep 14, 2018
AB			**EQ 50MG BASE**	**A204003**	**001**	Jun 29, 2015
AB			**EQ 100MG BASE**	**A204003**	**002**	Jun 29, 2015
AB		CASI PHARMS INC	**EQ 50MG BASE**	**A204028**	**001**	Jun 29, 2015
AB			**EQ 100MG BASE**	**A204028**	**002**	Jun 29, 2015
AB		LUPIN LTD	**EQ 50MG BASE**	**A204172**	**001**	Jun 29, 2015
AB			**EQ 100MG BASE**	**A204172**	**002**	Jun 29, 2015
AB		MYLAN PHARMS INC	**EQ 50MG BASE**	**A204095**	**001**	Jun 29, 2015
AB			**EQ 100MG BASE**	**A204095**	**002**	Jun 29, 2015
AB		WEST-WARD PHARMS INT	**EQ 25MG BASE**	**A204082**	**002**	Aug 28, 2017
AB			**EQ 50MG BASE**	**A204082**	**001**	Feb 16, 2016
AB			**EQ 100MG BASE**	**A204083**	**001**	Feb 16, 2016
AB		YICHANG HUMANWELL	**EQ 50MG BASE**	**A210014**	**001**	Oct 01, 2018
AB			**EQ 100MG BASE**	**A210014**	**002**	Oct 01, 2018
AB		ZYDUS PHARMS USA INC	**EQ 50MG BASE**	**A204020**	**001**	Oct 11, 2017
AB			**EQ 100MG BASE**	**A204020**	**002**	Oct 11, 2017

PRISTIQ

AB	**+**	PF PRISM CV	**EQ 25MG BASE**	**N021992**	**003**	Aug 20, 2014
AB	**+!**		**EQ 50MG BASE**	**N021992**	**001**	Feb 29, 2008
AB	**+!**		**EQ 100MG BASE**	**N021992**	**002**	Feb 29, 2008

DEUTETRABENAZINE

TABLET;ORAL

AUSTEDO

	+	TEVA BRANDED PHARM	6MG	N208082	001	Apr 03, 2017
	+		9MG	N208082	002	Apr 03, 2017
	+!		12MG	N208082	003	Apr 03, 2017

DEXAMETHASONE

CONCENTRATE;ORAL

DEXAMETHASONE INTENSOL

	!	WEST-WARD PHARMS INT	1MG/ML	A088252	001	Sep 01, 1983

ELIXIR;ORAL

DEXAMETHASONE

AA		LANNETT CO INC	**0.5MG/5ML**	**A091188**	**001**	May 11, 2011
AA		LYNE	**0.5MG/5ML**	**A090891**	**001**	Jul 12, 2011
AA	**!**	STI PHARMA LLC	**0.5MG/5ML**	**A084754**	**001**	
AA		WOCKHARDT BIO AG	**0.5MG/5ML**	**A088254**	**001**	Jul 27, 1983

IMPLANT;INTRAVITREAL

OZURDEX

	+!	ALLERGAN	0.7MG	N022315	001	Jun 17, 2009

DEXAMETHASONE

INSERT;OPHTHALMIC

DEXTENZA

	+!	OCULAR THERAPEUTIX	0.4MG	N208742	001	Nov 30, 2018

SOLUTION;ORAL

DEXAMETHASONE

	!	WEST-WARD PHARMS INT	0.5MG/5ML	A088248	001	Sep 01, 1983

SUSPENSION;INTRAOCULAR

DEXYCU KIT

	+!	EYEPOINT PHARMS	9%	N208912	001	Feb 09, 2018

SUSPENSION/DROPS;OPHTHALMIC

MAXIDEX

	+!	NOVARTIS PHARMS CORP	0.1%	N013422	001	

TABLET;ORAL

DEXAMETHASONE

AB		ECR	**1.5MG**	**A040700**	**001**	Aug 15, 2008
AB		LARKEN LABS INC	**1.5MG**	**A201270**	**001**	Jul 17, 2017
AB		WEST-WARD PHARMS INT	**1.5MG**	**A084610**	**001**	
BP		FERA PHARMS LLC	0.5MG	A088481	002	Apr 28, 1983
BP			0.75MG	A088481	003	Apr 28, 1983
BP			4MG	A088481	004	Apr 28, 1983
BP			6MG	A088481	001	Nov 28, 1983
BP		WEST-WARD PHARMS INT	0.5MG	A084611	001	
BP			0.75MG	A084613	001	
BP			1MG	A088306	001	Sep 15, 1983
BP			2MG	A087916	001	Aug 26, 1982
BP			4MG	A084612	001	
BP	!		6MG	A088316	001	Sep 15, 1983
BP		XSPIRE PHARMA	1.5MG	A088237	001	Apr 28, 1983

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP		AMNEAL PHARMS CO	**EQ 4MG PHOSPHATE/ML**	**A208689**	**001**	Aug 22, 2018
AP		AUROBINDO PHARMA LTD	**EQ 4MG PHOSPHATE/ML**	**A206781**	**001**	Dec 01, 2015
AP		FRESENIUS KABI USA	**EQ 4MG PHOSPHATE/ML**	**A084916**	**001**	
AP			**EQ 4MG PHOSPHATE/ML**	**A203129**	**001**	Sep 30, 2015
AP	**!**		**EQ 10MG PHOSPHATE/ML**	**A040572**	**001**	Apr 22, 2005
AP			**EQ 10MG PHOSPHATE/ML**	**A209192**	**001**	Jul 06, 2018
AP	**!**	LUITPOLD	**EQ 4MG PHOSPHATE/ML**	**A087440**	**001**	Jul 21, 1982
AP		MYLAN LABS LTD	**EQ 4MG PHOSPHATE/ML**	**A040803**	**001**	Aug 29, 2008
AP			**EQ 10MG PHOSPHATE/ML**	**A040802**	**001**	Aug 29, 2008
AP		SOMERSET THERAPS LLC	**EQ 4MG PHOSPHATE/ML**	**A207521**	**001**	Jun 08, 2018
AP		WEST-WARD PHARMS INT	**EQ 4MG PHOSPHATE/ML**	**A084282**	**001**	
AP	**!**		**EQ 10MG PHOSPHATE/ML**	**A087702**	**001**	Sep 07, 1982

DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE

AP		AMNEAL PHARMS CO	**EQ 10MG PHOSPHATE/ML**	**A208690**	**001**	Aug 22, 2018
AP	**!**	FRESENIUS KABI USA	**EQ 10MG PHOSPHATE/ML**	**A040491**	**001**	Apr 11, 2003
AP		SOMERSET THERAPS LLC	**EQ 10MG PHOSPHATE/ML**	**A207442**	**001**	Apr 19, 2018

SOLUTION/DROPS;OPHTHALMIC, OTIC

DEXAMETHASONE SODIUM PHOSPHATE

AT		BAUSCH AND LOMB	**EQ 0.1% PHOSPHATE**	**A040069**	**001**	Jul 26, 1996
AT	**!**	SANDOZ INC	**EQ 0.1% PHOSPHATE**	**A088771**	**001**	Jan 16, 1985

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

MAXITROL

AT	**+!**	NOVARTIS PHARMS CORP	**0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**N050065**	**002**	

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT		BAUSCH AND LOMB	**0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A064063**	**001**	Jul 25, 1994
AT		PERRIGO CO TENNESSEE	**0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A062938**	**001**	Jul 31, 1989

SUSPENSION/DROPS;OPHTHALMIC

DEXASPORIN

AT		BAUSCH AND LOMB	**0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A064135**	**001**	Sep 13, 1995

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS;OPHTHALMIC

MAXITROL

AT	**+!**	NOVARTIS PHARMS CORP	**0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**N050023**	**002**	
AT		SANDOZ INC	**0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A062341**	**001**	May 22, 1984

DEXAMETHASONE; TOBRAMYCIN

OINTMENT;OPHTHALMIC

TOBRADEX

	+!	NOVARTIS PHARMS CORP	0.1%;0.3%	N050616	001	Sep 28, 1988

SUSPENSION/DROPS;OPHTHALMIC

TOBRADEX

AB	**+!**	NOVARTIS PHARMS CORP	**0.1%;0.3%**	**N050592**	**001**	Aug 18, 1988

TOBRAMYCIN AND DEXAMETHASONE

AB		BAUSCH AND LOMB	**0.1%;0.3%**	**A064134**	**001**	Oct 27, 1999

TOBRADEX ST

	+!	NOVARTIS PHARMS CORP	0.05%;0.3%	N050818	001	Feb 13, 2009

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

DEXCHLORPHENIRAMINE MALEATE

AA	**!**	WOCKHARDT BIO AG	**2MG/5ML**	**A088251**	**001**	Mar 23, 1984

POLMON

AA		CAPELLON PHARMS LLC	**2MG/5ML**	**A202520**	**001**	Jul 16, 2018

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE;ORAL

DEXILANT

AB	**+!**	TAKEDA PHARMS USA	**60MG**	**N022287**	**002**	Jan 30, 2009

DEXLANSOPRAZOLE

AB		PAR PHARM INC	**60MG**	**A202294**	**001**	Apr 19, 2017

DEXILANT

	+	TAKEDA PHARMS USA	30MG	N022287	001	Jan 30, 2009

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP		ACCORD HLTHCARE	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A204023**	**001**	Feb 09, 2016
AP		ACTAVIS INC	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A204686**	**001**	Oct 17, 2016
AP		AKORN INC	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A202585**	**001**	Nov 24, 2014
AP		AUROBINDO PHARMA LTD	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A205867**	**001**	Mar 17, 2016
AP		BAXTER HLTHCARE CORP	**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A208532**	**001**	Aug 21, 2018
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A208532**	**002**	Aug 21, 2018
AP		FRESENIUS KABI USA	**EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)**	**A208129**	**001**	Nov 29, 2018
AP			**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A201072**	**001**	Sep 18, 2015
AP			**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A208129**	**002**	Nov 29, 2018
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A208129**	**003**	Nov 29, 2018
AP		JIANGSU HENGRUI MED	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A209065**	**001**	Sep 19, 2017
AP		LUITPOLD	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A203773**	**001**	May 12, 2017
AP		MYLAN INSTITUTIONAL	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A202881**	**001**	Aug 18, 2014
AP		PAR STERILE PRODUCTS	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A203972**	**001**	Aug 18, 2014
AP		SANDOZ INC	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A091465**	**001**	Jun 14, 2016
AP		SUN PHARM INDS INC	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A202126**	**001**	Aug 20, 2015
AP		TEVA PHARMS USA	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A205272**	**001**	Nov 28, 2017
AP		WEST-WARD PHARMS INT	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A205046**	**001**	Apr 26, 2017
AP		ZYDUS PHARMS USA INC	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A206798**	**001**	Feb 27, 2018

PRECEDEX

AP	**+!**	HOSPIRA	**EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)**	**N021038**	**004**	Nov 14, 2014
AP	**+!**		**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**N021038**	**001**	Dec 17, 1999
AP	**+!**		**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**N021038**	**002**	Mar 13, 2013
AP	**+!**		**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**N021038**	**003**	Mar 13, 2013

SOLUTION;INTRAVENOUS

DEXMEDETOMIDINE HYDROCHLORIDE

	+!	HQ SPCLT PHARMA	EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)	N206628	002	Oct 21, 2015
	+		EQ 200MG BASE/50ML (EQ 4MCG BASE/ML)	N206628	003	Jun 22, 2018
	+		EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)	N206628	001	Oct 21, 2015
	+		EQ 400MG BASE/100ML (EQ 4MCG BASE/ML)	N206628	004	Jun 22, 2018

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		ADARE PHARMS INC	5MG	A210279	001	Oct 09, 2018
AB			10MG	A210279	002	Oct 09, 2018
AB			15MG	A210279	003	Oct 09, 2018
AB			20MG	A210279	004	Oct 09, 2018
AB			25MG	A210279	005	Oct 09, 2018
AB			30MG	A210279	006	Oct 09, 2018
AB			35MG	A210279	007	Oct 09, 2018
AB			40MG	A210279	008	Oct 09, 2018
AB		IMPAX LABS INC	5MG	A079108	001	Aug 05, 2015
AB			10MG	A079108	002	Aug 05, 2015
AB			15MG	A079108	003	May 19, 2014
AB			20MG	A079108	004	Dec 21, 2015
AB			25MG	A203614	001	Jul 05, 2017
AB			30MG	A079108	005	Nov 21, 2013
AB			35MG	A203614	002	Jul 05, 2017
AB		INTELLIPHARMACEUTICS	15MG	A078992	003	Nov 18, 2013
AB			30MG	A078992	004	Nov 18, 2013
AB		MYLAN PHARMS INC	5MG	A204266	001	Aug 25, 2015
AB			10MG	A204266	002	Aug 25, 2015
AB			15MG	A204266	003	Aug 25, 2015
AB			20MG	A204266	004	Dec 21, 2015
AB			30MG	A202580	001	Aug 28, 2013
AB			40MG	A204266	007	Aug 25, 2015
AB		PAR PHARM INC	5MG	A202842	001	Nov 30, 2016
AB			10MG	A202842	002	Nov 30, 2016
AB			15MG	A202842	003	Nov 30, 2016
AB			20MG	A202842	004	Nov 30, 2016
AB			25MG	A202842	005	Nov 30, 2016
AB			30MG	A202842	006	Nov 30, 2016
AB			35MG	A202842	007	Nov 30, 2016
AB			40MG	A202842	008	Nov 30, 2016
AB		TEVA PHARMS USA	5MG	A078908	001	Nov 19, 2013
AB			10MG	A078908	002	Nov 19, 2013
AB			15MG	A078908	004	May 19, 2014
AB			20MG	A078908	003	Nov 19, 2013
AB			25MG	A202731	001	Jul 05, 2017
AB			30MG	A202731	003	May 19, 2014
AB			35MG	A202731	004	Jul 05, 2017
AB			40MG	A202731	002	Nov 19, 2013

FOCALIN XR

AB	+	NOVARTIS	5MG	N021802	001	May 26, 2005
AB	+		10MG	N021802	002	May 26, 2005
AB	+		15MG	N021802	004	Aug 01, 2006
AB	+		20MG	N021802	003	May 26, 2005
AB	+		25MG	N021802	008	Apr 21, 2011
AB	+		30MG	N021802	005	Oct 23, 2009
AB	+		35MG	N021802	007	Apr 21, 2011
AB	+!		40MG	N021802	006	Aug 11, 2010

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		ABHAI INC	2.5MG	A206931	001	Dec 04, 2015
AB			5MG	A206931	002	Dec 04, 2015
AB			10MG	A206931	003	Dec 04, 2015
AB		CEDIPROF INC	5MG	A209211	001	Sep 19, 2018
AB			10MG	A209211	002	Sep 19, 2018
AB		LANNETT CO INC	2.5MG	A209468	001	Sep 25, 2017
AB			5MG	A209468	002	Sep 25, 2017
AB			10MG	A209468	003	Sep 25, 2017
AB		NOVEL LABS INC	2.5MG	A204534	001	Dec 04, 2015
AB			5MG	A204534	002	Dec 04, 2015
AB			10MG	A204534	003	Dec 04, 2015
AB		RHODES PHARMS	2.5MG	A208756	001	Nov 20, 2017
AB			5MG	A208756	002	Nov 20, 2017
AB			10MG	A208756	003	Nov 20, 2017
AB		SUN PHARM INDUSTRIES	2.5MG	A201231	001	Sep 24, 2015
AB			5MG	A201231	002	Sep 24, 2015
AB			10MG	A201231	003	Sep 24, 2015
AB		TEVA PHARMS	2.5MG	A077107	003	Jan 29, 2007

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB			**5MG**	**A077107**	**001**	Jan 29, 2007
AB			**10MG**	**A077107**	**002**	Jan 29, 2007
AB		TRIS PHARMA INC	**2.5MG**	**A207901**	**001**	Aug 26, 2016
AB			**5MG**	**A207901**	**002**	Aug 26, 2016
AB			**10MG**	**A207901**	**003**	Aug 26, 2016

FOCALIN

AB	**+**	NOVARTIS	**2.5MG**	**N021278**	**001**	Nov 13, 2001
AB	**+**		**5MG**	**N021278**	**002**	Nov 13, 2001
AB	**+!**		**10MG**	**N021278**	**003**	Nov 13, 2001

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXRAZOXANE HYDROCHLORIDE

AP		GLAND PHARMA LTD	**EQ 500MG BASE/VIAL**	**A207321**	**001**	Nov 28, 2016
AP		MYLAN INSTITUTIONAL	**EQ 250MG BASE/VIAL**	**A200752**	**001**	Oct 19, 2011
AP			**EQ 500MG BASE/VIAL**	**A200752**	**002**	Oct 19, 2011
AP		WEST-WARD PHARMS INT	**EQ 250MG BASE/VIAL**	**A076068**	**001**	Sep 28, 2004
AP			**EQ 500MG BASE/VIAL**	**A076068**	**002**	Sep 28, 2004

ZINECARD

AP	**+!**	PHARMACIA AND UPJOHN	**EQ 250MG BASE/VIAL**	**N020212**	**001**	May 26, 1995
AP	**+!**		**EQ 500MG BASE/VIAL**	**N020212**	**002**	May 26, 1995

TOTECT

	+!	CLINIGEN HLTHCARE	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXEDRINE

AB	**+**	IMPAX LABS INC	**5MG**	**N017078**	**001**	
AB	**+**		**10MG**	**N017078**	**002**	
AB	**+!**		**15MG**	**N017078**	**003**	

DEXTROAMPHETAMINE SULFATE

AB		ACTAVIS ELIZABETH	**5MG**	**A203901**	**001**	Nov 30, 2012
AB			**10MG**	**A203901**	**002**	Nov 30, 2012
AB			**15MG**	**A203901**	**003**	Nov 30, 2012
AB		MAYNE PHARMA	**5MG**	**A076137**	**001**	Jan 18, 2002
AB			**10MG**	**A076137**	**002**	Jan 18, 2002
AB			**15MG**	**A076137**	**003**	Jan 18, 2002
AB		MYLAN PHARMS INC	**5MG**	**A206735**	**001**	Jan 27, 2016
AB			**10MG**	**A206735**	**002**	Jan 27, 2016
AB			**15MG**	**A206735**	**003**	Jan 27, 2016
AB		NESHER PHARMS	**5MG**	**A209111**	**001**	Jun 27, 2017
AB			**10MG**	**A209111**	**002**	Jun 27, 2017
AB			**15MG**	**A209111**	**003**	Jun 27, 2017
AB		SPECGX LLC	**5MG**	**A076353**	**001**	May 06, 2003
AB			**10MG**	**A076353**	**002**	May 06, 2003
AB			**15MG**	**A076353**	**003**	May 06, 2003
AB		VINTAGE PHARMS	**5MG**	**A205673**	**001**	Oct 31, 2017
AB			**10MG**	**A205673**	**002**	Oct 31, 2017
AB			**15MG**	**A205673**	**003**	Oct 31, 2017

SOLUTION;ORAL

DEXTROAMPHETAMINE SULFATE

AA	**!**	OUTLOOK PHARMS	**5MG/5ML**	**A040776**	**001**	Jan 29, 2008
AA		TRIS PHARMA INC	**5MG/5ML**	**A203644**	**001**	May 29, 2013

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

AA		ARBOR PHARMS LLC	**5MG**	**A090533**	**002**	Oct 25, 2011
AA			**10MG**	**A090533**	**004**	Oct 25, 2011
AA		AUROLIFE PHARMA LLC	**5MG**	**A202893**	**001**	Jul 31, 2013
AA			**10MG**	**A202893**	**002**	Jul 31, 2013
AA		AVANTHI INC	**5MG**	**A203548**	**001**	Nov 23, 2015
AA			**10MG**	**A203548**	**002**	Nov 23, 2015
AA		BARR	**5MG**	**A040361**	**001**	Jan 31, 2001
AA	**!**		**10MG**	**A040361**	**002**	Jan 31, 2001
AA		NESHER PHARMS	**5MG**	**A206588**	**001**	Mar 28, 2016
AA			**10MG**	**A206588**	**002**	Mar 28, 2016
AA		NOVEL LABS INC	**5MG**	**A204330**	**001**	Mar 16, 2016
AA			**10MG**	**A204330**	**002**	Mar 16, 2016
AA		NUVO PHARM	**5MG**	**A210059**	**001**	Oct 18, 2017
AA			**10MG**	**A210059**	**002**	Oct 18, 2017

DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

AA		SPECGX LLC	**5MG**	**A040436**	**001**	Jan 29, 2002
AA			**10MG**	**A040436**	**002**	Jan 29, 2002
		ARBOR PHARMS LLC	2.5MG	A090533	001	Oct 25, 2011
			7.5MG	A090533	003	Oct 25, 2011
			15MG	A090533	005	Oct 25, 2011
			20MG	A090533	006	Oct 25, 2011
			30MG	A090533	007	Oct 25, 2011

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE DM

AA	**!**	VINTAGE	**15MG/5ML;6.25MG/5ML**	**A040649**	**001**	Feb 14, 2006

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		HI TECH PHARMA	**15MG/5ML;6.25MG/5ML**	**A040027**	**001**	Jul 31, 1996

PROMETHAZINE W/ DEXTROMETHORPHAN

AA		WOCKHARDT BIO AG	**15MG/5ML;6.25MG/5ML**	**A088864**	**001**	Jan 04, 1985

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE;ORAL

DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE

AB		ACTAVIS ELIZABETH	**20MG;10MG**	**A202934**	**001**	Oct 10, 2017

NUEDEXTA

AB	**+!**	AVANIR PHARMS	**20MG;10MG**	**N021879**	**001**	Oct 29, 2010

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**10GM/100ML**	**N019626**	**004**	Feb 02, 1988
AP	**+!**	BAXTER HLTHCARE	**10GM/100ML**	**N016694**	**001**	
AP		FRESENIUS KABI USA	**10GM/100ML**	**A209448**	**001**	Jul 16, 2018
AP	**+!**	ICU MEDICAL INC	**10GM/100ML**	**N018080**	**001**	

DEXTROSE 5% IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**50MG/ML**	**N016730**	**002**	
AP	**+!**		**5GM/100ML**	**N016730**	**001**	
AP	**+!**		**5GM/100ML**	**N019626**	**002**	Feb 02, 1988
AP	**+!**	BAXTER HLTHCARE	**50MG/ML**	**N016673**	**003**	Oct 30, 1985
AP	**+!**		**50MG/ML**	**N020179**	**002**	Dec 07, 1992
AP	**+!**		**5GM/100ML**	**N016673**	**001**	
AP	**+!**		**5GM/100ML**	**N020179**	**001**	Dec 07, 1992
AP		FRESENIUS KABI USA	**50MG/ML**	**A207449**	**001**	Oct 21, 2016
AP	**+!**	HOSPIRA	**5GM/100ML**	**N019466**	**001**	Jul 15, 1985
AP	**+!**		**5GM/100ML**	**N019479**	**001**	Sep 17, 1985
AP	**+!**	ICU MEDICAL INC	**50MG/ML**	**N016367**	**002**	

DEXTROSE 50% IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**50GM/100ML**	**N020047**	**001**	Jul 02, 1991
AP	**+!**	ICU MEDICAL INC	**50GM/100ML**	**N018563**	**001**	Mar 23, 1982

DEXTROSE 70% IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**70GM/100ML**	**N019626**	**005**	Feb 18, 2015
AP	**+!**	BAXTER HLTHCARE	**70GM/100ML**	**N017521**	**006**	Mar 26, 1982
AP	**+!**		**70GM/100ML**	**N020047**	**003**	Jul 02, 1991
AP	**+!**	ICU MEDICAL INC	**70GM/100ML**	**N018561**	**001**	Mar 23, 1982
AP	**+!**		**70GM/100ML**	**N019893**	**001**	Dec 26, 1989
		DEXTROSE 20% IN PLASTIC CONTAINER				
	+!	ICU MEDICAL INC	20GM/100ML	N018564	001	Mar 23, 1982
		DEXTROSE 25%				
	+!	HOSPIRA	250MG/ML	N019445	002	Nov 23, 1998
		DEXTROSE 30% IN PLASTIC CONTAINER				
	+!	ICU MEDICAL INC	30GM/100ML	N019345	001	Jan 26, 1985
		DEXTROSE 40% IN PLASTIC CONTAINER				
	+!	ICU MEDICAL INC	40GM/100ML	N018562	001	Mar 23, 1982
		DEXTROSE 50%				
	+	HOSPIRA	500MG/ML	N019445	003	Sep 03, 2014
		DEXTROSE 50% IN PLASTIC CONTAINER				
	+	HOSPIRA	500MG/ML	N019445	001	Jun 03, 1986

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

	ICU MEDICAL INC	5GM/100ML;21MG/100ML;128MG/100ML;234MG/100ML	N017610	001	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE;INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML;26MG/100ML;320MG/100ML	N019873	001	Jun 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5GM/100ML;31MG/100ML;141MG/100ML;20MG/100ML;12MG/100ML;260MG/100ML	N017484	001	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

	ICU MEDICAL INC	5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100ML	N019513	001	May 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

	ICU MEDICAL INC	5GM/100ML;30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N017609	001	

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

AP	**+** BAXTER HLTHCARE	**5GM/100ML;150MG/100ML**	**N017634**	**001**	

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

AP	**+** BAXTER HLTHCARE	**5GM/100ML;224MG/100ML**	**N017634**	**003**	

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

AP	**+** BAXTER HLTHCARE	**5GM/100ML;300MG/100ML**	**N017634**	**002**	

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;150MG/100ML**	**N019699**	**004**	Sep 29, 1989

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;300MG/100ML**	**N019699**	**006**	Sep 29, 1989

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ICU MEDICAL INC	**5GM/100ML;224MG/100ML**	**N018371**	**003**	

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	5GM/100ML;75MG/100ML	N017634	004	

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

	ICU MEDICAL INC	5GM/100ML;149MG/100ML	N018371	001	

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

	ICU MEDICAL INC	5GM/100ML;298MG/100ML	N018371	002	

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ

AP	BAXTER HLTHCARE	**5GM/100ML;75MG/100ML;200MG/100ML**	**N018037**	**006**	Apr 13, 1982
AP		**5GM/100ML;150MG/100ML;200MG/100ML**	**N018037**	**007**	Apr 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K)

AP	BAXTER HLTHCARE	**5GM/100ML;224MG/100ML;200MG/100ML**	**N018037**	**004**	

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ

AP	BAXTER HLTHCARE	**5GM/100ML;150MG/100ML;200MG/100ML**	**N018037**	**008**	Apr 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K)

AP	BAXTER HLTHCARE	**5GM/100ML;300MG/100ML;200MG/100ML**	**N018037**	**001**	

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ

AP	BAXTER HLTHCARE	**5GM/100ML;224MG/100ML;200MG/100ML**	**N018037**	**005**	Apr 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ

AP	BAXTER HLTHCARE	**5GM/100ML;300MG/100ML;200MG/100ML**	**N018037**	**009**	Apr 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ

AP	BAXTER HLTHCARE	**5GM/100ML;75MG/100ML;200MG/100ML**	**N018037**	**002**	

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K)

AP	BAXTER HLTHCARE	**5GM/100ML;150MG/100ML;200MG/100ML**	**N018037**	**003**	

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**5GM/100ML;75MG/100ML;330MG/100ML**	**N018629**	**005**	Mar 23, 1982
AP		**5GM/100ML;150MG/100ML;330MG/100ML**	**N018629**	**002**	Mar 23, 1982

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;224MG/100ML;330MG/100ML**	**N018629**	**003**	Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;150MG/100ML;330MG/100ML**	**N018629**	**004**	Mar 23, 1982
AP			**5GM/100ML;300MG/100ML;330MG/100ML**	**N018629**	**006**	Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;224MG/100ML;330MG/100ML**	**N018629**	**007**	Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;300MG/100ML;330MG/100ML**	**N018629**	**008**	Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;75MG/100ML;330MG/100ML**	**N018629**	**001**	Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;300MG/100ML;450MG/100ML**	**N018008**	**010**	

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;75MG/100ML;200MG/100ML**	**N019630**	**008**	Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;75MG/100ML;330MG/100ML**	**N019630**	**014**	Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;75MG/100ML;450MG/100ML**	**N019630**	**020**	Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;75MG/100ML;900MG/100ML**	**N019630**	**026**	Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;150MG/100ML;200MG/100ML**	**N019630**	**010**	Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;150MG/100ML;330MG/100ML**	**N019630**	**016**	Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;150MG/100ML;450MG/100ML**	**N019630**	**022**	Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;150MG/100ML;900MG/100ML**	**N019630**	**028**	Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;300MG/100ML;200MG/100ML**	**N019630**	**012**	Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;300MG/100ML;330MG/100ML**	**N019630**	**018**	Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;300MG/100ML;450MG/100ML**	**N019630**	**024**	Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;300MG/100ML;900MG/100ML**	**N019630**	**030**	Feb 17, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;75MG/100ML;450MG/100ML**	**N018008**	**005**	Apr 28, 1982
AP			**5GM/100ML;150MG/100ML;450MG/100ML**	**N018008**	**006**	Apr 28, 1982
AP	**+!**	ICU MEDICAL INC	**5GM/100ML;74.5MG/100ML;450MG/100ML**	**N018362**	**009**	Jul 05, 1983
AP	**+!**		**5GM/100ML;149MG/100ML;450MG/100ML**	**N018362**	**005**	Mar 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;150MG/100ML;450MG/100ML**	**N018008**	**007**	Apr 28, 1982
AP	**+!**	ICU MEDICAL INC	**5GM/100ML;149MG/100ML;450MG/100ML**	**N018362**	**010**	Jul 05, 1983

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;150MG/100ML;900MG/100ML**	**N019308**	**005**	Apr 05, 1985
AP	**+!**	ICU MEDICAL INC	**5GM/100ML;149MG/100ML;900MG/100ML**	**N019691**	**005**	Mar 24, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;224MG/100ML;450MG/100ML**	**N018008**	**008**	Apr 28, 1982
AP	**+!**	ICU MEDICAL INC	**5GM/100ML;224MG/100ML;450MG/100ML**	**N018362**	**002**	

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;300MG/100ML;450MG/100ML**	**N018008**	**009**	Apr 28, 1982
AP	**+!**	ICU MEDICAL INC	**5GM/100ML;298MG/100ML;450MG/100ML**	**N018362**	**003**	

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;300MG/100ML;900MG/100ML**	**N019308**	**007**	Apr 05, 1985
AP	**+!**	ICU MEDICAL INC	**5GM/100ML;298MG/100ML;900MG/100ML**	**N019691**	**009**	Mar 24, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;37MG/100ML;200MG/100ML	N019630	031	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;37MG/100ML;450MG/100ML	N019630	037	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;37MG/100ML;900MG/100ML	N019630	043	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML;37MG/100ML;110MG/100ML	N019630	001	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML;37MG/100ML;200MG/100ML	N019630	007	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML;37MG/100ML;330MG/100ML	N019630	013	Feb 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;37MG/100ML;450MG/100ML N019630 019 Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;37MG/100ML;900MG/100ML N019630 025 Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;75MG/100ML;200MG/100ML N019630 032 Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;75MG/100ML;450MG/100ML N019630 038 Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;75MG/100ML;900MG/100ML N019630 044 Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;75MG/100ML;300MG/100ML N019630 049 May 07, 1992

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;75MG/100ML;110MG/100ML N019630 002 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;110MG/100ML;200MG/100ML N019630 033 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;110MG/100ML;450MG/100ML N019630 039 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;110MG/100ML;900MG/100ML N019630 045 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;110MG/100ML;300MG/100ML N019630 050 May 07, 1992

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML;110MG/100ML N019630 003 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML;200MG/100ML N019630 009 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML;330MG/100ML N019630 015 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML;450MG/100ML N019630 021 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML;900MG/100ML N019630 027 Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;150MG/100ML;200MG/100ML N019630 034 Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;150MG/100ML;450MG/100ML N019630 040 Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;150MG/100ML;900MG/100ML N019630 046 Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;150MG/100ML;300MG/100ML N019630 051 May 07, 1992

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;150MG/100ML;110MG/100ML N019630 004 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;220MG/100ML;200MG/100ML N019630 035 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;220MG/100ML;450MG/100ML N019630 041 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;220MG/100ML;900MG/100ML N019630 047 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;220MG/100ML;300MG/100ML N019630 052 May 07, 1992

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;110MG/100ML N019630 005 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;200MG/100ML N019630 011 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;330MG/100ML N019630 017 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;450MG/100ML N019630 023 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;900MG/100ML N019630 029 Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;300MG/100ML;200MG/100ML N019630 036 Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;300MG/100ML;450MG/100ML N019630 042 Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;300MG/100ML;900MG/100ML N019630 048 Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;300MG/100ML;300MG/100ML N019630 053 May 07, 1992

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;300MG/100ML;110MG/100ML N019630 006 Feb 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
+	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;225MG/100ML	N018365	002	Jul 05, 1983
+		5GM/100ML;149MG/100ML;225MG/100ML	N018365	006	Mar 28, 1988
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876	001	Jan 17, 1986
		5GM/100ML;149MG/100ML;300MG/100ML	N018876	006	Mar 28, 1988
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;900MG/100ML	N019308	004	Apr 05, 1985
		5GM/100ML;150MG/100ML;900MG/100ML	N019308	002	Apr 05, 1985
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;224MG/100ML;225MG/100ML	N018365	008	Mar 28, 1988
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;224MG/100ML;300MG/100ML	N018876	007	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
+	ICU MEDICAL INC	5GM/100ML;149MG/100ML;225MG/100ML	N018365	001	
+		5GM/100ML;298MG/100ML;225MG/100ML	N018365	009	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;298MG/100ML;300MG/100ML	N018876	008	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;900MG/100ML	N019308	003	Apr 05, 1985
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;149MG/100ML;300MG/100ML	N018876	002	Jan 17, 1986
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;224MG/100ML;225MG/100ML	N018365	003	Jul 05, 1983
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;224MG/100ML;300MG/100ML	N018876	003	Jan 17, 1986
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;900MG/100ML	N019308	006	Apr 05, 1985
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;298MG/100ML;225MG/100ML	N018365	004	Jul 05, 1983
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;298MG/100ML;300MG/100ML	N018876	004	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;225MG/100ML	N018365	005	Mar 28, 1988
		5GM/100ML;149MG/100ML;225MG/100ML	N018365	007	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876	005	Mar 28, 1988
		5GM/100ML;149MG/100ML;300MG/100ML	N018876	009	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;450MG/100ML	N018008	004	
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;900MG/100ML	N019308	001	Apr 05, 1985

DEXTROSE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP	B BRAUN	**2.5GM/100ML;450MG/100ML**	**N019631**	**004**	Feb 24, 1988
AP **+!**	BAXTER HLTHCARE	**2.5GM/100ML;450MG/100ML**	**N016697**	**001**	
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER					
AP	B BRAUN	**5GM/100ML;200MG/100ML**	**N019631**	**007**	Feb 24, 1988
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER					
AP	B BRAUN	**5GM/100ML;330MG/100ML**	**N019631**	**008**	Feb 24, 1988
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	B BRAUN	**5GM/100ML;450MG/100ML**	**N019631**	**009**	Feb 24, 1988
AP **+**	ICU MEDICAL INC	**5GM/100ML;450MG/100ML**	**N017607**	**001**	
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	B BRAUN	**5GM/100ML;900MG/100ML**	**N019631**	**010**	Feb 24, 1988
AP **+!**	ICU MEDICAL INC	**5GM/100ML;900MG/100ML**	**N017585**	**001**	
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER					
AP	BAXTER HLTHCARE	**5GM/100ML;200MG/100ML**	**N016689**	**001**	
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER					
AP	BAXTER HLTHCARE	**5GM/100ML;330MG/100ML**	**N016687**	**001**	
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	BAXTER HLTHCARE	**5GM/100ML;450MG/100ML**	**N016683**	**001**	
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	BAXTER HLTHCARE	**5GM/100ML;900MG/100ML**	**N016678**	**001**	
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER					
	B BRAUN	10GM/100ML;110MG/100ML	N019631	011	Feb 24, 1988
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER					
	B BRAUN	10GM/100ML;200MG/100ML	N019631	012	Feb 24, 1988

DEXTROSE; SODIUM CHLORIDE							
INJECTABLE;INJECTION							
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER							
		B BRAUN	10GM/100ML;330MG/100ML		N019631	013	Feb 24, 1988
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
		B BRAUN	10GM/100ML;450MG/100ML		N019631	014	Feb 24, 1988
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
		B BRAUN	10GM/100ML;900MG/100ML		N019631	015	Feb 24, 1988
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER							
		B BRAUN	2.5GM/100ML;110MG/100ML		N019631	001	Feb 24, 1988
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER							
		B BRAUN	2.5GM/100ML;200MG/100ML		N019631	002	Feb 24, 1988
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER							
		B BRAUN	2.5GM/100ML;330MG/100ML		N019631	003	Feb 24, 1988
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
		B BRAUN	2.5GM/100ML;900MG/100ML		N019631	005	Feb 24, 1988
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER							
		B BRAUN	3.3GM/100ML;300MG/100ML		N019631	016	Jan 19, 1990
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER							
		B BRAUN	5GM/100ML;110MG/100ML		N019631	006	Feb 24, 1988
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER							
	+!	ICU MEDICAL INC	5GM/100ML;225MG/100ML		N017606	001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER							
	+!	ICU MEDICAL INC	5GM/100ML;300MG/100ML		N017799	001	
DIATRIZOATE MEGLUMINE							
SOLUTION;URETHRAL							
CYSTOGRAFIN							
	+	BRACCO	30%		N010040	018	
CYSTOGRAFIN DILUTE							
	+	BRACCO	18%		N010040	022	Nov 09, 1982
DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM							
SOLUTION;ORAL, RECTAL							
GASTROGRAFIN							
AA	**+!**	BRACCO	**66%;10%**		**N011245**	**003**	
MD-GASTROVIEW							
AA		LIEBEL-FLARSHEIM	**66%;10%**		**A087388**	**001**	
DIAZEPAM							
CONCENTRATE;ORAL							
DIAZEPAM							
AA		LANNETT CO INC	**5MG/ML**		**A204433**	**001**	Apr 14, 2014
DIAZEPAM INTENSOL							
AA	**!**	WEST-WARD PHARMS INT	**5MG/ML**		**A071415**	**001**	Apr 03, 1987
GEL;RECTAL							
DIASTAT							
	+	VALEANT PHARMS NORTH	2.5MG/0.5ML (5MG/ML)		N020648	001	Jul 29, 1997
DIASTAT ACUDIAL							
	+	VALEANT PHARMS NORTH	10MG/2ML (5MG/ML)		N020648	007	Sep 15, 2005
	+!		20MG/4ML (5MG/ML)		N020648	006	Sep 15, 2005
INJECTABLE;INJECTION							
DIAZEPAM							
	!	HOSPIRA	10MG/2ML (5MG/ML)		A072079	001	Dec 20, 1988
	!		50MG/10ML (5MG/ML)		A071583	001	Oct 13, 1987
SOLUTION;ORAL							
DIAZEPAM							
AA		LANNETT CO INC	**5MG/5ML**		**A206477**	**001**	Jun 24, 2016
AA	**!**	WEST-WARD PHARMS INT	**5MG/5ML**		**A070928**	**001**	Apr 03, 1987
TABLET;ORAL							
DIAZEPAM							
AB		BARR	**2MG**		**A070152**	**001**	Nov 01, 1985
AB			**10MG**		**A070154**	**001**	Nov 01, 1985
AB		IVAX SUB TEVA PHARMS	**2MG**		**A071307**	**001**	Dec 10, 1986
AB			**5MG**		**A071321**	**001**	Dec 10, 1986
AB			**10MG**		**A071322**	**001**	Dec 10, 1986
AB		MAYNE PHARMA	**2MG**		**A071134**	**001**	Feb 03, 1987
AB			**5MG**		**A071135**	**001**	Feb 03, 1987
AB			**10MG**		**A071136**	**001**	Feb 03, 1987
AB		MYLAN	**2MG**		**A070325**	**002**	Sep 04, 1985

DIAZEPAM
TABLET;ORAL
DIAZEPAM

AB			**5MG**	**A070325**	**003**	Sep 04, 1985
AB			**10MG**	**A070325**	**001**	Sep 04, 1985
AB		VINTAGE PHARMS	**2MG**	**A077749**	**001**	Mar 31, 2006
AB			**5MG**	**A077749**	**002**	Mar 31, 2006
AB			**10MG**	**A077749**	**003**	Mar 31, 2006

VALIUM

AB	**+**	ROCHE	**2MG**	**N013263**	**002**	
AB	**+**		**5MG**	**N013263**	**004**	
AB	**+!**		**10MG**	**N013263**	**006**	

DIAZOXIDE
SUSPENSION;ORAL
PROGLYCEM

+!	TEVA BRANDED PHARM	50MG/ML	N017453	001	

DICHLORPHENAMIDE
TABLET;ORAL
KEVEYIS

+!	STRONGBRIDGE US	50MG	N011366	002	Aug 07, 2015

DICLOFENAC
CAPSULE;ORAL
ZORVOLEX

+	IROKO PHARMS LLC	18MG	N204592	001	Oct 18, 2013
+!		35MG	N204592	002	Oct 18, 2013

DICLOFENAC EPOLAMINE
PATCH;TOPICAL
FLECTOR

+!	INST BIOCHEM	1.3%	N021234	001	Jan 31, 2007

SYSTEM;TOPICAL
LICART

+!	IBSA INST BIO	1.3%	N206976	001	Dec 19, 2018

DICLOFENAC POTASSIUM
CAPSULE;ORAL
DICLOFENAC POTASSIUM

AB		BIONPHARMA INC	**25MG**	**A204648**	**001**	Feb 23, 2016

ZIPSOR

AB	**+!**	ASSERTIO	**25MG**	**N022202**	**001**	Jun 16, 2009

FOR SOLUTION;ORAL
CAMBIA

AB	**+!**	ASSERTIO	**50MG**	**N022165**	**001**	Jun 17, 2009

DICLOFENAC POTASSIUM

AB		PAR FORM	**50MG**	**A202964**	**001**	May 02, 2016

TABLET;ORAL
DICLOFENAC POTASSIUM

AB		APOTEX	**50MG**	**A076561**	**001**	Mar 18, 2004
AB		CASI PHARMS INC	**50MG**	**A075229**	**001**	Nov 20, 1998
AB	**!**	MYLAN	**50MG**	**A075463**	**001**	Jul 26, 1999
AB		TEVA	**50MG**	**A075219**	**001**	Aug 06, 1998

DICLOFENAC SODIUM
GEL;TOPICAL
DICLOFENAC SODIUM

AB		ACTAVIS MID ATLANTIC	**3%**	**A206493**	**001**	Dec 02, 2015
AB		AMNEAL PHARMS	**1%**	**A208077**	**001**	Mar 18, 2016
AB		CIPLA	**1%**	**A209903**	**001**	Aug 03, 2018
AB		GLENMARK PHARMS LTD	**3%**	**A208301**	**001**	Sep 13, 2016
AB		HI-TECH PHARMACAL	**1%**	**A209484**	**001**	Nov 21, 2018
AB		PERRIGO UK FINCO	**3%**	**A210893**	**001**	Jul 27, 2018
AB		TARO	**3%**	**A206298**	**001**	Apr 28, 2016
AB		TOLMAR	**3%**	**A200936**	**001**	Oct 28, 2013

SOLARAZE

AB	**+!**	FOUGERA PHARMS	**3%**	**N021005**	**001**	Oct 16, 2000

VOLTAREN

AB	**+!**	GLAXOSMITHKLINE CONS	**1%**	**N022122**	**001**	Oct 17, 2007

SOLUTION;TOPICAL
DICLOFENAC SODIUM

AT		AMNEAL PHARMS	**1.5%**	**A206116**	**001**	Sep 02, 2016
AT	**!**	APOTEX INC	**1.5%**	**A202027**	**001**	May 27, 2014

DICLOFENAC SODIUM

SOLUTION;TOPICAL

DICLOFENAC SODIUM

AT		LUPIN LTD	**1.5%**	**A204132**	**001**	Aug 20, 2015
AT		NOVEL LABS INC	**1.5%**	**A205878**	**001**	Dec 09, 2015
AT		RICONPHARMA LLC	**1.5%**	**A206715**	**001**	Aug 07, 2017
AT		TARO	**1.5%**	**A203818**	**001**	Nov 26, 2014
AT		TELIGENT PHARMA INC	**1.5%**	**A202769**	**001**	Jul 08, 2015
AT		TWI PHARMS	**1.5%**	**A202393**	**001**	Nov 24, 2014
AT		WATSON LABS INC	**1.5%**	**A202852**	**001**	Nov 24, 2014
AT		ZYDUS PHARMS USA INC	**1.5%**	**A206411**	**001**	Apr 17, 2018

PENNSAID

	+!	HZNP	2%	N204623	001	Jan 16, 2014

SOLUTION/DROPS;OPHTHALMIC

DICLOFENAC SODIUM

AT		AKORN	**0.1%**	**A077845**	**001**	Apr 17, 2008
AT		ALTAIRE PHARMS INC	**0.1%**	**A203383**	**001**	Nov 16, 2015
AT		BAUSCH AND LOMB	**0.1%**	**A078792**	**001**	Dec 28, 2007
AT		RISING PHARMS	**0.1%**	**A078553**	**001**	Dec 28, 2007
AT		SANDOZ INC	**0.1%**	**A078031**	**001**	Feb 06, 2008

VOLTAREN

AT	**+!**	NOVARTIS	**0.1%**	**N020037**	**001**	Mar 28, 1991

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM

AB		ACTAVIS ELIZABETH	**50MG**	**A074514**	**001**	Mar 26, 1996
AB			**75MG**	**A074514**	**002**	Mar 26, 1996
AB		CARLSBAD	**25MG**	**A075185**	**002**	Nov 13, 1998
AB			**50MG**	**A075185**	**003**	Nov 13, 1998
AB			**75MG**	**A075185**	**001**	Nov 13, 1998
AB	**!**	CASI PHARMS INC	**25MG**	**A074376**	**001**	Sep 28, 1995
AB	**!**		**50MG**	**A074376**	**002**	Sep 28, 1995
AB	**!**		**75MG**	**A074394**	**001**	Nov 30, 1995
AB		MYLAN PHARMS INC	**50MG**	**A075281**	**002**	Feb 12, 2002
AB			**75MG**	**A075281**	**003**	Feb 12, 2002
AB		UNIQUE PHARM LABS	**25MG**	**A090066**	**001**	Dec 01, 2010
AB			**50MG**	**A090066**	**002**	Dec 01, 2010
AB			**75MG**	**A077863**	**003**	Jun 08, 2007

TABLET, EXTENDED RELEASE;ORAL

DICLOFENAC SODIUM

AB	**!**	DEXCEL LTD	**100MG**	**A076201**	**001**	Nov 06, 2002
AB		MYLAN	**100MG**	**A076152**	**001**	Dec 13, 2001
AB		VPNA	**100MG**	**A075492**	**001**	Feb 11, 2000

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

ARTHROTEC

AB	**+**	GD SEARLE LLC	**50MG;0.2MG**	**N020607**	**001**	Dec 24, 1997
AB	**+!**		**75MG;0.2MG**	**N020607**	**002**	Dec 24, 1997

DICLOFENAC SODIUM AND MISOPROSTOL

AB		ACTAVIS LABS FL INC	**50MG;0.2MG**	**A201089**	**001**	Jul 09, 2012
AB			**75MG;0.2MG**	**A201089**	**002**	Jul 09, 2012
AB		AMNEAL PHARMS	**50MG;0.2MG**	**A203995**	**001**	Nov 25, 2016
AB			**75MG;0.2MG**	**A203995**	**002**	Nov 25, 2016
AB		EXELA HOLDINGS	**50MG;0.2MG**	**A200540**	**001**	Mar 14, 2014
AB			**75MG;0.2MG**	**A200540**	**002**	Mar 14, 2014
AB		SANDOZ	**50MG;0.2MG**	**A200158**	**001**	May 09, 2013
AB			**75MG;0.2MG**	**A200158**	**002**	May 09, 2013

DICLOXACILLIN SODIUM

CAPSULE;ORAL

DICLOXACILLIN SODIUM

AB		SANDOZ	**EQ 250MG BASE**	**A061454**	**001**	
AB	**!**		**EQ 500MG BASE**	**A061454**	**003**	
AB		TEVA	**EQ 250MG BASE**	**A062286**	**001**	Jun 03, 1982
AB			**EQ 500MG BASE**	**A062286**	**002**	Jun 03, 1982
		SANDOZ	EQ 125MG BASE	A061454	002	

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

BENTYL

AB	**+!**	ALLERGAN SALES LLC	**10MG**	**N007409**	**003**	Oct 15, 1984

DICYCLOMINE HYDROCHLORIDE

AB		LANNETT	**10MG**	**A084285**	**001**	
AB		MYLAN	**10MG**	**A040319**	**001**	Sep 07, 1999
AB		WATSON LABS	**10MG**	**A085082**	**001**	Jun 19, 1986
AB		WEST WARD	**10MG**	**A040204**	**001**	Feb 28, 1997

INJECTABLE;INJECTION

BENTYL

AP	**+!**	ALLERGAN SALES LLC	**10MG/ML**	**N008370**	**001**	Oct 15, 1984

BENTYL PRESERVATIVE FREE

AP	**+!**	ALLERGAN SALES LLC	**10MG/ML**	**N008370**	**002**	Oct 15, 1984

DICYCLOMINE HYDROCHLORIDE

AP		AKORN INC	**10MG/ML**	**A207084**	**001**	May 04, 2018
AP		APC PHARMS LLC	**10MG/ML**	**A210979**	**001**	Jul 02, 2018
AP		LUITPOLD	**10MG/ML**	**A208353**	**001**	Feb 17, 2017
AP		RENAISSANCE SSA LLC	**10MG/ML**	**A207076**	**001**	Nov 02, 2018

DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)

AP		WEST-WARD PHARMS INT	**10MG/ML**	**A040465**	**001**	Jun 30, 2003

SYRUP;ORAL

DICYCLOMINE HYDROCHLORIDE

	!	GENERICS	10MG/5ML	A040169	001	Mar 24, 2005

TABLET;ORAL

BENTYL

AB	**+!**	ALLERGAN SALES LLC	**20MG**	**N007409**	**001**	Oct 15, 1984

DICYCLOMINE HYDROCHLORIDE

AB		HIKMA PHARMS	**20MG**	**A040161**	**001**	Oct 01, 1996
AB		LANNETT	**20MG**	**A040230**	**001**	Feb 26, 1999
AB		MYLAN	**20MG**	**A040317**	**001**	Sep 07, 1999
AB		WATSON LABS	**20MG**	**A085223**	**001**	Jul 30, 1986

DIDANOSINE

CAPSULE, DELAYED REL PELLETS;ORAL

DIDANOSINE

AB		AURO BINDO PHARMA	**125MG**	**A090094**	**001**	Sep 24, 2008
AB			**200MG**	**A090094**	**002**	Sep 24, 2008
AB			**250MG**	**A090094**	**003**	Sep 24, 2008
AB			**400MG**	**A090094**	**004**	Sep 24, 2008

VIDEX EC

AB	**+**	BRISTOL MYERS SQUIBB	**125MG**	**N021183**	**001**	Oct 31, 2000
AB	**+**		**200MG**	**N021183**	**002**	Oct 31, 2000
AB	**+**		**250MG**	**N021183**	**003**	Oct 31, 2000
AB	**+!**		**400MG**	**N021183**	**004**	Oct 31, 2000

FOR SOLUTION;ORAL

VIDEX

	+!	BRISTOL-MYERS SQUIBB	10MG/ML	N020156	001	Oct 09, 1991

DIENOGEST; ESTRADIOL VALERATE

TABLET;ORAL

NATAZIA

	+!	BAYER HLTHCARE	N/A,2MG,3MG,N/A,N/A;3MG,2MG,2MG,1MG,N/A	N022252	001	May 06, 2010

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

DIETHYLPROPION HYDROCHLORIDE

AA		AVANTHI INC	**25MG**	**A201212**	**001**	Dec 22, 2010
AA		LANNETT CO INC	**25MG**	**A200177**	**001**	Jul 18, 2011

TENUATE

AA	**+!**	TEVA BRANDED PHARM	**25MG**	**N011722**	**002**	

TABLET, EXTENDED RELEASE;ORAL

DIETHYLPROPION HYDROCHLORIDE

AB		LANNETT CO INC	**75MG**	**A091680**	**001**	Oct 24, 2011

TENUATE DOSPAN

AB	**+!**	TEVA BRANDED PHARM	**75MG**	**N012546**	**001**	

DIFLORASONE DIACETATE

CREAM;TOPICAL

DIFLORASONE DIACETATE

BX	!	FOUGERA PHARMS	0.05%	A076263	001	Dec 20, 2002
BX	!	TARO	0.05%	A075508	001	Apr 24, 2000

OINTMENT;TOPICAL

DIFLORASONE DIACETATE

AB		AKORN	**0.05%**	**A206572**	**001**	Jul 24, 2015
AB		FOUGERA PHARMS	**0.05%**	**A075374**	**001**	Apr 27, 1999
AB		RISING PHARMS	**0.05%**	**A207440**	**001**	Feb 27, 2017
AB	**!**	TARO	**0.05%**	**A075331**	**001**	May 14, 1999
AB		TELIGENT PHARMA INC	**0.05%**	**A210753**	**001**	Jun 12, 2018

DIFLUNISAL

TABLET;ORAL

DIFLUNISAL

AB		HERITAGE PHARMA	**500MG**	**A202845**	**001**	Mar 08, 2012
AB	**!**	TEVA	**500MG**	**A073673**	**001**	Jul 31, 1992
AB		ZYDUS PHARMS USA INC	**500MG**	**A203547**	**001**	Jun 16, 2017

DIFLUPREDNATE

EMULSION;OPHTHALMIC

DUREZOL

	+!	NOVARTIS PHARMS CORP	0.05%	N022212	001	Jun 23, 2008

DIGOXIN

ELIXIR;ORAL

DIGOXIN

	+!	WEST-WARD PHARMS INT	0.05MG/ML	N021648	001	Aug 26, 2004

INJECTABLE;INJECTION

DIGOXIN

AP		SANDOZ INC	**0.25MG/ML**	**A040481**	**001**	Aug 21, 2003
AP		WEST-WARD PHARMS INT	**0.25MG/ML**	**A083391**	**001**	

LANOXIN

AP	**+!**	COVIS PHARMA BV	**0.25MG/ML**	**N009330**	**002**	

LANOXIN PEDIATRIC

	+!	COVIS PHARMA BV	0.1MG/ML	N009330	004	

TABLET;ORAL

DIGOXIN

AB		HIKMA INTL PHARMS	**0.125MG**	**A077002**	**002**	Oct 30, 2007
AB			**0.25MG**	**A077002**	**001**	Oct 30, 2007
AB		IMPAX LABS	**0.125MG**	**A078556**	**001**	Jul 20, 2009
AB			**0.25MG**	**A078556**	**002**	Jul 20, 2009
AB		MYLAN PHARMS INC	**0.125MG**	**A040282**	**001**	Dec 23, 1999
AB			**0.25MG**	**A040282**	**002**	Dec 23, 1999
AB		STEVENS J	**0.125MG**	**A076268**	**001**	Jul 26, 2002
AB			**0.25MG**	**A076268**	**002**	Jul 26, 2002
AB		SUN PHARM INDS INC	**0.125MG**	**A076363**	**001**	Jan 31, 2003
AB			**0.25MG**	**A076363**	**002**	Jan 31, 2003

LANOXIN

AB	**+**	CONCORDIA PHARMS INC	**0.125MG**	**N020405**	**002**	Sep 30, 1997
AB	**+!**		**0.25MG**	**N020405**	**004**	Sep 30, 1997
	+		0.0625MG	N020405	001	Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION

D.H.E. 45

AP	**+!**	VALEANT	**1MG/ML**	**N005929**	**001**	

DIHYDROERGOTAMINE MESYLATE

AP		HIKMA PHARMS	**1MG/ML**	**A206621**	**001**	Sep 15, 2017
AP		PADDOCK LLC	**1MG/ML**	**A040475**	**001**	Apr 28, 2003
AP		SAGENT PHARMS	**1MG/ML**	**A207264**	**001**	Jul 11, 2018
AP		WEST-WARD PHARMS INT	**1MG/ML**	**A040453**	**001**	Jun 09, 2003

SPRAY, METERED;NASAL

MIGRANAL

	+!	VALEANT	0.5MG/INH	N020148	001	Dec 08, 1997

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE							
AB2		APOTEX	**120MG**	**A074943**	**003**	Dec 19, 2000
AB2			**180MG**	**A074943**	**002**	Dec 19, 2000
AB2			**240MG**	**A074943**	**001**	Aug 06, 1998
AB2		MYLAN	**120MG**	**A075124**	**002**	Mar 18, 1998
AB2			**180MG**	**A075124**	**003**	Mar 18, 1998
AB2	!		**240MG**	**A075124**	**001**	Mar 18, 1998
CARDIZEM CD							
AB3	+	VALEANT INTL	**120MG**	**N020062**	**001**	Aug 10, 1992
AB3	+		**180MG**	**N020062**	**002**	Dec 27, 1991
AB3	+		**240MG**	**N020062**	**003**	Dec 27, 1991
AB3	+		**300MG**	**N020062**	**004**	Dec 27, 1991
AB3	+!		**360MG**	**N020062**	**005**	Aug 24, 1999
CARTIA XT							
AB3		ACTAVIS LABS FL INC	**120MG**	**A074752**	**002**	Jul 09, 1998
AB3			**180MG**	**A074752**	**001**	Jul 09, 1998
AB3			**240MG**	**A074752**	**003**	Jul 09, 1998
AB3			**300MG**	**A074752**	**004**	Jul 09, 1998
DILTIAZEM HYDROCHLORIDE							
AB3		ACTAVIS ELIZABETH	**360MG**	**A202463**	**001**	Dec 07, 2012
AB3		PAR PHARM	**120MG**	**A074984**	**001**	Dec 20, 1999
AB3			**180MG**	**A074984**	**002**	Dec 20, 1999
AB3			**240MG**	**A074984**	**003**	Dec 20, 1999
AB3			**300MG**	**A074984**	**004**	Dec 20, 1999
AB3			**360MG**	**A209766**	**001**	May 30, 2018
AB3		SUN PHARM INDS LTD	**120MG**	**A203023**	**001**	Jun 08, 2017
AB3			**180MG**	**A203023**	**002**	Jun 08, 2017
AB3			**240MG**	**A203023**	**003**	Jun 08, 2017
AB3			**300MG**	**A203023**	**004**	Jun 08, 2017
AB3			**360MG**	**A203023**	**005**	Jun 08, 2017
AB3		SUN PHARMA GLOBAL	**120MG**	**A090492**	**001**	Oct 28, 2011
AB3			**180MG**	**A090492**	**002**	Oct 28, 2011
AB3			**240MG**	**A090492**	**003**	Oct 28, 2011
AB3			**300MG**	**A090492**	**004**	Oct 28, 2011
AB3			**360MG**	**A090492**	**005**	Oct 28, 2011
AB3		TWI PHARMS	**120MG**	**A205231**	**001**	Aug 30, 2018
AB3			**180MG**	**A205231**	**002**	Aug 30, 2018
AB3			**240MG**	**A205231**	**003**	Aug 30, 2018
AB3			**300MG**	**A205231**	**004**	Aug 30, 2018
AB3			**360MG**	**A205231**	**005**	Aug 30, 2018
AB3		VALEANT PHARMS NORTH	**120MG**	**A075116**	**001**	Dec 23, 1999
AB3			**180MG**	**A075116**	**002**	Dec 23, 1999
AB3			**240MG**	**A075116**	**003**	Dec 23, 1999
AB3			**300MG**	**A075116**	**004**	Dec 23, 1999
AB3		ZYDUS PHARMS USA INC	**120MG**	**A206534**	**001**	Aug 08, 2017
AB3			**180MG**	**A206534**	**002**	Aug 08, 2017
AB3			**240MG**	**A206534**	**003**	Aug 08, 2017
AB3			**300MG**	**A206534**	**004**	Aug 08, 2017
AB3			**360MG**	**A206534**	**005**	Aug 08, 2017
AB4		SANDOZ	**120MG**	**A091022**	**001**	Sep 28, 2012
AB4			**180MG**	**A091022**	**002**	Sep 28, 2012
AB4			**240MG**	**A091022**	**003**	Sep 28, 2012
AB4			**300MG**	**A091022**	**004**	Sep 28, 2012
AB4			**360MG**	**A091022**	**005**	Sep 28, 2012
AB4			**420MG**	**A091022**	**006**	Sep 28, 2012
AB4		SUN PHARMA GLOBAL	**120MG**	**A090421**	**001**	Nov 15, 2010
AB4			**180MG**	**A090421**	**002**	Nov 15, 2010
AB4			**240MG**	**A090421**	**003**	Nov 15, 2010
AB4			**300MG**	**A090421**	**004**	Nov 15, 2010
AB4			**360MG**	**A090421**	**005**	Nov 15, 2010
AB4		ZYDUS PHARMS USA INC	**120MG**	**A206641**	**001**	Aug 11, 2017
AB4			**180MG**	**A206641**	**002**	Aug 11, 2017
AB4			**240MG**	**A206641**	**003**	Aug 11, 2017
AB4			**300MG**	**A206641**	**004**	Aug 11, 2017
AB4			**360MG**	**A206641**	**005**	Aug 11, 2017
AB4			**420MG**	**A206641**	**006**	Aug 11, 2017

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTZAC

AB4		APOTEX INC	**120MG**	**A076395**	**001**	Feb 01, 2006
AB4			**180MG**	**A076395**	**002**	Feb 01, 2006
AB4			**240MG**	**A076395**	**003**	Feb 01, 2006
AB4			**300MG**	**A076395**	**004**	Feb 01, 2006
AB4			**360MG**	**A076395**	**005**	Feb 01, 2006

TAZTIA XT

AB4		ACTAVIS LABS FL INC	**120MG**	**A075401**	**001**	Apr 10, 2003
AB4			**180MG**	**A075401**	**002**	Apr 10, 2003
AB4			**240MG**	**A075401**	**003**	Apr 10, 2003
AB4			**300MG**	**A075401**	**004**	Apr 10, 2003
AB4			**360MG**	**A075401**	**005**	Apr 10, 2003

TIAZAC

AB4	+	VALEANT PHARMS NORTH	**120MG**	**N020401**	**001**	Sep 11, 1995
AB4	+		**180MG**	**N020401**	**002**	Sep 11, 1995
AB4	+		**240MG**	**N020401**	**003**	Sep 11, 1995
AB4	+		**300MG**	**N020401**	**004**	Sep 11, 1995
AB4	+		**360MG**	**N020401**	**005**	Sep 11, 1995
AB4	+!		**420MG**	**N020401**	**006**	Oct 16, 1998

DILTIAZEM HYDROCHLORIDE

BC	!	MYLAN	120MG	A074910	003	May 02, 1997
			60MG	A074910	001	May 02, 1997
			90MG	A074910	002	May 02, 1997

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

AP		AKORN INC	**5MG/ML**	**A075086**	**001**	Apr 09, 1998
AP	!	ATHENEX INC	**5MG/ML**	**A074617**	**001**	Feb 28, 1996
AP		HIKMA FARMACEUTICA	**5MG/ML**	**A202651**	**001**	Aug 09, 2012
AP		HOSPIRA	**5MG/ML**	**A074941**	**001**	Apr 15, 1998
AP		INTL MEDICATION	**5MG/ML**	**A075749**	**001**	Nov 21, 2001
AP		WEST-WARD PHARMS INT	**5MG/ML**	**A078538**	**001**	Dec 17, 2008
	!	HOSPIRA	100MG/VIAL	A075853	001	Dec 17, 2002

TABLET;ORAL

CARDIZEM

AB	+	VALEANT INTL	**30MG**	**N018602**	**001**	Nov 05, 1982
AB	+		**60MG**	**N018602**	**002**	Nov 05, 1982
AB	+		**90MG**	**N018602**	**003**	Dec 08, 1986
AB	+!		**120MG**	**N018602**	**004**	Dec 08, 1986

DILTIAZEM HYDROCHLORIDE

AB		MYLAN	**30MG**	**A072838**	**004**	Nov 05, 1992
AB			**60MG**	**A072838**	**003**	Nov 05, 1992
AB			**90MG**	**A072838**	**002**	Nov 05, 1992
AB			**120MG**	**A072838**	**001**	Nov 05, 1992
AB		TEVA	**30MG**	**A074185**	**001**	May 31, 1995
AB			**60MG**	**A074185**	**002**	May 31, 1995
AB			**90MG**	**A074185**	**003**	May 31, 1995
AB			**120MG**	**A074185**	**004**	May 31, 1995

TABLET, EXTENDED RELEASE;ORAL

CARDIZEM LA

AB	+	VALEANT INTL	**120MG**	**N021392**	**001**	Feb 06, 2003
AB	+		**180MG**	**N021392**	**002**	Feb 06, 2003
AB	+		**240MG**	**N021392**	**003**	Feb 06, 2003
AB	+		**300MG**	**N021392**	**004**	Feb 06, 2003
AB	+		**360MG**	**N021392**	**005**	Feb 06, 2003
AB	+!		**420MG**	**N021392**	**006**	Feb 06, 2003

DILTIAZEM HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	**120MG**	**A077686**	**006**	Mar 15, 2010
AB			**180MG**	**A077686**	**005**	Mar 15, 2010
AB			**240MG**	**A077686**	**004**	Mar 15, 2010
AB			**300MG**	**A077686**	**003**	Mar 15, 2010
AB			**360MG**	**A077686**	**002**	Mar 15, 2010
AB			**420MG**	**A077686**	**001**	Mar 15, 2010

DIMENHYDRINATE
INJECTABLE;INJECTION
DIMENHYDRINATE

	!	FRESENIUS KABI USA	50MG/ML	A040519	001	Jun 23, 2004

DIMERCAPROL
INJECTABLE;INJECTION
BAL

	+!	AKORN	10%	N005939	001	

DIMETHYL FUMARATE
CAPSULE, DELAYED RELEASE;ORAL
TECFIDERA

	+	BIOGEN IDEC INC	120MG	N204063	001	Mar 27, 2013
	+!		240MG	N204063	002	Mar 27, 2013

DIMETHYL SULFOXIDE
SOLUTION;INTRAVESICAL
DIMETHYL SULFOXIDE

AT		MYLAN INSTITUTIONAL	**50%**	**A076185**	**001**	Nov 29, 2002

RIMSO-50

AT	**+!**	MYLAN INSTITUTIONAL	**50%**	**N017788**	**001**	

DINOPROSTONE
GEL;ENDOCERVICAL
PREPIDIL

	+!	PHARMACIA AND UPJOHN	0.5MG/3GM	N019617	001	Dec 09, 1992

INSERT, EXTENDED RELEASE;VAGINAL
CERVIDIL

	+!	FERRING PHARMS INC	10MG	N020411	001	Mar 30, 1995

SUPPOSITORY;VAGINAL
PROSTIN E2

	+!	PHARMACIA AND UPJOHN	20MG	N017810	001	

DIPHENHYDRAMINE HYDROCHLORIDE
CAPSULE;ORAL
DIPHENHYDRAMINE HYDROCHLORIDE

	!	BARR	50MG	A080738	001	

ELIXIR;ORAL
DIPHENHYDRAMINE HYDROCHLORIDE

	!	PHARM ASSOC	12.5MG/5ML	A087513	001	Feb 10, 1982

INJECTABLE;INJECTION
DIPHENHYDRAMINE HYDROCHLORIDE

AP		APP PHARMS	**50MG/ML**	**A040466**	**001**	May 28, 2002
AP		HOSPIRA	**50MG/ML**	**A040140**	**001**	Nov 20, 1998
AP		MICRO LABS	**50MG/ML**	**A205723**	**001**	Aug 22, 2018
AP		MYLAN INSTITUTIONAL	**50MG/ML**	**A040498**	**001**	Jul 12, 2005
AP	**!**	WEST-WARD PHARMS INT	**50MG/ML**	**A080817**	**002**	

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

AP		FRESENIUS KABI USA	**50MG/ML**	**A091526**	**001**	Mar 26, 2013

DIPYRIDAMOLE
INJECTABLE;INJECTION
DIPYRIDAMOLE

AP	**!**	ATHENEX INC	**5MG/ML**	**A074939**	**001**	Apr 13, 1998
AP		FRESENIUS KABI USA	**5MG/ML**	**A074956**	**001**	Sep 30, 1998
AP		WEST-WARD PHARMS INT	**5MG/ML**	**A074521**	**001**	Oct 18, 1996

TABLET;ORAL
DIPYRIDAMOLE

AB		BARR	**25MG**	**A087184**	**001**	Oct 03, 1990
AB			**50MG**	**A087716**	**001**	Oct 03, 1990
AB			**75MG**	**A087717**	**001**	Oct 03, 1990
AB		IMPAX LABS	**25MG**	**A040782**	**001**	Jul 18, 2007
AB			**50MG**	**A040782**	**002**	Jul 18, 2007
AB			**75MG**	**A040782**	**003**	Jul 18, 2007
AB		MURTY PHARMS	**25MG**	**A040733**	**001**	Feb 13, 2007
AB			**50MG**	**A040733**	**002**	Feb 13, 2007
AB			**75MG**	**A040733**	**003**	Feb 13, 2007
AB		ZYDUS PHARMS USA INC	**25MG**	**A040874**	**001**	Jan 28, 2008
AB			**50MG**	**A040874**	**002**	Jan 28, 2008
AB			**75MG**	**A040874**	**003**	Jan 28, 2008

DIPYRIDAMOLE

TABLET;ORAL

PERSANTINE

AB	+	BOEHRINGER INGELHEIM	**25MG**	**N012836**	**003**	Dec 22, 1986
AB	+		**50MG**	**N012836**	**004**	Feb 06, 1987
AB	+!		**75MG**	**N012836**	**005**	Feb 06, 1987

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

DISOPYRAMIDE PHOSPHATE

AB		MAYNE PHARMA	**EQ 100MG BASE**	**A070173**	**001**	May 31, 1985
AB			**EQ 150MG BASE**	**A070173**	**002**	May 31, 1985
AB		TEVA	**EQ 100MG BASE**	**A070101**	**001**	Feb 22, 1985
AB			**EQ 150MG BASE**	**A070102**	**001**	Feb 22, 1985

NORPACE

AB	+	GD SEARLE LLC	**EQ 100MG BASE**	**N017447**	**001**	
AB	+!		**EQ 150MG BASE**	**N017447**	**002**	

CAPSULE, EXTENDED RELEASE;ORAL

NORPACE CR

	+	GD SEARLE LLC	EQ 100MG BASE	N018655	001	Jul 20, 1982
	+!		EQ 150MG BASE	N018655	002	Jul 20, 1982

DISULFIRAM

TABLET;ORAL

ANTABUSE

AB		ODYSSEY PHARMS	**250MG**	**A088482**	**001**	Dec 08, 1983
AB	!		**500MG**	**A088483**	**001**	Dec 08, 1983

DISULFIRAM

AB		ALVOGEN MALTA	**250MG**	**A091681**	**001**	Aug 08, 2013
AB		CHARTWELL MOLECULES	**250MG**	**A091563**	**001**	Dec 31, 2012
AB			**500MG**	**A091563**	**002**	Dec 31, 2012
AB		MYLAN PHARMS INC	**250MG**	**A203916**	**001**	Mar 04, 2015
AB			**500MG**	**A203916**	**002**	Mar 04, 2015
AB		SIGMAPHARM LABS LLC	**250MG**	**A091619**	**001**	Mar 28, 2011
AB			**500MG**	**A091619**	**002**	Mar 28, 2011
AB		WEST-WARD PHARMS INT	**250MG**	**A202652**	**001**	Feb 05, 2014
AB			**500MG**	**A202652**	**002**	Feb 05, 2014

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL

DEPAKOTE

AB	+!	ABBVIE	**EQ 125MG VALPROIC ACID**	**N019680**	**001**	Sep 12, 1989

DIVALPROEX SODIUM

AB		DR REDDYS LABS LTD	**EQ 125MG VALPROIC ACID**	**A078979**	**001**	Jan 23, 2009
AB		MYLAN	**EQ 125MG VALPROIC ACID**	**A090407**	**001**	Mar 28, 2011
AB		ZYDUS PHARMS USA INC	**EQ 125MG VALPROIC ACID**	**A078919**	**001**	Jan 27, 2009

TABLET, DELAYED RELEASE;ORAL

DEPAKOTE

AB	+	ABBVIE	**EQ 125MG VALPROIC ACID**	**N018723**	**003**	Oct 26, 1984
AB	+		**EQ 250MG VALPROIC ACID**	**N018723**	**001**	Mar 10, 1983
AB	+!		**EQ 500MG VALPROIC ACID**	**N018723**	**002**	Mar 10, 1983

DIVALPROEX SODIUM

AB		ACTAVIS LABS FL INC	**EQ 500MG VALPROIC ACID**	**A079080**	**001**	Feb 25, 2011
AB		ANCHEN PHARMS	**EQ 500MG VALPROIC ACID**	**A078411**	**001**	Nov 03, 2008
AB		APOTEX INC	**EQ 125MG VALPROIC ACID**	**A077615**	**003**	Jul 29, 2008
AB			**EQ 250MG VALPROIC ACID**	**A077615**	**002**	Jul 29, 2008
AB			**EQ 500MG VALPROIC ACID**	**A077615**	**001**	Jul 29, 2008
AB		AUROBINDO PHARMA LTD	**EQ 125MG VALPROIC ACID**	**A090554**	**001**	Apr 21, 2011
AB			**EQ 250MG VALPROIC ACID**	**A090554**	**002**	Apr 21, 2011
AB			**EQ 500MG VALPROIC ACID**	**A090554**	**003**	Apr 21, 2011
AB		DR REDDYS LABS LTD	**EQ 125MG VALPROIC ACID**	**A078755**	**001**	Jul 29, 2008
AB			**EQ 250MG VALPROIC ACID**	**A078755**	**002**	Jul 29, 2008
AB			**EQ 500MG VALPROIC ACID**	**A078755**	**003**	Jul 29, 2008
AB		LUPIN	**EQ 125MG VALPROIC ACID**	**A078790**	**001**	Jul 29, 2008
AB			**EQ 250MG VALPROIC ACID**	**A078790**	**002**	Jul 29, 2008
AB			**EQ 500MG VALPROIC ACID**	**A078790**	**003**	Jul 29, 2008
AB		MYLAN	**EQ 125MG VALPROIC ACID**	**A090062**	**001**	Mar 17, 2009
AB			**EQ 250MG VALPROIC ACID**	**A090062**	**002**	Mar 17, 2009
AB			**EQ 500MG VALPROIC ACID**	**A090062**	**003**	Mar 17, 2009
AB		ORCHID HLTHCARE	**EQ 125MG VALPROIC ACID**	**A078853**	**001**	Nov 25, 2008
AB			**EQ 250MG VALPROIC ACID**	**A078853**	**002**	Nov 25, 2008

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM

AB			**EQ 500MG VALPROIC ACID**	**A078853**	**003**	Nov 25, 2008
AB		PRINSTON INC	**EQ 125MG VALPROIC ACID**	**A090210**	**001**	Nov 30, 2009
AB			**EQ 250MG VALPROIC ACID**	**A090210**	**002**	Nov 30, 2009
AB			**EQ 500MG VALPROIC ACID**	**A090210**	**003**	Nov 30, 2009
AB		SANDOZ	**EQ 125MG VALPROIC ACID**	**A078290**	**003**	Jul 29, 2008
AB			**EQ 250MG VALPROIC ACID**	**A078290**	**002**	Jul 29, 2008
AB			**EQ 500MG VALPROIC ACID**	**A078290**	**001**	Jul 29, 2008
AB		SUN PHARM INDS	**EQ 125MG VALPROIC ACID**	**A078597**	**001**	Jul 29, 2008
AB			**EQ 250MG VALPROIC ACID**	**A078597**	**002**	Jul 29, 2008
AB			**EQ 500MG VALPROIC ACID**	**A078597**	**003**	Jul 29, 2008
AB		TEVA	**EQ 125MG VALPROIC ACID**	**A076941**	**001**	Jul 29, 2008
AB			**EQ 250MG VALPROIC ACID**	**A076941**	**002**	Jul 29, 2008
AB			**EQ 500MG VALPROIC ACID**	**A076941**	**003**	Jul 29, 2008
AB		UNICHEM LABS LTD	**EQ 125MG VALPROIC ACID**	**A079163**	**001**	Apr 05, 2011
AB			**EQ 250MG VALPROIC ACID**	**A079163**	**002**	Apr 05, 2011
AB			**EQ 500MG VALPROIC ACID**	**A079163**	**003**	Apr 05, 2011
AB		UPSHER SMITH LABS	**EQ 125MG VALPROIC ACID**	**A078182**	**001**	Jul 29, 2008
AB			**EQ 250MG VALPROIC ACID**	**A078182**	**002**	Jul 29, 2008
AB			**EQ 500MG VALPROIC ACID**	**A078182**	**003**	Jul 29, 2008
AB		WOCKHARDT	**EQ 125MG VALPROIC ACID**	**A077296**	**001**	Jul 31, 2008
AB			**EQ 250MG VALPROIC ACID**	**A077296**	**002**	Jul 31, 2008
AB			**EQ 500MG VALPROIC ACID**	**A077296**	**003**	Jul 31, 2008
AB		ZYDUS PHARMS USA INC	**EQ 125MG VALPROIC ACID**	**A077100**	**001**	Mar 05, 2009
AB			**EQ 250MG VALPROIC ACID**	**A077100**	**002**	Mar 05, 2009
AB			**EQ 500MG VALPROIC ACID**	**A077100**	**003**	Mar 05, 2009

TABLET, EXTENDED RELEASE;ORAL

DEPAKOTE ER

AB	+	ABBVIE	**EQ 250MG VALPROIC ACID**	**N021168**	**002**	May 31, 2002
AB	+!		**EQ 500MG VALPROIC ACID**	**N021168**	**001**	Aug 04, 2000

DIVALPROEX SODIUM

AB		AMNEAL PHARMS	**EQ 250MG VALPROIC ACID**	**A203730**	**001**	May 29, 2015
AB			**EQ 500MG VALPROIC ACID**	**A203730**	**002**	May 29, 2015
AB		ANCHEN PHARMS	**EQ 250MG VALPROIC ACID**	**A078445**	**001**	Feb 26, 2009
AB			**EQ 500MG VALPROIC ACID**	**A078445**	**002**	Aug 04, 2009
AB		AUROBINDO PHARMA LTD	**EQ 250MG VALPROIC ACID**	**A202419**	**001**	Jun 02, 2014
AB			**EQ 500MG VALPROIC ACID**	**A202419**	**002**	Jun 02, 2014
AB		DR REDDYS LABS LTD	**EQ 250MG VALPROIC ACID**	**A090161**	**001**	Mar 15, 2012
AB		IMPAX LABS	**EQ 250MG VALPROIC ACID**	**A078791**	**001**	May 06, 2009
AB			**EQ 500MG VALPROIC ACID**	**A078791**	**002**	Aug 04, 2009
AB		MYLAN	**EQ 250MG VALPROIC ACID**	**A077567**	**001**	Jan 29, 2009
AB			**EQ 500MG VALPROIC ACID**	**A077567**	**002**	Jan 29, 2009
AB		REDDYS	**EQ 500MG VALPROIC ACID**	**A090070**	**001**	Mar 12, 2012
AB		WOCKHARDT	**EQ 250MG VALPROIC ACID**	**A078705**	**002**	Feb 10, 2009
AB			**EQ 500MG VALPROIC ACID**	**A078705**	**001**	Aug 04, 2009
AB		ZYDUS PHARMS USA INC	**EQ 250MG VALPROIC ACID**	**A078239**	**001**	Feb 27, 2009
AB			**EQ 500MG VALPROIC ACID**	**A078239**	**002**	Aug 04, 2009

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE

AP		HOSPIRA	**EQ 12.5MG BASE/ML**	**A074086**	**001**	Nov 29, 1993
AP	!		**EQ 12.5MG BASE/ML**	**A074292**	**001**	Feb 16, 1995
AP		WEST-WARD PHARMS INT	**EQ 12.5MG BASE/ML**	**A074277**	**001**	Oct 31, 1994

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+!	BAXTER HLTHCARE	**EQ 50MG BASE/100ML**	**N020255**	**001**	Oct 19, 1993
AP	+!		**EQ 100MG BASE/100ML**	**N020255**	**003**	Oct 19, 1993
AP	+!		**EQ 200MG BASE/100ML**	**N020255**	**004**	Oct 19, 1993
AP	+!		**EQ 400MG BASE/100ML**	**N020255**	**005**	Oct 19, 1993
AP	+!	HOSPIRA	**EQ 50MG BASE/100ML**	**N020201**	**003**	Oct 19, 1993
AP	+!		**EQ 100MG BASE/100ML**	**N020201**	**002**	Oct 19, 1993
AP	+!		**EQ 200MG BASE/100ML**	**N020201**	**001**	Oct 19, 1993
AP	+!		**EQ 400MG BASE/100ML**	**N020201**	**006**	Jul 07, 1994

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

AP	**+**	ACCORD HLTHCARE	**20MG/ML (20MG/ML)**	**N201195**	**003**	Apr 20, 2012
AP	**+**		**80MG/4ML (20MG/ML)**	**N201195**	**004**	Apr 20, 2012
AP	**+!**		**160MG/8ML (20MG/ML)**	**N201195**	**005**	Apr 20, 2012
AP		ACTAVIS LLC	**20MG/ML (20MG/ML)**	**N203551**	**001**	Apr 12, 2013
AP			**80MG/4ML (20MG/ML)**	**N203551**	**002**	Apr 12, 2013
AP		AMNEAL PHARMS CO	**20MG/ML (20MG/ML)**	**A209640**	**001**	Jan 19, 2018
AP			**80MG/4ML (20MG/ML)**	**A209640**	**002**	Jan 19, 2018
AP			**160MG/8ML (20MG/ML)**	**A209640**	**003**	Jan 19, 2018
AP		CIPLA	**20MG/2ML (10MG/ML)**	**A209634**	**001**	Aug 24, 2018
AP			**80MG/8ML (10MG/ML)**	**A209634**	**002**	Aug 24, 2018
AP			**160MG/16ML (10MG/ML)**	**A209634**	**003**	Aug 24, 2018
AP		DFB ONCOLOGY LTD	**20MG/ML (20MG/ML)**	**A206177**	**001**	Jan 20, 2017
AP			**80MG/4ML (20MG/ML)**	**A206177**	**002**	Jan 20, 2017
AP		DR REDDYS LABS LTD	**20MG/ML (20MG/ML)**	**A204193**	**001**	Nov 05, 2014
AP			**80MG/4ML (20MG/ML)**	**A204193**	**002**	Nov 05, 2014
AP		EAGLE PHARMS	**20MG/ML (20MG/ML)**	**N205934**	**001**	Dec 22, 2015
AP			**80MG/4ML (20MG/ML)**	**N205934**	**002**	Dec 22, 2015
AP			**160MG/8ML (20MG/ML)**	**N205934**	**003**	Dec 22, 2015
AP	**+!**	HOSPIRA INC	**20MG/2ML (10MG/ML)**	**N022234**	**001**	Mar 08, 2011
AP	**+!**		**80MG/8ML (10MG/ML)**	**N022234**	**002**	Mar 08, 2011
AP	**+!**		**160MG/16ML (10MG/ML)**	**N022234**	**003**	Mar 08, 2011
AP		INGENUS PHARMS LLC	**20MG/2ML (10MG/ML)**	**A207563**	**001**	Aug 31, 2017
AP			**80MG/8ML (10MG/ML)**	**A207563**	**002**	Aug 31, 2017
AP			**160MG/16ML (10MG/ML)**	**A207563**	**003**	Aug 31, 2017
AP		JIANGSU HENGRUI MED	**20MG/ML (20MG/ML)**	**A207252**	**001**	Aug 09, 2017
AP			**80MG/4ML (20MG/ML)**	**A207252**	**002**	Aug 09, 2017
AP			**160MG/8ML (20MG/ML)**	**A207252**	**003**	Aug 09, 2017
AP		MYLAN LABS LTD	**20MG/2ML (10MG/ML)**	**A210072**	**001**	Jul 02, 2018
AP			**80MG/8ML (10MG/ML)**	**A210848**	**001**	Jul 06, 2018
AP		SANDOZ	**20MG/2ML (10MG/ML)**	**N201525**	**001**	Jun 29, 2011
AP			**80MG/8ML (10MG/ML)**	**N201525**	**002**	Jun 29, 2011
AP			**160MG/16ML (10MG/ML)**	**N201525**	**003**	Jun 29, 2011
AP		TEVA PHARMS USA	**20MG/ML (20MG/ML)**	**A203877**	**001**	Sep 16, 2015
AP			**80MG/4ML (20MG/ML)**	**A203877**	**002**	Sep 16, 2015

TAXOTERE

AP	**+!**	SANOFI AVENTIS US	**20MG/ML (20MG/ML)**	**N020449**	**003**	Aug 03, 2010
AP	**+!**		**80MG/4ML (20MG/ML)**	**N020449**	**004**	Aug 02, 2010
AP	**+!**		**160MG/8ML (20MG/ML)**	**N020449**	**005**	Apr 13, 2012

DOCETAXEL

		ACTAVIS LLC	140MG/7ML (20MG/ML)	N203551	003	Apr 12, 2013
		DFB ONCOLOGY LTD	200MG/10ML (20MG/ML)	A206177	003	Jan 20, 2017
	+	HOSPIRA INC	20MG/ML (20MG/ML)	N022234	004	Jun 23, 2016
	+		80MG/4ML (20MG/ML)	N022234	005	Jun 23, 2016
	+		160MG/8ML (20MG/ML)	N022234	007	Jan 24, 2017
	!	JIANGSU HENGRUI MED	40MG/ML	A203170	001	Feb 15, 2017

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

AP		MYLAN LABS LTD	**160MG/16ML (10MG/ML)**	**A208859**	**001**	Apr 30, 2018

DOFETILIDE

CAPSULE;ORAL

DOFETILIDE

AB		BIONPHARMA INC	**0.125MG**	**A208625**	**001**	Apr 10, 2018
AB			**0.25MG**	**A208625**	**002**	Apr 10, 2018
AB			**0.5MG**	**A208625**	**003**	Apr 10, 2018
AB		MAYNE PHARMA INC	**0.125MG**	**A207058**	**001**	Jun 06, 2016
AB			**0.25MG**	**A207058**	**002**	Jun 06, 2016
AB			**0.5MG**	**A207058**	**003**	Jun 06, 2016
AB		PAR PHARM INC	**0.125MG**	**A208519**	**001**	Oct 09, 2018
AB			**0.25MG**	**A208519**	**002**	Oct 09, 2018
AB			**0.5MG**	**A208519**	**003**	Oct 09, 2018
AB		SIGMAPHARM LABS LLC	**0.125MG**	**A207746**	**001**	Mar 26, 2018
AB			**0.25MG**	**A207746**	**002**	Mar 26, 2018
AB			**0.5MG**	**A207746**	**003**	Mar 26, 2018
AB		SUN PHARMA GLOBAL	**0.125MG**	**A210466**	**001**	Oct 09, 2018
AB			**0.25MG**	**A210466**	**002**	Oct 09, 2018
AB			**0.5MG**	**A210466**	**003**	Oct 09, 2018

DOFETILIDE

CAPSULE;ORAL

TIKOSYN

AB	**+**	PFIZER	**0.125MG**	**N020931**	**001**	Oct 01, 1999
AB	**+**		**0.25MG**	**N020931**	**002**	Oct 01, 1999
AB	**+!**		**0.5MG**	**N020931**	**003**	Oct 01, 1999

DOLUTEGRAVIR SODIUM

TABLET;ORAL

TIVICAY

+	VIIV HLTHCARE	EQ 10MG BASE	N204790	002	Jun 09, 2016
+		EQ 25MG BASE	N204790	003	Jun 09, 2016
+!		EQ 50MG BASE	N204790	001	Aug 12, 2013

DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE

TABLET;ORAL

JULUCA

+!	VIIV HLTHCARE	EQ 50MG BASE;EQ 25MG BASE	N210192	001	Nov 21, 2017

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

ARICEPT

AB	**+**	EISAI INC	**5MG**	**N020690**	**002**	Nov 25, 1996
AB	**+!**		**10MG**	**N020690**	**001**	Nov 25, 1996
AB	**+!**		**23MG**	**N022568**	**001**	Jul 23, 2010

DONEPEZIL HYDROCHLORIDE

AB	ACI HEALTHCARE LTD	**5MG**	**A078662**	**001**	May 31, 2011
AB		**10MG**	**A078662**	**002**	May 31, 2011
AB	ACTAVIS ELIZABETH	**23MG**	**A202415**	**001**	Dec 17, 2015
AB	ALEMBIC PHARMS LTD	**5MG**	**A201724**	**001**	Feb 25, 2013
AB		**10MG**	**A201724**	**002**	Feb 25, 2013
AB	AUROBINDO	**5MG**	**A090056**	**001**	May 31, 2011
AB		**10MG**	**A090056**	**002**	May 31, 2011
AB	CADILA PHARMS LTD	**5MG**	**A204609**	**001**	Sep 19, 2017
AB		**10MG**	**A204609**	**002**	Sep 19, 2017
AB	CIPLA LTD	**5MG**	**A077518**	**001**	May 31, 2011
AB		**10MG**	**A077518**	**002**	May 31, 2011
AB	CSPC OUYI PHARM CO	**5MG**	**A202114**	**001**	Jul 05, 2013
AB		**10MG**	**A202114**	**002**	Jul 05, 2013
AB	DEXCEL PHARMA	**23MG**	**A203713**	**001**	Feb 19, 2016
AB	DR REDDYS LABS LTD	**5MG**	**A201001**	**001**	May 31, 2011
AB		**10MG**	**A201001**	**002**	May 31, 2011
AB		**23MG**	**A202723**	**001**	Jul 24, 2013
AB	HETERO LABS LTD V	**5MG**	**A203034**	**001**	Jan 30, 2015
AB		**10MG**	**A203034**	**002**	Jan 30, 2015
AB	HISUN PHARM HANGZHOU	**23MG**	**A202410**	**001**	Mar 24, 2017
AB	INDICUS PHARMA	**5MG**	**A201634**	**001**	Jun 13, 2012
AB		**10MG**	**A201634**	**002**	Jun 13, 2012
AB		**23MG**	**A203419**	**001**	Apr 12, 2016
AB	JUBILANT GENERICS	**5MG**	**A090768**	**001**	May 31, 2011
AB		**10MG**	**A090768**	**002**	May 31, 2011
AB	LUPIN LTD	**23MG**	**A202782**	**001**	Oct 30, 2015
AB	MACLEODS PHARMS LTD	**5MG**	**A201146**	**001**	Aug 17, 2012
AB		**10MG**	**A201146**	**002**	Aug 17, 2012
AB		**23MG**	**A202631**	**001**	Jan 22, 2014
AB	MYLAN PHARMS INC	**5MG**	**A090521**	**001**	May 31, 2011
AB		**10MG**	**A090521**	**002**	May 31, 2011
AB		**23MG**	**A202656**	**001**	Oct 22, 2015
AB	OSMOTICA PHARM US	**23MG**	**A203114**	**001**	Jan 26, 2016
AB	PAR PHARM	**23MG**	**A202542**	**001**	Jul 24, 2013
AB	PLIVA HRVATSKA DOO	**5MG**	**A090425**	**001**	May 31, 2011
AB		**10MG**	**A090425**	**002**	May 31, 2011
AB	PRINSTON INC	**5MG**	**A200292**	**001**	May 31, 2011
AB		**10MG**	**A200292**	**002**	May 31, 2011
AB	SANDOZ	**5MG**	**A090290**	**001**	May 31, 2011
AB		**10MG**	**A090290**	**002**	May 31, 2011
AB	SCIEGEN PHARMS INC	**5MG**	**A203907**	**001**	Oct 29, 2014
AB		**10MG**	**A203907**	**002**	Oct 29, 2014
AB	STRIDES VIVIMED	**5MG**	**A090551**	**001**	May 31, 2011
AB		**10MG**	**A090551**	**002**	May 31, 2011
AB	SUN PHARM INDS	**5MG**	**A090493**	**001**	May 31, 2011
AB		**10MG**	**A090493**	**002**	May 31, 2011
AB	SUN PHARM INDS LTD	**23MG**	**A204293**	**001**	Jun 05, 2015

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

AB		TEVA	**5MG**	**A077344**	**001**	May 31, 2011
AB			**10MG**	**A077344**	**002**	May 31, 2011
AB		TORRENT PHARMS	**5MG**	**A090686**	**001**	May 31, 2011
AB			**10MG**	**A090686**	**002**	May 31, 2011
AB		TWI PHARMS	**23MG**	**A203104**	**001**	Oct 29, 2014
AB		UNICHEM LABS LTD	**5MG**	**A203656**	**001**	Jun 23, 2016
AB			**10MG**	**A203656**	**002**	Jun 23, 2016
AB		WOCKHARDT	**5MG**	**A091267**	**001**	May 31, 2011
AB			**10MG**	**A091267**	**002**	May 31, 2011
AB		ZYDUS PHARMS USA INC	**5MG**	**A090100**	**001**	Oct 24, 2012
AB			**10MG**	**A090100**	**002**	Oct 24, 2012
AB			**23MG**	**A203162**	**001**	Aug 31, 2017

TABLET, ORALLY DISINTEGRATING;ORAL

DONEPEZIL HYDROCHLORIDE

AB		HISUN PHARM HANGZHOU	**5MG**	**A205269**	**001**	Jul 27, 2018
AB			**10MG**	**A205269**	**002**	Jul 27, 2018
AB		MACLEODS PHARMS LTD	**5MG**	**A201787**	**001**	Dec 14, 2012
AB			**10MG**	**A201787**	**002**	Dec 14, 2012
AB		SANDOZ	**5MG**	**A091198**	**001**	May 10, 2011
AB	**!**		**10MG**	**A091198**	**002**	May 10, 2011
AB		UNICHEM LABS LTD	**5MG**	**A204831**	**001**	Nov 10, 2016
AB			**10MG**	**A204831**	**002**	Nov 10, 2016

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

NAMZARIC

+		ALLERGAN SALES LLC	10MG;7MG	N206439	003 Jul 18, 2016
+			10MG;14MG	N206439	001 Dec 23, 2014
+			10MG;21MG	N206439	004 Jul 18, 2016
+!			10MG;28MG	N206439	002 Dec 23, 2014

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOPAMINE HYDROCHLORIDE

AP		HIKMA INTL PHARMS	**40MG/ML**	**A207707**	**001**	Apr 11, 2018
AP			**80MG/ML**	**A207707**	**002**	Apr 11, 2018
AP	**+!**	HOSPIRA	**40MG/ML**	**N018132**	**001**	
AP	**+!**		**80MG/100ML**	**N018132**	**002**	Feb 04, 1982
AP	**+!**		**80MG/ML**	**N018132**	**004**	Jul 09, 1982
AP	**+!**		**160MG/100ML**	**N018132**	**003**	Feb 04, 1982
AP	**!**	LUITPOLD	**40MG/ML**	**A070799**	**001**	Feb 11, 1987
AP	**!**		**80MG/ML**	**A070820**	**001**	Feb 11, 1987

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%

AP	**+!**	B BRAUN	**80MG/100ML**	**N019099**	**002**	Oct 15, 1986
AP	**+!**		**320MG/100ML**	**N019099**	**004**	Oct 15, 1986

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**160MG/100ML**	**N019099**	**003**	Oct 15, 1986

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**80MG/100ML**	**N019615**	**001**	Mar 27, 1987
AP	**+!**		**160MG/100ML**	**N019615**	**002**	Mar 27, 1987
AP	**+!**		**320MG/100ML**	**N019615**	**003**	Mar 27, 1987
AP	**+!**	HOSPIRA	**80MG/100ML**	**N018826**	**001**	Sep 30, 1983
AP	**+!**		**160MG/100ML**	**N018826**	**002**	Sep 30, 1983
AP	**+!**		**320MG/100ML**	**N018826**	**003**	Sep 30, 1983

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

+!		B BRAUN	40MG/100ML	N019099	001	Oct 15, 1986

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

+!		BAXTER HLTHCARE	640MG/100ML	N019615	004	Mar 27, 1987

DORAVIRINE

TABLET;ORAL

PIFELTRO

+!		MSD MERCK CO	100MG	N210806	001	Aug 30, 2018

DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

DELSTRIGO

	+!	MSD MERCK CO	100MG;300MG;300MG	N210807	001	Aug 30, 2018

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT		BAUSCH AND LOMB	**EQ 2% BASE**	**A090143**	**001**	Jun 25, 2009
AT		HI TECH PHARMA	**EQ 2% BASE**	**A077846**	**001**	Oct 28, 2008
AT		LUITPOLD	**EQ 2% BASE**	**A079186**	**001**	Nov 18, 2009
AT		SANDOZ INC	**EQ 2% BASE**	**A078748**	**001**	Nov 06, 2008
AT			**EQ 2% BASE**	**A078981**	**001**	Apr 13, 2009

TRUSOPT

AT	**+!**	MERCK	**EQ 2% BASE**	**N020408**	**001**	Dec 09, 1994

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

COSOPT

AT	**+!**	OAK PHARMS INC	**EQ 2% BASE;EQ 0.5% BASE**	**N020869**	**001**	Apr 07, 1998

COSOPT PF

AT	**+!**	OAK PHARMS INC	**EQ 2% BASE;EQ 0.5% BASE**	**N202667**	**001**	Feb 01, 2012

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT		AKORN INC	**EQ 2% BASE;EQ 0.5% BASE**	**A203058**	**001**	Sep 22, 2014
AT		AUROBINDO PHARMA LTD	**EQ 2% BASE;EQ 0.5% BASE**	**A207630**	**001**	Jul 24, 2018
AT		BAUSCH AND LOMB	**EQ 2% BASE;EQ 0.5% BASE**	**A090037**	**001**	Jul 14, 2009
AT		HI TECH PHARMA	**EQ 2% BASE;EQ 0.5% BASE**	**A077847**	**001**	Oct 28, 2008
AT		SANDOZ	**EQ 2% BASE;EQ 0.5% BASE**	**A078749**	**001**	Nov 06, 2008
AT		SANDOZ INC	**EQ 2% BASE;EQ 0.5% BASE**	**A090604**	**001**	Nov 18, 2009
AT		TEVA PHARMS	**EQ 2% BASE;EQ 0.5% BASE**	**A078704**	**001**	Sep 28, 2009

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOPRAM

AP	**+!**	WEST-WARD PHARMS INT	**20MG/ML**	**N014879**	**001**	

DOXAPRAM HYDROCHLORIDE

AP		ATHENEX INC	**20MG/ML**	**A076266**	**001**	Jan 10, 2003

DOXAZOSIN MESYLATE

TABLET;ORAL

CARDURA

AB	**+!**	PFIZER	**EQ 1MG BASE**	**N019668**	**001**	Nov 02, 1990
AB	**+**		**EQ 2MG BASE**	**N019668**	**002**	Nov 02, 1990
AB	**+**		**EQ 4MG BASE**	**N019668**	**003**	Nov 02, 1990
AB	**+**		**EQ 8MG BASE**	**N019668**	**004**	Nov 02, 1990

DOXAZOSIN MESYLATE

AB		ACCORD HLTHCARE	**EQ 1MG BASE**	**A202824**	**001**	Jun 11, 2014
AB			**EQ 2MG BASE**	**A202824**	**002**	Jun 11, 2014
AB			**EQ 4MG BASE**	**A202824**	**003**	Jun 11, 2014
AB			**EQ 8MG BASE**	**A202824**	**004**	Jun 11, 2014
AB		ANI PHARMS INC	**EQ 1MG BASE**	**A075432**	**001**	Oct 18, 2000
AB			**EQ 2MG BASE**	**A075432**	**002**	Oct 18, 2000
AB			**EQ 4MG BASE**	**A075432**	**003**	Oct 18, 2000
AB			**EQ 8MG BASE**	**A075432**	**004**	Oct 18, 2000
AB		APOTEX	**EQ 1MG BASE**	**A075580**	**001**	Oct 18, 2000
AB			**EQ 2MG BASE**	**A075580**	**002**	Oct 18, 2000
AB			**EQ 4MG BASE**	**A075580**	**003**	Oct 18, 2000
AB			**EQ 8MG BASE**	**A075580**	**004**	Oct 18, 2000
AB		DAVA PHARMS INC	**EQ 1MG BASE**	**A076161**	**001**	Jun 10, 2004
AB			**EQ 2MG BASE**	**A076161**	**002**	Jun 10, 2004
AB			**EQ 4MG BASE**	**A076161**	**003**	Jun 10, 2004
AB			**EQ 8MG BASE**	**A076161**	**004**	Jun 10, 2004
AB		HERITAGE PHARMA	**EQ 1MG BASE**	**A205210**	**001**	Feb 13, 2018
AB			**EQ 2MG BASE**	**A205210**	**002**	Feb 13, 2018
AB			**EQ 4MG BASE**	**A205210**	**003**	Feb 13, 2018
AB			**EQ 8MG BASE**	**A205210**	**004**	Feb 13, 2018
AB		MYLAN	**EQ 1MG BASE**	**A075509**	**001**	Oct 19, 2000
AB			**EQ 2MG BASE**	**A075509**	**002**	Oct 19, 2000
AB			**EQ 4MG BASE**	**A075509**	**003**	Oct 19, 2000
AB			**EQ 8MG BASE**	**A075509**	**004**	Oct 19, 2000
AB		PLIVA	**EQ 1MG BASE**	**A075750**	**001**	Jun 08, 2001
AB			**EQ 2MG BASE**	**A075750**	**002**	Jun 08, 2001
AB			**EQ 4MG BASE**	**A075750**	**003**	Jun 08, 2001

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

AB			**EQ 8MG BASE**	**A075750**	**004**	Jun 08, 2001
AB		TEVA	**EQ 1MG BASE**	**A075536**	**001**	Oct 18, 2000
AB			**EQ 2MG BASE**	**A075536**	**002**	Oct 18, 2000
AB			**EQ 4MG BASE**	**A075536**	**003**	Oct 18, 2000
AB			**EQ 8MG BASE**	**A075536**	**004**	Oct 18, 2000
AB		UPSHER SMITH LABS	**EQ 1MG BASE**	**A209013**	**001**	Apr 17, 2018
AB			**EQ 2MG BASE**	**A209013**	**002**	Apr 17, 2018
AB			**EQ 4MG BASE**	**A209013**	**003**	Apr 17, 2018
AB			**EQ 8MG BASE**	**A209013**	**004**	Apr 17, 2018
AB		ZYDUS PHARMS USA INC	**EQ 1MG BASE**	**A208719**	**001**	Jul 07, 2017
AB			**EQ 2MG BASE**	**A208719**	**002**	Jul 07, 2017
AB			**EQ 4MG BASE**	**A208719**	**003**	Jul 07, 2017
AB			**EQ 8MG BASE**	**A208719**	**004**	Jul 07, 2017

TABLET, EXTENDED RELEASE;ORAL

CARDURA XL

	+	PFIZER	EQ 4MG BASE	N021269	001	Feb 22, 2005
	+!		EQ 8MG BASE	N021269	002	Feb 22, 2005

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB		AMNEAL PHARMS CO	**EQ 10MG BASE**	**A207482**	**001**	Jun 28, 2017
AB			**EQ 25MG BASE**	**A207482**	**002**	Jun 28, 2017
AB			**EQ 50MG BASE**	**A207482**	**003**	Jun 28, 2017
AB			**EQ 75MG BASE**	**A207482**	**004**	Jun 28, 2017
AB			**EQ 100MG BASE**	**A207482**	**005**	Jun 28, 2017
AB		MYLAN PHARMS INC	**EQ 10MG BASE**	**A070791**	**002**	May 13, 1986
AB	**!**		**EQ 25MG BASE**	**A070791**	**003**	May 13, 1986
AB			**EQ 50MG BASE**	**A070791**	**001**	May 13, 1986
AB			**EQ 75MG BASE**	**A070791**	**004**	May 13, 1986
AB	**!**		**EQ 100MG BASE**	**A070791**	**005**	May 13, 1986
AB		PAR PHARM	**EQ 50MG BASE**	**A071595**	**001**	Nov 09, 1987
AB			**EQ 100MG BASE**	**A071422**	**001**	Nov 09, 1987
	!		EQ 150MG BASE	A071669	001	Nov 09, 1987

CONCENTRATE;ORAL

DOXEPIN HYDROCHLORIDE

AA		LANNETT CO INC	**EQ 10MG BASE/ML**	**A074721**	**001**	Dec 29, 1998
AA	**!**	TEVA PHARMS	**EQ 10MG BASE/ML**	**A071609**	**001**	Nov 09, 1987
AA		WOCKHARDT BIO AG	**EQ 10MG BASE/ML**	**A071918**	**001**	Jul 20, 1988

CREAM;TOPICAL

ZONALON

	+!	MYLAN PHARMS INC	5%	N020126	001	Apr 01, 1994

TABLET;ORAL

SILENOR

	+	PERNIX THERAPS LLC	EQ 3MG BASE	N022036	001	Mar 17, 2010
	+!		EQ 6MG BASE	N022036	002	Mar 17, 2010

DOXERCALCIFEROL

CAPSULE;ORAL

DOXERCALCIFEROL

AB		RISING PHARMS	**0.5MCG**	**A201518**	**001**	Sep 09, 2016
AB			**1MCG**	**A201518**	**002**	Sep 09, 2016
AB			**2.5MCG**	**A201518**	**003**	Sep 09, 2016
AB		WEST-WARD PHARMS INT	**0.5MCG**	**A091433**	**001**	Sep 23, 2011
AB			**1MCG**	**A091433**	**002**	Jan 14, 2014
AB			**2.5MCG**	**A091433**	**003**	Jan 14, 2014

HECTOROL

AB	**+**	SANOFI	**0.5MCG**	**N020862**	**002**	Apr 23, 2004
AB	**+**		**1MCG**	**N020862**	**003**	Jul 13, 2009
AB	**+!**		**2.5MCG**	**N020862**	**001**	Jun 09, 1999

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP		AKORN INC	**2MCG/ML (2MCG/ML)**	**A203929**	**002**	Mar 28, 2016
AP			**4MCG/2ML (2MCG/ML)**	**A203929**	**001**	May 07, 2015
AP		AMNEAL PHARMS CO	**2MCG/ML (2MCG/ML)**	**A208974**	**001**	May 24, 2017
AP			**4MCG/2ML (2MCG/ML)**	**A208974**	**002**	May 24, 2017
AP			**4MCG/2ML (2MCG/ML)**	**A208975**	**001**	May 24, 2017
AP		HIKMA PHARMS	**4MCG/2ML (2MCG/ML)**	**A091101**	**001**	Aug 30, 2013
AP	**+**	HOSPIRA INC	**4MCG/2ML (2MCG/ML)**	**N208614**	**001**	Jul 24, 2018

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL						
AP		LUPIN LTD	**4MCG/2ML (2MCG/ML)**	**A210801**	**001**	Nov 01, 2018
AP		SANDOZ INC	**4MCG/2ML (2MCG/ML)**	**A091333**	**001**	May 05, 2014
AP			**4MCG/2ML (2MCG/ML)**	**A200926**	**001**	Feb 04, 2014
HECTOROL						
AP	+	SANOFI	**2MCG/ML (2MCG/ML)**	**N021027**	**002**	Apr 06, 2000
AP	+!		**4MCG/2ML (2MCG/ML)**	**N021027**	**001**	Apr 06, 2000
DOXERCALCIFEROL						
	+!	HOSPIRA INC	10MCG/5ML (2MCG/ML)	N208614	002	Jul 24, 2018

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE						
AP		ACTAVIS INC	**2MG/ML**	**A203622**	**001**	Jun 27, 2014
AP			**200MG/100ML**	**A203622**	**002**	Jun 27, 2014
AP		AMNEAL PHARMS CO	**20MG/VIAL**	**A208888**	**001**	Feb 17, 2017
AP			**50MG/VIAL**	**A208888**	**002**	Feb 17, 2017
AP		FRESENIUS KABI USA	**2MG/ML**	**A063277**	**001**	Oct 26, 1995
AP		GLAND PHARMA LTD	**2MG/ML**	**A209825**	**001**	Aug 11, 2017
AP		MYLAN LABS LTD	**2MG/ML**	**A200901**	**001**	Feb 14, 2012
AP			**50MG/VIAL**	**A200170**	**002**	Oct 28, 2011
AP		PHARMACHEMIE BV	**2MG/ML**	**A063336**	**001**	Feb 28, 1995
AP			**10MG/VIAL**	**A063097**	**001**	May 21, 1990
AP			**20MG/VIAL**	**A063097**	**002**	May 21, 1990
AP			**50MG/VIAL**	**A063097**	**003**	May 21, 1990
AP			**200MG/100ML**	**A063336**	**004**	Feb 28, 1995
AP	+!	PHARMACIA AND UPJOHN	**2MG/ML**	**N050629**	**001**	Dec 23, 1987
AP	+!		**200MG/100ML**	**N050629**	**002**	May 03, 1988
AP		SAGENT PHARMS	**2MG/ML**	**A091495**	**001**	Mar 18, 2013
AP		SUN PHARM INDS	**2MG/ML**	**A091418**	**001**	Feb 15, 2012
AP		TEVA PHARMS USA	**2MG/ML**	**A064140**	**001**	Jul 28, 1995
AP			**200MG/100ML**	**A064140**	**002**	Jul 28, 1995
AP		WEST-WARD PHARMS INT	**2MG/ML**	**A062975**	**001**	Mar 17, 1989
AP	!		**10MG/VIAL**	**A062921**	**001**	Mar 17, 1989
AP	!		**20MG/VIAL**	**A062921**	**002**	Mar 17, 1989
AP	!		**50MG/VIAL**	**A062921**	**003**	Mar 17, 1989
AP			**200MG/100ML**	**A064097**	**001**	Sep 13, 1994
	+	PHARMACIA AND UPJOHN	150MG/75ML	N050629	003	Mar 28, 2011

INJECTABLE, LIPOSOMAL;INJECTION

DOXIL (LIPOSOMAL)						
AB	+	JANSSEN RES AND DEV	**20MG/10ML (2MG/ML)**	**N050718**	**001**	Nov 17, 1995
AB	+		**50MG/25ML (2MG/ML)**	**N050718**	**002**	Jun 13, 2000
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)						
AB		DR REDDYS LABS LTD	**20MG/10ML (2MG/ML)**	**A208657**	**001**	May 15, 2017
AB			**50MG/25ML (2MG/ML)**	**A208657**	**002**	May 15, 2017
AB	!	SUN PHARMA GLOBAL	**20MG/10ML (2MG/ML)**	**A203263**	**001**	Feb 04, 2013
AB	!		**50MG/25ML (2MG/ML)**	**A203263**	**002**	Feb 04, 2013

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE						
AB		ALEMBIC PHARMS LTD	**EQ 75MG BASE**	**A209165**	**001**	Jul 28, 2017
AB			**EQ 100MG BASE**	**A209165**	**002**	Jul 28, 2017
AB		G AND W LABS INC	**EQ 50MG BASE**	**A204446**	**001**	May 28, 2015
AB			**EQ 75MG BASE**	**A204446**	**002**	May 28, 2015
AB			**EQ 100MG BASE**	**A204446**	**003**	May 28, 2015
AB		IMPAX LABS INC	**EQ 150MG BASE**	**A200065**	**001**	Feb 17, 2011
AB		LUPIN LTD	**EQ 50MG BASE**	**A204234**	**001**	Mar 05, 2014
AB			**EQ 75MG BASE**	**A204234**	**002**	Mar 05, 2014
AB			**EQ 100MG BASE**	**A204234**	**003**	Mar 05, 2014
AB		MAYNE PHARMA INC	**EQ 50MG BASE**	**A209396**	**001**	Sep 29, 2017
AB			**EQ 75MG BASE**	**A209396**	**002**	Sep 29, 2017
AB			**EQ 100MG BASE**	**A209396**	**003**	Sep 29, 2017
AB		MYLAN PHARMS INC	**EQ 150MG BASE**	**A202778**	**001**	Jun 08, 2012
AB		PAR PHARM	**EQ 50MG BASE**	**A065055**	**001**	Dec 01, 2000
AB			**EQ 100MG BASE**	**A065055**	**002**	Dec 01, 2000
AB	!		**EQ 150MG BASE**	**A065055**	**003**	Jul 15, 2005
AB		SUN PHARM INDS LTD	**EQ 50MG BASE**	**A065053**	**001**	Nov 22, 2000
AB			**EQ 75MG BASE**	**A065053**	**003**	Sep 10, 2003

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB			**EQ 100MG BASE**	**A065053**	**002**	Nov 22, 2000
AB		ZYDUS PHARMS USA INC	**EQ 50MG BASE**	**A205115**	**001**	Feb 18, 2016
AB			**EQ 75MG BASE**	**A205115**	**002**	Feb 18, 2016
AB			**EQ 100MG BASE**	**A205115**	**003**	Feb 18, 2016

MONODOX

AB	**+**	AQUA PHARMS	**EQ 50MG BASE**	**N050641**	**002**	Feb 10, 1992
AB	**+**		**EQ 75MG BASE**	**N050641**	**003**	Oct 18, 2006
AB	**+!**		**EQ 100MG BASE**	**N050641**	**001**	Dec 29, 1989

ORACEA

	+!	GALDERMA LABS LP	40MG	N050805	001	May 26, 2006

FOR SUSPENSION;ORAL

DOXYCYCLINE

AB		CHARTWELL LIFE SCI	**EQ 25MG BASE/5ML**	**A065454**	**001**	Jul 16, 2008
AB		LUPIN LTD	**EQ 25MG BASE/5ML**	**A201678**	**001**	Mar 18, 2013

VIBRAMYCIN

AB	**+!**	PFIZER	**EQ 25MG BASE/5ML**	**N050006**	**001**	

TABLET;ORAL

DOXYCYCLINE

AB		HERITAGE PHARMS INC	**EQ 50MG BASE**	**A091605**	**001**	Dec 20, 2011
AB			**EQ 75MG BASE**	**A091605**	**002**	Dec 20, 2011
AB			**EQ 100MG BASE**	**A091605**	**003**	Dec 20, 2011
AB			**EQ 150MG BASE**	**A091605**	**004**	Dec 20, 2011
AB		LANNETT CO INC	**EQ 50MG BASE**	**A065285**	**001**	Dec 08, 2005
AB			**EQ 75MG BASE**	**A065285**	**003**	Jul 30, 2008
AB			**EQ 100MG BASE**	**A065285**	**002**	Dec 08, 2005
AB			**EQ 150MG BASE**	**A065285**	**004**	Jul 30, 2008
AB		MYLAN	**EQ 50MG BASE**	**A065377**	**001**	Nov 07, 2006
AB			**EQ 75MG BASE**	**A065377**	**002**	Nov 07, 2006
AB			**EQ 100MG BASE**	**A065377**	**003**	Nov 07, 2006
AB			**EQ 150MG BASE**	**A065427**	**001**	Jun 07, 2007
AB		PAR PHARM	**EQ 50MG BASE**	**A065070**	**001**	Dec 15, 2000
AB			**EQ 75MG BASE**	**A065070**	**003**	Dec 30, 2002
AB			**EQ 100MG BASE**	**A065070**	**002**	Dec 15, 2000
AB	**!**		**EQ 150MG BASE**	**A065070**	**004**	Jul 14, 2005
AB		SUN PHARM INDS LTD	**EQ 50MG BASE**	**A065356**	**001**	May 31, 2006
AB			**EQ 75MG BASE**	**A065356**	**002**	May 31, 2006
AB			**EQ 100MG BASE**	**A065356**	**003**	May 31, 2006
AB			**EQ 150MG BASE**	**A065356**	**004**	Jul 29, 2010
AB		ZYDUS PHARMS USA INC	**EQ 50MG BASE**	**A209582**	**001**	Sep 28, 2017
AB			**EQ 75MG BASE**	**A209582**	**002**	Sep 28, 2017
AB			**EQ 100MG BASE**	**A209582**	**003**	Sep 28, 2017
AB			**EQ 150MG BASE**	**A209582**	**004**	Sep 28, 2017

DOXYCYCLINE CALCIUM

SUSPENSION;ORAL

VIBRAMYCIN

	+!	PFIZER	EQ 50MG BASE/5ML	N050480	001	

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

AB		ACTAVIS LABS FL INC	**EQ 50MG BASE**	**A062031**	**002**	Oct 13, 1982
AB			**EQ 100MG BASE**	**A062031**	**001**	
AB		AJANTA PHARMA LTD	**EQ 50MG BASE**	**A211012**	**001**	Sep 24, 2018
AB			**EQ 100MG BASE**	**A211012**	**002**	Sep 24, 2018
AB		ALEMBIC PHARMS LTD	**EQ 50MG BASE**	**A210527**	**001**	Jun 13, 2018
AB			**EQ 100MG BASE**	**A210527**	**002**	Jun 13, 2018
AB		AMNEAL PHARMS	**EQ 100MG BASE**	**A207289**	**001**	Jun 27, 2016
AB		CHARTWELL LIFE SCI	**EQ 50MG BASE**	**A062500**	**001**	Sep 11, 1984
AB			**EQ 100MG BASE**	**A062500**	**002**	Sep 11, 1984
AB		HIKMA INTL PHARMS	**EQ 50MG BASE**	**A062396**	**002**	Nov 07, 1984
AB			**EQ 100MG BASE**	**A062396**	**001**	May 07, 1984
AB		MYLAN	**EQ 50MG BASE**	**A062337**	**001**	Mar 29, 1982
AB			**EQ 100MG BASE**	**A062337**	**002**	Mar 29, 1982
AB		SUN PHARM INDUSTRIES	**EQ 50MG BASE**	**A062676**	**002**	Jul 10, 1986
AB			**EQ 100MG BASE**	**A062676**	**001**	Jul 10, 1986
AB		ZYDUS PHARMS USA INC	**EQ 50MG BASE**	**A207774**	**001**	May 31, 2018

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

AB			**EQ 100MG BASE**	**A207774**	**002**	May 31, 2018

VIBRAMYCIN

AB	**+!**	PFIZER	**EQ 100MG BASE**	**N050007**	**002**	

INJECTABLE;INJECTION

DOXY 100

AP	**!**	FRESENIUS KABI USA	**EQ 100MG BASE/VIAL**	**A062475**	**001**	Dec 09, 1983

DOXY 200

AP	**!**	FRESENIUS KABI USA	**EQ 200MG BASE/VIAL**	**A062475**	**002**	Dec 09, 1983

DOXYCYCLINE

AP		MYLAN LABS LTD	**EQ 100MG BASE/VIAL**	**A091406**	**001**	Aug 21, 2012
AP	**!**	WEST-WARD PHARMS INT	**EQ 100MG BASE/VIAL**	**A062569**	**001**	Mar 09, 1988
AP		ZYDUS PHARMS USA INC	**EQ 100MG BASE/VIAL**	**A207757**	**001**	Sep 28, 2017
AP			**EQ 200MG BASE/VIAL**	**A207757**	**002**	Sep 28, 2017

SYSTEM, EXTENDED RELEASE;PERIODONTAL

ATRIDOX

	+!	TOLMAR	50MG	N050751	001	Sep 03, 1998

TABLET;ORAL

ACTICLATE

AB	**+**	AQUA PHARMS LLC	**EQ 75MG BASE**	**N205931**	**001**	Jul 25, 2014
AB	**+!**		**EQ 150MG BASE**	**N205931**	**002**	Jul 25, 2014

DOXYCYCLINE HYCLATE

AB		ACTAVIS LABS FL INC	**EQ 100MG BASE**	**A062421**	**001**	Feb 02, 1983
AB		AMNEAL PHARMS CO	**EQ 75MG BASE**	**A209372**	**001**	Oct 06, 2017
AB			**EQ 150MG BASE**	**A209372**	**002**	Oct 06, 2017
AB		CARIBE HOLDINGS	**EQ 100MG BASE**	**A062269**	**002**	Nov 08, 1982
AB		CHARTWELL LIFE SCI	**EQ 100MG BASE**	**A062505**	**001**	Sep 11, 1984
AB		EMCURE PHARMS LTD	**EQ 100MG BASE**	**A209969**	**001**	Nov 09, 2018
AB	**!**	HIKMA INTL PHARMS	**EQ 100MG BASE**	**A065095**	**001**	Jul 02, 2003
AB		IVAX SUB TEVA PHARMS	**EQ 20MG BASE**	**A065163**	**001**	May 13, 2005
AB	**!**	LANNETT CO INC	**EQ 20MG BASE**	**A065277**	**001**	Nov 10, 2005
AB		LARKEN LABS	**EQ 20MG BASE**	**A065287**	**001**	Feb 28, 2006
AB		LUPIN LTD	**EQ 75MG BASE**	**A208818**	**001**	Sep 27, 2017
AB			**EQ 150MG BASE**	**A208818**	**002**	Sep 27, 2017
AB		MAYNE PHARMA INC	**EQ 75MG BASE**	**A208765**	**001**	Jun 14, 2017
AB			**EQ 150MG BASE**	**A208765**	**002**	Jun 14, 2017
AB		MYLAN	**EQ 100MG BASE**	**A062432**	**001**	Feb 15, 1983
AB		NOVEL LABS INC	**EQ 100MG BASE**	**A207558**	**001**	Sep 06, 2017
AB		SUN PHARM INDUSTRIES	**EQ 20MG BASE**	**A065134**	**001**	May 13, 2005
AB			**EQ 100MG BASE**	**A062677**	**001**	Jul 10, 1986
AB		ZYDUS PHARMS USA INC	**EQ 100MG BASE**	**A207773**	**001**	Oct 30, 2017
		CARIBE HOLDINGS	EQ 50MG BASE	A062269	003	Oct 05, 1983

TABLET, DELAYED RELEASE;ORAL

DORYX

AB	**+**	MAYNE PHARMA	**EQ 50MG BASE**	**N050795**	**006**	Dec 19, 2014
AB	**+**		**EQ 75MG BASE**	**N050795**	**001**	May 06, 2005
AB	**+**		**EQ 100MG BASE**	**N050795**	**002**	May 06, 2005
AB	**+**		**EQ 150MG BASE**	**N050795**	**003**	Jun 20, 2008
AB	**+!**		**EQ 200MG BASE**	**N050795**	**005**	Apr 11, 2013

DOXYCYCLINE HYCLATE

AB		ACTAVIS ELIZABETH	**EQ 50MG BASE**	**A090134**	**003**	May 22, 2018
AB			**EQ 75MG BASE**	**A090134**	**001**	Dec 14, 2011
AB			**EQ 100MG BASE**	**A090134**	**002**	Dec 14, 2011
AB			**EQ 200MG BASE**	**A090134**	**004**	May 22, 2018
AB		HERITAGE PHARMS INC	**EQ 75MG BASE**	**A200856**	**001**	Apr 30, 2013
AB			**EQ 100MG BASE**	**A200856**	**002**	Apr 30, 2013
AB			**EQ 150MG BASE**	**A200856**	**003**	Apr 30, 2013
AB			**EQ 200MG BASE**	**A200856**	**004**	Nov 13, 2018
AB		MYLAN	**EQ 50MG BASE**	**A090431**	**003**	May 23, 2016
AB			**EQ 75MG BASE**	**A090431**	**001**	Dec 28, 2010
AB			**EQ 100MG BASE**	**A090431**	**002**	Dec 28, 2010
AB			**EQ 200MG BASE**	**A090431**	**005**	May 19, 2016
AB		MYLAN PHARMS INC	**EQ 150MG BASE**	**A091052**	**001**	Feb 08, 2012
AB		PRINSTON INC	**EQ 150MG BASE**	**A207494**	**001**	Nov 15, 2016
AB			**EQ 200MG BASE**	**A207494**	**002**	Nov 15, 2016
AB		ZYDUS PHARMS USA	**EQ 75MG BASE**	**A206772**	**001**	Dec 21, 2018

DOXYCYCLINE HYCLATE

TABLET, DELAYED RELEASE;ORAL

DOXYCYCLINE HYCLATE

INC

AB			**EQ 100MG BASE**	**A206772**	**002**	Dec 21, 2018
AB			**EQ 150MG BASE**	**A206772**	**003**	Dec 21, 2018

DORYX MPC

	+!	MAYNE PHARMA	EQ 120MG BASE	N050795	008	May 20, 2016

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE;ORAL

DICLEGIS

AB	**+!**	DUCHESNAY	**10MG;10MG**	**N021876**	**001**	Apr 08, 2013

DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	**10MG;10MG**	**A205811**	**001**	Aug 19, 2016
AB		PAR PHARM INC	**10MG;10MG**	**A208518**	**001**	Dec 06, 2017

TABLET, EXTENDED RELEASE;ORAL

BONJESTA

	+!	DUCHESNAY	20MG;20MG	N209661	001	Nov 07, 2016

DRONABINOL

CAPSULE;ORAL

DRONABINOL

AB		AKORN INC	**2.5MG**	**A079217**	**001**	Jun 20, 2014
AB			**5MG**	**A079217**	**002**	Jun 20, 2014
AB			**10MG**	**A079217**	**003**	Jun 20, 2014
AB		LANNETT CO INC	**2.5MG**	**A201463**	**001**	May 18, 2018
AB			**5MG**	**A201463**	**002**	May 18, 2018
AB			**10MG**	**A201463**	**003**	May 18, 2018
AB		SVC PHARMA	**2.5MG**	**A078292**	**001**	Jun 27, 2008
AB			**5MG**	**A078292**	**002**	Jun 27, 2008
AB			**10MG**	**A078292**	**003**	Jun 27, 2008

MARINOL

AB	**+**	ABBVIE	**2.5MG**	**N018651**	**001**	May 31, 1985
AB	**+!**		**5MG**	**N018651**	**002**	May 31, 1985
AB	**+**		**10MG**	**N018651**	**003**	May 31, 1985

SOLUTION;ORAL

SYNDROS

	+!	INSYS DEV CO INC	5MG/ML	N205525	001	Mar 23, 2017

DRONEDARONE HYDROCHLORIDE

TABLET;ORAL

MULTAQ

	+!	SANOFI AVENTIS US	EQ 400MG BASE	N022425	001	Jul 01, 2009

DROPERIDOL

INJECTABLE;INJECTION

DROPERIDOL

AP		EUROHLTH INTL SARL	**2.5MG/ML**	**A208197**	**001**	Dec 14, 2017
AP		HOSPIRA	**2.5MG/ML**	**A071981**	**001**	Feb 29, 1988
AP		LUITPOLD	**2.5MG/ML**	**A072123**	**001**	Oct 24, 1988

INAPSINE

AP	**+!**	AKORN INC	**2.5MG/ML**	**N016796**	**001**	

DROSPIRENONE; ESTRADIOL

TABLET;ORAL

ANGELIQ

	+	BAYER HLTHCARE	0.25MG;0.5MG	N021355	001	Feb 29, 2012
	+!		0.5MG;1MG	N021355	002	Sep 28, 2005

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB		BARR	**3MG;0.02MG**	**A078515**	**001**	Mar 30, 2009
AB		GLENMARK PHARMS LTD	**3MG;0.02MG**	**A204296**	**001**	Aug 17, 2015
AB		JUBILANT CADISTA	**3MG;0.02MG**	**A209423**	**001**	Dec 22, 2017
AB		MYLAN LABS LTD	**3MG;0.02MG**	**A202594**	**001**	Oct 22, 2015
AB		PII	**3MG;0.02MG**	**A203291**	**001**	Jul 18, 2017
AB		WATSON LABS	**3MG;0.02MG**	**A078833**	**001**	Nov 28, 2011

LO-ZUMANDIMINE

AB		AUROBINDO PHARMA LTD	**3MG;0.02MG**	**A209632**	**001**	Feb 27, 2018

LORYNA

AB		LABS LEON FARMA	**3MG;0.02MG**	**A079221**	**001**	Mar 28, 2011

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

MELAMISA

AB		NOVAST LABS	**3MG;0.02MG**	**A202016**	**001**	Jan 26, 2016

NIKKI

AB		LUPIN LTD	**3MG;0.02MG**	**A201661**	**001**	May 27, 2014

YAZ

AB	**+!**	BAYER HLTHCARE	**3MG;0.02MG**	**N021676**	**001**	Mar 16, 2006

TABLET;ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

AB		ACCORD HLTHCARE	**3MG;0.03MG**	**A207245**	**001**	Nov 22, 2016
AB		APOTEX INC	**3MG;0.03MG**	**A205876**	**001**	Sep 21, 2016
AB		BARR	**3MG;0.03MG**	**A077527**	**001**	May 09, 2008
AB		GLENMARK PHARMS LTD	**3MG;0.03MG**	**A204848**	**001**	Mar 25, 2016
AB		JUBILANT CADISTA	**3MG;0.03MG**	**A210017**	**001**	Sep 10, 2018
AB		LUPIN LTD	**3MG;0.03MG**	**A201663**	**001**	Dec 18, 2012
AB		MAYNE PHARMA	**3MG;0.03MG**	**A090081**	**001**	Sep 07, 2010
AB		MYLAN LABS LTD	**3MG;0.03MG**	**A202131**	**001**	May 04, 2015

SYEDA

AB		LABS LEON FARMA	**3MG;0.03MG**	**A090114**	**001**	Mar 28, 2011

YAELA

AB		NOVAST LABS	**3MG;0.03MG**	**A202015**	**001**	Nov 19, 2014

YASMIN

AB	**+!**	BAYER HLTHCARE	**3MG;0.03MG**	**N021098**	**001**	May 11, 2001

ZUMANDIMINE

AB		AUROBINDO PHARMA LTD	**3MG;0.03MG**	**A209407**	**001**	Mar 26, 2018

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET;ORAL

BEYAZ

AB		BAYER HLTHCARE	**3MG,N/A;0.02MG,N/A;0.451MG,0.451MG**	**N022532**	**001**	Sep 24, 2010

DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM

AB		LUPIN LTD	**3MG,N/A;0.02MG,N/A;0.451MG,0.451MG**	**A205947**	**001**	Jun 13, 2018
AB		WATSON LABS INC	**3MG,N/A;0.02MG,N/A;0.451MG,0.451MG**	**A203593**	**001**	Oct 11, 2016
AB			**3MG,N/A;0.03MG,N/A;0.451MG,0.451MG**	**A203594**	**001**	Oct 11, 2016

SAFYRAL

AB	**+!**	BAYER HLTHCARE	**3MG,N/A;0.03MG,N/A;0.451MG,0.451MG**	**N022574**	**001**	Dec 16, 2010

TYDEMY

AB		LUPIN LTD	**3MG,N/A;0.03MG,N/A;0.451MG,0.451MG**	**A205948**	**001**	Dec 12, 2017

DROXIDOPA

CAPSULE;ORAL

NORTHERA

	+	LUNDBECK NA LTD	100MG	N203202	001	Feb 18, 2014
	+		200MG	N203202	002	Feb 18, 2014
	+!		300MG	N203202	003	Feb 18, 2014

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

CYMBALTA

AB	**+**	LILLY	**EQ 20MG BASE**	**N021427**	**001**	Aug 03, 2004
AB	**+**		**EQ 30MG BASE**	**N021427**	**002**	Aug 03, 2004
AB	**+!**		**EQ 60MG BASE**	**N021427**	**004**	Aug 03, 2004

DULOXETINE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**EQ 20MG BASE**	**A090776**	**001**	Dec 17, 2013
AB			**EQ 30MG BASE**	**A090776**	**002**	Dec 17, 2013
AB			**EQ 60MG BASE**	**A090776**	**003**	Dec 17, 2013
AB		AJANTA PHARMA LTD	**EQ 20MG BASE**	**A208706**	**001**	Jan 06, 2017
AB			**EQ 30MG BASE**	**A208706**	**002**	Jan 06, 2017
AB			**EQ 60MG BASE**	**A208706**	**003**	Jan 06, 2017
AB		ALEMBIC PHARMS LTD	**EQ 20MG BASE**	**A202949**	**001**	Jun 09, 2014
AB			**EQ 30MG BASE**	**A202949**	**002**	Jun 09, 2014
AB			**EQ 60MG BASE**	**A202949**	**003**	Jun 09, 2014
AB		ALKEM LABS LTD	**EQ 20MG BASE**	**A203197**	**001**	Aug 26, 2015
AB			**EQ 30MG BASE**	**A203197**	**002**	Aug 26, 2015
AB			**EQ 60MG BASE**	**A203197**	**003**	Aug 26, 2015
AB		ANCHEN PHARMS	**EQ 20MG BASE**	**A090780**	**001**	Oct 28, 2015
AB			**EQ 30MG BASE**	**A090780**	**002**	Oct 28, 2015
AB			**EQ 60MG BASE**	**A090780**	**003**	Oct 28, 2015
AB		APOTEX INC	**EQ 20MG BASE**	**A202045**	**001**	Jun 11, 2014
AB			**EQ 30MG BASE**	**A202045**	**002**	Jun 11, 2014
AB			**EQ 60MG BASE**	**A202045**	**003**	Jun 11, 2014
AB		AUROBINDO PHARMA	**EQ 20MG BASE**	**A090778**	**001**	Dec 11, 2013

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

	LTD					
AB		**EQ 30MG BASE**	**A090778**	**002**	Dec 11, 2013
AB		**EQ 60MG BASE**	**A090778**	**003**	Dec 11, 2013
AB	BRECKENRIDGE PHARM	**EQ 20MG BASE**	**A203088**	**001**	Jun 11, 2014
AB		**EQ 30MG BASE**	**A203088**	**002**	Jun 11, 2014
AB		**EQ 40MG BASE**	**A203088**	**004**	May 18, 2018
AB		**EQ 60MG BASE**	**A203088**	**003**	Jun 11, 2014
AB	CSPC OUYI PHARM CO	**EQ 20MG BASE**	**A211310**	**001**	Oct 16, 2018
AB		**EQ 30MG BASE**	**A211310**	**002**	Oct 16, 2018
AB		**EQ 60MG BASE**	**A211310**	**003**	Oct 16, 2018
AB	HETERO LABS LTD III	**EQ 20MG BASE**	**A204343**	**001**	Aug 03, 2016
AB		**EQ 30MG BASE**	**A204343**	**002**	Aug 03, 2016
AB		**EQ 60MG BASE**	**A204343**	**003**	Aug 03, 2016
AB	INVENTIA HLTHCARE	**EQ 20MG BASE**	**A202336**	**001**	Oct 28, 2015
AB		**EQ 30MG BASE**	**A202336**	**002**	Oct 28, 2015
AB		**EQ 60MG BASE**	**A202336**	**003**	Oct 28, 2015
AB	LUPIN LTD	**EQ 20MG BASE**	**A090694**	**001**	Dec 11, 2013
AB		**EQ 30MG BASE**	**A090694**	**002**	Dec 11, 2013
AB		**EQ 40MG BASE**	**A090694**	**003**	Dec 11, 2013
AB		**EQ 60MG BASE**	**A090694**	**004**	Dec 11, 2013
AB	MACLEODS PHARMS LTD	**EQ 20MG BASE**	**A204815**	**001**	Mar 23, 2017
AB		**EQ 30MG BASE**	**A204815**	**002**	Mar 23, 2017
AB		**EQ 60MG BASE**	**A204815**	**003**	Mar 23, 2017
AB	MARKSANS PHARMA	**EQ 20MG BASE**	**A090723**	**001**	Dec 11, 2013
AB		**EQ 30MG BASE**	**A090723**	**002**	Dec 11, 2013
AB		**EQ 60MG BASE**	**A090723**	**003**	Dec 11, 2013
AB	PRINSTON INC	**EQ 20MG BASE**	**A206653**	**001**	May 18, 2017
AB		**EQ 30MG BASE**	**A206653**	**002**	May 18, 2017
AB		**EQ 60MG BASE**	**A206653**	**003**	May 18, 2017
AB	SUN PHARMA GLOBAL	**EQ 20MG BASE**	**A090745**	**001**	Dec 11, 2013
AB		**EQ 30MG BASE**	**A090745**	**002**	Dec 11, 2013
AB		**EQ 60MG BASE**	**A090745**	**003**	Dec 11, 2013
AB	TEVA PHARMS USA	**EQ 20MG BASE**	**A090783**	**001**	Dec 11, 2013
AB		**EQ 30MG BASE**	**A090783**	**002**	Dec 11, 2013
AB		**EQ 60MG BASE**	**A090783**	**003**	Dec 11, 2013
AB	TORRENT PHARMS LTD	**EQ 20MG BASE**	**A090774**	**001**	Dec 11, 2013
AB		**EQ 30MG BASE**	**A090774**	**002**	Dec 11, 2013
AB		**EQ 60MG BASE**	**A090774**	**003**	Dec 11, 2013
AB	ZYDUS HLTHCARE	**EQ 20MG BASE**	**A090739**	**001**	Jan 08, 2014
AB		**EQ 30MG BASE**	**A090739**	**002**	Jan 08, 2014
AB		**EQ 60MG BASE**	**A090739**	**003**	Jan 08, 2014
AB	ZYDUS PHARMS USA INC	**EQ 20MG BASE**	**A090728**	**001**	Jan 08, 2014
AB		**EQ 30MG BASE**	**A090728**	**002**	Jan 08, 2014
AB		**EQ 60MG BASE**	**A090728**	**003**	Jan 08, 2014

DUTASTERIDE

CAPSULE;ORAL

AVODART

AB	**+!**	GLAXOSMITHKLINE	**0.5MG**	**N021319**	**001**	Nov 20, 2001

DUTASTERIDE

AB		ACTAVIS LABS FL INC	**0.5MG**	**A202808**	**001**	Nov 20, 2015
AB		AMNEAL PHARMS	**0.5MG**	**A203118**	**001**	Nov 20, 2015
AB		APOTEX INC	**0.5MG**	**A204292**	**001**	Nov 24, 2015
AB		ASCENT PHARMS INC	**0.5MG**	**A206574**	**001**	Oct 21, 2016
AB		AUROLIFE PHARMA LLC	**0.5MG**	**A202660**	**001**	Nov 20, 2015
AB		BARR	**0.5MG**	**A090095**	**001**	Dec 21, 2010
AB		BIONPHARMA INC	**0.5MG**	**A200899**	**001**	Nov 20, 2015
AB		BRECKENRIDGE PHARM	**0.5MG**	**A204705**	**001**	Nov 20, 2015
AB			**0.5MG**	**A208227**	**001**	Jun 22, 2018
AB		HERITAGE PHARMS INC	**0.5MG**	**A207935**	**001**	Oct 13, 2017
AB		HUMANWELL PURACAP	**0.5MG**	**A209909**	**001**	Nov 21, 2017
AB		INTERGEL PHARMS INC	**0.5MG**	**A206373**	**001**	Mar 17, 2016
AB		MARKSANS PHARMA	**0.5MG**	**A204376**	**001**	Apr 07, 2017
AB		RISING PHARMS	**0.5MG**	**A202530**	**001**	Nov 20, 2015
AB		STRIDES PHARMA	**0.5MG**	**A204262**	**001**	Nov 20, 2015
AB		VINTAGE PHARMS LLC	**0.5MG**	**A202421**	**001**	Nov 20, 2015
AB		WEST-WARD PHARMS INT	**0.5MG**	**A202204**	**001**	Nov 23, 2015
AB		ZYDUS PHARMS USA	**0.5MG**	**A204373**	**001**	Oct 04, 2017

DUTASTERIDE							
CAPSULE;ORAL							
DUTASTERIDE							
		INC					
DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE							
CAPSULE;ORAL							
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE							
AB		ACTAVIS LABS FL INC	**0.5MG;0.4MG**	**A202975**	**001**	Nov 20, 2015
AB		ANCHEN PHARMS	**0.5MG;0.4MG**	**A202509**	**001**	Feb 26, 2014
AB		ZYDUS PHARMS USA INC	**0.5MG;0.4MG**	**A207769**	**001**	May 24, 2018
JALYN							
AB	**+!**	GLAXOSMITHKLINE	**0.5MG;0.4MG**	**N022460**	**001**	Jun 14, 2010
DUVELISIB							
CAPSULE;ORAL							
COPIKTRA							
	+	VERASTEM INC	15MG	N211155	001	Sep 24, 2018
	+!		25MG	N211155	002	Sep 24, 2018
DYCLONINE HYDROCHLORIDE							
SOLUTION;TOPICAL							
DYCLOPRO							
	!	NOVOCOL INC	0.5%	A200480	001	Nov 20, 2018
	!		1%	A200480	002	Nov 20, 2018
ECHOTHIOPHATE IODIDE							
FOR SOLUTION;OPHTHALMIC							
PHOSPHOLINE IODIDE							
	+!	WYETH PHARMS	0.125%	N011963	001		
ECONAZOLE NITRATE							
AEROSOL, FOAM;TOPICAL							
ECOZA							
	+!	GLENMARK	1%	N205175	001	Oct 24, 2013
CREAM;TOPICAL							
ECONAZOLE NITRATE							
AB		CASI PHARMS INC	**1%**	**A076075**	**001**	Nov 26, 2002
AB		MYLAN PHARMS INC	**1%**	**A210364**	**001**	Apr 18, 2018
AB	**!**	PERRIGO NEW YORK	**1%**	**A076479**	**001**	Jun 23, 2004
AB		TARO	**1%**	**A076005**	**001**	Nov 26, 2002
AB		TELIGENT PHARMA INC	**1%**	**A076574**	**001**	Dec 17, 2004
SPECTAZOLE							
AB	**+**	ALVOGEN MALTA	**1%**	**N018751**	**001**	Dec 23, 1982
EDARAVONE							
SOLUTION;INTRAVENOUS							
RADICAVA							
	+!	MITSUBISHI TANABE	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017
	+!		60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018
EDETATE CALCIUM DISODIUM							
INJECTABLE;INJECTION							
CALCIUM DISODIUM VERSENATE							
	+!	MEDICIS	200MG/ML	N008922	001		
EDOXABAN TOSYLATE							
TABLET;ORAL							
SAVAYSA							
	+	DAIICHI SANKYO INC	EQ 15MG BASE	N206316	001	Jan 08, 2015
	+		EQ 30MG BASE	N206316	002	Jan 08, 2015
	+!		EQ 60MG BASE	N206316	003	Jan 08, 2015
EFAVIRENZ							
CAPSULE;ORAL							
EFAVIRENZ							
AB		AUROBINDO PHARMA LTD	**50MG**	**A078064**	**001**	Dec 15, 2017
AB			**200MG**	**A078064**	**003**	Dec 15, 2017
SUSTIVA							
AB	**+**	BRISTOL MYERS SQUIBB	**50MG**	**N020972**	**001**	Sep 17, 1998
AB	**+!**		**200MG**	**N020972**	**003**	Sep 17, 1998
EFAVIRENZ							
		AUROBINDO PHARMA LTD	100MG	A078064	002	Dec 15, 2017

EFAVIRENZ

TABLET;ORAL

EFAVIRENZ

AB		AUROBINDO PHARMA LTD	**600MG**	**A077673**	**001**	Sep 21, 2018
AB			**600MG**	**A205322**	**001**	Aug 30, 2018
AB		CIPLA	**600MG**	**A204766**	**001**	Jun 15, 2018
AB		HETERO LABS LTD III	**600MG**	**A078886**	**001**	Apr 27, 2018
AB		MYLAN PHARMS INC	**600MG**	**A091471**	**001**	Feb 17, 2016
AB		STRIDES PHARMA	**600MG**	**A204869**	**001**	Mar 12, 2018

SUSTIVA

AB	**+!**	BRISTOL MYERS SQUIBB	**600MG**	**N021360**	**002**	Feb 01, 2002

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

ATRIPLA

AB	**+!**	GILEAD SCIENCES	**600MG;200MG;300MG**	**N021937**	**001**	Jul 12, 2006

EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

AB		AUROBINDO PHARMA LTD	**600MG;200MG;300MG**	**A203041**	**001**	Sep 04, 2018
AB		TEVA PHARMS USA	**600MG;200MG;300MG**	**A091215**	**001**	Nov 09, 2018

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

SYMFI

	+!	MYLAN LABS LTD	600MG;300MG;300MG	N022142	001	Mar 22, 2018

SYMFI LO

	+!	MYLAN PHARMS INC	400MG;300MG;300MG	N208255	001	Feb 05, 2018

EFINACONAZOLE

SOLUTION;TOPICAL

JUBLIA

	+!	VALEANT PHARMS INTL	10%	N203567	001	Jun 06, 2014

EFLORNITHINE HYDROCHLORIDE

CREAM;TOPICAL

VANIQA

	+!	SKINMEDICA	13.9%	N021145	001	Jul 27, 2000

ELAGOLIX SODIUM

TABLET;ORAL

ORILISSA

	+	ABBVIE INC	EQ 150MG BASE	N210450	001	Jul 23, 2018
	+!		EQ 200MG BASE	N210450	002	Jul 23, 2018

ELBASVIR; GRAZOPREVIR

TABLET;ORAL

ZEPATIER

	+!	MERCK SHARP DOHME	50MG;100MG	N208261	001	Jan 28, 2016

ELETRIPTAN HYDROBROMIDE

TABLET;ORAL

ELETRIPTAN HYDROBROMIDE

AB		AJANTA PHARMA LTD	**EQ 20MG BASE**	**A205186**	**001**	Aug 29, 2017
AB			**EQ 40MG BASE**	**A205186**	**002**	Aug 29, 2017
AB		AMNEAL PHARMS CO	**EQ 20MG BASE**	**A206787**	**001**	May 25, 2018
AB			**EQ 40MG BASE**	**A206787**	**002**	May 25, 2018
AB		AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A210708**	**001**	Jan 15, 2019
AB			**EQ 40MG BASE**	**A210708**	**002**	Jan 15, 2019
AB		MYLAN PHARMS INC	**EQ 20MG BASE**	**A205152**	**001**	Aug 11, 2017
AB			**EQ 40MG BASE**	**A205152**	**002**	Aug 11, 2017
AB		TEVA PHARMS USA	**EQ 20MG BASE**	**A202040**	**001**	Jun 27, 2017
AB			**EQ 40MG BASE**	**A202040**	**002**	Jun 27, 2017
AB		ZYDUS PHARMS USA INC	**EQ 20MG BASE**	**A206409**	**001**	Jun 16, 2017
AB			**EQ 40MG BASE**	**A206409**	**002**	Jun 16, 2017

RELPAX

AB	**+**	PFIZER IRELAND	**EQ 20MG BASE**	**N021016**	**001**	Dec 26, 2002
AB	**+!**		**EQ 40MG BASE**	**N021016**	**002**	Dec 26, 2002

ELIGLUSTAT TARTRATE
CAPSULE;ORAL
CERDELGA

+!	GENZYME CORP	EQ 84MG BASE	N205494	001	Aug 19, 2014

ELTROMBOPAG OLAMINE
FOR SUSPENSION;ORAL
PROMACTA KIT

+	NOVARTIS PHARMS CORP	EQ 12.5MG ACID/PACKET	N207027	002	Sep 27, 2018
+!		EQ 25MG ACID/PACKET	N207027	001	Aug 24, 2015

TABLET;ORAL
PROMACTA

+	NOVARTIS PHARMS CORP	EQ 12.5MG ACID	N022291	004	Oct 20, 2011
+		EQ 25MG ACID	N022291	001	Nov 20, 2008
+		EQ 50MG ACID	N022291	002	Nov 20, 2008
+!		EQ 75MG ACID	N022291	003	Sep 08, 2009
+!		EQ 100MG ACID	N022291	005	Nov 16, 2012

ELUXADOLINE
TABLET;ORAL
VIBERZI

+	ALLERGAN HOLDINGS	75MG	N206940	001	May 27, 2015
+!		100MG	N206940	002	May 27, 2015

EMEDASTINE DIFUMARATE
SOLUTION/DROPS;OPHTHALMIC
EMADINE

+!	NOVARTIS PHARMS CORP	0.05%	N020706	001	Dec 29, 1997

EMPAGLIFLOZIN
TABLET;ORAL
JARDIANCE

+	BOEHRINGER INGELHEIM	10MG	N204629	001	Aug 01, 2014
+!		25MG	N204629	002	Aug 01, 2014

EMPAGLIFLOZIN; LINAGLIPTIN
TABLET;ORAL
GLYXAMBI

+	BOEHRINGER INGELHEIM	10MG;5MG	N206073	001	Jan 30, 2015
+!		25MG;5MG	N206073	002	Jan 30, 2015

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
TABLET;ORAL
SYNJARDY

+	BOEHRINGER INGELHEIM	5MG;500MG	N206111	001	Aug 26, 2015
+		5MG;1GM	N206111	002	Aug 26, 2015
+		12.5MG;500MG	N206111	003	Aug 26, 2015
+!		12.5MG;1GM	N206111	004	Aug 26, 2015

TABLET, EXTENDED RELEASE;ORAL
SYNJARDY XR

+	BOEHRINGER INGELHEIM	5MG;1GM	N208658	001	Dec 09, 2016
+		10MG;1GM	N208658	002	Dec 09, 2016
+		12.5MG;1GM	N208658	003	Dec 09, 2016
+!		25MG;1GM	N208658	004	Dec 09, 2016

EMTRICITABINE
CAPSULE;ORAL
EMTRICITABINE

AB	CIPLA	**200MG**	**A091168**	**001**	Jul 02, 2018

EMTRIVA

AB	**+!**	GILEAD	**200MG**	**N021500**	**001**	Jul 02, 2003

SOLUTION;ORAL
EMTRIVA

+!	GILEAD	10MG/ML	N021896	001	Sep 28, 2005

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE						
TABLET;ORAL						
ODEFSEY						
	+!	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE	N208351	001	Mar 01, 2016
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE						
TABLET;ORAL						
COMPLERA						
	+!	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;300MG	N202123	001	Aug 10, 2011
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE						
TABLET;ORAL						
DESCOVY						
	+!	GILEAD SCIENCES INC	200MG;EQ 25MG BASE	N208215	001	Apr 04, 2016
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE						
TABLET;ORAL						
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE						
AB		AMNEAL PHARMS CO	**100MG;150MG**	**A209721**	**001**	Aug 22, 2018
AB			**133MG;200MG**	**A209721**	**002**	Aug 22, 2018
AB			**167MG;250MG**	**A209721**	**003**	Aug 22, 2018
AB			**200MG;300MG**	**A209721**	**004**	Aug 22, 2018
AB		AUROBINDO PHARMA LTD	**200MG;300MG**	**A090513**	**001**	Jan 26, 2018
AB		MYLAN PHARMS INC	**200MG;300MG**	**A206436**	**001**	Apr 09, 2018
AB		TEVA PHARMS USA	**200MG;300MG**	**A090894**	**001**	Jun 08, 2017
TRUVADA						
AB	**+**	GILEAD	**100MG;150MG**	**N021752**	**002**	Mar 10, 2016
AB	**+**		**133MG;200MG**	**N021752**	**003**	Mar 10, 2016
AB	**+**		**167MG;250MG**	**N021752**	**004**	Mar 10, 2016
AB	**+!**		**200MG;300MG**	**N021752**	**001**	Aug 02, 2004
ENALAPRIL MALEATE						
FOR SOLUTION;ORAL						
EPANED KIT						
	+!	SILVERGATE PHARMS	1MG/ML	N204308	001	Aug 13, 2013
SOLUTION;ORAL						
EPANED						
	+!	SILVERGATE PHARMS	1MG/ML	N208686	001	Sep 20, 2016
TABLET;ORAL						
ENALAPRIL MALEATE						
AB		APOTEX	**2.5MG**	**A075178**	**002**	Mar 23, 2001
AB			**5MG**	**A075178**	**001**	Mar 23, 2001
AB			**10MG**	**A075178**	**003**	Mar 23, 2001
AB			**20MG**	**A075178**	**004**	Mar 23, 2001
AB		MYLAN	**5MG**	**A075480**	**002**	Aug 22, 2000
AB			**10MG**	**A075480**	**003**	Aug 22, 2000
AB		SANDOZ INC	**2.5MG**	**A075496**	**001**	Aug 22, 2000
AB			**5MG**	**A075496**	**002**	Aug 22, 2000
AB			**10MG**	**A075459**	**001**	Aug 22, 2000
AB			**20MG**	**A075459**	**002**	Aug 22, 2000
AB		TARO	**2.5MG**	**A075657**	**001**	Jan 23, 2001
AB			**5MG**	**A075657**	**002**	Jan 23, 2001
AB			**10MG**	**A075657**	**003**	Jan 23, 2001
AB			**20MG**	**A075657**	**004**	Jan 23, 2001
AB		TEVA	**2.5MG**	**A075479**	**001**	Aug 22, 2000
AB			**5MG**	**A075479**	**002**	Aug 22, 2000
AB			**10MG**	**A075479**	**003**	Aug 22, 2000
AB			**20MG**	**A075479**	**004**	Aug 22, 2000
AB		WOCKHARDT LTD	**2.5MG**	**A075483**	**001**	Aug 22, 2000
AB			**5MG**	**A075483**	**002**	Aug 22, 2000
AB			**10MG**	**A075483**	**003**	Aug 22, 2000
AB			**20MG**	**A075483**	**004**	Aug 22, 2000
VASOTEC						
AB	**+**	VALEANT PHARMS NORTH	**2.5MG**	**N018998**	**005**	Jul 26, 1988
AB	**+**		**5MG**	**N018998**	**001**	Dec 24, 1985
AB	**+**		**10MG**	**N018998**	**002**	Dec 24, 1985
AB	**+!**		**20MG**	**N018998**	**003**	Dec 24, 1985

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB		APOTEX INC	**5MG;12.5MG**	**A076486**	**001**	Oct 27, 2004
AB			**10MG;25MG**	**A076486**	**002**	Oct 27, 2004
AB		DR REDDYS LABS LTD	**5MG;12.5MG**	**A075909**	**001**	Oct 15, 2001
AB			**10MG;25MG**	**A075909**	**002**	Oct 15, 2001
AB		G AND W LABS INC	**5MG;12.5MG**	**A075727**	**001**	Sep 18, 2001
AB			**10MG;25MG**	**A075727**	**002**	Sep 18, 2001
AB		MYLAN	**5MG;12.5MG**	**A075624**	**001**	Sep 18, 2001
AB			**10MG;25MG**	**A075624**	**002**	Sep 18, 2001
AB		TARO PHARM INDS	**5MG;12.5MG**	**A075788**	**001**	Sep 18, 2001
AB			**10MG;25MG**	**A075788**	**002**	Sep 18, 2001

VASERETIC

AB	**+**	VALEANT INTL	**5MG;12.5MG**	**N019221**	**003**	Jul 12, 1995
AB	**+!**		**10MG;25MG**	**N019221**	**001**	Oct 31, 1986

ENALAPRILAT

INJECTABLE;INJECTION

ENALAPRILAT

AP	**!**	ATHENEX INC	**1.25MG/ML**	**A075634**	**001**	Aug 22, 2000
AP		HIKMA FARMACEUTICA	**1.25MG/ML**	**A078687**	**001**	Dec 23, 2008
AP	**!**	HOSPIRA	**1.25MG/ML**	**A075458**	**001**	Aug 22, 2000
AP		TEVA PHARMS USA	**1.25MG/ML**	**A075578**	**001**	Aug 22, 2000

ENASIDENIB MESYLATE

TABLET;ORAL

IDHIFA

	+	CELGENE CORP	EQ 50MG BASE	N209606	001	Aug 01, 2017
	+!		EQ 100MG BASE	N209606	002	Aug 01, 2017

ENCORAFENIB

CAPSULE;ORAL

BRAFTOVI

	+	ARRAY BIOPHARMA INC	50MG	N210496	001	Jun 27, 2018
	+!		75MG	N210496	002	Jun 27, 2018

ENFUVIRTIDE

INJECTABLE;SUBCUTANEOUS

FUZEON

	+!	ROCHE	90MG/VIAL	N021481	001	Mar 13, 2003

ENOXAPARIN SODIUM

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

ENOXAPARIN SODIUM

AB		SANDOZ INC	**300MG/3ML (100MG/ML)**	**A078660**	**001**	Nov 28, 2011

LOVENOX

AB	**+**	SANOFI AVENTIS US	**300MG/3ML (100MG/ML)**	**N020164**	**009**	Jan 23, 2003

INJECTABLE;SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

AP		AMPHASTAR PHARM	**30MG/0.3ML (100MG/ML)**	**A076684**	**001**	Sep 19, 2011
AP			**40MG/0.4ML (100MG/ML)**	**A076684**	**002**	Sep 19, 2011
AP			**60MG/0.6ML (100MG/ML)**	**A076684**	**003**	Sep 19, 2011
AP			**80MG/0.8ML (100MG/ML)**	**A076684**	**004**	Sep 19, 2011
AP			**100MG/ML (100MG/ML)**	**A076684**	**005**	Sep 19, 2011
AP			**120MG/0.8ML (150MG/ML)**	**A076684**	**006**	Sep 19, 2011
AP			**150MG/ML (150MG/ML)**	**A076684**	**007**	Sep 19, 2011
AP		APOTEX INC	**30MG/0.3ML (100MG/ML)**	**A078990**	**001**	Sep 28, 2018
AP			**40MG/0.4ML (100MG/ML)**	**A078990**	**002**	Sep 28, 2018
AP			**60MG/0.6ML (100MG/ML)**	**A078990**	**003**	Sep 28, 2018
AP			**80MG/0.8ML (100MG/ML)**	**A078990**	**004**	Sep 28, 2018
AP			**100MG/ML (100MG/ML)**	**A078990**	**005**	Sep 28, 2018
AP			**120MG/0.8ML (150MG/ML)**	**A078990**	**006**	Sep 28, 2018
AP			**150MG/ML (150MG/ML)**	**A078990**	**007**	Sep 28, 2018
AP		SANDOZ	**30MG/0.3ML (100MG/ML)**	**A077857**	**002**	Jul 23, 2010
AP			**40MG/0.4ML (100MG/ML)**	**A077857**	**003**	Jul 23, 2010
AP			**60MG/0.6ML (100MG/ML)**	**A077857**	**004**	Jul 23, 2010
AP			**80MG/0.8ML (100MG/ML)**	**A077857**	**005**	Jul 23, 2010
AP			**100MG/ML (100MG/ML)**	**A077857**	**001**	Jul 23, 2010
AP			**120MG/0.8ML (150MG/ML)**	**A077857**	**006**	Jul 23, 2010
AP			**150MG/ML (150MG/ML)**	**A077857**	**007**	Jul 23, 2010
AP		TEVA	**30MG/0.3ML (100MG/ML)**	**A076726**	**001**	Jun 23, 2014
AP			**40MG/0.4ML (100MG/ML)**	**A076726**	**002**	Jun 23, 2014
AP			**60MG/0.6ML (100MG/ML)**	**A076726**	**003**	Jun 23, 2014
AP			**80MG/0.8ML (100MG/ML)**	**A076726**	**004**	Jun 23, 2014

ENOXAPARIN SODIUM						
INJECTABLE;SUBCUTANEOUS						
ENOXAPARIN SODIUM (PRESERVATIVE FREE)						
AP			**100MG/ML (100MG/ML)**	**A076726**	**005**	Jun 23, 2014
AP			**120MG/0.8ML (150MG/ML)**	**A076726**	**006**	Jun 23, 2014
AP			**150MG/ML (150MG/ML)**	**A076726**	**007**	Jun 23, 2014
LOVENOX (PRESERVATIVE FREE)						
AP	+	SANOFI AVENTIS US	**30MG/0.3ML (100MG/ML)**	**N020164**	**001**	Mar 29, 1993
AP	+		**40MG/0.4ML (100MG/ML)**	**N020164**	**002**	Jan 30, 1998
AP	+		**60MG/0.6ML (100MG/ML)**	**N020164**	**003**	Mar 27, 1998
AP	+		**80MG/0.8ML (100MG/ML)**	**N020164**	**004**	Mar 27, 1998
AP	+!		**100MG/ML (100MG/ML)**	**N020164**	**005**	Mar 27, 1998
AP	+		**120MG/0.8ML (150MG/ML)**	**N020164**	**007**	Jun 02, 2000
AP	+		**150MG/ML (150MG/ML)**	**N020164**	**008**	Jun 02, 2000
ENTACAPONE						
TABLET;ORAL						
COMTAN						
AB	+!	ORION PHARMA	**200MG**	**N020796**	**001**	Oct 19, 1999
ENTACAPONE						
AB		AJANTA PHARMA LTD	**200MG**	**A205792**	**001**	Aug 31, 2017
AB		AUROBINDO PHARMA LTD	**200MG**	**A203437**	**001**	Jun 19, 2015
AB		MACLEODS PHARMS LTD	**200MG**	**A207210**	**001**	Jun 05, 2017
AB		SUN PHARMA GLOBAL	**200MG**	**A090690**	**001**	Jul 16, 2012
AB		SUNSHINE LAKE	**200MG**	**A206669**	**001**	Oct 03, 2018
AB		WOCKHARDT LTD	**200MG**	**A078941**	**001**	Aug 16, 2012
ENTECAVIR						
SOLUTION;ORAL						
BARACLUDE						
	+!	BRISTOL MYERS SQUIBB	0.05MG/ML	N021798	001	Mar 29, 2005
TABLET;ORAL						
BARACLUDE						
AB	+	BRISTOL MYERS SQUIBB	**0.5MG**	**N021797**	**001**	Mar 29, 2005
AB	+!		**1MG**	**N021797**	**002**	Mar 29, 2005
ENTECAVIR						
AB		ACCORD HLTHCARE	**0.5MG**	**A205824**	**001**	Aug 25, 2017
AB			**1MG**	**A205824**	**002**	Aug 25, 2017
AB		AMNEAL PHARMS	**0.5MG**	**A206652**	**001**	Nov 12, 2015
AB			**1MG**	**A206652**	**002**	Nov 12, 2015
AB		AUROBINDO PHARMA LTD	**0.5MG**	**A206217**	**001**	Aug 26, 2015
AB			**1MG**	**A206217**	**002**	Aug 26, 2015
AB		BRECKENRIDGE PHARM	**0.5MG**	**A208721**	**001**	Mar 15, 2018
AB			**1MG**	**A208721**	**002**	Mar 15, 2018
AB		CASI PHARMS INC	**0.5MG**	**A206672**	**001**	May 11, 2017
AB			**1MG**	**A206672**	**002**	May 11, 2017
AB		CIPLA	**0.5MG**	**A206872**	**001**	Dec 06, 2016
AB			**1MG**	**A206872**	**002**	Dec 06, 2016
AB		HETERO LABS LTD V	**0.5MG**	**A205740**	**001**	Aug 21, 2015
AB			**1MG**	**A205740**	**002**	Aug 21, 2015
AB		PAR PHARM INC	**0.5MG**	**A206294**	**001**	Nov 23, 2016
AB			**1MG**	**A206294**	**002**	Nov 23, 2016
AB		PRINSTON INC	**0.5MG**	**A208782**	**001**	Oct 10, 2017
AB			**1MG**	**A208782**	**002**	Oct 10, 2017
AB		TEVA PHARMS USA	**0.5MG**	**A202122**	**001**	Aug 26, 2014
AB			**1MG**	**A202122**	**002**	Aug 26, 2014
AB		ZYDUS PHARMS USA INC	**0.5MG**	**A206745**	**001**	Jun 23, 2017
AB			**1MG**	**A206745**	**002**	Jun 23, 2017
ENZALUTAMIDE						
CAPSULE;ORAL						
XTANDI						
	+!	ASTELLAS	40MG	N203415	001	Aug 31, 2012

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

	AKOVAZ					
AP	**+!**	FLAMEL IRELAND LTD	**50MG/ML (50MG/ML)**	**N208289**	**001**	Apr 29, 2016
	CORPHEDRA					
AP		PAR STERILE PRODUCTS	**50MG/ML (50MG/ML)**	**N208943**	**001**	Jan 27, 2017
	EPHEDRINE SULFATE					
AP		AKORN INC	**50MG/ML (50MG/ML)**	**N208609**	**001**	Mar 01, 2017
AP		SANDOZ INC	**50MG/ML (50MG/ML)**	**A209784**	**001**	Aug 23, 2017

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

	ELESTAT					
AT	**+!**	ALLERGAN	**0.05%**	**N021565**	**001**	Oct 16, 2003
	EPINASTINE HYDROCHLORIDE					
AT		AKORN	**0.05%**	**A204055**	**001**	May 05, 2017
AT		APOTEX	**0.05%**	**A090919**	**001**	Oct 31, 2011
AT		BRECKENRIDGE PHARM	**0.05%**	**A090870**	**001**	Mar 14, 2011
AT		CASI PHARMS INC	**0.05%**	**A203384**	**001**	Dec 07, 2016
AT		SOMERSET THERAPS LLC	**0.05%**	**A090951**	**001**	Oct 31, 2011
AT		SUN PHARM INDS	**0.05%**	**A091626**	**001**	Oct 31, 2011

EPINEPHRINE

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

	EPINEPHRINE (AUTOINJECTOR)					
AB		TEVA PHARMS USA	**0.15MG/DELIVERY**	**A090589**	**002**	Aug 16, 2018
AB			**0.3MG/DELIVERY**	**A090589**	**001**	Aug 16, 2018
	EPIPEN					
AB	**+!**	MYLAN SPECIALITY LP	**0.3MG/DELIVERY**	**N019430**	**001**	Dec 22, 1987
	EPIPEN JR.					
AB	**+!**	MYLAN SPECIALITY LP	**0.15MG/DELIVERY**	**N019430**	**002**	Dec 22, 1987
	ADRENACLICK					
BX	+!	IMPAX	EQ 0.15MG/DELIVERY	N020800	003	Nov 25, 2009
BX	+!		EQ 0.3MG/DELIVERY	N020800	004	Nov 25, 2009

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

	ADRENALIN					
AP	**+!**	PAR STERILE PRODUCTS	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**N204200**	**001**	Dec 07, 2012
	EPINEPHRINE					
AP		LUITPOLD	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A207568**	**001**	Jul 06, 2018
	AUVI-Q					
BX	+!	KALEO INC	EQ 0.15MG/DELIVERY	N201739	002	Aug 10, 2012
BX	+		EQ 0.3MG/DELIVERY	N201739	001	Aug 10, 2012
	ADRENALIN					
	+!	PAR STERILE PRODUCTS	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013
	AUVI-Q					
	+	KALEO INC	EQ 0.1MG/DELIVERY	N201739	003	Nov 17, 2017
	SYMJEPI					
	+!	ADAMIS PHARMS CORP	0.15MG/0.3ML (0.15MG/0.3ML)	N207534	002	Sep 27, 2018
	+!		0.3MG/0.3ML (0.3MG/0.3ML)	N207534	001	Jun 15, 2017

SOLUTION;IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

	EPINEPHRINE					
	+!	BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

	LIGNOSPAN FORTE					
	!	DEPROCO	EQ 0.02MG BASE/ML;2%	A088389	001	Jan 22, 1985
	LIGNOSPAN STANDARD					
	!	DEPROCO	EQ 0.01MG BASE/ML;2%	A088390	001	Jan 22, 1985

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

	CITANEST FORTE DENTAL					
AP	**+!**	DENTSPLY PHARM	**0.005MG/ML;4%**	**N021383**	**001**	
	PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE					
AP		SEPTODONT INC	**0.005MG/ML;4%**	**A078959**	**001**	Aug 30, 2011

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

AP		HOSPIRA	**0.005MG/ML;0.5%**	**A089635**	**001**	Jun 21, 1988
AP			**0.005MG/ML;1.5%**	**A088571**	**001**	Sep 13, 1985
AP			**0.005MG/ML;1.5%**	**A089645**	**001**	Jun 21, 1988
AP			**0.005MG/ML;2%**	**A089651**	**001**	Jun 21, 1988
AP			**0.01MG/ML;1%**	**A089644**	**001**	Jun 21, 1988
AP	**!**		**0.01MG/ML;2%**	**A089646**	**001**	Jun 21, 1988

XYLOCAINE W/ EPINEPHRINE

AP	**+!**	FRESENIUS KABI USA	**0.005MG/ML;0.5%**	**N006488**	**012**	
AP	**+!**		**0.005MG/ML;1.5%**	**N006488**	**017**	
AP	**+!**		**0.005MG/ML;2%**	**N006488**	**019**	Nov 13, 1986
AP	**+!**		**0.01MG/ML;1%**	**N006488**	**004**	
AP	**+!**		**0.02MG/ML;2%**	**N006488**	**005**	
	+!		0.005MG/ML;1%	N006488	018	Nov 13, 1986

EPIRUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

ELLENCE

AP	**+!**	PFIZER INC	**200MG/100ML (2MG/ML)**	**N050778**	**001**	Sep 15, 1999
AP	**+**		**50MG/25ML (2MG/ML)**	**N050778**	**002**	Sep 15, 1999

EPIRUBICIN HYDROCHLORIDE

AP		ACTAVIS TOTOWA	**10MG/5ML (2MG/ML)**	**A065445**	**001**	Sep 18, 2008
AP			**50MG/25ML (2MG/ML)**	**A065445**	**002**	Sep 18, 2008
AP			**200MG/100ML (2MG/ML)**	**A065445**	**003**	Sep 18, 2008
AP		AKORN INC	**50MG/25ML (2MG/ML)**	**A090163**	**001**	Jun 24, 2009
AP		CIPLA LTD	**50MG/25ML (2MG/ML)**	**A065361**	**001**	Oct 22, 2007
AP			**200MG/100ML (2MG/ML)**	**A065361**	**002**	Oct 22, 2007
AP		FRESENIUS KABI USA	**10MG/5ML (2MG/ML)**	**A065408**	**001**	Oct 15, 2007
AP			**50MG/25ML (2MG/ML)**	**A065408**	**002**	Oct 15, 2007
AP			**150MG/75ML (2MG/ML)**	**A065408**	**003**	Oct 15, 2007
AP			**200MG/100ML (2MG/ML)**	**A065408**	**004**	Oct 15, 2007
AP			**200MG/100ML (2MG/ML)**	**A065411**	**001**	Aug 20, 2007
AP			**50MG/25ML (2MG/ML)**	**A065411**	**002**	Aug 20, 2007
AP		HISUN PHARM HANGZHOU	**50MG/25ML (2MG/ML)**	**A090075**	**001**	Mar 25, 2010
AP			**200MG/100ML (2MG/ML)**	**A090075**	**002**	Mar 25, 2010
AP		HOSPIRA	**10MG/5ML (2MG/ML)**	**A065343**	**001**	Apr 19, 2007
AP			**150MG/75ML (2MG/ML)**	**A065343**	**003**	Apr 19, 2007
AP			**200MG/100ML (2MG/ML)**	**A065343**	**004**	Apr 19, 2007
AP		IMPAX LABS INC	**50MG/25ML (2MG/ML)**	**A065331**	**001**	Aug 09, 2007
AP			**200MG/100ML (2MG/ML)**	**A065331**	**002**	Aug 09, 2007
AP		MYLAN LABS LTD	**50MG/25ML (2MG/ML)**	**A091599**	**001**	Mar 12, 2012
AP			**200MG/100ML (2MG/ML)**	**A091599**	**002**	Mar 12, 2012
AP		WEST-WARD PHARMS INT	**50MG/25ML (2MG/ML)**	**A065289**	**001**	Jun 27, 2007
AP			**200MG/100ML (2MG/ML)**	**A065289**	**002**	Jun 27, 2007

EPLERENONE

TABLET;ORAL

EPLERENONE

AB		ACCORD HLTHCARE	**25MG**	**A206922**	**001**	Jul 13, 2017
AB			**50MG**	**A206922**	**002**	Jul 13, 2017
AB		APOTEX	**25MG**	**A078482**	**001**	Jul 30, 2008
AB			**50MG**	**A078482**	**002**	Jul 30, 2008
AB		BRECKENRIDGE PHARM	**25MG**	**A208283**	**001**	Sep 14, 2018
AB			**50MG**	**A208283**	**002**	Sep 14, 2018
AB		MYLAN PHARMS INC	**25MG**	**A203896**	**001**	Feb 02, 2017
AB			**50MG**	**A203896**	**002**	Feb 02, 2017
AB		SANDOZ	**25MG**	**A078510**	**001**	Aug 01, 2008
AB			**50MG**	**A078510**	**002**	Aug 01, 2008

INSPRA

AB	**+**	GD SEARLE LLC	**25MG**	**N021437**	**001**	Sep 27, 2002
AB	**+!**		**50MG**	**N021437**	**002**	Sep 27, 2002

EPOPROSTENOL SODIUM

INJECTABLE;INJECTION

EPOPROSTENOL SODIUM

AP		TEVA PHARMS USA	**EQ 0.5MG BASE/VIAL**	**A078396**	**001**	Apr 23, 2008
AP			**EQ 1.5MG BASE/VIAL**	**A078396**	**002**	Apr 23, 2008

FLOLAN

AP	**+!**	GLAXOSMITHKLINE LLC	**EQ 0.5MG BASE/VIAL**	**N020444**	**001**	Sep 20, 1995
AP	**+!**		**EQ 1.5MG BASE/VIAL**	**N020444**	**002**	Sep 20, 1995

EPOPROSTENOL SODIUM

INJECTABLE;INJECTION

VELETRI

+	ACTELION PHARMS LTD	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012
+!		EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008

EPROSARTAN MESYLATE

TABLET;ORAL

EPROSARTAN MESYLATE

AB	MYLAN PHARMS INC	**EQ 400MG BASE**	**A202012**	**001**	Nov 16, 2011
AB !		**EQ 600MG BASE**	**A202012**	**002**	Nov 16, 2011

EPTIFIBATIDE

INJECTABLE;INJECTION

EPTIFIBATIDE

AP	ACCORD HLTHCARE	**2MG/ML**	**A205557**	**001**	Nov 06, 2017
AP		**75MG/100ML**	**A205557**	**002**	Nov 06, 2017
AP	AKORN	**2MG/ML**	**A204589**	**001**	Apr 18, 2017
AP		**75MG/100ML**	**A204589**	**002**	Apr 18, 2017
AP	AMNEAL PHARMS	**2MG/ML**	**A205581**	**001**	Dec 08, 2016
AP		**75MG/100ML**	**A205581**	**002**	Dec 08, 2016
AP	AUROBINDO PHARMA LTD	**2MG/ML**	**A206127**	**001**	Dec 08, 2015
AP		**75MG/100ML**	**A206127**	**002**	Dec 08, 2015
AP	CELERITY PHARMS	**2MG/ML**	**A208554**	**001**	Nov 23, 2018
AP		**75MG/100ML**	**A208554**	**002**	Nov 23, 2018
AP	MYLAN LABS LTD	**2MG/ML**	**A203258**	**001**	Jul 20, 2018
AP		**75MG/100ML**	**A203258**	**002**	Jul 20, 2018
AP	SAGENT PHARMS	**2MG/ML**	**A204693**	**001**	Mar 07, 2018
AP		**75MG/100ML**	**A204693**	**002**	Mar 07, 2018
AP	TEVA PHARMS USA	**2MG/ML**	**A090854**	**001**	Jun 12, 2015

INTEGRILIN

AP +!	SCHERING	**2MG/ML**	**N020718**	**001**	May 18, 1998
AP +!		**75MG/100ML**	**N020718**	**002**	May 18, 1998

ERAVACYCLINE DIHYDROCHLORIDE

POWDER;INTRAVENOUS

XERAVA

+!	TETRAPHASE PHARMS	EQ 50MG BASE/VIAL	N211109	001	Aug 27, 2018

ERGOCALCIFEROL

CAPSULE;ORAL

DRISDOL

AA +!	US PHARM HOLDINGS	**50,000 IU**	**N003444**	**001**	

ERGOCALCIFEROL

AA	ORIT LABS LLC	**50,000 IU**	**A040833**	**001**	May 20, 2009
AA	PURACAP PHARM LLC	**50000IU**	**A204276**	**001**	Dec 07, 2018
AA	SIGMAPHARM LABS LLC	**50,000 IU**	**A091004**	**001**	Jul 14, 2010
AA	STRIDES PHARMA	**50,000 IU**	**A090455**	**001**	Aug 03, 2010
AA	SUN PHARM INDS INC	**50,000 IU**	**A040865**	**001**	Dec 29, 2009

VITAMIN D

AA	BIONPHARMA INC	**50,000 IU**	**A080704**	**001**	

ERGOLOID MESYLATES

TABLET;ORAL

ERGOLOID MESYLATES

!	SUN PHARM INDUSTRIES	1MG	A081113	001	Oct 31, 1991

ERGOTAMINE TARTRATE

TABLET;SUBLINGUAL

ERGOMAR

!	TERSERA THERAPS LLC	2MG	A087693	001	Feb 24, 1983

ERIBULIN MESYLATE

SOLUTION;INTRAVENOUS

HALAVEN

+!	EISAI INC	1MG/2ML (0.5MG/ML)	N201532	001	Nov 15, 2010

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

TARCEVA

+	OSI PHARMS	EQ 25MG BASE	N021743	001	Nov 18, 2004
+		EQ 100MG BASE	N021743	002	Nov 18, 2004
+!		EQ 150MG BASE	N021743	003	Nov 18, 2004

ERTAPENEM SODIUM

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

ERTAPENEM SODIUM

AP		ACS DOBFAR SPA	**EQ 1GM BASE/VIAL**	**A208790**	**001**	Apr 16, 2018
AP		AUROBINDO PHARMA LTD	**EQ 1GM BASE/VIAL**	**A209133**	**001**	Jun 25, 2018

INVANZ

AP	**+!**	MERCK SHARP DOHME	**EQ 1GM BASE/VIAL**	**N021337**	**001**	Nov 21, 2001

ERTUGLIFLOZIN

TABLET;ORAL

STEGLATRO

+		MERCK SHARP DOHME	5MG	N209803	001 Dec 19, 2017
+!			15MG	N209803	002 Dec 19, 2017

ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

SEGLUROMET

+		MERCK SHARP DOHME	2.5MG;500MG	N209806	001 Dec 19, 2017
+			2.5MG;1GM	N209806	002 Dec 19, 2017
+			7.5MG;500MG	N209806	003 Dec 19, 2017
+!			7.5MG;1GM	N209806	004 Dec 19, 2017

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

STEGLUJAN

+		MERCK SHARP DOHME	5MG;EQ 100MG BASE	N209805	001 Dec 19, 2017
+!			15MG;EQ 100MG BASE	N209805	002 Dec 19, 2017

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL

ERYC

AB	**+!**	MAYNE PHARMA	**250MG**	**N050536**	**001**	

ERYTHROMYCIN

AB		ARBOR PHARMS LLC	**250MG**	**A062746**	**001**	Dec 22, 1986

GEL;TOPICAL

ERYGEL

AT	**+!**	MYLAN PHARMS INC	**2%**	**N050617**	**001**	Oct 21, 1987

ERYTHROMYCIN

AT		FOUGERA PHARMS	**2%**	**A064184**	**001**	Sep 30, 1997
AT		PERRIGO CO	**2%**	**A063211**	**001**	Jan 29, 1993
AT		TELIGENT PHARMA INC	**2%**	**A208154**	**001**	Jul 19, 2017

OINTMENT;OPHTHALMIC

ERYTHROMYCIN

AT		AKORN	**0.5%**	**A064030**	**001**	Jul 18, 1996
AT		BAUSCH AND LOMB	**0.5%**	**A064067**	**001**	Jul 29, 1994
AT	**!**	PERRIGO CO TENNESSEE	**0.5%**	**A062447**	**001**	Sep 26, 1983

SOLUTION;TOPICAL

ERYTHROMYCIN

AT	**!**	PERRIGO NEW YORK	**2%**	**A063038**	**001**	Jan 11, 1991
AT		TELIGENT PHARMA INC	**2%**	**A208100**	**001**	Nov 20, 2017
AT		WOCKHARDT BIO AG	**2%**	**A062825**	**001**	Oct 23, 1987

SWAB;TOPICAL

ERYTHROMYCIN

AT		AKORN	**2%**	**A090215**	**001**	May 12, 2010
AT	**!**	PERRIGO CO	**2%**	**A064126**	**001**	Jul 03, 1996

TABLET;ORAL

ERYTHROMYCIN

AB		AMNEAL PHARMS CO	**250MG**	**A209720**	**001**	Mar 09, 2018
AB			**500MG**	**A209720**	**002**	Mar 09, 2018
AB		ARBOR PHARMS LLC	**250MG**	**A061621**	**001**	
AB	**!**		**500MG**	**A061621**	**002**	

TABLET, DELAYED RELEASE;ORAL

ERY-TAB

		ARBOR PHARMS LLC	250MG	A062298	001
			333MG	A062298	003 Mar 29, 1982
	!		500MG	A062298	002

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

	ERYPED					
AB	**+!**	ARBOR PHARMS LLC	**EQ 400MG BASE/5ML**	**N050207**	**002**	
	ERYTHROMYCIN ETHYLSUCCINATE					
AB		ANI PHARMS INC	**EQ 400MG BASE/5ML**	**A062055**	**002**	Nov 02, 2018
	E.E.S.					
AB1	**+**	ARBOR PHARMS LLC	**EQ 200MG BASE/5ML**	**N050207**	**001**	
	ERYTHROMYCIN ETHYLSUCCINATE					
AB1		ANI PHARMS INC	**EQ 200MG BASE/5ML**	**A062055**	**001**	
	ERYPED					
AB2	**+**	ARBOR PHARMS LLC	**EQ 200MG BASE/5ML**	**N050207**	**003**	Mar 30, 1987
	ERYTHROMYCIN ETHYLSUCCINATE					
AB2		ANI PHARMS INC	**EQ 200MG BASE/5ML**	**A062055**	**003**	Nov 02, 2018

TABLET;ORAL

	E.E.S. 400					
BX	!	ARBOR PHARMS LLC	EQ 400MG BASE	A061905	002	Aug 12, 1982
	ERYTHROMYCIN ETHYLSUCCINATE					
BX	!	ARBOR PHARMS LLC	EQ 400MG BASE	A061904	001	

ERYTHROMYCIN LACTOBIONATE

INJECTABLE;INJECTION

	ERYTHROCIN					
AP		HOSPIRA	**EQ 500MG BASE/VIAL**	**A062638**	**001**	Oct 31, 1986
AP	**+!**		**EQ 500MG BASE/VIAL**	**N050609**	**001**	Sep 24, 1986

ERYTHROMYCIN STEARATE

TABLET;ORAL

	ERYTHROCIN STEARATE					
	!	ARBOR PHARMS LLC	EQ 250MG BASE	A060359	001	

ESCITALOPRAM OXALATE

SOLUTION;ORAL

	ESCITALOPRAM OXALATE					
AA		AMNEAL PHARMS	**EQ 5MG BASE/5ML**	**A202227**	**001**	Mar 14, 2012
AA		ANTRIM PHARMS LLC	**EQ 5MG BASE/5ML**	**A203967**	**001**	May 26, 2015
AA		AUROBINDO PHARMA LTD	**EQ 5MG BASE/5ML**	**A079062**	**001**	Apr 02, 2012
AA		HETERO LABS LTD III	**EQ 5MG BASE/5ML**	**A202221**	**001**	Jun 12, 2012
AA		LANNETT CO INC	**EQ 5MG BASE/5ML**	**A090477**	**001**	Jun 12, 2013
AA		MACLEODS PHARMS LTD	**EQ 5MG BASE/5ML**	**A202754**	**001**	Mar 31, 2016
AA		TARO	**EQ 5MG BASE/5ML**	**A079121**	**001**	May 03, 2012
	LEXAPRO					
AA	**+!**	ALLERGAN SALES LLC	**EQ 5MG BASE/5ML**	**N021365**	**001**	Nov 27, 2002

TABLET;ORAL

	ESCITALOPRAM OXALATE					
AB		ACCORD HLTHCARE	**EQ 5MG BASE**	**A202389**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A202389**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A202389**	**003**	Sep 11, 2012
AB		AMNEAL PHARMS	**EQ 5MG BASE**	**A205619**	**001**	May 17, 2017
AB			**EQ 10MG BASE**	**A205619**	**002**	May 17, 2017
AB			**EQ 20MG BASE**	**A205619**	**003**	May 17, 2017
AB		APOTEX INC	**EQ 5MG BASE**	**A078777**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A078777**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A078777**	**003**	Sep 11, 2012
AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A090432**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A090432**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A090432**	**003**	Sep 11, 2012
AB		HIKMA PHARMS	**EQ 5MG BASE**	**A078766**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A078766**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A078766**	**003**	Sep 11, 2012
AB		INVAGEN PHARMS	**EQ 5MG BASE**	**A078604**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A078604**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A078604**	**003**	Sep 11, 2012
AB		JUBILANT GENERICS	**EQ 5MG BASE**	**A202280**	**001**	Sep 12, 2012
AB			**EQ 10MG BASE**	**A202280**	**002**	Sep 12, 2012
AB			**EQ 20MG BASE**	**A202280**	**003**	Sep 12, 2012
AB		LUPIN LTD	**EQ 5MG BASE**	**A078169**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A078169**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A078169**	**003**	Sep 11, 2012
AB		MACLEODS PHARMS LTD	**EQ 5MG BASE**	**A202210**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A202210**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A202210**	**003**	Sep 11, 2012

ESCITALOPRAM OXALATE

TABLET;ORAL

ESCITALOPRAM OXALATE

AB		PHARM ASSOC	**EQ 5MG BASE**	**A077512**	**001**	Sep 12, 2012
AB			**EQ 10MG BASE**	**A077512**	**002**	Sep 12, 2012
AB			**EQ 20MG BASE**	**A077512**	**003**	Sep 12, 2012
AB		PRINSTON INC	**EQ 5MG BASE**	**A078032**	**001**	Aug 28, 2015
AB			**EQ 10MG BASE**	**A078032**	**002**	Aug 28, 2015
AB			**EQ 20MG BASE**	**A078032**	**003**	Aug 28, 2015
AB		TEVA PHARMS USA	**EQ 5MG BASE**	**A076765**	**001**	Mar 14, 2012
AB			**EQ 10MG BASE**	**A076765**	**002**	Mar 14, 2012
AB			**EQ 20MG BASE**	**A076765**	**003**	Mar 14, 2012
AB		TORRENT PHARMS LTD	**EQ 5MG BASE**	**A090939**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A090939**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A090939**	**003**	Sep 11, 2012
AB		ZYDUS PHARMS USA INC	**EQ 5MG BASE**	**A077734**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A077734**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A077734**	**003**	Sep 11, 2012

LEXAPRO

AB	**+**	ALLERGAN SALES LLC	**EQ 5MG BASE**	**N021323**	**001**	Aug 14, 2002
AB	**+**		**EQ 10MG BASE**	**N021323**	**002**	Aug 14, 2002
AB	**+!**		**EQ 20MG BASE**	**N021323**	**003**	Aug 14, 2002

ESLICARBAZEPINE ACETATE

TABLET;ORAL

APTIOM

+	SUNOVION PHARMS INC	200MG	N022416	001	Nov 08, 2013
+		400MG	N022416	002	Nov 08, 2013
+		600MG	N022416	003	Nov 08, 2013
+!		800MG	N022416	004	Nov 08, 2013

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

BREVIBLOC

AP	**+!**	BAXTER HLTHCARE	**10MG/ML**	**N019386**	**006**	Feb 25, 2003

ESMOLOL HYDROCHLORIDE

AP		AUROBINDO PHARMA LTD	**10MG/ML**	**A205520**	**001**	Jul 23, 2015
AP		FRESENIUS KABI USA	**10MG/ML**	**A076573**	**001**	May 02, 2005
AP		LUITPOLD	**10MG/ML**	**A201126**	**001**	Feb 20, 2015
AP		MYLAN INSTITUTIONAL	**10MG/ML**	**A076474**	**001**	May 02, 2005
AP		MYLAN LABS LTD	**10MG/ML**	**A206608**	**001**	Jun 08, 2018
AP			**20MG/ML**	**A206608**	**002**	Jun 08, 2018
AP		SAGENT PHARMS	**10MG/ML**	**A207107**	**001**	Jun 08, 2018
AP			**20MG/ML**	**A207107**	**002**	Jun 08, 2018
AP		WEST-WARD PHARMS INT	**10MG/ML**	**A076323**	**001**	Aug 10, 2004

BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	2GM/100ML	N019386	005	Jan 27, 2003

BREVIBLOC IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	1GM/100ML	N019386	004	Feb 16, 2001

SOLUTION;INTRAVENOUS

ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

+!	HQ SPCLT PHARMA	2GM/100ML (20MG/ML)	N205703	002	Apr 07, 2016

ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER

+!	HQ SPCLT PHARMA	2.5GM/250ML (10MG/ML)	N205703	001	Apr 07, 2016

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AB		ALKEM LABS LTD	**EQ 20MG BASE**	**A208333**	**001**	Oct 20, 2017
AB			**EQ 40MG BASE**	**A208333**	**002**	Oct 20, 2017
AB		AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A205606**	**001**	Apr 21, 2016
AB			**EQ 40MG BASE**	**A205606**	**002**	Apr 21, 2016
AB		DR REDDYS LABS LTD	**EQ 20MG BASE**	**A078279**	**001**	Sep 25, 2015
AB			**EQ 40MG BASE**	**A078279**	**002**	Sep 25, 2015
AB		HEC PHARM	**EQ 20MG BASE**	**A207265**	**002**	May 18, 2018
AB			**EQ 40MG BASE**	**A207265**	**001**	May 18, 2018
AB		IVAX SUB TEVA PHARMS	**EQ 20MG BASE**	**A078003**	**001**	Jan 26, 2015
AB			**EQ 40MG BASE**	**A078003**	**002**	Jan 26, 2015
AB		LANNETT CO INC	**EQ 20MG BASE**	**A205563**	**001**	Sep 01, 2017
AB			**EQ 40MG BASE**	**A205563**	**002**	Sep 01, 2017

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

	ESOMEPRAZOLE MAGNESIUM					
AB		MYLAN PHARMS INC	**EQ 20MG BASE**	**A078936**	**001**	Aug 02, 2015
AB			**EQ 40MG BASE**	**A078936**	**002**	Aug 03, 2015
AB		SUN PHARM INDS LTD	**EQ 20MG BASE**	**A209735**	**001**	Apr 30, 2018
AB			**EQ 40MG BASE**	**A209735**	**002**	Apr 30, 2018
AB		TORRENT PHARMS LTD	**EQ 20MG BASE**	**A203636**	**001**	Oct 19, 2015
AB			**EQ 40MG BASE**	**A203636**	**002**	Oct 19, 2015
	NEXIUM					
AB	+	ASTRAZENECA PHARMS	**EQ 20MG BASE**	**N021153**	**001**	Feb 20, 2001
AB	+!		**EQ 40MG BASE**	**N021153**	**002**	Feb 20, 2001
	ESOMEPRAZOLE MAGNESIUM					
BX		HETERO LABS LTD III	EQ 20MG BASE	A202784	001	Sep 21, 2015
BX			EQ 40MG BASE	A202784	002	Sep 21, 2015

FOR SUSPENSION, DELAYED RELEASE;ORAL

	NEXIUM					
	+	ASTRAZENECA PHARMS	EQ 2.5MG BASE/PACKET	N021957	003	Dec 15, 2011
	+		EQ 5MG BASE/PACKET	N021957	004	Dec 15, 2011
	+		EQ 10MG BASE/PACKET	N022101	001	Feb 27, 2008
	+		EQ 20MG BASE/PACKET	N021957	001	Oct 20, 2006
	+!		EQ 40MG BASE/PACKET	N021957	002	Oct 20, 2006

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

	VIMOVO					
	+	HORIZON	EQ 20MG BASE;375MG	N022511	002	Apr 30, 2010
	+!		EQ 20MG BASE;500MG	N022511	001	Apr 30, 2010

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

	ESOMEPRAZOLE SODIUM					
AP		ACCORD HLTHCARE	**EQ 40MG BASE/VIAL**	**A205379**	**001**	Sep 25, 2015
AP	!	AUROBINDO PHARMA LTD	**EQ 40MG BASE/VIAL**	**A204657**	**002**	Aug 10, 2016
AP		DEVA HOLDING AS	**EQ 40MG BASE/VIAL**	**A207181**	**001**	Mar 06, 2017
AP		MYLAN LABS LTD	**EQ 40MG BASE/VIAL**	**A202686**	**002**	May 17, 2017
AP		SUN PHARMA GLOBAL	**EQ 40MG BASE/VIAL**	**A200882**	**002**	Mar 18, 2013
	NEXIUM IV					
AP	+!	ASTRAZENECA PHARMS	**EQ 40MG BASE/VIAL**	**N021689**	**002**	Mar 31, 2005

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE;ORAL

	ESOMEPRAZOLE STRONTIUM					
	+!	R2 PHARMA LLC	49.3MG	N202342	002	Aug 06, 2013

ESTAZOLAM

TABLET;ORAL

	ESTAZOLAM					
AB		MAYNE PHARMA	**1MG**	**A074921**	**001**	Jul 10, 1997
AB	!		**2MG**	**A074921**	**002**	Jul 10, 1997
AB		PAR PHARM	**1MG**	**A074826**	**001**	Jul 03, 1997
AB			**2MG**	**A074826**	**002**	Jul 03, 1997
AB		WATSON LABS	**1MG**	**A074818**	**001**	Aug 19, 1997
AB			**2MG**	**A074818**	**002**	Aug 19, 1997

ESTRADIOL

CREAM;VAGINAL

	ESTRACE					
AB	!	ALLERGAN SALES LLC	**0.01%**	**A086069**	**001**	Jan 31, 1984
	ESTRADIOL					
AB		ALVOGEN PINE BROOK	**0.01%**	**A209767**	**001**	Mar 05, 2018
AB		MYLAN PHARMS INC	**0.01%**	**A208788**	**001**	Dec 29, 2017
AB		PERRIGO UK FINCO	**0.01%**	**A210194**	**001**	Jan 22, 2018
AB		TEVA PHARMS USA	**0.01%**	**A210488**	**001**	Mar 30, 2018

FILM, EXTENDED RELEASE;TRANSDERMAL

	CLIMARA					
AB	+	BAYER HLTHCARE	**0.06MG/24HR**	**N020375**	**006**	May 27, 2003
	ESTRADIOL					
AB		MYLAN TECHNOLOGIES	**0.06MG/24HR**	**A075182**	**005**	Jul 20, 2006
AB1			**0.025MG/24HR**	**A201675**	**001**	Dec 19, 2014
AB1			**0.0375MG/24HR**	**A201675**	**002**	Dec 19, 2014
AB1			**0.05MG/24HR**	**A201675**	**003**	Dec 19, 2014
AB1			**0.075MG/24HR**	**A201675**	**004**	Dec 19, 2014
AB1			**0.1MG/24HR**	**A201675**	**005**	Dec 19, 2014

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

VIVELLE-DOT

AB1	**+**	NOVARTIS	**0.025MG/24HR**	**N020538**	**009**	May 03, 2002
AB1	**+**		**0.0375MG/24HR**	**N020538**	**005**	Jan 08, 1999
AB1	**+**		**0.05MG/24HR**	**N020538**	**006**	Jan 08, 1999
AB1	**+**		**0.075MG/24HR**	**N020538**	**007**	Jan 08, 1999
AB1	**+!**		**0.1MG/24HR**	**N020538**	**008**	Jan 08, 1999

CLIMARA

AB2	**+**	BAYER HLTHCARE	**0.025MG/24HR**	**N020375**	**004**	Mar 05, 1999
AB2	**+**		**0.0375MG/24HR**	**N020375**	**005**	May 27, 2003
AB2	**+**		**0.05MG/24HR**	**N020375**	**001**	Dec 22, 1994
AB2	**+**		**0.075MG/24HR**	**N020375**	**003**	Mar 23, 1998
AB2	**+!**		**0.1MG/24HR**	**N020375**	**002**	Dec 22, 1994

ESTRADIOL

AB2		MYLAN TECHNOLOGIES	**0.025MG/24HR**	**A075182**	**003**	Jan 26, 2005
AB2			**0.0375MG/24HR**	**A075182**	**004**	Jul 20, 2006
AB2			**0.05MG/24HR**	**A075182**	**006**	Feb 24, 2000
AB2			**0.075MG/24HR**	**A075182**	**002**	Jan 26, 2005
AB2			**0.1MG/24HR**	**A075182**	**001**	Feb 24, 2000
AB3			**0.025MG/24HR**	**A206685**	**001**	Aug 15, 2018
AB3			**0.0375MG/24HR**	**A206685**	**002**	Aug 15, 2018
AB3			**0.05MG/24HR**	**A206685**	**003**	Aug 15, 2018
AB3			**0.075MG/24HR**	**A206685**	**004**	Aug 15, 2018
AB3			**0.1MG/24HR**	**A206685**	**005**	Aug 15, 2018

MINIVELLE

AB3	**+**	NOVEN	**0.025MG/24HR**	**N203752**	**005**	Sep 23, 2014
AB3	**+**		**0.0375MG/24HR**	**N203752**	**001**	Oct 29, 2012
AB3	**+**		**0.05MG/24HR**	**N203752**	**003**	Oct 29, 2012
AB3	**+**		**0.075MG/24HR**	**N203752**	**002**	Oct 29, 2012
AB3	**+!**		**0.1MG/24HR**	**N203752**	**004**	Oct 29, 2012

ALORA

BX		ALLERGAN SALES LLC	0.025MG/24HR	N020655	004	Apr 05, 2002
BX			0.05MG/24HR	N020655	001	Dec 20, 1996
BX			0.075MG/24HR	N020655	002	Dec 20, 1996
BX			0.1MG/24HR	N020655	003	Dec 20, 1996

MENOSTAR

	+!	BAYER HLTHCARE	0.014MG/24HR	N021674	001	Jun 08, 2004

GEL;TRANSDERMAL

DIVIGEL

	+	VERTICAL PHARMS LLC	0.1%	N022038	001	Jun 04, 2007

GEL, METERED;TRANSDERMAL

ELESTRIN

	+!	MYLAN SPECIALITY LP	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006

ESTROGEL

	+!	ASCEND THERAPS US	0.06% (1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004

INSERT;VAGINAL

IMVEXXY

	+	THERAPEUTICSMD INC	0.004MG	N208564	001	May 29, 2018
	+!		0.01MG	N208564	002	May 29, 2018

INSERT, EXTENDED RELEASE;VAGINAL

ESTRING

	+!	PHARMACIA AND UPJOHN	0.0075MG/24HR	N020472	001	Apr 26, 1996

SPRAY;TRANSDERMAL

EVAMIST

	+!	PERRIGO PHARMA INTL	1.53MG/SPRAY	N022014	001	Jul 27, 2007

TABLET;ORAL

ESTRADIOL

AB		BARR LABS INC	**0.5MG**	**A040197**	**001**	Oct 22, 1997
AB			**1MG**	**A040197**	**002**	Oct 22, 1997
AB	**!**		**2MG**	**A040197**	**003**	Oct 22, 1997
AB		EPIC PHARMA INC	**0.5MG**	**A040275**	**001**	Dec 29, 1998
AB			**1MG**	**A040275**	**002**	Dec 29, 1998
AB			**2MG**	**A040275**	**003**	Dec 29, 1998
AB		MAYNE PHARMA	**0.5MG**	**A040114**	**003**	Mar 14, 1996
AB			**1MG**	**A040114**	**001**	Mar 14, 1996
AB			**2MG**	**A040114**	**002**	Mar 14, 1996
AB		MYLAN	**0.5MG**	**A040326**	**001**	Apr 21, 1999
AB			**1MG**	**A040326**	**002**	Apr 21, 1999
AB			**2MG**	**A040326**	**003**	Apr 21, 1999

ESTRADIOL

TABLET;VAGINAL

ESTRADIOL

AB		AMNEAL PHARMS	**10MCG**	**A205256**	**001**	May 29, 2015
AB		GLENMARK PHARMS LTD	**10MCG**	**A210264**	**001**	Sep 14, 2018
AB		TEVA PHARMS USA	**10MCG**	**A206388**	**001**	Jul 21, 2017

VAGIFEM

AB	**+!**	NOVO NORDISK INC	**10MCG**	**N020908**	**002**	Nov 25, 2009

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL

FEMRING

	+	MILLICENT	EQ 0.05MG BASE/24HR	N021367 001	Mar 20, 2003
	+!		EQ 0.1MG BASE/24HR	N021367 002	Mar 20, 2003

ESTRADIOL CYPIONATE

INJECTABLE;INJECTION

DEPO-ESTRADIOL

	!	PHARMACIA AND UPJOHN	5MG/ML	A085470 003	

ESTRADIOL VALERATE

INJECTABLE;INJECTION

DELESTROGEN

AO	**+!**	PAR STERILE PRODUCTS	**20MG/ML**	**N009402**	**004**	
AO	**+!**		**40MG/ML**	**N009402**	**003**	

ESTRADIOL VALERATE

AO		LUITPOLD	**20MG/ML**	**A090920**	**001**	Jan 19, 2010
AO			**40MG/ML**	**A090920**	**002**	Jan 19, 2010

DELESTROGEN

	+!	PAR STERILE PRODUCTS	10MG/ML	N009402 002		

ESTRADIOL; LEVONORGESTREL

FILM, EXTENDED RELEASE;TRANSDERMAL

CLIMARA PRO

	+!	BAYER HLTHCARE	0.045MG/24HR;0.015MG/24HR	N021258 001		Nov 21, 2003

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE;TRANSDERMAL

COMBIPATCH

	+	NOVEN PHARMS INC	0.05MG/24HR;0.14MG/24HR	N020870 001		Aug 07, 1998
	+!		0.05MG/24HR;0.25MG/24HR	N020870 002		Aug 07, 1998

TABLET;ORAL

ACTIVELLA

AB	**+**	AMNEAL PHARMS LLC	**0.5MG;0.1MG**	**N020907**	**002**	Dec 28, 2006
AB	**+!**		**1MG;0.5MG**	**N020907**	**001**	Nov 18, 1998

AMABELZ

AB		LUPIN LTD	**0.5MG;0.1MG**	**A203339**	**001**	Jun 20, 2016
AB			**1MG;0.5MG**	**A203339**	**002**	Jun 20, 2016

ESTRADIOL AND NORETHINDRONE ACETATE

AB		ACCORD HLTHCARE	**1MG;0.5MG**	**A210233**	**001**	Feb 28, 2018
AB		BARR	**1MG;0.5MG**	**A079193**	**001**	May 11, 2010
AB		BRECKENRIDGE PHARM	**0.5MG;0.1MG**	**A078324**	**002**	Jun 09, 2011
AB			**1MG;0.5MG**	**A078324**	**001**	Apr 17, 2008
AB		MYLAN LABS LTD	**0.5MG;0.1MG**	**A207261**	**001**	Feb 10, 2017
AB			**1MG;0.5MG**	**A207261**	**002**	Feb 10, 2017
AB		TEVA PHARMS USA	**0.5MG;0.1MG**	**A200747**	**001**	Mar 08, 2012

ESTRADIOL; NORGESTIMATE

TABLET;ORAL

ESTRADIOL AND NORGESTIMATE

	!	BARR	1MG,1MG;N/A,0.09MG	A076812 001		Apr 29, 2005

ESTRADIOL; PROGESTERONE

CAPSULE;ORAL

BIJUVA

	+!	THERAPEUTICSMD INC	1MG;100MG	N210132 001		Oct 28, 2018

ESTRAMUSTINE PHOSPHATE SODIUM

CAPSULE;ORAL

EMCYT

	+!	PHARMACIA AND UPJOHN	EQ 140MG PHOSPHATE	N018045 001		

ESTROGENS, CONJUGATED						
CREAM;TOPICAL, VAGINAL						
PREMARIN						
+!	WYETH PHARMS	0.625MG/GM	N020216	001		
INJECTABLE;INJECTION						
PREMARIN						
+!	WYETH PHARMS	25MG/VIAL	N010402	001		
TABLET;ORAL						
PREMARIN						
+	WYETH PHARMS	0.3MG	N004782	003		
+		0.45MG	N004782	006	Jul 16, 2003	
+!		0.625MG	N004782	004		
+!		0.9MG	N004782	005	Jan 26, 1984	
+!		1.25MG	N004782	001		
ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE						
TABLET;ORAL-28						
PREMPHASE 14/14						
+!	WYETH PHARMS	0.625MG,0.625MG;N/A,5MG	N020527	002	Nov 17, 1995	
PREMPRO						
+!	WYETH PHARMS	0.3MG;1.5MG	N020527	005	Jun 04, 2003	
+!		0.45MG;1.5MG	N020527	004	Mar 12, 2003	
+!		0.625MG;2.5MG	N020527	001	Nov 17, 1995	
+!		0.625MG;5MG	N020527	003	Jan 09, 1998	
ESTROGENS, ESTERIFIED						
TABLET;ORAL						
MENEST						
	MONARCH PHARMS	0.3MG	A084951	001		
		0.625MG	A084948	001		
		1.25MG	A084950	001		
!		2.5MG	A084949	001		
ESTROPIPATE						
TABLET;ORAL						
ESTROPIPATE						
	MYLAN	0.75MG	A040359	001	Aug 26, 1999	
		1.5MG	A040359	002	Aug 26, 1999	
OGEN 5						
	PHARMACIA AND UPJOHN	6MG	A083220	004		
ESZOPICLONE						
TABLET;ORAL						
ESZOPICLONE						
AB	AUROBINDO PHARMA LTD	**1MG**	**A208451**	**001**	Sep 15, 2016	
AB		**2MG**	**A208451**	**002**	Sep 15, 2016	
AB		**3MG**	**A208451**	**003**	Sep 15, 2016	
AB	DR REDDYS LABS LTD	**1MG**	**A091024**	**001**	Apr 15, 2014	
AB		**2MG**	**A091024**	**002**	Apr 15, 2014	
AB		**3MG**	**A091024**	**003**	Apr 15, 2014	
AB	GLENMARK GENERICS	**1MG**	**A091166**	**001**	Apr 15, 2014	
AB		**2MG**	**A091166**	**002**	Apr 15, 2014	
AB		**3MG**	**A091166**	**003**	Apr 15, 2014	
AB	LUPIN LTD	**1MG**	**A091124**	**001**	Sep 13, 2011	
AB		**2MG**	**A091124**	**002**	Sep 13, 2011	
AB		**3MG**	**A091124**	**003**	Sep 13, 2011	
AB	MACLEODS PHARMS LTD	**1MG**	**A202929**	**001**	Jan 30, 2015	
AB		**2MG**	**A202929**	**002**	Jan 30, 2015	
AB		**3MG**	**A202929**	**003**	Jan 30, 2015	
AB	MYLAN PHARMS INC	**1MG**	**A091151**	**001**	Mar 26, 2013	
AB		**2MG**	**A091151**	**002**	Mar 26, 2013	
AB		**3MG**	**A091151**	**003**	Mar 26, 2013	
AB	ORCHID HLTHCARE	**1MG**	**A091113**	**001**	Jun 10, 2014	
AB		**2MG**	**A091113**	**002**	Jun 10, 2014	
AB		**3MG**	**A091113**	**003**	Jun 10, 2014	
AB	SUN PHARMA GLOBAL	**1MG**	**A091103**	**001**	Apr 03, 2013	
AB		**2MG**	**A091103**	**002**	Apr 03, 2013	
AB		**3MG**	**A091103**	**003**	Apr 03, 2013	
AB	TEVA	**1MG**	**A091169**	**001**	May 23, 2011	
AB		**2MG**	**A091169**	**002**	May 23, 2011	
AB		**3MG**	**A091169**	**003**	May 23, 2011	
AB	WEST-WARD PHARMS INT	**1MG**	**A091153**	**001**	Apr 15, 2014	

ESZOPICLONE
TABLET;ORAL
ESZOPICLONE

AB			**2MG**	**A091153**	**002**	Apr 15, 2014
AB			**3MG**	**A091153**	**003**	Apr 15, 2014

LUNESTA

AB	**+**	SUNOVION PHARMS INC	**1MG**	**N021476**	**001**	Dec 15, 2004
AB	**+**		**2MG**	**N021476**	**002**	Dec 15, 2004
AB	**+!**		**3MG**	**N021476**	**003**	Dec 15, 2004

ETELCALCETIDE
SOLUTION;INTRAVENOUS
PARSABIV

+!	KAI PHARMS INC	2.5MG/0.5ML (2.5MG/0.5ML)	N208325	001	Feb 07, 2017
+!		5MG/ML (5MG/ML)	N208325	002	Feb 07, 2017
+!		10MG/2ML (5MG/ML)	N208325	003	Feb 07, 2017

ETEPLIRSEN
SOLUTION;INTRAVENOUS
EXONDYS 51

+!	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N206488	001	Sep 19, 2016
+!		500MG/10ML (50MG/ML)	N206488	002	Sep 19, 2016

ETHACRYNATE SODIUM
INJECTABLE;INJECTION
EDECRIN

AP	**+!**	ATON	**EQ 50MG BASE/VIAL**	**N016093**	**001**	

ETHACRYNATE SODIUM

AP		MYLAN INSTITUTIONAL	**EQ 50MG BASE/VIAL**	**A204634**	**001**	Aug 23, 2016
AP		PAR STERILE PRODUCTS	**EQ 50MG BASE/VIAL**	**A205473**	**001**	Jul 29, 2015
AP		ZYDUS PHARMS USA INC	**EQ 50MG BASE/VIAL**	**A207758**	**001**	Nov 17, 2017

ETHACRYNIC ACID
TABLET;ORAL
EDECRIN

AB	**+!**	ATON	**25MG**	**N016092**	**001**	

ETHACRYNIC ACID

AB		ALVOGEN	**25MG**	**A205709**	**001**	Jul 24, 2018
AB		AMNEAL PHARMS CO	**25MG**	**A208805**	**001**	May 08, 2018
AB		EDENBRIDGE PHARMS	**25MG**	**A205609**	**001**	Jun 30, 2016
AB		PAR PHARM INC	**25MG**	**A208501**	**001**	Jul 21, 2017
AB		WEST-WARD PHARMS INT	**25MG**	**A207262**	**001**	Feb 23, 2017

ETHAMBUTOL HYDROCHLORIDE
TABLET;ORAL
ETHAMBUTOL HYDROCHLORIDE

AB		AKORN	**100MG**	**A075095**	**001**	Nov 30, 1999
AB			**400MG**	**A075095**	**002**	Nov 30, 1999
AB		BARR	**400MG**	**A076057**	**001**	Nov 26, 2001
AB		LUPIN	**100MG**	**A078939**	**001**	Jun 17, 2009
AB			**400MG**	**A078939**	**002**	Jun 17, 2009

MYAMBUTOL

AB	**+**	STI PHARMA LLC	**100MG**	**N016320**	**001**	
AB	**+!**		**400MG**	**N016320**	**003**	

ETHANOLAMINE OLEATE
INJECTABLE;INJECTION
ETHAMOLIN

+!	QOL MEDCL	50MG/ML	N019357	001	Dec 22, 1988

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE
TABLET;ORAL-28
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

AB		MYLAN LABS LTD	**0.035MG;1MG**	**A204703**	**001**	Jul 28, 2016
AB			**0.05MG;1MG**	**A204704**	**001**	Feb 09, 2016

KELNOR

AB		BARR	**0.035MG;1MG**	**A076785**	**001**	May 23, 2005

MALMOREDE

AB		NOVAST LABS	**0.05MG;1MG**	**A209547**	**001**	Jul 25, 2018

ZOVIA 1/35E-28

AB		MAYNE PHARMA	**0.035MG;1MG**	**A072721**	**001**	Dec 30, 1991

ZOVIA 1/50E-28

AB	**!**	WATSON LABS	**0.05MG;1MG**	**A072723**	**001**	Dec 30, 1991

ETHINYL ESTRADIOL; ETONOGESTREL

RING;VAGINAL

NUVARING

	+!	ORGANON SUB MERCK	0.015MG/24HR;0.12MG/24HR	N021187	001	Oct 03, 2001

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

		ASHLYNA				
AB		GLENMARK GENERICS	**0.03MG,0.01MG;0.15MG,N/A**	**A203163**	**001**	Feb 23, 2015
		DAYSEE				
AB		LUPIN LTD	**0.03MG,0.01MG;0.15MG,N/A**	**A091467**	**001**	Apr 10, 2013
		FAYOSIM				
AB		LUPIN LTD	**0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A**	**A205943**	**001**	Mar 29, 2016
		ICLEVIA				
AB		AUROBINDO PHARMA LTD	**0.03MG;0.15MG**	**A206850**	**001**	Jun 29, 2018
		INTROVALE				
AB		LABS LEON FARMA	**0.03MG;0.15MG**	**A079064**	**001**	Sep 27, 2010
		JAIMIESS				
AB		LABS LEON FARMA	**0.03MG,0.01MG;0.15MG,N/A**	**A203770**	**001**	Dec 27, 2017
		LEVONORGESTREL AND ETHINYL ESTRADIOL				
AB		AMNEAL PHARMS	**0.03MG;0.15MG**	**A203871**	**001**	Nov 13, 2015
AB			**0.03MG,0.01MG;0.15MG,N/A**	**A203872**	**001**	Dec 22, 2015
AB		GLENMARK GENERICS	**0.02MG;0.09MG**	**A202791**	**001**	Apr 09, 2015
AB		GLENMARK PHARMS LTD	**0.03MG;0.15MG**	**A203164**	**001**	Jun 12, 2015
AB		LUPIN LTD	**0.03MG;0.15MG**	**A091440**	**001**	Oct 23, 2012
AB		MYLAN LABS LTD	**0.03MG;0.15MG**	**A200490**	**001**	Apr 21, 2015
AB	!	WATSON LABS	**0.02MG;0.09MG**	**A079218**	**001**	Jun 06, 2011
		LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL				
AB		LABS LEON FARMA	**0.02MG,0.1MG;0.01MG,N/A**	**A205131**	**001**	Dec 14, 2017
AB		LUPIN LTD	**0.02MG,0.1MG;0.01MG,N/A**	**A091674**	**001**	Oct 26, 2011
AB		MAYNE PHARMA	**0.02MG,0.1MG;0.01MG,N/A**	**A200407**	**001**	Oct 25, 2011
AB			**0.03MG,0.01MG;0.15MG,N/A**	**A078834**	**001**	May 31, 2011
AB		MYLAN LABS LTD	**0.02MG,0.15MG; 0.025MG,0.15MG;0.03MG,0.15MG;**	**A206053**	**001**	Oct 02, 2017
AB			**0.02MG,0.1MG;0.01MG,N/A**	**A200493**	**001**	Jun 17, 2015
AB			**0.03MG,0.01MG;0.15MG,N/A**	**A200492**	**001**	May 27, 2015
		LO SIMPESSE				
AB		AUROBINDO PHARMA LTD	**0.02MG,0.1MG;0.01MG,N/A**	**A206852**	**001**	Apr 28, 2017
		LOSEASONIQUE				
AB		TEVA BRANDED PHARM	**0.02MG,0.1MG;0.01MG,N/A**	**N022262**	**001**	Oct 24, 2008
		QUARTETTE				
AB	+!	TEVA BRANDED PHARM	**0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A**	**N204061**	**001**	Mar 28, 2013
		QUASENSE				
AB		WATSON LABS	**0.03MG;0.15MG**	**A077101**	**001**	Sep 06, 2006
		SEASONALE				
AB	+!	TEVA BRANDED PHARM	**0.03MG;0.15MG**	**N021544**	**001**	Sep 05, 2003
		SEASONIQUE				
AB	+!	TEVA BRANDED PHARM	**0.03MG,0.01MG;0.15MG,N/A**	**N021840**	**001**	May 25, 2006
		SETLAKIN				
AB		NOVAST LABS	**0.03MG;0.15MG**	**A090716**	**001**	Sep 15, 2014
		SIMPESSE				
AB		AUROBINDO PHARMA LTD	**0.03MG,0.01MG;0.15MG,N/A**	**A206851**	**001**	Apr 07, 2017
		BALCOLTRA				
		AVION PHARMS	0.02MG;0.1MG	N208612	001	Jan 09, 2018

TABLET;ORAL-28

		ALTAVERA				
AB		LABS LEON FARMA	**0.03MG;0.15MG**	**A079102**	**001**	Aug 03, 2010
		AYUNA				
AB		AUROBINDO PHARMA LTD	**0.03MG;0.15MG**	**A206866**	**001**	Sep 23, 2016
		ELIFEMME				
AB		LABS LEON FARMA	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A202507**	**001**	Dec 04, 2015
		ENPRESSE-28				
AB		DURAMED PHARMS BARR	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A075809**	**002**	Jul 16, 2001
		KURVELO				
AB		LUPIN LTD	**0.03MG;0.15MG**	**A091408**	**001**	Oct 17, 2012

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL-28

		LEVONEST				
AB		NOVAST LABS LTD	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A090719**	**001**	Dec 29, 2010
		LEVONORGESTREL AND ETHINYL ESTRADIOL				
AB		AMNEAL PHARMS	**0.03MG;0.15MG**	**A201095**	**001**	Dec 08, 2014
AB		LUPIN LTD	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A200248**	**001**	Nov 19, 2015
AB		MYLAN LABS LTD	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A202970**	**001**	Mar 23, 2018
AB			**0.03MG;0.15MG**	**A091663**	**001**	Dec 21, 2012
		LEVORA 0.15/30-28				
AB	**!**	MAYNE PHARMA	**0.03MG;0.15MG**	**A073594**	**001**	Dec 13, 1993
		MARLISSA				
AB		GLENMARK GENERICS	**0.03MG;0.15MG**	**A091452**	**001**	Feb 29, 2012
		MYZILRA				
AB		VINTAGE PHARMS LLC	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A077502**	**001**	Nov 23, 2011
		PORTIA-28				
AB		BARR	**0.03MG;0.15MG**	**A075866**	**002**	May 23, 2002
		TRIVORA-28				
AB	**!**	MAYNE PHARMA	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A074538**	**002**	Dec 18, 1997
		AFIRMELLE				
AB1		AUROBINDO PHARMA LTD	**0.02MG;0.1MG**	**A206886**	**001**	Nov 14, 2016
		AVIANE-28				
AB1		DURAMED PHARMS BARR	**0.02MG;0.1MG**	**A075796**	**001**	Apr 30, 2001
		CERINTA				
AB1		SUN PHARM INDS LTD	**0.02MG;0.1MG**	**A202817**	**001**	Jan 07, 2019
		FALMINA				
AB1		NOVAST LABS LTD	**0.02MG;0.1MG**	**A090721**	**001**	Mar 28, 2012
		LEVONORGESTREL AND ETHINYL ESTRADIOL				
AB1		AMNEAL PHARMS	**0.02MG;0.1MG**	**A201108**	**001**	Feb 05, 2014
AB1		LUPIN LTD	**0.02MG;0.1MG**	**A091425**	**001**	Jan 18, 2013
AB1	**!**	MAYNE PHARMA	**0.02MG;0.1MG**	**A076625**	**001**	Nov 18, 2004
AB1		MYLAN LABS LTD	**0.02MG;0.1MG**	**A200245**	**001**	Oct 09, 2013
		ORSYTHIA				
AB1		VINTAGE PHARMS LLC	**0.02MG;0.1MG**	**A077099**	**001**	May 11, 2011
		VIENVA				
AB1		LABS LEON FARMA	**0.02MG;0.1MG**	**A201088**	**001**	May 21, 2015
		LESSINA-28				
AB2		BARR	**0.02MG;0.1MG**	**A075803**	**002**	Mar 20, 2002
		LEVONORGESTREL AND ETHINYL ESTRADIOL				
AB2	**!**	MAYNE PHARMA	**0.02MG;0.1MG**	**A077681**	**001**	May 31, 2006
AB2		MYLAN LABS LTD	**0.02MG;0.1MG**	**A202247**	**001**	Dec 08, 2014

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

		XULANE				
	!	MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

		NORINYL 1+35 21-DAY				
AB		ALLERGAN SALES LLC	**0.035MG;1MG**	**N017565**	**001**	
		NORTREL 1/35-21				
AB		BARR	**0.035MG;1MG**	**A072693**	**001**	Feb 28, 1992
		NORTREL 7/7/7				
		BARR	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A075478	001	Aug 30, 2002

TABLET;ORAL-28

		ALYACEN 1/35				
AB		GLENMARK GENERICS	**0.035MG;1MG**	**A091634**	**001**	Jan 19, 2012
		ALYACEN 7/7/7				
AB		GLENMARK GENERICS	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**A091636**	**001**	Jan 19, 2012
		ARANELLE				
AB		BARR	**0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG**	**A076783**	**001**	Sep 29, 2004
		BALZIVA-28				
AB	**!**	BARR	**0.035MG;0.4MG**	**A076238**	**001**	Apr 22, 2004
		BREVICON 28-DAY				
AB		ALLERGAN SALES LLC	**0.035MG;0.5MG**	**N017743**	**001**	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

	BRIELLYN					
AB	GLENMARK GENERICS	**0.035MG;0.4MG**	**A090538**	**001**	Mar 22, 2011
	CYCLAFEM 0.5/35					
AB	VINTAGE PHARMS	**0.035MG;0.5MG**	**A203413**	**001**	Dec 16, 2015
	CYCLAFEM 1/35					
AB	VINTAGE PHARMS LLC	**0.035MG;1MG**	**A076337**	**001**	Nov 12, 2010
	CYCLAFEM 7/7/7					
AB	VINTAGE PHARMS LLC	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**A076338**	**001**	Nov 16, 2010
	CYONANZ					
AB	AUROBINDO PHARMA LTD	**0.035MG;0.5MG**	**A207055**	**001**	Oct 21, 2016
	DASETTA 1/35					
AB	NOVAST LABS LTD	**0.035MG;1MG**	**A090948**	**001**	Dec 22, 2011
	DASETTA 7/7/7					
AB	NOVAST LABS LTD	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**A090946**	**001**	Dec 22, 2011
	GILDAGIA					
AB	VINTAGE PHARMS	**0.035MG;0.4MG**	**A078376**	**001**	Nov 06, 2012
	NORETHINDRONE AND ETHINYL ESTRADIOL					
AB	ACCORD HLTHCARE	**0.035MG;1MG**	**A206864**	**001**	Apr 28, 2017
AB	MAYNE PHARMA	**0.035MG;0.5MG**	**A070686**	**001**	Jan 29, 1987
AB	WATSON LABS	**0.035MG;0.4MG**	**A078323**	**001**	Feb 04, 2010
AB	WATSON LABS TEVA	**0.035MG;1MG**	**A070687**	**001**	Jan 29, 1987
	NORINYL 1+35 28-DAY					
AB	ALLERGAN SALES LLC	**0.035MG;1MG**	**N017565**	**002**	
	NORTREL 0.5/35-28					
AB	BARR	**0.035MG;0.5MG**	**A072695**	**001**	Feb 28, 1992
	NORTREL 1/35-28					
AB	BARR	**0.035MG;1MG**	**A072696**	**001**	Feb 28, 1992
	NORTREL 7/7/7					
AB	BARR	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**A075478**	**002**	Aug 30, 2002
	NYLIA 1/35					
AB	AUROBINDO PHARMA LTD	**0.035MG;1MG**	**A207056**	**001**	Oct 21, 2016
	NYLIA 7/7/7					
AB	AUROBINDO PHARMA LTD	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**A207054**	**001**	Oct 21, 2016
	ORTHO-NOVUM 1/35-28					
AB	**+!** JANSSEN PHARMS	**0.035MG;1MG**	**N017919**	**002**	
	ORTHO-NOVUM 7/7/7-28					
AB	**+!** JANSSEN PHARMS	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**N018985**	**002**	Apr 04, 1984
	PHILITH					
AB	NOVAST LABS LTD	**0.035MG;0.4MG**	**A090947**	**001**	Dec 22, 2011
	PIRMELLA 1/35					
AB	LUPIN LTD	**0.035MG;1MG**	**A201512**	**001**	Apr 24, 2013
	PIRMELLA 7/7/7					
AB	LUPIN LTD	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**A201510**	**001**	Apr 24, 2013
	TRI-NORINYL 28-DAY					
AB	**+!** MAYNE PHARMA	**0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG**	**N018977**	**002**	Apr 13, 1984
	VYFEMLA					
AB	LUPIN LTD	**0.035MG;0.4MG**	**A201886**	**001**	Sep 26, 2013
	WERA					
AB	**!** NOVAST LABS LTD	**0.035MG;0.5MG**	**A091204**	**001**	Mar 27, 2012
	NORETHINDRONE AND ETHINYL ESTRADIOL					
	! MYLAN LABS LTD	0.05MG;1MG	A203006	001	Aug 05, 2013
	NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)					
	WATSON LABS TEVA	0.035MG,0.035MG;0.5MG,1MG	A071044	001	Apr 01, 1988

TABLET, CHEWABLE;ORAL

	FEMCON FE					
AB	**+!** APIL	**0.035MG;0.4MG**	**N021490**	**001**	Nov 14, 2003
	KAITLIB FE					
AB	LUPIN LTD	**0.025MG;0.8MG**	**A203448**	**001**	Dec 17, 2015
	NEXESTA FE					
AB	AUROBINDO PHARMA LTD	**0.035MG;0.4MG**	**A207535**	**001**	Feb 02, 2017
	NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
AB	ACCORD HLTHCARE	**0.035MG;0.4MG**	**A207066**	**001**	Mar 29, 2017
AB	AMNEAL PHARMS	**0.035MG;0.4MG**	**A078892**	**001**	Sep 26, 2011

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET, CHEWABLE;ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	**+!**	APIL	**0.025MG;0.8MG**	**N022573**	**001**	Dec 22, 2010
AB		BARR	**0.035MG;0.4MG**	**A078965**	**001**	Aug 05, 2010
AB		LUPIN LTD	**0.035MG;0.4MG**	**A091332**	**001**	Mar 23, 2016
AB		MYLAN LABS LTD	**0.025MG;0.8MG**	**A203371**	**001**	Apr 23, 2014
AB			**0.035MG;0.4MG**	**A202086**	**001**	Apr 01, 2015

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL

TAYTULLA

	+!	APIL	0.02MG;1MG	N204426	001	Apr 19, 2013

TABLET;ORAL

AUROVELA 24 FE

AB		AUROBINDO PHARMA LTD	**0.02MG;1MG**	**A207504**	**001**	Jun 15, 2017

BLISOVI 24 FE

AB		LUPIN LTD	**0.02MG;1MG**	**A091398**	**001**	Oct 28, 2015

FEMHRT

AB		APIL	**0.0025MG;0.5MG**	**N021065**	**001**	Jan 14, 2005

FYAVOLV

AB		LUPIN LTD	**0.005MG;1MG**	**A204213**	**002**	Dec 10, 2015
AB			**0.0025MG;0.5MG**	**A204213**	**001**	Dec 10, 2015

GILDESS 24 FE

AB		VINTAGE PHARMS	**0.02MG;1MG**	**A090293**	**001**	Dec 01, 2014

LARIN 24 FE

AB		NOVAST LABS	**0.02MG;1MG**	**A202994**	**001**	Feb 18, 2015

LERIBANE

AB		NOVAST LABS	**0.0025MG;0.5MG**	**A203435**	**002**	Jun 03, 2016
AB			**0.005MG;1MG**	**A203435**	**001**	Jun 03, 2016

LOESTRIN 24 FE

AB	**+**	APIL	**0.02MG;1MG**	**N021871**	**001**	Feb 17, 2006

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	**!**	BARR LABS INC	**0.005MG;1MG**	**A076221**	**001**	Nov 06, 2009
AB		GLENMARK GENERICS	**0.0025MG;0.5MG**	**A203038**	**001**	Apr 02, 2015
AB			**0.005MG;1MG**	**A203038**	**002**	Apr 02, 2015
AB		MYLAN LABS LTD	**0.0025MG;0.5MG**	**A207260**	**001**	Feb 02, 2017
AB			**0.005MG;1MG**	**A207259**	**001**	Dec 27, 2016

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	**!**	AMNEAL PHARMS	**0.02MG;1MG**	**A078267**	**001**	Sep 01, 2009
AB		BARR LABS INC	**0.02MG;1MG**	**A090938**	**001**	Dec 01, 2014
AB		GLENMARK PHARMS LTD	**0.02MG;1MG**	**A204847**	**001**	Nov 17, 2017
AB		MYLAN LABS LTD	**0.02MG;1MG**	**A202742**	**001**	Oct 30, 2014

LO LOESTRIN FE

	+!	APIL	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010

TABLET;ORAL-21

AUROVELA 1.5/30

AB		AUROBINDO PHARMA LTD	**0.03MG;1.5MG**	**A207581**	**001**	Jun 26, 2017

AUROVELA 1/20

AB		AUROBINDO PHARMA LTD	**0.02MG;1MG**	**A207506**	**001**	Jun 16, 2017

GILDESS 1.5/30

AB		VINTAGE PHARMS LLC	**0.03MG;1.5MG**	**A077075**	**002**	Jul 24, 2012

GILDESS 1/20

AB		VINTAGE PHARMS LLC	**0.02MG;1MG**	**A077077**	**002**	Jul 24, 2012

JUNEL 1.5/30

AB		BARR	**0.03MG;1.5MG**	**A076381**	**001**	May 30, 2003

JUNEL 1/20

AB		BARR	**0.02MG;1MG**	**A076380**	**001**	May 30, 2003

LARIN 1.5/30

AB		NOVAST LABS	**0.03MG;1.5MG**	**A202996**	**001**	Mar 20, 2014

LARIN 1/20

AB		NOVAST LABS	**0.02MG;1MG**	**A202995**	**001**	Dec 04, 2013

LOESTRIN 21 1.5/30

AB		APIL	**0.03MG;1.5MG**	**N017875**	**001**	

LOESTRIN 21 1/20

AB		APIL	**0.02MG;1MG**	**N017876**	**001**	

MICROGESTIN 1.5/30

AB		MAYNE PHARMA	**0.03MG;1.5MG**	**A075548**	**002**	Jul 30, 2003

MICROGESTIN 1/20

AB		MAYNE PHARMA	**0.02MG;1MG**	**A075647**	**002**	Jul 30, 2003

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL-21

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	GLENMARK PHARMS LTD	**0.02MG;1MG**	**A206969**	**001**	Jan 20, 2016
AB	MYLAN LABS LTD	**0.02MG;1MG**	**A202771**	**001**	Nov 06, 2013
AB		**0.03MG;1.5MG**	**A202770**	**001**	Feb 19, 2015

TRI-LEGEST 21

	BARR	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A076405	001	Oct 26, 2007

TABLET;ORAL-28

AUROVELA FE 1.5/30

AB	AUROBINDO PHARMA LTD	**0.03MG;1.5MG**	**A207580**	**001**	Jun 15, 2017

AUROVELA FE 1/20

AB	AUROBINDO PHARMA LTD	**0.02MG;1MG**	**A207505**	**001**	Jun 16, 2017

BLISOVI FE 1.5/30

AB	LUPIN LTD	**0.03MG;1.5MG**	**A201585**	**001**	Nov 18, 2015

BLISOVI FE 1/20

AB	LUPIN LTD	**0.02MG;1MG**	**A201584**	**001**	Nov 18, 2015

ESTROSTEP FE

AB	**+!** APIL	**0.02MG,0.03MG,0.035MG;1MG,1MG,1MG**	**N020130**	**002**	Oct 09, 1996

GILDESS FE 1.5/30

AB	VINTAGE PHARMS LLC	**0.03MG;1.5MG**	**A077075**	**001**	Apr 28, 2005

GILDESS FE 1/20

AB	VINTAGE PHARMS LLC	**0.02MG;1MG**	**A077077**	**001**	May 20, 2005

HAILEY 1.5/30

AB	GLENMARK PHARMS	**0.03MG;1.5MG**	**A209297**	**001**	Jun 05, 2018

HAILEY FE 1.5/30

AB	GLENMARK PHARMS	**0.03MG;1.5MG**	**A209031**	**001**	Jun 05, 2018

HAILEY FE 1/20

AB	GLENMARK PHARMS LTD	**0.02MG;1MG**	**A206597**	**001**	Nov 21, 2017

JUNEL FE 1.5/30

AB	BARR	**0.03MG;1.5MG**	**A076064**	**001**	Sep 18, 2003

JUNEL FE 1/20

AB	BARR	**0.02MG;1MG**	**A076081**	**001**	Sep 18, 2003

LARIN FE 1.5/30

AB	NOVAST LABS	**0.03MG;1.5MG**	**A091453**	**001**	Aug 23, 2013

LARIN FE 1/20

AB	NOVAST LABS	**0.02MG;1MG**	**A091454**	**001**	Aug 26, 2013

LOESTRIN FE 1.5/30

AB	**+!** APIL	**0.03MG;1.5MG**	**N017355**	**001**	

LOESTRIN FE 1/20

AB	**+** APIL	**0.02MG;1MG**	**N017354**	**001**	

MICROGESTIN FE 1.5/30

AB	MAYNE PHARMA	**0.03MG;1.5MG**	**A075548**	**001**	Feb 05, 2001

MICROGESTIN FE 1/20

AB	MAYNE PHARMA	**0.02MG;1MG**	**A075647**	**001**	Feb 05, 2001

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	MAYNE PHARMA	**0.02MG,0.03MG,0.035MG;1MG,1MG,1MG**	**A076629**	**001**	Mar 18, 2010
AB	MYLAN LABS LTD	**0.02MG;1MG**	**A202772**	**001**	Nov 14, 2013
AB		**0.02MG,0.03MG,0.035MG;1MG,1MG,1MG**	**A205069**	**001**	Jun 22, 2018
AB		**0.03MG;1.5MG**	**A202741**	**001**	Feb 20, 2015

TRI-LEGEST FE

AB	BARR	**0.02MG,0.03MG,0.035MG;1MG,1MG,1MG**	**A076105**	**001**	Oct 26, 2007

TABLET, CHEWABLE;ORAL

MIBELAS 24 FE

AB	LUPIN ATLANTIS	**0.02MG;1MG**	**A206287**	**001**	May 24, 2016

MINASTRIN 24 FE

AB	**+!** APIL	**0.02MG;1MG**	**N203667**	**001**	May 08, 2013

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	AMNEAL PHARMS	**0.02MG;1MG**	**A207514**	**001**	Sep 11, 2017
AB	CHEMO RESEARCH SL	**0.02MG;1MG**	**A209609**	**001**	Jul 16, 2018
AB	GLENMARK PHARMS LTD	**0.02MG;1MG**	**A210369**	**001**	Dec 26, 2017
AB	MYLAN LABS LTD	**0.02MG;1MG**	**A206120**	**001**	Sep 12, 2017

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

ESTARYLLA

AB	LABS LEON FARMA	**0.035MG;0.25MG**	**A090794**	**001**	Jan 30, 2013

MILI

AB	AUROBINDO PHARMA LTD	**0.035MG;0.25MG**	**A205449**	**001**	Jul 07, 2016

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

	MONO-LINYAH					
AB	NOVAST LABS LTD	**0.035MG;0.25MG**	**A090523**	**001**	May 23, 2012	
	NORGESTIMATE AND ETHINYL ESTRADIOL					
AB	AMNEAL PHARMS	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A203870**	**001**	Nov 12, 2015	
AB		**0.035MG;0.25MG**	**A203865**	**001**	Oct 27, 2015	
AB		**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A203873**	**001**	May 12, 2016	
AB	GLENMARK GENERICS	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A200494**	**001**	Jun 17, 2011	
AB		**0.035MG;0.25MG**	**A200538**	**001**	Apr 05, 2012	
AB	GLENMARK PHARMS	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A204057**	**001**	Feb 23, 2016	
AB	LUPIN LTD	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A205588**	**001**	Apr 26, 2016	
AB		**0.035MG;0.25MG**	**A205630**	**001**	Oct 27, 2016	
AB	LUPIN PHARMS	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A200541**	**001**	Jun 25, 2012	
AB	MYLAN LABS LTD	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A202132**	**001**	Sep 09, 2015	
AB		**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A201897**	**001**	Jan 27, 2016	
AB		**0.035MG;0.25MG**	**A201896**	**001**	Jan 27, 2016	
AB	OC PHARMA	**0.035MG;0.035MG;0.035MG;0.18MG;0.215MG; 0.25MG**	**A200383**	**001**	Apr 07, 2015	
AB		**0.035MG;0.25MG**	**A200384**	**001**	Apr 07, 2015	
	ORTHO CYCLEN-28					
AB	**+!** JANSSEN PHARMS	**0.035MG;0.25MG**	**N019653**	**002**	Dec 29, 1989	
	ORTHO TRI-CYCLEN					
AB	**+!** JANSSEN PHARMS	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**N019697**	**001**	Jul 03, 1992	
	ORTHO TRI-CYCLEN LO					
AB	**+!** JANSSEN PHARMS	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**N021241**	**001**	Aug 22, 2002	
	PREVIFEM					
AB	VINTAGE PHARMS LLC	**0.035MG;0.25MG**	**A076334**	**001**	Jan 09, 2004	
	SPRINTEC					
AB	BARR	**0.035MG;0.25MG**	**A075804**	**001**	Sep 25, 2002	
	TRI LO SPRINTEC					
AB	BARR LABS INC	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A076784**	**001**	Jun 29, 2009	
	TRI-ESTARYLLA					
AB	LABS LEON FARMA	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A090793**	**001**	Jan 30, 2013	
	TRI-LINYAH					
AB	NOVAST LABS LTD	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A090524**	**001**	May 30, 2012	
	TRI-LO-ESTARYLLA					
AB	LABS LEON FARMA	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A091232**	**001**	Jun 29, 2015	
	TRI-LO-MILI					
AB	AUROBINDO PHARMA LTD	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A205762**	**001**	Nov 04, 2016	
	TRI-MILI					
AB	AUROBINDO PHARMA LTD	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A205441**	**001**	Jul 06, 2016	
	TRI-PREVIFEM					
AB	VINTAGE PHARMS LLC	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A076335**	**001**	Mar 26, 2004	
	TRI-SPRINTEC					
AB	BARR	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A075808**	**001**	Dec 29, 2003	

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-21

	CRYSELLE					
AB	DURAMED PHARMS BARR	**0.03MG;0.3MG**	**A075840**	**001**	Nov 30, 2001	

TABLET;ORAL-28

	CRYSELLE					
AB	DURAMED PHARMS BARR	**0.03MG;0.3MG**	**A075840**	**002**	Nov 30, 2001	
	ELINEST					
AB	NOVAST LABS LTD	**0.03MG;0.3MG**	**A091105**	**001**	Mar 28, 2012	
	LOW-OGESTREL-28					
AB	MAYNE PHARMA	**0.03MG;0.3MG**	**A075288**	**002**	Jul 28, 1999	

ETHINYL ESTRADIOL; NORGESTREL
TABLET;ORAL-28
OGESTREL 0.5/50-28

	!	WATSON LABS	0.05MG;0.5MG	A075406	002	Dec 15, 1999

ETHINYL ESTRADIOL; SEGESTERONE ACETATE
RING;VAGINAL
ANNOVERA

	+!	THERAPEUTICSMD INC	0.013MG/24HR;0.15MG/24HR	N209627	001	Aug 10, 2018

ETHIODIZED OIL
OIL;INTRALYMPHATIC, INTRAUTERINE
LIPIODOL

	+!	GUERBET	EQ 4.8GM IODINE/10ML (EQ 480MG IODINE/ML)	N009190	001	

ETHIONAMIDE
TABLET;ORAL
TRECATOR

	+!	WYETH PHARMS	250MG	N013026	002	

ETHOSUXIMIDE
CAPSULE;ORAL
ETHOSUXIMIDE

AB		AKORN	**250MG**	**A040686**	**001**	May 28, 2008
AB		BIONPHARMA INC	**250MG**	**A040430**	**001**	Oct 28, 2002
AB		HERITAGE PHARMS INC	**250MG**	**A200892**	**001**	Sep 25, 2012

ZARONTIN

AB	**+!**	PARKE DAVIS	**250MG**	**N012380**	**001**	

SYRUP;ORAL
ETHOSUXIMIDE

AA		MIKART	**250MG/5ML**	**A040506**	**001**	Dec 22, 2003
AA		PHARM ASSOC	**250MG/5ML**	**A040253**	**001**	Nov 22, 2000
AA		TEVA PHARMS	**250MG/5ML**	**A081306**	**001**	Jul 30, 1993

ZARONTIN

AA	**!**	PARKE-DAVIS	**250MG/5ML**	**A080258**	**001**	

ETHOTOIN
TABLET;ORAL
PEGANONE

	+!	RECORDATI RARE	250MG	N010841	001	

ETIDRONATE DISODIUM
TABLET;ORAL
ETIDRONATE DISODIUM

		MYLAN	200MG	A075800	001	Jan 24, 2003
	!		400MG	A075800	002	Jan 24, 2003

ETODOLAC
CAPSULE;ORAL
ETODOLAC

AB		ANI PHARMS INC	**200MG**	**A075126**	**001**	Sep 16, 1999
AB			**300MG**	**A075126**	**002**	Sep 16, 1999
AB		APOTEX	**200MG**	**A075419**	**001**	Jul 28, 2000
AB			**300MG**	**A075419**	**002**	Jul 28, 2000
AB		TARO	**200MG**	**A075078**	**001**	Apr 30, 1998
AB	**!**		**300MG**	**A075078**	**002**	Apr 30, 1998

TABLET;ORAL
ETODOLAC

AB		AMNEAL PHARMS CO	**400MG**	**A208834**	**001**	Jun 07, 2018
AB			**500MG**	**A208834**	**002**	Jun 07, 2018
AB		APOTEX INC	**400MG**	**A076004**	**001**	Dec 03, 2002
AB			**500MG**	**A076004**	**002**	Dec 03, 2002
AB		EDENBRIDGE PHARMS	**400MG**	**A209888**	**001**	Nov 30, 2018
AB			**500MG**	**A209888**	**002**	Nov 30, 2018
AB		SANDOZ	**400MG**	**A074903**	**001**	Apr 11, 1997
AB			**500MG**	**A074903**	**002**	Apr 19, 1999
AB		TARO PHARM INDS	**400MG**	**A075074**	**001**	Mar 11, 1998
AB	**!**		**500MG**	**A075074**	**002**	Apr 25, 2000
AB		TEVA	**400MG**	**A075009**	**001**	Nov 26, 1997
AB			**500MG**	**A075009**	**002**	Dec 28, 1999

TABLET, EXTENDED RELEASE;ORAL
ETODOLAC

AB		TARO	**400MG**	**A076174**	**001**	Mar 13, 2003
AB			**500MG**	**A076174**	**002**	Mar 13, 2003
AB			**600MG**	**A076174**	**003**	Mar 13, 2003

ETODOLAC							
TABLET, EXTENDED RELEASE;ORAL							
ETODOLAC							
AB		TEVA	**400MG**	**A075665**	**003**	Feb 05, 2001
AB			**500MG**	**A075665**	**002**	Jul 31, 2000
AB	!		**600MG**	**A075665**	**001**	Jul 31, 2000
AB		ZYDUS PHARMS USA INC	**400MG**	**A091134**	**001**	Jan 23, 2014
AB			**500MG**	**A091134**	**002**	Jan 23, 2014
AB			**600MG**	**A091134**	**003**	Jan 23, 2014
ETOMIDATE							
INJECTABLE;INJECTION							
AMIDATE							
AP	+!	HOSPIRA	**2MG/ML**	**N018227**	**001**	Sep 07, 1982
ETOMIDATE							
AP		AUROBINDO PHARMA LTD	**2MG/ML**	**A206126**	**001**	Feb 24, 2017
AP		EMCURE PHARMS LTD	**2MG/ML**	**A204618**	**001**	Aug 13, 2014
AP		GLAND PHARMA LTD	**2MG/ML**	**A209058**	**001**	Apr 18, 2017
AP		HIKMA FARMACEUTICA	**2MG/ML**	**A202354**	**001**	Feb 25, 2016
AP		LUITPOLD	**2MG/ML**	**A078867**	**001**	Dec 22, 2009
AP		MYLAN LABS LTD	**2MG/ML**	**A078289**	**001**	Jan 02, 2009
AP			**2MG/ML**	**A201044**	**001**	Feb 07, 2017
AP		PAR STERILE PRODUCTS	**2MG/ML**	**A091297**	**001**	Jun 20, 2012
AP		WEST-WARD PHARMS INT	**2MG/ML**	**A074593**	**001**	Nov 04, 1996
AP		ZYDUS PHARMS USA INC	**2MG/ML**	**A202360**	**001**	Jul 18, 2014
ETONOGESTREL							
IMPLANT;IMPLANTATION							
NEXPLANON							
	+!	ORGANON USA INC	68MG/IMPLANT	N021529	002	May 31, 2011
ETOPOSIDE							
CAPSULE;ORAL							
ETOPOSIDE							
	!	MYLAN	50MG	A075635	001	Sep 19, 2001
INJECTABLE;INJECTION							
ETOPOSIDE							
AP		ACCORD HLTHCARE	**20MG/ML**	**A074513**	**001**	Mar 14, 1996
AP	!	FRESENIUS KABI USA	**20MG/ML**	**A074983**	**001**	Sep 30, 1998
AP		MYLAN LABS LTD	**20MG/ML**	**A203507**	**001**	Nov 20, 2017
AP			**20MG/ML**	**A204927**	**001**	Oct 31, 2017
AP		TEVA PHARMS USA	**20MG/ML**	**A074529**	**001**	Jul 24, 1996
AP		WEST-WARD PHARMS INT	**20MG/ML**	**A074290**	**001**	Jul 17, 1995
ETOPOSIDE PHOSPHATE							
INJECTABLE;INJECTION							
ETOPOPHOS PRESERVATIVE FREE							
	+!	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N020457	001	May 17, 1996
ETRAVIRINE							
TABLET;ORAL							
INTELENCE							
	+	JANSSEN R AND D	25MG	N022187	003	Mar 26, 2012
	+		100MG	N022187	001	Jan 18, 2008
	+!		200MG	N022187	002	Dec 22, 2010
EVEROLIMUS							
TABLET;ORAL							
EVEROLIMUS							
AB		WEST-WARD PHARMS INT	**0.25MG**	**A206133**	**001**	Apr 12, 2018
AB			**0.5MG**	**A206133**	**002**	Apr 12, 2018
AB			**0.75MG**	**A206133**	**003**	Apr 12, 2018
ZORTRESS							
AB	+	NOVARTIS	**0.25MG**	**N021560**	**001**	Apr 20, 2010
AB	+		**0.5MG**	**N021560**	**002**	Apr 20, 2010
AB	+!		**0.75MG**	**N021560**	**003**	Apr 20, 2010
AFINITOR							
	+	NOVARTIS	2.5MG	N022334	003	Jul 09, 2010
	+		5MG	N022334	001	Mar 30, 2009

EVEROLIMUS

TABLET;ORAL

AFINITOR

+		7.5MG	N022334	004	Mar 30, 2012
+!		10MG	N022334	002	Mar 30, 2009

TABLET, FOR SUSPENSION;ORAL

AFINITOR DISPERZ

+	NOVARTIS PHARM	2MG	N203985	001	Aug 29, 2012
+		3MG	N203985	002	Aug 29, 2012
+!		5MG	N203985	003	Aug 29, 2012

EXEMESTANE

TABLET;ORAL

AROMASIN

AB	**+!**	PHARMACIA AND UPJOHN	**25MG**	**N020753**	**001**	Oct 21, 1999

EXEMESTANE

AB		ALVOGEN MALTA	**25MG**	**A200898**	**001**	Jul 28, 2014
AB		AMNEAL PHARMS	**25MG**	**A206421**	**001**	Dec 28, 2018
AB		CIPLA	**25MG**	**A210323**	**001**	Apr 27, 2018
AB		MYLAN PHARMS INC	**25MG**	**A203315**	**001**	Mar 10, 2017
AB		UPSHER SMITH LABS	**25MG**	**A209208**	**001**	Jul 26, 2017
AB		WEST-WARD PHARMS INT	**25MG**	**A077431**	**001**	Apr 01, 2011
AB		ZYDUS PHARMS USA INC	**25MG**	**A202602**	**001**	Oct 03, 2018

EXENATIDE

SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

BYDUREON BCISE

+!	ASTRAZENECA AB	2MG/0.85ML (2MG/0.85ML)	N209210	001	Oct 20, 2017

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

BYDUREON

+!	ASTRAZENECA AB	2MG/VIAL	N022200	001	Jan 27, 2012

BYDUREON PEN

+!	ASTRAZENECA AB	2MG	N022200	002	Feb 28, 2014

INJECTABLE;SUBCUTANEOUS

BYETTA

+!	ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005
+!		600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005

EZETIMIBE

TABLET;ORAL

EZETIMIBE

AB		ACCORD HLTHCARE	**10MG**	**A211550**	**001**	Oct 26, 2018
AB		ALKEM LABS LTD	**10MG**	**A209234**	**001**	Dec 21, 2017
AB		AMNEAL PHARMS CO	**10MG**	**A208803**	**001**	Jun 12, 2017
AB		APOTEX INC	**10MG**	**A208332**	**001**	Jun 12, 2017
AB		AUROBINDO PHARMA LTD	**10MG**	**A209838**	**001**	Aug 25, 2017
AB		GLENMARK PHARMS LTD	**10MG**	**A078560**	**001**	Jun 26, 2015
AB		OHM LABS INC	**10MG**	**A207311**	**001**	Jun 12, 2017
AB		SANDOZ INC	**10MG**	**A203931**	**001**	Jun 12, 2017
AB		TEVA PHARMS USA	**10MG**	**A078724**	**001**	Jun 12, 2017
AB		WATSON LABS INC	**10MG**	**A200831**	**001**	Jun 12, 2017
AB		ZYDUS PHARMS USA INC	**10MG**	**A204331**	**001**	Jun 12, 2017

ZETIA

AB	**+!**	MSD INTL GMBH	**10MG**	**N021445**	**001**	Oct 25, 2002

EZETIMIBE; SIMVASTATIN

TABLET;ORAL

EZETIMIBE AND SIMVASTATIN

AB		ALKEM LABS LTD	**10MG;10MG**	**A209222**	**001**	Dec 22, 2017
AB			**10MG;20MG**	**A209222**	**002**	Dec 22, 2017
AB			**10MG;40MG**	**A209222**	**003**	Dec 22, 2017
AB			**10MG;80MG**	**A209222**	**004**	Dec 22, 2017
AB		AMNEAL PHARMS CO	**10MG;10MG**	**A208831**	**001**	Nov 21, 2017
AB			**10MG;20MG**	**A208831**	**002**	Nov 21, 2017
AB			**10MG;40MG**	**A208831**	**003**	Nov 21, 2017
AB			**10MG;80MG**	**A208831**	**004**	Nov 21, 2017
AB		ANI PHARMS INC	**10MG;10MG**	**A201890**	**001**	Apr 26, 2017
AB			**10MG;20MG**	**A201890**	**002**	Apr 26, 2017
AB			**10MG;40MG**	**A201890**	**003**	Apr 26, 2017

EZETIMIBE; SIMVASTATIN

TABLET;ORAL

EZETIMIBE AND SIMVASTATIN

AB			**10MG;80MG**	**A201890**	**004**	Apr 26, 2017
AB		DR REDDYS LABS SA	**10MG;10MG**	**A200909**	**001**	Apr 26, 2017
AB			**10MG;20MG**	**A200909**	**002**	Apr 26, 2017
AB			**10MG;40MG**	**A200909**	**003**	Apr 26, 2017
AB			**10MG;80MG**	**A200909**	**004**	Apr 26, 2017
AB		WATSON LABS INC	**10MG;10MG**	**A202968**	**001**	Apr 26, 2017
AB			**10MG;20MG**	**A202968**	**002**	Apr 26, 2017
AB			**10MG;40MG**	**A202968**	**003**	Apr 26, 2017
AB			**10MG;80MG**	**A202968**	**004**	Apr 26, 2017

VYTORIN

AB	+	MSD INTL	**10MG;10MG**	**N021687**	**001**	Jul 23, 2004
AB	+		**10MG;20MG**	**N021687**	**002**	Jul 23, 2004
AB	+		**10MG;40MG**	**N021687**	**003**	Jul 23, 2004
AB	+!		**10MG;80MG**	**N021687**	**004**	Jul 23, 2004

FAMCICLOVIR

TABLET;ORAL

FAMCICLOVIR

AB		APOTEX	**125MG**	**A091480**	**001**	Jul 22, 2011
AB			**250MG**	**A091480**	**002**	Jul 22, 2011
AB			**500MG**	**A091480**	**003**	Jul 22, 2011
AB		AUROBINDO PHARMA LTD	**125MG**	**A091114**	**001**	Mar 21, 2011
AB			**250MG**	**A091114**	**002**	Mar 21, 2011
AB			**500MG**	**A091114**	**003**	Mar 21, 2011
AB		CIPLA	**125MG**	**A078278**	**001**	Mar 21, 2011
AB			**250MG**	**A078278**	**002**	Mar 21, 2011
AB			**500MG**	**A078278**	**003**	Mar 21, 2011
AB		HETERO LABS LTD V	**125MG**	**A202438**	**001**	Sep 10, 2014
AB			**250MG**	**A202438**	**002**	Sep 10, 2014
AB			**500MG**	**A202438**	**003**	Sep 10, 2014
AB		MACLEODS PHARMS LTD	**125MG**	**A201022**	**001**	Jan 12, 2012
AB			**250MG**	**A201022**	**002**	Jan 12, 2012
AB			**500MG**	**A201022**	**003**	Jan 12, 2012
AB		MYLAN	**125MG**	**A201333**	**001**	Mar 24, 2011
AB			**250MG**	**A201333**	**002**	Mar 24, 2011
AB			**500MG**	**A201333**	**003**	Mar 24, 2011
AB		TEVA PHARMS	**125MG**	**A077487**	**001**	Aug 24, 2007
AB			**250MG**	**A077487**	**002**	Aug 24, 2007
AB	!		**500MG**	**A077487**	**003**	Aug 24, 2007
AB		WEST-WARD PHARMS INT	**125MG**	**A090128**	**001**	Mar 21, 2011
AB			**250MG**	**A090128**	**002**	Mar 21, 2011
AB			**500MG**	**A090128**	**003**	Mar 21, 2011

FAMOTIDINE

FOR SUSPENSION;ORAL

FAMOTIDINE

AB		HI-TECH PHARMA CO	**40MG/5ML**	**A201995**	**001**	May 30, 2014
AB		LUPIN LTD	**40MG/5ML**	**A090440**	**001**	Jun 29, 2010
AB		NAVINTA LLC	**40MG/5ML**	**A091020**	**001**	May 27, 2010
AB		NOVEL LABS INC	**40MG/5ML**	**A201695**	**001**	Dec 17, 2012

PEPCID

AB	+!	SALIX PHARMS	**40MG/5ML**	**N019527**	**001**	Feb 02, 1987

INJECTABLE;INJECTION

FAMOTIDINE

AP		ATHENEX INC	**10MG/ML**	**A075651**	**001**	Apr 16, 2001
AP			**10MG/ML**	**A075684**	**001**	Apr 16, 2001
AP		FRESENIUS KABI USA	**10MG/ML**	**A075709**	**001**	Apr 16, 2001
AP		MYLAN LABS LTD	**10MG/ML**	**A078641**	**001**	Jun 25, 2008
AP	!	WEST-WARD PHARMS INT	**10MG/ML**	**A075488**	**001**	Apr 16, 2001

FAMOTIDINE PRESERVATIVE FREE

AP		ATHENEX INC	**10MG/ML**	**A075622**	**001**	Apr 16, 2001
AP			**10MG/ML**	**A075825**	**001**	Apr 17, 2001
AP		FRESENIUS KABI USA	**10MG/ML**	**A075813**	**001**	Apr 16, 2001
AP		MYLAN LABS LTD	**10MG/ML**	**A078642**	**001**	Jun 25, 2008
AP	!	WEST-WARD PHARMS INT	**10MG/ML**	**A075486**	**001**	Apr 16, 2001

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

	!	BAXTER HLTHCARE	0.4MG/ML	A075591	001	May 10, 2001

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

AB		ALEMBIC PHARMS LTD	**20MG**	**A078916**	**001**	May 22, 2009
AB			**40MG**	**A078916**	**002**	May 22, 2009
AB		APOTEX	**20MG**	**A075611**	**001**	Jul 23, 2001
AB			**40MG**	**A075611**	**002**	Jul 23, 2001
AB		AUROBINDO PHARMA LTD	**20MG**	**A206530**	**001**	Dec 22, 2015
AB			**40MG**	**A206530**	**002**	Dec 22, 2015
AB		CARLSBAD	**20MG**	**A075805**	**001**	Apr 16, 2001
AB			**40MG**	**A075805**	**002**	Apr 16, 2001
AB		DR REDDYS LABS LTD	**20MG**	**A075718**	**001**	Apr 16, 2001
AB			**40MG**	**A075718**	**002**	Apr 16, 2001
AB		IVAX SUB TEVA PHARMS	**20MG**	**A075511**	**001**	Apr 16, 2001
AB			**40MG**	**A075511**	**002**	Apr 16, 2001
AB		MYLAN	**20MG**	**A075704**	**001**	Apr 16, 2001
AB			**40MG**	**A075704**	**002**	Apr 16, 2001
AB		PERRIGO R AND D	**20MG**	**A077352**	**002**	Jul 27, 2005
AB			**40MG**	**A077352**	**001**	Jul 27, 2005
AB		TEVA	**20MG**	**A075311**	**001**	Apr 16, 2001
AB			**40MG**	**A075311**	**002**	Apr 16, 2001
AB		WOCKHARDT LTD	**20MG**	**A075786**	**001**	Apr 16, 2001
AB			**40MG**	**A075786**	**002**	Apr 16, 2001

PEPCID

AB	**+**	VALEANT PHARMS NORTH	**20MG**	**N019462**	**001**	Oct 15, 1986
AB	**+!**		**40MG**	**N019462**	**002**	Oct 15, 1986

FAMOTIDINE; IBUPROFEN

TABLET;ORAL

DUEXIS

+!	HORIZON	26.6MG;800MG	N022519	001	Apr 23, 2011

FEBUXOSTAT

TABLET;ORAL

ULORIC

+	TAKEDA PHARMS USA	40MG	N021856	001	Feb 13, 2009
+!		80MG	N021856	002	Feb 13, 2009

FELBAMATE

SUSPENSION;ORAL

FELBAMATE

AB		AMNEAL PHARMS	**600MG/5ML**	**A202385**	**001**	Dec 16, 2011
AB		TARO PHARM	**600MG/5ML**	**A206314**	**001**	Jun 16, 2017

FELBATOL

AB	**+!**	MYLAN SPECIALITY LP	**600MG/5ML**	**N020189**	**003**	Jul 29, 1993

TABLET;ORAL

FELBAMATE

AB		ALVOGEN MALTA	**400MG**	**A204595**	**001**	Jan 11, 2016
AB			**600MG**	**A204595**	**002**	Jan 11, 2016
AB		AMNEAL PHARMS	**400MG**	**A201680**	**001**	Sep 13, 2011
AB			**600MG**	**A201680**	**002**	Sep 13, 2011
AB		ANI PHARMS INC	**400MG**	**A202284**	**001**	Nov 04, 2015
AB			**600MG**	**A202284**	**002**	Nov 04, 2015
AB		TARO PHARM	**400MG**	**A207093**	**001**	Apr 20, 2017
AB			**600MG**	**A207093**	**002**	Apr 20, 2017
AB		ZYDUS PHARMS USA INC	**400MG**	**A208970**	**001**	May 30, 2017
AB			**600MG**	**A208970**	**002**	May 30, 2017

FELBATOL

AB	**+**	MYLAN SPECIALITY LP	**400MG**	**N020189**	**001**	Jul 29, 1993
AB	**+!**		**600MG**	**N020189**	**002**	Jul 29, 1993

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE

AB		AUROBINDO PHARMA LTD	**2.5MG**	**A203417**	**001**	Jan 17, 2013
AB			**5MG**	**A203417**	**002**	Jan 17, 2013
AB			**10MG**	**A203417**	**003**	Jan 17, 2013
AB		GLENMARK GENERICS	**2.5MG**	**A090365**	**001**	Dec 17, 2010
AB			**5MG**	**A090365**	**002**	Dec 17, 2010
AB			**10MG**	**A090365**	**003**	Dec 17, 2010

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE

AB		HERITAGE PHARMS INC	2.5MG	A201964	001	Nov 08, 2013
AB			5MG	A201964	002	Nov 08, 2013
AB			10MG	A201964	003	Nov 08, 2013
AB		JUBILANT GENERICS	2.5MG	A203983	001	Aug 19, 2016
AB			5MG	A203983	002	Aug 19, 2016
AB			10MG	A203983	003	Aug 19, 2016
AB		MYLAN	2.5MG	A078855	001	Apr 17, 2008
AB			5MG	A078855	002	Apr 17, 2008
AB	!		10MG	A078855	003	Apr 17, 2008
AB		ORCHID HLTHCARE	2.5MG	A203032	001	May 21, 2015
AB			5MG	A203032	002	May 21, 2015
AB			10MG	A203032	003	May 21, 2015
AB		SUN PHARM INDS LTD	2.5MG	A091200	001	Dec 13, 2013
AB			5MG	A091200	002	Dec 13, 2013
AB			10MG	A091200	003	Dec 13, 2013
AB		SUN PHARM INDUSTRIES	2.5MG	A075896	001	Nov 02, 2004
AB			5MG	A075896	002	Nov 02, 2004
AB			10MG	A075896	003	Nov 02, 2004
AB		TORRENT PHARMS LTD	2.5MG	A202170	001	Nov 28, 2011
AB			5MG	A202170	002	Nov 28, 2011
AB			10MG	A202170	003	Nov 28, 2011
AB		VINTAGE PHARMS LLC	2.5MG	A200815	001	Oct 28, 2011
AB			5MG	A200815	002	Oct 28, 2011
AB			10MG	A200815	003	Oct 28, 2011
AB		YILING PHARM LTD	2.5MG	A210847	001	Oct 26, 2018
AB			5MG	A210847	002	Oct 26, 2018
AB			10MG	A210847	003	Oct 26, 2018

FENOFIBRATE

CAPSULE;ORAL

ANTARA (MICRONIZED)

AB	+	LUPIN ATLANTIS	43MG	N021695	001	Nov 30, 2004
AB	+!		130MG	N021695	003	Nov 30, 2004

FENOFIBRATE

AB		SUN PHARM INDS LTD	43MG	A201748	001	Oct 31, 2014
AB			130MG	A201748	002	Oct 31, 2014

FENOFIBRATE (MICRONIZED)

AB		AJANTA PHARMA LTD	67MG	A210705	001	Sep 10, 2018
AB			134MG	A210705	002	Sep 10, 2018
AB			200MG	A210705	003	Sep 10, 2018
AB		AMERIGEN PHARMS LTD	67MG	A209504	001	Apr 30, 2018
AB			134MG	A209504	002	Apr 30, 2018
AB			200MG	A209504	003	Apr 30, 2018
AB		APOTEX INC	43MG	A202252	001	Jul 26, 2013
AB			130MG	A202252	002	Jul 26, 2013
AB		CNTY LINE PHARMS	67MG	A207805	001	Nov 16, 2017
AB			134MG	A207805	002	Nov 16, 2017
AB			200MG	A207805	003	Nov 16, 2017
AB		DR REDDYS LABS SA	43MG	A090859	001	Mar 01, 2012
AB			130MG	A090859	002	Mar 01, 2012
AB		GLENMARK PHARMS LTD	67MG	A205566	001	Apr 07, 2017
AB			134MG	A205566	002	Apr 07, 2017
AB			200MG	A205566	003	Apr 07, 2017
AB		IMPAX LABS	67MG	A075868	001	Oct 27, 2003
AB			134MG	A075868	002	Oct 27, 2003
AB	!		200MG	A075868	003	Oct 27, 2003
AB		INVAGEN PHARMS	67MG	A207378	001	Mar 28, 2017
AB			134MG	A207378	002	Mar 28, 2017
AB			200MG	A207378	003	Mar 28, 2017
AB		MYLAN PHARMS INC	43MG	A202579	001	Jan 10, 2013
AB			67MG	A202676	001	Oct 23, 2012
AB			130MG	A202579	002	Jan 10, 2013
AB			134MG	A202676	002	Oct 23, 2012
AB			200MG	A202676	003	Oct 23, 2012
AB		RHODES PHARMS	67MG	A075753	001	Sep 03, 2002
AB			134MG	A075753	002	Apr 09, 2002
AB			200MG	A075753	003	Apr 09, 2002
AB		TORRENT PHARMS LTD	67MG	A210782	001	Jun 26, 2018
AB			134MG	A210782	002	Jun 26, 2018

FENOFIBRATE							
CAPSULE;ORAL							
FENOFIBRATE (MICRONIZED)							
AB			**200MG**		**A210782**	**003**	Jun 26, 2018
ANTARA (MICRONIZED)							
	+	LUPIN ATLANTIS	30MG		N021695	004	Oct 18, 2013
	+		90MG		N021695	005	Oct 18, 2013
LIPOFEN							
	+	CIPHER PHARMS INC	50MG		N021612	001	Jan 11, 2006
	+!		150MG		N021612	003	Jan 11, 2006
TABLET;ORAL							
FENOFIBRATE							
AB		AJANTA PHARMA LTD	**54MG**		**A210138**	**001**	Jul 23, 2018
AB			**160MG**		**A210138**	**002**	Jul 23, 2018
AB		AMNEAL PHARMS LLC	**48MG**		**A209951**	**001**	Feb 09, 2018
AB			**54MG**		**A209950**	**001**	Mar 19, 2018
AB			**145MG**		**A209951**	**002**	Feb 09, 2018
AB			**160MG**		**A209950**	**002**	Mar 19, 2018
AB		AUROBINDO PHARMA LTD	**48MG**		**A205118**	**001**	May 05, 2016
AB			**145MG**		**A205118**	**002**	May 05, 2016
AB		CIPLA	**48MG**		**A208709**	**001**	Dec 15, 2016
AB			**145MG**		**A208709**	**002**	Dec 15, 2016
AB		CNTY LINE PHARMS	**54MG**		**A207803**	**001**	Dec 19, 2017
AB			**160MG**		**A207803**	**002**	Dec 19, 2017
AB		GRAVITI PHARMS	**54MG**		**A210606**	**001**	Aug 17, 2018
AB			**160MG**		**A210606**	**002**	Aug 17, 2018
AB		HETERO LABS LTD III	**48MG**		**A204598**	**001**	Jul 12, 2016
AB			**145MG**		**A204598**	**002**	Jul 12, 2016
AB		IMPAX LABS	**54MG**		**A076509**	**001**	Mar 26, 2008
AB	**!**		**160MG**		**A076509**	**002**	Mar 26, 2008
AB		LUPIN LTD	**48MG**		**A090856**	**001**	Dec 23, 2011
AB			**54MG**		**A204019**	**001**	Aug 17, 2015
AB			**145MG**		**A090856**	**002**	Dec 23, 2011
AB			**160MG**		**A204019**	**002**	Aug 17, 2015
AB		MYLAN	**40MG**		**A204475**	**001**	Jun 23, 2016
AB			**54MG**		**A076520**	**001**	Oct 25, 2007
AB			**120MG**		**A204475**	**002**	Jun 23, 2016
AB			**160MG**		**A076520**	**003**	Oct 25, 2007
AB		MYLAN PHARMS INC	**48MG**		**A202856**	**001**	Dec 07, 2012
AB			**145MG**		**A202856**	**002**	Dec 07, 2012
AB		PRINSTON INC	**48MG**		**A211080**	**001**	Aug 28, 2018
AB			**145MG**		**A211080**	**002**	Aug 28, 2018
AB		RHODES PHARMS	**54MG**		**A076433**	**001**	May 13, 2005
AB			**160MG**		**A076433**	**002**	May 13, 2005
AB		SUN PHARM INDS LTD	**48MG**		**A200884**	**001**	Sep 07, 2017
AB			**54MG**		**A076635**	**001**	Oct 31, 2005
AB			**145MG**		**A200884**	**002**	Sep 07, 2017
AB			**160MG**		**A076635**	**003**	Oct 31, 2005
AB		VALEANT PHARMS NORTH	**48MG**		**A090715**	**001**	Apr 05, 2012
AB			**145MG**		**A090715**	**002**	Apr 05, 2012
FENOGLIDE							
AB	**+**	SANTARUS INC	**40MG**		**N022118**	**001**	Aug 10, 2007
AB	**+!**		**120MG**		**N022118**	**002**	Aug 10, 2007
TRICOR							
AB	**+**	ABBVIE	**48MG**		**N021656**	**001**	Nov 05, 2004
AB	**+!**		**145MG**		**N021656**	**002**	Nov 05, 2004
TRIGLIDE							
BX	+!	SKYEPHARMA AG	160MG		N021350	002	May 07, 2005
FENOFIBRATE							
		SUN PHARM INDS LTD	107MG		A076635	002	Oct 31, 2005
FENOFIBRIC ACID							
TABLET;ORAL							
FIBRICOR							
	+	ARALEZ PHARMS INC	35MG		N022418	001	Aug 14, 2009
	+!		105MG		N022418	002	Aug 14, 2009

FENOLDOPAM MESYLATE						
INJECTABLE;INJECTION						
CORLOPAM						
AP	**+!**	HOSPIRA	**EQ 10MG BASE/ML**	**N019922**	**001**	Sep 23, 1997
FENOLDOPAM MESYLATE						
AP		SANDOZ INC	**EQ 10MG BASE/ML**	**A077155**	**001**	Feb 15, 2005
AP		WEST-WARD PHARMS INT	**EQ 10MG BASE/ML**	**A076582**	**001**	Oct 12, 2004
FENOPROFEN CALCIUM						
CAPSULE;ORAL						
NALFON						
	+	XSPIRE PHARMA	EQ 200MG BASE	N017604	003	
	+!		EQ 400MG BASE	N017604	004	Jul 21, 2009
TABLET;ORAL						
FENOPROFEN CALCIUM						
	!	XSPIRE PHARMA	EQ 600MG BASE	A072267	001	Aug 17, 1988
FENTANYL						
FILM, EXTENDED RELEASE;TRANSDERMAL						
DURAGESIC-100						
AB	**+**	JANSSEN PHARMS	**100MCG/HR**	**N019813**	**001**	Aug 07, 1990
DURAGESIC-12						
AB	**+**	JANSSEN PHARMS	**12.5MCG/HR**	**N019813**	**005**	Feb 04, 2005
DURAGESIC-25						
AB	**+!**	JANSSEN PHARMS	**25MCG/HR**	**N019813**	**004**	Aug 07, 1990
DURAGESIC-37						
AB	**+**	JANSSEN PHARMS	**37.5MCG/HR**	**N019813**	**006**	Jan 24, 2018
DURAGESIC-50						
AB	**+**	JANSSEN PHARMS	**50MCG/HR**	**N019813**	**003**	Aug 07, 1990
DURAGESIC-75						
AB	**+**	JANSSEN PHARMS	**75MCG/HR**	**N019813**	**002**	Aug 07, 1990
FENTANYL-100						
AB		3M DRUG DELIVERY	**100MCG/HR**	**A202097**	**005**	Nov 04, 2016
AB		AVEVA	**100MCG/HR**	**A077449**	**004**	Oct 20, 2008
AB		LAVIPHARM LABS	**100MCG/HR**	**A077051**	**004**	Aug 04, 2006
AB		MAYNE PHARMA	**100MCG/HR**	**A077062**	**004**	Aug 20, 2007
AB		MYLAN TECHNOLOGIES	**100MCG/HR**	**A076258**	**004**	Jan 28, 2005
AB		SPECGX LLC	**100MCG/HR**	**A077154**	**004**	Feb 09, 2011
FENTANYL-12						
AB		3M DRUG DELIVERY	**12.5MCG/HR**	**A202097**	**001**	Nov 04, 2016
AB		AVEVA	**12.5MCG/HR**	**A077449**	**005**	Sep 11, 2015
AB		MYLAN TECHNOLOGIES	**12.5MCG/HR**	**A076258**	**005**	Jan 23, 2007
AB		SPECGX LLC	**12.5MCG/HR**	**A077154**	**005**	Jun 11, 2015
FENTANYL-25						
AB		3M DRUG DELIVERY	**25MCG/HR**	**A202097**	**002**	Nov 04, 2016
AB		AVEVA	**25MCG/HR**	**A077449**	**001**	Oct 20, 2008
AB		LAVIPHARM LABS	**25MCG/HR**	**A077051**	**001**	Aug 04, 2006
AB		MAYNE PHARMA	**25MCG/HR**	**A077062**	**001**	Aug 20, 2007
AB		MYLAN TECHNOLOGIES	**25MCG/HR**	**A076258**	**001**	Jan 28, 2005
AB		SPECGX LLC	**25MCG/HR**	**A077154**	**001**	Feb 09, 2011
FENTANYL-37						
AB		AVEVA	**37.5MCG/HR**	**A077449**	**006**	Dec 06, 2017
AB		MYLAN TECHNOLOGIES	**37.5MCG/HR**	**A076258**	**006**	Dec 29, 2014
FENTANYL-50						
AB		3M DRUG DELIVERY	**50MCG/HR**	**A202097**	**003**	Nov 04, 2016
AB		AVEVA	**50MCG/HR**	**A077449**	**002**	Oct 20, 2008
AB		LAVIPHARM LABS	**50MCG/HR**	**A077051**	**002**	Aug 04, 2006
AB		MAYNE PHARMA	**50MCG/HR**	**A077062**	**002**	Aug 20, 2007
AB		MYLAN TECHNOLOGIES	**50MCG/HR**	**A076258**	**002**	Jan 28, 2005
AB		SPECGX LLC	**50MCG/HR**	**A077154**	**002**	Feb 09, 2011
FENTANYL-62						
AB		AVEVA	**62.5MCG/HR**	**A077449**	**007**	Dec 06, 2017
FENTANYL-75						
AB		3M DRUG DELIVERY	**75MCG/HR**	**A202097**	**004**	Nov 04, 2016
AB		AVEVA	**75MCG/HR**	**A077449**	**003**	Oct 20, 2008
AB		LAVIPHARM LABS	**75MCG/HR**	**A077051**	**003**	Aug 04, 2006
AB		MAYNE PHARMA	**75MCG/HR**	**A077062**	**003**	Aug 20, 2007
AB		MYLAN TECHNOLOGIES	**75MCG/HR**	**A076258**	**003**	Jan 28, 2005
AB		SPECGX LLC	**75MCG/HR**	**A077154**	**003**	Feb 09, 2011
FENTANYL-87						
AB		AVEVA	**87.5MCG/HR**	**A077449**	**008**	Dec 06, 2017

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-62

	MYLAN TECHNOLOGIES	62.5MCG/HR	A076258	007	Dec 29, 2014

FENTANYL-87

	MYLAN TECHNOLOGIES	87.5MCG/HR	A076258	008	Dec 29, 2014

SPRAY;SUBLINGUAL

SUBSYS

+	INSYS DEV CO INC	0.1MG	N202788	001	Jan 04, 2012
+		0.2MG	N202788	002	Jan 04, 2012
+!		0.4MG	N202788	003	Jan 04, 2012
+		0.6MG	N202788	004	Jan 04, 2012
+		0.8MG	N202788	005	Jan 04, 2012
+		1.2MG	N202788	006	Aug 30, 2012
+		1.6MG	N202788	007	Aug 30, 2012

FENTANYL CITRATE

INJECTABLE;INJECTION

FENTANYL CITRATE

AP		HOSPIRA	**EQ 0.05MG BASE/ML**	**N019115**	**001**	Jan 12, 1985

FENTANYL CITRATE PRESERVATIVE FREE

AP		HOSPIRA	**EQ 0.05MG BASE/ML**	**A072786**	**001**	Sep 24, 1991
AP	**+!**	WEST-WARD PHARMS INT	**EQ 0.05MG BASE/ML**	**N019101**	**001**	Jul 11, 1984

SUBLIMAZE PRESERVATIVE FREE

AP	**+!**	AKORN	**EQ 0.05MG BASE/ML**	**N016619**	**001**	

SPRAY, METERED;NASAL

LAZANDA

+	ELEFSEE PHARMS INTL	EQ 0.1MG BASE	N022569	001	Jun 30, 2011
+		EQ 0.3MG BASE	N022569	003	Dec 21, 2015
+!		EQ 0.4MG BASE	N022569	002	Jun 30, 2011

TABLET;BUCCAL, SUBLINGUAL

FENTORA

+	CEPHALON	EQ 0.1MG BASE	N021947	001	Sep 25, 2006
+		EQ 0.2MG BASE	N021947	002	Sep 25, 2006
+!		EQ 0.4MG BASE	N021947	003	Sep 25, 2006
+		EQ 0.6MG BASE	N021947	004	Sep 25, 2006
+		EQ 0.8MG BASE	N021947	005	Sep 25, 2006

TABLET;SUBLINGUAL

ABSTRAL

AB	**+**	SENTYNL THERAPS INC	**EQ 0.1MG BASE**	**N022510**	**001**	Jan 07, 2011
AB	**+**		**EQ 0.2MG BASE**	**N022510**	**002**	Jan 07, 2011
AB	**+**		**EQ 0.3MG BASE**	**N022510**	**003**	Jan 07, 2011
AB	**+!**		**EQ 0.4MG BASE**	**N022510**	**004**	Jan 07, 2011
AB	**+**		**EQ 0.6MG BASE**	**N022510**	**005**	Jan 07, 2011
AB	**+**		**EQ 0.8MG BASE**	**N022510**	**006**	Jan 07, 2011

FENTANYL CITRATE

AB		ACTAVIS LABS FL INC	**EQ 0.1MG BASE**	**A207338**	**001**	Nov 17, 2017
AB			**EQ 0.2MG BASE**	**A207338**	**002**	Nov 17, 2017
AB			**EQ 0.3MG BASE**	**A207338**	**003**	Nov 17, 2017
AB			**EQ 0.4MG BASE**	**A207338**	**004**	Nov 17, 2017
AB			**EQ 0.6MG BASE**	**A207338**	**005**	Nov 17, 2017
AB			**EQ 0.8MG BASE**	**A207338**	**006**	Nov 17, 2017

TROCHE/LOZENGE;TRANSMUCOSAL

ACTIQ

AB	**+**	CEPHALON	**EQ 0.2MG BASE**	**N020747**	**001**	Nov 04, 1998
AB	**+!**		**EQ 0.4MG BASE**	**N020747**	**002**	Nov 04, 1998
AB	**+**		**EQ 0.6MG BASE**	**N020747**	**003**	Nov 04, 1998
AB	**+**		**EQ 0.8MG BASE**	**N020747**	**004**	Nov 04, 1998
AB	**+**		**EQ 1.2MG BASE**	**N020747**	**005**	Nov 04, 1998
AB	**+**		**EQ 1.6MG BASE**	**N020747**	**006**	Nov 04, 1998

FENTANYL CITRATE

AB		SPECGX LLC	**EQ 0.2MG BASE**	**A078907**	**001**	Oct 30, 2009
AB			**EQ 0.4MG BASE**	**A078907**	**002**	Oct 30, 2009
AB			**EQ 0.6MG BASE**	**A078907**	**003**	Oct 30, 2009
AB			**EQ 0.8MG BASE**	**A078907**	**004**	Oct 30, 2009
AB			**EQ 1.2MG BASE**	**A078907**	**005**	Oct 30, 2009
AB			**EQ 1.6MG BASE**	**A078907**	**006**	Oct 30, 2009

FERRIC CARBOXYMALTOSE
INJECTABLE;INTRAVENOUS
INJECTAFER

	+!	LUITPOLD	750MG IRON/15ML (50MG IRON/ML)	N203565	001	Jul 25, 2013

FERRIC CITRATE
TABLET;ORAL
AURYXIA

	+!	KERYX BIOPHARMS	EQ 210MG IRON	N205874	001	Sep 05, 2014

FERRIC HEXACYANOFERRATE(II)
CAPSULE;ORAL
RADIOGARDASE (PRUSSIAN BLUE)

	+!	HEYL CHEMISCH	500MG	N021626	001	Oct 02, 2003

FERRIC PYROPHOSPHATE CITRATE
FOR SOLUTION;INTRAVENOUS
TRIFERIC

	+!	ROCKWELL MEDICAL INC	272MG IRON/PACKET	N208551	001	Apr 25, 2016

SOLUTION;INTRAVENOUS
TRIFERIC

	+!	ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)	N206317	001	Jan 23, 2015

FERUMOXYTOL
SOLUTION;INTRAVENOUS
FERAHEME

	+!	AMAG PHARMS INC	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180	001	Jun 30, 2009

FESOTERODINE FUMARATE
TABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATE

AB		AUROBINDO PHARMA LTD	**4MG**	**A205007**	**001**	Feb 17, 2017
AB			**8MG**	**A205007**	**002**	Feb 17, 2017
AB		ZYDUS PHARMS USA INC	**4MG**	**A204946**	**001**	Oct 03, 2017
AB			**8MG**	**A204946**	**002**	Oct 03, 2017

TOVIAZ

AB	**+**	PFIZER	**4MG**	**N022030**	**001**	Oct 31, 2008
AB	**+!**		**8MG**	**N022030**	**002**	Oct 31, 2008

FEXOFENADINE HYDROCHLORIDE
TABLET;ORAL
FEXOFENADINE HYDROCHLORIDE

AB		BARR	**30MG**	**A076191**	**001**	Aug 31, 2005
AB			**60MG**	**A076191**	**002**	Aug 31, 2005
AB			**180MG**	**A076191**	**003**	Aug 31, 2005
AB		DR REDDYS LABS LTD	**30MG**	**A076502**	**001**	Apr 11, 2006
AB			**60MG**	**A076502**	**002**	Apr 11, 2006
AB			**180MG**	**A076502**	**003**	Apr 11, 2006
AB		MYLAN	**30MG**	**A077081**	**002**	Apr 11, 2008
AB			**60MG**	**A077081**	**003**	Apr 11, 2008
AB			**180MG**	**A077081**	**001**	Apr 16, 2007
AB		TEVA	**30MG**	**A076447**	**001**	Sep 01, 2005
AB			**60MG**	**A076447**	**002**	Sep 01, 2005
AB			**180MG**	**A076447**	**003**	Sep 01, 2005

FIDAXOMICIN
TABLET;ORAL
DIFICID

	+!	CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011

FINAFLOXACIN
SUSPENSION/DROPS;OTIC
XTORO

	+!	MERLION PHARMS GMBH	0.3%	N206307	001	Dec 17, 2014

FINASTERIDE
TABLET;ORAL
FINASTERIDE

AB		ACCORD HLTHCARE	**1MG**	**A091643**	**001**	Nov 05, 2013
AB			**5MG**	**A090121**	**001**	Feb 23, 2010
AB		ACTAVIS TOTOWA	**1MG**	**A078371**	**001**	Nov 05, 2013
AB		ACTAVIS TOTOWA TEVA	**5MG**	**A077914**	**001**	Mar 28, 2007
AB		ALKEM LABS LTD	**1MG**	**A207750**	**001**	Jan 06, 2017
AB			**5MG**	**A204304**	**001**	Jan 05, 2017

FINASTERIDE

TABLET;ORAL

FINASTERIDE

AB		AUROBINDO PHARMA	**5MG**	**A078341**	**001**	Oct 30, 2007
AB		AUROBINDO PHARMA LTD	**1MG**	**A203687**	**001**	Nov 05, 2013
AB		CIPLA	**1MG**	**A077335**	**001**	Nov 20, 2014
AB		DR REDDYS LABS INC	**1MG**	**A076436**	**001**	Jul 28, 2006
AB		DR REDDYS LABS LTD	**5MG**	**A076437**	**001**	Feb 28, 2007
AB		HETERO LABS LTD III	**1MG**	**A090060**	**001**	Jul 01, 2013
AB			**5MG**	**A090061**	**001**	Jun 07, 2010
AB		MYLAN	**5MG**	**A077578**	**001**	Dec 18, 2006
AB		SUN PHARMA GLOBAL	**1MG**	**A090508**	**001**	Jul 01, 2013
AB			**5MG**	**A090507**	**001**	Aug 16, 2011
AB		TEVA	**1MG**	**A076905**	**001**	Nov 05, 2013
AB			**5MG**	**A076511**	**001**	Dec 15, 2006
AB		ZYDUS PHARMS USA INC	**5MG**	**A078900**	**001**	Dec 28, 2009

PROPECIA

AB	**+!**	MERCK	**1MG**	**N020788**	**001**	Dec 19, 1997

PROSCAR

AB	**+!**	MERCK	**5MG**	**N020180**	**001**	Jun 19, 1992

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL

GILENYA

	+	NOVARTIS	EQ 0.25MG BASE	N022527	002	May 11, 2018
	+!		EQ 0.5MG BASE	N022527	001	Sep 21, 2010

FISH OIL TRIGLYCERIDES

EMULSION;INTRAVENOUS

OMEGAVEN

	+!	FRESENIUS KABI USA	5GM/50ML (0.1GM/ML)	N210589	001	Jul 27, 2018
	+!		10GM/100ML (0.1GM/ML)	N210589	002	Jul 27, 2018

FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL

EMULSION;INTRAVENOUS

SMOFLIPID 20%

	+!	FRESENIUS KABI USA	3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (100ML)	N207648	001	Jul 13, 2016
	+!		3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (250ML)	N207648	002	Jul 13, 2016
	+!		3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (500ML)	N207648	003	Jul 13, 2016
	+!		3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (1000ML)	N207648	004	Aug 10, 2018

FLAVOXATE HYDROCHLORIDE

TABLET;ORAL

FLAVOXATE HYDROCHLORIDE

AB		EPIC PHARMA	**100MG**	**A076835**	**001**	Nov 30, 2005
AB	**!**	PADDOCK LLC	**100MG**	**A076831**	**001**	Dec 16, 2004

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

AB		AMNEAL PHARM	**50MG**	**A075442**	**001**	Jul 31, 2001
AB			**100MG**	**A075442**	**002**	Jul 31, 2001
AB			**150MG**	**A075442**	**003**	Jul 31, 2001
AB		ANI PHARMS INC	**50MG**	**A075882**	**001**	Oct 28, 2002
AB			**100MG**	**A075882**	**002**	Oct 28, 2002
AB			**150MG**	**A075882**	**003**	Oct 28, 2002
AB		AUROBINDO PHARMA LTD	**50MG**	**A202821**	**001**	Nov 03, 2017
AB			**100MG**	**A202821**	**002**	Nov 03, 2017
AB			**150MG**	**A202821**	**003**	Nov 03, 2017
AB		SUN PHARM INDS LTD	**50MG**	**A076421**	**001**	Mar 28, 2003
AB			**100MG**	**A076421**	**002**	Mar 28, 2003
AB			**150MG**	**A076421**	**003**	Mar 28, 2003
AB		WEST-WARD PHARMS INT	**50MG**	**A076278**	**001**	Jan 14, 2003
AB			**100MG**	**A076278**	**002**	Jan 14, 2003
AB	**!**		**150MG**	**A076278**	**003**	Jan 14, 2003

TAMBOCOR

AB	**+**	CNTY LINE PHARMS	**50MG**	**N018830**	**004**	Aug 23, 1988
AB	**+**		**100MG**	**N018830**	**001**	Oct 31, 1985

FLECAINIDE ACETATE							
TABLET;ORAL							
TAMBOCOR							
AB	**+**		**150MG**	**N018830**	**003**	Jun 03, 1988	
FLIBANSERIN							
TABLET;ORAL							
ADDYI							
	+!	SPROUT PHARMS	100MG	N022526	001	Aug 18, 2015	
FLORBETABEN F-18							
SOLUTION;INTRAVENOUS							
NEURACEQ							
	+!	LIFE MOLECULAR	30ML (1.4-135mCi/ML)	N204677	001	Mar 19, 2014	
FLORBETAPIR F-18							
SOLUTION;INTRAVENOUS							
AMYVID							
	+!	AVID RADIOPHARMS INC	10-30ML (13.5-51mCi/ML)	N202008	002	Apr 06, 2012	
	+!		10-50ML (13.5-51mCi/ML)	N202008	003	Apr 06, 2012	
FLOXURIDINE							
INJECTABLE;INJECTION							
FLOXURIDINE							
AP		FRESENIUS KABI USA	**500MG/VIAL**	**A075837**	**001**	Feb 22, 2001	
AP		LUITPOLD	**500MG/VIAL**	**A203008**	**001**	Nov 22, 2017	
AP	**!**	WEST-WARD PHARMS INT	**500MG/VIAL**	**A075387**	**001**	Apr 16, 2000	
FLUCICLOVINE F-18							
SOLUTION;INTRAVENOUS							
AXUMIN							
	+!	BLUE EARTH	9-221mCi/ML	N208054	001	May 27, 2016	
FLUCONAZOLE							
FOR SUSPENSION;ORAL							
DIFLUCAN							
AB	**+**	PFIZER	**50MG/5ML**	**N020090**	**001**	Dec 23, 1993	
AB	**+!**		**200MG/5ML**	**N020090**	**002**	Dec 23, 1993	
FLUCONAZOLE							
AB		AUROBINDO PHARMA LTD	**50MG/5ML**	**A079150**	**001**	Sep 18, 2009	
AB			**200MG/5ML**	**A079150**	**002**	Sep 18, 2009	
AB		IVAX SUB TEVA PHARMS	**50MG/5ML**	**A077523**	**001**	Sep 12, 2007	
AB			**200MG/5ML**	**A077523**	**002**	Sep 12, 2007	
AB		WEST-WARD PHARMS INT	**50MG/5ML**	**A076246**	**001**	Jul 29, 2004	
AB			**200MG/5ML**	**A076246**	**002**	Jul 29, 2004	
INJECTABLE;INJECTION							
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP		HIKMA FARMACEUTICA	**200MG/100ML (2MG/ML)**	**A078764**	**001**	Jan 30, 2012	
AP			**400MG/200ML (2MG/ML)**	**A078764**	**002**	Jan 30, 2012	
AP	**!**	HOSPIRA	**200MG/100ML (2MG/ML)**	**A076304**	**001**	Jul 29, 2004	
AP	**!**		**400MG/200ML (2MG/ML)**	**A076304**	**002**	Jul 29, 2004	
AP		RENAISSANCE SSA LLC	**200MG/100ML (2MG/ML)**	**A077988**	**001**	May 26, 2010	
AP			**400MG/200ML (2MG/ML)**	**A077988**	**002**	May 26, 2010	
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%							
AP		BAXTER HLTHCARE CORP	**200MG/100ML (2MG/ML)**	**A077947**	**001**	May 26, 2010	
AP			**400MG/200ML (2MG/ML)**	**A077947**	**002**	May 26, 2010	
AP		FRESENIUS KABI USA	**200MG/100ML (2MG/ML)**	**A076145**	**001**	Jul 29, 2004	
AP			**400MG/200ML (2MG/ML)**	**A076145**	**002**	Jul 29, 2004	
AP		HIKMA FARMACEUTICA	**200MG/100ML (2MG/ML)**	**A076736**	**001**	Aug 23, 2005	
AP		WEST-WARD PHARMS INT	**200MG/100ML (2MG/ML)**	**A076087**	**001**	Jul 29, 2004	
AP			**400MG/200ML (2MG/ML)**	**A076087**	**003**	Jul 29, 2004	
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP		BAXTER HLTHCARE	**200MG/100ML (2MG/ML)**	**A076766**	**001**	Jul 29, 2004	
AP			**400MG/200ML (2MG/ML)**	**A076766**	**002**	Jul 29, 2004	
AP		HIKMA FARMACEUTICA	**200MG/100ML (2MG/ML)**	**A078698**	**001**	Jan 30, 2012	
AP			**400MG/200ML (2MG/ML)**	**A078698**	**002**	Jan 30, 2012	
AP		HOSPIRA	**200MG/100ML (2MG/ML)**	**A076303**	**001**	Jul 29, 2004	
AP			**400MG/200ML (2MG/ML)**	**A076303**	**002**	Jul 29, 2004	
AP	**!**	INFORLIFE	**200MG/100ML (2MG/ML)**	**A079104**	**001**	Jul 30, 2009	
AP	**!**		**400MG/200ML (2MG/ML)**	**A079104**	**002**	Jul 30, 2009	

FLUCONAZOLE

INJECTABLE;INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		RENAISSANCE SSA LLC	**200MG/100ML (2MG/ML)**	**A077909**	**001**	May 26, 2010
AP			**400MG/200ML (2MG/ML)**	**A077909**	**002**	May 26, 2010
AP		WEST-WARD PHARMS INT	**200MG/100ML (2MG/ML)**	**A078107**	**001**	Jul 30, 2008
AP			**400MG/200ML (2MG/ML)**	**A078107**	**002**	Jul 30, 2008

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

		WEST-WARD PHARMS INT	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		RENAISSANCE SSA LLC	100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015

TABLET;ORAL

DIFLUCAN

AB	**+**	PFIZER	**50MG**	**N019949**	**001**	Jan 29, 1990
AB	**+**		**100MG**	**N019949**	**002**	Jan 29, 1990
AB	**+**		**150MG**	**N019949**	**004**	Jun 30, 1994
AB	**+!**		**200MG**	**N019949**	**003**	Jan 29, 1990

FLUCONAZOLE

AB		APOTEX	**50MG**	**A076665**	**001**	Jul 29, 2004
AB			**100MG**	**A076665**	**002**	Jul 29, 2004
AB			**150MG**	**A076665**	**003**	Jul 29, 2004
AB			**200MG**	**A076665**	**004**	Jul 29, 2004
AB		AUROBINDO PHARMA	**50MG**	**A077731**	**001**	Oct 07, 2008
AB			**100MG**	**A077731**	**002**	Oct 07, 2008
AB			**150MG**	**A077731**	**003**	Oct 07, 2008
AB			**200MG**	**A077731**	**004**	Oct 07, 2008
AB		DR REDDYS LABS INC	**50MG**	**A076658**	**001**	Jul 29, 2004
AB			**100MG**	**A076658**	**002**	Jul 29, 2004
AB			**150MG**	**A076658**	**003**	Jul 29, 2004
AB			**200MG**	**A076658**	**004**	Jul 29, 2004
AB		GLENMARK GENERICS	**50MG**	**A077253**	**001**	Jan 25, 2006
AB			**100MG**	**A077253**	**002**	Jan 25, 2006
AB			**150MG**	**A077253**	**003**	Jan 25, 2006
AB			**200MG**	**A077253**	**004**	Jan 25, 2006
AB		HARRIS PHARM	**50MG**	**A078423**	**001**	Mar 07, 2011
AB			**100MG**	**A078423**	**002**	Mar 07, 2011
AB			**150MG**	**A078423**	**003**	Mar 07, 2011
AB			**200MG**	**A078423**	**004**	Mar 07, 2011
AB		IVAX SUB TEVA PHARMS	**50MG**	**A076077**	**001**	Jul 29, 2004
AB			**100MG**	**A076077**	**002**	Jul 29, 2004
AB			**150MG**	**A076077**	**003**	Jul 29, 2004
AB			**200MG**	**A076077**	**004**	Jul 29, 2004
AB		MYLAN	**50MG**	**A076351**	**001**	Jul 29, 2004
AB			**100MG**	**A076351**	**002**	Jul 29, 2004
AB			**150MG**	**A076351**	**003**	Jul 29, 2004
AB			**200MG**	**A076351**	**004**	Jul 29, 2004
AB		TARO	**50MG**	**A076507**	**001**	Jul 29, 2004
AB			**100MG**	**A076507**	**002**	Jul 29, 2004
AB			**150MG**	**A076507**	**003**	Jul 29, 2004
AB			**200MG**	**A076507**	**004**	Jul 29, 2004
AB		TEVA	**50MG**	**A074681**	**001**	Jul 29, 2004
AB			**100MG**	**A074681**	**002**	Jul 29, 2004
AB			**150MG**	**A074681**	**003**	Jul 29, 2004
AB			**200MG**	**A074681**	**004**	Jul 29, 2004
AB		UNIQUE PHARM LABS	**50MG**	**A076957**	**001**	Sep 28, 2005
AB			**100MG**	**A076957**	**002**	Sep 28, 2005
AB			**150MG**	**A076957**	**004**	Feb 27, 2017
AB			**200MG**	**A076957**	**003**	Sep 28, 2005
AB		ZYDUS PHARMS USA INC	**50MG**	**A208963**	**001**	Feb 16, 2017
AB			**100MG**	**A208963**	**002**	Feb 16, 2017
AB			**150MG**	**A208963**	**003**	Feb 16, 2017
AB			**200MG**	**A208963**	**004**	Feb 16, 2017

FLUCYTOSINE

CAPSULE;ORAL

ANCOBON

AB	**+**	VALEANT	**250MG**	**N017001**	**001**	
AB	**+!**		**500MG**	**N017001**	**002**	

FLUCYTOSINE

CAPSULE;ORAL

FLUCYTOSINE

AB		NOVEL LABS INC	**250MG**	**A204652**	**001**	Jul 07, 2017
AB			**500MG**	**A204652**	**002**	Jul 07, 2017
AB		RECIPHARM	**250MG**	**A207536**	**001**	Jun 18, 2018
AB			**500MG**	**A207536**	**002**	Jun 18, 2018
AB		SIGMAPHARM LABS LLC	**250MG**	**A201566**	**001**	Jun 28, 2011
AB			**500MG**	**A201566**	**002**	Jun 28, 2011
AB		WEST-WARD PHARMS INT	**250MG**	**A206550**	**001**	Oct 17, 2017
AB			**500MG**	**A206550**	**002**	Oct 17, 2017

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

AP		ACTAVIS LLC	**50MG/2ML (25MG/ML)**	**A203738**	**001**	Feb 28, 2017
AP		ACTAVIS TOTOWA	**50MG/VIAL**	**A078610**	**001**	Feb 11, 2009
AP		AREVA PHARMS	**50MG/2ML (25MG/ML)**	**A090724**	**001**	Sep 27, 2010
AP		CUSTOPHARM INC	**50MG/VIAL**	**A076349**	**001**	Aug 28, 2003
AP	**!**	FRESENIUS KABI USA	**50MG/2ML (25MG/ML)**	**A078393**	**001**	Oct 15, 2007
AP			**50MG/VIAL**	**A078544**	**001**	Oct 15, 2007
AP	**!**	HOSPIRA	**50MG/VIAL**	**A077790**	**001**	Apr 06, 2007
AP		MYLAN LABS LTD	**50MG/2ML (25MG/ML)**	**A200647**	**001**	Dec 21, 2011
AP			**50MG/VIAL**	**A200648**	**001**	Oct 16, 2012
AP		SAGENT PHARMS	**50MG/2ML (25MG/ML)**	**A076661**	**001**	Apr 28, 2004
AP	**+!**	SANDOZ	**50MG/2ML (25MG/ML)**	**N022137**	**001**	Sep 21, 2007

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP		3D IMAGING DRUG	**20-300mCi/ML**	**A203778**	**001**	Oct 30, 2015
AP		BIOMEDCL RES FDN	**20-300mCi/ML**	**A203710**	**001**	May 01, 2015
AP			**20-300mCi/ML**	**A203837**	**001**	May 01, 2015
AP		BRIGHAM WOMENS	**20-300mCi/ML**	**A203816**	**001**	Oct 30, 2014
AP		CARDINAL HEALTH 414	**20-300mCi/ML**	**A203603**	**001**	Nov 13, 2015
AP		CHILDRENS HOSP MI	**20-300mCi/ML**	**A204385**	**001**	Oct 29, 2014
AP		CPDC	**20-300mCi/ML**	**A204525**	**001**	Oct 29, 2014
AP		ESSENTIAL ISOTOPES	**20-300mCi/ML**	**A203946**	**001**	Feb 05, 2014
AP	**+!**	FEINSTEIN	**20-400mCi/ML**	**N021870**	**002**	Nov 21, 2008
AP		GLOBAL ISOTOPES LLC	**20-300mCi/ML**	**A204463**	**001**	Oct 21, 2014
AP	**!**	HOUSTON CYCLOTRON	**20-500mCi/ML**	**A203665**	**001**	Feb 14, 2013
AP		JUBILANT DRAXIMAGE	**20-300mCi/ML**	**A203920**	**001**	Jun 23, 2015
AP		KETTERING MEDCTR	**4-40mCi/ML**	**A204759**	**001**	Oct 27, 2015
AP		KREITCHMAN PET CTR	**10-100mCi/ML**	**A203942**	**001**	Apr 11, 2016
AP		LANTHEUS MEDICAL	**20-200mCi/ML**	**A203664**	**001**	Feb 04, 2014
AP		MA GENERAL HOSP	**20-300mCi/ML**	**A204333**	**001**	Sep 25, 2014
AP		MCPRF	**20-240mCi/ML**	**A203612**	**001**	Aug 05, 2013
AP		MEM SLOAN-KETTERING	**20-300mCi/ML**	**A208679**	**001**	Dec 08, 2016
AP		METHODIST HOSP RES	**20-300mCi/ML**	**A203904**	**001**	Apr 23, 2015
AP		MIPS CRF	**20-300mCi/ML**	**A204472**	**001**	Sep 11, 2015
AP		NCM USA BRONX LLC	**20-300mCi/ML**	**A204512**	**001**	Jan 07, 2015
AP	**!**	PETNET	**20-200mCi/ML**	**A079086**	**001**	Feb 25, 2011
AP	**!**	QUEEN HAMAMATSU PET	**10-100mCi/ML**	**A203771**	**001**	Aug 31, 2015
AP		SHERTECH LABS LLC	**20-300mCi/ML**	**A204264**	**001**	Dec 18, 2014
AP		SOFIE	**20-300mCi/ML**	**A203591**	**001**	Aug 31, 2015
AP		TRUSTEES UNIV PA	**20-200mCi/ML**	**A203801**	**001**	Oct 29, 2014
AP	**!**	UCLA BIOMEDICAL	**4-40mCi/ML**	**A203811**	**001**	Jun 27, 2013
AP		UCSF RODIOPHARM	**20-300mCi/ML**	**A203902**	**001**	May 09, 2014
AP		UIHC PET IMAGING	**20-300mCi/ML**	**A203990**	**001**	Aug 06, 2014
AP		UNIV MICHIGAN	**20-300mCi/ML**	**A204531**	**001**	Jul 17, 2015
AP		UNIV TX MD ANDERSON	**20-300mCi/ML**	**A203246**	**002**	Jan 13, 2014
AP		UNIV UTAH CYCLOTRON	**20-300mCi/ML**	**A204498**	**001**	Jun 23, 2015
AP		WI MEDCL CYCLOTRON	**20-500mCi/ML**	**A203709**	**001**	Oct 23, 2013
AP		WUSM CYCLOTRON	**20-300mCi/ML**	**A203935**	**001**	Feb 05, 2014
		HOT SHOTS NM LLC	4-500mCi/ML	A203937	001	Oct 30, 2014
		NORTHLAND	4-500mCi/ML	A203994	001	Feb 04, 2015
		PRECISION NUCLEAR	20-500mCi/ML	A204546	001	Apr 07, 2015
		SPECTRON MRC LLC	4-500mCi/ML	A203911	001	Apr 22, 2015
		UNIV TX MD ANDERSON	20-150mCi/ML	A203246	001	Jan 13, 2014

FLUDROCORTISONE ACETATE							
TABLET;ORAL							
FLUDROCORTISONE ACETATE							
AB		BARR	**0.1MG**	**A040425**	**001**	Jan 21, 2003
AB		HIKMA PHARMS	**0.1MG**	**A091302**	**001**	Jul 22, 2011
AB	!	IMPAX LABS	**0.1MG**	**A040431**	**001**	Mar 18, 2002
FLUMAZENIL							
INJECTABLE;INJECTION							
FLUMAZENIL							
AP		FRESENIUS KABI USA	**0.5MG/5ML (0.1MG/ML)**	**A076955**	**002**	Oct 12, 2004
AP			**1MG/10ML (0.1MG/ML)**	**A076955**	**001**	Oct 12, 2004
AP		HIKMA FARMACEUTICA	**0.5MG/5ML (0.1MG/ML)**	**A078527**	**001**	Mar 23, 2009
AP			**1MG/10ML (0.1MG/ML)**	**A078527**	**002**	Mar 23, 2009
AP		MYLAN LABS LTD	**0.5MG/5ML (0.1MG/ML)**	**A078595**	**001**	May 13, 2008
AP	!		**1MG/10ML (0.1MG/ML)**	**A078595**	**002**	May 13, 2008
AP		SAGENT PHARMS	**0.5MG/5ML (0.1MG/ML)**	**A090584**	**001**	Aug 28, 2012
AP			**1MG/10ML (0.1MG/ML)**	**A090584**	**002**	Aug 28, 2012
AP		SANDOZ INC	**0.5MG/5ML (0.1MG/ML)**	**A077071**	**001**	May 03, 2005
AP			**1MG/10ML (0.1MG/ML)**	**A077071**	**002**	May 03, 2005
AP		WEST-WARD PHARMS INT	**0.5MG/5ML (0.1MG/ML)**	**A076256**	**002**	Oct 12, 2004
AP			**0.5MG/5ML (0.1MG/ML)**	**A076787**	**002**	Oct 12, 2004
AP			**1MG/10ML (0.1MG/ML)**	**A076256**	**001**	Oct 12, 2004
AP			**1MG/10ML (0.1MG/ML)**	**A076787**	**001**	Oct 12, 2004
FLUNISOLIDE							
AEROSOL, METERED;INHALATION							
AEROSPAN HFA							
	+!	MYLAN SPECIALITY LP	0.078MG/INH	N021247	001	Jan 27, 2006
SPRAY, METERED;NASAL							
FLUNISOLIDE							
AB	!	BAUSCH AND LOMB	**0.025MG/SPRAY**	**A074805**	**001**	Feb 20, 2002
AB		HI TECH PHARMA CO	**0.025MG/SPRAY**	**A077704**	**001**	Aug 03, 2006
FLUOCINOLONE ACETONIDE							
CREAM;TOPICAL							
FLUOCINOLONE ACETONIDE							
AT		FOUGERA PHARMS INC	**0.01%**	**A088170**	**001**	Dec 16, 1982
AT			**0.025%**	**A088169**	**001**	Dec 16, 1982
AT		G AND W LABS	**0.01%**	**A089526**	**001**	Jul 26, 1988
AT		G AND W LABS INC	**0.025%**	**A210747**	**001**	Nov 05, 2018
AT		TARO	**0.025%**	**A087104**	**001**	Apr 27, 1982
SYNALAR							
AT	+!	MEDIMETRIKS PHARMS	**0.01%**	**N012787**	**004**	
AT	+!		**0.025%**	**N012787**	**002**	
AT	+!		**0.025%**	**N012787**	**005**	
IMPLANT;INTRAVITREAL							
ILUVIEN							
	+!	ALIMERA SCIENCES INC	0.19MG	N201923	001	Sep 26, 2014
RETISERT							
	+!	BAUSCH AND LOMB	0.59MG	N021737	001	Apr 08, 2005
YUTIQ							
	+!	EYEPOINT PHARMS	0.18MG	N210331	001	Oct 12, 2018
OIL;TOPICAL							
DERMA-SMOOTHE/FS							
AT	+!	HILL DERMAC	**0.01%**	**N019452**	**001**	Feb 03, 1988
AT	+!		**0.01%**	**N019452**	**002**	Nov 09, 2005
FLUCINOLONE ACETONIDE							
AT		GLENMARK PHARMS LTD	**0.01%**	**A210556**	**001**	Oct 25, 2018
FLUOCINOLONE ACETONIDE							
AT		AKORN	**0.01%**	**A091514**	**001**	Jun 25, 2015
AT		IDENTI PHARMS INC	**0.01%**	**A201759**	**001**	Oct 17, 2011
AT			**0.01%**	**A201764**	**001**	Oct 17, 2011
AT		LYNE	**0.01%**	**A090982**	**001**	Apr 25, 2016
AT			**0.01%**	**A203377**	**001**	Apr 25, 2016
AT		PERRIGO ISRAEL	**0.01%**	**A202847**	**001**	Aug 09, 2013
AT			**0.01%**	**A202848**	**001**	Aug 09, 2013
AT		TARO	**0.01%**	**A202368**	**001**	May 19, 2016
AT			**0.01%**	**A209336**	**001**	May 19, 2016
FLUOCINONIDE ACETONIDE							
AT		GLENMARK PHARMS LTD	**0.01%**	**A210539**	**001**	Oct 26, 2018

FLUOCINOLONE ACETONIDE

OIL/DROPS;OTIC

DERMOTIC

AT	**+!**	HILL DERMAC	**0.01%**	**N019452**	**003**	Nov 09, 2005

FLAC

AT		PATRIN PHARMA INC	**0.01%**	**A210736**	**001**	Apr 11, 2018

FLUOCINOLONE ACETONIDE

AT		AKORN	**0.01%**	**A202705**	**001**	Sep 09, 2016
AT		IDENTI PHARMS INC	**0.01%**	**A091306**	**001**	Oct 17, 2011
AT		LYNE	**0.01%**	**A203378**	**001**	Apr 25, 2016
AT		PERRIGO ISRAEL	**0.01%**	**A202849**	**001**	Jul 17, 2017

FLUOCINONIDE ACETONIDE

AT		GLENMARK PHARMS LTD	**0.01%**	**A211815**	**001**	Dec 14, 2018

OINTMENT;TOPICAL

FLUOCINOLONE ACETONIDE

AT		FOUGERA PHARMS INC	**0.025%**	**A088168**	**001**	Dec 16, 1982
AT		G AND W LABS	**0.025%**	**A089524**	**001**	Jul 26, 1988
AT		TARO	**0.025%**	**A040041**	**001**	Sep 15, 1994

SYNALAR

AT	**+!**	MEDIMETRIKS PHARMS	**0.025%**	**N013960**	**001**	

SHAMPOO;TOPICAL

CAPEX

	+!	GALDERMA LABS LP	0.01%	N020001	001	Aug 27, 1990

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

AT		ACTAVIS LABS UT INC	**0.01%**	**A208386**	**001**	Oct 21, 2016
AT		FOUGERA PHARMS INC	**0.01%**	**A088167**	**001**	Dec 16, 1982
AT		GAVIS PHARMS LLC	**0.01%**	**A206422**	**001**	Sep 02, 2015
AT		TARO	**0.01%**	**A089124**	**001**	Sep 11, 1985

SYNALAR

AT	**+!**	MEDIMETRIKS PHARMS	**0.01%**	**N015296**	**001**	

FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM;TOPICAL

TRI-LUMA

	+!	GALDERMA LABS LP	0.01%;4%;0.05%	N021112	001	Jan 18, 2002

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM;TOPICAL

NEO-SYNALAR

	!	MEDIMETRIKS PHARMS	0.025%;EQ 3.5MG BASE/GM	A060700	001	

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

AB		AMNEAL PHARMS LLC	**0.1%**	**A211111**	**001**	Jun 04, 2018
AB		FOUGERA PHARMS INC	**0.1%**	**A200735**	**001**	Jul 14, 2014
AB		GLENMARK GENERICS	**0.1%**	**A091282**	**001**	Jul 14, 2014
AB		PERRIGO ISRAEL	**0.1%**	**A090256**	**001**	Jan 14, 2014
AB		TARO	**0.1%**	**A200734**	**001**	Jul 14, 2014

VANOS

AB	**+!**	MEDICIS	**0.1%**	**N021758**	**001**	Feb 11, 2005

FLUOCINONIDE

AB1		AMNEAL PHARMS LLC	**0.05%**	**A210554**	**001**	Aug 21, 2018
AB1		FOUGERA PHARMS INC	**0.05%**	**A073030**	**001**	Oct 17, 1994
AB1		G AND W LABS INC	**0.05%**	**A073085**	**001**	Feb 14, 1992
AB1		TARO	**0.05%**	**A071500**	**001**	Jun 10, 1987
AB1	**+!**		**0.05%**	**N019117**	**001**	Jun 26, 1984
AB1		TELIGENT PHARMA INC	**0.05%**	**A211410**	**001**	Oct 16, 2018
AB1		TEVA	**0.05%**	**A072488**	**001**	Feb 06, 1989

FLUOCINONIDE EMULSIFIED BASE

AB2		FOUGERA PHARMS	**0.05%**	**A076586**	**001**	Jun 23, 2004
AB2		G AND W LABS INC	**0.05%**	**A074204**	**001**	Jun 13, 1995
AB2	**!**	TARO PHARM INDS LTD	**0.05%**	**A072494**	**001**	Jan 19, 1989
AB2		TEVA	**0.05%**	**A072490**	**001**	Feb 07, 1989

LIDEX-E

AB2	**+**	CNTY LINE PHARMS	**0.05%**	**N016908**	**003**	

GEL;TOPICAL

FLUOCINONIDE

AB	**+**	CNTY LINE PHARMS	**0.05%**	**N017373**	**001**	
AB		FOUGERA PHARMS INC	**0.05%**	**A072933**	**001**	Dec 30, 1994
AB		G AND W LABS INC	**0.05%**	**A072537**	**001**	Feb 07, 1989
AB	**!**	TARO	**0.05%**	**A074935**	**001**	Jul 29, 1997
AB		TELIGENT PHARMA INC	**0.05%**	**A209030**	**001**	Jun 19, 2018

FLUOCINONIDE							
OINTMENT;TOPICAL							
FLUOCINONIDE							
AB		FOUGERA PHARMS	**0.05%**	**A074905**	**001**	Aug 26, 1997
AB		NOVEL LABS INC	**0.05%**	**A207538**	**001**	Jul 31, 2017
AB	**!**	TARO	**0.05%**	**A075008**	**001**	Jun 30, 1999
AB		TELIGENT PHARMA INC	**0.05%**	**A207680**	**001**	Sep 28, 2018
AB		TEVA	**0.05%**	**A073481**	**001**	Dec 27, 1991
LIDEX							
AB	**+**	CNTY LINE PHARMS	**0.05%**	**N016909**	**002**	
SOLUTION;TOPICAL							
FLUOCINONIDE							
AT		ENCUBE ETHICALS	**0.05%**	**A209699**	**001**	Nov 29, 2018
AT		FOUGERA PHARMS INC	**0.05%**	**A072934**	**001**	Feb 27, 1995
AT		G AND W LABS INC	**0.05%**	**A071535**	**001**	Dec 02, 1988
AT		GLASSHOUSE PHARMS	**0.05%**	**A209118**	**001**	Apr 23, 2018
AT		MACLEODS PHARMS LTD	**0.05%**	**A209283**	**001**	Apr 23, 2018
AT		NOVEL LABS INC	**0.05%**	**A206003**	**001**	Jul 21, 2017
AT	**!**	TARO	**0.05%**	**A074799**	**001**	Dec 31, 1996
AT		TEVA	**0.05%**	**A072511**	**001**	Feb 07, 1989
AT		ZYDUS PHARMS USA INC	**0.05%**	**A208948**	**001**	Jul 17, 2018
LIDEX							
AT	**+**	CNTY LINE PHARMS	**0.05%**	**N018849**	**001**	Apr 06, 1984
FLUORESCEIN SODIUM							
INJECTABLE;INTRAVENOUS							
AK-FLUOR 10%							
AP	**+**	AKORN	**EQ 500MG BASE/5ML (EQ 100MG BASE/ML)**	**N022186**	**001**	Aug 08, 2008
FLUORESCITE							
AP	**+!**	ALCON LABS INC	**EQ 500MG BASE/5ML (EQ 100MG BASE/ML)**	**N021980**	**001**	Mar 28, 2006
AK-FLUOR 25%							
	+!	AKORN	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	N022186	002	Aug 08, 2008
FLUOROMETHOLONE							
OINTMENT;OPHTHALMIC							
FML							
	+!	ALLERGAN	0.1%	N017760	001	Sep 04, 1985
SUSPENSION/DROPS;OPHTHALMIC							
FML							
	+!	ALLERGAN	0.1%	N016851	002	Jul 28, 1982
FML FORTE							
		ALLERGAN	0.25%	N019216	001	Apr 23, 1986
FLUOROMETHOLONE ACETATE							
SUSPENSION/DROPS;OPHTHALMIC							
FLAREX							
	+!	NOVARTIS PHARMS CORP	0.1%	N019079	001	Feb 11, 1986
FLUOROURACIL							
CREAM;TOPICAL							
CARAC							
AB	**+!**	VALEANT PHARMS NORTH	**0.5%**	**N020985**	**001**	Oct 27, 2000
EFUDEX							
AB	**+!**	VALEANT PHARM INTL	**5%**	**N016831**	**003**	
FLUOROURACIL							
AB		MAYNE PHARMA	**5%**	**A077524**	**001**	Apr 11, 2008
AB		MYLAN PHARMS INC	**0.5%**	**A203122**	**001**	Apr 20, 2015
AB		TARO	**5%**	**A090368**	**001**	Mar 05, 2010
FLUOROPLEX							
	+!	AQUA PHARMS	1%	N016988	001	
TOLAK							
	+!	HILL DERMACEUTICALS	4%	N022259	001	Sep 18, 2015
INJECTABLE;INJECTION							
FLUOROURACIL							
AP	**!**	ACCORD HLTHCARE	**500MG/10ML (50MG/ML)**	**A040743**	**002**	Apr 26, 2007
AP	**!**		**1GM/20ML (50MG/ML)**	**A040743**	**001**	Apr 26, 2007
AP	**!**		**2.5GM/50ML (50MG/ML)**	**A040798**	**002**	Apr 26, 2007
AP	**!**		**5GM/100ML (50MG/ML)**	**A040798**	**001**	Apr 26, 2007
AP	**!**	FRESENIUS KABI USA	**500MG/10ML (50MG/ML)**	**A040279**	**002**	Sep 30, 1998
AP	**!**		**1GM/20ML (50MG/ML)**	**A040279**	**001**	Sep 30, 1998
AP	**!**		**2.5GM/50ML (50MG/ML)**	**A040278**	**001**	Sep 30, 1998
AP	**!**		**5GM/100ML (50MG/ML)**	**A040278**	**002**	Sep 30, 1998

FLUOROURACIL

INJECTABLE;INJECTION

FLUOROURACIL

AP		GLAND PHARMA LTD	**500MG/10ML (50MG/ML)**	**A210123**	**001**	Oct 27, 2017
AP			**1GM/20ML (50MG/ML)**	**A210123**	**002**	Oct 27, 2017
AP			**2.5GM/50ML (50MG/ML)**	**A210124**	**001**	Dec 26, 2017
AP			**5GM/100ML (50MG/ML)**	**A210124**	**002**	Dec 26, 2017
AP		MYLAN LABS LTD	**500MG/10ML (50MG/ML)**	**A202668**	**001**	Jul 17, 2012
AP			**1GM/20ML (50MG/ML)**	**A202668**	**002**	Jul 17, 2012
AP			**2.5GM/50ML (50MG/ML)**	**A202669**	**001**	Jul 17, 2012
AP			**5GM/100ML (50MG/ML)**	**A202669**	**002**	Jul 17, 2012
AP		SAGENT PHARMS	**500MG/10ML (50MG/ML)**	**A203608**	**001**	May 11, 2017
AP			**1GM/20ML (50MG/ML)**	**A203608**	**002**	May 11, 2017
AP			**2.5GM/50ML (50MG/ML)**	**A203609**	**001**	Feb 17, 2016
AP			**5GM/100ML (50MG/ML)**	**A203609**	**002**	Feb 17, 2016
AP	**!**	TEVA PHARMS USA	**500MG/10ML (50MG/ML)**	**A040333**	**001**	Jan 27, 2000
AP	**!**		**2.5GM/50ML (50MG/ML)**	**A040334**	**001**	Feb 25, 2000
AP	**!**		**5GM/100ML (50MG/ML)**	**A040334**	**002**	Feb 25, 2000

SOLUTION;TOPICAL

EFUDEX

AT	**+!**	VALEANT PHARM INTL	**2%**	**N016831**	**001**	
AT	**+!**		**5%**	**N016831**	**002**	

FLUOROURACIL

AT		TARO PHARM	**2%**	**A076526**	**001**	Nov 05, 2003
AT			**5%**	**A076526**	**002**	Nov 05, 2003

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	**EQ 40MG BASE**	**A090223**	**003**	Mar 19, 2009
AB		AUROBINDO PHARMA	**EQ 40MG BASE**	**A078619**	**003**	Jan 31, 2008
AB		HERITAGE PHARMS INC	**EQ 40MG BASE**	**A201336**	**003**	Oct 01, 2012
AB		IVAX SUB TEVA PHARMS	**EQ 40MG BASE**	**A075245**	**003**	Sep 28, 2004
AB		MARKSANS PHARMA	**EQ 40MG BASE**	**A075465**	**003**	Aug 02, 2001
AB		PAR PHARM	**EQ 40MG BASE**	**A076922**	**003**	Dec 16, 2004
AB		SANDOZ	**EQ 40MG BASE**	**A075049**	**003**	Jan 29, 2002
AB		SCIEGEN PHARMS INC	**EQ 40MG BASE**	**A204597**	**003**	Mar 16, 2015
AB		SUN PHARM INDS LTD	**EQ 40MG BASE**	**A076990**	**001**	Dec 13, 2004
AB		TEVA	**EQ 40MG BASE**	**A075452**	**003**	Jan 29, 2002

PROZAC

AB	**+!**	ELI LILLY AND CO	**EQ 40MG BASE**	**N018936**	**003**	Jun 15, 1999

FLUOXETINE HYDROCHLORIDE

AB1		ALEMBIC PHARMS LTD	**EQ 10MG BASE**	**A090223**	**001**	Mar 19, 2009
AB1			**EQ 20MG BASE**	**A090223**	**002**	Mar 19, 2009
AB1		AUROBINDO PHARMA	**EQ 10MG BASE**	**A078619**	**001**	Jan 31, 2008
AB1			**EQ 20MG BASE**	**A078619**	**002**	Jan 31, 2008
AB1		BARR	**EQ 10MG BASE**	**A074803**	**002**	Jan 30, 2002
AB1			**EQ 20MG BASE**	**A074803**	**001**	Aug 02, 2001
AB1		HERITAGE PHARMS INC	**EQ 10MG BASE**	**A201336**	**001**	Oct 01, 2012
AB1			**EQ 20MG BASE**	**A201336**	**002**	Oct 01, 2012
AB1		IVAX SUB TEVA PHARMS	**EQ 10MG BASE**	**A075245**	**002**	Jan 31, 2002
AB1			**EQ 20MG BASE**	**A075245**	**001**	Jan 31, 2002
AB1		LANDELA PHARM	**EQ 10MG BASE**	**A075464**	**001**	Jan 30, 2002
AB1			**EQ 20MG BASE**	**A075464**	**002**	Jan 30, 2002
AB1		MARKSANS PHARMA	**EQ 10MG BASE**	**A075465**	**001**	Jan 29, 2002
AB1			**EQ 20MG BASE**	**A075465**	**002**	Jan 29, 2002
AB1		SANDOZ	**EQ 10MG BASE**	**A075049**	**001**	Aug 02, 2001
AB1			**EQ 20MG BASE**	**A075049**	**002**	Jan 29, 2002
AB1		SCIEGEN PHARMS INC	**EQ 10MG BASE**	**A204597**	**001**	Mar 16, 2015
AB1			**EQ 20MG BASE**	**A204597**	**002**	Mar 16, 2015
AB1		SPECGX LLC	**EQ 10MG BASE**	**A075658**	**001**	Jan 29, 2002
AB1			**EQ 20MG BASE**	**A075658**	**002**	Jan 29, 2002
AB1		TEVA	**EQ 10MG BASE**	**A075452**	**001**	Jan 29, 2002
AB1			**EQ 20MG BASE**	**A075452**	**002**	Jan 29, 2002
AB1		TEVA PHARMS USA	**EQ 10MG BASE**	**A076001**	**001**	Jan 29, 2002
AB1			**EQ 20MG BASE**	**A076001**	**002**	Jan 29, 2002

PROZAC

AB1	**+**	ELI LILLY AND CO	**EQ 10MG BASE**	**N018936**	**006**	Dec 23, 1992
AB1	**+**		**EQ 20MG BASE**	**N018936**	**001**	Dec 29, 1987

FLUOXETINE HYDROCHLORIDE

		MYLAN	EQ 10MG BASE	A078045	001	Nov 17, 2008

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

	!		EQ 20MG BASE	A078045	002	Nov 17, 2008

CAPSULE, DELAYED REL PELLETS;ORAL

FLUOXETINE HYDROCHLORIDE

AB		BARR	**EQ 90MG BASE**	**A076237**	**001**	Mar 24, 2010
AB		DR REDDYS LABS LTD	**EQ 90MG BASE**	**A078572**	**001**	Mar 22, 2010

PROZAC WEEKLY

AB	**+!**	LILLY	**EQ 90MG BASE**	**N021235**	**001**	Feb 26, 2001

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

AA		LANNETT CO INC	**EQ 20MG BASE/5ML**	**A077849**	**001**	Feb 09, 2007
AA	**!**	PHARM ASSOC	**EQ 20MG BASE/5ML**	**A076015**	**001**	Jan 30, 2002
AA		SPECGX LLC	**EQ 20MG BASE/5ML**	**A075920**	**001**	Jan 29, 2002
AA		TEVA	**EQ 20MG BASE/5ML**	**A075506**	**001**	Aug 02, 2001
AA		WOCKHARDT BIO AG	**EQ 20MG BASE/5ML**	**A075514**	**001**	Aug 29, 2002

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	**EQ 10MG BASE**	**A208698**	**001**	Apr 05, 2017
AB			**EQ 20MG BASE**	**A208698**	**002**	Apr 05, 2017
AB	**+!**	ALVOGEN	**EQ 60MG BASE**	**N202133**	**001**	Oct 06, 2011
AB		APPCO PHARMA LLC	**EQ 60MG BASE**	**A211477**	**001**	Nov 21, 2018
AB		DR REDDYS LABS LTD	**EQ 10MG BASE**	**A076006**	**001**	Jan 30, 2002
AB			**EQ 20MG BASE**	**A076006**	**002**	Apr 23, 2018
AB		INVENTIA HLTHCARE	**EQ 60MG BASE**	**A209695**	**001**	Nov 20, 2017
AB		MYLAN	**EQ 10MG BASE**	**A075755**	**001**	Aug 02, 2001
AB	**!**		**EQ 20MG BASE**	**A075755**	**002**	Aug 02, 2001
AB		PAR FORM	**EQ 10MG BASE**	**A203836**	**001**	Aug 19, 2016
AB			**EQ 20MG BASE**	**A203836**	**002**	Aug 19, 2016
AB		PAR PHARM INC	**EQ 60MG BASE**	**A209419**	**001**	Nov 16, 2017
AB		SCIEGEN PHARMS INC	**EQ 60MG BASE**	**A211282**	**001**	Jan 10, 2019
AB		TEVA	**EQ 10MG BASE**	**A075872**	**001**	Jan 29, 2002
AB			**EQ 20MG BASE**	**A075872**	**002**	Jan 04, 2019
AB		TEVA PHARMS USA	**EQ 60MG BASE**	**A211051**	**001**	Dec 03, 2018
AB1		TORRENT PHARMS LTD	**EQ 10MG BASE**	**A206937**	**001**	Oct 21, 2016
AB1			**EQ 20MG BASE**	**A206937**	**002**	Oct 21, 2016

SARAFEM

AB1	**+**	APIL	**EQ 10MG BASE**	**N021860**	**001**	May 19, 2006
AB1	**+**		**EQ 15MG BASE**	**N021860**	**002**	May 19, 2006
AB1	**+!**		**EQ 20MG BASE**	**N021860**	**003**	May 19, 2006

SELFEMRA

AB1		TEVA PHARMS USA	**EQ 10MG BASE**	**A200151**	**001**	Feb 03, 2014
AB1			**EQ 15MG BASE**	**A200151**	**002**	Feb 03, 2014
AB1			**EQ 20MG BASE**	**A200151**	**003**	Feb 03, 2014

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE;ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB		PAR PHARM	**EQ 25MG BASE;EQ 3MG BASE**	**A077742**	**001**	Nov 02, 2012
AB			**EQ 25MG BASE;EQ 6MG BASE**	**A077742**	**002**	Nov 02, 2012
AB			**EQ 25MG BASE;EQ 12MG BASE**	**A077742**	**003**	Nov 02, 2012
AB			**EQ 50MG BASE;EQ 6MG BASE**	**A077742**	**004**	Nov 02, 2012
AB			**EQ 50MG BASE;EQ 12MG BASE**	**A077742**	**005**	Nov 02, 2012
AB		SANDOZ	**EQ 25MG BASE;EQ 3MG BASE**	**A078901**	**005**	Nov 16, 2012
AB			**EQ 25MG BASE;EQ 6MG BASE**	**A078901**	**001**	Nov 16, 2012
AB			**EQ 25MG BASE;EQ 12MG BASE**	**A078901**	**003**	Nov 16, 2012
AB			**EQ 50MG BASE;EQ 6MG BASE**	**A078901**	**002**	Nov 16, 2012
AB			**EQ 50MG BASE;EQ 12MG BASE**	**A078901**	**004**	Nov 16, 2012
AB		TEVA PHARMS	**EQ 25MG BASE;EQ 3MG BASE**	**A202074**	**001**	Mar 25, 2013
AB			**EQ 25MG BASE;EQ 6MG BASE**	**A077528**	**001**	Jun 19, 2012
AB			**EQ 25MG BASE;EQ 12MG BASE**	**A077528**	**002**	Jun 19, 2012
AB			**EQ 50MG BASE;EQ 6MG BASE**	**A077528**	**003**	Jun 19, 2012
AB			**EQ 50MG BASE;EQ 12MG BASE**	**A077528**	**004**	Jun 19, 2012

SYMBYAX

AB	**+**	LILLY	**EQ 25MG BASE;EQ 3MG BASE**	**N021520**	**001**	Apr 09, 2007
AB	**+**		**EQ 25MG BASE;EQ 6MG BASE**	**N021520**	**002**	Dec 24, 2003
AB	**+**		**EQ 25MG BASE;EQ 12MG BASE**	**N021520**	**004**	Dec 24, 2003
AB	**+!**		**EQ 50MG BASE;EQ 6MG BASE**	**N021520**	**003**	Dec 24, 2003
AB	**+**		**EQ 50MG BASE;EQ 12MG BASE**	**N021520**	**005**	Dec 24, 2003

FLUOXYMESTERONE						
TABLET;ORAL						
FLUOXYMESTERONE						
	!	USL PHARMA	10MG	A088342	001	Oct 21, 1983
FLUPHENAZINE DECANOATE						
INJECTABLE;INJECTION						
FLUPHENAZINE DECANOATE						
AO		AUROBINDO PHARMA LTD	**25MG/ML**	**A207739**	**001**	Oct 17, 2017
AO	**!**	FRESENIUS KABI USA	**25MG/ML**	**A071413**	**001**	Jul 14, 1987
AO		MYLAN LABS LTD	**25MG/ML**	**A075918**	**001**	Aug 17, 2001
AO		PAR STERILE PRODUCTS	**25MG/ML**	**A203732**	**001**	Jul 03, 2014
AO		WEST-WARD PHARMS INT	**25MG/ML**	**A074531**	**001**	Aug 30, 1996
FLUPHENAZINE HYDROCHLORIDE						
CONCENTRATE;ORAL						
FLUPHENAZINE HYDROCHLORIDE						
	!	PHARM ASSOC	5MG/ML	A074725	001	Sep 16, 1996
ELIXIR;ORAL						
FLUPHENAZINE HYDROCHLORIDE						
	!	PHARM ASSOC	2.5MG/5ML	A040146	001	Aug 21, 1996
INJECTABLE;INJECTION						
FLUPHENAZINE HYDROCHLORIDE						
	!	FRESENIUS KABI USA	2.5MG/ML	A089556	001	Apr 16, 1987
TABLET;ORAL						
FLUPHENAZINE HYDROCHLORIDE						
AB		LANNETT CO INC	**1MG**	**A089743**	**002**	Aug 25, 1988
AB			**2.5MG**	**A089743**	**003**	Aug 25, 1988
AB			**5MG**	**A089743**	**004**	Aug 25, 1988
AB			**10MG**	**A089743**	**001**	Aug 25, 1988
AB		MYLAN	**1MG**	**A089804**	**002**	Aug 12, 1988
AB			**2.5MG**	**A089804**	**003**	Aug 12, 1988
AB			**5MG**	**A089804**	**004**	Aug 12, 1988
AB	**!**		**10MG**	**A089804**	**001**	Aug 12, 1988
AB		SANDOZ	**1MG**	**A089586**	**002**	Oct 16, 1987
AB			**2.5MG**	**A089586**	**003**	Oct 16, 1987
AB			**5MG**	**A089586**	**004**	Oct 16, 1987
AB			**10MG**	**A089586**	**001**	Oct 16, 1987
FLURANDRENOLIDE						
CREAM;TOPICAL						
CORDRAN SP						
AT	**+!**	AQUA PHARMS	**0.05%**	**N012806**	**002**	
FLURANDRENOLIDE						
AT		CINTEX SVCS	**0.05%**	**A205342**	**001**	Apr 13, 2016
CORDRAN SP						
	+!	AQUA PHARMS	0.025%	N012806	003	
LOTION;TOPICAL						
CORDRAN						
AT	**+!**	AQUA PHARMS	**0.05%**	**N013790**	**001**	
FLURANDRENOLIDE						
AT		CINTEX SVCS	**0.05%**	**A205343**	**001**	Dec 22, 2016
AT		PERRIGO UK FINCO	**0.05%**	**A207133**	**001**	Aug 30, 2016
OINTMENT;TOPICAL						
CORDRAN						
AT	**+!**	AQUA PHARMS	**0.05%**	**N012806**	**001**	
FLURANDRENOLIDE						
AT		TELIGENT PHARMA INC	**0.05%**	**A207851**	**001**	Dec 30, 2016
TAPE;TOPICAL						
CORDRAN						
	+!	AQUA PHARMS LLC	0.004MG/SQ CM	N016455	001	
FLURAZEPAM HYDROCHLORIDE						
CAPSULE;ORAL						
FLURAZEPAM HYDROCHLORIDE						
		MYLAN PHARMS INC	15MG	A070345	002	Nov 27, 1985
	!		30MG	A070345	001	Nov 27, 1985

FLURBIPROFEN						
TABLET;ORAL						
FLURBIPROFEN						
AB		MYLAN	**50MG**	**A074358**	**001**	Jun 20, 1994
AB	**!**		**100MG**	**A074358**	**002**	Jun 20, 1994
AB		SUN PHARM INDS INC	**50MG**	**A075058**	**001**	Apr 27, 2001
AB			**100MG**	**A075058**	**002**	Apr 27, 2001
AB		TEVA	**100MG**	**A074431**	**001**	May 31, 1995
FLURBIPROFEN SODIUM						
SOLUTION/DROPS;OPHTHALMIC						
FLURBIPROFEN SODIUM						
AT		BAUSCH AND LOMB	**0.03%**	**A074447**	**001**	Jan 04, 1995
OCUFEN						
AT	**+!**	ALLERGAN	**0.03%**	**N019404**	**001**	Dec 31, 1986
FLUTAMIDE						
CAPSULE;ORAL						
FLUTAMIDE						
AB		ACTAVIS LABS FL INC	**125MG**	**A075820**	**001**	Sep 18, 2001
AB	**!**	CIPLA	**125MG**	**A075780**	**001**	Sep 19, 2001
AB		PAR PHARM	**125MG**	**A075298**	**001**	Sep 18, 2001
FLUTEMETAMOL F-18						
INJECTABLE;INTRAVENOUS						
VIZAMYL						
	+!	GE HEALTHCARE	121.5mCi/30ML (4.05mCi/ML)	N203137	002	Oct 25, 2013
FLUTICASONE FUROATE						
POWDER;INHALATION						
ARNUITY ELLIPTA						
	+!	GLAXOSMITHKLINE	0.05MG/INH	N205625	003	May 17, 2018
	+!		0.1MG/INH	N205625	001	Aug 20, 2014
	+!		0.2MG/INH	N205625	002	Aug 20, 2014
FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE						
POWDER;INHALATION						
TRELEGY ELLIPTA						
	+!	GLAXOSMITHKLINE	0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	N209482	001	Sep 18, 2017
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE						
POWDER;INHALATION						
BREO ELLIPTA						
	+!	GLAXO GRP LTD	0.1MG/INH;EQ 0.025MG BASE/INH	N204275	001	May 10, 2013
	+!		0.2MG/INH;EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015
FLUTICASONE PROPIONATE						
AEROSOL, METERED;INHALATION						
FLOVENT HFA						
	+!	GLAXO GRP LTD	0.044MG/INH	N021433	003	May 14, 2004
	+!		0.11MG/INH	N021433	002	May 14, 2004
	+!		0.22MG/INH	N021433	001	May 14, 2004
CREAM;TOPICAL						
FLUTICASONE PROPIONATE						
AB		ANDA REPOSITORY	**0.05%**	**A076633**	**001**	May 14, 2004
AB		FOUGERA PHARMS	**0.05%**	**A076451**	**001**	May 14, 2004
AB		G AND W LABS	**0.05%**	**A077055**	**001**	Jun 30, 2006
AB	**!**	PERRIGO NEW YORK	**0.05%**	**A076793**	**001**	May 14, 2004
LOTION;TOPICAL						
CUTIVATE						
AB	**+!**	FOUGERA PHARMS	**0.05%**	**N021152**	**001**	Mar 31, 2005
FLUTICASONE PROPIONATE						
AB		GLENMARK GENERICS	**0.05%**	**A090759**	**001**	May 02, 2011
AB		PERRIGO ISRAEL	**0.05%**	**A091553**	**001**	Jul 30, 2013
OINTMENT;TOPICAL						
FLUTICASONE PROPIONATE						
AB		G AND W LABS	**0.005%**	**A077168**	**001**	Mar 03, 2006
AB	**!**	PERRIGO NEW YORK	**0.005%**	**A076668**	**001**	May 14, 2004
POWDER;INHALATION						
ARMONAIR RESPICLICK						
	+	TEVA PHARM	0.055MG/INH	N208798	001	Jan 27, 2017
	+		0.113MG/INH	N208798	002	Jan 27, 2017
	+!		0.232MG/INH	N208798	003	Jan 27, 2017
FLOVENT DISKUS 100						
	+!	GLAXO GRP LTD	0.1MG/INH	N020833	002	Sep 29, 2000

FLUTICASONE PROPIONATE							
POWDER;INHALATION							
FLOVENT DISKUS 250							
	+!	GLAXO GRP LTD	0.25MG/INH	N020833	003	Sep 29, 2000
FLOVENT DISKUS 50							
	+!	GLAXO GRP LTD	0.05MG/INH	N020833	001	Sep 29, 2000
SPRAY, METERED;NASAL							
FLUTICASONE PROPIONATE							
AB		APOTEX INC	**0.05MG/SPRAY**	**A077538**	**001**	Sep 12, 2007
AB		HI TECH PHARMA	**0.05MG/SPRAY**	**A077570**	**001**	Jan 16, 2008
AB	!	WEST-WARD PHARMS INT	**0.05MG/SPRAY**	**A076504**	**001**	Feb 22, 2006
AB		WOCKHARDT BIO AG	**0.05MG/SPRAY**	**A078492**	**001**	Jan 09, 2012
XHANCE							
	+!	OPTINOSE US INC	0.093MG	N209022	001	Sep 18, 2017
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE							
AEROSOL, METERED;INHALATION							
ADVAIR HFA							
	+!	GLAXO GRP LTD	0.045MG/INH;EQ 0.021MG BASE/INH	N021254	001	Jun 08, 2006
	+!		0.115MG/INH;EQ 0.021MG BASE/INH	N021254	002	Jun 08, 2006
	+!		0.23MG/INH;EQ 0.021MG BASE/INH	N021254	003	Jun 08, 2006
POWDER;INHALATION							
ADVAIR DISKUS 100/50							
	+!	GLAXO GRP LTD	0.1MG/INH;EQ 0.05MG BASE/INH	N021077	001	Aug 24, 2000
ADVAIR DISKUS 250/50							
	+!	GLAXO GRP LTD	0.25MG/INH;EQ 0.05MG BASE/INH	N021077	002	Aug 24, 2000
ADVAIR DISKUS 500/50							
	+!	GLAXO GRP LTD	0.5MG/INH;EQ 0.05MG BASE/INH	N021077	003	Aug 24, 2000
AIRDUO RESPICLICK							
	+	TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	001	Jan 27, 2017
	+		0.113MG/INH;EQ 0.014MG BASE/INH	N208799	002	Jan 27, 2017
	+!		0.232MG;EQ 0.014MG BASE/INH	N208799	003	Jan 27, 2017
FLUVASTATIN SODIUM							
CAPSULE;ORAL							
FLUVASTATIN SODIUM							
AB		MYLAN PHARMS INC	**EQ 20MG BASE**	**A090595**	**001**	Apr 11, 2012
AB	!		**EQ 40MG BASE**	**A090595**	**002**	Apr 11, 2012
AB		TEVA PHARMS	**EQ 20MG BASE**	**A078407**	**001**	Jun 12, 2012
AB			**EQ 40MG BASE**	**A078407**	**002**	Jun 12, 2012
TABLET, EXTENDED RELEASE;ORAL							
FLUVASTATIN SODIUM							
AB		MYLAN PHARMS INC	**EQ 80MG BASE**	**A202458**	**001**	Sep 11, 2015
AB		TEVA PHARMS USA	**EQ 80MG BASE**	**A079011**	**001**	Jan 27, 2016
LESCOL XL							
AB	+!	NOVARTIS	**EQ 80MG BASE**	**N021192**	**001**	Oct 06, 2000
FLUVOXAMINE MALEATE							
CAPSULE, EXTENDED RELEASE;ORAL							
FLUVOXAMINE MALEATE							
AB		ACTAVIS ELIZABETH	**100MG**	**A091482**	**001**	Apr 23, 2013
AB	!		**150MG**	**A091482**	**002**	Nov 18, 2013
AB		ANCHEN PHARMS	**100MG**	**A091476**	**001**	Mar 13, 2013
AB			**150MG**	**A091476**	**002**	Mar 13, 2013
AB		TORRENT PHARMS LTD	**100MG**	**A203240**	**001**	Oct 31, 2014
AB			**150MG**	**A203240**	**002**	Oct 31, 2014
TABLET;ORAL							
FLUVOXAMINE MALEATE							
AB		ANI PHARMS INC	**25MG**	**A075897**	**001**	Jan 25, 2001
AB			**50MG**	**A075897**	**002**	Jan 25, 2001
AB			**100MG**	**A075897**	**003**	Jan 25, 2001
AB		APOTEX	**25MG**	**A075902**	**001**	May 07, 2001
AB			**50MG**	**A075902**	**002**	May 07, 2001
AB			**100MG**	**A075902**	**003**	May 07, 2001
AB		MYLAN	**25MG**	**A075889**	**001**	Nov 29, 2000
AB			**50MG**	**A075889**	**002**	Nov 29, 2000
AB			**100MG**	**A075889**	**003**	Nov 29, 2000
AB		TEVA	**25MG**	**A075893**	**001**	Sep 10, 2002
AB			**50MG**	**A075893**	**002**	Sep 10, 2002
AB			**100MG**	**A075893**	**003**	Sep 10, 2002
AB		UPSHER SMITH LABS	**25MG**	**A075888**	**001**	Nov 29, 2000
AB			**50MG**	**A075888**	**002**	Nov 29, 2000
AB	!		**100MG**	**A075888**	**003**	Nov 29, 2000

FLUVOXAMINE MALEATE						
TABLET;ORAL						
LUVOX						
AB		ANI PHARMS	**25MG**	**N021519**	**001**	Dec 20, 2007
AB			**50MG**	**N021519**	**002**	Dec 20, 2007
AB			**100MG**	**N021519**	**003**	Dec 20, 2007
FOLIC ACID						
INJECTABLE;INJECTION						
FOLIC ACID						
	!	FRESENIUS KABI USA	5MG/ML	A089202	001	Feb 18, 1986
TABLET;ORAL						
FOLIC ACID						
AA	**!**	AMNEAL PHARM	**1MG**	**A040625**	**001**	Jul 21, 2005
AA		ANBISON LAB	**1MG**	**A091145**	**001**	Jul 12, 2013
AA		CADILA PHARMS LTD	**1MG**	**A202437**	**001**	Jan 27, 2014
AA		CHARTWELL MOLECULAR	**1MG**	**A090035**	**001**	Jun 09, 2009
AA		HIKMA PHARMS	**1MG**	**A080600**	**001**	
AA		LEADING PHARMA LLC	**1MG**	**A040796**	**001**	Jan 12, 2009
AA		NUVO PHARMS INC	**1MG**	**A204418**	**001**	Jul 28, 2015
AA		VINTAGE	**1MG**	**A040756**	**001**	Jun 04, 2010
AA	**!**	WATSON LABS	**1MG**	**A080680**	**001**	
FOLLITROPIN ALFA/BETA						
INJECTABLE;SUBCUTANEOUS						
FOLLISTIM AQ						
	+!	ORGANON USA INC	300 IU/0.36ML	N021211	001	Mar 23, 2004
	+!		600 IU/0.72ML	N021211	002	Mar 23, 2004
	+!		900 IU/1.08ML	N021211	004	Feb 11, 2005
GONAL-F						
	+!	EMD SERONO	450 IU/VIAL	N020378	005	Mar 26, 2004
	+		1,050 IU/VIAL	N020378	004	Feb 28, 2001
GONAL-F RFF						
	+!	EMD SERONO	75 IU/VIAL	N021765	002	Mar 25, 2004
GONAL-F RFF REDI-JECT						
	+!	EMD SERONO	300 IU/0.5ML	N021684	001	May 25, 2004
	+!		450 IU/0.75ML	N021684	002	May 25, 2004
	+!		900 IU/1.5ML	N021684	003	May 25, 2004
FOMEPIZOLE						
INJECTABLE;INJECTION						
ANTIZOL						
AP	**+!**	PAR PHARM INC	**1.5GM/1.5ML (1GM/ML)**	**N020696**	**001**	Dec 04, 1997
FOMEPIZOLE						
AP		LUITPOLD	**1.5GM/1.5ML (1GM/ML)**	**A078368**	**001**	Dec 14, 2007
AP		MYLAN INSTITUTIONAL	**1.5GM/1.5ML (1GM/ML)**	**A078639**	**001**	Mar 03, 2008
AP		NAVINTA LLC	**1.5GM/1.5ML (1GM/ML)**	**A078537**	**001**	Mar 06, 2008
FONDAPARINUX SODIUM						
INJECTABLE;SUBCUTANEOUS						
ARIXTRA						
AP	**+!**	MYLAN IRELAND LTD	**2.5MG/0.5ML**	**N021345**	**001**	Dec 07, 2001
AP	**+!**		**5MG/0.4ML**	**N021345**	**002**	May 28, 2004
AP	**+!**		**7.5MG/0.6ML**	**N021345**	**003**	May 28, 2004
AP	**+!**		**10MG/0.8ML**	**N021345**	**004**	May 28, 2004
FONDAPARINUX SODIUM						
AP		AUROBINDO PHARMA LTD	**2.5MG/0.5ML**	**A206918**	**001**	Dec 26, 2017
AP			**5MG/0.4ML**	**A206918**	**002**	Dec 26, 2017
AP			**7.5MG/0.6ML**	**A206918**	**003**	Dec 26, 2017
AP			**10MG/0.8ML**	**A206918**	**004**	Dec 26, 2017
AP		DR REDDYS LABS LTD	**2.5MG/0.5ML**	**A091316**	**001**	Jul 11, 2011
AP			**5MG/0.4ML**	**A091316**	**002**	Jul 11, 2011
AP			**7.5MG/0.6ML**	**A091316**	**003**	Jul 11, 2011
AP			**10MG/0.8ML**	**A091316**	**004**	Jul 11, 2011
AP		JIANGSU HENGRUI MED	**2.5MG/0.5ML**	**A206812**	**001**	May 15, 2018
AP			**5MG/0.4ML**	**A206812**	**002**	May 15, 2018
AP			**7.5MG/0.6ML**	**A206812**	**003**	May 15, 2018
AP			**10MG/0.8ML**	**A206812**	**004**	May 15, 2018
AP		SCINOPHARM TAIWAN	**2.5MG/0.5ML**	**A208615**	**001**	Nov 14, 2018
AP			**5MG/0.4ML**	**A208615**	**002**	Nov 14, 2018
AP			**7.5MG/0.6ML**	**A208615**	**003**	Nov 14, 2018
AP			**10MG/0.8ML**	**A208615**	**004**	Nov 14, 2018

FORMOTEROL FUMARATE						
SOLUTION;INHALATION						
PERFOROMIST						
	+!	MYLAN SPECLT	0.02MG/2ML	N022007	001	May 11, 2007
FORMOTEROL FUMARATE; GLYCOPYRROLATE						
AEROSOL, METERED;INHALATION						
BEVESPI AEROSPHERE						
	+!	ASTRAZENECA PHARMS	0.0048MG/INH;0.0090MG/INH	N208294	001	Apr 25, 2016
FORMOTEROL FUMARATE; MOMETASONE FUROATE						
AEROSOL, METERED;INHALATION						
DULERA						
	+!	MERCK SHARP DOHME	0.005MG/INH;0.1MG/INH	N022518	001	Jun 22, 2010
	+!		0.005MG/INH;0.2MG/INH	N022518	002	Jun 22, 2010
FOSAMPRENAVIR CALCIUM						
SUSPENSION;ORAL						
LEXIVA						
	+!	VIIV HLTHCARE	EQ 50MG BASE/ML	N022116	001	Jun 14, 2007
TABLET;ORAL						
FOSAMPRENAVIR CALCIUM						
AB		MYLAN PHARMS INC	**EQ 700MG BASE**	**A204060**	**001**	Apr 15, 2016
LEXIVA						
AB	**+!**	VIIV HLTHCARE	**EQ 700MG BASE**	**N021548**	**001**	Oct 20, 2003
FOSAPREPITANT DIMEGLUMINE						
POWDER;INTRAVENOUS						
EMEND						
AP	**+!**	MERCK AND CO INC	**EQ 150MG BASE/VIAL**	**N022023**	**002**	Nov 12, 2010
FOSAPREPITANT DIMEGLUMINE						
AP		FRESENIUS KABI USA	**EQ 150MG BASE/VIAL**	**A206197**	**001**	Jun 09, 2016
FOSCARNET SODIUM						
INJECTABLE;INJECTION						
FOSCAVIR						
	+!	CLINIGEN HLTHCARE	2.4GM/100ML	N020068	001	Sep 27, 1991
FOSFOMYCIN TROMETHAMINE						
FOR SOLUTION;ORAL						
MONUROL						
	+!	ZAMBON SPA	EQ 3GM BASE/PACKET	N050717	001	Dec 19, 1996
FOSINOPRIL SODIUM						
TABLET;ORAL						
FOSINOPRIL SODIUM						
AB		APOTEX INC	**10MG**	**A076906**	**001**	May 17, 2005
AB			**20MG**	**A076906**	**002**	May 17, 2005
AB			**40MG**	**A076906**	**003**	May 17, 2005
AB		AUROBINDO PHARMA LTD	**10MG**	**A091163**	**001**	Mar 30, 2011
AB			**20MG**	**A091163**	**002**	Mar 30, 2011
AB			**40MG**	**A091163**	**003**	Mar 30, 2011
AB		INVAGEN PHARMS	**10MG**	**A077222**	**001**	Apr 20, 2005
AB			**20MG**	**A077222**	**002**	Apr 20, 2005
AB			**40MG**	**A077222**	**003**	Apr 20, 2005
AB		PRINSTON INC	**10MG**	**A205670**	**001**	Aug 29, 2016
AB			**20MG**	**A205670**	**002**	Aug 29, 2016
AB			**40MG**	**A205670**	**003**	Aug 29, 2016
AB		TEVA	**10MG**	**A076139**	**001**	Nov 25, 2003
AB			**20MG**	**A076139**	**002**	Nov 25, 2003
AB	**!**		**40MG**	**A076139**	**003**	Nov 25, 2003
AB		UPSHER SMITH LABS	**10MG**	**A076483**	**001**	Apr 23, 2004
AB			**20MG**	**A076483**	**002**	Apr 23, 2004
AB			**40MG**	**A076483**	**003**	Apr 23, 2004
FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE						
TABLET;ORAL						
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE						
AB		AUROBINDO PHARMA	**10MG;12.5MG**	**A079245**	**001**	Jul 09, 2009
AB			**20MG;12.5MG**	**A079245**	**002**	Jul 09, 2009
AB		EMCURE PHARMS LTD	**10MG;12.5MG**	**A079025**	**001**	Sep 17, 2010
AB	**!**		**20MG;12.5MG**	**A079025**	**002**	Sep 17, 2010
AB		INVAGEN PHARMS	**10MG;12.5MG**	**A090228**	**001**	Jul 09, 2009
AB			**20MG;12.5MG**	**A090228**	**002**	Jul 09, 2009
AB		SANDOZ	**10MG;12.5MG**	**A076961**	**001**	Sep 28, 2005
AB			**20MG;12.5MG**	**A076961**	**002**	Sep 28, 2005

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE						
POWDER;INTRAVENOUS						
AKYNZEO						
	+!	HELSINN HLTHCARE	EQ 235MG BASE;EQ 0.25MG BASE	N210493	001	Apr 19, 2018
FOSPHENYTOIN SODIUM						
INJECTABLE;INJECTION						
CEREBYX						
AP	**+!**	PARKE DAVIS	**EQ 50MG PHENYTOIN NA/ML**	**N020450**	**001**	Aug 05, 1996
FOSPHENYTOIN SODIUM						
AP		AMNEAL PHARMS CO	**EQ 50MG PHENYTOIN NA/ML**	**A078476**	**001**	Mar 18, 2008
AP		FRESENIUS KABI USA	**EQ 50MG PHENYTOIN NA/ML**	**A078052**	**001**	Aug 06, 2007
AP		HIKMA FARMACEUTICA	**EQ 50MG PHENYTOIN NA/ML**	**A078765**	**001**	Dec 02, 2009
AP		LUITPOLD	**EQ 50MG PHENYTOIN NA/ML**	**A078277**	**001**	Aug 06, 2007
AP			**EQ 50MG PHENYTOIN NA/ML**	**A090099**	**001**	May 13, 2010
AP		MYLAN LABS LTD	**EQ 50MG PHENYTOIN NA/ML**	**A078736**	**001**	Jun 08, 2010
AP		SUN PHARMA GLOBAL	**EQ 50MG PHENYTOIN NA/ML**	**A078417**	**001**	Mar 18, 2008
AP		WEST-WARD PHARMS INT	**EQ 50MG PHENYTOIN NA/ML**	**A077481**	**001**	Aug 06, 2007
AP			**EQ 50MG PHENYTOIN NA/ML**	**A077989**	**001**	Aug 06, 2007
AP		WOCKHARDT	**EQ 50MG PHENYTOIN NA/ML**	**A078137**	**001**	Aug 06, 2007
FOSTAMATINIB DISODIUM						
TABLET;ORAL						
TAVALISSE						
	+	RIGEL PHARMS INC	EQ 100MG BASE	N209299	001	Apr 17, 2018
	+!		EQ 150MG BASE	N209299	002	Apr 17, 2018
FROVATRIPTAN SUCCINATE						
TABLET;ORAL						
FROVA						
AB	**+!**	ENDO PHARMS	**EQ 2.5MG BASE**	**N021006**	**001**	Nov 08, 2001
FROVATRIPTAN SUCCINATE						
AB		AMNEAL PHARMS CO	**EQ 2.5MG BASE**	**A211292**	**001**	Nov 06, 2018
AB		GLENMARK PHARMS LTD	**EQ 2.5MG BASE**	**A204730**	**001**	Mar 11, 2016
AB		MYLAN PHARMS INC	**EQ 2.5MG BASE**	**A202931**	**001**	Aug 28, 2014
FULVESTRANT						
INJECTABLE;INTRAMUSCULAR						
FASLODEX						
	+!	ASTRAZENECA	50MG/ML	N021344	001	Apr 25, 2002
FUROSEMIDE						
INJECTABLE;INJECTION						
FUROSEMIDE						
AP		AMNEAL PHARMS CO	**10MG/ML**	**A207552**	**001**	Jul 20, 2016
AP	**!**	BAXTER HLTHCARE CORP	**10MG/ML**	**A202747**	**001**	Jan 27, 2014
AP		EMCURE PHARMS LTD	**10MG/ML**	**A203428**	**001**	Aug 26, 2014
AP		FRESENIUS KABI USA	**10MG/ML**	**N018902**	**001**	May 22, 1984
AP		HOSPIRA	**10MG/ML**	**A075241**	**001**	May 28, 1999
AP			**10MG/ML**	**N018667**	**001**	May 28, 1982
AP		WOCKHARDT	**10MG/ML**	**A077941**	**001**	Mar 22, 2007
SOLUTION;ORAL						
FUROSEMIDE						
AA	**!**	WEST-WARD PHARMS INT	**10MG/ML**	**A070434**	**001**	Apr 22, 1987
AA		WOCKHARDT BIO AG	**10MG/ML**	**A070655**	**001**	Oct 02, 1987
		WEST-WARD PHARMS INT	40MG/5ML	A070433	001	Apr 22, 1987
TABLET;ORAL						
FUROSEMIDE						
AB		IPCA LABS LTD	**20MG**	**A078010**	**001**	Sep 18, 2006
AB			**40MG**	**A078010**	**002**	Sep 18, 2006
AB			**80MG**	**A078010**	**003**	Sep 18, 2006
AB		IVAX SUB TEVA PHARMS	**20MG**	**N018413**	**001**	Nov 30, 1983
AB			**40MG**	**N018413**	**002**	Nov 30, 1983
AB		LEADING PHARMA LLC	**20MG**	**A077293**	**001**	Nov 09, 2005
AB			**40MG**	**A077293**	**002**	Nov 09, 2005
AB			**80MG**	**A077293**	**003**	Nov 09, 2005
AB		MYLAN	**20MG**	**N018487**	**001**	
AB			**40MG**	**N018487**	**002**	
AB			**80MG**	**A070082**	**001**	Oct 29, 1986
AB		PRINSTON INC	**20MG**	**A076796**	**001**	Mar 26, 2004
AB			**40MG**	**A076796**	**002**	Mar 26, 2004

FUROSEMIDE

TABLET;ORAL

FUROSEMIDE

AB			**80MG**	**A076796**	**003**	Mar 26, 2004
AB		SANDOZ	**20MG**	**N018569**	**002**	
AB			**40MG**	**N018569**	**001**	
AB			**80MG**	**N018569**	**005**	Aug 14, 1984
AB		WEST-WARD PHARMS INT	**20MG**	**N018823**	**001**	Nov 10, 1983
AB			**40MG**	**N018823**	**002**	Nov 10, 1983
AB			**80MG**	**A070086**	**001**	Jan 24, 1986

LASIX

AB	**+**	US PHARM HOLDINGS	**20MG**	**N016273**	**002**	
AB	**+**		**40MG**	**N016273**	**001**	
AB	**+!**		**80MG**	**N016273**	**003**	

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

AB		ACI HEALTHCARE LTD	**100MG**	**A206943**	**001**	May 14, 2018
AB			**300MG**	**A206943**	**002**	May 14, 2018
AB			**400MG**	**A206943**	**003**	May 14, 2018
AB		ACTAVIS ELIZABETH	**100MG**	**A075350**	**001**	Sep 12, 2003
AB			**300MG**	**A075350**	**002**	Sep 12, 2003
AB			**400MG**	**A075350**	**003**	Sep 12, 2003
AB		ALKEM	**100MG**	**A090858**	**001**	Dec 17, 2010
AB			**300MG**	**A090858**	**002**	Dec 17, 2010
AB			**400MG**	**A090858**	**003**	Dec 17, 2010
AB		AMNEAL PHARMS NY	**100MG**	**A078428**	**001**	Jul 25, 2007
AB			**300MG**	**A078428**	**002**	Jul 25, 2007
AB			**400MG**	**A078428**	**003**	Jul 25, 2007
AB		APOTEX INC	**100MG**	**A075360**	**001**	Apr 06, 2005
AB			**300MG**	**A075360**	**002**	Apr 06, 2005
AB			**400MG**	**A075360**	**003**	Apr 06, 2005
AB		AUROBINDO PHARMA LTD	**100MG**	**A078787**	**001**	Jan 31, 2008
AB			**300MG**	**A078787**	**002**	Jan 31, 2008
AB			**400MG**	**A078787**	**003**	Jan 31, 2008
AB		EPIC PHARMA LLC	**100MG**	**A207099**	**001**	Mar 24, 2017
AB			**300MG**	**A207099**	**002**	Mar 24, 2017
AB			**400MG**	**A207099**	**003**	Mar 24, 2017
AB		INVAGEN PHARMS	**100MG**	**A090705**	**001**	Dec 30, 2009
AB			**300MG**	**A090705**	**002**	Dec 30, 2009
AB			**400MG**	**A090705**	**003**	Dec 30, 2009
AB		JIANGSU HENGRUI MED	**100MG**	**A091008**	**001**	Oct 26, 2017
AB			**300MG**	**A091008**	**002**	Oct 26, 2017
AB			**400MG**	**A091008**	**003**	Oct 26, 2017
AB		MARKSANS PHARMA	**100MG**	**A090007**	**001**	Jul 21, 2011
AB			**300MG**	**A090007**	**002**	Jul 21, 2011
AB			**400MG**	**A090007**	**003**	Jul 21, 2011
AB		MYLAN	**100MG**	**A090158**	**001**	Feb 14, 2011
AB			**300MG**	**A090158**	**002**	Feb 14, 2011
AB			**400MG**	**A090158**	**003**	Feb 14, 2011
AB		SCIEGEN PHARMS INC	**100MG**	**A204989**	**001**	Feb 18, 2016
AB			**300MG**	**A204989**	**002**	Feb 18, 2016
AB			**400MG**	**A204989**	**003**	Feb 18, 2016
AB		STRIDES PHARMA	**100MG**	**A211314**	**001**	Oct 16, 2018
AB			**300MG**	**A211314**	**002**	Oct 16, 2018
AB			**400MG**	**A211314**	**003**	Oct 16, 2018
AB		SUN PHARM INDS LTD	**100MG**	**A077242**	**001**	Aug 24, 2006
AB			**300MG**	**A077242**	**002**	Aug 24, 2006
AB			**400MG**	**A077242**	**003**	Aug 24, 2006
AB		TARO PHARM	**100MG**	**A077261**	**001**	Aug 02, 2013
AB			**300MG**	**A077261**	**002**	Aug 02, 2013
AB			**400MG**	**A077261**	**003**	Aug 02, 2013
AB		TEVA PHARMS	**100MG**	**A075435**	**001**	Oct 08, 2004
AB			**300MG**	**A075435**	**002**	Oct 08, 2004
AB			**400MG**	**A075435**	**003**	Oct 08, 2004

NEURONTIN

AB	**+**	PFIZER PHARMS	**100MG**	**N020235**	**001**	Dec 30, 1993
AB	**+**		**300MG**	**N020235**	**002**	Dec 30, 1993
AB	**+!**		**400MG**	**N020235**	**003**	Dec 30, 1993

GABAPENTIN

SOLUTION;ORAL

GABAPENTIN

AA		ACELLA PHARMS LLC	**250MG/5ML**	**A076403**	**001**	May 01, 2012
AA		AMNEAL PHARMS	**250MG/5ML**	**A202024**	**001**	Mar 23, 2012
AA		HI TECH PHARMA	**250MG/5ML**	**A078974**	**001**	Feb 18, 2011
AA		TARO	**250MG/5ML**	**A076672**	**001**	Jul 03, 2013
AA		TRIS PHARMA INC	**250MG/5ML**	**A091286**	**001**	Mar 14, 2016

NEURONTIN

AA	**+!**	PARKE DAVIS	**250MG/5ML**	**N021129**	**001**	Mar 02, 2000

TABLET;ORAL

GABAPENTIN

AB		ACI HEALTHCARE LTD	**600MG**	**A203244**	**002**	Jul 12, 2013
AB			**800MG**	**A203244**	**001**	Jul 12, 2013
AB		ACTAVIS ELIZABETH	**600MG**	**A075694**	**001**	Oct 21, 2004
AB			**800MG**	**A075694**	**002**	Oct 21, 2004
AB		ALKEM LABS LTD	**600MG**	**A206402**	**001**	Dec 23, 2015
AB			**800MG**	**A206402**	**002**	Dec 23, 2015
AB		APOTEX INC	**100MG**	**A077894**	**001**	Oct 10, 2006
AB			**300MG**	**A077894**	**002**	Oct 10, 2006
AB			**400MG**	**A077894**	**003**	Oct 10, 2006
AB			**600MG**	**A077661**	**004**	Sep 13, 2006
AB			**800MG**	**A077661**	**005**	Sep 13, 2006
AB		AUROBINDO PHARMA LTD	**600MG**	**A200651**	**001**	Oct 06, 2011
AB			**800MG**	**A200651**	**002**	Oct 06, 2011
AB		CSPC OUYI PHARM CO	**600MG**	**A207057**	**001**	Oct 26, 2017
AB			**800MG**	**A207057**	**002**	Oct 26, 2017
AB		GLENMARK PHARMS LTD	**600MG**	**A077662**	**001**	Aug 18, 2006
AB			**800MG**	**A077662**	**002**	Aug 18, 2006
AB		INVAGEN PHARMS	**600MG**	**A202764**	**001**	Oct 16, 2012
AB			**800MG**	**A202764**	**002**	Oct 16, 2012
AB		IVAX SUB TEVA PHARMS	**100MG**	**A076017**	**001**	Apr 28, 2004
AB			**300MG**	**A076017**	**002**	Apr 28, 2004
AB			**400MG**	**A076017**	**003**	Apr 28, 2004
AB			**600MG**	**A076017**	**004**	Apr 29, 2005
AB			**800MG**	**A076017**	**005**	Apr 29, 2005
AB		LUPIN LTD	**600MG**	**A209306**	**001**	Aug 24, 2018
AB			**800MG**	**A209306**	**002**	Aug 24, 2018
AB		MYLAN PHARMS INC	**600MG**	**A090335**	**001**	Jun 01, 2010
AB			**800MG**	**A090335**	**002**	Jun 01, 2010
AB		SCIEGEN PHARMS INC	**600MG**	**A205101**	**001**	Feb 04, 2016
AB			**800MG**	**A205101**	**002**	Feb 04, 2016
AB		SUN PHARM INDS LTD	**600MG**	**A077525**	**001**	Aug 24, 2006
AB			**800MG**	**A077525**	**002**	Aug 24, 2006
AB		TEVA PHARMS USA	**600MG**	**A205807**	**001**	Mar 10, 2017
AB			**800MG**	**A205807**	**002**	Mar 10, 2017
AB		ZYDUS PHARMS USA INC	**600MG**	**A078926**	**001**	Feb 11, 2011
AB			**800MG**	**A078926**	**002**	Feb 11, 2011

NEURONTIN

AB	**+**	PFIZER PHARMS	**600MG**	**N020882**	**001**	Oct 09, 1998
AB	**+!**		**800MG**	**N020882**	**002**	Oct 09, 1998

GRALISE

BX	+!	ASSERTIO	300MG	N022544	001	Jan 28, 2011
BX	+!		600MG	N022544	002	Jan 28, 2011

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE;ORAL

HORIZANT

	+	ARBOR PHARMS LLC	300MG	N022399	002	Dec 13, 2011
	+!		600MG	N022399	001	Apr 06, 2011

GADOBENATE DIMEGLUMINE

INJECTABLE;INTRAVENOUS

MULTIHANCE

	+!	BRACCO	2.645GM/5ML (529MG/ML)	N021357	001	Nov 23, 2004
	+!		5.29GM/10ML (529MG/ML)	N021357	002	Nov 23, 2004
	+!		7.935GM/15ML (529MG/ML)	N021357	003	Nov 23, 2004
	+!		10.58GM/20ML (529MG/ML)	N021357	004	Nov 23, 2004

MULTIHANCE MULTIPACK

	+!	BRACCO	26.45GM/50ML (529MG/ML)	N021358	001	Nov 23, 2004
	+!		52.9GM/100ML (529MG/ML)	N021358	002	Nov 23, 2004

GADOBUTROL

SOLUTION;INTRAVENOUS

GADAVIST

+!	BAYER HLTHCARE	1.20944GM/2ML (604.72MG/ML)	N201277	006	Dec 18, 2013
+!		4.5354GM/7.5ML (604.72MG/ML)	N201277	001	Mar 14, 2011
+!		6.0472GM/10ML (604.72MG/ML)	N201277	002	Mar 14, 2011
+!		9.0708GM/15ML (604.72MG/ML)	N201277	003	Mar 14, 2011
+!		18.1416GM/30ML (604.72MG/ML)	N201277	004	Mar 14, 2011
+!		39.3068GM/65ML (604.72MG/ML)	N201277	005	Mar 14, 2011

GADODIAMIDE

INJECTABLE;INJECTION

OMNISCAN

+!	GE HEALTHCARE	287MG/ML	N020123	001	Jan 08, 1993
+!		28.7GM/100ML (287MG/ML)	N022066	002	Sep 05, 2007

GADOPENTETATE DIMEGLUMINE

INJECTABLE;INJECTION

MAGNEVIST

+!	BAYER HLTHCARE	469.01MG/ML	N019596	001	Jun 02, 1988
+!		469.01MG/ML	N021037	001	Mar 10, 2000

GADOTERATE MEGLUMINE

SOLUTION;INTRAVENOUS

DOTAREM

+!	GUERBET	37.69GM/100ML (376.9MG/ML)	N204781	001	Mar 20, 2013
+!		1.8845GM/5ML (376.9MG/ML)	N204781	005	Mar 31, 2017
+!		3.769GM/10ML (376.9MG/ML)	N204781	002	Mar 20, 2013
+!		5.6535GM/15ML (376.9MG/ML)	N204781	003	Mar 20, 2013
+!		7.538GM/20ML (376.9MG/ML)	N204781	004	Mar 20, 2013

GADOTERIDOL

INJECTABLE;INJECTION

PROHANCE

+!	BRACCO	279.3MG/ML	N020131	001	Nov 16, 1992

PROHANCE MULTIPACK

+!	BRACCO	279.3MG/ML	N021489	001	Oct 09, 2003

GADOXETATE DISODIUM

SOLUTION;INTRAVENOUS

EOVIST

+!	BAYER HLTHCARE	1.8143GM/10ML (181.43MG/ML)	N022090	001	Jul 03, 2008
+		2.72145GM/15ML (181.43MG/ML)	N022090	002	Feb 04, 2013

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL

GALANTAMINE HYDROBROMIDE

AB		AUROBINDO PHARMA LTD	**EQ 8MG BASE**	**A204895**	**001**	Aug 05, 2016
AB			**EQ 16MG BASE**	**A204895**	**002**	Aug 05, 2016
AB			**EQ 24MG BASE**	**A204895**	**003**	Aug 05, 2016
AB		BARR	**EQ 8MG BASE**	**A078189**	**001**	Sep 15, 2008
AB			**EQ 16MG BASE**	**A078189**	**002**	Sep 15, 2008
AB			**EQ 24MG BASE**	**A078189**	**003**	Sep 15, 2008
AB		SUN PHARMA GLOBAL	**EQ 8MG BASE**	**A090178**	**001**	Feb 02, 2011
AB			**EQ 16MG BASE**	**A090178**	**002**	Feb 02, 2011
AB			**EQ 24MG BASE**	**A090178**	**003**	Feb 02, 2011
AB		WATSON LABS	**EQ 8MG BASE**	**A079028**	**001**	Dec 15, 2008
AB			**EQ 16MG BASE**	**A079028**	**002**	Dec 15, 2008
AB			**EQ 24MG BASE**	**A079028**	**003**	Dec 15, 2008

RAZADYNE ER

AB	**+!**	JANSSEN PHARMS	**EQ 8MG BASE**	**N021615**	**001**	Apr 01, 2005
AB	**+**		**EQ 16MG BASE**	**N021615**	**002**	Apr 01, 2005
AB	**+**		**EQ 24MG BASE**	**N021615**	**003**	Apr 01, 2005

SOLUTION;ORAL

GALANTAMINE HYDROBROMIDE

!	WEST-WARD PHARMS INT	4MG/ML	A078185	001	Jan 30, 2009

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

AB		APOTEX INC	**EQ 4MG BASE**	**A077781**	**001**	Sep 27, 2011
AB			**EQ 8MG BASE**	**A077781**	**002**	Sep 27, 2011
AB			**EQ 12MG BASE**	**A077781**	**003**	Sep 27, 2011
AB		AUROBINDO PHARMA LTD	**EQ 4MG BASE**	**A090957**	**001**	Mar 29, 2011
AB			**EQ 8MG BASE**	**A090957**	**002**	Mar 29, 2011

GALANTAMINE HYDROBROMIDE

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

AB		**EQ 12MG BASE**	**A090957**	**003**	Mar 29, 2011
AB	BARR	**EQ 4MG BASE**	**A077605**	**001**	Aug 28, 2008
AB		**EQ 8MG BASE**	**A077605**	**002**	Aug 28, 2008
AB		**EQ 12MG BASE**	**A077605**	**003**	Aug 28, 2008
AB	DR REDDYS LABS LTD	**EQ 4MG BASE**	**A077593**	**001**	Sep 11, 2008
AB		**EQ 8MG BASE**	**A077593**	**002**	Sep 11, 2008
AB		**EQ 12MG BASE**	**A077593**	**003**	Sep 11, 2008
AB	MYLAN	**EQ 4MG BASE**	**A077590**	**001**	May 29, 2009
AB		**EQ 8MG BASE**	**A077590**	**002**	May 29, 2009
AB		**EQ 12MG BASE**	**A077590**	**003**	May 29, 2009
AB	SANDOZ	**EQ 4MG BASE**	**A077589**	**001**	Jun 22, 2009
AB		**EQ 8MG BASE**	**A077589**	**002**	Jun 22, 2009
AB		**EQ 12MG BASE**	**A077589**	**003**	Jun 22, 2009
AB	TEVA PHARMS	**EQ 4MG BASE**	**A077587**	**001**	Jul 09, 2009
AB		**EQ 8MG BASE**	**A077587**	**002**	Jul 09, 2009
AB		**EQ 12MG BASE**	**A077587**	**003**	Jul 09, 2009
AB	WEST-WARD PHARMS INT	**EQ 4MG BASE**	**A077608**	**001**	Feb 11, 2009
AB		**EQ 8MG BASE**	**A077608**	**002**	Feb 11, 2009
AB		**EQ 12MG BASE**	**A077608**	**003**	Feb 11, 2009
AB	YABAO PHARM	**EQ 4MG BASE**	**A077604**	**001**	Feb 06, 2009
AB		**EQ 8MG BASE**	**A077604**	**002**	Feb 06, 2009
AB		**EQ 12MG BASE**	**A077604**	**003**	Feb 06, 2009
AB	ZYDUS PHARMS USA INC	**EQ 4MG BASE**	**A078898**	**001**	Feb 17, 2011
AB		**EQ 8MG BASE**	**A078898**	**002**	Feb 17, 2011
AB		**EQ 12MG BASE**	**A078898**	**003**	Feb 17, 2011

RAZADYNE

AB	**+!** JANSSEN PHARMS	**EQ 4MG BASE**	**N021169**	**001**	Feb 28, 2001
AB	**+**	**EQ 8MG BASE**	**N021169**	**002**	Feb 28, 2001
AB	**+**	**EQ 12MG BASE**	**N021169**	**003**	Feb 28, 2001

GALLIUM CITRATE GA-67

INJECTABLE;INJECTION

GALLIUM CITRATE GA 67

BS	LANTHEUS MEDCL	2mCi/ML	N017478	001	
BS	MALLINKRODT NUCLEAR	2mCi/ML	N018058	001	

GALLIUM DOTATATE GA-68

POWDER;INTRAVENOUS

NETSPOT

	+! AAA USA INC	2.1-5.5mCi/ML	N208547	001	Jun 01, 2016

GANCICLOVIR

GEL;OPHTHALMIC

ZIRGAN

	+! BAUSCH AND LOMB	0.15%	N022211	001	Sep 15, 2009

GANCICLOVIR

SOLUTION;INTRAVENOUS

GANCICLOVIR

	+! EXELA PHARMA SCS LLC	500MG/250ML (2MG/ML)	N209347	001	Feb 17, 2017

GANCICLOVIR SODIUM

INJECTABLE;INJECTION

CYTOVENE

AP	**+!** ROCHE PALO	**EQ 500MG BASE/VIAL**	**N019661**	**001**	Jun 23, 1989

GANCICLOVIR

AP	FRESENIUS KABI USA	**EQ 500MG BASE/VIAL**	**A090658**	**001**	Jun 21, 2010
AP	HAINAN POLY PHARM	**EQ 500MG BASE/VIAL**	**A204204**	**001**	Nov 08, 2018
AP	LUITPOLD	**EQ 500MG BASE/VIAL**	**A202624**	**001**	Sep 18, 2013
AP	MYLAN LABS LTD	**EQ 500MG BASE/VIAL**	**A204560**	**001**	Nov 17, 2017
AP	PAR STERILE PRODUCTS	**EQ 500MG BASE/VIAL**	**A204950**	**001**	Dec 06, 2016

GANCICLOVIR SODIUM

AP	PHARMASCIENCE INC	**EQ 500MG BASE/VIAL**	**A207645**	**001**	Dec 08, 2017

GANIRELIX ACETATE

INJECTABLE;INJECTION

GANIRELIX ACETATE

AP	**+!**	ORGANON USA INC	**EQ 250MCG BASE/0.5ML**	**N021057**	**001**	Jul 29, 1999
AP		SUN PHARM INDS LTD	**EQ 250MCG BASE/0.5ML**	**A204246**	**001**	Nov 30, 2018

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

GATIFLOXACIN

AT		HI-TECH PHARMA CO	**0.5%**	**A203189**	**001**	Sep 03, 2014
AT		LUPIN LTD	**0.5%**	**A202653**	**001**	Aug 28, 2013
AT		MYLAN PHARMS INC	**0.5%**	**A206446**	**001**	Jun 08, 2018
AT		SANDOZ INC	**0.5%**	**A204227**	**001**	Jul 11, 2016

ZYMAXID

AT	**+!**	ALLERGAN	**0.5%**	**N022548**	**001**	May 18, 2010

ZYMAR

	+!	ALLERGAN	0.3%	N021493	001	Mar 28, 2003

GEFITINIB

TABLET;ORAL

IRESSA

	+!	ASTRAZENECA PHARMS	250MG	N206995	001	Jul 13, 2015

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

AP		ACCORD HLTHCARE	**EQ 200MG BASE/VIAL**	**A091594**	**001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A091594**	**002**	Jul 25, 2011
AP			**EQ 2GM BASE/VIAL**	**A091594**	**003**	Jul 25, 2011
AP		ACTAVIS INC	**200MG/5.26ML (38MG/ML)**	**A204549**	**001**	Apr 11, 2016
AP			**1GM/26.3ML (38MG/ML)**	**A204549**	**002**	Apr 11, 2016
AP			**2GM/52.6ML (38MG/ML)**	**A204549**	**003**	Apr 11, 2016
AP		ACTAVIS TOTOWA	**EQ 200MG BASE/VIAL**	**A079160**	**001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A079160**	**002**	Jul 25, 2011
AP			**EQ 2GM BASE/VIAL**	**A079160**	**003**	Jul 28, 2016
AP		APOTEX INC	**200MG/5.26ML (38MG/ML)**	**A206776**	**001**	May 23, 2017
AP			**1GM/26.3ML (38MG/ML)**	**A206776**	**002**	May 23, 2017
AP			**2GM/52.6ML (38MG/ML)**	**A206776**	**003**	May 23, 2017
AP		CIPLA	**EQ 200MG BASE/VIAL**	**A078759**	**001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A078759**	**002**	Jul 25, 2011
AP		DR REDDYS LABS LTD	**EQ 200MG BASE/VIAL**	**A091365**	**001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A091365**	**002**	Jul 25, 2011
AP			**EQ 2GM BASE/VIAL**	**A202997**	**001**	May 07, 2013
AP		EMCURE PHARMS LTD	**EQ 200MG BASE/VIAL**	**A202063**	**001**	Sep 11, 2012
AP			**EQ 1GM BASE/VIAL**	**A202063**	**002**	Sep 11, 2012
AP		FRESENIUS KABI ONCOL	**EQ 200MG BASE/VIAL**	**A090799**	**001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A090799**	**002**	Jul 25, 2011
AP			**EQ 2GM BASE/VIAL**	**A090799**	**003**	May 16, 2011
AP		FRESENIUS KABI USA	**EQ 2GM BASE/VIAL**	**A090242**	**003**	May 16, 2011
AP		GLAND PHARMA LTD	**EQ 200MG BASE/VIAL**	**A204520**	**001**	Jan 05, 2016
AP			**EQ 1GM BASE/VIAL**	**A204520**	**002**	Jan 05, 2016
AP		HOSPIRA	**EQ 200MG BASE/VIAL**	**A078339**	**001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A078339**	**002**	Jul 25, 2011
AP	**+!**	HOSPIRA INC	**200MG/5.26ML (38MG/ML)**	**N200795**	**001**	Aug 04, 2011
AP	**+!**		**1GM/26.3ML (38MG/ML)**	**N200795**	**002**	Aug 04, 2011
AP	**!**		**EQ 2GM BASE/VIAL**	**A079183**	**001**	Nov 15, 2010
AP	**+!**		**2GM/52.6ML (38MG/ML)**	**N200795**	**003**	Aug 04, 2011
AP		JIANGSU HANSOH PHARM	**EQ 200MG BASE/VIAL**	**A202485**	**001**	May 07, 2013
AP			**EQ 1GM BASE/VIAL**	**A202485**	**002**	May 07, 2013
AP		LUITPOLD	**EQ 200MG BASE/VIAL**	**A202031**	**001**	May 07, 2013
AP			**EQ 1GM BASE/VIAL**	**A202031**	**002**	May 07, 2013
AP		MYLAN LABS LTD	**EQ 200MG BASE/VIAL**	**A200145**	**001**	Jul 25, 2011
AP			**200MG/5.26ML (38MG/ML)**	**A205242**	**001**	Dec 06, 2017
AP			**EQ 1GM BASE/VIAL**	**A200145**	**002**	Jul 25, 2011
AP			**1GM/26.3ML (38MG/ML)**	**A205242**	**002**	Dec 06, 2017
AP			**EQ 2GM BASE/VIAL**	**A200145**	**003**	Jul 25, 2011
AP			**2GM/52.6ML (38MG/ML)**	**A205242**	**003**	Dec 06, 2017
AP		SAGENT PHARMS	**200MG/5.26ML (38MG/ML)**	**A209077**	**001**	Jul 20, 2018
AP			**1GM/26.3ML (38MG/ML)**	**A209077**	**002**	Jul 20, 2018
AP			**2GM/52.6ML (38MG/ML)**	**A209077**	**003**	Jul 20, 2018
AP		SUN PHARMA GLOBAL	**EQ 200MG BASE/VIAL**	**A078433**	**001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A078433**	**002**	Jul 25, 2011

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

AP		TEVA PHARMS	**EQ 200MG BASE/VIAL**	**A077983**	**002**	Jan 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A077983**	**001**	Jan 25, 2011

GEMZAR

AP	**+!**	LILLY	**EQ 200MG BASE/VIAL**	**N020509**	**001**	May 15, 1996
AP	**+!**		**EQ 1GM BASE/VIAL**	**N020509**	**002**	May 15, 1996

SOLUTION;INTRAVENOUS

GEMCITABINE HYDROCHLORIDE

+!	ACCORD HLTHCARE	1GM/10ML (100MG/ML)	N209604	002	Aug 03, 2017
+!		1.5GM/15ML (100MG/ML)	N209604	003	Aug 03, 2017
+!		2GM/20ML (100MG/ML)	N209604	004	Aug 03, 2017
+!		200MG/2ML (100MG/ML)	N209604	001	Aug 03, 2017

INFUGEM

+!	SUN PHARM INDS LTD	EQ 1200MG BASE/120ML (EQ 10MG BASE/ML)	N208313	001	Jul 16, 2018
+!		EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)	N208313	002	Jul 16, 2018
+!		EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)	N208313	003	Jul 16, 2018
+!		EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)	N208313	004	Jul 16, 2018
+!		EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)	N208313	005	Jul 16, 2018
+!		EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)	N208313	006	Jul 16, 2018
+!		EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)	N208313	007	Jul 16, 2018
+!		EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)	N208313	008	Jul 16, 2018
+!		EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)	N208313	009	Jul 16, 2018
+!		EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)	N208313	010	Jul 16, 2018

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

AB		APOTEX	**600MG**	**A075034**	**001**	Jul 20, 1998
AB		AUROBINDO PHARMA LTD	**600MG**	**A202726**	**001**	Sep 16, 2015
AB		CADILA PHARMS LTD	**600MG**	**A203266**	**001**	Jun 17, 2016
AB		CARIBE HOLDINGS	**600MG**	**A078012**	**001**	Mar 26, 2007
AB		CHARTWELL MOLECULES	**600MG**	**A074270**	**001**	Sep 27, 1993
AB		HIKMA PHARMS	**600MG**	**A078599**	**001**	Aug 16, 2010
AB		IMPAX PHARMS	**600MG**	**A078207**	**001**	Jun 01, 2007
AB		INVAGEN PHARMS	**600MG**	**A077836**	**001**	Jul 27, 2006
AB		NORTHSTAR HLTHCARE	**600MG**	**A079072**	**001**	Sep 13, 2010
AB		SUN PHARM INDS INC	**600MG**	**A079239**	**001**	Dec 29, 2008
AB		TEVA	**600MG**	**A074256**	**001**	Oct 31, 1993
AB		ZYDUS PHARMS USA INC	**600MG**	**A204189**	**001**	Aug 28, 2018

LOPID

AB	**+!**	PFIZER PHARMS	**600MG**	**N018422**	**003**	Nov 20, 1986

GEMIFLOXACIN MESYLATE

TABLET;ORAL

FACTIVE

AB	**+!**	LG CHEM LTD	**EQ 320MG BASE**	**N021158**	**001**	Apr 04, 2003

GEMIFLOXACIN MESYLATE

AB		ORCHID HLTHCARE	**EQ 320MG BASE**	**A090466**	**001**	Jun 15, 2015

GENTAMICIN SULFATE

CREAM;TOPICAL

GENTAMICIN SULFATE

AT		G AND W LABS INC	**EQ 0.1% BASE**	**A064056**	**001**	Apr 29, 1994
AT	**!**	PERRIGO NEW YORK	**EQ 0.1% BASE**	**A062307**	**001**	

INJECTABLE;INJECTION

GENTAMICIN SULFATE

AP		FRESENIUS KABI USA	**EQ 10MG BASE/ML**	**A062366**	**002**	Feb 06, 1986
AP	**!**		**EQ 40MG BASE/ML**	**A062366**	**001**	Aug 04, 1983
AP		HOSPIRA	**EQ 10MG BASE/ML**	**A062420**	**001**	Aug 15, 1983
AP			**EQ 10MG BASE/ML**	**A062612**	**004**	Feb 20, 1986
AP			**EQ 40MG BASE/ML**	**A062420**	**002**	Aug 15, 1983

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**EQ 1.2MG BASE/ML**	**A062373**	**007**	Sep 07, 1982
AP			**EQ 1.6MG BASE/ML**	**A062373**	**008**	Sep 07, 1982
AP			**EQ 80MG BASE/100ML**	**A062373**	**002**	Sep 07, 1982
AP			**EQ 100MG BASE/100ML**	**A062373**	**005**	Sep 07, 1982
AP		HOSPIRA	**EQ 1.2MG BASE/ML**	**A062414**	**001**	Aug 15, 1983
AP			**EQ 1.6MG BASE/ML**	**A062414**	**003**	Aug 15, 1983
AP			**EQ 80MG BASE/100ML**	**A062414**	**008**	Aug 15, 1983
AP			**EQ 100MG BASE/100ML**	**A062414**	**010**	Aug 15, 1983

GENTAMICIN SULFATE

INJECTABLE;INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	!	BAXTER HLTHCARE	EQ 2MG BASE/ML	A062373	009	Sep 07, 1982
	!		EQ 120MG BASE/100ML	A062373	006	Sep 07, 1982

OINTMENT;OPHTHALMIC

GENTAMICIN SULFATE

AT	**!**	AKORN	**EQ 0.3% BASE**	**A064093**	**001**	Aug 31, 1995
AT		PERRIGO CO TENNESSEE	**EQ 0.3% BASE**	**A065024**	**001**	Jul 30, 2004

OINTMENT;TOPICAL

GENTAMICIN SULFATE

AT		FOUGERA PHARMS INC	**EQ 0.1% BASE**	**A062533**	**001**	Oct 05, 1984
AT		G AND W LABS INC	**EQ 0.1% BASE**	**A064054**	**001**	Apr 29, 1994
AT	**!**	PERRIGO NEW YORK	**EQ 0.1% BASE**	**A062351**	**001**	Feb 18, 1982
AT		TARO	**EQ 0.1% BASE**	**A062477**	**001**	Dec 23, 1983
AT		TELIGENT PHARMA INC	**EQ 0.1% BASE**	**A209233**	**001**	Dec 31, 2018

SOLUTION/DROPS;OPHTHALMIC

GENOPTIC

AT	**!**	ALLERGAN	**EQ 0.3% BASE**	**A062452**	**001**	Oct 10, 1984

GENTAK

AT		AKORN	**EQ 0.3% BASE**	**A064163**	**001**	Oct 12, 2001

GENTAMICIN SULFATE

AT		AKORN	**EQ 0.3% BASE**	**A062635**	**001**	Jan 08, 1987
AT		BAUSCH AND LOMB	**EQ 0.3% BASE**	**A064048**	**001**	May 11, 1994
AT		PERRIGO CO TENNESSEE	**EQ 0.3% BASE**	**A065121**	**001**	Jan 30, 2004
AT		SANDOZ INC	**EQ 0.3% BASE**	**A062196**	**001**	

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

OINTMENT;OPHTHALMIC

PRED-G

	+!	ALLERGAN	EQ 0.3% BASE;0.6%	N050612	001	Dec 01, 1989

SUSPENSION/DROPS;OPHTHALMIC

PRED-G

	+!	ALLERGAN	EQ 0.3% BASE;1%	N050586	001	Jun 10, 1988

GILTERITINIB FUMARATE

TABLET;ORAL

XOSPATA

	+!	ASTELLAS	EQ 40MG BASE	N211349	001	Nov 28, 2018

GLASDEGIB

TABLET;ORAL

DAURISMO

	+	PFIZER INC	25MG	N210656	001	Nov 21, 2018
	+!		100MG	N210656	002	Nov 21, 2018

GLATIRAMER ACETATE

INJECTABLE;SUBCUTANEOUS

COPAXONE

AP	**+!**	TEVA PHARMS USA	**20MG/ML**	**N020622**	**002**	Feb 12, 2002
AP	**+!**		**40MG/ML**	**N020622**	**003**	Jan 28, 2014

GLATIRAMER ACETATE

AP		MYLAN PHARMS INC	**20MG/ML**	**A091646**	**001**	Oct 03, 2017
AP			**40MG/ML**	**A206936**	**001**	Oct 03, 2017

GLATOPA

AP		SANDOZ INC	**20MG/ML**	**A090218**	**001**	Apr 16, 2015
AP			**40MG/ML**	**A206921**	**001**	Feb 12, 2018

GLECAPREVIR; PIBRENTASVIR

TABLET;ORAL

MAVYRET

	+!	ABBVIE INC	100MG;40MG	N209394	001	Aug 03, 2017

GLIMEPIRIDE

TABLET;ORAL

AMARYL

AB	**+!**	SANOFI AVENTIS US	**1MG**	**N020496**	**001**	Nov 30, 1995
AB	**+**		**2MG**	**N020496**	**002**	Nov 30, 1995
AB	**+**		**4MG**	**N020496**	**003**	Nov 30, 1995

GLIMEPIRIDE

AB		ACCORD HLTHCARE	**1MG**	**A078181**	**001**	Aug 23, 2007
AB			**2MG**	**A078181**	**002**	Aug 23, 2007
AB			**4MG**	**A078181**	**003**	Aug 23, 2007
AB		AUROBINDO PHARMA	**1MG**	**A202759**	**001**	Jun 29, 2012

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

		LTD				
AB			**2MG**	**A202759**	**002**	Jun 29, 2012
AB			**4MG**	**A202759**	**003**	Jun 29, 2012
AB		CARLSBAD	**1MG**	**A077911**	**001**	Sep 22, 2009
AB			**2MG**	**A077911**	**002**	Sep 22, 2009
AB			**4MG**	**A077911**	**003**	Sep 22, 2009
AB		DR REDDYS LABS LTD	**1MG**	**A077091**	**001**	Oct 06, 2005
AB			**2MG**	**A077091**	**002**	Oct 06, 2005
AB			**4MG**	**A077091**	**003**	Oct 06, 2005
AB		INDOCO REMEDIES	**1MG**	**A202112**	**001**	Apr 17, 2013
AB			**2MG**	**A202112**	**002**	Apr 17, 2013
AB			**4MG**	**A202112**	**003**	Apr 17, 2013
AB		INVAGEN PHARMS	**1MG**	**A077295**	**001**	Oct 06, 2005
AB			**2MG**	**A077295**	**002**	Oct 06, 2005
AB			**4MG**	**A077295**	**003**	Oct 06, 2005
AB		MYLAN	**1MG**	**A077624**	**001**	Nov 28, 2005
AB			**2MG**	**A077624**	**002**	Nov 28, 2005
AB			**4MG**	**A077624**	**003**	Nov 28, 2005
AB		PRINSTON INC	**1MG**	**A077370**	**001**	Dec 23, 2005
AB			**2MG**	**A077370**	**002**	Dec 23, 2005
AB			**4MG**	**A077370**	**003**	Dec 23, 2005
AB			**8MG**	**A077370**	**004**	Dec 23, 2005
AB		TEVA	**1MG**	**A076802**	**001**	Oct 06, 2005
AB			**2MG**	**A076802**	**002**	Oct 06, 2005
AB			**4MG**	**A076802**	**003**	Oct 06, 2005
AB		VIVA HLTHCARE	**1MG**	**A091220**	**001**	Jun 29, 2012
AB			**2MG**	**A091220**	**002**	Jun 29, 2012
AB			**4MG**	**A091220**	**004**	Jun 29, 2012
AB			**8MG**	**A091220**	**006**	Jun 29, 2012
			3MG	A091220	003	Jun 29, 2012
			6MG	A091220	005	Jun 29, 2012

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

DUETACT

AB	**+!**	TAKEDA PHARMS USA	**2MG;30MG**	**N021925**	**001**	Jul 28, 2006
AB	**+**		**4MG;30MG**	**N021925**	**002**	Jul 28, 2006

PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE

AB		SANDOZ	**2MG;30MG**	**A201049**	**001**	Jan 04, 2013
AB			**4MG;30MG**	**A201049**	**002**	Jan 04, 2013

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

AB		ACCORD HLTHCARE	**5MG**	**A074550**	**001**	Sep 11, 1997
AB			**10MG**	**A074550**	**002**	Sep 11, 1997
AB		ANI PHARMS INC	**5MG**	**A074497**	**001**	Aug 31, 1995
AB			**10MG**	**A074497**	**002**	Aug 31, 1995
AB		APOTEX	**5MG**	**A075795**	**001**	Jun 13, 2001
AB			**10MG**	**A075795**	**002**	Jun 13, 2001
AB		MYLAN	**5MG**	**A074226**	**001**	May 10, 1994
AB			**10MG**	**A074226**	**002**	May 10, 1994
AB		SANDOZ	**5MG**	**A074305**	**001**	Apr 07, 1995
AB			**10MG**	**A074305**	**002**	Apr 07, 1995
AB		SUN PHARM INDS INC	**5MG**	**A077820**	**001**	Jul 11, 2006
AB			**10MG**	**A077820**	**002**	Jul 11, 2006
AB		WATSON LABS TEVA	**5MG**	**A074223**	**001**	Feb 27, 1995
AB			**10MG**	**A074223**	**002**	Feb 27, 1995

GLUCOTROL

AB	**+**	PFIZER	**5MG**	**N017783**	**001**	May 08, 1984
AB	**+!**		**10MG**	**N017783**	**002**	May 08, 1984

TABLET, EXTENDED RELEASE;ORAL

GLIPIZIDE

AB		AUROBINDO PHARMA LTD	**2.5MG**	**A206928**	**001**	May 12, 2017
AB			**5MG**	**A206928**	**002**	May 12, 2017
AB			**10MG**	**A206928**	**003**	May 12, 2017
AB		MYLAN PHARMS INC	**2.5MG**	**A202298**	**001**	May 19, 2015
AB			**5MG**	**A202298**	**002**	May 19, 2015
AB			**10MG**	**A202298**	**003**	May 19, 2015
AB		PAR PHARM	**5MG**	**A076159**	**002**	Sep 20, 2013

GLIPIZIDE

TABLET, EXTENDED RELEASE;ORAL

GLIPIZIDE

AB			**10MG**	**A076159**	**001**	Sep 20, 2013
AB		UNIQUE PHARM LABS	**2.5MG**	**A204720**	**001**	Dec 29, 2016
AB			**5MG**	**A204720**	**002**	Dec 29, 2016
AB			**10MG**	**A204720**	**003**	Dec 29, 2016
AB		WATSON LABS	**2.5MG**	**A076467**	**003**	Mar 27, 2006
AB			**5MG**	**A076467**	**001**	Sep 08, 2003
AB			**10MG**	**A076467**	**002**	Nov 07, 2003
AB		ZYDUS PHARMS USA INC	**2.5MG**	**A203499**	**001**	Jul 16, 2018
AB			**5MG**	**A203499**	**002**	Jul 16, 2018
AB			**10MG**	**A203499**	**003**	Jul 16, 2018

GLUCOTROL XL

AB	**+**	PFIZER	**2.5MG**	**N020329**	**003**	Aug 10, 1999
AB	**+**		**5MG**	**N020329**	**001**	Apr 26, 1994
AB	**+!**		**10MG**	**N020329**	**002**	Apr 26, 1994

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB		EPIC PHARMA LLC	**2.5MG;250MG**	**A077507**	**001**	Oct 27, 2005
AB			**2.5MG;500MG**	**A077507**	**002**	Oct 27, 2005
AB			**5MG;500MG**	**A077507**	**003**	Oct 27, 2005
AB		HERITAGE PHARMS INC	**2.5MG;250MG**	**A078728**	**001**	Jun 23, 2010
AB			**2.5MG;500MG**	**A078728**	**002**	Jun 23, 2010
AB			**5MG;500MG**	**A078728**	**003**	Jun 23, 2010
AB		MYLAN	**2.5MG;250MG**	**A078083**	**001**	Apr 12, 2007
AB			**2.5MG;500MG**	**A078083**	**002**	Apr 12, 2007
AB			**5MG;500MG**	**A078083**	**003**	Apr 12, 2007
AB		SUN PHARM INDS INC	**2.5MG;250MG**	**A077620**	**001**	Jan 11, 2008
AB			**2.5MG;500MG**	**A077620**	**002**	Jan 11, 2008
AB			**5MG;500MG**	**A077620**	**003**	Jan 11, 2008
AB		TEVA PHARMS	**2.5MG;250MG**	**A077270**	**001**	Oct 28, 2005
AB			**2.5MG;500MG**	**A077270**	**002**	Oct 28, 2005
AB	**!**		**5MG;500MG**	**A077270**	**003**	Oct 28, 2005
AB		ZYDUS PHARMS USA INC	**2.5MG;250MG**	**A078905**	**001**	Jan 31, 2011
AB			**2.5MG;500MG**	**A078905**	**002**	Jan 31, 2011
AB			**5MG;500MG**	**A078905**	**003**	Jan 31, 2011

GLUCAGON

INJECTABLE;INJECTION

GLUCAGON

	+!	LILLY	1MG/VIAL	N020928	001	Sep 11, 1998

GLUCAGON HYDROCHLORIDE

INJECTABLE;INJECTION

GLUCAGEN

	+!	NOVO NORDISK	EQ 1MG BASE/VIAL	N020918	001	Jun 22, 1998

POWDER;INTRAMUSCULAR, INTRAVENOUS

GLUCAGON

	+!	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849	001	May 08, 2015

GLYBURIDE

TABLET;ORAL

GLYBURIDE (MICRONIZED)

AB		DAVA PHARMS INC	**1.5MG**	**A074591**	**001**	Dec 22, 1997
AB			**3MG**	**A074591**	**002**	Dec 22, 1997
AB			**4.5MG**	**A074591**	**003**	Dec 22, 1997
AB			**6MG**	**A074591**	**004**	Dec 22, 1997
AB		HIKMA	**1.5MG**	**A075890**	**001**	Jul 31, 2003
AB			**3MG**	**A075890**	**002**	Jul 31, 2003
AB			**6MG**	**A075890**	**003**	Jul 31, 2003
AB		MYLAN	**1.5MG**	**A074792**	**001**	Jun 26, 1998
AB			**3MG**	**A074792**	**002**	Jun 26, 1998
AB			**6MG**	**A074792**	**003**	Aug 17, 1999
AB		TEVA	**1.5MG**	**A074686**	**001**	Apr 20, 1999
AB			**3MG**	**A074686**	**002**	Apr 20, 1999
AB			**4.5MG**	**A074686**	**003**	Apr 20, 1999
AB			**6MG**	**A074686**	**004**	Apr 20, 1999

GLYNASE

AB	**+**	PHARMACIA AND UPJOHN	**1.5MG**	**N020051**	**001**	Mar 04, 1992

GLYBURIDE

TABLET;ORAL

GLYNASE

AB	**+**		**3MG**	**N020051**	**002**	Mar 04, 1992
AB	**+!**		**6MG**	**N020051**	**004**	Sep 24, 1993

GLYBURIDE

AB1		AUROBINDO PHARMA	**1.25MG**	**A077537**	**001**	Oct 18, 2007
AB1			**2.5MG**	**A077537**	**002**	Oct 18, 2007
AB1			**5MG**	**A077537**	**003**	Oct 18, 2007
AB1		CADILA PHARMS LTD	**1.25MG**	**A203379**	**001**	Jan 04, 2019
AB1			**2.5MG**	**A203379**	**002**	Jan 04, 2019
AB1			**5MG**	**A203379**	**003**	Jan 04, 2019
AB1		EPIC PHARMA LLC	**1.25MG**	**A076257**	**001**	Jun 27, 2002
AB1			**2.5MG**	**A076257**	**002**	Jun 27, 2002
AB1			**5MG**	**A076257**	**003**	Jun 27, 2002
AB1		HERITAGE PHARMS INC	**1.25MG**	**A090937**	**001**	Feb 28, 2011
AB1			**2.5MG**	**A090937**	**002**	Feb 28, 2011
AB1			**5MG**	**A090937**	**003**	Feb 28, 2011
AB1		PHARMADAX INC	**1.25MG**	**A203581**	**001**	Apr 14, 2016
AB1			**2.5MG**	**A203581**	**002**	Apr 14, 2016
AB1			**5MG**	**A203581**	**003**	Apr 14, 2016
AB1		TEVA	**1.25MG**	**A074388**	**001**	Aug 29, 1995
AB1			**2.5MG**	**A074388**	**002**	Aug 29, 1995
AB1	**!**		**5MG**	**A074388**	**003**	Aug 29, 1995
AB1		ZYDUS PHARMS USA INC	**1.25mg**	**A206749**	**001**	May 10, 2016
AB1			**2.5mg**	**A206749**	**002**	May 10, 2016
AB1			**5MG**	**A206749**	**003**	May 10, 2016

DIABETA

AB2	**+**	SANOFI AVENTIS US	**1.25MG**	**N017532**	**001**	May 01, 1984
AB2	**+**		**2.5MG**	**N017532**	**002**	May 01, 1984
AB2	**+!**		**5MG**	**N017532**	**003**	May 01, 1984

GLYBURIDE

AB2		IMPAX LABS INC	**1.25MG**	**A206079**	**001**	Sep 30, 2015
AB2			**2.5MG**	**A206079**	**002**	Sep 30, 2015
AB2			**5MG**	**A206079**	**003**	Sep 30, 2015

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**1.25MG;250MG**	**A076716**	**001**	Jun 28, 2005
AB			**2.5MG;500MG**	**A076716**	**002**	Jun 28, 2005
AB			**5MG;500MG**	**A076716**	**003**	Jun 28, 2005
AB		AUROBINDO PHARMA	**1.25MG;250MG**	**A077870**	**001**	Nov 14, 2007
AB	**!**		**2.5MG;500MG**	**A077870**	**002**	Nov 14, 2007
AB			**5MG;500MG**	**A077870**	**003**	Nov 14, 2007
AB		HERITAGE PHARMS INC	**1.25MG;250MG**	**A079009**	**001**	Jun 03, 2009
AB			**2.5MG;500MG**	**A079009**	**002**	Jun 03, 2009
AB			**5MG;500MG**	**A079009**	**003**	Jun 03, 2009
AB		IMPAX LABS INC	**1.25MG;250MG**	**A076345**	**001**	Feb 18, 2004
AB			**2.5MG;500MG**	**A076345**	**002**	Feb 18, 2004
AB			**5MG;500MG**	**A076345**	**003**	Feb 18, 2004
AB		ZYDUS PHARMS USA INC	**1.25MG;250MG**	**A206748**	**001**	Feb 29, 2016
AB			**2.5MG;500MG**	**A206748**	**002**	Feb 29, 2016
AB			**5MG;500MG**	**A206748**	**003**	Feb 29, 2016

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL

RAVICTI

	+!	HORIZON THERAPS INC	1.1GM/ML	N203284	001	Feb 01, 2013

GLYCINE

SOLUTION;IRRIGATION

AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER

AT	**+!**	BAXTER HLTHCARE	**1.5GM/100ML**	**N017865**	**001**	

GLYCINE 1.5% IN PLASTIC CONTAINER

AT		B BRAUN	**1.5GM/100ML**	**N016784**	**001**	
AT		ICU MEDICAL INC	**1.5GM/100ML**	**N018315**	**001**	

GLYCOPYRROLATE

INJECTABLE;INJECTION

GLYCOPYRROLATE

AP		AMNEAL PHARMS CO	**0.2MG/ML**	**A208973**	**001**	Jun 15, 2017
AP		AUROBINDO PHARMA LTD	**0.2MG/ML**	**A210244**	**001**	Nov 28, 2018
AP		FRESENIUS KABI USA	**0.2MG/ML**	**A209024**	**001**	Oct 31, 2018
AP			**0.2MG/ML**	**A209328**	**001**	Oct 27, 2017
AP	**!**	HIKMA FARMACEUTICA	**0.2MG/ML**	**A090963**	**001**	Sep 21, 2011
AP		LUITPOLD	**0.2MG/ML**	**A089335**	**001**	Jul 23, 1986
AP		PIRAMAL CRITICAL	**0.2MG/ML**	**A210842**	**001**	Oct 25, 2018
AP		PRINSTON INC	**0.2MG/ML**	**A210927**	**001**	Oct 31, 2018
AP		SOMERSET THERAPS LLC	**0.2MG/ML**	**A207639**	**001**	Jun 23, 2017

POWDER;INHALATION

SEEBRI

	+!	SUNOVION PHARMS INC	15.6MCG/INH	N207923	001	Oct 29, 2015

SOLUTION;INHALATION

LONHALA MAGNAIR KIT

	+!	SUNOVION RESP	25MCG/ML	N208437	001	Dec 05, 2017

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

GLYRX-PF

		EXELA PHARMA SCS LLC	0.2MG/ML (0.2MG/ML)	N210997	001	Jul 11, 2018
			0.4MG/2ML (0.2MG/ML)	N210997	002	Jul 11, 2018

SOLUTION;ORAL

CUVPOSA

	+!	MERZ PHARMS	1MG/5ML	N022571	001	Jul 28, 2010

TABLET;ORAL

GLYCOPYRROLATE

AA		AUROLIFE PHARMA LLC	**1MG**	**A202675**	**001**	Apr 15, 2013
AA		BOSCOGEN	**1MG**	**A091182**	**001**	Feb 03, 2014
AA			**2MG**	**A091182**	**002**	Feb 03, 2014
AA		DR REDDYS LABS LTD	**1MG**	**A040847**	**001**	Mar 21, 2008
AA			**2MG**	**A040847**	**002**	Mar 21, 2008
AA		HERITAGE PHARMS INC	**1MG**	**A207201**	**001**	Jan 03, 2017
AA			**2MG**	**A207201**	**002**	Jan 03, 2017
AA		LEADING PHARMA LLC	**1MG**	**A090195**	**001**	Sep 21, 2012
AA			**2MG**	**A090195**	**002**	Sep 21, 2012
AA		NATCO PHARMA LTD	**1MG**	**A091413**	**001**	Jun 20, 2016
AA			**2MG**	**A091413**	**002**	Jun 20, 2016
AA		ORIT LABS LLC	**1MG**	**A203657**	**001**	Nov 30, 2018
AA			**2MG**	**A203657**	**002**	Nov 30, 2018
AA		OXFORD PHARMS	**1MG**	**A090020**	**001**	Oct 19, 2011
AA			**2MG**	**A090020**	**002**	Oct 19, 2011
AA	**!**	PAR PHARM	**1MG**	**A040653**	**001**	Aug 31, 2006
AA	**!**		**2MG**	**A040653**	**002**	Aug 31, 2006
AA		RISING PHARMS	**1MG**	**A040821**	**001**	Dec 29, 2008
AA			**2MG**	**A040821**	**002**	Dec 29, 2008
AA		SUN PHARM INDS LTD	**1MG**	**A040844**	**001**	Aug 18, 2009
AA			**2MG**	**A040844**	**002**	Aug 18, 2009
		NEXGEN PHARMA	1.5MG	A091522	001	Mar 12, 2012

GLYCOPYRROLATE ; INDACATEROL MALEATE

POWDER;INHALATION

UTIBRON

	+!	SUNOVION PHARMS INC	15.6MCG/INH;27.5MCG/INH	N207930	001	Oct 29, 2015

GLYCOPYRRONIUM TOSYLATE

CLOTH;TOPICAL

QBREXZA

	+!	DERMIRA INC	EQ 2.4% BASE	N210361	001	Jun 28, 2018

GONADOTROPIN, CHORIONIC

INJECTABLE;INJECTION

CHORIONIC GONADOTROPIN

AP	**+!**	FERRING	**10,000 UNITS/VIAL**	**N017016**	**007**	
AP	**+!**	FRESENIUS KABI USA	**10,000 UNITS/VIAL**	**N017067**	**002**	

PREGNYL

AP	**+!**	ORGANON USA INC	**10,000 UNITS/VIAL**	**N017692**	**001**	

CHORIONIC GONADOTROPIN

	+!	FERRING	5,000 UNITS/VIAL	N017016	006	

GOSERELIN ACETATE

IMPLANT;IMPLANTATION

ZOLADEX

	+!	TERSERA THERAPS LLC	EQ 3.6MG BASE	N019726	001	Dec 29, 1989
	+!		EQ 10.8MG BASE	N020578	001	Jan 11, 1996

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT		AMRING PHARMS	**0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML**	**A065187**	**001**	Oct 28, 2005
AT	**!**	BAUSCH AND LOMB	**0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML**	**A064047**	**001**	Jan 31, 1996

NEOSPORIN

AT	**!**	MONARCH PHARMS	**0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML**	**A060582**	**001**	

GRANISETRON

FILM, EXTENDED RELEASE;TRANSDERMAL

SANCUSO

	+!	KYOWA KIRIN	3.1MG/24HR	N022198	001	Sep 12, 2008

INJECTION, EXTENDED RELEASE;SUBCUTANEOUS

SUSTOL

	+!	HERON THERAPS INC	10MG/0.4ML (10MG/0.4ML)	N022445	001	Aug 09, 2016

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

AP		AKORN INC	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A079119**	**001**	Sep 10, 2009
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A079078**	**001**	Sep 14, 2009
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A079078**	**002**	Sep 14, 2009
AP		AUROBINDO PHARMA LTD	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A204238**	**001**	Jul 06, 2016
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A204238**	**002**	Jul 06, 2016
AP		BLUEPHARMA	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078863**	**001**	Jun 30, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078880**	**001**	Jun 30, 2008
AP		CIPLA LTD	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078262**	**001**	Dec 31, 2007
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078258**	**001**	Jun 30, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078258**	**002**	Jun 30, 2008
AP		FRESENIUS KABI USA	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078522**	**001**	Dec 31, 2007
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078090**	**001**	Jun 30, 2008
AP		HIKMA FARMACEUTICA	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078629**	**001**	Dec 23, 2009
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078629**	**002**	Dec 23, 2009
AP		LUITPOLD	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A091274**	**001**	Sep 22, 2010
AP		MYLAN ASI	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A091136**	**001**	Apr 09, 2010
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A091136**	**002**	Apr 09, 2010
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A091137**	**002**	Apr 09, 2010
AP		MYLAN LABS LTD	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A203454**	**001**	Apr 04, 2017
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A203454**	**002**	Apr 04, 2017
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A203453**	**001**	Jan 31, 2017
AP		SANDOZ INC	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078534**	**001**	Apr 30, 2009
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078531**	**001**	Apr 30, 2009
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078835**	**001**	Jun 30, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078531**	**002**	Apr 30, 2009
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078835**	**002**	Jun 30, 2008
AP	**!**	TEVA PHARMS USA	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078392**	**001**	Dec 31, 2007
AP	**!**		**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A077297**	**001**	Jun 30, 2008
AP		WEST-WARD PHARMS INT	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A077913**	**001**	Jun 26, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A077186**	**001**	Jun 30, 2008
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A077187**	**001**	Jun 30, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A077177**	**001**	Dec 31, 2007
AP		WOCKHARDT USA	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078566**	**001**	Feb 29, 2008
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078564**	**001**	Jun 30, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078565**	**001**	Jun 30, 2008

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

AP		BLUEPHARMA	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078863**	**002**	Jun 30, 2008
AP	**!**	FRESENIUS KABI USA	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078096**	**001**	Jun 30, 2008

TABLET;ORAL

GRANISETRON HYDROCHLORIDE

AB		APOTEX INC	**EQ 1MG BASE**	**A078843**	**001**	Feb 27, 2008
AB		CHARTWELL MOLECULAR	**EQ 1MG BASE**	**A078037**	**001**	Feb 27, 2008
AB		DR REDDYS LABS LTD	**EQ 1MG BASE**	**A078846**	**001**	Feb 27, 2009
AB		MYLAN	**EQ 1MG BASE**	**A078725**	**001**	Jan 30, 2008
AB		NATCO PHARMA	**EQ 1MG BASE**	**A078969**	**001**	Jun 22, 2009

GRANISETRON HYDROCHLORIDE

TABLET;ORAL

GRANISETRON HYDROCHLORIDE

AB		ORCHID HLTHCARE	**EQ 1MG BASE**	**A078678**	**001**	Feb 13, 2008
AB		TARO PHARM	**EQ 1MG BASE**	**A090817**	**001**	May 28, 2010
AB	**!**	TEVA PHARMS	**EQ 1MG BASE**	**A078080**	**001**	Dec 31, 2007
AB		WEST-WARD PHARMS INT	**EQ 1MG BASE**	**A077842**	**001**	Dec 31, 2007

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL

GRISEOFULVIN

AB	**!**	ACTAVIS MID ATLANTIC	**125MG/5ML**	**A065394**	**001**	Jul 06, 2007
AB		CHARTWELL RX	**125MG/5ML**	**A065200**	**001**	Mar 02, 2005
AB		CIPLA	**125MG/5ML**	**A065354**	**001**	Sep 10, 2007
AB		VINTAGE PHARMS	**125MG/5ML**	**A065438**	**001**	Oct 08, 2010

TABLET;ORAL

GRISEOFULVIN

AB	**!**	SANDOZ INC	**500MG**	**A091592**	**002**	Aug 07, 2013
AB		SIGMAPHARM LABS LLC	**500MG**	**A202482**	**001**	Oct 22, 2012
		SANDOZ INC	250MG	A091592	001	Aug 07, 2013

GRISEOFULVIN, ULTRAMICROSIZE

TABLET;ORAL

GRIS-PEG

AB	**+**	VALEANT PHARMS INC	**125MG**	**N050475**	**001**	
AB	**+!**		**250MG**	**N050475**	**002**	

GRISEOFULVIN, ULTRAMICROSIZE

AB		MOUNTAIN	**125MG**	**A204371**	**001**	Jan 09, 2014
AB			**250MG**	**A204371**	**002**	Jan 09, 2014
AB		SANDOZ INC	**125MG**	**A202805**	**001**	Dec 26, 2018
AB			**250MG**	**A202805**	**002**	Dec 26, 2018

GRISEOFULVIN,ULTRAMICROSIZE

AB		SIGMAPHARM LABS LLC	**125MG**	**A202545**	**001**	Oct 22, 2012
AB			**250MG**	**A202545**	**002**	Oct 22, 2012

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

OBREDON

	+!	SOVEREIGN PHARMS	200MG/5ML;2.5MG/5ML	N205474	001	Nov 14, 2014

TABLET;ORAL

XTRELUS

	+!	ECI PHARMS LLC	400MG;5MG	N208085	001	Apr 25, 2018

GUANABENZ ACETATE

TABLET;ORAL

GUANABENZ ACETATE

		ANI PHARMS INC	EQ 4MG BASE	A074149	001	Apr 07, 1995
	!		EQ 8MG BASE	A074149	002	Apr 07, 1995

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

AB		AMNEAL PHARM	**EQ 1MG BASE**	**A075109**	**001**	Nov 25, 1998
AB			**EQ 2MG BASE**	**A075109**	**002**	Nov 25, 1998
AB	**!**	MYLAN	**EQ 1MG BASE**	**A074796**	**001**	Jan 27, 1997
AB	**!**		**EQ 2MG BASE**	**A074796**	**002**	Jan 27, 1997
AB		WATSON LABS	**EQ 1MG BASE**	**A074145**	**001**	Oct 17, 1995
AB			**EQ 2MG BASE**	**A074145**	**002**	Oct 17, 1995

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**EQ 1MG BASE**	**A200881**	**001**	Oct 05, 2012
AB			**EQ 2MG BASE**	**A200881**	**002**	Oct 05, 2012
AB			**EQ 3MG BASE**	**A200881**	**003**	Oct 05, 2012
AB			**EQ 4MG BASE**	**A200881**	**004**	Oct 05, 2012
AB		APOTEX INC	**EQ 1MG BASE**	**A205430**	**001**	Jul 25, 2018
AB			**EQ 2MG BASE**	**A205430**	**002**	Jul 25, 2018
AB			**EQ 3MG BASE**	**A205430**	**003**	Jul 25, 2018
AB			**EQ 4MG BASE**	**A205430**	**004**	Jul 25, 2018
AB		MYLAN PHARMS INC	**EQ 1MG BASE**	**A202578**	**001**	Jun 02, 2015
AB			**EQ 2MG BASE**	**A202578**	**002**	Jun 02, 2015
AB			**EQ 3MG BASE**	**A202578**	**003**	Jun 02, 2015
AB			**EQ 4MG BASE**	**A202578**	**004**	Jun 02, 2015
AB		SANDOZ INC	**EQ 1MG BASE**	**A202568**	**001**	Jun 03, 2015

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE						
AB			**EQ 2MG BASE**	**A202568**	**002**	Jun 03, 2015
AB			**EQ 3MG BASE**	**A202568**	**003**	Jun 03, 2015
AB			**EQ 4MG BASE**	**A202568**	**004**	Jun 03, 2015
AB		SUN PHARM INDS LTD	**EQ 1MG BASE**	**A205689**	**001**	Nov 16, 2017
AB			**EQ 2MG BASE**	**A205689**	**002**	Nov 16, 2017
AB			**EQ 3MG BASE**	**A205689**	**003**	Nov 16, 2017
AB			**EQ 4MG BASE**	**A205689**	**004**	Nov 16, 2017
AB		TEVA PHARMS USA	**EQ 1MG BASE**	**A201382**	**001**	Jun 02, 2015
AB			**EQ 2MG BASE**	**A201382**	**002**	Jun 02, 2015
AB			**EQ 3MG BASE**	**A201382**	**003**	Jun 02, 2015
AB			**EQ 4MG BASE**	**A201382**	**004**	Jun 02, 2015
AB		TWI PHARMS	**EQ 1MG BASE**	**A201408**	**001**	Jun 02, 2015
AB			**EQ 2MG BASE**	**A201408**	**002**	Jun 02, 2015
AB			**EQ 3MG BASE**	**A201408**	**003**	Jun 02, 2015
AB			**EQ 4MG BASE**	**A201408**	**004**	Jun 02, 2015
INTUNIV						
AB	**+**	SHIRE	**EQ 1MG BASE**	**N022037**	**001**	Sep 02, 2009
AB	**+**		**EQ 2MG BASE**	**N022037**	**002**	Sep 02, 2009
AB	**+**		**EQ 3MG BASE**	**N022037**	**003**	Sep 02, 2009
AB	**+!**		**EQ 4MG BASE**	**N022037**	**004**	Sep 02, 2009

GUANIDINE HYDROCHLORIDE

TABLET;ORAL

GUANIDINE HYDROCHLORIDE					
		MERCK SHARP DOHME	125MG	N001546	001

HALCINONIDE

CREAM;TOPICAL

HALOG					
	+!	SUN PHARM INDS INC	0.1%	N017556	001

OINTMENT;TOPICAL

HALOG					
	+!	SUN PHARM INDS INC	0.1%	N017824	001

HALOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

HALOBETASOL PROPIONATE						
	+!	MAYNE PHARMA	0.05%	N210566	001	May 24, 2018

CREAM;TOPICAL

HALOBETASOL PROPIONATE						
AB		FOUGERA PHARMS	**0.05%**	**A077001**	**001**	Dec 16, 2004
AB	**!**	G AND W LABS	**0.05%**	**A078162**	**001**	Apr 24, 2007
AB		PERRIGO ISRAEL	**0.05%**	**A077123**	**001**	Dec 16, 2004
AB		TARO	**0.05%**	**A077227**	**001**	Aug 04, 2005
ULTRAVATE						
AB	**+**	SUN PHARM INDS INC	**0.05%**	**N019967**	**001**	Dec 27, 1990

LOTION;TOPICAL

BRYHALI						
		DOW PHARM	0.01%	N209355	001	Nov 06, 2018
ULTRAVATE						
	+!	SUN PHARM INDUSTRIES	0.05%	N208183	001	Nov 06, 2015

OINTMENT;TOPICAL

HALOBETASOL PROPIONATE						
AB	**!**	G AND W LABS	**0.05%**	**A077721**	**001**	Sep 07, 2006
AB		G AND W LABS INC	**0.05%**	**A077109**	**001**	Jun 14, 2005
AB		PERRIGO ISRAEL	**0.05%**	**A076872**	**001**	Dec 16, 2004
AB		TARO	**0.05%**	**A076994**	**001**	Dec 16, 2004
AB		TELIGENT PHARMA INC	**0.05%**	**A209978**	**001**	Mar 20, 2018
ULTRAVATE						
AB	**+**	SUN PHARM INDS INC	**0.05%**	**N019968**	**001**	Dec 17, 1990

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL						
AB		MYLAN	**0.5MG**	**A070278**	**006**	Jun 10, 1986
AB			**1MG**	**A070278**	**004**	Jun 10, 1986
AB			**2MG**	**A070278**	**001**	Jun 10, 1986
AB			**5MG**	**A070278**	**005**	Jun 10, 1986
AB			**10MG**	**A070278**	**002**	Jul 16, 2009
AB			**20MG**	**A070278**	**003**	Jul 16, 2009
AB		SANDOZ	**0.5MG**	**A071206**	**001**	Nov 17, 1986

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

AB			**1MG**	**A071207**	**001**	Nov 17, 1986
AB	!		**2MG**	**A071208**	**001**	Nov 17, 1986
AB			**5MG**	**A071209**	**001**	Nov 17, 1986
AB			**10MG**	**A071210**	**001**	Mar 11, 1988
AB			**20MG**	**A071211**	**001**	Mar 11, 1988
AB		ZYDUS PHARMS USA	**5MG**	**A077580**	**003**	Nov 29, 2007
AB			**10MG**	**A077580**	**004**	Nov 29, 2007
AB			**20MG**	**A077580**	**005**	Nov 29, 2007

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION

HALDOL

AO	+!	JANSSEN PHARMS	**EQ 50MG BASE/ML**	**N018701**	**001**	Jan 14, 1986
AO	+!		**EQ 100MG BASE/ML**	**N018701**	**002**	Jan 31, 1997

HALOPERIDOL DECANOATE

AO		FRESENIUS KABI USA	**EQ 50MG BASE/ML**	**A074893**	**001**	Dec 19, 1997
AO			**EQ 100MG BASE/ML**	**A074893**	**002**	Dec 19, 1997
AO		GLAND PHARMA LTD	**EQ 50MG BASE/ML**	**A205241**	**001**	May 12, 2017
AO			**EQ 100MG BASE/ML**	**A205241**	**002**	May 12, 2017
AO		MYLAN LABS LTD	**EQ 50MG BASE/ML**	**A075440**	**001**	Feb 28, 2000
AO			**EQ 100MG BASE/ML**	**A075440**	**002**	Feb 28, 2000
AO		SOMERSET THERAPS LLC	**EQ 50MG BASE/ML**	**A209101**	**001**	Jul 03, 2018
AO			**EQ 100MG BASE/ML**	**A209101**	**002**	Jul 03, 2018
AO		TEVA PHARMS USA	**EQ 50MG BASE/ML**	**A075393**	**001**	May 11, 1999
AO			**EQ 100MG BASE/ML**	**A075393**	**002**	May 11, 1999
AO		WEST-WARD PHARMS INT	**EQ 50MG BASE/ML**	**A074811**	**001**	Jan 30, 1998
AO			**EQ 100MG BASE/ML**	**A075305**	**001**	Sep 28, 1998

HALOPERIDOL LACTATE

CONCENTRATE;ORAL

HALOPERIDOL

AA		LANNETT CO INC	**EQ 2MG BASE/ML**	**A073364**	**001**	Sep 28, 1993
AA		PHARM ASSOC	**EQ 2MG BASE/ML**	**A073037**	**001**	Feb 26, 1993
AA	!	TEVA PHARMS	**EQ 2MG BASE/ML**	**A071617**	**001**	Dec 01, 1988

INJECTABLE;INJECTION

HALDOL

AP	+!	JANSSEN PHARMS	**EQ 5MG BASE/ML**	**N015923**	**001**	

HALOPERIDOL

AP		AKORN	**EQ 5MG BASE/ML**	**A204849**	**001**	Sep 06, 2017
AP		FRESENIUS KABI USA	**EQ 5MG BASE/ML**	**A075689**	**001**	Mar 09, 2001
AP		GLAND PHARMA LTD	**EQ 5MG BASE/ML**	**A076774**	**001**	Aug 25, 2004
AP		MYLAN LABS LTD	**EQ 5MG BASE/ML**	**A078347**	**001**	Sep 14, 2009
AP		SAGENT PHARMS	**EQ 5MG BASE/ML**	**A091637**	**001**	Sep 02, 2011
AP			**EQ 5MG BASE/ML**	**A200742**	**001**	Sep 02, 2011
AP		TEVA PHARMS USA	**EQ 5MG BASE/ML**	**A076035**	**001**	Aug 29, 2001
AP		WEST-WARD PHARMS INT	**EQ 5MG BASE/ML**	**A075858**	**001**	Jun 18, 2001

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

AP		CASI PHARMS INC	**5,000 UNITS/ML**	**A091659**	**001**	Jun 08, 2011
AP	+!	FRESENIUS KABI USA	**1,000 UNITS/ML**	**N017029**	**001**	
AP			**5,000 UNITS/ML**	**A206552**	**001**	Jun 10, 2016
AP	+!		**5,000 UNITS/ML**	**N017651**	**006**	
AP	+!		**10,000 UNITS/ML**	**N017029**	**003**	
AP	+!		**20,000 UNITS/ML**	**N017029**	**004**	
AP		GLAND PHARMA LTD	**5,000 UNITS/ML**	**A205323**	**001**	Feb 06, 2017
AP		HOSPIRA INC	**1,000 UNITS/ML**	**A090571**	**001**	Aug 31, 2009
AP			**5,000 UNITS/ML**	**A090571**	**002**	Aug 31, 2009
AP			**10,000 UNITS/ML**	**A090571**	**003**	Aug 31, 2009
AP		MYLAN LABS LTD	**1,000 UNITS/ML**	**A203851**	**001**	Nov 30, 2017
AP			**5,000 UNITS/ML**	**A203851**	**002**	Nov 30, 2017
AP			**10,000 UNITS/ML**	**A203851**	**003**	Nov 30, 2017
AP			**20,000 UNITS/ML**	**A203852**	**001**	Nov 30, 2017
AP		NANJING KING-FRIEND	**1,000 UNITS/ML**	**A211005**	**001**	Dec 14, 2018
AP		SAGENT PHARMS	**1,000 UNITS/ML**	**A090808**	**001**	Jun 30, 2010
AP			**5,000 UNITS/ML**	**A090808**	**002**	Jun 30, 2010
AP			**10,000 UNITS/ML**	**A090808**	**003**	Jun 30, 2010

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

AP			**20,000 UNITS/ML**	**A090809**	**001**	Jun 30, 2010
AP		SANDOZ	**1,000 UNITS/ML**	**A091682**	**001**	Jun 08, 2011
AP			**5,000 UNITS/ML**	**A091682**	**002**	Jun 08, 2011
AP			**10,000 UNITS/ML**	**A201002**	**001**	Jun 08, 2011
AP		SHENZHEN TECHDOW	**1,000 UNITS/ML**	**A202957**	**001**	Jun 12, 2014
AP			**5,000 UNITS/ML**	**A202733**	**001**	Jun 12, 2014
AP			**5,000 UNITS/ML**	**A202957**	**002**	Jun 12, 2014
AP			**10,000 UNITS/ML**	**A203198**	**001**	Jun 12, 2014
AP			**20,000 UNITS/ML**	**A203198**	**002**	Jun 12, 2014
AP	**+!**	WEST-WARD PHARMS INT	**1,000 UNITS/ML**	**N017037**	**001**	
AP	**+!**		**5,000 UNITS/ML**	**N017037**	**002**	
AP	**+!**		**10,000 UNITS/ML**	**N017037**	**003**	

HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**200 UNITS/100ML**	**N018609**	**001**	Apr 28, 1982

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**200 UNITS/100ML**	**N019953**	**001**	Jul 20, 1992
AP	**+!**	HOSPIRA	**200 UNITS/100ML**	**N018916**	**010**	Jun 23, 1989

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		HOSPIRA	**10,000 UNITS/100ML**	**N019339**	**003**	Mar 27, 1985

HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**200 UNITS/100ML**	**N018609**	**002**	Apr 28, 1982

HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	**+!**	HOSPIRA	**200 UNITS/100ML**	**N018916**	**011**	Jun 23, 1989

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**4,000 UNITS/100ML**	**N019952**	**001**	Jul 20, 1992
AP		HOSPIRA	**4,000 UNITS/100ML**	**N019805**	**001**	Jan 25, 1989

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**5,000 UNITS/100ML**	**N019952**	**004**	Jul 20, 1992
AP	**+!**		**10,000 UNITS/100ML**	**N019952**	**005**	Jul 20, 1992
AP		HOSPIRA	**5,000 UNITS/100ML**	**N019339**	**004**	Mar 27, 1985
AP			**5,000 UNITS/100ML**	**N019805**	**002**	Jan 25, 1989
AP			**10,000 UNITS/100ML**	**N019339**	**002**	Mar 27, 1985

HEPARIN SODIUM IN PLASTIC CONTAINER

AP	**+!**	FRESENIUS KABI USA	**1,000 UNITS/ML**	**N017029**	**013**	Dec 05, 1985
AP	**+!**		**5,000 UNITS/ML**	**N017029**	**014**	Dec 05, 1985
AP	**+!**		**10,000 UNITS/ML**	**N017029**	**015**	Dec 05, 1985
AP	**+!**		**20,000 UNITS/ML**	**N017029**	**016**	Dec 05, 1985

HEPARIN SODIUM PRESERVATIVE FREE

AP	**+!**	FRESENIUS KABI USA	**1,000 UNITS/ML**	**N017029**	**010**	Apr 28, 1986
AP		SAGENT PHARMS	**1,000 UNITS/ML**	**A090810**	**001**	Jun 30, 2010
AP		SHENZHEN TECHDOW	**1,000 UNITS/ML**	**A202732**	**001**	Jun 12, 2014
		HEPARIN SODIUM				
	+!	FRESENIUS KABI USA	10,000 UNITS/ML	N017029	020	Mar 31, 2011
	!	HOSPIRA	5,000 UNITS/ML	A088100	001	Apr 28, 1983
	+!	PFIZER	1,000 UNITS/ML	N201370	001	Jul 21, 2011
	+!		5,000 UNITS/ML	N201370	002	Jul 21, 2011
	+!		10,000 UNITS/ML	N201370	003	Jul 21, 2011
		STERINOVA INC	5,000 UNITS/0.5ML	A208827	001	Nov 19, 2018
		HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
		HOSPIRA	5,000 UNITS/100ML	N019339	001	Mar 27, 1985
		HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
		HOSPIRA	5,000 UNITS/100ML	N018916	006	Jan 31, 1984
		HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
		HOSPIRA	5,000 UNITS/100ML	N018916	007	Jan 31, 1984
			10,000 UNITS/100ML	N018916	008	Jan 31, 1984
		HEPARIN SODIUM PRESERVATIVE FREE				
	+!	FRESENIUS KABI USA	10,000 UNITS/ML	N017029	019	Nov 22, 2010
	!	HOSPIRA	10,000 UNITS/ML	A089522	001	May 04, 1987
	+!	PFIZER	1,000 UNITS/ML	N201370	004	Jul 21, 2011

HEXACHLOROPHENE

SPONGE;TOPICAL

PRE-OP

AT	**+!**	DAVIS AND GECK	**480MG**	**N017433**	**001**	

PRE-OP II

AT	**+**	DAVIS AND GECK	**480MG**	**N017433**	**002**	

HEXAMINOLEVULINATE HYDROCHLORIDE							
FOR SOLUTION;INTRAVESICAL							
CYSVIEW KIT							
	+!	PHOTOCURE ASA	100MG/VIAL	N022555	001	May 28, 2010	
HISTRELIN ACETATE							
IMPLANT;SUBCUTANEOUS							
SUPPRELIN LA							
	+!	ENDO PHARM	50MG	N022058	001	May 03, 2007	
VANTAS							
	+!	ENDO PHARM	50MG	N021732	001	Oct 12, 2004	
HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE							
SYRUP;ORAL							
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE							
AA		ABHAI LLC	**1.5MG/5ML;5MG/5ML**	**A207487**	**001**	Feb 21, 2017	
AA		ACTAVIS MID ATLANTIC	**1.5MG/5ML;5MG/5ML**	**A088017**	**001**	Jul 05, 1983	
AA	**!**	HI TECH PHARMA	**1.5MG/5ML;5MG/5ML**	**A040613**	**001**	Feb 08, 2008	
AA		NOVEL LABS INC	**1.5MG/5ML;5MG/5ML**	**A203535**	**001**	Feb 13, 2017	
AA		PADDOCK LLC	**1.5MG/5ML;5MG/5ML**	**A205731**	**001**	Feb 15, 2017	
AA		WOCKHARDT BIO AG	**1.5MG/5ML;5MG/5ML**	**A088008**	**001**	Mar 03, 1983	
TABLET;ORAL							
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE							
AA		AVANTHI INC	**1.5MG;5MG**	**A207176**	**001**	Aug 07, 2017	
AA		NOVEL LABS INC	**1.5MG;5MG**	**A091528**	**001**	Apr 20, 2011	
TUSSIGON							
AA	**!**	KING PHARMS	**1.5MG;5MG**	**A088508**	**001**	Jul 30, 1985	
HYALURONIDASE							
INJECTABLE;INJECTION							
AMPHADASE							
	+!	AMPHASTAR PHARM	150 UNITS/ML	N021665	001	Oct 26, 2004	
VITRASE							
	+!	BAUSCH AND LOMB	200 UNITS/VIAL	N021640	002	Dec 02, 2004	
HYALURONIDASE RECOMBINANT HUMAN							
INJECTABLE;INJECTION							
HYLENEX RECOMBINANT							
	+!	HALOZYME THERAP	150 UNITS/ML	N021859	001	Dec 02, 2005	
HYDRALAZINE HYDROCHLORIDE							
INJECTABLE;INJECTION							
HYDRALAZINE HYDROCHLORIDE							
AP	**!**	AKORN	**20MG/ML**	**A040730**	**001**	Apr 21, 2009	
AP		FRESENIUS KABI USA	**20MG/ML**	**A040388**	**001**	Mar 13, 2001	
AP		LUITPOLD	**20MG/ML**	**A040136**	**001**	Jun 30, 1997	
AP		MYLAN INSTITUTIONAL	**20MG/ML**	**A204680**	**001**	Apr 28, 2016	
AP		NAVINTA LLC	**20MG/ML**	**A202938**	**001**	Mar 28, 2013	
AP		X-GEN PHARMS INC	**20MG/ML**	**A203110**	**001**	Jun 29, 2015	
TABLET;ORAL							
HYDRALAZINE HYDROCHLORIDE							
AA		ALKEM LABS LTD	**10MG**	**A200737**	**001**	Dec 07, 2012	
AA			**25MG**	**A200737**	**002**	Dec 07, 2012	
AA			**50MG**	**A200737**	**003**	Dec 07, 2012	
AA			**100MG**	**A200737**	**004**	Dec 07, 2012	
AA		APPCO PHARMA LLC	**10MG**	**A209251**	**001**	Jul 09, 2018	
AA			**25MG**	**A209251**	**002**	Jul 09, 2018	
AA			**50MG**	**A209251**	**003**	Jul 09, 2018	
AA			**100MG**	**A209251**	**004**	Jul 09, 2018	
AA		CADILA PHARMS LTD	**25MG**	**A203845**	**001**	Sep 18, 2014	
AA			**50MG**	**A203845**	**002**	Sep 18, 2014	
AA			**100MG**	**A203845**	**003**	Sep 18, 2014	
AA		GLENMARK PHARMS LTD	**10MG**	**A090527**	**001**	May 27, 2009	
AA			**25MG**	**A090527**	**002**	May 27, 2009	
AA			**50MG**	**A090527**	**003**	May 27, 2009	
AA			**100MG**	**A090527**	**004**	May 27, 2009	
AA		HERITAGE PHARMS INC	**10MG**	**A086242**	**001**	Feb 04, 2010	
AA			**25MG**	**A086242**	**003**		
AA			**50MG**	**A086242**	**002**		
AA			**100MG**	**A086242**	**004**	Feb 04, 2010	
AA		HETERO LABS LTD III	**10MG**	**A040901**	**001**	Sep 12, 2008	
AA			**25MG**	**A040901**	**002**	Sep 12, 2008	
AA			**50MG**	**A040901**	**003**	Sep 12, 2008	
AA			**100MG**	**A040901**	**004**	Sep 12, 2008	

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

AA		INVAGEN PHARMS	**10MG**	**A090255**	**001**	Dec 15, 2008
AA			**25MG**	**A090255**	**002**	Dec 15, 2008
AA			**50MG**	**A090255**	**003**	Dec 15, 2008
AA			**100MG**	**A090255**	**004**	Dec 15, 2008
AA		PAR PHARM	**10MG**	**A087836**	**001**	Oct 05, 1982
AA			**25MG**	**A086961**	**002**	
AA			**50MG**	**A086962**	**001**	
AA			**100MG**	**A088391**	**001**	Sep 27, 1983
AA	**!**	PLIVA	**10MG**	**A089097**	**001**	Dec 18, 1985
AA	**!**		**25MG**	**A088467**	**001**	May 01, 1984
AA	**!**		**50MG**	**A088468**	**001**	May 01, 1984
AA	**!**		**100MG**	**A089098**	**001**	Dec 18, 1985
AA		SCIEGEN PHARMS INC	**10MG**	**A205236**	**001**	May 26, 2017
AA			**25MG**	**A205236**	**002**	May 26, 2017
AA			**50MG**	**A205236**	**003**	May 26, 2017
AA			**100MG**	**A205236**	**004**	May 26, 2017
AA		STRIDES PHARMA	**25MG**	**A200770**	**001**	May 03, 2013
AA			**50MG**	**A200770**	**002**	May 03, 2013
AA			**100MG**	**A200770**	**003**	May 03, 2013

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDRA-ZIDE

		PAR PHARM	25MG;25MG	A088957	001	Oct 21, 1985
	!		50MG;50MG	A088946	001	Oct 21, 1985

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET;ORAL

BIDIL

	+!	ARBOR PHARMS LLC	37.5MG;20MG	N020727	001	Jun 23, 2005

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	**12.5MG**	**A200645**	**001**	Nov 30, 2010
AB		AUROBINDO PHARMA	**12.5MG**	**A078164**	**001**	Sep 18, 2007
AB		IPCA LABS LTD	**12.5MG**	**A079237**	**001**	Apr 02, 2009
AB		IVAX SUB TEVA PHARMS	**12.5MG**	**A077005**	**001**	Jul 13, 2005
AB		JUBILANT CADISTA	**12.5MG**	**A078391**	**001**	Feb 11, 2008
AB		MYLAN	**12.5MG**	**A075640**	**001**	Jan 28, 2000
AB		PRINSTON INC	**12.5MG**	**A075907**	**001**	Sep 17, 2002
AB		SCIEGEN PHARMS INC	**12.5MG**	**A203561**	**001**	Jan 14, 2019
AB		SUN PHARM INDS INC	**12.5MG**	**A090651**	**001**	Apr 07, 2014
AB		UNICHEM	**12.5MG**	**A090510**	**001**	Jan 19, 2010

MICROZIDE

AB	**+!**	ALLERGAN SALES LLC	**12.5MG**	**N020504**	**001**	Dec 27, 1996

TABLET;ORAL

HYDROCHLOROTHIAZIDE

AB		ACCORD HLTHCARE	**12.5MG**	**A202556**	**001**	Sep 24, 2012
AB			**25MG**	**A202556**	**002**	Sep 24, 2012
AB			**50MG**	**A202556**	**003**	Sep 24, 2012
AB		ACTAVIS ELIZABETH	**12.5MG**	**A040707**	**001**	Feb 27, 2007
AB		AUROBINDO PHARMA	**25MG**	**A040780**	**001**	Jul 20, 2007
AB			**50MG**	**A040780**	**002**	Jul 20, 2007
AB		HERITAGE PHARMS INC	**25MG**	**A085182**	**002**	
AB			**50MG**	**A085182**	**001**	
AB		HIKMA INTL PHARMS	**50MG**	**A084878**	**001**	
AB		IPCA LABS LTD	**12.5MG**	**A040807**	**001**	Jul 20, 2007
AB			**25MG**	**A040807**	**002**	Jul 20, 2007
AB			**50MG**	**A040807**	**003**	Jul 20, 2007
AB		IVAX SUB TEVA PHARMS	**25MG**	**A083177**	**001**	
AB	**!**		**50MG**	**A083177**	**002**	
AB		LEADING PHARMA LLC	**12.5MG**	**A040702**	**003**	May 10, 2017
AB			**25MG**	**A040702**	**001**	Mar 16, 2007
AB			**50MG**	**A040702**	**002**	Mar 16, 2007
AB		MYLAN PHARMS INC	**25MG**	**A040735**	**002**	Jan 23, 2007
AB			**50MG**	**A040735**	**003**	Jan 23, 2007
AB		OXFORD PHARMS	**25MG**	**A087059**	**001**	
AB			**50MG**	**A087068**	**001**	

HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDROCHLOROTHIAZIDE

AB		PRINSTON INC	**25MG**	**A040412**	**001**	Mar 29, 2002
AB			**50MG**	**A040412**	**002**	Mar 29, 2002
AB		SCIEGEN PHARMS INC	**25MG**	**A203018**	**001**	Jul 23, 2014
AB			**50MG**	**A203018**	**002**	Jul 23, 2014
AB		SUN PHARM INDS INC	**12.5MG**	**A040857**	**001**	May 30, 2008
AB			**25MG**	**A040810**	**001**	Mar 27, 2007
AB			**50MG**	**A040810**	**002**	Mar 27, 2007
AB		UNICHEM	**25MG**	**A040907**	**001**	Aug 15, 2008
AB			**50MG**	**A040907**	**002**	Aug 15, 2008

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

AVALIDE

AB	**+!**	SANOFI AVENTIS US	**12.5MG;150MG**	**N020758**	**002**	Sep 30, 1997
AB	**+!**		**12.5MG;300MG**	**N020758**	**003**	Aug 31, 1998

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	**12.5MG;150MG**	**A091370**	**001**	Oct 15, 2012
AB			**12.5MG;300MG**	**A091370**	**002**	Oct 15, 2012
AB			**25MG;300MG**	**A091370**	**003**	Oct 12, 2016
AB		APOTEX INC	**12.5MG;150MG**	**A201505**	**001**	Oct 15, 2012
AB			**12.5MG;300MG**	**A201505**	**002**	Oct 15, 2012
AB		AUROBINDO PHARMA LTD	**12.5MG;150MG**	**A203630**	**001**	Feb 22, 2013
AB			**12.5MG;300MG**	**A203630**	**002**	Feb 22, 2013
AB			**25MG;300MG**	**A203630**	**003**	Mar 31, 2016
AB		DR REDDYS LABS LTD	**12.5MG;150MG**	**A203500**	**001**	Sep 27, 2012
AB			**12.5MG;300MG**	**A203500**	**002**	Sep 27, 2012
AB		HISUN PHARM HANGZHOU	**12.5MG;150MG**	**A207896**	**001**	Oct 14, 2016
AB			**12.5MG;300MG**	**A207896**	**002**	Oct 14, 2016
AB		LUPIN LTD	**12.5MG;150MG**	**A201524**	**001**	Feb 27, 2013
AB			**12.5MG;300MG**	**A201524**	**002**	Feb 27, 2013
AB		MACLEODS PHARMS LTD	**12.5MG;150MG**	**A202414**	**001**	Sep 27, 2012
AB			**12.5MG;300MG**	**A202414**	**002**	Sep 27, 2012
AB		PRINSTON INC	**12.5MG;150MG**	**A203072**	**001**	May 09, 2014
AB			**12.5MG;300MG**	**A203072**	**002**	May 09, 2014
AB		SANDOZ	**12.5MG;150MG**	**A077446**	**001**	Sep 27, 2012
AB			**12.5MG;300MG**	**A077446**	**002**	Sep 27, 2012
AB		TEVA	**12.5MG;150MG**	**A077369**	**001**	Mar 30, 2012
AB			**12.5MG;300MG**	**A077369**	**002**	Mar 30, 2012
AB		UNICHEM LABS LTD	**12.5MG;150MG**	**A207018**	**001**	Sep 19, 2017
AB			**12.5MG;300MG**	**A207018**	**002**	Sep 19, 2017
AB		WEST-WARD PHARMS INT	**12.5MG;150MG**	**A090351**	**001**	Oct 15, 2012
AB			**12.5MG;300MG**	**A090351**	**002**	Oct 15, 2012
AB			**25MG;300MG**	**A090351**	**003**	Jun 08, 2017

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB		AUROBINDO	**12.5MG;10MG**	**A077606**	**001**	Mar 14, 2006
AB			**12.5MG;20MG**	**A077606**	**002**	Mar 14, 2006
AB			**25MG;20MG**	**A077606**	**003**	Mar 14, 2006
AB		HIKMA INTL PHARMS	**12.5MG;10MG**	**A076265**	**001**	Jul 08, 2002
AB			**12.5MG;20MG**	**A076265**	**002**	Jul 08, 2002
AB			**25MG;20MG**	**A076265**	**003**	Jul 08, 2002
AB		INVAGEN PHARMS	**12.5MG;10MG**	**A204058**	**001**	May 23, 2017
AB			**12.5MG;20MG**	**A204058**	**002**	May 23, 2017
AB			**25MG;20MG**	**A204058**	**003**	May 23, 2017
AB		IVAX SUB TEVA PHARMS	**12.5MG;10MG**	**A075776**	**001**	Jul 01, 2002
AB			**12.5MG;20MG**	**A075776**	**002**	Jul 01, 2002
AB			**25MG;20MG**	**A075776**	**003**	Jul 01, 2002
AB		LUPIN	**12.5MG;10MG**	**A077912**	**001**	Sep 27, 2006
AB			**12.5MG;20MG**	**A077912**	**002**	Sep 27, 2006
AB			**25MG;20MG**	**A077912**	**003**	Sep 27, 2006
AB		MYLAN	**12.5MG;10MG**	**A076113**	**001**	Jul 01, 2002
AB			**12.5MG;20MG**	**A076113**	**002**	Jul 01, 2002
AB			**25MG;20MG**	**A076113**	**003**	Jul 01, 2002
AB		PRINSTON INC	**12.5MG;10MG**	**A076230**	**001**	Jul 01, 2002
AB			**12.5MG;20MG**	**A076230**	**002**	Jul 01, 2002

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE						
AB			**25MG;20MG**	**A076230**	**003**	Jul 01, 2002
AB		SANDOZ	**12.5MG;10MG**	**A076262**	**001**	Jul 01, 2002
AB			**12.5MG;20MG**	**A076262**	**002**	Jul 01, 2002
AB			**25MG;20MG**	**A076262**	**003**	Jul 01, 2002
AB		SUN PHARM INDS LTD	**12.5MG;10MG**	**A076007**	**001**	Jul 01, 2002
AB			**12.5MG;20MG**	**A076007**	**002**	Jul 01, 2002
AB			**25MG;20MG**	**A076007**	**003**	Jul 01, 2002
AB		WATSON LABS	**12.5MG;10MG**	**A076194**	**003**	Jul 01, 2002
AB			**12.5MG;20MG**	**A076194**	**001**	Jul 01, 2002
AB			**25MG;20MG**	**A076194**	**002**	Jul 01, 2002
ZESTORETIC						
AB	+	ALVOGEN MALTA	**12.5MG;10MG**	**N019888**	**003**	Nov 18, 1993
AB	+!		**12.5MG;20MG**	**N019888**	**001**	Sep 20, 1990
AB	+!		**25MG;20MG**	**N019888**	**002**	Jul 20, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

HYZAAR						
AB	+	MERCK SHARP DOHME	**12.5MG;100MG**	**N020387**	**003**	Oct 20, 2005
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE						
AB		ALEMBIC PHARMS LTD	**12.5MG;50MG**	**A091617**	**001**	Feb 17, 2012
AB			**12.5MG;100MG**	**A091617**	**002**	Feb 17, 2012
AB			**25MG;100MG**	**A091617**	**003**	Feb 17, 2012
AB		AUROBINDO PHARMA	**12.5MG;50MG**	**A091629**	**001**	Oct 06, 2010
AB			**12.5MG;100MG**	**A091629**	**002**	Oct 06, 2010
AB	!		**25MG;100MG**	**A091629**	**003**	Jan 06, 2010
AB		CADISTA PHARMS	**12.5MG;50MG**	**A201845**	**001**	Sep 18, 2012
AB			**12.5MG;100MG**	**A201845**	**002**	Sep 18, 2012
AB			**25MG;100MG**	**A201845**	**003**	Sep 18, 2012
AB		IPCA LABS LTD	**12.5MG;50MG**	**A201682**	**001**	Mar 01, 2013
AB			**12.5MG;100MG**	**A201682**	**002**	Mar 01, 2013
AB			**25MG;100MG**	**A201682**	**003**	Mar 01, 2013
AB		LUPIN LTD	**12.5MG;50MG**	**A078245**	**001**	Oct 06, 2010
AB			**12.5MG;100MG**	**A078245**	**002**	May 21, 2010
AB			**25MG;100MG**	**A078245**	**003**	Oct 06, 2010
AB		MACLEODS PHARMS LTD	**12.5MG;50MG**	**A202289**	**001**	Aug 09, 2012
AB			**12.5MG;100MG**	**A202289**	**002**	Aug 09, 2012
AB			**25MG;100MG**	**A202289**	**003**	Aug 09, 2012
AB		MYLAN	**12.5MG;50MG**	**A091652**	**001**	Oct 06, 2010
AB			**12.5MG;100MG**	**A091652**	**002**	Apr 06, 2010
AB			**25MG;100MG**	**A091652**	**003**	Oct 06, 2010
AB		PRINSTON INC	**12.5MG;50MG**	**A204901**	**001**	Nov 06, 2017
AB			**12.5MG;100MG**	**A204901**	**002**	Nov 06, 2017
AB			**25MG;100MG**	**A204901**	**003**	Nov 06, 2017
AB		SANDOZ	**12.5MG;50MG**	**A077948**	**001**	Oct 06, 2010
AB			**12.5MG;100MG**	**A077948**	**003**	Aug 19, 2010
AB			**25MG;100MG**	**A077948**	**002**	Oct 06, 2010
AB		TEVA PHARMS	**12.5MG;50MG**	**A077157**	**001**	Apr 06, 2010
AB			**12.5MG;100MG**	**A077157**	**002**	Apr 06, 2010
AB			**25MG;100MG**	**A077157**	**003**	Apr 06, 2010
AB		TORRENT PHARMS	**12.5MG;50MG**	**A090528**	**001**	Oct 06, 2010
AB			**12.5MG;100MG**	**A090528**	**003**	Apr 06, 2010
AB			**25MG;100MG**	**A090528**	**002**	Oct 06, 2010
AB		UNICHEM LABS LTD	**12.5MG;50MG**	**A204832**	**001**	Jul 21, 2017
AB			**12.5MG;100MG**	**A204832**	**002**	Jul 21, 2017
AB			**25MG;100MG**	**A204832**	**003**	Jul 21, 2017
AB		WEST-WARD PHARMS INT	**12.5MG;50MG**	**A077732**	**002**	Oct 06, 2010
AB			**12.5MG;100MG**	**A077732**	**001**	Apr 06, 2010
AB			**25MG;100MG**	**A077732**	**003**	Oct 06, 2010
AB		ZYDUS PHARMS USA INC	**12.5MG;50MG**	**A078385**	**001**	Oct 06, 2010
AB			**25MG;100MG**	**A078385**	**002**	Oct 06, 2010

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE						
		MYLAN	15MG;250MG	A070265	002	Jan 23, 1986
	!		25MG;250MG	A070265	001	Jan 23, 1986

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DUTOPROL

	+	CONCORDIA PHARMS INC	12.5MG;EQ 25MG TARTRATE	N021956	001	Aug 28, 2006
	+		12.5MG;EQ 50MG TARTRATE	N021956	002	Aug 28, 2006
	+!		12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL

LOPRESSOR HCT

AB	**+**	US PHARMS HOLDINGS I	**25MG;50MG**	**N018303**	**001**	Dec 31, 1984
AB	**+!**		**25MG;100MG**	**N018303**	**002**	Dec 31, 1984

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	**25MG;50MG**	**A202870**	**001**	Nov 06, 2013
AB			**25MG;100MG**	**A202870**	**002**	Nov 06, 2013
AB			**50MG;100MG**	**A202870**	**003**	Nov 06, 2013
AB		MYLAN	**25MG;50MG**	**A076792**	**001**	Aug 20, 2004
AB			**25MG;100MG**	**A076792**	**002**	Aug 20, 2004
AB			**50MG;100MG**	**A076792**	**003**	Aug 20, 2004
AB		SUN PHARM INDS	**25MG;50MG**	**A090654**	**001**	Jan 19, 2012
AB			**25MG;100MG**	**A090654**	**002**	Jan 19, 2012
AB			**50MG;100MG**	**A090654**	**003**	Jan 19, 2012

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		GLENMARK PHARMS	**12.5MG;7.5MG**	**A090718**	**001**	Mar 17, 2010
AB			**12.5MG;15MG**	**A090718**	**002**	Mar 17, 2010
AB			**25MG;15MG**	**A090718**	**003**	Mar 17, 2010
AB		HERITAGE PHARMS INC	**12.5MG;7.5MG**	**A202150**	**001**	Mar 07, 2014
AB			**12.5MG;15MG**	**A202150**	**002**	Mar 07, 2014
AB			**25MG;15MG**	**A202150**	**003**	Mar 07, 2014
AB		TEVA	**12.5MG;7.5MG**	**A076980**	**001**	Mar 07, 2007
AB			**12.5MG;15MG**	**A076980**	**003**	Mar 07, 2007
AB	**!**		**25MG;15MG**	**A076980**	**002**	Mar 07, 2007

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

BENICAR HCT

AB	**+**	DAIICHI SANKYO	**12.5MG;20MG**	**N021532**	**002**	Jun 05, 2003
AB	**+**		**12.5MG;40MG**	**N021532**	**003**	Jun 05, 2003
AB	**+!**		**25MG;40MG**	**N021532**	**005**	Jun 05, 2003

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	**12.5MG;20MG**	**A204233**	**001**	Apr 24, 2017
AB			**12.5MG;40MG**	**A204233**	**002**	Apr 24, 2017
AB			**25MG;40MG**	**A204233**	**003**	Apr 24, 2017
AB		AUROBINDO PHARMA LTD	**12.5MG;20MG**	**A205391**	**001**	Apr 24, 2017
AB			**12.5MG;40MG**	**A205391**	**002**	Apr 24, 2017
AB			**25MG;40MG**	**A205391**	**003**	Apr 24, 2017
AB		MYLAN PHARMS INC	**12.5MG;20MG**	**A078827**	**001**	Oct 26, 2016
AB			**12.5MG;40MG**	**A078827**	**002**	Oct 26, 2016
AB			**25MG;40MG**	**A078827**	**003**	Oct 26, 2016
AB		PRINSTON INC	**12.5MG;20MG**	**A207804**	**001**	Apr 24, 2017
AB			**12.5MG;40MG**	**A207804**	**002**	Apr 24, 2017
AB			**25MG;40MG**	**A207804**	**003**	Apr 24, 2017
AB		TEVA PHARMS USA	**12.5MG;20MG**	**A200532**	**001**	Apr 24, 2017
AB			**12.5MG;40MG**	**A200532**	**002**	Apr 24, 2017
AB			**25MG;40MG**	**A200532**	**003**	Apr 24, 2017
AB		TORRENT PHARMS LTD	**12.5MG;20MG**	**A206515**	**001**	May 03, 2017
AB			**12.5MG;40MG**	**A206515**	**002**	May 03, 2017
AB			**25MG;40MG**	**A206515**	**003**	May 03, 2017

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	**!**	MYLAN	**25MG;80MG**	**A070947**	**001**	Apr 01, 1987
	!		25MG;40MG	A070947	002	Mar 04, 1987

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

ACCURETIC						
AB	+	PFIZER PHARMS	**12.5MG;EQ 10MG BASE**	**N020125**	**001**	Dec 28, 1999
AB	+		**12.5MG;EQ 20MG BASE**	**N020125**	**002**	Dec 28, 1999
AB	+!		**25MG;EQ 20MG BASE**	**N020125**	**003**	Dec 28, 1999
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE						
AB		APOTEX CORP	**12.5MG;EQ 10MG BASE**	**A091524**	**001**	Mar 12, 2013
AB			**12.5MG;EQ 20MG BASE**	**A091524**	**002**	Mar 12, 2013
AB			**25MG;EQ 20MG BASE**	**A091524**	**003**	Mar 12, 2013
AB		AUROBINDO PHARMA	**12.5MG;EQ 10MG BASE**	**A078450**	**001**	Aug 24, 2007
AB			**12.5MG;EQ 20MG BASE**	**A078450**	**002**	Aug 24, 2007
AB			**25MG;EQ 20MG BASE**	**A078450**	**003**	Aug 24, 2007
AB		INVAGEN PHARMS	**12.5MG;EQ 10MG BASE**	**A201356**	**001**	Apr 20, 2011
AB			**12.5MG;EQ 20MG BASE**	**A201356**	**002**	Apr 20, 2011
AB			**25MG;EQ 20MG BASE**	**A201356**	**003**	Apr 20, 2011
AB		MYLAN	**12.5MG;EQ 10MG BASE**	**A077093**	**001**	Mar 28, 2005
AB			**12.5MG;EQ 20MG BASE**	**A077093**	**002**	Mar 28, 2005
AB			**25MG;EQ 20MG BASE**	**A077093**	**003**	Mar 28, 2005
QUINARETIC						
AB		GAVIS PHARMS	**12.5MG;EQ 10MG BASE**	**A076374**	**001**	Mar 31, 2004
AB			**12.5MG;EQ 20MG BASE**	**A076374**	**002**	Mar 31, 2004
AB			**25MG;EQ 20MG BASE**	**A076374**	**003**	Mar 31, 2004

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL

ALDACTAZIDE						
AB	+	GD SEARLE LLC	**25MG;25MG**	**N012616**	**004**	Dec 30, 1982
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE						
AB		MYLAN	**25MG;25MG**	**A086513**	**001**	
AB		SUN PHARM INDUSTRIES	**25MG;25MG**	**A089534**	**001**	Jul 02, 1987
ALDACTAZIDE						
	+!	GD SEARLE LLC	50MG;50MG	N012616	005	Dec 30, 1982

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL

MICARDIS HCT						
AB	+	BOEHRINGER INGELHEIM	**12.5MG;40MG**	**N021162**	**001**	Nov 17, 2000
AB	+		**12.5MG;80MG**	**N021162**	**002**	Nov 17, 2000
AB	+!		**25MG;80MG**	**N021162**	**003**	Apr 19, 2004
TELMISARTAN AND HYDROCHLOROTHIAZIDE						
AB		ALEMBIC PHARMS LTD	**12.5MG;40MG**	**A203010**	**001**	Feb 25, 2014
AB			**12.5MG;80MG**	**A203010**	**002**	Feb 25, 2014
AB			**25MG;80MG**	**A203010**	**003**	Feb 25, 2014
AB		AUROBINDO PHARMA LTD	**12.5MG;40MG**	**A208727**	**001**	Dec 15, 2016
AB			**12.5MG;80MG**	**A208727**	**002**	Dec 15, 2016
AB			**25MG;80MG**	**A208727**	**003**	Dec 15, 2016
AB		LUPIN LTD	**12.5MG;40MG**	**A091351**	**001**	Aug 07, 2014
AB			**12.5MG;80MG**	**A091351**	**002**	Aug 07, 2014
AB			**25MG;80MG**	**A091351**	**003**	Aug 07, 2014
AB		MACLEODS PHARMS LTD	**12.5MG;40MG**	**A204169**	**001**	Nov 02, 2015
AB			**12.5MG;80MG**	**A204169**	**002**	Nov 02, 2015
AB			**25MG;80MG**	**A204169**	**003**	Nov 02, 2015
AB		MYLAN PHARMS INC	**12.5MG;40MG**	**A091648**	**001**	Feb 25, 2014
AB			**12.5MG;80MG**	**A091648**	**002**	Feb 25, 2014
AB			**25MG;80MG**	**A091648**	**003**	Feb 25, 2014
AB		PRINSTON INC	**12.5MG;40MG**	**A209028**	**001**	Nov 06, 2017
AB			**12.5MG;80MG**	**A209028**	**002**	Nov 06, 2017
AB			**25MG;80MG**	**A209028**	**003**	Nov 06, 2017
AB		TORRENT PHARMS LTD	**12.5MG;40MG**	**A201192**	**001**	Feb 25, 2014
AB			**12.5MG;80MG**	**A201192**	**002**	Feb 25, 2014
AB			**25MG;80MG**	**A201192**	**003**	Feb 25, 2014
AB		ZYDUS PHARMS USA INC	**12.5MG;40MG**	**A204221**	**001**	Aug 15, 2017
AB			**12.5MG;80MG**	**A204221**	**002**	Aug 15, 2017
AB			**25MG;80MG**	**A204221**	**003**	Aug 15, 2017

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL

DYAZIDE

AB	**+!**	GLAXOSMITHKLINE LLC	**25MG;37.5MG**	**N016042**	**003**	Mar 03, 1994

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	**!**	CASI PHARMS INC	**25MG;50MG**	**A073191**	**001**	Jul 31, 1991
AB		DURAMED PHARMS BARR	**25MG;37.5MG**	**A075052**	**001**	Jun 18, 1999
AB		IVAX SUB TEVA PHARMS	**25MG;50MG**	**A074259**	**001**	Mar 30, 1995
AB		LANNETT CO INC	**25MG;37.5MG**	**A201407**	**001**	Dec 09, 2011
AB		MYLAN	**25MG;37.5MG**	**A074701**	**001**	Jun 07, 1996
AB		SANDOZ	**25MG;37.5MG**	**A074821**	**001**	Jun 05, 1997

TABLET;ORAL

MAXZIDE

AB	**+!**	MYLAN PHARMS INC	**50MG;75MG**	**N019129**	**001**	Oct 22, 1984

MAXZIDE-25

AB	**+**	MYLAN PHARMS INC	**25MG;37.5MG**	**N019129**	**003**	May 13, 1988

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		ANI PHARMS INC	**50MG;75MG**	**A073467**	**001**	Jan 31, 1996
AB		APOTEX INC	**25MG;37.5MG**	**A071251**	**002**	May 05, 1998
AB			**50MG;75MG**	**A071251**	**001**	Apr 17, 1988
AB		PLIVA	**25MG;37.5MG**	**A074026**	**001**	Apr 26, 1996
AB		SANDOZ	**25MG;37.5MG**	**A073281**	**001**	Apr 30, 1992
AB			**50MG;75MG**	**A072011**	**001**	Jun 17, 1988
AB		WATSON LABS	**25MG;37.5MG**	**A073449**	**001**	Sep 23, 1993
AB			**50MG;75MG**	**A071851**	**001**	Nov 30, 1988
AB		ZYDUS PHARMS USA INC	**25MG;37.5MG**	**A208360**	**001**	Jun 29, 2018
AB			**50MG;75MG**	**A208360**	**002**	Jun 29, 2018

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

DIOVAN HCT

AB	**+**	NOVARTIS	**12.5MG;80MG**	**N020818**	**001**	Mar 06, 1998
AB	**+**		**12.5MG;160MG**	**N020818**	**002**	Mar 06, 1998
AB	**+**		**12.5MG;320MG**	**N020818**	**004**	Apr 28, 2006
AB	**+**		**25MG;160MG**	**N020818**	**003**	Jan 17, 2002
AB	**+!**		**25MG;320MG**	**N020818**	**005**	Apr 28, 2006

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	**12.5MG;80MG**	**A201662**	**001**	Mar 21, 2013
AB			**12.5MG;160MG**	**A201662**	**002**	Mar 21, 2013
AB			**12.5MG;320MG**	**A201662**	**003**	Mar 21, 2013
AB			**25MG;160MG**	**A201662**	**004**	Mar 21, 2013
AB			**25MG;320MG**	**A201662**	**005**	Mar 21, 2013
AB		AUROBINDO PHARMA LTD	**12.5MG;80MG**	**A202519**	**001**	Mar 21, 2013
AB			**12.5MG;160MG**	**A202519**	**002**	Mar 21, 2013
AB			**12.5MG;320MG**	**A202519**	**003**	Mar 21, 2013
AB			**25MG;160MG**	**A202519**	**004**	Mar 21, 2013
AB			**25MG;320MG**	**A202519**	**005**	Mar 21, 2013
AB		LUPIN LTD	**12.5MG;80MG**	**A078946**	**003**	Mar 21, 2013
AB			**12.5MG;160MG**	**A078946**	**004**	Mar 21, 2013
AB			**12.5MG;320MG**	**A078946**	**001**	Mar 21, 2013
AB			**25MG;160MG**	**A078946**	**005**	Mar 21, 2013
AB			**25MG;320MG**	**A078946**	**002**	Mar 21, 2013
AB		MACLEODS PHARMS LTD	**12.5MG;80MG**	**A203145**	**001**	Apr 19, 2013
AB			**12.5MG;160MG**	**A203145**	**002**	Apr 19, 2013
AB			**12.5MG;320MG**	**A203145**	**003**	Apr 19, 2013
AB			**25MG;160MG**	**A203145**	**004**	Apr 19, 2013
AB			**25MG;320MG**	**A203145**	**005**	Apr 19, 2013
AB		MYLAN PHARMS INC	**12.5MG;80MG**	**A078020**	**001**	Sep 21, 2012
AB			**12.5MG;160MG**	**A078020**	**002**	Sep 21, 2012
AB			**12.5MG;320MG**	**A078020**	**004**	Sep 21, 2012
AB			**25MG;160MG**	**A078020**	**003**	Sep 21, 2012
AB			**25MG;320MG**	**A078020**	**005**	Sep 21, 2012
AB		PRINSTON INC	**12.5MG;80MG**	**A206083**	**001**	Feb 08, 2016
AB			**12.5MG;160MG**	**A206083**	**002**	Feb 08, 2016
AB			**12.5MG;320MG**	**A206083**	**003**	Feb 08, 2016
AB			**25MG;160MG**	**A206083**	**004**	Feb 08, 2016
AB			**25MG;320MG**	**A206083**	**005**	Feb 08, 2016

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

ZOHYDRO ER

+!	PERNIX IRELAND PAIN	10MG	N202880	001	Oct 25, 2013
+		15MG	N202880	002	Oct 25, 2013
+		20MG	N202880	003	Oct 25, 2013
+		30MG	N202880	004	Oct 25, 2013
+		40MG	N202880	005	Oct 25, 2013
+		50MG	N202880	006	Oct 25, 2013

TABLET, EXTENDED RELEASE;ORAL

HYSINGLA

+!	PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014
+		30MG	N206627	002	Nov 20, 2014
+		40MG	N206627	003	Nov 20, 2014
+		60MG	N206627	004	Nov 20, 2014
+		80MG	N206627	005	Nov 20, 2014
+		100MG	N206627	006	Nov 20, 2014
+		120MG	N206627	007	Nov 20, 2014

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

AB	ACTAVIS LABS FL INC	**7.5MG;200MG**	**A076604**	**001**	Dec 31, 2003
AB	AMNEAL PHARMS NY	**5MG;200MG**	**A076642**	**002**	Mar 18, 2004
AB !		**7.5MG;200MG**	**A076642**	**001**	Oct 12, 2004
AB	AUROLIFE PHARMA LLC	**7.5MG;200MG**	**A204575**	**001**	Jun 02, 2016
AB	SUN PHARM INDS INC	**2.5MG;200MG**	**A091633**	**001**	May 28, 2013
AB		**5MG;200MG**	**A091633**	**002**	May 28, 2013
AB		**7.5MG;200MG**	**A091633**	**003**	May 28, 2013
AB		**10MG;200MG**	**A091633**	**004**	May 28, 2013
AB	TEVA	**7.5MG;200MG**	**A076023**	**001**	Apr 11, 2003
AB	VINTAGE PHARMS	**5MG;200MG**	**A077727**	**001**	Nov 06, 2006
AB		**7.5MG;200MG**	**A077723**	**001**	Nov 06, 2006
AB		**10MG;200MG**	**A077723**	**002**	Nov 06, 2006

REPREXAIN

AB	AMNEAL PHARMS NY	**2.5MG;200MG**	**A076642**	**003**	Oct 19, 2007
AB		**10MG;200MG**	**A076642**	**004**	Oct 19, 2007

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	MAYNE PHARMA INC	**5MG/5ML;60MG/5ML**	**A205658**	**001**	Nov 17, 2015
AA	PADDOCK LLC	**5MG/5ML;60MG/5ML**	**A204658**	**001**	Apr 29, 2014

REZIRA

AA +!	CYPRESS PHARM	**5MG/5ML;60MG/5ML**	**N022442**	**001**	Jun 08, 2011

HYDROCORTISONE

CREAM;TOPICAL

ALA-CORT

AT	CROWN LABS	**2.5%**	**A080706**	**007**	Jan 05, 2016
AT		**1%**	**A080706**	**006**	

ANUSOL HC

AT	SALIX PHARMS	**2.5%**	**A088250**	**001**	Jun 06, 1984

HYDROCORTISONE

AT	ACTAVIS MID ATLANTIC	**1%**	**A087795**	**001**	May 03, 1983
AT		**2.5%**	**A089682**	**001**	Mar 10, 1988
AT !	FOUGERA PHARMS INC	**1%**	**A080693**	**003**	
AT !		**2.5%**	**A089414**	**001**	Dec 16, 1986
AT	LANNETT CO INC	**2.5%**	**A040503**	**001**	Mar 12, 2004
AT	PERRIGO NEW YORK	**2.5%**	**A085025**	**001**	
AT	RISING PHARMS	**2.5%**	**A040879**	**001**	Aug 20, 2010
AT	TARO PHARM INDS LTD	**2.5%**	**A088799**	**001**	Nov 09, 1984
AT	TELIGENT PHARMA INC	**2.5%**	**A203810**	**001**	Jul 23, 2018

ENEMA;RECTAL

COLOCORT

AB	PADDOCK LLC	**100MG/60ML**	**A075172**	**001**	Dec 03, 1999

CORTENEMA

AB +!	ANI PHARMS	**100MG/60ML**	**N016199**	**001**	

HYDROCORTISONE

AB	TEVA PHARMS	**100MG/60ML**	**A074171**	**001**	May 27, 1994

LOTION;TOPICAL

HYDROCORTISONE

AT !	FOUGERA PHARMS	**2.5%**	**A040351**	**001**	Jul 25, 2000

HYDROCORTISONE							
LOTION;TOPICAL							
HYDROCORTISONE							
AT		LANNETT CO INC	**2.5%**	**A040417**	**001**	Jul 30, 2003
AT		TARO	**2.5%**	**A040247**	**001**	Jul 23, 1999
AT		TELIGENT PHARMA INC	**2.5%**	**A203804**	**001**	Jul 27, 2018
STIE-CORT						
AT		PERRIGO CO	**2.5%**	**A089074**	**001**	Nov 26, 1985
ALA-SCALP						
		CROWN LABS	2%	A083231	001	
OINTMENT;TOPICAL						
HYDROCORTISONE						
AT		ACTAVIS MID ATLANTIC	**1%**	**A087796**	**001**	Oct 13, 1982
AT	!	FOUGERA PHARMS	**1%**	**A080692**	**001**	
AT	!	FOUGERA PHARMS INC	**2.5%**	**A081203**	**001**	May 28, 1993
AT		PERRIGO NEW YORK	**2.5%**	**A085027**	**001**	
AT		TARO	**1%**	**A086257**	**001**	
HYDROCORTISONE IN ABSORBASE						
AT		CMP PHARMA INC	**1%**	**A088138**	**001**	Sep 06, 1985
SOLUTION;TOPICAL						
TEXACORT						
	!	MISSION PHARMA	2.5%	A081271	001	Apr 17, 1992
TABLET;ORAL						
CORTEF						
AB	+	PHARMACIA AND UPJOHN	**5MG**	**N008697**	**003**	
AB	+		**10MG**	**N008697**	**001**	
AB	+!		**20MG**	**N008697**	**002**	
HYDROCORTISONE						
AB		HIKMA INTL PHARMS	**5MG**	**A083365**	**002**	Feb 23, 2015
AB			**10MG**	**A083365**	**003**	Feb 23, 2015
AB			**20MG**	**A083365**	**001**	
AB		IMPAX LABS INC	**5MG**	**A040646**	**001**	Mar 30, 2007
AB			**10MG**	**A040646**	**002**	Mar 30, 2007
AB			**20MG**	**A040646**	**003**	Mar 30, 2007
AB		PII	**5MG**	**A207029**	**001**	Apr 27, 2017
AB			**10MG**	**A207029**	**002**	Apr 27, 2017
AB			**20MG**	**A207029**	**003**	Apr 27, 2017
AB		VINTAGE	**5MG**	**A040761**	**001**	Jul 16, 2007
AB			**10MG**	**A040761**	**002**	Jul 16, 2007
AB			**20MG**	**A040761**	**003**	Jul 16, 2007
HYDROCORTISONE ACETATE						
AEROSOL, METERED;RECTAL						
CORTIFOAM						
	+!	MYLAN SPECIALITY LP	10%	N017351	001	Feb 10, 1982
CREAM;TOPICAL						
MICORT-HC						
		SEBELA IRELAND LTD	2.5%	A040396	001	Feb 27, 2001
HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE						
CREAM;TOPICAL						
CORTISPORIN						
	+!	MONARCH PHARMS	0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050218	001	Aug 09, 1985
HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE						
AEROSOL, METERED;TOPICAL						
EPIFOAM						
BX		MYLAN SPECIALITY LP	1%;1%	A086457	001	
PROCTOFOAM HC						
BX		MYLAN SPECIALITY LP	1%;1%	A086195	001	
CREAM;TOPICAL						
PRAMOSONE						
		SEBELA IRELAND LTD	0.5%;1%	A083778	001	
			1%;1%	A085368	001	
LOTION;TOPICAL						
PRAMOSONE						
		SEBELA IRELAND LTD	1%;1%	A085980	001	
			2.5%;1%	A085979	001	

HYDROCORTISONE ACETATE; UREA

CREAM;TOPICAL

U-CORT

	TARO	1%;10%	A089472	001	Jun 13, 1988

HYDROCORTISONE BUTYRATE

CREAM;TOPICAL

HYDROCORTISONE BUTYRATE

AB1	TARO PHARM INDS	**0.1%**	**A076654**	**001**	Aug 03, 2005

LOCOID

AB1	**+!** PRECISION DERMAT	**0.1%**	**N018514**	**001**	Mar 31, 1982

HYDROCORTISONE BUTYRATE

AB2	ACTAVIS MID ATLANTIC	**0.1%**	**A205134**	**001**	Dec 08, 2017
AB2	GLENMARK GENERICS	**0.1%**	**A202145**	**001**	Sep 27, 2013

LOCOID LIPOCREAM

AB2	**+!** PRECISION DERMAT	**0.1%**	**N020769**	**001**	Sep 08, 1997

LOTION;TOPICAL

HYDROCORTISONE BUTYRATE

AB	LUPIN LTD	**0.1%**	**A210209**	**001**	Aug 17, 2018
AB	TELIGENT PHARMA INC	**0.1%**	**A209556**	**001**	Nov 21, 2017

LOCOID

AB	**+!** PRECISION DERMAT	**0.1%**	**N022076**	**001**	May 18, 2007

OINTMENT;TOPICAL

HYDROCORTISONE BUTYRATE

AB	TARO	**0.1%**	**A076842**	**001**	Dec 27, 2004

LOCOID

AB	**+!** PRECISION DERMAT	**0.1%**	**N018652**	**001**	Oct 29, 1982

SOLUTION;TOPICAL

HYDROCORTISONE BUTYRATE

AT	TARO PHARM INDS	**0.1%**	**A076364**	**001**	Jan 14, 2004

LOCOID

AT	**+!** PRECISION DERMAT	**0.1%**	**N019116**	**001**	Feb 25, 1987

HYDROCORTISONE PROBUTATE

CREAM;TOPICAL

PANDEL

	+! FOUGERA PHARMS	0.1%	N020453	001	Feb 28, 1997

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE;INJECTION

SOLU-CORTEF

	+! PHARMACIA AND UPJOHN	EQ 100MG BASE/VIAL	N009866	001	
	+!	EQ 250MG BASE/VIAL	N009866	002	
	+!	EQ 500MG BASE/VIAL	N009866	003	
	+!	EQ 1GM BASE/VIAL	N009866	004	

HYDROCORTISONE VALERATE

CREAM;TOPICAL

HYDROCORTISONE VALERATE

AB	GLENMARK PHARMS LTD	**0.2%**	**A211129**	**001**	Oct 12, 2018
AB	PERRIGO NEW YORK	**0.2%**	**A075666**	**001**	May 24, 2000
AB	**!** TARO	**0.2%**	**A075042**	**001**	Aug 25, 1998

OINTMENT;TOPICAL

HYDROCORTISONE VALERATE

AB	GLENMARK PHARMS LTD	**0.2%**	**A211750**	**001**	Dec 14, 2018
AB	**!** TARO	**0.2%**	**A075043**	**001**	Aug 25, 1998

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT	**!** BAUSCH AND LOMB	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A064053**	**001**	Dec 29, 1995
AT	SANDOZ INC	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A062423**	**001**	Aug 25, 1983

SUSPENSION/DROPS;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

	! SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062874	001	May 11, 1988

SUSPENSION/DROPS;OTIC

CASPORYN HC

AT	**+!** CASPER PHARMA LLC	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**N060613**	**001**	

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT	AMRING PHARMS	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A065219**	**001**	May 01, 2006
AT	SANDOZ INC	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A062488**	**001**	Nov 06, 1985

OTICAIR

AT	BAUSCH AND LOMB	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A064065**	**001**	Aug 28, 1996

HYDROGEN PEROXIDE							
SOLUTION;TOPICAL							
ESKATA							
	+!	ACLARIS	40%	N209305	001	Dec 14, 2017
HYDROMORPHONE HYDROCHLORIDE							
INJECTABLE;INJECTION							
DILAUDID							
AP	**+!**	FRESENIUS KABI USA	**1MG/ML**	**N019034**	**003**	Apr 30, 2009
AP	**+!**		**2MG/ML**	**N019034**	**004**	Apr 30, 2009
HYDROMORPHONE HYDROCHLORIDE							
AP		AKORN	**10MG/ML**	**A078228**	**001**	Apr 14, 2010
AP			**10MG/ML**	**A078261**	**001**	Apr 14, 2010
AP		BARR	**10MG/ML**	**A076444**	**001**	Apr 25, 2003
AP		EUROHLTH INTL SARL	**2MG/ML**	**A202159**	**001**	Apr 27, 2018
AP		HOSPIRA INC	**1MG/ML**	**N200403**	**001**	Dec 01, 2011
AP			**2MG/ML**	**N200403**	**002**	Dec 01, 2011
AP			**4MG/ML**	**N200403**	**003**	Dec 01, 2011
AP			**10MG/ML**	**A078591**	**001**	Jun 17, 2008
SOLUTION;ORAL							
DILAUDID							
AA	**+!**	RHODES PHARMS	**5MG/5ML**	**N019891**	**001**	Dec 07, 1992
HYDROMORPHONE HYDROCHLORIDE							
AA		ASCENT PHARMS INC	**5MG/5ML**	**A210176**	**001**	Oct 27, 2017
AA		WEST-WARD PHARMS INT	**5MG/5ML**	**A074653**	**001**	Jul 29, 1998
TABLET;ORAL							
DILAUDID							
AB	**+**	RHODES PHARMS	**2MG**	**N019892**	**003**	Nov 09, 2007
AB	**+**		**4MG**	**N019892**	**002**	Nov 09, 2007
AB	**+!**		**8MG**	**N019892**	**001**	Dec 07, 1992
HYDROMORPHONE HYDROCHLORIDE							
AB		ASCENT PHARMS INC	**2MG**	**A210506**	**001**	Jan 17, 2018
AB			**4MG**	**A210506**	**002**	Jan 17, 2018
AB			**8MG**	**A210506**	**003**	Jan 17, 2018
AB		AUROLIFE PHARMA LLC	**2MG**	**A205814**	**001**	May 13, 2016
AB			**4MG**	**A205814**	**002**	May 13, 2016
AB			**8MG**	**A205814**	**003**	May 13, 2016
AB		ELITE LABS	**8MG**	**A076723**	**001**	Oct 18, 2005
AB		LANNETT CO INC	**2MG**	**A077471**	**002**	Dec 09, 2009
AB			**4MG**	**A077471**	**003**	Dec 09, 2009
AB			**8MG**	**A077471**	**001**	Dec 09, 2009
AB		SPECGX LLC	**2MG**	**A076855**	**002**	Sep 19, 2007
AB			**4MG**	**A076855**	**003**	Sep 19, 2007
AB			**8MG**	**A076855**	**001**	Dec 23, 2004
AB		WEST-WARD PHARMS INT	**4MG**	**A074597**	**003**	May 29, 2009
AB			**8MG**	**A074597**	**001**	Jul 29, 1998
TABLET, EXTENDED RELEASE;ORAL							
EXALGO							
AB	**+**	SPECGX LLC	**8MG**	**N021217**	**001**	Mar 01, 2010
AB	**+**		**12MG**	**N021217**	**002**	Mar 01, 2010
AB	**+**		**16MG**	**N021217**	**003**	Mar 01, 2010
AB	**+!**		**32MG**	**N021217**	**004**	Aug 24, 2012
HYDROMORPHONE HYDROCHLORIDE							
AB		OSMOTICA	**8MG**	**A205629**	**001**	Jul 07, 2016
AB			**12MG**	**A205629**	**002**	Jul 07, 2016
AB			**16MG**	**A205629**	**003**	Jul 07, 2016
AB			**32MG**	**A205629**	**004**	Jul 07, 2016
AB		PADDOCK LLC	**8MG**	**A204278**	**001**	Apr 06, 2015
AB			**12MG**	**A204278**	**002**	Apr 06, 2015
AB			**16MG**	**A204278**	**003**	Apr 06, 2015
AB			**32MG**	**A204278**	**004**	Sep 20, 2017
HYDROXOCOBALAMIN							
INJECTABLE;INJECTION							
CYANOKIT							
	+!	SERB SA	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011
HYDROXOCOBALAMIN							
	!	ACTAVIS LLC	1MG/ML	A085998	001	

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE						
SOLUTION/DROPS;OPHTHALMIC						
PAREMYD						
	+!	AKORN	1%;0.25%	N019261	001	Jan 30, 1992
HYDROXYCHLOROQUINE SULFATE						
TABLET;ORAL						
HYDROXYCHLOROQUINE SULFATE						
AB		ALKALOIDA ZRT	**200MG**	**A201691**	**001**	May 08, 2018
AB		AMNEAL PHARMS CO	**200MG**	**A210577**	**001**	May 15, 2018
AB		HIKMA PHARMS	**200MG**	**A040760**	**001**	Aug 15, 2007
AB		IPCA LABS LTD	**200MG**	**A040766**	**001**	Jun 14, 2007
AB		LUPIN LTD	**200MG**	**A210543**	**001**	Jul 06, 2018
AB		MYLAN	**200MG**	**A040274**	**001**	May 29, 1998
AB		RISING PHARMS	**200MG**	**A210959**	**001**	Jan 15, 2019
AB		SANDOZ	**200MG**	**A040104**	**001**	Nov 30, 1995
AB		TEVA PHARMS	**200MG**	**A040081**	**001**	Sep 30, 1994
AB		TWI PHARMS	**200MG**	**A210441**	**001**	May 01, 2018
AB		WATSON LABS	**200MG**	**A040133**	**001**	Nov 30, 1995
AB		ZYDUS PHARMS USA INC	**200MG**	**A040657**	**001**	Sep 21, 2007
PLAQUENIL						
AB	**+!**	CONCORDIA PHARMS INC	**200MG**	**N009768**	**001**	
HYDROXYPROGESTERONE CAPROATE						
SOLUTION;INTRAMUSCULAR						
HYDROXYPROGESTERONE CAPROATE						
AP		LUITPOLD	**250MG/ML (250MG/ML)**	**A210723**	**001**	Jun 21, 2018
AP		SLAYBACK PHARMA LLC	**1250MG/5ML (250MG/ML)**	**A210618**	**001**	Dec 28, 2018
MAKENA						
AP	**+!**	AMAG PHARMA USA	**1250MG/5ML (250MG/ML)**	**N021945**	**001**	Feb 03, 2011
MAKENA PRESERVATIVE FREE						
AP	**+!**	AMAG PHARMA USA	**250MG/ML (250MG/ML)**	**N021945**	**002**	Feb 19, 2016
HYDROXYPROGESTERONE CAPROATE						
	!	ASPEN GLOBAL INC	250MG/ML (250MG/ML)	A200271	001	Aug 24, 2015
SOLUTION;SUBCUTANEOUS						
MAKENA (AUTOINJECTOR)						
	+!	AMAG PHARMA USA	275MG/1.1ML (250MG/ML)	N021945	004	Feb 14, 2018
HYDROXYPROPYL CELLULOSE						
INSERT;OPHTHALMIC						
LACRISERT						
	+!	ATON	5MG	N018771	001	
HYDROXYUREA						
CAPSULE;ORAL						
HYDREA						
AB	**+!**	BRISTOL MYERS SQUIBB	**500MG**	**N016295**	**001**	
HYDROXYUREA						
AB		BARR	**500MG**	**A075143**	**001**	Oct 16, 1998
AB		PAR PHARM	**500MG**	**A075340**	**001**	Feb 24, 1999
DROXIA						
	+	BRISTOL MYERS SQUIBB	200MG	N016295	002	Feb 25, 1998
	+		300MG	N016295	003	Feb 25, 1998
	+		400MG	N016295	004	Feb 25, 1998
TABLET;ORAL						
SIKLOS						
	+	ADDMEDICA SAS	100MG	N208843	001	Dec 21, 2017
	+		1GM	N208843	002	Dec 21, 2017
HYDROXYZINE HYDROCHLORIDE						
INJECTABLE;INJECTION						
HYDROXYZINE HYDROCHLORIDE						
	!	LUITPOLD	25MG/ML	A087408	001	
	!		50MG/ML	A087408	002	
SYRUP;ORAL						
HYDROXYZINE HYDROCHLORIDE						
AA	**!**	HI TECH PHARMA	**10MG/5ML**	**A040010**	**001**	Oct 28, 1994
AA		LANNETT CO INC	**10MG/5ML**	**A201674**	**001**	Aug 21, 2013
AA	**!**	VINTAGE PHARMS	**10MG/5ML**	**A040391**	**001**	Apr 10, 2002
AA	**!**	WOCKHARDT BIO AG	**10MG/5ML**	**A087294**	**001**	Apr 12, 1982

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

AB		AMNEAL PHARM	**10MG**	**A040808**	**001**	Sep 24, 2008
AB			**25MG**	**A040808**	**002**	Sep 24, 2008
AB			**50MG**	**A040808**	**003**	Sep 24, 2008
AB		ECI PHARMS LLC	**10MG**	**A040804**	**001**	Jun 30, 2008
AB			**25MG**	**A040804**	**002**	Jun 30, 2008
AB			**50MG**	**A040804**	**003**	Jun 30, 2008
AB		ELITE LABS INC	**10MG**	**A040604**	**002**	Dec 28, 2004
AB			**25MG**	**A040604**	**003**	Dec 28, 2004
AB			**50MG**	**A040604**	**001**	Dec 28, 2004
AB		HERITAGE PHARMA	**10MG**	**A204279**	**001**	Aug 20, 2014
AB			**25MG**	**A204279**	**002**	Aug 20, 2014
AB			**50MG**	**A204279**	**003**	Aug 20, 2014
AB		HETERO LABS LTD III	**10MG**	**A040805**	**001**	May 29, 2008
AB			**25MG**	**A040805**	**002**	May 29, 2008
AB			**50MG**	**A040805**	**003**	May 29, 2008
AB		INVAGEN PHARMS	**10MG**	**A040812**	**001**	Mar 12, 2008
AB			**25MG**	**A040812**	**002**	Mar 12, 2008
AB			**50MG**	**A040812**	**003**	Mar 12, 2008
AB		KVK TECH	**10MG**	**A040786**	**001**	Mar 20, 2007
AB			**25MG**	**A040787**	**001**	Mar 20, 2007
AB			**50MG**	**A040788**	**001**	Mar 20, 2007
AB		MYLAN	**10MG**	**A091176**	**001**	Jun 07, 2010
AB			**25MG**	**A091176**	**002**	Jun 07, 2010
AB			**50MG**	**A091176**	**003**	Jun 07, 2010
AB		NORTHSTAR HLTHCARE	**10MG**	**A040840**	**002**	Mar 31, 2008
AB			**25MG**	**A040840**	**003**	Mar 31, 2008
AB			**50MG**	**A040840**	**001**	Mar 31, 2008
AB		NUVO PHARM	**10MG**	**A207120**	**001**	Mar 29, 2017
AB			**50MG**	**A207122**	**001**	Mar 29, 2017
AB		NUVO PHARMS INC	**25MG**	**A207121**	**001**	Mar 29, 2017
AB	**!**	PLIVA	**10MG**	**A088617**	**001**	Jan 10, 1986
AB	**!**		**25MG**	**A088618**	**001**	Jan 10, 1986
AB	**!**		**50MG**	**A088619**	**001**	Jan 10, 1986
AB		PRINSTON INC	**10MG**	**A040579**	**001**	May 27, 2005
AB			**25MG**	**A040574**	**001**	May 27, 2005
AB			**50MG**	**A040580**	**001**	May 27, 2005

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

AB		BARR	**EQ 25MG HYDROCHLORIDE**	**A088496**	**001**	Jun 15, 1984
AB			**EQ 50MG HYDROCHLORIDE**	**A088487**	**001**	Jun 15, 1984
AB		HERITAGE PHARMA	**EQ 25MG HYDROCHLORIDE**	**A201507**	**001**	Jun 03, 2013
AB			**EQ 50MG HYDROCHLORIDE**	**A201507**	**002**	Jun 03, 2013
AB		IMPAX LABS INC	**EQ 25MG HYDROCHLORIDE**	**A040156**	**001**	Jul 15, 1996
AB			**EQ 50MG HYDROCHLORIDE**	**A040156**	**002**	Jul 15, 1996
AB		SANDOZ	**EQ 25MG HYDROCHLORIDE**	**A087479**	**001**	
AB			**EQ 50MG HYDROCHLORIDE**	**A086183**	**001**	

VISTARIL

AB	**+**	PFIZER	**EQ 25MG HYDROCHLORIDE**	**N011459**	**002**	
AB	**+!**		**EQ 50MG HYDROCHLORIDE**	**N011459**	**004**	

HYDROXYZINE PAMOATE

		BARR	EQ 100MG HYDROCHLORIDE	A088488	001	Jun 15, 1984

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS

BONIVA

AP	**+!**	ROCHE	**EQ 3MG BASE/3ML**	**N021858**	**001**	Jan 06, 2006

IBANDRONATE SODIUM

AP		ACCORD HLTHCARE	**EQ 3MG BASE/3ML**	**A206058**	**001**	Feb 05, 2016
AP		APOTEX INC	**EQ 3MG BASE/3ML**	**A204222**	**001**	Oct 16, 2015
AP		AUROBINDO PHARMA LTD	**EQ 3MG BASE/3ML**	**A205332**	**001**	Aug 19, 2015
AP		EMCURE PHARMS LTD	**EQ 3MG BASE/3ML**	**A203987**	**001**	Sep 02, 2014
AP		MYLAN LABS LTD	**EQ 3MG BASE/3ML**	**A202671**	**001**	Sep 02, 2014
AP		SAGENT PHARMS	**EQ 3MG BASE/3ML**	**A202235**	**001**	Sep 02, 2014
AP		SUN PHARM INDS LTD	**EQ 3MG BASE/3ML**	**A090853**	**001**	Feb 14, 2014

TABLET;ORAL

BONIVA

AB	**+!**	HOFFMANN LA ROCHE	**EQ 150MG BASE**	**N021455**	**002**	Mar 24, 2005

IBANDRONATE SODIUM						
TABLET;ORAL						
IBANDRONATE SODIUM						
AB		APOTEX INC	**EQ 150MG BASE**	**A078948**	**001**	Mar 19, 2012
AB		AUROBINDO PHARMA LTD	**EQ 150MG BASE**	**A204502**	**001**	Mar 11, 2016
AB		DR REDDYS LABS LTD	**EQ 150MG BASE**	**A078997**	**001**	Apr 30, 2012
AB		MACLEODS PHARMS LTD	**EQ 150MG BASE**	**A206887**	**001**	Oct 31, 2017
AB		ORCHID HLTHCARE	**EQ 150MG BASE**	**A078998**	**001**	Mar 19, 2012
AB		SUN PHARM INDUSTRIES	**EQ 150MG BASE**	**A078996**	**001**	Aug 15, 2012
AB		WATSON LABS TEVA	**EQ 150MG BASE**	**A079003**	**001**	Mar 20, 2012
IBRUTINIB						
CAPSULE;ORAL						
IMBRUVICA						
+		PHARMACYCLICS INC	70MG	N205552	002	Dec 20, 2017
+!			140MG	N205552	001	Nov 13, 2013
TABLET;ORAL						
IMBRUVICA						
+		PHARMACYCLICS INC	140MG	N210563	001	Feb 16, 2018
+			280MG	N210563	002	Feb 16, 2018
+			420MG	N210563	003	Feb 16, 2018
+!			560MG	N210563	004	Feb 16, 2018
IBUPROFEN						
SOLUTION;INTRAVENOUS						
CALDOLOR						
+!		CUMBERLAND PHARMS	800MG/8ML (100MG/ML)	N022348	002	Jun 11, 2009
SUSPENSION;ORAL						
IBUPROFEN						
AB	**!**	ACTAVIS MID ATLANTIC	**100MG/5ML**	**A074978**	**001**	Mar 25, 1998
AB		HI-TECH PHARMACAL	**100MG/5ML**	**A205647**	**001**	Nov 03, 2016
AB		PERRIGO R AND D	**100MG/5ML**	**A076925**	**001**	Sep 23, 2004
AB		TARO	**100MG/5ML**	**A209204**	**001**	Jun 23, 2017
		AUROBINDO PHARMA LTD	100MG/5ML	A209178	001	Feb 16, 2018
TABLET;ORAL						
IBU-TAB						
AB		ALRA	**400MG**	**A071058**	**001**	Aug 11, 1988
AB			**600MG**	**A071059**	**001**	Aug 11, 1988
IBUPROFEN						
AB		AMNEAL PHARMS NY	**400MG**	**A071334**	**001**	Nov 25, 1986
AB			**400MG**	**A078558**	**001**	Jun 18, 2007
AB			**600MG**	**A071335**	**001**	Nov 25, 1986
AB			**600MG**	**A078558**	**002**	Jun 18, 2007
AB			**800MG**	**A071935**	**001**	Oct 13, 1987
AB			**800MG**	**A078558**	**003**	Jun 18, 2007
AB		CONTRACT PHARMACAL	**400MG**	**A071268**	**002**	Oct 15, 1986
AB			**600MG**	**A071268**	**001**	Oct 15, 1986
AB			**800MG**	**A071268**	**003**	Jul 01, 1988
AB		DR REDDYS LA	**400MG**	**A075682**	**001**	Nov 14, 2001
AB			**600MG**	**A075682**	**002**	Nov 14, 2001
AB	**!**		**800MG**	**A075682**	**003**	Nov 14, 2001
AB		DR REDDYS LABS INC	**400MG**	**A076112**	**001**	Oct 31, 2001
AB			**600MG**	**A076112**	**002**	Oct 31, 2001
AB			**800MG**	**A076112**	**003**	Oct 31, 2001
AB		GRANULES INDIA LTD	**400MG**	**A091625**	**001**	Sep 15, 2015
AB			**600MG**	**A091625**	**002**	Sep 15, 2015
AB			**800MG**	**A091625**	**003**	Sep 15, 2015
AB		HEC PHARM	**400MG**	**A204062**	**001**	Sep 10, 2018
AB			**600MG**	**A204062**	**002**	Sep 10, 2018
AB			**800MG**	**A204062**	**003**	Sep 10, 2018
AB		MARKSANS PHARMA	**400MG**	**A090796**	**001**	Dec 21, 2010
AB			**600MG**	**A090796**	**002**	Dec 21, 2010
AB			**800MG**	**A090796**	**003**	Dec 21, 2010
AB		PERRIGO R AND D	**400MG**	**A077114**	**001**	Jul 18, 2005
AB			**600MG**	**A077114**	**002**	Jul 18, 2005
AB			**800MG**	**A077114**	**003**	Jul 18, 2005
AB		SHANDONG XINHUA	**400MG**	**A202413**	**001**	Nov 23, 2016
AB			**600MG**	**A202413**	**002**	Nov 23, 2016
AB			**800MG**	**A202413**	**003**	Nov 23, 2016
AB		STRIDES PHARMA	**400MG**	**A078329**	**001**	Feb 05, 2009

IBUPROFEN

TABLET;ORAL

IBUPROFEN

AB			**600MG**	**A078329 002**	Feb 05, 2009
AB			**800MG**	**A078329 003**	Feb 05, 2009
AB		VINTAGE PHARMS	**400MG**	**A071644 001**	Feb 01, 1988

IBUPROFEN LYSINE

INJECTABLE;INTRAVENOUS

IBUPROFEN LYSINE

AP		X-GEN PHARMS INC	**EQ 20MG BASE/2ML (EQ 10MG BASE/ML)**	**A202402 001**	Mar 30, 2016

NEOPROFEN

AP	**+!**	RECORDATI RARE	**EQ 20MG BASE/2ML (EQ 10MG BASE/ML)**	**N021903 001**	Apr 13, 2006

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE HYDROCHLORIDE AND IBUPROFEN

AB		ACTAVIS ELIZABETH	**400MG;5MG**	**A078769 001**	Jan 04, 2008
AB	**!**	BARR LABS INC	**400MG;5MG**	**A078316 001**	Nov 29, 2007

IBUTILIDE FUMARATE

INJECTABLE;INJECTION

CORVERT

AP	**+!**	PHARMACIA AND UPJOHN	**0.1MG/ML**	**N020491 001**	Dec 28, 1995

IBUTILIDE FUMARATE

AP		LUITPOLD	**0.1MG/ML**	**A090240 001**	Jan 11, 2010
AP		MYLAN INSTITUTIONAL	**0.1MG/ML**	**A090643 001**	Jan 11, 2010

ICATIBANT ACETATE

INJECTABLE;SUBCUTANEOUS

FIRAZYR

	+!	SHIRE ORPHAN THERAP	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N022150 001	Aug 25, 2011

ICODEXTRIN

SOLUTION;INTRAPERITONEAL

EXTRANEAL

	+!	BAXTER HLTHCARE	7.5GM/100ML	N021321 001	Dec 20, 2002

ICOSAPENT ETHYL

CAPSULE;ORAL

VASCEPA

	+	AMARIN PHARMS	500MG	N202057 002	Feb 16, 2017
	+!		1GM	N202057 001	Jul 26, 2012

IDARUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

IDAMYCIN PFS

AP	**+!**	PHARMACIA AND UPJOHN	**1MG/ML**	**N050734 001**	Feb 17, 1997

IDARUBICIN HYDROCHLORIDE

AP		FRESENIUS KABI USA	**1MG/ML**	**A065440 001**	Aug 04, 2009
AP		MYLAN LABS LTD	**1MG/ML**	**A200144 001**	Oct 11, 2012
AP		WEST-WARD PHARMS INT	**1MG/ML**	**A065275 001**	Dec 14, 2006
AP			**1MG/ML**	**A065288 001**	May 15, 2007

IDARUBICIN HYDROCHLORIDE PFS

AP		TEVA PHARMS USA	**1MG/ML**	**A065036 001**	May 01, 2002

IDELALISIB

TABLET;ORAL

ZYDELIG

	+	GILEAD SCIENCES INC	100MG	N205858 001	Jul 23, 2014
	+!		150MG	N205858 002	Jul 23, 2014

IFOSFAMIDE

INJECTABLE;INJECTION

IFEX

AP	**+**	BAXTER HLTHCARE	**1GM/VIAL**	**N019763 001**	Dec 30, 1988
AP	**+**		**3GM/VIAL**	**N019763 002**	Dec 30, 1988

IFOSFAMIDE

AP	**!**	FRESENIUS KABI USA	**1GM/VIAL**	**A076078 001**	May 28, 2002
AP	**!**		**3GM/VIAL**	**A076078 002**	May 28, 2002
AP		MYLAN LABS LTD	**1GM/20ML (50MG/ML)**	**A201689 001**	Nov 26, 2012
AP			**3GM/60ML (50MG/ML)**	**A201689 002**	Nov 26, 2012
AP	**!**	TEVA PHARMS USA	**1GM/20ML (50MG/ML)**	**A076657 001**	Apr 04, 2007
AP	**!**		**3GM/60ML (50MG/ML)**	**A076657 002**	Apr 04, 2007

IFOSFAMIDE
INJECTABLE;INJECTION
IFOSFAMIDE

AP		WEST-WARD PHARMS INT	**1GM/20ML (50MG/ML)**	**A076619**	**001**	Jun 29, 2011
AP			**3GM/60ML (50MG/ML)**	**A076619**	**002**	Jun 29, 2011

ILOPERIDONE
TABLET;ORAL
FANAPT

AB	**+!**	VANDA PHARMS INC	**1MG**	**N022192**	**001**	May 06, 2009
AB	**+**		**2MG**	**N022192**	**002**	May 06, 2009
AB	**+**		**4MG**	**N022192**	**003**	May 06, 2009
AB	**+**		**6MG**	**N022192**	**004**	May 06, 2009
AB	**+**		**8MG**	**N022192**	**005**	May 06, 2009
AB	**+**		**10MG**	**N022192**	**006**	May 06, 2009
AB	**+**		**12MG**	**N022192**	**007**	May 06, 2009

ILOPERIDONE

AB		INVENTIA HLTHCARE	**1MG**	**A207231**	**001**	Nov 28, 2016
AB			**2MG**	**A207231**	**002**	Nov 28, 2016
AB			**4MG**	**A207231**	**003**	Nov 28, 2016
AB			**6MG**	**A207231**	**004**	Nov 28, 2016
AB			**8MG**	**A207231**	**005**	Nov 28, 2016
AB			**10MG**	**A207231**	**006**	Nov 28, 2016
AB			**12MG**	**A207231**	**007**	Nov 28, 2016

ILOPROST
SOLUTION;INHALATION
VENTAVIS

	+!	ACTELION PHARMS LTD	10MCG/ML (10MCG/ML)	N021779	002	Dec 08, 2005
	+!		20MCG/ML (20MCG/ML)	N021779	003	Aug 07, 2009

IMATINIB MESYLATE
TABLET;ORAL
GLEEVEC

AB	**+**	NOVARTIS	**EQ 100MG BASE**	**N021588**	**001**	Apr 18, 2003
AB	**+!**		**EQ 400MG BASE**	**N021588**	**002**	Apr 18, 2003

IMATINIB MESYLATE

AB		APOTEX INC	**EQ 100MG BASE**	**A079179**	**001**	Aug 05, 2016
AB			**EQ 400MG BASE**	**A079179**	**002**	Aug 05, 2016
AB		DR REDDYS LABS LTD	**EQ 100MG BASE**	**A206547**	**001**	Aug 13, 2018
AB			**EQ 400MG BASE**	**A206547**	**002**	Aug 13, 2018
AB		MYLAN PHARMS INC	**EQ 100MG BASE**	**A204644**	**001**	Jun 21, 2017
AB			**EQ 400MG BASE**	**A204644**	**002**	Jun 21, 2017
AB		SUN PHARMA GLOBAL	**EQ 100MG BASE**	**A078340**	**001**	Dec 03, 2015
AB			**EQ 400MG BASE**	**A078340**	**002**	Dec 03, 2015
AB		TEVA PHARMS USA	**EQ 100MG BASE**	**A204285**	**001**	Aug 04, 2016
AB			**EQ 400MG BASE**	**A204285**	**002**	Aug 04, 2016
AB		WEST-WARD PHARMS INT	**EQ 100MG BASE**	**A207586**	**001**	Jul 13, 2018
AB			**EQ 400MG BASE**	**A207586**	**002**	Jul 13, 2018

IMIGLUCERASE
INJECTABLE;INJECTION
CEREZYME

	+	GENZYME	200 UNITS/VIAL	N020367	001	May 23, 1994
	+!		400 UNITS/VIAL	N020367	002	Sep 22, 1999

IMIPRAMINE HYDROCHLORIDE
TABLET;ORAL
IMIPRAMINE HYDROCHLORIDE

AB		LEADING PHARMA LLC	**10MG**	**A040903**	**001**	Oct 24, 2012
AB			**25MG**	**A040903**	**002**	Oct 24, 2012
AB			**50MG**	**A040903**	**003**	Oct 24, 2012
AB		LUPIN LTD	**10MG**	**A090441**	**002**	Mar 11, 2010
AB			**25MG**	**A090441**	**003**	Mar 11, 2010
AB			**50MG**	**A090441**	**001**	Mar 11, 2010
AB		PAR PHARM	**10MG**	**A088292**	**001**	Oct 21, 1983
AB			**25MG**	**A088262**	**001**	Oct 21, 1983
AB			**50MG**	**A088276**	**001**	Oct 21, 1983
AB		SANDOZ	**10MG**	**A084936**	**002**	
AB			**25MG**	**A083745**	**001**	
AB			**50MG**	**A084937**	**001**	
AB		SPECGX LLC	**10MG**	**A087846**	**002**	May 22, 1984
AB			**25MG**	**A087846**	**003**	May 22, 1984

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL

IMIPRAMINE HYDROCHLORIDE

AB		SUN PHARM INDUSTRIES	**10MG**	**A081048**	**001**	Jun 05, 1990
AB			**25MG**	**A081049**	**001**	Jun 05, 1990
AB			**50MG**	**A081050**	**001**	Jun 05, 1990

TOFRANIL

AB	**!**	SPECGX LLC	**50MG**	**A087846**	**001**	May 22, 1984

IMIPRAMINE HYDROCHLORIDE

		OXFORD PHARMS	10MG	A040751	003	Feb 28, 2008
			25MG	A040751	002	Feb 28, 2008

IMIPRAMINE PAMOATE

CAPSULE;ORAL

IMIPRAMINE PAMOATE

AB		LUPIN LTD	**EQ 75MG HYDROCHLORIDE**	**A090444**	**001**	Apr 16, 2010
AB			**EQ 100MG HYDROCHLORIDE**	**A090444**	**002**	Apr 16, 2010
AB			**EQ 125MG HYDROCHLORIDE**	**A090444**	**003**	Apr 16, 2010
AB			**EQ 150MG HYDROCHLORIDE**	**A090444**	**004**	Apr 16, 2010
AB	**!**	WEST-WARD PHARMS INT	**EQ 75MG HYDROCHLORIDE**	**A091099**	**001**	Apr 16, 2010
AB			**EQ 100MG HYDROCHLORIDE**	**A091099**	**002**	Apr 16, 2010
AB			**EQ 125MG HYDROCHLORIDE**	**A091099**	**003**	Apr 16, 2010
AB			**EQ 150MG HYDROCHLORIDE**	**A091099**	**004**	Apr 16, 2010

IMIQUIMOD

CREAM;TOPICAL

ALDARA

AB	**+!**	MEDICIS	**5%**	**N020723**	**001**	Feb 27, 1997

IMIQUIMOD

AB		ANDA REPOSITORY	**5%**	**A091044**	**001**	Feb 28, 2011
AB		APOTEX INC	**5%**	**A091308**	**001**	Apr 06, 2012
AB		FOUGERA PHARMS	**5%**	**A078548**	**001**	Feb 25, 2010
AB		GLENMARK GENERICS	**5%**	**A201994**	**001**	Mar 06, 2012
AB		PERRIGO ISRAEL	**5%**	**A078837**	**001**	Sep 07, 2010
AB		TARO	**5%**	**A200173**	**001**	Apr 15, 2011

ZYCLARA

	+!	MEDICIS	2.5%	N022483	002	Jul 15, 2011
	+!		3.75%	N022483	001	Mar 25, 2010

INAMRINONE LACTATE

INJECTABLE;INJECTION

AMRINONE LACTATE

	!	WEST-WARD PHARMS INT	EQ 5MG BASE/ML	A075513	001	May 09, 2000

INDACATEROL MALEATE

POWDER;INHALATION

ARCAPTA NEOHALER

	+!	SUNOVION PHARMS INC	EQ 75MCG BASE	N022383	001	Jul 01, 2011

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

AB		ACTAVIS ELIZABETH	**1.25MG**	**A074722**	**001**	Jun 17, 1996
AB			**2.5MG**	**A074722**	**002**	Jun 17, 1996
AB		AMERIGEN PHARMS LTD	**1.25MG**	**A075201**	**001**	Dec 04, 1998
AB			**2.5MG**	**A075201**	**002**	Dec 04, 1998
AB		ANI PHARMS INC	**1.25MG**	**A074299**	**002**	Apr 29, 1996
AB			**2.5MG**	**A074299**	**001**	Jul 27, 1995
AB		MYLAN	**1.25MG**	**A074461**	**002**	Mar 26, 1997
AB	**!**		**2.5MG**	**A074461**	**001**	Mar 27, 1996

INDINAVIR SULFATE

CAPSULE;ORAL

CRIXIVAN

	+	MERCK SHARP DOHME	EQ 200MG BASE	N020685	003	Mar 13, 1996
	+!		EQ 400MG BASE	N020685	001	Mar 13, 1996

INDIUM IN-111 CHLORIDE							
INJECTABLE;INJECTION							
INDICLOR							
	+!	GE HEALTHCARE	2mCi/0.2ML		N019862	001	Dec 29, 1992
INDIUM IN 111 CHLORIDE							
	+!	MALLINKRODT NUCLEAR	5mCi/0.5ML		N019841	001	Sep 27, 1994
INDIUM IN-111 OXYQUINOLINE							
INJECTABLE;INJECTION							
INDIUM IN 111 OXYQUINOLINE							
	+!	GE HEALTHCARE	1mCi/ML		N019044	001	Dec 24, 1985
INDIUM IN-111 PENTETATE DISODIUM							
INJECTABLE;INTRATHECAL							
MPI INDIUM DTPA IN 111							
	+!	GE HEALTHCARE	1mCi/ML		N017707	001	Feb 18, 1982
INDIUM IN-111 PENTETREOTIDE KIT							
INJECTABLE;INJECTION							
OCTREOSCAN							
	+!	MALLINKRODT NUCLEAR	3mCi/ML		N020314	001	Jun 02, 1994
INDOCYANINE GREEN							
INJECTABLE;INJECTION							
IC-GREEN							
AP	**+!**	AKORN	**25MG/VIAL**		**N011525**	**001**	
INDOCYANINE GREEN							
AP		DIAGNOSTIC GREEN	**25MG/VIAL**		**A040811**	**001**	Nov 21, 2007
POWDER;INTRAVENOUS, INTERSTITIAL							
SPY AGENT GREEN KIT							
	+!	NOVADAQ TECH	25MG/VIAL		N211580	001	Nov 21, 2018
INDOMETHACIN							
CAPSULE;ORAL							
INDOMETHACIN							
AB		GLENMARK GENERICS	**25MG**		**A091276**	**001**	Dec 22, 2010
AB			**50MG**		**A091276**	**002**	Dec 22, 2010
AB		HERITAGE PHARMS INC	**25MG**		**N018851**	**001**	May 18, 1984
AB			**50MG**		**N018851**	**002**	May 18, 1984
AB		HETERO LABS LTD III	**25MG**		**A091240**	**001**	Apr 12, 2011
AB			**50MG**		**A091240**	**002**	Apr 12, 2011
AB		IVAX SUB TEVA PHARMS	**25MG**		**A070719**	**001**	Feb 12, 1986
AB			**50MG**		**A070756**	**001**	Feb 12, 1986
AB		JUBILANT GENERICS	**25MG**		**A205215**	**001**	Aug 25, 2017
AB			**50MG**		**A205215**	**002**	Aug 25, 2017
AB		MYLAN	**25MG**		**N018858**	**001**	Apr 20, 1984
AB	**!**		**50MG**		**A070624**	**001**	Sep 04, 1985
AB		SANDOZ	**25MG**		**A070673**	**001**	Apr 29, 1987
AB			**50MG**		**A070674**	**001**	Apr 29, 1987
AB		SUN PHARM INDS INC	**25MG**		**A091401**	**001**	Mar 28, 2013
AB			**50MG**		**A091401**	**002**	Mar 28, 2013
AB		ZYDUS PHARMS USA INC	**25MG**		**A090403**	**001**	Nov 15, 2010
AB			**50MG**		**A090403**	**002**	Nov 15, 2010
TIVORBEX							
	+	IROKO PHARMS LLC	20MG		N204768	001	Feb 24, 2014
	+!		40MG		N204768	002	Feb 24, 2014
CAPSULE, EXTENDED RELEASE;ORAL							
INDOMETHACIN							
AB		AMNEAL PHARMS	**75MG**		**A091549**	**001**	Dec 01, 2010
AB		AUROBINDO PHARMA LTD	**75MG**		**A204243**	**001**	Dec 27, 2016
AB		AVANTHI INC	**75MG**		**A079175**	**001**	Mar 06, 2009
AB		CHARTWELL RX	**75MG**		**A200529**	**001**	Nov 30, 2010
AB		GLENMARK PHARMS LTD	**75MG**		**A203501**	**001**	Jun 22, 2017
AB		HETERO LABS LTD III	**75MG**		**A201807**	**001**	Sep 28, 2012
AB		JUBILANT GENERICS	**75MG**		**A202706**	**001**	Oct 05, 2015
AB		MYLAN PHARMS INC	**75MG**		**A202139**	**001**	Mar 20, 2014
AB		NOVAST LABS	**75MG**		**A204853**	**001**	May 08, 2017
AB	**!**	SANDOZ	**75MG**		**A074464**	**001**	May 28, 1998
AB		ZYDUS PHARMS USA INC	**75MG**		**A202711**	**001**	Sep 25, 2017

INDOMETHACIN						
INJECTABLE;INJECTION						
INDOMETHACIN						
+!	FRESENIUS KABI USA	EQ 1MG BASE/VIAL		N022536	001	Mar 17, 2010
SUPPOSITORY;RECTAL						
INDOMETHACIN						
!	G AND W LABS	50MG		A073314	001	Aug 31, 1992
SUSPENSION;ORAL						
INDOCIN						
+!	IROKO PHARMS	25MG/5ML		N018332	001	Oct 10, 1985
INDOMETHACIN SODIUM						
INJECTABLE;INJECTION						
INDOCIN						
AP **+!**	RECORDATI RARE	**EQ 1MG BASE/VIAL**		**N018878**	**001**	Jan 30, 1985
INDOMETHACIN SODIUM						
AP	HOSPIRA INC	**EQ 1MG BASE/VIAL**		**A204118**	**001**	Apr 19, 2016
AP	NAVINTA LLC	**EQ 1MG BASE/VIAL**		**A206561**	**001**	Jul 19, 2017
AP	WEST-WARD PHARMS INT	**EQ 1MG BASE/VIAL**		**A078713**	**001**	Jul 16, 2008
INGENOL MEBUTATE						
GEL;TOPICAL						
INGENOL MEBUTATE						
AB	PERRIGO UK FINCO	**0.015%**		**A209018**	**001**	Jan 07, 2019
AB		**0.05%**		**A209019**	**001**	Jan 09, 2019
PICATO						
AB **+!**	LEO LABS	**0.015%**		**N202833**	**001**	Jan 23, 2012
AB **+!**		**0.05%**		**N202833**	**002**	Jan 23, 2012
INOTERSEN SODIUM						
SOLUTION;SUBCUTANEOUS						
TEGSEDI						
+!	AKCEA THERAPS	EQ 284MG BASE/1.5ML (EQ 189.3MG BASE/ML)		N211172	001	Oct 05, 2018
INSULIN ASPART						
SOLUTION;INTRAVENOUS, SUBCUTANEOUS						
FIASP						
+!	NOVO	1000 UNITS/10ML (100 UNITS/ML)		N208751	001	Sep 29, 2017
SOLUTION;SUBCUTANEOUS						
FIASP FLEXTOUCH						
+!	NOVO	300 UNITS/3ML (100 UNITS/ML)		N208751	002	Sep 29, 2017
INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT						
INJECTABLE;SUBCUTANEOUS						
NOVOLOG MIX 70/30						
+!	NOVO NORDISK INC	700 UNITS/10ML; 300 UNITS/10ML (70 UNITS/ML; 30 UNITS/ML)		N021172	001	Nov 01, 2001
NOVOLOG MIX 70/30 FLEXPEN						
+!	NOVO NORDISK INC	210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)		N021172	004	May 03, 2002
INSULIN ASPART RECOMBINANT						
INJECTABLE;SUBCUTANEOUS						
NOVOLOG						
+!	NOVO NORDISK INC	1000 UNITS/10ML (100 UNITS/ML)		N020986	001	Jun 07, 2000
NOVOLOG FLEXPEN						
+!	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)		N020986	003	Jan 19, 2001
NOVOLOG PENFILL						
+!	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)		N020986	002	Jun 07, 2000
INSULIN ASPART; INSULIN DEGLUDEC						
SOLUTION;SUBCUTANEOUS						
RYZODEG 70/30						
+!	NOVO	90 UNITS/3ML;210 UNITS/3ML (30 UNITS/ML;70 UNITS/ML)		N203313	001	Sep 25, 2015
INSULIN DEGLUDEC						
SOLUTION;SUBCUTANEOUS						
TRESIBA						
+	NOVO	300 UNITS/3ML (100 UNITS/ML)		N203314	001	Sep 25, 2015
+!		600 UNITS/3ML (200 UNITS/ML)		N203314	002	Sep 25, 2015

INSULIN DEGLUDEC; LIRAGLUTIDE
SOLUTION;SUBCUTANEOUS
XULTOPHY 100/3.6

+!	NOVO	300 UNITS/3ML;10.8MG/3ML (100 UNITS/ML;3.6MG/ML)	N208583	001	Nov 21, 2016

INSULIN DETEMIR RECOMBINANT
INJECTABLE;SUBCUTANEOUS
LEVEMIR

+!	NOVO NORDISK INC	1000 UNITS/10ML (100 UNITS/ML)	N021536	001	Jun 16, 2005

LEVEMIR FLEXTOUCH

+!	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	005	Oct 31, 2013

INSULIN GLARGINE
SOLUTION;SUBCUTANEOUS
BASAGLAR

	ELI LILLY AND CO	300 UNITS/3ML (100 UNITS/ML)	N205692	001	Dec 16, 2015

INSULIN GLARGINE RECOMBINANT
INJECTABLE;INJECTION
LANTUS

+!	SANOFI AVENTIS US	100 UNITS/ML	N021081	001	Apr 20, 2000

LANTUS SOLOSTAR

+!	SANOFI AVENTIS US	300 UNITS/3ML (100 UNITS/ML)	N021081	002	Apr 27, 2007

SOLUTION;SUBCUTANEOUS
TOUJEO MAX SOLOSTAR

+!	SANOFI US SERVICES	900 UNITS/3ML (300 UNITS/ML)	N206538	002	Mar 26, 2018

TOUJEO SOLOSTAR

+!	SANOFI US SERVICES	450 UNITS/1.5ML (300 UNITS/ML)	N206538	001	Feb 25, 2015

INSULIN GLARGINE; LIXISENATIDE
SOLUTION;SUBCUTANEOUS
SOLIQUA 100/33

+!	SANOFI-AVENTIS US	300 UNITS/3ML;99MCG/3ML (100 UNITS/ML;33MCG/ML)	N208673	001	Nov 21, 2016

INSULIN GLULISINE RECOMBINANT
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
APIDRA

+!	SANOFI AVENTIS US	1000 UNITS/10ML (100 UNITS/ML)	N021629	001	Apr 16, 2004

INJECTABLE;SUBCUTANEOUS
APIDRA SOLOSTAR

+	SANOFI AVENTIS US	300 UNITS/3ML	N021629	003	Feb 24, 2009

INSULIN HUMAN
SOLUTION;SUBCUTANEOUS
HUMULIN R

+!	LILLY	10000 UNITS/20ML (500 UNITS/ML)	N018780	004	Mar 31, 1994

HUMULIN R KWIKPEN

+!	LILLY	1500 UNITS/3ML (500 UNITS/ML)	N018780	002	Dec 29, 2015

INSULIN LISPRO
SOLUTION;INTRAVENOUS, SUBCUTANEOUS
ADMELOG

+	SANOFI-AVENTIS US	300 UNITS/3ML (100 UNITS/ML)	N209196	003	Oct 19, 2018
+		1000 UNITS/10ML (100 UNITS/ML)	N209196	001	Dec 11, 2017

ADMELOG SOLOSTAR

+	SANOFI-AVENTIS US	300 UNITS/3ML (100 UNITS/ML)	N209196	002	Dec 11, 2017

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT
INJECTABLE;INJECTION
HUMALOG MIX 50/50

+!	LILLY	50 UNITS/ML;50 UNITS/ML	N021018	001	Dec 22, 1999

HUMALOG MIX 50/50 KWIKPEN

+!	LILLY	50 UNITS/ML;50 UNITS/ML	N021018	002	Sep 06, 2007

HUMALOG MIX 75/25

+!	LILLY	75 UNITS/ML;25 UNITS/ML	N021017	001	Dec 22, 1999

HUMALOG MIX 75/25 KWIKPEN

+!	LILLY	75 UNITS/ML;25 UNITS/ML	N021017	002	Sep 06, 2007

INSULIN LISPRO RECOMBINANT
INJECTABLE;INJECTION
HUMALOG

+!	LILLY	100 UNITS/ML	N020563	001	Jun 14, 1996

HUMALOG KWIKPEN

+!	LILLY	100 UNITS/ML	N020563	003	Sep 06, 2007

INSULIN LISPRO RECOMBINANT					
SOLUTION;SUBCUTANEOUS					
HUMALOG KWIKPEN					
+!	ELI LILLY AND CO	200 UNITS/ML	N205747	001	May 26, 2015
INSULIN RECOMBINANT HUMAN					
POWDER;INHALATION					
AFREZZA					
+	MANNKIND	4 UNITS/INH	N022472	001	Jun 27, 2014
+!		8 UNITS/INH	N022472	002	Jun 27, 2014
+		12 UNITS/INH	N022472	003	Apr 17, 2015
IOBENGUANE I-131					
SOLUTION;INTRAVENOUS					
AZEDRA					
+!	PROGENICS PHARMS INC	15mCi/ML	N209607	001	Jul 30, 2018
IOBENGUANE SULFATE I-123					
SOLUTION;INTRAVENOUS					
ADREVIEW					
+!	GE HEALTHCARE	10mCi/5ML (2mCi/ML)	N022290	001	Sep 19, 2008
IODIXANOL					
INJECTABLE;INJECTION					
VISIPAQUE 270					
+!	GE HEALTHCARE	55%	N020351	001	Mar 22, 1996
VISIPAQUE 320					
+!	GE HEALTHCARE	65.2%	N020351	002	Mar 22, 1996
		65.2%	N020808	002	Aug 29, 1997
IOFLUPANE I-123					
SOLUTION;INTRAVENOUS					
DATSCAN					
+!	GE HLTHCARE INC	5mCi/2.5ML (2mCi/ML)	N022454	001	Jan 14, 2011
IOHEXOL					
FOR SOLUTION;ORAL					
ORALTAG					
	INTERPHARMA PRAHA AS	9.7GM/BOT	N205383	001	Mar 26, 2015
INJECTABLE;INJECTION					
OMNIPAQUE 140					
+!	GE HEALTHCARE	30.2%	N018956	005	Nov 30, 1988
SOLUTION;INJECTION, ORAL					
OMNIPAQUE 350					
+!	GE HEALTHCARE	75.5%	N018956	004	Dec 26, 1985
		75.5%	N020608	003	Oct 24, 1995
SOLUTION;INJECTION, ORAL, RECTAL					
OMNIPAQUE 180					
+!	GE HEALTHCARE	38.8%	N018956	001	Dec 26, 1985
OMNIPAQUE 240					
+!	GE HEALTHCARE	51.8%	N018956	002	Dec 26, 1985
OMNIPAQUE 300					
+!	GE HEALTHCARE	64.7%	N018956	003	Dec 26, 1985
		64.7%	N020608	002	Oct 24, 1995
SOLUTION;ORAL					
OMNIPAQUE 12					
+!	GE HEALTHCARE	2.6%	N018956	009	Apr 17, 2018
OMNIPAQUE 9					
+!	GE HEALTHCARE	1.9%	N018956	008	Apr 17, 2018
IOPAMIDOL					
INJECTABLE;INJECTION					
ISOVUE-300					
AP **+!**	BRACCO	**61%**	**N018735**	**002**	Dec 31, 1985
ISOVUE-370					
AP **+!**	BRACCO	**76%**	**N018735**	**003**	Dec 31, 1985
SCANLUX-300					
AP	SANOCHEMIA CORP USA	**61%**	**A090394**	**001**	Jun 18, 2010
SCANLUX-370					
AP	SANOCHEMIA CORP USA	**76%**	**A090394**	**002**	Jun 18, 2010
ISOVUE-200					
+!	BRACCO	41%	N018735	006	Jul 07, 1987
ISOVUE-250					
+!	BRACCO	51%	N018735	007	Jul 06, 1992

IOPAMIDOL

INJECTABLE;INJECTION

ISOVUE-250						
+!		51%	N020327	002	Oct 12, 1994
ISOVUE-300						
+!	BRACCO	61%	N020327	003	Oct 12, 1994
ISOVUE-370						
+!	BRACCO	76%	N020327	004	Oct 12, 1994
ISOVUE-M 200						
+!	BRACCO	41%	N018735	001	Dec 31, 1985
ISOVUE-M 300						
+!	BRACCO	61%	N018735	004	Dec 31, 1985

IOPROMIDE

INJECTABLE;INJECTION

ULTRAVIST (PHARMACY BULK)						
+!	BAYER HLTHCARE	49.9%	N021425	003	Mar 12, 2004
+!		62.3%	N021425	001	Sep 20, 2002
+!		76.9%	N021425	002	Sep 20, 2002
ULTRAVIST 240						
+!	BAYER HLTHCARE	49.9%	N020220	003	May 10, 1995
ULTRAVIST 300						
+!	BAYER HLTHCARE	62.3%	N020220	002	May 10, 1995
ULTRAVIST 370						
+!	BAYER HLTHCARE	76.9%	N020220	001	May 10, 1995

IOTHALAMATE MEGLUMINE

INJECTABLE;INJECTION

CONRAY						
+!	LIEBEL-FLARSHEIM	60%	N013295	001	
CONRAY 43						
+!	LIEBEL-FLARSHEIM	43%	N013295	002	

SOLUTION;INTRAVESICAL

CYSTO-CONRAY II						
	LIEBEL-FLARSHEIM	17.2%	N017057	002	

IOTHALAMATE SODIUM I-125

INJECTABLE;INJECTION

GLOFIL-125						
	ISOTEX	250-300uCi/ML	N017279	001	

IOVERSOL

INJECTABLE;INJECTION

OPTIRAY 240						
+!	LIEBEL-FLARSHEIM	51%	N019710	002	Dec 30, 1988
OPTIRAY 300						
+!	LIEBEL-FLARSHEIM	64%	N019710	004	Jan 22, 1992
+!		64%	N020923	004	May 13, 1999
OPTIRAY 320						
+!	LIEBEL-FLARSHEIM	68%	N019710	001	Dec 30, 1988
+!		68%	N020923	002	May 29, 1998
OPTIRAY 350						
+!	LIEBEL-FLARSHEIM	74%	N019710	005	Jan 22, 1992
+!		74%	N020923	003	May 28, 1998

IPRATROPIUM BROMIDE

AEROSOL, METERED;INHALATION

ATROVENT HFA						
+!	BOEHRINGER INGELHEIM	0.021MG/INH	N021527	001	Nov 27, 2004

SOLUTION;INHALATION

IPRATROPIUM BROMIDE						
AN	AUROBINDO PHARMA LTD	**0.02%**	**A206543**	**001**	Oct 27, 2016
AN	LANDELA PHARM	**0.02%**	**A077072**	**001**	Jul 19, 2005
AN	NEPHRON	**0.02%**	**A075562**	**001**	Sep 27, 2001
AN !	RITEDOSE CORP	**0.02%**	**A075693**	**001**	Jan 26, 2001
AN	SUN PHARMA GLOBAL	**0.02%**	**A207903**	**001**	Jan 03, 2017
AN	WATSON LABS	**0.02%**	**A076291**	**001**	May 09, 2005

SPRAY, METERED;NASAL

IPRATROPIUM BROMIDE						
AB	APOTEX INC	**0.042MG/SPRAY**	**A076155**	**001**	Apr 18, 2003
AB	BAUSCH AND LOMB	**0.021MG/SPRAY**	**A076025**	**001**	Mar 31, 2003
AB		**0.042MG/SPRAY**	**A076103**	**001**	Mar 31, 2003
AB	MYLAN SPECIALITY LP	**0.021MG/SPRAY**	**A075552**	**001**	Mar 31, 2003

IPRATROPIUM BROMIDE

SPRAY, METERED;NASAL

IPRATROPIUM BROMIDE

AB			**0.042MG/SPRAY**	**A075553**	**001**	Mar 31, 2003
AB	!	WEST-WARD PHARMS INT	**0.021MG/SPRAY**	**A076664**	**001**	Nov 05, 2003
AB	!		**0.042MG/SPRAY**	**A076598**	**001**	Nov 05, 2003

IRBESARTAN

TABLET;ORAL

AVAPRO

AB	+	SANOFI AVENTIS US	**75MG**	**N020757**	**001**	Sep 30, 1997
AB	+		**150MG**	**N020757**	**002**	Sep 30, 1997
AB	+!		**300MG**	**N020757**	**003**	Sep 30, 1997

IRBESARTAN

AB		ALEMBIC PHARMS LTD	**75MG**	**A091236**	**001**	Oct 15, 2012
AB			**150MG**	**A091236**	**002**	Oct 15, 2012
AB			**300MG**	**A091236**	**003**	Oct 15, 2012
AB		AMNEAL PHARMS	**75MG**	**A204740**	**001**	Apr 17, 2018
AB			**150MG**	**A204740**	**002**	Apr 17, 2018
AB			**300MG**	**A204740**	**003**	Apr 17, 2018
AB		AUROBINDO PHARMA LTD	**75MG**	**A203081**	**001**	Sep 27, 2012
AB			**150MG**	**A203081**	**002**	Sep 27, 2012
AB			**300MG**	**A203081**	**003**	Sep 27, 2012
AB		CHARTWELL MOLECULAR	**75MG**	**A077205**	**001**	Nov 14, 2012
AB			**150MG**	**A077205**	**002**	Nov 14, 2012
AB			**300MG**	**A077205**	**003**	Nov 14, 2012
AB		HETERO LABS LTD V	**75MG**	**A202910**	**001**	Sep 27, 2012
AB			**150MG**	**A202910**	**002**	Sep 27, 2012
AB			**300MG**	**A202910**	**003**	Sep 27, 2012
AB		HISUN PHARM HANGZHOU	**75MG**	**A206194**	**001**	Jun 14, 2016
AB			**150MG**	**A206194**	**002**	Jun 14, 2016
AB			**300MG**	**A206194**	**003**	Jun 14, 2016
AB		JUBILANT GENERICS	**75MG**	**A203534**	**001**	Feb 23, 2015
AB			**150MG**	**A203534**	**002**	Feb 23, 2015
AB			**300MG**	**A203534**	**003**	Feb 23, 2015
AB		LUPIN LTD	**75MG**	**A201531**	**001**	Oct 15, 2012
AB			**150MG**	**A201531**	**002**	Oct 15, 2012
AB			**300MG**	**A201531**	**003**	Oct 15, 2012
AB		MACLEODS PHARMS LTD	**75MG**	**A202254**	**001**	Oct 03, 2012
AB			**150MG**	**A202254**	**002**	Oct 03, 2012
AB			**300MG**	**A202254**	**003**	Oct 03, 2012
AB		NEOPHARMA	**75MG**	**A203161**	**001**	Sep 27, 2012
AB			**150MG**	**A203161**	**002**	Sep 27, 2012
AB			**300MG**	**A203161**	**003**	Sep 27, 2012
AB		PRINSTON INC	**75MG**	**A203071**	**001**	Sep 27, 2012
AB			**150MG**	**A203071**	**002**	Sep 27, 2012
AB			**300MG**	**A203071**	**003**	Sep 27, 2012
AB		SANDOZ	**75MG**	**A077466**	**001**	Sep 27, 2012
AB			**150MG**	**A077466**	**002**	Sep 27, 2012
AB			**300MG**	**A077466**	**003**	Sep 27, 2012
AB		SCIEGEN PHARMS INC	**75MG**	**A204774**	**001**	Dec 07, 2015
AB			**150MG**	**A204774**	**002**	Dec 07, 2015
AB			**300MG**	**A204774**	**003**	Dec 07, 2015
AB		TEVA PHARMS	**75MG**	**A077159**	**001**	Mar 30, 2012
AB			**150MG**	**A077159**	**002**	Mar 30, 2012
AB			**300MG**	**A077159**	**003**	Mar 30, 2012
AB		UNICHEM LABS LTD	**75MG**	**A203020**	**001**	Dec 07, 2015
AB			**150MG**	**A203020**	**002**	Dec 07, 2015
AB			**300MG**	**A203020**	**003**	Dec 07, 2015
AB		WEST-WARD PHARMS INT	**75MG**	**A090201**	**001**	Oct 15, 2012
AB			**150MG**	**A090201**	**002**	Oct 15, 2012
AB			**300MG**	**A090201**	**003**	Oct 15, 2012
AB		ZYDUS PHARMS USA INC	**75MG**	**A079213**	**001**	Sep 27, 2012
AB			**150MG**	**A079213**	**002**	Sep 27, 2012
AB			**300MG**	**A079213**	**003**	Sep 27, 2012

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

CAMPTOSAR

AP	**+!**	PFIZER INC	**40MG/2ML (20MG/ML)**	**N020571**	**001**	Jun 14, 1996
AP	**+!**		**100MG/5ML (20MG/ML)**	**N020571**	**002**	Jun 14, 1996
AP	**+!**		**300MG/15ML (20MG/ML)**	**N020571**	**003**	Aug 05, 2010

IRINOTECAN HYDROCHLORIDE

AP		ACCORD HLTHCARE	**40MG/2ML (20MG/ML)**	**A079068**	**001**	Nov 21, 2008
AP			**100MG/5ML (20MG/ML)**	**A079068**	**002**	Nov 21, 2008
AP		ACTAVIS TOTOWA	**40MG/2ML (20MG/ML)**	**A078589**	**001**	Feb 27, 2008
AP			**100MG/5ML (20MG/ML)**	**A078589**	**002**	Feb 27, 2008
AP			**500MG/25ML (20MG/ML)**	**A078589**	**003**	Nov 18, 2015
AP		AKORN	**40MG/2ML (20MG/ML)**	**A090726**	**001**	Sep 16, 2009
AP			**100MG/5ML (20MG/ML)**	**A090726**	**002**	Sep 16, 2009
AP		CIPLA LTD	**40MG/2ML (20MG/ML)**	**A077219**	**001**	Feb 20, 2008
AP			**100MG/5ML (20MG/ML)**	**A077219**	**002**	Feb 20, 2008
AP		EMCURE PHARMS LTD	**40MG/2ML (20MG/ML)**	**A200771**	**001**	Feb 14, 2012
AP			**100MG/5ML (20MG/ML)**	**A200771**	**002**	Feb 14, 2012
AP		FRESENIUS KABI ONCOL	**40MG/2ML (20MG/ML)**	**A078188**	**001**	Feb 27, 2008
AP			**100MG/5ML (20MG/ML)**	**A078188**	**002**	Feb 27, 2008
AP		FRESENIUS KABI USA	**40MG/2ML (20MG/ML)**	**A077776**	**001**	Feb 27, 2008
AP			**100MG/5ML (20MG/ML)**	**A077776**	**002**	Feb 27, 2008
AP		HIKMA FARMACEUTICA	**40MG/2ML (20MG/ML)**	**A091032**	**001**	Dec 20, 2010
AP			**100MG/5ML (20MG/ML)**	**A091032**	**002**	Dec 20, 2010
AP		HISUN PHARM HANGZHOU	**40MG/2ML (20MG/ML)**	**A090016**	**001**	Jan 28, 2009
AP			**100MG/5ML (20MG/ML)**	**A090016**	**002**	Jan 28, 2009
AP		HOSPIRA	**40MG/2ML (20MG/ML)**	**A077915**	**001**	Feb 27, 2008
AP			**100MG/5ML (20MG/ML)**	**A077915**	**002**	Feb 27, 2008
AP	**!**		**500MG/25ML (20MG/ML)**	**A078796**	**001**	Feb 27, 2008
AP		INGENUS PHARMS LLC	**40MG/2ML (20MG/ML)**	**A206935**	**001**	May 26, 2017
AP			**100MG/5ML (20MG/ML)**	**A206935**	**002**	May 26, 2017
AP		INTAS PHARMS USA	**40MG/2ML (20MG/ML)**	**A203054**	**001**	Aug 31, 2017
AP			**100MG/5ML (20MG/ML)**	**A203054**	**002**	Aug 31, 2017
AP		JIANGSU HENGRUI MED	**40MG/2ML (20MG/ML)**	**A090675**	**002**	Dec 16, 2011
AP			**100MG/5ML (20MG/ML)**	**A090675**	**001**	Dec 16, 2011
AP		MUSTAFA NEVZAT ILAC	**40MG/2ML (20MG/ML)**	**A090393**	**002**	May 13, 2011
AP			**100MG/5ML (20MG/ML)**	**A090393**	**003**	May 13, 2011
AP		NEOPHARMA	**40MG/2ML (20MG/ML)**	**A078953**	**001**	Apr 15, 2010
AP			**100MG/5ML (20MG/ML)**	**A078953**	**002**	Apr 15, 2010
AP		PLIVA LACHEMA	**40MG/2ML (20MG/ML)**	**A078122**	**001**	Oct 31, 2008
AP			**100MG/5ML (20MG/ML)**	**A078122**	**002**	Oct 31, 2008
AP		QILU PHARM CO LTD	**40MG/2ML (20MG/ML)**	**A203380**	**001**	May 03, 2016
AP			**100MG/5ML (20MG/ML)**	**A203380**	**002**	May 03, 2016
AP			**300MG/15ML (20MG/ML)**	**A203380**	**003**	May 03, 2016
AP		SHILPA MEDICARE LTD	**40MG/2ML (20MG/ML)**	**A208718**	**001**	Dec 28, 2018
AP			**100MG/5ML (20MG/ML)**	**A208718**	**002**	Dec 28, 2018
AP		TEVA PHARMS USA	**40MG/2ML (20MG/ML)**	**A090101**	**002**	Feb 27, 2008
AP			**100MG/5ML (20MG/ML)**	**A090101**	**003**	Feb 27, 2008
AP			**500MG/25ML (20MG/ML)**	**A090101**	**001**	Nov 26, 2008
AP		WEST-WARD PHARMS INT	**40MG/2ML (20MG/ML)**	**A078753**	**001**	Dec 24, 2008
AP			**100MG/5ML (20MG/ML)**	**A078753**	**002**	Dec 24, 2008

INJECTABLE, LIPOSOMAL;INTRAVENOUS

ONIVYDE

	+!	IPSEN INC	EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML)	N207793	001	Oct 22, 2015

IRON DEXTRAN

INJECTABLE;INJECTION

DEXFERRUM

BP		LUITPOLD	EQ 50MG IRON/ML	N040024	001	Feb 23, 1996

INFED

BP	+!	ALLERGAN SALES LLC	EQ 50MG IRON/ML	N017441	001	

PROFERDEX

BP		NEW RIVER	EQ 50MG IRON/ML	N017807	001	

IRON SUCROSE

INJECTABLE;INTRAVENOUS

VENOFER

	+	LUITPOLD	EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135	002	Mar 20, 2005
	+!		EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N021135	001	Nov 06, 2000
	+		EQ 200MG BASE/10ML (EQ 20MG BASE/ML)	N021135	004	Feb 09, 2007

ISAVUCONAZONIUM SULFATE

CAPSULE;ORAL

CRESEMBA

	+!	ASTELLAS	186MG	N207500	001	Mar 06, 2015

POWDER;INTRAVENOUS

CRESEMBA

	+!	ASTELLAS	372MG	N207501	001	Mar 06, 2015

ISOCARBOXAZID

TABLET;ORAL

MARPLAN

	+!	VALIDUS PHARMS INC	10MG	N011961	001	

ISOFLURANE

LIQUID;INHALATION

FORANE

AN	**+!**	BAXTER HLTHCARE	**99.9%**	**N017624**	**001**	

ISOFLURANE

AN		HALOCARBON PRODS	**99.9%**	**A075225**	**001**	Oct 20, 1999
AN		PIRAMAL CRITICAL	**99.9%**	**A074416**	**001**	Sep 30, 1994
AN		PIRAMAL ENT	**99.9%**	**A074502**	**001**	Jun 27, 1995

ISONIAZID

INJECTABLE;INJECTION

ISONIAZID

	!	SANDOZ INC	100MG/ML	A040648	001	Jul 05, 2005

SYRUP;ORAL

ISONIAZID

	!	CMP PHARMA INC	50MG/5ML	A088235	001	Nov 10, 1983

TABLET;ORAL

ISONIAZID

AA		BARR	**100MG**	**A080936**	**001**	
AA			**300MG**	**A080937**	**002**	
AA		MIKART	**100MG**	**A040090**	**001**	Jun 26, 1997
AA			**300MG**	**A040090**	**002**	Jun 26, 1997
AA	**+!**	SANDOZ	**100MG**	**N008678**	**002**	
AA	**+!**		**300MG**	**N008678**	**003**	
AA		THEPHARMANETWORK LLC	**100MG**	**A202610**	**001**	Oct 29, 2014
AA			**300MG**	**A202610**	**002**	Oct 29, 2014

LANIAZID

AA		LANNETT	**300MG**	**A089776**	**001**	Jun 13, 1988

ISONIAZID; PYRAZINAMIDE; RIFAMPIN

TABLET;ORAL

RIFATER

	+!	SANOFI AVENTIS US	50MG;300MG;120MG	N050705	001	May 31, 1994

ISONIAZID; RIFAMPIN

CAPSULE;ORAL

RIFAMATE

	!	SANOFI AVENTIS US	150MG;300MG	A061884	001	

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE;INJECTION

ISOPROTERENOL HYDROCHLORIDE

AP		AMNEAL PHARMS CO	**0.2MG/ML**	**A210576**	**001**	Oct 17, 2018
AP		AMPHASTAR PHARMS INC	**0.2MG/ML**	**A210106**	**001**	Jun 18, 2018
AP		CIPLA	**0.2MG/ML**	**A210322**	**001**	Jun 12, 2018
AP		NEXUS PHARMS	**0.2MG/ML**	**A206961**	**001**	Aug 02, 2017

ISUPREL

AP	**+!**	VALEANT PHARMS NORTH	**0.2MG/ML**	**N010515**	**001**	

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE;ORAL

DILATRATE-SR

	+!	AUXILIUM PHARMS LLC	40MG	N019790	001	Sep 02, 1988

TABLET;ORAL

ISORDIL

AB	**+**	VALEANT PHARMS NORTH	**5MG**	**N012093**	**007**	Jul 29, 1988

ISOSORBIDE DINITRATE

AB		HIKMA INTL PHARMS	**5MG**	**A086067**	**001**	Oct 29, 1987
AB			**10MG**	**A086066**	**001**	Oct 29, 1987
AB			**20MG**	**A088088**	**001**	Nov 02, 1987

ISOSORBIDE DINITRATE

TABLET;ORAL

ISOSORBIDE DINITRATE

AB			**30MG**	**A040591**	**001**	Jan 10, 2007
AB		PAR PHARM	**5MG**	**A086923**	**001**	Mar 12, 1987
AB			**10MG**	**A086925**	**001**	Mar 12, 1987
AB			**20MG**	**A087537**	**001**	Oct 02, 1987
AB	!		**30MG**	**A087946**	**001**	Jan 12, 1988
AB		SANDOZ	**5MG**	**A086221**	**001**	Jan 07, 1988
AB			**10MG**	**A086223**	**001**	Jan 07, 1988
AB			**20MG**	**A089367**	**001**	Apr 07, 1988

ISORDIL

	+!	VALEANT PHARMS NORTH	40MG	N012093	001	Jul 29, 1988

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE DINITRATE

	!	SUN PHARM INDS INC	40MG	A040009	001	Dec 30, 1998

ISOSORBIDE MONONITRATE

TABLET;ORAL

ISOSORBIDE MONONITRATE

AB		ACTAVIS ELIZABETH	**10MG**	**A075037**	**002**	Oct 30, 1998
AB			**20MG**	**A075037**	**001**	Oct 30, 1998
AB		ANI PHARMS INC	**20MG**	**A075147**	**001**	Nov 27, 1998
AB		HIKMA PHARMS	**20MG**	**A075361**	**001**	Oct 05, 2000

MONOKET

AB	+	LANNETT CO INC	**10MG**	**N020215**	**002**	Jun 30, 1993
AB	+!		**20MG**	**N020215**	**001**	Jun 30, 1993

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE MONONITRATE

AB		DEXCEL LTD	**30MG**	**A075522**	**002**	Sep 20, 2016
AB			**60MG**	**A075522**	**001**	Apr 17, 2000
AB			**120MG**	**A210822**	**001**	Aug 29, 2018
AB		HIKMA PHARMS	**30MG**	**A076813**	**002**	Mar 30, 2006
AB			**60MG**	**A076813**	**001**	Jan 07, 2005
AB		LANNETT CO INC	**30MG**	**A075155**	**002**	Jan 13, 2000
AB			**60MG**	**A075155**	**001**	Oct 30, 1998
AB	!		**120MG**	**A075155**	**003**	Aug 04, 2000
AB		NESHER PHARMS	**30MG**	**A075395**	**001**	Mar 16, 2000
AB			**60MG**	**A075395**	**002**	Mar 16, 2000
AB			**120MG**	**A075395**	**003**	Mar 16, 2000
AB		RICONPHARMA LLC	**30MG**	**A210918**	**001**	Nov 05, 2018
AB			**60MG**	**A210918**	**002**	Nov 05, 2018
AB			**120MG**	**A210918**	**003**	Nov 05, 2018
AB		TORRENT PHARMS	**30MG**	**A200270**	**001**	Jun 03, 2011
AB			**60MG**	**A200495**	**001**	Jun 03, 2011
AB			**120MG**	**A200495**	**002**	Jun 03, 2011
AB		VINTAGE PHARMS	**30MG**	**A090598**	**001**	Aug 11, 2010
AB			**60MG**	**A090598**	**002**	Aug 11, 2010
AB			**120MG**	**A090598**	**003**	Aug 11, 2010

ISOSULFAN BLUE

INJECTABLE;INJECTION

ISOSULFAN BLUE

AP		AUROBINDO PHARMA LTD	**1%**	**A206831**	**001**	Feb 02, 2016
AP		BELOTECA INC	**1%**	**A210714**	**001**	Jan 16, 2019
AP	!	MYLAN INSTITUTIONAL	**1%**	**A090874**	**001**	Jul 20, 2010

ISOTRETINOIN

CAPSULE;ORAL

AMNESTEEM

AB		MYLAN PHARMS INC	**10MG**	**A075945**	**001**	Nov 08, 2002
AB			**20MG**	**A075945**	**002**	Nov 08, 2002
AB			**40MG**	**A075945**	**003**	Nov 08, 2002

CLARAVIS

AB		TEVA PHARMS USA	**10MG**	**A076356**	**001**	Apr 11, 2003
AB			**20MG**	**A076135**	**002**	Apr 11, 2003
AB			**30MG**	**A076135**	**003**	May 11, 2006
AB	!		**40MG**	**A076135**	**001**	Apr 11, 2003

ISOTRETINOIN

AB		AMNEAL PHARMS NY	**10MG**	**A207792**	**001**	Sep 29, 2017
AB			**20MG**	**A207792**	**002**	Sep 29, 2017
AB			**30MG**	**A207792**	**003**	Sep 29, 2017

ISOTRETINOIN

CAPSULE;ORAL

ISOTRETINOIN

AB			**40MG**	**A207792**	**004**	Sep 29, 2017

MYORISAN

AB		DOUGLAS PHARMS	**10MG**	**A076485**	**001**	Jan 19, 2012
AB			**20MG**	**A076485**	**002**	Jan 19, 2012
AB			**30MG**	**A076485**	**004**	Aug 25, 2015
AB			**40MG**	**A076485**	**003**	Jan 19, 2012

ZENATANE

AB		DR REDDYS LABS LTD	**10MG**	**A202099**	**001**	Mar 25, 2013
AB			**20MG**	**A202099**	**002**	Mar 25, 2013
AB			**30MG**	**A202099**	**004**	Feb 23, 2015
AB			**40MG**	**A202099**	**003**	Mar 25, 2013

ABSORICA

BX	+	SUN PHARM INDS INC	10MG	N021951	001	May 25, 2012
BX	+		20MG	N021951	002	May 25, 2012
BX	+		30MG	N021951	003	May 25, 2012
BX	+!		40MG	N021951	004	May 25, 2012
	+		25MG	N021951	005	Aug 15, 2014
	+		35MG	N021951	006	Aug 15, 2014

ISRADIPINE

CAPSULE;ORAL

ISRADIPINE

AB		ELITE LABS INC	**2.5MG**	**A077169**	**001**	Apr 24, 2006
AB			**5MG**	**A077169**	**002**	Apr 24, 2006
AB		WATSON LABS TEVA	**2.5MG**	**A077317**	**001**	Jan 05, 2006
AB	**!**		**5MG**	**A077317**	**002**	Jan 05, 2006

ITRACONAZOLE

CAPSULE;ORAL

ITRACONAZOLE

AB		ACCORD HLTHCARE	**100MG**	**A205991**	**001**	May 26, 2016
AB		ALEMBIC PHARMS LTD	**100MG**	**A206741**	**001**	Dec 13, 2016
AB		ALKEM LABS LTD	**100MG**	**A208591**	**001**	Jun 12, 2017
AB		AMNEAL PHARMS	**100MG**	**A205080**	**001**	Sep 26, 2016
AB		JUBILANT GENERICS	**100MG**	**A203445**	**001**	Feb 23, 2017
AB		MYLAN PHARMS INC	**100MG**	**A200463**	**001**	Jul 20, 2012
AB		PAR PHARM INC	**100MG**	**A205724**	**001**	Dec 13, 2016
AB		SANDOZ	**100MG**	**A076104**	**001**	May 28, 2004
AB		TORRENT PHARMS LTD	**100MG**	**A209460**	**001**	Aug 24, 2018
AB		ZYDUS PHARMS USA INC	**100MG**	**A204672**	**001**	Sep 19, 2017

SPORANOX

AB	**+!**	JANSSEN PHARMS	**100MG**	**N020083**	**001**	Sep 11, 1992

TOLSURA

	+!	MAYNE PHARMA INTL	65MG	N208901	001	Dec 11, 2018

SOLUTION;ORAL

ITRACONAZOLE

AA		AMNEAL PHARMS	**10MG/ML**	**A205573**	**001**	Oct 30, 2015

SPORANOX

AA	**+!**	JANSSEN PHARMS	**10MG/ML**	**N020657**	**001**	Feb 21, 1997

TABLET;ORAL

ONMEL

	+!	SEBELA IRELAND LTD	200MG	N022484	001	Apr 29, 2010

IVABRADINE HYDROCHLORIDE

TABLET;ORAL

CORLANOR

	+	AMGEN INC	EQ 5MG BASE	N206143	001	Apr 15, 2015
	+!		EQ 7.5MG BASE	N206143	002	Apr 15, 2015

IVACAFTOR

GRANULE;ORAL

KALYDECO

	+	VERTEX PHARMS INC	50MG/PACKET	N207925	001	Mar 17, 2015
	+!		75MG/PACKET	N207925	002	Mar 17, 2015

TABLET;ORAL

KALYDECO

	+!	VERTEX PHARMS	150MG	N203188	001	Jan 31, 2012

IVACAFTOR; IVACAFTOR, TEZACAFTOR						
TABLET, TABLET;ORAL						
SYMDEKO (COPACKAGED)						
	+!	VERTEX PHARMS INC	150MG,N/A;150MG, 100MG	N210491	001	Feb 12, 2018
IVACAFTOR; LUMACAFTOR						
GRANULE;ORAL						
ORKAMBI						
	+	VERTEX PHARMS INC	125MG/PACKET;100MG/PACKET	N211358	001	Aug 07, 2018
	+!		188MG/PACKET;150MG/PACKET	N211358	002	Aug 07, 2018
TABLET;ORAL						
ORKAMBI						
	+	VERTEX PHARMS INC	125MG;100MG	N206038	002	Sep 28, 2016
	+!		125MG;200MG	N206038	001	Jul 02, 2015
IVERMECTIN						
CREAM;TOPICAL						
SOOLANTRA						
	+!	GALDERMA LABS LP	1%	N206255	001	Dec 19, 2014
LOTION;TOPICAL						
SKLICE						
	+!	ARBOR PHARMS LLC	0.5%	N202736	001	Feb 07, 2012
TABLET;ORAL						
IVERMECTIN						
AB		EDENBRIDGE PHARMS	**3MG**	**A204154**	**001**	Oct 24, 2014
STROMECTOL						
AB	**+!**	MERCK SHARP DOHME	**3MG**	**N050742**	**002**	Oct 08, 1998
IVOSIDENIB						
TABLET;ORAL						
TIBSOVO						
	+!	AGIOS PHARMS INC	250MG	N211192	001	Jul 20, 2018
IXABEPILONE						
INJECTABLE;INTRAVENOUS						
IXEMPRA KIT						
	+!	R-PHARM US LLC	15MG/VIAL	N022065	001	Oct 16, 2007
	+!		45MG/VIAL	N022065	002	Oct 16, 2007
IXAZOMIB CITRATE						
CAPSULE;ORAL						
NINLARO						
	+	MILLENNIUM PHARMS	EQ 2.3MG BASE	N208462	001	Nov 20, 2015
	+		EQ 3MG BASE	N208462	002	Nov 20, 2015
	+!		EQ 4MG BASE	N208462	003	Nov 20, 2015
KETAMINE HYDROCHLORIDE						
INJECTABLE;INJECTION						
KETALAR						
AP	**+!**	PAR STERILE PRODUCTS	**EQ 10MG BASE/ML**	**N016812**	**001**	
AP	**+!**		**EQ 50MG BASE/ML**	**N016812**	**002**	
AP	**+!**		**EQ 100MG BASE/ML**	**N016812**	**003**	
KETAMINE HYDROCHLORIDE						
AP		HOSPIRA	**EQ 50MG BASE/ML**	**A074549**	**001**	Jun 27, 1996
AP			**EQ 100MG BASE/ML**	**A074549**	**002**	Jun 27, 1996
AP		MYLAN INSTITUTIONAL	**EQ 10MG BASE/ML**	**A076092**	**001**	Sep 30, 2008
AP			**EQ 50MG BASE/ML**	**A076092**	**002**	Dec 28, 2001
AP			**EQ 100MG BASE/ML**	**A076092**	**003**	Oct 25, 2002
AP		WEST-WARD PHARMS INT	**EQ 50MG BASE/ML**	**A074524**	**001**	Mar 22, 1996
AP			**EQ 100MG BASE/ML**	**A074524**	**002**	Mar 22, 1996
KETOCONAZOLE						
AEROSOL, FOAM;TOPICAL						
EXTINA						
AT	**+!**	MYLAN PHARMS INC	**2%**	**N021738**	**001**	Jun 12, 2007
KETOCONAZOLE						
AT		PERRIGO ISRAEL	**2%**	**A091550**	**001**	Aug 25, 2011
CREAM;TOPICAL						
KETOCONAZOLE						
AB		FOUGERA PHARMS	**2%**	**A076294**	**001**	Apr 28, 2004
AB	**!**	TEVA	**2%**	**A075581**	**001**	Apr 25, 2000
KETOZOLE						
AB		TARO	**2%**	**A075638**	**001**	Dec 18, 2002

KETOCONAZOLE						
GEL;TOPICAL						
XOLEGEL						
	+!	AQUA PHARMS	2%	N021946	001	Jul 28, 2006
SHAMPOO;TOPICAL						
KETOCONAZOLE						
AB		PERRIGO NEW YORK	**2%**	**A076419**	**001**	Jan 07, 2004
AB		TOLMAR	**2%**	**A076942**	**001**	Apr 11, 2005
NIZORAL						
AB	**+!**	JANSSEN PHARMS	**2%**	**N019927**	**001**	Aug 31, 1990
TABLET;ORAL						
KETOCONAZOLE						
AB		MYLAN	**200MG**	**A075597**	**001**	Dec 23, 1999
AB		STRIDES PHARMA	**200MG**	**A210457**	**001**	Jun 18, 2018
AB		TARO	**200MG**	**A075319**	**001**	Jun 15, 1999
AB	**!**	TEVA	**200MG**	**A075273**	**001**	Jun 15, 1999
KETOPROFEN						
CAPSULE;ORAL						
KETOPROFEN						
AB		HERITAGE PHARMS INC	**50MG**	**A074014**	**002**	Jan 29, 1993
AB			**75MG**	**A074014**	**003**	Jan 29, 1993
AB		TEVA	**50MG**	**A073516**	**001**	Dec 22, 1992
AB	**!**		**75MG**	**A073517**	**001**	Dec 22, 1992
		HERITAGE PHARMS INC	25MG	A074014	001	Jan 29, 1993
CAPSULE, EXTENDED RELEASE;ORAL						
KETOPROFEN						
	!	MYLAN	200MG	A075679	001	Feb 20, 2002
KETOROLAC TROMETHAMINE						
INJECTABLE;INJECTION						
KETOROLAC TROMETHAMINE						
AP		AMPHASTAR PHARM	**15MG/ML**	**A076209**	**001**	Jul 21, 2004
AP			**30MG/ML**	**A076209**	**002**	Jul 21, 2004
AP		BAXTER HLTHCARE CORP	**15MG/ML**	**A209900**	**002**	Jul 25, 2018
AP			**30MG/ML**	**A209900**	**001**	Sep 15, 2017
AP		FRESENIUS KABI USA	**15MG/ML**	**A075784**	**001**	Jan 11, 2002
AP			**15MG/ML**	**A203242**	**001**	Oct 07, 2015
AP			**30MG/ML**	**A075784**	**002**	Jan 11, 2002
AP			**30MG/ML**	**A203242**	**002**	Oct 07, 2015
AP		GLAND PHARMA LTD	**15MG/ML**	**A204216**	**001**	Nov 01, 2016
AP			**30MG/ML**	**A204216**	**002**	Nov 01, 2016
AP	**!**	HOSPIRA	**15MG/ML**	**A074802**	**001**	Jun 05, 1997
AP			**15MG/ML**	**A074993**	**001**	Jan 27, 1999
AP	**!**		**30MG/ML**	**A074802**	**002**	Jun 05, 1997
AP			**30MG/ML**	**A074993**	**002**	Jan 27, 1999
AP		SAGENT PHARMS	**15MG/ML**	**A091065**	**001**	Nov 27, 2013
AP			**30MG/ML**	**A091065**	**002**	Nov 27, 2013
AP		SANDOZ INC	**30MG/ML**	**A076271**	**002**	Oct 06, 2004
AP		WOCKHARDT	**15MG/ML**	**A077942**	**001**	Mar 27, 2007
AP			**30MG/ML**	**A077942**	**002**	Mar 27, 2007
SOLUTION/DROPS;OPHTHALMIC						
ACULAR						
AT	**+!**	ALLERGAN	**0.5%**	**N019700**	**001**	Nov 09, 1992
ACULAR LS						
AT	**+!**	ALLERGAN	**0.4%**	**N021528**	**001**	May 30, 2003
KETOROLAC TROMETHAMINE						
AT		AKORN	**0.4%**	**A078399**	**001**	Nov 05, 2009
AT			**0.5%**	**A078434**	**001**	Nov 05, 2009
AT		APOTEX INC	**0.4%**	**A077308**	**001**	Nov 05, 2009
AT			**0.5%**	**A076109**	**001**	Nov 05, 2009
AT		AUROBINDO PHARMA LTD	**0.4%**	**A205191**	**001**	Nov 15, 2018
AT		SANDOZ INC	**0.4%**	**A078721**	**001**	Nov 05, 2009
AT			**0.5%**	**A076583**	**001**	Nov 05, 2009
AT		SUN PHARMA GLOBAL	**0.5%**	**A090017**	**001**	Nov 05, 2009
ACUVAIL						
	+!	ALLERGAN	0.45%	N022427	001	Jul 22, 2009
SPRAY, METERED;NASAL						
SPRIX						
	+!	EGALET US INC	15.75MG/SPRAY	N022382	001	May 14, 2010

KETOROLAC TROMETHAMINE

TABLET;ORAL

KETOROLAC TROMETHAMINE

AB		CYCLE PHARMS LTD	**10MG**	**A210616**	**001**	Aug 16, 2018
AB	**!**	MYLAN	**10MG**	**A074761**	**001**	May 16, 1997
AB		PLIVA	**10MG**	**A075284**	**001**	Jun 23, 1999
AB		TEVA	**10MG**	**A074754**	**001**	May 16, 1997

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IRRIGATION

OMIDRIA

+!	OMEROS	EQ 0.3% BASE;EQ 1% BASE	N205388	001	May 30, 2014

L-GLUTAMINE

FOR SOLUTION;ORAL

ENDARI

+	EMMAUS MEDCL	5GM/PACKET	N208587	001	Jul 07, 2017

NUTRESTORE

+!	EMMAUS MEDCL	5GM/PACKET	N021667	001	Jun 10, 2004

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

LABETALOL HYDROCHLORIDE

AP		AKORN INC	**5MG/ML**	**A075431**	**001**	Nov 29, 1999
AP		GLAND PHARMA LTD	**5MG/ML**	**A090699**	**001**	Apr 03, 2012
AP	**!**	HOSPIRA	**5MG/ML**	**A075239**	**001**	Nov 29, 1999
AP	**!**		**5MG/ML**	**A075240**	**001**	Nov 29, 1999
AP		MYLAN ASI	**5MG/ML**	**A079134**	**001**	Feb 03, 2010
AP		WEST-WARD PHARMS INT	**5MG/ML**	**A075303**	**001**	May 28, 1999

TABLET;ORAL

LABETALOL HYDROCHLORIDE

AB		INNOGENIX	**100MG**	**A075215**	**001**	Jul 29, 1999
AB			**200MG**	**A075215**	**002**	Jul 29, 1999
AB			**300MG**	**A075215**	**003**	Jul 29, 1999
AB		IVAX SUB TEVA PHARMS	**100MG**	**A074787**	**001**	Aug 03, 1998
AB			**200MG**	**A074787**	**002**	Aug 03, 1998
AB			**300MG**	**A074787**	**003**	Aug 03, 1998
AB		PAR FORM	**100MG**	**A200908**	**001**	Jul 10, 2012
AB			**200MG**	**A200908**	**002**	Jul 10, 2012
AB			**300MG**	**A200908**	**003**	Jul 10, 2012
AB		SANDOZ	**100MG**	**A075113**	**001**	Aug 04, 1998
AB	**!**		**200MG**	**A075113**	**002**	Aug 04, 1998
AB			**300MG**	**A075113**	**003**	Aug 04, 1998
AB		TWI PHARMS	**100MG**	**A209603**	**001**	Jun 20, 2018
AB			**200MG**	**A209603**	**002**	Jun 20, 2018
AB			**300MG**	**A209603**	**003**	Jun 20, 2018
AB		WATSON LABS	**100MG**	**A075133**	**001**	Aug 03, 1998
AB			**200MG**	**A075133**	**002**	Aug 03, 1998
AB			**300MG**	**A075133**	**003**	Aug 03, 1998
AB		ZYDUS PHARMS USA INC	**100MG**	**A207743**	**001**	Sep 19, 2017
AB			**200MG**	**A207743**	**002**	Sep 19, 2017
AB			**300MG**	**A207743**	**003**	Sep 19, 2017

TRANDATE

AB		CNTY LINE PHARMS	**100MG**	**N018716**	**001**	May 24, 1985
AB			**200MG**	**N018716**	**002**	Aug 01, 1984
AB			**300MG**	**N018716**	**003**	Aug 01, 1984

LACOSAMIDE

SOLUTION;INTRAVENOUS

VIMPAT

+!	UCB INC	200MG/20ML (10MG/ML)	N022254	001	Oct 28, 2008

SOLUTION;ORAL

VIMPAT

+!	UCB INC	10MG/ML	N022255	001	Apr 20, 2010

TABLET;ORAL

VIMPAT

+	UCB INC	50MG	N022253	001	Oct 28, 2008
+		100MG	N022253	002	Oct 28, 2008
+		150MG	N022253	003	Oct 28, 2008
+!		200MG	N022253	004	Oct 28, 2008

LACTULOSE						
FOR SOLUTION;ORAL						
LACTULOSE						
	!	CUMBERLAND PHARMS	10GM/PACKET	A074712	001	Dec 10, 1997
	!		20GM/PACKET	A074712	002	Dec 10, 1997
SOLUTION;ORAL						
CONSTILAC						
AA		ALRA	**10GM/15ML**	**A071054**	**001**	Jul 26, 1988
LACTULOSE						
AA		ANI PHARMS	**10GM/15ML**	**A078430**	**001**	Nov 28, 2007
AA		BIO-PHARM INC	**10GM/15ML**	**A207786**	**001**	Jun 11, 2018
AA		FRESENIUS KABI	**10GM/15ML**	**A090503**	**001**	Jan 25, 2012
AA	!	HI TECH PHARMA	**10GM/15ML**	**A074076**	**001**	Jul 03, 1995
AA		LANNETT CO INC	**10GM/15ML**	**A075993**	**001**	Jul 26, 2001
AA		LIFEPHARMA	**10GM/15ML**	**A209517**	**001**	Nov 23, 2018
AA		PHARM ASSOC	**10GM/15ML**	**A074623**	**001**	Jul 30, 1996
AA		VISTAPHARM	**10GM/15ML**	**A074138**	**001**	Sep 30, 1992
AA		WEST-WARD PHARMS INT	**10GM/15ML**	**A073591**	**001**	May 29, 1992
AA		WOCKHARDT BIO AG	**10GM/15ML**	**A074602**	**001**	Nov 14, 1996
SOLUTION;ORAL, RECTAL						
CHOLAC						
AA		ALRA	**10GM/15ML**	**A071331**	**001**	Jul 26, 1988
ENULOSE						
AA	!	ACTAVIS MID ATLANTIC	**10GM/15ML**	**A071548**	**001**	Aug 15, 1988
GENERLAC						
AA		WOCKHARDT BIO AG	**10GM/15ML**	**A074603**	**001**	Oct 31, 1996
LACTULOSE						
AA		ANI PHARMS	**10GM/15ML**	**A090426**	**001**	Nov 21, 2008
AA		BIO-PHARM INC	**10GM/15ML**	**A203762**	**001**	Mar 27, 2015
AA		FRESENIUS KABI	**10GM/15ML**	**A090502**	**001**	Jan 25, 2012
AA		HI TECH PHARMA	**10GM/15ML**	**A074077**	**001**	Jul 03, 1995
LAMIVUDINE						
SOLUTION;ORAL						
EPIVIR						
AA	+!	VIIV HLTHCARE	**10MG/ML**	**N020596**	**001**	Nov 17, 1995
LAMIVUDINE						
AA		AUROBINDO PHARMA LTD	**10MG/ML**	**A077695**	**001**	Nov 21, 2016
AA		LANNETT CO INC	**10MG/ML**	**A203564**	**001**	Oct 31, 2014
EPIVIR-HBV						
	+!	GLAXOSMITHKLINE	5MG/ML	N021004	001	Dec 08, 1998
TABLET;ORAL						
EPIVIR						
AB	+	VIIV HLTHCARE	**150MG**	**N020564**	**001**	Nov 17, 1995
AB	+!		**300MG**	**N020564**	**003**	Jun 24, 2002
EPIVIR-HBV						
AB	+!	GLAXOSMITHKLINE	**100MG**	**N021003**	**001**	Dec 08, 1998
LAMIVUDINE						
AB		APOTEX	**150MG**	**A091606**	**001**	Dec 02, 2011
AB			**300MG**	**A091606**	**002**	Dec 02, 2011
AB		APOTEX INC	**100MG**	**A202941**	**001**	Jan 02, 2014
AB		ARISE PHARMS	**150MG**	**A206974**	**001**	Nov 21, 2016
AB			**300MG**	**A206974**	**002**	Nov 21, 2016
AB		AUROBINDO PHARMA LTD	**150MG**	**A077464**	**001**	Nov 21, 2016
AB			**150MG**	**A202032**	**001**	Nov 17, 2011
AB			**300MG**	**A077464**	**002**	Nov 21, 2016
AB			**300MG**	**A202032**	**002**	Nov 17, 2011
AB		CIPLA	**150MG**	**A077221**	**001**	Mar 03, 2017
AB			**300MG**	**A077221**	**002**	Mar 03, 2017
AB		ECI PHARMS LLC	**150MG**	**A203586**	**001**	Nov 21, 2016
AB		HETERO LABS LTD V	**100MG**	**A203260**	**001**	Jan 02, 2014
AB			**150MG**	**A203277**	**001**	Jan 06, 2014
AB			**300MG**	**A203277**	**002**	Jan 06, 2014
AB		LUPIN LTD	**150MG**	**A205217**	**001**	Dec 18, 2014
AB			**300MG**	**A205217**	**002**	Dec 18, 2014
AB		MYLAN PHARMS INC	**100MG**	**A204002**	**001**	Dec 31, 2014
AB			**150MG**	**A204528**	**001**	Mar 04, 2016
AB			**300MG**	**A204528**	**002**	Mar 04, 2016
AB		STRIDES PHARMA	**150MG**	**A090457**	**001**	Apr 19, 2018
AB			**300MG**	**A090457**	**002**	Apr 19, 2018

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE							
TABLET;ORAL							
CIMDUO							
	+!	MYLAN LABS LTD	300MG;300MG		N022141	001	Feb 28, 2018
TEMIXYS							
		CELLTRION	300MG;300MG		N211284	001	Nov 16, 2018
LAMIVUDINE; ZIDOVUDINE							
TABLET;ORAL							
COMBIVIR							
AB	**+!**	VIIV HLTHCARE	**150MG;300MG**		**N020857**	**001**	Sep 26, 1997
LAMIVUDINE AND ZIDOVUDINE							
AB		AUROBINDO PHARMA LTD	**150MG;300MG**		**A077558**	**001**	May 05, 2017
AB			**150MG;300MG**		**A202418**	**001**	May 15, 2012
AB		CIPLA	**150MG;300MG**		**A077411**	**001**	Sep 07, 2018
AB		HETERO LABS LTD III	**150MG;300MG**		**A079124**	**001**	Sep 17, 2015
AB		HETERO LABS LTD V	**150MG;300MG**		**A203259**	**001**	Feb 03, 2014
AB		LUPIN LTD	**150MG;300MG**		**A090246**	**001**	May 15, 2012
AB		MACLEODS PHARMS LTD	**150MG;300MG**		**A090679**	**001**	Aug 29, 2018
AB		MYLAN PHARMS INC	**150MG;300MG**		**A204005**	**001**	Aug 28, 2014
AB		SHANGHAI DESANO	**150MG;300MG**		**A206375**	**001**	Apr 10, 2018
AB		STRIDES PHARMA	**150MG;300MG**		**A079128**	**001**	May 13, 2015
LAMOTRIGINE							
TABLET;ORAL							
LAMICTAL							
AB	**+!**	GLAXOSMITHKLINE LLC	**25MG**		**N020241**	**005**	Dec 27, 1994
AB	**+**		**100MG**		**N020241**	**001**	Dec 27, 1994
AB	**+**		**150MG**		**N020241**	**002**	Dec 27, 1994
AB	**+**		**200MG**		**N020241**	**003**	Dec 27, 1994
LAMOTRIGINE							
AB		ALEMBIC PHARMS LTD	**25MG**		**A090607**	**001**	Jan 13, 2011
AB			**100MG**		**A090607**	**002**	Jan 13, 2011
AB			**150MG**		**A090607**	**003**	Jan 13, 2011
AB			**200MG**		**A090607**	**004**	Jan 13, 2011
AB		ALKEM LABS LTD	**25MG**		**A200694**	**001**	Jun 14, 2013
AB			**100MG**		**A200694**	**002**	Jun 14, 2013
AB			**150MG**		**A200694**	**003**	Jun 14, 2013
AB			**200MG**		**A200694**	**004**	Jun 14, 2013
AB		APOTEX INC	**25MG**		**A078625**	**001**	Jan 27, 2009
AB			**100MG**		**A078625**	**002**	Jan 27, 2009
AB			**150MG**		**A078625**	**003**	Jan 27, 2009
AB			**200MG**		**A078625**	**004**	Jan 27, 2009
AB		AUROBINDO PHARMA	**25MG**		**A078956**	**001**	Jan 27, 2009
AB			**100MG**		**A078956**	**002**	Jan 27, 2009
AB			**150MG**		**A078956**	**003**	Jan 27, 2009
AB			**200MG**		**A078956**	**004**	Jan 27, 2009
AB		CIPLA	**25MG**		**A077783**	**001**	Nov 01, 2010
AB			**100MG**		**A077783**	**002**	Nov 01, 2010
AB			**150MG**		**A077783**	**003**	Nov 01, 2010
AB			**200MG**		**A077783**	**004**	Nov 01, 2010
AB		DR REDDYS LABS LTD	**25MG**		**A076708**	**001**	Jan 27, 2009
AB			**100MG**		**A076708**	**002**	Jan 27, 2009
AB			**150MG**		**A076708**	**003**	Jan 27, 2009
AB			**200MG**		**A076708**	**004**	Jan 27, 2009
AB		GLENMARK GENERICS	**25MG**		**A090169**	**001**	May 12, 2012
AB			**100MG**		**A090169**	**002**	May 12, 2012
AB			**150MG**		**A090169**	**003**	May 12, 2012
AB			**200MG**		**A090169**	**004**	May 12, 2012
AB		JUBILANT CADISTA	**25MG**		**A079132**	**001**	Jan 27, 2009
AB			**100MG**		**A079132**	**002**	Jan 27, 2009
AB			**150MG**		**A079132**	**003**	Jan 27, 2009
AB			**200MG**		**A079132**	**004**	Jan 27, 2009
AB		LUPIN LTD	**25MG**		**A078691**	**001**	Jun 01, 2010
AB			**100MG**		**A078691**	**002**	Jun 01, 2010
AB			**150MG**		**A078691**	**003**	Jun 01, 2010
AB			**200MG**		**A078691**	**004**	Jun 01, 2010
AB		MYLAN	**25MG**		**A077420**	**001**	Jan 27, 2009
AB			**100MG**		**A077420**	**002**	Jan 27, 2009
AB			**150MG**		**A077420**	**003**	Jan 27, 2009
AB			**200MG**		**A077420**	**004**	Jan 27, 2009
AB		TARO PHARM INDS	**25MG**		**A078525**	**001**	Jan 27, 2009
AB			**100MG**		**A078525**	**002**	Jan 27, 2009

LAMOTRIGINE

TABLET;ORAL

LAMOTRIGINE

AB			**150MG**	**A078525**	**003**	Jan 27, 2009
AB			**200MG**	**A078525**	**004**	Jan 27, 2009
AB		TEVA	**25MG**	**A076388**	**001**	Aug 30, 2006
AB			**100MG**	**A076388**	**002**	Aug 30, 2006
AB			**150MG**	**A076388**	**003**	Aug 30, 2006
AB			**200MG**	**A076388**	**004**	Aug 30, 2006
AB		TORRENT PHARMS	**25MG**	**A078947**	**001**	Jan 27, 2009
AB			**100MG**	**A078947**	**002**	Jan 27, 2009
AB			**150MG**	**A078947**	**003**	Jan 27, 2009
AB			**200MG**	**A078947**	**004**	Jan 27, 2009
AB		UNICHEM LABS LTD	**25MG**	**A090170**	**001**	Oct 06, 2011
AB			**100MG**	**A090170**	**002**	Oct 06, 2011
AB			**150MG**	**A090170**	**003**	Oct 06, 2011
AB			**200MG**	**A090170**	**004**	Oct 06, 2011
AB		ZYDUS PHARMS USA	**25MG**	**A077633**	**001**	Jan 27, 2009
AB			**100MG**	**A077633**	**003**	Jan 27, 2009
AB			**150MG**	**A077633**	**004**	Jan 27, 2009
AB			**200MG**	**A077633**	**005**	Jan 27, 2009
			50MG	A077633	002	Jan 27, 2009
			250MG	A077633	006	Jan 27, 2009

TABLET, CHEWABLE;ORAL

LAMICTAL CD

AB	**+**	GLAXOSMITHKLINE LLC	**2MG**	**N020764**	**004**	Sep 08, 2000
AB	**+**		**5MG**	**N020764**	**001**	Aug 24, 1998
AB	**+!**		**25MG**	**N020764**	**002**	Aug 24, 1998

LAMOTRIGINE

AB		ALEMBIC PHARMS LTD	**5MG**	**A201168**	**001**	Jun 12, 2014
AB			**25MG**	**A201168**	**002**	Jun 12, 2014
AB		AUROBINDO PHARMA	**5MG**	**A090401**	**002**	Nov 04, 2009
AB			**25MG**	**A090401**	**003**	Nov 04, 2009
AB		DR REDDYS LABS LTD	**5MG**	**A076701**	**001**	Jan 22, 2009
AB			**25MG**	**A076701**	**002**	Jan 22, 2009
AB		GLENMARK PHARMS LTD	**5MG**	**A079099**	**001**	Feb 19, 2009
AB			**25MG**	**A079099**	**002**	Feb 19, 2009
AB		JUBILANT GENERICS	**5MG**	**A200220**	**001**	Feb 28, 2011
AB			**25MG**	**A200220**	**002**	Feb 28, 2011
AB		TARO	**5MG**	**A079204**	**001**	Feb 04, 2009
AB			**25MG**	**A079204**	**002**	Feb 04, 2009
AB		TEVA	**5MG**	**A076420**	**001**	Jun 21, 2006
AB			**25MG**	**A076420**	**002**	Jun 21, 2006
AB		WATSON LABS	**2MG**	**A076928**	**001**	Jan 22, 2009
AB			**5MG**	**A076928**	**002**	Jan 22, 2009
AB			**25MG**	**A076928**	**003**	Jan 22, 2009
AB		ZYDUS PHARMS USA INC	**5MG**	**A078009**	**002**	Jan 22, 2009
AB			**25MG**	**A078009**	**003**	Jan 22, 2009

TABLET, EXTENDED RELEASE;ORAL

LAMICTAL XR

AB	**+**	GLAXOSMITHKLINE LLC	**25MG**	**N022115**	**001**	May 29, 2009
AB	**+!**		**50MG**	**N022115**	**002**	May 29, 2009
AB	**+**		**100MG**	**N022115**	**003**	May 29, 2009
AB	**+!**		**200MG**	**N022115**	**004**	May 29, 2009
AB	**+**		**250MG**	**N022115**	**006**	Jun 21, 2011
AB	**+**		**300MG**	**N022115**	**005**	Apr 14, 2010

LAMOTRIGINE

AB		ACTAVIS ELIZABETH	**100MG**	**A200672**	**003**	Oct 17, 2013
AB			**200MG**	**A200672**	**004**	Oct 17, 2013
AB			**25MG**	**A200672**	**001**	Oct 17, 2013
AB			**50MG**	**A200672**	**002**	Oct 17, 2013
AB			**250MG**	**A203733**	**001**	Nov 13, 2013
AB			**300MG**	**A200672**	**005**	Oct 17, 2013
AB		AMNEAL PHARMS	**25MG**	**A207497**	**001**	Nov 30, 2018
AB			**50MG**	**A207497**	**002**	Nov 30, 2018
AB			**100MG**	**A207497**	**003**	Nov 30, 2018
AB			**200MG**	**A207497**	**004**	Nov 30, 2018
AB			**250MG**	**A207497**	**005**	Nov 30, 2018
AB			**300MG**	**A207497**	**006**	Nov 30, 2018
AB		ANCHEN PHARMS	**25MG**	**A201374**	**001**	Dec 26, 2012
AB			**50MG**	**A201374**	**002**	Dec 26, 2012
AB			**100MG**	**A201374**	**003**	Dec 26, 2012

LAMOTRIGINE

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

AB			**200MG**	**A201374**	**004**	Dec 26, 2012
AB			**250MG**	**A201374**	**005**	Dec 26, 2012
AB			**300MG**	**A201374**	**006**	Dec 26, 2012
AB		DR REDDYS LABS LTD	**25MG**	**A202383**	**001**	Jun 19, 2013
AB			**50MG**	**A202383**	**002**	Jun 19, 2013
AB			**100MG**	**A202383**	**003**	Jun 19, 2013
AB			**200MG**	**A202383**	**004**	Jun 19, 2013
AB			**300MG**	**A202383**	**005**	Jun 19, 2013
AB		HANDA PHARMS LLC	**100MG**	**A202887**	**003**	Jun 17, 2013
AB			**200MG**	**A202887**	**004**	Jun 17, 2013
AB		PAR PHARM	**25MG**	**A201791**	**001**	Jan 18, 2013
AB			**50MG**	**A201791**	**002**	Jan 18, 2013
AB			**100MG**	**A201791**	**003**	Jan 18, 2013
AB			**200MG**	**A201791**	**004**	Jan 18, 2013
AB			**250MG**	**A201791**	**005**	Jan 18, 2013
AB			**300MG**	**A201791**	**006**	Jan 18, 2013
AB		TORRENT PHARMS LTD	**25MG**	**A203370**	**001**	Dec 23, 2013
AB			**50MG**	**A203370**	**002**	Dec 23, 2013
AB			**100MG**	**A203370**	**003**	Dec 23, 2013
AB			**200MG**	**A203370**	**004**	Dec 23, 2013
AB		WOCKHARDT LTD	**25MG**	**A202498**	**001**	Jan 04, 2013
AB			**50MG**	**A202498**	**002**	Jan 04, 2013
AB			**100MG**	**A202498**	**003**	Jan 04, 2013
AB			**200MG**	**A202498**	**004**	Jan 04, 2013
AB			**300MG**	**A202498**	**005**	Jan 04, 2013

TABLET, ORALLY DISINTEGRATING;ORAL

LAMICTAL ODT

AB	**+**	GLAXOSMITHKLINE LLC	**25MG**	**N022251**	**001**	May 08, 2009
AB	**+!**		**50MG**	**N022251**	**002**	May 08, 2009
AB	**+**		**100MG**	**N022251**	**003**	May 08, 2009
AB	**+**		**200MG**	**N022251**	**004**	May 08, 2009

LAMOTRIGINE

AB		IMPAX LABS INC	**25MG**	**A200828**	**001**	Jul 15, 2013
AB			**50MG**	**A200828**	**002**	Jul 15, 2013
AB			**100MG**	**A200828**	**003**	Jul 15, 2013
AB			**200MG**	**A200828**	**004**	Jul 15, 2013
AB		PAR PHARM	**25MG**	**A204158**	**001**	Oct 27, 2015
AB			**50MG**	**A204158**	**002**	Oct 27, 2015
AB			**100MG**	**A204158**	**003**	Oct 27, 2015
AB			**200MG**	**A204158**	**004**	Oct 27, 2015
AB		SCIEGEN PHARMS INC	**25MG**	**A206382**	**001**	Jun 17, 2016
AB			**50MG**	**A206382**	**002**	Jun 17, 2016
AB			**100MG**	**A206382**	**003**	Jun 17, 2016
AB			**200MG**	**A206382**	**004**	Jun 17, 2016

LANREOTIDE ACETATE

SOLUTION;SUBCUTANEOUS

SOMATULINE DEPOT

+!	IPSEN PHARMA	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	N022074	001	Aug 30, 2007
+!		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	N022074	002	Aug 30, 2007
+!		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	N022074	003	Aug 30, 2007

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

AB		AJANTA PHARMA LTD	**15MG**	**A203957**	**001**	Oct 14, 2016
AB			**30MG**	**A203957**	**002**	Oct 14, 2016
AB		BRECKENRIDGE PHARM	**15MG**	**A203964**	**001**	Oct 17, 2018
AB			**30MG**	**A203964**	**002**	Oct 17, 2018
AB		DR REDDYS LABS LTD	**15MG**	**A091269**	**001**	Oct 15, 2010
AB			**30MG**	**A091269**	**002**	Oct 15, 2010
AB		INVENTIA HLTHCARE	**15MG**	**A205868**	**001**	Aug 30, 2017
AB			**30MG**	**A205868**	**002**	Aug 30, 2017
AB		KRKA TOVARNA ZDRAVIL	**15MG**	**A091212**	**001**	Sep 16, 2013
AB			**30MG**	**A091212**	**002**	Sep 16, 2013
AB		LABS LICONSA	**15MG**	**A203203**	**001**	Jul 25, 2016
AB			**30MG**	**A203203**	**002**	Jul 25, 2016
AB		LANNETT CO INC	**15MG**	**A207156**	**001**	Sep 28, 2017
AB			**30MG**	**A207156**	**002**	Sep 28, 2017

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

AB		MYLAN PHARMS INC	**15MG**	**A090763**	**001**	Nov 10, 2009
AB			**30MG**	**A090763**	**002**	Nov 10, 2009
AB		NATCO PHARMA LTD	**15MG**	**A201921**	**001**	Dec 18, 2012
AB			**30MG**	**A201921**	**002**	Dec 18, 2012
AB		SANDOZ	**15MG**	**A090331**	**001**	Apr 23, 2010
AB			**30MG**	**A090331**	**002**	Apr 23, 2010
AB		SUN PHARM INDS LTD	**15MG**	**A202637**	**001**	Sep 13, 2013
AB			**30MG**	**A091509**	**001**	Sep 13, 2013
AB		TEVA PHARMS	**15MG**	**A077255**	**001**	Nov 10, 2009
AB			**30MG**	**A077255**	**002**	Nov 10, 2009
AB		WOCKHARDT USA	**15MG**	**A202176**	**001**	Sep 14, 2012
AB			**30MG**	**A202176**	**002**	Sep 14, 2012
AB		ZYDUS HLTHCARE	**15MG**	**A202366**	**001**	Aug 19, 2013
AB			**30MG**	**A202366**	**002**	Aug 19, 2013

PREVACID

AB	**+**	TAKEDA PHARMS USA	**15MG**	**N020406**	**001**	May 10, 1995
AB	**+!**		**30MG**	**N020406**	**002**	May 10, 1995

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE

AB		MYLAN PHARMS INC	**15MG**	**A202396**	**001**	Nov 28, 2018
AB			**30MG**	**A202396**	**002**	Nov 28, 2018
AB		TEVA PHARMS USA	**15MG**	**A208784**	**001**	Sep 21, 2017
AB			**30MG**	**A208784**	**002**	Sep 21, 2017
AB		ZYDUS PHARMS USA INC	**15MG**	**A200816**	**001**	Nov 27, 2018
AB			**30MG**	**A200816**	**002**	Nov 27, 2018

PREVACID

AB	**+**	TAKEDA PHARMS USA	**15MG**	**N021428**	**001**	Aug 30, 2002
AB	**+!**		**30MG**	**N021428**	**002**	Aug 30, 2002

LANTHANUM CARBONATE

POWDER;ORAL

FOSRENOL

	+	SHIRE DEV LLC	EQ 750MG BASE	N204734	001	Sep 24, 2014
	+!		EQ 1GM BASE	N204734	002	Sep 24, 2014

TABLET, CHEWABLE;ORAL

FOSRENOL

AB	**+**	SHIRE LLC	**EQ 500MG BASE**	**N021468**	**002**	Oct 26, 2004
AB	**+**		**EQ 750MG BASE**	**N021468**	**003**	Nov 23, 2005
AB	**+!**		**EQ 1GM BASE**	**N021468**	**004**	Nov 23, 2005

LANTHANUM CARBONATE

AB		NATCO PHARMA LTD	**EQ 500MG BASE**	**A090978**	**001**	Aug 11, 2017
AB			**EQ 750MG BASE**	**A090978**	**002**	Aug 11, 2017
AB			**EQ 1GM BASE**	**A090978**	**003**	Aug 11, 2017

LAPATINIB DITOSYLATE

TABLET;ORAL

TYKERB

	+!	NOVARTIS PHARMS CORP	EQ 250MG BASE	N022059	001	Mar 13, 2007

LAROTRECTINIB

CAPSULE;ORAL

VITRAKVI

	+	LOXO ONCOLOGY INC	25MG	N210861	001	Nov 26, 2018
	+!		100MG	N210861	002	Nov 26, 2018

SOLUTION;ORAL

VITRAKVI

	+!	LOXO ONCOLOGY INC	20MG/ML	N211710	001	Nov 26, 2018

LATANOPROST

EMULSION;OPHTHALMIC

XELPROS

	+!	SUN PHARMA GLOBAL	0.005%	N206185	001	Sep 12, 2018

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

AT		AKORN	**0.005%**	**A090887**	**001**	Jul 19, 2011
AT		AMRING PHARMS	**0.005%**	**A200925**	**001**	Mar 22, 2011
AT		BAUSCH AND LOMB	**0.005%**	**A201006**	**001**	Mar 22, 2011
AT		DR REDDYS LABS LTD	**0.005%**	**A202077**	**001**	Feb 11, 2013
AT		FDC LTD	**0.005%**	**A202442**	**001**	Apr 22, 2016
AT		MYLAN	**0.005%**	**A201786**	**001**	Mar 22, 2011

LATANOPROST							
SOLUTION/DROPS;OPHTHALMIC							
LATANOPROST							
AT		SANDOZ INC	**0.005%**	**A091449**	**001**	Mar 22, 2011
XALATAN							
AT	**+!**	PHARMACIA AND UPJOHN	**0.005%**	**N020597**	**001**	Jun 05, 1996
LATANOPROSTENE BUNOD							
SOLUTION/DROPS;OPHTHALMIC							
VYZULTA							
	+!	BAUSCH AND LOMB	0.024%	N207795	001	Nov 02, 2017
LEDIPASVIR; SOFOSBUVIR							
TABLET;ORAL							
HARVONI							
	+!	GILEAD SCIENCES INC	90MG;400MG	N205834	001	Oct 10, 2014
LEFLUNOMIDE							
TABLET;ORAL							
ARAVA							
AB	**+**	SANOFI AVENTIS US	**10MG**	**N020905**	**001**	Sep 10, 1998
AB	**+!**		**20MG**	**N020905**	**002**	Sep 10, 1998
LEFLUNOMIDE							
AB		ALEMBIC PHARMS LTD	**10MG**	**A091369**	**001**	Nov 21, 2011
AB			**20MG**	**A091369**	**002**	Nov 21, 2011
AB		APOTEX INC	**10MG**	**A077090**	**001**	Sep 13, 2005
AB			**20MG**	**A077090**	**002**	Sep 13, 2005
AB		BARR	**10MG**	**A077083**	**001**	Sep 13, 2005
AB			**20MG**	**A077083**	**002**	Sep 13, 2005
AB		HERITAGE PHARMS INC	**10MG**	**A077086**	**001**	Sep 13, 2005
AB			**20MG**	**A077086**	**002**	Sep 13, 2005
AB		TEVA PHARMS	**10MG**	**A077084**	**001**	Sep 13, 2005
AB			**20MG**	**A077084**	**002**	Sep 13, 2005
ARAVA							
	+!	SANOFI AVENTIS US	100MG	N020905	003	Sep 10, 1998
LENALIDOMIDE							
CAPSULE;ORAL							
REVLIMID							
	+	CELGENE	2.5MG	N021880	005	Dec 21, 2011
	+		5MG	N021880	001	Dec 27, 2005
	+		10MG	N021880	002	Dec 27, 2005
	+		15MG	N021880	003	Jun 29, 2006
	+		20MG	N021880	006	Jun 05, 2013
	+!		25MG	N021880	004	Jun 29, 2006
LENVATINIB MESYLATE							
CAPSULE;ORAL							
LENVIMA							
	+	EISAI INC	EQ 4MG BASE	N206947	001	Feb 13, 2015
	+!		EQ 10MG BASE	N206947	002	Feb 13, 2015
LESINURAD							
TABLET;ORAL							
ZURAMPIC							
	+!	IRONWOOD PHARMS INC	200MG	N207988	001	Dec 22, 2015
LETERMOVIR							
SOLUTION;INTRAVENOUS							
PREVYMIS							
	+!	MERCK SHARP DOHME	240MG/12ML (20MG/ML)	N209940	001	Nov 08, 2017
	+!		480MG/24ML (20MG/ML)	N209940	002	Nov 08, 2017
TABLET;ORAL							
PREVYMIS							
	+	MERCK SHARP DOHME	240MG	N209939	001	Nov 08, 2017
	+!		480MG	N209939	002	Nov 08, 2017
LETROZOLE							
TABLET;ORAL							
FEMARA							
AB	**+!**	NOVARTIS PHARMS	**2.5MG**	**N020726**	**001**	Jul 25, 1997
LETROZOLE							
AB		ACCORD HLTHCARE	**2.5MG**	**A090934**	**001**	Jun 03, 2011
AB		APOTEX INC	**2.5MG**	**A091303**	**001**	Apr 19, 2012
AB		BEIJING YILING	**2.5MG**	**A205869**	**001**	Nov 14, 2018
AB		DR REDDYS LABS LTD	**2.5MG**	**A091191**	**001**	Jun 03, 2011

LETROZOLE

TABLET;ORAL

LETROZOLE

AB		EUGIA PHARMA	**2.5MG**	**A211717**	**001**	Jan 11, 2019
AB		FRESENIUS KABI ONCOL	**2.5MG**	**A090491**	**001**	Jun 03, 2011
AB		HIKMA PHARMS	**2.5MG**	**A203796**	**001**	Jun 03, 2016
AB		INDICUS PHARMA	**2.5MG**	**A201804**	**001**	Jun 03, 2011
AB		JIANGSU HENGRUI MED	**2.5MG**	**A202716**	**001**	May 16, 2013
AB		NATCO PHARMA LTD	**2.5MG**	**A200161**	**001**	Jun 03, 2011
AB		TEVA PHARMS	**2.5MG**	**A090289**	**001**	Jun 03, 2011
AB		VINTAGE PHARMS LLC	**2.5MG**	**A090789**	**001**	Jun 03, 2011
AB		WEST-WARD PHARMS INT	**2.5MG**	**A090838**	**001**	Jun 03, 2011

LETROZOLE; RIBOCICLIB SUCCINATE

TABLET, TABLET;ORAL

KISQALI FEMARA CO-PACK (COPACKAGED)

	+!	NOVARTIS PHARMS CORP	2.5MG,N/A;N/A,EQ 200MG BASE	N209935	001	May 04, 2017

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION

LEUCOVORIN CALCIUM

AP		FRESENIUS KABI USA	**EQ 10MG BASE/ML**	**A207226**	**001**	Jul 27, 2018
AP		INGENUS PHARMS LLC	**EQ 10MG BASE/VIAL**	**A210917**	**001**	Nov 23, 2018
AP		TEVA PHARMS USA	**EQ 100MG BASE/VIAL**	**A081277**	**001**	Sep 28, 1993
AP			**EQ 350MG BASE/VIAL**	**A040174**	**001**	Jun 12, 1997
AP	!	WEST-WARD PHARMS INT	**EQ 50MG BASE/VIAL**	**A089384**	**001**	Sep 14, 1987
AP	!		**EQ 100MG BASE/VIAL**	**A089717**	**001**	Mar 28, 1988

LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP		FRESENIUS KABI USA	**EQ 200MG BASE/VIAL**	**A040258**	**001**	Feb 26, 1999
AP	!		**EQ 500MG BASE/VIAL**	**A040286**	**001**	Feb 26, 1999
AP		MYLAN LABS LTD	**EQ 100MG BASE/VIAL**	**A203800**	**001**	May 19, 2017
AP			**EQ 200MG BASE/VIAL**	**A203800**	**002**	May 19, 2017
AP			**EQ 350MG BASE/VIAL**	**A203800**	**003**	May 19, 2017
AP		SAGENT PHARMS	**EQ 50MG BASE/VIAL**	**A200753**	**001**	Sep 06, 2012
AP			**EQ 100MG BASE/VIAL**	**A200753**	**002**	Sep 06, 2012
AP			**EQ 200MG BASE/VIAL**	**A200753**	**003**	Sep 06, 2012
AP			**EQ 350MG BASE/VIAL**	**A200855**	**001**	Sep 06, 2012
AP			**EQ 500MG BASE/VIAL**	**A209110**	**001**	Oct 26, 2017
AP	!	WEST-WARD PHARMS INT	**EQ 10MG BASE/ML**	**A040347**	**001**	Apr 25, 2000
AP	!		**EQ 200MG BASE/VIAL**	**A040056**	**001**	May 23, 1995
AP	!		**EQ 350MG BASE/VIAL**	**A040335**	**001**	Apr 20, 2000

LEUCOVORIN CALCIUM

		FRESENIUS KABI USA	EQ 10MG BASE/ML	A207241	001	Mar 14, 2018

TABLET;ORAL

LEUCOVORIN CALCIUM

AB		BARR	**EQ 5MG BASE**	**A071198**	**001**	Sep 24, 1987
AB			**EQ 25MG BASE**	**A071199**	**001**	Sep 24, 1987
AB		WEST-WARD PHARMS INT	**EQ 5MG BASE**	**A072733**	**001**	Feb 22, 1993
AB	!		**EQ 25MG BASE**	**A072736**	**001**	Feb 22, 1993
			EQ 10MG BASE	A072734	001	Feb 22, 1993
			EQ 15MG BASE	A072735	001	Feb 22, 1993

LEUPROLIDE ACETATE

FOR SUSPENSION;INTRAMUSCULAR

LUTRATE DEPOT KIT

	+!	GP-PHARM SA	22.5MG/VIAL	N205054	001	Aug 28, 2018

INJECTABLE;INJECTION

LEUPROLIDE ACETATE

AP	!	SANDOZ	**1MG/0.2ML**	**A074728**	**001**	Aug 04, 1998
AP		SUN PHARMA GLOBAL	**1MG/0.2ML**	**A078885**	**001**	Mar 09, 2009
AP		TEVA PHARMS USA	**1MG/0.2ML**	**A075471**	**001**	Oct 25, 2000

LUPRON DEPOT

	+!	ABBVIE ENDOCRINE INC	3.75MG	N020011	002	Oct 26, 1995
	+!		7.5MG/VIAL	N019732	001	Jan 26, 1989
	+!		11.25MG/VIAL	N020708	001	Mar 07, 1997
	+		22.5MG/VIAL	N020517	001	Dec 22, 1995
	+!		30MG/VIAL	N020517	002	May 30, 1997
	+!		45MG/VIAL	N020517	003	Jun 17, 2011

LEUPROLIDE ACETATE						
INJECTABLE;INJECTION						
LUPRON DEPOT-PED						
+!	ABBVIE ENDOCRINE INC	7.5MG/VIAL	N020263	002	Apr 16, 1993
+!		11.25MG/VIAL	N020263	005	Jan 21, 1994
+!		11.25MG/VIAL	N020263	007	Aug 15, 2011
+!		15MG/VIAL	N020263	006	Jan 21, 1994
+!		30MG/VIAL	N020263	008	Aug 15, 2011
INJECTABLE;SUBCUTANEOUS						
ELIGARD						
+!	TOLMAR THERAP	7.5MG/VIAL	N021343	001	Jan 23, 2002
+!		22.5MG/VIAL	N021379	001	Jul 24, 2002
+!		30MG/VIAL	N021488	001	Feb 13, 2003
+!		45MG/VIAL	N021731	001	Dec 14, 2004
LEUPROLIDE ACETATE; NORETHINDRONE ACETATE						
INJECTABLE, TABLET;INTRAMUSCULAR, ORAL						
LUPANETA PACK						
+	ABBVIE ENDOCRINE	3.75MG/VIAL,N/A;N/A,5MG	N203696	001	Dec 14, 2012
+!		11.25MG/VIAL,N/A;N/A,5MG	N203696	002	Dec 14, 2012
LEVALBUTEROL HYDROCHLORIDE						
SOLUTION;INHALATION						
LEVALBUTEROL HYDROCHLORIDE						
AN	AUROBINDO PHARMA LTD	**EQ 0.25% BASE**	**A207628**	**001**	Jan 31, 2017
AN		**EQ 0.0103% BASE**	**A207625**	**001**	Dec 30, 2016
AN		**EQ 0.021% BASE**	**A207625**	**002**	Dec 30, 2016
AN		**EQ 0.042% BASE**	**A207625**	**003**	Dec 30, 2016
AN	CIPLA	**EQ 0.021% BASE**	**A078171**	**002**	Dec 13, 2013
AN		**EQ 0.042% BASE**	**A078171**	**003**	Dec 13, 2013
AN		**EQ 0.0103% BASE**	**A078171**	**001**	Dec 13, 2013
AN	IMPAX LABS INC	**EQ 0.0103% BASE**	**A077756**	**003**	Apr 09, 2008
AN		**EQ 0.021% BASE**	**A077756**	**001**	Apr 09, 2008
AN		**EQ 0.042% BASE**	**A077756**	**002**	Apr 09, 2008
AN	MYLAN SPECIALITY LP	**EQ 0.0103% BASE**	**A077800**	**001**	Mar 15, 2013
AN		**EQ 0.021% BASE**	**A077800**	**002**	Mar 15, 2013
AN		**EQ 0.042% BASE**	**A077800**	**003**	Mar 15, 2013
AN		**EQ 0.25% BASE**	**A078309**	**001**	Mar 20, 2009
AN	RITEDOSE CORP	**EQ 0.0103% BASE**	**A203653**	**001**	Mar 22, 2016
AN		**EQ 0.021% BASE**	**A203653**	**002**	Mar 22, 2016
AN		**EQ 0.042% BASE**	**A203653**	**003**	Mar 22, 2016
AN	SUN PHARMA GLOBAL	**EQ 0.0103% BASE**	**A207820**	**001**	Nov 05, 2018
AN		**EQ 0.021% BASE**	**A207820**	**002**	Nov 05, 2018
AN		**EQ 0.042% BASE**	**A207820**	**003**	Nov 05, 2018
AN	TEVA PARENTERAL	**EQ 0.25% BASE**	**A200875**	**001**	Sep 11, 2014
AN	TEVA PHARMS USA	**EQ 0.0103% BASE**	**A090297**	**001**	Apr 26, 2013
AN		**EQ 0.021% BASE**	**A090297**	**002**	Apr 26, 2013
AN		**EQ 0.042% BASE**	**A090297**	**003**	Apr 26, 2013
XOPENEX						
AN **+!**	OAK PHARMS INC	**EQ 0.0103% BASE**	**N020837**	**003**	Jan 30, 2002
AN **+!**		**EQ 0.021% BASE**	**N020837**	**001**	Mar 25, 1999
AN **+!**		**EQ 0.042% BASE**	**N020837**	**002**	Mar 25, 1999
AN **+!**		**EQ 0.25% BASE**	**N020837**	**004**	Jul 18, 2003
LEVALBUTEROL TARTRATE						
AEROSOL, METERED;INHALATION						
XOPENEX HFA						
+!	SUNOVION	EQ 0.045MG BASE/INH	N021730	001	Mar 11, 2005
LEVETIRACETAM						
INJECTABLE;IV (INFUSION)						
KEPPRA						
AP **+!**	UCB INC	**500MG/5ML (100MG/ML)**	**N021872**	**001**	Jul 31, 2006
LEVETIRACETAM						
AP	AKORN	**500MG/5ML (100MG/ML)**	**A209934**	**001**	May 04, 2018
AP	AUROBINDO PHARMA LTD	**500MG/5ML (100MG/ML)**	**A204312**	**001**	Feb 01, 2016
AP	FRESENIUS KABI USA	**500MG/5ML (100MG/ML)**	**A090813**	**001**	May 26, 2010
AP		**500MG/5ML (100MG/ML)**	**A090876**	**001**	Aug 13, 2015
AP	HAINAN POLY PHARM	**500MG/5ML (100MG/ML)**	**A209781**	**001**	Mar 20, 2018
AP	HIKMA FARMACEUTICA	**500MG/5ML (100MG/ML)**	**A090981**	**001**	Oct 13, 2011
AP	HOSPIRA INC	**500MG/5ML (100MG/ML)**	**A202869**	**001**	Apr 06, 2012
AP	JUBILANT GENERICS	**500MG/5ML (100MG/ML)**	**A206838**	**001**	Jun 02, 2016

LEVETIRACETAM

INJECTABLE;IV (INFUSION)

LEVETIRACETAM						
AP		LUITPOLD	**500MG/5ML (100MG/ML)**	**A202143**	**001**	Jan 31, 2012
AP		MYLAN LABS LTD	**500MG/5ML (100MG/ML)**	**A203308**	**001**	Sep 16, 2016
AP		SAGENT PHARMS	**500MG/5ML (100MG/ML)**	**A091627**	**001**	Jun 26, 2013
AP		SUN PHARM INDS LTD	**500MG/5ML (100MG/ML)**	**A090754**	**001**	Jun 16, 2010
AP		X GEN PHARMS	**500MG/5ML (100MG/ML)**	**A091485**	**001**	Aug 05, 2011
LEVETIRACETAM IN SODIUM CHLORIDE						
AP		AUROBINDO PHARMA LTD	**500MG/100ML (5MG/ML)**	**A207160**	**001**	Jan 04, 2017
AP			**1000MG/100ML (10MG/ML)**	**A207160**	**002**	Jan 04, 2017
AP			**1500MG/100ML (15MG/ML)**	**A207160**	**003**	Jan 04, 2017
AP		GLAND PHARMA LTD	**500MG/100ML (5MG/ML)**	**A206880**	**001**	Oct 25, 2017
AP			**1000MG/100ML (10MG/ML)**	**A206880**	**002**	Oct 25, 2017
AP			**1500MG/100ML (15MG/ML)**	**A206880**	**003**	Oct 25, 2017
AP	**+!**	HQ SPECIALITY PHARMA	**500MG/100ML (5MG/ML)**	**N202543**	**001**	Nov 09, 2011
AP	**+!**		**1000MG/100ML (10MG/ML)**	**N202543**	**002**	Nov 09, 2011
AP	**+!**		**1500MG/100ML (15MG/ML)**	**N202543**	**003**	Nov 09, 2011

SOLUTION;ORAL

KEPPRA						
AA	**+!**	UCB INC	**100MG/ML**	**N021505**	**001**	Jul 15, 2003
LEVETIRACETAM						
AA		ACTAVIS MID ATLANTIC	**100MG/ML**	**A078976**	**001**	Jan 15, 2009
AA		AMNEAL PHARMS	**100MG/ML**	**A090992**	**001**	Oct 27, 2009
AA		AUROBINDO PHARMA LTD	**100MG/ML**	**A079063**	**001**	Jan 15, 2009
AA		BRECKENRIDGE PHARM	**100MG/ML**	**A079120**	**001**	Jan 16, 2009
AA		HETERO LABS LTD III	**100MG/ML**	**A203052**	**001**	Feb 28, 2013
AA		HI-TECH PHARMACAL	**100MG/ML**	**A090601**	**001**	Feb 28, 2012
AA		LANNETT CO INC	**100MG/ML**	**A090079**	**001**	Apr 11, 2012
AA			**100MG/ML**	**A090263**	**001**	Apr 03, 2009
AA		LUPIN LTD	**100MG/ML**	**A090893**	**001**	Oct 17, 2011
AA		ORIT LABS LLC	**100MG/ML**	**A203067**	**001**	May 09, 2013
AA		PHARM ASSOC	**100MG/ML**	**A201157**	**001**	Jun 04, 2015
AA		TARO	**100MG/ML**	**A078774**	**001**	Feb 10, 2009
AA		TOLMAR	**100MG/ML**	**A079107**	**001**	Jan 15, 2009
AA		TRIS PHARMA INC	**100MG/ML**	**A090461**	**001**	Sep 30, 2010
AA		WOCKHARDT BIO AG	**100MG/ML**	**A090028**	**001**	Mar 03, 2010

TABLET;ORAL

KEPPRA						
AB	**+**	UCB INC	**250MG**	**N021035**	**001**	Nov 30, 1999
AB	**+**		**500MG**	**N021035**	**002**	Nov 30, 1999
AB	**+**		**750MG**	**N021035**	**003**	Nov 30, 1999
AB	**+!**		**1GM**	**N021035**	**004**	Jan 06, 2006
LEVETIRACETAM						
AB		ACCORD HLTHCARE	**250MG**	**A090843**	**001**	Feb 14, 2011
AB			**500MG**	**A090843**	**002**	Feb 14, 2011
AB			**750MG**	**A090843**	**003**	Feb 14, 2011
AB			**1GM**	**A090843**	**004**	Feb 14, 2011
AB		ACI HEALTHCARE LTD	**250MG**	**A078042**	**001**	Jan 15, 2009
AB			**500MG**	**A078042**	**002**	Jan 15, 2009
AB			**750MG**	**A078042**	**003**	Jan 15, 2009
AB			**1GM**	**A078042**	**004**	Jan 15, 2009
AB		ACIC PHARMS	**250MG**	**A090767**	**001**	Jul 28, 2010
AB			**500MG**	**A090767**	**002**	Jul 28, 2010
AB			**750MG**	**A090767**	**003**	Jul 28, 2010
AB			**1GM**	**A090767**	**004**	Jul 28, 2010
AB		APOTEX INC	**250MG**	**A078869**	**001**	Mar 13, 2009
AB			**500MG**	**A078869**	**002**	Mar 13, 2009
AB			**750MG**	**A078869**	**003**	Mar 13, 2009
AB			**1GM**	**A078869**	**004**	Mar 13, 2009
AB		AUROBINDO PHARMA	**250MG**	**A078993**	**001**	Jan 15, 2009
AB			**500MG**	**A078993**	**002**	Jan 15, 2009
AB			**750MG**	**A078993**	**003**	Jan 15, 2009
AB			**1GM**	**A078993**	**004**	Jan 15, 2009
AB		BRECKENRIDGE PHARM	**250MG**	**A090511**	**001**	Aug 18, 2011
AB			**500MG**	**A090511**	**002**	Aug 18, 2011
AB			**750MG**	**A090511**	**003**	Aug 18, 2011
AB			**1GM**	**A090511**	**004**	Aug 18, 2011
AB		CHARTWELL RX	**250MG**	**A201293**	**001**	Jun 14, 2011

LEVETIRACETAM

TABLET;ORAL

LEVETIRACETAM

AB		500MG	A201293	002	Jun 14, 2011
AB		750MG	A201293	003	Jun 14, 2011
AB		1GM	A201293	004	Jun 14, 2011
AB	DR REDDYS LABS LTD	250MG	A076920	001	Jan 15, 2009
AB		500MG	A076920	002	Jan 15, 2009
AB		750MG	A076920	003	Jan 15, 2009
AB		1GM	A078904	001	Jan 15, 2009
AB	HETERO LABS LTD III	250MG	A090515	001	Oct 08, 2010
AB		500MG	A090515	002	Oct 08, 2010
AB		750MG	A090515	003	Oct 08, 2010
AB		1GM	A090515	004	Oct 08, 2010
AB	INVAGEN PHARMS	250MG	A078234	001	Jan 15, 2009
AB		500MG	A078234	002	Jan 15, 2009
AB		750MG	A078234	003	Jan 15, 2009
AB	LUPIN	250MG	A078154	001	Jan 15, 2009
AB		500MG	A078154	002	Jan 15, 2009
AB		750MG	A078154	003	Jan 15, 2009
AB		1GM	A090025	001	Jan 15, 2009
AB	MYLAN	250MG	A076919	001	Nov 04, 2008
AB		500MG	A076919	002	Nov 04, 2008
AB		750MG	A076919	003	Nov 04, 2008
AB		1GM	A090261	001	Dec 08, 2009
AB	ORCHID HLTHCARE	250MG	A078526	001	Jan 15, 2009
AB		500MG	A078526	002	Jan 15, 2009
AB		750MG	A078526	003	Jan 15, 2009
AB		1GM	A090484	001	Aug 05, 2010
AB	OXFORD PHARMS	250MG	A077319	001	Mar 20, 2009
AB		500MG	A077319	002	Mar 20, 2009
AB		750MG	A077319	003	Mar 20, 2009
AB	PRINSTON INC	250MG	A078106	001	Feb 10, 2009
AB		500MG	A078106	002	Feb 10, 2009
AB		750MG	A078106	003	Feb 10, 2009
AB		1GM	A078106	004	Feb 10, 2009
AB	SECAN PHARMS	500MG	A205102	004	Dec 16, 2015
AB		1GM	A205102	003	Dec 16, 2015
AB	TARO	250MG	A078960	004	Feb 01, 2010
AB		500MG	A078960	003	Feb 01, 2010
AB		750MG	A078960	002	Feb 01, 2010
AB		1GM	A078960	001	Feb 01, 2010
AB	TEVA PHARMS	250MG	A078101	001	Jan 15, 2009
AB		500MG	A078101	002	Jan 15, 2009
AB		750MG	A078101	003	Jan 15, 2009
AB		1GM	A078101	004	Jan 15, 2009
AB	TORRENT PHARMS	250MG	A078858	001	Jan 15, 2009
AB		500MG	A078858	002	Jan 15, 2009
AB		750MG	A078858	003	Jan 15, 2009
AB		1GM	A078858	004	Jan 15, 2009
AB	VINTAGE PHARMS	250MG	A091491	001	Dec 14, 2010
AB		500MG	A091491	002	Dec 14, 2010
AB		750MG	A091491	003	Dec 14, 2010
AB		1GM	A091491	004	Dec 14, 2010
AB	WOCKHARDT	250MG	A079042	001	Jan 15, 2009
AB		500MG	A079042	002	Jan 15, 2009
AB		750MG	A079042	003	Jan 15, 2009
AB		1GM	A079042	004	Jan 15, 2009
AB	ZYDUS PHARMS USA INC	250MG	A078918	001	Apr 29, 2009
AB		1GM	A078918	002	Apr 29, 2009

ROWEEPRA

AB	LOTUS PHARM CO LTD	250MG	A090906	002	Oct 31, 2016
AB		500MG	A090906	001	Nov 05, 2010
AB		750MG	A090906	003	Oct 31, 2016
AB		1GM	A090906	004	Oct 31, 2016

TABLET, EXTENDED RELEASE;ORAL

KEPPRA XR

AB	+	UCB INC	500MG	N022285	001	Sep 12, 2008
AB	+!		750MG	N022285	002	Feb 12, 2009

LEVETIRACETAM

AB	ACTAVIS ELIZABETH	500MG	A091557	001	Sep 12, 2011
AB		750MG	A091557	002	Sep 12, 2011

LEVETIRACETAM

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

AB		ACTAVIS LABS FL INC	**500MG**	**A091093**	**001**	Sep 12, 2011
AB			**750MG**	**A091093**	**002**	Sep 12, 2011
AB		ANCHEN PHARMS	**500MG**	**A091360**	**001**	Oct 04, 2011
AB			**750MG**	**A091360**	**002**	Oct 04, 2011
AB		APOTEX INC	**500MG**	**A091261**	**001**	Sep 12, 2011
AB			**750MG**	**A091261**	**002**	Sep 12, 2011
AB		DEXCEL PHARMA	**500MG**	**A202167**	**001**	Sep 04, 2015
AB			**750MG**	**A202167**	**002**	Sep 04, 2015
AB		ECI PHARMS LLC	**500MG**	**A204754**	**001**	Aug 26, 2016
AB			**750MG**	**A204754**	**002**	Aug 26, 2016
AB		INTELLIPHARMACEUTICS	**500MG**	**A204511**	**001**	Feb 23, 2016
AB			**750MG**	**A204511**	**002**	Feb 23, 2016
AB		LOTUS PHARM CO LTD	**500MG**	**A202095**	**002**	Jun 06, 2016
AB			**750MG**	**A202095**	**001**	Jun 06, 2016
AB		LUPIN LTD	**500MG**	**A091399**	**001**	Sep 12, 2011
AB			**750MG**	**A091399**	**002**	Sep 12, 2011
AB		PHARMADAX INC	**500MG**	**A201464**	**001**	May 25, 2012
AB			**750MG**	**A201464**	**002**	May 25, 2012
AB		PHARMTAK INC	**500MG**	**A207175**	**001**	Sep 28, 2017
AB			**750MG**	**A207175**	**002**	Sep 28, 2017
AB		PRINSTON INC	**500MG**	**A202533**	**001**	Jul 20, 2012
AB			**500MG**	**A203468**	**001**	May 21, 2015
AB			**750MG**	**A202533**	**002**	Jul 20, 2012
AB			**750MG**	**A203468**	**002**	May 21, 2015
AB		ROUSES POINT PHARMS	**500MG**	**A202524**	**001**	Aug 27, 2012
AB			**750MG**	**A202524**	**002**	Aug 27, 2012
AB		SUN PHARM INDUSTRIES	**500MG**	**A091285**	**001**	Sep 12, 2011
AB			**750MG**	**A091285**	**002**	Sep 12, 2011
AB		SUN PHARMA GLOBAL	**500MG**	**A203059**	**001**	Sep 09, 2013
AB			**750MG**	**A203059**	**002**	Sep 09, 2013
AB		TEVA PHARMS	**500MG**	**A091430**	**001**	Sep 12, 2011
AB			**750MG**	**A091430**	**002**	Sep 12, 2011
AB		TORRENT PHARMS LTD	**500MG**	**A091338**	**001**	May 29, 2012
AB			**750MG**	**A091338**	**002**	May 29, 2012

ELEPSIA XR

+	SPARC	1GM	N204417	001	Dec 20, 2018
+!		1.5GM	N204417	002	Dec 20, 2018

LEVETIRACETAM

	APOTEX INC	1GM	A202958	001	Feb 25, 2015

TABLET, FOR SUSPENSION;ORAL

SPRITAM

+	APRECIA PHARMS	250MG	N207958	001	Jul 31, 2015
+		500MG	N207958	002	Jul 31, 2015
+		750MG	N207958	003	Jul 31, 2015
+!		1GM	N207958	004	Jul 31, 2015

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AKBETA

AT		AKORN	**0.25%**	**A074779**	**001**	Oct 29, 1996
AT			**0.5%**	**A074780**	**001**	Oct 29, 1996

BETAGAN

AT	**+!**	ALLERGAN	**0.25%**	**N019814**	**001**	Jun 28, 1989
AT	**+!**		**0.5%**	**N019219**	**002**	Dec 19, 1985

LEVOBUNOLOL HYDROCHLORIDE

AT		BAUSCH AND LOMB	**0.5%**	**A074326**	**001**	Mar 04, 1994
AT		SANDOZ INC	**0.5%**	**A074850**	**001**	Oct 28, 1996

LEVOCARNITINE

INJECTABLE;INJECTION

CARNITOR

AP	**+!**	LEADIANT BIOSCI INC	**200MG/ML**	**N020182**	**001**	Dec 16, 1992

LEVOCARNITINE

AP		LUITPOLD	**200MG/ML**	**A075861**	**001**	Jun 22, 2001
AP		WEST-WARD PHARMS INT	**200MG/ML**	**A075567**	**001**	Mar 29, 2001

LEVOCARNITINE

SOLUTION;ORAL

CARNITOR

AA	**+!**	LEADIANT BIOSCI INC	**1GM/10ML**	**N019257**	**001**	Apr 10, 1986

CARNITOR SF

AA	**+**	LEADIANT BIOSCI INC	**1GM/10ML**	**N019257**	**002**	Mar 28, 2007

LEVOCARNITINE

AA		HI TECH PHARMA	**1GM/10ML**	**A077399**	**001**	Oct 25, 2007
AA		LYNE	**1GM/10ML**	**A076851**	**001**	Aug 10, 2004

TABLET;ORAL

CARNITOR

AB	**+!**	LEADIANT BIOSCI INC	**330MG**	**N018948**	**001**	Dec 27, 1985

LEVOCARNITINE

AB		ANDA REPOSITORY	**330MG**	**A076858**	**001**	Sep 20, 2004

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AA		APOTEX INC	**2.5MG/5ML**	**A202915**	**001**	Aug 21, 2014
AA	**!**	L PERRIGO CO	**2.5MG/5ML**	**A091263**	**001**	Nov 07, 2011
AA		LANNETT CO INC	**2.5MG/5ML**	**A204599**	**001**	May 15, 2017
AA		TARO PHARM INDS LTD	**2.5MG/5ML**	**A202673**	**001**	Jul 26, 2013

XYZAL

AA	**+**	SANOFI AVENTIS US	**2.5MG/5ML**	**N022157**	**001**	Jan 28, 2008

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB		APOTEX INC	**5MG**	**A203027**	**001**	Feb 13, 2015
AB		DR REDDYS LABS LTD	**5MG**	**A090392**	**001**	Feb 24, 2011
AB		GLENMARK GENERICS	**5MG**	**A090385**	**001**	Feb 24, 2011
AB		HETERO LABS LTD III	**5MG**	**A091264**	**001**	Jun 29, 2012
AB		MACLEODS PHARMS LTD	**5MG**	**A205564**	**001**	Jan 11, 2016
AB		MICRO LABS LTD INDIA	**5MG**	**A202046**	**001**	Sep 17, 2013
AB		NEOPHARMA	**5MG**	**A204323**	**001**	Dec 20, 2016
AB		SCIEGEN PHARMS INC	**5MG**	**A203646**	**001**	Sep 09, 2014
AB		SUN PHARM INDS LTD	**5MG**	**A201653**	**001**	Jun 26, 2015
AB		SUN PHARMA GLOBAL	**5MG**	**A090362**	**001**	Jan 31, 2013
AB		SYNTHON PHARMS	**5MG**	**A090229**	**001**	Nov 26, 2010
AB		TEVA PHARMS	**5MG**	**A090199**	**001**	Aug 22, 2011

XYZAL

AB	**+!**	SANOFI AVENTIS US	**5MG**	**N022064**	**001**	May 25, 2007

LEVODOPA

POWDER;INHALATION

INBRIJA

	+!	ACORDA	42MG	N209184	001	Dec 21, 2018

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN

AP	**!**	AUROBINDO PHARMA LTD	**EQ 500MG/20ML (EQ 25MG/ML)**	**A202328**	**001**	Jan 24, 2013
AP	**!**		**EQ 750MG/30ML (EQ 25MG/ML)**	**A202328**	**002**	Jan 24, 2013
AP		BAXTER HLTHCARE CORP	**EQ 500MG/20ML (EQ 25MG/ML)**	**A091436**	**001**	Jun 05, 2013

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		AUROBINDO PHARMA LTD	**EQ 250MG/50ML (EQ 5MG/ML)**	**A206919**	**001**	Feb 10, 2016
AP			**EQ 500MG/100ML (EQ 5MG/ML)**	**A206919**	**002**	Feb 10, 2016
AP			**EQ 750MG/150ML (EQ 5MG/ML)**	**A206919**	**003**	Feb 10, 2016
AP		BAXTER HLTHCARE CORP	**EQ 250MG/50ML (EQ 5MG/ML)**	**A091397**	**001**	Aug 08, 2013
AP			**EQ 500MG/100ML (EQ 5MG/ML)**	**A091397**	**002**	Aug 08, 2013
AP			**EQ 750MG/150ML (EQ 5MG/ML)**	**A091397**	**003**	Aug 08, 2013
AP		FRESENIUS KABI USA	**EQ 250MG/50ML (EQ 5MG/ML)**	**A200674**	**001**	Jun 19, 2013
AP			**EQ 500MG/100ML (EQ 5MG/ML)**	**A200674**	**002**	Jun 19, 2013
AP			**EQ 750MG/150ML (EQ 5MG/ML)**	**A200674**	**003**	Jun 19, 2013
AP		HIKMA FARMACEUTICA	**EQ 250MG/50ML (EQ 5MG/ML)**	**A091375**	**001**	Sep 16, 2011
AP			**EQ 500MG/100ML (EQ 5MG/ML)**	**A091375**	**002**	Sep 16, 2011
AP			**EQ 750MG/150ML (EQ 5MG/ML)**	**A091375**	**003**	Sep 16, 2011
AP		HOSPIRA INC	**EQ 250MG/50ML (EQ 5MG/ML)**	**A078579**	**001**	Sep 03, 2015
AP			**EQ 500MG/100ML (EQ 5MG/ML)**	**A078579**	**002**	Sep 03, 2015
AP			**EQ 750MG/150ML (EQ 5MG/ML)**	**A078579**	**003**	Sep 03, 2015
AP	**!**	INFORLIFE	**EQ 250MG/50ML (EQ 5MG/ML)**	**A090343**	**001**	Jul 07, 2011
AP	**!**		**EQ 500MG/100ML (EQ 5MG/ML)**	**A090343**	**002**	Jul 07, 2011

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	!		**EQ 750MG/150ML (EQ 5MG/ML)**	**A090343**	**003**	Jul 07, 2011

SOLUTION;ORAL

LEVOFLOXACIN

AA	!	HI TECH PHARMA	**250MG/10ML**	**A091678**	**001**	Jun 20, 2011
AA		LANNETT CO INC	**250MG/10ML**	**A205222**	**001**	May 25, 2018

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

AT		AKORN	**0.5%**	**A090268**	**001**	Dec 20, 2010
AT		MYLAN LABS LTD	**0.5%**	**A204899**	**001**	Dec 08, 2017
AT	!	RISING PHARMS	**0.5%**	**A077700**	**001**	Dec 20, 2010
AT		WATSON LABS TEVA	**0.5%**	**A076826**	**001**	Feb 10, 2011

TABLET;ORAL

LEVOFLOXACIN

AB		APOTEX INC	**250MG**	**A090787**	**001**	Sep 29, 2011
AB			**500MG**	**A090787**	**002**	Sep 29, 2011
AB			**750MG**	**A090787**	**003**	Sep 29, 2011
AB		AUROBINDO PHARMA LTD	**250MG**	**A201043**	**001**	Jun 20, 2011
AB			**500MG**	**A201043**	**002**	Jun 20, 2011
AB	!		**750MG**	**A201043**	**003**	Jun 20, 2011
AB		CIPLA LTD	**250MG**	**A076890**	**001**	Mar 30, 2012
AB			**500MG**	**A076890**	**002**	Mar 30, 2012
AB			**750MG**	**A076890**	**003**	Mar 30, 2012
AB		DR REDDYS LABS INC	**250MG**	**A076710**	**001**	Jun 20, 2011
AB			**500MG**	**A076710**	**002**	Jun 20, 2011
AB			**750MG**	**A076710**	**003**	Jun 20, 2011
AB		GLENMARK GENERICS	**250MG**	**A200250**	**001**	Jun 20, 2011
AB			**500MG**	**A200250**	**002**	Jun 20, 2011
AB			**750MG**	**A200250**	**003**	Jun 20, 2011
AB		HETERO LABS LTD V	**250MG**	**A202801**	**001**	Jan 08, 2015
AB			**500MG**	**A202801**	**002**	Jan 08, 2015
AB			**750MG**	**A202801**	**003**	Jan 08, 2015
AB		JUBILANT GENERICS	**250MG**	**A203613**	**001**	Jun 19, 2015
AB			**500MG**	**A203613**	**002**	Jun 19, 2015
AB		LUPIN	**250MG**	**A078424**	**001**	Jun 20, 2011
AB			**500MG**	**A078424**	**002**	Jun 20, 2011
AB			**750MG**	**A078424**	**003**	Jun 20, 2011
AB		MACLEODS PHARMS LTD	**250MG**	**A200839**	**001**	Mar 22, 2012
AB			**500MG**	**A200839**	**002**	Mar 22, 2012
AB			**750MG**	**A200839**	**003**	Mar 22, 2012
AB		ORCHID HLTHCARE	**250MG**	**A202200**	**001**	Jan 30, 2012
AB			**500MG**	**A202200**	**002**	Jan 30, 2012
AB			**750MG**	**A202200**	**003**	Jan 30, 2012
AB		SANDOZ	**250MG**	**A077438**	**001**	Jun 20, 2011
AB			**500MG**	**A077438**	**002**	Jun 20, 2011
AB			**750MG**	**A077438**	**003**	Jun 20, 2011
AB		TEVA	**250MG**	**A076361**	**001**	Jun 20, 2011
AB			**500MG**	**A076361**	**002**	Jun 20, 2011
AB			**750MG**	**A076361**	**003**	Jun 20, 2011
AB		TORRENT PHARMS	**250MG**	**A090722**	**001**	Jun 20, 2011
AB			**500MG**	**A090722**	**002**	Jun 20, 2011
AB			**750MG**	**A090722**	**003**	Jun 20, 2011
AB		WOCKHARDT	**250MG**	**A090367**	**001**	Jun 20, 2011
AB			**500MG**	**A090367**	**002**	Jun 20, 2011
AB			**750MG**	**A090367**	**003**	Jun 20, 2011
AB		ZYDUS PHARMS USA INC	**250MG**	**A077652**	**001**	Sep 07, 2012
AB			**500MG**	**A077652**	**002**	Sep 07, 2012
AB			**750MG**	**A077652**	**003**	Sep 07, 2012

LEVOLEUCOVORIN

POWDER;INTRAVENOUS

KHAPZORY

+!		SPECTRUM PHARMS	175MG/VIAL	N211226	001	Oct 19, 2018
+!			300MG/VIAL	N211226	002	Oct 19, 2018

LEVOLEUCOVORIN CALCIUM							
POWDER;INTRAVENOUS							
FUSILEV							
AP	**+!**	SPECTRUM PHARMS	**EQ 50MG BASE/VIAL**	**N020140**	**001**	Mar 07, 2008
LEVOLEUCOVORIN CALCIUM							
AP		ACTAVIS LLC	**EQ 50MG BASE/VIAL**	**A206516**	**001**	Feb 13, 2017
AP		AMNEAL PHARMS CO	**EQ 50MG BASE/VIAL**	**A207547**	**001**	Feb 13, 2017
AP		WEST-WARD PHARMS INT	**EQ 50MG BASE/VIAL**	**A206263**	**001**	Jun 16, 2016
	+!	ACTAVIS LLC	EQ 175MG BASE/VIAL	N208723	001	Sep 29, 2016
SOLUTION;INTRAVENOUS							
LEVOLEUCOVORIN CALCIUM							
AP		AMNEAL PHARMS CO	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A207548**	**001**	Sep 08, 2017
AP		GLAND PHARMA LTD	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A210892**	**001**	Sep 14, 2018
AP			**EQ 250MG BASE/25ML (EQ 10MG BASE/ML)**	**A210892**	**002**	Sep 14, 2018
AP		INGENUS PHARMS LLC	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A210623**	**001**	May 03, 2018
AP			**EQ 250MG BASE/25ML (EQ 10MG BASE/ML)**	**A210623**	**002**	May 03, 2018
AP		MYLAN TEORANTA	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A203576**	**001**	Oct 20, 2015
AP			**EQ 250MG BASE/25ML (EQ 10MG BASE/ML)**	**A203576**	**002**	Oct 20, 2015
AP		SANDOZ INC	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A203563**	**001**	Mar 09, 2015
AP	**!**		**EQ 250MG BASE/25ML (EQ 10MG BASE/ML)**	**A203563**	**002**	Mar 09, 2015
LEVOMILNACIPRAN HYDROCHLORIDE							
CAPSULE, EXTENDED RELEASE;ORAL							
FETZIMA							
	+	ALLERGAN SALES LLC	EQ 20MG BASE	N204168	001	Jul 25, 2013
	+		EQ 40MG BASE	N204168	002	Jul 25, 2013
	+		EQ 80MG BASE	N204168	003	Jul 25, 2013
	+!		EQ 120MG BASE	N204168	004	Jul 25, 2013
LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE							
INJECTABLE;INJECTION							
SCANDONEST L							
	!	DEPROCO	0.05MG/ML;2%	A088388	001	Oct 10, 1984
LEVONORGESTREL							
INTRAUTERINE DEVICE;INTRAUTERINE							
KYLEENA							
	+!	BAYER HLTHCARE	19.5MG	N208224	001	Sep 16, 2016
LILETTA							
		MEDICINES360	52MG	N206229	001	Feb 26, 2015
MIRENA							
	+!	BAYER HLTHCARE	52MG	N021225	001	Dec 06, 2000
SKYLA							
	+!	BAYER HLTHCARE	13.5MG	N203159	001	Jan 09, 2013
TABLET;ORAL							
LEVONORGESTREL							
AB		LOTUS PHARM CO LTD	**0.75MG**	**A202684**	**001**	Sep 02, 2016
AB		MYLAN LABS LTD	**0.75MG**	**A202740**	**001**	Sep 02, 2016
AB	**!**	PERRIGO R AND D	**0.75MG**	**A090740**	**001**	Dec 30, 2010
LEVORPHANOL TARTRATE							
TABLET;ORAL							
LEVORPHANOL TARTRATE							
AB	**!**	SENTYNL THERAPS INC	**2MG**	**A074278**	**001**	Mar 31, 2000
AB		VIRTUS PHARMS	**2MG**	**A211484**	**001**	Dec 13, 2018
		SENTYNL THERAPS INC	1MG	A074278	002	Jun 18, 2018
			3MG	A074278	003	Jun 18, 2018
LEVOTHYROXINE SODIUM							
CAPSULE;ORAL							
TIROSINT							
	+	INSTITUT BIOCHIMIQUE	0.013MG	N021924	013	Aug 01, 2007
	+		0.025MG	N021924	002	Oct 13, 2006
	+		0.05MG	N021924	003	Oct 13, 2006
	+		0.075MG	N021924	004	Oct 13, 2006
	+		0.088MG	N021924	010	Oct 02, 2009
	+		0.1MG	N021924	005	Oct 13, 2006
	+		0.112MG	N021924	008	Oct 02, 2009
	+		0.125MG	N021924	006	Oct 13, 2006
	+		0.137MG	N021924	009	Oct 02, 2009
	+		0.15MG	N021924	007	Oct 13, 2006
	+		0.175MG	N021924	011	Apr 25, 2017
	+!		0.200MG	N021924	012	Apr 25, 2017

LEVOTHYROXINE SODIUM

POWDER;INTRAVENOUS

LEVOTHYROXINE SODIUM

AP	**+!**	FRESENIUS KABI USA	**100MCG/VIAL**		**N202231**	**001**	Jun 24, 2011
AP	**+!**		**200MCG/VIAL**		**N202231**	**002**	Jun 24, 2011
AP	**+!**		**500MCG/VIAL**		**N202231**	**003**	Jun 24, 2011
AP		MAIA PHARMS INC	**100MCG/VIAL**		**A208749**	**001**	Dec 21, 2018
AP			**200MCG/VIAL**		**A208749**	**002**	Dec 21, 2018
AP			**500MCG/VIAL**		**A208749**	**003**	Dec 21, 2018
AP		PAR STERILE PRODUCTS	**200MCG/VIAL**		**A205366**	**001**	Dec 07, 2015
AP		PIRAMAL CRITICAL	**100MCG/VIAL**		**A206163**	**001**	Jun 29, 2016
AP			**500MCG/VIAL**		**A206163**	**002**	Jun 29, 2016

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

SYNTHROID

-->	**+**	ABBVIE	**--> AB1,AB2**	**0.025MG**	N021402	001	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.05MG**	N021402	002	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.075MG**	N021402	003	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.088MG**	N021402	004	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.1MG**	N021402	005	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.112MG**	N021402	006	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.125MG**	N021402	007	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.137MG**	N021402	008	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.15MG**	N021402	009	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.175MG**	N021402	010	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.2MG**	N021402	012	Jul 24, 2002
-->	**+!**		**--> AB1,AB2**	**0.3MG**	N021402	011	Jul 24, 2002

LEVO-T

-->	**+**	CEDIPROF INC	**--> AB1,AB2,AB3**	**0.025MG**	N021342	001	Mar 01, 2002
-->	**+**		**--> AB1,AB2,AB3**	**0.05MG**	N021342	002	Mar 01, 2002
-->	**+**		**--> AB1,AB2,AB3**	**0.075MG**	N021342	003	Mar 01, 2002
-->	**+**		**--> AB1,AB2,AB3**	**0.088MG**	N021342	004	Mar 01, 2002
-->	**+**		**--> AB1,AB2,AB3**	**0.1MG**	N021342	005	Mar 01, 2002
-->	**+**		**--> AB1,AB2,AB3**	**0.112MG**	N021342	006	Mar 01, 2002
-->	**+**		**--> AB1,AB2,AB3**	**0.125MG**	N021342	007	Mar 01, 2002
-->	**+**		**--> AB1,AB2,AB3**	**0.137MG**	N021342	012	Dec 08, 2003
-->	**+**		**--> AB1,AB2,AB3**	**0.15MG**	N021342	008	Mar 01, 2002
-->	**+**		**--> AB1,AB2,AB3**	**0.175MG**	N021342	009	Mar 01, 2002
-->	**+**		**--> AB1,AB2,AB3**	**0.2MG**	N021342	010	Mar 01, 2002
-->	**+!**		**--> AB1,AB2,AB3**	**0.3MG**	N021342	011	Mar 01, 2002

UNITHROID

-->	**+**	STEVENS J	**--> AB1,AB2,AB3**	**0.025MG**	N021210	001	Aug 21, 2000
-->	**+**		**--> AB1,AB2,AB3**	**0.05MG**	N021210	002	Aug 21, 2000
-->	**+**		**--> AB1,AB2,AB3**	**0.075MG**	N021210	003	Aug 21, 2000
-->	**+**		**--> AB1,AB2,AB3**	**0.088MG**	N021210	004	Aug 21, 2000
-->	**+**		**--> AB1,AB2,AB3**	**0.1MG**	N021210	005	Aug 21, 2000
-->	**+**		**--> AB1,AB2,AB3**	**0.112MG**	N021210	006	Aug 21, 2000
-->	**+**		**--> AB1,AB2,AB3**	**0.125MG**	N021210	007	Aug 21, 2000
-->	**+**		**--> AB1,AB2,AB3**	**0.137MG**	N021210	012	Feb 08, 2008
-->	**+**		**--> AB1,AB2,AB3**	**0.15MG**	N021210	008	Aug 21, 2000
-->	**+**		**--> AB1,AB2,AB3**	**0.175MG**	N021210	009	Aug 21, 2000
-->	**+**		**--> AB1,AB2,AB3**	**0.2MG**	N021210	010	Aug 21, 2000

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

	UNITHROID						
-->	+!		--> AB1,AB2,AB3	0.3MG	N021210	011	Aug 21, 2000
	LEVOTHYROXINE SODIUM						
-->		MYLAN	--> AB1,AB2,AB3,AB4	0.025MG	A076187	001	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.05MG	A076187	002	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.075MG	A076187	003	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.088MG	A076187	004	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.1MG	A076187	005	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.112MG	A076187	006	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.125MG	A076187	007	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.137MG	A076187	012	Dec 13, 2006
-->			--> AB1,AB2,AB3,AB4	0.15MG	A076187	008	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.175MG	A076187	009	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.2MG	A076187	010	Jun 05, 2002
-->	!		--> AB1,AB2,AB3,AB4	0.3MG	A076187	011	Jun 05, 2002
	LEVOXYL						
-->	+	KING PHARMS	--> AB1,AB3	0.025MG	N021301	001	May 25, 2001
-->	+		--> AB1,AB3	0.05MG	N021301	002	May 25, 2001
-->	+		--> AB1,AB3	0.075MG	N021301	003	May 25, 2001
-->	+		--> AB1,AB3	0.088MG	N021301	004	May 25, 2001
-->	+		--> AB1,AB3	0.1MG	N021301	005	May 25, 2001
-->	+		--> AB1,AB3	0.112MG	N021301	006	May 25, 2001
-->	+		--> AB1,AB3	0.125MG	N021301	007	May 25, 2001
-->	+		--> AB1,AB3	0.137MG	N021301	008	May 25, 2001
-->	+		--> AB1,AB3	0.15MG	N021301	009	May 25, 2001
-->	+		--> AB1,AB3	0.175MG	N021301	010	May 25, 2001
-->	+!		--> AB1,AB3	0.2MG	N021301	011	May 25, 2001
	EUTHYROX						
AB2		PROVELL	0.025MG		N021292	001	May 31, 2002
AB2			0.05MG		N021292	002	May 31, 2002
AB2			0.075MG		N021292	003	May 31, 2002
AB2			0.088MG		N021292	004	May 31, 2002
AB2			0.1MG		N021292	005	May 31, 2002
AB2			0.112MG		N021292	006	May 31, 2002
AB2			0.125MG		N021292	007	May 31, 2002
AB2			0.137MG		N021292	008	May 31, 2002
AB2			0.15MG		N021292	009	May 31, 2002
AB2			0.175MG		N021292	010	May 31, 2002
AB2			0.2MG		N021292	011	May 31, 2002

LIDOCAINE

OINTMENT;TOPICAL

	LIDOCAINE						
AT		ALEOR DERMACEUTICALS	5%		A211469	001	Nov 23, 2018
AT		ALKEM LABS LTD	5%		A207810	001	Mar 10, 2017
AT		AMNEAL PHARMS	5%		A206297	001	Aug 07, 2015
AT	!	FOUGERA PHARMS INC	5%		A080198	001	
AT		G AND W LABS INC	5%		A211019	001	Dec 12, 2018
AT		GLENMARK PHARMS LTD	5%		A206498	001	Sep 09, 2016
AT		RICONPHARMA LLC	5%		A208604	001	Sep 20, 2017
AT		SEPTODONT INC	5%		A040911	001	May 23, 2011
AT		STRIDES PHARMA	5%		A210958	001	Dec 11, 2018
AT		TARO	5%		A086724	001	
AT		TELIGENT PHARMA INC	5%		A205318	001	Feb 01, 2016
AT		TEVA PHARMS USA	5%		A210256	001	Jan 16, 2018
AT		VITRUVIAS THERAP	5%		A208822	001	Sep 25, 2017

LIDOCAINE						
PATCH;TOPICAL						
LIDOCAINE						
AB		ACTAVIS LABS UT INC	**5%**	**A200675**	**001**	Aug 23, 2012
AB		MYLAN TECHNOLOGIES	**5%**	**A202346**	**001**	Aug 07, 2015
LIDODERM						
AB	**+!**	TEIKOKU PHARMA USA	**5%**	**N020612**	**001**	Mar 19, 1999
ZTLIDO						
	+!	SCILEX PHARMS INC	1.8%	N207962	001	Feb 28, 2018
LIDOCAINE HYDROCHLORIDE						
GEL;OPHTHALMIC						
AKTEN						
	+!	AKORN	3.5%	N022221	001	Oct 07, 2008
INJECTABLE;INJECTION						
LIDOCAINE HYDROCHLORIDE						
AP		AUROBINDO PHARMA LTD	**1%**	**A207182**	**001**	Oct 30, 2017
AP			**2%**	**A207182**	**002**	Oct 30, 2017
AP		B BRAUN MEDICAL INC	**1%**	**A208474**	**001**	Aug 03, 2018
AP		HOSPIRA	**0.5%**	**A088328**	**001**	May 17, 1984
AP			**1%**	**A083158**	**001**	
AP			**1%**	**A088329**	**001**	May 17, 1984
AP			**2%**	**A040078**	**001**	Jun 23, 1995
AP			**2%**	**A083158**	**002**	
AP			**2%**	**A088294**	**001**	May 17, 1984
AP			**20%**	**A083158**	**003**	
AP		INTL MEDICATION	**1%**	**A083173**	**001**	
AP			**2%**	**A083173**	**002**	
AP		LUITPOLD	**1%**	**A080850**	**001**	
AP			**1%**	**A091564**	**001**	Aug 14, 2015
AP		SPECTRA MDCL DEVICES	**1%**	**A208017**	**001**	Apr 18, 2018
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER						
AP		B BRAUN	**200MG/100ML**	**N019830**	**002**	Apr 08, 1992
AP		BAXTER HLTHCARE	**200MG/100ML**	**N018461**	**002**	
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER						
AP		B BRAUN	**400MG/100ML**	**N019830**	**003**	Apr 08, 1992
AP		BAXTER HLTHCARE	**400MG/100ML**	**N018461**	**003**	
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER						
AP		B BRAUN	**800MG/100ML**	**N019830**	**004**	Apr 08, 1992
AP		BAXTER HLTHCARE	**800MG/100ML**	**N018461**	**004**	Feb 22, 1982
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER						
AP		FRESENIUS KABI USA	**1%**	**A088586**	**001**	Jul 24, 1985
AP		HOSPIRA	**0.5%**	**A088325**	**001**	Jul 31, 1984
AP			**1%**	**A088299**	**001**	Jul 31, 1984
AP			**2%**	**A088327**	**001**	Jul 31, 1984
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE						
AP		AUROBINDO PHARMA LTD	**1%**	**A203040**	**001**	Mar 14, 2013
AP			**1%**	**A203082**	**001**	Mar 14, 2013
AP			**2%**	**A203040**	**002**	Mar 14, 2013
AP			**2%**	**A203082**	**002**	Mar 14, 2013
AP		FRESENIUS KABI USA	**1%**	**A080404**	**002**	
AP			**2%**	**A080404**	**003**	
AP			**2%**	**N017584**	**001**	
AP			**4%**	**N017584**	**002**	
AP		HOSPIRA	**1%**	**A080408**	**001**	
AP			**1.5%**	**A080408**	**002**	
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER						
AP		HOSPIRA	**1%**	**A040302**	**001**	Sep 28, 1998
AP			**2%**	**A040302**	**002**	Sep 28, 1998
XYLOCAINE						
AP	**+!**	FRESENIUS KABI USA	**0.5%**	**N006488**	**008**	
AP	**+!**		**1%**	**N006488**	**007**	
AP	**+!**		**1.5%**	**N006488**	**010**	
AP	**+!**		**2%**	**N006488**	**002**	
XYLOCAINE PRESERVATIVE FREE						
AP	**+!**	FRESENIUS KABI USA	**1%**	**N016801**	**005**	Jan 19, 1988
AP	**+!**		**2%**	**N016801**	**001**	
AP	**+!**		**4%**	**N016801**	**002**	
AP	**+!**		**20%**	**N016801**	**004**	

LIDOCAINE HYDROCHLORIDE							
INJECTABLE;INJECTION							
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE							
	!	HOSPIRA	4%		A088295	001	May 17, 1984
INJECTABLE;SPINAL							
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%							
	!	HOSPIRA	5%		A083914	001	
JELLY;TOPICAL							
GLYDO							
AT		SAGENT PHARMS	**2%**		**A201094**	**001**	Apr 28, 2014
LIDOCAINE HYDROCHLORIDE							
AT		AKORN	**2%**		**A040433**	**001**	Feb 12, 2003
AT		INTL MEDICATION	**2%**		**A086283**	**001**	
XYLOCAINE							
AT	**+!**	OAK PHARMS	**2%**		**N008816**	**001**	
SOLUTION;ORAL							
LIDOCAINE HYDROCHLORIDE							
AT		HI TECH PHARMA	**2%**		**A040014**	**001**	Jul 10, 1995
AT		WOCKHARDT BIO AG	**2%**		**A087872**	**001**	Nov 18, 1982
LIDOCAINE HYDROCHLORIDE VISCOUS							
AT	**!**	LANNETT CO INC	**2%**		**A040708**	**001**	Feb 27, 2007
LIDOCAINE VISCOUS							
AT		WEST-WARD PHARMS INT	**2%**		**A088802**	**001**	Apr 26, 1985
SOLUTION;TOPICAL							
LARYNG-O-JET KIT							
AT		INTL MEDICATION	**4%**		**A086364**	**001**	
LIDOCAINE HYDROCHLORIDE							
AT		TELIGENT PHARMA INC	**4%**		**A204494**	**001**	Mar 12, 2014
AT	**!**	WEST-WARD PHARMS INT	**4%**		**A088803**	**001**	Apr 03, 1985
SYSTEM;INTRADERMAL							
ZINGO							
		POWDER PHARMS	0.5MG		N022114	001	Aug 16, 2007
LIDOCAINE; PRILOCAINE							
CREAM;TOPICAL							
EMLA							
AB	**+!**	ACTAVIS LABS UT INC	**2.5%;2.5%**		**N019941**	**001**	Dec 30, 1992
LIDOCAINE AND PRILOCAINE							
AB		FOUGERA PHARMS	**2.5%;2.5%**		**A076453**	**001**	Aug 18, 2003
AB		HI TECH PHARMA	**2.5%;2.5%**		**A076290**	**001**	Sep 25, 2003
AB		TELIGENT PHARMA INC	**2.5%;2.5%**		**A205887**	**001**	Jun 29, 2018
AB		TOLMAR	**2.5%;2.5%**		**A076320**	**001**	Aug 27, 2003
GEL;PERIODONTAL							
ORAQIX							
	+!	DENTSPLY PHARM	2.5%;2.5%		N021451	001	Dec 19, 2003
LIDOCAINE; TETRACAINE							
CREAM;TOPICAL							
PLIAGLIS							
	+!	TARO PHARMS	7%;7%		N021717	001	Jun 29, 2006
PATCH;TOPICAL							
SYNERA							
	+!	GALEN SPECIALTY	70MG;70MG		N021623	001	Jun 23, 2005
LIFITEGRAST							
SOLUTION/DROPS;OPHTHALMIC							
XIIDRA							
	+!	SHIRE DEV LLC	5%		N208073	001	Jul 11, 2016
LINACLOTIDE							
CAPSULE;ORAL							
LINZESS							
	+!	ALLERGAN SALES LLC	72MCG		N202811	003	Jan 25, 2017
	+!		145MCG		N202811	001	Aug 30, 2012
	+		290MCG		N202811	002	Aug 30, 2012
LINAGLIPTIN							
TABLET;ORAL							
TRADJENTA							
	+!	BOEHRINGER INGELHEIM	5MG		N201280	001	May 02, 2011

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

JENTADUETO

+	BOEHRINGER INGELHEIM	2.5MG;500MG	N201281	001	Jan 30, 2012
+		2.5MG;850MG	N201281	002	Jan 30, 2012
+!		2.5MG;1GM	N201281	003	Jan 30, 2012

TABLET, EXTENDED RELEASE;ORAL

JENTADUETO XR

+	BOEHRINGER INGELHEIM	2.5MG;1GM	N208026	001	May 27, 2016
+!		5MG;1GM	N208026	002	May 27, 2016

LINCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

LINCOCIN

AP	**+!**	PHARMACIA AND UPJOHN	**EQ 300MG BASE/ML**	**N050317**	**001**	

LINCOMYCIN

AP		X-GEN PHARMS INC	**EQ 300MG BASE/ML**	**A201746**	**001**	Jun 04, 2015

LINDANE

LOTION;TOPICAL

LINDANE

	!	OLTA PHARMS	1%	A087313	001	

SHAMPOO;TOPICAL

LINDANE

AT		OLTA PHARMS	**1%**	**A087266**	**001**	
AT	**!**	WOCKHARDT BIO AG	**1%**	**A088191**	**001**	Sep 18, 1984

LINEZOLID

FOR SUSPENSION;ORAL

LINEZOLID

AB		WEST-WARD PHARMS INT	**100MG/5ML**	**A200068**	**001**	Jun 03, 2015

ZYVOX

AB	**+!**	PHARMACIA AND UPJOHN	**100MG/5ML**	**N021132**	**001**	Apr 18, 2000

SOLUTION;INTRAVENOUS

LINEZOLID

AP		AUROBINDO PHARMA LTD	**600MG/300ML (2MG/ML)**	**A206917**	**001**	Aug 04, 2016
AP		FRESENIUS KABI USA	**600MG/300ML (2MG/ML)**	**A204764**	**001**	Mar 15, 2016
AP		HOSPIRA INC	**600MG/300ML (2MG/ML)**	**A205442**	**001**	Jul 07, 2015
AP		HQ SPCLT PHARMA	**200MG/100ML (2MG/ML)**	**A207001**	**001**	Jul 07, 2017
AP			**600MG/300ML (2MG/ML)**	**A207001**	**002**	Jul 07, 2017
AP		MYLAN LABS LTD	**200MG/100ML (2MG/ML)**	**A205154**	**001**	Dec 06, 2017
AP			**600MG/300ML (2MG/ML)**	**A205154**	**002**	Dec 06, 2017
AP		NANG KUANG PHARM CO	**200MG/100ML (2MG/ML)**	**A207354**	**001**	Dec 20, 2016
AP			**600MG/300ML (2MG/ML)**	**A207354**	**002**	Dec 20, 2016
AP		SAGENT PHARMS	**200MG/100ML (2MG/ML)**	**A204696**	**001**	Mar 02, 2017
AP			**600MG/300ML (2MG/ML)**	**A204696**	**002**	Mar 02, 2017
AP		SANDOZ INC	**200MG/100ML (2MG/ML)**	**A200904**	**001**	Jul 16, 2015
AP			**600MG/300ML (2MG/ML)**	**A200904**	**002**	Jul 16, 2015
AP		TEVA PHARMS	**600MG/300ML (2MG/ML)**	**A200222**	**001**	Jun 27, 2012

ZYVOX

AP	**+**	PHARMACIA AND UPJOHN	**200MG/100ML (2MG/ML)**	**N021131**	**001**	Apr 18, 2000
AP	**+!**		**600MG/300ML (2MG/ML)**	**N021131**	**003**	Apr 18, 2000

LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	+!	HOSPIRA INC	600MG/300ML (2MG/ML)	N206473	001	Jun 18, 2015

TABLET;ORAL

LINEZOLID

AB		ALEMBIC PHARMS LTD	**600MG**	**A205233**	**001**	Dec 21, 2015
AB		ALKEM LABS LTD	**600MG**	**A205517**	**001**	Dec 21, 2015
AB		AMNEAL PHARMS	**600MG**	**A204536**	**001**	Dec 21, 2015
AB		GATE PHARMS	**600MG**	**A091210**	**001**	Feb 05, 2016
AB		GLENMARK PHARMS	**600MG**	**A078987**	**001**	Dec 21, 2015
AB		HETERO LABS LTD V	**600MG**	**A204239**	**001**	Dec 21, 2015
AB		MYLAN PHARMS INC	**600MG**	**A078845**	**001**	Dec 21, 2015
AB		NOVEL LABS INC	**600MG**	**A207526**	**001**	Aug 22, 2016
AB		TEVA PHARMS USA	**600MG**	**A078061**	**001**	May 18, 2015
AB		ZYDUS PHARMS USA INC	**600MG**	**A206097**	**001**	Feb 22, 2017

LINEZOLID						
TABLET;ORAL						
ZYVOX						
AB	**+!**	PHARMACIA AND UPJOHN	**600MG**	**N021130**	**002**	Apr 18, 2000
LIOTHYRONINE SODIUM						
INJECTABLE;INJECTION						
LIOTHYRONINE SODIUM						
AP		X GEN PHARMS	**EQ 0.01MG BASE/ML**	**A076923**	**001**	Aug 17, 2005
TRIOSTAT						
AP	**+!**	PAR STERILE PRODUCTS	**EQ 0.01MG BASE/ML**	**N020105**	**001**	Dec 31, 1991
TABLET;ORAL						
CYTOMEL						
AB	**+**	KING PHARMS	**EQ 0.005MG BASE**	**N010379**	**001**	
AB	**+**		**EQ 0.025MG BASE**	**N010379**	**002**	
AB	**+!**		**EQ 0.05MG BASE**	**N010379**	**003**	
LIOTHYRONINE SODIUM						
AB		MAYNE PHARMA INC	**EQ 0.005MG BASE**	**A090097**	**001**	Mar 20, 2009
AB			**EQ 0.025MG BASE**	**A090097**	**002**	Mar 20, 2009
AB			**EQ 0.05MG BASE**	**A090097**	**003**	Mar 20, 2009
AB		MYLAN	**EQ 0.005MG BASE**	**A090326**	**001**	Jul 14, 2009
AB			**EQ 0.025MG BASE**	**A090326**	**002**	Jul 14, 2009
AB			**EQ 0.05MG BASE**	**A090326**	**003**	Jul 14, 2009
AB		SIGMAPHARM LABS LLC	**EQ 0.005MG BASE**	**A200295**	**001**	Nov 29, 2012
AB			**EQ 0.025MG BASE**	**A200295**	**002**	Nov 29, 2012
AB			**EQ 0.05MG BASE**	**A200295**	**003**	Nov 29, 2012
AB		SUN PHARM INDS LTD	**EQ 0.005MG BASE**	**A091382**	**001**	Apr 20, 2016
AB			**EQ 0.025MG BASE**	**A091382**	**002**	Apr 20, 2016
AB			**EQ 0.05MG BASE**	**A091382**	**003**	Apr 20, 2016
AB		TEVA PHARMS USA	**EQ 0.005MG BASE**	**A211510**	**001**	Oct 26, 2018
AB			**EQ 0.025MG BASE**	**A211510**	**002**	Oct 26, 2018
AB			**EQ 0.05MG BASE**	**A211510**	**003**	Oct 26, 2018
LIRAGLUTIDE RECOMBINANT						
SOLUTION;SUBCUTANEOUS						
SAXENDA						
	+!	NOVO	18MG/3ML (6MG/ML)	N206321	001	Dec 23, 2014
VICTOZA						
	+!	NOVO NORDISK INC	18MG/3ML (6MG/ML)	N022341	001	Jan 25, 2010
LISDEXAMFETAMINE DIMESYLATE						
CAPSULE;ORAL						
VYVANSE						
	+	SHIRE DEVELOPMENT	10MG	N021977	007	Oct 30, 2014
	+		20MG	N021977	004	Dec 10, 2007
	+		30MG	N021977	001	Feb 23, 2007
	+		40MG	N021977	005	Dec 10, 2007
	+		50MG	N021977	002	Feb 23, 2007
	+		60MG	N021977	006	Dec 10, 2007
	+!		70MG	N021977	003	Feb 23, 2007
TABLET, CHEWABLE;ORAL						
VYVANSE						
	+	SHIRE DEV LLC	10MG	N208510	001	Jan 28, 2017
	+		20MG	N208510	002	Jan 28, 2017
	+		30MG	N208510	003	Jan 28, 2017
	+		40MG	N208510	004	Jan 28, 2017
	+		50MG	N208510	005	Jan 28, 2017
	+!		60MG	N208510	006	Jan 28, 2017
LISINOPRIL						
SOLUTION;ORAL						
QBRELIS						
	+!	SILVERGATE PHARMS	1MG/ML	N208401	001	Jul 29, 2016
TABLET;ORAL						
LISINOPRIL						
AB		ACCORD HLTHCARE	**2.5MG**	**A202554**	**001**	Jul 30, 2013
AB			**5MG**	**A202554**	**002**	Jul 30, 2013
AB			**10MG**	**A202554**	**003**	Jul 30, 2013
AB			**20MG**	**A202554**	**004**	Jul 30, 2013
AB			**30MG**	**A202554**	**005**	Jul 30, 2013
AB			**40MG**	**A202554**	**006**	Jul 30, 2013
AB		APOTEX INC	**2.5MG**	**A076102**	**001**	Sep 30, 2002
AB			**5MG**	**A076102**	**002**	Sep 30, 2002

LISINOPRIL

TABLET;ORAL

LISINOPRIL

AB		**10MG**	**A076102**	**003**	Sep 30, 2002
AB		**20MG**	**A076102**	**004**	Sep 30, 2002
AB		**30MG**	**A076102**	**005**	Sep 30, 2002
AB		**40MG**	**A076102**	**006**	Sep 30, 2002
AB	AUROBINDO	**2.5MG**	**A077622**	**001**	Feb 22, 2006
AB		**5MG**	**A077622**	**002**	Feb 22, 2006
AB		**10MG**	**A077622**	**003**	Feb 22, 2006
AB		**20MG**	**A077622**	**004**	Feb 22, 2006
AB		**30MG**	**A077622**	**005**	Feb 22, 2006
AB		**40MG**	**A077622**	**006**	Feb 22, 2006
AB	CASI PHARMS INC	**2.5MG**	**A075994**	**001**	Jul 01, 2002
AB		**5MG**	**A075994**	**002**	Jul 01, 2002
AB		**10MG**	**A075994**	**003**	Jul 01, 2002
AB		**20MG**	**A075994**	**004**	Jul 01, 2002
AB		**30MG**	**A075994**	**005**	Jul 01, 2002
AB		**40MG**	**A075994**	**006**	Jul 01, 2002
AB	HIKMA INTL PHARMS	**2.5MG**	**A076063**	**001**	Jul 01, 2002
AB		**5MG**	**A076063**	**002**	Jul 01, 2002
AB		**10MG**	**A076063**	**003**	Jul 01, 2002
AB		**20MG**	**A076063**	**004**	Jul 01, 2002
AB		**30MG**	**A076063**	**006**	Jun 27, 2003
AB		**40MG**	**A076063**	**005**	Jul 01, 2002
AB	INVAGEN PHARMS	**2.5MG**	**A203508**	**001**	Oct 29, 2013
AB		**5MG**	**A203508**	**002**	Oct 29, 2013
AB		**10MG**	**A203508**	**003**	Oct 29, 2013
AB		**20MG**	**A203508**	**004**	Oct 29, 2013
AB		**30MG**	**A203508**	**005**	Oct 29, 2013
AB		**40MG**	**A203508**	**006**	Oct 29, 2013
AB	IVAX SUB TEVA PHARMS	**2.5MG**	**A075752**	**001**	Jul 01, 2002
AB		**5MG**	**A075752**	**002**	Jul 01, 2002
AB		**10MG**	**A075752**	**003**	Jul 01, 2002
AB		**20MG**	**A075752**	**004**	Jul 01, 2002
AB		**30MG**	**A075752**	**005**	Jul 01, 2002
AB		**40MG**	**A075752**	**006**	Jul 01, 2002
AB	LUPIN	**2.5MG**	**A077321**	**001**	Sep 09, 2005
AB		**5MG**	**A077321**	**002**	Sep 09, 2005
AB		**10MG**	**A077321**	**003**	Sep 09, 2005
AB		**20MG**	**A077321**	**004**	Sep 09, 2005
AB		**30MG**	**A077321**	**005**	Sep 09, 2005
AB		**40MG**	**A077321**	**006**	Sep 09, 2005
AB	MYLAN	**2.5MG**	**A076071**	**001**	Jul 01, 2002
AB		**5MG**	**A076071**	**002**	Jul 01, 2002
AB		**10MG**	**A076071**	**003**	Jul 01, 2002
AB		**20MG**	**A076071**	**004**	Jul 01, 2002
AB		**30MG**	**A076071**	**005**	Jul 01, 2002
AB		**40MG**	**A076071**	**006**	Jul 01, 2002
AB	PRINSTON INC	**2.5MG**	**A075743**	**001**	Jul 01, 2002
AB		**2.5MG**	**A076180**	**001**	Jul 01, 2002
AB		**5MG**	**A075743**	**002**	Jul 01, 2002
AB		**5MG**	**A076180**	**002**	Jul 01, 2002
AB		**10MG**	**A075743**	**003**	Jul 01, 2002
AB		**10MG**	**A076180**	**003**	Jul 01, 2002
AB		**20MG**	**A075743**	**004**	Jul 01, 2002
AB		**20MG**	**A076164**	**001**	Jul 01, 2002
AB		**30MG**	**A075743**	**005**	Jul 01, 2002
AB		**30MG**	**A076164**	**002**	Jul 01, 2002
AB		**40MG**	**A075743**	**006**	Jul 01, 2002
AB		**40MG**	**A076164**	**003**	Jul 01, 2002
AB	SUN PHARM INDS LTD	**2.5MG**	**A075944**	**001**	Jul 01, 2002
AB		**5MG**	**A075944**	**002**	Jul 01, 2002
AB		**10MG**	**A075944**	**003**	Jul 01, 2002
AB		**20MG**	**A075944**	**004**	Jul 01, 2002
AB		**30MG**	**A075944**	**006**	Feb 11, 2003
AB		**40MG**	**A075944**	**005**	Jul 01, 2002
AB	WATSON LABS	**2.5MG**	**A076059**	**001**	Jul 01, 2002
AB		**5MG**	**A076059**	**002**	Jul 01, 2002
AB		**10MG**	**A076059**	**003**	Jul 01, 2002
AB		**20MG**	**A076059**	**004**	Jul 01, 2002
AB		**30MG**	**A076059**	**005**	Jul 01, 2002

LISINOPRIL

TABLET;ORAL

LISINOPRIL

AB			**40MG**	**A076059**	**006**	Jul 01, 2002
AB		WOCKHARDT	**2.5MG**	**A078402**	**001**	Apr 19, 2007
AB			**5MG**	**A078402**	**002**	Apr 19, 2007
AB			**10MG**	**A078402**	**003**	Apr 19, 2007
AB			**20MG**	**A078402**	**004**	Apr 19, 2007
AB			**30MG**	**A078402**	**005**	Apr 19, 2007
AB			**40MG**	**A078402**	**006**	Apr 19, 2007

PRINIVIL

AB		MERCK	**5MG**	**N019558**	**001**	Dec 29, 1987
AB			**10MG**	**N019558**	**002**	Dec 29, 1987
AB			**20MG**	**N019558**	**003**	Dec 29, 1987
AB			**40MG**	**N019558**	**004**	Oct 25, 1988

ZESTRIL

AB	+	ALVOGEN MALTA	**2.5MG**	**N019777**	**005**	Apr 29, 1993
AB	+		**5MG**	**N019777**	**001**	May 19, 1988
AB	+		**10MG**	**N019777**	**002**	May 19, 1988
AB	+		**20MG**	**N019777**	**003**	May 19, 1988
AB	+		**30MG**	**N019777**	**006**	Jan 20, 1999
AB	+!		**40MG**	**N019777**	**004**	May 19, 1988

LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

AB		ALEMBIC LTD	**150MG**	**A079159**	**001**	Jan 12, 2009
AB			**300MG**	**A079159**	**002**	Jan 12, 2009
AB			**600MG**	**A079159**	**003**	Jan 12, 2009
AB		GLENMARK GENERICS	**150MG**	**A079139**	**001**	Feb 03, 2009
AB			**300MG**	**A079139**	**002**	Feb 03, 2009
AB			**600MG**	**A079139**	**003**	Feb 03, 2009
AB		HETERO LABS LTD III	**150MG**	**A090702**	**001**	Sep 25, 2009
AB			**300MG**	**A090702**	**002**	Sep 25, 2009
AB			**600MG**	**A090702**	**003**	Sep 25, 2009
AB		MYLAN PHARMS INC	**150MG**	**A076243**	**002**	Feb 24, 2003
AB			**300MG**	**A076243**	**001**	Jun 27, 2002
AB			**600MG**	**A078763**	**001**	Apr 15, 2008
AB	+	WEST-WARD PHARMS INT	**150MG**	**N017812**	**002**	Jan 28, 1987
AB	+		**300MG**	**N017812**	**001**	
AB	+!		**600MG**	**N017812**	**003**	Jan 28, 1987

TABLET;ORAL

LITHIUM CARBONATE

AB		SUN PHARM INDS INC	**300MG**	**A091027**	**001**	Jun 24, 2010
AB	+!	WEST-WARD PHARMS INT	**300MG**	**N018558**	**001**	Jan 29, 1982

TABLET, EXTENDED RELEASE;ORAL

LITHIUM CARBONATE

AB		ALEMBIC PHARMS LTD	**300MG**	**A204445**	**001**	Jun 10, 2015
AB		GLENMARK GENERICS	**450MG**	**A091616**	**001**	Feb 14, 2011
AB		GLENMARK PHARMS INC	**300MG**	**A091544**	**001**	Dec 27, 2010
AB		HERITAGE PHARMA	**300MG**	**A205532**	**001**	Sep 29, 2016
AB		MYLAN PHARMS INC	**300MG**	**A202288**	**001**	Jun 29, 2012
AB			**450MG**	**A202219**	**001**	Aug 08, 2012
AB		UNIQUE PHARM LABS	**300MG**	**A204779**	**001**	Jul 27, 2015
AB			**450MG**	**A205663**	**001**	Jun 05, 2017
AB		WEST-WARD PHARMS INT	**300MG**	**A076832**	**001**	Oct 28, 2004
AB	!		**450MG**	**A076691**	**001**	Jan 05, 2004

LITHOBID

AB	+!	ANI PHARMS INC	**300MG**	**N018027**	**001**	

LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE

AA	+!	WEST-WARD PHARMS INT	**EQ 300MG CARBONATE/5ML**	**N018421**	**001**	
AA		WOCKHARDT BIO AG	**EQ 300MG CARBONATE/5ML**	**A070755**	**001**	May 21, 1986

LIXISENATIDE
SOLUTION;SUBCUTANEOUS
ADLYXIN

+!	SANOFI-AVENTIS US	0.15MG/3ML (0.05MG/ML)	N208471	001	Jul 27, 2016
+!		0.3MG/3ML (0.1MG/ML)	N208471	002	Jul 27, 2016

LODOXAMIDE TROMETHAMINE
SOLUTION/DROPS;OPHTHALMIC
ALOMIDE

+!	NOVARTIS PHARMS CORP	EQ 0.1% BASE	N020191	001	Sep 23, 1993

LOFEXIDINE HYDROCHLORIDE
TABLET;ORAL
LUCEMYRA

+!	US WORLDMEDS LLC	EQ 0.18MG BASE	N209229	001	May 16, 2018

LOMITAPIDE MESYLATE
CAPSULE;ORAL
JUXTAPID

+	AEGERION	EQ 5MG BASE	N203858	001	Dec 21, 2012
+		EQ 10MG BASE	N203858	002	Dec 21, 2012
+		EQ 20MG BASE	N203858	003	Dec 21, 2012
+		EQ 30MG BASE	N203858	004	Apr 23, 2015
+		EQ 40MG BASE	N203858	005	Apr 23, 2015
+!		EQ 60MG BASE	N203858	006	Apr 23, 2015

LOMUSTINE
CAPSULE;ORAL
GLEOSTINE

+	CORDEN PHARMA	10MG	N017588	001	
+		40MG	N017588	002	
+!		100MG	N017588	003	

LOPERAMIDE HYDROCHLORIDE
CAPSULE;ORAL
LOPERAMIDE HYDROCHLORIDE

AB	**!**	MYLAN	**2MG**	**A072741**	**001**	Sep 18, 1991
AB		TEVA	**2MG**	**A073192**	**001**	Apr 30, 1992

LOPINAVIR; RITONAVIR
SOLUTION;ORAL
KALETRA

AA	**+!**	ABBVIE	**80MG/ML;20MG/ML**	**N021251**	**001**	Sep 15, 2000

LOPINAVIR AND RITONAVIR

AA		LANNETT CO INC	**80MG/ML;20MG/ML**	**A207407**	**001**	Dec 27, 2016

TABLET;ORAL
KALETRA

+	ABBVIE	100MG;25MG	N021906	002	Nov 09, 2007
+!		200MG;50MG	N021906	001	Oct 28, 2005

LORAZEPAM
CONCENTRATE;ORAL
LORAZEPAM

AA		AMNEAL PHARMS	**2MG/ML**	**A091383**	**001**	Dec 23, 2009
AA		ANDA REPOSITORY	**2MG/ML**	**A079244**	**001**	Apr 28, 2009
AA		HI-TECH PHARMA CO	**2MG/ML**	**A200169**	**001**	Jan 30, 2012
AA		LUPIN LTD	**2MG/ML**	**A091407**	**001**	Feb 19, 2013
AA		PHARM ASSOC	**2MG/ML**	**A090260**	**001**	Jun 15, 2010

LORAZEPAM INTENSOL

AA	**!**	WEST-WARD PHARMS INT	**2MG/ML**	**A072755**	**001**	Jun 28, 1991

INJECTABLE;INJECTION
ATIVAN

AP	**+!**	WEST-WARD PHARMS INT	**2MG/ML**	**N018140**	**001**	
AP	**+!**		**4MG/ML**	**N018140**	**002**	

LORAZEPAM

AP		AKORN	**2MG/ML**	**A075025**	**001**	Jul 23, 1998
AP		HOSPIRA	**2MG/ML**	**A074243**	**001**	Apr 12, 1994
AP			**2MG/ML**	**A074282**	**001**	May 27, 1994
AP			**4MG/ML**	**A074243**	**002**	Apr 12, 1994
AP			**4MG/ML**	**A074282**	**002**	May 27, 1994
AP		INTL MEDICATION SYS	**2MG/ML**	**A076150**	**001**	Nov 15, 2004

LORAZEPAM							
TABLET;ORAL							
ATIVAN							
AB	**+**	VALEANT INTL	**0.5MG**	**N017794**	**001**		
AB	**+**		**1MG**	**N017794**	**002**		
AB	**+!**		**2MG**	**N017794**	**003**		
LORAZEPAM							
AB		AMNEAL PHARMS	**0.5MG**	**A078826**	**001**	Jun 23, 2010	
AB			**1MG**	**A078826**	**002**	Jun 23, 2010	
AB			**2MG**	**A078826**	**003**	Jun 23, 2010	
AB		ANI PHARMS INC	**0.5MG**	**A077396**	**001**	Dec 13, 2006	
AB			**1MG**	**A077396**	**002**	Dec 13, 2006	
AB			**2MG**	**A077396**	**003**	Dec 13, 2006	
AB		AUROLIFE PHARMA LLC	**0.5MG**	**A203572**	**001**	Dec 22, 2017	
AB			**1MG**	**A203572**	**002**	Dec 22, 2017	
AB			**2MG**	**A203572**	**003**	Dec 22, 2017	
AB		LEADING PHARMA LLC	**0.5MG**	**A078203**	**001**	Jul 30, 2007	
AB			**1MG**	**A078203**	**002**	Jul 30, 2007	
AB			**2MG**	**A078203**	**003**	Jul 30, 2007	
AB		MYLAN	**0.5MG**	**A077657**	**001**	Mar 16, 2006	
AB			**1MG**	**A077657**	**002**	Mar 16, 2006	
AB			**2MG**	**A077657**	**003**	Mar 16, 2006	
AB		OXFORD PHARMS	**0.5MG**	**A077754**	**001**	May 10, 2006	
AB			**1MG**	**A077754**	**002**	May 10, 2006	
AB			**2MG**	**A077754**	**003**	May 10, 2006	
AB		SANDOZ	**0.5MG**	**A071141**	**002**	Apr 21, 1987	
AB			**1MG**	**A071141**	**003**	Apr 21, 1987	
AB			**2MG**	**A071141**	**001**	Apr 21, 1987	
AB		WATSON LABS	**0.5MG**	**A072926**	**001**	Oct 31, 1991	
AB			**1MG**	**A072927**	**001**	Oct 31, 1991	
AB			**2MG**	**A072928**	**001**	Oct 31, 1991	
LORCASERIN HYDROCHLORIDE							
TABLET;ORAL							
BELVIQ							
	+!	EISAI INC	10MG	N022529	001	Jun 27, 2012	
TABLET, EXTENDED RELEASE;ORAL							
BELVIQ XR							
	+!	EISAI INC	20MG	N208524	001	Jul 15, 2016	
LORLATINIB							
TABLET;ORAL							
LORBRENA							
	+	PFIZER INC	25MG	N210868	001	Nov 02, 2018	
	+!		100MG	N210868	002	Nov 02, 2018	
LOSARTAN POTASSIUM							
TABLET;ORAL							
COZAAR							
AB	**+!**	MERCK SHARP DOHME	**100MG**	**N020386**	**003**	Oct 13, 1998	
LOSARTAN POTASSIUM							
AB		ALEMBIC PHARMS LTD	**25MG**	**A090428**	**001**	Oct 06, 2010	
AB			**50MG**	**A090428**	**002**	Oct 06, 2010	
AB			**100MG**	**A090428**	**003**	Oct 06, 2010	
AB		AUROBINDO PHARMA	**25MG**	**A090083**	**001**	Oct 06, 2010	
AB			**50MG**	**A090083**	**002**	Oct 06, 2010	
AB			**100MG**	**A090083**	**003**	Oct 06, 2010	
AB		CADISTA PHARMS	**25MG**	**A201170**	**001**	Sep 18, 2012	
AB			**50MG**	**A201170**	**002**	Sep 18, 2012	
AB			**100MG**	**A201170**	**003**	Sep 18, 2012	
AB		HETERO LABS LTD V	**25MG**	**A203835**	**001**	Aug 12, 2015	
AB			**50MG**	**A203835**	**002**	Aug 12, 2015	
AB			**100MG**	**A203835**	**003**	Aug 12, 2015	
AB		IPCA LABS LTD	**25MG**	**A200290**	**001**	Aug 30, 2013	
AB			**50MG**	**A200290**	**002**	Aug 30, 2013	
AB			**100MG**	**A200290**	**003**	Aug 30, 2013	
AB		LUPIN LTD	**25MG**	**A078232**	**001**	Oct 06, 2010	
AB			**50MG**	**A078232**	**002**	Oct 06, 2010	
AB			**100MG**	**A078232**	**003**	Oct 06, 2010	
AB		MACLEODS PHARMS LTD	**25MG**	**A202230**	**001**	May 30, 2012	
AB			**50MG**	**A202230**	**002**	May 30, 2012	
AB			**100MG**	**A202230**	**003**	May 30, 2012	
AB		MYLAN	**25MG**	**A091590**	**001**	Oct 06, 2010	
AB			**50MG**	**A091590**	**002**	Oct 06, 2010	

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

AB		**100MG**	**A091590**	**003**	Oct 06, 2010
AB	PRINSTON INC	**25MG**	**A091497**	**001**	Jun 06, 2011
AB		**50MG**	**A091497**	**002**	Jun 06, 2011
AB		**100MG**	**A091497**	**003**	Jun 06, 2011
AB	SANDOZ	**25MG**	**A077424**	**001**	Oct 06, 2010
AB		**50MG**	**A077424**	**002**	Oct 06, 2010
AB		**100MG**	**A077424**	**003**	Oct 06, 2010
AB	STRIDES VIVIMED	**25MG**	**A090382**	**001**	Oct 06, 2010
AB		**50MG**	**A090382**	**002**	Oct 06, 2010
AB		**100MG**	**A090382**	**003**	Oct 06, 2010
AB	TEVA	**25MG**	**A076958**	**001**	Apr 06, 2010
AB		**50MG**	**A076958**	**002**	Apr 06, 2010
AB		**100MG**	**A076958**	**003**	Apr 06, 2010
AB	TORRENT PHARMS	**25MG**	**A090467**	**001**	Oct 06, 2010
AB		**50MG**	**A090467**	**002**	Oct 06, 2010
AB		**100MG**	**A090467**	**003**	Oct 06, 2010
AB	UNICHEM LABS LTD	**25MG**	**A203030**	**001**	Oct 14, 2015
AB		**50MG**	**A203030**	**002**	Oct 14, 2015
AB		**100MG**	**A203030**	**003**	Oct 14, 2015
AB	UPSHER SMITH LABS	**25MG**	**A090544**	**001**	Oct 06, 2010
AB		**50MG**	**A090544**	**002**	Oct 06, 2010
AB		**100MG**	**A090544**	**003**	Oct 06, 2010
AB	VIVA HLTHCARE	**25MG**	**A091541**	**001**	Sep 24, 2012
AB		**50MG**	**A091541**	**002**	Sep 24, 2012
AB		**100MG**	**A091541**	**003**	Sep 24, 2012
AB	WATSON LABS	**25MG**	**A091129**	**001**	Oct 06, 2010
AB		**50MG**	**A091129**	**002**	Oct 06, 2010
AB		**100MG**	**A091129**	**003**	Oct 06, 2010
AB	WEST-WARD PHARMS INT	**25MG**	**A077459**	**001**	Oct 06, 2010
AB		**50MG**	**A077459**	**002**	Oct 06, 2010
AB		**100MG**	**A077459**	**003**	Oct 06, 2010
AB	ZYDUS PHARMS USA INC	**25MG**	**A078243**	**001**	Oct 06, 2010
AB		**50MG**	**A078243**	**002**	Oct 06, 2010
AB		**100MG**	**A078243**	**003**	Oct 06, 2010

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC

LOTEMAX

+!	BAUSCH AND LOMB INC	0.5%	N202872	001	Sep 28, 2012

OINTMENT;OPHTHALMIC

LOTEMAX

+!	BAUSCH AND LOMB	0.5%	N200738	001	Apr 15, 2011

SUSPENSION/DROPS;OPHTHALMIC

ALREX

+!	BAUSCH AND LOMB	0.2%	N020803	001	Mar 09, 1998

INVELTYS

+!	KALA PHARMS INC	1%	N210565	001	Aug 22, 2018

LOTEMAX

+!	BAUSCH AND LOMB	0.5%	N020583	001	Mar 09, 1998

LOTEPREDNOL ETABONATE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC

ZYLET

+!	BAUSCH AND LOMB	0.5%;0.3%	N050804	001	Dec 14, 2004

LOVASTATIN

TABLET;ORAL

LOVASTATIN

AB	ACTAVIS ELIZABETH	**10MG**	**A075828**	**001**	Dec 17, 2001
AB		**20MG**	**A075828**	**002**	Dec 17, 2001
AB		**40MG**	**A075828**	**003**	Dec 17, 2001
AB	APOTEX INC	**10MG**	**A077748**	**001**	Feb 28, 2007
AB		**20MG**	**A077748**	**002**	Feb 28, 2007
AB		**40MG**	**A077748**	**003**	Feb 28, 2007
AB	CARLSBAD	**10MG**	**A075991**	**001**	Jun 05, 2002
AB		**20MG**	**A075991**	**002**	Jun 05, 2002
AB !		**40MG**	**A075991**	**003**	Jun 05, 2002
AB	LUPIN	**10MG**	**A078296**	**001**	Mar 14, 2008
AB		**20MG**	**A078296**	**002**	Nov 01, 2007

LOVASTATIN

TABLET;ORAL

LOVASTATIN

AB			**40MG**	**A078296**	**003**	Nov 01, 2007
AB		MYLAN	**10MG**	**A075451**	**001**	Dec 17, 2001
AB			**20MG**	**A075451**	**002**	Dec 17, 2001
AB			**40MG**	**A075451**	**003**	Dec 17, 2001
AB		SANDOZ	**10MG**	**A075300**	**001**	Dec 17, 2001
AB			**10MG**	**A075636**	**001**	Dec 17, 2001
AB			**20MG**	**A075300**	**002**	Dec 17, 2001
AB			**20MG**	**A075636**	**002**	Dec 17, 2001
AB			**40MG**	**A075300**	**003**	Dec 17, 2001
AB			**40MG**	**A075636**	**003**	Dec 17, 2001
AB		SUN PHARM INDUSTRIES	**10MG**	**A077520**	**001**	Apr 14, 2006
AB			**20MG**	**A077520**	**002**	Apr 14, 2006
AB			**40MG**	**A077520**	**003**	Apr 14, 2006
AB		TEVA	**10MG**	**A075551**	**003**	Dec 17, 2001
AB			**20MG**	**A075551**	**002**	Dec 17, 2001
AB			**40MG**	**A075551**	**001**	Dec 17, 2001

TABLET, EXTENDED RELEASE;ORAL

ALTOPREV

+		COVIS PHARMA BV	20MG	N021316	002 Jun 26, 2002
+			40MG	N021316	003 Jun 26, 2002
+!			60MG	N021316	004 Jun 26, 2002

LOXAPINE

POWDER;INHALATION

ADASUVE

+!		GALEN UK	10MG	N022549	001 Dec 21, 2012

LOXAPINE SUCCINATE

CAPSULE;ORAL

LOXAPINE SUCCINATE

AB		ELITE LABS INC	**EQ 5MG BASE**	**A076868**	**001**	Aug 04, 2005
AB			**EQ 10MG BASE**	**A076868**	**002**	Aug 04, 2005
AB			**EQ 25MG BASE**	**A076868**	**003**	Aug 04, 2005
AB			**EQ 50MG BASE**	**A076868**	**004**	Aug 04, 2005
AB		LANNETT CO INC	**EQ 5MG BASE**	**A090695**	**001**	Sep 26, 2011
AB			**EQ 10MG BASE**	**A090695**	**002**	Sep 26, 2011
AB			**EQ 25MG BASE**	**A090695**	**003**	Sep 26, 2011
AB			**EQ 50MG BASE**	**A090695**	**004**	Sep 26, 2011
AB		MYLAN	**EQ 5MG BASE**	**A076762**	**001**	Nov 01, 2004
AB			**EQ 10MG BASE**	**A076762**	**002**	Nov 01, 2004
AB			**EQ 25MG BASE**	**A076762**	**003**	Nov 01, 2004
AB			**EQ 50MG BASE**	**A076762**	**004**	Nov 01, 2004
AB		WATSON LABS	**EQ 5MG BASE**	**A072204**	**001**	Jun 15, 1988
AB			**EQ 10MG BASE**	**A072205**	**001**	Jun 15, 1988
AB	**!**		**EQ 25MG BASE**	**A072206**	**001**	Jun 15, 1988
AB			**EQ 50MG BASE**	**A072062**	**001**	Jun 15, 1988

LUBIPROSTONE

CAPSULE;ORAL

AMITIZA

+		SUCAMPO PHARMA LLC	8MCG	N021908	002 Apr 29, 2008
+!			24MCG	N021908	001 Jan 31, 2006

LULICONAZOLE

CREAM;TOPICAL

LUZU

+!		MEDICIS	1%	N204153	001 Nov 14, 2013

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LATUDA

AB	**+**	SUNOVION PHARMS INC	**20MG**	**N200603**	**003**	Dec 07, 2011
AB	**+!**		**40MG**	**N200603**	**001**	Oct 28, 2010
AB	**+**		**60MG**	**N200603**	**005**	Jul 12, 2013
AB	**+**		**80MG**	**N200603**	**002**	Oct 28, 2010
AB	**+**		**120MG**	**N200603**	**004**	Apr 26, 2012

LURASIDONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**20MG**	**A208049**	**001**	Jan 03, 2019
AB			**40MG**	**A208049**	**002**	Jan 03, 2019
AB			**60MG**	**A208049**	**003**	Jan 03, 2019
AB			**80MG**	**A208049**	**004**	Jan 03, 2019

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

AB		**120MG**	**A208049**	**005**	Jan 03, 2019
AB	AMNEAL PHARMS CO	**20MG**	**A208002**	**001**	Jan 03, 2019
AB		**40MG**	**A208002**	**002**	Jan 03, 2019
AB		**60MG**	**A208002**	**003**	Jan 03, 2019
AB		**80MG**	**A208002**	**004**	Jan 03, 2019
AB		**120MG**	**A208002**	**005**	Jan 03, 2019
AB	INVAGEN PHARMS	**20MG**	**A208028**	**001**	Jan 03, 2019
AB		**40MG**	**A208028**	**002**	Jan 03, 2019
AB		**60MG**	**A208028**	**003**	Jan 03, 2019
AB		**80MG**	**A208028**	**004**	Jan 03, 2019
AB		**120MG**	**A208028**	**005**	Jan 03, 2019
AB	LUPIN LTD	**20MG**	**A208031**	**001**	Jan 03, 2019
AB		**40MG**	**A208031**	**002**	Jan 03, 2019
AB		**60MG**	**A208031**	**003**	Jan 03, 2019
AB		**80MG**	**A208031**	**004**	Jan 03, 2019
AB		**120MG**	**A208031**	**005**	Jan 03, 2019
AB	SUN PHARMA GLOBAL	**20MG**	**A208066**	**001**	Jan 04, 2019
AB		**40MG**	**A208066**	**002**	Jan 04, 2019
AB		**60MG**	**A208066**	**003**	Jan 04, 2019
AB		**80MG**	**A208066**	**004**	Jan 04, 2019
AB		**120MG**	**A208066**	**005**	Jan 04, 2019
AB	TORRENT PHARMS LTD	**20MG**	**A208055**	**001**	Jan 03, 2019
AB		**40MG**	**A208055**	**002**	Jan 03, 2019
AB		**80MG**	**A208055**	**003**	Jan 03, 2019
AB		**120MG**	**A208055**	**004**	Jan 03, 2019

LUSUTROMBOPAG

TABLET;ORAL

MULPLETA

+!	SHIONOGI INC	3MG	N210923	001	Jul 31, 2018

LUTETIUM DOTATATE LU-177

SOLUTION;INTRAVENOUS

LUTATHERA

+!	AAA USA INC	10mCi/ML	N208700	001	Jan 26, 2018

MACIMORELIN ACETATE

FOR SOLUTION;ORAL

MACRILEN

+!	NOVO	EQ 60MG BASE/POUCH	N205598	001	Dec 20, 2017

MACITENTAN

TABLET;ORAL

OPSUMIT

+!	ACTELION PHARMS LTD	10MG	N204410	001	Oct 18, 2013

MAFENIDE ACETATE

CREAM;TOPICAL

SULFAMYLON

+!	MYLAN INSTITUTIONAL	EQ 85MG BASE/GM	N016763	001	

FOR SOLUTION;TOPICAL

MAFENIDE ACETATE

AT	NOVAST LABS	**5%**	**A206716**	**001**	Jul 31, 2017
AT	PAR FORM	**5%**	**A201511**	**001**	Feb 12, 2013

SULFAMYLON

AT	**+!** MYLAN INSTITUTIONAL	**5%**	**N019832**	**003**	Jun 05, 1998

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

+!	B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML	N019696	001	Sep 29, 1989

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

ISOLYTE S IN PLASTIC CONTAINER

	B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N019711	001	Sep 29, 1989

NORMOSOL-R IN PLASTIC CONTAINER

	ICU MEDICAL INC	30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N017586	001	

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML;526MG /100ML;502MG/100ML	N017378	001	

PLASMA-LYTE A IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML;526MG /100ML;502MG/100ML	N017378	002	Nov 22, 1982

SOLUTION;IRRIGATION

PHYSIOLYTE IN PLASTIC CONTAINER

	B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML;530MG /100ML;500MG/100ML	N019024	001	Jun 08, 1984

PHYSIOSOL IN PLASTIC CONTAINER

	ICU MEDICAL INC	30MG/100ML;37MG/100ML;222MG/100ML;526MG /100ML;502MG/100ML	N017637	002	Jul 08, 1982

MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

SOLUTION;INJECTION

NORMOCARB HF 25

+!	DIALYSIS SUPS	0.21GM/100ML;2.8GM/100ML;9.07GM/100ML	N021910	001	Jul 26, 2006

NORMOCARB HF 35

+!	DIALYSIS SUPS	0.21GM/100ML;3.97GM/100ML;8.3GM/100ML	N021910	002	Jul 26, 2006

MAGNESIUM SULFATE

INJECTABLE;INJECTION

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	**1GM/100ML**	**A206486**	**001**	Mar 07, 2016
AP	**+!**	HOSPIRA	**1GM/100ML**	**N020488**	**001**	Jul 11, 1995
AP		HQ SPCLT PHARMA	**1GM/100ML**	**A207349**	**001**	Mar 02, 2016
AP		MYLAN LABS LTD	**1GM/100ML**	**A209932**	**001**	Sep 10, 2018

MAGNESIUM SULFATE IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	**4GM/100ML (40MG/ML)**	**A206485**	**001**	Mar 15, 2016
AP			**4GM/50ML (80MG/ML)**	**A206485**	**002**	Mar 15, 2016
AP			**2GM/50ML (40MG/ML)**	**A206485**	**003**	Mar 15, 2016
AP			**20GM/500ML (40MG/ML)**	**A206485**	**004**	Mar 15, 2016
AP			**40GM/1000ML (40MG/ML)**	**A206485**	**005**	Mar 15, 2016
AP	**+**	HOSPIRA	**2GM/50ML (40MG/ML)**	**N020309**	**003**	Jan 26, 2007
AP	**+!**		**4GM/100ML (40MG/ML)**	**N020309**	**001**	Jun 24, 1994
AP	**+!**		**4GM/50ML (80MG/ML)**	**N020309**	**002**	Jun 24, 1994
AP	**+**		**20GM/500ML (40MG/ML)**	**N020309**	**004**	Jan 18, 1995
AP	**+**		**40GM/1000ML (40MG/ML)**	**N020309**	**005**	Jan 18, 1995
AP		HQ SPCLT PHARMA	**2GM/50ML (40MG/ML)**	**A207350**	**001**	Dec 06, 2017
AP			**4GM/100ML (40MG/ML)**	**A207350**	**002**	Dec 06, 2017
AP			**4GM/50ML (80MG/ML)**	**A207350**	**003**	Dec 06, 2017
AP			**20GM/500ML (40MG/ML)**	**A207350**	**004**	Dec 06, 2017
AP			**40GM/1000ML (40MG/ML)**	**A207350**	**005**	Dec 06, 2017
AP		MYLAN LABS LTD	**2GM/50ML (40MG/ML)**	**A209911**	**001**	Sep 14, 2018
AP			**4GM/100ML (40MG/ML)**	**A209911**	**002**	Sep 14, 2018

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+!	HOSPIRA	2GM/100ML	N020488	002	Jul 11, 1995

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

AP		EXELA PHARMA SCS LLC	**5GM/10ML (500MG/ML)**	**A206039**	**001**	Dec 18, 2014
AP	**+!**	FRESENIUS KABI USA	**5GM/10ML (500MG/ML)**	**N019316**	**001**	Sep 08, 1986
AP	**!**	HOSPIRA	**5GM/10ML (500MG/ML)**	**A075151**	**001**	Apr 25, 2000
	+!	FRESENIUS KABI USA	10GM/20ML (500MG/ML)	N019316	003	Jan 29, 2016
	+!		25GM/50ML (500MG/ML)	N019316	004	Jan 29, 2016
		HOSPIRA INC	10GM/20ML (500MG/ML)	A202411	001	May 14, 2015

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

+!	FRESENIUS KABI USA	1GM/2ML (500MG/ML)	N019316	002	Sep 08, 1986

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

TIS-U-SOL

AT		BAXTER HLTHCARE	**20MG/100ML;40MG/100ML;6.25MG/100ML;800MG/100ML;8.75MG/100ML**	**N018508**	**001**	Feb 19, 1982

TIS-U-SOL IN PLASTIC CONTAINER

AT		BAXTER HLTHCARE	**20MG/100ML;40MG/100ML;6.25MG/100ML;800MG/100ML;8.75MG/100ML**	**N018336**	**001**	

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

POWDER;ORAL

COLPREP KIT

+!	GATOR PHARMS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N204553	001	Dec 27, 2016

SOLUTION;ORAL

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

AA		NOVEL LABS INC	**1.6GM/BOT;3.13GM/BOT;17.5GM/BOT**	**A202511**	**001**	Feb 23, 2017

SUPREP BOWEL PREP KIT

AA	**+!**	BRAINTREE LABS	**1.6GM/BOT;3.13GM/BOT;17.5GM/BOT**	**N022372**	**001**	Aug 05, 2010

MALATHION

LOTION;TOPICAL

MALATHION

AT		SUVEN LIFE	**0.5%**	**A091559**	**001**	May 23, 2012

OVIDE

AT	**+!**	TARO PHARM INDS LTD	**0.5%**	**N018613**	**001**	Aug 02, 1982

MANGANESE CHLORIDE

INJECTABLE;INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

+!	HOSPIRA	EQ 0.1MG MANGANESE/ML	N018962	001	Jun 26, 1986

MANNITOL

INJECTABLE;INJECTION

MANNITOL 10% IN PLASTIC CONTAINER

AP		B BRAUN	**10GM/100ML**	**N020006**	**002**	Jul 26, 1993

MANNITOL 15% IN PLASTIC CONTAINER

AP		B BRAUN	**15GM/100ML**	**N020006**	**003**	Jul 26, 1993

MANNITOL 20% IN PLASTIC CONTAINER

AP		B BRAUN	**20GM/100ML**	**N020006**	**004**	Jul 26, 1993
AP		ICU MEDICAL INC	**20GM/100ML**	**N019603**	**004**	Jan 08, 1990

MANNITOL 25%

AP		FRESENIUS KABI USA	**12.5GM/50ML**	**A080677**	**001**	
AP		HOSPIRA	**12.5GM/50ML**	**N016269**	**006**	Aug 25, 1994
AP		INTL MEDICATION	**12.5GM/50ML**	**A083051**	**001**	
AP		LUITPOLD	**12.5GM/50ML**	**A087409**	**001**	Jan 21, 1982

MANNITOL 5% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML**	**N020006**	**001**	Jul 26, 1993

OSMITROL 10% IN WATER

AP		BAXTER HLTHCARE	**10GM/100ML**	**N013684**	**002**	

OSMITROL 10% IN WATER IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**10GM/100ML**	**N013684**	**006**	

OSMITROL 15% IN WATER

AP		BAXTER HLTHCARE	**15GM/100ML**	**N013684**	**004**	

OSMITROL 15% IN WATER IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**15GM/100ML**	**N013684**	**008**	

OSMITROL 20% IN WATER

AP		BAXTER HLTHCARE	**20GM/100ML**	**N013684**	**003**	

OSMITROL 20% IN WATER IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20GM/100ML**	**N013684**	**007**	

OSMITROL 5% IN WATER

AP		BAXTER HLTHCARE	**5GM/100ML**	**N013684**	**001**	

OSMITROL 5% IN WATER IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML**	**N013684**	**005**	

POWDER;INHALATION

ARIDOL KIT

+!	PHARMAXIS LTD	N/A,5MG,10MG,20MG,40MG	N022368	001	Oct 05, 2010

SOLUTION;IRRIGATION

RESECTISOL IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML	N016772	002	

MANNITOL; SORBITOL

SOLUTION;IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

+!	ICU MEDICAL INC	540MG/100ML;2.7GM/100ML	N018316	001	

MAPROTILINE HYDROCHLORIDE

TABLET;ORAL

MAPROTILINE HYDROCHLORIDE

	MYLAN	25MG	A072285	002	Oct 03, 1988
!		50MG	A072285	001	Oct 03, 1988
		75MG	A072285	003	Oct 03, 1988

MARAVIROC						
SOLUTION;ORAL						
SELZENTRY						
+!	VIIV HLTHCARE	20MG/ML	N208984	001	Nov 04, 2016
TABLET;ORAL						
SELZENTRY						
+	VIIV HLTHCARE	25MG	N022128	003	Nov 04, 2016
+		75MG	N022128	004	Nov 04, 2016
+		150MG	N022128	001	Aug 06, 2007
+!		300MG	N022128	002	Aug 06, 2007
MEBENDAZOLE						
TABLET, CHEWABLE;ORAL						
EMVERM						
!	IMPAX LABS INC	100MG	A073580	001	Jan 04, 1995
MECAMYLAMINE HYDROCHLORIDE						
TABLET;ORAL						
MECAMYLAMINE HYDROCHLORIDE						
!	NEXGEN PHARMA	2.5MG	A204054	001	Mar 19, 2013
MECASERMIN RECOMBINANT						
INJECTABLE;SUBCUTANEOUS						
INCRELEX						
+!	IPSEN INC	40MG/4ML (10MG/ML)	N021839	001	Aug 30, 2005
MECHLORETHAMINE HYDROCHLORIDE						
GEL;TOPICAL						
VALCHLOR						
+!	HELSINN	EQ 0.016% BASE	N202317	001	Aug 23, 2013
MECLIZINE HYDROCHLORIDE						
TABLET;ORAL						
MECLIZINE HYDROCHLORIDE						
AA	AMNEAL PHARMS	**12.5MG**	**A201451**	**001**	Feb 23, 2011
AA		**25MG**	**A201451**	**002**	Feb 23, 2011
AA	EPIC PHARMA LLC	**12.5MG**	**A200294**	**001**	Apr 13, 2012
AA		**25MG**	**A200294**	**002**	Apr 13, 2012
AA	JUBILANT CADISTA	**12.5MG**	**A040659**	**001**	Jun 04, 2010
AA		**25MG**	**A040659**	**002**	Jun 04, 2010
AA	MYLAN PHARMS INC	**12.5MG**	**A202640**	**001**	Sep 17, 2012
AA		**25MG**	**A202640**	**002**	Sep 17, 2012
AA	PAR PHARM	**12.5MG**	**A087127**	**001**	
AA		**25MG**	**A087128**	**001**	
AA	SANDOZ	**12.5MG**	**A084843**	**002**	May 22, 1989
AA		**25MG**	**A084092**	**003**	May 22, 1989
MECLOFENAMATE SODIUM						
CAPSULE;ORAL						
MECLOFENAMATE SODIUM						
	MYLAN	EQ 50MG BASE	A071081	002	Sep 03, 1986
!		EQ 100MG BASE	A071081	001	Sep 03, 1986
MEDROXYPROGESTERONE ACETATE						
INJECTABLE;INJECTION						
DEPO-PROVERA						
AB **+!**	PHARMACIA AND UPJOHN	**150MG/ML**	**N020246**	**001**	Oct 29, 1992
MEDROXYPROGESTERONE ACETATE						
AB	AMPHASTAR PHARMS INC	**150MG/ML**	**A077235**	**001**	Nov 28, 2017
AB		**150MG/ML**	**A077334**	**001**	Nov 28, 2017
AB	MYLAN LABS LTD	**150MG/ML**	**A210227**	**001**	Oct 12, 2018
AB	TEVA PHARMS USA	**150MG/ML**	**A076553**	**001**	Jul 28, 2004
DEPO-PROVERA						
+!	PHARMACIA AND UPJOHN	400MG/ML	N012541	003	
INJECTABLE;SUBCUTANEOUS						
DEPO-SUBQ PROVERA 104						
+!	PHARMACIA AND UPJOHN	104MG/0.65ML	N021583	001	Dec 17, 2004
TABLET;ORAL						
MEDROXYPROGESTERONE ACETATE						
AB	BARR	**2.5MG**	**A040159**	**001**	Aug 09, 1996
AB		**5MG**	**A040159**	**002**	Aug 09, 1996
AB		**10MG**	**A040159**	**003**	Aug 09, 1996

MEDROXYPROGESTERONE ACETATE

TABLET;ORAL

PROVERA

AB	+	PHARMACIA AND UPJOHN	**2.5MG**	**N011839**	**001**	
AB	+		**5MG**	**N011839**	**003**	
AB	+!		**10MG**	**N011839**	**004**	

MEFENAMIC ACID

CAPSULE;ORAL

MEFENAMIC ACID

AB		BELCHER PHARMS LLC	**250MG**	**A091608**	**001**	Jun 02, 2014
AB		BRECKENRIDGE PHARM	**250MG**	**A090359**	**001**	Feb 05, 2013
AB		LUPIN LTD	**250MG**	**A091322**	**001**	Jul 22, 2011
AB		MICRO LABS	**250MG**	**A090562**	**001**	Nov 19, 2010

PONSTEL

AB	+!	SHIONOGI INC	**250MG**	**N015034**	**003**	

MEFLOQUINE HYDROCHLORIDE

TABLET;ORAL

MEFLOQUINE HYDROCHLORIDE

AB	!	BARR	**250MG**	**A076392**	**001**	Dec 29, 2003
AB		WEST-WARD PHARMS INT	**250MG**	**A076523**	**001**	Oct 01, 2004

MEGESTROL ACETATE

SUSPENSION;ORAL

MEGACE ES

AB	+!	ENDO PHARMS INC	**125MG/ML**	**N021778**	**001**	Jul 05, 2005

MEGESTROL ACETATE

AB		BRECKENRIDGE PHARM	**125MG/ML**	**A204688**	**001**	Dec 01, 2017
AB		HI-TECH PHARMACAL	**40MG/ML**	**A203960**	**001**	Jun 09, 2017
AB		PAR PHARM	**40MG/ML**	**A075671**	**001**	Jul 25, 2001
AB		TEVA PHARMS	**40MG/ML**	**A075681**	**001**	May 05, 2003
AB		TWI PHARMS	**125MG/ML**	**A203139**	**001**	Aug 27, 2014
AB	!	WEST-WARD PHARMS INT	**40MG/ML**	**A075997**	**001**	Feb 15, 2002
AB		WOCKHARDT BIO AG	**40MG/ML**	**A076721**	**001**	Nov 01, 2004

TABLET;ORAL

MEGESTROL ACETATE

AB		BARR	**20MG**	**A074621**	**002**	Aug 16, 1996
AB			**40MG**	**A074621**	**001**	Nov 30, 1995
AB		PAR PHARM	**20MG**	**A072422**	**001**	Aug 08, 1988
AB	!		**40MG**	**A072423**	**001**	Aug 08, 1988
AB		WEST-WARD PHARMS INT	**20MG**	**A074458**	**001**	Sep 29, 1995
AB			**40MG**	**A074458**	**002**	Sep 29, 1995

MELOXICAM

CAPSULE;ORAL

VIVLODEX

	+	IROKO PHARMS LLC	5MG	N207233	001	Oct 22, 2015
	+!		10MG	N207233	002	Oct 22, 2015

TABLET;ORAL

MELOXICAM

AB		APOTEX INC	**7.5MG**	**A077882**	**001**	Jul 20, 2006
AB			**15MG**	**A077882**	**002**	Jul 20, 2006
AB		AUROBINDO PHARMA	**7.5MG**	**A078008**	**001**	Oct 02, 2006
AB			**15MG**	**A078008**	**002**	Oct 02, 2006
AB		BRECKENRIDGE PHARM	**7.5MG**	**A077920**	**001**	Jul 19, 2006
AB			**15MG**	**A077920**	**002**	Jul 19, 2006
AB		CIPLA	**7.5MG**	**A077929**	**001**	Jul 19, 2006
AB			**15MG**	**A077929**	**002**	Jul 19, 2006
AB		DR REDDYS LABS INC	**7.5MG**	**A077931**	**001**	Jul 25, 2006
AB			**15MG**	**A077931**	**002**	Jul 25, 2006
AB		GLENMARK GENERICS	**7.5MG**	**A077932**	**001**	Jul 19, 2006
AB			**15MG**	**A077932**	**002**	Jul 19, 2006
AB		LUPIN PHARMS	**7.5MG**	**A077944**	**001**	Jul 19, 2006
AB			**15MG**	**A077944**	**002**	Jul 19, 2006
AB		PURACAP PHARM	**7.5MG**	**A077938**	**001**	Jul 19, 2006
AB			**15MG**	**A077938**	**002**	Jul 19, 2006
AB		STRIDES PHARMA	**7.5MG**	**A077928**	**001**	May 13, 2009
AB			**15MG**	**A077928**	**002**	May 13, 2009
AB		TARO	**7.5MG**	**A078102**	**001**	Nov 07, 2006
AB			**15MG**	**A078102**	**002**	Nov 07, 2006

MELOXICAM

TABLET;ORAL

MELOXICAM

AB		TEVA PHARMS	**7.5MG**	**A077936**	**001**	Jul 19, 2006
AB			**15MG**	**A077936**	**002**	Jul 19, 2006
AB		UNICHEM	**7.5MG**	**A077927**	**001**	Dec 20, 2006
AB			**15MG**	**A077927**	**002**	Dec 20, 2006
AB		YUNG SHIN PHARM	**7.5MG**	**A077918**	**001**	Dec 07, 2006
AB			**15MG**	**A077918**	**002**	Dec 07, 2006
AB		ZYDUS PHARMS USA	**7.5MG**	**A077921**	**001**	Jul 19, 2006
AB			**15MG**	**A077921**	**002**	Jul 19, 2006

MOBIC

AB	**+**	BOEHRINGER INGELHEIM	**7.5MG**	**N020938**	**001**	Apr 13, 2000
AB	**+!**		**15MG**	**N020938**	**002**	Aug 23, 2000

TABLET, ORALLY DISINTEGRATING;ORAL

QMIIZ ODT

	+	TERSERA THERAPS LLC	7.5MG	N211210	001	Oct 19, 2018
	+!		15MG	N211210	002	Oct 19, 2018

MELPHALAN

TABLET;ORAL

ALKERAN

AB	**+!**	APOTEX INC	**2MG**	**N014691**	**002**	

MELPHALAN

AB		ALVOGEN MALTA	**2MG**	**A207809**	**001**	Mar 22, 2017

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

MELPHALAN HYDROCHLORIDE

AP		ACTAVIS LLC	**EQ 50MG BASE/VIAL**	**A206018**	**001**	Dec 19, 2016
AP		DR REDDYS LABS LTD	**EQ 50MG BASE/VIAL**	**A203655**	**001**	Dec 08, 2017
AP		FRESENIUS KABI USA	**EQ 50MG BASE/VIAL**	**A203393**	**001**	Dec 22, 2017
AP	**!**	MYLAN INSTITUTIONAL	**EQ 50MG BASE/VIAL**	**A090270**	**001**	Jun 09, 2009
AP		PAR STERILE PRODUCTS	**EQ 50MG BASE/VIAL**	**A204773**	**001**	Aug 22, 2016
AP		SAGENT PHARMS	**EQ 50MG BASE/VIAL**	**A201379**	**001**	Feb 28, 2017
AP		WEST-WARD PHARMS INT	**EQ 50MG BASE/VIAL**	**A090303**	**001**	Oct 28, 2010

POWDER;INTRAVENOUS

EVOMELA

	+!	SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

AB		AMNEAL PHARMS	**7MG**	**A205825**	**001**	Oct 12, 2016
AB			**14MG**	**A205825**	**002**	Oct 12, 2016
AB			**21MG**	**A205825**	**003**	Oct 12, 2016
AB			**28MG**	**A205825**	**004**	Oct 12, 2016
AB		ANCHEN PHARMS	**7MG**	**A205784**	**001**	Jun 09, 2017
AB			**14MG**	**A205784**	**002**	Jun 09, 2017
AB			**21MG**	**A205784**	**003**	Jun 09, 2017
AB			**28MG**	**A205784**	**004**	Jun 09, 2017
AB		APOTEX INC	**7MG**	**A206135**	**001**	Nov 22, 2016
AB			**14MG**	**A206135**	**002**	Nov 22, 2016
AB			**21MG**	**A206135**	**003**	Nov 22, 2016
AB			**28MG**	**A206135**	**004**	Nov 22, 2016
AB		LUPIN LTD	**7MG**	**A206028**	**001**	Sep 28, 2016
AB			**14MG**	**A206028**	**002**	Sep 28, 2016
AB			**21MG**	**A206028**	**003**	Sep 28, 2016
AB			**28MG**	**A206028**	**004**	Sep 28, 2016
AB		MYLAN PHARMS INC	**7MG**	**A206032**	**001**	Sep 28, 2016
AB			**14MG**	**A206032**	**002**	Sep 28, 2016
AB			**21MG**	**A206032**	**003**	Sep 28, 2016
AB			**28MG**	**A206032**	**004**	Sep 28, 2016
AB		SUN PHARMA GLOBAL	**7MG**	**A205905**	**001**	Sep 28, 2016
AB			**14MG**	**A205905**	**002**	Sep 28, 2016
AB			**21MG**	**A205905**	**003**	Sep 28, 2016
AB			**28MG**	**A205905**	**004**	Sep 28, 2016
AB		ZYDUS PHARMS USA INC	**7MG**	**A203293**	**001**	Aug 03, 2017
AB			**14MG**	**A203293**	**002**	Aug 03, 2017
AB			**21MG**	**A203293**	**003**	Aug 03, 2017
AB			**28MG**	**A203293**	**004**	Aug 03, 2017

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

NAMENDA XR

AB	+	FOREST LABS LLC	**7MG**	**N022525**	**001**	Jun 21, 2010
AB	+		**14MG**	**N022525**	**002**	Jun 21, 2010
AB	+		**21MG**	**N022525**	**003**	Jun 21, 2010
AB	+!		**28MG**	**N022525**	**004**	Jun 21, 2010

SOLUTION;ORAL

MEMANTINE HYDROCHLORIDE

AA		APOTEX INC	**2MG/ML**	**A209955**	**001**	Feb 09, 2018
AA	!	BIO-PHARM INC	**2MG/ML**	**A205446**	**001**	Dec 07, 2015
AA		LANNETT CO INC	**2MG/ML**	**A204033**	**001**	Oct 13, 2015
AA		MACLEODS PHARMS LTD	**2MG/ML**	**A202790**	**001**	Oct 13, 2015

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

AB		AJANTA PHARMA LTD	**5MG**	**A206528**	**001**	Nov 30, 2015
AB			**10MG**	**A206528**	**002**	Nov 30, 2015
AB		ALEMBIC PHARMS LTD	**5MG**	**A200891**	**001**	Oct 13, 2015
AB			**10MG**	**A200891**	**002**	Oct 13, 2015
AB		AMNEAL PHARMS	**5MG**	**A090041**	**001**	Apr 10, 2015
AB			**10MG**	**A090041**	**002**	Apr 10, 2015
AB		APOTEX INC	**5MG**	**A090244**	**001**	Jul 11, 2018
AB			**10MG**	**A090244**	**002**	Jul 11, 2018
AB		AUROBINDO PHARMA LTD	**5MG**	**A203175**	**001**	Oct 13, 2015
AB			**10MG**	**A203175**	**002**	Oct 13, 2015
AB		CSPC OUYI PHARM CO	**5MG**	**A209527**	**001**	May 07, 2018
AB			**10MG**	**A209527**	**002**	May 07, 2018
AB		DR REDDYS LABS LTD	**5MG**	**A090048**	**001**	Apr 14, 2010
AB			**10MG**	**A090048**	**002**	Apr 14, 2010
AB		JUBILANT GENERICS	**5MG**	**A091585**	**001**	Oct 13, 2015
AB			**10MG**	**A091585**	**002**	Oct 13, 2015
AB		LANNETT CO INC	**5MG**	**A207236**	**001**	Nov 10, 2016
AB			**10MG**	**A207236**	**002**	Nov 10, 2016
AB		LUPIN LTD	**5MG**	**A090051**	**001**	Apr 10, 2015
AB			**10MG**	**A090051**	**002**	Apr 10, 2015
AB		MACLEODS PHARMS LTD	**5MG**	**A202840**	**001**	Oct 13, 2015
AB			**10MG**	**A202840**	**002**	Oct 13, 2015
AB		MYLAN PHARMS INC	**5MG**	**A079225**	**001**	Jan 30, 2015
AB			**10MG**	**A079225**	**002**	Jan 30, 2015
AB		PURACAP PHARM LLC	**5MG**	**A206855**	**001**	Nov 17, 2015
AB			**10MG**	**A206855**	**002**	Nov 17, 2015
AB		STRIDES PHARMA	**5MG**	**A202350**	**001**	May 23, 2017
AB			**10MG**	**A202350**	**002**	May 23, 2017
AB		SUN PHARMA GLOBAL	**5MG**	**A090058**	**001**	May 05, 2010
AB			**10MG**	**A090058**	**002**	May 05, 2010
AB		TEVA PHARMS	**5MG**	**A090052**	**001**	Oct 25, 2011
AB			**10MG**	**A090052**	**002**	Oct 25, 2011
AB		TORRENT PHARMS LTD	**5MG**	**A200155**	**001**	Oct 13, 2015
AB			**10MG**	**A200155**	**002**	Oct 13, 2015
AB		UNICHEM LABS LTD	**5MG**	**A200022**	**001**	Oct 13, 2015
AB			**10MG**	**A200022**	**002**	Oct 13, 2015
AB		UPSHER SMITH LABS	**5MG**	**A090043**	**001**	Jul 31, 2015
AB			**10MG**	**A090043**	**002**	Jul 31, 2015
AB		WOCKHARDT LTD	**5MG**	**A090073**	**001**	Sep 04, 2015
AB			**10MG**	**A090073**	**002**	Sep 04, 2015
AB		ZYDUS PHARMS USA INC	**5MG**	**A090961**	**001**	Jul 10, 2017
AB			**10MG**	**A090961**	**002**	Jul 10, 2017

NAMENDA

AB	+	ALLERGAN SALES LLC	**5MG**	**N021487**	**001**	Oct 16, 2003
AB	+!		**10MG**	**N021487**	**002**	Oct 16, 2003

MENOTROPINS (FSH;LH)

INJECTABLE;SUBCUTANEOUS

MENOPUR

	+!	FERRING	75 IU/VIAL;75 IU/VIAL	N021663	001	Oct 29, 2004

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEMEROL

AP	**+!**	HOSPIRA	**25MG/ML**	**N021171**	**001**	
AP	**+!**		**50MG/ML**	**N021171**	**002**	
AP	**+!**		**75MG/ML**	**N021171**	**003**	
AP	**+!**		**100MG/ML**	**N021171**	**004**	

MEPERIDINE HYDROCHLORIDE

AP		WEST-WARD PHARMS INT	**25MG/ML**	**A080445**	**001**	
AP			**25MG/ML**	**A080455**	**007**	
AP			**50MG/ML**	**A080445**	**002**	
AP			**50MG/ML**	**A080455**	**008**	
AP			**75MG/ML**	**A080445**	**003**	
AP			**75MG/ML**	**A080455**	**009**	
AP			**100MG/ML**	**A080445**	**004**	
AP			**100MG/ML**	**A080455**	**010**	

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

	!	WEST-WARD PHARMS INT	10MG/ML	A081002	001	Jul 30, 1993

SYRUP;ORAL

MEPERIDINE HYDROCHLORIDE

	!	WEST-WARD PHARMS INT	50MG/5ML	A088744	001	Jan 30, 1985

TABLET;ORAL

DEMEROL

AA	**+!**	US PHARM HOLDINGS	**50MG**	**N005010**	**001**	
AA	**+!**		**100MG**	**N005010**	**004**	

MEPERIDINE HYDROCHLORIDE

AA		EPIC PHARMA	**50MG**	**A040331**	**001**	May 28, 1999
AA			**100MG**	**A040331**	**002**	May 28, 1999
AA		MIKART	**50MG**	**A040893**	**001**	Jun 24, 2009
AA			**100MG**	**A040893**	**003**	Jun 24, 2009
AA		SPECGX LLC	**50MG**	**A040352**	**001**	Jun 13, 2000
AA			**100MG**	**A040352**	**002**	Jun 13, 2000
AA		SUN PHARM INDS INC	**50MG**	**A040446**	**001**	Aug 08, 2002
AA			**100MG**	**A040446**	**002**	Aug 08, 2002
AA		VINTAGE PHARMS	**50MG**	**A040191**	**001**	Dec 17, 1998
AA			**100MG**	**A040191**	**002**	Dec 17, 1998
AA		WEST-WARD PHARMS INT	**50MG**	**A040110**	**001**	Mar 12, 1997
AA			**100MG**	**A040110**	**002**	Mar 12, 1997
		MIKART	75MG	A040893	002	Jun 24, 2009
			150MG	A040893	004	Jun 24, 2009

MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

CARBOCAINE

AP	**+!**	HOSPIRA	**1%**	**N012250**	**001**	
AP	**+!**		**1.5%**	**N012250**	**005**	
AP	**+!**		**2%**	**N012250**	**002**	

POLOCAINE

AP		FRESENIUS KABI USA	**1%**	**A089407**	**001**	Dec 01, 1986
AP			**2%**	**A089410**	**001**	Dec 01, 1986

POLOCAINE-MPF

AP		FRESENIUS KABI USA	**1%**	**A089406**	**001**	Dec 01, 1986
AP			**1.5%**	**A089408**	**001**	Dec 01, 1986
AP			**2%**	**A089409**	**001**	Dec 01, 1986

SCANDONEST PLAIN

AP	**!**	DEPROCO	**3%**	**A088387**	**001**	Oct 10, 1984

MEPROBAMATE

TABLET;ORAL

MEPROBAMATE

AA		ALEMBIC PHARMS LTD	**200MG**	**A090122**	**001**	Feb 18, 2009
AA			**400MG**	**A090122**	**002**	Feb 18, 2009
AA		INVAGEN PHARMS	**200MG**	**A040797**	**001**	Feb 27, 2008
AA			**400MG**	**A040797**	**002**	Feb 27, 2008
AA	**!**	WATSON LABS	**200MG**	**A083304**	**001**	
AA	**!**		**400MG**	**A083308**	**001**	

MERCAPTOPURINE							
SUSPENSION;ORAL							
PURIXAN							
	+!	NOVA LABS LTD	20MG/ML		N205919	001	Apr 28, 2014
TABLET;ORAL							
MERCAPTOPURINE							
AB		DR REDDYS LABS SA	**50MG**		**A040461**	**001**	Feb 11, 2004
AB		MYLAN	**50MG**		**A040594**	**001**	Jul 01, 2005
AB	!	WEST-WARD PHARMS INT	**50MG**		**A040528**	**001**	Feb 13, 2004
PURINETHOL							
AB	+	STASON PHARMS	**50MG**		**N009053**	**002**	
MEROPENEM							
INJECTABLE;INJECTION							
MEROPENEM							
AP		ACS DOBFAR	**500MG/VIAL**		**A091404**	**001**	Oct 26, 2011
AP			**1GM/VIAL**		**A091404**	**002**	Oct 26, 2011
AP		ACS DOBFAR SPA	**500MG/VIAL**		**A204139**	**001**	Jun 09, 2016
AP			**1GM/VIAL**		**A204139**	**002**	Jun 09, 2016
AP		AMNEAL PHARMS	**500MG/VIAL**		**A205883**	**001**	Apr 12, 2016
AP			**1GM/VIAL**		**A205883**	**002**	Apr 12, 2016
AP		AUROBINDO PHARMA LTD	**500MG/VIAL**		**A205835**	**001**	Mar 27, 2017
AP			**1GM/VIAL**		**A205835**	**002**	Mar 27, 2017
AP		DAEWOONG PHARM CO	**500MG/VIAL**		**A204854**	**001**	Dec 18, 2015
AP			**1GM/VIAL**		**A204854**	**002**	Dec 18, 2015
AP		GLAND PHARMA LTD	**500MG/VIAL**		**A206141**	**001**	Jun 08, 2016
AP			**1GM/VIAL**		**A206141**	**002**	Jun 08, 2016
AP		HOSPIRA INC	**500MG/VIAL**		**A090940**	**001**	Jun 22, 2010
AP			**1GM/VIAL**		**A090940**	**002**	Jun 22, 2010
AP		SAVIOR LIFETEC CORP	**500MG/VIAL**		**A206086**	**001**	Apr 19, 2016
AP			**1GM/VIAL**		**A206086**	**002**	Apr 19, 2016
MERREM							
AP	+!	PFIZER	**500MG/VIAL**		**N050706**	**003**	Jun 21, 1996
AP	+!		**1GM/VIAL**		**N050706**	**001**	Jun 21, 1996
POWDER;INTRAVENOUS							
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER							
		B BRAUN MEDICAL INC	500MG/VIAL		N202106	001	Apr 30, 2015
			1GM/VIAL		N202106	002	Apr 30, 2015
MEROPENEM; VABORBACTAM							
POWDER;INTRAVENOUS							
VABOMERE							
	+!	REMPEX PHARMS	1GM/VIAL;1GM/VIAL		N209776	001	Aug 29, 2017
MESALAMINE							
CAPSULE, DELAYED RELEASE;ORAL							
DELZICOL							
	+!	APIL	400MG		N204412	001	Feb 01, 2013
CAPSULE, EXTENDED RELEASE;ORAL							
APRISO							
	+!	VALEANT PHARMS INTL	375MG		N022301	001	Oct 31, 2008
PENTASA							
	+	SHIRE	250MG		N020049	001	May 10, 1993
	+!		500MG		N020049	002	Jul 08, 2004
ENEMA;RECTAL							
MESALAMINE							
AB		PERRIGO ISRAEL	**4GM/60ML**		**A076751**	**001**	Sep 17, 2004
ROWASA							
AB	+!	MYLAN SPECIALITY LP	**4GM/60ML**		**N019618**	**001**	Dec 24, 1987
SFROWASA							
AB	+	MYLAN SPECIALITY LP	**4GM/60ML**		**N019618**	**002**	Jun 20, 2008
SUPPOSITORY;RECTAL							
CANASA							
AB	+!	ALLERGAN SALES LLC	**1GM**		**N021252**	**002**	Nov 05, 2004
MESALAMINE							
AB		MYLAN PHARMS INC	**1GM**		**A204354**	**001**	Nov 24, 2015
TABLET, DELAYED RELEASE;ORAL							
ASACOL HD							
AB	+!	APIL	**800MG**		**N021830**	**001**	May 29, 2008
LIALDA							
AB	+!	SHIRE	**1.2GM**		**N022000**	**001**	Jan 16, 2007

MESALAMINE
TABLET, DELAYED RELEASE;ORAL
MESALAMINE

AB		ACTAVIS LABS FL	**1.2GM**	**A203817**	**001**	Mar 23, 2018
AB		MYLAN PHARMS INC	**1.2GM**	**A203574**	**001**	Nov 20, 2018
AB		ZYDUS PHARMS USA INC	**800MG**	**A203286**	**001**	Jul 21, 2017
AB			**1.2GM**	**A091640**	**001**	Jun 05, 2017

MESNA
INJECTABLE;INTRAVENOUS
MESNA

AP		FRESENIUS KABI USA	**100MG/ML**	**A075811**	**001**	Apr 26, 2001
AP		GLAND PHARMA LTD	**100MG/ML**	**A206992**	**001**	Dec 18, 2017
AP		SAGENT PHARMS	**100MG/ML**	**A090913**	**001**	Apr 13, 2010
AP		TEVA PHARMS USA	**100MG/ML**	**A075764**	**001**	Apr 27, 2001
AP		WEST-WARD PHARMS INT	**100MG/ML**	**A075739**	**001**	Jan 09, 2004

MESNEX

AP	**+!**	BAXTER HLTHCARE	**100MG/ML**	**N019884**	**001**	Dec 30, 1988

TABLET;ORAL
MESNEX

	+!	BAXTER HLTHCARE	400MG	N020855	001	Mar 21, 2002

MESTRANOL; NORETHINDRONE
TABLET;ORAL-28
NORINYL 1+50 28-DAY

	+!	ACTAVIS LABS UT INC	0.05MG;1MG	N016659	001	

METAPROTERENOL SULFATE
SYRUP;ORAL
METAPROTERENOL SULFATE

	!	LANNETT CO INC	10MG/5ML	A073632	001	Jul 22, 1992

TABLET;ORAL
METAPROTERENOL SULFATE

		PAR PHARM	10MG	A072024	001	Jun 28, 1988
	!		20MG	A072025	001	Jun 28, 1988

METAXALONE
TABLET;ORAL
METAXALONE

AB		ACTAVIS LABS FL INC	**800MG**	**A203695**	**001**	Jun 15, 2017
AB		AMNEAL PHARMS	**800MG**	**A203399**	**001**	Jun 21, 2013
AB		LANNETT CO INC	**800MG**	**A204770**	**001**	Nov 22, 2016
AB		RISING PHARMS	**800MG**	**A208774**	**001**	Sep 24, 2018
AB		SANDOZ	**800MG**	**A040445**	**001**	Mar 31, 2010
AB		SCIEGEN PHARMS INC	**800MG**	**A207466**	**001**	Aug 31, 2017

SKELAXIN

AB	**+!**	KING PHARMS	**800MG**	**N013217**	**003**	Aug 30, 2002

METAXALONE

		MOUNTAIN	400MG	A040486	001	Feb 27, 2015

METFORMIN HYDROCHLORIDE
SOLUTION;ORAL
RIOMET

	+!	SUN PHARM INDS LTD	500MG/5ML	N021591	001	Sep 11, 2003

TABLET;ORAL
GLUCOPHAGE

AB	**+**	BRISTOL MYERS SQUIBB	**500MG**	**N020357**	**001**	Mar 03, 1995
AB	**+**		**850MG**	**N020357**	**002**	Mar 03, 1995
AB	**+!**		**1GM**	**N020357**	**005**	Nov 05, 1998

METFORMIN HYDROCHLORIDE

AB		ALKEM	**500MG**	**A091184**	**001**	Nov 01, 2010
AB			**850MG**	**A091184**	**002**	Nov 01, 2010
AB			**1GM**	**A091184**	**003**	Nov 01, 2010
AB		AMNEAL PHARMS NY	**500MG**	**A077880**	**001**	Jun 05, 2006
AB			**850MG**	**A077880**	**002**	Jun 05, 2006
AB			**1GM**	**A077880**	**003**	Jun 05, 2006
AB		APOTEX	**500MG**	**A075984**	**001**	Apr 23, 2002
AB			**500MG**	**A090666**	**001**	Dec 07, 2011
AB			**850MG**	**A075984**	**002**	Apr 23, 2002
AB			**850MG**	**A090666**	**002**	Dec 07, 2011
AB			**1GM**	**A075984**	**003**	Apr 23, 2002
AB			**1GM**	**A090666**	**003**	Dec 07, 2011

METFORMIN HYDROCHLORIDE

TABLET;ORAL

METFORMIN HYDROCHLORIDE

AB	ATLAS PHARMS LLC	**500MG**	**A076033**	**001**	Jan 24, 2002
AB		**850MG**	**A076033**	**002**	Jan 24, 2002
AB		**1GM**	**A076033**	**003**	Jan 24, 2002
AB	AUROBINDO	**500MG**	**A077095**	**001**	Jan 14, 2005
AB		**850MG**	**A077095**	**002**	Jan 14, 2005
AB		**1GM**	**A077095**	**003**	Jan 14, 2005
AB	CHARTWELL LIFE SCI	**500MG**	**A075972**	**001**	Jan 24, 2002
AB		**850MG**	**A075972**	**002**	Jan 24, 2002
AB		**1GM**	**A075972**	**003**	Jan 24, 2002
AB	CSPC OUYI PHARM CO	**500MG**	**A205096**	**001**	Jul 11, 2016
AB		**850MG**	**A205096**	**002**	Jul 11, 2016
AB		**1GM**	**A205096**	**003**	Jul 11, 2016
AB	DR REDDYS LABS INC	**500MG**	**A077787**	**001**	Aug 23, 2006
AB		**850MG**	**A077787**	**002**	Aug 23, 2006
AB		**1GM**	**A077787**	**003**	Aug 23, 2006
AB	GLENMARK GENERICS	**500MG**	**A078170**	**001**	May 23, 2008
AB		**850MG**	**A078170**	**002**	May 23, 2008
AB		**1GM**	**A078170**	**003**	May 23, 2008
AB	GRANULES INDIA	**500MG**	**A090564**	**001**	Apr 22, 2010
AB		**850MG**	**A090564**	**002**	Apr 22, 2010
AB		**1GM**	**A090564**	**003**	Apr 22, 2010
AB	INDICUS PHARMA	**500MG**	**A079148**	**001**	Nov 25, 2008
AB		**850MG**	**A079148**	**002**	Nov 25, 2008
AB		**1GM**	**A079148**	**003**	Nov 25, 2008
AB	LAURUS LABS LTD	**500MG**	**A209882**	**001**	Aug 27, 2018
AB		**850MG**	**A209882**	**002**	Aug 27, 2018
AB		**1GM**	**A209882**	**003**	Aug 27, 2018
AB	MACLEODS PHARMS LTD	**500MG**	**A205330**	**001**	Oct 31, 2017
AB		**850MG**	**A205330**	**002**	Oct 31, 2017
AB		**1GM**	**A205330**	**003**	Oct 31, 2017
AB	MARKSANS PHARMA	**500MG**	**A090888**	**001**	Mar 12, 2012
AB		**850MG**	**A090888**	**002**	Mar 12, 2012
AB		**1GM**	**A090888**	**003**	Mar 12, 2012
AB	MYLAN	**500MG**	**A075973**	**001**	Jan 25, 2002
AB		**500MG**	**A075976**	**001**	Jan 24, 2002
AB		**850MG**	**A075973**	**002**	Jan 25, 2002
AB		**850MG**	**A075976**	**002**	Jan 24, 2002
AB		**1GM**	**A075973**	**003**	Jan 25, 2002
AB		**1GM**	**A075976**	**003**	Jan 24, 2002
AB	SANDOZ	**500MG**	**A075965**	**001**	Jan 25, 2002
AB		**850MG**	**A075965**	**002**	Jan 25, 2002
AB		**1GM**	**A075965**	**003**	Jan 25, 2002
AB	SCIEGEN PHARMS INC	**500MG**	**A203769**	**001**	Sep 11, 2013
AB		**850MG**	**A203769**	**002**	Sep 11, 2013
AB		**1GM**	**A203769**	**003**	Sep 11, 2013
AB	SUN PHARM INDS INC	**500MG**	**A075967**	**001**	Jan 29, 2002
AB		**850MG**	**A075967**	**002**	Jan 29, 2002
AB		**1GM**	**A075967**	**003**	Jan 29, 2002
AB	SUN PHARM INDUSTRIES	**500MG**	**A076038**	**001**	Feb 21, 2002
AB		**850MG**	**A076038**	**002**	Feb 21, 2002
AB		**1GM**	**A076038**	**003**	Feb 21, 2002
AB	SUNSHINE LAKE	**500MG**	**A208999**	**001**	Oct 12, 2018
AB		**850MG**	**A208999**	**002**	Oct 12, 2018
AB		**1GM**	**A208999**	**003**	Oct 12, 2018
AB	TEVA	**500MG**	**A075978**	**001**	Jan 25, 2002
AB		**850MG**	**A075978**	**002**	Jan 25, 2002
AB		**1GM**	**A075978**	**003**	Nov 05, 2002
AB	TORRENT PHARMS	**500MG**	**A077711**	**001**	Jan 24, 2007
AB		**850MG**	**A077711**	**002**	Jan 24, 2007
AB		**1GM**	**A077711**	**003**	Jan 24, 2007
AB	ZYDUS HLTHCARE	**500MG**	**A203686**	**001**	Aug 28, 2014
AB		**850MG**	**A203686**	**002**	Aug 28, 2014
AB		**1GM**	**A203686**	**003**	Aug 28, 2014
AB	ZYDUS PHARMS USA	**500MG**	**A077064**	**001**	Apr 18, 2005
AB		**850MG**	**A077064**	**002**	Apr 18, 2005
AB		**1GM**	**A077064**	**003**	Apr 18, 2005
	CHARTWELL LIFE SCI	625MG	A075972	005	Jan 24, 2002
		750MG	A075972	004	Jan 24, 2002

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GLUCOPHAGE XR							
AB	**+!**	BRISTOL MYERS SQUIBB	**750MG**	**N021202**	**004**	Apr 11, 2003
METFORMIN HYDROCHLORIDE							
AB		ACTAVIS LABS FL INC	**750MG**	**A076869**	**001**	Apr 12, 2005
AB		ALKEM LABS LTD	**750MG**	**A206145**	**002**	Oct 22, 2018
AB		AMNEAL PHARMS NY	**750MG**	**A078596**	**002**	Jan 03, 2008
AB		APOTEX	**750MG**	**A076706**	**002**	Dec 29, 2005
AB		AUROBINDO PHARMA LTD	**750MG**	**A079118**	**002**	Jul 20, 2012
AB		BARR	**750MG**	**A076863**	**001**	Oct 14, 2004
AB		BEXIMCO PHARMS USA	**750MG**	**A207427**	**002**	Dec 13, 2016
AB		CSPC OUYI PHARM CO	**750MG**	**A078321**	**002**	Apr 17, 2008
AB		GRANULES INDIA LTD	**750MG**	**A209313**	**002**	Mar 16, 2018
AB		INTELLIPHARMACEUTICS	**750MG**	**A202306**	**002**	Feb 23, 2017
AB		MACLEODS PHARMS LTD	**750MG**	**A206955**	**002**	Dec 07, 2016
AB		MARKSANS PHARMA	**750MG**	**A090295**	**002**	Apr 29, 2016
AB		NOSTRUM PHARMS LLC	**750MG**	**A076756**	**002**	Dec 12, 2011
AB		PRINSTON INC	**750MG**	**A208880**	**002**	Sep 10, 2018
AB		SUN PHARM INDS (IN)	**750MG**	**A077336**	**002**	Feb 09, 2006
AB		TEVA	**750MG**	**A076864**	**001**	Apr 12, 2005
AB		YICHANG HUMANWELL	**750MG**	**A211052**	**002**	Sep 24, 2018
AB		ZYDUS PHARMS USA	**750MG**	**A077078**	**001**	Apr 21, 2005
GLUCOPHAGE XR							
AB1	**+**	BRISTOL MYERS SQUIBB	**500MG**	**N021202**	**001**	Oct 13, 2000
METFORMIN HYDROCHLORIDE							
AB1		ACTAVIS LABS FL INC	**500MG**	**A076172**	**001**	Jun 16, 2004
AB1		ALIGNSCIENCE PHARMA	**500MG**	**A209303**	**001**	Mar 19, 2018
AB1		ALKEM LABS LTD	**500MG**	**A206145**	**001**	Oct 22, 2018
AB1		AMNEAL PHARMS NY	**500MG**	**A078596**	**001**	Jan 03, 2008
AB1		APOTEX	**500MG**	**A076706**	**001**	Dec 14, 2004
AB1		AUROBINDO PHARMA LTD	**500MG**	**A079118**	**001**	Jul 20, 2012
AB1		BEXIMCO PHARMS USA	**500MG**	**A207427**	**001**	Dec 13, 2016
AB1		CSPC OUYI PHARM CO	**500MG**	**A078321**	**001**	Apr 17, 2008
AB1		GRANULES INDIA LTD	**500MG**	**A209313**	**001**	Mar 16, 2018
AB1		INTELLIPHARMACEUTICS	**500MG**	**A202306**	**001**	Feb 23, 2017
AB1		INVENTIA HLTHCARE	**500MG**	**A201991**	**001**	Jan 18, 2012
AB1		MACLEODS PHARMS LTD	**500MG**	**A206955**	**001**	Dec 07, 2016
AB1		MARKSANS PHARMA	**500MG**	**A090295**	**001**	Apr 29, 2016
AB1		NOSTRUM PHARMS LLC	**500MG**	**A076756**	**001**	Jul 26, 2006
AB1		PRINSTON INC	**500MG**	**A208880**	**001**	Sep 10, 2018
AB1		SANDOZ	**500MG**	**A076873**	**001**	Dec 14, 2004
AB1		SUN PHARM INDS (IN)	**500MG**	**A077336**	**001**	Feb 09, 2006
AB1		TEVA	**500MG**	**A076269**	**001**	Jun 18, 2004
AB1		TORRENT PHARMS LTD	**500MG**	**A090014**	**001**	Dec 30, 2009
AB1		YICHANG HUMANWELL	**500MG**	**A211052**	**001**	Sep 24, 2018
AB1		ZYDUS PHARMS USA	**500MG**	**A077060**	**001**	Apr 20, 2005
FORTAMET							
AB2	**+**	ANDRX LABS LLC	**500MG**	**N021574**	**001**	Apr 27, 2004
AB2	**+!**		**1GM**	**N021574**	**002**	Apr 27, 2004
METFORMIN HYDROCHLORIDE							
AB2		LUPIN LTD	**500MG**	**A090692**	**001**	Jun 29, 2011
AB2			**1GM**	**A090692**	**002**	Jun 29, 2011
AB2		MYLAN PHARMS INC	**500MG**	**A200690**	**001**	Aug 01, 2012
AB2			**1GM**	**A200690**	**002**	Aug 01, 2012
AB2		NOSTRUM LABS INC	**500MG**	**A203832**	**001**	Dec 26, 2017
AB2			**1GM**	**A203832**	**002**	Dec 26, 2017
AB2		NOVAST LABS	**500MG**	**A209674**	**001**	Nov 02, 2018
AB2			**1GM**	**A209674**	**002**	Nov 02, 2018
AB2		QINGDAO BAHEAL PHARM	**500MG**	**A209993**	**001**	Dec 27, 2018
AB2			**1GM**	**A209993**	**002**	Dec 27, 2018
GLUMETZA							
AB3	**+**	SANTARUS INC	**500MG**	**N021748**	**001**	Jun 03, 2005
AB3	**+!**		**1GM**	**N021748**	**002**	Jun 03, 2005
METFORMIN HYDROCHLORIDE							
AB3		ACTAVIS LABS FL INC	**500MG**	**A203755**	**001**	Aug 01, 2016
AB3			**1GM**	**A203755**	**002**	Aug 01, 2016

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

AB3		LUPIN LTD	**500MG**	**A091664**	**001**	Jul 19, 2013
AB3			**1GM**	**A091664**	**002**	Jul 19, 2013
AB3		SUN PHARMA GLOBAL	**500MG**	**A202917**	**001**	Aug 01, 2016
AB3			**1GM**	**A202917**	**002**	Aug 01, 2016

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

ACTOPLUS MET

AB	**+**	TAKEDA PHARMS USA	**500MG;EQ 15MG BASE**	**N021842**	**001**	Aug 29, 2005
AB	**+!**		**850MG;EQ 15MG BASE**	**N021842**	**002**	Aug 29, 2005

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**500MG;EQ 15MG BASE**	**A200823**	**001**	Feb 13, 2013
AB			**850MG;EQ 15MG BASE**	**A200823**	**002**	Feb 13, 2013
AB		MACLEODS PHARMS LTD	**500MG;EQ 15MG BASE**	**A204802**	**001**	Nov 05, 2015
AB			**850MG;EQ 15MG BASE**	**A204802**	**002**	Nov 05, 2015
AB		MYLAN	**500MG;EQ 15MG BASE**	**A090406**	**001**	Feb 25, 2011
AB			**850MG;EQ 15MG BASE**	**A090406**	**002**	Feb 25, 2011
AB		SANDOZ	**500MG;EQ 15MG BASE**	**A091273**	**001**	Apr 16, 2013
AB			**850MG;EQ 15MG BASE**	**A091273**	**002**	Apr 16, 2013
AB		TEVA PHARMS USA	**500MG;EQ 15MG BASE**	**A091155**	**001**	Mar 10, 2014
AB			**850MG;EQ 15MG BASE**	**A091155**	**002**	Mar 10, 2014
AB		TORRENT PHARMS LTD	**500MG;EQ 15MG BASE**	**A202001**	**001**	Feb 13, 2013
AB			**850MG;EQ 15MG BASE**	**A202001**	**002**	Feb 13, 2013

TABLET, EXTENDED RELEASE;ORAL

ACTOPLUS MET XR

+	TAKEDA PHARMS USA	1GM;EQ 15MG BASE	N022024	001	May 12, 2009
+!		1GM;EQ 30MG BASE	N022024	002	May 12, 2009

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

KOMBIGLYZE XR

+	ASTRAZENECA AB	500MG;EQ 5MG BASE	N200678	001	Nov 05, 2010
+		1GM;EQ 2.5MG BASE	N200678	003	Nov 05, 2010
+!		1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

JANUMET

+	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N022044	001	Mar 30, 2007
+!		1GM;EQ 50MG BASE	N022044	002	Mar 30, 2007

TABLET, EXTENDED RELEASE;ORAL

JANUMET XR

+	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012
+		1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012
+!		1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012

METHACHOLINE CHLORIDE

FOR SOLUTION;INHALATION

PROVOCHOLINE

+!	METHAPHARM	100MG/VIAL	N019193	001	Oct 31, 1986

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL

METHADONE HYDROCHLORIDE

AA		VISTAPHARM	**10MG/ML**	**A040088**	**001**	Nov 30, 1994
AA		WEST-WARD PHARMS INT	**10MG/ML**	**A040180**	**001**	Apr 30, 1998

METHADONE HYDROCHLORIDE INTENSOL

AA		WEST-WARD PHARMS INT	**10MG/ML**	**A089897**	**001**	Sep 06, 1988

METHADOSE

AA	**+!**	SPECGX LLC	**10MG/ML**	**N017116**	**002**	

INJECTABLE;INJECTION

METHADONE HYDROCHLORIDE

AP		AKORN	**10MG/ML**	**A208306**	**001**	Oct 27, 2017
AP	**+!**	MYLAN INSTITUTIONAL	**10MG/ML**	**N021624**	**001**	

SOLUTION;ORAL

METHADONE HYDROCHLORIDE

AA		VISTAPHARM	**5MG/5ML**	**A090707**	**001**	Jun 30, 2010
AA			**10MG/5ML**	**A090707**	**002**	Jun 30, 2010
AA	**!**	WEST-WARD PHARMS INT	**5MG/5ML**	**A087393**	**001**	

METHADONE HYDROCHLORIDE						
SOLUTION;ORAL						
METHADONE HYDROCHLORIDE						
AA	**!**		**10MG/5ML**	**A087997**	**001**	Aug 30, 1982
TABLET;ORAL						
DOLOPHINE HYDROCHLORIDE						
AA	**+!**	WEST-WARD PHARMS INT	**5MG**	**N006134**	**002**	
AA	**+!**		**10MG**	**N006134**	**010**	
METHADONE HYDROCHLORIDE						
AA		ASCENT PHARMS INC	**5MG**	**A211228**	**001**	Jan 03, 2019
AA			**10MG**	**A211228**	**002**	Jan 03, 2019
AA		AUROLIFE PHARMA LLC	**5MG**	**A203502**	**001**	Aug 31, 2015
AA			**10MG**	**A203502**	**002**	Aug 31, 2015
AA		ELITE LABS INC	**5MG**	**A210484**	**001**	Aug 02, 2018
AA			**10MG**	**A210484**	**002**	Aug 02, 2018
AA		EPIC PHARMA LLC	**5MG**	**A090065**	**001**	Aug 18, 2015
AA			**10MG**	**A090065**	**002**	Aug 18, 2015
AA		SPECGX LLC	**5MG**	**A040517**	**001**	Apr 27, 2004
AA			**10MG**	**A040517**	**002**	Apr 27, 2004
AA		SUN PHARM INDUSTRIES	**5MG**	**A208305**	**001**	Mar 30, 2018
AA			**10MG**	**A208305**	**002**	Mar 30, 2018
AA		THEPHARMANETWORK LLC	**10MG**	**A090635**	**001**	Nov 25, 2009
AA		VISTAPHARM	**10MG**	**A040241**	**002**	May 29, 1998
METHADOSE						
AA		SPECGX LLC	**5MG**	**A040050**	**001**	Apr 15, 1993
AA			**10MG**	**A040050**	**002**	Apr 15, 1993
TABLET, FOR SUSPENSION;ORAL						
METHADONE HYDROCHLORIDE						
AA		SPECGX LLC	**40MG**	**A077142**	**001**	Jul 12, 2005
AA		VISTAPHARM	**40MG**	**A075082**	**001**	Mar 25, 1998
AA	**+!**	WEST-WARD PHARMS INT	**40MG**	**N017058**	**001**	
METHADOSE						
AA		SPECGX LLC	**40MG**	**A074184**	**001**	Apr 29, 1993
METHAMPHETAMINE HYDROCHLORIDE						
TABLET;ORAL						
DESOXYN						
AA	**+!**	RECORDATI RARE	**5MG**	**N005378**	**002**	
METHAMPHETAMINE HYDROCHLORIDE						
AA		MAYNE PHARMA INC	**5MG**	**A091189**	**001**	Apr 21, 2010
AA		WEST-WARD PHARMS INT	**5MG**	**A203846**	**001**	Nov 17, 2015
METHAZOLAMIDE						
TABLET;ORAL						
METHAZOLAMIDE						
AB		ANI PHARMS INC	**25MG**	**A040001**	**001**	Jun 30, 1993
AB			**50MG**	**A040001**	**002**	Jun 30, 1993
AB		MICRO LABS	**25MG**	**A207438**	**001**	Oct 05, 2018
AB			**50MG**	**A207438**	**002**	Oct 05, 2018
AB		MIKART	**25MG**	**A040062**	**001**	Jan 27, 1994
AB	**!**		**50MG**	**A040062**	**002**	Jan 27, 1994
AB		SANDOZ	**25MG**	**A040036**	**001**	Jun 30, 1993
AB			**50MG**	**A040036**	**002**	Jun 30, 1993
METHENAMINE HIPPURATE						
TABLET;ORAL						
HIPREX						
AB	**+!**	US PHARM HOLDINGS	**1GM**	**N017681**	**001**	
METHENAMINE HIPPURATE						
AB		AUROBINDO PHARMA LTD	**1GM**	**A205661**	**001**	Jul 05, 2016
AB		IMPAX LABS INC	**1GM**	**A076411**	**001**	Jun 20, 2003
UREX						
AB		CNTY LINE PHARMS	**1GM**	**N016151**	**001**	

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

AB		CASI PHARMS INC	**5MG**	**A040411**	**001**	Mar 27, 2001
AB			**10MG**	**A040411**	**002**	Mar 27, 2001
AB		ECI PHARMS LLC	**5MG**	**A040547**	**001**	Feb 18, 2005
AB			**10MG**	**A040547**	**002**	Feb 18, 2005
AB		HERITAGE PHARMA	**5MG**	**A040734**	**001**	Dec 14, 2007
AB			**10MG**	**A040734**	**002**	Dec 14, 2007
AB		MYLAN	**5MG**	**A040350**	**001**	Mar 29, 2000
AB	!		**10MG**	**A040350**	**002**	Mar 29, 2000
AB		RISING PHARMS	**5MG**	**A202068**	**001**	Mar 07, 2012
AB			**10MG**	**A202068**	**002**	Mar 07, 2012
AB		SUN PHARM INDS INC	**5MG**	**A040870**	**001**	Sep 25, 2007
AB			**10MG**	**A040870**	**002**	Sep 25, 2007

TAPAZOLE

AB		KING PHARMS LLC	**5MG**	**A040320**	**001**	Mar 31, 2000
AB			**10MG**	**A040320**	**002**	Mar 31, 2000

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

AP		AUROBINDO PHARMA LTD	**1GM/10ML (100MG/ML)**	**A206128**	**001**	May 27, 2016
AP		FRESENIUS KABI USA	**1GM/10ML (100MG/ML)**	**A209331**	**001**	Apr 17, 2018
AP		GLAND PHARMA LTD	**1GM/10ML (100MG/ML)**	**A211504**	**001**	Oct 26, 2018
AP		LUITPOLD	**1GM/10ML (100MG/ML)**	**A207496**	**001**	Jun 22, 2017
AP		MONTEREY PHARMS LLC	**1GM/10ML (100MG/ML)**	**A205354**	**001**	Oct 27, 2016
AP		MYLAN INSTITUTIONAL	**1GM/10ML (100MG/ML)**	**A204404**	**001**	Dec 05, 2014
AP		NAVINTA LLC	**1GM/10ML (100MG/ML)**	**A206071**	**001**	Nov 24, 2017
AP		RENAISSANCE SSA LLC	**1GM/10ML (100MG/ML)**	**A208116**	**001**	Jan 19, 2017
AP		SAGENT PHARMS	**1GM/10ML (100MG/ML)**	**A205404**	**001**	Jul 18, 2017
AP		SOMERSET THERAPS LLC	**1GM/10ML (100MG/ML)**	**A207522**	**001**	Jul 31, 2017

ROBAXIN

AP	**+!**	WEST-WARD PHARMS INT	**1GM/10ML (100MG/ML)**	**N011790**	**001**	

TABLET;ORAL

METHOCARBAMOL

AA		AUSTARPHARMA LLC	**500MG**	**A200958**	**001**	Oct 21, 2011
AA			**750MG**	**A200958**	**002**	Oct 21, 2011
AA		BEXIMCO PHARMS USA	**500MG**	**A208507**	**001**	Jul 21, 2017
AA			**750MG**	**A208507**	**002**	Jul 21, 2017
AA		DBL PHARMS	**500MG**	**A203550**	**001**	Feb 08, 2017
AA			**750MG**	**A203550**	**002**	Feb 08, 2017
AA		GRANULES INDIA LTD	**500MG**	**A209312**	**001**	May 07, 2018
AA			**750MG**	**A209312**	**002**	May 07, 2018
AA		HETERO LABS LTD III	**500MG**	**A090200**	**001**	Nov 06, 2009
AA			**750MG**	**A090200**	**002**	Nov 06, 2009
AA		HIKMA INTL PHARMS	**500MG**	**A085159**	**001**	
AA			**750MG**	**A085123**	**001**	
AA		OXFORD PHARMS	**500MG**	**A040489**	**001**	Jan 29, 2003
AA			**750MG**	**A040489**	**002**	Jan 29, 2003
AA		PRINSTON INC	**500MG**	**A086989**	**001**	
AA			**750MG**	**A086988**	**001**	
AA		WATSON LABS	**500MG**	**A084277**	**001**	
AA			**750MG**	**A084276**	**002**	

ROBAXIN

AA	**+!**	AUXILIUM PHARMS LLC	**500MG**	**N011011**	**004**	

ROBAXIN-750

AA	**+!**	AUXILIUM PHARMS LLC	**750MG**	**N011011**	**006**	

METHOHEXITAL SODIUM

INJECTABLE;INJECTION

BREVITAL SODIUM

	+!	PAR STERILE PRODUCTS	500MG/VIAL	N011559	001
	+!		2.5GM/VIAL	N011559	002

METHOTREXATE						
SOLUTION;SUBCUTANEOUS						
OTREXUP						
	+!	ANTARES PHARMA INC	10MG/0.4ML (10MG/0.4ML)	N204824	001	Oct 11, 2013
	+!		12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016
	+!		15MG/0.4ML (15MG/0.4ML)	N204824	002	Oct 11, 2013
	+!		17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016
	+!		20MG/0.4ML (20MG/0.4ML)	N204824	003	Oct 11, 2013
	+!		22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016
	+!		25MG/0.4ML (25MG/0.4ML)	N204824	004	Oct 11, 2013
RASUVO						
	+!	MEDAC PHARMA INC	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014
	+!		10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014
	+!		12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014
	+!		15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014
	+!		17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014
	+!		20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014
	+!		22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014
	+!		25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014
	+!		30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014
METHOTREXATE SODIUM						
INJECTABLE;INJECTION						
METHOTREXATE PRESERVATIVE FREE						
AP		FRESENIUS KABI USA	**EQ 25MG BASE/ML**	**A040265**	**001**	Feb 26, 1999
AP			**EQ 1GM BASE/VIAL**	**A040266**	**001**	Feb 26, 1999
METHOTREXATE SODIUM						
AP	**!**	FRESENIUS KABI USA	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A040263**	**001**	Feb 26, 1999
AP	**+!**	HOSPIRA	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**N011719**	**010**	Dec 15, 2004
AP	**!**	WEST-WARD PHARMS INT	**EQ 100MG BASE/4ML (EQ 25MG BASE/ML)**	**A089341**	**001**	Sep 16, 1986
METHOTREXATE SODIUM PRESERVATIVE FREE						
AP	**!**	ACCORD HLTHCARE	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A040767**	**001**	Apr 30, 2007
AP	**!**		**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A040768**	**001**	Apr 30, 2007
AP	**!**		**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A040716**	**001**	Apr 30, 2007
AP	**+!**	HOSPIRA	**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**N011719**	**012**	Apr 13, 2005
AP		MYLAN LABS LTD	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A201529**	**001**	Mar 29, 2012
AP			**EQ 100MG BASE/4ML (EQ 25MG BASE/ML)**	**A201529**	**002**	Mar 29, 2012
AP			**EQ 200MG BASE/8ML (EQ 25MG BASE/ML)**	**A201529**	**003**	Mar 29, 2012
AP			**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A201529**	**004**	Mar 29, 2012
AP			**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A201530**	**001**	Mar 29, 2012
AP		PHARMACHEMIE BV	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A040843**	**002**	Jan 11, 2010
AP			**EQ 100MG BASE/4ML (EQ 25MG BASE/ML)**	**A040843**	**003**	Feb 27, 2012
AP			**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A040843**	**004**	Jan 11, 2010
AP			**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A040843**	**001**	Jan 11, 2010
AP		SAGENT PHARMS	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A203407**	**001**	Aug 09, 2018
AP			**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A203407**	**002**	Aug 09, 2018
AP			**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A203407**	**003**	Aug 09, 2018
AP		SANDOZ INC	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A090039**	**001**	Mar 31, 2009
AP			**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A090039**	**002**	Mar 31, 2009
AP			**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A090029**	**001**	Mar 31, 2009
AP	**!**	WEST-WARD PHARMS INT	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A089340**	**001**	Sep 16, 1986
AP	**!**		**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A089343**	**001**	Sep 16, 1986
METHOTREXATE SODIUM						
	!	WEST-WARD PHARMS INT	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986
METHOTREXATE SODIUM PRESERVATIVE FREE						
	!	WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL	A040632	001	Aug 12, 2005
SOLUTION;ORAL						
XATMEP						
	+!	SILVERGATE PHARMS	EQ 2MG BASE/ML	N208400	001	Apr 25, 2017
TABLET;ORAL						
METHOTREXATE SODIUM						
AB		AMNEAL PHARMS	**EQ 2.5MG BASE**	**A210040**	**001**	Dec 22, 2017
AB		BARR	**EQ 2.5MG BASE**	**A081099**	**001**	Oct 15, 1990
AB	**+!**	DAVA PHARMS INC	**EQ 2.5MG BASE**	**N008085**	**002**	
AB		MYLAN	**EQ 2.5MG BASE**	**A081235**	**001**	May 15, 1992
AB		SUN PHARMA GLOBAL	**EQ 2.5MG BASE**	**A201749**	**001**	May 21, 2015
AB		WEST-WARD PHARMS INT	**EQ 2.5MG BASE**	**A040054**	**001**	Aug 01, 1994
AB		ZYDUS PHARMS USA INC	**EQ 2.5MG BASE**	**A207812**	**001**	Jan 13, 2017

METHOTREXATE SODIUM						
TABLET;ORAL						
TREXALL						
		BARR	EQ 5MG BASE	A040385	001	Mar 21, 2001
			EQ 7.5MG BASE	A040385	002	Mar 21, 2001
			EQ 10MG BASE	A040385	003	Mar 21, 2001
	!		EQ 15MG BASE	A040385	004	Mar 21, 2001
METHOXSALEN						
CAPSULE;ORAL						
METHOXSALEN						
AB		ACTAVIS INC	**10MG**	**A202603**	**001**	Jun 09, 2015
AB		STRIDES PHARMA	**10MG**	**A202687**	**001**	Jun 05, 2014
OXSORALEN-ULTRA						
AB	**+!**	DOW PHARM	**10MG**	**N019600**	**001**	Oct 30, 1986
INJECTABLE;INJECTION						
UVADEX						
	+!	MALLINCKRODT HOSP	0.02MG/ML	N020969	001	Feb 25, 1999
METHSCOPOLAMINE BROMIDE						
TABLET;ORAL						
METHSCOPOLAMINE BROMIDE						
AA		BAYSHORE PHARMS LLC	**2.5MG**	**A200602**	**001**	Sep 24, 2012
AA			**5MG**	**A200602**	**002**	Sep 24, 2012
AA		BRECKENRIDGE PHARM	**2.5MG**	**A040642**	**001**	Dec 06, 2011
AA			**5MG**	**A040642**	**002**	Dec 06, 2011
AA	**!**	VINTAGE PHARMS	**2.5MG**	**A040624**	**001**	Dec 28, 2006
AA	**!**		**5MG**	**A040624**	**002**	Dec 28, 2006
METHSUXIMIDE						
CAPSULE;ORAL						
CELONTIN						
	+!	PARKE DAVIS	300MG	N010596	008	
METHYCLOTHIAZIDE						
TABLET;ORAL						
METHYCLOTHIAZIDE						
	!	MYLAN PHARMS INC	5MG	A087672	001	Aug 17, 1982
METHYLDOPA						
TABLET;ORAL						
METHYLDOPA						
AB		ACCORD HLTHCARE	**250MG**	**A070084**	**001**	Oct 15, 1985
AB			**500MG**	**A070085**	**001**	Oct 15, 1985
AB		IVAX SUB TEVA PHARMS	**250MG**	**A070098**	**001**	Feb 20, 1986
AB			**500MG**	**A070343**	**001**	Feb 20, 1986
AB		MYLAN	**250MG**	**A070076**	**002**	Apr 18, 1985
AB	**!**		**500MG**	**A070076**	**001**	Apr 18, 1985
AB		WATSON LABS	**500MG**	**A070625**	**001**	Jun 06, 1986
METHYLDOPATE HYDROCHLORIDE						
INJECTABLE;INJECTION						
METHYLDOPATE HYDROCHLORIDE						
	!	LUITPOLD	50MG/ML	A071279	001	Oct 02, 1987
METHYLENE BLUE						
SOLUTION;INTRAVENOUS						
PROVAYBLUE						
	+!	PROVEPHARM SAS	50MG/10ML (5MG/ML)	N204630	001	Apr 08, 2016
METHYLERGONOVINE MALEATE						
INJECTABLE;INJECTION						
METHERGINE						
AP	**+!**	EDISON THERAPS LLC	**0.2MG/ML**	**N006035**	**004**	
METHYLERGONOVINE MALEATE						
AP		BRECKENRIDGE PHARM	**0.2MG/ML**	**A040889**	**001**	Sep 13, 2010
AP		LUITPOLD	**0.2MG/ML**	**A090193**	**001**	Nov 24, 2008
TABLET;ORAL						
METHYLERGONOVINE MALEATE						
AB		AMNEAL PHARMS	**0.2MG**	**A211483**	**001**	Sep 10, 2018
AB		GRANULES PHARMS	**0.2MG**	**A210424**	**001**	May 15, 2018
AB	**!**	NOVEL LABS INC	**0.2MG**	**A091577**	**001**	May 02, 2011

METHYLNALTREXONE BROMIDE							
SOLUTION;SUBCUTANEOUS							
RELISTOR							
	+!	SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010
	+!		12MG/0.6ML (12MG/0.6ML)	N021964	001	Apr 24, 2008
	+!		12MG/0.6ML (12MG/0.6ML)	N021964	003	Sep 27, 2010
TABLET;ORAL							
RELISTOR							
	+!	SALIX PHARMS INC	150MG	N208271	001	Jul 19, 2016
METHYLPHENIDATE							
FILM, EXTENDED RELEASE;TRANSDERMAL							
DAYTRANA							
	+	NOVEN PHARMS INC	10MG/9HR (1.1MG/HR)	N021514	001	Apr 06, 2006
	+		15MG/9HR (1.6MG/HR)	N021514	002	Apr 06, 2006
	+		20MG/9HR (2.2MG/HR)	N021514	003	Apr 06, 2006
	+!		30MG/9HR (3.3MG/HR)	N021514	004	Apr 06, 2006
TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL							
COTEMPLA XR-ODT							
	+	NEOS THERAPS INC	8.6MG	N205489	001	Jun 19, 2017
	+		17.3MG	N205489	002	Jun 19, 2017
	+		25.9MG	N205489	003	Jun 19, 2017
METHYLPHENIDATE HYDROCHLORIDE							
CAPSULE, EXTENDED RELEASE;ORAL							
METHYLPHENIDATE HYDROCHLORIDE							
AB1		BARR LABS INC	**10MG**	**A079031**	**004**	Oct 15, 2014
AB1			**20MG**	**A079031**	**001**	Jul 13, 2012
AB1			**30MG**	**A079031**	**002**	Jul 13, 2012
AB1			**40MG**	**A079031**	**003**	Jul 13, 2012
AB1		MAYNE PHARMA	**10MG**	**A200886**	**001**	Feb 26, 2018
AB1			**20MG**	**A078458**	**001**	Dec 01, 2011
AB1			**30MG**	**A078458**	**002**	Dec 01, 2011
AB1			**40MG**	**A078458**	**003**	Dec 01, 2011
RITALIN LA							
AB1	+	NOVARTIS	**10MG**	**N021284**	**004**	Apr 10, 2004
AB1	+		**20MG**	**N021284**	**001**	Jun 05, 2002
AB1	+		**30MG**	**N021284**	**002**	Jun 05, 2002
AB1	+		**40MG**	**N021284**	**003**	Jun 05, 2002
METADATE CD							
AB2	+	LANNETT CO INC	**10MG**	**N021259**	**003**	May 27, 2003
AB2	+		**20MG**	**N021259**	**001**	Apr 03, 2001
AB2	+		**30MG**	**N021259**	**002**	Jun 19, 2003
AB2	+		**40MG**	**N021259**	**004**	Feb 19, 2006
AB2	+		**50MG**	**N021259**	**005**	Feb 19, 2006
AB2	+!		**60MG**	**N021259**	**006**	Feb 19, 2006
METHYLPHENIDATE HYDROCHLORIDE							
AB2		IMPAX LABS INC	**10MG**	**A205105**	**001**	Jul 28, 2016
AB2			**20MG**	**A205105**	**002**	Jul 28, 2016
AB2			**30MG**	**A205105**	**003**	Jul 28, 2016
AB2			**40MG**	**A205105**	**004**	Jul 28, 2016
AB2			**50MG**	**A205105**	**005**	Jul 28, 2016
AB2			**60MG**	**A205105**	**006**	Jul 28, 2016
AB2		SPECGX LLC	**10MG**	**A203583**	**001**	Sep 29, 2015
AB2			**20MG**	**A203583**	**002**	Sep 29, 2015
AB2			**30MG**	**A203583**	**003**	Sep 29, 2015
AB2			**40MG**	**A203583**	**004**	Sep 29, 2015
AB2			**50MG**	**A203583**	**005**	Sep 29, 2015
AB2			**60MG**	**A203583**	**006**	Sep 29, 2015
AB2		TEVA PHARMS	**10MG**	**A077707**	**001**	Jul 19, 2012
AB2			**20MG**	**A077707**	**002**	Jul 19, 2012
AB2			**30MG**	**A077707**	**003**	Jul 19, 2012
AB2			**40MG**	**A078873**	**001**	Jul 19, 2012
AB2			**50MG**	**A078873**	**002**	Jul 19, 2012
AB2			**60MG**	**A078873**	**003**	Jul 19, 2012
APTENSIO XR							
AB3	+	RHODES PHARMS	**10MG**	**N205831**	**001**	Apr 17, 2015
AB3	+		**15MG**	**N205831**	**002**	Apr 17, 2015
AB3	+		**20MG**	**N205831**	**003**	Apr 17, 2015
AB3	+		**30MG**	**N205831**	**004**	Apr 17, 2015
AB3	+		**40MG**	**N205831**	**005**	Apr 17, 2015
AB3	+		**50MG**	**N205831**	**006**	Apr 17, 2015
AB3	+!		**60MG**	**N205831**	**007**	Apr 17, 2015

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB3		ACTAVIS ELIZABETH	**10MG**	**A208861**	**001**	Dec 13, 2018
AB3			**15MG**	**A208861**	**002**	Dec 13, 2018
AB3			**20MG**	**A208861**	**003**	Dec 13, 2018
AB3			**30MG**	**A208861**	**004**	Dec 13, 2018
AB3			**40MG**	**A208861**	**005**	Dec 13, 2018
AB3			**50MG**	**A208861**	**006**	Dec 13, 2018
AB3			**60MG**	**A208861**	**007**	Dec 13, 2018

JORNAY PM

	+	IRONSHORE PHARMS	20MG	N209311	001	Aug 08, 2018
	+		40MG	N209311	002	Aug 08, 2018
	+		60MG	N209311	003	Aug 08, 2018
	+		80MG	N209311	004	Aug 08, 2018
	+		100MG	N209311	005	Aug 08, 2018

METHYLPHENIDATE HYDROCHLORIDE

	!	MAYNE PHARMA	60MG	A078458	004	Jun 23, 2016

FOR SUSPENSION, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	**5MG/ML**	**A206049**	**001**	May 17, 2018

QUILLIVANT XR

AB	**+!**	NEXTWAVE PHARMS	**5MG/ML**	**N202100**	**001**	Sep 27, 2012

SOLUTION;ORAL

METHYLIN

AA	**+!**	SPECGX LLC	**5MG/5ML**	**N021419**	**001**	Dec 19, 2002
AA	**+!**		**10MG/5ML**	**N021419**	**002**	Dec 19, 2002

METHYLPHENIDATE HYDROCHLORIDE

AA		ABHAI LLC	**5MG/5ML**	**A207485**	**001**	Nov 18, 2016
AA			**10MG/5ML**	**A207485**	**002**	Nov 18, 2016
AA		BRECKENRIDGE PHARM	**5MG/5ML**	**A201466**	**001**	Nov 12, 2013
AA			**10MG/5ML**	**A201466**	**002**	Nov 12, 2013
AA		NOVEL LABS INC	**5MG/5ML**	**A204602**	**001**	Aug 14, 2015
AA			**10MG/5ML**	**A204602**	**002**	Aug 14, 2015
AA		TRIS PHARMA INC	**5MG/5ML**	**A091601**	**001**	Jul 23, 2010
AA			**10MG/5ML**	**A091601**	**002**	Jul 23, 2010
AA		WES PHARMA INC	**5MG/5ML**	**A210139**	**001**	Oct 03, 2018
AA			**10MG/5ML**	**A210139**	**002**	Oct 03, 2018

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		ABHAI INC	**5MG**	**A206932**	**001**	May 11, 2017
AB			**10MG**	**A206932**	**002**	May 11, 2017
AB			**20MG**	**A206932**	**003**	May 11, 2017
AB		ACTAVIS LABS FL INC	**5MG**	**A040220**	**001**	Aug 29, 1997
AB			**10MG**	**A040220**	**002**	Aug 29, 1997
AB			**20MG**	**A040220**	**003**	Aug 29, 1997
AB		ASCENT PHARMS INC	**5MG**	**A207416**	**001**	Sep 22, 2015
AB			**10MG**	**A207416**	**002**	Sep 22, 2015
AB			**20MG**	**A207416**	**003**	Sep 22, 2015
AB		AUROLIFE PHARMA LLC	**5MG**	**A209276**	**001**	Oct 25, 2018
AB			**10MG**	**A209276**	**002**	Oct 25, 2018
AB			**20MG**	**A209276**	**003**	Oct 25, 2018
AB		BIONPHARMA INC	**5MG**	**A209753**	**001**	Mar 02, 2018
AB			**10MG**	**A209753**	**002**	Mar 02, 2018
AB			**20MG**	**A209753**	**003**	Mar 02, 2018
AB		BRECKENRIDGE PHARM	**5MG**	**A207587**	**001**	Mar 03, 2017
AB			**10MG**	**A207587**	**002**	Mar 03, 2017
AB			**20MG**	**A207587**	**003**	Mar 03, 2017
AB		CNTY LINE PHARMS	**5MG**	**A206840**	**001**	Sep 15, 2016
AB			**10MG**	**A206840**	**002**	Sep 15, 2016
AB			**20MG**	**A206840**	**003**	Sep 15, 2016
AB		LANNETT CO INC	**5MG**	**A086429**	**001**	
AB			**10MG**	**A085799**	**001**	
AB			**20MG**	**A086428**	**001**	
AB		MOUNTAIN	**5MG**	**A091159**	**001**	Mar 12, 2014
AB			**10MG**	**A091159**	**002**	Mar 12, 2014
AB			**20MG**	**A091159**	**003**	Mar 12, 2014
AB		NOVEL LABS INC	**5MG**	**A207884**	**001**	Nov 13, 2015
AB			**10MG**	**A207884**	**002**	Nov 13, 2015
AB			**20MG**	**A207884**	**003**	Nov 13, 2015
AB		OXFORD PHARMS	**5MG**	**A202892**	**001**	Sep 23, 2014
AB			**10MG**	**A202892**	**002**	Sep 23, 2014

METHYLPHENIDATE HYDROCHLORIDE

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB			**20MG**	**A202892**	**003**	Sep 23, 2014
AB		SPECGX LLC	**5MG**	**A040300**	**001**	Nov 27, 1998
AB			**10MG**	**A040300**	**002**	Nov 27, 1998
AB			**20MG**	**A040300**	**003**	Nov 27, 1998
AB		SUN PHARM INDS INC	**5MG**	**A090710**	**001**	Mar 15, 2012
AB			**10MG**	**A090710**	**002**	Mar 15, 2012
AB			**20MG**	**A090710**	**003**	Mar 15, 2012

RITALIN

AB	**+**	NOVARTIS	**5MG**	**N010187**	**003**	
AB	**+**		**10MG**	**N010187**	**006**	
AB	**+!**		**20MG**	**N010187**	**010**	

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		ASCENT PHARMS INC	**2.5MG**	**A210354**	**001**	Dec 29, 2017
AB			**5MG**	**A210354**	**002**	Dec 29, 2017
AB			**10MG**	**A210354**	**003**	Dec 29, 2017
AB		BRECKENRIDGE PHARM	**2.5MG**	**A204954**	**001**	Jan 26, 2017
AB			**5MG**	**A204954**	**002**	Jan 26, 2017
AB			**10MG**	**A204954**	**003**	Jan 26, 2017
AB		NOVEL LABS INC	**2.5MG**	**A204115**	**001**	Feb 25, 2015
AB			**5MG**	**A204115**	**002**	Feb 25, 2015
AB	**!**		**10MG**	**A204115**	**003**	Feb 25, 2015
AB		RISING PHARMS	**2.5MG**	**A205756**	**001**	Nov 07, 2016
AB			**5MG**	**A205756**	**002**	Nov 07, 2016
AB			**10MG**	**A205756**	**003**	Nov 07, 2016

TABLET, EXTENDED RELEASE;ORAL

CONCERTA

AB	**+**	JANSSEN PHARMS	**18MG**	**N021121**	**001**	Aug 01, 2000
AB	**+**		**27MG**	**N021121**	**004**	Apr 01, 2002
AB	**+**		**36MG**	**N021121**	**002**	Aug 01, 2000
AB	**+!**		**54MG**	**N021121**	**003**	Dec 08, 2000

METADATE ER

AB	**!**	LANNETT CO INC	**20MG**	**A089601**	**001**	Jun 01, 1988

METHYLIN ER

AB		SPECGX LLC	**10MG**	**A075629**	**001**	May 09, 2000
AB			**20MG**	**A075629**	**002**	May 09, 2000

METHYLPHENIDATE HYDROCHLORIDE

AB		ABHAI LLC	**10MG**	**A207488**	**001**	Jun 09, 2015
AB			**20MG**	**A207488**	**002**	Jun 09, 2015
AB		ACTAVIS LABS FL	**18MG**	**A076772**	**001**	Mar 22, 2018
AB			**27MG**	**A076772**	**002**	Mar 22, 2018
AB			**36MG**	**A076772**	**003**	Mar 22, 2018
AB			**54MG**	**A076655**	**001**	Mar 21, 2018
AB		ALVOGEN PINE BROOK	**18MG**	**A210818**	**001**	Nov 30, 2018
AB			**27MG**	**A210818**	**002**	Nov 30, 2018
AB			**36MG**	**A210818**	**003**	Nov 30, 2018
AB			**54MG**	**A210818**	**004**	Nov 30, 2018
AB		AMNEAL PHARMS	**18MG**	**A207515**	**001**	Feb 01, 2018
AB			**27MG**	**A207515**	**002**	Feb 01, 2018
AB			**36MG**	**A207515**	**003**	Feb 01, 2018
AB			**54MG**	**A207515**	**004**	Feb 01, 2018
AB		ANI PHARMS INC	**18MG**	**A208607**	**001**	Jul 14, 2017
AB			**27MG**	**A208607**	**002**	Jul 14, 2017
AB			**36MG**	**A208607**	**003**	Jul 14, 2017
AB			**54MG**	**A208607**	**004**	Jul 14, 2017
AB		CNTY LINE PHARMS	**10MG**	**A204772**	**001**	Feb 29, 2016
AB			**20MG**	**A204772**	**002**	Feb 29, 2016
AB		GRANULES PHARMS	**10MG**	**A210992**	**001**	Nov 21, 2018
AB			**20MG**	**A210992**	**002**	Nov 21, 2018
AB		MYLAN PHARMS INC	**18MG**	**A206726**	**001**	Oct 21, 2016
AB			**27MG**	**A206726**	**002**	Oct 21, 2016
AB			**36MG**	**A206726**	**003**	Oct 21, 2016
AB			**54MG**	**A206726**	**004**	Oct 21, 2016
AB		OSMOTICA	**18MG**	**A205327**	**001**	Jul 28, 2017
AB			**27MG**	**A205327**	**002**	Jul 28, 2017
AB			**36MG**	**A205327**	**003**	Jul 28, 2017
AB			**54MG**	**A205327**	**004**	Jul 28, 2017
BX		LANNETT CO INC	18MG	A091695	001	Jul 09, 2013
BX			27MG	A091695	002	Jul 09, 2013

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

BX			36MG	A091695	003	Sep 23, 2013
BX			54MG	A091695	004	Sep 23, 2013
BX		SPECGX LLC	27MG	A202608	001	Dec 28, 2012
BX			36MG	A202608	002	Dec 28, 2012
BX			54MG	A202608	003	Dec 28, 2012
	!	OSMOTICA	72MG	A205327	005	Jul 28, 2017

TABLET, EXTENDED RELEASE, CHEWABLE;ORAL

QUILLICHEW ER

	+	NEXTWAVE PHARMS	20MG	N207960	001	Dec 04, 2015
	+		30MG	N207960	002	Dec 04, 2015
	+!		40MG	N207960	003	Dec 04, 2015

METHYLPREDNISOLONE

TABLET;ORAL

MEDROL

AB	**+**	PHARMACIA AND UPJOHN	**4MG**	**N011153**	**001**	
AB	**+**		**8MG**	**N011153**	**004**	
AB	**+**		**16MG**	**N011153**	**003**	
AB	**+!**		**32MG**	**N011153**	**006**	

METHYLPREDNISOLONE

AB		DURAMED PHARMS BARR	**4MG**	**A088497**	**001**	Feb 21, 1984
AB		JUBILANT CADISTA	**4MG**	**A040189**	**001**	Oct 31, 1997
AB			**8MG**	**A040189**	**002**	Oct 31, 1997
AB			**16MG**	**A040189**	**003**	Jul 20, 2007
AB			**32MG**	**A040189**	**004**	Jul 20, 2007
AB		RICONPHARMA LLC	**4MG**	**A210985**	**001**	Jan 09, 2019
AB		SANDOZ	**4MG**	**A040194**	**001**	Oct 31, 1997
AB		VINTAGE PHARMS	**4MG**	**A040183**	**001**	Dec 22, 1998
AB		WATSON LABS	**4MG**	**A040232**	**001**	Oct 16, 1997
AB		ZYDUS PHARMS USA INC	**4MG**	**A206751**	**001**	Apr 23, 2018
AB			**8MG**	**A206751**	**002**	Apr 23, 2018
AB			**16MG**	**A206751**	**003**	Apr 23, 2018
AB			**32MG**	**A206751**	**004**	Apr 23, 2018

MEDROL

	+	PHARMACIA AND UPJOHN	2MG	N011153	002	

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

DEPO-MEDROL

AB	**+!**	PHARMACIA AND UPJOHN	**20MG/ML**	**N011757**	**002**	
AB	**+!**		**40MG/ML**	**N011757**	**001**	
AB	**+!**		**80MG/ML**	**N011757**	**004**	

METHYLPREDNISOLONE ACETATE

AB		SAGENT PHARMS	**20MG/ML**	**A201835**	**001**	Jun 27, 2018
AB			**40MG/ML**	**A201835**	**002**	Jun 27, 2018
AB			**80MG/ML**	**A201835**	**003**	Jun 27, 2018
AB		SANDOZ INC	**40MG/ML**	**A040719**	**001**	Jan 29, 2009
AB			**40MG/ML**	**A040794**	**001**	Mar 05, 2009
AB			**80MG/ML**	**A040719**	**002**	Jan 29, 2009
AB			**80MG/ML**	**A040794**	**002**	Mar 05, 2009
AB		TEVA PHARMS USA	**40MG/ML**	**A040557**	**001**	Feb 23, 2005
AB			**40MG/ML**	**A040620**	**001**	Oct 27, 2006
AB			**80MG/ML**	**A040557**	**002**	Feb 23, 2005
AB			**80MG/ML**	**A040620**	**002**	Oct 27, 2006

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

A-METHAPRED

AP		HOSPIRA	**EQ 40MG BASE/VIAL**	**A040664**	**001**	Dec 20, 2005
AP			**EQ 125MG BASE/VIAL**	**A040665**	**001**	Dec 20, 2005

METHYLPREDNISOLONE SODIUM SUCCINATE

AP		AMNEAL PHARMS CO	**EQ 40MG BASE/VIAL**	**A207549**	**001**	Nov 09, 2016
AP			**EQ 125MG BASE/VIAL**	**A207549**	**002**	Nov 09, 2016
AP		AUROBINDO PHARMA LTD	**EQ 40MG BASE/VIAL**	**A207667**	**001**	Dec 15, 2015
AP			**EQ 125MG BASE/VIAL**	**A207667**	**002**	Dec 15, 2015
AP			**EQ 500MG BASE/VIAL**	**A207667**	**003**	Dec 15, 2015
AP			**EQ 2GM BASE/VIAL**	**A207667**	**004**	Dec 15, 2015

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

AP		FRESENIUS KABI USA	**EQ 40MG BASE/VIAL**	**A040583**	**001**	Jul 30, 2004
AP			**EQ 125MG BASE/VIAL**	**A040583**	**002**	Jul 30, 2004
AP			**EQ 1GM BASE/VIAL**	**A040612**	**001**	Aug 12, 2004
AP		HIKMA FARMACEUTICA	**EQ 500MG BASE/VIAL**	**A202691**	**001**	Feb 16, 2016
AP			**EQ 1GM BASE/VIAL**	**A202691**	**002**	Feb 16, 2016
AP		SAGENT PHARMS	**EQ 40MG BASE/VIAL**	**A040888**	**001**	Jul 18, 2011
AP			**EQ 125MG BASE/VIAL**	**A040888**	**002**	Jul 18, 2011
AP			**EQ 500MG BASE/VIAL**	**A040888**	**003**	Jul 18, 2011
AP			**EQ 1GM BASE/VIAL**	**A040888**	**004**	Jul 18, 2011
AP			**EQ 2GM BASE/VIAL**	**A040888**	**005**	Jul 18, 2011

SOLU-MEDROL

AP	**+!**	PHARMACIA AND UPJOHN	**EQ 40MG BASE/VIAL**	**N011856**	**003**	
AP	**+!**		**EQ 125MG BASE/VIAL**	**N011856**	**004**	
AP	**+!**		**EQ 500MG BASE/VIAL**	**N011856**	**005**	
AP	**+!**		**EQ 1GM BASE/VIAL**	**N011856**	**006**	
AP	**+!**		**EQ 2GM BASE/VIAL**	**N011856**	**007**	Feb 27, 1985

METHYLTESTOSTERONE

CAPSULE;ORAL

METHYLTESTOSTERONE

AB		IMPAX LABS INC	**10MG**	**A204851**	**001**	Sep 21, 2015

TESTRED

AB	**!**	VALEANT PHARM INTL	**10MG**	**A083976**	**001**	

TABLET;ORAL

ANDROID 25

BP		VALEANT PHARM INTL	25MG	A087147	001	

METHYLTESTOSTERONE

BP		IMPAX LABS	10MG	A080767	002	

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

METIPRANOLOL

AT		SANDOZ INC	**0.3%**	**A075720**	**001**	Aug 06, 2001

OPTIPRANOLOL

AT	**+!**	BAUSCH AND LOMB	**0.3%**	**N019907**	**001**	Dec 29, 1989

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

METOCLOPRAMIDE

AP		EMCURE PHARMS LTD	**EQ 5MG BASE/ML**	**A204756**	**001**	Dec 20, 2013

METOCLOPRAMIDE HYDROCHLORIDE

AP		FRESENIUS KABI USA	**EQ 5MG BASE/ML**	**A091392**	**001**	Apr 19, 2013
AP	**!**	HOSPIRA	**EQ 5MG BASE/ML**	**A073118**	**001**	Jan 17, 1991
AP		TEVA PHARMS USA	**EQ 5MG BASE/ML**	**A073135**	**001**	Nov 27, 1991

SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA		ANI PHARMS	**EQ 5MG BASE/5ML**	**A071402**	**001**	Jun 25, 1993
AA		PHARM ASSOC	**EQ 5MG BASE/5ML**	**A072744**	**001**	May 28, 1991
AA		VISTAPHARM	**EQ 5MG BASE/5ML**	**A075051**	**001**	Jan 26, 2001
AA	**!**	WOCKHARDT BIO AG	**EQ 5MG BASE/5ML**	**A074703**	**001**	Oct 31, 1997

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AB		IMPAX LABS INC	**EQ 5MG BASE**	**A071250**	**002**	Dec 28, 1995
AB			**EQ 10MG BASE**	**A071250**	**001**	Feb 03, 1988
AB		IPCA LABS LTD	**EQ 5MG BASE**	**A078807**	**001**	Jun 12, 2008
AB			**EQ 10MG BASE**	**A078807**	**002**	Jun 12, 2008
AB		PAR PHARM INC	**EQ 10MG BASE**	**A070581**	**001**	Oct 17, 1985
AB		TEVA	**EQ 5MG BASE**	**A072801**	**001**	Jun 15, 1993
AB			**EQ 10MG BASE**	**A070184**	**001**	Jul 29, 1985
AB		VINTAGE PHARMS	**EQ 5MG BASE**	**A077878**	**001**	Aug 28, 2006
AB			**EQ 10MG BASE**	**A077878**	**002**	Aug 28, 2006

REGLAN

AB	**+**	ANI PHARMS	**EQ 5MG BASE**	**N017854**	**002**	May 05, 1987
AB	**+!**		**EQ 10MG BASE**	**N017854**	**001**	

TABLET, ORALLY DISINTEGRATING;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

		NOVEL LABS INC	EQ 5MG BASE	A202191	001	Aug 15, 2014
	!		EQ 10MG BASE	A202191	002	Aug 15, 2014

METOLAZONE

TABLET;ORAL

METOLAZONE

AB		MYLAN	**2.5MG**	**A076698**	**001**	Dec 23, 2003
AB			**5MG**	**A076698**	**002**	Oct 19, 2004
AB			**10MG**	**A076698**	**003**	Oct 19, 2004
AB		SANDOZ	**2.5MG**	**A076732**	**001**	Dec 19, 2003
AB			**5MG**	**A076466**	**001**	Dec 19, 2003
AB			**10MG**	**A076466**	**002**	Dec 19, 2003

ZAROXOLYN

AB	+	LANNETT CO INC	**2.5MG**	**N017386**	**001**	
AB	+!		**5MG**	**N017386**	**002**	
AB	+!		**10MG**	**N017386**	**003**	

METOPROLOL SUCCINATE

CAPSULE, EXTENDED RELEASE;ORAL

KAPSPARGO SPRINKLE

+	SPIL	EQ 25MG TARTRATE	N210428	001	Jan 26, 2018
+		EQ 50MG TARTRATE	N210428	002	Jan 26, 2018
+		EQ 100MG TARTRATE	N210428	003	Jan 26, 2018
+!		EQ 200MG TARTRATE	N210428	004	Jan 26, 2018

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

AB		ACTAVIS ELIZABETH	**EQ 25MG TARTRATE**	**A204161**	**001**	Nov 25, 2016
AB			**EQ 50MG TARTRATE**	**A204161**	**002**	Nov 25, 2016
AB			**EQ 100MG TARTRATE**	**A204161**	**003**	Nov 25, 2016
AB			**EQ 200MG TARTRATE**	**A204161**	**004**	Nov 25, 2016
AB		ACTAVIS LABS FL INC	**EQ 25MG TARTRATE**	**A076862**	**002**	Aug 03, 2009
AB			**EQ 50MG TARTRATE**	**A076862**	**001**	Aug 03, 2009
AB			**EQ 100MG TARTRATE**	**A077298**	**001**	Apr 15, 2010
AB			**EQ 200MG TARTRATE**	**A077298**	**002**	Apr 15, 2010
AB		CIPLA	**EQ 50MG TARTRATE**	**A207465**	**001**	Oct 26, 2018
AB			**EQ 100MG TARTRATE**	**A207465**	**002**	Oct 26, 2018
AB			**EQ 200MG TARTRATE**	**A207465**	**003**	Oct 26, 2018
AB		DR REDDYS LABS LTD	**EQ 25MG TARTRATE**	**A090617**	**001**	Aug 01, 2012
AB			**EQ 50MG TARTRATE**	**A090617**	**002**	Aug 01, 2012
AB		MYLAN PHARMS INC	**EQ 25MG TARTRATE**	**A202033**	**001**	Dec 15, 2011
AB			**EQ 50MG TARTRATE**	**A202033**	**002**	Dec 15, 2011
AB			**EQ 100MG TARTRATE**	**A202033**	**003**	Dec 15, 2011
AB			**EQ 200MG TARTRATE**	**A202033**	**004**	Dec 15, 2011
AB		NOVAST LABS	**EQ 25MG TARTRATE**	**A204106**	**001**	Feb 06, 2018
AB			**EQ 50MG TARTRATE**	**A204106**	**002**	Feb 06, 2018
AB			**EQ 100MG TARTRATE**	**A204106**	**003**	Feb 06, 2018
AB			**EQ 200MG TARTRATE**	**A204106**	**004**	Feb 06, 2018
AB		REDDYS	**EQ 100MG TARTRATE**	**A078889**	**001**	Aug 15, 2012
AB			**EQ 200MG TARTRATE**	**A078889**	**002**	Aug 15, 2012
AB		TWI PHARMS	**EQ 25MG TARTRATE**	**A207206**	**001**	Dec 19, 2018
AB			**EQ 50MG TARTRATE**	**A207206**	**002**	Dec 19, 2018
AB			**EQ 100MG TARTRATE**	**A207206**	**003**	Dec 19, 2018
AB			**EQ 200MG TARTRATE**	**A207206**	**004**	Dec 19, 2018
AB		WOCKHARDT	**EQ 25MG TARTRATE**	**A090615**	**001**	Jul 22, 2010
AB			**EQ 50MG TARTRATE**	**A090615**	**002**	Jul 22, 2010
AB			**EQ 100MG TARTRATE**	**A090615**	**003**	Jul 22, 2010
AB			**EQ 200MG TARTRATE**	**A090615**	**004**	Jul 22, 2010
AB		ZYDUS PHARMS USA INC	**EQ 25MG TARTRATE**	**A203894**	**001**	Mar 23, 2018
AB			**EQ 50MG TARTRATE**	**A203894**	**002**	Mar 23, 2018
AB			**EQ 100MG TARTRATE**	**A203894**	**003**	Mar 23, 2018
AB			**EQ 200MG TARTRATE**	**A203894**	**004**	Mar 23, 2018

TOPROL-XL

AB	+	ARALEZ PHARMS	**EQ 25MG TARTRATE**	**N019962**	**004**	Feb 05, 2001
AB	+!		**EQ 50MG TARTRATE**	**N019962**	**001**	Jan 10, 1992
AB	+		**EQ 100MG TARTRATE**	**N019962**	**002**	Jan 10, 1992
AB	+!		**EQ 200MG TARTRATE**	**N019962**	**003**	Jan 10, 1992

METOPROLOL TARTRATE

INJECTABLE;INJECTION

LOPRESSOR

AP	+!	NOVARTIS	**1MG/ML**	**N018704**	**001**	Mar 30, 1984

METOPROLOL TARTRATE

AP		BAXTER HLTHCARE CORP	**1MG/ML**	**A078950**	**001**	Apr 29, 2013
AP		FRESENIUS KABI USA	**1MG/ML**	**A091045**	**001**	Oct 25, 2010
AP		GLAND PHARMA LTD	**1MG/ML**	**A204205**	**001**	Aug 27, 2014

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

AP		HIKMA FARMACEUTICA	**1MG/ML**	**A077761**	**001**	May 30, 2007
AP		HOSPIRA	**1MG/ML**	**A074133**	**001**	Dec 21, 1993
AP			**1MG/ML**	**A075160**	**001**	Jul 06, 1998
AP			**1MG/ML**	**A078085**	**001**	Apr 29, 2008
AP		LUITPOLD	**1MG/ML**	**A090386**	**001**	Sep 30, 2009
AP			**1MG/ML**	**A091307**	**001**	Dec 29, 2010
AP		MYLAN ASI	**1MG/ML**	**A090317**	**001**	Apr 19, 2010
AP		SANDOZ INC	**1MG/ML**	**A077360**	**001**	Oct 02, 2007
AP		WEST-WARD PHARMS INT	**1MG/ML**	**A076495**	**001**	Jul 07, 2003

TABLET;ORAL

LOPRESSOR

AB	+	US PHARMS HOLDINGS I	**50MG**	**N017963**	**001**	
AB	+		**100MG**	**N017963**	**002**	

METOPROLOL TARTRATE

AB		ALEMBIC PHARMS LTD	**25MG**	**A202871**	**001**	May 28, 2013
AB			**50MG**	**A202871**	**002**	May 28, 2013
AB			**100MG**	**A202871**	**003**	May 28, 2013
AB		AUROBINDO PHARMA	**25MG**	**A077739**	**001**	Sep 11, 2007
AB			**50MG**	**A077739**	**002**	Sep 11, 2007
AB			**100MG**	**A077739**	**003**	Sep 11, 2007
AB		IPCA LABS LTD	**25MG**	**A078459**	**001**	Jun 17, 2008
AB			**50MG**	**A078459**	**002**	Jun 17, 2008
AB			**100MG**	**A078459**	**003**	Jun 17, 2008
AB		MYLAN	**25MG**	**A076704**	**001**	Jan 16, 2004
AB			**50MG**	**A076704**	**002**	Jan 16, 2004
AB	!		**100MG**	**A076704**	**003**	Jan 16, 2004
AB		RUBICON RES PVT LTD	**25MG**	**A200981**	**001**	Oct 28, 2014
AB			**50MG**	**A200981**	**002**	Oct 28, 2014
AB			**100MG**	**A200981**	**003**	Oct 28, 2014
AB		SUN PHARM INDS INC	**25MG**	**A076670**	**001**	Jan 15, 2004
AB			**50MG**	**A074644**	**001**	Dec 10, 1996
AB			**100MG**	**A074644**	**002**	Dec 10, 1996
AB		SUN PHARM INDUSTRIES	**25MG**	**A073654**	**002**	Jul 15, 2009
AB			**50MG**	**A073654**	**003**	Dec 21, 1993
AB			**100MG**	**A073654**	**001**	Dec 21, 1993
AB		TEVA	**50MG**	**A074141**	**001**	Jan 31, 1995
AB			**100MG**	**A074141**	**002**	Jan 31, 1995
AB		WATSON LABS	**50MG**	**A074217**	**001**	May 27, 1994
AB			**100MG**	**A074217**	**002**	May 27, 1994
		MYLAN	37.5MG	A076704	004	Mar 18, 2015
			75MG	A076704	005	Mar 18, 2015

METRONIDAZOLE

CAPSULE;ORAL

FLAGYL

AB	+!	GD SEARLE LLC	**375MG**	**N020334**	**001**	May 03, 1995

METRONIDAZOLE

AB		ALEMBIC PHARMS LTD	**375MG**	**A079065**	**001**	Jun 23, 2009
AB		PAR PHARM	**375MG**	**A076522**	**001**	Jan 29, 2004

CREAM;TOPICAL

METROCREAM

AB	+!	GALDERMA LABS LP	**0.75%**	**N020531**	**001**	Sep 20, 1995

METRONIDAZOLE

AB		FOUGERA PHARMS	**0.75%**	**A076408**	**001**	May 28, 2004
AB		G AND W LABS	**0.75%**	**A077549**	**001**	Dec 19, 2007

NORITATE

	+!	VALEANT PHARMS NORTH	1%	N020743	001	Sep 26, 1997

GEL;TOPICAL

METROGEL

AB	+!	GALDERMA LABS LP	**0.75%**	**N019737**	**001**	Nov 22, 1988
AB	+!		**1%**	**N021789**	**001**	Jun 30, 2005

METRONIDAZOLE

AB		FOUGERA PHARMS	**0.75%**	**A077018**	**001**	Jun 06, 2006
AB		G AND W LABS INC	**0.75%**	**A078178**	**001**	Jan 19, 2011
AB		TARO	**0.75%**	**A077819**	**001**	Jul 18, 2006
AB		TARO PHARM	**1%**	**A204651**	**001**	Mar 14, 2017
AB		TOLMAR	**0.75%**	**A077547**	**001**	Jul 13, 2006

METRONIDAZOLE						
GEL;TOPICAL						
METRONIDAZOLE						
AB			**1%**	**A090903**	**001**	Jul 22, 2011
GEL;VAGINAL						
METROGEL-VAGINAL						
AB	**+!**	MEDICIS	**0.75%**	**N020208**	**001**	Aug 17, 1992
METRONIDAZOLE						
AB		TOLMAR	**0.75%**	**A077264**	**001**	Oct 31, 2006
VANDAZOLE						
BX		TEVA PHARMS	0.75%	N021806	001	May 20, 2005
NUVESSA						
	+!	CHEMO RESEARCH SL	1.3%	N205223	001	Mar 24, 2014
INJECTABLE;INJECTION						
FLAGYL I.V. RTU IN PLASTIC CONTAINER						
AP	**+!**	BAXTER HLTHCARE	**500MG/100ML**	**N018657**	**001**	
METRO I.V. IN PLASTIC CONTAINER						
AP	**+!**	B BRAUN	**500MG/100ML**	**N018900**	**001**	Sep 29, 1983
METRONIDAZOLE IN PLASTIC CONTAINER						
AP		BAXTER HLTHCARE CORP	**500MG/100ML**	**A078084**	**001**	Mar 31, 2008
AP	**+!**	HOSPIRA	**500MG/100ML**	**N018890**	**002**	Nov 18, 1983
AP		MYLAN LABS LTD	**500MG/100ML**	**A205531**	**001**	May 09, 2017
LOTION;TOPICAL						
METROLOTION						
AB	**+!**	GALDERMA LABS LP	**0.75%**	**N020901**	**001**	Nov 24, 1998
METRONIDAZOLE						
AB		FOUGERA PHARMS	**0.75%**	**A077197**	**001**	May 24, 2006
TABLET;ORAL						
FLAGYL						
AB	**+**	GD SEARLE LLC	**250MG**	**N012623**	**001**	
AB	**+!**		**500MG**	**N012623**	**003**	
METRONIDAZOLE						
AB		ALEMBIC PHARMS LTD	**250MG**	**A079067**	**001**	Mar 13, 2009
AB			**500MG**	**A079067**	**002**	Mar 13, 2009
AB		AUROBINDO PHARMA LTD	**250MG**	**A203974**	**001**	May 29, 2015
AB			**500MG**	**A203974**	**002**	May 29, 2015
AB		CADILA PHARMS LTD	**250MG**	**A209794**	**001**	Dec 12, 2017
AB			**500MG**	**A209794**	**002**	Dec 12, 2017
AB		FLAMINGO PHARMS	**250MG**	**A207309**	**001**	May 16, 2016
AB			**500MG**	**A207309**	**002**	May 16, 2016
AB		HERITAGE PHARMS INC	**250MG**	**A205245**	**001**	Sep 23, 2015
AB			**500MG**	**A205245**	**002**	Sep 23, 2015
AB		INNOGENIX	**250MG**	**A070772**	**001**	Jul 16, 1986
AB			**500MG**	**A070772**	**002**	Jul 16, 1986
AB		LUPIN LTD	**250MG**	**A209096**	**001**	Sep 12, 2017
AB			**500MG**	**A209096**	**002**	Sep 12, 2017
AB		ORIT LABS LLC	**250MG**	**A208681**	**001**	Jun 20, 2017
AB			**500MG**	**A208681**	**002**	Jun 20, 2017
AB		PLIVA	**500MG**	**A070033**	**001**	Dec 06, 1984
AB		STRIDES PHARMA	**250MG**	**A208162**	**001**	May 25, 2016
AB			**500MG**	**A208162**	**002**	May 25, 2016
AB		STRIDES VIVIMED	**250MG**	**A070040**	**001**	Jan 29, 1985
AB			**500MG**	**A070039**	**001**	Jan 29, 1985
AB		TEVA PHARMS USA	**250MG**	**A070027**	**001**	Nov 06, 1984
AB		UNICHEM LABS LTD	**250MG**	**A203458**	**001**	Jan 22, 2014
AB			**500MG**	**A203458**	**002**	Jan 22, 2014
AB		WATSON LABS	**250MG**	**A070035**	**001**	Dec 20, 1984
AB		WATSON LABS INC	**500MG**	**A070044**	**001**	Feb 08, 1985
AB		ZYDUS PHARMS USA INC	**250MG**	**A206560**	**001**	Nov 16, 2016
AB			**500MG**	**A206560**	**002**	Nov 16, 2016
METYRAPONE						
CAPSULE;ORAL						
METOPIRONE						
	+!	LABORATORIE HRA	250MG	N012911	002	Aug 09, 1996

METYROSINE							
CAPSULE;ORAL							
DEMSER							
	+!	ATON PHARMA VPNA	250MG		N017871	001	
MEXILETINE HYDROCHLORIDE							
CAPSULE;ORAL							
MEXILETINE HYDROCHLORIDE							
		TEVA	150MG		A074377	001	May 16, 1995
			200MG		A074377	002	May 16, 1995
	!		250MG		A074377	003	May 16, 1995
MICAFUNGIN SODIUM							
INJECTABLE;INTRAVENOUS							
MYCAMINE							
	+!	ASTELLAS	EQ 50MG BASE/VIAL		N021506	002	Mar 16, 2005
	+!		EQ 100MG BASE/VIAL		N021506	003	Jun 27, 2006
MICONAZOLE							
TABLET;BUCCAL							
ORAVIG							
	+!	MIDATECH PHARMA US	50MG		N022404	001	Apr 16, 2010
MICONAZOLE NITRATE							
SUPPOSITORY;VAGINAL							
MICONAZOLE NITRATE							
AB		ACTAVIS PHARMA	**200MG**		**A073508**	**001**	Nov 19, 1993
MONISTAT 3							
AB	**+!**	MEDTECH PRODUCTS	**200MG**		**N018888**	**001**	Aug 15, 1984
MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE							
OINTMENT;TOPICAL							
VUSION							
	+!	MYLAN PHARMS INC	0.25%;81.35%;15%		N021026	001	Feb 16, 2006
MIDAZOLAM HYDROCHLORIDE							
INJECTABLE;INJECTION							
MIDAZOLAM HYDROCHLORIDE							
AP		AKORN INC	**EQ 1MG BASE/ML**		**A075494**	**001**	Jun 30, 2000
AP			**EQ 5MG BASE/ML**		**A075494**	**002**	Jun 30, 2000
AP		FRESENIUS KABI USA	**EQ 1MG BASE/ML**		**A075154**	**002**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**		**A075154**	**001**	Jun 20, 2000
AP		GLAND PHARMA LTD	**EQ 1MG BASE/ML**		**A090696**	**001**	Feb 29, 2012
AP			**EQ 5MG BASE/ML**		**A090850**	**001**	Jan 25, 2012
AP	**!**	HOSPIRA	**EQ 1MG BASE/ML**		**A075293**	**001**	Jun 20, 2000
AP			**EQ 1MG BASE/ML**		**A075856**	**001**	Jun 13, 2002
AP	**!**		**EQ 5MG BASE/ML**		**A075293**	**002**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**		**A075856**	**002**	Jun 13, 2002
AP		WEST-WARD PHARMS INT	**EQ 1MG BASE/ML**		**A075243**	**001**	Jun 20, 2000
AP			**EQ 1MG BASE/ML**		**A075247**	**002**	Jun 23, 2000
AP			**EQ 1MG BASE/ML**		**A075324**	**001**	Jun 20, 2000
AP			**EQ 1MG BASE/ML**		**A075421**	**002**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**		**A075243**	**002**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**		**A075247**	**001**	Jun 23, 2000
AP			**EQ 5MG BASE/ML**		**A075324**	**002**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**		**A075421**	**001**	Jun 20, 2000
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE							
AP		FRESENIUS KABI USA	**EQ 1MG BASE/ML**		**A203460**	**001**	Aug 22, 2014
AP			**EQ 5MG BASE/ML**		**A203460**	**002**	Aug 22, 2014
AP	**!**	HOSPIRA	**EQ 1MG BASE/ML**		**A075857**	**001**	Jul 22, 2002
AP	**!**		**EQ 5MG BASE/ML**		**A075857**	**002**	Jul 22, 2002
AP		MYLAN ASI	**EQ 1MG BASE/ML**		**A090315**	**001**	Nov 29, 2010
AP			**EQ 5MG BASE/ML**		**A090315**	**002**	Nov 29, 2010
MIDOZALAM HYDROCHLORIDE							
AP		SAGENT STRIDES	**EQ 1MG BASE/ML**		**A090316**	**001**	May 04, 2011
AP			**EQ 5MG BASE/ML**		**A090316**	**002**	May 04, 2011
MIDAZOLAM HYDROCHLORIDE							
		FRESENIUS KABI USA	EQ 5MG BASE/ML		A208878	001	Mar 28, 2017
SOLUTION;INTRAMUSCULAR							
SEIZALAM							
	+!	MERIDIAN MEDCL TECHN	EQ 50MG BASE/10ML (EQ 5MG BASE/ML)		N209566	001	Sep 14, 2018

MIDAZOLAM HYDROCHLORIDE						
SYRUP;ORAL						
MIDAZOLAM HYDROCHLORIDE						
AA		HI TECH PHARMA	**EQ 2MG BASE/ML**	**A075958**	**001**	Sep 04, 2003
AA		PADDOCK LLC	**EQ 2MG BASE/ML**	**A076379**	**001**	May 02, 2005
AA	**!**	WEST-WARD PHARMS INT	**EQ 2MG BASE/ML**	**A075873**	**001**	Apr 30, 2002
MIDODRINE HYDROCHLORIDE						
TABLET;ORAL						
MIDODRINE HYDROCHLORIDE						
AB		APOTEX INC	**2.5MG**	**A077746**	**001**	Sep 12, 2006
AB			**5MG**	**A077746**	**002**	Sep 12, 2006
AB			**10MG**	**A077746**	**003**	Sep 12, 2006
AB		CASI PHARMS INC	**2.5MG**	**A076514**	**001**	Sep 11, 2003
AB			**5MG**	**A076514**	**002**	Sep 11, 2003
AB			**10MG**	**A076514**	**003**	Jul 02, 2004
AB		IMPAX PHARMS	**2.5MG**	**A076449**	**001**	May 27, 2004
AB			**5MG**	**A076449**	**002**	May 27, 2004
AB			**10MG**	**A076449**	**003**	Dec 16, 2005
AB		MYLAN PHARMS INC	**2.5MG**	**A076577**	**001**	Sep 10, 2003
AB	**!**		**5MG**	**A076577**	**002**	Sep 10, 2003
AB			**10MG**	**A076577**	**003**	Sep 10, 2003
AB		PAR PHARM INC	**2.5MG**	**A207169**	**001**	Oct 29, 2018
AB			**5MG**	**A207169**	**002**	Oct 29, 2018
AB			**10MG**	**A207169**	**003**	Oct 29, 2018
AB		UNIQUE PHARM LABS	**2.5MG**	**A207613**	**001**	Nov 02, 2018
AB			**5MG**	**A207613**	**002**	Nov 02, 2018
AB			**10MG**	**A207613**	**003**	Nov 02, 2018
ORVATEN						
AB		UPSHER SMITH LABS	**2.5MG**	**A076725**	**001**	Nov 03, 2004
AB			**5MG**	**A076725**	**002**	Nov 03, 2004
AB			**10MG**	**A076725**	**003**	Nov 03, 2004
MIDOSTAURIN						
CAPSULE;ORAL						
RYDAPT						
	+!	NOVARTIS PHARMS CORP	25MG	N207997	001	Apr 28, 2017
MIFEPRISTONE						
TABLET;ORAL						
KORLYM						
	+!	CORCEPT THERAP	300MG	N202107	001	Feb 17, 2012
MIFEPREX						
	+!	DANCO LABS LLC	200MG	N020687	001	Sep 28, 2000
MIGALASTAT HYDROCHLORIDE						
CAPSULE;ORAL						
GALAFOLD						
	+!	AMICUS THERAPS US	EQ 123MG BASE	N208623	001	Aug 10, 2018
MIGLITOL						
TABLET;ORAL						
GLYSET						
AB	**+!**	PHARMACIA AND UPJOHN	**25MG**	**N020682**	**001**	Dec 18, 1996
AB	**+**		**50MG**	**N020682**	**002**	Dec 18, 1996
AB	**+**		**100MG**	**N020682**	**003**	Dec 18, 1996
MIGLITOL						
AB		ORIENT PHARMA CO LTD	**25MG**	**A203965**	**001**	Feb 24, 2015
AB			**50MG**	**A203965**	**002**	Feb 24, 2015
AB			**100MG**	**A203965**	**003**	Feb 24, 2015
MIGLUSTAT						
CAPSULE;ORAL						
MIGLUSTAT						
AB		AMERIGEN PHARMS LTD	**100MG**	**A208342**	**001**	Apr 17, 2018
ZAVESCA						
AB	**+!**	ACTELION PHARMS LTD	**100MG**	**N021348**	**001**	Jul 31, 2003

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL

SAVELLA

+	ALLERGAN SALES LLC	12.5MG	N022256	001	Jan 14, 2009
+		25MG	N022256	002	Jan 14, 2009
+!		50MG	N022256	003	Jan 14, 2009
+		100MG	N022256	004	Jan 14, 2009

MILRINONE LACTATE

INJECTABLE;INJECTION

MILRINONE LACTATE

AP		FRESENIUS KABI USA	**EQ 1MG BASE/ML**	**A075936**	**001**	May 28, 2002
AP		GLAND PHARMA LTD	**EQ 1MG BASE/ML**	**A077190**	**001**	Oct 31, 2006
AP	!	HIKMA FARMACEUTICA	**EQ 1MG BASE/ML**	**A077966**	**001**	Dec 03, 2010
AP		HOSPIRA INC	**EQ 1MG BASE/ML**	**A203280**	**001**	Sep 03, 2014
AP		INTL MEDICATED	**EQ 1MG BASE/ML**	**A076013**	**001**	Aug 02, 2002
AP		WEST-WARD PHARMS INT	**EQ 1MG BASE/ML**	**A075530**	**001**	May 28, 2002
AP			**EQ 1MG BASE/ML**	**A075660**	**001**	May 28, 2002

MILRINONE LACTATE IN DEXTROSE 5%

AP		RENAISSANCE SSA LLC	**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A077151**	**002**	Jul 20, 2005

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	!	BAXTER HLTHCARE	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A075834**	**001**	May 28, 2002
AP	!		**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A075834**	**002**	May 28, 2002
AP		HOSPIRA	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A075885**	**001**	May 28, 2002
AP			**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A075885**	**002**	May 28, 2002
AP		WEST-WARD PHARMS INT	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A078113**	**001**	May 21, 2008
AP			**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A078113**	**002**	May 21, 2008

MILRINONE LACTATE IN PLASTIC CONTAINER

AP		HIKMA FARMACEUTICA	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A090038**	**001**	Jan 21, 2010
AP			**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A090038**	**002**	Jan 21, 2010

MILTEFOSINE

CAPSULE;ORAL

IMPAVIDO

+!	KNIGHT THERAPS	50MG	N204684	001	Mar 19, 2014

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL

DYNACIN

AB		CNTY LINE PHARMS	**EQ 50MG BASE**	**A063067**	**003**	Aug 14, 1990
AB			**EQ 75MG BASE**	**A063067**	**002**	Sep 15, 1999
AB			**EQ 100MG BASE**	**A063067**	**001**	Jul 31, 1990

MINOCIN

AB	+	PRECISION DERMAT	**EQ 50MG BASE**	**N050649**	**001**	May 31, 1990
AB	+		**EQ 100MG BASE**	**N050649**	**002**	May 31, 1990

MINOCYCLINE HYDROCHLORIDE

AB		AUROBINDO PHARMA	**EQ 50MG BASE**	**A065470**	**001**	Mar 11, 2008
AB			**EQ 75MG BASE**	**A065470**	**002**	Mar 11, 2008
AB			**EQ 100MG BASE**	**A065470**	**003**	Mar 11, 2008
AB		IMPAX LABS	**EQ 50MG BASE**	**A065005**	**001**	Mar 23, 1999
AB			**EQ 75MG BASE**	**A065005**	**003**	Apr 18, 2001
AB			**EQ 100MG BASE**	**A065005**	**002**	Mar 23, 1999
AB		SUN PHARM INDS INC	**EQ 50MG BASE**	**A090867**	**001**	May 13, 2013
AB			**EQ 75MG BASE**	**A090867**	**002**	May 13, 2013
AB			**EQ 100MG BASE**	**A090867**	**003**	May 13, 2013
AB		TORRENT PHARMA INC	**EQ 50MG BASE**	**A065062**	**001**	Nov 30, 2000
AB			**EQ 75MG BASE**	**A065062**	**002**	Nov 30, 2000
AB			**EQ 100MG BASE**	**A065062**	**003**	Nov 30, 2000
AB		WATSON LABS	**EQ 75MG BASE**	**A063065**	**002**	Jun 10, 1999
AB			**EQ 100MG BASE**	**A063065**	**001**	Dec 30, 1991
AB		WATSON LABS TEVA	**EQ 50MG BASE**	**A063181**	**001**	Dec 30, 1991
AB		ZYDUS WORLDWIDE	**EQ 50MG BASE**	**A063011**	**001**	Mar 02, 1992
AB			**EQ 75MG BASE**	**A063009**	**002**	Aug 12, 2003
AB	!		**EQ 100MG BASE**	**A063009**	**001**	Mar 02, 1992

CAPSULE, EXTENDED RELEASE;ORAL

XIMINO

	SUN PHARM INDS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012
		EQ 90MG BASE	N201922	003	Jul 11, 2012
		EQ 135MG BASE	N201922	005	Jul 11, 2012

INJECTABLE;INJECTION

MINOCIN

+!	REMPEX PHARMS	EQ 100MG BASE/VIAL	N050444	001	

MINOCYCLINE HYDROCHLORIDE

POWDER, EXTENDED RELEASE;DENTAL

ARESTIN

+!	ORAPHARMA	EQ 1MG BASE	N050781	001	Feb 16, 2001

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	DR REDDYS LABS LTD	**EQ 50MG BASE**	**A065436**	**001**	Dec 26, 2007
AB		**EQ 75MG BASE**	**A065436**	**002**	Dec 26, 2007
AB		**EQ 100MG BASE**	**A065436**	**003**	Dec 26, 2007
AB	PAR PHARM	**EQ 50MG BASE**	**A065131**	**001**	Apr 16, 2003
AB		**EQ 75MG BASE**	**A065131**	**002**	Apr 16, 2003
AB !		**EQ 100MG BASE**	**A065131**	**003**	Apr 16, 2003
AB	SUN PHARM INDUSTRIES	**EQ 50MG BASE**	**A090217**	**001**	Jan 29, 2016
AB		**EQ 75MG BASE**	**A090217**	**002**	Jan 29, 2016
AB		**EQ 100MG BASE**	**A090217**	**003**	Jan 29, 2016
AB	TORRENT PHARMA INC	**EQ 50MG BASE**	**A065156**	**001**	Jan 06, 2004
AB		**EQ 75MG BASE**	**A065156**	**002**	Jan 06, 2004
AB		**EQ 100MG BASE**	**A065156**	**003**	Jan 06, 2004

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	ALKEM LABS LTD	**EQ 45MG BASE**	**A204453**	**001**	Sep 28, 2016
AB		**EQ 65MG BASE**	**A204453**	**006**	Mar 16, 2018
AB		**EQ 80MG BASE**	**A204453**	**002**	Sep 28, 2016
AB		**EQ 90MG BASE**	**A204453**	**003**	Sep 28, 2016
AB		**EQ 105MG BASE**	**A204453**	**004**	Sep 28, 2016
AB		**EQ 115MG BASE**	**A204453**	**007**	Mar 16, 2018
AB		**EQ 135MG BASE**	**A204453**	**005**	Sep 28, 2016
AB	AUROBINDO PHARMA LTD	**EQ 45MG BASE**	**A202261**	**001**	Nov 19, 2012
AB		**EQ 65MG BASE**	**A202261**	**002**	Sep 28, 2018
AB		**EQ 80MG BASE**	**A202261**	**006**	Jun 13, 2016
AB		**EQ 90MG BASE**	**A202261**	**003**	Nov 19, 2012
AB		**EQ 105MG BASE**	**A202261**	**007**	Jun 13, 2016
AB		**EQ 115MG BASE**	**A202261**	**004**	Sep 28, 2018
AB		**EQ 135MG BASE**	**A202261**	**005**	Nov 19, 2012
AB	BARR LABS INC	**EQ 65MG BASE**	**A065485**	**004**	May 18, 2012
AB		**EQ 115MG BASE**	**A065485**	**005**	May 18, 2012
AB	LUPIN LTD	**EQ 45MG BASE**	**A091424**	**001**	Nov 30, 2011
AB		**EQ 55MG BASE**	**A091424**	**002**	Nov 30, 2011
AB		**EQ 90MG BASE**	**A091424**	**003**	Nov 30, 2011
AB		**EQ 135MG BASE**	**A091424**	**004**	Nov 30, 2011
AB	MYLAN PHARMS INC	**EQ 80MG BASE**	**A203443**	**002**	Aug 22, 2014
AB		**EQ 105MG BASE**	**A203443**	**003**	Aug 22, 2014
AB	SANDOZ	**EQ 45MG BASE**	**A090422**	**001**	Aug 13, 2009
AB		**EQ 90MG BASE**	**A090422**	**002**	Aug 13, 2009
AB !		**EQ 135MG BASE**	**A090422**	**003**	Aug 13, 2009
AB	SIDMAK LABS INDIA	**EQ 45MG BASE**	**A204394**	**001**	Dec 30, 2015
AB		**EQ 80MG BASE**	**A204394**	**004**	Dec 30, 2015
AB		**EQ 105MG BASE**	**A204394**	**005**	Dec 30, 2015
AB		**EQ 135MG BASE**	**A204394**	**007**	Dec 30, 2015
AB	SUN PHARM INDS LTD	**EQ 45MG BASE**	**A091118**	**001**	Sep 25, 2014
AB		**EQ 80MG BASE**	**A091118**	**004**	Sep 25, 2014
AB		**EQ 90MG BASE**	**A091118**	**005**	Sep 25, 2014
AB		**EQ 105MG BASE**	**A091118**	**006**	Sep 25, 2014
AB		**EQ 135MG BASE**	**A091118**	**008**	Sep 25, 2014
AB	ZYDUS PHARMS USA INC	**EQ 45MG BASE**	**A203553**	**001**	Nov 16, 2017
AB		**EQ 80MG BASE**	**A203553**	**004**	Nov 16, 2017
AB		**EQ 90MG BASE**	**A203553**	**005**	Nov 16, 2017
AB		**EQ 105MG BASE**	**A203553**	**006**	Nov 16, 2017
AB		**EQ 135MG BASE**	**A203553**	**008**	Nov 16, 2017

SOLODYN

AB +	MEDICIS	**EQ 55MG BASE**	**N050808**	**008**	Aug 27, 2010
AB +		**EQ 65MG BASE**	**N050808**	**004**	Jul 23, 2009
AB +		**EQ 80MG BASE**	**N050808**	**007**	Aug 27, 2010
AB +		**EQ 105MG BASE**	**N050808**	**006**	Aug 27, 2010
AB +!		**EQ 115MG BASE**	**N050808**	**005**	Jul 23, 2009

MINOLIRA

	EPI HLTH	EQ 105MG BASE	N209269	001	May 08, 2017
		EQ 135MG BASE	N209269	002	May 08, 2017

MINOXIDIL

TABLET;ORAL

MINOXIDIL

AB		PAR PHARM	**2.5MG**	**A071826**	**001**	Nov 14, 1988
AB			**10MG**	**A071839**	**001**	Nov 14, 1988
AB		SUN PHARM INDUSTRIES	**2.5MG**	**A072709**	**002**	Dec 14, 1995
AB			**10MG**	**A072709**	**001**	Dec 14, 1995
AB		WATSON LABS	**2.5MG**	**A071344**	**001**	Mar 03, 1987
AB	**!**		**10MG**	**A071345**	**001**	Mar 03, 1987

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

MYRBETRIQ

+!	APGDI	25MG	N202611	001	Jun 28, 2012
+!		50MG	N202611	002	Jun 28, 2012

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

AB		APOTEX INC	**15MG**	**A077666**	**001**	Aug 22, 2007
AB			**30MG**	**A077666**	**002**	Aug 22, 2007
AB			**45MG**	**A077666**	**003**	Aug 22, 2007
AB		AUROBINDO	**7.5MG**	**A076921**	**001**	Oct 22, 2004
AB			**15MG**	**A076921**	**002**	Oct 22, 2004
AB			**30MG**	**A076921**	**003**	Oct 22, 2004
AB			**45MG**	**A076921**	**004**	Oct 22, 2004
AB		MYLAN	**15MG**	**A076122**	**001**	Jun 19, 2003
AB			**30MG**	**A076122**	**002**	Jun 19, 2003
AB			**45MG**	**A076122**	**003**	Jun 19, 2003
AB		SUN PHARM INDS INC	**7.5MG**	**A076541**	**004**	Apr 22, 2004
AB			**15MG**	**A076541**	**001**	Apr 22, 2004
AB			**30MG**	**A076541**	**002**	Apr 22, 2004
AB			**45MG**	**A076541**	**003**	Apr 22, 2004
AB		TEVA	**15MG**	**A076119**	**001**	Jan 24, 2003
AB			**30MG**	**A076119**	**002**	Jan 24, 2003
AB			**45MG**	**A076119**	**003**	Jun 19, 2003
AB		UPSHER SMITH LABS	**15MG**	**A076219**	**001**	Jun 19, 2003
AB			**30MG**	**A076219**	**002**	Jun 19, 2003
AB			**45MG**	**A076219**	**003**	Jun 19, 2003
AB		WATSON LABS	**15MG**	**A076312**	**001**	Jun 19, 2003
AB			**30MG**	**A076312**	**002**	Jun 19, 2003
AB			**45MG**	**A076312**	**003**	Jun 19, 2003

REMERON

AB	**+!**	ORGANON USA INC	**15MG**	**N020415**	**001**	Jun 14, 1996
AB	**+**		**30MG**	**N020415**	**002**	Jun 14, 1996

TABLET, ORALLY DISINTEGRATING;ORAL

MIRTAZAPINE

AB		AUROBINDO PHARMA LTD	**15MG**	**A077376**	**002**	Dec 08, 2005
AB			**30MG**	**A077376**	**003**	Dec 08, 2005
AB			**45MG**	**A077376**	**004**	Feb 28, 2006
AB		IMPAX LABS INC	**15MG**	**A076901**	**001**	Jun 28, 2005
AB			**30MG**	**A076901**	**002**	Jun 28, 2005
AB			**45MG**	**A076901**	**003**	Jun 28, 2005
AB		ZYDUS PHARMS USA INC	**15MG**	**A205798**	**001**	Jun 01, 2017
AB			**30MG**	**A205798**	**002**	Jun 01, 2017
AB			**45MG**	**A205798**	**003**	Jun 01, 2017

REMERON SOLTAB

AB	**+!**	ORGANON USA INC	**15MG**	**N021208**	**001**	Jan 12, 2001
AB	**+**		**30MG**	**N021208**	**002**	Jan 12, 2001
AB	**+**		**45MG**	**N021208**	**003**	Jan 12, 2001

MISOPROSTOL

TABLET;ORAL

CYTOTEC

AB	**+**	GD SEARLE LLC	**0.1MG**	**N019268**	**003**	Sep 21, 1990
AB	**+!**		**0.2MG**	**N019268**	**001**	Dec 27, 1988

MISOPROSTOL

AB		IVAX SUB TEVA PHARMS	**0.1MG**	**A076095**	**001**	Jul 10, 2002
AB			**0.2MG**	**A076095**	**002**	Jul 10, 2002
AB		NOVEL LABS INC	**0.1MG**	**A091667**	**001**	Jul 25, 2012
AB			**0.2MG**	**A091667**	**002**	Jul 25, 2012

MITOMYCIN

FOR SOLUTION;TOPICAL

MITOSOL

+!	MOBIUS THERAP	0.2MG/VIAL	N022572	001	Feb 07, 2012

INJECTABLE;INJECTION

MITOMYCIN

AP	**!**	ACCORD HLTHCARE	**5MG/VIAL**	**A064144**	**001**	Apr 30, 1998
AP	**!**		**20MG/VIAL**	**A064144**	**002**	Apr 30, 1998
AP	**!**		**40MG/VIAL**	**A064144**	**003**	Aug 11, 2009
AP		MYLAN LABS LTD	**5MG/VIAL**	**A202670**	**001**	Oct 13, 2017
AP			**20MG/VIAL**	**A202670**	**002**	Oct 13, 2017
AP			**40MG/VIAL**	**A203386**	**001**	Oct 13, 2017
AP		WEST-WARD PHARMS INT	**5MG/VIAL**	**A064180**	**001**	Dec 23, 1999
AP			**20MG/VIAL**	**A064180**	**002**	Dec 23, 1999

MITOTANE

TABLET;ORAL

LYSODREN

+!	LABORATOIRE HRA	500MG	N016885	001	

MITOXANTRONE HYDROCHLORIDE

INJECTABLE;INJECTION

MITOXANTRONE HYDROCHLORIDE

AP		FRESENIUS KABI USA	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A077496**	**001**	Apr 11, 2006
AP			**EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)**	**A077496**	**002**	Apr 11, 2006
AP			**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A077496**	**003**	Apr 11, 2006
AP	**!**	HOSPIRA	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A076871**	**001**	Apr 11, 2006
AP	**!**		**EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)**	**A076871**	**002**	Apr 11, 2006
AP	**!**		**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A076871**	**003**	Apr 11, 2006
AP		MYLAN INSTITUTIONAL	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A078980**	**001**	Apr 13, 2009
AP			**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A078980**	**002**	Apr 13, 2009
AP		MYLAN LABS LTD	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A201014**	**001**	Dec 11, 2012
AP		TEVA PHARMS USA	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A077356**	**001**	Apr 11, 2006
AP			**EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)**	**A077356**	**002**	Apr 11, 2006
AP			**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A077356**	**003**	Apr 11, 2006
AP		WEST-WARD PHARMS INT	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A076611**	**001**	Apr 11, 2006
AP			**EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)**	**A076611**	**002**	Apr 11, 2006
AP			**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A076611**	**003**	Apr 11, 2006

MODAFINIL

TABLET;ORAL

MODAFINIL

AB		ALEMBIC PHARMS LTD	**100MG**	**A202700**	**001**	Oct 18, 2012
AB			**200MG**	**A202700**	**002**	Oct 18, 2012
AB		APOTEX INC	**100MG**	**A077667**	**001**	Feb 03, 2014
AB			**200MG**	**A077667**	**002**	Feb 03, 2014
AB		AUROBINDO PHARMA LTD	**100MG**	**A202566**	**001**	Sep 27, 2012
AB			**200MG**	**A202566**	**002**	Sep 27, 2012
AB		HERITAGE PHARMS INC	**100MG**	**A207196**	**001**	Aug 16, 2017
AB			**200MG**	**A207196**	**002**	Aug 16, 2017
AB		HIKMA PHARMS	**100MG**	**A090543**	**001**	Sep 26, 2012
AB			**200MG**	**A090543**	**002**	Sep 26, 2012
AB		MYLAN PHARMS INC	**100MG**	**A076594**	**001**	Jul 16, 2012
AB			**200MG**	**A076594**	**002**	Jul 16, 2012
AB		ORCHID HLTHCARE	**100MG**	**A078963**	**001**	Sep 26, 2012
AB			**200MG**	**A078963**	**002**	Sep 26, 2012
AB		WATSON LABS INC	**100MG**	**A076715**	**001**	Nov 01, 2012
AB			**200MG**	**A076715**	**002**	Nov 01, 2012
AB		ZYDUS PHARMS USA INC	**100MG**	**A209966**	**001**	Sep 14, 2017
AB			**200MG**	**A209966**	**002**	Sep 14, 2017

PROVIGIL

AB	**+**	CEPHALON	**100MG**	**N020717**	**001**	Dec 24, 1998
AB	**+!**		**200MG**	**N020717**	**002**	Dec 24, 1998

MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE

AB		APOTEX INC	**7.5MG**	**A078454**	**001**	Jun 02, 2008
AB			**15MG**	**A078454**	**002**	Jun 02, 2008
AB		CHARTWELL RX	**7.5MG**	**A077536**	**001**	Nov 30, 2006
AB			**15MG**	**A077536**	**002**	Nov 30, 2006

MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE

AB		GLENMARK GENERICS	**7.5MG**	**A090416**	**001**	Mar 30, 2010
AB			**15MG**	**A090416**	**002**	Mar 30, 2010
AB		TEVA	**7.5MG**	**A076204**	**001**	May 08, 2003
AB	**!**		**15MG**	**A076204**	**002**	May 08, 2003

MOLINDONE HYDROCHLORIDE

TABLET;ORAL

MOLINDONE HYDROCHLORIDE

		EPIC PHARMA LLC	5MG	A090453	001	Mar 20, 2015
			10MG	A090453	002	Mar 20, 2015
	!		25MG	A090453	003	Mar 20, 2015

MOMETASONE FUROATE

AEROSOL, METERED;INHALATION

ASMANEX HFA

	+	MERCK SHARP DOHME	0.10MG/INH	N205641	001	Apr 25, 2014
	+!		0.20MG/INH	N205641	002	Apr 25, 2014

CREAM;TOPICAL

ELOCON

AB	**+!**	MERCK SHARP DOHME	**0.1%**	**N019625**	**002**	Apr 19, 2013

MOMETASONE FUROATE

AB		ANDA REPOSITORY	**0.1%**	**A076591**	**001**	Apr 18, 2007
AB		FOUGERA PHARMS	**0.1%**	**A076171**	**001**	Apr 08, 2005
AB		G AND W LABS	**0.1%**	**A077447**	**001**	May 22, 2006
AB		GLENMARK GENERICS	**0.1%**	**A078541**	**001**	May 28, 2008
AB		TARO	**0.1%**	**A076679**	**001**	Dec 21, 2004

IMPLANT;IMPLANTATION

SINUVA

	+	INTERSECT ENT INC	1.35MG	N209310	001	Dec 08, 2017

LOTION;TOPICAL

ELOCON

AB	**+!**	MERCK SHARP DOHME	**0.1%**	**N019796**	**001**	Mar 30, 1989

MOMETASONE FUROATE

AB		ANDA REPOSITORY	**0.1%**	**A076499**	**001**	Nov 21, 2007
AB		FOUGERA PHARMS	**0.1%**	**A075919**	**001**	Nov 29, 2007
AB		G AND W LABS	**0.1%**	**A077678**	**001**	Nov 21, 2007
AB		GLENMARK GENERICS	**0.1%**	**A090506**	**001**	Aug 09, 2010
AB		PERRIGO ISRAEL	**0.1%**	**A077180**	**001**	Apr 06, 2005
AB		TARO	**0.1%**	**A076788**	**001**	Mar 15, 2006

OINTMENT;TOPICAL

ELOCON

AB	**+!**	MERCK SHARP DOHME	**0.1%**	**N019543**	**001**	Apr 30, 1987

MOMETASONE FUROATE

AB		ANDA REPOSITORY	**0.1%**	**A076481**	**001**	Nov 14, 2003
AB		FOUGERA PHARMS	**0.1%**	**A077061**	**001**	Mar 28, 2005
AB		G AND W LABS	**0.1%**	**A077401**	**001**	Jun 20, 2006
AB		GLENMARK GENERICS	**0.1%**	**A078571**	**001**	May 28, 2008
AB		PERRIGO NEW YORK	**0.1%**	**A076067**	**001**	Mar 18, 2002
AB		TORRENT PHARMS LTD	**0.1%**	**A207899**	**001**	Jul 13, 2018

POWDER;INHALATION

ASMANEX TWISTHALER

	+	MERCK SHARP DOHME	0.11MG/INH	N021067	002	Feb 01, 2008
	+!		0.22MG/INH	N021067	001	Mar 30, 2005

SPRAY, METERED;NASAL

MOMETASONE FUROATE

AB		AMNEAL PHARMS	**EQ 0.05MG BASE/SPRAY**	**A207989**	**001**	Apr 03, 2017
AB		APOTEX INC	**EQ 0.05MG BASE/SPRAY**	**A091161**	**001**	Mar 22, 2016

NASONEX

AB	**+!**	MERCK SHARP DOHME	**EQ 0.05MG BASE/SPRAY**	**N020762**	**001**	Oct 01, 1997

MONTELUKAST SODIUM

GRANULE;ORAL

MONTELUKAST SODIUM

AB		AJANTA PHARMA LTD	**EQ 4MG BASE/PACKET**	**A203438**	**001**	Jul 31, 2015
AB		DR REDDYS LABS LTD	**EQ 4MG BASE/PACKET**	**A202906**	**001**	Sep 17, 2012
AB		MYLAN PHARMS INC	**EQ 4MG BASE/PACKET**	**A202776**	**001**	Dec 18, 2012
AB		TEVA PHARMS	**EQ 4MG BASE/PACKET**	**A090955**	**001**	Aug 03, 2012
AB		TORRENT PHARMS LLC	**EQ 4MG BASE/PACKET**	**A210431**	**001**	Jul 31, 2018

SINGULAIR

AB	**+!**	MERCK	**EQ 4MG BASE/PACKET**	**N021409**	**001**	Jul 26, 2002

MONTELUKAST SODIUM

TABLET;ORAL

MONTELUKAST SODIUM

AB		ACCORD HLTHCARE	**EQ 10MG BASE**	**A202717**	**001**	Sep 21, 2012
AB		AJANTA PHARMA LTD	**EQ 10MG BASE**	**A203432**	**001**	Jul 31, 2015
AB		AMNEAL PHARMS	**EQ 10MG BASE**	**A204604**	**001**	Sep 04, 2015
AB		ANBISON LAB	**EQ 10MG BASE**	**A205683**	**001**	Jan 12, 2016
AB		AUROBINDO PHARMA LTD	**EQ 10MG BASE**	**A202468**	**001**	Aug 03, 2012
AB		CIPLA	**EQ 10MG BASE**	**A207463**	**001**	Oct 28, 2016
AB		CSPC OUYI PHARM CO	**EQ 10MG BASE**	**A209012**	**001**	Apr 24, 2017
AB		DR REDDYS LABS LTD	**EQ 10MG BASE**	**A201582**	**001**	Aug 06, 2012
AB		GLENMARK GENERICS	**EQ 10MG BASE**	**A090926**	**001**	Aug 03, 2012
AB		HETERO LABS LTD V	**EQ 10MG BASE**	**A202843**	**001**	Sep 10, 2014
AB		LANNETT CO INC	**EQ 10MG BASE**	**A201522**	**001**	Aug 03, 2012
AB		MACLEODS PHARMS LTD	**EQ 10MG BASE**	**A203366**	**001**	Sep 11, 2014
AB		MYLAN PHARMS INC	**EQ 10MG BASE**	**A079103**	**001**	Aug 03, 2012
AB		PERRIGO R AND D	**EQ 10MG BASE**	**A206112**	**001**	Apr 26, 2017
AB		SANDOZ INC	**EQ 10MG BASE**	**A200889**	**001**	Aug 03, 2012
AB		TEVA PHARMS	**EQ 10MG BASE**	**A078605**	**001**	Aug 03, 2012
AB		TORRENT PHARMS LTD	**EQ 10MG BASE**	**A201515**	**001**	Aug 03, 2012
AB		UNICHEM LABS LTD	**EQ 10MG BASE**	**A204290**	**001**	Oct 08, 2015
AB		UNIMARK REMEDIES LTD	**EQ 10MG BASE**	**A202859**	**001**	Oct 30, 2014
AB		VINTAGE PHARMS LLC	**EQ 10MG BASE**	**A091576**	**001**	Aug 03, 2012
AB		WEST-WARD PHARMS INT	**EQ 10MG BASE**	**A090655**	**001**	Aug 03, 2012

SINGULAIR

AB	**+!**	MSD MERCK CO	**EQ 10MG BASE**	**N020829**	**002**	Feb 20, 1998

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

AB		AJANTA PHARMA LTD	**EQ 4MG BASE**	**A203328**	**001**	Jul 31, 2015
AB			**EQ 5MG BASE**	**A203328**	**002**	Jul 31, 2015
AB		ANBISON LAB	**EQ 4MG BASE**	**A205695**	**001**	Nov 05, 2015
AB			**EQ 5MG BASE**	**A205695**	**002**	Nov 05, 2015
AB		AUROBINDO PHARMA LTD	**EQ 4MG BASE**	**A202096**	**001**	Aug 03, 2012
AB			**EQ 5MG BASE**	**A202096**	**002**	Aug 03, 2012
AB		CIPLA	**EQ 4MG BASE**	**A207464**	**001**	Dec 06, 2018
AB			**EQ 5MG BASE**	**A207464**	**002**	Dec 06, 2018
AB		CSPC OUYI PHARM CO	**EQ 4MG BASE**	**A209011**	**001**	Apr 18, 2017
AB			**EQ 5MG BASE**	**A209011**	**002**	Apr 18, 2017
AB		DR REDDYS LABS LTD	**EQ 4MG BASE**	**A201581**	**001**	Aug 06, 2012
AB			**EQ 5MG BASE**	**A201581**	**002**	Aug 06, 2012
AB		HETERO LABS LTD V	**EQ 4MG BASE**	**A204093**	**001**	May 22, 2015
AB			**EQ 5MG BASE**	**A204093**	**002**	May 22, 2015
AB		JUBILANT GENERICS	**EQ 4MG BASE**	**A203795**	**001**	Feb 27, 2015
AB			**EQ 5MG BASE**	**A203795**	**002**	Feb 27, 2015
AB		LANNETT CO INC	**EQ 4MG BASE**	**A200405**	**001**	Aug 03, 2012
AB			**EQ 5MG BASE**	**A200405**	**002**	Aug 03, 2012
AB		MACLEODS PHARMS LTD	**EQ 4MG BASE**	**A203582**	**001**	Mar 12, 2015
AB			**EQ 5MG BASE**	**A203582**	**002**	Mar 12, 2015
AB		MYLAN PHARMS INC	**EQ 4MG BASE**	**A079142**	**001**	Aug 03, 2012
AB			**EQ 5MG BASE**	**A079142**	**002**	Aug 03, 2012
AB		SANDOZ INC	**EQ 4MG BASE**	**A091414**	**001**	Aug 03, 2012
AB			**EQ 5MG BASE**	**A091414**	**002**	Aug 03, 2012
AB		TEVA PHARMS	**EQ 4MG BASE**	**A078723**	**001**	Aug 03, 2012
AB			**EQ 5MG BASE**	**A078723**	**002**	Aug 03, 2012
AB		TORRENT PHARMS LTD	**EQ 4MG BASE**	**A090984**	**001**	Aug 03, 2012
AB			**EQ 5MG BASE**	**A090984**	**002**	Aug 03, 2012
AB		UNICHEM LABS LTD	**EQ 4MG BASE**	**A208621**	**001**	Jul 02, 2018
AB			**EQ 5MG BASE**	**A208621**	**002**	Jul 02, 2018
AB		UNIMARK REMEDIES LTD	**EQ 4MG BASE**	**A203037**	**001**	Oct 30, 2014
AB			**EQ 5MG BASE**	**A203037**	**002**	Oct 30, 2014
AB		VINTAGE PHARMS LLC	**EQ 4MG BASE**	**A091588**	**001**	Aug 03, 2012
AB			**EQ 5MG BASE**	**A091588**	**002**	Aug 03, 2012
AB		WEST-WARD PHARMS INT	**EQ 4MG BASE**	**A091128**	**001**	Aug 03, 2012
AB			**EQ 5MG BASE**	**A091128**	**002**	Aug 03, 2012

SINGULAIR

AB	**+**	MSD MERCK CO	**EQ 4MG BASE**	**N020830**	**002**	Mar 03, 2000
AB	**+!**		**EQ 5MG BASE**	**N020830**	**001**	Feb 20, 1998

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

KADIAN							
AB	**+!**	ALLERGAN SALES LLC	**10MG**	**N020616**	**008**	Apr 20, 2007
AB	**+**		**20MG**	**N020616**	**001**	Jul 03, 1996
AB	**+**		**30MG**	**N020616**	**004**	Mar 09, 2001
AB	**+**		**40MG**	**N020616**	**009**	Jul 09, 2012
AB	**+**		**50MG**	**N020616**	**002**	Jul 03, 1996
AB	**+**		**60MG**	**N020616**	**005**	Mar 09, 2001
AB	**+**		**70MG**	**N020616**	**010**	Jul 09, 2012
AB	**+**		**80MG**	**N020616**	**006**	Oct 27, 2006
AB	**+!**		**100MG**	**N020616**	**003**	Jul 03, 1996
MORPHINE SULFATE							
AB		IMPAX LABS INC	**20MG**	**A200411**	**001**	Apr 12, 2016
AB			**30MG**	**A200411**	**002**	Apr 12, 2016
AB			**50MG**	**A200411**	**003**	Apr 12, 2016
AB			**60MG**	**A200411**	**004**	Apr 12, 2016
AB			**80MG**	**A200411**	**005**	Apr 12, 2016
AB			**100MG**	**A200411**	**006**	Apr 12, 2016
AB		PAR PHARM INC	**20MG**	**A200812**	**001**	Nov 10, 2011
AB			**30MG**	**A200812**	**002**	Nov 10, 2011
AB			**50MG**	**A200812**	**003**	Nov 10, 2011
AB			**60MG**	**A200812**	**004**	Nov 10, 2011
AB			**80MG**	**A200812**	**005**	Nov 10, 2011
AB			**100MG**	**A200812**	**006**	Nov 10, 2011
AB		TEVA PHARMS USA	**20MG**	**A202718**	**001**	Dec 29, 2014
AB			**30MG**	**A202718**	**002**	Dec 29, 2014
AB			**40MG**	**A202718**	**007**	Jun 03, 2015
AB			**50MG**	**A202718**	**003**	Dec 29, 2014
AB			**60MG**	**A202718**	**004**	Dec 29, 2014
AB			**70MG**	**A202718**	**008**	Jun 03, 2015
AB			**80MG**	**A202718**	**005**	Dec 29, 2014
AB			**100MG**	**A202718**	**006**	Dec 29, 2014
AB		UPSHER SMITH LABS	**10MG**	**A202104**	**001**	Jun 03, 2013
AB			**20MG**	**A202104**	**002**	Jun 03, 2013
AB			**30MG**	**A202104**	**003**	Jun 03, 2013
AB			**50MG**	**A202104**	**004**	Jun 03, 2013
AB			**60MG**	**A202104**	**005**	Jun 03, 2013
AB			**80MG**	**A202104**	**006**	Jun 03, 2013
AB			**100MG**	**A202104**	**007**	Jun 03, 2013
KADIAN							
	+	ALLERGAN SALES LLC	130MG	N020616	011	Jul 09, 2012
	+		150MG	N020616	012	Jul 09, 2012
	+!		200MG	N020616	007	Feb 27, 2007
MORPHINE SULFATE							
		ACTAVIS ELIZABETH	30MG	A079040	001	Jan 16, 2013
			45MG	A079040	002	Jan 16, 2013
			60MG	A079040	003	Jan 16, 2013
			75MG	A079040	004	Jan 16, 2013
			90MG	A079040	005	Jan 16, 2013
	!		120MG	A079040	006	Jan 16, 2013

INJECTABLE;INJECTION

ASTRAMORPH PF							
AP		FRESENIUS KABI USA	**0.5MG/ML**	**A071050**	**001**	Oct 07, 1986
AP			**0.5MG/ML**	**A071051**	**001**	Oct 07, 1986
AP			**1MG/ML**	**A071052**	**001**	Oct 07, 1986
AP			**1MG/ML**	**A071053**	**001**	Oct 07, 1986
DURAMORPH PF							
AP	**+!**	WEST-WARD PHARMS INT	**0.5MG/ML**	**N018565**	**001**	Sep 18, 1984
AP	**+!**		**1MG/ML**	**N018565**	**002**	Sep 18, 1984
INFUMORPH							
AP	**+!**	WEST-WARD PHARMS INT	**10MG/ML**	**N018565**	**003**	Jul 19, 1991
AP	**+!**		**25MG/ML**	**N018565**	**004**	Jul 19, 1991
MITIGO							
AP		PIRAMAL CRITICAL	**10MG/ML**	**A204393**	**001**	Jul 16, 2018
AP			**25MG/ML**	**A204393**	**002**	Jul 16, 2018
MORPHINE SULFATE							
AP		EUROHLTH INTL SARL	**4MG/ML**	**A205758**	**001**	May 21, 2015
AP			**8MG/ML**	**A205758**	**002**	May 21, 2015
AP			**10MG/ML**	**A205758**	**003**	May 21, 2015
AP		HOSPIRA	**0.5MG/ML**	**A071849**	**001**	May 11, 1988

MORPHINE SULFATE

INJECTABLE;INJECTION						
MORPHINE SULFATE						
AP			**0.5MG/ML**	**A073509**	**001**	Sep 30, 1992
AP			**1MG/ML**	**A071850**	**001**	May 11, 1988
AP			**1MG/ML**	**A073510**	**001**	Sep 30, 1992
AP	**+!**	HOSPIRA INC	**4MG/ML**	**N202515**	**002**	Nov 14, 2011
AP	**+!**		**8MG/ML**	**N202515**	**003**	Nov 14, 2011
AP	**+!**		**10MG/ML**	**N202515**	**004**	Nov 14, 2011
AP	**+!**	ICU MEDICAL INC	**1MG/ML**	**N019916**	**001**	Oct 30, 1992
	+!	HOSPIRA INC	2MG/ML	N202515	001	Nov 14, 2011
	+!	ICU MEDICAL INC	5MG/ML	N019916	002	Oct 27, 2006
	+!	MERIDIAN MEDCL TECHN	15MG/ML	N019999	001	Jul 12, 1990
SOLUTION;INTRAMUSCULAR, INTRAVENOUS						
MORPHINE SULFATE						
	+!	FRESENIUS KABI USA	2MG/ML (2MG/ML)	N204223	001	Oct 30, 2013
	+!		4MG/ML (4MG/ML)	N204223	002	Oct 30, 2013
	+!		5MG/ML (5MG/ML)	N204223	003	Oct 30, 2013
	+!		8MG/ML (8MG/ML)	N204223	004	Oct 30, 2013
	+!		10MG/ML (10MG/ML)	N204223	005	Oct 30, 2013
SOLUTION;ORAL						
MORPHINE SULFATE						
AA		ANI PHARMS INC	**10MG/5ML**	**A205509**	**001**	Apr 17, 2018
AA			**20MG/5ML**	**A205509**	**002**	Apr 17, 2018
AA			**100MG/5ML**	**A205509**	**003**	Apr 17, 2018
AA		HI-TECH PHARMACAL	**100MG/5ML**	**A208809**	**001**	Jul 06, 2017
AA		LANNETT CO INC	**10MG/5ML**	**A202309**	**001**	Nov 25, 2015
AA			**20MG/5ML**	**A202310**	**001**	Oct 30, 2015
AA		NOSTRUM LABS INC	**10MG/5ML**	**A201011**	**001**	Feb 05, 2014
AA			**20MG/5ML**	**A201011**	**002**	Feb 05, 2014
AA			**100MG/5ML**	**A201011**	**003**	Oct 06, 2016
AA		PADDOCK LLC	**100MG/5ML**	**A201574**	**001**	Aug 06, 2012
AA		PHARM ASSOC	**100MG/5ML**	**A206573**	**001**	Nov 14, 2016
AA		RHODES PHARMS	**10MG/5ML**	**A206308**	**001**	Jun 22, 2017
AA			**20MG/5ML**	**A206420**	**001**	Jul 12, 2016
AA			**100MG/5ML**	**A206308**	**002**	Jun 22, 2017
AA		SPECGX LLC	**100MG/5ML**	**A202348**	**001**	Jul 15, 2011
AA		TRIS PHARMA INC	**10MG/5ML**	**A203518**	**001**	May 12, 2015
AA			**20MG/5ML**	**A203519**	**001**	May 18, 2016
AA			**100MG/5ML**	**A203518**	**002**	May 12, 2015
AA		VISTAPHARM	**10MG/5ML**	**A201947**	**001**	Jan 05, 2012
AA			**20MG/5ML**	**A201947**	**002**	Jan 05, 2012
AA	**+**	WEST-WARD PHARMS INT	**10MG/5ML**	**N022195**	**001**	Mar 17, 2008
AA	**+**		**20MG/5ML**	**N022195**	**002**	Mar 17, 2008
AA	**+!**		**100MG/5ML**	**N022195**	**003**	Jan 25, 2010
		LANNETT CO INC	100MG/5ML	N201517	001	Jun 23, 2011
TABLET;ORAL						
MORPHINE SULFATE						
	+	WEST-WARD PHARMS INT	15MG	N022207	001	Mar 17, 2008
	+!		30MG	N022207	002	Mar 17, 2008
TABLET, EXTENDED RELEASE;ORAL						
MORPHINE SULFATE						
AB		ACTAVIS ELIZABETH	**15MG**	**A203849**	**001**	Apr 06, 2015
AB			**30MG**	**A203849**	**002**	Apr 06, 2015
AB			**60MG**	**A203849**	**003**	Apr 06, 2015
AB			**100MG**	**A203849**	**004**	Apr 06, 2015
AB			**200MG**	**A203849**	**005**	Apr 06, 2015
AB		DAVA PHARMS INC	**15MG**	**A075407**	**001**	Jan 28, 2000
AB		MAYNE PHARMA INC	**15MG**	**A205386**	**001**	Oct 28, 2016
AB			**30MG**	**A205386**	**002**	Oct 28, 2016
AB			**60MG**	**A205386**	**003**	Oct 28, 2016
AB			**100MG**	**A205386**	**004**	Oct 28, 2016
AB		MYLAN PHARMS INC	**15MG**	**A200824**	**001**	Oct 18, 2011
AB			**30MG**	**A200824**	**002**	Oct 18, 2011
AB			**60MG**	**A200824**	**003**	Oct 18, 2011
AB			**100MG**	**A200824**	**004**	Oct 18, 2011
AB			**200MG**	**A200824**	**005**	Oct 18, 2011
AB		NESHER PHARMS	**15MG**	**A076733**	**001**	May 19, 2004
AB			**30MG**	**A076720**	**002**	Dec 23, 2005
AB			**60MG**	**A076720**	**001**	May 19, 2004

MORPHINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

AB			**100MG**	**A077855**	**001**	Sep 27, 2007
AB			**200MG**	**A077855**	**002**	Sep 27, 2007
AB		NOVEL LABS INC	**15MG**	**A203602**	**001**	Dec 16, 2015
AB			**30MG**	**A203602**	**002**	Dec 16, 2015
AB			**60MG**	**A203602**	**003**	Dec 16, 2015
AB			**100MG**	**A203602**	**004**	Dec 16, 2015
AB			**200MG**	**A203602**	**005**	Dec 16, 2015
AB		RHODES PHARMS	**15MG**	**A074862**	**001**	Jul 07, 1998
AB			**30MG**	**A074862**	**002**	Jul 07, 1998
AB			**60MG**	**A074862**	**003**	Jul 07, 1998
AB			**100MG**	**A074769**	**001**	Jul 02, 1998
AB			**200MG**	**A074769**	**002**	Jul 02, 1998
AB		SPECGX LLC	**15MG**	**A076412**	**001**	Jul 31, 2003
AB			**30MG**	**A076412**	**002**	Jul 31, 2003
AB			**60MG**	**A076412**	**003**	Jul 31, 2003
AB			**100MG**	**A076438**	**001**	Jul 03, 2003
AB			**200MG**	**A076438**	**002**	Jul 03, 2003
AB		SUN PHARM INDS LTD	**15MG**	**A078761**	**001**	May 11, 2012
AB			**30MG**	**A078761**	**002**	May 11, 2012
AB			**60MG**	**A078761**	**003**	May 11, 2012
AB			**100MG**	**A078761**	**004**	May 11, 2012
AB			**200MG**	**A078761**	**005**	May 11, 2012
AB		SUN PHARM INDUSTRIES	**15MG**	**A205634**	**001**	Aug 25, 2016
AB			**30MG**	**A205634**	**002**	Aug 25, 2016
AB			**60MG**	**A205634**	**003**	Aug 25, 2016
AB			**100MG**	**A205634**	**004**	Aug 25, 2016
AB			**200MG**	**A205634**	**005**	Aug 25, 2016
AB		VINTAGE PHARMS LLC	**15MG**	**A075295**	**001**	Oct 28, 1998
AB			**30MG**	**A075295**	**002**	Oct 28, 1998
AB			**60MG**	**A075295**	**003**	Oct 28, 1998
AB			**100MG**	**A075295**	**004**	Sep 15, 2000
AB			**200MG**	**A075295**	**005**	Sep 15, 2000

MS CONTIN

AB	**+**	PURDUE PHARMA LP	**15MG**	**N019516**	**003**	Sep 12, 1989
AB	**+**		**30MG**	**N019516**	**001**	May 29, 1987
AB	**+**		**60MG**	**N019516**	**002**	Apr 08, 1988
AB	**+!**		**100MG**	**N019516**	**004**	Jan 16, 1990
AB	**+**		**200MG**	**N019516**	**005**	Nov 08, 1993

MORPHABOND ER

	+	DAIICHI SANKYO INC	15MG	N206544	001	Oct 02, 2015
	+		30MG	N206544	002	Oct 02, 2015
	+		60MG	N206544	003	Oct 02, 2015
	+!		100MG	N206544	004	Oct 02, 2015

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

EMBEDA

	+	ALPHARMA PHARMS	20MG;0.8MG	N022321	001	Aug 13, 2009
	+		30MG;1.2MG	N022321	002	Aug 13, 2009
	+		50MG;2MG	N022321	003	Aug 13, 2009
	+!		60MG;2.4MG	N022321	004	Aug 13, 2009
	+		80MG;3.2MG	N022321	005	Aug 13, 2009
	+		100MG;4MG	N022321	006	Aug 13, 2009

MOXIDECTIN

TABLET;ORAL

MOXIDECTIN

	+!	MDGH	2MG	N210867	001	Jun 13, 2018

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;INTRAVENOUS

MOXIFLOXACIN HYDROCHLORIDE

	+!	FRESENIUS KABI USA	EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)	N205572	001	Apr 03, 2015

MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

	!	MYLAN LABS LTD	400MG/250ML (1.6MG/ML)	A205833	001	May 05, 2017

SOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

AT1		AKORN	**EQ 0.5% BASE**	**A202916**	**001**	Nov 09, 2017
AT1		APOTEX INC	**EQ 0.5% BASE**	**A090080**	**001**	Jun 30, 2017
AT1		AUROBINDO PHARMA	**EQ 0.5% BASE**	**A206242**	**001**	Oct 04, 2017

MOXIFLOXACIN HYDROCHLORIDE						
SOLUTION/DROPS;OPHTHALMIC						
MOXIFLOXACIN HYDROCHLORIDE						
		LTD				
AT1		LUPIN LTD	**EQ 0.5% BASE**	**A202867**	**001**	Sep 04, 2014
AT1		WATSON LABS INC	**EQ 0.5% BASE**	**A202525**	**001**	Mar 06, 2015
VIGAMOX						
AT1	**+!**	NOVARTIS PHARMS CORP	**EQ 0.5% BASE**	**N021598**	**001**	Apr 15, 2003
MOXEZA						
AT2	**+!**	NOVARTIS PHARMS CORP	**EQ 0.5% BASE**	**N022428**	**001**	Nov 19, 2010
MOXIFLOXACIN HYDROCHLORIDE						
AT2		LUPIN LTD	**EQ 0.5% BASE**	**A204079**	**001**	May 28, 2015
TABLET;ORAL						
AVELOX						
AB	**+!**	BAYER HLTHCARE	**EQ 400MG BASE**	**N021085**	**001**	Dec 10, 1999
MOXIFLOXACIN HYDROCHLORIDE						
AB		AUROBINDO PHARMA LTD	**EQ 400MG BASE**	**A202632**	**001**	Mar 04, 2014
AB		CROSSMEDIKA SA	**EQ 400MG BASE**	**A205348**	**001**	Jan 14, 2016
AB		DR REDDYS LABS LTD	**EQ 400MG BASE**	**A076938**	**001**	Mar 04, 2014
AB		MSN LABS PVT LTD	**EQ 400MG BASE**	**A208682**	**001**	Sep 22, 2017
AB		MYLAN PHARMS INC	**EQ 400MG BASE**	**A204635**	**001**	Aug 31, 2015
AB		NOVEL LABS INC	**EQ 400MG BASE**	**A207285**	**001**	Feb 13, 2017
AB		SUNSHINE LAKE	**EQ 400MG BASE**	**A206295**	**001**	Sep 28, 2018
AB		TEVA PHARMS USA	**EQ 400MG BASE**	**A077437**	**001**	Feb 18, 2014
AB		TORRENT PHARMS LTD	**EQ 400MG BASE**	**A200160**	**001**	Apr 03, 2014
MUPIROCIN						
OINTMENT;TOPICAL						
MUPIROCIN						
AB		FOUGERA PHARMS	**2%**	**A065192**	**001**	Nov 30, 2005
AB		GLENMARK PHARMS	**2%**	**A090480**	**001**	Jun 08, 2011
AB	**!**	PERRIGO NEW YORK	**2%**	**A065123**	**001**	Nov 07, 2003
AB		TARO	**2%**	**A065170**	**001**	Sep 23, 2005
AB		TEVA	**2%**	**A065085**	**001**	Nov 07, 2003
CENTANY						
BX		PERRIGO NEW YORK	2%	N050788	001	Dec 04, 2002
MUPIROCIN CALCIUM						
CREAM;TOPICAL						
MUPIROCIN						
	!	GLENMARK PHARMS INC	EQ 2% BASE	A201587	001	Jan 24, 2013
MYCOPHENOLATE MOFETIL						
CAPSULE;ORAL						
CELLCEPT						
AB	**+!**	ROCHE PALO	**250MG**	**N050722**	**001**	May 03, 1995
MYCOPHENOLATE MOFETIL						
AB		ACCORD HLTHCARE	**250MG**	**A090253**	**001**	May 04, 2009
AB		ALKEM LABS LTD	**250MG**	**A200197**	**001**	Jun 13, 2013
AB		CONCORD BIOTECH LTD	**250MG**	**A210181**	**001**	Jan 08, 2019
AB		MYLAN	**250MG**	**A065520**	**001**	May 04, 2009
AB		SANDOZ	**250MG**	**A065379**	**001**	Oct 15, 2008
AB		STRIDES PHARMA	**250MG**	**A090055**	**001**	Jun 10, 2010
AB		TEVA PHARMS	**250MG**	**A065491**	**001**	May 06, 2009
AB		VINTAGE PHARMS LLC	**250MG**	**A090111**	**001**	Dec 22, 2009
AB		WEST-WARD PHARMS INT	**250MG**	**A065410**	**001**	Jul 29, 2008
AB		ZHEJIANG HISUN PHARM	**250MG**	**A204077**	**001**	Nov 13, 2017
SUSPENSION;ORAL						
CELLCEPT						
AB	**+!**	ROCHE PALO	**200MG/ML**	**N050759**	**001**	Oct 01, 1998
MYCOPHENOLATE MOFETIL						
AB		ALKEM LABS LTD	**200MG/ML**	**A203005**	**001**	Nov 14, 2014
TABLET;ORAL						
CELLCEPT						
AB	**+!**	ROCHE PALO	**500MG**	**N050723**	**001**	Jun 19, 1997
MYCOPHENOLATE MOFETIL						
AB		ACCORD HLTHCARE	**500MG**	**A065416**	**001**	May 04, 2009
AB		ALKEM LABS LTD	**500MG**	**A091249**	**001**	Nov 04, 2011
AB		MYLAN	**500MG**	**A065521**	**001**	May 04, 2009
AB		OXFORD PHARMS	**500MG**	**A090606**	**001**	Jul 16, 2010

MYCOPHENOLATE MOFETIL

TABLET;ORAL

MYCOPHENOLATE MOFETIL

AB		SANDOZ	**500MG**	**A065451**	**001**	Oct 15, 2008
AB		STRIDES PHARMA	**500MG**	**A090456**	**001**	Jun 10, 2010
AB		TEVA PHARMS	**500MG**	**A065457**	**001**	May 04, 2009
AB		WEST-WARD PHARMS INT	**500MG**	**A065413**	**001**	Jul 29, 2008
AB		ZHEJIANG HISUN PHARM	**500MG**	**A204076**	**001**	Nov 16, 2017

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION

CELLCEPT

AP	**+!**	ROCHE PALO	**500MG/VIAL**	**N050758**	**001**	Aug 12, 1998

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP		AKORN INC	**500MG/VIAL**	**A204043**	**001**	Feb 28, 2017
AP		MYLAN LABS LTD	**500MG/VIAL**	**A203859**	**001**	Mar 31, 2017
AP		PAR STERILE PRODUCTS	**500MG/VIAL**	**A203575**	**001**	Oct 28, 2016
AP		ZYDUS PHARMS USA INC	**500MG/VIAL**	**A204473**	**001**	Aug 31, 2017

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLIC ACID

AB		ACCORD HLTHCARE	**180MG**	**A202555**	**001**	Aug 23, 2017
AB			**360MG**	**A202555**	**002**	Aug 23, 2017
AB		APOTEX INC	**180MG**	**A091558**	**001**	Aug 21, 2012
AB			**360MG**	**A091558**	**002**	Aug 19, 2014
AB		MYLAN PHARMS INC	**180MG**	**A091248**	**002**	Jan 08, 2014
AB			**360MG**	**A091248**	**001**	Jan 08, 2014
AB		TEVA PHARMS USA	**180MG**	**A202720**	**001**	Oct 30, 2014
AB			**360MG**	**A202720**	**002**	Oct 30, 2014

MYFORTIC

AB	**+**	NOVARTIS	**180MG**	**N050791**	**001**	Feb 27, 2004
AB	**+!**		**360MG**	**N050791**	**002**	Feb 27, 2004

NABILONE

CAPSULE;ORAL

CESAMET

	+!	MYLAN SPECIALITY LP	1MG	N018677	001	Dec 26, 1985

NABUMETONE

TABLET;ORAL

NABUMETONE

AB		APOTEX INC	**500MG**	**A090427**	**001**	Dec 30, 2011
AB			**750MG**	**A090427**	**002**	Dec 30, 2011
AB		CASI PHARMS INC	**500MG**	**A075280**	**001**	Feb 25, 2002
AB			**750MG**	**A075280**	**002**	Feb 25, 2002
AB		CHARTWELL MOLECULES	**500MG**	**A076009**	**001**	Jan 24, 2003
AB			**750MG**	**A076009**	**002**	Jan 24, 2003
AB		IMPAX LABS INC	**500MG**	**A075189**	**001**	May 26, 2000
AB	**!**		**750MG**	**A075189**	**002**	Sep 24, 2001
AB		INVAGEN PHARMS	**500MG**	**A078671**	**001**	Mar 07, 2008
AB			**750MG**	**A078671**	**002**	Mar 07, 2008
AB		LUPIN LTD	**500MG**	**A090445**	**001**	Jan 12, 2011
AB			**750MG**	**A090445**	**002**	Jan 12, 2011
AB		MYLAN PHARMS INC	**500MG**	**A090516**	**001**	Jul 12, 2010
AB			**750MG**	**A090516**	**002**	Jul 12, 2010
AB		WATSON LABS	**500MG**	**A091083**	**001**	Jun 13, 2011
AB			**750MG**	**A091083**	**002**	Jun 13, 2011

NADOLOL

TABLET;ORAL

CORGARD

AB	**+**	US WORLDMEDS LLC	**20MG**	**N018063**	**005**	Oct 28, 1986
AB	**+**		**40MG**	**N018063**	**001**	
AB	**+!**		**80MG**	**N018063**	**002**	

NADOLOL

AB		AMNEAL PHARMS CO	**20MG**	**A208832**	**001**	Jun 02, 2017
AB			**40MG**	**A208832**	**002**	Jun 02, 2017
AB			**80MG**	**A208832**	**003**	Jun 02, 2017
AB		AUROBINDO PHARMA LTD	**40MG**	**A201893**	**001**	Sep 16, 2015
AB			**80MG**	**A201893**	**002**	Sep 16, 2015

NADOLOL

TABLET;ORAL

NADOLOL

AB		BEXIMCO PHARMS USA	**20MG**	**A210955**	**001**	Jul 23, 2018
AB			**40MG**	**A210955**	**002**	Jul 23, 2018
AB			**80MG**	**A210955**	**003**	Jul 23, 2018
AB		INVAGEN PHARMS	**20MG**	**A203455**	**001**	Dec 18, 2015
AB			**40MG**	**A203455**	**002**	Dec 18, 2015
AB			**80MG**	**A203455**	**003**	Dec 18, 2015
AB		IVAX SUB TEVA PHARMS	**20MG**	**A074229**	**001**	Aug 30, 1996
AB			**40MG**	**A074229**	**002**	Aug 30, 1996
AB			**80MG**	**A074255**	**001**	Jan 24, 1996
AB		LUPIN LTD	**20MG**	**A209309**	**001**	Oct 05, 2017
AB			**40MG**	**A209309**	**002**	Oct 05, 2017
AB			**80MG**	**A209309**	**003**	Oct 05, 2017
AB		MYLAN	**20MG**	**A074172**	**001**	Oct 31, 1993
AB			**40MG**	**A074172**	**002**	Oct 31, 1993
AB			**80MG**	**A074172**	**003**	Oct 31, 1993
AB		NOVAST LABS	**20MG**	**A210786**	**001**	Jun 01, 2018
AB			**40MG**	**A210786**	**002**	Jun 01, 2018
AB			**80MG**	**A210786**	**003**	Jun 01, 2018
AB		SANDOZ	**20MG**	**A074501**	**001**	Nov 09, 1995
AB			**40MG**	**A074501**	**002**	Nov 09, 1995
AB			**80MG**	**A074501**	**003**	Nov 09, 1995
AB		ZYDUS PHARMS USA INC	**20MG**	**A207761**	**001**	Jul 28, 2017
AB			**40MG**	**A207761**	**002**	Jul 28, 2017
AB			**80MG**	**A207761**	**003**	Jul 28, 2017

NAFARELIN ACETATE

SPRAY, METERED;NASAL

SYNAREL

	+!	GD SEARLE LLC	EQ 0.2MG BASE/SPRAY	N019886	001	Feb 13, 1990

NAFCILLIN SODIUM

INJECTABLE;INJECTION

NAFCILLIN SODIUM

AP		ANTIBIOTICE	**EQ 1GM BASE/VIAL**	**A090560**	**001**	Oct 03, 2011
AP			**EQ 2GM BASE/VIAL**	**A090560**	**002**	Oct 03, 2011
AP		AUROBINDO PHARMA LTD	**EQ 1GM BASE/VIAL**	**A091613**	**001**	Dec 26, 2012
AP			**EQ 2GM BASE/VIAL**	**A091613**	**002**	Dec 26, 2012
AP			**EQ 10GM BASE/VIAL**	**A091614**	**001**	Dec 26, 2012
AP		ISTITUTO BIO ITA SPA	**EQ 1GM BASE/VIAL**	**A090002**	**001**	Jun 30, 2011
AP			**EQ 2GM BASE/VIAL**	**A090002**	**002**	Jun 30, 2011
AP			**EQ 10GM BASE/VIAL**	**A090005**	**001**	Apr 20, 2011
AP		MYLAN LABS LTD	**EQ 1GM BASE/VIAL**	**A200002**	**001**	Apr 07, 2014
AP			**EQ 2GM BASE/VIAL**	**A200002**	**002**	Apr 07, 2014
AP		SAGENT PHARMS	**EQ 1GM BASE/VIAL**	**A090582**	**001**	Aug 24, 2012
AP			**EQ 2GM BASE/VIAL**	**A090582**	**002**	Aug 24, 2012
AP			**EQ 10GM BASE/VIAL**	**A090580**	**001**	Aug 24, 2012
AP	**!**	SANDOZ	**EQ 1GM BASE/VIAL**	**A062527**	**002**	Aug 02, 1984
AP	**!**		**EQ 1GM BASE/VIAL**	**A062732**	**001**	Dec 23, 1986
AP	**!**		**EQ 2GM BASE/VIAL**	**A062527**	**003**	Aug 02, 1984
AP	**!**		**EQ 2GM BASE/VIAL**	**A062732**	**002**	Dec 23, 1986
AP	**!**		**EQ 10GM BASE/VIAL**	**A062527**	**004**	Aug 02, 1984

NALLPEN IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050655	001	Oct 31, 1989
	+!		EQ 2GM BASE/100ML	N050655	002	Oct 31, 1989

NAFTIFINE HYDROCHLORIDE

CREAM;TOPICAL

NAFTIFINE HYDROCHLORIDE

AB		TARO PHARMS	**2%**	**A206901**	**001**	Jan 06, 2016
AB		TOLMAR	**2%**	**A206960**	**001**	Apr 10, 2017

NAFTIN

AB	**+!**	SEBELA IRELAND LTD	**2%**	**N019599**	**002**	Jan 13, 2012

NAFTIFINE HYDROCHLORIDE

	!	TARO PHARMS	1%	A205975	001	Sep 08, 2016

GEL;TOPICAL

NAFTIN

	+!	SEBELA IRELAND LTD	1%	N019356	001	Jun 18, 1990
	+!		2%	N204286	001	Jun 27, 2013

NALBUPHINE HYDROCHLORIDE

INJECTABLE;INJECTION

NALBUPHINE HYDROCHLORIDE

AP	**!**	HOSPIRA	**10MG/ML**	**A070914**	**001**	Feb 03, 1989
AP	**!**		**10MG/ML**	**A070915**	**001**	Feb 03, 1989
AP	**!**		**20MG/ML**	**A070916**	**001**	Feb 03, 1989
AP	**!**		**20MG/ML**	**A070918**	**001**	Feb 03, 1989
AP		MYLAN LABS LTD	**10MG/ML**	**A207595**	**001**	Jan 11, 2019
AP			**20MG/ML**	**A207595**	**002**	Jan 11, 2019

NALDEMEDINE TOSYLATE

TABLET;ORAL

SYMPROIC

	+!	SHIONOGI INC	EQ 0.2MG BASE	N208854	001	Mar 23, 2017

NALOXEGOL OXALATE

TABLET;ORAL

MOVANTIK

	+	ASTRAZENECA PHARMS	EQ 12.5MG BASE	N204760	001	Sep 16, 2014
	+!		EQ 25MG BASE	N204760	002	Sep 16, 2014

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE

AP		WEST-WARD PHARMS INT	**0.4MG/ML**	**A070299**	**001**	Sep 24, 1986

NALOXONE HYDROCHLORIDE

AP		AKORN	**0.4MG/ML**	**A208871**	**001**	Feb 28, 2017
AP			**0.4MG/ML**	**A208872**	**001**	Mar 14, 2017
AP	**!**	HOSPIRA	**0.4MG/ML**	**A070172**	**001**	Sep 24, 1986
AP	**!**		**0.4MG/ML**	**A070254**	**001**	Jan 07, 1987
AP	**!**		**0.4MG/ML**	**A070256**	**001**	Jan 07, 1987
AP	**!**		**0.4MG/ML**	**A070257**	**001**	Jan 07, 1987
AP		INTL MEDICATION	**0.4MG/ML**	**A070639**	**001**	Sep 24, 1986
AP		MYLAN INSTITUTIONAL	**0.4MG/ML**	**A204997**	**001**	Mar 06, 2014
AP			**0.4MG/ML**	**A205014**	**001**	Jun 29, 2016
AP		RENAISSANCE SSA LLC	**0.4MG/ML**	**A207846**	**001**	Dec 17, 2018
AP		SOMERSET THERAPS LLC	**0.4MG/ML**	**A207633**	**001**	Aug 08, 2017
AP			**0.4MG/ML**	**A207634**	**001**	Jul 26, 2017
	!	INTL MEDICATION	1MG/ML	A072076	001	Mar 24, 1988

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

EVZIO

	+!	KALEO INC	2MG/0.4ML (2MG/0.4ML)	N209862	001	Oct 19, 2016

SPRAY, METERED;NASAL

NARCAN

	+!	ADAPT	4MG/SPRAY	N208411	001	Nov 18, 2015

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

AB		GAVIS PHARMS	**EQ 0.5MG BASE;EQ 50MG BASE**	**A075735**	**001**	Jul 11, 2001
AB		SUN PHARM INDS LTD	**EQ 0.5MG BASE;EQ 50MG BASE**	**A075523**	**001**	Mar 17, 2000
AB	**!**	WATSON LABS	**EQ 0.5MG BASE;EQ 50MG BASE**	**A074736**	**001**	Jan 21, 1997

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

VIVITROL

	+!	ALKERMES	380MG/VIAL	N021897	001	Apr 13, 2006

NALTREXONE HYDROCHLORIDE

TABLET;ORAL

NALTREXONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**50MG**	**A091205**	**001**	Aug 17, 2011
AB		APOTEX INC	**50MG**	**A207905**	**001**	Jul 21, 2017
AB		BARR	**50MG**	**A074918**	**001**	May 08, 1998
AB		ELITE LABS	**50MG**	**A075274**	**001**	May 26, 1999
AB	**!**	SPECGX LLC	**50MG**	**A076264**	**002**	Mar 22, 2002
AB		SUN PHARMA GLOBAL	**50MG**	**A090356**	**001**	Feb 24, 2012
		SPECGX LLC	25MG	A076264	001	Mar 22, 2002
			100MG	A076264	003	Mar 22, 2002

NANDROLONE DECANOATE						
INJECTABLE;INJECTION						
NANDROLONE DECANOATE						
	!	LUITPOLD	200MG/ML	A091252	001	Aug 30, 2010
NAPROXEN						
SUSPENSION;ORAL						
NAPROSYN						
AB	**+!**	ATNAHS PHARMA US	**25MG/ML**	**N018965**	**001**	Mar 23, 1987
NAPROXEN						
AB		WEST-WARD PHARMS INT	**25MG/ML**	**A074190**	**001**	Mar 30, 1994
TABLET;ORAL						
NAPROSYN						
AB	**+!**	ATNAHS PHARMA US	**500MG**	**N017581**	**004**	Apr 15, 1982
NAPROXEN						
AB		AMNEAL PHARMS NY	**250MG**	**A075927**	**001**	Dec 18, 2001
AB			**375MG**	**A075927**	**002**	Dec 18, 2001
AB			**500MG**	**A075927**	**003**	Dec 18, 2001
AB		AUROBINDO PHARMA LTD	**250MG**	**A200429**	**001**	Nov 08, 2011
AB			**375MG**	**A200429**	**002**	Nov 08, 2011
AB			**500MG**	**A200429**	**003**	Nov 08, 2011
AB		GLENMARK GENERICS	**250MG**	**A078250**	**001**	Mar 28, 2007
AB			**375MG**	**A078250**	**002**	Mar 28, 2007
AB			**500MG**	**A078250**	**003**	Mar 28, 2007
AB		INVAGEN PHARMS	**250MG**	**A091305**	**001**	Aug 24, 2011
AB			**375MG**	**A091305**	**002**	Aug 24, 2011
AB			**500MG**	**A091305**	**003**	Aug 24, 2011
AB		MARKSANS PHARMA	**250MG**	**A091416**	**001**	Feb 14, 2011
AB			**375MG**	**A091416**	**002**	Feb 14, 2011
AB			**500MG**	**A091416**	**003**	Feb 14, 2011
AB		MYLAN	**250MG**	**A074121**	**001**	Dec 21, 1993
AB			**375MG**	**A074121**	**002**	Dec 21, 1993
AB			**500MG**	**A074121**	**003**	Dec 21, 1993
AB		PERRIGO R AND D	**250MG**	**A077339**	**001**	Apr 27, 2005
AB			**375MG**	**A077339**	**002**	Apr 27, 2005
AB			**500MG**	**A077339**	**003**	Apr 27, 2005
AB		TEVA	**250MG**	**A074201**	**001**	Dec 21, 1993
AB			**375MG**	**A074201**	**002**	Dec 21, 1993
AB			**500MG**	**A074201**	**003**	Dec 21, 1993
AB		ZYDUS PHARMS USA	**250MG**	**A078620**	**001**	Jun 07, 2007
AB			**375MG**	**A078620**	**002**	Jun 07, 2007
AB			**500MG**	**A078620**	**003**	Jun 07, 2007
TABLET, DELAYED RELEASE;ORAL						
EC-NAPROSYN						
AB	**+!**	ATNAHS PHARMA US	**375MG**	**N020067**	**002**	Oct 14, 1994
AB	**+!**		**500MG**	**N020067**	**003**	Oct 14, 1994
NAPROXEN						
AB		INVAGEN PHARMS	**375MG**	**A091432**	**001**	Sep 19, 2011
AB			**500MG**	**A091432**	**002**	Sep 19, 2011
AB		PLIVA	**375MG**	**A075337**	**001**	May 26, 1999
AB			**500MG**	**A075337**	**002**	May 26, 1999
AB		TEVA	**375MG**	**A075227**	**001**	Jun 30, 1998
AB			**500MG**	**A075227**	**002**	Jun 30, 1998
NAPROXEN SODIUM						
TABLET;ORAL						
ANAPROX DS						
AB	**+!**	ATNAHS PHARMA US	**EQ 500MG BASE**	**N018164**	**003**	Sep 30, 1987
NAPROXEN SODIUM						
AB		AMNEAL PHARMS NY	**EQ 250MG BASE**	**A078432**	**001**	Apr 25, 2007
AB			**EQ 500MG BASE**	**A078432**	**002**	Apr 25, 2007
AB		AUROBINDO PHARMA LTD	**EQ 250MG BASE**	**A200629**	**001**	Oct 31, 2011
AB			**EQ 500MG BASE**	**A200629**	**002**	Oct 31, 2011
AB		DR REDDYS LABS LTD	**EQ 250MG BASE**	**A078486**	**001**	Jul 26, 2007
AB			**EQ 500MG BASE**	**A078486**	**002**	Jul 26, 2007
AB		GLENMARK PHARMS LTD	**EQ 250MG BASE**	**A078314**	**001**	Apr 27, 2007
AB			**EQ 500MG BASE**	**A078314**	**002**	Apr 27, 2007
AB		TEVA	**EQ 250MG BASE**	**A074198**	**001**	Dec 21, 1993
AB			**EQ 500MG BASE**	**A074198**	**002**	Dec 21, 1993

NAPROXEN SODIUM						
TABLET, EXTENDED RELEASE;ORAL						
NAPRELAN						
AB	+	ALVOGEN MALTA	**EQ 375MG BASE**	**N020353**	**001**	Jan 05, 1996
AB	+		**EQ 500MG BASE**	**N020353**	**002**	Jan 05, 1996
AB	+!		**EQ 750MG BASE**	**N020353**	**003**	Jan 05, 1996
NAPROXEN SODIUM						
AB		ACTAVIS LABS FL INC	**EQ 375MG BASE**	**A075416**	**002**	Apr 23, 2003
AB			**EQ 500MG BASE**	**A075416**	**001**	Aug 27, 2002
AB			**EQ 750MG BASE**	**A075416**	**003**	Aug 11, 2016
NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE						
TABLET;ORAL						
SUMATRIPTAN AND NAPROXEN SODIUM						
AB		AUROBINDO PHARMA LTD	**500MG;EQ 85MG BASE**	**A207457**	**001**	Feb 15, 2018
AB		MYLAN PHARMS INC	**500MG;EQ 85MG BASE**	**A090872**	**001**	Sep 04, 2018
AB		SUN PHARMA GLOBAL	**500MG;EQ 85MG BASE**	**A202803**	**001**	Jul 20, 2018
TREXIMET						
AB	+!	PERNIX IRELAND LTD	**500MG;EQ 85MG BASE**	**N021926**	**001**	Apr 15, 2008
NARATRIPTAN HYDROCHLORIDE						
TABLET;ORAL						
AMERGE						
AB	+	GLAXOSMITHKLINE LLC	**EQ 1MG BASE**	**N020763**	**002**	Feb 10, 1998
AB	+!		**EQ 2.5MG BASE**	**N020763**	**001**	Feb 10, 1998
NARATRIPTAN						
AB		CASI PHARMS INC	**EQ 1MG BASE**	**A090288**	**001**	Jul 07, 2010
AB			**EQ 2.5MG BASE**	**A090288**	**002**	Jul 07, 2010
AB		HERITAGE PHARMS INC	**EQ 1MG BASE**	**A200502**	**001**	Feb 28, 2011
AB			**EQ 2.5MG BASE**	**A200502**	**002**	Feb 28, 2011
AB		MYLAN PHARMS INC	**EQ 1MG BASE**	**A202431**	**001**	May 31, 2012
AB			**EQ 2.5MG BASE**	**A202431**	**002**	May 31, 2012
AB		ORCHID HLTHCARE	**EQ 1MG BASE**	**A091441**	**001**	Apr 30, 2012
AB			**EQ 2.5MG BASE**	**A091441**	**002**	Apr 30, 2012
AB		PADDOCK LLC	**EQ 1MG BASE**	**A091326**	**001**	Jul 08, 2010
AB			**EQ 2.5MG BASE**	**A091326**	**002**	Jul 08, 2010
AB		SUN PHARM INDS LTD	**EQ 2.5MG BASE**	**A091552**	**001**	Feb 14, 2011
AB		TEVA PHARMS	**EQ 1MG BASE**	**A078751**	**001**	Jul 07, 2010
AB			**EQ 2.5MG BASE**	**A078751**	**002**	Jul 07, 2010
AB		WEST-WARD PHARMS INT	**EQ 1MG BASE**	**A090381**	**001**	Jul 07, 2010
AB			**EQ 2.5MG BASE**	**A090381**	**002**	Jul 07, 2010
NATAMYCIN						
SUSPENSION;OPHTHALMIC						
NATACYN						
	+!	NOVARTIS PHARMS CORP	5%	N050514	001	
NATEGLINIDE						
TABLET;ORAL						
NATEGLINIDE						
AB		ALVOGEN MALTA	**60MG**	**A205055**	**001**	Dec 11, 2015
AB			**120MG**	**A205055**	**002**	Dec 11, 2015
AB		DR REDDYS LABS LTD	**60MG**	**A077461**	**001**	Sep 09, 2009
AB			**120MG**	**A077461**	**002**	Sep 09, 2009
AB		PAR PHARM	**60MG**	**A077463**	**001**	Sep 09, 2009
AB			**120MG**	**A077463**	**002**	Sep 09, 2009
AB		WATSON LABS	**60MG**	**A077462**	**001**	Mar 30, 2011
AB			**120MG**	**A077462**	**002**	Mar 30, 2011
AB		WILSHIRE PHARMS INC	**60MG**	**A205544**	**001**	Jun 18, 2018
AB			**120MG**	**A205544**	**002**	Jun 18, 2018
AB		ZYDUS PHARMS USA INC	**60MG**	**A205248**	**001**	Jul 06, 2016
AB			**120MG**	**A205248**	**002**	Jul 06, 2016
STARLIX						
AB	+	NOVARTIS	**60MG**	**N021204**	**001**	Dec 22, 2000
AB	+!		**120MG**	**N021204**	**002**	Dec 22, 2000

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

BYSTOLIC

AB	**+**	ALLERGAN SALES LLC	**EQ 2.5MG BASE**	**N021742**	**002**	Dec 17, 2007
AB	**+**		**EQ 5MG BASE**	**N021742**	**003**	Dec 17, 2007
AB	**+**		**EQ 10MG BASE**	**N021742**	**004**	Dec 17, 2007
AB	**+!**		**EQ 20MG BASE**	**N021742**	**005**	Oct 08, 2008

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET;ORAL

BYVALSON

+!	ALLERGAN SALES LLC	EQ 5MG BASE;80MG	N206302	001	Jun 03, 2016

NEDOCROMIL SODIUM

SOLUTION/DROPS;OPHTHALMIC

ALOCRIL

AT	**+!**	ALLERGAN	**2%**	**N021009**	**001**	Dec 08, 1999

NEDOCROMIL SODIUM

AT		AKORN	**2%**	**A090638**	**001**	Aug 22, 2012

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

	TEVA	50MG	A076037	001	Sep 16, 2003
		100MG	A076037	002	Sep 16, 2003
		150MG	A076037	003	Sep 16, 2003
		200MG	A076037	004	Sep 16, 2003
!		250MG	A076037	005	Sep 16, 2003

NELARABINE

INJECTABLE;INTRAVENOUS

ARRANON

+!	NOVARTIS PHARMS CORP	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005

NELFINAVIR MESYLATE

TABLET;ORAL

VIRACEPT

+!	AGOURON PHARMS	EQ 250MG BASE	N020779	001	Mar 14, 1997
+!		EQ 625MG BASE	N021503	001	Apr 30, 2003

NEOMYCIN SULFATE

TABLET;ORAL

NEOMYCIN SULFATE

AA		BRECKENRIDGE PHARM	**500MG**	**A065468**	**001**	Mar 29, 2010
AA		LANNETT CO INC	**500MG**	**A204435**	**001**	Jun 10, 2016
AA	**!**	TEVA	**500MG**	**A060304**	**001**	
AA		X GEN PHARMS	**500MG**	**A065220**	**001**	Jul 28, 2006

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION;IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

AT		WATSON LABS	**EQ 40MG BASE/ML;200,000 UNITS/ML**	**A062664**	**001**	Apr 08, 1986
AT		X GEN PHARMS	**EQ 40MG BASE/ML;200,000 UNITS/ML**	**A065106**	**001**	Jan 31, 2006
AT			**EQ 40MG BASE/ML;200,000 UNITS/ML**	**A065108**	**001**	Jan 31, 2006

NEOSPORIN G.U. IRRIGANT

AT	**!**	MONARCH PHARMS	**EQ 40MG BASE/ML;200,000 UNITS/ML**	**A060707**	**001**	

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

BLOXIVERZ

AP	**+!**	AVADEL LEGACY	**5MG/10ML (0.5MG/ML)**	**N204078**	**001**	May 31, 2013
AP	**+!**		**10MG/10ML (1MG/ML)**	**N204078**	**002**	May 31, 2013

NEOSTIGMINE METHYLSULFATE

AP		AMNEAL PHARMS CO	**5MG/10ML (0.5MG/ML)**	**A210051**	**001**	Jun 15, 2018
AP			**10MG/10ML (1MG/ML)**	**A210051**	**002**	Jun 15, 2018
AP		AMPHASTAR PHARMS INC	**5MG/10ML (0.5MG/ML)**	**A209933**	**001**	Sep 25, 2017
AP			**10MG/10ML (1MG/ML)**	**A209933**	**002**	Sep 25, 2017
AP		DR REDDYS LABS LTD	**5MG/10ML (0.5MG/ML)**	**A209135**	**001**	Jul 10, 2018
AP			**10MG/10ML (1MG/ML)**	**A209135**	**002**	Jul 10, 2018
AP		EUROHLTH INTL SARL	**5MG/10ML (0.5MG/ML)**	**A207042**	**001**	Dec 28, 2015
AP			**10MG/10ML (1MG/ML)**	**A207042**	**002**	Dec 28, 2015
AP		LUITPOLD	**5MG/10ML (0.5MG/ML)**	**A209182**	**001**	May 04, 2018
AP			**10MG/10ML (1MG/ML)**	**A209182**	**002**	May 04, 2018
AP		PAR STERILE PRODUCTS	**5MG/10ML (0.5MG/ML)**	**A208405**	**001**	Apr 26, 2017

NEOSTIGMINE METHYLSULFATE						
SOLUTION;INTRAVENOUS						
NEOSTIGMINE METHYLSULFATE						
AP			**10MG/10ML (1MG/ML)**	**A208405**	**002**	Apr 26, 2017
AP	RENAISSANCE SSA LLC		**5MG/10ML (0.5MG/ML)**	**A210989**	**001**	Aug 22, 2018
AP			**10MG/10ML (1MG/ML)**	**A210989**	**002**	Aug 22, 2018
	FRESENIUS KABI USA		3MG/3ML (1MG/ML)	N203629	003	Sep 18, 2018
			5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015
			10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015
NEPAFENAC						
SUSPENSION/DROPS;OPHTHALMIC						
ILEVRO						
+!	NOVARTIS PHARMS CORP		0.3%	N203491	001	Oct 16, 2012
NEVANAC						
+!	NOVARTIS PHARMS CORP		0.1%	N021862	001	Aug 19, 2005
NERATINIB MALEATE						
TABLET;ORAL						
NERLYNX						
+!	PUMA BIOTECH		EQ 40MG BASE	N208051	001	Jul 17, 2017
NESIRITIDE RECOMBINANT						
FOR SOLUTION;INTRAVENOUS						
NATRECOR						
+!	SCIOS LLC		1.5MG/VIAL	N020920	001	Aug 10, 2001
NETARSUDIL DIMESYLATE						
SOLUTION/DROPS;OPHTHALMIC						
RHOPRESSA						
+!	AERIE PHARMS INC		EQ 0.02% BASE	N208254	001	Dec 18, 2017
NETUPITANT; PALONOSETRON HYDROCHLORIDE						
CAPSULE;ORAL						
AKYNZEO						
+!	HELSINN HLTHCARE		300MG;EQ 0.5MG BASE	N205718	001	Oct 10, 2014
NEVIRAPINE						
SUSPENSION;ORAL						
NEVIRAPINE						
AA	AUROBINDO		**50MG/5ML**	**A077702**	**001**	May 22, 2012
AA	CIPLA		**50MG/5ML**	**A207684**	**001**	Aug 03, 2017
VIRAMUNE						
AA	**+!** BOEHRINGER INGELHEIM		**50MG/5ML**	**N020933**	**001**	Sep 11, 1998
TABLET;ORAL						
NEVIRAPINE						
AB	AUROBINDO		**200MG**	**A077521**	**001**	May 22, 2012
AB	CIPLA		**200MG**	**A077956**	**001**	May 22, 2012
AB	HETERO LABS LTD III		**200MG**	**A078584**	**001**	May 22, 2012
AB	MACLEODS PHARMS LTD		**200MG**	**A090688**	**001**	Jan 14, 2019
AB	MICRO LABS LTD		**200MG**	**A203080**	**001**	May 22, 2012
AB	MYLAN LABS		**200MG**	**A078864**	**001**	May 22, 2012
AB	MYLAN PHARMS INC		**200MG**	**A202523**	**001**	May 22, 2012
AB	PRINSTON INC		**200MG**	**A078644**	**001**	May 22, 2012
AB	STRIDES PHARMA		**200MG**	**A078195**	**001**	May 22, 2012
VIRAMUNE						
AB	**+!** BOEHRINGER INGELHEIM		**200MG**	**N020636**	**001**	Jun 21, 1996
TABLET, EXTENDED RELEASE;ORAL						
NEVIRAPINE						
AB	ALVOGEN MALTA		**100MG**	**A204621**	**002**	Nov 09, 2015
AB			**400MG**	**A204621**	**001**	Jul 10, 2015
AB	AUROBINDO PHARMA LTD		**100MG**	**A208616**	**001**	Nov 23, 2016
AB			**400MG**	**A207698**	**001**	Feb 28, 2017
AB	CIPLA		**400MG**	**A206448**	**001**	Oct 15, 2015
AB	MACLEODS PHARMS LTD		**400MG**	**A206879**	**001**	Oct 06, 2017
AB	MYLAN PHARMS INC		**100MG**	**A206271**	**001**	Nov 09, 2015
AB			**400MG**	**A205651**	**001**	Oct 27, 2014
AB	SANDOZ INC		**400MG**	**A203411**	**001**	Apr 03, 2014
VIRAMUNE XR						
AB	**+** BOEHRINGER INGELHEIM		**100MG**	**N201152**	**002**	Nov 08, 2012
AB	**+!**		**400MG**	**N201152**	**001**	Mar 25, 2011

NIACIN

TABLET;ORAL

NIACIN

AA		WOCKHARDT	**500MG**	**A081134**	**001**	Apr 28, 1992

NIACOR

AA	!	AVONDALE PHARMS	**500MG**	**A040378**	**001**	May 03, 2000

TABLET, EXTENDED RELEASE;ORAL

NIACIN

AB		AMNEAL PHARMS	**500MG**	**A203578**	**001**	Jul 24, 2015
AB			**750MG**	**A204178**	**001**	Dec 11, 2015
AB			**1GM**	**A203578**	**002**	Jul 24, 2015
AB		AUROBINDO PHARMA LTD	**500MG**	**A209236**	**001**	Feb 01, 2018
AB			**750MG**	**A209236**	**002**	Feb 01, 2018
AB			**1GM**	**A209236**	**003**	Feb 01, 2018
AB		BARR	**500MG**	**A076378**	**001**	Apr 26, 2005
AB			**750MG**	**A076378**	**002**	Apr 26, 2005
AB			**1GM**	**A076250**	**001**	Apr 14, 2005
AB		JUBILANT GENERICS	**500MG**	**A209156**	**001**	May 14, 2018
AB			**750MG**	**A209156**	**002**	May 14, 2018
AB			**1GM**	**A209156**	**003**	May 14, 2018
AB		LANNETT CO INC	**500MG**	**A203899**	**001**	Jun 16, 2017
AB			**1GM**	**A203899**	**002**	Jun 16, 2017
AB		LUPIN LTD	**500MG**	**A090860**	**001**	Mar 20, 2014
AB			**750MG**	**A090892**	**001**	Mar 20, 2014
AB			**1GM**	**A090446**	**001**	Mar 20, 2014
AB		SUN PHARMA GLOBAL	**500MG**	**A200484**	**001**	Apr 23, 2014
AB			**750MG**	**A201273**	**001**	Apr 23, 2014
AB			**1GM**	**A200484**	**002**	Apr 23, 2014

NIASPAN

AB	+	ABBVIE	**500MG**	**N020381**	**002**	Jul 28, 1997
AB	+!		**750MG**	**N020381**	**003**	Jul 28, 1997
AB	+!		**1GM**	**N020381**	**004**	Jul 28, 1997

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

AB		ANI PHARMS INC	**20MG**	**A074439**	**001**	Dec 10, 1996
AB			**20MG**	**A074540**	**001**	Oct 28, 1996
AB			**30MG**	**A074439**	**002**	Dec 10, 1996
AB			**30MG**	**A074540**	**002**	Oct 28, 1996
AB		EPIC PHARMA	**20MG**	**A074928**	**001**	Mar 19, 1998
AB			**30MG**	**A074928**	**002**	Mar 19, 1998
AB		MYLAN	**20MG**	**A074642**	**001**	Jul 18, 1996
AB	!		**30MG**	**A074642**	**002**	Jul 18, 1996

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

		EXELA PHARMA SCIENCE	25MG/10ML (2.5MG/ML)	N022276	001	Jul 24, 2008

INJECTABLE;INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

+!		CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

+!		CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

+!		CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	002	Jul 31, 2008

NICOTINE

INHALANT;ORAL

NICOTROL

+!		PHARMACIA AND UPJOHN	4MG/CARTRIDGE	N020714	001	May 02, 1997

SPRAY, METERED;NASAL

NICOTROL

+!		PFIZER INC	0.5MG/SPRAY	N020385	001	Mar 22, 1996

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

AB		ACTAVIS ELIZABETH	**10MG**	**A072579**	**001**	Jan 08, 1991
AB			**20MG**	**A072556**	**001**	Sep 20, 1990
AB		HERITAGE PHARMA	**10MG**	**A202644**	**001**	Apr 25, 2013
AB			**20MG**	**A202644**	**002**	Apr 25, 2013
AB		INTERGEL PHARM	**10MG**	**A072781**	**001**	Jul 30, 1993

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

AB		LEADING PHARMA LLC	**10MG**	**A073250**	**001**	Oct 08, 1991
AB			**20MG**	**A074045**	**001**	Apr 30, 1992

PROCARDIA

AB	**+!**	PFIZER	**10MG**	**N018482**	**001**	

TABLET, EXTENDED RELEASE;ORAL

ADALAT CC

AB1	**+**	ALVOGEN	**30MG**	**N020198**	**001**	Apr 21, 1993
AB1	**+!**		**60MG**	**N020198**	**002**	Apr 21, 1993
AB1	**+!**		**90MG**	**N020198**	**003**	Apr 21, 1993

NIFEDIPINE

AB1		MYLAN	**30MG**	**A201071**	**001**	Dec 03, 2010
AB1			**60MG**	**A201071**	**002**	Dec 03, 2010
AB1			**90MG**	**A201071**	**003**	Dec 03, 2010
AB1		NOVAST LABS	**30MG**	**A202987**	**001**	Aug 25, 2016
AB1			**60MG**	**A202987**	**002**	Aug 25, 2016
AB1			**90MG**	**A202987**	**003**	Aug 25, 2016
AB1		PAR PHARM	**30MG**	**A077899**	**001**	Dec 13, 2006
AB1			**60MG**	**A077899**	**002**	Dec 13, 2006
AB1			**90MG**	**A077899**	**003**	May 25, 2012
AB1		VALEANT PHARMS NORTH	**30MG**	**A075269**	**001**	Dec 04, 2000
AB1			**60MG**	**A075269**	**002**	Dec 04, 2000
AB1			**90MG**	**A076070**	**001**	Aug 16, 2002
AB1		ZYDUS PHARMS USA INC	**30MG**	**A210184**	**001**	Jun 29, 2018
AB1			**60MG**	**A210184**	**002**	Jun 29, 2018
AB1			**90MG**	**A210184**	**003**	Jun 29, 2018
AB2		MYLAN	**30MG**	**A090649**	**001**	Jun 21, 2010
AB2			**60MG**	**A090649**	**002**	Jun 21, 2010
AB2			**90MG**	**A090649**	**003**	Jun 21, 2010
AB2		OSMOTICA PHARM US	**30MG**	**A077127**	**001**	Nov 21, 2005
AB2			**60MG**	**A077127**	**002**	Nov 21, 2005
AB2			**90MG**	**A077410**	**001**	Oct 03, 2007
AB2		TWI PHARMS	**30MG**	**A203126**	**001**	Apr 03, 2014
AB2			**60MG**	**A203126**	**002**	Apr 03, 2014
AB2			**90MG**	**A203126**	**003**	Apr 03, 2014
AB2		VALEANT PHARMS NORTH	**30MG**	**A075289**	**002**	Feb 06, 2001
AB2			**60MG**	**A075289**	**001**	Sep 27, 2000
AB2		ZYDUS PHARMS USA INC	**30MG**	**A210012**	**001**	Dec 19, 2017
AB2			**60MG**	**A210012**	**002**	Dec 19, 2017
AB2			**90MG**	**A210012**	**003**	Dec 19, 2017

PROCARDIA XL

AB2	**+**	PFIZER	**30MG**	**N019684**	**001**	Sep 06, 1989
AB2	**+**		**60MG**	**N019684**	**002**	Sep 06, 1989
AB2	**+!**		**90MG**	**N019684**	**003**	Sep 06, 1989

NILOTINIB HYDROCHLORIDE

CAPSULE;ORAL

TASIGNA

+		NOVARTIS	EQ 50MG BASE	N022068	003 Mar 22, 2018
+			EQ 150MG BASE	N022068	002 Jun 17, 2010
+!			EQ 200MG BASE	N022068	001 Oct 29, 2007

NILUTAMIDE

TABLET;ORAL

NILANDRON

AB	**+!**	CONCORDIA PHARMS INC	**150MG**	**N020169**	**002**	Apr 30, 1999

NILUTAMIDE

AB		ANI PHARMS INC	**150MG**	**A207631**	**001**	Jul 15, 2016

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

AB	**!**	BIONPHARMA INC	**30MG**	**A076740**	**001**	Jan 17, 2008
AB		HERITAGE PHARMS INC	**30MG**	**A077811**	**001**	May 02, 2007
AB		SOFGEN PHARMS	**30MG**	**A201832**	**001**	Jul 24, 2015
AB		SUN PHARM INDS INC	**30MG**	**A077067**	**001**	Apr 17, 2007
AB		THEPHARMANETWORK LLC	**30MG**	**A090103**	**001**	Apr 07, 2014

NIMODIPINE
SOLUTION;ORAL
NYMALIZE
+! ARBOR PHARMS LLC 60MG/20ML N203340 001 May 10, 2013

NINTEDANIB ESYLATE
CAPSULE;ORAL
OFEV
+ BOEHRINGER INGELHEIM EQ 100MG BASE N205832 001 Oct 15, 2014
+! EQ 150MG BASE N205832 002 Oct 15, 2014

NIRAPARIB TOSYLATE
CAPSULE;ORAL
ZEJULA
+! TESARO INC EQ 100MG BASE N208447 001 Mar 27, 2017

NISOLDIPINE
TABLET, EXTENDED RELEASE;ORAL
NISOLDIPINE
AB MYLAN **8.5MG** **A091001 001** Jan 26, 2011
AB **17MG** **A091001 002** Jan 26, 2011
AB **34MG** **A091001 004** Jan 26, 2011
SULAR
AB **+!** COVIS PHARMA BV **8.5MG** **N020356 008** Jan 02, 2008
AB **+!** **17MG** **N020356 007** Jan 02, 2008
AB **+!** **34MG** **N020356 005** Jan 02, 2008
NISOLDIPINE
MYLAN 20MG A079051 001 Jul 25, 2008
25.5MG A091001 003 Jan 26, 2011
! 30MG A079051 002 Jul 25, 2008
! 40MG A079051 003 Jul 25, 2008

NITAZOXANIDE
FOR SUSPENSION;ORAL
ALINIA
+! ROMARK 100MG/5ML N021498 001 Nov 22, 2002
TABLET;ORAL
ALINIA
+! ROMARK 500MG N021497 001 Jul 21, 2004

NITISINONE
CAPSULE;ORAL
ORFADIN
+ SWEDISH ORPHAN 2MG N021232 001 Jan 18, 2002
+ 5MG N021232 002 Jan 18, 2002
+ 10MG N021232 003 Jan 18, 2002
+! 20MG N021232 004 Jun 13, 2016
SUSPENSION;ORAL
ORFADIN
+! SWEDISH ORPHAN 4MG/ML N206356 001 Apr 22, 2016
TABLET;ORAL
NITYR
+ CYCLE PHARMS LTD 2MG N209449 001 Jul 26, 2017
+ 5MG N209449 002 Jul 26, 2017
+! 10MG N209449 003 Jul 26, 2017

NITRIC OXIDE
GAS;INHALATION
INOMAX
AA **+!** MALLINCKRODT HOSP **800PPM** **N020845 003** Dec 23, 1999
NOXIVENT
AA PRAXAIR DISTRIBUTION **800PPM** **A207141 002** Oct 02, 2018
100PPM A207141 001 Oct 02, 2018

NITROFURANTOIN
SUSPENSION;ORAL
FURADANTIN
AB **+!** CASPER PHARMA LLC **25MG/5ML** **N009175 001**
NITROFURANTOIN
AB ACTAVIS MID ATLANTIC **25MG/5ML** **A205180 001** May 03, 2016
AB AMNEAL PHARMS **25MG/5ML** **A201679 001** May 11, 2011
AB NOSTRUM LABS INC **25MG/5ML** **A201355 001** Aug 14, 2013
AB NOVEL LABS INC **25MG/5ML** **A201693 001** Sep 08, 2014

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

MACRODANTIN

AB	**+**	ALVOGEN MALTA	**25MG**	**N016620**	**003**		
AB	**+**		**50MG**	**N016620**	**001**		
AB	**+!**		**100MG**	**N016620**	**002**		

NITROFURANTOIN

AB		ACTAVIS LABS FL INC	**25MG**	**A091095**	**001**	Jun 18, 2015	
AB			**50MG**	**A091095**	**002**	Jun 18, 2015	
AB			**100MG**	**A091095**	**003**	Jun 18, 2015	
AB		IMPAX LABS INC	**50MG**	**A073671**	**001**	Jan 28, 1993	
AB			**100MG**	**A073652**	**001**	Jan 28, 1993	
AB		MYLAN	**50MG**	**A074967**	**001**	Jul 09, 1997	
AB			**100MG**	**A077025**	**001**	Aug 18, 2004	
AB		NOVEL LABS INC	**50MG**	**A203233**	**001**	Jul 09, 2018	
AB			**100MG**	**A203233**	**002**	Jul 09, 2018	
AB		SUN PHARM INDUSTRIES	**25MG**	**A201722**	**001**	Feb 16, 2016	
AB			**50MG**	**A201722**	**002**	Feb 16, 2016	
AB			**100MG**	**A201722**	**003**	Feb 16, 2016	
AB		ZYDUS PHARMS USA INC	**50MG**	**A205005**	**001**	Dec 12, 2017	
AB			**100MG**	**A205005**	**002**	Dec 12, 2017	

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

MACROBID

AB	**+!**	ALVOGEN MALTA	**75MG;25MG**	**N020064**	**001**	Dec 24, 1991	

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB		AMNEAL PHARMS	**75MG;25MG**	**A207372**	**001**	May 15, 2017	
AB		MYLAN	**75MG;25MG**	**A076648**	**001**	Mar 22, 2004	
AB		SANDOZ	**75MG;25MG**	**A077066**	**001**	Apr 05, 2005	
AB		SUNNY PHARMTECH INC	**75MG;25MG**	**A208516**	**001**	May 24, 2018	
AB		WATSON LABS INC	**75MG;25MG**	**A202250**	**001**	Jul 08, 2015	

NITROGLYCERIN

AEROSOL, METERED;SUBLINGUAL

NITROMIST

+!	MIST PHARMS LLC	0.4MG/SPRAY	N021780	001	Nov 02, 2006	

FILM, EXTENDED RELEASE;TRANSDERMAL

MINITRAN

AB1		MEDICIS	**0.4MG/HR**	**A089773**	**001**	Aug 30, 1996	
AB1		VALEANT PHARMS	**0.1MG/HR**	**A089771**	**001**	Aug 30, 1996	
AB1			**0.6MG/HR**	**A089774**	**001**	Aug 30, 1996	
AB1		VALEANT PHARMS NORTH	**0.2MG/HR**	**A089772**	**001**	Aug 30, 1996	

NITRO-DUR

AB1	**+!**	USPHARMA	**0.1MG/HR**	**N020145**	**001**	Apr 04, 1995	
AB1	**+!**		**0.2MG/HR**	**N020145**	**002**	Apr 04, 1995	
AB1	**+!**		**0.4MG/HR**	**N020145**	**004**	Apr 04, 1995	
AB1	**+!**		**0.6MG/HR**	**N020145**	**005**	Apr 04, 1995	

NITROGLYCERIN

AB2		HERCON PHARM	**0.2MG/HR**	**A089884**	**001**	Oct 30, 1998	
AB2			**0.4MG/HR**	**A089885**	**001**	Oct 30, 1998	
AB2			**0.6MG/HR**	**A089886**	**001**	Oct 30, 1998	
AB2	**!**	MYLAN TECHNOLOGIES	**0.2MG/HR**	**A074559**	**003**	Aug 30, 1996	
AB2	**!**		**0.4MG/HR**	**A074559**	**002**	Aug 30, 1996	
AB2	**!**		**0.6MG/HR**	**A074559**	**001**	Aug 30, 1996	

NITRO-DUR

+!	USPHARMA	0.3MG/HR	N020145	003	Apr 04, 1995	
+!		0.8MG/HR	N020145	006	Apr 04, 1995	

NITROGLYCERIN

!	MYLAN TECHNOLOGIES	0.1MG/HR	A074559	004	Feb 06, 1998	

INJECTABLE;INJECTION

NITROGLYCERIN IN DEXTROSE 5%

AP	**+!**	BAXTER HLTHCARE	**10MG/100ML**	**N019970**	**001**	Dec 29, 1989	
AP	**+!**		**20MG/100ML**	**N019970**	**002**	Dec 29, 1989	
AP	**+!**		**40MG/100ML**	**N019970**	**003**	Dec 29, 1989	

NITROGLYCERIN

!	LUITPOLD	5MG/ML	A072034	001	May 24, 1988	

OINTMENT;INTRA-ANAL

RECTIV

+!	ALLERGAN SALES LLC	0.4%	N021359	001	Jun 21, 2011	

NITROGLYCERIN						
OINTMENT;TRANSDERMAL						
NITROGLYCERIN						
	!	FOUGERA PHARMS INC	2%	A087355	001	Jul 08, 1988
POWDER;SUBLINGUAL						
GONITRO						
	+!	POHL BOSKAMP	0.4MG/PACKET	N208424	001	Jun 08, 2016
SPRAY, METERED;SUBLINGUAL						
NITROGLYCERIN						
AB		PERRIGO ISRAEL	**0.4MG/SPRAY**	**A091496**	**001**	Sep 20, 2013
NITROLINGUAL PUMPSPRAY						
AB	**+!**	POHL BOSKAMP	**0.4MG/SPRAY**	**N018705**	**002**	Jan 10, 1997
TABLET;SUBLINGUAL						
NITROGLYCERIN						
AB		ACTAVIS LABS FL INC	**0.3MG**	**A203693**	**001**	Oct 16, 2017
AB			**0.4MG**	**A203693**	**002**	Oct 16, 2017
AB			**0.6MG**	**A203693**	**003**	Oct 16, 2017
AB		DR REDDYS LABS INC	**0.3MG**	**A208191**	**001**	Aug 26, 2016
AB			**0.4MG**	**A208191**	**002**	Aug 26, 2016
AB			**0.6MG**	**A208191**	**003**	Aug 26, 2016
AB		GLENMARK PHARMS SA	**0.3MG**	**A206391**	**001**	Sep 19, 2017
AB			**0.4MG**	**A206391**	**002**	Sep 19, 2017
AB			**0.6MG**	**A206391**	**003**	Sep 19, 2017
AB		SIGMAPHARM LABS LLC	**0.3MG**	**A207745**	**001**	May 07, 2018
AB			**0.4MG**	**A207745**	**002**	May 07, 2018
AB			**0.6MG**	**A207745**	**003**	May 07, 2018
NITROSTAT						
AB	**+**	PFIZER PHARMS	**0.3MG**	**N021134**	**001**	May 01, 2000
AB	**+**		**0.4MG**	**N021134**	**002**	May 01, 2000
AB	**+!**		**0.6MG**	**N021134**	**003**	May 01, 2000
NIZATIDINE						
CAPSULE;ORAL						
NIZATIDINE						
AB		ANI PHARMS INC	**150MG**	**A075668**	**001**	Sep 12, 2002
AB			**300MG**	**A075668**	**002**	Sep 12, 2002
AB		DR REDDYS LABS LTD	**150MG**	**A077314**	**001**	Sep 15, 2005
AB			**300MG**	**A077314**	**002**	Sep 15, 2005
AB		GLENMARK GENERICS	**150MG**	**A090618**	**001**	Jul 15, 2011
AB			**300MG**	**A090618**	**002**	Jul 15, 2011
AB		MYLAN PHARMS INC	**150MG**	**A075806**	**001**	Jul 05, 2002
AB	**!**		**300MG**	**A075806**	**002**	Jul 05, 2002
AB		SANDOZ	**150MG**	**A076178**	**001**	Jul 05, 2002
AB			**300MG**	**A076178**	**002**	Jul 05, 2002
AB		WATSON LABS	**150MG**	**A075616**	**001**	Jul 09, 2002
AB			**300MG**	**A075616**	**002**	Jul 09, 2002
SOLUTION;ORAL						
NIZATIDINE						
	!	AMNEAL PHARMS	15MG/ML	A090576	001	Nov 18, 2009
NOREPINEPHRINE BITARTRATE						
INJECTABLE;INJECTION						
LEVOPHED						
AP	**+!**	HOSPIRA	**EQ 1MG BASE/ML**	**N007513**	**001**	
NOREPINEPHRINE BITARTRATE						
AP		AMNEAL PHARMS CO	**EQ 1MG BASE/ML**	**A210839**	**001**	Dec 17, 2018
AP		BAXTER HLTHCARE CORP	**EQ 1MG BASE/ML**	**A040859**	**001**	Mar 27, 2012
AP		HIKMA FARMACEUTICA	**EQ 1MG BASE/ML**	**A203662**	**001**	Nov 07, 2018
AP		MYLAN LABS LTD	**EQ 1MG BASE/ML**	**A211242**	**001**	Oct 04, 2018
AP		SANDOZ INC	**EQ 1MG BASE/ML**	**A211359**	**001**	Oct 18, 2018
AP		TEVA PHARMS USA	**EQ 1MG BASE/ML**	**A040455**	**001**	Mar 03, 2003
AP		WEST-WARD PHARMS INT	**EQ 1MG BASE/ML**	**A040462**	**001**	Oct 31, 2003
NORETHINDRONE						
TABLET;ORAL-28						
CAMILA						
AB1		MAYNE PHARMA	**0.35MG**	**A076177**	**001**	Oct 21, 2002
HEATHER						
AB1		GLENMARK GENERICS	**0.35MG**	**A090454**	**001**	Apr 23, 2010
INCASSIA						
AB1		AUROBINDO PHARMA LTD	**0.35MG**	**A207304**	**001**	Sep 23, 2016

NORETHINDRONE							
TABLET;ORAL-28							
NOR-QD							
AB1	**+!**	APIL	**0.35MG**	**N017060**	**001**		
NORETHINDRONE							
AB1		ACCORD HLTHCARE	**0.35MG**	**A206807**	**001**	Dec 13, 2016	
AB1		AMNEAL PHARMS	**0.35MG**	**A202260**	**001**	Aug 01, 2013	
AB1		LUPIN LTD	**0.35MG**	**A091325**	**001**	Sep 19, 2011	
AB1		MYLAN LABS LTD	**0.35MG**	**A201483**	**001**	Jun 24, 2013	
AB1		NOVAST LABS	**0.35MG**	**A202014**	**001**	Sep 13, 2013	
ERRIN							
AB2		MAYNE PHARMA	**0.35MG**	**A076225**	**001**	Oct 21, 2002	
JENCYCLA							
AB2		LUPIN LTD	**0.35MG**	**A091323**	**001**	Mar 28, 2013	
MICRONOR							
AB2	**+!**	JANSSEN PHARMS	**0.35MG**	**N016954**	**001**		
NORETHINDRONE							
AB2		GLENMARK GENERICS	**0.35MG**	**A091209**	**001**	Jul 22, 2010	
AB2		MYLAN LABS LTD	**0.35MG**	**A200980**	**001**	Jun 12, 2013	
AB2		NOVAST LABS	**0.35MG**	**A200961**	**001**	Sep 13, 2013	
NORETHINDRONE ACETATE							
TABLET;ORAL							
NORETHINDRONE ACETATE							
AB		AMNEAL PHARMS	**5MG**	**A200275**	**001**	Jul 30, 2012	
AB		AUROBINDO PHARMA LTD	**5MG**	**A204236**	**001**	Jan 08, 2016	
AB	**!**	BARR	**5MG**	**A075951**	**001**	May 25, 2001	
AB		GLENMARK GENERICS	**5MG**	**A091090**	**001**	Jul 21, 2010	
AB		MYLAN LABS LTD	**5MG**	**A205278**	**001**	Nov 10, 2016	
AB		PACK PHARMS LLC	**5MG**	**A206490**	**001**	Nov 05, 2018	
NORTRIPTYLINE HYDROCHLORIDE							
CAPSULE;ORAL							
NORTRIPTYLINE HYDROCHLORIDE							
AB		MAYNE PHARMA	**EQ 10MG BASE**	**A073556**	**002**	Mar 30, 1992	
AB			**EQ 25MG BASE**	**A073556**	**003**	Mar 30, 1992	
AB			**EQ 50MG BASE**	**A073556**	**004**	Mar 30, 1992	
AB			**EQ 75MG BASE**	**A073556**	**001**	Mar 30, 1992	
AB		TARO PHARM	**EQ 10MG BASE**	**A075520**	**004**	May 08, 2000	
AB			**EQ 25MG BASE**	**A075520**	**003**	May 08, 2000	
AB			**EQ 50MG BASE**	**A075520**	**001**	May 08, 2000	
AB			**EQ 75MG BASE**	**A075520**	**002**	May 08, 2000	
AB		TEVA	**EQ 10MG BASE**	**A074132**	**001**	Mar 27, 1995	
AB			**EQ 25MG BASE**	**A074132**	**002**	Mar 27, 1995	
AB			**EQ 50MG BASE**	**A074132**	**003**	Mar 27, 1995	
AB			**EQ 75MG BASE**	**A074132**	**004**	Mar 27, 1995	
PAMELOR							
AB	**+**	SPECGX LLC	**EQ 10MG BASE**	**N018013**	**001**		
AB	**+**		**EQ 25MG BASE**	**N018013**	**002**		
AB	**+**		**EQ 50MG BASE**	**N018013**	**004**		
AB	**+!**		**EQ 75MG BASE**	**N018013**	**003**		
SOLUTION;ORAL							
NORTRIPTYLINE HYDROCHLORIDE							
AA	**!**	PHARM ASSOC	**EQ 10MG BASE/5ML**	**A075606**	**001**	Aug 28, 2000	
AA		TARO	**EQ 10MG BASE/5ML**	**A077965**	**001**	Jun 20, 2006	
NUSINERSEN SODIUM							
SOLUTION;INTRATHECAL							
SPINRAZA							
	+!	BIOGEN IDEC	12MG/5ML (2.4MG/ML)	N209531	001	Dec 23, 2016	
NYSTATIN							
CREAM;TOPICAL							
NYSTATIN							
AT		ACTAVIS MID ATLANTIC	**100,000 UNITS/GM**	**A062949**	**001**	Jun 13, 1988	
AT		CROWN LABS INC	**100,000 UNITS/GM**	**A207733**	**001**	Sep 26, 2017	
AT		FOUGERA PHARMS	**100,000 UNITS/GM**	**A062129**	**001**		
AT		G AND W LABS INC	**100,000 UNITS/GM**	**A061966**	**001**		
AT		PERRIGO NEW YORK	**100,000 UNITS/GM**	**A062225**	**001**		
AT	**!**	TARO	**100,000 UNITS/GM**	**A064022**	**001**	Jan 29, 1993	
AT		VINTAGE	**100,000 UNITS/GM**	**A065315**	**001**	May 31, 2006	

NYSTATIN

OINTMENT;TOPICAL

NYSTATIN

AT		ACTAVIS MID ATLANTIC	**100,000 UNITS/GM**	**A062840**	**001**	Nov 13, 1987
AT	!	FOUGERA PHARMS	**100,000 UNITS/GM**	**A062124**	**002**	Sep 23, 1982
AT		G AND W LABS INC	**100,000 UNITS/GM**	**A209114**	**001**	Oct 06, 2017
AT		LYNE	**100,000 UNITS/GM**	**A209082**	**001**	May 21, 2018
AT		PERRIGO NEW YORK	**100,000 UNITS/GM**	**A062472**	**001**	Feb 13, 1984
AT		ZYDUS PHARMS USA INC	**100,000 UNITS/GM**	**A207767**	**001**	May 25, 2018

POWDER;TOPICAL

NYSTATIN

AT		EPIC PHARMA LLC	**100,000 UNITS/GM**	**A210532**	**001**	Apr 30, 2018
AT		GAVIS PHARMS	**100,000 UNITS/GM**	**A065138**	**001**	Jul 23, 2004
AT		LYNE	**100,000 UNITS/GM**	**A208838**	**001**	May 30, 2017
AT	!	MAYNE PHARMA INC	**100,000 UNITS/GM**	**A065203**	**001**	Jul 15, 2004
AT		NESHER PHARMS	**100,000 UNITS/GM**	**A208581**	**001**	Jun 08, 2017
AT		UPSHER SMITH LABS	**100,000 UNITS/GM**	**A065183**	**001**	May 03, 2005
AT		X GEN PHARMS	**100,000 UNITS/GM**	**A065175**	**001**	Dec 17, 2004

NYSTOP

AT		PADDOCK LLC	**100,000 UNITS/GM**	**A064118**	**001**	Aug 16, 1996

SUSPENSION;ORAL

NYSTATIN

AA		FOUGERA PHARMS INC	**100,000 UNITS/ML**	**A062517**	**001**	Jun 07, 1984
AA		HI TECH PHARMA	**100,000 UNITS/ML**	**A064042**	**001**	Feb 28, 1994
AA		LANNETT CO INC	**100,000 UNITS/ML**	**A065148**	**001**	Jun 28, 2005
AA		PHARM ASSOC	**100,000 UNITS/ML**	**A203621**	**001**	Jan 07, 2016
AA		TARO PHARM	**100,000 UNITS/ML**	**A062876**	**001**	Feb 29, 1988
AA		VISTAPHARM	**100,000 UNITS/ML**	**A064142**	**001**	Jun 25, 1998
AA			**100,000 UNITS/ML**	**A065422**	**001**	Mar 07, 2011
AA	!	WOCKHARDT BIO AG	**100,000 UNITS/ML**	**A062512**	**001**	Oct 29, 1984

TABLET;ORAL

NYSTATIN

AA		HERITAGE PHARMS INC	**500,000 UNITS**	**A062474**	**001**	Dec 22, 1983
AA		SUN PHARM INDUSTRIES	**500,000 UNITS**	**A062838**	**001**	Dec 22, 1988
AA	!	TEVA	**500,000 UNITS**	**A062506**	**001**	Jan 16, 1984

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYKACET

AT		G AND W LABS INC	**100,000 UNITS/GM;0.1%**	**A062367**	**001**	May 28, 1985

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT		AMNEAL PHARMS LLC	**100,000 UNITS/GM;0.1%**	**A209990**	**001**	Feb 15, 2018
AT		CROWN LABS INC	**100,000 UNITS/GM;0.1%**	**A207730**	**001**	Dec 26, 2017
AT		DR REDDYS LABS LTD	**100,000 UNITS/GM;0.1%**	**A208326**	**001**	Oct 26, 2016
AT		FOUGERA PHARMS INC	**100,000 UNITS/GM;0.1%**	**A062599**	**001**	Oct 08, 1985
AT		GLENMARK PHARMS LTD	**100,000 UNITS/GM;0.1%**	**A208136**	**001**	Oct 24, 2016
AT		LUPIN LTD	**100,000 UNITS/GM;0.1%**	**A208205**	**001**	May 31, 2018
AT		PERRIGO UK FINCO	**100,000 UNITS/GM;0.1%**	**A208479**	**001**	Aug 14, 2017
AT	!	TARO	**100,000 UNITS/GM;0.1%**	**A062364**	**001**	Dec 22, 1987

OINTMENT;TOPICAL

MYKACET

AT		G AND W LABS INC	**100,000 UNITS/GM;0.1%**	**A062733**	**001**	Mar 06, 1987

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT		AKORN	**100,000 UNITS/GM;0.1%**	**A207217**	**001**	Aug 04, 2017
AT		CROWN LABS INC	**100,000 UNITS/GM;0.1%**	**A207731**	**001**	Dec 26, 2017
AT		DR REDDYS LABS LTD	**100,000 UNITS/GM;0.1%**	**A207741**	**001**	Jan 31, 2017
AT		FOUGERA PHARMS INC	**100,000 UNITS/GM;0.1%**	**A062602**	**001**	Oct 09, 1985
AT		GLENMARK PHARMS LTD	**100,000 UNITS/GM;0.1%**	**A208300**	**001**	Jun 23, 2016
AT		PERRIGO UK FINCO	**100,000 UNITS/GM;0.1%**	**A207380**	**001**	Dec 20, 2016
AT		RISING PHARMS	**100,000 UNITS/GM;0.1%**	**A206785**	**001**	Dec 29, 2016
AT		STRIDES PHARMA	**100,000 UNITS/GM;0.1%**	**A210077**	**001**	Jan 29, 2018
AT	!	TARO	**100,000 UNITS/GM;0.1%**	**A063305**	**001**	Mar 29, 1993
AT		TELIGENT PHARMA INC	**100,000 UNITS/GM;0.1%**	**A208287**	**001**	Dec 30, 2016
AT		ZYDUS PHARMS USA INC	**100,000 UNITS/GM;0.1%**	**A207764**	**001**	Nov 08, 2018

OBETICHOLIC ACID							
TABLET;ORAL							
OCALIVA							
	+	INTERCEPT PHARMS INC	5MG		N207999	001	May 27, 2016
	+!		10MG		N207999	002	May 27, 2016
OCTREOTIDE ACETATE							
INJECTABLE;INJECTION							
OCTREOTIDE ACETATE							
AP		FRESENIUS KABI USA	**EQ 0.2MG BASE/ML**		**A077450**	**001**	Feb 10, 2006
AP			**EQ 1MG BASE/ML**		**A077450**	**002**	Feb 10, 2006
AP		SAGENT PHARMS	**EQ 0.2MG BASE/ML**		**A091041**	**001**	Nov 12, 2013
AP			**EQ 1MG BASE/ML**		**A091041**	**002**	Nov 12, 2013
AP		SUN PHARM INDS	**EQ 0.05MG BASE/ML**		**A077372**	**001**	Aug 14, 2007
AP			**EQ 0.1MG BASE/ML**		**A077372**	**002**	Aug 14, 2007
AP			**EQ 0.2MG BASE/ML**		**A077373**	**001**	Aug 14, 2007
AP			**EQ 0.5MG BASE/ML**		**A077372**	**003**	Aug 14, 2007
AP			**EQ 1MG BASE/ML**		**A077373**	**002**	Aug 14, 2007
AP		TEVA PHARMS USA	**EQ 0.05MG BASE/ML**		**A075957**	**001**	Oct 03, 2005
AP			**EQ 0.1MG BASE/ML**		**A075957**	**002**	Oct 03, 2005
AP			**EQ 0.2MG BASE/ML**		**A075959**	**001**	Nov 21, 2005
AP			**EQ 0.5MG BASE/ML**		**A075957**	**003**	Oct 03, 2005
AP			**EQ 1MG BASE/ML**		**A075959**	**002**	Nov 21, 2005
AP		USV NORTH AMERICA	**EQ 0.05MG BASE/ML**		**A204669**	**001**	Dec 27, 2018
AP			**EQ 0.1MG BASE/ML**		**A204669**	**002**	Dec 27, 2018
AP			**EQ 0.2MG BASE/ML**		**A203765**	**001**	Sep 07, 2018
AP			**EQ 0.5MG BASE/ML**		**A204669**	**003**	Dec 27, 2018
AP			**EQ 1MG BASE/ML**		**A203765**	**002**	Sep 07, 2018
AP	**!**	WEST-WARD PHARMS INT	**EQ 0.2MG BASE/ML**		**A076330**	**001**	Apr 08, 2005
AP	**!**		**EQ 1MG BASE/ML**		**A076330**	**002**	Apr 08, 2005
OCTREOTIDE ACETATE (PRESERVATIVE FREE)							
AP		FRESENIUS KABI USA	**EQ 0.05MG BASE/ML**		**A077457**	**001**	Feb 10, 2006
AP			**EQ 0.1MG BASE/ML**		**A077457**	**002**	Feb 10, 2006
AP			**EQ 0.5MG BASE/ML**		**A077457**	**003**	Feb 10, 2006
AP		MYLAN INSTITUTIONAL	**EQ 0.05MG BASE/ML**		**A079198**	**001**	Feb 10, 2011
AP			**EQ 0.1MG BASE/ML**		**A079198**	**002**	Feb 10, 2011
AP			**EQ 0.5MG BASE/ML**		**A079198**	**003**	Feb 10, 2011
AP		SAGENT PHARMS	**EQ 0.05MG BASE/ML**		**A090834**	**001**	Nov 12, 2013
AP			**EQ 0.1MG BASE/ML**		**A090834**	**002**	Nov 12, 2013
AP			**EQ 0.5MG BASE/ML**		**A090834**	**003**	Nov 12, 2013
AP	**!**	WEST-WARD PHARMS INT	**EQ 0.05MG BASE/ML**		**A076313**	**001**	Mar 28, 2005
AP	**!**		**EQ 0.1MG BASE/ML**		**A076313**	**003**	Mar 28, 2005
AP	**!**		**EQ 0.5MG BASE/ML**		**A076313**	**002**	Mar 28, 2005
SANDOSTATIN							
AP	**+!**	NOVARTIS	**EQ 0.05MG BASE/ML**		**N019667**	**001**	Oct 21, 1988
AP	**+!**		**EQ 0.1MG BASE/ML**		**N019667**	**002**	Oct 21, 1988
AP	**+!**		**EQ 0.2MG BASE/ML**		**N019667**	**004**	Jun 12, 1991
AP	**+!**		**EQ 0.5MG BASE/ML**		**N019667**	**003**	Oct 21, 1988
AP	**+!**		**EQ 1MG BASE/ML**		**N019667**	**005**	Jun 12, 1991
SANDOSTATIN LAR							
	+	NOVARTIS	EQ 10MG BASE/VIAL		N021008	001	Nov 25, 1998
	+		EQ 20MG BASE/VIAL		N021008	002	Nov 25, 1998
	+!		EQ 30MG BASE/VIAL		N021008	003	Nov 25, 1998
OFLOXACIN							
SOLUTION/DROPS;OPHTHALMIC							
OCUFLOX							
AT	**+!**	ALLERGAN	**0.3%**		**N019921**	**001**	Jul 30, 1993
OFLOXACIN							
AT		AKORN	**0.3%**		**A076407**	**001**	Apr 15, 2008
AT		ALTAIRE PHARMS INC	**0.3%**		**A202692**	**001**	Apr 29, 2013
AT		ALVOGEN	**0.3%**		**A076830**	**001**	Aug 31, 2004
AT		BAUSCH AND LOMB	**0.3%**		**A076622**	**001**	May 14, 2004
AT		FDC LTD	**0.3%**		**A078559**	**001**	Feb 25, 2009
AT		HI TECH PHARMA	**0.3%**		**A076615**	**001**	May 14, 2004
AT		SANDOZ INC	**0.3%**		**A076231**	**001**	May 14, 2004
SOLUTION/DROPS;OTIC							
OFLOXACIN							
AT		ALVOGEN	**0.3%**		**A090395**	**001**	Aug 11, 2009
AT		APOTEX INC	**0.3%**		**A076527**	**001**	Sep 28, 2007
AT	**!**	BAUSCH AND LOMB	**0.3%**		**A076128**	**001**	Mar 17, 2008

OFLOXACIN						
SOLUTION/DROPS;OTIC						
OFLOXACIN						
AT		HI TECH PHARMA	**0.3%**	**A076616**	**001**	Mar 17, 2008
AT		SANDOZ INC	**0.3%**	**A078222**	**001**	Mar 17, 2008
TABLET;ORAL						
OFLOXACIN						
AB		CADILA PHARMS LTD	**200MG**	**A091656**	**001**	Sep 18, 2014
AB			**300MG**	**A091656**	**002**	Sep 18, 2014
AB			**400MG**	**A091656**	**003**	Sep 18, 2014
AB		DR REDDYS LABS LTD	**200MG**	**A077098**	**001**	Feb 10, 2006
AB			**300MG**	**A077098**	**002**	Feb 10, 2006
AB			**400MG**	**A077098**	**003**	Feb 10, 2006
AB		LARKEN LABS	**400MG**	**A076093**	**003**	Sep 02, 2003
AB		TEVA	**200MG**	**A076182**	**001**	Sep 02, 2003
AB			**300MG**	**A076182**	**002**	Sep 02, 2003
AB	**!**		**400MG**	**A076182**	**003**	Sep 02, 2003
OLANZAPINE						
INJECTABLE;INTRAMUSCULAR						
OLANZAPINE						
AP		LUITPOLD	**10MG/VIAL**	**A201741**	**001**	Mar 20, 2012
AP		SANDOZ INC	**10MG/VIAL**	**A201588**	**001**	Oct 24, 2011
ZYPREXA						
AP	**+!**	LILLY	**10MG/VIAL**	**N021253**	**001**	Mar 29, 2004
TABLET;ORAL						
OLANZAPINE						
AB		ALKEM LABS LTD	**2.5MG**	**A202295**	**001**	Oct 20, 2015
AB			**5MG**	**A202295**	**002**	Oct 20, 2015
AB			**7.5MG**	**A202295**	**003**	Oct 20, 2015
AB			**10MG**	**A202295**	**004**	Oct 20, 2015
AB			**15MG**	**A202295**	**005**	Oct 20, 2015
AB			**20MG**	**A202295**	**006**	Oct 20, 2015
AB		APOTEX INC	**2.5MG**	**A090798**	**001**	Apr 23, 2012
AB			**5MG**	**A090798**	**002**	Apr 23, 2012
AB			**7.5MG**	**A090798**	**003**	Apr 23, 2012
AB			**10MG**	**A090798**	**004**	Apr 23, 2012
AB			**15MG**	**A090798**	**005**	Apr 23, 2012
AB			**20MG**	**A090798**	**006**	Apr 23, 2012
AB		AUROBINDO PHARMA LTD	**2.5MG**	**A202050**	**001**	Apr 23, 2012
AB			**5MG**	**A202050**	**002**	Apr 23, 2012
AB			**7.5MG**	**A202050**	**003**	Apr 23, 2012
AB			**10MG**	**A202050**	**004**	Apr 23, 2012
AB			**15MG**	**A202050**	**005**	Apr 23, 2012
AB			**20MG**	**A202050**	**006**	Apr 23, 2012
AB		DR REDDYS LABS LTD	**2.5MG**	**A076255**	**001**	Apr 23, 2012
AB			**5MG**	**A076255**	**002**	Apr 23, 2012
AB			**7.5MG**	**A076255**	**003**	Apr 23, 2012
AB			**10MG**	**A076255**	**004**	Apr 23, 2012
AB			**15MG**	**A076133**	**001**	Apr 23, 2012
AB			**20MG**	**A076133**	**002**	Oct 24, 2011
AB		HIKMA PHARMS	**2.5MG**	**A204866**	**001**	Jun 16, 2017
AB			**5MG**	**A204866**	**002**	Jun 16, 2017
AB			**7.5MG**	**A204866**	**003**	Jun 16, 2017
AB			**10MG**	**A204866**	**004**	Jun 16, 2017
AB			**15MG**	**A204866**	**005**	Jun 16, 2017
AB			**20MG**	**A204866**	**006**	Jun 16, 2017
AB		INVAGEN PHARMS	**2.5MG**	**A203333**	**001**	Mar 15, 2016
AB			**5MG**	**A203333**	**002**	Mar 15, 2016
AB			**7.5MG**	**A203333**	**003**	Mar 15, 2016
AB			**10MG**	**A203333**	**004**	Mar 15, 2016
AB			**15MG**	**A203333**	**005**	Mar 15, 2016
AB			**20MG**	**A203333**	**006**	Mar 15, 2016
AB		IVAX PHARMS INC	**20MG**	**A077301**	**001**	Apr 29, 2015
AB		JIANGSU HANSOH PHARM	**2.5MG**	**A209399**	**001**	Sep 24, 2018
AB			**5MG**	**A209399**	**002**	Sep 24, 2018
AB			**10MG**	**A209399**	**003**	Sep 24, 2018
AB		MACLEODS PHARMS LTD	**2.5MG**	**A202862**	**001**	Aug 15, 2014
AB			**5MG**	**A202862**	**002**	Aug 15, 2014
AB			**7.5MG**	**A202862**	**003**	Aug 15, 2014
AB			**10MG**	**A202862**	**004**	Aug 15, 2014

OLANZAPINE

TABLET;ORAL

OLANZAPINE

AB			15MG	A202862	005	Aug 15, 2014
AB			20MG	A202862	006	Aug 15, 2014
AB		ORCHID HLTHCARE	2.5MG	A202287	001	Apr 23, 2012
AB			5MG	A202287	002	Apr 23, 2012
AB			7.5MG	A202287	003	Apr 23, 2012
AB			10MG	A202287	004	Apr 23, 2012
AB			15MG	A202287	005	Apr 23, 2012
AB			20MG	A202287	006	Apr 23, 2012
AB		QILU PHARM CO LTD	2.5MG	A204319	001	Jan 27, 2016
AB			5MG	A204319	002	Jan 27, 2016
AB			7.5MG	A204319	003	Jan 27, 2016
AB			10MG	A204319	004	Jan 27, 2016
AB			15MG	A204319	005	Jan 27, 2016
AB			20MG	A204319	006	Jan 27, 2016
AB		SUN PHARM INDS	2.5MG	A091038	001	Apr 23, 2012
AB			5MG	A091038	002	Apr 23, 2012
AB			7.5MG	A091038	003	Apr 23, 2012
AB			10MG	A091038	004	Apr 23, 2012
AB			15MG	A091038	005	Apr 23, 2012
AB			20MG	A091038	006	Apr 23, 2012
AB		SUNSHINE LAKE	2.5MG	A206238	001	Nov 19, 2018
AB			5MG	A206238	002	Nov 19, 2018
AB			7.5MG	A206238	003	Nov 19, 2018
AB			10MG	A206238	004	Nov 19, 2018
AB			15MG	A206238	005	Nov 19, 2018
AB			20MG	A206238	006	Nov 19, 2018
AB		TEVA PHARMS	2.5MG	A076000	001	Oct 24, 2011
AB			5MG	A076000	002	Oct 24, 2011
AB			7.5MG	A076000	003	Oct 24, 2011
AB			10MG	A076000	004	Oct 24, 2011
AB			15MG	A076000	005	Oct 24, 2011
AB		TORRENT PHARMS LTD	2.5MG	A091434	001	Apr 23, 2012
AB			5MG	A091434	002	Apr 23, 2012
AB			7.5MG	A091434	003	Apr 23, 2012
AB			10MG	A091434	004	Apr 23, 2012
AB			15MG	A091434	005	Apr 23, 2012
AB			20MG	A091434	006	Apr 23, 2012
AB		ZYDUS PHARMS USA INC	2.5MG	A090459	001	Jul 16, 2018
AB			5MG	A090459	002	Jul 16, 2018
AB			7.5MG	A090459	003	Jul 16, 2018
AB			10MG	A090459	004	Jul 16, 2018
AB			15MG	A090459	005	Jul 16, 2018
AB			20MG	A090459	006	Jul 16, 2018

ZYPREXA

AB	+	LILLY	2.5MG	N020592	001	Sep 30, 1996
AB	+!		5MG	N020592	002	Sep 30, 1996
AB	+		7.5MG	N020592	003	Sep 30, 1996
AB	+		10MG	N020592	004	Sep 30, 1996
AB	+		15MG	N020592	005	Sep 09, 1997
AB	+		20MG	N020592	006	Sep 09, 1997

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

AB		APOTEX INC	5MG	A091265	001	Oct 24, 2011
AB			10MG	A091265	002	Oct 24, 2011
AB			15MG	A091265	003	Oct 24, 2011
AB			20MG	A091265	004	Oct 24, 2011
AB		AUROBINDO PHARMA LTD	5MG	A203708	001	May 15, 2014
AB			10MG	A203708	002	May 15, 2014
AB			15MG	A203708	003	May 15, 2014
AB			20MG	A203708	004	May 15, 2014
AB		BARR LABS INC	5MG	A077243	001	Jan 30, 2012
AB			10MG	A077243	002	Jan 30, 2012
AB			15MG	A077243	003	Jan 30, 2012
AB			20MG	A077243	004	Jan 30, 2012
AB		DR REDDYS LABS LTD	5MG	A076534	001	Oct 24, 2011
AB			10MG	A076534	002	Oct 24, 2011
AB			15MG	A076534	003	Oct 24, 2011
AB			20MG	A076534	004	Oct 24, 2011

OLANZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

AB		HEC PHARM	**5MG**	**A208146**	**001**	Jul 02, 2018
AB			**10MG**	**A208146**	**002**	Jul 02, 2018
AB			**15MG**	**A208146**	**003**	Jul 02, 2018
AB			**20MG**	**A208146**	**004**	Jul 02, 2018
AB		INVAGEN PHARMS	**5MG**	**A203456**	**001**	Mar 16, 2016
AB			**10MG**	**A203456**	**002**	Mar 16, 2016
AB			**15MG**	**A203456**	**003**	Mar 16, 2016
AB			**20MG**	**A203456**	**004**	Mar 16, 2016
AB		JUBILANT GENERICS	**5MG**	**A200221**	**001**	Sep 12, 2012
AB			**10MG**	**A200221**	**002**	Sep 12, 2012
AB			**15MG**	**A200221**	**003**	Sep 12, 2012
AB			**20MG**	**A200221**	**004**	Sep 12, 2012
AB		MACLEODS PHARMS LTD	**5MG**	**A203044**	**001**	Feb 20, 2015
AB			**10MG**	**A203044**	**002**	Feb 20, 2015
AB			**15MG**	**A203044**	**003**	Feb 20, 2015
AB			**20MG**	**A203044**	**004**	Feb 20, 2015
AB		MYLAN PHARMS INC	**5MG**	**A202285**	**001**	May 12, 2014
AB			**10MG**	**A202285**	**002**	May 12, 2014
AB			**15MG**	**A202285**	**003**	May 12, 2014
AB			**20MG**	**A202285**	**004**	May 12, 2014
AB		ORCHID HLTHCARE	**5MG**	**A202937**	**001**	Mar 02, 2015
AB			**10MG**	**A202937**	**002**	Mar 02, 2015
AB			**15MG**	**A202937**	**003**	Mar 02, 2015
AB			**20MG**	**A202937**	**004**	Mar 02, 2015
AB		PAR PHARM	**5MG**	**A078109**	**001**	Oct 24, 2011
AB			**10MG**	**A078109**	**002**	Oct 24, 2011
AB			**15MG**	**A078109**	**003**	Oct 24, 2011
AB			**20MG**	**A078109**	**004**	Oct 24, 2011
AB		SUN PHARM INDS	**5MG**	**A090881**	**001**	Feb 28, 2012
AB			**10MG**	**A090881**	**002**	Feb 28, 2012
AB			**15MG**	**A090881**	**003**	Feb 28, 2012
AB			**20MG**	**A090881**	**004**	Feb 28, 2012
AB		TORRENT PHARMS LLC	**5MG**	**A091415**	**001**	Oct 25, 2011
AB			**10MG**	**A091415**	**002**	Oct 25, 2011
AB			**15MG**	**A091415**	**003**	Oct 25, 2011
AB			**20MG**	**A091415**	**004**	Oct 25, 2011

ZYPREXA ZYDIS

AB	**+!**	LILLY	**5MG**	**N021086**	**001**	Apr 06, 2000
AB	**+**		**10MG**	**N021086**	**002**	Apr 06, 2000
AB	**+**		**15MG**	**N021086**	**003**	Apr 06, 2000
AB	**+**		**20MG**	**N021086**	**004**	Apr 06, 2000

OLANZAPINE PAMOATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ZYPREXA RELPREVV

+	ELI LILLY CO	EQ 210MG BASE/VIAL	N022173	001	Dec 11, 2009
+		EQ 300MG BASE/VIAL	N022173	002	Dec 11, 2009
+!		EQ 405MG BASE/VIAL	N022173	003	Dec 11, 2009

OLAPARIB

CAPSULE;ORAL

LYNPARZA

+!	ASTRAZENECA PHARMS	50MG	N206162	001	Dec 19, 2014

TABLET;ORAL

LYNPARZA

+	ASTRAZENECA PHARMS	100MG	N208558	001	Aug 17, 2017
+!		150MG	N208558	002	Aug 17, 2017

OLMESARTAN MEDOXOMIL

TABLET;ORAL

BENICAR

AB	**+**	DAIICHI SANKYO	**5MG**	**N021286**	**001**	Apr 25, 2002
AB	**+**		**20MG**	**N021286**	**003**	Apr 25, 2002
AB	**+!**		**40MG**	**N021286**	**004**	Apr 25, 2002

OLMESARTAN MEDOXOMIL

AB		ACCORD HLTHCARE	**5MG**	**A207662**	**001**	Apr 24, 2017
AB			**20MG**	**A207662**	**002**	Apr 24, 2017
AB			**40MG**	**A207662**	**003**	Apr 24, 2017
AB		ALEMBIC PHARMS LTD	**5MG**	**A203012**	**001**	Apr 24, 2017
AB			**20MG**	**A203012**	**002**	Apr 24, 2017
AB			**40MG**	**A203012**	**003**	Apr 24, 2017

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

AB		ALKEM LABS LTD	**5MG**	**A206763**	**001**	Apr 24, 2017
AB			**20MG**	**A206763**	**002**	Apr 24, 2017
AB			**40MG**	**A206763**	**003**	Apr 24, 2017
AB		AUROBINDO PHARMA LTD	**5MG**	**A204798**	**001**	Apr 24, 2017
AB			**20MG**	**A204798**	**002**	Apr 24, 2017
AB			**40MG**	**A204798**	**003**	Apr 24, 2017
AB		GLENMARK PHARMS LTD	**5MG**	**A203281**	**001**	May 25, 2017
AB			**20MG**	**A203281**	**002**	May 25, 2017
AB			**40MG**	**A203281**	**003**	May 25, 2017
AB		JUBILANT GENERICS	**5MG**	**A205482**	**001**	Apr 24, 2017
AB			**20MG**	**A205482**	**002**	Apr 24, 2017
AB			**40MG**	**A205482**	**003**	Apr 24, 2017
AB		LUPIN LTD	**5MG**	**A206631**	**001**	Apr 27, 2017
AB			**20MG**	**A206631**	**002**	Apr 27, 2017
AB			**40MG**	**A206631**	**003**	Apr 27, 2017
AB		MACLEODS PHARMS LTD	**5MG**	**A204814**	**001**	Apr 24, 2017
AB			**20MG**	**A204814**	**002**	Apr 24, 2017
AB			**40MG**	**A204814**	**003**	Apr 24, 2017
AB		MYLAN PHARMS INC	**5MG**	**A078276**	**001**	Oct 26, 2016
AB			**20MG**	**A078276**	**002**	Oct 26, 2016
AB			**40MG**	**A078276**	**003**	Oct 26, 2016
AB		QILU PHARM CO LTD	**5MG**	**A210552**	**001**	Jan 10, 2019
AB			**20MG**	**A210552**	**002**	Jan 10, 2019
AB			**40MG**	**A210552**	**003**	Jan 10, 2019
AB		SCIEGEN PHARMS INC	**5MG**	**A208130**	**001**	Jun 29, 2018
AB			**20MG**	**A208130**	**002**	Jun 29, 2018
AB			**40MG**	**A208130**	**003**	Jun 29, 2018
AB		TEVA PHARMS USA	**5MG**	**A091079**	**001**	Apr 24, 2017
AB			**20MG**	**A091079**	**002**	Apr 24, 2017
AB			**40MG**	**A091079**	**003**	Apr 24, 2017
AB		TORRENT PHARMS LTD	**5MG**	**A202375**	**001**	Apr 24, 2017
AB			**20MG**	**A202375**	**002**	Apr 24, 2017
AB			**40MG**	**A202375**	**003**	Apr 24, 2017
AB		ZYDUS PHARMS USA INC	**5MG**	**A205192**	**001**	Apr 24, 2017
AB			**20MG**	**A205192**	**002**	Apr 24, 2017
AB			**40MG**	**A205192**	**003**	Apr 24, 2017

OLODATEROL HYDROCHLORIDE

SPRAY, METERED;INHALATION

STRIVERDI RESPIMAT

+!	BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH	N203108	001	Jul 31, 2014

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

SPRAY, METERED;INHALATION

STIOLTO RESPIMAT

+!	BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH;EQ 0.0025MG BASE/INH	N206756	001	May 21, 2015

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

AT		AKORN	**EQ 0.2% BASE**	**A204723**	**001**	Dec 05, 2017
AT		AKORN INC	**EQ 0.1% BASE**	**A204532**	**001**	Jan 10, 2017
AT		ALEMBIC PHARMS LTD	**EQ 0.1% BASE**	**A209919**	**001**	Dec 07, 2018
AT		APOTEX INC	**EQ 0.1% BASE**	**A078350**	**001**	Dec 07, 2015
AT			**EQ 0.2% BASE**	**A090918**	**001**	Dec 05, 2017
AT		AUROBINDO PHARMA LTD	**EQ 0.1% BASE**	**A204812**	**001**	Dec 18, 2015
AT		BARR LABS INC	**EQ 0.2% BASE**	**A090848**	**001**	Jul 13, 2015
AT		CIPLA	**EQ 0.1% BASE**	**A206046**	**001**	Jul 26, 2017
AT			**EQ 0.2% BASE**	**A206087**	**001**	Dec 05, 2017
AT		MYLAN PHARMS INC	**EQ 0.1% BASE**	**A204392**	**001**	Mar 21, 2018
AT		SOMERSET THERAPS LLC	**EQ 0.1% BASE**	**A206306**	**001**	Dec 07, 2015
AT		USV NORTH AMERICA	**EQ 0.1% BASE**	**A203152**	**001**	Dec 07, 2015
AT		WOCKHARDT LTD	**EQ 0.1% BASE**	**A200810**	**001**	Jun 28, 2017

PATADAY

AT	**+!**	NOVARTIS PHARMS CORP	**EQ 0.2% BASE**	**N021545**	**001**	Dec 22, 2004

OLOPATADINE HYDROCHLORIDE						
SOLUTION/DROPS;OPHTHALMIC						
PATANOL						
AT	**+!**	NOVARTIS PHARMS CORP	**EQ 0.1% BASE**	**N020688**	**001**	Dec 18, 1996
PAZEO						
	+!	NOVARTIS PHARMS CORP	EQ 0.7% BASE	N206276	001	Jan 30, 2015
SPRAY, METERED;NASAL						
OLOPATADINE HYDROCHLORIDE						
AB		APOTEX INC	**0.665MG/SPRAY**	**A091572**	**001**	Oct 08, 2014
AB		PERRIGO ISRAEL	**0.665MG/SPRAY**	**A202853**	**001**	Jan 31, 2017
PATANASE						
AB	**+!**	NOVARTIS PHARMS CORP	**0.665MG/SPRAY**	**N021861**	**001**	Apr 15, 2008
OLSALAZINE SODIUM						
CAPSULE;ORAL						
DIPENTUM						
	+!	MYLAN SPECIALITY LP	250MG	N019715	001	Jul 31, 1990
OMACETAXINE MEPESUCCINATE						
POWDER;SUBCUTANEOUS						
SYNRIBO						
	+!	TEVA PHARMS INTL	3.5MG/VIAL	N203585	001	Oct 26, 2012
OMADACYCLINE TOSYLATE						
POWDER;INTRAVENOUS						
NUZYRA						
	+!	PARATEK PHARMS INC	EQ 100MG BASE/VIAL	N209817	001	Oct 02, 2018
TABLET;ORAL						
NUZYRA						
	+!	PARATEK PHARMS INC	EQ 150MG BASE	N209816	001	Oct 02, 2018
OMBITASVIR; PARITAPREVIR; RITONAVIR						
TABLET;ORAL						
TECHNIVIE						
	+!	ABBVIE INC	12.5MG;75MG;50MG	N207931	001	Jul 24, 2015
OMEGA-3-ACID ETHYL ESTERS						
CAPSULE;ORAL						
LOVAZA						
AB	**+!**	SMITHKLINE BEECHAM	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**N021654**	**001**	Nov 10, 2004
OMEGA-3-ACID ETHYL ESTERS						
AB		AMNEAL PHARMS	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A204940**	**001**	Nov 27, 2015
AB		APOTEX INC	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A090973**	**001**	Sep 30, 2014
AB		PAR PHARM INC	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A091018**	**001**	Jun 24, 2014
AB		STRIDES PHARMA	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A203893**	**001**	Sep 19, 2017
AB		TEVA PHARMS USA	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A091028**	**001**	Apr 07, 2014
OMEPRAZOLE						
CAPSULE, DELAYED REL PELLETS;ORAL						
OMEPRAZOLE						
AB		ACTAVIS LABS FL INC	**10MG**	**A075347**	**001**	May 30, 2008
AB			**20MG**	**A075347**	**002**	May 30, 2008
AB			**40MG**	**A075347**	**003**	May 30, 2008
AB		APOTEX	**10MG**	**A076048**	**001**	Oct 22, 2007
AB			**20MG**	**A076048**	**002**	Oct 22, 2007
AB			**40MG**	**A076048**	**003**	Jan 21, 2009
AB		AUROBINDO PHARMA LTD	**10MG**	**A203270**	**001**	Aug 19, 2015
AB			**20MG**	**A203270**	**002**	Aug 19, 2015
AB			**40MG**	**A203270**	**003**	Aug 19, 2015
AB		BRECKENRIDGE PHARM	**10MG**	**A203481**	**001**	Jul 03, 2017
AB			**20MG**	**A203481**	**002**	Jul 03, 2017
AB			**40MG**	**A203481**	**003**	Jul 03, 2017
AB		DR REDDYS LABS LTD	**10MG**	**A075576**	**003**	Oct 22, 2007
AB			**10MG**	**A078490**	**002**	Mar 16, 2009
AB			**20MG**	**A075576**	**002**	Oct 22, 2007
AB			**20MG**	**A078490**	**003**	Mar 16, 2009
AB			**40MG**	**A075576**	**001**	Jan 21, 2009

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

AB			**40MG**	**A078490**	**001**	Apr 17, 2009
AB		GLENMARK GENERICS	**10MG**	**A091672**	**001**	Oct 31, 2014
AB			**20MG**	**A091672**	**002**	Oct 31, 2014
AB			**40MG**	**A091672**	**003**	Oct 31, 2014
AB		IMPAX LABS	**10MG**	**A075785**	**001**	Oct 22, 2007
AB			**20MG**	**A075785**	**002**	Oct 22, 2007
AB			**40MG**	**A075785**	**003**	Jan 21, 2009
AB		LANNETT CO INC	**10MG**	**A075410**	**001**	Nov 01, 2002
AB			**20MG**	**A075410**	**002**	Nov 01, 2002
AB			**40MG**	**A075410**	**003**	Jan 23, 2009
AB		LUPIN LTD	**40MG**	**A202384**	**001**	Aug 25, 2015
AB		MYLAN	**10MG**	**A075876**	**001**	May 29, 2003
AB			**20MG**	**A075876**	**002**	May 29, 2003
AB			**40MG**	**A075876**	**003**	Jan 21, 2009
AB		MYLAN PHARMS INC	**10MG**	**A205070**	**001**	Jun 29, 2018
AB			**20MG**	**A205070**	**002**	Jun 29, 2018
AB			**40MG**	**A205070**	**003**	Jun 29, 2018
AB		SANDOZ	**10MG**	**A075757**	**001**	Jan 28, 2003
AB	**!**		**20MG**	**A075757**	**002**	Jan 28, 2003
AB	**!**		**40MG**	**A076515**	**001**	Jan 21, 2009
AB		TEVA PHARMS USA	**20MG**	**A204661**	**001**	Jun 13, 2017
AB			**40MG**	**A204661**	**002**	Jun 13, 2017
AB		ZYDUS PHARMS USA INC	**10MG**	**A091352**	**001**	Nov 19, 2012
AB			**20MG**	**A091352**	**002**	Nov 19, 2012
AB			**40MG**	**A091352**	**003**	Nov 19, 2012

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PRILOSEC

+	COVIS PHARMA BV	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008
+!		EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB		AJANTA PHARMA LTD	**20MG;1.1GM**	**A204228**	**001**	Jul 15, 2016
AB			**40MG;1.1GM**	**A204228**	**002**	Jul 15, 2016
AB		AUROLIFE PHARMA LLC	**20MG;1.1GM**	**A204922**	**001**	Aug 19, 2016
AB			**40MG;1.1GM**	**A204922**	**002**	Aug 19, 2016
AB		DR REDDYS LABS LTD	**20MG;1.1GM**	**A204068**	**001**	Jul 15, 2016
AB			**40MG;1.1GM**	**A204068**	**002**	Jul 15, 2016
AB		PAR PHARM	**20MG;1.1GM**	**A078966**	**001**	May 25, 2010
AB			**40MG;1.1GM**	**A078966**	**002**	May 25, 2010
AB		SCIEGEN PHARMS INC	**20MG;1.1GM**	**A207476**	**001**	Dec 06, 2016
AB			**40MG;1.1GM**	**A207476**	**002**	Dec 06, 2016
AB		ZYDUS PHARMS USA INC	**20MG;1.1GM**	**A203290**	**001**	May 25, 2018
AB			**40MG;1.1GM**	**A203290**	**002**	May 25, 2018

ZEGERID

AB	**+**	SANTARUS INC	**20MG;1.1GM**	**N021849**	**001**	Feb 27, 2006
AB	**+!**		**40MG;1.1GM**	**N021849**	**002**	Feb 27, 2006

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB		AJANTA PHARMA LTD	**20MG/PACKET;1.68GM/PACKET**	**A205545**	**001**	Jul 27, 2016
AB			**40MG/PACKET;1.68GM/PACKET**	**A205545**	**002**	Jul 27, 2016
AB		PAR PHARM	**20MG/PACKET;1.68GM/PACKET**	**A079182**	**001**	Apr 19, 2013
AB			**40MG/PACKET;1.68GM/PACKET**	**A079182**	**002**	Apr 19, 2013

ZEGERID

AB	**+**	SANTARUS INC	**20MG/PACKET;1.68GM/PACKET**	**N021636**	**001**	Jun 15, 2004
AB	**+!**		**40MG/PACKET;1.68GM/PACKET**	**N021636**	**002**	Dec 21, 2004

ONDANSETRON

FILM;ORAL

ZUPLENZ

+	MIDATECH PHARMA US	4MG	N022524	001	Jul 02, 2010
+!		8MG	N022524	002	Jul 02, 2010

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

AB		AUROBINDO PHARMA	**4MG**	**A090469**	**001**	Apr 12, 2010
AB			**8MG**	**A090469**	**002**	Apr 12, 2010

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

AB		BARR	**4MG**	**A076693**	**001**	Jun 25, 2007
AB			**8MG**	**A076693**	**002**	Jun 25, 2007
AB		GLENMARK GENERICS	**4MG**	**A078152**	**001**	Jun 27, 2007
AB			**8MG**	**A078152**	**002**	Jun 27, 2007
AB		MYLAN	**4MG**	**A078139**	**001**	Jun 25, 2007
AB			**8MG**	**A078139**	**002**	Jun 25, 2007
AB		SANDOZ	**4MG**	**A078050**	**001**	Aug 13, 2007
AB			**8MG**	**A078050**	**002**	Aug 13, 2007
AB		SUN PHARM INDS	**4MG**	**A077557**	**001**	Aug 02, 2007
AB			**8MG**	**A077557**	**002**	Aug 02, 2007
AB		SUN PHARM INDS LTD	**4MG**	**A078602**	**001**	Feb 24, 2011
AB			**8MG**	**A078602**	**002**	Feb 24, 2011
AB		TEVA	**4MG**	**A076810**	**001**	Jun 25, 2007
AB			**8MG**	**A076810**	**002**	Jun 25, 2007

ZOFRAN ODT

AB	+	NOVARTIS PHARMS CORP	**4MG**	**N020781**	**001**	Jan 27, 1999
AB	+!		**8MG**	**N020781**	**002**	Jan 27, 1999

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

AP		ACCORD HLTHCARE	**EQ 2MG BASE/ML**	**A206846**	**001**	Jul 13, 2015
AP		AUROBINDO PHARMA LTD	**EQ 2MG BASE/ML**	**A202599**	**001**	Dec 21, 2012
AP	!	BAXTER HLTHCARE CORP	**EQ 2MG BASE/ML**	**A078288**	**001**	Feb 22, 2013
AP		EMCURE PHARMS	**EQ 2MG BASE/ML**	**A090424**	**001**	Apr 16, 2010
AP		FRESENIUS KABI USA	**EQ 2MG BASE/ML**	**A076974**	**001**	Dec 26, 2006
AP		GLAND PHARMA LTD	**EQ 2MG BASE/ML**	**A079224**	**001**	Sep 25, 2009
AP			**EQ 2MG BASE/ML**	**A090648**	**001**	Jun 15, 2012
AP		HIKMA FARMACEUTICA	**EQ 2MG BASE/ML**	**A076781**	**001**	Dec 26, 2006
AP		HOSPIRA	**EQ 2MG BASE/ML**	**A077473**	**001**	Dec 26, 2006
AP			**EQ 2MG BASE/ML**	**A077840**	**001**	Jan 19, 2007
AP		LUITPOLD	**EQ 2MG BASE/ML**	**A079039**	**001**	Nov 18, 2008
AP		MYLAN LABS LTD	**EQ 2MG BASE/ML**	**A204906**	**001**	Jul 31, 2017
AP		QILU PHARM CO LTD	**EQ 2MG BASE/ML**	**A203711**	**001**	Sep 08, 2014
AP		SANDOZ INC	**EQ 2MG BASE/ML**	**A077430**	**001**	Jun 27, 2007
AP		TEVA	**EQ 2MG BASE/ML**	**A076876**	**001**	Nov 22, 2006
AP		WEST-WARD PHARMS INT	**EQ 2MG BASE/ML**	**A076967**	**001**	Dec 26, 2006
AP			**EQ 2MG BASE/ML**	**A077365**	**001**	Dec 26, 2006
AP		WOCKHARDT	**EQ 2MG BASE/ML**	**A077577**	**001**	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

AP		ACCORD HLTHCARE	**EQ 2MG BASE/ML**	**A206845**	**001**	Mar 10, 2016
AP		AUROBINDO PHARMA LTD	**EQ 2MG BASE/ML**	**A202600**	**001**	Dec 21, 2012
AP	!	BAXTER HLTHCARE CORP	**EQ 2MG BASE/ML**	**A078287**	**001**	Feb 22, 2013
AP		EMCURE PHARMS LTD	**EQ 2MG BASE/ML**	**A078945**	**001**	Jan 03, 2013
AP		FRESENIUS KABI USA	**EQ 2MG BASE/ML**	**A076972**	**001**	Dec 26, 2006
AP			**EQ 2MG BASE/ML**	**A202253**	**001**	Jul 19, 2013
AP		HIKMA FARMACEUTICA	**EQ 2MG BASE/ML**	**A076780**	**001**	Dec 26, 2006
AP		HOSPIRA	**EQ 2MG BASE/ML**	**A077548**	**001**	Dec 26, 2006
AP		LUITPOLD	**EQ 2MG BASE/ML**	**A079032**	**001**	Nov 18, 2008
AP		SANDOZ INC	**EQ 2MG BASE/ML**	**A077551**	**001**	Jun 27, 2007
AP		TEVA	**EQ 2MG BASE/ML**	**A076759**	**001**	Nov 22, 2006
AP		WEST-WARD PHARMS INT	**EQ 2MG BASE/ML**	**A077011**	**001**	Dec 26, 2006
AP			**EQ 2MG BASE/ML**	**A077541**	**001**	Dec 26, 2006
AP		WOCKHARDT	**EQ 2MG BASE/ML**	**A077716**	**001**	Dec 26, 2006

SOLUTION;ORAL

ONDANSETRON HYDROCHLORIDE

AA		AMNEAL PHARMS	**EQ 4MG BASE/5ML**	**A091483**	**001**	Jan 31, 2011
AA		APOTEX	**EQ 4MG BASE/5ML**	**A078127**	**001**	Jun 25, 2007
AA		AUROBINDO PHARMA	**EQ 4MG BASE/5ML**	**A078776**	**001**	Nov 28, 2007
AA		LANNETT CO INC	**EQ 4MG BASE/5ML**	**A091342**	**001**	Jan 27, 2011
AA		TARO	**EQ 4MG BASE/5ML**	**A077009**	**001**	Nov 30, 2007
AA		WEST-WARD PHARMS INT	**EQ 4MG BASE/5ML**	**A076960**	**001**	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE						
SOLUTION;ORAL						
ZOFRAN						
AA	**+!**	NOVARTIS PHARMS CORP	**EQ 4MG BASE/5ML**	**N020605**	**001**	Jan 24, 1997
TABLET;ORAL						
ONDANSETRON HYDROCHLORIDE						
AB		APOTEX	**EQ 4MG BASE**	**A077306**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A077306**	**002**	Jun 25, 2007
AB		AUROBINDO PHARMA	**EQ 4MG BASE**	**A078539**	**001**	Jul 31, 2007
AB			**EQ 8MG BASE**	**A078539**	**002**	Jul 31, 2007
AB			**EQ 24MG BASE**	**A078539**	**003**	Jul 31, 2007
AB		CASI PHARMS INC	**EQ 4MG BASE**	**A077517**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A077517**	**002**	Jun 25, 2007
AB			**EQ 24MG BASE**	**A077517**	**003**	Jun 25, 2007
AB		DR REDDYS LABS LTD	**EQ 4MG BASE**	**A076183**	**003**	Dec 26, 2006
AB			**EQ 8MG BASE**	**A076183**	**002**	Dec 26, 2006
AB			**EQ 24MG BASE**	**A076183**	**001**	Dec 26, 2006
AB		GLENMARK GENERICS	**EQ 4MG BASE**	**A077535**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A077535**	**002**	Jun 25, 2007
AB			**EQ 24MG BASE**	**A077535**	**003**	Jun 25, 2007
AB		IPCA LABS LTD	**EQ 4MG BASE**	**A203761**	**001**	Jan 23, 2014
AB			**EQ 8MG BASE**	**A203761**	**002**	Jan 23, 2014
AB		MYLAN	**EQ 4MG BASE**	**A076930**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A076930**	**002**	Jun 25, 2007
AB			**EQ 24MG BASE**	**A076930**	**004**	Jun 25, 2007
AB		NATCO PHARMA LTD	**EQ 4MG BASE**	**A077851**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A077851**	**002**	Jun 25, 2007
AB		PLIVA HRVATSKA DOO	**EQ 4MG BASE**	**A077112**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A077112**	**002**	Jun 25, 2007
AB			**EQ 24MG BASE**	**A077112**	**003**	Jun 25, 2007
AB		SUN PHARM INDS (IN)	**EQ 4MG BASE**	**A077050**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A077050**	**002**	Jun 25, 2007
AB		TEVA	**EQ 4MG BASE**	**A076252**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A076252**	**002**	Jun 25, 2007
AB			**EQ 24MG BASE**	**A076252**	**003**	Jun 25, 2007
ZOFRAN						
AB	**+**	NOVARTIS PHARMS CORP	**EQ 4MG BASE**	**N020103**	**001**	Dec 31, 1992
AB	**+**		**EQ 8MG BASE**	**N020103**	**002**	Dec 31, 1992
AB	**+!**		**EQ 24MG BASE**	**N020103**	**003**	Aug 27, 1999
ONDANSETRON HYDROCHLORIDE						
		DR REDDYS LABS LTD	EQ 16MG BASE	A076183	004	Dec 26, 2006
ORITAVANCIN DIPHOSPHATE						
POWDER;INTRAVENOUS						
ORBACTIV						
	+!	MELINTA THERAP	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014
ORLISTAT						
CAPSULE;ORAL						
XENICAL						
	+!	CHEPLAPHARM	120MG	N020766	001	Apr 23, 1999
ORPHENADRINE CITRATE						
INJECTABLE;INJECTION						
ORPHENADRINE CITRATE						
AP	**!**	AKORN	**30MG/ML**	**A040484**	**001**	May 24, 2006
AP		SAGENT PHARMS	**30MG/ML**	**A090585**	**001**	Aug 30, 2011
AP		WATSON LABS	**30MG/ML**	**A084779**	**001**	Mar 15, 1982
AP		WEST-WARD PHARMS INT	**30MG/ML**	**A040463**	**001**	Mar 04, 2003
TABLET, EXTENDED RELEASE;ORAL						
ORPHENADRINE CITRATE						
AB		ANDA REPOSITORY	**100MG**	**A040249**	**001**	Jan 29, 1999
AB		GAVIS PHARMS	**100MG**	**A040284**	**001**	Jun 19, 1998
AB		IMPAX PHARMS	**100MG**	**A040368**	**001**	Jun 23, 2000
AB		INVAGEN PHARMS	**100MG**	**A091158**	**001**	Jul 27, 2012
AB	**!**	SANDOZ	**100MG**	**A040327**	**001**	Feb 15, 2000

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB		AMNEAL PHARMS	**EQ 30MG BASE**	**A209093**	**001**	May 17, 2017
AB			**EQ 45MG BASE**	**A209093**	**002**	May 17, 2017
AB			**EQ 75MG BASE**	**A209093**	**003**	May 17, 2017
AB		HETERO LABS LTD III	**EQ 30MG BASE**	**A209438**	**001**	Feb 23, 2018
AB			**EQ 45MG BASE**	**A209438**	**002**	Feb 23, 2018
AB			**EQ 75MG BASE**	**A209438**	**003**	Feb 23, 2018
AB		LUPIN ATLANTIS	**EQ 30MG BASE**	**A208348**	**001**	Jan 09, 2018
AB			**EQ 45MG BASE**	**A208348**	**002**	Jan 09, 2018
AB			**EQ 75MG BASE**	**A208348**	**003**	Jan 09, 2018
AB		MACLEODS PHARMS LTD	**EQ 30MG BASE**	**A207211**	**001**	Sep 14, 2017
AB			**EQ 45MG BASE**	**A207211**	**002**	Sep 14, 2017
AB			**EQ 75MG BASE**	**A207211**	**003**	Sep 14, 2017
AB		NATCO PHARMA LTD	**EQ 30MG BASE**	**A202595**	**001**	Aug 03, 2016
AB			**EQ 45MG BASE**	**A202595**	**002**	Aug 03, 2016
AB			**EQ 75MG BASE**	**A202595**	**003**	Aug 03, 2016
AB		NESHER PHARMS	**EQ 30MG BASE**	**A208578**	**001**	Feb 24, 2017
AB			**EQ 45MG BASE**	**A208578**	**002**	Feb 24, 2017
AB			**EQ 75MG BASE**	**A208578**	**003**	Feb 24, 2017
AB		STRIDES PHARMA	**EQ 30MG BASE**	**A209421**	**001**	Jun 08, 2018
AB			**EQ 45MG BASE**	**A209421**	**002**	Jun 08, 2018
AB			**EQ 75MG BASE**	**A209421**	**003**	Jun 08, 2018

TAMIFLU

AB	+	ROCHE	**EQ 30MG BASE**	**N021087**	**003**	Jul 02, 2007
AB	+		**EQ 45MG BASE**	**N021087**	**002**	Jul 02, 2007
AB	+!		**EQ 75MG BASE**	**N021087**	**001**	Oct 27, 1999

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB		ALVOGEN PINE BROOK	**EQ 6MG BASE/ML**	**A208823**	**001**	Oct 31, 2017
AB		AMNEAL PHARMS NY	**EQ 6MG BASE/ML**	**A210186**	**001**	Feb 27, 2018
AB		LUPIN ATLANTIS	**EQ 6MG BASE/ML**	**A208347**	**001**	Feb 20, 2018
AB		NESHER PHARMS	**EQ 6MG BASE/ML**	**A209113**	**001**	Sep 14, 2017

TAMIFLU

AB	+!	ROCHE	**EQ 6MG BASE/ML**	**N021246**	**002**	Mar 21, 2011

OSIMERTINIB MESYLATE

TABLET;ORAL

TAGRISSO

	+	ASTRAZENECA PHARMS	EQ 40MG BASE	N208065	001	Nov 13, 2015
	+!		EQ 80MG BASE	N208065	002	Nov 13, 2015

OSPEMIFENE

TABLET;ORAL

OSPHENA

	+!	DUCHESNAY	60MG	N203505	001	Feb 26, 2013

OXACILLIN SODIUM

INJECTABLE;INJECTION

OXACILLIN SODIUM

AP		AUROBINDO PHARMA LTD	**EQ 1GM BASE/VIAL**	**A201539**	**001**	Jan 18, 2013
AP			**EQ 2GM BASE/VIAL**	**A201539**	**002**	Jan 18, 2013
AP			**EQ 10GM BASE/VIAL**	**A201538**	**001**	Jan 18, 2013
AP		HOSPIRA INC	**EQ 1GM BASE/VIAL**	**A203950**	**001**	Dec 11, 2015
AP			**EQ 2GM BASE/VIAL**	**A203950**	**002**	Dec 11, 2015
AP		RENAISSANCE SSA LLC	**EQ 1GM BASE/VIAL**	**A206681**	**001**	Sep 11, 2017
AP			**EQ 2GM BASE/VIAL**	**A206681**	**002**	Sep 11, 2017
AP			**EQ 10GM BASE/VIAL**	**A206760**	**001**	Oct 26, 2017
AP	!	SAGENT PHARMS	**EQ 1GM BASE/VIAL**	**A091246**	**001**	Mar 30, 2012
AP	!		**EQ 2GM BASE/VIAL**	**A091246**	**002**	Mar 30, 2012
AP	!		**EQ 10GM BASE/VIAL**	**A091245**	**001**	Mar 30, 2012
AP		WOCKHARDT BIO AG	**EQ 1GM BASE/VIAL**	**A207147**	**001**	Jul 31, 2017
AP			**EQ 2GM BASE/VIAL**	**A207147**	**002**	Jul 31, 2017
AP			**EQ 10GM BASE/VIAL**	**A207148**	**001**	Nov 24, 2017

BACTOCILL IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050640	001	Oct 26, 1989
	+!		EQ 40MG BASE/ML	N050640	002	Oct 26, 1989

OXALIPLATIN

INJECTABLE;IV (INFUSION)

ELOXATIN

AP	**+!**	SANOFI AVENTIS US	**50MG/10ML (5MG/ML)**	**N021759**	**001**	Jan 31, 2005
AP	**+!**		**100MG/20ML (5MG/ML)**	**N021759**	**002**	Jan 31, 2005

OXALIPLATIN

AP		ACCORD HLTHCARE	**50MG/10ML (5MG/ML)**	**A207474**	**001**	Mar 21, 2017
AP			**100MG/20ML (5MG/ML)**	**A207474**	**002**	Mar 21, 2017
AP			**200MG/40ML (5MG/ML)**	**A207474**	**003**	Mar 21, 2017
AP		ACTAVIS LLC	**50MG/10ML (5MG/ML)**	**A204880**	**001**	Mar 05, 2018
AP			**100MG/20ML (5MG/ML)**	**A204880**	**002**	Mar 05, 2018
AP		ACTAVIS TOTOWA	**50MG/VIAL**	**A078803**	**001**	Aug 08, 2012
AP			**100MG/VIAL**	**A078803**	**002**	Aug 08, 2012
AP		CIPLA	**50MG/10ML (5MG/ML)**	**A208523**	**001**	Feb 10, 2017
AP			**100MG/20ML (5MG/ML)**	**A208523**	**002**	Feb 10, 2017
AP		EUGIA PHARMA	**50MG/10ML (5MG/ML)**	**A205529**	**001**	Sep 06, 2017
AP			**100MG/20ML (5MG/ML)**	**A205529**	**002**	Sep 06, 2017
AP		FRESENIUS KABI USA	**50MG/10ML (5MG/ML)**	**A078811**	**001**	Jun 10, 2010
AP			**100MG/20ML (5MG/ML)**	**A078811**	**002**	Jun 10, 2010
AP			**50MG/VIAL**	**A078819**	**001**	Jun 02, 2010
AP			**50MG/10ML (5MG/ML)**	**A090030**	**001**	Jan 31, 2017
AP			**100MG/VIAL**	**A078819**	**002**	Jun 02, 2010
AP			**100MG/20ML (5MG/ML)**	**A090030**	**002**	Jan 31, 2017
AP			**200MG/40ML (5MG/ML)**	**A090030**	**003**	Jan 31, 2017
AP		GLAND PHARMA LTD	**50MG/10ML (5MG/ML)**	**A207325**	**001**	Feb 10, 2017
AP			**50MG/VIAL**	**A207385**	**001**	May 23, 2017
AP			**100MG/20ML (5MG/ML)**	**A207325**	**002**	Feb 10, 2017
AP			**100MG/VIAL**	**A207385**	**002**	May 23, 2017
AP			**200MG/40ML (5MG/ML)**	**A207325**	**003**	Oct 18, 2017
AP		HOSPIRA INC	**50MG/VIAL**	**A078815**	**001**	Sep 30, 2009
AP			**100MG/VIAL**	**A078815**	**002**	Sep 30, 2009
AP		HOSPIRA WORLDWIDE	**50MG/10ML (5MG/ML)**	**A078813**	**001**	Aug 07, 2009
AP			**100MG/20ML (5MG/ML)**	**A078813**	**002**	Aug 07, 2009
AP		INGENUS PHARMS LLC	**50MG/10ML (5MG/ML)**	**A207562**	**001**	Oct 16, 2018
AP			**100MG/20ML (5MG/ML)**	**A207562**	**002**	Oct 16, 2018
AP		JIANGSU HENGRUI MED	**50MG/10ML (5MG/ML)**	**A203869**	**001**	Jun 18, 2014
AP			**100MG/20ML (5MG/ML)**	**A203869**	**002**	Jun 18, 2014
AP		LUITPOLD	**50MG/10ML (5MG/ML)**	**A204378**	**001**	May 12, 2017
AP			**100MG/20ML (5MG/ML)**	**A204378**	**002**	May 12, 2017
AP		MYLAN LABS LTD	**50MG/10ML (5MG/ML)**	**A091358**	**001**	Aug 07, 2012
AP			**50MG/VIAL**	**A200979**	**001**	Aug 08, 2012
AP			**100MG/20ML (5MG/ML)**	**A091358**	**002**	Aug 07, 2012
AP			**100MG/VIAL**	**A200979**	**002**	Aug 08, 2012
AP			**200MG/40ML (5MG/ML)**	**A091358**	**003**	Nov 14, 2017
AP		QILU PHARM CO LTD	**50MG/10ML (5MG/ML)**	**A204368**	**001**	Jun 07, 2016
AP			**50MG/VIAL**	**A204616**	**001**	May 11, 2016
AP			**100MG/20ML (5MG/ML)**	**A204368**	**002**	Jun 07, 2016
AP			**100MG/VIAL**	**A204616**	**002**	May 11, 2016
AP	**!**		**200MG/40ML (5MG/ML)**	**A204368**	**003**	Jun 07, 2016
AP		SANDOZ	**50MG/10ML (5MG/ML)**	**A078817**	**001**	Jan 24, 2011
AP			**100MG/20ML (5MG/ML)**	**A078817**	**002**	Jan 24, 2011
AP	**!**	SUN PHARMA GLOBAL	**50MG/VIAL**	**A078818**	**001**	Aug 07, 2009
AP			**50MG/10ML (5MG/ML)**	**A202922**	**001**	Apr 08, 2014
AP	**!**		**100MG/VIAL**	**A078818**	**002**	Aug 07, 2009
AP			**100MG/20ML (5MG/ML)**	**A202922**	**002**	Apr 08, 2014
AP	**+!**	TEVA PHARMS	**50MG/10ML (5MG/ML)**	**N022160**	**001**	Aug 07, 2009
AP	**+!**		**100MG/20ML (5MG/ML)**	**N022160**	**002**	Aug 07, 2009

OXANDROLONE

TABLET;ORAL

OXANDROLONE

AB		PAR PHARM	**2.5MG**	**A077827**	**001**	Jun 22, 2007
AB	**!**		**10MG**	**A077827**	**002**	Jun 22, 2007
AB		UPSHER SMITH LABS	**2.5MG**	**A076761**	**001**	Dec 01, 2006
AB			**10MG**	**A078033**	**001**	Mar 22, 2007

OXAPROZIN

TABLET;ORAL

DAYPRO

AB	**+!**	GD SEARLE	**600MG**	**N018841**	**004**	Oct 29, 1992

OXAPROZIN

AB		AMNEAL PHARMS CO	**600MG**	**A208633**	**001**	May 04, 2017
AB		APOTEX INC	**600MG**	**A075987**	**001**	Sep 02, 2004

OXAPROZIN

TABLET;ORAL

OXAPROZIN

AB		DR REDDYS LABS LTD	**600MG**	**A075855**	**001**	Jan 31, 2001
AB		IVAX SUB TEVA PHARMS	**600MG**	**A075846**	**001**	May 13, 2002
AB		SANDOZ	**600MG**	**A075845**	**001**	Jan 31, 2001
AB		SUN PHARM INDS INC	**600MG**	**A075844**	**001**	Jan 03, 2002
AB		TEVA	**600MG**	**A075849**	**001**	Jul 03, 2002

OXAZEPAM

CAPSULE;ORAL

OXAZEPAM

AB		ACTAVIS ELIZABETH	**10MG**	**A072253**	**002**	Apr 14, 1988
AB			**15MG**	**A072253**	**003**	Apr 14, 1988
AB	**!**		**30MG**	**A072253**	**001**	Apr 14, 1988
AB		SANDOZ	**10MG**	**A071813**	**001**	Apr 19, 1988
AB			**15MG**	**A071756**	**001**	Apr 19, 1988
AB			**30MG**	**A071814**	**001**	Apr 19, 1988

OXCARBAZEPINE

SUSPENSION;ORAL

OXCARBAZEPINE

AB		AMNEAL PHARMS	**300MG/5ML**	**A202961**	**001**	Sep 17, 2012
AB		SUN PHARM INDS LTD	**300MG/5ML**	**A078734**	**001**	Jun 26, 2009
AB		WEST-WARD PHARMS INT	**300MG/5ML**	**A201193**	**001**	Oct 03, 2012

TRILEPTAL

AB	**+!**	NOVARTIS	**300MG/5ML**	**N021285**	**001**	May 25, 2001

TABLET;ORAL

OXCARBAZEPINE

AB		ANI PHARMS INC	**150MG**	**A078005**	**001**	Dec 11, 2007
AB			**300MG**	**A078005**	**002**	Dec 11, 2007
AB			**600MG**	**A078005**	**003**	Dec 11, 2007
AB		APOTEX INC	**150MG**	**A077747**	**001**	Apr 09, 2008
AB			**300MG**	**A077747**	**002**	Apr 09, 2008
AB			**600MG**	**A077747**	**003**	Apr 09, 2008
AB		BRECKENRIDGE PHARM	**150MG**	**A078069**	**001**	Jan 11, 2008
AB			**300MG**	**A078069**	**002**	Jan 11, 2008
AB			**600MG**	**A078069**	**003**	Jan 11, 2008
AB		GLENMARK PHARMS LTD	**150MG**	**A077802**	**001**	Oct 09, 2007
AB			**300MG**	**A077802**	**002**	Oct 09, 2007
AB			**600MG**	**A077802**	**003**	Oct 09, 2007
AB		SUN PHARM INDS	**150MG**	**A077794**	**001**	Oct 09, 2007
AB			**300MG**	**A077794**	**002**	Oct 09, 2007
AB			**600MG**	**A077794**	**003**	Oct 09, 2007
AB		TARO	**150MG**	**A077801**	**001**	Nov 15, 2007
AB			**300MG**	**A077801**	**002**	Nov 15, 2007
AB			**600MG**	**A077801**	**003**	Nov 15, 2007
AB		WEST-WARD PHARMS INT	**150MG**	**A077795**	**001**	Oct 09, 2007
AB			**300MG**	**A077795**	**002**	Oct 09, 2007
AB			**600MG**	**A077795**	**003**	Oct 09, 2007

TRILEPTAL

AB	**+**	NOVARTIS	**150MG**	**N021014**	**001**	Jan 14, 2000
AB	**+**		**300MG**	**N021014**	**002**	Jan 14, 2000
AB	**+!**		**600MG**	**N021014**	**003**	Jan 14, 2000

TABLET, EXTENDED RELEASE;ORAL

OXTELLAR XR

	+	SUPERNUS PHARMS	150MG	N202810	001	Oct 19, 2012
	+		300MG	N202810	002	Oct 19, 2012
	+!		600MG	N202810	003	Oct 19, 2012

OXICONAZOLE NITRATE

CREAM;TOPICAL

OXICONAZOLE NITRATE

AB		TARO PHARMS	**EQ 1% BASE**	**A205076**	**001**	Mar 07, 2016

OXISTAT

AB	**+!**	FOUGERA PHARMS	**EQ 1% BASE**	**N019828**	**001**	Dec 30, 1988

LOTION;TOPICAL

OXISTAT

	+!	FOUGERA PHARMS	EQ 1% BASE	N020209	001	Sep 30, 1992

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL

+!	ALLERGAN SALES LLC	3.9MG/24HR	N021351	002	Feb 26, 2003

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL

GELNIQUE

AB	**+!**	ALLERGAN SALES LLC	**10% (100MG/PACKET)**	**N022204**	**001**	Jan 27, 2009

OXYBUTYNIN CHLORIDE

AB		PAR PHARM INC	**10% (100MG/PACKET)**	**A207329**	**001**	May 31, 2018

SYRUP;ORAL

OXYBUTYNIN CHLORIDE

AA		LANNETT CO INC	**5MG/5ML**	**A074520**	**001**	Mar 29, 1996
AA			**5MG/5ML**	**A076682**	**001**	Dec 28, 2004
AA		PHARM ASSOC	**5MG/5ML**	**A075137**	**001**	Dec 18, 1998
AA	**!**	WOCKHARDT BIO AG	**5MG/5ML**	**A074868**	**001**	Feb 12, 1997

TABLET;ORAL

OXYBUTYNIN CHLORIDE

AB		ABHAI LLC	**5MG**	**A209335**	**001**	Dec 22, 2017
AB		APPCO PHARMA LLC	**5MG**	**A209025**	**001**	Dec 21, 2017
AB		NOVITIUM PHARMA	**5MG**	**A209823**	**001**	Oct 23, 2017
AB		TEVA PHARMS USA	**5MG**	**A071655**	**001**	Nov 14, 1988
AB		TULEX PHARMS INC	**5MG**	**A210125**	**001**	Sep 06, 2018
AB		UPSHER SMITH LABS	**5MG**	**A074625**	**001**	Jul 31, 1996
AB	**!**	VINTAGE PHARMS	**5MG**	**A075079**	**001**	Oct 31, 1997

TABLET, EXTENDED RELEASE;ORAL

DITROPAN XL

AB	**+**	JANSSEN PHARMS	**5MG**	**N020897**	**001**	Dec 16, 1998
AB	**+**		**10MG**	**N020897**	**002**	Dec 16, 1998

OXYBUTYNIN CHLORIDE

AB		ACCORD HLTHCARE	**5MG**	**A207138**	**001**	Feb 29, 2016
AB			**10MG**	**A207138**	**002**	Feb 29, 2016
AB			**15MG**	**A207138**	**003**	Feb 29, 2016
AB		AMNEAL PHARMS	**5MG**	**A204010**	**001**	Nov 23, 2015
AB			**10MG**	**A204010**	**002**	Nov 23, 2015
AB			**15MG**	**A204010**	**003**	Nov 23, 2015
AB		IMPAX PHARMS	**5MG**	**A076745**	**002**	May 09, 2007
AB			**10MG**	**A076745**	**003**	May 09, 2007
AB			**15MG**	**A076745**	**001**	Nov 09, 2006
AB		MYLAN	**5MG**	**A076702**	**001**	Nov 09, 2006
AB		MYLAN PHARMS INC	**10MG**	**A076644**	**001**	Nov 09, 2006
AB	**!**		**15MG**	**A076644**	**002**	May 10, 2007
AB		OSMOTICA PHARM US	**5MG**	**A078503**	**001**	Feb 04, 2009
AB			**10MG**	**A078503**	**002**	Feb 04, 2009
AB			**15MG**	**A078503**	**003**	Feb 04, 2009
AB		UNIQUE PHARM LABS	**5MG**	**A206121**	**001**	May 27, 2016
AB			**10MG**	**A206121**	**002**	May 27, 2016
AB			**15MG**	**A206121**	**003**	May 27, 2016
AB		ZYDUS PHARMS USA INC	**5MG**	**A202332**	**001**	Jun 26, 2017
AB			**10MG**	**A202332**	**002**	Jun 26, 2017
AB			**15MG**	**A202332**	**003**	Jun 26, 2017

OXYCODONE

CAPSULE, EXTENDED RELEASE;ORAL

XTAMPZA ER

+	COLLEGIUM PHARM INC	9MG	N208090	001	Apr 26, 2016
+		13.5MG	N208090	002	Apr 26, 2016
+		18MG	N208090	003	Apr 26, 2016
+		27MG	N208090	004	Apr 26, 2016
+!		36MG	N208090	005	Apr 26, 2016

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

AB		ANI PHARMS INC	**5MG**	**A205177**	**001**	Mar 31, 2016
AB		AVANTHI INC	**5MG**	**A202773**	**001**	Aug 17, 2015
AB	**+!**	GENUS LIFESCIENCES	**5MG**	**N200534**	**001**	Oct 20, 2010
AB		LANNETT CO INC	**5MG**	**A203823**	**001**	Aug 01, 2014
AB		MAYNE PHARMA INC	**5MG**	**A203107**	**001**	Jul 26, 2012
AB		NOVEL LABS INC	**5MG**	**A204752**	**001**	Aug 24, 2015

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA		ABHAI LLC	**5MG/5ML**	**A208593**	**001**	Jul 21, 2017
AA			**100MG/5ML**	**A208593**	**002**	Jul 21, 2017
AA		ANI PHARMS INC	**5MG/5ML**	**A204979**	**001**	Jun 01, 2015
AA			**100MG/5ML**	**A203447**	**001**	Aug 30, 2017
AA		ASCENT PHARMS INC	**5MG/5ML**	**A209021**	**001**	Nov 09, 2017
AA			**100MG/5ML**	**A209021**	**002**	Nov 09, 2017
AA	+	GENUS LIFESCIENCES	**5MG/5ML**	**N200535**	**002**	Aug 22, 2013
AA	+!		**100MG/5ML**	**N200535**	**001**	Oct 20, 2010
AA		HI-TECH PHARMACAL	**5MG/5ML**	**A208817**	**001**	Aug 10, 2017
AA			**100MG/5ML**	**A208795**	**001**	Aug 07, 2017
AA		LANNETT CO INC	**100MG/5ML**	**A204085**	**001**	Sep 09, 2014
AA		MAYNE PHARMA INC	**100MG/5ML**	**A204092**	**001**	Jun 05, 2014
AA		NOVEL LABS INC	**100MG/5ML**	**A204603**	**001**	Apr 29, 2015
AA		PHARM ASSOC	**100MG/5ML**	**A206822**	**001**	Aug 15, 2017
AA		SPECGX LLC	**5MG/5ML**	**A210758**	**001**	Apr 30, 2018
AA			**100MG/5ML**	**A210758**	**002**	Apr 30, 2018
AA	+!	VISTAPHARM	**5MG/5ML**	**N201194**	**001**	Jan 12, 2012
AA			**100MG/5ML**	**A202537**	**001**	Jul 30, 2012
AA		WES PHARMA INC	**5MG/5ML**	**A207511**	**001**	Nov 23, 2016
AA			**100MG/5ML**	**A209897**	**001**	Sep 06, 2017
AA		WEST-WARD PHARMS INT	**5MG/5ML**	**A204037**	**001**	Jul 15, 2013
AA			**100MG/5ML**	**A203208**	**001**	Jul 12, 2013
AA		WOCKHARDT BIO AG	**5MG/5ML**	**A206456**	**001**	Jun 16, 2015

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**5MG**	**A076636**	**003**	Apr 07, 2015
AB			**15MG**	**A076636**	**001**	Feb 06, 2004
AB			**30MG**	**A076636**	**002**	Feb 06, 2004
AB		ALVOGEN MALTA	**5MG**	**A202116**	**001**	Dec 30, 2011
AB			**15MG**	**A202116**	**002**	Dec 30, 2011
AB			**30MG**	**A202116**	**003**	Dec 30, 2011
AB		AMNEAL PHARMS	**5MG**	**A203638**	**001**	Jun 03, 2014
AB			**10MG**	**A203638**	**002**	Jun 03, 2014
AB			**15MG**	**A203638**	**003**	Jun 03, 2014
AB			**20MG**	**A203638**	**004**	Jun 03, 2014
AB			**30MG**	**A203638**	**005**	Jun 03, 2014
AB		ASCENT PHARMS INC	**15MG**	**A207418**	**001**	Aug 07, 2017
AB			**30MG**	**A207418**	**002**	Aug 07, 2017
AB		AUROLIFE PHARMA LLC	**5MG**	**A202160**	**001**	Nov 19, 2012
AB			**15MG**	**A202160**	**002**	Nov 19, 2012
AB			**30MG**	**A202160**	**003**	Nov 19, 2012
AB		AVANTHI INC	**5MG**	**A091393**	**001**	Aug 31, 2009
AB			**10MG**	**A091393**	**002**	Aug 31, 2009
AB			**15MG**	**A091393**	**003**	Aug 31, 2009
AB			**20MG**	**A091393**	**004**	Aug 31, 2009
AB			**30MG**	**A091393**	**005**	Aug 31, 2009
AB		EPIC PHARMA LLC	**5MG**	**A090895**	**001**	Aug 24, 2009
AB			**5MG**	**A202662**	**001**	Sep 22, 2015
AB			**10MG**	**A202662**	**002**	Sep 22, 2015
AB			**15MG**	**A090895**	**002**	Aug 24, 2009
AB			**15MG**	**A202662**	**003**	Sep 22, 2015
AB			**20MG**	**A202662**	**005**	Apr 27, 2017
AB			**30MG**	**A090895**	**003**	Aug 24, 2009
AB			**30MG**	**A202662**	**004**	Sep 22, 2015
AB		MAYNE PHARMA INC	**5MG**	**A091313**	**001**	Feb 18, 2011
AB			**10MG**	**A091313**	**004**	Apr 29, 2016
AB			**15MG**	**A091313**	**002**	Feb 18, 2011
AB			**20MG**	**A091313**	**005**	Apr 29, 2016
AB			**30MG**	**A091313**	**003**	Feb 18, 2011
AB		NESHER PHARMS	**5MG**	**A077290**	**001**	Dec 08, 2005
AB			**10MG**	**A077290**	**002**	Dec 08, 2005
AB			**15MG**	**A077290**	**003**	Dec 08, 2005
AB			**20MG**	**A077290**	**004**	Dec 08, 2005
AB			**30MG**	**A077290**	**005**	Dec 08, 2005
AB		NOVEL LABS INC	**5MG**	**A204021**	**001**	Jun 12, 2017
AB			**10MG**	**A204021**	**002**	Jun 12, 2017
AB			**15MG**	**A204021**	**003**	Jun 12, 2017
AB			**20MG**	**A204021**	**004**	Jun 12, 2017
AB			**30MG**	**A204021**	**005**	Jun 12, 2017

OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

AB		NUVO PHARM	**5MG**	**A207119**	**001**	Apr 12, 2016
AB			**10MG**	**A207119**	**002**	Apr 12, 2016
AB			**15MG**	**A207119**	**003**	Apr 12, 2016
AB			**20MG**	**A207119**	**004**	Apr 12, 2016
AB			**30MG**	**A207119**	**005**	Apr 12, 2016
AB		RHODES PHARMS	**5MG**	**A091490**	**001**	Mar 09, 2011
AB			**10MG**	**A091490**	**002**	Mar 09, 2011
AB			**15MG**	**A091490**	**003**	Mar 09, 2011
AB			**20MG**	**A091490**	**004**	Mar 09, 2011
AB			**30MG**	**A091490**	**005**	Mar 09, 2011
AB		SPECGX LLC	**5MG**	**A076758**	**003**	Mar 19, 2007
AB			**15MG**	**A076758**	**001**	Jun 30, 2004
AB			**30MG**	**A076758**	**002**	Jun 30, 2004
AB		SUN PHARM INDS INC	**5MG**	**A090659**	**001**	Apr 10, 2009
AB			**10MG**	**A090659**	**005**	Nov 06, 2012
AB			**15MG**	**A090659**	**002**	Apr 10, 2009
AB			**20MG**	**A090659**	**004**	Nov 06, 2012
AB			**30MG**	**A090659**	**003**	Apr 10, 2009
AB		VINTAGE PHARMS	**5MG**	**A077712**	**003**	Mar 02, 2009
AB			**10MG**	**A077712**	**004**	Apr 13, 2015
AB			**15MG**	**A077712**	**001**	Jan 31, 2007
AB			**20MG**	**A077712**	**005**	Apr 13, 2015
AB			**30MG**	**A077712**	**002**	Jan 31, 2007

ROXICODONE

AB	**+**	SPECGX LLC	**5MG**	**N021011**	**003**	May 15, 2009
AB	**+!**		**15MG**	**N021011**	**001**	Aug 31, 2000
AB	**+**		**30MG**	**N021011**	**002**	Aug 31, 2000

OXAYDO

		EGALET US INC	5MG	N202080	001	Jun 17, 2011
			7.5MG	N202080	002	Jun 17, 2011

TABLET, EXTENDED RELEASE;ORAL

OXYCONTIN

	+	PURDUE PHARMA LP	10MG	N022272	001	Apr 05, 2010
	+		15MG	N022272	002	Apr 05, 2010
	+		20MG	N022272	003	Apr 05, 2010
	+		30MG	N022272	004	Apr 05, 2010
	+!		40MG	N022272	005	Apr 05, 2010
	+		60MG	N022272	006	Apr 05, 2010
	+		80MG	N022272	007	Apr 05, 2010

OXYMETAZOLINE HYDROCHLORIDE

CREAM;TOPICAL

RHOFADE

	+!	ACLARIS	1%	N208552	001	Jan 18, 2017

OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE

SPRAY, METERED;NASAL

KOVANAZE

	+!	ST RENATUS	0.1MG/SPRAY;6MG/SPRAY	N208032	001	Jun 29, 2016

OXYMETHOLONE

TABLET;ORAL

ANADROL-50

	+!	MYLAN SPECIALITY LP	50MG	N016848	001	

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

OPANA

AB	**+**	ENDO PHARMS	**5MG**	**N021611**	**001**	Jun 22, 2006
AB	**+!**		**10MG**	**N021611**	**002**	Jun 22, 2006

OXYMORPHONE HYDROCHLORIDE

AB		ASCENT PHARMS INC	**5MG**	**A210175**	**001**	Feb 02, 2018
AB			**10MG**	**A210175**	**002**	Feb 02, 2018
AB		AUROLIFE PHARMA LLC	**5MG**	**A204459**	**001**	Apr 26, 2016
AB			**10MG**	**A204459**	**002**	Apr 26, 2016
AB		AVANTHI INC	**5MG**	**A203601**	**001**	Jan 30, 2013
AB			**10MG**	**A203601**	**002**	Jan 30, 2013
AB		EPIC PHARMA LLC	**5MG**	**A201187**	**001**	Dec 15, 2014
AB			**10MG**	**A201187**	**002**	Dec 15, 2014
AB		SPECGX LLC	**5MG**	**A202321**	**001**	Apr 25, 2013
AB			**10MG**	**A202321**	**002**	Apr 25, 2013

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

OXYMORPHONE HYDROCHLORIDE

AB		TEVA	**5MG**	**A091443**	**002**	Feb 15, 2011
AB			**10MG**	**A091443**	**001**	Feb 15, 2011
AB		WEST-WARD PHARMS INT	**5MG**	**A090964**	**001**	Sep 27, 2010
AB			**10MG**	**A090964**	**002**	Sep 27, 2010

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**5MG**	**A079046**	**003**	Jul 11, 2013
AB			**7.5MG**	**A079046**	**001**	Dec 13, 2010
AB			**10MG**	**A079046**	**004**	Jul 11, 2013
AB			**15MG**	**A079046**	**002**	Dec 13, 2010
AB			**20MG**	**A079046**	**005**	Jul 11, 2013
AB			**30MG**	**A079046**	**006**	Jul 11, 2013
AB			**40MG**	**A079046**	**007**	Jul 11, 2013
AB		IMPAX LABS	**5MG**	**A079087**	**001**	Jun 14, 2010
AB			**7.5MG**	**A079087**	**002**	Dec 21, 2010
AB			**10MG**	**A079087**	**003**	Jun 14, 2010
AB			**15MG**	**A079087**	**004**	Dec 21, 2010
AB			**20MG**	**A079087**	**005**	Jun 14, 2010
AB			**30MG**	**A079087**	**006**	Jul 22, 2010
AB		SPECGX LLC	**5MG**	**A202946**	**001**	Jun 27, 2014
AB			**7.5MG**	**A202946**	**002**	Jun 27, 2014
AB			**10MG**	**A202946**	**003**	Jun 27, 2014
AB			**15MG**	**A202946**	**004**	Jun 27, 2014
AB			**20MG**	**A202946**	**005**	Jun 27, 2014
AB			**30MG**	**A202946**	**006**	Jun 27, 2014
AB			**40MG**	**A202946**	**007**	Jun 27, 2014
AB		WEST-WARD PHARMS INT	**5MG**	**A200822**	**002**	Jul 15, 2013
AB			**7.5MG**	**A200822**	**003**	Jul 15, 2013
AB			**10MG**	**A200822**	**004**	Jul 15, 2013
AB			**15MG**	**A200822**	**005**	Jul 15, 2013
AB			**20MG**	**A200822**	**006**	Jul 15, 2013
AB			**30MG**	**A200822**	**007**	Jul 15, 2013
AB			**40MG**	**A200822**	**001**	Jul 15, 2013
	!	IMPAX LABS	40MG	A079087	007	Jun 14, 2010

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN

AP	**+!**	FRESENIUS KABI USA	**10USP UNITS/ML (10USP UNITS/ML)**	**N018248**	**001**	
AP	**+!**		**100USP UNITS/10ML (10USP UNITS/ML)**	**N018248**	**002**	
AP		HIKMA FARMACEUTICA	**10USP UNITS/ML (10USP UNITS/ML)**	**A200219**	**001**	Feb 13, 2013
AP		SAGENT PHARMS	**10USP UNITS/ML (10USP UNITS/ML)**	**A091676**	**001**	Jul 13, 2018
AP			**100USP UNITS/10ML (10USP UNITS/ML)**	**A091676**	**002**	Jul 13, 2018
AP	**+!**	WEST-WARD PHARMS INT	**10USP UNITS/ML (10USP UNITS/ML)**	**N018243**	**001**	
AP	**+!**		**100USP UNITS/10ML (10USP UNITS/ML)**	**N018243**	**002**	Jan 10, 2007

PITOCIN

AP	**+!**	PAR STERILE PRODUCTS	**10USP UNITS/ML (10USP UNITS/ML)**	**N018261**	**001**	
AP	**+**		**100USP UNITS/10ML (10USP UNITS/ML)**	**N018261**	**002**	Jul 27, 2007

OXYTOCIN

	+!	FRESENIUS KABI USA	300USP UNITS/30ML (10USP UNITS/ML)	N018248	003	Jul 27, 2007

PITOCIN

	+	PAR STERILE PRODUCTS	500USP UNITS/50ML (10USP UNITS/ML)	N018261	003	Sep 05, 2012

OZENOXACIN

CREAM;TOPICAL

XEPI

	+!	FERRER INTERNACIONAL	1%	N208945	001	Dec 11, 2017

PACLITAXEL

FOR SUSPENSION;IV (INFUSION)

ABRAXANE

	+!	ABRAXIS BIOSCIENCE	100MG/VIAL	N021660	001	Jan 07, 2005

INJECTABLE;INJECTION

PACITAXEL

AP		GLAND PHARMA LTD	**6MG/ML**	**A207326**	**001**	Aug 23, 2016

PACLITAXEL

INJECTABLE;INJECTION

PACLITAXEL

AP		ACCORD HLTHCARE	**6MG/ML**	**A205720**	**001**	Aug 17, 2018
AP		ACTAVIS TOTOWA	**6MG/ML**	**A090130**	**001**	Dec 09, 2009
AP		FRESENIUS KABI USA	**6MG/ML**	**A077574**	**001**	Nov 27, 2006
AP	**!**	HOSPIRA	**6MG/ML**	**A076131**	**001**	May 08, 2002
AP		MYLAN LABS LTD	**6MG/ML**	**A091540**	**001**	Sep 29, 2011
AP		SANDOZ INC	**6MG/ML**	**A078167**	**001**	Dec 26, 2007
AP		TEVA PHARMS	**6MG/ML**	**A075184**	**001**	Jan 25, 2002
AP		WEST-WARD PHARMS INT	**6MG/ML**	**A075190**	**001**	Jan 28, 2002

TAXOL

AP	**+**	HQ SPCLT PHARMA	**6MG/ML**	**N020262**	**001**	Dec 29, 1992

PALBOCICLIB

CAPSULE;ORAL

IBRANCE

	+	PFIZER INC	75MG	N207103	001	Feb 03, 2015
	+		100MG	N207103	002	Feb 03, 2015
	+!		125MG	N207103	003	Feb 03, 2015

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

INVEGA

AB	**+**	JANSSEN PHARMS	**1.5MG**	**N021999**	**006**	Aug 26, 2008
AB	**+**		**3MG**	**N021999**	**001**	Dec 19, 2006
AB	**+!**		**6MG**	**N021999**	**002**	Dec 19, 2006
AB	**+**		**9MG**	**N021999**	**003**	Dec 19, 2006

PALIPERIDONE

AB		ACTAVIS LABS FL INC	**1.5MG**	**A202645**	**001**	Aug 03, 2015
AB			**3MG**	**A202645**	**002**	Aug 03, 2015
AB			**6MG**	**A202645**	**003**	Aug 03, 2015
AB			**9MG**	**A202645**	**004**	Aug 03, 2015
AB		MYLAN PHARMS INC	**1.5MG**	**A203802**	**001**	Sep 24, 2015
AB			**3MG**	**A203802**	**002**	Sep 24, 2015
AB			**6MG**	**A203802**	**003**	Sep 24, 2015
AB			**9MG**	**A203802**	**004**	Sep 24, 2015
AB		SUN PHARMA GLOBAL	**1.5mg**	**A205618**	**001**	Apr 06, 2018
AB			**3MG**	**A205618**	**002**	Apr 06, 2018
AB			**6MG**	**A205618**	**003**	Apr 06, 2018
AB			**9MG**	**A205618**	**004**	Apr 06, 2018

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

INVEGA SUSTENNA

	+	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009
	+		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009
	+		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009
	+!		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009
	+		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009

INVEGA TRINZA

	+	JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946	001	May 18, 2015
	+		410MG/1.315ML (311.79MG/ML)	N207946	002	May 18, 2015
	+		546MG/1.75ML (312MG/ML)	N207946	003	May 18, 2015
	+!		819MG/2.625ML (312MG/ML)	N207946	004	May 18, 2015

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

ALOXI

AP	**+!**	HELSINN HLTHCARE	**EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)**	**N021372**	**002**	Feb 29, 2008
AP	**+!**		**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**N021372**	**001**	Jul 25, 2003

PALONOSETRON HYDROCHLORIDE

AP		AUROBINDO PHARMA LTD	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A204702**	**001**	Nov 06, 2018
AP		CIPLA	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A206396**	**001**	Sep 19, 2018
AP		DR REDDYS LABS LTD	**EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)**	**A201533**	**001**	Apr 21, 2016
AP			**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A201533**	**002**	Apr 21, 2016
AP		FRESENIUS KABI USA	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A206801**	**001**	Sep 19, 2018
AP			**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A206802**	**001**	Sep 19, 2018
AP		HOSPIRA INC	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A207005**	**001**	Sep 19, 2018
AP			**EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)**	**A207005**	**002**	Sep 19, 2018

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

AP		MYLAN INSTITUTIONAL	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A206416**	**001**	Sep 19, 2018
AP		QILU PHARM CO LTD	**EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)**	**A205648**	**002**	Sep 19, 2018
AP			**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A205648**	**001**	Sep 19, 2018
AP		SAGENT PHARMS	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A204289**	**001**	Sep 19, 2018
AP			**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A205870**	**001**	Sep 19, 2018
AP		SANDOZ INC	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A202521**	**001**	Oct 13, 2015
AP		TEVA PHARMS USA	**EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)**	**A090713**	**002**	Mar 23, 2018
AP			**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A090713**	**001**	Mar 23, 2018
AP		VIRTUS PHARM	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A209287**	**001**	Sep 19, 2018

SOLUTION;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

		EXELA PHARMA SCIENCE	EQ 0.25MG BASE/2ML (EQ 0.125MG BASE/ML)	N207963	001	Aug 22, 2016
	+	FRESENIUS KABI USA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N208109	001	Nov 21, 2017

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION

PAMIDRONATE DISODIUM

AP		AREVA PHARMS	**30MG/VIAL**	**A077433**	**001**	Nov 26, 2008
AP			**90MG/VIAL**	**A077433**	**003**	Nov 26, 2008
AP		FRESENIUS KABI USA	**30MG/VIAL**	**A075773**	**001**	May 06, 2002
AP			**30MG/10ML (3MG/ML)**	**A076207**	**001**	May 17, 2002
AP			**90MG/VIAL**	**A075773**	**002**	May 06, 2002
AP			**90MG/10ML (9MG/ML)**	**A076207**	**002**	May 17, 2002
AP	!	HOSPIRA	**30MG/10ML (3MG/ML)**	**A075841**	**001**	Jun 27, 2002
AP	!		**60MG/10ML (6MG/ML)**	**A075841**	**002**	Jun 27, 2002
AP	!		**90MG/10ML (9MG/ML)**	**A075841**	**003**	Jun 27, 2002
AP		LUITPOLD	**30MG/10ML (3MG/ML)**	**A078942**	**001**	Jul 25, 2008
AP			**90MG/10ML (9MG/ML)**	**A078942**	**002**	Jul 25, 2008
AP		MYLAN LABS LTD	**30MG/10ML (3MG/ML)**	**A078520**	**001**	Oct 31, 2008
AP			**90MG/10ML (9MG/ML)**	**A078520**	**002**	Oct 31, 2008
AP		PLIVA LACHEMA	**30MG/10ML (3MG/ML)**	**A078156**	**001**	Aug 19, 2008
AP			**60MG/10ML (6MG/ML)**	**A078156**	**002**	Aug 19, 2008
AP			**90MG/10ML (9MG/ML)**	**A078156**	**003**	Aug 19, 2008
AP		SAGENT PHARMS	**30MG/10ML (3MG/ML)**	**A078373**	**001**	Dec 23, 2008
AP			**90MG/10ML (9MG/ML)**	**A078373**	**002**	Dec 23, 2008
AP		SUN PHARMA GLOBAL	**30MG/VIAL**	**A077703**	**001**	Dec 24, 2008
AP			**90MG/VIAL**	**A077703**	**002**	Dec 24, 2008
AP		TEVA PHARMS USA	**30MG/10ML (3MG/ML)**	**A076153**	**001**	Mar 27, 2002
AP			**90MG/10ML (9MG/ML)**	**A076153**	**002**	Mar 27, 2002
AP		WEST-WARD PHARMS INT	**30MG/VIAL**	**A075290**	**001**	Apr 30, 2001
AP	**+!**		**30MG/10ML (3MG/ML)**	**N021113**	**001**	Mar 04, 2002
AP			**90MG/VIAL**	**A075290**	**003**	Apr 30, 2001
AP	**+!**		**90MG/10ML (9MG/ML)**	**N021113**	**002**	Mar 04, 2002
		AREVA PHARMS	60MG/VIAL	A077433	002	Nov 26, 2008

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE;ORAL

CREON

+	ABBVIE	60,000USP UNITS;12,000USP UNITS;38,000USP UNITS	N020725	002	Apr 30, 2009
+		15,000USP UNITS;3,000USP UNITS;9,500USP UNITS	N020725	004	Jul 12, 2011
+		30,000USP UNITS;6,000USP UNITS;19,000USP UNITS	N020725	001	Apr 30, 2009
+		180,000USP UNITS;36,000USP UNITS;114,000USP UNITS	N020725	005	Mar 14, 2013
+!		120,000USP UNITS;24,000USP UNITS;76,000USP UNITS	N020725	003	Apr 30, 2009

PANCREAZE

+	VIVUS INC	10,850USP UNITS;2,600USP UNITS;6,200USP UNITS	N022523	005	Mar 07, 2014
+		24,600USP UNITS; 4,200USP UNITS; 14,200USP UNITS	N022523	001	Apr 12, 2010
+		61,500USP UNITS; 10,500USP UNITS; 35,500USP UNITS	N022523	002	Apr 12, 2010
+		83,900USP UNITS; 21,000USP UNITS; 54,700USP UNITS	N022523	004	Apr 12, 2010
+!		98,400USP UNITS; 16,800USP UNITS; 56,800USP UNITS	N022523	003	Apr 12, 2010

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)						
CAPSULE, DELAYED RELEASE;ORAL						
PERTZYE						
+	DIGESTIVE CARE INC	30,250USP UNITS;8,000USP UNITS;28,750USP UNITS	N022175	001	May 17, 2012
+!		60,500USP UNITS;16,000USP UNITS;57,500USP UNITS	N022175	002	May 17, 2012
+		15,125USP UNITS;4,000USP UNITS;14,375USP UNITS	N022175	003	Oct 06, 2016
+		90,750USP UNITS;24,000USP UNITS;86,250USP UNITS	N022175	004	Jul 13, 2017
ZENPEP						
+	FOREST LABS INC	168,000USP UNITS;40,000USP UNITS;126,000USP UNITS	N022210	007	Mar 25, 2014
+		14,000USP UNITS;3,000USP UNITS;10,000USP UNITS	N022210	005	Jun 15, 2011
+		24,000USP UNITS;5,000USP UNITS;17,000USP UNITS	N022210	001	Aug 27, 2009
+		42,000USP UNITS;10,000USP UNITS;32,000USP UNITS	N022210	002	Aug 27, 2009
+		63,000USP UNITS;15,000USP UNITS;47,000USP UNITS	N022210	003	Aug 27, 2009
+		84,000USP UNITS;20,000USP UNITS;63,000USP UNITS	N022210	004	Aug 27, 2009
+!		105,000USP UNITS;25,000USP UNITS;79,000USP UNITS	N022210	006	Jul 13, 2011
TABLET;ORAL						
VIOKACE						
+	FOREST LABS INC	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542	001	Mar 01, 2012
+!		78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542	002	Mar 01, 2012
PANCURONIUM BROMIDE						
INJECTABLE;INJECTION						
PANCURONIUM BROMIDE						
AP	HOSPIRA	**1MG/ML**	**A072320**	**001**	Jan 19, 1989
AP **!**	TEVA PHARMS USA	**1MG/ML**	**A072759**	**001**	Jul 31, 1990
!		2MG/ML	A072760	001	Jul 31, 1990
PANOBINOSTAT LACTATE						
CAPSULE;ORAL						
FARYDAK						
+	NOVARTIS PHARMS CORP	EQ 10MG BASE	N205353	001	Feb 23, 2015
+		EQ 15MG BASE	N205353	002	Feb 23, 2015
+!		EQ 20MG BASE	N205353	003	Feb 23, 2015
PANTOPRAZOLE SODIUM						
FOR SUSPENSION, DELAYED RELEASE;ORAL						
PROTONIX						
+!	WYETH PHARMS	EQ 40MG BASE	N022020	001	Nov 14, 2007
INJECTABLE;IV (INFUSION)						
PANTOPRAZOLE SODIUM						
AP	AKORN INC	**EQ 40MG BASE/VIAL**	**A079197**	**001**	Nov 08, 2012
AP	AUROBINDO PHARMA LTD	**EQ 40MG BASE/VIAL**	**A205675**	**001**	Mar 30, 2016
AP	MYLAN LABS LTD	**EQ 40MG BASE/VIAL**	**A208580**	**001**	May 04, 2018
AP	SANDOZ INC	**EQ 40MG BASE/VIAL**	**A090296**	**001**	Jul 14, 2015
PROTONIX IV						
AP **+!**	WYETH PHARMS	**EQ 40MG BASE/VIAL**	**N020988**	**001**	Mar 22, 2001
POWDER;IV (INFUSION)						
PANTOPRAZOLE SODIUM						
	EXELA PHARMA SCS LLC	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017
TABLET, DELAYED RELEASE;ORAL						
PANTOPRAZOLE SODIUM						
AB	ACTAVIS TOTOWA	**EQ 20MG BASE**	**A090797**	**001**	Feb 07, 2011
AB		**EQ 40MG BASE**	**A090797**	**002**	Feb 07, 2011
AB	AMNEAL PHARMS	**EQ 20MG BASE**	**A205119**	**001**	Jan 26, 2016
AB		**EQ 40MG BASE**	**A205119**	**002**	Jan 26, 2016
AB	APOTEX INC	**EQ 20MG BASE**	**A090807**	**001**	May 02, 2012
AB		**EQ 40MG BASE**	**A090807**	**002**	May 02, 2012
AB	AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A202038**	**001**	Sep 28, 2012
AB		**EQ 40MG BASE**	**A202038**	**002**	Sep 28, 2012
AB	DR REDDYS LABS LTD	**EQ 20MG BASE**	**A077619**	**001**	Jan 19, 2011

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

AB			**EQ 40MG BASE**	**A077619**	**002**	Jan 19, 2011
AB		HETERO LABS LTD V	**EQ 20MG BASE**	**A202882**	**001**	Sep 10, 2014
AB			**EQ 40MG BASE**	**A202882**	**002**	Sep 10, 2014
AB		JUBILANT GENERICS	**EQ 20MG BASE**	**A090901**	**001**	Aug 30, 2011
AB			**EQ 40MG BASE**	**A090901**	**002**	Aug 30, 2011
AB		LANNETT CO INC	**EQ 20MG BASE**	**A078281**	**001**	Jan 20, 2011
AB			**EQ 40MG BASE**	**A078281**	**002**	Jan 20, 2011
AB		MACLEODS PHARMS LTD	**EQ 20MG BASE**	**A200821**	**001**	Feb 16, 2012
AB			**EQ 40MG BASE**	**A200821**	**002**	Feb 16, 2012
AB		MYLAN PHARMS INC	**EQ 20MG BASE**	**A090970**	**001**	Jan 19, 2011
AB			**EQ 40MG BASE**	**A090970**	**002**	Jan 19, 2011
AB		ORCHID HLTHCARE	**EQ 20MG BASE**	**A202052**	**001**	Dec 02, 2014
AB			**EQ 40MG BASE**	**A202052**	**002**	Dec 02, 2014
AB		PERRIGO R AND D	**EQ 20MG BASE**	**A203024**	**001**	May 07, 2014
AB		TEVA	**EQ 20MG BASE**	**A077056**	**001**	Aug 02, 2007
AB			**EQ 40MG BASE**	**A077056**	**002**	Aug 02, 2007
AB		TORRENT PHARMS	**EQ 20MG BASE**	**A090074**	**001**	Jan 19, 2011
AB			**EQ 40MG BASE**	**A090074**	**002**	Jan 19, 2011
AB		WOCKHARDT	**EQ 20MG BASE**	**A091231**	**001**	Jan 19, 2011
AB			**EQ 40MG BASE**	**A091231**	**002**	Jan 19, 2011

PROTONIX

AB	+	WYETH PHARMS	**EQ 20MG BASE**	**N020987**	**002**	Jun 12, 2001
AB	+!		**EQ 40MG BASE**	**N020987**	**001**	Feb 02, 2000

PARICALCITOL

CAPSULE;ORAL

PARICALCITOL

AB		AMNEAL PHARMS	**1MCG**	**A204327**	**001**	Jan 13, 2016
AB			**2MCG**	**A204327**	**002**	Jan 13, 2016
AB			**4MCG**	**A204327**	**003**	Jan 13, 2016
AB		AUROBINDO PHARMA LTD	**1MCG**	**A207672**	**001**	Jan 14, 2016
AB			**2MCG**	**A207672**	**002**	Jan 14, 2016
AB			**4MCG**	**A207672**	**003**	Jan 14, 2016
AB		BIONPHARMA INC	**1MCG**	**A202539**	**001**	Mar 27, 2014
AB			**2MCG**	**A202539**	**002**	Mar 27, 2014
AB			**4MCG**	**A202539**	**003**	Mar 27, 2014
AB		DR REDDYS LABS LTD	**1MCG**	**A091412**	**001**	Jun 24, 2014
AB			**2MCG**	**A091412**	**002**	Jun 24, 2014
AB			**4MCG**	**A091412**	**003**	Jun 24, 2014
AB		LOTUS PHARM CO LTD	**1MCG**	**A206710**	**001**	Feb 24, 2016
AB			**2MCG**	**A206710**	**002**	Feb 24, 2016
AB			**4MCG**	**A206710**	**003**	Feb 24, 2016
AB		MARKSANS PHARMA	**1MCG**	**A204948**	**001**	Oct 07, 2016
AB			**2MCG**	**A204948**	**002**	Oct 07, 2016
AB			**4MCG**	**A204948**	**003**	Oct 07, 2016
AB		RISING PHARMS	**1MCG**	**A202124**	**001**	Jun 24, 2014
AB			**2MCG**	**A202124**	**002**	Jun 24, 2014
AB			**4MCG**	**A202124**	**003**	Jun 24, 2014
AB		TEVA PHARMS USA	**1MCG**	**A090829**	**001**	Sep 27, 2013
AB			**2MCG**	**A090829**	**002**	Sep 27, 2013
AB	!		**4MCG**	**A090829**	**003**	Sep 27, 2013

ZEMPLAR

AB	+	ABBVIE	**1MCG**	**N021606**	**001**	May 26, 2005
AB	+		**2MCG**	**N021606**	**002**	May 26, 2005

SOLUTION;INTRAVENOUS

PARICALCITOL

AP		ACCORD HLTHCARE	**0.002MG/ML (0.002MG/ML)**	**N207174**	**001**	Feb 04, 2016
AP			**0.005MG/ML (0.005MG/ML)**	**N207174**	**002**	Feb 04, 2016
AP			**0.01MG/2ML (0.005MG/ML)**	**N207174**	**003**	Feb 04, 2016
AP		AKORN	**0.005MG/ML (0.005MG/ML)**	**A207692**	**001**	Oct 16, 2017
AP		AMNEAL PHARMS CO	**0.002MG/ML (0.002MG/ML)**	**A206699**	**001**	Mar 09, 2017
AP			**0.005MG/ML (0.005MG/ML)**	**A206699**	**002**	Mar 09, 2017
AP			**0.01MG/2ML (0.005MG/ML)**	**A206699**	**003**	Mar 09, 2017
AP		AUROBINDO PHARMA LTD	**0.002MG/ML (0.002MG/ML)**	**A205982**	**001**	Oct 09, 2018
AP			**0.005MG/ML (0.005MG/ML)**	**A205982**	**002**	Oct 09, 2018
AP			**0.01MG/2ML (0.005MG/ML)**	**A205982**	**003**	Oct 09, 2018
AP		DR REDDYS LABS LTD	**0.002MG/ML (0.002MG/ML)**	**A204910**	**001**	Aug 17, 2016
AP			**0.005MG/ML (0.005MG/ML)**	**A204910**	**002**	Aug 17, 2016

PARICALCITOL

SOLUTION;INTRAVENOUS

PARICALCITOL

AP			**0.01MG/2ML (0.005MG/ML)**	**A204910**	**003**	Aug 17, 2016
AP		HIKMA PHARMS	**0.002MG/ML (0.002MG/ML)**	**N205917**	**001**	Nov 18, 2014
AP			**0.005MG/ML (0.005MG/ML)**	**N205917**	**002**	Nov 18, 2014
AP			**0.01MG/2ML (0.005MG/ML)**	**N205917**	**003**	Nov 18, 2014
AP		HOSPIRA INC	**0.002MG/ML (0.002MG/ML)**	**N201657**	**001**	Oct 21, 2014
AP			**0.005MG/ML (0.005MG/ML)**	**N201657**	**002**	Oct 21, 2014
AP			**0.01MG/2ML (0.005MG/ML)**	**N201657**	**003**	Oct 21, 2014
AP		MYLAN LABS LTD	**0.002MG/ML (0.002MG/ML)**	**A203897**	**001**	Nov 02, 2017
AP			**0.005MG/ML (0.005MG/ML)**	**A203897**	**002**	Nov 02, 2017
AP			**0.01MG/2ML (0.005MG/ML)**	**A203897**	**003**	Nov 02, 2017
AP		SANDOZ INC	**0.002MG/ML (0.002MG/ML)**	**A091108**	**001**	Jul 27, 2011
AP			**0.005MG/ML (0.005MG/ML)**	**A091108**	**002**	Jul 27, 2011
AP			**0.01MG/2ML (0.005MG/ML)**	**A091108**	**003**	Jul 27, 2011

ZEMPLAR

AP	**+!**	ABBVIE	**0.002MG/ML (0.002MG/ML)**	**N020819**	**002**	Feb 01, 2000
AP	**+!**		**0.005MG/ML (0.005MG/ML)**	**N020819**	**001**	Apr 17, 1998
AP	**+!**		**0.01MG/2ML (0.005MG/ML)**	**N020819**	**003**	Feb 01, 2000

PAROMOMYCIN SULFATE

CAPSULE;ORAL

PAROMOMYCIN SULFATE

AA		HERITAGE PHARMS INC	**EQ 250MG BASE**	**A065173**	**001**	Dec 14, 2007
AA	**!**	SUN PHARM INDS INC	**EQ 250MG BASE**	**A064171**	**001**	Jun 30, 1997

PAROXETINE HYDROCHLORIDE

SUSPENSION;ORAL

PAXIL

	+!	APOTEX TECHNOLOGIES	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997

TABLET;ORAL

PAROXETINE

AB		PRINSTON INC	**EQ 10MG BASE**	**A203854**	**001**	Oct 31, 2014
AB			**EQ 20MG BASE**	**A203854**	**002**	Oct 31, 2014
AB			**EQ 30MG BASE**	**A203854**	**003**	Oct 31, 2014
AB			**EQ 40MG BASE**	**A203854**	**004**	Oct 31, 2014

PAROXETINE HYDROCHLORIDE

AB		APOTEX	**EQ 10MG BASE**	**A075356**	**001**	Jul 30, 2003
AB			**EQ 20MG BASE**	**A075356**	**002**	Jul 30, 2003
AB			**EQ 30MG BASE**	**A075356**	**003**	Jul 30, 2003
AB			**EQ 40MG BASE**	**A075356**	**004**	Jul 30, 2003
AB		AUROBINDO PHARMA	**EQ 10MG BASE**	**A078406**	**001**	Jul 25, 2007
AB			**EQ 20MG BASE**	**A078406**	**002**	Jul 25, 2007
AB			**EQ 30MG BASE**	**A078406**	**003**	Jul 25, 2007
AB			**EQ 40MG BASE**	**A078406**	**004**	Jul 25, 2007
AB		JUBILANT GENERICS	**EQ 10MG BASE**	**A205528**	**001**	Nov 27, 2015
AB			**EQ 20MG BASE**	**A205528**	**002**	Nov 27, 2015
AB			**EQ 30MG BASE**	**A205528**	**003**	Nov 27, 2015
AB			**EQ 40MG BASE**	**A205528**	**004**	Nov 27, 2015
AB		MYLAN	**EQ 10MG BASE**	**A078902**	**001**	Mar 13, 2008
AB			**EQ 20MG BASE**	**A078902**	**002**	Mar 13, 2008
AB			**EQ 30MG BASE**	**A078902**	**003**	Mar 13, 2008
AB			**EQ 40MG BASE**	**A078902**	**004**	Mar 13, 2008
AB		OXFORD PHARMS	**EQ 10MG BASE**	**A076968**	**001**	Jun 21, 2010
AB			**EQ 20MG BASE**	**A076968**	**002**	Jun 21, 2010
AB			**EQ 30MG BASE**	**A076968**	**003**	Jun 21, 2010
AB			**EQ 40MG BASE**	**A076968**	**004**	Jun 21, 2010
AB		SUN PHARM INDS INC	**EQ 10MG BASE**	**A078194**	**001**	Jun 29, 2007
AB			**EQ 20MG BASE**	**A078194**	**002**	Jun 29, 2007
AB			**EQ 30MG BASE**	**A078194**	**003**	Jun 29, 2007
AB			**EQ 40MG BASE**	**A078194**	**004**	Jun 29, 2007
AB		TEVA	**EQ 10MG BASE**	**A076618**	**001**	Aug 15, 2005
AB			**EQ 20MG BASE**	**A076618**	**002**	Aug 15, 2005
AB			**EQ 30MG BASE**	**A076618**	**003**	Aug 15, 2005
AB			**EQ 40MG BASE**	**A076618**	**004**	Aug 15, 2005
AB		ZYDUS PHARMS USA	**EQ 10MG BASE**	**A077584**	**001**	Mar 07, 2007
AB			**EQ 20MG BASE**	**A077584**	**002**	Mar 07, 2007
AB			**EQ 30MG BASE**	**A077584**	**003**	Mar 07, 2007
AB			**EQ 40MG BASE**	**A077584**	**004**	Mar 07, 2007

PAXIL

AB	**+**	APOTEX TECHNOLOGIES	**EQ 10MG BASE**	**N020031**	**001**	Dec 29, 1992
AB	**+**		**EQ 20MG BASE**	**N020031**	**002**	Dec 29, 1992

PAROXETINE HYDROCHLORIDE						
TABLET;ORAL						
PAXIL						
AB	**+**		**EQ 30MG BASE**	**N020031**	**003**	Dec 29, 1992
AB	**+!**		**EQ 40MG BASE**	**N020031**	**005**	Dec 29, 1992
TABLET, EXTENDED RELEASE;ORAL						
PAROXETINE HYDROCHLORIDE						
AB		LANNETT CO INC	**EQ 12.5MG BASE**	**A204744**	**001**	Jun 10, 2016
AB			**EQ 25MG BASE**	**A204744**	**002**	Jun 10, 2016
AB			**EQ 37.5MG BASE**	**A204744**	**003**	Jun 10, 2016
AB		LUPIN LTD	**EQ 12.5MG BASE**	**A204134**	**001**	Jan 20, 2017
AB			**EQ 25MG BASE**	**A204134**	**002**	Jan 20, 2017
AB			**EQ 37.5MG BASE**	**A204134**	**003**	Jan 20, 2017
AB		MYLAN	**EQ 12.5MG BASE**	**A077873**	**001**	Jun 29, 2007
AB			**EQ 25MG BASE**	**A077873**	**002**	Jun 29, 2007
AB			**EQ 37.5MG BASE**	**A091427**	**001**	Apr 14, 2011
AB		SCIECURE PHARMA INC	**EQ 12.5MG BASE**	**A209293**	**001**	Jun 12, 2018
AB			**EQ 25MG BASE**	**A209293**	**002**	Jun 12, 2018
AB			**EQ 37.5MG BASE**	**A209293**	**003**	Jun 12, 2018
PAXIL CR						
AB	**+**	APOTEX TECHNOLOGIES	**EQ 12.5MG BASE**	**N020936**	**001**	Feb 16, 1999
AB	**+**		**EQ 25MG BASE**	**N020936**	**002**	Feb 16, 1999
AB	**+!**		**EQ 37.5MG BASE**	**N020936**	**003**	Dec 06, 2000
PAROXETINE MESYLATE						
CAPSULE;ORAL						
BRISDELLE						
AB	**+!**	SEBELA IRELAND LTD	**EQ 7.5MG BASE**	**N204516**	**001**	Jun 28, 2013
PAROXETINE MESYLATE						
AB		ACTAVIS LABS FL INC	**EQ 7.5MG BASE**	**A207139**	**001**	Jun 20, 2017
AB		PRINSTON INC	**EQ 7.5MG BASE**	**A207188**	**001**	Aug 18, 2017
TABLET;ORAL						
PEXEVA						
	+	SEBELA IRELAND LTD	EQ 10MG BASE	N021299	001	Jul 03, 2003
	+		EQ 20MG BASE	N021299	002	Jul 03, 2003
	+		EQ 30MG BASE	N021299	003	Jul 03, 2003
	+!		EQ 40MG BASE	N021299	004	Jul 03, 2003
PASIREOTIDE DIASPARTATE						
SOLUTION;SUBCUTANEOUS						
SIGNIFOR						
	+	NOVARTIS	EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)	N200677	001	Dec 14, 2012
	+		EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)	N200677	002	Dec 14, 2012
	+!		EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)	N200677	003	Dec 14, 2012
PASIREOTIDE PAMOATE						
FOR SUSPENSION;INTRAMUSCULAR						
SIGNIFOR LAR KIT						
	+	NOVARTIS PHARMS CORP	EQ 10MG BASE/VIAL	N203255	004	Jun 29, 2018
	+		EQ 20MG BASE/VIAL	N203255	001	Dec 15, 2014
	+		EQ 30MG BASE/VIAL	N203255	005	Jun 29, 2018
	+		EQ 40MG BASE/VIAL	N203255	002	Dec 15, 2014
	+!		EQ 60MG BASE/VIAL	N203255	003	Dec 15, 2014
PATIROMER SORBITEX CALCIUM						
POWDER;ORAL						
VELTASSA						
	+	RELYPSA INC	EQ 8.4GM BASE/PACKET	N205739	001	Oct 21, 2015
	+		EQ 16.8GM BASE/PACKET	N205739	002	Oct 21, 2015
	+!		EQ 25.2GM BASE/PACKET	N205739	003	Oct 21, 2015
PATISIRAN SODIUM						
SOLUTION;INTRAVENOUS						
ONPATTRO						
	+!	ALNYLAM PHARMS INC	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N210922	001	Aug 10, 2018
PAZOPANIB HYDROCHLORIDE						
TABLET;ORAL						
VOTRIENT						
	+!	NOVARTIS PHARMS CORP	EQ 200MG BASE	N022465	001	Oct 19, 2009

PEGADEMASE BOVINE						
INJECTABLE;INJECTION						
ADAGEN						
+!	LEADIANT BIOSCI INC	250 UNITS/ML		N019818	001	Mar 21, 1990
PEGAPTANIB SODIUM						
INJECTABLE;INTRAVITREAL						
MACUGEN						
+!	VALEANT PHARMS LLC	EQ 0.3MG ACID/0.09ML		N021756	001	Dec 17, 2004
PEGVISOMANT						
INJECTABLE;SUBCUTANEOUS						
SOMAVERT						
+!	PHARMACIA AND UPJOHN	10MG/VIAL		N021106	001	Mar 25, 2003
+!		15MG/VIAL		N021106	002	Mar 25, 2003
+!		20MG/VIAL		N021106	003	Mar 25, 2003
+!		25MG/VIAL		N021106	004	Jul 31, 2014
+!		30MG/VIAL		N021106	005	Jul 31, 2014
PEMETREXED DISODIUM						
POWDER;INTRAVENOUS						
ALIMTA						
+!	LILLY	EQ 100MG BASE/VIAL		N021462	002	Sep 07, 2007
+!		EQ 500MG BASE/VIAL		N021462	001	Feb 04, 2004
PENCICLOVIR						
CREAM;TOPICAL						
DENAVIR						
+!	MYLAN PHARMS INC	1%		N020629	001	Sep 24, 1996
PENICILLAMINE						
CAPSULE;ORAL						
CUPRIMINE						
+!	ATON	250MG		N019853	001	
TABLET;ORAL						
DEPEN						
+!	MYLAN SPECIALITY LP	250MG		N019854	001	
PENICILLIN G BENZATHINE						
INJECTABLE;INJECTION						
BICILLIN L-A						
BC +!	KING PHARMS LLC	600,000 UNITS/ML		N050141	001	
PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE						
INJECTABLE;INJECTION						
BICILLIN C-R						
+!	KING PHARMS LLC	300,000 UNITS/ML;300,000 UNITS/ML		N050138	001	
BICILLIN C-R 900/300						
+!	KING PHARMS LLC	900,000 UNITS/2ML;300,000 UNITS/2ML		N050138	003	
PENICILLIN G POTASSIUM						
INJECTABLE;INJECTION						
PENICILLIN G POTASSIUM						
AP	ACS DOBFAR SPA	**20,000,000 UNITS/VIAL**		**A205043**	**002**	Oct 26, 2018
AP		**5,000,000 UNITS/VIAL**		**A205043**	**001**	Oct 26, 2018
AP	HANFORD GC	**5,000,000 UNITS/VIAL**		**A065149**	**002**	Jul 23, 2009
AP		**20,000,000 UNITS/VIAL**		**A065149**	**003**	Jul 23, 2009
AP	ISTITUTO BIO ITA SPA	**5,000,000 UNITS/VIAL**		**A065448**	**001**	Aug 18, 2009
AP		**20,000,000 UNITS/VIAL**		**A065448**	**002**	Aug 18, 2009
AP	SANDOZ	**5,000,000 UNITS/VIAL**		**A065079**	**002**	Aug 30, 2002
AP		**20,000,000 UNITS/VIAL**		**A065079**	**003**	Aug 30, 2002
PFIZERPEN						
AP **!**	PFIZER	**5,000,000 UNITS/VIAL**		**A060657**	**002**	
AP **!**		**20,000,000 UNITS/VIAL**		**A060657**	**003**	
PENICILLIN G POTASSIUM						
	HANFORD GC	1,000,000 UNITS/VIAL		A065149	001	Jul 23, 2009
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER						
+!	BAXTER HLTHCARE	20,000 UNITS/ML		N050638	001	Jun 25, 1990
+!		40,000 UNITS/ML		N050638	002	Jun 25, 1990
+!		60,000 UNITS/ML		N050638	003	Jun 25, 1990

PENICILLIN G PROCAINE

INJECTABLE;INJECTION

PENICILLIN G PROCAINE

	!	KING PHARMS LLC	300,000 UNITS/ML	A060101 002	
	!		600,000 UNITS/ML	A060101 001	

PENICILLIN G SODIUM

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

PENICILLIN G SODIUM

	!	SANDOZ	5,000,000 UNITS/VIAL	A065068 001	Feb 26, 2001

PENICILLIN V POTASSIUM

FOR SOLUTION;ORAL

PENICILLIN V POTASSIUM

AA		DAVA PHARMS INC	**EQ 125MG BASE/5ML**	**A062981 001**	Feb 10, 1989
AA			**EQ 250MG BASE/5ML**	**A062981 002**	Feb 10, 1989

PENICILLIN-VK

AA		TEVA	**EQ 125MG BASE/5ML**	**A060456 001**	
AA	**!**		**EQ 250MG BASE/5ML**	**A060456 002**	

TABLET;ORAL

PENICILLIN V POTASSIUM

AB		AUROBINDO PHARMA	**EQ 250MG BASE**	**A065435 001**	Apr 29, 2008
AB			**EQ 500MG BASE**	**A065435 002**	Apr 29, 2008
AB		DAVA PHARMS INC	**EQ 250MG BASE**	**A062936 001**	Nov 25, 1988
AB			**EQ 500MG BASE**	**A062935 001**	Nov 23, 1988
AB		HIKMA PHARMS	**EQ 250MG BASE**	**A090549 001**	Oct 11, 2013
AB			**EQ 500MG BASE**	**A090549 002**	Oct 11, 2013
AB		SANDOZ	**EQ 250MG BASE**	**A064071 001**	Nov 30, 1995
AB	**!**		**EQ 500MG BASE**	**A064071 002**	Nov 30, 1995

PENICILLIN-VK

AB		TEVA	**EQ 250MG BASE**	**A060711 002**	
AB			**EQ 500MG BASE**	**A060711 003**	

PENTAMIDINE ISETHIONATE

FOR SOLUTION;INHALATION

NEBUPENT

	+!	FRESENIUS KABI USA	300MG/VIAL	N019887 001	Jun 15, 1989

INJECTABLE;INJECTION

PENTAM

AP	**+!**	FRESENIUS KABI USA	**300MG/VIAL**	**N019264 001**	Oct 16, 1984

PENTAMIDINE ISETHIONATE

AP		SETON PHARMS	**300MG/VIAL**	**A206666 001**	Sep 28, 2017

PENTETATE CALCIUM TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS

PENTETATE CALCIUM TRISODIUM

	+!	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749 001	Aug 11, 2004

PENTETATE ZINC TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS

PENTETATE ZINC TRISODIUM

	+!	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751 001	Aug 11, 2004

PENTOBARBITAL SODIUM

INJECTABLE;INJECTION

NEMBUTAL SODIUM

AP	**!**	OAK PHARMS	**50MG/ML**	**A083246 001**	

PENTOBARBITAL SODIUM

AP		CUSTOPHARM INC	**50MG/ML**	**A203619 001**	Nov 13, 2017
AP		RENAISSANCE SSA LLC	**50MG/ML**	**A206677 001**	Nov 27, 2017
AP		SAGENT PHARMS	**50MG/ML**	**A206404 001**	May 23, 2016

PENTOSAN POLYSULFATE SODIUM

CAPSULE;ORAL

ELMIRON

	+!	JANSSEN PHARMS	100MG	N020193 001	Sep 26, 1996

PENTOSTATIN

INJECTABLE;INJECTION

NIPENT

AP	**+!**	HOSPIRA INC	**10MG/VIAL**	**N020122 001**	Oct 11, 1991

PENTOSTATIN

AP		MYLAN INSTITUTIONAL	**10MG/VIAL**	**A203554 001**	Sep 19, 2014
AP		WEST-WARD PHARMS INT	**10MG/VIAL**	**A077841 001**	Aug 07, 2007

PENTOXIFYLLINE						
TABLET, EXTENDED RELEASE;ORAL						
PENTOXIFYLLINE						
AB	**!**	APOTEX	**400MG**	**A075191**	**001**	Jun 09, 1999
AB		MYLAN	**400MG**	**A074425**	**001**	Jul 08, 1997
AB		VALEANT PHARMS	**400MG**	**A075028**	**001**	Jul 20, 1998
PENTOXIL						
AB		UPSHER SMITH LABS	**400MG**	**A074962**	**001**	Mar 31, 1999
PERAMIVIR						
SOLUTION;INTRAVENOUS						
RAPIVAB						
	+!	BIOCRYST	200MG/20ML (10MG/ML)	N206426	001	Dec 19, 2014
PERAMPANEL						
SUSPENSION;ORAL						
FYCOMPA						
	+!	EISAI INC	0.5MG/ML	N208277	001	Apr 29, 2016
TABLET;ORAL						
FYCOMPA						
	+	EISAI INC	2MG	N202834	001	Oct 22, 2012
	+		4MG	N202834	002	Oct 22, 2012
	+		6MG	N202834	003	Oct 22, 2012
	+		8MG	N202834	004	Oct 22, 2012
	+		10MG	N202834	005	Oct 22, 2012
	+!		12MG	N202834	006	Oct 22, 2012
PERFLUTREN						
INJECTABLE;INTRAVENOUS						
DEFINITY						
	+!	LANTHEUS MEDCL	6.52MG/ML	N021064	001	Jul 31, 2001
PERINDOPRIL ERBUMINE						
TABLET;ORAL						
PERINDOPRIL ERBUMINE						
AB		ANI PHARMS INC	**2MG**	**A078138**	**001**	Nov 10, 2009
AB			**4MG**	**A078138**	**002**	Nov 10, 2009
AB			**8MG**	**A078138**	**003**	Nov 10, 2009
AB		AUROBINDO PHARMA	**2MG**	**A079070**	**001**	Nov 10, 2009
AB			**4MG**	**A079070**	**002**	Nov 10, 2009
AB	**!**		**8MG**	**A079070**	**003**	Nov 10, 2009
AB		WEST-WARD PHARMS INT	**2MG**	**A090072**	**001**	Nov 10, 2009
AB			**4MG**	**A090072**	**002**	Nov 10, 2009
AB			**8MG**	**A090072**	**003**	Nov 10, 2009
PERMETHRIN						
CREAM;TOPICAL						
ELIMITE						
AB	**+!**	MYLAN PHARMS INC	**5%**	**N019855**	**001**	Aug 25, 1989
PERMETHRIN						
AB		ACTAVIS LABS	**5%**	**A074806**	**001**	Jan 23, 1998
AB		PERRIGO NEW YORK	**5%**	**A076369**	**001**	Apr 21, 2003
PERPHENAZINE						
TABLET;ORAL						
PERPHENAZINE						
AB		MYLAN PHARMS INC	**2MG**	**A206691**	**001**	Apr 14, 2017
AB			**4MG**	**A206691**	**002**	Apr 14, 2017
AB			**8MG**	**A206691**	**003**	Apr 14, 2017
AB			**16MG**	**A206691**	**004**	Apr 14, 2017
AB		SANDOZ	**2MG**	**A089685**	**002**	Dec 08, 1988
AB			**4MG**	**A089685**	**003**	Dec 08, 1988
AB			**8MG**	**A089685**	**001**	Dec 08, 1988
AB	**!**		**16MG**	**A089685**	**004**	Dec 08, 1988
AB		VINTAGE PHARMS	**2MG**	**A040226**	**001**	Dec 31, 1998
AB			**4MG**	**A040226**	**002**	Dec 31, 1998
AB			**8MG**	**A040226**	**003**	Dec 31, 1998
AB			**16MG**	**A040226**	**004**	Dec 31, 1998
AB		WATSON LABS INC	**2MG**	**A207582**	**001**	Oct 17, 2016
AB			**4MG**	**A207582**	**002**	Oct 17, 2016
AB			**8MG**	**A207582**	**003**	Oct 17, 2016
AB			**16MG**	**A207582**	**004**	Oct 17, 2016
AB		WILSHIRE PHARMS INC	**2MG**	**A205973**	**001**	Dec 17, 2015
AB			**4MG**	**A205973**	**002**	Dec 17, 2015
AB			**8MG**	**A205973**	**003**	Dec 17, 2015

PERPHENAZINE						
TABLET;ORAL						
PERPHENAZINE						
AB			**16MG**	**A205973**	**004**	Dec 17, 2015
PHENDIMETRAZINE TARTRATE						
CAPSULE, EXTENDED RELEASE;ORAL						
PHENDIMETRAZINE TARTRATE						
	+!	VIRTUS PHARMS	105MG	N018074	001	
TABLET;ORAL						
BONTRIL PDM						
AA	**!**	VALEANT	**35MG**	**A085272**	**001**	
PHENDIMETRAZINE TARTRATE						
AA		ELITE LABS INC	**35MG**	**A040762**	**001**	Jan 28, 2008
AA			**35MG**	**A203600**	**001**	Dec 27, 2017
AA		KVK TECH	**35MG**	**A091042**	**001**	Aug 31, 2010
AA		MIKART	**35MG**	**A089452**	**001**	Oct 30, 1991
AA		VIRTUS PHARMS	**35MG**	**A085588**	**001**	
PHENELZINE SULFATE						
TABLET;ORAL						
NARDIL						
AB	**+!**	PARKE DAVIS	**EQ 15MG BASE**	**N011909**	**002**	
PHENELZINE SULFATE						
AB		NOVEL LABS INC	**EQ 15MG BASE**	**A200181**	**001**	Dec 08, 2010
PHENOXYBENZAMINE HYDROCHLORIDE						
CAPSULE;ORAL						
DIBENZYLINE						
AB	**+!**	CONCORDIA PHARMS INC	**10MG**	**N008708**	**001**	
PHENOXYBENZAMINE HYDROCHLORIDE						
AB		PAR PHARM INC	**10MG**	**A204522**	**001**	Jan 24, 2017
AB		WEST-WARD PHARMS INT	**10MG**	**A201050**	**001**	Jul 16, 2012
PHENTERMINE HYDROCHLORIDE						
CAPSULE;ORAL						
ADIPEX-P						
AA	**!**	TEVA	**37.5MG**	**A088023**	**001**	Aug 02, 1983
PHENTERMINE HYDROCHLORIDE						
AA		AUROLIFE PHARMA LLC	**15MG**	**A204318**	**001**	Nov 09, 2016
AA			**30MG**	**A204318**	**002**	Nov 09, 2016
AA		BARR	**15MG**	**A090591**	**001**	Mar 18, 2010
AA			**30MG**	**A090591**	**002**	Mar 18, 2010
AA		ELITE LABS	**15MG**	**A202248**	**001**	Sep 28, 2012
AA			**30MG**	**A202248**	**002**	Sep 28, 2012
AA		ELITE LABS INC	**37.5MG**	**A040228**	**001**	Jun 19, 1997
AA		INVAGEN PHARMS	**15MG**	**A202858**	**001**	Feb 14, 2014
AA			**30MG**	**A202858**	**002**	Feb 14, 2014
AA			**30MG**	**A204414**	**001**	May 05, 2014
AA			**37.5MG**	**A202846**	**001**	Feb 05, 2014
AA		KVK TECH	**15MG**	**A040886**	**002**	Mar 31, 2008
AA			**30MG**	**A040875**	**001**	Mar 21, 2008
AA			**30MG**	**A040886**	**001**	Mar 31, 2008
AA			**37.5MG**	**A040887**	**001**	Apr 24, 2008
AA		LANNETT	**15MG**	**A087022**	**002**	Jan 20, 2012
AA			**30MG**	**A087022**	**001**	Feb 03, 1983
AA		LANNETT CO INC	**30MG**	**A091359**	**001**	Jul 16, 2010
AA			**37.5MG**	**A201961**	**001**	Jul 20, 2011
AA		NUVO PHARM	**15MG**	**A205019**	**001**	Dec 05, 2014
AA			**30MG**	**A205019**	**002**	Dec 05, 2014
AA			**37.5MG**	**A205017**	**001**	Sep 25, 2014
AA	**!**	SANDOZ	**15MG**	**A087190**	**002**	
AA	**!**		**30MG**	**A086945**	**001**	Jul 20, 1983
AA	**!**		**30MG**	**A087190**	**001**	
AA		SUN PHARM INDUSTRIES	**30MG**	**A040525**	**001**	Oct 23, 2003
TABLET;ORAL						
ADIPEX-P						
AA	**!**	TEVA	**37.5MG**	**A085128**	**001**	
LOMAIRA						
AA	**!**	AVANTHI INC	**8MG**	**A203495**	**001**	Sep 12, 2016

PHENTERMINE HYDROCHLORIDE

TABLET;ORAL

PHENTERMINE HYDROCHLORIDE

AA		AUROLIFE PHARMA LLC	**37.5MG**	**A203068**	**001**	Aug 06, 2014
AA		BARR	**37.5MG**	**A090470**	**001**	Aug 31, 2009
AA		ELITE LABS	**37.5MG**	**A200272**	**001**	Jan 31, 2011
AA		ELITE LABS INC	**37.5MG**	**A040190**	**001**	May 30, 1997
AA		INVAGEN PHARMS	**37.5MG**	**A202942**	**001**	Feb 05, 2014
AA		KVK TECH	**37.5MG**	**A040876**	**001**	Mar 31, 2008
AA		KVK TECH INC	**8MG**	**A203436**	**001**	Mar 17, 2017
AA		LANNETT	**37.5MG**	**A040555**	**001**	Apr 15, 2005
AA		NOVAST LABS	**37.5MG**	**A091451**	**001**	Sep 21, 2012
AA		NUVO PHARM	**37.5MG**	**A205008**	**001**	Sep 25, 2014
AA		POLYGEN PHARMS	**37.5MG**	**A206342**	**001**	Nov 18, 2016
AA		PRINSTON INC	**37.5MG**	**A040377**	**001**	Jan 04, 2002
AA		SUN PHARM INDS INC	**37.5MG**	**A040790**	**001**	Aug 21, 2007
AA		SUN PHARM INDUSTRIES	**37.5MG**	**A040526**	**001**	Oct 23, 2003

TABLET, ORALLY DISINTEGRATING;ORAL

PHENTERMINE HYDROCHLORIDE

	ZYDUS PHARMS USA INC	15MG	A204663	001	Jun 28, 2017
		30MG	A204663	002	Jun 28, 2017
		37.5MG	A204663	003	Jun 28, 2017

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL

QSYMIA

+		VIVUS	EQ 3.75MG BASE;23MG	N022580	001	Jul 17, 2012
+			EQ 7.5MG BASE;46MG	N022580	002	Jul 17, 2012
+			EQ 11.25MG BASE;69MG	N022580	003	Jul 17, 2012
+!			EQ 15MG BASE;92MG	N022580	004	Jul 17, 2012

PHENTOLAMINE MESYLATE

INJECTABLE;INJECTION

PHENTOLAMINE MESYLATE

AP		PRECISION DOSE INC	**5MG/VIAL**	**A207686**	**001**	Jul 14, 2017
AP	**!**	WEST-WARD PHARMS INT	**5MG/VIAL**	**A040235**	**001**	Mar 11, 1998

ORAVERSE

+!		SEPTODONT HOLDING	0.4MG/1.7ML	N022159	001	May 09, 2008

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

AP		AMNEAL PHARMS CO	**10MG/ML (10MG/ML)**	**A211079**	**001**	Jul 05, 2018
AP			**50MG/5ML (10MG/ML)**	**A211078**	**001**	Jul 19, 2018
AP			**100MG/10ML (10MG/ML)**	**A211078**	**002**	Jul 19, 2018
AP		CIPLA	**10MG/ML (10MG/ML)**	**A210334**	**001**	Apr 27, 2018
AP			**50MG/5ML (10MG/ML)**	**A210333**	**001**	Apr 27, 2018
AP			**100MG/10ML (10MG/ML)**	**A210333**	**002**	Apr 27, 2018
AP		PAR STERILE PRODUCTS	**10MG/ML (10MG/ML)**	**A210025**	**001**	Dec 21, 2018
AP			**50MG/5ML (10MG/ML)**	**A210025**	**002**	Dec 21, 2018
AP			**100MG/10ML (10MG/ML)**	**A210025**	**003**	Dec 21, 2018
AP	**+!**	WEST WARD PHARM CORP	**10MG/ML (10MG/ML)**	**N203826**	**001**	Dec 20, 2012

VAZCULEP

AP	**+**	AVADEL LEGACY	**10MG/ML (10MG/ML)**	**N204300**	**001**	Jun 27, 2014
AP	**+**		**50MG/5ML (10MG/ML)**	**N204300**	**002**	Jun 27, 2014
AP	**+!**		**100MG/10ML (10MG/ML)**	**N204300**	**003**	Jun 27, 2014

SOLUTION/DROPS;OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

+!	AKORN INC	2.5%	N207926	001	Jan 15, 2015
+!		10%	N207926	002	Jan 15, 2015
+!	PARAGON BIOTECK	2.5%	N203510	001	Mar 21, 2013
+!		10%	N203510	002	Mar 21, 2013

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA		HI-TECH PHARMACAL	**5MG/5ML;6.25MG/5ML**	**A040675**	**001**	Dec 23, 2014
AA	**!**	VINTAGE	**5MG/5ML;6.25MG/5ML**	**A040654**	**001**	Dec 07, 2006

PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE

AA		AMNEAL PHARMS	**5MG/5ML;6.25MG/5ML**	**A040902**	**001**	Aug 25, 2009

PHENYTOIN						
SUSPENSION;ORAL						
DILANTIN-125						
AB	**+!**	PARKE DAVIS	**125MG/5ML**	**N008762**	**001**	
PHENYTOIN						
AB		TARO	**125MG/5ML**	**A040521**	**001**	Mar 08, 2004
AB		VISTAPHARM	**125MG/5ML**	**A040342**	**001**	Jan 31, 2001
AB			**125MG/5ML**	**A040610**	**001**	Aug 18, 2005
AB		WOCKHARDT BIO AG	**125MG/5ML**	**A040420**	**001**	Apr 19, 2002
TABLET, CHEWABLE;ORAL						
DILANTIN						
AB	**!**	PFIZER	**50MG**	**A084427**	**001**	
PHENYTOIN						
AB		EPIC PHARMA LLC	**50MG**	**A040884**	**001**	Nov 28, 2014
AB		MYLAN PHARMS INC	**50MG**	**A200691**	**001**	Dec 26, 2012
AB		TARO	**50MG**	**A200565**	**001**	Apr 17, 2014
PHENYTOIN SODIUM						
CAPSULE;ORAL						
DILANTIN						
AB	**!**	PARKE-DAVIS	**100MG EXTENDED**	**A084349**	**002**	
EXTENDED PHENYTOIN SODIUM						
AB		AMNEAL PHARMS NY	**100MG EXTENDED**	**A040765**	**001**	Nov 12, 2008
AB		MYLAN	**100MG EXTENDED**	**A040298**	**001**	Dec 28, 1998
AB		SUN PHARM INDS	**200MG EXTENDED**	**A040731**	**001**	Jun 30, 2008
AB			**300MG EXTENDED**	**A040731**	**002**	Jun 30, 2008
AB		SUN PHARM INDS (IN)	**100MG EXTENDED**	**A040621**	**001**	Dec 11, 2006
AB		TARO	**100MG EXTENDED**	**A040684**	**001**	Sep 05, 2006
PHENYTEK						
AB		MYLAN	**200MG EXTENDED**	**A040298**	**002**	Dec 06, 2001
AB	**!**		**300MG EXTENDED**	**A040298**	**003**	Dec 06, 2001
PHENYTOIN SODIUM						
AB		AUROBINDO PHARMA LTD	**100MG EXTENDED**	**A204309**	**001**	Jun 10, 2015
DILANTIN						
	!	PARKE-DAVIS	30MG EXTENDED	A084349	001	
INJECTABLE;INJECTION						
PHENYTOIN SODIUM						
AP		ACELLA PHARMS LLC	**50MG/ML**	**A040573**	**001**	Sep 13, 2006
AP		LUITPOLD	**50MG/ML**	**A040781**	**001**	Dec 04, 2007
AP	**!**	WEST-WARD PHARMS INT	**50MG/ML**	**A084307**	**001**	
PHYTONADIONE						
INJECTABLE;INJECTION						
PHYTONADIONE						
BP	!	INTL MEDICATION	1MG/0.5ML	A083722	001	
VITAMIN K1						
BP	!	HOSPIRA	1MG/0.5ML	A087954	001	Jul 25, 1983
	!		10MG/ML	A087955	001	Jul 25, 1983
TABLET;ORAL						
MEPHYTON						
AB	**+!**	VALEANT PHARMS	**5MG**	**N010104**	**003**	
PHYTONADIONE						
AB		AMNEAL PHARMS CO	**5MG**	**A209373**	**001**	May 11, 2018
PILOCARPINE HYDROCHLORIDE						
SOLUTION;OPHTHALMIC						
ISOPTO CARPINE						
AT	**+**	NOVARTIS PHARMS CORP	**1%**	**N200890**	**001**	Jun 22, 2010
AT	**+**		**2%**	**N200890**	**002**	Jun 22, 2010
AT	**+!**		**4%**	**N200890**	**003**	Jun 22, 2010
PILOCARPINE HYDROCHLORIDE						
AT		AKORN INC	**1%**	**A204398**	**001**	Sep 27, 2017
AT			**2%**	**A204398**	**002**	Sep 27, 2017
AT			**4%**	**A204398**	**003**	Sep 27, 2017
TABLET;ORAL						
PILOCARPINE HYDROCHLORIDE						
AB		IMPAX LABS	**5MG**	**A077248**	**001**	Mar 31, 2006
AB			**7.5MG**	**A077248**	**002**	Mar 31, 2006
AB		INNOGENIX	**5MG**	**A076963**	**001**	Dec 22, 2004
AB			**7.5MG**	**A076963**	**002**	Feb 27, 2007
AB		LANNETT CO INC	**5MG**	**A077220**	**001**	Oct 14, 2005

PILOCARPINE HYDROCHLORIDE						
TABLET;ORAL						
PILOCARPINE HYDROCHLORIDE						
AB			**7.5MG**	**A077220**	**002**	May 06, 2009
AB		PERRIGO PHARMA INTL	**5MG**	**A076746**	**001**	Nov 16, 2004
SALAGEN						
AB	**+**	EISAI INC	**5MG**	**N020237**	**001**	Mar 22, 1994
AB	**+!**		**7.5MG**	**N020237**	**002**	Apr 18, 2003
PIMAVANSERIN TARTRATE						
CAPSULE;ORAL						
NUPLAZID						
	+!	ACADIA PHARMS INC	EQ 34MG BASE	N210793	001	Jun 28, 2018
TABLET;ORAL						
NUPLAZID						
	+!	ACADIA PHARMS INC	EQ 10MG BASE	N207318	002	Jun 28, 2018
	+!		EQ 17MG BASE	N207318	001	Apr 29, 2016
PIMECROLIMUS						
CREAM;TOPICAL						
ELIDEL						
AB	**+!**	VALEANT BERMUDA	**1%**	**N021302**	**001**	Dec 13, 2001
PIMECROLIMUS						
AB		ACTAVIS LABS UT INC	**1%**	**A209345**	**001**	Dec 27, 2018
PIMOZIDE						
TABLET;ORAL						
ORAP						
AB	**+**	TEVA	**1MG**	**N017473**	**003**	Aug 27, 1997
AB	**+!**		**2MG**	**N017473**	**001**	Jul 31, 1984
PIMOZIDE						
AB		PAR PHARM	**1MG**	**A204521**	**001**	Sep 28, 2015
AB			**2MG**	**A204521**	**002**	Sep 28, 2015
PINDOLOL						
TABLET;ORAL						
PINDOLOL						
AB		ANI PHARMS INC	**5MG**	**A073609**	**002**	Mar 29, 1993
AB			**10MG**	**A073609**	**001**	Mar 29, 1993
AB		MYLAN PHARMS INC	**5MG**	**A074019**	**001**	Sep 03, 1992
AB	**!**		**10MG**	**A074019**	**002**	Sep 03, 1992
AB		NOSTRUM LABS INC	**5MG**	**A205415**	**001**	Jan 13, 2016
AB			**10MG**	**A205415**	**002**	Jan 13, 2016
AB		SUN PHARM INDUSTRIES	**5MG**	**A074063**	**001**	Jan 27, 1994
AB			**10MG**	**A074063**	**002**	Jan 27, 1994
AB		ZYDUS PHARMS USA INC	**5MG**	**A209866**	**001**	Aug 18, 2017
AB			**10MG**	**A209866**	**002**	Aug 18, 2017
PIOGLITAZONE HYDROCHLORIDE						
TABLET;ORAL						
ACTOS						
AB	**+**	TAKEDA PHARMS USA	**EQ 15MG BASE**	**N021073**	**001**	Jul 15, 1999
AB	**+**		**EQ 30MG BASE**	**N021073**	**002**	Jul 15, 1999
AB	**+!**		**EQ 45MG BASE**	**N021073**	**003**	Jul 15, 1999
PIOGLITAZONE HYDROCHLORIDE						
AB		ACCORD HLTHCARE	**EQ 15MG BASE**	**A200044**	**001**	Feb 13, 2013
AB			**EQ 30MG BASE**	**A200044**	**002**	Feb 13, 2013
AB			**EQ 45MG BASE**	**A200044**	**003**	Feb 13, 2013
AB		AUROBINDO PHARMA LTD	**EQ 15MG BASE**	**A200268**	**001**	Feb 13, 2013
AB			**EQ 30MG BASE**	**A200268**	**002**	Feb 13, 2013
AB			**EQ 45MG BASE**	**A200268**	**003**	Feb 13, 2013
AB		BRECKENRIDGE PHARM	**EQ 15MG BASE**	**A078472**	**001**	Feb 13, 2013
AB			**EQ 30MG BASE**	**A078472**	**002**	Feb 13, 2013
AB			**EQ 45MG BASE**	**A078472**	**003**	Feb 13, 2013
AB		CELLTRION	**EQ 15MG BASE**	**A076798**	**001**	Oct 26, 2012
AB			**EQ 30MG BASE**	**A076798**	**002**	Oct 26, 2012
AB			**EQ 45MG BASE**	**A076798**	**003**	Oct 26, 2012
AB		LUPIN LTD	**EQ 15MG BASE**	**A204133**	**001**	Apr 07, 2014
AB			**EQ 30MG BASE**	**A204133**	**002**	Apr 07, 2014
AB			**EQ 45MG BASE**	**A204133**	**003**	Apr 07, 2014
AB		MACLEODS PHARMS LTD	**EQ 15MG BASE**	**A202467**	**001**	Feb 06, 2013
AB			**EQ 30MG BASE**	**A202467**	**002**	Feb 06, 2013

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

AB		**EQ 45MG BASE**	**A202467**	**003**	Feb 06, 2013
AB	MYLAN PHARMS INC	**EQ 15MG BASE**	**A076801**	**001**	Aug 17, 2012
AB		**EQ 30MG BASE**	**A076801**	**002**	Aug 17, 2012
AB		**EQ 45MG BASE**	**A076801**	**003**	Aug 17, 2012
AB	NEOPHARMA	**EQ 15MG BASE**	**A078383**	**001**	Mar 12, 2013
AB		**EQ 30MG BASE**	**A078383**	**002**	Mar 12, 2013
AB		**EQ 45MG BASE**	**A078383**	**003**	Mar 12, 2013
AB	PRINSTON INC	**EQ 15MG BASE**	**A207806**	**001**	Apr 17, 2018
AB		**EQ 30MG BASE**	**A207806**	**002**	Apr 17, 2018
AB		**EQ 45MG BASE**	**A207806**	**003**	Apr 17, 2018
AB	PURACAP PHARM LLC	**EQ 15MG BASE**	**A206738**	**001**	Oct 06, 2017
AB		**EQ 30MG BASE**	**A206738**	**002**	Oct 06, 2017
AB		**EQ 45MG BASE**	**A206738**	**003**	Oct 06, 2017
AB	SANDOZ	**EQ 15MG BASE**	**A078670**	**001**	Feb 13, 2013
AB		**EQ 30MG BASE**	**A078670**	**002**	Feb 13, 2013
AB		**EQ 45MG BASE**	**A078670**	**003**	Feb 13, 2013
AB	TEVA PHARMS USA	**EQ 15MG BASE**	**A077210**	**001**	Jan 10, 2014
AB		**EQ 30MG BASE**	**A077210**	**002**	Jan 10, 2014
AB		**EQ 45MG BASE**	**A077210**	**003**	Jan 10, 2014
AB	TORRENT PHARMS LTD	**EQ 15MG BASE**	**A091298**	**001**	Feb 13, 2013
AB		**EQ 30MG BASE**	**A091298**	**002**	Feb 13, 2013
AB		**EQ 45MG BASE**	**A091298**	**003**	Feb 13, 2013
AB	ZYDUS PHARMS USA INC	**EQ 15MG BASE**	**A202456**	**001**	Feb 13, 2013
AB		**EQ 30MG BASE**	**A202456**	**002**	Feb 13, 2013
AB		**EQ 45MG BASE**	**A202456**	**003**	Feb 13, 2013

PIPERACILLIN SODIUM

INJECTABLE;INJECTION

PIPERACILLIN

!	ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL	A065114	001	Nov 14, 2003
!		EQ 3GM BASE/VIAL	A065114	002	Nov 14, 2003
!		EQ 4GM BASE/VIAL	A065114	003	Nov 14, 2003
!		EQ 40GM BASE/VIAL	A065157	001	Jul 12, 2004

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP	APOLLO PHARMS INC	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A207847**	**001**	Jan 13, 2017
AP		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A207847**	**002**	Jan 13, 2017
AP		**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A207848**	**002**	Jan 13, 2017
AP		**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A207847**	**003**	Jan 13, 2017
AP		**EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL**	**A207848**	**001**	May 11, 2018
AP	AUROBINDO PHARMA LTD	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065498**	**001**	May 23, 2011
AP		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065498**	**002**	May 23, 2011
AP		**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065498**	**003**	May 23, 2011
AP	FRESENIUS KABI	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A203719**	**001**	May 18, 2018
AP		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A203719**	**002**	May 18, 2018
AP		**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A203719**	**003**	May 18, 2018
AP		**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A203720**	**001**	May 11, 2018
AP	FRESENIUS KABI USA	**EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL**	**A206204**	**001**	May 11, 2018
AP	HOSPIRA INC	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065386**	**001**	Sep 15, 2009
AP		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065386**	**002**	Sep 15, 2009
AP		**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065386**	**003**	Sep 15, 2009
AP		**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A065446**	**001**	Sep 15, 2009
AP	ISTITUTO BIO ITA SPA	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065523**	**001**	May 31, 2011
AP		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065523**	**002**	May 31, 2011
AP		**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065523**	**003**	May 31, 2011
AP		**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A090498**	**001**	May 31, 2011
AP	MYLAN LABS LTD	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065458**	**001**	Aug 15, 2014
AP		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065458**	**002**	Aug 15, 2014
AP		**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065458**	**003**	Aug 15, 2014
AP	QILU TIANHE	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A204959**	**001**	Aug 10, 2018
AP		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A204959**	**002**	Aug 10, 2018
AP		**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A204959**	**003**	Aug 10, 2018
AP	SANDOZ	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065362**	**001**	Oct 21, 2010
AP		**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065363**	**001**	Oct 21, 2010
AP		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065362**	**002**	Oct 21, 2010

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM						
INJECTABLE;INJECTION						
PIPERACILLIN AND TAZOBACTAM						
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065363**	**002**	Oct 21, 2010
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065362**	**003**	Oct 21, 2010
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065363**	**003**	Oct 21, 2010
AP		SANDOZ INC	**EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL**	**A203557**	**001**	Oct 29, 2014
AP		WOCKHARDT BIO AG	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A206996**	**001**	Mar 22, 2017
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A206996**	**002**	Mar 22, 2017
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A206996**	**003**	Mar 22, 2017
AP			**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A207146**	**001**	Mar 17, 2017
ZOSYN						
AP	**+!**	WYETH PHARMS	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**N050684**	**001**	Oct 22, 1993
AP	**+!**		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**N050684**	**002**	Oct 22, 1993
AP	**+!**		**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**N050684**	**003**	Oct 22, 1993
AP	**+!**		**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**N050684**	**004**	Oct 22, 1993
ZOSYN IN PLASTIC CONTAINER						
	+!	WYETH PHARMS	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N050750	001	Feb 24, 1998
	+!		EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N050750	002	Feb 24, 1998
	+!		EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N050750	003	Feb 24, 1998
PIRFENIDONE						
CAPSULE;ORAL						
ESBRIET						
	+!	GENENTECH INC	267MG	N022535	001	Oct 15, 2014
TABLET;ORAL						
ESBRIET						
	+	GENENTECH INC	267MG	N208780	001	Jan 11, 2017
	+!		801MG	N208780	003	Jan 11, 2017
PIROXICAM						
CAPSULE;ORAL						
FELDENE						
AB	**+**	PFIZER	**10MG**	**N018147**	**002**	Apr 06, 1982
AB	**+!**		**20MG**	**N018147**	**003**	Apr 06, 1982
PIROXICAM						
AB		BRECKENRIDGE PHARM	**10MG**	**A208991**	**001**	Feb 21, 2018
AB			**20MG**	**A208991**	**002**	Feb 21, 2018
AB		FLAMINGO PHARMS	**10MG**	**A207938**	**001**	Sep 09, 2016
AB			**20MG**	**A207938**	**002**	Sep 09, 2016
AB		HIKMA PHARMS	**10MG**	**A209256**	**001**	Aug 11, 2017
AB			**20MG**	**A209256**	**002**	Aug 11, 2017
AB		MICRO LABS	**10MG**	**A206152**	**001**	Dec 29, 2017
AB			**20MG**	**A206152**	**002**	Dec 29, 2017
AB		MYLAN IRELAND LTD	**10MG**	**A074116**	**001**	Jun 15, 1993
AB			**20MG**	**A074118**	**001**	Jun 15, 1993
AB		PII	**10MG**	**A206136**	**001**	Jun 20, 2017
AB			**20MG**	**A206136**	**002**	Jun 20, 2017
AB		STRIDES PHARMA	**10MG**	**A210347**	**001**	Jan 26, 2018
AB			**20MG**	**A210347**	**002**	Jan 26, 2018
AB		SUN PHARM INDUSTRIES	**10MG**	**A073536**	**002**	Jan 23, 2008
AB			**20MG**	**A073536**	**001**	Mar 12, 1993
AB		TEVA	**10MG**	**A074131**	**001**	Dec 11, 1992
AB			**20MG**	**A074131**	**002**	Dec 11, 1992
AB		UNICHEM LABS LTD	**10MG**	**A208340**	**001**	Apr 13, 2017
AB			**20MG**	**A208340**	**002**	Apr 13, 2017
AB		ZYDUS PHARMS USA INC	**10MG**	**A205585**	**001**	Jul 17, 2018
AB			**20MG**	**A205585**	**002**	Jul 17, 2018
PITAVASTATIN CALCIUM						
TABLET;ORAL						
LIVALO						
AB	**+**	KOWA CO	**EQ 1MG BASE**	**N022363**	**001**	Aug 03, 2009
AB	**+**		**EQ 2MG BASE**	**N022363**	**002**	Aug 03, 2009
AB	**+!**		**EQ 4MG BASE**	**N022363**	**003**	Aug 03, 2009
PITAVASTATIN CALCIUM						
AB		AUROBINDO PHARMA LTD	**EQ 1MG BASE**	**A206015**	**001**	Dec 20, 2016
AB			**EQ 2MG BASE**	**A206015**	**002**	Dec 20, 2016
AB			**EQ 4MG BASE**	**A206015**	**003**	Dec 20, 2016
AB		ORIENT PHARMA CO LTD	**EQ 1MG BASE**	**A205932**	**001**	Feb 03, 2017
AB			**EQ 2MG BASE**	**A205932**	**002**	Feb 03, 2017

PITAVASTATIN CALCIUM

TABLET;ORAL

PITAVASTATIN CALCIUM

AB			**EQ 4MG BASE**	**A205932**	**003**	Feb 03, 2017
AB		SAWAI USA	**EQ 1MG BASE**	**A205955**	**001**	Feb 03, 2017
AB			**EQ 2MG BASE**	**A205955**	**002**	Feb 03, 2017
AB			**EQ 4MG BASE**	**A205955**	**003**	Feb 03, 2017

PITAVASTATIN MAGNESIUM

TABLET;ORAL

ZYPITAMAG

	+	ZYDUS PHARMS USA INC	EQ 1MG BASE	N208379	001	Jul 14, 2017
	+		EQ 2MG BASE	N208379	002	Jul 14, 2017
	+!		EQ 4MG BASE	N208379	003	Jul 14, 2017

PLAZOMICIN SULFATE

SOLUTION;INTRAVENOUS

ZEMDRI

	+!	ACHAOGEN INC	EQ 500MG BASE/10ML (EQ 50MG BASE/ML)	N210303	001	Jun 25, 2018

PLECANATIDE

TABLET;ORAL

TRULANCE

	+!	SYNERGY PHARMS	3MG	N208745	001	Jan 19, 2017

PLERIXAFOR

SOLUTION;SUBCUTANEOUS

MOZOBIL

	+!	GENZYME	24MG/1.2ML (20MG/ML)	N022311	001	Dec 15, 2008

PODOFILOX

GEL;TOPICAL

CONDYLOX

	+!	ALLERGAN SALES LLC	0.5%	N020529	001	Mar 13, 1997

SOLUTION;TOPICAL

CONDYLOX

AT	**+!**	ALLERGAN SALES LLC	**0.5%**	**N019795**	**001**	Dec 13, 1990

PODOFILOX

AT		PADDOCK LLC	**0.5%**	**A075600**	**001**	Jan 29, 2002

POLIDOCANOL

SOLUTION;INTRAVENOUS

ASCLERA

	+	CHEMISCH FBRK KRSSLR	10MG/2ML (5MG/ML)	N021201	001	Mar 30, 2010
	+!		20MG/2ML (10MG/ML)	N021201	002	Mar 30, 2010

VARITHENA

	+!	PROVENSIS	77.5MG/7.75ML (10MG/ML)	N205098	002	Dec 21, 2017
	+!		180MG/18ML (10MG/ML)	N205098	001	Nov 25, 2013

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

GLYCOLAX

AA		LANNETT CO INC	**17GM/SCOOPFUL**	**A076652**	**001**	Jul 02, 2004

POLYETHYLENE GLYCOL 3350

AA		NEXGEN PHARMA INC	**17GM/SCOOPFUL**	**A077706**	**001**	Sep 27, 2006
AA		PADDOCK LLC	**17GM/SCOOPFUL**	**A077893**	**001**	May 26, 2006

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

LAX-LYTE WITH FLAVOR PACKS

AA		PADDOCK LLC	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**A079232**	**001**	Feb 25, 2010

NULYTELY

AA	**+!**	BRAINTREE	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**N019797**	**001**	Apr 22, 1991

NULYTELY-FLAVORED

AA	**+!**	BRAINTREE	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**N019797**	**002**	Nov 18, 1994

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

AA		BRECKENRIDGE PHARM	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**A202060**	**001**	Mar 08, 2017
AA		NOVEL LABS INC	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**A090019**	**001**	May 27, 2009
AA		STRIDES PHARMA	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**A204559**	**001**	Apr 13, 2015

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

TRILYTE

AA		MYLAN PHARMS INC	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**A076491**	**001**	Feb 05, 2004

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE WITH FLAVOR PACKS

AA		MYLAN SPECIALITY LP	**240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT**	**N018983**	**012**	Oct 08, 1998

GOLYTELY

AA	**+!**	BRAINTREE	**236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT**	**N019011**	**001**	Jul 13, 1984

PEG 3350 AND ELECTROLYTES

AA		NOVEL LABS INC	**236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT**	**A090231**	**001**	Jun 01, 2009
AA			**240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT**	**A090186**	**001**	Jun 01, 2009

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

AA		STRIDES PHARMA	**236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT**	**A204558**	**001**	Dec 21, 2018

GOLYTELY

	+!	BRAINTREE	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N019011	002	Jun 02, 1992

POLYMYXIN B SULFATE

INJECTABLE;INJECTION

POLYMYXIN B SULFATE

AP		AUROBINDO PHARMA LTD	**EQ 500,000 UNITS BASE/VIAL**	**A206589**	**001**	Apr 04, 2016
AP		FRESENIUS KABI USA	**EQ 500,000 UNITS BASE/VIAL**	**A065372**	**001**	Jan 10, 2008
AP		GLAND PHARMA LTD	**EQ 500,000 UNITS BASE/VIAL**	**A207322**	**001**	Apr 14, 2016
AP		MYLAN ASI	**EQ 500,000 UNITS BASE/VIAL**	**A090110**	**001**	Jun 29, 2011
AP	**!**	WEST-WARD PHARMS INT	**EQ 500,000 UNITS BASE/VIAL**	**A060716**	**001**	
AP		X GEN PHARMS	**EQ 500,000 UNITS BASE/VIAL**	**A063000**	**001**	Sep 30, 1994
AP		XELLIA PHARMS APS	**EQ 500,000 UNITS BASE/VIAL**	**A202766**	**001**	Jan 15, 2014

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

POLYTRIM

AT	**+!**	ALLERGAN	**10,000 UNITS/ML;EQ 1MG BASE/ML**	**N050567**	**001**	Oct 20, 1988

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT		AKORN INC	**10,000 UNITS/ML;EQ 1MG BASE/ML**	**A065006**	**001**	Dec 17, 1998
AT		BAUSCH AND LOMB	**10,000 UNITS/ML;EQ 1MG BASE/ML**	**A064120**	**001**	Feb 14, 1997
AT		SANDOZ INC	**10,000 UNITS/ML;EQ 1MG BASE/ML**	**A064211**	**001**	Apr 13, 1998

POMALIDOMIDE

CAPSULE;ORAL

POMALYST

	+	CELGENE	1MG	N204026	001	Feb 08, 2013
	+		2MG	N204026	002	Feb 08, 2013
	+		3MG	N204026	003	Feb 08, 2013
	+!		4MG	N204026	004	Feb 08, 2013

PONATINIB HYDROCHLORIDE

TABLET;ORAL

ICLUSIG

	+	ARIAD	EQ 15MG BASE	N203469	001	Dec 14, 2012
	+		EQ 30MG BASE	N203469	003	Apr 23, 2015
	+!		EQ 45MG BASE	N203469	002	Dec 14, 2012

PORACTANT ALFA

SUSPENSION;INTRATRACHEAL

CUROSURF

	+!	CHIESI USA INC	80MG/ML	N020744	001	Nov 18, 1999

PORFIMER SODIUM

INJECTABLE;INJECTION

PHOTOFRIN

		CONCORDIA LABS INC	75MG/VIAL	N020451	001	Dec 27, 1995

POSACONAZOLE							
SOLUTION;INTRAVENOUS							
NOXAFIL							
	+!	MERCK SHARP DOHME	300MG/16.7ML (18MG/ML)	N205596	001	Mar 13, 2014
SUSPENSION;ORAL							
NOXAFIL							
	+!	SCHERING	40MG/ML	N022003	001	Sep 15, 2006
TABLET, DELAYED RELEASE;ORAL							
NOXAFIL							
	+!	MERCK SHARP DOHME	100MG	N205053	001	Nov 25, 2013
POTASSIUM ACETATE							
INJECTABLE;INJECTION							
POTASSIUM ACETATE							
AP		EXELA PHARMA SCS LLC	**2MEQ/ML**	**A206203**	**001**	Dec 29, 2015
AP	**+!**	HOSPIRA	**2MEQ/ML**	**N018896**	**001**	Jul 20, 1984
POTASSIUM CHLORIDE							
CAPSULE, EXTENDED RELEASE;ORAL							
KLOR-CON							
AB		UPSHER SMITH LABS	**8MEQ**	**A203106**	**001**	Jul 10, 2015
AB			**10MEQ**	**A203106**	**002**	Jul 10, 2015
MICRO-K							
AB	**+**	NESHER PHARMS	**8MEQ**	**N018238**	**001**	
MICRO-K 10							
AB	**+**	NESHER PHARMS	**10MEQ**	**N018238**	**002**	May 14, 1984
POTASSIUM CHLORIDE							
AB		ACTAVIS LABS FL INC	**8MEQ**	**A077419**	**001**	Jun 02, 2008
AB	**!**		**10MEQ**	**A077419**	**002**	Jun 02, 2008
AB		ADARE PHARMS INC	**8MEQ**	**A208864**	**001**	Mar 17, 2017
AB			**10MEQ**	**A208864**	**002**	Mar 17, 2017
AB		AMNEAL PHARMS	**10MEQ**	**A202128**	**001**	Feb 22, 2013
AB		ANCHEN PHARMS	**8MEQ**	**A202886**	**001**	Dec 26, 2013
AB			**10MEQ**	**A202886**	**002**	Dec 26, 2013
AB		GLENMARK PHARMS LTD	**10MEQ**	**A202868**	**001**	Jan 19, 2016
AB		LANNETT CO INC	**8MEQ**	**A204210**	**001**	Mar 28, 2016
AB			**10MEQ**	**A204210**	**002**	Mar 28, 2016
AB		LUPIN LTD	**8MEQ**	**A203002**	**001**	Dec 18, 2015
AB			**10MEQ**	**A203002**	**002**	Dec 18, 2015
AB		NOVEL LABS INC	**8MEQ**	**A204828**	**001**	Aug 16, 2016
AB			**10MEQ**	**A204828**	**002**	Aug 16, 2016
AB		PADDOCK LLC	**8MEQ**	**A200185**	**001**	May 18, 2011
AB			**10MEQ**	**A200185**	**002**	May 18, 2011
AB		PII	**8MEQ**	**A205549**	**001**	Dec 08, 2015
AB			**10MEQ**	**A205549**	**002**	Dec 08, 2015
AB		TRIS PHARMA INC	**8MEQ**	**A201944**	**001**	Mar 04, 2016
AB			**10MEQ**	**A201944**	**002**	Mar 04, 2016
FOR SOLUTION;ORAL							
KLOR-CON							
AA		UPSHER SMITH LABS	**20MEQ**	**A209662**	**001**	Oct 23, 2017
POTASSIUM CHLORIDE							
AA		EPIC PHARMA LLC	**20MEQ**	**A210200**	**001**	Nov 23, 2018
AA		NOVEL LABS INC	**20MEQ**	**A210241**	**001**	Nov 21, 2018
AA	**+!**	PHARMA RES SOFTWARE	**20MEQ**	**N208019**	**001**	Aug 19, 2015
INJECTABLE;INJECTION							
POTASSIUM CHLORIDE							
AP		B BRAUN	**2MEQ/ML**	**A085870**	**001**	
AP		FRESENIUS KABI USA	**2MEQ/ML**	**A080225**	**001**	
AP	**!**	HOSPIRA	**2MEQ/ML**	**A080205**	**001**	
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER							
AP	**+!**	BAXTER HLTHCARE	**14.9MG/ML**	**N019904**	**001**	Dec 26, 1989
AP	**+!**		**746MG/100ML**	**N019904**	**005**	Dec 17, 1990
AP	**+**	ICU MEDICAL INC	**14.9MG/ML**	**N020161**	**005**	Nov 30, 1992
AP	**+**		**745MG/100ML**	**N020161**	**001**	Nov 30, 1992
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER							
AP	**+!**	BAXTER HLTHCARE	**29.8MG/ML**	**N019904**	**002**	Dec 26, 1989
AP	**+!**		**1.49GM/100ML**	**N019904**	**006**	Dec 17, 1990
AP	**+!**	ICU MEDICAL INC	**29.8MG/ML**	**N020161**	**006**	Aug 11, 1998
AP	**+**		**1.49GM/100ML**	**N020161**	**002**	Nov 30, 1992
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER							
AP	**+!**	BAXTER HLTHCARE	**2.98GM/100ML**	**N019904**	**004**	Dec 26, 1989
AP	**+!**	ICU MEDICAL INC	**2.98GM/100ML**	**N020161**	**004**	Aug 11, 1998

POTASSIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	**2MEQ/ML**	**A088901**	**001**	Jan 25, 1985
AP			**2MEQ/ML**	**A088908**	**001**	Jan 25, 1985
		POTASSIUM CHLORIDE				
	!	FRESENIUS KABI USA	3MEQ/ML	A080225	003	
		POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER				
	+!	BAXTER HLTHCARE	2.24GM/100ML	N019904	003	Dec 26, 1989

SOLUTION;ORAL

POTASSIUM CHLORIDE

AA		AMNEAL PHARMS LLC	**20MEQ/15ML**	**A210041**	**001**	Jul 19, 2018
AA			**40MEQ/15ML**	**A210041**	**002**	Jul 19, 2018
AA		APOTEX INC	**20MEQ/15ML**	**A211067**	**001**	Aug 08, 2018
AA			**40MEQ/15ML**	**A211067**	**002**	Aug 08, 2018
AA	+	GENUS LIFESCIENCES	**20MEQ/15ML**	**N206814**	**001**	Dec 22, 2014
AA	+!		**40MEQ/15ML**	**N206814**	**002**	Dec 22, 2014
AA		NOVEL LABS INC	**20MEQ/15ML**	**A209786**	**001**	Aug 29, 2018
AA			**40MEQ/15ML**	**A209786**	**002**	Aug 29, 2018

TABLET, EXTENDED RELEASE;ORAL

KLOR-CON M10

AB1		UPSHER SMITH LABS	**10MEQ**	**A074726**	**002**	Aug 09, 2000

KLOR-CON M20

AB1	!	UPSHER SMITH LABS	**20MEQ**	**A074726**	**001**	Nov 20, 1998

POTASSIUM CHLORIDE

AB1		ACTAVIS LABS FL INC	**10MEQ**	**A075604**	**001**	Apr 10, 2002
AB1			**20MEQ**	**A075604**	**002**	Apr 10, 2002
AB1		ADARE PHARMS INC	**20MEQ**	**A076368**	**001**	Aug 18, 2004
AB1		GLENMARK PHARMS LTD	**10MEQ**	**A203562**	**001**	Jul 26, 2016
AB1			**20MEQ**	**A203562**	**002**	Jul 26, 2016
AB1		NOVEL LABS INC	**10MEQ**	**A206347**	**001**	Jan 21, 2016
AB1			**20MEQ**	**A206347**	**002**	Jan 21, 2016

K-TAB

AB2	+!	ABBVIE	**20MEQ**	**N018279**	**003**	Nov 25, 2013

KLOR-CON

AB2	+	UPSHER SMITH LABS	**8MEQ**	**N019123**	**001**	Apr 17, 1986
AB2	+!		**10MEQ**	**N019123**	**002**	Apr 17, 1986

POTASSIUM CHLORIDE

AB2		AUROBINDO PHARMA LTD	**8MEQ**	**A210921**	**001**	Dec 19, 2018
AB2			**10MEQ**	**A210921**	**002**	Dec 19, 2018
AB2		MYLAN PHARMS INC	**8MEQ**	**A204662**	**001**	Aug 21, 2014
AB2			**10MEQ**	**A204662**	**002**	Aug 21, 2014
AB2		NOVEL LABS INC	**8MEQ**	**A206759**	**001**	Aug 09, 2016
AB2			**10MEQ**	**A206759**	**002**	Aug 09, 2016
AB2		PADDOCK LLC	**8MEQ**	**A205993**	**001**	Nov 05, 2015
AB2			**10MEQ**	**A205993**	**002**	Nov 05, 2015
AB2		SIGMAPHARM LABS LLC	**8MEQ**	**A207528**	**001**	Aug 19, 2016
AB2			**10MEQ**	**A207528**	**002**	Aug 19, 2016
AB2		STRIDES PHARMA	**8MEQ**	**A210733**	**001**	Aug 31, 2018
AB2			**10MEQ**	**A210733**	**002**	Aug 31, 2018
AB2		VITRUVIAS THERAP	**20MEQ**	**A209688**	**002**	Jan 12, 2018
AB2		YICHANG HUMANWELL	**8MEQ**	**A209314**	**001**	Jun 22, 2018
AB2			**10MEQ**	**A209314**	**002**	Jun 22, 2018

K-TAB

AB3	+	ABBVIE	**10MEQ**	**N018279**	**001**	

POTASSIUM CHLORIDE

AB3		VITRUVIAS THERAP	**10MEQ**	**A209688**	**001**	Jan 12, 2018
		K-TAB				
BC	+	ABBVIE	8MEQ	N018279	002	Aug 01, 1988
		KLOR-CON M15				
		UPSHER SMITH LABS	15MEQ	A074726	003	Jun 06, 2003

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		ICU MEDICAL INC	**149MG/100ML;450MG/100ML**	**A078446**	**001**	Sep 10, 2008

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	+!	BAXTER HLTHCARE	**150MG/100ML;450MG/100ML**	**N017648**	**005**	Nov 26, 2002

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		B BRAUN	**150MG/100ML;900MG/100ML**	**N019708**	**004**	Sep 29, 1989
AP	+	BAXTER HLTHCARE	**150MG/100ML;900MG/100ML**	**N017648**	**001**	

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	**300MG/100ML;900MG/100ML**	**N017648**	**002**	
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP		ICU MEDICAL INC	**149MG/100ML;900MG/100ML**	**N019686**	**001**	Oct 17, 1988
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP		ICU MEDICAL INC	**298MG/100ML;900MG/100ML**	**N019686**	**002**	Oct 17, 1988

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE

AB		MOUNTAIN	**5MEQ**	**A077440**	**001**	Jun 09, 2006
AB			**10MEQ**	**A077440**	**002**	Jun 09, 2006
AB		STRIDES PHARMA	**5MEQ**	**A206813**	**001**	Sep 11, 2017
AB			**10MEQ**	**A206813**	**002**	Sep 11, 2017
AB			**15MEQ**	**A206813**	**003**	Sep 11, 2017
AB		TEVA PHARMS USA INC	**5MEQ**	**A209758**	**001**	Mar 05, 2018
AB			**10MEQ**	**A209758**	**002**	Mar 05, 2018
AB			**15MEQ**	**A209758**	**003**	Mar 05, 2018
AB		ZYDUS PHARMS USA INC	**5MEQ**	**A203546**	**001**	Aug 06, 2014
AB			**10MEQ**	**A203546**	**002**	Aug 06, 2014
AB			**15MEQ**	**A203546**	**003**	Aug 06, 2014
UROCIT-K						
AB	+	MISSION PHARMA	**5MEQ**	**N019071**	**001**	Aug 30, 1985
AB	+		**10MEQ**	**N019071**	**002**	Aug 31, 1992
AB	+!		**15MEQ**	**N019071**	**003**	Dec 30, 2009

POVIDONE-IODINE

SOLUTION/DROPS;OPHTHALMIC

BETADINE

+!	ALCON PHARMS LTD	5%	N018634	001	Dec 17, 1986

PRALATREXATE

SOLUTION;INTRAVENOUS

FOLOTYN

+	ALLOS	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009
+!		40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009

PRALIDOXIME CHLORIDE

INJECTABLE;INJECTION

PRALIDOXIME CHLORIDE

+!	MERIDIAN MEDCL TECHN	300MG/ML	N018986	001	Apr 26, 1983

PROTOPAM CHLORIDE

+!	BAXTER HLTHCARE CORP	1GM/VIAL	N014134	001	

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

MIRAPEX

AB	+	BOEHRINGER INGELHEIM	**0.125MG**	**N020667**	**001**	Jul 01, 1997
AB	+!		**0.25MG**	**N020667**	**002**	Jul 01, 1997
AB	+		**0.5MG**	**N020667**	**006**	Feb 12, 1998
AB	+		**0.75MG**	**N020667**	**007**	Jul 30, 2007
AB	+		**1MG**	**N020667**	**003**	Jul 01, 1997
AB	+		**1.5MG**	**N020667**	**005**	Jul 01, 1997
PRAMIPEXOLE DIHYDROCHLORIDE						
AB		ALEMBIC PHARMS LTD	**0.125MG**	**A078894**	**001**	Oct 08, 2010
AB			**0.25MG**	**A078894**	**002**	Oct 08, 2010
AB			**0.5MG**	**A078894**	**003**	Oct 08, 2010
AB			**1MG**	**A078894**	**004**	Oct 08, 2010
AB			**1.5MG**	**A078894**	**005**	Oct 08, 2010
AB		APOTEX INC	**0.125MG**	**A090151**	**001**	Apr 30, 2012
AB			**0.25MG**	**A090151**	**002**	Apr 30, 2012
AB			**0.5MG**	**A090151**	**003**	Apr 30, 2012
AB			**0.75MG**	**A090151**	**006**	Apr 30, 2012
AB			**1MG**	**A090151**	**004**	Apr 30, 2012
AB			**1.5MG**	**A090151**	**005**	Apr 30, 2012
AB		AUROBINDO PHARMA LTD	**0.125MG**	**A202633**	**001**	Oct 26, 2012
AB			**0.25MG**	**A202633**	**002**	Oct 26, 2012
AB			**0.5MG**	**A202633**	**003**	Oct 26, 2012
AB			**0.75MG**	**A202633**	**004**	Oct 26, 2012

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB		1MG	A202633	005	Oct 26, 2012
AB		1.5MG	A202633	006	Oct 26, 2012
AB	BARR	0.125MG	A077724	001	Feb 19, 2008
AB		0.25MG	A077724	002	Feb 19, 2008
AB		0.5MG	A077724	003	Feb 19, 2008
AB		1MG	A077724	004	Feb 19, 2008
AB		1.5MG	A077724	005	Feb 19, 2008
AB	BRECKENRIDGE PHARM	0.125MG	A091450	001	Oct 08, 2010
AB		0.25MG	A091450	002	Oct 08, 2010
AB		0.5MG	A091450	003	Oct 08, 2010
AB		1MG	A091450	004	Oct 08, 2010
AB		1.5MG	A091450	005	Oct 08, 2010
AB	CSPC OUYI PHARM CO	0.25MG	A211088	001	Oct 03, 2018
AB		0.5MG	A211088	002	Oct 03, 2018
AB		0.75MG	A211088	003	Oct 03, 2018
AB		1MG	A211088	004	Oct 03, 2018
AB		1.5MG	A211088	005	Oct 03, 2018
AB	GLENMARK GENERICS	0.125MG	A090781	001	Oct 08, 2010
AB		0.25MG	A090781	002	Oct 08, 2010
AB		0.5MG	A090781	003	Oct 08, 2010
AB		0.75MG	A090781	006	Sep 11, 2015
AB		1MG	A090781	004	Oct 08, 2010
AB		1.5MG	A090781	005	Oct 08, 2010
AB	MACLEODS PHARMS LTD	0.125MG	A202164	001	Sep 20, 2012
AB		0.25MG	A202164	002	Sep 20, 2012
AB		0.5MG	A202164	003	Sep 20, 2012
AB		1MG	A202164	004	Sep 20, 2012
AB		1.5MG	A202164	005	Sep 20, 2012
AB	MYLAN	0.125MG	A077854	001	Oct 08, 2010
AB		0.25MG	A077854	002	Oct 08, 2010
AB		0.5MG	A077854	003	Oct 08, 2010
AB		0.75MG	A090764	001	Apr 09, 2010
AB		1MG	A077854	004	Oct 08, 2010
AB		1.5MG	A077854	005	Oct 08, 2010
AB	SCIEGEN PHARMS INC	0.125MG	A203855	001	Oct 28, 2014
AB		0.25MG	A203855	002	Oct 28, 2014
AB		0.5MG	A203855	003	Oct 28, 2014
AB		0.75MG	A203855	004	Oct 28, 2014
AB		1MG	A203855	005	Oct 28, 2014
AB		1.5MG	A203855	006	Oct 28, 2014
AB	STRIDES PHARMA	0.125MG	A202702	001	Jun 03, 2014
AB		0.25MG	A202702	002	Jun 03, 2014
AB		0.5MG	A202702	003	Jun 03, 2014
AB		0.75MG	A202702	004	Jun 03, 2014
AB		1MG	A202702	005	Jun 03, 2014
AB		1.5MG	A202702	006	Jun 03, 2014
AB	SUN PHARM INDS INC	0.125MG	A091683	001	Mar 27, 2013
AB		0.25MG	A091683	002	Mar 27, 2013
AB		0.5MG	A091683	003	Mar 27, 2013
AB		0.75MG	A091683	004	Mar 27, 2013
AB		1MG	A091683	005	Mar 27, 2013
AB		1.5MG	A091683	006	Mar 27, 2013
AB	TEVA PHARMS	0.125MG	A090241	001	Oct 08, 2010
AB		0.25MG	A090241	002	Oct 08, 2010
AB		0.5MG	A090241	003	Oct 08, 2010
AB		0.75MG	A090241	004	Oct 08, 2010
AB		1MG	A090241	005	Oct 08, 2010
AB		1.5MG	A090241	006	Oct 08, 2010
AB	TORRENT PHARMS	0.125MG	A090865	001	Oct 08, 2010
AB		0.25MG	A090865	002	Oct 08, 2010
AB		0.5MG	A090865	003	Oct 08, 2010
AB		0.75MG	A090865	004	Oct 08, 2010
AB		1MG	A090865	005	Oct 08, 2010
AB		1.5MG	A090865	006	Oct 08, 2010
AB	UNICHEM LABS LTD	0.125MG	A207011	001	Dec 19, 2018
AB		0.25MG	A207011	002	Dec 19, 2018
AB		0.5MG	A207011	003	Dec 19, 2018
AB		0.75MG	A207011	004	Dec 19, 2018
AB		1MG	A207011	005	Dec 19, 2018

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE							
AB			**1.5MG**	**A207011**	**006**	Dec 19, 2018
AB		ZYDUS PHARMS USA INC	**0.125MG**	**A078920**	**001**	Jul 06, 2010
AB			**0.25MG**	**A078920**	**002**	Jul 06, 2010
AB			**0.5MG**	**A078920**	**003**	Jul 06, 2010
AB			**1MG**	**A078920**	**004**	Jul 06, 2010
AB			**1.5MG**	**A078920**	**005**	Jul 06, 2010

TABLET, EXTENDED RELEASE;ORAL

MIRAPEX ER							
AB	**+!**	BOEHRINGER INGELHEIM	**0.375MG**	**N022421**	**001**	Feb 19, 2010
AB	**+**		**0.75MG**	**N022421**	**002**	Feb 19, 2010
AB	**+**		**1.5MG**	**N022421**	**003**	Feb 19, 2010
AB	**+**		**2.25MG**	**N022421**	**006**	Jun 17, 2011
AB	**+**		**3MG**	**N022421**	**004**	Feb 19, 2010
AB	**+**		**3.75MG**	**N022421**	**007**	Jun 17, 2011
AB	**+**		**4.5MG**	**N022421**	**005**	Feb 19, 2010
PRAMIPEXOLE DIHYDROCHLORIDE							
AB		ACTAVIS ELIZABETH	**0.375MG**	**A201963**	**001**	Apr 21, 2016
AB			**0.75MG**	**A201963**	**002**	Apr 21, 2016
AB			**1.5MG**	**A201963**	**003**	Apr 21, 2016
AB			**2.25MG**	**A203615**	**001**	Oct 14, 2016
AB			**3MG**	**A201963**	**004**	Apr 21, 2016
AB			**3.75MG**	**A203615**	**002**	Jan 03, 2017
AB			**4.5MG**	**A201963**	**005**	Apr 21, 2016
AB		ALEMBIC PHARMS LTD	**0.375MG**	**A204518**	**001**	Jan 02, 2019
AB			**0.75MG**	**A204518**	**002**	Jan 02, 2019
AB			**1.5MG**	**A204518**	**003**	Jan 02, 2019
AB			**2.25MG**	**A204518**	**004**	Jan 02, 2019
AB			**3MG**	**A204518**	**005**	Jan 02, 2019
AB			**3.75MG**	**A204518**	**006**	Jan 02, 2019
AB			**4.5MG**	**A204518**	**007**	Jan 02, 2019
AB		ANCHEN PHARMS	**0.375MG**	**A202206**	**001**	Feb 06, 2014
AB			**0.75MG**	**A202206**	**002**	Feb 06, 2014
AB			**1.5MG**	**A202206**	**003**	Feb 06, 2014
AB			**2.25MG**	**A202206**	**004**	Feb 06, 2014
AB			**3MG**	**A202206**	**005**	Feb 06, 2014
AB			**3.75MG**	**A202206**	**006**	Feb 06, 2014
AB			**4.5MG**	**A202206**	**007**	Feb 06, 2014
AB		DR REDDYS LABS LTD	**0.375MG**	**A203354**	**001**	Aug 07, 2015
AB			**0.75MG**	**A203354**	**002**	Aug 07, 2015
AB			**1.5MG**	**A203354**	**003**	Aug 07, 2015
AB			**3MG**	**A203354**	**004**	Aug 07, 2015
AB			**4.5MG**	**A203354**	**005**	Aug 07, 2015
AB		MACLEODS PHARMS LTD	**0.375MG**	**A206156**	**001**	Jun 24, 2016
AB			**0.75MG**	**A206156**	**002**	Jun 24, 2016
AB			**1.5MG**	**A206156**	**003**	Jun 24, 2016
AB			**2.25MG**	**A206156**	**004**	Jun 24, 2016
AB			**3MG**	**A206156**	**005**	Jun 24, 2016
AB			**3.75MG**	**A206156**	**007**	Jan 23, 2017
AB			**4.5MG**	**A206156**	**006**	Jun 24, 2016
AB		SANDOZ INC	**0.375MG**	**A202353**	**001**	Dec 04, 2014
AB			**0.75MG**	**A202353**	**002**	Dec 04, 2014
AB			**1.5MG**	**A202353**	**003**	Dec 04, 2014
AB			**3MG**	**A202353**	**004**	Dec 04, 2014
AB			**4.5MG**	**A202353**	**005**	Dec 04, 2014
AB		ZYDUS PHARMS USA INC	**0.375MG**	**A202891**	**001**	Dec 12, 2017
AB			**0.75MG**	**A202891**	**002**	Dec 12, 2017
AB			**1.5MG**	**A202891**	**003**	Dec 12, 2017
AB			**2.25MG**	**A202891**	**004**	Dec 12, 2017
AB			**3MG**	**A202891**	**005**	Dec 12, 2017
AB			**3.75MG**	**A202891**	**006**	Dec 12, 2017
AB			**4.5MG**	**A202891**	**007**	Dec 12, 2017

PRAMLINTIDE ACETATE

INJECTABLE;SUBCUTANEOUS

SYMLIN

+	ASTRAZENECA AB	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007
+!		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007

PRASTERONE

INSERT;VAGINAL

INTRAROSA

+!	AMAG PHARMS INC	6.5MG	N208470	001	Nov 16, 2016

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

EFFIENT

AB	**+**	ELI LILLY AND CO	**EQ 5MG BASE**	**N022307**	**001** Jul 10, 2009
AB	**+!**		**EQ 10MG BASE**	**N022307**	**002** Jul 10, 2009

PRASUGREL

AB		ACCORD HLTHCARE	**EQ 5MG BASE**	**A205987**	**001** Feb 02, 2018
AB			**EQ 10MG BASE**	**A205987**	**002** Feb 02, 2018
AB		AMNEAL PHARMS	**EQ 5MG BASE**	**A205913**	**001** Jun 19, 2018
AB			**EQ 10MG BASE**	**A205913**	**002** Jun 19, 2018
AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A205888**	**001** Oct 16, 2017
AB			**EQ 10MG BASE**	**A205888**	**002** Oct 16, 2017
AB		HEC PHARM	**EQ 5MG BASE**	**A206021**	**001** Jan 16, 2019
AB			**EQ 10MG BASE**	**A206021**	**002** Jan 16, 2019
AB		MYLAN PHARMS INC	**EQ 5MG BASE**	**A205927**	**001** Jul 12, 2017
AB			**EQ 10MG BASE**	**A205927**	**002** Jul 12, 2017
AB		PANACEA BIOTEC LTD	**EQ 5MG BASE**	**A205897**	**001** Oct 16, 2017
AB			**EQ 10MG BASE**	**A205897**	**002** Oct 16, 2017
AB		USPHARMA WINDLAS	**EQ 5MG BASE**	**A205790**	**001** Oct 16, 2017
AB			**EQ 10MG BASE**	**A205790**	**002** Oct 16, 2017

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVACHOL

AB	**+**	BRISTOL MYERS SQUIBB	**20MG**	**N019898**	**003** Oct 31, 1991
AB	**+**		**40MG**	**N019898**	**004** Mar 22, 1993
AB	**+!**		**80MG**	**N019898**	**008** Dec 18, 2001

PRAVASTATIN SODIUM

AB		ACCORD HLTHCARE	**10MG**	**A207068**	**001** Nov 17, 2016
AB			**20MG**	**A207068**	**002** Nov 17, 2016
AB			**40MG**	**A207068**	**003** Nov 17, 2016
AB			**80MG**	**A207068**	**004** Nov 17, 2016
AB		APOTEX INC	**10MG**	**A076341**	**001** Oct 23, 2006
AB			**20MG**	**A076341**	**002** Oct 23, 2006
AB			**40MG**	**A076341**	**003** Oct 23, 2006
AB			**80MG**	**A076341**	**004** Dec 28, 2007
AB		AUROBINDO PHARMA LTD	**10MG**	**A203367**	**001** Feb 02, 2017
AB			**20MG**	**A203367**	**002** Feb 02, 2017
AB			**40MG**	**A203367**	**003** Feb 02, 2017
AB			**80MG**	**A203367**	**004** Feb 02, 2017
AB		CHARTWELL RX	**10MG**	**A209869**	**001** Apr 13, 2018
AB			**20MG**	**A209869**	**002** Apr 13, 2018
AB			**40MG**	**A209869**	**003** Apr 13, 2018
AB			**80MG**	**A209869**	**004** Apr 13, 2018
AB		CIPLA	**10MG**	**A077904**	**001** Oct 23, 2006
AB			**20MG**	**A077904**	**002** Oct 23, 2006
AB			**40MG**	**A077904**	**003** Oct 23, 2006
AB			**80MG**	**A077904**	**004** Mar 22, 2016
AB		DR REDDYS LABS INC	**10MG**	**A076714**	**001** Oct 23, 2006
AB			**20MG**	**A076714**	**002** Oct 23, 2006
AB			**40MG**	**A076714**	**003** Oct 23, 2006
AB			**80MG**	**A076714**	**004** Dec 28, 2007
AB		GLENMARK GENERICS	**10MG**	**A077987**	**001** May 11, 2007
AB			**20MG**	**A077987**	**002** May 11, 2007
AB			**40MG**	**A077987**	**003** May 11, 2007
AB			**80MG**	**A077987**	**004** Dec 28, 2007
AB		HISUN PHARM HANGZHOU	**20MG**	**A206061**	**001** Nov 23, 2018
AB			**40MG**	**A206061**	**002** Nov 23, 2018
AB			**80MG**	**A206061**	**003** Nov 23, 2018
AB		LUPIN PHARMS	**10MG**	**A077917**	**001** Jan 08, 2008

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

AB			**20MG**	**A077917**	**002**	Jan 08, 2008
AB			**40MG**	**A077917**	**003**	Jan 08, 2008
AB			**80MG**	**A077917**	**004**	Jan 08, 2008
AB		MYLAN PHARMS INC	**10MG**	**A079187**	**001**	May 27, 2010
AB			**20MG**	**A079187**	**002**	May 27, 2010
AB			**40MG**	**A079187**	**003**	May 27, 2010
AB			**80MG**	**A079187**	**004**	May 27, 2010
AB		SANDOZ	**10MG**	**A076397**	**003**	Oct 23, 2006
AB			**20MG**	**A076397**	**002**	Oct 23, 2006
AB			**40MG**	**A076397**	**001**	Oct 23, 2006
AB			**80MG**	**A077491**	**001**	Feb 11, 2008
AB		TEVA	**10MG**	**A076056**	**001**	Apr 24, 2006
AB			**20MG**	**A076056**	**002**	Apr 24, 2006
AB			**40MG**	**A076056**	**003**	Apr 24, 2006
AB		TEVA PHARMS	**80MG**	**A077793**	**001**	Jan 15, 2008
AB		WATSON LABS	**10MG**	**A076939**	**004**	Oct 23, 2006
AB			**20MG**	**A076939**	**003**	Oct 23, 2006
AB			**40MG**	**A076939**	**002**	Oct 23, 2006
AB			**80MG**	**A076939**	**001**	Dec 28, 2007
AB		ZYDUS PHARMS USA	**10MG**	**A077751**	**001**	Apr 30, 2008
AB			**20MG**	**A077751**	**002**	Apr 30, 2008
AB			**40MG**	**A077751**	**003**	Apr 30, 2008
AB			**80MG**	**A077751**	**004**	Apr 30, 2008

PRAZIQUANTEL

TABLET;ORAL

BILTRICIDE

AB	**+!**	BAYER HLTHCARE	**600MG**	**N018714**	**001**	Dec 29, 1982

PRAZIQUANTEL

AB		PAR PHARM INC	**600MG**	**A208820**	**001**	Nov 27, 2017

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

MINIPRESS

AB	**+**	PFIZER	**EQ 1MG BASE**	**N017442**	**002**	
AB	**+!**		**EQ 2MG BASE**	**N017442**	**003**	
AB	**+**		**EQ 5MG BASE**	**N017442**	**001**	

PRAZOSIN HYDROCHLORIDE

AB		MYLAN	**EQ 1MG BASE**	**A072575**	**003**	May 16, 1989
AB			**EQ 2MG BASE**	**A072575**	**002**	May 16, 1989
AB			**EQ 5MG BASE**	**A072575**	**001**	May 16, 1989
AB		NOVITIUM PHARMA	**EQ 1MG BASE**	**A210971**	**001**	Oct 03, 2018
AB			**EQ 2MG BASE**	**A210971**	**002**	Oct 03, 2018
AB			**EQ 5MG BASE**	**A210971**	**003**	Oct 03, 2018
AB		TEVA PHARMS	**EQ 1MG BASE**	**A071745**	**002**	Sep 12, 1988
AB			**EQ 2MG BASE**	**A071745**	**003**	Sep 12, 1988
AB			**EQ 5MG BASE**	**A071745**	**001**	Sep 12, 1988

PREDNICARBATE

CREAM;TOPICAL

DERMATOP E EMOLLIENT

AB	**+!**	VALEANT BERMUDA	**0.1%**	**N020279**	**001**	Oct 29, 1993

PREDNICARBATE

AB		FOUGERA PHARMS	**0.1%**	**A077287**	**001**	Sep 19, 2006

OINTMENT;TOPICAL

DERMATOP

AB	**+!**	VALEANT PHARMS NORTH	**0.1%**	**N019568**	**001**	Sep 23, 1991

PREDNICARBATE

AB		FOUGERA PHARMS	**0.1%**	**A077236**	**001**	Mar 09, 2007

PREDNISOLONE

SYRUP;ORAL

PREDNISOLONE

AA	**!**	HI TECH PHARMA CO	**15MG/5ML**	**A040401**	**001**	Feb 27, 2003
AA		LANNETT CO INC	**15MG/5ML**	**A040775**	**001**	Sep 21, 2007
AA		PHARM ASSOC	**15MG/5ML**	**A040399**	**001**	Mar 05, 2003
AA		VISTAPHARM	**15MG/5ML**	**A040323**	**001**	May 13, 1999
AA		WOCKHARDT BIO AG	**15MG/5ML**	**A040313**	**001**	Sep 10, 2003

PRELONE

AA		TEVA	**15MG/5ML**	**A089081**	**001**	Feb 04, 1986

PREDNISOLONE							
TABLET;ORAL							
PREDNISOLONE							
	!	WATSON LABS	5MG		A080354	001	
PREDNISOLONE ACETATE							
SUSPENSION/DROPS;OPHTHALMIC							
OMNIPRED							
AB		NOVARTIS PHARMS CORP	**1%**		**N017469**	**001**	
PRED FORTE							
AB	**+!**	ALLERGAN	**1%**		**N017011**	**001**	
PRED MILD							
	+!	ALLERGAN	0.12%		N017100	001	
PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM							
OINTMENT;OPHTHALMIC							
BLEPHAMIDE S.O.P.							
	!	ALLERGAN	0.2%;10%		A087748	001	Dec 03, 1986
SUSPENSION;OPHTHALMIC							
BLEPHAMIDE							
	+!	ALLERGAN	0.2%;10%		N012813	002	
PREDNISOLONE SODIUM PHOSPHATE							
SOLUTION;ORAL							
PEDIAPRED							
AA	**+!**	SETON PHARM	**EQ 5MG BASE/5ML**		**N019157**	**001**	May 28, 1986
PREDNISOLONE SODIUM PHOSPHATE							
AA		CHARTWELL RX	**EQ 5MG BASE/5ML**		**A075988**	**001**	May 25, 2004
AA		EDENBRIDGE PHARMS	**EQ 10MG BASE/5ML**		**A203559**	**001**	Dec 20, 2016
AA			**EQ 20MG BASE/5ML**		**A203559**	**002**	Dec 20, 2016
AA		HI TECH PHARMA	**EQ 5MG BASE/5ML**		**A075183**	**001**	Mar 26, 2003
AA	**!**	PHARM ASSOC	**EQ 10MG BASE/5ML**		**A078465**	**001**	Mar 07, 2008
AA			**EQ 15MG BASE/5ML**		**A076913**	**001**	Apr 25, 2005
AA	**!**		**EQ 20MG BASE/5ML**		**A078988**	**001**	Jun 09, 2008
AA		VINTAGE	**EQ 15MG BASE/5ML**		**A079010**	**001**	May 26, 2009
AA		WOCKHARDT BIO AG	**EQ 5MG BASE/5ML**		**A075099**	**001**	Jun 28, 2002
AA	**!**		**EQ 15MG BASE/5ML**		**A076895**	**001**	Oct 04, 2004
	!	MISSION PHARMA	EQ 25MG BASE/5ML		A091396	001	Sep 13, 2010
SOLUTION/DROPS;OPHTHALMIC							
PREDNISOLONE SODIUM PHOSPHATE							
	!	BAUSCH AND LOMB	EQ 0.9% PHOSPHATE		A040070	001	Jul 29, 1994
TABLET, ORALLY DISINTEGRATING;ORAL							
ORAPRED ODT							
AB	**+**	CONCORDIA PHARMS INC	**EQ 10MG BASE**		**N021959**	**001**	Jun 01, 2006
AB	**+**		**EQ 15MG BASE**		**N021959**	**002**	Jun 01, 2006
AB	**+!**		**EQ 30MG BASE**		**N021959**	**003**	Jun 01, 2006
PREDNISOLONE SODIUM PHOSPHATE							
AB		MYLAN PHARMS INC	**EQ 10MG BASE**		**A202179**	**001**	Apr 10, 2013
AB			**EQ 15MG BASE**		**A202179**	**002**	Apr 10, 2013
AB			**EQ 30MG BASE**		**A202179**	**003**	Apr 10, 2013
PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM							
SOLUTION/DROPS;OPHTHALMIC							
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE							
AT	**!**	BAUSCH AND LOMB	**EQ 0.23% PHOSPHATE;10%**		**A074449**	**001**	Dec 29, 1995
AT		SANDOZ INC	**EQ 0.23% PHOSPHATE;10%**		**A073630**	**001**	May 27, 1993
PREDNISONE							
SOLUTION;ORAL							
PREDNISONE							
	!	WEST-WARD PHARMS INT	5MG/5ML		A088703	001	Nov 08, 1984
PREDNISONE INTENSOL							
	!	WEST-WARD PHARMS INT	5MG/ML		A088810	001	Feb 20, 1985
TABLET;ORAL							
PREDNISONE							
AB		GENEYORK PHARMS	**1MG**		**A211496**	**001**	Dec 28, 2018
AB			**2.5MG**		**A211495**	**001**	Dec 07, 2018
AB			**5MG**		**A211495**	**002**	Dec 07, 2018
AB			**10MG**		**A210525**	**001**	Dec 04, 2018
AB			**20MG**		**A210525**	**002**	Dec 04, 2018
AB			**50MG**		**A210525**	**003**	Dec 04, 2018
AB		HIKMA PHARMS	**50MG**		**A088465**	**001**	Jun 01, 1984

PREDNISONE
TABLET;ORAL
PREDNISONE

AB		JUBILANT CADISTA	**1MG**	**A040611**	**001**	Jun 06, 2005
AB			**5MG**	**A040362**	**002**	Aug 29, 2001
AB			**10MG**	**A040362**	**001**	Aug 29, 2001
AB			**20MG**	**A040362**	**003**	Jun 29, 2005
AB		MUTUAL PHARM	**5MG**	**A089245**	**001**	Dec 04, 1985
AB		MYLAN PHARMS INC	**5MG**	**A080292**	**001**	
AB			**10MG**	**A088832**	**001**	Dec 04, 1985
AB			**20MG**	**A083677**	**001**	
AB		SUN PHARM INDUSTRIES	**10MG**	**A089246**	**001**	Dec 04, 1985
AB			**20MG**	**A089247**	**001**	Dec 04, 1985
AB		VINTAGE PHARMS	**1MG**	**A040584**	**001**	Dec 21, 2004
AB			**2.5MG**	**A040581**	**001**	Dec 21, 2004
AB			**5MG**	**A040256**	**001**	Jul 12, 2002
AB			**10MG**	**A040256**	**002**	Jul 12, 2002
AB			**20MG**	**A040392**	**001**	Feb 12, 2003
AB		WATSON LABS	**5MG**	**A080356**	**001**	
AB			**10MG**	**A085162**	**001**	
AB			**20MG**	**A085161**	**001**	
AB	!	WEST-WARD PHARMS INT	**1MG**	**A087800**	**001**	Apr 22, 1982
AB	!		**2.5MG**	**A087801**	**001**	Apr 22, 1982
AB	!		**5MG**	**A080352**	**001**	
AB	!		**10MG**	**A084122**	**001**	
AB	!		**20MG**	**A087342**	**001**	
AB	!		**50MG**	**A084283**	**001**	

TABLET, DELAYED RELEASE;ORAL
PREDNISONE

AB		ACTAVIS LABS FL INC	**1MG**	**A204867**	**001**	Apr 25, 2017
AB			**2MG**	**A204867**	**002**	Apr 25, 2017
AB			**5MG**	**A204867**	**003**	Apr 25, 2017

RAYOS

AB	+	HORIZON PHARMA USA	**1MG**	**N202020**	**001**	Jul 26, 2012
AB	+		**2MG**	**N202020**	**002**	Jul 26, 2012
AB	+!		**5MG**	**N202020**	**003**	Jul 26, 2012

PREGABALIN
CAPSULE;ORAL
LYRICA

+	PF PRISM CV	25MG	N021446	001	Dec 30, 2004
+		50MG	N021446	002	Dec 30, 2004
+		75MG	N021446	003	Dec 30, 2004
+		100MG	N021446	004	Dec 30, 2004
+		150MG	N021446	005	Dec 30, 2004
+		200MG	N021446	006	Dec 30, 2004
+		225MG	N021446	007	Dec 30, 2004
+!		300MG	N021446	008	Dec 30, 2004

SOLUTION;ORAL
LYRICA

+!	PF PRISM CV	20MG/ML	N022488	001	Jan 04, 2010

TABLET, EXTENDED RELEASE;ORAL
LYRICA CR

+	PF PRISM CV	82.5MG	N209501	001	Oct 11, 2017
+		165MG	N209501	002	Oct 11, 2017
+!		330MG	N209501	003	Oct 11, 2017

PRILOCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
PRILOCAINE HYDROCHLORIDE

!	SEPTODONT INC	4%	A079235	001	Sep 29, 2010

PRIMAQUINE PHOSPHATE
TABLET;ORAL
PRIMAQUINE

AB	+!	SANOFI AVENTIS US	**EQ 15MG BASE**	**N008316**	**001**	

PRIMAQUINE PHOSPHATE

AB		ALVOGEN INC	**EQ 15MG BASE**	**A203924**	**001**	Feb 03, 2014
AB		BAYSHORE PHARMS LLC	**EQ 15MG BASE**	**A204476**	**001**	Feb 25, 2014
AB		NOVAST LABS	**EQ 15MG BASE**	**A206043**	**001**	Jun 23, 2016

PRIMIDONE
TABLET;ORAL

MYSOLINE						
AB	**+!**	VALEANT	**50MG**	**N009170**	**003**	
AB	**+**		**250MG**	**N009170**	**002**	
PRIMIDONE						
AB		AMNEAL PHARM	**50MG**	**A040866**	**001**	Apr 23, 2008
AB			**250MG**	**A040866**	**002**	Apr 23, 2008
AB		ANDA REPOSITORY	**50MG**	**A040626**	**001**	Sep 29, 2005
AB			**250MG**	**A040626**	**002**	Sep 29, 2005
AB		HIKMA INTL PHARMS	**250MG**	**A040667**	**002**	Jul 27, 2006
AB		LANNETT	**50MG**	**A084903**	**002**	May 24, 2001
AB			**250MG**	**A084903**	**001**	
AB		OXFORD PHARMS	**50MG**	**A040586**	**001**	Feb 24, 2005
AB			**250MG**	**A040586**	**002**	Feb 24, 2005
AB		WATSON LABS	**250MG**	**A083551**	**001**	

PROBENECID
TABLET;ORAL

PROBALAN						
AB		LANNETT	**500MG**	**A080966**	**001**	
PROBENECID						
AB	**!**	MYLAN	**500MG**	**A084211**	**002**	
AB		WATSON LABS TEVA	**500MG**	**A084442**	**004**	Mar 29, 1983

PROCAINAMIDE HYDROCHLORIDE
INJECTABLE;INJECTION

PROCAINAMIDE HYDROCHLORIDE						
AP	**!**	HOSPIRA	**100MG/ML**	**A089069**	**001**	Feb 12, 1986
AP		INTL MEDICATION	**100MG/ML**	**A088636**	**001**	Jul 31, 1984
AP		NEXUS PHARMS	**100MG/ML**	**A206332**	**001**	Oct 13, 2017
AP			**500MG/ML**	**A206332**	**002**	Oct 13, 2017
	!	HOSPIRA	500MG/ML	A089070	001	Feb 12, 1986

PROCARBAZINE HYDROCHLORIDE
CAPSULE;ORAL

MATULANE						
	+!	LEADIANT BIOSCI INC	EQ 50MG BASE	N016785	001	

PROCHLORPERAZINE
SUPPOSITORY;RECTAL

COMPRO						
AB		PADDOCK LLC	**25MG**	**A040246**	**001**	Jun 28, 2000
PROCHLORPERAZINE						
AB	**!**	G AND W LABS	**25MG**	**A040058**	**001**	Nov 24, 1993

PROCHLORPERAZINE EDISYLATE
INJECTABLE;INJECTION

PROCHLORPERAZINE EDISYLATE						
AP		ATHENEX INC	**EQ 5MG BASE/ML**	**A040540**	**001**	May 28, 2004
AP	**!**	EMCURE PHARMS LTD	**EQ 5MG BASE/ML**	**A204147**	**001**	Oct 15, 2013
AP		MYLAN LABS LTD	**EQ 5MG BASE/ML**	**A210710**	**001**	Oct 25, 2018
AP		WEST-WARD PHARMS INT	**EQ 5MG BASE/ML**	**A089903**	**001**	Aug 29, 1989

PROCHLORPERAZINE MALEATE
TABLET;ORAL

PROCHLORPERAZINE MALEATE						
AB		MYLAN	**EQ 5MG BASE**	**A040185**	**002**	Oct 28, 1996
AB			**EQ 10MG BASE**	**A040185**	**001**	Oct 28, 1996
AB		SANDOZ	**EQ 5MG BASE**	**A040101**	**001**	Jul 19, 1996
AB	**!**		**EQ 10MG BASE**	**A040101**	**002**	Jul 19, 1996
AB		TEVA PHARMS	**EQ 5MG BASE**	**A040120**	**001**	Jul 11, 1996
AB			**EQ 10MG BASE**	**A040120**	**002**	Jul 11, 1996
PROCOMP						
AB		JUBILANT CADISTA	**EQ 5MG BASE**	**A040268**	**001**	Feb 27, 1998
AB			**EQ 10MG BASE**	**A040268**	**002**	Feb 27, 1998

PROGESTERONE
CAPSULE;ORAL

PROGESTERONE						
AB		AMNEAL PHARMS NY	**100MG**	**A207724**	**001**	Sep 07, 2017
AB			**200MG**	**A207724**	**002**	Sep 07, 2017
AB		BIONPHARMA INC	**100MG**	**A200900**	**001**	Aug 16, 2013
AB			**200MG**	**A200900**	**002**	Aug 16, 2013
AB		DR REDDYS LABS INC	**100MG**	**A208801**	**001**	Feb 28, 2017

PROGESTERONE

CAPSULE;ORAL

PROGESTERONE

AB			**200MG**	**A208801**	**002**	Feb 28, 2017
AB		EUGIA PHARMA	**100MG**	**A211285**	**001**	Oct 26, 2018
AB			**200MG**	**A211285**	**002**	Oct 26, 2018
AB		SANDOZ INC	**100MG**	**A205229**	**001**	Oct 20, 2017
AB			**200MG**	**A205229**	**002**	Oct 20, 2017
AB		SOFGEN PHARMS	**100MG**	**A200456**	**001**	Sep 28, 2012
AB			**200MG**	**A200456**	**002**	Sep 28, 2012

PROMETRIUM

AB	**+**	VIRTUS PHARMS	**100MG**	**N019781**	**001**	May 14, 1998
AB	**+!**		**200MG**	**N019781**	**002**	Oct 15, 1999

GEL;VAGINAL

CRINONE

+!	ALLERGAN SALES LLC	4%	N020701	001	Jul 31, 1997
+!		8%	N020701	002	Jul 31, 1997

INJECTABLE;INJECTION

PROGESTERONE

AO	**+!**	ACTAVIS LABS UT INC	**50MG/ML**	**N017362**	**002**	
AO		EUGIA PHARMA	**50MG/ML**	**A210965**	**001**	Dec 06, 2018
AO		FRESENIUS KABI USA	**50MG/ML**	**A075906**	**001**	Apr 25, 2001
AO		HIKMA FARMACEUTICA	**50MG/ML**	**A091033**	**001**	Oct 28, 2010
AO		LUITPOLD	**50MG/ML**	**A090845**	**001**	Jun 22, 2009

INSERT;VAGINAL

ENDOMETRIN

+!	FERRING	100MG	N022057	001	Jun 21, 2007

PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

PROMETHAZINE HYDROCHLORIDE

AP	**!**	WEST-WARD PHARMS INT	**25MG/ML**	**A083312**	**001**	
AP	**!**		**50MG/ML**	**A083312**	**002**	
AP		X-GEN PHARMS	**25MG/ML**	**A040737**	**001**	Apr 24, 2008
AP			**50MG/ML**	**A040737**	**002**	Apr 24, 2008

SUPPOSITORY;RECTAL

PROMETHAZINE HYDROCHLORIDE

AB		G AND W LABS	**12.5MG**	**A040428**	**002**	Mar 31, 2003
AB	**!**		**25MG**	**A040428**	**001**	Feb 05, 2002
AB		PERRIGO NEW YORK	**12.5MG**	**A040500**	**001**	Jun 30, 2003
AB			**25MG**	**A040500**	**002**	Jun 30, 2003
AB		TARO	**12.5MG**	**A040603**	**001**	Oct 26, 2006
AB			**25MG**	**A040603**	**002**	Oct 26, 2006
AB		WATSON LABS INC	**12.5MG**	**A040479**	**001**	Jun 24, 2003
AB			**25MG**	**A040479**	**002**	Jun 24, 2003

PROMETHEGAN

!	G AND W LABS	50MG	A087165	001	Aug 14, 1987

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE

AA		AMNEAL PHARMS	**6.25MG/5ML**	**A040882**	**001**	Dec 30, 2009
AA		HI TECH PHARMA	**6.25MG/5ML**	**A040026**	**001**	Sep 25, 1998
AA		NOSTRUM LABS INC	**6.25MG/5ML**	**A040891**	**001**	Mar 13, 2009
AA		TARO	**6.25MG/5ML**	**A040718**	**001**	Apr 04, 2007
AA		TRIS PHARMA INC	**6.25MG/5ML**	**A091675**	**001**	Jun 28, 2012
AA		VINTAGE	**6.25MG/5ML**	**A040643**	**001**	Apr 26, 2006

PROMETHAZINE PLAIN

AA	**!**	WOCKHARDT BIO AG	**6.25MG/5ML**	**A087953**	**001**	Nov 15, 1982

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

AB		AMNEAL PHARMS NY	**12.5MG**	**A091179**	**001**	Dec 13, 2010
AB			**25MG**	**A091179**	**002**	Dec 13, 2010
AB			**50MG**	**A091179**	**003**	Dec 13, 2010
AB		KVK TECH	**12.5MG**	**A040712**	**002**	May 04, 2007
AB			**25MG**	**A040712**	**001**	Jul 31, 2006
AB			**50MG**	**A040712**	**003**	Jul 31, 2006
AB		PRINSTON INC	**12.5MG**	**A040622**	**001**	Jul 18, 2006
AB			**25MG**	**A040622**	**002**	Jul 18, 2006
AB			**50MG**	**A040622**	**003**	Jul 18, 2006
AB		QUAGEN	**12.5MG**	**A040673**	**001**	Mar 05, 2008
AB			**25MG**	**A040673**	**002**	Mar 05, 2008
AB			**50MG**	**A040673**	**003**	Mar 05, 2008
AB		SANDOZ	**25MG**	**A084176**	**003**	

PROMETHAZINE HYDROCHLORIDE

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

AB	**!**		**50MG**	**A084176**	**001**	
AB		STRIDES PHARMA	**12.5MG**	**A209177**	**001**	Jun 30, 2017
AB			**25MG**	**A209177**	**002**	Jun 30, 2017
AB			**50MG**	**A209177**	**003**	Jun 30, 2017
AB		SUN PHARM INDS INC	**12.5MG**	**A040863**	**001**	Dec 30, 2008
AB			**25MG**	**A040863**	**002**	Dec 30, 2008
AB			**50MG**	**A040863**	**003**	Dec 30, 2008
AB		WATSON LABS	**25MG**	**A083426**	**001**	
AB			**50MG**	**A083711**	**001**	
AB		ZYDUS PHARMS USA	**12.5MG**	**A040596**	**001**	Nov 18, 2005
AB			**25MG**	**A040596**	**002**	Nov 18, 2005
AB			**50MG**	**A040596**	**003**	Nov 18, 2005
		IMPAX LABS	12.5MG	A040791	002	Feb 12, 2008
			25MG	A040791	003	Feb 12, 2008

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PROPAFENONE HYDROCHLORIDE

AB		GLENMARK PHARMS LTD	**225MG**	**A205268**	**001**	Sep 08, 2017
AB			**325MG**	**A205268**	**002**	Sep 08, 2017
AB			**425MG**	**A205268**	**003**	Sep 08, 2017
AB		MYLAN PHARMS INC	**225MG**	**A203803**	**001**	Apr 29, 2016
AB			**325MG**	**A203803**	**002**	Apr 29, 2016
AB			**425MG**	**A203803**	**003**	Apr 29, 2016
AB		PAR PHARM	**225MG**	**A078540**	**001**	Oct 18, 2010
AB			**325MG**	**A078540**	**002**	Oct 18, 2010
AB			**425MG**	**A078540**	**003**	Oct 18, 2010
AB		SINOTHERAPEUTICS INC	**225MG**	**A210339**	**001**	Jan 04, 2019
AB			**325MG**	**A210339**	**002**	Jan 04, 2019
AB			**425MG**	**A210339**	**003**	Jan 04, 2019
AB		WATSON LABS INC	**225MG**	**A202688**	**001**	Aug 24, 2015
AB			**325MG**	**A202688**	**002**	Aug 24, 2015
AB			**425MG**	**A202688**	**003**	Aug 24, 2015
AB		WILSHIRE PHARMS INC	**225MG**	**A205956**	**001**	Jul 02, 2018
AB			**325MG**	**A205956**	**002**	Jul 02, 2018
AB			**425MG**	**A205956**	**003**	Jul 02, 2018

RYTHMOL SR

AB	**+**	GLAXOSMITHKLINE LLC	**225MG**	**N021416**	**001**	Sep 04, 2003
AB	**+**		**325MG**	**N021416**	**002**	Sep 04, 2003
AB	**+!**		**425MG**	**N021416**	**003**	Sep 04, 2003

TABLET;ORAL

PROPAFENONE HYDROCHLORIDE

AB		ANI PHARMS INC	**150MG**	**A076550**	**001**	Apr 23, 2004
AB			**225MG**	**A076550**	**002**	Apr 23, 2004
AB			**300MG**	**A076550**	**003**	Apr 23, 2004
AB		AUROBINDO PHARMA LTD	**150MG**	**A202445**	**001**	May 11, 2016
AB			**225MG**	**A202445**	**002**	May 11, 2016
AB			**300MG**	**A202445**	**003**	May 11, 2016
AB		SUN PHARM INDUSTRIES	**150MG**	**A075998**	**001**	Nov 29, 2001
AB			**225MG**	**A075998**	**002**	Nov 29, 2001
AB			**300MG**	**A075998**	**003**	Nov 29, 2001
AB		VINTAGE PHARMS	**150MG**	**A075938**	**001**	Oct 17, 2002
AB			**225MG**	**A075938**	**002**	Oct 17, 2002
AB	**!**		**300MG**	**A075938**	**003**	Oct 17, 2002
AB		WATSON LABS	**150MG**	**A075203**	**001**	Oct 24, 2000
AB			**225MG**	**A075203**	**002**	Oct 24, 2000

PROPANTHELINE BROMIDE

TABLET;ORAL

PROPANTHELINE BROMIDE

	!	WEST-WARD PHARMS INT	15MG	A080927	002	

PROPARACAINE HYDROCHLORIDE							
SOLUTION/DROPS;OPHTHALMIC							
ALCAINE							
AT		ALCON LABS INC	**0.5%**	**A080027**	**001**		
PROPARACAINE HYDROCHLORIDE							
AT	**!**	AKORN INC	**0.5%**	**A040277**	**001**	Mar 16, 2000	
AT		BAUSCH AND LOMB	**0.5%**	**A040074**	**001**	Sep 29, 1995	
PROPOFOL							
INJECTABLE;INJECTION							
DIPRIVAN							
AB	**+!**	FRESENIUS KABI USA	**10MG/ML**	**N019627**	**002**	Jun 11, 1996	
PROPOFOL							
AB		DR REDDYS LABS INC	**10MG/ML**	**A205067**	**001**	Nov 15, 2018	
AB		HOSPIRA	**10MG/ML**	**A077908**	**001**	Mar 17, 2006	
AB		SAGENT PHARMS	**10MG/ML**	**A075102**	**001**	Jan 04, 1999	
AB		WATSON LABS INC	**10MG/ML**	**A205307**	**001**	Dec 22, 2015	
PROPRANOLOL HYDROCHLORIDE							
CAPSULE, EXTENDED RELEASE;ORAL							
INDERAL LA							
AB	**+**	ANI PHARMS INC	**60MG**	**N018553**	**004**	Mar 18, 1987	
AB	**+**		**80MG**	**N018553**	**002**	Apr 19, 1983	
AB	**+**		**120MG**	**N018553**	**003**	Apr 19, 1983	
AB	**+!**		**160MG**	**N018553**	**001**	Apr 19, 1983	
PROPRANOLOL HYDROCHLORIDE							
AB		ACTAVIS ELIZABETH	**60MG**	**A078494**	**001**	Aug 10, 2007	
AB			**80MG**	**A078494**	**002**	Aug 10, 2007	
AB			**120MG**	**A078494**	**003**	Aug 10, 2007	
AB			**160MG**	**A078494**	**004**	Aug 10, 2007	
AB		NORTEC DEV ASSOC	**60MG**	**A078065**	**001**	Jan 26, 2007	
AB			**80MG**	**A078065**	**002**	Jan 26, 2007	
AB			**120MG**	**A078065**	**003**	Jan 26, 2007	
AB			**160MG**	**A078065**	**004**	Jan 26, 2007	
AB		RP SCHERER	**60MG**	**A078703**	**001**	Jul 15, 2011	
AB			**80MG**	**A078703**	**002**	Jul 15, 2011	
AB			**120MG**	**A078703**	**003**	Jul 15, 2011	
AB			**160MG**	**A078703**	**004**	Jul 15, 2011	
AB		ZYDUS PHARMS USA INC	**60MG**	**A090321**	**001**	Mar 25, 2011	
AB			**80MG**	**A090321**	**002**	Mar 25, 2011	
AB			**120MG**	**A090321**	**003**	Mar 25, 2011	
AB			**160MG**	**A090321**	**004**	Mar 25, 2011	
INNOPRAN XL							
BX		ANI PHARMS INC	80MG	N021438	001	Mar 12, 2003	
BX			120MG	N021438	002	Mar 12, 2003	
INJECTABLE;INJECTION							
PROPRANOLOL HYDROCHLORIDE							
AP		ATHENEX INC	**1MG/ML**	**A075792**	**001**	Aug 29, 2000	
AP		FRESENIUS KABI USA	**1MG/ML**	**A075826**	**001**	Aug 31, 2001	
	!	HIKMA FARMACEUTICA	1MG/ML	A077760	001	Jan 31, 2008	
SOLUTION;ORAL							
HEMANGEOL							
	+!	PIERRE FABRE DERMA	4.28MG/ML	N205410	001	Mar 14, 2014	
PROPRANOLOL HYDROCHLORIDE							
	!	WEST-WARD PHARMS INT	20MG/5ML	A070979	001	May 15, 1987	
	!		40MG/5ML	A070690	001	May 15, 1987	
TABLET;ORAL							
PROPRANOLOL HYDROCHLORIDE							
AB		IMPAX LABS INC	**10MG**	**A071972**	**001**	Apr 06, 1988	
AB			**20MG**	**A071972**	**002**	Apr 06, 1988	
AB			**40MG**	**A071972**	**003**	Apr 06, 1988	
AB			**60MG**	**A071976**	**002**	May 13, 1986	
AB	**!**		**80MG**	**A071976**	**001**	Apr 06, 1988	
AB		IPCA LABS LTD	**10MG**	**A078955**	**001**	Jun 02, 2008	
AB			**20MG**	**A078955**	**002**	Jun 02, 2008	
AB			**40MG**	**A078955**	**003**	Jun 02, 2008	
AB			**60MG**	**A078955**	**004**	Jun 02, 2008	
AB			**80MG**	**A078955**	**005**	Jun 02, 2008	
AB		MYLAN	**10MG**	**A070213**	**002**	Nov 19, 1985	
AB			**20MG**	**A070213**	**003**	Nov 19, 1985	
AB			**40MG**	**A070213**	**001**	Nov 19, 1985	
AB			**60MG**	**A070213**	**005**	Apr 08, 2011	

PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

AB			**80MG**	**A070213**	**004**	Nov 19, 1985
AB		NORTHSTAR HLTHCARE	**10MG**	**A078213**	**001**	Jan 10, 2008
AB			**20MG**	**A078213**	**002**	Jan 10, 2008
AB			**40MG**	**A078213**	**003**	Jan 10, 2008
AB			**60MG**	**A078213**	**004**	Jan 10, 2008
AB			**80MG**	**A078213**	**005**	Jan 10, 2008
AB		VINTAGE PHARMS	**10MG**	**A070221**	**002**	Aug 01, 1986
AB			**20MG**	**A070221**	**003**	Aug 01, 1986
AB			**40MG**	**A070219**	**001**	Aug 01, 1986
AB			**40MG**	**A070221**	**004**	Aug 01, 1986
AB			**60MG**	**A070221**	**005**	Sep 24, 1986
AB			**80MG**	**A070221**	**001**	Apr 14, 1986
AB		WATSON LABS	**10MG**	**A070175**	**001**	May 13, 1986
AB			**20MG**	**A070176**	**001**	May 13, 1986
AB			**40MG**	**A070177**	**001**	May 13, 1986
AB			**60MG**	**A070178**	**002**	Apr 23, 2018
AB			**80MG**	**A070178**	**001**	May 13, 1986

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

BD		ACTAVIS ELIZABETH	50MG	A080172	001	
BD	+!	DAVA PHARMS INC	50MG	N006188	001	

PROTAMINE SULFATE

INJECTABLE;INJECTION

PROTAMINE SULFATE

	!	FRESENIUS KABI USA	10MG/ML	A089454	001	Apr 07, 1987

PROTRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

PROTRIPTYLINE HYDROCHLORIDE

AB		EPIC PHARMA LLC	**5MG**	**A202220**	**001**	Nov 19, 2012
AB			**10MG**	**A202220**	**002**	Nov 19, 2012
AB		SIGMAPHARM LABS LLC	**5MG**	**A090462**	**001**	May 03, 2010
AB			**10MG**	**A090462**	**002**	May 03, 2010
AB		WEST-WARD PHARMS INT	**5MG**	**A078913**	**001**	Sep 16, 2008
AB			**10MG**	**A078913**	**002**	Sep 16, 2008

VIVACTIL

AB		ODYSSEY PHARMS	**5MG**	**A073644**	**001**	Aug 24, 1995
AB	**!**		**10MG**	**A073645**	**001**	Aug 24, 1995

PRUCALOPRIDE SUCCINATE

TABLET;ORAL

MOTEGRITY

	+	SHIRE DEV LLC	EQ 1MG BASE	N210166	001	Dec 14, 2018
	+!		EQ 2MG BASE	N210166	002	Dec 14, 2018

PYRAZINAMIDE

TABLET;ORAL

PYRAZINAMIDE

AB		AKORN	**500MG**	**A081319**	**001**	Jun 30, 1992
AB	**!**	DAVA PHARMS INC	**500MG**	**A080157**	**001**	

PYRIDOSTIGMINE BROMIDE

INJECTABLE;INJECTION

MESTINON

AP	**+!**	VALEANT PHARM INTL	**5MG/ML**	**N009830**	**001**	

REGONOL

AP		SANDOZ INC	**5MG/ML**	**N017398**	**001**	

SYRUP;ORAL

MESTINON

	+!	VALEANT PHARMS	60MG/5ML	N015193	001	

TABLET;ORAL

MESTINON

AB	**+!**	VALEANT PHARMS LLC	**60MG**	**N009829**	**002**	

PYRIDOSTIGMINE BROMIDE

AB		APNAR PHARMA LP	**60MG**	**A211181**	**001**	Jul 20, 2018
AB		IMPAX LABS	**60MG**	**A040502**	**001**	Apr 24, 2003
AB		ZYDUS PHARMS USA INC	**60MG**	**A205650**	**001**	Jun 22, 2015

PYRIDOSTIGMINE BROMIDE
TABLET, EXTENDED RELEASE;ORAL
MESTINON

AB	**+!**	VALEANT PHARMS LLC	**180MG**	**N011665**	**001**	

PYRIDOSTIGMINE BROMIDE

AB	ALVOGEN MALTA	**180MG**	**A204737**	**001**	Jun 26, 2015
AB	IMPAX LABS INC	**180MG**	**A203184**	**001**	Sep 15, 2015
AB	RISING PHARMS	**180MG**	**A205464**	**001**	Aug 15, 2017

PYRIDOXINE HYDROCHLORIDE
INJECTABLE;INJECTION
PYRIDOXINE HYDROCHLORIDE

	!	FRESENIUS KABI USA	100MG/ML	A080618	001

PYRIMETHAMINE
TABLET;ORAL
DARAPRIM

	+!	VYERA PHARMS LLC	25MG	N008578	001

QUAZEPAM
TABLET;ORAL
DORAL

	+!	GALT PHARMS	15MG	N018708	001	Dec 27, 1985

QUETIAPINE FUMARATE
TABLET;ORAL
QUETIAPINE FUMARATE

AB	ACCORD HLTHCARE	**EQ 25MG BASE**	**A202152**	**001**	Mar 27, 2012
AB		**EQ 50MG BASE**	**A202152**	**002**	Mar 27, 2012
AB		**EQ 100MG BASE**	**A202152**	**003**	Mar 27, 2012
AB		**EQ 200MG BASE**	**A202152**	**004**	Mar 27, 2012
AB		**EQ 300MG BASE**	**A202152**	**005**	Mar 27, 2012
AB		**EQ 400MG BASE**	**A202152**	**006**	Mar 27, 2012
AB	ALEMBIC PHARMS LTD	**EQ 25MG BASE**	**A203390**	**001**	Oct 28, 2014
AB		**EQ 50MG BASE**	**A203390**	**002**	Oct 28, 2014
AB		**EQ 100MG BASE**	**A203390**	**003**	Oct 28, 2014
AB		**EQ 200MG BASE**	**A203390**	**004**	Oct 28, 2014
AB		**EQ 300MG BASE**	**A203390**	**005**	Oct 28, 2014
AB		**EQ 400MG BASE**	**A203390**	**006**	Oct 28, 2014
AB	ALKEM LABS LTD	**EQ 25MG BASE**	**A201504**	**001**	Feb 12, 2013
AB		**EQ 50MG BASE**	**A201504**	**002**	Feb 12, 2013
AB		**EQ 100MG BASE**	**A201504**	**003**	Feb 12, 2013
AB		**EQ 150MG BASE**	**A201504**	**004**	Feb 12, 2013
AB		**EQ 200MG BASE**	**A201504**	**005**	Feb 12, 2013
AB		**EQ 300MG BASE**	**A201504**	**006**	Feb 12, 2013
AB		**EQ 400MG BASE**	**A201504**	**007**	Feb 12, 2013
AB	APOTEX INC	**EQ 25MG BASE**	**A090960**	**001**	Mar 27, 2012
AB		**EQ 50MG BASE**	**A090960**	**002**	Mar 27, 2012
AB		**EQ 100MG BASE**	**A090960**	**003**	Mar 27, 2012
AB		**EQ 200MG BASE**	**A090960**	**004**	Mar 27, 2012
AB		**EQ 300MG BASE**	**A090960**	**005**	Mar 27, 2012
AB		**EQ 400MG BASE**	**A090960**	**006**	Mar 27, 2012
AB	AUROBINDO PHARMA LTD	**EQ 25MG BASE**	**A091388**	**001**	Mar 27, 2012
AB		**EQ 50MG BASE**	**A091388**	**002**	Mar 27, 2012
AB		**EQ 100MG BASE**	**A091388**	**003**	Mar 27, 2012
AB		**EQ 150MG BASE**	**A091388**	**004**	Mar 27, 2012
AB		**EQ 200MG BASE**	**A091388**	**005**	Mar 27, 2012
AB		**EQ 300MG BASE**	**A091388**	**006**	Mar 27, 2012
AB		**EQ 400MG BASE**	**A091388**	**007**	Mar 27, 2012
AB	DR REDDYS LABS LTD	**EQ 25MG BASE**	**A077380**	**001**	Mar 27, 2012
AB		**EQ 50MG BASE**	**A077380**	**002**	Mar 27, 2012
AB		**EQ 100MG BASE**	**A077380**	**003**	Mar 27, 2012
AB		**EQ 150MG BASE**	**A077380**	**004**	Mar 27, 2012
AB		**EQ 200MG BASE**	**A077380**	**005**	Mar 27, 2012
AB		**EQ 300MG BASE**	**A077380**	**006**	Mar 27, 2012
AB		**EQ 400MG BASE**	**A077380**	**007**	Mar 27, 2012
AB	JUBILANT GENERICS	**EQ 25MG BASE**	**A203150**	**001**	Nov 26, 2013
AB	LUPIN LTD	**EQ 25MG BASE**	**A201109**	**001**	Mar 27, 2012
AB		**EQ 50MG BASE**	**A201109**	**002**	Mar 27, 2012
AB		**EQ 100MG BASE**	**A201109**	**003**	Mar 27, 2012
AB		**EQ 200MG BASE**	**A201109**	**004**	Mar 27, 2012
AB		**EQ 300MG BASE**	**A201109**	**005**	Mar 27, 2012
AB		**EQ 400MG BASE**	**A201109**	**006**	Mar 27, 2012
AB	MACLEODS PHARMS LTD	**EQ 25MG BASE**	**A203359**	**001**	May 17, 2016

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

AB			EQ 50MG BASE	A203359	002	May 17, 2016
AB			EQ 100MG BASE	A203359	003	May 17, 2016
AB			EQ 200MG BASE	A203359	004	May 17, 2016
AB			EQ 300MG BASE	A203359	005	May 17, 2016
AB			EQ 400MG BASE	A203359	006	May 17, 2016
AB		SANDOZ	EQ 25MG BASE	A078679	001	Dec 14, 2012
AB			EQ 50MG BASE	A078679	002	Dec 14, 2012
AB			EQ 100MG BASE	A078679	003	Dec 14, 2012
AB			EQ 150MG BASE	A078679	004	Dec 14, 2012
AB			EQ 200MG BASE	A078679	005	Dec 14, 2012
AB			EQ 300MG BASE	A078679	006	Dec 14, 2012
AB			EQ 400MG BASE	A078679	007	Dec 14, 2012
AB		SUN PHARMA GLOBAL	EQ 25MG BASE	A201190	001	Mar 27, 2012
AB			EQ 50MG BASE	A201190	002	Mar 27, 2012
AB			EQ 100MG BASE	A201190	003	Mar 27, 2012
AB			EQ 200MG BASE	A201190	004	Mar 27, 2012
AB			EQ 300MG BASE	A201190	005	Mar 27, 2012
AB			EQ 400MG BASE	A201190	006	Mar 27, 2012
AB		TEVA PHARMS	EQ 25MG BASE	A077745	001	Mar 27, 2012
AB			EQ 50MG BASE	A077745	002	Mar 27, 2012
AB			EQ 100MG BASE	A077745	003	Mar 27, 2012
AB			EQ 150MG BASE	A077745	004	Mar 27, 2012
AB			EQ 200MG BASE	A077745	005	Mar 27, 2012
AB			EQ 300MG BASE	A077745	006	Mar 27, 2012
AB			EQ 400MG BASE	A077745	007	Mar 27, 2012
AB		TORRENT PHARMS LTD	EQ 25MG BASE	A200363	001	Mar 27, 2012
AB			EQ 50MG BASE	A200363	002	Mar 27, 2012
AB			EQ 100MG BASE	A200363	003	Mar 27, 2012
AB			EQ 200MG BASE	A200363	004	Mar 27, 2012
AB			EQ 300MG BASE	A200363	005	Mar 27, 2012
AB			EQ 400MG BASE	A200363	006	Mar 27, 2012
AB		UNICHEM LABS LTD	EQ 25MG BASE	A202674	001	Mar 08, 2016
AB			EQ 50MG BASE	A202674	002	Mar 08, 2016
AB			EQ 100MG BASE	A202674	003	Mar 08, 2016
AB			EQ 200MG BASE	A202674	004	Mar 08, 2016
AB			EQ 300MG BASE	A202674	005	Mar 08, 2016
AB			EQ 400MG BASE	A202674	006	Mar 08, 2016
AB		WEST-WARD PHARMS INT	EQ 25MG BASE	A090120	001	Mar 27, 2012
AB			EQ 50MG BASE	A090749	001	Mar 27, 2012
AB			EQ 100MG BASE	A090749	002	Mar 27, 2012
AB			EQ 200MG BASE	A090749	003	Mar 27, 2012
AB			EQ 300MG BASE	A090749	004	Mar 27, 2012
AB			EQ 400MG BASE	A090749	005	Mar 27, 2012

SEROQUEL

AB	+!	ASTRAZENECA PHARMS	EQ 25MG BASE	N020639	001	Sep 26, 1997
AB	+		EQ 50MG BASE	N020639	007	Oct 04, 2005
AB	+		EQ 100MG BASE	N020639	002	Sep 26, 1997
AB	+		EQ 200MG BASE	N020639	003	Sep 26, 1997
AB	+!		EQ 300MG BASE	N020639	005	Jul 26, 2000
AB	+		EQ 400MG BASE	N020639	006	Oct 04, 2005

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

AB		ACCORD HLTHCARE	EQ 50MG BASE	A206252	001	Nov 29, 2017
AB			EQ 150MG BASE	A090681	001	May 09, 2017
AB			EQ 200MG BASE	A090681	002	May 09, 2017
AB			EQ 300MG BASE	A090681	003	May 09, 2017
AB			EQ 400MG BASE	A090681	004	Nov 01, 2016
AB		ALIGNSCIENCE PHARMA	EQ 150MG BASE	A209497	001	Sep 28, 2018
AB			EQ 200MG BASE	A209497	002	Sep 28, 2018
AB		AMNEAL PHARMS	EQ 400MG BASE	A211405	001	Oct 26, 2018
AB		ANCHEN PHARMS	EQ 150MG BASE	A090757	001	Dec 01, 2017
AB			EQ 200MG BASE	A090757	002	Dec 01, 2017
AB			EQ 300MG BASE	A090757	003	Dec 01, 2017
AB			EQ 400MG BASE	A090757	004	Dec 01, 2017
AB		AUROBINDO PHARMA LTD	EQ 50MG BASE	A207655	001	Nov 29, 2017
AB			EQ 150MG BASE	A207655	002	Nov 29, 2017
AB			EQ 200MG BASE	A207655	003	Nov 29, 2017
AB			EQ 300MG BASE	A207655	004	Nov 29, 2017

QUETIAPINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

AB			**EQ 400MG BASE**	**A207655**	**005**	Nov 29, 2017
AB		INTELLIPHARMACEUTICS	**EQ 50MG BASE**	**A202939**	**001**	May 09, 2017
AB			**EQ 150MG BASE**	**A202939**	**002**	May 09, 2017
AB			**EQ 200MG BASE**	**A202939**	**003**	May 09, 2017
AB			**EQ 300MG BASE**	**A202939**	**004**	May 09, 2017
AB			**EQ 400MG BASE**	**A202939**	**005**	May 09, 2017
AB		LUPIN LTD	**EQ 50MG BASE**	**A204203**	**001**	May 17, 2017
AB			**EQ 150MG BASE**	**A204203**	**002**	May 17, 2017
AB			**EQ 200MG BASE**	**A204203**	**003**	May 17, 2017
AB			**EQ 300MG BASE**	**A204203**	**004**	May 17, 2017
AB			**EQ 400MG BASE**	**A204203**	**005**	May 17, 2017
AB		MACLEODS PHARMS LTD	**EQ 150MG BASE**	**A204253**	**001**	Nov 29, 2017
AB			**EQ 200MG BASE**	**A204253**	**002**	Nov 29, 2017
AB			**EQ 300MG BASE**	**A204253**	**003**	Nov 29, 2017
AB			**EQ 400MG BASE**	**A204253**	**004**	Nov 29, 2017
AB		NOVAST LABS	**EQ 50MG BASE**	**A208947**	**001**	Nov 29, 2017
AB			**EQ 150MG BASE**	**A208947**	**002**	Nov 29, 2017
AB			**EQ 200MG BASE**	**A208947**	**003**	Nov 29, 2017
AB			**EQ 300MG BASE**	**A208947**	**004**	Nov 29, 2017
AB			**EQ 400MG BASE**	**A208947**	**005**	Nov 29, 2017
AB		PAR PHARM	**EQ 50MG BASE**	**A090482**	**001**	May 09, 2017
AB			**EQ 150MG BASE**	**A090482**	**002**	May 09, 2017
AB			**EQ 200MG BASE**	**A090482**	**003**	May 09, 2017
AB			**EQ 300MG BASE**	**A090482**	**004**	May 09, 2017
AB			**EQ 400MG BASE**	**A090482**	**005**	May 09, 2017
AB		PHARMADAX INC	**EQ 50MG BASE**	**A206260**	**001**	May 09, 2017
AB			**EQ 150MG BASE**	**A206260**	**002**	May 09, 2017
AB			**EQ 200MG BASE**	**A206260**	**003**	May 09, 2017
AB			**EQ 300MG BASE**	**A206260**	**004**	May 09, 2017
AB			**EQ 400MG BASE**	**A206260**	**005**	May 09, 2017
AB		SCIEGEN PHARMS INC	**EQ 50MG BASE**	**A209635**	**005**	Nov 16, 2018
AB			**EQ 150MG BASE**	**A209635**	**001**	Nov 29, 2017
AB			**EQ 200MG BASE**	**A209635**	**002**	Nov 29, 2017
AB			**EQ 300MG BASE**	**A209635**	**003**	Nov 29, 2017
AB			**EQ 400MG BASE**	**A209635**	**004**	Nov 29, 2017

SEROQUEL XR

AB	+	ASTRAZENECA	**EQ 50MG BASE**	**N022047**	**001**	May 17, 2007
AB	+		**EQ 150MG BASE**	**N022047**	**005**	Aug 11, 2008
AB	+!		**EQ 200MG BASE**	**N022047**	**002**	May 17, 2007
AB	+		**EQ 300MG BASE**	**N022047**	**003**	May 17, 2007
AB	+		**EQ 400MG BASE**	**N022047**	**004**	May 17, 2007

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

ACCUPRIL

AB	+	PFIZER PHARMS	**EQ 5MG BASE**	**N019885**	**001**	Nov 19, 1991
AB	+		**EQ 10MG BASE**	**N019885**	**002**	Nov 19, 1991
AB	+		**EQ 20MG BASE**	**N019885**	**003**	Nov 19, 1991
AB	+!		**EQ 40MG BASE**	**N019885**	**004**	Nov 19, 1991

QUINAPRIL HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A202725**	**001**	Apr 29, 2013
AB			**EQ 10MG BASE**	**A202725**	**002**	Apr 29, 2013
AB			**EQ 20MG BASE**	**A202725**	**003**	Apr 29, 2013
AB			**EQ 40MG BASE**	**A202725**	**004**	Apr 29, 2013
AB		INVAGEN PHARMS	**EQ 5MG BASE**	**A078457**	**001**	Aug 24, 2007
AB			**EQ 10MG BASE**	**A078457**	**002**	Aug 24, 2007
AB			**EQ 20MG BASE**	**A078457**	**003**	Aug 24, 2007
AB			**EQ 40MG BASE**	**A078457**	**004**	Aug 24, 2007
AB		LUPIN	**EQ 5MG BASE**	**A077690**	**001**	Jun 20, 2006
AB			**EQ 10MG BASE**	**A077690**	**002**	Jun 20, 2006
AB			**EQ 20MG BASE**	**A077690**	**003**	Jun 20, 2006
AB			**EQ 40MG BASE**	**A077690**	**004**	Jun 20, 2006
AB		MYLAN	**EQ 5MG BASE**	**A076694**	**001**	Dec 23, 2004
AB			**EQ 10MG BASE**	**A076694**	**002**	Dec 23, 2004
AB			**EQ 20MG BASE**	**A076694**	**003**	Dec 23, 2004
AB			**EQ 40MG BASE**	**A076694**	**004**	Dec 23, 2004
AB		PRINSTON INC	**EQ 5MG BASE**	**A205823**	**001**	Sep 15, 2016
AB			**EQ 10MG BASE**	**A205823**	**002**	Sep 15, 2016

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

AB			**EQ 20MG BASE**	**A205823**	**003**	Sep 15, 2016
AB			**EQ 40MG BASE**	**A205823**	**004**	Sep 15, 2016
AB		TEVA	**EQ 5MG BASE**	**A075504**	**001**	Aug 24, 2007
AB			**EQ 10MG BASE**	**A075504**	**002**	Aug 24, 2007
AB			**EQ 20MG BASE**	**A075504**	**003**	Aug 24, 2007
AB			**EQ 40MG BASE**	**A075504**	**004**	Aug 24, 2007

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

BX	!	SUN PHARM INDUSTRIES	324MG	A089338	001	Feb 11, 1987

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

AB		SANDOZ	**200MG**	**A088072**	**002**	
AB			**300MG**	**A088072**	**001**	Sep 26, 1983
AB		SUN PHARM INDUSTRIES	**200MG**	**A081030**	**001**	Apr 14, 1989
AB			**300MG**	**A081031**	**001**	Apr 14, 1989
AB	**!**	WATSON LABS	**200MG**	**A083288**	**001**	
AB	**!**		**300MG**	**A085583**	**001**	

QUININE SULFATE

CAPSULE;ORAL

QUALAQUIN

AB	**+!**	SUN PHARM INDUSTRIES	**324MG**	**N021799**	**001**	Aug 12, 2005

QUININE SULFATE

AB		AMNEAL PHARMS	**324MG**	**A203729**	**001**	Jul 15, 2015
AB		LUPIN LTD	**324MG**	**A203112**	**001**	Apr 24, 2015
AB		MYLAN PHARMS INC	**324MG**	**A202581**	**001**	Dec 14, 2012
AB		NOVAST LABS	**324MG**	**A204372**	**001**	Jul 22, 2015
AB		TEVA PHARMS	**324MG**	**A091661**	**001**	Sep 28, 2012

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE;ORAL

ACIPHEX SPRINKLE

	+	CERECOR INC	5MG	N204736	001	Mar 26, 2013
	+!		10MG	N204736	002	Mar 26, 2013

TABLET, DELAYED RELEASE;ORAL

ACIPHEX

AB	**+!**	EISAI INC	**20MG**	**N020973**	**002**	Aug 19, 1999

RABEPRAZOLE SODIUM

AB		ALKEM LABS LTD	**20MG**	**A208644**	**001**	Apr 24, 2018
AB		AMNEAL PHARMS	**20MG**	**A204179**	**001**	Jul 31, 2015
AB		AUROBINDO PHARMA LTD	**20MG**	**A205761**	**001**	Feb 17, 2017
AB		BRECKENRIDGE PHARM	**20MG**	**A204237**	**001**	Nov 18, 2015
AB		DR REDDYS LABS LTD	**20MG**	**A076824**	**001**	Nov 08, 2013
AB		LANNETT CO INC	**20MG**	**A090678**	**001**	Nov 08, 2013
AB		LUPIN LTD	**20MG**	**A078964**	**001**	Nov 08, 2013
AB		MYLAN PHARMS INC	**20MG**	**A076885**	**001**	Nov 08, 2013
AB		TEVA PHARMS USA	**20MG**	**A076822**	**001**	Nov 08, 2013
AB		TORRENT PHARMS LTD	**20MG**	**A202376**	**001**	Nov 08, 2013

RADIUM RA-223 DICHLORIDE

SOLUTION;INTRAVENOUS

XOFIGO

	+!	BAYER HLTHCARE	162mCi/6ML (27mCi/ML)	N203971	001	May 15, 2013

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

EVISTA

AB	**+!**	LILLY	**60MG**	**N020815**	**001**	Dec 09, 1997

RALOXIFENE HYDROCHLORIDE

AB		AMNEAL PHARMS	**60MG**	**A208206**	**001**	Apr 08, 2016
AB		AUROBINDO PHARMA LTD	**60MG**	**A204310**	**001**	Aug 28, 2015
AB		GLENMARK PHARMS LTD	**60MG**	**A204491**	**001**	Mar 22, 2016
AB		INVAGEN PHARMS	**60MG**	**A090842**	**001**	Sep 24, 2014
AB		SCIEGEN PHARMS INC	**60MG**	**A206384**	**001**	Oct 12, 2016

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

RALOXIFENE HYDROCHLORIDE

AB		TEVA PHARMS USA	**60MG**	**A078193**	**001**	Mar 04, 2014
AB		WATSON LABS INC	**60MG**	**A200825**	**001**	Jan 21, 2015

RALTEGRAVIR POTASSIUM

POWDER;ORAL

ISENTRESS

	+!	MERCK SHARP DOHME	EQ 100MG BASE/PACKET	N205786	001	Dec 20, 2013

TABLET;ORAL

ISENTRESS

	+!	MERCK SHARP DOHME	EQ 400MG BASE	N022145	001	Oct 12, 2007

ISENTRESS HD

	+!	MERCK SHARP DOHME	EQ 600MG BASE	N022145	002	May 26, 2017

TABLET, CHEWABLE;ORAL

ISENTRESS

	+	MERCK SHARP DOHME	EQ 25MG BASE	N203045	001	Dec 21, 2011
	+!		EQ 100MG BASE	N203045	002	Dec 21, 2011

RAMELTEON

TABLET;ORAL

RAMELTEON

AB		ACTAVIS LABS FL INC	**8MG**	**A091610**	**001**	Aug 19, 2015
AB		DR REDDYS LABS SA	**8MG**	**A091693**	**001**	Jul 26, 2013

ROZEREM

AB	**+!**	TAKEDA PHARMS USA	**8MG**	**N021782**	**001**	Jul 22, 2005

RAMIPRIL

CAPSULE;ORAL

ALTACE

AB	+	KING PHARMS LLC	**1.25MG**	**N019901**	**001**	Jan 28, 1991
AB	+		**2.5MG**	**N019901**	**002**	Jan 28, 1991
AB	+		**5MG**	**N019901**	**003**	Jan 28, 1991
AB	+!		**10MG**	**N019901**	**004**	Jan 28, 1991

RAMIPRIL

AB		ACCORD HLTHCARE	**1.25MG**	**A202392**	**001**	Apr 15, 2014
AB			**2.5MG**	**A202392**	**002**	Apr 15, 2014
AB			**5MG**	**A202392**	**003**	Apr 15, 2014
AB			**10MG**	**A202392**	**004**	Apr 15, 2014
AB		APOTEX	**1.25MG**	**A079116**	**001**	Jun 20, 2008
AB			**2.5MG**	**A079116**	**002**	Jun 20, 2008
AB			**5MG**	**A079116**	**003**	Jun 20, 2008
AB			**10MG**	**A079116**	**004**	Jun 20, 2008
AB		AUROBINDO PHARMA LTD	**1.25MG**	**A091604**	**001**	Jun 08, 2011
AB			**2.5MG**	**A091604**	**002**	Jun 08, 2011
AB			**5MG**	**A091604**	**003**	Jun 08, 2011
AB			**10MG**	**A091604**	**004**	Jun 08, 2011
AB		CHARTWELL MOLECULAR	**1.25MG**	**A078745**	**001**	Jun 18, 2008
AB			**2.5MG**	**A078745**	**002**	Jun 18, 2008
AB			**5MG**	**A078745**	**003**	Jun 18, 2008
AB			**10MG**	**A078745**	**004**	Jun 18, 2008
AB		DR REDDYS LABS LTD	**1.25MG**	**A078191**	**001**	Jun 18, 2008
AB			**2.5MG**	**A078191**	**002**	Jun 18, 2008
AB			**5MG**	**A078191**	**003**	Jun 18, 2008
AB			**10MG**	**A078191**	**004**	Jun 18, 2008
AB		LUPIN	**1.25MG**	**A077626**	**001**	Jun 09, 2008
AB			**2.5MG**	**A077626**	**002**	Jun 09, 2008
AB			**5MG**	**A077626**	**003**	Jun 09, 2008
AB			**10MG**	**A077626**	**004**	Jun 09, 2008
AB		TEVA PHARMS	**1.25MG**	**A077470**	**001**	Jun 18, 2008
AB			**2.5MG**	**A077470**	**002**	Jun 18, 2008
AB			**5MG**	**A077470**	**003**	Jun 18, 2008
AB			**10MG**	**A077470**	**004**	Jun 18, 2008
AB		WATSON LABS	**1.25MG**	**A076549**	**001**	Oct 24, 2005
AB			**2.5MG**	**A076549**	**002**	Oct 24, 2005
AB			**10MG**	**A076549**	**004**	Oct 24, 2005
AB		WEST-WARD PHARMS INT	**1.25MG**	**A077900**	**001**	Jun 18, 2008
AB			**2.5MG**	**A077900**	**002**	Jun 18, 2008
AB			**5MG**	**A077900**	**003**	Jun 18, 2008
AB			**10MG**	**A077900**	**004**	Jun 18, 2008
AB		ZYDUS PHARMS USA	**1.25MG**	**A078832**	**001**	Sep 02, 2008

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

AB		**2.5MG**	**A078832**	**002**	Sep 02, 2008
AB		**5MG**	**A078832**	**003**	Sep 02, 2008
AB		**10MG**	**A078832**	**004**	Sep 02, 2008

RANITIDINE

CAPSULE;ORAL

RANITIDINE

AB	NOVITIUM PHARMA	**EQ 150MG BASE**	**A210681**	**001**	Nov 23, 2018
AB		**EQ 300MG BASE**	**A210681**	**002**	Nov 23, 2018

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL

RANITIDINE HYDROCHLORIDE

AB	AJANTA PHARMA LTD	**EQ 150MG BASE**	**A209859**	**001**	Sep 27, 2018
AB		**EQ 300MG BASE**	**A209859**	**002**	Sep 27, 2018
AB	AUROBINDO PHARMA LTD	**EQ 150MG BASE**	**A211058**	**001**	Jul 16, 2018
AB		**EQ 300MG BASE**	**A211058**	**002**	Jul 16, 2018
AB	DR REDDYS LABS LTD	**EQ 150MG BASE**	**A075742**	**001**	Nov 29, 2000
AB		**EQ 300MG BASE**	**A075742**	**002**	Nov 29, 2000
AB	SANDOZ	**EQ 150MG BASE**	**A074655**	**001**	Oct 22, 1997
AB **!**		**EQ 300MG BASE**	**A074655**	**002**	Oct 22, 1997

INJECTABLE;INJECTION

RANITIDINE HYDROCHLORIDE

AP	MYLAN LABS LTD	**EQ 25MG BASE/ML**	**A079076**	**001**	Jun 09, 2016
AP	WEST-WARD PHARMS INT	**EQ 25MG BASE/ML**	**A074777**	**001**	Mar 02, 2005
AP		**EQ 25MG BASE/ML**	**A077458**	**001**	Feb 16, 2006
AP	ZYDUS PHARMS USA INC	**EQ 25MG BASE/ML**	**A091534**	**001**	Feb 22, 2013

ZANTAC

AP **+!**	TELIGENT	**EQ 25MG BASE/ML**	**N019090**	**001**	Oct 19, 1984

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

AA	ACTAVIS MID ATLANTIC	**EQ 15MG BASE/ML**	**A076124**	**001**	Feb 21, 2007
AA	AMNEAL PHARMS	**EQ 15MG BASE/ML**	**A078312**	**001**	Sep 02, 2008
AA	ANDA REPOSITORY	**EQ 15MG BASE/ML**	**A090054**	**001**	Nov 15, 2010
AA	AUROBINDO PHARMA LTD	**EQ 15MG BASE/ML**	**A090623**	**001**	Jul 28, 2010
AA	BIO PHARM INC	**EQ 15MG BASE/ML**	**A090102**	**001**	May 26, 2009
AA	BRECKENRIDGE PHARM	**EQ 15MG BASE/ML**	**A078684**	**001**	Aug 27, 2009
AA	HI TECH PHARMA	**EQ 15MG BASE/ML**	**A091078**	**001**	Mar 22, 2011
AA	LANNETT CO INC	**EQ 15MG BASE/ML**	**A078890**	**001**	Jul 01, 2010
AA		**EQ 15MG BASE/ML**	**A091288**	**001**	Dec 09, 2010
AA	NOSTRUM LABS INC	**EQ 15MG BASE/ML**	**A091091**	**001**	Sep 20, 2011
AA **!**	PHARM ASSOC	**EQ 15MG BASE/ML**	**A077405**	**001**	Sep 21, 2007
AA	TARO	**EQ 15MG BASE/ML**	**A077476**	**001**	Jun 13, 2011

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

AB	ACIC PHARMS	**EQ 150MG BASE**	**A203694**	**001**	Nov 30, 2017
AB		**EQ 300MG BASE**	**A203694**	**002**	Nov 30, 2017
AB	AMNEAL PHARMS NY	**EQ 150MG BASE**	**A077824**	**001**	Oct 13, 2006
AB **!**		**EQ 300MG BASE**	**A077824**	**002**	Oct 13, 2006
AB	APOTEX	**EQ 150MG BASE**	**A074680**	**001**	Sep 12, 1997
AB		**EQ 300MG BASE**	**A074680**	**002**	Sep 12, 1997
AB	DR REDDYS LABS INC	**EQ 150MG BASE**	**A076705**	**001**	Jul 27, 2005
AB		**EQ 300MG BASE**	**A076705**	**002**	Jul 27, 2005
AB	GLENMARK PHARMS INC	**EQ 150MG BASE**	**A078542**	**001**	Nov 19, 2008
AB		**EQ 300MG BASE**	**A078542**	**002**	Nov 19, 2008
AB	IVAX SUB TEVA PHARMS	**EQ 150MG BASE**	**A075165**	**001**	Sep 30, 1998
AB		**EQ 300MG BASE**	**A075165**	**002**	Sep 30, 1998
AB	PAR PHARM	**EQ 150MG BASE**	**A075180**	**001**	Jan 28, 1999
AB		**EQ 300MG BASE**	**A075180**	**002**	Jan 28, 1999
AB	SANDOZ	**EQ 150MG BASE**	**A074467**	**001**	Aug 29, 1997
AB		**EQ 300MG BASE**	**A074467**	**002**	Aug 29, 1997
AB	STRIDES PHARMA	**EQ 150MG BASE**	**A205512**	**001**	Aug 22, 2016
AB		**EQ 300MG BASE**	**A205512**	**002**	Aug 22, 2016
AB	TEVA	**EQ 150MG BASE**	**A074488**	**001**	Jul 31, 1997
AB		**EQ 300MG BASE**	**A074488**	**002**	Jul 31, 1997
AB	VIVIMED GLOBAL	**EQ 150MG BASE**	**A210010**	**001**	Aug 01, 2018

RANITIDINE HYDROCHLORIDE
TABLET;ORAL
RANITIDINE HYDROCHLORIDE

AB			**EQ 300MG BASE**	**A210010**	**002**	Aug 01, 2018
AB		WOCKHARDT LTD	**EQ 150MG BASE**	**A075208**	**001**	Dec 17, 1998
AB			**EQ 300MG BASE**	**A075208**	**002**	Dec 17, 1998

RANOLAZINE
TABLET, EXTENDED RELEASE;ORAL
RANEXA

+	GILEAD	500MG	N021526	002	Jan 27, 2006
+!		1GM	N021526	001	Feb 12, 2007

RASAGILINE MESYLATE
TABLET;ORAL
AZILECT

AB	**+**	TEVA	**EQ 0.5MG BASE**	**N021641**	**001**	May 16, 2006
AB	**+!**		**EQ 1MG BASE**	**N021641**	**002**	May 16, 2006

RASAGILINE MESYLATE

AB		ALKEM LABS LTD	**EQ 0.5MG BASE**	**A201889**	**001**	Oct 30, 2017
AB			**EQ 1MG BASE**	**A201889**	**002**	Oct 30, 2017
AB		MYLAN PHARMS INC	**EQ 0.5MG BASE**	**A201971**	**001**	May 15, 2017
AB			**EQ 1MG BASE**	**A201971**	**002**	May 15, 2017
AB		ORCHID HLTHCARE	**EQ 0.5MG BASE**	**A201970**	**001**	Mar 15, 2016
AB			**EQ 1MG BASE**	**A201970**	**002**	Mar 15, 2016
AB		SANDOZ INC	**EQ 0.5MG BASE**	**A201892**	**001**	Jul 27, 2018
AB			**EQ 1MG BASE**	**A201892**	**002**	Jul 27, 2018
AB		WATSON LABS INC	**EQ 0.5MG BASE**	**A201823**	**001**	Jul 01, 2013
AB			**EQ 1MG BASE**	**A201823**	**002**	Jul 01, 2013

REGADENOSON
SOLUTION;INTRAVENOUS
LEXISCAN

+!	ASTELLAS	0.4MG/5ML (0.08MG/ML)	N022161	001	Apr 10, 2008

REGORAFENIB
TABLET;ORAL
STIVARGA

+!	BAYER HLTHCARE	40MG	N203085	001	Sep 27, 2012

REMIFENTANIL HYDROCHLORIDE
INJECTABLE;INJECTION
REMIFENTANIL HYDROCHLORIDE

AP		FRESENIUS KABI USA	**EQ 1MG BASE/VIAL**	**A206223**	**001**	Jan 16, 2018
AP			**EQ 2MG BASE/VIAL**	**A206223**	**002**	Jan 16, 2018
AP			**EQ 5MG BASE/VIAL**	**A206223**	**003**	Jan 16, 2018

ULTIVA

AP	**+**	MYLAN INSTITUTIONAL	**EQ 1MG BASE/VIAL**	**N020630**	**001**	Jul 12, 1996
AP	**+**		**EQ 2MG BASE/VIAL**	**N020630**	**002**	Jul 12, 1996
AP	**+!**		**EQ 5MG BASE/VIAL**	**N020630**	**003**	Jul 12, 1996

REPAGLINIDE
TABLET;ORAL
PRANDIN

AB	**+**	GEMINI LABS LLC	**0.5MG**	**N020741**	**001**	Dec 22, 1997
AB	**+**		**1MG**	**N020741**	**002**	Dec 22, 1997
AB	**+!**		**2MG**	**N020741**	**003**	Dec 22, 1997

REPAGLINIDE

AB		ACTAVIS TOTOWA	**0.5MG**	**A090008**	**001**	Jan 22, 2014
AB			**1MG**	**A090008**	**002**	Jan 22, 2014
AB			**2MG**	**A090008**	**003**	Jan 22, 2014
AB		AUROBINDO PHARMA LTD	**0.5MG**	**A203820**	**001**	Jan 22, 2014
AB			**1MG**	**A203820**	**002**	Jan 22, 2014
AB			**2MG**	**A203820**	**003**	Jan 22, 2014
AB		BOSCOGEN	**0.5MG**	**A091517**	**001**	Apr 24, 2015
AB			**1MG**	**A091517**	**002**	Apr 24, 2015
AB			**2MG**	**A091517**	**003**	Apr 24, 2015
AB		CASI PHARMS INC	**0.5MG**	**A078555**	**001**	Nov 22, 2013
AB			**1MG**	**A078555**	**002**	Jan 22, 2014
AB			**2MG**	**A078555**	**003**	Jan 22, 2014
AB		MYLAN PHARMS INC	**0.5MG**	**A090252**	**001**	Aug 23, 2013
AB			**1MG**	**A090252**	**002**	Jan 22, 2014
AB			**2MG**	**A090252**	**003**	Jan 22, 2014
AB		PADDOCK LLC	**0.5MG**	**A201189**	**001**	Jul 17, 2013
AB			**1MG**	**A201189**	**002**	Jan 22, 2014

REPAGLINIDE
TABLET;ORAL
REPAGLINIDE

AB			**2MG**	**A201189**	**003**	Jan 22, 2014
AB		SUN PHARM INDS INC	**1MG**	**A077571**	**002**	Jul 11, 2013
AB			**2MG**	**A077571**	**003**	Jul 11, 2013

RETAPAMULIN
OINTMENT;TOPICAL
ALTABAX

	+!	AQUA PHARMS LLC	1%	N022055	001	Apr 12, 2007

REVEFENACIN
SOLUTION;INHALATION
YUPELRI

	+!	MYLAN IRELAND LTD	175MCG/3ML	N210598	001	Nov 09, 2018

RIBAVIRIN
CAPSULE;ORAL
REBETOL

AB	**+!**	MERCK SHARP DOHME	**200MG**	**N020903**	**002**	Jul 25, 2001

RIBASPHERE

AB		KADMON PHARMS LLC	**200MG**	**A076203**	**001**	Apr 06, 2004

RIBAVIRIN

AB		AUROBINDO PHARMA	**200MG**	**A079117**	**001**	Sep 17, 2009
AB		CASI PHARMS INC	**200MG**	**A076192**	**001**	Apr 06, 2004
AB		TEVA	**200MG**	**A076277**	**001**	Oct 04, 2004
AB		ZYDUS PHARMS USA	**200MG**	**A077224**	**001**	Oct 28, 2005

FOR SOLUTION;INHALATION
RIBAVIRIN

AN		NAVINTA LLC	**6GM/VIAL**	**A207366**	**001**	Oct 06, 2016

VIRAZOLE

AN	**+!**	VALEANT PHARM INTL	**6GM/VIAL**	**N018859**	**001**	Dec 31, 1985

SOLUTION;ORAL
REBETOL

	+!	SCHERING	40MG/ML	N021546	001	Jul 29, 2003

TABLET;ORAL
RIBAVIRIN

AB		AUROBINDO PHARMA	**200MG**	**A079111**	**001**	Sep 17, 2009
AB		KADMON PHARMS LLC	**200MG**	**A077456**	**001**	Dec 05, 2005
AB			**400MG**	**A077456**	**002**	Dec 05, 2005
AB	**!**		**600MG**	**A077456**	**003**	Dec 05, 2005
AB		SANDOZ	**200MG**	**A077743**	**001**	Oct 03, 2006
AB		SANDOZ INC	**200MG**	**A202546**	**001**	Aug 12, 2014
AB			**400MG**	**A202546**	**002**	Aug 12, 2014
AB			**500MG**	**A202546**	**003**	Aug 12, 2014
AB			**600MG**	**A202546**	**004**	Aug 12, 2014
AB		TEVA	**200MG**	**A077053**	**001**	Dec 05, 2005
AB		ZYDUS PHARMS USA	**200MG**	**A077094**	**001**	Dec 05, 2005
AB			**400MG**	**A077094**	**002**	Mar 16, 2007
AB			**500MG**	**A077094**	**004**	Apr 18, 2008
AB			**600MG**	**A077094**	**003**	Mar 16, 2007

RIBOCICLIB SUCCINATE
TABLET;ORAL
KISQALI

	+!	NOVARTIS PHARMS CORP	EQ 200MG BASE	N209092	001	Mar 13, 2017

RIBOFLAVIN 5'-PHOSPHATE SODIUM
SOLUTION/DROPS;OPHTHALMIC
PHOTREXA

	+!	AVEDRO INC	0.146%	N203324	001	Apr 15, 2016

PHOTREXA VISCOUS IN DEXTRAN 20%

	+!	AVEDRO INC	0.146%	N203324	002	Apr 15, 2016

RIFABUTIN
CAPSULE;ORAL
MYCOBUTIN

AB	**+!**	PHARMACIA AND UPJOHN	**150MG**	**N050689**	**001**	Dec 23, 1992

RIFABUTIN

AB		LUPIN LTD	**150MG**	**A090033**	**001**	Feb 24, 2014

RIFAMPIN

CAPSULE;ORAL

RIFADIN						
AB		SANOFI AVENTIS US	**150MG**	**A062303**	**001**	
AB	**+!**		**300MG**	**N050420**	**001**	
RIFAMPIN						
AB		AKORN	**150MG**	**A065028**	**001**	Mar 14, 2001
AB			**300MG**	**A065028**	**002**	Mar 14, 2001
AB		LANNETT CO INC	**150MG**	**A065390**	**001**	Mar 28, 2008
AB			**300MG**	**A065390**	**002**	Mar 28, 2008
AB		LUPIN PHARMS	**150MG**	**A090034**	**001**	Aug 21, 2013
AB			**300MG**	**A090034**	**002**	Aug 21, 2013
AB		SANDOZ	**150MG**	**A064150**	**002**	Jan 02, 1998
AB			**300MG**	**A064150**	**001**	May 28, 1997
RIMACTANE						
AB		OXFORD PHARMS	**300MG**	**N050429**	**001**	

INJECTABLE;INJECTION

RIFADIN						
AP	**+!**	SANOFI AVENTIS US	**600MG/VIAL**	**N050627**	**001**	May 25, 1989
RIFAMPIN						
AP		AKORN	**600MG/VIAL**	**A065502**	**001**	Sep 21, 2010
AP		EMCURE PHARMS LTD	**600MG/VIAL**	**A204101**	**001**	Aug 18, 2014
AP		FRESENIUS KABI USA	**600MG/VIAL**	**A091181**	**001**	Aug 21, 2014
AP		HIKMA PHARMS	**600MG/VIAL**	**A205039**	**001**	Mar 03, 2016
AP		MYLAN LABS LTD	**600MG/VIAL**	**A065421**	**001**	May 22, 2008
AP		WATSON PHARMS TEVA	**600MG/VIAL**	**A206736**	**001**	Jan 19, 2016
AP		WEST-WARD PHARMS INT	**600MG/VIAL**	**A064217**	**001**	Oct 29, 1999

RIFAMYCIN

TABLET, DELAYED RELEASE;ORAL

AEMCOLO						
	+!	COSMO TECHNOLOGIES	194MG	N210910	001	Nov 16, 2018

RIFAPENTINE

TABLET;ORAL

PRIFTIN						
	+!	SANOFI AVENTIS US	150MG	N021024	001	Jun 22, 1998

RIFAXIMIN

TABLET;ORAL

XIFAXAN						
	+!	SALIX PHARMS	200MG	N021361	001	May 25, 2004
	+!		550MG	N022554	001	Mar 24, 2010

RILPIVIRINE HYDROCHLORIDE

TABLET;ORAL

EDURANT						
	+!	JANSSEN PRODS	EQ 25MG BASE	N202022	001	May 20, 2011

RILUZOLE

SUSPENSION;ORAL

TIGLUTIK KIT						
	+!	ITALFARMACO SPA	50MG/10ML	N209080	001	Sep 05, 2018

TABLET;ORAL

RILUTEK						
AB	**+!**	COVIS PHARMA BV	**50MG**	**N020599**	**001**	Dec 12, 1995
RILUZOLE						
AB		ALKEM LABS LTD	**50MG**	**A204048**	**001**	Mar 30, 2016
AB		APOTEX CORP	**50MG**	**A091300**	**001**	Jun 18, 2013
AB		DAITO PHARMS CO LTD	**50MG**	**A204430**	**001**	Oct 16, 2018
AB		GLENMARK PHARMS LTD	**50MG**	**A091394**	**001**	Jun 18, 2013
AB		IMPAX LABS	**50MG**	**A076173**	**001**	Jan 29, 2003
AB		MYLAN PHARMS INC	**50MG**	**A203042**	**001**	Jul 01, 2013
AB		SUN PHARM INDS LTD	**50MG**	**A091417**	**001**	Jun 18, 2013

RIMANTADINE HYDROCHLORIDE

TABLET;ORAL

FLUMADINE						
AB	**+!**	SUN PHARM INDS INC	**100MG**	**N019649**	**001**	Sep 17, 1993
RIMANTADINE HYDROCHLORIDE						
AB		IMPAX LABS	**100MG**	**A076132**	**001**	Aug 30, 2002

RIOCIGUAT

TABLET;ORAL

ADEMPAS

	+	BAYER HLTHCARE	0.5MG	N204819	001	Oct 08, 2013
	+		1MG	N204819	002	Oct 08, 2013
	+		1.5MG	N204819	003	Oct 08, 2013
	+		2MG	N204819	004	Oct 08, 2013
	+!		2.5MG	N204819	005	Oct 08, 2013

RISEDRONATE SODIUM

TABLET;ORAL

ACTONEL

AB	**+**	APIL	**5MG**	**N020835**	**002**	Apr 14, 2000
AB	**+**		**30MG**	**N020835**	**001**	Mar 27, 1998
AB	**+!**		**35MG**	**N020835**	**003**	May 25, 2002
AB	**+!**		**150MG**	**N020835**	**005**	Apr 22, 2008

RISEDRONATE SODIUM

AB		APOTEX INC	**35MG**	**A090877**	**001**	Nov 30, 2015
AB			**75MG**	**A090877**	**002**	Jun 10, 2014
AB			**150MG**	**A090877**	**003**	Jun 10, 2014
AB		AUROBINDO PHARMA LTD	**5MG**	**A200296**	**001**	Nov 30, 2015
AB			**30MG**	**A200296**	**002**	Nov 30, 2015
AB			**35MG**	**A200296**	**003**	Nov 30, 2015
AB			**150MG**	**A206768**	**001**	Oct 21, 2016
AB		MACLEODS PHARMS LTD	**5MG**	**A203533**	**001**	Dec 09, 2015
AB			**30MG**	**A203533**	**002**	Dec 09, 2015
AB			**35MG**	**A203533**	**003**	Nov 29, 2016
AB		MYLAN PHARMS INC	**5MG**	**A200477**	**001**	Nov 30, 2015
AB			**30MG**	**A200477**	**002**	Nov 30, 2015
AB			**35MG**	**A200477**	**003**	Nov 30, 2015
AB			**75MG**	**A200477**	**004**	Jun 10, 2014
AB			**150MG**	**A200477**	**005**	Jun 10, 2014
AB		SUN PHARMA GLOBAL	**5MG**	**A090886**	**001**	Nov 30, 2015
AB			**30MG**	**A090886**	**002**	Nov 30, 2015
AB			**35MG**	**A090886**	**003**	Nov 30, 2015
AB			**75MG**	**A090886**	**004**	Jun 10, 2014
AB			**150MG**	**A090886**	**005**	Jun 10, 2014
AB		TEVA PHARMS USA	**5MG**	**A077132**	**001**	Oct 05, 2007
AB			**30MG**	**A077132**	**002**	Oct 05, 2007
AB			**35MG**	**A077132**	**003**	Oct 05, 2007
AB			**150MG**	**A079215**	**001**	Jun 13, 2014

TABLET, DELAYED RELEASE;ORAL

ATELVIA

AB	**+!**	APIL	**35MG**	**N022560**	**001**	Oct 08, 2010

RISEDRONATE SODIUM

AB		TEVA PHARMS USA	**35MG**	**A203217**	**001**	May 18, 2015
AB		ZYDUS PHARMS USA INC	**35MG**	**A203822**	**001**	Sep 11, 2018

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

PERSERIS KIT

	+	INDIVIOR INC	90MG	N210655	001	Jul 27, 2018
	+!		120MG	N210655	002	Jul 27, 2018

INJECTABLE;INTRAMUSCULAR

RISPERDAL CONSTA

	+	JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007
	+!		25MG/VIAL	N021346	001	Oct 29, 2003
	+		37.5MG/VIAL	N021346	002	Oct 29, 2003
	+		50MG/VIAL	N021346	003	Oct 29, 2003

SOLUTION;ORAL

RISPERDAL

AA	**+!**	JANSSEN PHARMS	**1MG/ML**	**N020588**	**001**	Jun 10, 1996

RISPERIDONE

AA		AMNEAL PHARMS	**1MG/ML**	**A091384**	**001**	May 25, 2011
AA		ANI PHARMS INC	**1MG/ML**	**A076440**	**001**	Jan 30, 2009
AA		APOTEX INC	**1MG/ML**	**A077719**	**001**	Jul 29, 2009
AA		AUROBINDO PHARMA LTD	**1MG/ML**	**A078452**	**001**	Sep 04, 2009
AA		BIO PHARM INC	**1MG/ML**	**A078909**	**001**	Jul 29, 2009
AA		LANNETT CO INC	**1MG/ML**	**A079158**	**001**	Dec 03, 2010
AA		TARO	**1MG/ML**	**A090347**	**001**	Feb 07, 2011
AA		TRIS PHARMA INC	**1MG/ML**	**A079059**	**001**	Dec 12, 2012

RISPERIDONE

SOLUTION;ORAL

RISPERIDONE

AA		WEST-WARD PHARMS INT	**1MG/ML**	**A076904**	**001**	Jul 29, 2009

TABLET;ORAL

RISPERDAL

AB	+	JANSSEN PHARMS	**0.25MG**	**N020272**	**008**	May 10, 1999
AB	+		**0.5MG**	**N020272**	**007**	Jan 27, 1999
AB	+!		**1MG**	**N020272**	**001**	Dec 29, 1993
AB	+		**2MG**	**N020272**	**002**	Dec 29, 1993
AB	+		**3MG**	**N020272**	**003**	Dec 29, 1993
AB	+		**4MG**	**N020272**	**004**	Dec 29, 1993

RISPERIDONE

AB		AJANTA PHARMA LTD	**0.25MG**	**A201003**	**001**	Aug 24, 2011
AB			**0.5MG**	**A201003**	**002**	Aug 24, 2011
AB			**1MG**	**A201003**	**003**	Aug 24, 2011
AB			**2MG**	**A201003**	**004**	Aug 24, 2011
AB			**3MG**	**A201003**	**005**	Aug 24, 2011
AB			**4MG**	**A201003**	**006**	Aug 24, 2011
AB		APOTEX INC	**0.25MG**	**A077953**	**001**	Sep 15, 2008
AB			**0.5MG**	**A077953**	**002**	Sep 15, 2008
AB			**1MG**	**A077953**	**003**	Sep 15, 2008
AB			**2MG**	**A077953**	**004**	Sep 15, 2008
AB			**3MG**	**A077953**	**005**	Sep 15, 2008
AB			**4MG**	**A077953**	**006**	Sep 15, 2008
AB		CEYONE	**0.25MG**	**A078269**	**001**	Oct 08, 2008
AB			**0.5MG**	**A078269**	**002**	Oct 08, 2008
AB			**1MG**	**A078269**	**003**	Oct 08, 2008
AB			**2MG**	**A078269**	**004**	Oct 08, 2008
AB			**3MG**	**A078269**	**005**	Oct 08, 2008
AB			**4MG**	**A078269**	**006**	Oct 08, 2008
AB		CHARTWELL MOLECULAR	**0.25MG**	**A077543**	**001**	May 18, 2011
AB			**0.5MG**	**A077543**	**002**	May 18, 2011
AB			**1MG**	**A077543**	**003**	May 18, 2011
AB			**2MG**	**A077543**	**004**	May 18, 2011
AB			**3MG**	**A077543**	**005**	May 18, 2011
AB			**4MG**	**A077543**	**006**	May 18, 2011
AB		DR REDDYS LABS LTD	**0.25MG**	**A076879**	**001**	Oct 24, 2008
AB			**0.5MG**	**A076879**	**002**	Oct 24, 2008
AB			**1MG**	**A076879**	**003**	Oct 24, 2008
AB			**2MG**	**A076879**	**004**	Oct 24, 2008
AB			**3MG**	**A076879**	**005**	Oct 24, 2008
AB			**4MG**	**A076879**	**006**	Oct 24, 2008
AB		MYLAN	**0.25MG**	**A076288**	**001**	Sep 15, 2008
AB			**0.5MG**	**A076288**	**002**	Sep 15, 2008
AB			**1MG**	**A076288**	**003**	Sep 15, 2008
AB			**2MG**	**A076288**	**004**	Sep 15, 2008
AB			**3MG**	**A076288**	**005**	Sep 15, 2008
AB			**4MG**	**A076288**	**006**	Sep 15, 2008
AB		OXFORD PHARMS	**0.25MG**	**A078071**	**001**	Jun 17, 2009
AB			**0.5MG**	**A078071**	**002**	Jun 17, 2009
AB			**1MG**	**A078071**	**003**	Jun 17, 2009
AB			**2MG**	**A078071**	**004**	Jun 17, 2009
AB			**3MG**	**A078071**	**005**	Jun 17, 2009
AB			**4MG**	**A078071**	**006**	Jun 17, 2009
AB		PLIVA HRVATSKA DOO	**0.25MG**	**A077769**	**001**	Oct 16, 2008
AB			**0.5MG**	**A077769**	**002**	Oct 16, 2008
AB			**1MG**	**A077769**	**003**	Oct 16, 2008
AB			**2MG**	**A077769**	**004**	Oct 16, 2008
AB			**3MG**	**A077769**	**005**	Oct 16, 2008
AB			**4MG**	**A077769**	**006**	Oct 16, 2008
AB		PRINSTON INC	**0.25MG**	**A077493**	**001**	Nov 29, 2011
AB			**0.5MG**	**A077493**	**002**	Nov 29, 2011
AB			**1MG**	**A077493**	**003**	Nov 29, 2011
AB			**2MG**	**A077493**	**004**	Nov 29, 2011
AB			**3MG**	**A077493**	**005**	Nov 29, 2011
AB			**4MG**	**A077493**	**006**	Nov 29, 2011
AB		RENATA	**0.25MG**	**A078707**	**001**	Dec 29, 2008
AB			**0.5MG**	**A078707**	**002**	Dec 29, 2008
AB			**1MG**	**A078707**	**003**	Dec 29, 2008
AB			**2MG**	**A078707**	**004**	Dec 29, 2008
AB			**3MG**	**A078707**	**005**	Dec 29, 2008

RISPERIDONE

TABLET;ORAL

RISPERIDONE

AB			4MG	A078707	006	Dec 29, 2008
AB		SANDOZ	0.25MG	A078528	001	Oct 16, 2009
AB			0.5MG	A078528	002	Oct 16, 2009
AB			1MG	A078528	003	Oct 16, 2009
AB			2MG	A078528	004	Oct 16, 2009
AB			3MG	A078528	005	Oct 16, 2009
AB			4MG	A078528	006	Oct 16, 2009
AB		SUN PHARM INDS INC	0.25MG	A078036	001	Mar 10, 2014
AB			0.5MG	A078036	002	Mar 10, 2014
AB			1MG	A078036	003	Mar 10, 2014
AB			2MG	A078036	004	Mar 10, 2014
AB			3MG	A078036	005	Mar 10, 2014
AB			4MG	A078036	006	Mar 10, 2014
AB		TEVA	0.25MG	A076228	001	Jun 30, 2008
AB			0.5MG	A076228	002	Jun 30, 2008
AB			1MG	A076228	003	Jun 30, 2008
AB			2MG	A076228	004	Jun 30, 2008
AB			3MG	A076228	005	Jun 30, 2008
AB			4MG	A076228	006	Jun 30, 2008
AB		TORRENT PHARMS	0.25MG	A079088	001	Oct 30, 2008
AB			0.5MG	A079088	002	Oct 30, 2008
AB			1MG	A079088	003	Oct 30, 2008
AB			2MG	A079088	004	Oct 30, 2008
AB			3MG	A079088	005	Oct 30, 2008
AB			4MG	A079088	006	Oct 30, 2008
AB		WOCKHARDT	0.25MG	A078871	001	Oct 09, 2008
AB			0.5MG	A078871	002	Oct 09, 2008
AB			1MG	A078871	003	Oct 09, 2008
AB			2MG	A078871	004	Oct 09, 2008
AB			3MG	A078871	005	Oct 09, 2008
AB			4MG	A078871	006	Oct 09, 2008
AB		ZYDUS PHARMS USA INC	0.25MG	A078040	001	Oct 16, 2008
AB			0.5MG	A078040	002	Oct 16, 2008
AB			1MG	A078040	003	Oct 16, 2008
AB			2MG	A078040	004	Oct 16, 2008
AB			3MG	A078040	005	Oct 16, 2008
AB			4MG	A078040	006	Oct 16, 2008

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERDAL

AB	+	JANSSEN PHARMS	0.5MG	N021444	001	Apr 02, 2003
AB	+!		1MG	N021444	002	Apr 02, 2003
AB	+		2MG	N021444	003	Apr 02, 2003
AB	+		3MG	N021444	004	Dec 23, 2004
AB	+		4MG	N021444	005	Dec 23, 2004

RISPERIDONE

AB		ACTAVIS LABS FL INC	0.5MG	A076996	001	Apr 19, 2011
AB			1MG	A076996	002	Apr 19, 2011
AB			2MG	A076996	003	Apr 19, 2011
AB			3MG	A076996	004	Apr 19, 2011
AB			4MG	A076996	005	Apr 19, 2011
AB		DR REDDYS LABS LTD	0.5MG	A077328	001	Feb 24, 2009
AB			1MG	A077328	002	Oct 05, 2009
AB			2MG	A077328	003	Feb 24, 2009
AB			3MG	A077328	004	Nov 30, 2009
AB			4MG	A077328	005	Nov 30, 2009
AB		JUBILANT GENERICS	0.5MG	A090839	001	Nov 04, 2011
AB			1MG	A090839	002	Nov 04, 2011
AB			2MG	A090839	003	Nov 04, 2011
AB			3MG	A090839	004	Nov 04, 2011
AB			4MG	A090839	005	Nov 04, 2011
AB		PAR PHARM	0.5MG	A077494	002	Apr 30, 2009
AB			1MG	A077494	003	Oct 26, 2009
AB			2MG	A077494	004	Apr 30, 2009
AB			3MG	A077494	005	Apr 30, 2009
AB			4MG	A077494	006	Apr 30, 2009
AB		SANDOZ	0.5MG	A078116	001	Dec 22, 2009
AB			1MG	A078116	002	Dec 22, 2009
AB			2MG	A078116	003	Dec 22, 2009
AB			3MG	A078116	004	Dec 22, 2009

RISPERIDONE
TABLET, ORALLY DISINTEGRATING;ORAL
RISPERIDONE

AB			**4MG**	**A078116**	**005**	Dec 22, 2009
AB		SUN PHARM INDS LTD	**0.5MG**	**A077542**	**001**	Aug 06, 2010
AB			**0.5MG**	**A078464**	**001**	Apr 08, 2013
AB			**1MG**	**A077542**	**002**	Aug 06, 2010
AB			**1MG**	**A078464**	**002**	Apr 08, 2013
AB			**2MG**	**A077542**	**003**	Aug 06, 2010
AB			**2MG**	**A078464**	**003**	Apr 08, 2013
AB			**3MG**	**A078464**	**004**	Apr 08, 2013
AB			**3MG**	**A078474**	**001**	Aug 06, 2010
AB			**4MG**	**A078464**	**005**	Apr 08, 2013
AB			**4MG**	**A078474**	**002**	Aug 06, 2010
AB		TEVA	**0.5MG**	**A076908**	**001**	Mar 12, 2012
AB			**1MG**	**A076908**	**002**	Mar 12, 2012
AB			**2MG**	**A076908**	**003**	Mar 12, 2012
AB		ZYDUS PHARMS USA	**0.5MG**	**A078516**	**001**	May 01, 2009
AB			**2MG**	**A078516**	**003**	May 01, 2009
		PAR PHARM	0.25MG	A077494	001	Apr 30, 2009

RITONAVIR
POWDER;ORAL
NORVIR

+!	ABBVIE INC	100MG/PACKET	N209512	001	Jun 07, 2017

SOLUTION;ORAL
NORVIR

+!	ABBVIE	80MG/ML	N020659	001	Mar 01, 1996

TABLET;ORAL
NORVIR

AB	**+!**	ABBVIE	**100MG**	**N022417**	**001**	Feb 10, 2010

RITONAVIR

AB		AMNEAL PHARMS LLC	**100MG**	**A208890**	**001**	Sep 17, 2018
AB		AUROBINDO PHARMA LTD	**100MG**	**A206614**	**001**	Sep 17, 2018
AB		HETERO LABS LTD III	**100MG**	**A204587**	**001**	Sep 17, 2018
AB		WEST-WARD PHARMS INT	**100MG**	**A202573**	**001**	Jan 15, 2015

RIVAROXABAN
TABLET;ORAL
XARELTO

+	JANSSEN PHARMS	2.5MG	N022406	004	Oct 11, 2018
+		10MG	N022406	001	Jul 01, 2011
+		15MG	N022406	002	Nov 04, 2011
+!		20MG	N022406	003	Nov 04, 2011

RIVASTIGMINE
FILM, EXTENDED RELEASE;TRANSDERMAL
EXELON

AB	**+**	NOVARTIS	**4.6MG/24HR**	**N022083**	**001**	Jul 06, 2007
AB	**+!**		**9.5MG/24HR**	**N022083**	**002**	Jul 06, 2007
AB	**+**		**13.3MG/24HR**	**N022083**	**005**	Aug 31, 2012

RIVASTIGMINE

AB		ALVOGEN MALTA	**4.6MG/24HR**	**A204403**	**001**	Sep 03, 2015
AB			**9.5MG/24HR**	**A204403**	**002**	Sep 03, 2015
AB			**13.3MG/24HR**	**A204403**	**003**	Aug 31, 2015
AB		AMNEAL PHARMS	**4.6MG/24HR**	**A207308**	**001**	Jan 08, 2019
AB			**9.5MG/24HR**	**A207308**	**002**	Jan 08, 2019
AB			**13.3MG/24HR**	**A207308**	**003**	Jan 08, 2019
AB		MYLAN TECHNOLOGIES	**4.6MG/24HR**	**A205622**	**001**	Jun 20, 2018
AB			**9.5MG/24HR**	**A205622**	**002**	Jun 20, 2018
AB			**13.3MG/24HR**	**A205622**	**003**	Jun 20, 2018

RIVASTIGMINE TARTRATE
CAPSULE;ORAL
EXELON

AB	**+!**	NOVARTIS	**EQ 1.5MG BASE**	**N020823**	**003**	Apr 21, 2000
AB	**+**		**EQ 3MG BASE**	**N020823**	**004**	Apr 21, 2000
AB	**+**		**EQ 4.5MG BASE**	**N020823**	**005**	Apr 21, 2000
AB	**+!**		**EQ 6MG BASE**	**N020823**	**006**	Apr 21, 2000

RIVASTIGMINE TARTRATE

AB		ALEMBIC PHARMS LTD	**EQ 1.5MG BASE**	**A091689**	**001**	Jun 12, 2012
AB			**EQ 3MG BASE**	**A091689**	**002**	Jun 12, 2012
AB			**EQ 4.5MG BASE**	**A091689**	**003**	Jun 12, 2012

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

AB		**EQ 6MG BASE**	**A091689**	**004**	Jun 12, 2012
AB	APOTEX INC	**EQ 1.5MG BASE**	**A091072**	**001**	May 16, 2013
AB		**EQ 3MG BASE**	**A091072**	**002**	May 16, 2013
AB		**EQ 4.5MG BASE**	**A091072**	**003**	May 16, 2013
AB		**EQ 6MG BASE**	**A091072**	**004**	May 16, 2013
AB	AUROBINDO PHARMA LTD	**EQ 1.5MG BASE**	**A204572**	**001**	Mar 25, 2016
AB		**EQ 3MG BASE**	**A204572**	**002**	Mar 25, 2016
AB		**EQ 4.5MG BASE**	**A204572**	**003**	Mar 25, 2016
AB		**EQ 6MG BASE**	**A204572**	**004**	Mar 25, 2016
AB	CADILA PHARMS LTD	**EQ 1.5MG BASE**	**A203844**	**001**	Feb 13, 2017
AB		**EQ 3MG BASE**	**A203844**	**002**	Feb 13, 2017
AB		**EQ 4.5MG BASE**	**A203844**	**003**	Feb 13, 2017
AB		**EQ 6MG BASE**	**A203844**	**004**	Feb 13, 2017
AB	CHARTWELL RX	**EQ 1.5MG BASE**	**A207797**	**001**	Sep 28, 2017
AB		**EQ 3MG BASE**	**A207797**	**002**	Sep 28, 2017
AB		**EQ 4.5MG BASE**	**A207797**	**003**	Sep 28, 2017
AB		**EQ 6MG BASE**	**A207797**	**004**	Sep 28, 2017
AB	DR REDDYS LABS INC	**EQ 1.5MG BASE**	**A077130**	**001**	Oct 31, 2007
AB		**EQ 3MG BASE**	**A077130**	**002**	Oct 31, 2007
AB		**EQ 4.5MG BASE**	**A077130**	**003**	Oct 31, 2007
AB		**EQ 6MG BASE**	**A077130**	**004**	Oct 31, 2007
AB	MACLEODS PHARMS LTD	**EQ 1.5MG BASE**	**A203148**	**001**	Aug 22, 2014
AB		**EQ 3MG BASE**	**A203148**	**002**	Aug 22, 2014
AB		**EQ 4.5MG BASE**	**A203148**	**003**	Aug 22, 2014
AB		**EQ 6MG BASE**	**A203148**	**004**	Aug 22, 2014
AB	ORCHID HLTHCARE	**EQ 1.5MG BASE**	**A090879**	**001**	Jun 10, 2015
AB		**EQ 3MG BASE**	**A090879**	**002**	Jun 10, 2015
AB		**EQ 4.5MG BASE**	**A090879**	**003**	Jun 10, 2015
AB		**EQ 6MG BASE**	**A090879**	**004**	Jun 10, 2015
AB	SUN PHARM INDS LTD	**EQ 1.5MG BASE**	**A077131**	**001**	Oct 22, 2007
AB		**EQ 3MG BASE**	**A077131**	**002**	Oct 22, 2007
AB		**EQ 4.5MG BASE**	**A077131**	**003**	Oct 22, 2007
AB		**EQ 6MG BASE**	**A077131**	**004**	Oct 22, 2007
AB	WATSON LABS	**EQ 1.5MG BASE**	**A077129**	**001**	Jan 08, 2008
AB		**EQ 3MG BASE**	**A077129**	**002**	Jan 08, 2008
AB		**EQ 4.5MG BASE**	**A077129**	**003**	Jan 08, 2008
AB		**EQ 6MG BASE**	**A077129**	**004**	Jan 08, 2008

RIZATRIPTAN BENZOATE

TABLET;ORAL

MAXALT

AB	**+!** MERCK	**EQ 10MG BASE**	**N020864**	**002**	Jun 29, 1998

RIZATRIPTAN BENZOATE

AB	ALKEM LABS LTD	**EQ 5MG BASE**	**A203269**	**001**	Feb 18, 2016
AB		**EQ 10MG BASE**	**A203269**	**002**	Feb 18, 2016
AB	AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A202490**	**001**	Dec 31, 2012
AB		**EQ 10MG BASE**	**A202490**	**002**	Dec 31, 2012
AB	CELLTRION	**EQ 5MG BASE**	**A077526**	**001**	Mar 26, 2013
AB		**EQ 10MG BASE**	**A077526**	**002**	Mar 26, 2013
AB	ECI PHARMS LLC	**EQ 5MG BASE**	**A202047**	**001**	Dec 31, 2012
AB		**EQ 10MG BASE**	**A202047**	**002**	Dec 31, 2012
AB	EMCURE PHARMS LTD	**EQ 5MG BASE**	**A204090**	**001**	Nov 26, 2013
AB		**EQ 10MG BASE**	**A204090**	**002**	Nov 26, 2013
AB	GLENMARK GENERICS	**EQ 5MG BASE**	**A201967**	**001**	Dec 31, 2012
AB		**EQ 10MG BASE**	**A201967**	**002**	Dec 31, 2012
AB	INVAGEN PHARMS	**EQ 5MG BASE**	**A204339**	**001**	Jul 01, 2013
AB		**EQ 10MG BASE**	**A204339**	**002**	Jul 01, 2013
AB	JUBILANT GENERICS	**EQ 5MG BASE**	**A203252**	**001**	Dec 31, 2014
AB		**EQ 10MG BASE**	**A203252**	**002**	Dec 31, 2014
AB	MACLEODS PHARMS LTD	**EQ 5MG BASE**	**A203147**	**001**	Feb 11, 2014
AB		**EQ 10MG BASE**	**A203147**	**002**	Feb 11, 2014
AB	MYLAN PHARMS INC	**EQ 5MG BASE**	**A201993**	**001**	Dec 31, 2012
AB		**EQ 10MG BASE**	**A201993**	**002**	Dec 31, 2012
AB	NATCO PHARMA LTD	**EQ 5MG BASE**	**A200482**	**001**	Dec 31, 2012
AB		**EQ 10MG BASE**	**A200482**	**002**	Dec 31, 2012
AB	SANDOZ	**EQ 5MG BASE**	**A079230**	**001**	Dec 31, 2012
AB		**EQ 10MG BASE**	**A079230**	**002**	Dec 31, 2012
AB	TEVA PHARMS	**EQ 5MG BASE**	**A077263**	**001**	Dec 31, 2012

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

AB			**EQ 10MG BASE**	**A077263**	**002**	Dec 31, 2012
AB		UNICHEM LABS LTD	**EQ 5MG BASE**	**A207836**	**001**	Mar 07, 2017
AB			**EQ 10MG BASE**	**A207836**	**002**	Mar 07, 2017

TABLET, ORALLY DISINTEGRATING;ORAL

MAXALT-MLT

AB	**+!**	MERCK	**EQ 10MG BASE**	**N020865**	**002**	Jun 29, 1998

RIZATRIPTAN BENZOATE

AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A203062**	**001**	Jul 01, 2013
AB			**EQ 10MG BASE**	**A203062**	**002**	Jul 01, 2013
AB		GLENMARK PHARMS LTD	**EQ 5MG BASE**	**A201914**	**001**	Jul 01, 2013
AB			**EQ 10MG BASE**	**A201914**	**002**	Jul 01, 2013
AB		JUBILANT GENERICS	**EQ 5MG BASE**	**A203334**	**001**	Oct 16, 2015
AB			**EQ 10MG BASE**	**A203334**	**002**	Oct 16, 2015
AB		MACLEODS PHARMS LTD	**EQ 5MG BASE**	**A203146**	**001**	Sep 19, 2014
AB			**EQ 10MG BASE**	**A203146**	**002**	Sep 19, 2014
AB		MYLAN PHARMS INC	**EQ 5MG BASE**	**A078173**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A078173**	**002**	Dec 31, 2012
AB		NATCO PHARMA LTD	**EQ 5MG BASE**	**A203478**	**001**	Jul 01, 2013
AB			**EQ 10MG BASE**	**A203478**	**002**	Jul 01, 2013
AB		PANACEA BIOTEC LTD	**EQ 5MG BASE**	**A204722**	**001**	Jan 11, 2017
AB			**EQ 10MG BASE**	**A204722**	**002**	Jan 11, 2017
AB		SANDOZ	**EQ 5MG BASE**	**A078739**	**001**	Jul 01, 2013
AB			**EQ 10MG BASE**	**A078739**	**002**	Jul 01, 2013
AB		UNICHEM LABS LTD	**EQ 5MG BASE**	**A207835**	**001**	Mar 07, 2017
AB			**EQ 10MG BASE**	**A207835**	**002**	Mar 07, 2017

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

AP		AUROBINDO PHARMA LTD	**50MG/5ML (10MG/ML)**	**A206206**	**001**	Apr 12, 2017
AP			**100MG/10ML (10MG/ML)**	**A206206**	**002**	Apr 12, 2017
AP		FRESENIUS KABI USA	**50MG/5ML (10MG/ML)**	**A078651**	**001**	Dec 29, 2008
AP			**100MG/10ML (10MG/ML)**	**A078651**	**002**	Dec 29, 2008
AP		GLAND PHARMA LTD	**50MG/5ML (10MG/ML)**	**A205656**	**001**	Apr 04, 2018
AP			**100MG/10ML (10MG/ML)**	**A205656**	**002**	Apr 04, 2018
AP		HOSPIRA	**50MG/5ML (10MG/ML)**	**A078519**	**001**	Nov 26, 2008
AP			**100MG/10ML (10MG/ML)**	**A078519**	**002**	Nov 26, 2008
AP		MYLAN INSTITUTIONAL	**50MG/5ML (10MG/ML)**	**A079199**	**001**	Nov 26, 2008
AP			**100MG/10ML (10MG/ML)**	**A079199**	**002**	Nov 26, 2008
AP		SAGENT PHARMS	**50MG/5ML (10MG/ML)**	**A091458**	**001**	Jul 28, 2010
AP			**100MG/10ML (10MG/ML)**	**A091458**	**002**	Jul 28, 2010
AP	**!**	SANDOZ INC	**50MG/5ML (10MG/ML)**	**A079195**	**001**	Dec 05, 2008
AP	**!**		**100MG/10ML (10MG/ML)**	**A079195**	**002**	Dec 05, 2008
AP		TAMARANG	**50MG/5ML (10MG/ML)**	**A091115**	**001**	Aug 27, 2012
AP			**100MG/10ML (10MG/ML)**	**A091115**	**002**	Aug 27, 2012
AP		TEVA PHARMS	**50MG/5ML (10MG/ML)**	**A078717**	**001**	Nov 26, 2008
AP			**100MG/10ML (10MG/ML)**	**A078717**	**002**	Nov 26, 2008
AP		WEST WARD PHARM CORP	**50MG/5ML (10MG/ML)**	**A204679**	**001**	Feb 28, 2017
AP			**100MG/10ML (10MG/ML)**	**A204679**	**002**	Feb 28, 2017

ROFLUMILAST

TABLET;ORAL

DALIRESP

AB	**+!**	ASTRAZENECA PHARMS	**500MCG**	**N022522**	**001**	Feb 28, 2011

ROFLUMILAST

AB		BRECKENRIDGE PHARM	**500MCG**	**A208236**	**001**	Oct 03, 2018
AB		HETERO LABS LTD III	**500MCG**	**A208213**	**001**	Nov 23, 2018
AB		TORRENT PHARMS LTD	**500MCG**	**A208272**	**001**	Aug 06, 2018

DALIRESP

	+	ASTRAZENECA PHARMS	250MCG	N022522	002	Jan 23, 2018

ROLAPITANT HYDROCHLORIDE

TABLET;ORAL

VARUBI

	+!	TERSERA THERAPS LLC	EQ 90MG BASE	N206500	001	Sep 01, 2015

ROMIDEPSIN

POWDER;INTRAVENOUS

ISTODAX

	+!	CELGENE	10MG/VIAL	N022393	001	Nov 05, 2009

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

REQUIP

AB	**+!**	GLAXOSMITHKLINE LLC	**EQ 0.25MG BASE**	**N020658**	**001**	Sep 19, 1997
AB	**+**		**EQ 0.5MG BASE**	**N020658**	**002**	Sep 19, 1997
AB	**+**		**EQ 1MG BASE**	**N020658**	**003**	Sep 19, 1997
AB	**+**		**EQ 2MG BASE**	**N020658**	**004**	Sep 19, 1997
AB	**+**		**EQ 3MG BASE**	**N020658**	**006**	Jan 27, 1999
AB	**+**		**EQ 4MG BASE**	**N020658**	**007**	Jan 27, 1999
AB	**+**		**EQ 5MG BASE**	**N020658**	**005**	Sep 19, 1997

ROPINIROLE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**EQ 0.25MG BASE**	**A204022**	**001**	Feb 28, 2017
AB			**EQ 0.5MG BASE**	**A204022**	**002**	Feb 28, 2017
AB			**EQ 1MG BASE**	**A204022**	**003**	Feb 28, 2017
AB			**EQ 2MG BASE**	**A204022**	**004**	Feb 28, 2017
AB			**EQ 3MG BASE**	**A204022**	**005**	Feb 28, 2017
AB			**EQ 4MG BASE**	**A204022**	**006**	Feb 28, 2017
AB			**EQ 5MG BASE**	**A204022**	**007**	Feb 28, 2017
AB		ALEMBIC LTD	**EQ 0.25MG BASE**	**A090429**	**001**	Mar 24, 2010
AB			**EQ 0.5MG BASE**	**A090429**	**002**	Mar 24, 2010
AB			**EQ 1MG BASE**	**A090429**	**003**	Mar 24, 2010
AB			**EQ 2MG BASE**	**A090429**	**004**	Mar 24, 2010
AB			**EQ 3MG BASE**	**A090429**	**005**	Mar 24, 2010
AB			**EQ 4MG BASE**	**A090429**	**006**	Mar 24, 2010
AB			**EQ 5MG BASE**	**A090429**	**007**	Mar 24, 2010
AB		APOTEX	**EQ 0.25MG BASE**	**A079165**	**001**	Feb 07, 2012
AB			**EQ 0.5MG BASE**	**A079165**	**002**	Feb 07, 2012
AB			**EQ 1MG BASE**	**A079165**	**003**	Feb 07, 2012
AB			**EQ 2MG BASE**	**A079165**	**004**	Feb 07, 2012
AB			**EQ 3MG BASE**	**A079165**	**005**	Feb 07, 2012
AB			**EQ 4MG BASE**	**A079165**	**006**	Feb 07, 2012
AB			**EQ 5MG BASE**	**A079165**	**007**	Feb 07, 2012
AB		GLENMARK GENERICS	**EQ 0.25MG BASE**	**A090135**	**001**	Feb 25, 2010
AB			**EQ 0.5MG BASE**	**A090135**	**002**	Feb 25, 2010
AB			**EQ 1MG BASE**	**A090135**	**003**	Feb 25, 2010
AB			**EQ 2MG BASE**	**A090135**	**004**	Feb 25, 2010
AB			**EQ 3MG BASE**	**A090135**	**005**	Feb 25, 2010
AB			**EQ 4MG BASE**	**A090135**	**006**	Feb 25, 2010
AB			**EQ 5MG BASE**	**A090135**	**007**	Feb 25, 2010
AB		MYLAN	**EQ 0.25MG BASE**	**A078881**	**001**	May 05, 2008
AB			**EQ 0.5MG BASE**	**A078881**	**002**	May 05, 2008
AB			**EQ 1MG BASE**	**A078881**	**003**	May 05, 2008
AB			**EQ 2MG BASE**	**A078881**	**004**	May 05, 2008
AB			**EQ 3MG BASE**	**A078881**	**005**	May 05, 2008
AB			**EQ 4MG BASE**	**A078881**	**006**	May 05, 2008
AB			**EQ 5MG BASE**	**A078881**	**007**	May 19, 2008
AB		ORCHID HLTHCARE	**EQ 0.25MG BASE**	**A079229**	**001**	Nov 28, 2012
AB			**EQ 0.5MG BASE**	**A079229**	**002**	Nov 28, 2012
AB			**EQ 1MG BASE**	**A079229**	**003**	Nov 28, 2012
AB			**EQ 2MG BASE**	**A079229**	**004**	Nov 28, 2012
AB			**EQ 3MG BASE**	**A079229**	**005**	Nov 28, 2012
AB			**EQ 4MG BASE**	**A079229**	**006**	Nov 28, 2012
AB			**EQ 5MG BASE**	**A079229**	**007**	Nov 28, 2012
AB		PRINSTON INC	**EQ 0.25MG BASE**	**A078110**	**001**	May 05, 2008
AB			**EQ 0.5MG BASE**	**A078110**	**002**	May 05, 2008
AB			**EQ 1MG BASE**	**A078110**	**003**	May 05, 2008
AB			**EQ 2MG BASE**	**A078110**	**004**	May 05, 2008
AB			**EQ 3MG BASE**	**A078110**	**005**	May 05, 2008
AB			**EQ 4MG BASE**	**A078110**	**006**	May 05, 2008
AB			**EQ 5MG BASE**	**A078110**	**007**	Jul 11, 2008
AB		WEST-WARD PHARMS INT	**EQ 0.25MG BASE**	**A077852**	**001**	May 05, 2008
AB			**EQ 0.5MG BASE**	**A077852**	**002**	May 05, 2008
AB			**EQ 1MG BASE**	**A077852**	**003**	May 05, 2008
AB			**EQ 2MG BASE**	**A077852**	**004**	May 05, 2008
AB			**EQ 3MG BASE**	**A077852**	**005**	May 05, 2008
AB			**EQ 4MG BASE**	**A077852**	**006**	May 05, 2008
AB			**EQ 5MG BASE**	**A077852**	**007**	May 19, 2008

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB		WOCKHARDT	**EQ 0.25MG BASE**	**A079050**	**001**	May 29, 2008
AB			**EQ 0.5MG BASE**	**A079050**	**002**	May 29, 2008
AB			**EQ 1MG BASE**	**A079050**	**003**	May 29, 2008
AB			**EQ 2MG BASE**	**A079050**	**004**	May 29, 2008
AB			**EQ 3MG BASE**	**A079050**	**005**	May 29, 2008
AB			**EQ 4MG BASE**	**A079050**	**006**	May 29, 2008
AB			**EQ 5MG BASE**	**A079050**	**007**	May 29, 2008
AB		ZYDUS PHARMS USA INC	**EQ 0.25MG BASE**	**A090411**	**001**	Jun 01, 2009
AB			**EQ 0.5MG BASE**	**A090411**	**002**	Jun 01, 2009
AB			**EQ 1MG BASE**	**A090411**	**003**	Jun 01, 2009
AB			**EQ 2MG BASE**	**A090411**	**004**	Jun 01, 2009
AB			**EQ 3MG BASE**	**A090411**	**005**	Jun 01, 2009
AB			**EQ 4MG BASE**	**A090411**	**006**	Jun 01, 2009
AB			**EQ 5MG BASE**	**A090411**	**007**	Jun 01, 2009

TABLET, EXTENDED RELEASE;ORAL

REQUIP XL

AB	**+!**	GLAXOSMITHKLINE LLC	**EQ 2MG BASE**	**N022008**	**001**	Jun 13, 2008
AB	**+**		**EQ 4MG BASE**	**N022008**	**003**	Jun 13, 2008
AB	**+**		**EQ 6MG BASE**	**N022008**	**006**	Apr 10, 2009
AB	**+**		**EQ 8MG BASE**	**N022008**	**004**	Jun 13, 2008
AB	**+**		**EQ 12MG BASE**	**N022008**	**005**	Oct 31, 2008

ROPINIROLE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**EQ 2MG BASE**	**A090869**	**001**	May 17, 2012
AB			**EQ 4MG BASE**	**A090869**	**002**	May 17, 2012
AB			**EQ 6MG BASE**	**A090869**	**003**	May 17, 2012
AB			**EQ 8MG BASE**	**A090869**	**004**	May 17, 2012
AB			**EQ 12MG BASE**	**A090869**	**005**	May 17, 2012
AB		ALEMBIC PHARMS LTD	**EQ 2MG BASE**	**A202786**	**001**	Apr 22, 2013
AB			**EQ 4MG BASE**	**A202786**	**002**	Apr 22, 2013
AB			**EQ 6MG BASE**	**A202786**	**003**	Apr 22, 2013
AB			**EQ 8MG BASE**	**A202786**	**004**	Apr 22, 2013
AB			**EQ 12MG BASE**	**A202786**	**005**	Apr 22, 2013
AB		DR REDDYS LABS LTD	**EQ 2MG BASE**	**A201576**	**001**	Jun 06, 2012
AB			**EQ 4MG BASE**	**A201576**	**002**	Jun 06, 2012
AB			**EQ 6MG BASE**	**A201576**	**003**	Jun 06, 2012
AB			**EQ 8MG BASE**	**A201576**	**004**	Jun 06, 2012
AB			**EQ 12MG BASE**	**A201576**	**005**	Jun 06, 2012
AB		SANDOZ INC	**EQ 2MG BASE**	**A201047**	**001**	Jun 06, 2012
AB			**EQ 4MG BASE**	**A201047**	**003**	Jun 06, 2012
AB			**EQ 6MG BASE**	**A201047**	**004**	Jun 06, 2012
AB			**EQ 8MG BASE**	**A201047**	**005**	Jun 06, 2012
AB			**EQ 12MG BASE**	**A201047**	**006**	Jun 06, 2012
AB		WATSON LABS INC	**EQ 2MG BASE**	**A200431**	**001**	Jun 06, 2012
AB			**EQ 4MG BASE**	**A200431**	**002**	Jun 06, 2012
AB			**EQ 6MG BASE**	**A200431**	**003**	Jun 06, 2012
AB			**EQ 8MG BASE**	**A200431**	**004**	Jun 06, 2012
AB			**EQ 12MG BASE**	**A200431**	**005**	Jun 06, 2012
AB		WOCKHARDT LTD	**EQ 2MG BASE**	**A091395**	**001**	Aug 27, 2012
AB			**EQ 4MG BASE**	**A091395**	**002**	Aug 27, 2012
AB			**EQ 6MG BASE**	**A091395**	**003**	Aug 27, 2012
AB			**EQ 8MG BASE**	**A091395**	**004**	Aug 27, 2012
AB			**EQ 12MG BASE**	**A091395**	**005**	Aug 27, 2012

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

NAROPIN

AP	**+**	FRESENIUS KABI USA	**20MG/10ML (2MG/ML)**	**N020533**	**001**	May 01, 1998
AP	**+**		**40MG/20ML (2MG/ML)**	**N020533**	**002**	Sep 24, 1996
AP	**+**		**100MG/20ML (5MG/ML)**	**N020533**	**003**	May 01, 1998
AP	**+**		**100MG/10ML (10MG/ML)**	**N020533**	**005**	Sep 24, 1996
AP	**+**		**150MG/20ML (7.5MG/ML)**	**N020533**	**004**	Sep 24, 1996
AP	**+**		**150MG/30ML (5MG/ML)**	**N020533**	**008**	Sep 24, 1996
AP	**+**		**200MG/100ML (2MG/ML)**	**N020533**	**006**	Sep 24, 1996
AP	**+!**		**200MG/20ML (10MG/ML)**	**N020533**	**011**	Sep 24, 1996
AP	**+**		**400MG/200ML (2MG/ML)**	**N020533**	**007**	Sep 24, 1996
AP	**+**		**500MG/100ML (5MG/ML)**	**N020533**	**009**	Jan 04, 2011
AP	**+**		**1GM/200ML (5MG/ML)**	**N020533**	**010**	Jan 04, 2011

ROPIVACAINE HYDROCHLORIDE

AP		AKORN	**200MG/100ML (2MG/ML)**	**A204636**	**001**	Mar 16, 2018

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

ROPIVACAINE HYDROCHLORIDE

AP			**400MG/200ML (2MG/ML)**	**A204636**	**002**	Mar 16, 2018
AP		AKORN INC	**150MG/30ML (5MG/ML)**	**A203955**	**001**	Apr 11, 2016
AP		AUROBINDO PHARMA LTD	**40MG/20ML (2MG/ML)**	**A205612**	**001**	Jul 13, 2016
AP			**100MG/20ML (5MG/ML)**	**A205612**	**003**	Jul 13, 2016
AP			**100MG/10ML (10MG/ML)**	**A205612**	**006**	Jul 13, 2016
AP			**150MG/30ML (5MG/ML)**	**A205612**	**004**	Jul 13, 2016
AP			**150MG/20ML (7.5MG/ML)**	**A205612**	**005**	Jul 13, 2016
AP			**200MG/100ML (2MG/ML)**	**A205612**	**002**	Jul 13, 2016
AP			**200MG/20ML (10MG/ML)**	**A205612**	**007**	Jul 13, 2016
AP		HOSPIRA	**20MG/10ML (2MG/ML)**	**A090194**	**001**	Sep 23, 2014
AP			**40MG/20ML (2MG/ML)**	**A090194**	**005**	Sep 23, 2014
AP			**100MG/10ML (10MG/ML)**	**A090194**	**004**	Sep 23, 2014
AP			**150MG/30ML (5MG/ML)**	**A090194**	**002**	Sep 23, 2014
AP			**150MG/20ML (7.5MG/ML)**	**A090194**	**003**	Sep 23, 2014
AP			**200MG/20ML (10MG/ML)**	**A090194**	**006**	Sep 23, 2014
AP		INFORLIFE	**200MG/100ML (2MG/ML)**	**A206166**	**001**	Jun 11, 2018
AP			**400MG/200ML (2MG/ML)**	**A206166**	**002**	Jun 11, 2018
AP			**500MG/100ML (5MG/ML)**	**A206166**	**003**	Jun 11, 2018
AP			**1GM/200ML (5MG/ML)**	**A206166**	**004**	Jun 11, 2018
AP		MYLAN ASI	**40MG/20ML (2MG/ML)**	**A090318**	**001**	Sep 23, 2014
AP			**150MG/30ML (5MG/ML)**	**A090318**	**002**	Sep 23, 2014
AP			**150MG/20ML (7.5MG/ML)**	**A090318**	**003**	Sep 23, 2014
AP			**200MG/20ML (10MG/ML)**	**A090318**	**004**	Sep 23, 2014
AP		NAVINTA LLC	**150MG/30ML (5MG/ML)**	**A078601**	**002**	Jul 17, 2014
AP			**200MG/20ML (10MG/ML)**	**A078601**	**003**	Jul 17, 2014
AP		SOMERSET THERAPS LLC	**20MG/10ML (2MG/ML)**	**A207636**	**001**	Jun 15, 2018
AP			**40MG/20ML (2MG/ML)**	**A207636**	**002**	Jun 15, 2018
AP			**100MG/20ML (5MG/ML)**	**A207636**	**003**	Jun 15, 2018
AP			**100MG/10ML (10MG/ML)**	**A207636**	**006**	Jun 15, 2018
AP			**150MG/30ML (5MG/ML)**	**A207636**	**004**	Jun 15, 2018
AP			**150MG/20ML (7.5MG/ML)**	**A207636**	**005**	Jun 15, 2018
AP			**200MG/20ML (10MG/ML)**	**A207636**	**007**	Jun 15, 2018

ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDIA

+		SB PHARMCO	EQ 2MG BASE	N021071	002	May 25, 1999
+			EQ 4MG BASE	N021071	003	May 25, 1999

ROSUVASTATIN CALCIUM

CAPSULE;ORAL

EZALLOR

+		SUN PHARMA GLOBAL	EQ 5MG BASE	N208647	001	Dec 18, 2018
+			EQ 10MG BASE	N208647	002	Dec 18, 2018
+			EQ 20MG BASE	N208647	003	Dec 18, 2018
+!			EQ 40MG BASE	N208647	004	Dec 18, 2018

TABLET;ORAL

CRESTOR

AB	**+**	IPR	**5MG**	**N021366**	**002**	Aug 12, 2003
AB	**+**		**10MG**	**N021366**	**003**	Aug 12, 2003
AB	**+**		**20MG**	**N021366**	**004**	Aug 12, 2003
AB	**+!**		**40MG**	**N021366**	**005**	Aug 12, 2003

ROSUVASTATIN CALCIUM

AB		ACCORD HLTHCARE	**5MG**	**A206434**	**001**	Oct 31, 2016
AB			**10MG**	**A206434**	**002**	Oct 31, 2016
AB			**20MG**	**A206434**	**003**	Oct 31, 2016
AB			**40MG**	**A206434**	**004**	Oct 31, 2016
AB		ALKEM LABS LTD	**5MG**	**A206465**	**001**	Mar 21, 2017
AB			**10MG**	**A206465**	**002**	Mar 21, 2017
AB			**20MG**	**A206465**	**003**	Mar 21, 2017
AB			**40MG**	**A206465**	**004**	Mar 21, 2017
AB		ALLIED	**5MG**	**A079168**	**001**	Jul 19, 2016
AB			**10MG**	**A079168**	**002**	Jul 19, 2016
AB			**20MG**	**A079168**	**003**	Jul 19, 2016
AB			**40MG**	**A079168**	**004**	Jul 19, 2016
AB		AMNEAL PHARMS CO	**5MG**	**A208850**	**001**	Oct 16, 2018
AB			**10MG**	**A208850**	**002**	Oct 16, 2018
AB			**20MG**	**A208850**	**003**	Oct 16, 2018
AB			**40MG**	**A208850**	**004**	Oct 16, 2018

ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSUVASTATIN CALCIUM

AB	APOTEX INC	**5MG**	**A079145**	**001**	Jul 19, 2016
AB		**10MG**	**A079145**	**002**	Jul 19, 2016
AB		**20MG**	**A079145**	**003**	Jul 19, 2016
AB		**40MG**	**A079145**	**004**	Jul 19, 2016
AB	AUROBINDO PHARMA LTD	**5MG**	**A079170**	**001**	Jul 19, 2016
AB		**10MG**	**A079170**	**002**	Jul 19, 2016
AB		**20MG**	**A079170**	**003**	Jul 19, 2016
AB		**40MG**	**A079170**	**004**	Jul 19, 2016
AB	BIOCON LTD	**5MG**	**A207752**	**001**	Oct 31, 2016
AB		**10MG**	**A207752**	**002**	Oct 31, 2016
AB		**20MG**	**A207752**	**003**	Oct 31, 2016
AB		**40MG**	**A207752**	**004**	Oct 31, 2016
AB	CADILA PHARMS LTD	**5MG**	**A207453**	**001**	Nov 23, 2016
AB		**10MG**	**A207453**	**002**	Nov 23, 2016
AB		**20MG**	**A207453**	**003**	Nov 23, 2016
AB		**40MG**	**A207453**	**004**	Nov 23, 2016
AB	CHANGZHOU PHARM	**5MG**	**A207408**	**001**	Oct 31, 2016
AB		**10MG**	**A207408**	**002**	Oct 31, 2016
AB		**20MG**	**A207408**	**003**	Oct 31, 2016
AB		**40MG**	**A207408**	**004**	Oct 31, 2016
AB	GLENMARK PHARMS	**5MG**	**A079172**	**001**	Jul 19, 2016
AB		**10MG**	**A079172**	**002**	Jul 19, 2016
AB		**20MG**	**A079172**	**003**	Jul 19, 2016
AB		**40MG**	**A079172**	**004**	Jul 19, 2016
AB	HETERO LABS LTD V	**5MG**	**A207616**	**001**	Oct 31, 2016
AB		**10MG**	**A207616**	**002**	Oct 31, 2016
AB		**20MG**	**A207616**	**003**	Oct 31, 2016
AB		**40MG**	**A207616**	**004**	Oct 31, 2016
AB	JUBILANT GENERICS	**5MG**	**A207062**	**001**	Oct 31, 2016
AB		**10MG**	**A207062**	**002**	Oct 31, 2016
AB		**20MG**	**A207062**	**003**	Oct 31, 2016
AB		**40MG**	**A207062**	**004**	Oct 31, 2016
AB	LUPIN LTD	**5MG**	**A205587**	**001**	Jul 31, 2017
AB		**10MG**	**A205587**	**002**	Jul 31, 2017
AB		**20MG**	**A205587**	**003**	Jul 31, 2017
AB		**40MG**	**A205587**	**004**	Jul 31, 2017
AB	MSN LABS PVT LTD	**5MG**	**A208898**	**001**	Nov 22, 2017
AB		**10MG**	**A208898**	**002**	Nov 22, 2017
AB		**20MG**	**A208898**	**003**	Nov 22, 2017
AB		**40MG**	**A208898**	**004**	Nov 22, 2017
AB	MYLAN PHARMS INC	**5MG**	**A079161**	**001**	Jul 19, 2016
AB		**10MG**	**A079161**	**002**	Jul 19, 2016
AB		**20MG**	**A079161**	**003**	Jul 19, 2016
AB		**40MG**	**A079161**	**004**	Jul 19, 2016
AB	SANDOZ INC	**5MG**	**A079171**	**001**	Jul 19, 2016
AB		**10MG**	**A079171**	**002**	Jul 19, 2016
AB		**20MG**	**A079171**	**003**	Jul 19, 2016
AB		**40MG**	**A079171**	**004**	Jul 19, 2016
AB	SUN PHARMA GLOBAL	**5MG**	**A079169**	**001**	Jul 19, 2016
AB		**10MG**	**A079169**	**002**	Jul 19, 2016
AB		**20MG**	**A079169**	**003**	Jul 19, 2016
AB		**40MG**	**A079169**	**004**	Jul 19, 2016
AB	TEVA PHARMS USA	**5MG**	**A079166**	**001**	Jul 19, 2016
AB		**10MG**	**A079166**	**002**	Jul 19, 2016
AB		**20MG**	**A079166**	**003**	Jul 19, 2016
AB		**40MG**	**A079166**	**004**	Jul 19, 2016
AB	TORRENT PHARMS LTD	**5MG**	**A201619**	**001**	Oct 31, 2016
AB		**10MG**	**A201619**	**002**	Oct 31, 2016
AB		**20MG**	**A201619**	**003**	Oct 31, 2016
AB		**40MG**	**A201619**	**004**	Oct 31, 2016
AB	WATSON LABS INC	**5MG**	**A079167**	**001**	Apr 29, 2016
AB		**10MG**	**A079167**	**002**	Apr 29, 2016
AB		**20MG**	**A079167**	**003**	Apr 29, 2016
AB		**40MG**	**A079167**	**004**	Apr 29, 2016

ROTIGOTINE
FILM, EXTENDED RELEASE;TRANSDERMAL
NEUPRO

+	UCB INC	1MG/24HR	N021829	004	Apr 02, 2012
+!		2MG/24HR	N021829	001	May 09, 2007
+		3MG/24HR	N021829	005	Apr 02, 2012
+		4MG/24HR	N021829	002	May 09, 2007
+		6MG/24HR	N021829	003	May 09, 2007
+		8MG/24HR	N021829	006	Apr 02, 2012

RUBIDIUM CHLORIDE RB-82
INJECTABLE;INJECTION
CARDIOGEN-82

	BRACCO	N/A	N019414	001	Dec 29, 1989

SOLUTION;INTRAVENOUS
RUBY-FILL

	JUBILANT DRAXIMAGE	N/A	N202153	001	Sep 30, 2016

RUCAPARIB CAMSYLATE
TABLET;ORAL
RUBRACA

+	CLOVIS ONCOLOGY INC	EQ 200MG BASE	N209115	001	Dec 19, 2016
+		EQ 250MG BASE	N209115	003	May 01, 2017
+!		EQ 300MG BASE	N209115	002	Dec 19, 2016

RUFINAMIDE
SUSPENSION;ORAL
BANZEL

+!	EISAI INC	40MG/ML	N201367	001	Mar 03, 2011

TABLET;ORAL
BANZEL

AB	**+**	EISAI INC	**200MG**	**N021911**	**002**	Nov 14, 2008
AB	**+!**		**400MG**	**N021911**	**003**	Nov 14, 2008

RUFINAMIDE

AB		GLENMARK PHARMS LTD	**200MG**	**A205075**	**001**	May 16, 2016
AB			**400MG**	**A205075**	**002**	May 16, 2016
AB		MYLAN PHARMS INC	**200MG**	**A205095**	**001**	May 16, 2016
AB			**400MG**	**A205095**	**002**	May 16, 2016
AB		WEST-WARD PHARMS INT	**200MG**	**A204988**	**001**	May 16, 2016
AB			**400MG**	**A204988**	**002**	May 16, 2016

RUXOLITINIB PHOSPHATE
TABLET;ORAL
JAKAFI

+	INCYTE CORP	EQ 5MG BASE	N202192	001	Nov 16, 2011
+		EQ 10MG BASE	N202192	002	Nov 16, 2011
+		EQ 15MG BASE	N202192	003	Nov 16, 2011
+		EQ 20MG BASE	N202192	004	Nov 16, 2011
+!		EQ 25MG BASE	N202192	005	Nov 16, 2011

SACROSIDASE
SOLUTION;ORAL
SUCRAID

+!	QOL MEDCL	8,500 IU/ML	N020772	001	Apr 09, 1998

SACUBITRIL; VALSARTAN
TABLET;ORAL
ENTRESTO

+	NOVARTIS PHARMS CORP	24MG;26MG	N207620	001	Jul 07, 2015
+		49MG;51MG	N207620	002	Jul 07, 2015
+!		97MG;103MG	N207620	003	Jul 07, 2015

SAFINAMIDE MESYLATE
TABLET;ORAL
XADAGO

+	US WORLDMEDS LLC	50MG	N207145	001	Mar 21, 2017
+!		100MG	N207145	002	Mar 21, 2017

SALMETEROL XINAFOATE
POWDER;INHALATION
SEREVENT

+!	GLAXOSMITHKLINE	EQ 0.05MG BASE/INH	N020692	001	Sep 19, 1997

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE;INJECTION						
QUADRAMET						
+!	LANTHEUS MEDICAL	50mCi/ML		N020570	001	Mar 28, 1997

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL						
KUVAN						
+!	BIOMARIN PHARM	100MG/PACKET		N205065	001	Dec 19, 2013
+		500MG/PACKET		N205065	002	Oct 27, 2015
TABLET;ORAL						
KUVAN						
+!	BIOMARIN PHARM	100MG		N022181	001	Dec 13, 2007

SAQUINAVIR MESYLATE

TABLET;ORAL						
INVIRASE						
+!	HOFFMANN-LA ROCHE	EQ 500MG BASE		N021785	001	Dec 17, 2004

SARECYCLINE HYDROCHLORIDE

TABLET;ORAL						
SEYSARA						
+	ALMIRALL	EQ 60MG BASE		N209521	001	Oct 01, 2018
+		EQ 100MG BASE		N209521	002	Oct 01, 2018
+!		EQ 150MG BASE		N209521	003	Oct 01, 2018

SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL						
ONGLYZA						
+	ASTRAZENECA AB	EQ 2.5MG BASE		N022350	001	Jul 31, 2009
+!		EQ 5MG BASE		N022350	002	Jul 31, 2009

SCOPOLAMINE

FILM, EXTENDED RELEASE;TRANSDERMAL						
SCOPOLAMINE						
AB	PERRIGO PHARMS CO	**1MG/72HR**		**A078830**	**001**	Jan 30, 2015
TRANSDERM SCOP						
AB **+!**	GLAXOSMITHKLINE CON	**1MG/72HR**		**N017874**	**001**	

SECNIDAZOLE

GRANULE;ORAL						
SOLOSEC						
+!	LUPIN	2GM/PACKET		N209363	001	Sep 15, 2017

SECOBARBITAL SODIUM

CAPSULE;ORAL						
SECONAL SODIUM						
!	VALEANT PHARMS NORTH	50MG		A086101	001	Oct 03, 1983
!		100MG		A086101	002	Oct 03, 1983

SECRETIN SYNTHETIC HUMAN

FOR SOLUTION;INTRAVENOUS						
CHIRHOSTIM						
+!	CHIRHOCLIN	16MCG/VIAL		N021256	001	Apr 09, 2004
+		40MCG/VIAL		N021256	002	Jun 21, 2007

SELEGILINE

FILM, EXTENDED RELEASE;TRANSDERMAL						
EMSAM						
+!	SOMERSET	6MG/24HR		N021336	001	Feb 27, 2006
+		9MG/24HR		N021336	002	Feb 27, 2006
+		12MG/24HR		N021336	003	Feb 27, 2006

SELEGILINE HYDROCHLORIDE

CAPSULE;ORAL						
SELEGILINE HYDROCHLORIDE						
AB **!**	APOTEX	**5MG**		**A075321**	**001**	Dec 04, 1998
AB	DAVA PHARMS INC	**5MG**		**A075352**	**001**	Nov 30, 1998
TABLET;ORAL						
SELEGILINE HYDROCHLORIDE						
AB **!**	APOTEX INC	**5MG**		**A074871**	**001**	Jun 06, 1997
AB	BOSCOGEN	**5MG**		**A074912**	**001**	Apr 30, 1998
AB	MYLAN	**5MG**		**A074866**	**001**	Nov 26, 1997
TABLET, ORALLY DISINTEGRATING;ORAL						
ZELAPAR						
+!	VALEANT PHARM INTL	1.25MG		N021479	001	Jun 14, 2006

SELENIUM SULFIDE						
LOTION/SHAMPOO;TOPICAL						
SELENIUM SULFIDE						
AT	**!**	PERRIGO NEW YORK	**2.5%**	**A089996**	**001**	Jan 10, 1991
AT		WOCKHARDT BIO AG	**2.5%**	**A088228**	**001**	Sep 01, 1983
SELEXIPAG						
TABLET;ORAL						
UPTRAVI						
	+	ACTELION PHARMS LTD	0.2MG	N207947	001	Dec 21, 2015
	+		0.4MG	N207947	002	Dec 21, 2015
	+		0.6MG	N207947	003	Dec 21, 2015
	+		0.8MG	N207947	004	Dec 21, 2015
	+		1MG	N207947	005	Dec 21, 2015
	+		1.2MG	N207947	006	Dec 21, 2015
	+		1.4MG	N207947	007	Dec 21, 2015
	+!		1.6MG	N207947	008	Dec 21, 2015
SEMAGLUTIDE						
SOLUTION;SUBCUTANEOUS						
OZEMPIC						
	+!	NOVO	2MG/1.5ML (1.34MG/ML)	N209637	001	Dec 05, 2017
SERTACONAZOLE NITRATE						
CREAM;TOPICAL						
ERTACZO						
	+!	VALEANT LUXEMBOURG	2%	N021385	001	Dec 10, 2003
SERTRALINE HYDROCHLORIDE						
CONCENTRATE;ORAL						
SERTRALINE HYDROCHLORIDE						
AA		AUROBINDO PHARMA	**EQ 20MG BASE/ML**	**A078861**	**001**	Oct 31, 2008
ZOLOFT						
AA	**+!**	PFIZER	**EQ 20MG BASE/ML**	**N020990**	**001**	Dec 07, 1999
TABLET;ORAL						
SERTRALINE HYDROCHLORIDE						
AB		ACCORD HLTHCARE	**EQ 25MG BASE**	**A202825**	**001**	Nov 07, 2014
AB			**EQ 50MG BASE**	**A202825**	**002**	Nov 07, 2014
AB			**EQ 100MG BASE**	**A202825**	**003**	Nov 07, 2014
AB		APOTEX INC	**EQ 25MG BASE**	**A076882**	**001**	Feb 06, 2007
AB			**EQ 50MG BASE**	**A076882**	**002**	Feb 06, 2007
AB			**EQ 100MG BASE**	**A076882**	**003**	Feb 06, 2007
AB		AUROBINDO PHARMA	**EQ 25MG BASE**	**A077206**	**001**	Feb 06, 2007
AB			**EQ 50MG BASE**	**A077206**	**002**	Feb 06, 2007
AB			**EQ 100MG BASE**	**A077206**	**003**	Feb 06, 2007
AB		AUSTARPHARMA LLC	**EQ 25MG BASE**	**A078677**	**001**	Mar 04, 2009
AB			**EQ 50MG BASE**	**A078677**	**002**	Mar 04, 2009
AB			**EQ 100MG BASE**	**A078677**	**003**	Mar 04, 2009
AB		INVAGEN PHARMS	**EQ 25MG BASE**	**A077397**	**001**	Feb 06, 2007
AB			**EQ 50MG BASE**	**A077397**	**002**	Feb 06, 2007
AB			**EQ 100MG BASE**	**A077397**	**003**	Feb 06, 2007
AB		LUPIN	**EQ 25MG BASE**	**A077670**	**001**	Feb 06, 2007
AB			**EQ 50MG BASE**	**A077670**	**002**	Feb 06, 2007
AB			**EQ 100MG BASE**	**A077670**	**003**	Feb 06, 2007
AB		MYLAN PHARMS INC	**EQ 25MG BASE**	**A078626**	**001**	Jan 31, 2008
AB			**EQ 50MG BASE**	**A078626**	**002**	Jan 31, 2008
AB		OXFORD PHARMS	**EQ 25MG BASE**	**A078175**	**001**	Jul 21, 2010
AB			**EQ 50MG BASE**	**A078175**	**002**	Jul 21, 2010
AB			**EQ 100MG BASE**	**A078175**	**003**	Jul 21, 2010
AB		SUN PHARM INDS LTD	**EQ 25MG BASE**	**A077977**	**001**	Feb 06, 2007
AB			**EQ 50MG BASE**	**A077977**	**002**	Feb 06, 2007
AB			**EQ 100MG BASE**	**A077977**	**003**	Feb 06, 2007
AB		TEVA	**EQ 25MG BASE**	**A076465**	**001**	Aug 11, 2006
AB			**EQ 50MG BASE**	**A076465**	**002**	Aug 11, 2006
AB			**EQ 100MG BASE**	**A076465**	**003**	Aug 11, 2006
AB		TORRENT PHARMS	**EQ 25MG BASE**	**A077765**	**001**	Feb 06, 2007
AB			**EQ 50MG BASE**	**A077765**	**002**	Feb 06, 2007
AB			**EQ 100MG BASE**	**A077765**	**003**	Feb 06, 2007
AB		WOCKHARDT	**EQ 25MG BASE**	**A078403**	**001**	Jan 08, 2008
AB			**EQ 50MG BASE**	**A078403**	**002**	Jan 08, 2008
AB			**EQ 100MG BASE**	**A078403**	**003**	Jan 08, 2008
AB		ZYDUS PHARMS USA	**EQ 25MG BASE**	**A077106**	**001**	Feb 06, 2007
AB			**EQ 50MG BASE**	**A077106**	**002**	Feb 06, 2007
AB			**EQ 100MG BASE**	**A077106**	**003**	Feb 06, 2007

SERTRALINE HYDROCHLORIDE						
TABLET;ORAL						
ZOLOFT						
AB	**+**	PFIZER	**EQ 25MG BASE**	**N019839**	**005**	Mar 06, 1996
AB	**+**		**EQ 50MG BASE**	**N019839**	**001**	Dec 30, 1991
AB	**+!**		**EQ 100MG BASE**	**N019839**	**002**	Dec 30, 1991
SERTRALINE HYDROCHLORIDE						
		SUN PHARM INDS LTD	EQ 150MG BASE	A077977	004	Feb 06, 2007
			EQ 200MG BASE	A077977	005	Feb 06, 2007
SEVELAMER CARBONATE						
FOR SUSPENSION;ORAL						
RENVELA						
AB	**+**	GENZYME	**800MG/PACKET**	**N022318**	**001**	Aug 12, 2009
AB	**+!**		**2.4GM/PACKET**	**N022318**	**002**	Feb 18, 2009
SEVELAMER CARBONATE						
AB		AUROBINDO PHARMA LTD	**800MG/PACKET**	**A207624**	**001**	Jun 13, 2017
AB			**2.4GM/PACKET**	**A207624**	**002**	Jun 13, 2017
AB		DR REDDYS LABS LTD	**800MG/PACKET**	**A210464**	**001**	Oct 25, 2018
AB			**2.4GM/PACKET**	**A210464**	**002**	Oct 25, 2018
TABLET;ORAL						
RENVELA						
AB	**+!**	SANOFI	**800MG**	**N022127**	**001**	Oct 19, 2007
SEVELAMER CARBONATE						
AB		AMNEAL PHARMS CO	**800MG**	**A207288**	**001**	Nov 28, 2017
AB		AUROBINDO PHARMA LTD	**800MG**	**A207179**	**001**	Jul 17, 2017
AB		DR REDDYS LABS LTD	**800MG**	**A206094**	**001**	Sep 29, 2017
AB		IMPAX LABS INC	**800MG**	**A090975**	**001**	Oct 23, 2017
AB		INVAGEN PHARMS	**800MG**	**A203860**	**001**	Oct 26, 2017
AB		TWI PHARMS	**800MG**	**A200959**	**001**	Mar 20, 2018
AB		WILSHIRE PHARMS INC	**800MG**	**A204451**	**001**	Nov 29, 2018
SEVELAMER HYDROCHLORIDE						
TABLET;ORAL						
RENAGEL						
	+	GENZYME	400MG	N021179	001	Jul 12, 2000
	+!		800MG	N021179	002	Jul 12, 2000
SEVOFLURANE						
LIQUID;INHALATION						
SEVOFLURANE						
AN		BAXTER HLTHCARE	**100%**	**A075895**	**001**	Jul 02, 2002
AN		HALOCARBON PRODS	**100%**	**A078650**	**001**	Nov 19, 2007
AN		SHANGHAI HENGRUI	**100%**	**A203793**	**001**	Nov 03, 2015
SOJOURN						
AN		PIRAMAL CRITICAL	**100%**	**A077867**	**001**	May 02, 2007
ULTANE						
AN	**+!**	ABBVIE	**100%**	**N020478**	**001**	Jun 07, 1995
SILDENAFIL CITRATE						
FOR SUSPENSION;ORAL						
REVATIO						
	+!	PFIZER	EQ 10MG BASE/ML	N203109	001	Aug 30, 2012
SOLUTION;INTRAVENOUS						
REVATIO						
AP	**+!**	PFIZER	**EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)**	**N022473**	**001**	Nov 18, 2009
SILDENAFIL CITRATE						
AP		AUROBINDO PHARMA LTD	**EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)**	**A203988**	**001**	Apr 01, 2015
TABLET;ORAL						
REVATIO						
AB	**+!**	PFIZER	**EQ 20MG BASE**	**N021845**	**001**	Jun 03, 2005
SILDENAFIL CITRATE						
AB		AJANTA PHARMA LTD	**EQ 20MG BASE**	**A210394**	**001**	May 04, 2018
AB			**EQ 25MG BASE**	**A206401**	**001**	Oct 12, 2018
AB			**EQ 50MG BASE**	**A206401**	**002**	Oct 12, 2018
AB			**EQ 100MG BASE**	**A206401**	**003**	Oct 12, 2018
AB		AMNEAL PHARMS	**EQ 20MG BASE**	**A202025**	**001**	Feb 28, 2013
AB		AMNEAL PHARMS NY	**EQ 25MG BASE**	**A202023**	**001**	Jun 27, 2018
AB			**EQ 50MG BASE**	**A202023**	**002**	Jun 27, 2018
AB			**EQ 100MG BASE**	**A202023**	**003**	Jun 27, 2018
AB		AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A203963**	**001**	Nov 18, 2015

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE						
AB		**EQ 25MG BASE**	**A203962**	**001**	Jun 11, 2018
AB		**EQ 50MG BASE**	**A203962**	**002**	Jun 11, 2018
AB		**EQ 100MG BASE**	**A203962**	**003**	Jun 11, 2018
AB	HEBEI CHANGSHAN	**EQ 20MG BASE**	**A202598**	**001**	Nov 06, 2012
AB	HETERO LABS LTD V	**EQ 20MG BASE**	**A203623**	**001**	Nov 26, 2014
AB		**EQ 25MG BASE**	**A202659**	**001**	Jun 11, 2018
AB		**EQ 50MG BASE**	**A202659**	**002**	Jun 11, 2018
AB		**EQ 100MG BASE**	**A202659**	**003**	Jun 11, 2018
AB	MACLEODS PHARMS LTD	**EQ 20MG BASE**	**A203814**	**001**	Dec 17, 2013
AB	MYLAN PHARMS INC	**EQ 20MG BASE**	**A201150**	**001**	Nov 09, 2012
AB	RUBICON RES PVT LTD	**EQ 20MG BASE**	**A204883**	**001**	Jun 20, 2016
AB		**EQ 25MG BASE**	**A204882**	**001**	Jun 11, 2018
AB		**EQ 50MG BASE**	**A204882**	**002**	Jun 11, 2018
AB		**EQ 100MG BASE**	**A204882**	**003**	Jun 11, 2018
AB	TEVA	**EQ 25MG BASE**	**A077342**	**001**	Mar 09, 2016
AB		**EQ 50MG BASE**	**A077342**	**002**	Mar 09, 2016
AB		**EQ 100MG BASE**	**A077342**	**003**	Mar 09, 2016
AB	TEVA PHARMS	**EQ 20MG BASE**	**A078380**	**001**	Jan 07, 2013
AB	TORRENT PHARMS LTD	**EQ 20MG BASE**	**A091479**	**001**	Nov 06, 2012
AB		**EQ 25MG BASE**	**A091448**	**001**	Jun 11, 2018
AB		**EQ 50MG BASE**	**A091448**	**002**	Jun 11, 2018
AB		**EQ 100MG BASE**	**A091448**	**003**	Jun 11, 2018
AB	WATSON LABS INC	**EQ 20MG BASE**	**A202503**	**001**	Nov 06, 2012
VIAGRA					
AB +	PFIZER INC	**EQ 25MG BASE**	**N020895**	**001**	Mar 27, 1998
AB +		**EQ 50MG BASE**	**N020895**	**002**	Mar 27, 1998
AB +!		**EQ 100MG BASE**	**N020895**	**003**	Mar 27, 1998

SILODOSIN

CAPSULE;ORAL

RAPAFLO						
AB +!	ALLERGAN SALES LLC	**4MG**	**N022206**	**001**	Oct 08, 2008
AB +		**8MG**	**N022206**	**002**	Oct 08, 2008
SILODOSIN						
AB	AJANTA PHARMA LTD	**4MG**	**A211060**	**001**	Dec 03, 2018
AB		**8MG**	**A211060**	**002**	Dec 03, 2018
AB	AMNEAL PHARMS CO	**4MG**	**A209745**	**001**	Dec 03, 2018
AB		**8MG**	**A209745**	**002**	Dec 03, 2018
AB	AUROBINDO PHARMA LTD	**4MG**	**A210626**	**001**	Dec 10, 2018
AB		**8MG**	**A210626**	**002**	Dec 10, 2018
AB	LUPIN LTD	**4MG**	**A206541**	**001**	Dec 03, 2018
AB		**8MG**	**A206541**	**002**	Dec 03, 2018
AB	MACLEODS PHARMS LTD	**4MG**	**A211166**	**001**	Dec 03, 2018
AB		**8MG**	**A211166**	**002**	Dec 03, 2018
AB	MSN LABS PVT LTD	**4MG**	**A210687**	**001**	Dec 03, 2018
AB		**8MG**	**A210687**	**002**	Dec 03, 2018
AB	SANDOZ INC	**4MG**	**A204726**	**001**	Mar 31, 2017
AB		**8MG**	**A204726**	**002**	Mar 31, 2017

SILVER SULFADIAZINE

CREAM;TOPICAL

SILVADENE					
AB +!	KING PHARMS LLC	**1%**	**N017381**	**001**	
SSD					
AB	DR REDDYS LA	**1%**	**N018578**	**001**	Feb 25, 1982
THERMAZENE					
AB	THEPHARMANETWORK LLC	**1%**	**N018810**	**001**	Dec 23, 1985

SIMVASTATIN

SUSPENSION;ORAL

FLOLIPID					
+	TCG FLUENT PHARMA	20MG/5ML	N206679	001	Apr 21, 2016
+!		40MG/5ML	N206679	002	Apr 21, 2016

TABLET;ORAL

SIMVASTATIN					
AB	ACCORD HLTHCARE	**5MG**	**A078155**	**005**	Apr 05, 2013
AB		**10MG**	**A078155**	**002**	Feb 26, 2008
AB		**20MG**	**A078155**	**003**	Feb 26, 2008
AB		**40MG**	**A078155**	**004**	Feb 26, 2008

SIMVASTATIN
TABLET;ORAL
SIMVASTATIN

AB			**80MG**	**A078155**	**001**	Feb 26, 2008
AB		AUROBINDO PHARMA	**5MG**	**A077691**	**001**	Dec 20, 2006
AB			**10MG**	**A077691**	**002**	Dec 20, 2006
AB			**20MG**	**A077691**	**003**	Dec 20, 2006
AB			**40MG**	**A077691**	**004**	Dec 20, 2006
AB			**80MG**	**A077691**	**005**	Dec 20, 2006
AB		BIOCON LIMITED	**5MG**	**A078034**	**001**	Dec 20, 2006
AB			**10MG**	**A078034**	**002**	Dec 20, 2006
AB			**20MG**	**A078034**	**003**	Dec 20, 2006
AB			**40MG**	**A078034**	**004**	Dec 20, 2006
AB			**80MG**	**A078034**	**005**	Dec 20, 2006
AB		DR REDDYS LABS INC	**5MG**	**A077752**	**005**	Jan 23, 2008
AB			**10MG**	**A077752**	**001**	Dec 20, 2006
AB			**20MG**	**A077752**	**002**	Dec 20, 2006
AB			**40MG**	**A077752**	**003**	Dec 20, 2006
AB			**80MG**	**A077752**	**004**	Dec 20, 2006
AB		HETERO LABS LTD III	**5MG**	**A200895**	**001**	Nov 25, 2014
AB			**10MG**	**A200895**	**002**	Nov 25, 2014
AB			**20MG**	**A200895**	**003**	Nov 25, 2014
AB			**40MG**	**A200895**	**004**	Nov 25, 2014
AB			**80MG**	**A200895**	**005**	Nov 25, 2014
AB		LUPIN	**5MG**	**A078103**	**005**	Apr 14, 2009
AB			**10MG**	**A078103**	**001**	May 11, 2007
AB			**20MG**	**A078103**	**002**	May 11, 2007
AB			**40MG**	**A078103**	**003**	May 11, 2007
AB			**80MG**	**A078103**	**004**	May 11, 2007
AB		OXFORD PHARMS	**5MG**	**A078735**	**001**	Aug 30, 2010
AB			**10MG**	**A078735**	**002**	Aug 30, 2010
AB			**20MG**	**A078735**	**003**	Aug 30, 2010
AB			**40MG**	**A078735**	**004**	Aug 30, 2010
AB			**80MG**	**A078735**	**005**	Aug 30, 2010
AB		VIVA HLTHCARE	**5MG**	**A090383**	**001**	Sep 16, 2011
AB			**10MG**	**A090383**	**002**	Sep 16, 2011
AB			**20MG**	**A090383**	**003**	Sep 16, 2011
AB			**40MG**	**A090383**	**004**	Sep 16, 2011
AB			**80MG**	**A090383**	**005**	Sep 16, 2011
AB		WATSON LABS TEVA	**5MG**	**A076685**	**001**	Dec 20, 2006
AB			**10MG**	**A076685**	**002**	Dec 20, 2006
AB			**20MG**	**A076685**	**003**	Dec 20, 2006
AB			**40MG**	**A076685**	**004**	Dec 20, 2006
AB			**80MG**	**A076685**	**005**	Dec 20, 2006
AB		ZYDUS PHARMS USA	**5MG**	**A077837**	**001**	Dec 20, 2006
AB			**10MG**	**A077837**	**002**	Dec 20, 2006
AB			**20MG**	**A077837**	**003**	Dec 20, 2006
AB			**40MG**	**A077837**	**004**	Dec 20, 2006
AB			**80MG**	**A077837**	**005**	Dec 20, 2006

ZOCOR

AB	**+**	MSD MERCK CO	**5MG**	**N019766**	**001**	Dec 23, 1991
AB	**+**		**10MG**	**N019766**	**002**	Dec 23, 1991
AB	**+**		**20MG**	**N019766**	**003**	Dec 23, 1991
AB	**+**		**40MG**	**N019766**	**004**	Dec 23, 1991
AB	**+!**		**80MG**	**N019766**	**005**	Jul 10, 1998

SINCALIDE
INJECTABLE;INJECTION
KINEVAC

+!	BRACCO	0.005MG/VIAL	N017697	001	

SINECATECHINS
OINTMENT;TOPICAL
VEREGEN

+!	FOUGERA PHARMS INC	15%	N021902	001	Oct 31, 2006

SIROLIMUS
SOLUTION;ORAL
RAPAMUNE

+!	PF PRISM CV	1MG/ML	N021083	001	Sep 15, 1999

TABLET;ORAL
RAPAMUNE

AB	**+**	PF PRISM CV	**0.5MG**	**N021110**	**004**	Jan 25, 2010
AB	**+**		**1MG**	**N021110**	**001**	Aug 25, 2000

SIROLIMUS						
TABLET;ORAL						
RAPAMUNE						
AB	**+!**		**2MG**	**N021110**	**002**	Aug 22, 2002
SIROLIMUS						
AB		DR REDDYS LABS LTD	**1MG**	**A201578**	**001**	Oct 27, 2014
AB			**2MG**	**A201578**	**002**	Oct 27, 2014
AB		ZYDUS PHARMS USA INC	**0.5MG**	**A201676**	**003**	Jan 08, 2014
SITAGLIPTIN PHOSPHATE						
TABLET;ORAL						
JANUVIA						
	+	MERCK SHARP DOHME	EQ 25MG BASE	N021995	001	Oct 16, 2006
	+		EQ 50MG BASE	N021995	002	Oct 16, 2006
	+!		EQ 100MG BASE	N021995	003	Oct 16, 2006
SODIUM ACETATE						
INJECTABLE;INJECTION						
SODIUM ACETATE						
		FRESENIUS KABI USA	4MEQ/ML	A206687	001	Oct 30, 2017
	+!	HOSPIRA	2MEQ/ML	N018893	001	May 04, 1983
SODIUM BENZOATE; SODIUM PHENYLACETATE						
SOLUTION;INTRAVENOUS						
AMMONUL						
AP	**+!**	MEDICIS	**10%;10% (5GM/50ML;5GM/50ML)**	**N020645**	**001**	Feb 17, 2005
SODIUM PHENYLACETATE AND SODIUM BENZOATE						
AP		AILEX PHARMS LLC	**10%;10% (5GM/50ML;5GM/50ML)**	**A207096**	**001**	Feb 24, 2016
AP		MAIA PHARMS INC	**10%;10% (5GM/50ML;5GM/50ML)**	**A208521**	**001**	May 08, 2017
AP		NAVINTA LLC	**10%;10% (5GM/50ML;5GM/50ML)**	**A205880**	**001**	Aug 04, 2016
SODIUM BICARBONATE						
INJECTABLE;INJECTION						
SODIUM BICARBONATE						
AP	**!**	HOSPIRA	**0.9MEQ/ML**	**A077394**	**001**	Nov 09, 2005
AP	**!**		**1MEQ/ML**	**A077394**	**002**	Nov 09, 2005
AP		HOSPIRA INC	**0.9MEQ/ML**	**A202494**	**001**	Mar 06, 2017
AP			**1MEQ/ML**	**A202432**	**001**	Sep 26, 2017
AP			**1MEQ/ML**	**A202494**	**002**	Mar 06, 2017
AP		INTL MEDICATION SYS	**1MEQ/ML**	**A203449**	**001**	Sep 19, 2017
		HOSPIRA INC	1MEQ/ML	A202495	001	Mar 06, 2017
SODIUM CHLORIDE						
INJECTABLE;INJECTION						
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		FRESENIUS KABI USA	**9MG/ML**	**A088911**	**001**	Feb 07, 1985
AP	**+!**	HOSPIRA	**9MG/ML**	**N018800**	**001**	Oct 29, 1982
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP	**+**	B BRAUN	**450MG/100ML**	**N019635**	**001**	Mar 09, 1988
AP		BAXTER HLTHCARE	**450MG/100ML**	**N018016**	**001**	
AP		FRESENIUS KABI USA	**450MG/100ML**	**A208122**	**001**	Jul 23, 2018
AP		HOSPIRA	**450MG/100ML**	**N019759**	**001**	Jun 08, 1988
AP	**+!**	ICU MEDICAL INC	**450MG/100ML**	**N018090**	**001**	
SODIUM CHLORIDE 0.9%						
AP		SPECTRA MDCL DEVICES	**9MG/ML**	**A206171**	**001**	Jul 21, 2017
AP		WEST-WARD PHARMS INT	**9MG/ML**	**A201850**	**001**	Jan 20, 2012
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	**+!**	B BRAUN	**900MG/100ML**	**N017464**	**001**	
AP	**+!**		**900MG/100ML**	**N019635**	**002**	Mar 09, 1988
AP	**+!**	BAXTER HLTHCARE	**9MG/ML**	**N016677**	**004**	Oct 30, 1985
AP	**+**		**9MG/ML**	**N020178**	**002**	Dec 07, 1992
AP	**+!**		**900MG/100ML**	**N016677**	**001**	
AP	**+!**		**900MG/100ML**	**N020178**	**001**	Dec 07, 1992
AP	**!**	FRESENIUS KABI USA	**9MG/ML**	**A088912**	**001**	Jan 10, 1985
AP			**900MG/100ML**	**A207310**	**001**	Sep 19, 2017
AP		FRESENIUS MEDCL	**900MG/100ML**	**A078177**	**001**	Apr 12, 2007
AP		HAEMONETICS	**900MG/100ML**	**A076316**	**001**	Oct 27, 2004
AP	**+!**	HOSPIRA	**9MG/ML**	**N018803**	**001**	Oct 29, 1982
AP	**+**		**9MG/ML**	**N019465**	**002**	Jul 15, 1985
AP	**+!**		**900MG/100ML**	**N019465**	**001**	Jul 15, 1985
AP	**+!**		**900MG/100ML**	**N019480**	**001**	Sep 17, 1985
AP	**+!**	ICU MEDICAL INC	**900MG/100ML**	**N016366**	**001**	

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		JUBILANT HOLLISTRSTR	**9MG/ML**	**A203352**	**001**	May 18, 2016
AP		LABORATORIOS GRIFOLS	**900MG/100ML**	**A207956**	**001**	May 25, 2017
AP	!	TARO	**9MG/ML**	**A077407**	**001**	Aug 11, 2006

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

AP		B BRAUN	**3GM/100ML**	**N019635**	**003**	Mar 09, 1988
AP	+!	BAXTER HLTHCARE	**3GM/100ML**	**N019022**	**001**	Nov 01, 1983

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML**	**N019635**	**004**	Mar 09, 1988
AP	+	BAXTER HLTHCARE	**5GM/100ML**	**N019022**	**002**	Nov 01, 1983

SODIUM CHLORIDE 0.9%

	+	B BRAUN	900MG/10ML	N019635	005	Aug 11, 2016
	+	MEDEFIL INC	90MG/10ML (9MG/ML)	N202832	006	Jan 06, 2012
		WEST-WARD PHARMS INT	9MG/ML	A201833	001	Sep 24, 2013

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	+!	LIEBEL-FLARSHEIM	405MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006
	+		1012.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006

SODIUM CHLORIDE IN PLASTIC CONTAINER

	+	HOSPIRA	2.5MEQ/ML	N018897	001	Jul 20, 1984

SOLUTION;IRRIGATION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AT	+!	B BRAUN	**900MG/100ML**	**N016733**	**001**
AT		BAXTER HLTHCARE	**900MG/100ML**	**N017427**	**001**
AT			**900MG/100ML**	**N017867**	**001**
AT		ICU MEDICAL INC	**900MG/100ML**	**N017514**	**001**
AT			**900MG/100ML**	**N018314**	**001**

SOLUTION FOR SLUSH;IRRIGATION

SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER

		BAXTER HLTHCARE	900MG/100ML	N019319	002	May 17, 1985

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE;INJECTION

FERRLECIT

AB	+!	SANOFI AVENTIS US	**62.5MG/5ML**	**N020955**	**001**	Feb 18, 1999

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB		WEST-WARD PHARMS INT	**62.5MG/5ML**	**A078215**	**001**	Mar 31, 2011

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

AP		3D IMAGING DRUG	**10-200mCi/ML**	**A203777**	**001**	Oct 19, 2015
AP		BIOMEDCL RES FDN	**10-200mCi/ML**	**A204351**	**001**	Jan 09, 2015
AP		CARDINAL HEALTH 414	**10-200mCi/ML**	**A203780**	**001**	Jul 30, 2015
AP		ESSENTIAL ISOTOPES	**10-200mCi/ML**	**A204541**	**001**	Oct 29, 2014
AP		GLOBAL ISOTOPES LLC	**10-200mCi/ML**	**A204464**	**001**	Oct 21, 2014
AP		HOT SHOTS NM LLC	**10-200mCi/ML**	**A204530**	**001**	Jul 29, 2015
AP	!	HOUSTON CYCLOTRON	**10-200mCi/ML**	**A203544**	**001**	Dec 26, 2012
AP		JUBILANT DRAXIMAGE	**10-200mCi/ML**	**A203968**	**001**	Oct 23, 2015
AP		KREITCHMAN PET CTR	**10-200mCi/ML**	**A203936**	**001**	May 19, 2016
AP		MIDWEST MEDCL	**10-200mCi/ML**	**A204440**	**001**	Nov 17, 2015
AP		MIPS CRF	**10-200mCi/ML**	**A204517**	**001**	Jul 21, 2015
AP		NCM USA BRONX LLC	**10-200mCi/ML**	**A204513**	**001**	Nov 28, 2014
AP		PETNET	**10-200mCi/ML**	**A203890**	**001**	Sep 28, 2015
AP		PRECISION NUCLEAR	**10-200mCi/ML**	**A204542**	**001**	Feb 27, 2015
AP		SHERTECH LABS LLC	**10-200mCi/ML**	**A204315**	**001**	Sep 22, 2014
AP		SOFIE	**10-200mCi/ML**	**A203592**	**001**	Aug 18, 2015
AP		SPECTRON MRC LLC	**10-200mCi/ML**	**A203912**	**001**	Apr 22, 2015
AP		UCSF RODIOPHARM	**10-200mCi/ML**	**A204437**	**001**	Mar 13, 2014
AP		UNIV UTAH CYCLOTRON	**10-200mCi/ML**	**A204497**	**001**	Apr 20, 2015
	!	MCPRF	10-91.5mCi/ML	A203605	001	Jun 28, 2013
		THE FEINSTEIN INST	20-600mCi/ML	A204328	001	Nov 19, 2014

SODIUM IODIDE I-123

CAPSULE;ORAL

SODIUM IODIDE I 123

AA	+!	CARDINAL HEALTH 418	**100uCi**	**N018671**	**001**	May 27, 1982
AA	+!		**200uCi**	**N018671**	**002**	May 27, 1982
AA		MALLINKRODT NUCLEAR	**100uCi**	**A071909**	**001**	Feb 28, 1989
AA			**200uCi**	**A071910**	**001**	Feb 28, 1989

SODIUM IODIDE I-131

CAPSULE;ORAL

SODIUM IODIDE I 131

+	JUBILANT DRAXIMAGE	0.009-0.1mCi	N021305	006	May 19, 2005

SOLUTION;ORAL

HICON

+!	JUBILANT DRAXIMAGE	250-1000mCi	N021305	007	Dec 05, 2011

SODIUM LACTATE

INJECTABLE;INJECTION

SODIUM LACTATE IN PLASTIC CONTAINER

+!	HOSPIRA	5MEQ/ML	N018947	001	Sep 05, 1984

SODIUM NITRITE

SOLUTION;INTRAVENOUS

SODIUM NITRITE

+!	HOPE PHARMS	300MG/10ML (30MG/ML)	N203922	001	Feb 14, 2012

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS

NITHIODOTE

+!	HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML (250MG/ML)	N201444	001	Jan 14, 2011

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION

NITROPRESS

AP	**!**	HOSPIRA	**25MG/ML**	**A071961**	**001**	Aug 01, 1988

SODIUM NITROPRUSSIDE

AP		AKORN	**25MG/ML**	**A208635**	**001**	May 04, 2017
AP		AMNEAL PHARMS CO	**25MG/ML**	**A209493**	**001**	Nov 07, 2017
AP		AMPHASTAR PHARMS INC	**25MG/ML**	**A209832**	**001**	Dec 18, 2017
AP		CIPLA	**25MG/ML**	**A210855**	**001**	Jul 16, 2018
AP		MEDICURE	**25MG/ML**	**A209584**	**001**	Aug 10, 2018
AP		MICRO LABS	**25MG/ML**	**A209352**	**001**	Dec 08, 2017
AP		MYLAN LABS LTD	**25MG/ML**	**A210763**	**001**	Apr 17, 2018
AP		NAMIGEN LLC	**25MG/ML**	**A207426**	**001**	Dec 08, 2016
AP		NEXUS PHARMS	**25MG/ML**	**A207499**	**001**	May 25, 2017
AP		RENAISSANCE SSA LLC	**25MG/ML**	**A209834**	**001**	Jun 26, 2018
AP		SOMERSET THERAPS LLC	**25MG/ML**	**A210882**	**001**	Aug 17, 2018
AP		SUN PHARM INDS LTD	**25MG/ML**	**A210467**	**001**	Nov 26, 2018

SOLUTION;INTRAVENOUS

NIPRIDE RTU IN SODIUM CHLORIDE 0.9%

+!	EXELA PHARMA SCS LLC	10MG/50ML (0.2MG/ML)	N209387	002	Dec 07, 2017
+!		20MG/100ML (0.2MG/ML)	N209387	003	Jul 13, 2018
+!		50MG/100ML (0.5MG/ML)	N209387	001	Mar 08, 2017

SODIUM OXYBATE

SOLUTION;ORAL

SODIUM OXYBATE

AA		WEST-WARD PHARMS INT	**500MG/ML**	**A202090**	**001**	Jan 17, 2017

XYREM

AA	**+!**	JAZZ PHARMS	**500MG/ML**	**N021196**	**001**	Jul 17, 2002

SODIUM PHENYLBUTYRATE

POWDER;ORAL

BUPHENYL

AB	**+!**	HORIZON PHARMA INC	**3GM/TEASPOONFUL**	**N020573**	**001**	Apr 30, 1996

SODIUM PHENYLBUTYRATE

AB		PAR PHARM	**3GM/TEASPOONFUL**	**A203918**	**001**	Jun 15, 2016
AB		SIGMAPHARM LABS LLC	**3GM/TEASPOONFUL**	**A202819**	**001**	Mar 22, 2013

TABLET;ORAL

BUPHENYL

AB	**+!**	HORIZON PHARMA INC	**500MG**	**N020572**	**001**	May 13, 1996

SODIUM PHENYLBUTYRATE

AB		ALVOGEN MALTA	**500MG**	**A090910**	**001**	Nov 18, 2011
AB		PAR PHARM	**500MG**	**A204395**	**001**	Apr 15, 2016

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET;ORAL

OSMOPREP

	+!	SALIX PHARMS	0.398GM;1.102GM	N021892	001	Mar 16, 2006

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE;INJECTION

SODIUM PHOSPHATES IN PLASTIC CONTAINER

	+!	HOSPIRA	142MG/ML;276MG/ML	N018892	001	May 10, 1983

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

KALEXATE

AA	**!**	KVK TECH	**454GM/BOT**	**A040905**	**001**	Mar 30, 2009

KIONEX

AA		PADDOCK LLC	**454GM/BOT**	**A040029**	**001**	Feb 06, 1998

SODIUM POLYSTYRENE SULFONATE

AA		APNAR PHARMA LP	**454GM/BOT**	**A206815**	**001**	Feb 18, 2016
AA		BELCHER PHARMS LLC	**454GM/BOT**	**A205727**	**001**	Feb 23, 2016
AA		CMP PHARMA INC	**454GM/BOT**	**A089910**	**001**	Jan 19, 1989
AA		ECI PHARMS LLC	**453.6GM/BOT**	**A090313**	**001**	Dec 21, 2011
AA		EPIC PHARMA LLC	**453.6GM/BOT**	**A202333**	**001**	Mar 19, 2014
AA		NUVO PHARMS INC	**454GM/BOT**	**A204071**	**001**	Nov 28, 2014

KALEXATE

		KVK TECH	15GM/BOT	A040905	002	Apr 03, 2015

SODIUM POLYSTYRENE SULFONATE

		NUVO PHARMS INC	15GM/BOT	A204071	002	Nov 28, 2014

SUSPENSION;ORAL, RECTAL

KIONEX

AA		PADDOCK LLC	**15GM/60ML**	**A040028**	**001**	Sep 17, 2007

SODIUM POLYSTYRENE SULFONATE

AA		PADDOCK LLC	**15GM/60ML**	**A090590**	**001**	May 13, 2011
AA		WEST-WARD PHARMS INT	**15GM/60ML**	**A089049**	**001**	Nov 17, 1986

SPS

AA	**!**	CMP PHARMA INC	**15GM/60ML**	**A087859**	**001**	Dec 08, 1982

SODIUM TETRADECYL SULFATE

INJECTABLE;INJECTION

SOTRADECOL

	!	MYLAN INSTITUTIONAL	20MG/2ML (10MG/ML)	A040541	001	Nov 12, 2004
	!		60MG/2ML (30MG/ML)	A040541	002	Nov 12, 2004

SODIUM THIOSULFATE

SOLUTION;INTRAVENOUS

SODIUM THIOSULFATE

	+!	HOPE PHARMS	12.5GM/50ML (250MG/ML)	N203923	001	Feb 14, 2012

SODIUM ZIRCONIUM CYCLOSILICATE

FOR SUSPENSION;ORAL

LOKELMA

	+	ASTRAZENECA PHARMS	5GM/PACKET	N207078	001	May 18, 2018
	+!		10GM/PACKET	N207078	002	May 18, 2018

SOFOSBUVIR

TABLET;ORAL

SOVALDI

	+!	GILEAD SCIENCES INC	400MG	N204671	001	Dec 06, 2013

SOFOSBUVIR; VELPATASVIR

TABLET;ORAL

EPCLUSA

	+!	GILEAD SCIENCES INC	400MG;100MG	N208341	001	Jun 28, 2016

SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR

TABLET;ORAL

VOSEVI

	+!	GILEAD SCIENCES INC	400MG;100MG;100MG	N209195	001	Jul 18, 2017

SOLIFENACIN SUCCINATE

TABLET;ORAL

SOLIFENACIN SUCCINATE

AB		TEVA PHARMS USA	**5MG**	**A091464**	**001**	Apr 02, 2014
AB			**10MG**	**A091464**	**002**	Apr 02, 2014

VESICARE

AB	**+**	ASTELLAS	**5MG**	**N021518**	**001**	Nov 19, 2004
AB	**+!**		**10MG**	**N021518**	**002**	Nov 19, 2004

SOMATROPIN						
INJECTABLE;INJECTION						
ZOMACTON						
BX	+!	FERRING	5MG/VIAL	N019774	002	Jan 04, 2002
	+		10MG/VIAL	N019774	003	Mar 07, 2012
SOMATROPIN RECOMBINANT						
INJECTABLE;INJECTION						
GENOTROPIN						
BX	+!	PHARMACIA AND UPJOHN	5.8MG/VIAL	N020280	006	Aug 24, 1995
HUMATROPE						
BX	+!	LILLY	5MG/VIAL	N019640	004	Mar 08, 1987
BX	+		6MG/VIAL	N019640	005	Feb 04, 1999
NORDITROPIN FLEXPRO						
BX		NOVO NORDISK INC	5MG/1.5ML	N021148	008	Mar 01, 2010
BX			10MG/1.5ML	N021148	009	Mar 01, 2010
OMNITROPE						
BX		SANDOZ	1.5MG/VIAL	N021426	002	May 30, 2006
BX			5MG/1.5ML	N021426	003	Jan 16, 2008
BX			5.8MG/VIAL	N021426	001	May 30, 2006
BX			10MG/1.5ML	N021426	004	Aug 25, 2008
SAIZEN						
BX	+	EMD SERONO	5MG/VIAL	N019764	002	Oct 08, 1996
SEROSTIM						
BX		EMD SERONO	5MG/VIAL	N020604	002	Aug 23, 1996
BX			6MG/VIAL	N020604	001	Aug 23, 1996
GENOTROPIN						
	+!	PHARMACIA AND UPJOHN	13.8MG/VIAL	N020280	007	Oct 23, 1996
GENOTROPIN PRESERVATIVE FREE						
	+	PHARMACIA AND UPJOHN	0.2MG/VIAL	N020280	001	Jan 27, 1998
	+		0.4MG/VIAL	N020280	002	Jan 27, 1998
	+		0.6MG/VIAL	N020280	003	Jan 27, 1998
	+		0.8MG/VIAL	N020280	005	Jan 27, 1998
	+		1MG/VIAL	N020280	008	Jan 27, 1998
	+		1.2MG/VIAL	N020280	009	Jan 27, 1998
	+		1.4MG/VIAL	N020280	010	Jan 27, 1998
	+		1.6MG/VIAL	N020280	011	Jan 27, 1998
	+		1.8MG/VIAL	N020280	012	Jan 27, 1998
	+!		2MG/VIAL	N020280	013	Jan 27, 1998
HUMATROPE						
	+!	LILLY	12MG/VIAL	N019640	006	Feb 04, 1999
	+!		24MG/VIAL	N019640	007	Feb 04, 1999
NORDITROPIN FLEXPRO						
		NOVO NORDISK INC	15MG/1.5ML	N021148	010	Mar 01, 2010
			30MG/3ML	N021148	011	Jan 23, 2015
NUTROPIN AQ NUSPIN						
	+!	GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008
	+!		10MG/2ML (5MG/ML)	N020522	005	Jan 03, 2008
	+!		20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008
SAIZEN						
	+!	EMD SERONO	8.8MG/VIAL	N019764	003	Aug 29, 2000
SEROSTIM						
		EMD SERONO	4MG/VIAL	N020604	003	Jul 25, 1997
ZORBTIVE						
	+!	EMD SERONO	8.8MG/VIAL	N021597	004	Dec 01, 2003
SONIDEGIB PHOSPHATE						
CAPSULE;ORAL						
ODOMZO						
	+!	SUN PHARMA GLOBAL	EQ 200MG BASE	N205266	001	Jul 24, 2015
SORAFENIB TOSYLATE						
TABLET;ORAL						
NEXAVAR						
	+!	BAYER HLTHCARE	EQ 200MG BASE	N021923	001	Dec 20, 2005

SORBITOL

SOLUTION;IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	3GM/100ML	N017863	001	

SORBITOL 3.3% IN PLASTIC CONTAINER

	B BRAUN	3.3GM/100ML	N016741	001	

SOTALOL HYDROCHLORIDE

SOLUTION;INTRAVENOUS

SOTALOL HYDROCHLORIDE

+!	ALTATHERA PHARMS LLC	150MG/10ML (15MG/ML)	N022306	001	Jul 02, 2009

SOLUTION;ORAL

SOTYLIZE

+!	ARBOR PHARMS LLC	5MG/ML (5MG/ML)	N205108	001	Oct 22, 2014

TABLET;ORAL

BETAPACE

AB1	**+**	COVIS PHARMA BV	**80MG**	**N019865**	**001**	Oct 30, 1992
AB1	**+**		**120MG**	**N019865**	**005**	Apr 20, 1994
AB1	**+!**		**160MG**	**N019865**	**002**	Oct 30, 1992
AB1	**+**		**240MG**	**N019865**	**003**	Oct 30, 1992

SORINE

AB1		UPSHER SMITH LABS	**80MG**	**A075500**	**001**	Apr 27, 2001
AB1			**120MG**	**A075500**	**004**	Apr 27, 2001
AB1			**160MG**	**A075500**	**002**	Apr 27, 2001
AB1			**240MG**	**A075500**	**003**	Apr 27, 2001

SOTALOL HYDROCHLORIDE

AB1		APOTEX INC	**80MG**	**A076140**	**001**	Sep 26, 2002
AB1			**120MG**	**A076140**	**002**	Sep 26, 2002
AB1			**160MG**	**A076140**	**003**	Sep 26, 2002
AB1			**240MG**	**A076140**	**004**	Sep 26, 2002
AB1		BEXIMCO PHARMS USA	**80MG**	**A207428**	**001**	Oct 21, 2016
AB1			**120MG**	**A207428**	**002**	Oct 21, 2016
AB1			**160MG**	**A207428**	**003**	Oct 21, 2016
AB1		OXFORD PHARMS	**80MG**	**A075563**	**001**	Nov 07, 2003
AB1			**120MG**	**A075563**	**002**	Nov 07, 2003
AB1			**160MG**	**A075563**	**003**	Nov 07, 2003
AB1			**240MG**	**A075563**	**004**	Nov 07, 2003
AB1		TEVA	**80MG**	**A075429**	**001**	May 01, 2000
AB1			**120MG**	**A075429**	**002**	May 01, 2000
AB1			**160MG**	**A075429**	**003**	May 01, 2000
AB1			**240MG**	**A075429**	**004**	May 01, 2000
AB1		UPSHER SMITH LABS	**80MG**	**A075366**	**001**	May 01, 2000
AB1			**120MG**	**A075366**	**002**	May 01, 2000
AB1			**160MG**	**A075366**	**003**	May 01, 2000
AB1			**240MG**	**A075366**	**004**	May 01, 2000

BETAPACE AF

AB2	**+**	COVIS PHARMA BV	**80MG**	**N021151**	**001**	Feb 22, 2000
AB2	**+**		**120MG**	**N021151**	**002**	Feb 22, 2000
AB2	**+!**		**160MG**	**N021151**	**003**	Feb 22, 2000

SOTALOL HYDROCHLORIDE

AB2		APOTEX	**80MG**	**A076214**	**001**	Aug 27, 2003
AB2			**120MG**	**A076214**	**002**	Aug 27, 2003
AB2			**160MG**	**A076214**	**003**	Aug 27, 2003
AB2		BEXIMCO PHARMS USA	**80MG**	**A207429**	**001**	Nov 02, 2018
AB2			**120MG**	**A207429**	**002**	Nov 02, 2018
AB2			**160MG**	**A207429**	**003**	Nov 02, 2018
AB2		EPIC PHARMA INC	**80MG**	**A077070**	**001**	Nov 04, 2005
AB2			**120MG**	**A077070**	**002**	Nov 04, 2005
AB2			**160MG**	**A077070**	**003**	Nov 04, 2005
AB2		MYLAN	**80MG**	**A077616**	**001**	Feb 07, 2007
AB2			**120MG**	**A077616**	**002**	Feb 07, 2007
AB2			**160MG**	**A077616**	**003**	Feb 07, 2007

SOYBEAN OIL

INJECTABLE;INJECTION

INTRALIPID 10%

AP	**+!**	FRESENIUS	**10%**	**N017643**	**001**	

INTRALIPID 20%

AP	**+!**	FRESENIUS	**20%**	**N018449**	**001**	
AP	**+!**		**20%**	**N020248**	**001**	Aug 07, 1996

NUTRILIPID 10%

AP	**+!**	B BRAUN	**10%**	**N019531**	**001**	May 28, 1993

SOYBEAN OIL							
INJECTABLE;INJECTION							
NUTRILIPID 20%							
AP	**+!**	B BRAUN	**20%**	**N019531**	**002**	May 28, 1993
INTRALIPID 30%							
	+!	FRESENIUS	30%	N019942	001	Dec 30, 1993
SPINOSAD							
SUSPENSION;TOPICAL							
NATROBA							
	+!	PARAPRO LLC	0.9%	N022408	001	Jan 18, 2011
SPIRONOLACTONE							
SUSPENSION;ORAL							
CAROSPIR							
	+!	CMP DEV LLC	25MG/5ML	N209478	001	Aug 04, 2017
TABLET;ORAL							
ALDACTONE							
AB	**+**	GD SEARLE LLC	**25MG**	**N012151**	**009**	Dec 30, 1983
AB	**+**		**50MG**	**N012151**	**008**	Dec 30, 1982
AB	**+!**		**100MG**	**N012151**	**010**	Dec 30, 1983
SPIRONOLACTONE							
AB		ACCORD HLTHCARE	**25MG**	**A203512**	**001**	Sep 19, 2016
AB			**50MG**	**A203512**	**002**	Sep 19, 2016
AB			**100MG**	**A203512**	**003**	Sep 19, 2016
AB		ACTAVIS ELIZABETH	**25MG**	**A040353**	**003**	Mar 15, 2006
AB			**50MG**	**A040353**	**001**	Jul 29, 1999
AB			**100MG**	**A040353**	**002**	Jul 29, 1999
AB		AMNEAL PHARMS	**25MG**	**A091426**	**001**	Jul 02, 2010
AB			**50MG**	**A091426**	**002**	Jul 02, 2010
AB			**100MG**	**A091426**	**003**	Jul 02, 2010
AB		CASI PHARMS INC	**25MG**	**A086809**	**001**	
AB		JUBILANT GENERICS	**25MG**	**A203253**	**001**	Apr 23, 2014
AB			**50MG**	**A203253**	**002**	Apr 23, 2014
AB			**100MG**	**A203253**	**003**	Apr 23, 2014
AB		MYLAN	**25MG**	**A040424**	**001**	Aug 20, 2001
AB			**50MG**	**A040424**	**002**	Aug 20, 2001
AB			**100MG**	**A040424**	**003**	Aug 20, 2001
AB		OXFORD PHARMS	**25MG**	**A040750**	**001**	Aug 29, 2006
AB			**50MG**	**A040750**	**002**	Aug 29, 2006
AB			**100MG**	**A040750**	**003**	Aug 29, 2006
AB		SUN PHARM INDUSTRIES	**25MG**	**A089424**	**001**	Jul 23, 1986
AB			**50MG**	**A089424**	**002**	Aug 11, 1999
AB			**100MG**	**A089424**	**003**	Aug 11, 1999
AB		ZYDUS PHARMS USA INC	**25MG**	**A205936**	**001**	Jul 18, 2018
AB			**50MG**	**A205936**	**002**	Jul 18, 2018
AB			**100MG**	**A205936**	**003**	Jul 18, 2018
STAVUDINE							
CAPSULE;ORAL							
STAVUDINE							
AB		AUROBINDO PHARMA	**15MG**	**A077672**	**003**	Dec 29, 2008
AB			**20MG**	**A077672**	**004**	Dec 29, 2008
AB			**30MG**	**A077672**	**001**	Dec 29, 2008
AB			**40MG**	**A077672**	**002**	Dec 29, 2008
AB		HETERO LABS LTD III	**15MG**	**A078957**	**001**	Dec 29, 2008
AB			**20MG**	**A078957**	**002**	Dec 29, 2008
AB			**30MG**	**A078957**	**003**	Dec 29, 2008
AB			**40MG**	**A078957**	**004**	Dec 29, 2008
AB		MYLAN	**15MG**	**A079069**	**001**	Dec 29, 2008
AB			**20MG**	**A079069**	**002**	Dec 29, 2008
AB			**30MG**	**A079069**	**003**	Dec 29, 2008
AB			**40MG**	**A079069**	**004**	Dec 29, 2008
ZERIT							
AB	**+**	BRISTOL MYERS SQUIBB	**15MG**	**N020412**	**002**	Jun 24, 1994
AB	**+**		**20MG**	**N020412**	**003**	Jun 24, 1994
AB	**+**		**30MG**	**N020412**	**004**	Jun 24, 1994
AB	**+!**		**40MG**	**N020412**	**005**	Jun 24, 1994
FOR SOLUTION;ORAL							
ZERIT							
	+!	BRISTOL-MYERS SQUIBB	1MG/ML	N020413	001	Sep 06, 1996

STERILE WATER FOR INJECTION

LIQUID;N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

AP	**+!**	HOSPIRA	**100%**	**N018802**	**001**	Oct 27, 1982

STERILE WATER FOR INJECTION

AP		FRESENIUS KABI USA	**100%**	**A209689**	**001**	Nov 24, 2017
AP		WEST-WARD PHARMS INT	**100%**	**A206369**	**001**	Sep 02, 2015

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**100%**	**N019633**	**001**	Feb 29, 1988
AP	**+!**	BAXTER HLTHCARE	**100%**	**N018632**	**001**	Jun 30, 1982
AP	**+!**		**100%**	**N018632**	**002**	Apr 19, 1988
AP		FRESENIUS KABI USA	**100%**	**A088400**	**001**	Jan 16, 1984
AP	**+!**	HOSPIRA	**100%**	**N018801**	**001**	Oct 27, 1982
AP	**+!**	ICU MEDICAL INC	**100%**	**N018233**	**001**	
AP	**+!**		**100%**	**N019869**	**001**	Dec 26, 1989
AP		TARO	**100%**	**A077393**	**001**	Aug 11, 2006

STERILE WATER FOR IRRIGATION

LIQUID;IRRIGATION

STERILE WATER

AT		BAXTER HLTHCARE	**100%**	**N017428**	**001**		

STERILE WATER IN PLASTIC CONTAINER

AT	**+**	B BRAUN	**100%**	**N016734**	**001**		
AT		BAXTER HLTHCARE	**100%**	**N017866**	**001**		
AT		ICU MEDICAL INC	**100%**	**N017513**	**001**		
AT			**100%**	**N018313**	**001**		

STIRIPENTOL

CAPSULE;ORAL

DIACOMIT

	+	BIOCODEX SA	250MG	N206709	001	Aug 20, 2018
	+!		500MG	N206709	002	Aug 20, 2018

FOR SUSPENSION;ORAL

DIACOMIT

	+	BIOCODEX SA	250MG/PACKET	N207223	001	Aug 20, 2018
	+!		500MG/PACKET	N207223	002	Aug 20, 2018

STREPTOMYCIN SULFATE

INJECTABLE;INJECTION

STREPTOMYCIN SULFATE

	!	X GEN PHARMS	EQ 1GM BASE/VIAL	A064210	001	Jun 30, 1998

STREPTOZOCIN

INJECTABLE;INJECTION

ZANOSAR

	+!	TEVA PHARMS USA	1GM/VIAL	N050577	001	May 07, 1982

STRONTIUM CHLORIDE SR-89

INJECTABLE;INJECTION

METASTRON

AP	**+!**	GE HEALTHCARE	**1mCi/ML**	**N020134**	**001**	Jun 18, 1993

STRONTIUM CHLORIDE SR-89

AP		BIO NUCLEONICS	**1mCi/ML**	**A075941**	**001**	Jan 06, 2003

SUCCIMER

CAPSULE;ORAL

CHEMET

	+!	RECORDATI RARE	100MG	N019998	002	Jan 30, 1991

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

ANECTINE

AP	**+!**	SANDOZ INC	**20MG/ML**	**N008453**	**002**		

QUELICIN

AP	**+!**	HOSPIRA	**20MG/ML**	**N008845**	**006**		

SUCCINYLCHOLINE CHLORIDE

AP		AMNEAL PHARMS CO	**20MG/ML**	**A211432**	**001**	Nov 16, 2018
AP		RENAISSANCE SSA LLC	**20MG/ML**	**A210231**	**001**	Jun 04, 2018
AP	**!**	ZYDUS PHARMS USA INC	**20MG/ML**	**A209467**	**001**	May 04, 2018

SUCRALFATE						
SUSPENSION;ORAL						
CARAFATE						
	+!	ALLERGAN SALES LLC	1GM/10ML	N019183	001	Dec 16, 1993
TABLET;ORAL						
CARAFATE						
AB	**+!**	ALLERGAN SALES LLC	**1GM**	**N018333**	**001**	
SUCRALFATE						
AB		TEVA	**1GM**	**A070848**	**001**	Mar 29, 1996
SUCROFERRIC OXYHYDROXIDE						
TABLET, CHEWABLE;ORAL						
VELPHORO						
	+!	VIFOR FRESENIUS	500MG	N205109	001	Nov 27, 2013
SUFENTANIL CITRATE						
INJECTABLE;INJECTION						
SUFENTA PRESERVATIVE FREE						
AP	**+!**	AKORN	**EQ 0.05MG BASE/ML**	**N019050**	**001**	May 04, 1984
SUFENTANIL CITRATE						
AP		HOSPIRA	**EQ 0.05MG BASE/ML**	**A074534**	**001**	Dec 11, 1996
AP		WEST-WARD PHARMS INT	**EQ 0.05MG BASE/ML**	**A074413**	**001**	Dec 15, 1995
TABLET;SUBLINGUAL						
DSUVIA						
	+!	ACELRX PHARMS	EQ 0.03MG BASE	N209128	001	Nov 02, 2018
SUGAMMADEX SODIUM						
SOLUTION;INTRAVENOUS						
BRIDION						
	+	ORGANON SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015
	+!		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225	001	Dec 15, 2015
SULCONAZOLE NITRATE						
CREAM;TOPICAL						
EXELDERM						
	+!	JOURNEY	1%	N018737	001	Feb 28, 1989
SOLUTION;TOPICAL						
EXELDERM						
	+!	JOURNEY	1%	N018738	001	Aug 30, 1985
SULFACETAMIDE SODIUM						
LOTION;TOPICAL						
KLARON						
AB	**+!**	VALEANT PHARMS NORTH	**10%**	**N019931**	**001**	Dec 23, 1996
SULFACETAMIDE SODIUM						
AB		FOUGERA PHARMS	**10%**	**A077015**	**001**	Nov 17, 2006
AB		PERRIGO CO TENNESSEE	**10%**	**A078649**	**001**	Mar 23, 2009
AB		TARO	**10%**	**A078668**	**001**	May 20, 2009
OINTMENT;OPHTHALMIC						
SULFACETAMIDE SODIUM						
	!	PERRIGO CO TENNESSEE	10%	A080029	001	
SOLUTION/DROPS;OPHTHALMIC						
BLEPH-10						
AT	**!**	ALLERGAN	**10%**	**A080028**	**001**	
SULFACETAMIDE SODIUM						
AT		AKORN	**10%**	**A040215**	**001**	May 25, 1999
AT		BAUSCH AND LOMB	**10%**	**A040066**	**001**	Dec 28, 1994
AT		SANDOZ INC	**10%**	**A089560**	**001**	Oct 18, 1988
SULFADIAZINE						
TABLET;ORAL						
SULFADIAZINE						
	!	SANDOZ	500MG	A040091	001	Jul 29, 1994
SULFAMETHOXAZOLE; TRIMETHOPRIM						
INJECTABLE;INJECTION						
SULFAMETHOXAZOLE AND TRIMETHOPRIM						
AP		MYLAN LABS LTD	**80MG/ML;16MG/ML**	**A206607**	**001**	Aug 30, 2017
AP	**!**	TEVA PHARMS USA	**80MG/ML;16MG/ML**	**A073303**	**001**	Oct 31, 1991
SUSPENSION;ORAL						
SULFAMETHOXAZOLE AND TRIMETHOPRIM						
AB		AUROBINDO PHARMA	**200MG/5ML;40MG/5ML**	**A091348**	**001**	Jun 08, 2010
AB	**!**	HI TECH PHARMA	**200MG/5ML;40MG/5ML**	**A074650**	**001**	Dec 29, 1997

SULFAMETHOXAZOLE; TRIMETHOPRIM						
SUSPENSION;ORAL						
SULFAMETHOXAZOLE AND TRIMETHOPRIM						
AB		LANNETT CO INC	**200MG/5ML;40MG/5ML**	**A077785**	**001**	Jan 24, 2007
SULFATRIM PEDIATRIC						
AB		PHARM ASSOC	**200MG/5ML;40MG/5ML**	**N018615**	**001**	Jan 07, 1983
TABLET;ORAL						
BACTRIM						
AB	+	SUN PHARM INDUSTRIES	**400MG;80MG**	**N017377**	**001**	
BACTRIM DS						
AB	+!	SUN PHARM INDUSTRIES	**800MG;160MG**	**N017377**	**002**	
SEPTRA						
AB		MONARCH PHARMS	**400MG;80MG**	**N017376**	**001**	
SEPTRA DS						
AB		MONARCH PHARMS	**800MG;160MG**	**N017376**	**002**	
SULFAMETHOXAZOLE AND TRIMETHOPRIM						
AB		AMNEAL PHARMS NY	**400MG;80MG**	**A076899**	**001**	Jan 27, 2005
AB			**800MG;160MG**	**A076899**	**002**	Jan 27, 2005
AB		AUROBINDO PHARMA	**400MG;80MG**	**A090624**	**001**	Feb 16, 2010
AB			**800MG;160MG**	**A090624**	**002**	Feb 16, 2010
AB		CHARTWELL MOLECULES	**400MG;80MG**	**A078060**	**002**	Jan 25, 2007
AB			**800MG;160MG**	**A078060**	**001**	Jan 25, 2007
AB		GLENMARK GENERICS	**400MG;80MG**	**A090828**	**002**	Dec 22, 2010
AB			**800MG;160MG**	**A090828**	**001**	Dec 22, 2010
AB		SUN PHARM INDUSTRIES	**400MG;80MG**	**A071017**	**002**	Aug 25, 1986
AB			**800MG;160MG**	**A071017**	**001**	Aug 25, 1986
AB		VISTA PHARMS	**400MG;80MG**	**A076817**	**001**	Oct 07, 2005
AB			**800MG;160MG**	**A076817**	**002**	Oct 07, 2005
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH						
AB		TEVA	**800MG;160MG**	**A070037**	**001**	Jun 02, 1987
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH						
AB		TEVA PHARMS	**400MG;80MG**	**A070030**	**001**	Jun 02, 1987
SULFANILAMIDE						
CREAM;VAGINAL						
AVC						
	+!	MYLAN SPECIALITY LP	15%	N006530	003	Jan 27, 1987
SULFASALAZINE						
TABLET;ORAL						
AZULFIDINE						
AB	+!	PHARMACIA AND UPJOHN	**500MG**	**N007073**	**001**	
SULFASALAZINE						
AB		VINTAGE PHARMS	**500MG**	**A040349**	**001**	Jan 11, 2002
AB		WATSON LABS	**500MG**	**A085828**	**001**	
TABLET, DELAYED RELEASE;ORAL						
AZULFIDINE EN-TABS						
AB	+!	PHARMACIA AND UPJOHN	**500MG**	**N007073**	**002**	Apr 06, 1983
SULFASALAZINE						
AB		VINTAGE PHARMS	**500MG**	**A075339**	**001**	Jan 11, 2002
SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES						
FOR SUSPENSION;INTRAVENOUS						
LUMASON						
	+!	BRACCO	60.7MG/25MG	N203684	001	Oct 15, 2014
SULINDAC						
TABLET;ORAL						
SULINDAC						
AB		EPIC PHARMA	**150MG**	**A072710**	**001**	Mar 25, 1991
AB			**200MG**	**A072711**	**001**	Mar 25, 1991
AB		MYLAN	**150MG**	**A073039**	**002**	Jun 22, 1993
AB			**200MG**	**A073039**	**001**	Jun 22, 1993
AB		SUN PHARM INDUSTRIES	**150MG**	**A072050**	**001**	Apr 17, 1991
AB			**200MG**	**A072051**	**001**	Apr 17, 1991
AB		WATSON LABS	**150MG**	**A071891**	**001**	Apr 03, 1990
AB	!		**200MG**	**A071795**	**001**	Apr 03, 1990

SUMATRIPTAN

SPRAY;NASAL

IMITREX

AB	**+!**	GLAXOSMITHKLINE	**5MG/SPRAY**	**N020626**	**001**	Aug 26, 1997
AB	**+!**		**20MG/SPRAY**	**N020626**	**003**	Aug 26, 1997

SUMATRIPTAN

AB		LANNETT CO INC	**5MG/SPRAY**	**A204841**	**001**	Feb 19, 2016
AB			**20MG/SPRAY**	**A204841**	**002**	Feb 19, 2016

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

IMITREX STATDOSE

AB	**+!**	GLAXOSMITHKLINE	**EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)**	**N020080**	**002**	Feb 01, 2006
AB	**+!**		**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**N020080**	**003**	Dec 23, 1996

SUMATRIPTAN SUCCINATE

AB		ANTARES PHARMA INC	**EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)**	**A078319**	**001**	Dec 10, 2015
AB			**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A078319**	**002**	Dec 10, 2015
AB		DR REDDYS LABS INC	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A090495**	**001**	Jan 29, 2014
AB		SUN PHARMA GLOBAL	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A090358**	**001**	Jun 21, 2011

IMITREX

AP	**+!**	GLAXOSMITHKLINE	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**N020080**	**001**	Dec 28, 1992

SUMATRIPTAN SUCCINATE

AP		AUROBINDO PHARMA LTD	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A202758**	**001**	Apr 23, 2013
AP		FRESENIUS KABI USA	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A079242**	**001**	Mar 02, 2009
AP		HIKMA FARMACEUTICA	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A200183**	**001**	Sep 16, 2013
AP		MYLAN ASI	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A090314**	**001**	Jun 10, 2010
AP			**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A090641**	**001**	Jul 28, 2010
AP		MYLAN LABS LTD	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A203322**	**001**	Apr 14, 2014
AP		PAR PHARM	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A077332**	**001**	Oct 09, 2009
AP		PAR STERILE PRODUCTS	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A077871**	**001**	Jul 09, 2009
AP		TEVA PHARMS USA	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A077907**	**001**	Feb 06, 2009
AP		WEST-WARD PHARMS INT	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A079123**	**001**	Feb 06, 2009
AP		WOCKHARDT	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A078593**	**001**	Feb 06, 2009

POWDER;INHALATION

ONZETRA XSAIL

	+!	AVANIR PHARMS	EQ 11MG BASE	N206099	001	Jan 27, 2016

SOLUTION;SUBCUTANEOUS

ZEMBRACE SYMTOUCH

	+	DR REDDYS LABS LTD	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001	Jan 28, 2016

TABLET;ORAL

IMITREX

AB	**+**	GLAXOSMITHKLINE	**EQ 25MG BASE**	**N020132**	**002**	Jun 01, 1995
AB	**+**		**EQ 50MG BASE**	**N020132**	**003**	Jun 01, 1995
AB	**+!**		**EQ 100MG BASE**	**N020132**	**001**	Jun 01, 1995

SUMATRIPTAN SUCCINATE

AB		APOTEX INC	**EQ 25MG BASE**	**A200263**	**001**	Jun 19, 2012
AB			**EQ 50MG BASE**	**A200263**	**002**	Jun 19, 2012
AB			**EQ 100MG BASE**	**A200263**	**003**	Jun 19, 2012
AB		AUROBINDO PHARMA	**EQ 25MG BASE**	**A078327**	**001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A078327**	**002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A078327**	**003**	Aug 10, 2009
AB		DR REDDYS LABS INC	**EQ 25MG BASE**	**A076847**	**001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A076847**	**002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A076847**	**003**	Aug 10, 2009
AB		MYLAN	**EQ 25MG BASE**	**A077744**	**001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A077744**	**002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A077744**	**003**	Aug 10, 2009
AB		ORCHID HLTHCARE	**EQ 25MG BASE**	**A078284**	**001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A078284**	**002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A078284**	**003**	Aug 10, 2009
AB		SUN PHARM INDS	**EQ 25MG BASE**	**A078295**	**001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A078295**	**002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A078295**	**003**	Aug 10, 2009
AB		SUN PHARM INDS LTD	**EQ 25MG BASE**	**A076554**	**001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A076554**	**002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A076572**	**001**	Feb 09, 2009
AB		WATSON LABS	**EQ 25MG BASE**	**A076933**	**001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A076933**	**002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A076933**	**003**	Aug 10, 2009

SUNITINIB MALATE

CAPSULE;ORAL

SUTENT

+	CPPI CV	EQ 12.5MG BASE	N021938	001	Jan 26, 2006
+		EQ 25MG BASE	N021938	002	Jan 26, 2006
+		EQ 37.5MG BASE	N021938	004	Mar 31, 2009
+!		EQ 50MG BASE	N021938	003	Jan 26, 2006

SUVOREXANT

TABLET;ORAL

BELSOMRA

+	MERCK SHARP DOHME	5MG	N204569	001	Aug 13, 2014
+		10MG	N204569	002	Aug 13, 2014
+		15MG	N204569	003	Aug 13, 2014
+!		20MG	N204569	004	Aug 13, 2014

TACROLIMUS

CAPSULE;ORAL

PROGRAF

AB	**+**	ASTELLAS	**EQ 0.5MG BASE**	**N050708**	**003**	Aug 24, 1998
AB	**+**		**EQ 1MG BASE**	**N050708**	**001**	Apr 08, 1994
AB	**+!**		**EQ 5MG BASE**	**N050708**	**002**	Apr 08, 1994

TACROLIMUS

AB		ACCORD HLTHCARE	**EQ 0.5MG BASE**	**A091195**	**001**	Aug 31, 2011
AB			**EQ 1MG BASE**	**A091195**	**002**	Aug 31, 2011
AB			**EQ 5MG BASE**	**A091195**	**003**	Aug 31, 2011
AB		BELCHER PHARMS LLC	**EQ 0.5MG BASE**	**A206651**	**001**	Nov 30, 2017
AB			**EQ 1MG BASE**	**A206651**	**002**	Nov 30, 2017
AB			**EQ 5MG BASE**	**A206651**	**003**	Nov 30, 2017
AB		DR REDDYS LABS LTD	**EQ 0.5MG BASE**	**A090509**	**001**	May 12, 2010
AB			**EQ 1MG BASE**	**A090509**	**002**	May 12, 2010
AB			**EQ 5MG BASE**	**A090509**	**003**	May 12, 2010
AB		MYLAN	**EQ 0.5MG BASE**	**A090596**	**001**	Sep 17, 2010
AB			**EQ 1MG BASE**	**A090596**	**002**	Sep 17, 2010
AB			**EQ 5MG BASE**	**A090596**	**003**	Sep 17, 2010
AB		PANACEA BIOTEC LTD	**EQ 0.5MG BASE**	**A090802**	**001**	Sep 28, 2012
AB			**EQ 1MG BASE**	**A090802**	**002**	Sep 28, 2012
AB			**EQ 5MG BASE**	**A090802**	**003**	Sep 28, 2012
AB		SANDOZ	**EQ 0.5MG BASE**	**A065461**	**001**	Aug 10, 2009
AB			**EQ 1MG BASE**	**A065461**	**002**	Aug 10, 2009
AB			**EQ 5MG BASE**	**A065461**	**003**	Aug 10, 2009
AB		STRIDES PHARMA	**EQ 0.5MG BASE**	**A090687**	**001**	Jul 22, 2014
AB			**EQ 1MG BASE**	**A090687**	**002**	Jul 22, 2014
AB			**EQ 5MG BASE**	**A090687**	**003**	Jul 22, 2014

CAPSULE, EXTENDED RELEASE;ORAL

ASTAGRAF XL

+	ASTELLAS	EQ 0.5MG BASE	N204096	001	Jul 19, 2013
+		EQ 1MG BASE	N204096	002	Jul 19, 2013
+!		EQ 5MG BASE	N204096	003	Jul 19, 2013

FOR SUSPENSION;ORAL

PROGRAF

+	ASTELLAS	EQ 0.2MG BASE/PACKET	N210115	001	May 24, 2018
+!		EQ 1MG BASE/PACKET	N210115	002	May 24, 2018

INJECTABLE;INJECTION

PROGRAF

AP	**+!**	ASTELLAS	**EQ 5MG BASE/ML**	**N050709**	**001**	Apr 08, 1994

TACROLIMUS

AP		HOSPIRA INC	**EQ 5MG BASE/ML**	**A203900**	**001**	Aug 25, 2017

OINTMENT;TOPICAL

PROTOPIC

AB	**+!**	LEO PHARMA AS	**0.03%**	**N050777**	**001**	Dec 08, 2000
AB	**+!**		**0.1%**	**N050777**	**002**	Dec 08, 2000

TACROLIMUS

AB		FOUGERA PHARMS INC	**0.03%**	**A200744**	**001**	Sep 09, 2014
AB			**0.1%**	**A200744**	**002**	Sep 09, 2014
AB		GLENMARK PHARMS LTD	**0.1%**	**A210393**	**001**	Apr 16, 2018

TABLET, EXTENDED RELEASE;ORAL

ENVARSUS XR

+	VELOXIS PHARMS INC	EQ 0.75MG BASE	N206406	001	Jul 10, 2015
+		EQ 1MG BASE	N206406	002	Jul 10, 2015
+!		EQ 4MG BASE	N206406	003	Jul 10, 2015

TADALAFIL						
TABLET;ORAL						
CIALIS						
AB	**+**	LILLY	**2.5MG**	**N021368**	**004**	Jan 07, 2008
AB	**+**		**5MG**	**N021368**	**001**	Nov 21, 2003
AB	**+**		**10MG**	**N021368**	**002**	Nov 21, 2003
TADALAFIL						
AB		TEVA PHARMS USA	**2.5MG**	**A090141**	**001**	May 22, 2018
AB			**5MG**	**A090141**	**002**	May 22, 2018
AB			**10MG**	**A090141**	**003**	May 22, 2018
CIALIS						
AB1	**+!**	LILLY	**20MG**	**N021368**	**003**	Nov 21, 2003
TADALAFIL						
AB1		TEVA PHARMS USA	**20MG**	**A090141**	**004**	May 22, 2018
ADCIRCA						
AB2	**+!**	ELI LILLY CO	**20MG**	**N022332**	**001**	May 22, 2009
TADALAFIL						
AB2		MYLAN PHARMS INC	**20MG**	**A200630**	**001**	Aug 03, 2018
TAFENOQUINE SUCCINATE						
TABLET;ORAL						
ARAKODA						
	+!	60 DEGREES PHARMS	EQ 100MG BASE	N210607	001	Aug 08, 2018
KRINTAFEL						
	+!	GLAXOSMITHKLINE	EQ 150MG BASE	N210795	001	Jul 20, 2018
TAFLUPROST						
SOLUTION/DROPS;OPHTHALMIC						
ZIOPTAN						
	+!	OAK PHARMS INC	0.0015%	N202514	001	Feb 10, 2012
TALAZOPARIB TOSYLATE						
CAPSULE;ORAL						
TALZENNA						
	+	PFIZER INC	EQ 0.25MG BASE	N211651	001	Oct 16, 2018
	+!		EQ 1MG BASE	N211651	002	Oct 16, 2018
TALC						
AEROSOL;INTRAPLEURAL						
SCLEROSOL						
	+!	LYMOL MEDCL	4GM/SPRAY	N020587	001	Dec 24, 1997
POWDER;INTRAPLEURAL						
STERITALC						
	+	NOVATECH SA	2GM/VIAL	N205555	001	May 01, 2017
	+		3GM/VIAL	N205555	002	May 01, 2017
	+!		4GM/VIAL	N205555	003	May 01, 2017
TALC						
	+!	LYMOL MEDCL	5GM/BOT	N021388	001	Dec 15, 2003
TALIGLUCERASE ALFA						
POWDER;INTRAVENOUS						
ELELYSO						
	+!	PFIZER	200 UNITS/VIAL	N022458	001	May 01, 2012
TAMOXIFEN CITRATE						
SOLUTION;ORAL						
SOLTAMOX						
		MIDATECH PHARMA US	EQ 20MG BASE/10ML	N021807	001	Oct 29, 2005
TABLET;ORAL						
TAMOXIFEN CITRATE						
AB		ACTAVIS LABS FL INC	**EQ 10MG BASE**	**A070929**	**001**	Feb 20, 2003
AB			**EQ 20MG BASE**	**A070929**	**002**	Feb 20, 2003
AB		APOTEX	**EQ 10MG BASE**	**A090878**	**001**	Sep 23, 2011
AB			**EQ 20MG BASE**	**A090878**	**002**	Sep 23, 2011
AB		MAYNE PHARMA	**EQ 10MG BASE**	**A075797**	**001**	Feb 20, 2003
AB	**!**		**EQ 20MG BASE**	**A075797**	**002**	Feb 20, 2003
AB		MYLAN	**EQ 10MG BASE**	**A074732**	**002**	Feb 20, 2003
AB			**EQ 20MG BASE**	**A074732**	**001**	Feb 20, 2003
AB		ZYDUS PHARMS USA INC	**EQ 10MG BASE**	**A206694**	**001**	Oct 27, 2017
AB			**EQ 20MG BASE**	**A206694**	**002**	Oct 27, 2017

TAMSULOSIN HYDROCHLORIDE							
CAPSULE;ORAL							
FLOMAX							
AB	**+!**	SANOFI AVENTIS US	**0.4MG**	**N020579**	**001**	Apr 15, 1997	
TAMSULOSIN HYDROCHLORIDE							
AB		ALKEM LABS LTD	**0.4MG**	**A207405**	**001**	Aug 11, 2017	
AB		ANCHEN PHARMS	**0.4MG**	**A202010**	**001**	Jan 04, 2013	
AB		AUROBINDO PHARMA LTD	**0.4MG**	**A202433**	**001**	Apr 30, 2013	
AB		IMPAX LABS	**0.4MG**	**A090377**	**001**	Mar 02, 2010	
AB		MACLEODS PHARMS LTD	**0.4MG**	**A204645**	**001**	Jan 20, 2017	
AB		MYLAN	**0.4MG**	**A090408**	**001**	Apr 27, 2010	
AB		SANDOZ	**0.4MG**	**A078015**	**001**	Apr 27, 2010	
AB		SUN PHARM INDS LTD	**0.4MG**	**A090931**	**001**	Jul 15, 2010	
AB		SYNTHON PHARMS	**0.4MG**	**A078801**	**001**	Apr 27, 2010	
AB		TEVA PHARMS	**0.4MG**	**A077630**	**001**	Apr 27, 2010	
AB		WOCKHARDT	**0.4MG**	**A078938**	**001**	Apr 27, 2010	
AB		ZYDUS PHARMS USA INC	**0.4MG**	**A078225**	**001**	Apr 27, 2010	
TAPENTADOL HYDROCHLORIDE							
TABLET;ORAL							
NUCYNTA							
	+	DEPO NF	EQ 50MG BASE	N022304	001	Nov 20, 2008	
	+		EQ 75MG BASE	N022304	002	Nov 20, 2008	
	+!		EQ 100MG BASE	N022304	003	Nov 20, 2008	
TABLET, EXTENDED RELEASE;ORAL							
NUCYNTA ER							
	+	DEPO NF	EQ 50MG BASE	N200533	001	Aug 25, 2011	
	+		EQ 100MG BASE	N200533	002	Aug 25, 2011	
	+		EQ 150MG BASE	N200533	003	Aug 25, 2011	
	+		EQ 200MG BASE	N200533	004	Aug 25, 2011	
	+!		EQ 250MG BASE	N200533	005	Aug 25, 2011	
TASIMELTEON							
CAPSULE;ORAL							
HETLIOZ							
	+!	VANDA PHARMS INC	20MG	N205677	001	Jan 31, 2014	
TAVABOROLE							
SOLUTION;TOPICAL							
KERYDIN							
	+!	ANACOR PHARMS INC	5%	N204427	001	Jul 07, 2014	
TAZAROTENE							
AEROSOL, FOAM;TOPICAL							
FABIOR							
	+!	MAYNE PHARMA	0.1%	N202428	001	May 11, 2012	
CREAM;TOPICAL							
AVAGE							
AB	**+!**	ALLERGAN	**0.1%**	**N021184**	**003**	Sep 30, 2002	
TAZAROTENE							
AB		G AND W LABS INC	**0.1%**	**A208662**	**001**	Dec 22, 2017	
AB		TARO PHARMS	**0.1%**	**A208258**	**001**	Apr 03, 2017	
TAZORAC							
AB	**+!**	ALLERGAN	**0.1%**	**N021184**	**002**	Sep 29, 2000	
	+!		0.05%	N021184	001	Sep 29, 2000	
GEL;TOPICAL							
TAZORAC							
	+!	ALLERGAN	0.05%	N020600	001	Jun 13, 1997	
	+!		0.1%	N020600	002	Jun 13, 1997	
TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT							
INJECTABLE;INJECTION							
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT							
BS	+!	DRAXIMAGE	N/A	N017881	001	Dec 30, 1987	
TECHNETIUM TC-99M BICISATE KIT							
INJECTABLE;INJECTION							
NEUROLITE							
	+!	LANTHEUS MEDCL	N/A	N020256	001	Nov 23, 1994	

TECHNETIUM TC-99M DISOFENIN KIT
INJECTABLE;INJECTION
HEPATOLITE
PHARMALUCENCE N/A N018467 001 Mar 16, 1982

TECHNETIUM TC-99M EXAMETAZIME KIT
INJECTABLE;INJECTION
CERETEC
+! GE HEALTHCARE N/A N019829 001 Dec 30, 1988
POWDER;INTRAVENOUS
DRAX EXAMETAZIME
JUBILANT DRAXIMAGE N/A N208870 001 Aug 17, 2017

TECHNETIUM TC-99M MEBROFENIN KIT
INJECTABLE;INJECTION
CHOLETEC
AP **+!** BRACCO **N/A** **N018963 001** Jan 21, 1987
TECHNETIUM TC-99M MEBROFENIN
AP PHARMALUCENCE **N/A** **A078242 001** Jan 29, 2008

TECHNETIUM TC-99M MEDRONATE
INJECTABLE;INJECTION
DRAXIMAGE MDP-25
+! JUBILANT DRAXIMAGE N/A N018035 002 Feb 27, 2004

TECHNETIUM TC-99M MEDRONATE KIT
INJECTABLE;INJECTION
CIS-MDP
PHARMALUCENCE N/A N018124 001

TECHNETIUM TC-99M MERTIATIDE KIT
INJECTABLE;INJECTION
TECHNESCAN MAG3
+! MALLINKRODT NUCLEAR N/A N019882 001 Jun 15, 1990

TECHNETIUM TC-99M OXIDRONATE KIT
INJECTABLE;INJECTION
TECHNESCAN
+! MALLINKRODT NUCLEAR N/A N018321 001

TECHNETIUM TC-99M PENTETATE KIT
INJECTABLE;INJECTION
DTPA
+! JUBILANT DRAXIMAGE N/A N018511 001 Dec 29, 1989

TECHNETIUM TC-99M PYROPHOSPHATE KIT
INJECTABLE;INJECTION
CIS-PYRO
AP PHARMALUCENCE **N/A** **N019039 001** Jun 30, 1987
TECHNESCAN PYP KIT
AP MALLINKRODT NUCLEAR **N/A** **N017538 001**

TECHNETIUM TC-99M RED BLOOD CELL KIT
INJECTABLE;INJECTION
ULTRATAG
+! MALLINKRODT NUCLEAR N/A N019981 001 Jun 10, 1991

TECHNETIUM TC-99M SESTAMIBI KIT
INJECTABLE;INJECTION
CARDIOLITE
AP **+!** LANTHEUS MEDCL **N/A** **N019785 001** Dec 21, 1990
TECHNETIUM TC 99M SESTAMIBI
AP CARDINAL HEALTH 414 **N/A** **A078809 001** Apr 28, 2009
AP JUBILANT DRAXIMAGE **N/A** **A078806 001** Apr 29, 2009
AP MALLINKRODT NUCLEAR **N/A** **A078098 001** Sep 22, 2008
AP PHARMALUCENCE **10-30mCi** **A079157 001** Jul 10, 2009

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
SOLUTION;INTRAVENOUS
TECHNELITE
+! LANTHEUS MEDCL 1-20 CI/GENERATOR N017771 002 Feb 12, 2014
ULTRA-TECHNEKOW FM
+! MALLINKRODT NUCLEAR 1-19 CI/GENERATOR N017243 003 Feb 18, 2014
SOLUTION;INTRAVENOUS, INTRAVESICULAR, OPHTHALMIC
RADIOGENIX SYSTEM
+ NORTHSTAR MEDICAL 30-1153mCi/GENERATOR N202158 001 Feb 08, 2018

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR							
SOLUTION;INTRAVENOUS, ORAL							
TECHNETIUM TC 99M GENERATOR							
	+!	GE HEALTHCARE	68-2703mCi/GENERATOR		N017693	002	Dec 13, 2013
TECHNETIUM TC-99M SULFUR COLLOID KIT							
SOLUTION;INJECTION, ORAL							
AN-SULFUR COLLOID							
	+!	PHARMALUCENCE	N/A		N017858	001	
TECHNETIUM TC-99M TETROFOSMIN KIT							
INJECTABLE;INJECTION							
MYOVIEW 30ML							
	+!	GE HEALTHCARE	N/A		N020372	002	Jul 07, 2005
TECHNETIUM TC-99M TILMANOCEPT							
INJECTABLE;INJECTION							
LYMPHOSEEK KIT							
	+!	CARDINAL HEALTH 414	N/A		N202207	001	Mar 13, 2013
TECOVIRIMAT							
CAPSULE;ORAL							
TPOXX							
	+!	SIGA TECHNOLOGIES	200MG		N208627	001	Jul 13, 2018
TEDIZOLID PHOSPHATE							
POWDER;INTRAVENOUS							
SIVEXTRO							
	+!	CUBIST PHARMS LLC	200MG/VIAL		N205436	001	Jun 20, 2014
TABLET;ORAL							
SIVEXTRO							
	+!	CUBIST PHARMS LLC	200MG		N205435	001	Jun 20, 2014
TEDUGLUTIDE RECOMBINANT							
POWDER;SUBCUTANEOUS							
GATTEX KIT							
	+!	NPS PHARMS INC	5MG/VIAL		N203441	001	Dec 21, 2012
TELAVANCIN HYDROCHLORIDE							
POWDER;INTRAVENOUS							
VIBATIV							
	+!	CUMBERLAND PHARMS	EQ 750MG BASE/VIAL		N022110	002	Sep 11, 2009
TELMISARTAN							
TABLET;ORAL							
MICARDIS							
AB	**+**	BOEHRINGER INGELHEIM	**20MG**		**N020850**	**003**	Apr 04, 2000
AB	**+**		**40MG**		**N020850**	**001**	Nov 10, 1998
AB	**+!**		**80MG**		**N020850**	**002**	Nov 10, 1998
TELMISARTAN							
AB		ALEMBIC PHARMS LTD	**20MG**		**A202130**	**001**	Jul 07, 2014
AB			**40MG**		**A202130**	**002**	Jul 07, 2014
AB			**80MG**		**A202130**	**003**	Jul 07, 2014
AB		AMNEAL PHARMS	**20MG**		**A204415**	**001**	Sep 08, 2015
AB			**40MG**		**A204415**	**002**	Sep 08, 2015
AB			**80MG**		**A204415**	**003**	Sep 08, 2015
AB		AUROBINDO PHARMA LTD	**20MG**		**A206511**	**001**	Sep 03, 2015
AB			**40MG**		**A206511**	**002**	Sep 03, 2015
AB			**80MG**		**A206511**	**003**	Sep 03, 2015
AB		CADILA PHARMS LTD	**20MG**		**A208605**	**001**	Jul 25, 2017
AB			**40MG**		**A208605**	**002**	Jul 25, 2017
AB			**80MG**		**A208605**	**003**	Jul 25, 2017
AB		GLENMARK PHARMS LTD	**20MG**		**A090032**	**001**	Jul 07, 2014
AB			**40MG**		**A090032**	**002**	Jul 07, 2014
AB			**80MG**		**A090032**	**003**	Jul 07, 2014
AB		HETERO LABS LTD V	**20MG**		**A205901**	**001**	Apr 22, 2016
AB			**40MG**		**A205901**	**002**	Apr 22, 2016
AB			**80MG**		**A205901**	**003**	Apr 22, 2016
AB		INVENTIA HLTHCARE	**20MG**		**A205150**	**001**	Oct 30, 2015
AB			**40MG**		**A205150**	**002**	Oct 30, 2015
AB			**80MG**		**A205150**	**003**	Oct 30, 2015
AB		JUBILANT GENERICS	**20MG**		**A204164**	**001**	Aug 22, 2016
AB			**40MG**		**A204164**	**002**	Aug 22, 2016
AB			**80MG**		**A204164**	**003**	Aug 22, 2016
AB		MICRO LABS	**20MG**		**A207016**	**001**	Oct 03, 2017

TELMISARTAN

TABLET;ORAL

TELMISARTAN

AB			**40MG**	**A207016**	**002**	Oct 03, 2017
AB			**80MG**	**A207016**	**003**	Oct 03, 2017
AB		MYLAN PHARMS INC	**20MG**	**A202397**	**001**	Jul 07, 2014
AB			**40MG**	**A202397**	**002**	Jul 07, 2014
AB			**80MG**	**A202397**	**003**	Jul 07, 2014
AB		PRINSTON INC	**20MG**	**A207882**	**001**	May 03, 2017
AB			**40MG**	**A207882**	**002**	May 03, 2017
AB			**80MG**	**A207882**	**003**	May 03, 2017
AB		SANDOZ INC	**20MG**	**A203867**	**001**	Nov 03, 2014
AB			**40MG**	**A203867**	**002**	Nov 03, 2014
AB			**80MG**	**A203867**	**003**	Nov 03, 2014
AB		TORRENT PHARMS LTD	**20MG**	**A203171**	**001**	Jul 07, 2014
AB			**40MG**	**A203171**	**002**	Jul 07, 2014
AB			**80MG**	**A203171**	**003**	Jul 07, 2014
AB		WATSON LABS	**20MG**	**A078710**	**001**	Jan 08, 2014
AB			**80MG**	**A078710**	**003**	Jan 08, 2014
AB		ZYDUS PHARMS USA INC	**20MG**	**A203325**	**001**	Aug 26, 2014
AB			**40MG**	**A203325**	**002**	Aug 26, 2014
AB			**80MG**	**A203325**	**003**	Aug 26, 2014

TELOTRISTAT ETIPRATE

TABLET;ORAL

XERMELO

	+!	LEXICON PHARMS INC	EQ 250MG BASE	N208794	001	Feb 28, 2017

TEMAZEPAM

CAPSULE;ORAL

RESTORIL

AB	+	SPECGX LLC	**7.5MG**	**N018163**	**003**	Oct 25, 1991
AB	+		**15MG**	**N018163**	**001**	
AB	+		**22.5MG**	**N018163**	**004**	Nov 02, 2004
AB	+!		**30MG**	**N018163**	**002**	

TEMAZEPAM

AB		ACTAVIS ELIZABETH	**15MG**	**A071620**	**002**	Aug 07, 1987
AB			**30MG**	**A071620**	**001**	Aug 07, 1987
AB		ALEMBIC PHARMS LTD	**7.5MG**	**A211542**	**001**	Nov 23, 2018
AB			**15MG**	**A211542**	**002**	Nov 23, 2018
AB			**22.5MG**	**A211542**	**003**	Nov 23, 2018
AB			**30MG**	**A211542**	**004**	Nov 23, 2018
AB		AMNEAL PHARMS	**7.5MG**	**A203482**	**001**	May 23, 2016
AB			**15MG**	**A203482**	**002**	May 23, 2016
AB			**22.5MG**	**A203482**	**003**	May 23, 2016
AB			**30MG**	**A203482**	**004**	May 23, 2016
AB		MYLAN	**7.5MG**	**A070920**	**002**	May 21, 2010
AB			**15MG**	**A070920**	**004**	Jul 07, 1986
AB			**22.5MG**	**A070920**	**003**	Jun 12, 2009
AB			**30MG**	**A070920**	**001**	Jul 10, 1986
AB		NOVEL LABS INC	**7.5MG**	**A071457**	**002**	Jun 22, 2012
AB			**15MG**	**A071456**	**001**	Apr 21, 1987
AB			**22.5MG**	**A071457**	**003**	Jun 22, 2012
AB			**30MG**	**A071457**	**001**	Apr 21, 1987
AB		PRINSTON INC	**7.5MG**	**A201781**	**001**	Jun 04, 2015
AB			**15MG**	**A201781**	**002**	Jun 04, 2015
AB			**22.5MG**	**A201781**	**003**	Jun 04, 2015
AB			**30MG**	**A201781**	**004**	Jun 04, 2015
AB		SANDOZ	**15MG**	**A071427**	**001**	Jan 12, 1988
AB			**30MG**	**A071428**	**001**	Jan 12, 1988
AB		SUN PHARM INDUSTRIES	**7.5MG**	**A078581**	**001**	Sep 08, 2009
AB			**22.5MG**	**A071175**	**002**	Sep 14, 2009

TEMOZOLOMIDE

CAPSULE;ORAL

TEMODAR

AB	+	MERCK SHARP DOHME	**5MG**	**N021029**	**001**	Aug 11, 1999
AB	+		**20MG**	**N021029**	**002**	Aug 11, 1999
AB	+		**100MG**	**N021029**	**003**	Aug 11, 1999
AB	+		**140MG**	**N021029**	**005**	Oct 19, 2006
AB	+		**180MG**	**N021029**	**006**	Oct 19, 2006
AB	+!		**250MG**	**N021029**	**004**	Aug 11, 1999

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

AB	ACCORD HLTHCARE	**5MG**	**A201528**	**001**	Feb 27, 2017
AB		**20MG**	**A201528**	**002**	Feb 27, 2017
AB		**100MG**	**A201528**	**003**	Feb 27, 2017
AB		**140MG**	**A201528**	**004**	Feb 27, 2017
AB		**180MG**	**A201528**	**005**	Feb 27, 2017
AB		**250MG**	**A201528**	**006**	Feb 27, 2017
AB	AMERIGEN PHARMS LTD	**5MG**	**A203490**	**001**	Jul 13, 2016
AB		**20MG**	**A203490**	**002**	Jul 13, 2016
AB		**100MG**	**A203490**	**003**	Jul 13, 2016
AB		**140MG**	**A203490**	**004**	Jul 13, 2016
AB		**180MG**	**A203490**	**005**	Jul 13, 2016
AB		**250MG**	**A203490**	**006**	Jul 13, 2016
AB	AMNEAL PHARMS	**5MG**	**A203691**	**001**	May 08, 2015
AB		**20MG**	**A203691**	**002**	May 08, 2015
AB		**100MG**	**A203691**	**003**	May 08, 2015
AB		**140MG**	**A203691**	**004**	May 08, 2015
AB		**180MG**	**A203691**	**005**	May 08, 2015
AB		**250MG**	**A203691**	**006**	May 08, 2015
AB	APOTEX INC	**5MG**	**A204159**	**001**	Jul 05, 2018
AB		**20MG**	**A204159**	**002**	Jul 05, 2018
AB		**100MG**	**A204159**	**003**	Jul 05, 2018
AB		**140MG**	**A204159**	**004**	Jul 05, 2018
AB		**180MG**	**A204159**	**005**	Jul 05, 2018
AB		**250MG**	**A204159**	**006**	Jul 05, 2018
AB	BARR	**5MG**	**A078879**	**001**	Mar 01, 2010
AB		**20MG**	**A078879**	**002**	Mar 01, 2010
AB		**100MG**	**A078879**	**003**	Mar 01, 2010
AB		**140MG**	**A078879**	**005**	Mar 01, 2010
AB		**180MG**	**A078879**	**006**	Mar 01, 2010
AB		**250MG**	**A078879**	**004**	Mar 01, 2010
AB	CHEMI SPA	**5MG**	**A204639**	**001**	Nov 23, 2016
AB		**20MG**	**A204639**	**002**	Nov 23, 2016
AB		**100MG**	**A204639**	**003**	Nov 23, 2016
AB		**140MG**	**A204639**	**004**	Nov 23, 2016
AB		**180MG**	**A204639**	**005**	Nov 23, 2016
AB		**250MG**	**A204639**	**006**	Nov 23, 2016
AB	DEVA HOLDING AS	**5MG**	**A207658**	**001**	Apr 26, 2017
AB		**20MG**	**A207658**	**002**	Apr 26, 2017
AB		**100MG**	**A207658**	**003**	Apr 26, 2017
AB		**140MG**	**A207658**	**004**	Apr 26, 2017
AB		**180MG**	**A207658**	**005**	Apr 26, 2017
AB		**250MG**	**A207658**	**006**	Apr 26, 2017
AB	IDT AUSTRALIA LTD	**5MG**	**A206413**	**001**	Apr 12, 2016
AB		**20MG**	**A206413**	**002**	Apr 12, 2016
AB		**100MG**	**A206413**	**003**	Apr 12, 2016
AB		**140MG**	**A206413**	**004**	Apr 12, 2016
AB		**180MG**	**A206413**	**005**	Apr 12, 2016
AB		**250MG**	**A206413**	**006**	Apr 12, 2016
AB	LANNETT CO INC	**5MG**	**A203898**	**001**	Feb 10, 2016
AB		**20MG**	**A203898**	**002**	Feb 10, 2016
AB		**100MG**	**A203898**	**003**	Feb 10, 2016
AB		**140MG**	**A203898**	**004**	Feb 10, 2016
AB		**180MG**	**A203898**	**005**	Feb 10, 2016
AB		**250MG**	**A203898**	**006**	Feb 10, 2016
AB	RISING PHARMS	**5MG**	**A206309**	**001**	Apr 27, 2016
AB		**20MG**	**A206309**	**002**	Apr 27, 2016
AB		**100MG**	**A206309**	**003**	Apr 27, 2016
AB		**140MG**	**A206309**	**004**	Apr 27, 2016
AB		**180MG**	**A206309**	**005**	Apr 27, 2016
AB		**250MG**	**A206309**	**006**	Apr 27, 2016
AB	SUN PHARMA GLOBAL	**5MG**	**A201742**	**001**	Feb 12, 2014
AB		**20MG**	**A201742**	**002**	Feb 12, 2014
AB		**100MG**	**A201742**	**003**	Feb 12, 2014
AB		**140MG**	**A201742**	**004**	Feb 12, 2014
AB		**180MG**	**A201742**	**005**	Feb 12, 2014
AB		**250MG**	**A201742**	**006**	Feb 12, 2014
AB	WATSON LABS TEVA	**5MG**	**A203959**	**001**	Apr 18, 2017
AB		**20MG**	**A203959**	**002**	Apr 18, 2017
AB		**100MG**	**A203959**	**003**	Apr 18, 2017

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

AB			**140MG**	**A203959**	**004**	Apr 18, 2017
AB			**250MG**	**A203959**	**005**	Apr 18, 2017
AB		ZYDUS PHARMS USA INC	**5MG**	**A206750**	**001**	Jul 31, 2017
AB			**20MG**	**A206750**	**002**	Jul 31, 2017
AB			**100MG**	**A206750**	**003**	Jul 31, 2017
AB			**140MG**	**A206750**	**004**	Jul 31, 2017
AB			**180MG**	**A206750**	**005**	Jul 31, 2017
AB			**250MG**	**A206750**	**006**	Jul 31, 2017

POWDER;INTRAVENOUS

TEMODAR

	+!	MERCK SHARP DOHME	100MG/VIAL	N022277	001	Feb 27, 2009

TEMSIROLIMUS

SOLUTION;INTRAVENOUS

TEMSIROLIMUS

AP		ACCORD HLTHCARE	**25MG/ML (25MG/ML)**	**A203153**	**001**	Jul 30, 2018

TORISEL

AP	**+!**	PF PRISM CV	**25MG/ML (25MG/ML)**	**N022088**	**001**	May 30, 2007

TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

VEMLIDY

	+!	GILEAD SCIENCES INC	EQ 25MG BASE	N208464	001	Nov 10, 2016

TENOFOVIR DISOPROXIL FUMARATE

POWDER;ORAL

VIREAD

	+!	GILEAD SCIENCES INC	40MG/SCOOPFUL	N022577	001	Jan 18, 2012

TABLET;ORAL

TENOFOVIR DISOPROXIL FUMARATE

AB		APOTEX INC	**300MG**	**A206481**	**001**	Jul 26, 2018
AB		AUROBINDO PHARMA LTD	**150MG**	**A090647**	**001**	Jan 26, 2018
AB			**200MG**	**A090647**	**002**	Jan 26, 2018
AB			**250MG**	**A090647**	**003**	Jan 26, 2018
AB			**300MG**	**A090647**	**004**	Jan 26, 2018
AB		CASI PHARMS INC	**300MG**	**A209550**	**001**	Feb 26, 2018
AB		CIPLA	**300MG**	**A078800**	**001**	Jan 26, 2018
AB		HETERO LABS LTD III	**300MG**	**A090636**	**001**	Jan 26, 2018
AB		MACLEODS PHARMS LTD	**300MG**	**A203232**	**001**	Jan 26, 2018
AB		MYLAN PHARMS INC	**150MG**	**A206569**	**001**	Nov 27, 2018
AB			**200MG**	**A206569**	**002**	Nov 27, 2018
AB			**250MG**	**A206569**	**003**	Nov 27, 2018
AB			**300MG**	**A206569**	**004**	Nov 27, 2018
AB		QILU PHARM CO LTD	**200MG**	**A209498**	**001**	Mar 02, 2018
AB			**250MG**	**A209498**	**002**	Mar 02, 2018
AB			**300MG**	**A209498**	**003**	Mar 02, 2018
AB		STRIDES PHARMA	**300MG**	**A090742**	**001**	Jan 26, 2018
AB		TEVA PHARMS USA	**150MG**	**A091612**	**002**	Jan 26, 2018
AB			**200MG**	**A091612**	**003**	Jan 26, 2018
AB			**250MG**	**A091612**	**004**	Jan 26, 2018
AB			**300MG**	**A091612**	**001**	Mar 18, 2015

VIREAD

AB	**+**	GILEAD SCIENCES INC	**150MG**	**N021356**	**002**	Jan 18, 2012
AB	**+**		**200MG**	**N021356**	**003**	Jan 18, 2012
AB	**+**		**250MG**	**N021356**	**004**	Jan 18, 2012
AB	**+!**		**300MG**	**N021356**	**001**	Oct 26, 2001

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

AB		APOTEX	**EQ 1MG BASE**	**A075498**	**001**	Apr 12, 2001
AB			**EQ 2MG BASE**	**A075498**	**002**	Apr 12, 2001
AB			**EQ 5MG BASE**	**A075498**	**003**	Apr 12, 2001
AB			**EQ 10MG BASE**	**A075498**	**004**	Apr 12, 2001
AB		IVAX SUB TEVA PHARMS	**EQ 1MG BASE**	**A075614**	**002**	Jan 30, 2001
AB			**EQ 2MG BASE**	**A075614**	**001**	Jan 30, 2001
AB			**EQ 5MG BASE**	**A075614**	**003**	Jan 30, 2001
AB			**EQ 10MG BASE**	**A075614**	**004**	Jan 30, 2001
AB		JUBILANT CADISTA	**EQ 1MG BASE**	**A075317**	**001**	Dec 20, 2004

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

AB			**EQ 2MG BASE**	**A075317 002**	Dec 20, 2004
AB			**EQ 5MG BASE**	**A075317 003**	Dec 20, 2004
AB			**EQ 10MG BASE**	**A075317 004**	Dec 20, 2004
AB		MYLAN PHARMS INC	**EQ 1MG BASE**	**A075140 002**	Feb 11, 2000
AB			**EQ 2MG BASE**	**A075140 003**	Feb 11, 2000
AB			**EQ 5MG BASE**	**A075140 001**	Feb 11, 2000
AB			**EQ 10MG BASE**	**A075140 004**	Feb 11, 2000
AB		SANDOZ	**EQ 1MG BASE**	**A074823 001**	Mar 30, 1998
AB	**!**		**EQ 2MG BASE**	**A074823 002**	Mar 30, 1998
AB			**EQ 5MG BASE**	**A074823 003**	Mar 30, 1998
AB			**EQ 10MG BASE**	**A074823 004**	Mar 30, 1998

TERBINAFINE HYDROCHLORIDE

TABLET;ORAL

LAMISIL

AB	**+!**	NOVARTIS	**EQ 250MG BASE**	**N020539 001**	May 10, 1996

TERBINAFINE HYDROCHLORIDE

AB		AUROBINDO PHARMA	**EQ 250MG BASE**	**A078297 001**	Jul 02, 2007
AB		BRECKENRIDGE PHARM	**EQ 250MG BASE**	**A077714 001**	Jun 04, 2010
AB		CIPLA	**EQ 250MG BASE**	**A077137 001**	Jul 02, 2007
AB		DR REDDYS LABS INC	**EQ 250MG BASE**	**A076390 001**	Jul 02, 2007
AB		GLENMARK GENERICS	**EQ 250MG BASE**	**A078157 001**	Jul 02, 2007
AB		HARRIS PHARM	**EQ 250MG BASE**	**A077919 001**	Jul 02, 2007
AB		INVAGEN PHARMS	**EQ 250MG BASE**	**A077533 001**	Jul 02, 2007
AB		ORCHID HLTHCARE	**EQ 250MG BASE**	**A078163 001**	Jul 02, 2007
AB		TEVA	**EQ 250MG BASE**	**A076377 001**	Jul 02, 2007

TERBUTALINE SULFATE

INJECTABLE;INJECTION

TERBUTALINE SULFATE

AP		AKORN	**1MG/ML**	**A078151 001**	Jan 07, 2008
AP	**!**	ATHENEX INC	**1MG/ML**	**A076770 001**	Apr 23, 2004
AP		FRESENIUS KABI USA	**1MG/ML**	**A076887 001**	May 26, 2004
AP		HIKMA FARMACEUTICA	**1MG/ML**	**A078630 001**	May 20, 2009
AP		UNITED BIOMEDCL	**1MG/ML**	**A200122 001**	Nov 08, 2013

TABLET;ORAL

BRETHINE

AB	**+**	ANI PHARMS INC	**2.5MG**	**N017849 001**	
AB	**+**		**5MG**	**N017849 002**	

TERBUTALINE SULFATE

AB		IMPAX LABS	**2.5MG**	**A075877 001**	Jun 26, 2001
AB			**5MG**	**A075877 002**	Jun 26, 2001
AB		LANNETT CO INC	**2.5MG**	**A077152 001**	Mar 25, 2005
AB	**!**		**5MG**	**A077152 002**	Mar 25, 2005

TERCONAZOLE

CREAM;VAGINAL

TERCONAZOLE

AB		FOUGERA PHARMS	**0.4%**	**A076712 001**	Feb 18, 2005
AB	**!**	TARO	**0.4%**	**A076043 001**	Jan 19, 2005
BX	+!	NYCOMED US	0.8%	N021735 001	Oct 01, 2004
BX	!	TARO	0.8%	A075953 001	Apr 06, 2004

SUPPOSITORY;VAGINAL

TERCONAZOLE

AB	**!**	PERRIGO NEW YORK	**80MG**	**A077149 001**	Mar 17, 2006
AB		TARO	**80MG**	**A077553 001**	Mar 09, 2007

TERIFLUNOMIDE

TABLET;ORAL

AUBAGIO

AB	**+**	SANOFI AVENTIS US	**7MG**	**N202992 001**	Sep 12, 2012
AB	**+!**		**14MG**	**N202992 002**	Sep 12, 2012

TERIFLUNOMIDE

AB		ACCORD HLTHCARE	**7MG**	**A209690 001**	Jan 07, 2019
AB			**14MG**	**A209690 002**	Jan 07, 2019
AB		AMNEAL PHARMS CO	**7MG**	**A209613 001**	Sep 28, 2018
AB			**14MG**	**A209613 002**	Sep 28, 2018
AB		APOTEX INC	**7MG**	**A209601 001**	Nov 02, 2018
AB			**14MG**	**A209601 002**	Nov 02, 2018
AB		AUROBINDO PHARMA LTD	**7MG**	**A209638 001**	Oct 26, 2018
AB			**14MG**	**A209638 002**	Oct 26, 2018

TERIFLUNOMIDE
TABLET;ORAL
TERIFLUNOMIDE

AB	GLENMARK PHARMS	**7MG**	**A209663**	**001**	Nov 15, 2018
AB		**14MG**	**A209663**	**002**	Nov 15, 2018
AB	SANDOZ INC	**7MG**	**A209710**	**001**	Jan 03, 2019
AB		**14MG**	**A209710**	**002**	Jan 03, 2019
AB	TEVA PHARMS USA	**7MG**	**A209700**	**001**	Sep 04, 2018
AB		**14MG**	**A209700**	**002**	Sep 04, 2018
AB	WATSON LABS TEVA	**7MG**	**A209549**	**001**	Jul 27, 2018
AB		**14MG**	**A209549**	**002**	Jul 27, 2018
AB	ZYDUS PHARMS USA INC	**7MG**	**A209668**	**001**	Nov 30, 2018
AB		**14MG**	**A209668**	**002**	Nov 30, 2018

TERIPARATIDE RECOMBINANT HUMAN
INJECTABLE;SUBCUTANEOUS
FORTEO

+!	LILLY	0.6MG/2.4ML (0.25MG/ML)	N021318	002	Jun 25, 2008

TESAMORELIN ACETATE
POWDER;SUBCUTANEOUS
EGRIFTA

+!	THERATECHNOLOGIES	EQ 1MG BASE/VIAL	N022505	001	Nov 10, 2010
+!		EQ 2MG BASE/VIAL	N022505	002	Nov 29, 2011

TESTOSTERONE
FILM, EXTENDED RELEASE;TRANSDERMAL
ANDRODERM

+!	ALLERGAN SALES LLC	2MG/24HR	N020489	003	Oct 20, 2011
+!		4MG/24HR	N020489	004	Oct 20, 2011

GEL;TRANSDERMAL
ANDROGEL

AB1	**+**	ABBVIE	**25MG/2.5GM PACKET**	**N021015**	**001**	Feb 28, 2000
AB1	**+!**		**50MG/5GM PACKET**	**N021015**	**002**	Feb 28, 2000

TESTOSTERONE

AB1		ACTAVIS LABS UT INC	**25MG/2.5GM PACKET**	**A076737**	**001**	Jan 27, 2006
AB1			**50MG/5GM PACKET**	**A076737**	**002**	Jan 27, 2006
AB1		PAR PHARM	**25MG/2.5GM PACKET**	**A076744**	**001**	May 23, 2007
AB1			**50MG/5GM PACKET**	**A076744**	**002**	May 23, 2007

ANDROGEL

AB2	**+**	ABBVIE	**1.62% (20.25MG/1.25GM PACKET)**	**N022309**	**002**	Sep 07, 2012
AB2	**+!**		**1.62% (40.5MG/2.5GM PACKET)**	**N022309**	**003**	Sep 07, 2012

TESTIM

AB2	**+!**	AUXILIUM PHARMS LLC	**50MG/5GM PACKET**	**N021454**	**001**	Oct 31, 2002

TESTOSTERONE

AB2		ACTAVIS LABS UT INC	**50MG/5GM PACKET**	**A091073**	**001**	Sep 18, 2017
AB2		PERRIGO UK FINCO	**1.62% (20.25MG/1.25GM PACKET)**	**A205781**	**001**	Jul 12, 2017
AB2			**1.62% (40.5MG/2.5GM PACKET)**	**A205781**	**002**	Jul 12, 2017

VOGELXO

AB2		UPSHER SMITH LABS	**50MG/5GM PACKET**	**N204399**	**002**	Jun 04, 2014

GEL, METERED;NASAL
NATESTO

	AYTU	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014

GEL, METERED;TRANSDERMAL
ANDROGEL

AB	**+!**	ABBVIE	**1.62% (20.25MG/1.25GM ACTUATION)**	**N022309**	**001**	Apr 29, 2011
AB	**+!**		**12.5MG/1.25GM ACTUATION**	**N021015**	**003**	Sep 26, 2003

FORTESTA

AB	**+!**	ENDO PHARMS	**10MG/0.5GM ACTUATION**	**N021463**	**001**	Dec 29, 2010

TESTOSTERONE

AB		ACTAVIS LABS UT INC	**10MG/0.5GM ACTUATION**	**A204571**	**001**	Aug 05, 2015
AB			**12.5MG/1.25GM ACTUATION**	**A076737**	**003**	Mar 09, 2015
AB		PERRIGO ISRAEL	**1.62% (20.25MG/1.25GM ACTUATION)**	**A204268**	**001**	Aug 04, 2015

VOGELXO

BX		UPSHER SMITH LABS	12.5MG/1.25GM ACTUATION	N204399	003	Jun 04, 2014

PELLET;IMPLANTATION
TESTOPEL

!	AUXILIUM PHARMS INC	75MG	A080911	001	

SOLUTION, METERED;TRANSDERMAL
TESTOSTERONE

AT		ACTAVIS LABS UT INC	**30MG/1.5ML ACTUATION**	**A205328**	**001**	Aug 07, 2017
AT		CIPLA	**30MG/1.5ML ACTUATION**	**A209533**	**001**	Jan 29, 2018
AT		LUPIN LTD	**30MG/1.5ML ACTUATION**	**A208061**	**001**	Oct 23, 2017

TESTOSTERONE

SOLUTION, METERED;TRANSDERMAL

TESTOSTERONE

AT	**!**	PERRIGO ISRAEL	**30MG/1.5ML ACTUATION**	**A204255**	**001**	Feb 28, 2017

TABLET, EXTENDED RELEASE;BUCCAL

STRIANT

	+!	AUXILIUM PHARMS LLC	30MG	N021543	001	Jun 19, 2003

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

DEPO-TESTOSTERONE

AO	**!**	PHARMACIA AND UPJOHN	**100MG/ML**	**A085635**	**002**	
AO	**!**		**200MG/ML**	**A085635**	**003**	

TESTOSTERONE CYPIONATE

AO		CIPLA	**100MG/ML**	**A210362**	**001**	Jun 19, 2018
AO			**200MG/ML**	**A210362**	**002**	Jun 19, 2018
AO		HIKMA FARMACEUTICA	**200MG/ML**	**A091244**	**001**	May 01, 2012
AO		LUITPOLD	**200MG/ML**	**A207742**	**001**	Jun 16, 2017
AO		MYLAN INSTITUTIONAL	**200MG/ML**	**A040652**	**001**	Dec 11, 2006
AO		PADDOCK LLC	**200MG/ML**	**A040530**	**001**	Jan 31, 2005
AO		SANDOZ INC	**100MG/ML**	**A040615**	**001**	Aug 10, 2006
AO			**200MG/ML**	**A040615**	**002**	Aug 10, 2006
AO		SUN PHARM INDS LTD	**100MG/ML**	**A201720**	**001**	Jun 03, 2013
AO			**200MG/ML**	**A201720**	**002**	Jun 03, 2013
AO		WATSON PHARMS INC	**200MG/ML**	**A086030**	**001**	
AO		WEST-WARD PHARMS INT	**100MG/ML**	**A090387**	**001**	Jul 15, 2010
AO			**200MG/ML**	**A090387**	**002**	Jul 15, 2010

TESTOSTERONE ENANTHATE

INJECTABLE;INJECTION

TESTOSTERONE ENANTHATE

AO		HIKMA FARMACEUTICA	**200MG/ML**	**A091120**	**001**	Sep 18, 2012
AO		NEXUS PHARMS	**200MG/ML**	**A040575**	**001**	Jun 14, 2006
AO	**!**	WATSON PHARMS INC	**200MG/ML**	**A085598**	**001**	

SOLUTION;SUBCUTANEOUS

XYOSTED (AUTOINJECTOR)

	+!	ANTARES PHARMA INC	50MG/0.5ML (50MG/0.5ML)	N209863	001	Sep 28, 2018
	+!		75MG/0.5ML (75MG/0.5ML)	N209863	002	Sep 28, 2018
	+!		100MG/0.5ML (100MG/0.5ML)	N209863	003	Sep 28, 2018

TESTOSTERONE UNDECANOATE

INJECTABLE;INTRAMUSCULAR

AVEED

	+!	ENDO PHARMS INC	750MG/3ML (250MG/ML)	N022219	001	Mar 05, 2014

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

AB		ACTAVIS LABS FL INC	**25MG**	**A206686**	**001**	Jul 07, 2017
AB		APICORE US	**12.5MG**	**A207682**	**001**	Jan 31, 2017
AB			**25MG**	**A207682**	**002**	Jan 31, 2017
AB		BIONPHARMA INC	**12.5MG**	**A208826**	**001**	Dec 18, 2017
AB			**25MG**	**A208826**	**002**	Dec 18, 2017
AB		DR REDDYS LABS LTD	**12.5MG**	**A209284**	**001**	Jan 08, 2018
AB			**25MG**	**A209284**	**002**	Jan 08, 2018
AB		HETERO LABS LTD V	**12.5MG**	**A204574**	**001**	Feb 03, 2016
AB			**25MG**	**A204574**	**002**	Feb 03, 2016
AB		LUPIN LTD	**12.5MG**	**A210544**	**001**	Apr 20, 2018
AB			**25MG**	**A210544**	**002**	Apr 20, 2018
AB		SUN PHARMA GLOBAL	**12.5MG**	**A206129**	**001**	Aug 17, 2015
AB			**25MG**	**A206129**	**002**	Aug 17, 2015

XENAZINE

AB	**+**	VALEANT PHARMS NORTH	**12.5MG**	**N021894**	**001**	Aug 15, 2008
AB	**+!**		**25MG**	**N021894**	**002**	Aug 15, 2008

TETRACAINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC

TETRACAINE HYDROCHLORIDE

	+!	ALCON LABS	0.5%	N208135	001	Feb 29, 2016

TETRACYCLINE HYDROCHLORIDE							
CAPSULE;ORAL							
ACHROMYCIN V							
AB	**+**	HERITAGE PHARMS INC	**250MG**	**N050278**	**003**		
AB	**+!**		**500MG**	**N050278**	**001**		
TETRACYCLINE HYDROCHLORIDE							
AB		AMNEAL PHARMS NY	**250MG**	**A210674**	**001**	Sep 18, 2018	
AB			**500MG**	**A210674**	**002**	Sep 18, 2018	
AB		BRECKENRIDGE PHARM	**250MG**	**A210662**	**001**	Nov 07, 2018	
AB			**500MG**	**A210662**	**002**	Nov 07, 2018	
AB		CHARTWELL TETRA	**250MG**	**A062752**	**001**	Aug 12, 1988	
AB			**500MG**	**A062752**	**002**	Aug 12, 1988	
AB		WATSON LABS	**250MG**	**A061837**	**001**		
AB			**500MG**	**A061837**	**002**		
TETRAHYDROZOLINE HYDROCHLORIDE							
SOLUTION;NASAL							
TYZINE							
	!	FOUGERA PHARMS	0.05%	A086576	002		
			0.1%	A086576	001		
SPRAY;NASAL							
TYZINE							
	!	FOUGERA PHARMS	0.1%	A086576	003		
THALIDOMIDE							
CAPSULE;ORAL							
THALOMID							
	+	CELGENE	50MG	N020785	001	Jul 16, 1998	
	+		100MG	N020785	002	Jan 17, 2003	
	+		150MG	N020785	004	Jan 10, 2007	
	+!		200MG	N020785	003	Jan 17, 2003	
THALLOUS CHLORIDE TL-201							
INJECTABLE;INJECTION							
THALLOUS CHLORIDE TL 201							
AP	**+!**	GE HEALTHCARE	**1mCi/ML**	**N018110**	**002**	Feb 27, 1996	
AP	**+!**	LANTHEUS MEDCL	**1mCi/ML**	**N017806**	**001**		
AP	**+!**	MALLINKRODT NUCLEAR	**1mCi/ML**	**N018150**	**001**		
THEOPHYLLINE							
CAPSULE, EXTENDED RELEASE;ORAL							
THEO-24							
		ACTIENT PHARMS	100MG	A087942	001	Aug 22, 1983	
	!	AUXILIUM PHARMS INC	400MG	A081034	001	Feb 28, 1992	
		AUXILIUM PHARMS LLC	200MG	A087943	001	Aug 22, 1983	
			300MG	A087944	001	Aug 22, 1983	
INJECTABLE;INJECTION							
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER							
	+!	B BRAUN	40MG/100ML	N019826	001	Aug 14, 1992	
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER							
	+!	B BRAUN	80MG/100ML	N019826	002	Aug 14, 1992	
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER							
	+!	B BRAUN	160MG/100ML	N019826	003	Aug 14, 1992	
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER							
	+!	B BRAUN	320MG/100ML	N019826	006	Aug 14, 1992	
SOLUTION;ORAL							
THEOPHYLLINE							
AA	**!**	LANNETT CO INC	**80MG/15ML**	**A091156**	**001**	Apr 13, 2011	
AA		TRIS PHARMA INC	**80MG/15ML**	**A091586**	**001**	Jun 15, 2012	
SOLUTION, ELIXIR;ORAL							
ELIXOPHYLLIN							
AA	**!**	NOSTRUM LABS INC	**80MG/15ML**	**A085186**	**001**		
THEOPHYLLINE							
AA		PHARM ASSOC	**80MG/15ML**	**A206344**	**001**	Dec 16, 2016	
TABLET, EXTENDED RELEASE;ORAL							
THEOCHRON							
AB		NOSTRUM PHARMS LLC	**100MG**	**A087400**	**003**	Feb 21, 1985	
AB			**200MG**	**A087400**	**004**	Feb 21, 1985	
THEOPHYLLINE							
AB		ALEMBIC PHARMS LTD	**300MG**	**A090430**	**001**	Oct 27, 2010	
AB		GLENMARK GENERICS	**400MG**	**A090355**	**001**	Jul 13, 2010	
AB			**600MG**	**A090355**	**002**	Jul 13, 2010	
AB		MYLAN IRELAND LTD	**400MG**	**A040560**	**003**	Apr 21, 2006	
AB	**!**		**600MG**	**A040560**	**002**	Apr 21, 2006	

THEOPHYLLINE
TABLET, EXTENDED RELEASE;ORAL
THEOPHYLLINE

AB	**!**	PLIVA	**100MG**	**A089807**	**001**	Apr 30, 1990
AB	**!**		**200MG**	**A089808**	**001**	Apr 30, 1990
AB			**300MG**	**A089763**	**001**	Apr 30, 1990
AB		RHODES PHARMS	**400MG**	**A087571**	**001**	Sep 01, 1982
AB			**600MG**	**A040086**	**001**	Apr 15, 1996
	!	ALEMBIC PHARMS LTD	450MG	A090430	002	Oct 27, 2010

THIAMINE HYDROCHLORIDE
INJECTABLE;INJECTION
THIAMINE HYDROCHLORIDE

AP	**!**	FRESENIUS KABI USA	**100MG/ML**	**A080556**	**001**	
AP		MYLAN INSTITUTIONAL	**100MG/ML**	**A091623**	**001**	Jun 25, 2012
AP		SAGENT PHARMS	**100MG/ML**	**A206106**	**001**	Dec 01, 2017

THIOGUANINE
TABLET;ORAL
THIOGUANINE

	+!	ASPEN GLOBAL INC	40MG	N012429	001	

THIORIDAZINE HYDROCHLORIDE
TABLET;ORAL
THIORIDAZINE HYDROCHLORIDE

AB		MYLAN	**10MG**	**A088004**	**002**	Mar 15, 1983
AB			**25MG**	**A088004**	**003**	Mar 15, 1983
AB			**50MG**	**A088004**	**004**	Mar 15, 1983
AB	**!**		**100MG**	**A088004**	**001**	Nov 18, 1983
AB		SUN PHARM INDUSTRIES	**10MG**	**A089953**	**004**	Aug 01, 1986
AB			**25MG**	**A089953**	**003**	Aug 01, 1986
AB			**50MG**	**A089953**	**002**	Aug 01, 1986
AB			**100MG**	**A089953**	**001**	Oct 07, 1988

THIOTEPA
INJECTABLE;INJECTION
THIOTEPA

AP		DR REDDYS LABS LTD	**15MG/VIAL**	**A210337**	**001**	May 04, 2018
AP		JIANGSU HENGRUI MED	**15MG/VIAL**	**A209150**	**001**	May 04, 2018
AP	**!**	WEST-WARD PHARMS INT	**15MG/VIAL**	**A075547**	**001**	Apr 02, 2001

POWDER;INTRAVENOUS
TEPADINA

	+!	ADIENNE SA	15MG/VIAL	N208264	001	Jan 26, 2017
	+!		100MG/VIAL	N208264	002	Jan 26, 2017

THIOTHIXENE
CAPSULE;ORAL
THIOTHIXENE

		MYLAN	1MG	A071093	002	Jun 23, 1987
			2MG	A071093	003	Jun 23, 1987
	!		5MG	A071093	004	Jun 23, 1987
			10MG	A071093	001	Jun 23, 1987

THYROTROPIN ALFA
INJECTABLE;INJECTION
THYROGEN

	+!	GENZYME	1.1MG/VIAL	N020898	001	Nov 30, 1998

TIAGABINE HYDROCHLORIDE
TABLET;ORAL
GABITRIL

AB	**+**	CEPHALON	**2MG**	**N020646**	**005**	Apr 16, 1999
AB	**+!**		**4MG**	**N020646**	**001**	Sep 30, 1997
AB	**+**		**12MG**	**N020646**	**002**	Sep 30, 1997
AB	**+**		**16MG**	**N020646**	**003**	Sep 30, 1997

TIAGABINE HYDROCHLORIDE

AB		AMNEAL PHARMS CO	**2MG**	**A208181**	**001**	Dec 08, 2017
AB			**4MG**	**A208181**	**002**	Dec 08, 2017
AB			**12MG**	**A208181**	**003**	Dec 08, 2017
AB			**16MG**	**A208181**	**004**	Dec 08, 2017
AB		SUN PHARM INDS	**2MG**	**A077555**	**001**	Nov 04, 2011
AB			**4MG**	**A077555**	**002**	Nov 04, 2011
AB		WILSHIRE PHARMS INC	**2MG**	**A206857**	**001**	Oct 13, 2017
AB			**4MG**	**A206857**	**002**	Oct 13, 2017

TIAGABINE HYDROCHLORIDE
TABLET;ORAL
TIAGABINE HYDROCHLORIDE

AB			**12MG**	**A206857**	**003**	Oct 13, 2017
AB			**16MG**	**A206857**	**004**	Oct 13, 2017

TICAGRELOR
TABLET;ORAL
BRILINTA

AB	**+**	ASTRAZENECA PHARMS	**60MG**	**N022433**	**002**	Sep 03, 2015
AB	**+!**		**90MG**	**N022433**	**001**	Jul 20, 2011

TICAGRELOR

AB		WATSON LABS INC	**60MG**	**A208390**	**001**	Sep 04, 2018
AB			**90MG**	**A208390**	**002**	Sep 04, 2018

TICLOPIDINE HYDROCHLORIDE
TABLET;ORAL
TICLOPIDINE HYDROCHLORIDE

AB		APOTEX	**250MG**	**A075089**	**001**	Jul 01, 1999
AB		SUN PHARM INDS INC	**250MG**	**A075526**	**001**	Sep 26, 2002
AB	**!**	TEVA	**250MG**	**A075149**	**001**	Aug 20, 1999

TIGECYCLINE
POWDER;INTRAVENOUS
TIGECYCLINE

AP		AMNEAL PHARMS LLC	**50MG/VIAL**	**N211158**	**001**	Aug 02, 2018
AP		APOTEX INC	**50MG/VIAL**	**A204439**	**001**	Dec 21, 2018
AP		FRESENIUS KABI USA	**50MG/VIAL**	**N205645**	**001**	Dec 01, 2016
AP		SANDOZ INC	**50MG/VIAL**	**A091620**	**001**	May 27, 2015

TYGACIL

AP	**+!**	PF PRISM CV	**50MG/VIAL**	**N021821**	**001**	Jun 15, 2005

TIGECYCLINE

		ACCORD HLTHCARE INC	50MG/VIAL	N208744	001	Jan 18, 2018

TIMOLOL
SOLUTION/DROPS;OPHTHALMIC
BETIMOL

AT	**+!**	OAK PHARMS INC	**EQ 0.25% BASE**	**N020439**	**001**	Mar 31, 1995
AT	**+!**		**EQ 0.5% BASE**	**N020439**	**002**	Mar 31, 1995

TIMOLOL

AT		AKORN	**EQ 0.25% BASE**	**A205309**	**001**	Sep 30, 2016
AT			**EQ 0.5% BASE**	**A205309**	**002**	Sep 30, 2016

TIMOLOL MALEATE
SOLUTION, GEL FORMING/DROPS;OPHTHALMIC
TIMOLOL MALEATE

AB		SANDOZ INC	**EQ 0.25% BASE**	**N020963**	**001**	Oct 21, 1998
AB			**EQ 0.5% BASE**	**N020963**	**002**	Oct 21, 1998

TIMOPTIC-XE

AB	**+!**	VALEANT PHARMS LLC	**EQ 0.25% BASE**	**N020330**	**001**	Nov 04, 1993
AB	**+!**		**EQ 0.5% BASE**	**N020330**	**002**	Nov 04, 1993

SOLUTION/DROPS;OPHTHALMIC
TIMOLOL MALEATE

AT		BAUSCH AND LOMB	**EQ 0.25% BASE**	**A074778**	**001**	Mar 25, 1997
AT		FDC LTD	**EQ 0.25% BASE**	**A077259**	**001**	Apr 30, 2008
AT		PACIFIC PHARMA	**EQ 0.25% BASE**	**A074746**	**001**	Mar 25, 1997
AT	**!**	SANDOZ INC	**EQ 0.25% BASE**	**A074261**	**001**	Apr 28, 1995
AT		WOCKHARDT	**EQ 0.25% BASE**	**A078771**	**001**	Sep 28, 2009

TIMOPTIC

AT	**+**	ATON	**EQ 0.25% BASE**	**N018086**	**001**	

TIMOLOL MALEATE

AT1		AKORN	**EQ 0.5% BASE**	**A074466**	**001**	Mar 25, 1997
AT1			**EQ 0.5% BASE**	**A074516**	**001**	Mar 25, 1997
AT1		BAUSCH AND LOMB	**EQ 0.5% BASE**	**A074776**	**001**	Mar 25, 1997
AT1		FDC LTD	**EQ 0.5% BASE**	**A077259**	**002**	Apr 30, 2008
AT1		HI TECH PHARMA	**EQ 0.5% BASE**	**A075163**	**001**	Sep 10, 2002
AT1		PACIFIC PHARMA	**EQ 0.5% BASE**	**A074747**	**001**	Mar 25, 1997
AT1	**!**	SANDOZ INC	**EQ 0.5% BASE**	**A074262**	**001**	Apr 28, 1995
AT1		WOCKHARDT	**EQ 0.5% BASE**	**A078771**	**002**	Sep 28, 2009

TIMOPTIC

AT1	**+**	ATON	**EQ 0.5% BASE**	**N018086**	**002**	

ISTALOL

AT2	**+!**	BAUSCH AND LOMB	**EQ 0.5% BASE**	**N021516**	**001**	Jun 04, 2004

TIMOLOL MALEATE						
SOLUTION/DROPS;OPHTHALMIC						
TIMOLOL MALEATE						
AT2	APOTEX INC	**EQ 0.5% BASE**	**A204936**	**001**	Apr 17, 2015	
TIMOPTIC IN OCUDOSE						
+!	ATON	EQ 0.25% BASE	N019463	001	Nov 05, 1986	
+!		EQ 0.5% BASE	N019463	002	Nov 05, 1986	
TABLET;ORAL						
TIMOLOL MALEATE						
	MYLAN	5MG	A072668	002	Jun 08, 1990	
		10MG	A072668	003	Jun 08, 1990	
!		20MG	A072668	001	Jun 08, 1990	
TINIDAZOLE						
TABLET;ORAL						
TINDAMAX						
AB +	MISSION PHARMA	**250MG**	**N021618**	**001**	May 17, 2004	
AB +!		**500MG**	**N021618**	**002**	May 17, 2004	
TINIDAZOLE						
AB	EDENBRIDGE PHARMS	**250MG**	**A203808**	**001**	Aug 04, 2015	
AB		**500MG**	**A203808**	**002**	Aug 04, 2015	
AB	NOVEL LABS INC	**250MG**	**A202044**	**001**	Apr 30, 2012	
AB		**500MG**	**A202044**	**002**	Apr 30, 2012	
AB	UNIQUE PHARM LABS	**250MG**	**A202489**	**001**	Oct 09, 2013	
AB		**500MG**	**A202489**	**002**	Oct 09, 2013	
AB	WEST-WARD PHARMS INT	**250MG**	**A201172**	**001**	Apr 30, 2012	
AB		**500MG**	**A201172**	**002**	Apr 30, 2012	
TIOPRONIN						
TABLET;ORAL						
THIOLA						
+!	MISSION PHARMA	100MG	N019569	001	Aug 11, 1988	
TIOTROPIUM BROMIDE						
POWDER;INHALATION						
SPIRIVA						
+!	BOEHRINGER INGELHEIM	EQ 0.018MG BASE/INH	N021395	001	Jan 30, 2004	
SPRAY, METERED;INHALATION						
SPIRIVA RESPIMAT						
+	BOEHRINGER INGELHEIM	EQ 0.00125MG BASE/INH	N021936	002	Sep 15, 2015	
+!		EQ 0.0025MG BASE/INH	N021936	001	Sep 24, 2014	
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE						
TABLET;ORAL						
LONSURF						
+	TAIHO ONCOLOGY	EQ 6.14MG BASE;15MG	N207981	001	Sep 22, 2015	
+!		EQ 8.19MG BASE;20MG	N207981	002	Sep 22, 2015	
TIPRANAVIR						
CAPSULE;ORAL						
APTIVUS						
+!	BOEHRINGER INGELHEIM	250MG	N021814	001	Jun 22, 2005	
SOLUTION;ORAL						
APTIVUS						
+!	BOEHRINGER INGELHEIM	100MG/ML	N022292	001	Jun 23, 2008	
TIROFIBAN HYDROCHLORIDE						
INJECTABLE;INJECTION						
AGGRASTAT						
+	MEDICURE	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N020913	002	May 17, 2002	
+!		EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)	N020913	003	Apr 20, 2000	
SOLUTION;INJECTION						
AGGRASTAT						
+!	MEDICURE	EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML)	N020912	002	Aug 31, 2016	

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

AB		APOTEX INC	**EQ 2MG BASE**	**A078868**	**001**	Feb 03, 2012
AB			**EQ 4MG BASE**	**A078868**	**002**	Feb 03, 2012
AB			**EQ 6MG BASE**	**A078868**	**003**	Feb 03, 2012
AB		JUBILANT GENERICS	**EQ 2MG BASE**	**A209605**	**001**	Aug 04, 2017
AB			**EQ 4MG BASE**	**A209605**	**002**	Aug 04, 2017
AB			**EQ 6MG BASE**	**A209605**	**003**	Aug 04, 2017
AB		MYLAN PHARMS INC	**EQ 2MG BASE**	**A091502**	**001**	Nov 09, 2012
AB			**EQ 4MG BASE**	**A091502**	**002**	Nov 09, 2012
AB			**EQ 6MG BASE**	**A091502**	**003**	Nov 09, 2012
AB		PAR PHARM INC	**EQ 2MG BASE**	**A207199**	**001**	Mar 14, 2017
AB			**EQ 4MG BASE**	**A207199**	**002**	Mar 14, 2017
AB			**EQ 6MG BASE**	**A207199**	**003**	Mar 14, 2017
AB		ZYDUS PHARMS USA INC	**EQ 2MG BASE**	**A208622**	**001**	Mar 03, 2017
AB			**EQ 4MG BASE**	**A208622**	**002**	Mar 03, 2017
AB			**EQ 6MG BASE**	**A208622**	**003**	Mar 03, 2017

ZANAFLEX

AB	**+**	COVIS PHARMA BV	**EQ 2MG BASE**	**N021447**	**001**	Aug 29, 2002
AB	**+**		**EQ 4MG BASE**	**N021447**	**002**	Aug 29, 2002
AB	**+!**		**EQ 6MG BASE**	**N021447**	**003**	Aug 29, 2002

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

AB		APOTEX	**EQ 2MG BASE**	**A076533**	**001**	Jan 16, 2004
AB			**EQ 4MG BASE**	**A076533**	**002**	Jan 16, 2004
AB		CASI PHARMS INC	**EQ 2MG BASE**	**A076280**	**001**	Nov 26, 2002
AB			**EQ 4MG BASE**	**A076280**	**002**	Jun 27, 2002
AB		DR REDDYS LABS INC	**EQ 2MG BASE**	**A076286**	**001**	Jul 03, 2002
AB			**EQ 4MG BASE**	**A076286**	**002**	Jul 03, 2002
AB		EPIC PHARMA LLC	**EQ 2MG BASE**	**A076347**	**001**	Oct 11, 2002
AB			**EQ 4MG BASE**	**A076347**	**002**	Oct 11, 2002
AB		MYLAN	**EQ 2MG BASE**	**A076354**	**001**	Mar 28, 2003
AB			**EQ 4MG BASE**	**A076354**	**002**	Mar 28, 2003
AB		OXFORD PHARMS	**EQ 2MG BASE**	**A076281**	**001**	Oct 20, 2003
AB			**EQ 4MG BASE**	**A076281**	**002**	Oct 20, 2003
AB		PAR PHARM INC	**EQ 2MG BASE**	**A207170**	**001**	Jan 26, 2017
AB			**EQ 4MG BASE**	**A207170**	**002**	Jan 26, 2017
AB		SUN PHARM INDS INC	**EQ 2MG BASE**	**A076416**	**001**	Sep 29, 2003
AB			**EQ 4MG BASE**	**A076416**	**002**	Sep 29, 2003
AB		TEVA	**EQ 2MG BASE**	**A076284**	**001**	Jul 03, 2002
AB			**EQ 4MG BASE**	**A076284**	**002**	Jul 03, 2002
AB		UNICHEM LABS LTD	**EQ 2MG BASE**	**A091283**	**001**	Nov 28, 2012
AB			**EQ 4MG BASE**	**A091283**	**002**	Nov 28, 2012
AB		ZYDUS PHARMS USA INC	**EQ 2MG BASE**	**A208187**	**001**	Mar 09, 2018
AB			**EQ 4MG BASE**	**A208187**	**002**	Mar 09, 2018

ZANAFLEX

AB	**+!**	COVIS PHARMA BV	**EQ 4MG BASE**	**N020397**	**001**	Nov 27, 1996

TOBRAMYCIN

OINTMENT;OPHTHALMIC

TOBREX

	+!	NOVARTIS PHARMS CORP	0.3%	N050555	001	

POWDER;INHALATION

TOBI PODHALER

	+!	MYLAN SPECIALITY LP	28MG	N201688	001	Mar 22, 2013

SOLUTION;INHALATION

KITABIS PAK

AN		PULMOFLOW INC	**300MG/5ML**	**N205433**	**001**	Dec 02, 2014

TOBI

AN	**+!**	MYLAN SPECIALITY LP	**300MG/5ML**	**N050753**	**001**	Dec 22, 1997

TOBRAMYCIN

AN		AKORN INC	**300MG/5ML**	**A201422**	**001**	May 28, 2014
AN		AMNEAL PHARMS	**300MG/5ML**	**A205501**	**001**	Jul 13, 2015
AN		DR REDDYS LABS SA	**300MG/5ML**	**A207080**	**001**	Jul 09, 2018
AN		LUPIN	**300MG/5ML**	**A208964**	**001**	Mar 22, 2017
AN		MYLAN PHARMS INC	**300MG/5ML**	**A209554**	**001**	Oct 13, 2017
AN		TEVA PHARMS USA	**300MG/5ML**	**A091589**	**001**	Oct 10, 2013

BETHKIS

	+!	CHIESI USA INC	300MG/4ML	N201820	001	Oct 12, 2012

TOBRAMYCIN						
SOLUTION/DROPS;OPHTHALMIC						
AKTOB						
AT		AKORN	**0.3%**	**A064096**	**001**	Jan 31, 1996
TOBRAMYCIN						
AT		BAUSCH AND LOMB	**0.3%**	**A064052**	**001**	Nov 29, 1993
AT		FERA PHARMS	**0.3%**	**A065026**	**001**	Sep 11, 2001
AT		SOMERSET THERAPS LLC	**0.3%**	**A207444**	**001**	Jun 28, 2017
TOBREX						
AT	**+!**	NOVARTIS PHARMS CORP	**0.3%**	**N050541**	**001**	
AT		SANDOZ INC	**0.3%**	**A062535**	**001**	Dec 13, 1984
TOBRAMYCIN SULFATE						
INJECTABLE;INJECTION						
TOBRAMYCIN SULFATE						
AP		AKORN	**EQ 40MG BASE/ML**	**A205179**	**001**	Sep 16, 2014
AP		BAXTER HLTHCARE CORP	**EQ 40MG BASE/ML**	**A206965**	**001**	Jul 01, 2016
AP		FRESENIUS KABI USA	**EQ 10MG BASE/ML**	**A065122**	**001**	Nov 29, 2002
AP	**!**		**EQ 40MG BASE/ML**	**A065122**	**002**	Nov 29, 2002
AP			**EQ 1.2GM BASE/VIAL**	**N050789**	**001**	Jul 13, 2004
AP	**!**	HOSPIRA	**EQ 10MG BASE/ML**	**A063112**	**001**	Apr 30, 1991
AP			**EQ 40MG BASE/ML**	**A063111**	**001**	Apr 30, 1991
AP		MYLAN LABS LTD	**EQ 40MG BASE/ML**	**A065407**	**001**	Mar 11, 2008
AP		TEVA PHARMS USA	**EQ 40MG BASE/ML**	**A063100**	**001**	Jan 30, 1992
AP		WEST-WARD PHARMS INT	**EQ 40MG BASE/ML**	**A063117**	**001**	Apr 26, 1991
AP	**!**	X GEN PHARMS	**EQ 1.2GM BASE/VIAL**	**A065013**	**001**	Aug 17, 2001
AP		XELLIA PHARMS APS	**EQ 1.2GM BASE/VIAL**	**A205685**	**001**	Sep 16, 2014
TOBRAMYCIN SULFATE (PHARMACY BULK)						
	!	FRESENIUS KABI USA	EQ 40MG BASE/ML	A065120	001	Nov 29, 2002
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
	!	HOSPIRA	EQ 1.2MG BASE/ML	A063081	003	Jul 31, 1990
	!		EQ 1.6MG BASE/ML	A063081	006	Jun 02, 1993
	!		EQ 80MG BASE/100ML	A063081	001	Jul 31, 1990
TOFACITINIB CITRATE						
TABLET;ORAL						
XELJANZ						
	+!	PF PRISM CV	EQ 5MG BASE	N203214	001	Nov 06, 2012
	+!		EQ 10MG BASE	N203214	002	May 30, 2018
TABLET, EXTENDED RELEASE;ORAL						
XELJANZ XR						
	+!	PFIZER INC	EQ 11MG BASE	N208246	001	Feb 23, 2016
TOLAZAMIDE						
TABLET;ORAL						
TOLAZAMIDE						
		MYLAN PHARMS INC	250MG	A070259	001	Jan 02, 1986
	!		500MG	A070259	003	Mar 17, 1986
TOLBUTAMIDE						
TABLET;ORAL						
TOLBUTAMIDE						
	!	MYLAN PHARMS INC	500MG	A086445	001	
TOLCAPONE						
TABLET;ORAL						
TASMAR						
AB	**+!**	VALEANT PHARMS LLC	**100MG**	**N020697**	**001**	Jan 29, 1998
TOLCAPONE						
AB		INGENUS PHARMS LLC	**100MG**	**A208937**	**001**	Aug 07, 2018
AB		PAR PHARM INC	**100MG**	**A204584**	**001**	Mar 26, 2015
TOLMETIN SODIUM						
CAPSULE;ORAL						
TOLMETIN SODIUM						
AB		MYLAN	**EQ 400MG BASE**	**A073393**	**001**	May 27, 1993
AB	**!**	TEVA	**EQ 400MG BASE**	**A073290**	**001**	Nov 27, 1991
TABLET;ORAL						
TOLMETIN SODIUM						
	!	MYLAN	EQ 600MG BASE	A074473	001	Aug 30, 1994

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

DETROL LA							
AB	**+**	PHARMACIA AND UPJOHN	**2MG**	**N021228**	**001**	Dec 22, 2000
AB	**+!**		**4MG**	**N021228**	**002**	Dec 22, 2000
TOLTERODINE TARTRATE							
AB		HETERO LABS LTD III	**2MG**	**A206419**	**001**	Dec 12, 2017
AB			**4MG**	**A206419**	**002**	Dec 12, 2017
AB		MYLAN PHARMS INC	**2MG**	**A201486**	**001**	Oct 31, 2013
AB			**4MG**	**A201486**	**002**	Oct 31, 2013
AB		TEVA PHARMS USA	**2MG**	**A079141**	**001**	Nov 22, 2016
AB			**4MG**	**A079141**	**002**	Nov 22, 2016
AB		TORRENT PHARMS LTD	**2MG**	**A203016**	**001**	Aug 11, 2015
AB			**4MG**	**A203016**	**002**	Aug 11, 2015

TABLET;ORAL

DETROL							
AB	**+**	PHARMACIA AND UPJOHN	**1MG**	**N020771**	**001**	Mar 25, 1998
AB	**+!**		**2MG**	**N020771**	**002**	Mar 25, 1998
TOLTERODINE TARTRATE							
AB		IVAX SUB TEVA PHARMS	**1MG**	**A077006**	**001**	Feb 23, 2015
AB			**2MG**	**A077006**	**002**	Feb 23, 2015
AB		MACLEODS PHARMS LTD	**1MG**	**A203409**	**001**	Aug 31, 2015
AB			**2MG**	**A203409**	**002**	Aug 31, 2015
AB		MYLAN PHARMS INC	**1MG**	**A202641**	**001**	Nov 27, 2012
AB			**2MG**	**A202641**	**002**	Nov 27, 2012

TOLVAPTAN

TABLET;ORAL

JYNARQUE						
	+	OTSUKA PHARM CO LTD	15MG	N204441	001	Apr 23, 2018
	+		30MG	N204441	002	Apr 23, 2018
	+		45MG	N204441	003	Apr 23, 2018
	+		60MG	N204441	004	Apr 23, 2018
	+!		90MG	N204441	005	Apr 23, 2018
SAMSCA						
	+	OTSUKA AMERICA PHARM	15MG	N022275	001	May 19, 2009
	+!		30MG	N022275	002	May 19, 2009

TOPIRAMATE

CAPSULE;ORAL

TOPAMAX							
AB	**+**	JANSSEN PHARMS	**15MG**	**N020844**	**001**	Oct 26, 1998
AB	**+!**		**25MG**	**N020844**	**002**	Oct 26, 1998
TOPIRAMATE							
AB		TEVA	**15MG**	**A076575**	**001**	Apr 17, 2009
AB			**25MG**	**A076575**	**002**	Apr 17, 2009
AB		WATSON LABS	**15MG**	**A077868**	**001**	Apr 15, 2009
AB			**25MG**	**A077868**	**002**	Apr 15, 2009
AB		ZYDUS PHARMS USA INC	**15MG**	**A078877**	**001**	Oct 14, 2009
AB			**25MG**	**A078877**	**002**	Oct 14, 2009

CAPSULE, EXTENDED RELEASE;ORAL

TOPIRAMATE							
AB		ZYDUS PHARMS USA INC	**25MG**	**A207382**	**001**	Nov 24, 2017
AB			**50MG**	**A207382**	**002**	Nov 24, 2017
AB			**100MG**	**A207382**	**003**	Nov 24, 2017
TROKENDI XR							
AB	**+**	SUPERNUS PHARMS	**25MG**	**N201635**	**001**	Aug 16, 2013
AB	**+**		**50MG**	**N201635**	**002**	Aug 16, 2013
AB	**+**		**100MG**	**N201635**	**003**	Aug 16, 2013
QUDEXY XR							
	+	UPSHER SMITH LABS	25MG	N205122	001	Mar 11, 2014
	+		50MG	N205122	002	Mar 11, 2014
	+		100MG	N205122	003	Mar 11, 2014
	+		150MG	N205122	004	Mar 11, 2014
	+!		200MG	N205122	005	Mar 11, 2014
TROKENDI XR							
	+!	SUPERNUS PHARMS	200MG	N201635	004	Aug 16, 2013

TOPIRAMATE

TABLET;ORAL

TOPAMAX

AB	+	JANSSEN PHARMS	**25MG**	**N020505**	**004**	Dec 24, 1996
AB	+		**50MG**	**N020505**	**005**	Dec 24, 1996
AB	+!		**100MG**	**N020505**	**001**	Dec 24, 1996
AB	+		**200MG**	**N020505**	**002**	Dec 24, 1996

TOPIRAMATE

AB	ACCORD HLTHCARE	**25MG**	**A076311**	**001**	Mar 27, 2009
AB		**50MG**	**A076311**	**002**	Mar 27, 2009
AB		**100MG**	**A076311**	**003**	Mar 27, 2009
AB		**200MG**	**A076311**	**004**	Mar 27, 2009
AB	APOTEX INC	**25MG**	**A077733**	**001**	Mar 27, 2009
AB		**50MG**	**A077733**	**002**	Mar 27, 2009
AB		**100MG**	**A077733**	**003**	Mar 27, 2009
AB		**200MG**	**A077733**	**004**	Mar 27, 2009
AB	AUROBINDO PHARMA	**25MG**	**A078462**	**001**	Mar 27, 2009
AB		**50MG**	**A078462**	**002**	Mar 27, 2009
AB		**100MG**	**A078462**	**003**	Mar 27, 2009
AB		**200MG**	**A078462**	**004**	Mar 27, 2009
AB	CIPLA LTD	**25MG**	**A076343**	**001**	Mar 27, 2009
AB		**50MG**	**A076343**	**002**	Mar 27, 2009
AB		**100MG**	**A076343**	**003**	Mar 27, 2009
AB		**200MG**	**A076343**	**004**	Mar 27, 2009
AB	GLENMARK GENERICS	**25MG**	**A077627**	**001**	Mar 27, 2009
AB		**50MG**	**A077627**	**002**	Mar 27, 2009
AB		**100MG**	**A077627**	**003**	Mar 27, 2009
AB		**200MG**	**A077627**	**004**	Mar 27, 2009
AB	INVAGEN PHARMS	**25MG**	**A079162**	**001**	Mar 27, 2009
AB		**50MG**	**A079162**	**002**	Mar 27, 2009
AB		**100MG**	**A079162**	**003**	Mar 27, 2009
AB		**200MG**	**A079162**	**004**	Mar 27, 2009
AB	LUPIN	**25MG**	**A078410**	**001**	Sep 11, 2013
AB		**50MG**	**A078410**	**002**	Sep 11, 2013
AB		**100MG**	**A078410**	**003**	Sep 11, 2013
AB		**200MG**	**A078410**	**004**	Sep 11, 2013
AB	SUN PHARM INDS LTD	**25MG**	**A076327**	**001**	Mar 27, 2009
AB		**100MG**	**A076327**	**002**	Mar 27, 2009
AB		**200MG**	**A076327**	**003**	Mar 27, 2009
AB	SUN PHARMA GLOBAL	**25MG**	**A090278**	**001**	Mar 27, 2009
AB		**50MG**	**A090278**	**002**	Mar 27, 2009
AB		**100MG**	**A090278**	**003**	Mar 27, 2009
AB		**200MG**	**A090278**	**004**	Mar 27, 2009
AB	TEVA	**25MG**	**A076317**	**001**	Mar 27, 2009
AB		**50MG**	**A076317**	**002**	Mar 27, 2009
AB		**100MG**	**A076317**	**003**	Mar 27, 2009
AB		**200MG**	**A076317**	**004**	Mar 27, 2009
AB	TORRENT PHARMS	**25MG**	**A079153**	**001**	Mar 27, 2009
AB		**50MG**	**A079153**	**002**	Mar 27, 2009
AB		**100MG**	**A079153**	**003**	Mar 27, 2009
AB		**200MG**	**A079153**	**004**	Mar 27, 2009
AB	UNICHEM LABS LTD	**25MG**	**A090162**	**001**	Mar 27, 2009
AB		**50MG**	**A090162**	**002**	Mar 27, 2009
AB		**100MG**	**A090162**	**003**	Mar 27, 2009
AB		**200MG**	**A090162**	**004**	Feb 19, 2013
AB	UPSHER SMITH LABS	**25MG**	**A078499**	**001**	Jan 07, 2010
AB		**50MG**	**A078499**	**002**	Jan 07, 2010
AB		**100MG**	**A078499**	**003**	Jan 07, 2010
AB		**200MG**	**A078499**	**004**	Jan 07, 2010
AB	ZYDUS PHARMS USA INC	**25MG**	**A078235**	**001**	Mar 27, 2009
AB		**50MG**	**A078235**	**002**	Mar 27, 2009
AB		**100MG**	**A078235**	**003**	Mar 27, 2009
AB		**200MG**	**A078235**	**004**	Mar 27, 2009

TOPOTECAN HYDROCHLORIDE

CAPSULE;ORAL

HYCAMTIN

+	NOVARTIS PHARMS CORP	EQ 0.25MG BASE	N020981	001	Oct 11, 2007
+!		EQ 1MG BASE	N020981	002	Oct 11, 2007

TOPOTECAN HYDROCHLORIDE						
INJECTABLE;INJECTION						
HYCAMTIN						
AP	**+!**	NOVARTIS PHARMS CORP	**EQ 4MG BASE/VIAL**	**N020671**	**001**	May 28, 1996
TOPOTECAN HYDROCHLORIDE						
AP		ACCORD HLTHCARE	**EQ 4MG BASE/VIAL**	**A202351**	**001**	Jun 26, 2013
AP		ACTAVIS TOTOWA	**EQ 4MG BASE/VIAL**	**A090620**	**001**	Dec 02, 2010
AP		CIPLA	**EQ 4MG BASE/VIAL**	**A091199**	**001**	Dec 01, 2010
AP		DR REDDYS LABS LTD	**EQ 4MG BASE/VIAL**	**A201191**	**001**	Mar 09, 2011
AP		FRESENIUS KABI USA	**EQ 4MG BASE/VIAL**	**A091089**	**001**	Nov 29, 2010
AP		HONG KONG	**EQ 4MG BASE/VIAL**	**A201166**	**001**	Aug 08, 2012
AP		MYLAN LABS LTD	**EQ 4MG BASE/VIAL**	**A091542**	**001**	Aug 28, 2012
AP		NOVAST LABS	**EQ 4MG BASE/VIAL**	**A206962**	**001**	Nov 30, 2016
AP		SAGENT PHARMS	**EQ 4MG BASE/VIAL**	**A091284**	**001**	Jan 26, 2011
SOLUTION;INTRAVENOUS						
TOPOTECAN HYDROCHLORIDE						
AP		ACCORD HLTHCARE	**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A204406**	**002**	Jul 06, 2017
AP	**+!**	HOSPIRA INC	**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**N200582**	**001**	Feb 02, 2011
AP		MYLAN LABS LTD	**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A206074**	**001**	Nov 24, 2017
AP		TEVA PHARMS USA	**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**N022453**	**001**	Dec 20, 2012
		ACCORD HLTHCARE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204406	001	Jul 06, 2017
TOREMIFENE CITRATE						
TABLET;ORAL						
FARESTON						
AB	**+!**	KYOWA KIRIN	**EQ 60MG BASE**	**N020497**	**001**	May 29, 1997
TOREMIFENE CITRATE						
AB		RISING PHARMS	**EQ 60MG BASE**	**A208813**	**001**	Dec 04, 2018
TORSEMIDE						
TABLET;ORAL						
DEMADEX						
AB	**+**	MYLAN SPECIALITY LP	**5MG**	**N020136**	**001**	Aug 23, 1993
AB	**+**		**10MG**	**N020136**	**002**	Aug 23, 1993
AB	**+!**		**20MG**	**N020136**	**003**	Aug 23, 1993
AB	**+**		**100MG**	**N020136**	**004**	Aug 23, 1993
TORSEMIDE						
AB		APOTEX INC	**5MG**	**A076894**	**001**	May 31, 2005
AB			**10MG**	**A076894**	**002**	May 31, 2005
AB			**20MG**	**A076894**	**003**	May 31, 2005
AB			**100MG**	**A076894**	**004**	May 31, 2005
AB		AUROBINDO PHARMA	**5MG**	**A078249**	**001**	Oct 17, 2007
AB			**10MG**	**A078249**	**002**	Oct 17, 2007
AB			**20MG**	**A078249**	**003**	Oct 17, 2007
AB			**100MG**	**A078249**	**004**	Oct 17, 2007
AB		HETERO LABS LTD III	**5MG**	**A079234**	**001**	Jan 27, 2009
AB			**10MG**	**A079234**	**002**	Jan 27, 2009
AB			**20MG**	**A079234**	**003**	Jan 27, 2009
AB			**100MG**	**A079234**	**004**	Jan 27, 2009
AB		PAR PHARM	**5MG**	**A076226**	**001**	May 27, 2003
AB			**10MG**	**A076226**	**002**	May 27, 2003
AB			**20MG**	**A076226**	**003**	May 27, 2003
AB			**100MG**	**A076226**	**004**	May 27, 2003
AB		PLIVA PHARM IND	**5MG**	**A076346**	**001**	May 30, 2003
AB			**10MG**	**A076346**	**002**	May 30, 2003
AB			**20MG**	**A076346**	**003**	May 30, 2003
AB			**100MG**	**A076346**	**004**	Oct 19, 2004
AB		TEVA	**5MG**	**A076110**	**001**	May 14, 2002
AB			**10MG**	**A076110**	**002**	May 14, 2002
AB			**20MG**	**A076110**	**003**	May 14, 2002
AB			**100MG**	**A076110**	**004**	May 14, 2002
AB		VINTAGE PHARMS	**5MG**	**A090613**	**001**	Mar 22, 2011
AB			**10MG**	**A090613**	**002**	Mar 22, 2011
AB			**20MG**	**A090613**	**003**	Mar 22, 2011
AB			**100MG**	**A090613**	**004**	Mar 22, 2011
AB		WEST-WARD PHARMS INT	**5MG**	**A076943**	**001**	Mar 01, 2005
AB			**10MG**	**A076943**	**002**	Mar 01, 2005
AB			**20MG**	**A076943**	**003**	Mar 01, 2005

TRABECTEDIN

POWDER;INTRAVENOUS

YONDELIS

	+!	JANSSEN PRODS	1MG/VIAL	N207953	001	Oct 23, 2015

TRAMADOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

CONZIP

	+!	CIPHER PHARMS INC	100MG	N022370	001	May 07, 2010
	+		150MG	N022370	004	Aug 01, 2011
	+		200MG	N022370	002	May 07, 2010
	+		300MG	N022370	003	May 07, 2010

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

AB		ACI HEALTHCARE LTD	**50MG**	**A202075**	**001**	Nov 28, 2011
AB		AMNEAL PHARMS	**50MG**	**A076003**	**001**	Jun 20, 2002
AB		APOTEX	**50MG**	**A075981**	**001**	Jul 10, 2002
AB		AUROBINDO PHARMA LTD	**50MG**	**A203494**	**001**	Mar 31, 2014
AB		CSPC OUYI PHARM CO	**50MG**	**A091498**	**001**	Mar 29, 2013
AB		IPCA LABS LTD	**50MG**	**A201973**	**001**	Nov 16, 2012
AB		MACLEODS PHARMS LTD	**50MG**	**A205702**	**001**	Sep 25, 2015
AB		MYLAN	**50MG**	**A075986**	**001**	Jun 21, 2002
AB		PLIVA	**50MG**	**A075982**	**001**	Jul 01, 2002
AB		SPECGX LLC	**50MG**	**A075983**	**001**	Jun 25, 2002
AB		SUN PHARM INDS INC	**50MG**	**A075964**	**001**	Jun 19, 2002
AB		SUN PHARM INDUSTRIES	**50MG**	**A076100**	**001**	Jun 20, 2002
AB		TEVA	**50MG**	**A075977**	**001**	Jun 19, 2002
AB		ZYDUS PHARMS USA INC	**50MG**	**A090404**	**001**	Jan 31, 2011

ULTRAM

AB	**+!**	JANSSEN PHARMS	**50MG**	**N020281**	**002**	Mar 03, 1995

TABLET, EXTENDED RELEASE;ORAL

TRAMADOL HYDROCHLORIDE

AB1		AUROBINDO PHARMA LTD	**100MG**	**A204421**	**001**	Oct 20, 2015
AB1			**200MG**	**A204421**	**002**	Oct 20, 2015
AB1			**300MG**	**A204421**	**003**	Oct 20, 2015
AB1	!	LUPIN LTD	**100MG**	**A200503**	**001**	Aug 29, 2011
AB1			**200MG**	**A200503**	**002**	Aug 29, 2011
AB1			**300MG**	**A200503**	**003**	Aug 29, 2011
AB1		MYLAN PHARMS INC	**100MG**	**A205257**	**001**	Dec 22, 2015
AB1			**200MG**	**A205257**	**002**	Dec 22, 2015
AB1			**300MG**	**A205257**	**003**	Dec 22, 2015
AB1		PAR PHARM INC	**100MG**	**A078783**	**001**	Nov 13, 2009
AB1			**200MG**	**A078783**	**002**	Nov 13, 2009
AB1			**300MG**	**A078783**	**003**	Sep 20, 2011
AB1		SUN PHARMA GLOBAL	**100MG**	**A201384**	**001**	Dec 07, 2011
AB1			**200MG**	**A201384**	**002**	Dec 07, 2011
AB1			**300MG**	**A201384**	**003**	Dec 07, 2011
AB2		ACTAVIS ELIZABETH	**100MG**	**A091609**	**001**	Jun 27, 2012
AB2			**200MG**	**A091609**	**002**	Jun 27, 2012
AB2			**300MG**	**A091609**	**003**	Jun 27, 2012
AB2		ANCHEN PHARMS	**100MG**	**A200491**	**001**	Jun 27, 2012
AB2			**200MG**	**A200491**	**002**	Jun 27, 2012
AB2			**300MG**	**A200491**	**003**	Jun 27, 2012
AB2	!	SUN PHARMA GLOBAL	**100MG**	**A091607**	**001**	Dec 30, 2011
AB2			**200MG**	**A091607**	**002**	Dec 30, 2011
AB2			**300MG**	**A091607**	**003**	Dec 30, 2011

TRAMETINIB DIMETHYL SULFOXIDE

TABLET;ORAL

MEKINIST

	+	NOVARTIS PHARMS CORP	EQ 0.5MG	N204114	001	May 29, 2013
	+!		EQ 2MG	N204114	003	May 29, 2013

TRANDOLAPRIL

TABLET;ORAL

TRANDOLAPRIL

AB		AUROBINDO PHARMA	**1MG**	**A078438**	**001**	Jun 12, 2007
AB			**2MG**	**A078438**	**002**	Jun 12, 2007
AB			**4MG**	**A078438**	**003**	Jun 12, 2007
AB		EPIC PHARMA	**1MG**	**A078508**	**003**	Jun 18, 2008

TRANDOLAPRIL

TABLET;ORAL

TRANDOLAPRIL

AB			**2MG**	**A078508**	**001**	Jun 18, 2008
AB			**4MG**	**A078508**	**002**	Jun 18, 2008
AB		LUPIN	**1MG**	**A077522**	**001**	Jun 12, 2007
AB			**2MG**	**A077522**	**002**	Jun 12, 2007
AB	!		**4MG**	**A077522**	**003**	Jun 12, 2007
AB		TEVA PHARMS	**1MG**	**A077489**	**001**	Dec 12, 2006
AB			**2MG**	**A077489**	**002**	Dec 12, 2006
AB			**4MG**	**A077489**	**003**	Dec 12, 2006

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TARKA

AB	+	ABBVIE	**1MG;240MG**	**N020591**	**003**	Oct 22, 1996
AB	+		**2MG;180MG**	**N020591**	**001**	Oct 22, 1996
AB	+		**2MG;240MG**	**N020591**	**004**	Oct 22, 1996
AB	+!		**4MG;240MG**	**N020591**	**002**	Oct 22, 1996

TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE

AB		GLENMARK GENERICS	**1MG;240MG**	**A079135**	**004**	Aug 30, 2010
AB			**2MG;180MG**	**A079135**	**001**	May 26, 2010
AB			**2MG;240MG**	**A079135**	**002**	May 26, 2010
AB			**4MG;240MG**	**A079135**	**003**	May 05, 2010

TRANEXAMIC ACID

INJECTABLE;INJECTION

CYKLOKAPRON

AP	+!	PHARMACIA AND UPJOHN	**100MG/ML**	**N019281**	**001**	Dec 30, 1986

TRANEXAMIC ACID

AP		ACIC PHARMS	**100MG/ML**	**A202436**	**001**	Feb 11, 2014
AP		AKORN	**100MG/ML**	**A202373**	**001**	Nov 17, 2011
AP			**100MG/ML**	**A206594**	**001**	Sep 28, 2017
AP			**100MG/ML**	**A206634**	**001**	Jun 09, 2016
AP		AMNEAL PHARMS CO	**100MG/ML**	**A208840**	**001**	Feb 28, 2017
AP		AUROBINDO PHARMA LTD	**100MG/ML**	**A205035**	**001**	Jan 14, 2016
AP		EMCURE PHARMS LTD	**100MG/ML**	**A203521**	**001**	Aug 12, 2014
AP		FRESENIUS KABI USA	**100MG/ML**	**A091596**	**001**	Mar 02, 2012
AP		GLAND PHARMA LTD	**100MG/ML**	**A207239**	**001**	Feb 13, 2017
AP		LUITPOLD	**100MG/ML**	**A201885**	**001**	Aug 10, 2011
AP		MYLAN INSTITUTIONAL	**100MG/ML**	**A091657**	**001**	Nov 03, 2011
AP		VIRTUS PHARMS	**100MG/ML**	**A202755**	**001**	Feb 25, 2016
AP		VIVA HLTHCARE	**100MG/ML**	**A206713**	**001**	Jun 27, 2017
AP		X-GEN PHARMS INC	**100MG/ML**	**A201580**	**001**	Jun 14, 2013
AP		ZYDUS PHARMS USA INC	**100MG/ML**	**A205228**	**001**	Jul 17, 2017

TABLET;ORAL

LYSTEDA

AB	+!	FERRING PHARMS INC	**650MG**	**N022430**	**001**	Nov 13, 2009

TRANEXAMIC ACID

AB		ACTAVIS LABS FL INC	**650MG**	**A202093**	**001**	Dec 27, 2012
AB		APOTEX INC	**650MG**	**A202286**	**001**	Jan 27, 2014
AB		MYLAN	**650MG**	**A205133**	**001**	Sep 21, 2015

TRANYLCYPROMINE SULFATE

TABLET;ORAL

PARNATE

AB	+!	CONCORDIA PHARMS INC	**EQ 10MG BASE**	**N012342**	**003**	Aug 16, 1985

TRANYLCYPROMINE SULFATE

AB		CNTY LINE PHARMS	**EQ 10MG BASE**	**A206856**	**001**	Apr 17, 2018
AB		PAR PHARM	**EQ 10MG BASE**	**A040640**	**001**	Jun 29, 2006

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

TRAVATAN Z

AT	+!	NOVARTIS PHARMS CORP	**0.004%**	**N021994**	**001**	Sep 21, 2006

TRAVOPROST

AT		APOTEX INC	**0.004%**	**A203431**	**001**	Jul 10, 2015
AT		MYLAN PHARMS INC	**0.004%**	**A205050**	**001**	Jul 07, 2017
	!	PAR PHARM	0.004%	A091340	001	Mar 01, 2013

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**50MG**	**A206923**	**001**	Sep 08, 2017
AB			**100MG**	**A206923**	**002**	Sep 08, 2017
AB			**150MG**	**A206923**	**003**	Sep 08, 2017
AB			**300MG**	**A206923**	**004**	Sep 08, 2017
AB		ALVOGEN	**50MG**	**A071636**	**001**	Apr 18, 1988
AB			**100MG**	**A071514**	**001**	Apr 18, 1988
AB		APOTEX	**50MG**	**A071258**	**001**	Mar 25, 1987
AB	!	APOTEX INC	**100MG**	**A071196**	**001**	Mar 25, 1987
AB			**150MG**	**A071196**	**002**	Apr 26, 1999
AB			**300MG**	**A071196**	**003**	Apr 26, 1999
AB		OXFORD PHARMS	**50MG**	**A072192**	**001**	Feb 02, 1989
AB			**100MG**	**A072193**	**001**	Feb 02, 1989
AB		PLIVA	**150MG**	**A071525**	**001**	Mar 09, 1988
AB		SUN PHARM INDUSTRIES	**50MG**	**A073137**	**002**	Mar 24, 1993
AB			**100MG**	**A073137**	**001**	Mar 24, 1993
AB			**150MG**	**A073137**	**003**	Dec 22, 1995
AB		TEVA PHARMS USA	**50MG**	**A071523**	**001**	Dec 11, 1987
AB			**100MG**	**A071524**	**001**	Dec 11, 1987
AB		TORRENT PHARMS LTD	**50MG**	**A202180**	**001**	Nov 27, 2013
AB			**100MG**	**A202180**	**002**	Nov 27, 2013
AB			**150MG**	**A202180**	**003**	Nov 27, 2013
AB			**300MG**	**A202180**	**004**	Nov 27, 2013
AB		ZYDUS PHARMS USA INC	**50MG**	**A205253**	**001**	Oct 10, 2017
AB			**100MG**	**A205253**	**002**	Oct 10, 2017
AB			**150MG**	**A205253**	**003**	Oct 10, 2017
AB			**300MG**	**A205253**	**004**	Oct 10, 2017

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS

REMODULIN

AP	**+!**	UNITED THERAP	**1MG/ML**	**N021272**	**001**	May 21, 2002
AP	**+!**		**2.5MG/ML**	**N021272**	**002**	May 21, 2002
AP	**+!**		**5MG/ML**	**N021272**	**003**	May 21, 2002
AP	**+!**		**10MG/ML**	**N021272**	**004**	May 21, 2002

TREPROSTINIL

AP		SANDOZ INC	**1MG/ML**	**A203649**	**001**	Nov 30, 2017
AP			**2.5MG/ML**	**A203649**	**002**	Nov 30, 2017
AP			**5MG/ML**	**A203649**	**003**	Nov 30, 2017
AP			**10MG/ML**	**A203649**	**004**	Nov 30, 2017

SOLUTION;INHALATION

TYVASO

+!	UNITED THERAP	0.6MG/ML	N022387	001	Jul 30, 2009

SOLUTION;INTRAVENOUS, SUBCUTANEOUS

REMODULIN

	UNITED THERAP	20MG/20ML (1MG/ML)	N208276	001	Jul 30, 2018
		50MG/20ML (2.5MG/ML)	N208276	002	Jul 30, 2018
		100MG/20ML (5MG/ML)	N208276	003	Jul 30, 2018
		200MG/20ML (10MG/ML)	N208276	004	Jul 30, 2018

TREPROSTINIL DIOLAMINE

TABLET, EXTENDED RELEASE;ORAL

ORENITRAM

+	UNITED THERAP	EQ 0.125MG BASE	N203496	001	Dec 20, 2013
+		EQ 0.25MG BASE	N203496	002	Dec 20, 2013
+		EQ 1MG BASE	N203496	003	Dec 20, 2013
+!		EQ 2.5MG BASE	N203496	004	Dec 20, 2013
+		EQ 5MG BASE	N203496	005	Oct 07, 2016

TRETINOIN

CAPSULE;ORAL

TRETINOIN

AB		ANCHEN PHARMS	**10MG**	**A201687**	**001**	Oct 24, 2012
AB	!	BARR LABS INC	**10MG**	**A077684**	**001**	Jun 22, 2007
AB		GLENMARK PHARMS LTD	**10MG**	**A208279**	**001**	Dec 23, 2016

CREAM;TOPICAL

AVITA

AB		MYLAN PHARMS INC	**0.025%**	**N020404**	**003**	Jan 14, 1997

RETIN-A

AB	**+!**	VALEANT BERMUDA	**0.025%**	**N019049**	**001**	Sep 16, 1988

TRETINOIN							
CREAM;TOPICAL							
RETIN-A							
AB	**+!**	VALEANT PHARMS NORTH	**0.1%**	**N017340**	**001**		
TRETINOIN							
AB		PERRIGO PHARMA INTL	**0.025%**	**A075264**	**001**	Dec 24, 1998	
AB			**0.1%**	**A075213**	**001**	Dec 24, 1998	
RETIN-A							
AB1	**+!**	VALEANT BERMUDA	**0.05%**	**N017522**	**001**		
TRETINOIN							
AB1		PERRIGO PHARMA INTL	**0.05%**	**A075265**	**001**	Dec 24, 1998	
RENOVA							
AB2	**+!**	VALEANT PHARMS NORTH	**0.05%**	**N019963**	**001**	Dec 29, 1995	
TRETINOIN							
AB2		ZO SKIN HEALTH	**0.05%**	**A076498**	**001**	Sep 15, 2005	
RENOVA							
	+!	VALEANT PHARMS NORTH	0.02%	N021108	001	Aug 31, 2000	
GEL;TOPICAL							
ATRALIN							
AB	**+!**	DOW PHARM	**0.05%**	**N022070**	**001**	Jul 26, 2007	
RETIN-A							
AB	**+!**	VALEANT INTL	**0.01%**	**N017955**	**001**		
AB	**+!**		**0.025%**	**N017579**	**002**		
RETIN-A MICRO							
AB	**+!**	VALEANT INTL	**0.04%**	**N020475**	**002**	May 10, 2002	
AB	**+!**		**0.1%**	**N020475**	**001**	Feb 07, 1997	
TRETINOIN							
AB		MYLAN PHARMS INC	**0.04%**	**A202567**	**001**	Jul 17, 2013	
AB			**0.05%**	**A207955**	**001**	Aug 13, 2015	
AB			**0.1%**	**A202026**	**001**	Jul 17, 2013	
AB		PERRIGO PHARMA INTL	**0.01%**	**A075589**	**001**	Jun 11, 2002	
AB			**0.025%**	**A075529**	**001**	Feb 22, 2000	
AVITA							
BT		MYLAN	0.025%	N020400	001	Jan 29, 1998	
RETIN-A-MICRO							
	+!	VALEANT INTL	0.06%	N020475	004	Oct 23, 2017	
	+!		0.08%	N020475	003	Jan 28, 2014	
LOTION;TOPICAL							
ALTRENO							
	+!	DOW PHARM	0.05%	N209353	001	Aug 23, 2018	
TRIAMCINOLONE ACETONIDE							
CREAM;TOPICAL							
TRIAMCINOLONE ACETONIDE							
AT		ALKEM LABS LTD	**0.025%**	**A207651**	**001**	Dec 26, 2017	
AT			**0.1%**	**A207651**	**002**	Dec 26, 2017	
AT			**0.5%**	**A207651**	**003**	Dec 26, 2017	
AT	**!**	FOUGERA PHARMS	**0.025%**	**A085692**	**001**		
AT	**!**		**0.1%**	**A085692**	**003**		
AT	**!**		**0.5%**	**A085692**	**002**		
AT		G AND W LABS	**0.025%**	**A089797**	**001**	May 31, 1991	
AT			**0.1%**	**A089798**	**001**	May 31, 1991	
AT		GLENMARK PHARMS LTD	**0.1%**	**A207117**	**001**	Aug 05, 2016	
AT		LANNETT CO INC	**0.025%**	**A040671**	**001**	Jun 09, 2006	
AT			**0.1%**	**A040671**	**002**	Jun 09, 2006	
AT		LUPIN ATLANTIS	**0.025%**	**A208763**	**001**	Feb 01, 2017	
AT			**0.1%**	**A208763**	**002**	Feb 01, 2017	
AT			**0.5%**	**A208763**	**003**	Feb 01, 2017	
AT		MACLEODS PHARMS LTD	**0.025%**	**A209535**	**001**	May 18, 2018	
AT			**0.1%**	**A209535**	**002**	May 18, 2018	
AT			**0.5%**	**A209535**	**003**	May 18, 2018	
AT	**+**	MYLAN PHARMS INC	**0.025%**	**N011601**	**003**		
AT	**+**		**0.1%**	**N011601**	**006**		
AT		PERRIGO NEW YORK	**0.025%**	**A086413**	**002**		
AT			**0.1%**	**A086413**	**003**		
AT			**0.1%**	**A086414**	**001**		
AT			**0.5%**	**A086413**	**001**		
AT		TARO PHARM INDS LTD	**0.1%**	**A040039**	**001**	Nov 26, 1997	
AT		TELIGENT PHARMA INC	**0.1%**	**A208848**	**001**	Sep 18, 2017	

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIDERM

AT		CROWN LABS	**0.025%**	**A088042**	**002**	Mar 25, 2015
AT			**0.1%**	**A088042**	**001**	Mar 19, 1984
AT			**0.5%**	**A088042**	**003**	Mar 25, 2015

FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR

ZILRETTA

	+!	FLEXION THERAPS INC	32MG/VIAL	N208845	001	Oct 06, 2017

INJECTABLE;INJECTION

KENALOG-40

AB	**+!**	APOTHECON	**40MG/ML**	**N014901**	**001**	

TRIAMCINOLONE ACETONIDE

AB		AMNEAL PHARMS CO	**40MG/ML**	**A207550**	**001**	Dec 11, 2017
AB		TEVA PHARMS USA	**40MG/ML**	**A209852**	**001**	Oct 05, 2018

KENALOG-10

	+	APOTHECON	10MG/ML	N012041	001	

INJECTABLE;INTRAVITREAL

TRIESENCE

	+!	NOVARTIS PHARMS CORP	40MG/ML (40MG/ML)	N022048	001	Nov 29, 2007

LOTION;TOPICAL

TRIAMCINOLONE ACETONIDE

AT		AKORN	**0.025%**	**A202374**	**001**	May 08, 2013
AT			**0.1%**	**A202374**	**002**	May 08, 2013
AT		FOUGERA PHARMS	**0.025%**	**A040467**	**001**	Apr 21, 2003
AT			**0.1%**	**A040467**	**002**	Apr 21, 2003
AT		G AND W LABS INC	**0.1%**	**A089129**	**001**	Aug 14, 1986
AT		LANNETT CO INC	**0.1%**	**A040672**	**002**	Dec 13, 2006
AT		TELIGENT PHARMA INC	**0.025%**	**A204608**	**001**	Jul 07, 2016
AT			**0.1%**	**A204606**	**001**	Jul 07, 2016
AT	**!**	WOCKHARDT BIO AG	**0.025%**	**A088450**	**001**	Apr 01, 1985
AT	**!**		**0.1%**	**A088451**	**001**	Apr 03, 1985

OINTMENT;TOPICAL

TRIAMCINOLONE ACETATE

AT		MACLEODS PHARMS LTD	**0.025%**	**A209828**	**001**	Nov 23, 2018
AT			**0.1%**	**A209828**	**002**	Nov 23, 2018
AT			**0.5%**	**A209828**	**003**	Nov 23, 2018

TRIAMCINOLONE ACETONIDE

AT		FOUGERA PHARMS	**0.025%**	**A085691**	**001**	
AT			**0.1%**	**A085691**	**003**	
AT			**0.5%**	**A085691**	**002**	
AT		G AND W LABS	**0.025%**	**A089795**	**001**	Dec 23, 1988
AT			**0.1%**	**A089796**	**001**	Dec 23, 1988
AT		G AND W LABS INC	**0.5%**	**A208925**	**001**	Oct 06, 2017
AT		GLENMARK PHARMS	**0.1%**	**A208320**	**001**	Aug 22, 2017
AT		GLENMARK PHARMS LTD	**0.5%**	**A206379**	**001**	Jul 22, 2016
AT		NOVEL LABS INC	**0.1%**	**A207365**	**001**	Oct 12, 2018
AT	**!**	PERRIGO NEW YORK	**0.025%**	**A087385**	**002**	
AT	**!**		**0.1%**	**A087385**	**003**	
AT	**!**		**0.5%**	**A087385**	**001**	
AT		TARO PHARM INDS LTD	**0.1%**	**A040037**	**001**	Sep 30, 1994
AT		TELIGENT PHARMA INC	**0.1%**	**A205373**	**001**	May 13, 2016
AT			**0.5%**	**A208590**	**001**	Mar 03, 2017

TRIAMCINOLONE ACETONIDE IN ABSORBASE

	!	CMP PHARMA INC	0.05%	A089595	001	Mar 23, 1995

PASTE;DENTAL

TRIAMCINOLONE ACETONIDE

AT		AKORN	**0.1%**	**A206312**	**001**	Aug 11, 2016
AT		G AND W LABS INC	**0.1%**	**A205592**	**001**	Jan 12, 2017
AT		LYNE	**0.1%**	**A040771**	**001**	Jul 01, 2010
AT	**!**	TARO	**0.1%**	**A070730**	**001**	Oct 01, 1986

SPRAY;TOPICAL

KENALOG

AT	**+!**	SUN PHARM INDS INC	**0.147MG/GM**	**N012104**	**001**	

TRIAMCINOLONE ACETONIDE

AT		AKORN	**0.147MG/GM**	**A207094**	**001**	Dec 07, 2016
AT		PERRIGO UK FINCO	**0.147MG/GM**	**A205782**	**001**	Apr 13, 2015
AT		RISING PHARMS	**0.147MG/GM**	**A206786**	**001**	Sep 08, 2017

TRIAMCINOLONE HEXACETONIDE							
INJECTABLE;INJECTION							
ARISTOSPAN							
	+!	SANDOZ INC	5MG/ML	N016466	001		
	+!		20MG/ML	N016466	002		
TRIAMTERENE							
CAPSULE;ORAL							
DYRENIUM							
	+	CONCORDIA PHARMS INC	50MG	N013174	001		
	+!		100MG	N013174	002		
TRIAZOLAM							
TABLET;ORAL							
HALCION							
AB	**+**	PHARMACIA AND UPJOHN	**0.125MG**	**N017892**	**003**	Apr 26, 1985	
AB	**+!**		**0.25MG**	**N017892**	**001**	Nov 15, 1982	
TRIAZOLAM							
AB		MYLAN PHARMS INC	**0.125MG**	**A074031**	**001**	Mar 25, 1994	
AB			**0.25MG**	**A074031**	**002**	Mar 25, 1994	
AB		WEST-WARD PHARMS INT	**0.125MG**	**A074224**	**001**	Jun 01, 1994	
AB			**0.25MG**	**A074224**	**002**	Jun 01, 1994	
TRIENTINE HYDROCHLORIDE							
CAPSULE;ORAL							
SYPRINE							
AB	**+!**	ATON	**250MG**	**N019194**	**001**	Nov 08, 1985	
TRIENTINE HYDROCHLORIDE							
AB		NAVINTA LLC	**250MG**	**A211251**	**001**	Jan 16, 2019	
AB		WATSON LABS TEVA	**250MG**	**A207567**	**001**	Feb 07, 2018	
TRIFLUOPERAZINE HYDROCHLORIDE							
TABLET;ORAL							
TRIFLUOPERAZINE HYDROCHLORIDE							
AB		MYLAN	**EQ 1MG BASE**	**A040209**	**001**	Jul 07, 1997	
AB			**EQ 2MG BASE**	**A040209**	**002**	Jul 07, 1997	
AB			**EQ 5MG BASE**	**A040209**	**003**	Jul 07, 1997	
AB	**!**		**EQ 10MG BASE**	**A040209**	**004**	Jul 07, 1997	
AB		SANDOZ	**EQ 1MG BASE**	**A085785**	**001**		
AB			**EQ 2MG BASE**	**A085786**	**001**		
AB			**EQ 5MG BASE**	**A085789**	**001**		
AB			**EQ 10MG BASE**	**A085788**	**001**		
TRIFLURIDINE							
SOLUTION/DROPS;OPHTHALMIC							
TRIFLURIDINE							
AT		HI-TECH PHARMACAL	**1%**	**A205438**	**001**	Jul 28, 2017	
AT		SANDOZ INC	**1%**	**A074311**	**001**	Oct 06, 1995	
VIROPTIC							
AT	**+!**	MONARCH PHARMS	**1%**	**N018299**	**001**		
TRIHEXYPHENIDYL HYDROCHLORIDE							
ELIXIR;ORAL							
TRIHEXYPHENIDYL HYDROCHLORIDE							
AA		MIKART	**2MG/5ML**	**A040251**	**001**	Sep 27, 1999	
AA	**!**	PHARM ASSOC	**2MG/5ML**	**A040177**	**001**	Apr 17, 1997	
TABLET;ORAL							
TRIHEXYPHENIDYL HYDROCHLORIDE							
AA		NATCO PHARMA LTD	**2MG**	**A091630**	**001**	Nov 17, 2010	
AA			**5MG**	**A091630**	**002**	Nov 17, 2010	
AA		NOVITIUM PHARMA	**2MG**	**A040254**	**001**	Dec 24, 1998	
AA			**5MG**	**A040254**	**002**	Dec 24, 1998	
AA	**!**	WATSON LABS	**2MG**	**A084363**	**001**		
AA	**!**		**5MG**	**A084364**	**001**		
TRIMETHADIONE							
TABLET;ORAL							
TRIDIONE							
	+!	ABBVIE	150MG	N005856	009		

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL

TIGAN

AB	**+!**	KING PHARMS LLC	**300MG**	**N017531**	**006**	Dec 13, 2001

TRIMETHOBENZAMIDE HYDROCHLORIDE

AB		GAVIS PHARMS	**300MG**	**A076546**	**001**	Aug 20, 2003
AB		SUN PHARM INDUSTRIES	**300MG**	**A076570**	**001**	Aug 28, 2003

INJECTABLE;INJECTION

TIGAN

AP	**+!**	PAR STERILE PRODUCTS	**100MG/ML**	**N017530**	**001**	

TRIMETHOBENZAMIDE HYDROCHLORIDE

AP		LUITPOLD	**100MG/ML**	**A091330**	**001**	Mar 08, 2011

TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE

AP		LUITPOLD	**100MG/ML**	**A091329**	**001**	Mar 08, 2011

TRIMETHOPRIM

TABLET;ORAL

TRIMETHOPRIM

AB	**+!**	MAYNE PHARMA	**100MG**	**N018679**	**001**	Jul 30, 1982
AB		NOVEL LABS INC	**100MG**	**A091437**	**001**	Jun 15, 2011
AB		WATSON LABS	**100MG**	**A070049**	**001**	Jun 06, 1985

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION;ORAL

PRIMSOL

	+!	ALLEGIS	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000

TRIMIPRAMINE MALEATE

CAPSULE;ORAL

SURMONTIL

AB	**+**	ODYSSEY PHARMS	**EQ 25MG BASE**	**N016792**	**001**	
AB	**+!**		**EQ 50MG BASE**	**N016792**	**002**	
AB	**+**		**EQ 100MG BASE**	**N016792**	**003**	Sep 15, 1982

TRIMIPRAMINE MALEATE

AB		CROSSMEDIKA SA	**EQ 25MG BASE**	**A208127**	**001**	Apr 15, 2016
AB			**EQ 50MG BASE**	**A208127**	**002**	Apr 15, 2016
AB			**EQ 100MG BASE**	**A208127**	**003**	Apr 15, 2016
AB		ELITE LABS INC	**EQ 25MG BASE**	**A077361**	**001**	Aug 02, 2006
AB			**EQ 50MG BASE**	**A077361**	**002**	Aug 02, 2006
AB			**EQ 100MG BASE**	**A077361**	**003**	Aug 02, 2006

TRIPTORELIN PAMOATE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

TRIPTODUR KIT

	+!	ARBOR PHARMS LLC	EQ 22.5MG BASE/VIAL	N208956	001	Jun 29, 2017

INJECTABLE;INTRAMUSCULAR

TRELSTAR

	+!	ALLERGAN SALES LLC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000
	+!		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001
	+!		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

MYDRIACYL

AT	**!**	NOVARTIS PHARMS CORP	**1%**	**A084306**	**001**	
AT	**!**	SANDOZ INC	**0.5%**	**A084305**	**001**	

TROPICACYL

AT		AKORN	**0.5%**	**A040314**	**001**	Sep 29, 2000
AT			**1%**	**A040315**	**001**	Sep 29, 2000

TROPICAMIDE

AT		BAUSCH AND LOMB	**0.5%**	**A040067**	**001**	Jul 27, 1994
AT			**1%**	**A040064**	**001**	Jul 27, 1994

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

TROSPIUM CHLORIDE

AB	**!**	ACTAVIS LABS FL INC	**60MG**	**A091289**	**001**	Oct 12, 2012
AB		PADDOCK LLC	**60MG**	**A201291**	**001**	May 24, 2013

TABLET;ORAL

TROSPIUM CHLORIDE

AB		APOTEX	**20MG**	**A091513**	**001**	Dec 06, 2011
AB	**!**	GLENMARK GENERICS	**20MG**	**A091575**	**001**	Aug 13, 2010
AB		HERITAGE PHARMS INC	**20MG**	**A204945**	**001**	Aug 30, 2016

TROSPIUM CHLORIDE

TABLET;ORAL

TROSPIUM CHLORIDE

AB		INVAGEN PHARMS	**20MG**	**A091688**	**001**	Aug 23, 2016
AB		PADDOCK LLC	**20MG**	**A091573**	**001**	Nov 17, 2010

TRYPAN BLUE

SOLUTION;OPHTHALMIC

MEMBRANEBLUE

	+!	DORC	0.15%	N022278	001	Feb 20, 2009

VISIONBLUE

	+!	DORC	0.06%	N021670	001	Dec 16, 2004

ULIPRISTAL ACETATE

TABLET;ORAL

ELLA

AB	**+!**	LAB HRA PHARMA	**30MG**	**N022474**	**001**	Aug 13, 2010

LOGILIA

AB		TEVA PHARMS USA	**30MG**	**A207952**	**001**	Feb 13, 2017

UMECLIDINIUM BROMIDE

POWDER;INHALATION

INCRUSE ELLIPTA

	+!	GLAXO GRP ENGLAND	EQ 62.5MCG BASE/INH	N205382	001	Apr 30, 2014

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

POWDER;INHALATION

ANORO ELLIPTA

	+!	GLAXOSMITHKLINE	EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	N203975	001	Dec 18, 2013

UREA, C-14

CAPSULE;ORAL

PYTEST

	+!	AVENT	1uCi	N020617	001	May 09, 1997

PYTEST KIT

	+!	AVENT	1uCi	N020617	002	May 09, 1997

URIDINE TRIACETATE

GRANULE;ORAL

VISTOGARD

	+!	WELLSTAT THERAP	10GM/PACKET	N208159	001	Dec 11, 2015

XURIDEN

	+!	WELLSTAT THERAP	2GM/PACKET	N208169	001	Sep 04, 2015

URSODIOL

CAPSULE;ORAL

ACTIGALL

AB	**+!**	ALLERGAN SALES LLC	**300MG**	**N019594**	**002**	Dec 31, 1987

URSODIOL

AB		ABHAI LLC	**300MG**	**A210707**	**001**	May 17, 2018
AB		AMNEAL PHARMS CO	**300MG**	**A211301**	**001**	Oct 16, 2018
AB		EPIC PHARMA	**300MG**	**A075517**	**001**	Mar 14, 2000
AB		LANNETT CO INC	**300MG**	**A079082**	**001**	Dec 15, 2008
AB		MYLAN	**300MG**	**A090530**	**001**	Feb 17, 2010
AB		TEVA PHARMS	**300MG**	**A075592**	**001**	May 25, 2000

TABLET;ORAL

URSO 250

AB	**+**	ALLERGAN SALES LLC	**250MG**	**N020675**	**001**	Dec 10, 1997

URSO FORTE

AB	**+!**	ALLERGAN SALES LLC	**500MG**	**N020675**	**002**	Jul 21, 2004

URSODIOL

AB		GLENMARK GENERICS	**250MG**	**A090801**	**001**	Jul 12, 2011
AB			**500MG**	**A090801**	**002**	Jul 12, 2011
AB		IMPAX LABS INC	**250MG**	**A200826**	**001**	Dec 23, 2011
AB			**500MG**	**A200826**	**002**	Dec 23, 2011
AB		PAR PHARM	**250MG**	**A202540**	**001**	Feb 14, 2013
AB			**500MG**	**A202540**	**002**	Feb 14, 2013
AB		ZYDUS WORLDWIDE	**250MG**	**A211145**	**001**	Oct 30, 2018
AB			**500MG**	**A211145**	**002**	Oct 30, 2018

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

AB		APOTEX INC	**EQ 500MG BASE**	**A090500**	**001**	Apr 04, 2014
AB			**EQ 1GM BASE**	**A090500**	**002**	Apr 04, 2014
AB		AUROBINDO PHARMA	**EQ 500MG BASE**	**A090682**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A090682**	**002**	May 24, 2010
AB		CIPLA	**EQ 500MG BASE**	**A077135**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A077135**	**002**	May 24, 2010
AB		HETERO LABS LTD V	**EQ 500MG BASE**	**A203047**	**001**	Apr 08, 2015
AB			**EQ 1GM BASE**	**A203047**	**002**	Apr 08, 2015
AB		JUBILANT GENERICS	**EQ 500MG BASE**	**A201506**	**001**	Apr 03, 2012
AB			**EQ 1GM BASE**	**A201506**	**002**	Apr 03, 2012
AB		MYLAN PHARMS INC	**EQ 500MG BASE**	**A078518**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A078518**	**002**	May 24, 2010
AB		SANDOZ	**EQ 500MG BASE**	**A077478**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A077478**	**002**	May 24, 2010
AB		SUN PHARM INDS LTD	**EQ 500MG BASE**	**A076588**	**001**	Jan 31, 2007
AB			**EQ 1GM BASE**	**A076588**	**002**	Jan 31, 2007
AB		TEVA PHARMS	**EQ 500MG BASE**	**A077655**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A077655**	**002**	May 24, 2010
AB		TIME-CAP LABS INC	**EQ 500MG BASE**	**A079012**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A079012**	**002**	May 24, 2010
AB		WATSON LABS INC	**EQ 500MG BASE**	**A090370**	**001**	Mar 16, 2011
AB			**EQ 1GM BASE**	**A090370**	**002**	Mar 16, 2011
AB		WEST-WARD PHARMS INT	**EQ 500MG BASE**	**A078656**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A078656**	**002**	May 24, 2010
AB		WOCKHARDT	**EQ 500MG BASE**	**A090216**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A090216**	**002**	May 24, 2010
AB		ZYDUS PHARMS USA INC	**EQ 500MG BASE**	**A079137**	**001**	Dec 29, 2017
AB			**EQ 1GM BASE**	**A079137**	**002**	Dec 29, 2017

VALTREX

AB	**+**	GLAXOSMITHKLINE	**EQ 500MG BASE**	**N020487**	**001**	Jun 23, 1995
AB	**+!**		**EQ 1GM BASE**	**N020487**	**002**	Jun 23, 1995

VALBENAZINE TOSYLATE

CAPSULE;ORAL

INGREZZA

+	NEUROCRINE	EQ 40MG BASE	N209241	001	Apr 11, 2017
+!		EQ 80MG BASE	N209241	002	Oct 04, 2017

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

VALCYTE

AB	**+!**	HOFFMANN LA ROCHE	**50MG/ML**	**N022257**	**001**	Aug 28, 2009

VALGANCICLOVIR HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	**50MG/ML**	**A205220**	**001**	Jul 18, 2016

TABLET;ORAL

VALCYTE

AB	**+!**	HOFFMANN LA ROCHE	**EQ 450MG BASE**	**N021304**	**001**	Mar 29, 2001

VALGANCICLOVIR HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**EQ 450MG BASE**	**A204750**	**001**	Mar 31, 2016
AB		CIPLA	**EQ 450MG BASE**	**A209672**	**001**	Nov 09, 2018
AB		DR REDDYS LABS LTD	**EQ 450MG BASE**	**A203511**	**001**	Nov 04, 2014
AB			**EQ 450MG BASE**	**A206876**	**001**	Dec 12, 2017
AB		ENDO PHARMS INC	**EQ 450MG BASE**	**A200790**	**001**	Nov 04, 2014
AB		HETERO LABS LTD V	**EQ 450MG BASE**	**A205166**	**001**	Mar 18, 2016

VALPROATE SODIUM

INJECTABLE;INJECTION

DEPACON

AP	**+!**	ABBVIE	**EQ 100MG BASE/ML**	**N020593**	**001**	Dec 30, 1996

VALPROATE SODIUM

AP		ATHENEX INC	**EQ 100MG BASE/ML**	**A076295**	**001**	Nov 14, 2002
AP		FRESENIUS KABI USA	**EQ 100MG BASE/ML**	**A076539**	**001**	Jun 26, 2003
AP		HIKMA FARMACEUTICA	**EQ 100MG BASE/ML**	**A078523**	**001**	Feb 17, 2010

VALPROIC ACID

CAPSULE;ORAL

DEPAKENE

AB	**+!**	ABBVIE	**250MG**	**N018081**	**001**	

VALPROIC ACID

AB		BIONPHARMA INC	**250MG**	**A073484**	**001**	Jun 29, 1993
AB		CATALENT	**250MG**	**A073229**	**001**	Oct 29, 1991
AB		SUN PHARM INDS LTD	**250MG**	**A091037**	**001**	Feb 22, 2013

SYRUP;ORAL

DEPAKENE

AA	**+!**	ABBVIE	**250MG/5ML**	**N018082**	**001**	

VALPROIC ACID

AA		ANI PHARMS INC	**250MG/5ML**	**A073178**	**001**	Aug 25, 1992
AA		ECI PHARMS LLC	**250MG/5ML**	**A090517**	**001**	May 28, 2010
AA		HIGH TECH PHARMA	**250MG/5ML**	**A074060**	**001**	Jan 13, 1995
AA		LANNETT CO INC	**250MG/5ML**	**A077960**	**001**	Oct 13, 2006
AA		PHARM ASSOC	**250MG/5ML**	**A075379**	**001**	Dec 15, 2000
AA		VISTAPHARM	**250MG/5ML**	**A075782**	**001**	Dec 22, 2000
AA		WOCKHARDT BIO AG	**250MG/5ML**	**A070868**	**001**	Jul 01, 1986

VALRUBICIN

SOLUTION;INTRAVESICAL

VALSTAR PRESERVATIVE FREE

	+!	ENDO PHARM	40MG/ML	N020892	001	Sep 25, 1998

VALSARTAN

TABLET;ORAL

DIOVAN

AB	**+**	NOVARTIS	**40MG**	**N021283**	**004**	Aug 14, 2002
AB	**+**		**80MG**	**N021283**	**001**	Jul 18, 2001
AB	**+**		**160MG**	**N021283**	**002**	Jul 18, 2001
AB	**+!**		**320MG**	**N021283**	**003**	Jul 18, 2001

VALSARTAN

AB	ALEMBIC PHARMS LTD	**40MG**	**A091367**	**001**	Jan 05, 2015
AB		**80MG**	**A091367**	**002**	Jan 05, 2015
AB		**160MG**	**A091367**	**003**	Jan 05, 2015
AB		**320MG**	**A091367**	**004**	Jan 05, 2015
AB	AMNEAL PHARMS	**40MG**	**A204011**	**001**	Jan 11, 2016
AB		**80MG**	**A204011**	**002**	Jan 11, 2016
AB		**160MG**	**A204011**	**003**	Jan 11, 2016
AB		**320MG**	**A204011**	**004**	Jan 11, 2016
AB	AUROBINDO PHARMA LTD	**40MG**	**A202223**	**001**	Jan 05, 2015
AB		**80MG**	**A202223**	**002**	Jan 05, 2015
AB		**160MG**	**A202223**	**003**	Jan 05, 2015
AB		**320MG**	**A202223**	**004**	Jan 05, 2015
AB	HETERO LABS LTD V	**40MG**	**A203311**	**001**	Jan 05, 2015
AB		**80MG**	**A203311**	**002**	Jan 05, 2015
AB		**160MG**	**A203311**	**003**	Jan 05, 2015
AB		**320MG**	**A203311**	**004**	Jan 05, 2015
AB	IVAX PHARMS	**40MG**	**A077530**	**001**	Jan 04, 2016
AB		**80MG**	**A077530**	**002**	Jan 04, 2016
AB		**160MG**	**A077530**	**003**	Jan 04, 2016
AB		**320MG**	**A077530**	**004**	Jan 04, 2016
AB	JUBILANT GENERICS	**40MG**	**A203536**	**001**	Jan 05, 2015
AB		**80MG**	**A203536**	**002**	Jan 05, 2015
AB		**160MG**	**A203536**	**003**	Jan 05, 2015
AB		**320MG**	**A203536**	**004**	Jan 05, 2015
AB	LUPIN LTD	**40MG**	**A201677**	**001**	Jan 05, 2015
AB		**80MG**	**A201677**	**002**	Jan 05, 2015
AB		**160MG**	**A201677**	**003**	Jan 05, 2015
AB		**320MG**	**A201677**	**004**	Jan 05, 2015
AB	MACLEODS PHARMS LTD	**40MG**	**A202696**	**001**	Sep 16, 2016
AB		**80MG**	**A202696**	**002**	Sep 16, 2016
AB		**160MG**	**A202696**	**003**	Sep 16, 2016
AB		**320MG**	**A202696**	**004**	Sep 16, 2016
AB	MYLAN PHARMS INC	**40MG**	**A090866**	**001**	Jan 05, 2015
AB		**80MG**	**A090866**	**002**	Jan 05, 2015
AB		**160MG**	**A090866**	**003**	Jan 05, 2015
AB		**320MG**	**A090866**	**004**	Jan 05, 2015
AB	OHM LABS INC	**40MG**	**A077492**	**001**	Jun 26, 2014
AB		**80MG**	**A077492**	**002**	Jun 26, 2014
AB		**160MG**	**A077492**	**003**	Jun 26, 2014
AB		**320MG**	**A077492**	**004**	Jun 26, 2014

VALSARTAN						
TABLET;ORAL						
VALSARTAN						
AB		PRINSTON INC	**40MG**	**A204821**	**001**	Jun 09, 2015
AB			**80MG**	**A204821**	**002**	Jun 09, 2015
AB			**160MG**	**A204821**	**003**	Jun 09, 2015
AB			**320MG**	**A204821**	**004**	Jun 09, 2015
AB		SQUARE PHARMS LTD	**40MG**	**A205347**	**001**	Apr 09, 2018
AB			**80MG**	**A205347**	**002**	Apr 09, 2018
AB			**160MG**	**A205347**	**003**	Apr 09, 2018
AB			**320MG**	**A205347**	**004**	Apr 09, 2018
AB		TORRENT PHARMS LTD	**40MG**	**A202728**	**001**	Jan 05, 2015
AB			**80MG**	**A202728**	**002**	Jan 05, 2015
AB			**160MG**	**A202728**	**003**	Jan 05, 2015
AB			**320MG**	**A202728**	**004**	Jan 05, 2015
AB		UNICHEM LABS LTD	**40MG**	**A209261**	**001**	May 04, 2018
AB			**80MG**	**A209261**	**002**	May 04, 2018
AB			**160MG**	**A209261**	**003**	May 04, 2018
AB			**320MG**	**A209261**	**004**	May 04, 2018
VANCOMYCIN HYDROCHLORIDE						
CAPSULE;ORAL						
VANCOCIN HYDROCHLORIDE						
AB	**+**	ANI PHARMS INC	**EQ 125MG BASE**	**N050606**	**001**	Apr 15, 1986
AB	**+!**		**EQ 250MG BASE**	**N050606**	**002**	Apr 15, 1986
VANCOMYCIN HYDROCHLORIDE						
AB		AKORN	**EQ 125MG BASE**	**A065478**	**001**	Apr 09, 2012
AB			**EQ 250MG BASE**	**A065478**	**002**	Apr 09, 2012
AB		LUPIN LTD	**EQ 125MG BASE**	**A090439**	**001**	Jan 28, 2015
AB			**EQ 250MG BASE**	**A090439**	**002**	Jan 28, 2015
AB		STRIDES PHARMA	**EQ 125MG BASE**	**A065490**	**001**	Apr 09, 2012
AB			**EQ 250MG BASE**	**A065490**	**002**	Apr 09, 2012
AB		WATSON LABS	**EQ 125MG BASE**	**A065510**	**001**	Apr 09, 2012
AB			**EQ 250MG BASE**	**A065510**	**002**	Apr 09, 2012
FOR SOLUTION;ORAL						
FIRVANQ KIT						
	+!	RXMTM THERAPS LLC	EQ 25MG BASE/ML	N208910	001	Jan 26, 2018
	+!		EQ 50MG BASE/ML	N208910	002	Jan 26, 2018
INJECTABLE;INJECTION						
VANCOMYCIN HYDROCHLORIDE						
AP		AUROBINDO PHARMA LTD	**EQ 500MG BASE/VIAL**	**A205780**	**001**	Mar 31, 2016
AP			**EQ 1GM BASE/VIAL**	**A205780**	**002**	Mar 31, 2016
AP			**EQ 5GM BASE/VIAL**	**A205779**	**001**	Mar 29, 2016
AP			**EQ 10GM BASE/VIAL**	**A205779**	**002**	Mar 29, 2016
AP		EMCURE PHARMS LTD	**EQ 500MG BASE/VIAL**	**A202275**	**001**	Oct 31, 2013
AP			**EQ 1GM BASE/VIAL**	**A202275**	**002**	Oct 31, 2013
AP			**EQ 10GM BASE/VIAL**	**A202464**	**001**	Oct 09, 2013
AP			**EQ 5GM BASE/VIAL**	**A202274**	**001**	Oct 31, 2013
AP	**!**	FRESENIUS KABI USA	**EQ 500MG BASE/VIAL**	**A062663**	**001**	Mar 17, 1987
AP			**EQ 750MG BASE/VIAL**	**A062663**	**005**	Aug 17, 2016
AP	**!**		**EQ 1GM BASE/VIAL**	**A062663**	**002**	Jul 31, 1987
AP	**!**		**EQ 5GM BASE/VIAL**	**A062663**	**003**	Jun 03, 1988
AP	**!**		**EQ 10GM BASE/VIAL**	**A062663**	**004**	Nov 28, 1997
AP		GLAND PHARMA LTD	**EQ 500MG BASE/VIAL**	**A205694**	**001**	Jan 21, 2016
AP			**EQ 1GM BASE/VIAL**	**A205694**	**002**	Jan 21, 2016
AP		HIKMA FARMACEUTICA	**EQ 5GM BASE/VIAL**	**A204360**	**001**	Oct 15, 2018
AP			**EQ 10GM BASE/VIAL**	**A204360**	**002**	Oct 15, 2018
AP		HIKMA PHARMS	**EQ 750MG BASE/VIAL**	**A206616**	**001**	Oct 03, 2018
AP	**!**	HOSPIRA	**EQ 500MG BASE/VIAL**	**A062911**	**001**	Aug 04, 1988
AP	**!**		**EQ 500MG BASE/VIAL**	**A062931**	**001**	Oct 29, 1992
AP	**!**		**EQ 750MG BASE/VIAL**	**A062912**	**002**	Jan 07, 2009
AP	**!**		**EQ 750MG BASE/VIAL**	**A062933**	**002**	May 27, 2009
AP	**!**		**EQ 1GM BASE/VIAL**	**A062912**	**001**	Aug 04, 1988
AP	**!**		**EQ 1GM BASE/VIAL**	**A062933**	**001**	Oct 29, 1992
AP	**!**		**EQ 5GM BASE/VIAL**	**A063076**	**001**	Dec 21, 1990
AP		HOSPIRA INC	**EQ 10GM BASE/VIAL**	**A065455**	**001**	Apr 29, 2009
AP		MUSTAFA NEVZAT ILAC	**EQ 500MG BASE/VIAL**	**A065401**	**001**	Jun 30, 2008
AP			**EQ 1GM BASE/VIAL**	**A065401**	**002**	Jun 30, 2008
AP		MYLAN LABS LTD	**EQ 500MG BASE/VIAL**	**A065397**	**001**	Dec 30, 2008
AP			**EQ 1GM BASE/VIAL**	**A065397**	**002**	Dec 30, 2008
AP			**EQ 5GM BASE/VIAL**	**A065432**	**001**	Dec 30, 2008
AP			**EQ 10GM BASE/VIAL**	**A091554**	**001**	Sep 19, 2011

VANCOMYCIN HYDROCHLORIDE						
INJECTABLE;INJECTION						
VANCOMYCIN HYDROCHLORIDE						
AP		SAGENT PHARMS	**EQ 5GM BASE/VIAL**	**A200837**	**001**	Aug 10, 2012
AP			**EQ 10GM BASE/VIAL**	**A200837**	**002**	Sep 02, 2014
AP		SANDOZ	**EQ 500MG BASE/VIAL**	**A090250**	**001**	Apr 27, 2010
AP			**EQ 1GM BASE/VIAL**	**A090250**	**002**	Apr 27, 2010
AP		SANDOZ INC	**EQ 5GM BASE/VIAL**	**A201048**	**001**	Aug 10, 2012
AP			**EQ 10GM BASE/VIAL**	**A201048**	**002**	Aug 10, 2012
AP		XELLIA PHARMS APS	**EQ 5GM BASE/VIAL**	**A204125**	**001**	Dec 28, 2015
AP			**EQ 10GM BASE/VIAL**	**A204125**	**002**	Dec 28, 2015
AP			**EQ 500MG BASE/VIAL**	**A204107**	**001**	Dec 28, 2015
AP			**EQ 1GM BASE/VIAL**	**A204107**	**002**	Dec 28, 2015
VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER						
	+!	BAXTER HLTHCARE	EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993
	+!		EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010
	+!		EQ 1GM BASE/200ML	N050671	003	Mar 01, 1999
POWDER;INTRAVENOUS						
VANCOMYCIN HYDROCHLORIDE						
	+!	MYLAN LABS LTD	EQ 250MG BASE/VIAL	N209481	001	Jul 10, 2018
	+!		EQ 750MG BASE/VIAL	N209481	002	Jul 10, 2018
	+!		EQ 1.25GM BASE/VIAL	N209481	003	Jul 10, 2018
	+!		EQ 1.5GM BASE/VIAL	N209481	004	Jul 10, 2018
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER						
		SAMSON MEDCL	EQ 100GM BASE	A091532	001	Jan 06, 2016
VANDETANIB						
TABLET;ORAL						
CAPRELSA						
	+	GENZYME CORP	100MG	N022405	001	Apr 06, 2011
	+!		300MG	N022405	002	Apr 06, 2011
VARDENAFIL HYDROCHLORIDE						
TABLET;ORAL						
LEVITRA						
AB	**+**	BAYER HLTHCARE	**5MG**	**N021400**	**001**	Aug 19, 2003
AB	**+**		**10MG**	**N021400**	**002**	Aug 19, 2003
AB	**+!**		**20MG**	**N021400**	**004**	Aug 19, 2003
VARDENAFIL HYDROCHLORIDE						
AB		AMNEAL PHARMS CO	**5MG**	**A210738**	**001**	Oct 31, 2018
AB			**10MG**	**A210738**	**002**	Oct 31, 2018
AB			**20MG**	**A210738**	**003**	Oct 31, 2018
AB		CROSSMEDIKA SA	**2.5MG**	**A209057**	**001**	Oct 31, 2018
AB			**5MG**	**A209057**	**002**	Oct 31, 2018
AB			**10MG**	**A209057**	**003**	Oct 31, 2018
AB			**20MG**	**A209057**	**004**	Oct 31, 2018
AB		TEVA PHARMS	**2.5MG**	**A091347**	**001**	May 03, 2012
AB			**5MG**	**A091347**	**002**	May 03, 2012
AB			**10MG**	**A091347**	**003**	May 03, 2012
AB			**20MG**	**A091347**	**004**	May 03, 2012
AB		ZYDUS PHARMS USA INC	**2.5MG**	**A208960**	**001**	Oct 31, 2018
AB			**5MG**	**A208960**	**002**	Oct 31, 2018
AB			**10MG**	**A208960**	**003**	Oct 31, 2018
AB			**20MG**	**A208960**	**004**	Oct 31, 2018
TABLET, ORALLY DISINTEGRATING;ORAL						
STAXYN						
AB	**+!**	BAYER HLTHCARE	**10MG**	**N200179**	**001**	Jun 17, 2010
VARDENAFIL HYDROCHLORIDE						
AB		ALEMBIC PHARMS LTD	**10MG**	**A208324**	**001**	Nov 16, 2018
VARENICLINE TARTRATE						
TABLET;ORAL						
CHANTIX						
	+	PF PRISM CV	EQ 0.5MG BASE	N021928	001	May 10, 2006
	+!		EQ 1MG BASE	N021928	002	May 10, 2006
VASOPRESSIN						
SOLUTION;IV (INFUSION)						
VASOSTRICT						
	+!	PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014
	+!		200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016

VECURONIUM BROMIDE

INJECTABLE;INJECTION

VECURONIUM BROMIDE

AP		AUROBINDO PHARMA LTD	**10MG/VIAL**	**A206670**	**001**	Dec 20, 2018
AP			**20MG/VIAL**	**A206670**	**002**	Dec 20, 2018
AP		GLAND PHARMA LTD	**10MG/VIAL**	**A205390**	**001**	May 26, 2016
AP			**20MG/VIAL**	**A205390**	**002**	May 26, 2016
AP		HOSPIRA	**10MG/VIAL**	**A075164**	**001**	Oct 21, 1999
AP			**20MG/VIAL**	**A075164**	**002**	Oct 21, 1999
AP		MYLAN LABS LTD	**10MG/VIAL**	**A090243**	**001**	May 11, 2010
AP			**20MG/VIAL**	**A090243**	**002**	May 11, 2010
AP		SAGENT PHARMS	**10MG/VIAL**	**A078274**	**001**	Dec 29, 2008
AP			**20MG/VIAL**	**A078274**	**002**	Dec 29, 2008
AP	**!**	SUN PHARMA GLOBAL	**10MG/VIAL**	**A079001**	**001**	Jun 17, 2009
AP	**!**		**20MG/VIAL**	**A079001**	**002**	Jun 17, 2009
AP		TEVA PHARMS USA	**10MG/VIAL**	**A074688**	**001**	Aug 25, 1999
AP			**20MG/VIAL**	**A074688**	**002**	Aug 25, 1999
AP		WEST-WARD PHARMS INT	**10MG/VIAL**	**A075549**	**001**	Jun 13, 2000
AP			**20MG/VIAL**	**A075549**	**002**	Jun 13, 2000

VELAGLUCERASE ALFA

INJECTABLE;INTRAVENOUS

VPRIV

		SHIRE HUMAN GENETIC	400 UNITS/VIAL	N022575	001	Feb 26, 2010

VEMURAFENIB

TABLET;ORAL

ZELBORAF

	+!	HOFFMANN LA ROCHE	240MG	N202429	001	Aug 17, 2011

VENETOCLAX

TABLET;ORAL

VENCLEXTA

	+	ABBVIE INC	10MG	N208573	001	Apr 11, 2016
	+		50MG	N208573	002	Apr 11, 2016
	+!		100MG	N208573	003	Apr 11, 2016

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

EFFEXOR XR

AB	**+**	WYETH PHARMS	**EQ 37.5MG BASE**	**N020699**	**001**	Oct 20, 1997
AB	**+**		**EQ 75MG BASE**	**N020699**	**002**	Oct 20, 1997
AB	**+!**		**EQ 150MG BASE**	**N020699**	**004**	Oct 20, 1997

VENLAFAXINE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**EQ 37.5MG BASE**	**A200834**	**001**	Apr 14, 2011
AB			**EQ 75MG BASE**	**A200834**	**002**	Apr 14, 2011
AB			**EQ 150MG BASE**	**A200834**	**003**	Apr 14, 2011
AB		DR REDDYS LABS LTD	**EQ 37.5MG BASE**	**A078421**	**001**	May 06, 2011
AB			**EQ 75MG BASE**	**A078421**	**002**	May 06, 2011
AB			**EQ 150MG BASE**	**A078421**	**003**	May 06, 2011
AB		INTELLIPHARMACEUTICS	**EQ 37.5MG BASE**	**A201272**	**001**	Nov 23, 2018
AB			**EQ 75MG BASE**	**A201272**	**002**	Nov 23, 2018
AB			**EQ 150MG BASE**	**A201272**	**003**	Nov 23, 2018
AB		MACLEODS PHARMS LTD	**EQ 37.5MG BASE**	**A204889**	**001**	Oct 05, 2017
AB			**EQ 75MG BASE**	**A204889**	**002**	Oct 05, 2017
AB			**EQ 150MG BASE**	**A204889**	**003**	Oct 05, 2017
AB		ORCHID HLTHCARE	**EQ 37.5MG BASE**	**A091123**	**001**	Jul 11, 2011
AB			**EQ 75MG BASE**	**A091123**	**002**	Jul 11, 2011
AB			**EQ 150MG BASE**	**A091123**	**003**	Jul 11, 2011
AB		TEVA	**EQ 37.5MG BASE**	**A076565**	**001**	Jun 28, 2010
AB			**EQ 75MG BASE**	**A076565**	**002**	Jun 28, 2010
AB			**EQ 150MG BASE**	**A076565**	**003**	Jun 28, 2010
AB		TORRENT PHARMS LLC	**EQ 37.5MG BASE**	**A090899**	**001**	Jun 01, 2011
AB			**EQ 75MG BASE**	**A090899**	**002**	Jun 01, 2011
AB			**EQ 150MG BASE**	**A090899**	**003**	Jun 01, 2011
AB		VALEANT PHARMS NORTH	**EQ 37.5MG BASE**	**A090071**	**001**	Apr 15, 2011
AB			**EQ 75MG BASE**	**A090071**	**002**	Apr 15, 2011
AB			**EQ 150MG BASE**	**A090071**	**003**	Apr 15, 2011
AB		WOCKHARDT	**EQ 37.5MG BASE**	**A078865**	**001**	Apr 14, 2011
AB			**EQ 75MG BASE**	**A078865**	**002**	Apr 14, 2011

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		**EQ 150MG BASE**	**A078865**	**003**	Apr 14, 2011
AB	ZYDUS PHARMS USA INC	**EQ 37.5MG BASE**	**A090174**	**001**	Apr 14, 2011
AB		**EQ 75MG BASE**	**A090174**	**002**	Apr 14, 2011
AB		**EQ 150MG BASE**	**A090174**	**003**	Apr 14, 2011

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	**EQ 25MG BASE**	**A078932**	**001**	Dec 14, 2010
AB		**EQ 37.5MG BASE**	**A078932**	**002**	Dec 14, 2010
AB		**EQ 50MG BASE**	**A078932**	**003**	Dec 14, 2010
AB		**EQ 75MG BASE**	**A078932**	**004**	Dec 14, 2010
AB		**EQ 100MG BASE**	**A078932**	**005**	Dec 14, 2010
AB	AMNEAL PHARMS	**EQ 25MG BASE**	**A079098**	**001**	May 11, 2010
AB		**EQ 37.5MG BASE**	**A079098**	**002**	May 11, 2010
AB		**EQ 50MG BASE**	**A079098**	**003**	May 11, 2010
AB		**EQ 75MG BASE**	**A079098**	**004**	May 11, 2010
AB		**EQ 100MG BASE**	**A079098**	**005**	May 11, 2010
AB	AUROBINDO PHARMA	**EQ 25MG BASE**	**A090555**	**001**	Apr 07, 2010
AB		**EQ 37.5MG BASE**	**A090555**	**002**	Apr 07, 2010
AB		**EQ 50MG BASE**	**A090555**	**003**	Apr 07, 2010
AB		**EQ 75MG BASE**	**A090555**	**004**	Apr 07, 2010
AB		**EQ 100MG BASE**	**A090555**	**005**	Apr 07, 2010
AB	CADILA PHARMS LTD	**EQ 25MG BASE**	**A206250**	**001**	Nov 21, 2018
AB		**EQ 37.5MG BASE**	**A206250**	**002**	Nov 21, 2018
AB		**EQ 50MG BASE**	**A206250**	**003**	Nov 21, 2018
AB		**EQ 75MG BASE**	**A206250**	**004**	Nov 21, 2018
AB		**EQ 100MG BASE**	**A206250**	**005**	Nov 21, 2018
AB	DR REDDYS LABS LTD	**EQ 25MG BASE**	**A078301**	**001**	Jun 13, 2008
AB		**EQ 37.5MG BASE**	**A078301**	**002**	Jun 13, 2008
AB		**EQ 50MG BASE**	**A078301**	**003**	Jun 13, 2008
AB		**EQ 75MG BASE**	**A078301**	**004**	Jun 13, 2008
AB		**EQ 100MG BASE**	**A078301**	**005**	Jun 13, 2008
AB	HERITAGE PHARMS INC	**EQ 25MG BASE**	**A078554**	**001**	Jan 09, 2009
AB		**EQ 37.5MG BASE**	**A078554**	**002**	Jan 09, 2009
AB		**EQ 50MG BASE**	**A078554**	**003**	Jan 09, 2009
AB		**EQ 75MG BASE**	**A078554**	**004**	Jan 09, 2009
AB		**EQ 100MG BASE**	**A078554**	**005**	Jan 09, 2009
AB	MYLAN	**EQ 25MG BASE**	**A077166**	**001**	Jun 13, 2008
AB		**EQ 37.5MG BASE**	**A077166**	**002**	Jun 13, 2008
AB		**EQ 50MG BASE**	**A077166**	**003**	Jun 13, 2008
AB		**EQ 75MG BASE**	**A077166**	**004**	Jun 13, 2008
AB		**EQ 100MG BASE**	**A077166**	**005**	Jun 13, 2008
AB	PRINSTON INC	**EQ 25MG BASE**	**A090027**	**001**	Aug 04, 2010
AB		**EQ 37.5MG BASE**	**A090027**	**002**	Aug 04, 2010
AB		**EQ 50MG BASE**	**A090027**	**003**	Aug 04, 2010
AB		**EQ 75MG BASE**	**A090027**	**004**	Aug 04, 2010
AB		**EQ 100MG BASE**	**A090027**	**005**	Aug 04, 2010
AB	SUN PHARM INDS INC	**EQ 25MG BASE**	**A078627**	**001**	Jun 13, 2008
AB		**EQ 37.5MG BASE**	**A078627**	**002**	Jun 13, 2008
AB		**EQ 50MG BASE**	**A078627**	**003**	Jun 13, 2008
AB		**EQ 75MG BASE**	**A078627**	**004**	Jun 13, 2008
AB		**EQ 100MG BASE**	**A078627**	**005**	Jun 13, 2008
AB	TEVA	**EQ 25MG BASE**	**A076690**	**001**	Aug 03, 2006
AB		**EQ 37.5MG BASE**	**A076690**	**002**	Aug 03, 2006
AB !		**EQ 50MG BASE**	**A076690**	**003**	Aug 03, 2006
AB		**EQ 75MG BASE**	**A076690**	**004**	Aug 03, 2006
AB		**EQ 100MG BASE**	**A076690**	**005**	Aug 03, 2006
AB	YAOPHARMA CO LTD	**EQ 25MG BASE**	**A202036**	**001**	May 28, 2015
AB		**EQ 37.5MG BASE**	**A202036**	**002**	May 28, 2015
AB		**EQ 50MG BASE**	**A202036**	**003**	May 28, 2015
AB		**EQ 75MG BASE**	**A202036**	**004**	May 28, 2015
AB		**EQ 100MG BASE**	**A202036**	**005**	May 28, 2015
AB	ZYDUS PHARMS USA	**EQ 25MG BASE**	**A077653**	**001**	Jun 13, 2008
AB		**EQ 37.5MG BASE**	**A077653**	**002**	Jun 13, 2008
AB		**EQ 50MG BASE**	**A077653**	**003**	Jun 13, 2008
AB		**EQ 75MG BASE**	**A077653**	**004**	Jun 13, 2008
AB		**EQ 100MG BASE**	**A077653**	**005**	Jun 13, 2008

VENLAFAXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		NOSTRUM LABS INC	EQ 150MG BASE	A205468	002	Mar 24, 2017
AB			EQ 225MG BASE	A205468	003	Mar 24, 2017
AB	+	OSMOTICA PHARM	EQ 37.5MG BASE	N022104	001	May 20, 2008
AB	+		EQ 75MG BASE	N022104	002	May 20, 2008
AB	+!		EQ 150MG BASE	N022104	003	May 20, 2008
AB	+		EQ 225MG BASE	N022104	004	May 20, 2008
AB		SUN PHARMA GLOBAL	EQ 37.5MG BASE	A091272	001	Aug 18, 2010
AB			EQ 75MG BASE	A091272	002	Aug 18, 2010
AB			EQ 150MG BASE	A091272	003	Aug 18, 2010
AB			EQ 225MG BASE	A091272	004	Jan 08, 2019

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERAPAMIL HYDROCHLORIDE

AB		MYLAN	100MG	A078306	001	Aug 09, 2007
AB			120MG	A075138	001	Apr 20, 1999
AB			180MG	A075138	002	Apr 20, 1999
AB			200MG	A078306	002	Aug 09, 2007
AB			240MG	A075138	003	Apr 20, 1999
AB			300MG	A078306	003	Aug 09, 2007

VERELAN

AB	+	RECRO GAINESVILLE	120MG	N019614	001	May 29, 1990
AB	+		180MG	N019614	003	Jan 09, 1992
AB	+		240MG	N019614	002	May 29, 1990

VERELAN PM

AB	+	RECRO GAINESVILLE	100MG	N020943	001	Nov 25, 1998
AB	+		200MG	N020943	002	Nov 25, 1998
AB	+!		300MG	N020943	003	Nov 25, 1998

VERELAN

	+!	RECRO GAINESVILLE	360MG	N019614	004	May 10, 1996

SOLUTION;INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

AP		AMNEAL PHARMS CO	5MG/2ML (2.5MG/ML)	A210994	001	Jul 13, 2018
AP			10MG/4ML (2.5MG/ML)	A210994	002	Jul 13, 2018
AP		EXELA PHARMA SCS LLC	5MG/2ML (2.5MG/ML)	N018925	001	Mar 30, 1984
AP			10MG/4ML (2.5MG/ML)	N018925	002	Apr 05, 2018
AP	!	HOSPIRA	5MG/2ML (2.5MG/ML)	A070738	001	May 06, 1987
AP	!		5MG/2ML (2.5MG/ML)	A075136	001	Oct 20, 1998
AP	!		5MG/2ML (2.5MG/ML)	A070737	001	May 06, 1987
AP	!		10MG/4ML (2.5MG/ML)	A070737	002	May 06, 1987
AP		MICRO LABS	5MG/2ML (2.5MG/ML)	A211370	001	Dec 28, 2018
AP			10MG/4ML (2.5MG/ML)	A211370	002	Dec 28, 2018
AP		SOMERSET THERAPS LLC	5MG/2ML (2.5MG/ML)	A211015	001	Jun 18, 2018
AP			5MG/2ML (2.5MG/ML)	A211035	001	Jun 18, 2018
AP			10MG/4ML (2.5MG/ML)	A211015	002	Jun 18, 2018
AP			10MG/4ML (2.5MG/ML)	A211035	002	Jun 18, 2018

TABLET;ORAL

CALAN

AB	+	GD SEARLE LLC	80MG	N018817	001	Sep 10, 1984
AB	+!		120MG	N018817	002	Sep 10, 1984

VERAPAMIL HYDROCHLORIDE

AB		HERITAGE PHARMS INC	40MG	A071881	002	Oct 14, 2015
AB			80MG	A071881	003	Apr 05, 1988
AB			120MG	A071881	001	Apr 05, 1988
AB		MYLAN	80MG	A071483	002	Feb 15, 1989
AB			120MG	A071483	001	Feb 15, 1989
AB		WATSON LABS	40MG	A072924	001	Jun 29, 1993
AB			80MG	A070995	001	Oct 01, 1986
AB			120MG	A070994	001	Oct 01, 1986

TABLET, EXTENDED RELEASE;ORAL

CALAN SR

AB	+!	PFIZER	120MG	N019152	003	Mar 06, 1991
AB	+!		240MG	N019152	001	Dec 16, 1986

VERAPAMIL HYDROCHLORIDE

AB		CADILA PHARMS LTD	180MG	A206173	001	May 05, 2017
AB			240MG	A206173	002	May 05, 2017
AB		GLENMARK GENERICS	120MG	A090700	001	Aug 03, 2011
AB	!		180MG	A090700	002	Aug 03, 2011

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

VERAPAMIL HYDROCHLORIDE

AB			**240MG**	**A078906**	**001**	Sep 17, 2009
AB		IVAX SUB TEVA PHARMS	**120MG**	**A073568**	**002**	Oct 10, 1997
AB			**180MG**	**A074330**	**001**	Jan 31, 1994
AB			**240MG**	**A073568**	**001**	Jul 31, 1992
AB		MYLAN	**120MG**	**A074587**	**002**	Feb 21, 1997
AB			**180MG**	**A074587**	**003**	Sep 09, 1997
AB			**240MG**	**A074587**	**001**	Mar 23, 1996
AB		PAR PHARM	**120MG**	**A075072**	**001**	May 25, 1999
AB			**240MG**	**A075072**	**003**	May 25, 1999
AB		SUN PHARM INDS INC	**120MG**	**A090529**	**001**	Dec 30, 2011
AB			**180MG**	**A090529**	**002**	Dec 30, 2011
AB			**240MG**	**A090529**	**003**	Dec 30, 2011

VERTEPORFIN

INJECTABLE;INJECTION

VISUDYNE

	+!	VALEANT LUXEMBOURG	15MG/VIAL	N021119	001	Apr 12, 2000

VIGABATRIN

FOR SOLUTION;ORAL

SABRIL

AA	**+!**	LUNDBECK PHARMS LLC	**500MG/PACKET**	**N022006**	**001**	Aug 21, 2009

VIGABATRIN

AA		AMNEAL PHARMS	**500MG/PACKET**	**A210155**	**001**	Mar 13, 2018
AA		DR REDDYS LABS LTD	**500MG/PACKET**	**A211481**	**001**	Nov 20, 2018
AA		PAR PHARM INC	**500MG/PACKET**	**A208218**	**001**	Apr 27, 2017
AA		TEVA PHARMS USA	**500MG/PACKET**	**A209824**	**001**	Apr 23, 2018

VIGADRONE

AA		AUCTA PHARMS	**500MG/PACKET**	**A210196**	**001**	Jun 21, 2018

TABLET;ORAL

SABRIL

AB	**+!**	LUNDBECK PHARMS LLC	**500MG**	**N020427**	**001**	Aug 21, 2009

VIGABATRIN

AB		TEVA PHARMS USA	**500MG**	**A209822**	**001**	Jan 14, 2019

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VIIBRYD

	+!	ALLERGAN SALES LLC	10MG	N022567	001	Jan 21, 2011
	+		20MG	N022567	002	Jan 21, 2011
	+		40MG	N022567	003	Jan 21, 2011

VINBLASTINE SULFATE

INJECTABLE;INJECTION

VINBLASTINE SULFATE

	!	FRESENIUS KABI USA	1MG/ML	A089515	001	Apr 29, 1987
	!	WEST-WARD PHARMS INT	10MG/VIAL	A089395	001	Apr 09, 1987

VINCRISTINE SULFATE

INJECTABLE;INJECTION

VINCRISTINE SULFATE PFS

AP	**!**	HOSPIRA	**1MG/ML**	**A071484**	**001**	Apr 19, 1988
AP		TEVA PHARMS USA	**1MG/ML**	**A075493**	**001**	Sep 01, 1999

INJECTABLE, LIPOSOMAL;INTRAVENOUS

MARQIBO KIT

	+!	TALON THERAP	5MG/5ML (1MG/ML)	N202497	001	Aug 09, 2012

VINORELBINE TARTRATE

INJECTABLE;INJECTION

NAVELBINE

AP	**+!**	PIERRE FABRE	**EQ 10MG BASE/ML**	**N020388**	**001**	Dec 23, 1994

VINORELBINE TARTRATE

AP		ACTAVIS TOTOWA	**EQ 10MG BASE/ML**	**A078011**	**001**	Jul 22, 2009
AP		DR REDDYS LABS LTD	**EQ 10MG BASE/ML**	**A202017**	**001**	Sep 12, 2013
AP		FRESENIUS KABI USA	**EQ 10MG BASE/ML**	**A076849**	**001**	Apr 18, 2005
AP		HOSPIRA	**EQ 10MG BASE/ML**	**A076827**	**001**	Jun 02, 2005
AP		JIANGSU HANSOH PHARM	**EQ 10MG BASE/ML**	**A091106**	**001**	Sep 26, 2012
AP		TEVA PHARMS USA	**EQ 10MG BASE/ML**	**A076028**	**001**	Feb 03, 2003
AP		WEST-WARD PHARMS INT	**EQ 10MG BASE/ML**	**A075992**	**001**	Jun 10, 2003

VINORELBINE TARTRATE						
INJECTABLE;INJECTION						
VINORELBINE TARTRATE						
AP			**EQ 10MG BASE/ML**	**A076461**	**001**	Dec 11, 2003
VISMODEGIB						
CAPSULE;ORAL						
ERIVEDGE						
	+!	GENENTECH	150MG	N203388	001	Jan 30, 2012
VITAMIN A PALMITATE						
INJECTABLE;INJECTION						
AQUASOL A						
	+!	CASPER PHARMA LLC	EQ 50,000 UNITS BASE/ML	N006823	001	
VORAPAXAR SULFATE						
TABLET;ORAL						
ZONTIVITY						
	+!	ARALEZ PHARMS	EQ 2.08MG BASE	N204886	001	May 08, 2014
VORICONAZOLE						
FOR SUSPENSION;ORAL						
VFEND						
AB	**+!**	PF PRISM CV	**200MG/5ML**	**N021630**	**001**	Dec 19, 2003
VORICONAZOLE						
AB		AMNEAL PHARMS	**200MG/5ML**	**A205034**	**001**	Apr 13, 2016
AB		NOVEL LABS INC	**200MG/5ML**	**A206799**	**001**	May 31, 2016
INJECTABLE;IV (INFUSION)						
VFEND						
AP	**+!**	PF PRISM CV	**200MG/VIAL**	**N021267**	**001**	May 24, 2002
VORICONAZOLE						
AP		ALVOGEN INC	**200MG/VIAL**	**A206398**	**001**	Mar 23, 2016
AP		HAINAN POLY PHARM	**200MG/VIAL**	**A211661**	**001**	Nov 30, 2018
AP		SANDOZ INC	**200MG/VIAL**	**A090862**	**001**	May 30, 2012
AP		ZYDUS PHARMS USA INC	**200MG/VIAL**	**A208983**	**001**	Jul 16, 2018
POWDER;IV (INFUSION)						
VORICONAZOLE						
		XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017
TABLET;ORAL						
VFEND						
AB	**+**	PF PRISM CV	**50MG**	**N021266**	**001**	May 24, 2002
AB	**+!**		**200MG**	**N021266**	**002**	May 24, 2002
VORICONAZOLE						
AB		AJANTA PHARMA LTD	**50MG**	**A206181**	**001**	May 24, 2016
AB			**200MG**	**A206181**	**002**	May 24, 2016
AB		AKORN	**50MG**	**A207049**	**001**	Sep 07, 2016
AB			**200MG**	**A207049**	**002**	Sep 07, 2016
AB		AUROBINDO PHARMA LTD	**50MG**	**A206837**	**001**	Jan 22, 2016
AB			**200MG**	**A206837**	**002**	Jan 22, 2016
AB		GLENMARK PHARMS LTD	**50MG**	**A203503**	**001**	Sep 02, 2015
AB			**200MG**	**A203503**	**002**	Sep 02, 2015
AB		MYLAN PHARMS INC	**50MG**	**A090547**	**001**	Apr 22, 2010
AB			**200MG**	**A090547**	**002**	Apr 22, 2010
AB		NOVEL LABS INC	**50MG**	**A207371**	**001**	May 24, 2016
AB			**200MG**	**A207371**	**002**	May 24, 2016
AB		PRINSTON INC	**50MG**	**A206654**	**001**	Aug 08, 2016
AB			**200MG**	**A206654**	**002**	Aug 08, 2016
AB		RISING PHARMS	**50MG**	**A206762**	**001**	May 24, 2016
AB			**200MG**	**A206762**	**002**	May 24, 2016
AB		SANDOZ INC	**50MG**	**A200265**	**001**	Dec 12, 2011
AB			**200MG**	**A200265**	**002**	Dec 12, 2011
AB		TEVA PHARMS	**50MG**	**A091658**	**001**	Apr 06, 2012
AB			**200MG**	**A091658**	**002**	Apr 06, 2012
AB		ZYDUS PHARMS USA INC	**50MG**	**A206747**	**001**	May 24, 2016
AB			**200MG**	**A206747**	**002**	May 24, 2016

VORINOSTAT							
CAPSULE;ORAL							
ZOLINZA							
	+!	MERCK	100MG	N021991	001	Oct 06, 2006
VORTIOXETINE HYDROBROMIDE							
TABLET;ORAL							
TRINTELLIX							
	+	TAKEDA PHARMS USA	EQ 5MG BASE	N204447	001	Sep 30, 2013
	+		EQ 10MG BASE	N204447	002	Sep 30, 2013
	+!		EQ 20MG BASE	N204447	004	Sep 30, 2013
WARFARIN SODIUM							
TABLET;ORAL							
COUMADIN							
AB	**+**	BRISTOL MYERS SQUIBB	**1MG**	**N009218**	**022**	Mar 01, 1990
AB	**+**		**2MG**	**N009218**	**013**	
AB	**+**		**2.5MG**	**N009218**	**018**	
AB	**+**		**3MG**	**N009218**	**025**	Nov 18, 1996
AB	**+**		**4MG**	**N009218**	**023**	Aug 24, 1993
AB	**+**		**5MG**	**N009218**	**007**	
AB	**+**		**6MG**	**N009218**	**026**	Nov 18, 1996
AB	**+**		**7.5MG**	**N009218**	**016**	
AB	**+!**		**10MG**	**N009218**	**005**	
JANTOVEN							
AB		USL PHARMA	**1MG**	**A040416**	**001**	Oct 02, 2003
AB			**2MG**	**A040416**	**002**	Oct 02, 2003
AB			**2.5MG**	**A040416**	**003**	Oct 02, 2003
AB			**3MG**	**A040416**	**004**	Oct 02, 2003
AB			**4MG**	**A040416**	**005**	Oct 02, 2003
AB			**5MG**	**A040416**	**006**	Oct 02, 2003
AB			**6MG**	**A040416**	**007**	Oct 02, 2003
AB			**7.5MG**	**A040416**	**008**	Oct 02, 2003
AB			**10MG**	**A040416**	**009**	Oct 02, 2003
WARFARIN SODIUM							
AB		AMNEAL PHARMS	**1MG**	**A202202**	**001**	Mar 04, 2013
AB			**2MG**	**A202202**	**002**	Mar 04, 2013
AB			**2.5MG**	**A202202**	**003**	Mar 04, 2013
AB			**3MG**	**A202202**	**004**	Mar 04, 2013
AB			**4MG**	**A202202**	**005**	Mar 04, 2013
AB			**5MG**	**A202202**	**006**	Mar 04, 2013
AB			**6MG**	**A202202**	**007**	Mar 04, 2013
AB			**7.5MG**	**A202202**	**008**	Mar 04, 2013
AB			**10MG**	**A202202**	**009**	Mar 04, 2013
AB		BARR	**1MG**	**A040145**	**001**	Mar 26, 1997
AB			**2MG**	**A040145**	**002**	Mar 26, 1997
AB			**2.5MG**	**A040145**	**003**	Mar 26, 1997
AB			**3MG**	**A040145**	**008**	Nov 05, 1998
AB			**4MG**	**A040145**	**004**	Mar 26, 1997
AB			**5MG**	**A040145**	**005**	Mar 26, 1997
AB			**6MG**	**A040145**	**009**	Nov 05, 1998
AB			**7.5MG**	**A040145**	**006**	Mar 26, 1997
AB			**10MG**	**A040145**	**007**	Mar 26, 1997
AB		INVAGEN PHARMS	**1MG**	**A090935**	**001**	May 25, 2011
AB			**2MG**	**A090935**	**002**	May 25, 2011
AB			**2.5MG**	**A090935**	**003**	May 25, 2011
AB			**3MG**	**A090935**	**004**	May 25, 2011
AB			**4MG**	**A090935**	**005**	May 25, 2011
AB			**5MG**	**A090935**	**006**	May 25, 2011
AB			**6MG**	**A090935**	**007**	May 25, 2011
AB			**7.5MG**	**A090935**	**008**	May 25, 2011
AB			**10MG**	**A090935**	**009**	May 25, 2011
AB		IPCA LABS LTD	**1MG**	**A200104**	**001**	Jun 27, 2013
AB			**2MG**	**A200104**	**002**	Jun 27, 2013
AB			**2.5MG**	**A200104**	**003**	Jun 27, 2013
AB			**3MG**	**A200104**	**004**	Jun 27, 2013
AB			**4MG**	**A200104**	**005**	Jun 27, 2013
AB			**5MG**	**A200104**	**006**	Jun 27, 2013
AB			**6MG**	**A200104**	**007**	Jun 27, 2013
AB			**7.5MG**	**A200104**	**008**	Jun 27, 2013
AB			**10MG**	**A200104**	**009**	Jun 27, 2013
AB		PLIVA	**1MG**	**A040616**	**009**	Jul 05, 2006
AB			**2MG**	**A040616**	**001**	Jul 05, 2006

WARFARIN SODIUM

TABLET;ORAL

WARFARIN SODIUM

AB		**2.5MG**	**A040616**	**002**	Jul 05, 2006
AB		**3MG**	**A040616**	**003**	Jul 05, 2006
AB		**4MG**	**A040616**	**004**	Jul 05, 2006
AB		**5MG**	**A040616**	**005**	Jul 05, 2006
AB		**6MG**	**A040616**	**006**	Jul 05, 2006
AB		**7.5MG**	**A040616**	**007**	Jul 05, 2006
AB		**10MG**	**A040616**	**008**	Jul 05, 2006
AB	TARO PHARM	**1MG**	**A040301**	**002**	Jul 15, 1999
AB		**2MG**	**A040301**	**003**	Jul 15, 1999
AB		**2.5MG**	**A040301**	**004**	Jul 15, 1999
AB		**3MG**	**A040301**	**005**	Jul 15, 1999
AB		**4MG**	**A040301**	**006**	Jul 15, 1999
AB		**5MG**	**A040301**	**007**	Jul 15, 1999
AB		**6MG**	**A040301**	**008**	Jul 15, 1999
AB		**7.5MG**	**A040301**	**009**	Jul 15, 1999
AB		**10MG**	**A040301**	**001**	Jul 15, 1999
AB	ZYDUS PHARMS USA	**1MG**	**A040663**	**001**	May 30, 2006
AB		**2MG**	**A040663**	**002**	May 30, 2006
AB		**2.5MG**	**A040663**	**003**	May 30, 2006
AB		**3MG**	**A040663**	**004**	May 30, 2006
AB		**4MG**	**A040663**	**005**	May 30, 2006
AB		**5MG**	**A040663**	**006**	May 30, 2006
AB		**6MG**	**A040663**	**007**	May 30, 2006
AB		**7.5MG**	**A040663**	**008**	May 30, 2006
AB		**10MG**	**A040663**	**009**	May 30, 2006

XENON XE-133

GAS;INHALATION

XENON XE 133

	LANTHEUS MEDCL	10mCi/VIAL	N017284	001	
		20mCi/VIAL	N017284	002	
	MALLINKRODT NUCLEAR	10mCi/VIAL	N018327	001	Mar 09, 1982
		20mCi/VIAL	N018327	002	Mar 09, 1982

ZAFIRLUKAST

TABLET;ORAL

ACCOLATE

AB	**+**	PAR PHARM INC	**10MG**	**N020547**	**003**	Sep 17, 1999
AB	**+!**		**20MG**	**N020547**	**001**	Sep 26, 1996

ZAFIRLUKAST

AB		DR REDDYS LABS LTD	**10MG**	**A090372**	**001**	Nov 18, 2010
AB			**20MG**	**A090372**	**002**	Nov 18, 2010

ZALEPLON

CAPSULE;ORAL

SONATA

AB	**+**	PFIZER	**5MG**	**N020859**	**001**	Aug 13, 1999
AB	**+!**		**10MG**	**N020859**	**002**	Aug 13, 1999

ZALEPLON

AB		AUROBINDO PHARMA	**5MG**	**A078829**	**001**	Jun 06, 2008
AB			**10MG**	**A078829**	**002**	Jun 06, 2008
AB		CIPLA LTD	**5MG**	**A077505**	**001**	Jun 20, 2008
AB			**10MG**	**A077505**	**002**	Jun 20, 2008
AB		HIKMA PHARMS	**5MG**	**A078147**	**001**	Nov 25, 2008
AB			**10MG**	**A078147**	**002**	Nov 25, 2008
AB		ORCHID HLTHCARE	**5MG**	**A090374**	**001**	Sep 17, 2009
AB			**10MG**	**A090374**	**002**	Sep 17, 2009
AB		TEVA PHARMS	**5MG**	**A077239**	**001**	Jun 06, 2008
AB			**10MG**	**A077239**	**002**	Jun 06, 2008
AB		UNICHEM	**5MG**	**A078989**	**001**	Jun 06, 2008
AB			**10MG**	**A078989**	**002**	Jun 06, 2008
AB		WEST-WARD PHARMS INT	**5MG**	**A077237**	**001**	Jun 06, 2008
AB			**10MG**	**A077237**	**002**	Jun 06, 2008

ZANAMIVIR

POWDER;INHALATION

RELENZA

	+!	GLAXOSMITHKLINE	5MG	N021036	001	Jul 26, 1999

ZICONOTIDE ACETATE

INJECTABLE;INTRATHECAL

PRIALT

	+!	TERSERA THERAPS LLC	100MCG/1ML (100MCG/ML)	N021060 002	Dec 28, 2004
	+!		500MCG/20ML (25MCG/ML)	N021060 001	Dec 28, 2004
	+!		500MCG/5ML (100MCG/ML)	N021060 004	Dec 28, 2004

ZIDOVUDINE

CAPSULE;ORAL

RETROVIR

AB	**+!**	VIIV HLTHCARE	**100MG**	**N019655 001**	Mar 19, 1987

ZIDOVUDINE

AB		AUROBINDO PHARMA LTD	**100MG**	**A078128 001**	Mar 27, 2006
AB		CIPLA LTD	**100MG**	**A078349 001**	May 23, 2007

INJECTABLE;INJECTION

RETROVIR

AP	**+!**	VIIV HLTHCARE	**10MG/ML**	**N019951 001**	Feb 02, 1990

ZIDOVUDINE

AP		LUITPOLD	**10MG/ML**	**A091457 001**	May 06, 2010

SYRUP;ORAL

RETROVIR

AA	**+!**	VIIV HLTHCARE	**50MG/5ML**	**N019910 001**	Sep 28, 1989

ZIDOVUDINE

AA		AUROBINDO	**50MG/5ML**	**A077268 001**	Sep 19, 2005
AA		CIPLA LTD	**50MG/5ML**	**A077981 001**	Jun 26, 2008

TABLET;ORAL

ZIDOVUDINE

AB		AUROBINDO	**300MG**	**A077267 001**	Sep 19, 2005
AB		CIPLA	**300MG**	**A090561 001**	Oct 27, 2010
AB	**!**	HETERO LABS LTD III	**300MG**	**A090092 001**	Apr 25, 2008
AB		MYLAN PHARMS INC	**300MG**	**A078922 001**	Feb 14, 2008
AB		WEST-WARD PHARMS INT	**300MG**	**A076844 001**	Sep 19, 2005

ZILEUTON

TABLET;ORAL

ZYFLO

	+!	CHIESI USA INC	600MG	N020471 003	Dec 09, 1996

TABLET, EXTENDED RELEASE;ORAL

ZILEUTON

AB		RISING PHARMS	**600MG**	**A204929 001**	Mar 17, 2017

ZYFLO CR

AB	**+!**	CHIESI USA INC	**600MG**	**N022052 001**	May 30, 2007

ZINC ACETATE

CAPSULE;ORAL

GALZIN

	+	TEVA	EQ 25MG ZINC	N020458 001	Jan 28, 1997
	+!		EQ 50MG ZINC	N020458 002	Jan 28, 1997

ZINC CHLORIDE

INJECTABLE;INJECTION

ZINC CHLORIDE IN PLASTIC CONTAINER

	+!	HOSPIRA	EQ 1MG ZINC/ML	N018959 001	Jun 26, 1986

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

GEODON

AB	**+!**	PFIZER	**EQ 20MG BASE**	**N020825 001**	Feb 05, 2001
AB	**+**		**EQ 40MG BASE**	**N020825 002**	Feb 05, 2001
AB	**+**		**EQ 60MG BASE**	**N020825 003**	Feb 05, 2001
AB	**+**		**EQ 80MG BASE**	**N020825 004**	Feb 05, 2001

ZIPRASIDONE HYDROCHLORIDE

AB		APOTEX INC	**EQ 20MG BASE**	**A077561 001**	Mar 02, 2012
AB			**EQ 40MG BASE**	**A077561 002**	Mar 02, 2012
AB			**EQ 60MG BASE**	**A077561 003**	Mar 02, 2012
AB			**EQ 80MG BASE**	**A077561 004**	Mar 02, 2012
AB		AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A204117 001**	Dec 27, 2016
AB			**EQ 40MG BASE**	**A204117 002**	Dec 27, 2016
AB			**EQ 60MG BASE**	**A204117 003**	Dec 27, 2016
AB			**EQ 80MG BASE**	**A204117 004**	Dec 27, 2016
AB		DR REDDYS LABS INC	**EQ 20MG BASE**	**A077565 001**	Mar 02, 2012
AB			**EQ 40MG BASE**	**A077565 002**	Mar 02, 2012

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

ZIPRASIDONE HYDROCHLORIDE

AB		**EQ 60MG BASE**	**A077565**	**003**	Mar 02, 2012
AB		**EQ 80MG BASE**	**A077565**	**004**	Mar 02, 2012
AB	LUPIN PHARMS	**EQ 20MG BASE**	**A077560**	**001**	Mar 02, 2012
AB		**EQ 40MG BASE**	**A077560**	**002**	Mar 02, 2012
AB		**EQ 60MG BASE**	**A077560**	**003**	Mar 02, 2012
AB		**EQ 80MG BASE**	**A077560**	**004**	Mar 02, 2012
AB	MACLEODS PHARMS LTD	**EQ 20MG BASE**	**A204375**	**001**	Feb 17, 2017
AB		**EQ 40MG BASE**	**A204375**	**002**	Feb 17, 2017
AB		**EQ 60MG BASE**	**A204375**	**003**	Feb 17, 2017
AB		**EQ 80MG BASE**	**A204375**	**004**	Feb 17, 2017
AB	SANDOZ INC	**EQ 20MG BASE**	**A077562**	**001**	Jun 01, 2012
AB		**EQ 40MG BASE**	**A077562**	**002**	Jun 01, 2012
AB		**EQ 60MG BASE**	**A077562**	**003**	Jun 01, 2012
AB		**EQ 80MG BASE**	**A077562**	**004**	Jun 01, 2012
AB	WOCKHARDT LTD	**EQ 20MG BASE**	**A090348**	**001**	Sep 05, 2012
AB		**EQ 40MG BASE**	**A090348**	**002**	Sep 05, 2012
AB		**EQ 60MG BASE**	**A090348**	**003**	Sep 05, 2012
AB		**EQ 80MG BASE**	**A090348**	**004**	Sep 05, 2012
AB	ZYDUS PHARMS USA INC	**EQ 20MG BASE**	**A208988**	**001**	Aug 22, 2017
AB		**EQ 40MG BASE**	**A208988**	**002**	Aug 22, 2017
AB		**EQ 60MG BASE**	**A208988**	**003**	Aug 22, 2017
AB		**EQ 80MG BASE**	**A208988**	**004**	Aug 22, 2017

ZIPRASIDONE MESYLATE

INJECTABLE;INTRAMUSCULAR

GEODON

+!	PFIZER	EQ 20MG BASE/ML	N020919	001	Jun 21, 2002

ZOLEDRONIC ACID

INJECTABLE;IV (INFUSION)

RECLAST

AP	**+!** NOVARTIS	**EQ 5MG BASE/100ML**	**N021817**	**001**	Apr 16, 2007

ZOLEDRONIC

AP	GLAND PHARMA LTD	**EQ 4MG BASE/100ML**	**A205749**	**001**	Jun 29, 2018

ZOLEDRONIC ACID

AP	ACCORD HLTHCARE	**EQ 4MG BASE/5ML**	**A205279**	**001**	Nov 28, 2016
AP	ACTAVIS INC	**EQ 4MG BASE/5ML**	**A202472**	**001**	Mar 04, 2013
AP	AKORN	**EQ 5MG BASE/100ML**	**A200918**	**001**	Aug 21, 2014
AP	AKORN INC	**EQ 4MG BASE/5ML**	**A202548**	**001**	May 22, 2014
AP	APOTEX INC	**EQ 5MG BASE/100ML**	**A204367**	**001**	Dec 24, 2015
AP	AUROBINDO PHARMA LTD	**EQ 4MG BASE/5ML**	**A207751**	**001**	Sep 26, 2016
AP		**EQ 5MG BASE/100ML**	**A209125**	**001**	Dec 08, 2017
AP	BPI LABS LLC	**EQ 4MG BASE/5ML**	**A207341**	**001**	Dec 29, 2017
AP	BRECKENRIDGE PHARM	**EQ 4MG BASE/5ML**	**A091170**	**001**	Mar 04, 2013
AP		**EQ 4MG BASE/5ML**	**A202571**	**001**	May 07, 2013
AP		**EQ 5MG BASE/100ML**	**A202163**	**001**	Aug 05, 2013
AP	CIPLA	**EQ 4MG BASE/100ML**	**A210174**	**001**	Oct 27, 2017
AP	DR REDDYS LABS LTD	**EQ 4MG BASE/5ML**	**A091186**	**001**	Mar 04, 2013
AP		**EQ 4MG BASE/100ML**	**A204344**	**001**	Nov 19, 2018
AP		**EQ 5MG BASE/100ML**	**A091363**	**001**	Mar 29, 2013
AP	EMCURE PHARMS LTD	**EQ 4MG BASE/5ML**	**A201783**	**001**	Mar 12, 2013
AP		**EQ 5MG BASE/100ML**	**A201801**	**001**	Mar 29, 2013
AP	FRESENIUS KABI USA	**EQ 4MG BASE/5ML**	**A091516**	**001**	Apr 23, 2015
AP	GLAND PHARMA LTD	**EQ 4MG BASE/5ML**	**A202930**	**001**	Aug 05, 2013
AP		**EQ 5MG BASE/100ML**	**A204217**	**001**	Aug 18, 2016
AP	HIKMA FARMACEUTICA	**EQ 4MG BASE/5ML**	**A202182**	**001**	Jun 03, 2013
AP	HOSPIRA INC	**EQ 4MG BASE/5ML**	**A090621**	**001**	Mar 19, 2015
AP		**EQ 5MG BASE/100ML**	**A202837**	**001**	Apr 05, 2013
AP	INFORLIFE	**EQ 4MG BASE/100ML**	**N203231**	**001**	Aug 02, 2013
AP		**EQ 5MG BASE/100ML**	**A202828**	**001**	Sep 23, 2013
AP	MYLAN LABS LTD	**EQ 4MG BASE/5ML**	**A202650**	**001**	Mar 04, 2013
AP		**EQ 5MG BASE/100ML**	**A203841**	**001**	Feb 14, 2017
AP		**EQ 5MG BASE/100ML**	**A205254**	**001**	Oct 27, 2017
AP	SAGENT PHARMS	**EQ 4MG BASE/5ML**	**A091493**	**001**	Nov 24, 2014
AP	USV NORTH AMERICA	**EQ 4MG BASE/5ML**	**A202923**	**001**	Sep 04, 2014

ZOMETA

AP	**+!** NOVARTIS	**EQ 4MG BASE/5ML**	**N021223**	**002**	Mar 07, 2003
AP	**+!**	**EQ 4MG BASE/100ML**	**N021223**	**003**	Jun 17, 2011

ZOLEDRONIC ACID
SOLUTION;IV (INFUSION)
ZOLEDRONIC ACID

	HOSPIRA INC	EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML)	N204016	001	Dec 28, 2015

ZOLMITRIPTAN
SPRAY;NASAL
ZOMIG

+	ASTRAZENECA	2.5MG/SPRAY	N021450	003	Sep 16, 2013
+!		5MG/SPRAY	N021450	004	Sep 30, 2003

TABLET;ORAL
ZOLMITRIPTAN

AB	AJANTA PHARMA LTD	**2.5MG**	**A204041**	**001**	May 20, 2016
AB		**5MG**	**A204041**	**002**	May 20, 2016
AB	ALEMBIC PHARMS LTD	**2.5MG**	**A204232**	**001**	Sep 30, 2015
AB		**5MG**	**A204232**	**002**	Sep 30, 2015
AB	AUROBINDO PHARMA LTD	**2.5MG**	**A207021**	**001**	May 11, 2016
AB		**5MG**	**A207021**	**002**	May 11, 2016
AB	GLENMARK GENERICS	**2.5MG**	**A201779**	**001**	May 14, 2013
AB		**5MG**	**A201779**	**002**	May 14, 2013
AB	INVAGEN PHARMS	**2.5MG**	**A204284**	**001**	Apr 09, 2014
AB		**5MG**	**A204284**	**002**	Apr 09, 2014
AB	JUBILANT GENERICS	**2.5MG**	**A202279**	**001**	Nov 20, 2014
AB		**5MG**	**A202279**	**002**	Nov 20, 2014
AB	MACLEODS PHARMS LTD	**2.5MG**	**A203772**	**001**	Sep 30, 2015
AB		**5MG**	**A203772**	**002**	Sep 30, 2015
AB	PLD ACQUISITIONS LLC	**2.5MG**	**A207867**	**001**	Feb 27, 2017
AB		**5MG**	**A207867**	**002**	Feb 27, 2017
AB	TEVA PHARMS USA	**2.5MG**	**A090861**	**001**	Mar 04, 2014
AB		**5MG**	**A090861**	**002**	Mar 04, 2014
AB	TWI PHARMS	**2.5MG**	**A206973**	**001**	Jun 30, 2017
AB		**5MG**	**A206973**	**002**	Jun 30, 2017
AB	ZYDUS PHARMS USA INC	**2.5MG**	**A203019**	**001**	Jul 11, 2018
AB		**5MG**	**A203019**	**002**	Jul 11, 2018

ZOMIG

AB	**+** IPR	**2.5MG**	**N020768**	**001**	Nov 25, 1997
AB	**+!**	**5MG**	**N020768**	**002**	Nov 25, 1997

TABLET, ORALLY DISINTEGRATING;ORAL
ZOLMITRIPTAN

AB	ALEMBIC PHARMS LTD	**2.5MG**	**A205074**	**001**	Dec 01, 2016
AB		**5MG**	**A205074**	**002**	Dec 01, 2016
AB	GLENMARK GENERICS	**2.5MG**	**A202560**	**001**	May 14, 2013
AB		**5MG**	**A202560**	**002**	May 14, 2013
AB	JUBILANT GENERICS	**2.5MG**	**A202956**	**001**	Sep 17, 2015
AB		**5MG**	**A202956**	**002**	Sep 17, 2015
AB	MACLEODS PHARMS LTD	**2.5MG**	**A204336**	**001**	Oct 22, 2015
AB		**5MG**	**A204336**	**002**	Oct 22, 2015
AB	ZYDUS PHARMS USA INC	**2.5MG**	**A202890**	**001**	May 15, 2013
AB		**5MG**	**A202890**	**002**	May 15, 2013

ZOMIG-ZMT

AB	**+** ASTRAZENECA	**2.5MG**	**N021231**	**001**	Feb 13, 2001
AB	**+!**	**5MG**	**N021231**	**002**	Sep 17, 2001

ZOLPIDEM TARTRATE
SPRAY, METERED;ORAL
ZOLPIMIST

+!	MAGNA PHARMS	5MG/SPRAY	N022196	001	Dec 19, 2008

TABLET;ORAL
AMBIEN

AB	**+** SANOFI AVENTIS US	**5MG**	**N019908**	**001**	Dec 16, 1992
AB	**+!**	**10MG**	**N019908**	**002**	Dec 16, 1992

ZOLPIDEM TARTRATE

AB	ACME LABS	**5MG**	**A077214**	**001**	Apr 23, 2007
AB		**10MG**	**A077214**	**002**	Apr 23, 2007
AB	APOTEX INC	**5MG**	**A077884**	**001**	Apr 23, 2007
AB		**10MG**	**A077884**	**002**	Apr 23, 2007
AB	AUROBINDO PHARMA	**5MG**	**A078413**	**001**	May 04, 2007
AB		**10MG**	**A078413**	**002**	May 04, 2007
AB	CIPLA LTD	**5MG**	**A077388**	**001**	Jul 30, 2012
AB		**10MG**	**A077388**	**002**	Jul 30, 2012

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

AB		INVAGEN PHARMS	5MG	A078184	001	Sep 07, 2007
AB			10MG	A078184	002	Sep 07, 2007
AB		MYLAN	5MG	A076578	001	Apr 23, 2007
AB			10MG	A076578	002	Apr 23, 2007
AB		SANDOZ INC	5MG	A077322	001	Apr 23, 2007
AB			10MG	A077322	002	Apr 23, 2007
AB		SUN PHARM INDS INC	5MG	A077359	001	Apr 23, 2007
AB			10MG	A077359	002	Apr 23, 2007
AB		TEVA	5MG	A076410	001	Apr 23, 2007
AB			10MG	A076410	002	Apr 23, 2007
AB		TORRENT PHARMS	5MG	A077903	001	Aug 17, 2007
AB			10MG	A077903	002	Aug 17, 2007
AB		VINTAGE	5MG	A078616	001	Nov 21, 2008
AB			10MG	A078616	002	Nov 21, 2008
AB		WOCKHARDT	5MG	A078426	001	May 15, 2007
AB			10MG	A078426	002	May 15, 2007
AB		YUNG SHIN PHARM	5MG	A077990	001	Apr 23, 2007
AB			10MG	A077990	002	Apr 23, 2007

TABLET;SUBLINGUAL

EDLUAR

AB	+	MYLAN SPECIALITY LP	5MG	N021997	001	Mar 13, 2009
AB	+!		10MG	N021997	002	Mar 13, 2009

INTERMEZZO

AB	+	PURDUE PHARMA	1.75MG	N022328	001	Nov 23, 2011
AB	+!		3.5MG	N022328	002	Nov 23, 2011

ZOLPIDEM TARTRATE

AB		DR REDDYS LABS INC	1.75MG	A204503	001	Nov 18, 2016
AB			3.5MG	A204503	002	Nov 18, 2016
AB		MYLAN PHARMS INC	5MG	A202657	001	Aug 08, 2016
AB			10MG	A202657	002	Aug 08, 2016
AB		NOVEL LABS INC	1.75MG	A204299	001	Jun 03, 2015
AB			3.5MG	A204299	002	Jun 03, 2015
AB		PAR FORM	5MG	A201509	001	Aug 01, 2016
AB			10MG	A201509	002	Aug 01, 2016
AB		PAR PHARM INC	1.75MG	A204229	001	Sep 11, 2017
AB			3.5MG	A204229	002	Sep 11, 2017

TABLET, EXTENDED RELEASE;ORAL

AMBIEN CR

AB	+	SANOFI AVENTIS US	6.25MG	N021774	002	Sep 02, 2005
AB	+!		12.5MG	N021774	001	Sep 02, 2005

ZOLPIDEM TARTRATE

AB		ACTAVIS ELIZABETH	6.25MG	A078179	002	Oct 13, 2010
AB			12.5MG	A078179	001	Jun 06, 2011
AB		ACTAVIS LABS FL INC	6.25MG	A090153	001	Mar 25, 2013
AB			12.5MG	A090153	002	Mar 25, 2013
AB		ANCHEN PHARMS	6.25MG	A078148	002	Apr 14, 2011
AB			12.5MG	A078148	001	Dec 03, 2010
AB		APOTEX INC	6.25MG	A200266	001	Sep 10, 2013
AB			12.5MG	A200266	002	Sep 10, 2013
AB		LUPIN LTD	6.25MG	A078970	001	Sep 11, 2013
AB			12.5MG	A078970	002	Sep 11, 2013
AB		SANDOZ	6.25MG	A090107	001	Jul 01, 2011
AB			12.5MG	A090107	002	Jul 01, 2011
AB		SUN PHARMA GLOBAL	6.25MG	A204170	001	Jan 24, 2017
AB			12.5MG	A204170	002	Jan 24, 2017

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN

AB	+	SUNOVION PHARMS INC	25MG	N020789	003	Aug 22, 2003
AB	+!		100MG	N020789	001	Mar 27, 2000

ZONISAMIDE

AB		APOTEX INC	25MG	A077642	001	Dec 22, 2005
AB			50MG	A077642	002	Dec 22, 2005
AB			100MG	A077642	003	Dec 22, 2005
AB		BLUEPHARMA	25MG	A077813	001	Aug 16, 2006
AB			50MG	A077813	002	Aug 16, 2006
AB			100MG	A077813	003	Aug 16, 2006
AB		GLENMARK GENERICS	25MG	A077651	001	Jan 30, 2006
AB			50MG	A077651	002	Jan 30, 2006

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

AB		**100MG**	**A077651**	**003**	Jan 30, 2006
AB	INVAGEN PHARMS	**25MG**	**A077869**	**001**	May 31, 2006
AB		**50MG**	**A077869**	**002**	May 31, 2006
AB		**100MG**	**A077869**	**003**	May 31, 2006
AB	MYLAN	**25MG**	**A077637**	**001**	Dec 22, 2005
AB		**50MG**	**A077637**	**002**	Dec 22, 2005
AB		**100MG**	**A077637**	**003**	Dec 22, 2005
AB	SUN PHARM INDS (IN)	**25MG**	**A077634**	**001**	Mar 17, 2006
AB		**50MG**	**A077634**	**002**	Mar 17, 2006
AB		**100MG**	**A077634**	**003**	Mar 17, 2006
AB	WOCKHARDT	**25MG**	**A077636**	**003**	Jul 27, 2006
AB		**50MG**	**A077636**	**002**	Jul 27, 2006
AB		**100MG**	**A077636**	**001**	Dec 22, 2005
AB	ZYDUS PHARMS USA	**25MG**	**A077625**	**001**	Oct 16, 2006
AB		**50MG**	**A077625**	**002**	Oct 16, 2006
AB		**100MG**	**A077625**	**003**	Oct 16, 2006

ACETAMINOPHEN					
SUPPOSITORY;RECTAL					
ACEPHEN					
	G AND W LABS	120MG	N018060	001	
		325MG	A072344	001	Mar 27, 1992
		650MG	A072237	001	Mar 27, 1992
ACETAMINOPHEN					
	PERRIGO NEW YORK	120MG	A070607	001	Apr 06, 1987
		650MG	A070608	001	Dec 01, 1986
+	TARO PHARM INDS LTD	120MG	N018337	003	Sep 12, 1983
+		325MG	N018337	002	
+!		650MG	N018337	001	
INFANTS' FEVERALL					
+	TARO PHARM INDS LTD	80MG	N018337	004	Aug 26, 1992
NEOPAP					
	POLYMEDICA	120MG	N016401	001	
TABLET, EXTENDED RELEASE;ORAL					
ACETAMINOPHEN					
	AUROBINDO PHARMA LTD	650MG	A207229	001	Nov 09, 2016
	HERITAGE PHARMA	650MG	A207035	001	May 31, 2018
	OHM LABS	650MG	A076200	001	Mar 19, 2002
	PERRIGO	650MG	A075077	001	Feb 25, 2000
	SUN PHARM INDS LTD	650MG	A078569	001	Dec 14, 2011
TYLENOL					
+!	J AND J CONSUMER INC	650MG	N019872	001	Jun 08, 1994
+!		650MG	N019872	002	Jan 11, 2001
ACETAMINOPHEN; ASPIRIN; CAFFEINE					
TABLET;ORAL					
ACETAMINOPHEN, ASPIRIN AND CAFFEINE					
	PERRIGO	250MG;250MG;65MG	A075794	001	Nov 26, 2001
EXCEDRIN (MIGRAINE)					
+!	GLAXOSMITHKLINE CONS	250MG;250MG;65MG	N020802	001	Jan 14, 1998
ADAPALENE					
GEL;TOPICAL					
DIFFERIN					
+!	GALDERMA LABS LP	0.1%	N020380	002	Jul 08, 2016
ALCOHOL; CHLORHEXIDINE GLUCONATE					
SOLUTION;TOPICAL					
AVAGARD					
+!	3M	61%;1%	N021074	001	Jun 07, 2001
ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE					
TABLET, CHEWABLE;ORAL					
GAVISCON					
+	SANOFI AVENTIS US	80MG;20MG	N018685	001	Dec 09, 1983
ASPIRIN					
CAPSULE;ORAL					
VAZALORE					
+!	PLX PHARMA	325MG	N203697	001	Jan 14, 2013
AVOBENZONE; ECAMSULE; OCTOCRYLENE					
CREAM;TOPICAL					
ANTHELIOS SX					
+!	LOREAL USA	2%;2%;10%	N021502	001	Jul 21, 2006
CAPITAL SOLEIL 15					
+!	LOREAL USA	2%;3%;10%	N021501	001	Oct 02, 2006
AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE					
CREAM;TOPICAL					
ANTHELIOS 20					
+!	LOREAL USA	2%;2%;10%;2%	N021471	001	Oct 05, 2006
ANTHELIOS 40					
+!	LOREAL USA	2%;3%;10%;5%	N022009	001	Mar 31, 2008
+!		2%;3%;10%;5%	N022009	002	Oct 29, 2009

BENTOQUATAM

LOTION;TOPICAL

IVY BLOCK

+!	STAND HOMEOPATH	5%	N020532	001	Aug 26, 1996

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

LUMIFY

+!	BAUSCH AND LOMB INC	0.025%	N208144	001	Dec 22, 2017

BUDESONIDE

SPRAY, METERED;NASAL

BUDESONIDE

	APOTEX INC	0.032MG/SPRAY	A078949	002	Nov 20, 2015

RHINOCORT ALLERGY

+!	ASTRAZENECA PHARMS	0.032MG/SPRAY	N020746	003	Mar 23, 2015

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL

BUTENAFINE HYDROCHLORIDE

	TARO PHARMS	1%	A205181	001	Nov 16, 2017

LOTRIMIN ULTRA

+!	BAYER HEALTHCARE LLC	1%	N021307	001	Dec 07, 2001

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE;ORAL

FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE

	PERRIGO R AND D	800MG;10MG;165MG	A077355	001	Feb 06, 2008
		800MG;10MG;165MG	A204782	001	Aug 29, 2016

PEPCID COMPLETE

+!	J AND J CONSUMER INC	800MG;10MG;165MG	N020958	001	Oct 16, 2000

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

	APOTEX INC	10MG	A207235	001	Aug 12, 2016
	AUROBINDO PHARMA LTD	10MG	A209107	001	Jul 20, 2018
+	BIONPHARMA INC	5MG	N022429	001	Jul 23, 2009
+!		10MG	N022429	004	Jul 23, 2009
	STRIDES PHARMA	10MG	A205291	001	Jul 21, 2017

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	AUROBINDO PHARMA LTD	10MG	A209107	002	Jul 20, 2018
+	BIONPHARMA INC	5MG	N022429	003	Jul 23, 2009
+!		10MG	N022429	002	Jul 23, 2009

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

	AMNEAL PHARMS	5MG/5ML	A090765	002	Oct 07, 2009
	APNAR PHARMA LP	5MG/5ML	A091327	001	Oct 17, 2011
	AUROBINDO PHARMA	5MG/5ML	A090750	002	Feb 02, 2010
	BIO PHARM INC	5MG/5ML	A090474	002	Mar 30, 2009
	LANNETT CO INC	5MG/5ML	A091130	001	Apr 22, 2011
	PERRIGO R AND D	5MG/5ML	A204226	001	Sep 09, 2013
		5MG/5ML	A090254	002	Apr 09, 2008
	TARO	5MG/5ML	A090182	002	Apr 22, 2008
		5MG/5ML	A201546	001	May 20, 2011
	TRIS PHARMA INC	5MG/5ML	A090572	001	Nov 16, 2012

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	AMNEAL PHARMS	5MG/5ML	A090765	001	Oct 07, 2009
	APNAR PHARMA LP	5MG/5ML	A091327	002	Oct 17, 2011
	AUROBINDO PHARMA	5MG/5ML	A090750	001	Feb 02, 2010
	BIO PHARM INC	5MG/5ML	A090474	001	Mar 30, 2009
	LANNETT CO INC	5MG/5ML	A091130	002	Apr 22, 2011
	PERRIGO R AND D	5MG/5ML	A090254	001	Apr 09, 2008
	TARO	5MG/5ML	A090182	001	Apr 22, 2008
		5MG/5ML	A201546	002	May 20, 2011
	TRIS PHARMA INC	5MG/5ML	A090572	002	Nov 16, 2012

CHILDREN'S ZYRTEC ALLERGY

+!	J AND J CONSUMER INC	5MG/5ML	N022155	002	Nov 16, 2007

CHILDREN'S ZYRTEC HIVES RELIEF

+!	J AND J CONSUMER INC	5MG/5ML	N022155	001	Nov 16, 2007

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY					
AMNEAL PHARMS NY	5MG	A078780	001	Jan 21, 2010	
	10MG	A078780	004	Jan 21, 2010	
APOTEX INC	5MG	A078317	001	Dec 27, 2007	
	10MG	A078317	002	Dec 27, 2007	
AUROBINDO PHARMA LTD	5MG	A090760	001	Aug 05, 2015	
	10MG	A090760	003	Aug 05, 2015	
CIPLA LTD	5MG	A077318	001	Jul 25, 2013	
	10MG	A077318	002	Jul 25, 2013	
CONTRACT PHARMACAL	5MG	A076047	001	Dec 27, 2007	
	10MG	A076047	002	Dec 27, 2007	
DR REDDYS LABS LTD	5MG	A078343	004	Jan 15, 2008	
	10MG	A078343	003	Jan 15, 2008	
GRANULES INDIA LTD	10MG	A209274	001	Dec 22, 2017	
IPCA LABS LTD	5MG	A202277	002	Mar 11, 2014	
	10MG	A202277	004	Mar 11, 2014	
MARKSANS PHARMA	5MG	A078933	001	Jun 15, 2010	
	10MG	A078933	002	Jun 15, 2010	
MYLAN	5MG	A076677	001	Dec 27, 2007	
	10MG	A076677	002	Dec 27, 2007	
ORCHID HLTHCARE	5MG	A078862	001	Feb 19, 2009	
	10MG	A078862	002	Feb 19, 2009	
PERRIGO R AND D	5MG	A078336	001	Dec 27, 2007	
	10MG	A078336	002	Dec 27, 2007	
PLD ACQUISITIONS	5MG	A077946	001	Dec 27, 2007	
	10MG	A077946	002	Dec 27, 2007	
SUN PHARM INDS INC	5MG	A077499	001	Dec 27, 2007	
	10MG	A077499	002	Dec 27, 2007	
SUN PHARM INDS LTD	5MG	A077498	001	Dec 27, 2007	
	10MG	A077498	002	Dec 27, 2007	
TARO	5MG	A078072	001	Jul 22, 2009	
	5MG	A078072	003	Jul 22, 2009	
TORRENT PHARMS LLC	5MG	A079191	001	Apr 15, 2010	
	10MG	A079191	004	Apr 15, 2010	
UNICHEM	5MG	A078680	003	Jun 26, 2009	
	10MG	A078680	004	Jun 26, 2009	
UNIQUE PHARM LABS	5MG	A077829	001	Aug 26, 2009	
	10MG	A077829	004	Aug 26, 2009	
WOCKHARDT	5MG	A078427	003	Dec 28, 2007	
	10MG	A078427	004	Dec 28, 2007	
CETIRIZINE HYDROCHLORIDE HIVES					
DR REDDYS LABS LTD	5MG	A078343	001	Jan 15, 2008	
	10MG	A078343	002	Jan 15, 2008	
IPCA LABS LTD	5MG	A202277	001	Mar 11, 2014	
	10MG	A202277	003	Mar 11, 2014	
MARKSANS PHARMA	5MG	A078933	003	Jun 15, 2010	
	10MG	A078933	004	Jun 15, 2010	
MYLAN	5MG	A076677	004	Dec 27, 2007	
	10MG	A076677	003	Dec 27, 2007	
ORCHID HLTHCARE	5MG	A078862	003	Feb 19, 2009	
	10MG	A078862	004	Feb 19, 2009	
PERRIGO R AND D	5MG	A078336	003	Dec 27, 2007	
	10MG	A078336	004	Dec 27, 2007	
SUN PHARM INDS INC	5MG	A077499	003	Dec 27, 2007	
	10MG	A077499	004	Dec 27, 2007	
SUN PHARM INDS LTD	5MG	A077498	003	Dec 27, 2007	
	10MG	A077498	004	Dec 27, 2007	
UNICHEM	5MG	A078680	001	Jun 26, 2009	
	10MG	A078680	002	Jun 26, 2009	
UNIQUE PHARM LABS	5MG	A077829	003	Aug 26, 2009	
!	10MG	A077829	002	Aug 26, 2009	
CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
AMNEAL PHARMS NY	5MG	A078780	003	Jan 21, 2010	
	10MG	A078780	002	Jan 21, 2010	
AUROBINDO PHARMA LTD	5MG	A090760	002	Aug 05, 2015	
	10MG	A090760	004	Aug 05, 2015	
TARO	10MG	A078072	002	Jul 22, 2009	
	10MG	A078072	004	Jul 22, 2009	
TORRENT PHARMS LLC	5MG	A079191	003	Apr 15, 2010	

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL					
CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
		10MG	A079191	002	Apr 15, 2010
ZYRTEC ALLERGY					
+!	J AND J CONSUMER INC	10MG	N019835	004	Nov 16, 2007
TABLET, CHEWABLE;ORAL					
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY					
	JUBILANT GENERICS	5MG	A091116	001	Feb 19, 2015
		10MG	A091116	002	Feb 19, 2015
	NOVEL LABS INC	5MG	A206793	001	Mar 08, 2016
		10MG	A206793	002	Mar 08, 2016
	SANDOZ	5MG	A078692	001	Feb 14, 2008
!		10MG	A078692	002	Feb 14, 2008
	SUN PHARMA GLOBAL	5MG	A090142	001	Aug 30, 2011
		10MG	A090142	002	Aug 30, 2011
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
	JUBILANT GENERICS	5MG	A091116	003	Feb 19, 2015
		10MG	A091116	004	Feb 19, 2015
	SUN PHARMA GLOBAL	5MG	A090142	003	Aug 30, 2011
		10MG	A090142	004	Aug 30, 2011
TABLET, ORALLY DISINTEGRATING;ORAL					
CETIRIZINE HYDROCHLORIDE ALLERGY					
	PERRIGO R AND D	10MG	A205490	001	Sep 02, 2015
ZYRTEC ALLERGY					
+!	J AND J CONSUMER INC	10MG	N022578	001	Sep 03, 2010

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL					
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	IVAX SUB TEVA PHARMS	5MG;120MG	A077170	001	Feb 25, 2008
	PERRIGO R AND D	5MG;120MG	A210719	001	Nov 16, 2018
	PLD ACQUISITIONS	5MG;120MG	A077991	001	Mar 05, 2008
	SUN PHARM INDS LTD	5MG;120MG	A090922	001	Sep 28, 2012
ZYRTEC-D 12 HOUR					
+!	J AND J CONSUMER INC	5MG;120MG	N021150	002	Nov 09, 2007

CHLORHEXIDINE GLUCONATE

AEROSOL, METERED;TOPICAL					
EXIDINE					
+!	XTTRIUM	4%	N019127	001	Dec 24, 1984
CLOTH;TOPICAL					
CHLORHEXIDINE GLUCONATE					
+!	SAGE PRODS	2%	N021669	001	Apr 25, 2005
READYPREP CHG					
	MEDLINE INDUSTRIES	2%	N207964	001	Nov 20, 2018
SOLUTION;TOPICAL					
BRIAN CARE					
	SOAPCO	4%	A071419	001	Dec 17, 1987
CHG SCRUB					
	ECOLAB	4%	N019258	002	Jul 22, 1986
CIDA-STAT					
	ECOLAB	2%	N019258	001	Jul 22, 1986
EXIDINE					
+!	XTTRIUM	2%	N019422	001	Dec 17, 1985
		4%	N019125	001	Dec 24, 1984
HIBICLENS					
+!	MOLNLYCKE HLTH	4%	N017768	001	
HIBISTAT					
+!	MOLNLYCKE HLTH	0.5%	N018300	001	
SPONGE;TOPICAL					
BIOSCRUB					
	GRIFFEN	4%	N019822	001	Mar 31, 1989
CHLORHEXIDINE GLUCONATE					
!	BECTON DICKINSON	4%	A072525	001	Oct 24, 1989

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SOLUTION;TOPICAL

SOLUPREP

+!	3M HEALTH CARE	2%;70%	N208288	001	Aug 08, 2018

SPONGE;TOPICAL

CHLORAPREP ONE-STEP

+!	BECTON DICKINSON CO	2%;70% (3ML)	N020832	001	Jul 14, 2000
+!		2%;70% (10.5ML)	N020832	004	Aug 20, 2003
+!		2%;70% (26ML)	N020832	006	Nov 21, 2006
+!		2%;70% (1ML)	N020832	008	Oct 23, 2008

CHLORAPREP ONE-STEP FREPP

+!	BECTON DICKINSON CO	2%;70% (1.5ML)	N020832	003	Apr 26, 2002

CHLORAPREP WITH TINT

+!	BECTON DICKINSON CO	2%;70% (26ML)	N020832	002	May 03, 2005
+!		2%;70% (10.5ML)	N020832	005	Apr 03, 2006
+!		2%;70% (3ML)	N020832	007	Oct 10, 2006

SWAB;TOPICAL

CHLORAPREP ONE-STEP SEPP

+!	BECTON DICKINSON CO	2%;70% (0.67ML)	N021555	001	Oct 07, 2002

CHLORAPREP SINGLE SWABSTICK

+!	BECTON DICKINSON CO	2%;70% (1.75ML)	N021555	002	May 10, 2005

CHLORAPREP TRIPLE SWABSTICK

+!	BECTON DICKINSON CO	2%;70% (5.25ML)	N021555	003	Jun 10, 2009

PREVANTICS MAXI SWABSTICK

+!	PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005

PREVANTICS SWAB

+!	PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005

PREVANTICS SWABSTICK

+!	PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE;ORAL

CHLOR-TRIMETON

+	BAYER HEALTHCARE LLC	12MG	N007638	002	

CHLORPHENIRAMINE MALEATE

!	AVANTHI INC	12MG	A040829	001	May 13, 2009

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET;ORAL

ADVIL ALLERGY AND CONGESTION RELIEF

+!	PFIZER	4MG;200MG;10MG	N022113	001	Dec 21, 2011

ADVIL MULTI-SYMPTOM COLD & FLU

+!	PFIZER	4MG;200MG;10MG	N022113	002	Apr 28, 2017

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION;ORAL

CHILDREN'S ADVIL ALLERGY SINUS

+!	PFIZER	1MG/5ML;100MG/5ML;15MG/5ML	N021587	001	Feb 24, 2004

TABLET;ORAL

ADVIL ALLERGY SINUS

+!	PFIZER	2MG;200MG;30MG	N021441	001	Dec 19, 2002

CIMETIDINE

TABLET;ORAL

CIMETIDINE

	APOTEX	100MG	A074948	001	Jun 19, 1998
		200MG	A074948	002	Jul 26, 2002
	IVAX SUB TEVA PHARMS	200MG	A075345	001	Jun 16, 1999
	L PERRIGO CO	200MG	A075285	001	Oct 29, 1998

TAGAMET HB

+!	MEDTECH PRODUCTS	200MG	N020238	002	Aug 21, 1996

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

!	L PERRIGO CO	1.34MG	A074512	001	Nov 22, 1995

CLOTRIMAZOLE

CREAM;VAGINAL

CLOTRIMAZOLE

!	ACTAVIS MID ATLANTIC	1%	A074165	001	Jul 16, 1993
	TARO	1%	A072641	001	Dec 04, 1995

CLOTRIMAZOLE

CREAM;VAGINAL

TRIVAGIZOLE 3

	TARO	2%	N021143	001	Apr 12, 2000

CROMOLYN SODIUM

SPRAY, METERED;NASAL

CROMOLYN SODIUM

!	BAUSCH AND LOMB	5.2MG/SPRAY	A075702	001	Jul 03, 2001
	PERRIGO	5.2MG/SPRAY	A075427	001	Dec 12, 2001

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

	ACTAVIS LABS FL	30MG;600MG	A091070	001	Aug 31, 2015
		60MG;1.2GM	A091070	002	Aug 31, 2015
	AMNEAL PHARMS	30MG;600MG	A209692	001	Nov 01, 2018
		60MG;1.2GM	A209692	002	Nov 01, 2018
	AUROBINDO PHARMA LTD	30MG;600MG	A206941	001	Mar 17, 2017
		60MG;1.2GM	A206941	002	Mar 17, 2017
	PERRIGO R AND D	30MG;600MG	A207602	002	Mar 05, 2018
		60MG;1.2GM	A207602	001	Mar 05, 2018

MUCINEX DM

+	RB HLTH	30MG;600MG	N021620	002	Apr 29, 2004
+!		60MG;1.2GM	N021620	001	Apr 29, 2004

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

DELSYM

+!	RB HLTH	EQ 30MG HYDROBROMIDE/5ML	N018658	001	Oct 08, 1982

DEXTROMETHORPHAN POLISTIREX

	AMNEAL PHARMS LLC	EQ 30MG HYDROBROMIDE/5ML	A203133	001	Jul 28, 2017
	TRIS PHARMA INC	EQ 30MG HYDROBROMIDE/5ML	A091135	001	May 25, 2012

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET;ORAL

ADVIL PM

+!	PFIZER	38MG;200MG	N021394	001	Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE CITRATE

	DR REDDYS LABS LTD	38MG;200MG	A090619	001	Jul 08, 2009
	PERRIGO R AND D	38MG;200MG	A079113	001	Dec 22, 2008

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

ADVIL PM

+!	PFIZER	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	N021393	001	Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

	BIONPHARMA INC	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A090397	001	Nov 22, 2010
	STRIDES PHARMA	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A200888	001	Mar 05, 2012

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

ALEVE PM

+!	BAYER HLTHCARE	25MG;220MG	N205352	001	Jan 17, 2014

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

	AMNEAL PHARMS CO	25MG;220MG	A209726	001	Oct 23, 2018

DOCOSANOL

CREAM;TOPICAL

ABREVA

+!	GLAXOSMITHKLINE	10%	N020941	001	Jul 25, 2000

DOCOSANOL

	ACTAVIS LABS UT INC	10%	A208754	001	Nov 19, 2018

DOXYLAMINE SUCCINATE

TABLET;ORAL

DOXYLAMINE SUCCINATE

	LNK	25MG	A040564	001	Aug 27, 2004
	PERRIGO	25MG	A040167	001	Sep 18, 1996

UNISOM

+!	CHATTEM	25MG	N018066	001	

EPINEPHRINE

AEROSOL, METERED;INHALATION

PRIMATENE MIST

+!	ARMSTRONG PHARMS	0.125MG/INH	N205920	001	Nov 07, 2018

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

	AUROBINDO PHARMA LTD	EQ 20MG BASE	A209339	001	Oct 16, 2017
	DR REDDYS LABS LTD	EQ 20MG BASE	A207673	001	May 15, 2018
	PERRIGO R AND D	EQ 20MG BASE	A207193	001	Aug 18, 2017

NEXIUM 24HR

+!	ASTRAZENECA LP	EQ 20MG BASE	N204655	001	Mar 28, 2014

TABLET, DELAYED RELEASE;ORAL

NEXIUM 24HR

+!	ASTRAZENECA LP	EQ 20MG BASE	N207920	001	Nov 23, 2015

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

	AUROBINDO PHARMA LTD	10MG	A206531	001	Apr 26, 2016
		20MG	A206531	002	Apr 26, 2016
	DR REDDYS LABS LTD	10MG	A075758	001	Aug 17, 2001
		20MG	A077367	001	Sep 25, 2006
	IVAX SUB TEVA PHARMS	10MG	A075512	001	Jul 26, 2001
	MYLAN	10MG	A075674	001	Dec 21, 2001
	PERRIGO	10MG	A075400	001	Mar 18, 2005
	PERRIGO R AND D	20MG	A077351	001	Sep 25, 2006
	SUN PHARM INDS LTD	10MG	A090283	001	Nov 17, 2009
		20MG	A090283	002	Nov 17, 2009
	TEVA	10MG	A075312	001	May 31, 2001
	WOCKHARDT	10MG	A077146	001	Mar 07, 2005
		20MG	A090837	001	Aug 04, 2010

PEPCID AC

+	J AND J CONSUMER INC	10MG	N020325	001	Apr 28, 1995
		10MG	N020902	001	Aug 05, 1999
+!		20MG	N020325	002	Sep 23, 2003

TABLET, CHEWABLE;ORAL

FAMOTIDINE

	PERRIGO	10MG	A075715	001	Aug 22, 2003

PEPCID AC

+!	J AND J CONSUMER INC	20MG	N020801	002	Dec 17, 2007

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL

CHILDREN'S ALLEGRA ALLERGY

+!	SANOFI AVENTIS US	30MG/5ML	N201373	001	Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

	ACTAVIS MID ATLANTIC	30MG/5ML	A203330	001	Nov 18, 2014

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

!	ACTAVIS MID ATLANTIC	30MG/5ML	A203330	002	Nov 18, 2014

TABLET;ORAL

ALLEGRA ALLERGY

+	SANOFI AVENTIS US	60MG	N020872	007	Jan 24, 2011
+!		180MG	N020872	010	Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

	AUROLIFE PHARMA LLC	30MG	A202039	001	Nov 19, 2014
	DR REDDYS LABS LTD	30MG	A076502	004	Apr 12, 2011
	HETERO LABS LTD V	30MG	A204097	001	Aug 19, 2016
	MYLAN	30MG	A077081	004	Jul 21, 2011
	SUN PHARM INDS	30MG	A091567	002	Feb 06, 2012
	TEVA	30MG	A076447	004	Apr 13, 2011
	WOCKHARDT LTD	30MG	A079112	002	Feb 08, 2012

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

	DR REDDYS LABS LTD	30MG	A076502	005	Apr 12, 2011
	MYLAN	30MG	A077081	005	Jul 21, 2011
	SUN PHARM INDS	30MG	A091567	001	Feb 06, 2012
	TEVA	30MG	A076447	005	Apr 13, 2011

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES					
	WOCKHARDT LTD	30MG	A079112	001	Feb 08, 2012
FEXOFENADINE HYDROCHLORIDE ALLERGY					
	AUROLIFE PHARMA LLC	60MG	A202039	002	Nov 19, 2014
		180MG	A202039	003	Nov 19, 2014
	DR REDDYS LABS LTD	60MG	A076502	006	Apr 12, 2011
		180MG	A076502	008	Apr 12, 2011
	HETERO LABS LTD V	60MG	A204097	002	Aug 19, 2016
		180MG	A204097	003	Aug 19, 2016
	MYLAN	60MG	A077081	006	Jul 21, 2011
		180MG	A077081	008	Jul 21, 2011
	SCIEGEN PHARMS INC	60MG	A204507	002	Sep 16, 2015
		180MG	A204507	003	Sep 16, 2015
	SUN PHARM INDS	60MG	A091567	004	Feb 06, 2012
		180MG	A091567	006	Feb 06, 2012
	TEVA	60MG	A076447	006	Apr 13, 2011
		180MG	A076447	008	Apr 13, 2011
	UNIQUE PHARM LABS	180MG	A210137	001	Aug 13, 2018
	WOCKHARDT LTD	60MG	A079112	004	Feb 08, 2012
		180MG	A079112	006	Feb 08, 2012
FEXOFENADINE HYDROCHLORIDE HIVES					
	DR REDDYS LABS LTD	60MG	A076502	007	Apr 12, 2011
		180MG	A076502	009	Apr 12, 2011
	MYLAN	60MG	A077081	007	Jul 21, 2011
		180MG	A077081	009	Jul 21, 2011
	SCIEGEN PHARMS INC	60MG	A204507	004	Sep 16, 2015
		180MG	A204507	005	Sep 16, 2015
	SUN PHARM INDS	60MG	A091567	003	Feb 06, 2012
		180MG	A091567	005	Feb 06, 2012
	TEVA	60MG	A076447	007	Apr 13, 2011
	WOCKHARDT LTD	60MG	A079112	003	Feb 08, 2012
		180MG	A079112	005	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION					
+!	SANOFI AVENTIS US	60MG;120MG	N020786	002	Jan 24, 2011
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION					
+!	SANOFI AVENTIS US	180MG;240MG	N021704	002	Jan 24, 2011
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	AUROBINDO PHARMA LTD	60MG;120MG	A209116	001	Oct 30, 2017
	DR REDDYS LABS LTD	60MG;120MG	A076667	001	Nov 18, 2014
		180MG;240MG	A079043	002	Jun 22, 2011
	SUN PHARMA GLOBAL	60MG;120MG	A090818	001	Jan 29, 2015

FLUTICASONE FUROATE

SPRAY, METERED;NASAL

FLONASE SENSIMIST ALLERGY RELIEF					
+!	GLAXOSMITHKLINE CONS	0.0275MG/SPRAY	N022051	002	Aug 02, 2016

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLONASE ALLERGY RELIEF					
+!	GLAXOSMITHKLINE CONS	0.05MG/SPRAY	N205434	001	Jul 23, 2014
FLUTICASONE PROPIONATE					
	APOTEX INC	0.05MG/SPRAY	A208150	001	Feb 29, 2016
	WEST-WARD PHARMS INT	0.05MG/SPRAY	A207957	001	May 26, 2016

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN					
	ACTAVIS LABS FL	1.2GM	A091009	002	Sep 03, 2015
	AMNEAL PHARMS	600MG	A207342	001	Jul 11, 2018
		1.2GM	A207342	002	Jul 11, 2018
	GUARDIAN DRUG	600MG	A209215	001	Sep 06, 2017
		1.2GM	A209215	002	Sep 06, 2017
	OHM LABS INC	600MG	A209254	001	Jul 16, 2018
		1.2GM	A209254	002	Jul 16, 2018
	PERRIGO R AND D	600MG	A078912	001	Nov 23, 2011

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

MUCINEX					
+	RB HLTH	600MG	N021282	001	Jul 12, 2002
+!		1.2GM	N021282	002	Dec 18, 2002

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	ACTAVIS LABS FL	600MG;60MG	A091071	001	May 27, 2015
		1.2GM;120MG	A091071	002	May 27, 2015
	DR REDDYS LABS LTD	600MG;60MG	A208369	001	Dec 29, 2017
		1.2GM;120MG	A208369	002	Dec 29, 2017
MUCINEX D					
+	RB HLTH	600MG;60MG	N021585	001	Jun 22, 2004
+!		1.2GM;120MG	N021585	002	Jun 22, 2004

IBUPROFEN

CAPSULE;ORAL

ADVIL LIQUI-GELS					
+!	PFIZER	EQ 200MG FREE ACID AND POTASSIUM SALT	N020402	001	Apr 20, 1995
ADVIL MIGRAINE LIQUI-GELS					
+!	PFIZER	EQ 200MG FREE ACID AND POTASSIUM SALT	N020402	002	Mar 16, 2000
IBUPROFEN					
	AMNEAL PHARMS	EQ 200MG FREE ACID AND POTASSIUM SALT	A202300	001	Dec 23, 2011
	ASCENT PHARMS INC	EQ 200MG FREE ACID AND POTASSIUM SALT	A206999	001	Dec 21, 2017
	AUROBINDO PHARMA LTD	EQ 200MG FREE ACID AND POTASSIUM SALT	A207753	001	Jun 29, 2018
	BIONPHARMA INC	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009
	HUMANWELL PURACAP	EQ 200MG FREE ACID AND POTASSIUM SALT	A206568	001	Jun 21, 2016
	MARKSANS PHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT	A079205	001	Jun 26, 2009
	P AND L DEV LLC	EQ 200MG FREE ACID AND POTASSIUM SALT	A077338	001	Jul 10, 2009
	SOFGEN PHARMS	EQ 200MG FREE ACID AND POTASSIUM SALT	A203599	001	Sep 07, 2016
	STRIDES PHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT	A204469	001	Mar 28, 2018
MIDOL LIQUID GELS					
+!	BIONPHARMA INC	200MG	N021472	001	Oct 18, 2002

SUSPENSION;ORAL

CHILDREN'S ADVIL					
	PFIZER	100MG/5ML	N020589	001	Jun 27, 1996
CHILDREN'S ADVIL-FLAVORED					
	PFIZER	100MG/5ML	N020589	002	Nov 07, 1997
CHILDREN'S ELIXSURE					
	MOBERG PHARMA NORTH	100MG/5ML	N021604	001	Jan 07, 2004
CHILDREN'S IBUPROFEN					
	PERRIGO	100MG/5ML	A074937	001	Dec 22, 1998
CHILDREN'S MOTRIN					
+!	J AND J CONSUMER INC	100MG/5ML	N020516	001	Jun 16, 1995
IBUPROFEN					
	ACTAVIS MID ATLANTIC	100MG/5ML	A074916	001	Apr 30, 1999
	APTAPHARMA INC	100MG/5ML	A210602	001	Nov 23, 2018
	ARISE PHARMS	100MG/5ML	A200457	001	Aug 18, 2011
	AUROBINDO PHARMA LTD	100MG/5ML	A209179	001	Apr 17, 2018
	GUARDIAN DRUG	100MG/5ML	A210149	001	Aug 17, 2018
	TARO	100MG/5ML	A209207	001	Jun 27, 2017

SUSPENSION/DROPS;ORAL

CHILDREN'S MOTRIN					
+!	J AND J CONSUMER INC	40MG/ML	N020603	001	Jun 10, 1996
IBUPROFEN					
	GUARDIAN DRUG	40MG/ML	A210755	001	Sep 26, 2018
	L PERRIGO CO	40MG/ML	A075217	001	Dec 16, 1998
	TRIS PHARMA INC	40MG/ML	A079058	001	Aug 31, 2009
PEDIATRIC ADVIL					
+!	PFIZER	100MG/2.5ML	N020812	001	Jan 30, 1998

TABLET;ORAL

ADVIL					
	PFIZER	200MG	N018989	001	May 18, 1984
IBU-TAB 200					
	ALRA	200MG	A071057	001	Aug 11, 1988
IBUPROFEN					
	AMNEAL PHARMS	200MG	A079233	001	Mar 18, 2014

IBUPROFEN

TABLET;ORAL					
IBUPROFEN					
	AMNEAL PHARMS NY	200MG	A071333	001	Feb 17, 1987
		200MG	A072199	001	May 23, 1988
	AUROBINDO PHARMA LTD	200MG	A208865	001	Nov 08, 2017
	AVEMA PHARMA	200MG	A076460	001	Nov 26, 2003
	CONTRACT PHARMACAL	200MG	A072299	001	Jul 01, 1988
	DR REDDYS LA	200MG	A075661	001	Dec 12, 2001
	DR REDDYS LABS INC	200MG	A076117	001	Nov 20, 2001
	GRANULES INDIA	200MG	A079174	001	Dec 10, 2010
	GRANULES INDIA LTD	200MG	A202312	001	Oct 07, 2016
	LNK	200MG	A075010	001	Mar 01, 1999
		200MG	A075139	001	Mar 01, 1999
	MARKSANS PHARMA	200MG	A091237	001	Feb 08, 2011
		200MG	A091239	001	Feb 01, 2011
	MCNEIL	200MG	A073019	001	Mar 30, 1994
	MERRO PHARM	200MG	A070985	001	Oct 02, 1987
	OHM	200MG	A071163	001	Jul 15, 1986
	PAR PHARM	200MG	A070481	001	Sep 24, 1986
	PERRIGO	200MG	A072096	001	Dec 08, 1987
		200MG	A075995	001	Mar 14, 2002
	PERRIGO R AND D	200MG	A077349	001	Jun 21, 2005
	SHANDONG XINHUA	200MG	A206990	001	Aug 21, 2018
		200MG	A207095	001	May 05, 2017
	STRIDES PHARMA	200MG	A079129	001	Mar 28, 2011
		200MG	A091355	001	Apr 04, 2011
		200MG	A206989	001	Jun 29, 2018
		200MG	A207052	001	May 30, 2017
	VINTAGE PHARMS	200MG	A071229	001	Apr 01, 1987
		200MG	A071639	001	Feb 02, 1988
IBUPROHM					
	OHM LABS	200MG	A071214	001	Dec 01, 1986
JUNIOR STRENGTH ADVIL					
	PFIZER	100MG	N020267	002	Dec 13, 1996
JUNIOR STRENGTH IBUPROFEN					
	L PERRIGO CO	100MG	A075367	001	Apr 22, 1999
JUNIOR STRENGTH MOTRIN					
	J AND J CONSUMER INC	100MG	N020602	001	Jun 10, 1996
MOTRIN IB					
+!	J AND J CONSUMER INC	200MG	N019012	003	Dec 17, 1990
TAB-PROFEN					
	PERRIGO	200MG	A072095	001	Dec 08, 1987
TABLET, CHEWABLE;ORAL					
CHILDREN'S ADVIL					
	PFIZER	50MG	N020944	001	Dec 18, 1998
IBUPROFEN					
!	PERRIGO	100MG	A076359	002	Jan 16, 2004
JUNIOR STRENGTH ADVIL					
	PFIZER	100MG	N020944	002	Dec 18, 1998

IBUPROFEN SODIUM

TABLET;ORAL					
ADVIL					
+!	PFIZER CONS HLTHCARE	EQ 200MG BASE	N201803	001	Jun 12, 2012
IBUPROFEN SODIUM					
	PERRIGO R AND D	EQ 200MG BASE	A206581	001	Aug 03, 2015

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET;ORAL					
ADVIL CONGESTION RELIEF					
+!	PFIZER	200MG;10MG	N022565	001	May 27, 2010
IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE					
	PERRIGO R AND D	200MG;10MG	A203200	001	Jul 03, 2014

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL					
ADVIL COLD AND SINUS					
+!	PFIZER	EQ 200MG FREE ACID AND POTASSIUM SALT;30MG	N021374	001	May 30, 2002
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	AUROBINDO PHARMA LTD	EQ 200MG FREE ACID AND POTASSIUM SALT;30MG	A209235	001	Dec 01, 2017
SUSPENSION;ORAL					
CHILDREN'S ADVIL COLD					
	PFIZER	100MG/5ML;15MG/5ML	N021373	001	Apr 18, 2002
CHILDREN'S MOTRIN COLD					
+!	J AND J CONSUMER INC	100MG/5ML;15MG/5ML	N021128	001	Aug 01, 2000
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	PERRIGO	100MG/5ML;15MG/5ML	A076478	001	Nov 05, 2003
TABLET;ORAL					
ADVIL COLD AND SINUS					
+!	PFIZER	200MG;30MG	N019771	001	Sep 19, 1989
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	DR REDDYS LABS LTD	200MG;30MG	A077628	001	Aug 14, 2006
IBUPROHM COLD AND SINUS					
	OHM LABS	200MG;30MG	A074567	001	Apr 17, 2001
SINE-AID IB					
	J AND J CONSUMER INC	200MG;30MG	N019899	001	Dec 31, 1992

INSULIN RECOMBINANT HUMAN

INJECTABLE;INJECTION					
HUMULIN R PEN					
+!	LILLY	100 UNITS/ML	N018780	005	Aug 06, 1998
NOVOLIN R					
+!	NOVO NORDISK INC	100 UNITS/ML	N019938	001	Jun 25, 1991

INSULIN RECOMBINANT HUMAN

INJECTABLE;INJECTION					
HUMULIN R					
+!	LILLY	100 UNITS/ML	N018780	001	Oct 28, 1982

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE;INJECTION					
HUMULIN 70/30					
+!	LILLY	30 UNITS/ML;70 UNITS/ML	N019717	001	Apr 25, 1989
HUMULIN 70/30 PEN					
+!	LILLY	30 UNITS/ML;70 UNITS/ML	N019717	002	Aug 06, 1998
NOVOLIN 70/30					
+!	NOVO NORDISK INC	30 UNITS/ML;70 UNITS/ML	N019991	001	Jun 25, 1991

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE;INJECTION					
HUMULIN N					
+!	LILLY	100 UNITS/ML	N018781	001	Oct 28, 1982
NOVOLIN N					
+!	NOVO NORDISK INC	100 UNITS/ML	N019959	001	Jul 01, 1991

IODINE POVACRYLEX; ISOPROPYL ALCOHOL

SPONGE;TOPICAL					
DURAPREP					
+!	3M	EQ 0.7% IODINE;74% (6ML)	N021586	001	Sep 29, 2006
+!		EQ 0.7% IODINE;74% (26ML)	N021586	002	Sep 29, 2006

KETOCONAZOLE

SHAMPOO;TOPICAL					
NIZORAL A-D					
+!	JOHNSON AND JOHNSON	1%	N020310	001	Oct 10, 1997

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC					
ALAWAY					
+!	BAUSCH AND LOMB	EQ 0.025% BASE	N021996	001	Dec 01, 2006
+		EQ 0.035% BASE	N021996	002	Feb 11, 2015
KETOTIFEN FUMARATE					
	AKORN	EQ 0.025% BASE	A077958	001	Jul 26, 2007
!	ALCON PHARMS LTD	EQ 0.025% BASE	A077200	001	Sep 02, 2008

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

	DR REDDYS LABS LTD	15MG	A202194	001	May 18, 2012
	LANNETT CO INC	15MG	A207157	001	Sep 29, 2017
	MYLAN PHARMS INC	15MG	A203187	001	Jun 01, 2016
	NATCO PHARMA LTD	15MG	A203306	001	Jan 13, 2016
	PERRIGO R AND D	15MG	A202319	001	May 18, 2012
	WOCKHARDT LTD	15MG	A202727	001	May 18, 2012

PREVACID 24 HR

+!	GLAXOSMITHKLINE CONS	15MG	N022327	001	May 18, 2009

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE

	DEXCEL PHARMA	15MG	N208025	001	Jun 07, 2016

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

XYZAL ALLERGY 24HR

+!	SANOFI AVENTIS US	2.5MG/5ML	N209090	001	Jan 31, 2017

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

	DR REDDYS LABS LTD	5MG	A210375	001	Jan 19, 2018
	MICRO LABS	5MG	A211551	001	Nov 20, 2018

XYZAL ALLERGY 24HR

+!	SANOFI AVENTIS US	5MG	N209089	001	Jan 31, 2017

LEVONORGESTREL

TABLET;ORAL

ATHENTIA NEXT

	AUROBINDO PHARMA LTD	1.5MG	A206867	001	Dec 08, 2015

FALLBACK SOLO

	LUPIN LTD	1.5MG	A201446	001	Jun 19, 2014

HER STYLE

	NOVAST LABS	1.5MG	A207976	001	Mar 11, 2016

LEVONORGESTREL

	AMNEAL PHARMS	1.5MG	A204044	001	Jul 03, 2018
	APOTEX INC	1.5MG	A205329	001	Sep 18, 2018
	FDN CONSUMER	1.5MG	A200670	001	Jul 12, 2012
	GLENMARK PHARMS LTD	1.5MG	A207044	001	Mar 25, 2016
	LOTUS PHARM CO LTD	0.75MG	A202684	001	Sep 02, 2016
	MYLAN LABS LTD	0.75MG	A202740	001	Sep 02, 2016
		1.5MG	A202739	001	Oct 31, 2014
	NOVEL LABS INC	1.5MG	A202508	001	Feb 22, 2013
	OC PHARMA	1.5MG	A202380	001	May 29, 2015
!	PERRIGO R AND D	0.75MG	A090740	001	Dec 30, 2010
		1.5MG	A202334	001	Aug 20, 2014
	RECKITT BENCKISER	1.5MG	A202246	001	Jun 05, 2015

OPCICON ONE-STEP

	SUN PHARM INDS LTD	1.5MG	A202635	001	Sep 11, 2014

PLAN B ONE-STEP

+!	FDN CONSUMER	1.5MG	N021998	001	Jul 10, 2009

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

+	BIONPHARMA INC	1MG	N021855	001	Aug 04, 2005
+!		2MG	N021855	002	Aug 04, 2005

SOLUTION;ORAL

IMODIUM A-D

+!	J AND J CONSUMER INC	1MG/5ML	N019487	001	Mar 01, 1988

LOPERAMIDE HYDROCHLORIDE

	HI TECH PHARMA	1MG/5ML	A074352	001	Nov 17, 1995
	PERRIGO	1MG/5ML	A073243	001	Jan 21, 1992
	WOCKHARDT BIO AG	1MG/5ML	A074730	001	Aug 28, 1997

SUSPENSION;ORAL

IMODIUM A-D

+!	J AND J CONSUMER INC	1MG/7.5ML	N019487	002	Jul 08, 2004

LOPERAMIDE HYDROCHLORIDE

	PERRIGO R AND D	1MG/7.5ML	A091292	001	May 20, 2011

LOPERAMIDE HYDROCHLORIDE

TABLET;ORAL					
IMODIUM A-D					
+!	J AND J CONSUMER INC	2MG	N019860	001	Nov 22, 1989
LOPERAMIDE HYDROCHLORIDE					
	AUROBINDO PHARMA LTD	2MG	A206548	001	Dec 15, 2015
	L PERRIGO CO	2MG	A075232	001	Jan 06, 2000
	LNK	2MG	A076497	001	Jun 10, 2003
	OHM LABS	2MG	A074091	001	Dec 10, 1992

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL					
IMODIUM MULTI-SYMPTOM RELIEF					
+!	J AND J CONSUMER INC	2MG;125MG	N021140	001	Nov 30, 2000
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE					
	PERRIGO R AND D	2MG;125MG	A209837	001	Sep 05, 2018
	SUN PHARM INDS LTD	2MG;125MG	A077500	001	Sep 06, 2006
TABLET, CHEWABLE;ORAL					
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE					
!	PERRIGO	2MG;125MG	A076029	001	Aug 30, 2002

LORATADINE

CAPSULE;ORAL					
CLARITIN					
+!	BAYER HEALTHCARE LLC	10MG	N021952	001	Jun 16, 2008
LORATADINE					
	BIONPHARMA INC	10MG	A202538	001	Dec 21, 2018
	MARKSANS PHARMA	10MG	A206214	001	Sep 23, 2016
SUSPENSION;ORAL					
LORATADINE					
+!	TARO	1MG/ML	N021734	001	Oct 04, 2005
SYRUP;ORAL					
CLARITIN					
+!	BAYER HEALTHCARE LLC	1MG/ML	N020641	002	Nov 27, 2002
LORATADINE					
	AUROBINDO PHARMA LTD	1MG/ML	A208931	001	Jun 29, 2018
	LANNETT CO INC	1MG/ML	A077421	001	Jun 29, 2006
	PERRIGO	1MG/ML	A075728	001	Aug 20, 2004
	TARO	1MG/ML	A076805	001	Aug 20, 2004
	TARO PHARM	1MG/ML	A201865	001	Jul 31, 2015
	TEVA	1MG/ML	A075505	001	Nov 07, 2003
	WOCKHARDT BIO AG	1MG/ML	A075815	001	Aug 20, 2004
TABLET;ORAL					
CLARITIN					
+!	BAYER HEALTHCARE LLC	10MG	N019658	002	Nov 27, 2002
CLARITIN HIVES RELIEF					
+!	BAYER HEALTHCARE LLC	10MG	N019658	003	Nov 19, 2003
LORATADINE					
	APOTEX INC	10MG	A076471	001	Feb 14, 2006
	AUROBINDO PHARMA LTD	10MG	A208314	001	Apr 16, 2018
	MYLAN	10MG	A075790	001	Nov 07, 2008
		10MG	A076154	001	Aug 20, 2003
		10MG	A078447	001	Aug 12, 2011
	PERRIGO	10MG	A076301	001	Jun 25, 2004
	PLD ACQUISITIONS LLC	10MG	A075209	001	Jan 21, 2003
	SUN PHARM INDS LTD	10MG	A076134	001	Aug 18, 2003
TABLET, CHEWABLE;ORAL					
CHILDREN'S CLARITIN					
+!	BAYER HEALTHCARE LLC	5MG	N021891	001	Aug 23, 2006
CLARITIN					
+	BAYER HEALTHCARE LLC	10MG	N021891	002	Nov 21, 2018
LORATADINE					
	SUN PHARMA GLOBAL	5MG	A210088	001	Apr 16, 2018

LORATADINE

TABLET, ORALLY DISINTEGRATING;ORAL

ALAVERT					
	PFIZER	10MG	N021375	001	Dec 19, 2002
CLARITIN HIVES RELIEF REDITAB					
+!	BAYER HEALTHCARE LLC	10MG	N020704	003	Nov 19, 2003
CLARITIN REDITABS					
+!	BAYER HEALTHCARE LLC	5MG	N021993	001	Dec 12, 2006
+!		10MG	N020704	002	Nov 27, 2002
LORATADINE					
	ACTAVIS LABS FL INC	10MG	A075990	001	Nov 03, 2003
	AUROBINDO PHARMA LTD	10MG	A208477	001	Apr 11, 2018
	PERRIGO PHARMA INTL	10MG	A076011	001	Sep 29, 2003
	PFIZER	10MG	A075822	001	Feb 10, 2003
LORATADINE REDIDOSE					
	SUN PHARM INDS LTD	10MG	A077153	001	Apr 11, 2007

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CLARITIN-D					
+!	BAYER HEALTHCARE LLC	5MG;120MG	N019670	002	Nov 27, 2002
CLARITIN-D 24 HOUR					
+!	BAYER HEALTHCARE LLC	10MG;240MG	N020470	002	Nov 27, 2002
LORATADINE AND PSEUDOEPHEDRINE SULFATE					
	ACTAVIS LABS FL INC	10MG;240MG	A075706	001	Feb 21, 2003
	PERRIGO PHARMA INTL	5MG;120MG	A076050	001	Jan 30, 2003
		10MG;240MG	A075989	001	Mar 04, 2004
	SUN PHARM INDS LTD	10MG;240MG	A076557	001	Sep 22, 2004

MENTHOL; METHYL SALICYLATE

PATCH;TOPICAL

SALONPAS					
+!	HISAMITSU PHARM CO	3%;10%	N022029	001	Feb 20, 2008
+		3%;10%	N022029	002	Nov 05, 2012

MICONAZOLE NITRATE

CREAM;TOPICAL, VAGINAL

MICONAZOLE 3 COMBINATION PACK					
	PERRIGO	2%,4%	A076357	001	Mar 30, 2004
MONISTAT 3 COMBINATION PACK					
+	MEDTECH PRODUCTS	2%,4%	N021261	003	Jun 17, 2003
MONISTAT 3 COMBINATION PACK (PREFILLED)					
+!	MEDTECH PRODUCTS	2%,4%	N021261	001	Feb 02, 2001

CREAM;VAGINAL

MICONAZOLE 3					
	TARO	4%	A076773	001	Mar 02, 2005
MICONAZOLE 7					
	ACTAVIS MID ATLANTIC	2%	A074164	001	Mar 29, 1996
MICONAZOLE NITRATE					
	G AND W LABS INC	2%	A074366	001	Feb 22, 1996
	PERRIGO	2%	A074760	001	May 15, 1997
	PERRIGO R AND D	4%	A091366	001	Jan 15, 2010
	TARO PHARMS	2%	A074444	001	Jan 13, 1997
MONISTAT 3					
+!	MEDTECH PRODUCTS	4%	N020827	001	Mar 30, 1998
MONISTAT 7					
+!	MEDTECH PRODUCTS	2%	N017450	002	Feb 15, 1991

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK					
	ACTAVIS MID ATLANTIC	2%,200MG	A074926	001	Apr 16, 1999
MICONAZOLE NITRATE					
	PERRIGO R AND D	2%,1.2GM	A079114	001	Jun 02, 2010
MICONAZOLE NITRATE COMBINATION PACK					
	PERRIGO	2%,200MG	A075329	001	Apr 20, 1999
MONISTAT 1 COMBINATION PACK					
+!	MEDTECH PRODUCTS	2%,1.2GM	N021308	001	Jun 29, 2001
MONISTAT 3 COMBINATION PACK					
+!	MEDTECH PRODUCTS	2%,200MG	N020670	002	Apr 16, 1996

MICONAZOLE NITRATE

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

MONISTAT 7 COMBINATION PACK					
+!	MEDTECH PRODUCTS	2%,100MG	N020288	002	Apr 26, 1993
SUPPOSITORY;VAGINAL					
MICONAZOLE NITRATE					
	ACTAVIS PHARMA	100MG	A073507	001	Nov 19, 1993
	G AND W LABS	100MG	A074414	001	Apr 30, 1997
!	PERRIGO	100MG	A074395	001	Mar 20, 1997
MONISTAT 7					
+!	MEDTECH PRODUCTS	100MG	N018520	002	Feb 15, 1991

MINOXIDIL

AEROSOL, FOAM;TOPICAL					
MEN'S ROGAINE					
+!	JOHNSON AND JOHNSON	5%	N021812	001	Jan 20, 2006
MINOXIDIL					
	PERRIGO ISRAEL	5%	A091344	001	Apr 28, 2011
MINOXIDIL (FOR MEN)					
	TARO PHARM	5%	A209074	001	Dec 31, 2018
	WATSON LABS INC	5%	A208092	001	Feb 17, 2017
MINOXIDIL (FOR WOMEN)					
	WATSON LABS INC	5%	A208092	002	Jul 27, 2017
WOMEN'S ROGAINE					
+!	JOHNSON AND JOHNSON	5%	N021812	002	Feb 28, 2014
SOLUTION;TOPICAL					
MINOXIDIL (FOR MEN)					
	ACTAVIS MID ATLANTIC	2%	A074588	001	Apr 05, 1996
	HI TECH PHARMA	2%	A074731	001	Dec 24, 1996
	L PERRIGO CO	2%	A075357	001	Jul 30, 1999
	WOCKHARDT BIO AG	2%	A074767	001	Feb 28, 1997
MINOXIDIL (FOR WOMEN)					
	HI TECH PHARMA	2%	A074731	002	May 11, 2005
	L PERRIGO CO	2%	A075357	002	Jul 30, 1999
MINOXIDIL EXTRA STRENGTH (FOR MEN)					
	ACTAVIS MID ATLANTIC	5%	A075518	001	Nov 17, 2000
	AVACOR PRODS	5%	A075619	001	Nov 17, 2000
	PERRIGO	5%	A075598	001	Jun 13, 2001
	PERRIGO NEW YORK	5%	A075737	001	Mar 15, 2002
	WOCKHARDT BIO AG	5%	A075438	001	Feb 27, 2003
ROGAINE (FOR MEN)					
+!	JOHNSON AND JOHNSON	2%	N019501	002	Feb 09, 1996
ROGAINE (FOR WOMEN)					
+!	JOHNSON AND JOHNSON	2%	N019501	003	Feb 09, 1996
ROGAINE EXTRA STRENGTH (FOR MEN)					
+!	JOHNSON AND JOHNSON	5%	N020834	001	Nov 14, 1997
THEROXIDIL					
	EI INC	2%	A078176	001	Nov 09, 2007
		5%	A076239	001	Aug 24, 2004

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS;OPHTHALMIC					
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE					
	AKORN INC	0.025%;0.3%	A202795	001	Jan 24, 2013
	ALTAIRE PHARMS INC	0.02675%;0.315%	A078208	001	Sep 27, 2010
NAPHCON-A					
+!	ALCON	0.025%;0.3%	N020226	001	Jun 08, 1994
OPCON-A					
+!	BAUSCH AND LOMB	0.02675%;0.315%	N020065	001	Jun 08, 1994
VISINE					
+!	JOHNSON AND JOHNSON	0.025%;0.3%	N020485	001	Jan 31, 1996

NAPROXEN SODIUM

CAPSULE;ORAL					
NAPROXEN SODIUM					
+!	BIONPHARMA INC	EQ 200MG BASE	N021920	001	Feb 17, 2006
	CATALENT	EQ 200MG BASE	A202807	001	Jan 04, 2019
	PURACAP PHARM LLC	EQ 200MG BASE	A208363	001	Mar 15, 2018
TABLET;ORAL					
ALEVE					
+!	BAYER	EQ 200MG BASE	N020204	002	Jan 11, 1994

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM					
	AMNEAL PHARMS NY	EQ 200MG BASE	A079096	001	Dec 16, 2008
	AUROBINDO PHARMA LTD	EQ 200MG BASE	A205497	001	Mar 18, 2016
	CONTRACT PHARMACAL	EQ 200MG BASE	A074635	001	Jan 13, 1997
	DR REDDYS LABS INC	EQ 200MG BASE	A075168	001	Jul 28, 1998
	GRANULES INDIA	EQ 200MG BASE	A091353	001	Sep 20, 2011
	LNK INTL INC	EQ 200MG BASE	A204872	001	Jan 23, 2017
	MARKSANS PHARMA	EQ 200MG BASE	A090545	001	Mar 16, 2011
	NOVELGENIX THERAPS	EQ 200MG BASE	A207612	001	Nov 16, 2018
	PERRIGO	EQ 200MG BASE	A074661	001	Jan 13, 1997
	SUN PHARM INDS LTD	EQ 200MG BASE	A091183	001	May 20, 2011

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALEVE-D SINUS & COLD					
+!	BAYER	200MG;120MG	N021076	001	Nov 29, 1999
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	DR REDDYS LABS INC	EQ 220MG BASE;120MG	A077381	001	Sep 27, 2006
	PERRIGO	EQ 200MG BASE;120MG	A076518	001	Mar 17, 2004

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

HABITROL					
+	DR REDDYS LABS SA	7MG/24HR	N020076	004	Nov 12, 1999
+		14MG/24HR	N020076	005	Nov 12, 1999
+!		21MG/24HR	N020076	006	Nov 12, 1999
NICODERM CQ					
+	SANOFI AVENTIS US	7MG/24HR	N020165	006	Aug 02, 1996
+		14MG/24HR	N020165	005	Aug 02, 1996
+!		21MG/24HR	N020165	004	Aug 02, 1996
NICOTINE					
	AVEVA	7MG/24HR	A074612	002	Jul 28, 2003
		14MG/24HR	A074612	003	Oct 20, 1997
		21MG/24HR	A074612	001	Oct 20, 1997

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICORETTE					
+	GLAXOSMITHKLINE	EQ 2MG BASE	N018612	002	Feb 09, 1996
+		EQ 2MG BASE	N018612	004	Sep 25, 2000
+!		EQ 4MG BASE	N020066	002	Feb 09, 1996
+		EQ 4MG BASE	N020066	004	Sep 25, 2000
NICORETTE (MINT)					
+	GLAXOSMITHKLINE	EQ 2MG BASE	N018612	003	Dec 23, 1998
+		EQ 4MG BASE	N020066	003	Dec 23, 1998
NICOTINE POLACRILEX					
	ACTAVIS LABS NY INC	EQ 2MG BASE	A074507	001	Mar 15, 1999
		EQ 2MG BASE	A076569	001	Jul 29, 2004
		EQ 2MG BASE	A078699	001	Dec 29, 2008
		EQ 2MG BASE	A079216	001	Jul 08, 2009
		EQ 2MG BASE	A204794	001	May 10, 2016
		EQ 4MG BASE	A074707	001	Mar 19, 1999
		EQ 4MG BASE	A076568	002	Jul 29, 2004
		EQ 4MG BASE	A078697	001	Dec 29, 2008
		EQ 4MG BASE	A079038	001	Jul 08, 2009
		EQ 4MG BASE	A079219	001	Jul 08, 2009
		EQ 4MG BASE	A204833	001	Feb 26, 2016
	L PERRIGO CO	EQ 2MG BASE	A076775	001	Sep 16, 2004
		EQ 2MG BASE	A076776	001	Sep 16, 2004
		EQ 2MG BASE	A076777	001	Sep 16, 2004
		EQ 4MG BASE	A076778	001	Sep 16, 2004
		EQ 4MG BASE	A076779	001	Sep 16, 2004
		EQ 4MG BASE	A076789	001	Sep 16, 2004
	PERRIGO R AND D	EQ 2MG BASE	A078325	001	Oct 30, 2006
		EQ 2MG BASE	A078547	001	May 24, 2007
		EQ 2MG BASE	A078967	001	Apr 23, 2008
		EQ 2MG BASE	A091349	001	Jul 20, 2011
		EQ 2MG BASE	A206394	001	Dec 15, 2016
		EQ 4MG BASE	A078326	001	Oct 30, 2006
		EQ 4MG BASE	A078546	001	May 24, 2007
		EQ 4MG BASE	A078968	001	Apr 23, 2008

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

		EQ 4MG BASE	A091354	001	Jul 20, 2011
		EQ 4MG BASE	A206393	001	Dec 15, 2016
	WATSON LABS	EQ 2MG BASE	A079044	001	Jul 08, 2009

TROCHE/LOZENGE;ORAL

NICORETTE

+	GLAXOSMITHKLINE CONS	EQ 2MG BASE	N021330	001	Oct 31, 2002
+		EQ 2MG BASE	N022360	001	May 18, 2009
+!		EQ 4MG BASE	N021330	002	Oct 31, 2002
+!		EQ 4MG BASE	N022360	002	May 18, 2009

NICOTINE POLACRILEX

	PERRIGO R AND D	EQ 2MG BASE	A077007	001	Jan 31, 2006
		EQ 2MG BASE	A090711	001	Jul 10, 2009
		EQ 2MG BASE	A090821	001	Jul 10, 2009
		EQ 2MG BASE	A203690	001	Oct 09, 2012
		EQ 4MG BASE	A077007	002	Jan 31, 2006
		EQ 4MG BASE	A090711	002	Jul 10, 2009
		EQ 4MG BASE	A090821	002	Jul 10, 2009
		EQ 4MG BASE	A203690	002	Oct 09, 2012
	WATSON LABS INC	EQ 2MG BASE	A209206	001	Jun 26, 2018
		EQ 4MG BASE	A209206	002	Jun 26, 2018
	WATSON LABS TEVA	EQ 2MG BASE	A209519	001	Jul 02, 2018
		EQ 4MG BASE	A209519	002	Jul 02, 2018

NIZATIDINE

TABLET;ORAL

AXID AR

+!	PFIZER	75MG	N020555	001	May 09, 1996

NONOXYNOL-9

SPONGE;VAGINAL

TODAY

+!	MAYER LABS INC	1GM	N018683	001	Apr 01, 1983

OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE

+!	DEXCEL PHARMA	20MG	N022032	001	Dec 04, 2007
	DR REDDYS LABS LTD	20MG	A207740	001	Nov 05, 2018
	SUN PHARM INDS LTD	20MG	A207891	001	Oct 12, 2018

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

OMEPRAZOLE

+	DEXCEL PHARMA	20MG	N209400	001	Jul 05, 2017

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

!	DR REDDYS LABS LTD	EQ 20MG BASE	A078878	001	Jun 05, 2009
	SPIL	EQ 20MG BASE	A210593	001	Jul 20, 2018

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

	AUROBINDO PHARMA LTD	EQ 20MG BASE	A206877	001	Jun 06, 2018
	PERRIGO R AND D	EQ 20MG BASE	A204152	001	Jul 30, 2015

PRILOSEC OTC

+!	ASTRAZENECA PHARMS	EQ 20MG BASE	N021229	001	Jun 20, 2003

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

	ACTAVIS ELIZABETH	20MG;1.1GM	A204137	001	Jul 15, 2016
	AUROLIFE PHARMA LLC	20MG;1.1GM	A204923	001	Nov 07, 2016
	PAR PHARM	20MG;1.1GM	A201946	001	Jul 15, 2016
	PERRIGO R AND D	20MG;1.1GM	A201361	001	Jul 15, 2016
	ZYDUS PHARMS USA INC	20MG;1.1GM	A203345	001	Mar 16, 2018

ZEGERID OTC

+!	BAYER HEALTHCARE LLC	20MG;1.1GM	N022281	001	Dec 01, 2009

FOR SUSPENSION;ORAL

ZEGERID OTC

+!	BAYER HEALTHCARE LLC	20MG/PACKET;1.68GM/PACKET	N022283	001	Jun 17, 2013

ORLISTAT

CAPSULE;ORAL					
ALLI					
+!	GLAXOSMITHKLINE CONS	60MG	N021887	001	Feb 07, 2007

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL					
OXYTROL FOR WOMEN					
+!	ALLERGAN SALES LLC	3.9MG/24HR	N202211	001	Jan 25, 2013

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC					
VISINE L.R.					
+!	JOHNSON AND JOHNSON	0.025%	N019407	001	Mar 31, 1989

PERMETHRIN

LOTION;TOPICAL					
NIX					
+!	MEDTECH PRODUCTS	1%	N019918	001	May 02, 1990
PERMETHRIN					
	ACTAVIS MID ATLANTIC	1%	A075014	001	Mar 28, 2000
	PERRIGO NEW YORK	1%	A076090	001	Dec 20, 2001

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL					
GLYCOLAX					
	LANNETT CO INC	17GM/PACKET	A090600	001	Oct 06, 2009
		17GM/SCOOPFUL	A090600	002	Oct 06, 2009
MIRALAX					
+!	BAYER HEALTHCARE LLC	17GM/SCOOPFUL	N022015	001	Oct 06, 2006
POLYETHYLENE GLYCOL 3350					
	ANI PHARMS INC	17GM/SCOOPFUL	A202850	001	Dec 15, 2015
	APNAR PHARMA LP	17GM/SCOOPFUL	A202071	001	Dec 28, 2012
	AUROBINDO PHARMA LTD	17GM/SCOOPFUL	A209017	001	Apr 09, 2018
	MYLAN	17GM/PACKET	A078915	001	Oct 06, 2009
		17GM/SCOOPFUL	A078915	002	Oct 06, 2009
	NEXGEN PHARMA	17GM/SCOOPFUL	A090812	001	Oct 07, 2009
	NOVEL LABS INC	17GM/SCOOPFUL	A091077	001	Oct 06, 2009
	NUVO PHARMS INC	17GM/SCOOPFUL	A206105	001	Oct 28, 2016
	PAR PHARM	17GM/SCOOPFUL	A079214	001	Jan 31, 2013
	PERRIGO R AND D	17GM/PACKET	A090685	001	Oct 06, 2009
		17GM/SCOOPFUL	A090685	002	Oct 06, 2009
	STRIDES PHARMA	17GM/SCOOPFUL	A203928	001	Aug 24, 2016
		17GM/PACKET	A203928	002	Aug 24, 2016

POTASSIUM IODIDE

SOLUTION;ORAL					
POTASSIUM IODIDE					
	MISSION PHARMACAL CO	65MG/ML	A206211	001	Mar 24, 2016
THYROSHIELD					
!	ARCO PHARMS LLC	65MG/ML	A077218	001	Jan 12, 2005
TABLET;ORAL					
IOSAT					
+	ANBEX	65MG	N018664	002	May 12, 2011
+!		130MG	N018664	001	Oct 14, 1982
THYROSAFE					
!	RECIP	65MG	A076350	001	Sep 10, 2002

POVIDONE-IODINE

SOLUTION;TOPICAL					
POVIDONE IODINE					
+!	ALLEGIANCE HLTHCARE	1%	N019522	001	Mar 31, 1989
SPONGE;TOPICAL					
E-Z SCRUB 201					
+!	BECTON DICKINSON	20%	N019240	001	Nov 29, 1985
E-Z SCRUB 241					
+!	BECTON DICKINSON	10%	N019476	001	Jan 07, 1987

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL					
PSEUDOEPHEDRINE HYDROCHLORIDE					
	AUROBINDO PHARMA LTD	120MG	A209008	001	Jun 09, 2017
	L PERRIGO CO	120MG	A075153	001	Feb 26, 1999
	SUN PHARM INDS LTD	120MG	A077442	001	Sep 28, 2005
SUDAFED 12 HOUR					
!	MCNEIL CONS	120MG	A073585	001	Oct 31, 1991
SUDAFED 24 HOUR					
+!	J AND J CONSUMER INC	240MG	N020021	002	Dec 15, 1992

PURIFIED WATER

SOLUTION;OPHTHALMIC					
PUR-WASH					
+!	NIAGARA PHARMS	98.3%	N022305	001	Sep 01, 2011

RANITIDINE HYDROCHLORIDE

TABLET;ORAL					
RANITIDINE HYDROCHLORIDE					
	APOTEX INC	EQ 75MG BASE	A075167	001	May 04, 2000
		EQ 150MG BASE	A200172	001	May 31, 2012
	AUROBINDO PHARMA LTD	EQ 75MG BASE	A207579	001	Nov 13, 2017
		EQ 150MG BASE	A207578	001	Nov 13, 2017
	DR REDDYS LABS LTD	EQ 75MG BASE	A075294	001	Mar 28, 2000
		EQ 150MG BASE	A078192	001	Aug 31, 2007
	GRANULES INDIA LTD	EQ 150MG BASE	A210243	001	Aug 20, 2018
		EQ 150MG BASE	A210243	002	Aug 20, 2018
	IVAX SUB TEVA PHARMS	EQ 75MG BASE	A075296	001	Jan 14, 2000
	MYLAN	EQ 75MG BASE	A075497	001	Jan 14, 2000
	PERRIGO	EQ 75MG BASE	A076195	001	Aug 30, 2002
	PERRIGO R AND D	EQ 150MG BASE	A091429	001	May 11, 2011
		EQ 150MG BASE	A091429	002	May 11, 2011
	STRIDES PHARMA	EQ 75MG BASE	A201745	001	Feb 29, 2012
		EQ 150MG BASE	A200536	001	Jun 28, 2011
	STRIDES VIVIMED	EQ 75MG BASE	A209160	001	Mar 05, 2018
		EQ 150MG BASE	A209161	001	Feb 22, 2018
	WOCKHARDT	EQ 75MG BASE	A076760	001	Feb 24, 2006
ZANTAC 150					
+!	SANOFI US	EQ 150MG BASE	N021698	001	Aug 31, 2004
+		EQ 150MG BASE	N021698	002	Mar 13, 2007
ZANTAC 75					
+	SANOFI US	EQ 75MG BASE	N020520	001	Dec 19, 1995

SODIUM CHLORIDE

AEROSOL, METERED;INHALATION					
BRONCHO SALINE					
+!	BLAIREX	0.9%	N019912	001	Sep 03, 1992

SODIUM FLUORIDE; TRICLOSAN

PASTE;DENTAL					
COLGATE TOTAL					
+!	COLGATE PALMOLIVE	0.24%;0.3%	N020231	001	Jul 11, 1997

TERBINAFINE

GEL;TOPICAL					
LAMISIL AT					
+!	GLAXOSMITHKLINE CONS	1%	N021958	001	Jul 24, 2006

TERBINAFINE HYDROCHLORIDE

CREAM;TOPICAL					
LAMISIL					
+!	GLAXOSMITHKLINE	1%	N020980	001	Mar 09, 1999
TERBINAFINE HYDROCHLORIDE					
	TARO	1%	A077511	001	Jul 02, 2007
SOLUTION;TOPICAL					
LAMISIL AT					
+!	GLAXOSMITHKLINE CONS	1%	N021124	001	Mar 17, 2000
SPRAY;TOPICAL					
LAMISIL AT					
+!	GLAXOSMITHKLINE CONS	1%	N021124	002	Mar 17, 2000

TIOCONAZOLE

OINTMENT;VAGINAL

TIOCONAZOLE				
	PERRIGO	6.5%	A075915 001	Nov 21, 2001
VAGISTAT-1				
+!	COMBE	6.5%	N020676 001	Feb 11, 1997

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

NASACORT ALLERGY 24 HOUR				
+!	SANOFI AVENTIS US	0.055MG/SPRAY	N020468 002	Oct 11, 2013
TRIAMCINOLONE ACETONIDE				
	PERRIGO ISRAEL	0.055MG/SPRAY	A078104 002	Nov 14, 2014

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT 4% SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

HAEMONETICS MANUFACTURING INC	N760305	Jun 30, 1978

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)

INJECTABLE; INJECTION

CITRA LABS LLC	N020037	Aug 26, 2003

ACD-A SOLUTION

TERUMO BCT INC	A010228	Feb 25, 2002

ADSOL WITH ACD-A

FENWAL INC	N000922	Aug 29, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A

HAEMONETICS CORP	A980728	Feb 06, 2002

AS3 SOLUTION/ACD-A

TERUMO BCT INC	N001214	May 29, 2002

NONE

HAEMONETICS MANUFACTURING INC	A710497	Nov 06, 1987

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC	N160918	Mar 17, 1978

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD-A)

INJECTABLE; INJECTION

NONE

ARTERIOCYTE MEDICAL SYSTEMS, INC	N160767	May 11, 2012

ANTICOAGULANT CITRATE PHOSPHATE 2X DEXTROSE SOLUTION (CP2D)

INJECTABLE; INJECTION

CITRATE PHOSPHATE DOUBLE DEXTROSE/ADDITIVE SOLUTION 3

HAEMONETICS CORP	N000127	Jan 18, 2002

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION

INJECTABLE; INJECTION

NONE

TERUMO MEDICAL CORP	N820528	Nov 03, 1982

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION (CPDA)

INJECTABLE; INJECTION

CPDA-1 BLOOD-PACK UNIT (PL 146 PLASTIC) 250, 450, 500 ML BLOOD PACK UNITS

FENWAL INC	N770420	May 12, 1978

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP

INJECTABLE; INJECTION

BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER

FENWAL INC	N940404	Jul 28, 1994

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE-1 SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS MANUFACTURING INC	N800077	Nov 06, 1980

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION

ADSOL IN PLASTIC CONTAINER

FENWAL INC		N900223	Dec 27, 1991

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

INJECTABLE; INJECTION

CPD ANTICOAGULANT IN PL 2209 PLASTIC CONTAINER

FENWAL INC		N900224	Dec 27, 1991

MACOPRODUCTIONS SAS CPD/AS-1: MACOPHARMA LEUCOFLEX MTL1 LEUKOREDUCTION SYSTEM FOR BLOOD COMPONENTS KNOWN AS MTL1-WB

MACOPRODUCTIONS SAS		N040083	Nov 21, 2005

NONE

TERUMO BCT INC		A070025	Jan 06, 2008

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC		N170401	Dec 06, 1977
		N811012	Jun 28, 1983
HAEMONETICS MANUFACTURING INC		N800222	Aug 23, 1982
TERUMO MEDICAL CORP		N781211	Jun 10, 1981

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-1: DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

ADSOL RED BLOOD CELL PRESERVATIVE SOLUTION

FENWAL INC		N811104	May 16, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-5: DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

OPTISOL RED BLOOD CELL PRESERVATIVE SOLUTION

TERUMO MEDICAL CORP		N880217	Oct 07, 1988

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH: AS-3: CITRIC ACID USP; MONOBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE; DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-3 NUTRICEL ADDITIVE SYSTEM

HAEMONETICS MANUFACTURING INC	0.042GM/100ML;0.276GM/100ML; 0.410GM/100ML;0.30GM/100ML; 1.10GM/100ML;0.588GM/100ML	N820915	Oct 19, 1984

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH: AS-2: CITRIC ACID USP; DIBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE; DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-2 NUTRICEL ADDITIVE SYSTEM

MEDSEP CORP	0.042GM/100ML;0.285GM/100ML; 0.718GM/100ML;0.017GM/100ML; 0.396GM/100ML;0.588GM/100ML	N820915	Sep 22, 1983

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT SODIUM CITRATE 4% SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS CORPORATION		N980123	Mar 03, 2000
TERUMO BCT		N125608	Jun 26, 2018

ANTICOAGULANT SODIUM CITRATE SOLUTION

INJECTABLE; INJECTION

TRICITRASOL

CYTOSOL LABORATORIES INC		N010409	Jul 10, 2003

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC		N770923	Jan 20, 1978
TERUMO MEDICAL CORP		N781214	Feb 08, 1980

CORD BLOOD STERILE COLLECTION BAG, ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

STERILE CORD BLOOD COLLECTION UNIT

NONE

MACOPHARMA		N125552	Dec 21, 2016

DEXTRAN 1 IN SODIUM CHLORIDE 0.6%

INJECTABLE; INJECTION

PROMIT

MEDA AB		N830715	Oct 30, 1984

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION

LMD IN GLASS BOTTLE

HOSPIRA INC	10GM/100ML;5GM/100ML	A720563	Oct 30, 1992

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

LMD IN PLASTIC CONTAINER

HOSPIRA INC	10GM/100ML;0.9GM/100ML	A720562	Oct 30, 1992

HETASTARCH 6% IN LACTATED ELECTROLYTE INJECTION

INJECTABLE; INJECTION

HEXTEND

BIOTIME INC	6GM/100ML	N200952	Mar 31, 1999

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA INC	6GM/100ML;0.9GM/100ML	A740193	Jan 30, 1995

HESPAN IN PLASTIC CONTAINER

B BRAUN MEDICAL INC	6GM/100ML;0.9GM/100ML	N890105	Apr 04, 1991

NONE

TEVA PARENTERAL MEDICINES INC	6GM/100ML;0.9GM/100ML	A740592	Nov 12, 1998

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

HYDROXYETHYL STARCH 130/0.4 IN 6% SODIUM CHLORIDE 0.9%

STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE INFUSED DIRECTLY TO THE PATIENT.

NONE				
B. BRAUN MEDICAL			A110013	Jan 09, 2015
VOLUVEN				
FRESENIUS KABI DEUTSCHLAND GMBH	6GM/100ML;0.9GM/100ML		N070012	Dec 27, 2007

ISOPLATE SOLUTION IN THE 500 ML EXCEL CONTAINER

STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE INFUSED DIRECTLY TO THE PATIENT.

ISOPLATE SOLUTION				
HAEMONETICS CORP			N90067	Mar 05, 2013

LEUKOCYTE REDUCTION FILTRATION SYSTEM FOR WHOLE BLOOD WITH CPD ANTICOAGULANT AND SOLX ADDITIVE

INJECTABLE; INJECTION

LEUKOSEP HWB-600-XL				
HAEMONETICS CORP			N110059	Apr 25, 2013

RED BLOOD CELL PROCESSING SOLUTION

STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE INFUSED DIRECTLY TO THE PATIENT.

REJUVESOL				
CITRA LABS LLC			N950522	Feb 26, 1997

SODIUM CHLORIDE; SODIUM ACETATE; SODIUM CITRATE DIHYDRATE; SODIUM PHOSPHATE, DIABASIC ANHYDROUS; SODIUM PHOSPHATE MONOBASIC, MONOHYDRATE

STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE INFUSED DIRECTLY TO THE PATIENT.

INTERSOL SOLUTION				
FENWAL INC.	2.26G/500ML; 2.21G/500ML; 1.59G/500ML; 1.53G/500ML; 0.465G/500ML		N080041	Dec 09, 2009

ABARELIX					
INJECTABLE;INTRAMUSCULAR					
PLENAXIS					
	SPECIALITY EUROPEAN	100MG/VIAL	N021320	001	Nov 25, 2003
ACAMPROSATE CALCIUM					
TABLET, DELAYED RELEASE;ORAL					
CAMPRAL					
+	FOREST LABS	333MG **	N021431	001	Jul 29, 2004
ACEBUTOLOL HYDROCHLORIDE					
CAPSULE;ORAL					
ACEBUTOLOL HYDROCHLORIDE					
	WATSON LABS	EQ 200MG BASE	A074007	001	Oct 18, 1995
		EQ 400MG BASE	A074007	002	Oct 18, 1995
SECTRAL					
+	PROMIUS PHARMA	EQ 200MG BASE	N018917	001	Dec 28, 1984
+		EQ 400MG BASE	N018917	003	Dec 28, 1984
ACETAMINOPHEN					
INJECTABLE;INJECTION					
INJECTAPAP					
	ORTHO MCNEIL PHARM	100MG/ML	N017785	001	Mar 07, 1986
SUPPOSITORY;RECTAL					
ACEPHEN					
	G AND W LABS	120MG	A072218	001	Mar 27, 1992
		325MG	N018060	003	Dec 18, 1986
		650MG	N018060	002	
ACETAMINOPHEN					
	ABLE	120MG	A073106	001	Feb 27, 1995
		325MG	A073107	001	Feb 27, 1995
		650MG	A073108	001	Feb 27, 1995
	ACINO PRODS	120MG	A071010	001	May 12, 1987
		650MG	A071011	001	May 12, 1987
TYLENOL					
	J AND J CONSUMER INC	120MG	N017756	002	
		650MG	N017756	001	
TABLET, EXTENDED RELEASE;ORAL					
ACETAMINOPHEN					
	SUN PHARM INDS LTD	650MG	A090205	001	Nov 18, 2009
ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE					
CAPSULE;ORAL					
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE					
	MIKART	150MG;180MG;15MG	A081095	001	Oct 26, 1990
		150MG;180MG;30MG	A081096	001	Oct 26, 1990
		150MG;180MG;60MG	A081097	001	Oct 26, 1990
CODEINE, ASPIRIN, APAP FORMULA NO. 2					
	SCHERER LABS	150MG;180MG;15MG	A085640	001	
CODEINE, ASPIRIN, APAP FORMULA NO. 3					
	SCHERER LABS	150MG;180MG;30MG	A085639	001	
CODEINE, ASPIRIN, APAP FORMULA NO. 4					
	SCHERER LABS	150MG;180MG;60MG	A085638	001	
ACETAMINOPHEN; BUTALBITAL					
CAPSULE;ORAL					
BANCAP					
	FOREST PHARMS	325MG;50MG	A088889	001	Jan 16, 1986
BUCET					
	MALLINCKRODT	650MG;50MG	A088991	001	Jun 28, 1985
PHRENILIN FORTE					
	VALEANT	650MG;50MG	A088831	001	Jun 19, 1985
TENCON					
	MALLINCKRODT	650MG;50MG	A089405	001	May 15, 1990
TRIAPRIN					
	DUNHALL	325MG;50MG	A089268	001	Jul 02, 1987
TABLET;ORAL					
BUTALBITAL AND ACETAMINOPHEN					
	HALSEY	325MG;50MG	A089568	001	Oct 05, 1988
	WATSON LABS	325MG;50MG	A087550	001	Oct 19, 1984

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

BUTAPAP				
MIKART	650MG;50MG	A089988	001	Oct 26, 1992
PHRENILIN				
VALEANT	325MG;50MG **	A087811	001	Jun 19, 1985
SEDAPAP				
MAYRAND	650MG;50MG	A088944	001	Oct 17, 1985

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

ANOQUAN				
SHIRE	325MG;50MG;40MG	A087628	001	Oct 01, 1986
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE				
GILBERT LABS	325MG;50MG;40MG **	A088825	001	Dec 05, 1984
GRAHAM DM	325MG;50MG;40MG	A088743	001	Jul 18, 1985
	325MG;50MG;40MG	A088765	001	Mar 27, 1985
	325MG;50MG;40MG	A089067	001	Apr 19, 1985
HIKMA PHARMS	500MG;50MG;40MG	A040261	001	Oct 28, 1998
MALLINCKRODT	325MG;50MG;40MG	A088758	001	Mar 27, 1985
ESGIC-PLUS				
MIKART	500MG;50MG;40MG	A040085	001	Mar 28, 1996
FEMCET				
MALLINCKRODT	325MG;50MG;40MG	A089102	001	Jun 19, 1985
MEDIGESIC PLUS				
US CHEM	325MG;50MG;40MG	A089115	001	Jan 14, 1986
TRIAD				
MALLINCKRODT	325MG;50MG;40MG	A089023	001	Jun 19, 1985

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE				
ABLE	325MG;50MG;40MG	A040390	001	Jul 23, 2001
	500MG;50MG;40MG	A040394	001	Jul 23, 2001
GILBERT LABS	325MG;50MG;40MG	A087629	001	Nov 13, 1984
HIKMA PHARMS	500MG;50MG;40MG	A040336	001	Aug 18, 1999
MIKART	750MG;50MG;40MG	A040496	001	Dec 23, 2003
MIRROR PHARMS LLC	500MG;50MG;40MG	A040883	001	Dec 23, 2008
NOVAST LABS	325MG;50MG;40MG	A040864	001	Dec 01, 2008
SUN PHARM INDUSTRIES	325MG;50MG;40MG	A040601	001	Jul 29, 2005
VINTAGE PHARMS	500MG;50MG;40MG	A040513	001	Aug 25, 2003
WATSON LABS	325MG;50MG;40MG	A089536	001	Feb 16, 1988
	500MG;50MG;40MG	A040267	001	Jul 30, 1998
ESGIC				
FOREST PHARMS	325MG;50MG;40MG	A089660	001	Dec 23, 1988
ESGIC-PLUS				
MIKART	500MG;50MG;40MG	A089451	001	May 23, 1988

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE				
ABLE	325MG;50MG;40MG;30MG	A076528	001	Aug 21, 2003
HIKMA INTL PHARMS	325MG;50MG;40MG;30MG	A075618	001	Mar 23, 2001
PHRENILIN WITH CAFFEINE AND CODEINE				
VALEANT	325MG;50MG;40MG;30MG	A074911	001	Aug 22, 2001

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE				
MIKART	356.4MG;30MG;16MG	A040109	001	Aug 26, 1997
WRASER PHARMS LLC	356.4MG;30MG;16MG	A040688	001	Apr 03, 2007
DHC PLUS				
PHARM RES ASSOC	356.4MG;30MG;16MG	A088584	001	Mar 04, 1986
SYNALGOS-DC-A				
LEITNER PHARMS	356.4MG;30MG;16MG	A089166	001	May 14, 1986

TABLET;ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE				
BOCA PHARMA LLC	712.8MG;60MG;32MG	A040701	001	Apr 03, 2007
MIKART	712.8MG;60MG;32MG	A040316	001	Apr 28, 1999
WEST-WARD PHARM CORP	712.8MG;60MG;32MG	A040637	001	Sep 22, 2006

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE				
TABLET;ORAL				
TAVIST ALLERGY/SINUS/HEADACHE				
	NOVARTIS	500MG;EQ 0.25MG BASE;30MG	N021082 001	Mar 01, 2001
ACETAMINOPHEN; CODEINE PHOSPHATE				
CAPSULE;ORAL				
ACETAMINOPHEN AND CODEINE PHOSPHATE				
	TEVA	300MG;15MG	A088537 001	Jun 04, 1984
		300MG;30MG	A088324 001	Dec 29, 1983
		300MG;60MG	A088599 001	Jun 01, 1984
PHENAPHEN W/ CODEINE NO. 2				
	ROBINS AH	325MG;15MG	A084444 001	
PHENAPHEN W/ CODEINE NO. 3				
	ROBINS AH	325MG;30MG	A084445 001	
PHENAPHEN W/ CODEINE NO. 4				
	ROBINS AH	325MG;60MG	A084446 001	
PROVAL #3				
	SOLVAY	325MG;30MG	A085685 001	
TYLENOL W/ CODEINE NO. 3				
	ORTHO MCNEIL PHARM	300MG;30MG	A087422 001	
TYLENOL W/ CODEINE NO. 4				
	ORTHO MCNEIL PHARM	300MG;60MG	A087421 001	
SOLUTION;ORAL				
ACETAMINOPHEN AND CODEINE PHOSPHATE				
	ACI HEALTHCARE LTD	120MG/5ML;12MG/5ML	A086366 001	
	ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085861 001	
	DAVA PHARMS INC	120MG/5ML;12MG/5ML	A040098 001	Sep 20, 1996
TYLENOL W/ CODEINE				
	ORTHO MCNEIL PHARM	120MG/5ML;12MG/5ML	A085057 001	
SUSPENSION;ORAL				
CAPITAL AND CODEINE				
	ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085883 001	
	VALEANT PHARMS LLC	120MG/5ML;12MG/5ML	A086024 001	
TABLET;ORAL				
ACETAMINOPHEN AND CODEINE PHOSPHATE				
	ABLE	300MG;30MG	A040452 001	Aug 01, 2002
		300MG;60MG	A040459 001	Aug 01, 2002
	AM THERAP	300MG;15MG	A089478 001	Mar 03, 1987
		300MG;15MG	A089481 001	Mar 03, 1987
		300MG;30MG	A089479 001	Mar 03, 1987
		300MG;30MG	A089482 001	Mar 03, 1987
		300MG;60MG	A089480 001	Mar 03, 1987
		300MG;60MG	A089483 001	Mar 03, 1987
	DURAMED PHARMS BARR	300MG;15MG	A040223 001	Nov 18, 1997
		300MG;15MG	A088353 001	Feb 06, 1984
		300MG;30MG	A040223 002	Nov 18, 1997
		300MG;30MG	A088354 001	Feb 06, 1984
		300MG;60MG	A040223 003	Nov 18, 1997
		300MG;60MG	A088355 001	Feb 06, 1984
	EVERYLIFE	325MG;30MG	A085217 001	
	FOSUN PHARMA	300MG;30MG	A081250 001	Jul 16, 1992
		300MG;60MG	A081249 001	Jul 16, 1992
	HALSEY	300MG;15MG	A083871 001	
		300MG;30MG	A083872 001	
		300MG;60MG	A086549 001	
	KV PHARM	300MG;30MG	A085288 001	
		300MG;60MG	A085365 001	
		325MG;15MG	A085364 001	
		325MG;45MG **	A085363 001	
	LEDERLE	300MG;30MG	A087141 001	
	MIKART	300MG;30MG	A089238 001	Feb 25, 1986
		300MG;60MG	A089244 001	Feb 25, 1986
		650MG;30MG	A089231 001	Mar 03, 1986
		650MG;60MG	A089363 001	Sep 09, 1991
	MUTUAL PHARM	300MG;15MG	A085795 001	
		300MG;30MG	A085794 001	
		300MG;60MG	A087653 001	Apr 13, 1982
	PURACAP PHARM	300MG;30MG	A087762 001	Dec 10, 1982
	PUREPAC PHARM	300MG;30MG	A086681 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL				
ACETAMINOPHEN AND CODEINE PHOSPHATE				
	300MG;30MG	A089080	001	Jul 17, 1986
	300MG;60MG	A086683	001	
RHODES PHARMS	300MG;15MG	A089673	002	Feb 10, 1988
	300MG;30MG	A089673	003	Feb 10, 1988
	300MG;60MG	A089673	001	Feb 10, 1988
ROXANE	300MG;15MG	A084659	001	
	300MG;30MG	A084656	001	
	300MG;60MG	A084667	001	
	500MG;15MG	A089511	001	Apr 25, 1989
	500MG;30MG	A089512	001	Apr 25, 1989
	500MG;60MG	A089513	001	Apr 25, 1989
SANDOZ	300MG;15MG	A087433	001	
	300MG;30MG	A085291	002	
	300MG;30MG	A085917	001	
	300MG;60MG	A085964	001	
	300MG;60MG	A087423	001	
SUPERPHARM	300MG;15MG	A089183	001	Oct 18, 1985
	300MG;30MG	A089184	001	Oct 18, 1985
	300MG;30MG	A089253	001	May 19, 1986
	300MG;60MG	A089185	001	Oct 18, 1985
	300MG;60MG	A089254	001	May 19, 1986
USL PHARMA	300MG;30MG	A087919	001	Jun 22, 1982
	300MG;60MG	A087920	001	Jun 22, 1982
VALEANT PHARM INTL	300MG;30MG	A085896	001	
VITARINE	300MG;30MG	A085676	001	
WARNER CHILCOTT	300MG;15MG	A085992	001	
	300MG;30MG	A085218	002	
	300MG;60MG	A087306	001	
WATSON LABS	300MG;15MG	A087277	001	May 26, 1982
	300MG;15MG	A089997	001	Dec 28, 1994
	300MG;30MG	A087276	001	May 26, 1982
	300MG;30MG	A089998	001	Dec 28, 1994
	300MG;60MG	A087275	001	May 26, 1982
	300MG;60MG	A089999	001	Dec 28, 1994
WATSON LABS FLORIDA	300MG;15MG	A040443	001	Jan 22, 2003
	300MG;30MG	A040443	002	Jan 22, 2003
	300MG;60MG	A040443	003	Jan 22, 2003
WHITEWORTH TOWN PLSN	300MG;30MG	A084360	001	
	300MG;60MG	A085607	001	
CAPITAL AND CODEINE				
CARNRICK	325MG;30MG	A083643	001	
CODRIX				
WATSON LABS FLORIDA	500MG;15MG	A040447	001	Feb 26, 2003
	500MG;30MG	A040441	001	Mar 27, 2003
	500MG;60MG	A040488	001	Mar 28, 2003
EMPRACET W/ CODEINE PHOSPHATE #3				
GLAXOSMITHKLINE	300MG;30MG	A083951	001	
EMPRACET W/ CODEINE PHOSPHATE #4				
GLAXOSMITHKLINE	300MG;60MG	A083951	002	
PAPA-DEINE #3				
VANGARD	300MG;30MG	A088037	001	Mar 20, 1984
PAPA-DEINE #4				
VANGARD	300MG;60MG	A088715	001	Mar 20, 1984
PHENAPHEN-650 W/ CODEINE				
ROBINS AH	650MG;30MG	A085856	001	
TYLENOL W/ CODEINE				
ORTHO MCNEIL PHARM	325MG;7.5MG **	A085056	001	
	325MG;15MG **	A085056	002	
	325MG;30MG **	A085056	003	
	325MG;60MG **	A085056	004	
TYLENOL W/ CODEINE NO. 1				
JANSSEN PHARMS	300MG;7.5MG	A085055	001	
TYLENOL W/ CODEINE NO. 2				
JANSSEN PHARMS	300MG;15MG	A085055	002	

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL					
DRIXORAL PLUS					
	SCHERING PLOUGH	500MG;3MG;60MG	N019453	001	May 22, 1987

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE;ORAL					
ACETAMINOPHEN AND HYDROCODONE BITARTRATE					
	CENT PHARMS	500MG;5MG	A088898	001	Mar 27, 1985
ALLAY					
	IVAX PHARMS	500MG;5MG	A089907	001	Jan 13, 1989
BANCAP HC					
	FOREST PHARMS	500MG;5MG	A087961	001	Mar 17, 1983
CO-GESIC					
	CENT PHARMS	500MG;5MG	A089360	001	Mar 02, 1988
HYDROCODONE BITARTRATE AND ACETAMINOPHEN					
	MALLINCKRODT	500MG;5MG	A088956	001	Jul 19, 1985
		500MG;5MG	A089006	001	Aug 09, 1985
	MIKART	500MG;5MG	A081067	001	Nov 30, 1989
		500MG;5MG	A081068	001	Nov 30, 1989
		500MG;5MG	A081069	001	Nov 30, 1989
		500MG;5MG	A081070	001	Nov 30, 1989
		500MG;5MG	A089008	001	Feb 21, 1986
LORCET-HD					
	MALLINCKRODT	500MG;5MG	A087336	001	Jul 08, 1982
SOLUTION;ORAL					
HYDROCODONE BITARTRATE AND ACETAMINOPHEN					
	MALLINCKRODT	500MG/15ML;7.5MG/15ML	A040418	001	Jun 27, 2001
	MALLINCKRODT INC	500MG/15ML;10MG/15ML	A040508	001	Aug 29, 2003
	MIKART	500MG/15ML;5MG/15ML	A081226	001	Oct 27, 1992
		500MG/15ML;5MG/15ML	A089557	001	Apr 29, 1992
		500MG/15ML;7.5MG/15ML	A081051	001	Aug 28, 1992
	NESHER PHARMS	500MG/15ML;7.5MG/15ML	A040366	001	Jan 23, 2002
	PHARM ASSOC	500MG/15ML;7.5MG/15ML	A040182	001	Mar 13, 1998
	VINTAGE PHARMS	500MG/15ML;7.5MG/15ML	A040520	001	Oct 30, 2003
ZYFREL					
	CYPRESS PHARM INC	325MG/15ML;7.5MG/15ML	A090468	001	Apr 14, 2016
TABLET;ORAL					
ANEXSIA					
	MALLINCKRODT	500MG;5MG	A089160	001	Apr 23, 1987
		750MG;10MG	A040468	001	Oct 31, 2002
ANEXSIA 7.5/650					
	MALLINCKRODT	650MG;7.5MG	A089725	001	Sep 30, 1987
CO-GESIC					
	UCB INC	500MG;5MG	A087757	001	May 03, 1982
DURADYNE DHC					
	FOREST PHARMS	500MG;5MG	A087809	001	Mar 17, 1983
HY-PHEN					
	ASCHER	500MG;5MG	A087677	001	May 03, 1982
HYDROCODONE BITARTRATE AND ACETAMINOPHEN					
	ABLE	325MG;5MG	A040478	001	Nov 08, 2002
		325MG;7.5MG	A040464	001	Oct 23, 2002
		325MG;10MG	A040464	002	Oct 23, 2002
		500MG;5MG	A040477	001	Nov 06, 2002
		500MG;7.5MG	A040490	001	May 21, 2003
		500MG;10MG	A040473	001	Nov 06, 2002
		650MG;7.5MG	A040474	001	Jan 02, 2003
		650MG;10MG	A040476	001	Oct 23, 2002
		750MG;7.5MG	A040469	001	Oct 25, 2002
	AMNEAL PHARMS NY	500MG;5MG	A040729	001	Aug 25, 2006
		500MG;7.5MG	A040748	001	Aug 25, 2006
		500MG;10MG	A040813	001	Feb 23, 2007
		650MG;7.5MG	A040754	001	Aug 25, 2006
		650MG;10MG	A040757	001	Aug 25, 2006
		750MG;7.5MG	A040769	001	Aug 28, 2006
	APIL	500MG;10MG	A040148	002	Feb 14, 1997
	BARR	500MG;2.5MG	A040307	001	Jul 26, 2000
		500MG;5MG	A040308	001	Jul 26, 2000
		500MG;5MG	A088577	001	Dec 21, 1984
		500MG;7.5MG	A040307	002	Jul 26, 2000

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	500MG;10MG	A040309	001	Jul 26, 2000
	650MG;7.5MG	A040307	003	Jul 26, 2000
	650MG;10MG	A040307	004	Jul 26, 2000
	750MG;7.5MG	A040308	002	Jul 26, 2000
CARACO	500MG;5MG	A090265	001	Dec 23, 2008
	500MG;7.5MG	A090265	002	Dec 23, 2008
	500MG;10MG	A090265	003	Dec 23, 2008
	650MG;7.5MG	A090380	001	Dec 23, 2008
	650MG;10MG	A090380	002	Dec 23, 2008
	660MG;10MG	A090380	003	Dec 23, 2008
	750MG;7.5MG	A090380	004	Dec 23, 2008
HALSEY	500MG;5MG	A089554	001	Jun 12, 1987
IVAX PHARMS	500MG;5MG	A089696	001	Apr 21, 1988
MALLINCKRODT	500MG;5MG	A040084	002	Jun 01, 1995
	500MG;7.5MG	A040201	001	Feb 27, 1998
	500MG;10MG	A040201	002	Feb 27, 1998
	650MG;10MG	A040084	004	Oct 16, 1996
	660MG;10MG	A040084	003	Jul 29, 1996
	750MG;7.5MG	A040084	001	Jun 01, 1995
MIKART	500MG;2.5MG	A089698	001	Aug 25, 1989
	500MG;5MG	A089271	001	Jul 16, 1986
	500MG;5MG	A089697	001	Jan 28, 1992
	500MG;7.5MG	A089699	001	Aug 25, 1989
	650MG;5MG	A040849	001	Jun 09, 2010
	650MG;7.5MG	A089689	001	Jun 29, 1988
	650MG;10MG	A081223	001	May 29, 1992
MUTUAL PHARM	500MG;5MG	A040236	001	Sep 25, 1997
	650MG;7.5MG	A040240	002	Nov 26, 1997
	650MG;10MG	A040240	001	Nov 26, 1997
	750MG;7.5MG	A040236	002	Sep 25, 1997
RANBAXY	500MG;5MG	A040825	001	Aug 16, 2007
	500MG;10MG	A040824	001	Aug 16, 2007
RANBAXY LABS LTD	750MG;7.5MG	A040822	001	Aug 16, 2007
SANDOZ	500MG;5MG	A040149	001	Jan 27, 1997
	750MG;7.5MG	A040149	002	Jan 27, 1997
SUN PHARM INDS LTD	325MG;10MG	A040826	001	Aug 16, 2007
UCB INC	500MG;10MG	A040210	001	Aug 13, 1997
	650MG;7.5MG	A040134	001	Nov 21, 1996
USL PHARMA	500MG;5MG	A089290	001	May 29, 1987
	500MG;5MG	A089291	001	May 29, 1987
VINTAGE PHARMS	500MG;2.5MG	A040144	002	Apr 25, 1997
	500MG;5MG	A089831	001	Sep 07, 1988
	500MG;5MG	A089971	001	Dec 02, 1988
	500MG;7.5MG	A040144	001	Feb 22, 1996
	500MG;10MG	A040356	001	May 31, 2000
	650MG;7.5MG	A040155	001	Apr 14, 1997
	650MG;10MG	A040143	001	Feb 22, 1996
	660MG;10MG	A040358	001	May 31, 2000
	750MG;7.5MG	A040157	001	Apr 12, 1996
VINTAGE PHARMS LLC	500MG;5MG	A040281	001	Sep 30, 1998
	500MG;7.5MG	A040280	001	Sep 30, 1998
	650MG;7.5MG	A040280	002	Sep 30, 1998
	650MG;10MG	A040280	003	Sep 30, 1998
	750MG;7.5MG	A040281	002	Sep 30, 1998
WATSON LABS	325MG;7.5MG	A040248	001	Apr 28, 2000
	325MG;10MG	A040248	002	Apr 28, 2000
	500MG;2.5MG	A040123	003	Mar 04, 1996
	500MG;2.5MG	A081079	001	Aug 30, 1991
	500MG;5MG	A040122	001	Mar 04, 1996
	500MG;5MG	A089883	001	Dec 01, 1988
	500MG;7.5MG	A040123	004	Mar 04, 1996
	500MG;7.5MG	A081080	001	Aug 30, 1991
	650MG;7.5MG	A040094	001	Sep 29, 1995
	650MG;7.5MG	A040123	001	Mar 04, 1996
	650MG;10MG	A040094	002	Sep 29, 1995
	650MG;10MG	A040123	002	Mar 04, 1996

ACETAMINOPHEN; HYDROCODONE BITARTRATE					
TABLET;ORAL					
HYDROCODONE BITARTRATE AND ACETAMINOPHEN					
		660MG;10MG	A040094	003	Aug 08, 2000
		750MG;7.5MG	A040122	002	Mar 04, 1996
		750MG;7.5MG	A081083	001	Aug 30, 1991
		750MG;10MG	A040094	004	Mar 22, 1999
	WATSON LABS FLORIDA	500MG;5MG	A040493	001	May 28, 2003
		660MG;10MG	A040495	001	May 28, 2003
		750MG;7.5MG	A040494	001	May 28, 2003
LORTAB					
	UCB INC	500MG;5MG	A087722	001	Jul 09, 1982
		500MG;10MG	A040100	001	Jan 26, 1996
NORCET					
	ABANA	500MG;5MG	A088871	001	May 15, 1986
TYCOLET					
	ORTHO MCNEIL PHARM	500MG;5MG	A089385	001	Aug 27, 1986
VICODIN					
	ABBOTT	500MG;5MG	A085667	001	
	ABBVIE	500MG;5MG	A088058	001	Jan 07, 1983
VICODIN ES					
	ABBVIE	750MG;7.5MG	A089736	001	Dec 09, 1988
VICODIN HP					
	ABBVIE	660MG;10MG	A040117	001	Sep 23, 1996
ZYDONE					
	VINTAGE PHARMS LLC	400MG;5MG	A040288	001	Nov 27, 1998
		400MG;7.5MG	A040288	002	Nov 27, 1998
		400MG;10MG	A040288	003	Nov 27, 1998
ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE					
CAPSULE;ORAL					
OXYCODONE AND ACETAMINOPHEN					
	ACTAVIS ELIZABETH	500MG;5MG	A040199	001	Dec 30, 1998
	BARR	500MG;5MG	A040304	001	Oct 02, 2000
	DURAMED PHARMS BARR	500MG;5MG	A040289	001	Mar 16, 1999
	HALSEY	500MG;5MG	A089994	001	May 04, 1989
	MALLINCKRODT	500MG;5MG	A040257	001	Aug 04, 1998
	MUTUAL PHARM	500MG;5MG	A040219	001	Jan 22, 1998
	VINTAGE PHARMS	500MG;5MG	A040106	001	Jul 30, 1996
	VINTAGE PHARMS LLC	500MG;5MG	A040303	001	Dec 30, 1999
	WATSON LABS	500MG;5MG	A040234	001	Oct 30, 1997
ROXILOX					
	ROXANE	500MG;5MG	A040061	001	Jul 03, 1995
TYLOX					
	JANSSEN PHARMS	500MG;5MG	A088790	001	Dec 12, 1984
TYLOX-325					
	ORTHO MCNEIL PHARM	325MG;5MG	A088246	001	Nov 08, 1984
SOLUTION;ORAL					
OXYCODONE AND ACETAMINOPHEN					
	SPECGX LLC	325MG/5ML;5MG/5ML	A040680	001	Sep 29, 2006
OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN					
	VINTAGE PHARMS	325MG/5ML;5MG/5ML	A203573	001	Dec 18, 2014
ROXICET					
	WEST-WARD PHARMS INT	325MG/5ML;5MG/5ML	A089351	001	Dec 03, 1986
TABLET;ORAL					
OXYCODONE 2.5/APAP 500					
	BRISTOL MYERS SQUIBB	500MG;2.5MG	A085910	001	
OXYCODONE 5/APAP 500					
	BRISTOL MYERS SQUIBB	500MG;5MG	A085911	001	
OXYCODONE AND ACETAMINOPHEN					
	ACTAVIS ELIZABETH	325MG;5MG	A040203	001	Mar 15, 1999
		325MG;7.5MG	A040800	001	Apr 03, 2012
		325MG;10MG	A040800	002	Apr 03, 2012
	AMNEAL PHARMS NY	500MG;7.5MG	A040789	001	Nov 27, 2007
		650MG;10MG	A040789	002	Nov 27, 2007
	BARR	325MG;5MG	A087406	001	
	DURAMED PHARMS BARR	325MG;5MG	A040272	001	Jun 30, 1998
	MALLINCKRODT	500MG;7.5MG	A040550	001	Jun 30, 2004
		650MG;10MG	A040550	002	Jun 30, 2004
	MAYNE PHARMA INC	500MG;7.5MG	A090177	005	Oct 20, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE				
TABLET;ORAL				
OXYCODONE AND ACETAMINOPHEN				
	650MG;10MG	A090177	006	Oct 20, 2008
MIKART	400MG;2.5MG	A040679	001	May 16, 2006
	400MG;5MG	A040687	001	Apr 27, 2006
	400MG;7.5MG	A040698	001	Apr 27, 2006
	400MG;10MG	A040692	001	Apr 27, 2006
	500MG;10MG	A040676	001	Apr 19, 2006
WATSON LABS	500MG;7.5MG	A040371	001	Dec 29, 2000
	650MG;10MG	A040371	002	Dec 29, 2000
PERCOCET				
VINTAGE PHARMS LLC	325MG;5MG	A085106	002	
	500MG;7.5MG	A040341	001	Jul 26, 1999
	650MG;10MG	A040341	002	Jul 26, 1999
ROXICET 5/500				
ROXANE	500MG;5MG	A089775	001	Jan 12, 1989
TABLET, EXTENDED RELEASE;ORAL				
XARTEMIS XR				
+ MALLINCKRODT INC	325MG;7.5MG	N204031	001	Mar 11, 2014
ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE				
CAPSULE;ORAL				
TYLOX				
ORTHO MCNEIL PHARM	500MG;4.5MG;0.38MG	A085375	001	
ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE				
TABLET;ORAL				
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE				
GAVIS PHARMS	650MG;EQ 25MG BASE	A076202	001	Aug 02, 2002
WATSON LABS	650MG;EQ 25MG BASE	A074699	001	Mar 24, 2000
TALACEN				
SANOFI AVENTIS US	650MG;EQ 25MG BASE	N018458	001	Sep 23, 1982
ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE				
TABLET;ORAL				
DARVOCET				
AAIPHARMA LLC	325MG;32.5MG	N016844	001	
DOLENE AP-65				
LEDERLE	650MG;65MG	A085100	001	
PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN				
MYLAN	325MG;32MG	A083689	001	
	650MG;65MG	A083978	001	
SANDOZ	650MG;65MG	A089959	001	Jul 18, 1989
VINTAGE PHARMS	650MG;65MG	A040507	001	Jul 30, 2003
WATSON LABS	650MG;65MG	A040139	001	Dec 16, 1996
WYGESIC				
CARACO	650MG;65MG	A084999	001	
ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE				
TABLET;ORAL				
DARVOCET A500				
XANODYNE PHARM	500MG;100MG	A076429	001	Sep 10, 2003
DARVOCET-N 100				
XANODYNE PHARM	650MG;100MG	N017122	002	
DARVOCET-N 50				
XANODYNE PHARM	325MG;50MG	N017122	001	
PROPACET 100				
TEVA	650MG;100MG	A070107	001	Jun 12, 1985
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN				
ABLE	650MG;100MG	A075838	001	Jul 11, 2001
ACTAVIS ELIZABETH	650MG;100MG	A070910	001	Jan 02, 1987
CORNERSTONE	325MG;100MG	A076743	001	May 07, 2004
	500MG;100MG	A076750	001	Jun 28, 2004
HALSEY	325MG;50MG	A072105	001	May 13, 1988
	650MG;100MG	A072106	001	May 13, 1988
IVAX SUB TEVA PHARMS	650MG;100MG	A070146	001	Aug 02, 1985
MALLINCKRODT	650MG;100MG	A075738	001	Feb 02, 2001
MIRROR PHARMS	650MG;100MG	A077821	001	Feb 11, 2008
MUTUAL PHARM	325MG;50MG	A070115	001	Jun 12, 1985
	650MG;100MG	A070116	001	Jun 12, 1985

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET;ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

	650MG;100MG	A070615	001	Mar 21, 1986
	650MG;100MG	A070771	001	Mar 21, 1986
	650MG;100MG	A070775	001	Mar 21, 1986
MYLAN	650MG;100MG	A072195	001	Feb 16, 1988
MYLAN PHARMS INC	650MG;100MG	A070145	001	Jun 12, 1985
SANDOZ	650MG;100MG	A070443	001	Jan 23, 1986
SUPERPHARM	650MG;100MG	A071319	001	Jan 06, 1987
TEVA	650MG;100MG	A070732	001	Jan 03, 1986
	650MG;100MG	A074119	001	Dec 19, 1994
VINTAGE PHARMS	325MG;50MG	A074843	002	Feb 15, 2001
	650MG;100MG	A074843	001	Feb 12, 1997
WATSON LABS	325MG;50MG	A070398	001	Dec 18, 1986
	650MG;100MG	A070399	001	Dec 18, 1986
WATSON LABS FLORIDA	500MG;100MG	A077196	001	Jun 28, 2005
	650MG;100MG	A076609	001	Nov 16, 2004
WOCKHARDT LTD	325MG;50MG	A077677	001	Mar 16, 2007
	650MG;100MG	A077677	002	Mar 16, 2007

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

CSPC OUYI PHARM CO	325MG;37.5MG	A076914	001	Jul 26, 2006

ACETAZOLAMIDE

TABLET;ORAL

ACETAZOLAMIDE

ALRA	250MG	A083320	001	
ASCOT	250MG	A087686	001	Oct 20, 1982
SUN PHARM INDUSTRIES	250MG	A089753	001	Jun 22, 1988
VANGARD	250MG	A087654	001	Feb 05, 1982
WATSON LABS	250MG	A084498	002	
	250MG	A088882	001	Oct 22, 1985

DIAMOX

+ TEVA BRANDED PHARM	125MG **	N008943	001	
+	250MG **	N008943	002	

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

HOSPIRA	EQ 500MG BASE/VIAL	A040108	001	Oct 30, 1995

DIAMOX

+ TEVA WOMENS	EQ 500MG BASE/VIAL **	N009388	001	

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC

ACETASOL

ACTAVIS MID ATLANTIC	2%	A087146	001	

ACETIC ACID

KV PHARM	2%	A085493	001	

ORLEX

WARNER CHILCOTT	2%	A086845	001	

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS;OTIC

ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE

BAUSCH AND LOMB	2%;0.79%	A040063	001	Feb 25, 1994

BOROFAIR

PHARMAFAIR	2%;0.79%	A088606	001	Aug 21, 1985

DOMEBORO

BAYER PHARMS	2%;0.79%	A084476	001	

ACETIC ACID, GLACIAL; DESONIDE

SOLUTION/DROPS;OTIC

TRIDESILON

BAYER PHARMS	2%;0.05%	N017914	001	

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC				
ACETIC ACID W/ HYDROCORTISONE				
	KV PHARM	2%;1%	A085492 001	
HYDROCORTISONE AND ACETIC ACID				
	BAUSCH AND LOMB	2%;1%	A040097 001	Oct 31, 1994
	WOCKHARDT	2%;1%	A040168 001	Aug 30, 1996
ORLEX HC				
	WARNER CHILCOTT	2%;1%	A086844 001	

ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

SUSPENSION/DROPS;OTIC				
NEO-CORT-DOME				
	BAYER PHARMS	2%;1%;EQ 0.35% BASE	N050238 001	

ACETOHEXAMIDE

TABLET;ORAL				
ACETOHEXAMIDE				
	ANI PHARMS INC	250MG	A070869 001	Feb 09, 1987
		500MG	A070870 001	Feb 09, 1987
	USL PHARMA	250MG	A070753 001	Nov 03, 1986
		500MG	A070754 001	Nov 03, 1986
	WATSON LABS TEVA	250MG	A071893 001	Nov 25, 1987
		500MG	A071894 001	Nov 25, 1987
DYMELOR				
	LILLY	250MG	N013378 002	
		500MG	N013378 001	

ACETOPHENAZINE MALEATE

TABLET;ORAL				
TINDAL				
	SCHERING	20MG	N012254 002	

ACETRIZOATE SODIUM

SOLUTION;INTRAUTERINE				
SALPIX				
	ORTHO MCNEIL PHARM	53%	N009008 001	

ACETYLCHOLINE CHLORIDE

FOR SOLUTION;OPHTHALMIC				
MIOCHOL				
	NOVARTIS	20MG/VIAL	N016211 001	

ACETYLCYSTEINE

SOLUTION;INHALATION, ORAL				
ACETYLCYSTEINE				
	HOSPIRA	10%	A071364 001	May 01, 1989
		20%	A071365 001	May 01, 1989
	ROXANE	10%	A072323 001	Apr 30, 1992
		10%	A072621 001	Sep 30, 1992
		20%	A072324 001	Apr 30, 1992
		20%	A072622 001	Sep 30, 1992
MUCOMYST				
+	APOTHECON	10% **	N013601 002	
+		20% **	N013601 001	
MUCOSIL-10				
	DEY	10%	A070575 001	Oct 14, 1986
MUCOSIL-20				
	DEY	20%	A070576 001	Oct 14, 1986

ACETYLCYSTEINE; ISOPROTERENOL HYDROCHLORIDE

SOLUTION;INHALATION				
MUCOMYST W/ ISOPROTERENOL				
	MEAD JOHNSON	10%;0.05%	N017366 001	

ACETYLDIGITOXIN

TABLET;ORAL				
ACYLANID				
	NOVARTIS	0.1MG	N009436 001	

ACITRETIN				
CAPSULE;ORAL				
ACITRETIN				
MYLAN PHARMS INC	17.5MG	A203707	001	Sep 10, 2015
	22.5MG	A203707	002	Sep 10, 2015
ACRISORCIN				
CREAM;TOPICAL				
AKRINOL				
SCHERING	2MG/GM	N012470	001	
ACYCLOVIR				
CAPSULE;ORAL				
ACYCLOVIR				
ACTAVIS ELIZABETH	200MG	A074906	001	Aug 26, 1997
CHARTWELL MOLECULES	200MG	A074872	001	Apr 22, 1997
IVAX SUB TEVA PHARMS	200MG	A074674	001	Apr 22, 1997
LEK PHARM	200MG	A074750	001	Apr 22, 1997
MYLAN	200MG	A074727	001	Apr 22, 1997
	200MG	A074977	001	Apr 13, 1998
RANBAXY	200MG	A074975	001	Sep 30, 1998
ROXANE	200MG	A074570	002	Apr 22, 1997
TEVA	200MG	A074828	001	Apr 22, 1997
TEVA PHARMS	200MG	A074914	001	Nov 26, 1997
WATSON LABS	200MG	A075101	001	Apr 15, 1998
TABLET;ORAL				
ACYCLOVIR				
ACTAVIS ELIZABETH	400MG	A074870	001	Jun 05, 1997
	800MG	A074870	002	Jun 05, 1997
CHARTWELL MOLECULES	400MG	A074834	001	Apr 24, 1997
	800MG	A074834	002	Apr 24, 1997
IVAX SUB TEVA PHARMS	400MG	A074836	001	Apr 22, 1997
	800MG	A074836	002	Apr 22, 1997
LEK PHARM	400MG	A074658	001	Apr 22, 1997
	800MG	A074658	002	Apr 22, 1997
MYLAN	400MG	A074976	001	Apr 13, 1998
	800MG	A074976	002	Apr 13, 1998
MYLAN PHARMS INC	400MG	A075211	001	Sep 28, 1998
	800MG	A075211	002	Sep 28, 1998
SUN PHARM INDS LTD	400MG	A074980	001	Sep 30, 1998
	800MG	A074980	002	Sep 30, 1998
TEVA	200MG **	A074556	001	Apr 22, 1997
TEVA PHARMS	400MG	A075021	001	Mar 18, 1998
	800MG	A075021	002	Mar 18, 1998
ACYCLOVIR SODIUM				
INJECTABLE;INJECTION				
ACYCLOVIR				
ABBVIE	EQ 50MG BASE/ML	A075114	001	Jul 26, 1999
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE				
EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A074885	001	Dec 19, 1997
	EQ 1GM BASE/VIAL	A074885	002	Dec 19, 1997
ACYCLOVIR SODIUM				
APOTHECON	EQ 500MG BASE/VIAL	A074897	001	Feb 27, 1998
	EQ 1GM BASE/VIAL	A074897	002	Feb 27, 1998
ATHENEX INC	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997
	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997
EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A074913	001	Oct 15, 1997
	EQ 1GM BASE/VIAL	A074913	002	Oct 15, 1997
FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A075015	001	Apr 30, 1998
HIKMA PHARMS	EQ 500MG BASE/VIAL	A205771	001	Feb 29, 2016
	EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016
HOSPIRA	EQ 25MG BASE/ML	A074720	001	Apr 22, 1997
	EQ 50MG BASE/ML	A075065	001	Feb 25, 1999
	EQ 500MG BASE/VIAL	A074663	001	Apr 22, 1997
	EQ 500MG BASE/VIAL	A074758	001	Apr 22, 1997
	EQ 1GM BASE/VIAL	A074663	002	Apr 22, 1997
	EQ 1GM BASE/VIAL	A074758	002	Apr 22, 1997
MYLAN LABS LTD	EQ 500MG BASE/VIAL	A203927	001	Mar 29, 2017
	EQ 1GM BASE/VIAL	A203927	002	Mar 29, 2017
TEVA PARENTERAL	EQ 50MG BASE/ML	A075627	001	Mar 28, 2001

ACYCLOVIR SODIUM
INJECTABLE;INJECTION
ACYCLOVIR SODIUM

	EQ 500MG BASE/VIAL	A074969	001	Aug 26, 1997
	EQ 1GM BASE/VIAL	A074969	002	Aug 26, 1997
ZYDUS PHARMS USA INC	EQ 500MG BASE/VIAL	A206606	001	Jun 13, 2017
	EQ 1GM BASE/VIAL	A206606	002	Jun 13, 2017

ZOVIRAX

+	GLAXOSMITHKLINE	EQ 250MG BASE/VIAL **	N018603	003	Aug 30, 1983
+		EQ 500MG BASE/VIAL **	N018603	001	Oct 22, 1982
+		EQ 1GM BASE/VIAL **	N018603	002	Jun 29, 1989

ADAPALENE
SOLUTION;TOPICAL
DIFFERIN

+	GALDERMA LABS LP	0.1% **	N020338	001	May 31, 1996

ADENOSINE
INJECTABLE;INJECTION
ADENOCARD

+	ASTELLAS	3MG/ML	N019937	002	Oct 30, 1989

ADENOSINE

	TEVA PHARMS USA	3MG/ML	A076564	001	Jun 16, 2004
		3MG/ML	A078676	001	Jul 31, 2008
	WEST-WARD PHARMS INT	3MG/ML	A076501	001	Jun 16, 2004
	WOCKHARDT	3MG/ML	A090220	001	Jul 20, 2009

SOLUTION;INTRAVENOUS
ADENOSCAN

+	ASTELLAS	60MG/20ML (3MG/ML) **	N020059	001	May 18, 1995
+		90MG/30ML (3MG/ML) **	N020059	002	May 18, 1995

ALATROFLOXACIN MESYLATE
INJECTABLE;INJECTION
TROVAN PRESERVATIVE FREE

	PFIZER	EQ 200MG BASE/VIAL	N020760	001	Dec 18, 1997
		EQ 300MG BASE/VIAL	N020760	002	Dec 18, 1997

ALBENDAZOLE
TABLET, CHEWABLE;ORAL
ALBENZA

	AMEDRA PHARMS LLC	200MG	N207844	001	Jun 11, 2015

ALBUMIN CHROMATED CR-51 SERUM
INJECTABLE;INJECTION
CHROMALBIN

	ISO TEX	100uCi/VIAL	N017835	001
		250uCi/VIAL	N017835	002
		500uCi/VIAL	N017835	003

ALBUMIN IODINATED I-125 SERUM
INJECTABLE;INJECTION
RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN)

	BAYER PHARMS	2.5uCi/AMP	N017846	001

RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125

	MALLINCKRODT	6.67uCi/ML	N017844	003
		10uCi/ML	N017844	001
		100uCi/ML	N017844	002

ALBUMIN IODINATED I-131 SERUM
INJECTABLE;INJECTION
MEGATOPE

	ISO TEX	2mCi/VIAL	N017837	003
		5uCi/AMP	N017837	004
		20uCi/AMP	N017837	005

ALBUTEROL
AEROSOL, METERED;INHALATION
ALBUTEROL

	ARMSTRONG PHARMS	0.09MG/INH	A072273	001	Aug 14, 1996
	GENPHARM	0.09MG/INH	A073045	001	Aug 19, 1997
	IVAX SUB TEVA PHARMS	0.09MG/INH	A073272	001	Dec 28, 1995
	PLIVA	0.09MG/INH	A074072	001	Aug 01, 1996

ALBUTEROL				
AEROSOL, METERED;INHALATION				
PROVENTIL				
SCHERING	0.09MG/INH	N017559	001	
VENTOLIN				
GLAXOSMITHKLINE	0.09MG/INH	N018473	001	
ALBUTEROL SULFATE				
CAPSULE;INHALATION				
VENTOLIN ROTACAPS				
GLAXOSMITHKLINE	EQ 0.2MG BASE	N019489	001	May 04, 1988
SOLUTION;INHALATION				
ALBUTEROL SULFATE				
ACTAVIS MID ATLANTIC	EQ 0.083% BASE	A073533	001	Sep 26, 1995
APOTEX INC	EQ 0.021% BASE	A078623	001	Apr 05, 2010
	EQ 0.042% BASE	A078623	002	Apr 05, 2010
	EQ 0.083% BASE	A075717	001	Feb 02, 2007
	EQ 0.5% BASE	A076391	001	Apr 01, 2003
BAUSCH AND LOMB	EQ 0.083% BASE	A075358	001	Mar 29, 2000
COPLEY PHARM	EQ 0.083% BASE	A073495	001	May 28, 1993
	EQ 0.5% BASE	A073307	001	Nov 27, 1991
HI TECH PHARMA	EQ 0.083% BASE	A075063	001	Feb 09, 1999
LANDELA PHARM	EQ 0.083% BASE	A077569	001	Apr 04, 2006
MYLAN SPECLT	EQ 0.083% BASE **	A072652	001	Feb 21, 1992
ROXANE	EQ 0.083% BASE	A075129	001	Feb 13, 2001
TEVA PHARMS	EQ 0.083% BASE	A075343	001	Nov 09, 1999
WATSON LABS INC	EQ 0.083% BASE	A076370	001	Nov 24, 2003
WOCKHARDT EU OPERATN	EQ 0.083% BASE	A075394	001	Nov 22, 1999
PROVENTIL				
+ SCHERING	EQ 0.083% BASE **	N019243	002	Jan 14, 1987
+	EQ 0.5% BASE **	N019243	001	Jan 14, 1987
VENTOLIN				
+ GLAXOSMITHKLINE	EQ 0.083% BASE **	N019773	001	Apr 23, 1992
	EQ 0.5% BASE **	N019269	002	Jan 16, 1987
SYRUP;ORAL				
ALBUTEROL SULFATE				
ACTAVIS MID ATLANTIC	EQ 2MG BASE/5ML	A075262	001	Mar 30, 1999
MOVA	EQ 2MG BASE/5ML	A074302	001	Sep 30, 1994
WATSON LABS	EQ 2MG BASE/5ML	A073165	001	Apr 29, 1993
PROVENTIL				
+ SCHERING	EQ 2MG BASE/5ML **	N018062	001	Jan 19, 1983
VENTOLIN				
GLAXOSMITHKLINE	EQ 2MG BASE/5ML **	N019621	001	Jun 10, 1987
TABLET;ORAL				
ALBUTEROL SULFATE				
AM THERAP	EQ 2MG BASE	A072449	001	Dec 05, 1989
	EQ 4MG BASE	A072450	001	Dec 05, 1989
COPLEY PHARM	EQ 2MG BASE	A072966	001	Nov 22, 1991
	EQ 4MG BASE	A072967	001	Nov 22, 1991
DAVA PHARMS INC	EQ 2MG BASE	A072860	002	Dec 20, 1989
	EQ 4MG BASE	A072860	001	Dec 20, 1989
PLIVA	EQ 2MG BASE	A072316	001	Dec 05, 1989
	EQ 4MG BASE	A072317	001	Dec 05, 1989
TEVA	EQ 2MG BASE	A072619	001	Dec 05, 1989
	EQ 2MG BASE	A072779	001	Jun 25, 1993
	EQ 2MG BASE	A072938	001	Mar 30, 1990
	EQ 4MG BASE	A072620	001	Dec 05, 1989
	EQ 4MG BASE	A072780	001	Jun 25, 1993
	EQ 4MG BASE	A072939	001	Mar 30, 1990
UCB INC	EQ 2MG BASE	A073120	001	Sep 29, 1992
	EQ 4MG BASE	A073121	001	Sep 29, 1992
WARNER CHILCOTT	EQ 2MG BASE	A072817	001	Jan 09, 1990
	EQ 4MG BASE	A072818	001	Jan 09, 1990
WATSON LABS	EQ 2MG BASE	A072629	001	Jan 31, 1991
	EQ 2MG BASE	A072764	001	Aug 28, 1991
	EQ 4MG BASE	A072630	001	Jan 31, 1991
	EQ 4MG BASE	A072765	001	Aug 28, 1991
YAOPHARMA CO LTD	EQ 2MG BASE	A072151	001	Dec 05, 1989
	EQ 4MG BASE	A072152	001	Dec 05, 1989

ALBUTEROL SULFATE				
TABLET;ORAL				
PROVENTIL				
+ SCHERING	EQ 2MG BASE **	N017853	001	May 07, 1982
+	EQ 4MG BASE **	N017853	002	May 07, 1982
VENTOLIN				
GLAXOSMITHKLINE	EQ 2MG BASE	N019112	001	Jul 10, 1986
	EQ 4MG BASE	N019112	002	Jul 10, 1986
TABLET, EXTENDED RELEASE;ORAL				
PROVENTIL				
SCHERING	EQ 4MG BASE	N019383	001	Jul 13, 1987
VOLMAX				
MURO	EQ 4MG BASE	N019604	002	Dec 23, 1992
	EQ 8MG BASE	N019604	001	Dec 23, 1992
VOSPIRE ER				
DAVA PHARMS INC	EQ 8MG BASE	A076130	003	Sep 26, 2002
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE				
AEROSOL, METERED;INHALATION				
COMBIVENT				
BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH;0.018MG/INH	N020291	001	Oct 24, 1996
SOLUTION;INHALATION				
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE				
APOTEX INC	EQ 0.083% BASE;0.017%	A077117	001	Dec 31, 2007
FOSUN PHARMA	EQ 0.083% BASE;0.017%	A076867	001	Dec 21, 2006
TEVA PHARMS	EQ 0.083% BASE;0.017%	A076724	001	Dec 31, 2007
DUONEB				
+ MYLAN SPECIALITY LP	EQ 0.083% BASE;0.017% **	N020950	001	Mar 21, 2001
ALCLOMETASONE DIPROPIONATE				
CREAM;TOPICAL				
ACLOVATE				
+ FOUGERA PHARMS	0.05% **	N018707	001	Dec 14, 1982
OINTMENT;TOPICAL				
ACLOVATE				
+ FOUGERA PHARMS	0.05% **	N018702	001	Dec 14, 1982
ALCOHOL				
INJECTABLE;INJECTION				
ALCOHOL 5% IN DEXTROSE 5%				
MILES	5ML/100ML	A083483	001	
ALCOHOL; DEXTROSE				
INJECTABLE;INJECTION				
ALCOHOL 10% AND DEXTROSE 5%				
B BRAUN	10ML/100ML;5GM/100ML	N004589	006	
ALCOHOL 5% AND DEXTROSE 5%				
B BRAUN	5ML/100ML;5GM/100ML	N004589	004	
ALCOHOL 5% IN D5-W				
HOSPIRA	5ML/100ML;5GM/100ML	A083263	001	
ALCOHOL 5% IN DEXTROSE 5% IN WATER				
BAXTER HLTHCARE	5ML/100ML;5GM/100ML	A083256	001	
ALENDRONATE SODIUM				
SOLUTION;ORAL				
FOSAMAX				
+ MERCK	EQ 70MG BASE/75ML **	N021575	001	Sep 17, 2003
TABLET;ORAL				
ALENDRONATE SODIUM				
MYLAN	EQ 35MG BASE	A076584	003	Aug 04, 2008
	EQ 35MG BASE	A078638	001	Aug 04, 2008
	EQ 70MG BASE	A076584	004	Aug 04, 2008
	EQ 70MG BASE	A078638	002	Aug 04, 2008
TEVA PHARMS	EQ 35MG BASE	A076184	002	Aug 04, 2008
	EQ 70MG BASE	A076184	001	Feb 06, 2008
UPSHER SMITH LABS	EQ 5MG BASE	A075871	001	Apr 22, 2009
	EQ 10MG BASE	A075871	002	Apr 22, 2009
	EQ 35MG BASE	A075871	004	Apr 22, 2009
	EQ 40MG BASE	A075871	003	Apr 22, 2009
	EQ 70MG BASE	A075871	005	Apr 22, 2009

ALENDRONATE SODIUM

TABLET;ORAL				
FOSAMAX				
+	MERCK AND CO INC	EQ 5MG BASE **	N020560 003	Apr 25, 1997
+		EQ 10MG BASE **	N020560 001	Sep 29, 1995
+		EQ 35MG BASE **	N020560 004	Oct 20, 2000
+		EQ 40MG BASE **	N020560 002	Sep 29, 1995

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL				
ALFUZOSIN HYDROCHLORIDE				
	WOCKHARDT LTD	10MG	A090221 001	Aug 10, 2012

ALGLUCERASE

INJECTABLE;INJECTION				
CEREDASE				
	GENZYME	10 UNITS/ML	N020057 004	May 08, 1992
		80 UNITS/ML	N020057 003	Apr 05, 1991

ALISKIREN HEMIFUMARATE

CAPSULE, PELLET;ORAL				
TEKTURNA				
+	NODEN PHARMA	EQ 37.5MG BASE	N210709 001	Nov 14, 2017

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

TABLET;ORAL				
TEKAMLO				
	NOVARTIS	EQ 150MG BASE;EQ 5MG BASE	N022545 001	Aug 26, 2010
		EQ 150MG BASE;EQ 10MG BASE	N022545 002	Aug 26, 2010
		EQ 300MG BASE;EQ 5MG BASE	N022545 003	Aug 26, 2010
		EQ 300MG BASE;EQ 10MG BASE	N022545 004	Aug 26, 2010

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL				
AMTURNIDE				
	NOVARTIS	EQ 150MG BASE;EQ 5MG BASE;12.5MG	N200045 001	Dec 21, 2010
		EQ 300MG BASE;EQ 5MG BASE;12.5MG	N200045 002	Dec 21, 2010
		EQ 300MG BASE;EQ 5MG BASE;25MG	N200045 003	Dec 21, 2010
		EQ 300MG BASE;EQ 10MG BASE;12.5MG	N200045 004	Dec 21, 2010
		EQ 300MG BASE;EQ 10MG BASE;25MG	N200045 005	Dec 21, 2010

ALISKIREN HEMIFUMARATE; VALSARTAN

TABLET;ORAL				
VALTURNA				
	NOVARTIS	EQ 150MG BASE;160MG	N022217 001	Sep 16, 2009
		EQ 300MG BASE;320MG	N022217 002	Sep 16, 2009

ALKAVERVIR

TABLET;ORAL				
VERILOID				
	3M	2MG	N007336 002	
		3MG	N007336 003	

ALLOPURINOL

TABLET;ORAL				
ALLOPURINOL				
	FOSUN PHARMA	100MG	A070268 001	Dec 31, 1985
	MUTUAL PHARM	100MG	A070466 001	Dec 24, 1985
		300MG	A070467 001	Dec 24, 1985
	PURACAP PHARM	100MG	A070150 001	Dec 10, 1985
		300MG	A070147 001	Dec 10, 1985
	PUREPAC PHARM	100MG	A070579 001	Apr 14, 1986
		300MG	A070580 001	Apr 14, 1986
	SANDOZ	300MG	A070269 001	Dec 31, 1985
	SUPERPHARM	100MG	A070950 001	Nov 30, 1988
		300MG	A070951 001	Nov 30, 1988
	WATSON LABS	100MG	N018241 001	Nov 16, 1984
		100MG	N018785 001	Sep 28, 1984
		300MG	N018241 002	Nov 16, 1984
		300MG	N018785 002	Sep 28, 1984
LOPURIN				
	ABBOTT	100MG	N018297 001	
		300MG	N018297 002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

ALPRAZOLAM

SOLUTION;ORAL					
ALPRAZOLAM					
	ROXANE	0.5MG/5ML	A074314	001	Oct 31, 1993
TABLET;ORAL					
ALPRAZOLAM					
	ANI PHARMS INC	0.25MG	A074085	001	Feb 16, 1994
		0.5MG	A074085	002	Feb 16, 1994
		1MG	A074085	003	Feb 16, 1994
		2MG	A074085	004	Feb 26, 1996
	IVAX SUB TEVA PHARMS	0.25MG	A074294	001	Jul 29, 1994
		0.5MG	A074294	002	Jul 29, 1994
		1MG	A074294	003	Jul 29, 1994
		2MG	A074294	004	Jul 29, 1994
	MYLAN PHARMS INC	0.25MG	A074046	001	Oct 19, 1993
		0.5MG	A074046	002	Oct 19, 1993
		1MG	A074046	003	Oct 19, 1993
		2MG	A074046	004	May 07, 1997
	ROXANE	0.25MG	A074199	001	Oct 19, 1993
		0.5MG	A074199	002	Oct 19, 1993
		1MG	A074199	003	Oct 19, 1993
	WATSON LABS	0.25MG	A074456	001	Aug 31, 1995
		0.25MG	A074479	001	Jan 21, 1997
		0.5MG	A074456	002	Aug 31, 1995
		0.5MG	A074479	002	Jan 21, 1997
		1MG	A074456	003	Aug 31, 1995
		1MG	A074479	003	Jan 21, 1997
TABLET, EXTENDED RELEASE;ORAL					
ALPRAZOLAM					
	ACTAVIS LABS FL INC	0.5MG	A077198	001	May 13, 2010
		1MG	A077198	002	May 13, 2010
		2MG	A077198	003	May 13, 2010
		3MG	A077198	004	May 13, 2010
	ANI PHARMS INC	0.5MG	A077979	001	Feb 28, 2007
		1MG	A077979	002	Feb 28, 2007
		2MG	A077979	003	Feb 28, 2007
		3MG	A077979	004	Feb 28, 2007
	IMPAX LABS	0.5MG	A077968	004	May 24, 2007
		1MG	A077968	003	May 24, 2007
		2MG	A077968	002	May 24, 2007
		3MG	A077968	001	May 24, 2007
	IMPAX LABS INC	0.5MG	A077996	001	Jan 31, 2007
		1MG	A077996	002	Jan 31, 2007
		2MG	A077996	003	Jan 31, 2007
		3MG	A077996	004	Jan 31, 2007
	MYLAN	0.5MG	A077391	002	Jan 26, 2006
		1MG	A077391	003	Jan 26, 2006
		2MG	A077391	004	Jan 26, 2006
		3MG	A077391	001	Jan 26, 2006
	SANDOZ INC	0.5MG	A077777	001	Jun 30, 2006
		1MG	A077777	002	Jun 30, 2006
		2MG	A077777	003	Jun 30, 2006
		3MG	A077777	004	Jun 30, 2006
	VINTAGE PHARMS	0.5MG	A078442	001	Oct 15, 2007
		1MG	A078442	002	Oct 15, 2007
		2MG	A078442	003	Oct 15, 2007
		3MG	A078442	004	Oct 15, 2007
TABLET, ORALLY DISINTEGRATING;ORAL					
NIRAVAM					
+	UCB INC	0.25MG **	N021726	001	Jan 19, 2005
+		0.5MG **	N021726	002	Jan 19, 2005
+		1MG **	N021726	003	Jan 19, 2005
+		2MG **	N021726	004	Jan 19, 2005

ALPROSTADIL				
INJECTABLE;INJECTION				
CAVERJECT				
PFIZER	0.005MG/ML	N020755	001	Oct 31, 1997
	0.01MG/ML	N020755	002	Oct 01, 1997
	0.02MG/ML	N020755	003	Oct 01, 1997
+ PHARMACIA AND UPJOHN	0.005MG/VIAL	N020379	003	Jun 27, 1996
EDEX				
AUXILIUM PHARMS LLC	0.005MG/VIAL	N020649	001	Jun 12, 1997
ALSEROXYLON				
TABLET;ORAL				
RAUTENSIN				
NOVARTIS	2MG	N009215	001	
RAUWILOID				
3M	2MG	N008867	001	
ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE				
TABLET, CHEWABLE;ORAL				
ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE				
PENNEX	80MG;20MG	A089449	001	Nov 27, 1987
FOAMCOAT				
GUARDIAN DRUG	80MG;20MG	A071793	001	Sep 04, 1987
FOAMICON				
NOVARTIS	80MG;20MG	A072687	001	Jun 28, 1989
GAVISCON				
+ SANOFI AVENTIS US	160MG;40MG	N018685	002	Dec 09, 1983
AMANTADINE HYDROCHLORIDE				
CAPSULE;ORAL				
AMANTADINE HYDROCHLORIDE				
ACTAVIS ELIZABETH	100MG	A077659	001	Feb 23, 2006
LANNETT CO INC	100MG	A209221	001	Jun 15, 2017
WATSON LABS	100MG	A071382	001	Jan 21, 1987
SYMADINE				
SOLVAY	100MG	A071000	001	Sep 04, 1986
SYMMETREL				
+ ENDO PHARMS	100MG **	N016020	001	
SYRUP;ORAL				
AMANTADINE HYDROCHLORIDE				
G AND W LABS INC	50MG/5ML	A072655	001	Oct 30, 1990
LANNETT CO INC	50MG/5ML	A076352	001	Sep 10, 2004
TEVA PHARMS	50MG/5ML	A073115	001	Aug 23, 1991
VINTAGE	50MG/5ML	A077992	001	Dec 12, 2006
SYMMETREL				
+ ENDO PHARMS	50MG/5ML **	N016023	002	
TABLET;ORAL				
SYMMETREL				
+ ENDO PHARMS	100MG **	N018101	001	
AMBENONIUM CHLORIDE				
TABLET;ORAL				
MYTELASE				
SANOFI AVENTIS US	10MG	N010155	002	
AMCINONIDE				
CREAM;TOPICAL				
CYCLOCORT				
+ ASTELLAS	0.025%	N018116	001	
+	0.1%	N018116	002	
LOTION;TOPICAL				
CYCLOCORT				
+ ASTELLAS	0.1%	N019729	001	Jun 13, 1988
OINTMENT;TOPICAL				
CYCLOCORT				
+ ASTELLAS	0.1%	N018498	001	

AMDINOCILLIN				
INJECTABLE;INJECTION				
COACTIN				
ROCHE	250MG/VIAL	N050565	001	Dec 21, 1984
	500MG/VIAL	N050565	002	Dec 21, 1984
	1GM/VIAL	N050565	003	Dec 21, 1984
AMIFOSTINE				
INJECTABLE;INJECTION				
ETHYOL				
CLINIGEN HLTHCARE	375MG/VIAL	N020221	002	Sep 10, 1999
AMIKACIN SULFATE				
INJECTABLE;INJECTION				
AMIKACIN SULFATE				
ABBOTT	EQ 250MG BASE/ML	A063265	001	Nov 30, 1994
	EQ 250MG BASE/ML	A063266	001	Oct 31, 1994
HOSPIRA	EQ 50MG BASE/ML	A063263	001	Nov 30, 1994
	EQ 50MG BASE/ML	A063350	001	Jul 30, 1993
	EQ 62.5MG BASE/ML	A063283	001	Oct 31, 1994
	EQ 250MG BASE/ML	A063264	001	Nov 30, 1994
	EQ 250MG BASE/ML	A063350	002	Jul 30, 1993
	EQ 250MG BASE/ML	A064098	001	Jun 26, 1995
	EQ 250MG BASE/ML	A064099	001	Jun 20, 1995
IGI LABS INC	EQ 50MG BASE/ML	A063167	001	Dec 14, 1995
	EQ 250MG BASE/ML	A063169	001	Dec 14, 1995
TEVA PHARMS USA	EQ 50MG BASE/ML	A064045	001	Sep 28, 1993
WEST-WARD PHARMS INT	EQ 50MG BASE/ML	A063274	001	May 18, 1992
	EQ 250MG BASE/ML	A063275	001	May 18, 1992
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
HOSPIRA	EQ 500MG BASE/100ML	A064146	001	Apr 02, 1997
AMIKIN				
APOTHECON	EQ 50MG BASE/ML	A062311	001	
	EQ 50MG BASE/ML	A062562	001	Sep 20, 1984
+	EQ 50MG BASE/ML **	N050495	001	
	EQ 250MG BASE/ML	A062311	002	
	EQ 250MG BASE/ML	A062562	002	Sep 20, 1984
+	EQ 250MG BASE/ML **	N050495	002	
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
APOTHECON	EQ 5MG BASE/ML	N050618	002	Nov 30, 1987
	EQ 10MG BASE/ML	N050618	001	Nov 30, 1987
AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE				
TABLET;ORAL				
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
TEVA	EQ 5MG ANHYDROUS;50MG	A070795	001	Apr 17, 1988
WATSON LABS	EQ 5MG ANHYDROUS;50MG	A073334	001	Jul 19, 1991
YAOPHARMA CO LTD	EQ 5MG ANHYDROUS;50MG	A073357	001	Nov 27, 1991
HYDRO-RIDE				
PAR PHARM	EQ 5MG ANHYDROUS;50MG	A070347	001	Dec 25, 1990
MODURETIC 5-50				
+ MERCK	EQ 5MG ANHYDROUS;50MG **	N018201	001	
AMINO ACIDS				
INJECTABLE;INJECTION				
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE				
HOSPIRA	5.2% (5.2GM/100ML)	N018901	001	Apr 06, 1984
AMINOSYN 10% (PH6)				
ICU MEDICAL INC	10% (10GM/100ML)	N017673	008	Nov 18, 1985
AMINOSYN 3.5%				
ICU MEDICAL INC	3.5% (3.5GM/100ML)	N017789	004	
AMINOSYN 3.5% IN PLASTIC CONTAINER				
ABBOTT	3.5% (3.5GM/100ML)	N018804	001	May 15, 1984
	3.5% (3.5GM/100ML)	N018875	001	Aug 08, 1984
AMINOSYN 5%				
ICU MEDICAL INC	5% (5GM/100ML)	N017673	001	
AMINOSYN 7%				
ICU MEDICAL INC	7% (7GM/100ML)	N017673	002	
AMINOSYN 7% (PH6)				
ICU MEDICAL INC	7% (7GM/100ML)	N017673	006	Nov 18, 1985

AMINO ACIDS

INJECTABLE;INJECTION

AMINOSYN 8.5% (PH6)				
ICU MEDICAL INC	8.5% (8.5GM/100ML)	N017673	007	Nov 18, 1985
AMINOSYN II 10%				
ICU MEDICAL INC	10% (10GM/100ML)	N019438	005	Apr 03, 1986
AMINOSYN II 3.5%				
ICU MEDICAL INC	3.5% (3.5GM/100ML)	N019438	001	Apr 03, 1986
AMINOSYN II 3.5% IN PLASTIC CONTAINER				
ABBOTT	3.5% (3.5GM/100ML)	N019491	001	Oct 10, 1986
AMINOSYN II 5%				
ICU MEDICAL INC	5% (5GM/100ML)	N019438	002	Apr 03, 1986
AMINOSYN II 7%				
ICU MEDICAL INC	7% (7GM/100ML)	N019438	003	Apr 03, 1986
AMINOSYN II 8.5%				
ICU MEDICAL INC	8.5% (8.5GM/100ML)	N019438	004	Apr 03, 1986
AMINOSYN-HBC 7%				
ICU MEDICAL INC	7% (7GM/100ML)	N019374	001	Jul 12, 1985
AMINOSYN-HBC 7% IN PLASTIC CONTAINER				
ABBOTT	7% (7GM/100ML)	N019400	001	Jul 23, 1986
AMINOSYN-HF 8%				
ICU MEDICAL INC	8% (8GM/100ML)	A020345	001	Apr 04, 1996
AMINOSYN-RF 5.2%				
ICU MEDICAL INC	5.2% (5.2GM/100ML)	N018429	001	
BRANCHAMIN 4%				
BAXTER HLTHCARE	4% (4GM/100ML)	N018678	001	Sep 28, 1984
BRANCHAMIN 4% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4% (4GM/100ML)	N018684	001	Sep 28, 1984
FREAMINE 8.5%				
B BRAUN	8.5% (8.5GM/100ML)	N016822	001	
FREAMINE II 8.5%				
B BRAUN	8.5% (8.5GM/100ML)	N016822	002	
HEPATASOL 8%				
BAXTER HLTHCARE	8% (8GM/100ML)	A020360	001	Apr 04, 1996
NEOPHAM 6.4%				
HOSPIRA	6.4% (6.4GM/100ML)	N018792	001	Jan 17, 1984
NOVAMINE 11.4%				
HOSPIRA INC	11.4% (11.4GM/100ML)	N017957	003	Aug 09, 1982
NOVAMINE 15%				
HOSPIRA INC	15% (75GM/500ML)	N017957	004	Nov 28, 1986
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	15% (15GM/100ML) **	N020107	001	Feb 05, 1993
NOVAMINE 8.5%				
HOSPIRA INC	8.5% (8.5GM/100ML)	N017957	002	Aug 09, 1982
RENAMIN W/O ELECTROLYTES				
BAXTER HLTHCARE	6.5% (6.5GM/100ML)	N017493	007	Oct 15, 1982
TRAVASOL 10% W/O ELECTROLYTES				
BAXTER HLTHCARE	10% (10GM/100ML)	N017493	006	
TRAVASOL 5.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N017493	004	
TRAVASOL 8.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N017493	005	

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714	001	Sep 12, 1988
HOSPIRA INC	3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	001	Nov 07, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	4.25%;36.8MG/100ML;20GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714	002	Sep 12, 1988
HOSPIRA INC	4.25%;36.8MG/100ML;20GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	002	Nov 07, 1988

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT	4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714	004	Sep 12, 1988
HOSPIRA INC	4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	003	Nov 07, 1988

AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;2 2.4MG/100ML;261MG/100ML;205MG/100ML	N019714	003	Sep 12, 1988
HOSPIRA INC	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;2 2.4MG/100ML;261MG/100ML;205MG/100ML	N019683	004	Nov 07, 1988

AMINO ACIDS; DEXTROSE

INJECTABLE;INJECTION

AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	3.5%;25GM/100ML	N019118	001	Oct 11, 1984

AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	3.5%;5GM/100ML	N019120	001	Oct 11, 1984

AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%;25GM/100ML	N019119	001	Oct 11, 1984

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	3.5%;25GM/100ML	N019505	002	Nov 07, 1986
	3.5%;25GM/100ML	N019713	006	Sep 09, 1988
HOSPIRA	3.5%;25GM/100ML	N019681	001	Nov 01, 1988

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	3.5%;5GM/100ML	N019506	001	Nov 07, 1986
	3.5%;5GM/100ML	N019713	002	Sep 09, 1988
HOSPIRA	3.5%;5GM/100ML	N019681	002	Nov 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML	N019713	001	Sep 09, 1988
HOSPIRA	4.25%;10GM/100ML	N019681	004	Nov 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

ABBOTT	4.25%;20GM/100ML	N019713	004	Sep 09, 1988
HOSPIRA	4.25%;20GM/100ML	N019681	005	Nov 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%;25GM/100ML	N019504	002	Nov 07, 1986
	4.25%;25GM/100ML	N019713	005	Sep 09, 1988
HOSPIRA	4.25%;25GM/100ML	N019681	003	Nov 01, 1988

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	5%;25GM/100ML	N019565	001	Dec 17, 1986
	5%;25GM/100ML	N019713	003	Sep 09, 1988
HOSPIRA	5%;25GM/100ML	N019681	006	Nov 01, 1988

TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;10GM/100ML	N019520	002	Sep 23, 1988

TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;15GM/100ML	N019520	003	Sep 23, 1988

TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;20GM/100ML	N019520	004	Sep 23, 1988

TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;25GM/100ML	N019520	005	Sep 23, 1988

TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;5GM/100ML	N019520	001	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;10GM/100ML	N019520	007	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;15GM/100ML	N019520	008	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;20GM/100ML	N019520	009	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;25GM/100ML	N019520	010	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;5GM/100ML	N019520	006	Sep 23, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML;51MG/100ML;176.5MG/100 ML;22.4MG/100ML;104.5MG/100ML;205MG/100 ML	N019712	002	Sep 08, 1988
HOSPIRA INC	4.25%;10GM/100ML;51MG/100ML;176.5MG/100 ML;22.4MG/100ML;104.5MG/100ML;205MG/100 ML	N019682	003	Nov 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	3.5%;25GM/100ML;51MG/100ML;22.4MG/100ML ;261MG/100ML;205MG/100ML	N019564	002	Dec 16, 1986

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%;25GM/100ML;51MG/100ML;22.4MG/100M L;261MG/100ML;205MG/100ML	N019564	004	Dec 16, 1986

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;12 0MG/100ML;49.3MG/100ML	N019564	001	Dec 16, 1986
	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;12 0MG/100ML;49.3MG/100ML	N019712	001	Sep 08, 1988
HOSPIRA INC	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;12 0MG/100ML;49.3MG/100ML	N019682	001	Nov 01, 1988

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML;30MG/100ML;97MG/100ML; 120MG/100ML;49.3MG/100ML	N019564	003	Dec 16, 1986
HOSPIRA INC	4.25%;5GM/100ML;30MG/100ML;97MG/100ML;1 20MG/100ML;49.3MG/100ML	N019682	002	Nov 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;10GM/100ML;51MG/100ML;261MG/100ML ;216MG/100ML;112MG/100ML	N020147	002	Oct 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;15GM/100ML;51MG/100ML;261MG/100ML ;216MG/100ML;112MG/100ML	N020147	003	Oct 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;20GM/100ML;51MG/100ML;261MG/100ML ;216MG/100ML;112MG/100ML	N020147	004	Oct 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;25GM/100ML;51MG/100ML;261MG/100ML ;216MG/100ML;112MG/100ML	N020147	005	Oct 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;5GM/100ML;51MG/100ML;261MG/100ML; 216MG/100ML;112MG/100ML	N020147	001	Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;10GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML	N020147	007	Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;15GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML	N020147	008	Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;20GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML	N020147	009	Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;25GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML	N020147	010	Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;5GM/100ML;51MG/100ML;261MG/100ML; 297MG/100ML;77MG/100ML	N020147	006	Oct 23, 1995

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN 3.5% M IN PLASTIC CONTAINER

ABBOTT	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N018804	002	May 15, 1984
	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N018875	002	Aug 08, 1984

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN 3.5% M

ICU MEDICAL INC	3.5%;21MG/100ML;128MG/100ML;234MG/100ML	N017789	005	

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

AMINOSYN II 3.5% M IN PLASTIC CONTAINER

ABBOTT	3.5%;32MG/100ML;128MG/100ML;222MG/100ML;49MG/100ML	N019493	001	Oct 16, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE;INJECTION

VEINAMINE 8%

HOSPIRA INC	8%;61MG/100ML;211MG/100ML;56MG/100ML;38 8MG/100ML	N017957	001	

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 10% W/ ELECTROLYTES

ICU MEDICAL INC	10%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	004	Apr 03, 1986

AMINOSYN II 7% W/ ELECTROLYTES

ICU MEDICAL INC	7%;102MG/100ML;45MG/100ML;522MG/100ML;4 10MG/100ML	N019437	006	Apr 03, 1986

AMINOSYN II 8.5% W/ ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	005	Apr 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE;INJECTION

AMINOSYN II 8.5% W/ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;492MG/100ML;60MG/100ML;425MG/100ML	N019437	008	Oct 25, 2002

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

AMINOSYN II 3.5% M

ICU MEDICAL INC	3.5%;30MG/100ML;97MG/100ML;120MG/100ML;49MG/100ML	N019437	007	Apr 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N020177	001	Oct 23, 1995

TRAVASOL 3.5% W/ ELECTROLYTES

BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N017493	003	

TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML	N020173	001	Oct 27, 1995

TRAVASOL 5.5% W/ ELECTROLYTES

BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML	N017493	001	

TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML	N020173	002	Oct 27, 1995

TRAVASOL 8.5% W/ ELECTROLYTES

BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML	N017493	002	

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE				
INJECTABLE;INJECTION				
AMINOSYN 7% W/ ELECTROLYTES				
	ICU MEDICAL INC	7%;102MG/100ML;522MG/100ML;410MG/100ML	N017789 002	
AMINOSYN 8.5% W/ ELECTROLYTES				
	ICU MEDICAL INC	8.5%;102MG/100ML;522MG/100ML;410MG/100ML	N017673 005	
AMINOCAPROIC ACID				
INJECTABLE;INJECTION				
AMICAR				
+	CLOVER PHARMS	250MG/ML **	N015229 002	
AMINOCAPROIC ACID				
	ABRAXIS PHARM	250MG/ML	A070522 001	Jun 17, 1986
	BAXTER HLTHCARE	250MG/ML	N018590 001	Oct 29, 1982
	HOSPIRA	250MG/ML	A070888 001	Jun 16, 1988
SYRUP;ORAL				
AMINOCAPROIC ACID				
	AKORN	1.25GM/5ML	A074759 001	Sep 02, 1998
TABLET;ORAL				
AMINOCAPROIC				
	AKORN	500MG	A075602 001	May 24, 2001
AMINOGLUTETHIMIDE				
TABLET;ORAL				
CYTADREN				
	NOVARTIS	250MG	N018202 001	
AMINOHIPPURATE SODIUM				
INJECTABLE;INJECTION				
AMINOHIPPURATE SODIUM				
	MERCK	20%	N005619 001	
AMINOPHYLLINE				
ENEMA;RECTAL				
SOMOPHYLLIN				
	FISONS	300MG/5ML	N018232 001	Apr 02, 1982
INJECTABLE;INJECTION				
AMINOPHYLLIN				
	GD SEARLE LLC	25MG/ML	A087243 001	May 24, 1982
		25MG/ML	A087621 001	May 24, 1982
AMINOPHYLLINE				
	ABRAXIS PHARM	25MG/ML	A084568 001	
		25MG/ML	A087200 001	
		25MG/ML	A087250 001	Jan 06, 1982
		25MG/ML	A087886 001	Aug 30, 1983
		25MG/ML	A088407 001	Jan 25, 1984
	ELKINS SINN	25MG/ML	A087239 001	
	HOSPIRA	25MG/ML	A087601 001	Jul 23, 1982
	INTL MEDICATION	25MG/ML	A087209 001	Feb 01, 1982
		25MG/ML	A087867 001	Nov 10, 1983
		25MG/ML	A087868 001	Nov 10, 1983
	KING PHARMS	25MG/ML	A086606 001	
	LUITPOLD	25MG/ML	A087240 001	
	LYPHOMED	25MG/ML	A087431 001	
	PHARMA SERVE NY	25MG/ML	A087387 001	Jun 03, 1983
		25MG/ML	A087392 001	Dec 15, 1983
	SMITH AND NEPHEW	25MG/ML	A088429 001	May 30, 1985
		25MG/ML	A088749 001	May 30, 1985
	TEVA PARENTERAL	25MG/ML	A081142 001	Sep 25, 1991
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%				
	HOSPIRA	100MG/100ML	A088147 002	May 03, 1983
		200MG/100ML	A088147 003	May 03, 1983
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	HOSPIRA	100MG/100ML	N018924 001	Dec 12, 1984
		200MG/100ML	N018924 002	Dec 12, 1984
		400MG/100ML	N018924 003	Dec 12, 1984
		500MG/100ML	N018924 004	Dec 12, 1984
SOLUTION;ORAL				
AMINOPHYLLINE				
	MORTON GROVE	105MG/5ML	A088156 001	Dec 05, 1983

AMINOPHYLLINE				
SOLUTION;ORAL				
AMINOPHYLLINE				
ROXANE	105MG/5ML	A088126	001	Aug 19, 1983
AMINOPHYLLINE DYE FREE				
ACTAVIS MID ATLANTIC	105MG/5ML	A087727	001	Apr 16, 1982
SOMOPHYLLIN				
FISONS	105MG/5ML	A086466	001	
SOMOPHYLLIN-DF				
FISONS	105MG/5ML	A087045	001	
SUPPOSITORY;RECTAL				
TRUPHYLLINE				
G AND W LABS	250MG	A085498	001	Mar 23, 1983
	500MG	A085498	002	Jan 03, 1983
TABLET;ORAL				
AMINOPHYLLIN				
GD SEARLE LLC	100MG	N002386	002	
	200MG	N002386	003	
AMINOPHYLLINE				
ANI PHARMS INC	100MG	A085261	004	
	200MG	A085261	002	
ASCOT	100MG	A087522	001	Feb 12, 1982
	200MG	A087523	001	Feb 12, 1982
BARR	100MG	A088297	001	Aug 19, 1983
	200MG	A088298	001	Aug 19, 1983
DURAMED PHARMS BARR	100MG	A088182	001	Mar 31, 1983
	200MG	A088183	001	Mar 31, 1983
HALSEY	100MG	A084674	001	
HIKMA INTL PHARMS	100MG	A084540	001	
	200MG	A085003	001	
IMPAX LABS	100MG	A084574	001	
	200MG	A084576	001	
KV PHARM	100MG	A085284	001	
	200MG	A085289	001	
LANNETT	100MG	A084588	001	
	200MG	A084588	002	
PAL PAK	100MG	A084533	001	
PANRAY	100MG	A084552	001	
	200MG	A084552	002	
PUREPAC PHARM	100MG	A084699	001	
	200MG	A085333	001	
ROXANE	100MG	A087500	001	Feb 09, 1982
	200MG	A087501	001	Feb 09, 1982
VALEANT PHARM INTL	200MG	A084563	001	
VANGARD	100MG	A088314	001	Oct 03, 1983
	200MG	A088319	001	Oct 03, 1983
VINTAGE PHARMS	100MG	A085409	001	
	200MG	A085410	001	
WATSON LABS	100MG	A085567	001	
	200MG	A085564	001	
TABLET, DELAYED RELEASE;ORAL				
AMINOPHYLLINE				
IMPAX LABS	100MG	A084577	001	
	200MG	A084575	001	
TABLICAPS	100MG	A084632	002	
VALE	100MG	A084531	001	
	200MG	A084530	001	
TABLET, EXTENDED RELEASE;ORAL				
PHYLLOCONTIN				
PHARM RES ASSOC	225MG	A086760	001	
AMINOSALICYLATE SODIUM				
POWDER;ORAL				
P.A.S. SODIUM				
CENTURY PHARMS	4GM/PACKET	A080947	001	
SODIUM AMINOSALICYLATE				
HEXCEL	100%	A080097	001	

AMINOSALICYLATE SODIUM				
TABLET;ORAL				
PARASAL SODIUM				
PANRAY	500MG		N006811 006	
	1GM		N006811 011	
SODIUM P.A.S.				
LANNETT	500MG		A080138 002	
TEEBACIN				
CONSOLIDATED MIDLAND	500MG		N007320 002	
AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID				
TABLET;ORAL				
NEOPASALATE				
MEDPOINTE PHARM HLC	846MG;112MG		A080059 002	
AMINOSALICYLIC ACID				
TABLET;ORAL				
PARASAL				
PANRAY	500MG		N006811 001	
	1GM		N006811 002	
AMINOSALICYLIC ACID RESIN COMPLEX				
POWDER;ORAL				
REZIPAS				
BRISTOL MYERS SQUIBB	EQ 500MG BASE/GM		N009052 001	
AMIODARONE HYDROCHLORIDE				
INJECTABLE;INJECTION				
AMIODARONE HYDROCHLORIDE				
AKORN	50MG/ML		A076232 001	Jul 05, 2006
BEDFORD	50MG/ML		A076018 001	Oct 15, 2002
BEDFORD LABS	50MG/ML		A076299 001	Oct 24, 2002
BEN VENUE	50MG/ML		A076088 001	Oct 15, 2002
HOSPIRA	50MG/ML		A076108 001	Oct 15, 2002
INTL MEDICATION SYS	50MG/ML		N021594 001	Feb 04, 2004
PAR STERILE PRODUCTS	50MG/ML		A076394 001	Apr 25, 2003
TEVA PHARMS USA	50MG/ML		A076163 001	Sep 05, 2003
CORDARONE				
+ WYETH PHARMS INC	50MG/ML **		N020377 001	Aug 03, 1995
NEXTERONE				
+ BAXTER HLTHCARE	50MG/ML		N022325 001	Dec 24, 2008
TABLET;ORAL				
AMIODARONE HYDROCHLORIDE				
MYLAN	200MG		A075188 001	Feb 24, 1999
TEVA	200MG		A074895 001	Apr 16, 1999
CORDARONE				
+ WYETH PHARMS	200MG **		N018972 001	Dec 24, 1985
AMITRIPTYLINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
ENDEP				
ROCHE	40MG/ML		A085749 001	
INJECTABLE;INJECTION				
AMITRIPTYLINE HYDROCHLORIDE				
WATSON LABS	10MG/ML		A085594 001	
ELAVIL				
ASTRAZENECA	10MG/ML		N012704 001	
TABLET;ORAL				
AMITID				
BRISTOL MYERS SQUIBB	10MG		A086454 001	
	25MG		A086454 002	
	50MG		A086454 003	
	75MG		A086454 004	
	100MG		A086454 005	
AMITRIL				
WARNER CHILCOTT	10MG		A083939 001	
	25MG		A083937 001	
	50MG		A083938 002	
	75MG		A084957 001	
	100MG		A085093 001	
	150MG		A086295 001	

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AM THERAP	25MG	A088672	001	Nov 20, 1984
	50MG	A088673	001	Nov 20, 1984
	75MG	A088674	001	Nov 20, 1984
	100MG	A088675	001	Nov 20, 1984
ANI PHARMS INC	10MG	A085031	002	
	25MG	A085031	001	
	50MG	A085031	003	
	75MG	A085031	004	
COPLEY PHARM	10MG	A088421	001	Apr 30, 1984
	25MG	A088422	001	Apr 30, 1984
	50MG	A088423	001	Apr 30, 1984
	75MG	A088424	001	Apr 30, 1984
	100MG	A088425	001	Apr 30, 1984
	150MG	A088426	001	Apr 30, 1984
HALSEY	10MG	A085923	001	
	25MG	A085922	001	
	50MG	A085925	001	
	50MG	A087557	001	Mar 05, 1982
	75MG	A085926	001	May 20, 1983
	100MG	A085927	001	May 20, 1983
LEDERLE	10MG	A086744	001	
	10MG	A087366	001	Jan 04, 1982
	25MG	A086746	001	
	25MG	A087367	001	May 03, 1982
	50MG	A086743	001	
	50MG	A087181	001	Jan 04, 1982
	75MG	A086745	001	
	75MG	A087369	001	Jan 04, 1982
	100MG	A086747	001	
	100MG	A087368	001	May 03, 1982
	150MG	A087370	001	Jan 04, 1982
MUTUAL PHARM	10MG	A085744	001	
	25MG	A085627	001	
	50MG	A085745	001	
	75MG	A085743	001	
	100MG	A085742	002	May 11, 1982
	150MG	A089423	001	Feb 17, 1987
PAR PHARM	10MG	A088697	001	Sep 25, 1984
	25MG	A088698	001	Sep 25, 1984
	50MG	A088699	001	Sep 25, 1984
	75MG	A088700	001	Sep 25, 1984
	100MG	A088701	001	Sep 25, 1984
	150MG	A088702	001	Sep 25, 1984
PLIVA	10MG	A088883	001	Sep 26, 1984
	25MG	A088884	001	Sep 26, 1984
	50MG	A088885	001	Sep 26, 1984
	75MG	A088886	001	Sep 26, 1984
	100MG	A088887	001	Sep 26, 1984
	150MG	A088888	001	Sep 26, 1984
PUREPAC PHARM	10MG	A088075	001	Sep 16, 1983
	10MG	A088084	001	Jul 18, 1983
	25MG	A088076	001	May 20, 1983
	25MG	A088085	001	Jul 18, 1983
	50MG	A088077	001	Sep 16, 1983
	50MG	A088105	001	Jul 18, 1983
	75MG	A088078	001	Sep 16, 1983
	75MG	A088106	001	Jul 18, 1983
	100MG	A088079	001	Sep 16, 1983
	100MG	A088107	001	Jul 18, 1983
ROXANE	10MG	A086002	001	
	10MG	A086144	001	
	25MG	A085944	001	
	25MG	A086145	001	
	50MG	A085945	001	
	50MG	A086143	001	
	75MG	A086004	001	

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE					
		75MG		A086147 001	
		100MG		A086003 001	
		100MG		A086146 001	
		150MG		A086090 001	
		150MG		A086148 001	
	SUN PHARM INDS INC	10MG		A040816 002	Jun 27, 2008
		25MG		A040816 001	Jun 27, 2008
		50MG		A040816 003	Jun 27, 2008
		75MG		A040816 004	Jun 27, 2008
		100MG		A040816 005	Jun 27, 2008
		150MG		A040816 006	Jun 27, 2008
	SUPERPHARM	10MG		A088853 001	Nov 13, 1984
		25MG		A088854 001	Nov 13, 1984
		50MG		A088855 001	Nov 13, 1984
		75MG		A088856 001	Nov 13, 1984
		100MG		A088857 001	Nov 13, 1984
	TEVA	10MG		A086610 001	
		25MG		A086859 001	
		50MG		A086857 001	
		75MG		A086860 001	
		100MG		A085836 001	
		100MG		A086854 001	
		150MG		A086853 001	
	UCB INC	10MG		A085864 001	
		25MG		A085935 001	
		50MG		A085936 001	
		75MG		A086337 001	
		100MG		A086336 001	
		150MG		A086335 001	
	USL PHARMA	25MG		A087775 001	Feb 10, 1982
	VANGARD	10MG		A087632 001	Feb 01, 1982
		50MG		A087616 001	Feb 08, 1982
		75MG		A087617 001	Feb 05, 1982
		100MG		A087639 001	Feb 08, 1982
	WATSON LABS	10MG		A085816 001	
		10MG		A088620 001	Mar 02, 1984
		25MG		A085817 001	
		25MG		A088621 001	Mar 02, 1984
		50MG		A085815 001	
		50MG		A088622 001	Mar 02, 1984
		75MG		A085819 001	
		75MG		A088633 001	Mar 02, 1984
		100MG		A085820 001	
		100MG		A088634 001	Mar 02, 1984
		150MG		A085821 001	
		150MG		A088635 001	Mar 02, 1984
	WEST WARD	10MG		A087647 001	Mar 05, 1982
		25MG		A087278 001	
ELAVIL					
+	ASTRAZENECA	10MG **		N012703 001	
+		25MG **		N012703 003	
+		50MG **		N012703 004	
+		75MG **		N012703 005	
+		100MG **		N012703 006	
+		150MG **		N012703 007	
ENDEP					
	ROCHE	10MG		A083639 001	
		25MG		A083639 002	
		50MG		A083639 003	
		75MG		A083639 004	
		100MG		A083639 005	
		150MG		A085303 001	

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL				
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE				
FRONTIDA BIOPHARM	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986
	EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986
PAR PHARM	EQ 12.5MG BASE;5MG	A072277	001	May 09, 1988
	EQ 25MG BASE;10MG	A072278	001	May 09, 1988
USL PHARMA	EQ 12.5MG BASE;5MG	A070477	001	Jan 12, 1988
	EQ 25MG BASE;10MG	A070478	001	Jan 12, 1988
WATSON LABS	EQ 25MG BASE;10MG	A072053	001	Dec 16, 1988
WATSON LABS TEVA	EQ 12.5MG BASE;5MG	A072052	001	Dec 16, 1988
LIMBITROL				
+ HERITAGE PHARMS INC	EQ 12.5MG BASE;5MG **	N016949	001	
LIMBITROL DS				
+ HERITAGE PHARMS INC	EQ 25MG BASE;10MG **	N016949	002	

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL				
ETRAFON 2-10				
SCHERING	10MG;2MG **	N014713	007	
ETRAFON 2-25				
SCHERING	25MG;2MG **	N014713	004	
ETRAFON-A				
SCHERING	10MG;4MG **	N014713	002	
ETRAFON-FORTE				
SCHERING	25MG;4MG **	N014713	006	
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE				
FOSUN PHARMA	10MG;2MG	A071062	001	Nov 27, 1987
	10MG;4MG	A071862	001	Dec 21, 1987
	25MG;2MG	A071063	001	Nov 27, 1987
	25MG;4MG	A071064	001	Nov 27, 1987
	50MG;4MG	A071863	001	Dec 21, 1987
IVAX SUB TEVA PHARMS	10MG;2MG	A070935	001	Sep 11, 1986
	10MG;4MG	A070937	001	Sep 11, 1986
	25MG;2MG	A070936	001	Sep 11, 1986
	25MG;4MG	A070938	001	Sep 11, 1986
	50MG;4MG	A070939	001	Sep 12, 1986
PAR PHARM	10MG;2MG	A070565	001	Sep 11, 1986
	10MG;4MG	A070620	001	Sep 11, 1986
	25MG;2MG	A070621	001	Sep 11, 1986
	25MG;4MG	A070595	001	Sep 11, 1986
	50MG;4MG	A070574	001	Sep 11, 1986
SUN PHARM INDUSTRIES	10MG;2MG	A071077	001	Nov 12, 1986
	10MG;4MG	A071078	001	Nov 12, 1986
	25MG;2MG	A070297	001	Nov 12, 1986
	25MG;4MG	A071079	001	Nov 12, 1986
WATSON LABS	10MG;2MG	A070373	001	Aug 25, 1986
	10MG;2MG	A072539	001	Feb 15, 1989
	10MG;2MG	A073007	001	Oct 17, 1991
	10MG;4MG	A070375	001	Aug 25, 1986
	10MG;4MG	A072540	001	Feb 15, 1989
	10MG;4MG	A073009	001	Oct 17, 1991
	25MG;2MG	A070374	001	Aug 25, 1986
	25MG;2MG	A072541	001	Feb 15, 1989
	25MG;2MG	A073008	001	Oct 17, 1991
	25MG;4MG	A070376	001	Aug 25, 1986
	25MG;4MG	A072134	001	Feb 15, 1989
	25MG;4MG	A073010	001	Oct 17, 1991
	50MG;4MG	A070377	001	Nov 04, 1986
	50MG;4MG	A071558	001	Mar 02, 1987
	50MG;4MG	A072135	001	Feb 15, 1989
TRIAVIL 2-10				
NEW RIVER	10MG;2MG **	N014715	004	
TRIAVIL 2-25				
NEW RIVER	25MG;2MG **	N014715	002	
TRIAVIL 4-10				
NEW RIVER	10MG;4MG **	N014715	003	
TRIAVIL 4-25				
NEW RIVER	25MG;4MG **	N014715	005	

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE				
TABLET;ORAL				
TRIAVIL 4-50				
NEW RIVER	50MG;4MG **	N014715	006	
AMLEXANOX				
PASTE;DENTAL				
APHTHASOL				
ULURU	5%	N020511	001	Dec 17, 1996
PATCH;TOPICAL				
AMLEXANOX				
ULURU	2MG	N021727	001	Sep 29, 2004
AMLODIPINE BESYLATE				
TABLET;ORAL				
AMLODIPINE BESYLATE				
AMNEAL PHARMS NY	EQ 2.5MG BASE	A078477	001	Jan 16, 2008
	EQ 5MG BASE	A078477	002	Jan 16, 2008
	EQ 10MG BASE	A078477	003	Jan 16, 2008
GEDEON RICHTER USA	EQ 2.5MG BASE	A077333	001	Jul 17, 2007
	EQ 5MG BASE	A077333	002	Jul 17, 2007
	EQ 10MG BASE	A077333	003	Jul 17, 2007
GENPHARM	EQ 2.5MG BASE	A077362	001	Jul 09, 2007
	EQ 5MG BASE	A077362	002	Jul 09, 2007
	EQ 10MG BASE	A077362	003	Jul 09, 2007
MYLAN PHARMS INC	EQ 2.5MG BASE	A078224	001	Feb 27, 2008
	EQ 5MG BASE	A078224	002	Feb 27, 2008
	EQ 10MG BASE	A078224	003	Feb 27, 2008
PURACAP PHARM	EQ 2.5MG BASE	A078131	001	Sep 04, 2007
	EQ 5MG BASE	A078131	002	Sep 04, 2007
	EQ 10MG BASE	A078131	003	Sep 04, 2007
SOVEREIGN PHARMS	EQ 2.5MG BASE	A204900	001	Jul 23, 2015
	EQ 5MG BASE	A204900	002	Jul 23, 2015
	EQ 10MG BASE	A204900	003	Jul 23, 2015
SUN PHARM INDUSTRIES	EQ 2.5MG BASE	A078081	001	Jan 31, 2008
	EQ 5MG BASE	A078081	002	Jan 31, 2008
	EQ 10MG BASE	A078081	003	Jan 31, 2008
SUNSHINE LAKE	EQ 2.5MG BASE	A206524	001	May 04, 2018
	EQ 5MG BASE	A206524	002	May 04, 2018
	EQ 10MG BASE	A206524	003	May 04, 2018
SYNTHON PHARMS	EQ 2.5MG BASE	A077080	001	Jun 27, 2007
	EQ 5MG BASE	A077080	002	Jun 27, 2007
	EQ 10MG BASE	A077080	003	Jun 27, 2007
YAOPHARMA CO LTD	EQ 2.5MG BASE	A076859	001	Sep 10, 2007
	EQ 5MG BASE	A076859	002	Sep 10, 2007
	EQ 10MG BASE	A076859	003	Sep 10, 2007
TABLET, ORALLY DISINTEGRATING;ORAL				
AMLODIPINE BESYLATE				
SYNTHON PHARMS	EQ 2.5MG BASE	N022026	001	Sep 27, 2007
	EQ 5MG BASE	N022026	002	Sep 27, 2007
	EQ 10MG BASE	N022026	003	Sep 27, 2007
AMLODIPINE MALEATE				
TABLET;ORAL				
AMVAZ				
DR REDDYS LABS INC	2.5MG	N021435	001	Oct 31, 2003
	5MG	N021435	002	Oct 31, 2003
	10MG	N021435	003	Oct 31, 2003
AMMONIA N-13				
INJECTABLE;INTRAVENOUS				
AMMONIA N 13				
CENTRAL RADIOPHARM	3.75-260mCi/ML	A204539	001	Jun 23, 2015
UNIV TX MD ANDERSON	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203933	001	Jun 27, 2014
AMMONIUM CHLORIDE				
INJECTABLE;INJECTION				
AMMONIUM CHLORIDE				
ABBOTT	5MEQ/ML	A083130	001	
GD SEARLE LLC	3MEQ/ML	A086205	001	

AMMONIUM CHLORIDE					
INJECTABLE;INJECTION					
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE					
	MCGAW	900MG/100ML	N006580	001	
AMMONIUM CHLORIDE 2.14%					
	B BRAUN	40MEQ/100ML	A085734	001	
AMMONIUM LACTATE					
CREAM;TOPICAL					
LAC-HYDRIN					
	SUN PHARM INDS INC	EQ 12% BASE **	N020508	001	Aug 29, 1996
LOTION;TOPICAL					
LAC-HYDRIN					
+	SUN PHARM INDS INC	EQ 12% BASE **	N019155	001	Apr 24, 1985
AMODIAQUINE HYDROCHLORIDE					
TABLET;ORAL					
CAMOQUIN HYDROCHLORIDE					
	PARKE DAVIS	EQ 200MG BASE	N006441	001	
AMOXAPINE					
TABLET;ORAL					
AMOXAPINE					
	UPSHER SMITH LABS	25MG	A072943	001	Jun 28, 1991
		50MG	A072944	001	Jun 28, 1991
		100MG	A072878	001	Jun 28, 1991
		150MG	A072879	001	Jun 28, 1991
	WATSON PHARMS TEVA	25MG	A072418	001	May 11, 1989
		50MG	A072419	001	May 11, 1989
		100MG	A072420	001	May 11, 1989
		150MG	A072421	001	May 11, 1989
ASENDIN					
	LEDERLE	25MG	N018021	001	
		50MG	N018021	002	
		100MG	N018021	003	
		150MG	N018021	004	
AMOXICILLIN					
CAPSULE;ORAL					
AMOXICILLIN					
	LABS ATRAL	250MG	A062528	001	Aug 07, 1985
		500MG	A062528	002	Aug 07, 1985
	MYLAN	250MG	A062067	001	
		500MG	A062067	002	
	SUN PHARM INDS LTD	250MG	A065016	001	Apr 08, 1999
		500MG	A065016	002	Apr 08, 1999
	TEVA	250MG	A062853	001	Dec 22, 1987
		250MG	A063030	001	Feb 28, 1989
		500MG	A062854	001	Dec 22, 1987
		500MG	A063031	001	Feb 28, 1989
AMOXIL					
+	GLAXOSMITHKLINE	250MG **	N050459	001	
+		500MG **	N050459	002	
TRIMOX					
	APOTHECON	250MG	A061885	001	
		250MG	A062098	001	
		250MG	A062152	001	
		250MG	A063099	001	Mar 20, 1992
		500MG	A061885	002	
		500MG	A062098	002	
		500MG	A062152	002	
		500MG	A063099	002	Mar 20, 1992
UTIMOX					
	PARKE DAVIS	250MG	A062107	001	
		500MG	A062107	002	
WYMOX					
	WYETH AYERST	250MG	A062120	001	
		500MG	A062120	002	
FOR SUSPENSION;ORAL					
AMOXICILLIN					
	AM ANTIBIOTICS	125MG/5ML	A062059	001	

AMOXICILLIN

FOR SUSPENSION;ORAL					
AMOXICILLIN					
		250MG/5ML	A062059	002	
	MYLAN	125MG/5ML	A062090	001	
		250MG/5ML	A062090	002	
	SUN PHARM INDS LTD	200MG/5ML	A065113	001	Nov 29, 2002
		400MG/5ML	A065113	002	Nov 29, 2002
	TEVA	125MG/5ML	A062946	001	Nov 01, 1988
		250MG/5ML	A063001	001	Jan 06, 1989
AMOXIL					
+	GLAXOSMITHKLINE	50MG/ML **	N050460	005	
+		125MG/5ML **	N050460	001	
+		250MG/5ML **	N050460	002	
+	NEOPHARMA	200MG/5ML **	N050760	001	Apr 15, 1999
+		400MG/5ML **	N050760	002	Apr 15, 1999
LAROTID					
+	GLAXOSMITHKLINE	50MG/ML **	N050460	006	
POLYMOX					
	APOTHECON	125MG/5ML	A061851	001	
		125MG/5ML	A062323	001	
		250MG/5ML	A061851	002	
		250MG/5ML	A062323	002	
TRIMOX					
	APOTHECON	50MG/ML	A061886	001	
		125MG/5ML	A061886	002	
		125MG/5ML	A062099	001	
		125MG/5ML	A062154	001	
		125MG/5ML	A062885	001	Mar 08, 1988
		250MG/5ML	A061886	003	
		250MG/5ML	A062099	002	
		250MG/5ML	A062154	002	
		250MG/5ML	A062885	002	Mar 08, 1988
UTIMOX					
	PARKE DAVIS	125MG/5ML	A062127	001	
		250MG/5ML	A062127	002	
WYMOX					
	WYETH AYERST	125MG/5ML	A062131	001	
		250MG/5ML	A062131	002	
TABLET;ORAL					
AMOXICILLIN					
	DAVA PHARMS INC	875MG	A065344	001	Jan 15, 2009
	SUN PHARM INDS LTD	500MG	A065059	001	Nov 24, 2000
		875MG	A065059	002	Nov 24, 2000
AMOXIL					
+	NEOPHARMA	500MG **	N050754	002	Jul 10, 1998
+		875MG **	N050754	001	Jul 10, 1998
TABLET, CHEWABLE;ORAL					
AMOXICILLIN					
	APOTHECON	125MG	A064131	001	May 06, 1996
		250MG	A064131	002	May 06, 1996
	DAVA PHARMS INC	125MG	A064139	001	Jan 29, 1996
		250MG	A064139	002	Jan 29, 1996
	SUN PHARM INDS LTD	125MG	A065021	001	Dec 23, 1999
		200MG	A065060	001	Nov 29, 2000
		250MG	A065021	002	Dec 23, 1999
		400MG	A065060	002	Nov 29, 2000
	TEVA	125MG	A064031	001	Dec 19, 1996
		250MG	A064031	002	Dec 19, 1996
AMOXIL					
+	NEOPHARMA	125MG **	N050542	002	
		200MG	N050761	001	Apr 15, 1999
+		250MG **	N050542	001	
		400MG	N050761	002	Apr 15, 1999
TABLET, EXTENDED RELEASE;ORAL					
MOXATAG					
+	PRAGMA	775MG	N050813	001	Jan 23, 2008

AMOXICILLIN

TABLET, FOR SUSPENSION;ORAL

AMOXICILLIN				
AUROBINDO PHARMA LTD	200MG	A065324	001	Jan 17, 2007
	400MG	A065324	002	Jan 17, 2007
DISPERMOX				
RANBAXY LABS LTD	200MG	A065080	002	Aug 11, 2003
	400MG	A065080	001	Aug 11, 2003
	600MG	A065159	001	Dec 04, 2003

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN				
TEVA PHARMS USA	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	A200218	001	Aug 30, 2013
PREVPAC				
+ TAKEDA PHARMS USA	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	N050757	001	Dec 02, 1997

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM				
SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003
	400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003
	600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007
AUGMENTIN '200'				
+ NEOPHARMA	200MG/5ML;EQ 28.5MG BASE/5ML	N050725	001	May 31, 1996
AUGMENTIN '400'				
+ NEOPHARMA	400MG/5ML;EQ 57MG BASE/5ML	N050725	002	May 31, 1996
AUGMENTIN ES-600				
+ NEOPHARMA	600MG/5ML;EQ 42.9MG BASE/5ML	N050755	001	Jun 22, 2001

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM				
APOTEX INC	250MG;EQ 125MG BASE	A065333	001	Feb 24, 2009
	500MG;EQ 125MG BASE	A065333	002	Feb 24, 2009
	875MG;EQ 125MG BASE	A065317	003	Oct 20, 2008
SUN PHARM INDS LTD	500MG;EQ 125MG BASE	A065109	001	Nov 04, 2002
	875MG;EQ 125MG BASE	A065102	001	Sep 17, 2002
AUGMENTIN '250'				
+ NEOPHARMA	250MG;EQ 125MG BASE **	N050564	001	Aug 06, 1984
AUGMENTIN '500'				
+ NEOPHARMA	500MG;EQ 125MG BASE **	N050564	002	Aug 06, 1984

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM				
SANDOZ	200MG;EQ 28.5MG BASE	A065065	001	Apr 18, 2002
	400MG;EQ 57MG BASE	A065065	002	Apr 18, 2002
SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003
	400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003
AUGMENTIN '125'				
+ NEOPHARMA	125MG;EQ 31.25MG BASE **	N050597	001	Jul 22, 1985
AUGMENTIN '200'				
+ NEOPHARMA	200MG;EQ 28.5MG BASE	N050726	001	May 31, 1996
AUGMENTIN '250'				
+ NEOPHARMA	250MG;EQ 62.5MG BASE **	N050597	002	Jul 22, 1985
AUGMENTIN '400'				
+ NEOPHARMA	400MG;EQ 57MG BASE	N050726	002	May 31, 1996

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

CAPSULE;ORAL

DELCOBESE				
TEVA	1.25MG;1.25MG;1.25MG;1.25MG **	A083564	001	
	2.5MG;2.5MG;2.5MG;2.5MG **	A083564	002	
	3.75MG;3.75MG;3.75MG;3.75MG **	A083564	003	
	5MG;5MG;5MG;5MG **	A083564	004	

TABLET;ORAL

DELCOBESE				
TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A083563	004	
	2.5MG;2.5MG;2.5MG;2.5MG	A083563	003	
	3.75MG;3.75MG;3.75MG;3.75MG	A083563	002	
	5MG;5MG;5MG;5MG	A083563	001	

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL				
ADDERALL 10				
+ TEVA WOMENS	2.5MG;2.5MG;2.5MG;2.5MG **	N011522	007	Feb 13, 1996
ADDERALL 12.5				
+ TEVA WOMENS	3.125MG;3.125MG;3.125MG;3.125MG **	N011522	012	Aug 31, 2000
ADDERALL 15				
+ TEVA WOMENS	3.75MG;3.75MG;3.75MG;3.75MG **	N011522	013	Aug 31, 2000
ADDERALL 20				
+ TEVA WOMENS	5MG;5MG;5MG;5MG **	N011522	008	Feb 13, 1996
ADDERALL 30				
+ TEVA WOMENS	7.5MG;7.5MG;7.5MG;7.5MG **	N011522	010	May 12, 1997
ADDERALL 5				
+ TEVA WOMENS	1.25MG;1.25MG;1.25MG;1.25MG **	N011522	009	May 12, 1997
ADDERALL 7.5				
+ TEVA WOMENS	1.875MG;1.875MG;1.875MG;1.875MG **	N011522	011	Aug 31, 2000
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE				
ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A040456	001	May 06, 2003
	2.5MG;2.5MG;2.5MG;2.5MG	A040456	002	May 06, 2003
	5MG;5MG;5MG;5MG	A040456	003	May 06, 2003
	7.5MG;7.5MG;7.5MG;7.5MG	A040456	004	May 06, 2003
TEVA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A040472	001	Sep 30, 2003
	2.5MG;2.5MG;2.5MG;2.5MG	A040472	002	Sep 30, 2003
	5MG;5MG;5MG;5MG	A040472	003	Sep 30, 2003
	7.5MG;7.5MG;7.5MG;7.5MG	A040472	004	Sep 30, 2003

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE;ORAL				
BIPHETAMINE 12.5				
UCB INC	EQ 6.25MG BASE;EQ 6.25MG BASE	N010093	007	
BIPHETAMINE 20				
UCB INC	EQ 10MG BASE;EQ 10MG BASE	N010093	003	
BIPHETAMINE 7.5				
UCB INC	EQ 3.75MG BASE;EQ 3.75MG BASE	N010093	009	

AMPHETAMINE SULFATE

TABLET;ORAL				
AMPHETAMINE SULFATE				
LANNETT	5MG	A083901	001	Aug 31, 1984
	10MG	A083901	002	Aug 31, 1984

AMPHOTERICIN B

CREAM;TOPICAL				
FUNGIZONE				
APOTHECON	3%	N050314	001	
INJECTABLE;INJECTION				
AMPHOTERICIN B				
ABBOTT	50MG/VIAL	A064141	001	Dec 23, 1996
ABRAXIS PHARM	50MG/VIAL	A062728	001	Apr 13, 1987
TEVA PARENTERAL	50MG/VIAL	A064062	001	Mar 31, 1995
FUNGIZONE				
APOTHECON	50MG/VIAL	A060517	001	
INJECTABLE, LIPID COMPLEX;INJECTION				
AMPHOTEC				
ALKOPHARMA USA	50MG/VIAL	N050729	001	Nov 22, 1996
	100MG/VIAL	N050729	002	Nov 22, 1996
LOTION;TOPICAL				
FUNGIZONE				
APOTHECON	3%	A060570	001	
OINTMENT;TOPICAL				
FUNGIZONE				
APOTHECON	3%	N050313	001	
SUSPENSION;ORAL				
FUNGIZONE				
BRISTOL MYERS SQUIBB	100MG/ML	N050341	003	

AMPICILLIN SODIUM

INJECTABLE;INJECTION				
AMPICILLIN SODIUM				
ACS DOBFAR SPA	EQ 500MG BASE/VIAL	A090884	001	Apr 03, 2013
	EQ 1GM BASE/VIAL	A090884	002	Apr 03, 2013
	EQ 2GM BASE/VIAL	A090884	003	Apr 03, 2013
APOTHECON	EQ 125MG BASE/VIAL	A062860	001	Feb 05, 1988
	EQ 250MG BASE/VIAL	A062860	002	Feb 05, 1988
	EQ 500MG BASE/VIAL	A062860	003	Feb 05, 1988
	EQ 1GM BASE/VIAL	A062860	004	Feb 05, 1988
	EQ 2GM BASE/VIAL	A062860	005	Feb 05, 1988
AUROBINDO PHARMA	EQ 125MG BASE/VIAL	A065499	001	Aug 17, 2010
CONSOLIDATED PHARM	EQ 125MG BASE/VIAL	A061936	005	
	EQ 250MG BASE/VIAL	A061936	001	
	EQ 500MG BASE/VIAL	A061936	002	
	EQ 1GM BASE/VIAL	A061936	003	
	EQ 2GM BASE/VIAL	A061936	004	
HANFORD GC	EQ 125MG BASE/VIAL	A062772	005	Apr 15, 1993
	EQ 500MG BASE/VIAL	A062772	008	Apr 15, 1993
	EQ 1GM BASE/VIAL	A062772	002	Apr 15, 1993
	EQ 2GM BASE/VIAL	A062772	004	Apr 15, 1993
INTL MEDICATION	EQ 1GM BASE/VIAL	A062634	002	Jan 09, 1987
	EQ 2GM BASE/VIAL	A062634	003	Jan 09, 1987
ISTITUTO BIO ITA SPA	EQ 125MG BASE/VIAL	A062797	001	Jul 12, 1993
LILLY	EQ 500MG BASE/VIAL	A062565	001	Apr 04, 1985
	EQ 1GM BASE/VIAL	A062565	002	Apr 04, 1985
	EQ 2GM BASE/VIAL	A062565	003	Jun 24, 1986
WATSON LABS INC	EQ 125MG BASE/VIAL	A062816	001	Oct 24, 1988
	EQ 250MG BASE/VIAL	A062816	002	Oct 24, 1988
	EQ 500MG BASE/VIAL	A062816	003	Oct 24, 1988
	EQ 1GM BASE/VIAL	A062816	004	Oct 24, 1988
	EQ 2GM BASE/VIAL	A062816	005	Oct 24, 1988
	EQ 10GM BASE/VIAL	A062994	001	Sep 15, 1988
WEST-WARD PHARMS INT	EQ 125MG BASE/VIAL	A062692	001	Jun 24, 1986
	EQ 250MG BASE/VIAL	A062692	002	Jun 24, 1986
	EQ 500MG BASE/VIAL	A062692	003	Jun 24, 1986
	EQ 1GM BASE/VIAL	A062692	004	Jun 24, 1986
	EQ 2GM BASE/VIAL	A062692	005	Jun 24, 1986
	EQ 10GM BASE/VIAL	A062692	006	Jun 24, 1986
OMNIPEN-N				
WYETH AYERST	EQ 125MG BASE/VIAL	A060626	001	
	EQ 125MG BASE/VIAL	A062718	001	Dec 16, 1986
	EQ 250MG BASE/VIAL	A060626	002	
	EQ 250MG BASE/VIAL	A062718	002	Dec 16, 1986
	EQ 500MG BASE/VIAL	A060626	003	
	EQ 500MG BASE/VIAL	A062718	003	Dec 16, 1986
	EQ 1GM BASE/VIAL	A060626	004	
	EQ 1GM BASE/VIAL	A062718	004	Dec 16, 1986
	EQ 2GM BASE/VIAL	A060626	005	
	EQ 2GM BASE/VIAL	A062718	005	Dec 16, 1986
PENBRITIN-S				
+ WYETH AYERST	EQ 125MG BASE/VIAL **	N050072	001	
+	EQ 250MG BASE/VIAL **	N050072	002	
+	EQ 500MG BASE/VIAL **	N050072	003	
+	EQ 1GM BASE/VIAL **	N050072	004	
+	EQ 2GM BASE/VIAL **	N050072	005	
+	EQ 4GM BASE/VIAL **	N050072	006	
POLYCILLIN-N				
BRISTOL	EQ 125MG BASE/VIAL **	N050309	001	
	EQ 250MG BASE/VIAL **	N050309	002	
	EQ 500MG BASE/VIAL **	N050309	003	
	EQ 1GM BASE/VIAL **	N050309	004	
	EQ 2GM BASE/VIAL **	N050309	005	
TOTACILLIN-N				
GLAXOSMITHKLINE	EQ 125MG BASE/VIAL	A060677	001	
	EQ 250MG BASE/VIAL	A060677	002	
	EQ 500MG BASE/VIAL	A060677	003	
	EQ 1GM BASE/VIAL	A060677	004	
	EQ 1GM BASE/VIAL	A062727	001	Dec 19, 1986

AMPICILLIN SODIUM

INJECTABLE;INJECTION				
TOTACILLIN-N				
	EQ 2GM BASE/VIAL		A060677	005
	EQ 2GM BASE/VIAL		A062727	002 Dec 19, 1986
	EQ 10GM BASE/VIAL		A060677	006

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION				
UNASYN				
PFIZER	EQ 500MG BASE/VIAL;EQ 250MG BASE/VIAL		N050608	003 Dec 31, 1986

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE;ORAL				
AMCILL				
PARKE DAVIS	EQ 250MG BASE		A062041	001
	EQ 500MG BASE		A062041	002
AMPICILLIN TRIHYDRATE				
AM ANTIBIOTICS	EQ 250MG BASE		A061602	001
	EQ 500MG BASE		A061602	002
IVAX SUB TEVA PHARMS	EQ 250MG BASE		A060765	001
	EQ 500MG BASE		A060765	002
LEDERLE	EQ 250MG BASE		A062208	001
	EQ 500MG BASE		A062208	002
MYLAN	EQ 250MG BASE		A061755	001
	EQ 500MG BASE		A061755	002
PUREPAC PHARM	EQ 250MG BASE		A061853	001
	EQ 500MG BASE		A061853	002
TEVA	EQ 250MG BASE		A061502	001
	EQ 500MG BASE		A061502	002
VITARINE	EQ 250MG BASE		A061387	001
	EQ 500MG BASE		A061387	003
OMNIPEN (AMPICILLIN)				
WYETH AYERST	250MG		A060624	001
	500MG		A060624	002
PENBRITIN				
WYETH AYERST	EQ 250MG BASE		A060908	001
	EQ 500MG BASE		A060908	002
PFIZERPEN-A				
PFIZER	EQ 250MG BASE		A062050	001
	EQ 500MG BASE		A062050	002
POLYCILLIN				
BRISTOL	EQ 250MG BASE		N050310	001
	EQ 500MG BASE		N050310	002
PRINCIPEN				
APOTHECON	EQ 250MG BASE		A062888	001 Mar 04, 1988
	EQ 500MG BASE		A062888	002 Mar 04, 1988
BRISTOL MYERS SQUIBB	EQ 250MG BASE		A061392	001
	EQ 500MG BASE		A061392	002
PRINCIPEN '250'				
APOTHECON	EQ 250MG BASE		A062157	002
	EQ 250MG BASE		N050056	001
PRINCIPEN '500'				
APOTHECON	EQ 500MG BASE		A062157	001
	EQ 500MG BASE		N050056	002
TOTACILLIN				
GLAXOSMITHKLINE	EQ 250MG BASE		A060060	001
	EQ 250MG BASE		A062212	001
	EQ 500MG BASE		A060060	002
	EQ 500MG BASE		A062212	002
FOR SUSPENSION;ORAL				
AMCILL				
PARKE DAVIS	EQ 125MG BASE/5ML		A062030	001
	EQ 250MG BASE/5ML		A062030	002
AMPICILLIN TRIHYDRATE				
AM ANTIBIOTICS	EQ 125MG BASE/5ML		A061601	001
	EQ 250MG BASE/5ML		A061601	002
MYLAN	EQ 125MG BASE/5ML		A061829	002
	EQ 250MG BASE/5ML		A061829	001
PUREPAC PHARM	EQ 125MG BASE/5ML		A061980	001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION;ORAL				
AMPICILLIN TRIHYDRATE				
		EQ 250MG BASE/5ML	A061980 002	
	TEVA	EQ 125MG BASE/5ML	A061370 001	
		EQ 250MG BASE/5ML	A061370 002	
OMNIPEN (AMPICILLIN)				
	WYETH AYERST	100MG/ML	A060625 001	
		125MG/5ML	A060625 002	
		250MG/5ML	A060625 003	
		500MG/5ML	A060625 004	
PENBRITIN				
	WYETH AYERST	EQ 100MG BASE/ML	N050019 001	
		EQ 125MG BASE/5ML	N050019 002	
		EQ 250MG BASE/5ML	N050019 003	
PFIZERPEN-A				
	PFIZER	EQ 125MG BASE/5ML	A062049 001	
		EQ 250MG BASE/5ML	A062049 002	
POLYCILLIN				
	APOTHECON	EQ 125MG BASE/5ML	A062297 001	
		EQ 250MG BASE/5ML	A062297 002	
	BRISTOL	EQ 100MG BASE/ML	N050308 004	
		EQ 125MG BASE/5ML	N050308 001	
		EQ 250MG BASE/5ML	N050308 002	
		EQ 500MG BASE/5ML	N050308 003	
PRINCIPEN				
	APOTHECON	EQ 100MG BASE/ML	A061394 001	
		EQ 125MG BASE/5ML	A061394 002	
		EQ 250MG BASE/5ML	A061394 003	
PRINCIPEN '125'				
	APOTHECON	EQ 125MG BASE/5ML	A060127 002	
		EQ 125MG BASE/5ML	A062151 001	
PRINCIPEN '250'				
	APOTHECON	EQ 250MG BASE/5ML	A060127 001	
		EQ 250MG BASE/5ML	A062151 002	
TOTACILLIN				
	GLAXOSMITHKLINE	EQ 125MG BASE/5ML	A060666 001	
		EQ 125MG BASE/5ML	A062223 001	
		EQ 250MG BASE/5ML	A060666 002	
		EQ 250MG BASE/5ML	A062223 002	
TABLET, CHEWABLE;ORAL				
POLYCILLIN				
	BRISTOL	EQ 125MG BASE	N050093 001	

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

CAPSULE;ORAL				
PRINCIPEN W/ PROBENECID				
	APOTHECON	EQ 389MG BASE;111MG	A062150 001	
		EQ 389MG BASE;111MG	N050488 001	
FOR SUSPENSION;ORAL				
POLYCILLIN-PRB				
	APOTHECON	EQ 3.5GM BASE/BOT;1GM/BOT	A061898 001	
	BRISTOL	EQ 3.5GM BASE/BOT;1GM/BOT	N050457 001	
PROBAMPACIN				
	G AND W LABS INC	EQ 3.5GM BASE/BOT;1GM/BOT	A061741 001	

AMPRENAVIR

CAPSULE;ORAL				
AGENERASE				
	GLAXOSMITHKLINE	50MG	N021007 001	Apr 15, 1999
		150MG	N021007 002	Apr 15, 1999
SOLUTION;ORAL				
AGENERASE				
+	GLAXOSMITHKLINE	15MG/ML **	N021039 001	Apr 15, 1999

ANAGRELIDE HYDROCHLORIDE				
CAPSULE;ORAL				
AGRYLIN				
+	SHIRE LLC	EQ 1MG BASE **	N020333 002	Mar 14, 1997
ANAGRELIDE HYDROCHLORIDE				
	MYLAN PHARMS INC	EQ 0.5MG BASE	A076811 001	Apr 18, 2005
		EQ 0.5MG BASE	A077613 001	Jun 27, 2006
		EQ 1MG BASE	A076811 002	Apr 18, 2005
		EQ 1MG BASE	A077613 002	Jun 27, 2006
	ROXANE	EQ 0.5MG BASE	A076489 001	Apr 18, 2005
		EQ 1MG BASE	A076489 002	Apr 18, 2005
	UPSHER SMITH LABS	EQ 0.5MG BASE	A076683 001	Apr 18, 2005
		EQ 1MG BASE	A076683 002	Apr 18, 2005
	WATSON LABS	EQ 0.5MG BASE	A076417 001	Apr 18, 2005
		EQ 1MG BASE	A076417 002	Apr 18, 2005
ANASTROZOLE				
TABLET;ORAL				
ANASTROZOLE				
	IMPAX LABS INC	1MG	A091242 001	May 31, 2012
	LANNETT CO INC	1MG	A091331 001	Jan 05, 2011
	SANDOZ	1MG	A079007 001	Jun 28, 2010
	SUN PHARM INDS LTD	1MG	A091177 001	Jul 15, 2011
	SYNTHON PHARMS	1MG	A078322 001	Jun 28, 2010
	WATSON LABS TEVA	1MG	A078984 001	Jun 28, 2010
ANGIOTENSIN II ACETATE				
SOLUTION;INTRAVENOUS				
GIAPREZA				
+	LA JOLLA PHARMA	EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	N209360 002	Dec 21, 2017
ANILERIDINE HYDROCHLORIDE				
TABLET;ORAL				
LERITINE				
	MERCK	EQ 25MG BASE	N010585 002	
ANILERIDINE PHOSPHATE				
INJECTABLE;INJECTION				
LERITINE				
	MERCK	25MG/ML	N010520 003	
ANISINDIONE				
TABLET;ORAL				
MIRADON				
	SCHERING	50MG	N010909 003	
ANISOTROPINE METHYLBROMIDE				
TABLET;ORAL				
ANISOTROPINE METHYLBROMIDE				
	WATSON LABS	50MG	A086046 001	
VALPIN 50				
	ENDO PHARMS	50MG	N013428 001	
ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
VASOCON-A				
	NOVARTIS	0.5%;0.05%	N018746 002	Jul 11, 1994
APOMORPHINE HYDROCHLORIDE				
INJECTABLE;SUBCUTANEOUS				
APOKYN				
	US WORLDMEDS	20MG/2ML (10MG/ML)	N021264 001	Apr 20, 2004
APROTININ				
INJECTABLE;INJECTION				
TRASYLOL				
	BAYER HLTHCARE	10,000KIU/ML	N020304 001	Dec 29, 1993

ARBUTAMINE HYDROCHLORIDE					
INJECTABLE;INJECTION					
GENESA					
	GENSIA AUTOMEDICS	0.05MG/ML	N020420	001	Sep 12, 1997
ARDEPARIN SODIUM					
INJECTABLE;INJECTION					
NORMIFLO					
+	PHARMACIA AND UPJOHN	5,000 UNITS/0.5ML **	N020227	002	May 23, 1997
+		10,000 UNITS/0.5ML **	N020227	001	May 23, 1997
ARGATROBAN					
SOLUTION;INTRAVENOUS					
ARGATROBAN IN DEXTROSE					
	SANDOZ	125MG/125ML (1MG/ML)	N201743	001	May 09, 2011
ARIPIPRAZOLE					
INJECTABLE;INTRAMUSCULAR					
ABILIFY					
	OTSUKA	9.75MG/1.3ML (7.5MG/ML)	N021866	001	Sep 20, 2006
SOLUTION;ORAL					
ABILIFY					
+	OTSUKA	1MG/ML **	N021713	001	Dec 10, 2004
TABLET;ORAL					
ARIPIPRAZOLE					
	MYLAN PHARMS INC	2MG	A206240	001	Sep 19, 2018
		5MG	A206240	002	Sep 19, 2018
		10MG	A206240	003	Sep 19, 2018
		15MG	A206240	004	Sep 19, 2018
		20MG	A206240	005	Sep 19, 2018
		30MG	A206240	006	Sep 19, 2018
TABLET, ORALLY DISINTEGRATING;ORAL					
ABILIFY					
+	OTSUKA	10MG **	N021729	002	Jun 07, 2006
+		15MG **	N021729	003	Jun 07, 2006
+		20MG **	N021729	004	Jun 07, 2006
+		30MG **	N021729	005	Jun 07, 2006
ARMODAFINIL					
TABLET;ORAL					
ARMODAFINIL					
	WATSON LABS INC	100MG	A200156	002	Aug 29, 2012
		200MG	A200156	004	Aug 29, 2012
NUVIGIL					
+	CEPHALON	100MG **	N021875	002	Mar 26, 2009
ARSENIC TRIOXIDE					
INJECTABLE;INJECTION					
TRISENOX					
+	CEPHALON	1MG/ML	N021248	001	Sep 25, 2000
ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E					
INJECTABLE;INJECTION					
BEROCCA PN					
	ROCHE	50MG/ML;0.03MG/ML;0.0025MG/ML;7.5MG/ML;100 IU/ML;0.2MG/ML;20MG/ML;2MG/ML;1.8MG/ML;	N006071	003	Oct 10, 1985
ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E					
INJECTABLE;INJECTION					
M.V.C. 9+3					
	ABRAXIS PHARM	10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/	N018440	002	Aug 08, 1985
M.V.I.-12 ADULT					
	HOSPIRA	10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/	N008809	004	Aug 08, 1985
+		20MG/ML;0.006MG/ML;0.05MCG/ML;1.5MG/ML;0.0005MG/ML;0.06MG/ML;4MG/ML;0.6MG/ML;	N008809	006	Sep 09, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 ADULT

	0.36MG/ML;0.6MG/ML;0.1MG/ML;1MG/ML			

MVC PLUS

WATSON LABS	10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/	N018439	002	Aug 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 ADULT

HOSPIRA	20MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.6MG/ML;4MG/ML;0.4MG/ML;0.36MG/M	N008809	005	Apr 22, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 LYOPHILIZED

TELIGENT PHARMA INC	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL	N018933	002	Aug 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE;INJECTION

VITAPED

HOSPIRA	N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A,0.001MG/VIAL;400 IU/10ML,N/A;N/A,0.14MG/VIAL;N/A,17MG/VIAL;N/A,5MG/VIAL;0.2MG/10ML,N/A;N/A,1MG/VIAL;N/A,1.4MG/VIAL;N/A,1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML,N/A;7 IU/10ML,N/A	N020176	001	Dec 29, 1993

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC

NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM	A090145	001	Jan 25, 2012

ASPIRIN

TABLET;ORAL

BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

BAYER	500MG	N021317	001	Oct 18, 2001

TABLET, EXTENDED RELEASE;ORAL

8-HOUR BAYER

BAYER	650MG	N016030	001	

MEASURIN

BAYER	650MG	N016030	002	

ASPIRIN; BUTALBITAL

TABLET;ORAL

AXOTAL

SAVAGE LABS	650MG;50MG	A088305	001	Oct 13, 1983

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

NOSTRUM LABS INC	325MG;50MG;40MG	A078149	001	Jun 13, 2007
WATSON LABS	325MG;50MG;40MG	A086231	002	Feb 12, 1985

TABLET;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

ACTAVIS ELIZABETH	325MG;50MG;40MG	A086710	002	Aug 23, 1983
FOSUN PHARMA	325MG;50MG;40MG	A086398	002	Apr 06, 1984
HALSEY	325MG;50MG;40MG	A089448	001	Dec 01, 1986
IVAX PHARMS	325MG;50MG;40MG	A085441	002	Oct 31, 1984
PURACAP PHARM	325MG;50MG;40MG	A087048	002	Dec 09, 1983
QUANTUM PHARMICS	325MG;50MG;40MG	A088972	001	Jun 18, 1985
WATSON LABS	325MG;50MG;40MG	A086237	002	Mar 23, 1984

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET;ORAL

FIORINAL					
+	ALLERGAN SALES LLC	325MG;50MG;40MG **	N017534	003	Apr 16, 1986
LANORINAL					
	LANNETT	325MG;50MG;40MG	A086986	002	Oct 18, 1985

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE					
	VINTAGE PHARMS LLC	325MG;50MG;40MG;30MG	A075351	001	Mar 05, 1999
	WATSON LABS	325MG;50MG;40MG;30MG	A074359	001	Aug 31, 1995

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL

SYNALGOS-DC					
+	SUN PHARM INDUSTRIES	356.4MG;30MG;16MG	N011483	004	Sep 06, 1983

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

INVAGESIC					
	SANDOZ	385MG;30MG;25MG	A074817	001	Nov 27, 1996
INVAGESIC FORTE					
	SANDOZ	770MG;60MG;50MG	A074817	002	Nov 27, 1996
NORGESIC					
+	MEDICIS	385MG;30MG;25MG **	N013416	003	Oct 27, 1982
NORGESIC FORTE					
+	MEDICIS	770MG;60MG;50MG **	N013416	004	Oct 27, 1982
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE					
	STEVENS J	385MG;30MG;25MG	A074988	001	Apr 30, 1999
		770MG;60MG;50MG	A074988	002	Apr 30, 1999
ORPHENGESIC					
	GALT PHARMS	385MG;30MG;25MG	A075141	001	May 29, 1998
ORPHENGESIC FORTE					
	GALT PHARMS	770MG;60MG;50MG	A075141	002	May 29, 1998

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE;ORAL

COMPOUND 65					
	ALRA	389MG;32.4MG;65MG	A084553	002	Aug 17, 1983
DARVON COMPOUND					
	XANODYNE PHARM	389MG;32.4MG;32MG	N010996	006	Mar 08, 1983
DARVON COMPOUND-65					
	XANODYNE PHARM	389MG;32.4MG;65MG	N010996	007	Mar 08, 1983
PROPOXYPHENE COMPOUND 65					
	IVAX SUB TEVA PHARMS	389MG;32.4MG;65MG	A083077	002	Dec 07, 1984
	SANDOZ	389MG;32.4MG;65MG	A080044	002	Sep 16, 1983
	TEVA	389MG;32.4MG;65MG	A089025	001	Mar 29, 1985
PROPOXYPHENE COMPOUND-65					
	SANDOZ	389MG;32.4MG;65MG	A083101	002	Jun 24, 1985
PROPOXYPHENE HYDROCHLORIDE W/ ASPIRIN AND CAFFEINE					
	WATSON LABS	389MG;32.4MG;65MG	A085732	002	Sep 03, 1984

ASPIRIN; CARISOPRODOL

TABLET;ORAL

CARISOPRODOL AND ASPIRIN					
	OXFORD PHARMS	325MG;200MG	A040252	001	Dec 10, 1997
CARISOPRODOL COMPOUND					
	WATSON LABS	325MG;200MG	A088809	001	Oct 03, 1985
SOMA COMPOUND					
	MEDA PHARMS	325MG;200MG **	N012365	005	Jul 11, 1983

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE					
	OXFORD PHARMS	325MG;200MG;16MG	A040283	001	Dec 29, 1998
SOMA COMPOUND W/ CODEINE					
	MEDA PHARMS	325MG;200MG;16MG **	N012366	002	Jul 11, 1983

ASPIRIN; HYDROCODONE BITARTRATE

TABLET;ORAL

AZDONE				
SCHWARZ PHARMA	500MG;5MG **	A089420	001	Jan 25, 1988
VICOPRIN				
ABBOTT	500MG;5MG	A086333	001	Sep 14, 1983

ASPIRIN; MEPROBAMATE

TABLET;ORAL

EQUAGESIC				
SUN PHARM INDUSTRIES	325MG;200MG	N011702	003	Dec 29, 1983
MEPRO-ASPIRIN				
SANDOZ	325MG;200MG	A089127	001	Mar 02, 1987
MEPROBAMATE AND ASPIRIN				
PAR PHARM	325MG;200MG	A089126	001	Aug 19, 1986
MICRAININ				
MEDPOINTE PHARM HLC	325MG;200MG	A084978	001	
Q-GESIC				
QUANTUM PHARMICS	325MG;200MG	A088740	001	Jun 01, 1984

ASPIRIN; METHOCARBAMOL

TABLET;ORAL

METHOCARBAMOL AND ASPIRIN				
IVAX SUB TEVA PHARMS	325MG;400MG	A087211	001	Dec 22, 1982
MCNEIL	325MG;400MG	A089193	001	Feb 12, 1986
PAR PHARM	325MG;400MG	A089657	001	Nov 04, 1988
ROBAXISAL				
ROBINS AH	325MG;400MG	N012281	001	

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET;ORAL

CODOXY				
HALSEY	325MG;4.5MG;0.38MG	A087464	001	Jul 01, 1982
OXYCODONE AND ASPIRIN				
SUN PHARM INDUSTRIES	325MG;4.5MG;0.38MG	A040260	001	Jul 17, 1998
	325MG;4.5MG;0.38MG	A087794	001	May 26, 1982
WATSON LABS	325MG;4.5MG;0.38MG	A040255	001	Feb 27, 1998
OXYCODONE AND ASPIRIN (HALF-STRENGTH)				
ROXANE	325MG;2.25MG;0.19MG	A087742	001	Jun 04, 1982
PERCODAN				
ENDO PHARMS	325MG;4.5MG;0.38MG **	N007337	006	
PERCODAN-DEMI				
ENDO PHARMS	325MG;2.25MG;0.19MG **	N007337	005	
ROXIPRIN				
ROXANE	325MG;4.5MG;0.38MG	A087743	001	Jun 04, 1982

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL

TALWIN COMPOUND				
+ SANOFI AVENTIS US	325MG;EQ 12.5MG BASE **	N016891	001	

ASPIRIN; PRAVASTATIN SODIUM

TABLET, TABLET;ORAL

PRAVIGARD PAC (COPACKAGED)				
BRISTOL MYERS SQUIBB	325MG,N/A;N/A,80MG	N021387	006	Jun 24, 2003

TABLET, TABLET, TABLET;ORAL

PRAVIGARD PAC (COPACKAGED)				
BRISTOL MYERS SQUIBB	81MG,N/A;N/A,20MG	N021387	001	Jun 24, 2003
	81MG,N/A;N/A,40MG	N021387	002	Jun 24, 2003
	81MG,N/A;N/A,80MG	N021387	003	Jun 24, 2003
	325MG,N/A;N/A,20MG	N021387	004	Jun 24, 2003
	325MG,N/A;N/A,40MG	N021387	005	Jun 24, 2003

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE;ORAL

DARVON W/ ASA				
XANODYNE PHARM	325MG;65MG	N010996	005	

ASPIRIN; PROPOXYPHENE NAPSYLATE				
CAPSULE;ORAL				
DARVON-N W/ ASA				
	AAIPHARMA LLC	325MG;100MG	N016829 001	
TABLET;ORAL				
DARVON-N W/ ASA				
	AAIPHARMA LLC	325MG;100MG	N016863 001	
ATAZANAVIR SULFATE				
CAPSULE;ORAL				
REYATAZ				
+	BRISTOL MYERS SQUIBB	EQ 100MG BASE **	N021567 001	Jun 20, 2003
ATENOLOL				
INJECTABLE;INJECTION				
TENORMIN				
+	ASTRAZENECA	0.5MG/ML **	N019058 001	Sep 13, 1989
TABLET;ORAL				
ATENOLOL				
	ABLE	25MG	A076907 001	Jul 30, 2004
		50MG	A076907 002	Jul 30, 2004
		100MG	A076907 003	Jul 30, 2004
	APOTHECON	50MG	A073317 001	Mar 20, 1992
		100MG	A073318 001	Mar 20, 1992
	DAVA PHARMS INC	25MG	A074099 001	Apr 28, 1992
	MYLAN	25MG	A074126 003	Aug 26, 1998
		50MG	A074126 001	Mar 23, 1994
		100MG	A074126 002	Mar 23, 1994
	NORTHSTAR HLTHCARE	25MG	A078254 001	Sep 25, 2009
		50MG	A078254 002	Sep 25, 2009
		100MG	A078254 003	Sep 25, 2009
	NOSTRUM LABS	50MG	A074127 001	Feb 21, 1995
		100MG	A074127 002	Feb 21, 1995
	PLIVA	25MG	A074101 001	Jul 17, 1997
		50MG	A074101 002	Jul 17, 1997
		100MG	A074101 003	Jul 17, 1997
	SANDOZ	25MG	A074265 001	Feb 28, 1994
		50MG	A074265 002	Feb 28, 1994
		100MG	A074265 003	Feb 28, 1994
	SCS	50MG	A073676 001	Oct 30, 1992
		100MG	A073676 002	Oct 30, 1992
	TEVA	50MG	A073315 001	May 28, 1993
		100MG	A073316 001	May 28, 1993
	TEVA PHARMS	50MG	A074120 001	Feb 24, 1995
		100MG	A074120 002	Feb 24, 1995
	WATSON LABS	50MG	A073352 001	Dec 27, 1991
	WATSON LABS TEVA	100MG	A073353 001	Dec 27, 1991
ATENOLOL; CHLORTHALIDONE				
TABLET;ORAL				
ATENOLOL AND CHLORTHALIDONE				
	NOSTRUM LABS	50MG;25MG	A074404 001	May 14, 1998
		100MG;25MG	A074404 002	May 14, 1998
	PLIVA	50MG;25MG	A074107 001	Sep 24, 1997
		100MG;25MG	A074107 002	Sep 24, 1997
ATOMOXETINE HYDROCHLORIDE				
CAPSULE;ORAL				
ATOMOXETINE HYDROCHLORIDE				
	ZYDUS PHARMS USA INC	18MG	A079017 001	Sep 17, 2010
		25MG	A079017 002	Sep 17, 2010
		40MG	A079017 003	Sep 17, 2010
		60MG	A079017 004	Sep 17, 2010
		80MG	A079017 005	Sep 17, 2010
		100MG	A079017 006	Sep 17, 2010
STRATTERA				
	LILLY	5MG	N021411 001	Nov 26, 2002

ATORVASTATIN CALCIUM

TABLET;ORAL				
ATORVASTATIN CALCIUM				
TEVA PHARMS	EQ 10MG BASE	A078773	001	May 29, 2012
	EQ 20MG BASE	A078773	002	May 29, 2012
	EQ 40MG BASE	A078773	003	May 29, 2012
	EQ 80MG BASE	A078773	004	May 29, 2012

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL				
LIPTRUZET				
+ MERCK SHARP DOHME	EQ 10MG BASE;10MG **	N200153	001	May 03, 2013
+	EQ 20MG BASE;10MG **	N200153	002	May 03, 2013
+	EQ 40MG BASE;10MG **	N200153	003	May 03, 2013
+	EQ 80MG BASE;10MG **	N200153	004	May 03, 2013

ATOVAQUONE

TABLET;ORAL				
MEPRON				
+ GLAXOSMITHKLINE LLC	250MG **	N020259	001	Nov 25, 1992

ATRACURIUM BESYLATE

INJECTABLE;INJECTION				
ATRACURIUM BESYLATE				
BAXTER HLTHCARE	10MG/ML	A074824	001	Sep 30, 1997
BAXTER HLTHCARE CORP	10MG/ML	A074753	001	Jan 23, 1997
HOSPIRA	10MG/ML	A074632	001	Dec 23, 1996
	10MG/ML	A074740	001	Mar 28, 1997
TEVA PARENTERAL	10MG/ML	A074784	001	Jun 11, 1997
WATSON PHARMS TEVA	10MG/ML	A074945	001	Jul 28, 1998
ATRACURIUM BESYLATE PRESERVATIVE FREE				
BAXTER HLTHCARE	10MG/ML	A074825	001	Sep 30, 1997
BAXTER HLTHCARE CORP	10MG/ML	A074768	001	Jan 23, 1997
HOSPIRA	10MG/ML	A074633	001	Dec 23, 1996
	10MG/ML	A074639	001	Mar 25, 1997
	10MG/ML	A074741	001	Mar 28, 1997
WATSON LABS INC	10MG/ML	A074944	001	Jul 28, 1998
TRACRIUM				
+ HOSPIRA	10MG/ML **	N018831	002	Jun 20, 1985
TRACRIUM PRESERVATIVE FREE				
+ HOSPIRA	10MG/ML **	N018831	001	Nov 23, 1983

ATROPINE

INJECTABLE;INJECTION				
ATROPINE				
ABBVIE	EQ 2MG SULFATE/0.7ML	A071295	001	Jan 30, 1987
SOLUTION;INTRAMUSCULAR				
ATROPINE (AUTOINJECTOR)				
RAFA LABS LTD	EQ 2MG SULFATE/0.7ML (EQ 2MG SULFATE/0.7ML)	N212319	001	Jul 09, 2018

ATROPINE SULFATE

AEROSOL, METERED;INHALATION				
ATROPINE SULFATE				
US ARMY	EQ 0.36MG BASE/INH	N020056	001	Sep 19, 1990
SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, ENDOTRACHEAL				
ATROPINE SULFATE ANSYR PLASTIC SYRINGE				
+ HOSPIRA	0.5MG/5ML (0.1MG/ML)	N021146	001	Jul 09, 2001

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET;ORAL				
MOTOFEN HALF-STRENGTH				
SEBELA IRELAND LTD	0.025MG;0.5MG	N017744	001	

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

CAPSULE;ORAL				
DIPHENOXYLATE HYDROCHLORIDE W/ ATROPINE SULFATE				
SCHERER RP	0.025MG;2.5MG	A086440	001	
SOLUTION;ORAL				
COLONAID				
MEDPOINTE PHARM HLC	0.025MG/5ML;2.5MG/5ML	A085735	001	

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION;ORAL				
LOMANATE				
	ALPHARMA US PHARMS	0.025MG/5ML;2.5MG/5ML	A085746 001	
LOMOTIL				
	GD SEARLE LLC	0.025MG/5ML;2.5MG/5ML	N012699 001	
TABLET;ORAL				
COLONAID				
	MEDPOINTE PHARM HLC	0.025MG;2.5MG	A085737 001	
DI-ATRO				
	MD PHARM	0.025MG;2.5MG	A085266 001	
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE				
	ABLE	0.025MG;2.5MG	A040395 001	Nov 27, 2000
	ASCOT	0.025MG;2.5MG	A087934 001	Jul 19, 1983
	FOSUN PHARMA	0.025MG;2.5MG	A086173 001	
	HEATHER	0.025MG;2.5MG	A086798 001	
	HIKMA PHARMS	0.025MG;2.5MG	A087765 001	Mar 15, 1982
	INWOOD LABS	0.025MG;2.5MG	A085509 001	
	KV PHARM	0.025MG;2.5MG	A085659 001	
	LEDERLE	0.025MG;2.5MG	A086950 001	
	PARKE DAVIS	0.025MG;2.5MG	A087131 001	
	PVT FORM	0.025MG;2.5MG	A085766 001	
	R AND S PHARMA	0.025MG;2.5MG	A085035 001	
	ROXANE	0.025MG;2.5MG	A086057 001	
	SUN PHARM INDUSTRIES	0.025MG;2.5MG	A085506 001	
	USL PHARMA	0.025MG;2.5MG	A087842 001	Mar 29, 1982
	VALEANT PHARM INTL	0.025MG;2.5MG	A087195 001	Feb 16, 1982
	WATSON LABS	0.025MG;2.5MG	A085876 001	
LO-TROL				
	VANGARD	0.025MG;2.5MG	A088009 001	Mar 25, 1983
LOGEN				
	SUPERPHARM	0.025MG;2.5MG	A088962 001	May 10, 1985
LONOX				
	FOSUN PHARMA	0.025MG;2.5MG	A085311 002	
LOW-QUEL				
	HALSEY	0.025MG;2.5MG	A085211 001	

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION				
ENLON-PLUS				
	MYLAN INSTITUTIONAL	0.14MG/ML;10MG/ML	N019677 001	Nov 06, 1991
+		0.14MG/ML;10MG/ML	N019678 001	Nov 06, 1991

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION				
ATROPINE AND DEMEROL				
	ABBVIE	0.4MG/ML;50MG/ML	A087853 001	Nov 26, 1982
		0.4MG/ML;75MG/ML	A087847 001	Nov 26, 1982
		0.4MG/ML;100MG/ML	A087848 001	Nov 26, 1982
MEPERIDINE AND ATROPINE SULFATE				
	WYETH AYERST	0.4MG/ML;50MG/ML	A085121 001	
		0.4MG/ML;75MG/ML	A085121 002	
		0.4MG/ML;100MG/ML	A085121 003	

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE;INTRAMUSCULAR				
ATNAA				
	US ARMY	2.1MG/0.7ML;600MG/2ML	N021175 001	Jan 17, 2002

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION;TOPICAL				
SHADE UVAGUARD				
+	BAYER HEALTHCARE LLC	3%;7.5%;3%	N020045 001	Dec 07, 1992

AZATADINE MALEATE

TABLET;ORAL				
OPTIMINE				
	SCHERING	1MG	N017601 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE
TABLET, EXTENDED RELEASE;ORAL
TRINALIN

SCHERING	1MG;120MG	N018506	001	Mar 23, 1982

AZATHIOPRINE
TABLET;ORAL
IMURAN

+ SEBELA IRELAND LTD	25MG **	N016324	002	

AZATHIOPRINE SODIUM
INJECTABLE;INJECTION
IMURAN

+ CASPER PHARMA LLC	EQ 100MG BASE/VIAL **	N017391	001	

AZELASTINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
OPTIVAR

+ MYLAN SPECIALITY LP	0.05% **	N021127	001	May 22, 2000

SPRAY, METERED;NASAL
ASTEPRO

MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY	N022203	001	Oct 15, 2008

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE
SPRAY, METERED;NASAL
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

APOTEX INC	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	A207712	001	Apr 28, 2017

AZITHROMYCIN
CAPSULE;ORAL
ZITHROMAX

+ PFIZER	EQ 250MG BASE **	N050670	001	Nov 01, 1991

FOR SUSPENSION;ORAL
AZITHROMYCIN

SANDOZ	EQ 100MG BASE/5ML	A065297	001	Sep 18, 2006
	EQ 200MG BASE/5ML	A065297	002	Sep 18, 2006

FOR SUSPENSION, EXTENDED RELEASE;ORAL
ZMAX

+ PF PRISM CV	EQ 2GM BASE/BOT	N050797	001	Jun 10, 2005

INJECTABLE;INJECTION
AZITHROMYCIN

CSPC OUYI PHARM CO	EQ 500MG BASE/VIAL	A065265	001	Jan 18, 2007
TEVA PARENTERAL	EQ 500MG BASE/VIAL	N050809	001	Dec 19, 2006
	EQ 2.5GM BASE/VIAL	N050809	002	Dec 19, 2006

TABLET;ORAL
AZITHROMYCIN

APOTEX CORP	EQ 250MG BASE	A065507	001	Jul 13, 2011
	EQ 500MG BASE	A065509	001	Jul 13, 2011
	EQ 600MG BASE	A065508	001	Jul 13, 2011
MYLAN	EQ 250MG BASE	A065365	001	May 30, 2007
	EQ 500MG BASE	A065366	001	May 30, 2007

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE
FOR SUSPENSION, TABLET;ORAL
TROVAN/ZITHROMAX COMPLIANCE PAK

PFIZER	EQ 1GM BASE,N/A;N/A,EQ 100MG BASE	N050762	001	Dec 18, 1998

AZLOCILLIN SODIUM
INJECTABLE;INJECTION
AZLIN

BAYER PHARMS	EQ 2GM BASE/VIAL	A062388	001	Sep 08, 1982
	EQ 2GM BASE/VIAL	A062417	001	Oct 12, 1982
	EQ 2GM BASE/VIAL	N050562	001	Sep 03, 1982
	EQ 3GM BASE/VIAL	A062388	002	Sep 08, 1982
	EQ 3GM BASE/VIAL	A062417	002	Oct 12, 1982
	EQ 3GM BASE/VIAL	N050562	002	Sep 03, 1982
	EQ 4GM BASE/VIAL	A062388	003	Sep 08, 1982
	EQ 4GM BASE/VIAL	A062417	003	Oct 12, 1982
	EQ 4GM BASE/VIAL	N050562	003	Sep 03, 1982

AZTREONAM				
INJECTABLE;INJECTION				
AZACTAM				
BRISTOL MYERS SQUIBB	500MG/VIAL	N050580	001	Dec 31, 1986
AZACTAM IN PLASTIC CONTAINER				
BRISTOL MYERS SQUIBB	10MG/ML	N050632	003	May 24, 1989
AZTREONAM				
WEST-WARD PHARMS INT	1GM/VIAL	A065286	001	Mar 23, 2011
	2GM/VIAL	A065286	002	Mar 23, 2011
BACAMPICILLIN HYDROCHLORIDE				
FOR SUSPENSION;ORAL				
SPECTROBID				
PFIZER	125MG/5ML	N050556	001	Mar 23, 1982
TABLET;ORAL				
SPECTROBID				
PFIZER	400MG	N050520	001	
	800MG	N050520	002	Sep 12, 1983
BACITRACIN				
INJECTABLE;INJECTION				
BACITRACIN				
MYLAN ASI	50,000 UNITS/VIAL	A090211	001	May 11, 2010
PFIZER	50,000 UNITS/VIAL	A060282	001	
PHARMACIA AND UPJOHN	10,000 UNITS/VIAL	A060733	001	
OINTMENT;OPHTHALMIC				
BACIGUENT				
PHARMACIA AND UPJOHN	500 UNITS/GM	A060734	001	
BACITRACIN				
LILLY	500 UNITS/GM	A060687	001	
PHARMADERM	500 UNITS/GM	A062158	001	
PHARMAFAIR	500 UNITS/GM	A062453	001	Mar 28, 1984
OINTMENT;TOPICAL				
BACITRACIN				
COMBE	500 UNITS/GM	A062799	001	May 14, 1987
NASKA	500 UNITS/GM	A062857	001	Nov 13, 1987
POWDER;FOR RX COMPOUNDING				
BACI-RX				
X GEN PHARMS	5,000,000 UNITS/BOT	A061580	001	
BACITRACIN				
APOTHEKERNES	5,000,000 UNITS/BOT	A061699	001	
PADDOCK LLC	5,000,000 UNITS/BOT	A062456	001	Jul 27, 1983
BACITRACIN ZINC				
POWDER;FOR RX COMPOUNDING				
ZIBA-RX				
X GEN PHARMS	500,000 UNITS/BOT	A061737	001	
BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE				
OINTMENT;OPHTHALMIC				
CORTISPORIN				
+ CASPER PHARMA LLC	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM **	N050416	002	
ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE				
PHARMAFAIR	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062389	001	Jul 02, 1982
OINTMENT;TOPICAL				
NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE				
PHARMAFAIR	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062381	001	Sep 06, 1985
BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE				
OINTMENT;TOPICAL				
LANABIOTIC				
COMBE	400 UNITS/GM;40MG/GM;EQ 5MG BASE/GM;5,000 UNITS/GM	A062499	001	Jun 03, 1985

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE				
OINTMENT;OPHTHALMIC				
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE				
PHARMAFAIR	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062386	001	Sep 09, 1982
BACITRACIN-NEOMYCIN-POLYMYXIN				
PHARMADERM	400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062167	001	
NEO-POLYCIN				
DOW PHARM	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060647	001	
OINTMENT;TOPICAL				
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE				
NASKA	400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062833	001	Nov 09, 1987
BACITRACIN ZINC; POLYMYXIN B SULFATE				
AEROSOL;TOPICAL				
POLYSPORIN				
GLAXOSMITHKLINE	10,000 UNITS/GM;2,000,000 UNITS/GM	N050167	002	Mar 01, 1985
OINTMENT;OPHTHALMIC				
OCUMYCIN				
PHARMAFAIR	500 UNITS/GM;10,000 UNITS/GM	A062430	001	Apr 08, 1983
POLYSPORIN				
MONARCH PHARMS	500 UNITS/GM;10,000 UNITS/GM **	A061229	001	
OINTMENT;TOPICAL				
BACITRACIN ZINC-POLYMYXIN B SULFATE				
NASKA	500 UNITS/GM;10,000 UNITS/GM	A062849	001	Nov 13, 1987
BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE				
OINTMENT;OPHTHALMIC				
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE				
ALTANA	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060731	002	
BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE				
OINTMENT;OPHTHALMIC				
MYCITRACIN				
PHARMACIA AND UPJOHN	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A061048	001	
BACITRACIN; POLYMYXIN B SULFATE				
DISC;TOPICAL				
LANABIOTIC				
COMBE	500 UNITS/GM;5,000 UNITS/GM	N050598	001	Sep 22, 1986
BACLOFEN				
TABLET;ORAL				
BACLOFEN				
MYLAN	10MG	A077181	001	Jul 29, 2005
TEVA	10MG	A073043	001	Feb 27, 1992
	20MG	A073044	001	Feb 27, 1992
USL PHARMA	10MG	A071260	001	May 06, 1988
	20MG	A071261	001	May 06, 1988
WATSON LABS	10MG	A072824	001	Sep 18, 1991
	10MG	A073092	001	Jan 28, 1994
	10MG	A074698	001	Aug 20, 1996
	20MG	A072825	001	Sep 18, 1991
	20MG	A073093	001	Jan 28, 1994
	20MG	A074698	002	Aug 20, 1996
LIORESAL				
+ NOVARTIS	10MG **	N017851	001	
+	20MG **	N017851	003	Jan 20, 1982
TABLET, ORALLY DISINTEGRATING;ORAL				
KEMSTRO				
UCB INC	10MG	N021589	001	Oct 30, 2003
	20MG	N021589	002	Oct 30, 2003

BARIUM SULFATE				
FOR SUSPENSION;ORAL				
E-Z-CAT DRY				
+	BRACCO	40% (9GM/POUCH)	N208036 003	Jan 03, 2017
BECLOMETHASONE DIPROPIONATE				
AEROSOL, METERED;INHALATION				
BECLOVENT				
	GLAXOSMITHKLINE	0.042MG/INH	N018153 001	
QVAR 40				
+	TEVA BRANDED PHARM	0.04MG/INH	N020911 002	Sep 15, 2000
QVAR 80				
+	TEVA BRANDED PHARM	0.08MG/INH	N020911 001	Sep 15, 2000
VANCERIL				
	SCHERING	0.042MG/INH	N017573 001	
VANCERIL DOUBLE STRENGTH				
	SCHERING	0.084MG/INH	N020486 001	Dec 24, 1996
AEROSOL, METERED;NASAL				
BECONASE				
	GLAXOSMITHKLINE	0.042MG/INH	N018584 001	
VANCENASE				
	SCHERING	0.042MG/INH	N018521 001	
BECLOMETHASONE DIPROPIONATE MONOHYDRATE				
SPRAY, METERED;NASAL				
VANCENASE AQ				
	SCHERING	EQ 0.042MG DIPROP/SPRAY	N019589 001	Dec 23, 1987
		EQ 0.084MG DIPROP/SPRAY	N020469 001	Jun 26, 1996
BENAZEPRIL HYDROCHLORIDE				
TABLET;ORAL				
BENAZEPRIL HYDROCHLORIDE				
	ACTAVIS LABS FL INC	5MG	A076267 001	Feb 11, 2004
		10MG	A076267 002	Feb 11, 2004
		20MG	A076267 003	Feb 11, 2004
		40MG	A076267 004	Feb 11, 2004
	GENPHARM	5MG	A076476 001	Feb 11, 2004
		10MG	A076476 002	Feb 11, 2004
		20MG	A076476 003	Feb 11, 2004
		40MG	A076476 004	Feb 11, 2004
BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE				
TABLET;ORAL				
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
	ACTAVIS LABS FL INC	5MG;6.25MG	A076342 001	Feb 11, 2004
		10MG;12.5MG	A076342 002	Feb 11, 2004
		20MG;12.5MG	A076342 003	Feb 11, 2004
		20MG;25MG	A076342 004	Feb 11, 2004
	IVAX SUB TEVA PHARMS	5MG;6.25MG	A076348 001	Feb 11, 2004
		10MG;12.5MG	A076348 002	Feb 11, 2004
		20MG;12.5MG	A076348 003	Feb 11, 2004
		20MG;25MG	A076348 004	Feb 11, 2004
	MYLAN PHARMS INC	5MG;6.25MG	A076612 001	Feb 11, 2004
		10MG;12.5MG	A076612 002	Feb 11, 2004
		20MG;12.5MG	A076612 003	Feb 11, 2004
		20MG;25MG	A076612 004	Feb 11, 2004
	SUN PHARM INDS LTD	5MG;6.25MG	A077483 001	Sep 08, 2005
		10MG;12.5MG	A077483 002	Sep 08, 2005
		20MG;12.5MG	A077483 003	Sep 08, 2005
		20MG;25MG	A077483 004	Sep 08, 2005
LOTENSIN HCT				
+	US PHARMS HOLDINGS I	5MG;6.25MG **	N020033 001	May 19, 1992
BENDAMUSTINE HYDROCHLORIDE				
SOLUTION;IV (INFUSION)				
TREANDA				
+	CEPHALON	45MG/0.5ML (90MG/ML)	N022249 003	Sep 13, 2013
+		180MG/2ML (90MG/ML)	N022249 004	Sep 13, 2013

BENDROFLUMETHIAZIDE

TABLET;ORAL				
NATURETIN-10				
	APOTHECON	10MG	N012164 003	
NATURETIN-2.5				
	APOTHECON	2.5MG	N012164 001	
NATURETIN-5				
	APOTHECON	5MG	N012164 002	

BENDROFLUMETHIAZIDE; NADOLOL

TABLET;ORAL				
NADOLOL AND BENDROFLUMETHIAZIDE				
	MYLAN	5MG;40MG	A078688 001	Feb 15, 2008
		5MG;80MG	A078688 002	Feb 15, 2008

BENOXINATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC				
BENOXINATE HYDROCHLORIDE				
	SOLA BARNES HIND	0.4%	A084149 001	

BENTIROMIDE

SOLUTION;ORAL				
CHYMEX				
	SAVAGE LABS	500MG/7.5ML	N018366 001	Dec 29, 1983

BENZONATATE

CAPSULE;ORAL				
BENZONATATE				
	NESHER PHARMS	100MG	A040795 001	Oct 31, 2007
		200MG	A040795 002	Oct 31, 2007
TESSALON				
+	PFIZER	200MG **	N011210 003	Jun 25, 1999

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL				
BENZACLIN				
	VALEANT BERMUDA	5%;EQ 1% BASE	N050756 002	Apr 20, 2007

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL				
BENZPHETAMINE HYDROCHLORIDE				
	EPIC PHARMA LLC	50MG	A040714 001	Oct 29, 2007
	IMPAX LABS	50MG	A040845 001	Nov 18, 2008
	TEDOR PHARM	25MG	A040747 002	Nov 20, 2015
		50MG	A040747 001	Mar 30, 2007
DIDREX				
+	PHARMACIA AND UPJOHN	25MG **	N012427 003	
+		50MG **	N012427 002	

BENZQUINAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION				
EMETE-CON				
	PFIZER	EQ 50MG BASE/VIAL	N016820 001	
SUPPOSITORY;RECTAL				
EMETE-CON				
	ROERIG	EQ 100MG BASE	N016818 006	

BENZTHIAZIDE

TABLET;ORAL				
AQUATAG				
	SOLVAY	25MG	N016001 001	
		50MG	N016001 002	
BENZTHIAZIDE				
	PVT FORM	50MG	A083206 001	
EXNA				
	AH ROBINS INC	50MG	N012489 001	
FOVANE				
	PFIZER	50MG	N012128 002	
URESE				
	PFIZER	25MG	N012128 003	

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

CHARTWELL RX	1MG	A081265	002	Jan 23, 1992
	2MG	A081265	001	Jan 23, 1992
LANNETT CO INC	0.5MG **	A088877	001	Apr 11, 1985
	1MG **	A088894	001	Apr 11, 1985
	2MG **	A088895	001	Apr 11, 1985
OXFORD PHARMS	2MG	A040706	001	Feb 14, 2008
QUANTUM PHARMICS	0.5MG	A088514	001	Jan 31, 1984
	1MG	A088510	001	Jan 31, 1984
	2MG	A088511	001	Jan 31, 1984
USL PHARMA	0.5MG	A089211	001	Jun 14, 1988
	1MG	A089212	001	Jun 14, 1988
	2MG	A089213	001	Jun 14, 1988

COGENTIN

+ MERCK	0.5MG **	N009193	004	
+	1MG **	N009193	003	
+	2MG **	N009193	002	

BENZYL BENZOATE

EMULSION;TOPICAL

BENZYL BENZOATE

LANNETT	50%	A084535	001	

BEPRIDIL HYDROCHLORIDE

TABLET;ORAL

BEPADIN

MEDPOINTE PHARM HLC	200MG	N019001	001	Dec 28, 1990
	300MG	N019001	002	Dec 28, 1990
	400MG	N019001	003	Dec 28, 1990

VASCOR

JOHNSON AND JOHNSON	200MG	N019002	001	Dec 28, 1990
	300MG	N019002	002	Dec 28, 1990
	400MG	N019002	003	Dec 28, 1990

BETA CAROTENE

CAPSULE;ORAL

SOLATENE

ROCHE	30MG	N017589	001	

BETAMETHASONE

CREAM;TOPICAL

CELESTONE

SCHERING	0.2%	N014762	001	

SYRUP;ORAL

CELESTONE

MERCK SHARP DOHME	0.6MG/5ML	N014215	002	

TABLET;ORAL

CELESTONE

SCHERING	0.6MG	N012657	003	

BETAMETHASONE BENZOATE

CREAM;TOPICAL

UTICORT

PARKE DAVIS	0.025%	N016998	002	

GEL;TOPICAL

UTICORT

PARKE DAVIS	0.025%	N017244	001	

LOTION;TOPICAL

UTICORT

PARKE DAVIS	0.025%	N017528	001	

OINTMENT;TOPICAL

UTICORT

PARKE DAVIS	0.025%	N018089	001	

BETAMETHASONE DIPROPIONATE				
CREAM;TOPICAL				
ALPHATREX				
SAVAGE LABS	EQ 0.05% BASE	N019138	001	Jun 26, 1984
BETAMETHASONE DIPROPIONATE				
PERRIGO NEW YORK	EQ 0.05% BASE	A072536	001	Jan 31, 1990
	EQ 0.05% BASE	A074579	001	Nov 26, 1997
PHARMADERM	EQ 0.05% BASE	N019136	001	Jun 26, 1984
TARO	EQ 0.05% BASE	A071143	001	Jun 17, 1987
TEVA	EQ 0.05% BASE	A071476	001	Aug 10, 1987
DIPROSONE				
SCHERING	EQ 0.05% BASE	N017536	001	
CREAM, AUGMENTED;TOPICAL				
DIPROLENE				
SCHERING	EQ 0.05% BASE	N019408	001	Jan 31, 1986
DISC;TOPICAL				
DIPROSONE				
SCHERING	EQ 0.1% BASE	N017829	001	
GEL, AUGMENTED;TOPICAL				
DIPROLENE				
SCHERING	EQ 0.05% BASE	N019408	002	Nov 22, 1991
LOTION;TOPICAL				
ALPHATREX				
SAVAGE LABS	EQ 0.05% BASE	A070273	001	Aug 12, 1985
BETAMETHASONE DIPROPIONATE				
ALPHARMA US PHARMS	EQ 0.05% BASE	A071085	001	Feb 03, 1987
G AND W LABS INC	EQ 0.05% BASE	A071882	001	Jun 06, 1988
PHARMADERM	EQ 0.05% BASE	A070274	001	Aug 12, 1985
TARO	EQ 0.05% BASE	A072276	001	Aug 24, 1988
	EQ 0.05% BASE	A074272	001	Sep 30, 1994
DIPROSONE				
+ SCHERING	EQ 0.05% BASE **	N017781	001	
LOTION, AUGMENTED;TOPICAL				
DIPROLENE				
+ MERCK SHARP DOHME	EQ 0.05% BASE	N019716	001	Aug 01, 1988
OINTMENT;TOPICAL				
ALPHATREX				
SAVAGE LABS	EQ 0.05% BASE	N019143	001	Sep 04, 1984
BETAMETHASONE DIPROPIONATE				
PERRIGO NEW YORK	EQ 0.05% BASE	A072526	001	Jan 31, 1990
PHARMADERM	EQ 0.05% BASE	N019140	001	Sep 04, 1984
TEVA	EQ 0.05% BASE	A071477	001	Aug 10, 1987
DIPROSONE				
SCHERING	EQ 0.05% BASE	N017691	001	
BETAMETHASONE SODIUM PHOSPHATE				
INJECTABLE;INJECTION				
BETAMETHASONE SODIUM PHOSPHATE				
WATSON LABS	EQ 3MG BASE/ML	A085738	001	
CELESTONE				
+ SCHERING	EQ 3MG BASE/ML **	N017561	001	
BETAMETHASONE VALERATE				
CREAM;TOPICAL				
BETADERM				
ROACO	EQ 0.1% BASE	N018839	001	Jun 30, 1983
BETAMETHASONE VALERATE				
PERRIGO NEW YORK	EQ 0.1% BASE	A070053	001	Jun 10, 1986
PHARMADERM	EQ 0.1% BASE	N018860	002	Aug 31, 1983
PHARMAFAIR	EQ 0.1% BASE	A070485	001	May 29, 1987
TARO	EQ 0.1% BASE	A070062	001	May 14, 1985
BETATREX				
SAVAGE LABS	EQ 0.1% BASE	N018862	001	Aug 31, 1983
VALISONE				
SCHERING	EQ 0.01% BASE	N016322	002	
	EQ 0.1% BASE	N016322	001	
LOTION;TOPICAL				
BETA-VAL				
G AND W LABS INC	EQ 0.1% BASE	A070072	001	Jun 27, 1985

BETAMETHASONE VALERATE				
LOTION;TOPICAL				
BETAMETHASONE VALERATE				
PHARMADERM	EQ 0.1% BASE	N018870	001	Aug 31, 1983
PHARMAFAIR	EQ 0.1% BASE	A070484	001	May 29, 1987
TEVA PHARMS	EQ 0.1% BASE	A071883	001	Apr 22, 1988
BETATREX				
SAVAGE LABS	EQ 0.1% BASE	N018867	001	Aug 31, 1983
VALISONE				
SCHERING	EQ 0.1% BASE	N016932	001	
OINTMENT;TOPICAL				
BETAMETHASONE VALERATE				
PERRIGO NEW YORK	EQ 0.1% BASE	A071478	001	Dec 23, 1987
PHARMADERM	EQ 0.1% BASE	N018864	001	Aug 31, 1983
PHARMAFAIR	EQ 0.1% BASE	A070486	001	May 29, 1987
BETATREX				
SAVAGE LABS	EQ 0.1% BASE	N018863	001	Aug 31, 1983
VALISONE				
SCHERING	EQ 0.1% BASE	N016740	001	
BETAXOLOL HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
BETAXOLOL HYDROCHLORIDE				
APOTEX INC	EQ 0.5% BASE	A075446	001	Sep 28, 2000
TABLET;ORAL				
KERLONE				
SANOFI AVENTIS US	10MG	N019507	001	Oct 27, 1989
	20MG	N019507	002	Oct 27, 1989
BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE				
TABLET;ORAL				
KERLEDEX				
SANOFI AVENTIS US	5MG;12.5MG	N019807	001	Oct 30, 1992
	10MG;12.5MG	N019807	002	Oct 30, 1992
BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE				
SUSPENSION/DROPS;OPHTHALMIC				
BETOPTIC PILO				
ALCON	EQ 0.25% BASE;1.75%	N020619	001	Apr 17, 1997
BETAZOLE HYDROCHLORIDE				
INJECTABLE;INJECTION				
HISTALOG				
LILLY	50MG/ML	N009344	001	
BETHANECHOL CHLORIDE				
INJECTABLE;INJECTION				
URECHOLINE				
+ ODYSSEY PHARMS	5MG/ML **	N006536	001	
TABLET;ORAL				
BETHANECHOL CHLORIDE				
ABLE	5MG	A040492	001	Jul 27, 2004
	10MG	A040483	001	Jul 27, 2004
	25MG	A040485	001	Jul 27, 2004
	50MG	A040509	001	Jul 27, 2004
ACTAVIS ELIZABETH	5MG	A040552	001	Oct 28, 2004
	10MG	A040553	001	Oct 28, 2004
	25MG	A040554	001	Oct 28, 2004
	50MG	A040551	001	Oct 28, 2004
ASCOT	10MG	A088288	001	Jun 08, 1983
	25MG	A088289	001	Jun 08, 1983
IMPAX LABS	5MG	A040721	001	Nov 01, 2006
	10MG	A040721	002	Nov 01, 2006
	25MG	A040721	003	Nov 01, 2016
	50MG	A040721	004	Nov 01, 2006
IVAX SUB TEVA PHARMS	25MG	A084689	001	
LANNETT	5MG	A084702	001	
	10MG	A084712	001	
	25MG	A084074	001	
SANDOZ	5MG	A084353	001	
	10MG	A084378	001	
	10MG	A084379	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

BETHANECHOL CHLORIDE

TABLET;ORAL				
BETHANECHOL CHLORIDE				
	25MG		A084383 001	
	25MG		A084384 001	
SUN PHARM INDS INC	5MG		A040897 001	Apr 22, 2009
	10MG		A040897 002	Apr 22, 2009
	25MG		A040897 003	Apr 22, 2009
	50MG		A040897 004	Apr 22, 2009
WATSON LABS	5MG		A084402 001	
	5MG		A085230 002	
	5MG		A085841 001	
	10MG		A084408 001	
	10MG		A085228 001	
	10MG		A085842 001	
	25MG		A084441 001	
	25MG		A085229 001	
	25MG		A085839 001	
	50MG		A087397 001	
	50MG		A087444 001	
MYOTONACHOL				
GLENWOOD	5MG		A084188 001	
	10MG		A084188 003	
	25MG		A084188 004	
URECHOLINE				
+ ODYSSEY PHARMS	5MG **		N006536 003	
+	10MG **		N006536 002	
+	25MG **		N006536 004	
+	50MG **		N006536 005	

BETHANIDINE SULFATE

TABLET;ORAL				
TENATHAN				
ROBINS AH	10MG		N017675 001	
	25MG		N017675 002	

BICALUTAMIDE

TABLET;ORAL				
BICALUTAMIDE				
KUDCO IRELAND	50MG		A077995 001	Jul 06, 2009
ROXANE	50MG		A078285 001	Mar 24, 2011
SYNTHON PHARMS	50MG		A077973 001	Jul 06, 2009

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC				
LUMIGAN				
+ ALLERGAN	0.03% **		N021275 001	Mar 16, 2001

BIPERIDEN HYDROCHLORIDE

TABLET;ORAL				
AKINETON				
ABBVIE	2MG		N012003 001	

BIPERIDEN LACTATE

INJECTABLE;INJECTION				
AKINETON				
ABBVIE	5MG/ML		N012418 002	

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL				
HALFLYTELY				
+ BRAINTREE	5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM;N/A,5.6GM **		N021551 003	Jul 16, 2010
PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL				
NOVEL LABS INC	5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM;N/A,5.6GM		A202217 001	Aug 20, 2014

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL					
HELIDAC					
+	CASPER PHARMA LLC	262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,N/A,500MG **	N050719	001	Aug 15, 1996

BISOPROLOL FUMARATE

TABLET;ORAL					
BISOPROLOL FUMARATE					
	ANDA REPOSITORY	5MG	A075474	001	Oct 25, 2002
		10MG	A075474	002	Oct 25, 2002
ZEBETA					
+	TEVA WOMENS	5MG **	N019982	002	Jul 31, 1992
+		10MG **	N019982	001	Jul 31, 1992

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL					
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE					
	ACTAVIS ELIZABETH	2.5MG;6.25MG	A075672	001	Sep 25, 2000
		5MG;6.25MG	A075672	002	Sep 25, 2000
		10MG;6.25MG	A075672	003	Sep 25, 2000
	APOTHECON	2.5MG;6.25MG	A075642	002	Dec 27, 2000
		5MG;6.25MG	A075642	001	Dec 27, 2000
		10MG;6.25MG	A075642	003	Dec 27, 2000
	IVAX SUB TEVA PHARMS	2.5MG;6.25MG	A075632	001	Sep 27, 2000
		5MG;6.25MG	A075632	002	Sep 27, 2000
		10MG;6.25MG	A075632	003	Sep 27, 2000
	SANDOZ	2.5MG;6.25MG	A075527	001	Sep 25, 2000
		5MG;6.25MG	A075527	003	Sep 25, 2000
		10MG;6.25MG	A075527	002	Sep 25, 2000
	TEVA	2.5MG;6.25MG	A075686	001	Jan 19, 2001
		5MG;6.25MG	A075686	002	Jan 19, 2001
		10MG;6.25MG	A075686	003	Jan 19, 2001
	WATSON LABS TEVA	2.5MG;6.25MG	A075469	001	Sep 25, 2000
		5MG;6.25MG	A075469	002	Sep 25, 2000
		10MG;6.25MG	A075469	003	Sep 25, 2000

BITOLTEROL MESYLATE

AEROSOL, METERED;INHALATION					
TORNALATE					
	SANOFI AVENTIS US	0.37MG/INH	N018770	001	Dec 28, 1984
SOLUTION;INHALATION					
TORNALATE					
	SANOFI AVENTIS US	0.2%	N019548	001	Feb 19, 1992

BLEOMYCIN SULFATE

INJECTABLE;INJECTION					
BLENOXANE					
+	BRISTOL MYERS SQUIBB	EQ 15 UNITS BASE/VIAL **	N050443	001	
+		EQ 30 UNITS BASE/VIAL **	N050443	002	Sep 07, 1995
BLEOMYCIN SULFATE					
	PHARMACHEMIE BV	EQ 15 UNITS BASE/VIAL	A065201	001	Dec 13, 2007
	TEVA PARENTERAL	EQ 15 UNITS BASE/VIAL	A064084	001	Jun 01, 1996
		EQ 30 UNITS BASE/VIAL	A064084	002	Jun 01, 1996

BOCEPREVIR

CAPSULE;ORAL					
VICTRELIS					
	MERCK SHARP DOHME	200MG	N202258	001	May 13, 2011

BORTEZOMIB

POWDER;INTRAVENOUS, SUBCUTANEOUS					
BORTEZOMIB					
+	HOSPIRA INC	2.5MG/VIAL	N209191	001	Jul 12, 2018

BRETYLIUM TOSYLATE

INJECTABLE;INJECTION					
BRETYLIUM TOSYLATE					
	ABRAXIS PHARM	50MG/ML	A070134	001	Apr 29, 1986
		100MG/ML	A071298	001	Feb 13, 1987
	ASTRAZENECA	50MG/ML	A071151	001	Aug 10, 1987
		50MG/ML	A071152	001	Aug 10, 1987
		50MG/ML	A071153	001	Aug 10, 1987

BRETYLIUM TOSYLATE					
INJECTABLE;INJECTION					
BRETYLIUM TOSYLATE					
	EUROHLTH INTL SARL	50MG/ML	A070546	001	May 14, 1986
+	HOSPIRA	50MG/ML **	N019030	001	Apr 29, 1986
		50MG/ML	N019033	001	Apr 29, 1986
	INTL MEDICATION	50MG/ML	A070119	001	Apr 29, 1986
	LUITPOLD	50MG/ML	A070891	001	Jul 26, 1988
	WEST-WARD PHARMS INT	50MG/ML	A070545	001	May 14, 1986
BRETYLIUM TOSYLATE IN DEXTROSE 5%					
	ABBOTT	200MG/100ML	N019005	002	Apr 29, 1986
		400MG/100ML	N019005	003	Apr 29, 1986
		800MG/100ML	N019005	001	Apr 29, 1986
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	100MG/100ML	N019121	001	Apr 29, 1986
		200MG/100ML	N019121	002	Apr 29, 1986
		400MG/100ML	N019121	003	Apr 29, 1986
	BAXTER HLTHCARE	200MG/100ML	N019837	002	Apr 12, 1989
		400MG/100ML	N019837	001	Apr 12, 1989
	HOSPIRA INC	200MG/100ML	N019008	002	Apr 29, 1986
		400MG/100ML	N019008	003	Apr 29, 1986
		800MG/100ML	N019008	001	Apr 29, 1986
BRETYLOL					
	HOSPIRA	50MG/ML	N017954	001	
BRIMONIDINE TARTRATE					
SOLUTION/DROPS;OPHTHALMIC					
ALPHAGAN					
+	ALLERGAN	0.2% **	N020613	001	Sep 06, 1996
		0.5%	N020490	001	Mar 13, 1997
BRIMONIDINE TARTRATE					
	TEVA PARENTERAL	0.2%	A076372	001	Sep 10, 2004
BROMFENAC SODIUM					
SOLUTION/DROPS;OPHTHALMIC					
BROMDAY					
+	BAUSCH AND LOMB INC	EQ 0.09% ACID **	N021664	002	Oct 16, 2010
BROMFENAC SODIUM					
	AMRING PHARMS	EQ 0.09% ACID	A202030	001	Jan 09, 2013
	APOTEX INC	EQ 0.09% ACID	A202435	001	Jun 19, 2014
		EQ 0.09% ACID	A202620	001	Jun 23, 2014
	COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011
	PADDOCK LLC	EQ 0.09% ACID	A201941	001	Feb 10, 2015
XIBROM					
+	BAUSCH AND LOMB INC	EQ 0.09% ACID **	N021664	001	Mar 24, 2005
BROMOCRIPTINE MESYLATE					
CAPSULE;ORAL					
BROMOCRIPTINE MESYLATE					
	LEK PHARM	EQ 5MG BASE	A075100	001	Dec 10, 1998
BROMODIPHENHYDRAMINE HYDROCHLORIDE					
CAPSULE;ORAL					
AMBODRYL					
	PARKE DAVIS	25MG	N007984	001	
BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE					
SYRUP;ORAL					
AMBENYL					
	FOREST LABS	12.5MG/5ML;10MG/5ML	N009319	006	Jan 10, 1984
BROMANYL					
	ALPHARMA US PHARMS	12.5MG/5ML;10MG/5ML	A088343	001	Aug 15, 1984
BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE					
	WOCKHARDT	12.5MG/5ML;10MG/5ML	A088626	001	Oct 12, 1984
BROMPHENIRAMINE MALEATE					
ELIXIR;ORAL					
BROMPHENIRAMINE MALEATE					
	ALPHARMA US PHARMS	2MG/5ML	A086936	001	
	KV PHARM	2MG/5ML	A085466	001	
	PHARM ASSOC	2MG/5ML	A087517	001	
	USL PHARMA	2MG/5ML	A087964	001	Jan 25, 1983

BROMPHENIRAMINE MALEATE				
INJECTABLE;INJECTION				
BROMPHENIRAMINE MALEATE				
WATSON LABS	10MG/ML	A083821 001		
	100MG/ML	A083820 001		
DIMETANE-TEN				
WYETH AYERST	10MG/ML	N011418 002		
TABLET;ORAL				
BROMPHENIRAMINE MALEATE				
BARR	4MG	A084468 001		
IVAX SUB TEVA PHARMS	4MG	A084351 001		
NEWTRON PHARMS	4MG	A086987 001		
NEXGEN PHARMA INC	4MG	A086187 001		
PAR PHARM	4MG	A087009 001		
PIONEER PHARMS	4MG	A088604 001	Jul 13, 1984	
UPSHER SMITH LABS	4MG	A083215 001		
VITARINE	4MG	A085850 001		
WATSON LABS	4MG	A083123 001		
	4MG	A085769 001		
DIMETANE				
WYETH CONS	4MG	N010799 003		
TABLET, EXTENDED RELEASE;ORAL				
DIMETANE				
WYETH CONS	8MG	N010799 010	Jun 10, 1983	
	12MG	N010799 011	Jun 10, 1983	
BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE				
SYRUP;ORAL				
BROMANATE DM				
ALPHARMA US PHARMS	2MG/5ML;10MG/5ML;30MG/5ML	A088722 001	Mar 07, 1985	
BROMFED-DM				
WOCKHARDT	2MG/5ML;10MG/5ML;30MG/5ML	A089681 001	Dec 22, 1988	
DIMETANE-DX				
+ ROBINS AH	2MG/5ML;10MG/5ML;30MG/5ML **	N019279 001	Aug 24, 1984	
BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE				
TABLET, EXTENDED RELEASE;ORAL				
EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE				
ALZA	16MG;240MG	N019672 001	Mar 29, 1996	
BUCLIZINE HYDROCHLORIDE				
TABLET;ORAL				
BUCLADIN-S				
STUART PHARMS	50MG	N010911 006		
BUDESONIDE				
AEROSOL, METERED;NASAL				
RHINOCORT				
ASTRAZENECA	0.032MG/INH	N020233 001	Feb 14, 1994	
POWDER, METERED;INHALATION				
PULMICORT				
ASTRAZENECA	0.16MG/INH	N020441 002	Jun 24, 1997	
	0.32MG/INH	N020441 003	Jun 24, 1997	
BUMETANIDE				
INJECTABLE;INJECTION				
BUMETANIDE				
ATHENEX INC	0.25MG/ML	A074441 001	Jan 27, 1995	
HOSPIRA	0.25MG/ML	A074160 001	Oct 30, 1997	
TEVA PARENTERAL	0.25MG/ML	A074613 001	Nov 18, 1997	
BUMEX				
+ VALIDUS PHARMS	0.25MG/ML **	N018226 001	Feb 28, 1983	
BUPIVACAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
BUPIVACAINE HYDROCHLORIDE				
HOSPIRA	0.75%	A070587 001	Mar 03, 1987	
BUPIVACAINE HYDROCHLORIDE KIT				
HOSPIRA	0.075%	N019978 001	Sep 03, 1992	
	0.114%	N019978 002	Sep 03, 1992	
	0.23%	N019978 003	Sep 03, 1992	

BUPIVACAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE				
INTL MEDICATED	0.25%	A076012	001	Jan 09, 2002
	0.5%	A076012	002	Jan 09, 2002
	0.75%	A076012	003	Jan 09, 2002
INJECTABLE;SPINAL				
SENSORCAINE				
FRESENIUS KABI USA	0.75%	A071202	001	Apr 15, 1987
BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE				
INJECTABLE;INJECTION				
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE				
HOSPIRA	0.25%;0.005MG/ML	A071166	001	Jun 16, 1988
	0.5%;0.005MG/ML	A071169	001	Jun 16, 1988
	0.75%;0.005MG/ML	A071171	001	Jun 16, 1988
BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
DUOCAINE				
AMPHASTAR PHARMS INC	EQ 0.375% (37.5MG/10ML);EQ 1% (100MG/10ML)	N021496	001	May 23, 2003
BUPRENORPHINE HYDROCHLORIDE				
TABLET;SUBLINGUAL				
SUBUTEX				
+ INDIVIOR INC	EQ 2MG BASE **	N020732	002	Oct 08, 2002
+	EQ 8MG BASE **	N020732	003	Oct 08, 2002
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE				
TABLET;SUBLINGUAL				
SUBOXONE				
+ INDIVIOR INC	EQ 2MG BASE;EQ 0.5MG BASE **	N020733	001	Oct 08, 2002
+	EQ 8MG BASE;EQ 2MG BASE	N020733	002	Oct 08, 2002
BUPROPION HYDROCHLORIDE				
TABLET;ORAL				
BUPROPION HYDROCHLORIDE				
SANDOZ	75MG	A075613	002	Oct 10, 2000
	100MG	A075613	001	Oct 10, 2000
TEVA	75MG	A075310	001	Nov 29, 1999
	100MG	A075310	002	Nov 29, 1999
WELLBUTRIN				
+ GLAXOSMITHKLINE	50MG **	N018644	001	Dec 30, 1985
+	75MG **	N018644	002	Dec 30, 1985
+	100MG **	N018644	003	Dec 30, 1985
TABLET, EXTENDED RELEASE;ORAL				
BUPROPION HYDROCHLORIDE				
ACTAVIS LABS FL INC	300MG	A077715	002	Jun 13, 2007
IMPAX LABS	300MG	A077415	002	Dec 15, 2006
SANDOZ	100MG	A076845	001	Jul 14, 2005
	150MG	A076834	001	Jul 14, 2005
	150MG	A076845	002	Jul 14, 2005
WOCKHARDT LTD	100MG	A201331	001	Aug 30, 2012
	150MG	A201331	002	Aug 30, 2012
	200MG	A201331	003	Aug 30, 2012
WELLBUTRIN SR				
GLAXOSMITHKLINE	50MG	N020358	001	Oct 04, 1996
ZYBAN				
GLAXOSMITHKLINE	100MG	N020711	002	May 14, 1997
BUSPIRONE HYDROCHLORIDE				
CAPSULE;ORAL				
BUSPAR				
BRISTOL MYERS SQUIBB	5MG	N021190	001	Dec 20, 2000
	7.5MG	N021190	002	Dec 20, 2000
	10MG	N021190	003	Dec 20, 2000
	15MG	N021190	004	Dec 20, 2000
TABLET;ORAL				
BUSPAR				
+ BRISTOL MYERS SQUIBB	5MG **	N018731	001	Sep 29, 1986
+	10MG **	N018731	002	Sep 29, 1986

BUSPIRONE HYDROCHLORIDE				
TABLET;ORAL				
BUSPAR				
+	15MG **	N018731	003	Apr 22, 1996
+	30MG **	N018731	004	Apr 22, 1996
BUSPIRONE HYDROCHLORIDE				
APOTEX	5MG	A075521	001	Apr 05, 2002
	10MG	A075521	002	Apr 05, 2002
	15MG	A075521	003	Apr 05, 2002
EGIS	5MG	A075119	001	Mar 14, 2002
	10MG	A075119	002	Mar 14, 2002
	15MG	A075119	003	Jan 23, 2003
FOSUN PHARMA	5MG	A075413	001	Mar 19, 2002
	10MG	A075413	002	Mar 19, 2002
	15MG	A075413	003	Mar 19, 2002
IVAX SUB TEVA PHARMS	5MG **	A075385	001	Mar 01, 2002
	10MG **	A075385	002	Mar 01, 2002
	15MG **	A075385	003	Mar 01, 2002
MYLAN	5MG	A075467	001	Feb 28, 2002
	10MG	A075467	003	Feb 28, 2002
	15MG	A075467	004	Feb 28, 2002
NESHER PHARMS	5MG	A075572	001	Feb 27, 2002
	10MG	A075572	002	Feb 27, 2002
	15MG	A075572	003	Feb 27, 2002
OXFORD PHARMS	5MG	A075388	001	May 09, 2002
	10MG	A075388	002	May 09, 2002
	15MG	A075388	003	May 09, 2002
BUTABARBITAL SODIUM				
CAPSULE;ORAL				
BUTICAPS				
MEDPOINTE PHARM HLC	15MG	A085381	001	
	30MG	A085381	002	
	50MG	A085381	003	
	100MG	A085381	004	
ELIXIR;ORAL				
BUTABARB				
ALPHARMA US PHARMS	30MG/5ML	A085873	001	
BUTABARBITAL SODIUM				
WOCKHARDT	30MG/5ML	A085383	001	
BUTALAN				
LANNETT	33.3MG/5ML	A085880	001	
BUTISOL SODIUM				
MEDA PHARMS	30MG/5ML	A085380	001	
SARISOL				
HALSEY	30MG/5ML	A084723	001	
TABLET;ORAL				
BUTABARBITAL				
BUNDY	30MG	A085550	001	
BUTABARBITAL SODIUM				
SANDOZ	15MG	A084292	003	Feb 09, 1982
	15MG	A085938	001	
	30MG	A084272	002	
	30MG	A085934	001	
SOLVAY	16.2MG	A083606	001	
	32.4MG	A083898	001	
	48.6MG	A083897	001	
	97.2MG	A083896	001	
TEVA	15MG	A088632	001	May 18, 1985
	30MG	A088631	001	May 01, 1985
WATSON LABS	15MG	A085764	001	
	30MG	A085772	001	
WHITEWORTH TOWN PLSN	15MG	A083325	002	
	30MG	A083337	001	
BUTISOL SODIUM				
MYLAN SPECIALITY LP	15MG	N000793	002	
	50MG	N000793	003	
	100MG	N000793	005	

BUTABARBITAL SODIUM				
TABLET;ORAL				
SARISOL NO. 1				
HALSEY	15MG		A084719 001	
SARISOL NO. 2				
HALSEY	30MG		A084719 002	
SODIUM BUTABARBITAL				
HIKMA PHARMS	15MG		A085418 001	
	30MG		A085432 001	
IVAX SUB TEVA PHARMS	15MG		A083484 001	
	30MG		A084040 001	
LANNETT	15MG		A085849 001	
	30MG		A085866 001	
	100MG		A085881 001	
MARSHALL PHARMA	16.2MG		A083524 001	
	32.4MG		A083858 001	
BUTENAFINE HYDROCHLORIDE				
CREAM;TOPICAL				
MENTAX-TC				
MYLAN	1%		N021408 001	Oct 17, 2002
BUTOCONAZOLE NITRATE				
CREAM;VAGINAL				
BUTOCONAZOLE NITRATE				
PERRIGO PHARMA INTL	2%		N019881 001	Feb 07, 1997
FEMSTAT				
ROCHE PALO	2%		N019215 001	Nov 25, 1985
FEMSTAT 3				
+ BAYER	2%		N020421 001	Dec 21, 1995
SUPPOSITORY;VAGINAL				
FEMSTAT				
ROCHE PALO	100MG		N019359 001	Nov 25, 1985
BUTORPHANOL TARTRATE				
INJECTABLE;INJECTION				
BUTORPHANOL TARTRATE				
BAXTER HLTHCARE CORP	2MG/ML		A075697 001	Oct 23, 2001
HIKMA FARMACEUTICA	2MG/ML		A078247 001	Apr 29, 2009
HOSPIRA	1MG/ML		A075342 001	Nov 04, 1999
	1MG/ML		A075559 001	Mar 20, 2000
	2MG/ML		A075342 002	Nov 04, 1999
	2MG/ML		A075559 002	Mar 20, 2000
BUTORPHANOL TARTRATE PRESERVATIVE FREE				
BAXTER HLTHCARE CORP	1MG/ML		A075695 001	Oct 23, 2001
	2MG/ML		A075695 002	Oct 23, 2001
HOSPIRA	1MG/ML		A074620 001	Jan 22, 1997
	1MG/ML		A075170 001	Sep 28, 1998
	2MG/ML		A074620 002	Jan 22, 1997
	2MG/ML		A075170 002	Sep 28, 1998
STADOL				
+ APOTHECON	2MG/ML **		N017857 004	
STADOL PRESERVATIVE FREE				
+ APOTHECON	1MG/ML **		N017857 001	
+	2MG/ML **		N017857 002	
SPRAY, METERED;NASAL				
STADOL				
BRISTOL MYERS SQUIBB	1MG/SPRAY **		N019890 001	Dec 12, 1991
CABERGOLINE				
TABLET;ORAL				
CABERGOLINE				
APOTEX CORP	0.5MG		A201503 001	Mar 08, 2013
IMPAX LABS INC	0.5MG		A077843 001	Jul 03, 2007
DOSTINEX				
+ PHARMACIA AND UPJOHN	0.5MG **		N020664 001	Dec 23, 1996

CAFFEINE; ERGOTAMINE TARTRATE				
SUPPOSITORY;RECTAL				
CAFERGOT				
+ NOVARTIS	100MG;2MG **	N009000	002	
TABLET;ORAL				
CAFERGOT				
NOVARTIS	100MG;1MG	N006620	001	
WIGRAINE				
ORGANON USA INC	100MG;1MG	A086562	001	
CALCIFEDIOL				
CAPSULE;ORAL				
CALDEROL				
ORGANON USA INC	0.02MG	N018312	001	
	0.05MG	N018312	002	
CALCIPOTRIENE				
OINTMENT;TOPICAL				
DOVONEX				
+ LEO PHARMA AS	0.005% **	N020273	001	Dec 29, 1993
SOLUTION;TOPICAL				
DOVONEX				
+ LEO PHARM	0.005% **	N020611	001	Mar 03, 1997
CALCITONIN HUMAN				
INJECTABLE;INJECTION				
CIBACALCIN				
NOVARTIS	0.5MG/VIAL	N018470	001	Oct 31, 1986
CALCITONIN SALMON				
INJECTABLE;INJECTION				
CALCIMAR				
SANOFI AVENTIS US	200 IU/ML	N017769	001	
	400 IU/VIAL	N017497	001	
CALCITONIN-SALMON				
IGI LABS INC	200 IU/ML	A073690	001	Apr 14, 1995
MIACALCIN				
MYLAN IRELAND LTD	100 IU/ML	N017808	001	Jul 03, 1986
SPRAY, METERED;NASAL				
MIACALCIN				
+ MYLAN IRELAND LTD	200 IU/SPRAY	N020313	002	Aug 17, 1995
CALCITONIN SALMON RECOMBINANT				
SPRAY, METERED;NASAL				
FORTICAL				
UPSHER SMITH LABS	200 IU/SPRAY **	N021406	001	Aug 12, 2005
CALCITRIOL				
INJECTABLE;INJECTION				
CALCIJEX				
+ ABBVIE	0.001MG/ML **	N018874	001	Sep 25, 1986
+	0.002MG/ML **	N018874	002	Sep 25, 1986
CALCITRIOL				
AKORN	0.002MG/ML	A078066	002	Jan 29, 2008
FRESENIUS KABI USA	0.001MG/ML	A075836	001	Dec 31, 2002
	0.002MG/ML	A075836	002	Dec 31, 2002
FRESENIUS MEDCL	0.001MG/ML	A075766	001	Feb 20, 2003
	0.002MG/ML	A075766	002	Feb 20, 2003
HOSPIRA	0.001MG/ML	A075816	001	Jan 16, 2004
	0.002MG/ML	A075816	002	Jan 16, 2004
LUITPOLD	0.001MG/ML	A075746	001	Sep 26, 2003
	0.002MG/ML	A075746	002	Sep 26, 2003
ROCKWELL MEDCL	0.001MG/ML	A076206	001	Sep 17, 2003
SAGENT PHARMS	0.001MG/ML	A077102	001	Feb 08, 2006
TEVA PARENTERAL	0.001MG/ML	A075823	001	Mar 31, 2003
	0.002MG/ML	A075823	002	Mar 31, 2003

CALCIUM ACETATE

CAPSULE;ORAL

PHOSLO

FRESENIUS MEDCL	333.5MG	N021160	001	Apr 02, 2001
	667MG	N021160	002	Apr 02, 2001

TABLET;ORAL

CALCIUM ACETATE

WEST-WARD PHARMS INT	667MG	A077693	001	Jan 30, 2008

ELIPHOS

CYPRESS PHARM	667MG	A078502	001	Nov 25, 2008

PHOSLO

+ FRESENIUS MEDCL	667MG **	N019976	001	Dec 10, 1990

CALCIUM CARBONATE; RISEDRONATE SODIUM

TABLET, TABLET;ORAL

ACTONEL WITH CALCIUM (COPACKAGED)

+ WARNER CHILCOTT	EQ 500MG BASE,N/A;N/A,35MG **	N021823	001	Aug 12, 2005

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

METHOTREXATE SODIUM

AKORN	0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML	N020079	001	Feb 26, 1999

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE CORP	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE CORP	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE CORP	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

NAVSTEL

ALCON PHARMS LTD	0.154MG/ML;0.92MG/ML;0.2MG/ML;0.184MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML	N022193	001	Jul 24, 2008

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML;120MG/100ML;330MG/100ML;88MG/100ML	N019864	001	Jun 10, 1993
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML;120MG/100ML;330MG/100ML;88MG/100ML	N018271	001	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE;INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N019867	001	Dec 20, 1993
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N018269	002	Jan 17, 1983

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	37MG/100ML;5GM/100ML;30MG/100ML;119MG/100ML;161MG/100ML;94MG/100ML;138MG/100ML **	N017390	001	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION;INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER				
B BRAUN	510MG/100ML;30GM/100ML;200MG/100ML;9.2GM/100ML;9.6GM/100ML	N018807	001	Aug 26, 1983
	510MG/100ML;30GM/100ML;200MG/100ML;9.4GM/100ML;11GM/100ML	N018807	003	Aug 26, 1983
DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER				
B BRAUN	510MG/100ML;50GM/100ML;200MG/100ML;9.2GM/100ML;9.6GM/100ML	N018807	002	Aug 26, 1983
	510MG/100ML;50GM/100ML;200MG/100ML;9.4GM/100ML;11GM/100ML	N018807	004	Aug 26, 1983
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
B BRAUN	29MG/100ML;2.5GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N018460	006	Jan 29, 1986
DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
B BRAUN	29MG/100ML;1.5GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N018460	001	
DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
B BRAUN	29MG/100ML;4.25GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N018460	003	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	002	
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	003	
DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	007	Jun 24, 1988
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	001	
DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	004	Jul 07, 1982
DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	005	Jul 07, 1982
DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	008	Jun 24, 1988

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	006	Jul 07, 1982
DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
B BRAUN	26MG/100ML;1.5GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N018460	007	Jan 29, 1986
	26MG/100ML;1.5GM/100ML;15MG/100ML;560MG/100ML;390MG/100ML	N018460	002	
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
B BRAUN	26MG/100ML;2.5GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N018460	005	Nov 02, 1983
	26MG/100ML;5GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N018460	008	Jan 29, 1986
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
B BRAUN	26MG/100ML;4.25GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N018460	009	Jan 29, 1986
	26MG/100ML;4.25GM/100ML;15MG/100ML;560MG/100ML;390MG/100ML	N018460	004	
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	001	
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	003	
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	002	
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	007	Jul 09, 1984
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	008	Jul 09, 1984
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	010	Nov 18, 1985
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	009	Jul 09, 1984
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	011	Nov 18, 1985
INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
FRESENIUS	18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	A020374	001	Jun 13, 1994
INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
FRESENIUS	18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	A020374	002	Jun 13, 1994
INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER				
FRESENIUS	18.4MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	A020374	003	Jun 13, 1994
INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
FRESENIUS	18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	A020374	004	Jun 13, 1994

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER				
B BRAUN	20MG/100ML;5GM/100ML;30MG/100ML;380MG/100ML;600MG/100ML	N018258	001	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER				
HOSPIRA	33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML	N018254	001	
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER				
B BRAUN	33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML	N018256	001	
	33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML	N020000	001	Apr 17, 1992
BAXTER HLTHCARE	33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML	N016695	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER

	B BRAUN	4MG/100ML;4GM/100ML;6MG/100ML;120MG/100 ML;62MG/100ML	N019634	002	Feb 24, 1988

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

	B BRAUN	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N017510	001	
	MILES	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N018499	001	

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N019685	005	Oct 17, 1988
+		20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N019685	006	Oct 17, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N019685	007	Oct 17, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML	N019685	008	Oct 17, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N019685	003	Oct 17, 1988

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML	N019685	004	Oct 17, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N019685	001	Oct 17, 1988

CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

	FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;538MG/100ML;448MG/100ML	N019395	001	Mar 26, 1986

INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

	FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;538MG/100ML;448MG/100ML	N019395	002	Mar 26, 1986

INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

	FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;538MG/100ML;448MG/100ML	N019395	003	Mar 26, 1986

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

	ABBOTT	16.5MG/ML;25.4MG/ML;74.6MG/ML;121MG/ML;16.1MG/ML	N019399	001	Jun 16, 1986

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE;INJECTION

ISOLYTE E IN PLASTIC CONTAINER

	B BRAUN	35MG/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N018899	001	Oct 31, 1983
		35MG/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N019718	001	Sep 29, 1989

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER

	BAXTER HLTHCARE	36.8MG/100ML;30.5MG/100ML;74.6MG/100ML;640MG/100ML;496MG/100ML;89.6MG/100ML	N017438	001	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

ACETATED RINGER'S IN PLASTIC CONTAINER

	B BRAUN	20MG/100ML;30MG/100ML;380MG/100ML;600MG/100ML	N018725	001	Nov 29, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION				
RINGER'S IN PLASTIC CONTAINER				
	B BRAUN	33MG/100ML;30MG/100ML;860MG/100ML	N018721 001	Nov 09, 1982
SOLUTION;IRRIGATION				
RINGER'S IN PLASTIC CONTAINER				
	ABBOTT	33MG/100ML;30MG/100ML;860MG/100ML	N018462 001	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION				
LACTATED RINGER'S IN PLASTIC CONTAINER				
	ABBOTT	20MG/100ML;30MG/100ML;600MG/100ML;310MG /100ML	N019485 001	Oct 24, 1985
	B BRAUN	20MG/100ML;30MG/100ML;600MG/100ML;310MG /100ML	N018023 001	
	MILES	20MG/100ML;30MG/100ML;600MG/100ML;310MG /100ML	N018417 001	
SOLUTION;IRRIGATION				
LACTATED RINGER'S IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	20MG/100ML;30MG/100ML;600MG/100ML;310MG /100ML	N019933 001	Aug 29, 1989

CALCIUM GLUCEPTATE

INJECTABLE;INJECTION				
CALCIUM GLUCEPTATE				
	ABBOTT	EQ 90MG CALCIUM/5ML	A080001 001	
		EQ 90MG CALCIUM/5ML	A083159 001	
	ABRAXIS PHARM	EQ 90MG CALCIUM/5ML	A089373 001	Apr 30, 1987
	LILLY	EQ 90MG CALCIUM/5ML	N006470 001	

CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

INJECTABLE;INJECTION				
ISOPAQUE 440				
	GE HEALTHCARE	0.78MG/ML;75.9MG/ML;0.15MG/ML;16.6MG/ML	N016847 001	

CALCIUM; MEGLUMINE; METRIZOIC ACID

INJECTABLE;INJECTION				
ISOPAQUE 280				
	GE HEALTHCARE	0.35MG/ML;140.1MG/ML;461.8MG/ML	N017506 001	

CANDESARTAN CILEXETIL

TABLET;ORAL				
CANDESARTAN CILEXETIL				
	APOTEX INC	4MG	A202079 001	Jan 10, 2014
		8MG	A202079 002	Jan 10, 2014
		16MG	A202079 003	Jan 10, 2014
		32MG	A202079 004	Jan 10, 2014

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL				
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE				
	APOTEX INC	16MG;12.5MG	A202884 001	Dec 04, 2012
		32MG;12.5MG	A202884 002	Dec 04, 2012
		32MG;25MG	A202884 003	Jun 03, 2013

CANDICIDIN

OINTMENT;VAGINAL				
VANOBID				
	SANOFI AVENTIS US	0.6MG/GM	A061596 001	
TABLET;VAGINAL				
VANOBID				
	SANOFI AVENTIS US	3MG	A061613 001	

CAPTOPRIL

TABLET;ORAL				
CAPOTEN				
+	PAR PHARM	12.5MG **	N018343 005	Jan 17, 1985
+		25MG **	N018343 002	
+		37.5MG **	N018343 006	Sep 17, 1986
+		50MG **	N018343 001	
+		75MG **	N018343 007	Jun 13, 1995
+		100MG **	N018343 003	
+		150MG **	N018343 004	Jun 13, 1995

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

APOTEX	12.5MG	A074737	001	Oct 28, 1998
	25MG	A074737	002	Oct 28, 1998
	50MG	A074737	003	Oct 28, 1998
	100MG	A074737	004	Oct 28, 1998
APOTHECON	12.5MG	A074472	001	Mar 31, 1995
	25MG	A074472	002	Mar 31, 1995
	50MG	A074472	003	Mar 31, 1995
	100MG	A074472	004	Mar 31, 1995
BOSCOGEN	12.5MG	A074677	004	May 30, 1997
	25MG	A074677	002	May 30, 1997
	50MG	A074677	001	May 30, 1997
	100MG	A074677	003	May 30, 1997
DAVA PHARMS INC	12.5MG	A074423	001	Feb 13, 1996
	25MG	A074423	002	Feb 13, 1996
	50MG	A074423	003	Feb 13, 1996
	100MG	A074423	004	Feb 13, 1996
EGIS PHARMS	12.5MG	A074748	004	May 29, 1997
	25MG	A074748	002	May 29, 1997
	50MG	A074748	001	May 29, 1997
	100MG	A074748	003	May 29, 1997
G AND W LABS INC	12.5MG	A074433	001	Feb 13, 1996
	12.5MG	A074462	001	Feb 13, 1996
	12.5MG	A074483	001	Feb 13, 1996
	12.5MG	A074590	004	Aug 30, 1996
	25MG	A074433	002	Feb 13, 1996
	25MG	A074462	002	Feb 13, 1996
	25MG	A074483	002	Feb 13, 1996
	25MG	A074590	002	Aug 30, 1996
	50MG	A074433	003	Feb 13, 1996
	50MG	A074462	003	Feb 13, 1996
	50MG	A074483	003	Feb 13, 1996
	50MG	A074590	001	Aug 30, 1996
	100MG	A074433	004	Feb 13, 1996
	100MG	A074462	004	Feb 13, 1996
	100MG	A074483	004	Feb 13, 1996
	100MG	A074590	003	Aug 30, 1996
OXFORD PHARMS	12.5MG	A074418	001	Feb 13, 1996
	25MG	A074418	002	Feb 13, 1996
	50MG	A074418	003	Feb 13, 1996
	100MG	A074418	004	Feb 13, 1996
PAR PHARM	12.5MG	A074493	001	Feb 13, 1996
	25MG	A074493	002	Feb 13, 1996
	50MG	A074493	003	Feb 13, 1996
	100MG	A074493	004	Feb 13, 1996
PUREPAC PHARM	12.5MG	A074640	001	Mar 31, 1997
	25MG	A074640	002	Mar 31, 1997
	50MG	A074640	003	Mar 31, 1997
	100MG	A074640	004	Mar 31, 1997
SANDOZ	12.5MG	A074481	001	Feb 13, 1996
	25MG	A074481	002	Feb 13, 1996
	50MG	A074481	003	Feb 13, 1996
	100MG	A074481	004	Feb 13, 1996
WATSON LABS	12.5MG	A074451	001	Feb 13, 1996
	12.5MG	A074576	001	Apr 23, 1996
	25MG	A074451	002	Feb 13, 1996
	25MG	A074576	002	Apr 23, 1996
	50MG	A074451	003	Feb 13, 1996
	50MG	A074576	003	Apr 23, 1996
	100MG	A074451	004	Feb 13, 1996
	100MG	A074576	004	Apr 23, 1996
YAOPHARMA CO LTD	12.5MG	A074363	001	Nov 09, 1995
	12.5MG	A074519	001	Feb 13, 1996
	25MG	A074363	002	Nov 09, 1995
	25MG	A074519	002	Feb 13, 1996
	50MG	A074363	003	Nov 09, 1995
	50MG	A074519	003	Feb 13, 1996

CAPTOPRIL				
TABLET;ORAL				
CAPTOPRIL				
	100MG		A074363 004	Nov 09, 1995
	100MG		A074519 004	Feb 13, 1996
CAPTOPRIL; HYDROCHLOROTHIAZIDE				
TABLET;ORAL				
CAPOZIDE 25/15				
+ APOTHECON	25MG;15MG **		N018709 001	Oct 12, 1984
CAPOZIDE 25/25				
+ APOTHECON	25MG;25MG **		N018709 002	Oct 12, 1984
CAPOZIDE 50/15				
+ APOTHECON	50MG;15MG **		N018709 004	Oct 12, 1984
CAPOZIDE 50/25				
+ APOTHECON	50MG;25MG **		N018709 003	Oct 12, 1984
CAPTOPRIL AND HYDROCHLOROTHIAZIDE				
G AND W LABS INC	25MG;15MG		A074827 001	Dec 29, 1997
	25MG;25MG		A074827 002	Dec 29, 1997
	50MG;15MG		A074827 004	Dec 29, 1997
	50MG;25MG		A074827 003	Dec 29, 1997
IVAX SUB TEVA PHARMS	25MG;15MG		A075055 001	Jun 18, 1998
	25MG;25MG		A075055 002	Jun 18, 1998
	50MG;15MG		A075055 004	Jun 18, 1998
	50MG;25MG		A075055 003	Jun 18, 1998
VINTAGE PHARMS LLC	25MG;15MG		A074788 001	Dec 29, 1997
	25MG;25MG		A074788 002	Dec 29, 1997
	50MG;15MG		A074788 004	Dec 29, 1997
	50MG;25MG		A074788 003	Dec 29, 1997
WATSON LABS	50MG;25MG		A074832 001	Dec 29, 1997
CARBACHOL				
SOLUTION;INTRAOCULAR				
CARBACHOL				
PHARMAFAIR	0.01%		A070292 001	May 21, 1986
CARBASTAT				
NOVARTIS	0.01%		A073677 001	Apr 28, 1995
CARBAMAZEPINE				
SOLUTION;INTRAVENOUS				
CARNEXIV				
+ LUNDBECK PHARMS LLC	200MG/20ML (10MG/ML)		N206030 001	Oct 07, 2016
SUSPENSION;ORAL				
CARBAMAZEPINE				
TARO	100MG/5ML		A075875 001	Dec 21, 2000
TABLET;ORAL				
CARBAMAZEPINE				
ACTAVIS ELIZABETH	200MG		A071696 001	Nov 09, 1987
INWOOD LABS	200MG		A070231 001	Aug 14, 1986
PLIVA	200MG		A071479 001	Jul 24, 1987
USL PHARMA	200MG		A070300 001	May 15, 1986
WARNER CHILCOTT	200MG		A070429 001	Jan 02, 1987
TERIL				
TARO	200MG		A076525 001	Sep 26, 2003
TABLET, CHEWABLE;ORAL				
CARBAMAZEPINE				
JUBILANT CADISTA	100MG		A071940 001	Feb 01, 1988
CARBENICILLIN DISODIUM				
INJECTABLE;INJECTION				
GEOPEN				
ROERIG	EQ 1GM BASE/VIAL		N050306 001	
	EQ 2GM BASE/VIAL		N050306 004	
	EQ 5GM BASE/VIAL		N050306 002	
	EQ 10GM BASE/VIAL		N050306 006	
	EQ 30GM BASE/VIAL		N050306 007	
PYOPEN				
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL		N050298 001	
	EQ 2GM BASE/VIAL		N050298 002	
	EQ 5GM BASE/VIAL		N050298 003	
	EQ 10GM BASE/VIAL		N050298 006	

CARBENICILLIN DISODIUM				
INJECTABLE;INJECTION				
PYOPEN				
	EQ 20GM BASE/VIAL		N050298 007	
CARBENICILLIN INDANYL SODIUM				
TABLET;ORAL				
GEOCILLIN				
PFIZER	EQ 382MG BASE		N050435 001	
CARBIDOPA; LEVODOPA				
TABLET;ORAL				
CARBIDOPA AND LEVODOPA				
ANI PHARMS INC	10MG;100MG		A073587 002	Jun 29, 1995
	25MG;100MG		A073587 001	Jun 29, 1995
	25MG;250MG		A073587 003	Jun 29, 1995
SCS	10MG;100MG		A074080 001	Mar 25, 1994
	25MG;100MG		A074080 002	Mar 25, 1994
	25MG;250MG		A074080 003	Mar 25, 1994
WATSON LABS	10MG;100MG		A073381 001	Sep 28, 1993
	25MG;100MG		A073382 001	Sep 28, 1993
	25MG;250MG		A073383 001	Sep 28, 1993
TABLET, EXTENDED RELEASE;ORAL				
CARBIDOPA AND LEVODOPA				
KV PHARM	50MG;200MG		A076663 001	Jun 24, 2004
TABLET, FOR SUSPENSION;ORAL				
CARBILEV				
RANBAXY	10MG;100MG		A076643 001	Jun 10, 2005
	25MG;100MG		A076643 002	Jun 10, 2005
	25MG;250MG		A076643 003	Jun 10, 2005
TABLET, ORALLY DISINTEGRATING;ORAL				
CARBIDOPA AND LEVODOPA				
IMPAX LABS	10MG;100MG		A090631 001	Jun 08, 2010
	25MG;100MG		A090631 002	Jun 08, 2010
	25MG;250MG		A090631 003	Jun 08, 2010
PARCOPA				
UCB INC	10MG;100MG **		A076699 001	Aug 27, 2004
	25MG;100MG **		A076699 002	Aug 27, 2004
	25MG;250MG **		A076699 003	Aug 27, 2004
CARBINOXAMINE MALEATE				
ELIXIR;ORAL				
CLISTIN				
+ MCNEIL	4MG/5ML **		N008955 001	
SOLUTION;ORAL				
CARBINOXAMINE MALEATE				
CYPRESS PHARM	4MG/5ML		A090418 001	May 04, 2010
TABLET;ORAL				
CARBINOXAMINE MALEATE				
CYPRESS PHARM	4MG		A090417 001	Aug 23, 2010
CLISTIN				
+ ORTHO MCNEIL PHARM	4MG **		N008915 001	
CARBOPLATIN				
INJECTABLE;INJECTION				
CARBOPLATIN				
CIPLA LTD	50MG/VIAL		A077383 001	Jan 27, 2006
	150MG/VIAL		A077383 002	Jan 27, 2006
	450MG/VIAL		A077383 003	Jan 27, 2006
FRESENIUS KABI USA	50MG/VIAL		A076235 001	Oct 14, 2004
	150MG/VIAL		A076235 002	Oct 14, 2004
	450MG/VIAL		A076235 003	Oct 14, 2004
HOSPIRA	50MG/VIAL		A076473 001	Oct 27, 2004
	150MG/VIAL		A076473 002	Oct 27, 2004
	450MG/VIAL		A076473 003	Oct 27, 2004
MYLAN LABS LTD	50MG/VIAL		A091510 001	May 29, 2012
	150MG/VIAL		A091510 002	May 29, 2012
	450MG/VIAL		A091510 003	May 29, 2012
PLIVA	50MG/VIAL		A076602 001	Nov 16, 2004
	150MG/VIAL		A076602 002	Nov 16, 2004
	450MG/VIAL		A076602 003	Nov 16, 2004

CARBOPLATIN				
INJECTABLE;INJECTION				
CARBOPLATIN				
SANDOZ	50MG/VIAL	A076959	001	Mar 18, 2005
	150MG/VIAL	A076959	002	Mar 18, 2005
	450MG/VIAL	A076959	003	Mar 18, 2005
WATSON LABS TEVA	50MG/VIAL	A076162	001	Oct 14, 2004
	150MG/VIAL	A076162	002	Oct 14, 2004
	450MG/VIAL	A076162	003	Oct 14, 2004
WEST-WARD PHARMS INT	50MG/VIAL	A076099	001	Oct 14, 2004
	150MG/VIAL	A076099	002	Oct 14, 2004
	450MG/VIAL	A076099	003	Oct 14, 2004
PARAPLATIN				
+ CORDEN PHARMA	50MG/VIAL **	N019880	001	Mar 03, 1989
+	150MG/VIAL **	N019880	002	Mar 03, 1989
+	450MG/VIAL **	N019880	003	Mar 03, 1989
INJECTABLE;IV (INFUSION)				
CARBOPLATIN				
ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012
	150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012
	450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012
	600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012
FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A077247	001	Oct 21, 2004
	50MG/5ML (10MG/ML)	A077266	001	Feb 15, 2006
	150MG/15ML (10MG/ML)	A077247	002	Oct 21, 2004
	150MG/15ML (10MG/ML)	A077266	002	Feb 15, 2006
MYLAN LABS LTD	1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011
PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077679	001	Feb 25, 2009
	150MG/15ML (10MG/ML)	A077679	002	Feb 25, 2009
	450MG/45ML (10MG/ML)	A077679	003	Feb 25, 2009
TEVA PARENTERAL	50MG/5ML (10MG/ML)	A077389	001	Mar 30, 2007
	150MG/15ML (10MG/ML)	A077389	002	Mar 30, 2007
	450MG/45ML (10MG/ML)	A077389	003	Mar 30, 2007
PARAPLATIN				
+ CORDENPHARMA	50MG/5ML (10MG/ML) **	N020452	001	Jul 14, 2003
+	150MG/15ML (10MG/ML) **	N020452	002	Jul 14, 2003
+	450MG/45ML (10MG/ML) **	N020452	003	Jul 14, 2003
+	600MG/60ML (10MG/ML) **	N020452	004	Jan 15, 2004
CARISOPRODOL				
CAPSULE;ORAL				
SOMA				
+ MYLAN SPECIALITY LP	250MG	N011792	003	
TABLET;ORAL				
CARISOPRODOL				
ABLE	350MG	A040421	001	Jun 21, 2001
EPIC PHARMA LLC	350MG	A040397	001	Sep 21, 2000
FOSUN PHARMA	350MG	A081025	001	Apr 13, 1989
OXFORD PHARMS	350MG	A040188	001	Mar 07, 1997
PIONEER PHARMS	350MG	A089390	001	Oct 13, 1988
SANDOZ	350MG	A089566	001	Aug 30, 1988
SUN PHARM INDS LTD	350MG	A040755	001	Feb 27, 2007
WATSON LABS	350MG	A040152	001	Dec 03, 1996
	350MG	A085433	001	
WATSON LABS TEVA	350MG	A086179	001	
RELA				
SCHERING	350MG	N012155	001	
CARPHENAZINE MALEATE				
CONCENTRATE;ORAL				
PROKETAZINE				
WYETH AYERST	50MG/ML	N014173	001	
TABLET;ORAL				
PROKETAZINE				
WYETH AYERST	12.5MG	N012768	001	
	25MG	N012768	002	
	50MG	N012768	004	

CARPROFEN				
TABLET;ORAL				
RIMADYL				
	ROCHE	100MG	N018550 002	Dec 31, 1987
		150MG	N018550 003	Dec 31, 1987
CARTEOLOL HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
CARTEOLOL HYDROCHLORIDE				
	APOTEX INC	1%	A076097 001	Feb 06, 2002
OCUPRESS				
+	NOVARTIS	1% **	N019972 001	May 23, 1990
TABLET;ORAL				
CARTROL				
	ABBVIE	2.5MG	N019204 001	Dec 28, 1988
		5MG	N019204 002	Dec 28, 1988
		10MG	N019204 003	Dec 28, 1988
CARVEDILOL				
TABLET;ORAL				
CARVEDILOL				
	HIKMA	3.125MG	A077887 001	Sep 07, 2007
		6.25MG	A077887 002	Sep 07, 2007
		12.5MG	A077887 003	Sep 07, 2007
		25MG	A077887 004	Sep 07, 2007
	PLIVA HRVATSKA DOO	3.125MG	A078240 001	Oct 30, 2007
		6.25MG	A078240 002	Oct 30, 2007
		12.5MG	A078240 003	Oct 30, 2007
		25MG	A078240 004	Oct 30, 2007
	WOCKHARDT LTD	3.125MG	A078786 001	Dec 22, 2009
		6.25MG	A078786 002	Dec 22, 2009
		12.5MG	A078786 003	Dec 22, 2009
		25MG	A078786 004	Dec 22, 2009
CEFACLOR				
CAPSULE;ORAL				
CECLOR				
+	LILLY	EQ 250MG BASE **	N050521 001	
+		EQ 500MG BASE **	N050521 002	
CEFACLOR				
	CEPH INTL	EQ 250MG BASE	A062205 001	
		EQ 500MG BASE	A062205 002	
	DAVA PHARMS INC	EQ 250MG BASE	A064107 001	Apr 27, 1995
		EQ 500MG BASE	A064107 002	Apr 27, 1995
	IVAX SUB TEVA PHARMS	EQ 250MG BASE	A064061 001	Apr 27, 1995
		EQ 500MG BASE	A064061 002	Apr 27, 1995
	RANBAXY	EQ 250MG BASE	A064156 001	Aug 28, 1997
		EQ 500MG BASE	A064156 002	Aug 28, 1997
	TEVA	EQ 250MG BASE	A064081 001	Sep 16, 1996
		EQ 250MG BASE	A064145 001	Jun 24, 1996
		EQ 500MG BASE	A064081 002	Sep 16, 1996
		EQ 500MG BASE	A064145 002	Jun 24, 1996
	WATSON LABS INC	EQ 250MG BASE	A064148 001	May 23, 1996
		EQ 500MG BASE	A064148 002	May 23, 1996
FOR SUSPENSION;ORAL				
CECLOR				
+	LILLY	EQ 125MG BASE/5ML **	N050522 001	
+		EQ 250MG BASE/5ML **	N050522 002	
CEFACLOR				
	DAVA PHARMS INC	EQ 125MG BASE/5ML	A064114 001	Apr 28, 1995
		EQ 187MG BASE/5ML	A064115 001	Apr 28, 1995
		EQ 250MG BASE/5ML	A064116 001	Apr 28, 1995
		EQ 375MG BASE/5ML	A064110 001	Apr 28, 1995
	FACTA FARMA	EQ 125MG BASE/5ML	A062206 001	
		EQ 187MG BASE/5ML	A062206 003	Apr 20, 1988
		EQ 250MG BASE/5ML	A062206 002	
		EQ 375MG BASE/5ML	A062206 004	Apr 20, 1988
	IVAX SUB TEVA PHARMS	EQ 125MG BASE/5ML	A064087 001	Apr 28, 1995
		EQ 187MG BASE/5ML	A064086 001	Apr 28, 1995
		EQ 250MG BASE/5ML	A064085 001	Apr 28, 1995
		EQ 375MG BASE/5ML	A064070 001	Apr 28, 1995

CEFACLOR

FOR SUSPENSION;ORAL				
CEFACLOR				
RANBAXY	EQ 125MG BASE/5ML	A064166	001	Oct 02, 1997
	EQ 187MG BASE/5ML	A064165	001	Oct 02, 1997
	EQ 250MG BASE/5ML	A064164	001	Oct 02, 1997
	EQ 375MG BASE/5ML	A064155	001	Oct 02, 1997
WATSON LABS INC	EQ 125MG BASE/5ML	A064204	001	Feb 18, 1998
	EQ 187MG BASE/5ML	A064205	001	Feb 18, 1998
	EQ 250MG BASE/5ML	A064206	001	Feb 18, 1998
	EQ 375MG BASE/5ML	A064207	001	Feb 18, 1998
TABLET, CHEWABLE;ORAL				
RANICLOR				
RANBAXY LABS LTD	EQ 125MG BASE	A065092	001	Dec 22, 2003
	EQ 187MG BASE	A065092	002	Dec 22, 2003
	EQ 250MG BASE	A065092	003	Dec 22, 2003
	EQ 375MG BASE	A065092	004	Dec 22, 2003
TABLET, EXTENDED RELEASE;ORAL				
CECLOR CD				
LILLY	EQ 375MG BASE	N050673	001	Jun 28, 1996
	EQ 500MG BASE	N050673	002	Jun 28, 1996
CEFACLOR				
WORLD GEN	EQ 500MG BASE	A065057	001	Jan 05, 2001

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL				
CEFADROXIL				
CSPC OUYI PHARM CO	EQ 500MG BASE	A205072	001	Jul 28, 2017
IVAX SUB TEVA PHARMS	EQ 500MG BASE	A062766	001	Mar 03, 1987
PUREPAC PHARM	EQ 500MG BASE	A063017	001	Jan 05, 1989
RANBAXY LABS LTD	EQ 500MG BASE	A065015	001	Jun 22, 1999
SANDOZ	EQ 500MG BASE	A062291	001	
TEVA	EQ 500MG BASE	A062695	001	Feb 10, 1989
DURICEF				
WARNER CHILCOTT	EQ 250MG BASE	N050512	002	
+	EQ 500MG BASE **	N050512	001	
ULTRACEF				
BRISTOL	EQ 500MG BASE	A062378	001	Mar 16, 1982
FOR SUSPENSION;ORAL				
CEFADROXIL				
ANI PHARMS INC	EQ 125MG BASE/5ML	A062698	001	Mar 01, 1989
	EQ 250MG BASE/5ML	A062698	002	Mar 01, 1989
	EQ 250MG BASE/5ML	A065278	001	Jan 20, 2006
	EQ 500MG BASE/5ML	A062698	003	Mar 01, 1989
	EQ 500MG BASE/5ML	A065278	002	Jan 20, 2006
APOTHECON	EQ 125MG BASE/5ML	A062334	001	
	EQ 250MG BASE/5ML	A062334	002	
	EQ 500MG BASE/5ML	A062334	003	
SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003
	EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003
	EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003
DURICEF				
+ WARNER CHILCOTT	EQ 125MG BASE/5ML **	N050527	002	
+	EQ 250MG BASE/5ML **	N050527	003	
+	EQ 500MG BASE/5ML **	N050527	001	
ULTRACEF				
BRISTOL	EQ 125MG BASE/5ML	A062376	001	Mar 16, 1982
	EQ 250MG BASE/5ML	A062376	002	Mar 16, 1982
	EQ 500MG BASE/5ML	A062376	003	Mar 16, 1982
TABLET;ORAL				
CEFADROXIL				
RANBAXY	EQ 1GM BASE	A065018	001	Apr 23, 1999
DURICEF				
+ WARNER CHILCOTT	EQ 1GM BASE **	N050528	001	
ULTRACEF				
APOTHECON	EQ 1GM BASE	A062390	001	Jun 10, 1982
BRISTOL	EQ 1GM BASE	A062408	001	Aug 31, 1982

CEFAMANDOLE NAFATE

INJECTABLE;INJECTION

MANDOL				
LILLY	EQ 500MG BASE/VIAL	N050504	001	
	EQ 1GM BASE/VIAL	A062560	001	Sep 10, 1985
	EQ 1GM BASE/VIAL	N050504	002	
	EQ 2GM BASE/VIAL	A062560	002	Sep 10, 1985
	EQ 2GM BASE/VIAL	N050504	003	
	EQ 10GM BASE/VIAL	N050504	004	

CEFAZOLIN SODIUM

INJECTABLE;INJECTION

ANCEF				
+ GLAXOSMITHKLINE	EQ 250MG BASE/VIAL **	N050461	001	
+	EQ 500MG BASE/VIAL	N050461	002	
+	EQ 1GM BASE/VIAL **	N050461	003	
+	EQ 5GM BASE/VIAL **	N050461	004	
+	EQ 10GM BASE/VIAL **	N050461	005	
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566	003	Jun 08, 1983
	EQ 20MG BASE/ML	N050566	004	Jun 08, 1983
ANCEF IN PLASTIC CONTAINER				
BAXTER HLTHCARE	EQ 10MG BASE/ML	A063002	001	Mar 28, 1991
ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566	001	Jun 08, 1983
	EQ 20MG BASE/ML	N050566	002	Jun 08, 1983
CEFAZOLIN AND DEXTROSE				
B BRAUN	EQ 500MG BASE/VIAL	N050779	001	Jul 27, 2000
CEFAZOLIN SODIUM				
ABRAXIS PHARM	EQ 500MG BASE/VIAL	A062688	002	Nov 17, 1986
	EQ 1GM BASE/VIAL	A062688	003	Nov 17, 1986
	EQ 10GM BASE/VIAL	A062688	004	Nov 17, 1986
	EQ 20GM BASE/VIAL	A062688	005	Aug 03, 1987
AUROBINDO PHARMA	EQ 500MG BASE/VIAL	A065395	001	Aug 08, 2008
	EQ 1GM BASE/VIAL	A065395	002	Aug 08, 2008
BEDFORD	EQ 250MG BASE/VIAL	A062894	001	Jul 21, 1988
	EQ 500MG BASE/VIAL	A062894	002	Jul 21, 1988
	EQ 1GM BASE/VIAL	A062894	003	Jul 21, 1988
	EQ 5GM BASE/VIAL	A062894	004	Jul 21, 1988
	EQ 10GM BASE/VIAL	A062894	005	Jul 21, 1988
CEPHAZONE PHARMA	EQ 500MG BASE/VIAL	A065280	001	Mar 18, 2009
	EQ 1GM BASE/VIAL	A065280	002	Mar 18, 2009
	EQ 10GM BASE/VIAL	A065295	001	Mar 18, 2009
	EQ 20GM BASE/VIAL	A065296	001	Mar 18, 2009
FACTA FARMA	EQ 500MG BASE/VIAL	A063214	001	Dec 27, 1991
	EQ 1GM BASE/VIAL	A063207	001	Dec 27, 1991
	EQ 10GM BASE/VIAL	A063209	001	Dec 27, 1991
	EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999
FRESENIUS KABI USA	EQ 500MG BASE/VIAL **	A064169	001	Aug 14, 1998
	EQ 1GM BASE/VIAL **	A064169	002	Aug 14, 1998
	EQ 10GM BASE/VIAL	A064170	001	Mar 18, 1998
	EQ 20GM BASE/VIAL	A064170	002	Mar 18, 1998
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	A064033	001	Oct 31, 1993
STERI PHARMA	EQ 500MG BASE/VIAL	A063216	001	Dec 27, 1991
	EQ 1GM BASE/VIAL	A063208	001	Dec 27, 1991
TEVA PHARMS	EQ 250MG BASE/VIAL	A063016	001	Mar 14, 1989
	EQ 500MG BASE/VIAL	A063016	002	Mar 14, 1989
	EQ 1GM BASE/VIAL	A063016	003	Mar 14, 1989
	EQ 5GM BASE/VIAL	A063018	001	Mar 05, 1990
	EQ 10GM BASE/VIAL	A063018	002	Mar 05, 1990
WATSON LABS INC	EQ 250MG BASE/VIAL	A062988	001	Dec 29, 1989
	EQ 500MG BASE/VIAL	A062988	002	Dec 29, 1989
	EQ 1GM BASE/VIAL	A062988	003	Dec 29, 1989
	EQ 5GM BASE/VIAL	A062989	001	Dec 29, 1989
	EQ 10GM BASE/VIAL	A062989	002	Dec 29, 1989
	EQ 20GM BASE/VIAL	A062989	003	Dec 29, 1989
WEST-WARD PHARMS INT	EQ 250MG BASE/VIAL	A062807	001	Jan 12, 1988
	EQ 500MG BASE/VIAL	A062807	002	Jan 12, 1988
	EQ 1GM BASE/VIAL	A062807	003	Jan 12, 1988
	EQ 5GM BASE/VIAL	A062807	004	Jan 12, 1988

CEFAZOLIN SODIUM				
INJECTABLE;INJECTION				
CEFAZOLIN SODIUM				
	EQ 10GM BASE/VIAL	A062807	005	Jan 12, 1988
	EQ 20GM BASE/VIAL	A062807	006	Jan 12, 1988
KEFZOL				
ACS DOBFAR	EQ 250MG BASE/VIAL	A061773	001	
	EQ 500MG BASE/VIAL	A061773	002	
	EQ 1GM BASE/VIAL	A061773	003	
	EQ 10GM BASE/VIAL	A061773	004	
	EQ 20GM BASE/VIAL	A061773	005	Sep 08, 1987
LILLY	EQ 500MG BASE/VIAL	A062557	001	Sep 10, 1985
	EQ 1GM BASE/VIAL	A062557	002	Sep 10, 1985
CEFDINIR				
CAPSULE;ORAL				
OMNICEF				
+ ABBVIE	300MG **	N050739	001	Dec 04, 1997
FOR SUSPENSION;ORAL				
OMNICEF				
+ ABBVIE	125MG/5ML **	N050749	001	Dec 04, 1997
+	250MG/5ML **	N050749	002	Jul 29, 2004
CEFDITOREN PIVOXIL				
TABLET;ORAL				
SPECTRACEF				
VANSEN PHARMA	200MG	N021222	001	Aug 29, 2001
	400MG	N021222	002	Jul 21, 2008
CEFEPIME HYDROCHLORIDE				
INJECTABLE;INJECTION				
CEFEPIME HYDROCHLORIDE				
FOSUN PHARMA	EQ 500MG BASE/VIAL	A090291	001	Dec 21, 2010
	EQ 1GM BASE/VIAL	A090291	002	Dec 21, 2010
	EQ 2GM BASE/VIAL	A090291	003	Dec 21, 2010
CEFIXIME				
FOR SUSPENSION;ORAL				
SUPRAX				
+ LEDERLE	100MG/5ML **	N050622	001	Apr 28, 1989
TABLET;ORAL				
SUPRAX				
+ LEDERLE	200MG **	N050621	001	Apr 28, 1989
+	400MG **	N050621	002	Apr 28, 1989
CEFMENOXIME HYDROCHLORIDE				
INJECTABLE;INJECTION				
CEFMAX				
TAP PHARM	EQ 500MG BASE/VIAL	N050571	001	Dec 30, 1987
	EQ 1GM BASE/VIAL	N050571	002	Dec 30, 1987
	EQ 2GM BASE/VIAL	N050571	003	Dec 30, 1987
CEFMETAZOLE SODIUM				
INJECTABLE;INJECTION				
ZEFAZONE				
+ PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL **	N050637	001	Dec 11, 1989
+	EQ 2GM BASE/VIAL **	N050637	002	Dec 11, 1989
ZEFAZONE IN PLASTIC CONTAINER				
+ PHARMACIA AND UPJOHN	EQ 20MG BASE/ML **	N050683	001	Dec 29, 1992
+	EQ 40MG BASE/ML **	N050683	002	Dec 29, 1992
CEFONICID SODIUM				
INJECTABLE;INJECTION				
MONOCID				
GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	N050579	001	May 23, 1984
	EQ 1GM BASE/VIAL	A063295	001	Jul 26, 1993
	EQ 1GM BASE/VIAL	N050579	002	May 23, 1984
	EQ 2GM BASE/VIAL	N050579	003	May 23, 1984
	EQ 10GM BASE/VIAL	N050579	004	May 23, 1984

CEFOPERAZONE SODIUM

INJECTABLE;INJECTION				
CEFOBID				
PFIZER	EQ 1GM BASE/VIAL	A063333	001	Mar 31, 1995
	EQ 1GM BASE/VIAL	N050551	001	Nov 18, 1982
	EQ 2GM BASE/VIAL	A063333	002	Mar 31, 1995
	EQ 2GM BASE/VIAL	N050551	002	Nov 18, 1982
	EQ 10GM BASE/VIAL	N050551	003	Mar 05, 1990
CEFOBID IN PLASTIC CONTAINER				
PFIZER	EQ 20MG BASE/ML	N050613	002	Jul 31, 1987
	EQ 40MG BASE/ML	N050613	001	Jul 23, 1986

CEFORANIDE

INJECTABLE;INJECTION				
PRECEF				
APOTHECON	500MG/VIAL	A062579	001	Nov 26, 1984
	1GM/VIAL	A062579	002	Nov 26, 1984
	2GM/VIAL	A062579	003	Nov 26, 1984
	10GM/VIAL	A062579	004	Nov 26, 1984
	20GM/VIAL	A062579	005	Nov 26, 1984
BRISTOL	500MG/VIAL	N050554	001	May 24, 1984
	1GM/VIAL	N050554	002	May 24, 1984
	2GM/VIAL	N050554	003	May 24, 1984
	10GM/VIAL	N050554	004	May 24, 1984
	20GM/VIAL	N050554	005	May 24, 1984

CEFOTAXIME SODIUM

INJECTABLE;INJECTION				
CEFOTAXIME				
FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A064200	001	Mar 24, 2000
	EQ 1GM BASE/VIAL	A064200	002	Mar 24, 2000
	EQ 2GM BASE/VIAL	A064200	003	Mar 24, 2000
	EQ 10GM BASE/VIAL	A064201	001	Mar 24, 2000
	EQ 20GM BASE/VIAL	A064201	002	Mar 24, 2000
CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER				
B BRAUN	EQ 2GM BASE	N050792	001	Jul 29, 2004
CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER				
B BRAUN	EQ 1GM BASE	N050792	002	Jul 29, 2004
CEFOTAXIME SODIUM				
AUROBINDO PHARMA	EQ 500MG BASE/VIAL	A065517	001	Nov 06, 2009
	EQ 1GM BASE/VIAL	A065517	002	Nov 06, 2009
	EQ 2GM BASE/VIAL	A065517	003	Nov 06, 2009
AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065516	001	Nov 06, 2009
CEPHAZONE PHARMA	EQ 10GM BASE/VIAL	A065348	001	Jan 25, 2010
LUPIN	EQ 500MG BASE/VIAL	A065124	001	Sep 24, 2003
	EQ 1GM BASE/VIAL	A065124	002	Sep 24, 2003
	EQ 2GM BASE/VIAL	A065124	003	Sep 24, 2003
CLAFORAN				
SANOFI AVENTIS US	EQ 1GM BASE/VIAL	A062659	001	Jan 13, 1987
	EQ 2GM BASE/VIAL	A062659	002	Jan 13, 1987
+ US PHARM HOLDINGS	EQ 500MG BASE/VIAL	N050547	001	
+	EQ 1GM BASE/VIAL	N050547	002	
+	EQ 2GM BASE/VIAL	N050547	003	
+	EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER				
US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	002	May 20, 1985
	EQ 40MG BASE/ML	N050596	004	May 20, 1985
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	001	May 20, 1985
	EQ 40MG BASE/ML	N050596	003	May 20, 1985

CEFOTETAN DISODIUM

INJECTABLE;INJECTION				
CEFOTAN				
TELIGENT	EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988
TELIGENT PHARMA INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993
	EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993
CEFOTAN IN PLASTIC CONTAINER				
TELIGENT	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993
	EQ 40MG BASE/ML	N050694	001	Jul 30, 1993

CEFOTIAM HYDROCHLORIDE

INJECTABLE;INJECTION					
CERADON					
	TAKEDA	EQ 1GM BASE/VIAL	N050601	001	Dec 30, 1988

CEFOXITIN SODIUM

INJECTABLE;INJECTION					
CEFOXITIN					
	ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A065467	001	Aug 31, 2011
		EQ 2GM BASE/VIAL	A065467	002	Aug 31, 2011
		EQ 10GM BASE/VIAL	A065464	001	Aug 31, 2011
	FRESENIUS KABI USA	EQ 1GM BASE/VIAL **	A065012	001	Jul 03, 2000
		EQ 2GM BASE/VIAL **	A065012	002	Jul 03, 2000
		EQ 10GM BASE/VIAL	A065011	001	Jul 03, 2000
MEFOXIN					
	MYLAN INSTITUTIONAL	EQ 1GM BASE/VIAL	A062757	001	Jan 08, 1987
+		EQ 1GM BASE/VIAL **	N050517	001	
		EQ 2GM BASE/VIAL	A062757	002	Jan 08, 1987
+		EQ 2GM BASE/VIAL **	N050517	002	
+		EQ 10GM BASE/VIAL **	N050517	003	
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
+	MERCK	EQ 20MG BASE/ML **	N050581	003	Sep 20, 1984
+		EQ 40MG BASE/ML **	N050581	004	Sep 20, 1984
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
+	MERCK	EQ 20MG BASE/ML **	N050581	002	Sep 20, 1984
+		EQ 40MG BASE/ML **	N050581	001	Sep 20, 1984

CEFPIRAMIDE SODIUM

INJECTABLE;INJECTION					
CEFPIRAMIDE SODIUM					
	WYETH AYERST	EQ 1GM BASE/VIAL	N050633	002	Jan 31, 1989
		EQ 2GM BASE/VIAL	N050633	003	Jan 31, 1989
		EQ 10GM BASE/VIAL	N050633	005	Jan 31, 1989

CEFPODOXIME PROXETIL

FOR SUSPENSION;ORAL					
BANAN					
	SANKYO	EQ 50MG BASE/5ML	N050688	002	Aug 07, 1992
		EQ 100MG BASE/5ML	N050688	001	Aug 07, 1992
CEFPODOXIME PROXETIL					
	SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002
		EQ 100MG BASE/5ML	A065082	002	May 31, 2002
VANTIN					
+	PHARMACIA AND UPJOHN	EQ 50MG BASE/5ML **	N050675	001	Aug 07, 1992
+		EQ 100MG BASE/5ML **	N050675	002	Aug 07, 1992
TABLET;ORAL					
BANAN					
	SANKYO	EQ 100MG BASE	N050687	001	Aug 07, 1992
		EQ 200MG BASE	N050687	002	Aug 07, 1992
CEFPODOXIME PROXETIL					
	SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003
		EQ 200MG BASE	A065083	002	Aug 20, 2003
VANTIN					
+	PHARMACIA AND UPJOHN	EQ 100MG BASE **	N050674	001	Aug 07, 1992
+		EQ 200MG BASE **	N050674	002	Aug 07, 1992

CEFPROZIL

FOR SUSPENSION;ORAL					
CEFPROZIL					
	RANBAXY LABS LTD	125MG/5ML	A065202	001	Jun 30, 2006
		250MG/5ML	A065202	002	Jun 30, 2006
CEFZIL					
+	CORDEN PHARMA	125MG/5ML	N050665	001	Dec 23, 1991
+		250MG/5ML	N050665	002	Dec 23, 1991
TABLET;ORAL					
CEFPROZIL					
	RANBAXY LABS LTD	250MG	A065198	001	Dec 13, 2006
		500MG	A065198	002	Dec 13, 2006
CEFZIL					
+	CORDEN PHARMA	250MG	N050664	001	Dec 23, 1991
+		500MG	N050664	002	Dec 23, 1991

CEFTAZIDIME

INJECTABLE;INJECTION

CEFTAZIDIME

ACS DOBFAR	500MG/VIAL	A062640	001	Nov 20, 1985
AUROBINDO PHARMA LTD	500MG/VIAL	A065481	001	May 28, 2010
	1GM/VIAL	A065481	002	May 28, 2010
	2GM/VIAL	A065481	003	May 28, 2010
	6GM/VIAL	A065482	001	May 28, 2010

CEPTAZ

GLAXOSMITHKLINE	500MG/VIAL	N050646	001	Sep 27, 1990
	1GM/VIAL	N050646	002	Sep 27, 1990
	2GM/VIAL	N050646	003	Sep 27, 1990
	10GM/VIAL	N050646	004	Sep 27, 1990

PENTACEF

GLAXOSMITHKLINE	1GM/VIAL	A063322	001	Nov 07, 1995
	1GM/VIAL	A064006	001	Mar 31, 1992
	2GM/VIAL	A063322	002	Nov 07, 1995
	2GM/VIAL	A064006	002	Mar 31, 1992
	6GM/VIAL	A064008	001	Mar 31, 1992
	10GM/VIAL	A064008	002	Mar 31, 1992

TAZIDIME

LILLY	1GM/VIAL	A062655	001	Nov 20, 1985
	2GM/VIAL	A062655	002	Nov 20, 1985

TAZIDIME IN PLASTIC CONTAINER

LILLY	1GM/VIAL	A062739	001	Jul 10, 1986
	2GM/VIAL	A062739	002	Jul 10, 1986

CEFTAZIDIME SODIUM

INJECTABLE;INJECTION

CEFTAZIDIME SODIUM IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	A063221	001	Apr 29, 1993
	EQ 20MG BASE/ML	A063221	002	Apr 29, 1993
	EQ 40MG BASE/ML	A063221	003	Apr 29, 1993

FORTAZ IN PLASTIC CONTAINER

	TELIGENT	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989
+		EQ 20MG BASE/ML	N050634	002	Apr 28, 1989
+		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989

CEFTIBUTEN DIHYDRATE

CAPSULE;ORAL

CEDAX

SI PHARMS	EQ 400MG BASE	N050685	002	Dec 20, 1995

FOR SUSPENSION;ORAL

CEDAX

+	SI PHARMS	EQ 90MG BASE/5ML **	N050686	001	Dec 20, 1995
+		EQ 180MG BASE/5ML **	N050686	002	Dec 20, 1995

CEFTIZOXIME SODIUM

INJECTABLE;INJECTION

CEFIZOX

ASTELLAS	EQ 500MG BASE/VIAL	N050560	001	Sep 15, 1983
	EQ 1GM BASE/VIAL	A063294	002	Mar 31, 1994
	EQ 1GM BASE/VIAL	N050560	002	Sep 15, 1983
	EQ 2GM BASE/VIAL	A063294	003	Mar 31, 1994
	EQ 2GM BASE/VIAL	N050560	003	Sep 15, 1983
	EQ 10GM BASE/VIAL	N050560	005	Mar 19, 1993

CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER

ASTELLAS	EQ 20MG BASE/ML	N050589	001	Oct 03, 1984
	EQ 40MG BASE/ML	N050589	002	Oct 03, 1984

CEFIZOX IN PLASTIC CONTAINER

ASTELLAS	EQ 20MG BASE/ML	N050589	003	Apr 13, 1995
	EQ 40MG BASE/ML	N050589	004	Apr 13, 1995

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION

CEFTRIAXONE

AGILA SPECLTS	EQ 10GM BASE/VIAL	A091068	001	Jan 07, 2013
AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065504	001	Jul 31, 2008
BEDFORD	EQ 10GM BASE/VIAL	A065475	001	Aug 18, 2008
FACTA FARMA	EQ 10GM BASE/VIAL	A065269	001	Feb 28, 2007
FRESENIUS KABI USA	EQ 10GM BASE/VIAL	A065252	001	Feb 15, 2006

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION					
CEFTRIAXONE					
	HOSPIRA INC	EQ 1GM BASE/VIAL	A065231	001	Aug 02, 2005
		EQ 1GM BASE/VIAL	A202563	001	Aug 20, 2012
		EQ 2GM BASE/VIAL	A065231	002	Aug 02, 2005
		EQ 2GM BASE/VIAL	A202563	002	Aug 20, 2012
	LUPIN	EQ 10GM BASE/VIAL	A065263	001	Sep 12, 2006
	TEVA	EQ 10GM BASE/VIAL	A065274	001	May 01, 2006
ROCEPHIN					
	HOFFMANN LA ROCHE	EQ 250MG BASE/VIAL	A063239	001	Aug 13, 1993
		EQ 500MG BASE/VIAL	A062654	001	Apr 30, 1987
		EQ 500MG BASE/VIAL	A063239	002	Aug 13, 1993
		EQ 1GM BASE/VIAL	A062654	002	Apr 30, 1987
		EQ 1GM BASE/VIAL	A063239	003	Aug 13, 1993
		EQ 2GM BASE/VIAL	A062654	003	Apr 30, 1987
+		EQ 10GM BASE/VIAL	N050585	005	Dec 21, 1984
	ROCHE	EQ 250MG BASE/VIAL	A062510	001	Mar 12, 1985
		EQ 500MG BASE/VIAL	A062510	002	Mar 12, 1985
		EQ 1GM BASE/VIAL	A062510	003	Mar 12, 1985
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER					
+	HOFFMANN LA ROCHE	EQ 10MG BASE/ML **	N050624	001	Feb 11, 1987
+		EQ 20MG BASE/ML **	N050624	002	Feb 11, 1987
+		EQ 40MG BASE/ML **	N050624	003	Feb 11, 1987
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS					
CEFTRIAXONE					
	AUROBINDO PHARMA LTD	EQ 250MG BASE/VIAL	A065505	001	Jul 31, 2008
		EQ 500MG BASE/VIAL	A065505	002	Jul 31, 2008
		EQ 1GM BASE/VIAL	A065505	003	Jul 31, 2008
		EQ 2GM BASE/VIAL	A065505	004	Jul 31, 2008
	BEDFORD	EQ 250MG BASE/VIAL	A065465	001	Aug 18, 2008
		EQ 500MG BASE/VIAL	A065465	002	Aug 18, 2008
		EQ 1GM BASE/VIAL	A065465	003	Aug 18, 2008
		EQ 2GM BASE/VIAL	A065465	004	Aug 18, 2008
	CEPHAZONE PHARMA	EQ 250MG BASE/VIAL	A065294	001	Mar 26, 2007
		EQ 500MG BASE/VIAL	A065294	002	Mar 26, 2007
		EQ 1GM BASE/VIAL	A065294	003	Mar 26, 2007
		EQ 2GM BASE/VIAL	A065294	004	Mar 26, 2007
	FACTA FARMA	EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007
		EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007
	FRESENIUS KABI USA	EQ 250MG BASE/VIAL	A065245	001	Feb 15, 2006
		EQ 500MG BASE/VIAL	A065245	002	Feb 15, 2006
		EQ 1GM BASE/VIAL	A065245	003	Feb 15, 2006
		EQ 2GM BASE/VIAL	A065245	004	Feb 15, 2006
	TEVA	EQ 1GM BASE/VIAL	A065262	001	Jun 29, 2006
		EQ 2GM BASE/VIAL	A065262	002	Jun 29, 2006
	TEVA PHARMS USA	EQ 250MG BASE/VIAL	A065227	001	Mar 15, 2007
		EQ 500MG BASE/VIAL	A065227	002	Mar 15, 2007
		EQ 1GM BASE/VIAL	A065227	003	Mar 15, 2007
		EQ 2GM BASE/VIAL	A065227	004	Mar 15, 2007
ROCEPHIN					
+	HOFFMANN LA ROCHE	EQ 250MG BASE/VIAL	N050585	001	Dec 21, 1984
+		EQ 500MG BASE/VIAL	N050585	002	Dec 21, 1984
+		EQ 1GM BASE/VIAL	N050585	003	Dec 21, 1984
+		EQ 2GM BASE/VIAL	N050585	004	Dec 21, 1984

CEFTRIAXONE SODIUM; LIDOCAINE

INJECTABLE;INJECTION					
ROCEPHIN KIT					
	HOFFMANN LA ROCHE	EQ 500MG BASE/VIAL,N/A;N/A,1%	N050585	007	May 08, 1996
		EQ 1GM BASE/VIAL,N/A;N/A,1%	N050585	006	May 08, 1996

CEFUROXIME AXETIL

FOR SUSPENSION;ORAL					
CEFTIN					
+	GLAXOSMITHKLINE	EQ 125MG BASE/5ML	N050672	001	Jun 30, 1994
+		EQ 250MG BASE/5ML	N050672	002	Apr 29, 1997
CEFUROXIME AXETIL					
	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008
		EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

CEFUROXIME AXETIL

TABLET;ORAL

CEFTIN

+	GLAXOSMITHKLINE	EQ 125MG BASE	N050605	001	Dec 28, 1987
+		EQ 250MG BASE	N050605	002	Dec 28, 1987
+		EQ 500MG BASE	N050605	003	Dec 28, 1987

CEFUROXIME AXETIL

FOSUN PHARMA	EQ 250MG BASE	A065126	001	Oct 28, 2003
	EQ 500MG BASE	A065126	002	Oct 28, 2003
RANBAXY LABS LTD	EQ 125MG BASE	A065043	003	Feb 15, 2002
	EQ 250MG BASE	A065043	002	Feb 15, 2002
	EQ 500MG BASE	A065043	001	Feb 15, 2002
SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003
	EQ 250MG BASE	A065118	002	Apr 25, 2003
	EQ 500MG BASE	A065118	003	Apr 25, 2003

CEFUROXIME SODIUM

INJECTABLE;INJECTION

CEFUROXIME SODIUM

FRESENIUS KABI USA	EQ 1.5GM BASE/VIAL	A065001	002	May 30, 2001
	EQ 7.5GM BASE/VIAL	A065002	001	Sep 28, 1998
TEVA PHARMS	EQ 7.5GM BASE/VIAL	A064191	001	Apr 16, 1998
WATSON LABS INC	EQ 1.5GM BASE/VIAL	A064035	002	Feb 26, 1993
	EQ 7.5GM BASE/VIAL	A064036	001	Feb 26, 1993

CEFUROXIME SODIUM IN PLASTIC CONTAINER

SAMSON MEDCL	EQ 75GM BASE/VIAL	A065251	001	Dec 30, 2009
	EQ 225GM BASE/VIAL	A065251	002	Dec 30, 2009

KEFUROX

ACS DOBFAR	EQ 1.5GM BASE/VIAL	A062591	002	Jan 10, 1986
	EQ 7.5GM BASE/VIAL	A062591	003	Dec 17, 1987
LILLY	EQ 1.5GM BASE/VIAL	A062592	002	Jan 10, 1986

KEFUROX IN PLASTIC CONTAINER

LILLY	EQ 1.5GM BASE/VIAL	A062590	002	Jan 10, 1986

ZINACEF IN PLASTIC CONTAINER

TELIGENT	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989
+	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

FRESENIUS KABI USA	EQ 750MG BASE/VIAL	A065001	001	May 30, 2001
TEVA PHARMS	EQ 750MG BASE/VIAL	A064192	002	Apr 16, 1998
	EQ 1.5GM BASE/VIAL	A064192	001	Apr 16, 1998
WATSON LABS INC	EQ 750MG BASE/VIAL	A064035	001	Feb 26, 1993

KEFUROX

ACS DOBFAR	EQ 750MG BASE/VIAL	A062591	001	Jan 10, 1986

INJECTABLE;INTRAVENOUS

KEFUROX

LILLY	EQ 750MG BASE/VIAL	A062592	001	Jan 10, 1986

KEFUROX IN PLASTIC CONTAINER

LILLY	EQ 750MG BASE/VIAL	A062590	001	Jan 10, 1986

CELLULOSE SODIUM PHOSPHATE

POWDER;ORAL

CALCIBIND

MISSION PHARMA	2.5GM/PACKET	N018757	002	Dec 28, 1982
	300GM/BOT	N018757	003	Oct 16, 1984

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

APOTHECON	EQ 250MG BASE	A062973	001	Nov 08, 1988
	EQ 250MG BASE	A063063	001	Sep 29, 1989
	EQ 250MG BASE	A063186	001	Dec 30, 1994
	EQ 500MG BASE	A062974	001	Nov 23, 1988
	EQ 500MG BASE	A063063	002	Sep 29, 1989
	EQ 500MG BASE	A063186	002	Dec 30, 1994
BARR	EQ 250MG BASE	A062773	001	Jun 26, 1987
	EQ 500MG BASE	A062775	001	Apr 22, 1987
FACTA FARMA	EQ 250MG BASE	A062118	001	
	EQ 500MG BASE	A062118	002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A061969	001	
	EQ 500MG BASE	A061969	002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

CEPHALEXIN				
CAPSULE;ORAL				
CEPHALEXIN				
PUREPAC PHARM	EQ 250MG BASE	A062809	001	Apr 22, 1987
	EQ 500MG BASE	A062809	002	Apr 22, 1987
STEVENS J	EQ 250MG BASE	A062870	001	Mar 17, 1988
	EQ 500MG BASE	A062869	001	Mar 17, 1988
SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999
	EQ 500MG BASE	A065007	002	Sep 16, 1999
TEVA	EQ 250MG BASE	A062760	001	Apr 24, 1987
	EQ 250MG BASE	A062821	001	Feb 05, 1988
	EQ 500MG BASE	A062761	001	Apr 24, 1987
	EQ 500MG BASE	A062823	001	Feb 05, 1988
YOSHITOMI	EQ 250MG BASE	A062872	001	Jun 20, 1988
	EQ 500MG BASE	A062871	001	Jul 05, 1988
KEFLEX				
+ PRAGMA	EQ 333MG BASE **	N050405	004	May 12, 2006
FOR SUSPENSION;ORAL				
CEPHALEXIN				
APOTHECON	EQ 125MG BASE/5ML	A062986	001	Apr 18, 1991
	EQ 250MG BASE/5ML	A062987	001	Jul 25, 1989
BARR	EQ 125MG BASE/5ML	A062778	001	Aug 06, 1987
	EQ 250MG BASE/5ML	A062777	001	Aug 06, 1987
FACTA FARMA	EQ 100MG BASE/ML **	A062117	001	
	EQ 125MG BASE/5ML **	A062117	002	
	EQ 250MG BASE/5ML **	A062117	003	
HIKMA PHARMS	EQ 125MG BASE/5ML	A065444	001	Aug 28, 2009
	EQ 250MG BASE/5ML	A065444	002	Aug 28, 2009
SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065081	001	Jul 27, 2001
	EQ 250MG BASE/5ML	A065081	002	Jul 27, 2001
TEVA	EQ 125MG BASE/5ML	A062767	001	Jun 16, 1987
	EQ 125MG BASE/5ML	A062873	001	May 23, 1988
	EQ 250MG BASE/5ML	A062768	001	Jun 16, 1987
	EQ 250MG BASE/5ML	A062867	001	Apr 15, 1988
VITARINE	EQ 125MG BASE/5ML	A062779	001	Dec 22, 1987
	EQ 250MG BASE/5ML	A062781	001	Dec 22, 1987
KEFLEX				
+ PRAGMA	EQ 100MG BASE/ML **	N050406	003	
+	EQ 125MG BASE/5ML **	N050406	001	
+	EQ 250MG BASE/5ML **	N050406	002	
TABLET;ORAL				
CEPHALEXIN				
BARR	EQ 250MG BASE	A062826	001	Aug 17, 1987
	EQ 500MG BASE	A062827	001	Aug 17, 1987
VITARINE	EQ 250MG BASE	A062863	001	Aug 11, 1988
	EQ 500MG BASE	A062863	002	Aug 11, 1988
	EQ 1GM BASE	A062863	003	Aug 11, 1988
KEFLET				
LILLY	EQ 250MG BASE	A062745	001	Dec 01, 1986
	EQ 250MG BASE	N050440	003	Feb 26, 1987
	EQ 500MG BASE	A062745	002	Dec 01, 1986
	EQ 500MG BASE	N050440	001	
	EQ 1GM BASE	N050440	002	
TABLET, FOR SUSPENSION;ORAL				
PANIXINE DISPERDOSE				
RANBAXY LABS LTD	EQ 125MG BASE	A065100	002	Sep 11, 2003
	EQ 250MG BASE	A065100	001	Sep 11, 2003
CEPHALEXIN HYDROCHLORIDE				
TABLET;ORAL				
KEFTAB				
LILLY	EQ 250MG BASE	N050614	001	Oct 29, 1987
	EQ 333MG BASE	N050614	003	May 16, 1988
	EQ 500MG BASE	N050614	002	Oct 29, 1987

CEPHALOGLYCIN				
CAPSULE;ORAL				
KAFOCIN				
LILLY	250MG	N050219	001	
CEPHALOTHIN SODIUM				
INJECTABLE;INJECTION				
CEPHALOTHIN				
INTL MEDICATION	EQ 500MG BASE/VIAL	A062426	001	May 03, 1985
	EQ 1GM BASE/VIAL	A062426	002	May 03, 1985
	EQ 2GM BASE/VIAL	A062426	003	May 03, 1985
	EQ 4GM BASE/VIAL	A062426	004	May 03, 1985
CEPHALOTHIN SODIUM				
ABBOTT	EQ 1GM BASE/VIAL	A062547	001	Sep 11, 1985
	EQ 1GM BASE/VIAL	A062548	001	Sep 11, 1985
	EQ 2GM BASE/VIAL	A062547	002	Sep 11, 1985
	EQ 2GM BASE/VIAL	A062548	002	Sep 11, 1985
ABRAXIS PHARM	EQ 1GM BASE/VIAL	A062666	002	Jun 10, 1987
	EQ 2GM BASE/VIAL	A062666	001	Jun 10, 1987
BRISTOL	EQ 1GM BASE/VIAL	A062464	001	May 07, 1984
	EQ 2GM BASE/VIAL	A062464	002	May 07, 1984
	EQ 4GM BASE/VIAL	A062464	003	May 07, 1984
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	EQ 20MG BASE/ML	A062422	003	Jan 31, 1984
	EQ 20MG BASE/ML	A062422	005	Jul 16, 1991
	EQ 20MG BASE/ML	A062730	001	Mar 05, 1987
	EQ 40MG BASE/ML	A062422	004	Jan 31, 1984
	EQ 40MG BASE/ML	A062422	006	Jul 16, 1991
	EQ 40MG BASE/ML	A062730	002	Mar 05, 1987
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	EQ 20MG BASE/ML	A062422	001	Jan 31, 1984
	EQ 40MG BASE/ML	A062422	002	Jan 31, 1984
KEFLIN				
LILLY	EQ 1GM BASE/VIAL	N050482	001	
	EQ 2GM BASE/VIAL	N050482	002	
	EQ 4GM BASE/VIAL	N050482	003	
	EQ 20GM BASE/VIAL	N050482	007	
KEFLIN IN PLASTIC CONTAINER				
LILLY	EQ 1GM BASE/VIAL	A062549	001	Sep 10, 1985
	EQ 2GM BASE/VIAL	A062549	002	Sep 10, 1985
SEFFIN				
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	A062435	001	Nov 15, 1983
	EQ 2GM BASE/VIAL	A062435	002	Nov 15, 1983
	EQ 10GM BASE/VIAL	A062435	003	Nov 15, 1983
CEPHAPIRIN SODIUM				
INJECTABLE;INJECTION				
CEFADYL				
APOTHECON	EQ 500MG BASE/VIAL	A062961	001	Sep 20, 1988
	EQ 500MG BASE/VIAL	N050446	005	
	EQ 1GM BASE/VIAL	A061769	001	
	EQ 1GM BASE/VIAL	A062724	001	Dec 23, 1986
	EQ 1GM BASE/VIAL	A062961	002	Sep 20, 1988
	EQ 1GM BASE/VIAL	N050446	001	
	EQ 2GM BASE/VIAL	A061769	002	
	EQ 2GM BASE/VIAL	A062724	002	Dec 23, 1986
	EQ 2GM BASE/VIAL	A062961	003	Sep 20, 1988
	EQ 2GM BASE/VIAL	N050446	002	
	EQ 4GM BASE/VIAL	A061769	003	
	EQ 4GM BASE/VIAL	A062961	004	Sep 20, 1988
	EQ 4GM BASE/VIAL	N050446	003	
	EQ 20GM BASE/VIAL	N050446	004	
CEPHAPIRIN SODIUM				
ABRAXIS PHARM	EQ 500MG BASE/VIAL	A062723	001	Nov 17, 1986
	EQ 1GM BASE/VIAL	A062723	002	Nov 17, 1986
	EQ 2GM BASE/VIAL	A062723	003	Nov 17, 1986
	EQ 4GM BASE/VIAL	A062723	004	Nov 17, 1986
	EQ 20GM BASE/VIAL	A062723	005	Nov 17, 1986
WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A062720	001	Jul 02, 1987
	EQ 1GM BASE/VIAL	A062720	002	Jul 02, 1987

CEPHAPIRIN SODIUM				
INJECTABLE;INJECTION				
CEPHAPIRIN SODIUM				
	EQ 2GM BASE/VIAL	A062720	003	Jul 02, 1987
	EQ 20GM BASE/VIAL	A062720	004	Jul 02, 1987
CEPHRADINE				
CAPSULE;ORAL				
ANSPOR				
GLAXOSMITHKLINE	250MG	A061859	001	
	500MG	A061859	002	
CEPHRADINE				
BARR	250MG	A062850	001	Apr 22, 1988
	500MG	A062851	001	Apr 22, 1988
IVAX SUB TEVA PHARMS	250MG	A062762	001	Mar 06, 1987
	500MG	A062762	002	Mar 06, 1987
TEVA	250MG	A062683	001	Jan 09, 1987
	500MG	A062683	002	Jan 09, 1987
VITARINE	250MG	A062813	001	Feb 25, 1988
	500MG	A062813	002	Feb 25, 1988
VELOSEF				
APOTHECON	250MG	A061764	001	
	500MG	A061764	002	
VELOSEF '250'				
ERSANA	250MG	N050548	001	
VELOSEF '500'				
ERSANA	500MG	N050548	002	
FOR SUSPENSION;ORAL				
ANSPOR				
GLAXOSMITHKLINE	125MG/5ML	A061866	001	
	250MG/5ML	A061866	002	
CEPHRADINE				
BARR	125MG/5ML	A062858	001	May 19, 1988
	250MG/5ML	A062859	001	May 19, 1988
TEVA	125MG/5ML	A062693	001	Jan 09, 1987
	250MG/5ML	A062693	002	Jan 09, 1987
VELOSEF '125'				
APOTHECON	125MG/5ML	A061763	001	
VELOSEF '250'				
APOTHECON	250MG/5ML	A061763	002	
INJECTABLE;INJECTION				
VELOSEF				
APOTHECON	250MG/VIAL	A061976	001	
	500MG/VIAL	A061976	002	
	1GM/VIAL	A061976	004	
	2GM/VIAL	A061976	003	
	4GM/VIAL	A061976	005	
TABLET;ORAL				
VELOSEF				
BRISTOL MYERS SQUIBB	1GM	N050530	001	
CERIVASTATIN SODIUM				
TABLET;ORAL				
BAYCOL				
BAYER PHARMS	0.05MG	N020740	001	Jun 26, 1997
	0.1MG	N020740	002	Jun 26, 1997
	0.2MG	N020740	003	Jun 26, 1997
	0.3MG	N020740	004	Jun 26, 1997
	0.4MG	N020740	005	May 24, 1999
	0.8MG	N020740	006	Jul 24, 2000
CERULETIDE DIETHYLAMINE				
INJECTABLE;INJECTION				
TYMTRAN				
PHARMACIA AND UPJOHN	0.02MG/ML	N018296	001	

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL					
CETIRIZINE HYDROCHLORIDE					
	ACTAVIS MID ATLANTIC	5MG/5ML	A078617	001	Feb 02, 2010
	APOTEX INC	5MG/5ML	A078412	001	Jun 18, 2008
	AUROBINDO PHARMA LTD	5MG/5ML	A090751	001	Dec 16, 2009
	RANBAXY LABS LTD	5MG/5ML	A077472	001	Jun 18, 2008
	WOCKHARDT	5MG/5ML	A078757	001	Aug 28, 2009
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY					
	ACTAVIS MID ATLANTIC	5MG/5ML	A090378	002	May 09, 2008
	APOTEX INC	5MG/5ML	A090188	002	Apr 22, 2008
	CYPRESS PHARM	5MG/5ML	A090300	001	Oct 10, 2008
	RANBAXY LABS LTD	5MG/5ML	A090183	002	Apr 24, 2008
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
	ACTAVIS MID ATLANTIC	5MG/5ML	A090378	001	May 09, 2008
	APOTEX INC	5MG/5ML	A090188	001	Apr 22, 2008
	CYPRESS PHARM	5MG/5ML	A090300	002	Oct 10, 2008
	RANBAXY LABS LTD	5MG/5ML	A090183	001	Apr 24, 2008
ZYRTEC					
	J AND J CONSUMER INC	5MG/5ML **	N020346	001	Sep 27, 1996
TABLET;ORAL					
CETIRIZINE HYDROCHLORIDE ALLERGY					
	ACTAVIS ELIZABETH	5MG	A078615	003	Dec 28, 2007
		10MG	A078615	004	Dec 28, 2007
ZYRTEC ALLERGY					
+	J AND J CONSUMER INC	5MG	N019835	003	Nov 16, 2007
ZYRTEC HIVES RELIEF					
+	J AND J CONSUMER INC	5MG	N019835	005	Nov 16, 2007
+		10MG	N019835	006	Nov 16, 2007
TABLET, CHEWABLE;ORAL					
CETIRIZINE HYDROCHLORIDE ALLERGY					
	SUN PHARM INDS INC	5MG	A077631	004	Jan 11, 2008
		10MG	A077631	003	Jan 11, 2008
CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
	SUN PHARM INDS INC	5MG	A077631	001	Jan 11, 2008
		10MG	A077631	002	Jan 11, 2008
CHILDREN'S ZYRTEC ALLERGY					
+	J AND J CONSUMER INC	5MG **	N021621	003	Nov 16, 2007
+		10MG **	N021621	004	Nov 16, 2007
CHILDREN'S ZYRTEC HIVES RELIEF					
+	J AND J CONSUMER INC	5MG **	N021621	005	Nov 16, 2007
+		10MG **	N021621	006	Nov 16, 2007

CETRORELIX

INJECTABLE;INJECTION					
CETROTIDE					
	EMD SERONO INC	EQ 3MG BASE/ML	N021197	002	Aug 11, 2000

CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

FOR SUSPENSION;INTRATRACHEAL					
EXOSURF NEONATAL					
	GLAXOSMITHKLINE	12MG/VIAL;108MG/VIAL;8MG/VIAL	N020044	001	Aug 02, 1990

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL					
CEVIMELINE HYDROCHLORIDE					
	APOTEX INC	30MG	A091260	001	Aug 25, 2011

CHENODIOL

TABLET;ORAL					
CHENIX					
+	LEADIANT BIOSCI INC	250MG **	N018513	002	Jul 28, 1983

CHLOPHEDIANOL HYDROCHLORIDE

SYRUP;ORAL					
ULO					
	3M	25MG/5ML	N012126	001	

CHLORAMPHENICOL

CREAM;TOPICAL				
CHLOROMYCETIN				
	PARKE DAVIS	1%	N050183 001	
FOR SOLUTION;OPHTHALMIC				
CHLOROMYCETIN				
	PARKEDALE	25MG/VIAL	N050143 001	
INJECTABLE;INJECTION				
CHLOROMYCETIN				
	PARKE DAVIS	250MG/ML	N050153 001	
OINTMENT;OPHTHALMIC				
CHLORAMPHENICOL				
	ALTANA	1%	A060133 001	
CHLOROFAIR				
	PHARMAFAIR	1%	A062439 001	Apr 21, 1983
CHLOROMYCETIN				
	PARKEDALE	1%	N050156 001	
CHLOROPTIC S.O.P.				
	ALLERGAN	1%	A061187 001	
ECONOCHLOR				
	ALCON	1%	A061648 001	
SOLUTION/DROPS;OPHTHALMIC				
CHLORAMPHENICOL				
	AKORN	0.5%	A062042 001	
	ALCON	0.5%	A062628 001	Sep 25, 1985
CHLOROFAIR				
	PHARMAFAIR	0.5%	A062437 001	Apr 14, 1983
CHLOROPTIC				
	ALLERGAN	0.5%	N050091 001	
ECONOCHLOR				
	ALCON	0.5%	A061645 001	
OPHTHOCHLOR				
	PARKEDALE	0.5%	A061220 001	
OPTOMYCIN				
	OPTOPICS	0.5%	A062171 001	Mar 31, 1982
SOLUTION/DROPS;OTIC				
CHLOROMYCETIN				
	PARKEDALE	0.5%	N050205 001	

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE;INJECTION				
CHLORAMPHENICOL				
	ELKINS SINN	EQ 1GM BASE/VIAL	A062406 001	Nov 09, 1982
CHLORAMPHENICOL SODIUM SUCCINATE				
	GRUPPO LEPETIT	EQ 1GM BASE/VIAL	A062278 001	
CHLOROMYCETIN				
+	PARKEDALE	EQ 1GM BASE/VIAL	N050155 001	
MYCHEL-S				
	ANGUS	EQ 1GM BASE/VIAL	A060132 001	

CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

OINTMENT;TOPICAL				
ELASE-CHLOROMYCETIN				
	PARKE DAVIS	10MG/GM;666 UNITS/GM;1 UNITS/GM	N050294 001	

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

FOR SUSPENSION;OPHTHALMIC				
CHLOROMYCETIN HYDROCORTISONE				
	PARKEDALE	12.5MG/VIAL;25MG/VIAL	N050202 001	

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC				
OPHTHOCORT				
	PARKEDALE	10MG/GM;5MG/GM;10,000 UNITS/GM	N050201 002	

CHLORAMPHENICOL; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC				
CHLOROMYXIN				
	PARKE DAVIS	1%;10,000 UNITS/GM	N050203 002	

CHLORAMPHENICOL; PREDNISOLONE				
OINTMENT;OPHTHALMIC				
CHLOROPTIC-P S.O.P.				
ALLERGAN	1%;0.5%	A061188	001	
CHLORDIAZEPOXIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
LIBRELEASE				
VALEANT PHARM INTL	30MG	N017813	001	Sep 12, 1983
TABLET;ORAL				
LIBRITABS				
VALEANT PHARM INTL	5MG	A085482	001	
	10MG	A085481	001	
	25MG	A085488	001	
CHLORDIAZEPOXIDE HYDROCHLORIDE				
CAPSULE;ORAL				
A-POXIDE				
ABBOTT	5MG	A085447	001	
	5MG	A085517	001	
	10MG	A085447	002	
	10MG	A085518	001	
	25MG	A085447	003	
	25MG	A085513	001	
CHLORDIAZACHEL				
RACHELLE	5MG	A085086	001	
	10MG	A084639	001	
	25MG	A085087	001	
CHLORDIAZEPOXIDE HYDROCHLORIDE				
ASCOT	5MG	A087525	001	Jan 07, 1982
	10MG	A087524	001	Jan 07, 1982
	25MG	A087512	001	Jan 07, 1982
FERRANTE	5MG	A085118	001	
	10MG	A085119	001	
	25MG	A085120	001	
HALSEY	5MG	A085340	001	
	10MG	A085339	001	
	25MG	A084685	001	
IMPAX LABS	5MG	A086213	001	
	10MG	A085113	001	
	25MG	A086212	001	
IVAX SUB TEVA PHARMS	5MG	A083741	001	
	10MG	A083742	001	
	25MG	A083570	001	
LEDERLE	5MG	A086892	001	
	5MG	A087234	001	
	10MG	A086876	001	
	10MG	A087037	001	
	25MG	A086893	001	
	25MG	A087231	001	
MAST MM	10MG	A086217	001	
MYLAN	5MG	A084886	001	
	10MG	A084601	001	
	25MG	A084887	001	
PARKE DAVIS	5MG	A085163	001	
	10MG	A084598	001	
	25MG	A085164	001	
PIONEER PHARMS	10MG	A089533	001	Jul 15, 1988
	25MG	A089558	001	Jul 15, 1988
PUREPAC PHARM	5MG	A085155	001	
	10MG	A084939	002	
	25MG	A085144	001	
ROXANE	5MG	A084706	001	
	10MG	A084700	001	
	25MG	A084705	001	
SUPERPHARM	5MG	A088987	001	Apr 25, 1985
	10MG	A088986	001	Apr 25, 1985
	25MG	A088988	001	Apr 25, 1985
TEVA	5MG	A088705	001	Jan 18, 1985
	10MG	A088706	001	Jan 18, 1985

CHLORDIAZEPOXIDE HYDROCHLORIDE				
CAPSULE;ORAL				
CHLORDIAZEPOXIDE HYDROCHLORIDE				
	25MG	A086494	001	
	25MG	A088707	001	Jan 18, 1985
UPSHER SMITH LABS	5MG	A084678	001	
	10MG	A084041	001	
	25MG	A084679	002	
UPSHER-SMITH LABS	5MG	A084919	001	
	10MG	A084920	001	
	25MG	A084823	001	
USL PHARMA	5MG	A084644	001	
	10MG	A084623	001	
	25MG	A084645	001	
VANGARD	5MG	A088129	001	Mar 28, 1983
	10MG	A088010	001	Mar 28, 1983
	25MG	A088130	001	Mar 28, 1983
WATSON LABS	5MG	A086383	001	
	10MG	A086294	001	
	25MG	A086382	001	
WEST WARD	5MG	A085014	001	
	10MG	A085000	001	
	25MG	A085294	001	
LIBRIUM				
+ VALEANT PHARM INTL	5MG **	N012249	002	
+	10MG **	N012249	001	
+	25MG **	N012249	003	
LYGEN				
ALRA	5MG	A085107	001	
	10MG	A085009	001	
	25MG	A085108	001	
INJECTABLE;INJECTION				
LIBRIUM				
VALEANT PHARMS LLC	100MG/AMP	N012301	001	
CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED				
TABLET;ORAL				
MENRIUM 10-4				
ROCHE	10MG;0.4MG	N014740	006	
MENRIUM 5-2				
ROCHE	5MG;0.2MG	N014740	002	
MENRIUM 5-4				
ROCHE	5MG;0.4MG	N014740	004	
CHLORHEXIDINE GLUCONATE				
SOLUTION;DENTAL				
CHLORHEXIDINE GLUCONATE				
BAJAJ	0.12%	A075561	001	Nov 14, 2000
SOLUTION;TOPICAL				
DYNA-HEX				
BAJAJ	0.75%	N020111	001	Sep 11, 1997
EXIDINE				
XTTRIUM	2.5%	N019421	001	Dec 17, 1985
MICRODERM				
J AND J	4%	A072255	001	Apr 15, 1991
PREVACARE R				
J AND J	0.5%	A072292	001	Jan 28, 1992
STERI-STAT				
MATRIX MEDCL	4%	A070104	001	Jul 24, 1986
SPONGE;TOPICAL				
CHLORHEXIDINE GLUCONATE				
KENDALL IL	4%	N019490	001	Mar 27, 1987
E-Z SCRUB				
BECTON DICKINSON	4%	A073416	001	Mar 14, 2000
HIBICLENS				
+ MOLNLYCKE HLTH	4% **	N018423	001	
MICRODERM				
J AND J	4%	A072295	001	Feb 28, 1991
PHARMASEAL SCRUB CARE				
CAREFUSION 2200	4%	N019793	001	Dec 02, 1988

CHLORMERODRIN HG-197

INJECTABLE;INJECTION				
CHLORMERODRIN HG 197				
	BRACCO	0.6-1.4mCi/ML	N017269 001	

CHLORMEZANONE

TABLET;ORAL				
TRANCOPAL				
	SANOFI AVENTIS US	100MG	N011467 003	
		200MG	N011467 005	

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
NESACAINE-MPF				
	FRESENIUS KABI USA	2%	N009435 003	
		3%	N009435 004	

CHLOROQUINE HYDROCHLORIDE

INJECTABLE;INJECTION				
ARALEN HYDROCHLORIDE				
	SANOFI AVENTIS US	EQ 40MG BASE/ML	N006002 002	

CHLOROQUINE PHOSPHATE

TABLET;ORAL				
ARALEN				
+	SANOFI AVENTIS US	EQ 300MG BASE	N006002 001	
CHLOROQUINE PHOSPHATE				
	IMPAX LABS	EQ 150MG BASE	A080880 001	
		EQ 300MG BASE	A040516 001	Aug 29, 2003
	MD PHARM	EQ 150MG BASE	A087228 001	
	PUREPAC PHARM	EQ 150MG BASE	A080886 001	
	TEVA	EQ 150MG BASE	A087504 001	Jan 13, 1982
	WATSON LABS	EQ 150MG BASE	A087979 001	Dec 21, 1982
		EQ 300MG BASE	A088030 001	Dec 21, 1982

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

TABLET;ORAL				
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE				
	SANOFI AVENTIS US	EQ 300MG BASE;EQ 45MG BASE	N014860 002	

CHLOROTHIAZIDE

TABLET;ORAL				
CHLOROTHIAZIDE				
	ABC HOLDING	250MG	A085569 001	
	HIKMA INTL PHARMS	250MG	A086028 001	Jul 14, 1982
		500MG	A087736 001	Jul 14, 1982
	LEDERLE	250MG	A086940 001	
		500MG	A086938 001	
	SANDOZ	250MG	A085485 001	
	WATSON LABS	250MG	A085165 001	
		250MG	A085173 001	
		250MG	A086795 001	Aug 15, 1983
		500MG	A084026 001	Sep 01, 1982
		500MG	A086796 001	Aug 15, 1983
DIURIL				
+	OAK PHARMS AKORN	250MG **	N011145 004	
+		500MG **	N011145 002	

CHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL				
ALDOCLOR-150				
	MERCK	150MG;250MG	N016016 001	
ALDOCLOR-250				
	MERCK	250MG;250MG	N016016 002	
METHYLDOPA AND CHLOROTHIAZIDE				
	PAR PHARM	150MG;250MG	A070783 001	Nov 06, 1987
		250MG;250MG	A070654 001	Nov 06, 1987

CHLOROTHIAZIDE; RESERPINE

TABLET;ORAL				
CHLOROTHIAZIDE AND RESERPINE				
HIKMA PHARMS	250MG;0.125MG	A088557	001	Dec 22, 1983
	500MG;0.125MG	A088365	001	Dec 22, 1983
CHLOROTHIAZIDE W/ RESERPINE				
WATSON LABS	250MG;0.125MG	A084853	001	
	500MG;0.125MG	A088151	001	Jun 09, 1983
CHLOROTHIAZIDE-RESERPINE				
MYLAN	250MG;0.125MG	A087744	001	May 06, 1982
	500MG;0.125MG	A087745	001	May 06, 1982
DIUPRES-250				
MERCK	250MG;0.125MG	N011635	003	Aug 26, 1987
DIUPRES-500				
MERCK	500MG;0.125MG	N011635	006	Aug 26, 1987

CHLOROTRIANISENE

CAPSULE;ORAL				
CHLOROTRIANISENE				
BANNER PHARMACAPS	12MG	A084652	001	
TACE				
SANOFI AVENTIS US	12MG	N008102	004	
	25MG	N011444	001	
	72MG	N016235	001	

CHLOROXINE

SHAMPOO;TOPICAL				
CAPITROL				
WESTWOOD SQUIBB	2%	N017594	001	

CHLORPHENESIN CARBAMATE

TABLET;ORAL				
MAOLATE				
PAMLAB LLC	400MG	N014217	002	

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL				
CHLORPHENIRAMINE MALEATE				
AUROLIFE PHARMA LLC	12MG	A070797	001	Aug 12, 1988
TELDRIN				
GLAXOSMITHKLINE	8MG	N017369	001	
	12MG	N017369	002	
INJECTABLE;INJECTION				
CHLOR-TRIMETON				
SCHERING PLOUGH	10MG/ML	N008826	001	
	100MG/ML	N008794	001	
CHLORPHENIRAMINE MALEATE				
BEL MAR	10MG/ML	A080821	001	
ELKINS SINN	10MG/ML	A080797	001	
WATSON LABS	10MG/ML	A083593	001	
	10MG/ML	A086096	001	
	100MG/ML	A086095	001	
PYRIDAMAL 100				
BEL MAR	100MG/ML	A083733	001	
SYRUP;ORAL				
CHLOR-TRIMETON				
SCHERING	2MG/5ML	N006921	006	
CHLORPHENIRAMINE MALEATE				
PHARM ASSOC	2MG/5ML	A087520	001	Feb 10, 1982
TABLET;ORAL				
ANTAGONATE				
BAYER PHARMS	4MG	A083381	001	
CHLOR-TRIMETON				
SCHERING	4MG	N006921	002	
CHLORPHENIRAMINE MALEATE				
ANABOLIC	4MG	A083078	001	
AUROLIFE PHARMA LLC	4MG	A080961	001	
BELL PHARMA	4MG	A083062	001	
ELKINS SINN	4MG	A080938	001	
IMPAX LABS	4MG	A080809	001	
IVAX SUB TEVA PHARMS	4MG	A080779	001	

CHLORPHENIRAMINE MALEATE

TABLET;ORAL				
CHLORPHENIRAMINE MALEATE				
KV PHARM	4MG	A087164	001	
LEDERLE	4MG	A086941	001	
NEWTRON PHARMS	4MG	A086519	001	
PANRAY	4MG	A083243	001	
PHARMAVITE	4MG	A085104	001	
PHARMERAL	4MG	A083753	001	
PIONEER PHARMS	4MG	A088556	001	Jul 13, 1984
PUREPAC PHARM	4MG	A086306	001	
PVT FORM	4MG	A080786	001	
ROXANE	4MG	A080626	001	
SUN PHARM INDUSTRIES	4MG	A080700	001	
VITARINE	4MG	A085837	001	
WATSON LABS	4MG	A080696	001	
	4MG	A080791	001	
	4MG	A085139	001	
WEST WARD	4MG	A083787	001	
KLOROMIN				
HALSEY	4MG	A083629	001	
PHENETRON				
LANNETT	4MG	A080846	001	
TABLET, EXTENDED RELEASE;ORAL				
CHLOR-TRIMETON				
BAYER HEALTHCARE LLC	8MG	N007638	001	
EFIDAC 24 CHLORPHENIRAMINE MALEATE				
ALZA	16MG	N019746	002	Nov 18, 1994

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION;ORAL				
HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE				
TRIS PHARMA INC	4MG/5ML;5MG/5ML	A206438	001	Jan 27, 2015

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL				
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE				
BIO-PHARM INC	4MG/5ML;5MG/5ML;60MG/5ML	A206660	001	May 15, 2017
TRIS PHARMA INC	4MG/5ML;5MG/5ML;60MG/5ML	A203838	001	Nov 26, 2014

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
COLD CAPSULE IV				
GRAHAM DM	12MG;75MG	N018793	001	Apr 25, 1985
COLD CAPSULE V				
GRAHAM DM	8MG;75MG	N018794	001	Apr 23, 1985
TABLET, EXTENDED RELEASE;ORAL				
TRIAMINIC-12				
NOVARTIS	12MG;75MG	N018115	001	

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
CODIMAL-L.A. 12				
SCHWARZ PHARMA	12MG;120MG	N018935	001	Apr 15, 1985
ISOCLOR				
FISONS	8MG;120MG	N018747	001	Mar 06, 1986
PSEUDOEPHEDRINE HYDROCHLORIDE AND CHLORPHENIRAMINE MALEATE				
CENT PHARMS	8MG;120MG	N019428	001	Aug 02, 1988
GRAHAM DM	8MG;120MG	N018844	001	Mar 20, 1985
	12MG;120MG	N018843	001	Mar 18, 1985
KV PHARM	12MG;120MG	A071455	001	Mar 01, 1989

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL				
CHLOR-TRIMETON				
+ BAYER HEALTHCARE LLC	8MG;120MG	N018397	001	

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX				
SUSPENSION, EXTENDED RELEASE;ORAL				
CODEPREX				
	LANNETT CO INC	EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML	N021369 001	Jun 21, 2004
PENNTUSS				
	FISONS	EQ 4MG MALEATE/5ML;EQ 10MG BASE/5ML	N018928 001	Aug 14, 1985
CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX				
SUSPENSION, EXTENDED RELEASE;ORAL				
TUSSIONEX PENNKINETIC				
+	UCB INC	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	N019111 001	Dec 31, 1987
CHLORPHENTERMINE HYDROCHLORIDE				
TABLET;ORAL				
PRE-SATE				
	PARKE DAVIS	EQ 65MG BASE	N014696 001	
CHLORPROMAZINE				
SUPPOSITORY;RECTAL				
THORAZINE				
+	GLAXOSMITHKLINE	25MG **	N009149 024	
+		100MG **	N009149 033	
CHLORPROMAZINE HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
THORAZINE				
	GLAXOSMITHKLINE	30MG	N011120 016	
		75MG	N011120 017	
		150MG	N011120 018	
		200MG	N011120 019	
		300MG	N011120 020	
CONCENTRATE;ORAL				
CHLORPROMAZINE HYDROCHLORIDE				
	ACTAVIS MID ATLANTIC	100MG/ML	A086863 001	
	PHARM ASSOC	30MG/ML	A040231 001	Dec 30, 1999
		100MG/ML	A040224 001	Jan 26, 1999
	WOCKHARDT	30MG/ML	A087032 001	Jul 08, 1982
		100MG/ML	A087053 001	
CHLORPROMAZINE HYDROCHLORIDE INTENSOL				
	CYCLE PHARMS LTD	30MG/ML	A088157 001	Apr 27, 1983
		100MG/ML	A088158 001	Apr 27, 1983
SONAZINE				
	FOSUN PHARMA	30MG/ML	A080983 004	
		100MG/ML	A080983 005	
THORAZINE				
+	GLAXOSMITHKLINE	30MG/ML **	N009149 032	
+		100MG/ML **	N009149 043	
INJECTABLE;INJECTION				
CHLORPROMAZINE HYDROCHLORIDE				
	ABRAXIS PHARM	25MG/ML	A084911 001	
	MARSAM PHARMS LLC	25MG/ML	A089563 001	Apr 15, 1988
	WATSON LABS	25MG/ML	A080365 001	
		25MG/ML	A085591 001	
	WYETH AYERST	25MG/ML	A080370 001	
THORAZINE				
+	GLAXOSMITHKLINE	25MG/ML **	N009149 011	
SYRUP;ORAL				
CHLORPROMAZINE HYDROCHLORIDE				
	ALPHARMA US PHARMS	10MG/5ML	A086712 001	
SONAZINE				
	FOSUN PHARMA	10MG/5ML	A083040 001	
THORAZINE				
+	GLAXOSMITHKLINE	10MG/5ML **	N009149 022	
TABLET;ORAL				
CHLORPROMAZINE HYDROCHLORIDE				
	ABBOTT	10MG	A084414 001	
		25MG	A084415 001	
		50MG	A084411 001	
		100MG	A084412 001	
		200MG	A084413 001	

CHLORPROMAZINE HYDROCHLORIDE

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

CYCLE PHARMS LTD	10MG	A085331 001	
	25MG	A085331 002	
	50MG	A085331 003	
	100MG	A085331 004	
	200MG	A085331 005	
IVAX SUB TEVA PHARMS	10MG	A083549 001	
	25MG	A083549 002	
	50MG	A083549 003	
	100MG	A083574 001	
	200MG	A083575 001	
KV PHARM	10MG	A085750 002	Jan 04, 1982
	25MG	A085751 001	
	50MG	A085484 001	
	100MG	A085752 001	
	200MG	A085748 002	Jan 04, 1982
LEDERLE	10MG	A084803 001	
	25MG	A084801 001	
	50MG	A084800 001	
	100MG	A084789 001	
	200MG	A084802 001	
PUREPAC PHARM	10MG	A080403 004	
	25MG	A080403 001	
	50MG	A080403 002	
	100MG	A080403 003	
	200MG	A080403 005	
PVT FORM	25MG	A080340 001	
	50MG	A080340 002	
	200MG	A080340 003	
SANDOZ	10MG **	A080439 001	
	25MG **	A080439 002	
	50MG **	A080439 003	
	100MG **	A080439 004	
	200MG **	A080439 005	
VANGARD	10MG	A088038 001	Aug 16, 1982
	25MG	A087645 001	
	50MG	A087646 001	
WATSON LABS	10MG	A085959 001	
	25MG	A085956 001	
	50MG	A085960 001	
	100MG	A085957 001	
	200MG	A085958 001	
WEST WARD	10MG	A087783 001	Sep 16, 1982
	25MG	A087865 001	Sep 16, 1982
	50MG	A087878 001	Sep 15, 1982
	100MG	A087884 001	Sep 15, 1982
	200MG	A087880 001	Sep 16, 1982

PROMAPAR

PARKE DAVIS	10MG	A086886 001	
	25MG	A084423 001	
	50MG	A086887 001	
	100MG	A086888 001	
	200MG	A086885 001	

THORAZINE

GLAXOSMITHKLINE	10MG **	N009149 002	
	25MG **	N009149 007	
	50MG **	N009149 013	
	100MG **	N009149 018	
	200MG **	N009149 020	

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

ANI PHARMS INC	100MG	A088768 001	Oct 11, 1984
	100MG	A088812 001	Oct 19, 1984
	100MG	A088840 001	Oct 25, 1984
	100MG	A088918 001	Oct 16, 1984
	100MG	A088921 001	Apr 12, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

CHLORPROPAMIDE				
TABLET;ORAL				
CHLORPROPAMIDE				
	100MG	A089446	001	Nov 17, 1986
	250MG	A087353	001	
	250MG	A088813	001	Oct 19, 1984
	250MG	A088919	001	Oct 16, 1984
	250MG	A088922	001	Apr 12, 1985
	250MG	A089447	001	Nov 17, 1986
AUROLIFE PHARMA LLC	100MG	A088725	001	Aug 31, 1984
	250MG	A088726	001	Aug 31, 1984
DAVA PHARMS INC	100MG	A089561	001	Sep 04, 1987
	250MG	A089562	001	Sep 04, 1987
HALSEY	100MG	A089321	001	Jan 16, 1986
	250MG	A088662	001	Jan 09, 1986
PAR PHARM	100MG	A088175	001	Feb 27, 1984
	250MG	A088176	001	Feb 27, 1984
SANDOZ	250MG	A084669	001	
SUPERPHARM	100MG	A088694	001	Sep 17, 1984
	250MG	A088695	001	Sep 17, 1984
USL PHARMA	100MG	A088708	001	Aug 30, 1984
	250MG	A088709	001	Aug 30, 1984
WATSON LABS	100MG	A086865	001	Sep 24, 1984
	100MG	A088608	001	Apr 12, 1984
	250MG	A086866	001	
	250MG	A088568	001	Apr 12, 1984
WATSON LABS TEVA	100MG	A088852	001	Sep 26, 1984
	250MG	A088826	001	Sep 26, 1984
DIABINESE				
+ PFIZER	100MG	N011641	003	
+	250MG	N011641	006	
GLUCAMIDE				
ANI PHARMS INC	250MG	A088641	001	Oct 11, 1984
CHLORPROTHIXENE				
CONCENTRATE;ORAL				
TARACTAN				
ROCHE	100MG/5ML	N016149	002	
INJECTABLE;INJECTION				
TARACTAN				
ROCHE	12.5MG/ML	N012487	001	
TABLET;ORAL				
TARACTAN				
ROCHE	10MG	N012486	005	
	25MG	N012486	004	
	50MG	N012486	003	
	100MG	N012486	001	
CHLORTETRACYCLINE HYDROCHLORIDE				
OINTMENT;OPHTHALMIC				
AUREOMYCIN				
LEDERLE	1%	N050404	001	
CHLORTHALIDONE				
TABLET;ORAL				
CHLORTHALIDONE				
ABBOTT	25MG	A087364	001	
	50MG	A087384	001	
ASCOT	25MG	A087698	001	Oct 20, 1982
	50MG	A087699	001	Oct 20, 1982
BARR LABS INC	25MG	A088902	001	Sep 19, 1985
	50MG	A088903	001	Sep 19, 1985
DAVA PHARMS INC	25MG	A087451	001	
	50MG	A087450	001	
G AND W LABS INC	50MG	A088651	001	May 30, 1985
IVAX PHARMS	25MG	A087555	001	
	25MG	A088164	001	Jan 09, 1984
	50MG	A087176	001	
	50MG	A087947	001	Feb 27, 1984
KV PHARM	25MG	A087311	001	
	50MG	A087312	001	

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

MUTUAL PHARM	25MG	A087292	001	
	25MG	A089738	001	Sep 19, 1988
	50MG	A087293	001	
	50MG	A089739	001	Sep 19, 1988
PIONEER PHARMS	50MG	A089591	001	Jul 21, 1988
PUREPAC PHARM	25MG	A088139	001	Jul 16, 1986
	50MG	A088140	001	Aug 11, 1983
SANDOZ	25MG	A087380	001	
	50MG	A087118	001	
	50MG	A087381	001	
SUPERPHARM	25MG	A087473	001	Feb 09, 1983
	50MG	A087247	001	Feb 09, 1983
USL PHARMA	25MG	A089051	001	Jun 01, 1987
	50MG	A089052	001	Jun 01, 1987
VANGARD	25MG	A088012	001	Jul 14, 1982
	50MG	A088073	001	Mar 25, 1983
WARNER CHILCOTT	25MG	A087515	001	Jan 24, 1983
	50MG	A087516	001	Feb 09, 1983
WATSON LABS	25MG	A087050	001	
	25MG	A087100	001	
	25MG	A087296	001	
	25MG	A087706	001	
	50MG	A087029	001	
	50MG	A087082	001	
	50MG	A087521	001	
	50MG	A087689	001	

HYGROTON

+ SANOFI AVENTIS US	25MG **	N012283	004	
+	50MG **	N012283	003	

THALITONE

+ CASPER PHARMA LLC	15MG **	N019574	001	Dec 20, 1988
	25MG	N019574	002	Feb 12, 1992
MONARCH PHARMS	25MG	A088051	001	Nov 12, 1982

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE

PAR PHARM	15MG;0.1MG	A071179	001	Dec 16, 1987
	15MG;0.2MG	A071178	001	Dec 16, 1987
	15MG;0.3MG	A071142	001	Dec 16, 1987

CLORPRES

MYLAN	15MG;0.1MG	A071325	003	Feb 09, 1987
	15MG;0.2MG	A071325	002	Feb 09, 1987
	15MG;0.3MG	A071325	001	Feb 09, 1987

COMBIPRES

+ BOEHRINGER INGELHEIM	15MG;0.1MG **	N017503	001	
+	15MG;0.2MG **	N017503	002	
+	15MG;0.3MG **	N017503	003	Apr 10, 1984

CHLORTHALIDONE; METOPROLOL TARTRATE

CAPSULE;ORAL

LOPRESSIDONE

NOVARTIS	25MG;100MG	N019451	001	Dec 31, 1987
	25MG;200MG	N019451	002	Dec 31, 1987

CHLORTHALIDONE; RESERPINE

TABLET;ORAL

DEMI-REGROTON

SANOFI AVENTIS US	25MG;0.125MG	N015103	002

REGROTON

SANOFI AVENTIS US	50MG;0.25MG	N015103	001

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

ACTAVIS ELIZABETH	250MG	A088928	001	May 08, 1987
	500MG	A040113	001	Sep 29, 1995
AUROLIFE PHARMA LLC	250MG	A089852	001	May 04, 1988
	500MG	A089853	001	May 04, 1988
BARR	500MG	A089895	001	May 04, 1988
OHM LABS	250MG	A081298	001	Dec 29, 1993
	500MG	A081299	001	Dec 29, 1993
PAR PHARM	250MG	A087981	001	Sep 20, 1983
PIONEER PHARMS	250MG	A089592	001	Jan 06, 1989
	500MG	A089948	001	Jan 06, 1989
SUN PHARM INDUSTRIES	500MG	A089970	001	Sep 27, 1990
WATSON LABS	250MG	A086901	001	
	250MG	A086948	001	Aug 09, 1982
	500MG	A040137	001	Aug 09, 1996
	500MG	A081019	001	Jul 29, 1991
	500MG	A081040	001	Aug 22, 1989

PARAFLEX

+ ORTHO MCNEIL PHARM	250MG **	N011300	003	

PARAFON FORTE DSC

+ JANSSEN R AND D	500MG **	N011529	002	Jun 15, 1987

STRIFON FORTE DSC

FERNDALE LABS	500MG	A081008	001	Dec 23, 1988

CHOLESTYRAMINE

BAR, CHEWABLE;ORAL

CHOLYBAR

PARKE DAVIS	EQ 4GM RESIN/BAR	A071621	001	May 26, 1988
	EQ 4GM RESIN/BAR	A071739	001	May 26, 1988

POWDER;ORAL

CHOLESTYRAMINE

IVAX SUB TEVA PHARMS	EQ 4GM RESIN/PACKET	A074771	001	Jul 09, 1997
	EQ 4GM RESIN/SCOOPFUL	A074771	002	Jul 09, 1997
TEVA	EQ 4GM RESIN/PACKET	A074347	001	May 28, 1998
	EQ 4GM RESIN/SCOOPFUL	A074347	002	May 28, 1998

CHOLESTYRAMINE LIGHT

TEVA	EQ 4GM RESIN/PACKET	A074348	001	May 28, 1998
	EQ 4GM RESIN/SCOOPFUL	A074348	002	May 28, 1998
TEVA PHARMS	EQ 4GM RESIN/PACKET	A074555	001	Sep 30, 1998
	EQ 4GM RESIN/SCOOPFUL	A074555	002	Sep 30, 1998

LOCHOLEST

SANDOZ	EQ 4GM RESIN/PACKET	A074561	001	Aug 15, 1996
	EQ 4GM RESIN/SCOOPFUL	A074561	002	Aug 15, 1996

LOCHOLEST LIGHT

SANDOZ	EQ 4GM RESIN/PACKET	A074562	001	Aug 15, 1996
	EQ 4GM RESIN/SCOOPFUL	A074562	002	Aug 15, 1996

QUESTRAN

+ BRISTOL MYERS	EQ 4GM RESIN/PACKET **	N016640	001	
+	EQ 4GM RESIN/SCOOPFUL **	N016640	003	

QUESTRAN LIGHT

+ BRISTOL MYERS	EQ 4GM RESIN/PACKET **	N019669	001	Dec 05, 1988
+	EQ 4GM RESIN/SCOOPFUL **	N019669	003	Dec 05, 1988

TABLET;ORAL

QUESTRAN

APOTHECON	EQ 800MG RESIN	A073403	002	Dec 27, 1999
	EQ 1GM RESIN	A073403	001	Apr 28, 1994

CHORIOGONADOTROPIN ALFA

INJECTABLE;INJECTION

OVIDREL

EMD SERONO	0.25MG/VIAL	N021149	001	Sep 20, 2000

CHROMIC CHLORIDE

INJECTABLE;INJECTION

CHROMIC CHLORIDE

ABRAXIS PHARM	EQ 0.004MG CHROMIUM/ML	N019271	001	May 05, 1987

CHROMIC PHOSPHATE P-32				
INJECTABLE;INJECTION				
PHOSPHOCOL P32				
MALLINKRODT NUCLEAR	5mCi/ML	N017084 001		
CHYMOPAPAIN				
INJECTABLE;INJECTION				
CHYMODIACTIN				
CHART MEDCL	4,000 UNITS/VIAL	N018663 002	Aug 21, 1984	
+	10,000 UNITS/VIAL **	N018663 001	Nov 10, 1982	
DISCASE				
ABBOTT	12,500 UNITS/VIAL	N018625 001	Jan 18, 1984	
CHYMOTRYPSIN				
FOR SOLUTION;OPHTHALMIC				
ALPHA CHYMAR				
SOLA BARNES HIND	750 UNITS/VIAL	N011837 001		
CATARASE				
CIBA	300 UNITS/VIAL	N016938 001		
NOVARTIS	150 UNITS/VIAL	N018121 001		
ZOLYSE				
ALCON	750 UNITS/VIAL	N011903 001		
CICLOPIROX				
SOLUTION;TOPICAL				
CICLOPIROX				
MYLAN PHARMS INC	8%	A078567 001	Sep 18, 2007	
TEVA PHARMS	8%	A078079 001	Sep 18, 2007	
CIDOFOVIR				
INJECTABLE;INJECTION				
VISTIDE				
+ GILEAD SCIENCES INC	EQ 75MG BASE/ML **	N020638 001	Jun 26, 1996	
CILASTATIN SODIUM; IMIPENEM				
INJECTABLE;INJECTION				
PRIMAXIN				
MERCK	EQ 250MG BASE/VIAL;250MG/VIAL	A062756 001	Jan 08, 1987	
	EQ 500MG BASE/VIAL;500MG/VIAL	A062756 002	Jan 08, 1987	
POWDER;INTRAMUSCULAR				
PRIMAXIN				
MERCK	EQ 500MG BASE/VIAL;500MG/VIAL	N050630 001	Dec 14, 1990	
	EQ 750MG BASE/VIAL;750MG/VIAL	N050630 002	Dec 14, 1990	
POWDER;INTRAVENOUS				
IMIPENEM AND CILASTATIN				
HOSPIRA INC	EQ 250MG BASE/VIAL;250MG/VIAL	A090825 001	Nov 16, 2011	
PRIMAXIN				
+ MERCK	EQ 250MG BASE/VIAL;250MG/VIAL	N050587 001	Nov 26, 1985	
CILOSTAZOL				
TABLET;ORAL				
CILOSTAZOL				
ACTAVIS ELIZABETH	100MG	A077028 002	Nov 26, 2004	
EPIC PHARMA LLC	50MG	A077150 001	Mar 11, 2005	
	100MG	A077022 001	Nov 23, 2004	
IVAX SUB TEVA PHARMS	100MG	A077020 002	Mar 01, 2005	
MYLAN	50MG	A077323 002	Apr 20, 2006	
	100MG	A077323 001	Apr 20, 2006	
MYLAN PHARMS INC	50MG	A077019 001	Nov 23, 2004	
	100MG	A077019 002	Nov 23, 2004	
PLIVA HRVATSKA DOO	50MG	A077898 001	Oct 29, 2007	
	100MG	A077898 002	Oct 29, 2007	
PLETAL				
+ OTSUKA	50MG **	N020863 001	Jan 15, 1999	
+	100MG **	N020863 002	Jan 15, 1999	
CIMETIDINE				
SUSPENSION;ORAL				
TAGAMET HB 200				
GLAXOSMITHKLINE	200MG/20ML	N020951 001	Jul 09, 1999	

CIMETIDINE

TABLET;ORAL

CIMETIDINE

CHARTWELL MOLECULES	200MG	A074329	002	May 17, 1994
	300MG	A074329	003	May 17, 1994
	400MG	A074329	004	May 17, 1994
	800MG	A074329	001	May 17, 1994
CONTRACT PHARMACAL	200MG	A074961	001	Jun 19, 1998
	200MG	A074963	001	Jun 19, 1998
CYCLE PHARMS LTD	300MG	A074361	001	Dec 23, 1994
	400MG	A074361	002	Dec 23, 1994
	800MG	A074371	001	Dec 23, 1994
DAVA PHARMS INC	300MG	A074340	001	Jun 23, 1995
	400MG	A074340	002	Jun 23, 1995
	800MG	A074339	001	Jun 23, 1995
IVAX SUB TEVA PHARMS	200MG	A074401	001	May 30, 1995
	200MG	A074424	001	Jul 28, 1995
	300MG	A074401	002	May 30, 1995
	300MG	A074424	002	Jul 28, 1995
	400MG	A074401	003	May 30, 1995
	400MG	A074424	003	Jul 28, 1995
	800MG	A074402	001	May 30, 1995
	800MG	A074424	004	Jul 28, 1995
PERRIGO	100MG	A074972	001	Jun 19, 1998
PLIVA	200MG	A074568	001	Feb 27, 1997
	300MG	A074568	002	Feb 27, 1997
	400MG	A074568	003	Feb 27, 1997
SANDOZ INC	100MG	A075122	001	Jun 19, 1998
	200MG	A074250	001	Jun 29, 1995
	200MG	A075122	002	Jun 19, 1998
	300MG	A074250	002	Jun 29, 1995
	400MG	A074250	003	Jun 29, 1995
	800MG	A074250	004	Jun 29, 1995
TEVA	200MG	A074365	001	Feb 28, 1995
	300MG	A074365	002	Feb 28, 1995
	400MG	A074365	003	Feb 28, 1995
	800MG	A074365	004	Feb 28, 1995
UPSHER SMITH LABS	200MG	A074506	001	Jan 24, 1996
	300MG	A074506	002	Jan 24, 1996
	400MG	A074506	003	Jan 24, 1996
	800MG	A074506	004	Jan 24, 1996
WATSON LABS INC	200MG	A074349	001	Aug 30, 1996
	300MG	A074349	002	Aug 30, 1996
	400MG	A074349	003	Aug 30, 1996
	800MG	A074316	001	Feb 28, 1996
WATSON LABS TEVA	200MG	A075425	001	Jul 29, 1999
YAOPHARMA CO LTD	200MG	A074100	001	Jan 31, 1995
	300MG	A074100	002	Jan 31, 1995
	400MG	A074100	003	Jan 31, 1995
	800MG	A074100	004	Jan 31, 1995

TAGAMET

GLAXOSMITHKLINE	200MG **	N017920	002	
	300MG **	N017920	003	
	400MG **	N017920	004	Dec 14, 1983
	800MG **	N017920	005	Apr 30, 1986

TAGAMET HB

+ MEDTECH PRODUCTS	100MG **	N020238	001	Jun 19, 1995

CIMETIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CIMETIDINE HYDROCHLORIDE

HOSPIRA	EQ 300MG BASE/2ML	A074296	001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074344	001	Jan 31, 1995
	EQ 300MG BASE/2ML	A074345	001	Jan 31, 1995
	EQ 300MG BASE/2ML	A074412	001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074422	001	Jan 31, 1995
LUITPOLD	EQ 300MG BASE/2ML	A074353	001	Dec 20, 1994
TEVA PARENTERAL	EQ 300MG BASE/2ML	A074252	001	Nov 26, 1997
VINTAGE PHARMS LLC	EQ 300MG BASE/2ML	A074005	001	Aug 31, 1994

CIMETIDINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
HOSPIRA	EQ 6MG BASE/ML	A074269	001	Dec 27, 1994
	EQ 90MG BASE/100ML	A074468	005	Dec 29, 1994
	EQ 120MG BASE/100ML	A074468	006	Dec 29, 1994
	EQ 180MG BASE/100ML	A074468	003	Dec 29, 1994
	EQ 240MG BASE/100ML	A074468	004	Dec 29, 1994
	EQ 360MG BASE/100ML	A074468	001	Dec 29, 1994
	EQ 480MG BASE/100ML	A074468	002	Dec 29, 1994
TAGAMET				
GLAXOSMITHKLINE	EQ 300MG BASE/2ML **	N017939	002	
TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
+ GLAXOSMITHKLINE	EQ 6MG BASE/ML **	N019434	001	Oct 31, 1985
SOLUTION;ORAL				
CIMETIDINE HYDROCHLORIDE				
ANI PHARMS INC	EQ 300MG BASE/5ML	A074859	001	Jul 09, 1998
	EQ 300MG BASE/5ML	A075110	001	Jun 18, 1998
APOTEX INC	EQ 300MG BASE/5ML	A075560	001	Mar 15, 2000
CYCLE PHARMS LTD	EQ 300MG BASE/5ML	A074541	001	Aug 05, 1997
G AND W LABS INC	EQ 300MG BASE/5ML	A074176	001	Jun 01, 1994
LANNETT CO INC	EQ 300MG BASE/5ML	A074251	001	Dec 22, 1994
TAGAMET				
GLAXOSMITHKLINE	EQ 300MG BASE/5ML **	N017924	001	
CINOXACIN				
CAPSULE;ORAL				
CINOBAC				
LILLY	250MG	N018067	001	
	500MG	N018067	002	
CINOXACIN				
TEVA	250MG	A073005	001	Feb 28, 1992
	500MG	A073006	001	Feb 28, 1992
CIPROFLOXACIN				
INJECTABLE;INJECTION				
CIPRO				
+ BAYER HLTHCARE	400MG/40ML (10MG/ML) **	N019847	001	Dec 26, 1990
+	200MG/20ML (10MG/ML) **	N019847	002	Dec 26, 1990
	1200MG/120ML (10MG/ML) **	N019847	003	Dec 26, 1990
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER				
+ BAYER HLTHCARE	200MG/100ML **	N019857	001	Dec 26, 1990
+	400MG/200ML **	N019857	002	Dec 26, 1990
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
BAYER PHARMS	200MG/100ML	N019858	001	Dec 26, 1990
CIPROFLOXACIN				
BEDFORD LABS	200MG/20ML (10MG/ML)	A076992	001	Aug 28, 2006
	400MG/40ML (10MG/ML)	A076992	002	Aug 28, 2006
	1200MG/120ML (10MG/ML)	A076993	001	Aug 28, 2006
FRESENIUS KABI USA	200MG/20ML (10MG/ML)	A076484	001	Aug 28, 2006
	400MG/40ML (10MG/ML)	A076484	002	Aug 28, 2006
TEVA PHARMS USA	200MG/20ML (10MG/ML)	A077782	001	Aug 28, 2006
	400MG/40ML (10MG/ML)	A077782	002	Aug 28, 2006
CIPROFLOXACIN IN DEXTROSE 5%				
HIKMA FARMACEUTICA	200MG/100ML	A076757	001	Apr 21, 2008
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	200MG/100ML	A077888	001	Mar 18, 2008
	400MG/200ML	A077888	002	Mar 18, 2008
BEDFORD	200MG/100ML	A078114	001	Mar 18, 2008
	400MG/200ML	A078114	002	Mar 18, 2008
TEVA PHARMS	200MG/100ML	A077138	001	Mar 18, 2008
	400MG/200ML	A077138	002	Mar 18, 2008
CIPROFLOXACIN HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
CIPROFLOXACIN HYDROCHLORIDE				
AMRING PHARMS	EQ 0.3% BASE	A078598	001	Jan 16, 2008
APOTEX INC	EQ 0.3% BASE	A075928	001	Jun 09, 2004

CIPROFLOXACIN HYDROCHLORIDE

TABLET;ORAL				
CIPRO				
+	BAYER HLTHCARE	EQ 100MG BASE	N019537 001	Apr 08, 1996
+		EQ 750MG BASE	N019537 004	Oct 22, 1987
CIPROFLOXACIN HYDROCHLORIDE				
	ANI PHARMS INC	EQ 100MG BASE	A075939 001	Mar 03, 2005
		EQ 250MG BASE	A075939 002	Jun 09, 2004
		EQ 500MG BASE	A075939 003	Jun 09, 2004
		EQ 750MG BASE	A075939 004	Jun 09, 2004
	BARR	EQ 250MG BASE	A074124 001	Jun 09, 2004
		EQ 500MG BASE	A074124 002	Jun 09, 2004
		EQ 750MG BASE	A074124 003	Jun 09, 2004
	FOSUN PHARMA	EQ 250MG BASE	A076593 002	Jun 09, 2004
		EQ 500MG BASE	A076593 003	Jun 09, 2004
		EQ 750MG BASE	A076593 004	Jun 09, 2004
	MYLAN	EQ 100MG BASE	A075817 001	Jun 25, 2007
		EQ 250MG BASE	A075685 002	Jun 09, 2004
		EQ 250MG BASE	A075817 002	Jun 09, 2004
		EQ 500MG BASE	A075685 003	Jun 09, 2004
		EQ 750MG BASE	A075685 001	Jun 09, 2004
		EQ 750MG BASE	A075817 004	Jun 09, 2004
	NOSTRUM LABS	EQ 250MG BASE	A076138 001	Jun 09, 2004
		EQ 500MG BASE	A076138 002	Jun 09, 2004
		EQ 750MG BASE	A076138 003	Jun 09, 2004
	PLIVA	EQ 100MG BASE	A076426 001	Jun 15, 2005
		EQ 250MG BASE	A076426 002	Jun 15, 2005
		EQ 500MG BASE	A076426 003	Jun 15, 2005
		EQ 750MG BASE	A076426 004	Jun 15, 2005
	SUN PHARM INDS LTD	EQ 250MG BASE	A075747 001	Jun 09, 2004
		EQ 500MG BASE	A075747 002	Jun 09, 2004
		EQ 750MG BASE	A075747 003	Jun 09, 2004
	TEVA	EQ 250MG BASE	A076136 001	Jun 09, 2004
		EQ 500MG BASE	A076136 002	Jun 09, 2004
		EQ 750MG BASE	A076136 003	Jun 09, 2004
TABLET, EXTENDED RELEASE;ORAL				
PROQUIN XR				
	DEPOMED INC	EQ 500MG BASE	N021744 001	May 19, 2005

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL				
CIPRO XR				
	BAYER HLTHCARE	212.6MG;EQ 287.5MG BASE **	N021473 001	Dec 13, 2002
		425.2MG;EQ 574.9MG BASE **	N021473 002	Aug 28, 2003
CIPROFLOXACIN EXTENDED RELEASE				
	ACTAVIS LABS FL INC	212.6MG;EQ 287.5MG BASE	A077417 001	Nov 30, 2010
		425.2MG;EQ 574.9MG BASE	A077809 001	Nov 30, 2010
	DR REDDYS LABS LTD	212.6MG;EQ 287.5MG BASE	A077701 002	Oct 31, 2007
	FOSUN PHARMA	212.6MG;EQ 287.5MG BASE	A078712 001	Dec 11, 2007

CISAPRIDE MONOHYDRATE

SUSPENSION;ORAL				
PROPULSID				
	JANSSEN PHARMS	EQ 1MG BASE/ML	N020398 001	Sep 15, 1995
TABLET;ORAL				
PROPULSID				
	JANSSEN PHARMS	EQ 10MG BASE	N020210 001	Jul 29, 1993
		EQ 20MG BASE	N020210 002	Dec 23, 1993
TABLET, ORALLY DISINTEGRATING;ORAL				
PROPULSID QUICKSOLV				
	JANSSEN PHARMA	EQ 20MG BASE	N020767 001	Nov 07, 1997

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION				
CISATRACURIUM BESYLATE				
	HOSPIRA INC	EQ 2MG BASE/ML	A203236 001	Mar 30, 2018
		EQ 2MG BASE/ML	A203238 001	Mar 30, 2018
		EQ 10MG BASE/ML	A203236 002	Mar 30, 2018

CISPLATIN				
INJECTABLE;INJECTION				
CISPLATIN				
BEDFORD	10MG/VIAL	A074713	001	Nov 14, 2000
	50MG/VIAL	A074713	002	Nov 14, 2000
TEVA PHARMS USA	1MG/ML	A074814	001	May 16, 2000
PLATINOL				
+ HQ SPCLT PHARMA	10MG/VIAL	N018057	001	
+	50MG/VIAL	N018057	002	
PLATINOL-AQ				
+ HQ SPCLT PHARMA	0.5MG/ML	N018057	003	Jul 18, 1984
CITALOPRAM HYDROBROMIDE				
CAPSULE;ORAL				
CITALOPRAM HYDROBROMIDE				
MYLAN PHARMS INC	EQ 10MG BASE	A077668	001	Feb 28, 2007
	EQ 20MG BASE	A077668	002	Feb 28, 2007
	EQ 40MG BASE	A077668	003	Feb 28, 2007
SOLUTION;ORAL				
CELEXA				
+ FOREST LABS	EQ 10MG BASE/5ML **	N021046	001	Dec 22, 1999
CITALOPRAM HYDROBROMIDE				
APOTEX INC	EQ 10MG BASE/5ML	A077601	001	Nov 15, 2005
TABLET;ORAL				
CELEXA				
ALLERGAN SALES LLC	EQ 60MG BASE	N020822	004	Jul 17, 1998
CITALOPRAM HYDROBROMIDE				
ACTAVIS ELIZABETH	EQ 10MG BASE	A077033	001	Oct 28, 2004
	EQ 20MG BASE	A077033	002	Oct 28, 2004
	EQ 40MG BASE	A077033	003	Oct 28, 2004
EPIC PHARMA LLC	EQ 10MG BASE	A077036	001	Oct 28, 2004
	EQ 20MG BASE	A077036	002	Oct 28, 2004
	EQ 40MG BASE	A077036	003	Oct 28, 2004
FOSUN PHARMA	EQ 10MG BASE	A077035	001	Oct 28, 2004
	EQ 10MG BASE	A077040	001	Aug 17, 2005
	EQ 20MG BASE	A077035	002	Oct 28, 2004
	EQ 20MG BASE	A077040	002	Aug 17, 2005
	EQ 40MG BASE	A077035	003	Oct 28, 2004
	EQ 40MG BASE	A077040	003	Aug 17, 2005
MYLAN	EQ 10MG BASE	A077039	001	Feb 03, 2005
	EQ 20MG BASE	A077039	002	Feb 03, 2005
	EQ 40MG BASE	A077039	003	Feb 03, 2005
MYLAN PHARMS INC	EQ 10MG BASE	A077037	001	Nov 05, 2004
	EQ 20MG BASE	A077037	002	Nov 05, 2004
	EQ 40MG BASE	A077037	003	Nov 05, 2004
NATCO PHARMA LTD	EQ 20MG BASE	A077141	002	Apr 10, 2008
	EQ 40MG BASE	A077141	001	Apr 10, 2008
ROXANE	EQ 10MG BASE	A077041	001	Nov 23, 2004
	EQ 20MG BASE	A077041	002	Nov 23, 2004
	EQ 40MG BASE	A077041	003	Nov 23, 2004
SUN PHARM INDUSTRIES	EQ 10MG BASE	A077052	001	Jul 03, 2006
	EQ 20MG BASE	A077052	002	Jul 03, 2006
	EQ 40MG BASE	A077052	003	Jul 03, 2006
TARO	EQ 10MG BASE	A077278	001	Mar 22, 2006
	EQ 20MG BASE	A077278	002	Mar 22, 2006
	EQ 40MG BASE	A077278	003	Mar 22, 2006
TEVA PHARMS	EQ 10MG BASE	A077213	001	Mar 31, 2006
	EQ 20MG BASE	A077213	002	Mar 31, 2006
	EQ 40MG BASE	A077213	003	Mar 31, 2006
WATSON LABS	EQ 10MG BASE	A077034	001	Jun 30, 2005
	EQ 20MG BASE	A077034	002	Jun 30, 2005
	EQ 40MG BASE	A077034	003	Jun 30, 2005
TABLET, ORALLY DISINTEGRATING;ORAL				
CITALOPRAM HYDROBROMIDE				
BIOVAIL LABS INTL	EQ 10MG BASE	N021763	001	Dec 20, 2005
	EQ 20MG BASE	N021763	002	Dec 20, 2005
	EQ 40MG BASE	N021763	003	Dec 20, 2005

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION;IRRIGATION					
IRRIGATING SOLUTION G IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	3.24GM/100ML;380MG/100ML;430MG/100ML	N018519	001	Jun 22, 1982
UROLOGIC G IN PLASTIC CONTAINER					
	HOSPIRA	3.24GM/100ML;380MG/100ML;430MG/100ML	N018904	001	May 27, 1983

CLADRIBINE

INJECTABLE;INJECTION					
LEUSTATIN					
+	JANSSEN PHARMS	1MG/ML **	N020229	001	Feb 26, 1993

CLARITHROMYCIN

FOR SUSPENSION;ORAL					
BIAXIN					
+	ABBVIE	125MG/5ML	N050698	001	Dec 23, 1993
		187MG/5ML	N050698	003	Sep 30, 1998
+		250MG/5ML	N050698	002	Dec 23, 1993
CLARITHROMYCIN					
	SUN PHARM INDS LTD	125MG/5ML	A065382	001	Aug 30, 2007
		250MG/5ML	A065382	002	Aug 30, 2007
TABLET;ORAL					
BIAXIN					
+	ABBVIE	250MG **	N050662	001	Oct 31, 1991
+		500MG **	N050662	002	Oct 31, 1991
CLARITHROMYCIN					
	IVAX SUB TEVA PHARMS	250MG	A065137	001	May 31, 2005
		500MG	A065137	002	May 31, 2005
	MYLAN	250MG	A065195	001	Mar 11, 2005
		500MG	A065195	002	Mar 11, 2005
	SUN PHARM INDS LTD	250MG	A065174	001	Sep 24, 2004
		500MG	A065174	002	Sep 24, 2004
TABLET, EXTENDED RELEASE;ORAL					
BIAXIN XL					
+	ABBVIE	500MG **	N050775	001	Mar 03, 2000
CLARITHROMYCIN					
	ANI PHARMS INC	500MG	A065250	001	Aug 25, 2005
	RANBAXY	1GM	A065210	001	Jan 26, 2005

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE;INJECTION					
TIMENTIN					
	GLAXOSMITHKLINE	EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	A062691	001	Dec 19, 1986
		EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	001	Apr 01, 1985
		EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	002	Apr 01, 1985
		EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL	N050590	003	Aug 18, 1987
TIMENTIN IN PLASTIC CONTAINER					
	GLAXOSMITHKLINE	EQ 100MG BASE/100ML;EQ 3GM BASE/100ML	N050658	001	Dec 15, 1989

CLEMASTINE FUMARATE

SYRUP;ORAL					
CLEMASTINE FUMARATE					
	ACTAVIS MID ATLANTIC	EQ 0.5MG BASE/5ML	A074075	001	Oct 31, 1993
	APOTEX INC	EQ 0.5MG BASE/5ML	A075703	001	Nov 27, 2000
	LANNETT CO INC	EQ 0.5MG BASE/5ML	A074884	001	Dec 17, 1997
	TEVA PHARMS	EQ 0.5MG BASE/5ML	A073095	001	Apr 21, 1992
	WOCKHARDT BIO AG	EQ 0.5MG BASE/5ML	A074863	001	Mar 13, 1998
TAVIST					
+	NOVARTIS	EQ 0.5MG BASE/5ML **	N018675	001	Jun 28, 1985
TABLET;ORAL					
CLEMASTINE FUMARATE					
	ANI PHARMS INC	1.34MG	A073282	001	Jan 31, 1992
		1.34MG	A073282	002	Dec 03, 1992
	PLD ACQUISITIONS LLC	1.34MG	A073458	001	Oct 31, 1993
	SANDOZ	2.68MG	A073459	001	Oct 31, 1993
TAVIST					
+	NOVARTIS	2.68MG	N017661	001	
TAVIST-1					
+	GLAXOSMITHKLINE CONS	1.34MG	N020925	001	Aug 21, 1992
	NOVARTIS	1.34MG	N017661	002	
		1.34MG	N017661	003	Aug 21, 1992

CLEVIDIPINE				
EMULSION;INTRAVENOUS				
CLEVIPREX				
+ CHIESI USA INC	125MG/250ML (0.5MG/ML)	N022156	003	Nov 08, 2013
CLIDINIUM BROMIDE				
CAPSULE;ORAL				
QUARZAN				
ROCHE	2.5MG	N010355	001	
	5MG	N010355	002	
CLINDAMYCIN HYDROCHLORIDE				
CAPSULE;ORAL				
CLEOCIN				
PHARMACIA AND UPJOHN	EQ 75MG BASE	A061809	001	
	EQ 150MG BASE	A061809	002	
CLINDAMYCIN HYDROCHLORIDE				
MYLAN PHARMS INC	EQ 75MG BASE	A091225	001	May 31, 2011
	EQ 150MG BASE	A091225	002	May 31, 2011
	EQ 300MG BASE	A091225	003	May 31, 2011
TEVA	EQ 75MG BASE	A063027	001	Sep 20, 1989
WATSON LABS	EQ 75MG BASE	A063082	001	Jul 31, 1991
CLINDAMYCIN PALMITATE HYDROCHLORIDE				
FOR SOLUTION;ORAL				
CLEOCIN				
PHARMACIA AND UPJOHN	EQ 75MG BASE/5ML **	A061827	001	
CLINDAMYCIN PHOSPHATE				
CREAM;VAGINAL				
CLEOCIN				
PHARMACIA AND UPJOHN	EQ 2% BASE	N050680	001	Aug 11, 1992
INJECTABLE;INJECTION				
CLEOCIN PHOSPHATE				
PHARMACIA AND UPJOHN	EQ 150MG BASE/ML	A061839	001	
CLINDAMYCIN PHOSPHATE				
ABRAXIS PHARM	EQ 150MG BASE/ML	A062747	001	Jun 03, 1988
BEDFORD	EQ 150MG BASE/ML	A063163	001	Jun 30, 1994
BRISTOL MYERS SQUIBB	EQ 150MG BASE/ML	A062908	001	Feb 01, 1989
IGI LABS INC	EQ 150MG BASE/ML	A062928	001	Feb 13, 1989
LOCH	EQ 150MG BASE/ML	A062905	001	May 09, 1988
MARSAM PHARMS LLC	EQ 150MG BASE/ML	A062913	001	Oct 20, 1988
SOLOPAK	EQ 150MG BASE/ML	A062819	001	Mar 15, 1988
	EQ 150MG BASE/ML	A062852	001	Mar 17, 1988
TEVA PARENTERAL	EQ 150MG BASE/ML	A063041	001	Dec 29, 1989
	EQ 150MG BASE/ML	A063282	001	May 29, 1992
WATSON LABS	EQ 150MG BASE/ML	A062900	001	Jun 08, 1988
	EQ 150MG BASE/ML	A063079	001	Mar 05, 1990
WEST-WARD PHARMS INT	EQ 150MG BASE/ML	A062806	001	Oct 15, 1987
	EQ 150MG BASE/ML	A062953	001	Apr 21, 1988
	EQ 150MG BASE/ML	A063068	001	Aug 28, 1989
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%				
ABRAXIS PHARM	EQ 12MG BASE/ML	N050636	001	Dec 22, 1989
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT LABS	EQ 6MG BASE/ML	A065027	001	Jun 29, 2001
	EQ 12MG BASE/ML	A065027	002	Jun 29, 2001
	EQ 18MG BASE/ML	A065027	003	Jun 29, 2001
BAXTER HLTHCARE	EQ 6MG BASE/ML	N050648	001	Dec 29, 1989
	EQ 12MG BASE/ML	N050648	002	Dec 29, 1989
	EQ 900MG BASE/100ML	N050648	003	Dec 29, 1989
SOLUTION;TOPICAL				
CLEOCIN T				
PHARMACIA AND UPJOHN	EQ 1% BASE	A062363	001	Feb 08, 1982
CLINDAMYCIN PHOSPHATE				
BOCA PHARMA LLC	EQ 1% BASE	A062944	001	Jan 11, 1989
NOVAST LABS	EQ 1% BASE	A064108	001	Sep 27, 1996
VINTAGE PHARMS	EQ 1% BASE	A062930	001	Jun 28, 1989
WOCKHARDT BIO AG	EQ 1% BASE	A063304	001	Jul 15, 1997

CLIOQUINOL; NYSTATIN				
OINTMENT;TOPICAL				
NYSTAFORM				
BAYER PHARMS	10MG/GM;100,000 UNITS/GM	N050235	001	
CLOBAZAM				
TABLET;ORAL				
ONFI				
LUNDBECK PHARMS LLC	5MG	N202067	001	Oct 21, 2011
CLOBETASOL PROPIONATE				
CREAM;TOPICAL				
CLOBETASOL PROPIONATE				
TEVA PHARMS USA	0.05%	A074087	001	Feb 16, 1994
CLOBETASOL PROPIONATE (EMOLLIENT)				
NOVAST LABS	0.05%	A075733	001	Aug 22, 2001
TEMOVATE				
+ FOUGERA PHARMS	0.05% **	N019322	001	Dec 27, 1985
TEMOVATE E				
+ FOUGERA PHARMS	0.05% **	N020340	001	Jun 17, 1994
GEL;TOPICAL				
TEMOVATE				
+ FOUGERA PHARMS	0.05% **	N020337	001	Apr 29, 1994
OINTMENT;TOPICAL				
CLOBETASOL PROPIONATE				
ACTAVIS MID ATLANTIC	0.05%	A074128	001	Aug 03, 1994
TEMOVATE				
+ FOUGERA PHARMS	0.05% **	N019323	001	Dec 27, 1985
SOLUTION;TOPICAL				
TEMOVATE				
+ FOUGERA PHARMS	0.05% **	N019966	001	Feb 22, 1990
SPRAY;TOPICAL				
CLOBETASOL PROPIONATE				
APOTEX INC	0.05%	A210446	001	Apr 17, 2018
CLOFAZIMINE				
CAPSULE;ORAL				
LAMPRENE				
+ NOVARTIS	50MG	N019500	002	Dec 15, 1986
	100MG	N019500	001	Dec 15, 1986
CLOFIBRATE				
CAPSULE;ORAL				
ATROMID-S				
WYETH AYERST	500MG	N016099	002	
CLOFIBRATE				
BANNER PHARMACAPS	500MG	A073396	001	Mar 20, 1992
SANDOZ	500MG	A072191	001	May 02, 1988
TEVA	500MG	A072600	001	Jul 25, 1991
USL PHARMA	500MG	A070531	001	Jun 16, 1986
WATSON LABS	500MG	A071603	001	Sep 18, 1987
CLOMIPHENE CITRATE				
TABLET;ORAL				
CLOMID				
+ SANOFI AVENTIS US	50MG	N016131	002	
MILOPHENE				
MILEX	50MG	A072196	001	Dec 20, 1988
SEROPHENE				
EMD SERONO	50MG	N018361	001	Mar 22, 1982
CLOMIPRAMINE HYDROCHLORIDE				
CAPSULE;ORAL				
CLOMIPRAMINE HYDROCHLORIDE				
TEVA	25MG	A074849	001	Apr 04, 1997
	50MG	A074849	002	Apr 04, 1997
	75MG	A074849	003	Apr 04, 1997
WATSON LABS	25MG	A074600	001	Nov 27, 1996
	25MG	A074751	001	Sep 30, 1998
	50MG	A074600	002	Nov 27, 1996
	50MG	A074751	002	Sep 30, 1998
	75MG	A074600	003	Nov 27, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

CLOMIPRAMINE HYDROCHLORIDE
CAPSULE;ORAL
CLOMIPRAMINE HYDROCHLORIDE

	75MG	A074751	003	Sep 30, 1998

CLONAZEPAM
TABLET;ORAL
CLONAZEPAM

APOTEX INC	0.5MG	A075468	001	Oct 06, 2000
	1MG	A075468	002	Oct 06, 2000
	2MG	A075468	003	Oct 06, 2000
MYLAN PHARMS INC	0.5MG	A074940	001	Oct 30, 1997
	1MG	A074940	002	Oct 30, 1997
	2MG	A074940	003	Oct 30, 1997
SANDOZ	0.5MG	A074925	001	Sep 30, 1997
	1MG	A074925	002	Sep 30, 1997
	2MG	A074925	003	Sep 30, 1997
TEVA	0.5MG	A074920	001	Aug 04, 1998
	1MG	A074920	002	Aug 04, 1998
	2MG	A074920	003	Aug 04, 1998

KLONOPIN

ROCHE	0.125MG	N017533	005	Apr 09, 1997
	0.25MG	N017533	006	Apr 09, 1997

TABLET, ORALLY DISINTEGRATING;ORAL
KLONOPIN RAPIDLY DISINTEGRATING

+	ROCHE	0.125MG **	N020813	001	Dec 23, 1997
+		0.25MG **	N020813	002	Dec 23, 1997
+		0.5MG **	N020813	003	Dec 23, 1997
+		1MG **	N020813	004	Dec 23, 1997
+		2MG **	N020813	005	Dec 23, 1997

CLONIDINE
SUSPENSION, EXTENDED RELEASE;ORAL
CLONIDINE

TRIS PHARMA INC	EQ 0.09MG BASE/ML	N022499	001	Dec 03, 2009

TABLET, EXTENDED RELEASE;ORAL
CLONIDINE

TRIS PHARMA INC	EQ 0.17MG BASE	N022500	001	Dec 03, 2009
	EQ 0.26MG BASE	N022500	002	Dec 03, 2009

CLONIDINE HYDROCHLORIDE
TABLET;ORAL
CLONIDINE HYDROCHLORIDE

AM THERAP	0.1MG	A070881	001	Jul 08, 1986
	0.2MG	A070882	001	Jul 08, 1986
	0.3MG	A070883	001	Jul 08, 1986
AUROLIFE PHARMA LLC	0.1MG	A070886	002	Aug 31, 1988
	0.2MG	A070886	001	Aug 31, 1988
	0.3MG	A070886	003	Aug 31, 1988
CHARTWELL MOLECULES	0.1MG	A071785	002	Apr 05, 1988
	0.2MG	A071785	003	Apr 05, 1988
	0.3MG	A071785	001	Apr 05, 1988
DURAMED PHARMS BARR	0.1MG	A071103	001	Aug 14, 1986
	0.2MG	A071102	001	Aug 14, 1986
	0.3MG	A071101	001	Aug 14, 1986
INTERPHARM	0.1MG	A071252	001	Oct 01, 1986
	0.2MG	A071253	001	Oct 01, 1986
	0.3MG	A071254	001	Oct 01, 1986
PAR PHARM	0.1MG	A070461	001	Jul 08, 1986
	0.2MG	A070460	001	Jul 08, 1986
	0.3MG	A070459	001	Jul 08, 1986
TEVA	0.1MG	A070747	001	Jul 08, 1986
	0.2MG	A070702	001	Jul 08, 1986
	0.3MG	A070659	001	Jul 08, 1986
WARNER CHILCOTT	0.1MG	A072138	001	Jun 13, 1988
	0.2MG	A072139	001	Jun 13, 1988
	0.3MG	A072140	001	Jun 13, 1988
WATSON LABS	0.1MG	A070395	001	Mar 23, 1987
	0.1MG	A070965	001	Jul 08, 1986
	0.2MG	A070396	001	Mar 23, 1987
	0.2MG	A070964	001	Jul 08, 1986

CLONIDINE HYDROCHLORIDE					
TABLET;ORAL					
CLONIDINE HYDROCHLORIDE					
		0.3MG	A070397	001	Mar 23, 1987
		0.3MG	A070963	001	Jul 08, 1986
TABLET, EXTENDED RELEASE;ORAL					
CLONIDINE HYDROCHLORIDE					
	ACTAVIS ELIZABETH	0.2MG	A202792	002	May 15, 2015
		0.2MG	A203320	002	May 15, 2015
	ANCHEN PHARMS	0.1MG	A202983	001	Apr 02, 2014
		0.2MG	A202983	002	Apr 02, 2014
		0.2MG	A202984	002	Sep 30, 2013
JENLOGA					
+	CONCORDIA PHARMS INC	0.1MG **	N022331	001	Sep 30, 2009
+		0.2MG **	N022331	002	May 25, 2010
KAPVAY					
+	CONCORDIA PHARMS INC	0.2MG **	N022331	004	Sep 28, 2010
CLOPIDOGREL BISULFATE					
TABLET;ORAL					
CLOPIDOGREL BISULFATE					
	ACTAVIS TOTOWA	EQ 75MG BASE	A090307	001	May 28, 2013
CLORAZEPATE DIPOTASSIUM					
CAPSULE;ORAL					
CLORAZEPATE DIPOTASSIUM					
	ABLE	3.75MG	A071777	001	Jul 14, 1987
		7.5MG	A071778	001	Jul 14, 1987
		15MG	A071779	001	Jul 14, 1987
	AM THERAP	3.75MG	A071429	001	Jun 23, 1987
		7.5MG	A071430	001	Jun 23, 1987
		15MG	A071431	001	Jun 23, 1987
	AUROLIFE PHARMA LLC	3.75MG	A072112	002	Aug 11, 2017
		7.5MG	A072112	003	Aug 11, 2017
		15MG	A072112	001	Aug 26, 1988
	DAVA PHARMS INC	3.75MG	A071742	001	Dec 14, 1987
		7.5MG	A071743	001	Dec 14, 1987
		15MG	A071744	001	Dec 14, 1987
	GD SEARLE LLC	3.75MG	A071727	001	Dec 18, 1987
		7.5MG	A071728	001	Dec 18, 1987
		15MG	A071729	001	Dec 18, 1987
	MYLAN	3.75MG	A071509	001	Oct 19, 1987
		7.5MG	A071510	001	Oct 19, 1987
		15MG	A071511	001	Oct 19, 1987
	PUREPAC PHARM	3.75MG	A071924	001	Apr 25, 1988
		7.5MG	A071925	001	Apr 25, 1988
		15MG	A071926	001	Apr 25, 1988
	QUANTUM PHARMICS	3.75MG	A071549	001	Sep 12, 1988
		7.5MG	A071550	001	Sep 12, 1988
		15MG	A071522	001	Sep 12, 1988
	USL PHARMA	3.75MG	A071242	001	Jun 23, 1987
		7.5MG	A071243	001	Jun 23, 1987
		15MG	A071244	001	Jun 23, 1987
	WARNER CHILCOTT	3.75MG	A071774	001	Mar 01, 1988
		7.5MG	A071775	001	Mar 01, 1988
		15MG	A071776	001	Mar 01, 1988
	WATSON LABS	3.75MG	A071878	001	Mar 15, 1988
		7.5MG	A071879	001	Mar 15, 1988
		15MG	A071860	001	Mar 15, 1988
TRANXENE					
	RECORDATI RARE	3.75MG **	N017105	001	
		7.5MG **	N017105	002	
		15MG **	N017105	003	
TABLET;ORAL					
CLORAZEPATE DIPOTASSIUM					
	ABLE	3.75MG	A071780	001	Jun 26, 1987
		7.5MG	A071781	001	Jun 26, 1987
		15MG	A071782	001	Jun 26, 1987
	AM THERAP	3.75MG	A071747	001	Jun 23, 1987
		7.5MG	A071748	001	Jun 23, 1987

CLORAZEPATE DIPOTASSIUM				
TABLET;ORAL				
CLORAZEPATE DIPOTASSIUM				
	15MG	A071749	001	Jun 23, 1987
AUROLIFE PHARMA LLC	3.75MG	A072512	001	May 11, 1990
	7.5MG	A072513	001	May 11, 1990
	15MG	A072514	001	May 11, 1990
LEDERLE	3.75MG	A072013	001	Dec 15, 1987
	7.5MG	A072014	001	Dec 15, 1987
	15MG	A072015	001	Dec 15, 1987
PUREPAC PHARM	3.75MG	A072330	001	Aug 08, 1988
	7.5MG	A072331	001	Aug 08, 1988
	15MG	A072332	001	Aug 08, 1988
QUANTUM PHARMICS	3.75MG	A071730	001	Oct 26, 1987
	7.5MG	A071731	001	Oct 26, 1987
	15MG	A071702	001	Oct 26, 1987
SUN PHARM INDS LTD	3.75MG	A076911	001	Sep 29, 2004
	7.5MG	A076911	002	Sep 29, 2004
	15MG	A076911	003	Sep 29, 2004
WARNER CHILCOTT	3.75MG	A071828	001	Mar 03, 1988
	7.5MG	A071829	001	Mar 03, 1988
	15MG	A071830	001	Mar 03, 1988
WATSON LABS	3.75MG	A071852	001	Feb 09, 1988
	7.5MG	A071853	001	Feb 09, 1988
	15MG	A071854	001	Feb 09, 1988
TRANXENE				
RECORDATI RARE	3.75MG **	N017105	006	
+	15MG **	N017105	008	
TRANXENE SD				
RECORDATI RARE	11.25MG **	N017105	005	
	22.5MG **	N017105	004	
CLOTRIMAZOLE				
CREAM;TOPICAL				
LOTRIMIN				
SCHERING PLOUGH	1% **	N017619	001	
MYCELEX				
BAYER HEALTHCARE LLC	1%	N018183	001	
CREAM;VAGINAL				
GYNE-LOTRIMIN				
+ BAYER HEALTHCARE LLC	1% **	N018052	002	Nov 30, 1990
GYNE-LOTRIMIN 3				
+ BAYER HEALTHCARE LLC	2%	N020574	001	Nov 24, 1998
MYCELEX-7				
BAYER HEALTHCARE LLC	1%	N018230	002	Dec 26, 1991
CREAM, TABLET;TOPICAL, VAGINAL				
GYNE-LOTRIMIN 3 COMBINATION PACK				
+ BAYER HEALTHCARE LLC	1%,200MG	N020526	002	Jul 29, 1996
GYNE-LOTRIMIN COMBINATION PACK				
+ BAYER HEALTHCARE LLC	1%,100MG	N020289	002	Apr 26, 1993
MYCELEX-7 COMBINATION PACK				
BAYER HEALTHCARE LLC	1%,100MG	N020389	002	Jun 23, 1994
LOTION;TOPICAL				
LOTRIMIN				
SCHERING	1%	N018813	001	Feb 17, 1984
SOLUTION;TOPICAL				
LOTRIMIN				
+ SCHERING PLOUGH	1%	N017613	001	
MYCELEX				
+ BAYER HLTHCARE	1% **	N018181	001	
TABLET;VAGINAL				
GYNE-LOTRIMIN				
+ BAYER HEALTHCARE LLC	100MG	N017717	002	Nov 30, 1990
GYNE-LOTRIMIN 3				
+ BAYER HEALTHCARE LLC	200MG	N020525	001	Jul 29, 1996
GYNIX				
TEVA PHARMS	100MG	A073249	001	Feb 13, 1998
MYCELEX-7				
BAYER HEALTHCARE LLC	100MG	N018182	002	Dec 26, 1991

CLOTRIMAZOLE

TABLET;VAGINAL					
MYCELEX-G					
	BAYER PHARMS	500MG	N019069	001	Apr 19, 1985
TROCHE/LOZENGE;ORAL					
MYCELEX					
+	BAYER HLTHCARE	10MG **	N018713	001	Jun 17, 1983

CLOXACILLIN SODIUM

CAPSULE;ORAL					
CLOXACILLIN SODIUM					
	APOTHECON	EQ 250MG BASE	A061452	001	
		EQ 500MG BASE	A061452	002	
	TEVA	EQ 250MG BASE	A062240	001	
		EQ 500MG BASE	A062240	002	
CLOXAPEN					
	GLAXOSMITHKLINE	EQ 250MG BASE	A061806	001	
		EQ 250MG BASE	A062233	001	
		EQ 500MG BASE	A061806	002	
		EQ 500MG BASE	A062233	002	
FOR SOLUTION;ORAL					
CLOXACILLIN SODIUM					
	TEVA	EQ 125MG BASE/5ML	A062268	001	
		EQ 125MG BASE/5ML	A062978	001	Apr 06, 1989
TEGOPEN					
	APOTHECON	EQ 125MG BASE/5ML	A061453	001	
		EQ 125MG BASE/5ML	N050192	001	

CLOZAPINE

TABLET;ORAL					
CLOZAPINE					
	MYLAN	12.5MG	A075417	003	Apr 15, 2010
	PAR PHARM	25MG	A075162	001	Apr 26, 2005
		100MG	A075162	002	Apr 26, 2005
	SANDOZ	25MG	A074546	001	Aug 30, 1996
		100MG	A074546	002	Aug 30, 1996
	ZYDUS PHARMS USA INC	25MG	A209480	001	Dec 06, 2017
		50MG	A209480	002	Dec 06, 2017
		100MG	A209480	003	Dec 06, 2017
		200MG	A209480	004	Dec 06, 2017
TABLET, ORALLY DISINTEGRATING;ORAL					
FAZACLO ODT					
	JAZZ PHARMS III	50MG	N021590	003	Jun 03, 2005

COBALT CHLORIDE CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR

N/A;N/A					
RUBRATOPE-57 KIT					
	BRACCO	N/A;N/A;N/A;N/A	N016089	001	

COBALT CHLORIDE CO-60; CYANOCOBALAMIN; CYANOCOBALAMIN CO-60; INTRINSIC FACTOR

N/A;N/A					
RUBRATOPE-60 KIT					
	BRACCO	N/A;N/A;N/A;N/A	N016090	001	

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL					
PHENERGAN VC W/ CODEINE					
+	ANI PHARMS	10MG/5ML;5MG/5ML;6.25MG/5ML **	N008306	005	Apr 02, 1984
PHERAZINE VC W/ CODEINE					
	HALSEY	10MG/5ML;5MG/5ML;6.25MG/5ML	A088870	001	Mar 02, 1987
PROMETHAZINE VC W/ CODEINE					
	CENCI	10MG/5ML;5MG/5ML;6.25MG/5ML	A088816	001	Nov 22, 1985
	WOCKHARDT	10MG/5ML;5MG/5ML;6.25MG/5ML	A088896	001	Jan 04, 1985

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL					
PHENERGAN W/ CODEINE					
+	ANI PHARMS	10MG/5ML;6.25MG/5ML **	N008306	004	Apr 02, 1984
PHERAZINE W/ CODEINE					
	HALSEY	10MG/5ML;6.25MG/5ML	A088739	001	Dec 23, 1988
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE					
	PHARM ASSOC	10MG/5ML;6.25MG/5ML	A089647	001	Dec 22, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE				
SYRUP;ORAL				
PROMETHAZINE W/ CODEINE				
CENCI	10MG/5ML;6.25MG/5ML	A088814	001	Nov 22, 1985
CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE				
SYRUP;ORAL				
ACTIFED W/ CODEINE				
GLAXOSMITHKLINE	10MG/5ML;30MG/5ML;1.25MG/5ML	N012575	003	Apr 04, 1984
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE				
CENCI	10MG/5ML;30MG/5ML;1.25MG/5ML	A089018	001	Jul 23, 1986
TRIPROLIDINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE				
WOCKHARDT	10MG/5ML;30MG/5ML;1.25MG/5ML	A088833	001	Nov 16, 1984
CODEINE SULFATE				
SOLUTION;ORAL				
CODEINE SULFATE				
WEST-WARD PHARMS INT	30MG/5ML	N202245	001	Jun 30, 2011
COLCHICINE; PROBENECID				
TABLET;ORAL				
COLBENEMID				
+ MERCK	0.5MG;500MG **	N012383	001	
PROBEN-C				
WATSON LABS	0.5MG;500MG	A085552	001	
PROBENECID AND COLCHICINE				
ANI PHARMS INC	0.5MG;500MG	A083734	001	
BEECHAM	0.5MG;500MG	A084321	001	
IMPAX LABS	0.5MG;500MG	A083720	002	
SANDOZ	0.5MG;500MG	A086130	001	
PROBENECID W/ COLCHICINE				
LEDERLE	0.5MG;500MG	A086954	001	
WATSON LABS	0.5MG;500MG	A083221	001	
COLESEVELAM HYDROCHLORIDE				
CAPSULE;ORAL				
WELCHOL				
DAIICHI SANKYO	375MG	N021141	001	May 26, 2000
COLISTIN SULFATE				
SUSPENSION;ORAL				
COLY-MYCIN S				
PARKE DAVIS	EQ 25MG BASE/5ML	N050355	001	
CONIVAPTAN HYDROCHLORIDE				
INJECTABLE;INTRAVENOUS				
VAPRISOL				
CUMBERLAND PHARMS	20MG/4ML (5MG/ML)	N021697	001	Dec 29, 2005
COPPER				
INTRAUTERINE DEVICE;INTRAUTERINE				
CU-7				
GD SEARLE LLC	89MG	N017408	001	
TATUM-T				
GD SEARLE LLC	120MG	N018205	001	
CORTICOTROPIN				
INJECTABLE;INJECTION				
ACTH				
PARKEDALE	25 UNITS/VIAL	N008317	002	
	40 UNITS/VIAL	N008317	004	
ACTHAR				
SANOFI AVENTIS US	25 UNITS/VIAL	N007504	002	
	40 UNITS/VIAL	N007504	003	
CORTICOTROPIN				
ORGANICS LAGRANGE	40 UNITS/ML	N010831	001	
	80 UNITS/ML	N010831	002	
WATSON LABS	40 UNITS/VIAL	A088772	001	Nov 21, 1984
H.P. ACTHAR GEL				
MALLINCKRODT ARD	40 UNITS/ML	N008372	006	
PURIFIED CORTROPHIN GEL				
ANI PHARMS INC	40 UNITS/ML	N008975	001	
	80 UNITS/ML	N008975	002	

CORTICOTROPIN-ZINC HYDROXIDE				
INJECTABLE;INJECTION				
CORTROPHIN-ZINC				
	ANI PHARMS INC	40 UNITS/ML	N009854 001	
CORTISONE ACETATE				
INJECTABLE;INJECTION				
CORTISONE ACETATE				
	PHARMACIA AND UPJOHN	25MG/ML	N008126 002	
	WATSON LABS	25MG/ML	A083147 003	
		25MG/ML	A085677 001	
		50MG/ML	A083147 004	
		50MG/ML	A085677 002	
CORTONE				
	MERCK	25MG/ML	N007110 002	
		50MG/ML	N007110 003	
TABLET;ORAL				
CORTISONE ACETATE				
	BARR	25MG	A083471 001	
	ELKINS SINN	25MG	A080836 001	
	EVERYLIFE	25MG	A084246 001	
	HEATHER	25MG	A085736 001	
	IMPAX LABS	25MG	N009458 001	
	INWOOD LABS	25MG	A080731 001	
	IVAX SUB TEVA PHARMS	25MG	A080630 001	
		25MG	A083536 001	
	LANNETT	25MG	A080694 001	
	PANRAY	5MG	N008284 002	
		25MG	N008284 001	
	PHARMACIA AND UPJOHN	5MG	N008126 003	
		10MG	N008126 004	
		25MG	N008126 001	
	PUREPAC PHARM	25MG	A080493 001	
	VITARINE	25MG	A080333 001	
	WATSON LABS	25MG	A085884 001	
	WHITEWORTH TOWN PLSN	25MG	A080341 001	
CORTONE				
+	MERCK	25MG **	N007750 003	
COSYNTROPIN				
SOLUTION;INTRAVENOUS				
COSYNTROPIN				
	SANDOZ INC	0.25MG/ML (0.25MG/ML)	N022028 001	Feb 21, 2008
CROMOLYN SODIUM				
AEROSOL, METERED;INHALATION				
INTAL				
	KING PHARMS LLC	0.8MG/INH	N018887 001	Dec 05, 1985
CAPSULE;INHALATION				
INTAL				
+	SANOFI AVENTIS US	20MG **	N016990 001	
CAPSULE;ORAL				
GASTROCROM				
	UCB INC	100MG	N019188 001	Dec 22, 1989
CONCENTRATE;ORAL				
CROMOLYN SODIUM				
	GENERA PHARMS	100MG/5ML	A090954 001	Dec 18, 2009
SOLUTION;INHALATION				
CROMOLYN SODIUM				
	ACTAVIS MID ATLANTIC	10MG/ML	A075067 001	Jul 19, 1999
	APOTEX INC	10MG/ML	A075333 001	Apr 30, 2002
	BAUSCH AND LOMB	10MG/ML	A075585 001	Dec 21, 2000
	FERA PHARMS LLC	10MG/ML	A075437 001	Apr 21, 2000
	ROXANE	10MG/ML	A075175 001	Sep 30, 1999
	WATSON LABS	10MG/ML	A076469 001	Jun 17, 2005
INTAL				
+	KING PHARMS LLC	10MG/ML **	N018596 001	May 28, 1982
SOLUTION/DROPS;OPHTHALMIC				
CROLOM				
	BAUSCH AND LOMB	4%	A074443 001	Jan 30, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

CROMOLYN SODIUM				
SOLUTION/DROPS;OPHTHALMIC				
CROMOLYN SODIUM				
APOTEX INC	4%	A075615	001	Jan 26, 2001
CROMOPTIC				
KING PHARMS	4%	A075088	001	Apr 27, 1999
OPTICROM				
+ ALLERGAN	4% **	N018155	001	Oct 03, 1984
SPRAY, METERED;NASAL				
CROMOLYN SODIUM				
ACTAVIS MID ATLANTIC	5.2MG/SPRAY	A074800	001	Jul 26, 2001
HH AND P	5.2MG/SPRAY	A077976	001	Sep 07, 2007
NASALCROM				
+ BLACKSMITH BRANDS	5.2MG/SPRAY **	N020463	001	Jan 03, 1997
CRYPTENAMINE ACETATES				
INJECTABLE;INJECTION				
UNITENSEN				
MEDPOINTE PHARM HLC	260CSR UNIT/ML	N008814	001	
CRYPTENAMINE TANNATES				
TABLET;ORAL				
UNITENSEN				
MEDPOINTE PHARM HLC	260CSR UNIT	N009217	001	
CUPRIC SULFATE				
INJECTABLE;INJECTION				
CUPRIC SULFATE				
ABRAXIS PHARM	EQ 0.4MG COPPER/ML	N019350	001	May 05, 1987
CYANOCOBALAMIN				
GEL, METERED;NASAL				
NASCOBAL				
PAR PHARM	0.5MG/INH	N019722	001	Nov 05, 1996
INJECTABLE;INJECTION				
BERUBIGEN				
PHARMACIA AND UPJOHN	1MG/ML	N006798	001	
BETALIN 12				
LILLY	0.1MG/ML	A080855	001	
	1MG/ML	A080855	002	
COBAVITE				
WATSON LABS	0.1MG/ML	A083013	001	
	1MG/ML	A083064	001	
CYANOCOBALAMIN				
ABRAXIS PHARM	0.03MG/ML	A080510	003	
	0.1MG/ML	A080510	001	
	1MG/ML	A080510	002	
AKORN	1MG/ML	A087969	001	Nov 10, 1983
DELL LABS	0.03MG/ML	A080689	001	
	0.1MG/ML	A080689	002	
	1MG/ML	A080689	003	
FRESENIUS KABI USA	0.1MG/ML	A080557	002	
LUITPOLD	0.03MG/ML	A080668	001	
LYPHOMED	1MG/ML	A083075	001	
MYLAN INSTITUTIONAL	1MG/ML	A040451	001	Sep 23, 2003
SANOFI AVENTIS US	1MG/ML	A080564	001	
SOLOPAK	1MG/ML	A087551	001	Feb 29, 1984
WARNER CHILCOTT	1MG/ML	N007085	002	
WATSON LABS	0.1MG/ML	A080573	002	
	0.1MG/ML	A083120	001	
	1MG/ML	A080573	001	
	1MG/ML	A083120	002	
WYETH AYERST	0.1MG/ML	A080554	001	
	1MG/ML	A080554	002	
DODEX				
ACCORD HLTHCARE	1MG/ML	A083022	001	
REDISOL				
MERCK	1MG/ML	N006668	010	
RUBIVITE				
BEL MAR	0.03MG/ML	N010791	004	
	0.05MG/ML	N010791	001	

CYANOCOBALAMIN
INJECTABLE;INJECTION
RUBIVITE

	0.1MG/ML	N010791 002	
	0.12MG/ML	N010791 005	
	1MG/ML	N010791 003	

RUBRAMIN PC

BRISTOL MYERS SQUIBB	0.1MG/ML	N006799 002	
+	1MG/ML **	N006799 004	
+	1MG/ML **	N006799 010	Apr 28, 1988

RUVITE

SAVAGE LABS	1MG/ML	A080570 002	

VI-TWEL

BAYER HLTHCARE	1MG/ML	N007012 002	

SPRAY, METERED;NASAL
CALOMIST

PAR PHARM	25MCG/SPRAY	N022102 001	Jul 27, 2007

TABLET;ORAL
CYANOCOBALAMIN

WEST WARD	1MG	A084264 001	

CYANOCOBALAMIN CO-57
CAPSULE;ORAL
RUBRATOPE-57

BRACCO	0.5-1uCi	N016089 002	

CYANOCOBALAMIN CO-60
CAPSULE;ORAL
RUBRATOPE-60

BRACCO	0.5-1uCi	N016090 002	

CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; CYANOCOBALAMIN CO-58
N/A;N/A
DICOPAC KIT

GE HEALTHCARE	N/A;N/A;N/A	N017406 001	

CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR
N/A;N/A
CYANOCOBALAMIN CO 57 SCHILLING TEST KIT

MALLINCKRODT	0.1MG;0.5uCi;60MG	N016635 001	

CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE
INJECTABLE;INJECTION
DEPINAR

ARMOUR PHARM	0.5MG/ML;2.3MG/ML;1MG/ML	N011208 001	

CYCLACILLIN
FOR SUSPENSION;ORAL
CYCLAPEN-W

WYETH AYERST	125MG/5ML	N050508 001	
	250MG/5ML	N050508 002	
	500MG/5ML	N050508 003	

TABLET;ORAL
CYCLACILLIN

TEVA	250MG	A062895 001	Aug 04, 1988
	500MG	A062895 002	Aug 04, 1988

CYCLAPEN-W

WYETH AYERST	250MG	N050509 001	
	500MG	N050509 002	

CYCLIZINE LACTATE
INJECTABLE;INJECTION
MAREZINE

GLAXOSMITHKLINE	50MG/ML	N009495 001	

CYCLOBENZAPRINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

TWI PHARMS INC	15MG	A091281 001	Jan 31, 2013
	30MG	A091281 002	Jan 31, 2013

TABLET;ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

SANDOZ	10MG	A073683 001	Feb 26, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

CYCLOBENZAPRINE HYDROCHLORIDE					
TABLET;ORAL					
CYCLOBENZAPRINE HYDROCHLORIDE					
	UPSHER SMITH LABS	5MG	A072854	002	Feb 03, 2006
		10MG	A072854	001	Nov 19, 1991
	WATSON LABS	10MG	A073143	001	Nov 27, 1991
		10MG	A074436	001	Nov 30, 1994
FLEXERIL					
+	JANSSEN RES AND DEV	5MG **	N017821	001	
+		10MG **	N017821	002	
CYCLOPENTOLATE HYDROCHLORIDE					
SOLUTION/DROPS;OPHTHALMIC					
AK-PENTOLATE					
	AKORN	1%	A085555	001	
AKPENTOLATE					
	AKORN	2%	A040165	001	Jan 13, 1997
CYCLOPENTOLATE HYDROCHLORIDE					
	ALCON PHARMS LTD	1%	A089162	001	Jan 24, 1991
	SOLA BARNES HIND	1%	A084150	001	
		1%	A084863	001	
PENTOLAIR					
	PHARMAFAIR	0.5%	A088643	001	Feb 09, 1987
		1%	A088150	001	Feb 25, 1983
CYCLOPHOSPHAMIDE					
INJECTABLE;INJECTION					
CYCLOPHOSPHAMIDE					
	BAXTER HLTHCARE	100MG/VIAL	A088371	001	Jul 03, 1986
		200MG/VIAL	A088372	001	Jul 03, 1986
		500MG/VIAL	A088373	001	Jul 03, 1986
		1GM/VIAL	A088374	001	Sep 24, 1986
CYTOXAN					
+	BAXTER HLTHCARE	100MG/VIAL **	N012142	001	
+		200MG/VIAL **	N012142	002	
CYTOXAN (LYOPHILIZED)					
+	BAXTER HLTHCARE	500MG/VIAL	N012142	003	
+		500MG/VIAL **	N012142	008	Jan 04, 1984
+		1GM/VIAL	N012142	004	Aug 30, 1982
+		1GM/VIAL **	N012142	010	Sep 24, 1985
+		2GM/VIAL	N012142	005	Aug 30, 1982
+		2GM/VIAL **	N012142	009	Dec 10, 1985
LYOPHILIZED CYTOXAN					
+	BAXTER HLTHCARE	100MG/VIAL **	N012142	006	Dec 05, 1985
+		200MG/VIAL **	N012142	007	Dec 10, 1985
NEOSAR					
	BEDFORD	100MG/VIAL	A087442	001	Feb 16, 1982
		200MG/VIAL	A087442	002	Feb 16, 1982
		500MG/VIAL	A087442	003	Feb 16, 1982
		1GM/VIAL	A087442	004	Jul 08, 1983
		2GM/VIAL	A087442	005	Mar 30, 1989
	TEVA PARENTERAL	100MG/VIAL	A040015	001	Apr 29, 1993
		200MG/VIAL	A040015	002	Apr 29, 1993
		500MG/VIAL	A040015	003	Apr 29, 1993
		1GM/VIAL	A040015	004	Apr 29, 1993
		2GM/VIAL	A040015	005	Apr 29, 1993
TABLET;ORAL					
CYCLOPHOSPHAMIDE					
	ROXANE	25MG	A040032	001	Aug 17, 1999
		50MG	A040032	002	Aug 17, 1999
CYTOXAN					
+	BAXTER HLTHCARE	25MG **	N012141	002	
+		50MG **	N012141	001	
CYCLOSPORINE					
CAPSULE;ORAL					
GENGRAF					
	ABBVIE	50MG	A065003	002	May 12, 2000
NEORAL					
+	NOVARTIS	50MG **	N050715	003	Jul 14, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

CYCLOSPORINE				
SOLUTION;ORAL				
CYCLOSPORINE				
APOTEX INC	100MG/ML	A065167	001	Jan 05, 2005
CYCLOTHIAZIDE				
TABLET;ORAL				
ANHYDRON				
LILLY	2MG	N013157	002	
FLUIDIL				
PHARMACIA AND UPJOHN	2MG	N018173	001	
CYCRIMINE HYDROCHLORIDE				
TABLET;ORAL				
PAGITANE				
LILLY	1.25MG	N008951	001	
	2.5MG	N008951	002	
CYPROHEPTADINE HYDROCHLORIDE				
SYRUP;ORAL				
CYPROHEPTADINE HYDROCHLORIDE				
ACTAVIS MID ATLANTIC	2MG/5ML **	A086833	001	
HALSEY	2MG/5ML	A089199	001	Jul 03, 1986
MORTON GROVE	2MG/5ML	A087001	001	Nov 04, 1982
NASKA	2MG/5ML	A089021	001	Dec 21, 1987
PERIACTIN				
+ MERCK	2MG/5ML **	N013220	002	
TABLET;ORAL				
CYPROHEPTADINE HYDROCHLORIDE				
AM THERAP	4MG	A088798	001	Feb 15, 1985
ASCOT	4MG	A087685	001	Oct 25, 1982
CHARTWELL RX	4MG	A088212	001	May 26, 1983
DURAMED PHARMS BARR	4MG	A088232	001	Oct 25, 1983
FOSUN PHARMA	4MG	A086808	001	
HALSEY	4MG	A089057	001	Jul 03, 1986
KV PHARM	4MG	A086737	001	
MD PHARM	4MG	A087566	001	Nov 10, 1982
MYLAN	4MG	A086678	001	
PIONEER PHARMS	4MG	A087839	001	Feb 08, 1984
PLIVA	4MG	A088205	001	Jul 26, 1983
SUPERPHARM	4MG	A087405	001	
VITARINE	4MG	A087284	001	
WATSON LABS	4MG	A085245	001	
	4MG	A086165	001	
	4MG	A086580	001	
PERIACTIN				
+ MERCK	4MG **	N012649	001	
CYSTEINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
CYSTEINE HYDROCHLORIDE				
+ HOSPIRA	7.25% **	N019523	001	Oct 22, 1986
CYTARABINE				
INJECTABLE;INJECTION				
CYTARABINE				
+ TEVA PARENTERAL	100MG/VIAL **	N016793	001	
+	500MG/VIAL **	N016793	002	
+	1GM/VIAL **	N016793	003	Dec 21, 1987
+	2GM/VIAL **	N016793	004	Dec 21, 1987
CYTOSAR-U				
TEVA PHARMS USA	100MG/VIAL	A075206	001	Dec 30, 1998
	500MG/VIAL	A075206	002	Dec 30, 1998
	1GM/VIAL	A075206	004	Dec 30, 1998
	2GM/VIAL	A075206	003	Dec 30, 1998
INJECTABLE, LIPOSOMAL;INJECTION				
DEPOCYT				
+ PACIRA PHARMS INC	10MG/ML	N021041	001	Apr 01, 1999

DACARBAZINE				
INJECTABLE;INJECTION				
DACARBAZINE				
ABRAXIS PHARM	100MG/VIAL		A070962 001	Aug 28, 1986
	200MG/VIAL		A070990 001	Aug 28, 1986
DTIC-DOME				
+ BAYER HLTHCARE	100MG/VIAL **		N017575 001	
+	200MG/VIAL **		N017575 002	
DACTINOMYCIN				
INJECTABLE;INJECTION				
DACTINOMYCIN				
WEST-WARD PHARMS INT	0.5MG/VIAL		A090304 001	Mar 16, 2010
DALFOPRISTIN; QUINUPRISTIN				
INJECTABLE;INTRAVENOUS				
SYNERCID				
KING PHARMS	420MG/VIAL;180MG/VIAL		N050748 002	Aug 24, 2000
DALTEPARIN SODIUM				
INJECTABLE;INJECTION				
FRAGMIN				
PFIZER INC	7,500 IU/0.75ML		N020287 008	Apr 04, 2002
INJECTABLE;SUBCUTANEOUS				
FRAGMIN				
PFIZER INC	10,000IU/0.4ML (25,000IU/ML)		N020287 002	May 01, 2007
	95,000IU/9.5ML (10,000IU/ML)		N020287 007	Apr 04, 2002
DANAPAROID SODIUM				
INJECTABLE;INJECTION				
ORGARAN				
ASPEN GLOBAL INC	750 UNITS/0.6ML		N020430 001	Dec 24, 1996
DANAZOL				
CAPSULE;ORAL				
DANAZOL				
AM THERAP	200MG		A071569 001	Dec 30, 1987
DANOCRINE				
SANOFI AVENTIS US	50MG **		N017557 003	
	100MG **		N017557 004	
	200MG **		N017557 002	
DAPIPRAZOLE HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
DAPIPRAZOLE HYDROCHLORIDE				
+ FERA PHARMS	0.5% **		N019849 001	Dec 31, 1990
DAPTOMYCIN				
POWDER;IV (INFUSION)				
CUBICIN				
CUBIST PHARMS LLC	250MG/VIAL		N021572 001	Sep 12, 2003
DARUNAVIR ETHANOLATE				
TABLET;ORAL				
PREZISTA				
+ JANSSEN PRODS	EQ 300MG BASE **		N021976 001	Jun 23, 2006
+	EQ 400MG BASE **		N021976 003	Oct 21, 2008
DASATINIB				
TABLET;ORAL				
DASATINIB				
APOTEX INC	20MG		A202103 001	Jun 10, 2016
	50MG		A202103 002	Jun 10, 2016
	70MG		A202103 003	Jun 10, 2016
	100MG		A202103 004	Jun 10, 2016
DAUNORUBICIN CITRATE				
INJECTABLE, LIPOSOMAL;INJECTION				
DAUNOXOME				
GALEN (UK)	EQ 2MG BASE/ML		N050704 002	Apr 08, 1996

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION				
CERUBIDINE				
	SANOFI AVENTIS US	EQ 20MG BASE/VIAL	A061876 001	
	WYETH AYERST	EQ 20MG BASE/VIAL **	N050484 001	
DAUNORUBICIN HYDROCHLORIDE				
	TEVA PARENTERAL	EQ 20MG BASE/VIAL	A064212 001	Jun 23, 1998
		EQ 50MG BASE/VIAL	A064212 002	May 03, 1999

DECAMETHONIUM BROMIDE

INJECTABLE;INJECTION				
SYNCURINE				
	GLAXOSMITHKLINE	1MG/ML	N006931 002	

DEFEROXAMINE MESYLATE

INJECTABLE;INJECTION				
DEFEROXAMINE MESYLATE				
	WATSON LABS	500MG/VIAL	A076806 001	Mar 31, 2006
		2GM/VIAL	A076806 002	Mar 31, 2006

DEMECARIUM BROMIDE

SOLUTION/DROPS;OPHTHALMIC				
HUMORSOL				
	MERCK	0.125%	N011860 002	
		0.25%	N011860 001	

DEMECLOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL				
DECLOMYCIN				
	LEDERLE	150MG	N050262 001	
SYRUP;ORAL				
DECLOMYCIN				
	LEDERLE	75MG/5ML	N050257 001	
TABLET;ORAL				
DECLOMYCIN				
	COREPHARMA	75MG	N050261 001	
		150MG	N050261 002	
		300MG	N050261 003	
DEMECLOCYCLINE HYDROCHLORIDE				
	IMPAX LABS	150MG	A065094 001	Mar 22, 2004
		300MG	A065094 002	Mar 22, 2004

DESERPIDINE

TABLET;ORAL				
HARMONYL				
	ABBVIE	0.1MG	N010796 001	
		0.25MG	N010796 002	

DESERPIDINE; HYDROCHLOROTHIAZIDE

TABLET;ORAL				
ORETICYL 25				
	ABBVIE	0.125MG;25MG	N012148 001	
ORETICYL 50				
	ABBVIE	0.125MG;50MG	N012148 003	
ORETICYL FORTE				
	ABBVIE	0.25MG;25MG	N012148 002	

DESERPIDINE; METHYCLOTHIAZIDE

TABLET;ORAL				
ENDURONYL				
	ABBOTT	0.25MG;5MG	N012775 001	
ENDURONYL FORTE				
	ABBOTT	0.5MG;5MG	N012775 002	
METHYCLOTHIAZIDE AND DESERPIDINE				
	WATSON LABS	0.25MG;5MG	A088486 001	Aug 10, 1984
		0.5MG;5MG	A088452 001	Aug 10, 1984

DESIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL				
PERTOFRANE				
SANOFI AVENTIS US	25MG	N013621	001	
	50MG	N013621	002	
TABLET;ORAL				
DESIPRAMINE HYDROCHLORIDE				
ANI PHARMS INC	25MG	A071803	002	Dec 08, 1987
	50MG	A071803	003	Dec 08, 1987
	75MG	A071803	004	Dec 08, 1987
	100MG	A071803	001	May 29, 1997
	150MG	A071803	005	May 29, 1997
USL PHARMA	25MG	A071864	001	Sep 09, 1987
	50MG	A071865	001	Sep 09, 1987
	75MG	A071866	001	Sep 09, 1987
	100MG	A071867	001	Sep 09, 1987

DESIRUDIN RECOMBINANT

INJECTABLE;SUBCUTANEOUS				
IPRIVASK				
+ VALEANT PHARMS NORTH	15MG/VIAL	N021271	001	Apr 04, 2003

DESLANOSIDE

INJECTABLE;INJECTION				
CEDILANID-D				
NOVARTIS	0.2MG/ML	N009282	002	

DESMOPRESSIN ACETATE

INJECTABLE;INJECTION				
DDAVP				
FERRING PHARMS INC	0.015MG/ML	N018938	002	Apr 25, 1995
DESMOPRESSIN ACETATE				
BEDFORD	0.004MG/ML	A074575	001	Feb 18, 2000
HOSPIRA	0.004MG/ML	A075220	001	Aug 28, 2000
TEVA PHARMS USA	0.004MG/ML	A074888	001	Oct 15, 1997
DESMOPRESSIN ACETATE PRESERVATIVE FREE				
BEDFORD	0.004MG/ML	A074574	001	Feb 18, 2000
SOLUTION;NASAL				
CONCENTRAID				
FERRING	0.01%	N019776	001	Dec 26, 1990
SPRAY, METERED;NASAL				
DDAVP				
+ FERRING PHARMS INC	0.01MG/SPRAY **	N017922	002	Feb 06, 1989
STIMATE				
FERRING PHARMS INC	0.15MG/SPRAY	N020355	001	Mar 07, 1994
TABLET;ORAL				
DESMOPRESSIN ACETATE				
FERRING	0.1MG	N021795	001	May 08, 2008
	0.2MG	N021795	002	May 08, 2008

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-21				
DESOGEN				
ORGANON USA INC	0.15MG;0.03MG	N020071	001	Dec 10, 1992
DESOGESTREL AND ETHINYL ESTRADIOL				
DURAMED PHARMS BARR	0.15MG;0.03MG	A075256	001	Aug 12, 1999
ORTHO-CEPT				
JANSSEN PHARMS	0.15MG;0.03MG	N020301	001	Dec 14, 1992
TABLET;ORAL-28				
MIRCETTE				
+ TEVA BRANDED PHARM	0.15MG,N/A;0.02MG,0.01MG **	N020713	001	Apr 22, 1998
ORTHO-CEPT				
JANSSEN PHARMS	0.15MG;0.03MG	N020301	002	Dec 14, 1992

DESOXIMETASONE

CREAM;TOPICAL				
TOPICORT				
+ TARO PHARM INDS LTD	0.25% **	N017856	001	
TOPICORT LP				
+ TARO PHARM INDS LTD	0.05% **	N018309	001	

DESOXIMETASONE				
GEL;TOPICAL				
TOPICORT				
+ TARO PHARM INDS LTD	0.05% **	N018586	001	Mar 29, 1982
OINTMENT;TOPICAL				
DESOXIMETASONE				
ALTANA	0.25%	A073440	001	Apr 01, 1998
TOPICORT				
+ TARO PHARM INDS LTD	0.25% **	N018763	001	Sep 30, 1983
DESOXYCORTICOSTERONE ACETATE				
INJECTABLE;INJECTION				
DOCA				
ORGANON USA INC	5MG/ML	N001104	001	
PELLET;IMPLANTATION				
PERCORTEN				
NOVARTIS	125MG	N005151	001	
DESOXYCORTICOSTERONE PIVALATE				
INJECTABLE;INJECTION				
PERCORTEN				
NOVARTIS	25MG/ML	N008822	001	
DESVENLAFAXINE FUMARATE				
TABLET, EXTENDED RELEASE;ORAL				
DESVENLAFAXINE				
+ SUN PHARMA GLOBAL	EQ 50MG BASE	N205583	001	Jan 28, 2014
+	EQ 100MG BASE	N205583	002	Jan 28, 2014
TEVA PHARMS USA	EQ 50MG BASE	N205208	001	Oct 11, 2013
	EQ 100MG BASE	N205208	002	Oct 11, 2013
DEXAMETHASONE				
AEROSOL;TOPICAL				
AEROSEB-DEX				
ALLERGAN HERBERT	0.01% **	A083296	002	
DECASPRAY				
+ MERCK	0.04% **	N012731	002	
ELIXIR;ORAL				
DECADRON				
MERCK	0.5MG/5ML	N012376	002	
DEXAMETHASONE				
ALPHARMA US PHARMS	0.5MG/5ML	A088997	001	Oct 10, 1986
HEXADROL				
ASPEN GLOBAL INC	0.5MG/5ML	N012674	001	
GEL;TOPICAL				
DECADERM				
MERCK	0.1%	N013538	001	
SUSPENSION/DROPS;OPHTHALMIC				
DEXAMETHASONE				
WATSON LABS	0.1%	A089170	001	May 09, 1989
TABLET;ORAL				
DECADRON				
+ MERCK	0.25MG **	N011664	004	
+	0.5MG **	N011664	001	
+	0.75MG **	N011664	002	
+	1.5MG **	N011664	003	
+	4MG **	N011664	005	
+	6MG **	N011664	006	Jul 30, 1982
DEXAMETHASONE				
ANI PHARMS INC	0.75MG	A080399	001	
IMPAX LABS	0.75MG	A085376	001	
PAR PHARM	0.25MG	A088149	001	Apr 28, 1983
PHOENIX LABS NY	0.75MG	A083806	001	
PVT FORM	0.75MG	A083420	001	
ROXANE	0.25MG	A084614	001	
SUN PHARM INDUSTRIES	0.25MG	A084013	001	
	0.25MG	A084764	001	
	0.5MG	A084084	001	
	0.5MG	A084766	001	
	0.75MG	A084081	001	
	0.75MG	A084765	001	

DEXAMETHASONE				
TABLET;ORAL				
DEXAMETHASONE				
		1.5MG	A084086 001	
		1.5MG	A084763 001	
	UPSHER SMITH	0.75MG	A087534 001	
		1.5MG	A087533 001	
	WATSON LABS	0.25MG	A085455 001	
		0.5MG	A085458 001	
		0.75MG	A080968 001	
		0.75MG	A084457 001	
		0.75MG	A085818 001	
		1.5MG	A085456 001	
		1.5MG	A085840 001	
	WHITEWORTH TOWN PLSN	0.75MG	A084327 001	
DEXONE 0.5				
	SOLVAY	0.5MG	A084991 001	
DEXONE 0.75				
	SOLVAY	0.75MG	A084993 001	
DEXONE 1.5				
	SOLVAY	1.5MG	A084990 001	
DEXONE 4				
	SOLVAY	4MG	A084992 001	
HEXADROL				
	ASPEN GLOBAL INC	0.5MG	N012675 004	
		0.75MG	N012675 007	
		1.5MG	N012675 009	
		4MG	N012675 010	
DEXAMETHASONE ACETATE				
INJECTABLE;INJECTION				
DECADRON-LA				
+	MERCK	EQ 8MG BASE/ML **	N016675 001	
DEXAMETHASONE ACETATE				
	WATSON LABS	EQ 8MG BASE/ML	A084315 001	
	WATSON LABS TEVA	EQ 16MG BASE/ML	A087711 001	May 24, 1982
DEXAMETHASONE SODIUM PHOSPHATE				
AEROSOL;NASAL				
DEXACORT				
	UCB INC	EQ 0.1MG PHOSPHATE/INH	N014242 001	
AEROSOL, METERED;INHALATION				
DEXACORT				
	UCB INC	EQ 0.1MG PHOSPHATE/INH	N013413 001	
CREAM;TOPICAL				
DECADRON				
	MERCK	EQ 0.1% PHOSPHATE	N011983 002	
INJECTABLE;INJECTION				
DECADRON				
+	MERCK	EQ 4MG PHOSPHATE/ML **	N012071 002	
+		EQ 24MG PHOSPHATE/ML **	N012071 004	
DEXACEN-4				
	CENT PHARMS	EQ 4MG PHOSPHATE/ML	A084342 001	
DEXAMETHASONE				
	ABRAXIS PHARM	EQ 4MG PHOSPHATE/ML	A088448 001	Jan 25, 1984
	FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A088469 001	Jan 25, 1984
DEXAMETHASONE SODIUM PHOSPHATE				
	AKORN	EQ 4MG PHOSPHATE/ML	A084493 001	
	BEL MAR	EQ 4MG PHOSPHATE/ML	A084752 001	
	DELL LABS	EQ 4MG PHOSPHATE/ML	A083161 001	
	INTL MEDICATION	EQ 20MG PHOSPHATE/ML	A088522 001	Feb 17, 1984
	LYPHOMED	EQ 4MG PHOSPHATE/ML	A087065 001	
	TEVA PARENTERAL	EQ 4MG PHOSPHATE/ML	A081125 001	Aug 31, 1990
		EQ 10MG PHOSPHATE/ML	A081126 001	Aug 31, 1990
	WATSON LABS	EQ 4MG PHOSPHATE/ML	A083702 001	
		EQ 4MG PHOSPHATE/ML	A084355 001	
		EQ 4MG PHOSPHATE/ML	A089169 001	Apr 09, 1986
		EQ 10MG PHOSPHATE/ML	A087668 001	Jul 01, 1982
		EQ 24MG PHOSPHATE/ML	A085606 001	
	WYETH AYERST	EQ 4MG PHOSPHATE/ML	A085641 001	

DEXAMETHASONE SODIUM PHOSPHATE				
INJECTABLE;INJECTION				
HEXADROL				
+	ASPEN GLOBAL INC	EQ 4MG PHOSPHATE/ML **	N014694 002	
+		EQ 10MG PHOSPHATE/ML **	N014694 003	
		EQ 20MG PHOSPHATE/ML	N014694 004	
OINTMENT;OPHTHALMIC				
DECADRON				
	MERCK	EQ 0.05% PHOSPHATE	N011977 001	
DEXAIR				
	PHARMAFAIR	EQ 0.05% PHOSPHATE	A088071 001	Dec 28, 1982
MAXIDEX				
	ALCON	EQ 0.05% PHOSPHATE	A083342 001	
SOLUTION/DROPS;OPHTHALMIC				
DEXAIR				
	PHARMAFAIR	EQ 0.1% PHOSPHATE	A088433 001	Dec 15, 1983
DEXAMETHASONE SODIUM PHOSPHATE				
	SOLA BARNES HIND	EQ 0.1% PHOSPHATE	A084170 001	
		EQ 0.1% PHOSPHATE	A084173 001	
SOLUTION/DROPS;OPHTHALMIC, OTIC				
DECADRON				
	MERCK	EQ 0.1% PHOSPHATE	N011984 001	
SOLUTION/DROPS;OTIC				
DEXAMETHASONE SODIUM PHOSPHATE				
	AKORN	EQ 0.1% PHOSPHATE	A084855 001	
DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
DECADRON W/ XYLOCAINE				
	MERCK	EQ 4MG PHOSPHATE/ML;10MG/ML	N013334 002	
DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE				
OINTMENT;OPHTHALMIC				
NEODECADRON				
	MERCK	EQ 0.05% PHOSPHATE;EQ 3.5MG BASE/GM	N050324 001	
SOLUTION/DROPS;OPHTHALMIC				
NEODECADRON				
	MERCK	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N050322 001	
NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE				
	BAUSCH AND LOMB	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A064055 001	Oct 30, 1995
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE				
	ALCON PHARMS LTD	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A062714 001	Jul 21, 1986
	PHARMAFAIR	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A062539 001	Jan 10, 1985
DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE				
OINTMENT;OPHTHALMIC				
DEXACIDIN				
	NOVARTIS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062566 001	Feb 22, 1985
DEXASPORIN				
	PHARMAFAIR	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062411 001	May 16, 1983
SUSPENSION/DROPS;OPHTHALMIC				
DEXACIDIN				
	NOVARTIS	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062544 001	Oct 29, 1984
DEXASPORIN				
	PHARMAFAIR	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062428 001	May 18, 1983
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE				
	ALCON PHARMS LTD	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062721 001	Nov 17, 1986
DEXBROMPHENIRAMINE MALEATE				
SYRUP;ORAL				
DISOMER				
	SCHERING	2MG/5ML	N011814 002	
TABLET;ORAL				
DISOMER				
	SCHERING	2MG	N011814 001	

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE				
TABLET;ORAL				
DISOPHROL				
SCHERING	2MG;60MG	N012394	002	
TABLET, EXTENDED RELEASE;ORAL				
BROMPHERIL				
COPLEY PHARM	6MG;120MG	A089116	001	Jan 22, 1987
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE				
AVANTHI INC	6MG;120MG	A078648	001	Feb 27, 2013
DISOBROM				
SANDOZ	6MG;120MG	A070770	001	Sep 30, 1991
DISOPHROL				
SCHERING PLOUGH	6MG;120MG	N013483	004	Sep 13, 1982
DRIXORAL				
+ SCHERING PLOUGH	6MG;120MG **	N013483	003	Sep 13, 1982
RESPORAL				
PIONEER PHARMS	6MG;120MG	A089139	001	Jun 16, 1988
DEXCHLORPHENIRAMINE MALEATE				
SYRUP;ORAL				
POLARAMINE				
SCHERING	2MG/5ML	A086837	001	Jul 19, 1982
TABLET;ORAL				
DEXCHLORPHENIRAMINE MALEATE				
ANI PHARMS INC	2MG	A088682	001	Jan 17, 1986
POLARAMINE				
SCHERING	2MG	A086835	001	
DEXLANSOPRAZOLE				
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL				
DEXILANT SOLUTAB				
+ TAKEDA PHARMS USA	30MG	N208056	001	Jan 26, 2016
DEXTROAMPHETAMINE SULFATE				
CAPSULE;ORAL				
DEXAMPEX				
TEVA	15MG	A085355	001	
CAPSULE, EXTENDED RELEASE;ORAL				
DEXTROAMPHETAMINE SULFATE				
ABLE	5MG	A076814	001	Aug 25, 2004
	10MG	A076814	002	Aug 25, 2004
	15MG	A076814	003	Aug 25, 2004
ELIXIR;ORAL				
DEXEDRINE				
GLAXOSMITHKLINE	5MG/5ML **	A083902	001	
TABLET;ORAL				
DEXAMPEX				
TEVA	5MG	A083735	001	
	10MG	A083735	002	
DEXEDRINE				
GLAXOSMITHKLINE	5MG	A084935	001	
DEXTROAMPHETAMINE SULFATE				
ANI PHARMS INC	5MG	A085370	001	
EPIC PHARMA LLC	5MG	A090652	001	Mar 07, 2014
	10MG	A090652	002	Mar 07, 2014
HALSEY	10MG	A083930	001	
LANNETT	5MG	A083903	001	
	10MG	A083903	003	
	15MG	A085652	001	
MAST MM	5MG	A086521	001	
NESHER PHARMS	5MG	A040365	001	Oct 31, 2002
	10MG	A040367	001	Oct 31, 2002
PUREPAC PHARM	5MG	A084125	001	
SANDOZ	10MG	A085371	001	
VINTAGE PHARMS LLC	5MG	A040299	001	May 13, 1999
VITARINE	5MG	A084986	001	
	10MG	A085892	001	
DEXTROSTAT				
SHIRE	5MG **	A084051	001	
	10MG **	A084051	002	

DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

FERNDEX

FERNDALE LABS	5MG	A084001	001	

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHERAZINE DM

HALSEY	15MG/5ML;6.25MG/5ML	A088913	001	Mar 02, 1987

PROMETH W/ DEXTROMETHORPHAN

G AND W LABS INC	15MG/5ML;6.25MG/5ML **	A088762	001	Oct 31, 1984

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

	AMNEAL PHARMS	15MG/5ML;6.25MG/5ML	A090575	001	Feb 08, 2011
+	ANI PHARMS	15MG/5ML;6.25MG/5ML **	N011265	002	Apr 02, 1984
	TRIS PHARMA INC	15MG/5ML;6.25MG/5ML	A091687	001	Jun 28, 2012

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML	N018046	001	
MILES	10GM/100ML	N018504	001	

DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	2.5GM/100ML	N018358	001	
	2.5GM/100ML	N019626	001	Feb 02, 1988

DEXTROSE 20% IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	20GM/100ML	N017521	004	

DEXTROSE 30% IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	30GM/100ML	N017521	003	

DEXTROSE 38.5% IN PLASTIC CONTAINER

ABBOTT	38.5GM/100ML	N018923	001	Sep 19, 1984

DEXTROSE 40% IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	40GM/100ML	N017521	002	

DEXTROSE 5% IN PLASTIC CONTAINER

	DHL	5GM/100ML	N019971	001	Sep 28, 1995
+	ICU MEDICAL INC	50MG/ML	N019222	001	Jul 13, 1984

DEXTROSE 50% IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	50GM/100ML	N017521	001	
	ICU MEDICAL INC	50GM/100ML	N019894	001	Dec 26, 1989

DEXTROSE 60%

B BRAUN	60GM/100ML	N017995	002	Sep 22, 1982

DEXTROSE 60% IN PLASTIC CONTAINER

	B BRAUN	60GM/100ML	N017995	001	
+	BAXTER HLTHCARE	60GM/100ML	N017521	005	Mar 26, 1982
		60GM/100ML	N020047	002	Jul 02, 1991
	HOSPIRA	60GM/100ML	N019346	001	Jan 25, 1985

DEXTROSE 7.7% IN PLASTIC CONTAINER

	B BRAUN	7.7GM/100ML	N019626	003	Feb 02, 1988

DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;32MG/100ML;128MG/100ML;234MG/100ML	N017385	001	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE;INJECTION

ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML;26MG/100ML;320MG/100ML	N019025	001	Dec 27, 1984

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;53MG/100ML;100MG/100ML;100MG/100ML;180MG/100ML;280MG/100ML;16MG/100ML	N019515	001	May 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;220MG/100ML;140MG/100ML	N019844	001	Jun 10, 1993
ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;220MG/100ML;140MG/100ML	N018273	001	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N019843	001	Aug 09, 1993
ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N018274	001	
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	5GM/100ML;30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N017451	001	

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;37MG/100ML	N019699	001	Sep 29, 1989
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;75MG/100ML	N018744	001	Nov 09, 1982
	5GM/100ML;75MG/100ML	N019699	002	Sep 29, 1989
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;110MG/100ML	N019699	003	Sep 29, 1989
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;150MG/100ML	N018744	002	Nov 09, 1982
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;220MG/100ML	N018744	003	Nov 09, 1982
	5GM/100ML;220MG/100ML	N019699	005	Sep 29, 1989
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;300MG/100ML	N018744	004	Nov 09, 1982

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;111MG/100ML;256MG/100ML;146MG/100ML;207MG/100ML	N019514	001	May 08, 1986

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML;280MG/100ML;91MG/100ML	N019870	001	Jun 10, 1993
ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML;280MG/100ML;91MG/100ML	N018270	001	

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5GM/100ML;205MG/100ML;100MG/100ML;120MG/100ML;220MG/100ML	N018840	001	Jun 29, 1983

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%				
B BRAUN	5GM/100ML;75MG/100ML;200MG/100ML	N018268	009	
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;150MG/100ML;200MG/100ML	N018268	004	
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;220MG/100ML;200MG/100ML	N018268	005	
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;300MG/100ML;200MG/100ML	N018268	006	
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;75MG/100ML;330MG/100ML	N018268	011	Jan 18, 1986

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;150MG/100ML;330MG/100ML N018268 012 Jan 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;330MG/100ML N018268 013 Jan 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;300MG/100ML;330MG/100ML N018268 014 Jan 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%
B BRAUN 5GM/100ML;75MG/100ML;450MG/100ML N018268 010

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;150MG/100ML;450MG/100ML N018268 001

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;450MG/100ML N018268 002

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;300MG/100ML;450MG/100ML N018268 003

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;224MG/100ML;450MG/100ML N018008 003

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;300MG/100ML;450MG/100ML N018008 001

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;75MG/100ML;450MG/100ML N018008 002

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
\+ ICU MEDICAL INC 5GM/100ML;74.5MG/100ML;900MG/100ML N019691 002 Mar 24, 1988
\+ 5GM/100ML;149MG/100ML;900MG/100ML N019691 004 Mar 24, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
\+ ICU MEDICAL INC 5GM/100ML;224MG/100ML;450MG/100ML N018362 006 Mar 28, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
\+ ICU MEDICAL INC 5GM/100ML;224MG/100ML;900MG/100ML N019691 006 Mar 24, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
\+ ICU MEDICAL INC 5GM/100ML;298MG/100ML;450MG/100ML N018362 007 Mar 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
\+ ICU MEDICAL INC 5GM/100ML;298MG/100ML;900MG/100ML N019691 008 Mar 24, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
\+ ICU MEDICAL INC 5GM/100ML;224MG/100ML;900MG/100ML N019691 007 Mar 24, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
\+ ICU MEDICAL INC 5GM/100ML;74.5MG/100ML;450MG/100ML N018362 008 Mar 28, 1988
\+ 5GM/100ML;149MG/100ML;450MG/100ML N018362 004 Mar 28, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
\+ ICU MEDICAL INC 5GM/100ML;74.5MG/100ML;900MG/100ML N019691 001 Mar 24, 1988
\+ 5GM/100ML;149MG/100ML;900MG/100ML N019691 003 Mar 24, 1988

DEXTROSE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;200MG/100ML N018386 001

DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;450MG/100ML N018229 001

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;900MG/100ML N018047 001
BAXTER HLTHCARE 10GM/100ML;900MG/100ML N016696 001

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 2.5GM/100ML;450MG/100ML N018030 001
HOSPIRA 2.5GM/100ML;450MG/100ML N018096 001

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 2.5GM/100ML;900MG/100ML N018376 001

DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
ABBOTT 3.3GM/100ML;300MG/100ML N018055 001

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML N018030 005

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;200MG/100ML N018030 004
MILES 5GM/100ML;200MG/100ML N018399 001

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;225MG/100ML N019482 001 Oct 04, 1985

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;300MG/100ML N019486 001 Oct 04, 1985
MILES 5GM/100ML;300MG/100ML N018501 001

DEXTROSE; SODIUM CHLORIDE				
INJECTABLE;INJECTION				
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;330MG/100ML	N018030 003		
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
ABBOTT	5GM/100ML;450MG/100ML	N019484 001	Oct 04, 1985	
B BRAUN	5GM/100ML;450MG/100ML	N018030 002		
MILES	5GM/100ML;450MG/100ML	N018400 001		
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
ABBOTT	5GM/100ML;900MG/100ML	N019483 001	Oct 04, 1985	
B BRAUN	5GM/100ML;900MG/100ML	N018026 001		
MILES	5GM/100ML;900MG/100ML	N018500 001		
DEXTROTHYROXINE SODIUM				
TABLET;ORAL				
CHOLOXIN				
ABBVIE	1MG	N012302 005		
	2MG	N012302 002		
	4MG	N012302 004		
	6MG	N012302 006		
DEZOCINE				
INJECTABLE;INJECTION				
DALGAN				
ASTRAZENECA	5MG/ML	N019082 001	Dec 29, 1989	
	10MG/ML	N019082 002	Dec 29, 1989	
	15MG/ML	N019082 003	Dec 29, 1989	
DIATRIZOATE MEGLUMINE				
INJECTABLE;INJECTION				
ANGIOVIST 282				
BAYER HLTHCARE	60%	A087726 001	Sep 23, 1982	
CARDIOGRAFIN				
BRACCO	85%	N011620 002		
DIATRIZOATE MEGLUMINE				
BRACCO	76%	N010040 017		
HYPAQUE				
GE HEALTHCARE	30%	N016403 002		
	60%	N016403 001		
RENO-60				
BRACCO	60%	N010040 016		
RENO-DIP				
BRACCO	30%	N010040 012		
UROVIST MEGLUMINE DIU/CT				
BAYER HLTHCARE	30%	A087739 001	Sep 23, 1982	
SOLUTION;URETERAL				
RENO-30				
BRACCO	30%	N010040 021		
UROVIST CYSTO				
BAYER HLTHCARE	30%	A087729 001	Sep 23, 1982	
UROVIST CYSTO PEDIATRIC				
BAYER HLTHCARE	30%	A087731 001	Sep 23, 1982	
SOLUTION;URETHRAL				
HYPAQUE-CYSTO				
GE HEALTHCARE	30%	N016403 003		
DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM				
INJECTABLE;INJECTION				
ANGIOVIST 292				
BAYER HLTHCARE	52%;8%	A087724 001	Sep 23, 1982	
ANGIOVIST 370				
BAYER HLTHCARE	66%;10%	A087723 001	Sep 23, 1982	
DIATRIZOATE-60				
INTL MEDICATION	52%;8%	A088166 001	Jun 17, 1983	
HYPAQUE-76				
GE HEALTHCARE	66%;10%	A086505 001		
HYPAQUE-M,75%				
GE HEALTHCARE	50%;25%	N010220 003		
HYPAQUE-M,90%				
GE HEALTHCARE	60%;30%	N010220 002		

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE;INJECTION					
MD-60					
	MALLINCKRODT	52%;8%	A087074	001	
MD-76					
	MALLINCKRODT	66%;10%	A087073	001	
MD-76R					
+	LIEBEL-FLARSHEIM	66%;10%	N019292	001	Sep 29, 1989
RENOCAL-76					
	BRACCO	66%;10%	A089347	001	Jun 01, 1988
RENOGRAFIN-60					
	BRACCO	52%;8%	N010040	006	
RENOGRAFIN-76					
+	BRACCO	66%;10%	N010040	001	
RENOVIST					
	BRACCO	34.3%;35%	N010040	020	
RENOVIST II					
	BRACCO	28.5%;29.1%	N010040	019	
SOLUTION;ORAL, RECTAL					
GASTROVIST					
	BAYER HLTHCARE	66%;10%	A087728	001	Sep 23, 1982

DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

SOLUTION;INTRAUTERINE					
SINOGRAFIN					
+	BRACCO	52.7%;26.8%	N011324	002	

DIATRIZOATE SODIUM

FOR SOLUTION;ORAL, RECTAL					
HYPAQUE					
	GE HEALTHCARE	100%	N011386	001	
INJECTABLE;INJECTION					
HYPAQUE					
	GE HEALTHCARE	25%	N009561	003	
		50%	N009561	001	
MD-50					
	MALLINCKRODT	50%	A087075	001	
UROVIST SODIUM 300					
	BAYER HLTHCARE	50%	A087725	001	Sep 23, 1982
SOLUTION;ORAL, RECTAL					
HYPAQUE					
	GE HEALTHCARE	40%	N011386	003	
SOLUTION;URETERAL					
HYPAQUE SODIUM 20%					
	GE HEALTHCARE	20%	N009561	002	

DIAZEPAM

CAPSULE, EXTENDED RELEASE;ORAL					
VALRELEASE					
	ROCHE	15MG	N018179	001	
GEL;RECTAL					
DIASTAT					
+	VALEANT PHARMS NORTH	5MG/ML (5MG/ML) **	N020648	002	Jul 29, 1997
+		10MG/2ML (5MG/ML) **	N020648	003	Jul 29, 1997
+		15MG/3ML (5MG/ML) **	N020648	004	Jul 29, 1997
+		20MG/4ML (5MG/ML) **	N020648	005	Jul 29, 1997
INJECTABLE;INJECTION					
DIAZEPAM					
	ABRAXIS PHARM	5MG/ML	A070662	001	Jun 25, 1986
	HOSPIRA	5MG/ML	A071584	001	Oct 13, 1987
	MARSAM PHARMS LLC	5MG/ML	A072371	001	Jan 29, 1993
	PARENTA PHARMS	5MG/ML	A076815	001	Apr 15, 2004
	US ARMY	5MG/ML **	N020124	001	Dec 05, 1990
	WARNER CHILCOTT	5MG/ML	A071613	001	Oct 22, 1987
		5MG/ML	A071614	001	Oct 22, 1987
	WATSON LABS	5MG/ML	A070296	001	Feb 12, 1986
		5MG/ML	A070911	001	Aug 28, 1986
		5MG/ML	A070912	001	Aug 28, 1986
		5MG/ML	A070930	001	Dec 01, 1986
	WATSON LABS INC	5MG/ML	A072370	001	Jan 29, 1993
		5MG/ML	A072397	001	Jan 29, 1993

DIAZEPAM					
INJECTABLE;INJECTION					
DIAZEPAM					
	WEST-WARD PHARMS INT	5MG/ML	A070311	001	Dec 16, 1985
		5MG/ML	A070312	001	Dec 16, 1985
		5MG/ML	A070313	001	Dec 16, 1985
		5MG/ML	A071308	001	Jul 17, 1987
		5MG/ML	A071309	001	Jul 17, 1987
		5MG/ML	A071310	001	Jul 17, 1987
DIZAC					
	PHARMACIA AND UPJOHN	5MG/ML **	N019287	001	Jun 18, 1993
VALIUM					
+	ROCHE	5MG/ML **	N016087	001	
TABLET;ORAL					
DIAZEPAM					
	ACTAVIS ELIZABETH	2MG	A070781	001	Mar 19, 1986
		5MG	A070706	001	Mar 19, 1986
		10MG	A070707	001	Mar 19, 1986
	DAVA PHARMS INC	2MG	A070228	002	Sep 26, 1985
		5MG	A070228	003	Sep 26, 1985
		10MG	A070228	001	Sep 26, 1985
	DURAMED PHARMS BARR	2MG	A070894	001	Aug 27, 1986
		5MG	A070895	001	Aug 27, 1986
		10MG	A070896	001	Aug 27, 1986
	FERNDALE LABS	2MG	A070903	001	Apr 01, 1987
		5MG	A070904	001	Apr 01, 1987
		10MG	A070905	001	Apr 01, 1987
	HALSEY	2MG	A070987	001	Aug 15, 1986
		5MG	A070996	001	Aug 15, 1986
		10MG	A070956	001	Aug 15, 1986
	IVAX SUB TEVA PHARMS	2MG	A070360	001	Sep 04, 1985
		5MG	A070361	001	Sep 04, 1985
		10MG	A070362	001	Sep 04, 1985
	MARTEC USA LLC	10MG	A072402	001	Apr 25, 1989
	PIONEER PHARMS	2MG	A070787	001	Aug 02, 1988
		5MG	A070788	001	Aug 02, 1988
		10MG	A070776	001	Aug 02, 1988
	ROXANE	2MG	A070356	001	Jun 17, 1986
		5MG	A070357	001	Jun 17, 1986
		10MG	A070358	001	Jun 17, 1986
	TEVA PHARMS	5MG	A070153	001	Nov 01, 1985
	UPSHER SMITH LABS	2MG	A070302	001	Dec 20, 1985
		5MG	A070303	001	Dec 20, 1985
		10MG	A070304	001	Dec 20, 1985
	VIRTUS PHARMS	2MG	A070462	001	Feb 25, 1986
		5MG	A070463	001	Feb 25, 1986
		10MG	A070464	001	Feb 25, 1986
	WARNER CHILCOTT	2MG	A070209	001	Sep 04, 1985
		5MG	A070210	001	Sep 04, 1985
		10MG	A070222	001	Sep 04, 1985
	WATSON LABS	2MG	A070456	001	Nov 01, 1985
		5MG	A070457	001	Nov 01, 1985
		10MG	A070458	001	Nov 01, 1985
Q-PAM					
	QUANTUM PHARMICS	2MG	A070423	001	Dec 12, 1985
		2MG	A072431	001	Apr 29, 1988
		5MG	A070424	001	Dec 12, 1985
		5MG	A072432	001	Apr 29, 1988
		10MG	A070425	001	Dec 12, 1985
		10MG	A072433	001	Apr 29, 1988
DIAZOXIDE					
CAPSULE;ORAL					
PROGLYCEM					
	TEVA BRANDED PHARM	50MG	N017425	001	
		100MG	N017425	002	
INJECTABLE;INJECTION					
DIAZOXIDE					
	ABRAXIS PHARM	15MG/ML	A071519	001	Aug 26, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DIAZOXIDE				
INJECTABLE;INJECTION				
HYPERSTAT				
SCHERING	15MG/ML	N016996	001	
DIBUCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
HEAVY SOLUTION NUPERCAINE				
NOVARTIS	2.5MG/ML	N006203	001	
DICHLORPHENAMIDE				
TABLET;ORAL				
DARANIDE				
+ STRONGBRIDGE US	50MG **	N011366	001	
DICLOFENAC POTASSIUM				
TABLET;ORAL				
CATAFLAM				
+ NOVARTIS	25MG **	N020142	001	Nov 24, 1993
	50MG **	N020142	002	Nov 24, 1993
DICLOFENAC POTASSIUM				
SANDOZ	50MG	A075582	001	Feb 23, 2001
SUN PHARM INDUSTRIES	50MG	A075470	001	Feb 21, 2002
WATSON LABS TEVA	50MG	A075152	001	Nov 27, 1998
DICLOFENAC SODIUM				
SOLUTION;INTRAVENOUS				
DYLOJECT				
+ JAVELIN PHARMS INC	37.5MG/ML (37.5MG/ML)	N022396	001	Dec 23, 2014
SOLUTION;TOPICAL				
PENNSAID				
+ NUVO PHARMS INC	1.5% **	N020947	001	Nov 04, 2009
SOLUTION/DROPS;OPHTHALMIC				
DICLOFENAC SODIUM				
APOTEX INC	0.1%	A077600	001	Nov 13, 2008
FALCON PHARMS	0.1%	N020809	001	May 04, 1998
TABLET, DELAYED RELEASE;ORAL				
DICLOFENAC SODIUM				
ALLIED	50MG	A074986	001	Feb 26, 1999
	75MG	A074986	002	Feb 26, 1999
PLIVA	50MG	A074432	002	Jul 29, 1999
	75MG	A074432	003	Jul 29, 1999
ROXANE	25MG	A074391	001	Jun 29, 1995
	50MG	A074391	002	Jun 29, 1995
	75MG	A074391	003	Jun 29, 1995
TEVA	50MG	A074723	001	Mar 30, 1999
	75MG	A074390	001	Aug 15, 1996
TEVA PHARMS	25MG	A074459	001	Jun 25, 1997
	50MG	A074459	002	Jun 25, 1997
	75MG	A074459	003	Jun 25, 1997
VOLTAREN				
+ NOVARTIS	25MG **	N019201	001	Jul 28, 1988
+	50MG **	N019201	002	Jul 28, 1988
+	75MG **	N019201	003	Jul 28, 1988
TABLET, EXTENDED RELEASE;ORAL				
DICLOFENAC SODIUM				
ACTAVIS ELIZABETH	100MG	A075910	001	Jan 07, 2002
VOLTAREN-XR				
+ NOVARTIS	100MG **	N020254	001	Mar 08, 1996
DICLOXACILLIN SODIUM				
CAPSULE;ORAL				
DYCILL				
GLAXOSMITHKLINE	EQ 250MG BASE	A060254	002	
	EQ 250MG BASE	A062238	001	
	EQ 500MG BASE	A060254	003	
	EQ 500MG BASE	A062238	002	
PATHOCIL				
WYETH AYERST	EQ 250MG BASE	N050011	002	
	EQ 500MG BASE	N050011	003	Mar 28, 1983

DICLOXACILLIN SODIUM				
FOR SUSPENSION;ORAL				
DICLOXACILLIN SODIUM				
APOTHECON	EQ 62.5MG BASE/5ML	A061455 001		
DYNAPEN				
APOTHECON	EQ 62.5MG BASE/5ML	N050337 002		
PATHOCIL				
WYETH AYERST	EQ 62.5MG BASE/5ML	N050092 001		
DICUMAROL				
CAPSULE;ORAL				
DICUMAROL				
LILLY	25MG	N005509 003		
	50MG	N005509 001		
TABLET;ORAL				
DICUMAROL				
ABBVIE	25MG	N005545 003		
	50MG	N005545 004		
	100MG	N005545 005		
DICYCLOMINE HYDROCHLORIDE				
CAPSULE;ORAL				
DICYCLOMINE HYDROCHLORIDE				
PIONEER PHARMS	10MG	A089361 001	Jan 10, 1989	
SUN PHARM INDUSTRIES	10MG	A084505 001	Oct 21, 1986	
WATSON LABS	10MG	A083179 001	Feb 12, 1986	
INJECTABLE;INJECTION				
DICYCLOMINE HYDROCHLORIDE				
WATSON LABS	10MG/ML	A080614 001	Feb 11, 1986	
SYRUP;ORAL				
BENTYL				
+ APTALIS PHARMA US	10MG/5ML **	N007961 002	Oct 15, 1984	
DICYCLOMINE HYDROCHLORIDE				
ALPHARMA US PHARMS	10MG/5ML	A084479 001		
TABLET;ORAL				
DICYCLOMINE HYDROCHLORIDE				
PIONEER PHARMS	20MG	A088585 001	Aug 20, 1986	
SUN PHARM INDUSTRIES	20MG	A084600 001	Jul 29, 1985	
WATSON LABS	20MG	A084361 001	Feb 06, 1986	
DIDANOSINE				
CAPSULE, DELAYED REL PELLETS;ORAL				
DIDANOSINE				
BARR	200MG	A077167 001	Dec 03, 2004	
	250MG	A077167 002	Dec 03, 2004	
	400MG	A077167 003	Dec 03, 2004	
MYLAN PHARMS INC	125MG	A090788 001	Apr 08, 2010	
	200MG	A090788 002	Apr 08, 2010	
	250MG	A090788 003	Apr 08, 2010	
	400MG	A090788 004	Apr 08, 2010	
FOR SOLUTION;ORAL				
DIDANOSINE				
AUROBINDO PHARMA	10MG/ML	A078112 001	Mar 08, 2007	
VIDEX				
BRISTOL MYERS SQUIBB	100MG/PACKET	N020155 003	Oct 09, 1991	
	167MG/PACKET	N020155 004	Oct 09, 1991	
	250MG/PACKET	N020155 005	Oct 09, 1991	
	375MG/PACKET	N020155 006	Oct 09, 1991	
TABLET, CHEWABLE;ORAL				
VIDEX				
+ BRISTOL MYERS SQUIBB	25MG **	N020154 002	Oct 09, 1991	
+	50MG **	N020154 003	Oct 09, 1991	
+	100MG **	N020154 004	Oct 09, 1991	
+	150MG **	N020154 005	Oct 09, 1991	
+	200MG **	N020154 006	Oct 28, 1999	
TABLET, FOR SUSPENSION;ORAL				
DIDANOSINE				
AUROBINDO	100MG	A077275 001	Aug 14, 2012	
	150MG	A077275 002	Aug 14, 2012	
	200MG	A077275 003	Aug 14, 2012	

DIENESTROL

CREAM;VAGINAL			
DIENESTROL			
ORTHO MCNEIL PHARM	0.01%	N006110 005	
DV			
SANOFI AVENTIS US	0.01%	A083518 001	
ESTRAGUARD			
SOLVAY	0.01%	A084436 001	
SUPPOSITORY;VAGINAL			
DV			
SANOFI AVENTIS US	0.7MG	A083517 001	

DIETHYLCARBAMAZINE CITRATE

TABLET;ORAL			
HETRAZAN			
LEDERLE	50MG	N006459 001	

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL			
DIETHYLPROPION HYDROCHLORIDE			
CHARTWELL RX	25MG	A088267 001	Aug 25, 1983
	25MG	A088268 001	Aug 25, 1983
EPIC PHARMA LLC	25MG	A040828 001	Nov 05, 2008
SANDOZ	25MG	A085916 001	
TEVA	25MG	A088642 001	Sep 20, 1984
UCB INC	25MG	A085544 001	
WATSON LABS	25MG	A085741 001	
TENUATE			
SANOFI AVENTIS US	25MG	N017668 001	
TEPANIL			
3M	25MG	N011673 001	
TABLET, EXTENDED RELEASE;ORAL			
TENUATE			
SANOFI AVENTIS US	75MG	N017669 001	
TEPANIL TEN-TAB			
3M	75MG	N017956 001	

DIETHYLSTILBESTROL

INJECTABLE;INJECTION			
STILBESTROL			
BRISTOL MYERS SQUIBB	0.2MG/ML	N004056 003	
	0.5MG/ML	N004056 004	
	1MG/ML	N004056 005	
	5MG/ML	N004056 006	
SUPPOSITORY;VAGINAL			
DIETHYLSTILBESTROL			
LILLY	0.1MG	N004040 001	
	0.5MG	N004040 002	
STILBESTROL			
BRISTOL MYERS SQUIBB	0.1MG	N004056 001	
	0.5MG	N004056 002	
TABLET;ORAL			
DIETHYLSTILBESTROL			
LILLY	0.1MG	N004041 002	
	0.5MG	N004041 003	
	1MG	N004041 004	
	5MG	N004041 005	
STILBESTROL			
TABLICAPS	0.5MG	A083004 001	
	1MG	A083002 001	
	5MG	A083006 001	
STILBETIN			
BRISTOL MYERS SQUIBB	0.1MG	N004056 007	
	0.25MG	N004056 017	
	0.5MG	N004056 008	
	1MG	N004056 009	
	5MG	N004056 010	
TABLET, DELAYED RELEASE;ORAL			
DIETHYLSTILBESTROL			
LILLY	0.1MG	N004039 002	
	0.25MG	N004039 005	

DIETHYLSTILBESTROL				
TABLET, DELAYED RELEASE;ORAL				
DIETHYLSTILBESTROL				
	0.5MG		N004039 003	
	1MG		N004039 004	
	5MG		N004039 006	
STILBESTROL				
TABLICAPS	0.5MG		A083003 001	
	1MG		A083005 001	
	5MG		A083007 001	
STILBETIN				
BRISTOL MYERS SQUIBB	0.1MG		N004056 011	
	0.5MG		N004056 012	
	1MG		N004056 013	
	5MG		N004056 014	
DIETHYLSTILBESTROL DIPHOSPHATE				
INJECTABLE;INJECTION				
STILPHOSTROL				
BAYER PHARMS	250MG/5ML		N010010 001	
TABLET;ORAL				
STILPHOSTROL				
BAYER PHARMS	50MG		N010010 002	
DIFLORASONE DIACETATE				
CREAM;TOPICAL				
DIFLORASONE DIACETATE				
FOUGERA PHARMS	0.05%		A075187 001	Mar 30, 1998
FLORONE				
PHARMACIA AND UPJOHN	0.05% **		N017741 001	
FLORONE E				
PHARMACIA AND UPJOHN	0.05%		N019259 001	Aug 28, 1985
PSORCON				
+ TARO PHARMS NORTH	0.05% **		N020205 001	Nov 20, 1992
OINTMENT;TOPICAL				
PSORCON				
+ PHARMACIA AND UPJOHN	0.05%		N019260 001	Aug 28, 1985
PSORCON E				
PHARMACIA AND UPJOHN	0.05%		N017994 001	
DIFLUNISAL				
TABLET;ORAL				
DIFLUNISAL				
ANI PHARMS INC	500MG		A074604 001	Jun 10, 1996
PUREPAC PHARM	250MG		A074285 001	May 07, 1996
	500MG		A074285 002	May 07, 1996
SOCORRO	250MG		A073562 001	Nov 27, 1992
	500MG		A073563 001	Nov 27, 1992
TEVA	250MG		A073679 001	Jul 31, 1992
WATSON LABS	250MG		A074400 001	Jul 17, 1997
	500MG		A074400 002	Jul 17, 1997
DOLOBID				
+ MERCK	250MG **		N018445 001	Apr 19, 1982
+	500MG **		N018445 002	Apr 19, 1982
DIGITOXIN				
INJECTABLE;INJECTION				
CRYSTODIGIN				
LILLY	0.2MG/ML		A084100 005	
DIGOXIN				
CAPSULE;ORAL				
LANOXICAPS				
GLAXOSMITHKLINE LLC	0.05MG		N018118 002	Jul 26, 1982
	0.1MG		N018118 003	Jul 26, 1982
	0.15MG		N018118 004	Sep 24, 1984
	0.2MG		N018118 001	Jul 26, 1982
INJECTABLE;INJECTION				
DIGOXIN				
ABRAXIS PHARM	0.25MG/ML		A083217 001	
HOSPIRA	0.25MG/ML		A040093 001	May 16, 1996
	0.25MG/ML		A040206 001	Aug 28, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DIGOXIN				
INJECTABLE;INJECTION				
DIGOXIN				
	WYETH AYERST	0.25MG/ML	A084386 001	
DIGOXIN PEDIATRIC				
	HOSPIRA	0.1MG/ML	A040092 001	Apr 25, 1996
TABLET;ORAL				
LANOXIN				
+	CONCORDIA PHARMS INC	0.1875MG	N020405 003	Sep 30, 1997
		0.375MG	N020405 005	Sep 30, 1997
		0.5MG	N020405 006	Sep 30, 1997
DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
EMBOLEX				
	NOVARTIS	0.5MG/0.5ML;2,500 UNITS/0.5ML;5.33MG/0.5ML	N018885 001	Nov 30, 1984
		0.5MG/0.7ML;5,000 UNITS/0.7ML;7.46MG/0.7ML	N018885 002	Nov 30, 1984
DILTIAZEM HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
CARDIZEM SR				
+	BIOVAIL	60MG **	N019471 001	Jan 23, 1989
+		90MG **	N019471 002	Jan 23, 1989
+		120MG **	N019471 003	Jan 23, 1989
+		180MG **	N019471 004	Jan 23, 1989
DILACOR XR				
+	ALLERGAN SALES LLC	120MG **	N020092 001	May 29, 1992
+		180MG **	N020092 002	May 29, 1992
+		240MG **	N020092 003	May 29, 1992
DILT-CD				
	APOTEX	120MG	A076151 001	May 20, 2004
		180MG	A076151 002	May 20, 2004
		240MG	A076151 003	May 20, 2004
		300MG	A076151 004	May 20, 2004
DILTIAZEM HYDROCHLORIDE				
	ACTAVIS LABS FL INC	120MG	A074852 001	Oct 10, 1997
		180MG	A074852 002	Oct 10, 1997
		240MG	A074852 003	Oct 10, 1997
	BIOVAIL	60MG	A074845 001	Sep 15, 1999
		90MG	A074845 002	Sep 15, 1999
		120MG	A074845 003	Sep 15, 1999
		120MG	N020939 001	Jan 28, 2000
		180MG	N020939 002	Jan 28, 2000
		240MG	N020939 003	Jan 28, 2000
		300MG	N020939 004	Jan 28, 2000
		360MG	N020939 005	Sep 14, 2001
		420MG	N020939 006	Sep 14, 2001
	NESHER PHARMS	120MG	A076563 002	Sep 12, 2006
		180MG	A076563 003	Sep 12, 2006
		240MG	A076563 004	Sep 12, 2006
		300MG	A076563 005	Sep 12, 2006
		360MG	A076563 006	Sep 12, 2006
		420MG	A076563 001	Sep 12, 2006
	TEVA	60MG	A074079 001	Nov 30, 1993
		90MG	A074079 002	Nov 30, 1993
		120MG	A074079 003	Nov 30, 1993
INJECTABLE;INJECTION				
CARDIZEM				
	BIOVAIL	100MG/VIAL **	N020792 001	Sep 05, 1997
+	BIOVAIL LABS INTL	5MG/ML **	N020027 001	Oct 24, 1991
+		25MG/VIAL **	N020027 003	Aug 18, 1995
DILTIAZEM HYDROCHLORIDE				
	HOSPIRA	5MG/ML	A075004 001	Feb 16, 2000
		5MG/ML	A075106 001	Apr 29, 1999
	MYLAN LABS LTD	5MG/ML	A075375 001	Sep 30, 1999
	TEVA PHARMS USA	5MG/ML	A074894 001	Aug 26, 1997

DILTIAZEM HYDROCHLORIDE

TABLET;ORAL

DILTIAZEM HYDROCHLORIDE

APOTHECON	30MG	A074051	001	Mar 31, 1993
	60MG	A074051	002	Mar 31, 1993
	90MG	A074051	003	Mar 31, 1993
	120MG	A074051	004	Mar 31, 1993
CHARTWELL MOLECULES	30MG	A074093	001	Nov 05, 1992
	60MG	A074093	002	Nov 05, 1992
	90MG	A074093	003	Nov 05, 1992
	120MG	A074093	004	Nov 05, 1992
IVAX SUB TEVA PHARMS	30MG	A074168	001	Mar 03, 1995
	60MG	A074168	002	Mar 03, 1995
	90MG	A074168	003	Mar 03, 1995
	120MG	A074168	004	Mar 03, 1995
TEVA	30MG	A074084	001	Feb 25, 1994
	60MG	A074084	002	Feb 25, 1994
TEVA PHARMS	30MG	A074067	001	Nov 05, 1992
	60MG	A074067	002	Nov 05, 1992
	90MG	A074067	003	Nov 05, 1992
	120MG	A074067	004	Nov 05, 1992

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE;ORAL

TIAMATE

MERCK	EQ 120MG HYDROCHLORIDE	N020506	001	Oct 04, 1996
	EQ 180MG HYDROCHLORIDE	N020506	002	Oct 04, 1996
	EQ 240MG HYDROCHLORIDE	N020506	003	Oct 04, 1996

DILTIAZEM MALATE; ENALAPRIL MALEATE

TABLET, EXTENDED RELEASE;ORAL

TECZEM

BIOVAIL	EQ 180MG HYDROCHLORIDE;5MG	N020507	001	Oct 04, 1996

DIMENHYDRINATE

INJECTABLE;INJECTION

DIMENHYDRINATE

BAXTER HLTHCARE	50MG/ML	A084767	001
WATSON LABS	50MG/ML	A083531	001
WATSON LABS TEVA	50MG/ML	A080615	001
WYETH AYERST	50MG/ML	A084316	001

LIQUID;ORAL

DIMENHYDRINATE

ALRA	12.5MG/4ML	A080715	001

TABLET;ORAL

DIMENHYDRINATE

HEATHER	50MG	A080841	001
NEXGEN PHARMA INC	50MG	A085985	001
WATSON LABS	50MG	A085166	001

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE;INTRAVENOUS

IMAGENT

VESSELON SPV LLC	0.92MG/VIAL;0.092MG/VIAL	N021191	001	May 31, 2002

DINOPROST TROMETHAMINE

INJECTABLE;INJECTION

PROSTIN F2 ALPHA

PHARMACIA AND UPJOHN	EQ 5MG BASE/ML	N017434	001

DIPHEMANIL METHYLSULFATE

TABLET;ORAL

PRANTAL

SCHERING	100MG	N008114	004	

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL

BENADRYL

MCNEIL CONS	25MG	N005845	007	
	50MG	N005845	001	

DIPHENHYDRAMINE HYDROCHLORIDE

ALRA	25MG	A080519	004	
	50MG	A080519	003	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL				
DIPHENHYDRAMINE HYDROCHLORIDE				
ANABOLIC	50MG	A083275	001	
ELKINS SINN	25MG	A085701	001	
	50MG	A085701	002	
FOSUN PHARMA	25MG	A080832	001	
	25MG	A080845	002	
	50MG	A080832	002	
	50MG	A080845	001	
HALSEY	50MG	A087914	001	Jun 04, 1984
HEATHER	25MG	A084524	001	
	50MG	A083953	001	
HIKMA INTL PHARMS	50MG	A083567	001	
IMPAX LABS	25MG	A080807	001	
	50MG	A080807	002	
IVAX SUB TEVA PHARMS	25MG	A080762	001	
	50MG	A080762	002	
LANNETT	25MG	A080868	001	
	50MG	A080868	002	
LEDERLE	25MG	A086874	001	
	50MG	A086875	001	
LNK	25MG	A087977	001	Jan 27, 1983
	50MG	A087978	001	Jan 27, 1983
MK LABS	25MG	A083087	001	
	50MG	A083087	002	
MUTUAL PHARM	25MG	A084506	001	
NEWTRON PHARMS	25MG	A086543	001	
	50MG	A086544	001	
NEXGEN PHARMA INC	25MG	A083634	001	
PERRIGO	25MG	A083061	001	
	50MG	A083061	002	
PIONEER PHARMS	25MG	A089101	001	Dec 20, 1985
	50MG	A088880	001	Dec 20, 1985
PUREPAC PHARM	25MG	A085156	001	
	50MG	A085150	001	
PVT FORM	25MG	A083027	001	
	50MG	A083027	002	
ROXANE	50MG	A080635	001	
SUN PHARM INDUSTRIES	25MG	A089488	001	Jan 02, 1987
	50MG	A089489	001	Jan 02, 1987
SUPERPHARM	25MG	A089040	001	May 15, 1985
	50MG	A089041	001	May 15, 1985
TEVA	25MG	A085874	001	
	50MG	A085874	002	
VALEANT PHARM INTL	25MG	A080596	001	
	50MG	A080592	001	
VANGARD	25MG	A088034	001	Oct 27, 1982
	50MG	A087630	001	
WATSON LABS	25MG	A080728	001	
	25MG	A083797	001	
	25MG	A085138	001	
	50MG	A080727	001	
	50MG	A083797	002	
	50MG	A085083	001	
WHITEWORTH TOWN PLSN	25MG	A083441	001	
	50MG	A080800	001	
ELIXIR;ORAL				
BELIX				
HALSEY	12.5MG/5ML	A086586	001	Oct 03, 1983
BENADRYL				
MCNEIL CONS	12.5MG/5ML	N005845	004	
DIBENIL				
CENCI	12.5MG/5ML	A088304	001	Dec 16, 1983
DIPHEN				
USL PHARMA	12.5MG/5ML	A084640	001	
DIPHENHYDRAMINE HYDROCHLORIDE				
BUNDY	12.5MG/5ML	A083674	001	
CENCI	12.5MG/5ML	A087941	001	Dec 17, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR;ORAL				
DIPHENHYDRAMINE HYDROCHLORIDE				
	KV PHARM	12.5MG/5ML	A085621 001	
	LANNETT	12.5MG/5ML	A080939 002	
	LEDERLE	12.5MG/5ML	A086937 001	
	MK LABS	12.5MG/5ML	A083088 002	
	NASKA	12.5MG/5ML	A088680 001	May 31, 1985
	PERRIGO	12.5MG/5ML	A083063 001	
	PUREPAC PHARM	12.5MG/5ML	A083237 001	Jan 25, 1982
	PVT FORM	12.5MG/5ML	A085287 001	
	ROXANE	12.5MG/5ML	A080643 001	
HYDRAMINE				
	ALPHARMA US PHARMS	12.5MG/5ML	A080763 002	
INJECTABLE;INJECTION				
BENADRYL				
	MCNEIL CONS	10MG/ML	N006146 001	
+		50MG/ML **	N006146 002	
BENADRYL PRESERVATIVE FREE				
+	MCNEIL CONS	50MG/ML **	N009486 001	
DIPHENHYDRAMINE HYDROCHLORIDE				
	BEL MAR	10MG/ML	A080822 001	
	EUROHLTH INTL SARL	50MG/ML	A083183 001	
	LYPHOMED	10MG/ML	A087066 001	
	WATSON LABS	10MG/ML	A083533 001	
	WATSON LABS TEVA	10MG/ML	A080873 001	
		50MG/ML	A080873 002	
	WYETH AYERST	50MG/ML	A080577 001	
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE				
	ABRAXIS PHARM	50MG/ML	A080586 002	
	INTL MEDICATION	50MG/ML	A084094 001	
	WATSON LABS TEVA	50MG/ML	A080873 003	
SYRUP;ORAL				
ANTITUSSIVE				
	PERRIGO	12.5MG/5ML	A071292 001	Apr 10, 1987
BELDIN				
	HALSEY	12.5MG/5ML	A089179 001	Jun 05, 1986
BENYLIN				
	PARKE DAVIS	12.5MG/5ML	N006514 004	
DIPHEN				
	MORTON GROVE	12.5MG/5ML	A070118 001	Oct 01, 1985
DIPHENHYDRAMINE HYDROCHLORIDE				
	ALPHARMA US PHARMS	12.5MG/5ML	A070497 001	Apr 25, 1989
	CUMBERLAND SWAN	12.5MG/5ML	A073611 001	Aug 20, 1992
	HI TECH PHARMA	12.5MG/5ML	A072416 001	Sep 28, 1990
HYDRAMINE				
	ALPHARMA US PHARMS	12.5MG/5ML	A070205 001	Jan 28, 1986
SILPHEN				
	LANNETT CO INC	12.5MG/5ML	A072646 001	Feb 27, 1992
VICKS FORMULA 44				
	WARNER CHILCOTT	12.5MG/5ML	A070524 001	Jan 14, 1987

DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL				
BENYLIN				
	PARKE DAVIS	12.5MG/5ML;30MG/5ML	N019014 001	Jun 11, 1985

DIPHENIDOL HYDROCHLORIDE

TABLET;ORAL				
VONTROL				
	GLAXOSMITHKLINE	EQ 25MG BASE	N016033 001	

DIPHENYLPYRALINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
HISPRIL				
	GLAXOSMITHKLINE	5MG	N011945 001	

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC				
AKPRO				
AKORN	0.1%	A074382	001	Sep 29, 1995
DIPIVEFRIN HYDROCHLORIDE				
BAUSCH AND LOMB	0.1%	A074188	001	May 19, 1995
FALCON PHARMS	0.1%	A073636	001	Jun 30, 1994
PROPINE				
ALLERGAN	0.1%	N018239	001	

DIPYRIDAMOLE

INJECTABLE;INJECTION				
DIPYRIDAMOLE				
HOSPIRA	5MG/ML	A074601	001	Dec 19, 1997
MYLAN LABS LTD	5MG/ML	A075769	001	Nov 27, 2002
TEVA PHARMS USA	5MG/ML	A074952	001	Nov 26, 1997
IV PERSANTINE				
+ BOEHRINGER INGELHEIM	5MG/ML **	N019817	001	Dec 13, 1990
TABLET;ORAL				
DIPYRIDAMOLE				
ANI PHARMS INC	25MG	A086944	002	Apr 16, 1991
	50MG	A086944	001	Feb 25, 1992
	75MG	A086944	003	Feb 25, 1992
GLENMARK GENERICS	25MG	A088999	001	Feb 05, 1991
	50MG	A089000	001	Feb 05, 1991
	75MG	A089001	001	Feb 05, 1991
LANNETT CO INC	25MG	A040898	001	Apr 23, 2008
	50MG	A040898	002	Apr 23, 2008
	75MG	A040898	003	Apr 23, 2008
OXFORD PHARMS	25MG	A040542	001	Apr 21, 2006
	50MG	A040542	002	Apr 21, 2006
	75MG	A040542	003	Apr 21, 2006
PUREPAC PHARM	25MG	A089425	001	Jul 12, 1990
	50MG	A089426	001	Jul 12, 1990
	75MG	A089427	001	Jul 12, 1990
WATSON LABS	50MG	A087160	001	Jun 07, 1996

DIRITHROMYCIN

TABLET, DELAYED RELEASE;ORAL				
DYNABAC				
LILLY RES LABS	250MG	N050678	001	Jun 19, 1995

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL				
DISOPYRAMIDE PHOSPHATE				
AUROLIFE PHARMA LLC	EQ 100MG BASE	A070470	001	Dec 10, 1985
	EQ 150MG BASE	A070471	001	Dec 10, 1985
INTERPHARM	EQ 100MG BASE	A071190	001	Jan 15, 1987
	EQ 150MG BASE	A071191	001	Jan 15, 1987
IVAX SUB TEVA PHARMS	EQ 100MG BASE	A070186	001	Nov 18, 1985
	EQ 150MG BASE	A070187	001	Nov 18, 1985
MYLAN	EQ 100MG BASE	A070138	001	Jun 14, 1985
	EQ 150MG BASE	A070139	001	Jun 14, 1985
SUN PHARM INDUSTRIES	EQ 100MG BASE	A070351	001	Dec 17, 1985
	EQ 150MG BASE	A070352	001	Dec 17, 1985
SUPERPHARM	EQ 100MG BASE	A070940	001	Feb 09, 1987
	EQ 150MG BASE	A070941	001	Feb 09, 1987
WATSON LABS	EQ 100MG BASE	A070240	001	Feb 02, 1986
	EQ 150MG BASE	A070241	001	Feb 02, 1986
CAPSULE, EXTENDED RELEASE;ORAL				
DISOPYRAMIDE PHOSPHATE				
NESHER PHARMS	EQ 150MG BASE	A071200	001	Dec 15, 1987

DISULFIRAM

TABLET;ORAL				
ANTABUSE				
+ TEVA WOMENS	250MG **	N007883	003	
+	500MG **	N007883	002	
DISULFIRAM				
PAR PHARM	250MG	A088792	001	Aug 14, 1984
	500MG	A088793	001	Aug 14, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISULFIRAM

TABLET;ORAL

DISULFIRAM				
WATSON LABS	250MG	A086889	001	
	250MG	A087973	001	Aug 05, 1983
	500MG	A087974	001	Aug 05, 1983
WATSON LABS TEVA	500MG	A086890	001	

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DEPAKOTE CP				
ABBOTT	EQ 250MG BASE	N019794	001	Jul 11, 1990
	EQ 500MG BASE	N019794	002	Jul 11, 1990
DIVALPROEX SODIUM				
MYLAN	EQ 125MG VALPROIC ACID	A077254	001	Jul 29, 2008
	EQ 250MG VALPROIC ACID	A077254	002	Jul 29, 2008
	EQ 500MG VALPROIC ACID	A077254	003	Jul 29, 2008

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM				
G AND W LABS INC	EQ 500MG VALPROIC ACID	A078700	001	Aug 03, 2009

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE				
BAXTER HLTHCARE	EQ 12.5MG BASE/ML	A074381	001	Sep 26, 1996
HOSPIRA	EQ 1.25GM BASE/100ML	A074634	001	Sep 27, 1996
LUITPOLD	EQ 12.5MG BASE/ML	A074545	001	Jun 25, 1998
TELIGENT PHARMA INC	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995
TEVA PARENTERAL	EQ 12.5MG BASE/ML	A074206	001	Oct 19, 1993
WATSON LABS	EQ 12.5MG BASE/ML	A074114	001	Nov 30, 1993
WATSON LABS INC	EQ 12.5MG BASE/ML	A074279	001	Feb 18, 1998
	EQ 12.5MG BASE/ML	A074995	001	Mar 31, 1998
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%				
HOSPIRA	EQ 50MG BASE/100ML	N020269	001	Oct 19, 1993
	EQ 100MG BASE/100ML	N020269	002	Oct 19, 1993
	EQ 200MG BASE/100ML	N020269	003	Oct 19, 1993
DOBUTREX				
+ LILLY	EQ 12.5MG BASE/ML	N017820	002	

DOCETAXEL

INJECTABLE;INJECTION

DOCEFREZ				
+ SUN PHARMA GLOBAL	20MG/VIAL	N022534	001	May 03, 2011
+	80MG/VIAL	N022534	002	May 03, 2011
DOCETAXEL				
+ ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195	001	Jun 08, 2011
+	80MG/2ML (40MG/ML)	N201195	002	Jun 08, 2011
APOTEX INC	20MG/0.5ML (40MG/ML)	N022312	001	Jan 11, 2012
	80MG/2ML (40MG/ML)	N022312	002	Jan 11, 2012
+ HOSPIRA INC	120MG/6ML (20MG/ML)	N022234	006	Jun 23, 2016
PFIZER LABS	20MG/2ML (10MG/ML)	N202356	001	Mar 13, 2014
	80MG/8ML (10MG/ML)	N202356	002	Mar 13, 2014
	130MG/13ML (10MG/ML)	N202356	003	Mar 13, 2014
	200MG/20ML (10MG/ML)	N202356	004	Mar 13, 2014
TAXOTERE				
+ SANOFI AVENTIS US	40MG/ML **	N020449	001	May 14, 1996

DOLASETRON MESYLATE

INJECTABLE;INJECTION

ANZEMET				
+ US PHARM HOLDINGS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997
+	100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997
	500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001

TABLET;ORAL

ANZEMET				
+ US PHARM HOLDINGS	50MG	N020623	001	Sep 11, 1997
+	100MG	N020623	002	Sep 11, 1997

DONEPEZIL HYDROCHLORIDE

SOLUTION;ORAL				
ARICEPT				
	EISAI INC	5MG/5ML	N021719 001	Oct 18, 2004
TABLET;ORAL				
DONEPEZIL HYDROCHLORIDE				
	ACCORD HLTHCARE	5MG	A201335 001	Aug 29, 2011
		10MG	A201335 002	Aug 29, 2011
	APOTEX	5MG	A078841 001	Jun 02, 2011
		10MG	A078841 002	Jun 02, 2011
	HIKMA PHARMS	5MG	A090247 001	May 31, 2011
		10MG	A090247 002	May 31, 2011
	SUN PHARM INDS LTD	5MG	A076786 001	Nov 26, 2010
		10MG	A076786 002	Nov 26, 2010
TABLET, ORALLY DISINTEGRATING;ORAL				
ARICEPT ODT				
+	EISAI INC	5MG	N021720 001	Oct 18, 2004
+		10MG	N021720 002	Oct 18, 2004
DONEPEZIL HYDROCHLORIDE				
	BARR	5MG	A078388 002	Nov 26, 2010
		10MG	A078388 001	Nov 26, 2010
	SUN PHARM INDUSTRIES	5MG	A077975 002	Dec 11, 2009
		10MG	A077975 001	Dec 11, 2009
	ZYDUS PHARMS USA INC	5MG	A090175 001	May 10, 2011
		10MG	A090175 002	May 10, 2011

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE				
	AMNEAL PHARMS	10MG;14MG	A208328 001	Jan 27, 2017
		10MG;28MG	A208328 002	Jan 27, 2017

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION				
DOPAMINE HYDROCHLORIDE				
	ABBOTT	40MG/ML	A070656 001	Jan 24, 1989
		80MG/ML	A070657 001	Jan 24, 1989
	ABRAXIS PHARM	40MG/ML	A070012 001	Jun 12, 1985
		40MG/ML	A070058 001	Mar 20, 1985
		80MG/ML	A070013 001	Jun 12, 1985
		80MG/ML	A070059 001	Mar 20, 1985
		160MG/ML	A070364 001	Dec 04, 1985
	BAXTER HLTHCARE	40MG/ML	N018398 001	
		80MG/ML	N018398 002	Mar 22, 1982
	HOSPIRA	40MG/ML	A074403 001	May 23, 1996
	IGI LABS INC	40MG/ML	A070087 001	Oct 23, 1985
		80MG/ML	A070089 001	Oct 23, 1985
		80MG/ML	A070090 001	Oct 23, 1985
		80MG/ML	A070091 001	Oct 23, 1985
		160MG/ML	A070092 001	Oct 23, 1985
		160MG/ML	A070093 001	Oct 23, 1985
		160MG/ML	A070094 001	Oct 23, 1985
	INTL MEDICATION	40MG/ML	N018014 001	
	LUITPOLD	160MG/ML	A070826 001	Feb 11, 1987
	LYPHOMED	40MG/ML	N018549 001	Mar 11, 1983
	SMITH AND NEPHEW	40MG/ML	A070011 001	Aug 29, 1985
		40MG/ML	A070046 001	Aug 29, 1985
		80MG/ML	A070047 001	Aug 29, 1985
	TELIGENT	40MG/ML	N018656 001	Jun 28, 1983
	TEVA PARENTERAL	40MG/ML	A072999 001	Oct 23, 1991
		80MG/ML	A073000 001	Oct 23, 1991
	WARNER CHILCOTT	40MG/ML	A070558 001	Sep 20, 1985
		40MG/ML	N018138 001	
		80MG/ML	A070559 001	Sep 20, 1985
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5%				
	HOSPIRA	1.6MG/ML	N020542 001	Aug 30, 1995
INTROPIN				
	HOSPIRA	40MG/ML	N017395 001	
		80MG/ML	N017395 002	
		160MG/ML	N017395 003	

DORIPENEM

INJECTABLE;INTRAVENOUS

DORIBAX

+	SHIONOGI INC	250MG/VIAL	N022106 002	Oct 05, 2010
+		500MG/VIAL	N022106 001	Oct 12, 2007

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

APOTEX INC	EQ 2% BASE	A078395 001	Oct 28, 2008
TEVA PHARMS	EQ 2% BASE	A078756 001	Dec 04, 2008
WATSON LABS INC	EQ 2% BASE	A202053 001	Sep 11, 2014
ZAMBON SPA	EQ 2% BASE	A091034 001	Dec 04, 2013

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

APOTEX INC	EQ 2% BASE;EQ 0.5% BASE	A078201 001	Oct 28, 2008
LANNETT CO INC	EQ 2% BASE;EQ 0.5% BASE	A201998 001	Dec 17, 2014
WATSON LABS INC	EQ 2% BASE;EQ 0.5% BASE	A202054 001	Sep 03, 2014
ZAMBON SPA	EQ 2% BASE;EQ 0.5% BASE	A091180 001	Dec 04, 2013

DOXACURIUM CHLORIDE

INJECTABLE;INJECTION

NUROMAX

ABBVIE	EQ 1MG BASE/ML	N019946 001	Mar 07, 1991

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOXAPRAM HYDROCHLORIDE

WATSON LABS	20MG/ML	A073529 001	Jan 30, 1992

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

ACTAVIS ELIZABETH	EQ 1MG BASE	A075574 001	Oct 18, 2000
	EQ 2MG BASE	A075574 002	Oct 18, 2000
	EQ 4MG BASE	A075574 003	Oct 18, 2000
	EQ 8MG BASE	A075574 004	Oct 18, 2000
GENPHARM	EQ 1MG BASE	A075466 001	Oct 18, 2000
	EQ 2MG BASE	A075466 002	Oct 18, 2000
	EQ 4MG BASE	A075466 003	Oct 18, 2000
	EQ 8MG BASE	A075466 004	Oct 18, 2000
IVAX SUB TEVA PHARMS	EQ 1MG BASE	A075453 001	Oct 18, 2000
	EQ 2MG BASE	A075453 002	Oct 18, 2000
	EQ 4MG BASE	A075453 003	Oct 18, 2000
	EQ 8MG BASE	A075453 004	Oct 18, 2000
NESHER PHARMS	EQ 1MG BASE	A075609 001	Oct 18, 2000
	EQ 2MG BASE	A075609 002	Oct 18, 2000
	EQ 4MG BASE	A075609 003	Oct 18, 2000
	EQ 8MG BASE	A075609 004	Oct 18, 2000
TEVA	EQ 1MG BASE	A075353 001	Jan 12, 2001
	EQ 2MG BASE	A075353 002	Jan 12, 2001
	EQ 4MG BASE	A075353 003	Jan 12, 2001
	EQ 8MG BASE	A075353 004	Jan 12, 2001
WATSON LABS INC	EQ 1MG BASE	A075426 001	Oct 18, 2000
	EQ 2MG BASE	A075426 002	Oct 18, 2000
	EQ 4MG BASE	A075426 003	Oct 18, 2000
	EQ 8MG BASE	A075426 004	Oct 18, 2000
YAOPHARMA CO LTD	EQ 1MG BASE	A075646 001	Oct 18, 2000
	EQ 2MG BASE	A075646 002	Oct 18, 2000
	EQ 4MG BASE	A075646 003	Oct 18, 2000
	EQ 8MG BASE	A075646 004	Oct 18, 2000

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

DAVA PHARMS INC	EQ 10MG BASE	A071685 001	Jan 05, 1988
	EQ 25MG BASE	A071686 001	Jan 05, 1988
	EQ 50MG BASE	A071673 001	Jan 05, 1988
	EQ 75MG BASE	A071674 001	Jan 05, 1988
	EQ 100MG BASE	A071675 001	Jan 05, 1988

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL				
DOXEPIN HYDROCHLORIDE				
	EQ 150MG BASE	A071676	001	Jan 05, 1988
NEW RIVER	EQ 10MG BASE	N016987	001	
	EQ 25MG BASE	N016987	002	
	EQ 50MG BASE	N016987	003	
	EQ 75MG BASE	N016987	006	
	EQ 100MG BASE	N016987	004	
	EQ 150MG BASE	N016987	007	Apr 13, 1987
PAR PHARM	EQ 10MG BASE	A071697	001	Nov 09, 1987
	EQ 25MG BASE	A071437	001	Nov 09, 1987
	EQ 75MG BASE	A071608	001	Nov 09, 1987
PUREPAC PHARM	EQ 10MG BASE	A073054	001	Dec 28, 1990
	EQ 25MG BASE	A072109	001	Dec 28, 1990
	EQ 50MG BASE	A073055	001	Dec 28, 1990
	EQ 75MG BASE	A072386	001	Sep 08, 1988
	EQ 100MG BASE	A072110	001	Sep 08, 1988
	EQ 150MG BASE	A072387	001	Sep 08, 1988
QUANTUM PHARMICS	EQ 10MG BASE	A070972	001	Sep 29, 1987
	EQ 25MG BASE	A070973	001	Sep 29, 1987
	EQ 50MG BASE	A070931	001	Sep 29, 1987
	EQ 75MG BASE	A070932	001	Sep 29, 1987
	EQ 100MG BASE	A072375	001	Mar 15, 1989
	EQ 150MG BASE	A072376	001	Mar 15, 1989
SANDOZ	EQ 10MG BASE	A071487	001	Mar 02, 1987
	EQ 25MG BASE	A070827	001	May 15, 1986
	EQ 50MG BASE	A070828	001	May 15, 1986
	EQ 75MG BASE	A070825	001	May 15, 1986
	EQ 100MG BASE	A071562	001	Mar 02, 1987
SUN PHARM INDUSTRIES	EQ 25MG BASE	A071502	001	Feb 18, 1988
	EQ 50MG BASE	A071653	001	Feb 18, 1988
	EQ 75MG BASE	A071654	001	Feb 18, 1988
	EQ 100MG BASE	A071521	001	Feb 18, 1988
WATSON LABS	EQ 10MG BASE	A070952	001	Mar 04, 1987
	EQ 10MG BASE	A071485	001	Apr 30, 1987
	EQ 10MG BASE	A072985	001	Mar 29, 1991
	EQ 25MG BASE	A070953	001	May 15, 1986
	EQ 25MG BASE	A071486	001	Apr 30, 1987
	EQ 25MG BASE	A072986	001	Mar 29, 1991
	EQ 50MG BASE	A070954	001	May 15, 1986
	EQ 50MG BASE	A071238	001	Apr 30, 1987
	EQ 75MG BASE	A071326	001	Apr 30, 1987
	EQ 75MG BASE	A071763	001	Feb 09, 1988
	EQ 100MG BASE	A070955	001	May 15, 1986
	EQ 100MG BASE	A071239	001	Apr 30, 1987
	EQ 150MG BASE	A071764	001	Feb 09, 1988
WATSON LABS TEVA	EQ 50MG BASE	A072987	001	Mar 29, 1991
SINEQUAN				
+ PFIZER	EQ 10MG BASE **	N016798	003	
+	EQ 25MG BASE **	N016798	001	
+	EQ 50MG BASE **	N016798	002	
+	EQ 75MG BASE **	N016798	006	
+	EQ 100MG BASE **	N016798	005	
+	EQ 150MG BASE **	N016798	007	
CONCENTRATE;ORAL				
DOXEPIN HYDROCHLORIDE				
PHARM ASSOC	EQ 10MG BASE/ML	A075924	001	Jan 15, 2004
SINEQUAN				
+ PFIZER	EQ 10MG BASE/ML **	N017516	001	
TABLET;ORAL				
DOXEPIN HYDROCHLORIDE				
ACTAVIS ELIZABETH	EQ 3MG BASE	A201951	001	Jul 26, 2013
	EQ 6MG BASE	A201951	002	Jul 26, 2013
MYLAN PHARMS INC	EQ 3MG BASE	A202337	001	Jan 20, 2016
	EQ 6MG BASE	A202337	002	Jan 20, 2016

DOXORUBICIN HYDROCHLORIDE				
INJECTABLE;INJECTION				
ADRIAMYCIN PFS				
PHARMACIA AND UPJOHN	2MG/ML	A063165	001	Jan 30, 1991
	200MG/100ML	A063165	002	Jan 30, 1991
DOXORUBICIN HYDROCHLORIDE				
ALVOGEN INC	2MG/ML	A065515	001	Nov 08, 2012
MYLAN LABS LTD	10MG/VIAL	A200170	001	Oct 28, 2011
PHARMACIA AND UPJOHN	10MG/VIAL	N050467	001	
	20MG/VIAL	N050467	003	May 20, 1985
	50MG/VIAL	N050467	002	
	150MG/VIAL	N050467	004	Jul 22, 1987
SANDOZ INC	2MG/ML	A200146	001	Jul 18, 2012
RUBEX				
BRISTOL MYERS SQUIBB	10MG/VIAL	A062926	001	Apr 13, 1989
	50MG/VIAL	A062926	002	Apr 13, 1989
	100MG/VIAL	A062926	003	Apr 13, 1989
DOXYCYCLINE				
CAPSULE;ORAL				
DOXYCYCLINE				
PAR PHARM	EQ 75MG BASE	A065055	004	Apr 18, 2005
SANDOZ INC	EQ 50MG BASE	A065032	001	Jun 30, 2000
	EQ 100MG BASE	A065032	002	Jun 30, 2000
WATSON LABS	EQ 50MG BASE	A065041	001	Apr 28, 2000
	EQ 100MG BASE	A065041	002	Apr 28, 2000
FOR SUSPENSION;ORAL				
DOXYCHEL				
RACHELLE	EQ 25MG BASE/5ML	A061720	001	
TABLET;ORAL				
DOXYCYCLINE				
SANDOZ INC	EQ 50MG BASE	A065353	001	Nov 27, 2006
	EQ 75MG BASE	A065353	002	Nov 27, 2006
	EQ 100MG BASE	A065353	003	Nov 27, 2006
SUN PHARM INDUSTRIES	EQ 50MG BASE	A065471	001	Apr 17, 2009
	EQ 75MG BASE	A065471	002	Apr 17, 2009
	EQ 100MG BASE	A065471	003	Apr 17, 2009
DOXYCYCLINE HYCLATE				
CAPSULE;ORAL				
ACTICLATE CAP				
+ AQUA PHARMS	EQ 75MG BASE	N208253	001	Apr 26, 2016
DOXY-LEMMON				
TEVA	EQ 50MG BASE	A062497	001	Aug 23, 1984
	EQ 100MG BASE	A062497	002	Jun 15, 1984
DOXYCYCLINE HYCLATE				
HALSEY	EQ 50MG BASE	A062119	002	May 24, 1985
	EQ 100MG BASE	A062119	001	May 24, 1985
HEATHER	EQ 50MG BASE	A062463	001	Dec 07, 1983
	EQ 100MG BASE	A062463	002	Dec 07, 1983
HIKMA INTL PHARMS	EQ 20MG BASE	A065103	001	May 13, 2005
INTERPHARM	EQ 50MG BASE	A062763	001	Sep 02, 1988
	EQ 100MG BASE	A062763	002	Sep 02, 1988
MUTUAL PHARM	EQ 50MG BASE	A062418	001	Jan 28, 1983
	EQ 100MG BASE	A062418	002	Jan 28, 1983
PAR PHARM	EQ 50MG BASE	A062434	001	Oct 19, 1984
	EQ 100MG BASE	A062442	001	Dec 22, 1983
PVT FORM	EQ 50MG BASE	A062631	001	Jul 24, 1986
	EQ 100MG BASE	A062631	002	Jul 24, 1986
RANBAXY	EQ 50MG BASE	A062479	001	Dec 23, 1983
	EQ 100MG BASE	A062479	002	Dec 23, 1983
SUPERPHARM	EQ 50MG BASE	A062469	001	Oct 31, 1984
	EQ 100MG BASE	A062469	002	Oct 31, 1984
WARNER CHILCOTT	EQ 50MG BASE	A062594	001	Dec 05, 1985
	EQ 100MG BASE	A062594	002	Dec 05, 1985
WATSON LABS	EQ 50MG BASE	A061717	001	
	EQ 50MG BASE	A062142	001	
	EQ 100MG BASE	A061717	002	
	EQ 100MG BASE	A062142	002	

DOXYCYCLINE HYCLATE

CAPSULE;ORAL					
PERIOSTAT					
+	COLLAGENEX	EQ 20MG BASE **	N050744	001	Sep 30, 1998
VIBRAMYCIN					
+	PFIZER	EQ 50MG BASE **	N050007	001	
CAPSULE, COATED PELLETS;ORAL					
DOXYCYCLINE HYCLATE					
	PLIVA	EQ 100MG BASE	A063187	001	Jun 30, 1992
CAPSULE, DELAYED RELEASE;ORAL					
DORYX					
+	MAYNE PHARMA INTL	EQ 75MG BASE	N050582	002	Aug 13, 2001
+		EQ 100MG BASE	N050582	001	Jul 22, 1985
	WARNER CHILCOTT	EQ 100MG BASE	A062653	001	Oct 30, 1985
DOXYCYCLINE HYCLATE					
	MEDICIS	EQ 75MG BASE	A065281	001	Dec 21, 2005
		EQ 100MG BASE	A065281	002	Dec 21, 2005
INJECTABLE;INJECTION					
DOXYCHEL HYCLATE					
	RACHELLE	EQ 100MG BASE/VIAL	A061953	001	
DOXYCYCLINE					
	WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983
		EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983
		EQ 200MG BASE/VIAL	A062569	002	Mar 09, 1988
DOXYCYCLINE HYCLATE					
	WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A062992	001	Feb 16, 1989
		EQ 200MG BASE/VIAL	A062992	002	Feb 16, 1989
VIBRAMYCIN					
+	PFIZER	EQ 100MG BASE/VIAL **	N050442	002	
+		EQ 200MG BASE/VIAL **	N050442	001	
TABLET;ORAL					
DOXY-LEMMON					
	TEVA	EQ 100MG BASE	A062581	001	Mar 15, 1985
DOXYCYCLINE HYCLATE					
	EPIC PHARMA LLC	EQ 20MG BASE	A065182	001	May 13, 2005
	HEATHER	EQ 100MG BASE	A062462	001	May 11, 1983
	INTERPHARM	EQ 100MG BASE	A062764	001	Sep 02, 1988
	MUTUAL PHARM	EQ 100MG BASE	A062391	001	Sep 30, 1982
	SUPERPHARM	EQ 100MG BASE	A062494	001	Feb 20, 1985
	VINTAGE PHARMS	EQ 100MG BASE	A062538	001	Apr 07, 1986
	WARNER CHILCOTT	EQ 100MG BASE	A062593	001	Aug 28, 1985
	WATSON LABS	EQ 50MG BASE	A062392	001	Mar 31, 1983
		EQ 100MG BASE	A062392	002	Mar 31, 1983
LYMEPAK					
+	CHARTWELL PHARMA	EQ 100MG BASE	N209844	001	Jun 15, 2018
PERIOSTAT					
+	GALDERMA LABS LP	EQ 20MG BASE **	N050783	001	Feb 02, 2001
VIBRA-TABS					
+	PFIZER	EQ 100MG BASE **	N050533	001	
TABLET, DELAYED RELEASE;ORAL					
DORYX					
+	MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013
DORYX MPC					
+	MAYNE PHARMA	EQ 60MG BASE **	N050795	007	May 20, 2016
DOXYCYCLINE HYCLATE					
	IMPAX LABS INC	EQ 75MG BASE	A090505	001	Dec 28, 2010
		EQ 100MG BASE	A090505	002	Dec 28, 2010
	MYLAN	EQ 80MG BASE	A090431	004	Apr 29, 2016

DOXYLAMINE SUCCINATE

CAPSULE;ORAL					
UNISOM					
	PFIZER	25MG	N019440	001	Feb 05, 1986
TABLET;ORAL					
DECAPRYN					
	SANOFI AVENTIS US	12.5MG	N006412	015	
		25MG	N006412	014	
DOXY-SLEEP-AID					
	PAR PHARM	25MG	A070156	001	Jul 02, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DOXYLAMINE SUCCINATE

TABLET;ORAL

DOXYLAMINE SUCCINATE

COPLEY PHARM	25MG	A088900	002	Feb 12, 1988
QUANTUM PHARMICS	25MG	A088603	001	Aug 07, 1984

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BENDECTIN

SANOFI AVENTIS US	10MG;10MG **	N010598	002

DROMOSTANOLONE PROPIONATE

INJECTABLE;INJECTION

DROLBAN

LILLY	50MG/ML	N012936	001	

DRONABINOL

CAPSULE;ORAL

DRONABINOL

INSYS THERAP	2.5MG	A078501	001	Aug 19, 2011
	5MG	A078501	002	Aug 19, 2011
	10MG	A078501	003	Aug 19, 2011

DROPERIDOL

INJECTABLE;INJECTION

DROPERIDOL

ABRAXIS PHARM	2.5MG/ML	A070992	001	Nov 17, 1986
	2.5MG/ML	A070993	001	Nov 17, 1986
ASTRAZENECA	2.5MG/ML	A072018	001	Oct 20, 1988
HOSPIRA	2.5MG/ML	A071645	001	Apr 07, 1988
	2.5MG/ML	A072272	001	Aug 31, 1995
IGI LABS INC	2.5MG/ML	A072019	001	Oct 19, 1988
	2.5MG/ML	A072020	001	Oct 19, 1988
	2.5MG/ML	A072021	001	Oct 19, 1988
LUITPOLD	2.5MG/ML	A072335	001	Oct 24, 1988
SMITH AND NEPHEW	2.5MG/ML	A071750	001	Sep 06, 1988
SOLOPAK	2.5MG/ML	A071754	001	Sep 06, 1988
	2.5MG/ML	A071755	001	Sep 06, 1988
WATSON LABS	2.5MG/ML	A073520	001	Nov 27, 1991
	2.5MG/ML	A073521	001	Nov 27, 1991
	2.5MG/ML	A073523	001	Nov 27, 1991

DROPERIDOL; FENTANYL CITRATE

INJECTABLE;INJECTION

FENTANYL CITRATE AND DROPERIDOL

ASTRAZENECA	2.5MG/ML;EQ 0.05MG BASE/ML	A072026	001	Apr 13, 1989
	2.5MG/ML;EQ 0.05MG BASE/ML	A072027	001	Apr 13, 1989
	2.5MG/ML;EQ 0.05MG BASE/ML	A072028	001	Apr 13, 1989
HOSPIRA	2.5MG/ML;EQ 0.05MG BASE/ML	A071982	001	May 04, 1988

INNOVAR

AKORN MFG	2.5MG/ML;EQ 0.05MG BASE/ML	N016049	001

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

MYLAN PHARMS INC	0.5MG	A203241	001	Jun 14, 2016

DYCLONINE HYDROCHLORIDE

SOLUTION;TOPICAL

DYCLONE

+ ASTRAZENECA	0.5% **	N009925	002
+	1% **	N009925	001

DYDROGESTERONE

TABLET;ORAL

GYNOREST

SOLVAY	5MG **	N017388	001
	10MG **	N017388	002

DYPHYLLINE
ELIXIR;ORAL
NEOTHYLLINE
TEVA 160MG/15ML N007794 003
INJECTABLE;INJECTION
NEOTHYLLINE
TEVA 250MG/ML N009088 001
TABLET;ORAL
DILOR
SAVAGE LABS 200MG A084514 001
DILOR-400
SAVAGE LABS 400MG A084751 001
LUFYLLIN
MYLAN SPECIALITY LP 200MG A084566 001
400MG A084566 002
NEOTHYLLINE
TEVA 200MG N007794 001
400MG N007794 002

ECHOTHIOPHATE IODIDE
FOR SOLUTION;OPHTHALMIC
PHOSPHOLINE IODIDE
WYETH PHARMS 0.03% N011963 002
0.06% N011963 004
0.25% N011963 003

EDETATE CALCIUM DISODIUM
TABLET;ORAL
CALCIUM DISODIUM VERSENATE
MEDICIS 500MG N008922 002

EDROPHONIUM CHLORIDE
INJECTABLE;INJECTION
EDROPHONIUM CHLORIDE
HOSPIRA 10MG/ML A040131 001 Feb 24, 1998
WATSON LABS 10MG/ML A040044 001 Mar 20, 1996
EDROPHONIUM CHLORIDE PRESERVATIVE FREE
WATSON LABS 10MG/ML A040043 001 Mar 20, 1996
ENLON
MYLAN INSTITUTIONAL 10MG/ML A088873 001 Aug 06, 1985
REVERSOL
ORGANON USA INC 10MG/ML A089624 001 May 13, 1988
TENSILON
\+ TELIGENT 10MG/ML ** N007959 001
TENSILON PRESERVATIVE FREE
\+ TELIGENT 10MG/ML ** N007959 002

EFAVIRENZ
CAPSULE;ORAL
SUSTIVA
\+ BRISTOL MYERS SQUIBB 100MG ** N020972 002 Sep 17, 1998
TABLET;ORAL
SUSTIVA
\+ BRISTOL MYERS SQUIBB 300MG ** N021360 001 Feb 01, 2002

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
TABLET;ORAL
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE
AUROBINDO PHARMA LTD 600MG;300MG;300MG N022343 001 Aug 15, 2018

EFLORNITHINE HYDROCHLORIDE
INJECTABLE;INJECTION
ORNIDYL
SANOFI AVENTIS US 200MG/ML N019879 002 Nov 28, 1990

ELVITEGRAVIR
TABLET;ORAL
VITEKTA
\+ GILEAD SCIENCES INC 85MG N203093 001 Sep 24, 2014
\+ 150MG N203093 002 Sep 24, 2014

ENALAPRIL MALEATE

TABLET;ORAL

ENALAPRIL MALEATE

APOTHECON	2.5MG	A075583	001	Aug 22, 2000
	5MG	A075583	002	Aug 22, 2000
	10MG	A075583	003	Aug 22, 2000
	20MG	A075583	004	Aug 22, 2000
IVAX SUB TEVA PHARMS	2.5MG	A075482	001	Aug 22, 2000
	5MG	A075482	002	Aug 22, 2000
	10MG	A075482	003	Aug 22, 2000
	20MG	A075482	004	Aug 22, 2000
KRKA DD NOVO MESTO	2.5MG	A075370	001	Aug 22, 2000
	5MG	A075370	002	Aug 22, 2000
	10MG	A075369	001	Aug 22, 2000
	20MG	A075369	002	Aug 22, 2000
MYLAN	2.5MG	A075472	001	Aug 22, 2000
	2.5MG	A075480	001	Aug 22, 2000
	5MG	A075472	002	Aug 22, 2000
	10MG	A075472	003	Aug 22, 2000
	20MG	A075472	004	Aug 22, 2000
	20MG	A075480	004	Aug 22, 2000
SANDOZ	2.5MG	A075048	001	Aug 22, 2000
	5MG	A075048	002	Aug 22, 2000
	10MG	A075048	003	Aug 22, 2000
	20MG	A075048	004	Aug 22, 2000
SANDOZ INC	2.5MG	A075621	001	Aug 22, 2000
	5MG	A075621	002	Aug 22, 2000
	10MG	A075621	003	Aug 22, 2000
	20MG	A075621	004	Aug 22, 2000
SUN PHARM INDS LTD	2.5MG	A075556	001	Aug 22, 2000
	5MG	A075556	002	Aug 22, 2000
	10MG	A075556	003	Aug 22, 2000
	20MG	A075556	004	Aug 22, 2000
WATSON LABS	2.5MG	A075501	001	Aug 22, 2000
	5MG	A075501	002	Aug 22, 2000
	10MG	A075501	003	Aug 22, 2000
	20MG	A075501	004	Aug 22, 2000

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

LEXXEL

ASTRAZENECA	5MG;2.5MG	N020668	002	Oct 28, 1998
	5MG;5MG	N020668	001	Dec 27, 1996

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

IVAX SUB TEVA PHARMS	5MG;12.5MG	A075736	001	Mar 25, 2003
	10MG;25MG	A075736	002	Mar 25, 2003
UPSHER SMITH LABS	5MG;12.5MG	A076116	001	Sep 19, 2001
	10MG;25MG	A076116	002	Sep 19, 2001

ENALAPRILAT

INJECTABLE;INJECTION

ENALAPRILAT

HOSPIRA	1.25MG/ML	A075456	001	Aug 22, 2000
	1.25MG/ML	A075571	001	Aug 22, 2000

VASOTEC

+	BIOVAIL LABS INTL	1.25MG/ML **	N019309	001	Feb 09, 1988

ENFLURANE

LIQUID;INHALATION

ENFLURANE

ABBOTT	99.9%	A070803	001	Sep 08, 1987
PIRAMAL CRITICAL	99.9%	A074396	001	Jul 29, 1994

ETHRANE

BAXTER HLTHCARE	99.9%	N017087	001

ENOXACIN
TABLET;ORAL
PENETREX
SANOFI AVENTIS US 200MG N019616 004 Dec 31, 1991
400MG N019616 005 Dec 31, 1991

ENOXAPARIN SODIUM
INJECTABLE;SUBCUTANEOUS
LOVENOX (PRESERVATIVE FREE)
+ SANOFI AVENTIS US 90MG/0.6ML (150MG/ML) ** N020164 006 Jun 02, 2000

ENTACAPONE
TABLET;ORAL
ENTACAPONE
MYLAN PHARMS INC 200MG A202394 001 May 13, 2013

EPINEPHRINE
AEROSOL, METERED;INHALATION
BRONKAID MIST
STERLING 0.25MG/INH N016803 001
EPINEPHRINE
ARMSTRONG PHARMS 0.2MG/INH A087907 001 May 23, 1984
PRIMATENE MIST
WYETH CONS 0.2MG/INH N016126 001
INJECTABLE;INJECTION
SUS-PHRINE SULFITE FREE
FOREST LABS 1.5MG/AMP N007942 003 Feb 05, 1999
5MG/ML N007942 001
INJECTABLE;INTRAMUSCULAR
EPI E Z PEN JR
MYLAN SPECIALITY LP 0.15MG/DELIVERY N019430 004 Aug 03, 1995
EPIPEN E Z PEN
MYLAN SPECIALITY LP 0.3MG/DELIVERY N019430 003 Aug 03, 1995
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
TWINJECT 0.15
IMPAX EQ 0.15MG/DELIVERY N020800 002 May 28, 2004
TWINJECT 0.3
IMPAX EQ 0.3MG/DELIVERY N020800 001 May 30, 2003

EPINEPHRINE BITARTRATE
AEROSOL, METERED;INHALATION
BRONITIN MIST
WYETH CONS 0.3MG/INH N016126 002
MEDIHALER-EPI
3M 0.3MG/INH N010374 003

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
DURANEST
+ ASTRAZENECA 0.005MG/ML;1% ** N017751 006
+ 0.005MG/ML;1.5% ** N017751 007
+ DENTSPLY PHARM 0.005MG/ML;1.5% ** N021384 001

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
CITANEST FORTE
ASTRAZENECA 0.005MG/ML;4% N014763 008

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
DURANEST
+ ASTRAZENECA 0.005MG/ML;0.5% ** N017751 004

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE
CARLISLE 0.01MG/ML;2% A084720 001
0.02MG/ML;2% A084732 001
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE
BELMORA LLC 0.01MG/ML;2% A080504 004 Oct 19, 1983
0.02MG/ML;2% A080504 005 Oct 19, 1983
EASTMAN KODAK 0.01MG/ML;2% A040057 002 Feb 26, 1993
0.02MG/ML;2% A040057 001 Feb 26, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE				
HOSPIRA	0.005MG/ML;1%	A089649	001	Jun 21, 1988
	0.005MG/ML;1.5%	A089650	001	Jun 21, 1988
	0.01MG/ML;2%	A078772	001	May 12, 2008
	0.02MG/ML;2%	A078772	002	May 12, 2008
WEST-WARD PHARMS INT	0.01MG/ML;1%	A080406	001	
	0.01MG/ML;2%	A080406	002	
LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE				
ABBOTT	0.01MG/ML;1%	A083154	001	
BEL MAR	0.01MG/ML;1%	A080820	001	
	0.01MG/ML;2%	A080757	001	
DELL LABS	0.01MG/ML;1%	A083389	001	
	0.01MG/ML;2%	A083390	001	
INTL MEDICATION	0.01MG/ML;1%	A086402	001	
WATSON LABS	0.01MG/ML;1%	A080377	003	
	0.01MG/ML;1%	A085463	001	
	0.01MG/ML;2%	A080377	004	
LIDOCATON				
PHARMATON	0.01MG/ML;2%	A084729	001	Aug 17, 1983
	0.02MG/ML;2%	A084728	001	Aug 17, 1983
OCTOCAINE				
SEPTODONT	0.01MG/ML;2%	A084048	001	
	0.02MG/ML;2%	A084048	002	
XYLOCAINE DENTAL WITH EPINEPHRINE				
DENTSPLY PHARM	0.01MG/ML;2%	N021381	001	
	0.02MG/ML;2%	N021381	002	
XYLOCAINE W/ EPINEPHRINE				
ASTRAZENECA	0.005MG/ML;1%	N010418	006	
	0.005MG/ML;1.5%	N010418	010	
	0.005MG/ML;2%	N010418	008	
FRESENIUS KABI USA	0.01MG/ML;2%	N006488	003	
PATCH;IONTOPHORESIS, TOPICAL				
LIDOSITE TOPICAL SYSTEM KIT				
VYTERIS	1.05MG/PATCH;100MG/PATCH	N021504	001	May 06, 2004
SOLUTION;IONTOPHORESIS				
IONTOCAINE				
IOMED	0.01MG/ML;2%	N020530	001	Dec 21, 1995
SOLUTION;IONTOPHORESIS, TOPICAL				
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE				
EMPI	0.01MG/ML;2%	N021486	001	Oct 26, 2004

EPINEPHRINE; PROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
PROCAINE HYDROCHLORIDE W/ EPINEPHRINE				
BEL MAR	0.02MG/ML;1%	A080758	001	
	0.02MG/ML;2%	A080759	001	

EPIRUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION				
EPIRUBICIN HYDROCHLORIDE				
EBEWE PHARMA	50MG/25ML (2MG/ML)	A065339	001	Dec 22, 2009
	200MG/100ML (2MG/ML)	A065339	002	Dec 22, 2009
HOSPIRA	50MG/25ML (2MG/ML)	A065343	002	Apr 19, 2007
MUSTAFA NEVSAT	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011
	200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011
MYLAN INSTITUTIONAL	50MG/25ML (2MG/ML)	A065371	001	Nov 28, 2007
	200MG/100ML (2MG/ML)	A065371	002	Nov 28, 2007
POWDER;INTRAVENOUS				
EPIRUBICIN HYDROCHLORIDE				
HOSPIRA	50MG/VIAL	N050807	001	Sep 15, 2006
	200MG/VIAL	N050807	002	Sep 15, 2006

EPLERENONE

TABLET;ORAL				
INSPRA				
GD SEARLE LLC	100MG	N021437	003	Sep 27, 2002

EPROSARTAN MESYLATE

TABLET;ORAL				
TEVETEN				
ABBVIE	EQ 300MG BASE	N020738	004	Dec 22, 1997
+	EQ 400MG BASE	N020738	005	Dec 22, 1997
+	EQ 600MG BASE	N020738	006	May 27, 1999

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL				
TEVETEN HCT				
ABBVIE	600MG;12.5MG	N021268	001	Nov 01, 2001
	600MG;25MG	N021268	002	Nov 01, 2001

EPTIFIBATIDE

INJECTABLE;INJECTION				
EPTIFIBATIDE				
TEVA PHARMS USA	75MG/100ML	A091555	001	Jun 05, 2015

ERGOCALCIFEROL

CAPSULE;ORAL				
DELTALIN				
LILLY	50,000 IU	A080884	001	
VITAMIN D				
CHASE CHEM	50,000 IU	A080747	001	
EVERYLIFE	50,000 IU	A080956	001	
IMPAX LABS	50,000 IU	A080951	001	
LANNETT	50,000 IU	A080825	001	
VITARINE	50,000 IU	A084053	001	
WEST WARD	50,000 IU	A083102	001	

ERGOLOID MESYLATES

CAPSULE;ORAL				
HYDERGINE LC				
NOVARTIS	1MG	N018706	001	Jan 18, 1983
SOLUTION;ORAL				
HYDERGINE				
NOVARTIS	1MG/ML	N018418	001	
TABLET;ORAL				
ERGOLOID MESYLATES				
MUTUAL PHARM	1MG	A088891	001	Nov 01, 1985
WATSON LABS	1MG	A086433	001	May 27, 1982
	1MG	A087244	001	Aug 16, 1982
GERIMAL				
WATSON LABS	1MG	A088207	001	Mar 22, 1984
HYDERGINE				
NOVARTIS	0.5MG	N017993	003	
+	1MG	N017993	001	
TABLET;SUBLINGUAL				
ALKERGOT				
SANDOZ	0.5MG	A085153	001	
	1MG	A087417	001	
CIRCANOL				
3M	0.5MG	A084868	001	
	1MG	A085809	001	
DEAPRIL-ST				
BRISTOL MYERS SQUIBB	1MG	A085020	002	
ERGOLOID MESYLATES				
KV PHARM	0.5MG	A085899	001	
	0.5MG	A086265	001	
	1MG	A085900	001	
	1MG	A086264	001	
LEDERLE	0.5MG	A086984	001	
	1MG	A086985	001	
SUN PHARM INDUSTRIES	0.5MG	A087407	001	
	1MG	A087552	001	
SUPERPHARM	0.5MG	A089233	001	Sep 23, 1986
	1MG	A089234	001	Sep 23, 1986
VANGARD	0.5MG	A088013	001	Sep 20, 1982
	1MG	A088014	001	Sep 20, 1982
WATSON LABS	0.5MG	A084930	001	
	0.5MG	A087233	001	

ERGOLOID MESYLATES				
TABLET;SUBLINGUAL				
ERGOLOID MESYLATES				
	1MG		A085177 001	
	1MG		A087183 001	
GERIMAL				
WATSON LABS	0.5MG		A086189 001	
	1MG		A086188 001	
HYDERGINE				
NOVARTIS	0.5MG		N009087 002	
	1MG		N009087 001	
HYDROGENATED ERGOT ALKALOIDS				
IVAX PHARMS	0.5MG		A087186 001	
	1MG		A087185 001	
ERGOTAMINE TARTRATE				
AEROSOL, METERED;INHALATION				
MEDIHALER ERGOTAMINE				
3M	0.36MG/INH		N012102 001	
TABLET;SUBLINGUAL				
ERGOSTAT				
WATSON LABS INC	2MG		A088337 001	Jun 08, 1984
WIGRETTES				
ORGANON USA INC	2MG		A086750 001	Jul 29, 1982
ERLOTINIB HYDROCHLORIDE				
TABLET;ORAL				
ERLOTINIB HYDROCHLORIDE				
MYLAN PHARMS INC	EQ 25MG BASE		A091002 001	Jun 11, 2014
	EQ 100MG BASE		A091002 002	Jun 11, 2014
	EQ 150MG BASE		A091002 003	Jun 11, 2014
TEVA PHARMS USA	EQ 100MG BASE		A091059 002	Aug 28, 2015
	EQ 150MG BASE		A091059 003	Aug 28, 2015
ERYTHROMYCIN				
CAPSULE, DELAYED REL PELLETS;ORAL				
ERYC				
PARKE DAVIS	250MG		A062546 001	Jul 25, 1985
	250MG		A062618 001	Sep 25, 1985
WARNER CHILCOTT LLC	250MG		A062338 001	
ERYC 125				
PARKE DAVIS	125MG		A062648 001	Oct 24, 1985
ERYC SPRINKLES				
HOSPIRA	125MG		N050593 001	Jul 22, 1985
ERYTHROMYCIN				
BARR	250MG		A063098 001	May 04, 1989
GEL;TOPICAL				
E-GLADES				
MYLAN PHARMS INC	2%		A065009 001	Mar 18, 2002
EMGEL				
ALTANA	2%		A063107 001	Aug 23, 1991
LOTION;TOPICAL				
E-SOLVE 2				
SYOSSET	2%		A062467 001	Jul 03, 1985
OINTMENT;OPHTHALMIC				
ERYTHROMYCIN				
PHARMADERM	5MG/GM		A062446 001	Sep 26, 1983
PHARMAFAIR	5MG/GM		A062481 001	Apr 05, 1984
ILOTYCIN				
DISTA	0.5%		N050368 001	
OINTMENT;TOPICAL				
AKNE-MYCIN				
+ DOW PHARM	2%		N050584 001	Jan 10, 1985
POWDER;FOR RX COMPOUNDING				
ERYTHROMYCIN				
PADDOCK LLC	100%		N050610 001	Nov 07, 1986
SOLUTION;TOPICAL				
A/T/S				
TARO	2%		A062405 001	Nov 18, 1982

ERYTHROMYCIN				
SOLUTION;TOPICAL				
C-SOLVE-2				
FOUGERA PHARMS	2%	A062468	001	Jul 03, 1985
ERYDERM				
ARBOR PHARMS INC	2%	A062290	001	
ERYMAX				
MERZ PHARMS	2%	A062508	002	Jul 11, 1985
ERYTHRA-DERM				
ANDA REPOSITORY	2%	A062687	001	Feb 05, 1988
ERYTHRO-STATIN				
HI TECH PHARMA	2%	A064101	001	Oct 22, 1996
ERYTHROMYCIN				
ALPHARMA US PHARMS	1.5%	A062328	001	Apr 19, 1982
	2%	A062326	001	Apr 19, 1982
	2%	A062327	001	Apr 19, 1982
	2%	A062342	001	Feb 25, 1982
	2%	A062957	001	Jul 21, 1988
BAUSCH AND LOMB	2%	A064039	001	Jan 27, 1994
FOUGERA PHARMS	2%	A064187	001	Sep 30, 1997
LILLY	2%	N050532	001	
PHARMAFAIR	1.5%	A062485	001	Jul 11, 1984
	2%	A062616	001	Jul 25, 1985
RENAISSANCE PHARMA	2%	A064127	001	Feb 14, 1997
SANSAC				
DOW PHARM	2%	A062522	001	Jan 24, 1985
STATICIN				
+ WESTWOOD SQUIBB	1.5% **	N050526	001	
T-STAT				
WESTWOOD SQUIBB	2% **	A062436	001	Mar 09, 1983
SWAB;TOPICAL				
C-SOLVE-2				
IVAX SUB TEVA PHARMS	2%	A062751	001	Jul 30, 1993
ERYCETTE				
+ JOHNSON AND JOHNSON	2% **	N050594	001	Feb 15, 1985
ERYTHROMYCIN				
FOUGERA PHARMS	2%	A065320	001	Jul 25, 2006
MYLAN PHARMS INC	2%	A064128	001	Jul 03, 1996
T-STAT				
WESTWOOD SQUIBB	2%	A062748	001	Jul 23, 1987
TABLET, COATED PARTICLES;ORAL				
PCE				
+ ARBOR PHARMS LLC	333MG	N050611	001	Sep 09, 1986
+	500MG	N050611	002	Aug 22, 1990
TABLET, DELAYED RELEASE;ORAL				
E-BASE				
BARR	333MG	A063028	001	May 15, 1990
	333MG	A063086	001	May 15, 1990
	500MG	A062999	001	Nov 25, 1988
E-MYCIN				
ARBOR PHARMS INC	250MG	A060272	001	
	333MG	A060272	002	
ILOTYCIN				
DISTA	250MG	A061910	001	
R-P MYCIN				
SOLVAY	250MG	A061659	001	
ROBIMYCIN				
ROBINS AH	250MG	A061633	001	
ERYTHROMYCIN ESTOLATE				
CAPSULE;ORAL				
ERYTHROMYCIN ESTOLATE				
BARR	EQ 125MG BASE	A062162	001	
	EQ 250MG BASE	A062162	002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A062237	001	
WATSON LABS	EQ 250MG BASE	A062087	001	
ILOSONE				
LILLY	EQ 125MG BASE	A061897	001	
	EQ 250MG BASE	A061897	002	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

ERYTHROMYCIN ESTOLATE				
FOR SUSPENSION;ORAL				
ILOSONE				
DISTA	EQ 125MG BASE/5ML	A061893 001		
SUSPENSION;ORAL				
ERYTHROMYCIN ESTOLATE				
ALPHARMA US PHARMS	EQ 125MG BASE/5ML	A062353 001	Nov 18, 1982	
	EQ 250MG BASE/5ML	A062409 001	Dec 16, 1982	
G AND W LABS INC	EQ 125MG BASE/5ML	A062169 001	Oct 17, 1990	
	EQ 250MG BASE/5ML	A062169 002	Oct 17, 1990	
LIFE LABS	EQ 250MG BASE/5ML	A062362 001	Dec 17, 1982	
ILOSONE				
LILLY	EQ 125MG BASE/5ML	A061894 001		
	EQ 125MG BASE/5ML	N050010 001		
	EQ 250MG BASE/5ML	A061894 002		
	EQ 250MG BASE/5ML	N050010 002		
SUSPENSION/DROPS;ORAL				
ILOSONE				
LILLY	EQ 100MG BASE/ML	A061894 003		
TABLET;ORAL				
ILOSONE				
LILLY	EQ 500MG BASE	A061896 001		
TABLET, CHEWABLE;ORAL				
ILOSONE				
DISTA	EQ 125MG BASE	A061895 001		
	EQ 250MG BASE	A061895 002		
ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL				
SUSPENSION;ORAL				
ILOSONE SULFA				
LILLY	EQ 125MG BASE/5ML;EQ 600MG BASE/5ML	N050599 001	Sep 29, 1989	
ERYTHROMYCIN ETHYLSUCCINATE				
GRANULE;ORAL				
PEDIAMYCIN				
ROSS LABS	EQ 200MG BASE/5ML	A062305 001		
SUSPENSION;ORAL				
E-MYCIN E				
PHARMACIA AND UPJOHN	EQ 200MG BASE/5ML	A062198 001		
	EQ 400MG BASE/5ML	A062198 002		
E.E.S. 200				
ARBOR PHARMS LLC	EQ 200MG BASE/5ML **	A061639 001		
E.E.S. 400				
ARBOR PHARMS LLC	EQ 400MG BASE/5ML **	A061639 002		
ERYTHROMYCIN ETHYLSUCCINATE				
ALPHARMA US PHARMS	EQ 200MG BASE/5ML	A062200 001		
	EQ 400MG BASE/5ML	A062200 002		
DISTA	EQ 200MG BASE/5ML	A062177 001		
	EQ 400MG BASE/5ML	A062177 002		
NASKA	EQ 400MG BASE/5ML	A062674 001	Mar 10, 1987	
PARKE DAVIS	EQ 200MG BASE/5ML	A062231 001		
	EQ 400MG BASE/5ML	A062231 002		
PHARMAFAIR	EQ 200MG BASE/5ML	A062559 001	Mar 15, 1985	
	EQ 400MG BASE/5ML	A062558 001	Mar 15, 1985	
PEDIAMYCIN				
ARBOR PHARMS LLC	EQ 200MG BASE/5ML	A062304 001		
PEDIAMYCIN 400				
ARBOR PHARMS LLC	EQ 400MG BASE/5ML	A062304 002		
WYAMYCIN E				
WYETH AYERST	EQ 200MG BASE/5ML	A062123 002		
	EQ 400MG BASE/5ML	A062123 001		
SUSPENSION/DROPS;ORAL				
PEDIAMYCIN				
ROSS LABS	EQ 100MG BASE/2.5ML	A062305 002		
TABLET;ORAL				
E.E.S. 400				
ARBOR PHARMS LLC	EQ 400MG BASE	A061905 001		
ERYTHROMYCIN ETHYLSUCCINATE				
BARR	EQ 400MG BASE	A062256 001		
MYLAN	EQ 400MG BASE	A062847 001	Sep 14, 1988	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

ERYTHROMYCIN ETHYLSUCCINATE				
TABLET, CHEWABLE;ORAL				
E.E.S.				
	ARBOR PHARMS INC	EQ 200MG BASE	N050297 002	
ERYPED				
	ARBOR PHARMS INC	EQ 200MG BASE	N050297 003	Jul 05, 1988
PEDIAMYCIN				
	ROSS LABS	EQ 200MG BASE	A062306 001	
ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL				
GRANULE;ORAL				
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL				
	BARR	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	A062759 001	May 20, 1988
ERYZOLE				
	ALRA	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	A062758 001	Jun 15, 1988
PEDIAZOLE				
	ROSS LABS	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	N050529 001	
ERYTHROMYCIN GLUCEPTATE				
INJECTABLE;INJECTION				
ILOTYCIN GLUCEPTATE				
	DISTA	EQ 250MG BASE/VIAL	N050370 001	
		EQ 500MG BASE/VIAL	N050370 002	
		EQ 1GM BASE/VIAL	N050370 003	
ERYTHROMYCIN LACTOBIONATE				
INJECTABLE;INJECTION				
ERYTHROCIN				
	ABBOTT	EQ 500MG BASE/VIAL	A062586 001	Jan 04, 1988
		EQ 1GM BASE/VIAL	A062586 002	Jan 04, 1988
	HOSPIRA	EQ 500MG BASE/VIAL	N050182 002	
		EQ 1GM BASE/VIAL	A062638 002	Oct 31, 1986
		EQ 1GM BASE/VIAL	N050182 003	
+		EQ 1GM BASE/VIAL	N050609 002	Sep 24, 1986
ERYTHROMYCIN				
	ELKINS SINN	EQ 500MG BASE/VIAL	A062563 001	Mar 28, 1985
		EQ 1GM BASE/VIAL	A062563 002	Mar 28, 1985
ERYTHROMYCIN LACTOBIONATE				
	ABRAXIS PHARM	EQ 500MG BASE/VIAL	A062604 001	Nov 24, 1986
		EQ 1GM BASE/VIAL	A062604 002	Nov 24, 1986
	BAXTER HLTHCARE	EQ 500MG BASE/VIAL	A062993 001	May 09, 1989
		EQ 1GM BASE/VIAL	A062993 002	May 09, 1989
	TEVA PARENTERAL	EQ 500MG BASE/VIAL	A063253 001	Jul 30, 1993
		EQ 1GM BASE/VIAL	A063253 002	Jul 30, 1993
ERYTHROMYCIN STEARATE				
TABLET;ORAL				
BRISTAMYCIN				
	BRISTOL	EQ 250MG BASE	A061304 001	
		EQ 250MG BASE	A061887 001	
ERYPAR				
	PARKE DAVIS	EQ 250MG BASE	A062032 001	
		EQ 500MG BASE	A062032 002	
	WARNER CHILCOTT	EQ 250MG BASE	A062322 001	
ERYTHROCIN STEARATE				
	ARBOR PHARMS LLC	EQ 125MG BASE	A060359 002	
		EQ 500MG BASE	A060359 003	
ERYTHROMYCIN STEARATE				
	ANI PHARMS INC	EQ 250MG BASE	A061461 001	
		EQ 250MG BASE	A061591 001	
		EQ 500MG BASE	A061461 002	
		EQ 500MG BASE	A063179 001	May 15, 1990
	LEDERLE	EQ 250MG BASE	A062089 001	
		EQ 500MG BASE	A062089 002	
	MYLAN	EQ 250MG BASE	A061505 001	
		EQ 500MG BASE	A061505 002	
	PUREPAC PHARM	EQ 250MG BASE	A061743 001	
	WATSON LABS	EQ 250MG BASE	A062121 002	
		EQ 500MG BASE	A062121 001	
ETHRIL 250				
	BRISTOL MYERS SQUIBB	EQ 250MG BASE	A061605 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

ERYTHROMYCIN STEARATE

TABLET;ORAL				
ETHRIL 500				
	BRISTOL MYERS SQUIBB	EQ 500MG BASE	A061605 002	
PFIZER-E				
	PFIZER	EQ 250MG BASE	A061791 001	
		EQ 500MG BASE	A061791 002	
WYAMYCIN S				
	WYETH AYERST	EQ 250MG BASE	A061675 001	
		EQ 500MG BASE	A061675 002	

ESCITALOPRAM OXALATE

CAPSULE;ORAL				
ESCITALOPRAM OXALATE				
	MYLAN PHARMS INC	EQ 5MG BASE	A077660 001	Jul 31, 2007
		EQ 10MG BASE	A077660 002	Jul 31, 2007
		EQ 20MG BASE	A077660 003	Jul 31, 2007
TABLET;ORAL				
ESCITALOPRAM OXALATE				
	MYLAN PHARMS INC	EQ 5MG BASE	A077550 001	May 14, 2015
		EQ 10MG BASE	A077550 002	May 14, 2015
		EQ 20MG BASE	A077550 003	May 14, 2015

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION				
BREVIBLOC				
	BAXTER HLTHCARE	10MG/ML	N019386 003	Aug 15, 1988
		20MG/ML	N019386 007	May 28, 2003

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS				
ESOMEPRAZOLE SODIUM				
	AUROBINDO PHARMA LTD	EQ 20MG BASE/VIAL	A204657 001	Aug 10, 2016
	MYLAN LABS LTD	EQ 20MG BASE/VIAL	A202686 001	May 17, 2017
	SUN PHARMA GLOBAL	EQ 20MG BASE/VIAL	A200882 001	Mar 18, 2013
NEXIUM IV				
+	ASTRAZENECA PHARMS	EQ 20MG BASE/VIAL **	N021689 001	Mar 31, 2005

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE;ORAL				
ESOMEPRAZOLE STRONTIUM				
+	R2 PHARMA LLC	24.65MG	N202342 001	Aug 06, 2013

ESTAZOLAM

TABLET;ORAL				
PROSOM				
+	ABBOTT	1MG **	N019080 001	Dec 26, 1990
+		2MG **	N019080 002	Dec 26, 1990

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL				
ESCLIM				
	WOMEN FIRST HLTHCARE	0.025MG/24HR	N020847 001	Aug 04, 1998
		0.0375MG/24HR	N020847 002	Aug 04, 1998
		0.05MG/24HR	N020847 003	Aug 04, 1998
		0.075MG/24HR	N020847 004	Aug 04, 1998
		0.1MG/24HR	N020847 005	Aug 04, 1998
ESTRADERM				
+	NOVARTIS	0.05MG/24HR	N019081 002	Sep 10, 1986
+		0.1MG/24HR	N019081 003	Sep 10, 1986
ESTRADIOL				
	ORTHO MCNEIL PHARM	0.05MG/24HR	N021048 001	Sep 20, 1999
		0.075MG/24HR	N021048 002	Sep 20, 1999
		0.1MG/24HR	N021048 003	Sep 20, 1999
FEMPATCH				
	PARKE DAVIS	0.025MG/24HR	N020417 001	Dec 03, 1996
VIVELLE				
	NOVARTIS	0.025MG/24HR	N020323 005	Aug 16, 2000
		0.0375MG/24HR	N020323 001	Oct 28, 1994
		0.05MG/24HR	N020323 002	Oct 28, 1994
		0.075MG/24HR	N020323 003	Oct 28, 1994
		0.1MG/24HR	N020323 004	Oct 28, 1994

ESTRADIOL				
GEL;TOPICAL				
ESTROGEL				
ASCEND THERAPS US	0.06%	N021166 001		Feb 09, 2004
TABLET;ORAL				
ESTRACE				
BRISTOL MYERS SQUIBB	0.5MG	A081295 001		Jun 30, 1993
	1MG	A084499 001		
	2MG	A084500 001		
ESTRADIOL				
LANNETT HOLDINGS INC	0.5MG	A040138 001		Jan 30, 1998
	1MG	A040138 002		Jan 30, 1998
	2MG	A040138 003		Jan 30, 1998
USL PHARMA	0.5MG	A040297 001		Apr 17, 2002
	1MG	A040297 002		Apr 17, 2002
	2MG	A040297 003		Apr 17, 2002
GYNODIOL				
DURAMED PHARMS BARR	0.5MG	A040212 001		Dec 29, 1997
	1MG	A040212 002		Dec 29, 1997
	1.5MG	A040212 003		Dec 29, 1997
	2MG	A040212 004		Dec 29, 1997
INNOFEM				
NOVO NORDISK INC	0.5MG	A040312 001		Nov 19, 1999
	1MG	A040312 002		Nov 19, 1999
	2MG	A040312 003		Nov 19, 1999
TABLET;VAGINAL				
VAGIFEM				
+ NOVO NORDISK INC	25MCG **	N020908 001		Mar 26, 1999
ESTRADIOL ACETATE				
TABLET;ORAL				
FEMTRACE				
+ APIL	0.45MG	N021633 001		Aug 20, 2004
+	0.9MG	N021633 002		Aug 20, 2004
+	1.8MG	N021633 003		Aug 20, 2004
ESTRADIOL CYPIONATE				
INJECTABLE;INJECTION				
DEPO-ESTRADIOL				
PHARMACIA AND UPJOHN	1MG/ML	A085470 001		
	3MG/ML	A085470 002		
ESTRADIOL CYPIONATE				
WATSON LABS	5MG/ML	A085620 001		
ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE				
INJECTABLE;INTRAMUSCULAR				
LUNELLE				
PHARMACIA AND UPJOHN	5MG/0.5ML;25MG/0.5ML	N020874 001		Oct 05, 2000
ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE				
INJECTABLE;INJECTION				
DEPO-TESTADIOL				
PHARMACIA AND UPJOHN	2MG/ML;50MG/ML	N017968 001		
TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE				
WATSON LABS	2MG/ML;50MG/ML	A085603 001		Mar 13, 1986
ESTRADIOL HEMIHYDRATE				
EMULSION;TOPICAL				
ESTRASORB				
+ EXELTIS USA INC	0.25%	N021371 001		Oct 09, 2003
ESTRADIOL VALERATE				
INJECTABLE;INJECTION				
ESTRADIOL VALERATE				
FOSUN PHARMA	10MG/ML	A040628 001		Oct 04, 2007
	20MG/ML	A040628 002		Oct 04, 2007
	40MG/ML	A040628 003		Oct 04, 2007
WATSON LABS	10MG/ML	A083546 001		
	40MG/ML	A083714 001		
WATSON LABS INC	20MG/ML	A083547 001		

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE				
INJECTABLE;INJECTION				
DITATE-DS				
	SAVAGE LABS	8MG/ML;180MG/ML	A086423 001	
TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE				
	WATSON LABS	4MG/ML;90MG/ML	A085865 001	
		8MG/ML;180MG/ML	A085860 001	
ESTRADIOL; NORGESTIMATE				
TABLET;ORAL				
PREFEST				
+	TEVA WOMENS	1MG,1MG;N/A,0.09MG **	N021040 001	Oct 22, 1999
ESTROGENS, CONJUGATED				
TABLET;ORAL				
PREMARIN				
	WYETH PHARMS	2.5MG	N004782 002	
ESTROGENS, CONJUGATED SYNTHETIC A				
CREAM;VAGINAL				
SYNTHETIC CONJUGATED ESTROGENS A				
	TEVA WOMENS	0.625MG/GM	N021788 001	Nov 28, 2008
TABLET;ORAL				
CENESTIN				
+	TEVA BRANDED PHARM	0.3MG **	N020992 001	Jun 21, 2002
+		0.45MG **	N020992 005	Feb 05, 2004
+		0.625MG **	N020992 002	Mar 24, 1999
+		0.9MG **	N020992 003	Mar 24, 1999
+		1.25MG **	N020992 004	Mar 13, 2000
ESTROGENS, CONJUGATED SYNTHETIC B				
TABLET;ORAL				
ENJUVIA				
	TEVA BRANDED PHARM	0.3MG	N021443 001	Dec 20, 2004
		0.45MG	N021443 002	Dec 20, 2004
		0.625MG **	N021443 003	May 10, 2004
		0.9MG	N021443 005	Apr 27, 2007
		1.25MG **	N021443 004	May 10, 2004
ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE				
TABLET;ORAL-28				
PREMPHASE (PREMARIN;CYCRIN 14/14)				
	WYETH PHARMS INC	0.625MG,0.625MG;N/A,5MG	N020303 002	Dec 30, 1994
PREMPRO (PREMARIN;CYCRIN)				
	WYETH PHARMS INC	0.625MG,0.625MG;2.5MG,2.5MG	N020303 001	Dec 30, 1994
ESTROGENS, CONJUGATED; MEPROBAMATE				
TABLET;ORAL				
MILPREM-200				
	MEDPOINTE PHARM HLC	0.45MG;200MG	N011045 002	
MILPREM-400				
	MEDPOINTE PHARM HLC	0.45MG;400MG	N011045 001	
PMB 200				
	WYETH AYERST	0.45MG;200MG	N010971 005	
PMB 400				
	WYETH AYERST	0.45MG;400MG	N010971 003	
ESTROGENS, ESTERIFIED				
TABLET;ORAL				
AMNESTROGEN				
	BRISTOL MYERS SQUIBB	0.3MG	A083266 001	
		0.625MG	A083266 002	
		1.25MG	A083266 003	
		2.5MG	A083266 004	
ESTERIFIED ESTROGENS				
	PVT FORM	0.625MG	A083414 001	
		1.25MG	A083765 001	
		2.5MG	A085907 001	
	SANDOZ	1.25MG	A085302 001	
ESTRATAB				
	SOLVAY	0.3MG	A086715 001	
		0.625MG	A083209 001	
		1.25MG	A083856 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

ESTROGENS, ESTERIFIED				
TABLET;ORAL				
ESTRATAB				
	2.5MG		A083857 001	
EVEX				
ROCHE PALO	0.625MG		A084215 001	
	1.25MG		A083376 002	
FEMOGEN				
PVT FORM	0.625MG		A085076 001	
	1.25MG		A085008 001	
	2.5MG		A085007 001	
ESTRONE				
INJECTABLE;INJECTION				
ESTROGENIC SUBSTANCE				
WYETH AYERST	2MG/ML		A083488 001	
ESTRONE				
WATSON LABS	2MG/ML		A083397 001	
WATSON LABS TEVA	5MG/ML		A085239 001	
NATURAL ESTROGENIC SUBSTANCE-ESTRONE				
WATSON LABS	2MG/ML		A085237 001	Nov 23, 1982
THEELIN				
PARKEDALE	1MG/ML		N003977 001	
	2MG/ML		N003977 002	
	5MG/ML		N003977 003	
ESTROPIPATE				
CREAM;VAGINAL				
OGEN				
PHARMACIA AND UPJOHN	1.5MG/GM		A084710 001	
TABLET;ORAL				
ESTROPIPATE				
BARR	0.75MG		A040135 001	Nov 27, 1996
	1.5MG		A040135 002	Nov 27, 1996
	3MG		A040135 003	Nov 27, 1996
DURAMED PHARMS BARR	0.75MG		A040296 001	Nov 01, 1999
	1.5MG		A040296 002	Nov 01, 1999
	3MG		A040296 003	Nov 01, 1999
MYLAN	3MG		A040359 003	Aug 26, 1999
WATSON LABS	0.75MG		A081213 001	Sep 23, 1993
	1.5MG		A081214 001	Sep 23, 1993
	6MG		A081216 001	Sep 23, 1993
WATSON LABS TEVA	3MG		A081215 001	Sep 23, 1993
OGEN .625				
PHARMACIA AND UPJOHN	0.75MG		A083220 001	
OGEN 1.25				
PHARMACIA AND UPJOHN	1.5MG		A083220 002	
OGEN 2.5				
PHARMACIA AND UPJOHN	3MG		A083220 003	
ORTHO-EST				
SUN PHARM INDS INC	0.75MG		A089567 001	Feb 27, 1991
	1.5MG		A089582 001	Jul 17, 1991
ESZOPICLONE				
TABLET;ORAL				
ESZOPICLONE				
WOCKHARDT LTD	1MG		A091165 001	Jul 14, 2011
	2MG		A091165 002	Jul 14, 2011
	3MG		A091165 003	Jul 14, 2011
ETHACRYNIC ACID				
TABLET;ORAL				
EDECRIN				
ATON	50MG		N016092 002	
ETHAMBUTOL HYDROCHLORIDE				
TABLET;ORAL				
MYAMBUTOL				
STI PHARMA LLC	200MG		N016320 002	
	500MG		N016320 004	

ETHCHLORVYNOL

CAPSULE;ORAL				
ETHCHLORVYNOL				
BANNER PHARMACAPS	100MG		A084463 001	
	200MG		A084463 002	
	500MG		A084463 003	
	750MG		A084463 004	
PLACIDYL				
ABBVIE	100MG		N010021 004	
	200MG		N010021 007	
	500MG		N010021 002	
	750MG		N010021 010	

ETHINAMATE

CAPSULE;ORAL				
VALMID				
DISTA	500MG		N009750 001	

ETHINYL ESTRADIOL

TABLET;ORAL				
ESTINYL				
SCHERING	0.02MG		N005292 001	
	0.05MG		N005292 002	
	0.5MG		N005292 003	
FEMINONE				
PHARMACIA AND UPJOHN	0.05MG		N016649 001	
LYNORAL				
ORGANON USA INC	0.01MG		N005490 003	
	0.05MG		N005490 002	

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-21				
DEMULEN 1/35-21				
GD SEARLE LLC	0.035MG;1MG **		N018168 001	
DEMULEN 1/50-21				
GD SEARLE LLC	0.05MG;1MG		N016927 001	
ZOVIA 1/35E-21				
WATSON PHARMS TEVA	0.035MG;1MG		A072720 001	Dec 30, 1991
ZOVIA 1/50E-21				
WATSON LABS	0.05MG;1MG		A072722 001	Dec 30, 1991
TABLET;ORAL-28				
DEMULEN 1/35-28				
GD SEARLE LLC	0.035MG;1MG **		N018160 001	
DEMULEN 1/50-28				
GD SEARLE LLC	0.05MG;1MG **		N016936 001	

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

TABLET;ORAL-28				
NORQUEST FE				
GD SEARLE LLC	0.035MG;75MG;1MG		N018926 001	Jul 18, 1986

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE

TABLET;ORAL-28				
NORLESTRIN FE 1/50				
PARKE DAVIS	0.05MG;75MG;1MG		N016766 001	
NORLESTRIN FE 2.5/50				
PARKE DAVIS	0.05MG;75MG;2.5MG		N016854 001	

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL				
LYBREL				
+ WYETH PHARMS INC	0.02MG;0.09MG **		N021864 001	May 22, 2007
PREVEN EMERGENCY CONTRACEPTIVE KIT				
TEVA BRANDED PHARM	0.05MG;0.25MG		N020946 001	Sep 01, 1998
TABLET;ORAL-21				
ALESSE				
+ CADENCE HEALTH	0.02MG;0.1MG **		N020683 001	Mar 27, 1997
AVIANE-21				
DURAMED PHARMS BARR	0.02MG;0.1MG		A075796 002	Apr 30, 2001
ENPRESSE-21				
DURAMED PHARMS BARR	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG		A075809 001	Jul 16, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL-21					
LESSINA-21					
	BARR	0.02MG;0.1MG	A075803	001	Mar 20, 2002
LEVLITE					
+	BAYER HLTHCARE	0.02MG;0.1MG **	N020860	001	Jul 13, 1998
LEVONORGESTREL AND ETHINYL ESTRADIOL					
	BARR	0.02MG;0.1MG	A075862	001	Apr 29, 2003
LEVORA 0.15/30-21					
	WATSON LABS	0.03MG;0.15MG	A073592	001	Dec 13, 1993
NORDETTE-21					
	TEVA BRANDED PHARM	0.03MG;0.15MG	N018668	001	May 10, 1982
PORTIA-21					
	BARR	0.03MG;0.15MG	A075866	001	May 23, 2002
TRIPHASIL-21					
+	WYETH PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG **	N019192	001	Nov 01, 1984
TRIVORA-21					
	MAYNE PHARMA	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A074538	001	Dec 18, 1997
TABLET;ORAL-28					
ALESSE					
+	CADENCE HEALTH	0.02MG;0.1MG **	N020683	002	Mar 27, 1997
LEVLITE					
+	BAYER HLTHCARE	0.02MG;0.1MG **	N020860	002	Jul 13, 1998
LEVONORGESTREL AND ETHINYL ESTRADIOL					
	BARR	0.02MG;0.1MG	A075862	002	Apr 29, 2003
NORDETTE-28					
+	TEVA BRANDED PHARM	0.03MG;0.15MG **	N018782	001	Jul 21, 1982
TRIPHASIL-28					
+	WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG **	N019190	001	Nov 01, 1984

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL					
ORTHO EVRA					
+	JANSSEN PHARMS	0.035MG/24HR;0.15MG/24HR **	N021180	001	Nov 20, 2001

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21					
BALZIVA-21					
	BARR	0.035MG;0.4MG	A076198	001	Apr 22, 2004
BREVICON 21-DAY					
	ALLERGAN SALES LLC	0.035MG;0.5MG	N017566	001	
GENCEPT 10/11-21					
	BARR	0.035MG,0.035MG;0.5MG,1MG	A072694	001	Feb 28, 1992
MODICON 21					
	ORTHO MCNEIL PHARM	0.035MG;0.5MG **	N017488	001	
N.E.E. 1/35 21					
	LPI	0.035MG;1MG	A071541	001	Dec 14, 1987
NORCEPT-E 1/35 21					
	ORTHO MCNEIL PHARM	0.035MG;1MG	A071545	001	Feb 09, 1989
NORETHIN 1/35E-21					
	WATSON PHARMS TEVA	0.035MG;1MG	A071480	001	Apr 12, 1988
NORETHINDRONE AND ETHINYL ESTRADIOL					
	WATSON LABS	0.035MG;0.4MG	A078379	001	Feb 23, 2010
		0.035MG;0.5MG	A070684	001	Jan 29, 1987
	WATSON PHARMS TEVA	0.035MG;1MG	A070685	001	Jan 29, 1987
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)					
	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071043	001	Apr 01, 1988
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)					
	WATSON LABS TEVA	0.035MG,0.035MG;0.5MG,1MG	A071041	001	Sep 24, 1991
NORTREL 0.5/35-21					
	BARR	0.035MG;0.5MG	A072692	001	Feb 28, 1992
ORTHO-NOVUM 1/35-21					
	ORTHO MCNEIL PHARM	0.035MG;1MG **	N017489	002	
ORTHO-NOVUM 10/11-21					
+	ORTHO MCNEIL JANSSEN	0.035MG,0.035MG;0.5MG,1MG **	N018354	001	Jan 11, 1982
ORTHO-NOVUM 7/14-21					
	ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG **	N019004	001	Apr 04, 1984

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21					
ORTHO-NOVUM 7/7/7-21					
	JANSSEN PHARMS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	N018985	001	Apr 04, 1984
OVCON-35					
+	WARNER CHILCOTT	0.035MG;0.4MG **	N018127	001	
OVCON-50					
	WARNER CHILCOTT	0.05MG;1MG	N018128	001	
TRI-NORINYL 21-DAY					
	MAYNE PHARMA	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N018977	001	Apr 13, 1984
TABLET;ORAL-28					
GENCEPT 10/11-28					
	BARR	0.035MG,0.035MG;0.5MG,1MG	A072697	001	Feb 28, 1992
MODICON 28					
+	JANSSEN PHARMS	0.035MG;0.5MG	N017735	001	
N.E.E. 1/35 28					
	LPI	0.035MG;1MG	A071542	001	Dec 14, 1987
NORCEPT-E 1/35 28					
	ORTHO MCNEIL PHARM	0.035MG;1MG	A071546	001	Feb 09, 1989
NORETHIN 1/35E-28					
	WATSON LABS	0.035MG;1MG	A071481	001	Apr 12, 1988
NORETHINDRONE AND ETHINYL ESTRADIOL					
	MYLAN LABS LTD	0.035MG;0.4MG	A200897	001	May 11, 2015
		0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A200486	001	Dec 28, 2015
		0.035MG;0.5MG	A200488	001	Oct 21, 2015
		0.035MG;1MG	A200489	001	Oct 21, 2015
	WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A076393	001	Feb 04, 2010
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)					
	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071042	001	Sep 24, 1991
ORTHO-NOVUM 10/11-28					
+	ORTHO MCNEIL JANSSEN	0.035MG,0.035MG;0.5MG,1MG	N018354	002	Jan 11, 1982
ORTHO-NOVUM 7/14-28					
	ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG **	N019004	002	Apr 04, 1984
OVCON-35					
+	WARNER CHILCOTT LLC	0.035MG;0.4MG **	N017716	001	
OVCON-50					
	WARNER CHILCOTT LLC	0.05MG;1MG **	N017576	001	

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL					
FEMHRT					
+	APIL	0.005MG;1MG **	N021065	002	Oct 15, 1999
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
	MYLAN LABS LTD	0.01MG,0.01MG;1MG,N/A	A205049	001	May 31, 2016
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
	APOTEX INC	0.02MG;1MG	A208639	001	Mar 21, 2018
TABLET;ORAL-21					
ESTROSTEP 21					
+	APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG **	N020130	001	Oct 09, 1996
NORLESTRIN 21 1/50					
	PARKE DAVIS	0.05MG;1MG	N016749	001	
NORLESTRIN 21 2.5/50					
	PARKE DAVIS	0.05MG;2.5MG	N016852	001	
TABLET;ORAL-28					
NORLESTRIN 28 1/50					
	PARKE DAVIS	0.05MG;1MG	N016723	001	
TABLET, CHEWABLE, TABLET;ORAL					
LO MINASTRIN FE					
+	APIL	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-21					
ORTHO CYCLEN-21					
	JANSSEN PHARMS	0.035MG;0.25MG	N019653	001	Dec 29, 1989
ORTHO TRI-CYCLEN					
	JANSSEN PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	N019697	002	Jul 03, 1992

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28				
NORGESTIMATE AND ETHINYL ESTRADIOL				
WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG	A090479	001	Mar 09, 2011
	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG	A076626	001	Aug 17, 2006
	0.035MG;0.25MG	A076627	001	Aug 17, 2006

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-21				
LO/OVRAL				
CADENCE HEALTH	0.03MG;0.3MG	N017612	001	
LOW-OGESTREL-21				
MAYNE PHARMA	0.03MG;0.3MG	A075288	001	Jul 28, 1999
OGESTREL 0.5/50-21				
WATSON LABS	0.05MG;0.5MG	A075406	001	Dec 15, 1999
OVRAL				
WYETH PHARMS	0.05MG;0.5MG	N016672	001	
TABLET;ORAL-28				
LO/OVRAL-28				
WYETH PHARMS	0.03MG;0.3MG **	N017802	001	
NORGESTREL AND ETHINYL ESTRADIOL				
MYLAN LABS LTD	0.03MG;0.3MG	A201828	001	Jun 21, 2016
	0.05MG;0.5MG	A202875	001	May 08, 2017
OVRAL-28				
WYETH PHARMS	0.05MG;0.5MG	N016806	001	

ETHOPROPAZINE HYDROCHLORIDE

TABLET;ORAL				
PARSIDOL				
PARKE DAVIS	10MG	N009078	003	
	50MG	N009078	006	
	100MG	N009078	008	

ETHOTOIN

TABLET;ORAL				
PEGANONE				
RECORDATI RARE	500MG	N010841	003	

ETHOXZOLAMIDE

TABLET;ORAL				
CARDRASE				
PHARMACIA AND UPJOHN	62.5MG	N011047	002	
	125MG	N011047	001	
ETHAMIDE				
ALLERGAN	125MG	N016144	001	

ETHYLESTRENOL

ELIXIR;ORAL				
MAXIBOLIN				
ORGANON USA INC	2MG/5ML	N014006	002	
TABLET;ORAL				
MAXIBOLIN				
ORGANON USA INC	2MG	N014005	002	

ETHYNODIOL DIACETATE; MESTRANOL

TABLET;ORAL-20				
OVULEN				
GD SEARLE LLC	1MG;0.1MG	N016029	002	
TABLET;ORAL-21				
OVULEN-21				
GD SEARLE LLC	1MG;0.1MG	N016029	003	
TABLET;ORAL-28				
OVULEN-28				
GD SEARLE LLC	1MG;0.1MG	N016705	001	

ETIDOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
DURANEST				
+ ASTRAZENECA	0.5% **	N017751 003		
+	1% **	N017751 005		
ETIDRONATE DISODIUM				
INJECTABLE;INJECTION				
DIDRONEL				
MGI PHARMA INC	50MG/ML	N019545 001	Apr 20, 1987	
TABLET;ORAL				
DIDRONEL				
+ APIL	200MG **	N017831 001		
+	400MG **	N017831 002		
ETODOLAC				
CAPSULE;ORAL				
ETODOLAC				
ANI PHARMS INC	200MG	A074840 001	Aug 29, 1997	
	200MG	A074899 001	Jul 08, 1997	
	300MG	A074840 002	Aug 29, 1997	
	300MG	A074899 002	Jul 08, 1997	
CHARTWELL MOLECULES	200MG	A074842 001	Jul 17, 1997	
	300MG	A074842 002	Jul 17, 1997	
ECI PHARMS LLC	300MG	A074929 001	Jan 30, 1998	
MYLAN	200MG	A074932 001	May 16, 1997	
	200MG	A075071 001	Sep 30, 1998	
	300MG	A074932 002	May 16, 1997	
	300MG	A075071 002	Sep 30, 1998	
SANDOZ	200MG	A074942 001	Sep 30, 1997	
	300MG	A074942 002	Sep 30, 1997	
WATSON LABS	200MG	A074844 001	Dec 23, 1997	
	300MG	A074844 002	Dec 23, 1997	
LODINE				
+ WYETH PHARMS INC	200MG **	N018922 002	Jan 31, 1991	
+	300MG	N018922 003	Jan 31, 1991	
TABLET;ORAL				
ETODOLAC				
CHARTWELL MOLECULES	400MG	A074841 001	Jun 27, 1997	
ECI PHARMS LLC	400MG	A074927 001	Oct 30, 1997	
IVAX SUB TEVA PHARMS	400MG	A074883 001	Feb 28, 1997	
	500MG	A074883 002	Nov 20, 1998	
MYLAN	400MG	A075012 001	Sep 30, 1998	
	500MG	A075012 002	Sep 30, 1998	
MYLAN PHARMS INC	400MG	A075104 001	Feb 06, 1998	
	500MG	A075104 002	Nov 20, 1998	
OXFORD PHARMS	400MG	A074819 001	Feb 28, 1997	
	500MG	A074819 002	Apr 28, 1998	
RANBAXY LABS LTD	400MG	A075226 001	Nov 24, 1998	
	500MG	A075226 002	Nov 24, 1998	
SANDOZ	400MG	A074839 001	Jul 11, 1997	
	400MG	A074846 001	Feb 28, 1997	
TEVA	400MG	A074847 001	Apr 23, 1999	
	500MG	A074847 002	Apr 23, 1999	
WATSON LABS	400MG	A074892 001	Apr 16, 1997	
	400MG	A075069 001	Apr 16, 1998	
	500MG	A074892 002	Oct 29, 1998	
LODINE				
+ WYETH PHARMS INC	400MG **	N018922 004	Jul 29, 1993	
+	500MG **	N018922 005	Jun 28, 1996	
TABLET, EXTENDED RELEASE;ORAL				
ETODOLAC				
ACTAVIS ELIZABETH	400MG	A075696 001	Jul 31, 2000	
ANI PHARMS INC	400MG	A075943 001	Jul 26, 2002	
	500MG	A075943 002	Jul 26, 2002	
	600MG	A075943 003	Jul 26, 2002	
WATSON LABS FLORIDA	400MG	A075829 001	Nov 30, 2001	
	500MG	A075829 002	Nov 30, 2001	
LODINE XL				
WYETH PHARMS INC	400MG **	N020584 001	Oct 25, 1996	

ETODOLAC					
TABLET, EXTENDED RELEASE;ORAL					
LODINE XL					
	500MG **		N020584	003	Jan 20, 1998
+	600MG **		N020584	002	Oct 25, 1996
ETONOGESTREL					
IMPLANT;IMPLANTATION					
IMPLANON					
ORGANON USA INC	68MG/IMPLANT		N021529	001	Jul 17, 2006
ETOPOSIDE					
CAPSULE;ORAL					
VEPESID					
+ DAVA PHARMS INC	50MG		N019557	001	Dec 30, 1986
+	100MG		N019557	002	Dec 30, 1986
INJECTABLE;INJECTION					
ETOPOSIDE					
HOSPIRA	20MG/ML		A074320	001	Aug 30, 1995
	20MG/ML		A074351	001	Aug 30, 1995
PHARMACHEMIE BV	20MG/ML		A074227	001	Feb 22, 1996
PIERRE FABRE	20MG/ML		A074813	001	Jul 09, 1997
TEVA PARENTERAL	20MG/ML		A074510	001	Jun 29, 1995
TEVA PHARMS USA	20MG/ML		A074284	001	Feb 10, 1994
WATSON LABS	20MG/ML		A074228	001	Oct 15, 1996
WATSON LABS INC	20MG/ML		A074968	001	Jan 09, 1998
TOPOSAR					
TEVA PARENTERAL	20MG/ML		A074166	001	Feb 27, 1995
VEPESID					
+ CORDEN PHARMA	20MG/ML **		N018768	001	Nov 10, 1983
ETOPOSIDE PHOSPHATE					
INJECTABLE;INJECTION					
ETOPOPHOS PRESERVATIVE FREE					
BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL		N020906	001	Feb 27, 1998
	EQ 1GM BASE/VIAL		N020906	002	Feb 27, 1998
ETRETINATE					
CAPSULE;ORAL					
TEGISON					
ROCHE	10MG		N019369	001	Sep 30, 1986
	25MG		N019369	002	Sep 30, 1986
EVANS BLUE					
INJECTABLE;INJECTION					
EVANS BLUE					
PARKE DAVIS	0.5% **		N008041	001	
EZOGABINE					
TABLET;ORAL					
POTIGA					
+ GLAXOSMITHKLINE	50MG		N022345	001	Jun 10, 2011
+	200MG		N022345	002	Jun 10, 2011
+	300MG		N022345	003	Jun 10, 2011
+	400MG		N022345	004	Jun 10, 2011
FAMCICLOVIR					
TABLET;ORAL					
FAMVIR					
+ NOVARTIS	125MG **		N020363	003	Dec 11, 1995
+	250MG **		N020363	001	Apr 26, 1996
+	500MG **		N020363	002	Jun 29, 1994
FAMOTIDINE					
INJECTABLE;INJECTION					
FAMOTIDINE					
APOTEX INC	10MG/ML		A075942	001	Aug 02, 2002
APOTHECON	10MG/ML		A075707	001	Apr 16, 2001
HOSPIRA	10MG/ML		A075705	001	Apr 16, 2001
	10MG/ML		A075870	001	Nov 23, 2001
	10MG/ML		A075905	001	Nov 23, 2001
WEST-WARD PHARMS INT	10MG/ML		A075799	001	Apr 30, 2002

FAMOTIDINE

INJECTABLE;INJECTION					
FAMOTIDINE PRESERVATIVE FREE					
	APOTEX INC	10MG/ML	A076324	001	Nov 27, 2002
	APOTHECON	10MG/ML	A075708	001	Apr 16, 2001
	HOSPIRA	10MG/ML	A075669	001	Apr 16, 2001
	WEST-WARD PHARMS INT	10MG/ML	A075789	001	Apr 30, 2002
FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)					
	APOTEX INC	10MG/ML	A076322	001	Nov 27, 2002
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER					
	ABBVIE	0.4MG/ML	A075729	001	Dec 17, 2001
PEPCID					
+	MERCK	10MG/ML **	N019510	001	Nov 04, 1986
PEPCID PRESERVATIVE FREE					
+	MERCK	10MG/ML **	N019510	004	Nov 04, 1986
PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER					
+	MERCK SHARP DOHME	0.4MG/ML **	N020249	001	Feb 18, 1994
TABLET;ORAL					
FAMOTIDINE					
	ACTAVIS ELIZABETH	20MG	A075650	001	Sep 14, 2001
		40MG	A075650	002	Sep 14, 2001
	APOTEX	10MG	A075610	001	Mar 12, 2002
	MYLAN PHARMS INC	20MG	A075457	001	Apr 18, 2001
		40MG	A075457	002	Apr 18, 2001
	PLD ACQUISITIONS	20MG	A075302	001	Apr 16, 2001
		40MG	A075302	002	Apr 16, 2001
	SANDOZ	10MG	A076101	001	Oct 21, 2002
		20MG	A075607	001	May 10, 2001
		20MG	A075793	001	Apr 16, 2001
		40MG	A075607	002	May 10, 2001
		40MG	A075793	002	Apr 16, 2001
	SUN PHARM INDUSTRIES	20MG	A075639	002	Dec 12, 2001
		40MG	A075639	001	Dec 12, 2001
	WATSON LABS	10MG	A075404	001	Nov 28, 2001
		20MG	A075062	002	Apr 16, 2001
		40MG	A075062	001	Apr 16, 2001
TABLET, CHEWABLE;ORAL					
PEPCID AC					
+	J AND J CONSUMER INC	10MG **	N020801	001	Sep 24, 1998
TABLET, ORALLY DISINTEGRATING;ORAL					
FLUXID					
	UCB INC	20MG	N021712	001	Sep 24, 2004
		40MG	N021712	002	Sep 24, 2004
PEPCID RPD					
	MERCK	20MG	N020752	001	May 28, 1998
		40MG	N020752	002	May 28, 1998

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL					
FELODIPINE					
	WOCKHARDT LTD	2.5MG	A091484	001	Aug 15, 2012
		5MG	A091484	002	Aug 15, 2012
		10MG	A091484	003	Aug 15, 2012
PLENDIL					
+	ASTRAZENECA	2.5MG **	N019834	004	Sep 22, 1994
+		5MG **	N019834	001	Jul 25, 1991
+		10MG **	N019834	002	Jul 25, 1991

FENOFIBRATE

CAPSULE;ORAL					
ANTARA (MICRONIZED)					
	LUPIN ATLANTIS	87MG	N021695	002	Nov 30, 2004
LIPIDIL					
	ABBVIE	100MG	N019304	001	Dec 31, 1993
LIPOFEN					
	CIPHER PHARMS INC	100MG	N021612	002	Jan 11, 2006
TRICOR (MICRONIZED)					
+	ABBVIE	67MG **	N019304	002	Feb 09, 1998
+		134MG **	N019304	003	Jun 30, 1999
+		200MG **	N019304	004	Jun 30, 1999

FENOFIBRATE				
TABLET;ORAL				
FENOFIBRATE				
	MYLAN	107MG	A076520 002	Dec 29, 2005
TRICOR				
+	ABBVIE INC	54MG **	N021203 001	Sep 04, 2001
+		160MG **	N021203 003	Sep 04, 2001
TRIGLIDE				
	SKYEPHARMA AG	50MG	N021350 001	May 07, 2005
FENOLDOPAM MESYLATE				
INJECTABLE;INJECTION				
FENOLDOPAM MESYLATE				
	LUITPOLD	EQ 10MG BASE/ML	A076656 001	Dec 01, 2003
	TEVA PARENTERAL	EQ 10MG BASE/ML	A077826 001	Mar 07, 2007
FENOPROFEN CALCIUM				
CAPSULE;ORAL				
FENOPROFEN CALCIUM				
	AM THERAP	EQ 200MG BASE	A072307 001	Aug 22, 1988
		EQ 300MG BASE	A072308 001	Aug 22, 1988
	AUROLIFE PHARMA LLC	EQ 200MG BASE	A072394 001	Oct 17, 1988
		EQ 300MG BASE	A072395 001	Oct 17, 1988
	HALSEY	EQ 200MG BASE	A072355 001	Aug 17, 1988
		EQ 300MG BASE	A072356 001	Aug 17, 1988
	PAR PHARM	EQ 200MG BASE	A072437 001	Aug 22, 1988
		EQ 300MG BASE	A072438 001	Aug 22, 1988
	QUANTUM PHARMICS	EQ 200MG BASE	A072214 001	Aug 17, 1988
		EQ 300MG BASE	A071738 001	Aug 17, 1988
	WARNER CHILCOTT	EQ 200MG BASE	A072946 001	Apr 30, 1991
		EQ 300MG BASE	A072472 001	Apr 30, 1991
	WATSON LABS	EQ 200MG BASE	A072294 001	Aug 17, 1988
		EQ 200MG BASE	A072981 001	Aug 19, 1991
		EQ 300MG BASE	A072293 001	Aug 17, 1988
		EQ 300MG BASE	A072982 001	Aug 19, 1991
NALFON				
	XSPIRE PHARMA	EQ 300MG BASE	N017604 002	
TABLET;ORAL				
FENOPROFEN CALCIUM				
	ACTAVIS ELIZABETH	EQ 600MG BASE	A072274 001	May 02, 1988
	AM THERAP	EQ 600MG BASE	A072309 001	Aug 17, 1988
	AUROLIFE PHARMA LLC	EQ 600MG BASE	A072396 001	Oct 17, 1988
	DAVA PHARMS INC	EQ 600MG BASE	A072326 001	Aug 17, 1988
	HALSEY	EQ 600MG BASE	A072357 001	Aug 17, 1988
	IVAX SUB TEVA PHARMS	EQ 600MG BASE	A072557 001	Aug 29, 1988
	PAR PHARM	EQ 600MG BASE	A072429 001	Aug 17, 1988
	QUANTUM PHARMICS	EQ 600MG BASE	A072194 001	Aug 17, 1988
	SUN PHARM INDUSTRIES	EQ 600MG BASE	A072902 001	Dec 21, 1990
	USL PHARMA	EQ 600MG BASE	A072362 001	Aug 17, 1988
	WATSON LABS	EQ 600MG BASE	A072165 001	Aug 17, 1988
		EQ 600MG BASE	A072602 001	Oct 11, 1988
	WATSON LABS TEVA	EQ 600MG BASE	A072407 001	Aug 17, 1988
NALFON				
	DISTA	EQ 600MG BASE	N017710 001	
FENTANYL				
FILM, EXTENDED RELEASE;TRANSDERMAL				
FENTANYL-100				
	ACTAVIS LABS UT INC	100MCG/HR	A076709 004	Aug 20, 2007
	NOVEN	100MCG/HR	A077775 004	Oct 16, 2009
FENTANYL-25				
	ACTAVIS LABS UT INC	25MCG/HR	A076709 001	Aug 20, 2007
	NOVEN	25MCG/HR	A077775 001	Oct 16, 2009
FENTANYL-50				
	ACTAVIS LABS UT INC	50MCG/HR	A076709 002	Aug 20, 2007
	NOVEN	50MCG/HR	A077775 002	Oct 16, 2009
FENTANYL-75				
	ACTAVIS LABS UT INC	75MCG/HR	A076709 003	Aug 20, 2007
	NOVEN	75MCG/HR	A077775 003	Oct 16, 2009

FENTANYL CITRATE				
FILM;BUCCAL				
ONSOLIS				
BDSI	EQ 0.2MG BASE	N022266	001	Jul 16, 2009
	EQ 0.4MG BASE	N022266	002	Jul 16, 2009
	EQ 0.6MG BASE	N022266	003	Jul 16, 2009
	EQ 0.8MG BASE	N022266	004	Jul 16, 2009
	EQ 1.2MG BASE	N022266	005	Jul 16, 2009
INJECTABLE;INJECTION				
FENTANYL CITRATE				
ABBOTT	EQ 0.05MG BASE/ML	A070636	001	Apr 30, 1990
	EQ 0.05MG BASE/ML	A070637	001	Apr 30, 1990
WATSON LABS	EQ 0.05MG BASE/ML	A073488	001	Jun 30, 1992
FENTANYL CITRATE PRESERVATIVE FREE				
WATSON LABS INC	EQ 0.05MG BASE/ML	A074917	001	Feb 03, 1998
TABLET;BUCCAL, SUBLINGUAL				
FENTANYL CITRATE				
WATSON LABS	EQ 0.1MG BASE	A079075	001	Jan 07, 2011
	EQ 0.2MG BASE	A079075	002	Jan 07, 2011
	EQ 0.4MG BASE	A079075	003	Jan 07, 2011
	EQ 0.6MG BASE	A079075	004	Jan 07, 2011
	EQ 0.8MG BASE	A079075	005	Jan 07, 2011
FENTORA				
+ CEPHALON	EQ 0.3MG BASE **	N021947	006	Mar 02, 2007
TROCHE/LOZENGE;ORAL				
FENTANYL				
CEPHALON	EQ 0.1MG BASE	N020195	007	Oct 30, 1995
	EQ 0.2MG BASE	N020195	001	Oct 04, 1993
	EQ 0.3MG BASE	N020195	002	Oct 04, 1993
	EQ 0.4MG BASE	N020195	003	Oct 04, 1993
TROCHE/LOZENGE;TRANSMUCOSAL				
FENTANYL CITRATE				
PAR PHARM	EQ 0.2MG BASE	A077312	001	Oct 30, 2009
	EQ 0.4MG BASE	A077312	002	Oct 30, 2009
	EQ 0.6MG BASE	A077312	003	Oct 30, 2009
	EQ 0.8MG BASE	A077312	004	Oct 30, 2009
	EQ 1.2MG BASE	A077312	005	Oct 30, 2009
	EQ 1.6MG BASE	A077312	006	Oct 30, 2009
FENTANYL HYDROCHLORIDE				
SYSTEM;IONTOPHORESIS, TRANSDERMAL				
IONSYS				
+ THE MEDICINES CO	EQ 40MCG BASE/ACTIVATION	N021338	001	May 22, 2006
FERRIC AMMONIUM CITRATE				
FOR SOLUTION;ORAL				
FERRISELTZ				
OTSUKA	600MG/PACKET	N020292	001	Oct 14, 1997
FERRIC PYROPHOSPHATE CITRATE				
SOLUTION;INTRAVENOUS				
TRIFERIC				
+ ROCKWELL MEDICAL INC	272MG IRON/50ML (5.44MG IRON/ML)	N206317	002	Sep 04, 2015
FERROUS CITRATE, FE-59				
INJECTABLE;INJECTION				
FERROUS CITRATE FE 59				
MALLINCKRODT	25uCi/ML	N016729	001	
FERROUS SULFATE; FOLIC ACID				
CAPSULE;ORAL				
FOLVRON				
LEDERLE	182MG;0.33MG	N006012	003	
FERUMOXIDES				
INJECTABLE;INJECTION				
FERIDEX I.V.				
AMAG PHARMS INC	EQ 11.2MG IRON/ML	N020416	001	Aug 30, 1996

FERUMOXSIL
SUSPENSION;ORAL
GASTROMARK
AMAG PHARMS INC EQ 0.175MG IRON/ML N020410 001 Dec 06, 1996

FESOTERODINE FUMARATE
TABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATE
ALKEM LABS LTD 4MG A204827 001 Dec 10, 2015
8MG A204827 002 Dec 10, 2015

FEXOFENADINE HYDROCHLORIDE
CAPSULE;ORAL
ALLEGRA
SANOFI AVENTIS US 60MG ** N020625 001 Jul 25, 1996
FEXOFENADINE HYDROCHLORIDE
BARR 60MG A076169 001 Jul 13, 2005
SUSPENSION;ORAL
ALLEGRA
\+ SANOFI AVENTIS US 30MG/5ML N021963 001 Oct 16, 2006
CHILDREN'S ALLEGRA HIVES
\+ SANOFI AVENTIS US 30MG/5ML N201373 002 Jan 24, 2011
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY
TARO PHARM 30MG/5ML A208123 001 Nov 09, 2017
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES
TARO PHARM 30MG/5ML A208123 002 Nov 09, 2017
FEXOFENADINE HYDROCHLORIDE
ACTAVIS MID ATLANTIC 30MG/5ML A201311 001 Jul 25, 2012
TABLET;ORAL
ALLEGRA HIVES
\+ SANOFI AVENTIS US 60MG N020872 008 Jan 24, 2011
\+ 180MG N020872 009 Jan 24, 2011
CHILDREN'S ALLEGRA ALLERGY
\+ SANOFI AVENTIS US 30MG N020872 005 Jan 24, 2011
CHILDREN'S ALLEGRA HIVES
\+ SANOFI AVENTIS US 30MG N020872 006 Jan 24, 2011
TABLET, ORALLY DISINTEGRATING;ORAL
CHILDREN'S ALLEGRA ALLERGY
\+ SANOFI AVENTIS US 30MG N021909 002 Jan 24, 2011
CHILDREN'S ALLEGRA HIVES
\+ SANOFI AVENTIS US 30MG N021909 003 Jan 24, 2011
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY
DR REDDYS LABS LTD 30MG A202978 001 Jan 18, 2013
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES
DR REDDYS LABS LTD 30MG A202978 002 Jan 18, 2013

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE
BARR 60MG;120MG A076236 001 Apr 14, 2005
IMPAX PHARMS 60MG;120MG A076298 001 Nov 12, 2010

FIBRINOGEN, I-125
INJECTABLE;INJECTION
IBRIN
GE HEALTHCARE 154uCi/VIAL N017879 001
RADIONUCLIDE-LABELED (125 I) FIBRINOGEN (HUMAN) SENSOR
ABBOTT 140uCi/ML N017787 001

FINASTERIDE
TABLET;ORAL
FINASTERIDE
GEDEON RICHTER USA 5MG A077251 001 Dec 22, 2006
IVAX SUB TEVA PHARMS 5MG A076340 001 Jun 19, 2006
MYLAN PHARMS INC 1MG A078161 001 Nov 05, 2013

FLAVOXATE HYDROCHLORIDE

TABLET;ORAL

FLAVOXATE HYDROCHLORIDE

IMPAX PHARMS	100MG	A076234	001	Aug 28, 2003

URISPAS

ORTHO MCNEIL JANSSEN	100MG	N016769	001	

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

ANI PHARMS INC	50MG	A076030	001	Oct 28, 2002
	100MG	A076030	002	Oct 28, 2002
	150MG	A076030	003	Oct 28, 2002
APOTEX INC	50MG	A079164	001	Jul 09, 2009
	100MG	A079164	002	Jul 09, 2009
	150MG	A079164	003	Jul 09, 2009

TAMBOCOR

CNTY LINE PHARMS	200MG	N018830	002	Oct 31, 1985

FLORBETAPIR F-18

SOLUTION;INTRAVENOUS

AMYVID

AVID RADIOPHARMS INC	10ML (13.5-51mCi/ML)	N202008	001	Apr 06, 2012

FLOXURIDINE

INJECTABLE;INJECTION

FUDR

+ HOSPIRA	500MG/VIAL **	N016929	001	

FLUCONAZOLE

FOR SUSPENSION;ORAL

FLUCONAZOLE

SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004
	200MG/5ML	A076332	002	Jul 29, 2004
TARO PHARM INDS	50MG/5ML	A076918	001	Dec 18, 2006
	200MG/5ML	A076918	002	Dec 18, 2006

INJECTABLE;INJECTION

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

+ PFIZER	200MG/100ML (2MG/ML)	N019950	003	Sep 29, 1992
+	400MG/200ML (2MG/ML)	N019950	005	Jul 08, 1994

DIFLUCAN IN SODIUM CHLORIDE 0.9%

+ PFIZER	200MG/100ML (2MG/ML)	N019950	001	Jan 29, 1990
+	400MG/200ML (2MG/ML)	N019950	006	Jan 29, 1990

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ PFIZER	200MG/100ML (2MG/ML)	N019950	002	Jan 29, 1990
+	400MG/200ML (2MG/ML)	N019950	004	Jan 29, 1990

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

MYLAN LABS LTD	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005
	400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

TEVA PHARMS USA	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004
	400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA	200MG/100ML (2MG/ML)	A076617	001	Jul 29, 2004
	400MG/200ML (2MG/ML)	A076617	002	Jul 29, 2004
MYLAN LABS LTD	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005
	400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005
TEVA PHARMS	200MG/100ML (2MG/ML)	A076837	001	Jan 13, 2005
	400MG/200ML (2MG/ML)	A076837	002	Jan 13, 2005

TABLET;ORAL

FLUCONAZOLE

ANI PHARMS INC	50MG	A076086	001	Jul 29, 2004
	100MG	A076086	002	Jul 29, 2004
	150MG	A076086	003	Jul 29, 2004
	200MG	A076086	004	Jul 29, 2004
GEDEON RICHTER USA	50MG	A076432	001	Jul 29, 2004
	100MG	A076432	002	Jul 29, 2004
	150MG	A076432	003	Jul 29, 2004
	200MG	A076432	004	Jul 29, 2004
MYLAN PHARMS INC	50MG	A076042	001	Jul 29, 2004
	100MG	A076042	002	Jul 29, 2004

FLUCONAZOLE					
TABLET;ORAL					
FLUCONAZOLE					
		150MG	A076042	003	Jul 29, 2004
		200MG	A076042	004	Jul 29, 2004
	PLIVA	50MG	A076424	001	Jul 29, 2004
		100MG	A076424	002	Jul 29, 2004
		150MG	A076424	003	Jul 29, 2004
		200MG	A076424	004	Jul 29, 2004
	RANBAXY LABS LTD	50MG	A076386	001	Jul 29, 2004
		100MG	A076386	002	Jul 29, 2004
		150MG	A076386	003	Jul 29, 2004
		200MG	A076386	004	Jul 29, 2004
	ROXANE	50MG	A076213	001	Jul 29, 2004
		100MG	A076213	002	Jul 29, 2004
		150MG	A076213	003	Jul 29, 2004
		200MG	A076213	004	Jul 29, 2004
FLUDARABINE PHOSPHATE					
INJECTABLE;INJECTION					
FLUDARA					
+	GENZYME CORP	50MG/VIAL **	N020038	001	Apr 18, 1991
TABLET;ORAL					
OFORTA					
	SANOFI AVENTIS US	10MG	N022273	001	Dec 18, 2008
FLUDEOXYGLUCOSE F-18					
INJECTABLE;INJECTION					
FLUDEOXYGLUCOSE F18					
+	DOWNSTATE CLINCL	4-40mCi/ML **	N020306	001	Aug 19, 1994
+		4-90mCi/ML **	N020306	002	Sep 25, 2001
INJECTABLE;INTRAVENOUS					
FLUDEOXYGLUCOSE F18					
+	FEINSTEIN	20-200mCi/ML	N021870	001	Aug 19, 2005
	MIDWEST MEDCL	20-200mCi/ML	A203736	001	Nov 19, 2015
	WEILL MEDCL COLL	10-100mCi/ML **	N021768	001	Aug 05, 2004
FLUDROCORTISONE ACETATE					
TABLET;ORAL					
FLORINEF					
+	CASPER PHARMA LLC	0.1MG **	N010060	001	
FLUMAZENIL					
INJECTABLE;INJECTION					
FLUMAZENIL					
	BAXTER HLTHCARE CORP	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004
		1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004
	TEVA PHARMS USA	0.5MG/5ML (0.1MG/ML)	A076589	002	Oct 12, 2004
		1MG/10ML (0.1MG/ML)	A076589	001	Oct 12, 2004
ROMAZICON					
+	HOFFMANN LA ROCHE	1MG/10ML (0.1MG/ML) **	N020073	001	Dec 20, 1991
+		0.5MG/5ML (0.1MG/ML) **	N020073	002	Dec 20, 1991
FLUMETHASONE PIVALATE					
CREAM;TOPICAL					
LOCORTEN					
	NOVARTIS	0.03%	N016379	001	
FLUNISOLIDE					
AEROSOL, METERED;INHALATION					
AEROBID					
	ROCHE PALO	0.25MG/INH	N018340	001	Aug 17, 1984
SPRAY, METERED;NASAL					
FLUNISOLIDE					
	APOTEX INC	0.029MG/SPRAY	A077436	001	Aug 09, 2007
NASALIDE					
	IVAX RES	0.025MG/SPRAY **	N018148	001	
NASAREL					
	TEVA BRANDED PHARM	0.029MG/SPRAY	N020409	001	Mar 08, 1995

FLUOCINOLONE ACETONIDE				
CREAM;TOPICAL				
FLUOCET				
ALPHARMA US PHARMS	0.025%	A088360	001	Jan 16, 1984
FLUOCINOLONE ACETONIDE				
ALPHARMA US PHARMS	0.01%	A088361	001	Jan 16, 1984
G AND W LABS	0.025%	A089525	001	Jul 26, 1988
PERRIGO NEW YORK	0.01%	A086810	001	Mar 04, 1982
	0.025%	A086811	001	Mar 04, 1982
PHARMADERM	0.01%	A088047	001	Dec 16, 1982
	0.025%	A088045	001	Dec 16, 1982
PHARMAFAIR	0.01%	A088499	001	Aug 02, 1984
	0.025%	A088506	001	Aug 02, 1984
TARO	0.01%	A040035	001	Oct 31, 1994
	0.01%	A087102	001	Apr 27, 1982
	0.025%	A040042	001	Oct 31, 1994
USL PHARMA	0.01%	A088757	001	Feb 11, 1985
	0.025%	A088756	001	Mar 28, 1985
FLUONID				
ALLERGAN HERBERT	0.025%	A087156	002	Sep 06, 1984
FLUOTREX				
SAVAGE LABS	0.01%	A088174	001	May 06, 1983
	0.025%	A088173	001	Mar 09, 1983
SYNALAR-HP				
MEDIMETRIKS PHARMS	0.2%	N016161	002	
GEL;TOPICAL				
FLUONID				
ALLERGAN HERBERT	0.025%	A087300	001	May 27, 1982
OINTMENT;TOPICAL				
FLUOCINOLONE ACETONIDE				
PHARMADERM	0.025%	A088046	001	Dec 16, 1982
PHARMAFAIR	0.025%	A088507	001	Feb 27, 1984
USL PHARMA	0.025%	A088742	001	Feb 08, 1985
FLUONID				
ALLERGAN HERBERT	0.025%	A087157	001	Sep 06, 1984
FLUOTREX				
SAVAGE LABS	0.025%	A088172	001	Mar 09, 1983
SOLUTION;TOPICAL				
FLUOCINOLONE ACETONIDE				
ALPHARMA US PHARMS	0.01%	A087159	001	Jun 16, 1982
BAUSCH AND LOMB	0.01%	A040059	001	Dec 20, 1993
G AND W LABS INC	0.01%	A207441	001	Sep 28, 2016
GLASSHOUSE PHARMS	0.01%	A209596	001	Dec 26, 2017
MORTON GROVE	0.01%	A088312	001	Jan 27, 1984
PHARMADERM	0.01%	A088048	001	Dec 16, 1982
PHARMAFAIR	0.01%	A088449	001	Feb 08, 1984
FLUONID				
ALLERGAN HERBERT	0.01%	A087158	001	Mar 17, 1983
FLUOTREX				
SAVAGE LABS	0.01%	A088171	001	Mar 09, 1983
FLUOCINONIDE				
CREAM;TOPICAL				
FLUOCINONIDE				
PERRIGO NEW YORK	0.05%	A071790	001	Jul 13, 1988
LIDEX				
+ CNTY LINE PHARMS	0.05%	N016908	002	
SOLUTION;TOPICAL				
FLUOCINONIDE				
TARO	0.05%	A072857	001	Aug 02, 1989
TEVA PHARMS	0.05%	A072522	001	Sep 28, 1990
FLUORESCEIN SODIUM				
INJECTABLE;INJECTION				
FUNDUSCEIN-25				
+ NOVARTIS	25% **	N017869	001	

FLUOROMETHOLONE				
CREAM;TOPICAL				
OXYLONE				
PHARMACIA AND UPJOHN	0.025%	N011748	001	
SUSPENSION/DROPS;OPHTHALMIC				
FLUOR-OP				
NOVARTIS	0.1%	A070185	001	Feb 27, 1986
FLUOROMETHOLONE ACETATE; TOBRAMYCIN				
SUSPENSION/DROPS;OPHTHALMIC				
TOBRASONE				
ALCON	0.1%;0.3%	N050628	001	Jul 21, 1989
FLUOROMETHOLONE; SULFACETAMIDE SODIUM				
SUSPENSION/DROPS;OPHTHALMIC				
FML-S				
ALLERGAN	0.1%;10%	N019525	001	Sep 29, 1989
FLUOROURACIL				
INJECTABLE;INJECTION				
ADRUCIL				
PHARMACIA AND UPJOHN	50MG/ML	A081222	001	Jun 28, 1991
	50MG/ML	N017959	001	
TEVA PARENTERAL	50MG/ML	A040023	001	Oct 18, 1991
	50MG/ML	A081225	001	Aug 28, 1991
FLUOROURACIL				
ABIC	50MG/ML	A088929	001	Mar 04, 1986
ABRAXIS PHARM	50MG/ML	A089152	001	Mar 21, 1986
	50MG/ML	A089428	001	Jan 12, 1987
	50MG/ML	A089519	001	Mar 12, 1987
BEDFORD	50MG/ML	A089508	001	Jan 26, 1988
EBEWE PHARMA	500MG/10ML (50MG/ML)	A040772	001	Aug 11, 2008
FRESENIUS KABI USA	50MG/ML	A040291	001	Mar 24, 1999
	50MG/ML	A040379	001	Nov 15, 2000
MARCHAR	50MG/ML	A087791	001	Jan 18, 1983
SANDOZ	2.5GM/50ML (50MG/ML)	A091299	001	May 02, 2011
	5GM/100ML (50MG/ML)	A091299	002	May 02, 2011
SMITH AND NEPHEW	50MG/ML	A088766	001	Dec 28, 1984
	50MG/ML	A088767	001	Dec 28, 1984
	50MG/ML	A089434	001	Mar 26, 1987
SPECTRUM PHARMS	50MG/ML	A087792	001	Oct 13, 1982
+	500MG/10ML (50MG/ML) **	N012209	001	
+	2.5GM/50ML (50MG/ML)	N012209	002	Jul 29, 2016
SOLUTION;TOPICAL				
FLUOROPLEX				
ELORAC	1%	N016765	001	
FLUOXETINE HYDROCHLORIDE				
CAPSULE;ORAL				
FLUOXETINE				
SUN PHARM INDUSTRIES	EQ 10MG BASE	A075787	001	Jan 29, 2002
	EQ 20MG BASE	A075787	002	Jan 29, 2002
WATSON LABS	EQ 10MG BASE	A075662	001	Jan 29, 2002
	EQ 20MG BASE	A075662	002	Jan 29, 2002
FLUOXETINE HYDROCHLORIDE				
ANI PHARMS INC	EQ 10MG BASE	A076287	001	May 20, 2008
	EQ 20MG BASE	A076287	002	May 20, 2008
BARR	EQ 40MG BASE	A076251	001	May 18, 2005
CARLSBAD	EQ 10MG BASE	A076022	001	Jan 30, 2002
	EQ 20MG BASE	A076022	002	Jan 30, 2002
CR DOUBLE CRANE	EQ 10MG BASE	A076165	001	Feb 01, 2002
	EQ 20MG BASE	A076165	002	Feb 01, 2002
MYLAN	EQ 10MG BASE	A075207	001	Jan 30, 2002
	EQ 20MG BASE	A075207	002	Jan 30, 2002
	EQ 40MG BASE	A075207	003	May 25, 2007
MYLAN PHARMS INC	EQ 10MG BASE	A075577	001	Jan 29, 2002
	EQ 20MG BASE	A075577	002	Jan 29, 2002
PAR PHARM	EQ 10MG BASE	A076922	001	Dec 16, 2004
	EQ 20MG BASE	A076922	002	Dec 16, 2004
SANDOZ	EQ 10MG BASE	A075807	001	Jan 29, 2002
	EQ 10MG BASE	A077469	001	Nov 17, 2008

FLUOXETINE HYDROCHLORIDE				
CAPSULE;ORAL				
FLUOXETINE HYDROCHLORIDE				
	EQ 20MG BASE	A075807	002	Jan 29, 2002
	EQ 20MG BASE	A077469	002	Nov 17, 2008
WOCKHARDT LTD	EQ 10MG BASE	A078143	001	Jan 16, 2008
	EQ 20MG BASE	A078143	002	Jan 16, 2008
	EQ 40MG BASE	A078143	003	Jan 16, 2008
PROZAC				
ELI LILLY AND CO	EQ 60MG BASE	N018936	004	Jun 15, 1999
SARAFEM				
+ ELI LILLY AND CO	EQ 10MG BASE **	N018936	007	Jul 06, 2000
+	EQ 20MG BASE **	N018936	008	Jul 06, 2000
SOLUTION;ORAL				
FLUOXETINE HYDROCHLORIDE				
ACTAVIS MID ATLANTIC	EQ 20MG BASE/5ML	A075690	001	Jan 31, 2002
APOTEX INC	EQ 20MG BASE/5ML	A075292	001	Feb 07, 2002
AUROBINDO PHARMA LTD	EQ 20MG BASE/5ML	A079209	001	Mar 20, 2009
HI TECH PHARMA	EQ 20MG BASE/5ML	A075525	001	Jun 27, 2002
LANNETT CO INC	EQ 20MG BASE/5ML	A076458	001	May 14, 2004
PROZAC				
+ LILLY	EQ 20MG BASE/5ML **	N020101	001	Apr 24, 1991
TABLET;ORAL				
FLUOXETINE HYDROCHLORIDE				
BARR	EQ 10MG BASE	A075810	001	Feb 01, 2002
FOSUN PHARMA	EQ 10MG BASE	A076024	001	Jan 29, 2002
IVAX SUB TEVA PHARMS	EQ 10MG BASE	A075865	001	Feb 28, 2002
	EQ 40MG BASE	A075865	003	Aug 30, 2004
PROZAC				
+ LILLY	EQ 10MG BASE **	N020974	001	Mar 09, 1999
+	EQ 20MG BASE **	N020974	002	Mar 09, 1999
FLUOXYMESTERONE				
TABLET;ORAL				
ANDROID-F				
VALEANT PHARM INTL	10MG	A087196	001	
FLUOXYMESTERONE				
VALEANT PHARM INTL	10MG	A088221	001	May 05, 1983
WATSON LABS	2MG	A088260	001	Dec 06, 1983
	5MG	A088265	001	Dec 06, 1983
	10MG	A088309	001	Dec 06, 1983
HALOTESTIN				
PHARMACIA AND UPJOHN	2MG	N010611	002	
	5MG	N010611	006	
	10MG	N010611	010	
ORA-TESTRYL				
BRISTOL MYERS SQUIBB	2MG	N011359	001	
	5MG	N011359	002	
FLUPHENAZINE DECANOATE				
INJECTABLE;INJECTION				
FLUPHENAZINE DECANOATE				
HOSPIRA	25MG/ML	A074966	001	Apr 16, 1998
TEVA PARENTERAL	25MG/ML	A074795	001	Sep 10, 1996
PROLIXIN DECANOATE				
+ BRISTOL MYERS SQUIBB	25MG/ML **	N016727	001	
FLUPHENAZINE ENANTHATE				
INJECTABLE;INJECTION				
PROLIXIN ENANTHATE				
APOTHECON	25MG/ML **	N016110	001	
FLUPHENAZINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
FLUPHENAZINE HYDROCHLORIDE				
ANI PHARMS INC	5MG/ML	A073058	001	Aug 30, 1991
PERMITIL				
SCHERING	5MG/ML **	N016008	001	
PROLIXIN				
APOTHECON	5MG/ML	A070533	001	Nov 07, 1985

FLUPHENAZINE HYDROCHLORIDE				
ELIXIR;ORAL				
FLUPHENAZINE HYDROCHLORIDE				
	ANI PHARMS INC	2.5MG/5ML	A081310 001	Apr 29, 1993
PROLIXIN				
+	APOTHECON	2.5MG/5ML **	N012145 003	
INJECTABLE;INJECTION				
PROLIXIN				
	APOTHECON	2.5MG/ML **	N011751 005	
TABLET;ORAL				
FLUPHENAZINE HYDROCHLORIDE				
	WATSON LABS	1MG	A088555 001	Dec 18, 1987
		2.5MG	A088544 001	Dec 18, 1987
		5MG	A088527 001	Dec 18, 1987
		10MG	A088550 001	Dec 18, 1987
PERMITIL				
	SCHERING	0.25MG	N012034 001	
		2.5MG	N012034 004	
		5MG	N012034 005	
		10MG	N012034 006	
PROLIXIN				
+	APOTHECON	1MG **	N011751 004	
+		2.5MG **	N011751 001	
+		5MG **	N011751 003	
+		10MG **	N011751 002	
TABLET, EXTENDED RELEASE;ORAL				
PERMITIL				
	SCHERING	1MG	N012419 004	
FLUPREDNISOLONE				
TABLET;ORAL				
ALPHADROL				
	PHARMACIA AND UPJOHN	1.5MG	N012259 002	
FLURANDRENOLIDE				
LOTION;TOPICAL				
FLURANDRENOLIDE				
	ALPHARMA US PHARMS	0.05%	A087203 001	Apr 29, 1982
OINTMENT;TOPICAL				
CORDRAN				
+	AQUA PHARMS	0.025% **	N012806 004	
FLURANDRENOLIDE; NEOMYCIN SULFATE				
CREAM;TOPICAL				
CORDRAN N				
	LILLY	0.05%;EQ 3.5MG BASE/GM	N050346 001	
OINTMENT;TOPICAL				
CORDRAN N				
	LILLY	0.05%;EQ 3.5MG BASE/GM	N050345 001	
FLURAZEPAM HYDROCHLORIDE				
CAPSULE;ORAL				
DALMANE				
	VALEANT PHARM INTL	15MG **	N016721 001	
+		30MG **	N016721 002	
FLURAZEPAM HYDROCHLORIDE				
	AUROLIFE PHARMA LLC	15MG	A071717 002	Jul 31, 1991
		30MG	A071717 001	Jul 31, 1991
	HALSEY	15MG	A071808 001	Jan 07, 1988
		30MG	A071809 001	Jan 07, 1988
	HIKMA INTL PHARMS	15MG	A071107 001	Dec 08, 1986
	HIKMA PHARMS	30MG	A071108 001	Dec 08, 1986
	PAR PHARM	15MG	A070444 001	Mar 20, 1986
		30MG	A070445 001	Mar 20, 1986
	PUREPAC PHARM	15MG	A071927 001	Sep 09, 1987
		30MG	A071551 001	Sep 09, 1987
	SUN PHARM INDUSTRIES	15MG	A070454 001	Aug 04, 1986
		30MG	A070455 001	Aug 04, 1986
	SUPERPHARM	15MG	A071659 001	Aug 04, 1988
		30MG	A071660 001	Aug 04, 1988
	USL PHARMA	15MG	A070562 001	Jul 09, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

FLURAZEPAM HYDROCHLORIDE					
CAPSULE;ORAL					
FLURAZEPAM HYDROCHLORIDE					
	30MG		A070563	001	Jul 09, 1987
WARNER CHILCOTT	15MG		A071767	001	Dec 04, 1987
	30MG		A071768	001	Dec 04, 1987
WATSON LABS	15MG		A071205	001	Nov 25, 1986
	15MG		A072368	001	Mar 30, 1989
	30MG		A071068	001	Nov 25, 1986
	30MG		A072369	001	Mar 30, 1989
FLURBIPROFEN					
TABLET;ORAL					
ANSAID					
PHARMACIA AND UPJOHN	50MG		N018766	002	Oct 31, 1988
	100MG		N018766	003	Oct 31, 1988
FLURBIPROFEN					
AUROLIFE PHARMA LLC	50MG		A074448	001	Jul 28, 1995
	100MG		A074448	002	Jul 28, 1995
IVAX SUB TEVA PHARMS	50MG		A074411	001	May 31, 1995
	100MG		A074411	002	May 31, 1995
PLIVA	50MG		A074647	001	Apr 01, 1997
	100MG		A074647	002	Apr 01, 1997
TEVA	50MG		A074405	002	May 24, 1995
	100MG		A074405	001	May 24, 1995
THERAGEN	100MG		A074560	002	May 16, 1997
FLUTAMIDE					
CAPSULE;ORAL					
EULEXIN					
+ SCHERING	125MG		N018554	001	Jan 27, 1989
FLUTAMIDE					
MYLAN	125MG		A076224	001	May 09, 2003
YAOPHARMA CO LTD	125MG		A075818	001	Sep 18, 2001
FLUTEMETAMOL F-18					
INJECTABLE;INTRAVENOUS					
VIZAMYL					
+ GE HEALTHCARE	40.5mCi/10ML (4.05mCi/ML)		N203137	001	Oct 25, 2013
FLUTICASONE PROPIONATE					
AEROSOL, METERED;INHALATION					
FLOVENT					
GLAXOSMITHKLINE	0.044MG/INH		N020548	001	Mar 27, 1996
	0.11MG/INH		N020548	002	Mar 27, 1996
	0.22MG/INH		N020548	003	Mar 27, 1996
CREAM;TOPICAL					
CUTIVATE					
+ FOUGERA PHARMS	0.05% **		N019958	001	Dec 18, 1990
FLUTICASONE PROPIONATE					
NESHER PHARMS	0.05%		A076865	001	Sep 10, 2004
OINTMENT;TOPICAL					
CUTIVATE					
+ FOUGERA PHARMS	0.005%		N019957	001	Dec 14, 1990
FLUTICASONE PROPIONATE					
FOUGERA PHARMS	0.005%		A076300	001	May 14, 2004
TARO PHARM INDS	0.005%		A077145	001	Jun 14, 2005
POWDER;INHALATION					
FLOVENT					
GLAXOSMITHKLINE	0.044MG/INH		N020549	001	Nov 07, 1997
	0.088MG/INH		N020549	002	Nov 07, 1997
	0.22MG/INH		N020549	003	Nov 07, 1997
SPRAY, METERED;NASAL					
FLONASE					
+ GLAXOSMITHKLINE	0.05MG/SPRAY **		N020121	001	Oct 19, 1994

FLUVASTATIN SODIUM

CAPSULE;ORAL					
LESCOL					
+	NOVARTIS	EQ 20MG BASE **	N020261	001	Dec 31, 1993
+		EQ 40MG BASE **	N020261	002	Dec 31, 1993

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL					
LUVOX CR					
+	JAZZ PHARMS	100MG **	N022033	001	Feb 28, 2008
+		150MG **	N022033	002	Feb 28, 2008
TABLET;ORAL					
FLUVOXAMINE MALEATE					
	ACTAVIS ELIZABETH	25MG	A075901	001	Dec 28, 2000
		50MG	A075901	002	Dec 28, 2000
		100MG	A075901	003	Dec 28, 2000
	ANI PHARMS INC	25MG	A075898	001	Mar 12, 2001
		50MG	A075898	002	Mar 12, 2001
		100MG	A075898	003	Mar 12, 2001
	ECI PHARMS LLC	25MG	A075900	001	Feb 23, 2006
		50MG	A075900	002	Feb 23, 2006
		100MG	A075900	003	Feb 23, 2006
	MYLAN	50MG	A075950	001	Oct 15, 2001
		100MG	A075950	002	Oct 15, 2001
	SUN PHARM INDUSTRIES	25MG	A076125	001	Apr 29, 2002
		50MG	A076125	002	Apr 29, 2002
		100MG	A076125	003	Apr 29, 2002
	SYNTHON PHARMS	25MG	A075899	001	Jan 17, 2001
		50MG	A075899	002	Jan 17, 2001
		100MG	A075899	003	Jan 17, 2001
	UPSHER SMITH LABS	25MG	A075887	001	Jan 05, 2001
		50MG	A075887	002	Jan 05, 2001
		100MG	A075887	003	Jan 05, 2001
	WATSON LABS	25MG	A075894	001	Apr 18, 2001
		50MG	A075894	002	Apr 18, 2001
		100MG	A075894	003	Apr 18, 2001
LUVOX					
+	SOLVAY	25MG **	N020243	001	Dec 05, 1994
+		50MG **	N020243	002	Dec 05, 1994
+		100MG **	N020243	003	Dec 05, 1994
+		150MG **	N020243	004	Dec 05, 1994

FOLIC ACID

INJECTABLE;INJECTION					
FOLIC ACID					
	BEN VENUE	5MG/ML	A081066	001	Dec 29, 1993
FOLVITE					
	WYETH PHARMS INC	5MG/ML	N005897	008	
TABLET;ORAL					
FOLIC ACID					
	BARR	1MG	A089177	001	Jan 08, 1986
	CONTRACT PHARMACAL	1MG	A085061	001	
	EVERYLIFE	1MG	A080755	001	
	HALSEY	1MG	A083598	001	
	IMPAX LABS	1MG	A080686	001	
	IVAX SUB TEVA PHARMS	1MG	A083000	001	
	JUBILANT CADISTA	1MG	A040514	001	Jun 14, 2005
	LANNETT	1MG	A080816	001	
	LILLY	1MG	N006135	003	
	MK LABS	1MG	A083526	001	
	NEXGEN PHARMA INC	1MG	A084915	001	
	PHARMERAL	1MG	A084158	001	
	PIONEER PHARMS	1MG	A088949	001	Sep 13, 1985
	PUREPAC PHARM	1MG	A080784	001	
	SANDOZ	1MG	A084472	001	
	SUN PHARM INDUSTRIES	1MG	A040582	001	Jul 18, 2005
	TABLICAPS	1MG	A083133	002	
	UDL	1MG	A088199	001	Mar 29, 1983
	USL PHARMA	1MG	A087828	001	May 13, 1982
	VALEANT PHARM INTL	1MG	A080903	001	

FOLIC ACID

TABLET;ORAL				
FOLIC ACID				
VANGARD	1MG	A088730	001	Mar 23, 1984
VINTAGE PHARMS	1MG	A086296	001	
WATSON LABS	1MG	A083141	001	
	1MG	A085141	002	
WHITEWORTH TOWN PLSN	1MG	A080691	002	
FOLICET				
MISSION PHARMA	1MG	A087438	001	
FOLVITE				
WYETH PHARMS INC	1MG	N005897	004	

FOLLITROPIN ALFA/BETA

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS				
FOLLISTIM				
ORGANON USA INC	75 IU/VIAL	N020582	001	Sep 29, 1997
	150 IU/VIAL	N020582	002	Sep 29, 1997
INJECTABLE;SUBCUTANEOUS				
FOLLISTIM AQ				
ORGANON USA INC	75 IU/0.5ML	N021273	001	Aug 26, 2005
	150 IU/0.18ML	N021211	003	Feb 11, 2004
	150 IU/0.5ML	N021273	002	Aug 26, 2005
GONAL-F				
EMD SERONO	37.5 IU/VIAL	N020378	003	May 25, 2000
	37.5 IU/VIAL	N021765	001	Mar 25, 2004
	75 IU/VIAL	N020378	001	Sep 29, 1997
	150 IU/VIAL	N020378	002	Sep 29, 1997
	150 IU/VIAL	N021765	003	Mar 25, 2004

FOMEPIZOLE

INJECTABLE;INJECTION				
FOMEPIZOLE				
MYLAN INSTITUTIONAL	1.5GM/1.5ML (1GM/ML)	A079033	001	Apr 07, 2009

FOMIVIRSEN SODIUM

INJECTABLE;INJECTION				
VITRAVENE PRESERVATIVE FREE				
NOVARTIS	6.6MG/ML	N020961	001	Aug 26, 1998

FORMOTEROL FUMARATE

POWDER;INHALATION				
FORADIL				
+ NOVARTIS	0.012MG/INH	N020831	001	Feb 16, 2001
FORADIL CERTIHALER				
NOVARTIS	0.0085MG/INH	N021592	001	Dec 15, 2006

FOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS				
EMEND				
+ MERCK AND CO INC	EQ 115MG BASE/VIAL **	N022023	001	Jan 25, 2008

FOSCARNET SODIUM

INJECTABLE;INJECTION				
FOSCARNET SODIUM				
HOSPIRA	2.4GM/100ML	A077174	001	May 31, 2005

FOSINOPRIL SODIUM

TABLET;ORAL				
FOSINOPRIL SODIUM				
ACTAVIS LABS FL INC	10MG	A076620	001	Oct 15, 2004
	20MG	A076620	002	Oct 15, 2004
	40MG	A076620	003	Oct 15, 2004
RANBAXY LABS LTD	10MG	A076580	001	Apr 23, 2004
	20MG	A076580	002	Apr 23, 2004
	40MG	A076580	003	Apr 23, 2004
UPSHER SMITH LABS	10MG	A076188	001	Oct 08, 2004
	20MG	A076188	002	Oct 08, 2004
	40MG	A076188	003	Oct 08, 2004
WATSON LABS	10MG	A076987	001	Dec 23, 2004
	10MG	A077531	001	Aug 31, 2006
	20MG	A076987	002	Dec 23, 2004
	20MG	A077531	002	Aug 31, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

FOSINOPRIL SODIUM

TABLET;ORAL

FOSINOPRIL SODIUM

		40MG	A076987	003	Dec 23, 2004
		40MG	A077531	003	Aug 31, 2006

MONOPRIL

+	BRISTOL MYERS SQUIBB	10MG **	N019915	002	May 16, 1991
+		20MG **	N019915	003	May 16, 1991
+		40MG **	N019915	004	Mar 28, 1995

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

	ACTAVIS LABS FL INC	10MG;12.5MG	A076608	001	Dec 03, 2004
		20MG;12.5MG	A076608	002	Dec 03, 2004
	MYLAN	10MG;12.5MG	A077705	001	Aug 14, 2006
		20MG;12.5MG	A077705	002	Aug 14, 2006
	SUN PHARM INDS LTD	10MG;12.5MG	A076739	001	Dec 17, 2004
		20MG;12.5MG	A076739	002	Dec 17, 2004
	TEVA	10MG;12.5MG	A076945	001	Jul 05, 2006
		20MG;12.5MG	A076945	002	Jul 05, 2006
	WATSON LABS	10MG;12.5MG	A077144	001	Aug 16, 2005
		20MG;12.5MG	A077144	002	Aug 16, 2005

MONOPRIL-HCT

+	BRISTOL MYERS SQUIBB	10MG;12.5MG **	N020286	002	Nov 30, 1994
+		20MG;12.5MG **	N020286	001	Nov 30, 1994

FOSPHENYTOIN SODIUM

INJECTABLE;INJECTION

FOSPHENYTOIN SODIUM

	APOTEX INC	EQ 50MG PHENYTOIN NA/ML	A078126	001	Aug 06, 2007
	HOSPIRA	EQ 50MG PHENYTOIN NA/ML	A078158	001	Aug 06, 2007
	TEVA PHARMS USA	EQ 50MG PHENYTOIN NA/ML	A076886	001	Aug 06, 2007

FOSPROPOFOL DISODIUM

SOLUTION;INTRAVENOUS

LUSEDRA

	EISAI INC	1050MG/30ML (35MG/ML)	N022244	001	Dec 12, 2008

FURAZOLIDONE

SUSPENSION;ORAL

FUROXONE

	SHIRE	50MG/15ML	N011323	002	

TABLET;ORAL

FUROXONE

	SHIRE	100MG	N011270	002	

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

	ABRAXIS PHARM	10MG/ML	N018507	001	Jul 30, 1982
		10MG/ML	N019036	001	Aug 13, 1984
	ACCORD HLTHCARE	10MG/ML	A070017	001	Dec 15, 1986
	ASTRAZENECA	10MG/ML	A070014	001	Sep 09, 1985
	HOSPIRA	10MG/ML	A070578	001	Jul 08, 1987
		10MG/ML	A072080	001	Aug 13, 1991
		10MG/ML	A074337	001	Oct 31, 1994
	IGI LABS INC	10MG/ML	A070095	001	Sep 09, 1985
		10MG/ML	A070096	001	Sep 09, 1985
	INTL MEDICATION	10MG/ML	N018025	001	
+	LUITPOLD	10MG/ML **	N018579	001	Nov 30, 1983
	MARSAM PHARMS LLC	10MG/ML	A074017	001	Jun 30, 1994
	SMITH AND NEPHEW	10MG/ML	A070023	001	Feb 05, 1986
		10MG/ML	A070078	001	Feb 05, 1986
	WARNER CHILCOTT	10MG/ML	N018420	001	Feb 26, 1982
	WATSON LABS	10MG/ML	A070019	001	Sep 22, 1986
		10MG/ML	A070604	001	Jan 02, 1987
	WEST-WARD PHARMS INT	10MG/ML	A071439	001	Sep 14, 1990
		10MG/ML	N018267	001	
	WYETH AYERST	10MG/ML	N018670	001	Jul 20, 1982

FUROSEMIDE

INJECTABLE;INJECTION				
LASIX				
+	SANOFI AVENTIS US	10MG/ML **	N016363 001	
SOLUTION;ORAL				
LASIX				
	SANOFI AVENTIS US	10MG/ML	N017688 001	
TABLET;ORAL				
FUROSEMIDE				
	DAVA PHARMS INC	20MG	N018415 001	Jul 27, 1982
		40MG	N018415 002	Jul 27, 1982
		80MG	N018415 003	Nov 26, 1984
	INTL MEDICATION	20MG	N018753 001	Feb 28, 1984
		40MG	N018753 002	Feb 28, 1984
	KALAPHARM	20MG	N018868 001	Jun 28, 1983
		40MG	N018868 002	Jun 28, 1983
	SANDOZ	40MG	N018750 002	Jul 30, 1984
	SUN PHARM INDS INC	20MG	A091258 001	Apr 01, 2014
		40MG	A091258 002	Apr 01, 2014
		40MG	N018790 001	Nov 29, 1983
		80MG	A091258 003	Apr 01, 2014
	SUN PHARM INDUSTRIES	20MG	A070043 001	Sep 26, 1985
		80MG	A070100 001	Jan 26, 1988
	SUPERPHARM	20MG	N018370 002	Jun 26, 1984
		40MG	N018370 001	Feb 10, 1983
	WARNER CHILCOTT	20MG	N018419 001	Jan 31, 1983
		40MG	N018419 002	Jan 31, 1983
		80MG	N018419 003	Nov 13, 1984
	WATSON LABS	20MG	A070412 001	Feb 26, 1986
		20MG	A071379 001	Jan 02, 1987
		20MG	N018369 001	May 14, 1982
		40MG	A070413 001	Feb 26, 1986
		40MG	A070450 001	Nov 22, 1985
		40MG	N018369 002	May 14, 1982
		80MG	A071594 001	Feb 09, 1988
	WATSON LABS TEVA	20MG	A070449 001	Nov 22, 1985
		80MG	A070528 001	Jan 07, 1986

GABAPENTIN

CAPSULE;ORAL				
GABAPENTIN				
	CSPC OUYI PHARM CO	100MG	A075477 001	Mar 23, 2005
		300MG	A075477 002	Mar 23, 2005
		400MG	A075477 003	Mar 23, 2005
	HIKMA	100MG	A078150 001	Sep 25, 2007
		300MG	A078150 002	Sep 25, 2007
		400MG	A078150 003	Sep 25, 2007
	SANDOZ	100MG	A075428 001	Jan 24, 2006
		100MG	A075539 001	Apr 06, 2005
		300MG	A075428 002	Jan 24, 2006
		300MG	A075539 002	Apr 06, 2005
		400MG	A075428 003	Jan 24, 2006
		400MG	A075539 003	Apr 06, 2005
	SUN PHARM INDS LTD	100MG	A076606 001	Oct 07, 2005
		300MG	A076606 002	Oct 07, 2005
		400MG	A076606 003	Oct 07, 2005
	SUN PHARM INDUSTRIES	100MG	A076537 001	Jun 30, 2005
		300MG	A076537 002	Jun 30, 2005
		400MG	A076537 003	Jun 30, 2005
	WATSON LABS	100MG	A075485 003	May 11, 2007
		300MG	A075485 002	May 11, 2007
		400MG	A075485 001	May 11, 2007
TABLET;ORAL				
GABAPENTIN				
	HIKMA PHARMS	600MG	A078782 001	Jul 21, 2011
		800MG	A078782 002	Jul 21, 2011
	RANBAXY	600MG	A076605 001	Sep 14, 2005
		800MG	A076605 002	Sep 14, 2005
	SANDOZ	600MG	A076120 001	Jan 27, 2006
		600MG	A076877 001	Jul 06, 2006

GABAPENTIN
TABLET;ORAL
GABAPENTIN

	800MG	A076120	002	Jan 27, 2006
	800MG	A076877	002	Jul 06, 2006
TEVA	600MG	A075827	001	Dec 15, 2004
	800MG	A075827	002	Dec 15, 2004

GADODIAMIDE
INJECTABLE;INJECTION
OMNISCAN

GE HEALTHCARE	14.35GM/50ML (287MG/ML)	N022066	001	Sep 05, 2007

GADOFOSVESET TRISODIUM
SOLUTION;INTRAVENOUS
ABLAVAR

LANTHEUS MEDCL	2440MG/10ML (244MG/ML)	N021711	001	Dec 22, 2008
	3660MG/15ML (244MG/ML)	N021711	002	Dec 22, 2008

GADOVERSETAMIDE
INJECTABLE;INJECTION
OPTIMARK

+	LIEBEL-FLARSHEIM	1654.5MG/5ML (330.9MG/ML)	N020937	001	Dec 08, 1999
+		3309MG/10ML (330.9MG/ML)	N020937	002	Dec 08, 1999
+		4963.5MG/15ML (330.9MG/ML)	N020937	003	Dec 08, 1999
+		6618MG/20ML (330.9MG/ML)	N020937	004	Dec 08, 1999
+		16.545GM/50ML (330.9MG/ML)	N020975	001	Dec 08, 1999

OPTIMARK IN PLASTIC CONTAINER

+	LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N020976	002	Dec 08, 1999
+		4963.5MG/15ML (330.9MG/ML)	N020976	003	Dec 08, 1999
+		6618MG/20ML (330.9MG/ML)	N020976	004	Dec 08, 1999
+		9927MG/30ML (330.9MG/ML)	N020976	001	Dec 08, 1999

GALANTAMINE HYDROBROMIDE
CAPSULE, EXTENDED RELEASE;ORAL
GALANTAMINE HYDROBROMIDE

IMPAX LABS	EQ 8MG BASE	A078484	001	May 27, 2009
	EQ 16MG BASE	A078484	002	May 27, 2009
	EQ 24MG BASE	A078484	003	May 27, 2009
MYLAN	EQ 8MG BASE	A090900	001	Jan 24, 2011
	EQ 16MG BASE	A090900	002	Jan 24, 2011
	EQ 24MG BASE	A090900	003	Jan 24, 2011

SOLUTION;ORAL
RAZADYNE

JANSSEN PHARMS	4MG/ML **	N021224	001	Jun 22, 2001

TABLET;ORAL
GALANTAMINE HYDROBROMIDE

ACTAVIS ELIZABETH	EQ 4MG BASE	A077585	001	Sep 15, 2009
	EQ 8MG BASE	A077585	002	Sep 15, 2009
	EQ 12MG BASE	A077585	003	Sep 15, 2009
MYLAN	EQ 4MG BASE	A077603	001	Aug 28, 2008
	EQ 8MG BASE	A077603	002	Aug 28, 2008
	EQ 12MG BASE	A077603	003	Aug 28, 2008

GALLAMINE TRIETHIODIDE
INJECTABLE;INJECTION
FLAXEDIL

DAVIS AND GECK	20MG/ML	N007842	001	
	100MG/ML	N007842	002	

GALLIUM CITRATE GA-67
INJECTABLE;INJECTION
GALLIUM CITRATE GA 67

GE HEALTHCARE	1mCi/ML	N017700	001	

NEOSCAN

GE HEALTHCARE	2mCi/ML	N017655	001	

GALLIUM NITRATE					
INJECTABLE;INJECTION					
GANITE					
	CHAPTER 7 TRUSTEE	25MG/ML **	N019961	002	Jan 17, 1991
GANCICLOVIR					
CAPSULE;ORAL					
CYTOVENE					
+	ROCHE PALO	250MG **	N020460	001	Dec 22, 1994
+		500MG **	N020460	002	Dec 12, 1997
GANCICLOVIR					
	RANBAXY LABS LTD	250MG	A076457	001	Jun 27, 2003
		500MG	A076457	002	Jun 27, 2003
IMPLANT;IMPLANTATION					
VITRASERT					
	BAUSCH AND LOMB	4.5MG	N020569	001	Mar 04, 1996
GANCICLOVIR SODIUM					
INJECTABLE;INJECTION					
GANCICLOVIR SODIUM					
	WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A076222	001	Jul 16, 2003
GATIFLOXACIN					
SOLUTION/DROPS;OPHTHALMIC					
GATIFLOXACIN					
	APOTEX INC	0.3%	A079084	001	Aug 19, 2011
GEFITINIB					
TABLET;ORAL					
IRESSA					
	ASTRAZENECA	250MG	N021399	001	May 05, 2003
GEMCITABINE HYDROCHLORIDE					
INJECTABLE;INJECTION					
GEMCITABINE HYDROCHLORIDE					
	HAMELN RDS GMBH	EQ 200MG BASE/VIAL	A090663	001	Sep 10, 2012
		EQ 1GM BASE/VIAL	A090663	002	Sep 10, 2012
	SAGENT PHARMS	EQ 200MG BASE/VIAL	A091597	001	May 07, 2013
		EQ 1GM BASE/VIAL	A091597	002	May 07, 2013
GEMFIBROZIL					
CAPSULE;ORAL					
GEMFIBROZIL					
	MYLAN	300MG	A073466	001	Jan 25, 1993
	PUREPAC PHARM	300MG	A072929	001	Jan 29, 1993
LOPID					
	PFIZER PHARMS	200MG	N018422	001	
		300MG	N018422	002	
TABLET;ORAL					
GEMFIBROZIL					
	MYLAN	600MG	A074452	001	Feb 16, 1995
	PUREPAC PHARM	600MG	A074360	001	Aug 31, 1994
	WATSON LABS	600MG	A074156	001	Oct 24, 1994
		600MG	A074442	001	Apr 28, 1995
	YAOPHARMA CO LTD	600MG	A074615	001	Sep 29, 1995
GEMTUZUMAB OZOGAMICIN					
INJECTABLE;INJECTION					
MYLOTARG					
	WYETH PHARMS INC	5MG/VIAL	N021174	001	May 17, 2000
GENTAMICIN SULFATE					
CREAM;TOPICAL					
GARAMYCIN					
	SCHERING	EQ 0.1% BASE **	A060462	001	
GENTAFAIR					
	PHARMAFAIR	EQ 0.1% BASE	A062458	001	Sep 01, 1983
GENTAMICIN SULFATE					
	ALPHARMA US PHARMS	EQ 0.1% BASE	A062471	001	Sep 27, 1983
	FOUGERA PHARMS INC	EQ 0.1% BASE	A062531	001	Jul 05, 1984
	PHARMADERM	EQ 1MG BASE/GM	A062530	001	Jul 05, 1984
	TARO	EQ 0.1% BASE	A062427	001	May 26, 1983

GENTAMICIN SULFATE

INJECTABLE;INJECTION

APOGEN				
KING PHARMS	EQ 10MG BASE/ML	A062289	001	
	EQ 40MG BASE/ML	A062289	002	
BRISTAGEN				
BRISTOL	EQ 40MG BASE/ML	A062288	001	
GARAMYCIN				
SCHERING	EQ 1MG BASE/ML **	A061716	002	
	EQ 10MG BASE/ML **	A061739	001	
	EQ 40MG BASE/ML **	A061716	001	
GENTAFAIR				
PHARMAFAIR	EQ 40MG BASE/ML	A062493	001	Aug 28, 1985
GENTAMICIN				
INTL MEDICATION	EQ 1MG BASE/ML	A062325	003	Jun 23, 1982
	EQ 40MG BASE/ML	A062325	001	
	EQ 100MG BASE/100ML	A062325	004	Jun 23, 1982
GENTAMICIN SULFATE				
ABBOTT	EQ 1.2MG BASE/ML	A062413	001	Aug 11, 1983
	EQ 1.4MG BASE/ML	A062413	002	Aug 11, 1983
	EQ 1.6MG BASE/ML	A062413	003	Aug 11, 1983
	EQ 1.8MG BASE/ML	A062413	004	Aug 11, 1983
	EQ 2MG BASE/ML	A062413	005	Aug 11, 1983
	EQ 60MG BASE/100ML	A062413	006	Aug 11, 1983
	EQ 70MG BASE/100ML	A062413	007	Aug 11, 1983
	EQ 80MG BASE/100ML	A062413	008	Aug 11, 1983
	EQ 90MG BASE/100ML	A062413	009	Aug 11, 1983
	EQ 100MG BASE/100ML	A062413	010	Aug 11, 1983
FRESENIUS KABI USA	EQ 10MG BASE/ML	A062356	001	Mar 04, 1982
	EQ 40MG BASE/ML	A062356	002	Mar 04, 1982
KALAPHARM	EQ 40MG BASE/ML	A062354	001	Apr 05, 1982
PHARM SPEC	EQ 40MG BASE/ML	A062340	001	Mar 28, 1983
SOLOPAK	EQ 10MG BASE/ML	A062507	001	Jun 06, 1985
	EQ 40MG BASE/ML	A062507	002	Jun 06, 1985
TEVA PARENTERAL	EQ 10MG BASE/ML	A063149	001	Nov 21, 1991
	EQ 40MG BASE/ML	A063106	002	Nov 21, 1991
WATSON LABS	EQ 10MG BASE/ML	A062318	002	
	EQ 40MG BASE/ML	A062318	001	
WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A062251	002	
	EQ 40MG BASE/ML	A062251	001	
WYETH AYERST	EQ 10MG BASE/ML	A062264	001	
	EQ 40MG BASE/ML	A062264	002	
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	EQ 0.8MG BASE/ML	A062814	001	Aug 28, 1987
	EQ 1.2MG BASE/ML	A062814	002	Aug 28, 1987
	EQ 1.4MG BASE/ML	A062814	003	Aug 28, 1987
	EQ 1.6MG BASE/ML	A062814	004	Aug 28, 1987
	EQ 1.8MG BASE/ML	A062814	005	Aug 28, 1987
	EQ 2MG BASE/ML	A062814	006	Aug 28, 1987
	EQ 2.4MG BASE/ML	A062814	007	Aug 28, 1987
	EQ 40MG BASE/100ML	A062814	008	Aug 28, 1987
	EQ 60MG BASE/100ML	A062814	009	Aug 28, 1987
	EQ 70MG BASE/100ML	A062814	010	Aug 28, 1987
	EQ 80MG BASE/100ML	A062814	011	Aug 28, 1987
	EQ 90MG BASE/100ML	A062814	012	Aug 28, 1987
	EQ 100MG BASE/100ML	A062814	013	Aug 28, 1987
	EQ 120MG BASE/100ML	A062814	014	Aug 28, 1987
BAXTER HLTHCARE	EQ 0.8MG BASE/ML	A062373	001	Sep 07, 1982
	EQ 2.4MG BASE/ML	A062373	010	Sep 07, 1982
	EQ 40MG BASE/100ML	A062373	003	Sep 07, 1982
	EQ 60MG BASE/100ML	A062373	004	Sep 07, 1982
HOSPIRA	EQ 1.2MG BASE/ML	A062588	001	Jan 06, 1986
	EQ 1.4MG BASE/ML	A062414	002	Aug 15, 1983
	EQ 1.4MG BASE/ML	A062588	002	Jan 06, 1986
	EQ 1.6MG BASE/ML	A062588	003	Jan 06, 1986
	EQ 1.8MG BASE/ML	A062414	004	Aug 15, 1983
	EQ 1.8MG BASE/ML	A062588	004	Jan 06, 1986
	EQ 2MG BASE/ML	A062414	005	Aug 15, 1983
	EQ 2MG BASE/ML	A062588	005	Jan 06, 1986

GENTAMICIN SULFATE				
INJECTABLE;INJECTION				
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	EQ 60MG BASE/100ML	A062414	006	Aug 15, 1983
	EQ 60MG BASE/100ML	A062588	006	Jan 06, 1986
	EQ 70MG BASE/100ML	A062414	007	Aug 15, 1983
	EQ 70MG BASE/100ML	A062588	007	Jan 06, 1986
	EQ 80MG BASE/100ML	A062588	008	Jan 06, 1986
	EQ 90MG BASE/100ML	A062414	009	Aug 15, 1983
	EQ 90MG BASE/100ML	A062588	009	Jan 06, 1986
	EQ 100MG BASE/100ML	A062588	010	Jan 06, 1986
U-GENCIN				
PHARMACIA AND UPJOHN	EQ 10MG BASE/ML	A062248	001	
	EQ 40MG BASE/ML	A062248	002	
INJECTABLE;INTRATHECAL				
GARAMYCIN				
+ SCHERING	EQ 2MG BASE/ML **	N050505	001	
OINTMENT;OPHTHALMIC				
GARAMYCIN				
SCHERING	EQ 0.3% BASE	N050425	001	
GENTACIDIN				
NOVARTIS	EQ 0.3% BASE	A062501	001	Jul 26, 1984
GENTAFAIR				
PHARMAFAIR	EQ 3MG BASE/GM	A062443	001	May 26, 1983
OINTMENT;TOPICAL				
GARAMYCIN				
SCHERING	EQ 0.1% BASE **	A060463	001	
GENTAFAIR				
PHARMAFAIR	EQ 0.1% BASE	A062444	001	May 26, 1983
GENTAMICIN SULFATE				
ALPHARMA US PHARMS	EQ 0.1% BASE	A062496	001	Mar 14, 1984
PHARMADERM	EQ 0.1% BASE	A062534	001	Oct 10, 1984
SOLUTION/DROPS;OPHTHALMIC				
GARAMYCIN				
+ SCHERING	EQ 0.3% BASE **	N050039	002	
GENTACIDIN				
NOVARTIS	EQ 0.3% BASE	A062480	001	Mar 30, 1984
GENTAFAIR				
PHARMAFAIR	EQ 0.3% BASE	A062440	001	May 03, 1983
GENTAMICIN SULFATE				
ALCON PHARMS LTD	EQ 0.3% BASE	A062523	001	Nov 25, 1985
PACO	EQ 3MG BASE/ML	A062932	001	Nov 07, 1988
GENTIAN VIOLET				
SUPPOSITORY;VAGINAL				
GVS				
SAVAGE LABS	0.4%	A083513	001	
TAMPON;VAGINAL				
GENAPAX				
KEY PHARMS	5MG	A085017	001	
GLATIRAMER ACETATE				
FOR SOLUTION;SUBCUTANEOUS				
COPAXONE				
TEVA PHARMS USA	20MG/VIAL	N020622	001	Dec 20, 1996
GLIMEPIRIDE				
TABLET;ORAL				
GLIMEPIRIDE				
ACTAVIS LABS FL INC	1MG	A076995	001	Apr 27, 2010
	2MG	A076995	002	Apr 27, 2010
	4MG	A076995	003	Apr 27, 2010
EPIC PHARMA LLC	1MG	A077274	001	Oct 06, 2005
	2MG	A077274	002	Oct 06, 2005
	4MG	A077274	003	Oct 06, 2005
HIKMA PHARMS	1MG	A078952	001	Aug 01, 2013
	2MG	A078952	002	Aug 01, 2013
	4MG	A078952	003	Aug 01, 2013
MYLAN	1MG	A077486	001	Feb 10, 2006
	2MG	A077486	002	Feb 10, 2006
	4MG	A077486	003	Feb 10, 2006

GLIMEPIRIDE

TABLET;ORAL				
GLIMEPIRIDE				
RANBAXY	3MG		A077366 001	Oct 06, 2005
	6MG		A077366 002	Oct 06, 2005
RANBAXY LABS LTD	1MG		A076875 001	Oct 06, 2005
	2MG		A076875 002	Oct 06, 2005
	4MG		A076875 003	Oct 06, 2005
	8MG		A076875 004	Oct 06, 2005
WATSON LABS	1MG		A077280 001	Feb 03, 2006
	2MG		A077280 002	Feb 03, 2006
	4MG		A077280 003	Feb 03, 2006

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL				
AVANDARYL				
+ SB PHARMCO	1MG;4MG **		N021700 001	Nov 23, 2005
+	2MG;4MG **		N021700 002	Nov 23, 2005
+	2MG;8MG **		N021700 004	Mar 30, 2007
+	4MG;4MG **		N021700 003	Nov 23, 2005
+	4MG;8MG **		N021700 005	Mar 30, 2007
ROSIGLITAZONE MALEATE AND GLIMEPIRIDE				
TEVA PHARMS USA	1MG;4MG		A078709 001	Apr 01, 2016
	2MG;4MG		A078709 002	Apr 01, 2016
	2MG;8MG		A078709 004	Apr 01, 2016
	4MG;4MG		A078709 003	Apr 01, 2016
	4MG;8MG		A078709 005	Apr 01, 2016

GLIPIZIDE

TABLET;ORAL				
GLIPIZIDE				
ANI PHARMS INC	5MG		A074387 001	Mar 04, 1996
	10MG		A074387 002	Mar 04, 1996
BARR LABS INC	5MG		A074619 001	Apr 04, 1997
	10MG		A074619 002	Apr 04, 1997
MYLAN	5MG		A074438 001	Jun 20, 1995
	10MG		A074438 002	Jun 20, 1995
OXFORD PHARMS	5MG		A074378 001	Nov 28, 1994
	10MG		A074378 002	Nov 28, 1994
SANDOZ	5MG		A074542 001	Jun 20, 1995
	10MG		A074542 002	Jun 20, 1995
WATSON LABS	5MG		A074370 001	Nov 22, 1994
	10MG		A074370 002	Nov 22, 1994
GLUCOTROL				
PFIZER	2.5MG		N017783 003	May 11, 1993

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL				
METAGLIP				
+ BRISTOL MYERS SQUIBB	2.5MG;250MG **		N021460 001	Oct 21, 2002
+	2.5MG;500MG **		N021460 002	Oct 21, 2002
+	5MG;500MG **		N021460 003	Oct 21, 2002

GLUCAGON HYDROCHLORIDE

INJECTABLE;INJECTION				
GLUCAGON				
+ LILLY	EQ 1MG BASE/VIAL **		N012122 001	
+	EQ 10MG BASE/VIAL **		N012122 002	

GLUTETHIMIDE

CAPSULE;ORAL				
DORIDEN				
SANOFI AVENTIS US	500MG		N009519 008	
TABLET;ORAL				
DORIDEN				
SANOFI AVENTIS US	250MG		N009519 002	
	500MG		N009519 005	
GLUTETHIMIDE				
HALSEY	250MG		A089458 001	Oct 10, 1986
	500MG		A089459 001	Oct 10, 1986
LANNETT	250MG		A083475 001	
	500MG		A085571 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

GLUTETHIMIDE

TABLET;ORAL				
GLUTETHIMIDE				
	UCB INC	500MG	A085171 001	
	UPSHER SMITH LABS	500MG	A083234 002	
	VITARINE	500MG	A087297 001	
	WATSON LABS	500MG	A084362 001	
		500MG	A085763 001	

GLYBURIDE

TABLET;ORAL				
GLYBURIDE				
	ACTAVIS ELIZABETH	1.5MG	A075947 001	Nov 14, 2002
		3MG	A075947 002	Nov 14, 2002
		6MG	A075947 003	Nov 14, 2002
GLYBURIDE (MICRONIZED)				
	SANOFI AVENTIS US	1.5MG	N020055 001	Apr 17, 1992
		3MG	N020055 002	Apr 17, 1992
		6MG	N020055 003	Mar 08, 2000
	YAOPHARMA CO LTD	1.5MG	A075174 001	Jun 22, 1998
		3MG	A075174 002	Jun 22, 1998
GLYNASE				
+	PHARMACIA AND UPJOHN	4.5MG **	N020051 003	Sep 24, 1993
MICRONASE				
+	PHARMACIA AND UPJOHN	1.25MG **	N017498 001	May 01, 1984
		2.5MG	N017498 002	May 01, 1984
+		5MG **	N017498 003	May 01, 1984

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL				
GLUCOVANCE				
+	BRISTOL MYERS SQUIBB	1.25MG;250MG **	N021178 001	Jul 31, 2000
+		2.5MG;500MG **	N021178 002	Jul 31, 2000
+		5MG;500MG **	N021178 003	Jul 31, 2000
GLYBURIDE AND METFORMIN HYDROCHLORIDE				
	IMPAX LABS INC	1.25MG;250MG	A076731 001	Nov 19, 2004
		2.5MG;500MG	A076731 002	Nov 19, 2004
		5MG;500MG	A076731 003	Nov 19, 2004
	TEVA	1.25MG;250MG	A076821 001	Jan 27, 2005
		2.5MG;500MG	A076821 002	Jan 27, 2005
		5MG;500MG	A076821 003	Jan 27, 2005

GLYCINE

SOLUTION;IRRIGATION				
GLYCINE 1.5% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	1.5GM/100ML	N018522 001	Feb 19, 1982
	HOSPIRA	1.5GM/100ML	N017633 001	

GLYCOPYRROLATE

INJECTABLE;INJECTION				
GLYCOPYRROLATE				
	ABRAXIS PHARM	0.2MG/ML	A088475 001	Jun 12, 1984
	HOSPIRA	0.2MG/ML	A089393 001	Jun 15, 1988
	TEVA PARENTERAL	0.2MG/ML	A081169 001	Sep 10, 1991
	WATSON LABS	0.2MG/ML	A086947 001	Jun 24, 1983
ROBINUL				
	ROBINS AH	0.2MG/ML	N014764 001	
+	WEST-WARD PHARMS INT	0.2MG/ML **	N017558 001	
TABLET;ORAL				
GLYCOPYRROLATE				
	HIKMA INTL PHARMS	1MG	A040836 001	Mar 05, 2009
		2MG	A040836 002	Mar 05, 2009
	RENATA	1MG	A040568 001	Dec 22, 2004
		2MG	A040568 002	Dec 22, 2004
	WATSON LABS	1MG	A085562 001	
		1MG	A086902 001	
		2MG	A085563 001	
		2MG	A086178 001	
		2MG	A086900 001	
ROBINUL				
+	CASPER PHARMA LLC	1MG	N012827 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

GLYCOPYRROLATE

TABLET;ORAL

ROBINUL FORTE

+	CASPER PHARMA LLC	2MG	N012827	002	

GONADORELIN ACETATE

INJECTABLE;INJECTION

LUTREPULSE KIT

	FERRING	0.8MG/VIAL	N019687	001	Oct 10, 1989
		3.2MG/VIAL	N019687	002	Oct 10, 1989

GONADORELIN HYDROCHLORIDE

INJECTABLE;INJECTION

FACTREL

	WEST-WARD PHARMS INT	EQ 0.1MG BASE/VIAL	N018123	001	Sep 30, 1982
		EQ 0.2MG BASE/VIAL	N018123	002	Sep 30, 1982
		EQ 0.5MG BASE/VIAL	N018123	003	Sep 30, 1982

GONADOTROPIN, CHORIONIC

INJECTABLE;INJECTION

A.P.L.

	FERRING	5,000 UNITS/VIAL	N017055	001	
		10,000 UNITS/VIAL	N017055	002	
		20,000 UNITS/VIAL	N017055	003	

CHORIONIC GONADOTROPIN

	BEL MAR	5,000 UNITS/VIAL	N017054	001	
		10,000 UNITS/VIAL	N017054	002	
	FERRING	2,000 UNITS/VIAL	N017016	009	Dec 27, 1984
		2,000 UNITS/VIAL	N017016	011	Feb 16, 1990
		15,000 UNITS/VIAL	N017016	010	Feb 15, 1985
		20,000 UNITS/VIAL	N017016	004	
	FRESENIUS KABI USA	5,000 UNITS/VIAL	N017067	001	
		15,000 UNITS/VIAL	N017067	004	
		20,000 UNITS/VIAL	N017067	003	

FOLLUTEIN

	BRISTOL MYERS SQUIBB	10,000 UNITS/VIAL	N017056	001	

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OPHTHALMIC

NEO-POLYCIN

	DOW PHARM	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A060427	001	

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

	IPHARM	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062818	001	Oct 11, 1988
	WATSON LABS	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062788	001	Jun 11, 1987

NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN

	PHARMAFAIR	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062383	001	Aug 31, 1982

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

	BAXTER HLTHCARE CORP	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197	001	Dec 31, 2007
		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008
		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008
	SANDOZ INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078808	001	Apr 29, 2008
	TEVA PHARMS USA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077963	001	Jan 03, 2008

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

	TEVA PHARMS USA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165	001	Dec 31, 2007

KYTRIL

+	ROCHE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) **	N020239	003	Sep 17, 2004
+		EQ 1MG BASE/ML (EQ 1MG BASE/ML) **	N020239	004	Mar 11, 1994
+		EQ 3MG BASE/ML **	N020239	001	Dec 29, 1993
+		EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **	N020239	002	Mar 11, 1994

SOLUTION;ORAL

GRANISOL

	PEDIATRX	EQ 2MG BASE/10ML	A078334	001	Feb 28, 2008

KYTRIL

+	ROCHE	EQ 2MG BASE/10ML **	N021238	001	Jun 27, 2001

GRANISETRON HYDROCHLORIDE

TABLET;ORAL				
GRANISETRON HYDROCHLORIDE				
BARR	EQ 1MG BASE	A078221	001	Dec 31, 2007
EPIC PHARMA LLC	EQ 1MG BASE	A078260	001	Dec 31, 2007
KYTRIL				
+ ROCHE	EQ 1MG BASE **	N020305	001	Mar 16, 1995
+	EQ 2MG BASE **	N020305	002	Jun 15, 1998

GREPAFLOXACIN HYDROCHLORIDE

TABLET;ORAL				
RAXAR				
OTSUKA	EQ 200MG BASE	N020695	001	Nov 06, 1997
	EQ 400MG BASE	N020695	002	May 14, 1998
	EQ 600MG BASE	N020695	003	May 14, 1998

GRISEOFULVIN, MICROCRYSTALLINE

CAPSULE;ORAL				
GRISACTIN				
WYETH AYERST	125MG	N050051	002	
	250MG	N050051	001	
SUSPENSION;ORAL				
GRIFULVIN V				
+ JOHNSON AND JOHNSON	125MG/5ML **	N050448	001	
TABLET;ORAL				
FULVICIN-U/F				
CHARTWELL RX	250MG	A060569	002	
	500MG	A060569	001	
GRIFULVIN V				
J AND J	125MG	A060618	001	
	250MG	A060618	002	
	500MG	A060618	003	
VALEANT LUXEMBOURG	125MG	A062279	001	
	250MG **	A062279	002	
GRISACTIN				
WYETH AYERST	500MG	A060212	001	

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL				
GRIFULVIN V				
VALEANT LUXEMBOURG	125MG/5ML **	A062483	001	Jan 26, 1984
TABLET;ORAL				
GRIFULVIN V				
VALEANT LUXEMBOURG	500MG	A062279	003	

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET;ORAL				
FULVICIN P/G				
CHARTWELL RX	125MG	A061996	001	
	250MG	A061996	002	
FULVICIN P/G 165				
CHARTWELL RX	165MG	A061996	003	Apr 06, 1982
FULVICIN P/G 330				
CHARTWELL RX	330MG	A061996	004	Apr 06, 1982
GRISACTIN ULTRA				
WYETH AYERST	125MG	A062178	001	
	165MG	A062438	001	Nov 17, 1983
	250MG	A062178	002	
	330MG	A062438	002	Nov 17, 1983
ULTRAGRIS-165				
PLIVA	165MG	A062645	001	Jun 30, 1992
ULTRAGRIS-330				
PLIVA	330MG	A062646	001	Jun 30, 1992

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION;ORAL				
FLOWTUSS				
BKK PHARMS	200MG/5ML;2.5MG/5ML	N022424	001	May 14, 2015

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE				
SOLUTION;ORAL				
HYCOFENIX				
+	BKK PHARMS	200MG/5ML;2.5MG/5ML;30MG/5ML	N022279 001	May 14, 2015
GUANABENZ ACETATE				
TABLET;ORAL				
GUANABENZ ACETATE				
	ANI PHARMS INC	EQ 4MG BASE	A074267 001	Jun 01, 1994
		EQ 8MG BASE	A074267 002	Jun 01, 1994
	WATSON LABS	EQ 4MG BASE	A074025 001	Feb 28, 1994
		EQ 8MG BASE	A074025 002	Feb 28, 1994
	YAOPHARMA CO LTD	EQ 4MG BASE	A074517 001	Sep 30, 1998
		EQ 8MG BASE	A074517 002	Sep 30, 1998
WYTENSIN				
	WYETH AYERST	EQ 4MG BASE	N018587 001	Sep 07, 1982
		EQ 8MG BASE	N018587 002	Sep 07, 1982
		EQ 16MG BASE	N018587 003	Sep 07, 1982
GUANADREL SULFATE				
TABLET;ORAL				
HYLOREL				
	PHARMACIA AND UPJOHN	10MG	N018104 001	Dec 29, 1982
		25MG	N018104 002	Dec 29, 1982
GUANETHIDINE MONOSULFATE				
TABLET;ORAL				
GUANETHIDINE MONOSULFATE				
	WATSON LABS	EQ 10MG SULFATE	A086113 001	Mar 26, 1985
		EQ 25MG SULFATE	A086114 001	Mar 26, 1985
ISMELIN				
	NOVARTIS	EQ 10MG SULFATE	N012329 001	
		EQ 25MG SULFATE	N012329 002	
GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE				
TABLET;ORAL				
ESIMIL				
	NOVARTIS	10MG;25MG	N013553 001	
GUANFACINE HYDROCHLORIDE				
TABLET;ORAL				
GUANFACINE HYDROCHLORIDE				
	EPIC PHARMA LLC	EQ 1MG BASE	A074673 001	Feb 28, 1997
		EQ 2MG BASE	A074673 002	Feb 28, 1997
	WATSON LABS	EQ 1MG BASE	A074762 001	Jun 25, 1997
		EQ 2MG BASE	A074762 002	Jun 25, 1997
TENEX				
+	PROMIUS PHARMA	EQ 1MG BASE	N019032 001	Oct 27, 1986
+		EQ 2MG BASE	N019032 002	Nov 07, 1988
		EQ 3MG BASE	N019032 003	Nov 07, 1988
TABLET, EXTENDED RELEASE;ORAL				
GUANFACINE HYDROCHLORIDE				
	IMPAX LABS INC	EQ 1MG BASE	A202238 001	Oct 20, 2015
		EQ 2MG BASE	A202238 002	Oct 20, 2015
		EQ 3MG BASE	A202238 003	Oct 20, 2015
		EQ 4MG BASE	A202238 004	Oct 20, 2015
HALAZEPAM				
TABLET;ORAL				
PAXIPAM				
	SCHERING	20MG	N017736 003	
		40MG	N017736 004	
HALCINONIDE				
CREAM;TOPICAL				
HALOG				
	WESTWOOD SQUIBB	0.025%	N017818 001	
HALOG-E				
	SUN PHARM INDS INC	0.1%	N018234 001	
OINTMENT;TOPICAL				
HALOG				
	BRISTOL MYERS SQUIBB	0.025%	N018125 001	

HALCINONIDE				
SOLUTION;TOPICAL				
HALOG				
	SUN PHARM INDS INC	0.1%	N017823 001	
HALOBETASOL PROPIONATE				
OINTMENT;TOPICAL				
HALOBETASOL PROPIONATE				
	FOUGERA PHARMS	0.05%	A076903 001	Dec 16, 2004
HALOFANTRINE HYDROCHLORIDE				
TABLET;ORAL				
HALFAN				
	GLAXOSMITHKLINE	250MG	N020250 001	Jul 24, 1992
HALOPERIDOL				
TABLET;ORAL				
HALDOL				
+	ORTHO MCNEIL	0.5MG **	N015921 001	
+		1MG **	N015921 002	
+		2MG **	N015921 003	
+		5MG **	N015921 004	
+		10MG **	N015921 005	
+		20MG **	N015921 006	Feb 02, 1982
HALDOL SOLUTAB				
	ORTHO MCNEIL PHARM	1MG	N017079 001	
HALOPERIDOL				
	ANDA REPOSITORY	0.5MG	A071156 001	Jan 02, 1987
		1MG	A071157 001	Jan 02, 1987
		2MG	A071172 001	Jan 02, 1987
		5MG	A071212 001	Jan 07, 1988
		10MG	A071173 001	Jan 07, 1988
		20MG	A071177 001	Jan 07, 1988
	CYCLE PHARMS LTD	0.5MG	A071128 001	Feb 17, 1987
		1MG	A071129 001	Feb 17, 1987
		2MG	A071130 001	Feb 17, 1987
		5MG	A071131 001	Feb 17, 1987
		10MG	A071132 001	May 12, 1987
		20MG	A071133 001	May 12, 1987
	DURAMED PHARMS BARR	0.5MG	A071216 001	Dec 04, 1986
		1MG	A071217 001	Dec 04, 1986
		2MG	A071218 001	Dec 04, 1986
		5MG	A071219 001	Dec 04, 1986
		10MG	A071220 001	Jul 07, 1987
		20MG	A071221 001	Jul 07, 1987
	LEDERLE	0.5MG	A072727 001	Sep 19, 1989
		1MG	A072728 001	Sep 19, 1989
		2MG	A072729 001	Sep 19, 1989
		5MG	A072730 001	Sep 19, 1989
		10MG	A072731 001	Sep 19, 1989
		20MG	A072732 001	Sep 19, 1989
	PAR PHARM	20MG	A071328 001	Jul 20, 1987
	PUREPAC PHARM	0.5MG	A071071 001	Nov 03, 1986
		1MG	A071072 001	Nov 03, 1986
		2MG	A071073 001	Nov 03, 1986
		5MG	A071074 001	Nov 03, 1986
		10MG	A071075 001	Aug 04, 1987
		20MG	A071076 001	Aug 04, 1987
	QUANTUM PHARMICS	0.5MG	A071255 001	Feb 17, 1987
		1MG	A071269 001	Feb 17, 1987
		2MG	A071256 001	Feb 17, 1987
		5MG	A071257 001	Feb 17, 1987
	ROYCE LABS	0.5MG	A071722 001	Dec 24, 1987
		1MG	A071723 001	Dec 24, 1987
		2MG	A071724 001	Dec 24, 1987
		5MG	A071725 001	Dec 24, 1987
		10MG	A072121 001	Dec 24, 1987
		20MG	A072122 001	Dec 24, 1987
	SCS	0.5MG	A070720 001	Jun 10, 1986
		1MG	A070721 001	Jun 10, 1986
		2MG	A070722 001	Jun 10, 1986

HALOPERIDOL
TABLET;ORAL
HALOPERIDOL

	5MG	A070723	001	Jun 10, 1986
	10MG	A070724	001	Jun 10, 1986
	20MG	A070725	001	Sep 24, 1986
VINTAGE	0.5MG	A071235	002	Nov 03, 1986
	1MG	A071235	003	Nov 03, 1986
	2MG	A071235	001	Nov 03, 1986
	5MG	A071235	004	Nov 03, 1986
	10MG	A071235	005	Jul 20, 1987
WATSON LABS	0.5MG	A070981	001	Mar 06, 1987
	0.5MG	A071571	001	Jun 03, 1988
	1MG	A070982	001	Mar 06, 1987
	1MG	A071572	001	Jun 03, 1988
	2MG	A070983	001	Mar 06, 1987
	2MG	A071573	001	Jun 03, 1988
	5MG	A070984	001	Mar 06, 1987
	5MG	A071374	001	Jun 03, 1988
	10MG	A071375	001	Jun 03, 1988
	10MG	A072113	001	Aug 27, 1991
	20MG	A071376	001	Jun 03, 1988
	20MG	A072353	001	Aug 27, 1991

HALOPERIDOL DECANOATE
INJECTABLE;INJECTION
HALOPERIDOL DECANOATE

HOSPIRA	EQ 50MG BASE/ML	A075176	001	Feb 09, 2000
	EQ 100MG BASE/ML	A075176	002	Feb 09, 2000
SANDOZ INC	EQ 50MG BASE/ML	A076463	001	Jun 24, 2005
	EQ 100MG BASE/ML	A076463	002	Jun 24, 2005

HALOPERIDOL LACTATE
CONCENTRATE;ORAL
HALDOL

ORTHO MCNEIL	EQ 2MG BASE/ML **	N015922	001	

HALOPERIDOL

ALPHARMA	EQ 2MG BASE/ML	A070318	001	Apr 11, 1986
MORTON GROVE	EQ 2MG BASE/ML	A070710	001	Mar 07, 1986
SCS	EQ 2MG BASE/ML	A070726	001	Jun 10, 1986
TEVA	EQ 2MG BASE/ML	A071015	001	Aug 25, 1987

HALOPERIDOL INTENSOL

CYCLE PHARMS LTD	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988

INJECTABLE;INJECTION
HALOPERIDOL

ABRAXIS PHARM	EQ 5MG BASE/ML	A071187	001	Jan 20, 1987
BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004
	EQ 5MG BASE/ML	A076828	001	Aug 25, 2004
FOSUN PHARMA	EQ 5MG BASE/ML	A076464	001	Sep 29, 2004
MARSAM PHARMS LLC	EQ 5MG BASE/ML	A072516	001	Feb 25, 1993
	EQ 5MG BASE/ML	A072517	001	Feb 25, 1993
SMITH AND NEPHEW	EQ 5MG BASE/ML	A070802	001	Dec 14, 1987
SOLOPAK	EQ 5MG BASE/ML	A070800	001	Dec 14, 1987
	EQ 5MG BASE/ML	A070801	001	Dec 14, 1987
	EQ 5MG BASE/ML	A070864	001	Dec 14, 1987
WATSON LABS	EQ 5MG BASE/ML	A070713	001	May 17, 1988
	EQ 5MG BASE/ML	A070714	001	May 17, 1988
	EQ 5MG BASE/ML	A070744	001	May 17, 1988

SOLUTION;ORAL
HALOPERIDOL LACTATE

ACTAVIS MID ATLANTIC	EQ 1MG BASE/ML	A074536	001	Nov 02, 1995

HALOPROGIN
CREAM;TOPICAL
HALOTEX

WESTWOOD SQUIBB	1%	N016942	001	

SOLUTION;TOPICAL
HALOTEX

WESTWOOD SQUIBB	1%	N016943	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

HALOTHANE				
LIQUID;INHALATION				
FLUOTHANE				
WYETH AYERST	99.99%	N011338 001		
HALOTHANE				
BH	99.99%	A084977 001		
HALOCARBON	99.99%	A080810 001		
HOSPIRA	99.99%	A083254 001		
HEPARIN CALCIUM				
INJECTABLE;INJECTION				
CALCIPARINE				
SANOFI AVENTIS US	25,000 UNITS/ML	N018237 001		
HEPARIN SODIUM				
INJECTABLE;INJECTION				
HEPARIN LOCK FLUSH				
HOSPIRA	100 UNITS/ML	N005264 010		
INTL MEDICATION	10 UNITS/ML	A086357 001		
	500 UNITS/ML	A086357 002		
LUITPOLD	10 UNITS/ML	A089063 001	Oct 09, 1985	
	100 UNITS/ML	A089064 001	Oct 09, 1985	
PARKE DAVIS	10 UNITS/ML	N017346 006		
SMITH AND NEPHEW	10 UNITS/ML	A087904 001	Apr 20, 1983	
	10 UNITS/ML	A087958 001	Apr 20, 1983	
	10 UNITS/ML	A088458 001	Jul 26, 1984	
	10 UNITS/ML	A088580 001	Oct 25, 1984	
	100 UNITS/ML	A087906 001	Apr 20, 1983	
	100 UNITS/ML	A087959 001	Apr 20, 1983	
	100 UNITS/ML	A088460 001	Jul 26, 1984	
	100 UNITS/ML	A088581 001	Oct 25, 1984	
SOLOPAK	10 UNITS/ML	A087903 001	Apr 20, 1983	
	10 UNITS/ML	A088457 001	Oct 25, 1984	
	100 UNITS/ML	A087905 001	Apr 20, 1983	
	100 UNITS/ML	A088459 001	Jul 26, 1984	
HEPARIN SODIUM				
ABRAXIS PHARM	1,000 UNITS/ML	N017033 001		
	1,000 UNITS/ML	N017979 001		
	5,000 UNITS/ML	N017979 003		
	10,000 UNITS/ML	N017979 002		
AKORN	1,000 UNITS/ML	N017486 001		
	5,000 UNITS/ML	N017486 002		
	10,000 UNITS/ML	N017486 003		
	20,000 UNITS/ML	N017486 004		
	40,000 UNITS/ML	N017486 005		
CHAMBERLIN PARENTERL	1,000 UNITS/ML	N017130 001		
	5,000 UNITS/ML	N017130 002		
	10,000 UNITS/ML	N017130 003		
	20,000 UNITS/ML	N017130 004		
DELL LABS	1,000 UNITS/ML	N017540 001		
	5,000 UNITS/ML	N017540 002		
	10,000 UNITS/ML	N017540 003		
	20,000 UNITS/ML	N017540 004		
	40,000 UNITS/ML	N017540 005		
FRESENIUS KABI USA	1,000 UNITS/ML	N017651 005		
	5,000 UNITS/ML	N017029 002		
	10,000 UNITS/ML	N017651 003		
	20,000 UNITS/ML	N017651 008		
HOSPIRA	2,500 UNITS/ML	A088099 001	Apr 28, 1983	
	10,000 UNITS/ML	A040095 001	Jul 26, 1996	
LILLY	1,000 UNITS/ML	N005521 001		
	10,000 UNITS/ML	N005521 002		
	20,000 UNITS/ML	N005521 004		
LUITPOLD	1,000 UNITS/ML	A087452 001	Oct 31, 1983	
ORGANON USA INC	1,000 UNITS/ML	N000552 008		
	5,000 UNITS/ML	N000552 009		
	10,000 UNITS/ML	N000552 010		
PARKE DAVIS	1,000 UNITS/ML	N017346 001		
	5,000 UNITS/ML	N017346 002		
	7,500 UNITS/ML	N017346 003		

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM					
		10,000 UNITS/ML	N017346	004	
		20,000 UNITS/ML	N017346	005	
	PHARM SPEC	1,000 UNITS/ML	N017780	001	
		5,000 UNITS/ML	N017780	002	
		10,000 UNITS/ML	N017780	003	
		20,000 UNITS/ML	N017780	004	
		40,000 UNITS/ML	N017780	005	
	PHARMACIA AND UPJOHN	1,000 UNITS/ML	N004570	001	
		5,000 UNITS/ML	N004570	002	
		10,000 UNITS/ML	N004570	003	
	SMITH AND NEPHEW	1,000 UNITS/ML	A088239	001	Jul 26, 1984
	SOLOPAK	1,000 UNITS/ML	A087043	001	
		5,000 UNITS/ML	A087077	001	
		5,000 UNITS/0.5ML	A087395	001	
		10,000 UNITS/ML	A087107	001	
		10,000 UNITS/0.5ML	A087363	001	
	WATSON LABS	1,000 UNITS/ML	N017064	002	
		2,500 UNITS/ML	N017064	015	
		3,000 UNITS/ML	N017064	016	
		4,000 UNITS/ML	N017064	017	
		5,000 UNITS/ML	N017064	003	
		6,000 UNITS/ML	N017064	018	
		7,500 UNITS/ML	N017064	019	
		10,000 UNITS/ML	N017064	004	
		20,000 UNITS/ML	N017064	005	
		40,000 UNITS/ML	N017064	006	
	WATSON LABS INC	1,000 UNITS/ML	A040007	001	Jun 07, 1996
		1,000 UNITS/ML	A040008	001	Oct 10, 1995
+	WEST-WARD PHARMS INT	1,000 UNITS/ML **	N017007	001	
+		2,500 UNITS/ML **	N017007	007	
+		5,000 UNITS/ML **	N017007	002	
+		5,000 UNITS/0.5ML **	N017007	010	
		5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986
+		7,500 UNITS/ML **	N017007	003	
+		10,000 UNITS/ML **	N017007	004	
+		15,000 UNITS/ML **	N017007	005	
+		20,000 UNITS/ML **	N017007	006	
HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER					
	MCGAW	200 UNITS/100ML	N019130	001	Dec 31, 1984
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	200 UNITS/100ML	N019042	001	Mar 29, 1985
HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	2,000 UNITS/100ML	N018814	002	Jul 09, 1985
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%					
	HOSPIRA	10,000 UNITS/100ML	N018911	006	Jan 30, 1985
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%					
	HOSPIRA	10,000 UNITS/100ML	N018911	001	Jan 30, 1985
		10,000 UNITS/100ML	N018916	005	Jan 31, 1984
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%					
	HOSPIRA	10,000 UNITS/100ML	N018911	003	Jan 30, 1985
		10,000 UNITS/100ML	N018916	002	Jan 31, 1984
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%					
	HOSPIRA	5,000 UNITS/100ML	N018911	007	Jan 30, 1985
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
	B BRAUN	5,000 UNITS/100ML	N019802	001	Jul 20, 1992
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%					
	HOSPIRA	5,000 UNITS/100ML	N018911	005	Jan 30, 1985
		5,000 UNITS/100ML	N018916	003	Jan 31, 1984
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER					
	MCGAW	200 UNITS/100ML	N019130	003	Dec 31, 1984
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	200 UNITS/100ML	N019042	002	Mar 29, 1985
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	4,000 UNITS/100ML	N018814	001	Oct 31, 1983
HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	5,000 UNITS/100ML	N018814	003	Jul 09, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER				
	10,000 UNITS/100ML	N018814	004	Jul 02, 1987
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%				
HOSPIRA	5,000 UNITS/100ML	N018911	009	Jan 30, 1985
	10,000 UNITS/100ML	N018911	008	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019134	001	Mar 29, 1985
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019802	005	Jul 20, 1992
	10,000 UNITS/100ML	N019802	002	Jul 20, 1992
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	5,000 UNITS/100ML	N018911	004	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019135	001	Mar 29, 1985
	5,000 UNITS/100ML	N019802	003	Jul 20, 1992
HOSPIRA	5,000 UNITS/100ML	N018916	009	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	500 UNITS/100ML	N018609	003	Apr 28, 1982
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
MCGAW	1,000 UNITS/100ML	N019130	002	Dec 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%				
HOSPIRA	100 UNITS/ML	N018911	002	Jan 30, 1985
	100 UNITS/ML	N018916	004	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	1,000 UNITS/100ML	N018916	001	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	1,000 UNITS/100ML	N019042	004	Mar 29, 1985
HEPARIN SODIUM PRESERVATIVE FREE				
HOSPIRA	2,000 UNITS/ML	N005264	013	Apr 07, 1986
	2,500 UNITS/ML	N005264	014	Apr 07, 1986
PHARMA SERVE NY	1,000 UNITS/ML	A086129	001	
WATSON LABS INC	1,000 UNITS/ML	A089464	001	Jun 03, 1986
LIPO-HEPIN				
3M	1,000 UNITS/0.5ML	N017027	001	
	1,000 UNITS/ML	N017027	006	
	5,000 UNITS/0.5ML	N017027	002	
	5,000 UNITS/ML	N017027	008	
	7,500 UNITS/0.5ML	N017027	010	
	10,000 UNITS/0.5ML	N017027	003	
	10,000 UNITS/ML	N017027	009	
	15,000 UNITS/0.5ML	N017027	011	
	20,000 UNITS/0.5ML	N017027	004	
	20,000 UNITS/ML	N017027	007	
	40,000 UNITS/ML	N017027	005	
LIQUAEMIN LOCK FLUSH				
ORGANON USA INC	100 UNITS/ML	N000552	007	
LIQUAEMIN SODIUM				
ORGANON USA INC	1,000 UNITS/ML	N000552	004	
	5,000 UNITS/ML	N000552	003	
	10,000 UNITS/ML	N000552	005	
	20,000 UNITS/ML	N000552	001	
	40,000 UNITS/ML	N000552	002	
LIQUAEMIN SODIUM PRESERVATIVE FREE				
ORGANON USA INC	1,000 UNITS/ML	N000552	011	Apr 11, 1986
	5,000 UNITS/ML	N000552	012	Apr 11, 1986
	10,000 UNITS/ML	N000552	013	Apr 11, 1986
PANHEPRIN				
HOSPIRA	1,000 UNITS/ML	N005264	004	
	5,000 UNITS/ML	N005264	006	
	10,000 UNITS/ML	N005264	007	
	20,000 UNITS/ML	N005264	008	
	40,000 UNITS/ML	N005264	009	
SODIUM HEPARIN				
ABRAXIS PHARM	5,000 UNITS/ML	N017033	002	
	10,000 UNITS/ML	N017033	003	
	20,000 UNITS/ML	N017033	004	
BAXTER HLTHCARE	1,000 UNITS/ML	N017036	001	Mar 04, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

HETACILLIN
FOR SUSPENSION;ORAL
VERSAPEN
BRISTOL — EQ 112.5MG AMPICIL/ML — A061398 001
EQ 112.5MG AMPICIL/5ML — N050060 001
EQ 112.5MG AMPICIL/ML — N050060 003
EQ 225MG AMPICIL/5ML — A061398 002

HETACILLIN POTASSIUM
CAPSULE;ORAL
VERSAPEN-K
BRISTOL — EQ 225MG AMPICIL — A061396 001
EQ 450MG AMPICIL — A061396 002

HEXACHLOROPHENE
AEROSOL;TOPICAL
SEPTISOL
VESTAL LABS — 0.23% — N017424 001
TURGEX
XTTRIUM — 3% — N018375 001
EMULSION;TOPICAL
HEXA-GERM
HUNTINGTON LABS — 3% — N017411 001
PHISOHEX
SANOFI AVENTIS US — 3% — N006882 001
3% — N008402 001
SOY-DOME
BAYER PHARMS — 3% — N017405 001
TURGEX
XTTRIUM — 3% — N019055 001 Nov 30, 1984
SOAP;TOPICAL
GAMOPHEN
ARBROOK — 2% — N006270 003
SOLUTION;TOPICAL
DIAL
DIAL — 0.25% — N017421 002
GERMA-MEDICA
HUNTINGTON LABS — 1% — N017412 001
GERMA-MEDICA "MG"
HUNTINGTON LABS — 0.25% — N017412 002
SEPTI-SOFT
CALGON — 0.25% — N017460 001
SEPTISOL
VESTAL LABS — 0.25% — N017423 001
SPONGE;TOPICAL
E-Z SCRUB
BECTON DICKINSON — 450MG — N017452 001
HEXASCRUB
PROF DSPLS — 3% — N018363 001
PHISO-SCRUB
SANOFI AVENTIS US — 3% — N017446 001
SCRUBTEAM SURGICAL SPONGEBRUSH
3M — 330MG — N017413 001

HEXAFLUORENIUM BROMIDE
INJECTABLE;INJECTION
MYLAXEN
MEDPOINTE PHARM HLC — 20MG/ML — N009789 003

HEXOCYCLIUM METHYLSULFATE
TABLET;ORAL
TRAL
ABBVIE — 25MG — N010599 001

HEXYLCAINE HYDROCHLORIDE
SOLUTION;TOPICAL
CYCLAINE
MERCK — 5% — N008472 001

HISTAMINE PHOSPHATE
INJECTABLE;INJECTION
HISTAMINE PHOSPHATE

LILLY	EQ 0.1MG BASE/ML	N000734	003	
	EQ 0.2MG BASE/ML	N000734	002	
	EQ 1MG BASE/ML	N000734	001	

HISTRELIN ACETATE
INJECTABLE;INJECTION
SUPPRELIN

SHIRE	EQ 0.2MG BASE/ML	N019836	001	Dec 24, 1991
	EQ 0.5MG BASE/ML	N019836	002	Dec 24, 1991
	EQ 1MG BASE/ML	N019836	003	Dec 24, 1991

HOMATROPINE METHYLBROMIDE
TABLET;ORAL
HOMAPIN-10

MISSION PHARMA	10MG	A086308	001	

HOMAPIN-5

MISSION PHARMA	5MG	A086309	001	

TABLET, CHEWABLE;ORAL
EQUIPIN

MISSION PHARMA	3MG	A086310	001	

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE
SYRUP;ORAL
HYCODAN

+	GENUS LIFESCIENCES	1.5MG/5ML;5MG/5ML **	N005213	002	Jul 26, 1988

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

BIO-PHARM INC	1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017
IVAX SUB TEVA PHARMS	1.5MG/5ML;5MG/5ML	A040285	001	Jul 19, 1999

HYDROPANE

HALSEY	1.5MG/5ML;5MG/5ML	A088066	001	Jun 28, 1985

TABLET;ORAL
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

ACTAVIS ELIZABETH	1.5MG;5MG	A040295	001	Dec 01, 2000

HYCODAN

+	GENUS LIFESCIENCES	1.5MG;5MG **	N005213	001	Jul 26, 1988

HYALURONIDASE
INJECTABLE;INJECTION
HYDASE

AKORN INC	150 UNITS/ML	N021716	001	Oct 25, 2005

VITRASE

BAUSCH AND LOMB	6,200 UNITS/VIAL	N021640	001	May 05, 2004

WYDASE

BAXTER HLTHCARE	150 UNITS/ML **	N006343	002
	150 UNITS/VIAL **	N006343	006
	1,500 UNITS/VIAL **	N006343	005

HYDRALAZINE HYDROCHLORIDE
INJECTABLE;INJECTION
APRESOLINE

+	NOVARTIS	20MG/ML **	N008303	003

HYDRALAZINE HYDROCHLORIDE

ABRAXIS PHARM	20MG/ML	A089532	001	Aug 11, 1987
SMITH AND NEPHEW	20MG/ML	A088518	001	Apr 20, 1984
SOLOPAK	20MG/ML	A088517	001	Aug 22, 1985
TEVA PARENTERAL	20MG/ML	A040373	001	Feb 23, 2000

TABLET;ORAL
APRESOLINE

+	NOVARTIS	10MG **	N008303	004
+		25MG **	N008303	001
+		50MG **	N008303	002
+		100MG **	N008303	005

DRALZINE

TEVA	25MG	A084301	001	

HYDRALAZINE HYDROCHLORIDE

ACTAVIS ELIZABETH	25MG	A088560	001	Oct 04, 1984
	50MG	A088649	001	Oct 18, 1984
ACTAVIS GRP PTC	10MG	A091679	001	Mar 04, 2013
	25MG	A091679	002	Mar 04, 2013

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

	50MG	A091679	003	Mar 04, 2013
	100MG	A091679	004	Mar 04, 2013
ANDA REPOSITORY	10MG	A089359	001	Jul 25, 1986
	25MG	A089258	001	May 05, 1986
	50MG	A089259	001	May 05, 1986
	100MG	A088729	001	Apr 11, 1985
ASCOT	25MG	A088310	001	Dec 19, 1984
	50MG	A088311	001	Dec 19, 1984
CHARTWELL RX	10MG	A088846	001	Feb 26, 1985
	25MG	A088847	001	Feb 26, 1985
	50MG	A088848	001	Feb 26, 1985
	100MG	A088849	001	Feb 26, 1985
HALSEY	10MG	A089218	001	Jan 22, 1986
	25MG	A089130	001	Jan 15, 1986
	50MG	A089222	001	Jan 22, 1986
	100MG	A089178	001	Jan 15, 1986
HERITAGE PHARMS INC	10MG	A040858	001	Feb 26, 2010
	25MG	A040858	002	Feb 26, 2010
	50MG	A040858	003	Feb 26, 2010
	100MG	A040858	004	Feb 26, 2010
IMPAX LABS	25MG	A084922	001	
	50MG	A084923	001	
IVAX SUB TEVA PHARMS	10MG	A084443	001	
	25MG	A084437	001	
	50MG	A084469	002	
	100MG	A084581	001	
MUTUAL PHARM	10MG	A088728	001	Apr 11, 1985
	25MG	A084106	002	
	50MG	A084107	002	
MYLAN	10MG	A090413	001	Dec 08, 2010
	25MG	A090413	002	Dec 08, 2010
	50MG	A090413	003	Dec 08, 2010
	100MG	A090413	004	Dec 08, 2010
PUREPAC PHARM	25MG	A088177	001	Jul 29, 1983
	50MG	A088178	001	Aug 15, 1983
QUANTUM PHARMICS	10MG	A088671	001	May 01, 1984
	25MG	A088657	001	Jun 15, 1984
	50MG	A088652	001	May 08, 1984
	100MG	A088686	001	May 01, 1984
SUPERPHARM	10MG	A088787	001	Aug 28, 1984
	25MG	A088788	001	Aug 28, 1984
	50MG	A088789	001	Aug 28, 1984
UPSHER SMITH LABS	10MG	A083241	001	
	25MG	A083560	001	
	50MG	A083561	001	
UPSHER-SMITH LABS	50MG	A085088	001	
USL PHARMA	25MG	A087780	001	Mar 29, 1982
	50MG	A087751	001	Mar 29, 1982
VANGARD	25MG	A087712	001	
	50MG	A087908	001	May 07, 1982
VITARINE	25MG	A086088	001	
WATSON LABS	25MG	A084504	001	
	25MG	A085532	002	May 24, 1982
	50MG	A084503	001	
	50MG	A085533	002	May 25, 1982
WEST WARD	25MG	A088240	001	May 27, 1983
	50MG	A088241	001	May 27, 1983

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

APRESAZIDE

NOVARTIS	25MG;25MG	A084735	001	
	50MG;50MG	A084810	001	
	100MG;50MG	A084811	001	

HYDRA-ZIDE

PAR PHARM	100MG;50MG	A088961	001	Oct 21, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE;ORAL				
HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
SOLVAY	25MG;25MG	A087608	001	Feb 08, 1982
	50MG;50MG	A087213	001	Feb 08, 1982
	100MG;50MG	A087609	001	Feb 08, 1982
SUPERPHARM	25MG;25MG	A089200	001	Feb 09, 1987
	50MG;50MG	A089201	001	Feb 09, 1987
WATSON LABS	25MG;25MG	A085457	001	Mar 04, 1982
	50MG;50MG	A085446	001	Mar 04, 1982
	100MG;50MG	A085440	001	Mar 04, 1982
HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 100/50				
IVAX PHARMS	100MG;50MG	A088358	001	Apr 10, 1984
HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 25/25				
IVAX PHARMS	25MG;25MG	A088356	001	Apr 10, 1984
HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 50/50				
IVAX PHARMS	50MG;50MG	A088357	001	Apr 10, 1984
TABLET;ORAL				
APRESOLINE-ESIDRIX				
NOVARTIS	25MG;15MG	N012026	002	
HYDRALAZINE AND HYDROCHLOROTHIAZIDE				
WATSON LABS	25MG;15MG	A085827	001	
HYDROCHLOROTHIAZIDE W/ HYDRALAZINE				
WATSON LABS	25MG;15MG	A085373	001	

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET;ORAL				
CAM-AP-ES				
CHARTWELL RX	25MG;15MG;0.1MG	A084897	001	
HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE AND RESERPINE				
IVAX SUB TEVA PHARMS	25MG;15MG;0.1MG	A084291	001	
HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE				
MYLAN	25MG;15MG;0.1MG	A087085	001	
HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE				
WATSON LABS	25MG;15MG;0.1MG	A085771	001	
HYDRAP-ES				
SANDOZ	25MG;15MG;0.1MG	A084876	001	
HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE				
WATSON LABS	25MG;15MG;0.1MG	A083770	001	
HYDROSERPINE PLUS (R-H-H)				
IVAX SUB TEVA PHARMS	25MG;15MG;0.1MG	A083877	001	
RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
SOLVAY	25MG;15MG;0.1MG	A088376	001	Oct 28, 1983
SUN PHARM INDUSTRIES	25MG;15MG;0.1MG	A088570	001	Apr 10, 1984
WATSON LABS	25MG;15MG;0.1MG	A085549	001	
	25MG;15MG;0.1MG	A087556	001	
RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HYDROCHLORIDE				
LEDERLE	25MG;15MG;0.1MG	A087709	001	May 13, 1982
SER-A-GEN				
SOLVAY	25MG;15MG;0.1MG	A087210	001	
SER-AP-ES				
NOVARTIS	25MG;15MG;0.1MG	N012193	005	
UNIPRES				
SOLVAY	25MG;15MG;0.1MG	A085893	001	
	25MG;15MG;0.1MG	A086298	001	

HYDRALAZINE HYDROCHLORIDE; RESERPINE

TABLET;ORAL				
DRALSERP				
SANDOZ	25MG;0.1MG	A084617	001	
SERPASIL-APRESOLINE				
NOVARTIS	25MG;0.1MG	N009296	004	
	50MG;0.2MG	N009296	002	

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL				
HYDROCHLOROTHIAZIDE				
APOTEX	12.5MG	A078389	001	May 16, 2008
HIKMA INTL PHARMS	12.5MG	A077885	001	Nov 26, 2007
LANNETT CO INC	12.5MG	A091662	001	Jan 27, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

HYDROCHLOROTHIAZIDE

SOLUTION;ORAL				
HYDROCHLOROTHIAZIDE				
MORTON GROVE	50MG/5ML	A089661	001	Jun 20, 1988
ROXANE	50MG/5ML	A088587	001	Jul 02, 1984
HYDROCHLOROTHIAZIDE INTENSOL				
ROXANE	100MG/ML	A088588	001	Jul 02, 1984
TABLET;ORAL				
ESIDRIX				
NOVARTIS	25MG	N011793	005	
	50MG	N011793	008	
	100MG	N011793	009	
HYDRO-D				
HALSEY	25MG	A086504	001	
	50MG	A083891	002	
HYDROCHLOROTHIAZIDE				
ABC HOLDING	50MG	A085672	001	
ACTAVIS ELIZABETH	25MG	A085054	002	
	50MG	A085208	001	
ALRA	25MG	A086369	001	
	50MG	A083554	001	
APOTEX	25MG	A040774	001	Oct 03, 2007
	50MG	A040774	002	Oct 03, 2007
ASCOT	25MG	A087539	001	Feb 03, 1982
	50MG	A087540	001	Feb 03, 1982
AUROLIFE PHARMA LLC	25MG	A083899	001	
	50MG	A085219	001	
BARR	50MG	A084771	001	
CHARTWELL RX	25MG	A085683	001	
	50MG	A083965	001	
DAVA PHARMS INC	100MG	A087060	001	
ELKINS SINN	50MG	A085152	002	
HEATHER	50MG	A084135	001	
HIKMA INTL PHARMS	25MG	A084878	002	Jul 12, 2006
IMPAX LABS	25MG	A084029	001	
	50MG	A083607	002	
	100MG	A085098	001	
INWOOD LABS	25MG	A084776	001	
	25MG	A085067	001	
	50MG	A084776	002	
IVAX SUB TEVA PHARMS	50MG	A084658	001	
	100MG	A085022	001	
JUBILANT CADISTA	25MG	A040809	001	Sep 04, 2007
	50MG	A040809	002	Sep 04, 2007
LANNETT CO INC	25MG	A084325	001	
	50MG	A084324	001	
MAST MM	25MG	A086192	001	
	50MG	A086192	002	
MYLAN	25MG	A084880	001	
	50MG	A085112	001	
MYLAN PHARMS INC	12.5MG	A040770	001	Jan 23, 2007
PVT FORM	50MG	A086597	001	
ROXANE	25MG	A085004	001	
	50MG	A084536	002	
	50MG	A085005	001	
SOLVAY	25MG	A085323	001	
SUN PHARM INDUSTRIES	25MG	A083972	001	
	50MG	A083972	002	
	100MG	A083972	003	
SUPERPHARM	25MG	A088827	001	Dec 28, 1984
	50MG	A088828	001	Dec 28, 1984
	100MG	A088829	001	Dec 28, 1984
TEVA	25MG	A088924	001	Feb 07, 1985
	50MG	A088923	001	Feb 07, 1985
USL PHARMA	25MG	A087827	001	Apr 19, 1982
	50MG	A087752	001	Apr 19, 1982
VANGARD	25MG	A087638	001	
	50MG	A087610	001	
WARNER CHILCOTT	25MG	A087586	001	May 03, 1982

HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDROCHLOROTHIAZIDE

	50MG	A087587	001	May 03, 1982
WATSON LABS	25MG	A081189	001	Jan 24, 1992
	25MG	A083458	001	
	25MG	A085232	002	
	50MG	A083456	001	
	50MG	A085233	001	
	50MG	A086087	001	
	50MG	A086594	001	
	100MG	A081190	001	Jan 24, 1992
	100MG	A085099	001	
	100MG	A087002	001	
WATSON LABS TEVA	50MG	A083232	001	
WEST WARD	25MG	A084899	001	
WHITEWORTH TOWN PLSN	25MG	A083809	002	
	50MG	A083809	001	
	100MG	A085347	001	
YAOPHARMA CO LTD	25MG	A087565	001	Mar 09, 1982
	50MG	A084912	001	

HYDRODIURIL

+ MERCK	25MG **	N011835	003	
+	50MG **	N011835	006	
+	100MG **	N011835	007	

ORETIC

ABBVIE	25MG	N011971	001	
	50MG	N011971	002	

ZIDE

SOLVAY	50MG	A083925	001	

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

AVALIDE

+ SANOFI AVENTIS US	12.5MG;75MG **	N020758	001	Sep 30, 1997
+	25MG;300MG **	N020758	004	Mar 15, 2005

IRBESARTAN AND HYDROCHLOROTHIAZIDE

ATLAS PHARMS LLC	12.5MG;150MG	A203036	001	Jan 15, 2016
	12.5MG;300MG	A203036	002	Jan 15, 2016
	25MG;300MG	A203036	003	Jan 15, 2016
MYLAN PHARMS INC	12.5MG;150MG	A077969	001	Sep 27, 2012
	12.5MG;300MG	A077969	002	Sep 27, 2012
	25MG;300MG	A077969	003	Jul 20, 2016
TEVA	25MG;300MG	A077369	003	Mar 30, 2012
WATSON LABS INC	12.5MG;150MG	A091539	001	Oct 22, 2012
	12.5MG;300MG	A091539	002	Oct 22, 2012

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET;ORAL

NORMOZIDE

SCHERING	25MG;100MG	N019046	001	Apr 06, 1987
	25MG;200MG	N019046	002	Apr 06, 1987
	25MG;300MG	N019046	003	Apr 06, 1987
	25MG;400MG	N019046	004	Apr 06, 1987

TRANDATE HCT

GLAXOSMITHKLINE	25MG;100MG	N019174	001	Apr 10, 1987
	25MG;200MG	N019174	002	Apr 10, 1987
	25MG;300MG	N019174	003	Apr 10, 1987
	25MG;400MG	N019174	004	Apr 10, 1987

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

APOTEX INC	12.5MG;10MG	A076674	001	Oct 05, 2004
	12.5MG;20MG	A076674	002	Oct 05, 2004
	25MG;20MG	A076674	003	Oct 05, 2004
SANDOZ	12.5MG;10MG	A075926	001	Jul 01, 2002
	12.5MG;20MG	A075926	002	Jul 01, 2002
	25MG;20MG	A075926	003	Jul 01, 2002
TEVA	12.5MG;10MG	A075869	001	Jul 01, 2002
	12.5MG;20MG	A075869	002	Jul 01, 2002

HYDROCHLOROTHIAZIDE; LISINOPRIL					
TABLET;ORAL					
LISINOPRIL AND HYDROCHLOROTHIAZIDE					
		25MG;20MG	A075869	003	Jul 01, 2002
PRINZIDE					
+	MERCK	12.5MG;10MG **	N019778	003	Nov 18, 1993
+		12.5MG;20MG **	N019778	001	Feb 16, 1989
+		25MG;20MG **	N019778	002	Feb 16, 1989
HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM					
TABLET;ORAL					
HYZAAR					
+	MERCK SHARP DOHME	12.5MG;50MG	N020387	001	Apr 28, 1995
+		25MG;100MG	N020387	002	Nov 10, 1998
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE					
	APOTEX	12.5MG;50MG	A090150	001	Oct 06, 2010
		12.5MG;100MG	A090150	002	Aug 11, 2010
		25MG;100MG	A090150	003	Oct 06, 2010
	WATSON LABS	12.5MG;50MG	A200180	001	Jan 12, 2011
		12.5MG;100MG	A200180	002	Jan 12, 2011
		25MG;100MG	A200180	003	Jan 12, 2011
HYDROCHLOROTHIAZIDE; METHYLDOPA					
TABLET;ORAL					
ALDORIL 15					
	MERCK	15MG;250MG	N013402	001	
ALDORIL 25					
	MERCK	25MG;250MG	N013402	002	
ALDORIL D30					
	MERCK	30MG;500MG	N013402	003	
ALDORIL D50					
	MERCK	50MG;500MG	N013402	004	
METHYLDOPA AND HYDROCHLOROTHIAZIDE					
	DAVA PHARMS INC	15MG;250MG	A072507	001	Jun 02, 1989
		25MG;250MG	A072508	001	Jun 02, 1989
		30MG;500MG	A072509	001	Jun 02, 1989
		50MG;500MG	A072510	001	Jun 02, 1989
	IVAX SUB TEVA PHARMS	15MG;250MG	A071458	001	Mar 08, 1988
		25MG;250MG	A071459	001	Mar 08, 1988
		30MG;500MG	A071460	001	Mar 08, 1988
		50MG;500MG	A071461	001	Mar 08, 1988
	PAR PHARM	15MG;250MG	A070616	001	Feb 02, 1987
		25MG;250MG	A070612	001	Feb 02, 1987
		30MG;500MG	A070613	001	Feb 02, 1987
		50MG;500MG	A070614	001	Feb 02, 1987
	PARKE DAVIS	15MG;250MG	A071897	001	Nov 23, 1987
		25MG;250MG	A071898	001	Nov 23, 1987
		30MG;500MG	A071899	001	Nov 23, 1987
		50MG;500MG	A071900	001	Nov 23, 1987
	PUREPAC PHARM	15MG;250MG	A070853	001	Oct 08, 1986
		25MG;250MG	A070688	001	Apr 24, 1986
		30MG;500MG	A070854	001	Oct 08, 1986
		50MG;500MG	A070689	001	Apr 24, 1986
	SANDOZ	15MG;250MG	A070829	001	Mar 09, 1987
		25MG;250MG	A070830	001	Mar 09, 1987
	TEVA	15MG;250MG	A071819	001	Apr 08, 1988
		25MG;250MG	A071820	001	Apr 08, 1988
		30MG;500MG	A071821	001	Apr 08, 1988
		50MG;500MG	A071822	001	Apr 08, 1988
	WATSON LABS	15MG;250MG	A070365	001	Mar 19, 1986
		15MG;250MG	A070958	001	Feb 06, 1989
		15MG;250MG	A071920	001	Aug 29, 1988
		25MG;250MG	A070366	001	Apr 16, 1986
		25MG;250MG	A070959	001	Jan 19, 1989
		25MG;250MG	A071921	001	Aug 29, 1988
		30MG;500MG	A070367	001	Mar 19, 1986
		30MG;500MG	A071069	001	Jan 19, 1989
		30MG;500MG	A071922	001	Aug 29, 1988
		50MG;500MG	A070368	001	Apr 16, 1986
		50MG;500MG	A070960	001	Feb 06, 1989

HYDROCHLOROTHIAZIDE; METHYLDOPA				
TABLET;ORAL				
METHYLDOPA AND HYDROCHLOROTHIAZIDE				
	50MG;500MG	A071923	001	Aug 29, 1988
YAOPHARMA CO LTD	15MG;250MG	A070182	001	Jan 15, 1986
	25MG;250MG	A070183	001	Jan 15, 1986
	30MG;500MG	A070543	001	Jan 15, 1986
	50MG;500MG	A070544	001	Jan 15, 1986
HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE				
TABLET;ORAL				
LOPRESSOR HCT				
+ US PHARMS HOLDINGS I	50MG;100MG **	N018303	003	Dec 31, 1984
HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE				
TABLET;ORAL				
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
CHARTWELL RX	12.5MG;7.5MG	A090096	001	Sep 25, 2008
	12.5MG;15MG	A090096	002	Sep 25, 2008
	25MG;15MG	A090096	003	Sep 25, 2008
UNIRETIC				
UCB INC	12.5MG;7.5MG **	N020729	001	Jun 27, 1997
	12.5MG;15MG **	N020729	003	Feb 14, 2002
	25MG;15MG **	N020729	002	Jun 27, 1997
HYDROCHLOROTHIAZIDE; PINDOLOL				
TABLET;ORAL				
VISKAZIDE				
NOVARTIS	25MG;5MG	N018872	001	Jul 22, 1987
	25MG;10MG	N018872	002	Jul 22, 1987
HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
INDERIDE LA 120/50				
WYETH AYERST	50MG;120MG	N019059	002	Jul 03, 1985
INDERIDE LA 160/50				
WYETH AYERST	50MG;160MG	N019059	003	Jul 03, 1985
INDERIDE LA 80/50				
WYETH AYERST	50MG;80MG	N019059	001	Jul 03, 1985
TABLET;ORAL				
INDERIDE-40/25				
+ WYETH PHARMS INC	25MG;40MG **	N018031	001	
INDERIDE-80/25				
+ WYETH PHARMS INC	25MG;80MG **	N018031	002	
PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE				
DURAMED PHARMS BARR	25MG;40MG	A071126	001	Mar 02, 1987
	25MG;80MG	A071127	001	Mar 02, 1987
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
ACTAVIS ELIZABETH	25MG;40MG	A070851	001	May 15, 1986
	25MG;80MG	A070852	001	May 15, 1986
ANI PHARMS INC	25MG;40MG	A070704	001	Oct 01, 1986
	25MG;40MG	A072042	001	Mar 14, 1988
	25MG;80MG	A070705	001	Oct 01, 1986
	25MG;80MG	A072043	001	Mar 14, 1988
IVAX SUB TEVA PHARMS	25MG;40MG	A071552	001	Dec 01, 1988
	25MG;80MG	A071553	001	Dec 01, 1988
WARNER CHILCOTT	25MG;40MG	A071771	001	Jan 26, 1988
	25MG;80MG	A071772	001	Jan 26, 1988
WATSON LABS	25MG;40MG	A070301	001	Apr 18, 1986
	25MG;40MG	A071498	001	Dec 18, 1991
	25MG;80MG	A070305	001	Apr 18, 1986
	25MG;80MG	A071501	001	Dec 18, 1991
YAOPHARMA CO LTD	25MG;40MG	A071060	001	Aug 26, 1987
	25MG;80MG	A071061	001	Aug 26, 1987
HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE				
TABLET;ORAL				
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
SUN PHARM INDS LTD	12.5MG;EQ 10MG BASE	A078211	001	Mar 04, 2009
	12.5MG;EQ 20MG BASE	A078211	002	Mar 04, 2009
	25MG;EQ 20MG BASE	A078211	003	Mar 04, 2009

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET;ORAL				
H.R.-50				
	WHITEWORTH TOWN PLSN	50MG;0.125MG	A085338 001	
HYDRO-RESERP				
	ABC HOLDING	50MG;0.125MG	A084714 002	Jun 29, 1982
HYDRO-SERP "25"				
	SANDOZ	25MG;0.125MG	A084827 001	
HYDRO-SERP "50"				
	SANDOZ	50MG;0.125MG	A085213 001	
HYDROCHLOROTHIAZIDE W/ RESERPINE				
	IVAX SUB TEVA PHARMS	25MG;0.1MG	A083572 001	
		25MG;0.125MG	A083571 001	
		50MG;0.1MG	A083568 001	
		50MG;0.125MG	A083573 001	
	PHARMERAL	25MG;0.125MG	A085421 001	
		50MG;0.125MG	A085420 001	
	ROXANE	50MG;0.125MG	A084603 001	
	WATSON LABS	25MG;0.125MG	A084466 001	
		25MG;0.125MG	A085317 001	
		25MG;0.125MG	A086330 002	
		50MG;0.125MG	A083666 001	
		50MG;0.125MG	A084467 001	
		50MG;0.125MG	A086331 001	
HYDROPRES 25				
	MERCK	25MG;0.125MG	N011958 002	
HYDROPRES 50				
	MERCK	50MG;0.125MG	N011958 003	
RESERPINE AND HYDROCHLOROTHIAZIDE				
	BARR	25MG;0.125MG	A084580 001	
		50MG;0.125MG	A084579 001	
	SANDOZ	50MG;0.125MG	A088200 001	Jan 31, 1984
RESERPINE AND HYDROCHLOROTHIAZIDE-50				
	WEST WARD	50MG;0.125MG	A088189 001	May 10, 1984
SERPASIL-ESIDRIX #1				
	NOVARTIS	25MG;0.1MG	N011878 003	
SERPASIL-ESIDRIX #2				
	NOVARTIS	50MG;0.1MG	N011878 005	

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL				
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE				
	ASCOT	25MG;25MG	A088025 001	Nov 23, 1984
	MUTUAL PHARM	25MG;25MG	A087267 001	
	PUREPAC PHARM	25MG;25MG	A087999 001	Nov 06, 1985
	SUPERPHARM	25MG;25MG	A089137 001	Aug 26, 1985
	WATSON LABS	25MG;25MG	A087398 001	
	YAOPHARMA CO LTD	25MG;25MG	A086881 001	
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE				
	IVAX PHARMS	25MG;25MG	A087004 002	May 24, 1982
	LEDERLE	25MG;25MG	A087511 001	
	PARKE DAVIS	25MG;25MG	A087948 001	Feb 22, 1983
	PUREPAC PHARM	25MG;25MG	A088054 001	Aug 18, 1983
	UPSHER SMITH	25MG;25MG	A087553 001	
	USL PHARMA	25MG;25MG	A087651 001	
	VANGARD	25MG;25MG	A087655 001	
	WATSON LABS	25MG;25MG	A085974 001	
		25MG;25MG	A086026 001	

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET;ORAL				
TIMOLIDE 10-25				
	MERCK	25MG;10MG	N018061 001	

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL				
DYAZIDE				
	GLAXOSMITHKLINE LLC	25MG;50MG	N016042 002	
TRIAMTERENE AND HYDROCHLOROTHIAZIDE				
	ANI PHARMS INC	25MG;37.5MG	A074970 001	Jan 06, 1998
	NOVARTIS	25MG;37.5MG	A074857 001	Sep 09, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL				
TRIAMTERENE AND HYDROCHLOROTHIAZIDE				
VITARINE	25MG;50MG	A071737	001	Feb 12, 1988
TABLET;ORAL				
TRIAMTERENE AND HYDROCHLOROTHIAZIDE				
AM THERAP	50MG;75MG	A072022	001	Apr 17, 1988
QUANTUM PHARMICS	50MG;75MG	A071980	001	Apr 17, 1988
WATSON LABS	50MG;75MG	A071969	001	Apr 17, 1988

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL				
VALSARTAN AND HYDROCHLOROTHIAZIDE				
APOTEX INC	12.5MG;80MG	A203026	001	Mar 21, 2013
	12.5MG;160MG	A203026	002	Mar 21, 2013
	12.5MG;320MG	A203026	003	Mar 21, 2013
	25MG;160MG	A203026	004	Mar 21, 2013
	25MG;320MG	A203026	005	Mar 21, 2013
WATSON LABS TEVA	12.5MG;80MG	A091519	001	Mar 21, 2013
	12.5MG;160MG	A091519	002	Mar 21, 2013
	12.5MG;320MG	A091519	003	Mar 21, 2013
	25MG;160MG	A091519	004	Mar 21, 2013
	25MG;320MG	A091519	005	Mar 21, 2013

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE;ORAL				
VANTRELA ER				
+ TEVA BRANDED PHARM	15MG	N207975	001	Jan 17, 2017
+	30MG	N207975	002	Jan 17, 2017
+	45MG	N207975	003	Jan 17, 2017
+	60MG	N207975	004	Jan 17, 2017
+	90MG	N207975	005	Jan 17, 2017

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL				
HYDROCODONE BITARTRATE AND IBUPROFEN				
ACTAVIS LABS FL INC	5MG;200MG	A077454	001	Jun 23, 2010
VICOPROFEN				
+ ABBVIE	7.5MG;200MG	N020716	001	Sep 23, 1997

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP;ORAL				
CODAMINE				
ALPHARMA US PHARMS	5MG/5ML;25MG/5ML	A075103	001	Sep 29, 2000

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL				
HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE				
TRIS PHARMA INC	5MG/5ML;60MG/5ML	A203839	001	Oct 28, 2014

HYDROCORTAMATE HYDROCHLORIDE

OINTMENT;TOPICAL				
MAGNACORT				
PFIZER	0.5%	N010554	001	

HYDROCORTISONE

AEROSOL;TOPICAL				
AEROSEB-HC				
ALLERGAN HERBERT	0.5%	A085805	001	
CREAM;TOPICAL				
CORT-DOME				
BAYER PHARMS	0.5%	N009585	003	
	1%	N009585	001	
DERMACORT				
MONARCH PHARMS	1%	A083011	002	
ELDECORT				
VALEANT PHARM INTL	1%	A080459	001	
	2.5%	A084055	001	
FLEXICORT				
WESTWOOD SQUIBB	0.5%	A087136	003	Apr 08, 1982
	1%	A087136	002	Apr 08, 1982
	2.5%	A087136	001	Apr 08, 1982

HYDROCORTISONE

CREAM;TOPICAL				
H-CORT				
	PHARM ASSOC	0.5%	A086823 001	
HC #1				
	BAYER PHARMS	0.5%	A080438 001	
HC #4				
	BAYER PHARMS	1%	A080438 002	
HC (HYDROCORTISONE)				
	C AND M PHARMA	0.5%	A080482 003	
		1%	A080482 004	
HI-COR				
	C AND M PHARMA	2.5%	A080483 001	
HYDROCORTISONE				
	ALPHARMA US PHARMS	2.5%	A089754 001	Feb 01, 1989
	ALTANA	0.5%	A080848 002	
		1%	A080848 003	
	AMBIX	1%	A086080 001	
		2.5%	A086271 001	
	EVERYLIFE	0.5%	A080452 001	
		1%	A080452 002	
	G AND W LABS	1%	A084059 001	
	INGRAM PHARM	0.5%	A080456 002	
		1%	A080456 003	
	IVAX PHARMS	1%	A085733 001	
	NASKA	1%	A089706 001	Mar 10, 1988
	PERRIGO NEW YORK	0.5%	A084970 002	
		1%	A085026 001	
	PHARMADERM	1%	A088845 001	Feb 27, 1986
		2.5%	A089413 001	Dec 16, 1986
	PHARMAFAIR	1%	A087838 001	Jul 28, 1982
	STIEFEL	1%	A086170 001	
	SYOSSET	0.5%	A085527 001	
	TARO	0.5%	A086154 001	
	TARO PHARM INDS LTD	1%	A086155 001	
	TEVA	0.5%	A080400 002	
		1%	A080400 003	
		1%	A085191 001	
		2.5%	A080400 004	
	TOPIDERM	1%	A089273 001	Feb 17, 1989
	USL PHARMA	1%	A088027 001	Sep 27, 1983
		2.5%	A088029 001	Sep 27, 1983
	WHITEWORTH TOWN PLSN	1%	A080496 002	
HYTONE				
	VALEANT INTL	1% **	A080472 003	
		2.5% **	A080472 004	
NOGENIC HC				
	IVAX PHARMS	1%	A087427 001	Apr 04, 1988
NUTRACORT				
	DOW PHARM	0.5%	A080442 002	
		1%	A080442 003	
PENECORT				
	ALLERGAN HERBERT	1%	A088216 001	Jun 06, 1984
PROCTOCORT				
	MONARCH PHARMS	1%	A083011 001	
SYNACORT				
	MEDICIS	0.5%	A087459 001	
		1%	A087458 001	
		2.5%	A087457 001	
GEL;TOPICAL				
NUTRACORT				
	HEALTHPOINT	1%	A084698 001	
PENECORT				
	ALLERGAN HERBERT	1%	A088215 001	Jun 06, 1984
INJECTABLE;INJECTION				
CORTEF				
	PHARMACIA AND UPJOHN	50MG/ML	N009864 001	

HYDROCORTISONE

LOTION;TOPICAL				
ACTICORT				
BAKER NORTON	1%	A086535	001	
ALA-CORT				
CROWN LABS	1%	A083201	001	
BALNEOL-HC				
SOLVAY	1%	A088041	001	Dec 03, 1982
BETA-HC				
BETA DERMAC	1%	A089495	001	Jan 25, 1988
CETACORT				
DOW PHARM	0.5%	A080426	002	
	1%	A080426	001	
CORT-DOME				
BAYER PHARMS	0.5%	N009895	003	
	1%	N009895	001	
DERMACORT				
SOLVAY	0.5%	A084573	002	
	1%	A086462	001	
EPICORT				
BLULINE	0.5%	A083219	002	
GLYCORT				
HERAN	1%	A087489	001	Oct 03, 1983
H-CORT				
PHARM ASSOC	0.5%	A086824	001	
HYDROCORTISONE				
ALPHARMA US PHARMS	0.5%	A087317	001	Jun 07, 1982
	1%	A087315	001	Jun 07, 1982
MERICON	0.5%	A085282	001	
	1%	A085282	002	Feb 26, 1987
NASKA	1%	A089705	001	Apr 25, 1988
PERRIGO NEW YORK	0.5%	A085662	001	
	1%	A085663	001	
TARO	1%	A089024	001	Feb 12, 1986
HYTONE				
VALEANT INTL	1% **	A080473	003	
	2.5% **	A080473	004	Nov 30, 1982
NUTRACORT				
DOW PHARM	0.5%	A080443	002	
	1%	A080443	003	
	2.5%	A087644	001	Aug 24, 1982
STIE-CORT				
PERRIGO CO	1%	A089066	001	Nov 25, 1985
OINTMENT;TOPICAL				
CORTRIL				
PFIZER GLOBAL	1%	N009176	001	
	2.5%	N009176	002	
HC (HYDROCORTISONE)				
C AND M PHARMA	0.5%	A080481	001	
	1%	A080481	002	
HYDROCORTISONE				
ALTANA	0.5%	A080489	002	
	1%	A080489	003	
AMBIX	1%	A086079	001	
	2.5%	A086272	001	
NASKA	1%	A089704	001	Mar 10, 1988
PERRIGO NEW YORK	0.5%	A084969	003	
	1%	A085028	001	
PHARMADERM	1%	A088842	001	Feb 09, 1987
TARO	0.5%	A086256	001	
	2.5%	A040310	001	Dec 29, 2000
USL PHARMA	1%	A088061	001	Sep 27, 1983
	2.5%	A088039	001	Sep 27, 1983
HYTONE				
DERMIK LABS	1% **	A080474	003	
	2.5% **	A080474	004	
PENECORT				
ALLERGAN HERBERT	2.5%	A088217	001	Jun 06, 1984

HYDROCORTISONE				
POWDER;FOR RX COMPOUNDING				
H-CORT				
TORCH	100%	A087834	001	Mar 29, 1982
HYDRO-RX				
X GEN PHARMS	100%	A085982	001	
HYDROCORTISONE				
PADDOCK LLC	100%	A088082	001	Apr 08, 1983
SOLUTION;TOPICAL				
PENECORT				
ALLERGAN HERBERT	1%	A088214	001	Jun 06, 1984
TEXACORT				
MISSION PHARMA	1%	A080425	001	
TABLET;ORAL				
CORTRIL				
PFIZER	10MG	N009127	005	
	20MG	N009127	003	
HYDROCORTISONE				
BARR	20MG	A083999	001	
ELKINS SINN	20MG	A080624	001	
FERRANTE	10MG	A080568	001	
	20MG	A080568	002	
IMPAX LABS	20MG	A080781	001	
INWOOD LABS	20MG	A080732	001	
LANNETT	20MG	A085070	001	
NEXGEN PHARMA INC	20MG	A083140	001	
PANRAY	10MG	N009659	001	
	20MG	N009659	002	
PARKE DAVIS	20MG	A084243	001	
PUREPAC PHARM	10MG	A084247	003	Aug 31, 1982
	20MG	A080395	001	
	20MG	A084247	002	
ROXANE	10MG	A088539	001	Mar 21, 1984
SANDOZ	20MG	A080642	002	
WATSON LABS	20MG	A080355	001	
WHITEWORTH TOWN PLSN	10MG	A080344	001	
	20MG	A080344	002	
HYDROCORTONE				
MERCK	10MG	N008506	007	
	20MG	N008506	011	
TABLET;VAGINAL				
CORTRIL				
PFIPHARMECS	10MG	N009796	001	
HYDROCORTISONE ACETATE				
CREAM;TOPICAL				
HEMSOL-HC				
ABLE	1%	A081274	001	Jun 19, 1992
HYDROCORTISONE ACETATE				
CENCI	1%	A080419	001	Jan 25, 1982
FERNDALE LABS	2.5%	A040259	001	Jul 29, 1999
PARKE DAVIS	1%	A089914	001	Jan 03, 1989
PUREPAC PHARM	0.5%	A086050	001	
	1%	A086052	001	
MICORT-HC				
SEBELA IRELAND LTD	2%	A040398	001	Mar 29, 2002
INJECTABLE;INJECTION				
CORTEF ACETATE				
PHARMACIA AND UPJOHN	50MG/ML	N009378	002	
CORTRIL				
PFIZER	25MG/ML	N009164	001	
HYDROCORTISONE ACETATE				
AKORN	25MG/ML	N009637	001	
	50MG/ML	N009637	002	
BEL MAR	25MG/ML	A083739	001	
	50MG/ML	A083739	002	
WATSON LABS	25MG/ML	A083128	001	
	25MG/ML	A083759	001	
	50MG/ML	A083759	002	
	50MG/ML	A085214	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

HYDROCORTISONE ACETATE

INJECTABLE;INJECTION				
HYDROCORTONE				
	MERCK	25MG/ML	N008228 001	
		50MG/ML	N008228 004	
LOTION;TOPICAL				
DRICORT				
	INGRAM PHARM	0.5%	A086207 001	
OINTMENT;OPHTHALMIC				
HYDROCORTISONE ACETATE				
	FERA PHARMS	0.5%	A080828 001	
OINTMENT;OPHTHALMIC, OTIC				
HYDROCORTONE				
	MERCK	1.5%	N009018 003	
OINTMENT;TOPICAL				
CORTEF ACETATE				
	PHARMACIA AND UPJOHN	1%	N008917 002	
+		2.5% **	N008917 001	
PASTE;TOPICAL				
ORABASE HCA				
	COLGATE	0.5%	A083205 001	
POWDER;FOR RX COMPOUNDING				
HYDROCORTISONE ACETATE				
	X GEN PHARMS	100%	A085981 001	

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

CREAM;TOPICAL				
NEO-CORTEF				
	PHARMACIA AND UPJOHN	1%;EQ 3.5MG BASE/GM	A061049 001	
		2.5%;EQ 3.5MG BASE/GM	A061049 002	
OINTMENT;OPHTHALMIC				
NEO-CORTEF				
	PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	A060610 001	
		1.5%;EQ 3.5MG BASE/GM	A060610 002	
OINTMENT;TOPICAL				
NEO-CORTEF				
	PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	A060751 001	
		1%;EQ 3.5MG BASE/GM	A060751 002	
		2.5%;EQ 3.5MG BASE/GM	A060751 003	
SUSPENSION/DROPS;OPHTHALMIC				
COR-OTICIN				
	AKORN	1.5%;EQ 3.5MG BASE/ML	A060188 001	
NEO-CORTEF				
	PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/ML	A060612 002	
		1.5%;EQ 3.5MG BASE/ML	A060612 001	

HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

SUSPENSION;OPHTHALMIC				
TERRA-CORTRIL				
	PFIZER	1.5%;EQ 5MG BASE/ML	A061016 001	

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED;TOPICAL				
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%				
	GENUS LIFESCIENCES	1%;1%	A089440 001	May 17, 1988
LOTION;TOPICAL				
PRAMOSONE				
	FERNDALE LABS	0.5%;1%	A083213 002	

HYDROCORTISONE ACETATE; UREA

CREAM;TOPICAL				
CARMOL HC				
	FOUGERA PHARMS	1%;10%	A080505 001	

HYDROCORTISONE BUTYRATE

CREAM;TOPICAL				
LOCOID				
	YAMANOUCHI	0.1%	N018795 001	Jan 07, 1983
OINTMENT;TOPICAL				
LOCOID				
	YAMANOUCHI	0.1%	N019106 001	Jul 03, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

HYDROCORTISONE BUTYRATE

SOLUTION;TOPICAL				
LOCOID				
	YAMANOUCHI	0.1%	N019819 001	Sep 15, 1988

HYDROCORTISONE CYPIONATE

SUSPENSION;ORAL				
CORTEF				
	PHARMACIA AND UPJOHN	EQ 10MG BASE/5ML	N009900 001	

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE;INJECTION				
HYDROCORTONE				
	MERCK	EQ 50MG BASE/ML	N012052 001	

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE;INJECTION				
A-HYDROCORT				
	ABBOTT	EQ 100MG BASE/VIAL	A085928 001	
		EQ 100MG BASE/VIAL	A089577 001	Apr 11, 1989
		EQ 250MG BASE/VIAL	A089578 001	Apr 11, 1989
		EQ 500MG BASE/VIAL	A089579 001	Apr 11, 1989
		EQ 1GM BASE/VIAL	A089580 001	Apr 11, 1989
	HOSPIRA	EQ 100MG BASE/VIAL	A040666 001	Apr 06, 2006
		EQ 100MG BASE/VIAL	A085929 001	
		EQ 250MG BASE/VIAL	A085930 001	
		EQ 500MG BASE/VIAL	A085931 001	
		EQ 1GM BASE/VIAL	A085932 001	
HYDROCORTISONE SODIUM SUCCINATE				
	ABRAXIS PHARM	EQ 100MG BASE/VIAL	A088667 001	Jun 08, 1984
		EQ 100MG BASE/VIAL	A088712 001	Jun 08, 1984
		EQ 250MG BASE/VIAL	A088668 001	Jun 08, 1984
		EQ 500MG BASE/VIAL	A088669 001	Jun 08, 1984
		EQ 1GM BASE/VIAL	A088670 001	Jun 08, 1984
	BAXTER HLTHCARE	EQ 100MG BASE/VIAL	A086619 001	
		EQ 250MG BASE/VIAL	A087567 001	
		EQ 500MG BASE/VIAL	A087568 001	
		EQ 1GM BASE/VIAL	A087569 001	
	INTL MEDICATION	EQ 100MG BASE/VIAL	A087532 001	Mar 19, 1982
	WATSON LABS	EQ 100MG BASE/VIAL	A084737 002	
		EQ 100MG BASE/VIAL	A084738 001	
		EQ 250MG BASE/VIAL	A084737 001	
		EQ 500MG BASE/VIAL	A084747 001	
		EQ 1GM BASE/VIAL	A084748 001	

HYDROCORTISONE VALERATE

CREAM;TOPICAL				
HYDROCORTISONE VALERATE				
	G AND W LABS INC	0.2%	A074489 001	Aug 12, 1998
WESTCORT				
+	SUN PHARM INDS INC	0.2% **	N017950 001	
OINTMENT;TOPICAL				
HYDROCORTISONE VALERATE				
	FOUGERA PHARMS	0.2%	A075085 001	Jul 31, 2001
WESTCORT				
+	SUN PHARM INDS INC	0.2% **	N018726 001	Aug 08, 1983

HYDROCORTISONE; NEOMYCIN SULFATE

CREAM;TOPICAL				
NEO-CORT-DOME				
	BAYER PHARMS	0.5%;EQ 3.5MG BASE/GM	N050237 006	Jun 05, 1984
		1%;EQ 3.5MG BASE/GM	N050237 005	Jun 05, 1984

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC				
CORTISPORIN				
+	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050479 001	
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE				
	AMRING PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065216 001	Oct 31, 2005
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE				
	PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062394 001	Sep 29, 1982

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC				
OTOCORT				
	WATSON LABS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A060730 002	
SUSPENSION/DROPS;OPHTHALMIC				
CORTISPORIN				
	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050169 001	
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE				
	PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062623 001	Sep 24, 1985
SUSPENSION/DROPS;OTIC				
NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE				
	PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062617 001	Sep 18, 1985
OTICAIR				
	PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062399 001	Nov 18, 1982
OTOBIONE				
	SCHERING	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A061816 001	
OTOCORT				
	ACTAVIS LABS FL INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062521 001	Jul 11, 1985
PEDIOTIC				
	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062822 001	Sep 29, 1987

HYDROCORTISONE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC				
OTOBIOTIC				
	SCHERING	5MG/ML;EQ 10,000 UNITS BASE/ML	A062302 001	
PYOCIDIN				
	FOREST LABS	5MG/ML;EQ 10,000 UNITS BASE/ML	A061606 001	

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

OINTMENT;OPHTHALMIC				
ACHROMYCIN				
	LEDERLE	1.5%;1%	N050272 001	

HYDROCORTISONE; UREA

CREAM;TOPICAL				
ALPHADERM				
	BIOGLAN	1%;10%	A086008 001	
CALMURID HC				
	PHARMACIA AND UPJOHN	1%;10%	A083947 001	

HYDROFLUMETHIAZIDE

TABLET;ORAL				
DIUCARDIN				
	WYETH AYERST	50MG	A083383 001	
HYDROFLUMETHIAZIDE				
	PAR PHARM	50MG	A088850 001	May 31, 1985
	WATSON LABS	50MG	A088031 001	Apr 06, 1983
		50MG	A088528 001	Aug 15, 1984
SALURON				
+	SHIRE LLC	50MG	N011949 001	

HYDROFLUMETHIAZIDE; RESERPINE

TABLET;ORAL				
HYDROFLUMETHIAZIDE AND RESERPINE				
	USL PHARMA	50MG;0.125MG	A088195 001	Oct 26, 1983
	WATSON LABS	25MG;0.125MG	A088127 001	Mar 22, 1983
		50MG;0.125MG	A088110 001	Mar 22, 1983
RESERPINE AND HYDROFLUMETHIAZIDE				
	IVAX PHARMS	50MG;0.125MG	A088932 001	Jan 11, 1985
	PAR PHARM	50MG;0.125MG	A088907 001	Sep 20, 1985
SALUTENSIN				
	SHIRE	50MG;0.125MG	N012359 003	
SALUTENSIN-DEMI				
	SHIRE	25MG;0.125MG	N012359 004	

HYDROMORPHONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
PALLADONE				
	PURDUE PHARMA LP	12MG	N021044 001	Sep 24, 2004
		16MG	N021044 002	Sep 24, 2004
		24MG	N021044 003	Sep 24, 2004
		32MG	N021044 004	Sep 24, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION				
DILAUDID				
+	FRESENIUS KABI USA	4MG/ML	N019034 005	Apr 30, 2009
DILAUDID-HP				
+	FRESENIUS KABI USA	10MG/ML	N019034 001	Jan 11, 1984
		250MG/VIAL	N019034 002	Aug 04, 1994
HYDROMORPHONE HYDROCHLORIDE				
	HOSPIRA	10MG/ML	A074598 001	Jun 19, 1997
	WATSON LABS	10MG/ML	A074317 001	Aug 23, 1995
TABLET;ORAL				
HYDROMORPHONE HYDROCHLORIDE				
	NESHER PHARMS	2MG	A077311 001	Nov 09, 2005
		4MG	A077311 002	Nov 09, 2005
		8MG	A077311 003	Nov 09, 2005
TABLET, EXTENDED RELEASE;ORAL				
HYDROMORPHONE HYDROCHLORIDE				
	ACTAVIS LABS FL INC	8MG	A202144 001	May 12, 2014
		12MG	A202144 002	May 12, 2014
		16MG	A202144 003	May 12, 2014
		32MG	A202144 004	Jun 30, 2016

HYDROXOCOBALAMIN

INJECTABLE;INJECTION				
ALPHAREDISOL				
	MERCK	1MG/ML	A080778 001	
CYANOKIT				
	SERB SA	2.5GM/VIAL (5GM/KIT)	N022041 002	Dec 15, 2006
HYDROXOCOBALAMIN				
	ABRAXIS PHARM	1MG/ML	A084921 001	
	WATSON LABS	1MG/ML	A085528 001	
HYDROXOMIN				
	BEL MAR	1MG/ML	A084629 001	

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS;OPHTHALMIC				
PAREDRINE				
	PHARMICS	1%	N000004 004	

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL				
HYDROXYCHLOROQUINE SULFATE				
	SANDOZ	200MG	A040150 001	Jan 27, 1996

HYDROXYPROGESTERONE CAPROATE

INJECTABLE;INJECTION				
HYDROXYPROGESTERONE CAPROATE				
	AKORN	125MG/ML	N018004 001	
	ALLERGAN SALES LLC	125MG/ML	N017439 001	
		250MG/ML	N017439 002	
SOLUTION;INTRAMUSCULAR				
DELALUTIN				
+	BRISTOL MYERS SQUIBB	125MG/ML (125MG/ML) **	N010347 004	
+		125MG/ML (125MG/ML) **	N016911 001	
+		250MG/ML (250MG/ML) **	N010347 002	
+		250MG/ML (250MG/ML) **	N016911 002	

HYDROXYSTILBAMIDINE ISETHIONATE

INJECTABLE;INJECTION				
HYDROXYSTILBAMIDINE ISETHIONATE				
	SANOFI AVENTIS US	225MG/AMP	N009166 001	

HYDROXYUREA

CAPSULE;ORAL				
HYDROXYUREA				
	BARR	250MG	A075143 002	Sep 21, 2000
	BARR LABS INC	250MG	A075020 002	Jun 26, 2000
		500MG	A075020 001	Jul 30, 1998
	ROXANE	500MG	A074476 001	Aug 18, 1995
TABLET;ORAL				
HYDROXYUREA				
	BARR	1GM	A075734 001	Aug 29, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

HYDROXYZINE HYDROCHLORIDE

INJECTABLE;INJECTION				
HYDROXYZINE				
	BAXTER HLTHCARE	50MG/ML	A085551 002	
HYDROXYZINE HYDROCHLORIDE				
	ALTANA	25MG/ML	A087273 001	Apr 20, 1982
		50MG/ML	A087273 002	Apr 20, 1982
	BAXTER HLTHCARE	25MG/ML	A085551 001	
	FRESENIUS KABI USA	25MG/ML	A087329 001	
		25MG/ML	A088184 001	Mar 31, 1983
		50MG/ML	A087329 002	
		50MG/ML	A088185 001	Mar 31, 1983
	HOSPIRA	25MG/ML	A087416 001	
		50MG/ML	A086821 001	
		50MG/ML	A087546 001	
	PHARMAFAIR	25MG/ML	A088862 001	Feb 14, 1986
		25MG/ML	A089106 001	Feb 14, 1986
		50MG/ML	A088881 001	Feb 14, 1986
		50MG/ML	A089107 001	Feb 14, 1986
	SMITH AND NEPHEW	25MG/ML	A087592 001	
	SOLOPAK	25MG/ML	A086822 001	
		25MG/ML	A087591 001	
		50MG/ML	A087310 001	
		50MG/ML	A087593 001	
		50MG/ML	A087595 001	
		50MG/ML	A087596 001	
	WATSON LABS	25MG/ML	A085778 001	
		25MG/ML	A087274 001	
		50MG/ML	A085779 001	
		50MG/ML	A087274 002	
	WYETH AYERST	25MG/ML	A086258 001	
		50MG/ML	A086258 002	
ORGATRAX				
	ORGANON USA INC	25MG/ML	A087014 001	
		50MG/ML	A087014 002	
VISTARIL				
+	PFIZER	25MG/ML **	N011111 001	
+		50MG/ML **	N011111 002	
SYRUP;ORAL				
ATARAX				
	ROERIG	10MG/5ML **	N010485 001	
HYDROXYZINE HYDROCHLORIDE				
	ALPHARMA US PHARMS	10MG/5ML	A088785 001	Feb 03, 1988
	KV PHARM	10MG/5ML	A087730 001	Jul 01, 1982
	STI PHARMA LLC	10MG/5ML	A086880 001	
TABLET;ORAL				
ATARAX				
+	PFIZER	10MG **	N010392 001	
+		25MG **	N010392 004	
+		50MG **	N010392 006	
+		100MG **	N010392 005	
HYDROXYZINE HYDROCHLORIDE				
	ABLE	10MG	A040559 001	Jul 22, 2004
		25MG	A040562 001	Jul 22, 2004
		50MG	A040563 001	Jul 22, 2004
	ACTAVIS ELIZABETH	10MG	A089071 001	Jul 22, 1986
		25MG	A089072 001	Jul 22, 1986
		50MG	A089073 001	Jul 22, 1986
	AUROLIFE PHARMA LLC	10MG	A087871 002	Dec 20, 1982
		25MG	A087871 003	Dec 20, 1982
		50MG	A087871 001	Dec 20, 1982
	HALSEY	10MG	A089366 001	May 02, 1988
		25MG	A089117 001	May 02, 1988
		50MG	A089396 001	May 02, 1988
	IVAX PHARMS	10MG	A087216 001	
		25MG	A087410 001	
		50MG	A087411 001	
	KV PHARM	10MG	A087819 001	Jun 23, 1982
		25MG	A087820 001	Jun 23, 1982

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE				
	50MG	A087821	001	Jun 23, 1982
	100MG	A087822	001	Jun 23, 1982
MUTUAL PHARM	10MG	A088409	001	Nov 15, 1983
	25MG	A087857	001	Apr 18, 1983
	50MG	A087860	001	Apr 18, 1983
PLIVA	100MG	A081054	001	Sep 25, 1995
PUREPAC PHARM	10MG	A088120	001	Sep 25, 1984
	25MG	A088121	001	Sep 25, 1984
	50MG	A088122	001	Sep 25, 1984
QUANTUM PHARMICS	10MG	A088540	001	Oct 22, 1985
	25MG	A088551	001	Oct 22, 1985
	50MG	A088529	001	Oct 22, 1985
SANDOZ	10MG	A087246	002	
	25MG	A085247	001	
	50MG	A087245	001	
SUN PHARM INDS INC	10MG	A040899	001	Jun 10, 2008
	25MG	A040899	002	Jun 10, 2008
	50MG	A040899	003	Jun 10, 2008
SUN PHARM INDUSTRIES	10MG	A089381	001	May 19, 1986
	25MG	A089382	001	May 19, 1986
	50MG	A089383	001	May 19, 1986
	100MG	A087862	001	Apr 18, 1983
SUPERPHARM	10MG	A088794	001	Dec 05, 1984
	25MG	A088795	001	Dec 05, 1984
	50MG	A088796	001	Dec 05, 1984
USL PHARMA	10MG	A089121	001	Mar 20, 1986
	25MG	A089122	001	Mar 20, 1986
	50MG	A089123	001	Mar 20, 1986
VINTAGE	10MG	A087602	001	Jan 22, 1982
	25MG	A087603	001	Jan 22, 1982
	50MG	A087604	001	Jan 22, 1982
WATSON LABS	10MG	A081149	001	Mar 18, 1994
	10MG	A086827	001	
	10MG	A088348	001	Sep 15, 1983
	25MG	A081150	001	Mar 18, 1994
	25MG	A086829	001	
	25MG	A088349	001	Sep 15, 1983
	50MG	A081151	001	Mar 18, 1994
	50MG	A086836	001	
	50MG	A088350	001	Sep 15, 1983

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HY-PAM "25"				
TEVA	EQ 25MG HYDROCHLORIDE	A088713	001	Mar 04, 1985
HYDROXYZINE PAMOATE				
DURAMED PHARMS BARR	EQ 25MG HYDROCHLORIDE	A088593	001	Feb 29, 1984
	EQ 50MG HYDROCHLORIDE	A088594	001	Feb 29, 1984
	EQ 100MG HYDROCHLORIDE	A088595	001	Feb 29, 1984
IVAX SUB TEVA PHARMS	EQ 25MG HYDROCHLORIDE	A087761	001	Mar 05, 1982
	EQ 50MG HYDROCHLORIDE	A087760	001	Mar 05, 1982
PAR PHARM	EQ 25MG HYDROCHLORIDE	A087656	001	Jun 11, 1982
	EQ 25MG HYDROCHLORIDE	A089145	001	Mar 17, 1986
	EQ 50MG HYDROCHLORIDE	A087657	001	Jun 11, 1982
	EQ 50MG HYDROCHLORIDE	A089146	001	Mar 17, 1986
	EQ 100MG HYDROCHLORIDE	A087658	001	Jun 11, 1982
SANDOZ	EQ 25MG HYDROCHLORIDE	A081127	001	Jun 28, 1991
	EQ 50MG HYDROCHLORIDE	A081128	001	Jun 28, 1991
	EQ 100MG HYDROCHLORIDE	A081129	001	Jun 28, 1991
SUPERPHARM	EQ 25MG HYDROCHLORIDE	A089031	001	Jan 02, 1987
	EQ 50MG HYDROCHLORIDE	A089032	001	Jan 02, 1987
	EQ 100MG HYDROCHLORIDE	A089033	001	Jan 02, 1987
VANGARD	EQ 25MG HYDROCHLORIDE	A088392	001	Sep 19, 1983
	EQ 50MG HYDROCHLORIDE	A088393	001	Sep 19, 1983
WATSON LABS	EQ 25MG HYDROCHLORIDE	A081165	001	Jul 31, 1991
	EQ 25MG HYDROCHLORIDE	A086698	001	
	EQ 25MG HYDROCHLORIDE	A086840	001	Jul 01, 1982

HYDROXYZINE PAMOATE				
CAPSULE;ORAL				
HYDROXYZINE PAMOATE				
	EQ 50MG HYDROCHLORIDE	A086695	001	
	EQ 50MG HYDROCHLORIDE	A086705	001	Jul 01, 1982
	EQ 50MG HYDROCHLORIDE	A087767	001	Aug 16, 1982
	EQ 100MG HYDROCHLORIDE	A086697	001	
	EQ 100MG HYDROCHLORIDE	A086728	001	Oct 05, 1982
	EQ 100MG HYDROCHLORIDE	A087790	001	Aug 16, 1982
VISTARIL				
PFIZER	EQ 100MG HYDROCHLORIDE **	N011459	006	
SUSPENSION;ORAL				
VISTARIL				
PFIZER	EQ 25MG HYDROCHLORIDE/5ML	N011795	001	
IBANDRONATE SODIUM				
TABLET;ORAL				
BONIVA				
+ HOFFMANN LA ROCHE	EQ 2.5MG BASE **	N021455	001	May 16, 2003
IBANDRONATE SODIUM				
MYLAN PHARMS INC	EQ 150MG BASE	A078995	001	Mar 19, 2012
IBUPROFEN				
CAPSULE;ORAL				
IBUPROFEN				
CONTRACT PHARMACAL	200MG	A074782	001	Jul 06, 1998
MIDOL				
BAYER	200MG **	A070626	001	Sep 02, 1987
	200MG **	A071002	001	Sep 02, 1987
SOLUTION;INTRAVENOUS				
CALDOLOR				
CUMBERLAND PHARMS	400MG/4ML (100MG/ML)	N022348	001	Jun 11, 2009
SUSPENSION;ORAL				
CHILDREN'S ADVIL				
WYETH CONS	100MG/5ML	N019833	002	Sep 19, 1989
IBU				
ABBOTT	100MG/5ML	N019784	001	Dec 18, 1989
MOTRIN				
+ MCNEIL CONSUMER	100MG/5ML **	N019842	001	Sep 19, 1989
SUSPENSION/DROPS;ORAL				
MOTRIN				
MCNEIL	40MG/ML	N020476	001	May 25, 1995
TABLET;ORAL				
ACHES-N-PAIN				
LEDERLE	200MG	A071065	001	May 28, 1987
CAP-PROFEN				
PERRIGO	200MG	A072097	001	Dec 08, 1987
IBU				
BASF	400MG	A070083	001	Feb 22, 1985
	400MG	N018197	001	
	600MG	A070088	001	Feb 08, 1985
	600MG	A070099	001	Mar 29, 1985
	800MG	A070745	001	Jul 23, 1986
IBU-TAB				
ALRA	800MG	A071965	001	Aug 11, 1988
IBUPRIN				
PLIVA	200MG	A071773	001	Jul 16, 1987
IBUPROFEN				
ABBOTT	600MG	A070556	001	Jun 14, 1985
	800MG	A071264	001	Jul 25, 1986
ANI PHARMS INC	200MG	A071144	001	Jan 20, 1987
	200MG	A072901	001	Dec 19, 1991
	200MG	A072903	001	Dec 19, 1991
AUROLIFE PHARMA LLC	300MG	A070736	002	Jun 12, 1986
	400MG	A070736	003	Jun 12, 1986
	600MG	A070736	001	Jun 12, 1986
	800MG	A071938	001	Jan 14, 1988
CONTRACT PHARMACAL	200MG	A071265	001	Oct 15, 1986
	200MG	A071265	002	Sep 10, 1987
	200MG	A071735	001	Sep 10, 1987

IBUPROFEN

TABLET;ORAL

IBUPROFEN

	200MG	A073691	001	Feb 25, 1994
	200MG	A074931	001	Jul 20, 1998
HALSEY	200MG	A071027	001	Sep 29, 1987
	300MG	A071028	001	Mar 23, 1987
	400MG	A071029	001	Mar 23, 1987
	600MG	A071030	001	Mar 23, 1987
	800MG	A072137	001	Feb 05, 1988
IVAX SUB TEVA PHARMS	200MG	A071154	001	Oct 27, 1987
	200MG	A072040	001	Apr 29, 1988
	400MG	A071145	001	Sep 23, 1986
	600MG	A071146	001	Sep 23, 1986
	800MG	A071769	001	May 08, 1987
J AND J CONSUMER INC	400MG	A070081	001	Jun 16, 1986
LEDERLE	400MG	A070629	001	Sep 19, 1986
	600MG	A070630	001	Sep 19, 1986
LEINER	300MG	A071266	001	Oct 15, 1986
LNK	100MG	A076741	001	Jun 17, 2004
MCNEIL	600MG	A070476	001	Jun 16, 1986
MYLAN	200MG	A071870	001	May 05, 1988
	600MG	A070057	001	Sep 24, 1985
	800MG	A071999	001	Dec 03, 1987
MYLAN PHARMS INC	400MG	A070045	001	Sep 24, 1985
NORTHSTAR HLTHCARE	400MG	A078132	001	Sep 10, 2007
	600MG	A078132	002	Sep 10, 2007
	800MG	A078132	003	Sep 10, 2007
OHM LABS	400MG	A070818	001	Dec 26, 1985
P AND L DEV LLC	200MG	A070733	001	Sep 19, 1986
PAR PHARM	200MG	A071575	001	May 08, 1987
	300MG	A070328	001	Aug 06, 1985
	400MG	A070329	001	Aug 06, 1985
	600MG	A070330	001	Aug 06, 1985
	800MG	A070986	001	Jul 25, 1986
PERRIGO	200MG	A072098	001	Dec 08, 1987
PLIVA	400MG	A071666	001	Jun 18, 1987
	600MG	A071667	001	Jun 18, 1987
	800MG	A071668	001	Jun 18, 1987
PUREPAC PHARM	200MG	A071122	001	Oct 03, 1986
	200MG	A071664	001	Feb 03, 1987
	300MG	A071123	001	Sep 19, 1986
	400MG	A071124	001	Sep 19, 1986
	600MG	A071125	001	Sep 19, 1986
	800MG	A071964	001	Feb 01, 1988
SANDOZ	200MG	A071807	001	Feb 25, 1988
	200MG	A074525	001	Dec 15, 1995
	200MG	A074533	001	Dec 15, 1995
	400MG	A072064	001	Jan 14, 1988
	600MG	A072065	001	Jan 14, 1988
	800MG	A072169	001	Dec 11, 1987
SUN PHARM INDUSTRIES	200MG	A070493	001	Dec 24, 1985
	200MG	A070908	001	Sep 26, 1986
	200MG	A071462	001	Oct 02, 1986
	400MG	A070079	001	Jul 24, 1985
	600MG	A070080	001	Jul 24, 1985
	800MG	A071448	001	Feb 18, 1987
SUPERPHARM	600MG	A070709	001	Apr 25, 1986
TEVA	200MG	A073141	001	May 29, 1992
	400MG	A073343	001	Jun 30, 1992
	600MG	A073344	001	Jun 30, 1992
	800MG	A073345	001	Jun 30, 1992
VINTAGE PHARMS	200MG	A072249	001	Jan 10, 1989
	300MG	A071230	001	Oct 22, 1986
	400MG	A071231	001	Oct 22, 1986
	600MG	A071232	001	Oct 22, 1986
	800MG	A072004	001	Nov 18, 1987
WATSON LABS	200MG	A070435	001	Mar 05, 1986
	200MG	A071765	001	Sep 04, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

IBUPROFEN

TABLET;ORAL

IBUPROFEN

	200MG	A071905	001	Mar 08, 1988
	300MG	A071338	001	Dec 01, 1986
	400MG	A070038	001	Sep 06, 1985
	400MG	A070436	001	Aug 21, 1985
	600MG	A070041	001	Sep 06, 1985
	600MG	A070437	001	Aug 21, 1985
	800MG	A071547	001	Jul 02, 1987
	800MG	A071911	001	Oct 13, 1987

IBUPROHM

OHM LABS	400MG	A070469	001	Aug 29, 1985

MEDIPREN

MCNEIL	200MG	A070475	001	Feb 06, 1986
	200MG	A071215	001	Jun 26, 1986

MIDOL

BAYER	200MG	A070591	001	Sep 02, 1987
	200MG	A071001	001	Sep 02, 1987

MOTRIN

+	MCNEIL CONSUMER	300MG **	N017463	003	
+		400MG **	N017463	002	
+		600MG **	N017463	004	
+		800MG **	N017463	005	May 22, 1985
	MCNEIL PED	100MG	N020418	001	Nov 16, 1994

MOTRIN MIGRAINE PAIN

J AND J CONSUMER INC	200MG	N019012	004	Feb 25, 2000

NUPRIN

BRISTOL MYERS	200MG	A072035	001	Feb 16, 1988
	200MG	A072036	001	Feb 16, 1988
J AND J CONSUMER INC	200MG	N019012	001	May 18, 1984
	200MG	N019012	002	Jul 29, 1987

RUFEN

BASF	600MG	N018197	002	Mar 05, 1984

TABLET, CHEWABLE;ORAL

CHILDREN'S MOTRIN

+	J AND J CONSUMER INC	50MG	N020601	001	Nov 15, 1996

IBUPROFEN

PERRIGO	50MG	A076359	001	Jan 16, 2004

JUNIOR STRENGTH MOTRIN

+	J AND J CONSUMER INC	100MG	N020601	003	Nov 15, 1996

MOTRIN

MCNEIL PED	50MG	N020135	001	Nov 16, 1994
	100MG	N020135	002	Nov 16, 1994

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

COMBUNOX

FOREST LABS	400MG;5MG **	N021378	001	Nov 26, 2004

OXYCODONE HYDROCHLORIDE AND IBUPROFEN

WATSON LABS	400MG;5MG	A078394	001	Nov 26, 2007

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET;ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

CONTRACT PHARMACAL	200MG;30MG	A075588	001	Apr 08, 2002

IBUTILIDE FUMARATE

INJECTABLE;INJECTION

IBUTILIDE FUMARATE

MYLAN INSTITUTIONAL	0.1MG/ML	A090924	001	Jan 11, 2010

IDARUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

IDAMYCIN

PHARMACIA AND UPJOHN	5MG/VIAL	N050661	002	Sep 27, 1990
	10MG/VIAL	N050661	001	Sep 27, 1990
	20MG/VIAL	N050661	003	Apr 25, 1995

IDARUBICIN HYDROCHLORIDE

SANDOZ	1MG/ML	A091293	001	Mar 29, 2011
TEVA PARENTERAL	5MG/VIAL	A065037	003	May 01, 2002

IDARUBICIN HYDROCHLORIDE				
INJECTABLE;INJECTION				
IDARUBICIN HYDROCHLORIDE				
	10MG/VIAL	A065037	002	May 01, 2002
	20MG/VIAL	A065037	001	May 01, 2002
IDOXURIDINE				
OINTMENT;OPHTHALMIC				
STOXIL				
GLAXOSMITHKLINE	0.5%	N015868	001	
SOLUTION/DROPS;OPHTHALMIC				
DENDRID				
+ ALCON	0.1%	N014169	001	
HERPLEX				
ALLERGAN	0.1%	N013935	002	
STOXIL				
GLAXOSMITHKLINE	0.1%	N013934	001	
IFOSFAMIDE				
INJECTABLE;INJECTION				
IFOSFAMIDE				
FRESENIUS KABI USA	1GM/20ML (50MG/ML)	A090181	001	Sep 22, 2009
	3GM/60ML (50MG/ML)	A090181	002	Sep 22, 2009
IFOSFAMIDE; MESNA				
INJECTABLE;INJECTION				
IFEX/MESNEX KIT				
BAXTER HLTHCARE	1GM/VIAL;100MG/ML	N019763	003	Oct 10, 1992
	3GM/VIAL;100MG/ML	N019763	004	Oct 10, 1992
INJECTABLE;INTRAVENOUS				
IFOSFAMIDE/MESNA KIT				
TEVA PHARMS USA	1GM/20ML;1GM/10ML (50MG/ML;100MG/ML)	A075874	001	Feb 26, 2002
	3GM/60ML;1GM/10ML (50MG/ML;100MG/ML)	A075874	002	Feb 26, 2002
ILOPROST				
SOLUTION;INHALATION				
VENTAVIS				
ACTELION PHARMS LTD	20MCG/2ML (10MCG/ML)	N021779	001	Dec 29, 2004
IMATINIB MESYLATE				
CAPSULE;ORAL				
GLEEVEC				
+ NOVARTIS	EQ 50MG BASE **	N021335	001	May 10, 2001
+	EQ 100MG BASE **	N021335	002	May 10, 2001
IMIPRAMINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
IMIPRAMINE HYDROCHLORIDE				
NOVARTIS	25MG/ML	A086765	001	
INJECTABLE;INJECTION				
TOFRANIL				
NOVARTIS	12.5MG/ML	N011838	002	
TABLET;ORAL				
IMIPRAMINE HYDROCHLORIDE				
LEDERLE	10MG	A086269	001	
	25MG	A086267	001	
	50MG	A086268	001	
OXFORD PHARMS	50MG	A040751	001	Feb 28, 2008
PAR PHARM	10MG	A089422	001	Jul 14, 1987
	25MG	A089497	001	Jul 14, 1987
ROXANE	10MG	A083799	001	
	25MG	A083799	002	
	50MG	A083799	003	
SANDOZ	10MG	A085200	001	
	25MG	A084869	002	
	50MG	A085133	001	
TEVA	10MG	A083729	001	
	25MG	A083729	004	
	50MG	A083729	003	
USL PHARMA	25MG	A087776	001	Feb 10, 1982
VANGARD	10MG	A088036	001	Nov 03, 1982
	25MG	A087619	001	Feb 09, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL				
IMIPRAMINE HYDROCHLORIDE				
	50MG	A087631	001	Jan 04, 1982
WATSON LABS	10MG	A085220	001	
	10MG	A085875	001	
	25MG	A084252	002	
	25MG	A085878	001	
	50MG	A085221	001	
	50MG	A085877	001	
WEST WARD	25MG	A088222	001	May 26, 1983
	50MG	A088223	001	May 26, 1983
JANIMINE				
ABBOTT	10MG	N017895	001	
	25MG	N017895	002	
	50MG	N017895	003	
PRAMINE				
ALRA	10MG	A083827	001	
	25MG	A083827	002	
	50MG	A083827	003	
PRESAMINE				
SANOFI AVENTIS US	10MG	N011836	006	
	25MG	N011836	003	
	50MG	N011836	007	

IMIPRAMINE PAMOATE

CAPSULE;ORAL				
IMIPRAMINE PAMOATE				
MYLAN PHARMS INC	EQ 75MG HYDROCHLORIDE	A202338	001	Jun 28, 2013
	EQ 100MG HYDROCHLORIDE	A202338	002	Jun 28, 2013
	EQ 125MG HYDROCHLORIDE	A202338	003	Jun 28, 2013
	EQ 150MG HYDROCHLORIDE	A202338	004	Jun 28, 2013
TOFRANIL-PM				
+ SPECGX LLC	EQ 75MG HYDROCHLORIDE **	N017090	001	
+	EQ 100MG HYDROCHLORIDE **	N017090	004	
+	EQ 125MG HYDROCHLORIDE **	N017090	003	
+	EQ 150MG HYDROCHLORIDE **	N017090	002	

IMIQUIMOD

CREAM;TOPICAL				
IMIQUIMOD				
G AND W LABS INC	5%	A200481	001	Apr 18, 2011
STRIDES PHARMA	5%	A202002	001	Jun 24, 2014

INAMRINONE LACTATE

INJECTABLE;INJECTION				
AMRINONE LACTATE				
BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	A075542	001	May 10, 2000
HOSPIRA	EQ 5MG BASE/ML	A074616	001	Aug 03, 1998
INOCOR				
SANOFI AVENTIS US	EQ 5MG BASE/ML	N018700	001	Jul 31, 1984

INDAPAMIDE

TABLET;ORAL				
INDAPAMIDE				
ANI PHARMS INC	1.25MG	A074498	002	Feb 12, 1998
	2.5MG	A074498	001	Oct 31, 1996
MYLAN PHARMS INC	1.25MG	A075105	001	Jul 23, 1998
	2.5MG	A075105	002	Jul 23, 1998
TEVA	1.25MG	A074665	001	Apr 04, 1997
	2.5MG	A074665	002	Apr 04, 1997
WATSON LABS	1.25MG	A074585	001	Sep 26, 1996
	2.5MG	A074585	002	Sep 26, 1996
YAOPHARMA CO LTD	1.25MG	A074594	001	May 23, 1996
	2.5MG	A074594	002	May 23, 1996
LOZOL				
+ SANOFI AVENTIS US	1.25MG **	N018538	002	Apr 29, 1993
+	2.5MG **	N018538	001	Jul 06, 1983

INDECAINIDE HYDROCHLORIDE				
TABLET, EXTENDED RELEASE;ORAL				
DECABID				
LILLY	EQ 50MG BASE	N019693	001	Dec 29, 1989
	EQ 75MG BASE	N019693	002	Dec 29, 1989
	EQ 100MG BASE	N019693	003	Dec 29, 1989
INDINAVIR SULFATE				
CAPSULE;ORAL				
CRIXIVAN				
MERCK SHARP DOHME	EQ 100MG BASE	N020685	006	Apr 19, 2000
	EQ 333MG BASE	N020685	005	Dec 17, 1998
INDIUM IN-111 OXYQUINOLINE				
INJECTABLE;INJECTION				
INDIUM IN 111 OXYQUINOLINE				
BWXT ITG	1mCi/ML	A202586	001	Jul 25, 2018
INDOCYANINE GREEN				
INJECTABLE;INJECTION				
IC-GREEN				
AKORN	10MG/VIAL **	N011525	003	
	40MG/VIAL **	N011525	004	
	50MG/VIAL **	N011525	002	
INDOMETHACIN				
CAPSULE;ORAL				
INDO-LEMMON				
TEVA	25MG	A070266	001	Nov 07, 1985
	50MG	A070267	001	Nov 07, 1985
INDOCIN				
+ IROKO PHARMS LLC	25MG **	N016059	001	
+	50MG **	N016059	002	
INDOMETHACIN				
ABLE	25MG	A076666	001	Dec 17, 2003
	50MG	A076666	002	Dec 17, 2003
CHARTWELL MOLECULES	25MG	N018829	002	Aug 06, 1984
	50MG	A070651	001	Mar 05, 1986
	50MG	N018829	001	Aug 06, 1984
CYCLE PHARMS LTD	25MG	A070353	001	Jun 18, 1985
	50MG	A070354	001	Jun 18, 1985
DURAMED PHARMS BARR	25MG	A070326	001	Oct 18, 1985
	50MG	A070327	001	Oct 18, 1985
HALSEY	25MG	A070782	001	Jun 03, 1987
	50MG	A070635	001	Jun 03, 1987
IVAX SUB TEVA PHARMS	25MG	N018730	001	May 04, 1984
	50MG	N018730	002	May 04, 1984
MUTUAL PHARM	25MG	A070067	001	Oct 03, 1986
	50MG	A070068	001	Oct 03, 1986
MYLAN	50MG	N018858	002	Apr 20, 1984
PARKE DAVIS	25MG	N018806	001	Nov 23, 1984
	50MG	N018806	002	Nov 23, 1984
PIONEER PHARMS	25MG	A070813	001	Aug 11, 1986
	50MG	A070592	001	Aug 11, 1986
PLIVA	25MG	A071148	001	Mar 18, 1987
	50MG	A071149	001	Mar 18, 1987
SUN PHARM INDUSTRIES	25MG	A070900	002	Feb 09, 1987
	50MG	A070900	001	Feb 09, 1987
SUPERPHARM	25MG	A070487	001	Oct 10, 1986
	50MG	A070488	001	Oct 10, 1986
TEVA	25MG	A071342	001	Apr 18, 1988
	50MG	A071343	001	Apr 18, 1988
WATSON LABS	25MG	A070529	001	Oct 18, 1985
	25MG	A070784	001	Aug 20, 1986
	25MG	A072996	001	Jul 31, 1991
	25MG	N018690	001	Jul 31, 1984
	50MG	A070530	001	Oct 18, 1985
	50MG	A070785	001	Aug 20, 1986
	50MG	A071635	001	May 18, 1987
	50MG	A072997	001	Jul 31, 1991
	50MG	N018690	002	Jul 31, 1984

INDOMETHACIN

CAPSULE, EXTENDED RELEASE;ORAL				
INDOCIN SR				
+ IROKO PHARMS	75MG **	N018185	001	Feb 23, 1982
INDOMETHACIN				
ABLE	75MG	A076114	001	Feb 06, 2002
INWOOD LABS	75MG	A072410	001	Mar 15, 1989
WATSON LABS INC	75MG	A202572	001	Dec 09, 2013
SUPPOSITORY;RECTAL				
INDOCIN				
+ IROKO PHARMS	50MG **	N017814	001	Aug 13, 1984
SUSPENSION;ORAL				
INDOMETHACIN				
CYCLE PHARMS LTD	25MG/5ML	A071412	001	Mar 18, 1987

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT

INJECTABLE;SUBCUTANEOUS				
NOVOLOG MIX 50/50				
NOVO NORDISK INC	50 UNITS/ML;50 UNITS/ML	N021810	001	Aug 26, 2008
NOVOLOG MIX 70/30 PENFILL				
NOVO NORDISK INC	210 UNITS/3ML;90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)	N021172	002	Nov 01, 2001
	210 UNITS/3ML;90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)	N021172	003	Nov 01, 2001

INSULIN ASPART RECOMBINANT

INJECTABLE;SUBCUTANEOUS				
NOVOLOG FLEXTOUCH				
+ NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	005	Oct 31, 2013
NOVOLOG INNOLET				
NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	004	Apr 23, 2004

INSULIN DETEMIR RECOMBINANT

INJECTABLE;SUBCUTANEOUS				
LEVEMIR FLEXPEN				
NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	002	Jun 16, 2005
LEVEMIR INNOLET				
NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	003	Jun 16, 2005
LEVEMIR PENFILL				
NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	004	Jun 16, 2005

INSULIN GLULISINE RECOMBINANT

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS				
APIDRA				
+ SANOFI AVENTIS US	300 UNITS/3ML (100 UNITS/ML)	N021629	002	Dec 20, 2005

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE;INJECTION				
HUMALOG MIX 50/50 PEN				
LILLY	50 UNITS/ML;50 UNITS/ML	N021018	003	Dec 22, 1999
HUMALOG MIX 75/25 PEN				
LILLY	75 UNITS/ML;25 UNITS/ML	N021017	003	Dec 22, 1999

INSULIN LISPRO RECOMBINANT

INJECTABLE;INJECTION				
HUMALOG PEN				
LILLY	100 UNITS/ML	N020563	002	Aug 06, 1998

INSULIN PORK

INJECTABLE;INJECTION				
ILETIN I				
LILLY	500 UNITS/ML	N017931	001	
INSULIN				
NOVO NORDISK INC	40 UNITS/ML	N017926	001	
REGULAR INSULIN				
NOVO NORDISK INC	100 UNITS/ML	N017926	003	

INSULIN PURIFIED BEEF

INJECTABLE;INJECTION				
REGULAR ILETIN II				
LILLY	100 UNITS/ML	N018478	001	

INSULIN PURIFIED PORK

INJECTABLE;INJECTION				
ILETIN II				
	LILLY	500 UNITS/ML	N018344 002	
REGULAR ILETIN II (PORK)				
	LILLY	100 UNITS/ML	N018344 001	
REGULAR PURIFIED PORK INSULIN				
	NOVO NORDISK INC	100 UNITS/ML	N018381 001	
VELOSULIN				
	NOVO NORDISK INC	100 UNITS/ML	N018193 001	

INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE;INJECTION				
INSULIN NORDISK MIXTARD (PORK)				
	NOVO NORDISK INC	30 UNITS/ML;70 UNITS/ML	N018195 001	

INSULIN RECOMBINANT HUMAN

INJECTABLE;INJECTION				
HUMULIN BR				
	LILLY	100 UNITS/ML	N019529 001	Apr 28, 1986
VELOSULIN BR				
	NOVO NORDISK INC	100 UNITS/ML	N021028 001	Jul 19, 1999
POWDER;INHALATION				
EXUBERA				
	PFIZER	1MG/INH	N021868 001	Jan 27, 2006
		3MG/INH	N021868 002	Jan 27, 2006

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE;INJECTION				
HUMULIN 50/50				
	LILLY	50 UNITS/ML;50 UNITS/ML	N020100 001	Apr 29, 1992

INSULIN RECOMBINANT PURIFIED HUMAN

INJECTABLE;INJECTION				
NOVOLIN R				
	NOVO NORDISK INC	100 UNITS/ML	N018778 001	Aug 30, 1983
VELOSULIN BR HUMAN				
	NOVO NORDISK INC	100 UNITS/ML	N019450 001	May 30, 1986

INSULIN RECOMBINANT PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE;INJECTION				
MIXTARD HUMAN 70/30				
	BAYER PHARMS	30 UNITS/ML;70 UNITS/ML	N019585 001	Mar 11, 1988
NOVOLIN 70/30				
	NOVO NORDISK INC	30 UNITS/ML;70 UNITS/ML	N019441 001	Jul 11, 1986

INSULIN SUSP ISOPHANE BEEF

INJECTABLE;INJECTION			
NPH INSULIN			
	NOVO NORDISK INC	40 UNITS/ML	N017929 001
		100 UNITS/ML	N017929 003

INSULIN SUSP ISOPHANE BEEF/PORK

INJECTABLE;INJECTION			
NPH ILETIN I (BEEF-PORK)			
	LILLY	40 UNITS/ML	N017936 001
		100 UNITS/ML	N017936 002

INSULIN SUSP ISOPHANE PURIFIED BEEF

INJECTABLE;INJECTION			
NPH ILETIN II			
	LILLY	100 UNITS/ML	N018479 001

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE;INJECTION			
INSULIN INSULATARD NPH NORDISK			
	NOVO NORDISK INC	100 UNITS/ML	N018194 001
NPH ILETIN II (PORK)			
	LILLY	100 UNITS/ML	N018345 001
NPH PURIFIED PORK ISOPHANE INSULIN			
	NOVO NORDISK INC	100 UNITS/ML	N018623 001

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE;INJECTION				
INSULATARD NPH HUMAN				
	NOVO NORDISK INC	100 UNITS/ML	N019449 001	May 30, 1986
NOVOLIN N				
	NOVO NORDISK INC	100 UNITS/ML	N019065 001	Jan 23, 1985

INSULIN SUSP PROTAMINE ZINC BEEF/PORK

INJECTABLE;INJECTION				
PROTAMINE ZINC & ILETIN I (BEEF-PORK)				
	LILLY	40 UNITS/ML	N017932 001	
		100 UNITS/ML	N017932 002	

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF

INJECTABLE;INJECTION				
PROTAMINE ZINC AND ILETIN II				
	LILLY	100 UNITS/ML	N018476 001	
PROTAMINE ZINC INSULIN				
	BRISTOL MYERS SQUIBB	40 UNITS/ML	N017928 001	
		100 UNITS/ML	N017928 003	

INSULIN SUSP PROTAMINE ZINC PURIFIED PORK

INJECTABLE;INJECTION				
PROTAMINE ZINC AND ILETIN II (PORK)				
	LILLY	100 UNITS/ML	N018346 001	

INSULIN ZINC SUSP BEEF

INJECTABLE;INJECTION				
LENTE INSULIN				
	NOVO NORDISK INC	40 UNITS/ML	N017998 001	
		100 UNITS/ML	N017998 003	

INSULIN ZINC SUSP EXTENDED BEEF

INJECTABLE;INJECTION				
ULTRALENTE INSULIN				
	NOVO NORDISK INC	100 UNITS/ML	N017997 003	

INSULIN ZINC SUSP EXTENDED PURIFIED BEEF

INJECTABLE;INJECTION				
ULTRALENTE				
	NOVO NORDISK INC	100 UNITS/ML	N018385 001	

INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN

INJECTABLE;INJECTION				
HUMULIN U				
	LILLY	40 UNITS/ML	N019571 001	Jun 10, 1987
		100 UNITS/ML	N019571 002	Jun 10, 1987

INSULIN ZINC SUSP PROMPT BEEF

INJECTABLE;INJECTION				
SEMILENTE INSULIN				
	NOVO NORDISK INC	100 UNITS/ML	N017996 003	

INSULIN ZINC SUSP PROMPT PURIFIED PORK

INJECTABLE;INJECTION				
SEMILENTE				
	NOVO NORDISK INC	100 UNITS/ML	N018382 001	

INSULIN ZINC SUSP PURIFIED BEEF

INJECTABLE;INJECTION				
LENTE ILETIN II				
	LILLY	100 UNITS/ML	N018477 001	

INSULIN ZINC SUSP PURIFIED BEEF/PORK

INJECTABLE;INJECTION				
LENTARD				
	NOVO NORDISK INC	100 UNITS/ML	N018384 001	

INSULIN ZINC SUSP PURIFIED PORK

INJECTABLE;INJECTION				
LENTE				
	NOVO NORDISK INC	100 UNITS/ML	N018383 001	
LENTE ILETIN II (PORK)				
	LILLY	100 UNITS/ML	N018347 001	

INSULIN ZINC SUSP RECOMBINANT HUMAN				
INJECTABLE;INJECTION				
HUMULIN L				
	LILLY	100 UNITS/ML	N019377 002	Sep 30, 1985
NOVOLIN L				
	NOVO NORDISK INC	100 UNITS/ML	N019965 001	Jun 25, 1991
INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN				
INJECTABLE;INJECTION				
NOVOLIN L				
	NOVO NORDISK INC	100 UNITS/ML	N018777 001	Aug 30, 1983
INULIN				
INJECTABLE;INJECTION				
INULIN AND SODIUM CHLORIDE				
	ISO TEX	100MG/ML	N002282 001	
INVERT SUGAR				
INJECTABLE;INJECTION				
TRAVERT 10% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	10GM/100ML	N016717 001	
IOBENGUANE SULFATE I-131				
INJECTABLE;INJECTION				
IOBENGUANE SULFATE I 131				
	PHARMALUCENCE	2.3mCi/ML	N020084 001	Mar 25, 1994
IOCETAMIC ACID				
TABLET;ORAL				
CHOLEBRINE				
	MALLINCKRODT	750MG	N017129 001	
IODAMIDE MEGLUMINE				
INJECTABLE;INJECTION				
RENOVUE-65				
	BRACCO	65%	N017902 001	
RENOVUE-DIP				
	BRACCO	24%	N017903 001	
IODIPAMIDE MEGLUMINE				
INJECTABLE;INJECTION				
CHOLOGRAFIN MEGLUMINE				
	BRACCO	10.3%	N009321 007	
+		52%	N009321 003	
IODIPAMIDE SODIUM				
INJECTABLE;INJECTION				
CHOLOGRAFIN SODIUM				
	BRACCO	20%	N009321 001	
IODIXANOL				
INJECTABLE;INJECTION				
VISIPAQUE 270				
	GE HEALTHCARE	55%	N020808 001	Aug 29, 1997
IODOHIPPURATE SODIUM I-123				
INJECTABLE;INJECTION				
NEPHROFLOW				
	GE HEALTHCARE	1mCi/ML	N018289 001	Dec 28, 1984
IODOHIPPURATE SODIUM I-131				
INJECTABLE;INJECTION				
HIPPURAN I 131				
	MALLINCKRODT	0.25mCi/ML	N016666 001	
HIPPUTOPE				
	BRACCO	1-2mCi/VIAL	N015419 002	
IODOHIPPURATE SODIUM I 131				
	PHARMALUCENCE	0.2mCi/ML	N017313 001	

IODOXAMATE MEGLUMINE				
INJECTABLE;INJECTION				
CHOLOVUE				
BRACCO	9.9%	N018077 001		
	40.3%	N018076 001		
IOFETAMINE HYDROCHLORIDE I-123				
INJECTABLE;INJECTION				
SPECTAMINE				
IMP	1mCi/ML	N019432 001	Dec 24, 1987	
IOHEXOL				
INJECTABLE;INJECTION				
OMNIPAQUE 210				
GE HEALTHCARE	45.3%	N018956 006	Jun 30, 1989	
SOLUTION;INJECTION, ORAL, RECTAL				
OMNIPAQUE 240				
GE HEALTHCARE	51.8%	N020608 001	Oct 24, 1995	
SOLUTION;URETHRAL				
OMNIPAQUE 70				
GE HEALTHCARE	15.1%	N018956 007	Jun 01, 1994	
IOPAMIDOL				
INJECTABLE;INJECTION				
IOPAMIDOL				
BAXTER HLTHCARE	41%	A074629 001	Nov 06, 1996	
	51%	A074629 004	Mar 31, 1998	
	61%	A074629 002	Nov 06, 1996	
	76%	A074629 003	Nov 06, 1996	
HOSPIRA	61%	A074734 001	Dec 10, 1996	
	76%	A074734 002	Dec 10, 1996	
IOPAMIDOL-200				
COOK IMAGING	41%	A074881 001	Jul 28, 2000	
HOSPIRA	41%	A074898 001	Dec 30, 1997	
IOPAMIDOL-200 IN PLASTIC CONTAINER				
HOSPIRA	41%	A074636 001	Dec 30, 1997	
IOPAMIDOL-250				
COOK IMAGING	51%	A074881 002	Jul 28, 2000	
FRESENIUS KABI USA	51%	A074679 001	Apr 02, 1997	
HOSPIRA	51%	A074898 002	Dec 30, 1997	
	51%	A075005 001	Feb 24, 1998	
IOPAMIDOL-250 IN PLASTIC CONTAINER				
HOSPIRA	51%	A074636 002	Dec 30, 1997	
IOPAMIDOL-300				
ABBVIE	61%	A074638 001	Apr 30, 1997	
COOK IMAGING	61%	A074881 003	Jul 28, 2000	
FRESENIUS KABI USA	61%	A074679 002	Apr 02, 1997	
HOSPIRA	61%	A074898 003	Dec 30, 1997	
	61%	A075005 002	Feb 24, 1998	
IOPAMIDOL-300 IN PLASTIC CONTAINER				
HOSPIRA	61%	A074636 003	Dec 30, 1997	
	61%	A074637 001	Apr 03, 1997	
IOPAMIDOL-370				
COOK IMAGING	76%	A074881 004	Jul 28, 2000	
FRESENIUS KABI USA	76%	A074679 003	Apr 02, 1997	
HOSPIRA	76%	A074898 004	Dec 30, 1997	
	76%	A075005 003	Feb 24, 1998	
IOPAMIDOL-370 IN PLASTIC CONTAINER				
HOSPIRA	76%	A074636 004	Dec 30, 1997	
ISOVUE-128				
BRACCO	26%	N018735 005	Oct 21, 1986	
ISOVUE-200				
BRACCO	41%	N020327 001	Oct 12, 1994	
IOPANOIC ACID				
TABLET;ORAL				
TELEPAQUE				
GE HEALTHCARE	500MG	N008032 001		

IOPHENDYLATE
INJECTABLE;INJECTION
PANTOPAQUE
ALCON 100% N005319 001

IOPROMIDE
INJECTABLE;INJECTION
ULTRAVIST 150
\+ BAYER HLTHCARE 31.2% N020220 004 May 10, 1995
ULTRAVIST 300 IN PLASTIC CONTAINER
\+ BAYER HLTHCARE 62.3% N020220 005 Nov 18, 2008

IOTHALAMATE MEGLUMINE
INJECTABLE;INJECTION
CONRAY 30
\+ LIEBEL-FLARSHEIM 30% N016983 001

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM
INJECTABLE;INJECTION
VASCORAY
MALLINCKRODT 52%;26% N016783 001

IOTHALAMATE SODIUM
INJECTABLE;INJECTION
ANGIO-CONRAY
MALLINCKRODT 80% N013319 001
CONRAY 325
MALLINCKRODT 54.3% N017685 001
CONRAY 400
MALLINCKRODT 66.8% N014295 001

IOTROLAN
INJECTABLE;INTRATHECAL
OSMOVIST 190
BAYER HLTHCARE 40.6% N019580 001 Dec 07, 1989
OSMOVIST 240
BAYER HLTHCARE 51.3% N019580 002 Dec 07, 1989

IOVERSOL
INJECTABLE;INJECTION
OPTIRAY 160
LIEBEL-FLARSHEIM 34% N019710 003 Dec 30, 1988
OPTIRAY 240
LIEBEL-FLARSHEIM 51% N020923 001 May 28, 1998

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM
INJECTABLE;INJECTION
HEXABRIX
GUERBET 39.3%;19.6% N018905 002 Jul 26, 1985

IOXILAN
INJECTABLE;INJECTION
OXILAN-300
GUERBET 62% N020316 001 Dec 21, 1995
OXILAN-350
GUERBET 73% N020316 002 Dec 21, 1995

IPODATE CALCIUM
GRANULE;ORAL
ORAGRAFIN CALCIUM
BRACCO 3GM/PACKET N012968 001

IPODATE SODIUM
CAPSULE;ORAL
BILIVIST
BAYER HLTHCARE 500MG A087768 001 Aug 11, 1982
ORAGRAFIN SODIUM
BRACCO 500MG N012967 001

IPRATROPIUM BROMIDE				
AEROSOL, METERED;INHALATION				
ATROVENT				
BOEHRINGER INGELHEIM	0.018MG/INH	N019085	001	Dec 29, 1986
SOLUTION;INHALATION				
ATROVENT				
+ BOEHRINGER INGELHEIM	0.02% **	N020228	001	Sep 29, 1993
IPRATROPIUM BROMIDE				
ACTAVIS MID ATLANTIC	0.02%	A075111	001	Apr 22, 1999
APOTEX INC	0.02%	A075441	001	Mar 28, 2001
BAUSCH AND LOMB INC	0.02%	A075835	001	Oct 15, 2001
MYLAN SPECIALITY LP	0.02%	A074755	001	Jan 10, 1997
PHARMASCIENCE INC	0.02%	A075507	001	Jan 19, 2001
ROXANE	0.02%	A075867	001	Jul 22, 2002
TEVA PHARMS USA	0.02%	A075313	001	Feb 07, 2000
SPRAY, METERED;NASAL				
ATROVENT				
+ BOEHRINGER INGELHEIM	0.021MG/SPRAY	N020393	001	Oct 20, 1995
+	0.042MG/SPRAY	N020394	001	Oct 20, 1995
IPRATROPIUM BROMIDE				
APOTEX INC	0.021MG/SPRAY	A076156	001	Apr 18, 2003
IRBESARTAN				
TABLET;ORAL				
IRBESARTAN				
AJANTA PHARMA LTD	75MG	A203685	001	Dec 10, 2015
	150MG	A203685	002	Dec 10, 2015
	300MG	A203685	003	Dec 10, 2015
APOTEX INC	75MG	A200832	001	Oct 15, 2012
	150MG	A200832	002	Oct 15, 2012
	300MG	A200832	003	Oct 15, 2012
MYLAN PHARMS INC	75MG	A200461	001	Sep 27, 2012
	150MG	A200461	002	Sep 27, 2012
	300MG	A200461	003	Sep 27, 2012
WATSON LABS INC	75MG	A090720	001	Oct 12, 2012
	150MG	A090720	002	Oct 12, 2012
	300MG	A090720	003	Oct 12, 2012
IRINOTECAN HYDROCHLORIDE				
INJECTABLE;INJECTION				
IRINOTECAN HYDROCHLORIDE				
SANDOZ	40MG/2ML (20MG/ML)	A077994	001	Feb 27, 2008
	100MG/5ML (20MG/ML)	A077994	002	Feb 27, 2008
SANDOZ INC	40MG/2ML (20MG/ML)	A090137	001	Nov 12, 2009
	100MG/5ML (20MG/ML)	A090137	002	Nov 12, 2009
SUN PHARMA GLOBAL	40MG/2ML (20MG/ML)	A078805	001	Apr 21, 2008
	100MG/5ML (20MG/ML)	A078805	002	Apr 21, 2008
IRON DEXTRAN				
INJECTABLE;INJECTION				
IRON DEXTRAN				
SANOFI AVENTIS US	EQ 50MG IRON/ML	N010787	002	
IRON SUCROSE				
INJECTABLE;INTRAVENOUS				
VENOFER				
LUITPOLD	EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)	N021135	005	Mar 29, 2013
	EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML)	N021135	003	Mar 29, 2005
ISOETHARINE HYDROCHLORIDE				
SOLUTION;INHALATION				
BETA-2				
NEPHRON	1%	A086711	001	
BRONKOSOL				
SANOFI AVENTIS US	0.25%	N012339	009	
	1%	N012339	008	
ISOETHARINE HYDROCHLORIDE				
ALPHARMA US PHARMS	1%	A087101	001	
ASTRAZENECA	0.062%	A087937	001	Nov 15, 1982
	0.062%	A089614	001	Jun 13, 1991
	0.125%	A087938	001	Nov 15, 1982
	0.125%	A089615	001	Jun 13, 1991

ISOETHARINE HYDROCHLORIDE				
SOLUTION;INHALATION				
ISOETHARINE HYDROCHLORIDE				
	0.167%	A088470	001	Mar 14, 1984
	0.167%	A089616	001	Jun 13, 1991
	0.2%	A088471	001	Mar 14, 1984
	0.2%	A089617	001	Jun 13, 1991
	0.25%	A088472	001	Mar 14, 1984
	0.25%	A089618	001	Jun 13, 1991
BAXTER HLTHCARE	0.08%	A088144	001	Jul 29, 1983
	0.14%	A088145	001	Mar 26, 1984
	0.25%	A088146	001	Aug 01, 1983
DEY	0.08%	A088187	001	Dec 03, 1982
	0.1%	A087389	001	
	0.17%	A087390	001	
	0.25%	A088188	001	Dec 03, 1982
	1%	A086763	001	
INTL MEDICATION	0.077%	A086651	001	
	0.08%	A086651	002	
	0.1%	A086651	003	
	0.143%	A086651	004	
	0.167%	A086651	005	
	0.2%	A086651	006	
	0.25%	A086651	007	
	1%	A086651	008	
PARKE DAVIS	0.5%	A085997	001	
	1%	A085889	001	
ROXANE	0.1%	A087396	001	
	0.125%	A087025	001	
	0.167%	A088226	001	Sep 16, 1983
	0.2%	A087324	001	
	0.25%	A088275	001	Jun 03, 1983
	1%	A086899	001	
ISOETHARINE HYDROCHLORIDE S/F				
DEY	0.08%	A089817	001	Nov 22, 1988
	0.1%	A089818	001	Nov 22, 1988
	0.17%	A089819	001	Nov 22, 1988
	0.25%	A089820	001	Nov 22, 1988
	1%	A089252	001	Sep 15, 1986
ISOETHARINE MESYLATE				
AEROSOL, METERED;INHALATION				
BRONKOMETER				
SANOFI AVENTIS US	0.34MG/INH	N012339	007	
ISOETHARINE MESYLATE				
ALPHARMA US PHARMS	0.34MG/INH	A087858	001	Aug 21, 1984
ISOFLURANE				
LIQUID;INHALATION				
ISOFLURANE				
HOSPIRA	99.9%	A074097	001	Jan 25, 1993
WATSON LABS INC	99.9%	A074393	001	May 12, 1995
ISOFLUROPHATE				
OINTMENT;OPHTHALMIC				
FLOROPRYL				
MERCK	0.025%	N010656	001	
ISONIAZID				
INJECTABLE;INJECTION				
NYDRAZID				
SANDOZ	100MG/ML **	N008662	001	
RIMIFON				
ROCHE	25MG/ML	N008420	002	
	100MG/ML	N008420	003	
SYRUP;ORAL				
ISONIAZID				
MIKART	50MG/5ML	A081118	001	Jul 21, 1997
LANIAZID				
LANNETT	50MG/5ML	A089243	001	Feb 03, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

ISONIAZID				
SYRUP;ORAL				
RIMIFON				
ROCHE	50MG/5ML	N008420	001	
TABLET;ORAL				
DOW-ISONIAZID				
DOW PHARM	300MG	A080330	002	
HYZYD				
MEDPOINTE PHARM HLC	100MG	A080134	003	
	300MG	A080134	004	
INH				
NOVARTIS	300MG	A080935	001	
ISONIAZID				
DURAMED PHARMS BARR	100MG	A088231	001	Mar 17, 1983
	300MG	A088119	001	Mar 17, 1983
HALSEY	50MG	A083632	001	
HIKMA INTL PHARMS	100MG	A080212	001	
	300MG	A087425	001	
IMPAX LABS	100MG	A080153	001	
IVAX SUB TEVA PHARMS	100MG	A080270	001	
	300MG	A083610	001	
LILLY	100MG	N008499	002	
	300MG	N008499	003	
MK LABS	100MG	A080941	001	
NEXGEN PHARMA INC	100MG	A084050	001	
PANRAY	50MG	N008428	001	
	100MG	N008428	002	
	300MG	N008428	003	
PERRIGO	100MG	A083060	001	
PHARMAVITE	100MG	A085091	001	
PHOENIX LABS NY	50MG	A080368	001	
	100MG	A080368	002	
PUREPAC PHARM	50MG	A080132	003	Jul 14, 1982
	100MG	A080132	004	Jul 14, 1982
SUN PHARM INDUSTRIES	100MG	A080136	001	
	300MG	A083633	001	
WATSON LABS	50MG	A080522	001	
	100MG	A080401	001	
	100MG	A080523	001	
	100MG	A085790	001	
	300MG	A080521	001	
	300MG	A083178	001	
	300MG	A085784	001	
WHITEWORTH TOWN PLSN	100MG	A080120	002	
LANIAZID				
LANNETT	50MG	A080140	001	
	100MG	A080140	002	
NYDRAZID				
BRISTOL MYERS SQUIBB	100MG	N008392	003	
STANOZIDE				
EVERYLIFE	100MG	A080126	001	
	300MG	A080126	002	
ISONIAZID; RIFAMPIN				
CAPSULE;ORAL				
RIFAMPIN AND ISONIAZID				
HIKMA INTL PHARMS	150MG;300MG	A065221	001	Jul 29, 2005
ISOPROPAMIDE IODIDE				
TABLET;ORAL				
DARBID				
GLAXOSMITHKLINE	EQ 5MG BASE	N010744	001	
ISOPROTERENOL HYDROCHLORIDE				
AEROSOL, METERED;INHALATION				
ISOPROTERENOL HYDROCHLORIDE				
3M	0.12MG/INH	N010375	004	
ALPHARMA US PHARMS	0.12MG/INH	A085904	001	
ISUPREL				
SANOFI AVENTIS US	0.103MG/INH	N011178	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

ISOPROTERENOL HYDROCHLORIDE				
DISC;INHALATION				
NORISODRINE AEROTROL				
ABBOTT	0.25%	N016814	001	
INJECTABLE;INJECTION				
ISOPROTERENOL HYDROCHLORIDE				
ABRAXIS PHARM	0.2MG/ML	A083431	001	
BAXTER HLTHCARE	0.2MG/ML	A083486	001	
HOSPIRA	0.02MG/ML	A083283	001	
	0.2MG/ML	A083346	001	
INTL MEDICATION	0.2MG/ML	A083724	001	
SOLUTION;INHALATION				
AEROLONE				
LILLY	0.25%	N007245	001	
ISOPROTERENOL HYDROCHLORIDE				
ARMOUR PHARM	0.031%	A087935	001	Nov 18, 1982
	0.062%	A087936	001	Nov 18, 1982
DEY	0.5%	A086764	001	Jan 04, 1982
PARKE DAVIS	0.25%	A085994	001	
	0.5%	A085540	001	
ISUPREL				
SANOFI AVENTIS US	0.5%	N006327	002	
	1%	N006327	003	
VAPO-ISO				
FISONS	0.5%	N016813	001	
TABLET;RECTAL, SUBLINGUAL				
ISUPREL				
SANOFI AVENTIS US	10MG	N006328	001	
	15MG	N006328	002	
ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE				
AEROSOL, METERED;INHALATION				
DUO-MEDIHALER				
3M	0.16MG/INH;0.24MG/INH	N013296	001	
ISOPROTERENOL SULFATE				
AEROSOL, METERED;INHALATION				
MEDIHALER-ISO				
3M	0.08MG/INH	N010375	003	
POWDER;INHALATION				
NORISODRINE				
ABBVIE	10%	N006905	003	
	25%	N006905	002	
ISOSORBIDE				
SOLUTION;ORAL				
ISMOTIC				
ALCON	100GM/220ML	N017063	001	
ISOSORBIDE DINITRATE				
CAPSULE, EXTENDED RELEASE;ORAL				
ISORDIL				
WYETH AYERST	40MG	N012882	002	Jul 29, 1988
TABLET;ORAL				
ISORDIL				
+ VALEANT PHARMS NORTH	10MG **	N012093	002	Jul 29, 1988
+	20MG **	N012093	006	Jul 29, 1988
+	30MG **	N012093	005	Jul 29, 1988
ISOSORBIDE DINITRATE				
SUN PHARM INDUSTRIES	5MG	A086166	002	Sep 19, 1986
	10MG	A086169	001	Sep 19, 1986
	20MG	A086167	001	Sep 19, 1986
	30MG	A087564	001	Sep 18, 1986
SUPERPHARM	5MG	A089190	001	Feb 17, 1987
	10MG	A089191	001	Feb 17, 1987
	20MG	A089192	001	Feb 17, 1987
WATSON LABS	5MG	A086034	001	Jan 06, 1988
	10MG	A086032	001	Jan 07, 1988
SORBITRATE				
ASTRAZENECA	5MG	N016192	001	Apr 01, 1996
	10MG	N016192	002	Apr 01, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

ISOSORBIDE DINITRATE

TABLET;ORAL					
SORBITRATE					
		20MG	A086405	002	Aug 21, 1990
		30MG	A088124	001	Aug 21, 1990
		40MG	A088125	001	Aug 21, 1990
TABLET;SUBLINGUAL					
ISORDIL					
+	BIOVAIL	2.5MG **	N012940	004	Jul 29, 1988
+		5MG **	N012940	003	Jul 29, 1988
+		10MG **	N012940	005	Jul 29, 1988
ISOSORBIDE DINITRATE					
	HIKMA INTL PHARMS	2.5MG	A086054	001	Oct 29, 1987
		5MG	A086055	001	Nov 02, 1987
	SANDOZ	2.5MG	A086225	001	Feb 19, 1988
		5MG	A086222	001	Feb 19, 1988
	SUN PHARM INDUSTRIES	2.5MG	A084204	001	Sep 18, 1986
		5MG	A086168	001	Sep 18, 1986
		10MG	A087545	001	Sep 18, 1986
	WATSON LABS	2.5MG **	A086033	001	Feb 26, 1988
	WATSON LABS TEVA	5MG **	A086031	001	Sep 29, 1987
SORBITRATE					
	ASTRAZENECA	2.5MG	N016191	002	Apr 01, 1996
		5MG	N016191	001	Apr 01, 1996
TABLET, CHEWABLE;ORAL					
SORBITRATE					
	ASTRAZENECA	5MG	N016776	002	Apr 01, 1996
		10MG	N016776	003	Apr 01, 1996
TABLET, EXTENDED RELEASE;ORAL					
ISORDIL					
	WYETH AYERST	40MG	N012882	001	Jul 29, 1988
ISOSORBIDE DINITRATE					
	IMPAX LABS INC	40MG	A040723	001	Mar 17, 2008

ISOSORBIDE MONONITRATE

TABLET;ORAL					
ISMO					
	PROMIUS PHARMA	20MG	N019091	001	Dec 30, 1991
TABLET, EXTENDED RELEASE;ORAL					
IMDUR					
+	SCHERING PLOUGH	30MG **	N020225	001	Aug 12, 1993
+		60MG **	N020225	002	Aug 12, 1993
+		120MG **	N020225	003	Mar 30, 1995
ISOSORBIDE MONONITRATE					
	ACCORD HLTHCARE	30MG	A209684	001	Oct 24, 2017
		60MG	A209684	002	Oct 24, 2017
		120MG	A209684	003	Oct 24, 2017
	ACTAVIS ELIZABETH	30MG	A075306	001	Dec 31, 1998
		60MG	A075306	002	Dec 31, 1998
	ALKERMES GAINESVILLE	60MG	A075041	001	Sep 22, 1998
	IVAX SUB TEVA PHARMS	30MG	A075448	002	Aug 07, 2001
		60MG	A075448	001	Jun 19, 2000
		120MG	A075448	003	Aug 07, 2001
	SKYEPHARMA AG	60MG	A075166	001	Oct 07, 1999

ISOSULFAN BLUE

INJECTABLE;INJECTION					
LYMPHAZURIN					
+	COVIDIEN	1% **	N018310	001	

ISOTRETINOIN

CAPSULE;ORAL					
ACCUTANE					
+	HOFFMANN LA ROCHE	10MG **	N018662	002	May 07, 1982
+		20MG **	N018662	004	Mar 28, 1983
+		40MG **	N018662	003	May 07, 1982
SOTRET					
	SUN PHARM INDS LTD	10MG	A076041	001	Dec 24, 2002
		20MG	A076041	002	Dec 24, 2002
		30MG	A076503	001	Jun 20, 2003
		40MG	A076041	003	Dec 24, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

ISRADIPINE				
CAPSULE;ORAL				
DYNACIRC				
+ SMITHKLINE BEECHAM	2.5MG	N019546	001	Dec 20, 1990
+	5MG	N019546	002	Dec 20, 1990
TABLET, EXTENDED RELEASE;ORAL				
DYNACIRC CR				
+ GLAXOSMITHKLINE LLC	5MG **	N020336	001	Jun 01, 1994
+	10MG **	N020336	002	Jun 01, 1994
ISRADIPINE				
MYLAN PHARMS INC	5MG	A201067	001	Nov 27, 2015
	10MG	A201067	002	Nov 27, 2015
ITRACONAZOLE				
INJECTABLE;INJECTION				
SPORANOX				
JANSSEN PHARMS	10MG/ML	N020966	001	Mar 30, 1999
IVERMECTIN				
TABLET;ORAL				
STROMECTOL				
MERCK SHARP DOHME	6MG	N050742	001	Nov 22, 1996
KANAMYCIN SULFATE				
CAPSULE;ORAL				
KANTREX				
APOTHECON	EQ 500MG BASE	A060516	001	
	EQ 500MG BASE	A061911	001	
	EQ 500MG BASE	A062726	001	Mar 06, 1987
INJECTABLE;INJECTION				
KANAMYCIN				
WEST-WARD PHARMS INT	EQ 75MG BASE/2ML	A062324	001	
	EQ 500MG BASE/2ML	A062324	002	
	EQ 1GM BASE/3ML	A062324	003	
KANAMYCIN SULFATE				
ABRAXIS PHARM	EQ 75MG BASE/2ML	A062504	001	Apr 05, 1984
	EQ 500MG BASE/2ML	A062504	002	Apr 05, 1984
	EQ 1GM BASE/3ML	A062504	003	Apr 05, 1984
FRESENIUS KABI USA	EQ 500MG BASE/2ML	A065111	001	Dec 17, 2002
	EQ 1GM BASE/3ML	A065111	002	Dec 17, 2002
INTL MEDICATION	EQ 500MG BASE/2ML	A062466	001	Sep 30, 1983
	EQ 1GM BASE/3ML	A062466	002	Sep 30, 1983
LOCH	EQ 75MG BASE/2ML	A063021	001	Jul 31, 1992
	EQ 500MG BASE/2ML	A063022	001	Jul 31, 1992
	EQ 1GM BASE/3ML	A063025	001	Jul 31, 1992
PHARMAFAIR	EQ 75MG BASE/2ML	A062668	001	May 07, 1987
	EQ 500MG BASE/2ML	A062672	001	May 07, 1987
	EQ 1GM BASE/3ML	A062669	001	May 07, 1987
SOLOPAK	EQ 75MG BASE/2ML	A062605	003	Feb 26, 1986
	EQ 500MG BASE/2ML	A062605	001	Feb 26, 1986
	EQ 1GM BASE/3ML	A062605	002	Feb 26, 1986
WARNER CHILCOTT	EQ 1GM BASE/3ML	A063092	001	Oct 11, 1989
WATSON LABS	EQ 1GM BASE/3ML	A062520	003	May 09, 1985
KANTREX				
APOTHECON	EQ 75MG BASE/2ML	A061655	003	
	EQ 75MG BASE/2ML	A061901	003	
	EQ 75MG BASE/2ML	A062564	001	Sep 21, 1984
	EQ 500MG BASE/2ML	A061655	001	
	EQ 500MG BASE/2ML	A061901	001	
	EQ 500MG BASE/2ML	A062564	002	Sep 21, 1984
	EQ 1GM BASE/3ML	A061655	002	
	EQ 1GM BASE/3ML	A061901	002	
	EQ 1GM BASE/3ML	A062564	003	Sep 21, 1984
KLEBCIL				
KING PHARMS	EQ 75MG BASE/2ML	A062170	001	
	EQ 500MG BASE/2ML	A062170	002	
	EQ 1GM BASE/3ML	A062170	003	

KETOCONAZOLE					
CREAM;TOPICAL					
NIZORAL					
+	JANSSEN PHARMA	2%	N019084	001	Dec 31, 1985
SUSPENSION;ORAL					
NIZORAL					
	JANSSEN PHARMA	100MG/5ML	A070767	001	Nov 07, 1986
TABLET;ORAL					
KETOCONAZOLE					
	AAIPHARMA LLC	200MG	A075341	001	Jul 27, 1999
	APOTEX	200MG	A075912	001	Jan 10, 2002
	PLIVA	200MG	A075362	001	Jun 15, 1999
	SUN PHARM INDUSTRIES	200MG	A075314	001	Jun 15, 1999
	TEVA	200MG	A074971	001	Jun 15, 1999
NIZORAL					
+	JANSSEN PHARMS	200MG **	N018533	001	
KETOPROFEN					
CAPSULE;ORAL					
KETOPROFEN					
	AUROLIFE PHARMA LLC	50MG	A074024	001	Dec 29, 1995
		75MG	A074024	002	Dec 29, 1995
	MYLAN	50MG	A074035	002	Dec 31, 1996
		75MG	A074035	003	Dec 31, 1996
	TEVA	25MG	A073515	001	Dec 22, 1992
ORUDIS					
+	WYETH AYERST	25MG **	N018754	001	Jul 31, 1987
+		50MG **	N018754	002	Jan 09, 1986
+		75MG **	N018754	003	Jan 09, 1986
CAPSULE, EXTENDED RELEASE;ORAL					
KETOPROFEN					
	ACTAVIS LABS FL INC	100MG	A075270	002	Mar 24, 1999
		150MG	A075270	003	Mar 24, 1999
		200MG	A075270	001	Mar 24, 1999
	ALKERMES GAINESVILLE	200MG	A074879	001	Dec 10, 1997
	MYLAN	100MG	A075679	003	Feb 20, 2002
		150MG	A075679	002	Feb 20, 2002
ORUVAIL					
+	WYETH PHARMS INC	100MG **	N019816	003	Feb 08, 1995
+		150MG **	N019816	002	Feb 08, 1995
+		200MG **	N019816	001	Sep 24, 1993
FILM;ORAL					
NEXCEDE					
	NOVARTIS	12.5MG	N022470	001	Nov 25, 2009
TABLET;ORAL					
ACTRON					
	BAYER	12.5MG	N020499	001	Oct 06, 1995
KETOPROFEN					
	PERRIGO	12.5MG	A075364	001	Feb 07, 2002
ORUDIS KT					
+	WYETH CONS	12.5MG **	N020429	001	Oct 06, 1995
KETOROLAC TROMETHAMINE					
INJECTABLE;INJECTION					
KETOROLAC TROMETHAMINE					
	APOTEX INC	30MG/ML	A075626	001	Jul 24, 2001
		30MG/ML	A077201	001	Oct 14, 2005
	APOTHECON	15MG/ML	A075348	001	Nov 28, 2000
		30MG/ML	A075348	002	Nov 28, 2000
	BAXTER HLTHCARE CORP	15MG/ML	A075631	002	Jun 29, 2001
		30MG/ML	A075631	001	Jun 29, 2001
	BEDFORD	15MG/ML	A075230	002	Oct 25, 1999
		30MG/ML	A075230	001	Oct 25, 1999
	GLAND PHARMA LTD	15MG/ML	A076722	001	Jul 27, 2004
		30MG/ML	A076722	002	Jul 27, 2004
	HOSPIRA	15MG/ML	A074801	001	Jun 05, 1997
		30MG/ML	A074801	002	Jun 05, 1997
	LUITPOLD	15MG/ML	A078145	001	Jan 14, 2008
		30MG/ML	A078145	002	Jan 14, 2008
	MYLAN LABS LTD	15MG/ML	A078299	001	Jul 16, 2007

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION					
KETOROLAC TROMETHAMINE					
		15MG/ML	A201155	001	Aug 04, 2014
		30MG/ML	A078299	002	Jul 16, 2007
		30MG/ML	A201155	002	Aug 04, 2014
	SANDOZ INC	15MG/ML	A076271	001	Oct 06, 2004
	SUN PHARMA GLOBAL	15MG/ML	A078737	001	Oct 06, 2008
		30MG/ML	A078737	002	Oct 06, 2008
	WEST-WARD PHARMS INT	15MG/ML **	A075222	001	Apr 26, 1999
		15MG/ML	A075299	001	Nov 03, 1999
		15MG/ML	A075772	001	Jul 21, 2004
		30MG/ML **	A075222	002	Apr 26, 1999
		30MG/ML **	A075228	001	Apr 26, 1999
		30MG/ML	A075299	002	Nov 03, 1999
		30MG/ML	A075772	002	Jul 21, 2004
	WOCKHARDT	30MG/ML	A077943	001	Mar 27, 2007
TORADOL					
+	ROCHE PALO	15MG/ML **	N019698	001	Nov 30, 1989
+		30MG/ML **	N019698	002	Nov 30, 1989
SOLUTION/DROPS;OPHTHALMIC					
ACULAR PRESERVATIVE FREE					
	ALLERGAN	0.5%	N020811	001	Nov 03, 1997
KETOROLAC TROMETHAMINE					
	AKORN	0.45%	A203376	001	Feb 10, 2014
TABLET;ORAL					
KETOROLAC TROMETHAMINE					
	CYCLE PHARMS LTD	10MG	A074790	001	Jun 26, 1997
	WATSON LABS	10MG	A074955	001	Sep 19, 1997
TORADOL					
+	ROCHE PALO	10MG **	N019645	001	Dec 20, 1991

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC					
KETOTIFEN FUMARATE					
	APOTEX INC	EQ 0.025% BASE	A077354	001	May 09, 2006
ZADITOR					
+	ALCON PHARMA	EQ 0.025% BASE **	N021066	002	Oct 19, 2006

KRYPTON, KR-81M

GAS;INHALATION					
MPI KRYPTON 81M GENERATOR					
	GE HEALTHCARE	N/A	N018088	001	

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION					
LABETALOL HYDROCHLORIDE					
	AKORN INC	5MG/ML	A075524	001	Nov 29, 1999
	APOTHECON	5MG/ML	A075355	001	Nov 29, 1999
	BAXTER HLTHCARE CORP	5MG/ML	A076051	001	Jul 05, 2002
	HOSPIRA	5MG/ML	A075242	001	Sep 30, 1999
NORMODYNE					
	SCHERING	5MG/ML	N018686	001	Aug 01, 1984
TRANDATE					
+	SEBELA IRELAND LTD	5MG/ML **	N019425	001	Dec 31, 1985
TABLET;ORAL					
LABETALOL HYDROCHLORIDE					
	APOTHECON	100MG	A075223	001	Nov 20, 1998
		200MG	A075223	002	Nov 20, 1998
		300MG	A075223	003	Nov 20, 1998
	TEVA	100MG	A074989	001	Sep 30, 1998
		200MG	A074989	002	Sep 30, 1998
		300MG	A074989	003	Sep 30, 1998
NORMODYNE					
+	SCHERING	100MG **	N018687	001	Aug 31, 1987
+		200MG **	N018687	002	Aug 01, 1984
+		300MG **	N018687	003	Aug 01, 1984
+		400MG **	N018687	004	Aug 01, 1984
TRANDATE					
+	CNTY LINE PHARMS	400MG **	N018716	004	Aug 01, 1984

LACTULOSE					
SOLUTION;ORAL					
CHRONULAC					
+	SANOFI AVENTIS US	10GM/15ML **	N017884	001	
CONSTULOSE					
	ACTAVIS MID ATLANTIC	10GM/15ML	A070288	001	Aug 15, 1988
DUPHALAC					
	SOLVAY	10GM/15ML	A072372	001	Mar 22, 1989
EVALOSE					
	TEVA PHARMS	10GM/15ML	A073497	001	May 28, 1993
LACTULOSE					
	APOTEX INC	10GM/15ML	A075911	001	Feb 21, 2002
	MORTON GROVE	10GM/15ML	A071841	001	Sep 22, 1988
	PACO	10GM/15ML	A073160	001	Aug 25, 1992
LAXILOSE					
	NOSTRUM LABS	10GM/15ML	A073686	001	May 28, 1993
SOLUTION;ORAL, RECTAL					
ACILAC					
	NOSTRUM LABS	10GM/15ML	A073685	001	May 28, 1993
CEPHULAC					
+	SANOFI AVENTIS US	10GM/15ML **	N017657	001	
GENERLAC					
	MORTON GROVE	10GM/15ML	A071842	001	Sep 27, 1988
HEPTALAC					
	TEVA PHARMS	10GM/15ML	A073504	001	May 28, 1993
LACTULOSE					
	APOTEX INC	10GM/15ML	A076645	001	Jul 28, 2003
	PACO	10GM/15ML	A072029	001	Aug 25, 1992
	ROXANE	10GM/15ML	A073590	001	May 29, 1992
	SOLVAY	10GM/15ML	N017906	001	
PORTALAC					
	SOLVAY	10GM/15ML	A072374	001	Mar 22, 1989
LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE					
TABLET;ORAL					
LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE					
+	MICRO LABS	150MG;200MG;300MG	N205626	001	Aug 13, 2018
LAMIVUDINE; RALTEGRAVIR POTASSIUM					
TABLET;ORAL					
DUTREBIS					
	MERCK SHARP DOHME	150MG;EQ 300MG BASE	N206510	001	Feb 06, 2015
LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE					
TABLET;ORAL					
LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE					
	AUROBINDO PHARMA LTD	300MG;300MG	N022344	001	May 15, 2018
LAMIVUDINE; ZIDOVUDINE					
TABLET;ORAL					
LAMIVUDINE AND ZIDOVUDINE					
	PHARMACARE	150MG;300MG	N022018	001	Mar 17, 2017
	TEVA PHARMS	150MG;300MG	A079081	001	May 25, 2011
LAMOTRIGINE					
TABLET;ORAL					
LAMICTAL					
+	GLAXOSMITHKLINE LLC	50MG **	N020241	006	Dec 27, 1994
+		250MG **	N020241	004	Dec 27, 1994
LAMOTRIGINE					
	ACTAVIS TOTOWA	25MG	A078669	001	Apr 08, 2011
		100MG	A078669	002	Apr 08, 2011
		150MG	A078669	003	Apr 08, 2011
		200MG	A078669	004	Apr 08, 2011
	HIKMA PHARMS	25MG	A078134	001	Apr 19, 2011
		100MG	A078134	002	Apr 19, 2011
		150MG	A078134	003	Apr 19, 2011
		200MG	A078134	004	Apr 19, 2011
	MYLAN	25MG	A077428	001	Jan 27, 2009
		100MG	A077428	002	Jan 27, 2009
		150MG	A077428	003	Jan 27, 2009
		200MG	A077428	004	Jan 27, 2009

LAMOTRIGINE

TABLET;ORAL				
LAMOTRIGINE				
MYLAN LABS LTD	25MG	A078443	001	Feb 11, 2009
	100MG	A078443	002	Feb 11, 2009
	150MG	A078443	003	Feb 11, 2009
	200MG	A078443	004	Feb 11, 2009
PHARMASCIENCE INC	25MG	A078310	001	Feb 04, 2009
	100MG	A078310	002	Feb 04, 2009
	150MG	A078310	003	Feb 04, 2009
	200MG	A078310	004	Feb 04, 2009
ROXANE	25MG	A077392	001	Jan 27, 2009
	100MG	A077392	002	Jan 27, 2009
	150MG	A077392	003	Jan 27, 2009
	200MG	A077392	004	Jan 27, 2009
SANDOZ	25MG	A078645	001	Jan 27, 2009
	100MG	A078645	002	Jan 27, 2009
	150MG	A078645	003	Jan 27, 2009
	200MG	A078645	004	Jan 27, 2009
WOCKHARDT	25MG	A078982	001	Jan 27, 2009
	100MG	A078982	002	Jan 27, 2009
	150MG	A078982	003	Jan 27, 2009
	200MG	A078982	004	Jan 27, 2009
TABLET, CHEWABLE;ORAL				
LAMICTAL CD				
GLAXOSMITHKLINE LLC	100MG	N020764	003	Aug 24, 1998
LAMOTRIGINE				
MYLAN	5MG	A076630	001	Jan 22, 2009
	25MG	A076630	002	Jan 22, 2009
SANDOZ	5MG	A078409	002	Jan 22, 2009
	25MG	A078409	003	Jan 22, 2009
TABLET, EXTENDED RELEASE;ORAL				
LAMOTRIGINE				
HANDA PHARMS LLC	25MG	A202887	001	Jun 17, 2013
	50MG	A202887	002	Jun 17, 2013

LANSOPRAZOLE

FOR SUSPENSION, DELAYED RELEASE;ORAL				
PREVACID				
TAKEDA PHARMS NA	15MG/PACKET	N021281	001	May 03, 2001
	30MG/PACKET	N021281	002	May 03, 2001
INJECTABLE;INTRAVENOUS				
PREVACID IV				
+ TAKEDA PHARMS NA	30MG/VIAL **	N021566	001	May 27, 2004
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL				
LANSOPRAZOLE				
ANI PHARMS INC	15MG	A078730	001	Oct 15, 2010
	30MG	A078730	002	Oct 15, 2010

LANSOPRAZOLE; NAPROXEN

CAPSULE, DELAYED REL PELLETS, TABLET;ORAL				
PREVACID NAPRAPAC 250 (COPACKAGED)				
+ TAKEDA PHARMS NA	15MG,N/A;N/A,250MG **	N021507	002	Nov 14, 2003
PREVACID NAPRAPAC 375 (COPACKAGED)				
TAKEDA PHARMS NA	15MG,N/A;N/A,375MG	N021507	003	Nov 14, 2003
PREVACID NAPRAPAC 500 (COPACKAGED)				
TAKEDA PHARMS NA	15MG,N/A;N/A,500MG	N021507	004	Nov 14, 2003

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL				
FOSRENOL				
SHIRE LLC	EQ 250MG BASE	N021468	001	Oct 26, 2004

LAPYRIUM CHLORIDE; UNDECOYLIUM CHLORIDE IODINE COMPLEX

SOLUTION;TOPICAL			
VIRAC REX			
CHESEBROUGH PONDS	0.5%;1.8%	N011914	001

LATANOPROST				
SOLUTION/DROPS;OPHTHALMIC				
LATANOPROST				
APOTEX INC	0.005%	A077697	001	Mar 22, 2011
LEFLUNOMIDE				
TABLET;ORAL				
LEFLUNOMIDE				
FOSUN PHARMA	10MG	A077087	001	Sep 13, 2005
	20MG	A077087	002	Sep 13, 2005
SANDOZ	10MG	A077085	001	Sep 13, 2005
	20MG	A077085	002	Sep 13, 2005
LEPIRUDIN RECOMBINANT				
INJECTABLE;INJECTION				
REFLUDAN				
BAYER HLTHCARE	50MG/VIAL	N020807	001	Mar 06, 1998
LETROZOLE				
TABLET;ORAL				
LETROZOLE				
ACTAVIS TOTOWA	2.5MG	A090292	001	Jul 13, 2011
IMPAX LABS	2.5MG	A091638	001	Jun 03, 2011
LANNETT CO INC	2.5MG	A091098	001	Jun 03, 2011
	2.5MG	A202048	001	Oct 29, 2014
MYLAN	2.5MG	A078190	001	Dec 24, 2008
SUN PHARM INDS LTD	2.5MG	A091466	001	Jun 03, 2011
SYNTHON PHARMS	2.5MG	A090196	001	Jun 03, 2011
LEUCOVORIN CALCIUM				
FOR SOLUTION;ORAL				
LEUCOVORIN CALCIUM				
HOSPIRA	EQ 60MG BASE/VIAL	N008107	003	Jan 30, 1987
INJECTABLE;INJECTION				
LEUCOVORIN CALCIUM				
ABIC	EQ 3MG BASE/ML	A089352	001	Jun 01, 1988
	EQ 50MG BASE/VIAL	A089353	001	Jun 01, 1988
ABRAXIS PHARM	EQ 50MG BASE/VIAL	A088939	001	Dec 01, 1986
ELKINS SINN	EQ 50MG BASE/VIAL	A070480	001	Jan 02, 1987
	EQ 100MG BASE/VIAL	A081224	001	Jun 03, 1994
+ HOSPIRA	EQ 3MG BASE/ML **	N008107	001	
+	EQ 50MG BASE/VIAL **	N008107	002	
+	EQ 100MG BASE/VIAL **	N008107	004	May 23, 1988
+	EQ 350MG BASE/VIAL **	N008107	005	Apr 05, 1989
PHARMACHEMIE	EQ 350MG BASE/VIAL	A040262	001	Dec 15, 1999
PHARMACHEMIE USA	EQ 50MG BASE/VIAL	A089628	001	Apr 17, 1997
	EQ 100MG BASE/VIAL	A089915	001	Apr 17, 1997
TEVA PARENTERAL	EQ 50MG BASE/VIAL	A081278	001	Sep 28, 1993
LEUCOVORIN CALCIUM PRESERVATIVE FREE				
HOSPIRA	EQ 10MG BASE/ML **	A040147	001	Jun 25, 1997
LUITPOLD	EQ 50MG BASE/VIAL	A040338	001	Jan 31, 2001
TEVA PARENTERAL	EQ 10MG BASE/ML	A040332	001	Jun 28, 1999
WELLCOVORIN				
GLAXOSMITHKLINE	EQ 5MG BASE/ML	A087439	001	Oct 19, 1982
	EQ 25MG BASE/VIAL	A089833	001	Jan 23, 1989
	EQ 50MG BASE/VIAL	A089465	001	Jan 23, 1989
	EQ 100MG BASE/VIAL	A089834	001	Jan 23, 1989
TABLET;ORAL				
LEUCOVORIN CALCIUM				
ANI PHARMS INC	EQ 15MG BASE	A075327	001	Mar 24, 1999
EPIC PHARMA LLC	EQ 5MG BASE	A074544	001	Aug 28, 1997
	EQ 25MG BASE	A074544	002	Aug 28, 1997
PAR PHARM	EQ 5MG BASE	A071600	001	Oct 14, 1987
	EQ 25MG BASE	A071598	001	Oct 14, 1987
PHARMACHEMIE	EQ 5MG BASE	A073099	001	Mar 28, 1997
	EQ 25MG BASE	A073101	001	Mar 28, 1997
XANODYNE PHARM	EQ 5MG BASE	N018459	001	Jan 30, 1986
	EQ 10MG BASE	A071962	001	Nov 19, 1987
	EQ 15MG BASE	A071104	001	Mar 04, 1987
WELLCOVORIN				
+ GLAXOSMITHKLINE	EQ 5MG BASE **	N018342	001	Jul 08, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

LEUCOVORIN CALCIUM				
TABLET;ORAL				
WELLCOVORIN				
+		EQ 25MG BASE **	N018342 002	Jul 08, 1983
LEUPROLIDE ACETATE				
IMPLANT;IMPLANTATION				
VIADUR				
	ORTHO MCNEIL JANSSEN	EQ 65MG BASE	N021088 001	Mar 03, 2000
INJECTABLE;INJECTION				
LEUPROLIDE ACETATE				
	GENZYME	1MG/0.2ML	A075721 001	Nov 29, 2001
LUPRON				
+	ABBVIE ENDOCRINE INC	1MG/0.2ML	N019010 001	Apr 09, 1985
LUPRON DEPOT				
+	ABBVIE ENDOCRINE INC	3.75MG/VIAL **	N020011 001	Oct 22, 1990
LUPRON DEPOT-PED				
+	ABBVIE ENDOCRINE INC	3.75MG/VIAL,7.5MG/VIAL **	N020263 003	Apr 16, 1993
+		7.5MG/VIAL,7.5MG/VIAL **	N020263 004	Apr 16, 1993
LEVALLORPHAN TARTRATE				
INJECTABLE;INJECTION				
LORFAN				
	ROCHE	1MG/ML	N010423 001	
LEVAMISOLE HYDROCHLORIDE				
TABLET;ORAL				
ERGAMISOL				
	JANSSEN PHARMA	EQ 50MG BASE	N020035 001	Jun 18, 1990
LEVETIRACETAM				
SOLUTION;ORAL				
LEVETIRACETAM				
	ACI HEALTHCARE LTD	100MG/ML	A078582 001	Jan 15, 2009
	APOTEX INC	100MG/ML	A090187 001	Aug 05, 2011
TABLET;ORAL				
LEVETIRACETAM				
	ACTAVIS LABS FL INC	250MG	A077408 001	Mar 02, 2009
		500MG	A077408 002	Mar 02, 2009
		750MG	A077408 003	Mar 02, 2009
	FOSUN PHARMA	250MG	A077324 001	Jan 15, 2009
		500MG	A077324 002	Jan 15, 2009
		750MG	A077324 003	Jan 15, 2009
		1GM	A077324 004	Jan 15, 2009
	MYLAN	250MG	A078731 001	Feb 10, 2009
		500MG	A078731 002	Feb 10, 2009
		750MG	A078731 003	Feb 10, 2009
		1GM	A078731 004	Feb 10, 2009
	WATSON LABS INC	250MG	A078797 002	Jan 15, 2009
		500MG	A078797 003	Jan 15, 2009
		750MG	A078797 004	Jan 15, 2009
		1GM	A078797 001	Jan 15, 2009
TABLET, EXTENDED RELEASE;ORAL				
LEVETIRACETAM				
	MYLAN PHARMS INC	500MG	A200475 001	Dec 19, 2011
		750MG	A200475 002	Dec 19, 2011
		1GM	A200475 003	Dec 07, 2015
	SANDOZ	500MG	A091668 001	Nov 01, 2012
		750MG	A091668 002	Nov 01, 2012
	VIRTUS PHARMS	500MG	A091291 001	Sep 12, 2011
		750MG	A091291 002	Sep 12, 2011
LEVOBETAXOLOL HYDROCHLORIDE				
SUSPENSION/DROPS;OPHTHALMIC				
BETAXON				
	ALCON PHARMS LTD	EQ 0.5% BASE	N021114 001	Feb 23, 2000

LEVOBUNOLOL HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
LEVOBUNOLOL HYDROCHLORIDE				
	ALCON LABS INC	0.25%	A074851 001	Oct 28, 1996
	APOTEX INC	0.25%	A075473 001	Aug 03, 2000
		0.5%	A075475 001	Aug 03, 2000
	BAUSCH AND LOMB	0.25%	A074307 001	Mar 04, 1994
LEVOBUPIVACAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
CHIROCAINE				
	PURDUE PHARMA LP	EQ 2.5MG BASE/ML	N020997 001	Aug 05, 1999
		EQ 5MG BASE/ML	N020997 002	Aug 05, 1999
		EQ 7.5MG BASE/ML	N020997 003	Aug 05, 1999
LEVOCABASTINE HYDROCHLORIDE				
SUSPENSION/DROPS;OPHTHALMIC				
LIVOSTIN				
	NOVARTIS	EQ 0.05% BASE	N020219 001	Nov 10, 1993
LEVOCARNITINE				
INJECTABLE;INJECTION				
LEVOCARNITINE				
	TEVA PHARMS USA	200MG/ML	A075881 001	Mar 29, 2001
SOLUTION;ORAL				
CARNITOR				
	LEADIANT BIOSCI INC	1GM/10ML	N018948 002	Apr 27, 1988
LEVOCETIRIZINE DIHYDROCHLORIDE				
TABLET;ORAL				
LEVOCETIRIZINE DIHYDROCHLORIDE				
	FOSUN PHARMA	5MG	A090486 001	Mar 26, 2013
LEVODOPA				
CAPSULE;ORAL				
BENDOPA				
	VALEANT PHARM INTL	100MG	N016948 003	
		250MG	N016948 001	
		500MG	N016948 002	
DOPAR				
	SHIRE	100MG	N016913 003	
		250MG	N016913 001	
		500MG	N016913 002	
LARODOPA				
	ROCHE	100MG	N016912 002	
		250MG	N016912 001	
		500MG	N016912 006	
TABLET;ORAL				
DOPAR				
	SHIRE	250MG	N016913 004	
		500MG	N016913 005	
LARODOPA				
	ROCHE	100MG	N016912 005	
		250MG	N016912 003	
		500MG	N016912 004	
LEVOFLOXACIN				
INJECTABLE;INJECTION				
LEVAQUIN				
+	JANSSEN PHARMS	EQ 500MG/20ML (EQ 25MG/ML)	N020635 001	Dec 20, 1996
+		EQ 750MG/30ML (EQ 25MG/ML)	N020635 004	Dec 20, 1996
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
+	JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML) **	N020635 002	Dec 20, 1996
+		EQ 500MG/100ML (EQ 5MG/ML) **	N020635 003	Dec 20, 1996
+		EQ 750MG/150ML (EQ 5MG/ML) **	N020635 005	Dec 20, 1996
LEVOFLOXACIN				
	AKORN	EQ 500MG/20ML (EQ 25MG/ML)	A091644 001	Jun 20, 2011
		EQ 750MG/30ML (EQ 25MG/ML)	A091644 002	Jun 20, 2011
	EMCURE PHARMS LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202590 001	Jan 24, 2013
		EQ 750MG/30ML (EQ 25MG/ML)	A202590 002	Jan 24, 2013
	HOSPIRA INC	EQ 500MG/20ML (EQ 25MG/ML)	A078577 001	Aug 12, 2015
		EQ 750MG/30ML (EQ 25MG/ML)	A078577 002	Aug 12, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

LEVOFLOXACIN				
INJECTABLE;INJECTION				
LEVOFLOXACIN				
MYLAN ASI	EQ 500MG/20ML (EQ 25MG/ML)	A200560	001	Jun 20, 2011
	EQ 750MG/30ML (EQ 25MG/ML)	A200560	002	Jun 20, 2011
ZYDUS PHARMS USA INC	EQ 500MG/20ML (EQ 25MG/ML)	A205968	001	Jun 01, 2017
	EQ 750MG/30ML (EQ 25MG/ML)	A205968	002	Jun 01, 2017
SOLUTION;ORAL				
LEVAQUIN				
+ JANSSEN PHARMS	250MG/10ML	N021721	001	Oct 21, 2004
SOLUTION/DROPS;OPHTHALMIC				
IQUIX				
+ SANTEN	1.5% **	N021571	001	Mar 01, 2004
LEVOFLOXACIN				
APOTEX INC	0.5%	A078282	001	Dec 20, 2010
QUIXIN				
+ SANTEN	0.5% **	N021199	001	Aug 18, 2000
TABLET;ORAL				
LEVAQUIN				
+ JANSSEN PHARMS	250MG	N020634	001	Dec 20, 1996
+	500MG	N020634	002	Dec 20, 1996
+	750MG	N020634	003	Sep 08, 2000
LEVOFLOXACIN				
MYLAN	250MG	A076276	001	Jun 20, 2011
	500MG	A076276	002	Jun 20, 2011
	750MG	A077097	001	Jun 20, 2011
WATSON LABS INC	250MG	A201484	001	Nov 22, 2013
	500MG	A201484	002	Nov 22, 2013
	750MG	A201484	003	Nov 22, 2013
LEVOLEUCOVORIN CALCIUM				
SOLUTION;INTRAVENOUS				
FUSILEV				
+ SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) **	N020140	002	Apr 29, 2011
+	EQ 250MG BASE/25ML (EQ 10MG BASE/ML) **	N020140	003	Apr 29, 2011
LEVOMEPROMAZINE				
INJECTABLE;INJECTION				
LEVOPROME				
IMMUNEX	20MG/ML	N015865	001	
LEVOMETHADYL ACETATE HYDROCHLORIDE				
CONCENTRATE;ORAL				
ORLAAM				
+ ROXANE	10MG/ML **	N020315	001	Jul 09, 1993
LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN				
SOLVAY	0.05MG/ML;2%	A085010	001	
CARBOCAINE W/ NEO-COBEFRIN				
EASTMAN KODAK	0.05MG/ML;2%	N012125	002	
ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN				
SEPTODONT INC	0.05MG/ML;2%	A084697	001	
MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN				
BELMORA LLC	0.05MG/ML;2%	A084850	002	Oct 21, 1983
POLOCAINE W/ LEVONORDEFRIN				
DENTSPLY PHARM	0.05MG/ML;2%	A089517	001	Apr 14, 1988
LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN				
EASTMAN KODAK	0.05MG/ML;2%;0.4%	N008592	007	
LEVONORGESTREL				
IMPLANT;IMPLANTATION				
JADELLE				
+ POPULATION COUNCIL	75MG/IMPLANT **	N020544	001	Nov 01, 1996
LEVONORGESTREL				
WYETH PHARMS INC	75MG/IMPLANT	N020627	001	Aug 15, 1996

LEVONORGESTREL				
IMPLANT;IMPLANTATION				
NORPLANT				
	POPULATION COUNCIL	36MG/IMPLANT	N019897 001	Dec 10, 1990
NORPLANT SYSTEM IN PLASTIC CONTAINER				
	WYETH PHARMS INC	36MG/IMPLANT	N020088 001	Dec 10, 1990
TABLET;ORAL				
LEVONORGESTREL				
	FDN CONSUMER	0.75MG **	A078665 001	Aug 28, 2009
	LUPIN LTD	0.75MG	A091328 001	Jan 23, 2013
	WATSON LABS	0.75MG	A078666 001	Jun 24, 2009
PLAN B				
+	FDN CONSUMER	0.75MG **	N021045 001	Jul 28, 1999
+		0.75MG **	N021045 002	Aug 24, 2006
LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS				
CAPSULE;ORAL				
NOVRAD				
	LILLY	EQ 50MG BASE	N012928 006	
		EQ 100MG BASE	N012928 004	
SUSPENSION;ORAL				
NOVRAD				
	LILLY	EQ 50MG BASE/5ML	N012928 002	
LEVORPHANOL TARTRATE				
INJECTABLE;INJECTION				
LEVO-DROMORAN				
	VALEANT PHARM INTL	2MG/ML	N008719 001	Dec 19, 1991
TABLET;ORAL				
LEVO-DROMORAN				
+	VALEANT PHARM INTL	2MG **	N008720 001	Dec 19, 1991
LEVOTHYROXINE SODIUM				
SOLUTION;ORAL				
TIROSINT-SOL				
+	INSTITUT BIOCHIMIQUE	13MCG/ML	N206977 001	Dec 15, 2016
+		25MCG/ML	N206977 002	Dec 15, 2016
+		50MCG/ML	N206977 003	Dec 15, 2016
+		75MCG/ML	N206977 004	Dec 15, 2016
+		88MCG/ML	N206977 005	Dec 15, 2016
+		100MCG/ML	N206977 006	Dec 15, 2016
+		112MCG/ML	N206977 007	Dec 15, 2016
+		125MCG/ML	N206977 008	Dec 15, 2016
+		137MCG/ML	N206977 009	Dec 15, 2016
+		150MCG/ML	N206977 010	Dec 15, 2016
+		175MCG/ML	N206977 011	Dec 15, 2016
+		200MCG/ML	N206977 012	Dec 15, 2016
TABLET;ORAL				
EUTHYROX				
	PROVELL	0.3MG	N021292 012	May 31, 2002
LEVOLET				
	GENUS LIFESCIENCES	0.025MG	N021137 001	Jun 06, 2003
		0.05MG	N021137 002	Jun 06, 2003
		0.075MG	N021137 003	Jun 06, 2003
		0.088MG	N021137 004	Jun 06, 2003
		0.1MG	N021137 005	Jun 06, 2003
		0.112MG	N021137 006	Jun 06, 2003
		0.125MG	N021137 007	Jun 06, 2003
		0.137MG	N021137 008	Jun 06, 2003
		0.15MG	N021137 009	Jun 06, 2003
		0.175MG	N021137 010	Jun 06, 2003
		0.2MG	N021137 011	Jun 06, 2003
		0.3MG	N021137 012	Jun 06, 2003
LEVOTHYROXINE SODIUM				
	MERCK KGAA	0.025MG	A076752 001	Jun 16, 2005
		0.05MG	A076752 002	Jun 16, 2005
		0.075MG	A076752 003	Jun 16, 2005
		0.088MG	A076752 004	Jun 16, 2005
		0.1MG	A076752 005	Jun 16, 2005
		0.112MG	A076752 006	Jun 16, 2005
		0.125MG	A076752 007	Jun 16, 2005

LEVOTHYROXINE SODIUM				
TABLET;ORAL				
LEVOTHYROXINE SODIUM				
	0.15MG	A076752	008	Jun 16, 2005
	0.175MG	A076752	009	Jun 16, 2005
	0.2MG	A076752	010	Jun 16, 2005
	0.3MG	A076752	011	Jun 16, 2005
LEVOXYL				
+ KING PHARMS	0.3MG **	N021301	012	May 25, 2001
THYRO-TABS				
+ LLOYD	0.025MG **	N021116	001	Oct 24, 2002
+	0.05MG **	N021116	002	Oct 24, 2002
+	0.075MG **	N021116	003	Oct 24, 2002
+	0.088MG **	N021116	010	Oct 24, 2002
+	0.1MG **	N021116	004	Oct 24, 2002
+	0.112MG **	N021116	011	Oct 24, 2002
+	0.125MG **	N021116	005	Oct 24, 2002
+	0.137MG **	N021116	012	Dec 07, 2004
+	0.15MG **	N021116	006	Oct 24, 2002
+	0.175MG **	N021116	007	Oct 24, 2002
+	0.2MG **	N021116	008	Oct 24, 2002
+	0.3MG **	N021116	009	Oct 24, 2002
LIDOCAINE				
AEROSOL;ORAL				
XYLOCAINE				
ASTRAZENECA	10%	N014394	001	
FILM, EXTENDED RELEASE;BUCCAL				
DENTIPATCH				
NOVEN	23MG/PATCH	N020575	001	May 21, 1996
OINTMENT;TOPICAL				
ALPHACAINE				
CARLISLE	5%	A084944	001	
	5%	A084946	001	
	5%	A084947	001	
LIDOCAINE				
BELMORA LLC	5%	A080210	001	
XYLOCAINE				
+ ASTRAZENECA	5% **	N008048	001	
PATCH;TOPICAL				
DENTIPATCH				
NOVEN	46.1MG/PATCH	N020575	002	May 21, 1996
SOLUTION;TOPICAL				
XYLOCAINE				
ASTRAZENECA	5%	N014127	001	
SUPPOSITORY;RECTAL				
XYLOCAINE				
ASTRAZENECA	100MG	N013077	001	
LIDOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
ALPHACAINE HYDROCHLORIDE				
CARLISLE	2%	A084721	001	
LIDOCAINE HYDROCHLORIDE				
ABBOTT	10%	A087980	001	Feb 02, 1983
	20%	A089362	001	May 25, 1988
ABRAXIS PHARM	1%	A080420	001	
	1%	A086761	001	
	1.5%	A080420	005	
	2%	A080420	002	
	2%	A080420	004	
	2%	A086761	002	
	2%	N017508	001	
	4%	N017508	002	
	20%	N017508	004	
AKORN	1%	A085037	001	
	2%	A085037	002	
BEL MAR	1%	A080710	001	
	2%	A080760	001	
BELMORA LLC	2%	A080504	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
LIDOCAINE HYDROCHLORIDE				
DELL LABS	1%	A083387	001	
	2%	A083388	001	
ELKINS SINN	0.5%	A085131	001	
	4%	A084626	001	
GD SEARLE LLC	1%	A083135	001	
	2%	A083135	002	
HOSPIRA	1%	A040013	001	Jun 23, 1995
	1.5%	A088330	001	May 17, 1984
	2%	A088331	001	May 17, 1984
INTL MEDICATION	1%	N017701	002	
	2%	N017701	001	
	1GM/VIAL	N018543	001	
	2GM/VIAL	N018543	002	
LUITPOLD	2%	A083198	001	
LYPHOMED	1%	A080390	001	
	2%	A080390	002	
MILES	1%	A080414	001	
	2%	A080414	002	
MYLAN LABS LTD	0.5%	A091056	001	Dec 08, 2010
	0.5%	A091058	001	Sep 30, 2010
	1%	A091056	002	Dec 08, 2010
	1%	A091058	002	Sep 30, 2010
	2%	A202242	001	Apr 11, 2014
WATSON LABS	1%	A080377	001	
	1%	A083627	001	
	2%	A080377	002	
	2%	A083627	002	
WEST-WARD PHARMS INT	1%	A080407	001	
	2%	A080407	002	
WYETH AYERST	1%	A083083	001	
	2%	A083083	002	
LIDOCAINE HYDROCHLORIDE 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	100MG/100ML	N018461	001	
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	200MG/100ML	N018967	001	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5%				
HOSPIRA	200MG/100ML	A083158	005	
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	200MG/100ML	N018954	001	Jul 09, 1985
HOSPIRA	200MG/100ML	N018388	001	
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	400MG/100ML	N018967	002	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5%				
HOSPIRA	400MG/100ML	A083158	006	
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER				
HOSPIRA	400MG/100ML	N018388	002	
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	800MG/100ML	N018967	003	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER				
HOSPIRA	800MG/100ML	N018388	003	Nov 05, 1982
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER				
HOSPIRA	1.5%	A088326	001	Jul 31, 1984
	10%	A088367	001	Jul 31, 1984
	20%	A088368	001	Jul 31, 1984
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE				
INTL MEDICATION	4%	N017702	002	
	20%	N017702	001	
MYLAN LABS LTD	2%	A090665	001	Sep 27, 2010
WEST-WARD PHARMS INT	1%	A084625	001	
	2%	A084625	002	
LIDOCATON				
PHARMATON	2%	A084727	001	Aug 17, 1983
LIDOPEN				
MERIDIAN MEDCL TECHN	10%	N017549	001	
XYLOCAINE				
ASTRAZENECA	1%	N010418	005	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

LIDOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
XYLOCAINE				
	1.5%	N010418 009		
	2%	N010418 007		
XYLOCAINE 4% PRESERVATIVE FREE				
+ FRESENIUS KABI USA	4%	N010417 001		
XYLOCAINE DENTAL				
DENTSPLY PHARM	2%	N021380 001		
XYLOCAINE PRESERVATIVE FREE				
FRESENIUS KABI USA	10%	N016801 003		
INJECTABLE;SPINAL				
XYLOCAINE 1.5% W/ DEXTROSE 7.5%				
FRESENIUS KABI USA	1.5%	N016297 001		
XYLOCAINE 5% W/ GLUCOSE 7.5%				
ASTRAZENECA	5%	N010496 002	Jul 07, 1982	
JELLY;TOPICAL				
ANESTACON				
BLUEPHARMA	2%	A080429 001		
LIDOCAINE HYDROCHLORIDE				
G AND W LABS INC	2%	A081318 001	Apr 29, 1993	
WATSON LABS INC	2%	A040837 001	Mar 23, 2011	
SOLUTION;ORAL				
LIDOCAINE HYDROCHLORIDE VISCOUS				
ACTAVIS MID ATLANTIC	2%	A086578 001		
INTL MEDICATION	2%	A086389 001	Feb 02, 1982	
XYLOCAINE VISCOUS				
FRESENIUS KABI USA	2% **	N009470 001		
SOLUTION;TOPICAL				
LARYNGOTRACHEAL ANESTHESIA KIT				
KENDALL IL	4%	A087931 001	Jun 10, 1983	
LIDOCAINE HYDROCHLORIDE				
LANNETT CO INC	4%	A040710 001	Feb 27, 2007	
PACO	4%	A089688 001	Jun 30, 1989	
WOCKHARDT BIO AG	4%	A087881 001	Nov 18, 1982	
LTA II KIT				
HOSPIRA	4%	A080409 001		
	4%	A088542 001	Jul 31, 1984	
PEDIATRIC LTA KIT				
ABBOTT	2%	A088572 001	Jul 31, 1984	
HOSPIRA	2%	A085995 001		
XYLOCAINE 4% PRESERVATIVE FREE				
+ FRESENIUS KABI USA	4%	N010417 002		
LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE				
INJECTABLE;INJECTION				
TERRAMYCIN				
PFIZER	2%;50MG/ML	A060567 001		
	2%;125MG/ML	A060567 002		
LIDOCAINE; PRILOCAINE				
DISC;TOPICAL				
EMLA				
ASTRAZENECA	2.5%;2.5%	N020962 001	Feb 04, 1998	
LINCOMYCIN HYDROCHLORIDE				
CAPSULE;ORAL				
LINCOCIN				
PHARMACIA AND UPJOHN	EQ 250MG BASE	N050316 001		
	EQ 500MG BASE	N050316 002		
INJECTABLE;INJECTION				
LINCOMYCIN HYDROCHLORIDE				
WATSON LABS	EQ 300MG BASE/ML	A063180 001	Apr 16, 1991	
LINDANE				
CREAM;TOPICAL				
KWELL				
REED AND CARNRICK	1%	A084218 001		
	1%	N006309 001		

LINDANE				
LOTION;TOPICAL				
GAMENE				
	SOLA BARNES HIND	1%	A084989 001	
KWELL				
	REED AND CARNRICK	1%	A084218 002	
		1%	N006309 003	
LINDANE				
	WOCKHARDT	1%	A088190 001	Aug 16, 1984
SCABENE				
	STIEFEL	1%	A086769 001	
SHAMPOO;TOPICAL				
GAMENE				
	SOLA BARNES HIND	1%	A084988 001	
KWELL				
	REED AND CARNRICK	1%	A084219 001	
		1%	N010718 001	
SCABENE				
	STIEFEL	1%	A087940 001	Apr 08, 1983
LINEZOLID				
SOLUTION;INTRAVENOUS				
ZYVOX				
+	PHARMACIA AND UPJOHN	400MG/200ML (2MG/ML)	N021131 002	Apr 18, 2000
TABLET;ORAL				
ZYVOX				
+	PHARMACIA AND UPJOHN	400MG **	N021130 001	Apr 18, 2000
LIOTHYRONINE SODIUM				
TABLET;ORAL				
LIOTHYRONINE SODIUM				
	WATSON LABS	EQ 0.025MG BASE	A085755 001	Jan 25, 1982
		EQ 0.05MG BASE	A085753 001	Feb 03, 1982
LIOTRIX (T4;T3)				
TABLET;ORAL				
EUTHROID-0.5				
	PARKE DAVIS	0.03MG;0.0075MG	N016680 001	
EUTHROID-1				
	PARKE DAVIS	0.06MG;0.015MG	N016680 002	
EUTHROID-2				
	PARKE DAVIS	0.12MG;0.03MG	N016680 003	
EUTHROID-3				
	PARKE DAVIS	0.18MG;0.045MG	N016680 004	
THYROLAR-0.25				
+	ALLERGAN SALES LLC	0.0125MG;0.0031MG	N016807 001	
THYROLAR-0.5				
+	ALLERGAN SALES LLC	0.025MG;0.0063MG	N016807 005	
THYROLAR-1				
+	ALLERGAN SALES LLC	0.05MG;0.0125MG	N016807 004	
THYROLAR-2				
+	ALLERGAN SALES LLC	0.1MG;0.025MG	N016807 002	
THYROLAR-3				
+	ALLERGAN SALES LLC	0.15MG;0.0375MG	N016807 003	
THYROLAR-5				
	ALLERGAN SALES LLC	0.25MG;0.0625MG	N016807 006	
LISINOPRIL				
TABLET;ORAL				
LISINOPRIL				
	SANDOZ	2.5MG	A075903 001	Jul 01, 2002
		2.5MG	A075999 001	Jul 01, 2002
		5MG	A075903 002	Jul 01, 2002
		5MG	A075999 002	Jul 01, 2002
		10MG	A075903 003	Jul 01, 2002
		10MG	A075999 003	Jul 01, 2002
		20MG	A075903 004	Jul 01, 2002
		20MG	A075999 004	Jul 01, 2002
		30MG	A075903 005	Jul 01, 2002
		30MG	A075999 005	Jul 01, 2002
		40MG	A075903 006	Jul 01, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

LISINOPRIL				
TABLET;ORAL				
LISINOPRIL				
	40MG	A075999	006	Jul 01, 2002
TEVA	2.5MG	A075783	001	Jul 01, 2002
	5MG	A075783	002	Jul 01, 2002
	10MG	A075783	003	Jul 01, 2002
	20MG	A075783	004	Jul 01, 2002
	30MG	A075783	005	Jul 01, 2002
	40MG	A075783	006	Jul 01, 2002
PRINIVIL				
MERCK	2.5MG	N019558	006	Jan 28, 1994
LITHIUM CARBONATE				
CAPSULE;ORAL				
ESKALITH				
NOVEN THERAP	300MG	N016860	001	
LITHIUM CARBONATE				
ABLE	150MG	A076823	001	Jun 29, 2004
	300MG	A076121	001	Sep 27, 2001
	300MG	A076823	002	Jun 29, 2004
	600MG	A076823	003	Jun 29, 2004
APOTEX INC	300MG	A076795	001	Nov 22, 2004
USL PHARMA	300MG	A072542	001	Feb 01, 1989
WATSON LABS	300MG	A070407	001	Mar 19, 1987
LITHONATE				
SOLVAY	300MG	N016782	001	
TABLET;ORAL				
ESKALITH				
JDS PHARMS	300MG	N017971	001	
LITHANE				
BAYER PHARMS	300MG	N018833	001	Jul 18, 1985
LITHIUM CARBONATE				
HIKMA INTL PHARMS	300MG	A078715	001	Dec 28, 2010
PFIZER	300MG	N016834	001	
LITHOTABS				
SOLVAY	300MG	N016980	001	
TABLET, EXTENDED RELEASE;ORAL				
ESKALITH CR				
JDS PHARMS	450MG **	N018152	001	Mar 29, 1982
LITHIUM CARBONATE				
ABLE	300MG	A076382	001	Apr 21, 2003
BARR	300MG	A076170	001	Jun 10, 2002
	450MG	A076366	001	Aug 21, 2003
HIKMA INTL PHARMS	450MG	A076490	001	Jun 17, 2003
LITHIUM CITRATE				
SYRUP;ORAL				
LITHONATE				
SOLVAY	EQ 300MG CARBONATE/5ML	N017672	001	
LOMEFLOXACIN HYDROCHLORIDE				
TABLET;ORAL				
MAXAQUIN				
PHARMACIA	EQ 400MG BASE	N020013	001	Feb 21, 1992
LOMUSTINE				
CAPSULE;ORAL				
GLEOSTINE				
+ CORDEN PHARMA	5MG	N017588	004	Dec 19, 2014
LOPERAMIDE HYDROCHLORIDE				
CAPSULE;ORAL				
IMODIUM				
J AND J CONSUMER INC	2MG **	N017690	001	
+	2MG **	N017694	001	
LOPERAMIDE HYDROCHLORIDE				
ROXANE	2MG	A073080	001	Nov 27, 1991
TEVA	2MG	A073122	001	Aug 30, 1991
YAOPHARMA CO LTD	2MG	A072993	001	Aug 28, 1992

LOPERAMIDE HYDROCHLORIDE					
SOLUTION;ORAL					
IMODIUM					
	JANSSEN PHARMS	1MG/5ML	N019037	001	Jul 31, 1984
LOPERAMIDE HYDROCHLORIDE					
	ALLIED	1MG/5ML	A073079	001	Apr 30, 1992
	ALPHARMA US PHARMS	1MG/5ML	A073187	001	Sep 15, 1992
	DURAMED PHARMS BARR	1MG/5ML	A074991	001	Dec 29, 1997
	TEVA	1MG/5ML	A073478	001	Jun 23, 1995
	WATSON LABS	1MG/5ML	A073062	001	May 28, 1993
TABLET;ORAL					
LOPERAMIDE HYDROCHLORIDE					
	ABLE	2MG	A073528	001	Nov 30, 1993
	CONTRACT PHARMACAL	2MG	A073254	001	Jul 30, 1993
	PERRIGO	2MG	A074194	001	Oct 30, 1992
TABLET, CHEWABLE;ORAL					
IMODIUM A-D EZ CHEWS					
+	J AND J CONSUMER INC	2MG	N020448	001	Jul 24, 1997
LOPERAMIDE HYDROCHLORIDE; SIMETHICONE					
TABLET, CHEWABLE;ORAL					
IMODIUM MULTI-SYMPTOM RELIEF					
+	J AND J CONSUMER INC	2MG;125MG	N020606	001	Jun 26, 1996
LOPINAVIR; RITONAVIR					
CAPSULE;ORAL					
KALETRA					
	ABBVIE	133.3MG;33.3MG	N021226	001	Sep 15, 2000
LORACARBEF					
CAPSULE;ORAL					
LORABID					
	KING PHARMS	200MG	N050668	001	Dec 31, 1991
		400MG	N050668	002	Apr 05, 1996
FOR SUSPENSION;ORAL					
LORABID					
	KING PHARMS	100MG/5ML	N050667	001	Dec 31, 1991
		200MG/5ML	N050667	002	Dec 31, 1991
LORATADINE					
SYRUP;ORAL					
CLARITIN HIVES RELIEF					
+	BAYER HEALTHCARE LLC	1MG/ML **	N020641	003	Nov 19, 2003
LORATADINE					
	APOTEX INC	1MG/ML	A075565	001	Oct 05, 2004
	RANBAXY LABS LTD	1MG/ML	A076529	001	Aug 20, 2004
TABLET;ORAL					
LORATADINE					
	PERRIGO	10MG	N021512	001	Jun 24, 2004
LORATADINE; PSEUDOEPHEDRINE SULFATE					
TABLET, EXTENDED RELEASE;ORAL					
LORATADINE AND PSEUDOEPHEDRINE SULFATE					
	ACTAVIS LABS FL INC	5MG;120MG	A076208	001	Jan 28, 2004
LORAZEPAM					
INJECTABLE;INJECTION					
LORAZEPAM					
	AKORN	2MG/ML	A074974	001	Jul 23, 1998
	BEDFORD	2MG/ML	A077076	001	Jul 13, 2005
		4MG/ML	A077076	002	Jul 13, 2005
	DAVA PHARMS INC	2MG/ML	A074793	001	Mar 16, 2000
		4MG/ML	A074793	002	Mar 16, 2000
	HOSPIRA	2MG/ML	A074280	001	May 27, 1994
		2MG/ML	A074300	001	Apr 12, 1994
		4MG/ML	A074280	002	May 27, 1994
		4MG/ML	A074300	003	Mar 19, 1997
	MYLAN ASI	2MG/ML	A200217	001	Apr 04, 2017
		2MG/ML	A200542	001	Apr 28, 2017
		4MG/ML	A200217	002	Apr 04, 2017
		4MG/ML	A200542	002	Apr 28, 2017
	WATSON LABS	2MG/ML	A074276	001	Apr 15, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

LORAZEPAM				
INJECTABLE;INJECTION				
LORAZEPAM				
	4MG/ML	A074276	002	Apr 15, 1994
WATSON LABS INC	1MG/0.5ML	A074551	003	Sep 12, 1996
	2MG/ML	A074535	001	Sep 12, 1996
	2MG/ML	A074551	001	Sep 12, 1996
	4MG/ML	A074535	002	Sep 12, 1996
	4MG/ML	A074551	002	Sep 12, 1996
WEST-WARD PHARMS INT	2MG/ML	A074496	001	Sep 28, 1998
	4MG/ML	A074496	002	Sep 28, 1998
LORAZEPAM PRESERVATIVE FREE				
BEDFORD LABS	2MG/ML	A077074	001	Jul 13, 2005
	4MG/ML	A077074	002	Jul 13, 2005
SOLUTION;ORAL				
LORAZEPAM				
ROXANE	0.5MG/5ML	A074648	001	Mar 18, 1997
TABLET;ORAL				
LORAZ				
QUANTUM PHARMICS	0.5MG	A070200	001	Aug 09, 1985
	1MG	A070201	001	Aug 09, 1985
	2MG	A070202	001	Aug 09, 1985
LORAZEPAM				
AM THERAP	0.5MG	A070727	001	Mar 07, 1986
	1MG	A070728	001	Mar 07, 1986
	2MG	A070729	001	Mar 07, 1986
ANDA REPOSITORY	0.5MG	A072555	002	Mar 29, 1991
	1MG	A072555	003	Mar 29, 1991
	2MG	A072555	001	Mar 29, 1991
HALSEY	0.5MG	A071434	001	Sep 01, 1987
	1MG	A071435	001	Sep 01, 1987
	2MG	A071436	001	Sep 01, 1987
MUTUAL PHARM	0.5MG	A070472	001	Dec 10, 1985
	1MG	A070473	001	Dec 10, 1985
	2MG	A070474	001	Dec 10, 1985
MYLAN	0.5MG	A071591	002	Oct 13, 1987
	1MG	A071591	003	Oct 13, 1987
	2MG	A071591	001	Oct 13, 1987
PAR PHARM	0.5MG	A070675	001	Dec 01, 1986
	1MG	A070676	001	Dec 01, 1986
	2MG	A070677	001	Dec 01, 1986
SANDOZ	0.5MG	A071193	001	Apr 15, 1988
	1MG	A071194	001	Apr 15, 1988
	2MG	A071195	001	Apr 15, 1988
SUN PHARM INDS LTD	0.5MG	A076045	001	Aug 29, 2001
	1MG	A076045	002	Aug 29, 2001
	2MG	A076045	003	Aug 29, 2001
SUPERPHARM	0.5MG	A071245	001	Feb 09, 1987
	1MG	A071246	001	Feb 09, 1987
	2MG	A071247	001	Feb 09, 1987
USL PHARMA	1MG	A070539	001	Dec 22, 1986
	2MG	A070540	001	Dec 22, 1986
WARNER CHILCOTT	1MG	A071038	001	Jan 12, 1988
	2MG	A071039	001	Jan 12, 1988
WATSON LABS	0.5MG	A071086	001	Mar 23, 1987
	0.5MG	A071117	001	Jul 24, 1986
	1MG	A071087	001	Mar 23, 1987
	1MG	A071118	001	Jul 24, 1986
	2MG	A071088	001	Mar 23, 1987
	2MG	A071110	001	Jul 24, 1986
LOSARTAN POTASSIUM				
TABLET;ORAL				
COZAAR				
+ MERCK SHARP DOHME	25MG	N020386	001	Apr 14, 1995
+	50MG	N020386	002	Apr 14, 1995
LOSARTAN POTASSIUM				
APOTEX CORP	25MG	A090790	001	Oct 06, 2010
	50MG	A090790	002	Oct 06, 2010
	100MG	A090790	003	Oct 06, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

LOTEPREDNOL ETABONATE				
SUSPENSION/DROPS;OPHTHALMIC				
LOTEMAX				
	PHARMOS	0.5%	N020841 001	Mar 09, 1998
LOVASTATIN				
TABLET;ORAL				
LOVASTATIN				
	MYLAN	10MG	A075935 001	Dec 17, 2001
		20MG	A075935 002	Dec 17, 2001
		40MG	A075935 003	Dec 17, 2001
MEVACOR				
+	MERCK	10MG **	N019643 002	Mar 28, 1991
+		20MG **	N019643 003	Aug 31, 1987
+		40MG **	N019643 004	Dec 14, 1988
TABLET, EXTENDED RELEASE;ORAL				
ALTOPREV				
	COVIS PHARMA BV	10MG	N021316 001	Jun 26, 2002
LOXAPINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
LOXITANE C				
	ACTAVIS LABS UT INC	EQ 25MG BASE/ML	N017658 001	
INJECTABLE;INJECTION				
LOXITANE IM				
	ACTAVIS LABS UT INC	EQ 50MG BASE/ML	N018039 001	
LOXAPINE SUCCINATE				
CAPSULE;ORAL				
LOXITANE				
+	ACTAVIS LABS UT INC	EQ 5MG BASE **	N017525 001	
+		EQ 10MG BASE **	N017525 002	
+		EQ 25MG BASE **	N017525 003	
+		EQ 50MG BASE **	N017525 004	
TABLET;ORAL				
LOXITANE				
+	ACTAVIS LABS UT INC	EQ 10MG BASE **	N017525 006	
+		EQ 25MG BASE **	N017525 007	
+		EQ 50MG BASE **	N017525 008	
LUCINACTANT				
SUSPENSION;INTRATRACHEAL				
SURFAXIN				
	WINDTREE THERAP	8.5ML	N021746 001	Mar 06, 2012
LUTROPIN ALFA				
INJECTABLE;SUBCUTANEOUS				
LUVERIS				
	EMD SERONO	75 IU/VIAL	N021322 001	Oct 08, 2004
LYPRESSIN				
SOLUTION;NASAL				
DIAPID				
	NOVARTIS	0.185MG/ML	N016755 001	
MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE				
INJECTABLE;INJECTION				
PLASMA-LYTE 56 IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	32MG/100ML;128MG/100ML;234MG/100ML	N019047 001	Jun 15, 1984
MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE				
INJECTABLE;INJECTION				
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER				
	B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML	N019006 001	Apr 04, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE				
INJECTABLE;INJECTION				
ISOLYTE S IN PLASTIC CONTAINER				
B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML;530MG /100ML;500MG/100ML	N018252	001	
SOLUTION;IRRIGATION				
PHYSIOSOL IN PLASTIC CONTAINER				
HOSPIRA INC	14MG/100ML;37MG/100ML;222MG/100ML;526MG /100ML;502MG/100ML	N018406	001	
PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER				
HOSPIRA INC	30MG/100ML;37MG/100ML;222MG/100ML;526MG /100ML;502MG/100ML	N018406	002	Jul 08, 1982
SYNOVALYTE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML;526MG /100ML;502MG/100ML	N019326	001	Jan 25, 1985
MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE				
TABLET;ORAL				
MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE				
SANTARUS	343MG;20MG;750MG	N022456	001	Dec 04, 2009
	343MG;40MG;750MG	N022456	002	Dec 04, 2009
TABLET, CHEWABLE;ORAL				
ZEGERID				
SANTARUS	700MG;20MG;600MG	N021850	001	Mar 24, 2006
	700MG;40MG;600MG	N021850	002	Mar 24, 2006
MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE				
SOLUTION;ORAL				
SUCLEAR				
+ BRAINTREE LABS	1.6GM/BOT,3.13GM/BOT,17.5GM/BOT,N/A,N/A ,N/A,N/A;N/A,N/A,N/A,210GM,0.74GM,2.86G M,5.6GM **	N203595	001	Jan 18, 2013
MALATHION				
LOTION;TOPICAL				
MALATHION				
MYLAN PHARMS INC	0.5%	A078743	001	Mar 06, 2009
MANGAFODIPIR TRISODIUM				
INJECTABLE;INJECTION				
TESLASCAN				
IC TARGETS	37.9MG/ML	N020652	001	Nov 26, 1997
MANGANESE CHLORIDE TETRAHYDRATE				
FOR SOLUTION;ORAL				
LUMENHANCE				
BRACCO	3.49MG/GM	N020686	001	Dec 19, 1997
MANGANESE SULFATE				
INJECTABLE;INJECTION				
MANGANESE SULFATE				
ABRAXIS PHARM	EQ 0.1MG MANGANESE/ML	N019228	001	May 05, 1987
MANNITOL				
INJECTABLE;INJECTION				
MANNITOL 10%				
B BRAUN	10GM/100ML	N016080	002	
HOSPIRA	10GM/100ML	N016269	002	
MILES	10GM/100ML	N016472	002	
MANNITOL 10% IN PLASTIC CONTAINER				
ICU MEDICAL INC	10GM/100ML	N019603	002	Jan 08, 1987
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER				
B BRAUN	10GM/100ML	N016080	006	
MANNITOL 15%				
B BRAUN	15GM/100ML	N016080	003	
HOSPIRA	15GM/100ML	N016269	003	
MILES	15GM/100ML	N016472	005	
MANNITOL 15% IN PLASTIC CONTAINER				
ICU MEDICAL INC	15GM/100ML	N019603	003	Jan 08, 1990
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%				
B BRAUN	15GM/100ML	N016080	005	

MANNITOL

INJECTABLE;INJECTION

MANNITOL 20%

B BRAUN	20GM/100ML	N014738	001	
	20GM/100ML	N016080	004	
HOSPIRA	20GM/100ML	N016269	004	
MILES	20GM/100ML	N016472	004	

MANNITOL 25%

ABRAXIS PHARM	12.5GM/50ML	A086754	001	
HOSPIRA	12.5GM/50ML	N016269	005	
IGI LABS INC	12.5GM/50ML	A089239	001	May 06, 1987
	12.5GM/50ML	A089240	001	May 06, 1987
MERCK	12.5GM/50ML	N005620	001	
WATSON LABS	12.5GM/50ML	A087460	001	Jun 27, 1983

MANNITOL 5%

B BRAUN	5GM/100ML	N016080	001	
HOSPIRA	5GM/100ML	N016269	001	

MANNITOL 5% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML	N019603	001	Jan 08, 1987

MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%

B BRAUN	5GM/100ML	N016080	007	

SOLUTION;IRRIGATION

RESECTISOL

B BRAUN	5GM/100ML	N016704	002	

MANNITOL; SORBITOL

SOLUTION;IRRIGATION

SORBITOL-MANNITOL

HOSPIRA	540MG/100ML;2.7GM/100ML	A080224	001	

SORBITOL-MANNITOL IN PLASTIC CONTAINER

HOSPIRA	540MG/100ML;2.7GM/100ML	N017636	001	

MAPROTILINE HYDROCHLORIDE

TABLET;ORAL

LUDIOMIL

NOVARTIS	25MG	N017543	001	
	50MG	N017543	002	
	75MG	N017543	003	Sep 30, 1982

MAPROTILINE HYDROCHLORIDE

AM THERAP	25MG	A072129	001	Jan 14, 1988
	50MG	A072130	001	Jan 14, 1988
	75MG	A072131	001	Jan 14, 1988
WATSON LABS	25MG	A071943	001	Dec 30, 1987
	50MG	A071944	001	Dec 30, 1987
	75MG	A071945	001	Dec 30, 1987
	75MG	A072164	001	Jun 01, 1988
WATSON LABS TEVA	25MG	A072162	001	Jun 01, 1988
	50MG	A072163	001	Jun 01, 1988

MASOPROCOL

CREAM;TOPICAL

ACTINEX

UNIV AZ CANCER CTR	10%	N019940	001	Sep 04, 1992

MAZINDOL

TABLET;ORAL

MAZANOR

WYETH AYERST	1MG	N017980	002	
	2MG	N017980	001	

SANOREX

+ HEXIM	1MG **	N017247	001	
+	2MG **	N017247	002	

MEBENDAZOLE

TABLET, CHEWABLE;ORAL

VERMOX

+ JANSSEN PHARMS	100MG **	N017481	001	
+	500MG	N208398	001	Oct 19, 2016

MEBUTAMATE				
TABLET;ORAL				
DORMATE				
	MEDPOINTE PHARM HLC	600MG	N017374 001	
MECAMYLAMINE HYDROCHLORIDE				
TABLET;ORAL				
INVERSINE				
+	TARGACEPT	2.5MG **	N010251 001	
MECASERMIN RINFABATE RECOMBINANT				
INJECTABLE;SUBCUTANEOUS				
IPLEX				
	INSMED	36MG/0.6ML	N021884 001	Dec 12, 2005
MECHLORETHAMINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
MUSTARGEN				
+	RECORDATI RARE	10MG/VIAL	N006695 001	
MECLIZINE HYDROCHLORIDE				
TABLET;ORAL				
ANTIVERT				
	CASPER PHARMA LLC	12.5MG	N010721 006	
		25MG	N010721 004	
		50MG	N010721 001	Jan 20, 1982
MECLIZINE HYDROCHLORIDE				
	ABC HOLDING	12.5MG	A085253 001	
		25MG	A085252 001	
	AMNEAL PHARMS	50MG	A201451 003	Feb 23, 2011
	ANABOLIC	25MG	A085891 001	
	ANI PHARMS INC	12.5MG	A084975 001	
		25MG	A084657 001	
	BUNDY	12.5MG	A084382 001	
		25MG	A084872 001	
	IVAX SUB TEVA PHARMS	12.5MG	A083784 001	
	KV PHARM	12.5MG	A085524 001	
		25MG	A085523 001	
	MYLAN PHARMS INC	50MG	A202640 003	Sep 17, 2012
	PAR PHARM	50MG	A089674 001	Mar 31, 1988
	PLIVA	12.5MG	A088732 001	Dec 11, 1985
		25MG	A088734 001	Dec 11, 1985
	RISING PHARMS	12.5MG	A040179 001	Jan 30, 1997
		25MG	A040179 002	Jan 30, 1997
	SUPERPHARM	12.5MG	A089113 001	Aug 20, 1985
		25MG	A089114 001	Aug 20, 1985
	UDL	12.5MG	A088256 001	Jun 13, 1983
		25MG	A088257 001	Jun 13, 1983
	VANGARD	12.5MG	A087877 001	Apr 20, 1982
		25MG	A087620 001	Jan 04, 1982
	WATSON LABS	12.5MG	A085195 001	
		12.5MG	A085269 001	
		25MG	A085740 001	
TABLET, CHEWABLE;ORAL				
ANTIVERT				
	CASPER PHARMA LLC	25MG	N010721 005	
MECLIZINE HYDROCHLORIDE				
	IVAX SUB TEVA PHARMS	25MG	A084976 001	
	NEXGEN PHARMA INC	25MG	A086392 001	
	PLIVA	25MG	A088733 001	Dec 11, 1985
MECLOCYCLINE SULFOSALICYLATE				
CREAM;TOPICAL				
MECLAN				
	JOHNSON AND JOHNSON	1%	N050518 001	

MECLOFENAMATE SODIUM

CAPSULE;ORAL				
MECLODIUM				
QUANTUM PHARMICS	EQ 50MG BASE	A071380	001	Jul 14, 1987
	EQ 100MG BASE	A071381	001	Jul 14, 1987
MECLOFENAMATE SODIUM				
AM THERAP	EQ 50MG BASE	A071362	001	Feb 10, 1987
	EQ 100MG BASE	A071363	001	Feb 10, 1987
BARR	EQ 50MG BASE	A072848	001	Mar 20, 1989
	EQ 100MG BASE	A072809	001	Mar 20, 1989
FOSUN PHARMA	EQ 50MG BASE	A072262	001	Nov 29, 1988
	EQ 100MG BASE	A072263	001	Nov 29, 1988
PAR PHARM	EQ 50MG BASE	A072077	001	Mar 10, 1988
	EQ 100MG BASE	A072078	001	Mar 10, 1988
USL PHARMA	EQ 50MG BASE	A071007	001	Mar 25, 1988
	EQ 100MG BASE	A071008	001	Mar 25, 1988
VITARINE	EQ 50MG BASE	A071710	001	Jun 15, 1988
	EQ 100MG BASE	A071684	001	Jun 15, 1988
WATSON LABS	EQ 50MG BASE	A070400	001	Nov 25, 1986
	EQ 50MG BASE	A071468	001	Apr 15, 1987
	EQ 50MG BASE	A071640	001	Aug 11, 1987
	EQ 100MG BASE	A070401	001	Nov 25, 1986
	EQ 100MG BASE	A071641	001	Aug 11, 1987
WATSON LABS TEVA	EQ 100MG BASE	A071469	001	Apr 15, 1987
MECLOMEN				
PARKE DAVIS	EQ 50MG BASE	N018006	001	
	EQ 100MG BASE	N018006	002	

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION				
DEPO-PROVERA				
+ PHARMACIA AND UPJOHN	100MG/ML **	N012541	002	
MEDROXYPROGESTERONE ACETATE				
SANDOZ INC	150MG/ML	A078711	001	May 20, 2009
TEVA PHARMS USA	150MG/ML	A076552	001	Oct 27, 2004
TABLET;ORAL				
AMEN				
AMARIN PHARMS	10MG	A083242	001	
CURRETAB				
SOLVAY	10MG	A085686	001	
CYCRIN				
ESI	2.5MG	A081239	001	Oct 30, 1992
	5MG	A081240	001	Oct 30, 1992
	10MG	A089386	001	Sep 09, 1987
MEDROXYPROGESTERONE ACETATE				
DURAMED PHARMS BARR	2.5MG	A040311	001	Dec 01, 1999
	5MG	A040311	002	Dec 01, 1999
	10MG	A040311	003	Dec 01, 1999
USL PHARMA	10MG	A088484	001	Jul 26, 1984

MEDRYSONE

SUSPENSION;OPHTHALMIC				
HMS				
ALLERGAN	1%	N016624	003	

MEFLOQUINE HYDROCHLORIDE

TABLET;ORAL				
LARIAM				
+ ROCHE	250MG **	N019591	001	May 02, 1989
MEFLOQUINE HYDROCHLORIDE				
HIKMA INTL PHARMS	250MG	A077699	001	Apr 21, 2010
SANDOZ	250MG	A076175	001	Feb 20, 2002
US ARMY WALTER REED	250MG **	N019578	001	May 02, 1989

MEGESTROL ACETATE

SUSPENSION;ORAL				
MEGACE				
+ BRISTOL MYERS SQUIBB	40MG/ML **	N020264	001	Sep 10, 1993
MEGESTROL ACETATE				
APOTEX INC	40MG/ML	A077404	001	Feb 16, 2006

MEGESTROL ACETATE				
TABLET;ORAL				
MEGACE				
+	BRISTOL MYERS SQUIBB	20MG **	N016979 001	
+		40MG **	N016979 002	
MEGESTROL ACETATE				
	TEVA	40MG	A074745 001	Feb 27, 1998
	USL PHARMA	20MG	A070646 001	Oct 02, 1987
		40MG	A070647 001	Oct 02, 1987
MELOXICAM				
SUSPENSION;ORAL				
MOBIC				
+	BOEHRINGER INGELHEIM	7.5MG/5ML **	N021530 001	Jun 01, 2004
TABLET;ORAL				
MELOXICAM				
	ANDA REPOSITORY	7.5MG	A077935 001	Jul 19, 2006
		15MG	A077935 002	Jul 19, 2006
	CR DOUBLE CRANE	7.5MG	A078039 001	Dec 14, 2006
		15MG	A078039 002	Dec 14, 2006
	IMPAX LABS INC	7.5MG	A077930 001	Jul 19, 2006
		15MG	A077930 002	Jul 19, 2006
	MYLAN	7.5MG	A077923 001	Jul 19, 2006
		7.5MG	A077934 001	Jul 20, 2006
		15MG	A077923 002	Jul 19, 2006
		15MG	A077934 002	Jul 20, 2006
	ROXANE	7.5MG	A077925 001	Jul 19, 2006
		15MG	A077925 002	Jul 19, 2006
	SUN PHARM INDS INC	7.5MG	A077937 001	Jul 19, 2006
		15MG	A077937 002	Jul 19, 2006
	YABAO PHARM	7.5MG	A077933 001	Jul 19, 2006
		15MG	A077933 002	Jul 19, 2006
MELPHALAN HYDROCHLORIDE				
INJECTABLE;INJECTION				
ALKERAN				
+	APOTEX INC	EQ 50MG BASE/VIAL **	N020207 001	Nov 18, 1992
MELPHALAN HYDROCHLORIDE				
	MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL	A090299 001	Oct 27, 2009
MEMANTINE HYDROCHLORIDE				
SOLUTION;ORAL				
NAMENDA				
+	ALLERGAN SALES LLC	2MG/ML	N021627 001	Apr 18, 2005
TABLET;ORAL				
MEMANTINE HYDROCHLORIDE				
	ORCHID HLTHCARE	5MG	A090044 001	Mar 12, 2012
		10MG	A090044 002	Mar 12, 2012
MENADIOL SODIUM DIPHOSPHATE				
INJECTABLE;INJECTION				
KAPPADIONE				
	LILLY	10MG/ML	N005725 001	
SYNKAYVITE				
	ROCHE	5MG/ML	N003718 004	
		10MG/ML	N003718 006	
		37.5MG/ML	N003718 008	
TABLET;ORAL				
SYNKAYVITE				
	ROCHE	5MG	N003718 010	
MENADIONE				
TABLET;ORAL				
MENADIONE				
	LILLY	5MG	N002139 003	

MENOTROPINS (FSH;LH)				
INJECTABLE;INJECTION				
HUMEGON				
ORGANON USA INC	75 IU/VIAL;75 IU/VIAL	N020328	001	Sep 01, 1994
	150 IU/VIAL;150 IU/VIAL	N020328	002	Sep 01, 1994
MENOTROPINS				
FERRING	75 IU/VIAL;75 IU/VIAL	A073598	001	Jan 30, 1997
	150 IU/VIAL;150 IU/VIAL	A073599	001	Jan 30, 1997
PERGONAL				
SERONO	75 IU/AMP;75 IU/AMP	N017646	001	
	150 IU/AMP;150 IU/AMP	N017646	002	May 20, 1985
REPRONEX				
FERRING	150 IU/VIAL;150 IU/VIAL	N021047	002	Aug 27, 1999
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS				
REPRONEX				
FERRING	75 IU/VIAL;75 IU/VIAL	N021047	001	Aug 27, 1999
MEPENZOLATE BROMIDE				
SOLUTION;ORAL				
CANTIL				
SANOFI AVENTIS US	25MG/5ML	N010679	004	
TABLET;ORAL				
CANTIL				
+ SANOFI AVENTIS US	25MG	N010679	003	
MEPERIDINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
DEMEROL				
US PHARM HOLDINGS	25MG/ML	N005010	007	
	50MG/ML	N005010	002	
	75MG/ML	N005010	009	
	100MG/ML	N005010	003	
MEPERIDINE HYDROCHLORIDE				
ABBOTT	25MG/ML	A080388	001	
	50MG/ML	A080385	001	
	50MG/ML	A080387	001	
	75MG/ML	A080389	001	
	100MG/ML	A080386	001	
BAXTER HLTHCARE	25MG/ML	A088279	001	Jun 15, 1984
	50MG/ML	A088280	001	Jun 15, 1984
	75MG/ML	A088281	001	Jun 15, 1984
	100MG/ML	A088282	001	Jun 15, 1984
IGI LABS INC	25MG/ML	A089781	001	Mar 31, 1989
	50MG/ML	A089782	001	Mar 31, 1989
	50MG/ML	A089783	001	Mar 31, 1989
	50MG/ML	A089784	001	Mar 31, 1989
	75MG/ML	A089785	001	Mar 31, 1989
	100MG/ML	A089786	001	Mar 31, 1989
	100MG/ML	A089787	001	Mar 31, 1989
	100MG/ML	A089788	001	Mar 31, 1989
INTL MEDICATION	10MG/ML	A086332	001	
PARKE DAVIS	50MG/ML	A080364	002	
	75MG/ML	A080364	003	
	100MG/ML	A080364	001	
WATSON LABS	50MG/ML	A073444	001	Mar 17, 1992
	100MG/ML	A073445	001	Mar 17, 1992
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE				
HOSPIRA	10MG/ML	A040305	001	Mar 10, 1999
ICU MEDICAL INC	10MG/ML	A088432	001	Aug 16, 1984
INTL MEDICATION	10MG/ML	A081309	001	Aug 30, 1993
SPECGX LLC	10MG/ML	A040163	001	May 12, 1997
WATSON LABS	10MG/ML	A073443	001	Mar 17, 1992
SYRUP;ORAL				
DEMEROL				
US PHARM HOLDINGS	50MG/5ML **	N005010	005	
TABLET;ORAL				
MEPERIDINE HYDROCHLORIDE				
BARR	50MG	A088639	001	Jul 02, 1984
	100MG	A088640	001	Sep 19, 1984
DURAMED PHARMS BARR	50MG	A040318	001	Oct 05, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

MEPERIDINE HYDROCHLORIDE				
TABLET;ORAL				
MEPERIDINE HYDROCHLORIDE				
	100MG	A040318	002	Oct 05, 1999
SUN PHARM INDUSTRIES	50MG	A080448	001	
	100MG	A080448	002	
WATSON LABS	50MG	A040186	001	Jun 30, 1997
	100MG	A040186	002	Jun 30, 1997
WYETH AYERST	50MG	A080454	001	
MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
MEPERGAN				
WEST-WARD PHARMS INT	25MG/ML;25MG/ML	N011730	001	
MEPHENTERMINE SULFATE				
INJECTABLE;INJECTION				
WYAMINE SULFATE				
BAXTER HLTHCARE CORP	EQ 15MG BASE/ML	N008248	002	
	EQ 30MG BASE/ML	N008248	001	
MEPHENYTOIN				
TABLET;ORAL				
MESANTOIN				
+ NOVARTIS	100MG **	N006008	001	
MEPIVACAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
ARESTOCAINE HYDROCHLORIDE				
SOLVAY	3%	A084777	002	Apr 18, 1982
CARBOCAINE				
+ EASTMAN KODAK	3% **	N012125	003	
ISOCAINE HYDROCHLORIDE				
SEPTODONT INC	3%	A080925	001	
MEPIVACAINE HYDROCHLORIDE				
BELMORA LLC	3%	A083559	001	
HOSPIRA INC	3%	A040806	001	Apr 28, 2008
INTL MEDICATION SYS	1%	A087509	001	Oct 05, 1982
WATSON LABS	1%	A088769	001	Nov 20, 1984
	2%	A088770	001	Nov 20, 1984
POLOCAINE				
DENTSPLY PHARM	3%	A088653	001	Aug 21, 1984
MEPREDNISONE				
TABLET;ORAL				
BETAPAR				
SCHERING	4MG	N016053	002	
MEPROBAMATE				
CAPSULE;ORAL				
EQUANIL				
WYETH AYERST	400MG	N012455	002	
CAPSULE, EXTENDED RELEASE;ORAL				
MEPROSPAN				
MEDPOINTE PHARM HLC	200MG	N011284	001	
	400MG	N011284	002	
TABLET;ORAL				
AMOSENE				
FERNDALE LABS	400MG	A084030	001	
BAMATE				
ALRA	200MG	A080380	001	
	400MG	A080380	002	
EQUANIL				
WYETH AYERST	200MG	N010028	005	
	400MG	N010028	004	
MEPRIAM				
TEVA	400MG	N016069	001	
MEPROBAMATE				
AUROLIFE PHARMA LLC	400MG	A080655	001	
BARR	600MG	A084230	001	
ELKINS SINN	200MG	N015426	002	
	400MG	N015426	001	

MEPROBAMATE

TABLET;ORAL

MEPROBAMATE

	HEATHER	400MG	N016928	003	
		600MG	A084329	001	
	IMPAX LABS	200MG	N014322	002	
		400MG	N014322	001	
	IVAX SUB TEVA PHARMS	200MG	N015438	001	
		400MG	N015438	002	
		600MG	A084181	001	
	IVC INDS	400MG	A084153	001	
	LANNETT	200MG	N014882	002	
		400MG	N014882	001	
	LEDERLE	400MG	A086299	001	
	LEE KM	400MG	A089538	001	Nov 25, 1987
	MALLARD	400MG	N015072	002	
	MK LABS	200MG	N014368	004	
		400MG	N014368	002	
	MYLAN	400MG	A083618	001	
	NEXGEN PHARMA INC	200MG	A084220	001	
		400MG	A084589	001	
	PARKE DAVIS	200MG	A084744	001	
		400MG	A084744	002	
	PERRIGO	200MG	A084546	001	
		400MG	A084547	001	
	PHARMAVITE	400MG	A084438	001	
	PUREPAC PHARM	200MG	A084804	001	
		400MG	A084804	002	
	PVT FORM	400MG	N014601	001	
	ROXANE	600MG	A084332	001	
	SANDOZ	200MG	N014547	002	
		400MG	N014547	001	
	SCHERER LABS	400MG	A083343	001	
	SOLVAY	200MG	A084435	001	
	STANLABS PHARM	200MG	N014474	002	
		400MG	N014474	004	
	SUN PHARM INDUSTRIES	200MG	A080699	001	
		400MG	A080699	002	
	TABLICAPS	400MG	A083494	001	
	TARO	200MG	A200998	001	May 23, 2011
		400MG	A200998	002	May 23, 2011
	USL PHARMA	200MG	A087825	001	Mar 18, 1982
		400MG	A087826	001	Mar 18, 1982
	VALEANT PHARM INTL	200MG	N015139	006	
		400MG	N015139	005	
	VANGARD	400MG	A088011	001	Jul 14, 1982
	WATSON LABS	200MG	A085720	001	
		400MG	A085721	001	
		600MG	A084274	001	
		600MG	A085719	001	
	WEST WARD	200MG	N015417	003	
		400MG	N015417	002	
	WHITEWORTH TOWN PLSN	200MG	A083830	001	
		400MG	A083442	001	
MILTOWN					
+	MEDPOINTE PHARM HLC	200MG **	N009698	004	
+		400MG **	N009698	002	
		600MG	A083919	001	
NEURAMATE					
	HALSEY	200MG	N014359	002	
		400MG	N014359	001	
TRANMEP					
	SOLVAY	400MG	A084369	001	
		400MG	N016249	001	

MEQUINOL; TRETINOIN
SOLUTION;TOPICAL
SOLAGE
AQUA PHARMS 2%;0.01% N020922 001 Dec 10, 1999

MEROPENEM
INJECTABLE;INJECTION
MEROPENEM
SANDOZ 500MG/VIAL A091201 001 Mar 29, 2011
1GM/VIAL A091201 002 Mar 29, 2011

MERSALYL SODIUM; THEOPHYLLINE
INJECTABLE;INJECTION
MERSALYL-THEOPHYLLINE
WATSON LABS 100MG/ML;50MG/ML A084875 001

MESALAMINE
ENEMA;RECTAL
MESALAMINE
G AND W LABS INC 4GM/60ML A076841 001 Sep 30, 2004
SUPPOSITORY;RECTAL
CANASA
ALLERGAN SALES LLC 500MG N021252 001 Jan 05, 2001
ROWASA
\+ MEDA PHARMS 500MG ** N019919 001 Dec 18, 1990
TABLET, DELAYED RELEASE;ORAL
ASACOL
APIL 400MG N019651 001 Jan 31, 1992

MESNA
INJECTABLE;INTRAVENOUS
MESNA
MYLAN INSTITUTIONAL 100MG/ML A076488 001 Mar 08, 2012
MYLAN LABS LTD 100MG/ML A203364 001 Jul 18, 2014

MESORIDAZINE BESYLATE
CONCENTRATE;ORAL
SERENTIL
NOVARTIS EQ 25MG BASE/ML N016997 001
INJECTABLE;INJECTION
SERENTIL
NOVARTIS EQ 25MG BASE/ML N016775 001
TABLET;ORAL
SERENTIL
NOVARTIS EQ 10MG BASE N016774 001
EQ 25MG BASE N016774 002
EQ 50MG BASE N016774 003
EQ 100MG BASE N016774 004

MESTRANOL; NORETHINDRONE
TABLET;ORAL-20
NORINYL
ACTAVIS LABS UT INC 0.1MG;2MG N013625 004
TABLET;ORAL-21
NORETHIN 1/50M-21
WATSON LABS 0.05MG;1MG A071539 001 Apr 12, 1988
NORETHINDRONE AND MESTRANOL
WATSON LABS 0.05MG;1MG A070758 001 Jul 01, 1988
NORINYL 1+50 21-DAY
ACTAVIS LABS UT INC 0.05MG;1MG N013625 002
NORINYL 1+80 21-DAY
GD SEARLE LLC 0.08MG;1MG N016724 001
ORTHO-NOVUM 1/50 21
ORTHO MCNEIL PHARM 0.05MG;1MG N012728 004
ORTHO-NOVUM 1/80 21
ORTHO MCNEIL PHARM 0.08MG;1MG N016715 001
ORTHO-NOVUM 10-21
ORTHO MCNEIL PHARM 0.06MG;10MG N012728 001
ORTHO-NOVUM 2-21
ORTHO MCNEIL PHARM 0.1MG;2MG N012728 005

MESTRANOL; NORETHINDRONE				
TABLET;ORAL-28				
NORETHIN 1/50M-28				
WATSON LABS	0.05MG;1MG	A071540	001	Apr 12, 1988
NORETHINDRONE AND MESTRANOL				
WATSON LABS	0.05MG;1MG	A070759	001	Jul 01, 1988
NORINYL 1+80 28-DAY				
GD SEARLE LLC	0.08MG;1MG	N016725	001	
ORTHO-NOVUM 1/50 28				
ORTHO MCNEIL JANSSEN	0.05MG;1MG	N016709	001	
ORTHO-NOVUM 1/80 28				
ORTHO MCNEIL PHARM	0.08MG;1MG	N016715	002	
MESTRANOL; NORETHYNODREL				
TABLET;ORAL				
ENOVID				
GD SEARLE LLC	0.075MG;5MG	N010976	008	
	0.15MG;9.85MG	N010976	005	
TABLET;ORAL-20				
ENOVID				
GD SEARLE LLC	0.075MG;5MG	N010976	004	
ENOVID-E				
GD SEARLE LLC	0.1MG;2.5MG	N010976	006	
TABLET;ORAL-21				
ENOVID-E 21				
GD SEARLE LLC	0.1MG;2.5MG	N010976	007	
METAPROTERENOL SULFATE				
AEROSOL, METERED;INHALATION				
ALUPENT				
BOEHRINGER INGELHEIM	0.65MG/INH	N016402	001	
SOLUTION;INHALATION				
ALUPENT				
BOEHRINGER INGELHEIM	0.4%	N018761	002	Oct 10, 1986
	0.6%	N018761	001	Jun 30, 1983
	5%	N017659	001	
METAPROTERENOL SULFATE				
APOTEX INC	0.4%	A075402	001	Feb 28, 2001
	0.6%	A075403	001	Feb 28, 2001
ASTRAZENECA	0.4%	A071275	001	Jul 27, 1988
	0.6%	A071018	001	Jul 27, 1988
DEY	0.33%	A071806	001	Aug 05, 1988
	0.5%	A071805	001	Aug 05, 1988
	5%	A070805	001	Aug 17, 1987
MYLAN SPECIALITY LP	0.4%	A071786	001	Aug 05, 1988
	0.6%	A070804	001	Aug 17, 1987
NEPHRON	0.4%	A071855	001	Jul 14, 1988
	0.6%	A071726	001	Jul 14, 1988
WOCKHARDT	0.4%	A075586	001	May 30, 2002
	0.6%	A075586	002	May 30, 2002
	5%	A072190	001	Jun 07, 1988
PROMETA				
MURO	5%	A073340	001	Mar 30, 1992
SYRUP;ORAL				
ALUPENT				
BOEHRINGER INGELHEIM	10MG/5ML	N017571	001	
METAPROTERENOL SULFATE				
APOTEX INC	10MG/5ML	A075235	001	Jan 27, 2000
G AND W LABS INC	10MG/5ML	A072761	001	Feb 27, 1992
	10MG/5ML	A073034	001	Aug 30, 1991
MORTON GROVE	10MG/5ML	A071656	001	Oct 13, 1987
WOCKHARDT	10MG/5ML	A074702	001	Mar 24, 1997
PROMETA				
MURO	10MG/5ML	A072023	001	Sep 15, 1988
TABLET;ORAL				
ALUPENT				
BOEHRINGER INGELHEIM	10MG	N015874	002	
	20MG	N015874	001	
METAPROTERENOL SULFATE				
AM THERAP	10MG	A072054	001	Jun 23, 1988

METAPROTERENOL SULFATE				
TABLET;ORAL				
METAPROTERENOL SULFATE				
	20MG		A072055 001	Jun 23, 1988
TEVA	10MG		A072519 001	Mar 30, 1990
	20MG		A072520 001	Mar 30, 1990
USL PHARMA	10MG		A071013 001	Jan 25, 1988
	20MG		A071014 001	Jan 25, 1988
WATSON LABS	10MG		A073013 001	Jan 31, 1991
	20MG		A072795 001	Jan 31, 1991
METARAMINOL BITARTRATE				
INJECTABLE;INJECTION				
ARAMINE				
+ MERCK	EQ 10MG BASE/ML **		N009509 002	Dec 22, 1987
METARAMINOL BITARTRATE				
ABRAXIS PHARM	EQ 10MG BASE/ML		A080431 001	
ELKINS SINN	EQ 10MG BASE/ML		A083363 001	
FRESENIUS KABI USA	EQ 10MG BASE/ML		A080722 001	
GD SEARLE LLC	EQ 10MG BASE/ML		A086418 001	
	EQ 20MG BASE/ML		A086418 002	
METAXALONE				
TABLET;ORAL				
METAXALONE				
+ PRIMUS PHARMS	640MG **		N022503 001	Jun 01, 2015
SKELAXIN				
+ KING PHARMS	400MG **		N013217 001	
METFORMIN HYDROCHLORIDE				
TABLET;ORAL				
GLUCOPHAGE				
+ BRISTOL MYERS SQUIBB	625MG **		N020357 003	Nov 05, 1998
+	750MG **		N020357 004	Nov 05, 1998
METFORMIN HYDROCHLORIDE				
BARR	500MG		A075971 001	Jan 25, 2002
	850MG		A075971 002	Jan 25, 2002
	1GM		A075971 003	Jan 25, 2002
IPCA LABS LTD	500MG		A078422 001	Aug 06, 2007
	850MG		A078422 002	Aug 06, 2007
	1GM		A078422 003	Aug 06, 2007
IVAX SUB TEVA PHARMS	500MG		A075975 001	Jan 24, 2002
	625MG		A075975 004	Jan 24, 2002
	750MG		A075975 005	Jan 24, 2002
	850MG		A075975 002	Jan 24, 2002
	1GM		A075975 003	Jan 24, 2002
MYLAN PHARMS INC	500MG		A075969 001	Jan 29, 2002
	850MG		A075969 002	Jan 29, 2002
	1GM		A075969 003	Jan 29, 2002
PROVIDENT PHARM	500MG		A077853 001	Jul 28, 2006
	850MG		A077853 002	Jul 28, 2006
	1GM		A077853 003	Jul 28, 2006
SANDOZ	500MG		A075985 001	Jan 25, 2002
	850MG		A075985 002	Jan 25, 2002
	1GM		A075985 003	Jan 25, 2002
TEVA	500MG		A076328 001	Dec 16, 2002
	850MG		A076328 002	Dec 16, 2002
	1GM		A076328 003	Dec 16, 2002
WATSON LABS	500MG		A075979 001	Jan 24, 2002
	850MG		A075979 002	Jan 24, 2002
	1GM		A075979 003	Jan 24, 2002
WATSON LABS FLORIDA	500MG		A075961 001	Jan 25, 2002
	850MG		A075961 002	Jan 25, 2002
	1GM		A075961 003	Jan 25, 2002
TABLET, EXTENDED RELEASE;ORAL				
METFORMIN HYDROCHLORIDE				
ACTAVIS ELIZABETH	500MG		A076450 001	Oct 01, 2004
	750MG		A076878 001	Apr 13, 2005
BARR	500MG		A076496 001	Nov 25, 2005
IMPAX LABS	500MG		A076249 001	Jul 30, 2004
	750MG		A076985 001	Sep 13, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

METFORMIN HYDROCHLORIDE				
TABLET, EXTENDED RELEASE;ORAL				
METFORMIN HYDROCHLORIDE				
IVAX SUB TEVA PHARMS	500MG		A076545 001	Dec 01, 2003
MYLAN	500MG		A076650 001	Sep 13, 2005
	750MG		A077113 001	Sep 08, 2005
RANBAXY LABS LTD	500MG		A076413 001	Jun 18, 2004
	750MG		A077211 001	Jun 29, 2005
SANDOZ	500MG		A076223 001	Dec 14, 2004
SUN PHARM INDUSTRIES	500MG		A077124 001	Dec 21, 2005
TORRENT PHARMS LTD	750MG		A079226 001	Feb 18, 2010
WATSON LABS INC	500MG		A076818 001	Dec 14, 2004
METFORMIN HYDROCHLORIDE; REPAGLINIDE				
TABLET;ORAL				
PRANDIMET				
+ NOVO NORDISK INC	500MG;1MG		N022386 001	Jun 23, 2008
+	500MG;2MG		N022386 002	Jun 23, 2008
REPAGLINIDE AND METFORMIN HYDROCHLORIDE				
LUPIN LTD	500MG;1MG		A200624 001	Jul 15, 2015
	500MG;2MG		A200624 002	Jul 15, 2015
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE				
TABLET;ORAL				
AVANDAMET				
+ SB PHARMCO	500MG;EQ 1MG BASE **		N021410 001	Oct 10, 2002
+	500MG;EQ 2MG BASE **		N021410 002	Oct 10, 2002
+	500MG;EQ 4MG BASE **		N021410 003	Oct 10, 2002
+	1GM;EQ 2MG BASE **		N021410 004	Aug 25, 2003
+	1GM;EQ 4MG BASE **		N021410 005	Aug 25, 2003
ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE				
TEVA	500MG;EQ 2MG BASE		A077337 001	May 07, 2014
	500MG;EQ 1MG BASE		A077337 005	May 19, 2017
	500MG;EQ 4MG BASE		A077337 002	May 07, 2014
	1GM;EQ 4MG BASE		A077337 004	May 07, 2014
	1GM;EQ 2MG BASE		A077337 003	May 07, 2014
METHACHOLINE CHLORIDE				
FOR SOLUTION;INHALATION				
PROVOCHOLINE				
+ METHAPHARM	1600MG/VIAL		N019193 002	Aug 29, 2016
METHACYCLINE HYDROCHLORIDE				
CAPSULE;ORAL				
RONDOMYCIN				
MEDPOINTE PHARM HLC	EQ 140MG BASE		A060641 001	
	EQ 280MG BASE		A060641 002	
SYRUP;ORAL				
RONDOMYCIN				
MEDPOINTE PHARM HLC	EQ 70MG BASE/5ML		A060641 003	
METHADONE HYDROCHLORIDE				
POWDER;FOR RX COMPOUNDING				
METHADONE HYDROCHLORIDE				
MALLINCKRODT INC	50GM/BOT		N006383 002	
	100GM/BOT		N006383 003	
	500GM/BOT		N006383 004	
SYRUP;ORAL				
DOLOPHINE HYDROCHLORIDE				
WEST-WARD PHARMS INT	10MG/30ML		N006134 004	
TABLET;ORAL				
METHADONE HYDROCHLORIDE				
ROXANE	5MG		A088108 001	Mar 08, 1983
	10MG		A088109 001	Mar 08, 1983
	40MG		A074081 001	Apr 28, 1995
VISTAPHARM	5MG		A040241 001	May 29, 1998
TABLET, DISPERSIBLE;ORAL				
WESTADONE				
SANDOZ	2.5MG		N017108 001	

METHADONE HYDROCHLORIDE				
TABLET, EFFERVESCENT;ORAL				
WESTADONE				
SANDOZ	5MG		N017108 002	
	10MG		N017108 003	
	40MG		N017108 004	
METHAMPHETAMINE HYDROCHLORIDE				
TABLET;ORAL				
METHAMPEX				
TEVA	10MG		A083889 001	
METHAMPHETAMINE HYDROCHLORIDE				
ABLE	5MG		A040529 001	Feb 25, 2004
REXAR	5MG		A084931 001	
	10MG		A084931 002	
TEVA	5MG		A086359 001	
TABLET, EXTENDED RELEASE;ORAL				
DESOXYN				
RECORDATI RARE	5MG		N005378 004	
	10MG		N005378 003	
	15MG		N005378 005	
METHANTHELINE BROMIDE				
TABLET;ORAL				
BANTHINE				
SHIRE	50MG		N007390 001	
METHARBITAL				
TABLET;ORAL				
GEMONIL				
ABBVIE	100MG		N008322 001	
METHAZOLAMIDE				
TABLET;ORAL				
METHAZOLAMIDE				
APPLIED ANAL	25MG		A040011 001	Jul 17, 1997
	50MG		A040011 002	Jul 17, 1997
SANDOZ	25MG		A040102 001	Aug 28, 1996
	50MG		A040102 002	Aug 28, 1996
NEPTAZANE				
+ LEDERLE	25MG **		N011721 002	Nov 25, 1991
+	50MG **		N011721 001	
METHDILAZINE				
TABLET, CHEWABLE;ORAL				
TACARYL				
WESTWOOD SQUIBB	3.6MG		N011950 009	
METHDILAZINE HYDROCHLORIDE				
SYRUP;ORAL				
METHDILAZINE HYDROCHLORIDE				
ALPHARMA US PHARMS	4MG/5ML		A087122 001	
TACARYL				
WESTWOOD SQUIBB	4MG/5ML		N011950 007	
TABLET;ORAL				
TACARYL				
WESTWOOD SQUIBB	8MG		N011950 006	
METHICILLIN SODIUM				
INJECTABLE;INJECTION				
STAPHCILLIN				
APOTHECON	EQ 900MG BASE/VIAL		A061449 001	
	EQ 900MG BASE/VIAL		N050117 001	
	EQ 3.6GM BASE/VIAL		A061449 002	
	EQ 3.6GM BASE/VIAL		N050117 002	
	EQ 5.4GM BASE/VIAL		A061449 003	
	EQ 5.4GM BASE/VIAL		N050117 003	

METHIMAZOLE				
TABLET;ORAL				
METHIMAZOLE				
	ECI PHARMS LLC	15MG	A040619 003	Jul 12, 2005
		20MG	A040547 004	Feb 18, 2005
	MYLAN	20MG	A040350 003	Jun 07, 2001
TAPAZOLE				
+	KING PHARMS	5MG **	N007517 002	
+		10MG **	N007517 004	
METHIXENE HYDROCHLORIDE				
TABLET;ORAL				
TREST				
	NOVARTIS	1MG	N013420 001	
METHOCARBAMOL				
INJECTABLE;INJECTION				
METHOCARBAMOL				
	MARSAM PHARMS LLC	100MG/ML	A089849 001	Dec 27, 1991
	WATSON LABS	100MG/ML	A086459 001	
TABLET;ORAL				
DELAXIN				
	FERNDALE LABS	500MG	A085454 001	
FORBAXIN				
	FOREST LABS	750MG	A085136 001	
METHOCARBAMOL				
	ABLE	500MG	A040413 001	Mar 17, 2003
		750MG	A040413 002	Mar 17, 2003
	AM THERAP	500MG	A089417 001	Feb 11, 1987
		750MG	A089418 001	Feb 11, 1987
	ASCOT	500MG	A087660 001	Oct 27, 1982
		750MG	A087661 001	Oct 27, 1982
	CLONMEL HLTHCARE	500MG	A085961 001	
		750MG	A085963 001	
	FOSUN PHARMA	500MG	A084616 001	
		750MG	A084615 001	
	HEATHER	500MG	A084675 001	
		750MG	A084924 001	
	IMPAX LABS	500MG	A084927 001	
		750MG	A084928 001	
	INWOOD LABS	500MG	A085137 001	
	IVAX SUB TEVA PHARMS	500MG	A084648 001	
		750MG	A084649 001	
	KV PHARM	500MG	A085660 001	
		750MG	A085658 001	
	LANNETT CO INC	500MG	A084756 002	Mar 31, 2003
		750MG	A084756 001	
	MYLAN	500MG	A084259 001	
		750MG	A084323 001	
	NYLOS	750MG	A085033 001	
	PIONEER PHARMS	500MG	A088731 001	Dec 13, 1985
		750MG	A089082 001	Dec 13, 1985
	PURACAP PHARM	500MG	A084231 002	
		750MG	A084471 001	
	PUREPAC PHARM	500MG	A085718 001	
		750MG	A085718 002	
	ROXANE	500MG	A088646 001	Feb 29, 1984
		750MG	A088647 001	Feb 29, 1984
	SANDOZ	500MG	A087283 001	
		750MG	A087282 001	
	SOLVAY	500MG	A084448 001	
		750MG	A084449 001	
	SUN PHARM INDUSTRIES	500MG	A084488 001	
		750MG	A084486 001	
	SUPERPHARM	500MG	A087589 001	Jan 22, 1982
		750MG	A087590 001	Jan 22, 1982
	TABLICAPS	500MG	A084846 001	
	UPSHER SMITH	500MG	A087453 001	
		750MG	A087454 001	
	WATSON LABS	500MG	A083605 001	

METHOCARBAMOL					
TABLET;ORAL					
METHOCARBAMOL					
		500MG	A085180	001	
		750MG	A083605	002	
		750MG	A085192	001	
METHOHEXITAL SODIUM					
INJECTABLE;INJECTION					
BREVITAL SODIUM					
	PAR STERILE PRODUCTS	200MG/VIAL	N011559	004	Dec 21, 2012
		5GM/VIAL	N011559	003	
METHOTREXATE					
SOLUTION;SUBCUTANEOUS					
OTREXUP					
+	ANTARES PHARMA INC	7.5MG/0.4ML (7.5MG/0.4ML)	N204824	005	Nov 07, 2014
OTREXUP PFS					
+	ANTARES PHARMA INC	10MG/0.4ML (10MG/0.4ML)	N204824	009	May 31, 2017
+		15MG/0.6ML (15MG/0.6ML)	N204824	010	May 31, 2017
+		17.5MG/0.7ML (17.5MG/0.7ML)	N204824	011	May 31, 2017
+		20MG/0.8ML (20MG/0.8ML)	N204824	012	May 31, 2017
+		22.5MG/0.9ML (22.5MG/0.9ML)	N204824	013	May 31, 2017
+		25MG/ML (25MG/ML)	N204824	014	May 31, 2017
RASUVO					
+	MEDAC PHARMA INC	27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014
METHOTREXATE SODIUM					
INJECTABLE;INJECTION					
ABITREXATE					
	ABIC	EQ 25MG BASE/ML	A089161	001	Mar 10, 1987
		EQ 50MG BASE/VIAL	A089354	001	Jul 17, 1987
		EQ 100MG BASE/VIAL	A089355	001	Jul 17, 1987
		EQ 250MG BASE/VIAL	A089356	001	Jul 17, 1987
FOLEX					
	PHARMACIA AND UPJOHN	EQ 25MG BASE/VIAL	A087695	001	Apr 08, 1983
		EQ 50MG BASE/VIAL	A087695	002	Apr 08, 1983
		EQ 100MG BASE/VIAL	A087695	003	Apr 08, 1983
		EQ 250MG BASE/VIAL	A088954	001	Oct 24, 1985
FOLEX PFS					
	PHARMACIA AND UPJOHN	EQ 25MG BASE/ML	A081242	001	Aug 23, 1991
		EQ 25MG BASE/ML	A089180	001	Jan 03, 1986
METHOTREXATE LPF					
	HOSPIRA	EQ 25MG BASE/ML	N011719	007	Mar 31, 1982
METHOTREXATE PRESERVATIVE FREE					
	HOSPIRA	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N011719	014	Apr 13, 2005
+		EQ 500MG BASE/20ML (EQ 25MG BASE/ML) **	N011719	013	Apr 13, 2005
		EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)	N011719	011	Apr 13, 2005
METHOTREXATE SODIUM					
	ABRAXIS PHARM	EQ 2.5MG BASE/ML	A089323	001	Jun 13, 1986
		EQ 20MG BASE/VIAL	A088935	001	Oct 11, 1985
		EQ 25MG BASE/ML	A089263	001	Jun 13, 1986
		EQ 25MG BASE/ML	A089322	001	Jun 13, 1986
		EQ 50MG BASE/VIAL	A088936	001	Oct 11, 1985
		EQ 100MG BASE/VIAL	A088937	001	Oct 11, 1985
	FRESENIUS KABI USA	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040263	002	Feb 26, 1999
	HOSPIRA	EQ 2.5MG BASE/ML	N011719	004	
		EQ 20MG BASE/VIAL	N011719	001	
		EQ 25MG BASE/ML	N011719	005	
		EQ 50MG BASE/VIAL	N011719	003	
		EQ 100MG BASE/VIAL	N011719	006	
	NORBROOK	EQ 25MG BASE/ML	A088648	001	May 09, 1986
	PHARMACHEMIE USA	EQ 25MG BASE/ML	A089158	001	Jul 08, 1988
METHOTREXATE SODIUM PRESERVATIVE FREE					
	HOSPIRA	EQ 1GM BASE/VIAL	N011719	009	Apr 07, 1988
MEXATE					
	BRISTOL	EQ 20MG BASE/VIAL	A086358	001	
		EQ 50MG BASE/VIAL	A086358	002	
		EQ 100MG BASE/VIAL	A086358	003	
		EQ 250MG BASE/VIAL	A086358	004	

METHOTREXATE SODIUM				
INJECTABLE;INJECTION				
MEXATE-AQ				
BRISTOL MYERS	EQ 25MG BASE/ML	A088760	001	Feb 14, 1985
MEXATE-AQ PRESERVED				
BRISTOL MYERS SQUIBB	EQ 25MG BASE/ML	A089887	001	Apr 14, 1989
TABLET;ORAL				
METHOTREXATE SODIUM				
DURAMED PHARMS BARR	EQ 2.5MG BASE	A040233	001	Jun 17, 1999
METHOXAMINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
VASOXYL				
GLAXOSMITHKLINE	10MG/ML	N006772	002	
	20MG/ML	N006772	001	
METHOXSALEN				
CAPSULE;ORAL				
8-MOP				
+ VALEANT PHARM INTL	10MG	N009048	001	
METHOXSALEN				
ANI PHARMS INC	10MG	A087781	001	Jun 08, 1982
LOTION;TOPICAL				
OXSORALEN				
+ VALEANT PHARM INTL	1%	N009048	002	
METHSCOPOLAMINE BROMIDE				
TABLET;ORAL				
METHSCOPOLAMINE BROMIDE				
PVT FORM	2.5MG	A080970	001	
PAMINE				
FOUGERA PHARMS	2.5MG **	N008848	001	
PAMINE FORTE				
FOUGERA PHARMS	5MG **	N008848	002	Mar 25, 2003
METHSUXIMIDE				
CAPSULE;ORAL				
CELONTIN				
+ PARKE DAVIS	150MG	N010596	007	
METHYCLOTHIAZIDE				
TABLET;ORAL				
AQUATENSEN				
MEDPOINTE PHARM HLC	5MG	N017364	001	
ENDURON				
+ ABBVIE	2.5MG **	N012524	001	
+	5MG **	N012524	004	
METHYCLOTHIAZIDE				
IVAX PHARMS	2.5MG	A087913	001	Jun 03, 1982
	5MG	A087786	001	May 18, 1982
MYLAN	2.5MG	A087671	001	Aug 17, 1982
PAR PHARM	2.5MG	A089135	001	Feb 12, 1986
	5MG	A089136	001	Feb 12, 1986
USL PHARMA	5MG	A088745	001	Mar 21, 1985
WATSON LABS	2.5MG	A085487	001	Mar 11, 1982
	2.5MG	A088750	001	Sep 06, 1984
	5MG	A085476	001	Mar 11, 1982
	5MG	A088724	001	Sep 06, 1984
YAOPHARMA CO LTD	2.5MG	A089835	001	Aug 18, 1988
	5MG	A089837	001	Aug 18, 1988
METHYCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE				
TABLET;ORAL				
EUTRON				
ABBOTT	5MG;25MG	N016047	001	
METHYCLOTHIAZIDE; RESERPINE				
TABLET;ORAL				
DIUTENSEN-R				
MEDPOINTE PHARM HLC	2.5MG;0.1MG	N012708	005	

METHYL AMINOLEVULINATE HYDROCHLORIDE				
CREAM;TOPICAL				
METVIXIA				
GALDERMA LABS LP	EQ 16.8% BASE	N021415	001	Jul 27, 2004
METHYLDOPA				
SUSPENSION;ORAL				
ALDOMET				
MERCK	250MG/5ML	N018389	001	
TABLET;ORAL				
ALDOMET				
+ MERCK	125MG **	N013400	003	
+	250MG **	N013400	001	
+	500MG **	N013400	002	
METHYLDOPA				
ACCORD HLTHCARE	125MG	A070070	003	Oct 15, 1985
DURAMED PHARMS BARR	250MG	A071006	001	Dec 16, 1986
	500MG	A071009	001	Dec 16, 1986
HALSEY	125MG	A071751	001	Mar 28, 1988
	250MG	A071752	001	Mar 28, 1988
	500MG	A071753	001	Mar 28, 1988
PAR PHARM	125MG	A070535	001	Jan 02, 1987
	250MG	A070536	001	Jan 02, 1987
	500MG	A070537	001	Jan 02, 1987
PARKE DAVIS	125MG	A070331	001	Apr 15, 1986
	250MG	A070332	001	Apr 15, 1986
	500MG	A070333	001	Apr 15, 1986
PLIVA	125MG	A072126	001	Jul 07, 1988
	250MG	A072127	001	Jul 07, 1988
	500MG	A072128	001	Jul 07, 1988
PUREPAC PHARM	125MG	A070749	001	Feb 07, 1986
	250MG	A070750	001	Feb 07, 1986
	500MG	A070452	001	Feb 07, 1986
ROXANE	125MG	A070192	001	Apr 25, 1986
	250MG	A070193	001	Apr 25, 1986
	500MG	A070194	001	Apr 25, 1986
SUN PHARM INDUSTRIES	125MG	A070073	001	Oct 09, 1986
	250MG	A070060	001	Oct 09, 1986
	500MG	A070074	001	Oct 09, 1986
SUPERPHARM	250MG	A070669	001	Jun 23, 1989
	500MG	A070670	001	Jun 23, 1989
TEVA	125MG	A071105	001	Dec 05, 1986
	250MG	A071106	001	Dec 05, 1986
	500MG	A071067	001	Dec 05, 1986
WATSON LABS	125MG	A070245	001	Feb 25, 1986
	125MG	A070260	001	Jun 24, 1985
	250MG	A070246	001	Feb 25, 1986
	250MG	A070261	001	Jun 24, 1985
	250MG	A070703	001	Jun 06, 1986
	500MG	A070247	001	Feb 25, 1986
	500MG	A070262	001	Jun 24, 1985
YAOPHARMA CO LTD	125MG	A071700	001	Mar 02, 1988
	250MG	N018934	001	Jun 29, 1984
	500MG	N018934	002	Jun 29, 1984
METHYLDOPATE HYDROCHLORIDE				
INJECTABLE;INJECTION				
ALDOMET				
+ MERCK	50MG/ML **	N013401	001	
METHYLDOPATE HYDROCHLORIDE				
ABRAXIS PHARM	50MG/ML	A070652	001	Jun 03, 1986
BAXTER HLTHCARE	50MG/ML	A070291	001	Jul 01, 1986
HOSPIRA	50MG/ML	A070691	001	Jun 19, 1987
	50MG/ML	A070698	001	Jun 15, 1987
	50MG/ML	A070699	001	Jun 15, 1987
	50MG/ML	A070849	001	Jun 19, 1987
MARSAM PHARMS LLC	50MG/ML	A071812	001	Dec 22, 1987
SMITH AND NEPHEW	50MG/ML	A070841	001	Jan 02, 1987
TEVA PARENTERAL	50MG/ML	A072974	001	Nov 22, 1991

METHYLERGONOVINE MALEATE					
TABLET;ORAL					
METHERGINE					
+	EDISON THERAPS LLC	0.2MG **	N006035	003	
METHYLPHENIDATE HYDROCHLORIDE					
CAPSULE, EXTENDED RELEASE;ORAL					
RITALIN LA					
+	NOVARTIS	60MG **	N021284	005	Oct 27, 2014
TABLET;ORAL					
METHYLPHENIDATE HYDROCHLORIDE					
	ABLE	5MG	A040404	001	Mar 29, 2001
		10MG	A040404	002	Mar 29, 2001
		20MG	A040404	003	Mar 29, 2001
	ACTAVIS ELIZABETH	5MG	A040321	001	Feb 05, 2002
		10MG	A040321	002	Feb 05, 2002
		20MG	A040321	003	Feb 05, 2002
TABLET, CHEWABLE;ORAL					
METHYLIN					
+	SPECGX LLC	2.5MG **	N021475	001	Apr 15, 2003
+		5MG **	N021475	002	Apr 15, 2003
+		10MG **	N021475	003	Apr 15, 2003
TABLET, EXTENDED RELEASE;ORAL					
METADATE ER					
	LANNETT CO INC	10MG	A040306	001	Oct 20, 1999
METHYLPHENIDATE HYDROCHLORIDE					
	ABLE	20MG	A076032	001	May 09, 2001
	ACTAVIS ELIZABETH	20MG	A075450	001	Dec 21, 2001
	WATSON LABS	20MG	A040410	001	Feb 09, 2001
RITALIN-SR					
+	NOVARTIS	20MG	N018029	001	Mar 30, 1982
METHYLPREDNISOLONE					
TABLET;ORAL					
MEDROL					
	PHARMACIA AND UPJOHN	24MG	N011153	005	
METHYLPREDNISOLONE					
	HEATHER	4MG	A085650	001	
	PAR PHARM	16MG	A089207	001	Apr 25, 1988
		24MG	A089208	001	Apr 25, 1988
		32MG	A089209	001	Apr 25, 1988
	SANDOZ	4MG	A087341	001	
	TIANJIN TIANYAO	4MG	A204072	001	May 14, 2018
	WATSON LABS	4MG	A086161	001	Feb 09, 1982
		16MG	A086159	001	Feb 09, 1982
METHYLPREDNISOLONE ACETATE					
ENEMA;RECTAL					
MEDROL					
	PHARMACIA AND UPJOHN	40MG/BOT	N018102	001	
INJECTABLE;INJECTION					
M-PREDROL					
	BEL MAR	40MG/ML	A086666	001	
		80MG/ML	A087135	001	
METHYLPREDNISOLONE ACETATE					
	AKORN	40MG/ML	A086903	001	Oct 20, 1982
		80MG/ML	A086903	002	Oct 20, 1982
	WATSON LABS	20MG/ML	A085597	001	
		20MG/ML	A087248	001	
		40MG/ML	A085374	001	
		40MG/ML	A085600	001	
		80MG/ML	A085595	001	
		80MG/ML	A086507	001	
OINTMENT;TOPICAL					
MEDROL ACETATE					
	PHARMACIA AND UPJOHN	0.25%	N012421	001	
		1%	N012421	002	

METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE				
CREAM;TOPICAL				
NEO-MEDROL ACETATE				
	PHARMACIA AND UPJOHN	0.25%;EQ 3.5MG BASE/GM	A060611 002	
		1%;EQ 3.5MG BASE/GM	A060611 001	
METHYLPREDNISOLONE SODIUM SUCCINATE				
INJECTABLE;INJECTION				
A-METHAPRED				
	ABBOTT	EQ 40MG BASE/VIAL	A089573 001	Feb 22, 1991
		EQ 125MG BASE/VIAL	A089574 001	Feb 22, 1991
		EQ 500MG BASE/VIAL	A089575 001	Feb 22, 1991
		EQ 1GM BASE/VIAL	A089576 001	Feb 22, 1991
	HOSPIRA	EQ 40MG BASE/VIAL	A085853 001	
		EQ 125MG BASE/VIAL	A085855 001	
		EQ 500MG BASE/VIAL	A085854 001	
		EQ 500MG BASE/VIAL	A089173 001	Aug 18, 1987
		EQ 1GM BASE/VIAL	A085852 001	
		EQ 1GM BASE/VIAL	A089174 001	Aug 18, 1987
	HOSPIRA INC	EQ 40MG BASE/VIAL	A040793 001	Nov 25, 2008
		EQ 125MG BASE/VIAL	A040827 001	Nov 25, 2008
METHYLPREDNISOLONE				
	ELKINS SINN	EQ 125MG BASE/VIAL	A086906 002	
		EQ 500MG BASE/VIAL	A086906 003	
		EQ 1GM BASE/VIAL	A086906 004	
	ORGANON USA INC	EQ 500MG BASE/VIAL	A087535 001	Jun 25, 1982
		EQ 1GM BASE/VIAL	A087535 002	Jun 25, 1982
METHYLPREDNISOLONE SODIUM SUCCINATE				
	ABRAXIS PHARM	EQ 40MG BASE/VIAL	A088676 001	Jun 08, 1984
		EQ 40MG BASE/VIAL	A089143 001	Mar 28, 1986
		EQ 125MG BASE/VIAL	A088677 001	Jun 08, 1984
		EQ 125MG BASE/VIAL	A089144 001	Mar 28, 1986
		EQ 500MG BASE/VIAL	A088678 001	Jun 08, 1984
		EQ 500MG BASE/VIAL	A089186 001	Mar 28, 1986
		EQ 500MG BASE/VIAL	A089187 001	Mar 28, 1986
		EQ 1GM BASE/VIAL	A088679 001	Jun 08, 1984
		EQ 1GM BASE/VIAL	A089188 001	Mar 28, 1986
		EQ 1GM BASE/VIAL	A089189 001	Mar 28, 1986
	BEDFORD LABS	EQ 40MG BASE/VIAL	A040662 001	Feb 21, 2007
		EQ 125MG BASE/VIAL	A040641 002	Feb 21, 2007
		EQ 500MG BASE/VIAL	A040641 003	Feb 21, 2007
		EQ 500MG BASE/VIAL	A040709 001	Feb 21, 2007
		EQ 1GM BASE/VIAL	A040641 004	Feb 21, 2007
		EQ 1GM BASE/VIAL	A040709 002	Feb 21, 2007
	ELKINS SINN	EQ 40MG BASE/VIAL	A086906 001	
	INTL MEDICATION	EQ 40MG BASE/VIAL	A087812 001	Feb 09, 1983
		EQ 125MG BASE/VIAL	A087813 001	Feb 09, 1983
		EQ 500MG BASE/VIAL	A087851 001	Feb 09, 1983
		EQ 1GM BASE/VIAL	A087852 001	Feb 09, 1983
	TEVA PARENTERAL	EQ 125MG BASE/VIAL	A081266 001	Nov 30, 1992
		EQ 500MG BASE/VIAL	A081267 001	Nov 30, 1992
		EQ 1GM BASE/VIAL	A081268 001	Nov 30, 1992
	WATSON LABS	EQ 40MG BASE/VIAL	A086953 001	Jul 22, 1982
		EQ 125MG BASE/VIAL	A087030 001	Jul 22, 1982
		EQ 500MG BASE/VIAL	A088523 001	Jul 24, 1984
		EQ 1GM BASE/VIAL	A088524 001	Jul 24, 1984
METHYLPREDNISOLONE; NEOMYCIN SULFATE				
OINTMENT;OPHTHALMIC				
NEO-MEDROL				
	PHARMACIA AND UPJOHN	0.1%;EQ 3.5MG BASE/GM	A060645 001	
METHYLTESTOSTERONE				
CAPSULE;ORAL				
METHYLTESTOSTERONE				
	HEATHER	10MG	A084967 001	
VIRILON				
	STAR PHARMS FL	10MG	A087750 001	Nov 24, 1982

METHYLTESTOSTERONE				
TABLET;BUCCAL				
ANDROID 5				
	VALEANT PHARM INTL	5MG	A087222 001	
ORETON				
	SCHERING	10MG	A080281 001	
TABLET;BUCCAL, SUBLINGUAL				
METANDREN				
	NOVARTIS	5MG	N003240 004	
		10MG	N003240 001	
		10MG	N003240 005	
		25MG	N003240 003	
METHYLTESTOSTERONE				
	IMPAX LABS	10MG	A084287 001	
	LILLY	10MG	A080256 001	
		25MG	A080256 002	
	PUREPAC PHARM	10MG	A080308 001	
		10MG	A080475 001	
		10MG	A080475 002	
		25MG	A080475 003	
	PVT FORM	5MG	A083836 001	
	TABLICAPS	10MG	A085125 001	
	USL PHARMA	10MG	A080271 001	
TABLET;ORAL				
ANDROID 10				
	VALEANT PHARMS NORTH	10MG	A086450 001	
METHYLTESTOSTERONE				
	IMPAX LABS	25MG	A084310 001	
	INWOOD LABS	10MG	A080839 001	
		25MG	A080973 001	
	KV PHARM	10MG	A084312 001	
	LANNETT	10MG	A087092 001	Nov 05, 1982
		25MG	A087111 001	Jan 27, 1983
	PARKE DAVIS	10MG	A084244 001	
		25MG	A084241 001	
	PUREPAC PHARM	10MG	A080309 001	
		25MG	A080310 001	
	PVT FORM	5MG	A080214 001	
		10MG	A080214 002	
		25MG	A080214 003	
	TABLICAPS	10MG	A080313 001	
		25MG	A085270 001	
	WATSON LABS	10MG	A080933 001	
		25MG	A080931 001	
	WEST WARD	10MG	A084331 001	
		25MG	A084331 002	
		25MG	A084642 001	
ORETON METHYL				
	SCHERING	10MG	N003158 001	
		25MG	N003158 002	
METHYPRYLON				
CAPSULE;ORAL				
NOLUDAR				
	ROCHE	300MG	N009660 008	
ELIXIR;ORAL				
NOLUDAR				
	ROCHE	50MG/5ML	N009660 007	
TABLET;ORAL				
NOLUDAR				
	ROCHE	50MG	N009660 002	
		200MG	N009660 004	
METHYSERGIDE MALEATE				
TABLET;ORAL				
SANSERT				
	NOVARTIS	2MG	N012516 001	

METOCLOPRAMIDE HYDROCHLORIDE				
CONCENTRATE;ORAL				
METOCLOPRAMIDE INTENSOL				
ROXANE	EQ 10MG BASE/ML	A072995	001	Jan 30, 1992
INJECTABLE;INJECTION				
METOCLOPRAMIDE HYDROCHLORIDE				
BEDFORD	EQ 5MG BASE/ML	A072155	001	Mar 30, 1992
	EQ 5MG BASE/ML	A072244	001	Mar 30, 1992
	EQ 5MG BASE/ML	A072247	001	May 18, 1992
HOSPIRA	EQ 5MG BASE/ML	A070505	001	Jun 23, 1989
	EQ 5MG BASE/ML	A070506	001	Jun 22, 1989
	EQ 5MG BASE/ML	A070847	001	Nov 07, 1988
	EQ 5MG BASE/ML	A071291	001	Mar 03, 1989
	EQ 5MG BASE/ML	A071990	001	Jan 18, 1989
	EQ 5MG BASE/ML	A073117	001	Jan 17, 1991
	EQ 5MG BASE/ML	A074147	001	Aug 02, 1996
LYPHOMED	EQ 10MG BASE/2ML	A070293	001	Jan 24, 1986
NORBROOK	EQ 10MG BASE/2ML	A070892	001	Aug 26, 1988
SMITH AND NEPHEW	EQ 5MG BASE/ML	A070623	001	Mar 02, 1987
	EQ 10MG BASE/2ML	A070622	001	Mar 02, 1987
REGLAN				
WEST-WARD PHARMS INT	EQ 5MG BASE/ML	N017862	001	
	EQ 10MG BASE/ML	N017862	004	May 28, 1987
SOLUTION;ORAL				
METOCLOPRAMIDE HYDROCHLORIDE				
ACTAVIS MID ATLANTIC	EQ 5MG BASE/5ML	A071340	001	Aug 18, 1988
LANNETT CO INC	EQ 5MG BASE/5ML	A073680	001	Oct 27, 1992
MORTON GROVE	EQ 5MG BASE/5ML	A070949	001	Mar 06, 1987
PACO	EQ 5MG BASE/5ML	A071665	001	Dec 05, 1988
ROXANE	EQ 5MG BASE/5ML	A072038	001	Dec 05, 1988
TEVA	EQ 5MG BASE/5ML	A070819	001	Jul 10, 1987
	EQ 5MG BASE/5ML	A071315	001	Jun 30, 1993
REGLAN				
+ ROBINS AH	EQ 5MG BASE/5ML **	N018821	001	Mar 25, 1983
TABLET;ORAL				
CLOPRA				
QUANTUM PHARMICS	EQ 5MG BASE	A072384	001	Jun 02, 1988
	EQ 10MG BASE	A070294	001	Jul 29, 1985
CLOPRA-"YELLOW"				
QUANTUM PHARMICS	EQ 10MG BASE	A070632	001	Oct 28, 1985
MAXOLON				
KING PHARMS	EQ 10MG BASE	A070106	001	Mar 04, 1986
METOCLOPRAMIDE HYDROCHLORIDE				
CLONMEL	EQ 10MG BASE	A072639	001	May 09, 1991
HALSEY	EQ 10MG BASE	A070906	001	Oct 28, 1986
INTERPHARM	EQ 10MG BASE	A071213	001	Sep 24, 1986
MUTUAL PHARM	EQ 10MG BASE	A070660	001	Feb 10, 1987
NORTHSTAR HLTHCARE	EQ 5MG BASE	A078374	001	Nov 30, 2007
	EQ 10MG BASE	A078374	002	Nov 30, 2007
PAR PHARM	EQ 10MG BASE	A070342	001	Mar 25, 1986
SANDOZ	EQ 5MG BASE	A072436	001	Jun 22, 1989
	EQ 10MG BASE	A070850	001	Feb 03, 1987
SCHERING	EQ 10MG BASE	A070598	001	Feb 02, 1987
SUN PHARM INDUSTRIES	EQ 5MG BASE	A071536	002	Jan 16, 1997
	EQ 10MG BASE	A071536	001	Apr 28, 1993
SUPERPHARM	EQ 10MG BASE	A070926	001	Jun 26, 1987
USL PHARMA	EQ 10MG BASE	A070339	001	Jul 29, 1985
WATSON LABS	EQ 10MG BASE	A070363	001	Mar 02, 1987
	EQ 10MG BASE	A070453	001	Jun 06, 1986
	EQ 10MG BASE	A070511	001	Jan 22, 1986
	EQ 10MG BASE	A070645	001	May 11, 1987
YAOPHARMA CO LTD	EQ 5MG BASE	A074478	001	Oct 05, 1995
	EQ 10MG BASE	A072215	001	Jan 30, 1990
	EQ 10MG BASE	A074478	002	Oct 05, 1995
TABLET, ORALLY DISINTEGRATING;ORAL				
METOZOLV ODT				
+ SALIX PHARMS	EQ 5MG BASE	N022246	001	Sep 04, 2009
+	EQ 10MG BASE **	N022246	002	Sep 04, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

METOCLOPRAMIDE HYDROCHLORIDE				
TABLET, ORALLY DISINTEGRATING;ORAL				
REGLAN ODT				
MEDA PHARMS	EQ 5MG BASE	N021793	001	Jun 10, 2005
	EQ 10MG BASE	N021793	002	Jun 10, 2005
METOCURINE IODIDE				
INJECTABLE;INJECTION				
METUBINE IODIDE				
LILLY	2MG/ML	N006632	003	
METOLAZONE				
TABLET;ORAL				
DIULO				
GD SEARLE LLC	2.5MG	N018535	001	
	5MG	N018535	002	
	10MG	N018535	003	
METOLAZONE				
ROXANE	10MG	A076482	002	Apr 29, 2004
TEVA	2.5MG	A076600	001	Jan 06, 2004
	5MG	A076833	001	Mar 01, 2004
	10MG	A075543	003	Dec 24, 2003
WATSON LABS	10MG	A076891	001	Jul 21, 2004
MYKROX				
LANNETT CO INC	0.5MG	N019532	001	Oct 30, 1987
METOPROLOL FUMARATE				
TABLET, EXTENDED RELEASE;ORAL				
LOPRESSOR				
NOVARTIS	EQ 100MG TARTRATE	N019786	001	Dec 27, 1989
	EQ 200MG TARTRATE	N019786	002	Dec 27, 1989
	EQ 300MG TARTRATE	N019786	003	Dec 27, 1989
	EQ 400MG TARTRATE	N019786	004	Dec 27, 1989
METOPROLOL SUCCINATE				
TABLET, EXTENDED RELEASE;ORAL				
METOPROLOL SUCCINATE				
NESHER PHARMS	EQ 25MG TARTRATE	A077779	001	Mar 20, 2008
	EQ 50MG TARTRATE	A077176	001	May 14, 2008
	EQ 100MG TARTRATE	A076640	002	May 18, 2007
	EQ 200MG TARTRATE	A076640	001	May 18, 2007
SANDOZ	EQ 25MG TARTRATE	A076969	001	Jul 31, 2006
	EQ 50MG TARTRATE	A076969	002	May 18, 2007
	EQ 100MG TARTRATE	A076969	003	Mar 20, 2008
	EQ 200MG TARTRATE	A076969	004	Mar 20, 2008
METOPROLOL TARTRATE				
INJECTABLE;INJECTION				
METOPROLOL TARTRATE				
WATSON LABS	1MG/ML	A074032	001	Dec 21, 1993
TABLET;ORAL				
METOPROLOL TARTRATE				
APOTHECON	50MG	A074258	001	Jan 27, 1994
	100MG	A074258	002	Jan 27, 1994
MYLAN	50MG	A073666	001	Dec 21, 1993
	100MG	A073666	002	Dec 21, 1993
PUREPAC PHARM	50MG	A074380	001	Jul 29, 1994
	100MG	A074380	002	Jul 29, 1994
RENATA	50MG	A074453	001	Apr 27, 1995
	100MG	A074453	002	Apr 27, 1995
TEVA	50MG	A074143	001	Sep 30, 1994
	100MG	A074143	002	Sep 30, 1994
TEVA PHARMS	50MG	A074333	001	Jan 27, 1994
	100MG	A074333	002	Jan 27, 1994
YAOPHARMA CO LTD	50MG	A073288	001	Mar 25, 1994
	100MG	A073289	001	Mar 25, 1994

METRIZAMIDE				
INJECTABLE;INJECTION				
AMIPAQUE				
GE HEALTHCARE	2.5GM/VIAL	N017982	003	Sep 12, 1983
	3.75GM/VIAL	N017982	001	
	6.75GM/VIAL	N017982	002	
	13.5GM/VIAL	N017982	004	Sep 12, 1983
METRONIDAZOLE				
CAPSULE;ORAL				
METRONIDAZOLE				
ABLE	375MG	A076505	001	Nov 13, 2003
INJECTABLE;INJECTION				
FLAGYL I.V. RTU IN PLASTIC CONTAINER				
PFIZER	500MG/100ML	N018353	002	
METRO I.V.				
B BRAUN	500MG/100ML	N018674	001	Aug 31, 1982
METRONIDAZOLE				
ABBOTT	500MG/100ML	N018889	001	Nov 18, 1983
ABRAXIS PHARM	500MG/100ML	A070071	001	Dec 03, 1984
INTL MEDICATION	500MG/100ML	A070004	001	May 08, 1985
WATSON LABS	500MG/100ML	A070042	001	Dec 20, 1984
	500MG/100ML	A070170	001	Apr 01, 1986
WEST-WARD PHARMS INT	500MG/100ML	N018907	001	Mar 30, 1984
TABLET;ORAL				
METROMIDOL				
LABS AF	250MG	A074523	001	Oct 24, 1996
	500MG	A074523	002	Oct 24, 1996
METRONIDAZOLE				
ABLE	250MG	A076519	001	Jun 27, 2003
	500MG	A076519	002	Jun 27, 2003
CHARTWELL MOLECULES	250MG	N018845	001	Aug 18, 1983
	500MG	N018930	001	Aug 18, 1983
FOSUN PHARMA	250MG	N018620	001	Mar 04, 1982
	250MG	N018740	001	Oct 22, 1982
	500MG	N018620	002	Jun 02, 1983
	500MG	N018740	002	Oct 22, 1982
HALSEY	250MG	A070021	001	Apr 02, 1985
	500MG	A070593	001	Feb 27, 1986
IVAX SUB TEVA PHARMS	250MG	N018517	001	
	500MG	N018517	002	May 05, 1982
LNK	250MG	N019029	001	Apr 10, 1984
MUTUAL PHARM	250MG	N018818	001	Feb 16, 1983
	500MG	N018818	002	Feb 16, 1983
SUPERPHARM	250MG	A070008	001	Dec 11, 1984
	500MG	A070009	001	Dec 11, 1984
WATSON LABS	250MG	N018599	001	Sep 17, 1982
	250MG	N018764	001	Sep 17, 1982
	500MG	N018599	002	Feb 13, 1984
	500MG	N018764	002	Dec 20, 1982
PROTOSTAT				
ORTHO MCNEIL PHARM	250MG	N018871	001	Mar 02, 1983
	500MG	N018871	002	Mar 02, 1983
SATRIC				
SAVAGE LABS	250MG	A070029	001	Mar 19, 1985
	500MG	A070731	001	Jun 08, 1987
TABLET, EXTENDED RELEASE;ORAL				
FLAGYL ER				
+ GD SEARLE LLC	750MG	N020868	001	Nov 26, 1997
METRONIDAZOLE				
ABLE	750MG	A076462	001	Jun 25, 2003
ALEMBIC PHARMS LTD	750MG	A090222	001	May 05, 2010
METRONIDAZOLE HYDROCHLORIDE				
INJECTABLE;INJECTION				
FLAGYL I.V.				
PFIZER	EQ 500MG BASE/VIAL **	N018353	001	
METRONIDAZOLE HYDROCHLORIDE				
ABRAXIS PHARM	EQ 500MG BASE/VIAL	A070295	001	Oct 15, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

METYRAPONE				
TABLET;ORAL				
METOPIRONE				
LABORATORIE HRA	250MG	N012911	001	
MEXILETINE HYDROCHLORIDE				
CAPSULE;ORAL				
MEXILETINE HYDROCHLORIDE				
ANI PHARMS INC	150MG	A074450	001	May 16, 1996
	200MG	A074450	002	May 16, 1996
	250MG	A074450	003	May 16, 1996
WATSON LABS	150MG	A074711	001	Feb 26, 1997
	150MG	A074865	001	Apr 13, 1998
	200MG	A074711	002	Feb 26, 1997
	200MG	A074865	002	Apr 13, 1998
	250MG	A074711	003	Feb 26, 1997
	250MG	A074865	003	Apr 13, 1998
MEXITIL				
+ BOEHRINGER INGELHEIM	150MG	N018873	002	Dec 30, 1985
+	200MG	N018873	003	Dec 30, 1985
+	250MG	N018873	004	Dec 30, 1985
MEZLOCILLIN SODIUM MONOHYDRATE				
INJECTABLE;INJECTION				
MEZLIN				
BAYER PHARMS	EQ 1GM BASE/VIAL	A062333	001	
	EQ 1GM BASE/VIAL	A062372	005	Jan 13, 1983
	EQ 1GM BASE/VIAL	N050549	001	
	EQ 2GM BASE/VIAL	A062333	002	
	EQ 2GM BASE/VIAL	A062372	001	May 13, 1982
	EQ 2GM BASE/VIAL	N050549	002	
	EQ 3GM BASE/VIAL	A062333	003	
	EQ 3GM BASE/VIAL	A062372	002	May 13, 1982
	EQ 3GM BASE/VIAL	A062697	001	Jan 22, 1987
	EQ 3GM BASE/VIAL	N050549	003	
	EQ 4GM BASE/VIAL	A062333	004	
	EQ 4GM BASE/VIAL	A062372	003	May 13, 1982
	EQ 4GM BASE/VIAL	A062697	002	Jan 22, 1987
	EQ 4GM BASE/VIAL	N050549	004	
	EQ 20GM BASE/VIAL	A062372	004	Mar 02, 1988
	EQ 20GM BASE/VIAL	N050549	005	Mar 02, 1988
MICONAZOLE				
INJECTABLE;INJECTION				
MONISTAT				
JANSSEN PHARMA	10MG/ML	N018040	001	
MICONAZOLE NITRATE				
CREAM;TOPICAL				
MONISTAT-DERM				
INSIGHT PHARMS	2%	N017494	001	
CREAM;VAGINAL				
MICONAZOLE NITRATE				
TEVA	2%	A074136	001	Jan 04, 1995
TEVA PHARMS	2%	A074030	001	Oct 30, 1992
CREAM, SUPPOSITORY;TOPICAL, VAGINAL				
M-ZOLE 7 DUAL PACK				
ACTAVIS MID ATLANTIC	2%,100MG	A074586	001	Jul 17, 1997
MICONAZOLE 7 COMBINATION PACK				
G AND W LABS	2%,100MG	A076585	001	Mar 26, 2004
LOTION;TOPICAL				
MONISTAT-DERM				
INSIGHT PHARMS	2%	N017739	001	
TAMPON;VAGINAL				
MONISTAT 5				
PERSONAL PRODS	100MG	N018592	001	Oct 27, 1989

MIDAZOLAM HYDROCHLORIDE				
INJECTABLE;INJECTION				
MIDAZOLAM HYDROCHLORIDE				
AKORN INC	EQ 5MG BASE/ML	A075481	001	Jun 30, 2000
APOTHECON	EQ 1MG BASE/ML	A075620	001	Nov 01, 2000
	EQ 5MG BASE/ML	A075620	002	Nov 01, 2000
	EQ 5MG BASE/ML	A075641	001	Oct 19, 2000
BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000
	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000
BEDFORD	EQ 5MG BASE/ML	A075249	001	Jun 23, 2000
BEN VENUE	EQ 5MG BASE/ML	A075455	001	Jun 20, 2000
HOSPIRA	EQ 1MG BASE/ML	A075396	001	Jun 20, 2000
	EQ 5MG BASE/ML	A075396	002	Jun 20, 2000
	EQ 5MG BASE/ML	A075484	001	Jun 20, 2000
HOSPIRA INC	EQ 1MG BASE/ML	A075409	002	Jun 20, 2000
	EQ 5MG BASE/ML	A075409	001	Jun 20, 2000
IGI LABS INC	EQ 5MG BASE/ML	A075263	001	Jun 26, 2000
INTL MEDICATED	EQ 1MG BASE/ML	A076144	001	Jan 26, 2005
	EQ 5MG BASE/ML	A076144	002	Jan 26, 2005
INTL MEDICATION	EQ 1MG BASE/ML	A076020	001	Jul 16, 2004
	EQ 5MG BASE/ML	A076020	002	Jul 16, 2004
WOCKHARDT	EQ 1MG BASE/ML	A078141	001	May 30, 2008
	EQ 1MG BASE/ML	A078511	001	Nov 10, 2008
	EQ 5MG BASE/ML	A078141	002	May 30, 2008
	EQ 5MG BASE/ML	A078511	002	Nov 10, 2008
VERSED				
+ HLR	EQ 1MG BASE/ML **	N018654	002	May 26, 1987
+	EQ 5MG BASE/ML **	N018654	001	Dec 20, 1985
SYRUP;ORAL				
MIDAZOLAM HYDROCHLORIDE				
APOTEX INC	EQ 2MG BASE/ML	A077115	001	Sep 09, 2005
SUN PHARM INDS LTD	EQ 2MG BASE/ML	A076058	001	Mar 15, 2002
VERSED				
+ ROCHE	EQ 2MG BASE/ML **	N020942	001	Oct 15, 1998
MIDODRINE HYDROCHLORIDE				
TABLET;ORAL				
PROAMATINE				
+ SHIRE LLC	2.5MG	N019815	001	Sep 06, 1996
+	5MG	N019815	002	Sep 06, 1996
+	10MG	N019815	003	Mar 20, 2002
MILNACIPRAN HYDROCHLORIDE				
TABLET;ORAL				
MILNACIPRAN HYDROCHLORIDE				
AMNEAL PHARMS	12.5MG	A205081	001	Apr 22, 2016
	25MG	A205081	002	Apr 22, 2016
	50MG	A205081	003	Apr 22, 2016
	100MG	A205081	004	Apr 22, 2016
USPHARMA WINDLAS	12.5MG	A205071	001	Jan 27, 2016
	25MG	A205071	002	Jan 27, 2016
	50MG	A205071	003	Jan 27, 2016
	100MG	A205071	004	Jan 27, 2016
MILRINONE LACTATE				
INJECTABLE;INJECTION				
MILRINONE LACTATE				
BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A076427	001	Sep 21, 2004
HOSPIRA	EQ 1MG BASE/ML	A075830	001	May 28, 2002
	EQ 1MG BASE/ML	A075884	001	May 28, 2002
MYLAN INSTITUTIONAL	EQ 1MG BASE/ML	A076428	001	Jun 16, 2003
WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A075852	001	May 28, 2002
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076414	001	Aug 18, 2004
BAXTER HLTHCARE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076259	001	Aug 08, 2002
RENAISSANCE SSA LLC	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005
WEST-WARD PHARMS INT	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510	001	May 28, 2002
PRIMACOR				
+ SANOFI AVENTIS US	EQ 1MG BASE/ML **	N019436	001	Dec 31, 1987

MILRINONE LACTATE

INJECTABLE;INJECTION					
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER					
+	SANOFI AVENTIS US	EQ 10MG BASE/100ML **	N020343	001	Aug 09, 1994
+		EQ 15MG BASE/100ML **	N020343	002	Aug 09, 1994
+		EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML) **	N020343	003	Aug 09, 1994
+		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML) **	N020343	004	Aug 09, 1994

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL					
MINOCIN					
+	PRECISION DERMAT	EQ 75MG BASE **	N050649	003	Feb 12, 2001
	TRIAX PHARMS	EQ 50MG BASE	N050315	002	
		EQ 100MG BASE	N050315	001	
CAPSULE, EXTENDED RELEASE;ORAL					
XIMINO					
	SUN PHARM INDS LTD	EQ 67.5MG BASE	N201922	002	Jul 11, 2012
		EQ 112.5MG BASE	N201922	004	Jul 11, 2012
INJECTABLE;INJECTION					
MINOCIN					
	LEDERLE	EQ 100MG BASE/VIAL	A062139	001	
SUSPENSION;ORAL					
MINOCIN					
	PRECISION DERMAT	EQ 50MG BASE/5ML	N050445	001	
TABLET;ORAL					
MINOCYCLINE HYDROCHLORIDE					
+	TRIAX PHARMS	EQ 50MG BASE **	N050451	003	Aug 10, 1982
+		EQ 100MG BASE **	N050451	002	Aug 10, 1982
TABLET, EXTENDED RELEASE;ORAL					
MINOCYCLINE HYDROCHLORIDE					
	BARR LABS INC	EQ 45MG BASE	A065485	001	Mar 17, 2009
		EQ 80MG BASE	A065485	007	Apr 26, 2017
		EQ 90MG BASE	A065485	002	Mar 17, 2009
		EQ 105MG BASE	A065485	008	Apr 26, 2017
		EQ 135MG BASE	A065485	003	Mar 17, 2009
	IMPAX LABS INC	EQ 45MG BASE	A090024	001	Feb 03, 2009
		EQ 90MG BASE	A090024	002	Feb 03, 2009
		EQ 135MG BASE	A090024	003	Feb 03, 2009
	MYLAN PHARMS INC	EQ 45MG BASE	A090911	001	Jul 20, 2010
		EQ 90MG BASE	A090911	002	Jul 20, 2010
		EQ 135MG BASE	A090911	003	Jul 20, 2010
SOLODYN					
+	MEDICIS	EQ 45MG BASE **	N050808	001	May 08, 2006
+		EQ 90MG BASE **	N050808	002	May 08, 2006
+		EQ 135MG BASE **	N050808	003	May 08, 2006

MINOXIDIL

SOLUTION;TOPICAL					
MINOXIDIL (FOR MEN)					
	APOTEX INC	2%	A074924	001	Apr 29, 1998
	BAUSCH AND LOMB	2%	A074643	001	Apr 09, 1996
	COPLEY PHARM	2%	A074500	001	May 23, 1996
	SIGHT PHARMS	2%	A074743	002	Oct 18, 1996
	TEVA	2%	A074589	001	Apr 05, 1996
MINOXIDIL (FOR WOMEN)					
	APOTEX INC	2%	A074924	002	Apr 29, 1998
	SIGHT PHARMS	2%	A074743	001	Oct 18, 1996
MINOXIDIL EXTRA STRENGTH (FOR MEN)					
	APOTEX INC	5%	A075839	001	Oct 01, 2001
TABLET;ORAL					
LONITEN					
+	PHARMACIA AND UPJOHN	2.5MG **	N018154	001	
+		10MG **	N018154	003	
MINODYL					
	QUANTUM PHARMICS	2.5MG	A072153	001	Jul 13, 1988
		10MG	A071534	001	Mar 19, 1987
MINOXIDIL					
	ROYCE LABS	2.5MG	A071799	001	Nov 10, 1987
		10MG	A071796	001	Nov 10, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

MINOXIDIL				
TABLET;ORAL				
MINOXIDIL				
	USL PHARMA	2.5MG	A071537 001	Dec 16, 1988
MIPOMERSEN SODIUM				
SOLUTION;SUBCUTANEOUS				
KYNAMRO				
+	KASTLE THERAPS LLC	200MG/ML (200MG/ML)	N203568 001	Jan 29, 2013
MIRTAZAPINE				
TABLET;ORAL				
MIRTAZAPINE				
	ACTAVIS ELIZABETH	15MG	A076241 001	Jun 25, 2003
		15MG	A076308 001	Jun 20, 2003
		30MG	A076241 002	Jun 25, 2003
		30MG	A076308 002	Jun 20, 2003
		45MG	A076241 003	Jun 25, 2003
		45MG	A076308 003	Jun 20, 2003
	ACTAVIS LABS FL INC	15MG	A076336 001	Jun 20, 2003
		30MG	A076336 002	Jun 20, 2003
		45MG	A076336 003	Jun 20, 2003
	IVAX SUB TEVA PHARMS	15MG	A076244 001	Dec 22, 2003
		30MG	A076244 002	Dec 22, 2003
		45MG	A076244 003	Dec 22, 2003
	MYLAN PHARMS INC	15MG	A076176 001	Jun 19, 2003
		30MG	A076176 002	Jun 19, 2003
		45MG	A076176 003	Jun 19, 2003
	ROXANE	15MG	A076270 001	Jun 19, 2003
		30MG	A076270 002	Jun 19, 2003
		45MG	A076270 003	Jun 19, 2003
	UPSHER SMITH LABS	15MG	A076189 001	Jun 19, 2003
		30MG	A076189 002	Jun 19, 2003
		45MG	A076189 003	Jun 19, 2003
REMERON				
+	ORGANON USA INC	45MG	N020415 003	Mar 17, 1997
TABLET, ORALLY DISINTEGRATING;ORAL				
MIRTAZAPINE				
	ACTAVIS ELIZABETH	15MG	A076689 001	Aug 31, 2005
		15MG	A077959 001	Feb 14, 2011
		30MG	A076689 002	Aug 31, 2005
		30MG	A077959 002	Feb 14, 2011
		45MG	A076689 003	Aug 31, 2005
		45MG	A077959 003	Feb 14, 2011
	ACTAVIS LABS FL INC	15MG	A076307 001	Dec 17, 2003
		30MG	A076307 002	Dec 17, 2003
		45MG	A076307 003	Feb 28, 2006
MITOMYCIN				
INJECTABLE;INJECTION				
MITOMYCIN				
	HOSPIRA	20MG/VIAL	A064106 001	Nov 29, 1995
	WEST-WARD PHARMS INT	5MG/VIAL	A064117 001	Apr 19, 1995
		20MG/VIAL	A064117 002	Apr 19, 1995
		40MG/VIAL	A064117 003	Jun 02, 1999
MITOZYTREX				
+	SUPERGEN	5MG/VIAL **	N050763 001	Nov 14, 2002
MUTAMYCIN				
+	BRISTOL	5MG/VIAL **	N050450 001	
+		20MG/VIAL **	N050450 002	
	BRISTOL MYERS	5MG/VIAL	A062336 001	
		20MG/VIAL	A062336 002	
		40MG/VIAL	A062336 003	Mar 10, 1988
MITOXANTRONE HYDROCHLORIDE				
INJECTABLE;INJECTION				
MITOXANTRONE HYDROCHLORIDE				
	FRESENIUS KABI ONCOL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078606 001	May 14, 2008
		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A078606 002	May 14, 2008
		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078606 003	May 14, 2008

MITOXANTRONE HYDROCHLORIDE				
INJECTABLE;INJECTION				
NOVANTRONE				
EMD SERONO	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N019297	001	Dec 23, 1987
+	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML) **	N019297	002	Dec 23, 1987
+	EQ 30MG BASE/15ML (EQ 2MG BASE/ML) **	N019297	003	Dec 23, 1987
MIVACURIUM CHLORIDE				
INJECTABLE;INJECTION				
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBVIE	EQ 0.5MG BASE/ML	N020098	002	Jan 22, 1992
	EQ 50MG BASE/100ML	N020098	003	Jan 22, 1992
MIVACURIUM CHLORIDE				
MYLAN LABS LTD	EQ 2MG BASE/ML	A078562	001	Apr 30, 2009
SOLUTION;INTRAVENOUS				
MIVACRON				
+ ABBVIE	EQ 2MG BASE/ML (EQ 2MG BASE/ML) **	N020098	001	Jan 22, 1992
+	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N020098	004	Jan 22, 1992
+	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N020098	005	Jan 22, 1992
MOEXIPRIL HYDROCHLORIDE				
TABLET;ORAL				
UNIVASC				
UCB INC	7.5MG **	N020312	001	Apr 19, 1995
	15MG **	N020312	002	Apr 19, 1995
MOLINDONE HYDROCHLORIDE				
CAPSULE;ORAL				
MOBAN				
+ ENDO PHARMS	5MG **	N017111	001	
+	10MG **	N017111	002	
+	25MG **	N017111	003	
CONCENTRATE;ORAL				
MOBAN				
ENDO PHARMS	20MG/ML	N017938	001	
TABLET;ORAL				
MOBAN				
+ ENDO PHARMS	5MG **	N017111	004	
+	10MG **	N017111	005	
+	25MG **	N017111	006	
+	50MG **	N017111	007	
+	100MG **	N017111	008	
MOMETASONE FUROATE				
CREAM;TOPICAL				
ELOCON				
MERCK SHARP DOHME	0.1%	N019625	001	May 06, 1987
OINTMENT;TOPICAL				
MOMETASONE FUROATE				
TARO	0.1%	A076624	001	Dec 03, 2004
MONOBENZONE				
CREAM;TOPICAL				
BENOQUIN				
VALEANT PHARM INTL	20%	N008173	003	
MONOCTANOIN				
LIQUID;PERFUSION, BILIARY				
MOCTANIN				
ETHITEK	100%	N019368	001	Oct 29, 1985
MONTELUKAST SODIUM				
TABLET;ORAL				
MONTELUKAST SODIUM				
APOTEX CORP	EQ 10MG BASE	A201294	001	Aug 03, 2012
TABLET, CHEWABLE;ORAL				
MONTELUKAST SODIUM				
APOTEX INC	EQ 4MG BASE	A201508	001	Aug 03, 2012
	EQ 5MG BASE	A201508	002	Aug 03, 2012

MORICIZINE HYDROCHLORIDE

TABLET;ORAL				
ETHMOZINE				
	SHIRE	200MG	N019753 001	Jun 19, 1990
		250MG	N019753 002	Jun 19, 1990
		300MG	N019753 003	Jun 19, 1990

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL				
AVINZA				
	KING PHARMS LLC	30MG	N021260 001	Mar 20, 2002
		45MG	N021260 005	Dec 18, 2008
		60MG	N021260 002	Mar 20, 2002
		75MG	N021260 006	Dec 18, 2008
		90MG	N021260 003	Mar 20, 2002
		120MG	N021260 004	Mar 20, 2002
INJECTABLE;INJECTION				
MORPHINE SULFATE				
+	HOSPIRA INC	15MG/ML	N202515 005	Nov 14, 2011
	ICU MEDICAL INC	0.5MG/ML	N019917 001	Oct 30, 1992
	SPECGX LLC	1MG/ML	N020631 001	Jul 03, 1996
		2MG/ML	N020631 002	Jul 03, 1996
	WATSON LABS	0.5MG/ML	A073373 001	Sep 30, 1991
		0.5MG/ML	A073375 001	Sep 30, 1991
		1MG/ML	A073374 001	Sep 30, 1991
		1MG/ML	A073376 001	Sep 30, 1991
INJECTABLE, LIPOSOMAL;EPIDURAL				
DEPODUR				
	PACIRA PHARMS INC	10MG/ML (10MG/ML)	N021671 001	May 18, 2004
		15MG/1.5ML (10MG/ML)	N021671 002	May 18, 2004
		20MG/2ML (10MG/ML)	N021671 003	May 18, 2004
TABLET, EXTENDED RELEASE;ORAL				
ARYMO ER				
+	EGALET	15MG	N208603 001	Jan 09, 2017
+		30MG	N208603 002	Jan 09, 2017
+		60MG	N208603 003	Jan 09, 2017
MORPHINE SULFATE				
	EPIC PHARMA LLC	15MG	A091357 001	Jun 23, 2016
		30MG	A091357 002	Jun 23, 2016
		60MG	A091357 003	Jun 23, 2016
		100MG	A091357 004	Jun 23, 2016
		200MG	A091357 005	Jun 23, 2016
	WATSON LABS	100MG	A075656 001	Jan 30, 2001
ORAMORPH SR				
	XANODYNE PHARMS INC	15MG	N019977 004	Nov 23, 1994
		30MG	N019977 001	Aug 15, 1991
		60MG	N019977 002	Aug 15, 1991
		100MG	N019977 003	Aug 15, 1991

MOXALACTAM DISODIUM

INJECTABLE;INJECTION				
MOXAM				
	LILLY	EQ 250MG BASE/VIAL	N050550 001	
		EQ 500MG BASE/VIAL	N050550 002	
		EQ 1GM BASE/VIAL	N050550 003	
		EQ 2GM BASE/VIAL	N050550 004	
		EQ 10GM BASE/VIAL	N050550 008	

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;INTRAVENOUS				
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER				
+	BAYER HLTHCARE	400MG/250ML (1.6MG/ML) **	N021277 001	Nov 30, 2001

MUPIROCIN

OINTMENT;TOPICAL				
BACTROBAN				
+	GLAXOSMITHKLINE	2% **	N050591 001	Dec 31, 1987

MUPIROCIN CALCIUM				
CREAM;TOPICAL				
BACTROBAN				
+ GLAXOSMITHKLINE	EQ 2% BASE	N050746	001	Dec 11, 1997
OINTMENT;NASAL				
BACTROBAN				
+ GLAXOSMITHKLINE	EQ 2% BASE	N050703	001	Sep 18, 1995
MYCOPHENOLATE MOFETIL				
CAPSULE;ORAL				
MYCOPHENOLATE MOFETIL				
APOTEX CORP	250MG	A090419	001	Apr 22, 2009
DR REDDYS LABS LTD	250MG	A091315	001	Oct 27, 2011
JUBILANT CADISTA	250MG	A090762	001	Dec 15, 2014
ZYDUS PHARMS USA INC	250MG	A065433	001	May 04, 2009
TABLET;ORAL				
MYCOPHENOLATE MOFETIL				
APOTEX	500MG	A090499	001	Apr 22, 2009
DR REDDYS LABS LTD	500MG	A090464	001	Sep 13, 2010
JUBILANT CADISTA	500MG	A090661	001	Dec 15, 2014
ZYDUS PHARMS USA INC	500MG	A065477	001	May 04, 2009
NABUMETONE				
TABLET;ORAL				
NABUMETONE				
COPLEY PHARM	750MG	A075179	001	Jun 06, 2000
OXFORD PHARMS	500MG	A079093	001	Feb 27, 2009
	750MG	A079093	002	Feb 27, 2009
SANDOZ	500MG	A075590	001	Feb 25, 2002
	750MG	A075590	002	Feb 25, 2002
SCIEGEN PHARMS INC	500MG	A078420	001	Sep 24, 2008
	750MG	A078420	002	Sep 24, 2008
RELAFEN				
+ SMITHKLINE BEECHAM	500MG **	N019583	001	Dec 24, 1991
+	750MG **	N019583	002	Dec 24, 1991
NADOLOL				
TABLET;ORAL				
CORGARD				
US WORLDMEDS LLC	120MG	N018063	003	
	160MG	N018063	004	
NADOLOL				
IVAX SUB TEVA PHARMS	120MG	A074255	002	Jan 24, 1996
	160MG	A074255	003	Jan 24, 1996
TEVA PHARMS	80MG	A074368	001	Aug 31, 1994
	120MG	A074368	002	Aug 31, 1994
	160MG	A074368	003	Aug 31, 1994
NAFCILLIN SODIUM				
CAPSULE;ORAL				
UNIPEN				
WYETH AYERST	EQ 250MG BASE	N050111	001	
FOR SOLUTION;ORAL				
UNIPEN				
WYETH AYERST	EQ 250MG BASE/5ML	N050199	001	
INJECTABLE;INJECTION				
NAFCILLIN SODIUM				
APOTHECON	EQ 500MG BASE/VIAL	A061984	001	
	EQ 1GM BASE/VIAL	A061984	002	
	EQ 2GM BASE/VIAL	A061984	003	
	EQ 4GM BASE/VIAL	A061984	005	
SANDOZ	EQ 500MG BASE/VIAL	A062527	001	Aug 02, 1984
WATSON LABS INC	EQ 500MG BASE/VIAL	A062844	001	Oct 26, 1988
	EQ 1GM BASE/VIAL	A062844	002	Oct 26, 1988
	EQ 1.5GM BASE/VIAL	A062844	003	Oct 26, 1988
	EQ 2GM BASE/VIAL	A062844	004	Oct 26, 1988
	EQ 4GM BASE/VIAL	A062844	005	Oct 26, 1988
	EQ 10GM BASE/VIAL	A063008	001	Sep 29, 1988
NALLPEN				
GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	A061999	001	
	EQ 1GM BASE/VIAL	A061999	002	

NAFCILLIN SODIUM				
INJECTABLE;INJECTION				
NALLPEN				
	EQ 1GM BASE/VIAL	A062755	001	Dec 19, 1986
	EQ 2GM BASE/VIAL	A061999	003	
	EQ 2GM BASE/VIAL	A062755	002	Dec 19, 1986
	EQ 10GM BASE/VIAL	A061999	004	
UNIPEN				
WYETH AYERST	EQ 500MG BASE/VIAL **	A062717	001	Dec 16, 1986
+	EQ 500MG BASE/VIAL **	N050320	001	
	EQ 1GM BASE/VIAL **	A062717	002	Dec 16, 1986
	EQ 2GM BASE/VIAL **	A062717	004	Dec 16, 1986
+	EQ 2GM BASE/VIAL **	N050320	003	
+	EQ 4GM BASE/VIAL **	N050320	004	
+	EQ 10GM BASE/VIAL **	N050320	005	
+	EQ 20GM BASE/VIAL **	N050320	006	
UNIPEN IN PLASTIC CONTAINER				
+ WYETH AYERST	EQ 1GM BASE/VIAL **	N050320	002	
TABLET;ORAL				
UNIPEN				
WYETH AYERST	EQ 500MG BASE	N050462	001	
NAFTIFINE HYDROCHLORIDE				
CREAM;TOPICAL				
NAFTIN				
+ SEBELA IRELAND LTD	1%	N019599	001	Feb 29, 1988
NALBUPHINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
NALBUPHINE				
ABRAXIS PHARM	10MG/ML	A070751	001	Jul 02, 1986
	20MG/ML	A070752	001	Sep 24, 1986
NALBUPHINE HYDROCHLORIDE				
ABBOTT	20MG/ML	A070917	001	Feb 03, 1989
ABBVIE	1.5MG/ML	N020200	001	Mar 12, 1993
BARR	10MG/ML	A074471	001	Mar 19, 1998
	20MG/ML	A074471	002	Mar 19, 1998
IGI LABS INC	10MG/ML	A072070	001	Apr 10, 1989
	10MG/ML	A072071	001	Apr 10, 1989
	10MG/ML	A072072	001	Apr 10, 1989
	20MG/ML	A072073	001	Apr 10, 1989
	20MG/ML	A072074	001	Apr 10, 1989
	20MG/ML	A072075	001	Apr 10, 1989
NUBAIN				
+ PAR PHARM INC	10MG/ML **	N018024	001	
+	20MG/ML **	N018024	002	May 27, 1982
NALIDIXIC ACID				
SUSPENSION;ORAL				
NEGGRAM				
SANOFI AVENTIS US	250MG/5ML	N017430	001	
TABLET;ORAL				
NALIDIXIC ACID				
SUN PHARM INDUSTRIES	250MG	A070270	001	Jun 29, 1988
	500MG	A070271	001	Jun 29, 1988
	1GM	A070272	001	Jun 29, 1988
WATSON LABS	250MG	A071936	001	Jun 29, 1988
	500MG	A072061	001	Jun 29, 1988
	1GM	A071919	001	Jun 29, 1988
NEGGRAM				
SANOFI AVENTIS US	250MG	N014214	002	
	500MG	N014214	004	
	1GM	N014214	005	
NALMEFENE HYDROCHLORIDE				
INJECTABLE;INJECTION				
REVEX				
+ EUROHLTH INTL SARL	EQ 0.1MG BASE/ML **	N020459	001	Apr 17, 1995
+	EQ 1MG BASE/ML **	N020459	002	Apr 17, 1995

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION					
NALOXONE					
	WEST-WARD PHARMS INT	0.4MG/ML	A070298	001	Sep 24, 1986
		0.4MG/ML	A070496	001	Sep 24, 1986
	WYETH AYERST	0.02MG/ML	A070188	001	Sep 24, 1986
		0.02MG/ML	A070189	001	Sep 24, 1986
		0.4MG/ML	A070190	001	Sep 24, 1986
		0.4MG/ML	A070191	001	Sep 24, 1986
NALOXONE HYDROCHLORIDE					
	ABRAXIS PHARM	0.02MG/ML	A070648	001	Nov 17, 1986
		0.02MG/ML	A070661	001	Nov 17, 1986
		0.4MG/ML	A070649	001	Nov 17, 1986
		1MG/ML	A071604	001	Dec 16, 1988
	ASTRAZENECA	0.02MG/ML	A072081	001	Apr 11, 1989
	EUROHLTH INTL SARL	0.02MG/ML	A071272	001	May 24, 1988
		1MG/ML	A071273	001	May 24, 1988
		1MG/ML	A071274	001	May 24, 1988
		1MG/ML	A071287	001	May 24, 1988
	HOSPIRA	0.02MG/ML	A070171	001	Sep 24, 1986
		0.02MG/ML	A070252	001	Jan 16, 1987
		0.02MG/ML	A070253	001	Jan 16, 1987
		0.4MG/ML	A070255	001	Jan 07, 1987
	IGI LABS INC	0.02MG/ML	A072082	001	Apr 11, 1989
		0.02MG/ML	A072083	001	Apr 11, 1989
		0.02MG/ML	A072084	001	Apr 11, 1989
		0.02MG/ML	A072085	001	Apr 11, 1989
		0.4MG/ML	A072086	001	Apr 11, 1989
		0.4MG/ML	A072087	001	Apr 11, 1989
		0.4MG/ML	A072088	001	Apr 11, 1989
		0.4MG/ML	A072089	001	Apr 11, 1989
		0.4MG/ML	A072090	001	Apr 11, 1989
		1MG/ML	A072091	001	Apr 11, 1989
		1MG/ML	A072092	001	Apr 11, 1989
		1MG/ML	A072093	001	Apr 11, 1989
	INTL MEDICATION	0.4MG/ML	A070417	001	Sep 24, 1986
		1MG/ML	A072115	001	Apr 27, 1988
	MARSAM PHARMS LLC	0.4MG/ML	A071811	001	Jul 19, 1988
	SMITH AND NEPHEW	0.02MG/ML	A071671	001	Nov 17, 1987
		0.4MG/ML	A071681	001	Nov 17, 1987
		0.4MG/ML	A071682	001	Nov 17, 1987
	SOLOPAK	0.02MG/ML	A071672	001	Nov 17, 1987
		0.4MG/ML	A071683	001	Nov 17, 1987
	WATSON LABS	0.4MG/ML	A071339	001	Nov 18, 1987
NARCAN					
+	ADAPT	0.02MG/ML **	N016636	002	
+		0.4MG/ML **	N016636	001	
+		1MG/ML **	N016636	003	Jun 14, 1982
	BRISTOL MYERS SQUIBB	0.4MG/ML	A071083	001	Jul 28, 1988
		1MG/ML	A071084	001	Jul 28, 1988
		1MG/ML	A071311	001	Jul 28, 1988
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS					
EVZIO					
+	KALEO INC	0.4MG/0.4ML (0.4MG/0.4ML)	N205787	001	Apr 03, 2014
SPRAY, METERED;NASAL					
NARCAN					
+	ADAPT	2MG/SPRAY	N208411	002	Jan 24, 2017

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL					
TARGINIQ					
+	PURDUE PHARMA LP	5MG;10MG	N205777	001	Jul 23, 2014
+		10MG;20MG	N205777	002	Jul 23, 2014
+		20MG;40MG	N205777	003	Jul 23, 2014

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE				
TABLET;ORAL				
TALWIN NX				
	SANOFI AVENTIS US	EQ 0.5MG BASE;EQ 50MG BASE **	N018733 001	Dec 16, 1982
NALTREXONE HYDROCHLORIDE				
TABLET;ORAL				
NALTREXONE HYDROCHLORIDE				
	FOSUN PHARMA	50MG	A075434 001	Mar 08, 2000
REVIA				
	TEVA WOMENS	50MG	N018932 001	Nov 20, 1984
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
TROXYCA ER				
	PFIZER INC	1.2MG;10MG	N207621 001	Aug 19, 2016
		2.4MG;20MG	N207621 002	Aug 19, 2016
		3.6MG;30MG	N207621 003	Aug 19, 2016
		4.8MG;40MG	N207621 004	Aug 19, 2016
		7.2MG;60MG	N207621 005	Aug 19, 2016
		9.6MG;80MG	N207621 006	Aug 19, 2016
NANDROLONE DECANOATE				
INJECTABLE;INJECTION				
DECA-DURABOLIN				
	ASPEN GLOBAL INC	50MG/ML	N013132 001	Jun 12, 1986
		100MG/ML	N013132 002	Jun 12, 1986
+		200MG/ML **	N013132 003	Jun 12, 1986
NANDROLONE DECANOATE				
	ABRAXIS PHARM	100MG/ML	A088290 001	Oct 03, 1983
		200MG/ML	A088317 001	Oct 14, 1983
	AKORN	100MG/ML	A087519 001	Sep 28, 1983
	WATSON LABS	50MG/ML	A086385 001	Jan 13, 1984
		50MG/ML	A087598 001	Oct 06, 1983
		50MG/ML	A088554 001	Feb 10, 1986
		100MG/ML	A086598 001	Jan 13, 1984
		100MG/ML	A087599 001	Oct 06, 1983
		200MG/ML	A088128 001	Dec 05, 1983
NANDROLONE PHENPROPIONATE				
INJECTABLE;INJECTION				
DURABOLIN				
	ORGANON USA INC	25MG/ML	N011891 001	
		50MG/ML	N011891 002	
NANDROLONE PHENPROPIONATE				
	WATSON LABS	25MG/ML	A086386 001	Jun 17, 1983
		50MG/ML	A087488 001	Jun 17, 1983
NAPHAZOLINE HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
ALBALON				
	ALLERGAN	0.1% **	A080248 001	
NAFAZAIR				
	BAUSCH AND LOMB	0.1%	A040073 001	May 25, 1994
	PHARMAFAIR	0.1%	A088101 001	Apr 15, 1983
NAPHAZOLINE HYDROCHLORIDE				
	AKORN INC	0.1%	A083590 001	
NAPHCON FORTE				
	ALCON	0.1%	A080229 001	
OPCON				
	BAUSCH AND LOMB	0.1%	A087506 001	
VASOCON				
	NOVARTIS	0.1%	A080235 002	Mar 24, 1983
NAPROXEN				
TABLET;ORAL				
NAPROSYN				
+	ATNAHS PHARMA US	250MG	N017581 002	
+		375MG	N017581 003	
NAPROXEN				
	CHARTWELL MOLECULES	250MG	A074410 001	Apr 28, 1995
		375MG	A074410 002	Apr 28, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

NAPROXEN

TABLET;ORAL

NAPROXEN

	500MG		A074410 003	Apr 28, 1995
DAVA PHARMS INC	250MG		A074105 001	Dec 21, 1993
	375MG		A074105 002	Dec 21, 1993
	500MG		A074105 003	Dec 21, 1993
FOSUN PHARMA	250MG		A074140 001	Dec 21, 1993
	375MG		A074140 002	Dec 21, 1993
	500MG		A074140 003	Dec 21, 1993
HAMILTON PHARMS	250MG		A074110 001	Oct 30, 1992
	375MG		A074110 002	Oct 30, 1992
	500MG		A074110 003	Oct 30, 1992
HIKMA INTL PHARMS	250MG		A076494 001	Jan 14, 2004
	375MG		A076494 002	Jan 14, 2004
	500MG		A076494 003	Jan 14, 2004
IVAX SUB TEVA PHARMS	250MG		A074111 001	Feb 28, 1995
	375MG		A074111 002	Feb 28, 1995
	500MG		A074111 003	Feb 28, 1995
PLIVA	250MG		A074182 001	Jun 27, 1996
	375MG		A074182 002	Jun 27, 1996
	500MG		A074182 003	Jun 27, 1996
PUREPAC PHARM	250MG		A074263 001	Dec 21, 1993
	375MG		A074263 002	Dec 21, 1993
	500MG		A074263 003	Dec 21, 1993
ROXANE	250MG		A074211 001	Feb 28, 1994
	375MG		A074211 002	Feb 28, 1994
	500MG		A074211 003	Feb 28, 1994
TEVA	250MG		A074129 001	Dec 21, 1993
	250MG		A074216 001	Apr 11, 1996
	375MG		A074129 002	Dec 21, 1993
	375MG		A074216 002	Apr 11, 1996
	500MG		A074129 003	Dec 21, 1993
	500MG		A074216 003	Apr 11, 1996
TEVA PHARMS	250MG		A074207 001	Dec 21, 1993
	375MG		A074207 002	Dec 21, 1993
	500MG		A074207 003	Dec 21, 1993
WATSON LABS	250MG		A074457 001	May 31, 1995
	375MG		A074457 002	May 31, 1995
	500MG		A074457 003	May 31, 1995
WATSON LABS TEVA	250MG		A074163 001	Feb 10, 1995
	375MG		A074163 002	Feb 10, 1995
	500MG		A074163 003	Feb 10, 1995

TABLET, DELAYED RELEASE;ORAL

NAPROXEN

ACTAVIS ELIZABETH	375MG		A074936 001	Feb 24, 1998
	500MG		A074936 002	Feb 24, 1998
FOSUN PHARMA	375MG		A075061 001	Feb 18, 1998
	500MG		A075061 002	Feb 18, 1998
MYLAN PHARMS INC	375MG		A075390 001	Apr 19, 2001
	500MG		A075390 002	Apr 19, 2001

NAPROXEN SODIUM

TABLET;ORAL

ANAPROX

+ ATNAHS PHARMA US	EQ 250MG BASE		N018164 001	

NAPROXEN SODIUM

ABLE	EQ 250MG BASE		A076544 001	Aug 22, 2003
	EQ 500MG BASE		A076544 002	Aug 22, 2003
CONTRACT PHARMACAL	EQ 200MG BASE		A074789 001	Feb 27, 1997
HAMILTON PHARMS	EQ 250MG BASE		A074106 001	Aug 31, 1993
	EQ 500MG BASE		A074106 002	Aug 31, 1993
HIKMA	EQ 250MG BASE		A074480 002	Feb 18, 1998
	EQ 500MG BASE		A074480 001	May 14, 1996
IVAX SUB TEVA PHARMS	EQ 250MG BASE		A074230 001	Mar 14, 1995
	EQ 500MG BASE		A074230 002	Mar 14, 1995
MYLAN	EQ 250MG BASE		A074367 001	Aug 31, 1994
	EQ 500MG BASE		A074367 002	Aug 31, 1994
PLD ACQUISITIONS LLC	EQ 200MG BASE		A074646 001	Jan 13, 1997
PLIVA	EQ 250MG BASE		A074242 001	Jun 20, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

NAPROXEN SODIUM
TABLET;ORAL
NAPROXEN SODIUM

	EQ 500MG BASE	A074242	002	Jun 20, 1996
PUREPAC PHARM	EQ 250MG BASE	A074319	001	Mar 20, 1995
	EQ 500MG BASE	A074319	002	Mar 20, 1995
ROXANE	EQ 250MG BASE	A074257	001	Dec 21, 1993
	EQ 500MG BASE	A074257	002	Dec 21, 1993
SANDOZ	EQ 250MG BASE	A074162	001	Dec 21, 1993
	EQ 250MG BASE	A074495	001	Dec 05, 1994
	EQ 500MG BASE	A074162	002	Dec 21, 1993
	EQ 500MG BASE	A074495	002	Dec 05, 1994
TEVA	EQ 250MG BASE	A074142	001	Dec 21, 1993
	EQ 500MG BASE	A074142	002	Dec 21, 1993
TEVA PHARMS	EQ 250MG BASE	A074289	001	Jan 27, 1994
	EQ 500MG BASE	A074289	002	Jan 27, 1994
WATSON LABS	EQ 250MG BASE	A074195	001	Dec 21, 1993
	EQ 250MG BASE	A074455	001	May 31, 1995
	EQ 500MG BASE	A074195	002	Dec 21, 1993
	EQ 500MG BASE	A074455	002	May 31, 1995

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE
TABLET;ORAL
TREXIMET

+	PERNIX IRELAND LTD	60MG;EQ 10MG BASE	N021926	002	May 14, 2015

NARATRIPTAN HYDROCHLORIDE
TABLET;ORAL
NARATRIPTAN

APOTEX CORP	EQ 1MG BASE	A091373	001	Apr 22, 2011
	EQ 2.5MG BASE	A091373	002	Apr 22, 2011

NATEGLINIDE
TABLET;ORAL
NATEGLINIDE

TEVA PHARMS	60MG	A077467	001	Sep 09, 2009
	120MG	A077467	002	Sep 09, 2009

NEBIVOLOL HYDROCHLORIDE
TABLET;ORAL
NEBIVOLOL HYDROCHLORIDE

ALKEM LABS LTD	EQ 2.5MG BASE	A203741	001	Jun 24, 2015
	EQ 5MG BASE	A203741	002	Jun 24, 2015
	EQ 10MG BASE	A203741	003	Jun 24, 2015
	EQ 20MG BASE	A203741	004	Jun 24, 2015
AMERIGEN PHARMS LTD	EQ 2.5MG BASE	A203659	001	Apr 16, 2015
	EQ 5MG BASE	A203659	002	Apr 16, 2015
	EQ 10MG BASE	A203659	003	Apr 16, 2015
	EQ 20MG BASE	A203659	004	Apr 16, 2015
GLENMARK PHARMS LTD	EQ 2.5MG BASE	A203821	001	May 25, 2017
	EQ 5MG BASE	A203821	002	May 25, 2017
	EQ 10MG BASE	A203821	003	May 25, 2017
	EQ 20MG BASE	A203821	004	May 25, 2017
INDCHEMIE HEALTH	EQ 2.5MG BASE	A203828	001	Jul 29, 2015
	EQ 5MG BASE	A203828	002	Jul 29, 2015
	EQ 10MG BASE	A203828	003	Jul 29, 2015
	EQ 20MG BASE	A203828	004	Jul 29, 2015
TORRENT PHARMS LTD	EQ 2.5MG BASE	A203966	001	Mar 02, 2018
	EQ 5MG BASE	A203966	002	Mar 02, 2018
	EQ 10MG BASE	A203966	003	Mar 02, 2018
	EQ 20MG BASE	A203966	004	Mar 02, 2018
WATSON LABS INC	EQ 2.5MG BASE	A203683	001	Nov 27, 2015
	EQ 5MG BASE	A203683	002	Nov 27, 2015
	EQ 10MG BASE	A203683	003	Nov 27, 2015
	EQ 20MG BASE	A203683	004	Nov 27, 2015

NEDOCROMIL SODIUM				
AEROSOL, METERED;INHALATION				
TILADE				
	KING PHARMS LLC	1.75MG/INH	N019660 001	Dec 30, 1992
SOLUTION;INHALATION				
TILADE				
	SANOFI AVENTIS US	0.5%	N020750 001	Oct 01, 1997
NEFAZODONE HYDROCHLORIDE				
TABLET;ORAL				
NEFAZODONE HYDROCHLORIDE				
	ANI PHARMS INC	50MG	A076072 001	Sep 16, 2003
		100MG	A076072 002	Sep 16, 2003
		150MG	A076072 003	Sep 16, 2003
		200MG	A076072 004	Sep 16, 2003
		250MG	A076072 005	Sep 16, 2003
	DR REDDYS LABS INC	50MG	A076309 001	Sep 16, 2003
		100MG	A076309 002	Sep 16, 2003
		150MG	A076309 003	Sep 16, 2003
		200MG	A076309 004	Sep 16, 2003
		250MG	A076309 005	Sep 16, 2003
	FOSUN PHARMA	50MG	A076302 001	Sep 16, 2003
		100MG	A076302 002	Sep 16, 2003
		150MG	A076302 003	Sep 16, 2003
		200MG	A076302 004	Sep 16, 2003
		250MG	A076302 005	Sep 16, 2003
	IVAX SUB TEVA PHARMS	50MG	A075763 001	Sep 16, 2003
		100MG	A075763 002	Sep 16, 2003
		150MG	A075763 003	Sep 16, 2003
		200MG	A075763 004	Sep 16, 2003
		250MG	A075763 005	Sep 16, 2003
	MYLAN	100MG	A076129 002	Sep 16, 2003
		150MG	A076129 003	Sep 16, 2003
		200MG	A076129 004	Sep 16, 2003
		250MG	A076129 005	Sep 16, 2003
	ROXANE	50MG	A076196 001	Sep 16, 2003
		100MG	A076196 002	Sep 16, 2003
		150MG	A076196 003	Sep 16, 2003
		200MG	A076196 004	Sep 16, 2003
		250MG	A076196 005	Sep 16, 2003
	SUN PHARM INDS LTD	50MG	A076409 001	Sep 16, 2003
		100MG	A076409 002	Sep 16, 2003
		150MG	A076409 003	Sep 16, 2003
		200MG	A076409 004	Sep 16, 2003
		250MG	A076409 005	Sep 16, 2003
	WATSON LABS	100MG	A076073 002	Sep 16, 2003
		150MG	A076073 003	Sep 16, 2003
		200MG	A076073 004	Sep 16, 2003
		250MG	A076073 005	Sep 16, 2003
SERZONE				
+	BRISTOL MYERS SQUIBB	50MG **	N020152 001	Dec 22, 1994
+		100MG **	N020152 002	Dec 22, 1994
+		150MG **	N020152 003	Dec 22, 1994
+		200MG **	N020152 004	Dec 22, 1994
+		250MG **	N020152 005	Dec 22, 1994
+		300MG **	N020152 006	Dec 22, 1994
NELFINAVIR MESYLATE				
POWDER;ORAL				
VIRACEPT				
	AGOURON PHARMS	EQ 50MG BASE/SCOOPFUL	N020778 001	Mar 14, 1997
NEOMYCIN SULFATE				
POWDER;FOR RX COMPOUNDING				
NEO-RX				
	X GEN PHARMS	100%	A061579 001	
SOLUTION;ORAL				
MYCIFRADIN				
	PHARMACIA AND UPJOHN	EQ 87.5MG BASE/5ML	N050285 001	

NEOMYCIN SULFATE

SOLUTION;ORAL				
NEO-FRADIN				
	X GEN PHARMS	EQ 87.5MG BASE/5ML	A065010 001	May 23, 2002
TABLET;ORAL				
MYCIFRADIN				
	PHARMACIA AND UPJOHN	EQ 350MG BASE	A060520 001	
NEOBIOTIC				
	PFIZER	EQ 350MG BASE	A060475 001	
NEOMYCIN SULFATE				
	BRISTOL MYERS SQUIBB	500MG	A060365 001	
	LANNETT	500MG	A060607 001	
	LILLY	500MG	A060385 001	
	ROXANE	500MG	A062173 001	
	SANDOZ	500MG	A061586 001	

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM;TOPICAL				
NEOSPORIN				
	GLAXOSMITHKLINE	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050176 002	Jan 14, 1985
OINTMENT;OPHTHALMIC				
STATROL				
	ALCON	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050344 002	
SOLUTION/DROPS;OPHTHALMIC				
STATROL				
	ALCON	EQ 3.5MG BASE/ML;16,250 UNITS/ML	A062339 001	Nov 30, 1984
		EQ 3.5MG BASE/ML;16,250 UNITS/ML	N050456 001	

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC				
POLY-PRED				
	ALLERGAN	EQ 0.35% BASE;10,000 UNITS/ML;0.5%	N050081 002	

NEOMYCIN SULFATE; PREDNISOLONE ACETATE

OINTMENT;OPHTHALMIC				
NEO-DELTA-CORTEF				
	PHARMACIA AND UPJOHN	EQ 3.5MG BASE/GM;0.25%	A061039 002	
		EQ 3.5MG BASE/GM;0.5%	A061039 001	
SUSPENSION/DROPS;OPHTHALMIC				
NEO-DELTA-CORTEF				
	PHARMACIA AND UPJOHN	EQ 3.5MG BASE/ML;0.25%	A061037 001	

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE

OINTMENT;OPHTHALMIC				
NEO-HYDELTRASOL				
	MERCK	EQ 3.5MG BASE/GM;EQ 0.25% PHOSPHATE	N050378 001	

NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL				
MYTREX A				
	SAVAGE LABS	EQ 3.5MG BASE/GM;0.1%	A062598 001	Jul 21, 1986
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE				
	FOUGERA	EQ 3.5MG BASE/GM;0.1%	A062600 001	Jul 21, 1986
	PHARMADERM	EQ 3.5MG BASE/GM;0.1%	A062595 001	Jul 21, 1986
OINTMENT;TOPICAL				
MYTREX A				
	SAVAGE LABS	EQ 3.5MG BASE/GM;0.1%	A062609 001	May 23, 1986
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE				
	FOUGERA	EQ 3.5MG BASE/GM;0.1%	A062608 001	May 23, 1986
	PHARMADERM	EQ 3.5MG BASE/GM;0.1%	A062607 001	May 23, 1986

NETILMICIN SULFATE

INJECTABLE;INJECTION				
NETROMYCIN				
	SCHERING	EQ 10MG BASE/ML	N050544 001	Feb 28, 1983
		EQ 25MG BASE/ML	N050544 002	Feb 28, 1983
		EQ 100MG BASE/ML	N050544 003	Feb 28, 1983

NEVIRAPINE
TABLET;ORAL
NEVIRAPINE

APOTEX INC	200MG	A203021	001	May 22, 2012
TECH ORGANIZED	200MG	A203176	001	May 22, 2012

TABLET, EXTENDED RELEASE;ORAL
NEVIRAPINE

APOTEX INC	400MG	A205258	001	Apr 03, 2014
TECH ORGANIZED	100MG	A207467	001	Jul 31, 2017
	400MG	A207467	002	Jul 31, 2017

NIACIN
CAPSULE;ORAL
WAMPOCAP

MEDPOINTE PHARM HLC	500MG	N011073	003	

TABLET;ORAL
NIACIN

EVERYLIFE	500MG	A083203	001	
HALSEY	500MG	A083453	001	
HIKMA PHARMS	500MG	A083718	001	
IMPAX LABS	500MG	A083115	001	
IVAX SUB TEVA PHARMS	500MG	A083180	001	
MK LABS	500MG	A083525	001	
PUREPAC PHARM	500MG	A083271	001	
SANDOZ	500MG	A083306	001	
TABLICAPS	500MG	A084237	001	
WATSON LABS	500MG	A083136	001	
	500MG	A083305	001	
	500MG	A085172	001	

NICOLAR

SANOFI AVENTIS US	500MG	A083823	001	

TABLET, EXTENDED RELEASE;ORAL
NIASPAN

ABBVIE	375MG	N020381	001	Jul 28, 1997

NIASPAN TITRATION STARTER PACK

ABBVIE	375MG;500MG;750MG	N020381	005	Jul 28, 1997

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE
SUSPENSION;ORAL
TPN

INTL MINERALS	15MG/5ML;3.75MG/5ML;600MG/5ML	N008378	003

NICARDIPINE HYDROCHLORIDE
CAPSULE;ORAL
CARDENE

CHIESI USA INC	20MG **	N019488	001	Dec 21, 1988
	30MG **	N019488	002	Dec 21, 1988

NICARDIPINE HYDROCHLORIDE

WATSON LABS	20MG	A074670	001	Oct 28, 1996
	30MG	A074670	002	Oct 28, 1996

CAPSULE, EXTENDED RELEASE;ORAL
CARDENE SR

+ CHIESI USA INC	30MG **	N020005	001	Feb 21, 1992
+	45MG **	N020005	002	Feb 21, 1992
+	60MG **	N020005	003	Feb 21, 1992

INJECTABLE;INJECTION
CARDENE

+ CHIESI USA INC	25MG/10ML (2.5MG/ML)	N019734	001	Jan 30, 1992

NICARDIPINE HYDROCHLORIDE

LUITPOLD	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009
MYLAN INSTITUTIONAL	25MG/10ML (2.5MG/ML)	A090664	001	Nov 17, 2009
NAVINTA LLC	25MG/10ML (2.5MG/ML)	A090125	001	Nov 17, 2009
SUN PHARMA GLOBAL	25MG/10ML (2.5MG/ML)	N078405	001	Nov 17, 2009
WEST-WARD PHARMS INT	25MG/10ML (2.5MG/ML)	A078714	001	Dec 28, 2009
WOCKHARDT	25MG/10ML (2.5MG/ML)	A090671	001	Nov 17, 2009

INJECTABLE;INTRAVENOUS
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER

+ CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	005	Nov 07, 2008

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

EXELA PHARMA SCIENCE	20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016
	40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

NICLOSAMIDE
TABLET, CHEWABLE;ORAL
NICLOCIDE
BAYER PHARMS 500MG N018669 001 May 14, 1982

NICOTINE
FILM, EXTENDED RELEASE;TRANSDERMAL
NICOTROL
MCNEIL CONS 15MG/16HR N020536 001 Jul 03, 1996
PROSTEP
AVEVA 11MG/24HR N019983 003 Dec 23, 1998
22MG/24HR N019983 004 Dec 23, 1998

NICOTINE POLACRILEX
GUM, CHEWING;BUCCAL
NICOTINE POLACRILEX
IVAX SUB TEVA PHARMS EQ 2MG BASE A076880 001 Feb 18, 2009
EQ 4MG BASE A077850 001 Feb 18, 2009
THRIVE
GLAXOSMITHKLINE CONS EQ 2MG BASE A077658 001 Jun 19, 2007
EQ 4MG BASE A077656 001 Jun 19, 2007

NIFEDIPINE
CAPSULE;ORAL
ADALAT
BAYER PHARMS 10MG N019478 001 Nov 27, 1985
20MG N019478 002 Sep 17, 1986
NIFEDIPINE
CHASE LABS NJ 10MG A072409 001 Jul 04, 1990
20MG A073421 001 Jun 19, 1991
TEVA 10MG A072651 001 Feb 19, 1992
PROCARDIA
\+ PFIZER 20MG ** N018482 002 Jul 24, 1986
TABLET, EXTENDED RELEASE;ORAL
AFEDITAB CR
WATSON LABS 60MG A075659 001 Oct 26, 2001
WATSON LABS TEVA 30MG A075128 001 Mar 10, 2000
NIFEDIPINE
MARTEC USA LLC 90MG A075414 003 Mar 23, 2004
MYLAN 30MG A075108 001 Dec 17, 1999
MYLAN LABS LTD 30MG A090602 001 Sep 13, 2010
60MG A090602 002 Sep 13, 2010
90MG A090602 003 Sep 13, 2010

NILUTAMIDE
TABLET;ORAL
NILANDRON
CONCORDIA PHARMS INC 50MG N020169 001 Sep 19, 1996

NIMODIPINE
CAPSULE;ORAL
NIMOTOP
\+ BAYER PHARMS 30MG ** N018869 001 Dec 28, 1988

NISOLDIPINE
TABLET, EXTENDED RELEASE;ORAL
SULAR
\+ COVIS PHARMA BV 10MG ** N020356 001 Feb 02, 1995
\+ 20MG ** N020356 002 Feb 02, 1995
\+ 25.5MG ** N020356 006 Jan 02, 2008
\+ 30MG ** N020356 003 Feb 02, 1995
\+ 40MG ** N020356 004 Feb 02, 1995

NITRIC OXIDE
GAS;INHALATION
INOMAX
\+ MALLINCKRODT HOSP 100PPM ** N020845 002 Dec 23, 1999

NITROFURANTOIN

CAPSULE;ORAL				
NITROFURANTOIN				
	WATSON LABS	50MG	A084326 001	
		100MG	A084326 002	
TABLET;ORAL				
FURADANTIN				
	PROCTER AND GAMBLE	50MG	N008693 001	
		100MG	N008693 002	
FURALAN				
	LANNETT	50MG	A080017 001	
		100MG	A080017 002	
NITROFURANTOIN				
	ELKINS SINN	50MG	A080003 001	
		100MG	A080003 002	
	IVAX SUB TEVA PHARMS	50MG	A080078 002	
		100MG	A080078 001	
	SANDOZ	50MG	A080043 001	
		100MG	A080043 002	
	WATSON LABS	50MG	A080447 001	
		50MG	A085797 001	
		100MG	A080447 002	
		100MG	A085796 001	
	WHITEWORTH TOWN PLSN	100MG	A084085 002	

NITROFURANTOIN SODIUM

INJECTABLE;INJECTION				
IVADANTIN				
	PROCTER AND GAMBLE	EQ 180MG BASE/VIAL	N012402 001	

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL				
NITROFURANTOIN				
	MYLAN	100MG	A074967 002	Jul 09, 1997
	SANDOZ	25MG	A074336 001	Jan 25, 1995
		50MG	A074336 002	Jan 25, 1995
		100MG	A074336 003	Jan 25, 1995
	WATSON LABS	25MG	A073696 001	Dec 31, 1992
		50MG	A073696 002	Dec 31, 1992
		100MG	A073696 003	Dec 31, 1992
NITROFURANTOIN MACROCRYSTALLINE				
	WATSON LABS	50MG	A070248 001	Jun 24, 1988
		100MG	A070249 001	Jun 24, 1988

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL				
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)				
	RANBAXY LABS LTD	75MG;25MG	A076951 001	Mar 30, 2005

NITROFURAZONE

CREAM;TOPICAL				
FURACIN				
	SHIRE	0.2%	A083789 001	
DRESSING;TOPICAL				
ACTIN-N				
	SHERWOOD MEDCL	0.2%	N017343 001	
OINTMENT;TOPICAL				
FURACIN				
	SHIRE	0.2%	N005795 001	
NITROFURAZONE				
	AMBIX	0.2%	A086077 001	
	LANNETT	0.2%	A084393 001	
	PERRIGO NEW YORK	0.2%	A084968 001	
	TARO	0.2%	A086156 001	
	WENDT	0.2%	A086766 001	
POWDER;TOPICAL				
FURACIN				
	SHIRE	0.2%	A083791 001	
SOLUTION;TOPICAL				
NITROFURAZONE				
	PERRIGO NEW YORK	0.2%	A085130 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

NITROFURAZONE
SOLUTION;TOPICAL
NITROFURAZONE

	WENDT	0.2%	A087081 001	

NITROGLYCERIN
AEROSOL;SUBLINGUAL
NITROLINGUAL

	POHL BOSKAMP	0.4MG/SPRAY	N018705 001	Oct 31, 1985

FILM, EXTENDED RELEASE;TRANSDERMAL
NITROGLYCERIN

	LANNETT CO INC	0.2MG/HR	A075115 001	Aug 10, 2004
		0.4MG/HR	A075115 002	Aug 10, 2004
	MYLAN TECHNOLOGIES	0.1MG/HR	A074992 004	Nov 12, 1999
		0.2MG/HR	A074992 003	Nov 12, 1999
		0.4MG/HR	A074992 002	Nov 12, 1999
		0.6MG/HR	A074992 001	Nov 12, 1999

TRANSDERM-NITRO

+	NOVARTIS	0.1MG/HR **	N020144 001	Feb 27, 1996
+		0.2MG/HR **	N020144 002	Feb 27, 1996
+		0.4MG/HR **	N020144 003	Feb 27, 1996
+		0.6MG/HR **	N020144 004	Feb 27, 1996
+		0.8MG/HR **	N020144 005	Feb 27, 1996

INJECTABLE;INJECTION
NITRO IV

	POHL BOSKAMP	5MG/ML	N018672 002	Aug 30, 1983

NITRO-BID

	SANOFI AVENTIS US	5MG/ML	N018621 001	Jan 05, 1982
		10MG/ML	A071159 001	Feb 28, 1990

NITROGLYCERIN

	ABRAXIS PHARM	5MG/ML	A070077 001	Dec 13, 1985
		5MG/ML	A071203 001	May 08, 1987
+	HOSPIRA	5MG/ML **	N018531 001	
	INTL MEDICATION	5MG/ML	A070026 001	Sep 10, 1985
	LUITPOLD	5MG/ML	A071492 001	May 24, 1988
	SMITH AND NEPHEW	5MG/ML	A070633 001	Jun 19, 1986
		5MG/ML	A070634 001	Jun 19, 1986

NITROGLYCERIN IN DEXTROSE 5%

	HOSPIRA	0.1MG/ML	A074083 001	Oct 26, 1994
		10MG/100ML	A071846 001	Aug 31, 1990
		20MG/100ML	A071847 001	Aug 31, 1990
		40MG/100ML	A071848 001	Aug 31, 1990

NITROL

	RORER	0.8MG/ML	N018774 001	Jan 19, 1983

NITRONAL

	POHL BOSKAMP	1MG/ML	N018672 001	Aug 30, 1983

NITROSTAT

	PARKE DAVIS	0.8MG/ML	N018588 001	
		5MG/ML	A070863 001	Jan 08, 1987
		5MG/ML	N018588 002	Dec 23, 1983
		10MG/ML	A070871 001	Jan 08, 1987
		10MG/ML	A070872 001	Jan 08, 1987

TRIDIL

	HOSPIRA	0.5MG/ML	N018537 002	Jun 16, 1983
		5MG/ML	N018537 001	

NIZATIDINE
CAPSULE;ORAL
AXID

	SMITHKLINE BEECHAM	150MG	N019508 001	Apr 12, 1988
		300MG	N019508 002	Apr 12, 1988

NIZATIDINE

	ANI PHARMS INC	150MG	A075461 001	Jul 08, 2002
		300MG	A075461 002	Jul 08, 2002
	APOTEX INC	150MG	A076383 001	Jan 23, 2003
		300MG	A076383 002	Jan 23, 2003
	MYLAN PHARMS INC	150MG	A075934 001	Jul 09, 2002
		300MG	A075934 002	Jul 09, 2002

NIZATIDINE					
SOLUTION;ORAL					
AXID					
+	BRAINTREE	15MG/ML **	N021494	001	May 25, 2004
NONOXYNOL-9					
AEROSOL;VAGINAL					
DELFEN					
	PERSONAL PRODS	12.5%	N014349	002	
NOREPINEPHRINE BITARTRATE					
INJECTABLE;INJECTION					
NOREPINEPHRINE BITARTRATE					
	METRICS PHARM	EQ 1MG BASE/ML	A040522	001	Sep 30, 2004
NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE					
INJECTABLE;INJECTION					
RAVOCAINE AND NOVOCAIN W/ LEVOPHED					
	EASTMAN KODAK	EQ 0.033MG BASE/ML;2%;0.4%	N008592	003	
NORETHINDRONE					
TABLET;ORAL					
NORLUTIN					
	PARKE DAVIS	5MG	N010895	002	
NORETHINDRONE ACETATE					
TABLET;ORAL					
AYGESTIN					
+	DURAMED RES	5MG	N018405	001	Apr 21, 1982
NORLUTATE					
	PARKE DAVIS	5MG	N012184	002	
NORFLOXACIN					
SOLUTION/DROPS;OPHTHALMIC					
CHIBROXIN					
	MERCK	0.3%	N019757	001	Jun 17, 1991
TABLET;ORAL					
NOROXIN					
+	MERCK	400MG **	N019384	002	Oct 31, 1986
NORGESTREL					
TABLET;ORAL					
OPILL					
+	LABORATOIRE HRA	0.075MG	N017031	001	
NORTRIPTYLINE HYDROCHLORIDE					
CAPSULE;ORAL					
AVENTYL HYDROCHLORIDE					
	LILLY	EQ 10MG BASE	N014684	001	
		EQ 25MG BASE	N014684	002	
NORTRIPTYLINE HYDROCHLORIDE					
	ANI PHARMS INC	EQ 10MG BASE	A074054	001	Dec 31, 1992
		EQ 25MG BASE	A074054	002	Dec 31, 1992
		EQ 50MG BASE	A074054	003	Dec 31, 1992
		EQ 75MG BASE	A074054	004	Dec 31, 1992
	AUROLIFE PHARMA LLC	EQ 10MG BASE	A074835	001	Jun 30, 1997
		EQ 25MG BASE	A074835	002	Jun 30, 1997
		EQ 50MG BASE	A074835	003	Jun 30, 1997
		EQ 75MG BASE	A074835	004	Jun 30, 1997
	MYLAN	EQ 10MG BASE	A074234	001	Jul 26, 1993
		EQ 25MG BASE	A074234	002	Jul 26, 1993
		EQ 50MG BASE	A074234	003	Jul 26, 1993
		EQ 75MG BASE	A074234	004	Jul 26, 1993
	TEVA	EQ 10MG BASE	A073667	001	Apr 11, 1996
		EQ 25MG BASE	A073667	002	Apr 11, 1996
		EQ 50MG BASE	A073667	003	Apr 11, 1996
		EQ 75MG BASE	A073667	004	Apr 11, 1996
SOLUTION;ORAL					
AVENTYL					
+	RANBAXY	EQ 10MG BASE/5ML **	N014685	001	
PAMELOR					
	SPECGX LLC	EQ 10MG BASE/5ML	N018012	001	

NYSTATIN

CREAM;TOPICAL				
CANDEX				
	BAYER PHARMS	100,000 UNITS/GM	A061810 001	
MYCOSTATIN				
	DELCOR ASSET CORP	100,000 UNITS/GM **	A060575 001	
MYKINAC				
	ALPHARMA US PHARMS	100,000 UNITS/GM	A062387 001	Jul 29, 1982
NILSTAT				
	LEDERLE	100,000 UNITS/GM	A061445 001	
NYSTATIN				
	TARO	100,000 UNITS/GM	A062457 001	Jul 28, 1983
LOTION;TOPICAL				
CANDEX				
	BAYER PHARMS	100,000 UNITS/ML	N050233 001	
OINTMENT;TOPICAL				
MYCOSTATIN				
	DELCOR ASSET CORP	100,000 UNITS/GM **	A060571 001	
MYKINAC				
	ALPHARMA US PHARMS	100,000 UNITS/GM	A062731 001	Sep 22, 1986
NILSTAT				
	LEDERLE	100,000 UNITS/GM	A061444 001	
PASTILLE;ORAL				
MYCOSTATIN				
	DELCOR ASSET CORP	200,000 UNITS	N050619 001	Apr 09, 1987
POWDER;ORAL				
BARSTATIN 100				
	BARLAN	100%	A062489 001	Apr 27, 1988
NILSTAT				
+	DAVA PHARMS INC	100% **	N050576 001	Dec 22, 1983
NYSTATIN				
	PADDOCK LLC	100%	A062613 001	Nov 26, 1985
POWDER;TOPICAL				
MYCOSTATIN				
	DELCOR ASSET CORP	100,000 UNITS/GM **	A060578 001	
NYSTATIN				
	NESHER PHARMS	100,000 UNITS/GM	A065321 001	Aug 18, 2006
SUPPOSITORY;VAGINAL				
NYSERT				
	WARNER CHILCOTT	100,000 UNITS	N050478 001	
SUSPENSION;ORAL				
MYCOSTATIN				
	DELCOR ASSET CORP	100,000 UNITS/ML	A061533 001	
NILSTAT				
+	GLENMARK GENERICS	100,000 UNITS/ML **	N050299 001	
NYSTATIN				
	ALPHARMA US PHARMS	100,000 UNITS/ML	A062571 001	Oct 29, 1985
	G AND W LABS INC	100,000 UNITS/ML	A062349 001	Jul 14, 1982
		100,000 UNITS/ML	A062776 001	Dec 17, 1987
	MORTON GROVE	100,000 UNITS/ML	A062835 001	Nov 19, 1987
	PHARMADERM	100,000 UNITS/ML	A062518 001	Jul 06, 1984
	PHARMAFAIR	100,000 UNITS/ML	A062541 001	Jan 16, 1985
	SOCORRO	100,000 UNITS/ML	A062832 001	Dec 27, 1991
	TEVA	100,000 UNITS/ML	A062670 001	Jun 18, 1987
NYSTEX				
	SAVAGE LABS	100,000 UNITS/ML	A062519 001	Jul 06, 1984
TABLET;ORAL				
MYCOSTATIN				
	DELCOR ASSET CORP	500,000 UNITS	A060574 001	
NILSTAT				
	LEDERLE	500,000 UNITS	A061151 001	
NYSTATIN				
	QUANTUM PHARMICS	500,000 UNITS	A062525 001	Oct 29, 1984
	SANDOZ	500,000 UNITS	A062065 001	
	USL PHARMA	500,000 UNITS	A062524 001	Nov 26, 1985
	WATSON LABS	500,000 UNITS	A062402 001	Dec 16, 1982
TABLET;VAGINAL				
KOROSTATIN				
	HOLLAND RANTOS	100,000 UNITS	A061718 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

NYSTATIN

TABLET;VAGINAL				
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS		A060577 001	
NILSTAT				
LEDERLE	100,000 UNITS		A061325 001	
NYSTATIN				
FOUGERA	100,000 UNITS		A062459 001	Nov 09, 1983
ODYSSEY PHARMS	100,000 UNITS		A062615 001	Oct 17, 1985
PHARMADERM	100,000 UNITS		A062460 001	Nov 09, 1983
QUANTUM PHARMICS	100,000 UNITS		A062509 001	Apr 03, 1984
SANDOZ	100,000 UNITS		A061965 001	
TEVA	100,000 UNITS		A062502 001	Dec 23, 1983
WATSON LABS	100,000 UNITS		A062176 001	

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL				
MYCO-TRIACET II				
TEVA	100,000 UNITS/GM;0.1%		A061954 002	Sep 20, 1985
MYCOLOG-II				
DELCOR ASSET CORP	100,000 UNITS/GM;0.1%	**	A060576 002	May 01, 1985
MYLAN PHARMS INC	100,000 UNITS/GM;0.1%	**	A062606 001	May 15, 1985
MYTREX F				
SAVAGE LABS	100,000 UNITS/GM;0.1%		A062597 001	Oct 08, 1985
NYSTATIN AND TRIAMCINOLONE ACETONIDE				
ALPHARMA US PHARMS	100,000 UNITS/GM;0.1%		A063010 001	Dec 20, 1988
PERRIGO NEW YORK	100,000 UNITS/GM;0.1%		A062186 002	Jun 06, 1985
PHARMAFAIR	100,000 UNITS/GM;0.1%		A062657 001	Jul 30, 1986
TARO	100,000 UNITS/GM;0.1%		A062347 001	Mar 30, 1987
NYSTATIN TRIAMCINOLONE ACETONIDE				
PHARMADERM	100,000 UNITS/GM;0.1%		A062596 001	Oct 08, 1985
OINTMENT;TOPICAL				
MYCO-TRIACET II				
TEVA	100,000 UNITS/GM;0.1%		A062045 002	Nov 26, 1985
MYCOLOG-II				
MYLAN PHARMS INC	100,000 UNITS/GM;0.1%	**	A060572 001	Jun 28, 1985
MYTREX F				
SAVAGE LABS	100,000 UNITS/GM;0.1%		A062601 001	Oct 09, 1985
NYSTATIN AND TRIAMCINOLONE ACETONIDE				
PERRIGO NEW YORK	100,000 UNITS/GM;0.1%		A062280 002	Oct 10, 1985
PHARMAFAIR	100,000 UNITS/GM;0.1%		A062656 001	Jul 30, 1986
NYSTATIN-TRIAMCINOLONE ACETONIDE				
PHARMADERM	100,000 UNITS/GM;0.1%		A062603 001	Oct 09, 1985

OCTREOTIDE ACETATE

INJECTABLE;INJECTION				
OCTREOTIDE ACETATE				
SUN PHARM INDS	EQ 0.05MG BASE/ML		A077329 001	Mar 04, 2008
	EQ 0.1MG BASE/ML		A077329 002	Mar 04, 2008
	EQ 0.2MG BASE/ML		A077330 001	Mar 04, 2008
	EQ 0.5MG BASE/ML		A077329 003	Mar 04, 2008
	EQ 1MG BASE/ML		A077331 001	Mar 04, 2008
WOCKHARDT USA	EQ 0.2MG BASE/ML		A090986 001	May 11, 2011
	EQ 1MG BASE/ML		A090986 002	May 11, 2011
OCTREOTIDE ACETATE PRESERVATIVE FREE				
WOCKHARDT USA	EQ 0.05MG BASE/ML		A090985 001	May 11, 2011
	EQ 0.1MG BASE/ML		A090985 002	May 11, 2011
	EQ 0.5MG BASE/ML		A090985 003	May 11, 2011

OFLOXACIN

INJECTABLE;INJECTION				
FLOXIN				
ORTHO MCNEIL PHARM	20MG/ML		N020087 002	Mar 31, 1992
	40MG/ML		N020087 003	Mar 31, 1992
FLOXIN IN DEXTROSE 5%				
ORTHO MCNEIL PHARM	400MG/100ML		N020087 001	Mar 31, 1992
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
ORTHO MCNEIL PHARM	4MG/ML		N020087 004	Mar 31, 1992
	400MG/100ML		N020087 005	Mar 31, 1992

OFLOXACIN				
INJECTABLE;INJECTION				
OFLOXACIN				
BEDFORD	40MG/ML	A075762	001	Jan 16, 2002
SOLUTION/DROPS;OPHTHALMIC				
OFLOXACIN				
APOTEX INC	0.3%	A076513	001	May 14, 2004
SANDOZ	0.3%	A076848	001	Nov 25, 2008
SOLUTION/DROPS;OTIC				
FLOXIN OTIC				
+ DAIICHI	0.3% **	N020799	001	Dec 16, 1997
TABLET;ORAL				
FLOXIN				
JANSSEN PHARMS	200MG **	N019735	001	Dec 28, 1990
	300MG **	N019735	002	Dec 28, 1990
	400MG **	N019735	003	Dec 28, 1990
OFLOXACIN				
LARKEN LABS	200MG	A076093	001	Sep 02, 2003
	300MG	A076093	002	Sep 02, 2003
RANBAXY LABS LTD	200MG	A076220	001	Sep 02, 2003
	300MG	A076220	002	Sep 02, 2003
	400MG	A076220	003	Sep 02, 2003
OLANZAPINE				
TABLET;ORAL				
OLANZAPINE				
AJANTA PHARMA LTD	2.5MG	A206711	001	Aug 30, 2016
	5MG	A206711	002	Aug 30, 2016
	7.5MG	A206711	003	Aug 30, 2016
	10MG	A206711	004	Aug 30, 2016
	15MG	A206711	005	Aug 30, 2016
	20MG	A206711	006	Aug 30, 2016
MYLAN PHARMS INC	2.5MG	A076866	001	Apr 23, 2012
	5MG	A076866	002	Apr 23, 2012
	7.5MG	A076866	003	Apr 23, 2012
	10MG	A076866	004	Apr 23, 2012
	15MG	A076866	005	Apr 23, 2012
	20MG	A076866	006	Apr 23, 2012
TABLET, ORALLY DISINTEGRATING;ORAL				
OLANZAPINE				
AJANTA PHARMA LTD	5MG	A204320	001	May 30, 2017
	10MG	A204320	002	May 30, 2017
	15MG	A204320	003	May 30, 2017
	20MG	A204320	004	May 30, 2017
OLIVE OIL; SOYBEAN OIL				
INJECTABLE;INJECTION				
CLINOLIPID 20%				
+ BAXTER HLTHCARE CORP	16%(160GM/1000ML);4% (40GM/1000ML)	N204508	001	Oct 03, 2013
OLOPATADINE HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
OLOPATADINE HYDROCHLORIDE				
ZAMBON SPA	EQ 0.1% BASE	A204706	001	Dec 07, 2015
OMEGA-3-ACID ETHYL ESTERS TYPE A				
CAPSULE;ORAL				
OMTRYG				
+ OSMOTICA	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014
OMEGA-3-CARBOXYLIC ACIDS				
CAPSULE;ORAL				
EPANOVA				
+ ASTRAZENECA PHARMS	1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	N205060	001	May 05, 2014

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL					
PRILOSEC					
+	ASTRAZENECA PHARMS	10MG **	N019810	003	Oct 05, 1995
+		20MG **	N019810	001	Sep 14, 1989
+		40MG **	N019810	002	Jan 15, 1998

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL					
ONDANSETRON					
	CHARTWELL MOLECULES	4MG	A077406	003	Dec 26, 2006
		8MG	A077406	004	Dec 26, 2006
		16MG	A077406	001	Dec 26, 2006
		24MG	A077406	002	Dec 26, 2006
	NESHER PHARMS	4MG	A077717	001	Jun 25, 2007
		8MG	A077717	002	Jun 25, 2007

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION					
ONDANSETRON HYDROCHLORIDE					
	APOTEX INC	EQ 2MG BASE/ML	A077368	001	Dec 26, 2006
	HOSPIRA	EQ 2MG BASE/ML	A076695	001	Dec 26, 2006
	LANNETT CO INC	EQ 2MG BASE/ML	A090116	001	Apr 14, 2010
		EQ 2MG BASE/ML	A090883	001	Aug 05, 2010
	LUITPOLD	EQ 2MG BASE/ML	A077582	001	Dec 26, 2006
	MYLAN LABS LTD	EQ 2MG BASE/ML	A078257	001	Apr 23, 2008
	PLIVA HRVATSKA DOO	EQ 2MG BASE/ML	A077544	001	Dec 26, 2006
	SAGENT PHARMS	EQ 2MG BASE/ML	A078180	001	Mar 26, 2007
	SUN PHARM INDS (IN)	EQ 2MG BASE/ML	A077172	001	Dec 26, 2006
ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER					
	HOSPIRA	EQ 0.64MG BASE/ML	A076978	001	Feb 26, 2007
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
	APOTEX INC	EQ 2MG BASE/ML	A077343	001	Dec 26, 2006
	HOSPIRA	EQ 2MG BASE/ML	A076696	001	Dec 26, 2006
	LUITPOLD	EQ 2MG BASE/ML	A077387	001	Dec 26, 2006
	MYLAN LABS LTD	EQ 2MG BASE/ML	A078244	001	Apr 23, 2008
	SUN PHARM INDS LTD	EQ 2MG BASE/ML	A077173	001	Dec 26, 2006
	TARO PHARMS IRELAND	EQ 2MG BASE/ML	A078014	001	Mar 21, 2008
ZOFRAN					
+	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML **	N020007	001	Jan 04, 1991
ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER					
+	GLAXOSMITHKLINE	EQ 0.64MG BASE/ML **	N020403	001	Jan 31, 1995
ZOFRAN PRESERVATIVE FREE					
+	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML **	N020007	003	Dec 10, 1993
TABLET;ORAL					
ONDANSETRON HYDROCHLORIDE					
	CHARTWELL MOLECULES	EQ 4MG BASE	A077303	001	Jun 25, 2007
		EQ 8MG BASE	A077303	002	Jun 25, 2007
		EQ 24MG BASE	A077303	004	Jun 25, 2007
	HIKMA INTL PHARMS	EQ 4MG BASE	A077545	001	Sep 06, 2007
		EQ 8MG BASE	A077545	002	Sep 06, 2007
		EQ 24MG BASE	A077545	003	Sep 06, 2007
	TARO	EQ 4MG BASE	A077729	001	Mar 28, 2011
		EQ 8MG BASE	A077729	002	Mar 28, 2011
		EQ 24MG BASE	A077729	003	Mar 28, 2011

ORPHENADRINE CITRATE

INJECTABLE;INJECTION					
NORFLEX					
+	TELIGENT	30MG/ML	N013055	001	
ORPHENADRINE CITRATE					
	WATSON LABS	30MG/ML	A087062	001	
TABLET, EXTENDED RELEASE;ORAL					
NORFLEX					
+	MEDICIS	100MG	N012157	001	
ORPHENADRINE CITRATE					
	ASCOT	100MG	A088067	001	Apr 06, 1983
	SANDOZ	100MG	A085046	001	
	WATSON LABS	100MG	A084303	001	

ORPHENADRINE HYDROCHLORIDE				
TABLET;ORAL				
DISIPAL				
3M	50MG	N010653	001	
OSELTAMIVIR PHOSPHATE				
FOR SUSPENSION;ORAL				
TAMIFLU				
ROCHE	EQ 12MG BASE/ML	N021246	001	Dec 14, 2000
OXACILLIN SODIUM				
CAPSULE;ORAL				
BACTOCILL				
GLAXOSMITHKLINE	EQ 250MG BASE	A061336	001	
	EQ 250MG BASE	A062241	001	
	EQ 500MG BASE	A061336	002	
	EQ 500MG BASE	A062241	002	
OXACILLIN SODIUM				
ANI PHARMS INC	EQ 250MG BASE	A062222	001	
	EQ 500MG BASE	A062222	002	
APOTHECON	EQ 250MG BASE	A061450	002	
	EQ 500MG BASE	A061450	001	
PROSTAPHLIN				
APOTHECON	EQ 500MG BASE	N050118	002	
FOR SOLUTION;ORAL				
BACTOCILL				
GLAXOSMITHKLINE	EQ 250MG BASE/5ML	A062321	001	
OXACILLIN SODIUM				
APOTHECON	EQ 250MG BASE/5ML	A061457	001	
TEVA	EQ 250MG BASE/5ML	A062252	001	
PROSTAPHLIN				
APOTHECON	EQ 250MG BASE/5ML	N050194	001	
INJECTABLE;INJECTION				
BACTOCILL				
GLAXOSMITHKLINE	EQ 500MG BASE/VIAL **	A061334	009	Mar 26, 1982
	EQ 1GM BASE/VIAL **	A061334	006	Mar 26, 1982
	EQ 1GM BASE/VIAL **	A062736	001	Dec 19, 1986
	EQ 2GM BASE/VIAL **	A061334	007	Mar 26, 1982
	EQ 2GM BASE/VIAL **	A062736	002	Dec 19, 1986
	EQ 4GM BASE/VIAL **	A061334	008	Mar 26, 1982
	EQ 10GM BASE/VIAL **	A061334	010	
OXACILLIN SODIUM				
+ APOTHECON	EQ 250MG BASE/VIAL **	N050195	001	
+	EQ 500MG BASE/VIAL **	N050195	002	
+	EQ 1GM BASE/VIAL **	N050195	003	
+	EQ 2GM BASE/VIAL **	N050195	004	
+	EQ 4GM BASE/VIAL **	N050195	005	
ELKINS SINN	EQ 250MG BASE/VIAL	A062711	001	Feb 03, 1989
	EQ 500MG BASE/VIAL	A062711	002	Feb 03, 1989
	EQ 1GM BASE/VIAL	A062711	003	Feb 03, 1989
	EQ 2GM BASE/VIAL	A062711	004	Feb 03, 1989
	EQ 4GM BASE/VIAL	A062711	005	Feb 03, 1989
	EQ 10GM BASE/VIAL	A062711	006	Feb 03, 1989
ISTITUTO BIO ITA SPA	EQ 125MG BASE/VIAL	A062798	003	Dec 11, 1995
	EQ 250MG BASE/VIAL	A062798	004	Dec 11, 1995
	EQ 500MG BASE/VIAL	A062798	005	Dec 11, 1995
	EQ 1GM BASE/VIAL	A062798	001	Dec 11, 1995
	EQ 2GM BASE/VIAL	A062798	002	Dec 11, 1995
MYLAN LABS LTD	EQ 1GM BASE/VIAL	A091486	001	Aug 25, 2014
	EQ 2GM BASE/VIAL	A091486	002	Aug 25, 2014
SANDOZ	EQ 250MG BASE/VIAL	A061490	001	
	EQ 500MG BASE/VIAL	A061490	002	
	EQ 1GM BASE/VIAL	A061490	003	
	EQ 2GM BASE/VIAL	A061490	004	
	EQ 10GM BASE/VIAL	A061490	006	May 09, 1991
WATSON LABS INC	EQ 250MG BASE/VIAL	A062856	001	Oct 26, 1988
	EQ 500MG BASE/VIAL	A062856	002	Oct 26, 1988
	EQ 1GM BASE/VIAL	A062856	003	Oct 26, 1988
	EQ 2GM BASE/VIAL	A062856	004	Oct 26, 1988
	EQ 4GM BASE/VIAL	A062856	005	Oct 26, 1988

OXACILLIN SODIUM				
INJECTABLE;INJECTION				
OXACILLIN SODIUM				
	EQ 10GM BASE/VIAL	A062984	001	Sep 29, 1988
POWDER;INTRAVENOUS				
OXACILLIN SODIUM				
SANDOZ	EQ 1GM BASE/VIAL	A062737	001	Dec 23, 1986
	EQ 2GM BASE/VIAL	A062737	002	Dec 23, 1986
OXALIPLATIN				
INJECTABLE;IV (INFUSION)				
ELOXATIN				
+ SANOFI AVENTIS US	50MG/VIAL **	N021492	001	Aug 09, 2002
+	100MG/VIAL **	N021492	002	Aug 09, 2002
+	200MG/40ML (5MG/ML) **	N021759	003	Nov 17, 2006
OXALIPLATIN				
FRESENIUS KABI ONCOL	50MG/VIAL	A078810	001	Aug 07, 2009
	100MG/VIAL	A078810	002	Aug 07, 2009
SANDOZ	50MG/VIAL	A090849	001	Apr 28, 2011
	100MG/VIAL	A090849	002	Apr 28, 2011
SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009
	100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009
OXAMNIQUINE				
CAPSULE;ORAL				
VANSIL				
PFIZER	250MG	N018069	001	
OXANDROLONE				
TABLET;ORAL				
OXANDRIN				
+ GEMINI LABS LLC	2.5MG	N013718	001	
+	10MG	N013718	002	Nov 05, 2001
OXANDROLONE				
ROXANE	2.5MG	A077249	001	Jul 10, 2007
	10MG	A077249	002	Jul 10, 2007
SANDOZ	2.5MG	A076897	001	Dec 01, 2006
	10MG	A076897	002	Dec 01, 2006
OXAPROZIN				
TABLET;ORAL				
OXAPROZIN				
ACTAVIS ELIZABETH	600MG	A075843	001	Oct 03, 2001
MYLAN	600MG	A075851	001	Aug 17, 2001
MYLAN PHARMS INC	600MG	A075847	001	Feb 28, 2001
SANDOZ	600MG	A075842	001	Apr 12, 2001
	600MG	A075850	001	Apr 27, 2001
WATSON LABS	600MG	A075848	001	Feb 09, 2001
OXAPROZIN POTASSIUM				
TABLET;ORAL				
DAYPRO ALTA				
GD SEARLE	600MG	N020776	001	Oct 17, 2002
OXAZEPAM				
CAPSULE;ORAL				
OXAZEPAM				
AM THERAP	10MG	A071955	001	Mar 03, 1988
	15MG	A071956	001	Mar 03, 1988
	30MG	A071957	001	Mar 03, 1988
FRONTIDA BIOPHARM	10MG	A071026	002	Aug 10, 1987
	15MG	A071026	003	Aug 10, 1987
	30MG	A071026	001	Aug 10, 1987
IVAX SUB TEVA PHARMS	10MG	A070943	001	Aug 03, 1987
	15MG	A070944	001	Aug 03, 1987
	30MG	A070945	001	Aug 03, 1987
MYLAN	10MG	A071713	001	Oct 20, 1987
	15MG	A071714	001	Oct 20, 1987
	30MG	A071715	001	Oct 20, 1987
WATSON LABS	15MG	A072953	001	Sep 28, 1990
	30MG	A072954	001	Sep 28, 1990
WATSON LABS TEVA	10MG	A072952	001	Sep 28, 1990

OXAZEPAM

CAPSULE;ORAL				
SERAX				
	ALPHARMA US PHARMS	10MG **	N015539 002	
		15MG **	N015539 004	
		30MG **	N015539 006	
ZAXOPAM				
	QUANTUM PHARMICS	10MG	A070650 001	Mar 01, 1988
		15MG	A070640 001	Mar 01, 1988
		30MG	A070641 001	Mar 01, 1988
TABLET;ORAL				
OXAZEPAM				
	PARKE DAVIS	15MG	A071508 001	Feb 02, 1987
	SUN PHARM INDUSTRIES	15MG	A070683 001	Jan 16, 1987
	WATSON LABS	15MG	A071494 001	Apr 21, 1987
SERAX				
	ALPHARMA US PHARMS	15MG **	N015539 008	

OXCARBAZEPINE

TABLET;ORAL				
OXCARBAZEPINE				
	JUBILANT CADISTA	150MG	A090239 001	Jan 25, 2010
		300MG	A090239 002	Jan 25, 2010
		600MG	A090239 003	Jan 25, 2010

OXPRENOLOL HYDROCHLORIDE

CAPSULE;ORAL				
TRASICOR				
	NOVARTIS	20MG	N018166 001	Dec 28, 1983
		40MG	N018166 002	Dec 28, 1983
		80MG	N018166 003	Dec 28, 1983
		160MG	N018166 004	Dec 28, 1983

OXTRIPHYLLINE

SOLUTION;ORAL				
CHOLEDYL				
	PARKE DAVIS	100MG/5ML	N009268 012	Nov 27, 1984
OXTRIPHYLLINE				
	MORTON GROVE	100MG/5ML	A088243 001	Dec 05, 1983
SYRUP;ORAL				
CHOLEDYL				
	PARKE DAVIS	50MG/5ML	N009268 011	
OXTRIPHYLLINE PEDIATRIC				
	MORTON GROVE	50MG/5ML	A088242 001	Dec 05, 1983
TABLET, DELAYED RELEASE;ORAL				
CHOLEDYL				
	PARKE DAVIS	100MG	N009268 003	
		200MG	N009268 007	
OXTRIPHYLLINE				
	WATSON LABS	100MG	A087866 001	Aug 25, 1983
		200MG	A087835 001	Aug 25, 1983
TABLET, EXTENDED RELEASE;ORAL				
CHOLEDYL SA				
	WARNER CHILCOTT LLC	400MG	A087863 001	May 24, 1983
		600MG	A086742 001	

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL				
OXYBUTYNIN				
	BARR LABS DIV TEVA	3.9MG/24HR	A090526 001	Mar 04, 2014
GEL, METERED;TRANSDERMAL				
GELNIQUE 3%				
+	ALLERGAN SALES LLC	3%	N202513 001	Dec 07, 2011

OXYBUTYNIN CHLORIDE

SYRUP;ORAL				
DITROPAN				
+	ORTHO MCNEIL JANSSEN	5MG/5ML **	N018211 001	
OXYBUTYNIN CHLORIDE				
	APOTEX INC	5MG/5ML	A074997 001	Oct 15, 1997
	MIKART	5MG/5ML	A075039 001	Jan 29, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

OXYBUTYNIN CHLORIDE					
TABLET;ORAL					
DITROPAN					
+	JANSSEN PHARMS	5MG **	N017577	001	
OXYBUTYNIN CHLORIDE					
	QUANTUM PHARMICS	5MG	A072296	001	Dec 08, 1988
	USL PHARMA	5MG	A070746	001	Mar 10, 1988
	WATSON LABS	5MG	A072485	001	Apr 19, 1989
TABLET, EXTENDED RELEASE;ORAL					
DITROPAN XL					
+	JANSSEN PHARMS	15MG **	N020897	003	Jun 22, 1999
OXYCODONE HYDROCHLORIDE					
TABLET;ORAL					
ROXYBOND					
	DAIICHI SANKYO INC	5MG	N209777	001	Apr 20, 2017
		15MG	N209777	002	Apr 20, 2017
		30MG	N209777	003	Apr 20, 2017
TABLET, EXTENDED RELEASE;ORAL					
ROXICODONE					
	ROXANE	10MG	N020932	001	Oct 26, 1998
		30MG	N020932	002	Oct 26, 1998
OXYMETAZOLINE HYDROCHLORIDE					
SOLUTION/DROPS;OPHTHALMIC					
OCUCLEAR					
	BAYER HEALTHCARE LLC	0.025%	N018471	001	May 30, 1986
OXYMORPHONE HYDROCHLORIDE					
INJECTABLE;INJECTION					
OPANA					
+	ENDO PHARMS	1MG/ML	N011707	002	
		1.5MG/ML	N011707	001	
SUPPOSITORY;RECTAL					
NUMORPHAN					
	ENDO PHARMS	5MG	N011738	004	
TABLET, EXTENDED RELEASE;ORAL					
OPANA ER					
	ENDO PHARMS	5MG **	N021610	001	Jun 22, 2006
+		5MG	N201655	001	Dec 09, 2011
		7.5MG **	N021610	005	Feb 29, 2008
+		7.5MG	N201655	002	Dec 09, 2011
		10MG **	N021610	002	Jun 22, 2006
+		10MG	N201655	003	Dec 09, 2011
		15MG **	N021610	006	Feb 29, 2008
+		15MG	N201655	004	Dec 09, 2011
		20MG **	N021610	003	Jun 22, 2006
+		20MG	N201655	005	Dec 09, 2011
		30MG **	N021610	007	Feb 29, 2008
+		30MG	N201655	006	Dec 09, 2011
		40MG **	N021610	004	Jun 22, 2006
+		40MG	N201655	007	Dec 09, 2011
OXYMORPHONE HYDROCHLORIDE					
	PAR PHARM	5MG	A200792	001	Oct 24, 2014
		7.5MG	A200792	002	Oct 24, 2014
		10MG	A200792	003	Oct 24, 2014
		15MG	A200792	004	Oct 24, 2014
		20MG	A200792	005	Oct 24, 2014
		30MG	A200792	006	Oct 24, 2014
		40MG	A200792	007	Oct 24, 2014
	SUN PHARM INDS LTD	5MG	A203506	001	Apr 24, 2015
		7.5MG	A203506	002	Apr 24, 2015
		10MG	A203506	003	Apr 24, 2015
		15MG	A203506	004	Apr 24, 2015
		20MG	A203506	005	Apr 24, 2015
		30MG	A203506	006	Apr 24, 2015
		40MG	A203506	007	Apr 24, 2015

OXYPHENBUTAZONE				
TABLET;ORAL				
OXYPHENBUTAZONE				
WATSON LABS	100MG		A088399 001	Sep 17, 1984
TANDEARIL				
NOVARTIS	100MG		N012542 004	Sep 03, 1982
OXYPHENCYCLIMINE HYDROCHLORIDE				
TABLET;ORAL				
DARICON				
PFIZER	10MG		N011612 001	
OXYPHENONIUM BROMIDE				
TABLET;ORAL				
ANTRENYL				
NOVARTIS	5MG		N008492 002	
OXYTETRACYCLINE				
TABLET;ORAL				
TERRAMYCIN				
PFIZER	250MG		N050287 001	
OXYTETRACYCLINE CALCIUM				
SYRUP;ORAL				
TERRAMYCIN				
PFIZER	EQ 125MG BASE/5ML		A060595 001	
OXYTETRACYCLINE HYDROCHLORIDE				
CAPSULE;ORAL				
OXY-KESSO-TETRA				
FERRANTE	EQ 250MG BASE		A060179 001	
OXYTETRACYCLINE HYDROCHLORIDE				
HIKMA PHARMS	EQ 250MG BASE		A060770 001	
IMPAX LABS	EQ 250MG BASE		A060760 001	
PROTER	EQ 250MG BASE		A060869 001	
PUREPAC PHARM	EQ 250MG BASE		A060634 001	
TERRAMYCIN				
PFIZER	EQ 125MG BASE		N050286 001	
	EQ 250MG BASE		N050286 002	
INJECTABLE;INJECTION				
TERRAMYCIN				
PFIZER	EQ 250MG BASE/VIAL		A060586 001	
	EQ 500MG BASE/VIAL		A060586 002	
OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE				
OINTMENT;OPHTHALMIC				
TERRAMYCIN W/ POLYMYXIN B SULFATE				
CASPER PHARMA LLC	EQ 5MG BASE/GM;10,000 UNITS/GM		N061015 001	
OINTMENT;OTIC				
TERRAMYCIN W/ POLYMYXIN				
PFIZER	EQ 5MG BASE/GM;10,000 UNITS/GM		A061841 001	
TABLET;VAGINAL				
TERRAMYCIN-POLYMYXIN				
PFIZER	EQ 100MG BASE;100,000 UNITS		A061009 001	
OXYTOCIN				
INJECTABLE;INJECTION				
OXYTOCIN				
TEVA PHARMS USA	10USP UNITS/ML (10USP UNITS/ML)		A077453 001	Jan 24, 2008
	100USP UNITS/10ML (10USP UNITS/ML)		A077453 002	Jan 24, 2008
OXYTOCIN 10 USP UNITS IN DEXTROSE 5%				
+ ABBOTT	1USP UNITS/100ML **		N019185 004	Mar 29, 1985
+	2USP UNITS/100ML **		N019185 003	Mar 29, 1985
OXYTOCIN 20 USP UNITS IN DEXTROSE 5%				
+ ABBOTT	2USP UNITS/100ML **		N019185 002	Mar 29, 1985
OXYTOCIN 5 USP UNITS IN DEXTROSE 5%				
+ ABBOTT	1USP UNITS/100ML **		N019185 001	Mar 29, 1985
SYNTOCINON				
NOVARTIS	10USP UNITS/ML		N018245 001	
SOLUTION;NASAL				
SYNTOCINON				
RTRX	40USP UNITS/ML		N012285 001	

PACLITAXEL				
INJECTABLE;INJECTION				
PACLITAXEL				
ACCORD HLTHCARE	6MG/ML	A075436	001	Nov 12, 2004
HOSPIRA	6MG/ML	A076233	001	Aug 01, 2002
MYLAN	6MG/ML	A075278	001	Jan 25, 2002
PLIVA LACHEMA	6MG/ML	A077413	001	Mar 12, 2008
TEVA PHARMS USA	6MG/ML	A075297	001	Jan 25, 2002
PALIPERIDONE				
TABLET, EXTENDED RELEASE;ORAL				
INVEGA				
+ JANSSEN PHARMS	12MG **	N021999	004	Dec 19, 2006
PALONOSETRON HYDROCHLORIDE				
CAPSULE;ORAL				
ALOXI				
+ HELSINN HLTHCARE	EQ 0.5MG BASE **	N022233	001	Aug 22, 2008
SOLUTION;INTRAVENOUS				
PALONOSETRON HYDROCHLORIDE				
DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016
	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016
PAMIDRONATE DISODIUM				
INJECTABLE;INJECTION				
AREDIA				
+ NOVARTIS	30MG/VIAL **	N020036	001	Oct 31, 1991
	60MG/VIAL	N020036	003	May 06, 1993
	90MG/VIAL	N020036	004	May 06, 1993
PAMIDRONATE DISODIUM				
AESGEN	30MG/VIAL	A075594	001	May 06, 2002
	90MG/VIAL	A075594	002	May 06, 2002
MN PHARMS	30MG/VIAL	A078300	001	Mar 10, 2009
	90MG/VIAL	A078300	002	Mar 10, 2009
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)				
CAPSULE;ORAL				
COTAZYM				
ORGANON USA INC	30,000USP UNITS;8,000USP UNITS;30,000USP UNITS	N020580	001	Dec 09, 1996
CAPSULE, DELAYED RELEASE;ORAL				
ULTRESA				
+ FOREST LABS INC	27,600USP UNITS;13,800USP UNITS;27,600USP UNITS	N022222	001	Mar 01, 2012
+	41,400USP UNITS;20,700USP UNITS;41,400USP UNITS	N022222	002	Mar 01, 2012
+	46,000USP UNITS;23,000USP UNITS;46,000USP UNITS	N022222	003	Mar 01, 2012
PANCURONIUM BROMIDE				
INJECTABLE;INJECTION				
PANCURONIUM BROMIDE				
ELKINS SINN	1MG/ML	A072058	001	Mar 23, 1988
	2MG/ML	A072059	001	Mar 23, 1988
	2MG/ML	A072060	001	Mar 23, 1988
HOSPIRA	2MG/ML	A072321	001	Jan 19, 1989
IGI LABS INC	1MG/ML	A072210	001	Mar 31, 1988
	2MG/ML	A072211	001	Mar 31, 1988
	2MG/ML	A072212	001	Mar 31, 1988
	2MG/ML	A072213	001	Mar 31, 1988
PAVULON				
+ ORGANON USA INC	1MG/ML	N017015	002	
+	2MG/ML	N017015	001	
PANTOPRAZOLE SODIUM				
TABLET, DELAYED RELEASE;ORAL				
PANTOPRAZOLE SODIUM				
SUN PHARM INDS LTD	EQ 20MG BASE	A077058	001	Sep 10, 2007
	EQ 20MG BASE	A200794	001	May 02, 2012
	EQ 40MG BASE	A077058	002	Sep 10, 2007
	EQ 40MG BASE	A200794	002	May 02, 2012

PARAMETHADIONE				
CAPSULE;ORAL				
PARADIONE				
	ABBVIE	150MG	N006800 003	
		300MG	N006800 001	
SOLUTION;ORAL				
PARADIONE				
	ABBVIE	300MG/ML	N006800 002	
PARAMETHASONE ACETATE				
TABLET;ORAL				
HALDRONE				
	LILLY	1MG	N012772 005	
		2MG	N012772 006	
PARGYLINE HYDROCHLORIDE				
TABLET;ORAL				
EUTONYL				
	ABBOTT	10MG	N013448 002	
		25MG	N013448 003	
		50MG	N013448 004	
PARICALCITOL				
CAPSULE;ORAL				
ZEMPLAR				
+	ABBVIE	4MCG **	N021606 003	May 26, 2005
PAROMOMYCIN SULFATE				
CAPSULE;ORAL				
HUMATIN				
	KING PFIZER	EQ 250MG BASE	A062310 001	
	PARKEDALE	EQ 250MG BASE	A060521 001	
SYRUP;ORAL				
HUMATIN				
	PARKE DAVIS	EQ 125MG BASE/5ML	A060522 001	
PAROXETINE HYDROCHLORIDE				
CAPSULE;ORAL				
PAXIL				
+	APOTEX TECHNOLOGIES	EQ 10MG BASE **	N020885 001	Oct 09, 1998
+		EQ 20MG BASE **	N020885 002	Oct 09, 1998
+		EQ 30MG BASE **	N020885 003	Oct 09, 1998
+		EQ 40MG BASE **	N020885 004	Oct 09, 1998
SUSPENSION;ORAL				
PAROXETINE HYDROCHLORIDE				
	APOTEX INC	EQ 10MG BASE/5ML	A077395 001	Dec 05, 2006
TABLET;ORAL				
PAROXETINE HYDROCHLORIDE				
	MYLAN PHARMS INC	EQ 10MG BASE	A075716 001	Mar 08, 2004
		EQ 20MG BASE	A075716 002	Mar 08, 2004
		EQ 30MG BASE	A075716 003	Mar 08, 2004
		EQ 40MG BASE	A075716 004	Mar 08, 2004
	ROXANE	EQ 10MG BASE	A078026 001	Jun 29, 2007
		EQ 20MG BASE	A078026 002	Jun 29, 2007
		EQ 30MG BASE	A078026 003	Jun 29, 2007
		EQ 40MG BASE	A078026 004	Jun 29, 2007
	TEVA PHARMS	EQ 10MG BASE	A077082 001	Jun 29, 2007
		EQ 20MG BASE	A077082 002	Jun 29, 2007
		EQ 30MG BASE	A077082 003	Jun 29, 2007
		EQ 40MG BASE	A077082 004	Jun 29, 2007
	UPSHER SMITH LABS	EQ 10MG BASE	A075566 001	Mar 08, 2004
		EQ 20MG BASE	A075566 002	Mar 08, 2004
		EQ 30MG BASE	A075566 003	Mar 08, 2004
		EQ 40MG BASE	A075566 004	Mar 08, 2004
PAXIL				
	APOTEX TECHNOLOGIES	EQ 50MG BASE	N020031 004	Dec 29, 1992

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL

VOTRIENT

NOVARTIS PHARMS CORP	EQ 400MG BASE	N022465	002	Oct 19, 2009

PEGINESATIDE ACETATE

SOLUTION;INTRAVENOUS, SUBCUTANEOUS

OMONTYS

TAKEDA PHARMS USA	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799	007	Mar 27, 2012
	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799	008	Mar 27, 2012

OMONTYS PRESERVATIVE FREE

TAKEDA PHARMS USA	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799	001	Mar 27, 2012
	EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799	002	Mar 27, 2012
	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799	003	Mar 27, 2012
	EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799	004	Mar 27, 2012
	EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799	005	Mar 27, 2012
	EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799	006	Mar 27, 2012

PEMIROLAST POTASSIUM

SOLUTION/DROPS;OPHTHALMIC

ALAMAST

SANTEN	0.1%	N021079	001	Sep 24, 1999

PEMOLINE

TABLET;ORAL

CYLERT

ABBOTT	18.75MG	N016832	001	
	37.5MG	N016832	002	
	75MG	N016832	003	

PEMOLINE

ACTAVIS ELIZABETH	18.75MG	A075595	001	Feb 28, 2000
	37.5MG	A075595	002	Feb 28, 2000
	75MG	A075595	003	Feb 28, 2000
FOSUN PHARMA	18.75MG	A075286	001	Dec 27, 1999
	37.5MG	A075286	002	Jun 30, 1999
	75MG	A075286	003	Jun 30, 1999
MALLINCKRODT	18.75MG	A075726	003	Mar 30, 2001
	37.5MG	A075726	002	Mar 30, 2001
	75MG	A075726	001	Mar 30, 2001
TEVA PHARMS	18.75MG	A075030	003	Feb 22, 2000
	37.5MG	A075030	001	Jan 29, 1999
	75MG	A075030	002	Jan 29, 1999
VINTAGE PHARMS	18.75MG	A075328	001	Apr 19, 2000
	37.5MG	A075328	002	Apr 19, 2000
	75MG	A075328	003	Apr 19, 2000
WATSON LABS	18.75MG	A075287	001	Jun 13, 2001
	37.5MG	A075287	002	Sep 18, 2000
	75MG	A075287	003	Sep 18, 2000

TABLET, CHEWABLE;ORAL

CYLERT

ABBOTT	37.5MG	N017703	001	

PEMOLINE

ACTAVIS ELIZABETH	37.5MG	A075678	001	Jul 26, 2000
TEVA PHARMS	37.5MG	A075555	001	Feb 18, 2000

PENBUTOLOL SULFATE

TABLET;ORAL

LEVATOL

+	AUXILIUM PHARMS LLC	10MG **	N018976	001	Dec 30, 1987
+		20MG **	N018976	004	Jan 05, 1989

PENICILLAMINE

CAPSULE;ORAL

CUPRIMINE

ATON	125MG	N019853	002	

PENICILLIN G BENZATHINE				
INJECTABLE;INJECTION				
BICILLIN L-A				
+	KING PHARMS LLC	300,000 UNITS/ML	N050141 003	
	WYETH AYERST	300,000 UNITS/ML	N050131 001	
PERMAPEN				
	CASPER PHARMA LLC	600,000 UNITS/ML	N060014 001	
SUSPENSION;ORAL				
BICILLIN				
	WYETH AYERST	300,000 UNITS/5ML	N050126 002	
TABLET;ORAL				
BICILLIN				
	WYETH AYERST	200,000 UNITS	N050128 001	
PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE				
INJECTABLE;INJECTION				
BICILLIN C-R				
+	KING PHARMS LLC	150,000 UNITS/ML;150,000 UNITS/ML	N050138 002	
PENICILLIN G POTASSIUM				
FOR SOLUTION;ORAL				
PENICILLIN				
	TEVA	200,000 UNITS/5ML	A060307 002	
		400,000 UNITS/5ML	A060307 004	
PENICILLIN G POTASSIUM				
	MYLAN	200,000 UNITS/5ML	A060752 003	
		250,000 UNITS/5ML	A060752 002	
		400,000 UNITS/5ML	A060752 001	
	PUREPAC PHARM	250,000 UNITS/5ML	A061740 001	
		400,000 UNITS/5ML	A061740 002	
PENICILLIN-2				
	TEVA	250,000 UNITS/5ML	A060307 003	
PENTIDS '200'				
	APOTHECON	200,000 UNITS/5ML	A062149 001	
PENTIDS '400'				
	APOTHECON	400,000 UNITS/5ML	A062149 002	
PFIZERPEN G				
	PFIZER	400,000 UNITS/5ML	A060587 001	
INJECTABLE;INJECTION				
PENICILLIN G POTASSIUM				
	APOTHECON	1,000,000 UNITS/VIAL	A060362 001	
		5,000,000 UNITS/VIAL	A060362 003	
		10,000,000 UNITS/VIAL	A060362 004	
		20,000,000 UNITS/VIAL	A060362 002	
	CONSOLIDATED PHARM	500,000 UNITS/VIAL	A060806 001	
		1,000,000 UNITS/VIAL	A060806 002	
		5,000,000 UNITS/VIAL	A060806 003	
		10,000,000 UNITS/VIAL	A060806 004	
	LILLY	200,000 UNITS/VIAL	A060384 004	
		500,000 UNITS/VIAL	A060384 003	
		1,000,000 UNITS/VIAL	A060384 002	
		5,000,000 UNITS/VIAL	A060384 001	
		20,000,000 UNITS/VIAL	A060384 005	
		20,000,000 UNITS/VIAL	A060601 001	
	PARKE DAVIS	1,000,000 UNITS/VIAL	A062003 001	
		5,000,000 UNITS/VIAL	A062003 002	
	PFIZER	20,000,000 UNITS/VIAL	A060074 003	
	SANDOZ	1,000,000 UNITS/VIAL **	A065079 001	Aug 30, 2002
	WATSON LABS INC	1,000,000 UNITS/VIAL	A062991 001	Sep 13, 1988
		5,000,000 UNITS/VIAL	A062991 002	Sep 13, 1988
		10,000,000 UNITS/VIAL	A062991 003	Sep 13, 1988
		20,000,000 UNITS/VIAL	A062991 004	Sep 13, 1988
PFIZERPEN				
	PFIZER	1,000,000 UNITS/VIAL **	A060657 001	
TABLET;ORAL				
PENICILLIN G POTASSIUM				
	APOTHECON	250,000 UNITS	A060392 003	
	IVAX SUB TEVA PHARMS	400,000 UNITS	A060073 004	
	LILLY	250,000 UNITS	A060403 001	
	MYLAN	200,000 UNITS	A060781 001	

PENICILLIN G POTASSIUM

TABLET;ORAL

PENICILLIN G POTASSIUM

	250,000 UNITS	A060781	002
	400,000 UNITS	A060781	003
	500,000 UNITS	A060781	005
	800,000 UNITS	A060781	004
PUREPAC PHARM	200,000 UNITS	A061588	001
	250,000 UNITS	A061588	002
	400,000 UNITS	A061588	003
TEVA	200,000 UNITS	A060306	001
	250,000 UNITS	A060306	002
	400,000 UNITS	A060306	003
	500,000 UNITS	A060306	004
WYETH AYERST	200,000 UNITS	A060413	001
	250,000 UNITS	A060413	002
	400,000 UNITS	A060413	003

PENTIDS '200'

APOTHECON	200,000 UNITS	A062155	001

PENTIDS '250'

APOTHECON	250,000 UNITS	A062155	002

PENTIDS '400'

APOTHECON	400,000 UNITS	A060392	004
	400,000 UNITS	A062155	003

PENTIDS '800'

APOTHECON	800,000 UNITS	A060392	005
	800,000 UNITS	A062155	004

PFIZERPEN G

PFIZER	50,000 UNITS	A060075	001
	100,000 UNITS	A060075	002
	200,000 UNITS	A060075	003
	250,000 UNITS	A060075	004
	400,000 UNITS	A060075	005
	800,000 UNITS	A060075	006

PENICILLIN G PROCAINE

INJECTABLE;INJECTION

DURACILLIN A.S.

LILLY	300,000 UNITS/ML	A060093	001

PENICILLIN G PROCAINE

CONSOLIDATED PHARM	300,000 UNITS/ML	A060800	001
	600,000 UNITS/1.2ML	A060800	002
PARKE DAVIS	300,000 UNITS/ML	A062029	001
PFIZER	300,000 UNITS/VIAL	A060099	001
	1,500,000 UNITS/VIAL	A060099	002

PFIZERPEN-AS

PFIZER	300,000 UNITS/ML	A060286	001
	600,000 UNITS/ML	A060286	002

PENICILLIN G SODIUM

INJECTABLE;INJECTION

PENICILLIN G SODIUM

BRISTOL MYERS SQUIBB	5,000,000 UNITS/VIAL	A061935	001
COPANOS	5,000,000 UNITS/VIAL	A061051	001
PHARMACIA AND UPJOHN	1,000,000 UNITS/VIAL	A061046	001

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

PENICILLIN G SODIUM

WATSON LABS INC	5,000,000 UNITS/VIAL	A063014	001	Sep 13, 1988

PENICILLIN V

FOR SUSPENSION;ORAL

V-CILLIN

LILLY	125MG/0.6ML	A060002	001

PENICILLIN V POTASSIUM

FOR SOLUTION;ORAL

BEEPEN-VK

GLAXOSMITHKLINE	EQ 125MG BASE/5ML	A062270	001
	EQ 250MG BASE/5ML	A062270	002

BETAPEN-VK

APOTHECON	EQ 125MG BASE/5ML	A061149	001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

PENICILLIN V POTASSIUM

FOR SOLUTION;ORAL			
BETAPEN-VK			
	EQ 250MG BASE/5ML		A061149 002
LEDERCILLIN VK			
LEDERLE	EQ 125MG BASE/5ML		A060136 001
	EQ 250MG BASE/5ML		A060136 002
PEN-VEE K			
WYETH AYERST	EQ 125MG BASE/5ML		A060007 001
	EQ 250MG BASE/5ML		A060007 002
PENAPAR-VK			
PARKE DAVIS	EQ 125MG BASE/5ML		A062002 001
	EQ 250MG BASE/5ML		A062002 002
PENICILLIN V POTASSIUM			
AM ANTIBIOTICS	EQ 125MG BASE/5ML		A061529 001
	EQ 250MG BASE/5ML		A061529 002
MYLAN	EQ 125MG BASE/5ML		A061624 002
	EQ 250MG BASE/5ML		A061624 001
PUREPAC PHARM	EQ 125MG BASE/5ML		A061758 001
	EQ 250MG BASE/5ML		A061758 002
PFIZERPEN VK			
PFIZER	EQ 125MG BASE/5ML		A061815 001
	EQ 250MG BASE/5ML		A061815 002
V-CILLIN K			
LILLY	EQ 125MG BASE/5ML		A060004 001
	EQ 250MG BASE/5ML		A060004 002
VEETIDS			
APOTHECON	EQ 125MG BASE/5ML		A061410 001
	EQ 250MG BASE/5ML		A061410 002
VEETIDS '125'			
APOTHECON	EQ 125MG BASE/5ML		A061206 001
	EQ 125MG BASE/5ML		A062153 001
VEETIDS '250'			
APOTHECON	EQ 250MG BASE/5ML		A061206 002
	EQ 250MG BASE/5ML		A062153 002
TABLET;ORAL			
BEEPEN-VK			
GLAXOSMITHKLINE	EQ 250MG BASE		A062273 001
	EQ 500MG BASE		A062273 002
BETAPEN-VK			
BRISTOL	EQ 250MG BASE		A061150 001
	EQ 500MG BASE		A061150 002
LEDERCILLIN VK			
LEDERLE	EQ 250MG BASE		A060134 001
	EQ 500MG BASE		A060134 002
PEN-VEE K			
WYETH AYERST	EQ 125MG BASE		A060006 001
	EQ 250MG BASE		A060006 002
	EQ 500MG BASE		A060006 003
PENAPAR-VK			
PARKE DAVIS	EQ 250MG BASE		A062001 001
	EQ 500MG BASE		A062001 002
PENICILLIN V POTASSIUM			
AM ANTIBIOTICS	EQ 250MG BASE		A061528 001
	EQ 500MG BASE		A061528 002
IVAX SUB TEVA PHARMS	EQ 125MG BASE		A060518 001
	EQ 250MG BASE		A060518 002
	EQ 500MG BASE		A060518 003
MYLAN	EQ 250MG BASE		A061530 001
	EQ 500MG BASE		A061530 002
PUREPAC PHARM	EQ 125MG BASE		A061571 001
	EQ 250MG BASE		A061571 002
	EQ 500MG BASE		A061571 003
PFIZERPEN VK			
PFIZER	EQ 250MG BASE		A061836 001
	EQ 500MG BASE		A061836 002
UTICILLIN VK			
PHARMACIA AND UPJOHN	EQ 250MG BASE		A061651 001
	EQ 500MG BASE		A061651 002

PENICILLIN V POTASSIUM				
TABLET;ORAL				
V-CILLIN K				
	LILLY	EQ 125MG BASE **	A060003 001	
		EQ 250MG BASE **	A060003 002	
		EQ 500MG BASE **	A060003 003	
VEETIDS				
	APOTHECON	EQ 250MG BASE	A061411 001	
		EQ 500MG BASE	A061411 002	
VEETIDS '250'				
	APOTHECON	EQ 250MG BASE	A061164 001	
		EQ 250MG BASE	A062156 002	
VEETIDS '500'				
	APOTHECON	EQ 500MG BASE	A061164 002	
		EQ 500MG BASE	A062156 001	
PENTAGASTRIN				
INJECTABLE;INJECTION				
PEPTAVLON				
+	WYETH AYERST	0.25MG/ML **	N017048 001	
PENTAMIDINE ISETHIONATE				
FOR SOLUTION;INHALATION				
NEBUPENT				
	FRESENIUS KABI USA	600MG/VIAL	N019887 002	Mar 22, 1996
INJECTABLE;INJECTION				
PENTACARINAT				
	ARMOUR PHARM	300MG/VIAL	A073447 001	Apr 28, 1994
PENTAMIDINE ISETHIONATE				
	BAXTER HLTHCARE	300MG/VIAL	A073617 001	Dec 18, 1995
	HOSPIRA	300MG/VIAL	A073479 001	Jun 30, 1992
	WATSON LABS	300MG/VIAL	A074303 001	Aug 17, 1995
PENTAZOCINE HYDROCHLORIDE				
TABLET;ORAL				
TALWIN 50				
	SANOFI AVENTIS US	EQ 50MG BASE	N016732 001	
PENTAZOCINE LACTATE				
INJECTABLE;INJECTION				
TALWIN				
+	HOSPIRA	EQ 30MG BASE/ML	N016194 001	
PENTETATE CALCIUM TRISODIUM YB-169				
INJECTABLE;INJECTION				
YTTERBIUM YB 169 DTPA				
	3M	2mCi/ML	N017518 001	
PENTOBARBITAL				
ELIXIR;ORAL				
NEMBUTAL				
	OAK PHARMS	18.2MG/5ML	A083244 001	
PENTOBARBITAL SODIUM				
CAPSULE;ORAL				
NEMBUTAL SODIUM				
	OAK PHARMS	30MG	A084095 001	
		50MG	A084093 001	
		100MG	A083245 001	
PENTOBARBITAL SODIUM				
	LANNETT	50MG	A085937 001	
		100MG	A085915 001	
	VITARINE	100MG	A083284 001	
	WHITEWORTH TOWN PLSN	100MG	A083338 001	
SODIUM PENTOBARBITAL				
	ANABOLIC	100MG	A084590 001	
	ELKINS SINN	100MG	A083368 001	
	EVERYLIFE	100MG	A083259 001	
	HALSEY	100MG	A084677 001	
	IVAX SUB TEVA PHARMS	50MG	A083461 001	
		100MG	A083461 002	
	PARKE DAVIS	100MG	A084156 001	
	PERRIGO	100MG	A084560 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

PENTOBARBITAL SODIUM				
CAPSULE;ORAL				
SODIUM PENTOBARBITAL				
PUREPAC PHARM	100MG		A083301 001	
VALEANT PHARM INTL	100MG		A083264 001	
WATSON LABS	100MG		A085791 001	
WYETH AYERST	100MG		A083239 001	
INJECTABLE;INJECTION				
PENTOBARBITAL SODIUM				
ELKINS SINN	50MG/ML		A083270 001	
SODIUM PENTOBARBITAL				
WYETH AYERST	50MG/ML		A083261 001	
SUPPOSITORY;RECTAL				
NEMBUTAL				
OAK PHARMS	30MG		A083247 001	Jan 25, 1982
	60MG		A083247 002	Jan 25, 1982
	120MG		A083247 003	Jan 25, 1982
	200MG		A083247 004	Jan 25, 1982
TABLET;ORAL				
PENTOBARBITAL SODIUM				
VITARINE	100MG		A083285 001	
SODIUM PENTOBARBITAL				
NEXGEN PHARMA INC	100MG		A084238 001	
PENTOLINIUM TARTRATE				
INJECTABLE;INJECTION				
ANSOLYSEN				
WYETH AYERST	10MG/ML		N009372 001	
PENTOXIFYLLINE				
TABLET, EXTENDED RELEASE;ORAL				
PENTOXIFYLLINE				
ACTAVIS ELIZABETH	400MG		A074878 001	Jul 09, 1997
HERITAGE PHARMS INC	400MG		A074877 001	Jul 08, 1997
IMPAX LABS	400MG		A075093 001	Aug 10, 1999
PLIVA	400MG		A074874 001	May 25, 1999
TEVA	400MG		A075199 001	Sep 03, 1999
WATSON LABS	400MG		A075107 001	Sep 04, 1998
TRENTAL				
+ US PHARM HOLDINGS	400MG **		N018631 001	Aug 30, 1984
PERFLUBRON				
LIQUID;ORAL				
IMAGENT				
ALLIANCE PHARM	100%		N020091 001	Aug 13, 1993
PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE				
PASTE;TOPICAL				
SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS				
US ARMY	50%;50%		N021084 001	Feb 17, 2000
PERGOLIDE MESYLATE				
TABLET;ORAL				
PERGOLIDE MESYLATE				
IVAX SUB TEVA PHARMS	EQ 0.05MG BASE		A076094 001	Sep 04, 2003
	EQ 0.25MG BASE		A076094 002	Sep 04, 2003
	EQ 1MG BASE		A076094 003	Sep 04, 2003
PAR PHARM	EQ 0.05MG BASE		A076061 001	Nov 27, 2002
	EQ 0.25MG BASE		A076061 002	Nov 27, 2002
	EQ 1MG BASE		A076061 003	Nov 27, 2002
PERMAX				
VALEANT PHARM INTL	EQ 0.05MG BASE		N019385 001	Dec 30, 1988
	EQ 0.25MG BASE		N019385 002	Dec 30, 1988
	EQ 1MG BASE		N019385 003	Dec 30, 1988
PERINDOPRIL ERBUMINE				
TABLET;ORAL				
ACEON				
+ SYMPLMED PHARMS LLC	2MG		N020184 001	Dec 30, 1993
+	4MG		N020184 002	Dec 30, 1993
+	8MG		N020184 003	Dec 30, 1993

PERINDOPRIL ERBUMINE
TABLET;ORAL
PERINDOPRIL ERBUMINE

APOTEX	2MG	A090463	001	Aug 30, 2010
	4MG	A090463	002	Aug 30, 2010
	8MG	A090463	003	Aug 30, 2010
LUPIN LTD	2MG	A078263	001	Jan 27, 2010
	4MG	A078263	002	Jan 27, 2010
	8MG	A078263	003	Jan 27, 2010

PERMETHRIN
LOTION;TOPICAL
NIX

GLAXOSMITHKLINE	1%	N019435	001	Mar 31, 1986

PERPHENAZINE
CONCENTRATE;ORAL
PERPHENAZINE

PHARM ASSOC	16MG/5ML	A040360	001	May 25, 2001

TRILAFON

SCHERING	16MG/5ML	N011557	001	

INJECTABLE;INJECTION
TRILAFON

SCHERING	5MG/ML	N011213	002	

SYRUP;ORAL
TRILAFON

SCHERING	2MG/5ML	N011294	002	

TABLET;ORAL
PERPHENAZINE

ANI PHARMS INC	2MG	A089707	001	Sep 10, 1987
	4MG	A089708	001	Sep 10, 1987
	8MG	A089456	001	Sep 10, 1987
	16MG	A089457	001	Sep 10, 1987

TRILAFON

+ SCHERING	2MG **	N010775	001	
+	4MG **	N010775	002	
+	8MG **	N010775	003	
+	16MG **	N010775	004	

TABLET, EXTENDED RELEASE;ORAL
TRILAFON

SCHERING	8MG	N011361	002	

PHENACEMIDE
TABLET;ORAL
PHENURONE

+ ABBVIE	500MG **	N007707	001	

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE
TABLET;ORAL
AZO GANTANOL

+ ROCHE	100MG;500MG **	N013294	001	Sep 10, 1987

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM
TABLET;ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE

ABLE	200MG,N/A,N/A;N/A,800MG,160MG	N021105	001	Jun 26, 2001

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE
TABLET;ORAL
AZO GANTRISIN

+ ROCHE	50MG;500MG **	N019358	001	Aug 31, 1990

PHENDIMETRAZINE TARTRATE
CAPSULE;ORAL
PHENAZINE

MAST MM	35MG	A086523	001
	35MG	A086524	001
	35MG	A086525	001

PHENDIMETRAZINE TARTRATE

SANDOZ	35MG	A085633	001
	35MG	A085694	001
	35MG	A085702	001
VIRTUS PHARMS	35MG	A085695	001

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

PHENDIMETRAZINE TARTRATE

CAPSULE;ORAL				
PHENDIMETRAZINE TARTRATE				
VITARINE	35MG	A085634	001	
	35MG	A085645	001	
	35MG	A085670	001	
	35MG	A086403	001	
	35MG	A086408	001	
	35MG	A086410	001	
	35MG	A087424	001	
SPRX-3				
SOLVAY	35MG	A085897	001	
STATOBEX				
TEVA	35MG	A085507	001	
X-TROZINE				
SHIRE RICHWOOD	35MG	A087394	001	Sep 22, 1982
CAPSULE, EXTENDED RELEASE;ORAL				
BONTRIL				
VALEANT	105MG	A088021	001	Sep 21, 1982
MELFIAT-105				
NUMARK	105MG	A087487	001	Oct 13, 1982
PHENDIMETRAZINE TARTRATE				
GRAHAM DM	105MG	A087214	001	May 26, 1982
	105MG	A088020	001	Aug 16, 1982
	105MG	A088028	001	Aug 16, 1982
	105MG	A088062	001	Sep 13, 1982
	105MG	A088063	001	Sep 10, 1982
	105MG	A088111	001	Oct 18, 1982
VIRTUS PHARMS	105MG	A087378	001	
SPRX-105				
NUMARK	105MG	A088024	001	Dec 22, 1982
X-TROZINE L.A.				
SHIRE RICHWOOD	105MG	A087371	001	Aug 24, 1982
TABLET;ORAL				
ADPHEN				
FERNDALE LABS	35MG	A083655	001	
ALPHAZINE				
SANDOZ	35MG	A085034	001	
CAM-METRAZINE				
ABC HOLDING	35MG	A085511	001	
CAMALL	35MG	A085756	001	
CHARTWELL RX	35MG	A083922	001	
	35MG	A085318	001	
	35MG	A085320	001	
	35MG	A085321	001	
DI-METREX				
PVT FORM	35MG	A085698	001	
MELFIAT				
NUMARK	35MG	A083790	002	
METRA				
FOREST PHARMS	35MG	A083754	001	
PHENAZINE				
MAST MM	35MG	A087305	001	
PHENAZINE-35				
ABC HOLDING	35MG	A085512	001	
PHENDIMETRAZINE TARTRATE				
BARR	35MG	A083644	001	
	35MG	A083684	001	
	35MG	A083686	001	
	35MG	A083687	001	
	35MG	A084831	001	
	35MG	A084834	001	
	35MG	A084835	001	
CHARTWELL RX	35MG	A085761	001	
	35MG	A085941	001	Jun 27, 1983
FERNDALE LABS	35MG	A086834	001	Sep 15, 1983
INWOOD LABS	35MG	A084740	001	
	35MG	A084741	001	
	35MG	A084742	001	

PHENDIMETRAZINE TARTRATE
TABLET;ORAL
PHENDIMETRAZINE TARTRATE

	35MG		A084743 001
IVAX PHARMS	35MG		A085611 001
	35MG		A085612 001
IVAX SUB TEVA PHARMS	35MG		A083682 001
KV PHARM	35MG		A084138 001
	35MG		A084141 001
	35MG		A085525 001
MFG CHEMISTS	35MG		A085914 001
NEXGEN PHARMA INC	35MG		A086020 001
NUMARK	35MG		A083790 001
PVT FORM	35MG		A085199 001
	35MG		A085697 001
SANDOZ	35MG		A085402 001
	35MG		A085830 001
	35MG		A086370 001
SOLVAY	35MG		A083993 001
USL PHARMA	35MG		A083805 001
	35MG		A084398 001
	35MG		A084399 001
VIRTUS PHARMS	35MG		A085497 001
	35MG		A086365 001
VITARINE	35MG		A085519 001
	35MG		A086005 001
	35MG		A086106 001
WATSON LABS	35MG		A085767 001
	35MG		A085768 001
	35MG		A085770 001
	35MG		A085773 001

PLEGINE

WYETH AYERST	35MG	**	N012248 001

STATOBEX

TEVA	35MG		A086013 001

STATOBEX-G

TEVA	35MG		A085095 001

X-TROZINE

SHIRE RICHWOOD	35MG		A086550 001
	35MG		A086551 001
	35MG		A086552 001
	35MG		A086553 001
	35MG		A086554 001

PHENINDIONE
TABLET;ORAL
HEDULIN

SANOFI AVENTIS US	50MG		N008767 002

PHENMETRAZINE HYDROCHLORIDE
TABLET;ORAL
PRELUDIN

BOEHRINGER INGELHEIM	25MG		N010460 005

TABLET, EXTENDED RELEASE;ORAL
PRELUDIN

BOEHRINGER INGELHEIM	50MG		N011752 004
	75MG		N011752 003

PHENPROCOUMON
TABLET;ORAL
LIQUAMAR

ORGANON USA INC	3MG		N011228 001

PHENSUXIMIDE
CAPSULE;ORAL
MILONTIN

PARKE DAVIS	500MG		N008855 004

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL				
FASTIN				
GLAXOSMITHKLINE	30MG **	N017352	001	
OBESTIN-30				
FERNDALE LABS	30MG	A087144	001	
OBY-TRIM				
SHIRE RICHWOOD	30MG	A087764	001	Mar 18, 1982
ONA-MAST				
MAST MM	30MG	A086511	001	
	30MG	A086516	001	
PHENTERMINE HYDROCHLORIDE				
ABC HOLDING	30MG	A085411	001	
ABLE	15MG	A040497	001	Mar 13, 2003
	30MG	A040403	001	Aug 30, 2001
	30MG	A040427	001	Aug 30, 2001
CAMALL	15MG	A086735	001	
	30MG	A087226	001	
CHARTWELL RX	18.75MG	A088576	001	May 23, 1984
	30MG	A085417	001	
	30MG	A086732	002	
	30MG	A087215	001	
	37.5MG	A087915	001	Dec 22, 1983
	37.5MG	A087918	001	Dec 22, 1983
	37.5MG	A087930	001	Oct 14, 1983
	37.5MG	A088610	001	Jun 04, 1984
	37.5MG	A088611	001	Jun 04, 1984
	37.5MG	A088625	001	Aug 23, 1984
DURAMED PHARMS BARR	30MG	A088948	001	Apr 25, 1986
ELITE LABS INC	15MG	A040460	001	Jan 14, 2003
	30MG	A040227	001	Jun 18, 1997
	30MG	A040448	001	Jan 22, 2003
IVAX PHARMS	30MG	A086329	001	
SANDOZ	30MG	A087208	001	
	30MG	A087223	001	
	37.5MG	A088414	001	Oct 19, 1983
SUN PHARM INDUSTRIES	37.5MG	A040527	001	Oct 23, 2003
TEVA	30MG	A086911	001	
	30MG	A087126	001	
	30MG	A087777	001	Nov 01, 1985
	30MG	A088612	001	Apr 04, 1984
	30MG	A088613	001	Apr 09, 1984
	30MG	A088614	001	Apr 09, 1984
TG UNITED INC	30MG	A040083	001	Mar 07, 1997
UPSHER SMITH LABS	30MG	A084487	001	Apr 09, 1982
	30MG	A088430	001	Mar 27, 1984
USL PHARMA	30MG	A088797	001	Dec 10, 1984
VITARINE	30MG	A087202	001	
	30MG	A087235	001	
WATSON LABS	30MG	A086740	001	Mar 21, 1985
TABLET;ORAL				
ONA-MAST				
MAST MM	8MG	A086260	001	
PHENTERMINE HYDROCHLORIDE				
ABLE	37.5MG	A040402	001	Aug 30, 2001
ACTAVIS ELIZABETH	37.5MG	A040276	001	Nov 25, 1998
CHARTWELL RX	8MG	A083923	001	
	8MG	A085319	001	
	37.5MG	A087805	001	Dec 06, 1982
	37.5MG	A088596	001	Apr 04, 1984
IVAX PHARMS	8MG	A085553	001	
SANDOZ	8MG	A085671	001	
	8MG	A085689	001	
SANDOZ INC	30MG	A088605	001	Sep 28, 1987
USL PHARMA	8MG	A083804	001	
	37.5MG	A088910	001	Jul 17, 1985
	37.5MG	A088917	001	Jul 17, 1985
VITARINE	8MG	A086453	001	
	8MG	A086456	001	

PHENTERMINE HYDROCHLORIDE

TABLET;ORAL				
PHENTERMINE HYDROCHLORIDE				
	WATSON LABS	8MG	A085739 001	
TORA				
	SOLVAY	8MG	A084035 001	
WILPO				
+	SANDOZ	8MG **	N012737 001	
TABLET, ORALLY DISINTEGRATING;ORAL				
SUPRENZA				
	CITIUS PHARMS	15MG **	N202088 001	Jun 13, 2011
		30MG **	N202088 002	Jun 13, 2011
		37.5MG **	N202088 003	Mar 27, 2012

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE;ORAL				
IONAMIN				
	UCB INC	EQ 15MG BASE **	N011613 004	
		EQ 30MG BASE **	N011613 002	
PHENTERMINE RESIN 30				
	QUANTUM PHARMICS	EQ 30MG BASE	A089120 001	Feb 04, 1988
PHENTERMINE RESIN COMPLEX				
	LANNETT CO INC	EQ 15MG BASE	A040872 001	Jul 28, 2011
		EQ 30MG BASE	A040872 002	Jul 28, 2011

PHENTOLAMINE MESYLATE

INJECTABLE;INJECTION				
REGITINE				
+	NOVARTIS	5MG/VIAL **	N008278 003	

PHENYL AMINOSALICYLATE

POWDER;ORAL				
PHENY-PAS-TEBAMIN				
	PHARM RES ASSOC	50%	N011695 002	
TABLET;ORAL				
PHENY-PAS-TEBAMIN				
	PHARM RES ASSOC	500MG	N011695 003	

PHENYLBUTAZONE

CAPSULE;ORAL				
AZOLID				
	SANOFI AVENTIS US	100MG	A087260 001	
BUTAZOLIDIN				
	NOVARTIS	100MG	N008319 009	
PHENYLBUTAZONE				
	FOSUN PHARMA	100MG	A087774 001	Jun 16, 1982
	IVAX PHARMS	100MG	A088218 001	Jun 24, 1983
	SUN PHARM INDUSTRIES	100MG	A088994 001	Dec 04, 1985
	WATSON LABS	100MG	A087756 001	Dec 17, 1982
TABLET;ORAL				
AZOLID				
	SANOFI AVENTIS US	100MG	A087091 001	
BUTAZOLIDIN				
	NOVARTIS	100MG	N008319 008	
PHENYLBUTAZONE				
	FOSUN PHARMA	100MG	A084339 001	
	SUN PHARM INDUSTRIES	100MG	A088863 001	Dec 04, 1985
	WATSON LABS	100MG	A086151 001	
		100MG	A087674 001	Apr 21, 1982

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL				
PHENERGAN VC				
+	ANI PHARMS	5MG/5ML;6.25MG/5ML **	N008604 003	Apr 02, 1984
PHERAZINE VC				
	HALSEY	5MG/5ML;6.25MG/5ML	A088868 001	Mar 02, 1987
PROMETH VC PLAIN				
	G AND W LABS INC	5MG/5ML;6.25MG/5ML	A088761 001	Nov 08, 1984
PROMETHAZINE VC PLAIN				
	CENCI	5MG/5ML;6.25MG/5ML	A088815 001	Nov 22, 1985
	WOCKHARDT	5MG/5ML;6.25MG/5ML	A088897 001	Jan 04, 1985

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE
SOLUTION/DROPS;OPHTHALMIC

PREFRIN-A				
	ALLERGAN	0.12%;0.1%	N007953 001	

PHENYTOIN
SUSPENSION;ORAL

DILANTIN-30				
	PARKE DAVIS	30MG/5ML	N008762 002	
PHENYTOIN				
	ACTAVIS MID ATLANTIC	125MG/5ML	A089892 001	Sep 25, 1992

PHENYTOIN SODIUM
CAPSULE;ORAL

DIPHENYLAN SODIUM				
	LANNETT	30MG PROMPT	A080857 001	
		100MG PROMPT	A080857 002	
EXTENDED PHENYTOIN SODIUM				
	ANI PHARMS INC	100MG EXTENDED	A040435 001	Jun 20, 2003
		100MG EXTENDED	A089441 001	Dec 18, 1986
	WOCKHARDT	30MG EXTENDED	A040759 001	Dec 18, 2007
	WOCKHARDT USA	100MG EXTENDED	A040732 001	Jan 30, 2008
PHENYTEX				
	WATSON LABS	100MG EXTENDED	A088711 001	Dec 21, 1984
PHENYTOIN SODIUM				
	PHARMERAL	100MG PROMPT	A085435 001	
	WATSON LABS	100MG PROMPT	A085894 001	
PROMPT PHENYTOIN SODIUM				
	ANI PHARMS INC	100MG PROMPT	A080259 001	
	WATSON LABS	100MG PROMPT	A080905 001	

INJECTABLE;INJECTION

DILANTIN				
	PARKE DAVIS	50MG/ML	N010151 001	
PHENYTOIN SODIUM				
	FRESENIUS KABI USA	50MG/ML	A089003 001	May 31, 1985
	HOSPIRA	50MG/ML	A089521 001	Mar 17, 1987
		50MG/ML	A089744 001	Dec 18, 1987
	MARSAM PHARMS LLC	50MG/ML	A089501 001	Oct 13, 1987
		50MG/ML	A089779 001	Nov 27, 1992
	SMITH AND NEPHEW	50MG/ML	A088519 001	Dec 19, 1984
		50MG/ML	A088521 001	Dec 18, 1984
	SOLOPAK	50MG/ML	A088520 001	Dec 17, 1984
	WARNER CHILCOTT	50MG/ML	A089900 001	Mar 30, 1990
	WATSON LABS	50MG/ML	A085434 001	

PHYTONADIONE
INJECTABLE;INJECTION

AQUAMEPHYTON				
+	TELIGENT	1MG/0.5ML **	N012223 002	
+		10MG/ML **	N012223 001	
KONAKION				
	ROCHE	1MG/0.5ML	N011745 001	
		10MG/ML	N011745 003	
PHYTONADIONE				
	GLAXOSMITHKLINE	1MG/0.5ML	A084060 001	
		10MG/ML	A084060 002	
VITAMIN K1				
	HOSPIRA	10MG/ML	A087956 001	Jul 25, 1983

PILOCARPINE
INSERT, EXTENDED RELEASE;OPHTHALMIC

OCUSERT PILO-20				
	AKORN	5MG	N017431 001	
OCUSERT PILO-40				
	AKORN	11MG	N017548 001	

PILOCARPINE HYDROCHLORIDE				
GEL;OPHTHALMIC				
PILOPINE HS				
ALCON	4%	N018796	001	Oct 01, 1984
PINACIDIL				
CAPSULE, EXTENDED RELEASE;ORAL				
PINDAC				
LEO PHARM	12.5MG	N019456	001	Dec 28, 1989
	25MG	N019456	002	Dec 28, 1989
PINDOLOL				
TABLET;ORAL				
PINDOLOL				
G AND W LABS INC	5MG	A073661	001	Oct 31, 1993
	5MG	A073687	001	Feb 26, 1993
	5MG	A074123	001	Apr 17, 1997
	10MG	A073661	002	Oct 31, 1993
	10MG	A073687	002	Feb 26, 1993
	10MG	A074123	002	Apr 17, 1997
MYLAN PHARMS INC	5MG	A074013	001	Sep 24, 1992
	10MG	A074018	001	Sep 24, 1992
NOSTRUM LABS	5MG	A074474	001	Oct 28, 1996
	10MG	A074474	002	Oct 28, 1996
PUREPAC PHARM	5MG	A074125	001	Apr 28, 1993
	10MG	A074125	002	Apr 28, 1993
WATSON LABS	5MG	A074437	001	Feb 27, 1995
	10MG	A074437	002	Feb 27, 1995
VISKEN				
+ NOVARTIS	5MG **	N018285	001	Sep 03, 1982
+	10MG **	N018285	002	Sep 03, 1982
PIPECURONIUM BROMIDE				
INJECTABLE;INJECTION				
ARDUAN				
ORGANON USA INC	10MG/VIAL	N019638	001	Jun 26, 1990
PIPERACETAZINE				
TABLET;ORAL				
QUIDE				
DOW PHARM	10MG	N013615	001	
	25MG	N013615	002	
PIPERACILLIN SODIUM				
INJECTABLE;INJECTION				
PIPRACIL				
WYETH PHARMS INC	EQ 2GM BASE/VIAL	A062750	001	Oct 13, 1987
+	EQ 2GM BASE/VIAL **	N050545	002	
	EQ 3GM BASE/VIAL	A062750	002	Oct 13, 1987
+	EQ 3GM BASE/VIAL **	N050545	003	
	EQ 4GM BASE/VIAL	A062750	003	Oct 13, 1987
+	EQ 4GM BASE/VIAL **	N050545	004	
+	EQ 40GM BASE/VIAL **	N050545	006	Sep 30, 1985
PIPERAZINE CITRATE				
SYRUP;ORAL				
ANTEPAR				
GLAXOSMITHKLINE	EQ 500MG BASE/5ML	N009102	001	
BRYREL				
SANOFI AVENTIS US	EQ 500MG BASE/5ML	N017796	001	
MULTIFUGE				
BLULINE	EQ 500MG BASE/5ML	N009452	001	
PIPERAZINE CITRATE				
ALPHARMA US PHARMS	EQ 500MG BASE/5ML	A080774	001	
LANNETT	EQ 500MG BASE/5ML	A080963	001	
LUITPOLD	EQ 500MG BASE/5ML	A080671	001	
VERMIDOL				
SOLVAY	EQ 500MG BASE/5ML	A080992	001	
TABLET;ORAL				
ANTEPAR				
GLAXOSMITHKLINE	EQ 500MG BASE	N009102	003	

PIPERAZINE CITRATE
TABLET;ORAL
PIPERAZINE CITRATE

	IMPAX LABS	EQ 250MG BASE	A080874 001	

PIPERONYL BUTOXIDE; PYRETHRINS
AEROSOL;TOPICAL
RID MOUSSE

	BAYER HEALTHCARE LLC	4%;EQ 0.33% BASE	N021043 001	Mar 07, 2000

PIPOBROMAN
TABLET;ORAL
VERCYTE

	ABBOTT	10MG	N016245 001	
		25MG	N016245 002	

PIRBUTEROL ACETATE
AEROSOL, METERED;INHALATION
MAXAIR

	MEDICIS	EQ 0.2MG BASE/INH	N020014 001	Nov 30, 1992
	VALEANT PHARMS	EQ 0.2MG BASE/INH	N019009 001	Dec 30, 1986

PIRFENIDONE
TABLET;ORAL
ESBRIET

+	GENENTECH INC	534MG	N208780 002	Jan 11, 2017

PIROXICAM
CAPSULE;ORAL
PIROXICAM

	CYCLE PHARMS LTD	10MG	A073651 001	Feb 26, 1993
		20MG	A073651 002	Feb 26, 1993
	EGIS	10MG	A074808 001	Jul 08, 1997
		20MG	A074808 002	Jul 08, 1997
	IVAX SUB TEVA PHARMS	10MG	A074148 001	Jun 03, 1996
		20MG	A074148 002	Jun 03, 1996
	MYLAN	10MG	A074043 001	Sep 22, 1992
		10MG	A074102 001	Jul 31, 1992
		20MG	A074043 002	Sep 22, 1992
		20MG	A074102 002	Jul 31, 1992
	SCS	10MG	A074036 001	May 29, 1992
		20MG	A074036 002	May 29, 1992
	TEVA	10MG	A073637 001	Jan 28, 1994
		20MG	A073638 001	Jan 28, 1994
	TEVA PHARMS	10MG	A074103 001	Aug 28, 1992
		20MG	A074103 002	Aug 28, 1992
	WATSON LABS	10MG	A074287 001	May 16, 1996
		10MG	A074460 001	Sep 29, 1995
		20MG	A074287 002	May 16, 1996
		20MG	A074460 002	Sep 29, 1995

PITAVASTATIN SODIUM
TABLET;ORAL
NIKITA

+	LUPIN LTD	EQ 1MG BASE	N209875 001	Aug 04, 2017
+		EQ 2MG BASE	N209875 002	Aug 04, 2017
+		EQ 4MG BASE	N209875 003	Aug 04, 2017

PLICAMYCIN
INJECTABLE;INJECTION
MITHRACIN

	PFIZER	2.5MG/VIAL	N050109 001	

PODOFILOX
SOLUTION;TOPICAL
PODOFILOX

	BAUSCH AND LOMB INC	0.5%	A090184 001	Jul 21, 2010

POLYESTRADIOL PHOSPHATE

INJECTABLE;INJECTION				
ESTRADURIN				
WYETH AYERST	40MG/AMP	N010753	001	

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL				
POLYETHYLENE GLYCOL 3350				
BRECKENRIDGE PHARM	17GM/SCOOPFUL	A077736	001	May 26, 2006
PADDOCK LLC	17GM/SCOOPFUL	A090567	001	Oct 15, 2009
TEVA PHARMS	17GM/SCOOPFUL	A077445	001	May 04, 2006

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL				
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE				
MYLAN	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A090409	001	Apr 02, 2010

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL				
CLENZ-LYTE				
PADDOCK LLC	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090769	001	Jun 07, 2010
SOLUTION;ORAL				
OCL				
HOSPIRA	6GM/100ML;75MG/100ML;168MG/100ML;146MG/100ML;1.29GM/100ML	N019284	001	Apr 30, 1986

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL				
COLYTE				
MYLAN SPECIALITY LP	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984
	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984
	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989
	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987
	360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984
COLYTE-FLAVORED				
MYLAN SPECIALITY LP	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991
	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991
PEG 3350 AND ELECTROLYTES				
MYLAN	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090928	001	Jan 28, 2010
POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES				
PADDOCK LLC	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A090712	001	Feb 25, 2010
FOR SUSPENSION;ORAL				
CO-LAV				
VINTAGE PHARMS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A073428	001	Jan 28, 1992
COLOVAGE				
DYNAPHARM	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	A071320	001	Apr 20, 1988
E-Z-EM PREP LYTE				
E Z EM	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A071278	001	Nov 21, 1988
GLYCOPREP				
GOLDLINE	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A072319	001	Dec 23, 1988
GO-EVAC				
VINTAGE PHARMS	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A073433	001	Apr 28, 1992
PEG-LYTE				
SANDOZ	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A073098	001	Aug 31, 1993

POLYMYXIN B SULFATE				
INJECTABLE;INJECTION				
AEROSPORIN				
	GLAXOSMITHKLINE	EQ 500,000 U BASE/VIAL	A062036 001	
POWDER;FOR RX COMPOUNDING				
POLY-RX				
	X GEN PHARMS	100,000,000 UNITS/BOT	A061578 001	
POLYMYXIN B SULFATE				
	PADDOCK LLC	100,000,000 UNITS/BOT	A062455 001	Jul 27, 1983
POLYTHIAZIDE				
TABLET;ORAL				
RENESE				
	PFIZER	1MG	N012845 001	
		2MG	N012845 002	
		4MG	N012845 003	
POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE				
CAPSULE;ORAL				
MINIZIDE				
	PFIZER	0.5MG;EQ 1MG BASE	N017986 001	
		0.5MG;EQ 2MG BASE	N017986 002	
		0.5MG;EQ 5MG BASE	N017986 003	
POLYTHIAZIDE; RESERPINE				
TABLET;ORAL				
RENESE-R				
	PFIZER	2MG;0.25MG	N013636 001	
POTASSIUM AMINOSALICYLATE				
CAPSULE;ORAL				
PASKALIUM				
	GLENWOOD	500MG	N009395 004	
POWDER;ORAL				
POTASSIUM AMINOSALICYLATE				
	HEXCEL	100%	A080098 001	
TABLET;ORAL				
PASKALIUM				
	GLENWOOD	1GM	N009395 003	
POTASSIUM CHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
K-LEASE				
	SAVAGE LABS	8MEQ	A073398 001	Jan 28, 1992
		10MEQ	A072427 001	Mar 28, 1990
POTASSIUM CHLORIDE				
	NESHER PHARMS	10MEQ	A070980 001	Feb 17, 1987
	TEVA	8MEQ	A073531 001	Apr 26, 1996
		10MEQ	A073532 001	Apr 26, 1996
FOR SUSPENSION, EXTENDED RELEASE;ORAL				
MICRO-K LS				
	KV PHARM	20MEQ/PACKET	N019561 003	Aug 26, 1988
INJECTABLE;INJECTION				
POTASSIUM CHLORIDE				
	ABRAXIS PHARM	2MEQ/ML	A080204 001	
		2MEQ/ML	A084290 001	
		2MEQ/ML	A086713 001	
		2MEQ/ML	A086714 001	
		2MEQ/ML	A087787 001	Apr 20, 1982
		2MEQ/ML	A087885 001	Feb 03, 1983
	AKORN	2MEQ/ML	A088286 001	Sep 05, 1985
	BAXTER HLTHCARE	2MEQ/ML	A080203 001	
		2MEQ/ML	A085499 001	
	FRESENIUS KABI USA	2MEQ/ML	A087817 001	Oct 20, 1982
	GD SEARLE LLC	1MEQ/ML	A086219 001	
		2MEQ/ML	A086219 002	
		2MEQ/ML	A086220 002	
		3MEQ/ML	A086219 003	
		3MEQ/ML	A086220 001	
		4MEQ/ML	A086219 004	
	HOSPIRA	1MEQ/ML	A080205 003	
		1MEQ/ML	A083345 003	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

POTASSIUM CHLORIDE

INJECTABLE;INJECTION					
POTASSIUM CHLORIDE					
		1.5MEQ/ML	A083345	001	
		2MEQ/ML	A083345	002	
		2.4MEQ/ML	A080205	004	
		3.2MEQ/ML	A080205	005	
	INTL MEDICATION	2MEQ/ML	A083163	001	
	LILLY	2MEQ/ML	N007865	002	
	LUITPOLD	2MEQ/ML	A080221	001	
		2MEQ/ML	A080736	001	
		2MEQ/ML	A087584	001	
		2MEQ/ML	A087585	001	
	MILES	1MEQ/ML	A080195	002	
		2MEQ/ML	A080195	001	
		3MEQ/ML	A080195	003	
		4MEQ/ML	A080195	004	
	PHARMA SERVE NY	2MEQ/ML	A086297	001	
		2MEQ/ML	A087362	001	Mar 08, 1983
	WATSON LABS	2MEQ/ML	A086208	001	
		2MEQ/ML	A089163	001	Mar 10, 1988
		2MEQ/ML	A089421	001	Jan 02, 1987
		3MEQ/ML	A086210	001	
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER					
+	ICU MEDICAL INC	2.24GM/100ML	N020161	003	Aug 11, 1998
TABLET, EXTENDED RELEASE;ORAL					
K+10					
	FUTURE PAK	10MEQ	A070999	001	Oct 22, 1987
K+8					
	FUTURE PAK	8MEQ	A070998	001	Jan 25, 1993
KAON CL					
	SAVAGE LABS	6.7MEQ	N017046	001	
KAON CL-10					
	SAVAGE LABS	10MEQ	N017046	002	
KLOTRIX					
	APOTHECON	10MEQ	N017850	001	
POTASSIUM CHLORIDE					
	COPLEY PHARM	8MEQ	A070618	001	Sep 09, 1987
	NESHER PHARMS	20MEQ	A076044	001	Apr 05, 2002
+	SCHERING	10MEQ **	N019439	002	Jun 13, 1986
+		20MEQ **	N019439	001	Jun 13, 1986
SLOW-K					
	NOVARTIS	8MEQ	N017476	002	
TEN-K					
	NOVARTIS	10MEQ	N019381	001	Apr 16, 1986

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION					
POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	37MG/100ML;900MG/100ML	N019708	001	Sep 29, 1989
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	75MG/100ML;900MG/100ML	N019708	002	Sep 29, 1989
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	110MG/100ML;900MG/100ML	N019708	003	Sep 29, 1989
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	220MG/100ML;900MG/100ML	N019708	005	Sep 29, 1989
POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%					
+	BAXTER HLTHCARE	224MG/100ML;900MG/100ML	N017648	003	
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	300MG/100ML;900MG/100ML	N019708	006	Sep 29, 1989
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER					
	B BRAUN	75MG/100ML;900MG/100ML	N018722	001	Nov 09, 1982
	BAXTER HLTHCARE	75MG/100ML;900MG/100ML	N017648	004	
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER					
	B BRAUN	150MG/100ML;900MG/100ML	N018722	002	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER					
	B BRAUN	220MG/100ML;900MG/100ML	N018722	003	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	B BRAUN	300MG/100ML;900MG/100ML	N018722	004	Nov 09, 1982

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE				
INJECTABLE;INJECTION				
THAM-E				
	HOSPIRA	370MG/VIAL;1.75GM/VIAL;36GM/VIAL	N013025 001	
POTASSIUM CITRATE				
FOR SOLUTION;ORAL				
POTASSIUM CITRATE				
+	UT SW MEDCTR	10MEQ/PACKET **	N019647 002	Oct 13, 1988
+		20MEQ/PACKET **	N019647 001	Oct 13, 1988
POTASSIUM IODIDE				
SOLUTION;ORAL				
POTASSIUM IODIDE				
	ROXANE	1GM/ML **	N018551 001	Feb 19, 1982
TABLET;ORAL				
THYRO-BLOCK				
	MEDA PHARMS	130MG	N018307 001	
POTASSIUM PERCHLORATE				
CAPSULE;ORAL				
PERCHLORACAP				
	MALLINCKRODT	200MG	N017551 001	
POVIDONE-IODINE				
SOLUTION;TOPICAL				
E-Z PREP				
	CLINIPAD	10%	N019382 001	Jul 25, 1989
SPONGE;TOPICAL				
E-Z PREP				
	CLINIPAD	5%	N019382 002	Jul 25, 1989
E-Z PREP 220				
	CLINIPAD	5%	N019382 003	Jul 25, 1989
PRALIDOXIME CHLORIDE				
INJECTABLE;INJECTION				
PRALIDOXIME CHLORIDE				
	BAXTER HLTHCARE CORP	300MG/ML	N018799 001	Dec 13, 1982
TABLET;ORAL				
PROTOPAM CHLORIDE				
	WYETH AYERST	500MG	N014122 002	
PRAMIPEXOLE DIHYDROCHLORIDE				
TABLET;ORAL				
MIRAPEX				
	BOEHRINGER INGELHEIM	1.25MG	N020667 004	Jul 01, 1997
PRAMIPEXOLE DIHYDROCHLORIDE				
	ACTAVIS GRP PTC	0.125MG	A091254 001	Nov 30, 2010
		0.25MG	A091254 002	Nov 30, 2010
		0.5MG	A091254 003	Nov 30, 2010
		0.75MG	A091254 004	Nov 30, 2010
		1MG	A091254 005	Nov 30, 2010
		1.5MG	A091254 006	Nov 30, 2010
	SANDOZ	0.125MG	A090190 001	Jul 06, 2010
		0.25MG	A090190 002	Jul 06, 2010
		0.5MG	A090190 003	Jul 06, 2010
		0.75MG	A090190 006	Oct 08, 2010
		1MG	A090190 004	Jul 06, 2010
		1.5MG	A090190 005	Jul 06, 2010
	WATSON LABS	0.125MG	A078551 001	Oct 08, 2010
		0.25MG	A078551 002	Oct 08, 2010
		0.5MG	A078551 003	Oct 08, 2010
		1MG	A078551 004	Oct 08, 2010
		1.5MG	A078551 005	Oct 08, 2010
PRAMLINTIDE ACETATE				
INJECTABLE;SUBCUTANEOUS				
SYMLIN				
	ASTRAZENECA AB	EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332 001	Mar 16, 2005

PRAVASTATIN SODIUM				
TABLET;ORAL				
PRAVACHOL				
+ BRISTOL MYERS SQUIBB	10MG **	N019898	002	Oct 31, 1991
PRAVASTATIN SODIUM				
MYLAN	10MG	A077013	001	Oct 23, 2006
	20MG	A077013	002	Oct 23, 2006
	40MG	A077013	003	Oct 23, 2006
	80MG	A077013	004	Dec 28, 2007
PLIVA HRVATSKA DOO	10MG	A077730	001	Nov 21, 2006
	20MG	A077730	002	Nov 21, 2006
	30MG	A077730	003	Nov 21, 2006
	40MG	A077730	005	Nov 21, 2006
RANBAXY LABS LTD	10MG	A076445	001	Apr 23, 2007
	20MG	A076445	002	Apr 23, 2007
	40MG	A076445	003	Apr 23, 2007
	80MG	A076445	004	Apr 23, 2007
PRAZEPAM				
CAPSULE;ORAL				
CENTRAX				
PARKE DAVIS	5MG	N018144	001	
	10MG	N018144	002	
	20MG	N018144	003	May 10, 1982
PRAZEPAM				
USL PHARMA	5MG	A070427	001	Nov 06, 1987
	10MG	A070428	001	Nov 06, 1987
TABLET;ORAL				
CENTRAX				
PARKE DAVIS	10MG	N017415	001	
PRAZOSIN HYDROCHLORIDE				
CAPSULE;ORAL				
PRAZOSIN HYDROCHLORIDE				
AM THERAP	EQ 1MG BASE	A072782	001	May 16, 1989
	EQ 2MG BASE	A072783	001	May 16, 1989
	EQ 5MG BASE	A072784	001	May 16, 1989
ANI PHARMS INC	EQ 1MG BASE	A072577	002	May 16, 1989
	EQ 2MG BASE	A072577	001	May 16, 1989
	EQ 5MG BASE	A072577	003	May 16, 1989
DAVA PHARMS INC	EQ 1MG BASE	A072705	001	May 16, 1989
	EQ 2MG BASE	A072706	001	May 16, 1989
	EQ 5MG BASE	A072707	001	May 16, 1989
PUREPAC PHARM	EQ 1MG BASE	A072991	001	May 16, 1989
	EQ 2MG BASE	A072921	001	May 16, 1989
	EQ 5MG BASE	A072992	001	May 16, 1989
WATSON LABS	EQ 1MG BASE	A072352	001	May 16, 1989
	EQ 2MG BASE	A072333	001	May 16, 1989
	EQ 5MG BASE	A072609	001	May 16, 1989
TABLET, EXTENDED RELEASE;ORAL				
MINIPRESS XL				
PFIZER	2.5MG	N019775	001	Jan 29, 1992
	5MG	N019775	002	Jan 29, 1992
PREDNISOLONE				
CREAM;TOPICAL				
METI-DERM				
SCHERING	0.5%	N010209	002	
SYRUP;ORAL				
PREDNISOLONE				
APOTEX INC	5MG/5ML	A040570	001	Aug 25, 2005
	15MG/5ML	A040571	001	Aug 25, 2005
IVAX SUB TEVA PHARMS	15MG/5ML	A040287	001	May 28, 1999
NESHER PHARMS	5MG/5ML	A040423	001	Oct 22, 2001
	15MG/5ML	A040364	001	Apr 10, 2002
TEVA PHARMS	15MG/5ML	A040322	001	Jan 19, 2000
WE PHARMS	15MG/5ML	A040192	001	May 28, 1998
PRELONE				
MURO	5MG/5ML	A089654	001	Jan 17, 1989

PREDNISOLONE

TABLET;ORAL				
CORTALONE				
	HALSEY	1MG	A080304 003	
		2.5MG	A080304 002	
		5MG	A080304 001	
DELTA-CORTEF				
	PHARMACIA AND UPJOHN	5MG	N009987 004	
FERNISOLONE-P				
	FERNDALE LABS	5MG	A083941 001	
PREDNISOLONE				
	AUROLIFE PHARMA LLC	5MG	A084773 001	
	BARR	5MG	A084426 002	
	BUNDY	5MG	A083675 001	
	CHARTWELL RX	5MG	A084542 001	
	ELKINS SINN	5MG	A080625 001	
	EVERYLIFE	1MG	A084439 001	
		2.5MG	A084439 002	
		5MG	A084439 003	
	FERRANTE	2.5MG	A080562 001	
		5MG	A080562 002	
	FOSUN PHARMA	5MG	A080339 001	
	HEATHER	5MG	A080326 001	
	IMPAX LABS	5MG	A080780 001	
	INWOOD LABS	5MG	A080748 001	
	IVAX SUB TEVA PHARMS	5MG	A080378 001	
	LANNETT	5MG	A080531 002	
	MARSHALL PHARMA	5MG	A080307 001	
	PANRAY	1MG	A080351 001	
		5MG	A080351 002	
	PHOENIX LABS NY	5MG	A080322 001	
	PUREPAC PHARM	5MG	A080325 001	
	PVT FORM	5MG	A080211 001	
	ROXANE	5MG	A080327 002	
	SPERTI	1MG	A080358 001	
		2.5MG	A080358 002	
		5MG	A080358 003	
	SUPERPHARM	5MG	A088892 001	Feb 26, 1985
	TABLICAPS	5MG	A085170 001	
	TEVA	5MG	A080398 001	
	UDL	5MG	A087987 001	Jan 18, 1983
	VALEANT PHARM INTL	5MG	A080236 001	
	VITARINE	5MG	A080534 001	
	WATSON LABS	5MG	A085085 002	
		5MG	A085415 001	
		5MG	A085416 001	
	WEST WARD	5MG	A080324 001	
	WHITEWORTH TOWN PLSN	5MG	A080342 001	
STERANE				
	PFIZER	5MG	N009996 001	

PREDNISOLONE ACETATE

INJECTABLE;INJECTION				
METICORTELONE				
	SCHERING	25MG/ML	N010255 002	
PREDNISOLONE ACETATE				
	AKORN	25MG/ML	A083032 001	
		50MG/ML	A084492 001	
	BEL MAR	25MG/ML	A083738 001	
		50MG/ML	A083738 002	
	CENT PHARMS	25MG/ML	A084717 001	
		50MG/ML	A084717 002	
	WATSON LABS	25MG/ML	A083398 001	
		25MG/ML	A083654 001	
		40MG/ML	A083767 001	
		50MG/ML	A083764 001	
		50MG/ML	A085781 001	
STERANE				
	PFIZER	25MG/ML	N011446 001	

PREDNISOLONE ACETATE

SUSPENSION;ORAL				
FLO-PRED				
	TARO	EQ 5MG BASE/5ML	N022067 001	Jan 17, 2008
		EQ 15MG BASE/5ML	N022067 002	Jan 17, 2008
SUSPENSION/DROPS;OPHTHALMIC				
ECONOPRED				
	ALCON	0.125%	N017468 001	

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT;OPHTHALMIC				
CETAPRED				
	ALCON	0.25%;10%	A087771 001	Aug 06, 1993
METIMYD				
	SCHERING	0.5%;10%	N010210 002	Sep 09, 1984
PREDSULFAIR				
	PHARMAFAIR	0.5%;10%	A088032 001	Apr 15, 1983
VASOCIDIN				
	NOVARTIS	0.5%;10%	A088791 001	Oct 05, 1984
SUSPENSION;OPHTHALMIC				
ISOPTO CETAPRED				
	ALCON	0.25%;10%	A087547 001	
SUSPENSION/DROPS;OPHTHALMIC				
METIMYD				
	SCHERING	0.5%;10%	N010210 001	
PREDAMIDE				
	AKORN	0.5%;10%	A088059 001	Jul 29, 1983
PREDSULFAIR				
	PHARMAFAIR	0.5%;10%	A088007 001	Apr 19, 1983
PREDSULFAIR II				
	PHARMAFAIR	0.2%;10%	A088837 001	Dec 24, 1985
SULPHRIN				
	BAUSCH AND LOMB	0.5%;10%	A088089 001	Dec 28, 1982

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE;INJECTION				
HYDELTRASOL				
	MERCK	EQ 20MG PHOSPHATE/ML	N011583 002	
PREDNISOLONE SODIUM PHOSPHATE				
	WATSON LABS	EQ 20MG PHOSPHATE/ML	A080517 001	
OINTMENT;OPHTHALMIC, OTIC				
HYDELTRASOL				
	MERCK	EQ 0.25% PHOSPHATE	N011028 001	
SOLUTION;ORAL				
ORAPRED				
	CONCORDIA PHARMS INC	EQ 15MG BASE/5ML **	A075117 001	Dec 14, 2000
PREDNISOLONE SODIUM PHOSPHATE				
	AMNEAL PHARMS	EQ 15MG BASE/5ML	A078345 001	Mar 10, 2009
	MEDICIS PHARMS	EQ 15MG BASE/5ML	A075250 001	Jul 12, 2002
	NESHER PHARMS	EQ 5MG BASE/5ML	A076982 001	May 24, 2005
		EQ 15MG BASE/5ML	A076988 001	May 24, 2005
	PHARM ASSOC	EQ 5MG BASE/5ML	A076123 001	Dec 23, 2002
	VINTAGE PHARMS	EQ 5MG BASE/5ML	A078416 001	Oct 31, 2007
	WE PHARMS	EQ 5MG BASE/5ML	A075181 001	Dec 23, 2002
SOLUTION/DROPS;OPHTHALMIC				
INFLAMASE FORTE				
	NOVARTIS	EQ 0.9% PHOSPHATE	A080751 002	
INFLAMASE MILD				
	NOVARTIS	EQ 0.11% PHOSPHATE	A080751 001	
METRETON				
	SCHERING	EQ 0.5% PHOSPHATE	A083834 001	
PREDAIR				
	PHARMAFAIR	EQ 0.11% PHOSPHATE	A088415 001	Feb 29, 1984
PREDAIR FORTE				
	PHARMAFAIR	EQ 0.9% PHOSPHATE	A088165 001	Mar 28, 1983
PREDNISOLONE SODIUM PHOSPHATE				
	AKORN	EQ 0.11% PHOSPHATE	A083358 001	
		EQ 0.9% PHOSPHATE	A083358 002	
	ALCON PHARMS LTD	EQ 0.11% PHOSPHATE	A081043 001	Oct 24, 1991
		EQ 0.9% PHOSPHATE	A081044 001	Oct 24, 1991

PREDNISOLONE SODIUM PHOSPHATE				
SOLUTION/DROPS;OPHTHALMIC				
PREDNISOLONE SODIUM PHOSPHATE				
	BAUSCH AND LOMB	EQ 0.11% PHOSPHATE	A040065 001	Jul 29, 1994
	SOLA BARNES HIND	EQ 0.11% PHOSPHATE	A084171 001	
		EQ 0.9% PHOSPHATE	A084168 001	
		EQ 0.9% PHOSPHATE	A084169 001	
		EQ 0.9% PHOSPHATE	A084172 001	
PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM				
SOLUTION/DROPS;OPHTHALMIC				
SULSTER				
	AKORN	EQ 0.23% PHOSPHATE;10%	A074511 001	Jul 30, 1996
VASOCIDIN				
+	NOVARTIS	EQ 0.23% PHOSPHATE;10% **	N018988 001	Aug 26, 1988
PREDNISOLONE TEBUTATE				
INJECTABLE;INJECTION				
HYDELTRA-TBA				
	MERCK	20MG/ML	N010562 001	
PREDNISOLONE TEBUTATE				
	WATSON LABS	20MG/ML	A083362 001	Feb 17, 1984
PREDNISONE				
SOLUTION;ORAL				
PREDNISONE				
	WOCKHARDT	5MG/5ML	A089726 001	Aug 02, 1988
SYRUP;ORAL				
LIQUID PRED				
	MURO	5MG/5ML	A087611 002	Sep 07, 1982
TABLET;ORAL				
CORTAN				
	HALSEY	20MG	A087480 001	
DELTA-DOME				
	BAYER PHARMS	5MG	A080293 001	
DELTASONE				
+	PHARMACIA AND UPJOHN	2.5MG **	N009986 005	
+		5MG **	N009986 002	
+		10MG **	N009986 006	
+		20MG **	N009986 007	
+		50MG **	N009986 008	
FERNISONE				
	FERNDALE LABS	5MG	A083364 001	
METICORTEN				
+	SCHERING	1MG **	N009766 002	
+		5MG **	N009766 001	
ORASONE				
	SOLVAY	1MG	A083009 001	
		5MG	A083009 002	
		10MG	A083009 003	
		20MG	A083009 004	
		50MG	A085999 001	
PARACORT				
	PARKE DAVIS	5MG	N010962 002	
PREDNICEN-M				
	SCHWARZ PHARMA	5MG	A084655 001	
PREDNISONE				
	AM THERAP	5MG	A089387 001	Nov 06, 1986
		10MG	A089388 001	Nov 06, 1986
		20MG	A089389 001	Nov 06, 1986
	AMNEAL PHARMS NY	5MG	A089597 001	Oct 05, 1987
		10MG	A089598 001	Oct 05, 1987
		20MG	A089599 001	Oct 05, 1987
	AUROLIFE PHARMA LLC	5MG	A084774 001	
		10MG	A089983 001	Jan 12, 1989
		20MG	A085813 001	
		50MG	A089984 001	Jan 12, 1989
	BUNDY	5MG	A083676 001	
	CHARTWELL RX	5MG	A083059 001	
	CONTRACT PHARMACAL	5MG	A080209 001	
	DURAMED PHARMS BARR	5MG	A088394 001	Oct 04, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

PREDNISONE

TABLET;ORAL

PREDNISONE

	10MG	A088395 001	Oct 04, 1983
	20MG	A088396 001	Oct 04, 1983
ELKINS SINN	5MG	A080491 001	
	20MG	A085811 001	
EVERYLIFE	1MG	A084440 001	
	2.5MG	A084440 002	
	5MG	A084440 003	
FERRANTE	2.5MG	A080563 001	
	5MG	A080563 002	
HALSEY	5MG	A080300 001	
HEATHER	5MG	A080320 001	
	10MG	A084341 001	
	20MG	A084417 001	
	20MG	A085543 001	
	50MG	A086946 001	
HIKMA PHARMS	1MG	A040890 001	Nov 01, 2010
	2.5MG	A040538 001	Jan 08, 2004
IMPAX LABS	5MG	A080782 001	
INWOOD LABS	1MG	A080328 001	
	2.5MG	A080306 001	
	5MG	A080279 001	
IVAX SUB TEVA PHARMS	5MG	A080283 001	
	10MG	A084133 001	
	20MG	A084134 001	
KV PHARM	5MG	A084236 001	
LANNETT	5MG	A080514 001	
	20MG	A084275 001	
LEDERLE	5MG	A086968 001	
MARSHALL PHARMA	5MG	A080301 001	
MUTUAL PHARM	5MG	A080701 001	
	10MG	A086595 001	
	20MG	A084634 001	
NYLOS	5MG	A085115 001	
PANRAY	1MG	A080350 001	
	2.5MG	A080350 002	
	5MG	A080350 003	
PHARMAVITE	5MG	A084662 002	
PHOENIX LABS NY	5MG	A080321 001	
	20MG	A083807 001	
PUREPAC PHARM	5MG	A080353 001	
	10MG	A086062 001	
	20MG	A086061 001	
PVT FORM	20MG	A085151 001	
REXALL	5MG	A080232 001	
ROXANE	20MG	N017109 001	
	25MG	A087833 001	May 04, 1982
SANDOZ	5MG	A080336 002	
SCHERER LABS	5MG	A080371 001	
SPERTI	1MG	A080359 001	
	2.5MG	A080359 002	
	5MG	A080359 003	
SUN PHARM INDUSTRIES	50MG	A086596 001	
SUPERPHARM	5MG	A088865 001	Oct 25, 1984
	10MG	A088866 001	Oct 25, 1984
	20MG	A088867 001	Oct 25, 1984
TEVA	5MG	A080397 001	
UDL	5MG	A087984 001	Jan 18, 1983
	10MG	A087985 001	Jan 18, 1983
	20MG	A087986 001	Jan 18, 1983
UPSHER SMITH	5MG	A087471 001	
	20MG	A087470 001	
VALEANT PHARM INTL	5MG	A080237 001	
VANGARD	5MG	A087682 001	Jan 15, 1982
	20MG	A087701 001	Jan 15, 1982
VITARINE	5MG	A080334 001	
	5MG	A080506 001	

PREDNISONE				
TABLET;ORAL				
PREDNISONE				
WATSON LABS	5MG		A085084 002	
	10MG		A087773 001	Jul 13, 1982
	20MG		A086813 001	
	50MG		A086867 001	
	50MG		A087772 001	Jul 13, 1982
WHITEWORTH TOWN PLSN	2.5MG		A084913 001	
	5MG		A080343 001	
	10MG		A089028 001	Jul 24, 1986
	20MG		A084913 002	
SERVISONE				
LEDERLE	5MG		A080223 001	
PRILOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
CITANEST				
+ ASTRAZENECA	1% **		N014763 004	
+	2% **		N014763 005	
+	3% **		N014763 003	
CITANEST PLAIN				
+ ASTRAZENECA	4% **		N014763 007	
CITANEST PLAIN DENTAL				
+ DENTSPLY PHARM	4%		N021382 001	
PRIMIDONE				
SUSPENSION;ORAL				
MYSOLINE				
NURO PHARMA	250MG/5ML		N010401 001	
TABLET;ORAL				
PRIMIDONE				
DR REDDYS LABS LTD	50MG		A040862 001	Oct 03, 2008
	250MG		A040862 002	Oct 03, 2008
HIKMA INTL PHARMS	50MG		A040667 001	Jul 27, 2006
IMPAX LABS	50MG		A040717 001	Feb 12, 2008
	250MG		A040717 002	Feb 12, 2008
WATSON LABS	250MG		A085052 001	
PROBENECID				
TABLET;ORAL				
BENEMID				
+ MERCK	500MG **		N007898 004	
PROBENECID				
IVAX SUB TEVA PHARMS	500MG		A083740 001	May 09, 1984
LEDERLE	500MG		A086917 001	
WATSON LABS	500MG		A086150 002	Apr 23, 1982
PROBUCOL				
TABLET;ORAL				
LORELCO				
SANOFI AVENTIS US	250MG		N017535 001	
	500MG		N017535 002	Jul 06, 1988
PROCAINAMIDE HYDROCHLORIDE				
CAPSULE;ORAL				
PROCAINAMIDE HYDROCHLORIDE				
ANI PHARMS INC	250MG		A089219 001	Jul 01, 1986
	375MG		A089219 002	Jul 01, 1986
	500MG		A089219 003	Jul 01, 1986
ASCOT	250MG		A087542 001	Jan 08, 1982
	375MG		A087697 001	Mar 01, 1983
	500MG		A087543 001	Jan 08, 1982
IVAX SUB TEVA PHARMS	250MG		A084604 001	
	375MG		A084595 001	
	500MG		A084606 001	
LANNETT	250MG		A083693 001	
	500MG		A084696 001	
LEDERLE	250MG		A086942 001	
	375MG		A086952 001	
	500MG		A086943 001	
ROXANE	250MG		A088989 001	Apr 26, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

PROCAINAMIDE HYDROCHLORIDE

CAPSULE;ORAL					
PROCAINAMIDE HYDROCHLORIDE					
	500MG		A088990	001	Apr 26, 1985
VANGARD	250MG		A087643	001	Jun 01, 1982
	500MG		A087875	001	Jun 01, 1982
WATSON LABS	250MG		A083287	001	
	250MG		A083795	001	
	250MG		A085167	001	
	375MG		A084403	001	
	375MG		A087020	001	
	500MG		A084280	001	
	500MG		A084357	001	
	500MG		A087021	001	
PROCAN					
PARKE DAVIS	250MG		A085804	001	
	375MG		A087502	001	
	500MG		A085079	001	
PROCAPAN					
PANRAY	250MG		A083553	002	
PRONESTYL					
+ APOTHECON	250MG	**	N007335	001	
+	375MG	**	N007335	004	
+	500MG	**	N007335	003	
INJECTABLE;INJECTION					
PROCAINAMIDE HYDROCHLORIDE					
ABRAXIS PHARM	100MG/ML		A089415	001	Nov 17, 1986
	500MG/ML		A089416	001	Nov 17, 1986
HOSPIRA	500MG/ML		A089537	001	Aug 25, 1987
INTL MEDICATION	500MG/ML		A088637	001	Jul 31, 1984
PHARMAFAIR	100MG/ML		A088824	001	Nov 20, 1985
	500MG/ML		A088830	001	Nov 20, 1985
SMITH AND NEPHEW	100MG/ML		A088530	001	Mar 04, 1985
	500MG/ML		A088531	001	Mar 04, 1985
SOLOPAK	500MG/ML		A088532	001	Mar 04, 1985
WARNER CHILCOTT	100MG/ML		A089528	001	May 03, 1988
	500MG/ML		A089529	001	May 03, 1988
WATSON LABS	100MG/ML		A087079	001	
	500MG/ML		A087080	001	
WEST-WARD PHARMS INT	100MG/ML		A089029	001	Apr 17, 1986
	500MG/ML		A089030	001	Apr 17, 1986
PRONESTYL					
+ APOTHECON	100MG/ML	**	N007335	002	
+	500MG/ML	**	N007335	005	
TABLET;ORAL					
PRONESTYL					
APOTHECON	250MG		N017371	001	
	375MG		N017371	002	
	500MG		N017371	003	
TABLET, EXTENDED RELEASE;ORAL					
PROCAINAMIDE HYDROCHLORIDE					
ANI PHARMS INC	250MG		A088958	001	Dec 02, 1985
	250MG		A089369	001	Aug 14, 1987
	500MG		A088959	001	Dec 02, 1985
	500MG		A088974	001	Jul 22, 1985
	500MG		A089369	002	Jan 09, 1987
	750MG		A089369	003	Aug 14, 1987
	750MG		A089438	001	Mar 23, 1987
	1GM		A040111	001	Dec 13, 1996
INWOOD LABS	500MG		A089840	001	Mar 06, 1989
SANDOZ	500MG		A089284	001	Jun 23, 1986
WATSON LABS	250MG		A088533	001	Dec 03, 1984
	250MG		A089026	001	Oct 22, 1985
	500MG		A088534	001	Dec 03, 1984
	500MG		A089027	001	Oct 22, 1985
	750MG		A088535	001	Nov 03, 1984
	750MG		A089042	001	Oct 22, 1985
	1GM		A089520	001	Jan 15, 1987

PROCAINAMIDE HYDROCHLORIDE				
TABLET, EXTENDED RELEASE;ORAL				
PROCAN SR				
	PARKE DAVIS	250MG	A086468 001	
	PARKEDALE	500MG	A086065 001	
		750MG	A087510 001	Apr 01, 1982
		1GM	A088489 001	Jan 16, 1985
PROCANBID				
	KING PHARMS	500MG	N020545 001	Jan 31, 1996
		1GM	N020545 002	Jan 31, 1996
PRONESTYL-SR				
	APOTHECON	500MG	A087361 001	
PROCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
NOVOCAIN				
	HOSPIRA	1%	A085362 003	
		2%	A085362 004	
		10%	A086797 001	
PROCAINE HYDROCHLORIDE				
	ABRAXIS PHARM	1%	A080384 002	
		1%	A080421 001	
		2%	A080384 003	
		2%	A080421 002	
	BEL MAR	1%	A080711 001	
		2%	A080756 001	
	ELKINS SINN	1%	A083315 001	
		2%	A083315 002	
	GD SEARLE LLC	1%	A086202 001	
		2%	A086202 002	
	HOSPIRA	1%	A080416 001	
		2%	A080416 002	
	MILES	1%	A080415 001	
		2%	A080415 002	
	WATSON LABS	1%	A080658 001	
		1%	A083535 001	
		2%	A080658 002	
		2%	A083535 002	
PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
ACHROMYCIN				
	LEDERLE	40MG/VIAL;100MG/VIAL	N050276 001	
		40MG/VIAL;250MG/VIAL	N050276 003	
TETRACYN				
	PFIZER	40MG/VIAL;100MG/VIAL	A060285 002	
		40MG/VIAL;250MG/VIAL	A060285 003	
PROCAINE MERETHOXYLLINE; THEOPHYLLINE				
INJECTABLE;INJECTION				
DICURIN PROCAINE				
	LILLY	100MG/ML;50MG/ML	N008869 001	
PROCHLORPERAZINE				
SUPPOSITORY;RECTAL				
COMPAZINE				
	GLAXOSMITHKLINE	2.5MG **	N011127 003	
		5MG **	N011127 001	
		25MG **	N011127 002	
PROCHLORPERAZINE				
	ABLE	2.5MG	A040407 001	Jul 11, 2001
		5MG	A040407 002	Jul 11, 2001
		25MG	A040407 003	Jul 11, 2001
PROCHLORPERAZINE EDISYLATE				
CONCENTRATE;ORAL				
COMPAZINE				
	GLAXOSMITHKLINE	EQ 10MG BASE/ML	N011276 001	
PROCHLORPERAZINE				
	ALPHARMA US PHARMS	EQ 10MG BASE/ML	A087153 001	Jun 08, 1982

PROCHLORPERAZINE EDISYLATE				
CONCENTRATE;ORAL				
PROCHLORPERAZINE EDISYLATE				
MORTON GROVE	EQ 10MG BASE/ML	A088598	001	Oct 25, 1984
INJECTABLE;INJECTION				
COMPAZINE				
+ GLAXOSMITHKLINE	EQ 5MG BASE/ML **	N010742	002	
PROCHLORPERAZINE				
BAXTER HLTHCARE	EQ 5MG BASE/ML	A087759	001	Oct 01, 1982
PROCHLORPERAZINE EDISYLATE				
HOSPIRA	EQ 5MG BASE/ML	A089703	001	Apr 07, 1988
MARSAM PHARMS LLC	EQ 5MG BASE/ML	A089675	001	Dec 05, 1988
SMITH AND NEPHEW	EQ 5MG BASE/ML	A089251	001	Dec 04, 1986
TEVA PARENTERAL	EQ 5MG BASE/ML	A040505	001	May 30, 2003
WATSON LABS	EQ 5MG BASE/ML	A089530	001	Jul 08, 1987
	EQ 5MG BASE/ML	A089605	001	Jul 08, 1987
	EQ 5MG BASE/ML	A089606	001	Jul 08, 1987
WEST-WARD PHARMS INT	EQ 5MG BASE/ML	A089523	001	May 03, 1988
WYETH AYERST	EQ 5MG BASE/ML	A086348	001	
SYRUP;ORAL				
COMPAZINE				
GLAXOSMITHKLINE	EQ 5MG BASE/5ML	N011188	001	
PROCHLORPERAZINE EDISYLATE				
ALPHARMA US PHARMS	EQ 5MG BASE/5ML	A087154	001	Sep 01, 1982
MORTON GROVE	EQ 5MG BASE/5ML	A088597	001	Oct 25, 1984
PROCHLORPERAZINE MALEATE				
CAPSULE, EXTENDED RELEASE;ORAL				
COMPAZINE				
GLAXOSMITHKLINE	EQ 10MG BASE	N011000	001	
	EQ 10MG BASE	N021019	001	Oct 06, 1999
	EQ 15MG BASE	N011000	002	
	EQ 15MG BASE	N021019	002	Oct 06, 1999
	EQ 30MG BASE	N011000	003	
	EQ 75MG BASE	N011000	004	
TABLET;ORAL				
COMPAZINE				
GLAXOSMITHKLINE	EQ 5MG BASE **	N010571	001	
	EQ 10MG BASE **	N010571	002	
	EQ 25MG BASE **	N010571	003	
PROCHLORPERAZINE				
WATSON LABS	EQ 5MG BASE	A085580	001	
	EQ 10MG BASE	A085178	001	
	EQ 25MG BASE	A085579	001	
PROCHLORPERAZINE MALEATE				
DURAMED PHARMS BARR	EQ 5MG BASE	A040207	001	May 01, 1997
	EQ 5MG BASE	A089484	001	Jan 20, 1987
	EQ 10MG BASE	A040207	002	May 01, 1997
	EQ 10MG BASE	A089485	001	Jan 20, 1987
	EQ 25MG BASE	A089486	001	Jan 20, 1987
IVAX SUB TEVA PHARMS	EQ 5MG BASE	A040162	001	Jan 20, 1998
	EQ 10MG BASE	A040162	002	Jan 20, 1998
SANDOZ	EQ 25MG BASE	A040101	003	Jul 19, 1996
PROCYCLIDINE HYDROCHLORIDE				
TABLET;ORAL				
KEMADRIN				
MONARCH PHARMS	2MG	N009818	005	
	5MG	N009818	003	
PROGESTERONE				
CAPSULE;ORAL				
PROGESTERONE				
TEVA PHARMS	100MG	A202121	001	Feb 29, 2012
	200MG	A202121	002	Feb 29, 2012
PROMETRIUM				
VIRTUS PHARMS	300MG	N019781	003	Oct 15, 1999
INJECTABLE;INJECTION				
PROGESTERONE				
LILLY	25MG/ML	N009238	002	
	50MG/ML	N009238	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

PROGESTERONE				
INSERT, EXTENDED RELEASE;INTRAUTERINE				
PROGESTASERT				
ALZA	38MG	N017553 001		
PROMAZINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
SPARINE				
WYETH AYERST	30MG/ML	N010942 001		
	100MG/ML	N010942 004		
INJECTABLE;INJECTION				
PROMAZINE HYDROCHLORIDE				
WATSON LABS	25MG/ML	A084510 001		
	50MG/ML	A084517 001		
SPARINE				
BAXTER HLTHCARE CORP	25MG/ML	N010349 008		
	50MG/ML	N010349 006		
SYRUP;ORAL				
SPARINE				
WYETH AYERST	10MG/5ML	N010942 003		
TABLET;ORAL				
SPARINE				
WYETH AYERST	10MG	N010348 006		
	25MG	N010348 001		
	50MG	N010348 002		
	100MG	N010348 003		
	200MG	N010348 004		
PROMETHAZINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
PHENERGAN				
WYETH AYERST	25MG/ML	N008857 002		
	50MG/ML	N008857 003		
PROMETHAZINE HYDROCHLORIDE				
ABBOTT	25MG/ML	A084223 001		
	50MG/ML	A084222 001		
AKORN	25MG/ML	A083955 002		
	50MG/ML	A083955 001		
BEDFORD LABS	25MG/ML	A040524 001	Mar 17, 2004	
	50MG/ML	A040524 002	Mar 17, 2004	
HOSPIRA	25MG/ML	A040372 001	Jun 08, 2000	
	50MG/ML	A040372 002	Jun 08, 2000	
	50MG/ML	A083838 002		
LUITPOLD	25MG/ML	A040515 001	Mar 19, 2003	
MARSAM PHARMS LLC	25MG/ML	A089463 001	May 02, 1988	
	50MG/ML	A089477 001	May 02, 1988	
MYLAN INSTITUTIONAL	25MG/ML	A040471 001	Nov 21, 2002	
SANDOZ	25MG/ML	A040593 001	Nov 08, 2006	
	50MG/ML	A040593 002	Nov 08, 2006	
TEVA PHARMS USA	25MG/ML **	A040454 001	Aug 22, 2002	
	50MG/ML **	A040454 002	Aug 22, 2002	
WATSON LABS	25MG/ML	A083532 001		
	25MG/ML	A084591 001		
	50MG/ML	A080629 002		
	50MG/ML	A083532 002		
WOCKHARDT	25MG/ML	A040785 001	Sep 26, 2008	
	50MG/ML	A040785 002	Sep 26, 2008	
ZIPAN-25				
ALTANA	25MG/ML	A083997 001		
ZIPAN-50				
ALTANA	50MG/ML	A083997 002		
SUPPOSITORY;RECTAL				
PHENERGAN				
+ MYLAN PHARMS INC	12.5MG **	N010926 002		
+	25MG **	N010926 001		
+	50MG **	N011689 001		
PROMETHACON				
POLYMEDICA	25MG	A084901 001		
	50MG	A084902 001		

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY;RECTAL				
PROMETHAZINE HYDROCHLORIDE				
ABLE	12.5MG	A040504	001	Apr 11, 2003
	25MG	A040504	002	Apr 11, 2003
	50MG	A040449	001	Feb 27, 2003
SYRUP;ORAL				
MYMETHAZINE FORTIS				
USL PHARMA	25MG/5ML	A087996	001	Jan 18, 1983
PROMETH FORTIS				
ALPHARMA US PHARMS	25MG/5ML	A084772	001	
PROMETH PLAIN				
ACTAVIS MID ATLANTIC	6.25MG/5ML	A085953	001	
PROMETHAZINE				
CENCI	6.25MG/5ML	A089013	001	Sep 20, 1985
PROMETHAZINE HYDROCHLORIDE				
KV PHARM	6.25MG/5ML	A085388	001	
	25MG/5ML	A085385	001	
PHARM ASSOC	6.25MG/5ML	A087518	001	
WHITEWORTH TOWN PLSN	6.25MG/5ML	A086395	001	
PROMETHAZINE HYDROCHLORIDE PLAIN				
+ ANI PHARMS	6.25MG/5ML **	N008381	004	Apr 18, 1984
+	25MG/5ML **	N008381	003	
TABLET;ORAL				
PHENERGAN				
+ DELCOR ASSET CORP	12.5MG **	N007935	002	
+	25MG **	N007935	003	
+	50MG **	N007935	004	
PROMETHAZINE HYDROCHLORIDE				
ABBOTT	12.5MG	A084160	001	
	25MG	A084166	001	
	50MG	A084539	001	
ABLE	12.5MG	A040558	001	Jul 01, 2004
	25MG	A040558	002	Jul 01, 2004
	50MG	A040558	003	Jul 01, 2004
IMPAX LABS	25MG	A084214	002	Jul 07, 1982
	50MG	A040791	001	May 20, 2008
IVAX SUB TEVA PHARMS	12.5MG	A083604	001	
	25MG	A083603	001	
	50MG	A083613	001	
LANNETT	12.5MG	A080949	001	
	25MG	A080949	002	
	50MG	A080949	003	
MYLAN	12.5MG	A091054	001	Aug 30, 2011
	25MG	A091054	002	Aug 30, 2011
	50MG	A091054	003	Aug 30, 2011
PVT FORM	12.5MG	A083214	001	
	25MG	A083658	001	
SANDOZ	12.5MG	A084176	002	May 22, 2009
	12.5MG	A084233	001	
	25MG	A085146	001	
	50MG	A085146	002	
SUN PHARM INDUSTRIES	12.5MG	A084555	001	
	25MG	A084554	001	
	50MG	A084557	001	
TABLICAPS	12.5MG	A084080	001	
	25MG	A084027	001	
TEVA	25MG	A089109	001	Sep 10, 1985
WATSON LABS	12.5MG	A083401	001	
	12.5MG	A083712	001	
	12.5MG	A085986	001	
	25MG	A083204	001	
	25MG	A085684	001	
	50MG	A083403	001	
	50MG	A085664	001	
REMSED				
BRISTOL MYERS SQUIBB	25MG	A083176	002	
	50MG	A083176	001	

PROPAFENONE HYDROCHLORIDE

TABLET;ORAL

PROPAFENONE HYDROCHLORIDE				
NESHER PHARMS	150MG	A076193	001	Feb 07, 2002
	225MG	A076193	002	Feb 07, 2002
	300MG	A076193	003	Feb 07, 2002
RYTHMOL				
+ GLAXOSMITHKLINE LLC	150MG	N019151	001	Nov 27, 1989
+	225MG	N019151	003	Nov 20, 1992
+	300MG	N019151	002	Nov 27, 1989

PROPANTHELINE BROMIDE

INJECTABLE;INJECTION

PRO-BANTHINE				
GD SEARLE LLC	30MG/VIAL	N008843	001	

TABLET;ORAL

PRO-BANTHINE				
+ SHIRE	7.5MG **	N008732	003	
+	15MG **	N008732	002	
PROPANTHELINE BROMIDE				
ASCOT	15MG	A087663	001	Oct 25, 1982
HEATHER	15MG	A085780	001	
IMPAX LABS	15MG	A084541	002	
MYLAN	15MG	A083706	001	
PAR PHARM	15MG	A088377	001	Dec 08, 1983
PVT FORM	15MG	A080977	001	
SANDOZ	15MG	A080928	001	
TABLICAPS	15MG	A084428	001	
WATSON LABS	15MG	A083029	002	
	15MG	A083151	001	
WEST-WARD PHARMS INT	7.5MG	A080927	001	

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

KAINAIR				
PHARMAFAIR	0.5%	A088087	001	Jun 07, 1983
OPHTHAINE				
+ APOTHECON	0.5% **	N008883	001	
OPHTHETIC				
+ ALLERGAN	0.5% **	N012583	001	
PARACAINE				
OPTOPICS	0.5%	A087681	001	Aug 05, 1982
PROPARACAINE HYDROCHLORIDE				
SOLA BARNES HIND	0.5%	A084144	001	
	0.5%	A084151	001	

PROPIOLACTONE

SOLUTION;IRRIGATION

BETAPRONE				
FOREST LABS	N/A	N011657	001	

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

LARGON				
WEST-WARD PHARMS INT	20MG/ML	N012382	002	

PROPOFOL

INJECTABLE;INJECTION

DIPRIVAN				
FRESENIUS KABI USA	10MG/ML	N019627	001	Oct 02, 1989
PROPOFOL				
TEVA PARENTERAL	10MG/ML	A075392	001	Sep 19, 2000
WEST-WARD PHARMS INT	10MG/ML	A074848	001	Apr 19, 2005

PROPOXYPHENE HYDROCHLORIDE

CAPSULE;ORAL

DARVON				
XANODYNE PHARM	32MG	N010997	001	
	65MG	N010997	003	
DOLENE				
HERITAGE PHARMS INC	65MG	A080530	001	

PROPOXYPHENE HYDROCHLORIDE

CAPSULE;ORAL				
KESSO-GESIC				
MK LABS	65MG	A083544	001	
PROPHENE 65				
HALSEY	65MG	A083538	002	
PROPOXYPHENE HYDROCHLORIDE				
ALRA	65MG	A083184	001	
IMPAX LABS	65MG	A083317	001	
IVAX SUB TEVA PHARMS	32MG	A083597	001	
MUTUAL PHARM	65MG	A083186	001	
MYLAN	32MG	A083528	001	
	65MG	A040569	001	Dec 16, 2004
	65MG	A083299	001	
NEXGEN PHARMA INC	65MG	A083185	001	
PAR PHARM	65MG	A080269	001	
PUREPAC PHARM	65MG	A083278	001	
PVT FORM	32MG	A083464	001	
	65MG	A083113	001	
ROXANE	32MG	A083089	001	
	65MG	A083089	002	
SANDOZ	32MG	A084014	001	
	65MG	A083125	002	
	65MG	A083688	001	
	65MG	A083870	002	
	65MG	A086495	001	
TEVA	65MG	A088615	001	Oct 22, 1984
VALEANT PHARM INTL	65MG	A080783	001	
VINTAGE PHARMS	65MG	A040908	001	Jul 17, 2009
WATSON LABS	65MG	A080908	002	
	65MG	A085190	001	
WEST WARD	65MG	A083501	001	
WHITEWORTH TOWN PLSN	65MG	A084551	001	
PROPOXYPHENE HYDROCHLORIDE 65				
WARNER CHILCOTT	65MG	A083786	001	

PROPOXYPHENE NAPSYLATE

SUSPENSION;ORAL				
DARVON-N				
AAIPHARMA LLC	50MG/5ML	N016861	001	
TABLET;ORAL				
DARVON-N				
XANODYNE PHARM	100MG	N016862	002	

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
PROPRANOLOL HYDROCHLORIDE				
INWOOD LABS	60MG	A072499	001	Apr 11, 1989
	80MG	A072500	001	Apr 11, 1989
	120MG	A072501	001	Apr 11, 1989
	160MG	A072502	001	Apr 11, 1989
MYLAN	60MG	A078022	001	Feb 15, 2007
	80MG	A078022	002	Feb 15, 2007
	120MG	A078022	003	Feb 15, 2007
	160MG	A078022	004	Feb 15, 2007
UPSHER SMITH LABS	60MG	A078311	001	Mar 06, 2009
	80MG	A078311	002	Mar 06, 2009
	120MG	A078311	003	Mar 06, 2009
	160MG	A078311	004	Mar 06, 2009
CONCENTRATE;ORAL				
PROPRANOLOL HYDROCHLORIDE INTENSOL				
ROXANE	80MG/ML	A071388	001	May 15, 1987
INJECTABLE;INJECTION				
PROPRANOLOL HYDROCHLORIDE				
+ BAXTER HLTHCARE CORP	1MG/ML	N016419	001	
FOSUN PHARMA	1MG/ML	A076400	001	Feb 26, 2003
SMITH AND NEPHEW	1MG/ML	A070135	001	Apr 15, 1986
	1MG/ML	A070137	001	Apr 15, 1986
SOLOPAK	1MG/ML	A070136	001	Apr 15, 1986

PROPRANOLOL HYDROCHLORIDE

SOLUTION;ORAL					
PROPRANOLOL HYDROCHLORIDE					
	MORTON GROVE	20MG/5ML	A071984	001	Mar 03, 1989
		40MG/5ML	A071985	001	Mar 03, 1989
SUSPENSION;ORAL					
INDERAL					
	WYETH AYERST	10MG/ML	N019536	001	Dec 12, 1986
TABLET;ORAL					
INDERAL					
+	WYETH PHARMS	10MG **	N016418	001	
+		20MG **	N016418	003	
+		40MG **	N016418	002	
+		60MG **	N016418	009	Oct 18, 1982
+		80MG **	N016418	004	
+		90MG **	N016418	010	Oct 18, 1982
PROPRANOLOL HYDROCHLORIDE					
	ANDA REPOSITORY	10MG	A070319	001	Oct 22, 1985
		20MG	A070320	001	Oct 22, 1985
		40MG	A070103	001	Oct 22, 1985
		60MG	A070321	001	Sep 24, 1986
		80MG	A070322	001	Aug 04, 1986
	ANI PHARMS INC	90MG	A071977	001	Apr 06, 1988
	DAVA PHARMS INC	10MG	A070125	001	Jul 30, 1985
		20MG	A070126	001	Jul 30, 1985
		40MG	A070127	001	Jul 30, 1985
		60MG	A071495	001	Dec 31, 1987
		80MG	A070128	001	Jul 30, 1985
		90MG	A071496	001	Dec 31, 1987
	DURAMED PHARMS BARR	10MG	A070306	001	Sep 09, 1985
		20MG	A070307	001	Sep 09, 1985
		40MG	A070308	001	Sep 09, 1985
		60MG	A070309	001	Oct 01, 1986
		80MG	A070310	001	Sep 09, 1985
		90MG	A071327	001	Oct 01, 1986
	INTERPHARM	10MG	A071368	001	May 05, 1987
		20MG	A071369	001	May 05, 1987
		40MG	A071370	001	May 05, 1987
		80MG	A071371	001	May 05, 1987
	IVAX SUB TEVA PHARMS	10MG	A072063	001	Jul 29, 1988
		20MG	A072066	001	Jul 29, 1988
		40MG	A072067	001	Jul 29, 1988
		60MG	A072068	001	Jul 29, 1988
		80MG	A072069	001	Jul 29, 1988
	LEDERLE	10MG	A072117	001	Jun 23, 1988
		20MG	A072118	001	Jun 23, 1988
		40MG	A072119	001	Jun 23, 1988
		80MG	A072120	001	Jun 23, 1988
	MYLAN	60MG	A072275	001	Jun 09, 1989
	PAR PHARM	90MG	A071288	001	Oct 22, 1986
	PUREPAC PHARM	10MG	A070814	001	Nov 03, 1986
		20MG	A070815	001	Nov 03, 1986
		40MG	A070816	001	Nov 03, 1986
		60MG	A070817	001	Nov 03, 1986
		80MG	A070757	001	Nov 03, 1986
	ROXANE	10MG	A070516	001	Jul 07, 1986
		20MG	A070517	001	Jul 07, 1986
		40MG	A070518	001	Jul 07, 1986
		60MG	A070519	001	Sep 24, 1986
		80MG	A070520	001	Jul 07, 1986
		90MG	A070521	001	Sep 24, 1986
	SANDOZ	10MG	A071658	001	Jul 05, 1988
		20MG	A071687	001	Jul 05, 1988
		40MG	A071688	001	Jul 05, 1988
		60MG	A072197	001	Jul 05, 1988
		80MG	A071689	001	Jul 05, 1988
		90MG	A072198	001	Jul 05, 1988
	SCHERING	10MG	A070120	001	Aug 06, 1985
		20MG	A070121	001	Aug 06, 1985

PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL				
PROPRANOLOL HYDROCHLORIDE				
	40MG	A070122	001	Aug 06, 1985
	60MG	A070123	001	Oct 29, 1986
	80MG	A070124	001	Aug 06, 1985
SUPERPHARM	10MG	A071515	001	Jun 08, 1988
	20MG	A071516	001	Jun 08, 1988
	40MG	A071517	001	Jun 08, 1988
	80MG	A071518	001	Jun 08, 1988
TEVA	10MG	A070232	001	Oct 07, 1987
	20MG	A070233	001	Jun 23, 1986
	40MG	A070234	001	Jun 23, 1986
WARNER CHILCOTT	10MG	A070438	001	Sep 15, 1986
	20MG	A070439	001	Sep 15, 1986
	40MG	A070440	001	Sep 15, 1986
	60MG	A070441	001	Sep 24, 1986
	80MG	A070442	001	Sep 15, 1986
WATSON LABS	10MG	A070140	001	Jul 30, 1985
	10MG	A070378	001	Mar 19, 1987
	20MG	A070141	001	Jul 30, 1985
	20MG	A070379	001	Mar 19, 1987
	40MG	A070142	001	Jul 30, 1985
	40MG	A070380	001	Mar 19, 1987
	60MG	A070143	001	Jan 15, 1987
	60MG	A070381	001	Mar 19, 1987
	60MG	A071098	001	Oct 06, 1986
	60MG	A071791	001	Jul 15, 1987
	80MG	A070144	001	Jul 30, 1985
	80MG	A070382	001	Mar 19, 1987
	80MG	A070551	001	Jul 10, 1986
	90MG	A071183	001	Oct 06, 1986
	90MG	A071792	001	Jul 15, 1987
WATSON LABS TEVA	10MG	A070548	001	Jul 10, 1986
	20MG	A070549	001	Apr 11, 1986
	40MG	A070550	001	Apr 11, 1986
YAOPHARMA CO LTD	10MG	A070663	001	Jun 13, 1986
	20MG	A070664	001	Jun 13, 1986
	40MG	A070665	001	Jun 13, 1986
	60MG	A070666	001	Oct 10, 1986
	80MG	A070667	001	Jun 13, 1986

PROPYLIODONE

SUSPENSION;INTRATRACHEAL			
DIONOSIL AQUEOUS			
GLAXOSMITHKLINE	50%	N009309	001
DIONOSIL OILY			
GLAXOSMITHKLINE	60%	N009309	002

PROPYLTHIOURACIL

TABLET;ORAL			
PROPYLTHIOURACIL			
ABBOTT	50MG	A084075	001
ANABOLIC	50MG	A080285	001
ANI PHARMS INC	50MG	A080215	001
CHARTWELL RX	50MG	A084543	001
HALSEY	50MG	A080015	001
HIKMA INTL PHARMS	50MG	A080154	001
IMPAX LABS	50MG	A080159	001
LANNETT	50MG	A080016	001
LILLY	50MG	N006213	001
SUN PHARM INDUSTRIES	50MG	A083982	001
TABLICAPS	50MG	A080840	001
WATSON LABS	50MG	A080932	001
	50MG	A085201	001

PROTAMINE SULFATE				
INJECTABLE;INJECTION				
PROTAMINE SULFATE				
+ LILLY	10MG/ML **	N006460	002	
PHARMACIA AND UPJOHN	50MG/VIAL	N007413	001	
	250MG/VIAL	N007413	002	Aug 02, 1984
WEST-WARD PHARMS INT	10MG/ML	A089474	001	Nov 05, 1986
	10MG/ML	A089475	001	Nov 05, 1986
PROTEIN HYDROLYSATE				
INJECTABLE;INJECTION				
AMINOSOL 5%				
ABBVIE	5%	N005932	012	Jan 31, 1985
HYPROTIGEN 5%				
B BRAUN	5%	N006170	003	Jan 10, 1984
PROTIRELIN				
INJECTABLE;INJECTION				
THYPINONE				
ABBOTT	0.5MG/ML	N017638	001	
THYREL TRH				
FERRING	0.5MG/ML	N018087	001	
PROTOKYLOL HYDROCHLORIDE				
TABLET;ORAL				
VENTAIRE				
SANOFI AVENTIS US	2MG	A083459	001	
PROTRIPTYLINE HYDROCHLORIDE				
TABLET;ORAL				
VIVACTIL				
TEVA WOMENS	5MG **	N016012	001	
	10MG **	N016012	002	
PSEUDOEPHEDRINE HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
NOVAFED				
SANOFI AVENTIS US	120MG	N017603	001	
SUDAFED 12 HOUR				
+ GLAXOSMITHKLINE	120MG **	N017941	002	
PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
ACTIFED				
GLAXOSMITHKLINE	120MG;5MG	N018996	001	Jun 17, 1985
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES				
KV PHARM	120MG;5MG	A071798	001	Mar 16, 1989
SYRUP;ORAL				
ACTAHIST				
CENCI	30MG/5ML;1.25MG/5ML	A088344	001	Feb 09, 1984
HISTAFED				
CENCI	30MG/5ML;1.25MG/5ML	A088283	001	Apr 20, 1984
MYFED				
USL PHARMA	30MG/5ML;1.25MG/5ML	A088116	001	Mar 04, 1983
TRILITRON				
NEWTRON PHARMS	30MG/5ML;1.25MG/5ML	A088474	001	Feb 12, 1985
TABLET;ORAL				
ALLERFED				
PVT FORM	60MG;2.5MG	A088860	001	Jan 31, 1985
CORPHED				
FOSUN PHARMA	60MG;2.5MG	A088602	001	Apr 11, 1985
PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE				
SANDOZ	60MG;2.5MG	A088193	001	May 17, 1983
TRILITRON				
NEWTRON PHARMS	60MG;2.5MG	A088515	001	Jan 09, 1985
TRIPHED				
TEVA	60MG;2.5MG	A088630	001	May 17, 1984
TRIPROLIDINE AND PSEUDOEPHEDRINE				
WATSON LABS	60MG;2.5MG	A088318	002	Jan 13, 1984
WEST WARD	60MG;2.5MG	A088117	001	Apr 19, 1983
TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE				
IVAX SUB TEVA PHARMS	60MG;2.5MG	A085273	001	Dec 12, 1984

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET;ORAL

TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

SUPERPHARM	60MG;2.5MG	A088578	001	Feb 21, 1985

TABLET, EXTENDED RELEASE;ORAL

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM	120MG;5MG	A072758	001	Nov 25, 1991

PSEUDOEPHEDRINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

PSEUDO-12

UCB INC	EQ 60MG HYDROCHLORIDE/5ML	N019401	001	Jun 19, 1987

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

AFRINOL

+ SCHERING PLOUGH	120MG	N018191	001	

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL

PYRIDOSTIGMINE BROMIDE

ANI PHARMS INC	30MG	A040512	002	Jul 20, 2005
	60MG	A040512	001	Oct 08, 2003
IMPAX LABS INC	60MG	A040457	001	Dec 26, 2002
SOLVAY	30MG	A089572	001	Nov 27, 1990
US ARMY	30MG	N020414	001	Feb 05, 2003

PYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION

HEXA-BETALIN

LILLY	100MG/ML	A080854	001	

PYRIDOXINE HYDROCHLORIDE

AKORN	100MG/ML	A087967	001	Oct 01, 1982
BEL MAR	100MG/ML	A080761	001	
DELL LABS	50MG/ML	A083771	001	
	100MG/ML	A083772	001	
ELKINS SINN	100MG/ML	A080581	001	
LUITPOLD	100MG/ML	A080669	001	
MYLAN INSTITUTIONAL	100MG/ML	A204879	001	Jul 14, 2016
WATSON LABS	100MG/ML	A080572	001	
	100MG/ML	A083760	001	

PYRILAMINE MALEATE

TABLET;ORAL

PYRILAMINE MALEATE

IMPAX LABS	25MG	A080808	001	
WATSON LABS	25MG	A085231	001	

PYRIMETHAMINE; SULFADOXINE

TABLET;ORAL

FANSIDAR

ROCHE	25MG;500MG	N018557	001	

PYRITHIONE ZINC

LOTION;TOPICAL

HEAD & SHOULDERS CONDITIONER

WARNER CHILCOTT	0.3%	N019412	002	Mar 10, 1986

PYRVINIUM PAMOATE

SUSPENSION;ORAL

POVAN

PARKE DAVIS	EQ 50MG BASE/5ML	N011964	001	

TABLET;ORAL

POVAN

PARKE DAVIS	EQ 50MG BASE	N012485	002	

QUAZEPAM

TABLET;ORAL

DORAL

GALT PHARMS	7.5MG	N018708	003	Feb 26, 1987

QUETIAPINE FUMARATE				
TABLET;ORAL				
QUETIAPINE FUMARATE				
ACTAVIS GRP PTC	EQ 25MG BASE	A201762	001	Feb 27, 2013
	EQ 50MG BASE	A201762	002	Feb 27, 2013
	EQ 100MG BASE	A201762	003	Feb 27, 2013
	EQ 150MG BASE	A201762	004	Feb 27, 2013
	EQ 200MG BASE	A201762	005	Feb 27, 2013
	EQ 300MG BASE	A201762	006	Feb 27, 2013
	EQ 400MG BASE	A201762	007	Feb 27, 2013
MYLAN PHARMS INC	EQ 25MG BASE	A090323	001	Mar 27, 2012
SEROQUEL				
+ ASTRAZENECA PHARMS	EQ 150MG BASE **	N020639	004	Dec 20, 1998
QUINAPRIL HYDROCHLORIDE				
TABLET;ORAL				
QUINAPRIL HYDROCHLORIDE				
ACTAVIS ELIZABETH	EQ 5MG BASE	A076459	001	Dec 22, 2004
	EQ 10MG BASE	A076459	002	Dec 22, 2004
	EQ 20MG BASE	A076459	003	Dec 22, 2004
	EQ 40MG BASE	A076459	004	Dec 22, 2004
ACTAVIS LABS FL INC	EQ 5MG BASE	A076049	001	Jan 14, 2005
	EQ 10MG BASE	A076049	002	Jan 14, 2005
	EQ 20MG BASE	A076049	003	Jan 14, 2005
	EQ 40MG BASE	A076049	004	Jan 14, 2005
APOTEX INC	EQ 5MG BASE	A076240	001	Jan 26, 2006
	EQ 10MG BASE	A076240	002	Jan 26, 2006
	EQ 20MG BASE	A076240	003	Jan 26, 2006
	EQ 40MG BASE	A076240	004	Jan 26, 2006
MYLAN	EQ 5MG BASE	A076036	001	Jan 28, 2005
	EQ 10MG BASE	A076036	002	Jan 28, 2005
	EQ 20MG BASE	A076036	003	Jan 28, 2005
	EQ 40MG BASE	A076036	004	Jan 28, 2005
SUN PHARM INDS LTD	EQ 5MG BASE	A076607	001	Dec 15, 2004
	EQ 5MG BASE	A090800	001	Jun 18, 2009
	EQ 10MG BASE	A076607	002	Dec 15, 2004
	EQ 10MG BASE	A090800	002	Jun 18, 2009
	EQ 20MG BASE	A076607	003	Dec 15, 2004
	EQ 20MG BASE	A090800	003	Jun 18, 2009
	EQ 40MG BASE	A076607	004	Dec 15, 2004
	EQ 40MG BASE	A090800	004	Jun 18, 2009
YAOPHARMA CO LTD	EQ 5MG BASE	A076803	001	Mar 02, 2005
	EQ 10MG BASE	A076803	002	Mar 02, 2005
	EQ 20MG BASE	A076803	003	Mar 02, 2005
	EQ 40MG BASE	A076803	004	Mar 02, 2005
QUINESTROL				
TABLET;ORAL				
ESTROVIS				
PARKE DAVIS	0.1MG	N016768	002	
	0.2MG	N016768	003	
QUINETHAZONE				
TABLET;ORAL				
HYDROMOX				
LEDERLE	50MG	N013264	001	
QUINETHAZONE; RESERPINE				
TABLET;ORAL				
HYDROMOX R				
LEDERLE	50MG;0.125MG	N013927	001	
QUINIDINE GLUCONATE				
INJECTABLE;INJECTION				
QUINIDINE GLUCONATE				
+ LILLY	80MG/ML	N007529	002	Feb 10, 1989
TABLET;ORAL				
QUINACT				
BAYER HLTHCARE	266MG	A085978	001	
	400MG	A086099	001	

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

DURAQUIN				
	WARNER CHILCOTT	330MG	N017917 001	
QUINAGLUTE				
	BAYER HLTHCARE	324MG	N016647 001	
QUINALAN				
	LANNETT	324MG	A088081 001	Feb 10, 1986
QUINATIME				
	WATSON LABS	324MG	A087448 001	
QUINIDINE GLUCONATE				
	ASCOT	324MG	A088582 001	Jun 17, 1985
	AUROLIFE PHARMA LLC	324MG	A089894 001	Dec 15, 1988
	CYCLE PHARMS LTD	324MG	A088431 001	Jan 06, 1984
	HALSEY	324MG	A089476 001	Apr 10, 1987
	SUPERPHARM	324MG	A089164 001	Nov 21, 1985
	WATSON LABS	324MG	A087785 001	Jan 24, 1983
		324MG	A087810 001	Sep 29, 1982

QUINIDINE POLYGALACTURONATE

TABLET;ORAL

CARDIOQUIN				
	PHARM RES ASSOC	275MG	N011642 002	

QUINIDINE SULFATE

CAPSULE;ORAL

CIN-QUIN				
	SOLVAY	200MG	A085296 001	
		300MG	A085297 001	
QUINIDINE SULFATE				
	LILLY	200MG	A085103 001	

TABLET;ORAL

CIN-QUIN				
	SOLVAY	100MG	A085299 001	
		200MG	A084932 001	
		300MG	A085298 001	
QUINIDINE SULFATE				
	BARR	200MG	A084177 001	
	CONTRACT PHARMACAL	200MG	A083808 001	
	CYCLE PHARMS LTD	200MG	A083640 001	
		300MG	A085632 001	
	DAVA PHARMS INC	200MG	A087011 001	
	ELKINS SINN	200MG	A083622 001	
	EVERYLIFE	200MG	A083439 001	
	HALSEY	200MG	A083583 001	
	HIKMA PHARMS	200MG	A083862 001	
	IMPAX LABS	200MG	A083347 001	
	IVAX SUB TEVA PHARMS	200MG	A084549 001	
	KING PHARMS	200MG	A085175 001	
	KV PHARM	200MG	A085276 001	
	LANNETT	200MG	A083743 001	
	LEDERLE	200MG	A086176 001	
	LILLY	200MG	A085038 001	
	PERRIGO	200MG	A085322 001	
	PHARMAVITE	200MG	A084627 001	
	PUREPAC PHARM	200MG	A084003 001	
	SANDOZ	200MG	A084631 001	
		200MG	A084914 001	
		300MG	A089839 001	Sep 29, 1988
	SCHERER LABS	200MG	A085068 001	
	SUN PHARM INDUSTRIES	100MG	A081029 001	Apr 14, 1989
	SUPERPHARM	200MG	A088973 001	Apr 10, 1985
	USL PHARMA	200MG	A087837 001	Apr 14, 1982
	VALEANT PHARM INTL	200MG	A083393 001	
	VANGARD	200MG	A087909 001	Jul 13, 1982
	VINTAGE PHARMS	200MG	A083963 001	
	WARNER CHILCOTT	200MG	A083879 001	
	WATSON LABS	100MG	A085584 001	
		200MG	A085140 002	
	WHITEWORTH TOWN PLSN	200MG	A085444 001	

QUINIDINE SULFATE				
TABLET;ORAL				
QUINORA				
	KEY PHARMS	200MG	A083576 001	
	SCHERING	300MG	A085222 001	
TABLET, EXTENDED RELEASE;ORAL				
QUINIDEX				
	WYETH PHARMS INC	300MG	N012796 002	
QUINIDINE SULFATE				
	G AND W LABS INC	300MG	A040045 001	Jun 30, 1994
RABEPRAZOLE SODIUM				
TABLET, DELAYED RELEASE;ORAL				
ACIPHEX				
+	EISAI INC	10MG **	N020973 001	May 29, 2002
RAMIPRIL				
CAPSULE;ORAL				
RAMIPRIL				
	ACTAVIS ELIZABETH	1.25MG	A077513 001	Jun 18, 2008
		2.5MG	A077513 002	Jun 18, 2008
		5MG	A077513 003	Jun 18, 2008
		10MG	A077513 004	Jun 18, 2008
	CIPLA	1.25MG	A077004 001	Aug 07, 2008
		2.5MG	A077004 002	Aug 07, 2008
		5MG	A077004 003	Aug 07, 2008
		10MG	A077004 004	Aug 07, 2008
	RANBAXY LABS LTD	5MG	A078849 001	Mar 06, 2009
		10MG	A078849 002	Mar 06, 2009
	WATSON LABS	5MG	A076549 003	Oct 24, 2005
	YAOPHARMA CO LTD	1.25MG	A077514 001	Jun 18, 2008
		2.5MG	A077514 002	Jun 18, 2008
		5MG	A077514 003	Jun 18, 2008
		10MG	A077514 004	Jun 18, 2008
TABLET;ORAL				
ALTACE				
+	KING PFIZER	1.25MG **	N022021 001	Feb 27, 2007
+		2.5MG **	N022021 002	Feb 27, 2007
+		5MG **	N022021 003	Feb 27, 2007
+		10MG **	N022021 004	Feb 27, 2007
RAMIPRIL				
	APOTEX INC	1.25MG	A091069 001	Dec 02, 2015
		2.5MG	A091069 002	Dec 02, 2015
		5MG	A091069 003	Dec 02, 2015
		10MG	A091069 004	Dec 02, 2015
	MYLAN PHARMS INC	1.25MG	A090650 001	Jun 30, 2011
		2.5MG	A090650 002	Jun 30, 2011
		5MG	A090650 003	Jun 30, 2011
		10MG	A090650 004	Jun 30, 2011
	ZYDUS PHARMS USA INC	1.25MG	A090697 001	Sep 24, 2009
		2.5MG	A090697 002	Sep 24, 2009
		5MG	A090697 003	Sep 24, 2009
		10MG	A090697 004	Sep 24, 2009
RANITIDINE BISMUTH CITRATE				
TABLET;ORAL				
TRITEC				
	GLAXOSMITHKLINE	400MG	N020559 001	Aug 08, 1996
RANITIDINE HYDROCHLORIDE				
CAPSULE;ORAL				
RANITIDINE HYDROCHLORIDE				
	MYLAN	EQ 150MG BASE	A075564 001	Oct 27, 2000
		EQ 300MG BASE	A075564 002	Oct 27, 2000
	TEVA	EQ 150MG BASE	A075557 001	Oct 31, 2003
		EQ 300MG BASE	A075557 002	Oct 31, 2003
ZANTAC 150				
+	GLAXOSMITHKLINE	EQ 150MG BASE **	N020095 001	Mar 08, 1994
ZANTAC 300				
+	GLAXOSMITHKLINE	EQ 300MG BASE **	N020095 002	Mar 08, 1994

RANITIDINE HYDROCHLORIDE

GRANULE, EFFERVESCENT;ORAL				
ZANTAC 150				
	GLAXO GRP LTD	EQ 150MG BASE/PACKET	N020251 002	Mar 31, 1994
INJECTABLE;INJECTION				
RANITIDINE HYDROCHLORIDE				
	BEDFORD	EQ 25MG BASE/ML	A074764 001	Nov 19, 2004
ZANTAC IN PLASTIC CONTAINER				
	TELIGENT	EQ 1MG BASE/ML	N019593 002	Sep 27, 1991
		EQ 50MG BASE/100ML	N019593 001	Dec 17, 1986
SYRUP;ORAL				
RANITIDINE HYDROCHLORIDE				
	APOTEX INC	EQ 15MG BASE/ML	A077602 001	Sep 17, 2007
	RANBAXY	EQ 15MG BASE/ML	A078448 001	Dec 13, 2007
	WOCKHARDT	EQ 15MG BASE/ML	A079211 001	May 26, 2009
		EQ 15MG BASE/ML	A079212 001	Feb 23, 2009
ZANTAC				
+	GLAXO GRP LTD	EQ 15MG BASE/ML	N019675 001	Dec 30, 1988
TABLET;ORAL				
RANITIDINE HYDROCHLORIDE				
	BOEHRINGER INGELHEIM	EQ 150MG BASE	A074662 001	Aug 29, 1997
		EQ 300MG BASE	A074662 002	Aug 29, 1997
	CONTRACT PHARMACAL	EQ 75MG BASE	A075094 001	Jun 21, 1999
	MYLAN	EQ 150MG BASE	A074023 001	Aug 22, 1997
		EQ 150MG BASE	A074552 001	Jul 30, 1998
		EQ 300MG BASE	A074023 002	Aug 22, 1997
		EQ 300MG BASE	A074552 002	Jul 30, 1998
	RANBAXY	EQ 75MG BASE	A075254 001	Jan 14, 2000
		EQ 150MG BASE	A075000 001	Jan 30, 1998
		EQ 300MG BASE	A075000 002	Jan 30, 1998
	SANDOZ	EQ 75MG BASE	A075519 001	Sep 26, 2002
	SUN PHARM INDS LTD	EQ 75MG BASE	A075132 001	Jan 14, 2000
		EQ 150MG BASE	A075439 001	Apr 19, 2000
		EQ 300MG BASE	A075439 002	Apr 19, 2000
	WATSON LABS	EQ 75MG BASE	A075212 001	Jan 14, 2000
		EQ 150MG BASE	A074864 001	Oct 20, 1997
		EQ 300MG BASE	A074864 002	Oct 20, 1997
	WATSON LABS INC	EQ 150MG BASE	A077426 001	Dec 19, 2005
		EQ 300MG BASE	A077426 002	Dec 19, 2005
	WOCKHARDT	EQ 75MG BASE	A078884 001	Jul 31, 2008
		EQ 150MG BASE	A078653 001	Nov 26, 2007
		EQ 150MG BASE	A078701 001	Nov 12, 2009
		EQ 300MG BASE	A078701 002	Dec 11, 2009
ZANTAC 150				
+	GLAXO GRP LTD	EQ 150MG BASE	N018703 001	Jun 09, 1983
ZANTAC 300				
+	GLAXO GRP LTD	EQ 300MG BASE	N018703 002	Dec 09, 1985
TABLET, EFFERVESCENT;ORAL				
ZANTAC 150				
	GLAXO GRP LTD	EQ 150MG BASE	N020251 001	Mar 31, 1994
ZANTAC 25				
	GLAXO GRP LTD	EQ 25MG BASE	N020251 003	Apr 01, 2004
ZANTAC 75				
+	SANOFI US	EQ 75MG BASE **	N020745 001	Feb 26, 1998

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL				
RANOLAZINE				
	LUPIN LTD	500MG	A201046 001	Jul 29, 2013
		1GM	A201046 002	Jul 29, 2013

RAPACURONIUM BROMIDE

INJECTABLE;INJECTION				
RAPLON				
	ORGANON USA INC	100MG/VIAL	N020984 001	Aug 18, 1999
		200MG/VIAL	N020984 002	Aug 18, 1999

RASAGILINE MESYLATE

TABLET;ORAL			
RASAGILINE MESYLATE			
APOTEX INC	EQ 0.5MG BASE	A201950 001	Sep 12, 2013
	EQ 1MG BASE	A201950 002	Sep 12, 2013

RAUWOLFIA SERPENTINA ROOT

TABLET;ORAL			
HIWOLFIA			
BOWMAN PHARMS	50MG	N009276 003	
	50MG	N009276 005	
	100MG	N009276 004	
HYSERPIN			
PHYS PRODS VA	50MG	N010581 001	
KOGLUCOID			
PANRAY	50MG	N009278 001	
	100MG	N009278 002	
RAUDIXIN			
APOTHECON	50MG	N008842 001	
	100MG	N008842 002	
RAUSERPIN			
FERNDALE LABS	50MG	N009926 002	
	100MG	N009926 004	
RAUVAL			
PAL PAK	50MG	N009108 002	
	100MG	N009108 004	
RAUWOLFIA SERPENTINA			
BUNDY	50MG	N009477 001	
	100MG	N009477 002	
HALSEY	50MG	A080498 001	
	100MG	A080498 002	
IMPAX LABS	50MG	N009273 001	
	100MG	N009273 002	
IVAX SUB TEVA PHARMS	50MG	N011521 001	
	100MG	N011521 002	
PUREPAC PHARM	50MG	A080842 001	
	100MG	A080842 002	
PVT FORM	50MG	A080583 001	
	100MG	A080583 002	
SOLVAY	50MG	A080500 001	
	100MG	A080500 002	
TABLICAPS	50MG	A083867 001	
	100MG	A083444 001	
VALEANT PHARM INTL	50MG	N009668 001	
	100MG	N009668 002	
WATSON LABS	50MG	A080907 001	
	100MG	A080914 001	
WOLFINA			
FOREST PHARMS	50MG	N009255 008	
	100MG	N009255 006	

RESCINNAMINE

CAPSULE;ORAL			
CINNASIL			
PANRAY	0.5MG	A084736 001	
TABLET;ORAL			
MODERIL			
PFIZER	0.25MG	N010686 003	
	0.5MG	N010686 006	

RESERPINE

ELIXIR;ORAL			
SERPASIL			
NOVARTIS	0.2MG/4ML	N009115 005	
INJECTABLE;INJECTION			
SANDRIL			
LILLY	2.5MG/ML	N010012 001	
SERPASIL			
NOVARTIS	2.5MG/ML	N009434 002	

RESERPINE

TABLET;ORAL

HISERPIA				
	BOWMAN PHARMS	0.1MG	N009631 002	
		0.25MG	N009631 004	
RAU-SED				
	BRISTOL MYERS SQUIBB	0.1MG	N009357 001	
		0.25MG	N009357 004	
		0.5MG	N009357 006	
		1MG	N009357 008	
RESERPINE				
	BARR	0.25MG	A080721 002	
	BELL PHARMA	0.1MG	A083058 001	
		0.25MG	A083058 002	
	BUNDY	0.1MG	N009663 001	
		0.25MG	N009663 003	
	CYCLE PHARMS LTD	0.1MG	N009859 001	
		0.25MG	N009859 002	
	ELKINS SINN	0.1MG	A083145 001	
		0.25MG	A083145 002	
	EVERYLIFE	0.1MG	N010441 001	
		0.25MG	N010441 002	
		0.5MG	N010441 003	
		1MG	N010441 004	
	HALSEY	0.1MG	A080457 002	
		0.25MG	A080457 001	
		1MG	A080457 003	
	HIKMA INTL PHARMS	0.1MG	A080975 001	
		0.25MG	A080975 002	
		1MG	A080975 003	
	IMPAX LABS	0.1MG	N009627 001	
		0.25MG	N009627 002	
	IVAX SUB TEVA PHARMS	0.1MG	N011185 001	
		0.25MG	N011185 002	
	MARSHALL PHARMA	0.1MG	A080492 001	
		0.25MG	A080492 002	
	MK LABS	0.1MG	A080525 002	
		0.25MG	A080525 001	
	MYLAN	1MG	A084974 001	
	PHARMAVITE	0.25MG	A084663 001	
	PUREPAC PHARM	0.1MG	A080753 002	
		0.25MG	A080753 001	
	PVT FORM	0.1MG	A086117 001	
		0.25MG	A080582 001	
		0.25MG	A085775 001	
		1MG	A080582 002	
	REXALL	0.25MG	A080637 001	
+	SANDOZ	0.1MG	N009838 001	
+		0.25MG	N009838 002	
	SOLVAY	0.25MG	A080446 001	
	TABLICAPS	0.25MG	A085207 001	
	TEVA	0.1MG	A089020 001	Mar 07, 1985
		0.25MG	A089019 001	Mar 07, 1985
	VALEANT PHARM INTL	0.1MG	N009667 001	
		0.25MG	N009667 002	
	WATSON LABS	0.1MG	A080679 001	
		0.25MG	A080393 001	
		0.25MG	A085401 001	
		1MG	A080749 001	
	WHITEWORTH TOWN PLSN	0.1MG	A080723 001	
		0.25MG	A080723 002	
		1MG	A080723 003	
SANDRIL				
	LILLY	0.1MG	N009376 004	
		0.25MG	N009376 001	
SERPALAN				
	LANNETT	0.1MG	N010124 001	
		0.25MG	N010124 002	

RESERPINE				
TABLET;ORAL				
SERPANRAY				
	PANRAY	0.1MG	N009391 001	
		0.25MG	N009391 002	
		1MG	N009391 004	
SERPASIL				
	NOVARTIS	0.1MG	N009115 001	
		0.25MG	N009115 003	
		1MG	N009115 004	
SERPATE				
	VALE	0.1MG	N009453 001	
		0.25MG	N009453 002	
SERPIVITE				
	VITARINE	0.25MG	N009645 002	
RESERPINE; TRICHLORMETHIAZIDE				
TABLET;ORAL				
METATENSIN #2				
	SANOFI AVENTIS US	0.1MG;2MG	N012972 001	
METATENSIN #4				
	SANOFI AVENTIS US	0.1MG;4MG	N012972 002	
NAQUIVAL				
	SCHERING	0.1MG;4MG	N012265 003	
TRICHLORMETHIAZIDE W/ RESERPINE				
	WATSON LABS	0.1MG;4MG	A085248 001	
RIBAVIRIN				
CAPSULE;ORAL				
REBETOL				
	MERCK SHARP DOHME	200MG**Indicated for use and comarketed with Interferon ALFA-2B, Recombinant (INTRON A), as Rebetron Combination Therapy**	N020903 001	Jun 03, 1998
TABLET;ORAL				
COPEGUS				
	ROCHE	200MG	N021511 001	Dec 03, 2002
		400MG	N021511 002	Jun 21, 2005
RIMANTADINE HYDROCHLORIDE				
SYRUP;ORAL				
FLUMADINE				
	FOREST LABS	50MG/5ML	N019650 001	Sep 17, 1993
TABLET;ORAL				
RIMANTADINE HYDROCHLORIDE				
	ACTAVIS ELIZABETH	100MG	A076375 001	Jan 14, 2003
	IMPAX LABS INC	100MG	A075916 001	Nov 02, 2001
RIMEXOLONE				
SUSPENSION/DROPS;OPHTHALMIC				
VEXOL				
	ALCON	1%	N020474 001	Dec 30, 1994
RISEDRONATE SODIUM				
TABLET;ORAL				
ACTONEL				
+	APIL	75MG **	N020835 004	Apr 16, 2007
TABLET, DELAYED RELEASE;ORAL				
RISEDRONATE SODIUM				
	IMPAX LABS INC	35MG	A205066 001	Jun 29, 2018
RISPERIDONE				
SOLUTION;ORAL				
RISPERIDONE				
	LANNETT CO INC	1MG/ML	A202386 001	Jan 12, 2015
	PRECISION DOSE	1MG/ML	A076797 001	Jun 28, 2010
	WOCKHARDT	1MG/ML	A078744 001	Oct 08, 2009
TABLET;ORAL				
RISPERDAL				
	JANSSEN PHARMS	5MG	N020272 005	Dec 29, 1993
RISPERIDONE				
	JUBILANT CADISTA	0.25MG	A078828 001	Mar 23, 2009
		0.5MG	A078828 002	Mar 23, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

RISPERIDONE

TABLET;ORAL					
RISPERIDONE					
	1MG		A078828	003	Mar 23, 2009
	2MG		A078828	004	Mar 23, 2009
	3MG		A078828	005	Mar 23, 2009
	4MG		A078828	006	Mar 23, 2009
RATIOPHARM	0.25MG		A077784	001	Jun 08, 2010
	0.5MG		A077784	002	Jun 08, 2010
	1MG		A077784	003	Jun 08, 2010
	2MG		A077784	004	Jun 08, 2010
	3MG		A077784	005	Jun 08, 2010
	4MG		A077784	006	Jun 08, 2010
SYNTHON PHARMS	0.25MG		A078187	001	Oct 22, 2009
	0.5MG		A078187	002	Oct 22, 2009
	1MG		A078187	003	Oct 22, 2009
	2MG		A078187	004	Oct 22, 2009
	3MG		A078187	005	Oct 22, 2009
	4MG		A078187	006	Oct 22, 2009
WATSON LABS	0.25MG		A077860	001	Dec 05, 2008
	0.5MG		A077860	002	Dec 05, 2008
	1MG		A077860	003	Dec 05, 2008
	2MG		A077860	004	Dec 05, 2008
	3MG		A077860	005	Dec 05, 2008
	4MG		A077860	006	Dec 05, 2008
WEST WARD PHARMS	0.25MG		A078740	001	May 29, 2009
	0.5MG		A078740	002	May 29, 2009
	1MG		A078740	003	May 29, 2009
	2MG		A078740	004	May 29, 2009
	3MG		A078740	005	May 29, 2009
	4MG		A078740	006	May 29, 2009
TABLET, ORALLY DISINTEGRATING;ORAL					
RISPERIDONE					
MYLAN PHARMS INC	0.25MG		A091537	006	Feb 12, 2013
	0.5MG		A091537	001	Mar 30, 2011
	1MG		A091537	002	Mar 30, 2011
	2MG		A091537	003	Mar 30, 2011
	3MG		A091537	004	Mar 30, 2011
	4MG		A091537	005	Mar 30, 2011

RITODRINE HYDROCHLORIDE

INJECTABLE;INJECTION					
RITODRINE HYDROCHLORIDE					
ABRAXIS PHARM	10MG/ML		A071188	001	Jul 23, 1987
	15MG/ML		A071189	001	Jul 23, 1987
HOSPIRA	10MG/ML		A071618	001	Feb 28, 1991
	15MG/ML		A071619	001	Feb 28, 1991
RITODRINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER					
HOSPIRA	30MG/100ML		A071438	001	Jan 22, 1991
YUTOPAR					
ASTRAZENECA	10MG/ML		N018580	001	
	15MG/ML		N018580	002	
TABLET;ORAL					
YUTOPAR					
ASTRAZENECA	10MG		N018555	001	

RITONAVIR

CAPSULE;ORAL					
NORVIR					
ABBOTT	100MG		N020680	001	Mar 01, 1996
+ ABBVIE	100MG		N020945	001	Jun 29, 1999

RIVASTIGMINE TARTRATE

SOLUTION;ORAL					
EXELON					
NOVARTIS	EQ 2MG BASE/ML		N021025	001	Apr 21, 2000

RIZATRIPTAN BENZOATE				
TABLET;ORAL				
MAXALT				
+	MERCK	EQ 5MG BASE	N020864 001	Jun 29, 1998
RIZATRIPTAN BENZOATE				
	APOTEX INC	EQ 5MG BASE	A202244 001	Dec 31, 2012
		EQ 10MG BASE	A202244 002	Dec 31, 2012
TABLET, ORALLY DISINTEGRATING;ORAL				
MAXALT-MLT				
+	MERCK	EQ 5MG BASE	N020865 001	Jun 29, 1998
RIZATRIPTAN BENZOATE				
	APOTEX INC	EQ 5MG BASE	A202477 001	Jul 01, 2013
		EQ 10MG BASE	A202477 002	Jul 01, 2013
ROCURONIUM BROMIDE				
INJECTABLE;INJECTION				
ZEMURON				
+	ORGANON USA INC	50MG/5ML (10MG/ML) **	N020214 001	Mar 17, 1994
+		10MG/ML (10MG/ML) **	N020214 002	Mar 17, 1994
+		100MG/10ML (10MG/ML) **	N020214 003	Mar 17, 1994
ROFECOXIB				
SUSPENSION;ORAL				
VIOXX				
	MERCK	12.5MG/5ML	N021052 001	May 20, 1999
		25MG/5ML	N021052 002	May 20, 1999
TABLET;ORAL				
VIOXX				
	MERCK	12.5MG	N021042 001	May 20, 1999
		25MG	N021042 002	May 20, 1999
		50MG	N021042 003	Feb 25, 2000
ROFLUMILAST				
TABLET;ORAL				
ROFLUMILAST				
	MYLAN PHARMS INC	500MCG	A208257 001	Jul 13, 2018
ROLAPITANT HYDROCHLORIDE				
EMULSION;INTRAVENOUS				
VARUBI				
+	TERSERA THERAPS LLC	EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)	N208399 001	Oct 25, 2017
ROPINIROLE HYDROCHLORIDE				
TABLET;ORAL				
ROPINIROLE HYDROCHLORIDE				
	EPIC PHARMA LLC	EQ 0.25MG BASE	A078230 001	May 20, 2008
		EQ 0.5MG BASE	A078230 002	May 20, 2008
		EQ 1MG BASE	A078230 003	May 20, 2008
		EQ 2MG BASE	A078230 004	May 20, 2008
		EQ 3MG BASE	A078230 005	May 20, 2008
		EQ 4MG BASE	A078230 006	May 20, 2008
		EQ 5MG BASE	A078230 007	May 20, 2008
	G AND W LABS INC	EQ 0.25MG BASE	A077460 001	May 05, 2008
		EQ 0.5MG BASE	A077460 002	May 05, 2008
		EQ 1MG BASE	A077460 003	May 05, 2008
		EQ 2MG BASE	A077460 004	May 05, 2008
		EQ 3MG BASE	A077460 005	May 05, 2008
		EQ 4MG BASE	A077460 006	May 05, 2008
		EQ 5MG BASE	A077460 007	May 19, 2008
TABLET, EXTENDED RELEASE;ORAL				
REQUIP XL				
+	GLAXOSMITHKLINE LLC	EQ 3MG BASE **	N022008 002	Jun 13, 2008
ROPINIROLE HYDROCHLORIDE				
	MYLAN PHARMS INC	EQ 2MG BASE	A200462 001	Oct 15, 2012
		EQ 3MG BASE	A200462 002	Oct 15, 2012
		EQ 4MG BASE	A200462 003	Oct 15, 2012
		EQ 6MG BASE	A200462 004	Oct 15, 2012
		EQ 8MG BASE	A200462 005	Oct 15, 2012
		EQ 12MG BASE	A200462 006	Oct 15, 2012

ROPIVACAINE HYDROCHLORIDE
SOLUTION;INJECTION
NAROPIN

FRESENIUS KABI USA	50MG/10ML (5MG/ML)	N020533	013	May 01, 1998
	75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996

ROSE BENGAL SODIUM I-131
INJECTABLE;INJECTION
ROBENGATOPE

BRACCO	0.5mCi/VIAL	N016224	001	
	1mCi/VIAL	N016224	002	
	2mCi/VIAL	N016224	003	

SODIUM ROSE BENGAL I 131

SORIN	0.5mCi/ML	N017318	001	

ROSIGLITAZONE MALEATE
TABLET;ORAL
AVANDIA

+ SB PHARMCO	EQ 8MG BASE	N021071	004	May 25, 1999

ROSIGLITAZONE MALEATE

TEVA	EQ 2MG BASE	A076747	001	Jan 25, 2013
	EQ 4MG BASE	A076747	002	Jan 25, 2013
	EQ 8MG BASE	A076747	003	Jan 25, 2013

RUFINAMIDE
TABLET;ORAL
BANZEL

+ EISAI INC	100MG **	N021911	001	Nov 14, 2008

SAFFLOWER OIL
INJECTABLE;INJECTION
LIPOSYN 10%

ABBOTT	10% (10GM/100ML)	N018203	001	

LIPOSYN 20%

ABBOTT	20% (20GM/100ML)	N018614	001	

SAFFLOWER OIL; SOYBEAN OIL
INJECTABLE;INJECTION
LIPOSYN II 10%

HOSPIRA	5%;5% (5GM/100ML)	N018997	001	Aug 27, 1984

LIPOSYN II 20%

HOSPIRA	10%;10% (10GM/100ML)	N018991	001	Aug 27, 1984

SALMETEROL XINAFOATE
AEROSOL, METERED;INHALATION
SEREVENT

GLAXOSMITHKLINE	EQ 0.021MG BASE/INH	N020236	001	Feb 04, 1994

SAQUINAVIR
CAPSULE;ORAL
FORTOVASE

+ HOFFMANN LA ROCHE	200MG **	N020828	001	Nov 07, 1997

SAQUINAVIR MESYLATE
CAPSULE;ORAL
INVIRASE

+ HOFFMANN LA ROCHE	EQ 200MG BASE	N020628	001	Dec 06, 1995

SARALASIN ACETATE
INJECTABLE;INJECTION
SARENIN

PROCTER AND GAMBLE	EQ 0.6MG BASE/ML	N018009	001	

SECOBARBITAL SODIUM
CAPSULE;ORAL
SECOBARBITAL SODIUM

ANABOLIC	100MG	A084422	001	
BARR	100MG	A084225	001	
EVERYLIFE	100MG	A085895	001	
HALSEY	100MG	A084676	001	
IVAX PHARMS	100MG	A085869	001	
KV PHARM	100MG	A085285	001	
LANNETT	50MG	A085909	001	
	100MG	A085903	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

SECOBARBITAL SODIUM

CAPSULE;ORAL				
SECOBARBITAL SODIUM				
PARKE DAVIS	100MG		A084762 001	
PERRIGO	100MG		A084561 001	
PUREPAC PHARM	100MG		A085867 001	
VALEANT PHARM INTL	100MG		A085477 001	
VITARINE	100MG		A085898 001	
	100MG		A086273 001	
WATSON LABS	100MG		A085792 001	
WEST WARD	100MG		A084926 001	
WHITEWORTH TOWN PLSN	100MG		A085798 001	
WYETH AYERST	100MG		A086390 001	
INJECTABLE;INJECTION				
SECOBARBITAL SODIUM				
ELKINS SINN	100MG/VIAL		A083281 001	
WYETH AYERST	50MG/ML		A083262 001	
SECONAL SODIUM				
LILLY	50MG/ML		N007392 002	
SUPPOSITORY;RECTAL				
SECONAL SODIUM				
LILLY	30MG		A086530 001	
	60MG		A086530 002	
	120MG		A086530 003	
	200MG		A086530 004	

SECRETIN

INJECTABLE;INJECTION				
SECRETIN-FERRING				
FERRING	75CU/VIAL		N018290 001	

SECRETIN SYNTHETIC PORCINE

FOR SOLUTION;INTRAVENOUS				
SECREFLO				
CHIRHOCLIN	16MCG/VIAL		N021136 001	Apr 04, 2002

SELEGILINE HYDROCHLORIDE

CAPSULE;ORAL				
ELDEPRYL				
+ SOMERSET	5MG		N020647 001	May 15, 1996
SELEGILINE HYDROCHLORIDE				
LANNETT CO INC	5MG		A075145 001	Sep 15, 2003
TABLET;ORAL				
SELEGILINE HYDROCHLORIDE				
CHARTWELL MOLECULES	5MG		A074565 001	Aug 02, 1996
	5MG		A074641 001	Aug 02, 1996
G AND W LABS INC	5MG		A074537 001	Aug 02, 1996
	5MG		A074744 001	Jan 27, 1997
	5MG		A074756 001	Nov 25, 1998
SIEGFRIED	5MG		A074672 001	Apr 01, 1997
+ SOMERSET	5MG **		N019334 001	Jun 05, 1989

SELENIUM SULFIDE

LOTION/SHAMPOO;TOPICAL				
EXSEL				
ALLERGAN HERBERT	2.5%		A083892 001	
SELENIUM SULFIDE				
ACTAVIS MID ATLANTIC	2.5%		A084394 001	
G AND W LABS INC	2.5%		A086209 001	
IVAX PHARMS	2.5%		A085777 001	
SELSUN				
+ CHATTEM	2.5%		N007936 001	

SELENOMETHIONINE SE-75

INJECTABLE;INJECTION				
SELENOMETHIONINE SE 75				
GE HEALTHCARE	250uCi/ML		N017257 001	
MALLINCKRODT	100uCi/ML		N017098 001	
PHARMALUCENCE	500uCi/ML		N017322 001	
SETHOTOPE				
BRACCO	85-550uCi/ML		N017047 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

SERMORELIN ACETATE				
INJECTABLE;INJECTION				
GEREF				
+	EMD SERONO	EQ 0.05MG BASE/AMP **	N019863 001	Dec 28, 1990
+	EMD SERONO INC	EQ 0.5MG BASE/VIAL **	N020443 001	Sep 26, 1997
+		EQ 1MG BASE/VIAL **	N020443 002	Sep 26, 1997
SERTRALINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
SERTRALINE HYDROCHLORIDE				
	ACI HEALTHCARE LTD	EQ 20MG BASE/ML	A076934 001	Jun 30, 2006
	RANBAXY LABS LTD	EQ 20MG BASE/ML	A078053 001	Feb 05, 2007
TABLET;ORAL				
SERTRALINE HYDROCHLORIDE				
	ACI HEALTHCARE LTD	EQ 25MG BASE	A076881 001	Feb 06, 2007
		EQ 50MG BASE	A076881 002	Feb 06, 2007
		EQ 100MG BASE	A076881 003	Feb 06, 2007
	ACTAVIS ELIZABETH	EQ 25MG BASE	A077345 001	Feb 06, 2007
		EQ 50MG BASE	A077345 002	Feb 06, 2007
		EQ 100MG BASE	A077345 003	Feb 06, 2007
	ANDA REPOSITORY	EQ 25MG BASE	A077818 001	Feb 06, 2007
		EQ 50MG BASE	A077818 002	Feb 06, 2007
		EQ 100MG BASE	A077818 003	Feb 06, 2007
	CHARTWELL MOLECULAR	EQ 25MG BASE	A077162 001	Feb 06, 2007
		EQ 50MG BASE	A077162 002	Feb 06, 2007
		EQ 100MG BASE	A077162 003	Feb 06, 2007
	FOSUN PHARMA	EQ 25MG BASE	A077713 001	Feb 06, 2007
		EQ 50MG BASE	A077713 002	Feb 06, 2007
		EQ 100MG BASE	A077713 003	Feb 06, 2007
	HIKMA PHARMS	EQ 25MG BASE	A077864 001	Aug 10, 2009
		EQ 50MG BASE	A077864 002	Aug 10, 2009
		EQ 100MG BASE	A077864 003	Aug 10, 2009
	IVAX SUB TEVA PHARMS	EQ 25MG BASE	A075719 003	Jun 30, 2006
		EQ 50MG BASE	A075719 001	Jun 30, 2006
		EQ 100MG BASE	A075719 002	Jun 30, 2006
	MYLAN	EQ 25MG BASE	A076671 001	Feb 06, 2007
		EQ 50MG BASE	A076671 002	Feb 06, 2007
		EQ 100MG BASE	A076671 003	Feb 06, 2007
	MYLAN PHARMS INC	EQ 25MG BASE	A076540 001	Mar 20, 2007
		EQ 50MG BASE	A076540 002	Mar 20, 2007
		EQ 100MG BASE	A076540 003	Mar 20, 2007
		EQ 100MG BASE	A078626 003	Jan 31, 2008
	PLIVA HRVATSKA DOO	EQ 25MG BASE	A077299 001	Feb 06, 2007
		EQ 50MG BASE	A077299 002	Feb 06, 2007
		EQ 100MG BASE	A077299 003	Feb 06, 2007
	SCIEGEN PHARMS INC	EQ 25MG BASE	A076442 001	Apr 30, 2007
		EQ 50MG BASE	A076442 002	Apr 30, 2007
		EQ 100MG BASE	A076442 003	Apr 30, 2007
	SUN PHARM INDS (IN)	EQ 25MG BASE	A078108 001	Feb 06, 2007
		EQ 50MG BASE	A078108 002	Feb 06, 2007
		EQ 100MG BASE	A078108 003	Feb 06, 2007
	WATSON LABS TEVA	EQ 25MG BASE	A077663 001	Feb 06, 2007
		EQ 50MG BASE	A077663 002	Feb 06, 2007
		EQ 100MG BASE	A077663 003	Feb 06, 2007
ZOLOFT				
+	PFIZER	EQ 150MG BASE **	N019839 003	Dec 30, 1991
+		EQ 200MG BASE **	N019839 004	Dec 30, 1991
SEVELAMER HYDROCHLORIDE				
CAPSULE;ORAL				
RENAGEL				
	GENZYME	403MG	N020926 001	Oct 30, 1998
SIBUTRAMINE HYDROCHLORIDE				
CAPSULE;ORAL				
MERIDIA				
	ABBOTT	5MG	N020632 001	Nov 22, 1997
		10MG	N020632 002	Nov 22, 1997
		15MG	N020632 003	Nov 22, 1997

SILDENAFIL CITRATE
TABLET;ORAL
SILDENAFIL CITRATE

	ACTAVIS GRP PTC	EQ 20MG BASE	A200149 001	Feb 25, 2013
	APOTEX CORP	EQ 20MG BASE	A091379 001	Nov 06, 2012

SILVER SULFADIAZINE
CREAM;TOPICAL
SSD AF

	DR REDDYS LA	1%	N018578 003	Jul 11, 1990

DRESSING;TOPICAL
SILDAFLO

	FRANKLIN PHARMS	1%	N019608 001	Nov 30, 1989

SIMEPREVIR SODIUM
CAPSULE;ORAL
OLYSIO

+	JANSSEN PRODS	EQ 150MG BASE	N205123 001	Nov 22, 2013

SIMETHICONE-CELLULOSE
SUSPENSION;ORAL
SONORX

	BRACCO	7.5MG/ML	N020773 001	Oct 29, 1998

SIMVASTATIN
TABLET;ORAL
SIMVASTATIN

	HISUN PHARM HANGZHOU	10MG	A206557 001	Nov 13, 2017
		20MG	A206557 002	Nov 13, 2017
		40MG	A206557 003	Nov 13, 2017
		80MG	A206557 004	Nov 13, 2017
	IVAX SUB TEVA PHARMS	5MG	A076052 001	Jun 23, 2006
		10MG	A076052 002	Jun 23, 2006
		20MG	A076052 003	Jun 23, 2006
		40MG	A076052 004	Jun 23, 2006
		80MG	A076052 005	Dec 20, 2006
	MYLAN PHARMS INC	5MG	A090868 001	Jun 08, 2010
		10MG	A090868 002	Jun 08, 2010
		20MG	A090868 003	Jun 08, 2010
		40MG	A090868 004	Jun 08, 2010
		80MG	A090868 005	Jun 08, 2010
	SUN PHARM INDS LTD	5MG	A076285 001	Dec 20, 2006
		10MG	A076285 002	Dec 20, 2006
		20MG	A076285 003	Dec 20, 2006
		40MG	A076285 004	Dec 20, 2006
		80MG	A076285 005	Jun 23, 2006
	YAOPHARMA CO LTD	5MG	A077766 001	Dec 20, 2006
		10MG	A077766 002	Dec 20, 2006
		20MG	A077766 003	Dec 20, 2006
		40MG	A077766 004	Dec 20, 2006
		80MG	A077766 005	Dec 20, 2006

TABLET, ORALLY DISINTEGRATING;ORAL
SIMVASTATIN

	SYNTHON PHARMS	10MG	N021961 001	Oct 09, 2007
		20MG	N021961 002	Oct 09, 2007
		40MG	N021961 003	Oct 09, 2007
		80MG	N021961 004	Oct 09, 2007

SIMVASTATIN; SITAGLIPTIN PHOSPHATE
TABLET;ORAL
JUVISYNC

+	MERCK SHARP DOHME	10MG;EQ 50MG BASE **	N202343 004	Sep 18, 2012
+		10MG;EQ 100MG BASE **	N202343 001	Oct 07, 2011
+		20MG;EQ 50MG BASE **	N202343 005	Sep 18, 2012
+		20MG;EQ 100MG BASE **	N202343 002	Oct 07, 2011
+		40MG;EQ 50MG BASE **	N202343 006	Sep 18, 2012
+		40MG;EQ 100MG BASE **	N202343 003	Oct 07, 2011

SIROLIMUS				
TABLET;ORAL				
RAPAMUNE				
+	PF PRISM CV	5MG **	N021110 003	Feb 23, 2004
SODIUM BENZOATE; SODIUM PHENYLACETATE				
SOLUTION;ORAL				
UCEPHAN				
	B BRAUN	100MG/ML;100MG/ML	N019530 001	Dec 23, 1987
SODIUM BICARBONATE				
INJECTABLE;INJECTION				
SODIUM BICARBONATE				
	HOSPIRA INC	0.5MEQ/ML	A202679 001	Mar 07, 2017
		0.5MEQ/ML	A202981 001	Mar 04, 2016
SODIUM BICARBONATE IN PLASTIC CONTAINER				
+	ABBOTT	0.9MEQ/ML **	N019443 001	Jun 03, 1986
+		1MEQ/ML **	N019443 002	Jun 03, 1986
SODIUM BICARBONATE; TARTARIC ACID				
GRANULE, EFFERVESCENT;ORAL				
BAROS				
	MALLINCKRODT INC	460MG/GM;420MG/GM	N018509 001	Aug 07, 1985
SODIUM CHLORIDE				
INJECTABLE;INJECTION				
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	ABRAXIS PHARM	9MG/ML	A088909 001	Feb 07, 1985
SODIUM CHLORIDE				
	ABBOTT	20GM/100ML	N017013 001	
	B BRAUN	20GM/100ML	N017038 001	
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	450MG/100ML	N018184 001	
	MILES	450MG/100ML	N018503 001	
SODIUM CHLORIDE 0.9%				
+	MEDEFIL INC	18MG/2ML (9MG/ML)	N202832 002	Jan 06, 2012
+		22.5MG/2.5ML (9MG/ML)	N202832 003	Jan 06, 2012
+		27MG/3ML (9MG/ML)	N202832 004	Jan 06, 2012
+		45MG/5ML (9MG/ML)	N202832 005	Jan 06, 2012
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	ABBOTT	9MG/ML	N019218 001	Jul 13, 1984
+	ICU MEDICAL INC	9MG/ML	N019217 001	Jul 13, 1984
+	MEDEFIL INC	9MG/ML (9MG/ML)	N202832 001	Jan 06, 2012
	MILES	900MG/100ML	N018502 001	
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER				
+	ABRAXIS PHARM	234MG/ML **	N019329 001	Apr 22, 1987
SOLUTION;IRRIGATION				
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	450MG/100ML	N017864 001	
		450MG/100ML	N018497 001	Feb 19, 1982
	HOSPIRA	450MG/100ML	N017670 001	
		450MG/100ML	N018380 001	
SODIUM CHLORIDE IN PLASTIC CONTAINER				
	MILES	900MG/100ML	N018247 001	
SODIUM CHROMATE CR-51				
INJECTABLE;INJECTION				
CHROMITOPE SODIUM				
	BRACCO	2mCi/VIAL	N013993 002	
		200uCi/ML	N013993 001	
SODIUM CHROMATE CR 51				
	MALLINKRODT NUCLEAR	100uCi/ML	N016708 001	
SODIUM FLUORIDE F-18				
INJECTABLE;INTRAVENOUS				
FLUORINE F-18				
+	GE HEALTHCARE	2mCi/ML **	N017042 001	
SODIUM FLUORIDE F 18				
	NIH NCI DCTD	10-200mCi/ML **	N022494 001	Jan 26, 2011
SODIUM FLUORIDE F-18				
	UIHC PET IMAGING	10-200mCi/ML	A204462 001	Nov 17, 2015
	UNIV TX MD ANDERSON	10-200mCi/ML	A203247 001	Dec 23, 2013

SODIUM IODIDE I-123

CAPSULE;ORAL				
SODIUM IODIDE I 123				
	CARDINAL HEALTH 418	400uCi	N018671 003	May 27, 1982
	GE HEALTHCARE	100uCi	N017630 001	
SOLUTION;ORAL				
SODIUM IODIDE I 123				
	GE HEALTHCARE	2mCi/ML **	N017630 002	

SODIUM IODIDE I-131

CAPSULE;ORAL				
IODOTOPE				
	BRACCO	1-130mCi	N010929 001	
		1-150mCi	N010929 003	
SODIUM IODIDE I 131				
	CIS	50uCi	N017316 001	
		100uCi	N017316 002	
	JUBILANT DRAXIMAGE	2-200mCi	N021305 004	Nov 18, 2004
	MALLINKRODT NUCLEAR	0.8-100mCi	N016515 002	
+		0.8-100mCi	N016517 001	
		15-100uCi	N016517 002	
SOLUTION;ORAL				
HICON				
	JUBILANT DRAXIMAGE	1-250mCi/0.25ML	N021305 002	Jan 24, 2003
		1-500mCi/0.5ML	N021305 003	Jan 24, 2003
		1-1000mCi/ML	N021305 005	Apr 04, 2006
IODOTOPE				
	BRACCO	7-106mCi/BOT	N010929 002	
SODIUM IODIDE I 131				
	CIS	50mCi/ML	N017315 001	
+	MALLINKRODT NUCLEAR	3.5-150mCi/VIAL	N016515 001	

SODIUM LACTATE

INJECTABLE;INJECTION				
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER				
	B BRAUN	1.87GM/100ML	N018186 001	
	BAXTER HLTHCARE	1.87GM/100ML	N016692 001	
	HOSPIRA	1.87GM/100ML	N018249 001	
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER				
	B BRAUN	1.87GM/100ML	N020004 001	Apr 21, 1992

SODIUM MONOFLUOROPHOSPHATE

GEL;DENTAL				
EXTRA-STRENGTH AIM				
	CHESEBROUGH PONDS	1.2%	N019518 002	Aug 06, 1986
PASTE;DENTAL				
EXTRA-STRENGTH AIM				
	CHESEBROUGH PONDS	1.2%	N019518 001	Jun 03, 1987

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION				
NIPRIDE				
	ROCHE	50MG/VIAL	N017546 001	
NITROPRESS				
	ABBOTT	50MG/VIAL	A071555 001	Nov 16, 1987
+	ABBVIE	50MG/VIAL **	N018450 001	
	HOSPIRA	50MG/VIAL	A070566 001	Jun 09, 1986
SODIUM NITROPRUSSIDE				
	ABRAXIS PHARM	50MG/VIAL	A070031 001	Jan 17, 1985
+	BAXTER HLTHCARE	50MG/VIAL **	N018581 001	Jul 28, 1982
	TEVA PARENTERAL	25MG/ML	A073465 001	Mar 30, 1992

SODIUM PHOSPHATE P-32

SOLUTION;INJECTION, ORAL				
PHOSPHOTOPE				
	BRACCO	1-8mCi/VIAL	N010927 001	
SODIUM PHOSPHATE P 32				
	MALLINCKRODT	0.67mCi/ML	N011777 001	
		1.5mCi/VIAL	N011777 002	

SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE				
TABLET;ORAL				
VISICOL				
	SALIX PHARMS	0.398GM;1.102GM	N021097 001	Sep 21, 2000
SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE				
TABLET;ORAL				
MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE				
	NOVEL LABS INC	0.398GM;1.102GM	A079247 001	Dec 30, 2011
SODIUM POLYSTYRENE SULFONATE				
POWDER;ORAL, RECTAL				
KAYEXALATE				
+	CONCORDIA PHARMS INC	453.6GM/BOT **	N011287 001	
SODIUM POLYSTYRENE SULFONATE				
	CITRUSPHRMA	454GM/BOT	A040909 001	Dec 03, 2008
	WOCKHARDT	453.6GM/BOT	A088786 001	Sep 11, 1984
SUSPENSION;ORAL, RECTAL				
SODIUM POLYSTYRENE SULFONATE				
	MORTON GROVE	15GM/60ML	A088717 001	Sep 11, 1984
	ROXANE	15GM/60ML	A088453 001	Nov 17, 1983
SODIUM SUCCINATE				
INJECTABLE;INJECTION				
SODIUM SUCCINATE				
	ELKINS SINN	30%	A080516 001	
SODIUM TETRADECYL SULFATE				
INJECTABLE;INJECTION				
SOTRADECOL				
+	ELKINS SINN	1% **	N005970 004	
+		3% **	N005970 005	
SODIUM THIOSULFATE				
INJECTABLE;INJECTION				
SODIUM THIOSULFATE				
	US ARMY	250MG/ML	N020166 001	Feb 14, 1992
SOMATREM				
INJECTABLE;INJECTION				
PROTROPIN				
	GENENTECH	5MG/VIAL	N019107 001	Oct 17, 1985
		10MG/VIAL	N019107 002	Oct 24, 1989
SOMATROPIN				
INJECTABLE;INJECTION				
ASELLACRIN 10				
	SERONO	10 IU/VIAL	N017726 001	
ASELLACRIN 2				
	SERONO	2 IU/VIAL	N017726 002	Jul 21, 1983
BIO-TROPIN				
	FERRING	4.8MG/VIAL	N019774 001	May 25, 1995
CRESCORMON				
	GENENTECH	4 IU/VIAL	N017992 001	
SOMATROPIN RECOMBINANT				
INJECTABLE;INJECTION				
ACCRETROPIN				
	EMERGENT	5MG/ML (5MG/ML)	N021538 001	Jan 23, 2008
GENOTROPIN PRESERVATIVE FREE				
+	PHARMACIA AND UPJOHN	1.5MG/VIAL	N020280 004	Aug 24, 1995
HUMATROPE				
	LILLY	2MG/VIAL	N019640 001	Jun 23, 1987
NORDITROPIN				
	NOVO NORDISK INC	4MG/VIAL	N019721 001	May 08, 1995
		5MG/1.5ML	N021148 001	Jun 20, 2000
		8MG/VIAL	N019721 002	May 08, 1995
		10MG/1.5ML	N021148 002	Jun 20, 2000
		15MG/1.5ML	N021148 003	Jun 20, 2000
NORDITROPIN NORDIFLEX				
	NOVO NORDISK INC	5MG/1.5ML	N021148 004	Oct 01, 2004
		10MG/1.5ML	N021148 005	Oct 01, 2004
		15MG/1.5ML	N021148 006	Oct 01, 2004

SOMATROPIN RECOMBINANT				
INJECTABLE;INJECTION				
NORDITROPIN NORDIFLEX				
	30MG/3ML	N021148	007	Mar 10, 2009
NUTROPIN				
GENENTECH	5MG/VIAL	N020168	001	Nov 17, 1993
	10MG/VIAL	N020168	002	Nov 17, 1993
NUTROPIN AQ				
GENENTECH	10MG/2ML (5MG/ML)	N020522	001	Dec 29, 1995
NUTROPIN AQ PEN				
+ GENENTECH	10MG/2ML (5MG/ML)	N020522	002	Apr 22, 2002
+	20MG/2ML (10MG/ML)	N020522	006	Jan 03, 2008
NUTROPIN DEPOT				
GENENTECH	13.5MG/VIAL	N021075	001	Dec 22, 1999
	18MG/VIAL	N021075	002	Dec 22, 1999
	22.5MG/VIAL	N021075	003	Dec 22, 1999
SAIZEN				
EMD SERONO	4MG/VIAL	N019764	005	Jan 16, 2007
	6MG/VIAL	N019764	001	Oct 08, 1996
SEROSTIM				
EMD SERONO	8.8MG/VIAL	N020604	004	Sep 06, 2001
VALTROPIN				
LG CHEM LTD	5MG/VIAL	N021905	001	Apr 19, 2007
ZORBTIVE				
EMD SERONO	4MG/VIAL	N021597	001	Dec 01, 2003
	5MG/VIAL	N021597	002	Dec 01, 2003
	6MG/VIAL	N021597	003	Dec 01, 2003
INJECTABLE;SUBCUTANEOUS				
SEROSTIM LQ				
EMD SERONO	6MG/0.5ML (6MG/0.5ML)	N020604	005	Feb 11, 2005
SORBITOL				
SOLUTION;IRRIGATION				
SORBITOL 3% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	3GM/100ML	N018512	001	May 27, 1982
SOTALOL HYDROCHLORIDE				
TABLET;ORAL				
BETAPACE				
COVIS PHARMA BV	320MG	N019865	004	Oct 30, 1992
BETAPACE AF				
COVIS PHARMA BV	40MG	N021151	006	Apr 02, 2003
	60MG	N021151	007	Apr 02, 2003
	100MG	N021151	005	Mar 14, 2003
SOTALOL HYDROCHLORIDE				
IMPAX PHARMS	80MG	A075663	001	Nov 07, 2000
	120MG	A075663	002	Nov 07, 2000
	160MG	A075663	003	Nov 07, 2000
	240MG	A075663	004	Nov 07, 2000
MYLAN	80MG	A075237	001	May 01, 2000
	80MG	A075725	001	Dec 19, 2000
	120MG	A075237	002	May 01, 2000
	120MG	A075725	002	Dec 19, 2000
	160MG	A075237	003	May 01, 2000
	160MG	A075725	003	Dec 19, 2000
	240MG	A075237	004	May 01, 2000
	240MG	A075725	004	Dec 19, 2000
SUN PHARM INDUSTRIES	80MG	A075515	001	Oct 15, 2001
	80MG	A076576	001	Apr 08, 2004
	120MG	A075515	004	Oct 15, 2001
	120MG	A076576	002	Apr 08, 2004
	160MG	A075515	002	Oct 15, 2001
	160MG	A076576	003	Apr 08, 2004
	240MG	A075515	003	Oct 15, 2001
TEVA	80MG	A076883	001	Jul 26, 2004
	120MG	A076883	002	Jul 26, 2004
	160MG	A076883	003	Jul 26, 2004
WATSON LABS	80MG	A075238	001	Jul 13, 2000
	120MG	A075238	002	Jul 13, 2000
	160MG	A075238	003	Jul 13, 2000

SOTALOL HYDROCHLORIDE				
TABLET;ORAL				
SOTALOL HYDROCHLORIDE				
	240MG	A075238	004	Jul 13, 2000
SOYBEAN OIL				
INJECTABLE;INJECTION				
LIPOSYN III 10%				
HOSPIRA	10%	N018969	001	Sep 24, 1984
LIPOSYN III 20%				
HOSPIRA	20%	N018970	001	Sep 25, 1984
LIPOSYN III 30%				
HOSPIRA	30%	N020181	001	Jan 13, 1998
SOYACAL 10%				
ALPHA THERA	10%	N018465	001	Jun 29, 1983
SOYACAL 20%				
ALPHA THERA	20%	N018786	001	Jun 29, 1983
TRAVAMULSION 10%				
BAXTER HLTHCARE	10%	N018660	001	Feb 26, 1982
TRAVAMULSION 20%				
BAXTER HLTHCARE	20%	N018758	001	Feb 15, 1983
SPARFLOXACIN				
TABLET;ORAL				
ZAGAM				
MYLAN	200MG	N020677	001	Dec 19, 1996
SPECTINOMYCIN HYDROCHLORIDE				
INJECTABLE;INJECTION				
TROBICIN				
PFIZER	EQ 2GM BASE/VIAL	N050347	001	
	EQ 4GM BASE/VIAL	N050347	002	
SPIRAPRIL HYDROCHLORIDE				
TABLET;ORAL				
RENORMAX				
SCHERING	3MG	N020240	001	Dec 29, 1994
	6MG	N020240	002	Dec 29, 1994
	12MG	N020240	003	Dec 29, 1994
	24MG	N020240	004	Dec 29, 1994
SPIRONOLACTONE				
TABLET;ORAL				
SPIRONOLACTONE				
ASCOT	25MG	A087687	001	Oct 20, 1982
AUROBINDO PHARMA LTD	25MG	A202187	001	Mar 06, 2014
	50MG	A202187	002	Mar 06, 2014
	100MG	A202187	003	Mar 06, 2014
IVAX PHARMS	25MG	A087108	001	
LEDERLE	25MG	A087634	001	
MUTUAL PHARM	25MG	A087265	001	
MYLAN	25MG	A087086	001	
PUREPAC PHARM	25MG	A087998	001	Oct 14, 1983
	25MG	A088053	001	Aug 25, 1983
SUPERPHARM	25MG	A089364	001	Nov 07, 1986
UPSHER SMITH	25MG	A087554	001	
VANGARD	25MG	A087648	001	Feb 01, 1982
WARNER CHILCOTT	25MG	A087952	001	Nov 18, 1982
WATSON LABS	25MG	A086898	002	Mar 02, 1982
	25MG	A087078	001	
STANOZOLOL				
TABLET;ORAL				
WINSTROL				
+ LUNDBECK INC	2MG	N012885	001	May 14, 1984
STAVUDINE				
CAPSULE;ORAL				
STAVUDINE				
MYLAN LABS LTD	30MG	A078775	001	Jan 05, 2009
	40MG	A078775	002	Jan 05, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

STAVUDINE				
CAPSULE;ORAL				
ZERIT				
	BRISTOL MYERS SQUIBB	5MG	N020412 001	Jun 24, 1994
CAPSULE, EXTENDED RELEASE;ORAL				
ZERIT XR				
	BRISTOL MYERS SQUIBB	37.5MG	N021453 001	Dec 31, 2002
		50MG	N021453 002	Dec 31, 2002
		75MG	N021453 003	Dec 31, 2002
		100MG	N021453 004	Dec 31, 2002
FOR SOLUTION;ORAL				
STAVUDINE				
	AUROBINDO PHARMA	1MG/ML	A077774 001	Dec 29, 2008
	CIPLA LTD	1MG/ML	A078030 001	Mar 20, 2009
STERILE WATER FOR INJECTION				
LIQUID;N/A				
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER				
	ABRAXIS PHARM	100%	A089099 001	Dec 29, 1987
		100%	A089100 001	Dec 29, 1987
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER				
	B BRAUN	100%	N019077 001	Mar 02, 1984
STERILE WATER FOR IRRIGATION				
LIQUID;IRRIGATION				
STERILE WATER IN PLASTIC CONTAINER				
	MILES	100%	N018246 001	
STREPTOMYCIN SULFATE				
INJECTABLE;INJECTION				
STREPTOMYCIN SULFATE				
	COPANOS	EQ 500MG BASE/ML	A060684 001	
	LILLY	EQ 1GM BASE/VIAL	A060107 001	
		EQ 1GM BASE/2ML	A060404 001	
		EQ 5GM BASE/VIAL	A060107 002	
	PFIZER	EQ 1GM BASE/VIAL **	A060076 001	
		EQ 1GM BASE/2.5ML	A060111 001	
		EQ 5GM BASE/VIAL **	A060076 002	
SUCCINYLCHOLINE CHLORIDE				
INJECTABLE;INJECTION				
ANECTINE				
	SANDOZ INC	50MG/ML	N008453 003	
		500MG/VIAL	N008453 001	
		1GM/VIAL	N008453 004	
QUELICIN PRESERVATIVE FREE				
+	HOSPIRA	20MG/ML	N008845 001	
		50MG/ML	N008845 002	
		100MG/ML	N008845 004	
SUCCINYLCHOLINE CHLORIDE				
	INTL MEDICATION	100MG/VIAL	A085400 001	Feb 04, 1982
	ORGANON USA INC	20MG/ML	A080997 001	
SUCOSTRIN				
	APOTHECON	20MG/ML	N008847 001	
		100MG/ML	N008847 003	
SUCRALFATE				
TABLET;ORAL				
SUCRALFATE				
	MYLAN IRELAND LTD	1GM	A074415 001	Jun 08, 1998
SUFENTANIL CITRATE				
INJECTABLE;INJECTION				
SUFENTANIL CITRATE				
	WATSON LABS	EQ 0.05MG BASE/ML	A074406 001	Dec 15, 1995
SULFACETAMIDE SODIUM				
OINTMENT;OPHTHALMIC				
BLEPH-10				
	ALLERGAN	10%	A084015 001	
CETAMIDE				
	ALCON	10%	A080021 001	

SULFACETAMIDE SODIUM				
OINTMENT;OPHTHALMIC				
SODIUM SULAMYD				
+ SCHERING	10% **	N005963	002	
SULFAIR 10				
PHARMAFAIR	10%	A088000	001	Dec 22, 1982
SOLUTION/DROPS;OPHTHALMIC				
BLEPH-30				
ALLERGAN	30%	A080028	002	
ISOPTO CETAMIDE				
ALCON	15%	A080020	002	
OCUSULF-10				
MIZA PHARMS USA	10%	A080660	001	
OCUSULF-30				
MIZA PHARMS USA	30%	A080660	002	
SODIUM SULAMYD				
+ SCHERING	10% **	N005963	001	
+	30% **	N005963	003	
SODIUM SULFACETAMIDE				
AKORN	10%	A083021	001	
	15%	A083021	002	
	30%	A083021	003	
SOLA BARNES HIND	10%	A084143	001	
	10%	A084145	001	
	30%	A084146	001	
	30%	A084147	001	
SULF-10				
NOVARTIS	10%	A080025	001	
SULF-15				
NOVARTIS	15%	A089047	001	Oct 31, 1995
SULFACEL-15				
OPTOPICS	15%	A080024	001	
SULFACETAMIDE SODIUM				
AKORN	30%	A040216	001	May 25, 1999
ALCON PHARMS LTD	30%	A089068	001	May 05, 1987
PHARMAFAIR	10%	A088947	001	May 17, 1985
SULFAIR 10				
PHARMAFAIR	10%	A087949	001	Dec 13, 1982
SULFAIR FORTE				
PHARMAFAIR	30%	A088385	001	Oct 13, 1983
SULFAIR-15				
PHARMAFAIR	15%	A088186	001	May 25, 1983
SULTEN-10				
BAUSCH AND LOMB	10%	A087818	001	Feb 03, 1983
SULFACYTINE				
TABLET;ORAL				
RENOQUID				
GLENWOOD	250MG	N017569	001	
SULFADIAZINE				
TABLET;ORAL				
SULFADIAZINE				
ABBVIE	300MG	N004125	005	
EVERYLIFE	500MG	A080088	001	
IMPAX LABS	500MG	A080081	001	
LANNETT	500MG	A080084	001	
LEDERLE	500MG	N004054	001	
+ LILLY	500MG	N004122	002	
SULFADIAZINE SODIUM				
INJECTABLE;INJECTION				
SULFADIAZINE SODIUM				
LEDERLE	250MG/ML	N004054	002	

SULFADIAZINE; SULFAMERAZINE				
SUSPENSION;ORAL				
SULFONAMIDES DUPLEX				
LILLY	250MG/5ML;250MG/5ML	N006317	007	
SULFAMETER				
TABLET;ORAL				
SULLA				
BAYER HLTHCARE	500MG	N016000	002	
SULFAMETHIZOLE				
TABLET;ORAL				
MICROSUL				
FOREST PHARMS	1GM	A086012	001	
PROKLAR				
FOREST PHARMS	500MG	A080273	001	
THIOSULFIL				
WYETH AYERST	250MG	N008565	001	
	500MG	N008565	004	
SULFAMETHOXAZOLE				
SUSPENSION;ORAL				
GANTANOL				
ROCHE	500MG/5ML	N013664	002	
TABLET;ORAL				
GANTANOL				
ROCHE	500MG	N012715	002	
GANTANOL-DS				
ROCHE	1GM	N012715	003	
SULFAMETHOXAZOLE				
ASCOT	500MG	A087662	001	Oct 20, 1982
AUROLIFE PHARMA LLC	500MG	A085844	001	
BARR	500MG	A087189	001	Jul 25, 1983
HEATHER	500MG	A086163	001	
WATSON LABS	500MG	A085053	001	
	1GM	A086000	001	
UROBAK				
SHIONOGI	500MG	A087307	001	
SULFAMETHOXAZOLE; TRIMETHOPRIM				
INJECTABLE;INJECTION				
BACTRIM				
+ SUN PHARM INDS INC	80MG/ML;16MG/ML **	N018374	001	
SEPTRA				
MONARCH PHARMS	80MG/ML;16MG/ML	N018452	001	
SULFAMETHOXAZOLE AND TRIMETHOPRIM				
ABRAXIS PHARM	80MG/ML;16MG/ML	A070223	001	Dec 29, 1987
BEDFORD	80MG/ML;16MG/ML	A072383	001	Apr 29, 1992
HOSPIRA	80MG/ML;16MG/ML	A073199	001	Sep 11, 1992
WATSON LABS	80MG/ML;16MG/ML	A071556	001	Dec 29, 1987
WEST-WARD PHARMS INT	80MG/ML;16MG/ML	A070627	001	Dec 29, 1987
	80MG/ML;16MG/ML	A070628	001	Dec 29, 1987
SUSPENSION;ORAL				
BACTRIM				
+ SUN PHARM INDUSTRIES	200MG/5ML;40MG/5ML **	N017560	001	
BACTRIM PEDIATRIC				
SUN PHARM INDUSTRIES	200MG/5ML;40MG/5ML **	N017560	002	
SEPTRA				
MONARCH PHARMS	200MG/5ML;40MG/5ML **	N017598	001	
SEPTRA GRAPE				
MONARCH PHARMS	200MG/5ML;40MG/5ML **	N017598	002	Feb 12, 1986
SULFAMETHOXAZOLE AND TRIMETHOPRIM				
ANI PHARMS INC	200MG/5ML;40MG/5ML	A070028	001	Jun 02, 1987
	200MG/5ML;40MG/5ML **	A077612	001	Nov 13, 2006
TEVA	200MG/5ML;40MG/5ML	N018812	001	Jan 28, 1983
	200MG/5ML;40MG/5ML	N018812	002	Jun 10, 1983
SULFATRIM				
PHARM ASSOC	200MG/5ML;40MG/5ML	N018615	002	Jan 07, 1983
SULMEPRIM				
USL PHARMA	200MG/5ML;40MG/5ML	A070063	001	Aug 01, 1986

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION;ORAL				
SULMEPRIM PEDIATRIC				
USL PHARMA	200MG/5ML;40MG/5ML	A070064	001	Aug 01, 1986
TRIMETH/SULFA				
ALPHARMA US PHARMS	200MG/5ML;40MG/5ML	A072289	001	May 23, 1988
	200MG/5ML;40MG/5ML	A072398	001	May 23, 1988
NASKA	200MG/5ML;40MG/5ML	A072399	001	May 23, 1988
TABLET;ORAL				
COTRIM				
TEVA	400MG;80MG	A070034	001	May 16, 1985
COTRIM D.S.				
TEVA	800MG;160MG	A070048	001	Mar 18, 1985
SULFAMETHOPRIM				
NOVEL LABS INC	400MG;80MG	A070022	001	Feb 15, 1985
SULFAMETHOPRIM-DS				
NOVEL LABS INC	800MG;160MG	A070032	001	Feb 15, 1985
SULFAMETHOXAZOLE AND TRIMETHOPRIM				
FOSUN PHARMA	400MG;80MG	A070889	001	Nov 13, 1986
	400MG;80MG	N018598	003	May 19, 1982
	800MG;160MG	A070890	001	Nov 13, 1986
HEATHER	400MG;80MG	N018946	001	Aug 10, 1984
	800MG;160MG	N018946	002	Aug 10, 1984
INTERPHARM	400MG;80MG	A071299	001	Oct 27, 1987
	800MG;160MG	A071300	001	Oct 27, 1987
MARTEC USA LLC	400MG;80MG	A072408	001	Dec 07, 1988
MUTUAL PHARM	400MG;80MG	A070006	001	Nov 14, 1984
PLIVA	400MG;80MG	A070215	001	Sep 10, 1985
	800MG;160MG	A070216	001	Sep 10, 1985
ROXANE	400MG;80MG	A072768	001	Aug 30, 1991
TEVA	400MG;80MG	N018242	001	
	800MG;160MG	N018242	002	
USL PHARMA	400MG;80MG	A070203	001	Nov 08, 1985
	800MG;160MG	A070204	001	Nov 08, 1985
WATSON LABS	400MG;80MG	A070002	001	Nov 07, 1984
	400MG;80MG	N018852	001	May 09, 1983
	800MG;160MG	A070000	001	Nov 07, 1984
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH				
FOSUN PHARMA	800MG;160MG	N018598	004	May 19, 1982
MARTEC USA LLC	800MG;160MG	A072417	001	Dec 07, 1988
MUTUAL PHARM	800MG;160MG	A070007	001	Nov 14, 1984
ROXANE	800MG;160MG	A072769	001	Aug 30, 1991
WATSON LABS	800MG;160MG	N018854	001	May 09, 1983
SULFATRIM-DS				
SUPERPHARM	800MG;160MG	A070066	001	Jun 24, 1985
SULFATRIM-SS				
SUPERPHARM	400MG;80MG	A070065	002	Jun 24, 1985
UROPLUS DS				
SHIONOGI	800MG;160MG	A071816	001	Sep 28, 1987
UROPLUS SS				
SHIONOGI	400MG;80MG	A071815	001	Sep 28, 1987

SULFANILAMIDE

CREAM;VAGINAL				
SULFANILAMIDE				
G AND W LABS INC	15%	A088718	001	Sep 19, 1985
SUPPOSITORY;VAGINAL				
AVC				
MYLAN SPECIALITY LP	1.05GM	N006530	004	Jan 27, 1987

SULFAPHENAZOLE

SUSPENSION;ORAL				
SULFABID				
PHARM RES ASSOC	500MG/5ML	N013093	001	
TABLET;ORAL				
SULFABID				
PURDUE FREDERICK	500MG	N013092	002	

SULFAPYRIDINE				
TABLET;ORAL				
SULFAPYRIDINE				
LILLY	500MG	N000159 001		
SULFASALAZINE				
SUSPENSION;ORAL				
AZULFIDINE				
PHARMACIA AND UPJOHN	250MG/5ML	N018605 001		
TABLET;ORAL				
S.A.S.-500				
SOLVAY	500MG	A083450 001		
SULFASALAZINE				
HERITAGE PHARMS INC	500MG	A080197 001		
SANDOZ	500MG	A086184 001		
SUN PHARM INDUSTRIES	500MG	A089590 001	Oct 19, 1987	
SUPERPHARM	500MG	A089339 001	Oct 26, 1987	
WATSON LABS	500MG	A084964 001		
	500MG	A087197 001		
TABLET, DELAYED RELEASE;ORAL				
SULFASALAZINE				
WATSON LABS	500MG	A088052 001	May 24, 1983	
SULFINPYRAZONE				
CAPSULE;ORAL				
ANTURANE				
+ NOVARTIS	200MG **	N011556 004		
SULFINPYRAZONE				
BARR	200MG	A087666 001	Sep 17, 1982	
IVAX PHARMS	200MG	A087770 001	Nov 19, 1982	
PAR PHARM	200MG	A088934 001	Sep 06, 1985	
VANGARD	200MG	A088666 001	Feb 17, 1984	
TABLET;ORAL				
ANTURANE				
NOVARTIS	100MG **	N011556 003		
SULFINPYRAZONE				
BARR	100MG	A087665 001	Sep 17, 1982	
IVAX PHARMS	100MG	A087769 001	Jun 01, 1982	
PAR PHARM	100MG	A088933 001	Sep 06, 1985	
WATSON LABS	100MG	A087667 001	May 26, 1982	
SULFISOXAZOLE				
TABLET;ORAL				
GANTRISIN				
ROCHE	500MG	N006525 001		
SOSOL				
MK LABS	500MG	A080036 001		
SOXAZOLE				
ALRA	500MG	A080366 001		
SULFALAR				
PARKE DAVIS	500MG	A084955 001		
SULFISOXAZOLE				
ANI PHARMS INC	500MG	A080142 001		
AUROLIFE PHARMA LLC	500MG	A085628 001		
BARR	500MG	A084031 001		
HEATHER	500MG	A080189 001		
IMPAX LABS	500MG	A080109 001		
LANNETT	500MG	A080085 001		
LEDERLE	500MG	A087649 001		
PHARMERAL	500MG	A084385 001		
PUREPAC PHARM	500MG	A080087 001		
ROXANE	500MG	A080082 001		
VALEANT PHARM INTL	500MG	A080268 002		
VITARINE	500MG	A087332 001		
WATSON LABS	500MG	A085534 001		
WEST WARD	500MG	A080379 001		
SULSOXIN				
SOLVAY	500MG	A080040 001		

SULFISOXAZOLE ACETYL

EMULSION;ORAL				
LIPO GANTRISIN				
	ROCHE	EQ 1GM BASE/5ML	N009182 009	
SUSPENSION;ORAL				
GANTRISIN PEDIATRIC				
	ROCHE	EQ 500MG BASE/5ML	N009182 004	
SYRUP;ORAL				
GANTRISIN				
	ROCHE	EQ 500MG BASE/5ML	N009182 002	

SULFISOXAZOLE DIOLAMINE

INJECTABLE;INJECTION				
GANTRISIN				
	ROCHE	EQ 400MG BASE/ML	N006917 001	
OINTMENT;OPHTHALMIC				
GANTRISIN				
	ROCHE	EQ 4% BASE	N008414 002	
SOLUTION/DROPS;OPHTHALMIC				
GANTRISIN				
	ROCHE	EQ 4% BASE	N007757 002	
SULFISOXAZOLE DIOLAMINE				
	SOLA BARNES HIND	EQ 4% BASE	A084148 001	

SULFOXONE SODIUM

TABLET, DELAYED RELEASE;ORAL				
DIASONE SODIUM				
	ABBVIE	165MG	N006044 003	

SULFUR

POWDER;TOPICAL				
BENSULFOID				
	POYTHRESS	33.32%	N002918 001	

SULINDAC

TABLET;ORAL				
CLINORIL				
+	MERCK	150MG **	N017911 001	
+		200MG **	N017911 002	
SULINDAC				
	ANI PHARMS INC	150MG	A072972 001	Feb 28, 1992
		200MG	A072973 001	Feb 28, 1992
	EPIC PHARMA LLC	150MG	A073262 002	Sep 06, 1991
		200MG	A073262 001	Sep 06, 1991
	FOSUN PHARMA	150MG	A072712 001	Aug 30, 1991
		200MG	A072713 001	Aug 30, 1991

SUMATRIPTAN

SPRAY;NASAL				
IMITREX				
	GLAXOSMITHKLINE	10MG/SPRAY	N020626 002	Aug 26, 1997

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS				
ALSUMA				
	MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377 001	Jun 29, 2010
SUMATRIPTAN SUCCINATE				
	FRESENIUS KABI USA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A079240 002	Sep 18, 2009
		EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A079240 001	Sep 18, 2009
	INJECTALIA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090310 001	Aug 11, 2010
	SANDOZ INC	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078067 002	Feb 06, 2009
		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078067 001	Feb 06, 2009
	TEVA PARENTERAL	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078318 001	Feb 06, 2009
		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078318 002	Feb 06, 2009
SUMAVEL DOSEPRO				
+	ENDO VENTURES LTD	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N022239 002	Nov 26, 2013
+		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239 001	Jul 15, 2009
SYSTEM;IONTOPHORESIS				
ZECUITY				
+	TEVA BRANDED PHARM	EQ 6.5MG BASE/4HR	N202278 001	Jan 17, 2013

SUMATRIPTAN SUCCINATE				
TABLET;ORAL				
SUMATRIPTAN SUCCINATE				
FOSUN PHARMA	EQ 25MG BASE	A076976	001	Aug 10, 2009
	EQ 50MG BASE	A076976	002	Aug 10, 2009
	EQ 100MG BASE	A076976	003	Aug 10, 2009
HIKMA PHARMS	EQ 25MG BASE	A078298	001	May 21, 2013
	EQ 50MG BASE	A078298	002	May 21, 2013
	EQ 100MG BASE	A078298	003	May 21, 2013
MYLAN	EQ 25MG BASE	A077163	001	Nov 02, 2009
	EQ 50MG BASE	A077163	002	Nov 02, 2009
	EQ 100MG BASE	A077163	003	Nov 02, 2009
ROXANE	EQ 25MG BASE	A078241	001	Aug 10, 2009
	EQ 50MG BASE	A078241	002	Aug 10, 2009
	EQ 100MG BASE	A078241	003	Aug 10, 2009
TEVA	EQ 25MG BASE	A076840	001	Feb 09, 2009
	EQ 50MG BASE	A076840	002	Feb 09, 2009
	EQ 100MG BASE	A076840	003	Feb 09, 2009
SUPROFEN				
SOLUTION/DROPS;OPHTHALMIC				
PROFENAL				
ALCON	1%	N019387	001	Dec 23, 1988
SUTILAINS				
OINTMENT;TOPICAL				
TRAVASE				
+ ABBOTT	82,000 UNITS/GM **	N012828	001	
TACRINE HYDROCHLORIDE				
CAPSULE;ORAL				
COGNEX				
SHIONOGI INC	EQ 10MG BASE	N020070	001	Sep 09, 1993
	EQ 20MG BASE	N020070	002	Sep 09, 1993
	EQ 30MG BASE	N020070	003	Sep 09, 1993
	EQ 40MG BASE	N020070	004	Sep 09, 1993
TACROLIMUS				
CAPSULE;ORAL				
TACROLIMUS				
WATSON LABS	EQ 5MG BASE	A090402	001	Jul 01, 2010
TALBUTAL				
TABLET;ORAL				
LOTUSATE				
SANOFI AVENTIS US	120MG	N009410	005	
TAMOXIFEN CITRATE				
TABLET;ORAL				
NOLVADEX				
+ ASTRAZENECA	EQ 10MG BASE **	N017970	001	
+	EQ 20MG BASE **	N017970	002	Mar 21, 1994
TAMOXIFEN CITRATE				
ACTAVIS LABS FL INC	EQ 10MG BASE	A076179	001	Feb 20, 2003
	EQ 20MG BASE	A076179	002	Feb 20, 2003
AEGIS PHARMS	EQ 10MG BASE	A076398	001	Mar 31, 2003
	EQ 20MG BASE	A076398	002	Mar 31, 2003
IVAX SUB TEVA PHARMS	EQ 10MG BASE	A075740	001	Feb 20, 2003
	EQ 20MG BASE	A075740	002	Feb 20, 2003
PHARMACHEMIE	EQ 10MG BASE	A074539	001	Mar 31, 2003
ROXANE	EQ 10MG BASE	A076027	001	Feb 20, 2003
	EQ 20MG BASE	A076027	002	Feb 20, 2003
TEVA	EQ 10MG BASE	A074504	001	Apr 28, 2003
	EQ 20MG BASE	A074504	002	Apr 28, 2003
TAPENTADOL HYDROCHLORIDE				
SOLUTION;ORAL				
NUCYNTA				
+ ASSERTIO	EQ 20MG BASE/ML	N203794	001	Oct 15, 2012

TECHNETIUM TC-99M ALBUMIN AGGREGATED
INJECTABLE;INJECTION
TC 99M-LUNGAGGREGATE
GE HEALTHCARE 5mCi/ML N017848 001

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
INJECTABLE;INJECTION
A-N STANNOUS AGGREGATED ALBUMIN
SYNCOR PHARMS N/A N017916 001
AN-MAA
PHARMALUCENCE N/A N017792 001
LUNGAGGREGATE REAGENT
GE HEALTHCARE N/A N017838 001
MACROTEC
BRACCO N/A N017833 001
PULMOLITE
\+ JUBILANT DRAXIMAGE N/A N017776 001
TECHNESCAN MAA
MALLINCKRODT N/A N017842 001
TECHNETIUM TC 99M MAA
GE HEALTHCARE N/A N017773 001

TECHNETIUM TC-99M ALBUMIN COLLOID KIT
INJECTABLE;INJECTION
MICROLITE
PHARMALUCENCE N/A N018263 001 Mar 25, 1983

TECHNETIUM TC-99M ALBUMIN KIT
INJECTABLE;INJECTION
TECHNETIUM TC 99M HSA
GE HEALTHCARE N/A N017775 001

TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT
INJECTABLE;INJECTION
INSTANT MICROSPHERES
3M N/A N017832 001

TECHNETIUM TC-99M APCITIDE
INJECTABLE;INJECTION
ACUTECT
CIS BIO INTL SA N/A N020887 001 Sep 14, 1998

TECHNETIUM TC-99M DEPREOTIDE
INJECTABLE;INJECTION
NEO TECT KIT
CIS BIO INTL SA N/A N021012 001 Aug 03, 1999

TECHNETIUM TC-99M ETIDRONATE KIT
INJECTABLE;INJECTION
CINTICHEM TECHNETIUM 99M HEDSPA
GE HEALTHCARE N/A N017653 001
MPI STANNOUS DIPHOSPHONATE
GE HEALTHCARE N/A N017667 001
OSTEOSCAN
MALLINCKRODT N/A N017454 001
TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT
GE HEALTHCARE N/A N017562 001

TECHNETIUM TC-99M FERPENTETATE KIT
INJECTABLE;INJECTION
RENOTEC
BRACCO N/A N017045 001

TECHNETIUM TC-99M GLUCEPTATE KIT
INJECTABLE;INJECTION
GLUCOSCAN
BRISTOL MYERS SQUIBB N/A N017907 001
TECHNESCAN GLUCEPTATE
DRAXIMAGE N/A N018272 001 Jan 27, 1982

TECHNETIUM TC-99M LIDOFENIN KIT
INJECTABLE;INJECTION
TECHNESCAN HIDA
DRAXIMAGE — N/A — N018489 001 Oct 31, 1986

TECHNETIUM TC-99M MEDRONATE
INJECTABLE;INJECTION
DRAXIMAGE MDP-10
JUBILANT DRAXIMAGE — N/A — N018035 001

TECHNETIUM TC-99M MEDRONATE KIT
INJECTABLE;INJECTION
AMERSCAN MDP KIT
GE HEALTHCARE — N/A — N018335 001 Aug 05, 1982
MDP-BRACCO
CARDINAL HEALTH 414 — N/A — N018107 001
OSTEOLITE
PHARMALUCENCE — N/A — N017972 001
TECHNETIUM TC 99M MPI MDP
GE HEALTHCARE — N/A — N018141 001
N/A — N018141 002 Jun 12, 1989

TECHNETIUM TC-99M PENTETATE KIT
INJECTABLE;INJECTION
AN-DTPA
JUBILANT DRAXIMAGE — N/A — N017714 001
MPI DTPA KIT - CHELATE
GE HEALTHCARE — N/A — N017255 001
TECHNETIUM TC-99M PENTETATE KIT
GE HEALTHCARE — N/A — N017264 002

TECHNETIUM TC-99M POLYPHOSPHATE KIT
INJECTABLE;INJECTION
SODIUM POLYPHOSPHATE-TIN KIT
GE HEALTHCARE — N/A — N017664 001

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT
INJECTABLE;INJECTION
PYROLITE
PHARMALUCENCE — N/A — N017684 001

TECHNETIUM TC-99M PYROPHOSPHATE KIT
INJECTABLE;INJECTION
PHOSPHOTEC
BRACCO — N/A — N017680 001

TECHNETIUM TC-99M RED BLOOD CELL KIT
INJECTABLE;INJECTION
RBC-SCAN
CADEMA — N/A — N020063 001 Jun 11, 1992

TECHNETIUM TC-99M SESTAMIBI KIT
INJECTABLE;INJECTION
MIRALUMA
LANTHEUS MEDCL — N/A — N019785 003 May 23, 1997

TECHNETIUM TC-99M SODIUM PERTECHNETATE
SOLUTION;INJECTION, ORAL
SODIUM PERTECHNETATE TC 99M
\+ GE HEALTHCARE — 2-100mCi/ML ** — N017471 001
\+ MALLINCKRODT — 10-60mCi/ML ** — N017725 001
PHARMALUCENCE — 12mCi/ML — N017321 001
24mCi/ML — N017321 002
48mCi/ML — N017321 003

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
SOLUTION;INJECTION, ORAL
MINITEC
BRACCO — 0.22-2.22 CI/GENERATOR — N017339 001
SOLUTION;INTRAVENOUS
TECHNELITE
LANTHEUS MEDCL — 0.0083-2.7 CI/GENERATOR — N017771 001
ULTRA-TECHNEKOW FM
MALLINKRODT NUCLEAR — 0.25-3 CI/GENERATOR — N017243 002

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
SOLUTION;INTRAVENOUS, ORAL
TECHNETIUM TC 99M GENERATOR
GE HEALTHCARE 830-16600mCi/GENERATOR N017693 001

TECHNETIUM TC-99M SUCCIMER KIT
INJECTABLE;INJECTION
MPI DMSA KIDNEY REAGENT
GE HEALTHCARE N/A N017944 001 May 18, 1982

TECHNETIUM TC-99M SULFUR COLLOID
SOLUTION;INJECTION, ORAL
TECHNETIUM TC 99M SULFUR COLLOID
GE HEALTHCARE 4mCi/ML N017456 001
SOLUTION;ORAL
TECHNETIUM TC 99M SULFUR COLLOID
MALLINCKRODT 3mCi/ML N017724 001

TECHNETIUM TC-99M SULFUR COLLOID KIT
SOLUTION;INJECTION, ORAL
TECHNECOLL
MALLINCKRODT N/A N017059 001
TECHNETIUM TC 99M TSC
GE HEALTHCARE N/A N017784 001
TESULOID
BRACCO N/A N016923 001

TECHNETIUM TC-99M TEBOROXIME KIT
INJECTABLE;INJECTION
CARDIOTEC
BRACCO N/A N019928 001 Dec 19, 1990

TECHNETIUM TC-99M TETROFOSMIN KIT
INJECTABLE;INJECTION
MYOVIEW
\+ GE HEALTHCARE N/A N020372 001 Feb 09, 1996

TEGASEROD MALEATE
TABLET;ORAL
ZELNORM
US WORLDMEDS LLC EQ 2MG BASE N021200 001 Jul 24, 2002
EQ 6MG BASE N021200 002 Jul 24, 2002

TELAPREVIR
TABLET;ORAL
INCIVEK
VERTEX PHARMS 375MG N201917 001 May 23, 2011

TELAVANCIN HYDROCHLORIDE
POWDER;INTRAVENOUS
VIBATIV
\+ CUMBERLAND PHARMS EQ 250MG BASE/VIAL N022110 001 Sep 11, 2009

TELBIVUDINE
SOLUTION;ORAL
TYZEKA
NOVARTIS 100MG/5ML N022154 001 Apr 28, 2009
TABLET;ORAL
TYZEKA
\+ NOVARTIS 600MG N022011 001 Oct 25, 2006

TELITHROMYCIN
TABLET;ORAL
KETEK
SANOFI AVENTIS US 300MG N021144 002 Feb 09, 2005
400MG N021144 001 Apr 01, 2004

TELMISARTAN
TABLET;ORAL
TELMISARTAN
WATSON LABS 40MG A078710 002 Jan 08, 2014

TEMAZEPAM				
CAPSULE;ORAL				
TEMAZ				
	QUANTUM PHARMICS	15MG	A070564 001	Oct 15, 1985
		30MG	A070547 001	Oct 15, 1985
TEMAZEPAM				
	DURAMED PHARMS BARR	15MG	A071708 001	Sep 29, 1988
		30MG	A071709 001	Sep 29, 1988
	SUN PHARM INDUSTRIES	15MG	A071174 001	Jul 10, 1986
		30MG	A071175 001	Jul 10, 1986
	USL PHARMA	15MG	A070489 001	Jul 07, 1986
		30MG	A070490 001	Jul 07, 1986
	WATSON LABS	15MG	A070383 001	Mar 23, 1987
		15MG	A071446 001	May 21, 1993
		30MG	A070384 001	Mar 23, 1987
		30MG	A071447 001	May 21, 1993
TEMOZOLOMIDE				
CAPSULE;ORAL				
TEMOZOLOMIDE				
	MYLAN PHARMS INC	5MG	A205227 001	Jun 29, 2016
		20MG	A205227 002	Jun 29, 2016
		100MG	A205227 003	Jun 29, 2016
		140MG	A205227 004	Jun 29, 2016
		180MG	A205227 005	Jun 29, 2016
		250MG	A205227 006	Jun 29, 2016
TENIPOSIDE				
INJECTABLE;INJECTION				
VUMON				
+	HQ SPECLT PHARMA	10MG/ML	N020119 001	Jul 14, 1992
TERAZOSIN HYDROCHLORIDE				
CAPSULE;ORAL				
HYTRIN				
+	ABBOTT	EQ 1MG BASE **	N020347 001	Dec 14, 1994
+		EQ 2MG BASE **	N020347 002	Dec 14, 1994
+		EQ 5MG BASE **	N020347 003	Dec 14, 1994
+		EQ 10MG BASE **	N020347 004	Dec 14, 1994
TERAZOSIN HYDROCHLORIDE				
	MYLAN TECHNOLOGIES	EQ 1MG BASE	A075384 001	Dec 01, 2000
		EQ 2MG BASE	A075384 002	Dec 01, 2000
		EQ 5MG BASE	A075384 003	Dec 01, 2000
		EQ 10MG BASE	A075384 004	Dec 01, 2000
	RANBAXY LABS LTD	EQ 1MG BASE	A076021 001	Aug 22, 2002
		EQ 2MG BASE	A076021 002	Aug 22, 2002
		EQ 5MG BASE	A076021 003	Aug 22, 2002
		EQ 10MG BASE	A076021 004	Aug 22, 2002
	SANDOZ	EQ 1MG BASE	A075667 001	Jul 28, 2000
		EQ 2MG BASE	A075667 002	Jul 28, 2000
		EQ 5MG BASE	A075667 003	Jul 28, 2000
		EQ 10MG BASE	A075667 004	Jul 28, 2000
TABLET;ORAL				
HYTRIN				
	ABBOTT	EQ 1MG BASE	N019057 001	Aug 07, 1987
		EQ 2MG BASE	N019057 002	Aug 07, 1987
		EQ 5MG BASE	N019057 003	Aug 07, 1987
		EQ 10MG BASE	N019057 004	Aug 07, 1987
TERAZOSIN HYDROCHLORIDE				
	IVAX SUB TEVA PHARMS	EQ 1MG BASE	A074530 001	Apr 21, 2000
		EQ 2MG BASE	A074530 002	Apr 21, 2000
		EQ 5MG BASE	A074530 003	Apr 21, 2000
		EQ 10MG BASE	A074530 004	Apr 21, 2000
	SANDOZ	EQ 1MG BASE	A074315 001	Dec 31, 1998
		EQ 1MG BASE	A074657 001	Apr 28, 2000
		EQ 2MG BASE	A074315 002	Dec 31, 1998
		EQ 2MG BASE	A074657 002	Apr 28, 2000
		EQ 5MG BASE	A074315 003	Dec 31, 1998
		EQ 5MG BASE	A074657 003	Apr 28, 2000
		EQ 10MG BASE	A074315 004	Dec 31, 1998
		EQ 10MG BASE	A074657 004	Apr 28, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

TERAZOSIN HYDROCHLORIDE				
TABLET;ORAL				
TERAZOSIN HYDROCHLORIDE				
TEVA	EQ 1MG BASE	A074446	001	May 18, 2000
	EQ 2MG BASE	A074446	002	May 18, 2000
	EQ 5MG BASE	A074446	003	May 18, 2000
	EQ 10MG BASE	A074446	004	May 18, 2000
TERBINAFINE				
GEL;TOPICAL				
LAMISIL				
GLAXOSMITHKLINE CONS	1%	N020846	001	Apr 29, 1998
TERBINAFINE HYDROCHLORIDE				
CREAM;TOPICAL				
LAMISIL				
NOVARTIS	1%	N020192	001	Dec 30, 1992
GRANULE;ORAL				
LAMISIL				
+ NOVARTIS	EQ 125MG BASE/PACKET	N022071	001	Sep 28, 2007
+	EQ 187.5MG BASE/PACKET	N022071	002	Sep 28, 2007
SOLUTION;TOPICAL				
LAMISIL				
GLAXOSMITHKLINE CONS	1%	N020749	001	Oct 17, 1997
TABLET;ORAL				
TERBINAFINE HYDROCHLORIDE				
APOTEX	EQ 250MG BASE	A078199	001	Jul 02, 2007
GEDEON RICHTER USA	EQ 250MG BASE	A077065	001	Jul 02, 2007
MYLAN	EQ 250MG BASE	A077136	001	Jul 02, 2007
	EQ 250MG BASE	A077195	001	Jul 02, 2007
ROXANE	EQ 250MG BASE	A077223	001	Jul 02, 2007
WOCKHARDT	EQ 250MG BASE	A078229	001	Jul 02, 2007
TERBUTALINE SULFATE				
AEROSOL, METERED;INHALATION				
BRETHAIRE				
NOVARTIS	0.2MG/INH	N018762	001	Aug 17, 1984
BRICANYL				
SANOFI AVENTIS US	0.2MG/INH	N018000	001	Mar 19, 1985
INJECTABLE;INJECTION				
BRETHINE				
+ PHARMACARE	1MG/ML **	N018571	001	
BRICANYL				
SANOFI AVENTIS US	1MG/ML	N017466	001	
TERBUTALINE SULFATE				
TEVA PHARMS USA	1MG/ML	A076853	001	Jul 20, 2004
TABLET;ORAL				
BRICANYL				
SANOFI AVENTIS US	2.5MG	N017618	001	
	5MG	N017618	002	
TERCONAZOLE				
CREAM;VAGINAL				
TERAZOL 3				
+ JANSSEN PHARMS	0.8%	N019964	001	Feb 21, 1991
TERAZOL 7				
+ JANSSEN PHARMS	0.4%	N019579	001	Dec 31, 1987
SUPPOSITORY;VAGINAL				
TERAZOL 3				
+ JANSSEN PHARMS	80MG	N019641	001	May 24, 1988
TERCONAZOLE				
FOUGERA PHARMS	80MG	A076850	001	Jul 12, 2006
TERIPARATIDE ACETATE				
INJECTABLE;INJECTION				
PARATHAR				
SANOFI AVENTIS US	200 UNITS/VIAL	N019498	001	Dec 23, 1987

TERIPARATIDE RECOMBINANT HUMAN				
INJECTABLE;SUBCUTANEOUS				
FORTEO				
	LILLY	0.75MG/3ML (0.25MG/ML)	N021318 001	Nov 26, 2002
TESTOLACTONE				
INJECTABLE;INJECTION				
TESLAC				
	BRISTOL MYERS SQUIBB	100MG/ML	N016119 001	
TABLET;ORAL				
TESLAC				
	BRISTOL MYERS SQUIBB	50MG	N016118 001	
		250MG	N016118 002	
TESTOSTERONE				
FILM, EXTENDED RELEASE;TRANSDERMAL				
ANDRODERM				
	ALLERGAN SALES LLC	2.5MG/24HR	N020489 001	Sep 29, 1995
		5MG/24HR	N020489 002	May 02, 1997
TESTODERM				
	ALZA	4MG/24HR	N019762 001	Oct 12, 1993
		6MG/24HR	N019762 002	Oct 12, 1993
TESTODERM TTS				
	ALZA	5MG/24HR	N020791 001	Dec 18, 1997
GEL;TRANSDERMAL				
TESTOSTERONE				
	ANI PHARMS INC	25MG/2.5GM PACKET	N202763 001	Feb 14, 2012
		50MG/5GM PACKET	N202763 002	Feb 14, 2012
	PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098 002	Jan 31, 2013
		50MG/5GM PACKET	N203098 003	Jan 31, 2013
GEL, METERED;TRANSDERMAL				
TESTOSTERONE				
	PERRIGO ISRAEL	12.5MG/1.25GM ACTUATION	N203098 001	Jan 31, 2013
INJECTABLE;INJECTION				
TESTOSTERONE				
	WATSON LABS	25MG/ML	A086420 001	May 10, 1983
		50MG/ML	A086419 001	Aug 23, 1983
		100MG/ML	A086417 001	Jul 07, 1983
SOLUTION, METERED;TRANSDERMAL				
AXIRON				
+	ELI LILLY AND CO	30MG/1.5ML ACTUATION **	N022504 001	Nov 23, 2010
TESTOSTERONE CYPIONATE				
INJECTABLE;INJECTION				
DEPO-TESTOSTERONE				
	PHARMACIA AND UPJOHN	50MG/ML	A085635 001	
TESTOSTERONE CYPIONATE				
	WATSON LABS	100MG/ML	A084401 001	
		100MG/ML	A086029 001	
		200MG/ML	A084401 002	
TESTOSTERONE ENANTHATE				
INJECTABLE;INJECTION				
DELATESTRYL				
	ENDO PHARMS	200MG/ML	N009165 001	
+		200MG/ML	N009165 003	
TESTOSTERONE ENANTHATE				
	MYLAN INSTITUTIONAL	200MG/ML	A040647 001	Oct 05, 2009
	WATSON LABS	100MG/ML	A083667 001	
		100MG/ML	A085599 001	
		200MG/ML	A083667 002	
TESTOSTERONE PROPIONATE				
INJECTABLE;INJECTION				
TESTOSTERONE PROPIONATE				
	BEL MAR	25MG/ML	A080741 001	
		50MG/ML	A080742 001	
		100MG/ML	A080743 001	
	ELKINS SINN	25MG/ML	A080276 001	
	LILLY	50MG/ML	A080254 002	
	WATSON LABS	25MG/ML	A080188 001	
		25MG/ML	A085490 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

TESTOSTERONE PROPIONATE				
INJECTABLE;INJECTION				
TESTOSTERONE PROPIONATE				
	50MG/ML		A080188 002	
	50MG/ML		A085490 002	
	100MG/ML		A080188 003	
	100MG/ML		A083595 003	
TETRACYCLINE HYDROCHLORIDE				
CAPSULE;ORAL				
BRISTACYCLINE				
BRISTOL	250MG		A061658 001	
	250MG		A061888 001	
	500MG		A061658 002	
	500MG		A061888 002	
CYCLOPAR				
WARNER CHILCOTT	250MG		A061725 001	
	250MG		A062175 001	
	250MG		A062332 001	
	500MG		A061725 002	
	500MG		A062332 002	
PANMYCIN				
PHARMACIA AND UPJOHN	250MG		A060347 001	
RETET				
SOLVAY	250MG		A061443 001	
	500MG		A061443 002	
ROBITET				
WYETH AYERST	250MG		A061734 001	
	500MG		A061734 002	
SUMYCIN				
APOTHECON	100MG		A060429 002	
	125MG		A060429 004	
	250MG		A060429 001	
	500MG		A060429 003	
TETRACHEL				
ANGUS	250MG		A060343 001	
	500MG		A060343 003	
TETRACYCLINE HYDROCHLORIDE				
ABBOTT	250MG		A061802 001	
	500MG		A061802 002	
ANI PHARMS INC	250MG		A061471 001	
ELKINS SINN	250MG		A060059 001	
FERRANTE	125MG		A060173 001	
	250MG		A060173 002	
HEATHER	250MG		A061148 001	
	500MG		A061148 002	
HIKMA PHARMS	250MG		A060768 001	
	500MG		A060768 002	
IMPAX LABS	100MG		A060469 002	
	250MG		A060469 001	
	500MG		A060469 003	
IVAX SUB TEVA PHARMS	250MG		A060704 001	
	500MG		A060704 002	
MAST MM	250MG		A062085 001	
MYLAN	250MG		A060783 001	
	500MG		A060783 002	
PUREPAC PHARM	250MG		A060290 001	
	500MG		A060290 002	
PVT FORM	250MG		A062686 001	Jul 24, 1986
	500MG		A062686 002	Jul 24, 1986
ROXANE	500MG		A061214 002	
SUN PHARM INDUSTRIES	250MG		A060736 001	
	500MG		A060736 002	
SUPERPHARM	250MG		A062540 001	Mar 21, 1985
	500MG		A062540 002	Mar 21, 1985
VALEANT PHARM INTL	250MG		A060471 001	
	500MG		A060471 002	
WARNER CHILCOTT	250MG		A062300 001	
	500MG		A062300 002	
WATSON LABS	250MG		A062103 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

TETRACYCLINE HYDROCHLORIDE				
CAPSULE;ORAL				
TETRACYCLINE HYDROCHLORIDE				
	250MG		A062343 001	
	500MG		A062103 002	
	500MG		A062343 002	
WYETH AYERST	250MG		A061685 001	
	500MG		A061685 002	
TETRACYN				
PFIPHARMECS	250MG		A060082 003	
	500MG		A060082 004	
FIBER, EXTENDED RELEASE;PERIODONTAL				
ACTISITE				
SCHIFF AND CO	12.7MG/FIBER		N050653 001	Mar 25, 1994
FOR SOLUTION;TOPICAL				
TOPICYCLINE				
SHIRE	2.2MG/ML		N050493 001	
INJECTABLE;INJECTION				
ACHROMYCIN				
LEDERLE	250MG/VIAL		N050273 002	
	500MG/VIAL		N050273 003	
TETRACYN				
PFIZER	250MG/VIAL		A060096 001	
	500MG/VIAL		A060096 002	
OINTMENT;OPHTHALMIC				
ACHROMYCIN				
STORZ	10MG/GM		N050266 001	
SUSPENSION;ORAL				
ACHROMYCIN V				
LEDERLE	125MG/5ML		N050263 002	
SUMYCIN				
PAR PHARM	125MG/5ML		A060400 001	
TETRACYCLINE HYDROCHLORIDE				
ALPHARMA US PHARMS	125MG/5ML		A060633 001	
FERRANTE	125MG/5ML		A060174 001	
PROTER	125MG/5ML		A060446 001	
PUREPAC PHARM	125MG/5ML		A060291 001	
TETRACYN				
PFIPHARMECS	125MG/5ML		A060095 001	
TETRAMED				
IVAX SUB TEVA PHARMS	125MG/5ML		A061468 001	
SUSPENSION/DROPS;OPHTHALMIC				
ACHROMYCIN				
STORZ	1%		N050268 001	
TABLET;ORAL				
PANMYCIN				
PHARMACIA AND UPJOHN	250MG		A061705 001	
	500MG		A061705 002	
SUMYCIN				
PAR PHARM	50MG		A061147 003	
	100MG		A061147 002	
	250MG		A061147 001	
	500MG		A061147 004	
TETRACYCLINE PHOSPHATE COMPLEX				
CAPSULE;ORAL				
TETREX				
BRISTOL	EQ 100MG HYDROCHLORIDE		A061653 001	
	EQ 250MG HYDROCHLORIDE		A061653 002	
	EQ 250MG HYDROCHLORIDE		A061889 002	
	EQ 250MG HYDROCHLORIDE		N050212 002	
	EQ 500MG HYDROCHLORIDE		A061653 003	
	EQ 500MG HYDROCHLORIDE		A061889 001	
	EQ 500MG HYDROCHLORIDE		N050212 003	

THALLOUS CHLORIDE TL-201				
INJECTABLE;INJECTION				
THALLOUS CHLORIDE TL 201				
BRACCO	1mCi/ML	N018548	001	Dec 30, 1982
TRACE LIFE	1mCi/ML	A075569	001	Nov 21, 2001
INJECTABLE;INTRAVENOUS				
THALLOUS CHLORIDE TL 201				
+ LANTHEUS MEDCL	2mCi/ML	N017806	002	Oct 09, 1998
MALLINKRODT NUCLEAR	2mCi/ML	A077698	001	Nov 09, 2006
THEOPHYLLINE				
CAPSULE;ORAL				
BRONKODYL				
SANOFI AVENTIS US	100MG	A085264	001	
	200MG	A085264	002	
ELIXOPHYLLIN				
FOREST LABS	100MG	A085545	001	Jul 31, 1984
	200MG	A083921	001	Jul 31, 1984
SOMOPHYLLIN-T				
FISONS	100MG	A087155	001	Feb 25, 1985
	200MG	A087155	002	Feb 25, 1985
	250MG	A087155	003	Feb 25, 1985
THEOPHYLLINE				
KV PHARM	100MG	A085263	001	
	200MG	A085263	002	
SCHERER RP	100MG	A084731	002	Nov 07, 1986
	200MG	A084731	001	Nov 07, 1986
	250MG	A084731	003	Nov 07, 1986
CAPSULE, EXTENDED RELEASE;ORAL				
AEROLATE III				
FLEMING PHARMS	65MG	A085075	003	Nov 24, 1986
AEROLATE JR				
FLEMING PHARMS	130MG	A085075	002	Nov 24, 1986
AEROLATE SR				
FLEMING PHARMS	260MG	A085075	001	Nov 24, 1986
ELIXOPHYLLIN SR				
FOREST LABS	125MG	A086826	001	Jan 29, 1985
	250MG	A086826	002	Jan 29, 1985
SLO-BID				
SANOFI AVENTIS US	50MG	A088269	001	Jan 31, 1985
	75MG	A089539	001	May 10, 1989
	100MG	A087892	001	Jan 31, 1985
	125MG	A089540	001	May 10, 1989
	200MG	A087893	001	Jan 31, 1985
	300MG	A087894	001	Jan 31, 1985
SLO-PHYLLIN				
SANOFI AVENTIS US	60MG	A085206	001	May 24, 1982
	125MG	A085203	001	May 24, 1982
	250MG	A085205	001	May 24, 1982
SOMOPHYLLIN-CRT				
GRAHAM DM	50MG	A087763	001	Feb 27, 1985
	100MG	A087194	001	
	200MG	A088382	001	Feb 27, 1985
	250MG	A087193	001	
	300MG	A088383	001	Feb 27, 1985
THEO-DUR				
SCHERING	50MG	A088022	001	Sep 10, 1985
	75MG	A088015	001	Sep 10, 1985
	125MG	A088016	001	Sep 10, 1985
	200MG	A087995	001	Sep 10, 1985
THEOBID				
WHITBY	260MG	A085983	001	Mar 20, 1985
THEOBID JR.				
WHITBY	130MG	A087854	001	Mar 20, 1985
THEOCLEAR L.A.-130				
SCHWARZ PHARMA	130MG	A086569	001	May 27, 1982
THEOCLEAR L.A.-260				
SCHWARZ PHARMA	260MG	A086569	002	May 27, 1982

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE;ORAL				
THEOPHYL-SR				
ORTHO MCNEIL PHARM	125MG	A086480	001	Feb 08, 1985
	250MG	A086471	001	Feb 08, 1985
THEOPHYLLINE				
CENT PHARMS	125MG	A088654	001	Feb 12, 1985
	250MG	A088689	001	Feb 12, 1985
HOSPIRA	100MG	A089976	001	Jan 04, 1995
	200MG	A089977	001	Jan 04, 1995
	300MG	A089932	001	Jan 04, 1995
INWOOD LABS	100MG	A040052	001	Feb 14, 1994
	125MG	A040052	002	Feb 14, 1994
	200MG	A040052	003	Feb 14, 1994
	300MG	A040052	004	Feb 14, 1994
SANDOZ	260MG	A087462	001	May 11, 1982
THEOPHYLLINE-SR				
SCHERER RP	300MG	A088255	001	Jun 12, 1986
THEOVENT				
SCHERING	125MG	A087010	001	Jan 31, 1985
	250MG	A087910	001	Jan 31, 1985
ELIXIR;ORAL				
ELIXOMIN				
CENCI	80MG/15ML	A088303	001	Jan 25, 1984
LANOPHYLLIN				
LANNETT	80MG/15ML	A084578	001	
THEOLIXIR				
PANRAY	80MG/15ML	A084559	001	
THEOPHYL-225				
ORTHO MCNEIL PHARM	112.5MG/15ML	A086485	001	
THEOPHYLLINE				
ALPHARMA US PHARMS	80MG/15ML	A089223	001	May 27, 1988
CENCI	80MG/15ML	A087679	001	Apr 15, 1982
CHARTWELL RX	80MG/15ML	A085952	001	
HALSEY	80MG/15ML	A085169	001	
PHARM ASSOC	80MG/15ML	A086720	001	
PRECISION DOSE	80MG/15ML	A085863	001	
ROXANE	80MG/15ML	A084739	001	
TARO	80MG/15ML	A089626	001	Oct 28, 1988
WOCKHARDT	80MG/15ML	A086748	001	
INJECTABLE;INJECTION				
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	40MG/100ML	N019083	001	Nov 07, 1984
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	80MG/100ML	N019083	002	Nov 07, 1984
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	160MG/100ML	N019083	003	Nov 07, 1984
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	200MG/100ML	N019212	001	Nov 07, 1984
	200MG/100ML	N019826	004	Aug 14, 1992
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	4MG/ML	N019212	003	Nov 07, 1984
	400MG/100ML	N019212	002	Nov 07, 1984
	400MG/100ML	N019826	005	Aug 14, 1992
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4MG/ML	N018649	007	Jul 26, 1982
	40MG/100ML	N018649	001	Jul 26, 1982
	80MG/100ML	N018649	002	Jul 26, 1982
	160MG/100ML	N018649	003	Jul 26, 1982
	200MG/100ML	N018649	004	Jul 26, 1982
	320MG/100ML	N018649	006	Nov 13, 1985
	400MG/100ML	N018649	005	Jul 26, 1982
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER				
+ HOSPIRA INC	4MG/ML	N019211	007	Dec 14, 1984
+	40MG/100ML	N019211	001	Dec 14, 1984
	80MG/100ML	N019211	002	Dec 14, 1984
+	160MG/100ML	N019211	003	Dec 14, 1984
	200MG/100ML	N019211	004	Dec 14, 1984
+	320MG/100ML	N019211	006	Jan 20, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

THEOPHYLLINE

INJECTABLE;INJECTION				
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER				
	400MG/100ML	N019211	005	Dec 14, 1984
SOLUTION;ORAL				
AEROLATE				
FLEMING PHARMS	150MG/15ML	A089141	001	Dec 03, 1986
THEOLAIR				
3M	80MG/15ML	A086107	001	
THEOPHYLLINE				
ROXANE	80MG/15ML	A087449	001	Sep 15, 1983
SUSPENSION;ORAL				
ELIXICON				
FOREST LABS	100MG/5ML	A085502	001	
SYRUP;ORAL				
ACCURBRON				
SANOFI AVENTIS US	150MG/15ML	A088746	001	Nov 22, 1985
AQUAPHYLLIN				
FERNDALE LABS	80MG/15ML	A087917	001	Jan 18, 1983
SLO-PHYLLIN				
SANOFI AVENTIS US	80MG/15ML	A085187	001	
THEOCLEAR-80				
CENT PHARMS	80MG/15ML	A087095	001	Mar 01, 1982
THEOPHYLLINE				
ALPHARMA US PHARMS	80MG/15ML	A086001	001	
	150MG/15ML	A086545	001	
TABLET;ORAL				
QUIBRON-T				
MONARCH PHARMS	300MG	A088656	001	Aug 22, 1985
SLO-PHYLLIN				
SANOFI AVENTIS US	100MG	A085202	001	
	200MG	A085204	001	
THEOCLEAR-100				
CENT PHARMS	100MG	A085353	002	
THEOCLEAR-200				
CENT PHARMS	200MG	A085353	001	
THEOLAIR				
MEDICIS	125MG	A086399	001	
	250MG	A086399	002	
THEOPHYL-225				
ORTHO MCNEIL PHARM	225MG	A084726	001	
TABLET, CHEWABLE;ORAL				
THEOPHYL				
ORTHO MCNEIL PHARM	100MG	A086506	001	Sep 12, 1985
TABLET, EXTENDED RELEASE;ORAL				
DURAPHYL				
FOREST LABS	100MG	A088503	001	Apr 03, 1985
	200MG	A088504	001	Apr 03, 1985
	300MG	A088505	001	Apr 03, 1985
LABID				
WARNER CHILCOTT	250MG	A087225	001	
QUIBRON-T/SR				
MONARCH PHARMS	300MG	A087563	001	Jun 21, 1983
SUSTAIRE				
ROERIG	100MG	A085665	001	
	300MG	A085665	002	
T-PHYL				
PHARM RES ASSOC	200MG	A088253	001	Aug 17, 1983
THEO-DUR				
SCHERING	100MG	A085328	001	
	200MG	A086998	001	
	300MG	A085328	002	
	450MG	A089131	001	Jun 25, 1986
THEOCHRON				
NOSTRUM PHARMS LLC	300MG	A087400	002	Jan 11, 1983
THEOLAIR-SR				
3M	200MG	A088369	001	Jul 16, 1987
	250MG	A086363	002	Jul 16, 1987
	300MG	A088364	001	Jul 16, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

THEOPHYLLINE				
TABLET, EXTENDED RELEASE;ORAL				
THEOLAIR-SR				
	500MG		A089132 001	Jul 16, 1987
THEOPHYLLINE				
ABLE	300MG		A040548 001	Apr 30, 2004
	400MG		A040543 001	Apr 27, 2004
	450MG		A040546 001	Apr 30, 2004
	600MG		A040539 001	Apr 27, 2004
INWOOD LABS	450MG		A040034 001	Apr 28, 1995
TEVA PHARMS	450MG		A081236 001	Nov 09, 1992
UNI-DUR				
SCHERING	400MG		A089822 001	Jan 04, 1995
	600MG		A089823 001	Jan 04, 1995
THEOPHYLLINE SODIUM GLYCINATE				
ELIXIR;ORAL				
SYNOPHYLATE				
CENT PHARMS	EQ 165MG BASE/15ML		N006333 008	
TABLET;ORAL				
ASBRON				
NOVARTIS	EQ 150MG BASE		A085148 001	
THIABENDAZOLE				
SUSPENSION;ORAL				
MINTEZOL				
MERCK SHARP DOHME	500MG/5ML		N016097 001	
TABLET, CHEWABLE;ORAL				
MINTEZOL				
MERCK SHARP DOHME	500MG		N016096 001	
THIAMINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
BETALIN S				
LILLY	100MG/ML		A080853 001	
THIAMINE HYDROCHLORIDE				
ABRAXIS PHARM	100MG/ML		A080509 001	
AKORN	100MG/ML		A087968 001	Oct 01, 1982
BEL MAR	100MG/ML		A080718 001	
	200MG/ML		A080712 001	
DELL LABS	100MG/ML		A083775 001	
HOSPIRA	100MG/ML		A040079 001	May 03, 1996
LUITPOLD	100MG/ML		A080667 001	
PARKE DAVIS	100MG/ML		A080770 001	
WATSON LABS	100MG/ML		A080571 001	
	100MG/ML		A083534 001	
	200MG/ML		A080571 002	
	200MG/ML		A083534 002	
WEST-WARD PHARMS INT	100MG/ML		A080575 001	
WYETH AYERST	100MG/ML		A080553 001	
THIAMYLAL SODIUM				
INJECTABLE;INJECTION				
SURITAL				
PARKEDALE	1GM/VIAL		N007600 003	
	5GM/VIAL		N007600 005	
	10GM/VIAL		N007600 009	
THIETHYLPERAZINE MALATE				
INJECTABLE;INJECTION				
TORECAN				
NOVARTIS	5MG/ML		N012754 002	
THIETHYLPERAZINE MALEATE				
SUPPOSITORY;RECTAL				
TORECAN				
NOVARTIS	10MG		N013247 001	
TABLET;ORAL				
TORECAN				
NOVARTIS	10MG		N012753 001	

THIOPENTAL SODIUM				
SUSPENSION;RECTAL				
PENTOTHAL				
ABBOTT	400MG/GM	N011679	001	
THIORIDAZINE				
SUSPENSION;ORAL				
MELLARIL-S				
NOVARTIS	EQ 25MG HYDROCHLORIDE/5ML **	N017923	001	
	EQ 100MG HYDROCHLORIDE/5ML **	N017923	002	
THIORIDAZINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
MELLARIL				
NOVARTIS	30MG/ML **	N011808	012	
	100MG/ML **	N011808	018	
THIORIDAZINE HYDROCHLORIDE				
ACTAVIS MID ATLANTIC	100MG/ML	A088229	001	Aug 23, 1983
ALPHARMA US PHARMS	30MG/ML	A087766	001	Apr 26, 1983
ANI PHARMS INC	30MG/ML	A089602	001	Nov 09, 1987
	100MG/ML	A089603	001	Nov 09, 1987
HI TECH PHARMA	30MG/ML	A040125	001	Aug 16, 1996
	100MG/ML	A040126	001	Aug 16, 1996
PHARM ASSOC	30MG/ML	A040187	001	Aug 28, 1997
	100MG/ML	A040213	001	May 29, 1998
SANDOZ	30MG/ML	A088307	001	Nov 23, 1983
	100MG/ML	A088308	001	Nov 23, 1983
WOCKHARDT	30MG/ML	A088258	001	Jul 25, 1983
	100MG/ML	A088227	001	Jul 05, 1983
THIORIDAZINE HYDROCHLORIDE INTENSOL				
ROXANE	30MG/ML	A088941	001	Dec 16, 1985
	100MG/ML	A088942	001	Dec 16, 1985
TABLET;ORAL				
MELLARIL				
+ NOVARTIS	10MG **	N011808	003	
+	15MG **	N011808	016	
+	25MG **	N011808	006	
+	50MG **	N011808	011	
+	100MG **	N011808	009	
+	150MG **	N011808	017	
+	200MG **	N011808	015	
THIORIDAZINE HYDROCHLORIDE				
ANI PHARMS INC	10MG	A088270	001	Apr 14, 1983
	10MG	A088493	001	May 17, 1985
	15MG	A088271	001	Apr 14, 1983
	25MG	A088272	001	Apr 14, 1983
	50MG	A088194	001	Apr 14, 1983
	100MG	A088273	001	Oct 03, 1983
	100MG	A088456	001	May 17, 1985
FOSUN PHARMA	10MG	A088131	001	Aug 30, 1983
	15MG	A088132	001	Aug 30, 1983
	25MG	A088133	001	Aug 30, 1983
	50MG	A088134	001	Aug 30, 1983
	100MG	A088135	001	Nov 20, 1984
	150MG	A088136	001	Sep 17, 1986
	200MG	A088137	001	Sep 17, 1986
MUTUAL PHARM	10MG	A088375	001	Nov 18, 1983
	25MG	A087264	001	Nov 18, 1983
	50MG	A088370	001	Nov 18, 1983
	100MG	A088379	001	Nov 16, 1983
MYLAN	10MG	A088332	001	Jun 27, 1983
	25MG	A088333	001	Jun 27, 1983
	50MG	A088334	001	Jun 27, 1983
	100MG	A088335	001	Nov 18, 1983
PAR PHARM	10MG	A088351	001	Dec 05, 1983
	15MG	A088352	001	Dec 05, 1983
	25MG	A088336	001	Dec 05, 1983
	50MG	A088322	001	Dec 05, 1983
	100MG	A088480	001	Dec 29, 1983
	150MG	A089764	001	Feb 09, 1988

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL

THIORIDAZINE HYDROCHLORIDE				
	200MG	A089765	001	Feb 09, 1988
ROXANE	10MG	A088663	001	Mar 15, 1984
	25MG	A088664	001	Mar 15, 1984
	50MG	A088665	001	Mar 15, 1984
	100MG	A089048	001	Feb 26, 1985
SUN PHARM INDUSTRIES	15MG	A088461	001	Nov 18, 1983
	150MG	A088737	001	Sep 26, 1984
	200MG	A088738	001	Oct 16, 1984
SUPERPHARM	10MG	A089103	001	Jul 02, 1985
	25MG	A089104	001	Jul 02, 1985
	50MG	A089105	001	Jul 02, 1985
WATSON LABS	10MG	A088412	001	Sep 12, 1983
	10MG	A088476	001	Nov 08, 1983
	10MG	A088561	001	May 11, 1984
	15MG	A088345	001	Jul 28, 1983
	15MG	A088562	001	May 11, 1984
	25MG	A088296	001	Jul 28, 1983
	25MG	A088478	001	Nov 08, 1983
	25MG	A088755	001	Jul 24, 1984
	50MG	A088323	001	Jul 28, 1983
	50MG	A088479	001	Nov 08, 1983
	50MG	A088563	001	May 11, 1984
	100MG	A088284	001	Aug 25, 1983
	100MG	A088564	001	May 11, 1984
	100MG	A088736	001	Jul 24, 1984
	150MG	A088410	001	Mar 05, 1984
	150MG	A088869	001	Jun 28, 1985
	200MG	A088381	001	Mar 14, 1984
WATSON LABS TEVA	15MG	A088477	001	Nov 08, 1983
	25MG	A088567	001	May 11, 1984
	200MG	A088872	001	Apr 26, 1985
WEST WARD	10MG	A088658	001	Mar 26, 1984
	15MG	A088659	001	Mar 26, 1984
	25MG	A088660	001	Mar 26, 1984
	50MG	A088661	001	Mar 26, 1984

THIOTEPA

INJECTABLE;INJECTION

THIOPLEX				
+ IMMUNEX	15MG/VIAL **	N020058	001	Dec 22, 1994
THIOTEPA				
FRESENIUS KABI USA	15MG/VIAL	A075698	001	Sep 20, 2001
IMMUNEX	15MG/VIAL	N011683	001	
TEVA PARENTERAL	15MG/VIAL **	A075730	001	Apr 20, 2001
	30MG/VIAL **	A075730	002	Apr 20, 2001

THIOTHIXENE

CAPSULE;ORAL

NAVANE				
+ PFIZER	1MG **	N016584	001	
+	2MG **	N016584	002	
+	5MG **	N016584	003	
+	10MG **	N016584	004	
+	20MG **	N016584	005	
THIOTHIXENE				
AM THERAP	1MG	A071884	001	Aug 12, 1987
	2MG	A071885	001	Aug 12, 1987
	5MG	A071886	001	Aug 12, 1987
	10MG	A071887	001	Aug 12, 1987
	20MG	A072200	001	Dec 17, 1987
SANDOZ	1MG	A071529	002	Jun 24, 1987
	2MG	A071529	003	Jun 24, 1987
	5MG	A071529	001	Jun 24, 1987
	10MG	A071529	004	Jun 24, 1987
WATSON LABS	1MG	A070600	001	Jun 05, 1987
	2MG	A070601	001	Jun 05, 1987
	2MG	A071626	001	Jun 25, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

THIOTHIXENE				
CAPSULE;ORAL				
THIOTHIXENE				
	5MG	A070602	001	Jun 05, 1987
	5MG	A071627	001	Jun 25, 1987
	10MG	A070603	001	Jun 05, 1987
	10MG	A071628	001	Jun 25, 1987
THIOTHIXENE HYDROCHLORIDE				
CONCENTRATE;ORAL				
NAVANE				
PFIZER	EQ 5MG BASE/ML	N016758	001	
THIOTHIXENE HYDROCHLORIDE				
ALPHARMA US PHARMS	EQ 5MG BASE/ML	A070969	001	Oct 16, 1987
PACO	EQ 1MG BASE/ML	A071917	001	Sep 20, 1989
	EQ 5MG BASE/ML	A071939	001	Dec 16, 1988
TEVA	EQ 5MG BASE/ML	A071184	001	Jun 22, 1987
TEVA PHARMS	EQ 5MG BASE/ML	A071554	001	Oct 16, 1987
THIOTHIXENE HYDROCHLORIDE INTENSOL				
CYCLE PHARMS LTD	EQ 5MG BASE/ML	A073494	001	Jun 30, 1992
INJECTABLE;INJECTION				
NAVANE				
PFIZER	EQ 2MG BASE/ML	N016904	001	
	EQ 10MG BASE/VIAL	N016904	002	
THYROGLOBULIN				
TABLET;ORAL				
PROLOID				
PARKE DAVIS	16MG	N002245	009	
	32MG	N002245	005	
	65MG	N002245	002	
	100MG	N002245	008	
	130MG	N002245	010	
	200MG	N002245	007	
	325MG	N002245	004	
THYROGLOBULIN				
IMPAX LABS	64.8MG	A080151	001	
THYROTROPIN				
INJECTABLE;INJECTION				
THYTROPAR				
SANOFI AVENTIS US	10 IU/VIAL	N008682	001	
TIAGABINE HYDROCHLORIDE				
TABLET;ORAL				
GABITRIL				
CEPHALON	6MG	N020646	006	Nov 29, 2005
	8MG	N020646	007	Nov 29, 2005
	10MG	N020646	008	Nov 29, 2005
	20MG	N020646	004	Sep 30, 1997
TICARCILLIN DISODIUM				
INJECTABLE;INJECTION				
TICAR				
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N050497	001	
	EQ 3GM BASE/VIAL	A062690	001	Dec 19, 1986
	EQ 3GM BASE/VIAL	N050497	002	
	EQ 6GM BASE/VIAL	N050497	003	
	EQ 20GM BASE/VIAL	N050497	004	
	EQ 30GM BASE/VIAL	N050497	005	Apr 04, 1984
TICLOPIDINE HYDROCHLORIDE				
TABLET;ORAL				
TICLID				
ROCHE PALO	125MG	N019979	001	Mar 24, 1993
	250MG	N019979	002	Oct 31, 1991
TICLOPIDINE HYDROCHLORIDE				
ACTAVIS ELIZABETH	250MG	A075253	001	Aug 20, 1999
MYLAN	250MG	A075161	001	Sep 13, 1999
	250MG	A075316	001	Nov 02, 1999
WATSON LABS	250MG	A075309	001	Apr 26, 2000
YAOPHARMA CO LTD	250MG	A075318	001	Aug 20, 1999

TICLOPIDINE HYDROCHLORIDE				
TABLET;ORAL				
TICLOPIDINE HYDROCHLORIDE				
	250MG	A075326	001	Aug 20, 1999
TILUDRONATE DISODIUM				
TABLET;ORAL				
SKELID				
+ SANOFI AVENTIS US	EQ 200MG BASE **	N020707	001	Mar 07, 1997
TIMOLOL MALEATE				
SOLUTION/DROPS;OPHTHALMIC				
TIMOLOL MALEATE				
AKORN	EQ 0.25% BASE	A074465	001	Mar 25, 1997
	EQ 0.25% BASE	A074515	001	Mar 25, 1997
APOTEX INC	EQ 0.25% BASE	A075411	001	Sep 08, 2000
	EQ 0.5% BASE	A075412	001	Sep 08, 2000
FOUGERA	EQ 0.25% BASE	A074667	001	Mar 25, 1997
	EQ 0.5% BASE	A074668	001	Mar 25, 1997
TABLET;ORAL				
BLOCADREN				
MERCK	5MG **	N018017	001	
	10MG **	N018017	002	
	20MG **	N018017	004	
TIMOLOL MALEATE				
QUANTUM PHARMICS	5MG	A072466	001	May 19, 1989
	10MG	A072467	001	May 19, 1989
	20MG	A072468	001	May 19, 1989
TEVA	5MG	A072648	001	Jun 16, 1993
	10MG	A072649	001	Jun 16, 1993
	20MG	A072650	001	Jun 16, 1993
USL PHARMA	5MG	A072001	001	Apr 11, 1989
	10MG	A072002	001	Apr 11, 1989
	20MG	A072003	001	Apr 11, 1989
WATSON LABS	5MG	A072269	001	Apr 11, 1989
	5MG	A072917	001	Jul 31, 1991
	10MG	A072270	001	Apr 11, 1989
	10MG	A072918	001	Jul 31, 1991
	20MG	A072271	001	Apr 11, 1989
	20MG	A072919	001	Jul 31, 1991
YAOPHARMA CO LTD	5MG	A072550	001	Apr 13, 1989
	10MG	A072551	001	Apr 13, 1989
	20MG	A072552	001	Apr 13, 1989
TINZAPARIN SODIUM				
INJECTABLE;INJECTION				
INNOHEP				
LEO PHARMA AS	20,000 IU/ML	N020484	001	Jul 14, 2000
TIOCONAZOLE				
CREAM;TOPICAL				
TZ-3				
PFIZER	1%	N018682	001	Feb 18, 1983
TIROFIBAN HYDROCHLORIDE				
INJECTABLE;INJECTION				
AGGRASTAT				
MEDICURE	EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML)	N020912	001	May 14, 1998
	EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)	N020913	001	May 14, 1998
TIZANIDINE HYDROCHLORIDE				
TABLET;ORAL				
TIZANIDINE HYDROCHLORIDE				
ACTAVIS ELIZABETH	EQ 2MG BASE	A076283	001	Jul 12, 2002
	EQ 4MG BASE	A076283	002	Jul 12, 2002
BARR	EQ 2MG BASE	A076371	001	Apr 09, 2003
	EQ 4MG BASE	A076371	002	Apr 09, 2003
IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076321	001	Sep 30, 2004
	EQ 4MG BASE	A076321	002	Sep 30, 2004
MYLAN PHARMS INC	EQ 2MG BASE	A076282	001	Dec 16, 2003
	EQ 4MG BASE	A076282	002	Dec 16, 2003

TIZANIDINE HYDROCHLORIDE				
TABLET;ORAL				
ZANAFLEX				
+	COVIS PHARMA BV	EQ 2MG BASE **	N020397 002	Feb 04, 2000
TOBRAMYCIN				
SOLUTION/DROPS;OPHTHALMIC				
TOBRAMYCIN				
	ALCON PHARMS LTD	0.3%	A063176 001	May 25, 1994
	APOTEX INC	0.3%	A065087 001	Feb 25, 2002
TOBRAMYCIN SULFATE				
INJECTABLE;INJECTION				
NEBCIN				
	LILLY	EQ 10MG BASE/ML	A062008 004	
		EQ 10MG BASE/ML	A062707 001	Apr 29, 1987
+		EQ 10MG BASE/ML **	N050477 005	
		EQ 40MG BASE/ML	A062008 001	
+		EQ 1.2GM BASE/VIAL **	N050519 001	
TOBRAMYCIN SULFATE				
	APOTHECON	EQ 10MG BASE/ML	A064021 001	May 31, 1994
		EQ 40MG BASE/ML	A064021 002	May 31, 1994
		EQ 40MG BASE/ML	A064026 001	May 31, 1994
	HOSPIRA	EQ 10MG BASE/ML	A063080 001	Apr 30, 1991
		EQ 40MG BASE/ML	A063161 001	May 29, 1991
	IGI LABS INC	EQ 10MG BASE/ML	A063119 001	Oct 31, 1994
		EQ 40MG BASE/ML	A063120 001	Oct 31, 1994
		EQ 40MG BASE/ML	A063121 001	Oct 31, 1994
		EQ 40MG BASE/ML	A063122 001	Oct 31, 1994
	WATSON LABS INC	EQ 10MG BASE/ML	A062945 001	Aug 09, 1989
		EQ 40MG BASE/ML	A062945 002	Aug 09, 1989
	WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A063113 001	Apr 26, 1991
		EQ 10MG BASE/ML	A063128 001	Nov 27, 1991
		EQ 40MG BASE/ML	A063118 001	Jul 29, 1991
		EQ 40MG BASE/ML	A063127 001	Nov 27, 1991
TOBRAMYCIN SULFATE (PHARMACY BULK)				
	HOSPIRA	EQ 40MG BASE/ML **	A063116 001	May 18, 1992
TOCAINIDE HYDROCHLORIDE				
TABLET;ORAL				
TONOCARD				
	ASTRAZENECA	400MG	N018257 001	Nov 09, 1984
		600MG	N018257 002	Nov 09, 1984
TOLAZAMIDE				
TABLET;ORAL				
TOLAZAMIDE				
	BARR	100MG	A070162 001	Jan 14, 1986
		250MG	A070163 001	Jan 14, 1986
		500MG	A070164 001	Jan 14, 1986
	DURAMED PHARMS BARR	100MG	A070165 001	Jan 10, 1986
		250MG	A070166 001	Jan 10, 1986
		500MG	A070167 001	Jan 10, 1986
	G AND W LABS INC	100MG	N018894 001	Nov 02, 1984
		250MG	N018894 002	Nov 02, 1984
		500MG	N018894 003	Nov 02, 1984
	INTERPHARM	250MG	A071270 001	Sep 23, 1986
		500MG	A071271 001	Sep 23, 1986
	PAR PHARM	100MG	A070159 001	Jan 06, 1986
		250MG	A070160 001	Jan 06, 1986
		500MG	A070161 001	Jan 06, 1986
	SUN PHARM INDUSTRIES	100MG	A071357 001	Jul 16, 1987
		250MG	A071358 001	Jul 16, 1987
		500MG	A071359 001	Jul 16, 1987
	SUPERPHARM	250MG	A070763 001	Jun 16, 1986
		500MG	A070764 001	Jun 16, 1986
	USL PHARMA	100MG	A071355 001	Jan 11, 1988
		250MG	A070168 001	Apr 02, 1986
		500MG	A070169 001	Apr 02, 1986
	WATSON LABS	100MG	A070242 001	Aug 01, 1986
		100MG	A070513 001	Jan 09, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

TOLAZAMIDE				
TABLET;ORAL				
TOLAZAMIDE				
	250MG	A070243	001	Aug 01, 1986
	250MG	A070514	001	Jan 09, 1986
	500MG	A070244	001	Aug 01, 1986
	500MG	A070515	001	Jan 09, 1986
YAOPHARMA CO LTD	100MG	A071633	001	Dec 09, 1987
	250MG	A070289	001	Mar 13, 1986
	500MG	A070290	001	Mar 13, 1986
TOLINASE				
+ PHARMACIA AND UPJOHN	100MG **	N015500	002	
+	250MG **	N015500	004	
+	500MG **	N015500	005	
TOLAZOLINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
PRISCOLINE				
NOVARTIS	25MG/ML	N006403	005	Feb 22, 1985
TOLBUTAMIDE				
TABLET;ORAL				
ORINASE				
PHARMACIA AND UPJOHN	250MG **	N010670	002	
	500MG **	N010670	001	
TOLBUTAMIDE				
ALRA	500MG	A086141	001	
ASCOT	500MG	A087541	001	Mar 01, 1983
BARR	500MG	A087121	001	
DAVA PHARMS INC	500MG	A086926	001	
IVAX PHARMS	500MG	A087093	001	
PARKE DAVIS	500MG	A086047	001	
PUREPAC PHARM	500MG	A088950	001	Jun 17, 1985
SANDOZ	500MG	N012678	001	
SUPERPHARM	500MG	A088893	001	Nov 19, 1984
VANGARD	500MG	A087876	001	Apr 20, 1982
WATSON LABS	250MG	A089110	001	May 29, 1987
	500MG	A086109	001	
	500MG	A087318	001	
	500MG	A089111	001	May 29, 1987
YAOPHARMA CO LTD	500MG	A086574	001	
TOLBUTAMIDE SODIUM				
INJECTABLE;INJECTION				
ORINASE DIAGNOSTIC				
PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL	N012095	001	
TOLCAPONE				
TABLET;ORAL				
TASMAR				
VALEANT PHARMS LLC	200MG	N020697	002	Jan 29, 1998
TOLMETIN SODIUM				
CAPSULE;ORAL				
TOLECTIN DS				
ORTHO MCNEIL JANSSEN	EQ 400MG BASE	N018084	001	
TOLMETIN SODIUM				
ACTAVIS ELIZABETH	EQ 400MG BASE	A073308	001	Jan 24, 1992
FOSUN PHARMA	EQ 400MG BASE	A073462	001	Apr 30, 1992
IVAX SUB TEVA PHARMS	EQ 400MG BASE	A073392	001	Jan 24, 1992
SUN PHARM INDUSTRIES	EQ 400MG BASE	A073311	001	Nov 27, 1991
TEVA	EQ 400MG BASE	A073519	001	May 29, 1992
TABLET;ORAL				
TOLECTIN				
ORTHO MCNEIL JANSSEN	EQ 200MG BASE	N017628	001	
TOLECTIN 600				
ORTHO MCNEIL JANSSEN	EQ 600MG BASE	N017628	002	Mar 08, 1989
TOLMETIN SODIUM				
ACTAVIS ELIZABETH	EQ 600MG BASE	A073527	001	Jun 30, 1992
FOSUN PHARMA	EQ 200MG BASE	A073588	001	Jul 31, 1992
	EQ 600MG BASE	A074002	001	Sep 27, 1993
G AND W LABS INC	EQ 600MG BASE	A074399	001	Mar 28, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

TOLMETIN SODIUM				
TABLET;ORAL				
TOLMETIN SODIUM				
	EQ 600MG BASE	A074729	001	Feb 27, 1997
SUN PHARM INDUSTRIES	EQ 200MG BASE	A073310	001	Nov 27, 1991
TOLTERODINE TARTRATE				
TABLET;ORAL				
TOLTERODINE TARTRATE				
APOTEX CORP	1MG	A200164	001	Sep 25, 2012
	2MG	A200164	002	Sep 25, 2012
TOLVAPTAN				
TABLET;ORAL				
SAMSCA				
+ OTSUKA AMERICA PHARM	60MG **	N022275	003	May 19, 2009
TOPIRAMATE				
CAPSULE;ORAL				
TOPAMAX SPRINKLE				
JANSSEN PHARMS	50MG	N020844	003	Oct 26, 1998
TOPIRAMATE				
BARR	15MG	A076448	001	Apr 15, 2009
	25MG	A076448	002	Apr 15, 2009
FOSUN PHARMA	15MG	A079206	001	Oct 14, 2009
	25MG	A079206	002	Oct 14, 2009
MYLAN	15MG	A078418	001	Oct 14, 2009
	25MG	A078418	002	Oct 14, 2009
TABLET;ORAL				
TOPAMAX				
JANSSEN PHARMS	300MG	N020505	003	Dec 24, 1996
	400MG	N020505	006	Dec 24, 1996
TOPIRAMATE				
ACTAVIS TOTOWA	25MG	A078637	001	Feb 27, 2013
	50MG	A078637	002	Feb 27, 2013
	100MG	A078637	003	Feb 27, 2013
	200MG	A078637	004	Feb 27, 2013
BARR	25MG	A076315	001	Mar 27, 2009
	100MG	A076315	002	Mar 27, 2009
	200MG	A076315	003	Mar 27, 2009
HIKMA PHARMS	25MG	A091185	001	Nov 25, 2013
	50MG	A091185	002	Nov 25, 2013
	100MG	A091185	003	Nov 25, 2013
	200MG	A091185	004	Nov 25, 2013
MYLAN	25MG	A076314	001	Mar 27, 2009
	50MG	A076314	002	Mar 27, 2009
	100MG	A076314	003	Mar 27, 2009
	200MG	A076314	004	Mar 27, 2009
PLIVA HRVATSKA DOO	25MG	A077905	001	Mar 30, 2009
	50MG	A077905	002	Mar 30, 2009
	100MG	A077905	003	Mar 30, 2009
	200MG	A077905	004	Mar 30, 2009
ROXANE	25MG	A076306	001	Mar 27, 2009
	50MG	A076306	002	Mar 27, 2009
	100MG	A076306	003	Mar 27, 2009
	200MG	A076306	004	Mar 27, 2009
WATSON LABS	25MG	A077643	001	Mar 27, 2009
	50MG	A077643	002	Mar 27, 2009
	100MG	A077643	003	Mar 27, 2009
	200MG	A077643	004	Mar 27, 2009
WOCKHARDT USA	25MG	A090353	001	Sep 01, 2010
	50MG	A090353	002	Sep 01, 2010
	100MG	A090353	003	Sep 01, 2010
	200MG	A090353	004	Sep 01, 2010

TOPOTECAN HYDROCHLORIDE					
INJECTABLE;INJECTION					
TOPOTECAN HYDROCHLORIDE					
	FRESENIUS KABI ONCOL	EQ 4MG BASE/VIAL	A091376	001	Nov 29, 2010
	SUN PHARM INDS LTD	EQ 4MG BASE/VIAL	A202203	001	Aug 29, 2013
SOLUTION;INTRAVENOUS					
TOPOTECAN					
+	SANDOZ INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML) **	N200199	001	Feb 25, 2011
+		EQ 3MG BASE/3ML (EQ 1MG BASE/ML) **	N200199	002	Feb 25, 2011
+		EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **	N200199	003	Feb 25, 2011
TORSEMIDE					
INJECTABLE;INJECTION					
DEMADEX					
+	ROCHE	50MG/5ML (10MG/ML) **	N020137	002	Aug 23, 1993
+		20MG/2ML (10MG/ML) **	N020137	001	Aug 23, 1993
TORSEMIDE					
	LUITPOLD	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010
		50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010
	WEST-WARD PHARMS INT	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008
		50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008
TABLET;ORAL					
TORSEMIDE					
	SUN PHARM INDS	5MG	A078478	001	Feb 26, 2008
		10MG	A078478	002	Feb 26, 2008
		20MG	A078478	003	Feb 26, 2008
		100MG	A078478	004	Feb 26, 2008
TRAMADOL HYDROCHLORIDE					
TABLET;ORAL					
TRAMADOL HYDROCHLORIDE					
	ACCORD HLTHCARE	50MG	A202390	001	May 16, 2013
	ACTAVIS ELIZABETH	50MG	A075960	001	Jun 19, 2002
	ASTA	50MG	A075974	001	Jul 12, 2002
	FOSUN PHARMA	50MG	A075968	001	Jun 25, 2002
	IVAX SUB TEVA PHARMS	50MG	A075963	001	Jul 03, 2002
	MYLAN PHARMS INC	50MG	A075980	001	Nov 21, 2002
	NORTHSTAR HLTHCARE	50MG	A078935	001	May 26, 2010
	WATSON LABS	50MG	A075962	001	Jun 24, 2002
ULTRAM					
	JANSSEN PHARMS	100MG	N020281	001	Mar 03, 1995
TABLET, EXTENDED RELEASE;ORAL					
RYZOLT					
+	PURDUE PHARMA	100MG **	N021745	001	Dec 30, 2008
+		200MG **	N021745	002	Dec 30, 2008
+		300MG **	N021745	003	Dec 30, 2008
ULTRAM ER					
+	VALEANT PHARMS	100MG	N021692	001	Sep 08, 2005
+		200MG	N021692	002	Sep 08, 2005
+		300MG	N021692	003	Sep 08, 2005
TABLET, ORALLY DISINTEGRATING;ORAL					
RYBIX ODT					
	SHIONOGI INC	50MG	N021693	001	May 05, 2005
TRAMETINIB DIMETHYL SULFOXIDE					
TABLET;ORAL					
MEKINIST					
+	NOVARTIS PHARMS CORP	EQ 1MG	N204114	002	May 29, 2013
TRANDOLAPRIL					
TABLET;ORAL					
MAVIK					
+	ABBVIE	1MG	N020528	001	Apr 26, 1996
+		2MG	N020528	002	Apr 26, 1996
+		4MG	N020528	003	Apr 26, 1996
TRANDOLAPRIL					
	CIPLA	1MG	A077307	002	Jun 12, 2007
		2MG	A077307	001	Jun 12, 2007
		4MG	A077307	003	Jun 12, 2007
	DR REDDYS LABS LTD	1MG	A078493	001	Aug 25, 2008
		2MG	A078493	002	Aug 25, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

TRANDOLAPRIL					
TABLET;ORAL					
TRANDOLAPRIL					
	4MG		A078493	003	Aug 25, 2008
EPIC PHARMA LLC	1MG		A077256	001	Jun 12, 2007
	2MG		A077256	002	Jun 12, 2007
	4MG		A077256	003	Jun 12, 2007
INVAGEN PHARMS	1MG		A078320	001	Jun 12, 2007
	2MG		A078320	002	Jun 12, 2007
	4MG		A078320	003	Jun 12, 2007
MYLAN	1MG		A078346	001	Apr 28, 2008
	2MG		A078346	002	Apr 28, 2008
	4MG		A078346	003	Apr 28, 2008
WATSON LABS	1MG		A077805	001	Jun 12, 2007
	2MG		A077805	002	Jun 12, 2007
	4MG		A077805	003	Jun 12, 2007
TRANEXAMIC ACID					
TABLET;ORAL					
CYKLOKAPRON					
PHARMACIA AND UPJOHN	500MG		N019280	001	Dec 30, 1986
TRANEXAMIC ACID					
AMERIGEN PHARMS LTD	650MG		A203256	001	Jul 25, 2016
TRAVOPROST					
SOLUTION/DROPS;OPHTHALMIC					
IZBA					
+ NOVARTIS PHARMS CORP	0.003% **		N204822	001	May 15, 2014
TRAVATAN					
+ ALCON PHARMS LTD	0.004% **		N021257	001	Mar 16, 2001
TRAZODONE HYDROCHLORIDE					
TABLET;ORAL					
DESYREL					
+ PRAGMA	50MG **		N018207	001	
+	100MG **		N018207	002	
+	150MG **		N018207	003	Mar 25, 1985
+	300MG **		N018207	004	Nov 07, 1988
TRAZODONE HYDROCHLORIDE					
AM THERAP	50MG		A071139	001	Oct 29, 1986
	100MG		A071140	001	Oct 29, 1986
AUROLIFE PHARMA LLC	50MG		A072484	001	Apr 30, 1990
FOSUN PHARMA	100MG		A072483	001	Apr 30, 1990
MYLAN	50MG		A071405	001	Feb 27, 1991
	100MG		A071406	001	Feb 27, 1991
MYLAN PHARMS INC	50MG		A090514	001	Jun 02, 2009
	100MG		A090514	002	Jun 02, 2009
	150MG		A090514	003	Jun 02, 2009
	300MG		A090514	004	Jun 02, 2009
QUANTUM PHARMICS	100MG		A070921	001	Dec 01, 1986
TEVA	150MG		A074357	001	Apr 30, 1997
USL PHARMA	50MG		A070491	001	Apr 29, 1987
	100MG		A070492	001	Apr 29, 1987
WATSON LABS	50MG		A070857	001	Oct 10, 1986
	50MG		A071112	001	Nov 17, 1986
	100MG		A070858	001	Oct 10, 1986
	100MG		A071113	001	Nov 17, 1986
TRIALODINE					
QUANTUM PHARMICS	50MG		A070942	001	Dec 01, 1986
TABLET, EXTENDED RELEASE;ORAL					
OLEPTRO					
+ ANGELINI PHARMA	150MG **		N022411	001	Feb 02, 2010
+	300MG **		N022411	002	Feb 02, 2010
TRETINOIN					
CAPSULE;ORAL					
VESANOID					
+ CHEPLAPHARM	10MG **		N020438	001	Nov 22, 1995
CREAM;TOPICAL					
TRETINOIN					
ALLERGAN SALES LLC	0.0375%		A090098	001	Mar 22, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

TRETINOIN				
CREAM;TOPICAL				
TRETINOIN				
	0.075%	A202209 001	Oct 11, 2012	
SOLUTION;TOPICAL				
RETIN-A				
+ VALEANT INTL	0.05%	N016921 001		
TRETINOIN				
TEVA PHARMS	0.05%	A074873 001	Jun 19, 1998	
WOCKHARDT	0.05%	A075260 001	Jan 25, 1999	
SWAB;TOPICAL				
RETIN-A				
VALEANT INTL	0.05%	N016921 002		
TRIAMCINOLONE				
TABLET;ORAL				
ARISTOCORT				
ASTELLAS	1MG	N011161 009		
	2MG	N011161 004		
	4MG	N011161 007		
	8MG	N011161 011		
	16MG	N011161 010		
KENACORT				
DELCOR ASSET CORP	1MG	N011283 003		
	2MG	N011283 008		
	4MG	N011283 006		
	8MG	N011283 010		
TRIAMCINOLONE				
BARR	2MG	A084286 001		
	2MG	A084318 001		
	4MG	A084267 001		
	4MG	A084319 001		
	8MG	A084268 001		
	8MG	A084320 001		
IMPAX LABS	4MG	A084340 001		
IVAX SUB TEVA PHARMS	4MG	A083750 001		
MYLAN	2MG	A084406 001		
PUREPAC PHARM	2MG	A084020 002		
	4MG	A084020 003		
ROXANE	2MG	A084708 001		
	4MG	A084709 001		
	8MG	A084707 001		
SANDOZ	4MG	A085601 001		
TEVA	4MG	A084775 001		
WATSON LABS	4MG	A084270 001		
	4MG	A085834 001		
TRIAMCINOLONE ACETONIDE				
AEROSOL, METERED;INHALATION				
AZMACORT				
ABBVIE	0.1MG/INH	N018117 001	Apr 23, 1982	
AEROSOL, METERED;NASAL				
NASACORT				
SANOFI AVENTIS US	0.055MG/INH	N019798 001	Jul 11, 1991	
CREAM;TOPICAL				
ARISTOCORT				
ASTELLAS	0.025%	A083017 003		
	0.1%	A083016 004		
	0.5%	A083015 002		
ARISTOCORT A				
ASTELLAS	0.025%	A083017 004		
	0.025%	A088818 001	Oct 16, 1984	
	0.1%	A083016 005		
	0.1%	A088819 001	Oct 16, 1984	
	0.5%	A083015 003		
	0.5%	A088820 001	Oct 16, 1984	
FLUTEX				
IVAX PHARMS	0.025%	A085539 001		
	0.1%	A085539 002		
	0.5%	A085539 003		

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL				
KENALOG				
	DELCOR ASSET CORP	0.5%	A083943 001	
KENALOG-H				
	DELCOR ASSET CORP	0.1%	A086240 001	
TRIACET				
	TEVA	0.025%	A084908 001	
		0.1%	A084908 002	
		0.5%	A084908 003	
TRIACORT				
	SOLVAY	0.1%	A087113 001	
TRIAMCINOLONE ACETONIDE				
	ACTAVIS MID ATLANTIC	0.1%	A087798 001	Jun 04, 1982
	ALPHARMA US PHARMS	0.025%	A087797 001	Jun 07, 1982
	AMBIX	0.025%	A087932 001	May 09, 1983
	MORTON GROVE	0.025%	A088094 001	Sep 01, 1983
		0.1%	A088095 001	Sep 01, 1983
		0.5%	A088096 001	Sep 01, 1983
	PHARMADERM	0.025%	A087990 001	Jul 07, 1983
		0.1%	A087991 001	Jul 07, 1983
		0.5%	A087992 001	Jul 07, 1983
	PHARMAFAIR	0.025%	A087921 001	Aug 10, 1982
		0.1%	A087912 001	Aug 10, 1982
		0.5%	A087922 001	Aug 10, 1982
	TARO	0.025%	A040038 001	Oct 26, 1994
		0.025%	A086277 001	
		0.1%	A086276 001	
		0.5%	A086275 001	
	TOPIDERM	0.025%	A089274 001	Feb 21, 1989
		0.1%	A089275 001	Feb 21, 1989
		0.5%	A089276 001	Feb 21, 1989
TRIATEX				
	IVAX PHARMS	0.025%	A087430 001	Nov 01, 1988
		0.1%	A087429 001	Nov 01, 1988
		0.5%	A087428 001	Nov 01, 1988
TRYMEX				
	SAVAGE LABS	0.025%	A088196 001	Mar 25, 1983
		0.1%	A088197 001	Mar 25, 1983
		0.5%	A088198 001	Mar 25, 1983
GEL;TOPICAL				
ARISTOGEL				
	ASTELLAS	0.1%	A083380 001	
INJECTABLE;INJECTION				
TRIAMCINOLONE ACETONIDE				
	PARNELL	3MG/ML	N019503 001	Oct 16, 1987
	SANDOZ INC	10MG/ML	A090166 001	May 27, 2009
		40MG/ML	A090164 001	Jun 01, 2009
	WATSON LABS	40MG/ML	A085825 001	
INJECTABLE;INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL				
TRIVARIS				
+	ALLERGAN	8MG/0.1ML (8MG/0.1ML) **	N022220 001	Jun 16, 2008
LOTION;TOPICAL				
KENALOG				
	DELCOR ASSET CORP	0.025% **	A084343 001	
+		0.025% **	N011602 003	
		0.1% **	A084343 002	
+		0.1% **	N011602 001	
TRIAMCINOLONE ACETONIDE				
	ALPHARMA US PHARMS	0.025%	A087191 001	Sep 08, 1982
		0.1%	A087192 001	Sep 08, 1982
OINTMENT;TOPICAL				
ARISTOCORT				
	ASTELLAS	0.1%	A080750 004	
		0.5% **	A080745 002	
ARISTOCORT A				
	ASTELLAS	0.1%	A080750 003	
		0.1%	A088780 001	Oct 01, 1984
		0.5% **	A080745 003	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

TRIAMCINOLONE ACETONIDE				
OINTMENT;TOPICAL				
ARISTOCORT A				
	0.5%	A088781	001	Oct 05, 1984
FLUTEX				
IVAX PHARMS	0.025%	A087375	001	Nov 01, 1988
	0.1%	A087377	001	Nov 01, 1988
	0.5%	A087376	001	Nov 01, 1988
KENALOG				
DELCOR ASSET CORP	0.5% **	A083944	001	
+ MYLAN PHARMS INC	0.025%	N011600	003	
+	0.1%	N011600	001	
TRIAMCINOLONE ACETONIDE				
ACTAVIS MID ATLANTIC	0.1%	A087799	001	Jun 07, 1982
ALPHARMA US PHARMS	0.5%	A089913	001	Dec 23, 1988
MORTON GROVE	0.025%	A088090	001	Sep 01, 1983
	0.1%	A088091	001	Sep 01, 1983
	0.5%	A088092	001	Sep 01, 1983
PHARMADERM	0.025%	A088692	001	Aug 02, 1984
	0.1%	A088690	001	Aug 02, 1984
TARO	0.025%	A040040	001	Sep 30, 1994
	0.025%	A040374	001	Jun 05, 2001
	0.1%	A087902	001	Dec 27, 1982
	0.5%	A040386	001	Jun 05, 2001
TRYMEX				
SAVAGE LABS	0.025%	A088693	001	Aug 02, 1984
	0.1%	A088691	001	Aug 02, 1984
PASTE;DENTAL				
KENALOG IN ORABASE				
+ DELCOR ASSET CORP	0.1% **	N012097	001	
ORALONE				
TARO	0.1%	A071383	001	Jul 06, 1987
SPRAY, METERED;NASAL				
ALLERNAZE				
LUPIN ATLANTIS	0.05MG/SPRAY	N020120	001	Feb 04, 2000
NASACORT HFA				
SANOFI AVENTIS US	0.055MG/SPRAY	N020784	001	Apr 07, 2004
TRIAMCINOLONE ACETONIDE				
PERRIGO ISRAEL	0.055MG/SPRAY	A078104	001	Jul 30, 2009
TRIAMCINOLONE DIACETATE				
INJECTABLE;INJECTION				
ARISTOCORT				
FOSUN PHARMA	25MG/ML	N011685	003	
+	40MG/ML **	N012802	001	
TRIAMCINOLONE DIACETATE				
AKORN	25MG/ML	A085122	001	
	40MG/ML	A086394	001	
WATSON LABS	40MG/ML	A084072	001	
	40MG/ML	A085529	001	
SYRUP;ORAL				
ARISTOCORT				
ASTELLAS	2MG/5ML	N011960	004	
KENACORT				
DELCOR ASSET CORP	EQ 4MG BASE/5ML	N012515	001	
TRIAZOLAM				
TABLET;ORAL				
HALCION				
PHARMACIA AND UPJOHN	0.5MG	N017892	002	Nov 15, 1982
TRIAZOLAM				
WATSON LABS	0.125MG	A074445	001	Oct 20, 1995
	0.25MG	A074445	002	Oct 20, 1995
TRICHLORMETHIAZIDE				
TABLET;ORAL				
METAHYDRIN				
SANOFI AVENTIS US	2MG	N012594	001	Jun 16, 1988
	4MG	N012594	002	Jun 16, 1988

TRICHLORMETHIAZIDE				
TABLET;ORAL				
NAQUA				
	SCHERING	2MG	N012265 001	
		4MG	N012265 002	
TRICHLOREX				
	LANNETT	4MG	A083436 001	
		4MG	A085630 001	
TRICHLORMAS				
	MAST MM	4MG	A086259 001	
TRICHLORMETHIAZIDE				
	CHARTWELL RX	4MG	A085568 001	
	IMPAX LABS	4MG	A083967 001	
	PAR PHARM	2MG	A087007 001	
		4MG	A087005 001	
	SANDOZ	4MG	A086171 001	
	WATSON LABS	2MG	A083847 001	
		2MG	A086458 001	
		4MG	A083462 001	
		4MG	A083855 001	
		4MG	A085962 001	
TRICLOFOS SODIUM				
SOLUTION;ORAL				
TRICLOS				
	SANOFI AVENTIS US	1.5GM/15ML	N016830 001	
TABLET;ORAL				
TRICLOS				
	SANOFI AVENTIS US	750MG	N016809 002	
TRIDIHEXETHYL CHLORIDE				
INJECTABLE;INJECTION				
PATHILON				
	LEDERLE	10MG/ML	N009729 001	
TABLET;ORAL				
PATHILON				
	LEDERLE	25MG	N009489 005	
TRIFLUOPERAZINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
STELAZINE				
+	GLAXOSMITHKLINE	EQ 10MG BASE/ML **	N011552 006	
TRIFLUOPERAZINE HYDROCHLORIDE				
	FOSUN PHARMA	EQ 10MG BASE/ML	A085787 001	Apr 15, 1982
	WOCKHARDT	EQ 10MG BASE/ML	A088143 001	Jul 26, 1983
INJECTABLE;INJECTION				
STELAZINE				
+	GLAXOSMITHKLINE	EQ 2MG BASE/ML **	N011552 005	
TABLET;ORAL				
STELAZINE				
+	GLAXOSMITHKLINE	EQ 1MG BASE **	N011552 001	
+		EQ 2MG BASE **	N011552 002	
+		EQ 5MG BASE **	N011552 003	
+		EQ 10MG BASE **	N011552 004	
TRIFLUOPERAZINE HYDROCHLORIDE				
	DURAMED PHARMS BARR	EQ 1MG BASE	A088967 001	Apr 23, 1985
		EQ 2MG BASE	A088968 001	Apr 23, 1985
		EQ 5MG BASE	A088969 001	Apr 23, 1985
		EQ 10MG BASE	A088970 001	Apr 23, 1985
	IVAX PHARMS	EQ 1MG BASE	A087612 001	Nov 19, 1982
		EQ 2MG BASE	A087613 001	Nov 19, 1982
		EQ 5MG BASE	A087328 001	Nov 19, 1982
		EQ 10MG BASE	A087614 001	Nov 19, 1982
	SANDOZ	EQ 1MG BASE	A040153 001	Oct 25, 1996
		EQ 2MG BASE	A040153 002	Oct 25, 1996
		EQ 5MG BASE	A040153 003	Oct 25, 1996
		EQ 10MG BASE	A040153 004	Oct 25, 1996
	WATSON LABS	EQ 1MG BASE	A085975 001	Jun 23, 1988
		EQ 2MG BASE	A085976 001	Jun 23, 1988
		EQ 5MG BASE	A085973 001	Jun 23, 1988
		EQ 10MG BASE	A088710 001	Jun 23, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

TRIFLUPROMAZINE				
SUSPENSION;ORAL				
VESPRIN				
	APOTHECON	EQ 50MG HYDROCHLORIDE/5ML	N011491 004	
TRIFLUPROMAZINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
VESPRIN				
	APOTHECON	3MG/ML	N011325 005	
		10MG/ML	N011325 004	
		20MG/ML	N011325 001	
TABLET;ORAL				
VESPRIN				
	BRISTOL MYERS SQUIBB	10MG	N011123 001	
		25MG	N011123 002	
		50MG	N011123 003	
TRIHEXYPHENIDYL HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
ARTANE				
	LEDERLE	5MG	N006773 010	
		5MG	N012947 001	
ELIXIR;ORAL				
ARTANE				
	LEDERLE	2MG/5ML	N006773 009	
TRIHEXYPHENIDYL HYDROCHLORIDE				
	PHARM VENTURES	2MG/5ML	A089514 001	Apr 07, 1989
TABLET;ORAL				
ARTANE				
+	LEDERLE	2MG **	N006773 005	
+		5MG **	N006773 003	
TREMIN				
	SCHERING	2MG	A080381 001	
		5MG	A080381 003	
TRIHEXYPHENIDYL HYDROCHLORIDE				
	HIKMA PHARMS	2MG	A040337 002	Feb 16, 2000
		5MG	A040337 001	Feb 16, 2000
	NYLOS	5MG	A085622 001	
	VANGARD	2MG	A088035 001	Jul 30, 1982
	WATSON LABS	2MG	A040184 001	Feb 06, 1998
		2MG	A085117 001	
		5MG	A040184 002	Feb 06, 1998
		5MG	A085105 001	
TRILOSTANE				
CAPSULE;ORAL				
MODRASTANE				
	BIOENVISION	30MG	N018719 002	Dec 31, 1984
		60MG	N018719 001	Dec 31, 1984
TRIMEPRAZINE TARTRATE				
CAPSULE, EXTENDED RELEASE;ORAL				
TEMARIL				
	ALLERGAN HERBERT	EQ 5MG BASE	N011316 004	
SYRUP;ORAL				
TEMARIL				
	ALLERGAN HERBERT	EQ 2.5MG BASE/5ML	N011316 003	
TRIMEPRAZINE TARTRATE				
	ALPHARMA US PHARMS	EQ 2.5MG BASE/5ML	A085015 001	Feb 18, 1982
	MORTON GROVE	EQ 2.5MG BASE/5ML	A088285 001	Apr 11, 1985
TABLET;ORAL				
TEMARIL				
	ALLERGAN HERBERT	EQ 2.5MG BASE	N011316 001	
TRIMETHADIONE				
CAPSULE;ORAL				
TRIDIONE				
	ABBVIE	300MG	N005856 005	
SOLUTION;ORAL				
TRIDIONE				
	ABBVIE	200MG/5ML	N005856 002	

TRIMETHAPHAN CAMSYLATE
INJECTABLE;INJECTION
ARFONAD

ROCHE	50MG/ML	N008983	001	

TRIMETHOBENZAMIDE HYDROCHLORIDE
INJECTABLE;INJECTION
TRIMETHOBENZAMIDE HYDROCHLORIDE

HOSPIRA	100MG/ML	A088804	001	Apr 03, 1987
SMITH AND NEPHEW	100MG/ML	A088960	001	Apr 04, 1986
	100MG/ML	A089043	001	Apr 04, 1986
SOLOPAK	100MG/ML	A089094	001	Apr 04, 1986
WATSON LABS	100MG/ML	A086577	001	Oct 19, 1982
	100MG/ML	A087939	001	Dec 28, 1982

TRIMETHOPRIM
TABLET;ORAL
PROLOPRIM

MONARCH PHARMS	100MG	N017943	001	
	200MG	N017943	003	Jul 14, 1982

TRIMETHOPRIM

SUN PHARM INDUSTRIES	100MG	A070494	001	Jan 22, 1986
	200MG	A070495	001	Sep 24, 1986
TEVA	200MG **	A071259	001	Jun 18, 1987

TRIMPEX

ROCHE	100MG	N017952	001	

TRIMPEX 200

ROCHE	200MG	N017952	002	Nov 09, 1982

TRIMETHOPRIM HYDROCHLORIDE
SOLUTION;ORAL
PRIMSOL

ALLEGIS	EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995

TRIMETREXATE GLUCURONATE
INJECTABLE;INJECTION
NEUTREXIN

MEDIMMUNE ONCOLOGY	EQ 25MG BASE/VIAL	N020326	001	Dec 17, 1993
	EQ 200MG BASE/VIAL	N020326	002	Jul 31, 1998

TRIMIPRAMINE MALEATE
CAPSULE;ORAL
TRIMIPRAMINE MALEATE

USL PHARMA	EQ 25MG BASE	A071283	001	Dec 08, 1987
	EQ 50MG BASE	A071284	001	Dec 08, 1987
	EQ 100MG BASE	A071285	001	Dec 08, 1987

TRIOXSALEN
TABLET;ORAL
TRISORALEN

VALEANT PHARM INTL	5MG	N012697	001	

TRIPELENNAMINE CITRATE
ELIXIR;ORAL
PBZ

NOVARTIS	EQ 25MG HYDROCHLORIDE/5ML	N005914	004	

TRIPELENNAMINE HYDROCHLORIDE
TABLET;ORAL
PBZ

NOVARTIS	25MG	A083149	001	
	50MG	N005914	002	

TRIPELENNAMINE HYDROCHLORIDE

ANABOLIC	50MG	A083037	001	
BARR	50MG	A080744	001	
HEATHER	50MG	A083989	001	
IMPAX LABS	50MG	A080785	001	
LANNETT	50MG	A083557	001	
NYLOS	50MG	A085412	001	
PARKE DAVIS	25MG	A083625	001	
	50MG	A083626	001	
WATSON LABS	50MG	A080713	001	
	50MG	A080790	001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

TRIPELENNAMINE HYDROCHLORIDE

TABLET;ORAL				
TRIPELENNAMINE HYDROCHLORIDE				
	50MG		A085188 001	
TABLET, EXTENDED RELEASE;ORAL				
PBZ-SR				
NOVARTIS	50MG		N010533 002	
	100MG		N010533 001	

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM;VAGINAL				
GYNE-SULF				
G AND W LABS	3.7%;2.86%;3.42%		A088607 001	Jun 09, 1986
SULTRIN				
ORTHO MCNEIL PHARM	3.7%;2.86%;3.42%		N005794 001	
TRIPLE SULFA				
ALPHARMA US PHARMS	3.7%;2.86%;3.42%		A087864 001	Sep 01, 1982
FOUGERA	3.7%;2.86%;3.42%		A086424 001	
PERRIGO NEW YORK	3.7%;2.86%;3.42%		A087285 001	Nov 15, 1982
TRYSUL				
SAVAGE LABS	3.7%;2.86%;3.42%		A087887 001	Jul 23, 1982
VAGILIA				
G AND W LABS INC	3.7%;2.86%;3.42%		A088821 001	Nov 09, 1987
TABLET;VAGINAL				
SULTRIN				
ORTHO MCNEIL PHARM	184MG;143.75MG;172.5MG		N005794 002	
TRIPLE SULFA				
FOUGERA	184MG;143.75MG;172.5MG		A088463 001	Jan 03, 1985
PHARMADERM	184MG;143.75MG;172.5MG		A088462 001	Jan 03, 1985

TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL				
ACTIDIL				
GLAXOSMITHKLINE	1.25MG/5ML		N011496 002	Jul 01, 1983
MYIDYL				
USL PHARMA	1.25MG/5ML		A087963 001	Jan 18, 1983
TRIPROLIDINE HYDROCHLORIDE				
ALPHARMA US PHARMS	1.25MG/5ML		A085940 001	
HALSEY	1.25MG/5ML		A088735 001	Jan 17, 1985
PHARM ASSOC	1.25MG/5ML		A087514 001	Feb 10, 1982
TABLET;ORAL				
ACTIDIL				
GLAXOSMITHKLINE	2.5MG		N011110 002	Jul 01, 1983
TRIPROLIDINE HYDROCHLORIDE				
VITARINE	2.5MG		A085610 001	
WATSON LABS	2.5MG		A085094 001	

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION;ORAL				
LANTRISUL				
LANNETT	167MG/5ML;167MG/5ML;167MG/5ML		A080123 002	
NEOTRIZINE				
LILLY	167MG/5ML;167MG/5ML;167MG/5ML		N006317 012	
SULFALOID				
FOREST PHARMS	167MG/5ML;167MG/5ML;167MG/5ML		A080100 001	
SULFOSE				
WYETH AYERST	167MG/5ML;167MG/5ML;167MG/5ML		A080013 002	
TERFONYL				
BRISTOL MYERS SQUIBB	167MG/5ML;167MG/5ML;167MG/5ML		N006904 002	
TRIPLE SULFA				
ALPHARMA US PHARMS	167MG/5ML;167MG/5ML;167MG/5ML		A080280 001	
TRIPLE SULFAS				
LEDERLE	167MG/5ML;167MG/5ML;167MG/5ML		N006920 003	
TABLET;ORAL				
NEOTRIZINE				
LILLY	167MG;167MG;167MG		N006317 011	
SULFA-TRIPLE #2				
IMPAX LABS	167MG;167MG;167MG		A080079 001	
SULFALOID				
FOREST PHARMS	167MG;167MG;167MG		A080099 001	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)				
TABLET;ORAL				
SULFOSE				
	WYETH AYERST	167MG;167MG;167MG	A080013 001	
TERFONYL				
	BRISTOL MYERS SQUIBB	167MG;167MG;167MG	N006904 001	
TRIPLE SULFA				
	PUREPAC PHARM	167MG;167MG;167MG	A080086 001	
TRIPLE SULFAS				
	LEDERLE	167MG;167MG;167MG	N006920 002	
TRIPLE SULFOID				
	PAL PAK	167MG;167MG;167MG	A080094 001	
TROGLITAZONE				
TABLET;ORAL				
PRELAY				
	SANKYO	200MG	N020719 001	Jan 29, 1997
		300MG	N020719 003	Aug 04, 1997
		400MG	N020719 002	Jan 29, 1997
REZULIN				
	PFIZER PHARMS	200MG	N020720 001	Jan 29, 1997
		300MG	N020720 003	Aug 04, 1997
		400MG	N020720 002	Jan 29, 1997
TROLAMINE POLYPEPTIDE OLEATE CONDENSATE				
SOLUTION/DROPS;OTIC				
CERUMENEX				
	PHARM RES ASSOC	10%	N011340 002	
TROLEANDOMYCIN				
CAPSULE;ORAL				
TAO				
	PFIZER	EQ 250MG BASE	N050336 002	
SUSPENSION;ORAL				
TAO				
	PFIZER	EQ 125MG BASE/5ML	N050332 001	
TROMETHAMINE				
INJECTABLE;INJECTION				
THAM				
+	HOSPIRA	3.6GM/100ML	N013025 002	
TROPICAMIDE				
SOLUTION/DROPS;OPHTHALMIC				
MYDRIACYL				
	ALCON	0.5% **	N012111 002	
		1% **	N012111 004	
MYDRIAFAIR				
	PHARMAFAIR	0.5%	A088274 001	Sep 16, 1983
		1%	A088230 001	Sep 16, 1983
TROPICAMIDE				
	AKORN	1%	A088447 001	Aug 28, 1985
	ALCON PHARMS LTD	1%	A089172 001	Dec 28, 1990
	MIZA PHARMS USA	0.5%	A087636 001	Jul 30, 1982
		1%	A087637 001	Aug 09, 1982
	WATSON LABS	0.5%	A089171 001	Dec 28, 1990
TROSPIUM CHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
SANCTURA XR				
+	ALLERGAN	60MG **	N022103 001	Aug 03, 2007
TROSPIUM CHLORIDE				
	UPSHER SMITH LABS	60MG	A091635 001	Apr 29, 2015
TABLET;ORAL				
SANCTURA				
+	ALLERGAN	20MG **	N021595 001	May 28, 2004

TROVAFLOXACIN MESYLATE
TABLET;ORAL
TROVAN

PFIZER	EQ 100MG BASE	N020759	001	Dec 18, 1997
	EQ 200MG BASE	N020759	002	Dec 18, 1997

TUBOCURARINE CHLORIDE
INJECTABLE;INJECTION
TUBOCURARINE CHLORIDE

BRISTOL MYERS SQUIBB	3MG/ML	N005657	001	
HOSPIRA	3MG/ML	N006095	001	
LILLY	3MG/ML	N006325	001	

TYROPANOATE SODIUM
CAPSULE;ORAL
BILOPAQUE

GE HEALTHCARE	750MG	N013731	001	

UNOPROSTONE ISOPROPYL
SOLUTION/DROPS;OPHTHALMIC
RESCULA

+	SUCAMPO PHARMA LLC	0.15% **	N021214	001	Aug 03, 2000

URACIL MUSTARD
CAPSULE;ORAL
URACIL MUSTARD

SHIRE	1MG	N012892	001	

UREA
INJECTABLE;INJECTION
STERILE UREA

HOSPIRA	40GM/VIAL	N017698	001	

UREAPHIL

HOSPIRA	40GM/VIAL	N012154	001	

UREA C-13
FOR SOLUTION;ORAL
BREATHTEK UBT FOR H-PYLORI

OTSUKA AMERICA	EQ 75MG/POUCH	N020586	002	May 10, 2001

HELICOSOL

METABOLIC SOLUTIONS	125MG/VIAL	N021092	001	Dec 17, 1999

MERETEK UBT KIT (W/ PRANACTIN)

OTSUKA AMERICA	125MG/VIAL	N020586	001	Sep 17, 1996

PYLORI-CHEK BREATH TEST

DXS DEVICES	100MG/VIAL	N020900	001	Feb 04, 1999

UROFOLLITROPIN
INJECTABLE;INTRAMUSCULAR
METRODIN

SERONO	75 IU/AMP	N019415	002	Sep 18, 1986
	150 IU/AMP	N019415	003	Sep 18, 1986

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
BRAVELLE

+	FERRING	75 IU/VIAL	N021289	001	May 06, 2002

INJECTABLE;SUBCUTANEOUS
FERTINEX

SERONO	75 IU/AMP	N019415	005	Aug 23, 1996
	150 IU/AMP	N019415	004	Aug 23, 1996

UROKINASE
INJECTABLE;INJECTION
KINLYTIC

MICROBIX BIOSYSTEMS	5,000 IU/VIAL	N021846	003	
	9,000 IU/VIAL	N021846	002	
	250,000 IU/VIAL	N021846	001	

URSODIOL
CAPSULE;ORAL
ACTIGALL

ALLERGAN SALES LLC	150MG	N019594	001	Dec 31, 1987

URSODIOL

IMPAX LABS INC	300MG	A077895	001	Jul 27, 2006

URSODIOL				
TABLET;ORAL				
URSODIOL				
TEVA PHARMS USA	250MG		A079184 001	May 13, 2009
	500MG		A079184 002	May 13, 2009
VALACYCLOVIR HYDROCHLORIDE				
TABLET;ORAL				
VALACYCLOVIR HYDROCHLORIDE				
MYLAN	EQ 500MG BASE		A078070 001	May 24, 2010
	EQ 1GM BASE		A078070 002	May 24, 2010
VALDECOXIB				
TABLET;ORAL				
BEXTRA				
GD SEARLE	10MG		N021341 002	Nov 16, 2001
	20MG		N021341 003	Nov 16, 2001
VALPROIC ACID				
CAPSULE;ORAL				
VALPROIC ACID				
PAR PHARM	250MG		A070431 001	Feb 28, 1986
SCHERER RP	250MG		A070195 001	Jul 02, 1987
USL PHARMA	250MG		A070631 001	Jun 11, 1987
CAPSULE, DELAYED RELEASE;ORAL				
STAVZOR				
+ BIONPHARMA INC	125MG **		N022152 001	Jul 29, 2008
+	250MG **		N022152 002	Jul 29, 2008
+	500MG **		N022152 003	Jul 29, 2008
SYRUP;ORAL				
VALPROIC ACID				
APOTEX INC	250MG/5ML		A077105 001	Jul 29, 2005
VALSARTAN				
CAPSULE;ORAL				
DIOVAN				
NOVARTIS	80MG		N020665 001	Dec 23, 1996
	160MG		N020665 002	Dec 23, 1996
SOLUTION;ORAL				
PREXXARTAN				
+ CARMEL BIOSCIENCES	20MG/5ML		N209139 001	Dec 19, 2017
+	80MG/20ML		N209139 002	Dec 19, 2017
TABLET;ORAL				
VALSARTAN				
WATSON LABS INC	40MG		A090642 001	Jan 05, 2015
	80MG		A090642 002	Jan 05, 2015
	160MG		A090642 003	Jan 05, 2015
	320MG		A090642 004	Jan 05, 2015
VANCOMYCIN HYDROCHLORIDE				
CAPSULE;ORAL				
VANCOMYCIN HYDROCHLORIDE				
FRESENIUS KABI USA	EQ 125MG BASE		A065453 001	Jun 18, 2012
	EQ 250MG BASE		A065453 002	Jun 18, 2012
FOR SOLUTION;ORAL				
VANCOCIN HYDROCHLORIDE				
ANI PHARMS INC	EQ 250MG BASE/5ML		A061667 002	Jul 13, 1983
	EQ 500MG BASE/6ML		A061667 001	
VANCOLED				
LEDERLE	EQ 250MG BASE/5ML		A063321 002	Oct 15, 1993
	EQ 500MG BASE/6ML		A063321 003	Oct 15, 1993
INJECTABLE;INJECTION				
VANCOCIN HYDROCHLORIDE				
ANI PHARMS INC	EQ 500MG BASE/VIAL **		A060180 001	
	EQ 500MG BASE/VIAL		A062476 001	Mar 15, 1984
	EQ 500MG BASE/VIAL		A062716 001	Mar 13, 1987
	EQ 500MG BASE/VIAL **		A062812 001	Nov 17, 1987
	EQ 1GM BASE/VIAL **		A060180 002	Mar 21, 1986
	EQ 1GM BASE/VIAL		A062476 002	Mar 21, 1986
	EQ 1GM BASE/VIAL		A062716 002	Mar 13, 1987
	EQ 1GM BASE/VIAL **		A062812 002	Nov 17, 1987
	EQ 10GM BASE/VIAL **		A062812 003	Nov 17, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

VANCOMYCIN HYDROCHLORIDE				
INJECTABLE;INJECTION				
VANCOLED				
WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL **	A062682	001	Jul 22, 1986
	EQ 1GM BASE/VIAL **	A062682	002	Mar 30, 1988
	EQ 2GM BASE/VIAL **	A062682	003	May 11, 1988
	EQ 5GM BASE/VIAL **	A062682	004	May 11, 1988
	EQ 10GM BASE/VIAL **	A062682	005	May 11, 1988
VANCOMYCIN HYDROCHLORIDE				
MYLAN LABS LTD	EQ 10GM BASE/VIAL	A091469	001	Jul 01, 2011
TEVA PHARMS USA	EQ 500MG BASE/VIAL	A201251	001	Dec 23, 2015
	EQ 1GM BASE/VIAL	A201251	002	Dec 23, 2015
	EQ 5GM BASE/VIAL	A201250	001	Dec 23, 2015
	EQ 10GM BASE/VIAL	A201250	002	Dec 23, 2015
WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A062879	001	Aug 02, 1988
	EQ 1GM BASE/VIAL	A062879	002	Aug 02, 1988
XELLIA PHARMS APS	EQ 500MG BASE/VIAL	A091377	001	Sep 09, 2015
	EQ 1GM BASE/VIAL	A091377	002	Sep 09, 2015
	EQ 5GM BASE/VIAL	A206243	001	Dec 23, 2015
	EQ 10GM BASE/VIAL	A206243	002	Dec 23, 2015
VANCOR				
PHARMACIA AND UPJOHN	EQ 500MG BASE/VIAL	A062956	001	Aug 01, 1988
	EQ 1GM BASE/VIAL	A062956	002	Aug 01, 1988
VARDENAFIL HYDROCHLORIDE				
TABLET;ORAL				
LEVITRA				
+ BAYER HLTHCARE	2.5MG	N021400	003	Aug 19, 2003
VASOPRESSIN TANNATE				
INJECTABLE;INJECTION				
PITRESSIN TANNATE				
+ PARKE DAVIS	5PRESSOR UNITS/ML **	N003402	001	
VECURONIUM BROMIDE				
INJECTABLE;INJECTION				
NORCURON				
+ ORGANON USA INC	10MG/VIAL **	N018776	002	Apr 30, 1984
+	20MG/VIAL **	N018776	003	Jan 03, 1992
VECURONIUM BROMIDE				
HOSPIRA	4MG/VIAL	A075558	001	Sep 11, 2001
WATSON LABS	10MG/VIAL	A074334	001	Aug 31, 1995
	20MG/VIAL	A074334	002	Aug 31, 1995
WEST-WARD PHARMS INT	10MG/VIAL	A075218	001	Aug 23, 1999
	20MG/VIAL	A075218	002	Aug 23, 1999
VELAGLUCERASE ALFA				
POWDER;INTRAVENOUS				
VPRIV				
SHIRE HUMAN GENETIC	200 UNITS/VIAL	N022575	002	Feb 26, 2010
VENLAFAXINE HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
EFFEXOR XR				
WYETH PHARMS	EQ 100MG BASE	N020699	003	Oct 20, 1997
VENLAFAXINE HYDROCHLORIDE				
ANCHEN PHARMS	EQ 37.5MG BASE	A078087	001	Mar 16, 2012
	EQ 75MG BASE	A078087	002	Mar 16, 2012
	EQ 150MG BASE	A078087	003	Mar 16, 2012
MYLAN	EQ 37.5MG BASE	A078789	001	Jun 01, 2011
	EQ 75MG BASE	A078789	002	Jun 01, 2011
	EQ 150MG BASE	A078789	003	Jun 01, 2011
TABLET;ORAL				
EFFEXOR				
+ WYETH PHARMS INC	EQ 12.5MG BASE **	N020151	001	Dec 28, 1993
+	EQ 25MG BASE **	N020151	002	Dec 28, 1993
+	EQ 37.5MG BASE **	N020151	006	Dec 28, 1993
+	EQ 50MG BASE **	N020151	003	Dec 28, 1993
+	EQ 75MG BASE **	N020151	004	Dec 28, 1993
+	EQ 100MG BASE **	N020151	005	Dec 28, 1993

VENLAFAXINE HYDROCHLORIDE				
TABLET;ORAL				
VENLAFAXINE HYDROCHLORIDE				
FOSUN PHARMA	EQ 25MG BASE	A077515	001	Jun 13, 2008
	EQ 37.5MG BASE	A077515	002	Jun 13, 2008
	EQ 50MG BASE	A077515	003	Jun 13, 2008
	EQ 75MG BASE	A077515	004	Jun 13, 2008
	EQ 100MG BASE	A077515	005	Jun 13, 2008
PLIVA HRVATSKA DOO	EQ 25MG BASE	A078517	001	Jun 13, 2008
	EQ 37.5MG BASE	A078517	002	Jun 13, 2008
	EQ 50MG BASE	A078517	003	Jun 13, 2008
	EQ 75MG BASE	A078517	004	Jun 13, 2008
	EQ 100MG BASE	A078517	005	Jun 13, 2008
VERAPAMIL HYDROCHLORIDE				
INJECTABLE;INJECTION				
CALAN				
GD SEARLE LLC	2.5MG/ML	N019038	001	Mar 30, 1984
ISOPTIN				
+ MT ADAMS	2.5MG/ML **	N018485	001	
VERAPAMIL HYDROCHLORIDE				
ABRAXIS PHARM	2.5MG/ML	A070348	001	May 01, 1986
BEDFORD	2.5MG/ML	A072888	001	Jul 28, 1995
HOSPIRA	2.5MG/ML	A070577	001	Feb 02, 1987
	2.5MG/ML	A070739	001	May 06, 1987
	2.5MG/ML	A070740	001	May 06, 1987
INTL MEDICATION	2.5MG/ML	A070451	001	Dec 16, 1985
LUITPOLD	2.5MG/ML	A070225	001	Nov 12, 1985
	2.5MG/ML	A070617	001	Nov 12, 1985
MARSAM PHARMS LLC	2.5MG/ML	A072233	001	Feb 26, 1993
	2.5MG/ML	A073485	001	Sep 27, 1993
SMITH AND NEPHEW	2.5MG/ML	A070696	001	Jul 31, 1987
	2.5MG/ML	A070697	001	Jul 31, 1987
SOLOPAK	2.5MG/ML	A070695	001	Jul 31, 1987
TABLET;ORAL				
CALAN				
GD SEARLE LLC	40MG	N018817	003	Feb 23, 1988
	160MG	N018817	004	Feb 23, 1988
ISOPTIN				
+ MT ADAMS	40MG	N018593	003	Nov 23, 1987
+	80MG	N018593	001	Mar 08, 1982
+	120MG	N018593	002	Mar 08, 1982
VERAPAMIL HYDROCHLORIDE				
ACTAVIS ELIZABETH	80MG	A071019	001	Sep 24, 1986
	120MG	A070468	001	Sep 24, 1986
MUTUAL PHARM	80MG	A070482	001	Sep 24, 1986
	120MG	A070483	001	Sep 24, 1986
PLIVA	40MG	A072751	001	Feb 23, 1996
	80MG	A072124	001	Jan 26, 1989
	120MG	A072125	001	Jan 26, 1989
SUN PHARM INDUSTRIES	80MG	A071489	002	Jan 13, 1988
	120MG	A071489	001	Jan 13, 1988
WARNER CHILCOTT	80MG	A070340	001	Sep 24, 1986
	120MG	A070341	001	Sep 24, 1986
WATSON LABS	40MG	A072799	001	Apr 28, 1989
	40MG	A072923	001	Jun 29, 1993
	80MG	A070855	001	Sep 24, 1986
	80MG	A071366	001	Oct 01, 1986
	120MG	A070856	001	Sep 24, 1986
	120MG	A071367	001	Oct 01, 1986
YAOPHARMA CO LTD	40MG	A073168	001	Jul 31, 1992
	80MG	A071423	001	May 24, 1988
	120MG	A071424	001	May 25, 1988
TABLET, EXTENDED RELEASE;ORAL				
CALAN SR				
+ PFIZER	180MG **	N019152	002	Dec 15, 1989
COVERA-HS				
GD SEARLE LLC	180MG	N020552	001	Feb 26, 1996
	240MG	N020552	002	Feb 26, 1996

VERAPAMIL HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
VERAPAMIL HYDROCHLORIDE

APOTEX CORP	120MG	A200878	001	Apr 20, 2012
	180MG	A200878	002	Apr 20, 2012
	240MG	A200878	003	Apr 20, 2012
PLIVA	240MG	A072922	001	Mar 01, 1996

VERATRUM VIRIDE ROOT
TABLET;ORAL
VERTAVIS

MEDPOINTE PHARM HLC	130CSR UNIT	N005691	002	

VIDARABINE
INJECTABLE;INJECTION
VIRA-A

PARKEDALE	EQ 187.4MG BASE/ML	N050523	001	

OINTMENT;OPHTHALMIC
VIRA-A

PARKEDALE	3%	N050486	001	

VINBLASTINE SULFATE
INJECTABLE;INJECTION
VELBAN

+ LILLY	10MG/VIAL	N012665	001	

VINBLASTINE SULFATE

ABRAXIS PHARM	10MG/VIAL	A089011	001	Nov 18, 1985
HOSPIRA	10MG/VIAL	A089565	001	Aug 18, 1987

VINCRISTINE SULFATE
INJECTABLE;INJECTION
ONCOVIN

LILLY	1MG/VIAL	N014103	001	
	1MG/ML	N014103	003	Mar 07, 1984
	5MG/VIAL	N014103	002	

VINCASAR PFS

TEVA PARENTERAL	1MG/ML	A071426	001	Jul 17, 1987

VINCREX

BRISTOL MYERS SQUIBB	5MG/VIAL	A070867	001	Jul 12, 1988

VINCRISTINE SULFATE

ABIC	1MG/ML	A070873	001	Feb 19, 1987
ABRAXIS PHARM	1MG/ML	A070411	001	Sep 10, 1986
FRESENIUS KABI USA	1MG/ML	A076296	001	Dec 20, 2002
	1MG/ML	A076401	001	Oct 28, 2003
HOSPIRA	1MG/VIAL	A071559	001	Apr 11, 1988
	2MG/VIAL	A071560	001	Apr 11, 1988
	5MG/VIAL	A071561	001	Apr 11, 1988

VINORELBINE TARTRATE
INJECTABLE;INJECTION
VINORELBINE TARTRATE

EBEWE PHARMA	EQ 10MG BASE/ML	A078408	001	Feb 13, 2008
MYLAN LABS LTD	EQ 10MG BASE/ML	A200148	001	Aug 31, 2012

VIOMYCIN SULFATE
INJECTABLE;INJECTION
VIOCIN SULFATE

PFIZER	EQ 1GM BASE/VIAL	A061086	001	
	EQ 5GM BASE/VIAL	A061086	002	

VITAMIN A
CAPSULE;ORAL
AQUASOL A

ASTRAZENECA	25,000USP UNITS	A083080	002	
	50,000USP UNITS	A083080	001	

VITAMIN A

BANNER PHARMACAPS	50,000USP UNITS	A083973	001	
CHASE CHEM	50,000 IU	A083351	001	
EVERYLIFE	50,000 IU	A083134	001	
IMPAX LABS	50,000USP UNITS	A080952	001	
WEST WARD	50,000USP UNITS	A080985	001	

VITAMIN A PALMITATE				
CAPSULE;ORAL				
AFAXIN				
	STERLING WINTHROP	EQ 50,000 UNITS BASE	A083187 001	
ALPHALIN				
	LILLY	EQ 50,000 UNITS BASE	A080883 001	
DEL-VI-A				
	DEL RAY LABS	EQ 50,000 UNITS BASE	A080830 001	
VI-DOM-A				
	BAYER PHARMS	EQ 50,000 UNITS BASE	A080972 001	
VITAMIN A				
	BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A080702 001	
	BRISTOL MYERS SQUIBB	EQ 50,000 UNITS BASE	A080860 001	
	CHASE CHEM	EQ 50,000 UNITS BASE	A080746 001	
		EQ 50,000 UNITS BASE	A083207 001	
	ELKINS SINN	EQ 50,000 UNITS BASE	A085479 001	
	EVERYLIFE	EQ 50,000 UNITS BASE	A080943 001	
		EQ 50,000 UNITS BASE	A083114 001	
	IMPAX LABS	EQ 50,000 UNITS BASE	A080953 001	
		EQ 50,000 UNITS BASE	A080955 001	
	IVAX SUB TEVA PHARMS	EQ 50,000 UNITS BASE	A083035 001	
		EQ 50,000 UNITS BASE	A083190 001	
	MK LABS	EQ 25,000 UNITS BASE	A083457 002	
		EQ 50,000 UNITS BASE	A083457 001	
	WEST WARD	EQ 50,000 UNITS BASE	A080967 001	
	WHARTON LABS	EQ 50,000 UNITS BASE	A083665 001	
VITAMIN A PALMITATE				
	ARCUM	EQ 50,000 UNITS BASE	A083311 001	
		EQ 50,000 UNITS BASE	A083321 001	
	BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A083948 001	
		EQ 50,000 UNITS BASE	A083981 001	
VITAMIN A SOLUBILIZED				
	TEVA	EQ 50,000 UNITS BASE	A080921 001	
INJECTABLE;INJECTION				
VITAMIN A PALMITATE				
	BEL MAR	EQ 50,000 UNITS BASE/ML	A080819 001	
VORICONAZOLE				
FOR SUSPENSION;ORAL				
VORICONAZOLE				
	MYLAN PHARMS INC	200MG/5ML	A202361 001	May 28, 2013
VORTIOXETINE HYDROBROMIDE				
TABLET;ORAL				
TRINTELLIX				
+	TAKEDA PHARMS USA	EQ 15MG BASE **	N204447 003	Sep 30, 2013
WARFARIN POTASSIUM				
TABLET;ORAL				
ATHROMBIN-K				
	PHARM RES ASSOC	2MG	N011771 007	
		5MG	N011771 004	
		10MG	N011771 005	
		25MG	N011771 006	
WARFARIN SODIUM				
INJECTABLE;INJECTION				
COUMADIN				
	BRISTOL MYERS SQUIBB	5MG/VIAL	N009218 024	Feb 07, 1995
		50MG/VIAL	N009218 020	
		75MG/VIAL	N009218 012	
TABLET;ORAL				
ATHROMBIN				
	PHARM RES ASSOC	5MG	N011771 003	
		10MG	N011771 002	
		25MG	N011771 001	
PANWARFIN				
	ABBOTT	2MG	N017020 001	
		2.5MG	N017020 002	
		5MG	N017020 003	
		7.5MG	N017020 004	

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

WARFARIN SODIUM				
TABLET;ORAL				
PANWARFIN				
	10MG	N017020	005	
WARFARIN SODIUM				
MYLAN	1MG	A040415	001	Sep 27, 2004
	2MG	A040415	002	Sep 27, 2004
	2.5MG	A040415	003	Sep 29, 2004
	3MG	A040415	004	Sep 27, 2004
	4MG	A040415	005	Sep 27, 2004
	5MG	A040415	006	Sep 27, 2004
	6MG	A040415	007	Sep 27, 2004
	7.5MG	A040415	008	Sep 27, 2004
	10MG	A040415	009	Sep 27, 2004
USL PHARMA	2MG	A088719	001	Jun 27, 1985
	2.5MG	A088720	001	Aug 06, 1985
	5MG	A088721	001	Jul 02, 1985
WATSON LABS	2MG	A086123	001	Aug 17, 1982
	2.5MG	A086120	001	Aug 17, 1982
	5MG	A086119	001	Aug 17, 1982
	7.5MG	A086118	001	Aug 17, 1982
	10MG	A086122	001	Aug 17, 1982
YAOPHARMA CO LTD	1MG	A040196	001	Sep 30, 1997
	2MG	A040196	002	Sep 30, 1997
	2.5MG	A040196	003	Sep 30, 1997
	3MG	A040196	008	Jul 26, 2000
	4MG	A040196	004	Sep 30, 1997
	5MG	A040196	005	Sep 30, 1997
	6MG	A040196	009	Jul 26, 2000
	7.5MG	A040196	006	Sep 30, 1997
	10MG	A040196	007	Sep 30, 1997
XENON XE-127				
GAS;INHALATION				
XENON XE 127				
MALLINCKRODT	5mCi/VIAL	N018536	001	Oct 01, 1982
	10mCi/VIAL	N018536	002	Oct 01, 1982
XENON XE-133				
GAS;INHALATION				
XENON XE 133				
GE HEALTHCARE	1 CI/AMP	N017256	002	
	10mCi/VIAL	N017687	002	
	20mCi/VIAL	N017687	003	
GEN ELECTRIC	5-100 CI/CYLINDER	N017550	001	
	0.25-5 CI/AMP	N017550	003	
XENON XE 133-V.S.S.				
GE HEALTHCARE	10mCi/VIAL	N017687	001	
INJECTABLE;INJECTION				
XENON XE 133				
GE HEALTHCARE	1.3-1.7 CI/AMP	N017256	001	
LANTHEUS MEDCL	6.3mCi/ML	N017283	001	
SOLUTION;INHALATION, INJECTION				
XENEISOL				
MALLINCKRODT	18-25mCi/AMP	N017262	002	
XYLOSE				
POWDER;ORAL				
XYLO-PFAN				
SAVAGE LABS	25GM/BOT	N017605	001	
XYLOSE				
LYNE	25GM/BOT	N018856	001	Mar 26, 1987
ZALCITABINE				
TABLET;ORAL				
HIVID				
ROCHE	0.375MG	N020199	001	Jun 19, 1992
	0.75MG	N020199	002	Jun 19, 1992

ZALEPLON				
CAPSULE;ORAL				
ZALEPLON				
	MYLAN	5MG	A077238 001	Jun 06, 2008
		10MG	A077238 002	Jun 06, 2008
	UPSHER SMITH LABS	5MG	A078095 001	Jun 06, 2008
		5MG	A078706 001	Jun 06, 2008
		10MG	A078095 002	Jun 06, 2008
		10MG	A078706 002	Jun 06, 2008
ZICONOTIDE ACETATE				
INJECTABLE;INTRATHECAL				
PRIALT				
	TERSERA THERAPS LLC	200MCG/2ML (100MCG/ML)	N021060 003	Dec 28, 2004
ZIDOVUDINE				
INJECTABLE;INJECTION				
ZIDOVUDINE				
	LIAONING CHENGDA	10MG/ML	A204538 001	Nov 26, 2013
TABLET;ORAL				
RETROVIR				
	VIIV HLTHCARE	200MG	N020518 001	Dec 19, 1995
+		300MG **	N020518 002	Oct 04, 1996
ZIDOVUDINE				
	AUROBINDO PHARMA	60MG	N022294 001	Jul 23, 2009
	HEC PHARM	300MG	A202058 001	Oct 07, 2011
	MATRIX LABS LTD	100MG	N200732 001	Feb 23, 2011
	RANBAXY LABS LTD	300MG	A077327 001	Sep 19, 2005
ZILEUTON				
TABLET;ORAL				
ZYFLO				
	CHIESI USA INC	300MG	N020471 001	Dec 09, 1996
ZINC SULFATE				
INJECTABLE;INJECTION				
ZINC SULFATE				
	ABRAXIS PHARM	EQ 1MG ZINC/ML	N019229 002	May 05, 1987
ZIPRASIDONE HYDROCHLORIDE				
CAPSULE;ORAL				
ZIPRASIDONE HYDROCHLORIDE				
	MYLAN PHARMS INC	EQ 20MG BASE	A202395 001	Oct 10, 2013
		EQ 40MG BASE	A202395 002	Oct 10, 2013
		EQ 60MG BASE	A202395 003	Oct 10, 2013
		EQ 80MG BASE	A202395 004	Oct 10, 2013
SUSPENSION;ORAL				
GEODON				
	PFIZER INC	EQ 10MG BASE/ML	N021483 001	Mar 29, 2006
ZOLEDRONIC ACID				
INJECTABLE;IV (INFUSION)				
ZOLEDRONIC ACID				
	SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018 001	Mar 04, 2013
		EQ 4MG BASE/5ML	A202746 001	Mar 04, 2013
ZOMETA				
+	NOVARTIS	EQ 4MG BASE/VIAL **	N021223 001	Aug 20, 2001
ZOLMITRIPTAN				
TABLET;ORAL				
ZOLMITRIPTAN				
	APOTEX INC	2.5MG	A202078 001	May 14, 2013
		5MG	A202078 002	May 14, 2013
	MYLAN PHARMS INC	2.5MG	A203186 001	May 14, 2013
		5MG	A203186 002	May 14, 2013
	SUN PHARMA GLOBAL	2.5MG	A203476 001	Nov 13, 2014
		5MG	A203476 002	Nov 13, 2014
TABLET, ORALLY DISINTEGRATING;ORAL				
ZOLMITRIPTAN				
	APOTEX INC	2.5MG	A202476 001	May 14, 2013
		5MG	A202476 002	May 14, 2013

ZOLPIDEM TARTRATE

TABLET;ORAL				
ZOLPIDEM TARTRATE				
DR REDDYS LABS LTD	5MG	A077985	001	Apr 23, 2007
	10MG	A077985	002	Apr 23, 2007
HIKMA	5MG	A078129	001	Apr 30, 2008
	10MG	A078129	002	Apr 30, 2008
MYLAN PHARMS INC	5MG	A078016	001	Apr 23, 2007
	10MG	A078016	002	Apr 23, 2007
STRIDES VIVIMED	5MG	A076062	001	Apr 23, 2007
	10MG	A076062	002	Apr 23, 2007
SUN PHARM INDS LTD	5MG	A078055	001	Apr 23, 2007
	10MG	A078055	002	Apr 23, 2007
SUN PHARM INDUSTRIES	5MG	A077288	001	Apr 23, 2007
	10MG	A077288	002	Apr 23, 2007
SYNTHON PHARMS	5MG	A077540	001	Apr 23, 2007
	10MG	A077540	002	Apr 23, 2007
WATSON LABS	5MG	A077773	001	Apr 23, 2007
	10MG	A077773	002	Apr 23, 2007
TABLET, EXTENDED RELEASE;ORAL				
ZOLPIDEM TARTRATE				
SYNTHON PHARMS	6.25MG	A078483	001	Apr 12, 2011
	12.5MG	A078483	002	Jun 06, 2011
TABLET, ORALLY DISINTEGRATING;ORAL				
TOVALT ODT				
BIOVAIL LABS INTL	5MG	N021412	001	Apr 25, 2007
	10MG	N021412	002	Apr 25, 2007

ZONISAMIDE

CAPSULE;ORAL				
ZONEGRAN				
+ SUNOVION PHARMS INC	50MG	N020789	002	Aug 22, 2003
ZONISAMIDE				
ANI PHARMS INC	25MG	A077639	001	Dec 22, 2005
	25MG	A077641	003	Dec 22, 2005
	50MG	A077639	002	Dec 22, 2005
	50MG	A077641	002	Dec 22, 2005
	100MG	A077639	003	Dec 22, 2005
	100MG	A077641	001	Dec 22, 2005
AUROBINDO PHARMA LTD	25MG	A077645	002	Sep 29, 2006
	50MG	A077645	003	Sep 29, 2006
	100MG	A077645	001	Dec 22, 2005
EPIC PHARMA LLC	25MG	A077876	001	Feb 21, 2007
	50MG	A077876	002	Feb 21, 2007
	100MG	A077876	003	Feb 21, 2007
MYLAN PHARMS INC	25MG	A077647	001	Dec 22, 2005
	50MG	A077647	002	Dec 22, 2005
	100MG	A077647	003	Dec 22, 2005
ROXANE	25MG	A077648	001	Dec 22, 2005
	50MG	A077648	002	Dec 22, 2005
	100MG	A077648	003	Dec 22, 2005
SUN PHARM INDUSTRIES	25MG	A077635	001	Dec 22, 2005
	50MG	A077635	002	Dec 22, 2005
	100MG	A077635	003	Dec 22, 2005
UPSHER SMITH LABS	25MG	A077644	001	Dec 22, 2005
	50MG	A077644	002	Dec 22, 2005
	100MG	A077644	003	Dec 22, 2005
WATSON LABS	25MG	A077650	001	Apr 20, 2006
	50MG	A077650	002	Apr 20, 2006
	100MG	A077650	003	Apr 20, 2006

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

ACETAMINOPHEN;ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG
325MG;325MG;50MG

ACETAMINOPHEN;ASPIRIN;BUTALBITAL;
CAFFEINE
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG;40MG
325MG;325MG;50MG;40MG

ACETAMINOPHEN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG

ACETAMINOPHEN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG

AMINOPHYLLINE
TABLET; ORAL
100MG;200MG

ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG
650MG;50MG

ASPIRIN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG
650MG;50MG;40MG

ASPIRIN;CAFFEINE;CARISOPRODOL
TABLET; ORAL
160MG;32MG;200MG

ASPIRIN;CAFFEINE;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
160MG;32MG;200MG;16MG

ASPIRIN;CARISOPRODOL
TABLET; ORAL
325MG;200MG

ASPIRIN;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
325MG;200MG;16MG

ASPIRIN;MEPROBAMATE
TABLET; ORAL
325MG;200MG

ASPIRIN;METHOCARBAMOL
TABLET; ORAL
325MG;400MG

CHLOROTHIAZIDE
TABLET; ORAL
250MG

HYDROXYZINE HYDROCHLORIDE
TABLET; ORAL
10MG;25MG;
50MG;100MG

PREDNISONE
TABLET; ORAL
1MG;2.5MG;5MG;10MG;
20MG;25MG;50MG

APPENDIX A - PRODUCT NAME INDEX

**** A ****

A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
ABACAVIR SULFATE, ABACAVIR SULFATE
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE
ABELCET, AMPHOTERICIN B
ABILIFY, ARIPIPRAZOLE
ABILIFY MAINTENA KIT, ARIPIPRAZOLE
ABILIFY MYCITE KIT, ARIPIPRAZOLE
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ABLYSINOL, ALCOHOL
ABRAXANE, PACLITAXEL
ABREVA, DOCOSANOL (OTC)
ABSORICA, ISOTRETINOIN
ABSTRAL, FENTANYL CITRATE
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACANYA, BENZOYL PEROXIDE
ACARBOSE, ACARBOSE
ACCOLATE, ZAFIRLUKAST
ACCUNEB, ALBUTEROL SULFATE
ACCUPRIL, QUINAPRIL HYDROCHLORIDE
ACCURETIC, HYDROCHLOROTHIAZIDE
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
ACEPHEN, ACETAMINOPHEN (OTC)
ACETADOTE, ACETYLCYSTEINE
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
ACETASOL HC, ACETIC ACID, GLACIAL
ACETAZOLAMIDE, ACETAZOLAMIDE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETIC ACID, ACETIC ACID, GLACIAL
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ACETYLCYSTEINE, ACETYLCYSTEINE
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
ACIPHEX, RABEPRAZOLE SODIUM
ACIPHEX SPRINKLE, RABEPRAZOLE SODIUM
ACITRETIN, ACITRETIN
ACTHREL, CORTICORELIN OVINE TRIFLUTATE
ACTICLATE, DOXYCYCLINE HYCLATE
ACTIGALL, URSODIOL
ACTIQ, FENTANYL CITRATE
ACTIVELLA, ESTRADIOL
ACTONEL, RISEDRONATE SODIUM
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOPLUS MET XR, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
ACULAR, KETOROLAC TROMETHAMINE
ACULAR LS, KETOROLAC TROMETHAMINE
ACUVAIL, KETOROLAC TROMETHAMINE
ACYCLOVIR, ACYCLOVIR
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACZONE, DAPSONE
ADAGEN, PEGADEMASE BOVINE
ADALAT CC, NIFEDIPINE
ADAPALENE, ADAPALENE
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ADASUVE, LOXAPINE
ADCIRCA, TADALAFIL
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE

APPENDIX A - PRODUCT NAME INDEX

**** A ****

ADDERALL XR 5, AMPHETAMINE ASPARTATE
ADDYI, FLIBANSERIN
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
ADEMPAS, RIOCIGUAT
ADENOSINE, ADENOSINE
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ADLYXIN, LIXISENATIDE
ADMELOG, INSULIN LISPRO
ADMELOG SOLOSTAR, INSULIN LISPRO
ADRENACLICK, EPINEPHRINE
ADRENALIN, EPINEPHRINE
ADREVIEW, IOBENGUANE SULFATE I-123
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVAIR HFA, FLUTICASONE PROPIONATE
ADVIL, IBUPROFEN (OTC)
ADVIL, IBUPROFEN SODIUM (OTC)
ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MULTI-SYMPTOM COLD & FLU, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ADZENYS ER, AMPHETAMINE
ADZENYS XR-ODT, AMPHETAMINE
AEMCOLO, RIFAMYCIN
AEROSPAN HFA, FLUNISOLIDE
AFINITOR, EVEROLIMUS
AFINITOR DISPERZ, EVEROLIMUS
AFIRMELLE, ETHINYL ESTRADIOL
AFREZZA, INSULIN RECOMBINANT HUMAN
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
AGGRENOX, ASPIRIN
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
AIRDUO RESPICLICK, FLUTICASONE PROPIONATE
AK-FLUOR 10%, FLUORESCEIN SODIUM
AK-FLUOR 25%, FLUORESCEIN SODIUM
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKOVAZ, EPHEDRINE SULFATE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKTEN, LIDOCAINE HYDROCHLORIDE
AKTIPAK, BENZOYL PEROXIDE
AKTOB, TOBRAMYCIN
AKYNZEO, FOSNETUPITANT CHLORIDE HYDROCHLORIDE
AKYNZEO, NETUPITANT
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
ALAVERT, LORATADINE (OTC)
ALAWAY, KETOTIFEN FUMARATE (OTC)
ALBENDAZOLE, ALBENDAZOLE
ALBENZA, ALBENDAZOLE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALCAINE, PROPARACAINE HYDROCHLORIDE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ALDARA, IMIQUIMOD
ALECENSA, ALECTINIB HYDROCHLORIDE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALEVE, NAPROXEN SODIUM (OTC)

APPENDIX A - PRODUCT NAME INDEX

**** A ****

ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)
ALFENTA, ALFENTANIL HYDROCHLORIDE
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALIMTA, PEMETREXED DISODIUM
ALINIA, NITAZOXANIDE
ALIQOPA, COPANLISIB DIHYDROCHLORIDE
ALKERAN, MELPHALAN
ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLI, ORLISTAT (OTC)
ALLOPURINOL, ALLOPURINOL
ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
ALLZITAL, ACETAMINOPHEN
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
ALOCRIL, NEDOCROMIL SODIUM
ALOMIDE, LODOXAMIDE TROMETHAMINE
ALOPRIM, ALLOPURINOL SODIUM
ALORA, ESTRADIOL
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
ALOXI, PALONOSETRON HYDROCHLORIDE
ALPHAGAN P, BRIMONIDINE TARTRATE
ALPRAZOLAM, ALPRAZOLAM
ALPROSTADIL, ALPROSTADIL
ALREX, LOTEPREDNOL ETABONATE
ALTABAX, RETAPAMULIN
ALTACE, RAMIPRIL
ALTAFLUOR BENOX, BENOXINATE HYDROCHLORIDE
ALTAVERA, ETHINYL ESTRADIOL
ALTOPREV, LOVASTATIN
ALTRENO, TRETINOIN
ALUNBRIG, BRIGATINIB
ALVESCO, CICLESONIDE
ALYACEN 1/35, ETHINYL ESTRADIOL
ALYACEN 7/7/7, ETHINYL ESTRADIOL
AMABELZ, ESTRADIOL
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMARYL, GLIMEPIRIDE
AMBIEN, ZOLPIDEM TARTRATE
AMBIEN CR, ZOLPIDEM TARTRATE
AMBISOME, AMPHOTERICIN B
AMCINONIDE, AMCINONIDE
AMELUZ, AMINOLEVULINIC ACID HYDROCHLORIDE
AMERGE, NARATRIPTAN HYDROCHLORIDE
AMICAR, AMINOCAPROIC ACID
AMIDATE, ETOMIDATE
AMIFOSTINE, AMIFOSTINE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMINO ACIDS, AMINO ACIDS
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSYN 10%, AMINO ACIDS
AMINOSYN 3.5% M, AMINO ACIDS
AMINOSYN 8.5%, AMINO ACIDS
AMINOSYN 8.5% W/ELECTROLYTES, AMINO ACIDS
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS

APPENDIX A - PRODUCT NAME INDEX

**** A ****

AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMITIZA, LUBIPROSTONE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
AMMONIA N 13, AMMONIA N-13
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AMMONIUM LACTATE, AMMONIUM LACTATE
AMMONUL, SODIUM BENZOATE
AMNESTEEM, ISOTRETINOIN
AMOXAPINE, AMOXAPINE
AMOXICILLIN, AMOXICILLIN
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXIL, AMOXICILLIN
AMPHADASE, HYALURONIDASE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
AMPHOTERICIN B, AMPHOTERICIN B
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMPYRA, DALFAMPRIDINE
AMRINONE LACTATE, INAMRINONE LACTATE
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
AMYVID, FLORBETAPIR F-18
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
ANADROL-50, OXYMETHOLONE
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ANAPROX DS, NAPROXEN SODIUM
ANASTROZOLE, ANASTROZOLE
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCOBON, FLUCYTOSINE
ANDRODERM, TESTOSTERONE
ANDROGEL, TESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
ANGELIQ, DROSPIRENONE
ANGIOMAX, BIVALIRUDIN
ANNOVERA, ETHINYL ESTRADIOL
ANORO ELLIPTA, UMECLIDINIUM BROMIDE
ANTABUSE, DISULFIRAM
ANTARA (MICRONIZED), FENOFIBRATE
ANTHELIOS 20, AVOBENZONE (OTC)
ANTHELIOS 40, AVOBENZONE (OTC)
ANTHELIOS SX, AVOBENZONE (OTC)
ANTIZOL, FOMEPIZOLE
ANUSOL HC, HYDROCORTISONE
APADAZ, ACETAMINOPHEN
APIDRA, INSULIN GLULISINE RECOMBINANT
APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT
APLENZIN, BUPROPION HYDROBROMIDE
APOKYN, APOMORPHINE HYDROCHLORIDE
APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
APREPITANT, APREPITANT
APRISO, MESALAMINE
APTENSIO XR, METHYLPHENIDATE HYDROCHLORIDE
APTIOM, ESLICARBAZEPINE ACETATE
APTIVUS, TIPRANAVIR

APPENDIX A - PRODUCT NAME INDEX

**** A ****

AQUASOL A, VITAMIN A PALMITATE
ARAKODA, TAFENOQUINE SUCCINATE
ARANELLE, ETHINYL ESTRADIOL
ARAVA, LEFLUNOMIDE
ARCAPTA NEOHALER, INDACATEROL MALEATE
ARESTIN, MINOCYCLINE HYDROCHLORIDE
ARGATROBAN, ARGATROBAN
ARGATROBAN IN 0.9% SODIUM CHLORIDE, ARGATROBAN
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ARICEPT, DONEPEZIL HYDROCHLORIDE
ARIDOL KIT, MANNITOL
ARIKAYCE KIT, AMIKACIN SULFATE
ARIMIDEX, ANASTROZOLE
ARIPIPRAZOLE, ARIPIPRAZOLE
ARISTADA, ARIPIPRAZOLE LAUROXIL
ARISTADA INITIO KIT, ARIPIPRAZOLE LAUROXIL
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
ARIXTRA, FONDAPARINUX SODIUM
ARMODAFINIL, ARMODAFINIL
ARMONAIR RESPICLICK, FLUTICASONE PROPIONATE
ARNUITY ELLIPTA, FLUTICASONE FUROATE
AROMASIN, EXEMESTANE
ARRANON, NELARABINE
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ARTHROTEC, DICLOFENAC SODIUM
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, ARTICAINE HYDROCHLORIDE
ASACOL HD, MESALAMINE
ASCLERA, POLIDOCANOL
ASCOR, ASCORBIC ACID
ASENAPINE MALEATE, ASENAPINE MALEATE
ASHLYNA, ETHINYL ESTRADIOL
ASMANEX HFA, MOMETASONE FUROATE
ASMANEX TWISTHALER, MOMETASONE FUROATE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ASTAGRAF XL, TACROLIMUS
ASTELIN, AZELASTINE HYDROCHLORIDE
ASTEPRO, AZELASTINE HYDROCHLORIDE
ASTRAMORPH PF, MORPHINE SULFATE
ATACAND, CANDESARTAN CILEXETIL
ATACAND HCT, CANDESARTAN CILEXETIL
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATELVIA, RISEDRONATE SODIUM
ATENOLOL, ATENOLOL
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATHENTIA NEXT, LEVONORGESTREL (OTC)
ATIVAN, LORAZEPAM
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATOVAQUONE, ATOVAQUONE
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRALIN, TRETINOIN
ATRIDOX, DOXYCYCLINE HYCLATE
ATRIPLA, EFAVIRENZ
ATROPEN, ATROPINE SULFATE
ATROPINE SULFATE, ATROPINE SULFATE
ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
ATROPINE SULFATE LIFESHIELD ABBOJECT SYRINGE, ATROPINE SULFATE
ATROVENT HFA, IPRATROPIUM BROMIDE
AUBAGIO, TERIFLUNOMIDE
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN XR, AMOXICILLIN

APPENDIX A - PRODUCT NAME INDEX

**** A ****

AUROVELA 1.5/30, ETHINYL ESTRADIOL
AUROVELA 1/20, ETHINYL ESTRADIOL
AUROVELA 24 FE, ETHINYL ESTRADIOL
AUROVELA FE 1.5/30, ETHINYL ESTRADIOL
AUROVELA FE 1/20, ETHINYL ESTRADIOL
AURYXIA, FERRIC CITRATE
AUSTEDO, DEUTETRABENAZINE
AUVI-Q, EPINEPHRINE
AVAGARD, ALCOHOL (OTC)
AVAGE, TAZAROTENE
AVALIDE, HYDROCHLOROTHIAZIDE
AVANDIA, ROSIGLITAZONE MALEATE
AVAPRO, IRBESARTAN
AVC, SULFANILAMIDE
AVEED, TESTOSTERONE UNDECANOATE
AVELOX, MOXIFLOXACIN HYDROCHLORIDE
AVIANE-28, ETHINYL ESTRADIOL
AVITA, TRETINOIN
AVODART, DUTASTERIDE
AVYCAZ, AVIBACTAM SODIUM
AXERT, ALMOTRIPTAN MALATE
AXID AR, NIZATIDINE (OTC)
AXUMIN, FLUCICLOVINE F-18
AYUNA, ETHINYL ESTRADIOL
AZACITIDINE, AZACITIDINE
AZACTAM, AZTREONAM
AZACTAM IN PLASTIC CONTAINER, AZTREONAM
AZASAN, AZATHIOPRINE
AZASITE, AZITHROMYCIN
AZATHIOPRINE, AZATHIOPRINE
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
AZEDRA, IOBENGUANE I-131
AZELAIC ACID, AZELAIC ACID
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZELEX, AZELAIC ACID
AZILECT, RASAGILINE MESYLATE
AZITHROMYCIN, AZITHROMYCIN
AZOPT, BRINZOLAMIDE
AZOR, AMLODIPINE BESYLATE
AZTREONAM, AZTREONAM
AZULFIDINE, SULFASALAZINE
AZULFIDINE EN-TABS, SULFASALAZINE

**** B ****

BACIIM, BACITRACIN
BACITRACIN, BACITRACIN
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN ZINC
BACLOFEN, BACLOFEN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BACTRIM, SULFAMETHOXAZOLE
BACTRIM DS, SULFAMETHOXAZOLE
BAL, DIMERCAPROL
BALANCED SALT, CALCIUM CHLORIDE
BALCOLTRA, ETHINYL ESTRADIOL
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BALZIVA-28, ETHINYL ESTRADIOL
BANZEL, RUFINAMIDE
BARACLUDE, ENTECAVIR
BASAGLAR, INSULIN GLARGINE
BAXDELA, DELAFLOXACIN MEGLUMINE
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
BEKYREE, DESOGESTREL

APPENDIX A - PRODUCT NAME INDEX

**** B ****

BELBUCA, BUPRENORPHINE HYDROCHLORIDE
BELEODAQ, BELINOSTAT
BELRAPZO, BENDAMUSTINE HYDROCHLORIDE
BELSOMRA, SUVOREXANT
BELVIQ, LORCASERIN HYDROCHLORIDE
BELVIQ XR, LORCASERIN HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
BENDEKA, BENDAMUSTINE HYDROCHLORIDE
BENICAR, OLMESARTAN MEDOXOMIL
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENZACLIN, BENZOYL PEROXIDE
BENZAMYCIN, BENZOYL PEROXIDE
BENZNIDAZOLE, BENZNIDAZOLE
BENZONATATE, BENZONATATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BEPREVE, BEPOTASTINE BESILATE
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
BETA-VAL, BETAMETHASONE VALERATE
BETADINE, POVIDONE-IODINE
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BETAPACE, SOTALOL HYDROCHLORIDE
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BETHKIS, TOBRAMYCIN
BETIMOL, TIMOLOL
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BEVESPI AEROSPHERE, FORMOTEROL FUMARATE
BEVYXXA, BETRIXABAN
BEXAROTENE, BEXAROTENE
BEYAZ, DROSPIRENONE
BICALUTAMIDE, BICALUTAMIDE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
BICNU, CARMUSTINE
BIDIL, HYDRALAZINE HYDROCHLORIDE
BIJUVA, ESTRADIOL
BIKTARVY, BICTEGRAVIR SODIUM
BILTRICIDE, PRAZIQUANTEL
BIMATOPROST, BIMATOPROST
BINOSTO, ALENDRONATE SODIUM
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)
BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, BISMUTH SUBSALICYLATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BIVALIRUDIN, BIVALIRUDIN
BIVALIRUDIN IN 0.9% SODIUM CHLORIDE, BIVALIRUDIN
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BLEPH-10, SULFACETAMIDE SODIUM
BLEPHAMIDE, PREDNISOLONE ACETATE
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLISOVI 24 FE, ETHINYL ESTRADIOL
BLISOVI FE 1.5/30, ETHINYL ESTRADIOL
BLISOVI FE 1/20, ETHINYL ESTRADIOL
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE

APPENDIX A - PRODUCT NAME INDEX

**** B ****

BONIVA, IBANDRONATE SODIUM
BONJESTA, DOXYLAMINE SUCCINATE
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
BORTEZOMIB, BORTEZOMIB
BOSULIF, BOSUTINIB MONOHYDRATE
BRAFTOVI, ENCORAFENIB
BREO ELLIPTA, FLUTICASONE FUROATE
BRETHINE, TERBUTALINE SULFATE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVICON 28-DAY, ETHINYL ESTRADIOL
BREVITAL SODIUM, METHOHEXITAL SODIUM
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)
BRIDION, SUGAMMADEX SODIUM
BRIELLYN, ETHINYL ESTRADIOL
BRILINTA, TICAGRELOR
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BRISDELLE, PAROXETINE MESYLATE
BRIVIACT, BRIVARACETAM
BROMFED-DM, BROMPHENIRAMINE MALEATE
BROMFENAC SODIUM, BROMFENAC SODIUM
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE,
BROMSITE, BROMFENAC SODIUM
BRONCHO SALINE, SODIUM CHLORIDE (OTC)
BROVANA, ARFORMOTEROL TARTRATE
BRYHALI, HALOBETASOL PROPIONATE
BSS, CALCIUM CHLORIDE
BSS PLUS, CALCIUM CHLORIDE
BUDESONIDE, BUDESONIDE (OTC)
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
BUMEX, BUMETANIDE
BUNAVAIL, BUPRENORPHINE HYDROCHLORIDE
BUPHENYL, SODIUM PHENYLBUTYRATE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE, BUPRENORPHINE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
BUSULFAN, BUSULFAN
BUSULFEX, BUSULFAN
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
BUTAPAP, ACETAMINOPHEN
BUTENAFINE HYDROCHLORIDE, BUTENAFINE HYDROCHLORIDE (OTC)
BUTISOL SODIUM, BUTABARBITAL SODIUM
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTRANS, BUPRENORPHINE
BYDUREON, EXENATIDE SYNTHETIC
BYDUREON BCISE, EXENATIDE
BYDUREON PEN, EXENATIDE SYNTHETIC
BYETTA, EXENATIDE SYNTHETIC
BYSTOLIC, NEBIVOLOL HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** B ****

BYVALSON, NEBIVOLOL HYDROCHLORIDE

**** C ****

CABERGOLINE, CABERGOLINE
CABOMETYX, CABOZANTINIB S-MALATE
CADUET, AMLODIPINE BESYLATE
CAFCIT, CAFFEINE CITRATE
CAFERGOT, CAFFEINE
CAFFEINE CITRATE, CAFFEINE CITRATE
CALAN, VERAPAMIL HYDROCHLORIDE
CALAN SR, VERAPAMIL HYDROCHLORIDE
CALCIPOTRIENE, CALCIPOTRIENE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCITONIN-SALMON, CALCITONIN SALMON
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
CALCIUM GLUCONATE, CALCIUM GLUCONATE
CALCIUM GLUCONATE IN SODIUM CHLORIDE, CALCIUM GLUCONATE
CALDOLOR, IBUPROFEN
CALQUENCE, ACALABRUTINIB
CAMBIA, DICLOFENAC POTASSIUM
CAMILA, NORETHINDRONE
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CANASA, MESALAMINE
CANCIDAS, CASPOFUNGIN ACETATE
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CAPECITABINE, CAPECITABINE
CAPEX, FLUOCINOLONE ACETONIDE
CAPITAL SOLEIL 15, AVOBENZONE (OTC)
CAPRELSA, VANDETANIB
CAPREOMYCIN SULFATE, CAPREOMYCIN SULFATE
CAPTOPRIL, CAPTOPRIL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CARAC, FLUOROURACIL
CARAFATE, SUCRALFATE
CARBAGLU, CARGLUMIC ACID
CARBAMAZEPINE, CARBAMAZEPINE
CARBATROL, CARBAMAZEPINE
CARBIDOPA, CARBIDOPA
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDURA, DOXAZOSIN MESYLATE
CARDURA XL, DOXAZOSIN MESYLATE
CARISOPRODOL, CARISOPRODOL
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARMUSTINE, CARMUSTINE
CARNITOR, LEVOCARNITINE

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CARNITOR SF, LEVOCARNITINE
CAROSPIR, SPIRONOLACTONE
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
CASODEX, BICALUTAMIDE
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CASPORYN HC, HYDROCORTISONE
CASSIPA, BUPRENORPHINE HYDROCHLORIDE
CATAPRES, CLONIDINE HYDROCHLORIDE
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
CAVERJECT, ALPROSTADIL
CAVERJECT IMPULSE, ALPROSTADIL
CAYSTON, AZTREONAM
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFAZOLIN IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFDINIR, CEFDINIR
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFIXIME, CEFIXIME
CEFOTAN, CEFOTETAN DISODIUM
CEFOTAXIME, CEFOTAXIME SODIUM
CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
CEFOTETAN, CEFOTETAN DISODIUM
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM
CEFOXITIN, CEFOXITIN SODIUM
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
CEFOXITIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFTAZIDIME, CEFTAZIDIME
CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM
CEFTRIAXONE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
CEFTRIAXONE SODIUM, CEFTRIAXONE SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CELEBREX, CELECOXIB
CELECOXIB, CELECOXIB
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CELEXA, CITALOPRAM HYDROBROMIDE
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
CELONTIN, METHSUXIMIDE
CENTANY, MUPIROCIN
CEPHALEXIN, CEPHALEXIN
CEQUA, CYCLOSPORINE
CERDELGA, ELIGLUSTAT TARTRATE
CEREBYX, FOSPHENYTOIN SODIUM
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CEREZYME, IMIGLUCERASE
CERINTA, ETHINYL ESTRADIOL
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CERVIDIL, DINOPROSTONE
CESAMET, NABILONE

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE
CETROTIDE, CETRORELIX
CETYLEV, ACETYLCYSTEINE
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHANTIX, VARENICLINE TARTRATE
CHEMET, SUCCIMER
CHENODIOL, CHENODIOL
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CLARITIN, LORATADINE (OTC)
CHILDREN'S ELIXSURE, IBUPROFEN (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CHOLAC, LACTULOSE
CHOLBAM, CHOLIC ACID
CHOLESTYRAMINE, CHOLESTYRAMINE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CHOLINE C-11, CHOLINE C-11
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CIALIS, TADALAFIL
CICLOPIROX, CICLOPIROX
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)
CIDOFOVIR, CIDOFOVIR
CILOSTAZOL, CILOSTAZOL
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CIMDUO, LAMIVUDINE
CIMETIDINE, CIMETIDINE (OTC)
CIMETIDINE, CIMETIDINE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CINVANTI, APREPITANT
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRODEX, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISPLATIN, CISPLATIN
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
CLADRIBINE, CLADRIBINE
CLARAVIS, ISOTRETINOIN
CLARINEX, DESLORATADINE
CLARINEX D 24 HOUR, DESLORATADINE
CLARINEX-D 12 HOUR, DESLORATADINE
CLARITHROMYCIN, CLARITHROMYCIN
CLARITIN, LORATADINE (OTC)
CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN-D, LORATADINE (OTC)
CLARITIN-D 24 HOUR, LORATADINE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLENPIQ, CITRIC ACID
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEVIPREX, CLEVIDIPINE
CLIMARA, ESTRADIOL
CLIMARA PRO, ESTRADIOL
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLINDAGEL, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
CLINDESSE, CLINDAMYCIN PHOSPHATE
CLINDETS, CLINDAMYCIN PHOSPHATE
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBEX, CLOBETASOL PROPIONATE
CLODERM, CLOCORTOLONE PIVALATE
CLOFARABINE, CLOFARABINE
CLOLAR, CLOFARABINE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE, CLONIDINE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLOROTEKAL, CHLOROPROCAINE HYDROCHLORIDE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOZAPINE, CLOZAPINE
CLOZARIL, CLOZAPINE
COARTEM, ARTEMETHER
CODEINE SULFATE, CODEINE SULFATE
COGENTIN, BENZTROPINE MESYLATE
COL-PROBENECID, COLCHICINE
COLAZAL, BALSALAZIDE DISODIUM
COLCHICINE, COLCHICINE
COLCRYS, COLCHICINE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
COLESTID, COLESTIPOL HYDROCHLORIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
COLGATE TOTAL, SODIUM FLUORIDE (OTC)
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
COLOCORT, HYDROCORTISONE
COLPREP KIT, MAGNESIUM SULFATE
COLY-MYCIN M, COLISTIMETHATE SODIUM
COLY-MYCIN S, COLISTIN SULFATE
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
COMBIGAN, BRIMONIDINE TARTRATE
COMBIPATCH, ESTRADIOL
COMBIVENT RESPIMAT, ALBUTEROL SULFATE
COMBIVIR, LAMIVUDINE
COMETRIQ, CABOZANTINIB S-MALATE
COMPLERA, EMTRICITABINE
COMPRO, PROCHLORPERAZINE
COMTAN, ENTACAPONE
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
CONDYLOX, PODOFILOX
CONRAY, IOTHALAMATE MEGLUMINE

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CONRAY 43, IOTHALAMATE MEGLUMINE
CONSENSI, AMLODIPINE BESYLATE
CONSTILAC, LACTULOSE
CONTRAVE, BUPROPION HYDROCHLORIDE
CONZIP, TRAMADOL HYDROCHLORIDE
COPAXONE, GLATIRAMER ACETATE
COPIKTRA, DUVELISIB
CORDRAN, FLURANDRENOLIDE
CORDRAN SP, FLURANDRENOLIDE
COREG, CARVEDILOL
COREG CR, CARVEDILOL PHOSPHATE
CORGARD, NADOLOL
CORLANOR, IVABRADINE HYDROCHLORIDE
CORLOPAM, FENOLDOPAM MESYLATE
CORMAX, CLOBETASOL PROPIONATE
CORPHEDRA, EPHEDRINE SULFATE
CORTEF, HYDROCORTISONE
CORTENEMA, HYDROCORTISONE
CORTIFOAM, HYDROCORTISONE ACETATE
CORTISONE ACETATE, CORTISONE ACETATE
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE ACETATE
CORTROSYN, COSYNTROPIN
CORVERT, IBUTILIDE FUMARATE
CORZIDE, BENDROFLUMETHIAZIDE
COSMEGEN, DACTINOMYCIN
COSOPT, DORZOLAMIDE HYDROCHLORIDE
COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
COSYNTROPIN, COSYNTROPIN
COTELLIC, COBIMETINIB FUMARATE
COTEMPLA XR-ODT, METHYLPHENIDATE
COUMADIN, WARFARIN SODIUM
COZAAR, LOSARTAN POTASSIUM
CREON, PANCRELIPASE (AMYLASE
CRESEMBA, ISAVUCONAZONIUM SULFATE
CRESTOR, ROSUVASTATIN CALCIUM
CRINONE, PROGESTERONE
CRIXIVAN, INDINAVIR SULFATE
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
CROMOLYN SODIUM, CROMOLYN SODIUM
CROTAN, CROTAMITON
CRYSELLE, ETHINYL ESTRADIOL
CUBICIN, DAPTOMYCIN
CUBICIN RF, DAPTOMYCIN
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CUPRIMINE, PENICILLAMINE
CUROSURF, PORACTANT ALFA
CUTIVATE, FLUTICASONE PROPIONATE
CUVPOSA, GLYCOPYRROLATE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYANOKIT, HYDROXOCOBALAMIN
CYCLAFEM 0.5/35, ETHINYL ESTRADIOL
CYCLAFEM 1/35, ETHINYL ESTRADIOL
CYCLAFEM 7/7/7, ETHINYL ESTRADIOL
CYCLESSA, DESOGESTREL
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPENTOLATE HYDROCHLORIDE, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYCLOSET, BROMOCRIPTINE MESYLATE
CYCLOSPORINE, CYCLOSPORINE
CYKLOKAPRON, TRANEXAMIC ACID
CYMBALTA, DULOXETINE HYDROCHLORIDE
CYONANZ, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
CYSTADANE, BETAINE
CYSTAGON, CYSTEAMINE BITARTRATE
CYSTARAN, CYSTEAMINE HYDROCHLORIDE
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE
CYTARABINE, CYTARABINE
CYTOMEL, LIOTHYRONINE SODIUM
CYTOTEC, MISOPROSTOL
CYTOVENE, GANCICLOVIR SODIUM

**** D ****

D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
DACARBAZINE, DACARBAZINE
DACOGEN, DECITABINE
DACTINOMYCIN, DACTINOMYCIN
DAKLINZA, DACLATASVIR DIHYDROCHLORIDE
DALFAMPRIDINE, DALFAMPRIDINE
DALIRESP, ROFLUMILAST
DALVANCE, DALBAVANCIN HYDROCHLORIDE
DANAZOL, DANAZOL
DANTRIUM, DANTROLENE SODIUM
DANTROLENE SODIUM, DANTROLENE SODIUM
DAPSONE, DAPSONE
DAPTOMYCIN, DAPTOMYCIN
DARAPRIM, PYRIMETHAMINE
DARIFENACIN, DARIFENACIN HYDROBROMIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DARUNAVIR ETHANOLATE, DARUNAVIR ETHANOLATE
DASETTA 1/35, ETHINYL ESTRADIOL
DASETTA 7/7/7, ETHINYL ESTRADIOL
DATSCAN, IOFLUPANE I-123
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DAURISMO, GLASDEGIB
DAYPRO, OXAPROZIN
DAYSEE, ETHINYL ESTRADIOL
DAYTRANA, METHYLPHENIDATE
DDAVP, DESMOPRESSIN ACETATE
DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DECITABINE, DECITABINE
DEFERASIROX, DEFERASIROX
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEFINITY, PERFLUTREN
DEFITELIO, DEFIBROTIDE SODIUM
DELESTROGEN, ESTRADIOL VALERATE
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELSTRIGO, DORAVIRINE
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
DELZICOL, MESALAMINE
DEMADEX, TORSEMIDE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DEMSER, METYROSINE
DENAVIR, PENCICLOVIR
DEPACON, VALPROATE SODIUM

APPENDIX A - PRODUCT NAME INDEX

**** D ****

DEPAKENE, VALPROIC ACID
DEPAKOTE, DIVALPROEX SODIUM
DEPAKOTE ER, DIVALPROEX SODIUM
DEPEN, PENICILLAMINE
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DERMA-SMOOTHE/FS, FLUOCINOLONE ACETONIDE
DERMABET, BETAMETHASONE VALERATE
DERMATOP, PREDNICARBATE
DERMATOP E EMOLLIENT, PREDNICARBATE
DERMOTIC, FLUOCINOLONE ACETONIDE
DESCOVY, EMTRICITABINE
DESFERAL, DEFEROXAMINE MESYLATE
DESFLURANE, DESFLURANE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESLORATADINE, DESLORATADINE
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DESOGEN, DESOGESTREL
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DESONATE, DESONIDE
DESONIDE, DESONIDE
DESOWEN, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
DESVENLAFAXINE, DESVENLAFAXINE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DETROL, TOLTERODINE TARTRATE
DETROL LA, TOLTERODINE TARTRATE
DEXAMETHASONE, DEXAMETHASONE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
DEXASPORIN, DEXAMETHASONE
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
DEXEDRINE, DEXTROAMPHETAMINE SULFATE
DEXFERRUM, IRON DEXTRAN
DEXILANT, DEXLANSOPRAZOLE
DEXLANSOPRAZOLE, DEXLANSOPRAZOLE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DEXTENZA, DEXAMETHASONE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, DEXTROMETHORPHAN HYDROBROMIDE
DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX A - PRODUCT NAME INDEX

**** D ****

DEXTROSE 25%, DEXTROSE
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER,
DEXTROSE 50%, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DEXYCU KIT, DEXAMETHASONE
DIABETA, GLYBURIDE
DIACOMIT, STIRIPENTOL
DIAMOX, ACETAZOLAMIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIASTAT, DIAZEPAM
DIASTAT ACUDIAL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DIAZEPAM INTENSOL, DIAZEPAM
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DICLEGIS, DOXYLAMINE SUCCINATE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE), DICYCLOMINE HYDROCHLORIDE
DIDANOSINE, DIDANOSINE

APPENDIX A - PRODUCT NAME INDEX

**** D ****

DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
DIFFERIN, ADAPALENE (OTC)
DIFFERIN, ADAPALENE
DIFICID, FIDAXOMICIN
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DIFLUCAN, FLUCONAZOLE
DIFLUNISAL, DIFLUNISAL
DIGOXIN, DIGOXIN
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DILANTIN, PHENYTOIN
DILANTIN, PHENYTOIN SODIUM
DILANTIN-125, PHENYTOIN
DILATRATE-SR, ISOSORBIDE DINITRATE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DILTZAC, DILTIAZEM HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE
DIOVAN, VALSARTAN
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIPENTUM, OLSALAZINE SODIUM
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIPRIVAN, PROPOFOL
DIPROLENE, BETAMETHASONE DIPROPIONATE
DIPROLENE AF, BETAMETHASONE DIPROPIONATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DISULFIRAM, DISULFIRAM
DITROPAN XL, OXYBUTYNIN CHLORIDE
DIURIL, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE SODIUM
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DIVIGEL, ESTRADIOL
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
DOCETAXEL, DOCETAXEL
DOCOSANOL, DOCOSANOL (OTC)
DOFETILIDE, DOFETILIDE
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPRAM, DOXAPRAM HYDROCHLORIDE
DOPTELET, AVATROMBOPAG MALEATE
DORAL, QUAZEPAM
DORYX, DOXYCYCLINE HYCLATE
DORYX MPC, DOXYCYCLINE HYCLATE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DOTAREM, GADOTERATE MEGLUMINE
DOVONEX, CALCIPOTRIENE
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE

APPENDIX A - PRODUCT NAME INDEX

**** D ****

DOXYCYCLINE, DOXYCYCLINE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
DRAX EXAMETAZIME, TECHNETIUM TC-99M EXAMETAZIME KIT
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
DRISDOL, ERGOCALCIFEROL
DRONABINOL, DRONABINOL
DROPERIDOL, DROPERIDOL
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
DROXIA, HYDROXYUREA
DSUVIA, SUFENTANIL CITRATE
DTPA, TECHNETIUM TC-99M PENTETATE KIT
DUAC, BENZOYL PEROXIDE
DUAVEE, BAZEDOXIFENE ACETATE
DUETACT, GLIMEPIRIDE
DUEXIS, FAMOTIDINE
DULERA, FORMOTEROL FUMARATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUODOTE, ATROPINE
DUOPA, CARBIDOPA
DURACLON, CLONIDINE HYDROCHLORIDE
DURAGESIC-100, FENTANYL
DURAGESIC-12, FENTANYL
DURAGESIC-25, FENTANYL
DURAGESIC-37, FENTANYL
DURAGESIC-50, FENTANYL
DURAGESIC-75, FENTANYL
DURAMORPH PF, MORPHINE SULFATE
DURAPREP, IODINE POVACRYLEX (OTC)
DUREZOL, DIFLUPREDNATE
DURLAZA, ASPIRIN
DUTASTERIDE, DUTASTERIDE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
DUTOPROL, HYDROCHLOROTHIAZIDE
DUVOID, BETHANECHOL CHLORIDE
DUZALLO, ALLOPURINOL
DYANAVEL XR, AMPHETAMINE
DYAZIDE, HYDROCHLOROTHIAZIDE
DYCLOPRO, DYCLONINE HYDROCHLORIDE
DYMISTA, AZELASTINE HYDROCHLORIDE
DYNACIN, MINOCYCLINE HYDROCHLORIDE
DYRENIUM, TRIAMTERENE

**** E ****

E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)
E-Z-HD, BARIUM SULFATE
E-Z-PAQUE, BARIUM SULFATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
EC-NAPROSYN, NAPROXEN
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ECOZA, ECONAZOLE NITRATE
EDARBI, AZILSARTAN KAMEDOXOMIL
EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
EDEX, ALPROSTADIL
EDLUAR, ZOLPIDEM TARTRATE
EDURANT, RILPIVIRINE HYDROCHLORIDE
EFAVIRENZ, EFAVIRENZ
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ

APPENDIX A - PRODUCT NAME INDEX

**** E ****

EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
EFFIENT, PRASUGREL HYDROCHLORIDE
EFUDEX, FLUOROURACIL
EGRIFTA, TESAMORELIN ACETATE
ELELYSO, TALIGLUCERASE ALFA
ELEPSIA XR, LEVETIRACETAM
ELESTAT, EPINASTINE HYDROCHLORIDE
ELESTRIN, ESTRADIOL
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ELIDEL, PIMECROLIMUS
ELIFEMME, ETHINYL ESTRADIOL
ELIGARD, LEUPROLIDE ACETATE
ELIMITE, PERMETHRIN
ELINEST, ETHINYL ESTRADIOL
ELIQUIS, APIXABAN
ELIXOPHYLLIN, THEOPHYLLINE
ELLA, ULIPRISTAL ACETATE
ELLENCE, EPIRUBICIN HYDROCHLORIDE
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE
ELMIRON, PENTOSAN POLYSULFATE SODIUM
ELOCON, MOMETASONE FUROATE
ELOXATIN, OXALIPLATIN
EMADINE, EMEDASTINE DIFUMARATE
EMBEDA, MORPHINE SULFATE
EMBELINE, CLOBETASOL PROPIONATE
EMBELINE E, CLOBETASOL PROPIONATE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
EMEND, APREPITANT
EMEND, FOSAPREPITANT DIMEGLUMINE
EMFLAZA, DEFLAZACORT
EMLA, LIDOCAINE
EMOQUETTE, DESOGESTREL
EMSAM, SELEGILINE
EMTRICITABINE, EMTRICITABINE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EMTRIVA, EMTRICITABINE
EMVERM, MEBENDAZOLE
ENABLEX, DARIFENACIN HYDROBROMIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRILAT, ENALAPRILAT
ENDARI, L-GLUTAMINE
ENDOMETRIN, PROGESTERONE
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
ENPRESSE-28, ETHINYL ESTRADIOL
ENSKYCE, DESOGESTREL
ENSTILAR, BETAMETHASONE DIPROPIONATE
ENTACAPONE, ENTACAPONE
ENTECAVIR, ENTECAVIR
ENTEREG, ALVIMOPAN
ENTOCORT EC, BUDESONIDE
ENTRESTO, SACUBITRIL
ENULOSE, LACTULOSE
ENVARSUS XR, TACROLIMUS
EOVIST, GADOXETATE DISODIUM
EPANED, ENALAPRIL MALEATE
EPANED KIT, ENALAPRIL MALEATE
EPCLUSA, SOFOSBUVIR
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPIDIOLEX, CANNABIDIOL
EPIDUO, ADAPALENE
EPIDUO FORTE, ADAPALENE
EPIFOAM, HYDROCORTISONE ACETATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** E ****

EPINEPHRINE, EPINEPHRINE
EPINEPHRINE (AUTOINJECTOR), EPINEPHRINE
EPIPEN, EPINEPHRINE
EPIPEN JR., EPINEPHRINE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
EPITOL, CARBAMAZEPINE
EPIVIR, LAMIVUDINE
EPIVIR-HBV, LAMIVUDINE
EPLERENONE, EPLERENONE
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
EPROSARTAN MESYLATE, EPROSARTAN MESYLATE
EPTIFIBATIDE, EPTIFIBATIDE
EPZICOM, ABACAVIR SULFATE
EQUETRO, CARBAMAZEPINE
ERAXIS, ANIDULAFUNGIN
ERGOCALCIFEROL, ERGOCALCIFEROL
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ERGOMAR, ERGOTAMINE TARTRATE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
ERIVEDGE, VISMODEGIB
ERLEADA, APALUTAMIDE
ERRIN, NORETHINDRONE
ERTACZO, SERTACONAZOLE NITRATE
ERTAPENEM SODIUM, ERTAPENEM SODIUM
ERY-TAB, ERYTHROMYCIN
ERYC, ERYTHROMYCIN
ERYGEL, ERYTHROMYCIN
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN, ERYTHROMYCIN
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ESBRIET, PIRFENIDONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESKATA, HYDROGEN PEROXIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ESOMEPRAZOLE STRONTIUM, ESOMEPRAZOLE STRONTIUM
ESTARYLLA, ETHINYL ESTRADIOL
ESTAZOLAM, ESTAZOLAM
ESTRACE, ESTRADIOL
ESTRADIOL, ESTRADIOL
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ESTRADIOL AND NORGESTIMATE, ESTRADIOL
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ESTRING, ESTRADIOL
ESTROGEL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
ESTROSTEP FE, ETHINYL ESTRADIOL
ESZOPICLONE, ESZOPICLONE
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
ETHACRYNIC ACID, ETHACRYNIC ACID
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
ETHAMOLIN, ETHANOLAMINE OLEATE
ETHOSUXIMIDE, ETHOSUXIMIDE
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ETHYOL, AMIFOSTINE
ETIDRONATE DISODIUM, ETIDRONATE DISODIUM
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE

APPENDIX A - PRODUCT NAME INDEX

**** E ****

ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
ETOPOSIDE, ETOPOSIDE
EUCRISA, CRISABOROLE
EURAX, CROTAMITON
EUTHYROX, LEVOTHYROXINE SODIUM **
EVAMIST, ESTRADIOL
EVEKEO, AMPHETAMINE SULFATE
EVEROLIMUS, EVEROLIMUS
EVISTA, RALOXIFENE HYDROCHLORIDE
EVOCLIN, CLINDAMYCIN PHOSPHATE
EVOMELA, MELPHALAN HYDROCHLORIDE
EVOTAZ, ATAZANAVIR SULFATE
EVOXAC, CEVIMELINE HYDROCHLORIDE
EVZIO, NALOXONE HYDROCHLORIDE
EXALGO, HYDROMORPHONE HYDROCHLORIDE
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
EXELDERM, SULCONAZOLE NITRATE
EXELON, RIVASTIGMINE
EXELON, RIVASTIGMINE TARTRATE
EXEMESTANE, EXEMESTANE
EXFORGE, AMLODIPINE BESYLATE
EXFORGE HCT, AMLODIPINE BESYLATE
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)
EXJADE, DEFERASIROX
EXONDYS 51, ETEPLIRSEN
EXPAREL, BUPIVACAINE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
EXTINA, KETOCONAZOLE
EXTRANEAL, ICODEXTRIN
EZALLOR, ROSUVASTATIN CALCIUM
EZETIMIBE, EZETIMIBE
EZETIMIBE AND ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
EZETIMIBE AND SIMVASTATIN, EZETIMIBE

**** F ****

FABIOR, TAZAROTENE
FACTIVE, GEMIFLOXACIN MESYLATE
FALLBACK SOLO, LEVONORGESTREL (OTC)
FALMINA, ETHINYL ESTRADIOL
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE (OTC)
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
FANAPT, ILOPERIDONE
FARESTON, TOREMIFENE CITRATE
FARXIGA, DAPAGLIFLOZIN
FARYDAK, PANOBINOSTAT LACTATE
FASLODEX, FULVESTRANT
FAYOSIM, ETHINYL ESTRADIOL
FAZACLO ODT, CLOZAPINE
FELBAMATE, FELBAMATE
FELBATOL, FELBAMATE
FELDENE, PIROXICAM
FELODIPINE, FELODIPINE
FEMARA, LETROZOLE
FEMCON FE, ETHINYL ESTRADIOL
FEMHRT, ETHINYL ESTRADIOL
FEMRING, ESTRADIOL ACETATE
FENOFIBRATE, FENOFIBRATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FENOGLIDE, FENOFIBRATE
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE

APPENDIX A - PRODUCT NAME INDEX

**** F ****

FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FENTANYL CITRATE, FENTANYL CITRATE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL
FENTORA, FENTANYL CITRATE
FERAHEME, FERUMOXYTOL
FERRIPROX, DEFERIPRONE
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FIASP, INSULIN ASPART
FIASP FLEXTOUCH, INSULIN ASPART
FIBRICOR, FENOFIBRIC ACID
FINACEA, AZELAIC ACID
FINASTERIDE, FINASTERIDE
FIORICET W/ CODEINE, ACETAMINOPHEN
FIORINAL, ASPIRIN
FIORINAL W/CODEINE, ASPIRIN
FIRAZYR, ICATIBANT ACETATE
FIRDAPSE, AMIFAMPRIDINE PHOSPHATE
FIRMAGON, DEGARELIX ACETATE
FIRVANQ KIT, VANCOMYCIN HYDROCHLORIDE
FLAC, FLUOCINOLONE ACETONIDE
FLAGYL, METRONIDAZOLE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLAREX, FLUOROMETHOLONE ACETATE
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLECTOR, DICLOFENAC EPOLAMINE
FLOLAN, EPOPROSTENOL SODIUM
FLOLIPID, SIMVASTATIN
FLOMAX, TAMSULOSIN HYDROCHLORIDE
FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
FLONASE SENSIMIST ALLERGY RELIEF, FLUTICASONE FUROATE (OTC)
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
FLOVENT HFA, FLUTICASONE PROPIONATE
FLOXURIDINE, FLOXURIDINE
FLUCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUCONAZOLE, FLUCONAZOLE
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCYTOSINE, FLUCYTOSINE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
FLUMADINE, RIMANTADINE HYDROCHLORIDE
FLUMAZENIL, FLUMAZENIL
FLUNISOLIDE, FLUNISOLIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE

APPENDIX A - PRODUCT NAME INDEX

**** F ****

FLUOCINONIDE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUORESCITE, FLUORESCEIN SODIUM
FLUOROPLEX, FLUOROURACIL
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUOXYMESTERONE, FLUOXYMESTERONE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLURANDRENOLIDE, FLURANDRENOLIDE
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
FLUTAMIDE, FLUTAMIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FML, FLUOROMETHOLONE
FML FORTE, FLUOROMETHOLONE
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FOLLISTIM AQ, FOLLITROPIN ALFA/BETA
FOLOTYN, PRALATREXATE
FOMEPIZOLE, FOMEPIZOLE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
FORANE, ISOFLURANE
FORFIVO XL, BUPROPION HYDROCHLORIDE
FORTAMET, METFORMIN HYDROCHLORIDE
FORTAZ, CEFTAZIDIME
FORTEO, TERIPARATIDE RECOMBINANT HUMAN
FORTESTA, TESTOSTERONE
FOSAMAX, ALENDRONATE SODIUM
FOSAMAX PLUS D, ALENDRONATE SODIUM
FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FOSCAVIR, FOSCARNET SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FOSRENOL, LANTHANUM CARBONATE
FRAGMIN, DALTEPARIN SODIUM
FREAMINE HBC 6.9%, AMINO ACIDS
FREAMINE III 10%, AMINO ACIDS
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5%, AMINO ACIDS
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
FROVA, FROVATRIPTAN SUCCINATE
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
FURADANTIN, NITROFURANTOIN
FUROSEMIDE, FUROSEMIDE
FUSILEV, LEVOLEUCOVORIN CALCIUM
FUZEON, ENFUVIRTIDE
FYAVOLV, ETHINYL ESTRADIOL
FYCOMPA, PERAMPANEL

**** G ****

GABAPENTIN, GABAPENTIN
GABITRIL, TIAGABINE HYDROCHLORIDE
GABLOFEN, BACLOFEN
GADAVIST, GADOBUTROL
GALAFOLD, MIGALASTAT HYDROCHLORIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67

APPENDIX A - PRODUCT NAME INDEX

**** G ****

GALZIN, ZINC ACETATE
GANCICLOVIR, GANCICLOVIR
GANCICLOVIR, GANCICLOVIR SODIUM
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
GANIRELIX ACETATE, GANIRELIX ACETATE
GASTROCROM, CROMOLYN SODIUM
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
GATIFLOXACIN, GATIFLOXACIN
GATTEX KIT, TEDUGLUTIDE RECOMBINANT
GAVISCON, ALUMINUM HYDROXIDE (OTC)
GELNIQUE, OXYBUTYNIN CHLORIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GEMFIBROZIL, GEMFIBROZIL
GEMIFLOXACIN MESYLATE, GEMIFLOXACIN MESYLATE
GEMZAR, GEMCITABINE HYDROCHLORIDE
GEN-XENE, CLORAZEPATE DIPOTASSIUM
GENERLAC, LACTULOSE
GENGRAF, CYCLOSPORINE
GENOPTIC, GENTAMICIN SULFATE
GENOTROPIN, SOMATROPIN RECOMBINANT
GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
GENTAK, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENVOYA, COBICISTAT
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
GIAPREZA, ANGIOTENSIN II ACETATE
GIAZO, BALSALAZIDE DISODIUM
GILDAGIA, ETHINYL ESTRADIOL
GILDESS 1.5/30, ETHINYL ESTRADIOL
GILDESS 1/20, ETHINYL ESTRADIOL
GILDESS 24 FE, ETHINYL ESTRADIOL
GILDESS FE 1.5/30, ETHINYL ESTRADIOL
GILDESS FE 1/20, ETHINYL ESTRADIOL
GILENYA, FINGOLIMOD HYDROCHLORIDE
GILOTRIF, AFATINIB DIMALEATE
GLATIRAMER ACETATE, GLATIRAMER ACETATE
GLATOPA, GLATIRAMER ACETATE
GLEEVEC, IMATINIB MESYLATE
GLEOLAN, AMINOLEVULINIC ACID HYDROCHLORIDE
GLEOSTINE, LOMUSTINE
GLIADEL, CARMUSTINE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLOFIL-125, IOTHALAMATE SODIUM I-125
GLUCAGEN, GLUCAGON HYDROCHLORIDE
GLUCAGON, GLUCAGON
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLUCOPHAGE, METFORMIN HYDROCHLORIDE
GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE
GLUCOTROL, GLIPIZIDE
GLUCOTROL XL, GLIPIZIDE
GLUMETZA, METFORMIN HYDROCHLORIDE
GLYBURIDE, GLYBURIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
GLYCOLAX, POLYETHYLENE GLYCOL 3350 (OTC)
GLYCOLAX, POLYETHYLENE GLYCOL 3350
GLYCOPYRROLATE, GLYCOPYRROLATE
GLYDO, LIDOCAINE HYDROCHLORIDE
GLYNASE, GLYBURIDE
GLYRX-PF, GLYCOPYRROLATE

APPENDIX A - PRODUCT NAME INDEX

**** G ****

GLYSET, MIGLITOL
GLYXAMBI, EMPAGLIFLOZIN
GOCOVRI, AMANTADINE HYDROCHLORIDE
GOLYTELY, POLYETHYLENE GLYCOL 3350
GONAL-F, FOLLITROPIN ALFA/BETA
GONAL-F RFF, FOLLITROPIN ALFA/BETA
GONAL-F RFF REDI-JECT, FOLLITROPIN ALFA/BETA
GONITRO, NITROGLYCERIN
GOPRELTO, COCAINE HYDROCHLORIDE
GRALISE, GABAPENTIN
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
GRISEOFULVIN,ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
GUAIFENESIN, GUAIFENESIN (OTC)
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
GUANABENZ ACETATE, GUANABENZ ACETATE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE
GYNAZOLE-1, BUTOCONAZOLE NITRATE

**** H ****

H.P. ACTHAR GEL, CORTICOTROPIN
HABITROL, NICOTINE (OTC)
HAILEY 1.5/30, ETHINYL ESTRADIOL
HAILEY FE 1.5/30, ETHINYL ESTRADIOL
HAILEY FE 1/20, ETHINYL ESTRADIOL
HALAVEN, ERIBULIN MESYLATE
HALCION, TRIAZOLAM
HALDOL, HALOPERIDOL DECANOATE
HALDOL, HALOPERIDOL LACTATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HALOG, HALCINONIDE
HALOPERIDOL, HALOPERIDOL
HALOPERIDOL, HALOPERIDOL LACTATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HARVONI, LEDIPASVIR
HEATHER, NORETHINDRONE
HECTOROL, DOXERCALCIFEROL
HEMABATE, CARBOPROST TROMETHAMINE
HEMANGEOL, PROPRANOLOL HYDROCHLORIDE
HEPARIN SODIUM, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPATAMINE 8%, AMINO ACIDS
HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT
HEPSERA, ADEFOVIR DIPIVOXIL
HER STYLE, LEVONORGESTREL (OTC)
HETLIOZ, TASIMELTEON
HEXALEN, ALTRETAMINE
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)

APPENDIX A - PRODUCT NAME INDEX

**** H ****

HICON, SODIUM IODIDE I-131
HIPREX, METHENAMINE HIPPURATE
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
HORIZANT, GABAPENTIN ENACARBIL
HUMALOG, INSULIN LISPRO RECOMBINANT
HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMATROPE, SOMATROPIN RECOMBINANT
HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
HUMULIN R, INSULIN HUMAN
HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN R KWIKPEN, INSULIN HUMAN
HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
HYCAMTIN, TOPOTECAN HYDROCHLORIDE
HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDREA, HYDROXYUREA
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
HYDROCORTISONE, HYDROCORTISONE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN
HYSINGLA, HYDROCODONE BITARTRATE
HYZAAR, HYDROCHLOROTHIAZIDE

**** I ****

IBANDRONATE SODIUM, IBANDRONATE SODIUM
IBRANCE, PALBOCICLIB
IBU-TAB, IBUPROFEN
IBU-TAB 200, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN LYSINE, IBUPROFEN LYSINE
IBUPROFEN SODIUM, IBUPROFEN SODIUM (OTC)
IBUPROHM, IBUPROFEN (OTC)
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
IC-GREEN, INDOCYANINE GREEN
ICLEVIA, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX

**** I ****

ICLUSIG, PONATINIB HYDROCHLORIDE
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
IDHIFA, ENASIDENIB MESYLATE
IDKIT:HP, CITRIC ACID
IFEX, IFOSFAMIDE
IFOSFAMIDE, IFOSFAMIDE
ILEVRO, NEPAFENAC
ILOPERIDONE, ILOPERIDONE
ILUVIEN, FLUOCINOLONE ACETONIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IMBRUVICA, IBRUTINIB
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
IMIQUIMOD, IMIQUIMOD
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
IMPAVIDO, MILTEFOSINE
IMPOYZ, CLOBETASOL PROPIONATE
IMURAN, AZATHIOPRINE
IMVEXXY, ESTRADIOL
INAPSINE, DROPERIDOL
INBRIJA, LEVODOPA
INCASSIA, NORETHINDRONE
INCRELEX, MECASERMIN RECOMBINANT
INCRUSE ELLIPTA, UMECLIDINIUM BROMIDE
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INDICLOR, INDIUM IN-111 CHLORIDE
INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
INDOCIN, INDOMETHACIN
INDOCIN, INDOMETHACIN SODIUM
INDOCYANINE GREEN, INDOCYANINE GREEN
INDOMETHACIN, INDOMETHACIN
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
INFASURF PRESERVATIVE FREE, CALFACTANT
INFED, IRON DEXTRAN
INFUGEM, GEMCITABINE HYDROCHLORIDE
INFUMORPH, MORPHINE SULFATE
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
INFUVITE PEDIATRIC, ASCORBIC ACID
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
INGENOL MEBUTATE, INGENOL MEBUTATE
INGREZZA, VALBENAZINE TOSYLATE
INJECTAFER, FERRIC CARBOXYMALTOSE
INLYTA, AXITINIB
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
INOMAX, NITRIC OXIDE
INSPRA, EPLERENONE
INTEGRILIN, EPTIFIBATIDE
INTELENCE, ETRAVIRINE
INTERMEZZO, ZOLPIDEM TARTRATE
INTRALIPID 10%, SOYBEAN OIL
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL
INTRAROSA, PRASTERONE
INTROVALE, ETHINYL ESTRADIOL
INTUNIV, GUANFACINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** I ****

INVANZ, ERTAPENEM SODIUM
INVEGA, PALIPERIDONE
INVEGA SUSTENNA, PALIPERIDONE PALMITATE
INVEGA TRINZA, PALIPERIDONE PALMITATE
INVELTYS, LOTEPREDNOL ETABONATE
INVIRASE, SAQUINAVIR MESYLATE
INVOKAMET, CANAGLIFLOZIN
INVOKAMET XR, CANAGLIFLOZIN
INVOKANA, CANAGLIFLOZIN
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
IOSAT, POTASSIUM IODIDE (OTC)
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRBESARTAN, IRBESARTAN
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRESSA, GEFITINIB
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ISENTRESS, RALTEGRAVIR POTASSIUM
ISENTRESS HD, RALTEGRAVIR POTASSIUM
ISIBLOOM, DESOGESTREL
ISOFLURANE, ISOFLURANE
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISONIAZID, ISONIAZID
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
ISOPTO ATROPINE, ATROPINE SULFATE
ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
ISORDIL, ISOSORBIDE DINITRATE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
ISOSULFAN BLUE, ISOSULFAN BLUE
ISOTRETINOIN, ISOTRETINOIN
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
ISRADIPINE, ISRADIPINE
ISTALOL, TIMOLOL MALEATE
ISTODAX, ROMIDEPSIN
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
ITRACONAZOLE, ITRACONAZOLE
IVERMECTIN, IVERMECTIN
IVY BLOCK, BENTOQUATAM (OTC)
IXEMPRA KIT, IXABEPILONE

**** J ****

JADENU, DEFERASIROX
JADENU SPRINKLE, DEFERASIROX
JAIMIESS, ETHINYL ESTRADIOL
JAKAFI, RUXOLITINIB PHOSPHATE
JALYN, DUTASTERIDE
JANTOVEN, WARFARIN SODIUM
JANUMET, METFORMIN HYDROCHLORIDE
JANUMET XR, METFORMIN HYDROCHLORIDE
JANUVIA, SITAGLIPTIN PHOSPHATE
JARDIANCE, EMPAGLIFLOZIN
JEANATOPE, ALBUMIN IODINATED I-125 SERUM
JENCYCLA, NORETHINDRONE
JENTADUETO, LINAGLIPTIN
JENTADUETO XR, LINAGLIPTIN
JEVTANA KIT, CABAZITAXEL
JORNAY PM, METHYLPHENIDATE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** J ****

JUBLIA, EFINACONAZOLE
JULUCA, DOLUTEGRAVIR SODIUM
JUNEL 1.5/30, ETHINYL ESTRADIOL
JUNEL 1/20, ETHINYL ESTRADIOL
JUNEL FE 1.5/30, ETHINYL ESTRADIOL
JUNEL FE 1/20, ETHINYL ESTRADIOL
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
JUXTAPID, LOMITAPIDE MESYLATE
JYNARQUE, TOLVAPTAN

**** K ****

K-TAB, POTASSIUM CHLORIDE
KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
KADIAN, MORPHINE SULFATE
KAITLIB FE, ETHINYL ESTRADIOL
KALETRA, LOPINAVIR
KALEXATE, SODIUM POLYSTYRENE SULFONATE
KALLIGA, DESOGESTREL
KALYDECO, IVACAFTOR
KAPSPARGO SPRINKLE, METOPROLOL SUCCINATE
KAPVAY, CLONIDINE HYDROCHLORIDE
KARBINAL ER, CARBINOXAMINE MALEATE
KARIVA, DESOGESTREL
KAZANO, ALOGLIPTIN BENZOATE
KEFLEX, CEPHALEXIN
KELNOR, ETHINYL ESTRADIOL
KENALOG, TRIAMCINOLONE ACETONIDE
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KENGREAL, CANGRELOR
KEPPRA, LEVETIRACETAM
KEPPRA XR, LEVETIRACETAM
KERYDIN, TAVABOROLE
KETALAR, KETAMINE HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
KETOZOLE, KETOCONAZOLE
KEVEYIS, DICHLORPHENAMIDE
KHAPZORY, LEVOLEUCOVORIN
KHEDEZLA, DESVENLAFAXINE
KIMIDESS, DESOGESTREL
KINEVAC, SINCALIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
KISQALI, RIBOCICLIB SUCCINATE
KISQALI FEMARA CO-PACK (COPACKAGED), LETROZOLE
KITABIS PAK, TOBRAMYCIN
KLARON, SULFACETAMIDE SODIUM
KLONOPIN, CLONAZEPAM
KLOR-CON, POTASSIUM CHLORIDE
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
KORLYM, MIFEPRISTONE
KOVANAZE, OXYMETAZOLINE HYDROCHLORIDE
KRINTAFEL, TAFENOQUINE SUCCINATE
KURVELO, ETHINYL ESTRADIOL
KUVAN, SAPROPTERIN DIHYDROCHLORIDE
KYBELLA, DEOXYCHOLIC ACID
KYLEENA, LEVONORGESTREL

APPENDIX A - PRODUCT NAME INDEX

**** K ****

KYPROLIS, CARFILZOMIB

**** L ****

LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LACRISERT, HYDROXYPROPYL CELLULOSE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTULOSE, LACTULOSE
LAMICTAL, LAMOTRIGINE
LAMICTAL CD, LAMOTRIGINE
LAMICTAL ODT, LAMOTRIGINE
LAMICTAL XR, LAMOTRIGINE
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
LAMISIL, TERBINAFINE HYDROCHLORIDE
LAMISIL AT, TERBINAFINE (OTC)
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
LAMIVUDINE, LAMIVUDINE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LANIAZID, ISONIAZID
LANORINAL, ASPIRIN
LANOXIN, DIGOXIN
LANOXIN PEDIATRIC, DIGOXIN
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
LANTHANUM CARBONATE, LANTHANUM CARBONATE
LANTUS, INSULIN GLARGINE RECOMBINANT
LANTUS SOLOSTAR, INSULIN GLARGINE RECOMBINANT
LARIN 1.5/30, ETHINYL ESTRADIOL
LARIN 1/20, ETHINYL ESTRADIOL
LARIN 24 FE, ETHINYL ESTRADIOL
LARIN FE 1.5/30, ETHINYL ESTRADIOL
LARIN FE 1/20, ETHINYL ESTRADIOL
LAROTID, AMOXICILLIN
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LASIX, FUROSEMIDE
LASTACAFT, ALCAFTADINE
LATANOPROST, LATANOPROST
LATISSE, BIMATOPROST
LATUDA, LURASIDONE HYDROCHLORIDE
LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
LAZANDA, FENTANYL CITRATE
LEFLUNOMIDE, LEFLUNOMIDE
LENVIMA, LENVATINIB MESYLATE
LERIBANE, ETHINYL ESTRADIOL
LESCOL XL, FLUVASTATIN SODIUM
LESSINA-28, ETHINYL ESTRADIOL
LETAIRIS, AMBRISENTAN
LETROZOLE, LETROZOLE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUKERAN, CHLORAMBUCIL
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LEVEMIR, INSULIN DETEMIR RECOMBINANT
LEVEMIR FLEXTOUCH, INSULIN DETEMIR RECOMBINANT
LEVETIRACETAM, LEVETIRACETAM
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVITRA, VARDENAFIL HYDROCHLORIDE
LEVO-T, LEVOTHYROXINE SODIUM **
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
LEVOCARNITINE, LEVOCARNITINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** L ****

LEVOFLOXACIN, LEVOFLOXACIN
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
LEVONEST, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVOPHED, NOREPINEPHRINE BITARTRATE
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
LEVOXYL, LEVOTHYROXINE SODIUM **
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE
LEXAPRO, ESCITALOPRAM OXALATE
LEXISCAN, REGADENOSON
LEXIVA, FOSAMPRENAVIR CALCIUM
LIALDA, MESALAMINE
LIBRAX, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
LICART, DICLOFENAC EPOLAMINE
LIDEX, FLUOCINONIDE
LIDEX-E, FLUOCINONIDE
LIDOCAINE, LIDOCAINE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDODERM, LIDOCAINE
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
LILETTA, LEVONORGESTREL
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
LINCOMYCIN, LINCOMYCIN HYDROCHLORIDE
LINDANE, LINDANE
LINEZOLID, LINEZOLID
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, LINEZOLID
LINZESS, LINACLOTIDE
LIORESAL, BACLOFEN
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
LIPIODOL, ETHIODIZED OIL
LIPITOR, ATORVASTATIN CALCIUM
LIPOFEN, FENOFIBRATE
LIQUID E-Z-PAQUE, BARIUM SULFATE
LISINOPRIL, LISINOPRIL
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
LITHOBID, LITHIUM CARBONATE
LITHOSTAT, ACETOHYDROXAMIC ACID
LIVALO, PITAVASTATIN CALCIUM
LO LOESTRIN FE, ETHINYL ESTRADIOL
LO SIMPESSE, ETHINYL ESTRADIOL
LO-ZUMANDIMINE, DROSPIRENONE
LOCOID, HYDROCORTISONE BUTYRATE
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE

APPENDIX A - PRODUCT NAME INDEX

** L **

LODOSYN, CARBIDOPA
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL
LOESTRIN 24 FE, ETHINYL ESTRADIOL
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL
LOGILIA, ULIPRISTAL ACETATE
LOKELMA, SODIUM ZIRCONIUM CYCLOSILICATE
LOMAIRA, PHENTERMINE HYDROCHLORIDE
LOMOTIL, ATROPINE SULFATE
LONHALA MAGNAIR KIT, GLYCOPYRROLATE
LONSURF, TIPIRACIL HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPID, GEMFIBROZIL
LOPINAVIR AND RITONAVIR, LOPINAVIR
LOPRESSOR, METOPROLOL TARTRATE
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPROX, CICLOPIROX
LOPURIN, ALLOPURINOL
LORATADINE, LORATADINE (OTC)
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE REDIDOSE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
LORAZEPAM INTENSOL, LORAZEPAM
LORBRENA, LORLATINIB
LORYNA, DROSPIRENONE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSEASONIQUE, ETHINYL ESTRADIOL
LOTEMAX, LOTEPREDNOL ETABONATE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTREL, AMLODIPINE BESYLATE
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
LOTRISONE, BETAMETHASONE DIPROPIONATE
LOTRONEX, ALOSETRON HYDROCHLORIDE
LOVASTATIN, LOVASTATIN
LOVAZA, OMEGA-3-ACID ETHYL ESTERS
LOVENOX, ENOXAPARIN SODIUM
LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
LOW-OGESTREL-28, ETHINYL ESTRADIOL
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
LUCEMYRA, LOFEXIDINE HYDROCHLORIDE
LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
LUMIFY, BRIMONIDINE TARTRATE (OTC)
LUMIGAN, BIMATOPROST
LUNESTA, ESZOPICLONE
LUPANETA PACK, LEUPROLIDE ACETATE
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-PED, LEUPROLIDE ACETATE
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
LUTATHERA, LUTETIUM DOTATATE LU-177
LUTRATE DEPOT KIT, LEUPROLIDE ACETATE
LUVOX, FLUVOXAMINE MALEATE
LUXIQ, BETAMETHASONE VALERATE
LUZU, LULICONAZOLE
LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT
LYNPARZA, OLAPARIB
LYRICA, PREGABALIN
LYRICA CR, PREGABALIN
LYSODREN, MITOTANE
LYSTEDA, TRANEXAMIC ACID

APPENDIX A - PRODUCT NAME INDEX

**** M ****

M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
M.V.I. ADULT, ASCORBIC ACID
M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID
M.V.I. PEDIATRIC, ASCORBIC ACID
MACRILEN, MACIMORELIN ACETATE
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
MACUGEN, PEGAPTANIB SODIUM
MAFENIDE ACETATE, MAFENIDE ACETATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNEVIST, GADOPENTETATE DIMEGLUMINE
MAKENA, HYDROXYPROGESTERONE CAPROATE
MAKENA (AUTOINJECTOR), HYDROXYPROGESTERONE CAPROATE
MAKENA PRESERVATIVE FREE, HYDROXYPROGESTERONE CAPROATE
MALARONE, ATOVAQUONE
MALARONE PEDIATRIC, ATOVAQUONE
MALATHION, MALATHION
MALMOREDE, ETHINYL ESTRADIOL
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 25%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARINOL, DRONABINOL
MARLISSA, ETHINYL ESTRADIOL
MARPLAN, ISOCARBOXAZID
MARQIBO KIT, VINCRISTINE SULFATE
MATULANE, PROCARBAZINE HYDROCHLORIDE
MAVYRET, GLECAPREVIR
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
MAXIDEX, DEXAMETHASONE
MAXIPIME, CEFEPIME HYDROCHLORIDE
MAXITROL, DEXAMETHASONE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEDROL, METHYLPREDNISOLONE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFENAMIC ACID, MEFENAMIC ACID
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEGACE ES, MEGESTROL ACETATE
MEGATOPE, ALBUMIN IODINATED I-131 SERUM
MEGESTROL ACETATE, MEGESTROL ACETATE
MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
MEKTOVI, BINIMETINIB
MELAMISA, DROSPIRENONE
MELOXICAM, MELOXICAM
MELPHALAN, MELPHALAN
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** M ****

MEMBRANEBLUE, TRYPAN BLUE
MEN'S ROGAINE, MINOXIDIL (OTC)
MENEST, ESTROGENS, ESTERIFIED
MENOPUR, MENOTROPINS (FSH
MENOSTAR, ESTRADIOL
MENTAX, BUTENAFINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPHYTON, PHYTONADIONE
MEPROBAMATE, MEPROBAMATE
MEPRON, ATOVAQUONE
MERCAPTOPURINE, MERCAPTOPURINE
MEROPENEM, MEROPENEM
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM
MERREM, MEROPENEM
MESALAMINE, MESALAMINE
MESNA, MESNA
MESNEX, MESNA
MESTINON, PYRIDOSTIGMINE BROMIDE
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METASTRON, STRONTIUM CHLORIDE SR-89
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHERGINE, METHYLERGONOVINE MALEATE
METHIMAZOLE, METHIMAZOLE
METHOCARBAMOL, METHOCARBAMOL
METHOCARBAMOL AND ASPIRIN, ASPIRIN
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOXSALEN, METHOXSALEN
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPATE HYDROCHLORIDE, METHYLDOPATE HYDROCHLORIDE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOLAZONE, METOLAZONE
METOPIRONE, METYRAPONE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROGEL-VAGINAL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE

APPENDIX A - PRODUCT NAME INDEX

**** M ****

METRONIDAZOLE, METRONIDAZOLE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MIACALCIN, CALCITONIN SALMON
MIBELAS 24 FE, ETHINYL ESTRADIOL
MICARDIS, TELMISARTAN
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICORT-HC, HYDROCORTISONE ACETATE
MICRO-K, POTASSIUM CHLORIDE
MICRO-K 10, POTASSIUM CHLORIDE
MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN 1/20, ETHINYL ESTRADIOL
MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
MICRONOR, NORETHINDRONE
MICROZIDE, HYDROCHLOROTHIAZIDE
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MIDOL LIQUID GELS, IBUPROFEN (OTC)
MIDOZALAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MIFEPREX, MIFEPRISTONE
MIGERGOT, CAFFEINE
MIGLITOL, MIGLITOL
MIGLUSTAT, MIGLUSTAT
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MILI, ETHINYL ESTRADIOL
MILRINONE LACTATE, MILRINONE LACTATE
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
MINASTRIN 24 FE, ETHINYL ESTRADIOL
MINIPRESS, PRAZOSIN HYDROCHLORIDE
MINIRIN, DESMOPRESSIN ACETATE
MINITRAN, NITROGLYCERIN
MINIVELLE, ESTRADIOL
MINOCIN, MINOCYCLINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOLIRA, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL (OTC)
MINOXIDIL, MINOXIDIL
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
MIOSTAT, CARBACHOL
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
MIRENA, LEVONORGESTREL
MIRTAZAPINE, MIRTAZAPINE
MIRVASO, BRIMONIDINE TARTRATE
MISOPROSTOL, MISOPROSTOL
MITIGARE, COLCHICINE
MITIGO, MORPHINE SULFATE
MITOMYCIN, MITOMYCIN
MITOSOL, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** M ****

MOBIC, MELOXICAM
MODAFINIL, MODAFINIL
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONO-LINYAH, ETHINYL ESTRADIOL
MONODOX, DOXYCYCLINE
MONOKET, ISOSORBIDE MONONITRATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MONUROL, FOSFOMYCIN TROMETHAMINE
MORPHABOND ER, MORPHINE SULFATE
MORPHINE SULFATE, MORPHINE SULFATE
MOTEGRITY, PRUCALOPRIDE SUCCINATE
MOTOFEN, ATROPINE SULFATE
MOTRIN IB, IBUPROFEN (OTC)
MOVANTIK, NALOXEGOL OXALATE
MOVIPREP, ASCORBIC ACID
MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
MOXIDECTIN, MOXIDECTIN
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN
MOZOBIL, PLERIXAFOR
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MS CONTIN, MORPHINE SULFATE
MUCINEX, GUAIFENESIN (OTC)
MUCINEX D, GUAIFENESIN (OTC)
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MULPLETA, LUSUTROMBOPAG
MULTAQ, DRONEDARONE HYDROCHLORIDE
MULTIHANCE, GADOBENATE DIMEGLUMINE
MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
MUPIROCIN, MUPIROCIN
MUPIROCIN, MUPIROCIN CALCIUM
MUSE, ALPROSTADIL
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
MYCAMINE, MICAFUNGIN SODIUM
MYCOBUTIN, RIFABUTIN
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
MYDAYIS, AMPHETAMINE ASPARTATE
MYDRIACYL, TROPICAMIDE
MYFORTIC, MYCOPHENOLIC ACID
MYKACET, NYSTATIN
MYLERAN, BUSULFAN
MYORISAN, ISOTRETINOIN
MYOVIEW 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
MYRBETRIQ, MIRABEGRON
MYSOLINE, PRIMIDONE
MYTESI, CROFELEMER
MYZILRA, ETHINYL ESTRADIOL

**** N ****

NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
NAFCILLIN SODIUM, NAFCILLIN SODIUM

APPENDIX A - PRODUCT NAME INDEX

**** N ****

NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
NAFTIN, NAFTIFINE HYDROCHLORIDE
NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
NALFON, FENOPROFEN CALCIUM
NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
NALOXONE, NALOXONE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NAMENDA, MEMANTINE HYDROCHLORIDE
NAMENDA XR, MEMANTINE HYDROCHLORIDE
NAMZARIC, DONEPEZIL HYDROCHLORIDE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPRELAN, NAPROXEN SODIUM
NAPROSYN, NAPROXEN
NAPROXEN, NAPROXEN
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NARCAN, NALOXONE HYDROCHLORIDE
NARDIL, PHENELZINE SULFATE
NAROPIN, ROPIVACAINE HYDROCHLORIDE
NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
NASCOBAL, CYANOCOBALAMIN
NASONEX, MOMETASONE FUROATE
NATACYN, NATAMYCIN
NATAZIA, DIENOGEST
NATEGLINIDE, NATEGLINIDE
NATESTO, TESTOSTERONE
NATRECOR, NESIRITIDE RECOMBINANT
NATROBA, SPINOSAD
NAVELBINE, VINORELBINE TARTRATE
NEBUPENT, PENTAMIDINE ISETHIONATE
NEDOCROMIL SODIUM, NEDOCROMIL SODIUM
NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
NEO-SYNALAR, FLUOCINOLONE ACETONIDE
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NEOPAP, ACETAMINOPHEN (OTC)
NEOPROFEN, IBUPROFEN LYSINE
NEORAL, CYCLOSPORINE
NEOSPORIN, BACITRACIN ZINC
NEOSPORIN, GRAMICIDIN
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NEPHRAMINE 5.4%, AMINO ACIDS
NERLYNX, NERATINIB MALEATE
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
NESINA, ALOGLIPTIN BENZOATE
NETSPOT, GALLIUM DOTATATE GA-68
NEUPRO, ROTIGOTINE
NEURACEQ, FLORBETABEN F-18
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
NEURONTIN, GABAPENTIN

APPENDIX A - PRODUCT NAME INDEX

**** N ****

NEVANAC, NEPAFENAC
NEVIRAPINE, NEVIRAPINE
NEXAVAR, SORAFENIB TOSYLATE
NEXESTA FE, ETHINYL ESTRADIOL
NEXIUM, ESOMEPRAZOLE MAGNESIUM
NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)
NEXIUM IV, ESOMEPRAZOLE SODIUM
NEXPLANON, ETONOGESTREL
NEXTERONE, AMIODARONE HYDROCHLORIDE
NIACIN, NIACIN
NIACOR, NIACIN
NIASPAN, NIACIN
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NICODERM CQ, NICOTINE (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICOTINE, NICOTINE (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NICOTROL, NICOTINE
NIFEDIPINE, NIFEDIPINE
NIKKI, DROSPIRENONE
NILANDRON, NILUTAMIDE
NILUTAMIDE, NILUTAMIDE
NIMBEX, CISATRACURIUM BESYLATE
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMODIPINE, NIMODIPINE
NINLARO, IXAZOMIB CITRATE
NIPENT, PENTOSTATIN
NIPRIDE RTU IN SODIUM CHLORIDE 0.9%, SODIUM NITROPRUSSIDE
NISOLDIPINE, NISOLDIPINE
NITHIODOTE, SODIUM NITRITE
NITRO-DUR, NITROGLYCERIN
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROGLYCERIN, NITROGLYCERIN
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN
NITROMIST, NITROGLYCERIN
NITROPRESS, SODIUM NITROPRUSSIDE
NITROSTAT, NITROGLYCERIN
NITYR, NITISINONE
NIX, PERMETHRIN (OTC)
NIZATIDINE, NIZATIDINE
NIZORAL, KETOCONAZOLE
NIZORAL A-D, KETOCONAZOLE (OTC)
NOCDURNA, DESMOPRESSIN ACETATE
NOCTIVA, DESMOPRESSIN ACETATE
NOR-QD, NORETHINDRONE
NORCO, ACETAMINOPHEN
NORDITROPIN FLEXPRO, SOMATROPIN RECOMBINANT
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
NORETHINDRONE, NORETHINDRONE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
NORINYL 1+50 28-DAY, MESTRANOL
NORITATE, METRONIDAZOLE
NORMOCARB HF 25, MAGNESIUM CHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** N ****

NORMOCARB HF 35, MAGNESIUM CHLORIDE
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
NORPACE, DISOPYRAMIDE PHOSPHATE
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
NORTHERA, DROXIDOPA
NORTREL 0.5/35-28, ETHINYL ESTRADIOL
NORTREL 1/35-21, ETHINYL ESTRADIOL
NORTREL 1/35-28, ETHINYL ESTRADIOL
NORTREL 7/7/7, ETHINYL ESTRADIOL
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NORVASC, AMLODIPINE BESYLATE
NORVIR, RITONAVIR
NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLOG, INSULIN ASPART RECOMBINANT
NOVOLOG FLEXPEN, INSULIN ASPART RECOMBINANT
NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT
NOVOLOG MIX 70/30 FLEXPEN, INSULIN ASPART PROTAMINE RECOMBINANT
NOVOLOG PENFILL, INSULIN ASPART RECOMBINANT
NOXAFIL, POSACONAZOLE
NOXIVENT, NITRIC OXIDE
NUCYNTA, TAPENTADOL HYDROCHLORIDE
NUCYNTA ER, TAPENTADOL HYDROCHLORIDE
NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE
NULYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350
NUPLAZID, PIMAVANSERIN TARTRATE
NUTRESTORE, L-GLUTAMINE
NUTRILIPID 10%, SOYBEAN OIL
NUTRILIPID 20%, SOYBEAN OIL
NUTROPIN AQ NUSPIN, SOMATROPIN RECOMBINANT
NUVARING, ETHINYL ESTRADIOL
NUVESSA, METRONIDAZOLE
NUVIGIL, ARMODAFINIL
NUZYRA, OMADACYCLINE TOSYLATE
NYLIA 1/35, ETHINYL ESTRADIOL
NYLIA 7/7/7, ETHINYL ESTRADIOL
NYMALIZE, NIMODIPINE
NYSTATIN, NYSTATIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTOP, NYSTATIN

**** O ****

OBREDON, GUAIFENESIN
OCALIVA, OBETICHOLIC ACID
OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCUFEN, FLURBIPROFEN SODIUM
OCUFLOX, OFLOXACIN
ODEFSEY, EMTRICITABINE
ODOMZO, SONIDEGIB PHOSPHATE
OFEV, NINTEDANIB ESYLATE
OFIRMEV, ACETAMINOPHEN
OFLOXACIN, OFLOXACIN
OGEN 5, ESTROPIPATE
OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
OLANZAPINE, OLANZAPINE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

APPENDIX A - PRODUCT NAME INDEX

**** O ****

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OLUMIANT, BARICITINIB
OLUX, CLOBETASOL PROPIONATE
OLUX E, CLOBETASOL PROPIONATE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OMEGAVEN, FISH OIL TRIGLYCERIDES
OMEPRAZOLE, OMEPRAZOLE (OTC)
OMEPRAZOLE, OMEPRAZOLE
OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMIDRIA, KETOROLAC TROMETHAMINE
OMNARIS, CICLESONIDE
OMNIPAQUE 12, IOHEXOL
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPAQUE 9, IOHEXOL
OMNIPRED, PREDNISOLONE ACETATE
OMNISCAN, GADODIAMIDE
OMNITROPE, SOMATROPIN RECOMBINANT
ONDANSETRON, ONDANSETRON
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONEXTON, BENZOYL PEROXIDE
ONFI, CLOBAZAM
ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
ONIVYDE, IRINOTECAN HYDROCHLORIDE
ONMEL, ITRACONAZOLE
ONPATTRO, PATISIRAN SODIUM
ONZETRA XSAIL, SUMATRIPTAN SUCCINATE
OPANA, OXYMORPHONE HYDROCHLORIDE
OPCICON ONE-STEP, LEVONORGESTREL (OTC)
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
OPSUMIT, MACITENTAN
OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
OPTIRAY 240, IOVERSOL
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
OPTISON, ALBUMIN HUMAN
ORABLOC, ARTICAINE HYDROCHLORIDE
ORACEA, DOXYCYCLINE
ORALTAG, IOHEXOL
ORAP, PIMOZIDE
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
ORAQIX, LIDOCAINE
ORAVERSE, PHENTOLAMINE MESYLATE
ORAVIG, MICONAZOLE
ORBACTIV, ORITAVANCIN DIPHOSPHATE
ORENITRAM, TREPROSTINIL DIOLAMINE
ORFADIN, NITISINONE
ORILISSA, ELAGOLIX SODIUM
ORKAMBI, IVACAFTOR
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
ORSYTHIA, ETHINYL ESTRADIOL
ORTHO CYCLEN-28, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL
ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX

**** O ****

ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
ORVATEN, MIDODRINE HYDROCHLORIDE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OSENI, ALOGLIPTIN BENZOATE
OSMITROL 10% IN WATER, MANNITOL
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 15% IN WATER, MANNITOL
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 20% IN WATER, MANNITOL
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 5% IN WATER, MANNITOL
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMOLEX ER, AMANTADINE HYDROCHLORIDE
OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
OSPHENA, OSPEMIFENE
OTEZLA, APREMILAST
OTICAIR, HYDROCORTISONE
OTIPRIO, CIPROFLOXACIN
OTOVEL, CIPROFLOXACIN HYDROCHLORIDE
OTREXUP, METHOTREXATE
OVIDE, MALATHION
OVIDREL, CHORIOGONADOTROPIN ALFA
OXACILLIN SODIUM, OXACILLIN SODIUM
OXALIPLATIN, OXALIPLATIN
OXANDROLONE, OXANDROLONE
OXAPROZIN, OXAPROZIN
OXAYDO, OXYCODONE HYDROCHLORIDE
OXAZEPAM, OXAZEPAM
OXCARBAZEPINE, OXCARBAZEPINE
OXICONAZOLE NITRATE, OXICONAZOLE NITRATE
OXISTAT, OXICONAZOLE NITRATE
OXSORALEN-ULTRA, METHOXSALEN
OXTELLAR XR, OXCARBAZEPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCET, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
OXYCONTIN, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
OXYTOCIN, OXYTOCIN
OXYTROL, OXYBUTYNIN
OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
OZEMPIC, SEMAGLUTIDE
OZURDEX, DEXAMETHASONE

**** P ****

PACERONE, AMIODARONE HYDROCHLORIDE
PACITAXEL, PACLITAXEL
PACLITAXEL, PACLITAXEL
PALIPERIDONE, PALIPERIDONE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCREAZE, PANCRELIPASE (AMYLASE
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PANDEL, HYDROCORTISONE PROBUTATE
PANRETIN, ALITRETINOIN
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARAGARD T 380A, COPPER
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
PARICALCITOL, PARICALCITOL
PARLODEL, BROMOCRIPTINE MESYLATE
PARNATE, TRANYLCYPROMINE SULFATE

APPENDIX A - PRODUCT NAME INDEX

**** P ****

PAROEX, CHLORHEXIDINE GLUCONATE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
PAROXETINE, PAROXETINE HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PAROXETINE MESYLATE, PAROXETINE MESYLATE
PARSABIV, ETELCALCETIDE
PASER, AMINOSALICYLIC ACID
PATADAY, OLOPATADINE HYDROCHLORIDE
PATANASE, OLOPATADINE HYDROCHLORIDE
PATANOL, OLOPATADINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAZEO, OLOPATADINE HYDROCHLORIDE
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
PEDIATRIC ADVIL, IBUPROFEN (OTC)
PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
PEGANONE, ETHOTOIN
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PENICILLIN-VK, PENICILLIN V POTASSIUM
PENLAC, CICLOPIROX
PENNSAID, DICLOFENAC SODIUM
PENTAM, PENTAMIDINE ISETHIONATE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PENTASA, MESALAMINE
PENTETATE CALCIUM TRISODIUM, PENTETATE CALCIUM TRISODIUM
PENTETATE ZINC TRISODIUM, PENTETATE ZINC TRISODIUM
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PENTOSTATIN, PENTOSTATIN
PENTOXIFYLLINE, PENTOXIFYLLINE
PENTOXIL, PENTOXIFYLLINE
PEPCID, FAMOTIDINE
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
PERCOCET, ACETAMINOPHEN
PERCODAN, ASPIRIN
PERFOROMIST, FORMOTEROL FUMARATE
PERIDEX, CHLORHEXIDINE GLUCONATE
PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PERIOCHIP, CHLORHEXIDINE GLUCONATE
PERIOGARD, CHLORHEXIDINE GLUCONATE
PERMETHRIN, PERMETHRIN (OTC)
PERMETHRIN, PERMETHRIN
PERPHENAZINE, PERPHENAZINE
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
PERSANTINE, DIPYRIDAMOLE
PERSERIS KIT, RISPERIDONE
PERTZYE, PANCRELIPASE (AMYLASE
PEXEVA, PAROXETINE MESYLATE
PFIZERPEN, PENICILLIN G POTASSIUM
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENELZINE SULFATE, PHENELZINE SULFATE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHENYTEK, PHENYTOIN SODIUM
PHENYTOIN, PHENYTOIN

APPENDIX A - PRODUCT NAME INDEX

**** P ****

PHENYTOIN SODIUM, PHENYTOIN SODIUM
PHILITH, ETHINYL ESTRADIOL
PHOSLO GELCAPS, CALCIUM ACETATE
PHOSLYRA, CALCIUM ACETATE
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
PHOTOFRIN, PORFIMER SODIUM
PHOTREXA, RIBOFLAVIN 5'-PHOSPHATE SODIUM
PHOTREXA VISCOUS IN DEXTRAN 20%, RIBOFLAVIN 5'-PHOSPHATE SODIUM
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYTONADIONE, PHYTONADIONE
PICATO, INGENOL MEBUTATE
PIFELTRO, DORAVIRINE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PIMECROLIMUS, PIMECROLIMUS
PIMOZIDE, PIMOZIDE
PIMTREA, DESOGESTREL
PINDOLOL, PINDOLOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIPERACILLIN, PIPERACILLIN SODIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PIRMELLA 1/35, ETHINYL ESTRADIOL
PIRMELLA 7/7/7, ETHINYL ESTRADIOL
PIROXICAM, PIROXICAM
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
PITOCIN, OXYTOCIN
PLAN B ONE-STEP, LEVONORGESTREL (OTC)
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLAVIX, CLOPIDOGREL BISULFATE
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLENVU, ASCORBIC ACID
PLIAGLIS, LIDOCAINE
PODOFILOX, PODOFILOX
POLMON, DEXCHLORPHENIRAMINE MALEATE
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POLYTRIM, POLYMYXIN B SULFATE
POMALYST, POMALIDOMIDE
PONSTEL, MEFENAMIC ACID
PORTIA-28, ETHINYL ESTRADIOL
POTASSIUM ACETATE, POTASSIUM ACETATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,

APPENDIX A - PRODUCT NAME INDEX

**** P ****

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,

APPENDIX A - PRODUCT NAME INDEX

**** P ****

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
POVIDONE IODINE, POVIDONE-IODINE (OTC)
PRADAXA, DABIGATRAN ETEXILATE MESYLATE
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAMOSONE, HYDROCORTISONE ACETATE
PRANDIN, REPAGLINIDE
PRASUGREL, PRASUGREL HYDROCHLORIDE
PRAVACHOL, PRAVASTATIN SODIUM
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRAZIQUANTEL, PRAZIQUANTEL
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PRE-OP, HEXACHLOROPHENE
PRE-OP II, HEXACHLOROPHENE
PRE-PEN, BENZYLPENICILLOYL POLYLYSINE
PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
PRECOSE, ACARBOSE
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PRED-G, GENTAMICIN SULFATE
PREDNICARBATE, PREDNICARBATE
PREDNISOLONE, PREDNISOLONE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISONE, PREDNISONE
PREDNISONE INTENSOL, PREDNISONE
PREGNYL, GONADOTROPIN, CHORIONIC
PRELONE, PREDNISOLONE
PREMARIN, ESTROGENS, CONJUGATED
PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PREPIDIL, DINOPROSTONE
PREPOPIK, CITRIC ACID
PRESTALIA, AMLODIPINE BESYLATE
PREVACID, LANSOPRAZOLE
PREVACID 24 HR, LANSOPRAZOLE (OTC)
PREVALITE, CHOLESTYRAMINE
PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVIFEM, ETHINYL ESTRADIOL
PREVYMIS, LETERMOVIR
PREZCOBIX, COBICISTAT

APPENDIX A - PRODUCT NAME INDEX

**** P ****

PREZISTA, DARUNAVIR ETHANOLATE
PRIALT, ZICONOTIDE ACETATE
PRIFTIN, RIFAPENTINE
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
PRILOSEC, OMEPRAZOLE MAGNESIUM
PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
PRIMAQUINE, PRIMAQUINE PHOSPHATE
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
PRIMATENE MIST, EPINEPHRINE (OTC)
PRIMAXIN, CILASTATIN SODIUM
PRIMIDONE, PRIMIDONE
PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE
PRINIVIL, LISINOPRIL
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISTIQ, DESVENLAFAXINE SUCCINATE
PROAIR HFA, ALBUTEROL SULFATE
PROAIR RESPICLICK, ALBUTEROL SULFATE
PROBALAN, PROBENECID
PROBENECID, PROBENECID
PROBENECID AND COLCHICINE, COLCHICINE
PROBUPHINE, BUPRENORPHINE HYDROCHLORIDE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROCALAMINE, AMINO ACIDS
PROCARDIA, NIFEDIPINE
PROCARDIA XL, NIFEDIPINE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROCOMP, PROCHLORPERAZINE MALEATE
PROCTOFOAM HC, HYDROCORTISONE ACETATE
PROCYSBI, CYSTEAMINE BITARTRATE
PROFERDEX, IRON DEXTRAN
PROGESTERONE, PROGESTERONE
PROGLYCEM, DIAZOXIDE
PROGRAF, TACROLIMUS
PROHANCE, GADOTERIDOL
PROHANCE MULTIPACK, GADOTERIDOL
PROLENSA, BROMFENAC SODIUM
PROMACTA, ELTROMBOPAG OLAMINE
PROMACTA KIT, ELTROMBOPAG OLAMINE
PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
PROMETRIUM, PROGESTERONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
PROPECIA, FINASTERIDE

APPENDIX A - PRODUCT NAME INDEX

**** P ****

PROPOFOL, PROPOFOL
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PROSCAR, FINASTERIDE
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
PROSTIN E2, DINOPROSTONE
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROTAMINE SULFATE, PROTAMINE SULFATE
PROTONIX, PANTOPRAZOLE SODIUM
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
PROTOPIC, TACROLIMUS
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
PROVAYBLUE, METHYLENE BLUE
PROVENTIL-HFA, ALBUTEROL SULFATE
PROVERA, MEDROXYPROGESTERONE ACETATE
PROVIGIL, MODAFINIL
PROVOCHOLINE, METHACHOLINE CHLORIDE
PROZAC, FLUOXETINE HYDROCHLORIDE
PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
PULMICORT FLEXHALER, BUDESONIDE
PULMICORT RESPULES, BUDESONIDE
PUR-WASH, PURIFIED WATER (OTC)
PURINETHOL, MERCAPTOPURINE
PURIXAN, MERCAPTOPURINE
PYLERA, BISMUTH SUBCITRATE POTASSIUM
PYRAZINAMIDE, PYRAZINAMIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
PYTEST, UREA, C-14
PYTEST KIT, UREA, C-14

**** Q ****

QBRELIS, LISINOPRIL
QBREXZA, GLYCOPYRRONIUM TOSYLATE
QMIIZ ODT, MELOXICAM
QNASL, BECLOMETHASONE DIPROPIONATE
QOLIANA, BRIMONIDINE TARTRATE
QSYMIA, PHENTERMINE HYDROCHLORIDE
QTERN, DAPAGLIFLOZIN
QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
QUALAQUIN, QUININE SULFATE
QUARTETTE, ETHINYL ESTRADIOL
QUASENSE, ETHINYL ESTRADIOL
QUDEXY XR, TOPIRAMATE
QUELICIN, SUCCINYLCHOLINE CHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE
QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINARETIC, HYDROCHLOROTHIAZIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
QUININE SULFATE, QUININE SULFATE
QUTENZA, CAPSAICIN
QVAR REDIHALER, BECLOMETHASONE DIPROPIONATE

**** R ****

R-GENE 10, ARGININE HYDROCHLORIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RADICAVA, EDARAVONE
RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)

APPENDIX A - PRODUCT NAME INDEX

**** R ****

RADIOGENIX SYSTEM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RAMELTEON, RAMELTEON
RAMIPRIL, RAMIPRIL
RANEXA, RANOLAZINE
RANITIDINE, RANITIDINE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RAPAFLO, SILODOSIN
RAPAMUNE, SIROLIMUS
RAPIVAB, PERAMIVIR
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RASUVO, METHOTREXATE
RAVICTI, GLYCEROL PHENYLBUTYRATE
RAYALDEE, CALCIFEDIOL
RAYOS, PREDNISONE
RAZADYNE, GALANTAMINE HYDROBROMIDE
RAZADYNE ER, GALANTAMINE HYDROBROMIDE
READI-CAT 2, BARIUM SULFATE
READI-CAT 2 SMOOTHIES, BARIUM SULFATE
READYPREP CHG, CHLORHEXIDINE GLUCONATE (OTC)
REBETOL, RIBAVIRIN
RECLAST, ZOLEDRONIC ACID
RECTIV, NITROGLYCERIN
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
REGONOL, PYRIDOSTIGMINE BROMIDE
RELENZA, ZANAMIVIR
RELISTOR, METHYLNALTREXONE BROMIDE
RELPAX, ELETRIPTAN HYDROBROMIDE
REMERON, MIRTAZAPINE
REMERON SOLTAB, MIRTAZAPINE
REMIFENTANIL HYDROCHLORIDE, REMIFENTANIL HYDROCHLORIDE
REMODULIN, TREPROSTINIL
RENACIDIN, CITRIC ACID
RENAGEL, SEVELAMER HYDROCHLORIDE
RENOVA, TRETINOIN
RENVELA, SEVELAMER CARBONATE
REPAGLINIDE, REPAGLINIDE
REPREXAIN, HYDROCODONE BITARTRATE
REQUIP, ROPINIROLE HYDROCHLORIDE
REQUIP XL, ROPINIROLE HYDROCHLORIDE
RESCRIPTOR, DELAVIRDINE MESYLATE
RESECTISOL IN PLASTIC CONTAINER, MANNITOL
RESTASIS, CYCLOSPORINE
RESTASIS MULTIDOSE, CYCLOSPORINE
RESTORIL, TEMAZEPAM
RETIN-A, TRETINOIN
RETIN-A MICRO, TRETINOIN
RETIN-A-MICRO, TRETINOIN
RETISERT, FLUOCINOLONE ACETONIDE
RETROVIR, ZIDOVUDINE
REVATIO, SILDENAFIL CITRATE
REVLIMID, LENALIDOMIDE
REVONTO, DANTROLENE SODIUM
REXULTI, BREXPIPRAZOLE
REYATAZ, ATAZANAVIR SULFATE
REZIRA, HYDROCODONE BITARTRATE
RHINOCORT ALLERGY, BUDESONIDE (OTC)
RHOFADE, OXYMETAZOLINE HYDROCHLORIDE
RHOPRESSA, NETARSUDIL DIMESYLATE
RIBASPHERE, RIBAVIRIN
RIBAVIRIN, RIBAVIRIN
RIDAURA, AURANOFIN
RIFABUTIN, RIFABUTIN
RIFADIN, RIFAMPIN

APPENDIX A - PRODUCT NAME INDEX

**** R ****

RIFAMATE, ISONIAZID
RIFAMPIN, RIFAMPIN
RIFATER, ISONIAZID
RILUTEK, RILUZOLE
RILUZOLE, RILUZOLE
RIMACTANE, RIFAMPIN
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
RIMSO-50, DIMETHYL SULFOXIDE
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
RIOMET, METFORMIN HYDROCHLORIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERDAL, RISPERIDONE
RISPERDAL CONSTA, RISPERIDONE
RISPERIDONE, RISPERIDONE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITONAVIR, RITONAVIR
RIVASTIGMINE, RIVASTIGMINE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROBAXIN, METHOCARBAMOL
ROBAXIN-750, METHOCARBAMOL
ROCALTROL, CALCITRIOL
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROFLUMILAST, ROFLUMILAST
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
ROWASA, MESALAMINE
ROWEEPRA, LEVETIRACETAM
ROXICET, ACETAMINOPHEN
ROXICODONE, OXYCODONE HYDROCHLORIDE
ROZEREM, RAMELTEON
RUBRACA, RUCAPARIB CAMSYLATE
RUBY-FILL, RUBIDIUM CHLORIDE RB-82
RUFINAMIDE, RUFINAMIDE
RYANODEX, DANTROLENE SODIUM
RYDAPT, MIDOSTAURIN
RYTARY, CARBIDOPA
RYTHMOL SR, PROPAFENONE HYDROCHLORIDE
RYZODEG 70/30, INSULIN ASPART

**** S ****

SABRIL, VIGABATRIN
SAFYRAL, DROSPIRENONE
SAIZEN, SOMATROPIN RECOMBINANT
SALAGEN, PILOCARPINE HYDROCHLORIDE
SALONPAS, MENTHOL (OTC)
SAMSCA, TOLVAPTAN
SANCUSO, GRANISETRON
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN, OCTREOTIDE ACETATE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SAPHRIS, ASENAPINE MALEATE
SARAFEM, FLUOXETINE HYDROCHLORIDE
SAVAYSA, EDOXABAN TOSYLATE
SAVELLA, MILNACIPRAN HYDROCHLORIDE
SAXENDA, LIRAGLUTIDE RECOMBINANT
SCANDONEST L, LEVONORDEFRIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SCANLUX-300, IOPAMIDOL
SCANLUX-370, IOPAMIDOL

APPENDIX A - PRODUCT NAME INDEX

**** S ****

SCLEROSOL, TALC
SCOPOLAMINE, SCOPOLAMINE
SEASONALE, ETHINYL ESTRADIOL
SEASONIQUE, ETHINYL ESTRADIOL
SECONAL SODIUM, SECOBARBITAL SODIUM
SEEBRI, GLYCOPYRROLATE
SEGLUROMET, ERTUGLIFLOZIN
SEIZALAM, MIDAZOLAM HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
SELFEMRA, FLUOXETINE HYDROCHLORIDE
SELZENTRY, MARAVIROC
SEMPREX-D, ACRIVASTINE
SENSIPAR, CINACALCET HYDROCHLORIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE
SEPTRA, SULFAMETHOXAZOLE
SEPTRA DS, SULFAMETHOXAZOLE
SEREVENT, SALMETEROL XINAFOATE
SERNIVO, BETAMETHASONE DIPROPIONATE
SEROMYCIN, CYCLOSERINE
SEROQUEL, QUETIAPINE FUMARATE
SEROQUEL XR, QUETIAPINE FUMARATE
SEROSTIM, SOMATROPIN RECOMBINANT
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SETLAKIN, ETHINYL ESTRADIOL
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SEVOFLURANE, SEVOFLURANE
SEYSARA, SARECYCLINE HYDROCHLORIDE
SFROWASA, MESALAMINE
SIGNIFOR, PASIREOTIDE DIASPARTATE
SIGNIFOR LAR KIT, PASIREOTIDE PAMOATE
SIKLOS, HYDROXYUREA
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILENOR, DOXEPIN HYDROCHLORIDE
SILODOSIN, SILODOSIN
SILVADENE, SILVER SULFADIAZINE
SIMBRINZA, BRIMONIDINE TARTRATE
SIMPESSE, ETHINYL ESTRADIOL
SIMVASTATIN, SIMVASTATIN
SINE-AID IB, IBUPROFEN (OTC)
SINEMET, CARBIDOPA
SINEMET CR, CARBIDOPA
SINGULAIR, MONTELUKAST SODIUM
SINUVA, MOMETASONE FUROATE
SIROLIMUS, SIROLIMUS
SIRTURO, BEDAQUILINE FUMARATE
SITAVIG, ACYCLOVIR
SIVEXTRO, TEDIZOLID PHOSPHATE
SKELAXIN, METAXALONE
SKLICE, IVERMECTIN
SKYLA, LEVONORGESTREL
SMOFLIPID 20%, FISH OIL
SODIUM ACETATE, SODIUM ACETATE
SODIUM BICARBONATE, SODIUM BICARBONATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
SODIUM IODIDE I 123, SODIUM IODIDE I-123

APPENDIX A - PRODUCT NAME INDEX

**** S ****

SODIUM IODIDE I 131, SODIUM IODIDE I-131
SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM NITRITE, SODIUM NITRITE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SODIUM OXYBATE, SODIUM OXYBATE
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, MAGNESIUM SULFATE
SODIUM THIOSULFATE, SODIUM THIOSULFATE
SOJOURN, SEVOFLURANE
SOLARAZE, DICLOFENAC SODIUM
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SOLIQUA 100/33, INSULIN GLARGINE
SOLODYN, MINOCYCLINE HYDROCHLORIDE
SOLOSEC, SECNIDAZOLE
SOLTAMOX, TAMOXIFEN CITRATE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOLUPREP, CHLORHEXIDINE GLUCONATE (OTC)
SOMA, CARISOPRODOL
SOMATULINE DEPOT, LANREOTIDE ACETATE
SOMAVERT, PEGVISOMANT
SONATA, ZALEPLON
SOOLANTRA, IVERMECTIN
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
SORIATANE, ACITRETIN
SORILUX, CALCIPOTRIENE
SORINE, SOTALOL HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE
SOTYLIZE, SOTALOL HYDROCHLORIDE
SOVALDI, SOFOSBUVIR
SPECTAZOLE, ECONAZOLE NITRATE
SPINRAZA, NUSINERSEN SODIUM
SPIRIVA, TIOTROPIUM BROMIDE
SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE
SPIRONOLACTONE, SPIRONOLACTONE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPORANOX, ITRACONAZOLE
SPRINTEC, ETHINYL ESTRADIOL
SPRITAM, LEVETIRACETAM
SPRIX, KETOROLAC TROMETHAMINE
SPRYCEL, DASATINIB
SPS, SODIUM POLYSTYRENE SULFONATE
SPY AGENT GREEN KIT, INDOCYANINE GREEN
SSD, SILVER SULFADIAZINE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA
STARLIX, NATEGLINIDE
STAVUDINE, STAVUDINE
STAXYN, VARDENAFIL HYDROCHLORIDE
STEGLATRO, ERTUGLIFLOZIN
STEGLUJAN, ERTUGLIFLOZIN
STENDRA, AVANAFIL
STERILE WATER, STERILE WATER FOR IRRIGATION
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION

APPENDIX A - PRODUCT NAME INDEX

**** S ****

STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
STERITALC, TALC
STIE-CORT, HYDROCORTISONE
STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE
STIVARGA, REGORAFENIB
STRATTERA, ATOMOXETINE HYDROCHLORIDE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
STRIANT, TESTOSTERONE
STRIBILD, COBICISTAT
STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE
STROMECTOL, IVERMECTIN
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
SUBLOCADE, BUPRENORPHINE
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE
SUBSYS, FENTANYL
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
SUCRAID, SACROSIDASE
SUCRALFATE, SUCRALFATE
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SULAR, NISOLDIPINE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFADIAZINE, SULFADIAZINE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE
SULFAMYLON, MAFENIDE ACETATE
SULFASALAZINE, SULFASALAZINE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
SULINDAC, SULINDAC
SUMATRIPTAN, SUMATRIPTAN
SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
SUPPRELIN LA, HISTRELIN ACETATE
SUPRANE, DESFLURANE
SUPRAX, CEFIXIME
SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE
SURMONTIL, TRIMIPRAMINE MALEATE
SURVANTA, BERACTANT
SUSTIVA, EFAVIRENZ
SUSTOL, GRANISETRON
SUTENT, SUNITINIB MALATE
SYEDA, DROSPIRENONE
SYMBICORT, BUDESONIDE
SYMBYAX, FLUOXETINE HYDROCHLORIDE
SYMDEKO (COPACKAGED), IVACAFTOR
SYMFI, EFAVIRENZ
SYMFI LO, EFAVIRENZ
SYMJEPI, EPINEPHRINE
SYMLIN, PRAMLINTIDE ACETATE
SYMPAZAN, CLOBAZAM
SYMPROIC, NALDEMEDINE TOSYLATE
SYMTUZA, COBICISTAT
SYNALAR, FLUOCINOLONE ACETONIDE
SYNAREL, NAFARELIN ACETATE
SYNDROS, DRONABINOL
SYNERA, LIDOCAINE
SYNERCID, DALFOPRISTIN
SYNJARDY, EMPAGLIFLOZIN
SYNJARDY XR, EMPAGLIFLOZIN

APPENDIX A - PRODUCT NAME INDEX

**** S ****

SYNRIBO, OMACETAXINE MEPESUCCINATE
SYNTHROID, LEVOTHYROXINE SODIUM **
SYPRINE, TRIENTINE HYDROCHLORIDE

**** T ****

TAB-PROFEN, IBUPROFEN (OTC)
TACLONEX, BETAMETHASONE DIPROPIONATE
TACROLIMUS, TACROLIMUS
TADALAFIL, TADALAFIL
TAFINLAR, DABRAFENIB MESYLATE
TAGAMET HB, CIMETIDINE (OTC)
TAGITOL V, BARIUM SULFATE
TAGRISSO, OSIMERTINIB MESYLATE
TALC, TALC
TALZENNA, TALAZOPARIB TOSYLATE
TAMBOCOR, FLECAINIDE ACETATE
TAMIFLU, OSELTAMIVIR PHOSPHATE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TAPAZOLE, METHIMAZOLE
TARCEVA, ERLOTINIB HYDROCHLORIDE
TARGRETIN, BEXAROTENE
TARKA, TRANDOLAPRIL
TASIGNA, NILOTINIB HYDROCHLORIDE
TASMAR, TOLCAPONE
TAVALISSE, FOSTAMATINIB DISODIUM
TAXOL, PACLITAXEL
TAXOTERE, DOCETAXEL
TAYTULLA, ETHINYL ESTRADIOL
TAZAROTENE, TAZAROTENE
TAZICEF, CEFTAZIDIME
TAZORAC, TAZAROTENE
TAZTIA XT, DILTIAZEM HYDROCHLORIDE
TECFIDERA, DIMETHYL FUMARATE
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNESCAN, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M GENERATOR, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT
TECHNIVIE, OMBITASVIR
TEFLARO, CEFTAROLINE FOSAMIL
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TEGSEDI, INOTERSEN SODIUM
TEKTURNA, ALISKIREN HEMIFUMARATE
TEKTURNA HCT, ALISKIREN HEMIFUMARATE
TELMISARTAN, TELMISARTAN
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TEMAZEPAM, TEMAZEPAM
TEMIXYS, LAMIVUDINE
TEMODAR, TEMOZOLOMIDE
TEMOZOLOMIDE, TEMOZOLOMIDE
TEMSIROLIMUS, TEMSIROLIMUS
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
TENUATE, DIETHYLPROPION HYDROCHLORIDE
TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
TEPADINA, THIOTEPA
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** T ****

TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TERCONAZOLE, TERCONAZOLE
TERIFLUNOMIDE, TERIFLUNOMIDE
TERIL, CARBAMAZEPINE
TESSALON, BENZONATATE
TESTIM, TESTOSTERONE
TESTOPEL, TESTOSTERONE
TESTOSTERONE, TESTOSTERONE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TESTRED, METHYLTESTOSTERONE
TETRABENAZINE, TETRABENAZINE
TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
TEXACORT, HYDROCORTISONE
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
THALOMID, THALIDOMIDE
THEO-24, THEOPHYLLINE
THEOCHRON, THEOPHYLLINE
THEOPHYLLINE, THEOPHYLLINE
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THERMAZENE, SILVER SULFADIAZINE
THEROXIDIL, MINOXIDIL (OTC)
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
THIOGUANINE, THIOGUANINE
THIOLA, TIOPRONIN
THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
THIOTEPA, THIOTEPA
THIOTHIXENE, THIOTHIXENE
THYROGEN, THYROTROPIN ALFA
THYROSAFE, POTASSIUM IODIDE (OTC)
THYROSHIELD, POTASSIUM IODIDE (OTC)
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
TIAZAC, DILTIAZEM HYDROCHLORIDE
TIBSOVO, IVOSIDENIB
TICAGRELOR, TICAGRELOR
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
TIGECYCLINE, TIGECYCLINE
TIGLUTIK KIT, RILUZOLE
TIKOSYN, DOFETILIDE
TIMOLOL, TIMOLOL
TIMOLOL MALEATE, TIMOLOL MALEATE
TIMOPTIC, TIMOLOL MALEATE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC-XE, TIMOLOL MALEATE
TINDAMAX, TINIDAZOLE
TINIDAZOLE, TINIDAZOLE
TIOCONAZOLE, TIOCONAZOLE (OTC)
TIROSINT, LEVOTHYROXINE SODIUM
TIS-U-SOL, MAGNESIUM SULFATE
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TIVICAY, DOLUTEGRAVIR SODIUM
TIVORBEX, INDOMETHACIN
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOBI, TOBRAMYCIN
TOBI PODHALER, TOBRAMYCIN
TOBRADEX, DEXAMETHASONE
TOBRADEX ST, DEXAMETHASONE
TOBRAMYCIN, TOBRAMYCIN

APPENDIX A - PRODUCT NAME INDEX

**** T ****

TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
TOBREX, TOBRAMYCIN
TODAY, NONOXYNOL-9 (OTC)
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TOLAK, FLUOROURACIL
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLCAPONE, TOLCAPONE
TOLMETIN SODIUM, TOLMETIN SODIUM
TOLSURA, ITRACONAZOLE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TOPAMAX, TOPIRAMATE
TOPICORT, DESOXIMETASONE
TOPIRAMATE, TOPIRAMATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TOPROL-XL, METOPROLOL SUCCINATE
TOREMIFENE CITRATE, TOREMIFENE CITRATE
TORISEL, TEMSIROLIMUS
TORSEMIDE, TORSEMIDE
TOTECT, DEXRAZOXANE HYDROCHLORIDE
TOUJEO MAX SOLOSTAR, INSULIN GLARGINE RECOMBINANT
TOUJEO SOLOSTAR, INSULIN GLARGINE RECOMBINANT
TOVIAZ, FESOTERODINE FUMARATE
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TPOXX, TECOVIRIMAT
TRACLEER, BOSENTAN
TRADJENTA, LINAGLIPTIN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRANDATE, LABETALOL HYDROCHLORIDE
TRANDOLAPRIL, TRANDOLAPRIL
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
TRANEXAMIC ACID, TRANEXAMIC ACID
TRANSDERM SCOP, SCOPOLAMINE
TRANXENE, CLORAZEPATE DIPOTASSIUM
TRANYLCYPROMINE SULFATE, TRANYLCYPROMINE SULFATE
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVATAN Z, TRAVOPROST
TRAVOPROST, TRAVOPROST
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TREANDA, BENDAMUSTINE HYDROCHLORIDE
TRECATOR, ETHIONAMIDE
TRELEGY ELLIPTA, FLUTICASONE FUROATE
TRELSTAR, TRIPTORELIN PAMOATE
TREPROSTINIL, TREPROSTINIL
TRESIBA, INSULIN DEGLUDEC
TRETINOIN, TRETINOIN
TREXALL, METHOTREXATE SODIUM
TREXIMET, NAPROXEN SODIUM
TREZIX, ACETAMINOPHEN
TRI LO SPRINTEC, ETHINYL ESTRADIOL
TRI-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LEGEST 21, ETHINYL ESTRADIOL
TRI-LEGEST FE, ETHINYL ESTRADIOL
TRI-LINYAH, ETHINYL ESTRADIOL
TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LO-MILI, ETHINYL ESTRADIOL
TRI-LUMA, FLUOCINOLONE ACETONIDE
TRI-MILI, ETHINYL ESTRADIOL
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX

**** T ****

TRI-PREVIFEM, ETHINYL ESTRADIOL
TRI-SPRINTEC, ETHINYL ESTRADIOL
TRIACIN-C, CODEINE PHOSPHATE
TRIAMCINOLONE ACETATE, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIAZOLAM, TRIAZOLAM
TRIBENZOR, AMLODIPINE BESYLATE
TRICOR, FENOFIBRATE
TRIDERM, TRIAMCINOLONE ACETONIDE
TRIDIONE, TRIMETHADIONE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
TRIESENCE, TRIAMCINOLONE ACETONIDE
TRIFERIC, FERRIC PYROPHOSPHATE CITRATE
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
TRIFLURIDINE, TRIFLURIDINE
TRIGLIDE, FENOFIBRATE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
TRILEPTAL, OXCARBAZEPINE
TRILIPIX, CHOLINE FENOFIBRATE
TRILYTE, POLYETHYLENE GLYCOL 3350
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
TRINTELLIX, VORTIOXETINE HYDROBROMIDE
TRIOSTAT, LIOTHYRONINE SODIUM
TRIPTODUR KIT, TRIPTORELIN PAMOATE
TRISENOX, ARSENIC TRIOXIDE
TRIUMEQ, ABACAVIR SULFATE
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
TRIVORA-28, ETHINYL ESTRADIOL
TRIZIVIR, ABACAVIR SULFATE
TROKENDI XR, TOPIRAMATE
TROPHAMINE, AMINO ACIDS
TROPHAMINE 10%, AMINO ACIDS
TROPICACYL, TROPICAMIDE
TROPICAMIDE, TROPICAMIDE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
TRULANCE, PLECANATIDE
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
TRUVADA, EMTRICITABINE
TUDORZA PRESSAIR, ACLIDINIUM BROMIDE
TUSSICAPS, CHLORPHENIRAMINE POLISTIREX
TUSSIGON, HOMATROPINE METHYLBROMIDE
TUXARIN ER, CHLORPHENIRAMINE MALEATE
TUZISTRA XR, CHLORPHENIRAMINE POLISTIREX
TWYNSTA, AMLODIPINE BESYLATE
TYBOST, COBICISTAT
TYDEMY, DROSPIRENONE
TYGACIL, TIGECYCLINE
TYKERB, LAPATINIB DITOSYLATE
TYLENOL, ACETAMINOPHEN (OTC)
TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
TYMLOS, ABALOPARATIDE
TYVASO, TREPROSTINIL
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

**** U ****

U-CORT, HYDROCORTISONE ACETATE
UCERIS, BUDESONIDE

APPENDIX A - PRODUCT NAME INDEX

**** U ****

ULESFIA, BENZYL ALCOHOL
ULORIC, FEBUXOSTAT
ULTACAN, ARTICAINE HYDROCHLORIDE
ULTACAN FORTE, ARTICAINE HYDROCHLORIDE
ULTANE, SEVOFLURANE
ULTIVA, REMIFENTANIL HYDROCHLORIDE
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRACET, ACETAMINOPHEN
ULTRAM, TRAMADOL HYDROCHLORIDE
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
ULTRAVATE, HALOBETASOL PROPIONATE
ULTRAVIST (PHARMACY BULK), IOPROMIDE
ULTRAVIST 240, IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
UNASYN, AMPICILLIN SODIUM
UNISOM, DOXYLAMINE SUCCINATE (OTC)
UNITHROID, LEVOTHYROXINE SODIUM **
UPTRAVI, SELEXIPAG
URECHOLINE, BETHANECHOL CHLORIDE
UREX, METHENAMINE HIPPURATE
UROCIT-K, POTASSIUM CITRATE
UROXATRAL, ALFUZOSIN HYDROCHLORIDE
URSO 250, URSODIOL
URSO FORTE, URSODIOL
URSODIOL, URSODIOL
UTIBRON, GLYCOPYRROLATE
UVADEX, METHOXSALEN

**** V ****

VABOMERE, MEROPENEM
VAGIFEM, ESTRADIOL
VAGISTAT-1, TIOCONAZOLE (OTC)
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALIUM, DIAZEPAM
VALNAC, BETAMETHASONE VALERATE
VALPROATE SODIUM, VALPROATE SODIUM
VALPROIC ACID, VALPROIC ACID
VALSARTAN, VALSARTAN
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSTAR PRESERVATIVE FREE, VALRUBICIN
VALTREX, VALACYCLOVIR HYDROCHLORIDE
VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
VANDAZOLE, METRONIDAZOLE
VANIQA, EFLORNITHINE HYDROCHLORIDE
VANOS, FLUOCINONIDE
VANTAS, HISTRELIN ACETATE
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VARIBAR HONEY, BARIUM SULFATE
VARIBAR NECTAR, BARIUM SULFATE
VARIBAR PUDDING, BARIUM SULFATE
VARIBAR THIN HONEY, BARIUM SULFATE
VARITHENA, POLIDOCANOL
VARUBI, ROLAPITANT HYDROCHLORIDE
VASCEPA, ICOSAPENT ETHYL
VASERETIC, ENALAPRIL MALEATE
VASOSTRICT, VASOPRESSIN
VASOTEC, ENALAPRIL MALEATE

APPENDIX A - PRODUCT NAME INDEX

**** V ****

VAZALORE, ASPIRIN (OTC)
VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE
VECTICAL, CALCITRIOL
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VELCADE, BORTEZOMIB
VELETRI, EPOPROSTENOL SODIUM
VELIVET, DESOGESTREL
VELPHORO, SUCROFERRIC OXYHYDROXIDE
VELTASSA, PATIROMER SORBITEX CALCIUM
VELTIN, CLINDAMYCIN PHOSPHATE
VEMLIDY, TENOFOVIR ALAFENAMIDE FUMARATE
VENCLEXTA, VENETOCLAX
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VENOFER, IRON SUCROSE
VENTAVIS, ILOPROST
VENTOLIN HFA, ALBUTEROL SULFATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VERDESO, DESONIDE
VEREGEN, SINECATECHINS
VERELAN, VERAPAMIL HYDROCHLORIDE
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERSACLOZ, CLOZAPINE
VERZENIO, ABEMACICLIB
VESICARE, SOLIFENACIN SUCCINATE
VFEND, VORICONAZOLE
VIAGRA, SILDENAFIL CITRATE
VIBATIV, TELAVANCIN HYDROCHLORIDE
VIBERZI, ELUXADOLINE
VIBISONE, CYANOCOBALAMIN
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VICTOZA, LIRAGLUTIDE RECOMBINANT
VIDAZA, AZACITIDINE
VIDEX, DIDANOSINE
VIDEX EC, DIDANOSINE
VIEKIRA PAK (COPACKAGED), DASABUVIR SODIUM
VIEKIRA XR, DASABUVIR SODIUM
VIENVA, ETHINYL ESTRADIOL
VIGABATRIN, VIGABATRIN
VIGADRONE, VIGABATRIN
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
VIIBRYD, VILAZODONE HYDROCHLORIDE
VIMOVO, ESOMEPRAZOLE MAGNESIUM
VIMPAT, LACOSAMIDE
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
VIOKACE, PANCRELIPASE (AMYLASE
VIORELE, DESOGESTREL
VIRACEPT, NELFINAVIR MESYLATE
VIRAMUNE, NEVIRAPINE
VIRAMUNE XR, NEVIRAPINE
VIRAZOLE, RIBAVIRIN
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VIROPTIC, TRIFLURIDINE
VISINE, NAPHAZOLINE HYDROCHLORIDE (OTC)
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISIONBLUE, TRYPAN BLUE
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VISTARIL, HYDROXYZINE PAMOATE
VISTOGARD, URIDINE TRIACETATE
VISUDYNE, VERTEPORFIN
VITAMIN D, ERGOCALCIFEROL

APPENDIX A - PRODUCT NAME INDEX

**** V ****

VITAMIN K1, PHYTONADIONE
VITRAKVI, LAROTRECTINIB
VITRASE, HYALURONIDASE
VITUZ, CHLORPHENIRAMINE MALEATE
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE
VIVELLE-DOT, ESTRADIOL
VIVITROL, NALTREXONE
VIVLODEX, MELOXICAM
VIZAMYL, FLUTEMETAMOL F-18
VIZIMPRO, DACOMITINIB
VOGELXO, TESTOSTERONE
VOLNEA, DESOGESTREL
VOLTAREN, DICLOFENAC SODIUM
VORICONAZOLE, VORICONAZOLE
VOSEVI, SOFOSBUVIR
VOSOL, ACETIC ACID, GLACIAL
VOSOL HC, ACETIC ACID, GLACIAL
VOSPIRE ER, ALBUTEROL SULFATE
VOTRIENT, PAZOPANIB HYDROCHLORIDE
VPRIV, VELAGLUCERASE ALFA
VRAYLAR, CARIPRAZINE HYDROCHLORIDE
VUSION, MICONAZOLE NITRATE
VYFEMLA, ETHINYL ESTRADIOL
VYTORIN, EZETIMIBE
VYVANSE, LISDEXAMFETAMINE DIMESYLATE
VYXEOS, CYTARABINE
VYZULTA, LATANOPROSTENE BUNOD

**** W ****

WARFARIN SODIUM, WARFARIN SODIUM
WELCHOL, COLESEVELAM HYDROCHLORIDE
WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
WERA, ETHINYL ESTRADIOL
WOMEN'S ROGAINE, MINOXIDIL (OTC)

**** X ****

XADAGO, SAFINAMIDE MESYLATE
XALATAN, LATANOPROST
XALKORI, CRIZOTINIB
XANAX, ALPRAZOLAM
XANAX XR, ALPRAZOLAM
XARELTO, RIVAROXABAN
XATMEP, METHOTREXATE SODIUM
XELJANZ, TOFACITINIB CITRATE
XELJANZ XR, TOFACITINIB CITRATE
XELODA, CAPECITABINE
XELPROS, LATANOPROST
XENAZINE, TETRABENAZINE
XENICAL, ORLISTAT
XENON XE 133, XENON XE-133
XEPI, OZENOXACIN
XERAVA, ERAVACYCLINE DIHYDROCHLORIDE
XERESE, ACYCLOVIR
XERMELO, TELOTRISTAT ETIPRATE
XHANCE, FLUTICASONE PROPIONATE
XIFAXAN, RIFAXIMIN
XIGDUO XR, DAPAGLIFLOZIN
XIIDRA, LIFITEGRAST
XIMINO, MINOCYCLINE HYDROCHLORIDE
XOFIGO, RADIUM RA-223 DICHLORIDE
XOFLUZA, BALOXAVIR MARBOXIL
XOLEGEL, KETOCONAZOLE
XOPENEX, LEVALBUTEROL HYDROCHLORIDE
XOPENEX HFA, LEVALBUTEROL TARTRATE

APPENDIX A - PRODUCT NAME INDEX

**** X ****

XOSPATA, GILTERITINIB FUMARATE
XTAMPZA ER, OXYCODONE
XTANDI, ENZALUTAMIDE
XTORO, FINAFLOXACIN
XTRELUS, GUAIFENESIN
XULANE, ETHINYL ESTRADIOL
XULTOPHY 100/3.6, INSULIN DEGLUDEC
XURIDEN, URIDINE TRIACETATE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYOSTED (AUTOINJECTOR), TESTOSTERONE ENANTHATE
XYREM, SODIUM OXYBATE
XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE
XYZAL ALLERGY 24HR, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)

**** Y ****

YAELA, DROSPIRENONE
YASMIN, DROSPIRENONE
YAZ, DROSPIRENONE
YONDELIS, TRABECTEDIN
YONSA, ABIRATERONE ACETATE
YOSPRALA, ASPIRIN
YUPELRI, REVEFENACIN
YUTIQ, FLUOCINOLONE ACETONIDE

**** Z ****

ZAFIRLUKAST, ZAFIRLUKAST
ZALEPLON, ZALEPLON
ZANAFLEX, TIZANIDINE HYDROCHLORIDE
ZANOSAR, STREPTOZOCIN
ZANTAC, RANITIDINE HYDROCHLORIDE
ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)
ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)
ZARONTIN, ETHOSUXIMIDE
ZAROXOLYN, METOLAZONE
ZAVESCA, MIGLUSTAT
ZEGERID, OMEPRAZOLE
ZEGERID OTC, OMEPRAZOLE (OTC)
ZEJULA, NIRAPARIB TOSYLATE
ZELAPAR, SELEGILINE HYDROCHLORIDE
ZELBORAF, VEMURAFENIB
ZEMBRACE SYMTOUCH, SUMATRIPTAN SUCCINATE
ZEMDRI, PLAZOMICIN SULFATE
ZEMPLAR, PARICALCITOL
ZENATANE, ISOTRETINOIN
ZENPEP, PANCRELIPASE (AMYLASE
ZEPATIER, ELBASVIR
ZERBAXA, CEFTOLOZANE SULFATE
ZERIT, STAVUDINE
ZERVIATE, CETIRIZINE HYDROCHLORIDE
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINOPRIL
ZETIA, EZETIMIBE
ZETONNA, CICLESONIDE
ZIAC, BISOPROLOL FUMARATE
ZIAGEN, ABACAVIR SULFATE
ZIANA, CLINDAMYCIN PHOSPHATE
ZIDOVUDINE, ZIDOVUDINE
ZILEUTON, ZILEUTON
ZILRETTA, TRIAMCINOLONE ACETONIDE
ZINACEF, CEFUROXIME SODIUM
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZINGO, LIDOCAINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** Z ****

ZIOPTAN, TAFLUPROST
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZIPSOR, DICLOFENAC POTASSIUM
ZIRGAN, GANCICLOVIR
ZITHROMAX, AZITHROMYCIN
ZOCOR, SIMVASTATIN
ZOFRAN, ONDANSETRON HYDROCHLORIDE
ZOFRAN ODT, ONDANSETRON
ZOHYDRO ER, HYDROCODONE BITARTRATE
ZOLADEX, GOSERELIN ACETATE
ZOLEDRONIC, ZOLEDRONIC ACID
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLINZA, VORINOSTAT
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLOFT, SERTRALINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZOLPIMIST, ZOLPIDEM TARTRATE
ZOMACTON, SOMATROPIN
ZOMETA, ZOLEDRONIC ACID
ZOMIG, ZOLMITRIPTAN
ZOMIG-ZMT, ZOLMITRIPTAN
ZONALON, DOXEPIN HYDROCHLORIDE
ZONEGRAN, ZONISAMIDE
ZONISAMIDE, ZONISAMIDE
ZONTIVITY, VORAPAXAR SULFATE
ZORBTIVE, SOMATROPIN RECOMBINANT
ZORTRESS, EVEROLIMUS
ZORVOLEX, DICLOFENAC
ZOSYN, PIPERACILLIN SODIUM
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOVIA 1/35E-28, ETHINYL ESTRADIOL
ZOVIA 1/50E-28, ETHINYL ESTRADIOL
ZOVIRAX, ACYCLOVIR
ZTLIDO, LIDOCAINE
ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE
ZUMANDIMINE, DROSPIRENONE
ZUPLENZ, ONDANSETRON
ZURAMPIC, LESINURAD
ZUTRIPRO, CHLORPHENIRAMINE MALEATE
ZYBAN, BUPROPION HYDROCHLORIDE
ZYCLARA, IMIQUIMOD
ZYDELIG, IDELALISIB
ZYFLO, ZILEUTON
ZYFLO CR, ZILEUTON
ZYKADIA, CERITINIB
ZYLET, LOTEPREDNOL ETABONATE
ZYLOPRIM, ALLOPURINOL
ZYMAR, GATIFLOXACIN
ZYMAXID, GATIFLOXACIN
ZYPITAMAG, PITAVASTATIN MAGNESIUM
ZYPREXA, OLANZAPINE
ZYPREXA RELPREVV, OLANZAPINE PAMOATE
ZYPREXA ZYDIS, OLANZAPINE
ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)
ZYTIGA, ABIRATERONE ACETATE
ZYVOX, LINEZOLID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** 3 ****

3D IMAGING DRUG
* 3D IMAGING DRUG DESIGN AND DEVELOPMENT LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

3M
* 3M CO
PERIDEX, CHLORHEXIDINE GLUCONATE
* 3M HEALTH CARE INC
AVAGARD, ALCOHOL (OTC)
DURAPREP, IODINE POVACRYLEX (OTC)

3M DRUG DELIVERY
* 3M DRUG DELIVERY SYSTEMS
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
PROVENTIL-HFA, ALBUTEROL SULFATE

3M HEALTH CARE
* 3M HEALTH CARE INFECTION PREVENTION DIV
SOLUPREP, CHLORHEXIDINE GLUCONATE (OTC)

**** 6 ****

60 DEGREES PHARMS
* 60 DEGREES PHARMACEUTICALS LLC
ARAKODA, TAFENOQUINE SUCCINATE

**** A ****

AAA USA INC
* ADVANCED ACCELERATOR APPLICATIONS USA INC
LUTATHERA, LUTETIUM DOTATATE LU-177
NETSPOT, GALLIUM DOTATATE GA-68

AAIPHARMA LLC
* AAIPHARMA LLC
AZASAN, AZATHIOPRINE

ABBVIE
* ABBVIE INC
ANDROGEL, TESTOSTERONE
CREON, PANCRELIPASE (AMYLASE
CYCLOSPORINE, CYCLOSPORINE
DEPACON, VALPROATE SODIUM
DEPAKENE, VALPROIC ACID
DEPAKOTE ER, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
GENGRAF, CYCLOSPORINE
K-TAB, POTASSIUM CHLORIDE
KALETRA, LOPINAVIR
MARINOL, DRONABINOL
NIASPAN, NIACIN
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMBEX, CISATRACURIUM BESYLATE
NORVIR, RITONAVIR
SURVANTA, BERACTANT
SYNTHROID, LEVOTHYROXINE SODIUM **
TARKA, TRANDOLAPRIL
TRICOR, FENOFIBRATE
TRIDIONE, TRIMETHADIONE
TRILIPIX, CHOLINE FENOFIBRATE
ULTANE, SEVOFLURANE
ZEMPLAR, PARICALCITOL

ABBVIE ENDOCRINE
* ABBVIE ENDOCRINE INC
LUPANETA PACK, LEUPROLIDE ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

ABBVIE ENDOCRINE INC
* ABBVIE ENDOCRINE INC
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-PED, LEUPROLIDE ACETATE

ABBVIE INC
* ABBVIE INC
DUOPA, CARBIDOPA
MAVYRET, GLECAPREVIR
NORVIR, RITONAVIR
ORILISSA, ELAGOLIX SODIUM
TECHNIVIE, OMBITASVIR
VENCLEXTA, VENETOCLAX
VIEKIRA PAK (COPACKAGED), DASABUVIR SODIUM
VIEKIRA XR, DASABUVIR SODIUM

ABHAI INC
* ABHAI INC
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

ABHAI LLC
* ABHAI LLC
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
URSODIOL, URSODIOL

ABON PHARMS LLC
* ABON PHARMACEUTICALS LLC
CLOFARABINE, CLOFARABINE

ABRAXIS BIOSCIENCE
* ABRAXIS BIOSCIENCE LLC
ABRAXANE, PACLITAXEL

ABRAXIS PHARM
* ABRAXIS PHARMACEUTICAL PRODUCTS
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE

ACADEMIC PHARMS INC
* ACADEMIC PHARMACEUTICALS INC
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE

ACADIA PHARMS INC
* ACADIA PHARMACEUTICALS INC
NUPLAZID, PIMAVANSERIN TARTRATE

ACCELRX LABS
* ACCELRX LABS LLC
CARISOPRODOL, CARISOPRODOL

ACCORD HLTHCARE
* ACCORD HEALTHCARE INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZACITIDINE, AZACITIDINE
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BIVALIRUDIN, BIVALIRUDIN
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CAPECITABINE, CAPECITABINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBOPLATIN, CARBOPLATIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACCORD HEALTHCARE INC
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CISPLATIN, CISPLATIN
CLONAZEPAM, CLONAZEPAM
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOZAPINE, CLOZAPINE
DALFAMPRIDINE, DALFAMPRIDINE
DECITABINE, DECITABINE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ENTECAVIR, ENTECAVIR
EPLERENONE, EPLERENONE
EPTIFIBATIDE, EPTIFIBATIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ETOPOSIDE, ETOPOSIDE
EZETIMIBE, EZETIMIBE
FINASTERIDE, FINASTERIDE
FLUOROURACIL, FLUOROURACIL
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ITRACONAZOLE, ITRACONAZOLE
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LISINOPRIL, LISINOPRIL
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHYLDOPA, METHYLDOPA
MITOMYCIN, MITOMYCIN
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PACLITAXEL, PACLITAXEL
PARICALCITOL, PARICALCITOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PRASUGREL, PRASUGREL HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RAMIPRIL, RAMIPRIL
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
SPIRONOLACTONE, SPIRONOLACTONE
TACROLIMUS, TACROLIMUS
TEMOZOLOMIDE, TEMOZOLOMIDE
TEMSIROLIMUS, TEMSIROLIMUS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACCORD HEALTHCARE INC
TERIFLUNOMIDE, TERIFLUNOMIDE
TOPIRAMATE, TOPIRAMATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

ACCORD HLTHCARE INC

* ACCORD HEALTHCARE INC USA
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
TIGECYCLINE, TIGECYCLINE

ACELLA PHARMS LLC

* ACELLA PHARMACEUTICALS LLC
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
PHENYTOIN SODIUM, PHENYTOIN SODIUM

ACELRX PHARMS

* ACELRX PHARMACEUTICALS INC
DSUVIA, SUFENTANIL CITRATE

ACHAOGEN INC

* ACHAOGEN INC
ZEMDRI, PLAZOMICIN SULFATE

ACI HEALTHCARE LTD

* ACI HEALTHCARE LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
LEVETIRACETAM, LEVETIRACETAM
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

ACIC PHARMS

* ACIC PHARMACEUTICALS INC
LEVETIRACETAM, LEVETIRACETAM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID

ACLARIS

* ACLARIS THERAPEUTICS INC
ESKATA, HYDROGEN PEROXIDE
RHOFADE, OXYMETAZOLINE HYDROCHLORIDE

ACORDA

* ACORDA THERAPEUTICS INC
AMPYRA, DALFAMPRIDINE
INBRIJA, LEVODOPA

ACS DOBFAR

* ACS DOBFAR SPA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFOXITIN, CEFOXITIN SODIUM
CEFTAZIDIME, CEFTAZIDIME
CEFTRIAXONE, CEFTRIAXONE SODIUM
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
MEROPENEM, MEROPENEM

ACS DOBFAR SPA

* ACS DOBFAR SPA
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
ERTAPENEM SODIUM, ERTAPENEM SODIUM
MEROPENEM, MEROPENEM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

ACTAVIS ELIZABETH

* ACTAVIS ELIZABETH LLC
ALPRAZOLAM, ALPRAZOLAM
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACTAVIS ELIZABETH LLC
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DEFERASIROX, DEFERASIROX
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, DEXTROMETHORPHAN HYDROBROMIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GABAPENTIN, GABAPENTIN
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
INDAPAMIDE, INDAPAMIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOVASTATIN, LOVASTATIN
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NIFEDIPINE, NIFEDIPINE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OXAZEPAM, OXAZEPAM
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SPIRONOLACTONE, SPIRONOLACTONE
TEMAZEPAM, TEMAZEPAM
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* ACTAVIS ELIZABETH LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
ALPRAZOLAM, ALPRAZOLAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
MORPHINE SULFATE, MORPHINE SULFATE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

ACTAVIS INC

* ACTAVIS INC
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
METHOXSALEN, METHOXSALEN
ZOLEDRONIC ACID, ZOLEDRONIC ACID

ACTAVIS LABS

* ACTAVIS LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
PERMETHRIN, PERMETHRIN

ACTAVIS LABS FL

* ACTAVIS LABORATORIES FL INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
MESALAMINE, MESALAMINE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

ACTAVIS LABS FL INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACTAVIS LABORATORIES FL INC
BUDESONIDE, BUDESONIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CABERGOLINE, CABERGOLINE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CLARITHROMYCIN, CLARITHROMYCIN
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DALFAMPRIDINE, DALFAMPRIDINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
DUTASTERIDE, DUTASTERIDE
FENTANYL CITRATE, FENTANYL CITRATE
FLUTAMIDE, FLUTAMIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
LEVETIRACETAM, LEVETIRACETAM
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NAPROXEN SODIUM, NAPROXEN SODIUM
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROGLYCERIN, NITROGLYCERIN
OMEPRAZOLE, OMEPRAZOLE
OXYCODONE AND ASPIRIN, ASPIRIN
PALIPERIDONE, PALIPERIDONE
PAROXETINE MESYLATE, PAROXETINE MESYLATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISONE, PREDNISONE
RAMELTEON, RAMELTEON
RISPERIDONE, RISPERIDONE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAZTIA XT, DILTIAZEM HYDROCHLORIDE
TETRABENAZINE, TETRABENAZINE
TRANEXAMIC ACID, TRANEXAMIC ACID
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

ACTAVIS LABS NY INC

* ACTAVIS LABORATORIES NY INC
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)

ACTAVIS LABS UT INC

* ACTAVIS LABORATORIES UT INC
AZELAIC ACID, AZELAIC ACID
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLONIDINE, CLONIDINE
DOCOSANOL, DOCOSANOL (OTC)
EMLA, LIDOCAINE
FIORICET W/ CODEINE, ACETAMINOPHEN
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
LIDOCAINE, LIDOCAINE
NORINYL 1+50 28-DAY, MESTRANOL
PROGESTERONE, PROGESTERONE
TESTOSTERONE, TESTOSTERONE

* ACTAVIS LABORATORIES UT INC INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
PIMECROLIMUS, PIMECROLIMUS
TESTOSTERONE, TESTOSTERONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

ACTAVIS LLC

* ACTAVIS LLC
AZACITIDINE, AZACITIDINE
DAPSONE, DAPSONE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE

* ACTAVIS LLC AN INDIRECT WHOLLY-OWNED SUB OF TEVA PHARMACEUTICALS USA INC
BUSULFAN, BUSULFAN
DOCETAXEL, DOCETAXEL
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
OXALIPLATIN, OXALIPLATIN

ACTAVIS MID ATLANTIC

* ACTAVIS MID ATLANTIC LLC
ACETASOL HC, ACETIC ACID, GLACIAL
ACYCLOVIR, ACYCLOVIR
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ADAPALENE, ADAPALENE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ENULOSE, LACTULOSE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
HYDROCORTISONE, HYDROCORTISONE
IBUPROFEN, IBUPROFEN (OTC)
LEVETIRACETAM, LEVETIRACETAM
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
NITROFURANTOIN, NITROFURANTOIN
NYSTATIN, NYSTATIN
PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
VALNAC, BETAMETHASONE VALERATE

* ACTAVIS MID ATLANTIC LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
IBUPROFEN, IBUPROFEN
M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
PERMETHRIN, PERMETHRIN (OTC)

ACTAVIS PHARMA

* ACTAVIS PHARMA INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
MICONAZOLE NITRATE, MICONAZOLE NITRATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)

ACTAVIS TOTOWA

* ACTAVIS TOTOWA LLC
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
REPAGLINIDE, REPAGLINIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACTAVIS TOTOWA LLC
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VINORELBINE TARTRATE, VINORELBINE TARTRATE

ACTAVIS TOTOWA TEVA

* ACTAVIS TOTOWA LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
FINASTERIDE, FINASTERIDE

ACTELION PHARMS

* ACTELION PHARMACEUTICALS LTD
TRACLEER, BOSENTAN

ACTELION PHARMS LTD

* ACTELION PHARMACEUTICALS LTD
OPSUMIT, MACITENTAN
TRACLEER, BOSENTAN
UPTRAVI, SELEXIPAG
VELETRI, EPOPROSTENOL SODIUM
VENTAVIS, ILOPROST
ZAVESCA, MIGLUSTAT

ACTIENT PHARMS

* ACTIENT PHARMACEUTICALS LLC
THEO-24, THEOPHYLLINE

ADAMAS PHARMA

* ADAMAS PHARMA LLC
GOCOVRI, AMANTADINE HYDROCHLORIDE

ADAMIS PHARMS CORP

* ADAMIS PHARMACEUTICALS CORP
SYMJEPI, EPINEPHRINE

ADAPT

* ADAPT PHARMA OPERATIONS LTD
NARCAN, NALOXONE HYDROCHLORIDE

ADARE PHARMS INC

* ADARE PHARMACEUTICALS INC
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

ADDMEDICA SAS

* ADDMEDICA SAS
SIKLOS, HYDROXYUREA

ADIENNE SA

* ADIENNE SA
TEPADINA, THIOTEPA

AEGERION

* AEGERION PHARMACEUTICALS INC
JUXTAPID, LOMITAPIDE MESYLATE

AERIE PHARMS INC

* AERIE PHARMACEUTICALS INC
RHOPRESSA, NETARSUDIL DIMESYLATE

AGIOS PHARMS INC

* AGIOS PHARMACEUTICALS INC
TIBSOVO, IVOSIDENIB

AGOURON PHARMS

* AGOURON PHARMACEUTICALS LLC
VIRACEPT, NELFINAVIR MESYLATE

AILEX PHARMS LLC

* AILEX PHARMACEUTICALS LLC
BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, BISMUTH
CROMOLYN SODIUM, CROMOLYN SODIUM
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE

AIPING PHARM INC

* AIPING PHARMACEUTICAL INC
BENZONATATE, BENZONATATE

AJANTA PHARMA LTD

* AJANTA PHARMA LTD
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AJANTA PHARMA LTD
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ENTACAPONE, ENTACAPONE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
LANSOPRAZOLE, LANSOPRAZOLE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILODOSIN, SILODOSIN
VORICONAZOLE, VORICONAZOLE
ZOLMITRIPTAN, ZOLMITRIPTAN

AKARX INC

* AKARX INC
DOPTELET, AVATROMBOPAG MALEATE

AKCEA THERAPS

* AKCEA THERAPEUTICS INC
TEGSEDI, INOTERSEN SODIUM

AKORN

* AKORN INC
ADENOSINE, ADENOSINE
AK-FLUOR 10%, FLUORESCEIN SODIUM
AK-FLUOR 25%, FLUORESCEIN SODIUM
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKTEN, LIDOCAINE HYDROCHLORIDE
AKTOB, TOBRAMYCIN
ALFENTA, ALFENTANIL HYDROCHLORIDE
ATROPINE SULFATE, ATROPINE SULFATE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN, BACITRACIN
BAL, DIMERCAPROL
BALANCED SALT, CALCIUM CHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CALCITRIOL, CALCITRIOL
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CARBOPLATIN, CARBOPLATIN
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CROMOLYN SODIUM, CROMOLYN SODIUM
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPTIFIBATIDE, EPTIFIBATIDE
ERYTHROMYCIN, ERYTHROMYCIN
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
GENTAK, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IC-GREEN, INDOCYANINE GREEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AKORN INC
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
LATANOPROST, LATANOPROST
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NEDOCROMIL SODIUM, NEDOCROMIL SODIUM
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OFLOXACIN, OFLOXACIN
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
PARICALCITOL, PARICALCITOL
PYRAZINAMIDE, PYRAZINAMIDE
RIFAMPIN, RIFAMPIN
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIMOLOL, TIMOLOL
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TROPICACYL, TROPICAMIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

AKORN INC

* AKORN INC
ACETYLCYSTEINE, ACETYLCYSTEINE
APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
CEFTRIAXONE, CEFTRIAXONE SODIUM
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CYCLOPENTOLATE HYDROCHLORIDE, CYCLOPENTOLATE HYDROCHLORIDE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DRONABINOL, DRONABINOL
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
INAPSINE, DROPERIDOL
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AKORN INC
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
TOBRAMYCIN, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

ALCON

* ALCON LABORATORIES INC
BSS PLUS, CALCIUM CHLORIDE
BSS, CALCIUM CHLORIDE
MIOSTAT, CARBACHOL
NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)

ALCON LABS

* ALCON LABORATORIES LTD
TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE

ALCON LABS INC

* ALCON LABORATORIES INC
ALCAINE, PROPARACAINE HYDROCHLORIDE
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
FLUORESCITE, FLUORESCEIN SODIUM
ISOPTO ATROPINE, ATROPINE SULFATE

ALCON PHARMS LTD

* ALCON PHARMACEUTICALS LTD
BETADINE, POVIDONE-IODINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)

ALEMBIC LTD

* ALEMBIC LTD
LITHIUM CARBONATE, LITHIUM CARBONATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE

ALEMBIC PHARMS LTD

* ALEMBIC PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CELECOXIB, CELECOXIB
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DESVENLAFAXINE, DESVENLAFAXINE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
FAMOTIDINE, FAMOTIDINE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
ITRACONAZOLE, ITRACONAZOLE
LAMOTRIGINE, LAMOTRIGINE
LEFLUNOMIDE, LEFLUNOMIDE
LINEZOLID, LINEZOLID
LITHIUM CARBONATE, LITHIUM CARBONATE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALEMBIC PHARMACEUTICALS LTD
MODAFINIL, MODAFINIL
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TEMAZEPAM, TEMAZEPAM
THEOPHYLLINE, THEOPHYLLINE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLMITRIPTAN, ZOLMITRIPTAN

ALEOR DERMACEUTICALS

* ALEOR DERMACEUTICALS LTD
LIDOCAINE, LIDOCAINE

ALIGNSCIENCE PHARMA

* ALIGNSCIENCE PHARMA INC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

ALIMERA SCIENCES INC

* ALIMERA SCIENCES INC
ILUVIEN, FLUOCINOLONE ACETONIDE

ALKALOIDA ZRT

* ALKALOIDA CHEMICAL CO ZRT
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE

ALKEM

* ALKEM LABORATORIES LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
GABAPENTIN, GABAPENTIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ALKEM LABS LTD

* ALKEM LABORATORIES LTD
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
CAPECITABINE, CAPECITABINE
CEFIXIME, CEFIXIME
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DALFAMPRIDINE, DALFAMPRIDINE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
EZETIMIBE, EZETIMIBE
FINASTERIDE, FINASTERIDE
GABAPENTIN, GABAPENTIN
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
ITRACONAZOLE, ITRACONAZOLE
LAMOTRIGINE, LAMOTRIGINE
LIDOCAINE, LIDOCAINE
LINEZOLID, LINEZOLID
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALKEM LABORATORIES LTD
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RILUZOLE, RILUZOLE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

ALKERMES
* ALKERMES INC
VIVITROL, NALTREXONE

ALKERMES INC
* ALKERMES INC
ARISTADA INITIO KIT, ARIPIPRAZOLE LAUROXIL
ARISTADA, ARIPIPRAZOLE LAUROXIL

ALLEGIANCE HLTHCARE
* ALLEGIANCE HEALTHCARE CORP
POVIDONE IODINE, POVIDONE-IODINE (OTC)

ALLEGIS
* ALLEGIS HOLDINGS LLC
PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE

ALLERGAN
* ALLERGAN
ACULAR LS, KETOROLAC TROMETHAMINE
ALPHAGAN P, BRIMONIDINE TARTRATE
BLEPH-10, SULFACETAMIDE SODIUM
GENOPTIC, GENTAMICIN SULFATE
ZYMAXID, GATIFLOXACIN
* ALLERGAN INC
ACULAR, KETOROLAC TROMETHAMINE
ACUVAIL, KETOROLAC TROMETHAMINE
ACZONE, DAPSONE
ALOCRIL, NEDOCROMIL SODIUM
ALPHAGAN P, BRIMONIDINE TARTRATE
AVAGE, TAZAROTENE
COMBIGAN, BRIMONIDINE TARTRATE
ELESTAT, EPINASTINE HYDROCHLORIDE
LASTACAFT, ALCAFTADINE
LATISSE, BIMATOPROST
LUMIGAN, BIMATOPROST
OCUFLOX, OFLOXACIN
OZURDEX, DEXAMETHASONE
POLYTRIM, POLYMYXIN B SULFATE
RESTASIS MULTIDOSE, CYCLOSPORINE
RESTASIS, CYCLOSPORINE
TAZORAC, TAZAROTENE
ZYMAR, GATIFLOXACIN
* ALLERGAN PHARMACEUTICAL
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLEPHAMIDE, PREDNISOLONE ACETATE
FML FORTE, FLUOROMETHOLONE
FML, FLUOROMETHOLONE
OCUFEN, FLURBIPROFEN SODIUM
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PRED-G, GENTAMICIN SULFATE

ALLERGAN HOLDINGS
* ALLERGAN HOLDINGS UNLTD CO
VIBERZI, ELUXADOLINE

ALLERGAN SALES LLC
* ALLERGAN SALES LLC
ACTIGALL, URSODIOL
ALORA, ESTRADIOL
ANDRODERM, TESTOSTERONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALLERGAN SALES LLC
AVYCAZ, AVIBACTAM SODIUM
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
BREVICON 28-DAY, ETHINYL ESTRADIOL
BYSTOLIC, NEBIVOLOL HYDROCHLORIDE
BYVALSON, NEBIVOLOL HYDROCHLORIDE
CANASA, MESALAMINE
CARAFATE, SUCRALFATE
CELEXA, CITALOPRAM HYDROBROMIDE
CONDYLOX, PODOFILOX
CRINONE, PROGESTERONE
DALVANCE, DALBAVANCIN HYDROCHLORIDE
ESTRACE, ESTRADIOL
FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
FIORINAL W/CODEINE, ASPIRIN
FIORINAL, ASPIRIN
GELNIQUE, OXYBUTYNIN CHLORIDE
INFED, IRON DEXTRAN
KADIAN, MORPHINE SULFATE
LEXAPRO, ESCITALOPRAM OXALATE
LINZESS, LINACLOTIDE
MICROZIDE, HYDROCHLOROTHIAZIDE
NAMENDA, MEMANTINE HYDROCHLORIDE
NAMZARIC, DONEPEZIL HYDROCHLORIDE
NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
OXYTROL, OXYBUTYNIN
PYLERA, BISMUTH SUBCITRATE POTASSIUM
RAPAFLO, SILODOSIN
RECTIV, NITROGLYCERIN
SAVELLA, MILNACIPRAN HYDROCHLORIDE
TEFLARO, CEFTAROLINE FOSAMIL
TRELSTAR, TRIPTORELIN PAMOATE
URSO 250, URSODIOL
URSO FORTE, URSODIOL
VIIBRYD, VILAZODONE HYDROCHLORIDE
VRAYLAR, CARIPRAZINE HYDROCHLORIDE

ALLERQUEST
* ALLERQUEST LLC
PRE-PEN, BENZYLPENICILLOYL POLYLYSINE

ALLIED
* ALLIED PHARMA INC
CLARITHROMYCIN, CLARITHROMYCIN
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

ALLIED PHARMA INC
* ALLIED PHARMA INC
CLARITHROMYCIN, CLARITHROMYCIN

ALLOS
* ALLOS THERAPEUTICS INC
FOLOTYN, PRALATREXATE

ALMIRALL
* ALMIRALL LLC
SEYSARA, SARECYCLINE HYDROCHLORIDE

ALNYLAM PHARMS INC
* ALNYLAM PHARMACEUTICALS INC
ONPATTRO, PATISIRAN SODIUM

ALPHARMA PHARMS
* ALPHARMA PHARMACEUTICALS LLC
EMBEDA, MORPHINE SULFATE

ALRA
* ALRA LABORATORIES INC
CHOLAC, LACTULOSE
CONSTILAC, LACTULOSE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALRA LABORATORIES INC
GEN-XENE, CLORAZEPATE DIPOTASSIUM
IBU-TAB 200, IBUPROFEN (OTC)
IBU-TAB, IBUPROFEN

ALTAIRE PHARMS INC

* ALTAIRE PHARMACEUTICALS INC
ALTAFLUOR BENOX, BENOXINATE HYDROCHLORIDE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
OFLOXACIN, OFLOXACIN

ALTATHERA PHARMS LLC

* ALTATHERA PHARMACEUTICALS LLC
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

ALVOGEN

* ALVOGEN GROUP HOLDINGS 2 LLC
DAPSONE, DAPSONE
ETHACRYNIC ACID, ETHACRYNIC ACID
OFLOXACIN, OFLOXACIN
* ALVOGEN GROUP HOLDINGS 3 LLC
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FORFIVO XL, BUPROPION HYDROCHLORIDE
* ALVOGEN GROUP HOLDINGS LLC
ADALAT CC, NIFEDIPINE
* ALVOGEN INC
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

ALVOGEN INC

* ALVOGEN INC
ACETYLCYSTEINE, ACETYLCYSTEINE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
VORICONAZOLE, VORICONAZOLE

ALVOGEN MALTA

* ALVOGEN MALTA OPERATIONS LTD
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BUDESONIDE, BUDESONIDE
CARBIDOPA, CARBIDOPA
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DISULFIRAM, DISULFIRAM
EXEMESTANE, EXEMESTANE
FELBAMATE, FELBAMATE
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
MELPHALAN, MELPHALAN
NAPRELAN, NAPROXEN SODIUM
NATEGLINIDE, NATEGLINIDE
NEVIRAPINE, NEVIRAPINE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RIVASTIGMINE, RIVASTIGMINE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
SPECTAZOLE, ECONAZOLE NITRATE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINOPRIL

ALVOGEN PINE BROOK

* ALVOGEN PINE BROOK LLC
ESTRADIOL, ESTRADIOL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

AM ANTIBIOTICS
* AMERICAN ANTIBIOTICS INC
AMOXICILLIN, AMOXICILLIN

AMAG PHARMA USA
* AMAG PHARMA USA INC
MAKENA (AUTOINJECTOR), HYDROXYPROGESTERONE CAPROATE
MAKENA PRESERVATIVE FREE, HYDROXYPROGESTERONE CAPROATE
MAKENA, HYDROXYPROGESTERONE CAPROATE

AMAG PHARMS INC
* AMAG PHARMACEUTICALS INC
FERAHEME, FERUMOXYTOL
INTRAROSA, PRASTERONE

AMARIN PHARMS
* AMARIN PHARMACEUTICALS IRELAND LTD
VASCEPA, ICOSAPENT ETHYL

AMERIGEN PHARMS LTD
* AMERIGEN PHARMACEUTICALS LTD
BEXAROTENE, BEXAROTENE
CARBIDOPA, CARBIDOPA
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
INDAPAMIDE, INDAPAMIDE
MIGLUSTAT, MIGLUSTAT
TEMOZOLOMIDE, TEMOZOLOMIDE

AMGEN
* AMGEN INC
SENSIPAR, CINACALCET HYDROCHLORIDE

AMGEN INC
* AMGEN INC
CORLANOR, IVABRADINE HYDROCHLORIDE

AMICUS THERAPS US
* AMICUS THERAPEUTICS US INC
GALAFOLD, MIGALASTAT HYDROCHLORIDE

AMNEAL PHARM
* AMNEAL PHARMACEUTICAL
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FOLIC ACID, FOLIC ACID
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE

AMNEAL PHARMS
* AMNEAL PHARMACEUTICALS
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ARIPIPRAZOLE, ARIPIPRAZOLE
ATOVAQUONE, ATOVAQUONE
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CAPECITABINE, CAPECITABINE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ENTECAVIR, ENTECAVIR
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESTRADIOL, ESTRADIOL
FELBAMATE, FELBAMATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMNEAL PHARMACEUTICALS
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
INDOMETHACIN, INDOMETHACIN
ITRACONAZOLE, ITRACONAZOLE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE, LIDOCAINE
LINEZOLID, LINEZOLID
LORAZEPAM, LORAZEPAM
MEROPENEM, MEROPENEM
METAXALONE, METAXALONE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NIACIN, NIACIN
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN
NIZATIDINE, NIZATIDINE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
QUININE SULFATE, QUININE SULFATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TELMISARTAN, TELMISARTAN
TEMAZEPAM, TEMAZEPAM
TEMOZOLOMIDE, TEMOZOLOMIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
WARFARIN SODIUM, WARFARIN SODIUM
* AMNEAL PHARMACEUTICALS HOLDINGS GMBH
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
* AMNEAL PHARMACEUTICALS OF NEW YORK LLC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUDESONIDE, BUDESONIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CELECOXIB, CELECOXIB
DUTASTERIDE, DUTASTERIDE
EPTIFIBATIDE, EPTIFIBATIDE
EXEMESTANE, EXEMESTANE
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMNEAL PHARMACEUTICALS OF NEW YORK LLC
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PARICALCITOL, PARICALCITOL
PRASUGREL, PRASUGREL HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RIVASTIGMINE, RIVASTIGMINE
SPIRONOLACTONE, SPIRONOLACTONE
TOBRAMYCIN, TOBRAMYCIN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VALSARTAN, VALSARTAN
VIGABATRIN, VIGABATRIN

AMNEAL PHARMS CO

* AMNEAL PHARMACEUTICALS CO GMBH
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ARGATROBAN, ARGATROBAN
BUMETANIDE, BUMETANIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
BUSULFAN, BUSULFAN
CARMUSTINE, CARMUSTINE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
CLOFARABINE, CLOFARABINE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DOCETAXEL, DOCETAXEL
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ERYTHROMYCIN, ERYTHROMYCIN
ETHACRYNIC ACID, ETHACRYNIC ACID
ETODOLAC, ETODOLAC
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
EZETIMIBE, EZETIMIBE
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
FUROSEMIDE, FUROSEMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
NADOLOL, NADOLOL
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OXAPROZIN, OXAPROZIN
PARICALCITOL, PARICALCITOL
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMNEAL PHARMACEUTICALS CO GMBH
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SILODOSIN, SILODOSIN
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TERIFLUNOMIDE, TERIFLUNOMIDE
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
URSODIOL, URSODIOL
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

AMNEAL PHARMS LLC

* AMNEAL PHARMACEUTICALS LLC
ACTIVELLA, ESTRADIOL
AZATHIOPRINE, AZATHIOPRINE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
FENOFIBRATE, FENOFIBRATE
FLUOCINONIDE, FLUOCINONIDE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
RITONAVIR, RITONAVIR
TIGECYCLINE, TIGECYCLINE

AMNEAL PHARMS NY

* AMNEAL PHARMACEUTICALS NY LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALPRAZOLAM, ALPRAZOLAM
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
REPREXAIN, HYDROCODONE BITARTRATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

* AMNEAL PHARMACEUTICALS OF NY LLC
BEXAROTENE, BEXAROTENE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
ISOTRETINOIN, ISOTRETINOIN
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PROGESTERONE, PROGESTERONE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

AMPHASTAR PHARM

* AMPHASTAR PHARMACEUTICAL INC
AMPHADASE, HYALURONIDASE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE

AMPHASTAR PHARMS INC

* AMPHASTAR PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMPHASTAR PHARMACEUTICALS INC
CORTROSYN, COSYNTROPIN
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE

AMRING PHARMS
* AMRING PHARMACEUTICALS INC
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
LATANOPROST, LATANOPROST
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE

ANACOR PHARMS INC
* ANACOR PHARMACEUTICALS INC
EUCRISA, CRISABOROLE
KERYDIN, TAVABOROLE

ANBEX
* ANBEX INC
IOSAT, POTASSIUM IODIDE (OTC)

ANBISON LAB
* ANBISON LABORATORY CO LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
MONTELUKAST SODIUM, MONTELUKAST SODIUM

ANCHEN PHARMS
* ANCHEN PHARMACEUTICALS INC
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRETINOIN, TRETINOIN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
* ANCHEN PHARMACEUTICALS TAIWAN INC
DIVALPROEX SODIUM, DIVALPROEX SODIUM
* ANCHEN PHARMACEUTICALS, INC
ALPRAZOLAM, ALPRAZOLAM
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN

ANDA REPOSITORY
* ANDA REPOSITORY LLC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
IMIQUIMOD, IMIQUIMOD
LEVOCARNITINE, LEVOCARNITINE
LORAZEPAM, LORAZEPAM
MOMETASONE FUROATE, MOMETASONE FUROATE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PRIMIDONE, PRIMIDONE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

ANDRX LABS LLC
* ANDRX LABS LLC
FORTAMET, METFORMIN HYDROCHLORIDE

ANI PHARMS
* ANI PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ANI PHARMACEUTICALS INC
CORTENEMA, HYDROCORTISONE
LACTULOSE, LACTULOSE
LUVOX, FLUVOXAMINE MALEATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE

ANI PHARMS INC

* ANI PHARMACEUTICALS INC
ALPRAZOLAM, ALPRAZOLAM
ARIMIDEX, ANASTROZOLE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ATACAND HCT, CANDESARTAN CILEXETIL
ATACAND, CANDESARTAN CILEXETIL
BRETHINE, TERBUTALINE SULFATE
CASODEX, BICALUTAMIDE
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CHOLESTYRAMINE, CHOLESTYRAMINE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ETODOLAC, ETODOLAC
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
FELBAMATE, FELBAMATE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GLIPIZIDE, GLIPIZIDE
GUANABENZ ACETATE, GUANABENZ ACETATE
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LITHOBID, LITHIUM CARBONATE
LORAZEPAM, LORAZEPAM
METHAZOLAMIDE, METHAZOLAMIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NILUTAMIDE, NILUTAMIDE
NIZATIDINE, NIZATIDINE
OXCARBAZEPINE, OXCARBAZEPINE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PINDOLOL, PINDOLOL
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALPROIC ACID, VALPROIC ACID
VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

ANTARES PHARMA INC

* ANTARES PHARMA INC
OTREXUP, METHOTREXATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
XYOSTED (AUTOINJECTOR), TESTOSTERONE ENANTHATE

ANTIBIOTICE

* ANTIBIOTICE SA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
NAFCILLIN SODIUM, NAFCILLIN SODIUM

ANTRIM PHARMS LLC

* ANTRIM PHARMACEUTICALS LLC
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE

APC PHARMS LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* APC PHARMACEUTICALS LLC
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE

APEX PHARMS INC

* APEX PHARMACEUTICALS INC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE

APGDI

* ASTELLAS PHARMA GLOBAL DEVELOPMENT INC
MYRBETRIQ, MIRABEGRON

APICORE US

* APICORE US LLC
TETRABENAZINE, TETRABENAZINE

APIL

* ALLERGAN PHARMACEUTICALS INTERNATIONAL LTD
ACTONEL, RISEDRONATE SODIUM
ASACOL HD, MESALAMINE
ATELVIA, RISEDRONATE SODIUM
DELZICOL, MESALAMINE
ENABLEX, DARIFENACIN HYDROBROMIDE
ESTROSTEP FE, ETHINYL ESTRADIOL
FEMCON FE, ETHINYL ESTRADIOL
FEMHRT, ETHINYL ESTRADIOL
LO LOESTRIN FE, ETHINYL ESTRADIOL
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL
LOESTRIN 24 FE, ETHINYL ESTRADIOL
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL
MINASTRIN 24 FE, ETHINYL ESTRADIOL
NOR-QD, NORETHINDRONE
NORCO, ACETAMINOPHEN
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
SARAFEM, FLUOXETINE HYDROCHLORIDE
TAYTULLA, ETHINYL ESTRADIOL

APNAR PHARMA LP

* APNAR PHARMA LP
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

APOLLO PHARMS INC

* APOLLO PHARMACEUTICALS INC
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM

APOPHARMA INC

* APOPHARMA INC
FERRIPROX, DEFERIPRONE

APOTEX

* APOTEX INC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CYCLOSPORINE, CYCLOSPORINE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPLERENONE, EPLERENONE
ETODOLAC, ETODOLAC
FAMCICLOVIR, FAMCICLOVIR

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* APOTEX INC
FAMOTIDINE, FAMOTIDINE
FLUCONAZOLE, FLUCONAZOLE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
LAMIVUDINE, LAMIVUDINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE

APOTEX CORP

* APOTEX CORP
CLARITHROMYCIN, CLARITHROMYCIN
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RILUZOLE, RILUZOLE

APOTEX INC

* APOTEX INC
ABACAVIR SULFATE, ABACAVIR SULFATE
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ACYCLOVIR, ACYCLOVIR
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALKERAN, MELPHALAN
ALPRAZOLAM, ALPRAZOLAM
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
ARIPIPRAZOLE, ARIPIPRAZOLE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATOVAQUONE, ATOVAQUONE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BENZONATATE, BENZONATATE
BICALUTAMIDE, BICALUTAMIDE
BIMATOPROST, BIMATOPROST
BIVALIRUDIN, BIVALIRUDIN
BUDESONIDE, BUDESONIDE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CALCITONIN-SALMON, CALCITONIN SALMON
CARBAMAZEPINE, CARBAMAZEPINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFPROZIL, CEFPROZIL
CELECOXIB, CELECOXIB
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CICLOPIROX, CICLOPIROX
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIVALPROEX SODIUM, DIVALPROEX SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* APOTEX INC

DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE, DUTASTERIDE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
EZETIMIBE, EZETIMIBE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IMATINIB MESYLATE, IMATINIB MESYLATE
IMIQUIMOD, IMIQUIMOD
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMIVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LEVONORGESTREL, LEVONORGESTREL (OTC)
LOVASTATIN, LOVASTATIN
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MODAFINIL, MODAFINIL
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
NABUMETONE, NABUMETONE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
OFLOXACIN, OFLOXACIN
OLANZAPINE, OLANZAPINE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OXCARBAZEPINE, OXCARBAZEPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERIDONE, RISPERIDONE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TEMOZOLOMIDE, TEMOZOLOMIDE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TERIFLUNOMIDE, TERIFLUNOMIDE
TIGECYCLINE, TIGECYCLINE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRANEXAMIC ACID, TRANEXAMIC ACID
TRAVOPROST, TRAVOPROST
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* APOTEX INC
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
* APOTEX INC ETOBICOKE SITE
ACYCLOVIR, ACYCLOVIR
ALLOPURINOL, ALLOPURINOL
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBAMAZEPINE, CARBAMAZEPINE
CARVEDILOL, CARVEDILOL
CILOSTAZOL, CILOSTAZOL
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DILTZAC, DILTIAZEM HYDROCHLORIDE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GABAPENTIN, GABAPENTIN
LEFLUNOMIDE, LEFLUNOMIDE
LISINOPRIL, LISINOPRIL
LORATADINE, LORATADINE (OTC)
MELOXICAM, MELOXICAM
MIRTAZAPINE, MIRTAZAPINE
OXAPROZIN, OXAPROZIN
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TORSEMIDE, TORSEMIDE
ZONISAMIDE, ZONISAMIDE
* APOTEX INC RICHMOND HILL
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BUDESONIDE, BUDESONIDE (OTC)
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
RISPERIDONE, RISPERIDONE
* APOTEX INC.
DILTZAC, DILTIAZEM HYDROCHLORIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE

APOTEX TECHNOLOGIES

* APOTEX TECHNOLOGIES INC
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE

APOTHECON

* APOTHECON INC DIV BRISTOL MYERS SQUIBB
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE

APP PHARMS

* APP PHARMACEUTICALS LLC
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE

APPCO PHARMA LLC

* APPCO PHARMA LLC
CHLORTHALIDONE, CHLORTHALIDONE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

APRECIA PHARMS

* APRECIA PHARMACEUTICALS LLC
SPRITAM, LEVETIRACETAM

APTAPHARMA INC

* APTAPHARMA INC
IBUPROFEN, IBUPROFEN (OTC)

AQUA PHARMS

* AQUA PHARMACEUTICALS
CORDRAN SP, FLURANDRENOLIDE
CORDRAN, FLURANDRENOLIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AQUA PHARMACEUTICALS
MONODOX, DOXYCYCLINE
VERDESO, DESONIDE
* AQUA PHARMACEUTICALS LLC
FLUOROPLEX, FLUOROURACIL
XOLEGEL, KETOCONAZOLE

AQUA PHARMS LLC
* AQUA PHARMACEUTICALS LLC
ACTICLATE, DOXYCYCLINE HYCLATE
ACZONE, DAPSONE
ALTABAX, RETAPAMULIN
AZELEX, AZELAIC ACID
CORDRAN, FLURANDRENOLIDE
VELTIN, CLINDAMYCIN PHOSPHATE

AQUESTIVE THERAP
* AQUESTIVE THERAPEUTICS
SYMPAZAN, CLOBAZAM

ARALEZ PHARMS
* ARALEZ PHARMACEUTICALS TRADING DAC
TOPROL-XL, METOPROLOL SUCCINATE
ZONTIVITY, VORAPAXAR SULFATE

ARALEZ PHARMS INC
* ARALEZ PHARMACEUTICALS INC
FIBRICOR, FENOFIBRIC ACID

ARBOR PHARMS LLC
* ARBOR PHARMACEUTICALS LLC
BIDIL, HYDRALAZINE HYDROCHLORIDE
CETYLEV, ACETYLCYSTEINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
EDARBI, AZILSARTAN KAMEDOXOMIL
EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
ERY-TAB, ERYTHROMYCIN
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN, ERYTHROMYCIN
EVEKEO, AMPHETAMINE SULFATE
GLIADEL, CARMUSTINE
HORIZANT, GABAPENTIN ENACARBIL
NYMALIZE, NIMODIPINE
SKLICE, IVERMECTIN
SOTYLIZE, SOTALOL HYDROCHLORIDE
TRIPTODUR KIT, TRIPTORELIN PAMOATE

ARCO PHARMS LLC
* ARCO PHARMACEUTICALS LLC
THYROSHIELD, POTASSIUM IODIDE (OTC)

AREVA PHARMS
* AREVA PHARMACEUTICALS INC
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

ARIAD
* ARIAD PHARMACEUTICALS INC
ALUNBRIG, BRIGATINIB
ICLUSIG, PONATINIB HYDROCHLORIDE

ARISE PHARMS
* ARISE PHARMACEUTICALS LLC
IBUPROFEN, IBUPROFEN (OTC)
LAMIVUDINE, LAMIVUDINE

ARMSTRONG PHARMS
* ARMSTRONG PHARMACEUTICALS INC
PRIMATENE MIST, EPINEPHRINE (OTC)

ARRAY BIOPHARMA INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ARRAY BIOPHARMA INC
BRAFTOVI, ENCORAFENIB
MEKTOVI, BINIMETINIB

ASCEND THERAPS US

* ASCEND THERAPEUTICS US LLC
ESTROGEL, ESTRADIOL

ASCENT PHARMS INC

* ASCENT PHARMACEUTICALS INC
DUTASTERIDE, DUTASTERIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN (OTC)
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE

ASPEN GLOBAL

* ASPEN GLOBAL INC
MYLERAN, BUSULFAN

ASPEN GLOBAL INC

* ASPEN GLOBAL INC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CYCLESSA, DESOGESTREL
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
LEUKERAN, CHLORAMBUCIL
MYLERAN, BUSULFAN
THIOGUANINE, THIOGUANINE

ASSERTIO

* ASSERTIO THERAPEUTICS INC
CAMBIA, DICLOFENAC POTASSIUM
GRALISE, GABAPENTIN
ZIPSOR, DICLOFENAC POTASSIUM

ASTELLAS

* ASTELLAS PHARMA US INC
AMBISOME, AMPHOTERICIN B
ASTAGRAF XL, TACROLIMUS
CRESEMBA, ISAVUCONAZONIUM SULFATE
LEXISCAN, REGADENOSON
MYCAMINE, MICAFUNGIN SODIUM
PROGRAF, TACROLIMUS
VESICARE, SOLIFENACIN SUCCINATE
XOSPATA, GILTERITINIB FUMARATE
XTANDI, ENZALUTAMIDE

ASTRAL

* ASTRAL STERITECH PVT LTD
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
CEFTRIAXONE SODIUM, CEFTRIAXONE SODIUM
CEFTRIAXONE, CEFTRIAXONE SODIUM

ASTRAZENECA

* ASTRAZENECA LP
PULMICORT FLEXHALER, BUDESONIDE
SYMBICORT, BUDESONIDE
* ASTRAZENECA PHARMACEUTICALS LP
FASLODEX, FULVESTRANT
ZOMIG, ZOLMITRIPTAN
ZOMIG-ZMT, ZOLMITRIPTAN
* ASTRAZENECA UK LTD
CALQUENCE, ACALABRUTINIB
SEROQUEL XR, QUETIAPINE FUMARATE

ASTRAZENECA AB

* ASTRAZENECA AB
BYDUREON BCISE, EXENATIDE
BYDUREON PEN, EXENATIDE SYNTHETIC
BYDUREON, EXENATIDE SYNTHETIC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ASTRAZENECA AB
BYETTA, EXENATIDE SYNTHETIC
FARXIGA, DAPAGLIFLOZIN
KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
QTERN, DAPAGLIFLOZIN
SYMLIN, PRAMLINTIDE ACETATE
XIGDUO XR, DAPAGLIFLOZIN

ASTRAZENECA LP

* ASTRAZENECA LP
NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)

ASTRAZENECA PHARMS

* ASTRAZENECA PHARMACEUTICALS LP
ALVESCO, CICLESONIDE
BEVESPI AEROSPHERE, FORMOTEROL FUMARATE
BRILINTA, TICAGRELOR
DALIRESP, ROFLUMILAST
IRESSA, GEFITINIB
LOKELMA, SODIUM ZIRCONIUM CYCLOSILICATE
LYNPARZA, OLAPARIB
MOVANTIK, NALOXEGOL OXALATE
NEXIUM IV, ESOMEPRAZOLE SODIUM
NEXIUM, ESOMEPRAZOLE MAGNESIUM
OMNARIS, CICLESONIDE
PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
PULMICORT RESPULES, BUDESONIDE
RHINOCORT ALLERGY, BUDESONIDE (OTC)
SEROQUEL, QUETIAPINE FUMARATE
TAGRISSO, OSIMERTINIB MESYLATE
TUDORZA PRESSAIR, ACLIDINIUM BROMIDE
ZETONNA, CICLESONIDE

ATHENEX INC

* ATHENEX INC
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
ENALAPRILAT, ENALAPRILAT
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
VALPROATE SODIUM, VALPROATE SODIUM

ATLAS PHARMS LLC

* ATLAS PHARMACEUTICALS LLC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ATNAHS PHARMA US

* ATNAHS PHARMA US LTD
ANAPROX DS, NAPROXEN SODIUM
EC-NAPROSYN, NAPROXEN
NAPROSYN, NAPROXEN

ATON

* ATON PHARMA INC
CUPRIMINE, PENICILLAMINE
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
LACRISERT, HYDROXYPROPYL CELLULOSE
LODOSYN, CARBIDOPA
SYPRINE, TRIENTINE HYDROCHLORIDE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC, TIMOLOL MALEATE

ATON PHARMA VPNA

* ATON PHARMA DIV VALEANT PHARMACEUTICALS NORTH AMERICA LLC
DEMSER, METYROSINE

AUCTA PHARMS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUCTA PHARMACEUTICALS LLC
VIGADRONE, VIGABATRIN

AUROBINDO

* AUROBINDO PHARMA LTD
AMOXICILLIN, AMOXICILLIN
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLARITHROMYCIN, CLARITHROMYCIN
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
NEVIRAPINE, NEVIRAPINE
ZIDOVUDINE, ZIDOVUDINE

AUROBINDO PHARMA

* AUROBINDO PHARMA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM

* AUROBINDO PHARMA LTD
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMPICILLIN SODIUM, AMPICILLIN SODIUM
ATENOLOL, ATENOLOL
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CARISOPRODOL, CARISOPRODOL
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DIDANOSINE, DIDANOSINE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MELOXICAM, MELOXICAM
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RIBAVIRIN, RIBAVIRIN
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
STAVUDINE, STAVUDINE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
TORSEMIDE, TORSEMIDE
TRANDOLAPRIL, TRANDOLAPRIL
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZALEPLON, ZALEPLON
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

AUROBINDO PHARMA LTD

* AUROBINDO PHARMA LIMITED
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
LEVOFLOXACIN, LEVOFLOXACIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

* AUROBINDO PHARMA LTD
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, ABACAVIR SULFATE
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ADENOSINE, ADENOSINE
AFIRMELLE, ETHINYL ESTRADIOL
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALPRAZOLAM, ALPRAZOLAM
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ARIPIPRAZOLE, ARIPIPRAZOLE
ARMODAFINIL, ARMODAFINIL
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATHENTIA NEXT, LEVONORGESTREL (OTC)
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
AUROVELA 1.5/30, ETHINYL ESTRADIOL
AUROVELA 1/20, ETHINYL ESTRADIOL
AUROVELA 24 FE, ETHINYL ESTRADIOL
AUROVELA FE 1.5/30, ETHINYL ESTRADIOL
AUROVELA FE 1/20, ETHINYL ESTRADIOL
AYUNA, ETHINYL ESTRADIOL
AZITHROMYCIN, AZITHROMYCIN
BIVALIRUDIN, BIVALIRUDIN
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CAFFEINE CITRATE, CAFFEINE CITRATE
CEFIXIME, CEFIXIME
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CELECOXIB, CELECOXIB
CEPHALEXIN, CEPHALEXIN
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOZAPINE, CLOZAPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
CYONANZ, ETHINYL ESTRADIOL
DALFAMPRIDINE, DALFAMPRIDINE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
EFAVIRENZ, EFAVIRENZ
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ENTACAPONE, ENTACAPONE
ENTECAVIR, ENTECAVIR
EPTIFIBATIDE, EPTIFIBATIDE
ERTAPENEM SODIUM, ERTAPENEM SODIUM
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ESZOPICLONE, ESZOPICLONE
ETOMIDATE, ETOMIDATE
EZETIMIBE, EZETIMIBE
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FELODIPINE, FELODIPINE
FENOFIBRATE, FENOFIBRATE
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
FINASTERIDE, FINASTERIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUCONAZOLE, FLUCONAZOLE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GEMFIBROZIL, GEMFIBROZIL
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
ICLEVIA, ETHINYL ESTRADIOL
INCASSIA, NORETHINDRONE
INDOMETHACIN, INDOMETHACIN
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
ISOSULFAN BLUE, ISOSULFAN BLUE
KALLIGA, DESOGESTREL
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD

LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LINEZOLID, LINEZOLID
LO SIMPESSE, ETHINYL ESTRADIOL
LO-ZUMANDIMINE, DROSPIRENONE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MEROPENEM, MEROPENEM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHOCARBAMOL, METHOCARBAMOL
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METRONIDAZOLE, METRONIDAZOLE
MILI, ETHINYL ESTRADIOL
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MODAFINIL, MODAFINIL
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NADOLOL, NADOLOL
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
NEVIRAPINE, NEVIRAPINE
NEXESTA FE, ETHINYL ESTRADIOL
NIACIN, NIACIN
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NYLIA 1/35, ETHINYL ESTRADIOL
NYLIA 7/7/7, ETHINYL ESTRADIOL
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARICALCITOL, PARICALCITOL
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRASUGREL, PRASUGREL HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
REPAGLINIDE, REPAGLINIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERIDONE, RISPERIDONE
RITONAVIR, RITONAVIR
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILODOSIN, SILODOSIN
SIMPESSE, ETHINYL ESTRADIOL
SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TERIFLUNOMIDE, TERIFLUNOMIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRI-LO-MILI, ETHINYL ESTRADIOL
TRI-MILI, ETHINYL ESTRADIOL
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VORICONAZOLE, VORICONAZOLE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLMITRIPTAN, ZOLMITRIPTAN
ZUMANDIMINE, DROSPIRENONE
* AUROBINDO PHARMA LTD INC
ZIDOVUDINE, ZIDOVUDINE

AUROLIFE PHARMA LLC
* AUROLIFE PHARMA LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DUTASTERIDE, DUTASTERIDE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

AUSTARPHARMA LLC
* AUSTARPHARMA LLC
METHOCARBAMOL, METHOCARBAMOL
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE

AUXILIUM PHARMS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUXILIUM PHARMACEUTICALS INC
TESTOPEL, TESTOSTERONE
THEO-24, THEOPHYLLINE

AUXILIUM PHARMS LLC

* AUXILIUM PHARMACEUTICALS LLC
DILATRATE-SR, ISOSORBIDE DINITRATE
EDEX, ALPROSTADIL
ROBAXIN, METHOCARBAMOL
ROBAXIN-750, METHOCARBAMOL
SEMPREX-D, ACRIVASTINE
STRIANT, TESTOSTERONE
TESTIM, TESTOSTERONE
THEO-24, THEOPHYLLINE

AVACOR PRODS

* AVACOR PRODUCTS LLC
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)

AVADEL LEGACY

* AVADEL LEGACY PHARMACEUTICALS LLC
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE
VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE

AVADEL SPECLT

* AVADEL SPECIALTY PHARMACEUTICALS LLC
NOCTIVA, DESMOPRESSIN ACETATE

AVANIR PHARMS

* AVANIR PHARMACEUTICALS
ONZETRA XSAIL, SUMATRIPTAN SUCCINATE
* AVANIR PHARMACEUTICALS INC
NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE

AVANTHI INC

* AVANTHI INC
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
INDOMETHACIN, INDOMETHACIN
LOMAIRA, PHENTERMINE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE

AVEDRO INC

* AVEDRO INC
PHOTREXA VISCOUS IN DEXTRAN 20%, RIBOFLAVIN 5'-PHOSPHATE SODIUM
PHOTREXA, RIBOFLAVIN 5'-PHOSPHATE SODIUM

AVEMA PHARMA

* AVEMA PHARMA SOLUTIONS
IBUPROFEN, IBUPROFEN (OTC)

AVENT

* AVENT INC
PYTEST KIT, UREA, C-14
PYTEST, UREA, C-14

AVERITAS

* AVERITAS PHARMA INC
QUTENZA, CAPSAICIN

AVEVA

* AVEVA DRUG DELIVERY SYSTEMS INC
CLONIDINE, CLONIDINE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL
NICOTINE, NICOTINE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

AVID RADIOPHARMS INC
* AVID RADIOPHARMACEUTICALS INC
AMYVID, FLORBETAPIR F-18

AVION PHARMS
* AVION PHARMACEUTICALS LLC
BALCOLTRA, ETHINYL ESTRADIOL

AVONDALE PHARMS
* AVONDALE PHARMACEUTICALS LLC
NIACOR, NIACIN

AYTU
* AYTU BIOSCIENCE INC
NATESTO, TESTOSTERONE
TUZISTRA XR, CHLORPHENIRAMINE POLISTIREX

** B **

B BRAUN
* B BRAUN MEDICAL INC
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINO ACIDS, AMINO ACIDS
BALANCED SALT, CALCIUM CHLORIDE
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
FREAMINE HBC 6.9%, AMINO ACIDS
FREAMINE III 10%, AMINO ACIDS
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5%, AMINO ACIDS
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPATAMINE 8%, AMINO ACIDS
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* B BRAUN MEDICAL INC
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
NEPHRAMINE 5.4%, AMINO ACIDS
NUTRILIPID 10%, SOYBEAN OIL
NUTRILIPID 20%, SOYBEAN OIL
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* B BRAUN MEDICAL INC
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCALAMINE, AMINO ACIDS
RESECTISOL IN PLASTIC CONTAINER, MANNITOL
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
TROPHAMINE 10%, AMINO ACIDS
TROPHAMINE, AMINO ACIDS

B BRAUN MEDICAL INC

* B BRAUN MEDICAL INC
CLOROTEKAL, CHLOROPROCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM

BARR

* BARR LABORATORIES INC
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ARANELLE, ETHINYL ESTRADIOL
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
BALZIVA-28, ETHINYL ESTRADIOL
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
DANAZOL, DANAZOL
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DUTASTERIDE, DUTASTERIDE
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ESTRADIOL AND NORGESTIMATE, ESTRADIOL
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
ISONIAZID, ISONIAZID
JUNEL 1.5/30, ETHINYL ESTRADIOL
JUNEL 1/20, ETHINYL ESTRADIOL
JUNEL FE 1.5/30, ETHINYL ESTRADIOL
JUNEL FE 1/20, ETHINYL ESTRADIOL
KARIVA, DESOGESTREL
KELNOR, ETHINYL ESTRADIOL
LEFLUNOMIDE, LEFLUNOMIDE
LESSINA-28, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BARR LABORATORIES INC
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NIACIN, NIACIN
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORTREL 0.5/35-28, ETHINYL ESTRADIOL
NORTREL 1/35-21, ETHINYL ESTRADIOL
NORTREL 1/35-28, ETHINYL ESTRADIOL
NORTREL 7/7/7, ETHINYL ESTRADIOL
ONDANSETRON, ONDANSETRON
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PORTIA-28, ETHINYL ESTRADIOL
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
SPRINTEC, ETHINYL ESTRADIOL
TEMOZOLOMIDE, TEMOZOLOMIDE
TREXALL, METHOTREXATE SODIUM
TRI-LEGEST 21, ETHINYL ESTRADIOL
TRI-LEGEST FE, ETHINYL ESTRADIOL
TRI-SPRINTEC, ETHINYL ESTRADIOL
WARFARIN SODIUM, WARFARIN SODIUM
* BARR PHARMACEUTICALS
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM

BARR LABS DIV TEVA

* BARR LABORATORIES INC SUB TEVA PHARMACEUTICALS USA
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
BUDESONIDE, BUDESONIDE

BARR LABS INC

* BARR LABORATORIES INC
ACITRETIN, ACITRETIN
CLOZAPINE, CLOZAPINE
DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
ESTRADIOL, ESTRADIOL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OLANZAPINE, OLANZAPINE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
TRETINOIN, TRETINOIN
TRI LO SPRINTEC, ETHINYL ESTRADIOL

BAUSCH AND LOMB

* BAUSCH AND LOMB INC
ALAWAY, KETOTIFEN FUMARATE (OTC)
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALREX, LOTEPREDNOL ETABONATE
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
ISTALOL, TIMOLOL MALEATE
LATANOPROST, LATANOPROST
LOTEMAX, LOTEPREDNOL ETABONATE
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
OFLOXACIN, OFLOXACIN
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
PROLENSA, BROMFENAC SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAUSCH AND LOMB INC
RETISERT, FLUOCINOLONE ACETONIDE
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
TIMOLOL MALEATE, TIMOLOL MALEATE
TROPICAMIDE, TROPICAMIDE
VITRASE, HYALURONIDASE
VYZULTA, LATANOPROSTENE BUNOD
ZIRGAN, GANCICLOVIR
ZYLET, LOTEPREDNOL ETABONATE

* BAUSCH AND LOMB PHARMACEUTICALS INC
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXASPORIN, DEXAMETHASONE
ERYTHROMYCIN, ERYTHROMYCIN
FLUNISOLIDE, FLUNISOLIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
OFLOXACIN, OFLOXACIN
OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
OTICAIR, HYDROCORTISONE
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TROPICAMIDE, TROPICAMIDE

BAUSCH AND LOMB INC

* BAUSCH AND LOMB INC
BEPREVE, BEPOTASTINE BESILATE
LOTEMAX, LOTEPREDNOL ETABONATE
LUMIFY, BRIMONIDINE TARTRATE (OTC)

BAXTER HLTHCARE

* BAXTER HEALTHCARE CORP
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFTRIAXONE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAXTER HEALTHCARE CORP
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
EXTRANEAL, ICODEXTRIN
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FORANE, ISOFLURANE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
IFEX, IFOSFAMIDE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAXTER HEALTHCARE CORP
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
MESNEX, MESNA
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
NEXTERONE, AMIODARONE HYDROCHLORIDE
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 10% IN WATER, MANNITOL
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 15% IN WATER, MANNITOL
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 20% IN WATER, MANNITOL
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 5% IN WATER, MANNITOL
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SEVOFLURANE, SEVOFLURANE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
STERILE WATER, STERILE WATER FOR IRRIGATION
SUPRANE, DESFLURANE
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TIS-U-SOL, MAGNESIUM SULFATE
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
* BAXTER HEALTHCARE INTERNATI0NAL SPECIALTY THERAPIES DIV

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAXTER HEALTHCARE INTERNATI0NAL SPECIALTY THERAPIES DIV
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

BAXTER HLTHCARE CORP

* BAXTER HEALTHCARE CORP
BIVALIRUDIN IN 0.9% SODIUM CHLORIDE, BIVALIRUDIN
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
CEFAZOLIN IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FUROSEMIDE, FUROSEMIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOFLOXACIN, LEVOFLOXACIN
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE

* BAXTER HEALTHCARE CORP ANESTHESIA AND CRITICAL CARE
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE

BAYER

* BAYER HEALTHCARE LLC
ALEVE, NAPROXEN SODIUM (OTC)
ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)

BAYER HEALTHCARE

* BAYER HEALTHCARE PHARMACEUTICALS INC
ALIQOPA, COPANLISIB DIHYDROCHLORIDE

BAYER HEALTHCARE LLC

* BAYER HEALTHCARE LLC
CHILDREN'S CLARITIN, LORATADINE (OTC)
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN, LORATADINE (OTC)
CLARITIN-D 24 HOUR, LORATADINE (OTC)
CLARITIN-D, LORATADINE (OTC)
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
ZEGERID OTC, OMEPRAZOLE (OTC)

BAYER HLTHCARE

* BAYER HEALTHCARE CONSUMER CARE
ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)

* BAYER HEALTHCARE PHARMACEUTICALS INC
ADEMPAS, RIOCIGUAT
ANGELIQ, DROSPIRENONE
AVELOX, MOXIFLOXACIN HYDROCHLORIDE
BEYAZ, DROSPIRENONE
BILTRICIDE, PRAZIQUANTEL
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BAYER HEALTHCARE PHARMACEUTICALS INC
CLIMARA PRO, ESTRADIOL
CLIMARA, ESTRADIOL
EOVIST, GADOXETATE DISODIUM
GADAVIST, GADOBUTROL
KYLEENA, LEVONORGESTREL
LEVITRA, VARDENAFIL HYDROCHLORIDE
MAGNEVIST, GADOPENTETATE DIMEGLUMINE
MENOSTAR, ESTRADIOL
MIRENA, LEVONORGESTREL
NATAZIA, DIENOGEST
NEXAVAR, SORAFENIB TOSYLATE
PRECOSE, ACARBOSE
SAFYRAL, DROSPIRENONE
SKYLA, LEVONORGESTREL
STAXYN, VARDENAFIL HYDROCHLORIDE
STIVARGA, REGORAFENIB
ULTRAVIST (PHARMACY BULK), IOPROMIDE
ULTRAVIST 240, IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
XOFIGO, RADIUM RA-223 DICHLORIDE
YASMIN, DROSPIRENONE
YAZ, DROSPIRENONE

BAYSHORE PHARMS LLC

* BAYSHORE PHARMACEUTICALS LLC
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE

BDSI

* BIODELIVERY SCIENCES INTERNATIONAL INC
BELBUCA, BUPRENORPHINE HYDROCHLORIDE
BUNAVAIL, BUPRENORPHINE HYDROCHLORIDE

BECTON DICKINSON

* BECTON DICKINSON AND CO
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)

BECTON DICKINSON CO

* BECTON DICKINSON AND CO
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)

BEIJING YILING

* BEIJING YILING BIO-ENGEERING AND TECHNOLOGY CO LTD
ANASTROZOLE, ANASTROZOLE
LETROZOLE, LETROZOLE

BELCHER PHARMS

* BELCHER PHARMACEUTICALS LLC
CEPHALEXIN, CEPHALEXIN
DESLORATADINE, DESLORATADINE

BELCHER PHARMS LLC

* BELCHER PHARMACEUTICALS LLC
ABLYSINOL, ALCOHOL
CEFIXIME, CEFIXIME
EPINEPHRINE, EPINEPHRINE
MEFENAMIC ACID, MEFENAMIC ACID
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
TACROLIMUS, TACROLIMUS

BELOTECA INC

* BELOTECA INC
ISOSULFAN BLUE, ISOSULFAN BLUE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

BEXIMCO PHARMS USA
* BEXIMCO PHARMACEUTICALS USA INC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
NADOLOL, NADOLOL
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

BEXIMCO USA
* BEXIMCO PHARMACEUTICALS USA INC
CARVEDILOL, CARVEDILOL

BI-COASTAL PHARMA
* BI-COASTAL PHARMA INTERNATIONAL LLC
DUVOID, BETHANECHOL CHLORIDE

BIO NUCLEONICS
* BIO NUCLEONICS INC
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89

BIO PHARM INC
* BIO PHARM INC
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE

BIO-PHARM INC
* BIO-PHARM INC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
LACTULOSE, LACTULOSE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE

BIOCODEX SA
* BIOCODEX SA
DIACOMIT, STIRIPENTOL

BIOCON LIMITED
* BIOCON LIMITED
SIMVASTATIN, SIMVASTATIN

BIOCON LTD
* BIOCON LTD
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

BIOCRYST
* BIOCRYST PHARMACEUTICALS INC
RAPIVAB, PERAMIVIR

BIOFRONTERA
* BIOFRONTERA BIOSCIENCE GMBH
AMELUZ, AMINOLEVULINIC ACID HYDROCHLORIDE

BIOGEN IDEC
* BIOGEN IDEC INC
SPINRAZA, NUSINERSEN SODIUM

BIOGEN IDEC INC
* BIOGEN IDEC INC
TECFIDERA, DIMETHYL FUMARATE

BIOMARIN PHARM
* BIOMARIN PHARMACEUTICAL INC
KUVAN, SAPROPTERIN DIHYDROCHLORIDE

BIOMEDCL RES FDN
* BIOMEDICAL RESEARCH FOUNDATION NORTHWEST LOUISANA
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

BIONPHARMA INC
* BIONPHARMA INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
BENZONATATE, BENZONATATE
BEXAROTENE, BEXAROTENE
CALCITRIOL, CALCITRIOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BIONPHARMA INC
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLOBAZAM, CLOBAZAM
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DOFETILIDE, DOFETILIDE
DUTASTERIDE, DUTASTERIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MIDOL LIQUID GELS, IBUPROFEN (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NIMODIPINE, NIMODIPINE
PARICALCITOL, PARICALCITOL
PROGESTERONE, PROGESTERONE
TETRABENAZINE, TETRABENAZINE
VALPROIC ACID, VALPROIC ACID
VITAMIN D, ERGOCALCIFEROL

BLAIREX
* BLAIREX LABORATORIES INC
BRONCHO SALINE, SODIUM CHLORIDE (OTC)

BLUE EARTH
* BLUE EARTH DIAGNOSTICS LTD
AXUMIN, FLUCICLOVINE F-18

BLUEPHARMA
* BLUEPHARMA US INC
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
ZONISAMIDE, ZONISAMIDE

BOEHRINGER INGELHEIM
* BOEHRINGER INGELHEIM
CATAPRES, CLONIDINE HYDROCHLORIDE
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
GILOTRIF, AFATINIB DIMALEATE
GLYXAMBI, EMPAGLIFLOZIN
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICARDIS, TELMISARTAN
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
* BOEHRINGER INGELHEIM PHARMACEUTICALS INC
AGGRENOX, ASPIRIN
APTIVUS, TIPRANAVIR
ATROVENT HFA, IPRATROPIUM BROMIDE
COMBIVENT RESPIMAT, ALBUTEROL SULFATE
JARDIANCE, EMPAGLIFLOZIN
JENTADUETO XR, LINAGLIPTIN
JENTADUETO, LINAGLIPTIN
MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
MOBIC, MELOXICAM
OFEV, NINTEDANIB ESYLATE
PERSANTINE, DIPYRIDAMOLE
PRADAXA, DABIGATRAN ETEXILATE MESYLATE
SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE
SPIRIVA, TIOTROPIUM BROMIDE
STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE
STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE
SYNJARDY XR, EMPAGLIFLOZIN
SYNJARDY, EMPAGLIFLOZIN
TRADJENTA, LINAGLIPTIN
TWYNSTA, AMLODIPINE BESYLATE
VIRAMUNE XR, NEVIRAPINE
VIRAMUNE, NEVIRAPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

BOSCOGEN

* BOSCOGEN INC
ACYCLOVIR, ACYCLOVIR
ANASTROZOLE, ANASTROZOLE
ARIPIPRAZOLE, ARIPIPRAZOLE
BICALUTAMIDE, BICALUTAMIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
REPAGLINIDE, REPAGLINIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE

BPI LABS LLC

* BPI LABS LLC
ZOLEDRONIC ACID, ZOLEDRONIC ACID

BRACCO

* BRACCO DIAGNOSTICS INC
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
E-Z-HD, BARIUM SULFATE
E-Z-PAQUE, BARIUM SULFATE
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
KINEVAC, SINCALIDE
LIQUID E-Z-PAQUE, BARIUM SULFATE
LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
MULTIHANCE, GADOBENATE DIMEGLUMINE
PROHANCE MULTIPACK, GADOTERIDOL
PROHANCE, GADOTERIDOL
READI-CAT 2 SMOOTHIES, BARIUM SULFATE
READI-CAT 2, BARIUM SULFATE
TAGITOL V, BARIUM SULFATE
VARIBAR HONEY, BARIUM SULFATE
VARIBAR NECTAR, BARIUM SULFATE
VARIBAR PUDDING, BARIUM SULFATE
VARIBAR THIN HONEY, BARIUM SULFATE

BRAINTREE

* BRAINTREE LABORATORIES INC
GOLYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350

BRAINTREE LABS

* BRAINTREE LABORATORIES INC
SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE

BRECKENRIDGE PHARM

* BRECKENRIDGE PHARMACEUTICAL INC
ALPRAZOLAM, ALPRAZOLAM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CILOSTAZOL, CILOSTAZOL
CLOBAZAM, CLOBAZAM
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE, DUTASTERIDE
ENTECAVIR, ENTECAVIR
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPLERENONE, EPLERENONE
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
LANSOPRAZOLE, LANSOPRAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BRECKENRIDGE PHARMACEUTICAL INC
LEVETIRACETAM, LEVETIRACETAM
MEFENAMIC ACID, MEFENAMIC ACID
MEGESTROL ACETATE, MEGESTROL ACETATE
MELOXICAM, MELOXICAM
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
OMEPRAZOLE, OMEPRAZOLE
OXCARBAZEPINE, OXCARBAZEPINE
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIROXICAM, PIROXICAM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
ROFLUMILAST, ROFLUMILAST
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

BRIGHAM WOMENS

* BRIGHAM AND WOMENS HOSP
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

BRIGHAM WOMENS HOSP

* BRIGHAM AND WOMENS HOSP INC
AMMONIA N 13, AMMONIA N-13

BRISTOL MYERS SQUIBB

* BRISTOL MYERS SQUIBB
AZACTAM, AZTREONAM
BARACLUDE, ENTECAVIR
PRAVACHOL, PRAVASTATIN SODIUM
* BRISTOL MYERS SQUIBB CO
AZACTAM IN PLASTIC CONTAINER, AZTREONAM
DROXIA, HYDROXYUREA
GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE
HYDREA, HYDROXYUREA
REYATAZ, ATAZANAVIR SULFATE
SPRYCEL, DASATINIB
SUSTIVA, EFAVIRENZ
VIDEX EC, DIDANOSINE
* BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
ELIQUIS, APIXABAN
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
GLUCOPHAGE, METFORMIN HYDROCHLORIDE
ZERIT, STAVUDINE
* BRISTOL MYERS SQUIBB PHARMA CO
COUMADIN, WARFARIN SODIUM

BRISTOL-MYERS SQUIBB

* BRISTOL-MYERS SQUIBB CO
DAKLINZA, DACLATASVIR DIHYDROCHLORIDE
EVOTAZ, ATAZANAVIR SULFATE
VIDEX, DIDANOSINE
ZERIT, STAVUDINE

** C **

CADILA PHARMS LTD

* CADILA PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
GEMFIBROZIL, GEMFIBROZIL
GLYBURIDE, GLYBURIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CADILA PHARMACEUTICALS LTD
OFLOXACIN, OFLOXACIN
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
TELMISARTAN, TELMISARTAN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

CADISTA PHARMS

* CADISTA PHARMACEUTICALS INC
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM

CALL INC

* CALL INC DBA ROCHESTER PHARMACEUTICALS
ADAPALENE, ADAPALENE

CAPELLON PHARMS LLC

* CAPELLON PHARMACEUTICALS LLC
POLMON, DEXCHLORPHENIRAMINE MALEATE

CARDINAL HEALTH 414

* CARDINAL HEALTH 414 LLC CARDINAL HEALTH NUCLEAR PHARMACY SERVICES
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

CARDINAL HEALTH 418

* CARDINAL HEALTH 418 INC
SODIUM IODIDE I 123, SODIUM IODIDE I-123

CARIBE HOLDINGS

* CARIBE HOLDINGS CAYMAN CO LTD DBA PURACAP CARIBE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
GEMFIBROZIL, GEMFIBROZIL

CARLSBAD

* CARLSBAD TECHNOLOGY INC
ACYCLOVIR, ACYCLOVIR
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FAMOTIDINE, FAMOTIDINE
GLIMEPIRIDE, GLIMEPIRIDE
LOVASTATIN, LOVASTATIN

CARLSBAD TECHNOLOGY

* CARLSBAD TECHNOLOGY INC
ACYCLOVIR, ACYCLOVIR

CASI PHARMS INC

* CASI PHARMACEUTICALS INC
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CEFPROZIL, CEFPROZIL
CILOSTAZOL, CILOSTAZOL
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ENTECAVIR, ENTECAVIR
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
HEPARIN SODIUM, HEPARIN SODIUM
LISINOPRIL, LISINOPRIL
METHIMAZOLE, METHIMAZOLE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
NABUMETONE, NABUMETONE
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
REPAGLINIDE, REPAGLINIDE
RIBAVIRIN, RIBAVIRIN
SPIRONOLACTONE, SPIRONOLACTONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CASI PHARMACEUTICALS INC
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

CASPER PHARMA LLC
* CASPER PHARMA LLC
AQUASOL A, VITAMIN A PALMITATE
CASPORYN HC, HYDROCORTISONE
FURADANTIN, NITROFURANTOIN
NEOSPORIN, BACITRACIN ZINC
ZYLOPRIM, ALLOPURINOL

CATALENT
* CATALENT PHARMA SOLUTIONS LLC
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
VALPROIC ACID, VALPROIC ACID

CATALYST PHARMS
* CATALYST PHARMACEUTICALS INC
FIRDAPSE, AMIFAMPRIDINE PHOSPHATE

CEDIPROF INC
* CEDIPROF INC
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
LEVO-T, LEVOTHYROXINE SODIUM **

CELATOR PHARMS
* CELATOR PHARMACEUTICALS INC
VYXEOS, CYTARABINE

CELERITY PHARMS
* CELERITY PHARMACEUTICALS LLC
EPTIFIBATIDE, EPTIFIBATIDE

CELGENE
* CELGENE CORP
ISTODAX, ROMIDEPSIN
POMALYST, POMALIDOMIDE
REVLIMID, LENALIDOMIDE
THALOMID, THALIDOMIDE
VIDAZA, AZACITIDINE

CELGENE CORP
* CELGENE CORP
IDHIFA, ENASIDENIB MESYLATE
OTEZLA, APREMILAST

CELLTRION
* CELLTRION INC
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TEMIXYS, LAMIVUDINE

CEPHALON
* CEPHALON INC
ACTIQ, FENTANYL CITRATE
FENTORA, FENTANYL CITRATE
GABITRIL, TIAGABINE HYDROCHLORIDE
NUVIGIL, ARMODAFINIL
PROVIGIL, MODAFINIL
TREANDA, BENDAMUSTINE HYDROCHLORIDE
TRISENOX, ARSENIC TRIOXIDE

CERECOR INC
* CERECOR INC
ACIPHEX SPRINKLE, RABEPRAZOLE SODIUM

CEYONE
* CEYONE PHARMA LLC
RISPERIDONE, RISPERIDONE

CHANGZHOU PHARM
* CHANGZHOU PHARMACEUTICAL FACTORY
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

CHARTWELL LIFE SCI
* CHARTWELL LIFE SCIENCE LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CHARTWELL LIFE SCIENCE LLC
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

CHARTWELL MOLECULAR
* CHARTWELL MOLECULAR HOLDINGS LLC
CARVEDILOL, CARVEDILOL
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
FOLIC ACID, FOLIC ACID
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IRBESARTAN, IRBESARTAN
RAMIPRIL, RAMIPRIL
RISPERIDONE, RISPERIDONE

CHARTWELL MOLECULES
* CHARTWELL MOLECULES LLC
DISULFIRAM, DISULFIRAM
GEMFIBROZIL, GEMFIBROZIL
NABUMETONE, NABUMETONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

CHARTWELL RX
* CHARTWELL RX SCIENCES LLC
CALCIUM ACETATE, CALCIUM ACETATE
CILOSTAZOL, CILOSTAZOL
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
INDOMETHACIN, INDOMETHACIN
LEVETIRACETAM, LEVETIRACETAM
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE

CHARTWELL TETRA
* CHARTWELL TETRA LLC
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

CHATTEM
* CHATTEM INC
UNISOM, DOXYLAMINE SUCCINATE (OTC)

CHEMI SPA
* CHEMI SPA
DECITABINE, DECITABINE
TEMOZOLOMIDE, TEMOZOLOMIDE

CHEMISCH FBRK KRSSLR
* CHEMISCHE FABRIK KREUSSLER & CO. GMBH
ASCLERA, POLIDOCANOL

CHEMO RESEARCH SL
* CHEMO RESEARCH SL
BENZNIDAZOLE, BENZNIDAZOLE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NUVESSA, METRONIDAZOLE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN

CHEPLAPHARM
* CHEPLAPHARM ARZNEIMITTEL GMBH
XENICAL, ORLISTAT

CHIESI USA INC
* CHIESI USA INC
BETHKIS, TOBRAMYCIN
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CLEVIPREX, CLEVIDIPINE
CUROSURF, PORACTANT ALFA
KENGREAL, CANGRELOR
ZYFLO CR, ZILEUTON
ZYFLO, ZILEUTON

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

CHILDRENS HOSP MI
* CHILDRENS HOSP MICHIGAN
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

CHINA RESOURCES
* CHINA RESOURCES SAIKE PHARMACEUTICAL CO LTD
  AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

CHIRHOCLIN
* CHIRHOCLIN INC
  CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN

CINTEX SVCS
* CINTEX SERVICES LLC
  FLURANDRENOLIDE, FLURANDRENOLIDE

CIPHER PHARMS INC
* CIPHER PHARMACEUTICALS INC
  CONZIP, TRAMADOL HYDROCHLORIDE
  LIPOFEN, FENOFIBRATE

CIPLA
* CIPLA LTD
  ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
  ABACAVIR SULFATE, ABACAVIR SULFATE
  ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
  ALENDRONATE SODIUM, ALENDRONATE SODIUM
  ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
  AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
  AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
  ANASTROZOLE, ANASTROZOLE
  ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
  AZACITIDINE, AZACITIDINE
  BIVALIRUDIN, BIVALIRUDIN
  BUDESONIDE, BUDESONIDE
  CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
  CELECOXIB, CELECOXIB
  CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
  DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
  DECITABINE, DECITABINE
  DICLOFENAC SODIUM, DICLOFENAC SODIUM
  DOCETAXEL, DOCETAXEL
  EFAVIRENZ, EFAVIRENZ
  EMTRICITABINE, EMTRICITABINE
  ENTECAVIR, ENTECAVIR
  EXEMESTANE, EXEMESTANE
  FAMCICLOVIR, FAMCICLOVIR
  FENOFIBRATE, FENOFIBRATE
  FINASTERIDE, FINASTERIDE
  FLUTAMIDE, FLUTAMIDE
  GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
  GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
  ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
  LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
  LAMIVUDINE, LAMIVUDINE
  LAMOTRIGINE, LAMOTRIGINE
  LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
  MELOXICAM, MELOXICAM
  METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
  MONTELUKAST SODIUM, MONTELUKAST SODIUM
  NEVIRAPINE, NEVIRAPINE
  OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
  OXALIPLATIN, OXALIPLATIN
  PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
  PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
  PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
  SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
  TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
  TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
  TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CIPLA LTD
TESTOSTERONE, TESTOSTERONE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
ZIDOVUDINE, ZIDOVUDINE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

CIPLA LTD
* CIPLA LTD
ALBENDAZOLE, ALBENDAZOLE
CARBOPLATIN, CARBOPLATIN
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
TOPIRAMATE, TOPIRAMATE
ZALEPLON, ZALEPLON
ZIDOVUDINE, ZIDOVUDINE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

CLINIGEN HLTHCARE
* CLINIGEN HEALTHCARE LTD
ETHYOL, AMIFOSTINE
FOSCAVIR, FOSCARNET SODIUM
TOTECT, DEXRAZOXANE HYDROCHLORIDE

CLOVER PHARMS
* CLOVER PHARMACEUTICALS CORP
AMICAR, AMINOCAPROIC ACID

CLOVIS ONCOLOGY INC
* CLOVIS ONCOLOGY INC
RUBRACA, RUCAPARIB CAMSYLATE

CMP DEV LLC
* CMP DEVELOPMENT LLC
CAROSPIR, SPIRONOLACTONE

CMP PHARMA INC
* CMP PHARMA INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
ISONIAZID, ISONIAZID
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SPS, SODIUM POLYSTYRENE SULFONATE
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE

CNTY LINE PHARMS
* COUNTY LINE PHARMACEUTICALS LLC
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CICLOPIROX, CICLOPIROX
DYNACIN, MINOCYCLINE HYDROCHLORIDE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
FLUOCINONIDE, FLUOCINONIDE
LIDEX, FLUOCINONIDE
LIDEX-E, FLUOCINONIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
TAMBOCOR, FLECAINIDE ACETATE
TRANDATE, LABETALOL HYDROCHLORIDE
TRANYLCYPROMINE SULFATE, TRANYLCYPROMINE SULFATE
UREX, METHENAMINE HIPPURATE

COLGATE PALMOLIVE
* COLGATE PALMOLIVE
COLGATE TOTAL, SODIUM FLUORIDE (OTC)

COLGATE PALMOLIVE CO
* COLGATE PALMOLIVE CO
PERIOGARD, CHLORHEXIDINE GLUCONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

COLGATE-PALMOLIVE CO
* COLGATE-PALMOLIVE CO
PERIOGARD, CHLORHEXIDINE GLUCONATE

COLLEGIUM PHARM INC
* COLLEGIUM PHARMACEUTICAL INC
XTAMPZA ER, OXYCODONE

COMBE
* COMBE INC
VAGISTAT-1, TIOCONAZOLE (OTC)

CONCORD BIOTECH LTD
* CONCORD BIOTECH LTD
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL

CONCORDIA LABS INC
* CONCORDIA LABORATORIES INC
PHOTOFRIN, PORFIMER SODIUM

CONCORDIA PHARMS INC
* CONCORDIA PHARMACEUTICALS INC
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DUTOPROL, HYDROCHLOROTHIAZIDE
DYRENIUM, TRIAMTERENE
KAPVAY, CLONIDINE HYDROCHLORIDE
LANOXIN, DIGOXIN
NILANDRON, NILUTAMIDE
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
PARNATE, TRANYLCYPROMINE SULFATE
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
UROXATRAL, ALFUZOSIN HYDROCHLORIDE

CONTRACT PHARMACAL
* CONTRACT PHARMACAL CORP
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

COOPERSURGICAL
* COOPERSURGICAL INC
PARAGARD T 380A, COPPER

CORCEPT THERAP
* CORCEPT THERAPEUTICS INC
KORLYM, MIFEPRISTONE

CORDEN PHARMA
* CORDEN PHARMA LATINA SPA
GLEOSTINE, LOMUSTINE

COSMO TECHNOLOGIES
* COSMO TECHNOLOGIES LTD
AEMCOLO, RIFAMYCIN

COVIS PHARMA BV
* COVIS PHARMA BV
ALTOPREV, LOVASTATIN
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAPACE, SOTALOL HYDROCHLORIDE
LANOXIN PEDIATRIC, DIGOXIN
LANOXIN, DIGOXIN
PRILOSEC, OMEPRAZOLE MAGNESIUM
RILUTEK, RILUZOLE
SULAR, NISOLDIPINE
ZANAFLEX, TIZANIDINE HYDROCHLORIDE

CPDC
* CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

CPPI CV
* CP PHARMACEUTICALS INTERNATIONAL CV
SUTENT, SUNITINIB MALATE

CRANE PHARMS LLC
* CRANE PHARMACEUTICALS LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CRANE PHARMACEUTICALS LLC
DAPTOMYCIN, DAPTOMYCIN

CROSSMEDIKA SA

* CROSSMEDIKA SA
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE

CROWN LABS

* CROWN LABORATORIES INC
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
TRIDERM, TRIAMCINOLONE ACETONIDE

CROWN LABS INC

* CROWN LABORATORIES INC
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN

CSPC NBP PHARM CO

* CSPC NBP PHARMACEUTICAL CO LTD
BENZONATATE, BENZONATATE

CSPC OUYI PHARM CO

* CSPC OUYI PHARMACEUTICAL CO LTD
AZITHROMYCIN, AZITHROMYCIN
CELECOXIB, CELECOXIB
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

CUBIST PHARMS

* CUBIST PHARMACEUTICALS INC
ENTEREG, ALVIMOPAN

CUBIST PHARMS LLC

* CUBIST PHARMACEUTICALS LLC
CUBICIN RF, DAPTOMYCIN
CUBICIN, DAPTOMYCIN
DIFICID, FIDAXOMICIN
SIVEXTRO, TEDIZOLID PHOSPHATE
ZERBAXA, CEFTOLOZANE SULFATE

CUMBERLAND PHARMS

* CUMBERLAND PHARMACEUTICALS INC
ACETADOTE, ACETYLCYSTEINE
CALDOLOR, IBUPROFEN
LACTULOSE, LACTULOSE
OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
VIBATIV, TELAVANCIN HYDROCHLORIDE

CUSTOPHARM INC

* CUSTOPHARM INC
ACETAMINOPHEN, ACETAMINOPHEN
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM

CUTANEA

* CUTANEA LIFE SCIENCES INC
AKTIPAK, BENZOYL PEROXIDE

CYCLE PHARMS LTD

* CYCLE PHARMACEUTICALS LTD
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
NITYR, NITISINONE

CYPRESS PHARM

* CYPRESS PHARMACEUTICAL INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CYPRESS PHARMACEUTICAL INC
REZIRA, HYDROCODONE BITARTRATE
VITUZ, CHLORPHENIRAMINE MALEATE
ZUTRIPRO, CHLORPHENIRAMINE MALEATE

**** D ****

DAEWOONG PHARM CO
* DAEWOONG PHARMACEUTICAL CO LTD
MEROPENEM, MEROPENEM

DAIICHI SANKYO
* DAIICHI SANKYO INC
AZOR, AMLODIPINE BESYLATE
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENICAR, OLMESARTAN MEDOXOMIL
TRIBENZOR, AMLODIPINE BESYLATE
WELCHOL, COLESEVELAM HYDROCHLORIDE

DAIICHI SANKYO INC
* DAIICHI SANKYO INC
EVOXAC, CEVIMELINE HYDROCHLORIDE
MORPHABOND ER, MORPHINE SULFATE
SAVAYSA, EDOXABAN TOSYLATE

DAITO PHARMS CO LTD
* DAITO PHARMACEUTICALS CO LTD
RILUZOLE, RILUZOLE

DANCO LABS LLC
* DANCO LABORATORIES LLC
MIFEPREX, MIFEPRISTONE

DAVA INTL INC
* DAVA INTERNATIONAL INC
ALPRAZOLAM, ALPRAZOLAM

DAVA PHARMS INC
* DAVA PHARMACEUTICALS INC
ACYCLOVIR, ACYCLOVIR
AMOXICILLIN, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ATENOLOL, ATENOLOL
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
GLYBURIDE (MICRONIZED), GLYBURIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
MORPHINE SULFATE, MORPHINE SULFATE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PYRAZINAMIDE, PYRAZINAMIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
VOSPIRE ER, ALBUTEROL SULFATE

DAVIS AND GECK
* DAVIS AND GECK DIV AMERICAN CYANAMID CO
PRE-OP II, HEXACHLOROPHENE
PRE-OP, HEXACHLOROPHENE

DBL PHARMS
* DBL PHARMACEUTICALS INC
METHOCARBAMOL, METHOCARBAMOL

DENTSPLY PHARM
* DENTSPLY PHARMACEUTICAL INC
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
ORAQIX, LIDOCAINE

DEPO NF
* DEPO NF SUB LLC A SUB OF ASSERTIO THERAPEUTICS INC
NUCYNTA ER, TAPENTADOL HYDROCHLORIDE
NUCYNTA, TAPENTADOL HYDROCHLORIDE

DEPROCO
* DEPROCO INC
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DEPROCO INC
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
SCANDONEST L, LEVONORDEFRIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE

DERMIRA INC
* DERMIRA INC
QBREXZA, GLYCOPYRRONIUM TOSYLATE

DEVA HOLDING AS
* DEVA HOLDING AS
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
TEMOZOLOMIDE, TEMOZOLOMIDE

DEXCEL LTD
* DEXCEL LTD
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

DEXCEL PHARMA
* DEXCEL PHARMA TECHNOLOGIES LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LEVETIRACETAM, LEVETIRACETAM
OMEPRAZOLE, OMEPRAZOLE (OTC)
PERIOCHIP, CHLORHEXIDINE GLUCONATE

DFB ONCOLOGY LTD
* DFB ONCOLOGY LTD
DOCETAXEL, DOCETAXEL

DIAGNOSTIC GREEN
* DIAGNOSTIC GREEN GMBH
INDOCYANINE GREEN, INDOCYANINE GREEN

DIALYSIS SUPS
* DIALYSIS SUPPLIES INC
NORMOCARB HF 25, MAGNESIUM CHLORIDE
NORMOCARB HF 35, MAGNESIUM CHLORIDE

DIGESTIVE CARE INC
* DIGESTIVE CARE INC
PERTZYE, PANCRELIPASE (AMYLASE

DORC
* DORC INTERNATIONAL BV
MEMBRANEBLUE, TRYPAN BLUE
VISIONBLUE, TRYPAN BLUE

DOUGLAS PHARMS
* DOUGLAS PHARMACEUTICALS AMERICA LTD
MYORISAN, ISOTRETINOIN

DOW PHARM
* DOW PHARMACEUTICAL SCIENCES
ACANYA, BENZOYL PEROXIDE
ALTRENO, TRETINOIN
ATRALIN, TRETINOIN
BRYHALI, HALOBETASOL PROPIONATE
ONEXTON, BENZOYL PEROXIDE
OXSORALEN-ULTRA, METHOXSALEN

DR REDDYS LA
* DR REDDYS LABORATORIES LOUISIANA LLC
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LOPURIN, ALLOPURINOL
SSD, SILVER SULFADIAZINE

DR REDDYS LABS INC
* DR REDDYS LABORATORIES INC
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AUGMENTIN '875', AMOXICILLIN
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DR REDDYS LABORATORIES INC
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LEVOFLOXACIN, LEVOFLOXACIN
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NITROGLYCERIN, NITROGLYCERIN
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PROGESTERONE, PROGESTERONE
PROPOFOL, PROPOFOL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
SIMVASTATIN, SIMVASTATIN
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

DR REDDYS LABS LTD

* DR REDDYS LABORATORIES LIMITED
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

* DR REDDYS LABORATORIES LTD
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZACITIDINE, AZACITIDINE
BIVALIRUDIN, BIVALIRUDIN
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLOFARABINE, CLOFARABINE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DECITABINE, DECITABINE
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOCETAXEL, DOCETAXEL
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESZOPICLONE, ESZOPICLONE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLIMEPIRIDE, GLIMEPIRIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DR REDDYS LABORATORIES LTD
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IMATINIB MESYLATE, IMATINIB MESYLATE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LATANOPROST, LATANOPROST
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM
NATEGLINIDE, NATEGLINIDE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NIZATIDINE, NIZATIDINE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OFLOXACIN, OFLOXACIN
OLANZAPINE, OLANZAPINE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMEPRAZOLE, OMEPRAZOLE
OMEPRAZOLE, OMEPRAZOLE (OTC)
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXAPROZIN, OXAPROZIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARICALCITOL, PARICALCITOL
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SIROLIMUS, SIROLIMUS
TACROLIMUS, TACROLIMUS
TETRABENAZINE, TETRABENAZINE
THIOTEPA, THIOTEPA
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VIGABATRIN, VIGABATRIN
VINORELBINE TARTRATE, VINORELBINE TARTRATE
ZAFIRLUKAST, ZAFIRLUKAST
ZEMBRACE SYMTOUCH, SUMATRIPTAN SUCCINATE
ZENATANE, ISOTRETINOIN
ZOLEDRONIC ACID, ZOLEDRONIC ACID

DR REDDYS LABS SA

* DR REDDYS LABORATORIES SA
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
FENOFIBRATE (MICRONIZED), FENOFIBRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DR REDDYS LABORATORIES SA
HABITROL, NICOTINE (OTC)
MERCAPTOPURINE, MERCAPTOPURINE
RAMELTEON, RAMELTEON
TOBRAMYCIN, TOBRAMYCIN

DRAXIMAGE
* DRAXIMAGE INC
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

DUCHESNAY
* DUCHESNAY INC
BONJESTA, DOXYLAMINE SUCCINATE
DICLEGIS, DOXYLAMINE SUCCINATE
OSPHENA, OSPEMIFENE

DURAMED PHARMS BARR
* DURAMED PHARMACEUTICALS INC SUB BARR LABORATORIES INC
AVIANE-28, ETHINYL ESTRADIOL
CRYSELLE, ETHINYL ESTRADIOL
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
ENPRESSE-28, ETHINYL ESTRADIOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VELIVET, DESOGESTREL

DUSA
* DUSA PHARMACEUTICALS INC
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE

REDDYS
* DOCTOR REDDYS LABORATORIES LTD
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

**** E ****

EAGLE PHARMS
* EAGLE PHARMACEUTICALS INC
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
BELRAPZO, BENDAMUSTINE HYDROCHLORIDE
BENDEKA, BENDAMUSTINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
RYANODEX, DANTROLENE SODIUM

ECI PHARMS LLC
* ECI PHARMACEUTICALS LLC
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LAMIVUDINE, LAMIVUDINE
LEVETIRACETAM, LEVETIRACETAM
METHIMAZOLE, METHIMAZOLE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
VALPROIC ACID, VALPROIC ACID
XTRELUS, GUAIFENESIN

ECOLAB
* ECOLAB INC
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)

ECR
* ECR PHARMACEUTICALS
DEXAMETHASONE, DEXAMETHASONE

ECR PHARMA
* ECR PHARMA
TUSSICAPS, CHLORPHENIRAMINE POLISTIREX

EDENBRIDGE PHARMS
* EDENBRIDGE PHARMACEUTICALS LLC
CARBIDOPA, CARBIDOPA
ETHACRYNIC ACID, ETHACRYNIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EDENBRIDGE PHARMACEUTICALS LLC
ETODOLAC, ETODOLAC
IVERMECTIN, IVERMECTIN
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
TINIDAZOLE, TINIDAZOLE

EDISON THERAPS LLC
* EDISON THERAPEUTICS LLC
METHERGINE, METHYLERGONOVINE MALEATE

EGALET US INC
* EGALET US INC
OXAYDO, OXYCODONE HYDROCHLORIDE
SPRIX, KETOROLAC TROMETHAMINE

EI INC
* EI INC
THEROXIDIL, MINOXIDIL (OTC)

EISAI INC
* EISAI INC
ACIPHEX, RABEPRAZOLE SODIUM
ARICEPT, DONEPEZIL HYDROCHLORIDE
BANZEL, RUFINAMIDE
BELVIQ XR, LORCASERIN HYDROCHLORIDE
BELVIQ, LORCASERIN HYDROCHLORIDE
FYCOMPA, PERAMPANEL
HALAVEN, ERIBULIN MESYLATE
HEXALEN, ALTRETAMINE
LENVIMA, LENVATINIB MESYLATE
PANRETIN, ALITRETINOIN
SALAGEN, PILOCARPINE HYDROCHLORIDE

ELEFSEE PHARMS INTL
* ELEFSEE PHARMACEUTICALS INTERNATIONAL LTD
LAZANDA, FENTANYL CITRATE

ELI LILLY AND CO
* ELI LILLY AND CO
BASAGLAR, INSULIN GLARGINE
EFFIENT, PRASUGREL HYDROCHLORIDE
HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
OLUMIANT, BARICITINIB
PROZAC, FLUOXETINE HYDROCHLORIDE
VERZENIO, ABEMACICLIB

ELI LILLY CO
* ELI LILLY CO
ADCIRCA, TADALAFIL
ZYPREXA RELPREVV, OLANZAPINE PAMOATE

ELITE LABS
* ELITE LABORATORIES INC
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

ELITE LABS INC
* ELITE LABORATORIES INC
DANTROLENE SODIUM, DANTROLENE SODIUM
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
ISRADIPINE, ISRADIPINE
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

EMCURE PHARMS
* EMCURE PHARMACEUTICALS LTD
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

EMCURE PHARMS LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EMCURE PHARMACEUTICALS LTD
ACARBOSE, ACARBOSE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ADENOSINE, ADENOSINE
AMIKACIN SULFATE, AMIKACIN SULFATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BICNU, CARMUSTINE
CIDOFOVIR, CIDOFOVIR
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ETOMIDATE, ETOMIDATE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FUROSEMIDE, FUROSEMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
RIFAMPIN, RIFAMPIN
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TRANEXAMIC ACID, TRANEXAMIC ACID
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

EMD SERONO
* EMD SERONO INC
GONAL-F RFF REDI-JECT, FOLLITROPIN ALFA/BETA
GONAL-F RFF, FOLLITROPIN ALFA/BETA
GONAL-F, FOLLITROPIN ALFA/BETA
OVIDREL, CHORIOGONADOTROPIN ALFA
SAIZEN, SOMATROPIN RECOMBINANT
SEROSTIM, SOMATROPIN RECOMBINANT
ZORBTIVE, SOMATROPIN RECOMBINANT

EMD SERONO INC
* EMD SERONO INC
CETROTIDE, CETRORELIX

EMERALD INTL LTD
* EMERALD INTERNATIONAL LTD
BACLOFEN, BACLOFEN

EMMAUS MEDCL
* EMMAUS MEDICAL INC
ENDARI, L-GLUTAMINE
NUTRESTORE, L-GLUTAMINE

ENCORE DERMAT
* ENCORE DERMATOLOGY INC
IMPOYZ, CLOBETASOL PROPIONATE

ENCUBE ETHICALS
* ENCUBE ETHICALS PVT LTD
FLUOCINONIDE, FLUOCINONIDE

ENDO PHARM
* ENDO PHARMACEUTICAL SOLUTIONS INC
SUPPRELIN LA, HISTRELIN ACETATE
VALSTAR PRESERVATIVE FREE, VALRUBICIN
VANTAS, HISTRELIN ACETATE

ENDO PHARMS
* ENDO PHARMACEUTICALS INC
FORTESTA, TESTOSTERONE
FROVA, FROVATRIPTAN SUCCINATE
OPANA, OXYMORPHONE HYDROCHLORIDE
PERCODAN, ASPIRIN

ENDO PHARMS INC
* ENDO PHARMACEUTICALS INC
AVEED, TESTOSTERONE UNDECANOATE
COLY-MYCIN S, COLISTIN SULFATE
MEGACE ES, MEGESTROL ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* ENDO PHARMACEUTICALS INC
NASCOBAL, CYANOCOBALAMIN
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE

EPI HLTH

* EPI HEALTH LLC
CLODERM, CLOCORTOLONE PIVALATE
MINOLIRA, MINOCYCLINE HYDROCHLORIDE
SITAVIG, ACYCLOVIR

EPIC PHARMA

* EPIC PHARMA INC
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
* EPIC PHARMA LLC
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
SULINDAC, SULINDAC
TRANDOLAPRIL, TRANDOLAPRIL
URSODIOL, URSODIOL

EPIC PHARMA INC

* EPIC PHARMA INC
ESTRADIOL, ESTRADIOL
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

EPIC PHARMA LLC

* EPIC PHARMA LLC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AZITHROMYCIN, AZITHROMYCIN
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
GABAPENTIN, GABAPENTIN
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLYBURIDE, GLYBURIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PHENYTOIN, PHENYTOIN
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

ESPERO

* ESPERO BIOPHARMA INC
DURLAZA, ASPIRIN

ESSENTIAL ISOTOPES

* ESSENTIAL ISOTOPES LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

ETHYPHARM

* ETHYPHARM
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

ETHYPHARM USA CORP

* ETHYPHARM USA CORP
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

EUGIA PHARMA

* EUGIA PHARMA SPECIALITIES LTD
CAPECITABINE, CAPECITABINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EUGIA PHARMA SPECIALITIES LTD
CARBOPLATIN, CARBOPLATIN
LETROZOLE, LETROZOLE
OXALIPLATIN, OXALIPLATIN
PROGESTERONE, PROGESTERONE

EUROHLTH INTL SARL

* EUROHEALTH INTERNATIONAL SARL
DROPERIDOL, DROPERIDOL
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE

EXALENZ BIOSCIENCE

* EXALENZ BIOSCIENCE LTD
IDKIT:HP, CITRIC ACID

EXELA HOLDINGS

* EXELA HOLDINGS INC
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM

EXELA PHARMA SCIENCE

* EXELA PHARMA SCIENCES
CAFFEINE CITRATE, CAFFEINE CITRATE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE

EXELA PHARMA SCS LLC

* EXELA PHARMA SCIENCES LLC
CAFFEINE CITRATE, CAFFEINE CITRATE
GANCICLOVIR, GANCICLOVIR
GLYRX-PF, GLYCOPYRROLATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
NIPRIDE RTU IN SODIUM CHLORIDE 0.9%, SODIUM NITROPRUSSIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
POTASSIUM ACETATE, POTASSIUM ACETATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

EXELIXIS

* EXELIXIS INC
COMETRIQ, CABOZANTINIB S-MALATE

EXELIXIS INC

* EXELIXIS INC
CABOMETYX, CABOZANTINIB S-MALATE

EYEPOINT PHARMS

* EYEPOINT PHARMACEUTICALS INC
DEXYCU KIT, DEXAMETHASONE
YUTIQ, FLUOCINOLONE ACETONIDE

EYEVANCE PHARMS

* EYEVANCE PHARMACEUTICALS LLC
ZERVIATE, CETIRIZINE HYDROCHLORIDE

LILLY

* ELI LILLY AND CO
ALIMTA, PEMETREXED DISODIUM
CIALIS, TADALAFIL
CYMBALTA, DULOXETINE HYDROCHLORIDE
EVISTA, RALOXIFENE HYDROCHLORIDE
FORTEO, TERIPARATIDE RECOMBINANT HUMAN
GEMZAR, GEMCITABINE HYDROCHLORIDE
GLUCAGON, GLUCAGON
HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG, INSULIN LISPRO RECOMBINANT
HUMATROPE, SOMATROPIN RECOMBINANT
HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* ELI LILLY AND CO
HUMULIN R KWIKPEN, INSULIN HUMAN
HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN R, INSULIN HUMAN
HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE
STRATTERA, ATOMOXETINE HYDROCHLORIDE
SYMBYAX, FLUOXETINE HYDROCHLORIDE
ZYPREXA ZYDIS, OLANZAPINE
ZYPREXA, OLANZAPINE

**** F ****

FDC LTD
* FDC LTD
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
LATANOPROST, LATANOPROST
OFLOXACIN, OFLOXACIN
TIMOLOL MALEATE, TIMOLOL MALEATE

FDN CONSUMER
* FOUNDATION CONSUMER HEALTHCARE LLC
LEVONORGESTREL, LEVONORGESTREL (OTC)
PLAN B ONE-STEP, LEVONORGESTREL (OTC)

FEINSTEIN
* FEINSTEIN INSTITUTE MEDICAL RESEARCH
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

FERA PHARMS
* FERA PHARMACEUTICALS LLC
TOBRAMYCIN, TOBRAMYCIN

FERA PHARMS LLC
* FERA PHARMACEUTICALS LLC
DEXAMETHASONE, DEXAMETHASONE

FERRER INTERNACIONAL
* FERRER INTERNACIONAL SA
XEPI, OZENOXACIN

FERRING
* FERRING PHARMACEUTICALS INC
ACTHREL, CORTICORELIN OVINE TRIFLUTATE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
ENDOMETRIN, PROGESTERONE
FIRMAGON, DEGARELIX ACETATE
MENOPUR, MENOTROPINS (FSH
MINIRIN, DESMOPRESSIN ACETATE
ZOMACTON, SOMATROPIN

FERRING PHARMS INC
* FERRING PHARMACEUTICALS INC
CERVIDIL, DINOPROSTONE
CLENPIQ, CITRIC ACID
DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DDAVP, DESMOPRESSIN ACETATE
LYSTEDA, TRANEXAMIC ACID
NOCDURNA, DESMOPRESSIN ACETATE
PREPOPIK, CITRIC ACID
STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE

FLAMEL IRELAND LTD
* FLAMEL IRELAND LIMITED
AKOVAZ, EPHEDRINE SULFATE

FLAMINGO PHARMS
* FLAMINGO PHARMACEUTICALS LTD
METRONIDAZOLE, METRONIDAZOLE
PIROXICAM, PIROXICAM

FLEXION THERAPS INC
* FLEXION THERAPEUTICS INC
ZILRETTA, TRIAMCINOLONE ACETONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** F ****

FOREST LABS INC
* FOREST LABORATORIES INC
VIOKACE, PANCRELIPASE (AMYLASE
ZENPEP, PANCRELIPASE (AMYLASE

FOREST LABS LLC
* FOREST LABORATORIES LLC
NAMENDA XR, MEMANTINE HYDROCHLORIDE
SAPHRIS, ASENAPINE MALEATE

FOUGERA PHARMS
* FOUGERA PHARMACEUTICALS INC
ADAPALENE, ADAPALENE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
AMCINONIDE, AMCINONIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CUTIVATE, FLUTICASONE PROPIONATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE, HYDROCORTISONE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
METRONIDAZOLE, METRONIDAZOLE
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
NYSTATIN, NYSTATIN
OXISTAT, OXICONAZOLE NITRATE
PANDEL, HYDROCORTISONE PROBUTATE
PREDNICARBATE, PREDNICARBATE
SOLARAZE, DICLOFENAC SODIUM
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TERCONAZOLE, TERCONAZOLE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

FOUGERA PHARMS INC
* FOUGERA PHARMACEUTICALS INC
ACYCLOVIR, ACYCLOVIR
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE, LIDOCAINE
NITROGLYCERIN, NITROGLYCERIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
TACROLIMUS, TACROLIMUS
VEREGEN, SINECATECHINS

FRESENIUS
* FRESENIUS KABI DEUTSCHLAND GMBH

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** F ****

* FRESENIUS KABI DEUTSCHLAND GMBH
INTRALIPID 10%, SOYBEAN OIL
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL

FRESENIUS KABI

* FRESENIUS KABI ANTI INFECTIVES SRL
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM

* FRESENIUS KABI AUSTRIA GMBH
LACTULOSE, LACTULOSE

FRESENIUS KABI ONCOL

* FRESENIUS KABI ONCOLOGY PLC
ANASTROZOLE, ANASTROZOLE
BICALUTAMIDE, BICALUTAMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LETROZOLE, LETROZOLE

FRESENIUS KABI USA

* FRESENIUS KABI USA LLC
ACETAMINOPHEN, ACETAMINOPHEN
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ADENOSINE, ADENOSINE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ARGATROBAN, ARGATROBAN
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ASTRAMORPH PF, MORPHINE SULFATE
ATROPINE SULFATE, ATROPINE SULFATE
AZITHROMYCIN, AZITHROMYCIN
AZTREONAM, AZTREONAM
BACITRACIN, BACITRACIN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BIVALIRUDIN, BIVALIRUDIN
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BORTEZOMIB, BORTEZOMIB
CAFFEINE CITRATE, CAFFEINE CITRATE
CALCIUM GLUCONATE, CALCIUM GLUCONATE
CARBOPLATIN, CARBOPLATIN
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CEFOTETAN, CEFOTETAN DISODIUM
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CISPLATIN, CISPLATIN
CLADRIBINE, CLADRIBINE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DAPTOMYCIN, DAPTOMYCIN
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPRIVAN, PROPOFOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** F **

* FRESENIUS KABI USA LLC
DIPYRIDAMOLE, DIPYRIDAMOLE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLOXURIDINE, FLOXURIDINE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUMAZENIL, FLUMAZENIL
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FUROSEMIDE, FUROSEMIDE
GANCICLOVIR, GANCICLOVIR SODIUM
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
INDOMETHACIN, INDOMETHACIN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LINEZOLID, LINEZOLID
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MANNITOL 25%, MANNITOL
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MESNA, MESNA
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** F ****

* FRESENIUS KABI USA LLC
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NAROPIN, ROPIVACAINE HYDROCHLORIDE
NEBUPENT, PENTAMIDINE ISETHIONATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OMEGAVEN, FISH OIL TRIGLYCERIDES
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
OXYTOCIN, OXYTOCIN
PACLITAXEL, PACLITAXEL
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PENTAM, PENTAMIDINE ISETHIONATE
PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROGESTERONE, PROGESTERONE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROTAMINE SULFATE, PROTAMINE SULFATE
PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
REMIFENTANIL HYDROCHLORIDE, REMIFENTANIL HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SMOFLIPID 20%, FISH OIL
SODIUM ACETATE, SODIUM ACETATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TIGECYCLINE, TIGECYCLINE
TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
VALPROATE SODIUM, VALPROATE SODIUM
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VIBISONE, CYANOCOBALAMIN
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

FRESENIUS MEDCL

* FRESENIUS MEDICAL CARE NORTH AMERICA
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** F ****

* FRESENIUS MEDICAL CARE NORTH AMERICA
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
PHOSLO GELCAPS, CALCIUM ACETATE
PHOSLYRA, CALCIUM ACETATE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

FRONTIDA BIOPHARM

* FRONTIDA BIOPHARM INC
CILOSTAZOL, CILOSTAZOL
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE

**** G ****

G AND W LABS

* G AND W LABORATORIES INC
ACEPHEN, ACETAMINOPHEN (OTC)
CICLOPIROX, CICLOPIROX
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
INDOMETHACIN, INDOMETHACIN
METRONIDAZOLE, METRONIDAZOLE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MOMETASONE FUROATE, MOMETASONE FUROATE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

G AND W LABS INC

* G AND W LABORATORIES INC
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
BETA-VAL, BETAMETHASONE VALERATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CICLOPIROX, CICLOPIROX
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DOXYCYCLINE, DOXYCYCLINE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
LIDOCAINE, LIDOCAINE
METRONIDAZOLE, METRONIDAZOLE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MYKACET, NYSTATIN
NYSTATIN, NYSTATIN
TAZAROTENE, TAZAROTENE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

GALDERMA LABS

* GALDERMA LABORATORIES INC
CLOBEX, CLOBETASOL PROPIONATE
EPIDUO FORTE, ADAPALENE

GALDERMA LABS LP

* GALDERMA LABORATORIES L P
CLOBEX, CLOBETASOL PROPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GALDERMA LABORATORIES LP
CAPEX, FLUOCINOLONE ACETONIDE
CLOBEX, CLOBETASOL PROPIONATE
DESOWEN, DESONIDE
DIFFERIN, ADAPALENE
DIFFERIN, ADAPALENE (OTC)
EPIDUO, ADAPALENE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE
MIRVASO, BRIMONIDINE TARTRATE
ORACEA, DOXYCYCLINE
SOOLANTRA, IVERMECTIN
TRI-LUMA, FLUOCINOLONE ACETONIDE
VECTICAL, CALCITRIOL

GALEN SPECIALTY
* GALEN SPECIALTY PHARMA US LLC
SYNERA, LIDOCAINE

GALEN UK
* GALEN LTD
ADASUVE, LOXAPINE

GALT PHARMS
* GALT PHARMACEUTICALS LLC
DORAL, QUAZEPAM

GATE PHARMS
* GATE PHARMACEUTICALS
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
LINEZOLID, LINEZOLID

GATOR PHARMS
* GATOR PHARMACEUTICALS INC
COLPREP KIT, MAGNESIUM SULFATE

GAVIS PHARMS
* GAVIS PHARMACEUTICALS LLC
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NYSTATIN, NYSTATIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
QUINARETIC, HYDROCHLOROTHIAZIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE

GAVIS PHARMS LLC
* GAVIS PHARMACEUTICALS LLC
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE

GD SEARLE
* GD SEARLE LLC
CELEBREX, CELECOXIB
DAYPRO, OXAPROZIN

GD SEARLE LLC
* GD SEARLE LLC
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ARTHROTEC, DICLOFENAC SODIUM
CALAN, VERAPAMIL HYDROCHLORIDE
CYTOTEC, MISOPROSTOL
FLAGYL, METRONIDAZOLE
INSPRA, EPLERENONE
LOMOTIL, ATROPINE SULFATE
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPACE, DISOPYRAMIDE PHOSPHATE
SYNAREL, NAFARELIN ACETATE

GE HEALTHCARE
* GE HEALTHCARE
ADREVIEW, IOBENGUANE SULFATE I-123
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
INDICLOR, INDIUM IN-111 CHLORIDE
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GE HEALTHCARE
METASTRON, STRONTIUM CHLORIDE SR-89
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MYOVIEW 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
OMNIPAQUE 12, IOHEXOL
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPAQUE 9, IOHEXOL
OMNISCAN, GADODIAMIDE
OPTISON, ALBUMIN HUMAN
TECHNETIUM TC 99M GENERATOR, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VIZAMYL, FLUTEMETAMOL F-18

GE HLTHCARE INC
* GE HEALTHCARE INC
DATSCAN, IOFLUPANE I-123

GEMINI LABS LLC
* GEMINI LABORATORIES LLC
PRANDIN, REPAGLINIDE

GENENTECH
* GENENTECH INC
ERIVEDGE, VISMODEGIB
NUTROPIN AQ NUSPIN, SOMATROPIN RECOMBINANT

GENENTECH INC
* GENENTECH INC
COTELLIC, COBIMETINIB FUMARATE
ESBRIET, PIRFENIDONE
XOFLUZA, BALOXAVIR MARBOXIL

GENERICS
* GENERICS INTERNATIONAL VENTURES ENTERPRISES LLC
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE

GENEYORK PHARMS
* GENEYORK PHARMACEUTICALS GROUP LLC
PREDNISONE, PREDNISONE

GENUS LIFESCIENCES
* GENUS LIFE SCIENCES INC
GOPRELTO, COCAINE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
YOSPRALA, ASPIRIN
* GENUS LIFESCIENCES INC
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN

GENZYME
* GENZYME CORP
CEREZYME, IMIGLUCERASE
CLOLAR, CLOFARABINE
MOZOBIL, PLERIXAFOR
RENAGEL, SEVELAMER HYDROCHLORIDE
RENVELA, SEVELAMER CARBONATE
THYROGEN, THYROTROPIN ALFA

GENZYME CORP
* GENZYME CORP
CAPRELSA, VANDETANIB
CERDELGA, ELIGLUSTAT TARTRATE

GILEAD
* GILEAD SCIENCES INC
CAYSTON, AZTREONAM
EMTRIVA, EMTRICITABINE
HEPSERA, ADEFOVIR DIPIVOXIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GILEAD SCIENCES INC
LETAIRIS, AMBRISENTAN
RANEXA, RANOLAZINE
TRUVADA, EMTRICITABINE

GILEAD SCIENCES

* GILEAD SCIENCES LLC
ATRIPLA, EFAVIRENZ

GILEAD SCIENCES INC

* GILEAD SCIENCES INC
BIKTARVY, BICTEGRAVIR SODIUM
COMPLERA, EMTRICITABINE
DESCOVY, EMTRICITABINE
EPCLUSA, SOFOSBUVIR
GENVOYA, COBICISTAT
HARVONI, LEDIPASVIR
ODEFSEY, EMTRICITABINE
SOVALDI, SOFOSBUVIR
STRIBILD, COBICISTAT
TYBOST, COBICISTAT
VEMLIDY, TENOFOVIR ALAFENAMIDE FUMARATE
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VOSEVI, SOFOSBUVIR
ZYDELIG, IDELALISIB

GLAND PHARMA LTD

* GLAND PHARMA LTD
ADENOSINE, ADENOSINE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
AZITHROMYCIN, AZITHROMYCIN
CARBOPLATIN, CARBOPLATIN
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CISPLATIN, CISPLATIN
CLOFARABINE, CLOFARABINE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
ETOMIDATE, ETOMIDATE
FLUOROURACIL, FLUOROURACIL
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM, HEPARIN SODIUM
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
MEROPENEM, MEROPENEM
MESNA, MESNA
METHOCARBAMOL, METHOCARBAMOL
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PACITAXEL, PACLITAXEL
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLEDRONIC, ZOLEDRONIC ACID

GLASSHOUSE PHARMS

* GLASSHOUSE PHARMACEUTICALS LTD CANADA
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLASSHOUSE PHARMACEUTICALS LTD CANADA
FLUOCINONIDE, FLUOCINONIDE

GLAXO GRP ENGLAND

* GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE
INCRUSE ELLIPTA, UMECLIDINIUM BROMIDE

GLAXO GRP LTD

* GLAXO GROUP LTD DBA GLAXOSMITHKLINE
FLOVENT HFA, FLUTICASONE PROPIONATE

* GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVAIR HFA, FLUTICASONE PROPIONATE
BREO ELLIPTA, FLUTICASONE FUROATE
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE

GLAXOSMITHKLINE

* GLAXOSMITHKLINE
ABREVA, DOCOSANOL (OTC)
AVODART, DUTASTERIDE
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
EPIVIR-HBV, LAMIVUDINE
IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
JALYN, DUTASTERIDE
MALARONE PEDIATRIC, ATOVAQUONE
MALARONE, ATOVAQUONE
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
RELENZA, ZANAMIVIR
VALTREX, VALACYCLOVIR HYDROCHLORIDE
WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
ZYBAN, BUPROPION HYDROCHLORIDE

* GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)

* GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND
ANORO ELLIPTA, UMECLIDINIUM BROMIDE
ARNUITY ELLIPTA, FLUTICASONE FUROATE
KRINTAFEL, TAFENOQUINE SUCCINATE
TRELEGY ELLIPTA, FLUTICASONE FUROATE

* GLAXOSMITHKLINE INTELLECTUAL PROPERTY LTD ENGLAND
SEREVENT, SALMETEROL XINAFOATE
VENTOLIN HFA, ALBUTEROL SULFATE

GLAXOSMITHKLINE CON

* GLAXOSMITHKLINE CONSUMER HEALTH
TRANSDERM SCOP, SCOPOLAMINE

GLAXOSMITHKLINE CONS

* GLAXOSMITHKLINE CONSUMER HEALTHCARE
ALLI, ORLISTAT (OTC)
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
FLONASE SENSIMIST ALLERGY RELIEF, FLUTICASONE FUROATE (OTC)
LAMISIL AT, TERBINAFINE (OTC)
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
PREVACID 24 HR, LANSOPRAZOLE (OTC)
VOLTAREN, DICLOFENAC SODIUM

GLAXOSMITHKLINE LLC

* GLAXOSMITHKLINE LLC
AMERGE, NARATRIPTAN HYDROCHLORIDE
DYAZIDE, HYDROCHLOROTHIAZIDE
FLOLAN, EPOPROSTENOL SODIUM
LAMICTAL CD, LAMOTRIGINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLAXOSMITHKLINE LLC
LAMICTAL ODT, LAMOTRIGINE
LAMICTAL XR, LAMOTRIGINE
LAMICTAL, LAMOTRIGINE
MEPRON, ATOVAQUONE
REQUIP XL, ROPINIROLE HYDROCHLORIDE
REQUIP, ROPINIROLE HYDROCHLORIDE
RYTHMOL SR, PROPAFENONE HYDROCHLORIDE

GLENMARK

* GLENMARK THERAPEUTICS INC USA
ECOZA, ECONAZOLE NITRATE

GLENMARK GENERICS

* GLENMARK GENERICS INC USA
ADAPALENE, ADAPALENE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
IMIQUIMOD, IMIQUIMOD
MOMETASONE FUROATE, MOMETASONE FUROATE
NIZATIDINE, NIZATIDINE
ZONISAMIDE, ZONISAMIDE
* GLENMARK GENERICS LIMITED
BRIELLYN, ETHINYL ESTRADIOL
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
* GLENMARK GENERICS LTD
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
ALYACEN 1/35, ETHINYL ESTRADIOL
ALYACEN 7/7/7, ETHINYL ESTRADIOL
ASHLYNA, ETHINYL ESTRADIOL
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
CARVEDILOL, CARVEDILOL
CICLOPIROX, CICLOPIROX
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DESOXIMETASONE, DESOXIMETASONE
ESZOPICLONE, ESZOPICLONE
FELODIPINE, FELODIPINE
FLUCONAZOLE, FLUCONAZOLE
FLUOCINONIDE, FLUOCINONIDE
HEATHER, NORETHINDRONE
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
LAMOTRIGINE, LAMOTRIGINE
LEVOFLOXACIN, LEVOFLOXACIN
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LITHIUM CARBONATE, LITHIUM CARBONATE
MARLISSA, ETHINYL ESTRADIOL
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NAPROXEN, NAPROXEN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
TOPIRAMATE, TOPIRAMATE
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLENMARK GENERICS LTD
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
URSODIOL, URSODIOL
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VIORELE, DESOGESTREL
ZOLMITRIPTAN, ZOLMITRIPTAN
* GLENMARK GENERICS LTD INDIA
INDOMETHACIN, INDOMETHACIN
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

GLENMARK PHARMS
* GLENMARK PHARMACEUTICALS INC
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
TERIFLUNOMIDE, TERIFLUNOMIDE
* GLENMARK PHARMACEUTICALS INC USA
CICLOPIROX, CICLOPIROX
CLOTRIMAZOLE, CLOTRIMAZOLE
MUPIROCIN, MUPIROCIN
* GLENMARK PHARMACEUTICALS LTD
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
* GLENMARK PHARMACEUTICALS SA
ATOVAQUONE, ATOVAQUONE
AZELAIC ACID, AZELAIC ACID
CALCIPOTRIENE, CALCIPOTRIENE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
DESONIDE, DESONIDE
HAILEY 1.5/30, ETHINYL ESTRADIOL
HAILEY FE 1.5/30, ETHINYL ESTRADIOL
LINEZOLID, LINEZOLID
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

GLENMARK PHARMS INC
* GLENMARK PHARMACEUTICALS INC USA
CALCIPOTRIENE, CALCIPOTRIENE
LITHIUM CARBONATE, LITHIUM CARBONATE
MUPIROCIN, MUPIROCIN CALCIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

GLENMARK PHARMS LTD
* GLENMARK PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESONIDE, DESONIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ESTRADIOL, ESTRADIOL
EZETIMIBE, EZETIMIBE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FLUCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE ACETONIDE, FLUOCINOLONE ACETONIDE
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
GABAPENTIN, GABAPENTIN
HAILEY FE 1/20, ETHINYL ESTRADIOL
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
INDOMETHACIN, INDOMETHACIN
LAMOTRIGINE, LAMOTRIGINE
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLENMARK PHARMACEUTICALS LTD
LIDOCAINE, LIDOCAINE
NAPROXEN SODIUM, NAPROXEN SODIUM
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OXCARBAZEPINE, OXCARBAZEPINE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RILUZOLE, RILUZOLE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
RUFINAMIDE, RUFINAMIDE
TACROLIMUS, TACROLIMUS
TELMISARTAN, TELMISARTAN
TRETINOIN, TRETINOIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VORICONAZOLE, VORICONAZOLE

GLENMARK PHARMS SA

* GLENMARK PHARMACEUTICALS SA SWITZERLAND
APREPITANT, APREPITANT
NITROGLYCERIN, NITROGLYCERIN

GLOBAL ISOTOPES LLC

* GLOBAL ISOTOPES LLC DBA ZEVACOR MOLECULAR
AMMONIA N 13, AMMONIA N-13
CHOLINE C-11, CHOLINE C-11
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

GP-PHARM SA

* GP-PHARM SA
LUTRATE DEPOT KIT, LEUPROLIDE ACETATE

GRANULES INDIA

* GRANULES INDIA LTD
IBUPROFEN, IBUPROFEN (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

GRANULES INDIA LTD

* GRANULES INDIA LTD
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

GRANULES PHARMS

* GRANULES PHARMACEUTICALS INC
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

GRAVITI PHARMS

* GRAVITI PHARMACEUTICALS PRIVATE LTD
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
FENOFIBRATE, FENOFIBRATE

GUARDIAN DRUG

* GUARDIAN DRUG CO
GUAIFENESIN, GUAIFENESIN (OTC)
IBUPROFEN, IBUPROFEN (OTC)

GUERBET

* GUERBET LLC
DOTAREM, GADOTERATE MEGLUMINE
LIPIODOL, ETHIODIZED OIL

GW RES LTD

* GW RESEARCH LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GW RESEARCH LTD
EPIDIOLEX, CANNABIDIOL

HANFORD GC
* GC HANFORD MANUFACTURING CO
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

POHL BOSKAMP
* G POHL BOSKAMP GMBH AND CO KG
GONITRO, NITROGLYCERIN

**** H ****

HAEMONETICS
* HAEMONETICS CORP
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

HAINAN POLY PHARM
* HAINAN POLY PHARMACEUTICAL CO LTD
AZITHROMYCIN, AZITHROMYCIN
GANCICLOVIR, GANCICLOVIR SODIUM
LEVETIRACETAM, LEVETIRACETAM
VORICONAZOLE, VORICONAZOLE

HALOCARBON PRODS
* HALOCARBON PRODUCTS CORP
ISOFLURANE, ISOFLURANE
SEVOFLURANE, SEVOFLURANE

HALOZYME THERAP
* HALOZYME THERAPEUTICS INC
HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN

HAMELN PHARMA PLUS
* HAMELN PHARMA PLUS GMBH
PENTETATE CALCIUM TRISODIUM, PENTETATE CALCIUM TRISODIUM
PENTETATE ZINC TRISODIUM, PENTETATE ZINC TRISODIUM

HANDA PHARMS LLC
* HANDA PHARMACEUTICALS LLC
LAMOTRIGINE, LAMOTRIGINE

HANGZHOU BINJIANG
* HANGZHOU MINSHENG BINJIANG PHARMACEUTICAL CO LTD
ALENDRONATE SODIUM, ALENDRONATE SODIUM

HANSAMED INC
* HANSAMED INC
ULTACAN FORTE, ARTICAINE HYDROCHLORIDE
ULTACAN, ARTICAINE HYDROCHLORIDE

HARRIS PHARM
* HARRIS PHARMACEUTICAL INC
FLUCONAZOLE, FLUCONAZOLE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

HEBEI CHANGSHAN
* HEBEI CHANGSHAN BIOCHEMICAL PHARMACEUTICAL CO LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE

HEC PHARM
* HEC PHARM USA INC
CLARITHROMYCIN, CLARITHROMYCIN
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
IBUPROFEN, IBUPROFEN
OLANZAPINE, OLANZAPINE
PRASUGREL, PRASUGREL HYDROCHLORIDE

HELSINN
* HELSINN BIREX PHARMACEUTICALS LTD
VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE

HELSINN HLTHCARE
* HELSINN HEALTHCARE SA
AKYNZEO, FOSNETUPITANT CHLORIDE HYDROCHLORIDE
AKYNZEO, NETUPITANT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HELSINN HEALTHCARE SA
ALOXI, PALONOSETRON HYDROCHLORIDE

HERCON PHARM

* HERCON PHARMACEUTICAL LLC
NITROGLYCERIN, NITROGLYCERIN

HERITAGE LIFE

* HERITAGE LIFE SCIENCES BARBADOS INC
CLOZARIL, CLOZAPINE

HERITAGE PHARMA

* HERITAGE PHARMA LABS INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAZOLAMIDE, ACETAZOLAMIDE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DIFLUNISAL, DIFLUNISAL
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
LITHIUM CARBONATE, LITHIUM CARBONATE
METHIMAZOLE, METHIMAZOLE
NIFEDIPINE, NIFEDIPINE

HERITAGE PHARMS INC

* HERITAGE PHARMACEUTICALS INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
ACYCLOVIR, ACYCLOVIR
ALPRAZOLAM, ALPRAZOLAM
CALCIUM ACETATE, CALCIUM ACETATE
CARISOPRODOL AND ASPIRIN, ASPIRIN
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DUTASTERIDE, DUTASTERIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
FELODIPINE, FELODIPINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
INDOMETHACIN, INDOMETHACIN
KETOPROFEN, KETOPROFEN
LEFLUNOMIDE, LEFLUNOMIDE
METRONIDAZOLE, METRONIDAZOLE
MODAFINIL, MODAFINIL
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NIMODIPINE, NIMODIPINE
NYSTATIN, NYSTATIN
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

HERON THERAPS INC

* HERON THERAPEUTICS INC
CINVANTI, APREPITANT
SUSTOL, GRANISETRON

HETERO LABS LTD III

* HETERO LABS LTD UNIT III

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HETERO LABS LTD UNIT III
ABACAVIR SULFATE, ABACAVIR SULFATE
ATOVAQUONE, ATOVAQUONE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLOBAZAM, CLOBAZAM
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
EFAVIRENZ, EFAVIRENZ
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FENOFIBRATE, FENOFIBRATE
FINASTERIDE, FINASTERIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
METHOCARBAMOL, METHOCARBAMOL
NEVIRAPINE, NEVIRAPINE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
RITONAVIR, RITONAVIR
ROFLUMILAST, ROFLUMILAST
SIMVASTATIN, SIMVASTATIN
STAVUDINE, STAVUDINE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TORSEMIDE, TORSEMIDE
ZIDOVUDINE, ZIDOVUDINE

HETERO LABS LTD V

* HETERO LABS LTD UNIT V
ACYCLOVIR, ACYCLOVIR
ARIPIPRAZOLE, ARIPIPRAZOLE
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ENTECAVIR, ENTECAVIR
FAMCICLOVIR, FAMCICLOVIR
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
IRBESARTAN, IRBESARTAN
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LEVOFLOXACIN, LEVOFLOXACIN
LINEZOLID, LINEZOLID
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MONTELUKAST SODIUM, MONTELUKAST SODIUM
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TELMISARTAN, TELMISARTAN
TETRABENAZINE, TETRABENAZINE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALSARTAN, VALSARTAN

HEYL CHEMISCH

* HEYL CHEMISCH PHARMAZEUTISHE FABRIK
RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)

HI TECH PHARMA

* HI TECH PHARMACAL CO INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
CALCIPOTRIENE, CALCIPOTRIENE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CICLOPIROX, CICLOPIROX

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HI TECH PHARMACAL CO INC
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CORMAX, CLOBETASOL PROPIONATE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
EMBELINE E, CLOBETASOL PROPIONATE
EMBELINE, CLOBETASOL PROPIONATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LACTULOSE, LACTULOSE
LEVOCARNITINE, LEVOCARNITINE
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
NYSTATIN, NYSTATIN
OFLOXACIN, OFLOXACIN
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TIMOLOL MALEATE, TIMOLOL MALEATE
VOSOL HC, ACETIC ACID, GLACIAL
VOSOL, ACETIC ACID, GLACIAL

HI TECH PHARMA CO

* HI TECH PHARMACAL CO INC
FLUNISOLIDE, FLUNISOLIDE
PREDNISOLONE, PREDNISOLONE

HI-TECH PHARMA CO

* HI-TECH PHARMACAL CO INC
BIMATOPROST, BIMATOPROST
FAMOTIDINE, FAMOTIDINE
GATIFLOXACIN, GATIFLOXACIN
LORAZEPAM, LORAZEPAM
PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE

HI-TECH PHARMACAL

* HI-TECH PHARMACAL CO INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BIMATOPROST, BIMATOPROST
BROMFENAC SODIUM, BROMFENAC SODIUM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESONIDE, DESONIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
IBUPROFEN, IBUPROFEN
LEVETIRACETAM, LEVETIRACETAM
MEGESTROL ACETATE, MEGESTROL ACETATE
MORPHINE SULFATE, MORPHINE SULFATE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE
TRIFLURIDINE, TRIFLURIDINE

HIGH TECH PHARMA

* HIGH TECHNOLOGY PHARMACAL CO INC
VALPROIC ACID, VALPROIC ACID

HIKMA

* HIKMA FARMACEUTICA LDA
CEFOTAXIME, CEFOTAXIME SODIUM
* HIKMA PHARMACEUTICALS
AMOXICILLIN, AMOXICILLIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HIKMA PHARMACEUTICALS
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEPHALEXIN, CEPHALEXIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
GLYBURIDE (MICRONIZED), GLYBURIDE

HIKMA FARMACEUTICA

* HIKMA FARMACEUTICA (PORTUGAL) SA
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CEFOXITIN, CEFOXITIN SODIUM
CEFTRIAXONE, CEFTRIAXONE SODIUM
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
ENALAPRILAT, ENALAPRILAT
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUMAZENIL, FLUMAZENIL
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PROGESTERONE, PROGESTERONE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
VALPROATE SODIUM, VALPROATE SODIUM

* HIKMA FARMACEUTICA PORTUGAL LDA
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE

* HIKMA FARMACEUTICA PORTUGAL SA
CEFOTETAN, CEFOTETAN DISODIUM
CEFTRIAXONE SODIUM, CEFTRIAXONE SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
ETOMIDATE, ETOMIDATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OXYTOCIN, OXYTOCIN
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

* HIKMA FARMACEUTICA SA
ZOLEDRONIC ACID, ZOLEDRONIC ACID

HIKMA INTL PHARMS

* HIKMA INTERNATIONAL PHARMACEUTICALS LLC
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL, CARISOPRODOL
CORTISONE ACETATE, CORTISONE ACETATE
DIGOXIN, DIGOXIN
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HIKMA INTERNATIONAL PHARMACEUTICALS LLC
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
METHOCARBAMOL, METHOCARBAMOL
MITIGARE, COLCHICINE
PRIMIDONE, PRIMIDONE

HIKMA PHARM CO LTD

* HIKMA PHARM CO LTD
ARGATROBAN, ARGATROBAN

HIKMA PHARMS

* HIKMA PHARMACEUTICALS
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
GEMFIBROZIL, GEMFIBROZIL
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LETROZOLE, LETROZOLE
MODAFINIL, MODAFINIL
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
RIFAMPIN, RIFAMPIN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

* HIKMA PHARMACEUTICALS CO LTD
PARICALCITOL, PARICALCITOL

* HIKMA PHARMACEUTICALS LLC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
DANTROLENE SODIUM, DANTROLENE SODIUM
DOXERCALCIFEROL, DOXERCALCIFEROL
FOLIC ACID, FOLIC ACID
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
OLANZAPINE, OLANZAPINE
PIROXICAM, PIROXICAM
PREDNISONE, PREDNISONE
ZALEPLON, ZALEPLON

HILL DERMAC

* HILL DERMACEUTICALS INC
DERMA-SMOOTHE/FS, FLUOCINOLONE ACETONIDE
DERMOTIC, FLUOCINOLONE ACETONIDE

HILL DERMACEUTICALS

* HILL DERMACEUTICALS INC
TOLAK, FLUOROURACIL

HISAMITSU PHARM CO

* HISAMITSU PHARMACEUTICAL CO INC
SALONPAS, MENTHOL (OTC)

HISUN PHARM HANGZHOU

* HISUN PHARMACEUTICAL (HANGZHOU) CO LTD
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

* HISUN PHARMACEUTICAL HANGZHOU CO LTD
CAPREOMYCIN SULFATE, CAPREOMYCIN SULFATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM

HOFFMANN LA ROCHE

* HOFFMANN LA ROCHE INC
BONIVA, IBANDRONATE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HOFFMANN LA ROCHE INC
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
XELODA, CAPECITABINE
ZELBORAF, VEMURAFENIB

HOFFMANN-LA ROCHE

* HOFFMANN-LA ROCHE INC
ALECENSA, ALECTINIB HYDROCHLORIDE
INVIRASE, SAQUINAVIR MESYLATE

HONG KONG

* HONG KONG KING-FRIEND INDUSTRIAL CO LTD
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
CYTARABINE, CYTARABINE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

HOPE PHARMS

* HOPE PHARMACEUTICALS
NITHIODOTE, SODIUM NITRITE
SODIUM NITRITE, SODIUM NITRITE
SODIUM THIOSULFATE, SODIUM THIOSULFATE

HORIZON

* HORIZON MEDICINES LLC
DUEXIS, FAMOTIDINE
VIMOVO, ESOMEPRAZOLE MAGNESIUM

HORIZON PHARMA INC

* HORIZON PHARMA INC
BUPHENYL, SODIUM PHENYLBUTYRATE

HORIZON PHARMA USA

* HORIZON PHARMA USA INC
PROCYSBI, CYSTEAMINE BITARTRATE
RAYOS, PREDNISONE

HORIZON THERAPS INC

* HORIZON THERAPEUTICS INC
RAVICTI, GLYCEROL PHENYLBUTYRATE

HOSPIRA

* HOSPIRA INC
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
ACETYLCYSTEINE, ACETYLCYSTEINE
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
AMIDATE, ETOMIDATE
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, ARTICAINE HYDROCHLORIDE
ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
ATROPINE SULFATE LIFESHIELD ABBOJECT SYRINGE, ATROPINE SULFATE
AZITHROMYCIN, AZITHROMYCIN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BUMETANIDE, BUMETANIDE
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CORLOPAM, FENOLDOPAM MESYLATE
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CYTARABINE, CYTARABINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HOSPIRA INC

DACARBAZINE, DACARBAZINE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DEXTROSE 25%, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50%, DEXTROSE
DIAZEPAM, DIAZEPAM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
ENALAPRILAT, ENALAPRILAT
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL CITRATE, FENTANYL CITRATE
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LEVOPHED, NOREPINEPHRINE BITARTRATE
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID
M.V.I. ADULT, ASCORBIC ACID
M.V.I. PEDIATRIC, ASCORBIC ACID
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
MANNITOL 25%, MANNITOL
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HOSPIRA INC
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MORPHINE SULFATE, MORPHINE SULFATE
NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PACLITAXEL, PACLITAXEL
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM ACETATE, POTASSIUM ACETATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROPOFOL, PROPOFOL
QUELICIN, SUCCINYLCHOLINE CHLORIDE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM ACETATE, SODIUM ACETATE
SODIUM BICARBONATE, SODIUM BICARBONATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
SUFENTANIL CITRATE, SUFENTANIL CITRATE
TAZICEF, CEFTAZIDIME
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
VITAMIN K1, PHYTONADIONE
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
* HOSPIRA WORLDWIDE, INC
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
NITROPRESS, SODIUM NITROPRUSSIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE

HOSPIRA INC

* HOSPIRA INC
ADENOSINE, ADENOSINE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
ARGATROBAN, ARGATROBAN
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
BIVALIRUDIN, BIVALIRUDIN
BORTEZOMIB, BORTEZOMIB
BUSULFAN, BUSULFAN
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
CEFOXITIN, CEFOXITIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HOSPIRA INC
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CLOFARABINE, CLOFARABINE
DAPTOMYCIN, DAPTOMYCIN
DOCETAXEL, DOCETAXEL
DOXERCALCIFEROL, DOXERCALCIFEROL
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
HEPARIN SODIUM, HEPARIN SODIUM
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, LINEZOLID
LINEZOLID, LINEZOLID
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAXIPIME, CEFEPIME HYDROCHLORIDE
MEROPENEM, MEROPENEM
MILRINONE LACTATE, MILRINONE LACTATE
MORPHINE SULFATE, MORPHINE SULFATE
NIPENT, PENTOSTATIN
OXACILLIN SODIUM, OXACILLIN SODIUM
OXALIPLATIN, OXALIPLATIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PARICALCITOL, PARICALCITOL
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
SODIUM BICARBONATE, SODIUM BICARBONATE
TACROLIMUS, TACROLIMUS
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

HOSPIRA WORLDWIDE
* HOSPIRA WORLDWIDE PTY
OXALIPLATIN, OXALIPLATIN

HOT SHOTS NM LLC
* HOT SHOTS NUCLEAR MEDICINE LLC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

HOUSTON CYCLOTRON
* HOUSTON CYCLOTRON PARTNERS LP
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

HQ SPCLT PHARMA
* HQ SPECIALTY PHARMA CORP
CALCIUM GLUCONATE IN SODIUM CHLORIDE, CALCIUM GLUCONATE
CISPLATIN, CISPLATIN
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
LINEZOLID, LINEZOLID
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TAXOL, PACLITAXEL

HQ SPECIALITY PHARMA
* HQ SPECIALITY PHARMA LLC
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM

HUMANWELL PURACAP
* HUMANWELL PURACAP PHARMACEUTICAL WUHAN CO LTD
DUTASTERIDE, DUTASTERIDE
IBUPROFEN, IBUPROFEN (OTC)

HZNP
* HZNP MEDICINES LLC
MIGERGOT, CAFFEINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HZNP MEDICINES LLC
PENNSAID, DICLOFENAC SODIUM

ROCHE

* HOFFMANN LA ROCHE INC
BONIVA, IBANDRONATE SODIUM
FUZEON, ENFUVIRTIDE
KLONOPIN, CLONAZEPAM
TAMIFLU, OSELTAMIVIR PHOSPHATE
VALIUM, DIAZEPAM

**** I ****

IBSA INST BIO

* IBSA INSTITUT BIOCHIMIQUE SA
LICART, DICLOFENAC EPOLAMINE

ICU MEDICAL INC

* ICU MEDICAL INC
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINOSYN 10%, AMINO ACIDS
AMINOSYN 3.5% M, AMINO ACIDS
AMINOSYN 8.5% W/ELECTROLYTES, AMINO ACIDS
AMINOSYN 8.5%, AMINO ACIDS
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MORPHINE SULFATE, MORPHINE SULFATE
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* ICU MEDICAL INC
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION

IDENTI PHARMS INC
* IDENTI PHARMACEUTICALS INC
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE

IDT AUSTRALIA LTD
* IDT AUSTRALIA LTD
TEMOZOLOMIDE, TEMOZOLOMIDE

IMPAX
* IMPAX LABORATORIES LLC
ADRENACLICK, EPINEPHRINE

IMPAX LABS
* IMPAX LABORATORIES INC
ACARBOSE, ACARBOSE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
DANTROLENE SODIUM, DANTROLENE SODIUM
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DIGOXIN, DIGOXIN
DIPYRIDAMOLE, DIPYRIDAMOLE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
OMEPRAZOLE, OMEPRAZOLE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RILUZOLE, RILUZOLE
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE

IMPAX LABS INC
* IMPAX LABORATORIES INC
ACITRETIN, ACITRETIN
ALBENZA, ALBENDAZOLE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
BUDESONIDE, BUDESONIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** I **

* IMPAX LABORATORIES INC
DEXEDRINE, DEXTROAMPHETAMINE SULFATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
EMVERM, MEBENDAZOLE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
LAMOTRIGINE, LAMOTRIGINE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MORPHINE SULFATE, MORPHINE SULFATE
NABUMETONE, NABUMETONE
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RYTARY, CARBIDOPA
SEVELAMER CARBONATE, SEVELAMER CARBONATE
URSODIOL, URSODIOL

IMPAX PHARMS
* IMPAX PHARMACEUTICALS
GEMFIBROZIL, GEMFIBROZIL
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

INCYTE CORP
* INCYTE CORP
JAKAFI, RUXOLITINIB PHOSPHATE

INDICUS PHARMA
* INDICUS PHARMA LLC
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LETROZOLE, LETROZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

INDIVIOR INC
* INDIVIOR INC
BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
PERSERIS KIT, RISPERIDONE
SUBLOCADE, BUPRENORPHINE
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE

INDOCO REMEDIES
* INDOCO REMEDIES LTD
ALLOPURINOL, ALLOPURINOL
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
GLIMEPIRIDE, GLIMEPIRIDE

INFORLIFE
* INFORLIFE SA
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

INGENUS PHARMS LLC
* INGENUS PHARMACEUTICALS LLC
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
CABERGOLINE, CABERGOLINE
CARBOPLATIN, CARBOPLATIN
CICLOPIROX, CICLOPIROX
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** I **

* INGENUS PHARMACEUTICALS LLC
CLOFARABINE, CLOFARABINE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
OXALIPLATIN, OXALIPLATIN
TOLCAPONE, TOLCAPONE

INGENUS PHARMS NJ
* INGENUS PHARMACEUTICALS NJ LLC
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN

INNOGENIX
* INNOGENIX LLC
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE

INSMED INC
* INSMED INC
ARIKAYCE KIT, AMIKACIN SULFATE

INST BIOCHEM
* INSTITUT BIOCHEMIQUE SA
FLECTOR, DICLOFENAC EPOLAMINE

INSTITUT BIOCHIMIQUE
* INSTITUT BIOCHIMIQUE SA (IBSA)
TIROSINT, LEVOTHYROXINE SODIUM

INSYS DEV CO INC
* INSYS DEVELOPMENT CO INC
SUBSYS, FENTANYL
SYNDROS, DRONABINOL

INTAS PHARMS USA
* INTAS PHARMACEUTICALS USA
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

INTELLIPHARMACEUTICS
* INTELLIPHARMACEUTICS CORP
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

INTERCEPT PHARMS INC
* INTERCEPT PHARMACEUTICALS INC
OCALIVA, OBETICHOLIC ACID

INTERGEL PHARM
* INTERGEL PHARMACEUTICAL INC
NIFEDIPINE, NIFEDIPINE

INTERGEL PHARMS INC
* INTERGEL PHARMACEUTICALS INC
DUTASTERIDE, DUTASTERIDE

INTERPHARMA PRAHA AS
* INTERPHARMA PRAHA AS
ORALTAG, IOHEXOL

INTERSECT ENT INC
* INTERSECT ENT INC
SINUVA, MOMETASONE FUROATE

INTL MEDICATED
* INTERNATIONAL MEDICATED SYSTEMS LTD
MILRINONE LACTATE, MILRINONE LACTATE

INTL MEDICATION
* INTERNATIONAL MEDICATION SYSTEM
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MANNITOL 25%, MANNITOL
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* INTERNATIONAL MEDICATION SYSTEM
PHYTONADIONE, PHYTONADIONE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
* INTERNATIONAL MEDICATION SYSTEMS LTD
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE

INTL MEDICATION SYS

* INTERNATIONAL MEDICATION SYSTEMS LTD
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
LORAZEPAM, LORAZEPAM
SODIUM BICARBONATE, SODIUM BICARBONATE

INVAGEN PHARMS

* INVAGEN PHARMACEUTICALS INC
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CALCIUM ACETATE, CALCIUM ACETATE
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GABAPENTIN, GABAPENTIN
GEMFIBROZIL, GEMFIBROZIL
GLIMEPIRIDE, GLIMEPIRIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NAPROXEN, NAPROXEN
OLANZAPINE, OLANZAPINE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZONISAMIDE, ZONISAMIDE

INVATECH PHARMA

* INVATECH PHARMA SOLUTIONS LLC
CALCITRIOL, CALCITRIOL
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE

INVENTIA HLTHCARE

* INVENTIA HEALTHCARE PRIVATE LTD
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
ILOPERIDONE, ILOPERIDONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* INVENTIA HEALTHCARE PRIVATE LTD
LANSOPRAZOLE, LANSOPRAZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
TELMISARTAN, TELMISARTAN

IONETIX

* IONETIX CORP
AMMONIA N 13, AMMONIA N-13

IPCA LABS LTD

* IPCA LABORATORIES LTD
ALLOPURINOL, ALLOPURINOL
ATENOLOL, ATENOLOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
FUROSEMIDE, FUROSEMIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM

IPR

* IPR PHARMACEUTICALS INC
CRESTOR, ROSUVASTATIN CALCIUM
ZOMIG, ZOLMITRIPTAN

IPSEN INC

* IPSEN BIOPHARMACEUTICALS INC
INCRELEX, MECASERMIN RECOMBINANT
ONIVYDE, IRINOTECAN HYDROCHLORIDE

IPSEN PHARMA

* IPSEN PHARMA BIOTECH SAS
SOMATULINE DEPOT, LANREOTIDE ACETATE

IROKO PHARMS

* IROKO PHARMACEUTICALS LLC
INDOCIN, INDOMETHACIN

IROKO PHARMS LLC

* IROKO PHARMACEUTICALS LLC
TIVORBEX, INDOMETHACIN
VIVLODEX, MELOXICAM
ZORVOLEX, DICLOFENAC

IRONSHORE PHARMS

* IRONSHORE PHARMACEUTICALS AND DEVELOPMENT INC
JORNAY PM, METHYLPHENIDATE HYDROCHLORIDE

IRONWOOD PHARMS INC

* IRONWOOD PHARMACEUTICALS INC
DUZALLO, ALLOPURINOL
ZURAMPIC, LESINURAD

ISO TEX

* ISO TEX DIAGNOSTICS INC
JEANATOPE, ALBUMIN IODINATED I-125 SERUM
MEGATOPE, ALBUMIN IODINATED I-131 SERUM

ISOTEX

* ISOTEX DIAGNOSTICS
GLOFIL-125, IOTHALAMATE SODIUM I-125

ISTITUTO BIO ITA SPA

* ISTITUTO BIOCHIMICO ITALIANO SPA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
NAFCILLIN SODIUM, NAFCILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* ISTITUTO BIOCHIMICO ITALIANO SPA
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PIPERACILLIN, PIPERACILLIN SODIUM

ITALFARMACO SPA

* ITALFARMACO SPA
TIGLUTIK KIT, RILUZOLE

IVAX PHARMS

* IVAX PHARMACEUTICALS INC
VALSARTAN, VALSARTAN

IVAX PHARMS INC

* IVAX PHARMACEUTICALS INC
OLANZAPINE, OLANZAPINE

IVAX SUB TEVA PHARMS

* IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUMETANIDE, BUMETANIDE
CABERGOLINE, CABERGOLINE
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLOZAPINE, CLOZAPINE
CYCLOSPORINE, CYCLOSPORINE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
GABAPENTIN, GABAPENTIN
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
INDOMETHACIN, INDOMETHACIN
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
METHYLDOPA, METHYLDOPA
MISOPROSTOL, MISOPROSTOL
NADOLOL, NADOLOL
OXAPROZIN, OXAPROZIN
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

**** J ****

J AND J CONSUMER INC

* JOHNSON AND JOHNSON CONSUMER INC MCNEIL CONSUMER HEALTHCARE DIVISION
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
MOTRIN IB, IBUPROFEN (OTC)
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
SINE-AID IB, IBUPROFEN (OTC)
SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** J ****

* JOHNSON AND JOHNSON CONSUMER INC MCNEIL CONSUMER HEALTHCARE DIVISION
TYLENOL, ACETAMINOPHEN (OTC)
ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)

JACOBUS

* JACOBUS PHARMACEUTICAL CO
DAPSONE, DAPSONE
PASER, AMINOSALICYLIC ACID

JANSSEN BIOTECH

* JANSSEN BIOTECH INC
ERLEADA, APALUTAMIDE
ZYTIGA, ABIRATERONE ACETATE

JANSSEN PHARMS

* JANSSEN PHARMACEUTICALS INC
AXERT, ALMOTRIPTAN MALATE
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
DITROPAN XL, OXYBUTYNIN CHLORIDE
DURAGESIC-100, FENTANYL
DURAGESIC-12, FENTANYL
DURAGESIC-25, FENTANYL
DURAGESIC-37, FENTANYL
DURAGESIC-50, FENTANYL
DURAGESIC-75, FENTANYL
ELMIRON, PENTOSAN POLYSULFATE SODIUM
HALDOL, HALOPERIDOL DECANOATE
HALDOL, HALOPERIDOL LACTATE
INVEGA SUSTENNA, PALIPERIDONE PALMITATE
INVEGA TRINZA, PALIPERIDONE PALMITATE
INVEGA, PALIPERIDONE
INVOKAMET XR, CANAGLIFLOZIN
INVOKAMET, CANAGLIFLOZIN
INVOKANA, CANAGLIFLOZIN
MICRONOR, NORETHINDRONE
NIZORAL, KETOCONAZOLE
ORTHO CYCLEN-28, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
RAZADYNE ER, GALANTAMINE HYDROBROMIDE
RAZADYNE, GALANTAMINE HYDROBROMIDE
RISPERDAL CONSTA, RISPERIDONE
RISPERDAL, RISPERIDONE
SPORANOX, ITRACONAZOLE
TOPAMAX, TOPIRAMATE
TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
ULTRACET, ACETAMINOPHEN
ULTRAM, TRAMADOL HYDROCHLORIDE
XARELTO, RIVAROXABAN

JANSSEN PRODS

* JANSSEN PRODUCTS LP
EDURANT, RILPIVIRINE HYDROCHLORIDE
PREZCOBIX, COBICISTAT
PREZISTA, DARUNAVIR ETHANOLATE
SYMTUZA, COBICISTAT
YONDELIS, TRABECTEDIN

JANSSEN R AND D

* JANSSEN RESEARCH AND DEVELOPMENT LLC
INTELENCE, ETRAVIRINE

JANSSEN RES AND DEV

* JANSSEN RESEARCH AND DEVELOPMENT LLC
DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE

JANSSEN THERAP

* JANSSEN THERAPEUTICS DIV JANSSEN PRODUCTS LP

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** J ****

* JANSSEN THERAPEUTICS DIV JANSSEN PRODUCTS LP
SIRTURO, BEDAQUILINE FUMARATE

JAZZ PHARMS

* JAZZ PHARMACEUTICALS INC
XYREM, SODIUM OXYBATE

JAZZ PHARMS III

* JAZZ PHARMACEUTICALS III INTERNATIONAL LTD
FAZACLO ODT, CLOZAPINE

JAZZ PHARMS INC

* JAZZ PHARMACEUTICALS INC
DEFITELIO, DEFIBROTIDE SODIUM

JIANGSU HANSOH PHARM

* JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
VINORELBINE TARTRATE, VINORELBINE TARTRATE

JIANGSU HENGRUI MED

* JIANGSU HENGRUI MEDICINE CO LTD
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
GABAPENTIN, GABAPENTIN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LETROZOLE, LETROZOLE
OXALIPLATIN, OXALIPLATIN
THIOTEPA, THIOTEPA

JOHNS HOPKINS UNIV

* JOHNS HOPKINS UNIV
AMMONIA N 13, AMMONIA N-13

JOHNSON AND JOHNSON

* JOHNSON AND JOHNSON CONSUMER INC
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISINE, NAPHAZOLINE HYDROCHLORIDE (OTC)
* JOHNSON AND JOHNSON GROUP CONSUMER COMPANIES
MEN'S ROGAINE, MINOXIDIL (OTC)
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
WOMEN'S ROGAINE, MINOXIDIL (OTC)
* JOHNSON AND JOHNSON HEALTHCARE PRODUCTS DIV MCNEIL-PPC INC
NIZORAL A-D, KETOCONAZOLE (OTC)

JOURNEY

* JOURNEY MEDICAL CORP
EXELDERM, SULCONAZOLE NITRATE

JUBILANT CADISTA

* JUBILANT CADISTA PHARMACEUTICALS INC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMOTRIGINE, LAMOTRIGINE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
PREDNISONE, PREDNISONE
PROCOMP, PROCHLORPERAZINE MALEATE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

JUBILANT DRAXIMAGE

* JUBILANT DRAXIMAGE INC
DRAX EXAMETAZIME, TECHNETIUM TC-99M EXAMETAZIME KIT
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
DTPA, TECHNETIUM TC-99M PENTETATE KIT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** J ****

* JUBILANT DRAXIMAGE INC
HICON, SODIUM IODIDE I-131
RUBY-FILL, RUBIDIUM CHLORIDE RB-82
SODIUM IODIDE I 131, SODIUM IODIDE I-131
* JUBILANT DRAXIMAGE RADIOPHARMACIES INC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
* JUBILANT DRAXIMAGE USA INC
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

JUBILANT GENERICS

* JUBILANT GENERICS LTD
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CELECOXIB, CELECOXIB
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FELODIPINE, FELODIPINE
INDOMETHACIN, INDOMETHACIN
IRBESARTAN, IRBESARTAN
ITRACONAZOLE, ITRACONAZOLE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NIACIN, NIACIN
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RISPERIDONE, RISPERIDONE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SPIRONOLACTONE, SPIRONOLACTONE
TELMISARTAN, TELMISARTAN
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALSARTAN, VALSARTAN
ZOLMITRIPTAN, ZOLMITRIPTAN

JUBILANT HOLLISTRSTR

* JUBILANT HOLLISTERSTIER LLC
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

STEVENS J

* JEROME STEVENS PHARMACEUTICALS INC
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
DIGOXIN, DIGOXIN
METHOCARBAMOL AND ASPIRIN, ASPIRIN
UNITHROID, LEVOTHYROXINE SODIUM **

**** K ****

GRIFFEN

* KW GRIFFEN CO
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)

KADMON PHARMS LLC

* KADMON PHARMACEUTICALS LLC
RIBASPHERE, RIBAVIRIN
RIBAVIRIN, RIBAVIRIN

KAI PHARMS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** K ****

* KAI PHARMACEUTICALS INC A WHOLLY OWNED SUBSIDIARY OF AMGEN INC
PARSABIV, ETELCALCETIDE

KALA PHARMS INC

* KALA PHARMACEUTICALS INC
INVELTYS, LOTEPREDNOL ETABONATE

KALEO INC

* KALEO INC
AUVI-Q, EPINEPHRINE
EVZIO, NALOXONE HYDROCHLORIDE

KEMPHARM

* KEMPHARM INC
APADAZ, ACETAMINOPHEN

KERYX BIOPHARMS

* KERYX BIOPHARMACEUTICALS INC
AURYXIA, FERRIC CITRATE

KETTERING MEDCTR

* KETTERING MEDCTR
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

KING PHARMS

* KING PHARMACEUTICALS INC
SYNERCID, DALFOPRISTIN
* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT LLC
CYTOMEL, LIOTHYRONINE SODIUM
LEVOXYL, LEVOTHYROXINE SODIUM **
TUSSIGON, HOMATROPINE METHYLBROMIDE
* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT LLC A SUB OF PFIZER INC
SKELAXIN, METAXALONE

KING PHARMS LLC

* KING PHARMACEUTICALS LLC
ALTACE, RAMIPRIL
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
CORZIDE, BENDROFLUMETHIAZIDE
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
SILVADENE, SILVER SULFADIAZINE
TAPAZOLE, METHIMAZOLE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE

KITOV PHARMS LTD

* KITOV PHARMACEUTICALS LTD
CONSENSI, AMLODIPINE BESYLATE

KNIGHT THERAPS

* KNIGHT THERAPEUTICS USA INC
IMPAVIDO, MILTEFOSINE

KOWA CO

* KOWA CO LTD
LIVALO, PITAVASTATIN CALCIUM

KREITCHMAN PET CTR

* KREITCHMAN PET CENTER
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

KRKA TOVARNA ZDRAVIL

* KRKA TOVARNA ZDRAVIL DD NOVO MESTO
LANSOPRAZOLE, LANSOPRAZOLE

KVK TECH

* KVK TECH INC
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
KALEXATE, SODIUM POLYSTYRENE SULFONATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** K ****

* KVK TECH INC
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

KVK TECH INC

* KVK TECH INC
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

KYOWA KIRIN

* KYOWA KIRIN INC
FARESTON, TOREMIFENE CITRATE
SANCUSO, GRANISETRON

KYTHERA BIOPHARMS

* KYTHERA BIOPHARMACEUTICALS INC
KYBELLA, DEOXYCHOLIC ACID

**** L ****

L PERRIGO CO

* L PERRIGO CO
CIMETIDINE, CIMETIDINE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

LA JOLLA PHARMA

* LA JOLLA PHARMA LLC
GIAPREZA, ANGIOTENSIN II ACETATE

LAB HRA PHARMA

* LABORATOIRE HRA PHARMA
ELLA, ULIPRISTAL ACETATE

LABORATOIRE HRA

* LABORATOIRE HRA PHARMA
LYSODREN, MITOTANE

LABORATORIE HRA

* LABORATORIE HRA PHARMA
METOPIRONE, METYRAPONE

LABORATORIOS GRIFOLS

* LABORATORIOS GRIFOLS SA
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

LABORATORIOS SALVAT

* LABORATORIOS SALVAT SA
OTOVEL, CIPROFLOXACIN HYDROCHLORIDE

LABS LEON FARMA

* LABORATORIOS LEON FARMA SA
ALTAVERA, ETHINYL ESTRADIOL
ELIFEMME, ETHINYL ESTRADIOL
ESTARYLLA, ETHINYL ESTRADIOL
INTROVALE, ETHINYL ESTRADIOL
ISIBLOOM, DESOGESTREL
JAIMIESS, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LORYNA, DROSPIRENONE
SYEDA, DROSPIRENONE
TRI-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL
VIENVA, ETHINYL ESTRADIOL
VOLNEA, DESOGESTREL

LABS LICONSA

* LABORATORIOUS LICONSA SA
LANSOPRAZOLE, LANSOPRAZOLE

LANDELA PHARM

* LANDELA PHARMACEUTICAL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LANDELA PHARMACEUTICAL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

LANNETT

* LANNETT CO INC
ACETAZOLAMIDE, ACETAZOLAMIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
LANIAZID, ISONIAZID
LANORINAL, ASPIRIN
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE
PROBALAN, PROBENECID

LANNETT CO INC

* LANNETT CO INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETIC ACID, ACETIC ACID, GLACIAL
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BACLOFEN, BACLOFEN
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CODEINE SULFATE, CODEINE SULFATE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DANAZOL, DANAZOL
DEXAMETHASONE, DEXAMETHASONE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DRONABINOL, DRONABINOL
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
GLYCOLAX, POLYETHYLENE GLYCOL 3350
GLYCOLAX, POLYETHYLENE GLYCOL 3350 (OTC)
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCORTISONE, HYDROCORTISONE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LACTULOSE, LACTULOSE
LAMIVUDINE, LAMIVUDINE
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
LOPINAVIR AND RITONAVIR, LOPINAVIR
LORATADINE, LORATADINE (OTC)
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LANNETT CO INC
METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METAXALONE, METAXALONE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MONOKET, ISOSORBIDE MONONITRATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MORPHINE SULFATE, MORPHINE SULFATE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NIACIN, NIACIN
NYSTATIN, NYSTATIN
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE, PREDNISOLONE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
RISPERIDONE, RISPERIDONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SUMATRIPTAN, SUMATRIPTAN
TEMOZOLOMIDE, TEMOZOLOMIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
THEOPHYLLINE, THEOPHYLLINE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
URSODIOL, URSODIOL
VALPROIC ACID, VALPROIC ACID
ZAROXOLYN, METOLAZONE

LANTHEUS MEDCL

* LANTHEUS MEDICAL IMAGING INC
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
DEFINITY, PERFLUTREN
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
XENON XE 133, XENON XE-133

LANTHEUS MEDICAL

* LANTHEUS MEDICAL IMAGING INC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

LARKEN LABS

* LARKEN LABORATORIES INC
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
OFLOXACIN, OFLOXACIN

LARKEN LABS INC

* LARKEN LABORATORIES INC
ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
ALLZITAL, ACETAMINOPHEN
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
DEXAMETHASONE, DEXAMETHASONE

LAURUS LABS LTD

* LAURUS LABS LTD
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

LAVIPHARM LABS

* LAVIPHARM LABORATORIES INC
FENTANYL-100, FENTANYL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** L **

* LAVIPHARM LABORATORIES INC
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL

LEADIANT BIOSCI INC

* LEADIANT BIOSCIENCES INC
ABELCET, AMPHOTERICIN B
ADAGEN, PEGADEMASE BOVINE
CARNITOR SF, LEVOCARNITINE
CARNITOR, LEVOCARNITINE
CYSTARAN, CYSTEAMINE HYDROCHLORIDE
MATULANE, PROCARBAZINE HYDROCHLORIDE

LEADING PHARMA LLC

* LEADING PHARMA LLC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
NIFEDIPINE, NIFEDIPINE

LEO LABS

* LEO LABORATORIES LTD
PICATO, INGENOL MEBUTATE

LEO PHARMA AS

* LEO PHARMA AS
DESONATE, DESONIDE
DOVONEX, CALCIPOTRIENE
ENSTILAR, BETAMETHASONE DIPROPIONATE
FINACEA, AZELAIC ACID
PROTOPIC, TACROLIMUS
TACLONEX, BETAMETHASONE DIPROPIONATE

LEXICON PHARMS INC

* LEXICON PHARMACEUTICALS INC
XERMELO, TELOTRISTAT ETIPRATE

LG CHEM LTD

* LG CHEM LTD
FACTIVE, GEMIFLOXACIN MESYLATE

LIEBEL-FLARSHEIM

* LIEBEL-FLARSHEIM CO LLC
CONRAY 43, IOTHALAMATE MEGLUMINE
CONRAY, IOTHALAMATE MEGLUMINE
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
OPTIRAY 240, IOVERSOL
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

LIFE MOLECULAR

* LIFE MOLECULAR IMAGING SA
NEURACEQ, FLORBETABEN F-18

LIFEPHARMA

* LIFEPHARMA FZE
LACTULOSE, LACTULOSE

LNK

* LNK INTERNATIONAL INC
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

LNK INTL INC

* LNK INTERNATIONAL INC
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** L **

LOREAL USA

* LOREAL USA PRODUCTS INC
ANTHELIOS 20, AVOBENZONE (OTC)
ANTHELIOS 40, AVOBENZONE (OTC)
ANTHELIOS SX, AVOBENZONE (OTC)
CAPITAL SOLEIL 15, AVOBENZONE (OTC)

LOTUS PHARM CO LTD

* LOTUS PHARMACEUTICAL CO LTD
ROWEEPRA, LEVETIRACETAM

* LOTUS PHARMACEUTICAL CO LTD NANTOU PLANT
CALCIUM ACETATE, CALCIUM ACETATE
LEVETIRACETAM, LEVETIRACETAM
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL, LEVONORGESTREL (OTC)
PARICALCITOL, PARICALCITOL

LOXO ONCOLOGY INC

* LOXO ONCOLOGY INC
VITRAKVI, LAROTRECTINIB

LUITPOLD

* LUITPOLD PHARMACEUTICALS INC
ACETYLCYSTEINE, ACETYLCYSTEINE
ADENOSINE, ADENOSINE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUSULFAN, BUSULFAN
CAFFEINE CITRATE, CAFFEINE CITRATE
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYCLOSPORINE, CYCLOSPORINE
DACTINOMYCIN, DACTINOMYCIN
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXFERRUM, IRON DEXTRAN
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
EPINEPHRINE, EPINEPHRINE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ETOMIDATE, ETOMIDATE
FLOXURIDINE, FLOXURIDINE
FOMEPIZOLE, FOMEPIZOLE
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
GANCICLOVIR, GANCICLOVIR SODIUM
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
INJECTAFER, FERRIC CARBOXYMALTOSE
LEVETIRACETAM, LEVETIRACETAM
LEVOCARNITINE, LEVOCARNITINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MANNITOL 25%, MANNITOL
METHOCARBAMOL, METHOCARBAMOL
METHYLDOPATE HYDROCHLORIDE, METHYLDOPATE HYDROCHLORIDE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LUITPOLD PHARMACEUTICALS INC
METOPROLOL TARTRATE, METOPROLOL TARTRATE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NITROGLYCERIN, NITROGLYCERIN
OLANZAPINE, OLANZAPINE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROGESTERONE, PROGESTERONE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
VENOFER, IRON SUCROSE
ZIDOVUDINE, ZIDOVUDINE

LUKARE MEDICAL LLC

* LUKARE MEDICAL LLC
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE

LUNDBECK NA LTD

* LUNDBECK NA LTD
NORTHERA, DROXIDOPA

LUNDBECK PHARMS LLC

* LUNDBECK PHARMACEUTICALS LLC
ONFI, CLOBAZAM
SABRIL, VIGABATRIN

LUPIN

* LUPIN INC
SOLOSEC, SECNIDAZOLE
TOBRAMYCIN, TOBRAMYCIN

* LUPIN LTD
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFPROZIL, CEFPROZIL
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOVASTATIN, LOVASTATIN
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
TOPIRAMATE, TOPIRAMATE
TRANDOLAPRIL, TRANDOLAPRIL

LUPIN ATLANTIS

* LUPIN ATLANTIS HOLDINGS SA
ANTARA (MICRONIZED), FENOFIBRATE
BUDESONIDE, BUDESONIDE
DESOXIMETASONE, DESOXIMETASONE
MIBELAS 24 FE, ETHINYL ESTRADIOL
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

LUPIN LTD

* LUPIN LIMITED

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LUPIN LIMITED
LEVETIRACETAM, LEVETIRACETAM
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
* LUPIN LTD
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE
AMABELZ, ESTRADIOL
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
ARMODAFINIL, ARMODAFINIL
ATOVAQUONE, ATOVAQUONE
AZITHROMYCIN, AZITHROMYCIN
BEKYREE, DESOGESTREL
BIMATOPROST, BIMATOPROST
BLISOVI 24 FE, ETHINYL ESTRADIOL
BLISOVI FE 1.5/30, ETHINYL ESTRADIOL
BLISOVI FE 1/20, ETHINYL ESTRADIOL
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CALCIUM ACETATE, CALCIUM ACETATE
CELECOXIB, CELECOXIB
CIPROFLOXACIN, CIPROFLOXACIN
CLARITHROMYCIN, CLARITHROMYCIN
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DAYSEE, ETHINYL ESTRADIOL
DECITABINE, DECITABINE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENSKYCE, DESOGESTREL
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESZOPICLONE, ESZOPICLONE
FALLBACK SOLO, LEVONORGESTREL (OTC)
FAMOTIDINE, FAMOTIDINE
FAYOSIM, ETHINYL ESTRADIOL
FENOFIBRATE, FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FYAVOLV, ETHINYL ESTRADIOL
GABAPENTIN, GABAPENTIN
GATIFLOXACIN, GATIFLOXACIN
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
JENCYCLA, NORETHINDRONE
KAITLIB FE, ETHINYL ESTRADIOL
KURVELO, ETHINYL ESTRADIOL
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LUPIN LTD
MEFENAMIC ACID, MEFENAMIC ACID
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NIACIN, NIACIN
NIKKI, DROSPIRENONE
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OMEPRAZOLE, OMEPRAZOLE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIRMELLA 1/35, ETHINYL ESTRADIOL
PIRMELLA 7/7/7, ETHINYL ESTRADIOL
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUININE SULFATE, QUININE SULFATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RIFABUTIN, RIFABUTIN
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILODOSIN, SILODOSIN
SUPRAX, CEFIXIME
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TESTOSTERONE, TESTOSTERONE
TETRABENAZINE, TETRABENAZINE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TYDEMY, DROSPIRENONE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VYFEMLA, ETHINYL ESTRADIOL
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

LUPIN PHARMS
* LUPIN PHARMACEUTICALS INC
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
DESLORATADINE, DESLORATADINE
MELOXICAM, MELOXICAM
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
RIFAMPIN, RIFAMPIN
SUPRAX, CEFIXIME
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

LYMOL MEDCL
* LYMOL MEDICAL CORP
SCLEROSOL, TALC
TALC, TALC

LYNE
* LYNE LABORATORIES INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
LEVOCARNITINE, LEVOCARNITINE
NYSTATIN, NYSTATIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** L **

PERRIGO

* L PERRIGO CO
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
FAMOTIDINE, FAMOTIDINE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)
MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
TAB-PROFEN, IBUPROFEN (OTC)
TIOCONAZOLE, TIOCONAZOLE (OTC)

** M **

MA GENERAL HOSP

* MASSACHUSETTS GENERAL HOSP
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

MACLEODS PHARMS LTD

* MACLEODS PHARMACEUTICALS LTD
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CELECOXIB, CELECOXIB
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DARIFENACIN, DARIFENACIN HYDROBROMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTACAPONE, ENTACAPONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESZOPICLONE, ESZOPICLONE
FAMCICLOVIR, FAMCICLOVIR
FLUOCINONIDE, FLUOCINONIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NEVIRAPINE, NEVIRAPINE
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RISEDRONATE SODIUM, RISEDRONATE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MACLEODS PHARMACEUTICALS LTD
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILODOSIN, SILODOSIN
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRIAMCINOLONE ACETATE, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLMITRIPTAN, ZOLMITRIPTAN

MAGNA PHARMS

* MAGNA PHARMACEUTICALS INC
ZOLPIMIST, ZOLPIDEM TARTRATE

MAIA PHARMS INC

* MAIA PHARMACEUTICALS INC
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE

MAINPOINTE

* MAINPOINTE PHARMACEUTICALS LLC
TUXARIN ER, CHLORPHENIRAMINE MALEATE

MALLINCKRODT ARD

* MALLINCKRODT ARD INC
H.P. ACTHAR GEL, CORTICOTROPIN

MALLINCKRODT HOSP

* MALLINCKRODT HOSP PRODUCTS IP LTD
INOMAX, NITRIC OXIDE
OFIRMEV, ACETAMINOPHEN
UVADEX, METHOXSALEN

MALLINKRODT NUCLEAR

* MALLINCKRODT NUCLEAR MEDICINE LLC
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
SODIUM IODIDE I 123, SODIUM IODIDE I-123
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNESCAN, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
XENON XE 133, XENON XE-133

MANNKIND

* MANNKIND CORP
AFREZZA, INSULIN RECOMBINANT HUMAN

MARINA BIOTECH

* MARINA BIOTECH INC
PRESTALIA, AMLODIPINE BESYLATE

MARKSANS PHARMA

* MARKSANS PHARMA LTD
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE, DUTASTERIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
IBUPROFEN, IBUPROFEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MARKSANS PHARMA LTD
IBUPROFEN, IBUPROFEN (OTC)
LORATADINE, LORATADINE (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
PARICALCITOL, PARICALCITOL

MARNEL PHARMS

* MARNEL PHARMACEUTICALS LLC
CROTAN, CROTAMITON

MAYER LABS INC

* MAYER LABORATORIES INC
TODAY, NONOXYNOL-9 (OTC)

MAYNE PHARMA

* MAYNE PHARMA INTERNATIONAL PTY LTD
DORYX MPC, DOXYCYCLINE HYCLATE
DORYX, DOXYCYCLINE HYCLATE
ERYC, ERYTHROMYCIN

* MAYNE PHARMA LLC
BUDESONIDE, BUDESONIDE
CAMILA, NORETHINDRONE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CLARITHROMYCIN, CLARITHROMYCIN
CLONIDINE, CLONIDINE
CLOZAPINE, CLOZAPINE
CYCLOSPORINE, CYCLOSPORINE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ERRIN, NORETHINDRONE
ESTAZOLAM, ESTAZOLAM
ESTRADIOL, ESTRADIOL
FABIOR, TAZAROTENE
FENTANYL-100, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
FLUOROURACIL, FLUOROURACIL
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LOW-OGESTREL-28, ETHINYL ESTRADIOL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN 1/20, ETHINYL ESTRADIOL
MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
SORILUX, CALCIPOTRIENE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRIMETHOPRIM, TRIMETHOPRIM
TRIVORA-28, ETHINYL ESTRADIOL
ZOVIA 1/35E-28, ETHINYL ESTRADIOL

MAYNE PHARMA INC

* MAYNE PHARMA INC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MAYNE PHARMA INC
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DOFETILIDE, DOFETILIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NYSTATIN, NYSTATIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

MAYNE PHARMA INTL
* MAYNE PHARMA INTERNATIONAL PTY LTD
TOLSURA, ITRACONAZOLE

MCGUFF
* MCGUFF PHARMACEUTICALS INC
ASCOR, ASCORBIC ACID

MCNEIL
* MCNEIL CONSUMER PRODUCTS CO DIV MCNEILAB INC
IBUPROFEN, IBUPROFEN (OTC)

MCNEIL CONS
* MCNEIL CONSUMER HEALTHCARE
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

MCPRF
* MAYO CLINIC PET RADIOCHEMISTRY FACILITY
AMMONIA N 13, AMMONIA N-13
CHOLINE C-11, CHOLINE C-11
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MDGH
* MEDICINES DEVELOPMENT FOR GLOBAL HEALTH
MOXIDECTIN, MOXIDECTIN

MEDAC PHARMA INC
* MEDAC PHARMA INC
RASUVO, METHOTREXATE

MEDEFIL INC
* MEDEFIL INC
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE

MEDICINES360
* MEDICINES360
LILETTA, LEVONORGESTREL

MEDICIS
* MEDICIS PHARMACEUTICAL CORP
ALDARA, IMIQUIMOD
AMMONUL, SODIUM BENZOATE
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
LOPROX, CICLOPIROX
LUZU, LULICONAZOLE
METROGEL-VAGINAL, METRONIDAZOLE
MINITRAN, NITROGLYCERIN
SOLODYN, MINOCYCLINE HYDROCHLORIDE
VANOS, FLUOCINONIDE
ZIANA, CLINDAMYCIN PHOSPHATE
ZYCLARA, IMIQUIMOD

MEDICURE
* MEDICURE INTERNATIONAL INC
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE

MEDIMETRIKS PHARMS
* MEDIMETRIKS PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MEDIMETRIKS PHARMACEUTICALS INC
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
LOPROX, CICLOPIROX
NEO-SYNALAR, FLUOCINOLONE ACETONIDE
SYNALAR, FLUOCINOLONE ACETONIDE

MEDLINE INDUSTRIES

* MEDLINE INDUSTRIES INC
READYPREP CHG, CHLORHEXIDINE GLUCONATE (OTC)

MEDTECH PRODUCTS

* MEDTECH PRODUCTS INC
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
NIX, PERMETHRIN (OTC)
TAGAMET HB, CIMETIDINE (OTC)

MELINTA

* MELINTA SUBSIDIARY CORP
BAXDELA, DELAFLOXACIN MEGLUMINE

MELINTA THERAP

* MELINTA THERAPEUTICS INC
ORBACTIV, ORITAVANCIN DIPHOSPHATE

MEM SLOAN-KETTERING

* MEMORIAL SLOAN-KETTERING CANCER CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

MERCK

* MERCK AND CO INC
CANCIDAS, CASPOFUNGIN ACETATE
EMEND, APREPITANT
FOSAMAX PLUS D, ALENDRONATE SODIUM
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
PRIMAXIN, CILASTATIN SODIUM
PROSCAR, FINASTERIDE
ZOLINZA, VORINOSTAT

* MERCK RESEARCH LABORATORIES DIV MERCK CO INC
PRINIVIL, LISINOPRIL
PROPECIA, FINASTERIDE
SINGULAIR, MONTELUKAST SODIUM
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE

MERCK AND CO INC

* MERCK AND CO INC
EMEND, FOSAPREPITANT DIMEGLUMINE
FOSAMAX, ALENDRONATE SODIUM

MERCK SHARP DOHME

* MERCK SHARP AND DOHME CORP
ASMANEX HFA, MOMETASONE FUROATE
ASMANEX TWISTHALER, MOMETASONE FUROATE
BELSOMRA, SUVOREXANT
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CLARINEX D 24 HOUR, DESLORATADINE
CLARINEX, DESLORATADINE
CLARINEX-D 12 HOUR, DESLORATADINE
COZAAR, LOSARTAN POTASSIUM
CRIXIVAN, INDINAVIR SULFATE
DIPROLENE AF, BETAMETHASONE DIPROPIONATE
DIPROLENE, BETAMETHASONE DIPROPIONATE
DULERA, FORMOTEROL FUMARATE
ELOCON, MOMETASONE FUROATE
GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE
HYZAAR, HYDROCHLOROTHIAZIDE
INVANZ, ERTAPENEM SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MERCK SHARP AND DOHME CORP
ISENTRESS HD, RALTEGRAVIR POTASSIUM
ISENTRESS, RALTEGRAVIR POTASSIUM
JANUMET XR, METFORMIN HYDROCHLORIDE
JANUMET, METFORMIN HYDROCHLORIDE
JANUVIA, SITAGLIPTIN PHOSPHATE
LOTRISONE, BETAMETHASONE DIPROPIONATE
NASONEX, MOMETASONE FUROATE
NOXAFIL, POSACONAZOLE
PREVYMIS, LETERMOVIR
REBETOL, RIBAVIRIN
SEGLUROMET, ERTUGLIFLOZIN
SINEMET CR, CARBIDOPA
SINEMET, CARBIDOPA
STEGLATRO, ERTUGLIFLOZIN
STEGLUJAN, ERTUGLIFLOZIN
STROMECTOL, IVERMECTIN
TEMODAR, TEMOZOLOMIDE
ZEPATIER, ELBASVIR

MERIDIAN MEDCL
* MERIDIAN MEDICAL TECHNOLOGIES INC
DUODOTE, ATROPINE

MERIDIAN MEDCL TECHN
* MERIDIAN MEDICAL TECHNOLOGIES INC
ATROPEN, ATROPINE SULFATE
MORPHINE SULFATE, MORPHINE SULFATE
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE
SEIZALAM, MIDAZOLAM HYDROCHLORIDE

MERLION PHARMS GMBH
* MERLION PHARMACEUTICALS GMBH
XTORO, FINAFLOXACIN

MERRO PHARM
* MERRO PHARMACEUTICAL CO LTD
IBUPROFEN, IBUPROFEN (OTC)

MERZ PHARMS
* MERZ PHARMACEUTICALS LLC
CUVPOSA, GLYCOPYRROLATE

METHAPHARM
* METHAPHARM INC
PROVOCHOLINE, METHACHOLINE CHLORIDE

METUCHEN PHARMS
* METUCHEN PHARMACEUTICALS LLC
STENDRA, AVANAFIL

MICRO LABS
* MICRO LABS LTD
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
CAFFEINE CITRATE, CAFFEINE CITRATE
CELECOXIB, CELECOXIB
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
MEFENAMIC ACID, MEFENAMIC ACID
METHAZOLAMIDE, METHAZOLAMIDE
PIROXICAM, PIROXICAM
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
TELMISARTAN, TELMISARTAN
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

MICRO LABS LTD
* MICRO LABS LTD
NEVIRAPINE, NEVIRAPINE

MICRO LABS LTD INDIA
* MICRO LABS LTD INDIA
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
CROMOLYN SODIUM, CROMOLYN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MICRO LABS LTD INDIA
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

MIDATECH PHARMA US

* MIDATECH PHARMA US INC
ORAVIG, MICONAZOLE
SOLTAMOX, TAMOXIFEN CITRATE
ZUPLENZ, ONDANSETRON

MIDWEST MEDCL

* MIDWEST MEDICAL ISOTOPES LLC CYCLOTRON DIV
AMMONIA N 13, AMMONIA N-13
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MIKART

* MIKART LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BENZONATATE, BENZONATATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTAPAP, ACETAMINOPHEN
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CHLORZOXAZONE, CHLORZOXAZONE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
ETHOSUXIMIDE, ETHOSUXIMIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
ISONIAZID, ISONIAZID
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

MIKART INC

* MIKART INC
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN

MILLENNIUM PHARMS

* MILLENNIUM PHARMACEUTICALS INC
NINLARO, IXAZOMIB CITRATE
VELCADE, BORTEZOMIB

MILLICENT

* MILLICENT HOLDINGS LTD
FEMRING, ESTRADIOL ACETATE

MIPS CRF

* MIPS CYCLOTRON AND RADIOCHEMISTRY FACILITY
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MISSION PHARMA

* MISSION PHARMACAL CO
BINOSTO, ALENDRONATE SODIUM
LITHOSTAT, ACETOHYDROXAMIC ACID
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
TEXACORT, HYDROCORTISONE
THIOLA, TIOPRONIN
TINDAMAX, TINIDAZOLE
UROCIT-K, POTASSIUM CITRATE

MISSION PHARMACAL CO

* MISSION PHARMACAL CO
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)

MIST PHARMS LLC

* MIST PHARMACEUTICALS LLC
NITROMIST, NITROGLYCERIN

MITSUBISHI TANABE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MITSUBISHI TANABE PHARMA CORP
RADICAVA, EDARAVONE

MOBERG PHARMA NORTH

* MOBERG PHARMA NORTH AMERICA LLC
CHILDREN'S ELIXSURE, IBUPROFEN (OTC)

MOBIUS THERAP

* MOBIUS THERAPEUTICS LLC
MITOSOL, MITOMYCIN

MOLNLYCKE HLTH

* MOLNLYCKE HEALTH CARE
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)

MONARCH PHARMS

* MONARCH PHARMACEUTICALS LLC
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE ACETATE
MENEST, ESTROGENS, ESTERIFIED
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSPORIN, GRAMICIDIN
SEPTRA DS, SULFAMETHOXAZOLE
SEPTRA, SULFAMETHOXAZOLE
VIROPTIC, TRIFLURIDINE

MONTEREY PHARMS LLC

* MONTEREY PHARMACEUTICALS LLC
METHOCARBAMOL, METHOCARBAMOL

MOUNTAIN

* MOUNTAIN LLC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
METAXALONE, METAXALONE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE

MSD INTL

* MSD INTERNATIONAL GMBH
VYTORIN, EZETIMIBE

MSD INTL GMBH

* MSD INTERNATIONAL GMBH
ZETIA, EZETIMIBE

MSD MERCK CO

* MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC
DELSTRIGO, DORAVIRINE
EMEND, APREPITANT
PIFELTRO, DORAVIRINE
SINGULAIR, MONTELUKAST SODIUM
ZOCOR, SIMVASTATIN

MSN LABS PVT LTD

* MSN LABORATORIES PRIVATE LTD
CAPECITABINE, CAPECITABINE
CLOFARABINE, CLOFARABINE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILODOSIN, SILODOSIN

MURTY PHARMS

* MURTY PHARMACEUTICALS INC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE

MUSTAFA NEVZAT ILAC

* MUSTAFA NEVZAT ILAC SANAYII AS (MN PHARMACEUTICALS)
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

MUTUAL PHARM

* MUTUAL PHARMACEUTICAL CO INC
PREDNISONE, PREDNISONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

MYLAN

* MYLAN PHARMACEUTICALS
FENOFIBRATE, FENOFIBRATE
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRANEXAMIC ACID, TRANEXAMIC ACID

* MYLAN PHARMACEUTICALS INC
ACARBOSE, ACARBOSE
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALLOPURINOL, ALLOPURINOL
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
AVITA, TRETINOIN
AZATHIOPRINE, AZATHIOPRINE
AZITHROMYCIN, AZITHROMYCIN
BACLOFEN, BACLOFEN
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BUDESONIDE, BUDESONIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CIMETIDINE, CIMETIDINE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLOZAPINE, CLOZAPINE
CYSTAGON, CYSTEAMINE BITARTRATE
DIAZEPAM, DIAZEPAM
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN PHARMACEUTICALS INC
ESTRADIOL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
ETIDRONATE DISODIUM, ETIDRONATE DISODIUM
ETOPOSIDE, ETOPOSIDE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FELODIPINE, FELODIPINE
FENOFIBRATE, FENOFIBRATE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FUROSEMIDE, FUROSEMIDE
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLIPIZIDE, GLIPIZIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
INDAPAMIDE, INDAPAMIDE
INDOMETHACIN, INDOMETHACIN
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LAMOTRIGINE, LAMOTRIGINE
LATANOPROST, LATANOPROST
LEVETIRACETAM, LEVETIRACETAM
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LORATADINE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOVASTATIN, LOVASTATIN
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MENTAX, BUTENAFINE HYDROCHLORIDE
MERCAPTOPURINE, MERCAPTOPURINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METOLAZONE, METOLAZONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIRTAZAPINE, MIRTAZAPINE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN PHARMACEUTICALS INC
NADOLOL, NADOLOL
NAPROXEN, NAPROXEN
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
NISOLDIPINE, NISOLDIPINE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
PHENYTEK, PHENYTOIN SODIUM
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PROBENECID, PROBENECID
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
STAVUDINE, STAVUDINE
SULINDAC, SULINDAC
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TACROLIMUS, TACROLIMUS
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TEMAZEPAM, TEMAZEPAM
THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
URSODIOL, URSODIOL
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZONISAMIDE, ZONISAMIDE

MYLAN ASI

* MYLAN ASI LLC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ADENOSINE, ADENOSINE
AZITHROMYCIN, AZITHROMYCIN
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN ASI LLC
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

MYLAN INSTITUTIONAL

* MYLAN INSTITUTIONAL INC
SULFAMYLON, MAFENIDE ACETATE

* MYLAN INSTITUTIONAL LLC
ACETYLCYSTEINE, ACETYLCYSTEINE
ALOPRIM, ALLOPURINOL SODIUM
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ARGATROBAN, ARGATROBAN
AZACITIDINE, AZACITIDINE
BIVALIRUDIN, BIVALIRUDIN
CARBOPLATIN, CARBOPLATIN
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CIDOFOVIR, CIDOFOVIR
COSYNTROPIN, COSYNTROPIN
DANTROLENE SODIUM, DANTROLENE SODIUM
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DURACLON, CLONIDINE HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
FOMEPIZOLE, FOMEPIZOLE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
ISOSULFAN BLUE, ISOSULFAN BLUE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PENTOSTATIN, PENTOSTATIN
RIMSO-50, DIMETHYL SULFOXIDE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
ULTIVA, REMIFENTANIL HYDROCHLORIDE

MYLAN IRELAND LTD

* MYLAN IRELAND LTD
ARIXTRA, FONDAPARINUX SODIUM
CARBAMAZEPINE, CARBAMAZEPINE
MIACALCIN, CALCITONIN SALMON
PIROXICAM, PIROXICAM
THEOPHYLLINE, THEOPHYLLINE
YUPELRI, REVEFENACIN

MYLAN LABS

* MYLAN LABORATORIES LTD
NEVIRAPINE, NEVIRAPINE

MYLAN LABS LTD

* MYLAN LABORATORIES LTD
ADENOSINE, ADENOSINE
AMIFOSTINE, AMIFOSTINE
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN LABORATORIES LTD
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
AZITHROMYCIN, AZITHROMYCIN
BACLOFEN, BACLOFEN
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
BUSULFAN, BUSULFAN
CAPREOMYCIN SULFATE, CAPREOMYCIN SULFATE
CARBOPLATIN, CARBOPLATIN
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CIMDUO, LAMIVUDINE
CISPLATIN, CISPLATIN
CLADRIBINE, CLADRIBINE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOFARABINE, CLOFARABINE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYTARABINE, CYTARABINE
DACTINOMYCIN, DACTINOMYCIN
DAPTOMYCIN, DAPTOMYCIN
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DOCETAXEL, DOCETAXEL
DOCETAXEL, DOCETAXEL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
EPTIFIBATIDE, EPTIFIBATIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ETOMIDATE, ETOMIDATE
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUMAZENIL, FLUMAZENIL
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
GANCICLOVIR, GANCICLOVIR SODIUM
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM, HEPARIN SODIUM
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LINEZOLID, LINEZOLID
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MITOMYCIN, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN LABORATORIES LTD
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARICALCITOL, PARICALCITOL
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
SYMFI, EFAVIRENZ
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

MYLAN PHARMS INC

* MYLAN PHARMACEUTICALS INC
ABACAVIR SULFATE, ABACAVIR SULFATE
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACITRETIN, ACITRETIN
ACYCLOVIR, ACYCLOVIR
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMNESTEEM, ISOTRETINOIN
ARMODAFINIL, ARMODAFINIL
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
AVITA, TRETINOIN
BACLOFEN, BACLOFEN
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CABERGOLINE, CABERGOLINE
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CAPECITABINE, CAPECITABINE
CAPTOPRIL, CAPTOPRIL
CELECOXIB, CELECOXIB
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOZAPINE, CLOZAPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN PHARMACEUTICALS INC
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DENAVIR, PENCICLOVIR
DESLORATADINE, DESLORATADINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIGOXIN, DIGOXIN
DISULFIRAM, DISULFIRAM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
EFAVIRENZ, EFAVIRENZ
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ELIMITE, PERMETHRIN
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EPLERENONE, EPLERENONE
EPROSARTAN MESYLATE, EPROSARTAN MESYLATE
ERYGEL, ERYTHROMYCIN
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESTRADIOL, ESTRADIOL
ESZOPICLONE, ESZOPICLONE
EVOCLIN, CLINDAMYCIN PHOSPHATE
EXEMESTANE, EXEMESTANE
EXTINA, KETOCONAZOLE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUOROURACIL, FLUOROURACIL
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
GABAPENTIN, GABAPENTIN
GATIFLOXACIN, GATIFLOXACIN
GLATIRAMER ACETATE, GLATIRAMER ACETATE
GLIPIZIDE, GLIPIZIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
INDOMETHACIN, INDOMETHACIN
ITRACONAZOLE, ITRACONAZOLE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LINEZOLID, LINEZOLID
LITHIUM CARBONATE, LITHIUM CARBONATE
LUXIQ, BETAMETHASONE VALERATE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MESALAMINE, MESALAMINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN PHARMACEUTICALS INC
MODAFINIL, MODAFINIL
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
NABUMETONE, NABUMETONE
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NEVIRAPINE, NEVIRAPINE
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OLUX E, CLOBETASOL PROPIONATE
OLUX, CLOBETASOL PROPIONATE
OMEPRAZOLE, OMEPRAZOLE
PALIPERIDONE, PALIPERIDONE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PERPHENAZINE, PERPHENAZINE
PHENYTOIN, PHENYTOIN
PINDOLOL, PINDOLOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRASUGREL, PRASUGREL HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISONE, PREDNISONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
QUININE SULFATE, QUININE SULFATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RASAGILINE MESYLATE, RASAGILINE MESYLATE
REPAGLINIDE, REPAGLINIDE
RILUZOLE, RILUZOLE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
RUFINAMIDE, RUFINAMIDE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
SYMFI LO, EFAVIRENZ
TADALAFIL, TADALAFIL
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOBRAMYCIN, TOBRAMYCIN
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAVOPROST, TRAVOPROST
TRETINOIN, TRETINOIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIAZOLAM, TRIAZOLAM
TRILYTE, POLYETHYLENE GLYCOL 3350
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VORICONAZOLE, VORICONAZOLE
VUSION, MICONAZOLE NITRATE
ZIDOVUDINE, ZIDOVUDINE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN PHARMACEUTICALS INC
ZONALON, DOXEPIN HYDROCHLORIDE
ZOVIRAX, ACYCLOVIR
* MYLAN PHARMACEUTICALS INC.
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
NIZATIDINE, NIZATIDINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

MYLAN SPECIALITY LP

* MYLAN SPECIALTY LP
ACCUNEB, ALBUTEROL SULFATE
AEROSPAN HFA, FLUNISOLIDE
ANADROL-50, OXYMETHOLONE
ASTELIN, AZELASTINE HYDROCHLORIDE
ASTEPRO, AZELASTINE HYDROCHLORIDE
AVC, SULFANILAMIDE
BUTISOL SODIUM, BUTABARBITAL SODIUM
CESAMET, NABILONE
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
CORTIFOAM, HYDROCORTISONE ACETATE
CROMOLYN SODIUM, CROMOLYN SODIUM
DEMADEX, TORSEMIDE
DEPEN, PENICILLAMINE
DIPENTUM, OLSALAZINE SODIUM
DYMISTA, AZELASTINE HYDROCHLORIDE
EDLUAR, ZOLPIDEM TARTRATE
ELESTRIN, ESTRADIOL
EPIFOAM, HYDROCORTISONE ACETATE
EPIPEN JR., EPINEPHRINE
EPIPEN, EPINEPHRINE
FELBATOL, FELBAMATE
GASTROCROM, CROMOLYN SODIUM
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
MUSE, ALPROSTADIL
PROCTOFOAM HC, HYDROCORTISONE ACETATE
ROWASA, MESALAMINE
SFROWASA, MESALAMINE
SOMA, CARISOPRODOL
TOBI PODHALER, TOBRAMYCIN
TOBI, TOBRAMYCIN

MYLAN SPECLT

* MYLAN SPECIALTY LP
PERFOROMIST, FORMOTEROL FUMARATE

MYLAN TECHNOLOGIES

* MYLAN TECHNOLOGIES INC
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CLONIDINE, CLONIDINE
ESTRADIOL, ESTRADIOL
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL
LIDOCAINE, LIDOCAINE
NITROGLYCERIN, NITROGLYCERIN
RIVASTIGMINE, RIVASTIGMINE
XULANE, ETHINYL ESTRADIOL

MYLAN TEORANTA

* MYLAN TEORANTA
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM

**** N ****

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

NALPROPION
* NALPROPION PHARMACEUTICALS INC
CONTRAVE, BUPROPION HYDROCHLORIDE

NAMIGEN LLC
* NAMIGEN LLC
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE

NANG KUANG PHARM CO
* NANG KUANG PHARMACEUTICAL CO LTD
LINEZOLID, LINEZOLID

NANJING KING-FRIEND
* NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO LTD
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
CARBOPLATIN, CARBOPLATIN
HEPARIN SODIUM, HEPARIN SODIUM

NAPO PHARMS INC
* NAPO PHARMACEUTICALS INC
MYTESI, CROFELEMER

NATCO PHARMA
* NATCO PHARMA LTD
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

NATCO PHARMA LTD
* NATCO PHARMA LIMITED
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
* NATCO PHARMA LTD
ALPRAZOLAM, ALPRAZOLAM
ANASTROZOLE, ANASTROZOLE
ARMODAFINIL, ARMODAFINIL
AZACITIDINE, AZACITIDINE
CARISOPRODOL, CARISOPRODOL
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
GLYCOPYRROLATE, GLYCOPYRROLATE
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LANTHANUM CARBONATE, LANTHANUM CARBONATE
LETROZOLE, LETROZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

NAVINTA LLC
* NAVINTA LLC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CARMUSTINE, CARMUSTINE
FAMOTIDINE, FAMOTIDINE
FOMEPIZOLE, FOMEPIZOLE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
METHOCARBAMOL, METHOCARBAMOL
RIBAVIRIN, RIBAVIRIN
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

NCM USA BRONX LLC
* NCM USA BRONX LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

NEOPHARMA
* NEOPHARMA INC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMOXIL, AMOXICILLIN
ANASTROZOLE, ANASTROZOLE
AUGMENTIN '125', AMOXICILLIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NEOPHARMA INC
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN XR, AMOXICILLIN
IRBESARTAN, IRBESARTAN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LAROTID, AMOXICILLIN
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE

NEOS THERAP INC
* NEOS THERAPEUTICS INC
HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX, CHLORPHENIRAMINE POLISTIREX

NEOS THERAPS
* NEOS THERAPEUTICS
ADZENYS XR-ODT, AMPHETAMINE

NEOS THERAPS INC
* NEOS THERAPEUTICS INC
ADZENYS ER, AMPHETAMINE
COTEMPLA XR-ODT, METHYLPHENIDATE

NEPHRON
* NEPHRON CORP
ALBUTEROL SULFATE, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
* NEPHRON PHARMACEUTICALS CORP
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE

NESHER PHARMS
* NESHER PHARMACEUTICALS USA LLC
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
MICRO-K 10, POTASSIUM CHLORIDE
MICRO-K, POTASSIUM CHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NYSTATIN, NYSTATIN
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

NEUROCRINE
* NEUROCRINE BIOSCIENCES INC
INGREZZA, VALBENAZINE TOSYLATE

NEW RIVER
* NEW RIVER PHARMACEUTICALS INC
PROFERDEX, IRON DEXTRAN

NEXGEN PHARMA
* NEXGEN PHARMA INC
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHENODIOL, CHENODIOL
GLYCOPYRROLATE, GLYCOPYRROLATE
MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)

NEXGEN PHARMA INC
* NEXGEN PHARMA INC
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350

NEXTWAVE PHARMS
* NEXTWAVE PHARMACEUTICALS INC
QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE
QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE

NEXUS PHARMS
* NEXUS PHARMACEUTICALS INC
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** N **

* NEXUS PHARMACEUTICALS INC
BUSULFAN, BUSULFAN
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE

NIAGARA PHARMS

* NIAGARA PHARMACEUTICALS INC
PUR-WASH, PURIFIED WATER (OTC)

NODEN PHARMA

* NODEN PHARMA DAC
TEKTURNA HCT, ALISKIREN HEMIFUMARATE
TEKTURNA, ALISKIREN HEMIFUMARATE

NORTEC DEV ASSOC

* NORTEC DEVELOPMENT ASSOC INC
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

NORTHLAND

* NORTHLAND NUCLEAR MEDICINE LLC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

NORTHSTAR HLTHCARE

* NORTHSTAR HEALTHCARE HOLDINGS LTD
ALLOPURINOL, ALLOPURINOL
BACLOFEN, BACLOFEN
GEMFIBROZIL, GEMFIBROZIL
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

NORTHSTAR MEDICAL

* NORTHSTAR MEDICAL RADIOISOTOPES LLC
RADIOGENIX SYSTEM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

NORTON WATERFORD

* NORTON WATERFORD LTD
QVAR REDIHALER, BECLOMETHASONE DIPROPIONATE

NOSTRUM LABS INC

* NOSTRUM LABORATORIES INC
ACETAZOLAMIDE, ACETAZOLAMIDE
CALCIUM ACETATE, CALCIUM ACETATE
CARISOPRODOL, CARISOPRODOL
DAPSONE, DAPSONE
ELIXOPHYLLIN, THEOPHYLLINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NITROFURANTOIN, NITROFURANTOIN
PINDOLOL, PINDOLOL
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

NOSTRUM PHARMS LLC

* NOSTRUM PHARMACEUTICALS LLC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
THEOCHRON, THEOPHYLLINE

NOVA LABS LTD

* NOVA LABORATORIES LTD
PURIXAN, MERCAPTOPURINE

NOVADAQ TECH

* NOVADAQ TECHNOLOGIES ULC
SPY AGENT GREEN KIT, INDOCYANINE GREEN

NOVARTIS

* NOVARTIS PHARMACEUTICALS CORP
AFINITOR, EVEROLIMUS
COARTEM, ARTEMETHER
DESFERAL, DEFEROXAMINE MESYLATE
DIOVAN HCT, HYDROCHLOROTHIAZIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NOVARTIS PHARMACEUTICALS CORP
DIOVAN, VALSARTAN
EXELON, RIVASTIGMINE
EXELON, RIVASTIGMINE TARTRATE
EXFORGE HCT, AMLODIPINE BESYLATE
EXFORGE, AMLODIPINE BESYLATE
EXJADE, DEFERASIROX
FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
GILENYA, FINGOLIMOD HYDROCHLORIDE
GLEEVEC, IMATINIB MESYLATE
LAMISIL, TERBINAFINE HYDROCHLORIDE
LESCOL XL, FLUVASTATIN SODIUM
LOPRESSOR, METOPROLOL TARTRATE
LOTREL, AMLODIPINE BESYLATE
MYFORTIC, MYCOPHENOLIC ACID
NEORAL, CYCLOSPORINE
RECLAST, ZOLEDRONIC ACID
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SANDOSTATIN, OCTREOTIDE ACETATE
SIGNIFOR, PASIREOTIDE DIASPARTATE
STARLIX, NATEGLINIDE
TASIGNA, NILOTINIB HYDROCHLORIDE
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TRILEPTAL, OXCARBAZEPINE
VIVELLE-DOT, ESTRADIOL
VOLTAREN, DICLOFENAC SODIUM
ZOMETA, ZOLEDRONIC ACID
ZORTRESS, EVEROLIMUS

NOVARTIS PHARM

* NOVARTIS PHARMACEUTICAL CORP
AFINITOR DISPERZ, EVEROLIMUS

NOVARTIS PHARMS

* NOVARTIS PHARMACEUTICALS CORP
FEMARA, LETROZOLE

NOVARTIS PHARMS CORP

* NOVARTIS PHARMACEUTICALS CORP
ALOMIDE, LODOXAMIDE TROMETHAMINE
ARGATROBAN, ARGATROBAN
ARRANON, NELARABINE
AZOPT, BRINZOLAMIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRODEX, CIPROFLOXACIN
DUREZOL, DIFLUPREDNATE
EMADINE, EMEDASTINE DIFUMARATE
ENTRESTO, SACUBITRIL
FARYDAK, PANOBINOSTAT LACTATE
FLAREX, FLUOROMETHOLONE ACETATE
HYCAMTIN, TOPOTECAN HYDROCHLORIDE
ILEVRO, NEPAFENAC
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
JADENU SPRINKLE, DEFERASIROX
JADENU, DEFERASIROX
KISQALI FEMARA CO-PACK (COPACKAGED), LETROZOLE
KISQALI, RIBOCICLIB SUCCINATE
MAXIDEX, DEXAMETHASONE
MAXITROL, DEXAMETHASONE
MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NOVARTIS PHARMACEUTICALS CORP
MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
MYDRIACYL, TROPICAMIDE
NATACYN, NATAMYCIN
NEVANAC, NEPAFENAC
OMNIPRED, PREDNISOLONE ACETATE
PATADAY, OLOPATADINE HYDROCHLORIDE
PATANASE, OLOPATADINE HYDROCHLORIDE
PATANOL, OLOPATADINE HYDROCHLORIDE
PAZEO, OLOPATADINE HYDROCHLORIDE
PROMACTA KIT, ELTROMBOPAG OLAMINE
PROMACTA, ELTROMBOPAG OLAMINE
RYDAPT, MIDOSTAURIN
SIGNIFOR LAR KIT, PASIREOTIDE PAMOATE
SIMBRINZA, BRIMONIDINE TARTRATE
TAFINLAR, DABRAFENIB MESYLATE
TOBRADEX ST, DEXAMETHASONE
TOBRADEX, DEXAMETHASONE
TOBREX, TOBRAMYCIN
TRAVATAN Z, TRAVOPROST
TRIESENCE, TRIAMCINOLONE ACETONIDE
TYKERB, LAPATINIB DITOSYLATE
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
VOTRIENT, PAZOPANIB HYDROCHLORIDE
ZOFRAN ODT, ONDANSETRON
ZOFRAN, ONDANSETRON HYDROCHLORIDE
ZYKADIA, CERITINIB

NOVAST LABS

* NOVAST LABORATORIES CHINA LTD
NORETHINDRONE, NORETHINDRONE
* NOVAST LABORATORIES LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
HER STYLE, LEVONORGESTREL (OTC)
INDOMETHACIN, INDOMETHACIN
LARIN 1.5/30, ETHINYL ESTRADIOL
LARIN 1/20, ETHINYL ESTRADIOL
LARIN 24 FE, ETHINYL ESTRADIOL
LARIN FE 1.5/30, ETHINYL ESTRADIOL
LARIN FE 1/20, ETHINYL ESTRADIOL
LERIBANE, ETHINYL ESTRADIOL
MAFENIDE ACETATE, MAFENIDE ACETATE
MALMOREDE, ETHINYL ESTRADIOL
MELAMISA, DROSPIRENONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NADOLOL, NADOLOL
NIFEDIPINE, NIFEDIPINE
NORETHINDRONE, NORETHINDRONE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PIMTREA, DESOGESTREL
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
PROBENECID AND COLCHICINE, COLCHICINE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUININE SULFATE, QUININE SULFATE
SETLAKIN, ETHINYL ESTRADIOL
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
YAELA, DROSPIRENONE

NOVAST LABS LTD

* NOVAST LABORATORIES LTD
DASETTA 1/35, ETHINYL ESTRADIOL
DASETTA 7/7/7, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NOVAST LABORATORIES LTD
ELINEST, ETHINYL ESTRADIOL
FALMINA, ETHINYL ESTRADIOL
LEVONEST, ETHINYL ESTRADIOL
MONO-LINYAH, ETHINYL ESTRADIOL
PHILITH, ETHINYL ESTRADIOL
TRI-LINYAH, ETHINYL ESTRADIOL
WERA, ETHINYL ESTRADIOL

NOVATECH SA

* NOVATECH SA
STERITALC, TALC

NOVEL LABS INC

* NOVEL LABORATORIES INC
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
CALCIPOTRIENE, CALCIPOTRIENE
CARBIDOPA, CARBIDOPA
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESOXIMETASONE, DESOXIMETASONE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
FAMOTIDINE, FAMOTIDINE
FLUCYTOSINE, FLUCYTOSINE
FLUOCINONIDE, FLUOCINONIDE
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
LEVONORGESTREL, LEVONORGESTREL (OTC)
LINEZOLID, LINEZOLID
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MISOPROSTOL, MISOPROSTOL
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
PHENELZINE SULFATE, PHENELZINE SULFATE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, MAGNESIUM SULFATE
TEMAZEPAM, TEMAZEPAM
TINIDAZOLE, TINIDAZOLE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIMETHOPRIM, TRIMETHOPRIM
VORICONAZOLE, VORICONAZOLE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

NOVELGENIX THERAPS

* NOVELGENIX THERAPEUTICS PVT LTD
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

NOVEN

* NOVEN PHARMACEUTICALS INC
MINIVELLE, ESTRADIOL

NOVEN PHARMS INC

* NOVEN PHARMACEUTICALS INC
COMBIPATCH, ESTRADIOL
DAYTRANA, METHYLPHENIDATE

NOVITIUM PHARMA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NOVITIUM PHARMA LLC
DAPSONE, DAPSONE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
RANITIDINE, RANITIDINE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

NOVO
* NOVO NORDISK INC
FIASP FLEXTOUCH, INSULIN ASPART
FIASP, INSULIN ASPART
MACRILEN, MACIMORELIN ACETATE
OZEMPIC, SEMAGLUTIDE
RYZODEG 70/30, INSULIN ASPART
SAXENDA, LIRAGLUTIDE RECOMBINANT
TRESIBA, INSULIN DEGLUDEC
XULTOPHY 100/3.6, INSULIN DEGLUDEC

NOVO NORDISK
* NOVO NORDISK PHARMACEUTICALS INC
GLUCAGEN, GLUCAGON HYDROCHLORIDE

NOVO NORDISK INC
* NOVO NORDISK INC
LEVEMIR FLEXTOUCH, INSULIN DETEMIR RECOMBINANT
LEVEMIR, INSULIN DETEMIR RECOMBINANT
NORDITROPIN FLEXPRO, SOMATROPIN RECOMBINANT
NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLOG FLEXPEN, INSULIN ASPART RECOMBINANT
NOVOLOG MIX 70/30 FLEXPEN, INSULIN ASPART PROTAMINE RECOMBINANT
NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT
NOVOLOG PENFILL, INSULIN ASPART RECOMBINANT
NOVOLOG, INSULIN ASPART RECOMBINANT
VAGIFEM, ESTRADIOL
VICTOZA, LIRAGLUTIDE RECOMBINANT

NOVOCOL INC
* NOVOCOL INC
DYCLOPRO, DYCLONINE HYDROCHLORIDE

NPS PHARMS INC
* NPS PHARMACEUTICALS INC
GATTEX KIT, TEDUGLUTIDE RECOMBINANT

NUVO PHARM
* NUVO PHARMACEUTICAL INC
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

NUVO PHARMS INC
* NUVO PHAMACEUTICALS INC
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
FOLIC ACID, FOLIC ACID
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

NXDC
* NX DEVELOPMENT CORP
GLEOLAN, AMINOLEVULINIC ACID HYDROCHLORIDE

NYCOMED US
* NYCOMED US INC
TERCONAZOLE, TERCONAZOLE

**** O ****

OAK PHARMS
* OAK PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** O ****

* OAK PHARMACEUTICALS INC
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
XYLOCAINE, LIDOCAINE HYDROCHLORIDE

OAK PHARMS AKORN

* OAK PHARMACEUTICALS INC SUB AKORN INC
COGENTIN, BENZTROPINE MESYLATE
DIURIL, CHLOROTHIAZIDE SODIUM

OAK PHARMS INC

* OAK PHARMACEUTICALS INC
ZIOPTAN, TAFLUPROST
* OAK PHARMACEUTICALS INC SUBSIDIARY OF AKORN INC
AZASITE, AZITHROMYCIN
BETIMOL, TIMOLOL
COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
COSOPT, DORZOLAMIDE HYDROCHLORIDE
XOPENEX, LEVALBUTEROL HYDROCHLORIDE

OC PHARMA

* OC PHARMA LLC
LEVONORGESTREL, LEVONORGESTREL (OTC)
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

OCULAR THERAPEUTIX

* OCULAR THERAPEUTIX INC
DEXTENZA, DEXAMETHASONE

ODYSSEY PHARMS

* ODYSSEY PHARMACEUTICALS INC
ANTABUSE, DISULFIRAM
SURMONTIL, TRIMIPRAMINE MALEATE
URECHOLINE, BETHANECHOL CHLORIDE
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE

OHM

* OHM CORP
IBUPROFEN, IBUPROFEN (OTC)

OHM LABS

* OHM LABORATORIES INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
IBUPROHM, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

OHM LABS INC

* OHM LABORATORIES INC
EZETIMIBE, EZETIMIBE
GUAIFENESIN, GUAIFENESIN (OTC)
VALSARTAN, VALSARTAN

OLTA PHARMS

* OLTA PHARMACEUTICALS CORP
LINDANE, LINDANE

OMEROS

* OMEROS CORP
OMIDRIA, KETOROLAC TROMETHAMINE

ONY

* ONY INC
INFASURF PRESERVATIVE FREE, CALFACTANT

ONYX THERAP

* ONYX THERAPEUTICS INC A WHOLLY OWNED SUB OF AMGEN INC
KYPROLIS, CARFILZOMIB

OPKO IRELAND GLOBAL

* OPKO IRELAND GLOBAL HOLDINGS LTD
RAYALDEE, CALCIFEDIOL

OPTINOSE US INC

* OPTINOSE US INC
XHANCE, FLUTICASONE PROPIONATE

ORAPHARMA

* ORAPHARMA INC
ARESTIN, MINOCYCLINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** O **

ORCHID HLTHCARE

* ORCHID HEALTHCARE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ESZOPICLONE, ESZOPICLONE
FELODIPINE, FELODIPINE
GEMIFLOXACIN MESYLATE, GEMIFLOXACIN MESYLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
MODAFINIL, MODAFINIL
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZALEPLON, ZALEPLON

OREXO US INC

* OREXO US INC
ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE

ORGANON SUB MERCK

* ORGANON USA INC A SUB OF MERCK AND CO INC
BRIDION, SUGAMMADEX SODIUM
NUVARING, ETHINYL ESTRADIOL

ORGANON USA INC

* ORGANON USA INC
DESOGEN, DESOGESTREL
FOLLISTIM AQ, FOLLITROPIN ALFA/BETA
GANIRELIX ACETATE, GANIRELIX ACETATE
NEXPLANON, ETONOGESTREL
PREGNYL, GONADOTROPIN, CHORIONIC
REMERON SOLTAB, MIRTAZAPINE
REMERON, MIRTAZAPINE

ORIENT PHARMA CO LTD

* ORIENT PHARMA CO LTD
CARISOPRODOL, CARISOPRODOL
MIGLITOL, MIGLITOL
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM

ORION PHARMA

* ORION PHARMA
COMTAN, ENTACAPONE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA

ORIT LABS LLC

* ORIT LABORATORIES LLC
BENZONATATE, BENZONATATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** O ****

* ORIT LABORATORIES LLC
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
ERGOCALCIFEROL, ERGOCALCIFEROL
GLYCOPYRROLATE, GLYCOPYRROLATE
LEVETIRACETAM, LEVETIRACETAM
METRONIDAZOLE, METRONIDAZOLE

ORPHAN EUROPE
* ORPHAN EUROPE
CARBAGLU, CARGLUMIC ACID
* ORPHAN EUROPE SARL
CYSTADANE, BETAINE

OSI PHARMS
* OSI PHARMACEUTICALS INC
TARCEVA, ERLOTINIB HYDROCHLORIDE

OSMOTICA
* OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

OSMOTICA PHARM
* OSMOTICA PHARMACEUTICAL
OSMOLEX ER, AMANTADINE HYDROCHLORIDE
* OSMOTICA PHARMACEUTICAL CORP
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

OSMOTICA PHARM CORP
* OSMOTICA PHARMACEUTICAL CORP
KHEDEZLA, DESVENLAFAXINE

OSMOTICA PHARM US
* OSMOTICA PHARMACEUTICAL US LLC
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

OTONOMY INC
* OTONOMY INC
OTIPRIO, CIPROFLOXACIN

OTSUKA
* OTSUKA PHARMACEUTICAL CO LTD
ABILIFY, ARIPIPRAZOLE

OTSUKA AMERICA PHARM
* OTSUKA AMERICA PHARMACEUTICAL INC
SAMSCA, TOLVAPTAN

OTSUKA PHARM
* OTSUKA PHARMACEUTICAL CO LTD
BUSULFEX, BUSULFAN

OTSUKA PHARM CO LTD
* OTSUKA PHARMACEUTICAL CO LTD
ABILIFY MAINTENA KIT, ARIPIPRAZOLE
ABILIFY MYCITE KIT, ARIPIPRAZOLE
DACOGEN, DECITABINE
JYNARQUE, TOLVAPTAN
REXULTI, BREXPIPRAZOLE

OUTLOOK PHARMS
* OUTLOOK PHARMACEUTICALS INC
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE

OXFORD PHARMS
* OXFORD PHARMACEUTICALS LLC
ALPRAZOLAM, ALPRAZOLAM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BACLOFEN, BACLOFEN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** O ****

* OXFORD PHARMACEUTICALS LLC
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LORAZEPAM, LORAZEPAM
METHOCARBAMOL, METHOCARBAMOL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE
RIMACTANE, RIFAMPIN
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE, SPIRONOLACTONE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

**** P ****

P AND L DEV LLC
* P AND L DEVELOPMENT LLC DBA PLD DEVELOPMENTS LLC
IBUPROFEN, IBUPROFEN (OTC)

PACIFIC PHARMA
* PACIFIC PHARMA
TIMOLOL MALEATE, TIMOLOL MALEATE
* PACIFIC PHARMA INC
TIMOLOL MALEATE, TIMOLOL MALEATE

PACIRA PHARMS INC
* PACIRA PHARMACEUTICALS INC
EXPAREL, BUPIVACAINE

PACK PHARMS LLC
* PACK PHARMACEUTICALS LLC
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE

PADDOCK LLC
* PADDOCK LABORATORIES LLC
ATOVAQUONE, ATOVAQUONE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CALCIUM ACETATE, CALCIUM ACETATE
CICLOPIROX, CICLOPIROX
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
COLOCORT, HYDROCORTISONE
COMPRO, PROCHLORPERAZINE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NYSTOP, NYSTATIN
PODOFILOX, PODOFILOX
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
REPAGLINIDE, REPAGLINIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PADDOCK LABORATORIES LLC
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE

PANACEA BIOTEC LTD

* PANACEA BIOTEC LTD
PRASUGREL, PRASUGREL HYDROCHLORIDE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TACROLIMUS, TACROLIMUS

PAR FORM

* PAR FORMULATIONS PRIVATE LTD
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
MAFENIDE ACETATE, MAFENIDE ACETATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

PAR PHARM

* PAR PHARMACEUTICAL
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
TESTOSTERONE, TESTOSTERONE

* PAR PHARMACEUTICAL INC
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
CABERGOLINE, CABERGOLINE
CALCITONIN-SALMON, CALCITONIN SALMON
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLONAZEPAM, CLONAZEPAM
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
ESTAZOLAM, ESTAZOLAM
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUTAMIDE, FLUTAMIDE
GLIPIZIDE, GLIPIZIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROXYUREA, HYDROXYUREA
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LAMOTRIGINE, LAMOTRIGINE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METRONIDAZOLE, METRONIDAZOLE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
NATEGLINIDE, NATEGLINIDE
NIFEDIPINE, NIFEDIPINE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OXANDROLONE, OXANDROLONE
PIMOZIDE, PIMOZIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PAR PHARMACEUTICAL INC
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TORSEMIDE, TORSEMIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRANYLCYPROMINE SULFATE, TRANYLCYPROMINE SULFATE
TRAVOPROST, TRAVOPROST
URSODIOL, URSODIOL
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

PAR PHARM INC

* PAR PHARMACEUTICAL INC
ACCOLATE, ZAFIRLUKAST
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
ANTIZOL, FOMEPIZOLE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
COLCHICINE, COLCHICINE
DEXLANSOPRAZOLE, DEXLANSOPRAZOLE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DOFETILIDE, DOFETILIDE
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
ENTECAVIR, ENTECAVIR
ETHACRYNIC ACID, ETHACRYNIC ACID
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
ITRACONAZOLE, ITRACONAZOLE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PRAZIQUANTEL, PRAZIQUANTEL
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOLCAPONE, TOLCAPONE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VIGABATRIN, VIGABATRIN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

PAR STERILE PRODUCTS

* PAR STERILE PRODUCTS LLC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ADRENALIN, EPINEPHRINE
ARGATROBAN, ARGATROBAN
BREVITAL SODIUM, METHOHEXITAL SODIUM
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
COLY-MYCIN M, COLISTIMETHATE SODIUM
CORPHEDRA, EPHEDRINE SULFATE
DANTRIUM, DANTROLENE SODIUM
DELESTROGEN, ESTRADIOL VALERATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
ETOMIDATE, ETOMIDATE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
GANCICLOVIR, GANCICLOVIR SODIUM
KETALAR, KETAMINE HYDROCHLORIDE
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PAR STERILE PRODUCTS LLC
PITOCIN, OXYTOCIN
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIOSTAT, LIOTHYRONINE SODIUM
VASOSTRICT, VASOPRESSIN

PARAGON BIOTECK
* PARAGON BIOTECK INC
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

PARAPRO LLC
* PARAPRO LLC
NATROBA, SPINOSAD

PARATEK PHARMS INC
* PARATEK PHARMACEUTICALS INC
NUZYRA, OMADACYCLINE TOSYLATE

PARKE DAVIS
* PARKE DAVIS DIV WARNER LAMBERT CO
CELONTIN, METHSUXIMIDE
CEREBYX, FOSPHENYTOIN SODIUM
DILANTIN-125, PHENYTOIN
NARDIL, PHENELZINE SULFATE
NEURONTIN, GABAPENTIN
ZARONTIN, ETHOSUXIMIDE

PARKE-DAVIS
* PARKE-DAVIS DIVISION OF PFIZER INC
DILANTIN, PHENYTOIN SODIUM
ZARONTIN, ETHOSUXIMIDE

PATRIN PHARMA INC
* PATRIN PHARMA INC
FLAC, FLUOCINOLONE ACETONIDE

PERNIX IRELAND LTD
* PERNIX IRELAND LTD
TREXIMET, NAPROXEN SODIUM

PERNIX IRELAND PAIN
* PERNIX IRELAND PAIN LIMITED
ZOHYDRO ER, HYDROCODONE BITARTRATE

PERNIX THERAPS LLC
* PERNIX THERAPEUTICS LLC
SILENOR, DOXEPIN HYDROCHLORIDE

PERRIGO
* PERRIGO CO
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)

PERRIGO CO
* PERRIGO CO OF TENESSEE INC
CICLOPIROX, CICLOPIROX
CLINDETS, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
ERYTHROMYCIN, ERYTHROMYCIN
STIE-CORT, HYDROCORTISONE

PERRIGO CO TENNESSEE
* PERRIGO CO TENNESSEE INC
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN ZINC
ERYTHROMYCIN, ERYTHROMYCIN
GENTAMICIN SULFATE, GENTAMICIN SULFATE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM

PERRIGO ISRAEL
* PERRIGO ISRAEL PHARMACEUTICALS LTD
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PERRIGO ISRAEL PHARMACEUTICALS LTD
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESOXIMETASONE, DESOXIMETASONE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GYNAZOLE-1, BUTOCONAZOLE NITRATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
MESALAMINE, MESALAMINE
MINOXIDIL, MINOXIDIL (OTC)
MOMETASONE FUROATE, MOMETASONE FUROATE
NITROGLYCERIN, NITROGLYCERIN
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
TESTOSTERONE, TESTOSTERONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)

PERRIGO NEW YORK

* PERRIGO NEW YORK INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
AMMONIUM LACTATE, AMMONIUM LACTATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CENTANY, MUPIROCIN
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
KETOCONAZOLE, KETOCONAZOLE
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
NYSTATIN, NYSTATIN
PERMETHRIN, PERMETHRIN
PERMETHRIN, PERMETHRIN (OTC)
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
TERCONAZOLE, TERCONAZOLE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PERRIGO PHARMA INTL

* PERRIGO PHARMA INTERNATIONAL DAC
CLINDESSE, CLINDAMYCIN PHOSPHATE
ENTOCORT EC, BUDESONIDE
EVAMIST, ESTRADIOL
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
TRETINOIN, TRETINOIN

PERRIGO PHARMS CO

* PERRIGO PHARMACEUTICALS CO
SCOPOLAMINE, SCOPOLAMINE

PERRIGO R AND D

* PERRIGO R AND D CO
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PERRIGO R AND D CO
DESLORATADINE, DESLORATADINE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN SODIUM, IBUPROFEN SODIUM (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NAPROXEN, NAPROXEN
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

PERRIGO UK FINCO

* PERRIGO UK FINCO LTD PARTNERSHIP
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ESTRADIOL, ESTRADIOL
FLURANDRENOLIDE, FLURANDRENOLIDE
INGENOL MEBUTATE, INGENOL MEBUTATE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
TESTOSTERONE, TESTOSTERONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PETNET

* PETNET SOLUTIONS INC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

PF PRISM CV

* PF PRISM CV
BOSULIF, BOSUTINIB MONOHYDRATE
CHANTIX, VARENICLINE TARTRATE
INLYTA, AXITINIB
LYRICA CR, PREGABALIN
LYRICA, PREGABALIN
PRISTIQ, DESVENLAFAXINE SUCCINATE
RAPAMUNE, SIROLIMUS
TORISEL, TEMSIROLIMUS
TYGACIL, TIGECYCLINE
VFEND, VORICONAZOLE
XALKORI, CRIZOTINIB
XELJANZ, TOFACITINIB CITRATE

PFIZER

* PFIZER CENTRAL RESEARCH
DIFLUCAN, FLUCONAZOLE
ZITHROMAX, AZITHROMYCIN
* PFIZER CHEMICALS DIV PFIZER INC
DIFLUCAN, FLUCONAZOLE
ZITHROMAX, AZITHROMYCIN
* PFIZER INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PFIZER INC
ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MULTI-SYMPTOM COLD & FLU, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ADVIL, IBUPROFEN (OTC)
ALAVERT, LORATADINE (OTC)
AXID AR, NIZATIDINE (OTC)
CADUET, AMLODIPINE BESYLATE
CALAN SR, VERAPAMIL HYDROCHLORIDE
CARDURA XL, DOXAZOSIN MESYLATE
CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
ELELYSO, TALIGLUCERASE ALFA
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
GLUCOTROL XL, GLIPIZIDE
GLUCOTROL, GLIPIZIDE
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
LIPITOR, ATORVASTATIN CALCIUM
LORATADINE, LORATADINE (OTC)
MERREM, MEROPENEM
NORVASC, AMLODIPINE BESYLATE
PEDIATRIC ADVIL, IBUPROFEN (OTC)
PROCARDIA, NIFEDIPINE
REVATIO, SILDENAFIL CITRATE
SONATA, ZALEPLON
TESSALON, BENZONATATE
TOVIAZ, FESOTERODINE FUMARATE
UNASYN, AMPICILLIN SODIUM
ZITHROMAX, AZITHROMYCIN
* PFIZER LABORATORIES DIV PFIZER INC
CARDURA, DOXAZOSIN MESYLATE
FELDENE, PIROXICAM
MINIPRESS, PRAZOSIN HYDROCHLORIDE
PFIZERPEN, PENICILLIN G POTASSIUM
PROCARDIA XL, NIFEDIPINE
UNASYN, AMPICILLIN SODIUM
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VISTARIL, HYDROXYZINE PAMOATE
* PFIZER PHARMACEUTICALS INC
DILANTIN, PHENYTOIN
ZOLOFT, SERTRALINE HYDROCHLORIDE
* PFIZER PHARMACEUTICALS PRODUCTION CORP LTD
TIKOSYN, DOFETILIDE

PFIZER CONS HLTHCARE

* PFIZER CONSUMER HEALTHCARE
ADVIL, IBUPROFEN SODIUM (OTC)

PFIZER INC

* PFIZER INC
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
DAURISMO, GLASDEGIB
ELLENCE, EPIRUBICIN HYDROCHLORIDE
FRAGMIN, DALTEPARIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

* PFIZER INC
IBRANCE, PALBOCICLIB
LORBRENA, LORLATINIB
NICOTROL, NICOTINE
TALZENNA, TALAZOPARIB TOSYLATE
VIAGRA, SILDENAFIL CITRATE
VIZIMPRO, DACOMITINIB
XELJANZ XR, TOFACITINIB CITRATE

PFIZER IRELAND

* PFIZER IRELAND PHARMACEUTICALS
RELPAX, ELETRIPTAN HYDROBROMIDE

PFIZER PHARMS

* PFIZER PHARMACEUTICALS LTD
ACCUPRIL, QUINAPRIL HYDROCHLORIDE
ACCURETIC, HYDROCHLOROTHIAZIDE
LOPID, GEMFIBROZIL
NEURONTIN, GABAPENTIN
NITROSTAT, NITROGLYCERIN

PHARM ASSOC

* PHARMACEUTICAL ASSOC INC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LORAZEPAM, LORAZEPAM
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
* PHARMACEUTICAL ASSOCIATES INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ETHOSUXIMIDE, ETHOSUXIMIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LACTULOSE, LACTULOSE
LEVETIRACETAM, LEVETIRACETAM
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
THEOPHYLLINE, THEOPHYLLINE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
VALPROIC ACID, VALPROIC ACID

PHARMA RES SOFTWARE

* PHARMA RESEARCH SOFTWARE SOLUTION LLC
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

PHARMACHEMIE BV

* PHARMACHEMIE BV
CARBOPLATIN, CARBOPLATIN
CISPLATIN, CISPLATIN
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM

PHARMACIA AND UPJOHN

* PHARMACIA AND UPJOHN
XANAX XR, ALPRAZOLAM
* PHARMACIA AND UPJOHN CO
AROMASIN, EXEMESTANE
AZULFIDINE EN-TABS, SULFASALAZINE
AZULFIDINE, SULFASALAZINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

* PHARMACIA AND UPJOHN CO
BACITRACIN, BACITRACIN
CAVERJECT IMPULSE, ALPROSTADIL
CAVERJECT, ALPROSTADIL
CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
CORTEF, HYDROCORTISONE
CORVERT, IBUTILIDE FUMARATE
CYKLOKAPRON, TRANEXAMIC ACID
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DETROL LA, TOLTERODINE TARTRATE
DETROL, TOLTERODINE TARTRATE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
ESTRING, ESTRADIOL
GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
GENOTROPIN, SOMATROPIN RECOMBINANT
GLYNASE, GLYBURIDE
GLYSET, MIGLITOL
HALCION, TRIAZOLAM
HEMABATE, CARBOPROST TROMETHAMINE
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
MEDROL, METHYLPREDNISOLONE
MYCOBUTIN, RIFABUTIN
NICOTROL, NICOTINE
OGEN 5, ESTROPIPATE
PREPIDIL, DINOPROSTONE
PROSTIN E2, DINOPROSTONE
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROVERA, MEDROXYPROGESTERONE ACETATE
R-GENE 10, ARGININE HYDROCHLORIDE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOMAVERT, PEGVISOMANT
XALATAN, LATANOPROST
XANAX, ALPRAZOLAM
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZYVOX, LINEZOLID

* PHARMACIA AND UPJOHN SUB PFIZER INC
DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE

PHARMACIA UPJOHN

* PHARMACIA AND UPJOHN CO A SUB OF PFIZER INC
COLESTID, COLESTIPOL HYDROCHLORIDE
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE

PHARMACYCLICS INC

* PHARMACYCLICS INC
IMBRUVICA, IBRUTINIB

PHARMADAX INC

* PHARMADAX INC
GLYBURIDE, GLYBURIDE
LEVETIRACETAM, LEVETIRACETAM
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

PHARMALUCENCE

* PHARMALUCENCE INC
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PHARMALUCENCE INC
HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT

PHARMASCIENCE INC
* PHARMASCIENCE INC
BUSULFAN, BUSULFAN
DECITABINE, DECITABINE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM

PHARMAXIS LTD
* PHARMAXIS LTD
ARIDOL KIT, MANNITOL

PHARMTAK INC
* PHARMTAK INC
LEVETIRACETAM, LEVETIRACETAM

PHOTOCURE ASA
* PHOTOCURE ASA
CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE

PIERRE FABRE
* PIERRE FABRE MEDICAMENT
NAVELBINE, VINORELBINE TARTRATE

PIERRE FABRE DERMA
* PIERRE FABRE DERMATOLOGIE
HEMANGEOL, PROPRANOLOL HYDROCHLORIDE

PIERREL
* PIERREL S.P.A.
ORABLOC, ARTICAINE HYDROCHLORIDE

PII
* PHARMACEUTICS INTERNATIONAL INC
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
HYDROCORTISONE, HYDROCORTISONE
PIROXICAM, PIROXICAM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

PIRAMAL CRITICAL
* PIRAMAL CRITICAL CARE INC
ISOFLURANE, ISOFLURANE
SOJOURN, SEVOFLURANE
* PIRAMAL CRITICAL CARE LTD
GABLOFEN, BACLOFEN
GLYCOPYRROLATE, GLYCOPYRROLATE
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
MITIGO, MORPHINE SULFATE

PIRAMAL ENT
* PIRAMAL ENTERPRISES LTD
ISOFLURANE, ISOFLURANE

PIRAMAL HLTHCARE UK
* PIRAMAL HEALTHCARE UK LTD
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CLOBAZAM, CLOBAZAM

PLD ACQUISITIONS
* PLD ACQUISITIONS LLC DBA AVENA PHARMA SOLUTIONS
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE

PLD ACQUISITIONS LLC
* PLD ACQUISITIONS LLC
LORATADINE, LORATADINE (OTC)
ZOLMITRIPTAN, ZOLMITRIPTAN

PLIVA
* PLIVA INC
AZITHROMYCIN, AZITHROMYCIN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CIMETIDINE, CIMETIDINE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PLIVA INC
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
METRONIDAZOLE, METRONIDAZOLE
NAPROXEN, NAPROXEN
THEOPHYLLINE, THEOPHYLLINE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
WARFARIN SODIUM, WARFARIN SODIUM

PLIVA HRVATSKA DOO
* PLIVA HRVATSKA DOO
ADAPALENE, ADAPALENE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
RISPERIDONE, RISPERIDONE

PLIVA LACHEMA
* PLIVA LACHEMA AS
CARBOPLATIN, CARBOPLATIN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

PLIVA PHARM IND
* PLIVA PHARMACEUTICAL INDUSTRY INC
TORSEMIDE, TORSEMIDE

PLX PHARMA
* PLX PHARMA INC
VAZALORE, ASPIRIN (OTC)

POHL BOSKAMP
* POHL BOSKAMP
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN

POLYGEN PHARMS
* POLYGEN PHARMACEUTICALS INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

POLYMEDICA
* POLYMEDICA INDUSTRIES INC
NEOPAP, ACETAMINOPHEN (OTC)

PORTOLA PHARMS INC
* PORTOLA PHARMACEUTICALS INC
BEVYXXA, BETRIXABAN

POWDER PHARMS
* POWDER PHARMACEUTICALS INC
ZINGO, LIDOCAINE HYDROCHLORIDE

PRAGMA
* PRAGMA PHARMACEUTICALS LLC
KEFLEX, CEPHALEXIN

PRAXAIR DISTRIBUTION
* PRAXAIR DISTRIBUTION INC
NOXIVENT, NITRIC OXIDE

PRECISION DERMAT
* PRECISION DERMATOLOGY INC
CLINDAGEL, CLINDAMYCIN PHOSPHATE
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LOCOID, HYDROCORTISONE BUTYRATE
MINOCIN, MINOCYCLINE HYDROCHLORIDE

PRECISION DOSE INC
* PRECISION DOSE INC
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE

PRECISION NUCLEAR
* PRECISION NUCLEAR LLC
AMMONIA N 13, AMMONIA N-13

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PRECISION NUCLEAR LLC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

PRINSTON INC

* PRINSTON PHARMACEUTICAL INC
ARIPIPRAZOLE, ARIPIPRAZOLE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CAPTOPRIL, CAPTOPRIL
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTECAVIR, ENTECAVIR
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FENOFIBRATE, FENOFIBRATE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FUROSEMIDE, FUROSEMIDE
GLIMEPIRIDE, GLIMEPIRIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LEVETIRACETAM, LEVETIRACETAM
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
NEVIRAPINE, NEVIRAPINE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PAROXETINE MESYLATE, PAROXETINE MESYLATE
PAROXETINE, PAROXETINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TEMAZEPAM, TEMAZEPAM
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE

PROF DSPLS

* PROFESSIONAL DISPOSABLES INC
PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)

PROGENICS PHARMS INC

* PROGENICS PHARMACEUTICALS INC
AZEDRA, IOBENGUANE I-131

PROMIUS PHARMA LLC

* PROMIUS PHARMA LLC
SERNIVO, BETAMETHASONE DIPROPIONATE

PROVELL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PROVELL PHARMACEUTICALS LLC
EUTHYROX, LEVOTHYROXINE SODIUM **

PROVENSIS
* PROVENSIS LTD
VARITHENA, POLIDOCANOL

PROVEPHARM SAS
* PROVEPHARM SAS
PROVAYBLUE, METHYLENE BLUE

PTC THERAP
* PTC THERAPEUTICS INC
EMFLAZA, DEFLAZACORT

PULMOFLOW INC
* PULMOFLOW INC
KITABIS PAK, TOBRAMYCIN

PUMA BIOTECH
* PUMA BIOTECHNOLOGY INC
NERLYNX, NERATINIB MALEATE

PURACAP PHARM
* PURACAP PHARMACEUTICAL LLC
MELOXICAM, MELOXICAM

PURACAP PHARM LLC
* PURACAP PHARMACEUTICAL LLC
BENZONATATE, BENZONATATE
ERGOCALCIFEROL, ERGOCALCIFEROL
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE

PURDUE GMP
* PURDUE GMP CENTER LLC DBA THE CHAO CENTER INDUSTRIAL PHARMACY
SEROMYCIN, CYCLOSERINE

PURDUE PHARMA
* PURDUE PHARMA PRODUCTS LP
INTERMEZZO, ZOLPIDEM TARTRATE

PURDUE PHARMA LP
* PURDUE PHARMA LP
BUTRANS, BUPRENORPHINE
HYSINGLA, HYDROCODONE BITARTRATE
MS CONTIN, MORPHINE SULFATE
OXYCONTIN, OXYCODONE HYDROCHLORIDE

**** Q ****

QILU PHARM CO LTD
* QILU PHARMACEUTICAL CO LTD
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFTRIAXONE, CEFTRIAXONE SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE

QILU TIANHE
* QILU TIANHE PHARMACEUTICAL CO LTD
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM

QINGDAO BAHEAL PHARM
* QINGDAO BAHEAL PHAMACEUTICAL CO LTD
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

QOL MEDCL
* QOL MEDICAL LLC
ETHAMOLIN, ETHANOLAMINE OLEATE
SUCRAID, SACROSIDASE

QUAGEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Q ****

* QUAGEN PHARMACEUTICALS LLC
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

QUEEN HAMAMATSU PET

* QUEEN HAMAMATSU PET IMAGING CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**** R ****

R-PHARM US LLC

* R-PHARM US LLC
IXEMPRA KIT, IXABEPILONE

R2 PHARMA LLC

* R2 PHARMA LLC
ESOMEPRAZOLE STRONTIUM, ESOMEPRAZOLE STRONTIUM

RADIUS HEALTH INC

* RADIUS HEALTH INC
TYMLOS, ABALOPARATIDE

RB HLTH

* RB HEALTH US LLC
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
MUCINEX D, GUAIFENESIN (OTC)
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MUCINEX, GUAIFENESIN (OTC)

RECIP

* RECIP AB
THYROSAFE, POTASSIUM IODIDE (OTC)

RECIPHARM

* RECIPHARM PHARMASERVICES PRIVATE LTD
FLUCYTOSINE, FLUCYTOSINE

RECKITT BENCKISER

* RECKITT BENCKISER LLC
LEVONORGESTREL, LEVONORGESTREL (OTC)

RECORDATI RARE

* RECORDATI RARE DISEASES INC
CHEMET, SUCCIMER
COSMEGEN, DACTINOMYCIN
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
INDOCIN, INDOMETHACIN SODIUM
NEOPROFEN, IBUPROFEN LYSINE
PEGANONE, ETHOTOIN
TRANXENE, CLORAZEPATE DIPOTASSIUM

RECRO GAINESVILLE

* RECRO GAINESVILLE LLC
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERELAN, VERAPAMIL HYDROCHLORIDE

RELYPSA INC

* RELYPSA INC
VELTASSA, PATIROMER SORBITEX CALCIUM

REMPEX PHARMS

* REMPEX PHARMACEUTICALS
MINOCIN, MINOCYCLINE HYDROCHLORIDE
* REMPEX PHARMACEUTICALS A WHOLLY OWNED SUB OF MELINTA THERAPEUTICS INC
VABOMERE, MEROPENEM

RENAISSANCE SSA LLC

* RENAISSANCE SSA LLC
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
METHOCARBAMOL, METHOCARBAMOL
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
OXACILLIN SODIUM, OXACILLIN SODIUM
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** R **

* RENAISSANCE SSA LLC
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE

RENATA

* RENATA LTD
RISPERIDONE, RISPERIDONE

RHODES PHARMS

* RHODES PHARMACEUTICALS LP
APTENSIO XR, METHYLPHENIDATE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
MORPHINE SULFATE, MORPHINE SULFATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE

RICONPHARMA LLC

* RICONPHARMA LLC
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CHLORTHALIDONE, CHLORTHALIDONE
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LIDOCAINE, LIDOCAINE
METHYLPREDNISOLONE, METHYLPREDNISOLONE

RIGEL PHARMS INC

* RIGEL PHARMACEUTICALS INC
TAVALISSE, FOSTAMATINIB DISODIUM

RISING PHARMS

* RISING PHARMACEUTICALS INC
ACETIC ACID, ACETIC ACID, GLACIAL
ALBUTEROL SULFATE, ALBUTEROL SULFATE
BUDESONIDE, BUDESONIDE
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CROMOLYN SODIUM, CROMOLYN SODIUM
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DOXERCALCIFEROL, DOXERCALCIFEROL
DUTASTERIDE, DUTASTERIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
LEVOFLOXACIN, LEVOFLOXACIN
METAXALONE, METAXALONE
METHIMAZOLE, METHIMAZOLE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
PARICALCITOL, PARICALCITOL
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
TEMOZOLOMIDE, TEMOZOLOMIDE
TOREMIFENE CITRATE, TOREMIFENE CITRATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VORICONAZOLE, VORICONAZOLE
ZILEUTON, ZILEUTON

ROCHE PALO

* ROCHE PALO ALTO LLC
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
CYTOVENE, GANCICLOVIR SODIUM

ROCKWELL MEDICAL INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** R **

* ROCKWELL MEDICAL INC
TRIFERIC, FERRIC PYROPHOSPHATE CITRATE

ROMARK
* ROMARK LABORATORIES
ALINIA, NITAZOXANIDE

ROUSES POINT PHARMS
* ROUSES POINT PHARMACEUTICALS LLC
LEVETIRACETAM, LEVETIRACETAM

RP SCHERER
* RP SCHERER TECHNOLOGIES LLC
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

RTRX
* RETROPHIN INC
CHOLBAM, CHOLIC ACID

RUBICON RES PVT LTD
* RUBICON RESEARCH PVT LTD
BACLOFEN, BACLOFEN
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE

RXMTM THERAPS LLC
* RXMTM THERAPEUTICS LLC A WHOLLY OWNED SUB OF CUTISPHARMA INC
FIRVANQ KIT, VANCOMYCIN HYDROCHLORIDE

** S **

SAGE PRODS
* SAGE PRODUCTS INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

SAGENT PHARMS
* SAGENT PHARMACEUTICALS INC
ACETYLCYSTEINE, ACETYLCYSTEINE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CAFFEINE CITRATE, CAFFEINE CITRATE
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
DAPTOMYCIN, DAPTOMYCIN
DECITABINE, DECITABINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
EPTIFIBATIDE, EPTIFIBATIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUMAZENIL, FLUMAZENIL
FLUOROURACIL, FLUOROURACIL
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLYDO, LIDOCAINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
IBANDRONATE SODIUM, IBANDRONATE SODIUM
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
LINEZOLID, LINEZOLID
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MESNA, MESNA
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
NAFCILLIN SODIUM, NAFCILLIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SAGENT PHARMACEUTICALS INC
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXACILLIN SODIUM, OXACILLIN SODIUM
OXYTOCIN, OXYTOCIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PROPOFOL, PROPOFOL
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

SAGENT STRIDES
* SAGENT STRIDES LLC
MIDOZALAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE

SALIX PHARMS
* SALIX PHARMACEUTICALS INC
ANUSOL HC, HYDROCORTISONE
DIURIL, CHLOROTHIAZIDE
MOVIPREP, ASCORBIC ACID
OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
PEPCID, FAMOTIDINE
RELISTOR, METHYLNALTREXONE BROMIDE
XIFAXAN, RIFAXIMIN

SALIX PHARMS INC
* SALIX PHARMACEUTICALS INC
PLENVU, ASCORBIC ACID
RELISTOR, METHYLNALTREXONE BROMIDE

SAMSON MEDCL
* SAMSON MEDICAL TECHNOLOGIES LLC
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFOXITIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
CEFTRIAXONE, CEFTRIAXONE SODIUM
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE

SANDOZ
* SANDOZ
DOCETAXEL, DOCETAXEL
* SANDOZ INC
ALPRAZOLAM, ALPRAZOLAM
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
APREPITANT, APREPITANT
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ATENOLOL, ATENOLOL
AZITHROMYCIN, AZITHROMYCIN
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BUMETANIDE, BUMETANIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CAFERGOT, CAFFEINE
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARVEDILOL, CARVEDILOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANDOZ INC
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFDINIR, CEFDINIR
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFTRIAXONE, CEFTRIAXONE SODIUM
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CLARITHROMYCIN, CLARITHROMYCIN
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
COSYNTROPIN, COSYNTROPIN
CYCLOSPORINE, CYCLOSPORINE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESLORATADINE, DESLORATADINE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
EPLERENONE, EPLERENONE
ETODOLAC, ETODOLAC
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FUROSEMIDE, FUROSEMIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE, GLIPIZIDE
HALOPERIDOL, HALOPERIDOL
HEPARIN SODIUM, HEPARIN SODIUM
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
ISONIAZID, ISONIAZID
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ITRACONAZOLE, ITRACONAZOLE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVOFLOXACIN, LEVOFLOXACIN
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOVASTATIN, LOVASTATIN
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOLAZONE, METOLAZONE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NADOLOL, NADOLOL
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NIZATIDINE, NIZATIDINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANDOZ INC
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OMEPRAZOLE, OMEPRAZOLE
OMNITROPE, SOMATROPIN RECOMBINANT
ONDANSETRON, ONDANSETRON
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXALIPLATIN, OXALIPLATIN
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PERPHENAZINE, PERPHENAZINE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIBAVIRIN, RIBAVIRIN
RIFAMPIN, RIFAMPIN
RISPERIDONE, RISPERIDONE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SULFADIAZINE, SULFADIAZINE
TACROLIMUS, TACROLIMUS
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TEMAZEPAM, TEMAZEPAM
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SANDOZ INC

* SANDOZ INC
ACETAMINOPHEN, ACETAMINOPHEN
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANGIOMAX, BIVALIRUDIN
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BIMATOPROST, BIMATOPROST
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BUDESONIDE, BUDESONIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSULFAN, BUSULFAN
CARBOPLATIN, CARBOPLATIN
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CEFIXIME, CEFIXIME
CEFTRIAXONE, CEFTRIAXONE SODIUM
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CROMOLYN SODIUM, CROMOLYN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANDOZ INC

DECITABINE, DECITABINE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIGOXIN, DIGOXIN
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EZETIMIBE, EZETIMIBE
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
FLUMAZENIL, FLUMAZENIL
GATIFLOXACIN, GATIFLOXACIN
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLATOPA, GLATIRAMER ACETATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
INFUVITE PEDIATRIC, ASCORBIC ACID
ISONIAZID, ISONIAZID
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
LATANOPROST, LATANOPROST
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
LINEZOLID, LINEZOLID
MAXITROL, DEXAMETHASONE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYDRIACYL, TROPICAMIDE
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEVIRAPINE, NEVIRAPINE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OFLOXACIN, OFLOXACIN
OLANZAPINE, OLANZAPINE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PACLITAXEL, PACLITAXEL
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARICALCITOL, PARICALCITOL
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PROGESTERONE, PROGESTERONE
QOLIANA, BRIMONIDINE TARTRATE
RASAGILINE MESYLATE, RASAGILINE MESYLATE
REGONOL, PYRIDOSTIGMINE BROMIDE
RIBAVIRIN, RIBAVIRIN
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILODOSIN, SILODOSIN
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TELMISARTAN, TELMISARTAN
TERIFLUNOMIDE, TERIFLUNOMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANDOZ INC
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TIGECYCLINE, TIGECYCLINE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBREX, TOBRAMYCIN
TREPROSTINIL, TREPROSTINIL
TRIFLURIDINE, TRIFLURIDINE
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SANOCHEMIA CORP USA

* SANOCHEMIA CORP USA
SCANLUX-300, IOPAMIDOL
SCANLUX-370, IOPAMIDOL

SANOFI

* SANOFI GENZYME
HECTOROL, DOXERCALCIFEROL
RENVELA, SEVELAMER CARBONATE

SANOFI AVENTIS US

* SANOFI AVENTIS US INC
JEVTANA KIT, CABAZITAXEL
* SANOFI AVENTIS US LLC
ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
AMARYL, GLIMEPIRIDE
AMBIEN CR, ZOLPIDEM TARTRATE
AMBIEN, ZOLPIDEM TARTRATE
APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT
APIDRA, INSULIN GLULISINE RECOMBINANT
ARAVA, LEFLUNOMIDE
AUBAGIO, TERIFLUNOMIDE
AVALIDE, HYDROCHLOROTHIAZIDE
AVAPRO, IRBESARTAN
CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
DIABETA, GLYBURIDE
ELOXATIN, OXALIPLATIN
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
FLOMAX, TAMSULOSIN HYDROCHLORIDE
GAVISCON, ALUMINUM HYDROXIDE (OTC)
LANTUS SOLOSTAR, INSULIN GLARGINE RECOMBINANT
LANTUS, INSULIN GLARGINE RECOMBINANT
LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
LOVENOX, ENOXAPARIN SODIUM
MULTAQ, DRONEDARONE HYDROCHLORIDE
NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
NICODERM CQ, NICOTINE (OTC)
PLAVIX, CLOPIDOGREL BISULFATE
PRIFTIN, RIFAPENTINE
PRIMAQUINE, PRIMAQUINE PHOSPHATE
RIFADIN, RIFAMPIN
RIFAMATE, ISONIAZID
RIFATER, ISONIAZID
TAXOTERE, DOCETAXEL
XYZAL ALLERGY 24HR, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE

SANOFI US

* SANOFI US
ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)
ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)

SANOFI US SERVICES

* SANOFI US SERVICES INC
TOUJEO MAX SOLOSTAR, INSULIN GLARGINE RECOMBINANT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANOFI US SERVICES INC
TOUJEO SOLOSTAR, INSULIN GLARGINE RECOMBINANT

SANOFI-AVENTIS US

* SANOFI-AVENTIS US LLC
ADLYXIN, LIXISENATIDE
ADMELOG SOLOSTAR, INSULIN LISPRO
ADMELOG, INSULIN LISPRO
SOLIQUA 100/33, INSULIN GLARGINE

SANTARUS INC

* SANTARUS INC
FENOGLIDE, FENOFIBRATE
GLUMETZA, METFORMIN HYDROCHLORIDE
ZEGERID, OMEPRAZOLE

SAOL THERAPS RES LTD

* SAOL THERAPEUTICS RESEARCH LTD
LIORESAL, BACLOFEN

SAREPTA THERAPS INC

* SAREPTA THERAPEUTICS INC
EXONDYS 51, ETEPLIRSEN

SAVIOR LIFETEC CORP

* SAVIOR LIFETEC CORP
MEROPENEM, MEROPENEM

SAWAI USA

* SAWAI USA INC
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM

SB PHARMCO

* SB PHARMCO PUERTO RICO INC
AVANDIA, ROSIGLITAZONE MALEATE

SCHERING

* SCHERING CORP
INTEGRILIN, EPTIFIBATIDE
NOXAFIL, POSACONAZOLE
REBETOL, RIBAVIRIN

SCIECURE PHARMA INC

* SCIECURE PHARMA INC
BUDESONIDE, BUDESONIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE

SCIEGEN PHARMS INC

* SCIEGEN PHARMACEUTICALS INC
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARISOPRODOL, CARISOPRODOL
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE

SCILEX PHARMS INC

* SCILEX PHARMACEUTICALS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SCILEX PHARMACEUTICALS
ZTLIDO, LIDOCAINE

SCINOPHARM TAIWAN

* SCINOPHARM TAIWAN LTD
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM

SCIOS LLC

* SCIOS LLC
NATRECOR, NESIRITIDE RECOMBINANT

SEBELA IRELAND LTD

* SEBELA IRELAND LTD
BRISDELLE, PAROXETINE MESYLATE
IMURAN, AZATHIOPRINE
LOTRONEX, ALOSETRON HYDROCHLORIDE
MICORT-HC, HYDROCORTISONE ACETATE
MOTOFEN, ATROPINE SULFATE
NAFTIN, NAFTIFINE HYDROCHLORIDE
ONMEL, ITRACONAZOLE
PEXEVA, PAROXETINE MESYLATE
PRAMOSONE, HYDROCORTISONE ACETATE
RIDAURA, AURANOFIN

SECAN PHARMS

* SECAN PHARMACEUTICALS INC
LEVETIRACETAM, LEVETIRACETAM

SENTYNL THERAPS INC

* SENTYNL THERAPEUTICS INC
ABSTRAL, FENTANYL CITRATE
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE

SEPTODONT

* SEPTODONT INC
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE

SEPTODONT HOLDING

* SEPTODONT HOLDING SAS
ORAVERSE, PHENTOLAMINE MESYLATE

SEPTODONT INC

* SEPTODONT INC
LIDOCAINE, LIDOCAINE
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE

SERB SA

* SERB SA
CYANOKIT, HYDROXOCOBALAMIN

SETON PHARM

* SETON PHARMACEUTICAL LLC
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE

SETON PHARMS

* SETON PHARMACEUTICALS LLC
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE

SHANDONG XINHUA

* SHANDONG XINHUA PHARMACEUTICAL CO LTD
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)

SHANGHAI DESANO

* SHANGHAI DESANO BIO-PHARMACEUTICALS CO LTD
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE

SHANGHAI HENGRUI

* SHANGHAI HENGRUI PHARMACEUTICAL CO LTD
DESFLURANE, DESFLURANE
SEVOFLURANE, SEVOFLURANE

SHENZHEN TECHDOW

* SHENZHEN TECHDOW PHARMACEUTICAL CO LTD
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM

SHERTECH LABS LLC

* SHERTECH LABORATORIES LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SHERTECH LABORATORIES LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

SHILPA MEDICARE

* SHILPA MEDICARE LTD
AZACITIDINE, AZACITIDINE

SHILPA MEDICARE LTD

* SHILPA MEDICARE LTD
CAPECITABINE, CAPECITABINE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

SHIONOGI INC

* SHIONOGI INC
MULPLETA, LUSUTROMBOPAG
PONSTEL, MEFENAMIC ACID
SYMPROIC, NALDEMEDINE TOSYLATE
ULESFIA, BENZYL ALCOHOL

SHIRE

* SHIRE DEVELOPMENT INC
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
CARBATROL, CARBAMAZEPINE
INTUNIV, GUANFACINE HYDROCHLORIDE
LIALDA, MESALAMINE
PENTASA, MESALAMINE

SHIRE DEV LLC

* SHIRE DEVELOPMENT LLC
FOSRENOL, LANTHANUM CARBONATE
MOTEGRITY, PRUCALOPRIDE SUCCINATE
MYDAYIS, AMPHETAMINE ASPARTATE
VYVANSE, LISDEXAMFETAMINE DIMESYLATE
XIIDRA, LIFITEGRAST

SHIRE DEVELOPMENT

* SHIRE DEVELOPMENT INC
VYVANSE, LISDEXAMFETAMINE DIMESYLATE

SHIRE HUMAN GENETIC

* SHIRE HUMAN GENETIC THERAPIES INC
VPRIV, VELAGLUCERASE ALFA

SHIRE LLC

* SHIRE DEVELOPMENT LLC
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
FOSRENOL, LANTHANUM CARBONATE

SHIRE ORPHAN THERAP

* SHIRE ORPHAN THERAPIES INC
FIRAZYR, ICATIBANT ACETATE

SIDMAK LABS INDIA

* SIDMAK LABORATORIES INDIA PVT LTD
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

SIGA TECHNOLOGIES

* SIGA TECHNOLOGIES INC
TPOXX, TECOVIRIMAT

SIGMAPHARM LABS LLC

* SIGMAPHARM LABORATORIES LLC
ACITRETIN, ACITRETIN
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
ASENAPINE MALEATE, ASENAPINE MALEATE
DISULFIRAM, DISULFIRAM
DOFETILIDE, DOFETILIDE
ERGOCALCIFEROL, ERGOCALCIFEROL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SIGMAPHARM LABORATORIES LLC
FLUCYTOSINE, FLUCYTOSINE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN,ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
NITROGLYCERIN, NITROGLYCERIN
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE

SILVERGATE PHARMS
* SILVERGATE PHARMACEUTICALS INC
EPANED KIT, ENALAPRIL MALEATE
EPANED, ENALAPRIL MALEATE
QBRELIS, LISINOPRIL
XATMEP, METHOTREXATE SODIUM

SINOTHERAPEUTICS INC
* SINOTHERAPEUTICS INC
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE

SKINMEDICA
* SKINMEDICA INC
VANIQA, EFLORNITHINE HYDROCHLORIDE

SKYEPHARMA AG
* SKYEPHARMA AG
TRIGLIDE, FENOFIBRATE

SLAYBACK PHARMA LLC
* SLAYBACK PHARMA LLC
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE

SMITHKLINE BEECHAM
* SMITHKLINE BEECHAM
LOVAZA, OMEGA-3-ACID ETHYL ESTERS
* SMITHKLINE BEECHAM (CORK) LTD IRELAND
COREG CR, CARVEDILOL PHOSPHATE
COREG, CARVEDILOL

SOAPCO
* SOAPCO INC
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)

SOFGEN PHARMS
* SOFGEN PHARMACEUTICALS
NIMODIPINE, NIMODIPINE
* SOFGEN PHARMACEUTICALS LLC
IBUPROFEN, IBUPROFEN (OTC)
PROGESTERONE, PROGESTERONE

SOFIE
* SOFIE CO DBA SOFIE (FKA ZEVACOR PHARMA INC)
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

SOLARIS PHARMA CORP
* SOLARIS PHARMA CORP
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE

SOMERSET
* SOMERSET PHARMACEUTICALS INC
EMSAM, SELEGILINE

SOMERSET THERAPS LLC
* SOMERSET THERAPEUTICS LLC
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
METHOCARBAMOL, METHOCARBAMOL
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SOMERSET THERAPEUTICS LLC
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
TOBRAMYCIN, TOBRAMYCIN
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

SOVEREIGN PHARMS
* SOVEREIGN PHARMACEUTICALS LLC
OBREDON, GUAIFENESIN

SPARC
* SUN PHARMA ADVANCED RESEARCH CO LTD
ELEPSIA XR, LEVETIRACETAM

SPECGX LLC
* SPECGX LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
EXALGO, HYDROMORPHONE HYDROCHLORIDE
FENTANYL CITRATE, FENTANYL CITRATE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
OXYCET, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
RESTORIL, TEMAZEPAM
ROXICODONE, OXYCODONE HYDROCHLORIDE
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

SPECTRA MDCL DEVICES
* SPECTRA MEDICAL DEVICES INC
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE

SPECTRON MRC LLC
* SPECTRON MRC LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

SPECTRUM PHARMS
* SPECTRUM PHARMACEUTICALS INC
BELEODAQ, BELINOSTAT
EVOMELA, MELPHALAN HYDROCHLORIDE
FUSILEV, LEVOLEUCOVORIN CALCIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SPECTRUM PHARMACEUTICALS INC
KHAPZORY, LEVOLEUCOVORIN

SPIL
* SUN PHARMA INDUSTRIES LTD
KAPSPARGO SPRINKLE, METOPROLOL SUCCINATE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)

SPROUT PHARMS
* SPROUT PHARMACEUTICALS INC
ADDYI, FLIBANSERIN

SQUARE PHARMS LTD
* SQUARE PHARMACEUTICALS LTD
VALSARTAN, VALSARTAN

ST RENATUS
* ST RENATUS LLC
KOVANAZE, OXYMETAZOLINE HYDROCHLORIDE

STAND HOMEOPATH
* STANDARD HOMEOPATHIC CO
IVY BLOCK, BENTOQUATAM (OTC)

STASON PHARMS
* STASON PHARMACEUTICALS INC
PURINETHOL, MERCAPTOPURINE

STERINOVA INC
* STERINOVA INC
HEPARIN SODIUM, HEPARIN SODIUM

STI PHARMA LLC
* STI PHARMA LLC
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DEXAMETHASONE, DEXAMETHASONE
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
TRIACIN-C, CODEINE PHOSPHATE

STIEFEL
* STIEFEL LABORATORIES INC
DUAC, BENZOYL PEROXIDE

STIEFEL LABS INC
* STIEFEL LABORATORIES INC
SORIATANE, ACITRETIN

STRIDES PHARMA
* STRIDES PHARMA GLOBAL PTE LTD
ABACAVIR SULFATE, ABACAVIR SULFATE
ACARBOSE, ACARBOSE
ACETAZOLAMIDE, ACETAZOLAMIDE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BENZONATATE, BENZONATATE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CALCITRIOL, CALCITRIOL
CARISOPRODOL, CARISOPRODOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DUTASTERIDE, DUTASTERIDE
EFAVIRENZ, EFAVIRENZ
ERGOCALCIFEROL, ERGOCALCIFEROL
GABAPENTIN, GABAPENTIN
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
KETOCONAZOLE, KETOCONAZOLE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LIDOCAINE, LIDOCAINE
MELOXICAM, MELOXICAM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* STRIDES PHARMA GLOBAL PTE LTD
METHOXSALEN, METHOXSALEN
METRONIDAZOLE, METRONIDAZOLE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NEVIRAPINE, NEVIRAPINE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
PIROXICAM, PIROXICAM
POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
TACROLIMUS, TACROLIMUS
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

STRIDES VIVIMED

* STRIDES VIVIMED PTE LTD
ALBENDAZOLE, ALBENDAZOLE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METRONIDAZOLE, METRONIDAZOLE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

STRONGBRIDGE US

* STRONGBRIDGE US INC
KEVEYIS, DICHLORPHENAMIDE

SUCAMPO PHARMA LLC

* SUCAMPO PHARMA AMERICAS LLC
AMITIZA, LUBIPROSTONE

SUN PHARM INDS

* SUN PHARMACEUTICAL INDUSTRIES LTD
CARBIDOPA AND LEVODOPA, CARBIDOPA
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
DESLORATADINE, DESLORATADINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OLANZAPINE, OLANZAPINE
ONDANSETRON, ONDANSETRON
OXCARBAZEPINE, OXCARBAZEPINE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE

SUN PHARM INDS (IN)

* SUN PHARMACEUTICAL INDUSTRIES LTD
CEPHALEXIN, CEPHALEXIN
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ZONISAMIDE, ZONISAMIDE

SUN PHARM INDS INC

* SUN PHARMACEUTICAL INDUSTRIES INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SUN PHARMACEUTICAL INDUSTRIES INC
ABSORICA, ISOTRETINOIN
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATENOLOL, ATENOLOL
BACLOFEN, BACLOFEN
BENZONATATE, BENZONATATE
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOZAPINE, CLOZAPINE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DIGOXIN, DIGOXIN
ERGOCALCIFEROL, ERGOCALCIFEROL
EURAX, CROTAMITON
FLUMADINE, RIMANTADINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLIPIZIDE, GLIPIZIDE
HALOG, HALCINONIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
INDOMETHACIN, INDOMETHACIN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
KENALOG, TRIAMCINOLONE ACETONIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
NIMODIPINE, NIMODIPINE
OXAPROZIN, OXAPROZIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
REPAGLINIDE, REPAGLINIDE
RISPERIDONE, RISPERIDONE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
ULTRAVATE, HALOBETASOL PROPIONATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SUN PHARM INDS LTD

* SUN PHARMACEUTICAL INDUSTRIES LTD
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZITHROMYCIN, AZITHROMYCIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SUN PHARMACEUTICAL INDUSTRIES LTD
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CERINTA, ETHINYL ESTRADIOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FAMOTIDINE, FAMOTIDINE (OTC)
FELODIPINE, FELODIPINE
FENOFIBRATE, FENOFIBRATE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
GANIRELIX ACETATE, GANIRELIX ACETATE
GLYCOPYRROLATE, GLYCOPYRROLATE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
INFUGEM, GEMCITABINE HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE REDIDOSE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
OMEPRAZOLE, OMEPRAZOLE (OTC)
ONDANSETRON, ONDANSETRON
OPCICON ONE-STEP, LEVONORGESTREL (OTC)
OXCARBAZEPINE, OXCARBAZEPINE
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
RILUZOLE, RILUZOLE
RIOMET, METFORMIN HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TOPIRAMATE, TOPIRAMATE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALPROIC ACID, VALPROIC ACID
XIMINO, MINOCYCLINE HYDROCHLORIDE

SUN PHARM INDUSTRIES

* SUN PHARMACEUTICAL INDUSTRIES INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SUN PHARMACEUTICAL INDUSTRIES INC
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BACTRIM DS, SULFAMETHOXAZOLE
BACTRIM, SULFAMETHOXAZOLE
CARISOPRODOL, CARISOPRODOL
CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
CHLORTHALIDONE, CHLORTHALIDONE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FELODIPINE, FELODIPINE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LOVASTATIN, LOVASTATIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
MORPHINE SULFATE, MORPHINE SULFATE
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NYSTATIN, NYSTATIN
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
PREDNISONE, PREDNISONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
QUALAQUIN, QUININE SULFATE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULINDAC, SULINDAC
TEMAZEPAM, TEMAZEPAM
THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
ULTRAVATE, HALOBETASOL PROPIONATE

SUN PHARMA GLOBAL

* SUN PHARMA GLOBAL FZE
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMIFOSTINE, AMIFOSTINE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BROMSITE, BROMFENAC SODIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CAFFEINE CITRATE, CAFFEINE CITRATE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
CEQUA, CYCLOSPORINE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DECITABINE, DECITABINE
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SUN PHARMA GLOBAL FZE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOFETILIDE, DOFETILIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTACAPONE, ENTACAPONE
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ESZOPICLONE, ESZOPICLONE
EZALLOR, ROSUVASTATIN CALCIUM
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
FINASTERIDE, FINASTERIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LORATADINE, LORATADINE (OTC)
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NIACIN, NIACIN
ODOMZO, SONIDEGIB PHOSPHATE
OXALIPLATIN, OXALIPLATIN
PALIPERIDONE, PALIPERIDONE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TEMOZOLOMIDE, TEMOZOLOMIDE
TETRABENAZINE, TETRABENAZINE
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
XELPROS, LATANOPROST
YONSA, ABIRATERONE ACETATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
* SUN PHARMA GLOBAL INC
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALPRAZOLAM, ALPRAZOLAM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
CARBOPLATIN, CARBOPLATIN
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

SUNGEN PHARMA
* SUNGEN PHARMA LLC
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE

SUNNY PHARMTECH INC
* SUNNY PHARMTECH INC
AMINOCAPROIC ACID, AMINOCAPROIC ACID
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN

SUNOVION
* SUNOVION PHARMACEUTICALS INC
BROVANA, ARFORMOTEROL TARTRATE
XOPENEX HFA, LEVALBUTEROL TARTRATE

SUNOVION PHARMS INC
* SUNOVION PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SUNOVION PHARMACEUTICALS INC
APTIOM, ESLICARBAZEPINE ACETATE
ARCAPTA NEOHALER, INDACATEROL MALEATE
LATUDA, LURASIDONE HYDROCHLORIDE
LUNESTA, ESZOPICLONE
SEEBRI, GLYCOPYRROLATE
UTIBRON, GLYCOPYRROLATE
ZONEGRAN, ZONISAMIDE

SUNOVION RESP
* SUNOVION RESPIRATORY DEVELOPMENT INC
LONHALA MAGNAIR KIT, GLYCOPYRROLATE

SUNSHINE LAKE
* SUNSHINE LAKE PHARMA CO LTD
AZITHROMYCIN, AZITHROMYCIN
CLARITHROMYCIN, CLARITHROMYCIN
ENTACAPONE, ENTACAPONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
OLANZAPINE, OLANZAPINE

SUNSTAR AMERICAS
* SUNSTAR AMERICAS INC
PAROEX, CHLORHEXIDINE GLUCONATE

SUPERNUS PHARMS
* SUPERNUS PHARMACEUTICALS INC
OXTELLAR XR, OXCARBAZEPINE
TROKENDI XR, TOPIRAMATE

SUVEN LIFE
* SUVEN LIFE SCIENCES LTD
MALATHION, MALATHION

SVC PHARMA
* SVC PHARMA LP
DRONABINOL, DRONABINOL

SWEDISH ORPHAN
* SWEDISH ORPHAN BIOVITRUM AB PUBL
ORFADIN, NITISINONE

SYNERGY PHARMS
* SYNERGY PHARMACEUTICALS INC
TRULANCE, PLECANATIDE

SYNTHON PHARMS
* SYNTHON PHARMACEUTICALS INC
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE

**** T ****

ACME LABS
* THE ACME LABORATORIES LTD
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

GEN HOSP
* THE GENERAL HOSPITAL CORP
AMMONIA N 13, AMMONIA N-13

METHODIST HOSP RES
* THE METHODIST HOSP RESEARCH INSTITUTE
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

RITEDOSE CORP
* THE RITEDOSE CORP
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

TAIHO ONCOLOGY
* TAIHO ONCOLOGY INC
LONSURF, TIPIRACIL HYDROCHLORIDE

TAKEDA PHARMS USA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

* TAKEDA PHARMACEUTICALS USA INC
ACTOPLUS MET XR, METFORMIN HYDROCHLORIDE
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
COLCRYS, COLCHICINE
DEXILANT, DEXLANSOPRAZOLE
DUETACT, GLIMEPIRIDE
KAZANO, ALOGLIPTIN BENZOATE
NESINA, ALOGLIPTIN BENZOATE
OSENI, ALOGLIPTIN BENZOATE
PREVACID, LANSOPRAZOLE
ROZEREM, RAMELTEON
TRINTELLIX, VORTIOXETINE HYDROBROMIDE
ULORIC, FEBUXOSTAT

TALON THERAP

* TALON THERAPEUTICS INC
MARQIBO KIT, VINCRISTINE SULFATE

TAMARANG

* TAMARANG SA
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

TARO

* TARO PHARMACEUTICAL INDUSTRIES LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
CARBAMAZEPINE, CARBAMAZEPINE
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FLUCONAZOLE, FLUCONAZOLE
FLUOROURACIL, FLUOROURACIL
GABAPENTIN, GABAPENTIN
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LORATADINE, LORATADINE (OTC)
MELOXICAM, MELOXICAM
METRONIDAZOLE, METRONIDAZOLE
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
PHENYTOIN, PHENYTOIN

* TARO PHARMACEUTICALS USA INC
ACETIC ACID, ACETIC ACID, GLACIAL
ACYCLOVIR, ACYCLOVIR
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ADAPALENE, ADAPALENE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
AMMONIUM LACTATE, AMMONIUM LACTATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
DAPSONE, DAPSONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TARO PHARMACEUTICALS USA INC
DERMABET, BETAMETHASONE VALERATE
DESONIDE, DESONIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
KETOZOLE, KETOCONAZOLE
LIDOCAINE, LIDOCAINE
LORATADINE, LORATADINE (OTC)
MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
PHENYTOIN, PHENYTOIN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
TERCONAZOLE, TERCONAZOLE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
U-CORT, HYDROCORTISONE ACETATE

TARO PHARM

* TARO PHARMACEUTICAL INDUSTRIES LTD
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DESLORATADINE, DESLORATADINE
DESONIDE, DESONIDE
FELBAMATE, FELBAMATE
FLUOROURACIL, FLUOROURACIL
GABAPENTIN, GABAPENTIN
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
LORATADINE, LORATADINE (OTC)
METRONIDAZOLE, METRONIDAZOLE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
TERIL, CARBAMAZEPINE
WARFARIN SODIUM, WARFARIN SODIUM

TARO PHARM INDS

* TARO PHARMACEUTICAL INDUSTRIES LTD
AMCINONIDE, AMCINONIDE
CARBAMAZEPINE, CARBAMAZEPINE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TARO PHARMACEUTICAL INDUSTRIES LTD
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
LAMOTRIGINE, LAMOTRIGINE

TARO PHARM INDS LTD

* TARO PHARMACEUTICAL INDUSTRIES LTD
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
DESLORATADINE, DESLORATADINE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE, HYDROCORTISONE
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
OVIDE, MALATHION
TOPICORT, DESOXIMETASONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

TARO PHARMS

* TARO PHARMACEUTICALS INC
BUTENAFINE HYDROCHLORIDE, BUTENAFINE HYDROCHLORIDE (OTC)
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
OXICONAZOLE NITRATE, OXICONAZOLE NITRATE
PLIAGLIS, LIDOCAINE
TAZAROTENE, TAZAROTENE
TOPICORT, DESOXIMETASONE

TASMAN PHARMA

* TASMAN PHARMA INC
VERSACLOZ, CLOZAPINE

TCG FLUENT PHARMA

* TCG FLUENT PHARMA INVESTORS LP
FLOLIPID, SIMVASTATIN

TEIKOKU PHARMA USA

* TEIKOKU PHARMA USA INC
LIDODERM, LIDOCAINE

TELIGENT

* TELIGENT OU
CEFOTAN, CEFOTETAN DISODIUM
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
FORTAZ, CEFTAZIDIME
ZANTAC, RANITIDINE HYDROCHLORIDE
ZINACEF, CEFUROXIME SODIUM

TELIGENT PHARMA INC

* TELIGENT PHARMA INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINONIDE, FLUOCINONIDE
FLURANDRENOLIDE, FLURANDRENOLIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE, LIDOCAINE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

TERSERA THERAPS LLC

* TERSERA THERAPEUTICS LLC
ERGOMAR, ERGOTAMINE TARTRATE
PRIALT, ZICONOTIDE ACETATE
QMIIZ ODT, MELOXICAM
VARUBI, ROLAPITANT HYDROCHLORIDE
ZOLADEX, GOSERELIN ACETATE

TESARO INC

* TESARO INC
ZEJULA, NIRAPARIB TOSYLATE

TETRAPHASE PHARMS

* TETRAPHASE PHARMACEUTICALS INC
XERAVA, ERAVACYCLINE DIHYDROCHLORIDE

TEVA

* TEVA NEUROSCIENCE INC
AZILECT, RASAGILINE MESYLATE
* TEVA PHARMACEUTICALS USA INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACYCLOVIR, ACYCLOVIR
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
ATENOLOL, ATENOLOL
AZITHROMYCIN, AZITHROMYCIN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CALCITRIOL, CALCITRIOL
CAPTOPRIL, CAPTOPRIL
CARVEDILOL, CARVEDILOL
CEFACLOR, CEFACLOR
CEFPROZIL, CEFPROZIL
CELECOXIB, CELECOXIB
CEPHALEXIN, CEPHALEXIN
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CILOSTAZOL, CILOSTAZOL
CIMETIDINE, CIMETIDINE
CLARITHROMYCIN, CLARITHROMYCIN
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOTRIMAZOLE, CLOTRIMAZOLE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DIFLUNISAL, DIFLUNISAL
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
EPITOL, CARBAMAZEPINE
ESZOPICLONE, ESZOPICLONE
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA PHARMACEUTICALS USA INC
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GALZIN, ZINC ACETATE
GEMFIBROZIL, GEMFIBROZIL
GLIMEPIRIDE, GLIMEPIRIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE, GLYBURIDE
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LAMOTRIGINE, LAMOTRIGINE
LEVOFLOXACIN, LEVOFLOXACIN
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LORATADINE, LORATADINE (OTC)
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOVASTATIN, LOVASTATIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MUPIROCIN, MUPIROCIN
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OFLOXACIN, OFLOXACIN
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
ORAP, PIMOZIDE
OXAPROZIN, OXAPROZIN
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENICILLIN-VK, PENICILLIN V POTASSIUM
PIROXICAM, PIROXICAM
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRELONE, PREDNISOLONE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIBAVIRIN, RIBAVIRIN
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SUCRALFATE, SUCRALFATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

* TEVA PHARMACEUTICALS USA INC
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TOPIRAMATE, TOPIRAMATE
TORSEMIDE, TORSEMIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

TEVA BRANDED PHARM

* TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC
AUSTEDO, DEUTETRABENAZINE
DIAMOX, ACETAZOLAMIDE
LOSEASONIQUE, ETHINYL ESTRADIOL
PROAIR HFA, ALBUTEROL SULFATE
PROAIR RESPICLICK, ALBUTEROL SULFATE
PROGLYCEM, DIAZOXIDE
QNASL, BECLOMETHASONE DIPROPIONATE
QUARTETTE, ETHINYL ESTRADIOL
SEASONALE, ETHINYL ESTRADIOL
SEASONIQUE, ETHINYL ESTRADIOL
TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
TENUATE, DIETHYLPROPION HYDROCHLORIDE
ZIAC, BISOPROLOL FUMARATE

TEVA PARENTERAL

* TEVA PARENTERAL MEDICINES INC
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

TEVA PHARM

* TEVA PHARMACEUTICAL INDUSTRIES LTD
AIRDUO RESPICLICK, FLUTICASONE PROPIONATE
ARMONAIR RESPICLICK, FLUTICASONE PROPIONATE

TEVA PHARMS

* TEVA PHARMACEUTICALS USA
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
AZITHROMYCIN, AZITHROMYCIN
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BUDESONIDE, BUDESONIDE
CARBAMAZEPINE, CARBAMAZEPINE
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFPROZIL, CEFPROZIL
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CROMOLYN SODIUM, CROMOLYN SODIUM
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
FAMCICLOVIR, FAMCICLOVIR
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
IRBESARTAN, IRBESARTAN
LANSOPRAZOLE, LANSOPRAZOLE
LEFLUNOMIDE, LEFLUNOMIDE
LETROZOLE, LETROZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA PHARMACEUTICALS USA
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LINEZOLID, LINEZOLID
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
MELOXICAM, MELOXICAM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUININE SULFATE, QUININE SULFATE
RAMIPRIL, RAMIPRIL
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TRANDOLAPRIL, TRANDOLAPRIL
URSODIOL, URSODIOL
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VANDAZOLE, METRONIDAZOLE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZALEPLON, ZALEPLON

TEVA PHARMS INTL

* TEVA PHARMACEUTICALS INTERNATIONAL GMBH
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
SYNRIBO, OMACETAXINE MEPESUCCINATE

TEVA PHARMS USA

* TEVA PHARMACEUTICALS USA
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ACITRETIN, ACITRETIN
ADENOSINE, ADENOSINE
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
ARGATROBAN IN 0.9% SODIUM CHLORIDE, ARGATROBAN
ARIPIPRAZOLE, ARIPIPRAZOLE
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BUDESONIDE, BUDESONIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CLARAVIS, ISOTRETINOIN
CLOZAPINE, CLOZAPINE
COPAXONE, GLATIRAMER ACETATE
DACARBAZINE, DACARBAZINE
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA PHARMACEUTICALS USA
DOCETAXEL, DOCETAXEL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
ENALAPRILAT, ENALAPRILAT
ENTECAVIR, ENTECAVIR
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
EPTIFIBATIDE, EPTIFIBATIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESTRADIOL, ESTRADIOL
ETOPOSIDE, ETOPOSIDE
EZETIMIBE, EZETIMIBE
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
GABAPENTIN, GABAPENTIN
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LINEZOLID, LINEZOLID
LOGILIA, ULIPRISTAL ACETATE
MESNA, MESNA
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OMEPRAZOLE, OMEPRAZOLE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PARICALCITOL, PARICALCITOL
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TADALAFIL, TADALAFIL
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN, TOBRAMYCIN
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VIGABATRIN, VIGABATRIN
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

* TEVA PHARMACEUTICALS USA
VINORELBINE TARTRATE, VINORELBINE TARTRATE
ZANOSAR, STREPTOZOCIN
ZOLMITRIPTAN, ZOLMITRIPTAN
* TEVA PHARMACEUTICALS USA INC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
CAPECITABINE, CAPECITABINE
CASSIPA, BUPRENORPHINE HYDROCHLORIDE
DAPTOMYCIN, DAPTOMYCIN
DARUNAVIR ETHANOLATE, DARUNAVIR ETHANOLATE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EPINEPHRINE (AUTOINJECTOR), EPINEPHRINE
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ESTRADIOL, ESTRADIOL
LIDOCAINE, LIDOCAINE
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
METRONIDAZOLE, METRONIDAZOLE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
SELFEMRA, FLUOXETINE HYDROCHLORIDE
TERIFLUNOMIDE, TERIFLUNOMIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

TEVA PHARMS USA INC
* TEVA PHARMACEUTICALS USA INC
POTASSIUM CITRATE, POTASSIUM CITRATE

THE FEINSTEIN INST
* THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

THEPHARMANETWORK LLC
* THEPHARMANETWORK LLC
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BENZONATATE, BENZONATATE
ISONIAZID, ISONIAZID
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
NIMODIPINE, NIMODIPINE
THERMAZENE, SILVER SULFADIAZINE

THERAPEUTICSMD INC
* THERAPEUTICSMD INC
ANNOVERA, ETHINYL ESTRADIOL
BIJUVA, ESTRADIOL
IMVEXXY, ESTRADIOL

THERATECHNOLOGIES
* THERATECHNOLOGIES INC
EGRIFTA, TESAMORELIN ACETATE

TIME-CAP LABS INC
* TIME-CAP LABORATORIES INC
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE

TITAN PHARMS
* TITAN PHARMACEUTICALS INC
PROBUPHINE, BUPRENORPHINE HYDROCHLORIDE

TOLMAR
* TOLMAR INC
ACYCLOVIR, ACYCLOVIR
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ADAPALENE, ADAPALENE
ATRIDOX, DOXYCYCLINE HYCLATE
AZELAIC ACID, AZELAIC ACID
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CICLOPIROX, CICLOPIROX

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TOLMAR INC
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
KETOCONAZOLE, KETOCONAZOLE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE AND PRILOCAINE, LIDOCAINE
METRONIDAZOLE, METRONIDAZOLE
NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE

TOLMAR THERAP

* TOLMAR THERAPEUTICS INC
ELIGARD, LEUPROLIDE ACETATE

TORPHARM

* TORPHARM INC
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE

TORRENT PHARMA INC

* TORRENT PHARMA INC
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

TORRENT PHARMS

* TORRENT PHARMACEUTICALS LIMITED
LEVOFLOXACIN, LEVOFLOXACIN
* TORRENT PHARMACEUTICALS LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CARBAMAZEPINE, CARBAMAZEPINE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
* TORRENT PHARMACEUTICALS LTD.
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE

TORRENT PHARMS LLC

* TORRENT PHARMACEUTICALS LLC
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
MONTELUKAST SODIUM, MONTELUKAST SODIUM
OLANZAPINE, OLANZAPINE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

TORRENT PHARMS LTD

* TORRENT PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ARIPIPRAZOLE, ARIPIPRAZOLE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CELECOXIB, CELECOXIB
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FELODIPINE, FELODIPINE
FENOFIBRATE (MICRONIZED), FENOFIBRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TORRENT PHARMACEUTICALS LTD
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
ITRACONAZOLE, ITRACONAZOLE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
ROFLUMILAST, ROFLUMILAST
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
VALSARTAN, VALSARTAN

TRIS PHARMA INC

* TRIS PHARMA INC
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
DYANAVEL XR, AMPHETAMINE
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
IBUPROFEN, IBUPROFEN (OTC)
KARBINAL ER, CARBINOXAMINE MALEATE
LEVETIRACETAM, LEVETIRACETAM
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
THEOPHYLLINE, THEOPHYLLINE

TRUSTEES UNIV PA

* TRUSTEES OF THE UNIV OF PENNSYLVANIA
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

TULEX PHARMS INC

* TULEX PHARMACEUTICALS INC
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

TWI PHARMS

* TWI PHARMACEUTICALS INC
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TWI PHARMACEUTICALS INC
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NIFEDIPINE, NIFEDIPINE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
ZOLMITRIPTAN, ZOLMITRIPTAN

**** U ****

UCB INC
* UCB INC
BRIVIACT, BRIVARACETAM
KEPPRA XR, LEVETIRACETAM
KEPPRA, LEVETIRACETAM
NEUPRO, ROTIGOTINE
VIMPAT, LACOSAMIDE

UCLA BIOMEDICAL
* UCLA BIOMEDICAL CYCLOTRON
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UCSF RODIOPHARM
* UCSF RADIOPHARMACEUTICAL FACILITY
AMMONIA N 13, AMMONIA N-13
CHOLINE C-11, CHOLINE C-11
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

UIHC PET IMAGING
* UNIV IOWA HOSPS AND CLINICS PET IMAGING CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UMEDICA LABS PVT LTD
* UMEDICA LABORATORIES PRIVATE LTD
CHLORTHALIDONE, CHLORTHALIDONE

UNICHEM
* UNICHEM LABORATORIES LTD
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MELOXICAM, MELOXICAM
ZALEPLON, ZALEPLON

UNICHEM LABS LTD
* UNICHEM LABORATORIES LIMITED
DIVALPROEX SODIUM, DIVALPROEX SODIUM
* UNICHEM LABORATORIES LTD
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
PIROXICAM, PIROXICAM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
VALSARTAN, VALSARTAN

UNICHEM PHARMS (USA)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** U ****

* UNICHEM PHARMACEUTICALS (USA) INC
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE

UNIMARK REMEDIES LTD

* UNIMARK REMEDIES LTD
MONTELUKAST SODIUM, MONTELUKAST SODIUM

UNIQUE PHARM LABS

* UNIQUE PHARMACEUTICAL LABORATORIES A DIVISION OF J.B. CHEMICALS AND PHARMACEUTICALS LTD
ATENOLOL, ATENOLOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FLUCONAZOLE, FLUCONAZOLE
GLIPIZIDE, GLIPIZIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
TINIDAZOLE, TINIDAZOLE

UNITED BIOMEDCL

* UNITED BIOMEDICAL INC
TERBUTALINE SULFATE, TERBUTALINE SULFATE

UNITED GUARDIAN

* UNITED GUARDIAN INC
RENACIDIN, CITRIC ACID

UNITED THERAP

* UNITED THERAPEUTICS CORP
ORENITRAM, TREPROSTINIL DIOLAMINE
REMODULIN, TREPROSTINIL
TYVASO, TREPROSTINIL

UNIV MICHIGAN

* UNIV MICHIGAN PET RADIOPHARMACEUTICAL PRODUCTION PROGRAM
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV TX MD ANDERSON

* UNIV TEXAS MD ANDERSON CANCER CENTER
CHOLINE C-11, CHOLINE C-11
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV UTAH CYCLOTRON

* UNIV UTAH CYCLOTRON RADIOCHEMISTRY LAB
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

UPSHER SMITH LABS

* UPSHER SMITH LABORATORIES LLC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BEXAROTENE, BEXAROTENE
BUMETANIDE, BUMETANIDE
CLOBAZAM, CLOBAZAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
EXEMESTANE, EXEMESTANE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KLOR-CON, POTASSIUM CHLORIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MORPHINE SULFATE, MORPHINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** U ****

* UPSHER SMITH LABORATORIES LLC
NYSTATIN, NYSTATIN
ORVATEN, MIDODRINE HYDROCHLORIDE
OXANDROLONE, OXANDROLONE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PACERONE, AMIODARONE HYDROCHLORIDE
PENTOXIL, PENTOXIFYLLINE
PREVALITE, CHOLESTYRAMINE
QUDEXY XR, TOPIRAMATE
SORINE, SOTALOL HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
VOGELXO, TESTOSTERONE

US PHARM HOLDINGS

* US PHARMACEUTICAL HOLDINGS II LLC
DEMEROL, MEPERIDINE HYDROCHLORIDE
DRISDOL, ERGOCALCIFEROL
HIPREX, METHENAMINE HIPPURATE
LASIX, FUROSEMIDE
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE

US PHARMS HOLDINGS I

* US PHARMACEUTICALS HOLDINGS I LLC
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPRESSOR, METOPROLOL TARTRATE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
PARLODEL, BROMOCRIPTINE MESYLATE

US WORLDMEDS

* US WORLDMEDS LLC
APOKYN, APOMORPHINE HYDROCHLORIDE
REVONTO, DANTROLENE SODIUM

US WORLDMEDS LLC

* US WORLDMEDS LLC
CORGARD, NADOLOL
LUCEMYRA, LOFEXIDINE HYDROCHLORIDE
XADAGO, SAFINAMIDE MESYLATE

USL PHARMA

* USL PHARMA LLC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
FLUOXYMESTERONE, FLUOXYMESTERONE
JANTOVEN, WARFARIN SODIUM

USPHARMA

* USPHARMA LTD
NITRO-DUR, NITROGLYCERIN

USPHARMA WINDLAS

* USPHARMA WINDLAS LLC
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
PRASUGREL, PRASUGREL HYDROCHLORIDE

USV NORTH AMERICA

* USV NORTH AMERICA INC
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

**** V ****

VALEANT

* VALEANT PHARMACEUTICALS INTERNATIONAL
ANCOBON, FLUCYTOSINE
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MYSOLINE, PRIMIDONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** V **

VALEANT BERMUDA
* VALEANT INTERNATIONAL BERMUDA
BENZACLIN, BENZOYL PEROXIDE
DERMATOP E EMOLLIENT, PREDNICARBATE
ELIDEL, PIMECROLIMUS
PENLAC, CICLOPIROX
RETIN-A, TRETINOIN
XERESE, ACYCLOVIR
ZOVIRAX, ACYCLOVIR

VALEANT INTL
* VALEANT INTERNATIONAL BARBADOS SRL
ATIVAN, LORAZEPAM
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
RETIN-A MICRO, TRETINOIN
RETIN-A, TRETINOIN
RETIN-A-MICRO, TRETINOIN
VASERETIC, ENALAPRIL MALEATE
WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
* VALEANT INTERNATIONAL SRL
BENZAMYCIN, BENZOYL PEROXIDE

VALEANT LUXEMBOURG
* VALEANT PHARMACEUTICALS LUXEMBOURG SARL
ERTACZO, SERTACONAZOLE NITRATE
TARGRETIN, BEXAROTENE
VISUDYNE, VERTEPORFIN

VALEANT PHARM INTL
* VALEANT PHARMACEUTICALS INTERNATIONAL
ANDROID 25, METHYLTESTOSTERONE
EFUDEX, FLUOROURACIL
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
MESTINON, PYRIDOSTIGMINE BROMIDE
TESTRED, METHYLTESTOSTERONE
VIRAZOLE, RIBAVIRIN
ZELAPAR, SELEGILINE HYDROCHLORIDE

VALEANT PHARMS
* VALEANT PHARMACEUTICALS NORTH AMERICA
MEPHYTON, PHYTONADIONE
* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
LIBRAX, CHLORDIAZEPOXIDE HYDROCHLORIDE
MESTINON, PYRIDOSTIGMINE BROMIDE
MINITRAN, NITROGLYCERIN
PENTOXIFYLLINE, PENTOXIFYLLINE

VALEANT PHARMS INC
* VALEANT PHARMACEUTICALS INTERNATIONAL INC
GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE

VALEANT PHARMS INTL
* VALEANT PHARMACEUTICALS INTERNATIONAL
APRISO, MESALAMINE
COLAZAL, BALSALAZIDE DISODIUM
GIAZO, BALSALAZIDE DISODIUM
JUBLIA, EFINACONAZOLE
UCERIS, BUDESONIDE

VALEANT PHARMS LLC
* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
MACUGEN, PEGAPTANIB SODIUM
MESTINON, PYRIDOSTIGMINE BROMIDE
TASMAR, TOLCAPONE
TIMOPTIC-XE, TIMOLOL MALEATE

VALEANT PHARMS NORTH
* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
APLENZIN, BUPROPION HYDROBROMIDE
CARAC, FLUOROURACIL
DERMATOP, PREDNICARBATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** V **

* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
DIASTAT ACUDIAL, DIAZEPAM
DIASTAT, DIAZEPAM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
FENOFIBRATE, FENOFIBRATE
ISORDIL, ISOSORBIDE DINITRATE
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
KLARON, SULFACETAMIDE SODIUM
MINITRAN, NITROGLYCERIN
NIFEDIPINE, NIFEDIPINE
NORITATE, METRONIDAZOLE
PEPCID, FAMOTIDINE
RENOVA, TRETINOIN
RETIN-A, TRETINOIN
SECONAL SODIUM, SECOBARBITAL SODIUM
TIAZAC, DILTIAZEM HYDROCHLORIDE
VASOTEC, ENALAPRIL MALEATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
XENAZINE, TETRABENAZINE

VALIDUS PHARMS
* VALIDUS PHARMACEUTICALS LLC
BUMEX, BUMETANIDE
EQUETRO, CARBAMAZEPINE
ROCALTROL, CALCITRIOL

VALIDUS PHARMS INC
* VALIDUS PHARMACEUTICALS INC
MARPLAN, ISOCARBOXAZID

VANDA PHARMS INC
* VANDA PHARMACEUTICALS INC
FANAPT, ILOPERIDONE
HETLIOZ, TASIMELTEON

VELOXIS PHARMS INC
* VELOXIS PHARMACEUTICALS INC
ENVARSUS XR, TACROLIMUS

VERASTEM INC
* VERASTEM INC
COPIKTRA, DUVELISIB

VEROSCIENCE
* VEROSCIENCE LLC
CYCLOSET, BROMOCRIPTINE MESYLATE

VERTEX PHARMS
* VERTEX PHARMACEUTICALS INC
KALYDECO, IVACAFTOR

VERTEX PHARMS INC
* VERTEX PHARMACEUTICALS INC
KALYDECO, IVACAFTOR
ORKAMBI, IVACAFTOR
SYMDEKO (COPACKAGED), IVACAFTOR

VERTICAL PHARMS LLC
* VERTICAL PHARMACEUTICALS LLC
DIVIGEL, ESTRADIOL

VIB
* VALEANT INTERNATIONAL BERMUDA
ZOVIRAX, ACYCLOVIR

VICURON
* VICURON PHARMACEUTICALS INC
ERAXIS, ANIDULAFUNGIN

VIFOR FRESENIUS
* VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE
VELPHORO, SUCROFERRIC OXYHYDROXIDE

VIIV HLTHCARE
* VIIV HEALTHCARE CO
COMBIVIR, LAMIVUDINE
EPIVIR, LAMIVUDINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** V **

* VIIV HEALTHCARE CO
EPZICOM, ABACAVIR SULFATE
JULUCA, DOLUTEGRAVIR SODIUM
LEXIVA, FOSAMPRENAVIR CALCIUM
RESCRIPTOR, DELAVIRDINE MESYLATE
RETROVIR, ZIDOVUDINE
SELZENTRY, MARAVIROC
TIVICAY, DOLUTEGRAVIR SODIUM
TRIUMEQ, ABACAVIR SULFATE
TRIZIVIR, ABACAVIR SULFATE
ZIAGEN, ABACAVIR SULFATE

VINTAGE

* VINTAGE PHARMACEUTICALS LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
FOLIC ACID, FOLIC ACID
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE, HYDROCORTISONE
NYSTATIN, NYSTATIN
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

VINTAGE PHARMS

* VINTAGE PHARMACEUTICALS
ALPRAZOLAM, ALPRAZOLAM
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYCLAFEM 0.5/35, ETHINYL ESTRADIOL
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
GILDAGIA, ETHINYL ESTRADIOL
GILDESS 24 FE, ETHINYL ESTRADIOL
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
KIMIDESS, DESOGESTREL
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

* VINTAGE PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
CARISOPRODOL, CARISOPRODOL
DIAZEPAM, DIAZEPAM
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LEVETIRACETAM, LEVETIRACETAM
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PERPHENAZINE, PERPHENAZINE
PREDNISONE, PREDNISONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** V **

* VINTAGE PHARMACEUTICALS INC
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
SULFASALAZINE, SULFASALAZINE
TORSEMIDE, TORSEMIDE

VINTAGE PHARMS LLC

* VINTAGE PHARMACEUTICALS LLC
CYCLAFEM 1/35, ETHINYL ESTRADIOL
CYCLAFEM 7/7/7, ETHINYL ESTRADIOL
DUTASTERIDE, DUTASTERIDE
EMOQUETTE, DESOGESTREL
FELODIPINE, FELODIPINE
GILDESS 1.5/30, ETHINYL ESTRADIOL
GILDESS 1/20, ETHINYL ESTRADIOL
GILDESS FE 1.5/30, ETHINYL ESTRADIOL
GILDESS FE 1/20, ETHINYL ESTRADIOL
LETROZOLE, LETROZOLE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MORPHINE SULFATE, MORPHINE SULFATE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYZILRA, ETHINYL ESTRADIOL
ORSYTHIA, ETHINYL ESTRADIOL
PERCOCET, ACETAMINOPHEN
PREVIFEM, ETHINYL ESTRADIOL
TRI-PREVIFEM, ETHINYL ESTRADIOL

VIRTUS PHARM

* VIRTUS PHARMACEUTICAL INC
ACARBOSE, ACARBOSE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE

VIRTUS PHARMS

* VIRTUS PHARMACEUTICALS LLC
DAPSONE, DAPSONE
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PROMETRIUM, PROGESTERONE
TRANEXAMIC ACID, TRANEXAMIC ACID

VISTA PHARMS

* VISTA PHARMACEUTICALS INC
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

VISTAPHARM

* VISTAPHARM INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LACTULOSE, LACTULOSE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NYSTATIN, NYSTATIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENYTOIN, PHENYTOIN
PREDNISOLONE, PREDNISOLONE
VALPROIC ACID, VALPROIC ACID

VITRUVIAS THERAP

* VITRUVIAS THERAPEUTICS
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
* VITRUVIAS THERAPEUTICS LLC
CYANOCOBALAMIN, CYANOCOBALAMIN
LIDOCAINE, LIDOCAINE

VIVA HLTHCARE

* VIVA HEALTHCARE FZ LLC
GLIMEPIRIDE, GLIMEPIRIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
SIMVASTATIN, SIMVASTATIN
TRANEXAMIC ACID, TRANEXAMIC ACID

VIVIMED GLOBAL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** V ****

* VIVIMED GLOBAL GENERICS PTE LTD
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

VIVUS

* VIVUS INC
QSYMIA, PHENTERMINE HYDROCHLORIDE

VIVUS INC

* VIVUS INC
PANCREAZE, PANCRELIPASE (AMYLASE

VPNA

* VALEANT PHARMACEUTICALS NORTH AMERICA
DICLOFENAC SODIUM, DICLOFENAC SODIUM

VYERA PHARMS LLC

* VYERA PHARMACEUTICALS LLC
DARAPRIM, PYRIMETHAMINE

**** W ****

WA UNIV SCH MED

* WASHINGTON UNIV SCHOOL MEDICINE
AMMONIA N 13, AMMONIA N-13
CHOLINE C-11, CHOLINE C-11

WATSON LABS

* WATSON LABORATORIES
FOLIC ACID, FOLIC ACID
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE

* WATSON LABORATORIES INC
ACARBOSE, ACARBOSE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALLOPURINOL, ALLOPURINOL
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXAPINE, AMOXAPINE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL, CARISOPRODOL
CHLORZOXAZONE, CHLORZOXAZONE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
COL-PROBENECID, COLCHICINE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ESTAZOLAM, ESTAZOLAM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE, GLIPIZIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LISINOPRIL, LISINOPRIL
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLDOPA, METHYLDOPA
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
MIRTAZAPINE, MIRTAZAPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** W ****

* WATSON LABORATORIES INC
NABUMETONE, NABUMETONE
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NATEGLINIDE, NATEGLINIDE
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NIZATIDINE, NIZATIDINE
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PRIMIDONE, PRIMIDONE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
QUASENSE, ETHINYL ESTRADIOL
QUINIDINE SULFATE, QUINIDINE SULFATE
RAMIPRIL, RAMIPRIL
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
SULFASALAZINE, SULFASALAZINE
SULINDAC, SULINDAC
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TELMISARTAN, TELMISARTAN
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
ZOVIA 1/50E-28, ETHINYL ESTRADIOL
* WATSON LABS INC
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

WATSON LABS INC

* WATSON LABORATORIES INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMMONIUM LACTATE, AMMONIUM LACTATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CELECOXIB, CELECOXIB
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
EZETIMIBE, EZETIMIBE
METRONIDAZOLE, METRONIDAZOLE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MODAFINIL, MODAFINIL
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
PERPHENAZINE, PERPHENAZINE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PROPOFOL, PROPOFOL
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RASAGILINE MESYLATE, RASAGILINE MESYLATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TICAGRELOR, TICAGRELOR
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

WATSON LABS TEVA

* WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
BICALUTAMIDE, BICALUTAMIDE
BUPRENORPHINE, BUPRENORPHINE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
EZETIMIBE AND ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
GLIPIZIDE, GLIPIZIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
ISRADIPINE, ISRADIPINE
LEVOFLOXACIN, LEVOFLOXACIN
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
PROBENECID, PROBENECID
SIMVASTATIN, SIMVASTATIN
TEMOZOLOMIDE, TEMOZOLOMIDE
TERIFLUNOMIDE, TERIFLUNOMIDE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

WATSON PHARMS INC

* WATSON PHARMACEUTICALS INC
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE

WATSON PHARMS TEVA

* WATSON PHARMACEUTICALS INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
RIFAMPIN, RIFAMPIN

WELLSTAT THERAP

* WELLSTAT THERAPEUTICS CORP
VISTOGARD, URIDINE TRIACETATE
XURIDEN, URIDINE TRIACETATE

WES PHARMA INC

* WES PHARMA INC
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

WEST WARD

* WEST WARD PHARMACEUTICAL CORP
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE

WEST WARD PHARM CORP

* WEST WARD PHARMACEUTICAL CORP
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

WEST-WARD PHARM CORP

* WEST-WARD PHARMACEUTICAL CORP
CEFOTETAN, CEFOTETAN DISODIUM

WEST-WARD PHARMS INT

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
ACARBOSE, ACARBOSE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ADENOSINE, ADENOSINE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
ALPRAZOLAM, ALPRAZOLAM
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMRINONE LACTATE, INAMRINONE LACTATE
ANASTROZOLE, ANASTROZOLE
ATIVAN, LORAZEPAM
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BUMETANIDE, BUMETANIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CAFCIT, CAFFEINE CITRATE
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CAPECITABINE, CAPECITABINE
CARBOPLATIN, CARBOPLATIN
CEFOXITIN, CEFOXITIN SODIUM
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CILOSTAZOL, CILOSTAZOL
CISPLATIN, CISPLATIN
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLADRIBINE, CLADRIBINE
CLARITHROMYCIN, CLARITHROMYCIN
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBAZAM, CLOBAZAM
CLOTRIMAZOLE, CLOTRIMAZOLE
CODEINE SULFATE, CODEINE SULFATE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYCLOSPORINE, CYCLOSPORINE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DALFAMPRIDINE, DALFAMPRIDINE
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE, DEXAMETHASONE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DIAZEPAM INTENSOL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE), DICYCLOMINE HYDROCHLORIDE
DIGOXIN, DIGOXIN
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISULFIRAM, DISULFIRAM
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
DOPRAM, DOXAPRAM HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DURAMORPH PF, MORPHINE SULFATE
DUTASTERIDE, DUTASTERIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESZOPICLONE, ESZOPICLONE
ETHACRYNIC ACID, ETHACRYNIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
ETOMIDATE, ETOMIDATE
ETOPOSIDE, ETOPOSIDE
EVEROLIMUS, EVEROLIMUS
EXEMESTANE, EXEMESTANE
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLOXURIDINE, FLOXURIDINE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUCONAZOLE, FLUCONAZOLE
FLUCYTOSINE, FLUCYTOSINE
FLUMAZENIL, FLUMAZENIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FUROSEMIDE, FUROSEMIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM, HEPARIN SODIUM
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
INFUMORPH, MORPHINE SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LACTULOSE, LACTULOSE
LETROZOLE, LETROZOLE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVOCARNITINE, LEVOCARNITINE
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LINEZOLID, LINEZOLID
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
LORAZEPAM INTENSOL, LORAZEPAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MERCAPTOPURINE, MERCAPTOPURINE
MESNA, MESNA
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** W ****

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
MITOMYCIN, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MORPHINE SULFATE, MORPHINE SULFATE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NALOXONE, NALOXONE HYDROCHLORIDE
NAPROXEN, NAPROXEN
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXCARBAZEPINE, OXCARBAZEPINE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
OXYTOCIN, OXYTOCIN
PACLITAXEL, PACLITAXEL
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PENTOSTATIN, PENTOSTATIN
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
PHENYTOIN SODIUM, PHENYTOIN SODIUM
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
PREDNISONE INTENSOL, PREDNISONE
PREDNISONE, PREDNISONE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
RISPERIDONE, RISPERIDONE
RITONAVIR, RITONAVIR
ROBAXIN, METHOCARBAMOL
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROXICET, ACETAMINOPHEN
RUFINAMIDE, RUFINAMIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX
SODIUM OXYBATE, SODIUM OXYBATE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
THIOTEPA, THIOTEPA
TINIDAZOLE, TINIDAZOLE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TORSEMIDE, TORSEMIDE
TRIAZOLAM, TRIAZOLAM
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VINBLASTINE SULFATE, VINBLASTINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
VINORELBINE TARTRATE, VINORELBINE TARTRATE
ZALEPLON, ZALEPLON
ZIDOVUDINE, ZIDOVUDINE

WI MEDCL CYCLOTRON

* WISCONSIN MEDICAL CYCLOTRON LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

WILSHIRE PHARMS INC

* WILSHIRE PHARMACEUTICALS INC
CARISOPRODOL, CARISOPRODOL
NATEGLINIDE, NATEGLINIDE
PERPHENAZINE, PERPHENAZINE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE

WOCKHARDT

* WOCKHARDT LTD
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AZITHROMYCIN, AZITHROMYCIN
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
CEFOTAXIME, CEFOTAXIME SODIUM
CEFPROZIL, CEFPROZIL
CEFTAZIDIME, CEFTAZIDIME
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CLARITHROMYCIN, CLARITHROMYCIN
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
FAMOTIDINE, FAMOTIDINE (OTC)
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FUROSEMIDE, FUROSEMIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LISINOPRIL, LISINOPRIL
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NIACIN, NIACIN
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZONISAMIDE, ZONISAMIDE

WOCKHARDT BIO AG

* WOCKHARDT BIO AG
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETIC ACID, ACETIC ACID, GLACIAL
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
BROMFED-DM, BROMPHENIRAMINE MALEATE
CARBAMAZEPINE, CARBAMAZEPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WOCKHARDT BIO AG
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYCLOSPORINE, CYCLOSPORINE
DEXAMETHASONE, DEXAMETHASONE
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FUROSEMIDE, FUROSEMIDE
GENERLAC, LACTULOSE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LACTULOSE, LACTULOSE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LINDANE, LINDANE
LITHIUM CITRATE, LITHIUM CITRATE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)
MEGESTROL ACETATE, MEGESTROL ACETATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
NYSTATIN, NYSTATIN
OXACILLIN SODIUM, OXACILLIN SODIUM
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENYTOIN, PHENYTOIN
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE, PREDNISOLONE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VALPROIC ACID, VALPROIC ACID

WOCKHARDT LTD

* WOCKHARDT LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CAPTOPRIL, CAPTOPRIL
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENTACAPONE, ENTACAPONE
FAMOTIDINE, FAMOTIDINE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

WOCKHARDT USA

* WOCKHARDT USA INC
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
* WOCKHARDT USA LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WOCKHARDT USA LLC
LANSOPRAZOLE, LANSOPRAZOLE

WRASER PHARMS
* WRASER PHARMACEUTICALS LLC
CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE

WRASER PHARMS LLC
* WRASER PHARMACEUTICALS LLC
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
TREZIX, ACETAMINOPHEN

WUSM CYCLOTRON
* WASHINGTON UNIV SCH MEDICINE CYCLOTRON FACILITY
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

WYETH PHARMS
* WYETH PHARMACEUTICALS LLC
DUAVEE, BAZEDOXIFENE ACETATE
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
PREMARIN, ESTROGENS, CONJUGATED
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTONIX, PANTOPRAZOLE SODIUM
TRECATOR, ETHIONAMIDE
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOSYN, PIPERACILLIN SODIUM

** X **

X GEN PHARMS
* X GEN PHARMACEUTICALS INC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
AMPHOTERICIN B, AMPHOTERICIN B
BACIIM, BACITRACIN
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
LEVETIRACETAM, LEVETIRACETAM
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NYSTATIN, NYSTATIN
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE

X-GEN PHARMS
* X-GEN PHARMACEUTICALS INC
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

X-GEN PHARMS INC
* X-GEN PHARMACEUTICALS INC
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
IBUPROFEN LYSINE, IBUPROFEN LYSINE
LINCOMYCIN, LINCOMYCIN HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID

XELLIA PHARMS APS
* XELLIA PHARMACEUTICALS APS
BACITRACIN, BACITRACIN
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
DAPTOMYCIN, DAPTOMYCIN
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE

XIAMEN LP PHARM CO
* XIAMEN LP PHARMACUETICAL CO LTD
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** X **

XSPIRE PHARMA
* XSPIRE PHARMA
NALFON, FENOPROFEN CALCIUM
* XSPIRE PHARMA LLC
DEXAMETHASONE, DEXAMETHASONE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM

XTTRIUM
* XTTRIUM LABORATORIES INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)

XYLOPIA
* XYLOPIA
ACETAZOLAMIDE, ACETAZOLAMIDE

** Y **

YABAO PHARM
* YABAO PHARMACEUTICAL CO LTD BEIJING
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE

YAOPHARMA CO LTD
* YAOPHARMA CO LTD
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

YICHANG HUMANWELL
* YICHANG HUMANWELL PHARMACEUTICAL CO LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

YILING PHARM LTD
* YILING PHARMACEUTICAL LTD
ACYCLOVIR, ACYCLOVIR
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
FELODIPINE, FELODIPINE

YUNG SHIN PHARM
* YUNG SHIN PHARMACEUTICAL INDUSTRIAL CO LTD
CEFACLOR, CEFACLOR
CEPHALEXIN, CEPHALEXIN
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
MELOXICAM, MELOXICAM
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

** Z **

ZAMBON SPA
* ZAMBON SPA ITALY
MONUROL, FOSFOMYCIN TROMETHAMINE

ZHEJIANG HISUN PHARM
* ZHEJIANG HISUN PHARMACEUTICAL CO LTD
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL

ZO SKIN HEALTH
* ZO SKIN HEALTH
TRETINOIN, TRETINOIN

ZYDUS HLTHCARE
* ZYDUS HEALTHCARE USA LLC
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ZYDUS PHARMS USA
* ZYDUS PHARMACEUTICALS USA INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATENOLOL, ATENOLOL
AZATHIOPRINE, AZATHIOPRINE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BENZONATATE, BENZONATATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
HALOPERIDOL, HALOPERIDOL
LAMOTRIGINE, LAMOTRIGINE
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN, NAPROXEN
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
RIBAVIRIN, RIBAVIRIN
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM
ZONISAMIDE, ZONISAMIDE

ZYDUS PHARMS USA INC

* ZYDUS PHARMACEUTICALS USA INC
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACETAZOLAMIDE, ACETAZOLAMIDE
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR
ALBENDAZOLE, ALBENDAZOLE
ALLOPURINOL, ALLOPURINOL
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
ARIPIPRAZOLE, ARIPIPRAZOLE
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BICALUTAMIDE, BICALUTAMIDE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CARBIDOPA, CARBIDOPA
CARVEDILOL, CARVEDILOL
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DESOXIMETASONE, DESOXIMETASONE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLUNISAL, DIFLUNISAL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
DUTASTERIDE, DUTASTERIDE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ENTECAVIR, ENTECAVIR
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE
EXEMESTANE, EXEMESTANE
EZETIMIBE, EZETIMIBE
FELBAMATE, FELBAMATE
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOCINONIDE, FLUOCINONIDE
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLIPIZIDE, GLIPIZIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
INDOMETHACIN, INDOMETHACIN
IRBESARTAN, IRBESARTAN
ITRACONAZOLE, ITRACONAZOLE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LINEZOLID, LINEZOLID
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MESALAMINE, MESALAMINE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
METRONIDAZOLE, METRONIDAZOLE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MODAFINIL, MODAFINIL
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NADOLOL, NADOLOL
NATEGLINIDE, NATEGLINIDE
NIFEDIPINE, NIFEDIPINE
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OMEPRAZOLE, OMEPRAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIROXICAM, PIROXICAM
POTASSIUM CITRATE, POTASSIUM CITRATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SIROLIMUS, SIROLIMUS
SPIRONOLACTONE, SPIRONOLACTONE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TEMOZOLOMIDE, TEMOZOLOMIDE
TERIFLUNOMIDE, TERIFLUNOMIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLMITRIPTAN, ZOLMITRIPTAN
ZYPITAMAG, PITAVASTATIN MAGNESIUM

ZYDUS WORLDWIDE

* ZYDUS WORLDWIDE DMCC
AZITHROMYCIN, AZITHROMYCIN
BACLOFEN, BACLOFEN
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
URSODIOL, URSODIOL

APPENDIX C

UNIFORM TERMS

DOSAGE FORMS

AEROSOL, FOAM
AEROSOL, METERED
CAPSULE
CAPSULE, DELAYED REL PELLETS
CAPSULE, DELAYED RELEASE
CAPSULE, EXTENDED RELEASE
CAPSULE, PELLET
CLOTH
CONCENTRATE
CREAM
CREAM, AUGMENTED
ELIXIR
EMULSION
ENEMA
FILM
FILM, EXTENDED RELEASE
FOR SOLUTION
FOR SUSPENSION
FOR SUSPENSION, DELAYED RELEASE
FOR SUSPENSION, EXTENDED RELEASE
GAS
GEL
GEL, AUGMENTED
GEL, METERED
GRANULE
GRANULE, DELAYED RELEASE
GUM, CHEWING
IMPLANT
INHALANT
INJECTABLE
INJECTABLE, LIPID COMPLEX
INJECTABLE, LIPOSOMAL
INJECTION, EXTENDED RELEASE
INSERT
INSERT, EXTENDED RELEASE
INTRAUTERINE DEVICE
JELLY
LIQUID
LOTION
LOTION, AUGMENTED
LOTION/SHAMPOO
OIL
OIL/DROPS
OINTMENT
OINTMENT, AUGMENTED
PASTE
PATCH
PELLET
POWDER
POWDER, EXTENDED RELEASE
POWDER, METERED
RING
SHAMPOO
SOLUTION
SOLUTION FOR SLUSH
SOLUTION, EXTENDED RELEASE
SOLUTION, GEL FORMING/DROPS
SOLUTION, METERED
SOLUTION/DROPS
SPONGE
SPRAY
SPRAY, METERED
SUPPOSITORY
SUSPENSION
SUSPENSION, EXTENDED RELEASE
SUSPENSION, LIPOSOMAL
SUSPENSION/DROPS
SWAB
SYRUP
SYSTEM
SYSTEM, EXTENDED RELEASE
TABLET
TABLET, CHEWABLE
TABLET, DELAYED RELEASE
TABLET, EFFERVESCENT
TABLET, EXTENDED RELEASE
TABLET, EXTENDED RELEASE, CHEWABLE
TABLET, FOR SUSPENSION
TABLET, ORALLY DISINTEGRATING
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE
TAPE
TROCHE/LOZENGE

Note: Terms comprise currently marketed products

APPENDIX C

UNIFORM TERMS

ROUTES OF ADMINISTRATION

BUCCAL
DENTAL
ENDOCERVICAL
ENDOTRACHEAL
ENTERAL
IMPLANTATION
INHALATION
INJECTION
INTRA-ANAL
INTRA-ARTERIAL
INTRA-ARTICULAR
INTRACRANIAL
INTRADERMAL
INTRAMUSCULAR
INTRAOCULAR
INTRAOSSESOUS
INTRAPERITONEAL
INTRAPLEURAL
INTRATHECAL
INTRATRACHEAL
INTRAUTERINE
INTRAVENOUS
INTRAVENOUS BOLUS
INTRAVESICAL
INTRAVITREAL
IONTOPHORESIS
IRRIGATION
IV (INFUSION)
N/A
NASAL
OPHTHALMIC
ORAL
ORAL-21
ORAL-28
OTIC
PERFUSION, CARDIAC
PERIODONTAL
RECTAL
SPINAL
SUBCUTANEOUS
SUBLINGUAL
TOPICAL
TRANSDERMAL
TRANSMUCOSAL
URETHRAL
VAGINAL

Note: Terms comprise currently marketed products

APPENDIX C

UNIFORM TERMS

ABBREVIATIONS

AMP	AMPULE
AMPICIL	AMPICILLIN
APPROX	APPROXIMATELY
BOT	BOTTLE
CI	CURIE
CSR	CAROTID SINUS REFLEX
CU	CLINICAL UNITS
DIPROP	DIPROPIONATE
ELECT	ELECTROLYTE
EQ	EQUIVALENT TO
ER	EXTENDED RELEASE
GM	GRAM
HBR	HYDROBROMIDE
HCL	HYDROCHLORIDE
HR	HOUR
IM	INTRAMUSCULAR
INH	INHALATION
IU	INTERNATIONAL UNITS
IV	INTRAVENOUS
KIU	KALLIKREIN INHIBITOR UNITS
MCG	MICROGRAM
mCi	MILLICURIE
MEQ	MILLIEQUIVALENT
MG	MILLIGRAM
ML	MILLILITER
N/A	NOT APPLICABLE
PPM	PARTS PER MILLION
REL	RELEASE
SQ CM	SQUARE CENTIMETER
SC	SUBCUTANEOUS
U	UNITS
uCi	MICROCURIE
UMOLAR	MICROMOLAR
USP	UNITED STATES PHARMACOPEIA

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

This *Addendum* identifies drugs that qualify under the Federal Food, Drug, and Cosmetic Act (FD&C Act) for periods of exclusivity and provides patent information that has been submitted to the Food and Drug Administration (FDA) concerning the listed drug products.

Exclusivity

During relevant exclusivity periods, certain abbreviated new drug applications (ANDAs) and applications described in Section 505(b)(2) of the FD&C Act (505(b)(2) applications) may not be submitted or approved as described below. This *Addendum* identifies drugs approved under section 505(c) of the FD&C Act that qualify under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments) for five-year and three-year periods of exclusivity pursuant to Section 505(c)(3)(E) and Section 505(j)(5)(F) and certain generic drugs approved under section 505(j) of the FD&C Act that have qualified for 180-day exclusivity pursuant to Section 505(j)(5)(B)(iv). This *Addendum* also identifies those drugs that have qualified for Orphan Drug Exclusivity pursuant to Section 527 of the FD&C Act, those drugs that have qualified for Pediatric Exclusivity pursuant to Section 505A of the FD&C Act, those drugs that have qualified for Generating Antibiotics Incentives Now (GAIN) exclusivity pursuant to Section 505E of the FD&C Act, and those generic drugs that have qualified for Competitive Generic Therapy (CGT) exclusivity pursuant to Section 505(j)(5)(B)(v) of the FD&C Act. This section is arranged in alphabetical order by active ingredient name followed by the proprietary name. Active ingredient headings for multiple ingredient fixed-combination drug products are arranged alphabetically.

For an explanation of the codes used in the *Addendum*, see the *Patent and Exclusivity Terms* Section. The exclusivity codes are general shorthand descriptions and do not necessarily identify, with specificity, the actual scope of exclusivity. Please note that beginning with the publication of the 38th edition of the Orange Book, individual descriptions of the protected use have been added to each Orphan Drug Exclusivity entry listed in the Orange Book. In previous editions of the Orange Book, Orphan Drug Exclusivity was not described with any specificity.

Exclusivity does not prevent the submission or approval of an application submitted pursuant to Section 505(b)(1) of the FD&C Act that would otherwise be blocked if it had been submitted pursuant to Section 505(b)(2) or 505(j), except in the case of Orphan Drug Exclusivity. Drugs approved under section 505(c) of the FD&C Act that may qualify for periods of exclusivity include:

(1) A new chemical entity, submitted in a new drug application under Section 505(b) of the FD&C Act and approved after September 24, 1984. A new chemical entity is an active ingredient that contains “no active ingredient (including any ester or salt of the active ingredient)” that has been approved by FDA in any other application submitted under Section 505(b) of the FD&C Act. An active ingredient would be eligible for 5-year exclusivity for a new chemical entity, provided that it meets the definition of a new chemical entity, regardless of whether that active ingredient is approved in a single-ingredient drug product, in a fixed-combination with another active ingredient that contains no other previously approved active moiety, or in a fixed-combination with

another active ingredient that contains a previously approved active moiety.[1] No subsequent ANDA or 505(b)(2) application for a drug that contains the same active moiety may be *submitted* for a period of *five years* from the date of approval of the original application, except that such an application may be *submitted* after *four years* if it contains a certification that a patent claiming the drug is invalid or will not be infringed by the product for which approval is sought. See Sections 505(j)(5)(F)(ii) and 505(c)(3)(E)(ii) of the FD&C Act.

(2) A new drug application approved after September 24, 1984, for a drug product containing "an active ingredient (including any ester or salt of the active ingredient)" that has been approved in an earlier new drug application and that includes reports of new clinical investigations (other than bioavailability studies). Such investigations must have been conducted or sponsored by the applicant and must have been essential to approval of the application. If these requirements are met, a subsequent ANDA or a 505(b)(2) application may not be approved for the exclusivity-protected "conditions of approval of such drug" before the expiration of *three years* from the date of approval of the original application. See Sections 505(j)(5)(F)(iii) and 505(c)(3)(E)(iii) of the FD&C Act. If an NDA has exclusivity only for a new indication or use, this exclusivity generally does not preclude the approval of an ANDA or 505(b)(2) application for indications and uses not covered by the exclusivity, assuming the proposed drug product will be safe and effective as labeled.

(3) A supplement to a new drug application for a drug containing a previously approved "active ingredient (including any ester or salt of the active ingredient)" approved after September 24, 1984, that contains reports of new clinical investigations (other than bioavailability studies) essential to the approval of the supplement and conducted or sponsored by the applicant. See Sections 505(j)(5)(F)(iv) and 505(c)(3)(E)(iv) of the FD&C Act. A subsequent ANDA or 505(b)(2) application may not be approved for an exclusivity-protected change approved in the supplement for *three years* from the date of approval of the supplement.

Patent Information

The FD&C Act requires that patent information be filed with all newly submitted Section 505(b) drug applications. No NDA may be approved after September 24, 1984, without the submission of patent information to the Agency. Effective August 18, 2003, this information must be filed using Form FDA 3542a "Patent Information Submitted with the Filing of an NDA, Amendment or Supplement".

Effective August 18, 2003, upon approval of an application, patent information for purposes of listing in the Orange Book must be submitted to the Agency within 30 days of the date of approval on Form FDA 3542 "Patent

[1] For more information on exclusivity for fixed-dose combination drug products that include new chemical entities, see FDA's guidance on *New Chemical Entity Exclusivity Determinations for Certain Fixed-Dose Combination Drug Products* at https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm386685.pdf.

Information Submitted Upon and After Approval of an NDA or Supplement."[2] In November 2017, the Agency began including in the Orange Book the patent submission date (i.e., the date on which the FDA receives patent information from the NDA holder) for each newly listed patent to facilitate assessments of whether patent information is untimely filed with respect to a pending 505(b)(2) application or ANDA.[3] Patent information on unapproved applications or on patents beyond the scope of the FD&C Act (i.e., process or manufacturing patents) will not be published. Form FDA 3542 will be the only form used for purposes of this publication.

The patents that FDA regards as covered by the statutory provisions for submission of patent information are: patents that claim the active ingredient(s); drug product patents, which include formulation/composition patents; method-of-use patents that claim one or more approved methods of using the approved drug product; and certain other patents as detailed in the regulations and on Form FDA 3542.[4] This information, as provided by the sponsor on Form FDA 3542, will be published as described above. As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that the patent claims either the drug substance or the drug product.

A requirement for submission of patent information to FDA for certain old antibiotics became effective October 7, 2008 under Section 4(b)(1) of the QI Program Supplemental Funding Act (Public Law 110-379) (QI Act).

Upon approval of an NDA or at such time as patent information is updated for the drug product, FDA adds to the Orange Book the patent number, expiration date, type of patent, and submission date... The Addendum lists patent and exclusivity information up to January of the Edition year. The monthly Cumulative Supplements to the annual edition list patent and exclusivity information changes since the Annual Edition Addendum. Since all parts of this publication are subject to changes, additions, or deletions, the Orange Book, updated daily, should be consulted for the most recent patent and exclusivity information.

[2] Please note that the date of approval for an NDA for a drug for which FDA intends to recommend controls under the Controlled Substances Act is the later of the date on the approval letter for the NDA or the date of issuance of the interim final rule controlling the drug (see Section 505(x)(1) and (2) of the FD&C Act).

[3] See 21 CFR 314.50(i)(4) and 314.94(a)(12)(vi). The submission date for patent information is determined in accordance with 21 CFR 314.53(d)(5).

4 See 21 CFR 314.53(c)(2)(ii)(M), (N)(*2*) and (N)(*3*).

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABACAVIR SULFATE - ZIAGEN							
N 020978	001	6641843	Feb 04, 2019	DP			
ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ							
N 205551	001	8129385	Oct 05, 2027	DS DP			
		9242986	Dec 08, 2029	DS DP			
ABALOPARATIDE - TYMLOS							
N 208743	001	7803770	Mar 26, 2028	U-2009		NCE	Apr 28, 2022
		8148333	Nov 08, 2027	DP			
		8748382	Oct 03, 2027	U-2009			
ABEMACICLIB - VERZENIO							
N 208716	001	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
		7855211	Dec 15, 2029	DS DP U-2135		NCE	Sep 28, 2022
		7855211	Dec 15, 2029	DS DP U-2251			
ABEMACICLIB - VERZENIO							
N 208716	002	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
		7855211	Dec 15, 2029	DS DP U-2135		NCE	Sep 28, 2022
		7855211	Dec 15, 2029	DS DP U-2251			
ABEMACICLIB - VERZENIO							
N 208716	003	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
		7855211	Dec 15, 2029	DS DP U-2135		NCE	Sep 28, 2022
		7855211	Dec 15, 2029	DS DP U-2251			
ABEMACICLIB - VERZENIO							
N 208716	004	7855211	Dec 15, 2029	DS DP U-1981		I-768	Feb 26, 2021
		7855211	Dec 15, 2029	DS DP U-2132		NCE	Sep 28, 2022
		7855211	Dec 15, 2029	DS DP U-2135			
		7855211	Dec 15, 2029	DS DP U-2251			
ABIRATERONE ACETATE - ZYTIGA							
N 202379	001	8822438	Aug 24, 2027	U-1579		I-765	Feb 07, 2021
		8822438	Aug 24, 2027	U-1580			
		8822438	Aug 24, 2027	U-2235			
ABIRATERONE ACETATE - ZYTIGA							
N 202379	002	8822438	Aug 24, 2027	U-1579		I-765	Feb 07, 2021
		8822438	Aug 24, 2027	U-1580			
		8822438	Aug 24, 2027	U-2235			
ABIRATERONE ACETATE - YONSA							
N 210308	001	9889144	Mar 17, 2034	DP			
ACALABRUTINIB - CALQUENCE							
N 210259	001	7459554	Nov 24, 2026	DS		NCE	Oct 31, 2022
		9290504	Jul 11, 2032	DS DP		ODE-175	Oct 31, 2024
		9758524	Jul 11, 2032	U-2145			
		9796721	Jul 01, 2036	DS DP U-2145			
ACETAMINOPHEN - OFIRMEV							
N 022450	001	6992218	Jun 06, 2021	DP		M-196	Jan 27, 2020
		6992218*PED	Dec 06, 2021			PED	Jul 27, 2020
		9399012	Sep 11, 2031	U-2261			
		9399012	Sep 11, 2031	U-2262			
		9399012*PED	Mar 11, 2032				
		9610265	Nov 13, 2028	U-2263			
		9610265*PED	May 13, 2029				
		9987238	Nov 13, 2028	U-2261			
		9987238*PED	May 13, 2029				
ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ							
N 208653	001	8461137	Feb 22, 2031	DS DP			
		8748413	Jul 01, 2030	DS DP			
		8828978	Jul 01, 2030	DP			
		9132125	Jul 01, 2030	DS DP U-2249			
		9549923	Jul 01, 2030	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR							
N 204031	001	6488962	Jun 20, 2020	DP			
		7976870	Jun 01, 2027	U-1498			
		8372432	Mar 11, 2029	DP U-1499			
		8377453	Nov 19, 2029	DP U-1499			
		8394408	Mar 11, 2029	DP			
		8597681	Dec 21, 2030	DP			
		8658631	May 16, 2032	DP			
		8668929	Mar 11, 2029	U-1499			
		8741885	May 16, 2032	DP U-1499			
		8980319	Dec 21, 2030	DP			
		8992975	May 16, 2032	DP			
		9050335	May 16, 2032	DP			
		9468636	May 16, 2032	U-1499			
ACETYLCYSTEINE - ACETADOTE							
N 021539	001	8148356	May 21, 2026	DP			
		8399445	Aug 24, 2025	U-1373			
		8653061	Aug 24, 2025	U-1373			
		8722738	Apr 06, 2032	U-1373			
		9327028	Jul 21, 2031	U-1839			
ACETYLCYSTEINE - CETYLEV							
N 207916	001	8747894	May 08, 2032	DP U-1373			
		9427421	May 08, 2032	DP			
		9561204	May 08, 2032	U-1373			
ACETYLCYSTEINE - CETYLEV							
N 207916	002	8747894	May 08, 2032	DP U-1373			
		9427421	May 08, 2032	DP			
		9561204	May 08, 2032	U-1373			
ACLIDINIUM BROMIDE - TUDORZA PRESSAIR							
N 202450	001	10034867	Jul 07, 2020	DP U-2431			
		10034867	Jul 07, 2020	DP U-2432			
		10085974	Mar 13, 2029	DP U-1263			
		6681768	Aug 07, 2022	DP			
		7078412	Jul 07, 2020	DS DP U-2431			
		8051851	Apr 22, 2027	DP			
		9056100	Jul 07, 2020	DP U-1263			
		9333195	Jul 07, 2020	DP U-1263			
		RE46417	Feb 10, 2025	DS DP U-1263			
ACYCLOVIR - SITAVIG							
N 203791	001	8592434	Jun 16, 2030	DP U-1460			
		8747896	Jun 03, 2027	DP U-1460			
		8791127	Mar 23, 2027	DP U-1460			
ACYCLOVIR; HYDROCORTISONE - XERESE							
N 022436	001	7223387	Nov 13, 2022	DP U-1006			
		7223387	Nov 13, 2022	DP U-1484			
ADAPALENE - DIFFERIN							
N 020380	002					RTO	Jul 08, 2019
ADAPALENE - DIFFERIN							
N 021753	001	7579377	Feb 23, 2025	U-818			
		7737181	Aug 29, 2024	DP			
		7834060	Mar 12, 2023	U-1078			
		7838558	Mar 12, 2023	DP			
		7868044	Mar 12, 2023	U-1078			
		8703820	Mar 12, 2023	U-1078			
ADAPALENE - DIFFERIN							
N 022502	001	7998467	May 31, 2028	DP U-1078			
		8435502	Sep 15, 2026	DP U-1078			
		8709392	Sep 15, 2026	DP U-1078			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ADAPALENE; BENZOYL PEROXIDE - EPIDUO								
N 022320	001	7820186	Nov 23, 2025		DP			
		7964202	Sep 01, 2024		DP U-1078			
		8071644	Jul 18, 2027		DP U-1078			
		8080537	Jul 18, 2027		U-1078			
		8105618	Dec 23, 2022		U-1078			
		8129362	Jul 18, 2027		U-1078			
		8241649	Dec 23, 2022		DP			
		8445543	Jul 12, 2027		U-1078			
		8809305	Dec 23, 2022		U-1078			
		8936800	Dec 23, 2022		DP U-1078			
ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE								
N 207917	001	8445543	Dec 23, 2022		U-1078			
		8703820	Mar 12, 2023		U-1078			
		8729127	Mar 12, 2023		U-1078			
		8785420	Dec 23, 2022		U-1078			
		8809305	Dec 23, 2022		U-1078			
		8936800	Dec 23, 2022		DP U-1078			
		9381179	Mar 12, 2023		U-1078			
		9387187	Mar 12, 2023		U-1078			
		9814690	Dec 23, 2022		DP U-1078			
AFATINIB DIMALEATE - GILOTRIF								
N 201292	001	10004743	Jul 05, 2030		DP		I-763	Jan 12, 2021
		8426586	Oct 10, 2029	DS			ODE-115	Apr 15, 2023
		8545884	Dec 19, 2029		DP		ODE-50	Jul 12, 2020
		9539258	Nov 09, 2026		U-1950			
		RE43431	Jan 22, 2022	DS				
AFATINIB DIMALEATE - GILOTRIF								
N 201292	002	10004743	Jul 05, 2030		DP		I-763	Jan 12, 2021
		8426586	Oct 10, 2029	DS			ODE-115	Apr 15, 2023
		8545884	Dec 19, 2029		DP		ODE-50	Jul 12, 2020
		9539258	Nov 09, 2026		U-1950			
		RE43431	Jan 22, 2022	DS				
AFATINIB DIMALEATE - GILOTRIF								
N 201292	003	10004743	Jul 05, 2030		DP		I-730	Apr 15, 2019
		8426586	Oct 10, 2029	DS			I-763	Jan 12, 2021
		8545884	Dec 19, 2029		DP		ODE-115	Apr 15, 2023
		9539258	Nov 09, 2026		U-1950		ODE-50	Jul 12, 2020
		RE43431	Jan 22, 2022	DS				
ALBUMIN HUMAN - OPTISON								
N 020899	001	6723303	Apr 20, 2021		DP			
ALBUTEROL SULFATE - ACCUNEB								
N 020949	001	6702997	Dec 28, 2021		U-558			
ALBUTEROL SULFATE - ACCUNEB								
N 020949	002	6702997	Dec 28, 2021		U-558			
ALBUTEROL SULFATE - VENTOLIN HFA								
N 020983	001	7500444	Feb 26, 2026		DP			
		7500444*PED	Aug 26, 2026					
		7832351	Jun 19, 2023		DP			
		9861771	Oct 11, 2020		DP			
ALBUTEROL SULFATE - PROAIR HFA								
N 021457	001	10022509	May 18, 2031		DP			
		10022510	May 18, 2031		DP			
		10086156	May 18, 2031		DP			
		7105152	Sep 12, 2023		DP			
		8132712	Sep 07, 2028		DP			
		9463289	May 18, 2031		DP			
		9808587	May 18, 2031		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALBUTEROL SULFATE - PROAIR RESPICLICK								
N 205636	001	10022510	May 18, 2031		DP		NPP	Apr 28, 2019
		10124131	May 18, 2031		DP			
		6701917	Jun 23, 2021		DP			
		6718972	Jun 23, 2021		DP			
		6748947	Jun 23, 2021		DP			
		6871646	Jun 23, 2021		DP			
		7540282	May 06, 2023		DP			
		8006690	Jun 23, 2021		DP			
		8651103	Mar 26, 2028		DP			
		8978966	Jan 13, 2032		DP			
		9216260	Jun 28, 2031		DP			
		9463288	May 19, 2025		DP			
		9731087	May 18, 2031		DP			
		9782550	Aug 28, 2035		DP			
		9782551	Aug 28, 2035		DP			
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - DUONEB								
N 020950	001	6632842	Dec 28, 2021		U-532			
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT								
N 021747	001	6988496	Feb 23, 2020		DP			
		7284474	Aug 26, 2024		DP			
		7396341	Oct 10, 2026		DP			
		7802568	Feb 26, 2019		DP			
		7837235	Mar 13, 2028		DP			
		7896264	May 26, 2025		DP			
		7988001	Aug 04, 2021		DP			
		8733341	Oct 16, 2030		DP			
		9027967	Mar 31, 2027		DP			
ALCAFTADINE - LASTACAFT								
N 022134	001	8664215	Dec 23, 2027		U-1493			
ALCOHOL - ABLYSINOL								
N 207987	001						ODE-192	Jun 21, 2025
ALCOHOL - ABLYSINOL								
N 207987	002						ODE-192	Jun 21, 2025
ALECTINIB HYDROCHLORIDE - ALECENSA								
N 208434	001	9126931	May 29, 2031	DS			I-756	Nov 06, 2020
		9365514	Mar 04, 2032		DP		NCE	Dec 11, 2020
		9440922	Jun 09, 2030		DP		ODE-105	Dec 11, 2022
							ODE-159	Nov 06, 2024
ALENDRONATE SODIUM - BINOSTO								
N 202344	001	7488496	Aug 11, 2023	DS	DP			
		7964212	Mar 06, 2023	DS	DP			
ALISKIREN HEMIFUMARATE - TEKTURNA								
N 021985	001	5559111*PED	Jan 21, 2019					
		8617595	Feb 19, 2026		DP			
		8617595*PED	Aug 19, 2026					
ALISKIREN HEMIFUMARATE - TEKTURNA								
N 021985	002	5559111*PED	Jan 21, 2019					
		8617595	Feb 19, 2026		DP			
		8617595*PED	Aug 19, 2026					
ALISKIREN HEMIFUMARATE - TEKTURNA								
N 210709	001						NP	Nov 14, 2020
							PED	May 14, 2021
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO								
N 022545	001	8613949	Dec 21, 2029		DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO								
N 022545	002	8613949	Dec 21, 2029		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO							
N 022545	003	8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO							
N 022545	004	8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N 200045	001	8183295	May 16, 2023	DP			
		8618174	Nov 15, 2021	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N 200045	002	8183295	May 16, 2023	DP			
		8618174	Nov 15, 2021	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N 200045	003	8183295	May 16, 2023	DP			
		8618174	Nov 15, 2021	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N 200045	004	8183295	May 16, 2023	DP			
		8618174	Nov 15, 2021	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N 200045	005	8183295	May 16, 2023	DP			
		8618174	Nov 15, 2021	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT							
N 022107	001	5559111*PED	Jan 21, 2019				
		8618172	Jul 13, 2028	DP			
		9023893	Mar 03, 2022	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT							
N 022107	002	5559111*PED	Jan 21, 2019				
		8618172	Jul 13, 2028	DP			
		9023893	Mar 03, 2022	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT							
N 022107	003	5559111*PED	Jan 21, 2019				
		8618172	Jul 13, 2028	DP			
		9023893	Mar 03, 2022	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT							
N 022107	004	5559111*PED	Jan 21, 2019				
		8618172	Jul 13, 2028	DP			
		9023893	Mar 03, 2022	DP			
ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA							
N 022217	001	8168616	Jul 03, 2026	DP			
ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA							
N 022217	002	8168616	Jul 03, 2026	DP			
ALLOPURINOL; LESINURAD - DUZALLO							
N 209203	001	8003681	Aug 25, 2025	DS			
		8084483	Aug 17, 2029			U-2104	
		8283369	Nov 26, 2028			U-2104	
		8357713	Nov 26, 2028	DP		U-2104	
		8546436	Feb 29, 2032	DS			
		8546437	Apr 29, 2029			U-2104	
		9216179	Aug 01, 2031			U-2104	
		9956205	Dec 28, 2031			U-2104	
ALLOPURINOL; LESINURAD - DUZALLO							
N 209203	002	8003681	Aug 25, 2025	DS			
		8084483	Aug 17, 2029			U-2104	
		8283369	Nov 26, 2028			U-2104	
		8357713	Nov 26, 2028	DP		U-2104	
		8546436	Feb 29, 2032	DS			
		8546437	Apr 29, 2029			U-2104	
		9216179	Aug 01, 2031			U-2104	
		9956205	Dec 28, 2031			U-2104	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALLOPURINOL; LESINURAD - DUZALLO							
N 209203	002	8003681	Aug 25, 2025	DS			
		8084483	Aug 17, 2029	U-2104			
		8283369	Nov 26, 2028	U-2104			
		8357713	Nov 26, 2028	DP U-2104			
		8546436	Feb 29, 2032	DS			
		8546437	Apr 29, 2029	U-2104			
		9216179	Aug 01, 2031	U-2104			
		9956205	Dec 28, 2031	U-2104			
ALOGLIPTIN BENZOATE - NESINA							
N 022271	001	6890898	Feb 02, 2019	U-1335		M-177	Apr 05, 2019
		7078381	Feb 02, 2019	U-1335			
		7459428	Feb 02, 2019	U-1336			
		7807689	Jun 27, 2028	DS DP U-1337			
		8173663	Dec 02, 2025	U-1338			
		8288539	Mar 15, 2025	DS			
		8697125	Jun 16, 2029	DP			
ALOGLIPTIN BENZOATE - NESINA							
N 022271	002	6890898	Feb 02, 2019	U-1335		M-177	Apr 05, 2019
		7078381	Feb 02, 2019	U-1335			
		7459428	Feb 02, 2019	U-1336			
		7807689	Jun 27, 2028	DS DP U-1337			
		8173663	Dec 02, 2025	U-1338			
		8288539	Mar 15, 2025	DS			
		8697125	Jun 16, 2029	DP			
ALOGLIPTIN BENZOATE - NESINA							
N 022271	003	6890898	Feb 02, 2019	U-1335		M-177	Apr 05, 2019
		7078381	Feb 02, 2019	U-1335			
		7459428	Feb 02, 2019	U-1336			
		7807689	Jun 27, 2028	DS DP U-1337			
		8173663	Dec 02, 2025	U-1338			
		8288539	Mar 15, 2025	DS			
		8697125	Jun 16, 2029	DP			
ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO							
N 203414	001	6890898	Feb 02, 2019	U-1335		M-177	Apr 05, 2019
		7078381	Feb 02, 2019	U-1335			
		7459428	Feb 02, 2019	U-1336			
		7807689	Jun 27, 2028	DS DP U-1337			
		8173663	Mar 15, 2025	U-1338			
		8288539	Jun 24, 2025	DS			
		8900638	May 24, 2029	DP			
ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO							
N 203414	002	6890898	Feb 02, 2019	U-1335		M-177	Apr 05, 2019
		7078381	Feb 02, 2019	U-1335			
		7459428	Feb 02, 2019	U-1336			
		7807689	Jun 27, 2028	DS DP U-1337			
		8173663	Mar 15, 2025	U-1338			
		8288539	Jun 24, 2025	DS			
		8900638	May 24, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426	001	6329404	Jun 19, 2021	DP U-1334		M-177	Apr 05, 2019
		6890898	Feb 02, 2019	U-1335			
		7078381	Feb 02, 2019	U-1335			
		7459428	Feb 02, 2019	U-1336			
		7807689	Jun 27, 2028	DS DP U-1337			
		8173663	Mar 15, 2025	U-1338			
		8288539	Mar 15, 2025	DS			
		8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426	002	6329404	Jun 19, 2021	DP U-1334		M-177	Apr 05, 2019
		6890898	Feb 02, 2019	U-1335			
		7078381	Feb 02, 2019	U-1335			
		7459428	Feb 02, 2019	U-1336			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426	002	7807689	Jun 27, 2028	DS DP U-1337			
		8173663	Mar 15, 2025	U-1338			
		8288539	Mar 15, 2025	DS			
		8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426	003	6329404	Jun 19, 2021	DP U-1334		M-177	Apr 05, 2019
		6890898	Feb 02, 2019	U-1335			
		7078381	Feb 02, 2019	U-1335			
		7459428	Feb 02, 2019	U-1336			
		7807689	Jun 27, 2028	DS DP U-1337			
		8173663	Mar 15, 2025	U-1338			
		8288539	Mar 15, 2025	DS			
		8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426	004	6329404	Jun 19, 2021	DP U-1334		M-177	Apr 05, 2019
		6890898	Feb 02, 2019	U-1335			
		7078381	Feb 02, 2019	U-1335			
		7459428	Feb 02, 2019	U-1336			
		7807689	Jun 27, 2028	DS DP U-1337			
		8173663	Mar 15, 2025	U-1338			
		8288539	Mar 15, 2025	DS			
		8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426	005	6329404	Jun 19, 2021	DP U-1334		M-177	Apr 05, 2019
		6890898	Feb 02, 2019	U-1335			
		7078381	Feb 02, 2019	U-1335			
		7459428	Feb 02, 2019	U-1336			
		7807689	Jun 27, 2028	DS DP U-1337			
		8173663	Mar 15, 2025	U-1338			
		8288539	Mar 15, 2025	DS			
		8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426	006	6890898	Feb 02, 2019	U-1335		M-177	Apr 05, 2019
		7078381	Feb 02, 2019	U-1335			
		7459428	Feb 02, 2019	U-1336			
		7807689	Jun 27, 2028	DS DP U-1337			
		8173663	Mar 15, 2025	U-1338			
		8288539	Mar 15, 2025	DS			
		8637079	Jun 04, 2029	DP			
ALVIMOPAN - ENTEREG							
N 021775	001	6469030	Nov 29, 2020	U-879			
		8112290	Jul 31, 2030	U-1443	Y		
		8645160	Jun 18, 2029	U-1485	Y		
		8946262	Feb 12, 2030	U-1655			
AMANTADINE HYDROCHLORIDE - GOCOVRI							
N 208944	001	10154971	Dec 04, 2034	U-2459		I-769	Aug 24, 2020
		8389578	Jan 22, 2028	U-2105		ODE-153	Aug 24, 2024
		8741343	Dec 02, 2030	U-2106			
		8796337	Nov 23, 2025	U-2106			
		8889740	Nov 23, 2025	DP			
		8895614	Nov 23, 2025	DP			
		8895615	Nov 23, 2025	U-2106			
		8895616	Nov 23, 2025	U-2106			
		8895617	Nov 23, 2025	U-2106			
		8895618	Nov 23, 2025	DP			
		9867791	Dec 02, 2030	U-2106			
		9867792	Dec 02, 2030	U-2106			
		9867793	Dec 02, 2030	U-2106			
		9877933	Dec 02, 2030	U-2224			
AMANTADINE HYDROCHLORIDE - GOCOVRI							
N 208944	002	10154971	Dec 04, 2034	U-2459		I-769	Aug 24, 2020
		8389578	Jan 22, 2028	U-2105		ODE-153	Aug 24, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMANTADINE HYDROCHLORIDE - GOCOVRI							
N 208944	002	8741343	Dec 02, 2030	U-2106			
		8796337	Nov 23, 2025	U-2106			
		8889740	Nov 23, 2025	DP			
		8895614	Nov 23, 2025	DP			
		8895615	Nov 23, 2025	U-2106			
		8895616	Nov 23, 2025	U-2106			
		8895617	Nov 23, 2025	U-2106			
		8895618	Nov 23, 2025	DP			
		9867791	Dec 02, 2030	U-2106			
		9867792	Dec 02, 2030	U-2106			
		9867793	Dec 02, 2030	U-2106			
		9877933	Dec 02, 2030	U-2224			
AMANTADINE HYDROCHLORIDE - OSMOLEX ER							
N 209410	001	8252331	Mar 13, 2030	DP			
		8574626	Nov 28, 2025	DP U-20			
AMANTADINE HYDROCHLORIDE - OSMOLEX ER							
N 209410	002	8252331	Mar 13, 2030	DP			
		8574626	Nov 28, 2025	DP U-20			
AMANTADINE HYDROCHLORIDE - OSMOLEX ER							
N 209410	003	8252331	Mar 13, 2030	DP			
		8574626	Nov 28, 2025	DP U-20			
AMBRISENTAN - LETAIRIS							
N 022081	001	8377933	Dec 11, 2027	U-1754			
		9474752	Dec 11, 2027	U-1754			
		9549926	Oct 14, 2031	U-1965			
AMBRISENTAN - LETAIRIS							
N 022081	002	8377933	Dec 11, 2027	U-1754			
		9474752	Dec 11, 2027	U-1754			
		9549926	Oct 14, 2031	U-1965			
AMIFAMPRIDINE PHOSPHATE - FIRDAPSE							
N 208078	001					NCE	Nov 28, 2023
						ODE-223	Nov 28, 2025
AMIKACIN SULFATE - ARIKAYCE KIT							
N 207356	001	7718189	Jun 06, 2025	DP U-2415		ODE-214	Sep 28, 2025
		8226975	Aug 15, 2028	DP			
		8632804	Dec 05, 2026	U-2416			
		8642075	Dec 05, 2026	DP			
		8679532	Dec 05, 2026	U-2415			
		8802137	Apr 08, 2024	DP U-2414			
		9566234	Jan 18, 2034	DP U-2415			
		9827317	Apr 08, 2024	DP U-2415			
		9895385	May 15, 2035	U-2417			
AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN							
N 020965	001	7723910	Jun 17, 2019	U-289		I-766	Mar 09, 2021
AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ							
N 208081	001	6559183	Nov 12, 2019	DP U-804		NP	May 10, 2019
AMINOLEVULINIC ACID HYDROCHLORIDE - GLEOLAN							
N 208630	001					ODE-146	Jun 06, 2024
AMIODARONE HYDROCHLORIDE - NEXTERONE							
N 022325	001	6869939	May 04, 2022	DP			
		7635773	Mar 13, 2029	DP			
AMIODARONE HYDROCHLORIDE - NEXTERONE							
N 022325	002	6869939	May 04, 2022	DP			
		7635773	Mar 13, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMIODARONE HYDROCHLORIDE - NEXTERONE							
N 022325	003	6869939	May 04, 2022	DP			
		7635773	Mar 13, 2029	DP			
AMLODIPINE BESYLATE - AMLODIPINE BESYLATE							
N 022026	001	6828339	Nov 20, 2022	DS			
AMLODIPINE BESYLATE - AMLODIPINE BESYLATE							
N 022026	002	6828339	Nov 20, 2022	DS			
AMLODIPINE BESYLATE - AMLODIPINE BESYLATE							
N 022026	003	6828339	Nov 20, 2022	DS			
AMLODIPINE BESYLATE; CELECOXIB - CONSENSI							
N 210045	001	9662315	Feb 28, 2030	DP U-2410		NC	May 31, 2021
AMLODIPINE BESYLATE; CELECOXIB - CONSENSI							
N 210045	002	9662315	Feb 28, 2030	DP U-2410		NC	May 31, 2021
AMLODIPINE BESYLATE; CELECOXIB - CONSENSI							
N 210045	003	9662315	Feb 28, 2030	DP U-2410		NC	May 31, 2021
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT							
N 022314	001	8101599	May 16, 2023	DP			
		8475839	May 16, 2023	DP			
		8475839*PED	Nov 16, 2023				
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT							
N 022314	002	8101599	May 16, 2023	DP			
		8475839	May 16, 2023	DP			
		8475839*PED	Nov 16, 2023				
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT							
N 022314	003	8101599	May 16, 2023	DP			
		8475839	May 16, 2023	DP			
		8475839*PED	Nov 16, 2023				
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT							
N 022314	004	8101599	May 16, 2023	DP			
		8475839	May 16, 2023	DP			
		8475839*PED	Nov 16, 2023				
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT							
N 022314	005	8101599	May 16, 2023	DP			
		8475839	May 16, 2023	DP			
		8475839*PED	Nov 16, 2023				
AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA							
N 205003	001	6696481	Apr 15, 2023	DS DP U-3			
		7846961	Oct 05, 2029	DS DP U-3			
AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA							
N 205003	002	6696481	Apr 15, 2023	DS DP U-3			
		7846961	Oct 05, 2029	DS DP U-3			
AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA							
N 205003	003	6696481	Apr 15, 2023	DS DP U-3			
		7846961	Oct 05, 2029	DS DP U-3			
AMLODIPINE BESYLATE; VALSARTAN - EXFORGE							
N 021990	002	6395728	Jul 08, 2019	DP			
AMLODIPINE BESYLATE; VALSARTAN - EXFORGE							
N 021990	003	6395728	Jul 08, 2019	DP			
AMLODIPINE BESYLATE; VALSARTAN - EXFORGE							
N 021990	004	6395728	Jul 08, 2019	DP			
AMLODIPINE BESYLATE; VALSARTAN - EXFORGE							
N 021990	005	6395728	Jul 08, 2019	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMOXICILLIN - MOXATAG							
N 050813	001	6544555	Oct 13, 2020	DS DP		U-897	
		6669948	Oct 13, 2020	DS DP		U-897	
		6723341	Oct 13, 2020	DS DP		U-897	
		8299052	May 07, 2027			U-1304	
		8357394	Dec 08, 2026	DP			
		8778924	Dec 08, 2026	DS DP		U-897	
AMOXICILLIN; CLAVULANATE POTASSIUM - AUGMENTIN XR							
N 050785	001	6746692	Apr 04, 2020	DP			
		6783773	Apr 04, 2020	DP			
		6878386	Apr 04, 2020			U-926	
		7217430	Apr 04, 2020	DP		U-926	
		7250176	Apr 04, 2020			U-926	
AMPHETAMINE - ADZENYS ER							
N 204325	001	8709491	Jun 28, 2032	DP			
		9017731	Jun 28, 2032	DP			
		9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT							
N 204326	001	8709491	Jun 28, 2032	DP			
		8840924	Apr 09, 2026	DP			
		9017731	Jun 28, 2032	DP			
		9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT							
N 204326	002	8709491	Jun 28, 2032	DP			
		8840924	Apr 09, 2026	DP			
		9017731	Jun 28, 2032	DP			
		9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT							
N 204326	003	8709491	Jun 28, 2032	DP			
		8840924	Apr 09, 2026	DP			
		9017731	Jun 28, 2032	DP			
		9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT							
N 204326	004	8709491	Jun 28, 2032	DP			
		8840924	Apr 09, 2026	DP			
		9017731	Jun 28, 2032	DP			
		9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT							
N 204326	005	8709491	Jun 28, 2032	DP			
		8840924	Apr 09, 2026	DP			
		9017731	Jun 28, 2032	DP			
		9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT							
N 204326	006	8709491	Jun 28, 2032	DP			
		8840924	Apr 09, 2026	DP			
		9017731	Jun 28, 2032	DP			
		9265737	Jun 28, 2032	DP			
AMPHETAMINE - DYANAVEL XR							
N 208147	001	10086087	Mar 15, 2027	DP			
		8062667	Mar 29, 2029	DP			
		8597684	Mar 15, 2027	DP			
		8747902	Mar 15, 2027	DP			
		8883217	Mar 15, 2027	DP			
		9675703	Mar 15, 2027	DP			
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 10							
N 011522	007	6384020	Jul 06, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 20								
N	011522	008	6384020	Jul 06, 2020				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 5								
N	011522	009	6384020	Jul 06, 2020				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 30								
N	011522	010	6384020	Jul 06, 2020				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 7.5								
N	011522	011	6384020	Jul 06, 2020				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 12.5								
N	011522	012	6384020	Jul 06, 2020				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 15								
N	011522	013	6384020	Jul 06, 2020				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS								
N	022063	001	6913768	May 24, 2023	DP	U-2025	NP	Jun 20, 2020
			8846100	Aug 24, 2029	DP			
			9173857	May 12, 2026		U-2025		
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS								
N	022063	002	6913768	May 24, 2023	DP	U-2025	NP	Jun 20, 2020
			8846100	Aug 24, 2029	DP			
			9173857	May 12, 2026		U-2025		
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS								
N	022063	003	6913768	May 24, 2023	DP	U-2025	NP	Jun 20, 2020
			8846100	Aug 24, 2029	DP			
			9173857	May 12, 2026		U-2025		
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS								
N	022063	004	6913768	May 24, 2023	DP	U-2025	NP	Jun 20, 2020
			8846100	Aug 24, 2029	DP			
			9173857	May 12, 2026		U-2025		
AMPHETAMINE SULFATE - AMPHETAMINE SULFATE								
A	211139	001					CGT	Mar 26, 2019
AMPHETAMINE SULFATE - AMPHETAMINE SULFATE								
A	211139	002					CGT	Mar 30, 2019
AMPHOTERICIN B - ABELCET								
N	050724	001	6406713	Jun 18, 2019	DS			
ANGIOTENSIN II ACETATE - GIAPREZA								
N	209360	001	10028995	Dec 18, 2034		U-2338	NCE	Dec 21, 2022
			9220745	Dec 18, 2034		U-2217		
			9220745	Dec 18, 2034		U-2218		
			9572856	Sep 20, 2030		U-2221		
			9867863	Dec 16, 2029		U-2231		
ANGIOTENSIN II ACETATE - GIAPREZA								
N	209360	002	10028995	Dec 18, 2034		U-2338	NCE	Dec 21, 2022
			9220745	Dec 18, 2034		U-2217		
			9220745	Dec 18, 2034		U-2218		
			9572856	Sep 20, 2030		U-2221		
			9867863	Dec 16, 2029		U-2231		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ANIDULAFUNGIN - ERAXIS						
N 021632 001	5965525	Feb 17, 2020	DS DP U-540			
	6960564	Apr 12, 2021	DP U-540			
	7709444	Apr 12, 2021	DP U-540			
ANIDULAFUNGIN - ERAXIS						
N 021632 002	5965525	Feb 17, 2020	DS DP U-540			
	6960564	Apr 12, 2021	DP U-540			
	7709444	Apr 12, 2021	DP U-540			
APALUTAMIDE - ERLEADA						
N 210951 001	10052314	Sep 23, 2033	U-2381		NCE	Feb 14, 2023
	10052314	Sep 23, 2033	U-2382			
	8445507	Sep 15, 2030	DS DP U-2237			
	8802689	Mar 27, 2027	U-2237			
	9388159	Mar 27, 2027	DS DP			
	9481663	Jun 04, 2033	DS DP U-2237			
	9884054	Sep 23, 2033	U-2237			
	9987261	Mar 27, 2027	DP			
APIXABAN - ELIQUIS						
N 202155 001	6413980	Dec 22, 2019	DS DP U-1200			
	6413980	Dec 22, 2019	DS DP U-1301			
	6413980	Dec 22, 2019	DS DP U-1302			
	6413980	Dec 22, 2019	DS DP U-1501			
	6967208	Nov 21, 2026	DS DP U-1167			
	6967208	Nov 21, 2026	DS DP U-1200			
	6967208	Nov 21, 2026	DS DP U-1301			
	6967208	Nov 21, 2026	DS DP U-1302			
	6967208	Nov 21, 2026	DS DP U-1323			
	6967208	Nov 21, 2026	DS DP U-1501			
	6967208	Nov 21, 2026	DS DP U-1502			
	6967208	Nov 21, 2026	DS DP U-1729			
	6967208	Nov 21, 2026	DS DP U-1730			
	9326945	Feb 24, 2031	DP			
APIXABAN - ELIQUIS						
N 202155 002	6413980	Dec 22, 2019	DS DP U-1200			
	6413980	Dec 22, 2019	DS DP U-1301			
	6413980	Dec 22, 2019	DS DP U-1302			
	6967208	Nov 21, 2026	DS DP U-1200			
	6967208	Nov 21, 2026	DS DP U-1301			
	6967208	Nov 21, 2026	DS DP U-1302			
	6967208	Nov 21, 2026	DS DP U-1323			
	9326945	Feb 24, 2031	DP			
APREMILAST - OTEZLA						
N 205437 001	10092541	May 29, 2034	U-2403		NCE	Mar 21, 2019
	6962940	Mar 19, 2023	U-1504			
	7208516	Mar 19, 2023	U-1505			
	7427638	Feb 16, 2028	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8802717	Mar 19, 2023	U-1561			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			
APREMILAST - OTEZLA						
N 205437 002	10092541	May 29, 2034	U-2403		NCE	Mar 21, 2019
	6962940	Mar 19, 2023	U-1504			
	7208516	Mar 19, 2023	U-1505			
	7427638	Feb 16, 2028	DS DP			
	7659302	Mar 19, 2023	U-1505			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
APREMILAST - OTEZLA						
N 205437 002	7659302	Mar 19, 2023	U-1595			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8802717	Mar 19, 2023	U-1561			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			
APREMILAST - OTEZLA						
N 205437 003	10092541	May 29, 2034	U-2403		NCE	Mar 21, 2019
	6962940	Mar 19, 2023	U-1504			
	7208516	Mar 19, 2023	U-1505			
	7427638	Feb 16, 2028	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8802717	Mar 19, 2023	U-1561			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			
APREPITANT - EMEND						
N 021549 001	8258132	Sep 26, 2027	DP U-1743			
	8258132	Sep 26, 2027	DP U-901			
APREPITANT - EMEND						
N 021549 002	8258132	Sep 26, 2027	DP U-1743			
	8258132	Sep 26, 2027	DP U-901			
APREPITANT - EMEND						
N 021549 003	8258132	Sep 26, 2027	DP U-1743			
	8258132	Sep 26, 2027	DP U-901			
APREPITANT - EMEND						
N 207865 001	8258132	Sep 26, 2027	DP U-1916			
APREPITANT - CINVANTI						
N 209296 001	9561229	Sep 18, 2035	DP U-2161			
	9808465	Sep 18, 2035	U-2161			
	9974742	Sep 18, 2035	DP			
	9974793	Sep 18, 2035	DP			
	9974794	Sep 18, 2035	DP U-2161			
ARFORMOTEROL TARTRATE - BROVANA						
N 021912 001	6472563	Nov 09, 2021	DS			
	6667344	Jun 22, 2021	DP			
	6720453	Nov 09, 2021	DS			
	6814953	Jun 22, 2021	U-793			
	7145036	Nov 09, 2021	DS			
	7348362	Jun 22, 2021	DP U-793			
	7462645	Jun 22, 2021	U-793			
	7465756	Jun 22, 2021	DP			
	7473710	Jun 22, 2021	U-793			
	7541385	Jun 22, 2021	U-793			
	8110706	Nov 09, 2021	DP			
ARGATROBAN - ARGATROBAN IN SODIUM CHLORIDE						
N 022434 001	7589106	Sep 26, 2027	DP U-1163			
	7687516	Sep 26, 2027	DP U-1164			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY						
N 021436 001	7053092	Jan 28, 2022	U-839		ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021436 002	7053092	Jan 28, 2022	U-839		ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021436 003	7053092	Jan 28, 2022	U-839		ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021436 004	7053092	Jan 28, 2022	U-839		ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021436 005	7053092	Jan 28, 2022	U-839		ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY						
N 021436 005	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021436 006	7053092	Jan 28, 2022	U-839		ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021713 001	6977257	Apr 24, 2022	DP		ODE-80	Dec 12, 2021
	6977257*PED	Oct 24, 2022				
	7053092	Jan 28, 2022	U-839			
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8759350	Mar 02, 2027	U-1529			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021729 002	7053092	Jan 28, 2022	U-839		ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021729 003	7053092	Jan 28, 2022	U-839		ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY						
N 021729 003	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021729 004	7053092	Jan 28, 2022	U-839		ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021729 005	7053092	Jan 28, 2022	U-839		ODE-80	Dec 12, 2021
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021866 001	7115587	Jul 21, 2024	DP U-764		ODE-80	Dec 12, 2021
	7115587*PED	Jan 21, 2025				
	7550445	Jul 21, 2024	DP			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 001	7807680	Oct 19, 2024	DP		I-746	Jul 27, 2020
	8030313	Oct 19, 2024	U-1632			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 002	7807680	Oct 19, 2024	DP		I-746	Jul 27, 2020
	8030313	Oct 19, 2024	U-1632			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 002	9089567	Jan 28, 2022	U-543			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 003	7807680	Oct 19, 2024	DP		I-746	Jul 27, 2020
	8030313	Oct 19, 2024	U-1632			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 004	7807680	Oct 19, 2024	DP		I-746	Jul 27, 2020
	8030313	Oct 19, 2024	U-1632			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 001	10097388	Sep 19, 2034	U-2169		I-746	Jul 27, 2020
	7053092	Jan 28, 2022	U-1529			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Nov 02, 2026	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022	U-543			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9270503	Sep 19, 2034	DP U-2169			
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP U-1529			
	9359302	Sep 25, 2022	DS DP U-1749			
	9359302	Sep 25, 2022	DS DP U-543			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9577864	Oct 03, 2033	DP U-2169			
	9787511	Sep 19, 2034	DP U-2169			
	9941931	Nov 04, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 002	10097388	Sep 19, 2034	U-2169		I-746	Jul 27, 2020
	7053092	Jan 28, 2022	U-1529			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Nov 02, 2026	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022	U-543			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9270503	Sep 19, 2034	DP U-2169			
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP U-1529			
	9359302	Sep 25, 2022	DS DP U-1749			
	9359302	Sep 25, 2022	DS DP U-543			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9577864	Oct 03, 2033	DP U-2169			
	9787511	Sep 19, 2034	DP U-2169			
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 003	10097388	Sep 19, 2034	U-2169		I-746	Jul 27, 2020
	7053092	Jan 28, 2022	U-1529			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Nov 02, 2026	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022	U-543			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9270503	Sep 19, 2034	DP U-2169			
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP U-1529			
	9359302	Sep 25, 2022	DS DP U-1749			
	9359302	Sep 25, 2022	DS DP U-543			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 003	9444503	Nov 19, 2027	DP U-2169			
	9577864	Oct 03, 2033	DP U-2169			
	9787511	Sep 19, 2034	DP U-2169			
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 004	10097388	Sep 19, 2034	U-2169		I-746	Jul 27, 2020
	7053092	Jan 28, 2022	U-1529			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Nov 02, 2026	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022	U-543			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9270503	Sep 19, 2034	DP U-2169			
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP U-1529			
	9359302	Sep 25, 2022	DS DP U-1749			
	9359302	Sep 25, 2022	DS DP U-543			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9577864	Oct 03, 2033	DP U-2169			
	9787511	Sep 19, 2034	DP U-2169			
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 005	10097388	Sep 19, 2034	U-2169		I-746	Jul 27, 2020
	7053092	Jan 28, 2022	U-1529			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Nov 02, 2026	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022	U-543			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9270503	Sep 19, 2034	DP U-2169			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 005	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP U-1529			
	9359302	Sep 25, 2022	DS DP U-1749			
	9359302	Sep 25, 2022	DS DP U-543			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9577864	Oct 03, 2033	DP U-2169			
	9787511	Sep 19, 2034	DP U-2169			
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 006	10097388	Sep 19, 2034	U-2169		I-746	Jul 27, 2020
	7053092	Jan 28, 2022	U-1529			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Nov 02, 2026	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022	U-543			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9270503	Sep 19, 2034	DP U-2169			
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP U-1529			
	9359302	Sep 25, 2022	DS DP U-1749			
	9359302	Sep 25, 2022	DS DP U-543			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9577864	Oct 03, 2033	DP U-2169			
	9787511	Sep 19, 2034	DP U-2169			
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 001	10112903	Jun 24, 2030	DS U-543		NCE	Oct 05, 2020
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-2402			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 002	10112903	Jun 24, 2030	DS U-543		NCE	Oct 05, 2020
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-2402			
	9526726	Mar 19, 2035	DP			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 003	10112903	Jun 24, 2030	DS U-543		NCE	Oct 05, 2020
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030	U-543			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE LAUROXIL - ARISTADA							
N 207533	003	9034867	Nov 07, 2032	DP U-543			
		9193685	Oct 24, 2033	DP U-543			
		9452131	Mar 19, 2035	U-2402			
		9526726	Mar 19, 2035	DP			
ARIPIPRAZOLE LAUROXIL - ARISTADA							
N 207533	004	10112903	Jun 24, 2030	DS U-543		NCE	Oct 05, 2020
		8431576	Oct 26, 2030	DS			
		8796276	Jun 24, 2030	U-543			
		9034867	Nov 07, 2032	DP U-543			
		9193685	Oct 24, 2033	DP U-543			
		9452131	Mar 19, 2035	U-2402			
ARIPIPRAZOLE LAUROXIL - ARISTADA INITIO KIT							
N 209830	001	10016415	Sep 08, 2035	DP		NCE	Oct 05, 2020
		10112903	Jun 24, 2030	DS U-543			
		8431576	Oct 26, 2030	DS			
		8796276	Jun 24, 2030	U-543			
ARMODAFINIL - NUVIGIL							
N 021875	001	7132570	Dec 18, 2023	DS DP			
		7297346	Nov 29, 2023	DP			
ARMODAFINIL - NUVIGIL							
N 021875	002	7132570	Dec 18, 2023	DS DP			
		7297346	Nov 29, 2023	DP			
ARMODAFINIL - NUVIGIL							
N 021875	003	7132570	Dec 18, 2023	DS DP			
		7297346	Nov 29, 2023	DP			
ARMODAFINIL - NUVIGIL							
N 021875	004	7132570	Dec 18, 2023	DS DP			
		7297346	Nov 29, 2023	DP			
ARMODAFINIL - NUVIGIL							
N 021875	005	7132570	Dec 18, 2023	DS DP			
		7297346	Nov 29, 2023	DP			
ARSENIC TRIOXIDE - TRISENOX							
N 021248	001					ODE-167	Jan 12, 2025
ARSENIC TRIOXIDE - TRISENOX							
N 021248	002					ODE-167	Jan 12, 2025
ASCORBIC ACID - ASCOR							
N 209112	001					ODE-160	Oct 02, 2024
ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - MOVIPREP							
N 021881	001	7169381	Sep 01, 2024	DS DP			
		7658914	Sep 01, 2024	DS DP			
ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENVU							
N 209381	001	10016504	Sep 10, 2033	DP		NP	May 04, 2021
		8999313	Sep 10, 2033	DP			
		9326969	Sep 10, 2033	U-2310			
		9592252	Aug 11, 2032	DP U-2310			
		9707297	Sep 10, 2033	DP			
ASENAPINE MALEATE - SAPHRIS							
N 022117	001	5763476	Jun 09, 2020	DP U-1960		D-166	Jan 13, 2020
		5763476	Jun 09, 2020	DP U-1961		I-597	Jan 13, 2020
		5763476	Jun 09, 2020	DP U-1962			
		5763476	Jun 09, 2020	DP U-1963			
		5763476	Jun 09, 2020	DP U-326			
		5763476*PED	Dec 09, 2020				
		7741358	Apr 06, 2026	DS DP U-1064			
		7741358	Apr 06, 2026	DS DP U-1960			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ASENAPINE MALEATE - SAPHRIS							
N 022117	001	7741358	Apr 06, 2026	DS DP U-1961			
		7741358	Apr 06, 2026	DS DP U-1962			
		7741358	Apr 06, 2026	DS DP U-1963			
		7741358*PED	Oct 06, 2026				
		8022228	Apr 06, 2026	DS DP			
		8022228*PED	Oct 06, 2026				
ASENAPINE MALEATE - SAPHRIS							
N 022117	002	5763476	Jun 09, 2020	DP U-1960		D-166	Jan 13, 2020
		5763476	Jun 09, 2020	DP U-1961		I-597	Jan 13, 2020
		5763476	Jun 09, 2020	DP U-1962			
		5763476	Jun 09, 2020	DP U-1963			
		5763476	Jun 09, 2020	DP U-326			
		5763476*PED	Dec 09, 2020				
		7741358	Apr 06, 2026	DS DP U-1064			
		7741358	Apr 06, 2026	DS DP U-1960			
		7741358	Apr 06, 2026	DS DP U-1961			
		7741358	Apr 06, 2026	DS DP U-1962			
		7741358	Apr 06, 2026	DS DP U-1963			
		7741358*PED	Oct 06, 2026				
		8022228	Apr 06, 2026	DS DP			
		8022228*PED	Oct 06, 2026				
ASENAPINE MALEATE - SAPHRIS							
N 022117	003	5763476	Jun 09, 2020	DP U-1893		D-166	Jan 13, 2020
		5763476	Jun 09, 2020	DP U-1966		I-597	Jan 13, 2020
		5763476*PED	Dec 09, 2020				
		7741358	Apr 06, 2026	DS DP U-1893			
		7741358	Apr 06, 2026	DS DP U-1966			
		7741358*PED	Oct 06, 2026				
		8022228	Apr 06, 2026	DS DP			
		8022228*PED	Oct 06, 2026				
ASPIRIN - VAZALORE							
N 203697	001	8865187	Mar 23, 2022	DP			
		9101637	Mar 23, 2022	U-1731			
		9101637	Mar 23, 2022	U-1732			
		9101637	Mar 23, 2022	U-1733			
		9216150	Sep 29, 2032	DP			
		9226892	Sep 29, 2032	U-1731			
		9226892	Sep 29, 2032	U-1732			
		9226892	Sep 29, 2032	U-1733			
		9351984	Dec 19, 2021	DP			
ASPIRIN; OMEPRAZOLE - YOSPRALA							
N 205103	001	6926907	Feb 28, 2023	DP U-1902		NC	Sep 14, 2019
		8206741	Feb 28, 2023	DP U-1902			
		9364439	May 31, 2022	DP U-1902			
		9539214	Mar 13, 2033	U-1902			
		9987231	Jan 02, 2033	U-2324			
ASPIRIN; OMEPRAZOLE - YOSPRALA							
N 205103	002	6926907	Feb 28, 2023	DP U-1902		NC	Sep 14, 2019
		8206741	Feb 28, 2023	DP U-1902			
		9364439	May 31, 2022	DP U-1902			
		9539214	Mar 13, 2033	U-1902			
		9987231	Jan 02, 2033	U-2324			
ATAZANAVIR SULFATE - REYATAZ							
N 021567	001	6087383*PED	Jun 21, 2019				
ATAZANAVIR SULFATE - REYATAZ							
N 021567	002	6087383*PED	Jun 21, 2019				
ATAZANAVIR SULFATE - REYATAZ							
N 021567	003	6087383*PED	Jun 21, 2019				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ATAZANAVIR SULFATE - REYATAZ							
N 021567	004	6087383*PED	Jun 21, 2019				
ATAZANAVIR SULFATE - REYATAZ							
N 206352	001	6087383*PED	Jun 21, 2019				
ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ							
N 206353	001	10039718	Oct 04, 2032	DP			
		6087383*PED	Jun 21, 2019				
		8148374	Sep 03, 2029	DS DP U-1279			
ATORVASTATIN CALCIUM - LIPITOR							
N 020702	001					M-204	Jun 23, 2020
ATORVASTATIN CALCIUM - LIPITOR							
N 020702	002					M-204	Jun 23, 2020
AVANAFIL - STENDRA							
N 202276	001	6656935	Apr 27, 2025	DS DP U-155			
		7501409	May 05, 2023	DP			
AVANAFIL - STENDRA							
N 202276	002	6656935	Apr 27, 2025	DS DP U-155			
		7501409	May 05, 2023	DP			
AVANAFIL - STENDRA							
N 202276	003	6656935	Apr 27, 2025	DS DP U-155			
		7501409	May 05, 2023	DP			
AVATROMBOPAG MALEATE - DOPTELET							
N 210238	001	7638536	May 05, 2025	DS DP		NCE	May 21, 2023
		8765764	Jan 15, 2023	U-2314			
AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ							
N 206494	001	7112592	Feb 24, 2022	DS DP U-2244			
		7112592	Feb 24, 2022	DS DP U-282			
		7612087	Nov 12, 2026	DP			
		8178554	Jul 24, 2021	DS DP U-2245			
		8178554	Jul 24, 2021	DS DP U-282			
		8471025	Aug 12, 2031	DS			
		8835455	Oct 08, 2030	DP			
		8969566	Jun 15, 2032	DS			
		9284314	Jun 15, 2032	DS			
		9695122	Jun 15, 2032	DS			
AXITINIB - INLYTA							
N 202324	001	6534524	Apr 29, 2025	DS DP			
		7141581	Jun 30, 2020	U-1220			
		8791140	Dec 14, 2030	DS			
AXITINIB - INLYTA							
N 202324	002	6534524	Apr 29, 2025	DS DP			
		7141581	Jun 30, 2020	U-1220			
		8791140	Dec 14, 2030	DS			
AZELAIC ACID - FINACEA							
N 207071	001	10117812	Oct 18, 2027	DP U-1796			
		6730288	Sep 08, 2019	DP			
		7700076	Sep 18, 2027	DP			
		8435498	Mar 01, 2024	U-1727			
		8722021	Oct 24, 2023	DP			
		8900554	Oct 24, 2023	DP			
		9211259	Feb 28, 2029	U-1796			
		9265725	Dec 08, 2027	DP			
AZELASTINE HYDROCHLORIDE - ASTEPRO							
N 022203	001	8071073	Jun 04, 2028	DP			
		8518919	Nov 22, 2025	U-1430			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AZELASTINE HYDROCHLORIDE - ASTEPRO							
N 022203	002	8071073	Jun 04, 2028	DP			
		8518919	Nov 22, 2025			U-1430	
		9919050	Nov 22, 2025	DP			
AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA							
N 202236	001	8163723	Aug 29, 2023			U-1667	
		8163723	Aug 29, 2023			U-644	
		8163723	Aug 29, 2023			U-707	
		8163723	Aug 29, 2023			U-77	
		8163723	Aug 29, 2023			U-81	
		8163723*PED	Feb 29, 2024				
		8168620	Feb 24, 2026	DP			
		9259428	Jun 13, 2023			U-644	
		9259428*PED	Dec 13, 2023				
		9901585	Jun 13, 2023	DP			
AZILSARTAN KAMEDOXOMIL - EDARBI							
N 200796	001	7157584	May 22, 2025	DS			
		7572920	Jan 07, 2025	DP		U-3	
		9066936	Mar 26, 2028	DP			
AZILSARTAN KAMEDOXOMIL - EDARBI							
N 200796	002	7157584	May 22, 2025	DS			
		7572920	Jan 07, 2025	DP		U-3	
		9066936	Mar 26, 2028	DP			
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR							
N 202331	001	7157584	May 22, 2025	DS			
		7572920	Jan 07, 2025	DP		U-3	
		9066936	Mar 26, 2028	DP			
		9169238	Feb 04, 2030	DP			
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR							
N 202331	002	7157584	May 22, 2025	DS			
		7572920	Jan 07, 2025	DP		U-3	
		9066936	Mar 26, 2028	DP			
		9169238	Feb 04, 2030	DP			
AZITHROMYCIN - ZMAX							
N 050797	001	6984403	Feb 14, 2024	DP		U-282	
		7887844	Feb 14, 2024	DP			
AZITHROMYCIN - AZASITE							
N 050810	001	6239113	Mar 31, 2019			U-709	
		6569443	Mar 31, 2019	DP		U-709	
		7056893	Mar 31, 2019	DP		U-709	
AZTREONAM - CAYSTON							
N 050814	001	7208141	Dec 20, 2021	DP		U-1031	
		7214364	Dec 20, 2021	DP			
		7427633	Dec 20, 2021	DP		U-1031	
		8399496	Dec 20, 2021	DP		U-1377	
BALOXAVIR MARBOXIL - XOFLUZA							
N 210854	001	8927710	May 05, 2031	DP			
		8987441	Sep 21, 2031	DS DP			
		9815835	Jun 14, 2030	DP			
BALOXAVIR MARBOXIL - XOFLUZA							
N 210854	002	8927710	May 05, 2031	DP			
		8987441	Sep 21, 2031	DS DP			
		9815835	Jun 14, 2030	DP			
BALSALAZIDE DISODIUM - COLAZAL							
N 020610	001	7452872	Aug 24, 2026			U-141	
		7625884	Aug 24, 2026			U-141	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BALSALAZIDE DISODIUM - GIAZO							
N 022205	001	7452872	Aug 24, 2026	U-1229			
		7625884	Aug 24, 2026	U-1229			
		8497256	Jun 23, 2031	U-1229			
		9192616	Aug 02, 2026	U-1229			
BARICITINIB - OLUMIANT							
N 207924	001	8158616	Jun 08, 2030	DS DP		NCE	May 31, 2023
		8420629	Mar 10, 2029	U-247			
BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE							
N 022247	001	5998402	Apr 04, 2019	DS DP U-594			
		6479535	May 06, 2019	DP U-594			
		6479535	May 06, 2019	DP U-904			
		7683051	Mar 10, 2027	DS DP U-594			
		7683051	Mar 10, 2027	DS DP U-904			
		8815934	May 06, 2019	DP			
BECLOMETHASONE DIPROPIONATE - QVAR 80							
N 020911	001	10022509	May 18, 2031	DP			
		10022510	May 18, 2031	DP			
		10086156	May 18, 2031	DP			
		9463289	May 18, 2031	DP			
		9808587	May 18, 2031	DP			
BECLOMETHASONE DIPROPIONATE - QVAR 40							
N 020911	002	10022509	May 18, 2031	DP			
		10022510	May 18, 2031	DP			
		10086156	May 18, 2031	DP			
		9463289	May 18, 2031	DP			
		9808587	May 18, 2031	DP			
BECLOMETHASONE DIPROPIONATE - QNASL							
N 202813	001	7780038	Jan 24, 2027	DP			
BECLOMETHASONE DIPROPIONATE - QNASL							
N 202813	002	7780038	Jan 24, 2027	DP			
BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER							
N 207921	001	10022509	May 18, 2031	DP			
		10022510	May 18, 2031	DP			
		10086156	May 18, 2031	DP			
		7637260	Aug 25, 2020	DP			
		8132712	Sep 07, 2028	DP			
		8931476	Jul 17, 2031	DP			
BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER							
N 207921	002	10022509	May 18, 2031	DP			
		10022510	May 18, 2031	DP			
		10086156	May 18, 2031	DP			
		7637260	Aug 25, 2020	DP			
		8132712	Sep 07, 2028	DP			
		8931476	Jul 17, 2031	DP			
BEDAQUILINE FUMARATE - SIRTURO							
N 204384	001	7498343	Dec 01, 2026	DS DP U-1321		ODE-38	Dec 28, 2019
		8546428	Mar 19, 2029	DS DP U-1321			
BELINOSTAT - BELEODAQ							
N 206256	001	6888027	Sep 27, 2021	DS DP U-1544		NCE	Jul 03, 2019
		8835501	Oct 27, 2027	DP		ODE-68	Jul 03, 2021
BENDAMUSTINE HYDROCHLORIDE - TREANDA							
N 022249	001	8436190	Oct 26, 2030	DP			
		8436190*PED	Apr 26, 2031				
		8445524	Mar 26, 2029	DS DP U-1402			
		8445524*PED	Sep 26, 2029				
		8609863	Jan 12, 2026	DP			
		8609863*PED	Jul 12, 2026				
		8669279	Mar 26, 2029	DP U-1402			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BENDAMUSTINE HYDROCHLORIDE - TREANDA							
N 022249	001	8669279*PED	Sep 26, 2029				
		8791270	Jan 12, 2026	DP U-1542			
		8791270*PED	Jul 12, 2026				
		8883836	Mar 26, 2029	DP U-1402			
		8883836*PED	Sep 26, 2029				
		8895756	Jan 12, 2026	DP			
		8895756*PED	Jul 12, 2026				
		9533955	Mar 26, 2029	DP U-1949			
		9533955	Mar 26, 2029	DP U-1952			
BENDAMUSTINE HYDROCHLORIDE - TREANDA							
N 022249	002	8436190	Oct 26, 2030	DP			
		8436190*PED	Apr 26, 2031				
		8445524	Mar 26, 2029	DS DP U-1402			
		8445524*PED	Sep 26, 2029				
		8609863	Jan 12, 2026	DP			
		8609863*PED	Jul 12, 2026				
		8669279	Mar 26, 2029	DP U-1402			
		8669279*PED	Sep 26, 2029				
		8791270	Jan 12, 2026	DP U-1542			
		8791270*PED	Jul 12, 2026				
		8883836	Mar 26, 2029	DP U-1402			
		8883836*PED	Sep 26, 2029				
		8895756	Jan 12, 2026	DP			
		8895756*PED	Jul 12, 2026				
		9533955	Mar 26, 2029	DP U-1949			
		9533955	Mar 26, 2029	DP U-1952			
BENDAMUSTINE HYDROCHLORIDE - TREANDA							
N 022249	003	8344006	Sep 23, 2029	DP U-1402			
		8344006*PED	Mar 23, 2030				
		8445524	Mar 26, 2029	DS			
		8445524*PED	Sep 26, 2029				
		8791270	Jan 12, 2026	DP U-1542			
		8791270*PED	Jul 12, 2026				
BENDAMUSTINE HYDROCHLORIDE - TREANDA							
N 022249	004	8344006	Sep 23, 2029	DP U-1402			
		8344006*PED	Mar 23, 2030				
		8445524	Mar 26, 2029	DS			
		8445524*PED	Sep 26, 2029				
		8791270	Jan 12, 2026	DP U-1542			
		8791270*PED	Jul 12, 2026				
BENDAMUSTINE HYDROCHLORIDE - BELRAPZO							
N 205580	001	10010533	Jan 28, 2031	DP			
		8609707	Aug 11, 2031	DP U-1971			
		8609707	Aug 11, 2031	DP U-1972			
		8791270	Jan 12, 2026	DP U-1971			
		8791270	Jan 12, 2026	DP U-1972			
		9265831	Jan 28, 2031	DP			
		9572796	Jan 28, 2031	DP U-1971			
		9572796	Jan 28, 2031	DP U-1972			
		9572797	Jan 28, 2031	U-1971			
		9572797	Jan 28, 2031	U-1972			
BENDAMUSTINE HYDROCHLORIDE - BENDEKA							
N 208194	001	10010533	Jan 28, 2031	DP		ODE-179	Dec 07, 2022
		10052385	Mar 15, 2033	U-1971			
		10052385	Mar 15, 2033	U-1972			
		8609707	Aug 11, 2031	DP U-1542			
		8791270	Jan 12, 2026	DP U-1790			
		9000021	Mar 15, 2033	U-1542			
		9034908	Mar 15, 2033	U-1542			
		9144568	Mar 15, 2033	U-1542			
		9265831	Jan 28, 2031	DP			
		9572796	Jan 28, 2031	DP U-1971			
		9572796	Jan 28, 2031	DP U-1972			
		9572797	Jan 28, 2031	U-1971			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BENDAMUSTINE HYDROCHLORIDE - BENDEKA							
N 208194	001	9572797	Jan 28, 2031	U-1972			
		9572887	Mar 15, 2033	U-1971			
		9572887	Mar 15, 2033	U-1972			
		9579384	Mar 15, 2033	U-1971			
		9579384	Mar 15, 2033	U-1972			
		9597397	Mar 15, 2033	U-1971			
		9597397	Mar 15, 2033	U-1972			
		9597398	Mar 15, 2033	U-1971			
		9597399	Mar 15, 2033	U-1971			
		9597399	Mar 15, 2033	U-1972			
BENZNIDAZOLE - BENZNIDAZOLE							
N 209570	001					NCE	Aug 29, 2022
						ODE-154	Aug 29, 2024
BENZNIDAZOLE - BENZNIDAZOLE							
N 209570	002					NCE	Aug 29, 2022
						ODE-154	Aug 29, 2024
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA							
N 050819	001	8288434	Aug 05, 2029	DP U-124			
		8663699	Jun 03, 2029	U-124			
		8895070	Jun 03, 2029	U-124			
		9078870	Jun 03, 2029	DP			
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON							
N 050819	002	10137142	Jun 03, 2029	DP U-916			
		8288434	Aug 05, 2029	DP U-1033			
		8288434	Aug 05, 2029	DP U-124			
		8288434	Aug 05, 2029	DP U-134			
		8288434	Aug 05, 2029	DP U-818			
		8288434	Aug 05, 2029	DP U-916			
		8288434	Aug 05, 2029	DP U-921			
		9504704	Jun 03, 2029	DP U-124			
		9504704	Jun 03, 2029	DP U-134			
		9504704	Jun 03, 2029	DP U-818			
		9504704	Jun 03, 2029	DP U-916			
		9561208	Jun 03, 2029	DP U-916			
BENZYL ALCOHOL - ULESFIA							
N 022129	001	6793931	Jul 11, 2022	DP U-970			
		7294342	May 19, 2024	U-970			
BEPOTASTINE BESILATE - BEPREVE							
N 022288	001	6780877	Sep 19, 2019	DS DP			
		8784789	Sep 05, 2024	DP			
		8877168	Jul 30, 2023	DP			
BESIFLOXACIN HYDROCHLORIDE - BESIVANCE							
N 022308	001	6685958	Jun 29, 2021	DP U-80			
		6699492	Mar 31, 2019	DP U-80			
		8415342	Nov 07, 2030	U-80			
		8481526	Jan 09, 2031	DS			
		8604020	Mar 12, 2030	DP			
		8937062	Nov 13, 2029	U-80			
BETAMETHASONE DIPROPIONATE - SERNIVO							
N 208079	001	9364485	Aug 31, 2030	DP U-1858		NDF	Feb 05, 2019
		9433630	Aug 31, 2030	DP U-1858			
		9439911	Aug 31, 2030	DP U-1858			
		9655907	Aug 31, 2030	DP U-1858			
		9775851	Aug 31, 2030	DP U-1858			
		9877974	Aug 31, 2030	DP U-1858			
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR							
N 207589	001	10130640	Jun 10, 2031	DP			
		6753013	Jan 27, 2020	DP U-1761			
		9119781	Jun 10, 2031	DP U-1761			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX							
N 021852	001	6753013	Jan 27, 2020	DP U-193			
		6753013	Jan 27, 2020	DP U-88			
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX							
N 022185	001	6753013	Jan 27, 2020	DP U-1761			
		6753013	Jan 27, 2020	DP U-193			
		6753013	Jan 27, 2020	DP U-88			
		6787529	Jan 27, 2020	DP U-1761			
		6787529	Jan 27, 2020	DP U-193			
		6787529	Jan 27, 2020	DP U-88			
BETRIXABAN - BEVYXXA							
N 208383	001	6376515	Sep 15, 2020	DS DP U-1167		NCE	Jun 23, 2022
		6376515	Sep 15, 2020	DS DP U-1502			
		6376515	Sep 15, 2020	DS DP U-2029			
		6376515	Sep 15, 2020	DS DP U-2030			
		6835739	Sep 15, 2020	DS DP			
		7598276	Nov 08, 2026	DS			
		8404724	Mar 29, 2031	DP U-2034			
		8518977	Sep 15, 2020	DS			
		8557852	Sep 08, 2028	U-1167			
		8557852	Sep 08, 2028	U-2030			
		8691847	Sep 15, 2020	DS DP U-2029			
		8691847	Sep 15, 2020	DS DP U-2035			
		8987463	Dec 28, 2030	DP			
		9555023	Nov 07, 2026	U-1502			
		9629831	Sep 15, 2020	U-1167			
		9629831	Sep 15, 2020	U-1502			
		9629831	Sep 15, 2020	U-2030			
		9629831	Sep 15, 2020	U-2035			
BETRIXABAN - BEVYXXA							
N 208383	002	6376515	Sep 15, 2020	DS DP U-1167		NCE	Jun 23, 2022
		6376515	Sep 15, 2020	DS DP U-1502			
		6376515	Sep 15, 2020	DS DP U-2029			
		6376515	Sep 15, 2020	DS DP U-2030			
		6835739	Sep 15, 2020	DS DP			
		7598276	Nov 08, 2026	DS			
		8404724	Mar 29, 2031	DP U-2034			
		8518977	Sep 15, 2020	DS			
		8557852	Sep 08, 2028	U-1167			
		8557852	Sep 08, 2028	U-2030			
		8691847	Sep 15, 2020	DS DP U-2029			
		8691847	Sep 15, 2020	DS DP U-2035			
		8987463	Dec 28, 2030	DP			
		9555023	Nov 07, 2026	U-1502			
		9629831	Sep 15, 2020	U-1167			
		9629831	Sep 15, 2020	U-1502			
		9629831	Sep 15, 2020	U-2030			
		9629831	Sep 15, 2020	U-2035			
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY							
N 210251	001	6642245	Nov 04, 2020	U-257		NCE	Feb 07, 2023
		6703396	Mar 09, 2021	DS DP			
		7390791	May 07, 2022	DS DP			
		7803788	Feb 02, 2022	U-257			
		8754065	Aug 15, 2032	DS DP U-257			
		9216996	Dec 19, 2033	DS DP			
		9296769	Aug 15, 2032	DS DP U-257			
		9708342	Jun 19, 2035	DS DP			
		9732092	Dec 19, 2033	DS DP			
BIMATOPROST - LUMIGAN							
N 022184	001	7851504	Jun 13, 2027	DS DP			
		8278353	Mar 16, 2025	DP			
		8299118	Mar 16, 2025	U-1295			
		8309605	Mar 16, 2025	U-1293			
		8309605	Mar 16, 2025	U-1294			
		8338479	Mar 16, 2025	DP U-1295			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BIMATOPROST - LUMIGAN							
N 022184	001	8524777	Mar 16, 2025	U-1235			
		8586630	Mar 16, 2025	U-1458			
		8772338	Mar 16, 2025	DP U-1528			
		8933120	Mar 16, 2025	DP			
		8933127	Mar 16, 2025	DP			
		9155716	Mar 16, 2025	DP U-1528			
		9241918	Mar 16, 2025	DP U-1814			
BIMATOPROST - LATISSE							
N 022369	001	8038988	Aug 25, 2023	DS DP U-1208			
		8101161	May 25, 2024	U-1217			
		8101161	May 25, 2024	U-1218			
		8263054	Jan 15, 2023	U-1277			
		8541466	Jan 31, 2021	U-1217			
		8632760	Jan 15, 2023	U-1487			
		8758733	Jan 15, 2023	U-1487			
		8906962	Jan 31, 2021	U-1217			
		8986715	Jan 15, 2023	U-1217			
		9216183	Jan 15, 2023	U-1487			
		9226931	Jan 15, 2023	U-1799			
		9579270	Jan 31, 2021	U-1975			
BINIMETINIB - MEKTOVI							
N 210498	001	10005761	Aug 27, 2030	U-2331		NCE	Jun 27, 2023
		7777050	Mar 13, 2023	DS DP		ODE-194	Jun 27, 2025
		8178693	Mar 13, 2023	DS DP			
		8193229	Mar 13, 2023	U-2330			
		8513293	Mar 13, 2023	U-2331			
		9314464	Jul 04, 2031	U-2332			
		9562016	Oct 18, 2033	DS DP			
		9593100	Aug 27, 2030	DP			
		9598376	Oct 18, 2033	U-2330			
		9850229	Aug 27, 2030	U-2333			
		9980944	Oct 18, 2033	U-2334			
BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - HALFLYTELY							
N 021551	003	7291324	Oct 22, 2022	U-837			
BIVALIRUDIN - ANGIOMAX							
N 020873	001	7582727	Jul 27, 2028	DP			
		7598343	Jul 27, 2028	DP			
BOCEPREVIR - VICTRELIS							
N 202258	001	7772178	Nov 11, 2027	DP U-1128			
		8119602	Mar 17, 2027	U-1233			
		RE43298	Dec 22, 2024	DS DP U-1128			
BORTEZOMIB - VELCADE							
N 021602	001	6713446	Jan 25, 2022	DS DP		ODE-76	Oct 08, 2021
		6713446*PED	Jul 25, 2022			PED	Apr 08, 2022
		6958319	Jan 25, 2022	DS DP			
		6958319*PED	Jul 25, 2022				
BORTEZOMIB - BORTEZOMIB							
N 205004	001	8962572	Nov 03, 2032	DP			
BOSENTAN - TRACLEER							
N 021290	001					NPP	Sep 05, 2020
BOSENTAN - TRACLEER							
N 021290	002					NPP	Sep 05, 2020
BOSENTAN - TRACLEER							
N 209279	001	7959945	Dec 28, 2027	DP		NP	Sep 05, 2020
		8309126	May 15, 2026	DP		ODE-161	Sep 05, 2024
BOSUTINIB MONOHYDRATE - BOSULIF							
N 203341	001	7417148	Jan 23, 2026	U-1283		I-759	Dec 19, 2020
		7767678	Nov 23, 2026	DS DP		ODE-163	Dec 19, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BOSUTINIB MONOHYDRATE - BOSULIF							
N 203341	001	7919625	Dec 11, 2025	DP		ODE-30	Sep 04, 2019
		RE42376	Apr 13, 2024	DS			
BOSUTINIB MONOHYDRATE - BOSULIF							
N 203341	002	7417148	Jan 23, 2026	U-1283		I-759	Dec 19, 2020
		7767678	Nov 23, 2026	DS DP		ODE-163	Dec 19, 2024
		7919625	Dec 11, 2025	DP		ODE-30	Sep 04, 2019
		RE42376	Apr 13, 2024	DS			
BOSUTINIB MONOHYDRATE - BOSULIF							
N 203341	003	7417148	Jan 23, 2026	U-1283		I-759	Dec 19, 2020
		7767678	Nov 23, 2026	DS DP		ODE-163	Dec 19, 2024
		7919625	Dec 11, 2025	DP		ODE-30	Sep 04, 2019
		RE42376	Apr 13, 2024	DS			
BREXPIPRAZOLE - REXULTI							
N 205422	001	7888362	Feb 23, 2027	DS		M-186	Sep 23, 2019
		8349840	Apr 12, 2026	DP U-1529		NCE	Jul 10, 2020
		8618109	Apr 12, 2026	U-543			
		9839637	Apr 12, 2026	DP U-1529			
		9839637	Apr 12, 2026	DP U-543			
BREXPIPRAZOLE - REXULTI							
N 205422	002	7888362	Feb 23, 2027	DS		M-186	Sep 23, 2019
		8349840	Apr 12, 2026	DP U-1529		NCE	Jul 10, 2020
		8618109	Apr 12, 2026	U-543			
		9839637	Apr 12, 2026	DP U-1529			
		9839637	Apr 12, 2026	DP U-543			
BREXPIPRAZOLE - REXULTI							
N 205422	003	7888362	Feb 23, 2027	DS		M-186	Sep 23, 2019
		8349840	Apr 12, 2026	DP U-1529		NCE	Jul 10, 2020
		8618109	Apr 12, 2026	U-543			
		9839637	Apr 12, 2026	DP U-1529			
		9839637	Apr 12, 2026	DP U-543			
BREXPIPRAZOLE - REXULTI							
N 205422	004	7888362	Feb 23, 2027	DS		M-186	Sep 23, 2019
		8349840	Apr 12, 2026	DP U-1529		NCE	Jul 10, 2020
		8618109	Apr 12, 2026	U-543			
		9839637	Apr 12, 2026	DP U-1529			
		9839637	Apr 12, 2026	DP U-543			
BREXPIPRAZOLE - REXULTI							
N 205422	005	7888362	Feb 23, 2027	DS		M-186	Sep 23, 2019
		8349840	Apr 12, 2026	DP U-1529		NCE	Jul 10, 2020
		8618109	Apr 12, 2026	U-543			
		9839637	Apr 12, 2026	DP U-1529			
		9839637	Apr 12, 2026	DP U-543			
BREXPIPRAZOLE - REXULTI							
N 205422	006	7888362	Feb 23, 2027	DS		M-186	Sep 23, 2019
		8349840	Apr 12, 2026	DP U-1529		NCE	Jul 10, 2020
		8618109	Apr 12, 2026	U-543			
		9839637	Apr 12, 2026	DP U-1529			
		9839637	Apr 12, 2026	DP U-543			
BRIGATINIB - ALUNBRIG							
N 208772	001	9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
		9273077	May 21, 2029	U-1927		ODE-142	Apr 28, 2024
		9611283	Apr 10, 2034	U-1927			
BRIGATINIB - ALUNBRIG							
N 208772	002	9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
		9273077	May 21, 2029	U-1927		ODE-142	Apr 28, 2024
		9611283	Apr 10, 2034	U-1927			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BRIGATINIB - ALUNBRIG							
N 208772	003	9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
		9273077	May 21, 2029	U-1927		ODE-142	Apr 28, 2024
		9611283	Apr 10, 2034	U-1927			
BRIMONIDINE TARTRATE - ALPHAGAN P							
N 021262	001	6562873	Jul 10, 2021				
		6627210	Jul 18, 2021	DP			
		6641834	Jul 28, 2021	DP			
		6673337	Jul 26, 2021	DP			
		9295641	Jul 10, 2021	U-1833			
		9295641*PED	Jan 10, 2022				
BRIMONIDINE TARTRATE - QOLIANA							
N 021764	001	7265117	Aug 19, 2025	DP			
BRIMONIDINE TARTRATE - ALPHAGAN P							
N 021770	001	6562873	Jul 10, 2021	DP			
		6627210	Jul 18, 2021	DP			
		6641834	Jul 28, 2021	DP			
		6673337	Jul 26, 2021	DP			
		8858961	Sep 02, 2023	DP			
		8858961*PED	Mar 02, 2024				
		9295641	Jul 10, 2021	U-1833			
		9295641*PED	Jan 10, 2022				
		9687443	Jul 10, 2021	DP			
		9687443*PED	Jan 10, 2022				
BRIMONIDINE TARTRATE - MIRVASO							
N 204708	001	7439241	Aug 25, 2025	U-1428			
		8053427	Jun 13, 2031	DP U-1428			
		8163725	Jun 13, 2031	DP			
		8231885	May 24, 2025	DP			
		8410102	May 24, 2025	U-1428			
		8426410	May 24, 2025	U-1428			
		8513247	Mar 25, 2031	DP U-1428			
		8513249	Mar 25, 2031	DP U-1428			
		8859551	May 25, 2024	U-1428			
		9861631	Mar 25, 2031	U-1428			
		9861632	Mar 25, 2031	U-1428			
BRIMONIDINE TARTRATE - LUMIFY							
N 208144	001	8293742	Jul 14, 2030	U-2222		NP	Dec 22, 2020
BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA							
N 204251	001	6316441	Dec 07, 2019	U-778			
		9044484	Oct 30, 2030	DP			
		9421265	Jun 17, 2030	DP			
BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN							
N 021398	001	7030149	Apr 19, 2022	U-849			
		7320976	Apr 19, 2022	U-849			
		7323463	Jan 19, 2023	DP	Y		
		7642258	Apr 19, 2022	DS DP U-1024			
		8133890	Apr 19, 2022	U-1235			
		8354409	Apr 19, 2022	DP U-1371			
		8748425	Apr 19, 2022	DP U-1524			
		9474751	Apr 19, 2022	DP U-1524			
		9770453	Apr 19, 2022	DP U-2131			
		9907801	Apr 19, 2022	DP U-2239			
		9907802	Apr 19, 2022	DP U-2240			
BRIVARACETAM - BRIVIACT							
N 205836	001	6784197	Feb 21, 2021	DS DP U-2295		NCE	May 12, 2021
		6911461	Feb 21, 2021	DS DP U-2295			
		8492416	Feb 21, 2021	U-2295			
BRIVARACETAM - BRIVIACT							
N 205836	002	6784197	Feb 21, 2021	DS DP U-2295		NCE	May 12, 2021
		6911461	Feb 21, 2021	DS DP U-2295			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BRIVARACETAM - BRIVIACT						
N 205836 002	8492416	Feb 21, 2021	U-2295			
BRIVARACETAM - BRIVIACT						
N 205836 003	6784197	Feb 21, 2021	DS DP U-2295		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
BRIVARACETAM - BRIVIACT						
N 205836 004	6784197	Feb 21, 2021	DS DP U-2295		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
BRIVARACETAM - BRIVIACT						
N 205836 005	6784197	Feb 21, 2021	DS DP U-2295		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
BRIVARACETAM - BRIVIACT						
N 205837 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6784197	Feb 21, 2021	DS DP U-2130			
	6911461	Feb 21, 2021	DS DP U-1815			
	6911461	Feb 21, 2021	DS DP U-2130			
	8492416	Feb 21, 2021	U-1815			
	8492416	Feb 21, 2021	U-2130			
BRIVARACETAM - BRIVIACT						
N 205838 001	6784197	Feb 21, 2021	DS DP U-2295		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
BROMFENAC SODIUM - PROLENSA						
N 203168 001	10085958	Nov 19, 2032	DP			
	8129431	Sep 11, 2025	DS DP			
	8669290	Jan 16, 2024	DP			
	8754131	Jan 16, 2024	DP			
	8871813	Jan 16, 2024	DP			
	8927606	Jan 16, 2024	U-100			
	8927606	Jan 16, 2024	U-1095			
	8927606	Jan 16, 2024	U-810			
	9144609	Jan 16, 2024	DP			
	9517220	Nov 11, 2033	U-1933			
	9561277	Jan 16, 2024	U-1933			
BROMFENAC SODIUM - BROMSITE						
N 206911 001	8778999	Aug 07, 2029	DP U-1834		NP	Apr 08, 2019
BROMOCRIPTINE MESYLATE - CYCLOSET						
N 020866 001	7888310	Jul 25, 2023	U-1433			
	8137992	Jul 25, 2023	U-1433			
	8137993	Jul 25, 2023	U-1433			
	8137994	Jul 25, 2023	U-1433			
	8431155	Apr 30, 2032	DP U-976			
	8613947	Apr 30, 2032	DP U-976			
	8877708	Jun 07, 2030	DP U-1706			
	9192576	Apr 30, 2032	DP U-976			
	9352025	Jun 07, 2030	U-2111			
	9352025	Jun 07, 2030	U-2112			
	9352025	Jun 07, 2030	U-2113			
	9352025	Jun 07, 2030	U-2114			
	9352025	Jun 07, 2030	U-2115			
	9352025	Jun 07, 2030	U-2116			
	9352025	Jun 07, 2030	U-2117			
	9352025	Jun 07, 2030	U-2118			
	9352025	Jun 07, 2030	U-2119			
	9522117	Apr 30, 2032	DP U-1939			
	9522117	Apr 30, 2032	DP U-976			
	9700555	Apr 30, 2032	DP U-2183			
	9700555	Apr 30, 2032	DP U-2184			
	9700555	Apr 30, 2032	DP U-2185			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BROMOCRIPTINE MESYLATE - CYCLOSET							
N 020866	001	9700555	Apr 30, 2032	DP U-2186			
		9700555	Apr 30, 2032	DP U-2187			
		9700555	Apr 30, 2032	DP U-2188			
		9700555	Apr 30, 2032	DP U-2189			
		9700555	Apr 30, 2032	DP U-2190			
		9700555	Apr 30, 2032	DP U-2191			
		9700555	Apr 30, 2032	DP U-2192			
		9700555	Apr 30, 2032	DP U-2193			
		9700555	Apr 30, 2032	DP U-2194			
		9700555	Apr 30, 2032	DP U-2195			
		9700555	Apr 30, 2032	DP U-2196			
		9700555	Apr 30, 2032	DP U-2197			
		9700555	Apr 30, 2032	DP U-2198			
		9895422	Jun 07, 2030	U-2114			
		9895422	Jun 07, 2030	U-2116			
		9895422	Jun 07, 2030	U-2281			
		9895422	Jun 07, 2030	U-2282			
		9895422	Jun 07, 2030	U-2283			
		9895422	Jun 07, 2030	U-2284			
		9895422	Jun 07, 2030	U-2285			
		9895422	Jun 07, 2030	U-2286			
		9895422	Jun 07, 2030	U-2287			
		9993474	Apr 30, 2032	U-2384			
		9993474	Apr 30, 2032	U-2385			
		9993474	Apr 30, 2032	U-2386			
		9993474	Apr 30, 2032	U-2387			
		9993474	Apr 30, 2032	U-2388			
		9993474	Apr 30, 2032	U-2389			
		9993474	Apr 30, 2032	U-2390			
		9993474	Apr 30, 2032	U-2391			
		9993474	Apr 30, 2032	U-2392			
		9993474	Apr 30, 2032	U-2393			
BUDESONIDE - ENTOCORT EC							
N 021324	001					M-178	Apr 29, 2019
						NPP	Apr 29, 2019
BUDESONIDE - UCERIS							
N 203634	001	10064878	Jun 09, 2020	DP U-1325			
		10105374	Jun 09, 2020	DP U-1325			
		10143698	Jun 09, 2020	DP U-1325			
		7410651	Jun 09, 2020	DP U-1325			
		7431943	Jun 09, 2020	DP			
		8293273	Jun 09, 2020	DP			
		8784888	Jun 09, 2020	DP			
		8895064	Sep 07, 2031	DP			
		9132093	Sep 07, 2031	DP			
		9192581	Sep 07, 2031	DP U-1325			
		9320716	Jun 09, 2020	DP U-1325			
		9532954	Jun 09, 2020	DP U-1325			
		RE43799	Jun 09, 2020	DP U-1325			
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT							
N 021929	001	10166247	Jan 29, 2023	DP U-2001		M-210	Sep 11, 2020
		10166247	Jan 29, 2023	DP U-2002		M-214	Dec 20, 2020
		10166247	Jan 29, 2023	DP U-2122		NPP	Jan 27, 2020
		7367333*PED	May 11, 2019			PED	Jul 27, 2020
		7587988	Apr 10, 2026	DP			
		7587988*PED	Oct 10, 2026				
		7759328	Jan 29, 2023	DP U-2001			
		7759328	Jan 29, 2023	DP U-2002			
		7759328	Jan 29, 2023	DP U-2122			
		7759328*PED	Jul 29, 2023				
		7967011	Aug 11, 2021	DP			
		7967011*PED	Feb 11, 2022				
		8143239	Jan 29, 2023	DP U-2001			
		8143239	Jan 29, 2023	DP U-2002			
		8143239	Jan 29, 2023	DP U-2122			
		8143239*PED	Jul 29, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT						
N 021929 001	8387615	Mar 26, 2027	DP			
	8387615*PED	Sep 26, 2027				
	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-2001			
	8575137	Jan 29, 2023	DP U-2002			
	8575137	Jan 29, 2023	DP U-2122			
	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT						
N 021929 002	10166247	Jan 29, 2023	DP U-2001		M-210	Sep 11, 2020
	10166247	Jan 29, 2023	DP U-2002		M-214	Dec 20, 2020
	10166247	Jan 29, 2023	DP U-2122			
	7367333*PED	May 11, 2019				
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	7759328	Jan 29, 2023	DP U-2001			
	7759328	Jan 29, 2023	DP U-2002			
	7759328	Jan 29, 2023	DP U-2122			
	7759328*PED	Jul 29, 2023				
	7897646*PED	Mar 09, 2019				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	8143239	Jan 29, 2023	DP U-2001			
	8143239	Jan 29, 2023	DP U-2002			
	8143239	Jan 29, 2023	DP U-2122			
	8143239*PED	Jul 29, 2023				
	8387615	Mar 26, 2027	DP			
	8387615*PED	Sep 26, 2027				
	8461211*PED	Mar 09, 2019				
	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-2001			
	8575137	Jan 29, 2023	DP U-2002			
	8575137	Jan 29, 2023	DP U-2122			
	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
BUPIVACAINE - EXPAREL						
N 022496 001	9585838	Dec 24, 2021	DP		I-771	Apr 06, 2021
BUPIVACAINE - EXPAREL						
N 022496 002	9585838	Dec 24, 2021	DP		I-771	Apr 06, 2021
BUPRENORPHINE - SUBLOCADE						
N 209819 001	8921387	Jan 06, 2032	DP U-2173		NP	Nov 30, 2020
	8921387	Jan 06, 2032	DP U-2174			
	8975270	Sep 05, 2031	DP U-2175			
	8975270	Sep 05, 2031	DP U-2206			
	9272044	Jun 06, 2031	U-2176			
	9272044	Jun 06, 2031	U-2177			
	9272044	Jun 06, 2031	U-2178			
	9272044	Jun 06, 2031	U-2209			
	9498432	Jun 06, 2031	DP U-2179			
	9782402	Jun 06, 2031	DP U-2176			
	9782402	Jun 06, 2031	DP U-2180			
	9782402	Jun 06, 2031	DP U-2207			
	9782402	Jun 06, 2031	DP U-2208			
	9827241	Jun 06, 2031	DP U-2174			
	9827241	Jun 06, 2031	DP U-2181			
	9827241	Jun 06, 2031	DP U-2206			
	9827241	Jun 06, 2031	DP U-2210			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE - SUBLOCADE								
N	209819	001	9827241	Jun 06, 2031	DP U-2211			
BUPRENORPHINE - SUBLOCADE								
N	209819	002	8921387	Jan 06, 2032	DP U-2173		NP	Nov 30, 2020
			8921387	Jan 06, 2032	DP U-2174			
			8975270	Sep 05, 2031	DP U-2175			
			8975270	Sep 05, 2031	DP U-2206			
			9272044	Jun 06, 2031	U-2176			
			9272044	Jun 06, 2031	U-2177			
			9272044	Jun 06, 2031	U-2178			
			9272044	Jun 06, 2031	U-2209			
			9498432	Jun 06, 2031	DP U-2179			
			9782402	Jun 06, 2031	DP U-2176			
			9782402	Jun 06, 2031	DP U-2180			
			9782402	Jun 06, 2031	DP U-2207			
			9782402	Jun 06, 2031	DP U-2208			
			9827241	Jun 06, 2031	DP U-2174			
			9827241	Jun 06, 2031	DP U-2181			
			9827241	Jun 06, 2031	DP U-2206			
			9827241	Jun 06, 2031	DP U-2210			
			9827241	Jun 06, 2031	DP U-2211			
BUPRENORPHINE HYDROCHLORIDE - PROBUPHINE								
N	204442	001	7736665	Apr 25, 2024	U-1878		NP	May 26, 2019
BUPRENORPHINE HYDROCHLORIDE - BELBUCA								
N	207932	001	7579019	Jan 22, 2020	U-1769			
			8147866	Jul 23, 2027	DP U-1769			
			9655843	Jul 23, 2027	DP U-1556			
			9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA								
N	207932	002	7579019	Jan 22, 2020	U-1769			
			8147866	Jul 23, 2027	DP U-1769			
			9655843	Jul 23, 2027	DP U-1556			
			9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA								
N	207932	003	7579019	Jan 22, 2020	U-1769			
			8147866	Jul 23, 2027	DP U-1769			
			9655843	Jul 23, 2027	DP U-1556			
			9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA								
N	207932	004	7579019	Jan 22, 2020	U-1769			
			8147866	Jul 23, 2027	DP U-1769			
			9655843	Jul 23, 2027	DP U-1556			
			9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA								
N	207932	005	7579019	Jan 22, 2020	U-1769			
			8147866	Jul 23, 2027	DP U-1769			
			9655843	Jul 23, 2027	DP U-1556			
			9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA								
N	207932	006	7579019	Jan 22, 2020	U-1769			
			8147866	Jul 23, 2027	DP U-1769			
			9655843	Jul 23, 2027	DP U-1556			
			9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA								
N	207932	007	7579019	Jan 22, 2020	U-1769			
			8147866	Jul 23, 2027	DP U-1769			
			9655843	Jul 23, 2027	DP U-1556			
			9901539	Dec 21, 2032	U-1556			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE							
N 022410	001	8017150	Feb 13, 2023	DP			
		8475832	Mar 26, 2030	DP U-1411			
		8603514	Apr 03, 2024	DP U-1464			
		9687454	Aug 07, 2029	DP U-1464			
		9855221	Feb 14, 2022	DP			
		9931305	Feb 14, 2022	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE							
N 022410	002	8017150	Feb 13, 2023	DP			
		8475832	Mar 26, 2030	DP U-1411			
		8603514	Apr 03, 2024	DP U-1464			
		9687454	Aug 07, 2029	DP U-1464			
		9855221	Feb 14, 2022	DP			
		9931305	Feb 14, 2022	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE							
N 022410	003	8017150	Feb 13, 2023	DP			
		8475832	Mar 26, 2030	DP U-1411			
		8603514	Apr 03, 2024	DP U-1464			
		9687454	Aug 07, 2029	DP U-1464			
		9855221	Feb 14, 2022	DP			
		9931305	Feb 14, 2022	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE							
N 022410	004	8017150	Feb 13, 2023	DP			
		8475832	Mar 26, 2030	DP U-1411			
		8603514	Apr 03, 2024	DP U-1464			
		9687454	Aug 07, 2029	DP U-1464			
		9855221	Feb 14, 2022	DP			
		9931305	Feb 14, 2022	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV							
N 204242	001	8454996	Sep 24, 2019	U-1421			
		8470361	May 22, 2030	DP U-1425			
		8658198	Dec 03, 2027	DP U-1494			
		8940330	Sep 18, 2032	DP			
		9259421	Sep 18, 2032	DP			
		9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV							
N 204242	002	8454996	Sep 24, 2019	U-1421			
		8470361	May 22, 2030	DP U-1425			
		8658198	Dec 03, 2027	DP U-1494			
		8940330	Sep 18, 2032	DP			
		9259421	Sep 18, 2032	DP			
		9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV							
N 204242	003	8454996	Sep 24, 2019	U-1421			
		8470361	May 22, 2030	DP U-1425			
		8658198	Dec 03, 2027	DP U-1494			
		8940330	Sep 18, 2032	DP			
		9259421	Sep 18, 2032	DP			
		9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV							
N 204242	004	8454996	Sep 24, 2019	U-1421			
		8470361	May 22, 2030	DP U-1425			
		8658198	Dec 03, 2027	DP U-1494			
		8940330	Sep 18, 2032	DP			
		9259421	Sep 18, 2032	DP			
		9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV							
N 204242	005	8454996	Sep 24, 2019	U-1421			
		8470361	May 22, 2030	DP U-1425			
		8658198	Dec 03, 2027	DP U-1494			
		8940330	Sep 18, 2032	DP			
		9259421	Sep 18, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV								
N	204242	005	9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV								
N	204242	006	8454996	Sep 24, 2019			U-1421	
			8470361	May 22, 2030	DP		U-1425	
			8658198	Dec 03, 2027	DP		U-1494	
			8940330	Sep 18, 2032	DP			
			9259421	Sep 18, 2032	DP			
			9439900	Sep 18, 2032	DP	Y		
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL								
N	205637	001	7579019	Jan 22, 2020			U-1521	
			8147866	Jul 23, 2027	DP		U-1521	
			8703177	Aug 20, 2032	DP			
			9522188	Apr 24, 2035	DP			
			9655843	Jul 23, 2027	DP		U-2017	
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL								
N	205637	002	7579019	Jan 22, 2020			U-1521	
			8147866	Jul 23, 2027	DP		U-1521	
			8703177	Aug 20, 2032	DP			
			9522188	Apr 24, 2035	DP			
			9655843	Jul 23, 2027	DP		U-2017	
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL								
N	205637	003	7579019	Jan 22, 2020			U-1521	
			8147866	Jul 23, 2027	DP		U-1521	
			8703177	Aug 20, 2032	DP			
			9522188	Apr 24, 2035	DP			
			9655843	Jul 23, 2027	DP		U-2017	
BUPROPION HYDROBROMIDE - APLENZIN								
N	022108	001	7241805	Jun 27, 2026	DP			
			7569610	Jun 27, 2026			U-997	
			7572935	Jun 27, 2026	DP			
			7585897	Jun 27, 2026	DP			
			7645802	Jun 27, 2026	DP			
			7649019	Jun 27, 2026	DP			
			7662407	Jun 27, 2026	DP			
			7671094	Jun 27, 2026	DP			
BUPROPION HYDROBROMIDE - APLENZIN								
N	022108	002	7241805	Jun 27, 2026	DP			
			7569610	Jun 27, 2026			U-997	
			7572935	Jun 27, 2026	DP			
			7585897	Jun 27, 2026	DP			
			7645802	Jun 27, 2026	DP			
			7649019	Jun 27, 2026	DP			
			7662407	Jun 27, 2026	DP			
			7671094	Jun 27, 2026	DP			
BUPROPION HYDROBROMIDE - APLENZIN								
N	022108	003	7241805	Jun 27, 2026	DP			
			7569610	Jun 27, 2026			U-997	
			7572935	Jun 27, 2026	DP			
			7585897	Jun 27, 2026	DP			
			7645802	Jun 27, 2026	DP			
			7649019	Jun 27, 2026	DP			
			7662407	Jun 27, 2026	DP			
			7671094	Jun 27, 2026	DP			
BUPROPION HYDROCHLORIDE - FORFIVO XL								
N	022497	001	7674479	Jun 25, 2027	DP			
BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE								
N	200063	001	7375111	Mar 26, 2025	DP			
			7462626	Jul 20, 2024			U-1583	
			8088786	Feb 03, 2029	DP			
			8318788	Nov 08, 2027			U-1584	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE							
N 200063	001	8722085	Nov 08, 2027	U-1585			
		8815889	Jul 20, 2024	U-1586			
		8916195	Feb 02, 2030	U-1639			
		9107837	Jun 04, 2027	U-1639			
		9125868	Nov 08, 2027	U-1585			
		9248123	Jan 13, 2032	U-1808			
CABAZITAXEL - JEVTANA KIT							
N 201023	001	5847170	Mar 26, 2021	DS DP		M-201	May 17, 2020
		5847170*PED	Sep 26, 2021			M-209	Sep 14, 2020
		7241907	Dec 10, 2025	DS		PED	Nov 17, 2020
		7241907*PED	Jun 10, 2026				
		8927592	Oct 27, 2030	U-1630			
		8927592*PED	Apr 27, 2031				
CABOZANTINIB S-MALATE - COMETRIQ							
N 203756	001	7579473	Aug 14, 2026	DS DP		ODE-33	Nov 29, 2019
		8877776	Oct 08, 2030	DS DP U-1617			
		9717720	Feb 10, 2032	DP			
CABOZANTINIB S-MALATE - COMETRIQ							
N 203756	002	7579473	Aug 14, 2026	DS DP		ODE-33	Nov 29, 2019
		8877776	Oct 08, 2030	DS DP U-1617			
		9717720	Feb 10, 2032	DP			
CABOZANTINIB S-MALATE - CABOMETYX							
N 208692	001	10039757	Jul 18, 2031	U-1480		I-760	Dec 19, 2020
		7579473	Aug 14, 2026	DS DP		NP	Apr 25, 2019
		8497284	Sep 24, 2024	U-1220			
		8877776	Oct 08, 2030	DS DP			
		9724342	Jul 09, 2033	DP			
CABOZANTINIB S-MALATE - CABOMETYX							
N 208692	002	10039757	Jul 18, 2031	U-1480		I-760	Dec 19, 2020
		7579473	Aug 14, 2026	DS DP		NP	Apr 25, 2019
		8497284	Sep 24, 2024	U-1220			
		8877776	Oct 08, 2030	DS DP			
		9724342	Jul 09, 2033	DP			
CABOZANTINIB S-MALATE - CABOMETYX							
N 208692	003	10039757	Jul 18, 2031	U-1480		I-760	Dec 19, 2020
		7579473	Aug 14, 2026	DS DP		NP	Apr 25, 2019
		8497284	Sep 24, 2024	U-1220			
		8877776	Oct 08, 2030	DS DP			
		9724342	Jul 09, 2033	DP			
CALCIFEDIOL - RAYALDEE							
N 208010	001	6582727	Aug 22, 2020	DP		NP	Jun 17, 2019
		8207149	Apr 25, 2028	U-1871			
		8361488	Jul 19, 2028	DP			
		8426391	Aug 27, 2028	U-1872			
		8778373	Apr 25, 2028	U-1873			
		8906410	Feb 02, 2027	DP			
		9408858	Apr 25, 2028	U-1888			
		9498486	Apr 25, 2028	U-1920			
		9861644	Mar 14, 2034	DP			
		9925147	Apr 25, 2028	DP U-2255			
		9925147	Apr 25, 2028	DP U-2256			
		9925147	Apr 25, 2028	DP U-2257			
		9925147	Apr 25, 2028	DP U-2258			
		9925147	Apr 25, 2028	DP U-2259			
		9943530	Feb 02, 2027	U-2274			
CALCIPOTRIENE - SORILUX							
N 022563	001	8263580	Sep 27, 2028	DP U-1280			
		8629128	May 26, 2026	DP U-1280			
		8629128	May 26, 2026	DP U-1767			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CALCITONIN SALMON RECOMBINANT - FORTICAL							
N 021406	001	6440392	Feb 02, 2021	DP U-227			
		RE40812	Feb 02, 2021	DP			
		RE43580	Feb 02, 2021	DP U-227			
CALCITRIOL - CALCIJEX							
N 018874	001	6051567	Aug 02, 2019				
		6265392	Aug 02, 2019				
		6274169	Aug 02, 2019				
CALCITRIOL - CALCIJEX							
N 018874	002	6051567	Aug 02, 2019				
		6265392	Aug 02, 2019				
		6274169	Aug 02, 2019				
CALCIUM ACETATE - PHOSLO							
N 021160	002	6576665	Apr 03, 2021				
CALCIUM ACETATE - PHOSLO GELCAPS							
N 021160	003	6576665	Apr 03, 2021				
		6875445	Jul 30, 2021	DP			
CALCIUM ACETATE - PHOSLYRA							
N 022581	001	8591938	Feb 23, 2030	DP U-1469			
		8592480	Jul 20, 2027	U-1469			
		9089528	Jul 20, 2027	U-1469			
CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE - PEPCID COMPLETE							
N 020958	001	6814978	Aug 26, 2021	DP			
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - NAVSTEL							
N 022193	001	7084130	Nov 29, 2021	DP U-891			
CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER							
N 207026	001					ODE-85	Jan 13, 2022
CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER							
N 207026	002					ODE-85	Jan 13, 2022
CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE							
N 210906	001	10130646	Jan 11, 2038	DP			
CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE							
N 210906	002	10130646	Jan 11, 2038	DP			
CANAGLIFLOZIN - INVOKANA							
N 204042	001	7943582	Feb 26, 2029	DS DP U-2441		I-733	May 20, 2019
		7943582	Feb 26, 2029	DS DP U-493		I-788	Oct 29, 2021
		7943788	Jul 14, 2027	DS DP		M-197	Feb 01, 2020
		8222219	Apr 11, 2025	U-2441			
		8222219	Apr 11, 2025	U-493			
		8513202	Dec 03, 2027	DS DP U-2441			
		8513202	Dec 03, 2027	DS DP U-493			
CANAGLIFLOZIN - INVOKANA							
N 204042	002	7943582	Feb 26, 2029	DS DP U-2441		I-733	May 20, 2019
		7943582	Feb 26, 2029	DS DP U-493		I-788	Oct 29, 2021
		7943788	Jul 14, 2027	DS DP		M-197	Feb 01, 2020
		8222219	Apr 11, 2025	U-2441			
		8222219	Apr 11, 2025	U-493			
		8513202	Dec 03, 2027	DS DP U-2441			
		8513202	Dec 03, 2027	DS DP U-493			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET							
N 204353	001	7943582	Feb 26, 2029	DS DP U-2441		I-735	May 20, 2019
		7943582	Feb 26, 2029	DS DP U-493		I-788	Oct 29, 2021
		7943788	Jul 14, 2027	DS DP		M-197	Feb 01, 2020
		8222219	Apr 11, 2025	U-2441			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET							
N 204353	001	8222219	Apr 11, 2025	U-493			
		8513202	Dec 03, 2027	DS DP U-2441			
		8513202	Dec 03, 2027	DS DP U-493			
		8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET							
N 204353	002	7943582	Feb 26, 2029	DS DP U-2441		I-735	May 20, 2019
		7943582	Feb 26, 2029	DS DP U-493		I-788	Oct 29, 2021
		7943788	Jul 14, 2027	DS DP		M-197	Feb 01, 2020
		8222219	Apr 11, 2025	U-2441			
		8222219	Apr 11, 2025	U-493			
		8513202	Dec 03, 2027	DS DP U-2441			
		8513202	Dec 03, 2027	DS DP U-493			
		8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET							
N 204353	003	7943582	Feb 26, 2029	DS DP U-2441		I-735	May 20, 2019
		7943582	Feb 26, 2029	DS DP U-493		I-788	Oct 29, 2021
		7943788	Jul 14, 2027	DS DP		M-197	Feb 01, 2020
		8222219	Apr 11, 2025	U-2441			
		8222219	Apr 11, 2025	U-493			
		8513202	Dec 03, 2027	DS DP U-2441			
		8513202	Dec 03, 2027	DS DP U-493			
		8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET							
N 204353	004	7943582	Feb 26, 2029	DS DP U-2441		I-735	May 20, 2019
		7943582	Feb 26, 2029	DS DP U-493		I-788	Oct 29, 2021
		7943788	Jul 14, 2027	DS DP		M-197	Feb 01, 2020
		8222219	Apr 11, 2025	U-2441			
		8222219	Apr 11, 2025	U-493			
		8513202	Dec 03, 2027	DS DP U-2441			
		8513202	Dec 03, 2027	DS DP U-493			
		8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR							
N 205879	001	6723340	Oct 25, 2021	DP		I-735	May 20, 2019
		7943582	Feb 26, 2029	DS DP U-2441		I-788	Oct 29, 2021
		7943582	Feb 26, 2029	DS DP U-493			
		7943788	Jul 14, 2027	DS DP			
		8222219	Apr 11, 2025	U-2441			
		8222219	Apr 11, 2025	U-493			
		8513202	Dec 03, 2027	DS DP U-2441			
		8513202	Dec 03, 2027	DS DP U-493			
		8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR							
N 205879	002	7943582	Feb 26, 2029	DS DP U-2441		I-735	May 20, 2019
		7943582	Feb 26, 2029	DS DP U-493		I-788	Oct 29, 2021
		7943788	Jul 14, 2027	DS DP			
		8222219	Apr 11, 2025	U-2441			
		8222219	Apr 11, 2025	U-493			
		8513202	Dec 03, 2027	DS DP U-2441			
		8513202	Dec 03, 2027	DS DP U-493			
		8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR							
N 205879	003	6723340	Oct 25, 2021	DP		I-735	May 20, 2019
		7943582	Feb 26, 2029	DS DP U-2441		I-788	Oct 29, 2021
		7943582	Feb 26, 2029	DS DP U-493			
		7943788	Jul 14, 2027	DS DP			
		8222219	Apr 11, 2025	U-2441			
		8222219	Apr 11, 2025	U-493			
		8513202	Dec 03, 2027	DS DP U-2441			
		8513202	Dec 03, 2027	DS DP U-493			
		8785403	Jul 30, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR							
N 205879	004	7943582	Feb 26, 2029	DS DP U-2441		I-735	May 20, 2019
		7943582	Feb 26, 2029	DS DP U-493		I-788	Oct 29, 2021
		7943788	Jul 14, 2027	DS DP			
		8222219	Apr 11, 2025	U-2441			
		8222219	Apr 11, 2025	U-493			
		8513202	Dec 03, 2027	DS DP U-2441			
		8513202	Dec 03, 2027	DS DP U-493			
		8785403	Jul 30, 2024	DP			
CANGRELOR - KENGREAL							
N 204958	001	10039780	Jul 10, 2035	U-2260		NCE	Jun 22, 2020
		6130208	Jun 29, 2023	DP U-1715			
		8680052	Mar 09, 2033	U-1715			
		8759316	May 13, 2029	U-1715			
		9295687	Jul 10, 2035	DP			
		9427448	Nov 10, 2030	U-1926			
		9439921	Jul 10, 2035	DP			
		9700575	Jul 10, 2035	DP			
		9925265	May 13, 2029	U-2260			
CANNABIDIOL - EPIDIOLEX							
N 210365	001	10092525	Jun 17, 2035	U-2427		NCE	Sep 28, 2023
		10111840	Jun 17, 2035	U-2442		ODE-216	Sep 28, 2025
		10111840	Jun 17, 2035	U-2443			
		10137095	Jun 17, 2035	U-2454			
		10137095	Jun 17, 2035	U-2455			
		9949937	Jun 17, 2035	U-2421			
		9956183	Jun 17, 2035	U-2422			
		9956183	Jun 17, 2035	U-2423			
		9956184	Jun 17, 2035	U-2424			
		9956185	Jun 17, 2035	U-2425			
		9956186	Jun 17, 2035	U-2426			
CAPSAICIN - QUTENZA							
N 022395	001	6239180	Jun 04, 2021	DP			
CARBAMAZEPINE - EQUETRO							
N 021710	001	6977253	May 19, 2024	U-693			
CARBAMAZEPINE - EQUETRO							
N 021710	002	6977253	May 19, 2024	U-693			
CARBAMAZEPINE - EQUETRO							
N 021710	003	6977253	May 19, 2024	U-693			
CARBAMAZEPINE - CARNEXIV							
N 206030	001	7635773	Mar 13, 2029	DP		ODE-124	Oct 07, 2023
		8410077	Mar 13, 2029	DP			
		9493582	Feb 27, 2033	DP			
		9629797	Nov 10, 2028	U-2004			
		9629797	Nov 10, 2028	U-2005			
		9629797	Nov 10, 2028	U-2006			
		9750822	Mar 13, 2029	DP			
		9770407	Nov 10, 2028	DP			
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 50							
N 021485	001	6500867	Jun 29, 2020	DP U-219			
		6797732	Jun 29, 2020	DP			
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 100							
N 021485	002	6500867	Jun 29, 2020	DP U-219			
		6797732	Jun 29, 2020	DP			
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 150							
N 021485	003	6500867	Jun 29, 2020	DP U-219			
		6797732	Jun 29, 2020	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 200							
N 021485	004	6500867	Jun 29, 2020	DP U-219			
		6797732	Jun 29, 2020	DP			
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 75							
N 021485	005	6500867	Jun 29, 2020	DP U-219			
		6797732	Jun 29, 2020	DP			
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 125							
N 021485	006	6500867	Jun 29, 2020	DP U-219			
		6797732	Jun 29, 2020	DP			
CARBIDOPA; LEVODOPA - RYTARY							
N 203312	001	7094427	May 29, 2022	DP U-1645	Y		
		8377474	Dec 26, 2028	DP U-1645			
		8377474	Dec 26, 2028	DP U-219			
		8454998	Dec 26, 2028	DP U-1645			
		8454998	Dec 26, 2028	DP U-1646			
		8454998	Dec 26, 2028	DP U-1647			
		8454998	Dec 26, 2028	DP U-1649			
		8454998	Dec 26, 2028	DP U-219			
		8557283	Dec 26, 2028	DP U-1645			
		8557283	Dec 26, 2028	DP U-219			
		9089607	Dec 26, 2028	DP U-1645			
		9089607	Dec 26, 2028	DP U-1720			
		9089608	Dec 26, 2028	DP			
		9463246	Dec 26, 2028	DP U-219			
		9533046	Dec 26, 2028	DP U-219			
		9901640	Dec 26, 2028	DP U-219			
CARBIDOPA; LEVODOPA - RYTARY							
N 203312	002	7094427	May 29, 2022	DP U-1645	Y		
		8377474	Dec 26, 2028	DP U-1645			
		8377474	Dec 26, 2028	DP U-219			
		8454998	Dec 26, 2028	DP U-1645			
		8454998	Dec 26, 2028	DP U-1646			
		8454998	Dec 26, 2028	DP U-1647			
		8454998	Dec 26, 2028	DP U-1649			
		8454998	Dec 26, 2028	DP U-219			
		8557283	Dec 26, 2028	DP U-1645			
		8557283	Dec 26, 2028	DP U-219			
		9089607	Dec 26, 2028	DP U-1645			
		9089607	Dec 26, 2028	DP U-1720			
		9089608	Dec 26, 2028	DP			
		9463246	Dec 26, 2028	DP U-219			
		9533046	Dec 26, 2028	DP U-219			
		9901640	Dec 26, 2028	DP U-219			
CARBIDOPA; LEVODOPA - RYTARY							
N 203312	003	7094427	May 29, 2022	DP U-1645	Y		
		8377474	Dec 26, 2028	DP U-1645			
		8377474	Dec 26, 2028	DP U-219			
		8454998	Dec 26, 2028	DP U-1645			
		8454998	Dec 26, 2028	DP U-1646			
		8454998	Dec 26, 2028	DP U-1647			
		8454998	Dec 26, 2028	DP U-1649			
		8454998	Dec 26, 2028	DP U-219			
		8557283	Dec 26, 2028	DP U-1645			
		8557283	Dec 26, 2028	DP U-219			
		9089607	Dec 26, 2028	DP U-1645			
		9089607	Dec 26, 2028	DP U-1720			
		9089608	Dec 26, 2028	DP			
		9463246	Dec 26, 2028	DP U-219			
		9533046	Dec 26, 2028	DP U-219			
		9901640	Dec 26, 2028	DP U-219			
CARBIDOPA; LEVODOPA - RYTARY							
N 203312	004	7094427	May 29, 2022	DP U-1645	Y		
		8377474	Dec 26, 2028	DP U-1645			
		8377474	Dec 26, 2028	DP U-219			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARBIDOPA; LEVODOPA - RYTARY							
N 203312	004	8454998	Dec 26, 2028	DP U-1645			
		8454998	Dec 26, 2028	DP U-1646			
		8454998	Dec 26, 2028	DP U-1647			
		8454998	Dec 26, 2028	DP U-1649			
		8454998	Dec 26, 2028	DP U-219			
		8557283	Dec 26, 2028	DP U-1645			
		8557283	Dec 26, 2028	DP U-219			
		9089607	Dec 26, 2028	DP U-1645			
		9089607	Dec 26, 2028	DP U-1720			
		9089608	Dec 26, 2028	DP			
		9463246	Dec 26, 2028	DP U-219			
		9533046	Dec 26, 2028	DP U-219			
		9901640	Dec 26, 2028	DP U-219			
CARBIDOPA; LEVODOPA - DUOPA							
N 203952	001					ODE-84	Jan 09, 2022
CARBINOXAMINE MALEATE - KARBINAL ER							
N 022556	001	8062667	Mar 29, 2029	DP			
		9522191	Jun 15, 2027	DP			
CARFILZOMIB - KYPROLIS							
N 202714	001	7232818	Apr 14, 2025	DS DP		D-172	Sep 28, 2021
		7417042	Jul 20, 2026	DS DP		I-722	Jan 21, 2019
		7491704	Apr 14, 2025	U-1260		I-723	Jan 21, 2019
		7737112	Dec 07, 2027	DP		ODE-27	Jul 20, 2019
		8129346	Apr 14, 2025	U-1260			
		8207125	Apr 14, 2025	DS DP			
		8207126	Apr 14, 2025	DP			
		8207127	Apr 14, 2025	U-1260			
		8207297	Apr 14, 2025	DS DP			
		9493582	Feb 27, 2033	DP			
		9511109	Oct 21, 2029	U-1924			
CARFILZOMIB - KYPROLIS							
N 202714	002	7232818	Apr 14, 2025	DS DP		D-172	Sep 28, 2021
		7417042	Jul 20, 2026	DS DP		I-722	Jan 21, 2019
		7491704	Apr 14, 2025	U-1260		I-723	Jan 21, 2019
		7737112	Dec 07, 2027	DP		ODE-27	Jul 20, 2019
		8129346	Apr 14, 2025	U-1260			
		8207125	Apr 14, 2025	DS DP			
		8207126	Apr 14, 2025	DP			
		8207127	Apr 14, 2025	U-1260			
		8207297	Apr 14, 2025	DS DP			
		9493582	Feb 27, 2033	DP			
		9511109	Oct 21, 2029	U-1924			
CARFILZOMIB - KYPROLIS							
N 202714	003	7232818	Apr 14, 2025	DS DP		D-172	Sep 28, 2021
		7417042	Jul 20, 2026	DS DP			
		7491704	Apr 14, 2025	U-2319			
		7491704	Apr 14, 2025	U-2320			
		7737112	Dec 07, 2027	DP			
		8129346	Apr 14, 2025	U-2319			
		8129346	Apr 14, 2025	U-2320			
		8207125	Apr 14, 2025	DS DP			
		8207126	Apr 14, 2025	DP			
		8207127	Apr 14, 2025	U-2319			
		8207127	Apr 14, 2025	U-2320			
		8207297	Apr 14, 2025	DS DP			
		9493582	Feb 27, 2033	DP			
		9511109	Oct 21, 2029	U-1924			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR							
N 204370	001	7737142	Mar 27, 2027	DS DP U-1750		M-213	Nov 09, 2020
		7943621	Dec 16, 2028	DS DP		NCE	Sep 17, 2020

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARIPRAZINE HYDROCHLORIDE - VRAYLAR							
N 204370	002	7737142	Mar 27, 2027	DS DP U-1750		M-213	Nov 09, 2020
		7943621	Dec 16, 2028	DS DP		NCE	Sep 17, 2020
CARIPRAZINE HYDROCHLORIDE - VRAYLAR							
N 204370	003	7737142	Mar 27, 2027	DS DP U-1750		M-213	Nov 09, 2020
		7943621	Dec 16, 2028	DS DP		NCE	Sep 17, 2020
CARIPRAZINE HYDROCHLORIDE - VRAYLAR							
N 204370	004	7737142	Mar 27, 2027	DS DP U-1750		M-213	Nov 09, 2020
		7943621	Dec 16, 2028	DS DP		NCE	Sep 17, 2020
CARVEDILOL PHOSPHATE - COREG CR							
N 022012	001	7268156	Jun 27, 2023	DS DP U-3			
		7268156	Jun 27, 2023	DS DP U-313			
		8101209	Sep 11, 2025	DP			
CARVEDILOL PHOSPHATE - COREG CR							
N 022012	002	7268156	Jun 27, 2023	DS DP U-3			
		7268156	Jun 27, 2023	DS DP U-313			
		8101209	Sep 11, 2025	DP			
CARVEDILOL PHOSPHATE - COREG CR							
N 022012	003	7268156	Jun 27, 2023	DS DP U-3			
		7268156	Jun 27, 2023	DS DP U-313			
		8101209	Sep 11, 2025	DP			
CARVEDILOL PHOSPHATE - COREG CR							
N 022012	004	7268156	Jun 27, 2023	DS DP U-3			
		7268156	Jun 27, 2023	DS DP U-313			
		8101209	Sep 11, 2025	DP			
CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE							
N 206110	001	9636407	Dec 21, 2032	DP			
CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE							
N 206110	002	9636407	Dec 21, 2032	DP			
CEFIXIME - SUPRAX							
N 202091	001	9233112	Dec 14, 2028	DP U-1676			
CEFTAROLINE FOSAMIL - TEFLARO							
N 200327	001	6417175	Apr 11, 2022	DS DP U-1676		NPP	May 27, 2019
		6906055	Dec 15, 2021	DS DP		NPP	May 27, 2019
		7419973	Dec 15, 2021	DP			
		8247400	Feb 10, 2031	DP U-282			
		9629861	Sep 21, 2030	DP			
CEFTAROLINE FOSAMIL - TEFLARO							
N 200327	002	6417175	Apr 11, 2022	DS DP U-1676		NPP	May 27, 2019
		6906055	Dec 15, 2021	DS DP		NPP	May 27, 2019
		7419973	Dec 15, 2021	DP			
		8247400	Feb 10, 2031	DP U-282			
		9629861	Sep 21, 2030	DP			
CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA							
N 206829	001	10125149	Aug 14, 2035	DP		NCE	Dec 19, 2019
		7129232	Oct 21, 2024	DS DP U-36		GAIN	Dec 19, 2024
		8476425	Sep 27, 2032	DS			
		8685957	Sep 27, 2032	DS U-36			
		8906898	May 28, 2034	DS DP			
		8968753	Mar 14, 2034	U-1672			
		8968753	Mar 14, 2034	U-1673			
		9320740	Mar 14, 2034	DP			
		9872906	Mar 14, 2034	DP			
CERITINIB - ZYKADIA							
N 205755	001	7153964	Feb 26, 2021	DS DP		M-199	May 26, 2020
		7893074	Apr 25, 2026	DS DP		NCE	Apr 29, 2019
		7964592	Jan 13, 2027	DS DP		ODE-145	May 26, 2024
		8039479	Jun 29, 2030	DS DP		ODE-66	Apr 29, 2021

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CERITINIB - ZYKADIA							
N 205755	001	8188276	Jan 31, 2023	DS DP			
		8377921	Nov 20, 2027	U-1179			
		8399450	Nov 20, 2027	DS DP			
		8703787	Feb 02, 2032	U-1179			
		8835430	Jan 31, 2023	DS DP			
		9018204	Jan 31, 2023	DS DP			
		9309229	Jan 18, 2032	DS DP			
		9416112	Jan 31, 2023	DS DP			
CETIRIZINE HYDROCHLORIDE - ZERVIATE							
N 208694	001	8829005	Mar 15, 2030	U-1680		NDF	May 30, 2020
		8829005*PED	Sep 15, 2030			PED	Nov 30, 2020
		9254286	Jul 09, 2032	DP			
		9254286*PED	Jan 09, 2033				
		9750684	Mar 15, 2030	DP			
		9993471	Mar 15, 2030	U-1680			
CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ZYRTEC-D 12 HOUR							
N 021150	002	6469009	Jul 13, 2019	DP U-295			
		7014867	Jun 10, 2022	DP			
		7226614	Jun 10, 2022	U-295			
CETRORELIX - CETROTIDE							
N 021197	001	6319192	Apr 23, 2019	U-426			
CETRORELIX - CETROTIDE							
N 021197	002	6319192	Apr 23, 2019	U-426			
CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE							
N 021669	001	7066916	Feb 17, 2024	U-737			
		7427574	Apr 25, 2026	DP			
		7595021	May 12, 2023	DP U-1022			
		7717889	Feb 27, 2025	DP U-1022			
		7935093	Oct 02, 2027	DP U-1022			
CHLORHEXIDINE GLUCONATE - READYPREP CHG							
N 207964	001					NP	Nov 20, 2021
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP							
N 020832	001	6536975	Nov 10, 2020	DP			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT							
N 020832	002	6729786	Mar 14, 2023	DP			
		6991394	Jan 31, 2024	DP			
		7182536	Dec 30, 2023	DP			
		7241065	Mar 14, 2023	DP			
		7422388	Apr 25, 2027	DP U-1397			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP							
N 020832	004	6536975	Nov 10, 2020	DP			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT							
N 020832	005	6536975	Nov 10, 2020	DP			
		6729786	Mar 14, 2023	DP			
		7241065	Mar 14, 2023	DP			
		7422388	Apr 25, 2027	DP U-1397			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP							
N 020832	006	6991394	Jan 31, 2024	DP			
		7182536	Dec 30, 2023	DP			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT							
N 020832	007	6536975	Nov 10, 2020	DP			
		6729786	Mar 14, 2023	DP			
		7241065	Mar 14, 2023	DP			
		7422388	Apr 25, 2027	DP U-1397			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWAB							
N 021524	001					M-221	Feb 14, 2021
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWABSTICK							
N 021524	002					M-221	Feb 14, 2021
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS MAXI SWABSTICK							
N 021524	003					M-221	Feb 14, 2021
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - SOLUPREP							
N 208288	001	8623935	Jul 26, 2029	DP U-1022		NP	Aug 08, 2021
CHLOROPROCAINE HYDROCHLORIDE - CLOROTEKAL							
N 208791	001					NP	Sep 26, 2020
CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE - TUXARIN ER							
N 206323	001	6248363	Nov 23, 2019	DP U-1716			
		6383471	Apr 06, 2019	DP U-1716			
		9066942	Jan 03, 2032	U-1716			
		9107921	Jan 03, 2032	DP			
CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS							
N 021441	001	7863287	Feb 28, 2027	DP			
CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR							
N 207768	001	8062667	Mar 29, 2029	DP			
		8790700	Mar 15, 2027	DP			
CHOLIC ACID - CHOLBAM							
N 205750	001					NCE	Mar 17, 2020
						ODE-91	Mar 17, 2022
CHOLIC ACID - CHOLBAM							
N 205750	002					NCE	Mar 17, 2020
						ODE-91	Mar 17, 2022
CHOLINE FENOFIBRATE - TRILIPIX							
N 022224	001	7259186	Jan 07, 2025	DS			
CHOLINE FENOFIBRATE - TRILIPIX							
N 022224	002	7259186	Jan 07, 2025	DS			
CHORIOGONADOTROPIN ALFA - OVIDREL							
N 021149	002	6706681	Mar 16, 2021	DP			
CICLESONIDE - ALVESCO							
N 021658	002	8371292	Feb 01, 2028	U-1355			
CICLESONIDE - ALVESCO							
N 021658	003	8371292	Feb 01, 2028	U-1355			
CICLESONIDE - OMNARIS							
N 022004	001	6767901	Oct 21, 2020	DP			
		6939559	Apr 21, 2019	DP			
		7235247	Apr 21, 2019	DP			
		8371292	Feb 01, 2028	U-1356			
		8383611	Oct 20, 2020	DP			
CICLESONIDE - ZETONNA							
N 202129	001	8371292	Feb 01, 2028	U-1357			
CINACALCET HYDROCHLORIDE - SENSIPAR							
N 021688	001	7829595	Sep 22, 2026	DP U-1098		M-200	May 23, 2020
		9375405	Sep 22, 2026	DP		ODE-78	Nov 21, 2021
CINACALCET HYDROCHLORIDE - SENSIPAR							
N 021688	002	7829595	Sep 22, 2026	DP U-1098		M-200	May 23, 2020
		9375405	Sep 22, 2026	DP		ODE-78	Nov 21, 2021

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CINACALCET HYDROCHLORIDE - SENSIPAR						
N 021688 003	7829595	Sep 22, 2026	DP U-1098		M-200	May 23, 2020
	9375405	Sep 22, 2026	DP		ODE-78	Nov 21, 2021
CIPROFLOXACIN - OTIPRIO						
N 207986 001	8318817	Apr 27, 2030	U-1792		I-770	Mar 02, 2021
	9205048	Apr 21, 2029	U-1793			
	9220796	Jul 01, 2035	DP			
	9233068	Dec 11, 2029	DP			
	9603796	Apr 21, 2029	DS DP U-2252			
CIPROFLOXACIN HYDROCHLORIDE - PROQUIN XR						
N 021744 001	6488962	Jun 20, 2020	DP			
CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - OTOVEL						
N 208251 001	8932610	Mar 24, 2030	DP U-1578		NC	Apr 29, 2019
CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR						
N 021473 001	7709022	Jun 23, 2021	DP			
	8187632	Jun 23, 2021	DP			
	8187632*PED	Dec 23, 2021				
CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR						
N 021473 002	7709022	Jun 23, 2021	DP			
	8187632	Jun 23, 2021	DP			
	8187632*PED	Dec 23, 2021				
CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX						
N 021537 001	6284804	Aug 10, 2020				
	6359016	Aug 10, 2020				
	8846650	Jun 04, 2025	DP U-1578			
	9149486	Sep 13, 2022	DP U-1578			
	9345714	Sep 13, 2022	DP U-1578			
	9402805	Sep 13, 2022	DP U-1578			
	9402805	Sep 13, 2022	DP U-1679			
CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK						
N 202535 001	8450338	Oct 10, 2028	DP		NPP	Aug 15, 2021
	8481083	Oct 10, 2028	DP			
CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIQ						
N 209589 001	9827231	Jun 23, 2034	DP U-2162			
CLEVIDIPINE - CLEVIPREX						
N 022156 001	10010537	Oct 10, 2031	DP			
	5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
CLEVIDIPINE - CLEVIPREX						
N 022156 002	10010537	Oct 10, 2031	DP			
	5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
CLEVIDIPINE - CLEVIPREX						
N 022156 003	10010537	Oct 10, 2031	DP			
	5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
CLINDAMYCIN PHOSPHATE - CLEOCIN						
N 050767 001	6495157	Jul 20, 2020	DP			
CLINDAMYCIN PHOSPHATE - CLINDAGEL						
N 050782 001	6387383	Aug 03, 2020	DP U-818			
CLINDAMYCIN PHOSPHATE - CLINDESSE						
N 050793 001	6899890	Apr 27, 2023	DP U-137			
	9789057	Dec 02, 2026	DP U-137			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CLINDAMYCIN PHOSPHATE - EVOCLIN							
N 050801	001	7141237	Jan 23, 2024	DS DP			
		7374747	Aug 09, 2026	DS DP U-921			
CLINDAMYCIN PHOSPHATE; TRETINOIN - ZIANA							
N 050802	001	6387383	Aug 03, 2020	DP U-916			
CLOBAZAM - SYMPAZAN							
N 210833	001	8603514	Apr 03, 2024	DP			
		8765167	Feb 20, 2024	DP			
CLOBAZAM - SYMPAZAN							
N 210833	002	8603514	Apr 03, 2024	DP			
		8765167	Feb 20, 2024	DP			
CLOBAZAM - SYMPAZAN							
N 210833	003	8603514	Apr 03, 2024	DP			
		8765167	Feb 20, 2024	DP			
CLOBETASOL PROPIONATE - CLOBEX							
N 021644	001	7316810	Jun 17, 2019	DP			
		7700081	Jan 03, 2022	U-1044			
		8066975	Jun 17, 2019	DP			
		8066976	Jun 17, 2019	DP			
CLOBETASOL PROPIONATE - OLUX E							
N 022013	001	6730288	Sep 08, 2019	DP			
		7029659	Sep 08, 2019	DP			
		8460641	Nov 05, 2028	DP U-1410			
		8962000	Aug 31, 2025	DP U-1410			
CLOBETASOL PROPIONATE - IMPOYZ							
N 209483	001	10064875	Aug 31, 2030	DP U-1408		NP	Nov 28, 2020
		10064875	Aug 31, 2030	DP U-1858			
		10064875	Aug 31, 2030	DP U-193			
		10064875	Aug 31, 2030	DP U-742			
		10064875	Aug 31, 2030	DP U-88			
		9855334	Mar 11, 2035	DP			
		9956231	Aug 31, 2030	DP U-1408			
		9956231	Aug 31, 2030	DP U-1761			
		9956231	Aug 31, 2030	DP U-1858			
		9956231	Aug 31, 2030	DP U-193			
		9956231	Aug 31, 2030	DP U-742			
		9956231	Aug 31, 2030	DP U-88			
CLOPIDOGREL BISULFATE - PLAVIX							
N 020839	001	6429210	Jun 10, 2019	DS DP			
		6504030	Jun 10, 2019	DS			
CLOPIDOGREL BISULFATE - PLAVIX							
N 020839	002	6429210	Jun 10, 2019	DS DP			
		6504030	Jun 10, 2019	DS			
COBICISTAT - TYBOST							
N 203094	001	10039718	Oct 04, 2032	DP			
		8148374	Sep 03, 2029	DS DP U-1279			
COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX							
N 205395	001	10039718	Oct 04, 2032	DP			
		7470506	Jun 23, 2019	U-1660			
		7470506*PED	Dec 23, 2019				
		7700645	Dec 26, 2026	DS DP			
		7700645*PED	Jun 26, 2027				
		8148374	Sep 03, 2029	DS DP U-1279			
		8518987	Feb 16, 2024	DS DP			
		8518987*PED	Aug 16, 2024				
		8597876	Jun 23, 2019	U-1660			
		8597876*PED	Dec 23, 2019				
		9889115	Jun 23, 2019	U-1660			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
COBICISTAT; DARUNAVIR ETHANOLATE; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA							
N 210455	001	10039718	Oct 04, 2032	DP		NC	Jul 17, 2020
		6642245	Nov 04, 2020	U-2352		NCE	Nov 05, 2020
		6703396	Mar 09, 2021	DS DP			
		7390791	May 07, 2022	DS DP			
		7470506	Jun 23, 2019	U-2352			
		7700645	Dec 26, 2026	DS DP			
		7803788	Feb 02, 2022	U-2352			
		8148374	Sep 03, 2029	DS DP U-2353			
		8148374	Sep 03, 2029	DS DP U-2364			
		8148374	Sep 03, 2029	DS DP U-2365			
		8518987	Feb 16, 2024	DS DP			
		8597876	Jun 23, 2019	U-2352			
		8754065	Aug 15, 2032	DS DP U-2352			
		9296769	Aug 15, 2032	DS DP U-2352			
		9889115	Jun 23, 2019	U-2352			
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA							
N 207561	001	10039718	Oct 04, 2032	DP		D-173	Dec 10, 2021
		6642245	Nov 04, 2020	U-257		NCE	Nov 05, 2020
		6642245*PED	May 04, 2021			NPP	Sep 25, 2020
		6703396	Mar 09, 2021	DS DP			
		6703396*PED	Sep 09, 2021				
		7176220	Aug 27, 2026	DS DP U-257			
		7390791	May 07, 2022	DS DP			
		7635704	Oct 26, 2026	DS DP U-257			
		7803788	Feb 02, 2022	U-257			
		8148374	Sep 03, 2029	DS DP U-1279			
		8633219	Apr 24, 2030	DP U-257			
		8754065	Aug 15, 2032	DS DP U-257			
		8981103	Oct 26, 2026	DS DP			
		9296769	Aug 15, 2032	DS DP U-257			
		9891239	Sep 03, 2029	DP U-257			
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD							
N 203100	001	10039718	Oct 04, 2032	DP		NPP	Jan 27, 2020
		6642245	Nov 04, 2020	U-257			
		6703396	Mar 09, 2021	DS DP			
		7176220	Aug 27, 2026	DS DP U-257			
		7635704	Oct 26, 2026	DS DP U-257			
		8148374	Sep 03, 2029	DS DP U-1279			
		8592397	Jan 13, 2024	DP U-257			
		8633219	Apr 24, 2030	DP U-257			
		8716264	Jan 13, 2024	DP U-257			
		8981103	Oct 26, 2026	DS DP			
		9457036	Jan 13, 2024	DP U-257			
		9744181	Jan 13, 2024	DP U-257			
		9891239	Sep 03, 2029	DP U-257			
COBIMETINIB FUMARATE - COTELLIC							
N 206192	001	7803839	Feb 01, 2027	DS DP		NCE	Nov 10, 2020
		8362002	Oct 05, 2026	U-1776		ODE-101	Nov 10, 2022
COCAINE HYDROCHLORIDE - GOPRELTO							
N 209963	001	10016407	Feb 07, 2037	U-2329		NCE	Dec 14, 2022
		10149843	Feb 07, 2037	U-2478			
		10149843	Feb 07, 2037	U-2479			
		9867815	Feb 07, 2037	U-2225			
		9867815	Feb 07, 2037	U-2226			
		9867815	Feb 07, 2037	U-2227			
COLCHICINE - COLCRYS							
N 022352	001	7601758	Feb 10, 2029	U-1007			
		7619004	Dec 03, 2028	U-1020			
		7820681	Feb 17, 2029	U-1020			
		7906519	Feb 17, 2029	U-1116			
		7915269	Feb 17, 2029	U-1007			
		7935731	Dec 03, 2028	U-1116			
		7964647	Oct 06, 2028	U-1007			
		7964648	Oct 06, 2028	U-1161			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
COLCHICINE - COLCRYS							
N 022352	001	7981938	Oct 06, 2028	U-1166			
		8093296	Oct 06, 2028	U-1007			
		8093297	Oct 06, 2028	U-1161			
		8093298	Oct 06, 2028	U-1116			
		8097655	Oct 06, 2028	U-1020			
		8415395	Oct 06, 2028	U-1007			
		8415396	Oct 06, 2028	U-1007			
		8440721	Feb 17, 2029	U-1007			
		8440722	Feb 17, 2029	U-1020			
COLCHICINE - MITIGARE							
N 204820	001	8927607	Aug 22, 2033	U-1020			
		9399036	Aug 22, 2033	U-1020			
		9555029	Aug 22, 2033	U-1020			
		9675613	Aug 22, 2033	U-1020			
		9789108	Aug 22, 2033	U-1020			
COLESEVELAM HYDROCHLORIDE - WELCHOL							
N 021176	001	7229613	Apr 17, 2022	U-851			
COLESEVELAM HYDROCHLORIDE - WELCHOL							
N 022362	001	7229613	Apr 17, 2022	U-493			
COLESEVELAM HYDROCHLORIDE - WELCHOL							
N 022362	002	7229613	Apr 17, 2022	U-493			
CONIVAPTAN HYDROCHLORIDE - VAPRISOL							
N 021697	001	5723606	Dec 15, 2019	DS DP U-698			
		5723606	Dec 15, 2019	DS DP U-868			
CONIVAPTAN HYDROCHLORIDE - VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER							
N 021697	002	5723606	Dec 15, 2019	DS DP U-698			
		5723606	Dec 15, 2019	DS DP U-868			
COPANLISIB DIHYDROCHLORIDE - ALIQOPA							
N 209936	001	7511041	May 13, 2024	DS DP		NCE	Sep 14, 2022
		9636344	Mar 29, 2032	U-2124		ODE-155	Sep 14, 2024
		RE46856	Oct 22, 2029	DS DP U-2124			
CRISABOROLE - EUCRISA							
N 207695	001	8039451	Jun 11, 2026	DS DP		NCE	Dec 14, 2021
		8168614	Jan 20, 2030	U-1932			
		8501712	Feb 16, 2027	U-1932			
		9682092	Feb 16, 2027	U-1932			
CRIZOTINIB - XALKORI							
N 202570	001	7230098	Aug 26, 2025	DS		ODE-111	Mar 11, 2023
		7825137	May 12, 2027	U-1179			
		7858643	Oct 08, 2029	DS DP			
		8217057	Nov 06, 2029	DS DP			
		8785632	Mar 01, 2025	DS			
CRIZOTINIB - XALKORI							
N 202570	002	7230098	Aug 26, 2025	DS		ODE-111	Mar 11, 2023
		7825137	May 12, 2027	U-1179			
		7858643	Oct 08, 2029	DS DP			
		8217057	Nov 06, 2029	DS DP			
		8785632	Mar 01, 2025	DS			
CROFELEMER - MYTESI							
N 202292	001	8962680	Oct 31, 2031	U-1319			
		9585868	Oct 31, 2031	DS U-1319			
CYANOCOBALAMIN - NASCOBAL							
N 021642	001	7229636	Aug 01, 2024	DP U-817			
		7404489	Mar 12, 2024	DP			
		7879349	Aug 01, 2024	DP U-1152			
		8003353	Aug 01, 2024	U-817			
		8940714	Feb 26, 2024	U-1152			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CYANOCOBALAMIN - NASCOBAL							
N 021642	001	9415007	Jul 28, 2024	U-1896			
CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX							
N 021777	001	7387793	Feb 26, 2025	DP			
		7544372	Nov 14, 2023	U-979			
		7790199	Nov 14, 2023	DP			
		7820203	Nov 14, 2023	DP			
		7829121	Nov 14, 2023	U-1088			
		8877245	Nov 14, 2023	U-979			
		9375410	Nov 14, 2023	U-1088			
		9399025	Nov 14, 2023	DP U-979			
CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX							
N 021777	002	7387793	Feb 26, 2025	DP			
		7544372	Nov 14, 2023	U-979			
		7790199	Nov 14, 2023	DP			
		7820203	Nov 14, 2023	DP			
		7829121	Nov 14, 2023	U-1088			
		8877245	Nov 14, 2023	U-979			
		9375410	Nov 14, 2023	U-1088			
		9399025	Nov 14, 2023	DP U-979			
CYCLOSPORINE - RESTASIS							
N 050790	001	8629111	Aug 27, 2024	DP			
		8633162	Aug 27, 2024	U-1479			
		8642556	Aug 27, 2024	DP			
		8648048	Aug 27, 2024	U-1483			
		8685930	Aug 27, 2024	DP			
		9248191	Aug 27, 2024	U-1479			
CYCLOSPORINE - RESTASIS MULTIDOSE							
N 050790	002	8292129	Feb 25, 2031	DP			
		8561859	Apr 16, 2032	DP			
		8629111	Aug 27, 2024	DP			
		8633162	Aug 27, 2024	U-1479			
		8642556	Aug 27, 2024	DP			
		8648048	Aug 27, 2024	U-1483			
		8685930	Aug 27, 2024	DP			
		9248191	Aug 27, 2024	U-1479			
		9669974	May 11, 2034	DP			
		9676525	Feb 07, 2034	DP			
CYCLOSPORINE - CEQUA							
N 210913	001	8980839	Aug 23, 2033	DP U-1483			
		9937225	Aug 23, 2033	DP U-1483			
CYSTEAMINE BITARTRATE - PROCYSBI							
N 203389	001	10143665	Aug 16, 2036	U-1399		M-216	Dec 22, 2020
		8026284	Sep 22, 2027	U-1399		ODE-162	Dec 22, 2024
		8026284*PED	Mar 22, 2028			ODE-45	Apr 30, 2020
		9173851	Jun 17, 2034	DP		ODE-97	Aug 14, 2022
		9173851*PED	Dec 17, 2034			PED	Oct 30, 2020
		9192590	Jan 26, 2027	U-1399		PED	Jun 22, 2021
		9192590*PED	Jul 26, 2027			PED	Feb 14, 2023
		9198882	Jan 26, 2027	U-1399			
		9198882*PED	Jul 26, 2027				
		9233077	Jun 17, 2034	DP			
		9233077*PED	Dec 17, 2034				
		9925156	Jan 26, 2027	DS DP U-1399			
		9925157	Jan 26, 2027	DS DP U-1399			
		9925158	Jan 26, 2027	DS DP U-1399			
CYSTEAMINE BITARTRATE - PROCYSBI							
N 203389	002	10143665	Aug 16, 2036	U-1399		M-216	Dec 22, 2020
		8026284	Sep 22, 2027	U-1399		ODE-162	Dec 22, 2024
		8026284*PED	Mar 22, 2028			ODE-45	Apr 30, 2020
		9173851	Jun 17, 2034	DP		ODE-97	Aug 14, 2022
		9173851*PED	Dec 17, 2034			PED	Oct 30, 2020
		9192590	Jan 26, 2027	U-1399		PED	Jun 22, 2021

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CYSTEAMINE BITARTRATE - PROCYSBI							
N 203389	002	9192590*PED	Jul 26, 2027			PED	Feb 14, 2023
		9198882	Jan 26, 2027	U-1399			
		9198882*PED	Jul 26, 2027				
		9233077	Jun 17, 2034	DP			
		9233077*PED	Dec 17, 2034				
		9925156	Jan 26, 2027	DS DP U-1399			
		9925157	Jan 26, 2027	DS DP U-1399			
		9925158	Jan 26, 2027	DS DP U-1399			
CYSTEAMINE HYDROCHLORIDE - CYSTARAN							
N 200740	001					ODE-31	Oct 02, 2019
CYTARABINE; DAUNORUBICIN - VYXEOS							
N 209401	001	10028912	Sep 29, 2034	DP U-2341		NP	Aug 03, 2020
		10028912	Sep 29, 2034	DP U-2342			
		7850990	Jan 23, 2027	DP U-2090			
		8022279	Sep 14, 2027	DP U-2090			
		8092828	Apr 01, 2029	U-2090			
		8431806	Apr 22, 2025	DP U-2090			
		8518437	Jun 07, 2026	DP			
		9271931	Jan 23, 2027	DP			
DABIGATRAN ETEXILATE MESYLATE - PRADAXA							
N 022512	001	6087380	Dec 28, 2021	DS DP U-1931			
		7866474	Aug 31, 2027	DP	Y		
		7932273	Sep 07, 2025	DS DP			
		9034822	Jan 20, 2031	U-1759			
		9925174	Jun 14, 2023	DP			
DABIGATRAN ETEXILATE MESYLATE - PRADAXA							
N 022512	002	6087380	Dec 28, 2021	DS DP U-1931			
		7866474	Aug 31, 2027	DP	Y		
		7932273	Sep 07, 2025	DS DP			
		9034822	Jan 20, 2031	U-1759			
		9925174	Jun 14, 2023	DP			
DABIGATRAN ETEXILATE MESYLATE - PRADAXA							
N 022512	003	6087380	Dec 28, 2021	DS DP U-1931			
		7866474	Aug 31, 2027	DP	Y		
		7932273	Sep 07, 2025	DS DP			
		9034822	Jan 20, 2031	U-1759			
		9925174	Jun 14, 2023	DP			
DABRAFENIB MESYLATE - TAFINLAR							
N 202806	001	7994185	Jan 20, 2030	DS DP U-1406		I-745	Jun 22, 2020
		7994185	Jan 20, 2030	DS DP U-2031		I-778	Apr 30, 2021
		7994185	Jan 20, 2030	DS DP U-2032		I-781	May 04, 2021
		7994185	Jan 20, 2030	DS DP U-2296		ODE-147	Jun 22, 2024
		8415345	Jan 20, 2030	DS DP U-1406		ODE-182	Apr 30, 2025
		8415345	Jan 20, 2030	DS DP U-2031		ODE-183	May 04, 2025
		8415345	Jan 20, 2030	DS DP U-2032		ODE-47	May 29, 2020
		8415345	Jan 20, 2030	DS DP U-2296		ODE-58	Jan 09, 2021
		8703781	Oct 15, 2030	DS DP U-1713			
		8703781	Oct 15, 2030	DS DP U-2032			
		8703781	Oct 15, 2030	DS DP U-2296			
		8703781	Oct 15, 2030	DS DP U-2297			
		8703781	Oct 15, 2030	DS DP U-2298			
		8835443	Jun 10, 2025	U-2026			
		8835443	Jun 10, 2025	U-2027			
		8835443	Jun 10, 2025	U-2296			
		8835443	Jun 10, 2025	U-2298			
		8952018	Oct 15, 2030	U-2027			
		9233956	May 04, 2029	U-1811			
		9233956	May 04, 2029	U-2031			
		9233956	May 04, 2029	U-2032			
		9233956	May 04, 2029	U-2296			
		9233956	May 04, 2029	U-2297			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DABRAFENIB MESYLATE - TAFINLAR							
N 202806	002	7994185	Jan 20, 2030	DS DP U-1406		I-745	Jun 22, 2020
		7994185	Jan 20, 2030	DS DP U-2031		I-778	Apr 30, 2021
		7994185	Jan 20, 2030	DS DP U-2032		I-781	May 04, 2021
		7994185	Jan 20, 2030	DS DP U-2296		ODE-147	Jun 22, 2024
		8415345	Jan 20, 2030	DS DP U-1406		ODE-182	Apr 30, 2025
		8415345	Jan 20, 2030	DS DP U-2031		ODE-183	May 04, 2025
		8415345	Jan 20, 2030	DS DP U-2032		ODE-47	May 29, 2020
		8415345	Jan 20, 2030	DS DP U-2296		ODE-58	Jan 09, 2021
		8703781	Oct 15, 2030	DS DP U-1713			
		8703781	Oct 15, 2030	DS DP U-2032			
		8703781	Oct 15, 2030	DS DP U-2296			
		8703781	Oct 15, 2030	DS DP U-2297			
		8703781	Oct 15, 2030	DS DP U-2298			
		8835443	Jun 10, 2025	U-2026			
		8835443	Jun 10, 2025	U-2027			
		8835443	Jun 10, 2025	U-2296			
		8835443	Jun 10, 2025	U-2298			
		8952018	Oct 15, 2030	U-2027			
		9233956	May 04, 2029	U-1811			
		9233956	May 04, 2029	U-2031			
		9233956	May 04, 2029	U-2032			
		9233956	May 04, 2029	U-2296			
		9233956	May 04, 2029	U-2297			
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA							
N 206843	001	8329159	Apr 13, 2028	DS		D-161	Feb 05, 2019
		8629171	Jun 13, 2031	DS DP U-1724		D-162	Feb 05, 2019
		8642025	Aug 11, 2027	DS DP U-1724		I-726	Feb 05, 2019
		8642025	Aug 11, 2027	DS DP U-1725		I-727	Feb 05, 2019
		8900566	Aug 08, 2027	U-1724		NCE	Jul 24, 2020
		8900566	Aug 08, 2027	U-1725			
		9421192	Aug 08, 2027	DS U-1724			
		9421192	Aug 08, 2027	DS U-1725			
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA							
N 206843	002	8329159	Apr 13, 2028	DS		D-161	Feb 05, 2019
		8629171	Jun 13, 2031	DS DP U-1724		D-162	Feb 05, 2019
		8642025	Aug 11, 2027	DS DP U-1724		I-726	Feb 05, 2019
		8642025	Aug 11, 2027	DS DP U-1725		I-727	Feb 05, 2019
		8900566	Aug 08, 2027	U-1724		NCE	Jul 24, 2020
		8900566	Aug 08, 2027	U-1725			
		9421192	Aug 08, 2027	DS U-1724			
		9421192	Aug 08, 2027	DS U-1725			
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA							
N 206843	003	9421192	Aug 08, 2027	DS U-1724			
		9421192	Aug 08, 2027	DS U-1725			
DACOMITINIB - VIZIMPRO							
N 211288	001	7772243	Aug 26, 2028	DS DP		NCE	Sep 27, 2023
		8623883	May 05, 2025	U-1403		ODE-206	Sep 27, 2025
						ODE-213	Sep 27, 2025
DACOMITINIB - VIZIMPRO							
N 211288	002	7772243	Aug 26, 2028	DS DP		NCE	Sep 27, 2023
		8623883	May 05, 2025	U-1403		ODE-206	Sep 27, 2025
						ODE-213	Sep 27, 2025
DACOMITINIB - VIZIMPRO							
N 211288	003	7772243	Aug 26, 2028	DS DP		NCE	Sep 27, 2023
		8623883	May 05, 2025	U-1403		ODE-206	Sep 27, 2025
						ODE-213	Sep 27, 2025
DALBAVANCIN HYDROCHLORIDE - DALVANCE							
N 021883	001	6900175	Dec 25, 2023	U-1517		D-154	Jan 20, 2019
		7115564	Nov 14, 2023	DP		NCE	May 23, 2019
		7119061	Nov 14, 2023	DP		GAIN	May 23, 2024
		8143212	Nov 14, 2023	U-1517			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DALFAMPRIDINE - DALFAMPRIDINE						
A 206863 001					PC	Mar 17, 2019
DALFAMPRIDINE - AMPYRA						
N 022250 001	8007826	May 26, 2027	U-1030			
	8354437	Dec 22, 2026	U-1030			
	8440703	Apr 08, 2025	U-1030			
	8663685	Jan 18, 2025	U-1030			
	9918973	Dec 13, 2024	U-1030			
DANTROLENE SODIUM - RYANODEX						
N 205579 001	7758890	Jul 01, 2025	DP		ODE-69	Jul 22, 2021
	8110225	Dec 24, 2022	DP			
	8604072	Dec 24, 2022	DP			
	8685460	Feb 15, 2023	U-1546			
	9884044	Jun 13, 2022	DP U-1546			
DAPAGLIFLOZIN - FARXIGA						
N 202293 001	6414126	Oct 04, 2020	DS DP U-2139		M-212	Oct 20, 2020
	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-2139			
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7456254	Jun 30, 2025	DP U-2139			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
	8721615	Jan 18, 2030	DP	Y		
	8906851	Aug 18, 2026	U-2139			
	9198925	Oct 04, 2020	U-2139			
	9198925	Oct 04, 2020	U-493			
	9238076	Apr 15, 2024	DP U-2139			
DAPAGLIFLOZIN - FARXIGA						
N 202293 002	6414126	Oct 04, 2020	DS DP U-2139		M-212	Oct 20, 2020
	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-2139			
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7456254	Jun 30, 2025	DP U-2139			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
	8721615	Jan 18, 2030	DP	Y		
	8906851	Aug 18, 2026	U-2139			
	9198925	Oct 04, 2020	U-2139			
	9198925	Oct 04, 2020	U-493			
	9238076	Apr 15, 2024	DP U-2139			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR							
N 205649	001	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
		6515117	Oct 04, 2020	DS DP U-493			
		6936590	Oct 04, 2020	U-493			
		7919598	Dec 16, 2029	DS			
		8501698	Jun 20, 2027	DP U-493			
		8685934	May 26, 2030	U-1522			
		9198925	Oct 04, 2020	U-493			
		9616028	Nov 12, 2030	DP			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR							
N 205649	002	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
		6515117	Oct 04, 2020	DS DP U-493			
		6936590	Oct 04, 2020	U-493			
		7919598	Dec 16, 2029	DS			
		8501698	Jun 20, 2027	DP U-493			
		8685934	May 26, 2030	U-1522			
		9198925	Oct 04, 2020	U-493			
		9616028	Nov 12, 2030	DP			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR							
N 205649	003	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
		6515117	Oct 04, 2020	DS DP U-493			
		6936590	Oct 04, 2020	U-493			
		7919598	Dec 16, 2029	DS			
		8501698	Jun 20, 2027	DP U-493			
		8685934	May 26, 2030	U-1522			
		9198925	Oct 04, 2020	U-493			
		9616028	Nov 12, 2030	DP			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR							
N 205649	004	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
		6515117	Oct 04, 2020	DS DP U-493			
		6936590	Oct 04, 2020	U-493			
		7919598	Dec 16, 2029	DS			
		8501698	Jun 20, 2027	DP U-493			
		8685934	May 26, 2030	U-1522			
		9198925	Oct 04, 2020	U-493			
		9616028	Nov 12, 2030	DP			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR							
N 205649	005	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
		6515117	Oct 04, 2020	DS DP U-493			
		6936590	Oct 04, 2020	U-493			
		7919598	Dec 16, 2029	DS			
		8501698	Jun 20, 2027	DP U-493			
		8685934	May 26, 2030	U-1522			
		9198925	Oct 04, 2020	U-493			
		9616028	Nov 12, 2030	DP			
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN							
N 209091	001	6414126	Oct 04, 2020	DS DP U-1976		M-175	Apr 05, 2019
		6414126	Oct 04, 2020	DS DP U-1977		NC	Feb 27, 2020
		6515117	Oct 04, 2020	DS DP U-1976		NCE	Jan 08, 2019
		6515117	Oct 04, 2020	DS DP U-1977			
		6936590	Oct 04, 2020	U-1976			
		6936590	Oct 04, 2020	U-1977			
		7919598	Dec 16, 2029	DS			
		8221786	Mar 21, 2028	DP			
		8361972	Mar 21, 2028	U-1976			
		8361972	Mar 21, 2028	U-1977			
		8501698	Jun 20, 2027	DP U-1976			
		8501698	Jun 20, 2027	DP U-1977			
		8628799	Jul 13, 2025	DP			
		8716251	Mar 21, 2028	DP			
		9198925	Oct 04, 2020	U-1976			
		9198925	Oct 04, 2020	U-1977			
		RE44186	Jul 31, 2023	DS DP U-1976			
		RE44186	Jul 31, 2023	DS DP U-1977			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DAPSONE - ACZONE						
N 207154 001	9161926	Nov 18, 2033	DP		NS	Feb 24, 2019
	9517219	Nov 18, 2033	U-1033			
DAPTOMYCIN - CUBICIN						
N 021572 002	8003673	Sep 04, 2028	U-1180		M-211	Sep 01, 2020
					NPP	Mar 29, 2020
DAPTOMYCIN - CUBICIN RF						
N 021572 003	9138456	Nov 23, 2030	DP		M-211	Sep 01, 2020
					NPP	Mar 29, 2020
DARUNAVIR ETHANOLATE - PREZISTA						
N 021976 001	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7470506	Jun 23, 2019	U-935			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
DARUNAVIR ETHANOLATE - PREZISTA						
N 021976 002	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7470506	Jun 23, 2019	U-935			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	9889115	Jun 23, 2019	U-1305			
DARUNAVIR ETHANOLATE - PREZISTA						
N 021976 003	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7470506	Jun 23, 2019	U-935			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
DARUNAVIR ETHANOLATE - PREZISTA						
N 021976 004	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7470506	Jun 23, 2019	U-935			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	9889115	Jun 23, 2019	U-1305			
DARUNAVIR ETHANOLATE - PREZISTA						
N 021976 005	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7470506	Jun 23, 2019	U-935			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	9889115	Jun 23, 2019	U-1305			
DARUNAVIR ETHANOLATE - PREZISTA						
N 021976 006	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7470506	Jun 23, 2019	U-935			
	7700645	Dec 26, 2026	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DARUNAVIR ETHANOLATE - PREZISTA						
N 021976 006	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	9889115	Jun 23, 2019	U-1305			
DARUNAVIR ETHANOLATE - PREZISTA						
N 202895 001	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	9889115	Jun 23, 2019	U-1305			
DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)						
N 206619 001	7148359	Jul 19, 2019	DP		D-163	Apr 22, 2019
	7364752	Nov 10, 2020	DP		NCE	Dec 19, 2019
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1840			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1840			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
	9139536	Nov 09, 2028	U-1753			
	9629841	Oct 18, 2033	DP U-1753			
DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR						
N 208624 001	10105365	Jan 02, 2035	DP U-1889		NCE	Dec 19, 2019
	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1840			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1840			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
	9139536	Nov 09, 2028	U-1753			
	9333204	Jan 02, 2035	DP U-1889			
	9744170	Jan 02, 2035	DP U-1889			
DASATINIB - SPRYCEL						
N 021986 001	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
	6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
	6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
	7125875	Apr 13, 2020	U-779		PED	May 09, 2021
	7125875	Apr 13, 2020	U-780		PED	Jun 21, 2022
	7125875*PED	Oct 13, 2020			PED	May 09, 2025
	7153856	Apr 28, 2020	U-780			
	7153856*PED	Oct 28, 2020				
	7491725	Mar 28, 2026	DS DP			
	7491725*PED	Sep 28, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DASATINIB - SPRYCEL						
N 021986 001	8680103	Feb 04, 2025	DP			
	8680103*PED	Aug 04, 2025				
DASATINIB - SPRYCEL						
N 021986 002	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
	6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
	6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
	7125875	Apr 13, 2020	U-779		PED	May 09, 2021
	7125875	Apr 13, 2020	U-780		PED	Jun 21, 2022
	7125875*PED	Oct 13, 2020			PED	May 09, 2025
	7153856	Apr 28, 2020	U-780			
	7153856*PED	Oct 28, 2020				
	7491725	Mar 28, 2026	DS DP			
	7491725*PED	Sep 28, 2026				
	8680103	Feb 04, 2025	DP			
	8680103*PED	Aug 04, 2025				
DASATINIB - SPRYCEL						
N 021986 003	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
	6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
	6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
	7125875	Apr 13, 2020	U-779		PED	May 09, 2021
	7125875	Apr 13, 2020	U-780		PED	Jun 21, 2022
	7125875*PED	Oct 13, 2020			PED	May 09, 2025
	7153856	Apr 28, 2020	U-780			
	7153856*PED	Oct 28, 2020				
	7491725	Mar 28, 2026	DS DP			
	7491725*PED	Sep 28, 2026				
	8680103	Feb 04, 2025	DP			
	8680103*PED	Aug 04, 2025				
DASATINIB - SPRYCEL						
N 021986 004	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
	6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
	6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
	7125875	Apr 13, 2020	U-779		PED	May 09, 2021
	7125875	Apr 13, 2020	U-780		PED	Jun 21, 2022
	7125875*PED	Oct 13, 2020			PED	May 09, 2025
	7153856	Apr 28, 2020	U-780			
	7153856*PED	Oct 28, 2020				
	7491725	Mar 28, 2026	DS DP			
	7491725*PED	Sep 28, 2026				
	8680103	Feb 04, 2025	DP			
	8680103*PED	Aug 04, 2025				
DASATINIB - SPRYCEL						
N 021986 005	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
	6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
	6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
	7125875	Apr 13, 2020	U-779		PED	May 09, 2021
	7125875	Apr 13, 2020	U-780		PED	Jun 21, 2022
	7125875*PED	Oct 13, 2020			PED	May 09, 2025
	7153856	Apr 28, 2020	U-780			
	7153856*PED	Oct 28, 2020				
	7491725	Mar 28, 2026	DS DP			
	7491725*PED	Sep 28, 2026				
	8680103	Feb 04, 2025	DP			
	8680103*PED	Aug 04, 2025				
DASATINIB - SPRYCEL						
N 021986 006	6596746	Jun 28, 2020	DS DP U-748		I-791	Dec 21, 2021
	6596746	Jun 28, 2020	DS DP U-780		NPP	Nov 09, 2020
	6596746*PED	Dec 28, 2020			ODE-164	Nov 09, 2024
	7125875	Apr 13, 2020	U-779		PED	May 09, 2021
	7125875	Apr 13, 2020	U-780		PED	Jun 21, 2022
	7125875*PED	Oct 13, 2020			PED	May 09, 2025
	7153856	Apr 28, 2020	U-780			
	7153856*PED	Oct 28, 2020				
	7491725	Mar 28, 2026	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DASATINIB - SPRYCEL							
N 021986	006	7491725*PED	Sep 28, 2026				
		8680103	Feb 04, 2025	DP			
		8680103*PED	Aug 04, 2025				
DEFERASIROX - EXJADE							
N 021882	001	6465504	Apr 05, 2019	DS DP		ODE-39	Jan 23, 2020
DEFERASIROX - EXJADE							
N 021882	002	6465504	Apr 05, 2019	DS DP		ODE-39	Jan 23, 2020
DEFERASIROX - EXJADE							
N 021882	003	6465504	Apr 05, 2019	DS DP		ODE-39	Jan 23, 2020
DEFERASIROX - JADENU							
N 206910	001	6465504	Apr 05, 2019	DS DP		ODE-39	Jan 23, 2020
		9283209	Nov 21, 2034	DS DP			
DEFERASIROX - JADENU							
N 206910	002	6465504	Apr 05, 2019	DS DP		ODE-39	Jan 23, 2020
		9283209	Nov 21, 2034	DS DP			
DEFERASIROX - JADENU							
N 206910	003	6465504	Apr 05, 2019	DS DP		ODE-39	Jan 23, 2020
		9283209	Nov 21, 2034	DS DP			
DEFERASIROX - JADENU SPRINKLE							
N 207968	001	6465504	Apr 05, 2019	DS DP			
DEFERASIROX - JADENU SPRINKLE							
N 207968	002	6465504	Apr 05, 2019	DS DP			
DEFERASIROX - JADENU SPRINKLE							
N 207968	003	6465504	Apr 05, 2019	DS DP			
DEFERIPRONE - FERRIPROX							
N 021825	001	7049328	Jun 28, 2021	U-735			
DEFERIPRONE - FERRIPROX							
N 208030	001	7049328	Jun 28, 2021	U-735			
		8703156	Oct 29, 2029	DP U-735			
DEFIBROTIDE SODIUM - DEFITELIO							
N 208114	001					NCE	Mar 30, 2021
						ODE-112	Mar 30, 2023
DEFLAZACORT - EMFLAZA							
N 208684	001					NCE	Feb 09, 2022
						ODE-130	Feb 09, 2024
DEFLAZACORT - EMFLAZA							
N 208684	002					NCE	Feb 09, 2022
						ODE-130	Feb 09, 2024
DEFLAZACORT - EMFLAZA							
N 208684	003					NCE	Feb 09, 2022
						ODE-130	Feb 09, 2024
DEFLAZACORT - EMFLAZA							
N 208684	004					NCE	Feb 09, 2022
						ODE-130	Feb 09, 2024
DEFLAZACORT - EMFLAZA							
N 208685	001					NCE	Feb 09, 2022
						ODE-130	Feb 09, 2024
DEGARELIX ACETATE - FIRMAGON							
N 022201	001	5925730	May 18, 2021	DS DP U-943			
		9415085	Apr 27, 2032	U-1895			
		9579359	Feb 10, 2029	U-1978			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEGARELIX ACETATE - FIRMAGON							
N 022201	002	5925730	May 18, 2021	DS DP U-943			
		9415085	Apr 27, 2032	U-1895			
		9579359	Feb 10, 2029	U-1978			
DELAFLOXACIN MEGLUMINE - BAXDELA							
N 208610	001	7728143	Nov 20, 2027	DS		NCE	Jun 19, 2022
		8252813	Oct 02, 2026	DP U-2028		GAIN	Jun 19, 2027
		8273892	Aug 06, 2026	DS			
		8648093	Oct 07, 2025	DP U-2028			
		8871938	Sep 23, 2029	DS			
		8969569	Oct 07, 2025	DP U-2028			
		9539250	Oct 07, 2025	DS DP U-2028			
		RE46617	Dec 28, 2029	DS			
DELAFLOXACIN MEGLUMINE - BAXDELA							
N 208611	001	7635773	Mar 13, 2029	DP		NCE	Jun 19, 2022
		7728143	Nov 20, 2027	DS		GAIN	Jun 19, 2027
		8252813	Oct 02, 2026	DP U-2028			
		8273892	Aug 06, 2026	DS			
		8410077	Mar 13, 2029	DP			
		8648093	Oct 07, 2025	DP U-2028			
		8871938	Sep 23, 2029	DS			
		9200088	Mar 13, 2029	DP			
		9493582	Feb 27, 2033	DP			
		9539250	Oct 07, 2025	DS DP U-2028			
		9750822	Mar 13, 2029	DP			
		RE46617	Dec 28, 2029	DS			
DELAVIRDINE MESYLATE - RESCRIPTOR							
N 020705	002	6177101	Jun 07, 2019				
DEOXYCHOLIC ACID - KYBELLA							
N 206333	001	7622130	Dec 10, 2027	U-1690			
		7754230	Dec 10, 2027	U-1690			
		8101593	Mar 02, 2030	DP			
		8242294	May 16, 2028	DS			
		8298556	Aug 03, 2025	U-1690			
		8367649	Mar 02, 2030	DP			
		8461140	Feb 21, 2028	DP			
		8546367	Feb 21, 2028	DP U-1690			
		8653058	Mar 02, 2030	DP			
		8846066	Feb 08, 2025	U-1690			
		8883770	Feb 21, 2028	DP			
		9522155	Feb 21, 2028	DP U-1940			
		9636349	Feb 21, 2028	U-1940			
		9949986	Feb 21, 2028	U-1940			
DESLORATADINE - CLARINEX							
N 021165	001	6100274	Jul 07, 2019				
		7405223	Jul 07, 2019	U-886			
DESLORATADINE - CLARINEX							
N 021312	001	6100274	Jul 07, 2019	DP			
		7618649	Dec 19, 2020	DP U-1017			
DESLORATADINE - CLARINEX							
N 021312	002	6100274	Jul 07, 2019	DP			
		7618649	Dec 19, 2020	DP U-1017			
DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR							
N 021313	001	6100274	Jul 07, 2019	DP			
		6709676	Feb 18, 2021	DP U-707			
		7618649	Dec 19, 2020	DP U-1017			
		8187630	Dec 19, 2020	DP U-1017			
DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX D 24 HOUR							
N 021605	001	6100274	Jul 07, 2019	DP			
		6979463	Mar 28, 2022	DP			
		7618649	Dec 19, 2020	DP U-1017			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX D 24 HOUR							
N 021605	001	7820199	Mar 28, 2022	DP			
DESMOPRESSIN ACETATE - NOCDURNA							
N 022517	001	7560429	Feb 02, 2024	DP U-2326		NP	Jun 21, 2021
		7947654	Dec 29, 2023	DP			
		8802624	Dec 29, 2023	U-2326			
		9220747	May 07, 2023	U-2326			
		9504647	May 07, 2023	DP U-2326			
		9919025	May 07, 2023	U-2326			
		9974826	Apr 13, 2030	U-2326			
DESMOPRESSIN ACETATE - NOCDURNA							
N 022517	002	10137167	May 21, 2029	U-2327		NP	Jun 21, 2021
		7560429	Feb 02, 2024	DP U-2326			
		7947654	Dec 29, 2023	DP			
		8802624	Dec 29, 2023	U-2326			
		9220747	May 07, 2023	U-2326			
		9504647	May 07, 2023	DP U-2326			
		9919025	May 07, 2023	U-2326			
		9974826	Apr 13, 2030	U-2327			
DESMOPRESSIN ACETATE - NOCTIVA							
N 201656	001	7405203	May 06, 2023	U-1980		NP	Mar 03, 2020
		7579321	May 06, 2023	U-1980			
		7799761	Sep 26, 2024	DP			
		9539302	Jun 15, 2030	DP			
DESMOPRESSIN ACETATE - NOCTIVA							
N 201656	002	7405203	May 06, 2023	U-1980		NP	Mar 03, 2020
		7579321	May 06, 2023	U-1980			
		9539302	Jun 15, 2030	DP			
DESONIDE - DESONATE							
N 021844	001	6387383	Aug 03, 2020	DS DP U-783			
DESONIDE - VERDESO							
N 021978	001	6730288	Sep 08, 2019	DP			
		7029659	Sep 08, 2019	DP			
		8460641	Nov 05, 2028	DP U-1412			
		8962000	Aug 31, 2025	DP U-1412			
		9492384	Aug 31, 2025	DP U-1412			
DESOXIMETASONE - TOPICORT							
N 204141	001	8277780	Sep 01, 2028	DP U-1408			
		8715624	May 26, 2026	DP U-1408			
DESVENLAFAXINE SUCCINATE - PRISTIQ							
N 021992	001	6673838	Mar 01, 2022	DS U-1364		M-222	Feb 06, 2021
		6673838	Mar 01, 2022	DS U-860			
		8269040	Jul 05, 2027	DS			
DESVENLAFAXINE SUCCINATE - PRISTIQ							
N 021992	002	6673838	Mar 01, 2022	DS U-1364		M-222	Feb 06, 2021
		6673838	Mar 01, 2022	DS U-860			
		8269040	Jul 05, 2027	DS			
DESVENLAFAXINE SUCCINATE - PRISTIQ							
N 021992	003	6673838	Mar 01, 2022	DS U-1364		M-222	Feb 06, 2021
		6673838	Mar 01, 2022	DS U-860			
		8269040	Jul 05, 2027	DS			
DEUTETRABENAZINE - AUSTEDO							
N 208082	001	8524733	Mar 27, 2031	DS DP		I-751	Aug 30, 2020
		9233959	Sep 18, 2033	DP		NCE	Apr 03, 2022
		9296739	Sep 18, 2033	DP		ODE-134	Apr 03, 2024
		9550780	Sep 18, 2033	DS DP U-1846			
		9550780	Sep 18, 2033	DS DP U-1995			
		9814708	Sep 18, 2033	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEUTETRABENAZINE - AUSTEDO						
N 208082 002	8524733	Mar 27, 2031	DS DP		I-751	Aug 30, 2020
	9233959	Sep 18, 2033	DP		NCE	Apr 03, 2022
	9296739	Sep 18, 2033	DP		ODE-134	Apr 03, 2024
	9550780	Sep 18, 2033	DS DP U-1846			
	9550780	Sep 18, 2033	DS DP U-1995			
	9814708	Sep 18, 2033	DP			
DEUTETRABENAZINE - AUSTEDO						
N 208082 003	8524733	Mar 27, 2031	DS DP		I-751	Aug 30, 2020
	9233959	Sep 18, 2033	DP		NCE	Apr 03, 2022
	9296739	Sep 18, 2033	DP		ODE-134	Apr 03, 2024
	9550780	Sep 18, 2033	DS DP U-1846			
	9550780	Sep 18, 2033	DS DP U-1995			
	9814708	Sep 18, 2033	DP			
DEXAMETHASONE - OZURDEX						
N 022315 001	10076526	Jan 09, 2023	DP			
	6726918	Oct 20, 2020	DP U-1204			
	6726918	Oct 20, 2020	DP U-1205			
	6899717	Nov 01, 2023	U-1206			
	7033605	Oct 20, 2020	DP			
	7767223	Nov 28, 2021	DP			
	8034366	Jan 09, 2023	DP U-1204			
	8034366	Jan 09, 2023	DP U-1205			
	8034370	Jan 09, 2023	DP			
	8043628	Oct 20, 2020	U-1205			
	8063031	Oct 20, 2020	DP			
	8088407	Oct 20, 2020	U-1205			
	8506987	Jan 09, 2023	U-1204			
	8506987	Jan 09, 2023	U-1205			
	9012437	Oct 20, 2020	U-1205			
	9192511	Jan 09, 2023	DP			
	9283178	Oct 20, 2020	U-1205			
	9592242	Oct 20, 2020	U-1989			
	9592242	Oct 20, 2020	U-1990			
	9775849	Oct 20, 2020	U-1989			
	9775849	Oct 20, 2020	U-1990			
DEXAMETHASONE - DEXYCU KIT						
N 208912 001	10022502	Sep 12, 2020	U-2340		NP	Feb 09, 2021
	10028965	May 23, 2034	U-2340			
	6960346	Jul 03, 2023	DP			
	7560120	Sep 05, 2022	DP			
DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST						
N 050818 001	7795316	Aug 03, 2028	DP U-1082			
	8101582	Dec 19, 2027	DP U-1082			
	8450287	Dec 19, 2027	DP			
DEXLANSOPRAZOLE - DEXILANT						
N 022287 001	6462058	Jun 15, 2020	DS DP U-949		NPP	Jul 08, 2019
	6462058	Jun 15, 2020	DS DP U-950		NPP	Jul 08, 2019
	6462058	Jun 15, 2020	DS DP U-951		NPP	Jul 08, 2019
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	7285668	Jun 15, 2020	DS			
	7790755	Aug 02, 2026	DP			
	8105626	Sep 27, 2026	DP			
	8173158	Mar 17, 2030	U-949			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-951			
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXLANSOPRAZOLE - DEXILANT						
N 022287 001	8722084	Oct 15, 2023	DP			
	8722084*PED	Apr 15, 2024				
	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
	9233103	Mar 05, 2032	U-1805			
	9238029	Jan 17, 2026	DP			
DEXLANSOPRAZOLE - DEXILANT						
N 022287 002	6462058	Jun 15, 2020	DS DP U-949		NPP	Jul 08, 2019
	6462058	Jun 15, 2020	DS DP U-950		NPP	Jul 08, 2019
	6462058	Jun 15, 2020	DS DP U-951		NPP	Jul 08, 2019
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	7285668	Jun 15, 2020	DS			
	7790755	Aug 02, 2026	DP			
	8105626	Sep 27, 2026	DP			
	8173158	Mar 17, 2030	U-949			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-951			
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8722084	Oct 15, 2023	DP			
	8722084*PED	Apr 15, 2024				
	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
	9233103	Mar 05, 2032	U-1805			
	9238029	Jan 17, 2026	DP			
DEXLANSOPRAZOLE - DEXILANT SOLUTAB						
N 208056 001	6328994	May 17, 2019	DP			
	6328994*PED	Nov 17, 2019				
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			
	6462058*PED	Dec 15, 2020				
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
	7431942	May 17, 2019	DP			
	7431942*PED	Nov 17, 2019				
	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8784885	Oct 15, 2023	DP			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	8871273*PED	Jul 11, 2028				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXLANSOPRAZOLE - DEXILANT SOLUTAB								
N 208056	001	9011926	Feb 24, 2026		DP			
		9145389	Jun 15, 2020	DS	DP			
		9238029	Jan 17, 2026		DP			
		9241910	Mar 10, 2029		DP			
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX								
N 021038	001	6716867	Mar 31, 2019				U-1472	
		6716867*PED	Oct 01, 2019					
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX								
N 021038	002	10016396	Jan 04, 2032		DP			
		6716867	Mar 31, 2019				U-1472	
		6716867*PED	Oct 01, 2019					
		8242158	Jan 04, 2032		DP			
		8242158*PED	Jul 04, 2032					
		8338470	Jan 04, 2032		DP			
		8338470*PED	Jul 04, 2032					
		8455527	Jan 04, 2032				U-421	
		8455527*PED	Jul 04, 2032					
		8648106	Jan 04, 2032		DP			
		8648106*PED	Jul 04, 2032					
		9320712	Jan 04, 2032		DP			
		9320712*PED	Jul 04, 2032					
		9616049	Jan 04, 2032		DP			
		9616049*PED	Jul 04, 2032					
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX								
N 021038	003	10016396	Jan 04, 2032		DP			
		6716867	Mar 31, 2019				U-1472	
		6716867*PED	Oct 01, 2019					
		8242158	Jan 04, 2032		DP			
		8242158*PED	Jul 04, 2032					
		8338470	Jan 04, 2032		DP			
		8338470*PED	Jul 04, 2032					
		8455527	Jan 04, 2032				U-421	
		8455527*PED	Jul 04, 2032					
		8648106	Jan 04, 2032		DP			
		8648106*PED	Jul 04, 2032					
		9320712	Jan 04, 2032		DP			
		9320712*PED	Jul 04, 2032					
		9616049	Jan 04, 2032		DP			
		9616049*PED	Jul 04, 2032					
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX								
N 021038	004	6716867	Mar 31, 2019				U-1472	
		6716867*PED	Oct 01, 2019					
		8242158	Jan 04, 2032		DP			
		8242158*PED	Jul 04, 2032					
		8338470	Jan 04, 2032		DP			
		8338470*PED	Jul 04, 2032					
		8455527	Jan 04, 2032				U-421	
		8455527*PED	Jul 04, 2032					
		8648106	Jan 04, 2032		DP			
		8648106*PED	Jul 04, 2032					
		9320712	Jan 04, 2032		DP			
		9320712*PED	Jul 04, 2032					
		9616049	Jan 04, 2032		DP			
		9616049*PED	Jul 04, 2032					
DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE								
N 206628	003	9649296	Apr 20, 2036		DP			
		9717796	Apr 20, 2036		DP			
DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE								
N 206628	004	9649296	Apr 20, 2036		DP			
		9717796	Apr 20, 2036		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR								
N 021802	001		6228398	Nov 01, 2019	DP U-676			
			6730325	Nov 01, 2019	DP U-676			
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR								
N 021802	002		6228398	Nov 01, 2019	DP U-676			
			6730325	Nov 01, 2019	DP U-676			
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR								
N 021802	003		6228398	Nov 01, 2019	DP U-676			
			6730325	Nov 01, 2019	DP U-676			
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR								
N 021802	004		6228398	Nov 01, 2019	DP U-676			
			6730325	Nov 01, 2019	DP U-676			
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR								
N 021802	005		6228398	Nov 01, 2019	DP U-676			
			6730325	Nov 01, 2019	DP U-676			
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR								
N 021802	006		6228398	Nov 01, 2019	DP U-676			
			6730325	Nov 01, 2019	DP U-676			
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR								
N 021802	007		6228398	Nov 01, 2019	DP U-676			
			6730325	Nov 01, 2019	DP U-676			
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR								
N 021802	008		6228398	Nov 01, 2019	DP U-676			
			6730325	Nov 01, 2019	DP U-676			
DEXRAZOXANE HYDROCHLORIDE - TOTECT								
N 022025	001		6727253	Mar 13, 2020	U-829			
DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM								
N 021620	001		6372252	Apr 28, 2020	DP			
			6955821	Apr 28, 2020	DP U-685			
			7838032	Apr 28, 2020	DP			
DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM								
N 021620	002		6372252	Apr 28, 2020	DP			
			6955821	Apr 28, 2020	DP U-685			
			7838032	Apr 28, 2020	DP			
DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA								
N 021879	001		7659282	Aug 13, 2026	U-1093			
			8227484	Jul 17, 2023	U-1093			
DICHLORPHENAMIDE - KEVEYIS								
N 011366	002						ODE-96	Aug 07, 2022
DICLOFENAC - ZORVOLEX								
N 204592	001		8679544	Apr 23, 2030	DP			
			8999387	Apr 23, 2030	U-55			
			9017721	Apr 23, 2030	DP			
			9173854	Apr 23, 2030	DP			
			9180095	Apr 23, 2030	U-55			
			9180096	Apr 23, 2030	DP			
			9186328	Apr 23, 2030	U-55			
DICLOFENAC - ZORVOLEX								
N 204592	002		8679544	Apr 23, 2030	DP			
			8999387	Apr 23, 2030	U-55			
			9017721	Apr 23, 2030	DP			
			9173854	Apr 23, 2030	DP			
			9180095	Apr 23, 2030	U-55			
			9180096	Apr 23, 2030	DP			
			9186328	Apr 23, 2030	U-55			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DICLOFENAC EPOLAMINE - FLECTOR							
N 021234	001	5607690	Apr 13, 2019	DP			
DICLOFENAC EPOLAMINE - LICART							
N 206976	001					NP	Dec 19, 2021
DICLOFENAC POTASSIUM - CAMBIA							
N 022165	001	7759394	Jun 16, 2026	DS DP U-436			
		8097651	Jun 16, 2026	DS DP U-436			
		8927604	Jun 16, 2026	U-436			
		9827197	Jun 16, 2026	DP			
DICLOFENAC POTASSIUM - ZIPSOR							
N 022202	001	6287594	Jan 15, 2019	DP			
		6365180	Jul 15, 2019	DP U-980			
		7662858	Feb 24, 2029	U-1035			
		7884095	Feb 24, 2029	U-1111			
		7939518	Feb 24, 2029	U-980			
		8110606	Feb 24, 2029	U-980			
		8623920	Feb 24, 2029	U-1482			
		9561200	Feb 24, 2029	U-1482			
DICLOFENAC SODIUM - PENNSAID							
N 020947	001	8217078	Jul 10, 2029	U-1248			
		8546450	Aug 09, 2030	U-1435			
		8546450	Aug 09, 2030	U-1436			
		8618164	Jul 10, 2029	U-1477			
		8741956	Jul 10, 2029	U-1435			
DICLOFENAC SODIUM - DYLOJECT							
N 022396	001	6407079	Jun 18, 2019	DP			
		8946292	Mar 22, 2027	U-1659			
DICLOFENAC SODIUM - PENNSAID							
N 204623	001	8217078	Jul 10, 2029	U-1477			
		8252838	Apr 21, 2028	DP U-1489			
		8546450	Aug 09, 2030	U-1435			
		8546450	Aug 09, 2030	U-1436			
		8563613	Oct 17, 2027	DP U-1488			
		8618164	Jul 10, 2029	U-1477			
		8741956	Jul 10, 2029	U-1435			
		8871809	Oct 17, 2027	U-1614			
		9066913	Oct 17, 2027	DP U-1488			
		9101591	Oct 17, 2027	DP U-1488			
		9132110	Oct 17, 2027	U-1488			
		9168304	Oct 17, 2027	DP			
		9168305	Oct 17, 2027	U-1488			
		9220784	Oct 17, 2027	U-1488			
		9339551	Oct 17, 2027	U-1488			
		9339552	Oct 17, 2027	DP U-1488			
		9370501	Jul 10, 2029	U-1614			
		9375412	Jul 10, 2029	U-1614			
		9415029	Jul 10, 2029	U-1614			
		9539335	Oct 17, 2027	U-1614			
DIENOGEST; DIENOGEST; DIENOGEST; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE - NATAZIA							
N 022252	001	8071577	May 13, 2026	DP U-1			
		8153616	Jan 30, 2028	U-1240			
DIFLUPREDNATE - DUREZOL							
N 022212	001	6114319	May 18, 2019	DP		ODE-26	Jun 13, 2019
		6114319*PED	Nov 18, 2019			PED	Dec 13, 2019
DILTIAZEM HYDROCHLORIDE - CARDIZEM LA							
N 021392	001	6923984	Feb 25, 2021	DP			
		7108866	Dec 17, 2019	DP U-107			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DILTIAZEM HYDROCHLORIDE - CARDIZEM LA									
N 021392	002		6923984	Feb 25, 2021		DP			
			7108866	Dec 17, 2019		DP U-107			
DILTIAZEM HYDROCHLORIDE - CARDIZEM LA									
N 021392	003		6923984	Feb 25, 2021		DP			
			7108866	Dec 17, 2019		DP U-107			
DILTIAZEM HYDROCHLORIDE - CARDIZEM LA									
N 021392	004		6923984	Feb 25, 2021		DP			
			7108866	Dec 17, 2019		DP U-107			
DILTIAZEM HYDROCHLORIDE - CARDIZEM LA									
N 021392	005		6923984	Feb 25, 2021		DP			
			7108866	Dec 17, 2019		DP U-107			
DILTIAZEM HYDROCHLORIDE - CARDIZEM LA									
N 021392	006		6923984	Feb 25, 2021		DP			
			7108866	Dec 17, 2019		DP U-107			
DIMETHYL FUMARATE - TECFIDERA									
N 204063	001		6509376	Apr 01, 2019		DP			
			7320999	Oct 20, 2019		U-1384			
			7619001	Jun 20, 2020		U-1384			
			7803840	Apr 01, 2019		U-1385			
			8399514	Feb 07, 2028		U-1384			
DIMETHYL FUMARATE - TECFIDERA									
N 204063	002		6509376	Apr 01, 2019		DP			
			7320999	Oct 20, 2019		U-1384			
			7619001	Jun 20, 2020		U-1384			
			7803840	Apr 01, 2019		U-1385			
			8399514	Feb 07, 2028		U-1384			
DIPHENHYDRAMINE CITRATE; IBUPROFEN - ADVIL PM									
N 021394	001		8263647	May 30, 2022		DP			
DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN - ADVIL PM									
N 021393	001		8883849	Jan 17, 2022		U-1618			
			9155718	Jan 17, 2022		DP			
DOCETAXEL - DOCETAXEL									
N 205934	001		8940786	Sep 30, 2033		DP U-1789			
			9308195	Sep 30, 2033		DP			
DOCETAXEL - DOCETAXEL									
N 205934	002		8940786	Sep 30, 2033		DP U-1789			
			9308195	Sep 30, 2033		DP			
DOCETAXEL - DOCETAXEL									
N 205934	003		8940786	Sep 30, 2033		DP U-1789			
			9308195	Sep 30, 2033		DP			
DOLUTEGRAVIR SODIUM - TIVICAY									
N 204790	001		8129385	Oct 05, 2027	DS	DP		I-758	Nov 21, 2020
			9242986	Dec 08, 2029	DS	DP			
DOLUTEGRAVIR SODIUM - TIVICAY									
N 204790	002		8129385	Oct 05, 2027	DS	DP		I-758	Nov 21, 2020
			9242986	Dec 08, 2029	DS	DP			
DOLUTEGRAVIR SODIUM - TIVICAY									
N 204790	003		8129385	Oct 05, 2027	DS	DP		I-758	Nov 21, 2020
			9242986	Dec 08, 2029	DS	DP			
DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA									
N 210192	001		6838464	Feb 26, 2021	DS	DP		NC	Nov 21, 2020
			7067522	Dec 20, 2019	DS	DP			
			7125879	Apr 21, 2025	DS	DP U-257			
			8080551	Apr 11, 2023	DS	DP			
			8101629	Aug 09, 2022		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA							
N 210192	001	8129385	Oct 05, 2027	DS DP			
		9242986	Dec 08, 2029	DS DP			
DONEPEZIL HYDROCHLORIDE - ARICEPT							
N 022568	001	8481565	Oct 04, 2026	DP			
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC							
N 206439	001	8039009	Mar 24, 2029			U-1641	
		8039009*PED	Sep 24, 2029				
		8058291	Dec 05, 2029			U-1641	
		8168209	Nov 22, 2025	DP			
		8168209*PED	May 22, 2026				
		8173708	Nov 22, 2025			U-1641	
		8173708*PED	May 22, 2026				
		8283379	Nov 22, 2025			U-1641	
		8283379*PED	May 22, 2026				
		8293794	Nov 22, 2025	DP			
		8329752	Nov 22, 2025	DP			
		8329752*PED	May 22, 2026				
		8338485	Nov 22, 2025	DP			
		8338486	Nov 22, 2025			U-1641	
		8362085	Nov 22, 2025			U-1641	
		8362085*PED	May 22, 2026				
		8580858	Nov 22, 2025			U-1641	
		8598233	Nov 22, 2025	DP			
		8598233*PED	May 22, 2026				
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC							
N 206439	002	8039009	Mar 24, 2029			U-1641	
		8039009*PED	Sep 24, 2029				
		8058291	Dec 05, 2029			U-1641	
		8168209	Nov 22, 2025	DP			
		8168209*PED	May 22, 2026				
		8173708	Nov 22, 2025			U-1641	
		8173708*PED	May 22, 2026				
		8283379	Nov 22, 2025			U-1641	
		8283379*PED	May 22, 2026				
		8293794	Nov 22, 2025	DP			
		8329752	Nov 22, 2025	DP			
		8329752*PED	May 22, 2026				
		8338485	Nov 22, 2025	DP			
		8338486	Nov 22, 2025			U-1641	
		8362085	Nov 22, 2025			U-1641	
		8362085*PED	May 22, 2026				
		8580858	Nov 22, 2025			U-1641	
		8598233	Nov 22, 2025	DP			
		8598233*PED	May 22, 2026				
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC							
N 206439	003	8039009	Mar 24, 2029			U-1641	
		8039009*PED	Sep 24, 2029				
		8058291	Dec 05, 2029			U-1641	
		8168209	Nov 22, 2025	DP			
		8168209*PED	May 22, 2026				
		8173708	Nov 22, 2025			U-1641	
		8173708*PED	May 22, 2026				
		8283379	Nov 22, 2025			U-1641	
		8283379*PED	May 22, 2026				
		8293794	Nov 22, 2025	DP			
		8329752	Nov 22, 2025	DP			
		8329752*PED	May 22, 2026				
		8338485	Nov 22, 2025	DP			
		8338486	Nov 22, 2025			U-1641	
		8362085	Nov 22, 2025			U-1641	
		8362085*PED	May 22, 2026				
		8580858	Nov 22, 2025			U-1641	
		8598233	Nov 22, 2025	DP			
		8598233*PED	May 22, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC							
N 206439	004	8039009	Mar 24, 2029	U-1641			
		8039009*PED	Sep 24, 2029				
		8058291	Dec 05, 2029	U-1641			
		8168209	Nov 22, 2025	DP			
		8168209*PED	May 22, 2026				
		8173708	Nov 22, 2025	U-1641			
		8173708*PED	May 22, 2026				
		8283379	Nov 22, 2025	U-1641			
		8283379*PED	May 22, 2026				
		8293794	Nov 22, 2025	DP			
		8329752	Nov 22, 2025	DP			
		8329752*PED	May 22, 2026				
		8338485	Nov 22, 2025	DP			
		8338486	Nov 22, 2025	U-1641			
		8362085	Nov 22, 2025	U-1641			
		8362085*PED	May 22, 2026				
		8580858	Nov 22, 2025	U-1641			
		8598233	Nov 22, 2025	DP			
		8598233*PED	May 22, 2026				
DORAVIRINE - PIFELTRO							
N 210806	001	8486975	Oct 07, 2031	DS DP U-2394		NCE	Aug 30, 2023
DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO							
N 210807	001	8486975	Oct 07, 2031	DS DP U-2395		NCE	Aug 30, 2023
DORIPENEM - DORIBAX							
N 022106	001	8247402	Mar 30, 2021	DS DP			
DORIPENEM - DORIBAX							
N 022106	002	8247402	Mar 30, 2021	DS DP			
DOXEPIN HYDROCHLORIDE - SILENOR							
N 022036	001	6211229	Feb 17, 2020	U-620			
		7915307	Aug 24, 2027	U-620			
		8513299	Sep 07, 2030	U-620			
		9107898	May 01, 2028	U-620			
		9486437	May 18, 2027	U-620			
		9532971	Jun 01, 2029	DP			
		9572814	Jul 20, 2027	U-620			
		9861607	May 18, 2027	U-620			
		9907780	Apr 11, 2028	DP			
DOXEPIN HYDROCHLORIDE - SILENOR							
N 022036	002	6211229	Feb 17, 2020	U-620			
		7915307	Aug 24, 2027	U-620			
		8513299	Sep 07, 2030	U-620			
		9107898	May 01, 2028	U-620			
		9486437	May 18, 2027	U-620			
		9532971	Jun 01, 2029	DP			
		9572814	Jul 20, 2027	U-620			
		9861607	May 18, 2027	U-620			
		9907780	Apr 11, 2028	DP			
DOXYCYCLINE - ORACEA							
N 050805	001	10058564	Apr 05, 2022	DS DP U-1063			
		7211267	Apr 05, 2022	U-925			
		7232572	Apr 05, 2022	U-925			
		7749532	Dec 19, 2027	DP U-1063			
		8206740	Dec 24, 2025	DP U-925			
		8394405	Apr 07, 2024	DP U-925			
		8394406	Apr 07, 2024	DP U-925			
		8470364	Apr 07, 2024	DP U-925			
		8603506	Apr 05, 2022	U-1063			
		8709478	Apr 07, 2024	U-1063			
		9241946	Apr 05, 2022	U-1063			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DOXYCYCLINE HYCLATE - DORYX								
N	050795	001	6958161	Dec 15, 2022	DP		U-918	
			8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX								
N	050795	002	6958161	Dec 15, 2022	DP		U-918	
			8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX								
N	050795	003	6958161	Dec 15, 2022	DP		U-918	
			8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX								
N	050795	004	6958161	Dec 15, 2022	DP		U-918	
			8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX								
N	050795	005	6958161	Dec 15, 2022	DP		U-918	
			8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX								
N	050795	006	6958161	Dec 15, 2022	DP		U-918	
			8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX MPC								
N	050795	007	6958161	Dec 15, 2022	DP		U-918	
			8715724	Feb 03, 2028	DP			
			9295652	Oct 23, 2034	DP		U-918	
			9446057	Dec 23, 2034	DP		U-918	
			9511031	Oct 23, 2034	DP			
DOXYCYCLINE HYCLATE - DORYX MPC								
N	050795	008	6958161	Dec 15, 2022	DP		U-918	
			8715724	Feb 03, 2028	DP			
			9295652	Oct 23, 2034	DP		U-918	
			9446057	Dec 23, 2034	DP		U-918	
			9511031	Oct 23, 2034	DP			
DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - DICLEGIS								
N	021876	001	6340695	Jun 21, 2021	DP		U-1382	
			7560122	Jan 25, 2019	DP			
DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - BONJESTA								
N	209661	001	7560122	Jan 25, 2019	DP			
			9089489	Feb 18, 2033	DP		U-1382	
			9375404	Feb 18, 2033	DP		U-1382	
			9526703	Feb 18, 2033	DP		U-1382	
			9937132	Feb 18, 2033	DP		U-1382	
DRONABINOL - SYNDROS								
N	205525	001	8222292	Aug 06, 2028	DS DP			
			9345771	Aug 06, 2028	DS DP			
DRONEDARONE HYDROCHLORIDE - MULTAQ								
N	022425	001	8410167	Apr 16, 2029			U-1387	
			8410167	Apr 16, 2029			U-1388	
			8602215	Jun 30, 2031			U-1473	
			9107900	Apr 16, 2029			U-1726	
			9107900	Apr 16, 2029			U-1728	
DROSPIRENONE; ESTRADIOL - ANGELIQ								
N	021355	001	8906890	Oct 22, 2031	DP			
DROSPIRENONE; ETHINYL ESTRADIOL - YASMIN								
N	021098	001	6787531	Aug 31, 2020	DP			
DROSPIRENONE; ETHINYL ESTRADIOL - YAZ								
N	021676	001	6787531	Aug 31, 2020	DP			
			6958326	Dec 20, 2021	DP			
			7163931	Dec 20, 2021			U-1	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ							
N 022532	001	6441168	Jul 30, 2022	DS			
		6958326	Dec 20, 2021	DP			
		7163931	Mar 03, 2022	U-1			
		8617597	Feb 08, 2030	DP			
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL							
N 022574	001	6441168	Apr 17, 2020	DS			
		6958326	Dec 20, 2021	DP			
		7163931	Mar 03, 2022	U-1			
		8617597	Feb 08, 2030	DP			
DROXIDOPA - NORTHERA							
N 203202	001					NCE	Feb 18, 2019
						ODE-61	Feb 18, 2021
DROXIDOPA - NORTHERA							
N 203202	002					NCE	Feb 18, 2019
						ODE-61	Feb 18, 2021
DROXIDOPA - NORTHERA							
N 203202	003					NCE	Feb 18, 2019
						ODE-61	Feb 18, 2021
DULOXETINE HYDROCHLORIDE - CYMBALTA							
N 021427	001	6596756	Sep 10, 2019	U-882			
DULOXETINE HYDROCHLORIDE - CYMBALTA							
N 021427	002	6596756	Sep 10, 2019	U-882			
DULOXETINE HYDROCHLORIDE - CYMBALTA							
N 021427	004	6596756	Sep 10, 2019	U-882			
DUVELISIB - COPIKTRA							
N 211155	001	8193182	Feb 13, 2030	DS		NCE	Sep 24, 2023
		9216982	Jan 05, 2029	U-2412		ODE-208	Sep 24, 2025
		9216982	Jan 05, 2029	U-2413		ODE-209	Sep 24, 2025
		9840505	Jan 10, 2032	U-2412			
		9840505	Jan 10, 2032	U-2413			
		RE46621	May 17, 2032	DS DP			
DUVELISIB - COPIKTRA							
N 211155	002	8193182	Feb 13, 2030	DS		NCE	Sep 24, 2023
		9216982	Jan 05, 2029	U-2412		ODE-208	Sep 24, 2025
		9216982	Jan 05, 2029	U-2413		ODE-209	Sep 24, 2025
		9840505	Jan 10, 2032	U-2412			
		9840505	Jan 10, 2032	U-2413			
		RE46621	May 17, 2032	DS DP			
ECONAZOLE NITRATE - ECOZA							
N 205175	001	10071054	Aug 08, 2031	DP			
EDARAVONE - RADICAVA							
N 209176	001	6933310	Nov 13, 2020	U-2013		NCE	May 05, 2022
						ODE-144	May 05, 2024
EDARAVONE - RADICAVA							
N 209176	002	6933310	Nov 13, 2020	U-2013			
EDOXABAN TOSYLATE - SAVAYSA							
N 206316	001	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
		9149532	Mar 28, 2028	DP			
EDOXABAN TOSYLATE - SAVAYSA							
N 206316	002	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
		9149532	Mar 28, 2028	DP			
EDOXABAN TOSYLATE - SAVAYSA							
N 206316	003	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
		9149532	Mar 28, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EFAVIRENZ - SUSTIVA							
N 020972	001	6238695	Apr 06, 2019	DP			
		6238695*PED	Oct 06, 2019				
		6555133	Apr 06, 2019	U-248			
		6555133*PED	Oct 06, 2019				
EFAVIRENZ - SUSTIVA							
N 020972	002	6238695	Apr 06, 2019	DP			
		6238695*PED	Oct 06, 2019				
		6555133	Apr 06, 2019	U-248			
		6555133*PED	Oct 06, 2019				
EFAVIRENZ - SUSTIVA							
N 020972	003	6238695	Apr 06, 2019	DP			
		6238695*PED	Oct 06, 2019				
		6555133	Apr 06, 2019	U-248			
		6555133*PED	Oct 06, 2019				
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA							
N 021937	001	6642245	Nov 04, 2020	U-1170			
		6642245	Nov 04, 2020	U-750			
		6703396	Mar 09, 2021	DS DP			
		8592397	Jan 13, 2024	DP U-1170			
		8592397	Jan 13, 2024	DP U-750			
		8598185	Apr 28, 2029	DP			
		8716264	Jan 13, 2024	DP U-257			
		9018192	Jun 13, 2026	U-1170			
		9018192	Jun 13, 2026	U-750			
		9457036	Jan 13, 2024	DP U-257			
		9545414	Jun 13, 2026	DP U-1170			
		9545414	Jun 13, 2026	DP U-750			
		9744181	Jan 13, 2024	DP U-257			
EFINACONAZOLE - JUBLIA							
N 203567	001	10105444	Jul 08, 2030	DP		NCE	Jun 06, 2019
		7214506	Oct 05, 2021	U-281			
		8039494	Jul 08, 2030	U-281			
		8486978	Oct 24, 2030	DP			
		9302009	Oct 24, 2030	DP			
		9566272	Jan 03, 2028	U-1969			
		9662394	Oct 02, 2034	DP			
		9861698	Jul 08, 2030	DP			
		9877955	Jan 03, 2028	U-1969			
ELAGOLIX SODIUM - ORILISSA							
N 210450	001	6872728	Jan 25, 2021	DS DP		NCE	Jul 23, 2023
		7056927	Sep 10, 2024	DS DP			
		7176211	Jul 06, 2024	U-2360			
		7179815	Mar 07, 2021	U-2360			
		7419983	Jul 06, 2024	DS DP U-2360			
		7462625	Jan 25, 2021	DS DP U-2360			
ELAGOLIX SODIUM - ORILISSA							
N 210450	002	6872728	Jan 25, 2021	DS DP		NCE	Jul 23, 2023
		7056927	Sep 10, 2024	DS DP			
		7176211	Jul 06, 2024	U-2360			
		7179815	Mar 07, 2021	U-2360			
		7419983	Jul 06, 2024	DS DP U-2360			
		7462625	Jan 25, 2021	DS DP U-2360			
ELBASVIR; GRAZOPREVIR - ZEPATIER							
N 208261	001	7973040	Jul 24, 2029	DS DP U-1813		NCE	Jan 28, 2021
		8871759	May 04, 2031	DS DP U-1813			
ELIGLUSTAT TARTRATE - CERDELGA							
N 205494	001	6916802	Apr 29, 2022	DS U-1571		NCE	Aug 19, 2019
		7196205	Jun 26, 2026	DS		ODE-73	Aug 19, 2021
		7253185	Apr 29, 2022	DP			
		7615573	Apr 29, 2022	U-1571			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 001	6280959*PED	Apr 30, 2019			ODE-210	Nov 16, 2025
	7160870	Nov 20, 2022	DS DP U-1306		ODE-75	Aug 26, 2021
	7160870	Nov 20, 2022	DS DP U-1575		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870	Nov 20, 2022	DS DP U-930			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481	May 24, 2021	U-2451			
	7332481	May 24, 2021	U-930			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686	May 24, 2021	DS DP U-2451			
	7473686	May 24, 2021	DS DP U-930			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704	May 24, 2021	U-2451			
	7790704	May 24, 2021	U-930			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8052993	Aug 01, 2027	DP U-1714			
	8052993	Aug 01, 2027	DP U-2451			
	8052993	Aug 01, 2027	DP U-930			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 002	6280959*PED	Apr 30, 2019			ODE-210	Nov 16, 2025
	7160870	Nov 20, 2022	DS DP U-1306		ODE-75	Aug 26, 2021
	7160870	Nov 20, 2022	DS DP U-1575		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870	Nov 20, 2022	DS DP U-930			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 002	7332481	May 24, 2021	U-1714			
	7332481	May 24, 2021	U-2451			
	7332481	May 24, 2021	U-930			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686	May 24, 2021	DS DP U-2451			
	7473686	May 24, 2021	DS DP U-930			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704	May 24, 2021	U-2451			
	7790704	May 24, 2021	U-930			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-1575			
	8052994	Aug 01, 2027	DP U-1714			
	8052994	Aug 01, 2027	DP U-2451			
	8052994	Aug 01, 2027	DP U-930			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 003	6280959*PED	Apr 30, 2019			ODE-210	Nov 16, 2025
	7160870	Nov 20, 2022	DS DP U-1306		ODE-75	Aug 26, 2021
	7160870	Nov 20, 2022	DS DP U-1575		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870	Nov 20, 2022	DS DP U-930			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481	May 24, 2021	U-2451			
	7332481	May 24, 2021	U-930			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 003	7473686	May 24, 2021	DS DP U-2451			
	7473686	May 24, 2021	DS DP U-930			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704	May 24, 2021	U-2451			
	7790704	May 24, 2021	U-930			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-1575			
	8062665	Aug 01, 2027	DP U-1714			
	8062665	Aug 01, 2027	DP U-2451			
	8062665	Aug 01, 2027	DP U-930			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 004	6280959*PED	Apr 30, 2019			ODE-210	Nov 16, 2025
	7160870	Nov 20, 2022	DS DP U-1306		ODE-75	Aug 26, 2021
	7160870	Nov 20, 2022	DS DP U-1575		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870	Nov 20, 2022	DS DP U-930			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481	May 24, 2021	U-2451			
	7332481	May 24, 2021	U-930			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686	May 24, 2021	DS DP U-2451			
	7473686	May 24, 2021	DS DP U-930			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 004	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704	May 24, 2021	U-2451			
	7790704	May 24, 2021	U-930			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-1575			
	8071129	Aug 01, 2027	DP U-1714			
	8071129	Aug 01, 2027	DP U-2451			
	8071129	Aug 01, 2027	DP U-930			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 005	6280959*PED	Apr 30, 2019			ODE-210	Nov 16, 2025
	7160870	Nov 20, 2022	DS DP U-1306		ODE-75	Aug 26, 2021
	7160870	Nov 20, 2022	DS DP U-1575		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870	Nov 20, 2022	DS DP U-930			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481	May 24, 2021	U-930			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686	May 24, 2021	DS DP U-930			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-930			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8052995	Aug 01, 2027	DP U-1306			
	8052995	Aug 01, 2027	DP U-1575			
	8052995*PED	Feb 01, 2028				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA KIT						
N 207027 001	6280959*PED	Apr 30, 2019			ODE-74	Aug 26, 2021
	7160870	Nov 20, 2022	DS DP U-1736		PED	Feb 26, 2022
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1736			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1736			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1736			
	7790704*PED	Nov 24, 2021				
	7795293	May 24, 2023	U-1736			
	7795293*PED	Nov 24, 2023				
ELUXADOLINE - VIBERZI						
N 206940 001	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
	8772325	Mar 14, 2025	U-1709			
	9115091	Jul 07, 2028	DS DP U-1738			
	9205076	Mar 14, 2025	U-1709			
	9364489	Jul 07, 2028	U-1709			
	9675587	Mar 14, 2033	DP			
	9700542	Mar 14, 2025	DP			
	9789125	Jul 07, 2028	DP U-1709			
	9789125	Jul 07, 2028	DP U-2152			
ELUXADOLINE - VIBERZI						
N 206940 002	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
	8772325	Mar 14, 2025	U-1709			
	9115091	Jul 07, 2028	DS DP U-1738			
	9205076	Mar 14, 2025	U-1709			
	9364489	Jul 07, 2028	U-1709			
	9675587	Mar 14, 2033	DP			
	9700542	Mar 14, 2025	DP			
	9789125	Jul 07, 2028	DP U-1709			
	9789125	Jul 07, 2028	DP U-2152			
ELVITEGRAVIR - VITEKTA						
N 203093 001	7176220	Aug 27, 2026	DS DP U-257			
	7635704	Oct 26, 2026	DS DP U-257			
	8981103	Oct 26, 2026	DS DP			
ELVITEGRAVIR - VITEKTA						
N 203093 002	7176220	Aug 27, 2026	DS DP U-257			
	7635704	Oct 26, 2026	DS DP U-257			
	8981103	Oct 26, 2026	DS DP			
EMPAGLIFLOZIN - JARDIANCE						
N 204629 001	7579449	Nov 05, 2025	DS		I-739	Dec 02, 2019
	7713938	Apr 15, 2027	DS DP		M-174	Mar 18, 2019
	8551957	Oct 14, 2029	U-1651		NCE	Aug 01, 2019
	9949997	May 17, 2034	U-2292			
	9949998	Jun 11, 2034	U-2290			
EMPAGLIFLOZIN - JARDIANCE						
N 204629 002	7579449	Nov 05, 2025	DS		I-739	Dec 02, 2019
	7713938	Apr 15, 2027	DS DP		M-174	Mar 18, 2019
	8551957	Oct 14, 2029	U-1651		NCE	Aug 01, 2019
	9949997	May 17, 2034	U-2292			
	9949998	Jun 11, 2034	U-2290			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN - JARDIANCE							
N 204629	002	7579449	Nov 05, 2025	DS		I-739	Dec 02, 2019
		7713938	Apr 15, 2027	DS DP		M-174	Mar 18, 2019
		8551957	Oct 14, 2029	U-1651		NCE	Aug 01, 2019
		9949997	May 17, 2034	U-2292			
		9949998	Jun 11, 2034	U-2290			
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI							
N 206073	001	6890898	Feb 02, 2019	U-1652		I-739	Dec 02, 2019
		7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
		7407955	May 02, 2025	DS DP			
		7459428	Feb 02, 2019	U-1651			
		7579449	Nov 05, 2025	DS			
		7713938	Apr 15, 2027	DS DP			
		8119648	Aug 12, 2023	U-1651			
		8178541	Aug 12, 2023	DP U-1653			
		8178541	Aug 12, 2023	DP U-1654			
		8551957	Oct 14, 2029	DP U-1651			
		8673927	May 04, 2027	U-1652			
		8883805	Nov 26, 2025	DP			
		9173859	May 04, 2027	DP U-1772			
		9949998	Jun 11, 2034	U-2290			
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI							
N 206073	002	6890898	Feb 02, 2019	U-1652		I-739	Dec 02, 2019
		7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
		7407955	May 02, 2025	DS DP			
		7459428	Feb 02, 2019	U-1651			
		7579449	Nov 05, 2025	DS			
		7713938	Apr 15, 2027	DS DP			
		8119648	Aug 12, 2023	U-1651			
		8178541	Aug 12, 2023	DP U-1653			
		8178541	Aug 12, 2023	DP U-1654			
		8551957	Oct 14, 2029	DP U-1651			
		8673927	May 04, 2027	U-1652			
		8883805	Nov 26, 2025	DP			
		9173859	May 04, 2027	DP U-1772			
		9949998	Jun 11, 2034	U-2290			
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY							
N 206111	001	7579449	Nov 05, 2025	DS		I-739	Dec 02, 2019
		7713938	Apr 15, 2027	DS DP		M-174	Mar 18, 2019
						NCE	Aug 01, 2019
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY							
N 206111	002	7579449	Nov 05, 2025	DS		I-739	Dec 02, 2019
		7713938	Apr 15, 2027	DS DP		M-174	Mar 18, 2019
						NCE	Aug 01, 2019
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY							
N 206111	003	7579449	Nov 05, 2025	DS		I-739	Dec 02, 2019
		7713938	Apr 15, 2027	DS DP		M-174	Mar 18, 2019
						NCE	Aug 01, 2019
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY							
N 206111	004	7579449	Nov 05, 2025	DS		I-739	Dec 02, 2019
		7713938	Apr 15, 2027	DS DP		M-174	Mar 18, 2019
						NCE	Aug 01, 2019
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR							
N 208658	001	6488962	Jun 20, 2020	DP		I-739	Dec 02, 2019
		7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
		7713938	Apr 15, 2027	DS DP			
		9949998	Jun 11, 2034	U-2290			
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR							
N 208658	002	6488962	Jun 20, 2020	DP		I-739	Dec 02, 2019
		7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
		7713938	Apr 15, 2027	DS DP			
		9949998	Jun 11, 2034	U-2290			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR							
N 208658	002	6488962	Jun 20, 2020	DP		I-739	Dec 02, 2019
		7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
		7713938	Apr 15, 2027	DS DP			
		9949998	Jun 11, 2034	U-2290			
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR							
N 208658	003	6488962	Jun 20, 2020	DP		I-739	Dec 02, 2019
		7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
		7713938	Apr 15, 2027	DS DP			
		9949998	Jun 11, 2034	U-2290			
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR							
N 208658	004	6488962	Jun 20, 2020	DP		I-739	Dec 02, 2019
		7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
		7713938	Apr 15, 2027	DS DP			
		9949998	Jun 11, 2034	U-2290			
EMTRICITABINE - EMTRIVA							
N 021500	001	6642245	Nov 04, 2020	U-257			
		6642245	Nov 04, 2020	U-541			
		6703396	Mar 09, 2021	DS DP			
EMTRICITABINE - EMTRIVA							
N 021896	001	6642245	Nov 04, 2020	U-257			
		6703396	Mar 09, 2021	DS DP			
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY							
N 208351	001	6642245	Nov 04, 2020	U-257		M-206	Aug 21, 2020
		6642245*PED	May 04, 2021			M-207	Aug 21, 2020
		6703396	Mar 09, 2021	DS DP		NCE	Nov 05, 2020
		6703396*PED	Sep 09, 2021				
		6838464	Feb 26, 2021	DS DP			
		7067522	Dec 20, 2019	DS DP			
		7125879	Apr 21, 2025	DS DP U-257			
		7390791	May 07, 2022	DS DP			
		7803788	Feb 02, 2022	U-257			
		8080551	Apr 11, 2023	DS DP			
		8101629	Aug 09, 2022	DP			
		8754065	Aug 15, 2032	DS DP U-257			
		9296769	Aug 15, 2032	DS DP U-257			
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA							
N 202123	001	6642245	Nov 04, 2020	U-257			
		6703396	Mar 09, 2021	DS DP			
		6838464	Feb 26, 2021	DS DP			
		7067522	Dec 20, 2019	DS DP			
		7125879	Apr 21, 2025	DS DP U-257			
		8080551	Apr 11, 2023	DS DP			
		8101629	Aug 09, 2022	DP			
		8592397	Jan 13, 2024	DP U-257			
		8716264	Jan 13, 2024	DP U-257			
		8841310	Dec 09, 2025	DP U-257			
		9457036	Jan 13, 2024	DP U-257			
		9744181	Jan 13, 2024	DP U-257			
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY							
N 208215	001	6642245	Nov 04, 2020	U-257		NCE	Nov 05, 2020
		6642245*PED	May 04, 2021			NPP	Sep 25, 2020
		6703396	Mar 09, 2021	DS DP			
		6703396*PED	Sep 09, 2021				
		7390791	May 07, 2022	DS DP			
		7803788	Feb 02, 2022	U-257			
		8754065	Aug 15, 2032	DS DP U-257			
		9296769	Aug 15, 2032	DS DP U-257			
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA							
N 021752	001	6642245	Nov 04, 2020	U-1170			
		6642245	Nov 04, 2020	U-248			
		6642245	Nov 04, 2020	U-541			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA							
N 021752	001	6703396	Mar 09, 2021	DS DP			
		8592397	Jan 13, 2024	DP U-1170			
		8592397	Jan 13, 2024	DP U-248			
		8592397	Jan 13, 2024	DP U-541			
		8716264	Jan 13, 2024	DP U-257			
		9457036	Jan 13, 2024	DP U-257			
		9744181	Jan 13, 2024	DP U-257			
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA							
N 021752	002	6642245	Nov 04, 2020	U-1170			
		6642245	Nov 04, 2020	U-248			
		6642245	Nov 04, 2020	U-541			
		6642245*PED	May 04, 2021				
		6703396	Mar 09, 2021	DS DP			
		6703396*PED	Sep 09, 2021				
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA							
N 021752	003	6642245	Nov 04, 2020	U-1170			
		6642245	Nov 04, 2020	U-248			
		6642245	Nov 04, 2020	U-541			
		6642245*PED	May 04, 2021				
		6703396	Mar 09, 2021	DS DP			
		6703396*PED	Sep 09, 2021				
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA							
N 021752	004	6642245	Nov 04, 2020	U-1170			
		6642245	Nov 04, 2020	U-248			
		6642245	Nov 04, 2020	U-541			
		6642245*PED	May 04, 2021				
		6703396	Mar 09, 2021	DS DP			
		6703396*PED	Sep 09, 2021				
ENALAPRIL MALEATE - EPANED KIT							
N 204308	001	8568747	Nov 06, 2032	DP			
		8778366	Nov 06, 2032	U-1723			
		8778366	Nov 06, 2032	U-185			
		8778366	Nov 06, 2032	U-1892			
		8778366	Nov 06, 2032	U-3			
		8778366	Nov 06, 2032	U-71			
		9855214	Nov 06, 2032	DP			
		9968553	Nov 06, 2032	U-1723			
		9968553	Nov 06, 2032	U-185			
		9968553	Nov 06, 2032	U-1892			
		9968553	Nov 06, 2032	U-3			
		9968553	Nov 06, 2032	U-71			
ENALAPRIL MALEATE - EPANED							
N 208686	001	10039745	Mar 25, 2036	DP			
		10154987	Mar 25, 2036	U-1723			
		10154987	Mar 25, 2036	U-185			
		10154987	Mar 25, 2036	U-1892			
		10154987	Mar 25, 2036	U-3			
		10154987	Mar 25, 2036	U-71			
		9669008	Mar 25, 2036	DP			
		9808442	Mar 25, 2036	U-1723			
		9808442	Mar 25, 2036	U-185			
		9808442	Mar 25, 2036	U-1892			
		9808442	Mar 25, 2036	U-3			
		9808442	Mar 25, 2036	U-71			
ENASIDENIB MESYLATE - IDHIFA							
N 209606	001	10093654	Aug 01, 2034	DS DP U-2087		NCE	Aug 01, 2022
		9512107	Jan 07, 2033	DS DP U-2087		ODE-151	Aug 01, 2024
		9732062	Sep 16, 2034	DS			
		9738625	Aug 01, 2034	DS			
ENASIDENIB MESYLATE - IDHIFA							
N 209606	002	10093654	Aug 01, 2034	DS DP U-2087		NCE	Aug 01, 2022
		9512107	Jan 07, 2033	DS DP U-2087		ODE-151	Aug 01, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ENASIDENIB MESYLATE - IDHIFA							
N 209606	002	9732062	Sep 16, 2034	DS			
		9738625	Aug 01, 2034	DS			
ENCORAFENIB - BRAFTOVI							
N 210496	001	10005761	Aug 27, 2030	U-2335		NCE	Jun 27, 2023
		8501758	Mar 04, 2031	DS DP		ODE-194	Jun 27, 2025
		8541575	Feb 26, 2030	DS DP U-2335			
		8946250	Jul 23, 2029	DS DP			
		9314464	Jul 04, 2031	U-2336			
		9387208	Nov 21, 2032	DP			
		9593099	Aug 27, 2030	DS			
		9593100	Aug 27, 2030	DP			
		9763941	Nov 21, 2032	U-2335			
		9850229	Aug 27, 2030	U-2337			
		9850230	Aug 27, 2030	U-2334			
ENCORAFENIB - BRAFTOVI							
N 210496	002	10005761	Aug 27, 2030	U-2335		NCE	Jun 27, 2023
		8501758	Mar 04, 2031	DS DP		ODE-194	Jun 27, 2025
		8541575	Feb 26, 2030	DS DP U-2335			
		8946250	Jul 23, 2029	DS DP			
		9314464	Jul 04, 2031	U-2336			
		9387208	Nov 21, 2032	DP			
		9593099	Aug 27, 2030	DS			
		9593100	Aug 27, 2030	DP			
		9763941	Nov 21, 2032	U-2335			
		9850229	Aug 27, 2030	U-2337			
		9850230	Aug 27, 2030	U-2334			
ENZALUTAMIDE - XTANDI							
N 203415	001	7709517	Aug 13, 2027	DS DP		I-786	Jul 13, 2021
		8183274	Aug 24, 2026	U-1281			
		8183274	Aug 24, 2026	U-1588			
		8183274	Aug 24, 2026	U-2345			
		9126941	May 15, 2026	U-1588			
		9126941	May 15, 2026	U-2345			
EPINEPHRINE - EPIPEN							
N 019430	001	7449012	Sep 11, 2025	DP			
		7794432	Sep 11, 2025	DP			
		8048035	Sep 11, 2025	DP			
		8870827	Sep 11, 2025	DP			
		9586010	Sep 11, 2025	DP			
EPINEPHRINE - EPIPEN JR.							
N 019430	002	7449012	Sep 11, 2025	DP			
		7794432	Sep 11, 2025	DP			
		8048035	Sep 11, 2025	DP			
		8870827	Sep 11, 2025	DP			
		9586010	Sep 11, 2025	DP			
EPINEPHRINE - TWINJECT 0.3							
N 020800	001	7297136	Jan 18, 2025	DP			
		7621891	Feb 04, 2025	DP			
EPINEPHRINE - TWINJECT 0.15							
N 020800	002	7297136	Jan 18, 2025	DP			
		7621891	Feb 04, 2025	DP			
EPINEPHRINE - ADRENACLICK							
N 020800	003	7905352	Apr 12, 2027	DP			
EPINEPHRINE - ADRENACLICK							
N 020800	004	7905352	Apr 12, 2027	DP			
EPINEPHRINE - AUVI-Q							
N 201739	001	7731686	Jun 01, 2026	DP			
		7731690	Jan 15, 2025	DP			
		7749194	Oct 30, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EPINEPHRINE - AUVI-Q						
N 201739 001	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
	9056170	Nov 23, 2024	DP			
	9149579	Jul 19, 2025			U-1758	
	9238108	Feb 20, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
	9724471	May 23, 2027	DP		U-2092	
	9737669	Nov 23, 2024	DP			
EPINEPHRINE - AUVI-Q						
N 201739 002	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
	9056170	Nov 23, 2024	DP			
	9149579	Jul 19, 2025			U-1758	
	9238108	Feb 20, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
	9724471	May 23, 2027	DP		U-2092	
	9737669	Nov 23, 2024	DP			
EPINEPHRINE - AUVI-Q						
N 201739 003	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
	9056170	Nov 23, 2024	DP			
	9149579	Jul 19, 2025			U-1758	
	9238108	Feb 20, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EPINEPHRINE - AUVI-Q							
N 201739	003	9724471	May 23, 2027	DP U-2092			
		9737669	Nov 23, 2024	DP			
		9833573	Nov 23, 2024	U-2172			
EPINEPHRINE - ADRENALIN							
N 204200	001	9119876	Mar 13, 2035	DP			
		9295657	Mar 13, 2035	U-1829			
EPINEPHRINE - ADRENALIN							
N 204640	001	10130592	Mar 13, 2035	DP			
		9119876	Mar 13, 2035	DP			
		9295657	Mar 13, 2035	U-1829			
EPINEPHRINE - EPINEPHRINE							
N 205029	001	10004700	Aug 14, 2034	DP U-2325			
		10039728	Aug 14, 2034	U-1828			
		9283197	Aug 15, 2034	DP U-1828			
		9283197	Aug 15, 2034	DP U-1829			
		9283197	Aug 15, 2034	DP U-1830			
EPINEPHRINE - PRIMATENE MIST							
N 205920	001	8367734	Jan 26, 2026	DP		NP	Nov 07, 2021
EPINEPHRINE; LIDOCAINE HYDROCHLORIDE - LIDOSITE TOPICAL SYSTEM KIT							
N 021504	001	6629968	Jun 30, 2020	DS DP			
		6635045	Jun 29, 2021	DS DP			
EPLERENONE - INSPRA							
N 021437	001	6410054	Dec 08, 2019	U-3			
		6410054	Dec 08, 2019	U-537			
		6410524	Nov 05, 2019	U-467			
		6495165	Dec 08, 2019	U-3			
		6495165	Dec 08, 2019	U-537			
		6534093	Dec 08, 2019	U-3			
		6534093	Dec 08, 2019	U-537			
		6558707	Dec 08, 2019	DP U-537			
		6747020	Nov 05, 2019	U-587			
		7157101	Dec 08, 2019	DP U-664			
EPLERENONE - INSPRA							
N 021437	002	6410054	Dec 08, 2019	U-3			
		6410054	Dec 08, 2019	U-537			
		6410524	Nov 05, 2019	U-467			
		6495165	Dec 08, 2019	U-3			
		6495165	Dec 08, 2019	U-537			
		6534093	Dec 08, 2019	U-3			
		6534093	Dec 08, 2019	U-537			
		6558707	Dec 08, 2019	DP U-537			
		6747020	Nov 05, 2019	U-587			
		7157101	Dec 08, 2019	DP U-664			
EPLERENONE - INSPRA							
N 021437	003	6410054	Dec 08, 2019	U-3			
		6410054	Dec 08, 2019	U-537			
		6410524	Nov 05, 2019	U-467			
		6495165	Dec 08, 2019	U-3			
		6495165	Dec 08, 2019	U-537			
		6534093	Dec 08, 2019	U-3			
		6534093	Dec 08, 2019	U-537			
		6558707	Dec 08, 2019	DP U-537			
		6747020	Nov 05, 2019	U-587			
		7157101	Dec 08, 2019	DP U-664			
EPOPROSTENOL SODIUM - VELETRI							
N 022260	001	8318802	Mar 15, 2027	DP			
		8598227	Feb 02, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EPOPROSTENOL SODIUM - VELETRI						
N 022260 002	8318802	Mar 15, 2027	DP			
	8598227	Feb 02, 2027				
ERAVACYCLINE DIHYDROCHLORIDE - XERAVA						
N 211109 001					NCE	Aug 27, 2023
					GAIN	Aug 27, 2028
ERIBULIN MESYLATE - HALAVEN						
N 201532 001	6214865	Jul 20, 2023	DS		I-721	Jan 28, 2019
	6469182	Jun 16, 2019	U-1096		ODE-107	Jan 28, 2023
	6469182	Jun 16, 2019	U-1812			
	7470720	Jun 16, 2019	DP			
	8097648	Jan 22, 2021	U-1096			
	RE46965	Jan 08, 2027	DP			
ERLOTINIB HYDROCHLORIDE - TARCEVA						
N 021743 001	5747498*PED	May 08, 2019			D-164	May 20, 2019
	6900221	Nov 09, 2020	DS DP U-1046		M-181	Jun 01, 2019
	6900221	Nov 09, 2020	DS DP U-1403		M-190	Oct 18, 2019
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613*PED	May 09, 2021				
	RE41065*PED	May 08, 2019				
ERLOTINIB HYDROCHLORIDE - TARCEVA						
N 021743 002	5747498*PED	May 08, 2019			D-164	May 20, 2019
	6900221	Nov 09, 2020	DS DP U-1046		M-181	Jun 01, 2019
	6900221	Nov 09, 2020	DS DP U-1403		M-190	Oct 18, 2019
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613*PED	May 09, 2021				
	RE41065*PED	May 08, 2019				
ERLOTINIB HYDROCHLORIDE - TARCEVA						
N 021743 003	5747498*PED	May 08, 2019			D-164	May 20, 2019
	6900221	Nov 09, 2020	DS DP U-1046		M-181	Jun 01, 2019
	6900221	Nov 09, 2020	DS DP U-1403		M-190	Oct 18, 2019
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613*PED	May 09, 2021				
	RE41065*PED	May 08, 2019				
ERTUGLIFLOZIN - STEGLATRO						
N 209803 001	8080580	Jul 13, 2030	DS DP U-2214		NCE	Dec 19, 2022
ERTUGLIFLOZIN - STEGLATRO						
N 209803 002	8080580	Jul 13, 2030	DS DP U-2214		NCE	Dec 19, 2022
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET						
N 209806 001	8080580	Jul 13, 2030	DS DP U-2214		NCE	Dec 19, 2022
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET						
N 209806 002	8080580	Jul 13, 2030	DS DP U-2214		NCE	Dec 19, 2022
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET								
N	209806	002	8080580	Jul 13, 2030	DS DP U-2214		NCE	Dec 19, 2022
			9308204	Oct 21, 2030	DP			
			9439902	Oct 21, 2030	U-2214			
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET								
N	209806	003	8080580	Jul 13, 2030	DS DP U-2214		NCE	Dec 19, 2022
			9308204	Oct 21, 2030	DP			
			9439902	Oct 21, 2030	U-2214			
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET								
N	209806	004	8080580	Jul 13, 2030	DS DP U-2214		NCE	Dec 19, 2022
			9308204	Oct 21, 2030	DP			
			9439902	Oct 21, 2030	U-2214			
ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN								
N	209805	001	6699871	Jul 26, 2022	DS DP U-2214		NCE	Dec 19, 2022
			6890898	Feb 02, 2019	U-2215			
			7078381	Feb 02, 2019	U-2216			
			7326708	Nov 24, 2026	DS DP U-2214			
			7459428	Feb 02, 2019	U-2215			
			8080580	Jul 13, 2030	DS DP U-2214			
			9308204	Oct 21, 2030	DP			
			9439901	Oct 21, 2030	U-2214			
ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN								
N	209805	002	6699871	Jul 26, 2022	DS DP U-2214		NCE	Dec 19, 2022
			6890898	Feb 02, 2019	U-2215			
			7078381	Feb 02, 2019	U-2216			
			7326708	Nov 24, 2026	DS DP U-2214			
			7459428	Feb 02, 2019	U-2215			
			8080580	Jul 13, 2030	DS DP U-2214			
			9308204	Oct 21, 2030	DP			
			9439901	Oct 21, 2030	U-2214			
ESCITALOPRAM OXALATE - LEXAPRO								
N	021323	001	6916941	Aug 12, 2022	DS DP			
			7420069	Aug 12, 2022	DP			
ESCITALOPRAM OXALATE - LEXAPRO								
N	021323	002	6916941	Aug 12, 2022	DS DP			
			7420069	Aug 12, 2022	DP			
ESCITALOPRAM OXALATE - LEXAPRO								
N	021323	003	6916941	Aug 12, 2022	DS DP			
			7420069	Aug 12, 2022	DP			
ESLICARBAZEPINE ACETATE - APTIOM								
N	022416	001	5753646	Jun 27, 2021	DS DP U-2041			
			8372431	Apr 17, 2030	DP			
			9206135	Apr 21, 2026	DS			
			9566244	Oct 23, 2028	DP			
			9643929	Apr 21, 2026	DP			
			9750747	Aug 24, 2032	U-2041			
			9750747	Aug 24, 2032	U-2121			
			9763954	Sep 13, 2028	U-2123			
ESLICARBAZEPINE ACETATE - APTIOM								
N	022416	002	5753646	Jun 27, 2021	DS DP U-2041			
			8372431	Apr 17, 2030	DP			
			9206135	Apr 21, 2026	DS			
			9566244	Oct 23, 2028	DP			
			9643929	Apr 21, 2026	DP			
			9750747	Aug 24, 2032	U-2041			
			9750747	Aug 24, 2032	U-2121			
			9763954	Sep 13, 2028	U-2123			
ESLICARBAZEPINE ACETATE - APTIOM								
N	022416	003	5753646	Jun 27, 2021	DS DP U-2041			
			8372431	Apr 17, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESLICARBAZEPINE ACETATE - APTIOM							
N 022416	003	9206135	Apr 21, 2026	DS			
		9566244	Oct 23, 2028	DP			
		9643929	Apr 21, 2026	DP			
		9750747	Aug 24, 2032			U-2041	
		9750747	Aug 24, 2032			U-2121	
		9763954	Sep 13, 2028			U-2123	
ESLICARBAZEPINE ACETATE - APTIOM							
N 022416	004	5753646	Jun 27, 2021	DS DP		U-2041	
		8372431	Apr 17, 2030	DP			
		9206135	Apr 21, 2026	DS			
		9566244	Oct 23, 2028	DP			
		9643929	Apr 21, 2026	DP			
		9750747	Aug 24, 2032			U-2041	
		9750747	Aug 24, 2032			U-2121	
		9763954	Sep 13, 2028			U-2123	
ESMOLOL HYDROCHLORIDE - BREVIBLOC IN PLASTIC CONTAINER							
N 019386	004	6310094	Jan 12, 2021				
		6528540	Jan 12, 2021				
ESMOLOL HYDROCHLORIDE - BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER							
N 019386	005	6310094	Jan 12, 2021				
		6528540	Jan 12, 2021				
ESMOLOL HYDROCHLORIDE - BREVIBLOC							
N 019386	006	6310094	Jan 12, 2021				
		6528540	Jan 12, 2021				
ESMOLOL HYDROCHLORIDE - BREVIBLOC							
N 019386	007	6310094	Jan 12, 2021				
		6528540	Jan 12, 2021				
ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER							
N 205703	001	6310094	Jan 12, 2021	DP			
		6528540	Jan 12, 2021	DP			
		8829054	Mar 15, 2033	DP			
		8835505	Mar 15, 2033	DP			
ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER							
N 205703	002	6310094	Jan 12, 2021	DP			
		6528540	Jan 12, 2021	DP			
		8829054	Mar 15, 2033	DP			
		8835505	Mar 15, 2033	DP			
ESOMEPRAZOLE MAGNESIUM - NEXIUM							
N 021153	001	6428810	Nov 03, 2019	DP		U-469	
		6428810	Nov 03, 2019	DP		U-729	
		6428810	Nov 03, 2019	DP		U-770	
ESOMEPRAZOLE MAGNESIUM - NEXIUM							
N 021153	002	6428810	Nov 03, 2019	DP		U-469	
		6428810	Nov 03, 2019	DP		U-729	
		6428810	Nov 03, 2019	DP		U-770	
ESOMEPRAZOLE MAGNESIUM - NEXIUM							
N 021957	001	6428810	Nov 03, 2019	DP		U-1207	
		6428810	Nov 03, 2019	DP		U-729	
		6428810	Nov 03, 2019	DP		U-773	
ESOMEPRAZOLE MAGNESIUM - NEXIUM							
N 021957	002	6428810	Nov 03, 2019	DP		U-1207	
		6428810	Nov 03, 2019	DP		U-729	
		6428810	Nov 03, 2019	DP		U-773	
ESOMEPRAZOLE MAGNESIUM - NEXIUM							
N 021957	003	6428810	Nov 03, 2019	DP		U-1207	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESOMEPRAZOLE MAGNESIUM - NEXIUM							
N 021957	004	6428810	Nov 03, 2019	DP U-1207			
ESOMEPRAZOLE MAGNESIUM - NEXIUM							
N 022101	001	6428810	Nov 03, 2019	DP U-858			
ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR							
N 204655	001	6428810	Nov 03, 2019	DP U-1509			
		6428810	Nov 03, 2019	DP U-1874			
		6428810*PED	May 03, 2020				
ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR							
N 207920	001	6428810	Nov 03, 2019	DP U-1785			
		6428810*PED	May 03, 2020				
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO							
N 022511	001	6926907	Feb 28, 2023	DP U-1052		NPP	Jul 06, 2020
		8557285	May 31, 2022	DP			
		8852636	May 31, 2022	DP U-1052			
		8858996	May 31, 2022	DP U-1052			
		8945621	Oct 17, 2031	U-1661			
		9161920	May 31, 2022	U-1760			
		9198888	May 31, 2022	U-1781			
		9220698	Mar 10, 2031	U-1781			
		9345695	May 31, 2022	DP			
		9393208	Sep 03, 2029	U-1781			
		9707181	May 31, 2022	DP			
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO							
N 022511	002	6926907	Feb 28, 2023	DP U-1052		NPP	Jul 06, 2020
		8557285	May 31, 2022	DP			
		8852636	May 31, 2022	DP U-1052			
		8858996	May 31, 2022	DP U-1052			
		8945621	Oct 17, 2031	U-1661			
		9161920	May 31, 2022	U-1760			
		9198888	May 31, 2022	U-1781			
		9345695	May 31, 2022	DP			
		9393208	Sep 03, 2029	U-1781			
		9707181	May 31, 2022	DP			
ESTRADIOL - VAGIFEM							
N 020908	002	7018992	Sep 17, 2022	U-1023			
ESTRADIOL - ELESTRIN							
N 021813	001	7198801	Jun 25, 2022	DP			
		7470433	Aug 03, 2021	DP			
ESTRADIOL - EVAMIST							
N 022014	001	6978945	Jul 31, 2022	DP			
ESTRADIOL - MINIVELLE							
N 203752	001	6841716	Apr 27, 2020	DP			
		8231906	Jul 04, 2030	DS DP			
		9730900	Jul 10, 2028	U-2086			
		9833419	Jul 10, 2028	DP			
ESTRADIOL - MINIVELLE							
N 203752	002	6841716	Apr 27, 2020	DP			
		8231906	Jul 04, 2030	DS DP			
		9730900	Jul 10, 2028	U-2086			
		9833419	Jul 10, 2028	DP			
ESTRADIOL - MINIVELLE							
N 203752	003	6841716	Apr 27, 2020	DP			
		8231906	Jul 04, 2030	DS DP			
		9730900	Jul 10, 2028	U-2086			
		9833419	Jul 10, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESTRADIOL - MINIVELLE							
N 203752	004	6841716	Apr 27, 2020	DP			
		8231906	Jul 04, 2030	DS DP			
		9730900	Jul 10, 2028	U-2086			
		9833419	Jul 10, 2028	DP			
ESTRADIOL - MINIVELLE							
N 203752	005	6841716	Apr 27, 2020	DP			
		8231906	Jul 04, 2030	DS DP			
		9724310	Jul 10, 2028	DS DP			
		9730900	Jul 10, 2028	DP U-2086			
		9833419	Jul 10, 2028	DP			
ESTRADIOL - IMVEXXY							
N 208564	001	9180091	Dec 20, 2033	DP U-2316		NP	May 29, 2021
		9180091	Dec 20, 2033	DP U-2317			
		9289382	Nov 21, 2032	DP			
ESTRADIOL - IMVEXXY							
N 208564	002	9180091	Dec 20, 2033	DP U-2316		NP	May 29, 2021
		9180091	Dec 20, 2033	DP U-2317			
		9289382	Nov 21, 2032	DP			
ESTRADIOL ACETATE - FEMTRACE							
N 021633	001	6962908	Dec 21, 2021	DP			
		7572779	Oct 02, 2025	U-904			
		7799771	Dec 21, 2021	DP			
ESTRADIOL ACETATE - FEMTRACE							
N 021633	002	6962908	Dec 21, 2021	DP			
		7572779	Oct 02, 2025	U-904			
		7799771	Dec 21, 2021	DP			
ESTRADIOL ACETATE - FEMTRACE							
N 021633	003	6962908	Dec 21, 2021	DP			
		7572779	Oct 02, 2025	U-904			
		7799771	Dec 21, 2021	DP			
ESTRADIOL; ESTRADIOL; NORGESTIMATE - PREFEST							
N 021040	001	6747019	Mar 20, 2020	U-311			
		7320970	Mar 30, 2020	DP U-844			
ESTRADIOL; PROGESTERONE - BIJUVA							
N 210132	001	10052386	Nov 21, 2032	DP		NP	Oct 28, 2021
		8633178	Nov 21, 2032	DP			
		8846648	Nov 21, 2032	U-2439			
		8846649	Nov 21, 2032	DP U-2439			
		8987237	Nov 21, 2032	DP			
		8993548	Nov 21, 2032	DP			
		8993549	Nov 21, 2032	DP			
		9006222	Nov 21, 2032	DP U-2439			
		9114145	Nov 21, 2032	U-2439			
		9114146	Nov 21, 2032	DP U-2439			
		9301920	Nov 21, 2032	DP U-2439			
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA							
N 021443	001	6660726	Mar 08, 2021	DS DP U-904			
		6660726	Mar 08, 2021	DS DP U-905			
		6855703	Feb 12, 2021	DS DP U-904			
		6855703	Feb 12, 2021	DS DP U-905			
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA							
N 021443	002	6660726	Mar 08, 2021	DS DP U-904			
		6660726	Mar 08, 2021	DS DP U-905			
		6855703	Feb 12, 2021	DS DP U-904			
		6855703	Feb 12, 2021	DS DP U-905			
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA							
N 021443	003	6660726	Mar 08, 2021	DS DP U-904			
		6660726	Mar 08, 2021	DS DP U-905			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA							
N 021443	003	6855703	Feb 12, 2021	DS DP U-904			
		6855703	Feb 12, 2021	DS DP U-905			
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA							
N 021443	004	6660726	Mar 08, 2021	DS DP U-904			
		6660726	Mar 08, 2021	DS DP U-905			
		6855703	Feb 12, 2021	DS DP U-904			
		6855703	Feb 12, 2021	DS DP U-905			
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA							
N 021443	005	6660726	Mar 08, 2021	DS DP U-904			
		6660726	Mar 08, 2021	DS DP U-905			
		6855703	Feb 12, 2021	DS DP U-904			
		6855703	Feb 12, 2021	DS DP U-905			
ETELCALCETIDE - PARSABIV							
N 208325	001	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
		8999932	Jul 29, 2030	DS DP U-2014			
		9278995	Jul 29, 2030	DS			
		9701712	Jul 29, 2030	DS DP U-2014			
		9820938	Jun 27, 2034	DP			
ETELCALCETIDE - PARSABIV							
N 208325	002	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
		8999932	Jul 29, 2030	DS DP U-2014			
		9278995	Jul 29, 2030	DS			
		9701712	Jul 29, 2030	DS DP U-2014			
		9820938	Jun 27, 2034	DP			
ETELCALCETIDE - PARSABIV							
N 208325	003	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
		8999932	Jul 29, 2030	DS DP U-2014			
		9278995	Jul 29, 2030	DS			
		9701712	Jul 29, 2030	DS DP U-2014			
		9820938	Jun 27, 2034	DP			
ETEPLIRSEN - EXONDYS 51							
N 206488	001	8486907	Jun 28, 2025	U-1904	Y	NCE	Sep 19, 2021
		9018368	Jun 28, 2025	DS DP		ODE-122	Sep 19, 2023
		9243245	Oct 27, 2028	DS U-2097			
		9243245	Oct 27, 2028	DS U-2098			
		9416361	May 04, 2021	DS			
		9506058	Mar 14, 2034	U-1918			
		9506058	Mar 14, 2034	U-1919			
ETEPLIRSEN - EXONDYS 51							
N 206488	002	8486907	Jun 28, 2025	U-1904	Y	NCE	Sep 19, 2021
		9018368	Jun 28, 2025	DS DP		ODE-122	Sep 19, 2023
		9243245	Oct 27, 2028	DS U-2097			
		9243245	Oct 27, 2028	DS U-2098			
		9416361	May 04, 2021	DS			
		9506058	Mar 14, 2034	U-1918			
		9506058	Mar 14, 2034	U-1919			
ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; NORGESTIMATE; NORGESTIMATE; NORGESTIMATE - ORTHO TRI-CYCLEN LO							
N 021241	001	6214815	Jun 09, 2019	U-112			
ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE							
N 021840	001	7320969	Jan 30, 2024	U-828			
		7615545	Jun 15, 2023	U-1			
		7855190	Dec 05, 2028	U-1			
		7858605	Jun 23, 2023	DP			
ETHINYL ESTRADIOL; LEVONORGESTREL - PREVEN EMERGENCY CONTRACEPTIVE KIT							
N 020946	001	6156742	Dec 05, 2020	U-374			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE							
N 022262	001	7615545	Jun 15, 2023	U-1			
		7855190	Dec 05, 2028	U-1			
		7858605	Jun 23, 2023	DP			
ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE							
N 204061	001	8415332	Mar 11, 2029	DP			
		8450299	Oct 07, 2025	U-1			
ETHINYL ESTRADIOL; LEVONORGESTREL - BALCOLTRA							
N 208612	001	6716814	Aug 16, 2021	DS DP			
ETHINYL ESTRADIOL; NORETHINDRONE - FEMCON FE							
N 021490	001	6667050	Apr 06, 2019	DP U-1			
ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
N 022573	001	6667050	Apr 06, 2019	DP U-828			
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO LOESTRIN FE							
N 022501	001	7704984	Feb 02, 2029	U-1090			
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MINASTRIN 24 FE							
N 203667	001	6667050	Apr 06, 2019	DP U-1			
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - TAYTULLA							
N 204426	001	6652880	Mar 29, 2020	DP			
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO MINASTRIN FE							
N 204654	001	6667050	Apr 06, 2019	DP U-1			
		7704984	Feb 02, 2029	U-1			
ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA							
N 209627	001					NCE	Aug 10, 2023
ETHIODIZED OIL - LIPIODOL							
N 009190	001					ODE-64	Apr 04, 2021
ETONOGESTREL - IMPLANON							
N 021529	001	9757552	Jul 28, 2030	DP U-1			
ETONOGESTREL - NEXPLANON							
N 021529	002	8722037	Sep 28, 2027	DP			
		8888745	Aug 28, 2026	DP			
		9757552	Jul 28, 2030	DP U-1			
ETRAVIRINE - INTELENCE							
N 022187	001	6878717	Nov 05, 2019	U-1016		NPP	Jul 16, 2021
		6878717	Nov 05, 2019	U-1237		PED	Jan 16, 2022
		6878717	Nov 05, 2019	U-2354			
		6878717	Nov 05, 2019	U-256			
		6878717*PED	May 05, 2020				
		7037917	Dec 13, 2020	DS DP U-1016			
		7037917	Dec 13, 2020	DS DP U-1237			
		7037917	Dec 13, 2020	DS DP U-2354			
		7037917	Dec 13, 2020	DS DP U-256			
		7037917*PED	Jun 13, 2021				
		7887845	Mar 25, 2019	DP			
		7887845*PED	Sep 25, 2019				
		8003789	Nov 01, 2019	DS DP			
		8003789*PED	May 01, 2020				
ETRAVIRINE - INTELENCE							
N 022187	002	6878717	Nov 05, 2019	U-1016		NPP	Jul 16, 2021
		6878717	Nov 05, 2019	U-1237		PED	Jan 16, 2022
		6878717	Nov 05, 2019	U-2354			
		6878717	Nov 05, 2019	U-256			
		6878717*PED	May 05, 2020				
		7037917	Dec 13, 2020	DS DP U-1016			
		7037917	Dec 13, 2020	DS DP U-1237			
		7037917	Dec 13, 2020	DS DP U-2354			
		7037917	Dec 13, 2020	DS DP U-256			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ETRAVIRINE - INTELENCE						
N 022187 002	7037917*PED	Jun 13, 2021				
	7887845	Mar 25, 2019	DP			
	7887845*PED	Sep 25, 2019				
	8003789	Nov 01, 2019	DS DP			
	8003789*PED	May 01, 2020				
ETRAVIRINE - INTELENCE						
N 022187 003	6878717	Nov 05, 2019	U-1016		NPP	Jul 16, 2021
	6878717	Nov 05, 2019	U-1237		PED	Jan 16, 2022
	6878717	Nov 05, 2019	U-2354			
	6878717	Nov 05, 2019	U-256			
	6878717*PED	May 05, 2020				
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-2354			
	7037917*PED	Jun 13, 2021				
	7887845	Mar 25, 2019	DP			
	7887845*PED	Sep 25, 2019				
	8003789	Nov 01, 2019	DS DP			
	8003789*PED	May 01, 2020				
EVEROLIMUS - ZORTRESS						
N 021560 001	5665772	Sep 09, 2019	DS DP U-1049			
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
EVEROLIMUS - ZORTRESS						
N 021560 002	5665772	Sep 09, 2019	DS DP U-1049			
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
EVEROLIMUS - ZORTRESS						
N 021560 003	5665772	Sep 09, 2019	DS DP U-1049			
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
EVEROLIMUS - AFINITOR						
N 022334 001	5665772	Sep 09, 2019	DS DP		I-724	Feb 26, 2019
	7297703	Dec 06, 2019	DP		ODE-108	Feb 26, 2023
	7741338	Dec 06, 2019	DP		ODE-24	Apr 26, 2019
	8410131	Nov 01, 2025	U-1368			
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
	9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR						
N 022334 002	5665772	Sep 09, 2019	DS DP		I-724	Feb 26, 2019
	7297703	Dec 06, 2019	DP		ODE-108	Feb 26, 2023
	7741338	Dec 06, 2019	DP		ODE-24	Apr 26, 2019
	8410131	Nov 01, 2025	U-1368			
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
	9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR						
N 022334 003	5665772	Sep 09, 2019	DS DP		I-724	Feb 26, 2019
	7297703	Dec 06, 2019	DP		ODE-108	Feb 26, 2023
	7741338	Dec 06, 2019	DP		ODE-24	Apr 26, 2019
	8410131	Nov 01, 2025	U-1368			
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EVEROLIMUS - AFINITOR						
N 022334 003	9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR						
N 022334 004	5665772	Sep 09, 2019	DS DP		I-724	Feb 26, 2019
	7297703	Dec 06, 2019	DP		ODE-108	Feb 26, 2023
	7741338	Dec 06, 2019	DP		ODE-24	Apr 26, 2019
	8410131	Nov 01, 2025	U-1368			
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
	9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR DISPERZ						
N 203985 001	5665772	Sep 09, 2019	DS DP		I-773	Apr 10, 2021
	7297703	Dec 06, 2019	DP		ODE-169	Apr 10, 2025
	8617598	Sep 27, 2022	DP			
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022	U-1541			
	8778962	Feb 18, 2022	U-2280			
	8778962*PED	Aug 18, 2022				
EVEROLIMUS - AFINITOR DISPERZ						
N 203985 002	5665772	Sep 09, 2019	DS DP		I-773	Apr 10, 2021
	7297703	Dec 06, 2019	DP		ODE-169	Apr 10, 2025
	8617598	Sep 27, 2022	DP			
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022	U-1541			
	8778962	Feb 18, 2022	U-2280			
	8778962*PED	Aug 18, 2022				
EVEROLIMUS - AFINITOR DISPERZ						
N 203985 003	5665772	Sep 09, 2019	DS DP		I-773	Apr 10, 2021
	7297703	Dec 06, 2019	DP		ODE-169	Apr 10, 2025
	8617598	Sep 27, 2022	DP			
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022	U-1541			
	8778962	Feb 18, 2022	U-2280			
	8778962*PED	Aug 18, 2022				
EXENATIDE - BYDUREON BCISE						
N 209210 001	6479065	Aug 10, 2020	DP		NP	Oct 20, 2020
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6872700	Jan 14, 2020	U-654			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	8329648	Aug 18, 2026	U-1313			
	8329648	Aug 18, 2026	U-2154			
	8329648	Aug 18, 2026	U-2155			
	8329648	Aug 18, 2026	U-2156			
	8431685	Apr 13, 2025	DP U-412			
	8461105	Apr 13, 2025	DP U-412			
	8895033	Oct 04, 2030	DP U-1313			
	8895033	Oct 04, 2030	DP U-2157			
	8895033	Oct 04, 2030	DP U-2158			
	8906851	Aug 18, 2026	U-1313			
	9238076	Apr 15, 2024	DP U-412			
	9884092	Aug 18, 2026	U-1313			
	9884092	Aug 18, 2026	U-2154			
	9884092	Aug 18, 2026	U-2155			
	9884092	Aug 18, 2026	U-2156			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EXENATIDE SYNTHETIC - BYETTA							
N 021773	001	6872700	Jan 14, 2020	U-654			
		6902744	Jan 14, 2020	DP			
EXENATIDE SYNTHETIC - BYETTA							
N 021773	002	6872700	Jan 14, 2020	U-654			
		6902744	Jan 14, 2020	DP			
EXENATIDE SYNTHETIC - BYDUREON							
N 022200	001	6414126	Oct 04, 2020	DS DP U-2139		M-212	Oct 20, 2020
		6414126	Oct 04, 2020	DS DP U-493		M-224	Apr 02, 2021
		6479065	Aug 10, 2020	DP			
		6495164	May 25, 2020	DP			
		6515117	Oct 04, 2020	DS DP U-2139			
		6515117	Oct 04, 2020	DS DP U-493			
		6667061	May 25, 2020	DP			
		6824822	Oct 09, 2022	DP			
		6872700	Jan 14, 2020	U-2288			
		6872700	Jan 14, 2020	U-654			
		6936590	Oct 04, 2020	U-493			
		7223440	Aug 31, 2021	DP			
		7456254	Jun 30, 2025	DP U-1223			
		7563871	Apr 15, 2024	DP			
		7612176	Apr 13, 2025	DP U-1223			
		7851502	Aug 19, 2028	DP			
		7919598	Dec 16, 2029	DS			
		8221786	Mar 21, 2028	DP			
		8329648	Aug 18, 2026	U-1313			
		8361972	Mar 21, 2028	U-2139			
		8361972	Mar 21, 2028	U-493			
		8431685	Apr 13, 2025	DP U-412			
		8461105	Apr 13, 2025	DP U-412			
		8501698	Jun 20, 2027	DP U-493			
		8685934	May 26, 2030	U-1522			
		8716251	Mar 21, 2028	DP			
		8906851	Aug 18, 2026	U-1313			
		9198925	Oct 04, 2020	U-2139			
		9198925	Oct 04, 2020	U-493			
		9238076	Apr 15, 2024	DP U-412			
		9884092	Aug 18, 2026	U-1313			
		9884092	Aug 18, 2026	U-2154			
		9884092	Aug 18, 2026	U-2155			
		9884092	Aug 18, 2026	U-2156			
EXENATIDE SYNTHETIC - BYDUREON PEN							
N 022200	002	6414126	Oct 04, 2020	DS DP U-2139		M-224	Apr 02, 2021
		6414126	Oct 04, 2020	DS DP U-493			
		6479065	Aug 10, 2020	DP			
		6495164	May 25, 2020	DP			
		6515117	Oct 04, 2020	DS DP U-2139			
		6515117	Oct 04, 2020	DS DP U-493			
		6667061	May 25, 2020	DP			
		6824822	Oct 09, 2022	DP			
		6872700	Jan 14, 2020	U-2288			
		6872700	Jan 14, 2020	U-654			
		6936590	Oct 04, 2020	U-493			
		7223440	Aug 31, 2021	DP			
		7456254	Jun 30, 2025	DP U-1223			
		7563871	Apr 15, 2024	DP			
		7612176	Apr 13, 2025	DP U-1223			
		7851502	Aug 19, 2028	DP			
		7919598	Dec 16, 2029	DS			
		8216180	Jan 12, 2028	DP			
		8221786	Mar 21, 2028	DP			
		8329648	Aug 18, 2026	U-1313			
		8361972	Mar 21, 2028	U-2139			
		8361972	Mar 21, 2028	U-493			
		8431685	Apr 13, 2025	DP U-412			
		8439864	Mar 25, 2028	DP			
		8461105	Apr 13, 2025	DP U-412			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EXENATIDE SYNTHETIC - BYDUREON PEN							
N 022200	002	8501698	Jun 20, 2027	DP U-493			
		8685934	May 26, 2030	U-1522			
		8690837	May 19, 2029	DP			
		8716251	Mar 21, 2028	DP			
		8721615	Jan 18, 2030	DP			
		8758292	Nov 12, 2027	DP			
		8827963	Feb 04, 2029	DP			
		8906851	Aug 18, 2026	U-1313			
		8998876	Jan 07, 2030	DP			
		9198925	Oct 04, 2020	U-2139			
		9198925	Oct 04, 2020	U-493			
		9238076	Apr 15, 2024	DP U-412			
		9320853	Mar 25, 2028	DP			
		9884092	Aug 18, 2026	U-1313			
		9884092	Aug 18, 2026	U-2154			
		9884092	Aug 18, 2026	U-2155			
		9884092	Aug 18, 2026	U-2156			
EZETIMIBE - ZETIA							
N 021445	001	7030106	Jan 25, 2022	DP			
		7612058	Oct 30, 2025	U-1027			
		7612058	Oct 30, 2025	U-1173			
		7612058*PED	Apr 30, 2026				
FAMOTIDINE - PEPCID AC							
N 020801	002	6814978	Aug 26, 2021	DP			
FAMOTIDINE; IBUPROFEN - DUEXIS							
N 022519	001	8067033	Jul 18, 2026	DP			
		8067451	Jul 18, 2026	DP U-1196			
		8309127	Jul 18, 2026	DP			
		8318202	Jul 18, 2026	DP			
		8449910	Jul 18, 2026	DP			
		8501228	Jul 18, 2026	U-1196			
FEBUXOSTAT - ULORIC							
N 021856	001	5614520	Mar 25, 2019	DS DP U-954		M-205	Aug 15, 2020
		6225474	Jun 18, 2019	DS			
		7361676	Mar 08, 2024	DP			
		8372872	Sep 08, 2031	U-1346			
		9107912	Sep 08, 2031	U-1346			
FEBUXOSTAT - ULORIC							
N 021856	002	5614520	Mar 25, 2019	DS DP U-954		M-205	Aug 15, 2020
		6225474	Jun 18, 2019	DS			
		7361676	Mar 08, 2024	DP			
		8372872	Sep 08, 2031	U-1346			
		9107912	Sep 08, 2031	U-1346			
FENOFIBRATE - TRIGLIDE							
N 021350	001	6696084	Sep 11, 2021	DS DP U-680			
FENOFIBRATE - TRIGLIDE							
N 021350	002	6696084	Sep 11, 2021	DS DP U-680			
FENOFIBRATE - TRICOR							
N 021656	001	6375986	Sep 21, 2020	DP U-615			
		7276249	Feb 21, 2023	DP			
		7320802	Feb 21, 2023	U-847			
FENOFIBRATE - TRICOR							
N 021656	002	6375986	Sep 21, 2020	DP U-615			
		7276249	Feb 21, 2023	DP			
		7320802	Feb 21, 2023	U-847			
FENOFIBRATE - ANTARA (MICRONIZED)							
N 021695	001	7101574	Aug 20, 2020	DS DP			
		7863331	Aug 08, 2020	U-1106			
		7863331	Aug 08, 2020	U-1107			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENOFIBRATE - ANTARA (MICRONIZED)						
N 021695 001	7101574	Aug 20, 2020	DS DP			
	7863331	Aug 08, 2020	U-1106			
	7863331	Aug 08, 2020	U-1107			
FENOFIBRATE - ANTARA (MICRONIZED)						
N 021695 003	7101574	Aug 20, 2020	DS DP			
	7863331	Aug 08, 2020	U-1106			
	7863331	Aug 08, 2020	U-1107			
FENOFIBRATE - ANTARA (MICRONIZED)						
N 021695 004	8026281	Apr 22, 2025	U-1447			
	8026281	Apr 22, 2025	U-1448			
FENOFIBRATE - ANTARA (MICRONIZED)						
N 021695 005	8026281	Apr 22, 2025	U-1447			
	8026281	Apr 22, 2025	U-1448			
	9314447	May 31, 2033	DP U-1447			
	9314447	May 31, 2033	DP U-1448			
FENOFIBRATE - FENOGLIDE						
N 022118 001	7658944	Dec 09, 2024	DP			
	8124125	Oct 01, 2024	DP U-1234			
	8481078	Oct 01, 2024	DP U-1416			
	9173847	Oct 01, 2024	DP			
FENOFIBRATE - FENOGLIDE						
N 022118 002	7658944	Dec 09, 2024	DP			
	8124125	Oct 01, 2024	DP U-1234			
	8481078	Oct 01, 2024	DP U-1416			
	9173847	Oct 01, 2024	DP			
FENOFIBRIC ACID - FIBRICOR						
N 022418 001	7569612	Aug 20, 2027	U-1000			
	7741373	Aug 20, 2027	U-1059			
	7741374	Aug 20, 2027	U-1060			
	7741374	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1000			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1061			
FENOFIBRIC ACID - FIBRICOR						
N 022418 002	7569612	Aug 20, 2027	U-1000			
	7741373	Aug 20, 2027	U-1059			
	7741374	Aug 20, 2027	U-1060			
	7741374	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1000			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1061			
FENTANYL - SUBSYS						
N 202788 001	10016403	Jan 25, 2027	DP			
	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS						
N 202788 002	10016403	Jan 25, 2027	DP			
	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENTANYL - SUBSYS							
N 202788	002	10016403	Jan 25, 2027	DP			
		8486972	Apr 27, 2030	DP			
		8486973	Apr 27, 2030	U-55			
		8835460	Jan 25, 2027	DP U-55			
		9241935	Jan 25, 2027	DP			
		9289387	Jan 25, 2027	DP U-55			
		9642797	Jan 25, 2027	DP U-55			
		9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS							
N 202788	003	10016403	Jan 25, 2027	DP			
		8486972	Apr 27, 2030	DP			
		8486973	Apr 27, 2030	U-55			
		8835459	Jan 25, 2027	DP			
		8835460	Jan 25, 2027	DP U-55			
		9241935	Jan 25, 2027	DP			
		9289387	Jan 25, 2027	DP U-55			
		9642797	Jan 25, 2027	DP U-55			
		9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS							
N 202788	004	10016403	Jan 25, 2027	DP			
		8486972	Apr 27, 2030	DP			
		8486973	Apr 27, 2030	U-55			
		8835459	Jan 25, 2027	DP			
		8835460	Jan 25, 2027	DP U-55			
		9241935	Jan 25, 2027	DP			
		9289387	Jan 25, 2027	DP U-55			
		9642797	Jan 25, 2027	DP U-55			
		9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS							
N 202788	005	10016403	Jan 25, 2027	DP			
		8486972	Apr 27, 2030	DP			
		8486973	Apr 27, 2030	U-55			
		8835460	Jan 25, 2027	DP U-55			
		9241935	Jan 25, 2027	DP			
		9289387	Jan 25, 2027	DP U-55			
		9642797	Jan 25, 2027	DP U-55			
		9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS							
N 202788	006	10016403	Jan 25, 2027	DP			
		8486972	Apr 27, 2030	DP			
		8486973	Apr 27, 2030	U-55			
		8835459	Jan 25, 2027	DP			
		8835460	Jan 25, 2027	DP U-55			
		9241935	Jan 25, 2027	DP			
		9289387	Jan 25, 2027	DP U-55			
		9642797	Jan 25, 2027	DP U-55			
		9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS							
N 202788	007	10016403	Jan 25, 2027	DP			
		8486972	Apr 27, 2030	DP			
		8486973	Apr 27, 2030	U-55			
		8835459	Jan 25, 2027	DP			
		8835460	Jan 25, 2027	DP U-55			
		9241935	Jan 25, 2027	DP			
		9289387	Jan 25, 2027	DP U-55			
		9642797	Jan 25, 2027	DP U-55			
		9642844	Jan 25, 2027	DP			
FENTANYL CITRATE - FENTORA							
N 021947	001	6200604	Mar 26, 2019	U-767			
		6974590	Mar 26, 2019	U-767			
		7862832	Jun 15, 2028	DP			
		7862833	Jun 15, 2028	DP			
		8092832	Dec 30, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENTANYL CITRATE - FENTORA						
N 021947 001	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
FENTANYL CITRATE - FENTORA						
N 021947 002	6200604	Mar 26, 2019	U-767			
	6974590	Mar 26, 2019	U-767			
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
FENTANYL CITRATE - FENTORA						
N 021947 003	6200604	Mar 26, 2019	U-767			
	6974590	Mar 26, 2019	U-767			
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
FENTANYL CITRATE - FENTORA						
N 021947 004	6200604	Mar 26, 2019	U-767			
	6974590	Mar 26, 2019	U-767			
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
FENTANYL CITRATE - FENTORA						
N 021947 005	6200604	Mar 26, 2019	U-767			
	6974590	Mar 26, 2019	U-767			
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
FENTANYL CITRATE - FENTORA						
N 021947 006	6200604	Mar 26, 2019	U-767			
	6974590	Mar 26, 2019	U-767			
FENTANYL CITRATE - ONSOLIS						
N 022266 001	7579019	Jan 22, 2020	U-767			
	9597288	Jul 23, 2027	DP U-767			
FENTANYL CITRATE - ONSOLIS						
N 022266 002	7579019	Jan 22, 2020	U-767			
	9597288	Jul 23, 2027	DP U-767			
FENTANYL CITRATE - ONSOLIS						
N 022266 003	7579019	Jan 22, 2020	U-767			
	9597288	Jul 23, 2027	DP U-767			
FENTANYL CITRATE - ONSOLIS						
N 022266 004	7579019	Jan 22, 2020	U-767			
	9597288	Jul 23, 2027	DP U-767			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENTANYL CITRATE - ONSOLIS							
N 022266	005	7579019	Jan 22, 2020	U-767			
		9597288	Jul 23, 2027	DP U-767			
FENTANYL CITRATE - ABSTRAL							
N 022510	001	6759059	Sep 24, 2019	DP U-767			
		6761910	Sep 24, 2019	DP U-767			
		7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL							
N 022510	002	6759059	Sep 24, 2019	DP U-767			
		6761910	Sep 24, 2019	DP U-767			
		7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL							
N 022510	003	6759059	Sep 24, 2019	DP U-767			
		6761910	Sep 24, 2019	DP U-767			
		7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL							
N 022510	004	6759059	Sep 24, 2019	DP U-767			
		6761910	Sep 24, 2019	DP U-767			
		7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL							
N 022510	005	6759059	Sep 24, 2019	DP U-767			
		6761910	Sep 24, 2019	DP U-767			
		7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL							
N 022510	006	6759059	Sep 24, 2019	DP U-767			
		6761910	Sep 24, 2019	DP U-767			
		7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - LAZANDA							
N 022569	001	8216604	Oct 03, 2024	U-767			
		8889176	Jan 16, 2024	U-767			
		9078814	Jan 08, 2024	DP			
		9731869	Jan 26, 2032	DP			
		9814705	Jan 08, 2024	DP			
FENTANYL CITRATE - LAZANDA							
N 022569	002	8216604	Oct 03, 2024	U-767			
		8889176	Jan 16, 2024	U-767			
		9078814	Jan 08, 2024	DP			
		9731869	Jan 26, 2032	DP			
		9814705	Jan 08, 2024	DP			
FENTANYL CITRATE - LAZANDA							
N 022569	003	9731869	Jan 26, 2032	DP			
		9814705	Jan 08, 2024	DP			
FENTANYL HYDROCHLORIDE - IONSYS							
N 021338	001	6181963	Nov 02, 2019	DP			
		6195582	Jan 28, 2019	DP U-736			
		6881208	Apr 19, 2022	U-736			
		6975902	Apr 01, 2024	DP			
		8301238	Sep 30, 2031	DP			
		8428708	May 21, 2032	U-736			
		8428709	Jun 11, 2032	DP U-736			
		8781571	Mar 31, 2032	DP U-736			
		9095706	Feb 03, 2033	DP			
		9364656	Sep 30, 2031	U-736			
		9731121	Oct 17, 2031	DP			
FERRIC CARBOXYMALTOSE - INJECTAFER							
N 203565	001	7612109	Feb 05, 2024	DS DP			
		7754702	Feb 13, 2027	DP U-1432			
		8895612	Jan 08, 2027	DP U-1620			
		9376505	Oct 20, 2023	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FERRIC CITRATE - AURYXIA							
N 205874	001	5753706	Feb 03, 2019	DP U-1577			
		7767851	Feb 18, 2024	DS DP			
		8093423	Apr 21, 2026	U-1577			
		8299298	Feb 18, 2024	DP			
		8338642	Feb 18, 2024	DS DP U-1577			
		8609896	Feb 18, 2024	DP			
		8754257	Feb 18, 2024	DP			
		8754258	Feb 18, 2024	DP			
		8846976	Feb 18, 2024	U-1577			
		8901349	Feb 18, 2024	U-1577			
		9050316	Feb 18, 2024	U-1577			
		9328133	Feb 18, 2024	DS DP U-1577			
		9387191	Jul 21, 2030	DP			
		9757416	Feb 18, 2024	DS DP U-1577			
FERRIC PYROPHOSPHATE CITRATE - TRIFERIC							
N 206317	001	7816404	Apr 17, 2029	DP U-1656			
FERUMOXYTOL - FERAHEME							
N 022180	001	6599498	Jun 30, 2023	DS DP		I-767	Feb 02, 2021
		7553479	Mar 08, 2020	DS DP			
		7871597	Mar 08, 2020	DS DP			
		8501158	Mar 08, 2020	U-1422			
		8591864	Mar 08, 2020	DP			
		8926947	Mar 08, 2020	DS DP			
FESOTERODINE FUMARATE - TOVIAZ							
N 022030	001	6858650	Jul 03, 2022	DS U-913			
		7384980	May 11, 2019	DS DP U-913			
		7807715	Jun 07, 2027	DP U-913			
		7855230	May 11, 2019	U-913			
		7985772	May 11, 2019	DS DP U-913			
		8088398	Jun 07, 2027	DP U-913			
		8338478	May 11, 2019	DS DP U-913			
		8501723	Jun 07, 2027	DP			
FESOTERODINE FUMARATE - TOVIAZ							
N 022030	002	6858650	Jul 03, 2022	DS U-913			
		7384980	May 11, 2019	DS DP U-913			
		7807715	Jun 07, 2027	DP U-913			
		7855230	May 11, 2019	U-913			
		7985772	May 11, 2019	DS DP U-913			
		8088398	Jun 07, 2027	DP U-913			
		8338478	May 11, 2019	DS DP U-913			
		8501723	Jun 07, 2027	DP			
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY							
N 021909	002	6723348	Nov 26, 2021	DP U-1466			
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES							
N 021909	003	6723348	Nov 26, 2021	DP			
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY							
N 201373	001	8933097	Aug 16, 2032	DP			
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES							
N 201373	002	8933097	Aug 16, 2032	DP			
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION							
N 021704	002	6613357	Dec 25, 2020	DP U-1159			
FIDAXOMICIN - DIFICID							
N 201699	001	7378508	Jul 31, 2027	DS DP			
		7863249	Jul 31, 2027	DS DP			
		7906489	Mar 04, 2027	U-319			
		8586551	Jul 15, 2023	DS DP			
		8859510	Jul 31, 2027	U-319			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FINAFLOXACIN - XTORO							
N 206307	001	8536167	Aug 08, 2031	U-1679		NCE	Dec 17, 2019
		9119859	Jul 02, 2030	U-1679		PED	Jun 17, 2020
		9504691	Nov 21, 2033	DP U-1679			
FINGOLIMOD HYDROCHLORIDE - GILENYA							
N 022527	001	5604229	Feb 18, 2019	DS U-1086		NPP	May 11, 2021
		5604229*PED	Aug 18, 2019			PED	Nov 11, 2021
		8324283	Mar 29, 2026	DP			
		8324283*PED	Sep 29, 2026				
		9187405	Jun 25, 2027	U-1086			
		9187405*PED	Dec 25, 2027				
FINGOLIMOD HYDROCHLORIDE - GILENYA							
N 022527	002	5604229	Feb 18, 2019	DS U-1086		NS	May 11, 2021
		5604229*PED	Aug 18, 2019			PED	Nov 11, 2021
		9592208	Mar 30, 2032	DP U-2315			
		9592208*PED	Sep 30, 2032				
FISH OIL TRIGLYCERIDES - OMEGAVEN							
N 210589	001	9566260	Nov 12, 2023	DP U-2366		NCE	Jul 27, 2023
		9629821	Nov 12, 2023	DP U-2367		ODE-202	Jul 27, 2025
FISH OIL TRIGLYCERIDES - OMEGAVEN							
N 210589	002	9566260	Nov 12, 2023	DP U-2366		NCE	Jul 27, 2023
		9629821	Nov 12, 2023	DP U-2367		ODE-202	Jul 27, 2025
FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%							
N 207648	001					NCE	Jul 13, 2021
FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%							
N 207648	002					NCE	Jul 13, 2021
FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%							
N 207648	003					NCE	Jul 13, 2021
FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%							
N 207648	004					NCE	Jul 13, 2021
FLIBANSERIN - ADDYI							
N 022526	001	7151103	May 09, 2023	U-1734		NCE	Aug 18, 2020
		7420057	Aug 01, 2022	DS DP			
		8227471	May 09, 2023	U-1734			
		9468639	Oct 16, 2022	U-1734			
FLORBETABEN F-18 - NEURACEQ							
N 204677	001	7807135	Mar 18, 2029	DS DP U-1497		NCE	Mar 21, 2019
FLORBETAPIR F-18 - AMYVID							
N 202008	001	7687052	Apr 30, 2027	DS DP			
		8506929	Apr 30, 2027	DS DP U-1423			
FLORBETAPIR F-18 - AMYVID							
N 202008	002	7687052	Apr 30, 2027	DS DP			
		8506929	Apr 30, 2027	DS DP U-1423			
FLORBETAPIR F-18 - AMYVID							
N 202008	003	7687052	Apr 30, 2027	DS DP			
		8506929	Apr 30, 2027	DS DP U-1423			
FLUCICLOVINE F-18 - AXUMIN							
N 208054	001	10010632	Nov 28, 2026	DP		NCE	May 27, 2021
		10124079	Dec 30, 2035	U-2450			
		5808146	Nov 09, 2020	DS			
		9387266	Nov 28, 2026	U-1879			
FLUDARABINE PHOSPHATE - OFORTA							
N 022273	001	7148207	Dec 20, 2022	DP U-944			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUOCINOLONE ACETONIDE - RETISERT								
N 021737	001	6217895	Mar 22, 2019		DP U-708			
		6548078	Mar 22, 2019		DP U-708			
FLUOCINOLONE ACETONIDE - ILUVIEN								
N 201923	001	6217895	Mar 22, 2019		DP U-1597			
		6375972	Apr 26, 2020		DP U-1597			
		6548078	Mar 22, 2019		DP U-1597			
		8252307	Jun 27, 2019		DP			
		8871241	Aug 12, 2027		DP			
FLUOCINOLONE ACETONIDE - YUTIQ								
N 210331	001	6217895	Mar 22, 2019		DP U-708		NP	Nov 12, 2021
		6375972	Apr 26, 2020		DP U-708			
		6548078	Mar 22, 2019		DP U-708			
		8252307	Jun 27, 2019		DP			
		8574613	Apr 26, 2020		DP			
		8574659	Apr 26, 2020		DP			
		8871241	Aug 12, 2027		DP			
		9192579	Apr 26, 2020		DP			
		9849085	Apr 26, 2020		U-708			
FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA								
N 021112	001	7915243	Sep 08, 2023		DP			
		7939516	Sep 08, 2023		DP			
		8247395	Oct 25, 2022		DP			
		8653053	Oct 25, 2022		DP			
FLUOCINONIDE - VANOS								
N 021758	001	6765001	Dec 21, 2021		DP			
		7220424	Jan 07, 2023		U-861			
		7794738	Sep 11, 2022		U-1084			
		8232264	Mar 09, 2023		DP			
FLUOROURACIL - CARAC								
N 020985	001	6670335	Jun 02, 2021		DP U-68			
FLUOROURACIL - TOLAK								
N 022259	001	7169401	Jul 18, 2023		DP			
FLUTEMETAMOL F-18 - VIZAMYL								
N 203137	001	7270800	Sep 03, 2025	DS	DP U-336			
		7351401	Jan 24, 2023	DS	DP U-336			
		8236282	May 21, 2024	DS	DP			
		8691185	Jan 24, 2023		U-336			
		8916131	Sep 16, 2028		DP			
FLUTEMETAMOL F-18 - VIZAMYL								
N 203137	002	7270800	Sep 03, 2025	DS	DP U-336			
		7351401	Jan 24, 2023	DS	DP U-336			
		8236282	May 21, 2024	DS	DP			
		8691185	Jan 24, 2023		U-336			
		8916131	Sep 16, 2028		DP			
FLUTICASONE FUROATE - FLONASE SENSIMIST ALLERGY RELIEF								
N 022051	002	6858596	Aug 03, 2021		DP U-1890			
		7101866	Aug 03, 2021	DS	DP U-1890			
		7541350	Aug 03, 2021		DP U-1890			
		8062264	Apr 05, 2026		DP			
		8147461	Oct 15, 2028		DP			
		8347879	Jul 15, 2028		DP			
		8752543	Apr 05, 2026		DP			
		9320862	Nov 06, 2024		DP			
FLUTICASONE FUROATE - ARNUITY ELLIPTA								
N 205625	001	7101866	Aug 03, 2021	DS	DP U-1559		NPP	May 17, 2021
		7629335	Aug 03, 2021		DP			
		8113199	Oct 23, 2027		DP			
		8161968	Feb 05, 2028		DP			
		8201556	Feb 05, 2029		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE FUROATE - ARNUITY ELLIPTA							
N 205625	001	8534281	Mar 08, 2030	DP			
		8746242	Oct 11, 2030	DP			
		9333310	Oct 02, 2027	DP			
FLUTICASONE FUROATE - ARNUITY ELLIPTA							
N 205625	002	7101866	Aug 03, 2021	DS DP U-1559			
		7629335	Aug 03, 2021	DP			
		8113199	Oct 23, 2027	DP			
		8161968	Feb 05, 2028	DP			
		8201556	Feb 05, 2029	DP			
		8534281	Mar 08, 2030	DP			
		8746242	Oct 11, 2030	DP			
		9333310	Oct 02, 2027	DP			
FLUTICASONE FUROATE - ARNUITY ELLIPTA							
N 205625	003	7101866	Aug 03, 2021	DS DP U-2349		NS	May 17, 2021
		7629335	Aug 03, 2021	DP			
		8113199	Oct 23, 2027	DP			
		8161968	Feb 05, 2028	DP			
		8201556	Feb 05, 2029	DP			
		8534281	Mar 08, 2030	DP			
		8746242	Oct 11, 2030	DP			
		9333310	Oct 02, 2027	DP			
FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA							
N 209482	001	6537983	Aug 03, 2021	DP U-2125		I-775	Apr 24, 2021
		6759398	Aug 03, 2021	DP U-2125			
		6878698	Aug 03, 2021	U-2134			
		7101866	Aug 03, 2021	DS DP U-2126			
		7439393	May 21, 2025	DS DP U-2127			
		7488827	Dec 18, 2027	DS DP			
		7498440	Apr 27, 2025	DS DP			
		7629335	Aug 03, 2021	DP			
		7776895	Sep 11, 2022	DP			
		8113199	Oct 23, 2027	DP			
		8161968	Feb 05, 2028	DP			
		8183257	Jul 27, 2025	U-2128			
		8309572	Apr 27, 2025	U-2129			
		8511304	Jun 14, 2027	DP			
		8534281	Mar 08, 2030	DP			
		8746242	Oct 11, 2030	DP			
		9333310	Oct 02, 2027	DP			
		9750726	Nov 29, 2030	DP			
		RE44874	Mar 23, 2023	DS DP U-2127			
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA							
N 204275	001	6537983	Aug 03, 2021	DP U-1401		M-202	May 15, 2020
		6537983	Aug 03, 2021	DP U-1691			
		6759398	Aug 03, 2021	DP U-1401			
		6759398	Aug 03, 2021	DP U-1691			
		6878698	Aug 03, 2021	U-1401			
		7101866	Aug 03, 2021	DS DP U-1401			
		7101866	Aug 03, 2021	DS DP U-1691			
		7439393	May 21, 2025	DS DP U-1401			
		7439393	May 21, 2025	DS DP U-1691			
		7439393	May 21, 2025	DS DP U-2099			
		7439393	May 21, 2025	DS DP U-2100			
		7629335	Aug 03, 2021	DP			
		7776895	Sep 11, 2022	DP			
		8113199	Oct 23, 2027	DP			
		8161968	Feb 05, 2028	DP			
		8511304	Jun 14, 2027	DP U-1424			
		8511304	Jun 14, 2027	DP U-1691			
		8534281	Mar 08, 2030	DP			
		8746242	Oct 11, 2030	DP			
		9333310	Oct 02, 2027	DP			
		RE44874	Mar 23, 2023	DS DP U-1548			
		RE44874	Mar 23, 2023	DS DP U-1691			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA								
N 204275	002	6537983	Aug 03, 2021		DP U-1691		M-202	May 15, 2020
		6759398	Aug 03, 2021		DP U-1691			
		7101866	Aug 03, 2021	DS	DP U-1691			
		7439393	May 21, 2025	DS	DP U-1691			
		7439393	May 21, 2025	DS	DP U-2099			
		7439393	May 21, 2025	DS	DP U-2100			
		7629335	Aug 03, 2021		DP			
		7776895	Sep 11, 2022		DP			
		8113199	Oct 23, 2027		DP			
		8161968	Feb 05, 2028		DP			
		8511304	Jun 14, 2027		DP U-1691			
		8534281	Mar 08, 2030		DP			
		8746242	Oct 11, 2030		DP			
		9333310	Oct 02, 2027		DP			
		RE44874	Mar 23, 2023	DS	DP U-1691			
FLUTICASONE PROPIONATE - CUTIVATE								
N 021152	001	7300669	Oct 20, 2019		DP U-835			
FLUTICASONE PROPIONATE - FLOVENT HFA								
N 021433	001	7500444	Feb 26, 2026		DP			
		7500444*PED	Aug 26, 2026					
		7832351	Jun 19, 2023		DP			
		9861771	Oct 11, 2020		DP			
FLUTICASONE PROPIONATE - FLOVENT HFA								
N 021433	002	6743413	Jun 01, 2021		U-581	Y		
		7500444	Feb 26, 2026		DP			
		7500444*PED	Aug 26, 2026					
		7832351	Jun 19, 2023		DP			
		9861771	Oct 11, 2020		DP			
FLUTICASONE PROPIONATE - FLOVENT HFA								
N 021433	003	7500444	Feb 26, 2026		DP			
		7500444*PED	Aug 26, 2026					
		7832351	Jun 19, 2023		DP			
		9861771	Oct 11, 2020		DP			
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK								
N 208798	001	10022510	May 18, 2031		DP		NP	Jan 27, 2020
		10124131	May 18, 2031		DP			
		6701917	Jun 23, 2021		DP			
		6718972	Jun 23, 2021		DP			
		6748947	Jun 23, 2021		DP			
		6871646	Jun 23, 2021		DP			
		7540282	May 06, 2023		DP			
		8006690	Jun 23, 2021		DP			
		8651103	Mar 26, 2028		DP			
		8714149	Feb 25, 2032		DP			
		8978966	Jan 13, 2032		DP			
		9216260	Jun 28, 2031		DP			
		9463288	May 19, 2025		DP			
		9616024	Sep 01, 2024		DP			
		9731087	May 18, 2031		DP			
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK								
N 208798	002	10022510	May 18, 2031		DP		NP	Jan 27, 2020
		10124131	May 18, 2031		DP			
		6701917	Jun 23, 2021		DP			
		6718972	Jun 23, 2021		DP			
		6748947	Jun 23, 2021		DP			
		6871646	Jun 23, 2021		DP			
		7540282	May 06, 2023		DP			
		8006690	Jun 23, 2021		DP			
		8651103	Mar 26, 2028		DP			
		8714149	Feb 25, 2032		DP			
		8978966	Jan 13, 2032		DP			
		9216260	Jun 28, 2031		DP			
		9463288	May 19, 2025		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK							
N 208798	002	9616024	Sep 01, 2024	DP			
		9731087	May 18, 2031	DP			
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK							
N 208798	003	10022510	May 18, 2031	DP		NP	Jan 27, 2020
		10124131	May 18, 2031	DP			
		6701917	Jun 23, 2021	DP			
		6718972	Jun 23, 2021	DP			
		6748947	Jun 23, 2021	DP			
		6871646	Jun 23, 2021	DP			
		7540282	May 06, 2023	DP			
		8006690	Jun 23, 2021	DP			
		8651103	Mar 26, 2028	DP			
		8714149	Feb 25, 2032	DP			
		8978966	Jan 13, 2032	DP			
		9216260	Jun 28, 2031	DP			
		9463288	May 19, 2025	DP			
		9616024	Sep 01, 2024	DP			
		9731087	May 18, 2031	DP			
FLUTICASONE PROPIONATE - XHANCE							
N 209022	001	10076614	Oct 20, 2034	DP		NP	Sep 18, 2020
		10076615	Jul 30, 2029	U-2133			
		10124132	Mar 06, 2027	DP U-2133			
		6715485	Mar 03, 2020	DP			
		7975690	Dec 29, 2025	U-2133			
		8327844	Oct 08, 2023	U-2133			
		8522778	May 11, 2022	DP			
		8550073	Oct 22, 2029	DP			
		8555878	Mar 20, 2020	DP			
		8978647	Aug 06, 2030	DP			
		9072857	Apr 10, 2021	DP			
		9468727	Jul 30, 2020	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50							
N 021077	001					M-214	Dec 20, 2020
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50							
N 021077	002					M-214	Dec 20, 2020
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50							
N 021077	003					M-214	Dec 20, 2020
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA							
N 021254	001	7500444	Feb 26, 2026	DP			
		7500444*PED	Aug 26, 2026				
		7832351	Jun 19, 2023	DP			
		9861771	Oct 11, 2020	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA							
N 021254	002	7500444	Feb 26, 2026	DP			
		7500444*PED	Aug 26, 2026				
		7832351	Jun 19, 2023	DP			
		9861771	Oct 11, 2020	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA							
N 021254	003	7500444	Feb 26, 2026	DP			
		7500444*PED	Aug 26, 2026				
		7832351	Jun 19, 2023	DP			
		9861771	Oct 11, 2020	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK							
N 208799	001	10022510	May 18, 2031	DP		NP	Jan 27, 2020
		10124131	May 18, 2031	DP			
		6701917	Jun 23, 2021	DP			
		6718972	Jun 23, 2021	DP			
		6748947	Jun 23, 2021	DP			
		6871646	Jun 23, 2021	DP			
		7540282	May 06, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK								
N 208799	001		8006690	Jun 23, 2021	DP			
			8651103	Mar 26, 2028	DP			
			8714149	Feb 25, 2032	DP			
			8978966	Jan 13, 2032	DP			
			9066957	Oct 06, 2034	DP U-645			
			9216260	Jun 28, 2031	DP			
			9415008	Oct 06, 2034	DP U-645			
			9463288	May 19, 2025	DP			
			9616024	Sep 01, 2024	DP			
			9731087	May 18, 2031	DP			
			9987229	Sep 01, 2024	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK								
N 208799	002		10022510	May 18, 2031	DP		NP	Jan 27, 2020
			10124131	May 18, 2031	DP			
			6701917	Jun 23, 2021	DP			
			6718972	Jun 23, 2021	DP			
			6748947	Jun 23, 2021	DP			
			6871646	Jun 23, 2021	DP			
			7540282	May 06, 2023	DP			
			8006690	Jun 23, 2021	DP			
			8651103	Mar 26, 2028	DP			
			8714149	Feb 25, 2032	DP			
			8978966	Jan 13, 2032	DP			
			9066957	Oct 06, 2034	DP U-645			
			9216260	Jun 28, 2031	DP			
			9463288	May 19, 2025	DP			
			9616024	Sep 01, 2024	DP			
			9731087	May 18, 2031	DP			
			9987229	Sep 01, 2024	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK								
N 208799	003		10022510	May 18, 2031	DP		NP	Jan 27, 2020
			10124131	May 18, 2031	DP			
			6701917	Jun 23, 2021	DP			
			6718972	Jun 23, 2021	DP			
			6748947	Jun 23, 2021	DP			
			6871646	Jun 23, 2021	DP			
			7540282	May 06, 2023	DP			
			8006690	Jun 23, 2021	DP			
			8651103	Mar 26, 2028	DP			
			8714149	Feb 25, 2032	DP			
			8978966	Jan 13, 2032	DP			
			9066957	Oct 06, 2034	DP U-645			
			9216260	Jun 28, 2031	DP			
			9463288	May 19, 2025	DP			
			9616024	Sep 01, 2024	DP			
			9731087	May 18, 2031	DP			
			9987229	Sep 01, 2024	DP			
FLUVASTATIN SODIUM - LESCOL XL								
N 021192	001		6242003	Apr 13, 2020				
FLUVOXAMINE MALEATE - LUVOX CR								
N 022033	001		7465462	May 10, 2020	DP U-929			
FLUVOXAMINE MALEATE - LUVOX CR								
N 022033	002		7465462	May 10, 2020	DP U-929			
FOLLITROPIN ALFA/BETA - GONAL-F								
N 020378	004		7563763	Aug 23, 2019	DP			
FOLLITROPIN ALFA/BETA - GONAL-F								
N 020378	005		7563763	Aug 23, 2019	DP			
FOLLITROPIN ALFA/BETA - FOLLISTIM AQ								
N 021211	001		7446090	Aug 23, 2019	DP			
			7563763	Aug 23, 2019	U-1183			
			7563763	Aug 23, 2019	U-1367			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FOLLITROPIN ALFA/BETA - FOLLISTIM AQ									
N 021211	001		7563763	Aug 23, 2019		U-993			
FOLLITROPIN ALFA/BETA - FOLLISTIM AQ									
N 021211	002		7446090	Aug 23, 2019		DP			
			7563763	Aug 23, 2019		U-1183			
			7563763	Aug 23, 2019		U-1367			
			7563763	Aug 23, 2019		U-993			
FOLLITROPIN ALFA/BETA - FOLLISTIM AQ									
N 021211	003		7446090	Aug 23, 2019		DP			
			7563763	Aug 23, 2019		U-1183			
			7563763	Aug 23, 2019		U-1367			
			7563763	Aug 23, 2019		U-993			
FOLLITROPIN ALFA/BETA - FOLLISTIM AQ									
N 021211	004		7446090	Aug 23, 2019		DP			
			7563763	Aug 23, 2019		U-1183			
			7563763	Aug 23, 2019		U-1367			
			7563763	Aug 23, 2019		U-993			
FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT									
N 021684	001		7446090	Aug 23, 2019		DP			
			7741268	Apr 02, 2024		DP			
FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT									
N 021684	002		7446090	Aug 23, 2019		DP			
			7741268	Apr 02, 2024		DP			
FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT									
N 021684	003		7446090	Aug 23, 2019		DP			
			7741268	Apr 02, 2024		DP			
FOMEPIZOLE - ANTIZOL									
N 020696	001		7553863	Jun 30, 2027	DS	DP			
FORMOTEROL FUMARATE - FORADIL									
N 020831	001		6488027	Mar 08, 2019					
			6887459	Nov 28, 2020		U-762			
FORMOTEROL FUMARATE - PERFOROMIST									
N 022007	001		6667344	Jun 22, 2021		DP			
			6814953	Jun 22, 2021		DP U-813			
			7348362	Jun 22, 2021		DP			
			7462645	Jun 22, 2021		DP U-813			
			8623922	Jun 22, 2021		DP			
			9730890	Jun 22, 2021		DP			
FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE									
N 208294	001		8324266	May 28, 2030		U-1841		NP	Apr 25, 2019
			8703806	May 28, 2030		U-1841			
			8808713	May 28, 2030		DP U-1841			
			8815258	Mar 17, 2031		U-1841			
			9415009	May 28, 2030		U-1841			
			9463161	May 28, 2030		DP U-1841			
FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA									
N 022518	001		7067502	May 21, 2020		DP U-1068		M-214	Dec 20, 2020
			7566705	May 21, 2020		DP U-1068			
FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA									
N 022518	002		7067502	May 21, 2020		DP U-1068		M-214	Dec 20, 2020
			7566705	May 21, 2020		DP U-1068			
FOSAMPRENAVIR CALCIUM - LEXIVA									
N 021548	001		6514953	Jul 15, 2019	DS	DP U-257			
FOSAPREPITANT DIMEGLUMINE - EMEND									
N 022023	001		5691336	Mar 04, 2019	DS	DP		NPP	Apr 03, 2021
			5691336*PED	Sep 04, 2019				PED	Oct 03, 2021

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FOSAPREPITANT DIMEGLUMINE - EMEND							
N 022023	002	5691336	Mar 04, 2019	DS DP U-2265		D-155	Feb 01, 2019
		5691336*PED	Sep 04, 2019			NPP	Apr 03, 2021
						PED	Oct 03, 2021
FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO							
N 210493	001	8426450	May 23, 2032	DS DP		NCE	Apr 19, 2023
		8895586	May 23, 2032	U-2301			
		9186357	Nov 18, 2030	U-2301			
		9403772	May 23, 2032	DS U-2301			
		9908907	May 23, 2032	DS DP			
FOSPROPOFOL DISODIUM - LUSEDRA							
N 022244	001	6204257	Jul 01, 2022	DS DP U-945			
FOSTAMATINIB DISODIUM - TAVALISSE							
N 209299	001	7449458	Sep 04, 2026	DS		NCE	Apr 17, 2023
		7538108	Mar 28, 2026	DS U-2294		ODE-174	Apr 17, 2025
		7989448	Jun 12, 2026	DS U-2294			
		8163902	Jun 17, 2026	DS U-2294			
		8211889	Jan 19, 2026	DS			
		8263122	Nov 24, 2030	DP			
		8445485	Jun 17, 2026	DP			
		8652492	Nov 06, 2028	DP			
		8771648	Jul 27, 2032	DP			
		8912170	Jun 17, 2026	U-2294			
		8951504	Jul 27, 2032	U-2294			
		9266912	Jan 19, 2026	U-2294			
		9283238	Jun 17, 2026	U-2294			
		9737554	Jan 19, 2026	DP			
FOSTAMATINIB DISODIUM - TAVALISSE							
N 209299	002	7449458	Sep 04, 2026	DS		NCE	Apr 17, 2023
		7538108	Mar 28, 2026	DS U-2294		ODE-174	Apr 17, 2025
		7989448	Jun 12, 2026	DS U-2294			
		8163902	Jun 17, 2026	DS U-2294			
		8211889	Jan 19, 2026	DS			
		8263122	Nov 24, 2030	DP			
		8445485	Jun 17, 2026	DP			
		8652492	Nov 06, 2028	DP			
		8771648	Jul 27, 2032	DP			
		8912170	Jun 17, 2026	U-2294			
		8951504	Jul 27, 2032	U-2294			
		9266912	Jan 19, 2026	U-2294			
		9283238	Jun 17, 2026	U-2294			
		9737554	Jan 19, 2026	DP			
FULVESTRANT - FASLODEX							
N 021344	001	6774122	Jan 09, 2021	U-1826		I-725	Feb 19, 2019
		6774122	Jan 09, 2021	U-2108		I-749	Aug 25, 2020
		6774122	Jan 09, 2021	U-2163			
		6774122	Jan 09, 2021	U-596			
		6774122*PED	Jul 09, 2021				
		7456160	Jan 09, 2021	U-1826			
		7456160	Jan 09, 2021	U-2108			
		7456160	Jan 09, 2021	U-2163			
		7456160	Jan 09, 2021	U-596			
		7456160*PED	Jul 09, 2021				
		8329680	Jan 09, 2021	U-1826			
		8329680	Jan 09, 2021	U-2108			
		8329680	Jan 09, 2021	U-2163			
		8329680	Jan 09, 2021	U-596			
		8329680*PED	Jul 09, 2021				
		8466139	Jan 09, 2021	U-1826			
		8466139	Jan 09, 2021	U-2108			
		8466139	Jan 09, 2021	U-2163			
		8466139	Jan 09, 2021	U-596			
		8466139*PED	Jul 09, 2021				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GABAPENTIN - NEURONTIN							
N 021129	001	7256216	May 28, 2022	DP			
GABAPENTIN - GRALISE							
N 022544	001	6488962	Jun 20, 2020	DP			
		6723340	Oct 25, 2021	DP			
		7438927	Feb 26, 2024	U-1114			
		7731989	Oct 25, 2022	DP			
		8192756	Oct 25, 2022	DP U-1114			
		8252332	Oct 25, 2022	DP U-1114			
		8333992	Oct 25, 2022	DP U-1114			
GABAPENTIN - GRALISE							
N 022544	002	6488962	Jun 20, 2020	DP			
		6723340	Oct 25, 2021	DP			
		7438927	Feb 26, 2024	U-1114			
		7731989	Oct 25, 2022	DP			
		8192756	Oct 25, 2022	DP U-1114			
		8252332	Oct 25, 2022	DP U-1114			
		8333992	Oct 25, 2022	DP U-1114			
GABAPENTIN ENACARBIL - HORIZANT							
N 022399	001	6818787	Nov 06, 2022	DS DP		ODE-25	Jun 06, 2019
		8026279	Nov 10, 2026	DS DP			
		8048917	Nov 06, 2022	DS DP U-1247			
		8114909	Apr 11, 2026	U-1231			
		8686034	Jan 24, 2025	U-1231			
		8686034	Jan 24, 2025	U-1247			
		8795725	Jun 10, 2029	DP U-1231			
		8795725	Jun 10, 2029	DP U-1247			
GABAPENTIN ENACARBIL - HORIZANT							
N 022399	002	6818787	Nov 06, 2022	DS DP		ODE-25	Jun 06, 2019
		8026279	Nov 10, 2026	DS DP			
		8048917	Nov 06, 2022	DS DP U-1247			
		8114909	Apr 11, 2026	U-1231			
		8686034	Jan 24, 2025	U-1231			
		8686034	Jan 24, 2025	U-1247			
		8795725	Jun 10, 2029	DP U-1231			
		8795725	Jun 10, 2029	DP U-1247			
GADOBUTROL - GADAVIST							
N 201277	002					I-731	Apr 27, 2019
GADOBUTROL - GADAVIST							
N 201277	006	5980864	Nov 09, 2021	DS DP U-1119			
GADOFOSVESET TRISODIUM - ABLAVAR							
N 021711	001	6676929	May 04, 2020	DP			
GADOFOSVESET TRISODIUM - ABLAVAR							
N 021711	002	6676929	May 04, 2020	DP			
GADOTERATE MEGLUMINE - DOTAREM							
N 204781	001					NPP	Aug 25, 2020
GADOTERATE MEGLUMINE - DOTAREM							
N 204781	002					NPP	Aug 25, 2020
GADOTERATE MEGLUMINE - DOTAREM							
N 204781	003					NPP	Aug 25, 2020
GADOTERATE MEGLUMINE - DOTAREM							
N 204781	004					NPP	Aug 25, 2020
GADOTERATE MEGLUMINE - DOTAREM							
N 204781	005					NPP	Aug 25, 2020

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GADOXETATE DISODIUM - EOVIST							
N 022090	001	6039931	Nov 13, 2021	U-1239			
GADOXETATE DISODIUM - EOVIST							
N 022090	002	6039931	Nov 13, 2021	U-1239			
GALANTAMINE HYDROBROMIDE - RAZADYNE ER							
N 021615	001	7160559	Dec 20, 2019	DP			
GALANTAMINE HYDROBROMIDE - RAZADYNE ER							
N 021615	002	7160559	Dec 20, 2019	DP			
GALANTAMINE HYDROBROMIDE - RAZADYNE ER							
N 021615	003	7160559	Dec 20, 2019	DP			
GALLIUM DOTATATE GA-68 - NETSPOT							
N 208547	001	9375498	Aug 10, 2032	DP		NCE	Jun 01, 2021
						ODE-120	Jun 01, 2023
GANCICLOVIR - GANCICLOVIR							
N 209347	001	9486530	Sep 02, 2034	DP			
GATIFLOXACIN - ZYMAR							
N 021493	001	6333045	Aug 20, 2019	DP	Y		
		6333045*PED	Feb 20, 2020				
GEFITINIB - IRESSA							
N 206995	001					ODE-95	Jul 13, 2022
GEMCITABINE HYDROCHLORIDE - INFUGEM							
N 208313	001	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM							
N 208313	002	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM							
N 208313	003	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM							
N 208313	004	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM							
N 208313	005	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM							
N 208313	006	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM							
N 208313	007	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM							
N 208313	008	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM							
N 208313	009	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM							
N 208313	010	9241948	Jul 01, 2033	DP			
GEMIFLOXACIN MESYLATE - FACTIVE							
N 021158	001	6262071	Sep 21, 2019	U-513			
		6331550	Sep 21, 2019	U-511			
		6340689	Sep 14, 2019	U-512			
		6455540	Sep 21, 2019	U-511			
		6803376	Sep 21, 2019	DS DP U-608			
		6803376	Sep 21, 2019	DS DP U-609			
GILTERITINIB FUMARATE - XOSPATA							
N 211349	001	8969336	Jan 27, 2031	DS DP		ODE-222	Nov 28, 2025
		9487491	Jul 28, 2030	U-2456			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GLASDEGIB - DAURISMO							
N 210656	001	8148401	Jan 30, 2031	DS DP		NCE	Nov 21, 2023
		8431597	Jun 29, 2028	DP		ODE-224	Nov 21, 2025
GLASDEGIB - DAURISMO							
N 210656	002	8148401	Jan 30, 2031	DS DP		NCE	Nov 21, 2023
		8431597	Jun 29, 2028	DP		ODE-224	Nov 21, 2025
GLATIRAMER ACETATE - COPAXONE							
N 020622	003	8232250	Aug 19, 2030	U-441			
		8399413	Aug 19, 2030	U-441			
		8969302	Aug 19, 2030	U-441			
		9155776	Aug 19, 2030	U-441			
		9402874	Aug 19, 2030	U-441			
GLECAPREVIR; PIBRENTASVIR - MAVYRET							
N 209394	001	10028937	Jun 10, 2030	U-2141		M-230	Aug 06, 2021
		10039754	Jun 10, 2030	U-2141		NCE	Aug 03, 2022
		8648037	Jan 19, 2032	DS DP U-2141			
		8937150	May 18, 2032	DS DP			
		9321807	Jun 05, 2035	DS			
		9586978	Jun 10, 2030	U-2141			
GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT							
N 021925	001	7700128	Jan 30, 2027	DP			
		8071130	Jun 08, 2028	DP			
GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT							
N 021925	002	7700128	Jan 30, 2027	DP			
		8071130	Jun 08, 2028	DP			
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL							
N 021700	001	7358366	Apr 19, 2020	DS	Y		
		7358366*PED	Oct 19, 2020				
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL							
N 021700	002	7358366	Apr 19, 2020	DS	Y		
		7358366*PED	Oct 19, 2020				
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL							
N 021700	003	7358366	Apr 19, 2020	DS	Y		
		7358366*PED	Oct 19, 2020				
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL							
N 021700	004	7358366	Apr 19, 2020	DS	Y		
		7358366*PED	Oct 19, 2020				
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL							
N 021700	005	7358366	Apr 19, 2020	DS	Y		
		7358366*PED	Oct 19, 2020				
GLIPIZIDE - GLUCOTROL XL							
N 020329	001	RE44459	Mar 26, 2019	U-1431			
GLIPIZIDE - GLUCOTROL XL							
N 020329	002	RE44459	Mar 26, 2019	U-1431			
GLIPIZIDE - GLUCOTROL XL							
N 020329	003	RE44459	Mar 26, 2019	U-1431			
GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE							
N 021178	001	6303146	Jul 14, 2019	U-412			
GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE							
N 021178	002	6303146	Jul 14, 2019	U-412			
GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE							
N 021178	003	6303146	Jul 14, 2019	U-412			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GLYCEROL PHENYLBUTYRATE - RAVICTI							
N 203284	001	10045958	Sep 22, 2030	U-1816		NPP	Apr 28, 2020
		10045959	Sep 22, 2030	U-1816		ODE-157	Apr 28, 2024
		8404215	Mar 09, 2032	U-1383		ODE-42	Feb 01, 2020
		8642012	Sep 22, 2030	U-1383			
		9095559	Mar 09, 2032	U-1383			
		9254278	Mar 09, 2032	U-1816			
		9326966	Mar 09, 2032	U-1816			
		9561197	Sep 22, 2030	U-1383			
		9962359	Sep 22, 2030	U-1816			
		9999608	Sep 22, 2030	U-1816			
GLYCOPYRROLATE - CUVPOSA							
N 022571	001	7638552	Aug 20, 2023	U-1076			
		7816396	Aug 20, 2023	U-1076			
GLYCOPYRROLATE - SEEBRI							
N 207923	001	7229607	Apr 09, 2021	U-1773			
		7736670	Jun 27, 2021	DP			
		8029768	Apr 09, 2021	U-1773			
		8048451	Jun 27, 2021	DP			
		8182838	Oct 20, 2028	DP			
		8303991	Jun 27, 2021	DP			
		8435567	Jun 27, 2021	DP			
		8479730	Oct 11, 2028	DP			
		8580306	Jun 27, 2021	DP			
		8956661	Jun 27, 2021	DP			
		9931304	Jun 27, 2021	DP			
		9962338	Jun 27, 2021	DP			
GLYCOPYRROLATE - LONHALA MAGNAIR KIT							
N 208437	001	6962151	Oct 27, 2020	DP		NP	Dec 05, 2020
		7316067	Sep 06, 2022	DP			
		7458372	Nov 18, 2024	DP			
		7931212	Nov 25, 2025	DP			
		8511581	Nov 08, 2023	DP			
		9168556	Sep 01, 2032	DP			
		9265900	Dec 07, 2028	DP			
		9604018	May 16, 2033	DP			
		9789270	Oct 30, 2030	DP			
GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON							
N 207930	001	6878721	Feb 25, 2025	DS DP U-1773			
		7229607	Apr 09, 2021	U-1773			
		7736670	Jun 27, 2021	DP			
		7820694	Jun 02, 2020	DP U-1773			
		8029768	Apr 09, 2021	U-1773			
		8048451	Jun 27, 2021	DP			
		8067437	Jun 02, 2020	U-1773			
		8182838	Oct 20, 2028	DP			
		8283362	Jun 02, 2020	DP U-1773			
		8303991	Jun 27, 2021	DP			
		8435567	Jun 27, 2021	DP			
		8479730	Oct 11, 2028	DP			
		8580306	Jun 27, 2021	DP			
		8658673	Jun 02, 2020	DP U-1773			
		8796307	Jun 02, 2020	DP			
		8956661	Jun 27, 2021	DP			
		9931304	Jun 27, 2021	DP			
		9962338	Jun 27, 2021	DP			
GLYCOPYRRONIUM TOSYLATE - QBREXZA							
N 210361	001	10004717	Feb 28, 2033	DP U-2398			
		10052267	Oct 17, 2028	DP U-2398			
		6433003	Apr 10, 2020	U-2398			
		8618160	Dec 10, 2029	DP U-2398			
		8859610	Feb 28, 2033	DP U-2398			
		9006462	Feb 28, 2033	DP			
		9259414	Feb 28, 2033	U-2398			
		9744105	Jul 18, 2030	DP U-2398			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GLYCOPYRRONIUM TOSYLATE - QBREXZA							
N 210361	001	10004717	Feb 28, 2033	DP U-2398			
		10052267	Oct 17, 2028	DP U-2398			
		6433003	Apr 10, 2020	U-2398			
		8618160	Dec 10, 2029	DP U-2398			
		8859610	Feb 28, 2033	DP U-2398			
		9006462	Feb 28, 2033	DP			
		9259414	Feb 28, 2033	U-2398			
		9744105	Jul 18, 2030	DP U-2398			
GOSERELIN ACETATE - ZOLADEX							
N 019726	001	7118552	Apr 13, 2022	DP			
		7220247	Apr 09, 2022	DP			
		7500964	Feb 26, 2021	DP			
GOSERELIN ACETATE - ZOLADEX							
N 020578	001	7118552	Apr 13, 2022	DP			
		7220247	Apr 09, 2022	DP			
		7500964	Feb 26, 2021	DP			
GRANISETRON - SANCUSO							
N 022198	001	7608282	Jan 22, 2025	DP U-1011			
GRANISETRON - SUSTOL							
N 022445	001	6613355	Jun 28, 2021	DP		NDF	Aug 09, 2019
		6790458	May 11, 2021	DP			
		8252304	Sep 28, 2024	DP			
		8252305	Sep 28, 2024	U-1891			
		8715710	Sep 28, 2024	DP			
		9913910	Sep 28, 2024	U-2253			
GUAIFENESIN - MUCINEX							
N 021282	001	6372252	Apr 28, 2020	U-489			
		6955821	Apr 28, 2020	DP U-489			
		7838032	Apr 28, 2020	DP			
GUAIFENESIN - MUCINEX							
N 021282	002	6372252	Apr 28, 2020	U-489			
		6955821	Apr 28, 2020	DP U-489			
		7838032	Apr 28, 2020	DP			
GUAIFENESIN; HYDROCODONE BITARTRATE - OBREDON							
N 205474	001	10105324	Nov 13, 2035	DS DP U-2023			
		9549907	Nov 13, 2035	DS DP U-2023			
		9808431	Nov 13, 2035	DS DP U-2023			
GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D							
N 021585	001	6372252	Apr 28, 2020	DP			
		6955821	Apr 28, 2020	DP U-686			
		7838032	Apr 28, 2020	DP			
GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D							
N 021585	002	6372252	Apr 28, 2020	DP			
		6955821	Apr 28, 2020	DP U-686			
		7838032	Apr 28, 2020	DP			
GUANFACINE HYDROCHLORIDE - INTUNIV							
N 022037	001	6287599	Dec 20, 2020	DP			
		6287599*PED	Jun 20, 2021				
		6811794	Jul 04, 2022	DP U-494			
		6811794*PED	Jan 04, 2023				
GUANFACINE HYDROCHLORIDE - INTUNIV							
N 022037	002	6287599	Dec 20, 2020	DP			
		6287599*PED	Jun 20, 2021				
		6811794	Jul 04, 2022	DP U-494			
		6811794*PED	Jan 04, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GUANFACINE HYDROCHLORIDE - INTUNIV							
N 022037	003	6287599	Dec 20, 2020	DP			
		6287599*PED	Jun 20, 2021				
		6811794	Jul 04, 2022	DP U-494			
		6811794*PED	Jan 04, 2023				
GUANFACINE HYDROCHLORIDE - INTUNIV							
N 022037	004	6287599	Dec 20, 2020	DP			
		6287599*PED	Jun 20, 2021				
		6811794	Jul 04, 2022	DP U-494			
		6811794*PED	Jan 04, 2023				
HALOBETASOL PROPIONATE - ULTRAVATE							
N 208183	001	8962028	Jun 19, 2033	DP U-1775			
HALOBETASOL PROPIONATE - BRYHALI							
N 209355	001					NP	Nov 06, 2021
HALOBETASOL PROPIONATE - HALOBETASOL PROPIONATE							
N 210566	001					NDF	May 24, 2021
HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT							
N 022555	001	7348361	Nov 06, 2020	DP U-1087		M-220	Feb 15, 2021
		7348361	Nov 06, 2020	DP U-2250			
HISTRELIN ACETATE - SUPPRELIN LA							
N 022058	001	8062652	Jun 16, 2026	U-1197			
HYALURONIDASE RECOMBINANT HUMAN - HYLENEX RECOMBINANT							
N 021859	001	7767429	Sep 23, 2027	DS DP			
HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE - BIDIL							
N 020727	001	6465463	Sep 08, 2020	U-71			
		6784177	Sep 08, 2020	U-71			
HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT							
N 021162	001	6358986	Jan 10, 2020				
HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT							
N 021162	002	6358986	Jan 10, 2020				
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880	001	10028946	Jul 25, 2033	U-1810			
		10092559	Sep 12, 2034	U-55			
		6228398	Nov 01, 2019	DP			
		6902742	Nov 01, 2019	DP			
		9132096	Sep 12, 2034	DP			
		9265760	Jul 25, 2033	U-1810			
		9326982	Jul 25, 2033	U-1810			
		9333201	Jul 25, 2033	U-1810			
		9339499	Jul 25, 2033	U-1810			
		9421200	Jul 25, 2033	U-1810			
		9433619	Jul 25, 2033	U-1810			
		9452163	Sep 12, 2034	U-55			
		9486451	Sep 12, 2034	U-55			
		9610286	Jul 25, 2033	U-1810			
		9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880	002	10028946	Jul 25, 2033	U-1810			
		10092559	Sep 12, 2034	U-55			
		6228398	Nov 01, 2019	DP			
		6902742	Nov 01, 2019	DP			
		9132096	Sep 12, 2034	DP			
		9265760	Jul 25, 2033	U-1810			
		9326982	Jul 25, 2033	U-1810			
		9333201	Jul 25, 2033	U-1810			
		9339499	Jul 25, 2033	U-1810			
		9421200	Jul 25, 2033	U-1810			
		9433619	Jul 25, 2033	U-1810			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 002	9452163	Sep 12, 2034	U-55			
	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 003	10028946	Jul 25, 2033	U-1810			
	10092559	Sep 12, 2034	U-55			
	6228398	Nov 01, 2019	DP			
	6902742	Nov 01, 2019	DP			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 004	10028946	Jul 25, 2033	U-1810			
	10092559	Sep 12, 2034	U-55			
	6228398	Nov 01, 2019	DP			
	6902742	Nov 01, 2019	DP			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 005	10028946	Jul 25, 2033	U-1810			
	10092559	Sep 12, 2034	U-55			
	6228398	Nov 01, 2019	DP			
	6902742	Nov 01, 2019	DP			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 006	10028946	Jul 25, 2033	U-1810			
	10092559	Sep 12, 2034	U-55			
	6228398	Nov 01, 2019	DP			
	6902742	Nov 01, 2019	DP			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 006	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 001	10130591	Nov 20, 2023	DP U-1819			
	6733783	Oct 30, 2021	DP U-1556			
	8309060	Nov 20, 2023	DP U-1556			
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP U-1556			
	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 002	10130591	Nov 20, 2023	DP U-1819			
	6733783	Oct 30, 2021	DP U-1556			
	8309060	Nov 20, 2023	DP U-1556			
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP U-1556			
	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 002	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020			U-1556	
	9682077	Oct 30, 2020			U-1556	
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 003	10130591	Nov 20, 2023	DP		U-1819	
	6733783	Oct 30, 2021	DP		U-1556	
	8309060	Nov 20, 2023	DP		U-1556	
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP		U-1556	
	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020			U-1556	
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027			U-1556	
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027			U-1556	
	9492391	Aug 24, 2027			U-1556	
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027			U-1556	
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020			U-1556	
	9682077	Oct 30, 2020			U-1556	
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 004	10130591	Nov 20, 2023	DP		U-1819	
	6733783	Oct 30, 2021	DP		U-1556	
	8309060	Nov 20, 2023	DP		U-1556	
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP		U-1556	
	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020			U-1556	
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027			U-1556	
	9095615	Aug 24, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 004	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 005	10130591	Nov 20, 2023	DP		U-1819	
	6733783	Oct 30, 2021	DP		U-1556	
	8309060	Nov 20, 2023	DP		U-1556	
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP		U-1556	
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 006	10130591	Nov 20, 2023	DP		U-1819	
	6733783	Oct 30, 2021	DP		U-1556	
	8309060	Nov 20, 2023	DP		U-1556	
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 006	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP		U-1556	
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020			U-1556	
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027			U-1556	
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027			U-1556	
	9492391	Aug 24, 2027			U-1556	
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027			U-1556	
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020			U-1556	
	9682077	Oct 30, 2020			U-1556	
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 007	10130591	Nov 20, 2023	DP		U-1819	
	6733783	Oct 30, 2021	DP		U-1556	
	8309060	Nov 20, 2023	DP		U-1556	
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP		U-1556	
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020			U-1556	
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027			U-1556	
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027			U-1556	
	9492391	Aug 24, 2027			U-1556	
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027			U-1556	
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020			U-1556	
	9682077	Oct 30, 2020			U-1556	
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - HYSINGLA									
N 206627	007		9872837	Dec 21, 2031		DP			
HYDROCODONE BITARTRATE - VANTRELA ER									
N 207975	001		8445018	Jul 31, 2029		DP			
			9216176	Sep 13, 2027		DP			
			9572803	Sep 13, 2027		DP			
HYDROCODONE BITARTRATE - VANTRELA ER									
N 207975	002		8445018	Jul 31, 2029		DP			
			9216176	Sep 13, 2027		DP			
			9572803	Sep 13, 2027		DP			
HYDROCODONE BITARTRATE - VANTRELA ER									
N 207975	003		8445018	Jul 31, 2029		DP			
			9216176	Sep 13, 2027		DP			
			9572803	Sep 13, 2027		DP			
HYDROCODONE BITARTRATE - VANTRELA ER									
N 207975	004		8445018	Jul 31, 2029		DP			
			9216176	Sep 13, 2027		DP			
			9572803	Sep 13, 2027		DP			
HYDROCODONE BITARTRATE - VANTRELA ER									
N 207975	005		8445018	Jul 31, 2029		DP			
			9216176	Sep 13, 2027		DP			
			9572803	Sep 13, 2027		DP			
HYDROCORTISONE BUTYRATE - LOCOID									
N 022076	001		7378405	Dec 19, 2026		DP			
			7981877	Jan 23, 2025		DP			
HYDROGEN PEROXIDE - ESKATA									
N 209305	001		10098910	Apr 21, 2035		DP	U-2205	NP	Dec 14, 2020
			7381427	Jun 08, 2022			U-2205		
			9675639	Jul 04, 2035		DP	U-2205		
			9980983	Apr 21, 2035			U-2205		
HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP									
N 019034	001		6589960	Nov 09, 2020		DP			
			9248229	Mar 12, 2034		DP			
			9731082	Apr 23, 2032		DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP									
N 019034	002		6589960	Nov 09, 2020		DP			
			9248229	Mar 12, 2034		DP			
			9731082	Apr 23, 2032		DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID									
N 019034	003		6589960	Nov 09, 2020	DS	DP			
			9248229	Mar 12, 2034		DP			
			9731082	Apr 23, 2032		DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID									
N 019034	004		6589960	Nov 09, 2020	DS	DP			
			9248229	Mar 12, 2034		DP			
			9731082	Apr 23, 2032		DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID									
N 019034	005		6589960	Nov 09, 2020	DS	DP			
			9248229	Mar 12, 2034		DP			
			9731082	Apr 23, 2032		DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID									
N 019891	001		6589960	Nov 09, 2020	DS	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID									
N 019892	001		6589960	Nov 09, 2020	DS	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES		PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROMORPHONE HYDROCHLORIDE - DILAUDID									
N	019892	002	6589960	Nov 09, 2020	DS	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID									
N	019892	003	6589960	Nov 09, 2020	DS	DP			
HYDROMORPHONE HYDROCHLORIDE - PALLADONE									
N	021044	001	6589960	Nov 09, 2020		DP			
HYDROMORPHONE HYDROCHLORIDE - PALLADONE									
N	021044	002	6589960	Nov 09, 2020		DP			
HYDROMORPHONE HYDROCHLORIDE - PALLADONE									
N	021044	003	6589960	Nov 09, 2020		DP			
HYDROMORPHONE HYDROCHLORIDE - PALLADONE									
N	021044	004	6589960	Nov 09, 2020		DP			
HYDROXYPROGESTERONE CAPROATE - MAKENA (AUTOINJECTOR)									
N	021945	004	8021335	Oct 04, 2026		DP			
			8562564	Jan 24, 2026		DP			
			9180259	Jan 24, 2026		DP			
			9533102	Jan 24, 2026		DP			
			9629959	Jan 24, 2026		DP			
			9789257	Feb 11, 2034		DP			
			9844558	May 02, 2036		U-2236			
			RE44846	Aug 10, 2019		DP			
HYDROXYUREA - SIKLOS									
N	208843	001						NP	Dec 21, 2020
								ODE-177	Dec 21, 2024
HYDROXYUREA - SIKLOS									
N	208843	002						NP	Dec 21, 2020
								ODE-177	Dec 21, 2024
IBANDRONATE SODIUM - BONIVA									
N	021455	001	6294196	Oct 07, 2019		DP			
IBANDRONATE SODIUM - BONIVA									
N	021455	002	6294196	Oct 07, 2019		DP			
			7192938	May 06, 2023		U-798			
			7410957	May 06, 2023		U-887			
			7718634	May 06, 2023		U-642			
IBRUTINIB - IMBRUVICA									
N	205552	001	10004746	Jun 03, 2031		U-1684		D-165	May 06, 2019
			10004746	Jun 03, 2031		U-1946		I-729	Mar 04, 2019
			10004746	Jun 03, 2031		U-2241		I-736	May 06, 2019
			10004746	Jun 03, 2031		U-2242		I-737	May 06, 2019
			10016435	Jun 03, 2031		U-1650		I-741	Jan 18, 2020
			10106548	Jun 03, 2033	DS	DP		I-753	Aug 02, 2020
			10125140	Jun 03, 2033	DS	DP		ODE-109	Mar 04, 2023
			7514444	Dec 28, 2026	DS	DP		ODE-117	May 06, 2023
			8008309	Dec 28, 2026	DS	DP		ODE-128	Jan 18, 2024
			8476284	Dec 28, 2026		U-1456		ODE-152	Aug 02, 2024
			8476284	Dec 28, 2026		U-1650		ODE-55	Nov 13, 2020
			8476284	Dec 28, 2026		U-1946		ODE-60	Feb 12, 2021
			8476284	Dec 28, 2026		U-1947		ODE-72	Jul 28, 2021
			8497277	Dec 28, 2026		U-1456		ODE-86	Jan 29, 2022
			8497277	Dec 28, 2026		U-1491			
			8497277	Dec 28, 2026		U-1650			
			8497277	Dec 28, 2026		U-1946			
			8497277	Dec 28, 2026		U-1947			
			8563563	Apr 26, 2027		U-1491			
			8563563	Apr 26, 2027		U-1650			
			8563563	Apr 26, 2027		U-1946			
			8563563	Apr 26, 2027		U-2219			
			8697711	Dec 28, 2026	DS	DP			
			8703780	Dec 28, 2026		U-1491			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 205552 001	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1683			
	8999999	Jun 03, 2031	U-1684			
	9125889	Jun 03, 2031	U-1745			
	9181257	Dec 28, 2026	DS DP			
	9296753	Oct 30, 2033	DS DP			
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9713617	Jun 03, 2033	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801883	Jun 03, 2031	U-2159			
	9814721	Jun 03, 2031	U-1947			
IBRUTINIB - IMBRUVICA						
N 205552 002	10004746	Jun 03, 2031	U-1684			
	10004746	Jun 03, 2031	U-1946			
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10016435	Jun 03, 2031	U-1650			
	10106548	Jun 03, 2033	DS DP			
	10125140	Jun 03, 2033	DS DP			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2228			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1491			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 205552 002	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9713617	Jun 03, 2033	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801883	Jun 03, 2031	U-2159			
	9814721	Jun 03, 2031	U-1947			
IBRUTINIB - IMBRUVICA						
N 210563 001	10004746	Jun 03, 2031	U-1684			
	10004746	Jun 03, 2031	U-1946			
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10010507	Mar 03, 2036	DP			
	10016435	Jun 03, 2031	U-1650			
	10106548	Jun 03, 2033	DS DP			
	10125140	Jun 03, 2033	DS DP			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 002	10004746	Jun 03, 2031	U-1684			
	10004746	Jun 03, 2031	U-1946			
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10010507	Mar 03, 2036	DP			
	10016435	Jun 03, 2031	U-1650			
	10106548	Jun 03, 2033	DS DP			
	10125140	Jun 03, 2033	DS DP			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
IBRUTINIB - IMBRUVICA						
N 210563 003	10004746	Jun 03, 2031	U-1684			
	10004746	Jun 03, 2031	U-1946			
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10010507	Mar 03, 2036	DP			
	10016435	Jun 03, 2031	U-1650			
	10106548	Jun 03, 2033	DS DP			
	10125140	Jun 03, 2033	DS DP			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 003	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
IBRUTINIB - IMBRUVICA						
N 210563 004	10004746	Jun 03, 2031	U-1684			
	10004746	Jun 03, 2031	U-1946			
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10010507	Mar 03, 2036	DP			
	10016435	Jun 03, 2031	U-1650			
	10106548	Jun 03, 2033	DS DP			
	10125140	Jun 03, 2033	DS DP			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA							
N 210563	004	8497277	Dec 28, 2026	U-2241			
		8497277	Dec 28, 2026	U-2242			
		8563563	Apr 26, 2027	U-1491			
		8563563	Apr 26, 2027	U-1650			
		8563563	Apr 26, 2027	U-1946			
		8563563	Apr 26, 2027	U-2241			
		8563563	Apr 26, 2027	U-2242			
		8697711	Dec 28, 2026	DS DP			
		8703780	Dec 28, 2026	U-1491			
		8703780	Dec 28, 2026	U-2242			
		8735403	Dec 28, 2026	DS DP			
		8754090	Jun 03, 2031	U-1456			
		8754091	Dec 28, 2026	DP			
		8952015	Dec 28, 2026	U-1456			
		8952015	Dec 28, 2026	U-1491			
		8952015	Dec 28, 2026	U-1650			
		8952015	Dec 28, 2026	U-1946			
		8952015	Dec 28, 2026	U-1947			
		8952015	Dec 28, 2026	U-2241			
		8952015	Dec 28, 2026	U-2242			
		8957079	Dec 28, 2026	DS DP			
		8999999	Jun 03, 2031	U-1491			
		8999999	Jun 03, 2031	U-1946			
		8999999	Jun 03, 2031	U-2241			
		8999999	Jun 03, 2031	U-2242			
		9125889	Jun 03, 2031	U-1650			
		9181257	Dec 28, 2026	DS			
		9296753	Oct 30, 2033	DS			
		9655857	Mar 03, 2036	DP			
		9725455	Jun 03, 2033	DS			
		9795604	Oct 24, 2034	U-2150			
		9801881	Jun 03, 2031	U-1491			
		9801881	Jun 03, 2031	U-2242			
		9801883	Jun 03, 2031	U-2159			
		9801883	Jun 03, 2031	U-2243			
		9814721	Jun 03, 2031	U-1947			
IBUPROFEN - CALDOLOR							
N 022348	001	6727286	Nov 27, 2021	DP U-981			
IBUPROFEN - CALDOLOR							
N 022348	002	6727286	Nov 27, 2021	DP U-981			
		8735452	Sep 30, 2029	U-981			
		8871810	Sep 30, 2029	U-1599			
		9012508	Sep 14, 2030	U-981			
		9072661	Mar 16, 2032	U-2264			
		9072710	Mar 16, 2032	U-2266			
		9114068	Sep 30, 2029	U-1735			
		9138404	Sep 30, 2029	U-1756			
		9295639	Sep 30, 2029	U-1756			
		9649284	Sep 30, 2029	U-2018			
IBUPROFEN LYSINE - NEOPROFEN							
N 021903	001	6342530	Nov 14, 2020	DP U-1127			
		6342530	Nov 14, 2020	DP U-794			
		6344479	Mar 20, 2021	DS DP U-794		Y	
		8415337	Mar 02, 2032	DS DP			
IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S MOTRIN COLD							
N 021128	001	6211246	Jun 10, 2019				
ICATIBANT ACETATE - FIRAZYR							
N 022150	001	5648333	Jul 15, 2019	DS DP U-1187			
ICOSAPENT ETHYL - VASCEPA							
N 202057	001	8188146	Jan 27, 2020	DS DP			
		8293727	Feb 09, 2030	U-1287			
		8293728	Feb 09, 2030	U-1287			
		8298554	Apr 29, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ICOSAPENT ETHYL - VASCEPA						
N 202057 001	8314086	Feb 09, 2030	U-1287			
	8318715	Feb 09, 2030	U-1287			
	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8431560	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8501225	Apr 29, 2030	U-1287			
	8518929	Apr 29, 2030	U-1287			
	8524698	Apr 29, 2030	U-1287			
	8546372	Apr 29, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-1478			
	8617594	Apr 29, 2030	U-1287			
	8623406	Apr 29, 2030	U-1478			
ICOSAPENT ETHYL - VASCEPA						
N 202057 002	8188146	Jan 27, 2020	DS DP			
	8293727	Feb 09, 2030	U-1287			
	8293728	Feb 09, 2030	U-1287			
	8298554	Apr 29, 2030	DP			
	8314086	Feb 09, 2030	U-1287			
	8318715	Feb 09, 2030	U-1287			
	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8501225	Apr 29, 2030	U-1287			
	8518929	Apr 29, 2030	U-1287			
	8524698	Apr 29, 2030	U-1287			
	8546372	Apr 29, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-1287			
	8617594	Apr 29, 2030	U-1287			
	8623406	Apr 29, 2030	U-1287			
IDELALISIB - ZYDELIG						
N 205858 001	6800620	Apr 24, 2021	DS U-1560		NCE	Jul 23, 2019
	6949535	Apr 24, 2021	DS U-1560		ODE-70	Jul 23, 2021
	8138195	Apr 24, 2021	DS DP U-1549		ODE-71	Jul 23, 2021
	8492389	Apr 24, 2021	DS DP			
	8637533	Apr 24, 2021	DS DP			
	8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	9149477	May 12, 2025	U-1757			
	9469643	Sep 02, 2033	DS			
	9492449	Mar 11, 2030	U-1914			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
	RE44638	Aug 05, 2025	DS DP			
IDELALISIB - ZYDELIG						
N 205858 002	6800620	Apr 24, 2021	DS U-1560		NCE	Jul 23, 2019
	6949535	Apr 24, 2021	DS U-1560		ODE-70	Jul 23, 2021
	8138195	Apr 24, 2021	DS DP U-1549		ODE-71	Jul 23, 2021
	8492389	Apr 24, 2021	DS DP			
	8637533	Apr 24, 2021	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IDELALISIB - ZYDELIG						
N 205858 002	8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	9149477	May 12, 2025	U-1757			
	9469643	Sep 02, 2033	DS			
	9492449	Mar 11, 2030	U-1914			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
	RE44638	Aug 05, 2025	DS DP			
ILOPERIDONE - FANAPT						
N 022192 001	8586610	Nov 02, 2027	U-1625		M-180	May 26, 2019
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 002	8586610	Nov 02, 2027	U-1625		M-180	May 26, 2019
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 003	8586610	Nov 02, 2027	U-1625		M-180	May 26, 2019
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 004	8586610	Nov 02, 2027	U-1625		M-180	May 26, 2019
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 005	8586610	Nov 02, 2027	U-1625		M-180	May 26, 2019
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 006	8586610	Nov 02, 2027	U-1625		M-180	May 26, 2019
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ILOPERIDONE - FANAPT						
N 022192 006	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 007	8586610	Nov 02, 2027	U-1625		M-180	May 26, 2019
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
IMATINIB MESYLATE - GLEEVEC						
N 021335 001	6894051	May 23, 2019	DS DP U-649			
	6958335	Dec 19, 2021	U-791			
	RE43932*PED	Jan 16, 2019				
IMATINIB MESYLATE - GLEEVEC						
N 021335 002	6894051	May 23, 2019	DS DP U-649			
	6958335	Dec 19, 2021	U-791			
	RE43932*PED	Jan 16, 2019				
IMATINIB MESYLATE - GLEEVEC						
N 021588 001	6894051	May 23, 2019	DS DP U-649		ODE-40	Jan 25, 2020
	6958335	Dec 19, 2021	U-1883			
	6958335	Dec 19, 2021	U-791			
	6958335*PED	Jun 19, 2022				
	RE43932*PED	Jan 16, 2019				
IMATINIB MESYLATE - GLEEVEC						
N 021588 002	6894051	May 23, 2019	DS DP U-649		ODE-40	Jan 25, 2020
	6958335	Dec 19, 2021	U-1883			
	6958335	Dec 19, 2021	U-791			
	6958335*PED	Jun 19, 2022				
	RE43932*PED	Jan 16, 2019				
IMIQUIMOD - ALDARA						
N 020723 001	7696159	Apr 01, 2024	DS U-1047			
	7696159	Apr 01, 2024	DS U-1048			
IMIQUIMOD - ZYCLARA						
N 022483 001	8236816	Dec 11, 2029	U-68			
	8299109	Dec 11, 2029	U-68			
	8598196	Aug 18, 2029	U-1455			
	8598196	Aug 18, 2029	U-172			
IMIQUIMOD - ZYCLARA						
N 022483 002	8222270	Dec 11, 2029	U-68			
INDACATEROL MALEATE - ARCAPTA NEOHALER						
N 022383 001	6878721	Feb 25, 2025	DS DP U-1168			
	8067437	Jun 02, 2020	U-1168			
	8479730	Oct 11, 2028	DP			
	8658673	Jun 02, 2020	DS DP U-1168			
	8796307	Jun 02, 2020	DS DP			
INDINAVIR SULFATE - CRIXIVAN						
N 020685 001	6689761	Feb 10, 2021	U-554			
INDINAVIR SULFATE - CRIXIVAN						
N 020685 003	6689761	Feb 10, 2021	U-554			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INDINAVIR SULFATE - CRIXIVAN							
N 020685	005	6689761	Feb 10, 2021	U-554			
INDINAVIR SULFATE - CRIXIVAN							
N 020685	006	6689761	Feb 10, 2021	U-554			
INDOCYANINE GREEN - SPY AGENT GREEN KIT							
N 211580	001	6915154	Aug 01, 2021	U-2460		NP	Nov 21, 2021
		7881777	Sep 22, 2021	U-2461			
		8185176	Jun 04, 2028	U-2462			
		8406860	Apr 09, 2029	U-2463			
		8647605	Feb 11, 2029	U-2464			
		8647605	Feb 11, 2029	U-2468			
		8892190	Aug 11, 2020	U-2465			
		9421280	Nov 24, 2025	U-2466			
		9421280	Nov 24, 2025	U-2467			
INDOMETHACIN - TIVORBEX							
N 204768	001	8734847	Apr 23, 2030	DP			
		8992982	Apr 23, 2030	DP			
		9089471	Apr 23, 2030	U-55			
INDOMETHACIN - TIVORBEX							
N 204768	002	8734847	Apr 23, 2030	DP			
		8992982	Apr 23, 2030	DP			
		9089471	Apr 23, 2030	U-55			
INGENOL MEBUTATE - PICATO							
N 202833	001	7410656	Oct 10, 2020	U-1222			
		8278292	Jul 06, 2027	DP			
		8372827	Dec 18, 2026	DP			
		8372828	Dec 18, 2026	DP			
		8377919	Dec 18, 2026	DP			
		8536163	Dec 18, 2026	U-1440			
		8716271	Dec 18, 2026	U-1440			
		8735375	Dec 18, 2026	U-1440			
		9789078	May 15, 2033	U-2138			
		9820959	Dec 18, 2026	DP U-1440			
		9833428	Dec 18, 2026	DP			
		9833429	Dec 18, 2026	DP			
		9861603	Dec 18, 2026	U-1440			
INGENOL MEBUTATE - PICATO							
N 202833	002	7410656	Oct 10, 2020	U-1222			
		8278292	Jul 06, 2027	DP			
		8372827	Dec 18, 2026	DP			
		8372828	Dec 18, 2026	DP			
		8377919	Dec 18, 2026	DP			
		8536163	Dec 18, 2026	U-1440			
		8716271	Dec 18, 2026	U-1440			
		8735375	Dec 18, 2026	U-1440			
		9820959	Dec 18, 2026	DP U-1440			
		9833428	Dec 18, 2026	DP			
		9833429	Dec 18, 2026	DP			
		9861603	Dec 18, 2026	U-1440			
INOTERSEN SODIUM - TEGSEDI							
N 211172	001	7015315	Mar 21, 2023	DS		NCE	Oct 05, 2023
		7101993	Sep 05, 2023	DS		ODE-212	Oct 05, 2025
		8101743	Apr 01, 2025	DS DP			
		8697860	Apr 29, 2031	DP			
		9061044	Apr 29, 2031	DS			
		9399774	Apr 29, 2031	U-2430			
INSULIN ASPART - FIASP							
N 208751	001	8324157	Jun 25, 2030	DP		NP	Sep 29, 2020
INSULIN ASPART - FIASP FLEXTOUCH							
N 208751	002	6899699	Jan 02, 2022	DP		NP	Sep 29, 2020
		7686786	Aug 03, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN ASPART - FIASP FLEXTOUCH								
N 208751	002	8324157	Jun 25, 2030		DP			
		8672898	Jan 02, 2022		DP			
		8684969	Oct 20, 2025		DP			
		8920383	Jul 17, 2026		DP			
		9108002	Jan 20, 2026		DP			
		9132239	Feb 01, 2032		DP			
		9457154	Jan 20, 2026		DP			
		9486588	Jan 02, 2022		DP			
		9616180	Jan 20, 2026		DP			
		9687611	Feb 27, 2027		DP			
		9775953	Jul 17, 2026		DP			
		9861757	Jan 20, 2026		DP			
INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN								
N 021172	004	6004297	Jan 28, 2019		DP			
		9265893	Sep 23, 2032		DP			
		RE41956	Jan 21, 2021		DP			
		RE43834	Jan 28, 2019		DP			
INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN								
N 020986	003	6004297	Jan 28, 2019		DP			
		9265893	Sep 23, 2032		DP			
		RE41956	Jan 21, 2021		DP			
		RE43834	Jan 28, 2019		DP			
INSULIN ASPART RECOMBINANT - NOVOLOG INNOLET								
N 020986	004	RE41956	Jan 21, 2021		DP			
INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH								
N 020986	005	6899699	Jan 02, 2022		DP			
		8672898	Jan 02, 2022		DP			
		8684969	Oct 20, 2025		DP			
		8920383	Jul 17, 2026		DP			
		9108002	Jan 20, 2026		DP			
		9132239	Feb 01, 2032		DP			
		9457154	Sep 27, 2027		DP			
		9486588	Jan 02, 2022		DP			
		9616180	Jan 20, 2026		DP			
		9687611	Feb 27, 2027		DP			
		9775953	Jul 17, 2026		DP			
		9861757	Jan 20, 2026		DP			
		RE46363	Aug 03, 2026		DP			
INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30								
N 203313	001	6899699	Jan 02, 2022		DP		NCE	Sep 25, 2020
		7615532	Jun 28, 2029	DS	DP		NPP	Dec 16, 2019
		8672898	Jan 02, 2022		DP			
		8684969	Oct 20, 2025		DP			
		8920383	Jul 17, 2026		DP			
		9108002	Jan 20, 2026		DP			
		9132239	Feb 01, 2032		DP			
		9457154	Sep 27, 2027		DP			
		9486588	Jan 02, 2022		DP			
		9616180	Jan 20, 2026		DP			
		9687611	Feb 27, 2027		DP			
		9775953	Jul 17, 2026		DP			
		9861757	Jan 20, 2026		DP			
		9884094	May 01, 2033		U-2238			
		RE46363	Aug 03, 2026		DP			
INSULIN DEGLUDEC - TRESIBA								
N 203314	001	6899699	Jan 02, 2022		DP		NCE	Sep 25, 2020
		7615532	Jun 28, 2029	DS	DP		NPP	Dec 16, 2019
		8672898	Jan 02, 2022		DP			
		8684969	Oct 20, 2025		DP			
		8920383	Jul 17, 2026		DP			
		9108002	Jan 20, 2026		DP			
		9132239	Feb 01, 2032		DP			
		9457154	Sep 27, 2027		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN DEGLUDEC - TRESIBA						
N 203314 001	9486588	Jan 02, 2022	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
INSULIN DEGLUDEC - TRESIBA						
N 203314 002	6899699	Jan 02, 2022	DP		NCE	Sep 25, 2020
	7615532	Jun 28, 2029	DS DP		NPP	Dec 16, 2019
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6						
N 208583 001	6268343	Aug 22, 2022	DS DP		NC	Nov 21, 2019
	6899699	Jan 02, 2022	DP		NCE	Sep 25, 2020
	7615532	Jun 28, 2029	DS DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DS DP			
	8920383	Jul 17, 2026	DP			
	8937042	May 05, 2029	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
INSULIN DETEMIR RECOMBINANT - LEVEMIR						
N 021536 001	5750497	Jun 16, 2019	DS DP U-668			
INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN						
N 021536 002	5750497	Jun 16, 2019	DS DP U-668			
	6004297	Jan 28, 2019	DP			
	9265893	Sep 23, 2032	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
INSULIN DETEMIR RECOMBINANT - LEVEMIR INNOLET						
N 021536 003	5750497	Jun 16, 2019	DS DP U-668			
INSULIN DETEMIR RECOMBINANT - LEVEMIR PENFILL						
N 021536 004	5750497	Jun 16, 2019	DS DP U-668			
INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH						
N 021536 005	5750497	Jun 16, 2019	DS DP U-668			
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH						
N 021536 005	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
INSULIN GLARGINE RECOMBINANT - LANTUS						
N 021081 001	7476652	Jul 23, 2023	DP			
	7713930	Jun 13, 2023	DP			
	7918833	Sep 23, 2027	DP			
INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR						
N 021081 002	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024			U-1832	
	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9717852	Apr 08, 2033	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 02, 2024	DP		U-2146	
INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR						
N 206538 001	7918833	Sep 23, 2027	DP			
	7918833*PED	Mar 23, 2028				
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024			U-1832	
	9233211	Mar 02, 2024	DP			
	9345750	May 18, 2031	DP		U-1855	
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 02, 2024	DP		U-2146	
INSULIN GLARGINE RECOMBINANT - TOUJEO MAX SOLOSTAR						
N 206538 002	7918833	Sep 23, 2027	DP			
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP		U-1832	
	9233211	Mar 02, 2024	DP			
	9345750	May 18, 2031	DP		U-1855	
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN GLARGINE RECOMBINANT - TOUJEO MAX SOLOSTAR						
N 206538 002	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 02, 2024	DP U-2146			
INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33						
N 208673 001	10029011	Aug 02, 2032	DP		NC	Nov 21, 2019
	10117909	Oct 09, 2029	DP		NCE	Jul 27, 2021
	7918833	Sep 23, 2027	DP			
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	U-1923			
	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
	9526764	Oct 09, 2029	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9707176	Nov 11, 2030	DP			
	9717852	Apr 08, 2033	DP			
	9775954	Mar 02, 2024	DP			
	9821032	May 09, 2032	U-2182			
	9827379	Mar 02, 2024	DP U-2146			
	9950039	Dec 10, 2035	U-2277			
	9950039	Dec 10, 2035	U-2278			
	9950039	Dec 10, 2035	U-2279			
	RE45313	Jul 12, 2020	DS DP			
INSULIN GLULISINE RECOMBINANT - APIDRA						
N 021629 001	6960561	Jan 25, 2023	DP U-471			
	7452860	Mar 22, 2022	DP			
	7696162	Mar 22, 2022	DP U-471			
INSULIN GLULISINE RECOMBINANT - APIDRA						
N 021629 002	6960561	Jan 25, 2023	DP U-471			
	7452860	Mar 22, 2022	DP			
	7696162	Mar 22, 2022	DP U-471			
INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR						
N 021629 003	6960561	Jan 25, 2023	DP U-471			
	7452860	Mar 22, 2022	DP			
	7696162	Mar 22, 2022	DP U-471			
	7918833	Sep 23, 2027	DP			
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9717852	Apr 08, 2033	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 02, 2024	DP U-2146			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN HUMAN - HUMULIN R							
N 018780	004	7291132	Aug 09, 2024	DP			
INSULIN LISPRO - ADMELOG							
N 209196	001					NP	Dec 11, 2020
INSULIN LISPRO - ADMELOG SOLOSTAR							
N 209196	002	7918833	Sep 23, 2027	DP		NP	Dec 11, 2020
		8512297	Sep 15, 2024	DP			
		8556864	Mar 03, 2024	DP			
		8603044	Mar 02, 2024	DP			
		8679069	Apr 12, 2025	DP			
		8992486	Jun 05, 2024	DP			
		9011391	Mar 26, 2024	DP U-1832			
		9233211	Mar 02, 2024	DP			
		9408979	Mar 02, 2024	DP			
		9526844	Mar 02, 2024	DP			
		9533105	Aug 17, 2024	DP			
		9561331	Aug 28, 2024	DP			
		9604008	Mar 02, 2024	DP			
		9604009	Aug 16, 2024	DP			
		9610409	Mar 02, 2024	DP			
		9623189	Aug 19, 2024	DP			
		9717852	Apr 08, 2033	DP			
		9775954	Mar 02, 2024	DP			
		9827379	Mar 04, 2024	DP U-2146			
INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 75/25 KWIKPEN							
N 021017	002	7291132	Aug 09, 2024	DP			
INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 50/50 KWIKPEN							
N 021018	002	7291132	Aug 09, 2024	DP			
INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN							
N 020563	003	7291132	Aug 09, 2024	DP			
INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN							
N 205747	001	7291132	Aug 09, 2024	DP			
INSULIN RECOMBINANT HUMAN - EXUBERA							
N 021868	001	6257233	May 14, 2019	U-704			
		6546929	May 14, 2019	U-704			
		6582728	Jun 24, 2020	DP			
INSULIN RECOMBINANT HUMAN - EXUBERA							
N 021868	002	6257233	May 14, 2019	U-704			
		6546929	May 14, 2019	U-704			
		6582728	Jun 24, 2020	DP			
INSULIN RECOMBINANT HUMAN - AFREZZA							
N 022472	001	10046031	Aug 11, 2029	U-2383			
		6444226	Jun 29, 2020	DP U-1534			
		6652885	Jun 29, 2020	U-1535			
		7305986	Jan 16, 2023	DP			
		7464706	Mar 02, 2023	DP			
		7648960	Jun 29, 2020	U-1535			
		7943178	Jun 29, 2020	DP U-1535			
		7943572	Aug 10, 2026	U-1539			
		8119593	Aug 11, 2029	U-1537			
		8146588	Apr 24, 2023	DP			
		8156936	Jan 16, 2023	DP			
		8215300	Nov 24, 2022	DP			
		8258095	Aug 11, 2029	U-1537			
		8389470	Jun 29, 2020	DP U-1621			
		8424518	Oct 17, 2031	DP			
		8485180	Mar 25, 2030	DP			
		8499757	Feb 19, 2032	DP			
		8551528	Jun 11, 2030	DP			
		8623817	Sep 18, 2029	U-1537			
		8636001	Jul 12, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN RECOMBINANT HUMAN - AFREZZA						
N 022472 001	8729019	Dec 26, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP		U-1538	
	8889099	Jun 29, 2020	DP		U-1621	
	8912193	Jun 12, 2029	DP		U-1538	
	8950397	Jul 20, 2021	DP			
	9192675	Jun 12, 2029	DP		U-1788	
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP		U-1861	
	9393372	Jul 04, 2029	DP			
	9446133	Jun 12, 2029	DP		U-1861	
	9511198	Feb 16, 2030			U-1929	
	9511198	Feb 16, 2030			U-1930	
	9597374	Oct 08, 2031			U-1987	
	9662461	Jun 12, 2029	DP		U-2019	
	9717689	Sep 14, 2026	DP			
	9943571	Aug 11, 2029			U-1537	
INSULIN RECOMBINANT HUMAN - AFREZZA						
N 022472 002	10046031	Aug 11, 2029			U-2383	
	6444226	Jun 29, 2020	DP		U-1534	
	6652885	Jun 29, 2020			U-1535	
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020			U-1535	
	7943178	Jun 29, 2020	DP		U-1535	
	7943572	Aug 10, 2026			U-1539	
	8119593	Aug 11, 2029			U-1537	
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8258095	Aug 11, 2029			U-1537	
	8389470	Jun 29, 2020	DP		U-1621	
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029			U-1537	
	8636001	Jul 12, 2032	DP			
	8729019	Dec 26, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP		U-1538	
	8889099	Jun 29, 2020	DP		U-1621	
	8912193	Jun 12, 2029	DP		U-1538	
	8950397	Jul 20, 2021	DP			
	9192675	Jun 12, 2029	DP		U-1788	
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP		U-1861	
	9393372	Jul 04, 2029	DP			
	9446133	Jun 12, 2029	DP		U-1861	
	9511198	Feb 16, 2030			U-1929	
	9511198	Feb 16, 2030			U-1930	
	9597374	Oct 08, 2031			U-1987	
	9662461	Jun 12, 2029	DP		U-2019	
	9717689	Sep 14, 2026	DP			
	9943571	Aug 11, 2029			U-1537	
INSULIN RECOMBINANT HUMAN - AFREZZA						
N 022472 003	10046031	Aug 11, 2029			U-2383	
	6444226	Jun 29, 2020	DP		U-1534	
	6652885	Jun 29, 2020			U-1535	
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020			U-1535	
	7943178	Jun 29, 2020	DP		U-1535	
	7943572	Aug 10, 2026			U-1539	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN RECOMBINANT HUMAN - AFREZZA							
N 022472	003	8119593	Aug 11, 2029	U-1537			
		8146588	Apr 24, 2023	DP			
		8156936	Jan 16, 2023	DP			
		8215300	Nov 24, 2022	DP			
		8258095	Aug 11, 2029	U-1537			
		8389470	Jun 29, 2020	DP U-1621			
		8424518	Oct 17, 2031	DP			
		8485180	Mar 25, 2030	DP			
		8499757	Feb 19, 2032	DP			
		8551528	Jun 11, 2030	DP			
		8623817	Sep 18, 2029	U-1537			
		8636001	Jul 12, 2032	DP			
		8729019	Dec 26, 2028	DP			
		8734845	Jun 11, 2030	DP			
		8778403	Jun 11, 2030	DP U-1538			
		8889099	Jun 29, 2020	DP U-1621			
		8912193	Jun 12, 2029	DP U-1538			
		8950397	Jul 20, 2021	DP			
		9192675	Jun 12, 2029	DP U-1788			
		9283193	Sep 14, 2026	DP			
		9339615	Oct 20, 2029	DP			
		9358352	Feb 15, 2031	DP U-1861			
		9393372	Jul 04, 2029	DP			
		9446133	Jun 12, 2029	DP U-1861			
		9511198	Feb 16, 2030	U-1929			
		9511198	Feb 16, 2030	U-1930			
		9597374	Oct 08, 2031	U-1987			
		9662461	Jun 12, 2029	DP U-2019			
		9717689	Sep 14, 2026	DP			
		9943571	Aug 11, 2029	U-1537			
INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30							
N 019717	001	7291132	Aug 09, 2024	DP			
INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30 PEN							
N 019717	002	7291132	Aug 09, 2024	DP			
INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN N							
N 018781	001	7291132	Aug 09, 2024	DP			
IOBENGUANE I-131 - AZEDRA							
N 209607	001					NP	Jul 30, 2021
						ODE-204	Jul 30, 2025
IODIXANOL - VISIPAQUE 320							
N 020351	002					I-752	Apr 05, 2020
IODIXANOL - VISIPAQUE 320							
N 020808	002					I-752	Apr 05, 2020
IPRATROPIUM BROMIDE - ATROVENT HFA							
N 021527	001	6739333	May 26, 2020	DP			
		6983743	May 26, 2020	DP			
		8474447	Jan 17, 2030	DP			
IRINOTECAN HYDROCHLORIDE - CAMPTOSAR							
N 020571	001	6403569	Apr 28, 2020	U-449			
		6794370	May 01, 2020	U-606			
IRINOTECAN HYDROCHLORIDE - CAMPTOSAR							
N 020571	002	6403569	Apr 28, 2020	U-449			
		6794370	May 01, 2020	U-606			
IRINOTECAN HYDROCHLORIDE - ONIVYDE							
N 207793	001	8147867	Aug 29, 2028	DS DP		ODE-99	Oct 22, 2022
		8329213	May 02, 2025	DS DP			
		8703181	May 02, 2025	U-1434			
		8992970	May 02, 2025	DS DP			
		9339497	Jun 12, 2033	U-1848			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IRINOTECAN HYDROCHLORIDE - ONIVYDE						
N 207793 001	9364473	Jun 12, 2033	U-1856			
	9452162	Jun 12, 2033	U-1899			
	9492442	Jun 12, 2033	U-1848			
	9492442	Jun 12, 2033	U-1899			
	9492442	Jun 12, 2033	U-1917			
	9717724	Jun 12, 2033	U-1848			
	9717724	Jun 12, 2033	U-2091			
	9724303	May 02, 2025	DS DP			
	9730891	May 02, 2025	U-1848			
	9782349	May 02, 2025	DS DP			
ISAVUCONAZONIUM SULFATE - CRESEMBA						
N 207500 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE-90	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
ISAVUCONAZONIUM SULFATE - CRESEMBA						
N 207501 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE-90	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
ISOTRETINOIN - ABSORICA						
N 021951 001	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 002	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 003	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 004	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 005	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 006	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
ITRACONAZOLE - ITRACONAZOLE						
A 205573 001					PC	Mar 17, 2019

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ITRACONAZOLE - SPORANOX						
N 020657 001	6407079	Jun 18, 2019				
ITRACONAZOLE - SPORANOX						
N 020966 001	6407079	Jun 18, 2019				
ITRACONAZOLE - ONMEL						
N 022484 001	8486456	Oct 03, 2028	DP U-1054			
ITRACONAZOLE - TOLSURA						
N 208901 001	8771739	Jul 25, 2023	DP			
	8921374	Jun 21, 2033	DP			
	9272046	Jun 21, 2033	DP			
	9713642	Jun 21, 2033	U-2453			
IVABRADINE HYDROCHLORIDE - CORLANOR						
N 206143 001	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
IVABRADINE HYDROCHLORIDE - CORLANOR						
N 206143 002	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
IVACAFTOR - KALYDECO						
N 203188 001	7495103	May 20, 2027	DS DP		NPP	Jul 31, 2020
	8324242	Aug 05, 2027	U-1311		ODE-186	Feb 21, 2021
	8324242	Aug 05, 2027	U-1906		ODE-187	Dec 29, 2021
	8354427	Jul 06, 2026	U-1311		ODE-189	Jul 31, 2024
	8354427	Jul 06, 2026	U-1905		ODE-190	May 17, 2024
	8410274	Dec 28, 2026	DP		ODE-199	Aug 15, 2025
	8629162	Jun 24, 2025	U-2234		ODE-20	Jan 31, 2019
	8754224	Dec 28, 2026	DS DP			
	9670163	Dec 28, 2026	DP U-1311			
IVACAFTOR - KALYDECO						
N 207925 001	7495103	May 20, 2027	DS DP		NPP	Jul 31, 2020
	8324242	Aug 05, 2027	U-1311		ODE-188	Mar 17, 2022
	8324242	Aug 05, 2027	U-1906		ODE-189	Jul 31, 2024
	8354427	Jul 06, 2026	U-1311		ODE-190	May 17, 2024
	8354427	Jul 06, 2026	U-1905		ODE-199	Aug 15, 2025
	8410274	Dec 28, 2026	DP		ODE-20	Jan 31, 2019
	8629162	Jun 24, 2025	U-2234			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-1311			
IVACAFTOR - KALYDECO						
N 207925 002	7495103	May 20, 2027	DS DP		NPP	Jul 31, 2020
	8324242	Aug 05, 2027	U-1311		ODE-188	Mar 17, 2022
	8324242	Aug 05, 2027	U-1906		ODE-189	Jul 31, 2024
	8354427	Jul 06, 2026	U-1311		ODE-190	May 17, 2024
	8354427	Jul 06, 2026	U-1905		ODE-199	Aug 15, 2025
	8410274	Dec 28, 2026	DP		ODE-20	Jan 31, 2019
	8629162	Jun 24, 2025	U-2234			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-1311			
IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)						
N 210491 001	10022352	Apr 09, 2027	DP U-2343		NCE	Feb 12, 2023
	10058546	Jul 15, 2033	U-2399		ODE-173	Feb 12, 2025
	10081621	Mar 25, 2031	DP U-2420			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-2246			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)							
N 210491	001	8410274	Dec 28, 2026	DP			
		8415387	Nov 12, 2027	U-2246			
		8598181	May 01, 2027	U-2246			
		8623905	May 01, 2027	DS DP			
		8629162	Jun 24, 2025	U-2247			
		8754224	Dec 28, 2026	DS DP			
		9012496	Jul 15, 2033	U-2248			
		9670163	Dec 28, 2026	DP U-2246			
		9931334	Dec 28, 2026	DP U-2275			
		9974781	Apr 09, 2027	DP U-2318			
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 206038	001	10076513	Dec 04, 2028	DP U-2411		M-218	Jan 25, 2021
		7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
		7973038	Nov 08, 2026	U-1973		ODE-123	Sep 28, 2023
		8324242	Aug 05, 2027	U-1311		ODE-93	Jul 02, 2022
		8324242	Aug 05, 2027	U-1911			
		8410274	Dec 28, 2026	DP			
		8507534	Sep 20, 2030	DS DP			
		8653103	Dec 04, 2028	DP			
		8716338	Sep 20, 2030	DP U-1718			
		8716338	Sep 20, 2030	DP U-1910			
		8741933	Nov 08, 2026	U-1717			
		8741933	Nov 08, 2026	U-1909			
		8754224	Dec 28, 2026	DS DP			
		8846718	Dec 04, 2028	U-1717			
		8846718	Dec 04, 2028	U-1908			
		8993600	Dec 11, 2030	DP			
		9150552	Dec 04, 2028	U-1908			
		9192606	Sep 29, 2029	DP U-1912			
		9216969	Nov 08, 2026	DS DP			
		9670163	Dec 28, 2026	DP U-1911			
		9931334	Dec 28, 2026	DP U-2276			
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 206038	002	7495103	May 20, 2027	DS DP		M-218	Jan 25, 2021
		7973038	Nov 08, 2026	U-1973		NCE	Jul 02, 2020
		8324242	Aug 05, 2027	U-1911		NPP	Sep 28, 2019
		8410274	Dec 28, 2026	DP		ODE-123	Sep 28, 2023
		8507534	Sep 20, 2030	DS DP		ODE-93	Jul 02, 2022
		8653103	Dec 04, 2028	DP			
		8716338	Sep 20, 2030	DP U-1910			
		8741933	Nov 08, 2026	U-1909			
		8754224	Dec 28, 2026	DS DP			
		8846718	Dec 04, 2028	U-1908			
		8993600	Dec 11, 2030	DP			
		9150552	Dec 04, 2028	U-1908			
		9192606	Sep 29, 2029	DP U-1912			
		9216969	Nov 08, 2026	DP			
		9670163	Dec 28, 2026	DP U-1911			
		9931334	Dec 28, 2026	DP U-2276			
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 211358	001	7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
		7973038	Nov 08, 2026	U-2374		NP	Aug 07, 2021
		8324242	Aug 05, 2027	U-2374		ODE-195	Aug 07, 2025
		8410274	Dec 28, 2026	DP			
		8507534	Sep 20, 2030	DS DP			
		8653103	Dec 04, 2028	DP			
		8716338	Sep 20, 2030	DP U-2396			
		8741933	Nov 08, 2026	U-2374			
		8754224	Dec 28, 2026	DS DP			
		8846718	Dec 04, 2028	U-2375			
		8993600	Dec 11, 2030	DP			
		9150552	Dec 04, 2028	U-2375			
		9192606	Sep 29, 2029	DP U-2397			
		9216969	Nov 08, 2026	DP			
		9670163	Dec 28, 2026	DP U-2376			
		9931334	Dec 28, 2026	DP U-2376			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 211358	001	7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
		7973038	Nov 08, 2026	U-2374		NP	Aug 07, 2021
		8324242	Aug 05, 2027	U-2374		ODE-195	Aug 07, 2025
		8410274	Dec 28, 2026	DP			
		8507534	Sep 20, 2030	DS DP			
		8653103	Dec 04, 2028	DP			
		8716338	Sep 20, 2030	DP U-2396			
		8741933	Nov 08, 2026	U-2374			
		8754224	Dec 28, 2026	DS DP			
		8846718	Dec 04, 2028	U-2375			
		8993600	Dec 11, 2030	DP			
		9150552	Dec 04, 2028	U-2375			
		9192606	Sep 29, 2029	DP U-2397			
		9216969	Nov 08, 2026	DP			
		9670163	Dec 28, 2026	DP U-2376			
		9931334	Dec 28, 2026	DP U-2376			
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 211358	002	7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
		7973038	Nov 08, 2026	U-2374		NP	Aug 07, 2021
		8324242	Aug 05, 2027	U-2374		ODE-195	Aug 07, 2025
		8410274	Dec 28, 2026	DP			
		8507534	Sep 20, 2030	DS DP			
		8653103	Dec 04, 2028	DP			
		8716338	Sep 20, 2030	DP U-2396			
		8741933	Nov 08, 2026	U-2374			
		8754224	Dec 28, 2026	DS DP			
		8846718	Dec 04, 2028	U-2375			
		8993600	Dec 11, 2030	DP			
		9150552	Dec 04, 2028	U-2375			
		9192606	Sep 29, 2029	DP U-2397			
		9216969	Nov 08, 2026	DP			
		9670163	Dec 28, 2026	DP U-2376			
		9931334	Dec 28, 2026	DP U-2376			
IVERMECTIN - SKLICE							
N 202736	001	8791153	Oct 12, 2027	DP			
		8927595	Oct 12, 2027	U-1782			
IVERMECTIN - SOOLANTRA							
N 206255	001	6133310	Apr 26, 2019	U-1631			
		7550440	Apr 22, 2024	DP U-1631			
		8080530	Apr 22, 2024	DP U-1631			
		8093219	Apr 22, 2024	DP U-1631			
		8415311	Apr 22, 2024	DP U-1631			
		8470788	Apr 22, 2024	DP U-1631			
		8815816	Apr 22, 2024	DP U-1631			
		9089587	Mar 13, 2034	U-1631			
		9233117	Mar 13, 2034	U-1631			
		9233118	Mar 13, 2034	U-1631			
		9782425	Mar 13, 2034	U-1631			
IVOSIDENIB - TIBSOVO							
N 211192	001	9474779	Aug 19, 2033	DS DP U-2350		NCE	Jul 20, 2023
		9850277	Jan 18, 2033	DS DP U-2350		ODE-203	Jul 20, 2025
		9968595	Mar 13, 2035	DP U-2351			
IXABEPILONE - IXEMPRA KIT							
N 022065	001	6670384	Jan 23, 2022	DP U-959			
		6670384	Jan 23, 2022	DP U-960			
		7022330	Jan 23, 2022	DP U-958			
		7312237	Aug 21, 2024	U-965			
		RE41393	Feb 08, 2022	U-961			
		RE41911	Sep 28, 2020	DS DP U-961			
IXABEPILONE - IXEMPRA KIT							
N 022065	002	6670384	Jan 23, 2022	DP U-959			
		6670384	Jan 23, 2022	DP U-960			
		7022330	Jan 23, 2022	DP U-958			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IXABEPILONE - IXEMPRA KIT							
N 022065	002	7312237	Aug 21, 2024	U-965			
		RE41393	Feb 08, 2022	U-961			
		RE41911	Sep 28, 2020	DS DP U-961			
IXAZOMIB CITRATE - NINLARO							
N 208462	001	7442830	Aug 06, 2027	DS DP U-2434		NCE	Nov 20, 2020
		7687662	Aug 06, 2027	DS DP		ODE-103	Nov 20, 2022
		8003819	Aug 06, 2027	DS DP U-2434			
		8530694	Aug 06, 2027	DS DP U-2434			
		8546608	Aug 12, 2024	DS			
		8859504	Jun 16, 2029	DS DP			
		8871745	Aug 06, 2027	U-2434			
		9175017	Jun 16, 2029	U-2434			
		9233115	Aug 12, 2024	U-2434			
IXAZOMIB CITRATE - NINLARO							
N 208462	002	7442830	Aug 06, 2027	DS DP U-2434		NCE	Nov 20, 2020
		7687662	Aug 06, 2027	DS DP		ODE-103	Nov 20, 2022
		8003819	Aug 06, 2027	DS DP U-2434			
		8530694	Aug 06, 2027	DS DP U-2434			
		8546608	Aug 12, 2024	DS			
		8859504	Jun 16, 2029	DS DP			
		8871745	Aug 06, 2027	U-2434			
		9175017	Jun 16, 2029	U-2434			
		9233115	Aug 12, 2024	U-2434			
IXAZOMIB CITRATE - NINLARO							
N 208462	003	7442830	Aug 06, 2027	DS DP U-2434		NCE	Nov 20, 2020
		7687662	Aug 06, 2027	DS DP		ODE-103	Nov 20, 2022
		8003819	Aug 06, 2027	DS DP U-2434			
		8530694	Aug 06, 2027	DS DP U-2434			
		8546608	Aug 12, 2024	DS			
		8859504	Jun 16, 2029	DS DP			
		8871745	Aug 06, 2027	U-2434			
		9175017	Jun 16, 2029	U-2434			
		9233115	Aug 12, 2024	U-2434			
KETOCONAZOLE - XOLEGEL							
N 021946	001	8232276	Nov 24, 2020	DP			
KETOROLAC TROMETHAMINE - ACULAR LS							
N 021528	001	8008338	May 24, 2027	DS DP U-1181			
		8207215	May 28, 2024	U-1251			
		8377982	May 28, 2024	U-1363			
		8377982*PED	Nov 28, 2024				
		8541463	May 28, 2024	U-1441			
		8541463*PED	Nov 28, 2024				
		8648107	May 28, 2024	DP			
		8906950	May 28, 2024	U-1626			
		8946281	May 28, 2024	U-1662			
		9216167	May 28, 2024	U-1800			
KETOROLAC TROMETHAMINE - ACUVAIL							
N 022427	001	7842714	Aug 15, 2029	DS DP			
		8512717	Mar 07, 2028	DP			
		8992952	Aug 05, 2024	DP			
		9192571	Mar 07, 2028	DP			
KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIDRIA							
N 205388	001	8173707	Jul 30, 2023	U-1518		NPP	Dec 08, 2020
		8173707*PED	Jan 30, 2024			PED	Jun 08, 2021
		8586633	Jul 30, 2023	DP			
		8586633*PED	Jan 30, 2024				
		9066856	Oct 23, 2033	DP			
		9066856*PED	Apr 23, 2034				
		9278101	Jul 30, 2023	U-1518			
		9278101*PED	Jan 30, 2024				
		9399040	Jul 30, 2023	DP			
		9399040*PED	Jan 30, 2024				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIDRIA							
N 205388	001	9486406	Oct 23, 2033	DP			
		9486406*PED	Apr 23, 2034				
		9855246	Oct 23, 2033	DP			
L-GLUTAMINE - ENDARI							
N 208587	001					I-748	Jul 07, 2020
						ODE-150	Jul 07, 2024
LACOSAMIDE - VIMPAT							
N 022253	001	RE38551	Mar 17, 2022	DS DP U-1567		NPP	Nov 03, 2020
		RE38551	Mar 17, 2022	DS DP U-2140			
LACOSAMIDE - VIMPAT							
N 022253	002	RE38551	Mar 17, 2022	DS DP U-1567		NPP	Nov 03, 2020
		RE38551	Mar 17, 2022	DS DP U-2140			
LACOSAMIDE - VIMPAT							
N 022253	003	RE38551	Mar 17, 2022	DS DP U-1567		NPP	Nov 03, 2020
		RE38551	Mar 17, 2022	DS DP U-2140			
LACOSAMIDE - VIMPAT							
N 022253	004	RE38551	Mar 17, 2022	DS DP U-1567		NPP	Nov 03, 2020
		RE38551	Mar 17, 2022	DS DP U-2140			
LACOSAMIDE - VIMPAT							
N 022254	001	RE38551	Mar 17, 2022	DS DP U-1565		M-217	Nov 03, 2020
		RE38551	Mar 17, 2022	DS DP U-1568			
LACOSAMIDE - VIMPAT							
N 022255	001	RE38551	Mar 17, 2022	DS DP U-1567		NPP	Nov 03, 2020
		RE38551	Mar 17, 2022	DS DP U-2140			
LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS							
N 206510	001	7169780	Oct 03, 2023	DS DP			
		7169780*PED	Apr 03, 2024				
		7217713	Oct 21, 2022	U-1663			
		7217713*PED	Apr 21, 2023				
		7435734	Oct 21, 2022	U-1663			
		7435734*PED	Apr 21, 2023				
		7754731	Mar 11, 2029	DS DP U-1663			
		7754731*PED	Sep 11, 2029				
		7820660	Apr 25, 2023	DS			
LAMOTRIGINE - LAMICTAL XR							
N 022115	001	8637512	Jun 14, 2028	DP			
		9144547	Sep 22, 2023	DP			
LAMOTRIGINE - LAMICTAL XR							
N 022115	002	8637512	Jun 14, 2028	DP			
		9144547	Sep 22, 2023	DP			
LAMOTRIGINE - LAMICTAL XR							
N 022115	003	8637512	Jun 14, 2028	DP			
		9144547	Sep 22, 2023	DP			
LAMOTRIGINE - LAMICTAL XR							
N 022115	004	8637512	Jun 14, 2028	DP			
		9144547	Sep 22, 2023	DP			
LAMOTRIGINE - LAMICTAL XR							
N 022115	005	8637512	Jun 14, 2028	DP			
		9144547	Sep 22, 2023	DP			
LAMOTRIGINE - LAMICTAL XR							
N 022115	006	8637512	Jun 14, 2028	DP			
		9144547	Sep 22, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LAMOTRIGINE - LAMICTAL ODT						
N 022251 001	7919115	Jan 04, 2029	DS DP			
	8840925	Jul 02, 2028	DP U-1596			
	9339504	Jul 02, 2028	DP U-1596			
LAMOTRIGINE - LAMICTAL ODT						
N 022251 004	7919115	Jan 04, 2029	DS DP			
	8840925	Jul 02, 2028	DP U-1596			
	9339504	Jul 02, 2028	DP U-1596			
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N 022074 001	5595760	Mar 08, 2020	DP U-831		I-754	Sep 15, 2020
					ODE-156	Sep 15, 2024
					ODE-82	Dec 16, 2021
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N 022074 002	5595760	Mar 08, 2020	DP U-831		I-754	Sep 15, 2020
					ODE-156	Sep 15, 2024
					ODE-82	Dec 16, 2021
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N 022074 003	5595760	Mar 08, 2020	DP U-831		I-754	Sep 15, 2020
					ODE-156	Sep 15, 2024
					ODE-82	Dec 16, 2021
LANSOPRAZOLE - PREVACID						
N 021428 001	6328994	May 17, 2019				
	7431942	May 17, 2019	DP			
	7875292	May 17, 2019	DP			
	9901546	May 17, 2019	DP			
	9901546*PED	Nov 17, 2019				
LANSOPRAZOLE - PREVACID						
N 021428 002	6328994	May 17, 2019				
	7431942	May 17, 2019	DP			
	7875292	May 17, 2019	DP			
	9901546	May 17, 2019	DP			
	9901546*PED	Nov 17, 2019				
LANSOPRAZOLE - PREVACID IV						
N 021566 001	7396841	Aug 17, 2021	DP U-947			
LANTHANUM CARBONATE - FOSRENOL						
N 021468 001	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
LANTHANUM CARBONATE - FOSRENOL						
N 021468 002	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
LANTHANUM CARBONATE - FOSRENOL						
N 021468 003	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
LANTHANUM CARBONATE - FOSRENOL						
N 021468 004	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
LANTHANUM CARBONATE - FOSRENOL						
N 204734 001	7465465	Aug 26, 2024	DP			
	8980327	Dec 01, 2030	DP			
	9023397	Dec 01, 2030	DP			
LANTHANUM CARBONATE - FOSRENOL						
N 204734 002	7465465	Aug 26, 2024	DP			
	8980327	Dec 01, 2030	DP			
	9023397	Dec 01, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LAPATINIB DITOSYLATE - TYKERB						
N 022059 001	6713485	Sep 29, 2020	DS DP U-1429		M-235	Dec 06, 2021
	6713485	Sep 29, 2020	DS DP U-800			
	6727256	Jan 08, 2019	DS DP U-1429			
	6727256	Jan 08, 2019	DS DP U-800			
	7157466	Nov 19, 2021	DS DP			
	8513262	Jan 08, 2019	DS DP			
	8821927	Sep 18, 2029	DS DP			
LAROTRECTINIB - VITRAKVI						
N 210861 001	10005783	Oct 21, 2029	U-2472		ODE-215	Nov 26, 2025
	10047097	Oct 21, 2029	U-2474		ODE-220	Nov 26, 2025
	8513263	Dec 23, 2029	DS DP		ODE-221	Nov 26, 2025
	8865698	Oct 21, 2029	U-2469			
	9127013	Oct 21, 2029	DS DP			
	9447104	Oct 21, 2029	U-2470			
	9676783	Oct 21, 2029	U-2469			
	9782414	Nov 16, 2035	U-2475			
LAROTRECTINIB - VITRAKVI						
N 210861 002	10005783	Oct 21, 2029	U-2472		ODE-215	Nov 26, 2025
	10047097	Oct 21, 2029	U-2474		ODE-220	Nov 26, 2025
	8513263	Dec 23, 2029	DS DP		ODE-221	Nov 26, 2025
	8865698	Oct 21, 2029	U-2469			
	9127013	Oct 21, 2029	DS DP			
	9447104	Oct 21, 2029	U-2470			
	9676783	Oct 21, 2029	U-2469			
	9782414	Nov 16, 2035	U-2475			
LAROTRECTINIB - VITRAKVI						
N 211710 001	10005783	Oct 21, 2029	U-2472		ODE-215	Nov 26, 2025
	10045991	Apr 04, 2037	U-2473		ODE-220	Nov 26, 2025
	10047097	Oct 21, 2029	U-2474		ODE-221	Nov 26, 2025
	10137127	Apr 04, 2037	DP			
	8513263	Dec 23, 2029	DS DP			
	8865698	Oct 21, 2029	U-2469			
	9127013	Oct 21, 2029	DS DP			
	9447104	Oct 21, 2029	U-2470			
	9676783	Oct 21, 2029	U-2469			
	9782414	Nov 16, 2035	U-2471			
LATANOPROST - XELPROS						
N 206185 001	9539262	Oct 15, 2028	DP U-2400			
	9629852	Sep 12, 2029	DP			
LATANOPROSTENE BUNOD - VYZULTA						
N 207795 001	7273946	Oct 03, 2025	DS DP U-2144			
	7629345	Jan 05, 2025	DP U-2144			
	7910767	Jan 05, 2025	DS DP U-2144			
	8058467	Jan 05, 2025	DS U-2144			
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 205834 001	10039779	Jan 30, 2034	DS DP U-2369		D-158	Feb 12, 2019
	10039779	Jan 30, 2034	DS DP U-2370		D-159	Feb 12, 2019
	7964580	Mar 26, 2029	DS DP U-1470		D-160	Feb 12, 2019
	8088368	May 12, 2030	DS DP		NCE	Oct 10, 2019
	8273341	May 12, 2030	U-1470		NPP	Apr 07, 2020
	8334270	Mar 21, 2028	DS DP U-1470		ODE-136	Apr 07, 2024
	8580765	Mar 21, 2028	DS DP U-1470			
	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
	8735372	Mar 21, 2028	U-1470			
	8822430	May 12, 2030	DS DP U-1470			
	8841278	May 12, 2030	DP U-1470			
	8889159	Mar 26, 2029	DP U-1470			
	9085573	Mar 21, 2028	DS DP U-1470			
	9284342	Sep 13, 2030	DS DP U-1470			
	9393256	Sep 14, 2032	U-1470			
	9511056	May 12, 2030	DP U-1470			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LENALIDOMIDE - REVLIMID						
N 021880 001	5635517	Oct 04, 2019	DS		ODE-131	Feb 22, 2024
	6315720	Oct 23, 2020	U-1210		ODE-49	Jun 05, 2020
	6561977	Oct 23, 2020	U-1210		ODE-88	Feb 17, 2022
	6755784	Oct 23, 2020	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID						
N 021880 002	5635517	Oct 04, 2019	DS		ODE-131	Feb 22, 2024
	6315720	Oct 23, 2020	U-1210		ODE-49	Jun 05, 2020
	6561977	Oct 23, 2020	U-1210		ODE-88	Feb 17, 2022
	6755784	Oct 23, 2020	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID						
N 021880 003	5635517	Oct 04, 2019	DS		ODE-131	Feb 22, 2024
	6315720	Oct 23, 2020	U-1210		ODE-49	Jun 05, 2020
	6561977	Oct 23, 2020	U-1210		ODE-88	Feb 17, 2022
	6755784	Oct 23, 2020	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID						
N 021880 004	5635517	Oct 04, 2019	DS		ODE-131	Feb 22, 2024
	6315720	Oct 23, 2020	U-1210		ODE-49	Jun 05, 2020
	6561977	Oct 23, 2020	U-1210		ODE-88	Feb 17, 2022
	6755784	Oct 23, 2020	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LENALIDOMIDE - REVLIMID						
N 021880 004	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID						
N 021880 005	5635517	Oct 04, 2019	DS		ODE-131	Feb 22, 2024
	6315720	Oct 23, 2020	U-1210		ODE-49	Jun 05, 2020
	6561977	Oct 23, 2020	U-1210		ODE-88	Feb 17, 2022
	6755784	Oct 23, 2020	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID						
N 021880 006	5635517	Oct 04, 2019	DS		ODE-131	Feb 22, 2024
	6315720	Oct 23, 2020	U-1210		ODE-49	Jun 05, 2020
	6561977	Oct 23, 2020	U-1210		ODE-88	Feb 17, 2022
	6755784	Oct 23, 2020	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			
LENVATINIB MESYLATE - LENVIMA						
N 206947 001	7253286	Oct 19, 2021	DS DP		I-734	May 13, 2019
	7612208	Sep 19, 2026	DS DP		I-787	Aug 15, 2021
	9006256	Jul 27, 2027	U-1695		NCE	Feb 13, 2020
					ODE-196	Aug 15, 2025
					ODE-87	Feb 13, 2022
LENVATINIB MESYLATE - LENVIMA						
N 206947 002	7253286	Oct 19, 2021	DS DP		I-734	May 13, 2019
	7612208	Sep 19, 2026	DS DP		I-787	Aug 15, 2021
	9006256	Jul 27, 2027	U-1695		NCE	Feb 13, 2020
					ODE-196	Aug 15, 2025
					ODE-87	Feb 13, 2022
LESINURAD - ZURAMPIC						
N 207988 001	8003681	Aug 25, 2025	DS		NCE	Dec 22, 2020
	8084483	Aug 17, 2029	U-1801			
	8283369	Nov 26, 2028	U-1802			
	8283369	Nov 26, 2028	U-1804			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LESINURAD - ZURAMPIC							
N 207988	001	8357713	Nov 26, 2028	DP U-1801			
		8357713	Nov 26, 2028	DP U-1802			
		8357713	Nov 26, 2028	DP U-1803			
		8546436	Feb 29, 2032	DS DP			
		8546437	Apr 29, 2029	U-1803			
		9216179	Aug 01, 2031	U-1806			
		9956205	Dec 28, 2031	U-2311			
LETERMOVIR - PREVYMIS							
N 209939	001	7196086	May 22, 2024	DS DP		NCE	Nov 08, 2022
		8513255	May 22, 2024	DS DP		ODE-165	Nov 08, 2024
LETERMOVIR - PREVYMIS							
N 209939	002	7196086	May 22, 2024	DS DP		NCE	Nov 08, 2022
		8513255	May 22, 2024	DS DP		ODE-165	Nov 08, 2024
LETERMOVIR - PREVYMIS							
N 209940	001	7196086	May 22, 2024	DS DP		NCE	Nov 08, 2022
		8513255	May 22, 2024	DS DP		ODE-165	Nov 08, 2024
LETERMOVIR - PREVYMIS							
N 209940	002	7196086	May 22, 2024	DS DP		NCE	Nov 08, 2022
		8513255	May 22, 2024	DS DP		ODE-165	Nov 08, 2024
LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED)							
N 209935	001	8324225	Jun 17, 2028	DS DP		NCE	Mar 13, 2022
		8415355	Feb 19, 2031	DS DP			
		8685980	May 25, 2030	DS DP			
		8962630	Dec 09, 2029	U-1981			
		9193732	Nov 09, 2031	DS DP			
		9416136	Aug 20, 2029	U-1981			
		9868739	Nov 09, 2031	U-1981			
LEUPROLIDE ACETATE - LUPRON DEPOT							
N 020517	003	7429559	Jan 13, 2019	DP			
		8815801	Jun 28, 2022	DP			
		8921326	Feb 05, 2031	DP U-1666			
LEUPROLIDE ACETATE - ELIGARD							
N 021343	001	6626870	Mar 27, 2020	DP			
LEUPROLIDE ACETATE - ELIGARD							
N 021379	001	6626870	Mar 27, 2020	DP			
		8470359	Oct 15, 2023	DS DP U-621			
		8840916	Nov 13, 2020	DP			
		9539333	Nov 13, 2020	DS DP U-621			
LEUPROLIDE ACETATE - ELIGARD							
N 021488	001	6626870	Mar 27, 2020	DP			
		8470359	Oct 15, 2023	DS DP U-621			
		8840916	Nov 13, 2020	DP			
		9539333	Nov 13, 2020	DS DP U-621			
LEUPROLIDE ACETATE - ELIGARD							
N 021731	001	6626870	Mar 27, 2020	DP			
		8470359	Oct 15, 2023	DS DP U-621			
		8840916	Nov 13, 2020	DP			
		9539333	Nov 13, 2020	DS DP U-621			
		9914802	Nov 13, 2020	DS DP U-1666			
LEUPROLIDE ACETATE - LUTRATE DEPOT KIT							
N 205054	001	9789064	Dec 15, 2020	DP			
LEVALBUTEROL HYDROCHLORIDE - XOPENEX							
N 020837	001	6451289	Mar 21, 2021				
LEVALBUTEROL HYDROCHLORIDE - XOPENEX							
N 020837	002	6451289	Mar 21, 2021				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVALBUTEROL HYDROCHLORIDE - XOPENEX								
N	020837	003	6451289	Mar 21, 2021				
LEVALBUTEROL HYDROCHLORIDE - XOPENEX								
N	020837	004	6451289	Mar 21, 2021	DP			
LEVALBUTEROL TARTRATE - XOPENEX HFA								
N	021730	001	7256310	Oct 08, 2024	DS DP		U-636	
			8765153	Dec 08, 2023	DP			
LEVETIRACETAM - KEPPRA								
N	021035	001	8802142	Jun 07, 2031	DP			
			8802142*PED	Dec 07, 2031				
LEVETIRACETAM - KEPPRA								
N	021035	002	8802142	Jun 07, 2031	DP			
			8802142*PED	Dec 07, 2031				
LEVETIRACETAM - KEPPRA								
N	021035	003	8802142	Jun 07, 2031	DP			
			8802142*PED	Dec 07, 2031				
LEVETIRACETAM - KEPPRA								
N	021035	004	8802142	Jun 07, 2031	DP			
			8802142*PED	Dec 07, 2031				
LEVETIRACETAM - KEPPRA XR								
N	022285	001	7858122	Sep 17, 2028	DP			
LEVETIRACETAM - KEPPRA XR								
N	022285	002	7858122	Sep 17, 2028	DP			
LEVETIRACETAM - ELEPSIA XR								
N	204417	001	8163306	Sep 03, 2027	DP			
			8425938	Feb 22, 2026	DP			
			8431156	Oct 31, 2027	DP			
			8470367	Feb 22, 2026	DP			
			8535717	Feb 22, 2026	DP			
LEVETIRACETAM - ELEPSIA XR								
N	204417	002	8163306	Sep 03, 2027	DP			
			8425938	Feb 22, 2026	DP			
			8431156	Oct 31, 2027	DP			
			8470367	Feb 22, 2026	DP			
			8535717	Feb 22, 2026	DP			
LEVETIRACETAM - SPRITAM								
N	207958	001	9339489	Mar 14, 2034	DP		U-1850	
			9669009	Mar 14, 2034			U-1850	
			9669009	Mar 14, 2034			U-2021	
			9669009	Mar 14, 2034			U-2022	
LEVETIRACETAM - SPRITAM								
N	207958	002	9339489	Mar 14, 2034	DP		U-1850	
			9669009	Mar 14, 2034			U-1850	
			9669009	Mar 14, 2034			U-2021	
			9669009	Mar 14, 2034			U-2022	
LEVETIRACETAM - SPRITAM								
N	207958	003	9339489	Mar 14, 2034	DP		U-1850	
			9669009	Mar 14, 2034			U-1850	
			9669009	Mar 14, 2034			U-2021	
			9669009	Mar 14, 2034			U-2022	
LEVETIRACETAM - SPRITAM								
N	207958	004	9339489	Mar 14, 2034	DP		U-1850	
			9669009	Mar 14, 2034			U-1850	
			9669009	Mar 14, 2034			U-2021	
			9669009	Mar 14, 2034			U-2022	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOCARNITINE - CARNITOR							
N 020182	001	6335369	Jan 18, 2021	U-433			
		6429230	Jan 18, 2021	U-433			
		6696493	Jan 18, 2021	U-433			
LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL ALLERGY 24HR							
N 209090	001	8633194	Oct 16, 2027	DP			
LEVOFLOXACIN - LEVAQUIN							
N 021721	001	6806256	Feb 26, 2022	DP			
LEVOLEUCOVORIN CALCIUM - FUSILEV							
N 020140	001	6500829	Mar 07, 2022	DS DP			
LEVOLEUCOVORIN CALCIUM - FUSILEV							
N 020140	002	6500829	Mar 07, 2022	DS DP			
LEVOLEUCOVORIN CALCIUM - FUSILEV							
N 020140	003	6500829	Mar 07, 2022	DS DP			
LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA							
N 204168	001	8481598	Mar 02, 2031	U-839			
		8865937	May 23, 2032	DS DP			
		RE43879	Jun 03, 2023	U-839			
LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA							
N 204168	002	8481598	Mar 02, 2031	U-839			
		8865937	May 23, 2032	DS DP			
		RE43879	Jun 03, 2023	U-839			
LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA							
N 204168	003	8481598	Mar 02, 2031	U-839			
		8865937	May 23, 2032	DS DP			
		RE43879	Jun 03, 2023	U-839			
LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA							
N 204168	004	8481598	Mar 02, 2031	U-839			
		8865937	May 23, 2032	DS DP			
		RE43879	Jun 03, 2023	U-839			
LEVONORGESTREL - MIRENA							
N 021225	001	9615965	Sep 16, 2029	DP U-2003			
		9668912	Apr 01, 2031	DP			
LEVONORGESTREL - SKYLA							
N 203159	001	7252839	Nov 13, 2023	DP			
		9615965	Sep 16, 2029	DP U-2003			
		9668912	Apr 01, 2031	DP			
LEVONORGESTREL - LILETTA							
N 206229	001	10028858	Mar 22, 2034	DP U-2348			
LEVONORGESTREL - KYLEENA							
N 208224	001	7252839	Nov 13, 2023	DP		NP	Sep 16, 2019
		9615965	Sep 16, 2029	DP U-2003			
		9668912	Apr 01, 2031	DP			
LEVORPHANOL TARTRATE - LEVORPHANOL TARTRATE							
A 211484	001					CGT	Jun 11, 2019
LEVOTHYROXINE SODIUM - LEVOXYL							
N 021301	001	6555581	Feb 15, 2022				
		7067148	Feb 15, 2022	DP			
		7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL							
N 021301	002	6555581	Feb 15, 2022				
		7067148	Feb 15, 2022	DP			
		7101569	Oct 02, 2023	U-759			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 003	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 004	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 005	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 006	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 007	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 008	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 009	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 010	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 011	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 012	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 001	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 002	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 003	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 004	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 005	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 006	6399101	Mar 30, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOTHYROXINE SODIUM - LEVO-T								
N	021342	007	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T								
N	021342	008	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T								
N	021342	009	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T								
N	021342	010	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T								
N	021342	011	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - TIROSINT								
N	021924	002	7691411	Mar 14, 2024	DP			
			7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT								
N	021924	003	7691411	Mar 14, 2024	DP			
			7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT								
N	021924	004	7691411	Mar 14, 2024	DP			
			7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT								
N	021924	005	7691411	Mar 14, 2024	DP			
			7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT								
N	021924	006	7691411	Mar 14, 2024	DP			
			7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT								
N	021924	007	7691411	Mar 14, 2024	DP			
			7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT								
N	021924	008	7691411	Mar 14, 2024	DP			
			7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT								
N	021924	009	7691411	Mar 14, 2024	DP			
			7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT								
N	021924	010	7691411	Mar 14, 2024	DP			
			7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT								
N	021924	013	7691411	Mar 14, 2024	DP			
			7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM								
N	202231	001	9006289	Oct 03, 2032	DP			
			9168238	Aug 29, 2032	DP			
			9168239	Aug 29, 2032	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM								
N	202231	002	9006289	Oct 03, 2032	DP			
			9168238	Aug 29, 2032	DP			
			9168239	Aug 29, 2032	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM								
N	202231	003	9006289	Oct 03, 2032	DP			
			9168238	Aug 29, 2032	DP			
			9168239	Aug 29, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LIDOCAINE - ZTLIDO							
N 207962	001	9283174	May 10, 2031	DP		NP	Feb 28, 2021
		9925264	May 10, 2031	DP U-2267			
		9931403	May 10, 2031	DP			
LIDOCAINE HYDROCHLORIDE - ZINGO							
N 022114	001	8540665	Oct 22, 2029	U-1438			
		9358338	Apr 27, 2035	U-1870			
		9370622	Sep 28, 2035	U-1870			
LIDOCAINE HYDROCHLORIDE - AKTEN							
N 022221	001	8759401	Jul 24, 2026	DP U-1523			
LIDOCAINE; TETRACAINE - SYNERA							
N 021623	001	6465709	Jul 07, 2020	DP			
LIDOCAINE; TETRACAINE - PLIAGLIS							
N 021717	001	6528086	Sep 28, 2019	DP			
LIFITEGRAST - XIIDRA							
N 208073	001	10124000	Nov 05, 2024	U-1900		NCE	Jul 11, 2021
		7314938	Mar 10, 2025	DS DP			
		7745460	Nov 05, 2024	DS DP U-1880			
		7790743	Nov 05, 2024	U-1880			
		7928122	Nov 05, 2024	DS DP			
		8084047	May 17, 2026	DS DP			
		8168655	May 09, 2029	U-1880			
		8367701	Apr 15, 2029	DP U-1880			
		8592450	May 17, 2026	U-1880			
		8927574	Nov 12, 2030	DP			
		9085553	Jul 25, 2033	DP			
		9216174	Nov 05, 2024	DP			
		9353088	Oct 21, 2030	DP			
		9447077	Apr 15, 2029	U-1900			
		9890141	Oct 21, 2030	DS			
LINACLOTIDE - LINZESS							
N 202811	001	7304036	Aug 30, 2026	DS DP U-1278			
		7304036	Aug 30, 2026	DS DP U-1516			
		7371727	Jan 28, 2024	DS			
		7704947	Jan 28, 2024	DS DP			
		7745409	Jan 28, 2024	DS DP			
		8080526	Jan 28, 2024	DS DP			
		8110553	Jan 28, 2024	U-1278			
		8748573	Oct 30, 2031	U-1515			
		8748573	Oct 30, 2031	U-1516			
		8802628	Nov 17, 2031	DP			
		8933030	Feb 17, 2031	DP			
		9708371	Aug 16, 2033	DP U-1515			
		9708371	Aug 16, 2033	DP U-1516			
LINACLOTIDE - LINZESS							
N 202811	002	7304036	Aug 30, 2026	DS DP U-1278			
		7304036	Aug 30, 2026	DS DP U-1516			
		7371727	Jan 28, 2024	DS			
		7704947	Jan 28, 2024	DS DP			
		7745409	Jan 28, 2024	DS DP			
		8080526	Jan 28, 2024	DS DP			
		8110553	Jan 28, 2024	U-1278			
		8748573	Oct 30, 2031	U-1515			
		8748573	Oct 30, 2031	U-1516			
		8802628	Nov 17, 2031	DP			
		8933030	Feb 17, 2031	DP			
		9708371	Aug 16, 2033	DP U-1515			
LINACLOTIDE - LINZESS							
N 202811	003	7304036	Aug 30, 2026	DS DP U-1516		NS	Jan 25, 2020
		7371727	Jan 28, 2024	DS			
		7704947	Jan 28, 2024	DS DP			
		7745409	Jan 28, 2024	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LINACLOTIDE - LINZESS							
N 202811	003	8080526	Jan 28, 2024	DS DP			
		8110553	Jan 28, 2024	U-1516			
		8933030	Feb 17, 2031	DP U-1516			
		9708371	Aug 16, 2033	DP U-1516			
LINAGLIPTIN - TRADJENTA							
N 201280	001	10034877	Aug 05, 2029	U-2347			
		6890898	Feb 02, 2019	U-1270			
		6890898	Feb 02, 2019	U-493			
		7078381	Feb 02, 2019	U-1270			
		7078381	Feb 02, 2019	U-493			
		7407955	May 02, 2025	DS DP			
		7459428	Feb 02, 2019	U-1270			
		7459428	Feb 02, 2019	U-493			
		8119648	Aug 12, 2023	U-1270			
		8119648	Aug 12, 2023	U-774			
		8178541	Aug 12, 2023	U-1244			
		8178541	Aug 12, 2023	U-1245			
		8178541	Aug 12, 2023	U-1270			
		8178541	Aug 12, 2023	U-775			
		8673927	May 04, 2027	U-1503			
		8846695	Jun 04, 2030	U-1503	Y		
		8853156	Mar 05, 2031	U-1642			
		8883805	Nov 26, 2025	DP			
		9173859	May 04, 2027	DP U-1503			
		9173859	May 04, 2027	DP U-1768			
		9486526	Aug 05, 2029	U-1915			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO							
N 201281	001	10022379	Apr 02, 2029	U-2339			
		6890898	Feb 02, 2019	U-1039			
		7078381	Feb 02, 2019	U-1039			
		7407955	May 02, 2025	DS DP			
		7459428	Feb 02, 2019	U-1039			
		8119648	Aug 12, 2023	U-802			
		8178541	Aug 12, 2023	DP U-775			
		8673927	May 04, 2027	U-1503			
		8846695	Jun 04, 2030	U-1503			
		8883805	Nov 26, 2025	DP			
		9155705	May 21, 2030	DP			
		9173859	May 04, 2027	DP U-1503			
		9415016	Apr 02, 2029	DP			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO							
N 201281	002	10022379	Apr 02, 2029	U-2339			
		6890898	Feb 02, 2019	U-1039			
		7078381	Feb 02, 2019	U-1039			
		7407955	May 02, 2025	DS DP			
		7459428	Feb 02, 2019	U-1039			
		8119648	Aug 12, 2023	U-802			
		8178541	Aug 12, 2023	DP U-775			
		8673927	May 04, 2027	U-1503			
		8846695	Jun 04, 2030	U-1503			
		8883805	Nov 26, 2025	DP			
		9155705	May 21, 2030	DP			
		9173859	May 04, 2027	DP U-1503			
		9415016	Apr 02, 2029	DP			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO							
N 201281	003	10022379	Apr 02, 2029	U-2339			
		6890898	Feb 02, 2019	U-1039			
		7078381	Feb 02, 2019	U-1039			
		7407955	May 02, 2025	DS DP			
		7459428	Feb 02, 2019	U-1039			
		8119648	Aug 12, 2023	U-802			
		8178541	Aug 12, 2023	DP U-775			
		8673927	May 04, 2027	U-1503			
		8846695	Jun 04, 2030	U-1503	Y		
		8883805	Nov 26, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO							
N 201281	003	9155705	May 21, 2030	DP			
		9173859	May 04, 2027	DP U-1503			
		9415016	Apr 02, 2029	DP			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR							
N 208026	001	10022379	Apr 02, 2029	U-2339			
		6488962	Jun 20, 2020	DP			
		6890898	Feb 02, 2019	U-803			
		7078381	Feb 02, 2019	U-803			
		7407955	May 02, 2025	DS DP			
		7459428	Feb 02, 2019	U-803			
		8119648	Aug 12, 2023	U-802			
		8178541	Aug 12, 2023	DP U-1853			
		8673927	May 04, 2027	U-1503			
		8883805	Nov 26, 2025	DP			
		9155705	May 21, 2030	DP			
		9173859	May 04, 2027	DP U-1503			
		9415016	Apr 02, 2029	DP			
		9555001	Mar 06, 2033	DP U-1967			
		9555001	Mar 06, 2033	DP U-1968			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR							
N 208026	002	10022379	Apr 02, 2029	U-2339			
		6488962	Jun 20, 2020	DP			
		6890898	Feb 02, 2019	U-803			
		7078381	Feb 02, 2019	U-803			
		7407955	May 02, 2025	DS DP			
		7459428	Feb 02, 2019	U-803			
		8119648	Aug 12, 2023	U-802			
		8178541	Aug 12, 2023	DP U-1853			
		8673927	May 04, 2027	U-1503			
		8883805	Nov 26, 2025	DP			
		9155705	May 21, 2030	DP			
		9173859	May 04, 2027	DP U-1503			
		9415016	Apr 02, 2029	DP			
		9555001	Mar 06, 2033	DP U-1967			
		9555001	Mar 06, 2033	DP U-1968			
LINEZOLID - ZYVOX							
N 021130	001	6514529	Mar 15, 2021	DP			
		6559305	Jan 29, 2021	DS			
LINEZOLID - ZYVOX							
N 021130	002	6514529	Mar 15, 2021	DP			
		6559305	Jan 29, 2021	DS			
LINEZOLID - ZYVOX							
N 021131	001	6559305	Jan 29, 2021	DS			
LINEZOLID - ZYVOX							
N 021131	002	6559305	Jan 29, 2021	DS			
		6559305*PED	Jul 29, 2021				
LINEZOLID - ZYVOX							
N 021131	003	6559305	Jan 29, 2021	DS			
		6559305*PED	Jul 29, 2021				
LINEZOLID - ZYVOX							
N 021132	001	6559305	Jan 29, 2021	DS			
LIRAGLUTIDE RECOMBINANT - VICTOZA							
N 022341	001	6004297	Jan 28, 2019	DP		I-750	Aug 25, 2020
		6268343	Aug 22, 2022	DS DP U-968		M-176	Apr 22, 2019
		8114833	Aug 13, 2025	DP			
		8846618	Jun 27, 2022	DP			
		9265893	Sep 23, 2032	DP			
		9968659	Jan 09, 2037	U-2313			
		RE41956	Jan 21, 2021	DP			
		RE43834	Jan 28, 2019	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LIRAGLUTIDE RECOMBINANT - VICTOZA							
N 022341	001	6004297	Jan 28, 2019	DP		I-750	Aug 25, 2020
		6268343	Aug 22, 2022	DS DP U-968		M-176	Apr 22, 2019
		8114833	Aug 13, 2025	DP			
		8846618	Jun 27, 2022	DP			
		9265893	Sep 23, 2032	DP			
		9968659	Jan 09, 2037	U-2313			
		RE41956	Jan 21, 2021	DP			
		RE43834	Jan 28, 2019	DP			
LIRAGLUTIDE RECOMBINANT - SAXENDA							
N 206321	001	6268343	Aug 22, 2022	DS DP U-1255			
		6899699	Jan 01, 2022	DP			
		8114833	Aug 13, 2025	DP			
		8672898	Jan 02, 2022	DP			
		8684969	Oct 20, 2025	DP			
		8846618	Jun 27, 2022	DP			
		8920383	Jul 17, 2026	DP			
		9108002	Jan 26, 2026	DP			
		9132239	Feb 01, 2032	DP			
		9457154	Sep 27, 2027	DP			
		9486588	Jan 02, 2022	DP			
		9616180	Jan 20, 2026	DP			
		9687611	Feb 27, 2027	DP			
		9775953	Jul 17, 2026	DP			
		9861757	Jan 20, 2026	DP			
		9968659	Jan 09, 2037	U-2438			
		RE46363	Aug 03, 2026	DP			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
N 021977	001	7105486	Feb 24, 2023	U-727		M-188	Oct 14, 2019
		7223735	Feb 24, 2023	DP			
		7655630	Feb 24, 2023	DS			
		7659253	Feb 24, 2023	DS DP U-727			
		7659254	Feb 24, 2023	U-1034			
		7662787	Feb 24, 2023	DS			
		7662788	Feb 24, 2023	U-727			
		7671030	Feb 24, 2023	DP U-727			
		7671031	Feb 24, 2023	U-727			
		7674774	Feb 24, 2023	DP U-842			
		7678770	Feb 24, 2023	U-842			
		7678771	Feb 24, 2023	DP U-842			
		7687466	Feb 24, 2023	DP			
		7687467	Feb 24, 2023	DP U-842			
		7700561	Feb 24, 2023	DP			
		7713936	Feb 24, 2023	U-727			
		7718619	Feb 24, 2023	DP U-842			
		7723305	Feb 24, 2023	DP U-842			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
N 021977	002	7105486	Feb 24, 2023	U-727		M-188	Oct 14, 2019
		7223735	Feb 24, 2023	DP			
		7655630	Feb 24, 2023	DS			
		7659253	Feb 24, 2023	DS DP U-727			
		7659254	Feb 24, 2023	U-1034			
		7662787	Feb 24, 2023	DS			
		7662788	Feb 24, 2023	U-727			
		7671030	Feb 24, 2023	DP U-727			
		7671031	Feb 24, 2023	U-727			
		7674774	Feb 24, 2023	DP U-842			
		7678770	Feb 24, 2023	U-842			
		7678771	Feb 24, 2023	DP U-842			
		7687466	Feb 24, 2023	DP			
		7687467	Feb 24, 2023	DP U-842			
		7700561	Feb 24, 2023	DP			
		7713936	Feb 24, 2023	U-727			
		7718619	Feb 24, 2023	DP U-842			
		7723305	Feb 24, 2023	DP U-842			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 003	7105486	Feb 24, 2023	U-727		M-188	Oct 14, 2019
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 004	7105486	Feb 24, 2023	U-727		M-188	Oct 14, 2019
	7105486	Feb 24, 2023	U-842			
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 005	7105486	Feb 24, 2023	U-842		M-188	Oct 14, 2019
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 006	7105486	Feb 24, 2023	U-727		M-188	Oct 14, 2019
	7105486	Feb 24, 2023	U-842			
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 006	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 007	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 001	7105486	Feb 24, 2023	U-727		M-188	Oct 14, 2019
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 002	7105486	Feb 24, 2023	U-727		M-188	Oct 14, 2019
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 003	7105486	Feb 24, 2023	U-727		M-188	Oct 14, 2019
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 004	7105486	Feb 24, 2023	U-727		M-188	Oct 14, 2019
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 005	7105486	Feb 24, 2023	U-727		M-188	Oct 14, 2019
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 006	7105486	Feb 24, 2023	U-727		M-188	Oct 14, 2019
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
N 208510	006	7687466	Feb 24, 2023	DP			
		7687467	Feb 24, 2023	DP U-727			
		7713936	Feb 24, 2023	U-727			
		7718619	Feb 24, 2023	DP U-727			
		7723305	Feb 24, 2023	DP U-727			
LISINOPRIL - QBRELIS							
N 208401	001	10039800	Nov 06, 2035	U-1723			
		10039800	Nov 06, 2035	U-185			
		10039800	Nov 06, 2035	U-1864			
		10039800	Nov 06, 2035	U-1991			
		10039800	Nov 06, 2035	U-3			
		10039800	Nov 06, 2035	U-71			
		10039800	Nov 06, 2035	U-8			
		9463183	Nov 06, 2035	DP			
		9616096	Nov 06, 2035	U-1723			
		9616096	Nov 06, 2035	U-185			
		9616096	Nov 06, 2035	U-1864			
		9616096	Nov 06, 2035	U-1991			
		9616096	Nov 06, 2035	U-3			
		9616096	Nov 06, 2035	U-71			
		9616096	Nov 06, 2035	U-8			
		9814751	Nov 06, 2035	DP			
LIXISENATIDE - ADLYXIN							
N 208471	001	10028910	Nov 11, 2030	DP		NCE	Jul 27, 2021
		8475414	Dec 28, 2030	DP U-1881			
		8882721	Jun 28, 2031	DP			
		8915888	Jun 08, 2030	DP U-1881			
		9072836	Mar 15, 2032	DP			
		9084853	Oct 05, 2031	DP			
		9308329	Dec 28, 2030	DP U-1881			
		9408893	Aug 27, 2032	U-1894			
		9440029	Jan 30, 2032	DP			
		9511193	Jan 19, 2032	DP			
		9707176	Nov 11, 2030	DP			
		9821032	May 09, 2032	U-2200			
		9855388	Apr 24, 2029	DP U-1881			
		9981013	Aug 30, 2030	U-2297			
		RE45313	Jul 12, 2020	DS DP			
LIXISENATIDE - ADLYXIN							
N 208471	002	10028910	Nov 11, 2030	DP		NCE	Jul 27, 2021
		8475414	Dec 28, 2030	DP U-1881			
		8882721	Jun 28, 2031	DP			
		8915888	Jun 08, 2030	DP U-1881			
		9072836	Mar 15, 2032	DP			
		9084853	Oct 05, 2031	DP			
		9308329	Dec 28, 2030	DP U-1881			
		9408893	Aug 27, 2032	U-1894			
		9440029	Jan 30, 2032	DP			
		9511193	Jan 19, 2032	DP			
		9707176	Nov 11, 2030	DP			
		9821032	May 09, 2032	U-2200			
		9855388	Apr 24, 2029	DP U-1881			
		9981013	Aug 30, 2030	U-2297			
		RE45313	Jul 12, 2020	DS DP			
LOFEXIDINE HYDROCHLORIDE - LUCEMYRA							
N 209229	001					NCE	May 16, 2023
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	001	10016404	Mar 07, 2025	U-1316		ODE-36	Dec 21, 2019
		5712279	Feb 21, 2020	DS DP U-1317			
		6492365	Dec 10, 2019	U-1318			
		7932268	Aug 19, 2027	U-1316			
		8618135	Mar 07, 2025	U-1316			
		9265758	Mar 07, 2025	U-1316			
		9364470	Mar 07, 2025	U-1851			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	001	9433617	Mar 07, 2025	U-1316			
		9861622	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	002	10016404	Mar 07, 2025	U-1316		ODE-36	Dec 21, 2019
		5712279	Feb 21, 2020	DS DP U-1317			
		6492365	Dec 10, 2019	U-1318			
		7932268	Aug 19, 2027	U-1316			
		8618135	Mar 07, 2025	U-1316			
		9265758	Mar 07, 2025	U-1316			
		9364470	Mar 07, 2025	U-1851			
		9433617	Mar 07, 2025	U-1316			
		9861622	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	003	10016404	Mar 07, 2025	U-1316		ODE-36	Dec 21, 2019
		5712279	Feb 21, 2020	DS DP U-1317			
		6492365	Dec 10, 2019	U-1318			
		7932268	Aug 19, 2027	U-1316			
		8618135	Mar 07, 2025	U-1316			
		9265758	Mar 07, 2025	U-1316			
		9364470	Mar 07, 2025	U-1851			
		9433617	Mar 07, 2025	U-1316			
		9861622	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	004	10016404	Mar 07, 2025	U-1316		ODE-36	Dec 21, 2019
		5712279	Feb 21, 2020	DS DP U-1317			
		6492365	Dec 10, 2019	U-1318			
		7932268	Aug 19, 2027	U-1316			
		8618135	Mar 07, 2025	U-1316			
		9265758	Mar 07, 2025	U-1316			
		9364470	Mar 07, 2025	U-1851			
		9433617	Mar 07, 2025	U-1316			
		9861622	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	005	10016404	Mar 07, 2025	U-1316		ODE-36	Dec 21, 2019
		5712279	Feb 21, 2020	DS DP U-1317			
		6492365	Dec 10, 2019	U-1318			
		7932268	Aug 19, 2027	U-1316			
		8618135	Mar 07, 2025	U-1316			
		9265758	Mar 07, 2025	U-1316			
		9364470	Mar 07, 2025	U-1851			
		9433617	Mar 07, 2025	U-1316			
		9861622	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	006	10016404	Mar 07, 2025	U-1316		ODE-36	Dec 21, 2019
		5712279	Feb 21, 2020	DS DP U-1317			
		6492365	Dec 10, 2019	U-1318			
		7932268	Aug 19, 2027	U-1316			
		8618135	Mar 07, 2025	U-1316			
		9265758	Mar 07, 2025	U-1316			
		9364470	Mar 07, 2025	U-1851			
		9433617	Mar 07, 2025	U-1316			
		9861622	Mar 07, 2025	U-1316			
LOPERAMIDE HYDROCHLORIDE - IMODIUM A-D EZ CHEWS							
N 020448	001	6814978	Aug 26, 2021	DP			
LOPINAVIR; RITONAVIR - KALETRA							
N 021226	001	7141593	May 22, 2020	DP			
		7432294	May 22, 2020	DP			
LOPINAVIR; RITONAVIR - KALETRA							
N 021251	001	6911214	Nov 28, 2021	DP U-895			
		8501219	Nov 28, 2021	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOPINAVIR; RITONAVIR - KALETRA						
N 021906 001	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP U-688			
	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8268349	Aug 25, 2024	DP			
	8309613	Dec 24, 2024	U-688			
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
	8691878	Aug 25, 2024	U-1513			
	8691878*PED	Feb 25, 2025				
LOPINAVIR; RITONAVIR - KALETRA						
N 021906 002	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP U-688			
	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8268349	Aug 25, 2024	DP			
	8309613	Dec 24, 2024	U-688			
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
	8691878	Aug 25, 2024	U-1513			
	8691878*PED	Feb 25, 2025				
LORCASERIN HYDROCHLORIDE - BELVIQ						
N 022529 001	6953787	Apr 10, 2023	DS DP U-1252			
	6953787	Apr 10, 2023	DS DP U-1253			
	6953787	Apr 10, 2023	DS DP U-1254			
	6953787	Apr 10, 2023	DS DP U-1255			
	7514422	Apr 10, 2023	U-1252			
	7514422	Apr 10, 2023	U-1253			
	7514422	Apr 10, 2023	U-1254			
	7514422	Apr 10, 2023	U-1255			
	7977329	Apr 10, 2023	DS DP U-1252			
	7977329	Apr 10, 2023	DS DP U-1253			
	7977329	Apr 10, 2023	DS DP U-1254			
	7977329	Apr 10, 2023	DS DP U-1255			
	8168624	Apr 18, 2029	DS DP			
	8207158	Apr 10, 2023	U-1252			
	8207158	Apr 10, 2023	U-1253			
	8207158	Apr 10, 2023	U-1254			
	8207158	Apr 10, 2023	U-1255			
	8273734	Apr 10, 2023	U-1254			
	8273734	Apr 10, 2023	U-1255			
	8367657	Apr 10, 2023	DS DP U-1252			
	8367657	Apr 10, 2023	DS DP U-1253			
	8367657	Apr 10, 2023	DS DP U-1254			
	8367657	Apr 10, 2023	DS DP U-1255			
	8546379	Apr 10, 2023	DS DP U-1252			
	8546379	Apr 10, 2023	DS DP U-1253			
	8546379	Apr 10, 2023	DS DP U-1254			
	8546379	Apr 10, 2023	DS DP U-1255			
	8575149	Apr 10, 2023	U-1452			
	8697686	Dec 20, 2025	DS DP			
	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025	U-1252			
	8980881	Dec 20, 2025	U-1253			
	8980881	Dec 20, 2025	U-1254			
	8980881	Dec 20, 2025	U-1255			
	8999970	Feb 07, 2033	U-1688			
	8999970	Feb 07, 2033	U-1689			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LORCASERIN HYDROCHLORIDE - BELVIQ							
N 022529	001	8999970	Feb 07, 2033	U-1692			
		9169213	Dec 06, 2032	U-1762			
		9169213	Dec 06, 2032	U-1763			
		9169213	Dec 06, 2032	U-1764			
		9169213	Dec 06, 2032	U-1765			
		9770455	Aug 31, 2031	U-2110			
LORCASERIN HYDROCHLORIDE - BELVIQ XR							
N 208524	001	6953787	Apr 10, 2023	DS DP U-1252			
		6953787	Apr 10, 2023	DS DP U-1253			
		6953787	Apr 10, 2023	DS DP U-1254			
		6953787	Apr 10, 2023	DS DP U-1255			
		7514422	Apr 10, 2023	U-1252			
		7514422	Apr 10, 2023	U-1253			
		7514422	Apr 10, 2023	U-1254			
		7514422	Apr 10, 2023	U-1255			
		7977329	Apr 10, 2023	DS DP U-1252			
		7977329	Apr 10, 2023	DS DP U-1253			
		7977329	Apr 10, 2023	DS DP U-1254			
		7977329	Apr 10, 2023	DS DP U-1255			
		8168624	Apr 18, 2029	DS DP			
		8207158	Apr 10, 2023	U-1252			
		8207158	Apr 10, 2023	U-1253			
		8207158	Apr 10, 2023	U-1254			
		8207158	Apr 10, 2023	U-1255			
		8273734	Apr 10, 2023	U-1254			
		8273734	Apr 10, 2023	U-1255			
		8367657	Apr 10, 2023	DS DP U-1252			
		8367657	Apr 10, 2023	DS DP U-1253			
		8367657	Apr 10, 2023	DS DP U-1254			
		8367657	Apr 10, 2023	DS DP U-1255			
		8546379	Apr 10, 2023	DS DP U-1252			
		8546379	Apr 10, 2023	DS DP U-1253			
		8546379	Apr 10, 2023	DS DP U-1254			
		8546379	Apr 10, 2023	DS DP U-1255			
		8575149	Apr 10, 2023	U-1452			
		8697686	Dec 20, 2025	DS DP			
		8946207	Jun 16, 2024	DP			
		8980881	Dec 20, 2025	U-1252			
		8980881	Dec 20, 2025	U-1253			
		8980881	Dec 20, 2025	U-1254			
		8980881	Dec 20, 2025	U-1255			
		8999970	Feb 07, 2033	U-1688			
		8999970	Feb 07, 2033	U-1689			
		8999970	Feb 07, 2033	U-1692			
		9169213	Dec 06, 2032	U-1884			
		9169213	Dec 06, 2032	U-1885			
		9169213	Dec 06, 2032	U-1886			
		9169213	Dec 06, 2032	U-1887			
		9770455	Aug 31, 2031	U-2110			
LORLATINIB - LORBRENA							
N 210868	001	8680111	Mar 05, 2033	DS DP		NCE	Nov 02, 2023
						ODE-217	Nov 02, 2025
						ODE-218	Nov 02, 2025
						ODE-219	Nov 02, 2025
LORLATINIB - LORBRENA							
N 210868	002	8680111	Mar 05, 2033	DS DP		NCE	Nov 02, 2023
						ODE-217	Nov 02, 2025
						ODE-218	Nov 02, 2025
						ODE-219	Nov 02, 2025
LOTEPREDNOL ETABONATE - LOTEMAX							
N 202872	001					M-229	Jul 20, 2021

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOTEPREDNOL ETABONATE - INVELTYS							
N 210565	001					NP	Aug 22, 2021
LOXAPINE - ADASUVE							
N 022549	001	6716416	May 20, 2022	DP			
		7052679	Oct 26, 2021	DP			
		7078020	Oct 26, 2021	DP U-1375			
		7090830	Oct 26, 2021	DP			
		7458374	Aug 18, 2024	DP			
		7537009	Oct 28, 2024	DP			
		7585493	Oct 26, 2021	DP			
		7601337	Oct 26, 2021	DP			
		8074644	Jul 25, 2022	DP			
		8173107	Oct 26, 2021	DP			
		8235037	Oct 26, 2021	DP			
		8387612	Oct 23, 2026	DP			
		8955512	Oct 26, 2021	DP			
		8991387	May 21, 2024	DP			
		9370629	May 20, 2024	DP			
		9439907	Oct 26, 2021	DP			
		9440034	Oct 26, 2021	DP			
		9687487	Oct 26, 2021	DS DP			
LUBIPROSTONE - AMITIZA							
N 021908	001	6414016	Sep 05, 2020	U-1392		M-225	Apr 26, 2021
		6414016	Sep 05, 2020	U-717			
		6583174	Oct 16, 2020	DP			
		6982283	Dec 04, 2022	U-1391			
		7064148	Aug 30, 2022	U-1404			
		7064148	Aug 30, 2022	U-739			
		7417067	Oct 16, 2020	DP			
		8026393	Oct 25, 2027	DP			
		8071613	Sep 05, 2020	U-1203			
		8071613	Sep 05, 2020	U-1393			
		8088934	May 18, 2021	DS			
		8097649	Oct 16, 2020	DP			
		8097653	Nov 14, 2022	U-1214			
		8097653	Nov 14, 2022	U-1394			
		8114890	Sep 05, 2020	DP			
		8338639	Jan 23, 2027	DP			
		8389542	Nov 14, 2022	DP U-1345			
		8389542	Nov 14, 2022	DP U-1395			
		8748481	Sep 01, 2025	U-1520			
		8779187	Jul 23, 2027	DP			
LUBIPROSTONE - AMITIZA							
N 021908	002	6414016	Sep 05, 2020	U-874		M-225	Apr 26, 2021
		6583174	Oct 16, 2020	DP			
		7064148	Aug 30, 2022	U-739			
		7064148	Aug 30, 2022	U-873			
		7417067	Oct 16, 2020	DP			
		7795312	Sep 17, 2024	U-1085			
		8026393	Oct 25, 2027	DP			
		8071613	Sep 05, 2020	U-1202			
		8088934	May 18, 2021	DS			
		8097649	Oct 16, 2020	DP			
		8114890	Sep 05, 2020	DP			
		8338639	Jan 23, 2027	DP			
		8748481	Sep 01, 2025	U-1519			
		8779187	Jan 23, 2027	DP			
LULICONAZOLE - LUZU							
N 204153	001	5900488	Jan 18, 2020	DS DP		NPP	Feb 20, 2021
		8980931	Apr 28, 2034	DP			
		9012484	Sep 06, 2033	DS DP U-540			
		9199977	Sep 06, 2033	DS DP			
		9453006	Sep 06, 2033	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603	001	5532372*PED	Jan 02, 2019			M-195	Jan 27, 2020
		8729085	May 26, 2026	DP		NPP	Jan 27, 2020
		8729085*PED	Nov 26, 2026			NPP	Mar 05, 2021
		8883794	May 26, 2026	DP		PED	Jul 27, 2020
		8883794*PED	Nov 26, 2026			PED	Jul 27, 2020
		9174975	Feb 20, 2024	U-1770			
		9174975*PED	Aug 20, 2024				
		9259423	May 23, 2031	U-1822			
		9259423*PED	Nov 23, 2031				
		9555027	May 26, 2026	DP U-543			
		9815827	Feb 20, 2024	U-2166			
		9815827	Feb 20, 2024	U-543			
		9827242	May 23, 2031	U-2199			
		9827242	May 23, 2031	U-2201			
		9907794	May 26, 2026	DP			
		RE45573	Jun 23, 2025	DS			
		RE45573*PED	Dec 23, 2025				
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603	002	5532372*PED	Jan 02, 2019			NPP	Jan 27, 2020
		8729085	May 26, 2026	DP		NPP	Mar 05, 2021
		8729085*PED	Nov 26, 2026			PED	Jul 27, 2020
		8883794	May 26, 2026	DP			
		8883794*PED	Nov 26, 2026				
		9174975	Feb 20, 2024	U-1770			
		9174975*PED	Aug 20, 2024				
		9259423	May 23, 2031	U-1822			
		9259423*PED	Nov 23, 2031				
		9555027	May 26, 2026	DP U-543			
		9815827	Feb 20, 2024	U-2166			
		9815827	Feb 20, 2024	U-543			
		9827242	May 23, 2031	U-2199			
		9827242	May 23, 2031	U-2201			
		9907794	May 26, 2026	DP			
		RE45573	Jun 23, 2025	DS			
		RE45573*PED	Dec 23, 2025				
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603	003	5532372*PED	Jan 02, 2019			M-195	Jan 27, 2020
		8729085	May 26, 2026	DP		NPP	Jan 27, 2020
		8729085*PED	Nov 26, 2026			NPP	Mar 05, 2021
		8883794	May 26, 2026	DP		PED	Jul 27, 2020
		8883794*PED	Nov 26, 2026			PED	Jul 27, 2020
		9174975	Feb 20, 2024	U-1770			
		9174975*PED	Aug 20, 2024				
		9259423	May 23, 2031	U-1822			
		9259423*PED	Nov 23, 2031				
		9555027	May 26, 2026	DP U-543			
		9815827	Feb 20, 2024	U-2166			
		9815827	Feb 20, 2024	U-543			
		9827242	May 23, 2031	U-2199			
		9827242	May 23, 2031	U-2201			
		9907794	May 26, 2026	DP			
		RE45573	Jun 23, 2025	DS			
		RE45573*PED	Dec 23, 2025				
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603	004	5532372*PED	Jan 02, 2019				
		8729085	May 26, 2026	DP			
		8729085*PED	Nov 26, 2026				
		8883794	May 26, 2026	DP			
		8883794*PED	Nov 26, 2026				
		9174975	Feb 20, 2024	U-1770			
		9174975*PED	Aug 20, 2024				
		9259423	May 23, 2031	U-1822			
		9259423*PED	Nov 23, 2031				
		9555027	May 26, 2026	DP U-543			
		9815827	Feb 20, 2024	U-2166			
		9815827	Feb 20, 2024	U-543			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603	004	9827242	May 23, 2031	U-2199			
		9827242	May 23, 2031	U-2201			
		9907794	May 26, 2026	DP			
		RE45573	Jun 23, 2025	DS			
		RE45573*PED	Dec 23, 2025				
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603	005	5532372*PED	Jan 02, 2019			M-195	Jan 27, 2020
		8729085	May 26, 2026	DP		NPP	Jan 27, 2020
		8729085*PED	Nov 26, 2026			NPP	Mar 05, 2021
		8883794	May 26, 2026	DP		PED	Jul 27, 2020
		8883794*PED	Nov 26, 2026			PED	Jul 27, 2020
		9174975	Feb 20, 2024	U-1770			
		9174975*PED	Aug 20, 2024				
		9259423	May 23, 2031	U-1822			
		9259423*PED	Nov 23, 2031				
		9555027	May 26, 2026	DP U-543			
		9815827	Feb 20, 2024	U-2166			
		9815827	Feb 20, 2024	U-543			
		9827242	May 23, 2031	U-2199			
		9827242	May 23, 2031	U-2201			
		9907794	May 26, 2026	DP			
		RE45573	Jun 23, 2025	DS			
		RE45573*PED	Dec 23, 2025				
LUSUTROMBOPAG - MULPLETA							
N 210923	001	7601746	Sep 05, 2024	DS DP U-2344		NCE	Jul 31, 2023
		8530668	Jan 21, 2030	DS DP			
		8889722	Jul 29, 2028	DS DP			
		9427402	Sep 29, 2031	DP			
LUTETIUM DOTATATE LU-177 - LUTATHERA							
N 208700	001					NCE	Jan 26, 2023
						ODE-166	Jan 26, 2025
MACIMORELIN ACETATE - MACRILEN							
N 205598	001	6861409	Aug 01, 2022	DS DP U-2220		NCE	Dec 20, 2022
		8192719	Oct 12, 2027	U-2220		ODE-170	Dec 20, 2024
MACITENTAN - OPSUMIT							
N 204410	001	7094781	Dec 05, 2025	DS DP		ODE-54	Oct 18, 2020
		8268847	Apr 18, 2029	U-1446			
		8367685	Oct 04, 2028	DP U-1445			
		9265762	May 29, 2027	DP U-1820			
MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 25							
N 021910	001	7300674	Mar 04, 2023	DP U-785			
MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE - SUPREP BOWEL PREP KIT							
N 022372	001	6946149	Mar 07, 2023	DP U-837			
MALATHION - OVIDE							
N 018613	001	7560445	Feb 01, 2027	DS DP U-986			
		7977324	Aug 14, 2026	DP			
MARAVIROC - SELZENTRY							
N 022128	001	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
		6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
		7368460	Nov 25, 2022	U-824			
		7576097	May 25, 2021	DS			
MARAVIROC - SELZENTRY							
N 022128	002	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
		6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
		7368460	Nov 25, 2022	U-824			
		7576097	May 25, 2021	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MARAVIROC - SELZENTRY							
N 022128	003	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
		6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
		7368460	Nov 25, 2022	U-824			
		7576097	May 25, 2021	DS			
MARAVIROC - SELZENTRY							
N 022128	004	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
		6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
		7368460	Nov 25, 2022	U-824			
		7576097	May 25, 2021	DS			
MARAVIROC - SELZENTRY							
N 208984	001	6586430	Dec 01, 2019	DS DP U-824		NP	Nov 04, 2019
		6667314	Aug 06, 2021	DS DP U-824			
		7368460	Nov 25, 2022	U-824			
		7576097	May 25, 2021	DS			
MEBENDAZOLE - VERMOX							
N 208398	001					NS	Oct 19, 2019
MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR							
N 202317	001	7838564	Mar 07, 2026	DP		ODE-51	Aug 23, 2020
		7872050	Jul 08, 2029	U-1427			
		8450375	Mar 07, 2026	DP			
		8501818	Mar 07, 2026	DP			
		8501819	Mar 07, 2026	U-1427			
		9382191	Mar 07, 2026	DP			
MEDROXYPROGESTERONE ACETATE - DEPO-SUBQ PROVERA 104							
N 021583	001	6495534	May 15, 2020	DP			
MEGESTROL ACETATE - MEGACE ES							
N 021778	001	6592903	Sep 21, 2020	DP			
		7101576	Apr 22, 2024	U-755			
		9040088	Apr 22, 2024	U-755			
		9101540	Apr 22, 2024	DP U-755			
		9101549	Apr 22, 2024	U-755			
		9107827	Apr 22, 2024	U-755			
MELOXICAM - MOBIC							
N 021530	001	6184220	Mar 25, 2019	DP			
MELOXICAM - VIVLODEX							
N 207233	001	9526734	Mar 31, 2033	DP			
		9649318	Mar 31, 2035	DP			
		9808468	Mar 31, 2035	U-2160			
		9808468	Mar 31, 2035	U-2165			
MELOXICAM - VIVLODEX							
N 207233	002	9526734	Mar 31, 2033	DP			
		9649318	Mar 31, 2035	DP			
		9808468	Mar 31, 2035	U-2160			
		9808468	Mar 31, 2035	U-2165			
MELOXICAM - QMIIZ ODT							
N 211210	001	8545879	Aug 31, 2030	DP			
MELOXICAM - QMIIZ ODT							
N 211210	002	8545879	Aug 31, 2030	DP			
MELPHALAN HYDROCHLORIDE - EVOMELA							
N 207155	001	10040872	Jan 30, 2034	DP		ODE-110	Mar 10, 2023
		8410077	Mar 13, 2029	DP			
		9200088	Mar 13, 2029	DP			
		9493582	Feb 27, 2033	DP			
MEMANTINE HYDROCHLORIDE - NAMENDA XR							
N 022525	001	8039009	Mar 24, 2029	U-539			
		8039009*PED	Sep 24, 2029				
		8168209	Nov 22, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MEMANTINE HYDROCHLORIDE - NAMENDA XR						
N 022525 001	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
MEMANTINE HYDROCHLORIDE - NAMENDA XR						
N 022525 002	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
MEMANTINE HYDROCHLORIDE - NAMENDA XR						
N 022525 003	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
MEMANTINE HYDROCHLORIDE - NAMENDA XR						
N 022525 004	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
MENTHOL; METHYL SALICYLATE - SALONPAS						
N 022029 001	8809615	Jan 03, 2030	DP			
	9233184	Aug 01, 2027	DP			
MENTHOL; METHYL SALICYLATE - SALONPAS						
N 022029 002	8809615	Jan 03, 2030	DP			
	9233184	Aug 01, 2027	DP			
MEQUINOL; TRETINOIN - SOLAGE						
N 020922 001	6353029	Aug 24, 2020				
MERCAPTOPURINE - PURIXAN						
N 205919 001						

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MEROPENEM; VABORBACTAM - VABOMERE							
N 209776	001	8680136	Aug 17, 2031	DS DP			
		9694025	Aug 08, 2031	U-2120			
MESALAMINE - SFROWASA							
N 019618	002	7645801	Jul 24, 2027	DS DP			
MESALAMINE - CANASA							
N 021252	001					M-187	Sep 02, 2019
MESALAMINE - CANASA							
N 021252	002	8217083	Jun 06, 2028	DP			
		8436051	Jun 06, 2028	DP			
MESALAMINE - ASACOL HD							
N 021830	001	6893662	Nov 15, 2021	DP		U-141	
		8580302	Nov 15, 2021	DP			
		9089492	Nov 15, 2021	DP			
MESALAMINE - LIALDA							
N 022000	001	6773720	Jun 08, 2020	DP			
MESALAMINE - APRISO							
N 022301	001	8865688	May 01, 2030	U-1310			
MESALAMINE - DELZICOL							
N 204412	001	6649180	Apr 13, 2020	DP			
METAXALONE - SKELAXIN							
N 013217	003	7122566	Feb 06, 2026	U-915			
		7714006	Dec 03, 2021	U-1050			
METFORMIN HYDROCHLORIDE - FORTAMET							
N 021574	001	6790459	Mar 17, 2021	U-604			
		6866866	Mar 17, 2021	DP			
METFORMIN HYDROCHLORIDE - FORTAMET							
N 021574	002	6790459	Mar 17, 2021	U-604			
		6866866	Mar 17, 2021	DP			
METFORMIN HYDROCHLORIDE - RIOMET							
N 021591	001	6890957	Sep 14, 2023	DP			
METFORMIN HYDROCHLORIDE - GLUMETZA							
N 021748	001	6488962	Jun 20, 2020	DS DP			
		6723340	Oct 25, 2021	DS DP			
METFORMIN HYDROCHLORIDE - GLUMETZA							
N 021748	002	7780987	Mar 23, 2025	DS DP			
		8323692	Mar 30, 2023	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET							
N 021842	001	9101660	Jan 22, 2027	DP			
		9320714	Feb 03, 2029	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET							
N 021842	002	9101660	Jan 22, 2027	DP			
		9320714	Feb 03, 2029	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR							
N 022024	001	6790459	Mar 17, 2021	U-974			
		6866866	Mar 17, 2021	DP			
		7785627	Jul 31, 2026	DP			
		7959946	Jul 31, 2026	DP			
		8470368	Sep 19, 2023	DP			
		8668931	Sep 19, 2023	DP			
		9060941	Sep 19, 2023	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR							
N 022024	002	6790459	Mar 17, 2021	U-974			
		6866866	Mar 17, 2021	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR							
N 022024	002	7785627	Jul 31, 2026	DP			
		7959946	Jul 31, 2026	DP			
		8470368	Sep 19, 2023	DP			
		8668931	Sep 19, 2023	DP			
		9060941	Sep 19, 2023	DP			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET							
N 021410	001	8236345	Oct 07, 2022	DP			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET							
N 021410	002	8236345	Oct 07, 2022	DP			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET							
N 021410	003	8236345	Oct 07, 2022	DP			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET							
N 021410	004	8236345	Oct 07, 2022	DP			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET							
N 021410	005	8236345	Oct 07, 2022	DP			
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR							
N 200678	001	8628799	Jul 13, 2025	DP		M-175	Apr 05, 2019
		9339472	Jul 13, 2025	DP		M-198	Feb 27, 2020
		RE44186	Jul 31, 2023	DS DP U-1097			
		RE44186	Jul 31, 2023	DS DP U-1838			
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR							
N 200678	002	9339472	Jul 13, 2025	DP		M-175	Apr 05, 2019
		RE44186	Jul 31, 2023	DS DP U-1097		M-198	Feb 27, 2020
		RE44186	Jul 31, 2023	DS DP U-1838			
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR							
N 200678	003	9339472	Jul 13, 2025	DP		M-175	Apr 05, 2019
		RE44186	Jul 31, 2023	DS DP U-1097		M-198	Feb 27, 2020
		RE44186	Jul 31, 2023	DS DP U-1838			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET							
N 022044	001	6699871	Jul 26, 2022	DS DP U-802			
		6890898	Feb 02, 2019	U-1996			
		7078381	Feb 02, 2019	U-1996			
		7125873	Jul 26, 2022	DP U-1036			
		7125873	Jul 26, 2022	DP U-1038			
		7125873	Jul 26, 2022	DP U-803			
		7326708	Nov 24, 2026	DS DP U-802			
		7459428	Feb 02, 2019	U-1996			
		8414921	Jul 21, 2028	DP U-1036			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET							
N 022044	002	6699871	Jul 26, 2022	DS DP U-802			
		6890898	Feb 02, 2019	U-1996			
		7078381	Feb 02, 2019	U-1996			
		7125873	Jul 26, 2022	DP U-1036			
		7125873	Jul 26, 2022	DP U-1038			
		7125873	Jul 26, 2022	DP U-803			
		7326708	Nov 24, 2026	DS DP U-802			
		7459428	Feb 02, 2019	U-1996			
		8414921	Jul 21, 2028	DP U-1036			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR							
N 202270	001	6699871	Jul 26, 2022	DS DP U-1227			
		6890898	Feb 02, 2019	U-1996			
		7078381	Feb 02, 2019	U-1996			
		7125873	Jul 26, 2022	DP U-1227			
		7326708	Nov 24, 2026	DS DP U-1227			
		7459428	Feb 02, 2019	U-1996			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR								
N 202270	002		6699871	Jul 26, 2022	DS DP U-1227			
			6890898	Feb 02, 2019	U-1996			
			7078381	Feb 02, 2019	U-1996			
			7125873	Jul 26, 2022	DP U-1227			
			7326708	Nov 24, 2026	DS DP U-1227			
			7459428	Feb 02, 2019	U-1996			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR								
N 202270	003		6699871	Jul 26, 2022	DS DP U-1227			
			6890898	Feb 02, 2019	U-1996			
			7078381	Feb 02, 2019	U-1996			
			7125873	Jul 26, 2022	DP U-1227			
			7326708	Nov 24, 2026	DS DP U-1227			
			7459428	Feb 02, 2019	U-1996			
METHOTREXATE - OTREXUP								
N 204824	001		6746429	Apr 12, 2020	DP			
			7744582	Aug 10, 2019	DP U-1442			
			7776015	Aug 10, 2019	DP			
			8021335	Oct 04, 2026	DP			
			8480631	Mar 19, 2030	DP U-1442			
			8562564	Jan 24, 2026	DP			
			8579865	Mar 19, 2030	DP U-1442			
			8945063	Mar 19, 2030	DP U-1442			
			9421333	Mar 19, 2030	DP U-1442			
			9533102	Jan 24, 2026	DP			
			9629959	Jan 24, 2026	DP			
			RE44846	Aug 10, 2019	DP			
			RE44847	Aug 10, 2019	DP U-1442			
METHOTREXATE - OTREXUP								
N 204824	002		6746429	Apr 12, 2020	DP			
			7744582	Aug 10, 2019	DP U-1442			
			7776015	Aug 10, 2019	DP			
			8021335	Oct 04, 2026	DP			
			8480631	Mar 19, 2030	DP U-1442			
			8562564	Jan 24, 2026	DP			
			8579865	Mar 19, 2030	DP U-1442			
			8945063	Mar 19, 2030	DP U-1442			
			9421333	Mar 19, 2030	DP U-1442			
			9533102	Jan 24, 2026	DP			
			9629959	Jan 24, 2026	DP			
			RE44846	Aug 10, 2019	DP			
			RE44847	Aug 10, 2019	DP U-1442			
METHOTREXATE - OTREXUP								
N 204824	003		6746429	Apr 12, 2020	DP			
			7744582	Aug 10, 2019	DP U-1442			
			7776015	Aug 10, 2019	DP			
			8021335	Oct 04, 2026	DP			
			8480631	Mar 19, 2030	DP U-1442			
			8562564	Jan 24, 2026	DP			
			8579865	Mar 19, 2030	DP U-1442			
			8945063	Mar 19, 2030	DP U-1442			
			9421333	Mar 19, 2030	DP U-1442			
			9533102	Jan 24, 2026	DP			
			9629959	Jan 24, 2026	DP			
			RE44846	Aug 10, 2019	DP			
			RE44847	Aug 10, 2019	DP U-1442			
METHOTREXATE - OTREXUP								
N 204824	004		6746429	Apr 12, 2020	DP			
			7744582	Aug 10, 2019	DP U-1442			
			7776015	Aug 10, 2019	DP			
			8021335	Oct 04, 2026	DP			
			8480631	Mar 19, 2030	DP U-1442			
			8562564	Jan 24, 2026	DP			
			8579865	Mar 19, 2030	DP U-1442			
			8945063	Mar 19, 2030	DP U-1442			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHOTREXATE - OTREXUP						
N 204824 004	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
METHOTREXATE - OTREXUP						
N 204824 005	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
METHOTREXATE - OTREXUP						
N 204824 006	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
METHOTREXATE - OTREXUP						
N 204824 007	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
METHOTREXATE - OTREXUP						
N 204824 008	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
METHOTREXATE - RASUVO						
N 205776 001	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 002	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 003	8664231	Jun 01, 2029	U-1442			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHOTREXATE - RASUVO								
N	205776	004	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO								
N	205776	005	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO								
N	205776	006	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO								
N	205776	007	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO								
N	205776	008	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO								
N	205776	009	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO								
N	205776	010	8664231	Jun 01, 2029	U-1442			
METHOTREXATE SODIUM - XATMEP								
N	208400	001	9259427	Jan 02, 2033	DP		ODE-137	Apr 25, 2024
			9855215	Jan 02, 2033	DP		ODE-138	Apr 25, 2024
METHYLENE BLUE - PROVAYBLUE								
N	204630	001					ODE-113	Apr 08, 2023
METHYLERGONOVINE MALEATE - METHYLERGONOVINE MALEATE								
A	211483	001					CGT	Mar 20, 2019
METHYLNALTREXONE BROMIDE - RELISTOR								
N	021964	001	8247425	Dec 31, 2030	U-1185			
			8420663	Sep 30, 2029	U-1185			
			8552025	Apr 08, 2024	DP			
			8822490	Sep 30, 2029	DP U-1185			
			9180125	Sep 30, 2029	DP U-1185			
			9492445	Sep 30, 2029	DP U-1185			
			9669096	Apr 08, 2024	DP			
METHYLNALTREXONE BROMIDE - RELISTOR								
N	021964	002	8247425	Dec 31, 2030	U-1185			
			8420663	Sep 30, 2029	U-1185			
			8552025	Apr 08, 2024	DP			
			8822490	Sep 30, 2029	DP U-1185			
			9180125	Sep 30, 2029	DP U-1185			
			9492445	Sep 30, 2029	DP U-1185			
			9669096	Apr 08, 2024	DP			
METHYLNALTREXONE BROMIDE - RELISTOR								
N	021964	003	8247425	Dec 31, 2030	U-1185			
			8420663	Sep 30, 2029	U-1185			
			8552025	Apr 08, 2024	DP			
			8822490	Sep 30, 2029	DP U-1185			
			9180125	Sep 30, 2029	DP U-1185			
			9492445	Sep 30, 2029	DP U-1185			
			9669096	Apr 08, 2024	DP			
METHYLNALTREXONE BROMIDE - RELISTOR								
N	208271	001	8420663	Sep 30, 2029	U-1185		NP	Jul 19, 2019
			8524276	Mar 10, 2031	DP			
			8956651	Mar 10, 2031	DP			
			9180125	Sep 30, 2029	DP U-1185			
			9314461	Mar 10, 2031	DP			
			9492445	Sep 30, 2029	DP U-1185			
			9724343	Sep 30, 2029	DP U-1185			
METHYLPHENIDATE - DAYTRANA								
N	021514	001	8632802	Oct 07, 2025	DP			
			9034370	Oct 07, 2025	DP			
			9668981	Oct 07, 2025	U-2024			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE - DAYTRANA								
N	021514	001	8632802	Oct 07, 2025	DP			
			9034370	Oct 07, 2025	DP			
			9668981	Oct 07, 2025	U-2024			
METHYLPHENIDATE - DAYTRANA								
N	021514	002	8632802	Oct 07, 2025	DP			
			9034370	Oct 07, 2025	DP			
			9668981	Oct 07, 2025	U-2024			
METHYLPHENIDATE - DAYTRANA								
N	021514	003	8632802	Oct 07, 2025	DP			
			9034370	Oct 07, 2025	DP			
			9668981	Oct 07, 2025	U-2024			
METHYLPHENIDATE - DAYTRANA								
N	021514	004	8632802	Oct 07, 2025	DP			
			9034370	Oct 07, 2025	DP			
			9668981	Oct 07, 2025	U-2024			
METHYLPHENIDATE - COTEMPLA XR-ODT								
N	205489	001	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
			9072680	Jun 28, 2032	DP			
			9089496	Jun 28, 2032	DP			
METHYLPHENIDATE - COTEMPLA XR-ODT								
N	205489	002	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
			9072680	Jun 28, 2032	DP			
			9089496	Jun 28, 2032	DP			
METHYLPHENIDATE - COTEMPLA XR-ODT								
N	205489	003	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
			9072680	Jun 28, 2032	DP			
			9089496	Jun 28, 2032	DP			
METHYLPHENIDATE HYDROCHLORIDE - METADATE CD								
N	021259	001	6344215	Oct 27, 2020	DP			
METHYLPHENIDATE HYDROCHLORIDE - METADATE CD								
N	021259	002	6344215	Oct 27, 2020	DP			
METHYLPHENIDATE HYDROCHLORIDE - METADATE CD								
N	021259	003	6344215	Oct 27, 2020	DP			
METHYLPHENIDATE HYDROCHLORIDE - METADATE CD								
N	021259	004	6344215	Oct 27, 2020	DP			
METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA								
N	021284	001	6228398	Nov 01, 2019	DP U-472			
METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA								
N	021284	002	6228398	Nov 01, 2019	DP U-472			
METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA								
N	021284	003	6228398	Nov 01, 2019	DP U-472			
METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA								
N	021284	004	6228398	Nov 01, 2019	DP U-472			
METHYLPHENIDATE HYDROCHLORIDE - METHYLIN								
N	021419	001	7691880	Oct 07, 2024	DP			
METHYLPHENIDATE HYDROCHLORIDE - METHYLIN								
N	021419	002	7691880	Oct 07, 2024	DP			
METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR								
N	202100	001	8062667	Mar 29, 2029	DP			
			8287903	Feb 15, 2031	DP			
			8465765	Feb 15, 2031	DP U-1415			
			8563033	Feb 15, 2031	DP U-1415			
			8778390	Feb 15, 2031	DP U-1543			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR							
N 202100	001	8956649	Feb 15, 2031	DP		U-1665	
		9040083	Feb 15, 2031	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831	001	10039719	Dec 16, 2019			U-2357	
		6419960	Dec 16, 2019	DP			
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP	Y		
		8580310	Dec 16, 2019	DP			
		9066869	Dec 16, 2019	DP			
		9801823	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831	002	10039719	Dec 16, 2019			U-2357	
		6419960	Dec 16, 2019	DP			
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP	Y		
		8580310	Dec 16, 2019	DP			
		9066869	Dec 16, 2019	DP			
		9801823	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831	003	10039719	Dec 16, 2019			U-2357	
		6419960	Dec 16, 2019	DP			
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP	Y		
		8580310	Dec 16, 2019	DP			
		9066869	Dec 16, 2019	DP			
		9801823	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831	004	10039719	Dec 16, 2019			U-2357	
		6419960	Dec 16, 2019	DP			
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP	Y		
		8580310	Dec 16, 2019	DP			
		9066869	Dec 16, 2019	DP			
		9801823	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831	005	10039719	Dec 16, 2019			U-2357	
		6419960	Dec 16, 2019	DP			
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP	Y		
		8580310	Dec 16, 2019	DP			
		9066869	Dec 16, 2019	DP			
		9801823	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831	006	10039719	Dec 16, 2019			U-2357	
		6419960	Dec 16, 2019	DP			
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP	Y		
		8580310	Dec 16, 2019	DP			
		9066869	Dec 16, 2019	DP			
		9801823	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831	007	10039719	Dec 16, 2019			U-2357	
		6419960	Dec 16, 2019	DP			
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP	Y		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831	007	8580310	Dec 16, 2019	DP			
		9066869	Dec 16, 2019	DP			
		9801823	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER							
N 207960	001	8202537	Mar 15, 2027	DP			
		8287903	Feb 15, 2031	DP			
		8999386	Aug 14, 2033	DP			
		9295642	Aug 14, 2033	DP U-1827			
		9545399	Aug 14, 2033	DP U-1827			
		9844544	Aug 14, 2033	DP U-2203			
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER							
N 207960	002	8202537	Mar 15, 2027	DP			
		8287903	Feb 15, 2031	DP			
		8999386	Aug 14, 2033	DP			
		9295642	Aug 14, 2033	DP U-1827			
		9545399	Aug 14, 2033	DP U-1827			
		9844544	Aug 14, 2033	DP U-2203			
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER							
N 207960	003	8202537	Mar 15, 2027	DP			
		8287903	Feb 15, 2031	DP			
		8999386	Aug 14, 2033	DP			
		9295642	Aug 14, 2033	DP U-1827			
		9545399	Aug 14, 2033	DP U-1827			
		9844544	Aug 14, 2033	DP U-2203			
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM							
N 209311	001	8916588	Mar 23, 2032	U-2357		NP	Aug 08, 2021
		8927010	Mar 23, 2032	DP			
		9023389	Mar 23, 2032	DP			
		9028868	Mar 23, 2032	U-2357			
		9034902	Mar 23, 2032	U-2357			
		9283214	Mar 23, 2032	DP			
		9498447	Mar 23, 2032	DP			
		9603809	Mar 23, 2032	U-2357			
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM							
N 209311	002	8916588	Mar 23, 2032	U-2357		NP	Aug 08, 2021
		8927010	Mar 23, 2032	DP			
		9023389	Mar 23, 2032	DP			
		9028868	Mar 23, 2032	U-2357			
		9034902	Mar 23, 2032	U-2357			
		9283214	Mar 23, 2032	DP			
		9498447	Mar 23, 2032	DP			
		9603809	Mar 23, 2032	U-2357			
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM							
N 209311	003	8916588	Mar 23, 2032	U-2357		NP	Aug 08, 2021
		8927010	Mar 23, 2032	DP			
		9023389	Mar 23, 2032	DP			
		9028868	Mar 23, 2032	U-2357			
		9034902	Mar 23, 2032	U-2357			
		9283214	Mar 23, 2032	DP			
		9498447	Mar 23, 2032	DP			
		9603809	Mar 23, 2032	U-2357			
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM							
N 209311	004	8916588	Mar 23, 2032	U-2357		NP	Aug 08, 2021
		8927010	Mar 23, 2032	DP			
		9023389	Mar 23, 2032	DP			
		9028868	Mar 23, 2032	U-2357			
		9034902	Mar 23, 2032	U-2357			
		9283214	Mar 23, 2032	DP			
		9498447	Mar 23, 2032	DP			
		9603809	Mar 23, 2032	U-2357			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM							
N 209311	005	8916588	Mar 23, 2032	U-2357		NP	Aug 08, 2021
		8927010	Mar 23, 2032	DP			
		9023389	Mar 23, 2032	DP			
		9028868	Mar 23, 2032	U-2357			
		9034902	Mar 23, 2032	U-2357			
		9283214	Mar 23, 2032	DP			
		9498447	Mar 23, 2032	DP			
		9603809	Mar 23, 2032	U-2357			
METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE							
N 210428	001	9504655	Jul 09, 2035	DP			
		9700530	Jul 09, 2035	DP			
METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE							
N 210428	002	9504655	Jul 09, 2035	DP			
		9700530	Jul 09, 2035	DP			
METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE							
N 210428	003	9504655	Jul 09, 2035	DP			
		9700530	Jul 09, 2035	DP			
METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE							
N 210428	004	9504655	Jul 09, 2035	DP			
		9700530	Jul 09, 2035	DP			
METRONIDAZOLE - METROGEL							
N 021789	001	6881726	Feb 21, 2022	DP U-743			
		7348317	Feb 21, 2022	DP U-743			
METRONIDAZOLE - VANDAZOLE							
N 021806	001	7456207	Sep 22, 2024	DP			
METRONIDAZOLE - NUVESSA							
N 205223	001	7893097	Feb 19, 2028	DP			
		8658678	Jun 27, 2028	U-1682			
		8877792	Feb 02, 2028	DP			
		8946276	Jun 28, 2032	U-1664			
		9198858	Jun 28, 2032	U-1664			
MICAFUNGIN SODIUM - MYCAMINE							
N 021506	002	6107458	Mar 16, 2019	DS DP U-650			
		6107458	Mar 16, 2019	DS DP U-845			
		6774104	Jan 08, 2021	DP U-650			
		6774104	Jan 08, 2021	DP U-845			
MICAFUNGIN SODIUM - MYCAMINE							
N 021506	003	6107458	Mar 16, 2019	DS DP U-650			
		6107458	Mar 16, 2019	DS DP U-845			
		6774104	Jan 08, 2021	DP U-650			
		6774104	Jan 08, 2021	DP U-845			
MICONAZOLE - ORAVIG							
N 022404	001	6916485	Sep 11, 2022	DP U-1051			
		7651698	Sep 11, 2022	U-1051			
		8518442	Sep 11, 2022	DP			
MICONAZOLE NITRATE; MICONAZOLE NITRATE - MONISTAT 1 COMBINATION PACK							
N 021308	001	6153635	Nov 28, 2020		Y		
MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION							
N 021026	001	8147852	Mar 30, 2028	U-1426			
MIDAZOLAM HYDROCHLORIDE - SEIZALAM							
N 209566	001					ODE-207	Sep 14, 2025
MIDOSTAURIN - RYDAPT							
N 207997	001	7973031	Oct 17, 2024	U-2007		NCE	Apr 28, 2022
		8222244	Oct 29, 2022	U-2007		ODE-140	Apr 28, 2024
		8575146	Dec 02, 2030	U-2008		ODE-141	Apr 28, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MIFEPRISTONE - KORLYM							
N 202107	001	10006924	Aug 12, 2036	U-1643		ODE-22	Feb 17, 2019
		10151763	Jan 18, 2037	U-1643			
		10166242	Apr 20, 2036	U-1643			
		10166243	Apr 20, 2036	U-1643			
		8921348	Aug 27, 2028	U-1643			
		9829495	Aug 15, 2036	U-1643			
		9943526	Apr 20, 2036	U-1643			
MIGALASTAT HYDROCHLORIDE - GALAFOLD							
N 208623	001	10076514	Mar 15, 2037	U-2371		NCE	Aug 10, 2023
		8592362	Feb 12, 2029	U-2371		ODE-205	Aug 10, 2025
		9000011	May 16, 2027	U-2371			
		9095584	Feb 12, 2029	U-2371			
		9480682	May 16, 2027	U-2371			
		9987263	May 16, 2027	U-2371			
		9999618	Apr 28, 2028	U-2372			
		9999618	Apr 28, 2028	U-2373			
MILNACIPRAN HYDROCHLORIDE - SAVELLA							
N 022256	001	6602911	Jan 14, 2023	U-882			
		6992110	Nov 05, 2021	U-882			
		7888342	Nov 05, 2021	U-882			
		7994220	Sep 19, 2029	U-819			
MILNACIPRAN HYDROCHLORIDE - SAVELLA							
N 022256	002	6602911	Jan 14, 2023	U-882			
		6992110	Nov 05, 2021	U-882			
		7888342	Nov 05, 2021	U-882			
		7994220	Sep 19, 2029	U-819			
MILNACIPRAN HYDROCHLORIDE - SAVELLA							
N 022256	003	6602911	Jan 14, 2023	U-882			
		6992110	Nov 05, 2021	U-882			
		7888342	Nov 05, 2021	U-882			
		7994220	Sep 19, 2029	U-819			
MILNACIPRAN HYDROCHLORIDE - SAVELLA							
N 022256	004	6602911	Jan 14, 2023	U-882			
		6992110	Nov 05, 2021	U-882			
		7888342	Nov 05, 2021	U-882			
		7994220	Sep 19, 2029	U-819			
MILTEFOSINE - IMPAVIDO							
N 204684	001					NCE	Mar 19, 2019
						ODE-63	Mar 19, 2021
MINOCYCLINE HYDROCHLORIDE - MINOCIN							
N 050444	001	9084802	May 12, 2031	U-282			
		9278105	May 12, 2031	U-282			
MINOCYCLINE HYDROCHLORIDE - ARESTIN							
N 050781	001	6682348	Mar 29, 2022	DP			
		7699609	Mar 29, 2022	DP			
MINOCYCLINE HYDROCHLORIDE - SOLODYN							
N 050808	001	7790705	Jun 24, 2025	U-1078			
		7919483	Mar 07, 2027	U-1078			
		8252776	Jun 24, 2025	U-124			
		8268804	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN							
N 050808	002	7541347	Apr 02, 2027	U-917			
		7544373	Apr 02, 2027	DP			
		7790705	Jun 24, 2025	U-1078			
		7919483	Mar 07, 2027	U-1078			
		8252776	Jun 24, 2025	U-124			
		8268804	Jun 24, 2025	U-1078			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N 050808 003	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N 050808 004	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
	9192615	Nov 17, 2031	DP			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N 050808 005	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
	9192615	Nov 17, 2031	DP			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N 050808 006	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
	8722650	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N 050808 007	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
	8722650	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N 050808 008	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
	8722650	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - XIMINO						
N 201922 001	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
MINOCYCLINE HYDROCHLORIDE - XIMINO						
N 201922 003	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
MINOCYCLINE HYDROCHLORIDE - XIMINO						
N 201922 005	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
MINOXIDIL - MEN'S ROGAINE						
N 021812 001	6946120	Apr 20, 2019	DP U-702			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MINOXIDIL - WOMEN'S ROGAINE							
N 021812	002	6946120	Apr 20, 2019	DP U-702			
MIPOMERSEN SODIUM - KYNAMRO							
N 203568	001	7015315	Mar 21, 2023	DS		ODE-41	Jan 29, 2020
		7101993	Sep 05, 2023	DS			
		7407943	Aug 01, 2021	U-1353			
		7511131	Jan 29, 2027	DS			
MIRABEGRON - MYRBETRIQ							
N 202611	001	6346532	Mar 27, 2022	DS DP		I-777	Apr 27, 2021
		6562375	Aug 01, 2020	DP			
		7342117	Nov 04, 2023	DS			
		7982049	Nov 04, 2023	DP			
		8772315	Oct 30, 2028	U-2300			
		8835474	Nov 04, 2023	U-1527			
		RE44872	Nov 04, 2023	U-1527			
MIRABEGRON - MYRBETRIQ							
N 202611	002	6346532	Mar 27, 2022	DS DP		I-777	Apr 27, 2021
		6562375	Aug 01, 2020	DP			
		7342117	Nov 04, 2023	DS			
		7982049	Nov 04, 2023	DP			
		8772315	Oct 30, 2028	U-2300			
		8835474	Nov 04, 2023	U-1527			
		RE44872	Nov 04, 2023	U-1527			
MITOMYCIN - MITOSOL							
N 022572	001	7806265	Feb 01, 2029	DP		ODE-21	Feb 07, 2019
		8186511	Jul 19, 2026	DP			
		9205075	Jul 19, 2026	DP			
		9539241	Jan 02, 2028	DS DP U-2095			
		9649428	May 21, 2029	U-2095			
MODAFINIL - PROVIGIL							
N 020717	001	7297346	Nov 29, 2023	DP			
MODAFINIL - PROVIGIL							
N 020717	002	7297346	Nov 29, 2023	DP			
MOMETASONE FUROATE - SINUVA							
N 209310	001	7544192	Nov 29, 2026	U-2272		NP	Dec 08, 2020
		7662141	Mar 12, 2024	U-2272			
		7713255	Mar 12, 2024	U-2272			
		7951130	Mar 12, 2024	U-2272			
		7951131	Mar 12, 2024	U-2272			
		7951133	Mar 12, 2024	U-2272			
		8025635	Jun 12, 2027	DP U-2272			
		8109918	Mar 12, 2024	U-2272			
		8763222	Feb 08, 2032	DP			
		9585681	Apr 04, 2026	U-2272			
MONTELUKAST SODIUM - SINGULAIR							
N 021409	001	8007830	Oct 24, 2022	DP			
MORPHINE SULFATE - MORPHINE SULFATE							
N 204223	001	9072781	Mar 12, 2034	DP			
		9192608	Mar 12, 2034	U-43			
		9192608	Mar 12, 2034	U-55			
		9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE							
N 204223	002	9072781	Mar 12, 2034	DP			
		9192608	Mar 12, 2034	U-43			
		9192608	Mar 12, 2034	U-55			
		9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE							
N 204223	003	9072781	Mar 12, 2034	DP			
		9192608	Mar 12, 2034	U-43			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MORPHINE SULFATE - MORPHINE SULFATE								
N 204223	003		9192608	Mar 12, 2034	U-55			
			9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE								
N 204223	004		9072781	Mar 12, 2034	DP			
			9192608	Mar 12, 2034	U-43			
			9192608	Mar 12, 2034	U-55			
			9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE								
N 204223	005		9072781	Mar 12, 2034	DP			
			9192608	Mar 12, 2034	U-43			
			9192608	Mar 12, 2034	U-55			
			9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHABOND ER								
N 206544	001		7955619	Aug 12, 2028	DP			
MORPHINE SULFATE - MORPHABOND ER								
N 206544	002		7955619	Aug 12, 2028	DP			
MORPHINE SULFATE - MORPHABOND ER								
N 206544	003		7955619	Aug 12, 2028	DP			
MORPHINE SULFATE - MORPHABOND ER								
N 206544	004		7955619	Aug 12, 2028	DP			
MORPHINE SULFATE - ARYMO ER								
N 208603	001		9044402	Jul 01, 2033	DP		U-1556	
			9549899	Jul 01, 2033	DP		U-1556	
MORPHINE SULFATE - ARYMO ER								
N 208603	002		9044402	Jul 01, 2033	DP		U-1556	
			9549899	Jul 01, 2033	DP		U-1556	
MORPHINE SULFATE - ARYMO ER								
N 208603	003		9044402	Jul 01, 2033	DP		U-1556	
			9549899	Jul 01, 2033	DP		U-1556	
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA								
N 022321	001		7682633	Jun 19, 2027	U-1510			
			7682634	Jun 19, 2027	DP			
			7815934	Dec 12, 2027	DP			
			8158156	Jun 19, 2027	U-1510			
			8623418	Nov 07, 2029	U-1640			
			8685443	Jul 03, 2025	U-1508			
			8685444	Jul 03, 2025	DP			
			8846104	Jun 19, 2027	DP			
			8877247	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA								
N 022321	002		7682633	Jun 19, 2027	U-1510			
			7682634	Jun 19, 2027	DP			
			7815934	Dec 12, 2027	DP			
			8158156	Jun 19, 2027	U-1510			
			8623418	Nov 07, 2029	U-1640			
			8685443	Jul 03, 2025	U-1508			
			8685444	Jul 03, 2025	DP			
			8846104	Jun 19, 2027	DP			
			8877247	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA								
N 022321	003		7682633	Jun 19, 2027	U-1510			
			7682634	Jun 19, 2027	DP			
			7815934	Dec 12, 2027	DP			
			8158156	Jun 19, 2027	U-1510			
			8623418	Nov 07, 2029	U-1640			
			8685443	Jul 03, 2025	U-1508			
			8685444	Jul 03, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA								
N 022321	003	8846104	Jun 19, 2027		DP			
		8877247	Jun 19, 2027		DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA								
N 022321	004	7682633	Jun 19, 2027		U-1510			
		7682634	Jun 19, 2027		DP			
		7815934	Dec 12, 2027		DP			
		8158156	Jun 19, 2027		U-1510			
		8623418	Nov 07, 2029		U-1640			
		8685443	Jul 03, 2025		U-1508			
		8685444	Jul 03, 2025		DP			
		8846104	Jun 19, 2027		DP			
		8877247	Jun 19, 2027		DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA								
N 022321	005	7682633	Jun 19, 2027		U-1510			
		7682634	Jun 19, 2027		DP			
		7815934	Dec 12, 2027		DP			
		8158156	Jun 19, 2027		U-1510			
		8623418	Nov 07, 2029		U-1640			
		8685443	Jul 03, 2025		U-1508			
		8685444	Jul 03, 2025		DP			
		8846104	Jun 19, 2027		DP			
		8877247	Jun 19, 2027		DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA								
N 022321	006	7682633	Jun 19, 2027		U-1510			
		7682634	Jun 19, 2027		DP			
		7815934	Dec 12, 2027		DP			
		8158156	Jun 19, 2027		U-1510			
		8623418	Nov 07, 2029		U-1640			
		8685443	Jul 03, 2025		U-1508			
		8685444	Jul 03, 2025		DP			
		8846104	Jun 19, 2027		DP			
		8877247	Jun 19, 2027		DP			
MOXIDECTIN - MOXIDECTIN								
N 210867	001						NCE	Jun 13, 2023
							ODE-193	Jun 13, 2025
MOXIFLOXACIN HYDROCHLORIDE - AVELOX								
N 021085	001	6610327	Oct 29, 2019		DP U-298		M-185	Sep 27, 2019
MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER								
N 021277	001	6548079	Jul 25, 2020		DP U-298		M-185	Sep 27, 2019
MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX								
N 021598	001	6716830	Sep 29, 2019		DP			
		7671070	Sep 29, 2019		U-709			
MOXIFLOXACIN HYDROCHLORIDE - MOXEZA								
N 022428	001	6716830	Sep 29, 2019		DP			
		7671070	Sep 29, 2019		DP U-709			
		8450311	May 29, 2029		DP			
		9114168	May 29, 2029		DP			
NAFTIFINE HYDROCHLORIDE - NAFTIN								
N 019599	002						M-191	Nov 10, 2019
NAFTIFINE HYDROCHLORIDE - NAFTIN								
N 204286	001	8778365	Jan 31, 2033		DP			
		9161914	Jan 31, 2033		U-540			
NALDEMEDINE TOSYLATE - SYMPROIC								
N 208854	001	9108975	Nov 11, 2031	DS	DP		NCE	Mar 23, 2022
		RE46365	Jan 11, 2028	DS	DP			
		RE46375	Oct 05, 2026	DS	DP U-1185			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NALOXEGOL OXALATE - MOVANTIK							
N 204760	001	7056500	Jun 29, 2024	DP U-1185		NCE	Sep 16, 2019
		7662365	Oct 18, 2022	DS DP			
		7786133	Dec 19, 2027	DS DP			
		8067431	Dec 16, 2024	U-1185			
		8617530	Oct 18, 2022	U-1185			
		9012469	Apr 02, 2032	DS DP			
NALOXEGOL OXALATE - MOVANTIK							
N 204760	002	7056500	Jun 29, 2024	DP U-1185		NCE	Sep 16, 2019
		7662365	Oct 18, 2022	DS DP			
		7786133	Dec 19, 2027	DS DP			
		8067431	Dec 16, 2024	U-1185			
		8617530	Oct 18, 2022	U-1185			
		9012469	Apr 02, 2032	DS DP			
NALOXONE HYDROCHLORIDE - EVZIO							
N 205787	001	10143972	May 24, 2031	U-2476			
		7731686	Jun 10, 2026	DP			
		7731690	Jan 15, 2025	DP			
		7749194	Oct 30, 2028	DP			
		7918823	Nov 23, 2024	DP			
		7947017	Mar 12, 2028	DP			
		8016788	Mar 21, 2025	DP			
		8021344	Nov 02, 2029	DP			
		8206360	Feb 27, 2027	DP			
		8226610	Apr 10, 2029	DP			
		8231573	Nov 25, 2028	DP			
		8313466	Nov 23, 2024	DP			
		8361029	Nov 23, 2024	DP			
		8425462	Nov 23, 2024	DP			
		8608698	Nov 23, 2024	DP			
		8627816	Feb 04, 2032	DP			
		8926594	Mar 31, 2026	DP			
		8939943	Feb 28, 2031	DP			
		9022022	Feb 28, 2031	DP			
		9056170	Nov 23, 2024	DP			
		9238108	Feb 20, 2027	DP			
		9278182	Feb 01, 2026	DP			
		9474869	Feb 28, 2031	DP U-1907			
		9517307	Jul 18, 2034	DP U-1925			
		9724471	May 23, 2027	DP U-2092			
		9737669	Nov 23, 2024	DP			
NALOXONE HYDROCHLORIDE - NARCAN							
N 208411	001	10085937	Mar 16, 2035	U-1903			
		9211253	Mar 16, 2035	DP			
		9468747	Mar 16, 2035	DP U-1903			
		9561177	Mar 16, 2035	DP U-1903			
		9629965	Mar 16, 2035	DP U-1903			
		9775838	Mar 16, 2035	U-1903			
NALOXONE HYDROCHLORIDE - NARCAN							
N 208411	002	9480644	Mar 16, 2035	DP U-1903			
		9707226	Mar 16, 2035	DP U-1903			
NALOXONE HYDROCHLORIDE - EVZIO							
N 209862	001	10143972	May 24, 2031	U-2476			
		7731686	Jun 01, 2026	DP			
		7731690	Jan 15, 2025	DP			
		7749194	Oct 30, 2028	DP			
		7918823	Nov 23, 2024	DP			
		7947017	Mar 12, 2028	DP			
		8016788	Mar 21, 2025	DP			
		8021344	Nov 02, 2029	DP			
		8206360	Feb 27, 2027	DP			
		8226610	Apr 10, 2029	DP			
		8231573	Nov 25, 2028	DP			
		8313466	Nov 23, 2024	DP			
		8361029	Nov 23, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NALOXONE HYDROCHLORIDE - EVZIO							
N 209862	001	8425462	Nov 23, 2024	DP			
		8608698	Nov 23, 2024	DP			
		8627816	Feb 04, 2032	DP			
		8926594	Mar 31, 2026	DP			
		8939943	Feb 28, 2031	DP			
		9022022	Feb 28, 2031	DP			
		9056170	Nov 23, 2024	DP			
		9238108	Feb 20, 2027	DP			
		9278182	Feb 01, 2026	DP			
		9474869	Feb 28, 2031	DP		U-1907	
		9517307	Jul 18, 2034	DP		U-1925	
		9724471	May 23, 2027	DP		U-2092	
		9737669	Nov 23, 2024	DP			
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ							
N 205777	001	8846090	Apr 04, 2023	DP			
		8846091	Apr 04, 2023	DP			
		8969369	May 10, 2022	DP		U-1556	
		9056051	May 10, 2022	DP		U-1556	
		9073933	Mar 30, 2025	DS			
		9084729	May 10, 2022	DP		U-1556	
		9161937	May 10, 2022	DP		U-1556	
		9168252	May 10, 2022	DP		U-1556	
		9283216	May 10, 2022	DP		U-1819	
		9283221	May 10, 2022	DP		U-1819	
		9345701	May 10, 2022	DP		U-1819	
		9511066	May 10, 2022			U-1921	
		9522919	Mar 30, 2025	DS DP			
		9555000	Apr 04, 2023	DP		U-1556	
		9907793	Apr 04, 2023	DP		U-1556	
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ							
N 205777	002	8846090	Apr 04, 2023	DP			
		8846091	Apr 04, 2023	DP			
		8969369	May 10, 2022	DP		U-1556	
		9056051	May 10, 2022	DP		U-1556	
		9073933	Mar 30, 2025	DS			
		9084729	May 10, 2022	DP		U-1556	
		9161937	May 10, 2022	DP		U-1556	
		9168252	May 10, 2022	DP		U-1556	
		9283216	May 10, 2022	DP		U-1819	
		9283221	May 10, 2022	DP		U-1819	
		9345701	May 10, 2022	DP		U-1819	
		9511066	May 10, 2022			U-1921	
		9522919	Mar 30, 2025	DS DP			
		9555000	Apr 04, 2023	DP		U-1556	
		9907793	Apr 04, 2023	DP		U-1556	
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ							
N 205777	003	8846090	Apr 04, 2023	DP			
		8846091	Apr 04, 2023	DP			
		8969369	May 10, 2022	DP		U-1556	
		9056051	May 10, 2022	DP		U-1556	
		9073933	Mar 30, 2025	DS			
		9084729	May 10, 2022	DP		U-1556	
		9161937	May 10, 2022	DP		U-1556	
		9168252	May 10, 2022	DP		U-1556	
		9283216	May 10, 2022	DP		U-1819	
		9283221	May 10, 2022	DP		U-1819	
		9345701	May 10, 2022	DP		U-1819	
		9511066	May 10, 2022			U-1921	
		9522919	Mar 30, 2025	DS DP			
NALTREXONE - VIVITROL							
N 021897	001	6264987	May 19, 2020	DP			
		6331317	Nov 12, 2019	DP			
		6379704	May 19, 2020	DP			
		6395304	Nov 12, 2019	DP			
		6495164	May 25, 2020	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NALTREXONE - VIVITROL							
N 021897	001	6495166	Nov 12, 2019	DP			
		6534092	May 19, 2020	DP			
		6537586	Nov 12, 2019	DP			
		6667061	May 25, 2020	DP			
		6713090	Nov 12, 2019	DP			
		6939033	Nov 12, 2019	DP			
		7799345	May 25, 2020	DP			
		7919499	Oct 15, 2029	U-1123			
		7919499	Oct 15, 2029	U-1124			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER							
N 207621	001	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
		8685443	Jul 03, 2025	U-1508			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER							
N 207621	002	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
		8685443	Jul 03, 2025	U-1508			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER							
N 207621	003	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
		8685443	Jul 03, 2025	U-1508			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER							
N 207621	004	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
		8685443	Jul 03, 2025	U-1508			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER							
N 207621	005	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
		8685443	Jul 03, 2025	U-1508			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER							
N 207621	006	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
		8685443	Jul 03, 2025	U-1508			
NAPROXEN SODIUM - NAPROXEN SODIUM							
N 021920	001	10022344	Mar 03, 2026	DP U-1731			
		10022344	Mar 03, 2026	DP U-1732			
		10028925	Mar 03, 2026	DP U-1731			
		10028925	Mar 03, 2026	DP U-1732			
		9693978	Mar 03, 2026	DP			
		9693979	Mar 03, 2026	DP			
NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET							
N 021926	001	7332183	Oct 02, 2025	DP U-867			
		7332183*PED	Apr 02, 2026				
NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET							
N 021926	002	7332183	Oct 02, 2025	DP U-1719			
		7332183*PED	Apr 02, 2026				
NATEGLINIDE - STARLIX							
N 021204	001	6559188	Sep 15, 2020	DP U-827			
		6878749	Sep 15, 2020	DP			
NATEGLINIDE - STARLIX							
N 021204	002	6559188	Sep 15, 2020	DP U-827			
		6878749	Sep 15, 2020	DP			
NEBIVOLOL HYDROCHLORIDE - BYSTOLIC							
N 021742	002	6545040	Dec 17, 2021	DP U-3			
NEBIVOLOL HYDROCHLORIDE - BYSTOLIC							
N 021742	003	6545040	Dec 17, 2021	DP U-3			
NEBIVOLOL HYDROCHLORIDE - BYSTOLIC							
N 021742	004	6545040	Dec 17, 2021	DP U-3			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NEBIVOLOL HYDROCHLORIDE - BYSTOLIC							
N 021742	005	6545040	Dec 17, 2021	DP U-3			
NEBIVOLOL HYDROCHLORIDE; VALSARTAN - BYVALSON							
N 206302	001	7803838	Aug 29, 2026	DP		NC	Jun 03, 2019
		7838552	Oct 04, 2027	U-185			
NEPAFENAC - NEVANAC							
N 021862	001	7834059	Jan 31, 2027	U-1095			
		8071648	Dec 02, 2025	DP			
		8324281	Dec 02, 2025	DP			
NEPAFENAC - ILEVRO							
N 203491	001	7947295	Jun 08, 2024	DP			
		8921337	Mar 31, 2032	DP			
		9662398	Dec 01, 2030	DP			
NERATINIB MALEATE - NERLYNX							
N 208051	001	10035788	Oct 15, 2028	U-2043		NCE	Jul 17, 2022
		6288082	Sep 24, 2019	DS DP U-2043			
		7399865	Dec 29, 2025	DS DP			
		7982043	Oct 08, 2025	U-2043			
		8518446	Nov 20, 2030	DP U-2043			
		8790708	Nov 05, 2030	DP U-2043			
		9139558	Oct 15, 2028	U-2043			
		9211291	Mar 24, 2030	U-2043			
		9630946	Oct 15, 2028	U-2043			
NETARSUDIL DIMESYLATE - RHOPRESSA							
N 208254	001	8394826	Nov 10, 2030	DS DP U-1524		NCE	Dec 18, 2022
		8450344	Jul 11, 2026	DS DP U-1524			
		9096569	Jul 11, 2026	DS DP U-1524			
		9415043	Mar 14, 2034	DS			
		9931336	Mar 14, 2034	DS DP U-1524			
NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO							
N 205718	001	6297375	Feb 22, 2020	DS		NCE	Oct 10, 2019
		8623826	Nov 18, 2030	U-2293			
		8951969	Nov 18, 2030	DP			
		9186357	Nov 18, 2030	U-2293			
		9271975	Sep 09, 2031	U-2293			
		9943515	Nov 18, 2030	U-2293			
		9951016	Sep 25, 2035	DS DP			
NEVIRAPINE - VIRAMUNE XR							
N 201152	001	8460704	Mar 12, 2029	U-1409			
NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER							
N 019734	002	7612102	Dec 26, 2027	DP			
		7659291	Apr 18, 2027	U-1029			
		8455524	Apr 18, 2027	U-1029			
		9364564	Dec 26, 2027	DP			
NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER							
N 019734	003	7612102	Dec 26, 2027	DP			
		7659291	Apr 18, 2027	U-1029			
		8455524	Apr 18, 2027	U-1029			
		9364564	Dec 26, 2027	DP			
NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER							
N 019734	004	7612102	Dec 26, 2027	DP			
		7659291	Apr 18, 2027	U-1029			
		8455524	Apr 18, 2027	U-1029			
		9364564	Dec 26, 2027	DP			
NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER							
N 019734	005	7612102	Dec 26, 2027	DP			
		7659291	Apr 18, 2027	U-1029			
		8455524	Apr 18, 2027	U-1029			
		9364564	Dec 26, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NICOTINE - NICODERM CQ						
N 020165 004	8075911	May 22, 2021	DP			
	8663680	Feb 13, 2020	DP			
	8999379	Feb 13, 2020	U-1686			
	9205059	Dec 15, 2019	DP			
NICOTINE - NICODERM CQ						
N 020165 005	8075911	May 22, 2021	DP			
	8663680	Feb 13, 2020	DP			
	8999379	Feb 13, 2020	U-1686			
	9205059	Dec 15, 2019	DP			
NICOTINE - NICODERM CQ						
N 020165 006	8075911	May 22, 2021	DP			
	8663680	Feb 13, 2020	DP			
	8999379	Feb 13, 2020	U-1686			
	9205059	Dec 15, 2019	DP			
NICOTINE POLACRILEX - NICORETTE						
N 018612 002	8323683	Apr 30, 2028				
NICOTINE POLACRILEX - NICORETTE						
N 020066 002	8323683	Apr 30, 2028	DP			
NICOTINE POLACRILEX - NICORETTE						
N 022360 001	8501164	Jun 14, 2029	DP			
	8940772	Apr 30, 2029	DP			
NICOTINE POLACRILEX - NICORETTE						
N 022360 002	8501164	Jun 14, 2029	DP			
	8940772	Apr 30, 2029	DP			
NILOTINIB HYDROCHLORIDE - TASIGNA						
N 022068 001	7169791	Jul 04, 2023	DS DP U-836		D-170	Dec 22, 2020
	7169791*PED	Jan 04, 2024			NPP	Mar 22, 2021
	8163904	Aug 23, 2028	DS DP		ODE-171	Mar 22, 2025
	8163904*PED	Feb 23, 2029			ODE-172	Mar 22, 2025
	8293756	Sep 25, 2027	DP		PED	Jun 22, 2021
	8293756*PED	Mar 25, 2028			PED	Sep 22, 2021
	8389537	Jul 18, 2026	DS DP U-1374		PED	Sep 22, 2025
	8389537*PED	Jan 18, 2027			PED	Sep 22, 2025
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DS DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DP U-1374			
	9061029*PED	Oct 07, 2032				
NILOTINIB HYDROCHLORIDE - TASIGNA						
N 022068 002	7169791	Jul 04, 2023	DS DP U-836		D-170	Dec 22, 2020
	7169791*PED	Jan 04, 2024			NPP	Mar 22, 2021
	8163904	Aug 23, 2028	DS DP		ODE-171	Mar 22, 2025
	8163904*PED	Feb 23, 2029			ODE-172	Mar 22, 2025
	8293756	Sep 25, 2027	DP		PED	Jun 22, 2021
	8293756*PED	Mar 25, 2028			PED	Sep 22, 2021
	8389537	Jul 18, 2026	DS DP U-1374		PED	Sep 22, 2025
	8389537*PED	Jan 18, 2027			PED	Sep 22, 2025
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DS DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DP U-1374			
	9061029*PED	Oct 07, 2032				
NILOTINIB HYDROCHLORIDE - TASIGNA						
N 022068 003	7169791	Jul 04, 2023	DS DP U-836		NPP	Mar 22, 2021
	7169791*PED	Jan 04, 2024			ODE-171	Mar 22, 2025
	8163904	Aug 23, 2028	DS DP		ODE-172	Mar 22, 2025
	8163904*PED	Feb 23, 2029			PED	Sep 22, 2021
	8293756	Sep 25, 2027	DP		PED	Sep 22, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NILOTINIB HYDROCHLORIDE - TASIGNA							
N 022068	003	8293756*PED	Mar 25, 2028			PED	Sep 22, 2025
		8389537	Jul 18, 2026	DS DP U-1374			
		8389537*PED	Jan 18, 2027				
		8415363	Jul 18, 2026	DS DP U-1407			
		8415363*PED	Jan 18, 2027				
		8501760	Jul 18, 2026	DS DP			
		8501760*PED	Jan 18, 2027				
		9061029	Apr 07, 2032	DS DP U-1374			
		9061029*PED	Oct 07, 2032				
NIMODIPINE - NYMALIZE							
N 203340	001					ODE-46	May 10, 2020
NINTEDANIB ESYLATE - OFEV							
N 205832	001	10105323	Jun 04, 2029	DP		NCE	Oct 15, 2019
		6762180	Oct 03, 2020	DS DP		ODE-77	Oct 15, 2021
		7119093	Feb 21, 2024	DS DP			
		7989474	Apr 06, 2024	U-1677			
		9907756	Jun 07, 2029	DP			
NINTEDANIB ESYLATE - OFEV							
N 205832	002	10105323	Jun 04, 2029	DP		NCE	Oct 15, 2019
		6762180	Oct 03, 2020	DS DP		ODE-77	Oct 15, 2021
		7119093	Feb 21, 2024	DS DP			
		7989474	Apr 06, 2024	U-1677			
		9907756	Jun 07, 2029	DP			
NIRAPARIB TOSYLATE - ZEJULA							
N 208447	001	8071623	Mar 22, 2030	DS DP		NCE	Mar 27, 2022
		8436185	Apr 24, 2029	DS		ODE-133	Mar 27, 2024
NITISINONE - ORFADIN							
N 021232	001					D-169	Sep 01, 2020
NITISINONE - ORFADIN							
N 021232	002					D-169	Sep 01, 2020
NITISINONE - ORFADIN							
N 021232	003					D-169	Sep 01, 2020
NITISINONE - ORFADIN							
N 021232	004					D-169	Sep 01, 2020
NITISINONE - ORFADIN							
N 206356	001	9301932	Feb 28, 2033	DP U-1836		D-169	Sep 01, 2020
NITRIC OXIDE - INOMAX							
N 020845	002	8282966	Jun 30, 2029	U-1286			
		8291904	Jan 06, 2031	DP U-1226			
		8293284	Jun 30, 2029	U-1286			
		8431163	Jun 30, 2029	U-1286			
		8431163*PED	Dec 30, 2029				
		8573209	Jan 06, 2031	DP			
		8573209*PED	Jul 06, 2031				
		8573210	Jan 06, 2031	DP U-1453			
		8573210*PED	Jul 06, 2031				
		8776794	Jan 06, 2031	DP U-1226			
		8776794*PED	Jul 06, 2031				
		8776795	Jan 06, 2031	DP U-1226			
		8776795*PED	Jul 06, 2031				
		8795741	Jun 30, 2029	U-1286			
		8795741*PED	Dec 30, 2029				
		8846112	Jun 30, 2029	U-1286			
		8846112*PED	Dec 30, 2029				
NITRIC OXIDE - INOMAX							
N 020845	003	8282966	Jun 30, 2029	U-1286			
		8291904	Jan 06, 2031	DP U-1226			
		8293284	Jun 30, 2029	U-1286			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NITRIC OXIDE - INOMAX							
N 020845	003	8431163	Jun 30, 2029	U-1286			
		8431163*PED	Dec 30, 2029				
		8573209	Jan 06, 2031	DP			
		8573209*PED	Jul 06, 2031				
		8573210	Jan 06, 2031	DP U-1453			
		8573210*PED	Jul 06, 2031				
		8776794	Jan 06, 2031	DP U-1226			
		8776794*PED	Jul 06, 2031				
		8776795	Jan 06, 2031	DP U-1226			
		8776795*PED	Jul 06, 2031				
		8795741	Jun 30, 2029	U-1286			
		8795741*PED	Dec 30, 2029				
		8846112	Jun 30, 2029	U-1286			
		8846112*PED	Dec 30, 2029				
		9265911	Jan 06, 2031	DP U-1824			
		9265911*PED	Jul 06, 2031				
		9279794	Feb 19, 2034	DP U-1823			
		9279794*PED	Aug 19, 2034				
		9295802	Jan 06, 2031	DP U-1226			
		9295802*PED	Jul 06, 2031				
		9408993	Jan 06, 2031	DP U-1824			
		9408993*PED	Jul 06, 2031				
		9770570	May 03, 2036	U-2148			
		9770570*PED	Nov 03, 2036				
NITROGLYCERIN - NITROLINGUAL PUMPSPRAY							
N 018705	002	7872049	Mar 12, 2029	DP U-2223			
NITROGLYCERIN - GONITRO							
N 208424	001	9101592	Mar 11, 2032	DP			
NIZATIDINE - AXID							
N 021494	001	6930119	Jul 17, 2022	DP			
NUSINERSEN SODIUM - SPINRAZA							
N 209531	001	7101993	Sep 05, 2023	DS		M-226	May 14, 2021
		7838657	Jul 11, 2027	DS		NCE	Dec 23, 2021
		8110560	Dec 05, 2025	U-1942		ODE-127	Dec 23, 2023
		8110560	Dec 05, 2025	U-1943			
		8110560	Dec 05, 2025	U-1944			
		8361977	May 27, 2030	DS DP			
		8980853	Nov 24, 2030	U-1941			
		9717750	Jun 17, 2030	U-1942			
		9717750	Jun 17, 2030	U-1943			
		9717750	Jun 17, 2030	U-2093			
		9717750	Jun 17, 2030	U-2094			
		9926559	Jan 09, 2034	U-1943			
OBETICHOLIC ACID - OCALIVA							
N 207999	001	10047117	Sep 06, 2033	U-1854		NCE	May 27, 2021
		10052337	Apr 26, 2036	DP		ODE-119	May 27, 2023
		10174073	Jun 17, 2033	DS			
		7138390	Nov 16, 2022	DS DP			
		8058267	Feb 21, 2022	U-1854			
		8377916	Feb 21, 2022	U-1854			
		9238673	Jun 17, 2033	DP			
OBETICHOLIC ACID - OCALIVA							
N 207999	002	10047117	Sep 06, 2033	U-1854		NCE	May 27, 2021
		10052337	Apr 26, 2036	DP		ODE-119	May 27, 2023
		10174073	Jun 17, 2033	DS			
		7138390	Nov 16, 2022	DS DP			
		8058267	Feb 21, 2022	U-1854			
		8377916	Feb 21, 2022	U-1854			
		9238673	Jun 17, 2033	DP			
OLAPARIB - LYNPARZA							
N 206162	001	7151102	Apr 29, 2022	DS DP		NCE	Dec 19, 2019
		7449464	Oct 11, 2024	DS DP		ODE-83	Dec 19, 2021

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLAPARIB - LYNPARZA							
N 206162	001	7981889	Oct 11, 2024	DS DP			
		8143241	Aug 12, 2027	U-1634			
		8247416	Sep 24, 2028	DS			
		8859562	Aug 04, 2031	U-1634			
		8912187	Mar 12, 2024	U-1634			
OLAPARIB - LYNPARZA							
N 208558	001	7151102	Apr 29, 2022	DS DP		I-762	Jan 12, 2021
		7449464	Oct 11, 2024	DS DP		I-776	Dec 19, 2021
		7981889	Oct 11, 2024	DS DP		NCE	Dec 19, 2019
		8143241	Aug 12, 2027	U-2101		NP	Aug 17, 2020
		8143241	Aug 12, 2027	U-2102		ODE-180	Aug 17, 2024
		8143241	Aug 12, 2027	U-2103		ODE-181	Aug 17, 2024
		8143241	Aug 12, 2027	U-2358		ODE-83	Dec 19, 2021
		8143241	Aug 12, 2027	U-2359			
		8475842	Dec 31, 2029	DP			
		8859562	Aug 04, 2031	U-2101			
		8859562	Aug 04, 2031	U-2102			
		8859562	Aug 04, 2031	U-2358			
		8859562	Aug 04, 2031	U-2359			
		8912187	Mar 12, 2024	U-2101			
		8912187	Mar 12, 2024	U-2102			
		8912187	Mar 12, 2024	U-2358			
		8912187	Mar 12, 2024	U-2359			
OLAPARIB - LYNPARZA							
N 208558	002	7151102	Apr 29, 2022	DS DP		I-762	Jan 12, 2021
		7449464	Oct 11, 2024	DS DP		I-776	Dec 19, 2021
		7981889	Oct 11, 2024	DS DP		NCE	Dec 19, 2019
		8143241	Aug 12, 2027	U-2101		NP	Aug 17, 2020
		8143241	Aug 12, 2027	U-2102		ODE-180	Aug 17, 2024
		8143241	Aug 12, 2027	U-2103		ODE-181	Aug 17, 2024
		8143241	Aug 12, 2027	U-2358		ODE-83	Dec 19, 2021
		8143241	Aug 12, 2027	U-2359			
		8475842	Dec 31, 2029	DP			
		8859562	Aug 04, 2031	U-2101			
		8859562	Aug 04, 2031	U-2102			
		8859562	Aug 04, 2031	U-2358			
		8859562	Aug 04, 2031	U-2359			
		8912187	Mar 12, 2024	U-2101			
		8912187	Mar 12, 2024	U-2102			
		8912187	Mar 12, 2024	U-2358			
		8912187	Mar 12, 2024	U-2359			
OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT							
N 203108	001	6988496	Feb 23, 2020	DP U-1547		NCE	Jul 31, 2019
		7056916	Dec 07, 2023	DS DP			
		7220742	May 12, 2025	DS DP U-1547			
		7284474	Aug 26, 2024	DP			
		7396341	Oct 10, 2026	DP U-1547			
		7491719	Nov 10, 2023	DS DP			
		7727984	Nov 10, 2023	DS			
		7786111	Nov 10, 2023	DP			
		7802568	Feb 26, 2019	DP			
		7837235	Mar 13, 2028	DP			
		7896264	May 26, 2025	DP			
		7988001	Aug 04, 2021	DP			
		8034809	May 12, 2025	U-1547			
		8044046	Nov 10, 2023	U-1547			
		8733341	Oct 16, 2030	DP			
		9027967	Mar 31, 2027	DP			
OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT							
N 206756	001	6846413*PED	Feb 28, 2019			M-173	Mar 18, 2019
		6977042*PED	Feb 28, 2019			M-233	Oct 05, 2021
		6988496	Feb 23, 2020	DP		NCE	Jul 31, 2019
		6988496*PED	Aug 23, 2020				
		7056916	Dec 07, 2023	DS DP			
		7220742	May 12, 2025	DS DP U-1703			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT							
N 206756	001	7284474	Aug 26, 2024	DP			
		7284474*PED	Feb 26, 2025				
		7396341	Oct 10, 2026	DP			
		7396341*PED	Apr 10, 2027				
		7491719	Nov 10, 2023	DS DP			
		7727984	Nov 10, 2023	DS			
		7786111	Nov 10, 2023	DP			
		7802568	Feb 26, 2019	DP			
		7802568*PED	Aug 26, 2019				
		7837235	Mar 13, 2028	DP			
		7837235*PED	Sep 13, 2028				
		7896264	May 26, 2025	DP			
		7988001	Aug 04, 2021	DP			
		8034809	May 12, 2025	U-1702			
		8044046	Nov 10, 2023	U-1702			
		8733341	Oct 16, 2030	DP			
		9027967	Mar 31, 2027	DP			
OLOPATADINE HYDROCHLORIDE - PATADAY							
N 021545	001	6995186	Nov 12, 2023	DP U-765			
		7402609	Jun 19, 2022	DP			
OLOPATADINE HYDROCHLORIDE - PATANASE							
N 021861	001	7977376	Feb 02, 2023	DP			
		8399508	Sep 17, 2022	U-726			
		8399508*PED	Mar 17, 2023				
OLOPATADINE HYDROCHLORIDE - PAZEO							
N 206276	001	8791154	May 19, 2032	DP U-1680			
		9533053	May 19, 2032	DP			
OMACETAXINE MEPESUCCINATE - SYNRIBO							
N 203585	001	6987103	Oct 26, 2026	U-1300		ODE-32	Oct 26, 2019
		RE45128	Mar 16, 2019	DS DP U-1576			
OMADACYCLINE TOSYLATE - NUZYRA							
N 209816	001	10111890	Aug 03, 2037	U-2444		NCE	Oct 02, 2023
		10124014	Mar 05, 2029	U-2449		GAIN	Oct 02, 2028
OMADACYCLINE TOSYLATE - NUZYRA							
N 209817	001	10124014	Mar 05, 2029	U-2449		NCE	Oct 02, 2023
						GAIN	Oct 02, 2028
OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE							
N 207931	001	7148359	Jul 19, 2019	DP		NCE	Dec 19, 2019
		7148359*PED	Jan 19, 2020				
		7364752	Nov 10, 2020	DP			
		7364752*PED	May 10, 2021				
		8268349	Aug 25, 2024	DP			
		8268349*PED	Feb 25, 2025				
		8399015	Aug 25, 2024	DP			
		8399015*PED	Feb 25, 2025				
		8420596	Apr 10, 2031	DS DP			
		8420596*PED	Oct 10, 2031				
		8642538	Sep 10, 2029	DS DP U-1638			
		8686026	Jun 09, 2031	DP			
		8691938	Apr 13, 2032	DS DP			
		9006387	Jun 10, 2030	U-1687			
		9044480	Apr 10, 2031	U-1638			
OMEGA-3-ACID ETHYL ESTERS TYPE A - OMTRYG							
N 204977	001					NCE	Apr 23, 2019
OMEGA-3-CARBOXYLIC ACIDS - EPANOVA							
N 205060	001	10117844	Jan 04, 2033	U-2447		NCE	May 05, 2019
		5792795	May 13, 2019	DP			
		5948818	May 13, 2019	DP			
		7960370	Feb 07, 2025	DP			
		8383678	Feb 07, 2025	DP U-1511			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OMEGA-3-CARBOXYLIC ACIDS - EPANOVA								
N 205060	001	9012501	Feb 07, 2025		DP U-1511			
		9050308	Jan 04, 2033		U-1511			
		9050309	Jan 04, 2033	DS				
		9132112	Feb 07, 2025		DP U-1511			
OMEPRAZOLE - OMEPRAZOLE								
N 022032	001	9023391	Aug 16, 2025		DP			
OMEPRAZOLE - OMEPRAZOLE								
N 209400	001	10076494	Dec 08, 2036		DP			
OMEPRAZOLE MAGNESIUM - PRILOSEC OTC								
N 021229	001	6403616	Nov 15, 2019					
		6428810	Nov 03, 2019					
OMEPRAZOLE MAGNESIUM - PRILOSEC								
N 022056	001	6428810	Nov 03, 2019		DP U-1817			
		6428810	Nov 03, 2019		DP U-864			
OMEPRAZOLE MAGNESIUM - PRILOSEC								
N 022056	002	6428810	Nov 03, 2019		DP U-864			
ONDANSETRON - ZUPLENZ								
N 022524	001	8580830	Nov 23, 2029		DP			
		9095577	Jul 13, 2030		DP			
ONDANSETRON - ZUPLENZ								
N 022524	002	8580830	Nov 23, 2029		DP			
		9095577	Jul 13, 2030		DP			
ORITAVANCIN DIPHOSPHATE - ORBACTIV								
N 206334	001	5840684	Nov 24, 2020	DS	DP U-1569		NCE	Aug 06, 2019
		8420592	Aug 29, 2029		U-1570		GAIN	Aug 06, 2024
		9649352	Jul 16, 2035		DP			
		9682061	Apr 26, 2030		U-1569			
OSIMERTINIB MESYLATE - TAGRISSO								
N 208065	001	8946235	Aug 08, 2032	DS	DP U-1777		I-774	Apr 18, 2021
		8946235	Aug 08, 2032	DS	DP U-2289		NCE	Nov 13, 2020
		9732058	Jul 25, 2032	DS	DP U-1777		ODE-102	Nov 13, 2022
		9732058	Jul 25, 2032	DS	DP U-2289		ODE-176	Apr 18, 2025
OSIMERTINIB MESYLATE - TAGRISSO								
N 208065	002	8946235	Aug 08, 2032	DS	DP U-1777		I-774	Apr 18, 2021
		8946235	Aug 08, 2032	DS	DP U-2289		NCE	Nov 13, 2020
		9732058	Jul 25, 2032	DS	DP U-1777		ODE-102	Nov 13, 2022
		9732058	Jul 25, 2032	DS	DP U-2289		ODE-176	Apr 18, 2025
OSPEMIFENE - OSPHENA								
N 203505	001	6245819	Jul 21, 2025		U-1370			
		8236861	Aug 11, 2026		U-1369			
		8236861	Aug 11, 2026		U-1370			
		8470890	Feb 13, 2024		U-1369			
		8470890	Feb 13, 2024		U-1370			
		8642079	Jul 09, 2028		DP			
		8772353	Feb 13, 2024		U-1369			
		8772353	Feb 13, 2024		U-1370			
		9241915	Feb 13, 2024		U-1369			
		9241915	Feb 13, 2024		U-1370			
		9566252	Jul 21, 2020		U-1370			
		9855224	Feb 13, 2024		U-1369			
		9855224	Feb 13, 2024		U-1370			
OXCARBAZEPINE - TRILEPTAL								
N 021285	001	8119148	Dec 19, 2020		DP U-724			
OXCARBAZEPINE - OXTELLAR XR								
N 202810	001	7722898	Apr 13, 2027		DP			
		7910131	Apr 13, 2027		U-1298			
		8617600	Apr 13, 2027		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXCARBAZEPINE - OXTELLAR XR						
N 202810 001	8821930	Apr 13, 2027	DP			
	9119791	Apr 13, 2027	U-1298			
	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
	9855278	Apr 13, 2027	DP			
OXCARBAZEPINE - OXTELLAR XR						
N 202810 002	7722898	Apr 13, 2027	DP			
	7910131	Apr 13, 2027	U-1298			
	8617600	Apr 13, 2027	DP			
	8821930	Apr 13, 2027	DP			
	9119791	Apr 13, 2027	U-1298			
	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
	9855278	Apr 13, 2027	DP			
OXCARBAZEPINE - OXTELLAR XR						
N 202810 003	7722898	Apr 13, 2027	DP			
	7910131	Apr 13, 2027	U-1298			
	8617600	Apr 13, 2027	DP			
	8821930	Apr 13, 2027	DP			
	9119791	Apr 13, 2027	U-1298			
	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
	9855278	Apr 13, 2027	DP			
OXYBUTYNIN - OXYTROL						
N 021351 002	6743441	Apr 26, 2020	DP U-318			
	7081249	Apr 26, 2020	DP U-318			
	7081250	Apr 26, 2020	DP U-318			
	7081251	Apr 26, 2020	DP U-318			
	7081252	Apr 26, 2020	DP U-318			
	7179483	Apr 26, 2020	DS DP U-318			
OXYBUTYNIN - OXYTROL FOR WOMEN						
N 202211 001	6743441	Apr 26, 2020	DP U-1329			
	7081249	Apr 26, 2020	DP U-1329			
	7081250	Apr 26, 2020	DP U-1329			
	7081251	Apr 26, 2020	DP U-1329			
	7081252	Apr 26, 2020	DP U-1329			
	7179483	Apr 26, 2020	U-1329			
OXYBUTYNIN - GELNIQUE 3%						
N 202513 001	7029694	Apr 26, 2020	DP U-318			
	7179483	Apr 26, 2020	U-318			
	7198801	Jun 25, 2022	DP			
	8241662	Apr 26, 2020	U-318			
OXYBUTYNIN CHLORIDE - GELNIQUE						
N 022204 001	7029694	Apr 26, 2020	DP U-318			
	7179483	Apr 26, 2020	U-318			
	8241662	Apr 26, 2020	U-318			
	8920392	Mar 26, 2031	U-1644			
	9259388	Nov 06, 2029	U-1644			
OXYCODONE - XTAMPZA ER						
N 208090 001	10004729	Dec 10, 2030	DP U-1556		NP	Apr 26, 2019
	7399488	Mar 24, 2025	DP			
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE - XTAMPZA ER						
N 208090 001	9968598	Sep 02, 2036	DP U-1556			
OXYCODONE - XTAMPZA ER						
N 208090 002	10004729	Dec 10, 2030	DP U-1556		NP	Apr 26, 2019
	7399488	Mar 24, 2025	DP			
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
	9968598	Sep 02, 2036	DP U-1556			
OXYCODONE - XTAMPZA ER						
N 208090 003	10004729	Dec 10, 2030	DP U-1556		NP	Apr 26, 2019
	7399488	Mar 24, 2025	DP			
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
	9968598	Sep 02, 2036	DP U-1556			
OXYCODONE - XTAMPZA ER						
N 208090 004	10004729	Dec 10, 2030	DP U-1556		NP	Apr 26, 2019
	7399488	Mar 24, 2025	DP			
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
	9968598	Sep 02, 2036	DP U-1556			
OXYCODONE - XTAMPZA ER						
N 208090 005	10004729	Dec 10, 2030	DP U-1556		NP	Apr 26, 2019
	7399488	Mar 24, 2025	DP			
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
	9968598	Sep 02, 2036	DP U-1556			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 001	10130591	Nov 20, 2023	DP U-1819			
	7674799	Mar 30, 2025	DP	Y		
	7674800	Mar 30, 2025	DS	Y		
	7683072	Mar 30, 2025	DS	Y		
	7776314	Apr 19, 2025	DP	Y		
	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9060976	Aug 06, 2022	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 002	10130591	Nov 20, 2023	DP U-1819			
	7674799	Mar 30, 2025	DP	Y		
	7674800	Mar 30, 2025	DS	Y		
	7683072	Mar 30, 2025	DS	Y		
	7776314	Apr 19, 2025	DP	Y		
	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9060976	Aug 06, 2022	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 003	10130591	Nov 20, 2023	DP U-1819			
	7674799	Mar 30, 2025	DP	Y		
	7674800	Mar 30, 2025	DS	Y		
	7683072	Mar 30, 2025	DS	Y		
	7776314	Apr 19, 2025	DP	Y		
	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9060976	Aug 06, 2022	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 004	10130591	Nov 20, 2023	DP U-1819			
	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	004	8894987	Mar 29, 2030	DP			
		8894988	Aug 24, 2027	DP			
		9060976	Aug 06, 2022	DP			
		9073933	Mar 30, 2025	DS			
		9492389	Aug 24, 2027	DP			
		9492391	Aug 24, 2027			U-1556	
		9492392	Aug 24, 2027	DP			
		9492393	Aug 24, 2027			U-1556	
		9522919	Mar 30, 2025	DS DP			
		9675610	Jun 16, 2023	DP			
		9763933	Aug 24, 2027	DP			
		9770416	Aug 24, 2027	DP			
		9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	005	10130591	Nov 20, 2023	DP		U-1819	
		8309060	Nov 20, 2023	DP		U-1556	
		8808741	Aug 24, 2027			U-1556	
		8894988	Aug 24, 2027	DP			
		9060976	Aug 06, 2022	DP			
		9073933	Mar 30, 2025	DS			
		9492389	Aug 24, 2027	DP			
		9492391	Aug 24, 2027			U-1556	
		9492392	Aug 24, 2027	DP			
		9492393	Aug 24, 2027			U-1556	
		9522919	Mar 30, 2025	DS DP			
		9675610	Jun 16, 2023	DP			
		9763933	Aug 24, 2027	DP			
		9770416	Aug 24, 2027	DP			
		9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	006	10130591	Nov 20, 2023	DP		U-1819	
		8309060	Nov 20, 2023	DP		U-1556	
		8808741	Aug 24, 2027			U-1556	
		8894988	Aug 24, 2027	DP			
		9060976	Aug 06, 2022	DP			
		9073933	Mar 30, 2025	DS			
		9492389	Aug 24, 2027	DP			
		9492391	Aug 24, 2027			U-1556	
		9492392	Aug 24, 2027	DP			
		9492393	Aug 24, 2027			U-1556	
		9522919	Mar 30, 2025	DS DP			
		9675610	Jun 16, 2023	DP			
		9763933	Aug 24, 2027	DP			
		9770416	Aug 24, 2027	DP			
		9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	007	10130591	Nov 20, 2023	DP		U-1819	
		8309060	Nov 20, 2023	DP		U-1556	
		8808741	Aug 24, 2027			U-1556	
		8894988	Aug 24, 2027	DP			
		9060976	Aug 06, 2022	DP			
		9073933	Mar 30, 2025	DS			
		9492389	Aug 24, 2027	DP			
		9492391	Aug 24, 2027			U-1556	
		9492392	Aug 24, 2027	DP			
		9492393	Aug 24, 2027			U-1556	
		9522919	Mar 30, 2025	DS DP			
		9675610	Jun 16, 2023	DP			
		9763933	Aug 24, 2027	DP			
		9770416	Aug 24, 2027	DP			
		9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXAYDO							
N 202080	001	7201920	Mar 16, 2025	DP			
		7510726	Nov 26, 2023	DP			
		7981439	Nov 26, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE HYDROCHLORIDE - OXAYDO								
N 202080	001		8409616	Nov 26, 2023	DP			
			8637540	Nov 26, 2023	DP			
			9492443	May 26, 2024	DP			
OXYCODONE HYDROCHLORIDE - OXAYDO								
N 202080	002		7201920	Mar 16, 2025	DP			
			7510726	Nov 26, 2023	DP			
			7981439	Nov 26, 2023	DP			
			8409616	Nov 26, 2023	DP			
			8637540	Nov 26, 2023	DP			
			9492443	May 26, 2024	DP			
OXYCODONE HYDROCHLORIDE - ROXYBOND								
N 209777	001		7955619	Aug 12, 2028	DP		NP	Apr 20, 2020
OXYCODONE HYDROCHLORIDE - ROXYBOND								
N 209777	002		7955619	Aug 12, 2028	DP		NP	Apr 20, 2020
OXYCODONE HYDROCHLORIDE - ROXYBOND								
N 209777	003		7955619	Aug 12, 2028	DP		NP	Apr 20, 2020
OXYMETAZOLINE HYDROCHLORIDE - RHOFADE								
N 208552	001		7812049	May 02, 2028	U-1959		NP	Jan 18, 2020
			8420688	Aug 02, 2024	U-1959			
			8815929	Jan 22, 2024	U-1959			
			8883838	Dec 01, 2031	DP			
			9974773	Jun 11, 2035	U-2306			
OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE - KOVANAZE								
N 208032	001		6413499	Mar 20, 2020	U-1876		NC	Jun 29, 2019
			8580282	Apr 02, 2030	DP U-1876			
			9308191	Apr 02, 2030	DP U-1876			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 021610	001		7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 021610	002		7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 021610	003		7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 021610	004		7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 021610	005		7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 021610	006		7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 021610	007		7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 201655	001		7851482	Jul 10, 2029	DS			
			8075872	Nov 20, 2023	DP			
			8114383	Aug 08, 2024	DP			
			8192722	Sep 15, 2025	DP			
			8309060	Nov 20, 2023	DP			
			8309122	Feb 04, 2023	DP			
			8329216	Feb 04, 2023	DP			
			8808737	Jun 21, 2027	U-1598			
			8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 201655	002		7851482	Jul 10, 2029	DS			
			8075872	Nov 20, 2023	DP			
			8114383	Aug 08, 2024	DP			
			8192722	Sep 15, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N	201655	002	8309060	Nov 20, 2023	DP			
			8309122	Feb 04, 2023	DP			
			8329216	Feb 04, 2023	DP			
			8808737	Jun 21, 2027	U-1598			
			8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N	201655	003	7851482	Jul 10, 2029	DS			
			8075872	Nov 20, 2023	DP			
			8114383	Aug 08, 2024	DP			
			8192722	Sep 15, 2025	DP			
			8309060	Nov 20, 2023	DP			
			8309122	Feb 04, 2023	DP			
			8329216	Feb 04, 2023	DP			
			8808737	Jun 21, 2027	U-1598			
			8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N	201655	004	7851482	Jul 10, 2029	DS			
			8075872	Nov 20, 2023	DP			
			8114383	Aug 08, 2024	DP			
			8192722	Sep 15, 2025	DP			
			8309060	Nov 20, 2023	DP			
			8309122	Feb 04, 2023	DP			
			8329216	Feb 04, 2023	DP			
			8808737	Jun 21, 2027	U-1598			
			8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N	201655	005	7851482	Jul 10, 2029	DS			
			8075872	Nov 20, 2023	DP			
			8114383	Aug 08, 2024	DP			
			8192722	Sep 15, 2025	DP			
			8309060	Nov 20, 2023	DP			
			8309122	Feb 04, 2023	DP			
			8329216	Feb 04, 2023	DP			
			8808737	Jun 21, 2027	U-1598			
			8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N	201655	006	7851482	Jul 10, 2029	DS			
			8075872	Nov 20, 2023	DP			
			8114383	Aug 08, 2024	DP			
			8192722	Sep 15, 2025	DP			
			8309060	Nov 20, 2023	DP			
			8309122	Feb 04, 2023	DP			
			8329216	Feb 04, 2023	DP			
			8808737	Jun 21, 2027	U-1598			
			8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N	201655	007	7851482	Jul 10, 2029	DS			
			8075872	Nov 20, 2023	DP			
			8114383	Aug 08, 2024	DP			
			8192722	Sep 15, 2025	DP			
			8309060	Nov 20, 2023	DP			
			8309122	Feb 04, 2023	DP			
			8329216	Feb 04, 2023	DP			
			8808737	Jun 21, 2027	U-1598			
			8871779	Nov 22, 2029	DS			
OZENOXACIN - XEPI								
N	208945	001	6335447	Apr 06, 2019	DS		NCE	Dec 11, 2022
			9180200	Jan 29, 2032	DP U-805			
			9399014	Dec 15, 2029	U-805			
PACLITAXEL - ABRAXANE								
N	021660	001	7758891	Feb 21, 2026	U-1434		ODE-52	Sep 06, 2020
			7820788	Oct 27, 2024	DP U-1092			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PACLITAXEL - ABRAXANE						
N 021660 001	7820788	Oct 27, 2024	DP U-1290			
	7820788	Oct 27, 2024	DP U-1434			
	7923536	Dec 09, 2023	U-1117			
	7923536	Dec 09, 2023	U-1290			
	7923536	Dec 09, 2023	U-1434			
	8034375	Aug 13, 2026	U-1290			
	8138229	Dec 09, 2023	DP U-1092			
	8138229	Dec 09, 2023	DP U-1290			
	8138229	Dec 09, 2023	DP U-1434			
	8268348	Feb 21, 2026	U-1290			
	8314156	Dec 09, 2023	U-1290			
	8314156	Dec 09, 2023	U-1434			
	8853260	Oct 10, 2020	DP U-1092			
	8853260	Oct 10, 2020	DP U-1290			
	8853260	Oct 10, 2020	DP U-1434			
	9101543	Feb 21, 2026	U-1434			
	9393318	Mar 04, 2032	U-1290			
	9511046	Jan 12, 2034	U-1434			
	9597409	Mar 04, 2032	U-1290			
PALBOCICLIB - IBRANCE						
N 207103 001	6936612	Jan 22, 2023	DS DP		I-725	Feb 19, 2019
	7208489	Jan 16, 2023	DS DP		NCE	Feb 03, 2020
	7456168	Jan 16, 2023	U-1998			
PALBOCICLIB - IBRANCE						
N 207103 002	6936612	Jan 22, 2023	DS DP		I-725	Feb 19, 2019
	7208489	Jan 16, 2023	DS DP		NCE	Feb 03, 2020
	7456168	Jan 16, 2023	U-1998			
PALBOCICLIB - IBRANCE						
N 207103 003	6936612	Jan 22, 2023	DS DP		I-725	Feb 19, 2019
	7208489	Jan 16, 2023	DS DP		NCE	Feb 03, 2020
	7456168	Jan 16, 2023	U-1998			
PALIPERIDONE PALMITATE - INVEGA SUSTENNA						
N 022264 001	9439906	Jan 26, 2031	U-1901		M-215	Dec 20, 2020
	9439906	Jan 26, 2031	U-543			
PALIPERIDONE PALMITATE - INVEGA SUSTENNA						
N 022264 002	9439906	Jan 26, 2031	U-1901		M-215	Dec 20, 2020
	9439906	Jan 26, 2031	U-543			
PALIPERIDONE PALMITATE - INVEGA SUSTENNA						
N 022264 003	9439906	Jan 26, 2031	U-1901		M-215	Dec 20, 2020
	9439906	Jan 26, 2031	U-543			
PALIPERIDONE PALMITATE - INVEGA SUSTENNA						
N 022264 004	9439906	Jan 26, 2031	U-1901		M-215	Dec 20, 2020
	9439906	Jan 26, 2031	U-543			
PALIPERIDONE PALMITATE - INVEGA SUSTENNA						
N 022264 005	9439906	Jan 26, 2031	U-1901		M-215	Dec 20, 2020
	9439906	Jan 26, 2031	U-543			
PALIPERIDONE PALMITATE - INVEGA TRINZA						
N 207946 001	10143693	Apr 05, 2036	U-2457			
	10143693	Apr 05, 2036	U-2458			
PALIPERIDONE PALMITATE - INVEGA TRINZA						
N 207946 002	10143693	Apr 05, 2036	U-2457			
	10143693	Apr 05, 2036	U-2458			
PALIPERIDONE PALMITATE - INVEGA TRINZA						
N 207946 003	10143693	Apr 05, 2036	U-2457			
	10143693	Apr 05, 2036	U-2458			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PALIPERIDONE PALMITATE - INVEGA TRINZA						
N 207946 004	10143693	Apr 05, 2036	U-2457			
	10143693	Apr 05, 2036	U-2458			
PALONOSETRON HYDROCHLORIDE - ALOXI						
N 021372 001	7947724	Jan 30, 2024	DP			
	7947724*PED	Jul 30, 2024				
	7947725	Jan 30, 2024	DP			
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
	8729094	Jan 30, 2024	DP U-528			
	8729094*PED	Jul 30, 2024				
	9066980	Jan 30, 2024	DP U-528			
	9066980*PED	Jul 30, 2024				
	9125905	Jan 30, 2024	DP			
	9125905*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
	9457020	Jan 30, 2024	DP			
	9457020*PED	Jul 30, 2024				
	9457021	Jan 30, 2024	DP			
	9457021*PED	Jul 30, 2024				
PALONOSETRON HYDROCHLORIDE - ALOXI						
N 021372 002	7947724	Jan 30, 2024	DP			
	7947724*PED	Jul 30, 2024				
	7947725	Jan 30, 2024	DP			
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
	9457020	Jan 30, 2024	DP			
	9457020*PED	Jul 30, 2024				
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP						
N 022210 001	7658918	Feb 20, 2028	DP			
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028	U-1274			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP U-1274			
	8562980	Feb 20, 2028	DP U-1274			
	8562981	Feb 20, 2028	U-1274			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP						
N 022210 002	7658918	Feb 20, 2028	DP			
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028	U-1274			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP U-1274			
	8562980	Feb 20, 2028	DP U-1274			
	8562981	Feb 20, 2028	U-1274			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP						
N 022210 003	7658918	Feb 20, 2028	DP			
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028	U-1274			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP U-1274			
	8562980	Feb 20, 2028	DP U-1274			
	8562981	Feb 20, 2028				
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP						
N 022210 004	7658918	Feb 20, 2028	DP			
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028	U-1274			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP U-1274			
	8562980	Feb 20, 2028	DP U-1274			
	8562981	Feb 20, 2028	U-1274			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP						
N 022210 005	8221747	Feb 20, 2028	DP			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP U-1274			
	8562980	Feb 20, 2028	DP U-1274			
	8562981	Feb 20, 2028	U-1274			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP						
N 022210 006	8221747	Feb 20, 2028	DP			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP U-1274			
	8562980	Feb 20, 2028	DP U-1274			
	8562981	Feb 20, 2028	U-1274			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP						
N 022210 007	8221747	Feb 20, 2028	DP			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP U-1274			
	8562980	Feb 20, 2028	DP U-1274			
	8562981	Feb 20, 2028	U-1274			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE						
N 022523 005	8221747	Feb 20, 2028	DP			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP U-1274			
	8562980	Feb 20, 2028	DP U-1274			
	8562981	Feb 20, 2028	DP U-1274			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON						
N 020725 001	9198871	Feb 07, 2030	DP U-1787			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON						
N 020725 002	9198871	Feb 07, 2030	DP U-1787			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON						
N 020725 003	9198871	Feb 07, 2030	DP U-1787			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON						
N 020725 004	9198871	Feb 07, 2030	DP U-1787		M-93	Jul 29, 2019
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON						
N 020725 005	9198871	Feb 07, 2030	DP U-1787		M-93	Jul 29, 2019
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 001	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE-89	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 001	8883842	Jun 13, 2028	U-1669			
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 002	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE-89	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 003	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE-89	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
PANTOPRAZOLE SODIUM - PROTONIX IV						
N 020988 001	6780881	Nov 17, 2021	DP			
	7351723	Nov 17, 2021	DP			
	8754108	Nov 17, 2021	DP			
	8754108*PED	May 17, 2022				
PANTOPRAZOLE SODIUM - PROTONIX						
N 022020 001	7544370	Jun 07, 2026	DP			
	7550153	Sep 30, 2024	U-859			
	7553498	Sep 30, 2024	U-859			
	7838027	Sep 30, 2024	DP U-859			
PARICALCITOL - ZEMPLAR						
N 021606 001					NPP	Oct 18, 2019
					NPP	Oct 18, 2019
					ODE-125	Oct 18, 2023
PARICALCITOL - ZEMPLAR						
N 021606 002					NPP	Oct 18, 2019
					NPP	Oct 18, 2019
					ODE-125	Oct 18, 2023
PARICALCITOL - ZEMPLAR						
N 021606 003					NPP	Oct 18, 2019
					NPP	Oct 18, 2019
					ODE-125	Oct 18, 2023
PAROXETINE HYDROCHLORIDE - PAXIL						
N 020885 001	6063927	Apr 23, 2019				
PAROXETINE HYDROCHLORIDE - PAXIL						
N 020885 002	6063927	Apr 23, 2019				
PAROXETINE HYDROCHLORIDE - PAXIL						
N 020885 003	6063927	Apr 23, 2019				
PAROXETINE HYDROCHLORIDE - PAXIL						
N 020885 004	6063927	Apr 23, 2019				
PAROXETINE MESYLATE - PEXEVA						
N 021299 001	7598271	May 04, 2025	DS			
PAROXETINE MESYLATE - PEXEVA						
N 021299 002	7598271	May 04, 2025	DS			
PAROXETINE MESYLATE - PEXEVA						
N 021299 003	7598271	May 04, 2025	DS			
PAROXETINE MESYLATE - PEXEVA						
N 021299 004	7598271	May 04, 2025	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PAROXETINE MESYLATE - BRISDELLE							
N 204516	001	7598271	May 04, 2025	DS			
		8658663	Apr 06, 2029	DS DP U-904			
		8946251	Aug 04, 2026	DS DP U-904			
		9393237	Aug 04, 2026	U-904			
PASIREOTIDE DIASPARTATE - SIGNIFOR							
N 200677	001	7473761	Dec 14, 2026	DS DP		ODE-34	Dec 14, 2019
		8299209	Dec 27, 2025	DS DP			
PASIREOTIDE DIASPARTATE - SIGNIFOR							
N 200677	002	7473761	Dec 14, 2026	DS DP		ODE-34	Dec 14, 2019
		8299209	Dec 27, 2025	DS DP			
PASIREOTIDE DIASPARTATE - SIGNIFOR							
N 200677	003	7473761	Dec 14, 2026	DS DP		ODE-34	Dec 14, 2019
		8299209	Dec 27, 2025	DS DP			
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT							
N 203255	001	7473761	Dec 14, 2026	DS DP		I-785	Jun 29, 2021
		7759308	Oct 25, 2026	DP		ODE-81	Dec 15, 2021
		8822637	Aug 06, 2023	U-1629			
		9351923	May 23, 2028	DP			
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT							
N 203255	002	7473761	Dec 14, 2026	DS DP		I-785	Jun 29, 2021
		7759308	Oct 25, 2026	DP		ODE-81	Dec 15, 2021
		8822637	Aug 06, 2023	U-1629			
		9351923	May 23, 2028	DP			
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT							
N 203255	003	7473761	Dec 14, 2026	DS DP		I-785	Jun 29, 2021
		7759308	Oct 25, 2026	DP		ODE-81	Dec 15, 2021
		8822637	Aug 06, 2023	U-1629			
		9351923	May 23, 2028	DP			
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT							
N 203255	004					I-785	Jun 29, 2021
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT							
N 203255	005					I-785	Jun 29, 2021
PATIROMER SORBITEX CALCIUM - VELTASSA							
N 205739	001	7556799	Feb 27, 2025	U-1766		NCE	Oct 21, 2020
		8147873	Mar 11, 2026	DP			
		8216560	Mar 14, 2027	U-1766			
		8282913	Mar 11, 2026	DP			
		8287847	Mar 30, 2024	U-1766			
		8337824	May 29, 2030	DS U-1766			
		8475780	Mar 30, 2024	U-1766			
		8778324	Mar 30, 2024	U-1766			
		8889115	Mar 30, 2024	U-1766			
		9492476	Oct 08, 2033	U-1766			
		9925212	Oct 08, 2033	U-1766			
PATIROMER SORBITEX CALCIUM - VELTASSA							
N 205739	002	7556799	Feb 27, 2025	U-1766		NCE	Oct 21, 2020
		8147873	Mar 11, 2026	DP			
		8216560	Mar 14, 2027	U-1766			
		8282913	Mar 11, 2026	DP			
		8287847	Mar 30, 2024	U-1766			
		8337824	May 29, 2030	DS U-1766			
		8475780	Mar 30, 2024	U-1766			
		8778324	Mar 30, 2024	U-1766			
		8889115	Mar 30, 2024	U-1766			
		9492476	Oct 08, 2033	U-1766			
		9925212	Oct 08, 2033	U-1766			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PATIROMER SORBITEX CALCIUM - VELTASSA							
N 205739	003	7556799	Feb 27, 2025	U-1766		NCE	Oct 21, 2020
		8147873	Mar 11, 2026	DP			
		8216560	Mar 14, 2027	U-1766			
		8282913	Mar 11, 2026	DP			
		8287847	Mar 30, 2024	U-1766			
		8337824	May 29, 2030	DS U-1766			
		8475780	Mar 30, 2024	U-1766			
		8778324	Mar 30, 2024	U-1766			
		8889115	Mar 30, 2024	U-1766			
		9492476	Oct 08, 2033	U-1766			
		9925212	Oct 08, 2033	U-1766			
PATISIRAN SODIUM - ONPATTRO							
N 210922	001	8058069	Apr 15, 2029	DP		NCE	Aug 10, 2023
		8158601	Nov 10, 2030	DP U-2378		ODE-197	Aug 10, 2025
		8168775	Oct 20, 2029	DS DP U-2378			
		8334373	May 27, 2025	DS DP			
		8362231	Mar 30, 2021	DS DP			
		8372968	Mar 30, 2021	DS DP			
		8492359	Apr 15, 2029	DP			
		8552171	Mar 30, 2021	DS DP			
		8642076	Oct 03, 2027	DP			
		8741866	Oct 20, 2029	U-2378			
		8778902	Mar 30, 2021	U-2378			
		8802644	Oct 21, 2030	DP U-2378			
		8822668	Apr 15, 2029	DP U-2378			
		8895718	Mar 30, 2021	DS DP			
		8895721	Mar 30, 2021	DS DP			
		9193753	Mar 30, 2021	U-2378			
		9234196	Oct 20, 2029	DP U-2378			
		9364435	Apr 15, 2029	DP U-2378			
		9567582	Mar 30, 2021	DS DP			
		9943538	Nov 04, 2023	DP			
		9943539	Nov 04, 2023	DP			
PAZOPANIB HYDROCHLORIDE - VOTRIENT							
N 022465	001	7105530	Oct 19, 2023	DS DP		ODE-23	Apr 26, 2019
		7262203	Dec 19, 2021	DS DP			
		8114885	Dec 19, 2021	DS DP			
PAZOPANIB HYDROCHLORIDE - VOTRIENT							
N 022465	002	7105530	Oct 19, 2023	DS DP		ODE-23	Apr 26, 2019
		7262203	Dec 19, 2021	DS DP			
		8114885	Dec 19, 2021	DS DP			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE							
N 202799	001	7084245	May 12, 2024	DS DP U-1238			
		7414105	May 12, 2024	DS DP U-1238			
		7528104	May 12, 2024	DS DP			
		7550433	Jun 02, 2026	U-1238			
		7919118	May 12, 2024	DS DP			
		7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE							
N 202799	002	7084245	May 12, 2024	DS DP U-1238			
		7414105	May 12, 2024	DS DP U-1238			
		7528104	May 12, 2024	DS DP			
		7550433	Jun 02, 2026	U-1238			
		7919118	May 12, 2024	DS DP			
		7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE							
N 202799	003	7084245	May 12, 2024	DS DP U-1238			
		7414105	May 12, 2024	DS DP U-1238			
		7528104	May 12, 2024	DS DP			
		7550433	Jun 02, 2026	U-1238			
		7919118	May 12, 2024	DS DP			
		7919461	Jun 02, 2026	U-1238			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE							
N 202799	004	7084245	May 12, 2024	DS DP U-1238			
		7414105	May 12, 2024	DS DP U-1238			
		7528104	May 12, 2024	DS DP			
		7550433	Jun 02, 2026	U-1238			
		7919118	May 12, 2024	DS DP			
		7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE							
N 202799	005	7084245	May 12, 2024	DS DP U-1238			
		7414105	May 12, 2024	DS DP U-1238			
		7528104	May 12, 2024	DS DP			
		7550433	Jun 02, 2026	U-1238			
		7919118	May 12, 2024	DS DP			
		7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE							
N 202799	006	7084245	May 12, 2024	DS DP U-1238			
		7414105	May 12, 2024	DS DP U-1238			
		7528104	May 12, 2024	DS DP			
		7550433	Jun 02, 2026	U-1238			
		7919118	May 12, 2024	DS DP			
		7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS							
N 202799	007	7084245	May 12, 2024	DS DP U-1238			
		7414105	May 12, 2024	DS DP U-1238			
		7528104	May 12, 2024	DS DP			
		7550433	Jun 02, 2026	U-1238			
		7919118	May 12, 2024	DS DP			
		7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS							
N 202799	008	7084245	May 12, 2024	DS DP U-1238			
		7414105	May 12, 2024	DS DP U-1238			
		7528104	May 12, 2024	DS DP			
		7550433	Jun 02, 2026	U-1238			
		7919118	May 12, 2024	DS DP			
		7919461	Jun 02, 2026	U-1238			
PEMETREXED DISODIUM - ALIMTA							
N 021462	001	7772209	Nov 24, 2021	U-1296			
PEMETREXED DISODIUM - ALIMTA							
N 021462	002	7772209	Nov 24, 2021	U-1296			
PENCICLOVIR - DENAVIR							
N 020629	001	6469015	Oct 22, 2019	U-501			
		6579981	Jun 17, 2020	U-501			
PERAMIVIR - RAPIVAB							
N 206426	001	6503745	Nov 05, 2019	DS		NCE	Dec 19, 2019
		6562861	Dec 17, 2019	DS		NPP	Sep 20, 2020
		8778997	May 07, 2027	U-1627			
PERAMPANEL - FYCOMPA							
N 202834	001	6949571	Jun 08, 2021	DS DP U-106			
		6949571	Jun 08, 2021	DS DP U-2088			
		6949571	Jun 08, 2021	DS DP U-2089			
		6949571	Jun 08, 2021	DS DP U-2428			
		6949571	Jun 08, 2021	DS DP U-2429			
		8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA							
N 202834	002	6949571	Jun 08, 2021	DS DP U-106			
		6949571	Jun 08, 2021	DS DP U-2088			
		6949571	Jun 08, 2021	DS DP U-2089			
		6949571	Jun 08, 2021	DS DP U-2428			
		6949571	Jun 08, 2021	DS DP U-2429			
		8772497	Jul 01, 2026	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PERAMPANEL - FYCOMPA							
N 202834	002	6949571	Jun 08, 2021	DS DP U-106			
		6949571	Jun 08, 2021	DS DP U-2088			
		6949571	Jun 08, 2021	DS DP U-2089			
		6949571	Jun 08, 2021	DS DP U-2428			
		6949571	Jun 08, 2021	DS DP U-2429			
		8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA							
N 202834	003	6949571	Jun 08, 2021	DS DP U-106			
		6949571	Jun 08, 2021	DS DP U-2088			
		6949571	Jun 08, 2021	DS DP U-2089			
		6949571	Jun 08, 2021	DS DP U-2428			
		6949571	Jun 08, 2021	DS DP U-2429			
		8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA							
N 202834	004	6949571	Jun 08, 2021	DS DP U-106			
		6949571	Jun 08, 2021	DS DP U-2088			
		6949571	Jun 08, 2021	DS DP U-2089			
		6949571	Jun 08, 2021	DS DP U-2428			
		6949571	Jun 08, 2021	DS DP U-2429			
		8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA							
N 202834	005	6949571	Jun 08, 2021	DS DP U-106			
		6949571	Jun 08, 2021	DS DP U-2088			
		6949571	Jun 08, 2021	DS DP U-2089			
		6949571	Jun 08, 2021	DS DP U-2428			
		6949571	Jun 08, 2021	DS DP U-2429			
		8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA							
N 202834	006	6949571	Jun 08, 2021	DS DP U-106			
		6949571	Jun 08, 2021	DS DP U-2088			
		6949571	Jun 08, 2021	DS DP U-2089			
		6949571	Jun 08, 2021	DS DP U-2428			
		6949571	Jun 08, 2021	DS DP U-2429			
		8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA							
N 208277	001	6949571	Jun 08, 2021	DS DP U-106			
		6949571	Jun 08, 2021	DS DP U-2088			
		6949571	Jun 08, 2021	DS DP U-2089			
		6949571	Jun 08, 2021	DS DP U-2428			
		6949571	Jun 08, 2021	DS DP U-2429			
		8772497	Jul 01, 2026	DS			
PERFLUTREN - DEFINITY							
N 021064	001	8658205	Jun 18, 2019	DP			
		8685441	Jan 13, 2019	U-665			
		9545457	Jan 13, 2019	U-665			
		9789210	Mar 16, 2037	U-665			
PHENTERMINE HYDROCHLORIDE - SUPRENZA							
N 202088	001	8440170	Mar 14, 2029	DP			
PHENTERMINE HYDROCHLORIDE - SUPRENZA							
N 202088	002	8440170	Mar 14, 2029	DP			
PHENTERMINE HYDROCHLORIDE - SUPRENZA							
N 202088	003	8440170	Mar 14, 2029	DP			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA							
N 022580	001	7056890	Jun 14, 2020	DP U-1262			
		7553818	Jun 14, 2020	U-1262			
		7659256	Jun 14, 2020	DP U-1262			
		7674776	Jun 14, 2020	DP U-1262			
		8580298	May 15, 2029	DP			
		8580299	Jun 14, 2029	U-1262			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 001	8895057	Jun 09, 2028	U-1262			
	8895058	Jun 09, 2028	DP			
	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 002	7056890	Jun 14, 2020	DP U-1262			
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029	U-1262			
	8895057	Jun 09, 2028	U-1262			
	8895058	Jun 09, 2028	DP			
	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 003	7056890	Jun 14, 2020	DP U-1262			
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029	U-1262			
	8895057	Jun 09, 2028	U-1262			
	8895058	Jun 09, 2028	DP			
	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 004	7056890	Jun 14, 2020	DP U-1262			
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029	U-1262			
	8895057	Jun 09, 2028	U-1262			
	8895058	Jun 09, 2028	DP			
	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
PHENTOLAMINE MESYLATE - ORAVERSE						
N 022159 001	6764678	May 11, 2021	U-967		NPP	Mar 18, 2019
	6872390	May 11, 2021	DP			
	7229630	Jun 20, 2023	DP			
	7569230	Oct 17, 2023	U-967			
	7575757	Apr 21, 2025	DP			
PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE						
N 203510 001	8859623	Nov 14, 2033	U-1594			
PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE						
N 203510 002	8859623	Nov 14, 2033	U-1594			
PIMAVANSERIN TARTRATE - NUPLAZID						
N 207318 001	6756393	Mar 06, 2021	DS DP		NCE	Apr 29, 2021
	6815458	Mar 06, 2021	DS DP U-1843			
	7115634	Oct 06, 2021	DS DP			
	7601740	Jun 17, 2027	DS DP			
	7659285	Aug 24, 2026	U-1844			
	7732615	Jun 03, 2028	DS DP			
	7858789	Dec 13, 2020	DS DP			
	7923564	Sep 26, 2025	DS DP			
	8110574	Dec 13, 2020	DS DP			
	8618130	Jan 15, 2024	U-1845			
	8921393	Jan 15, 2024	U-1846			
	9296694	Mar 06, 2021	DS DP			
	9566271	Jan 15, 2024	U-1974			
	9765053	Jul 27, 2022	U-1974			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PIMAVANSERIN TARTRATE - NUPLAZID							
N 207318	001	6756393	Mar 06, 2021	DS DP		NCE	Apr 29, 2021
		6815458	Mar 06, 2021	DS DP U-1843			
		7115634	Oct 06, 2021	DS DP			
		7601740	Jun 17, 2027	DS DP			
		7659285	Aug 24, 2026	U-1844			
		7732615	Jun 03, 2028	DS DP			
		7858789	Dec 13, 2020	DS DP			
		7923564	Sep 26, 2025	DS DP			
		8110574	Dec 13, 2020	DS DP			
		8618130	Jan 15, 2024	U-1845			
		8921393	Jan 15, 2024	U-1846			
		9296694	Mar 06, 2021	DS DP			
		9566271	Jan 15, 2024	U-1974			
		9765053	Jul 27, 2022	U-1974			
PIMAVANSERIN TARTRATE - NUPLAZID							
N 207318	002	10028944	Jan 15, 2024	U-1974			
		6756393	Mar 06, 2021	DS DP			
		6815458	Mar 06, 2021	DS DP U-1843			
		7115634	Oct 06, 2021	DS DP			
		7601740	Jun 17, 2027	DS DP			
		7659285	Aug 24, 2026	U-1844			
		7732615	Jun 03, 2028	DS DP			
		7858789	Dec 13, 2020	DS DP			
		7923564	Sep 26, 2025	DS DP			
		8110574	Dec 13, 2020	DS DP			
		8618130	Jan 15, 2024	U-1845			
		8921393	Jan 15, 2024	U-1846			
		9296694	Mar 06, 2021	DS DP			
		9566271	Jan 15, 2024	U-1974			
		9765053	Jul 27, 2022	U-1974			
PIMAVANSERIN TARTRATE - NUPLAZID							
N 210793	001	10028944	Jan 15, 2024			NCE	Apr 29, 2021
		6756393	Mar 06, 2021	DS DP			
		6815458	Mar 06, 2021	DS DP U-1843			
		7115634	Oct 06, 2021	DS DP			
		7601740	Jun 17, 2027	DS DP			
		7659285	Aug 24, 2026	U-1844			
		7732615	Jun 03, 2028	DS DP			
		7858789	Dec 13, 2020	DS DP			
		7923564	Sep 26, 2025	DS DP			
		8110574	Dec 13, 2020	DS DP			
		8618130	Jan 15, 2024	U-1845			
		8921393	Jan 15, 2024	U-1846			
		9296694	Mar 06, 2021	DS DP			
		9566271	Jan 15, 2024				
		9765053	Jul 27, 2022	U-1974			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN							
N 050684	001	6900184	Apr 14, 2023	DP U-282			
		7915229	Apr 14, 2023	DP			
		8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN							
N 050684	002	6900184	Apr 14, 2023	DP U-282			
		7915229	Apr 14, 2023	DP			
		8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN							
N 050684	003	6900184	Apr 14, 2023	DP U-282			
		7915229	Apr 14, 2023	DP			
		8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN							
N 050684	004	6900184	Apr 14, 2023	DP U-282			
		7915229	Apr 14, 2023	DP			
		8133883	Apr 14, 2023	DP U-282			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER							
N 050750	001	6207661	Feb 22, 2019	DP			
		6900184	Apr 14, 2023	DP U-282			
		7915229	Apr 14, 2023	DP			
		8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER							
N 050750	002	6207661	Feb 22, 2019	DP			
		6900184	Apr 14, 2023	DP U-282			
		7915229	Apr 14, 2023	DP			
		8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER							
N 050750	003	6207661	Feb 22, 2019	DP			
		6900184	Apr 14, 2023	DP U-282			
		7915229	Apr 14, 2023	DP			
		8133883	Apr 14, 2023	DP U-282			
PIRFENIDONE - ESBRIET							
N 022535	001	7566729	Apr 22, 2029	U-1600		NCE	Oct 15, 2019
		7635707	Apr 22, 2029	U-1609		ODE-77	Oct 15, 2021
		7696236	Dec 18, 2027	U-1601			
		7767225	Sep 22, 2026	DP U-1602			
		7767700	Dec 18, 2027	U-1601			
		7816383	Jan 08, 2030	U-1603			
		7910610	Jan 08, 2030	U-1604			
		7988994	Sep 22, 2026	DP U-1602			
		8013002	Jan 08, 2030	U-1603			
		8084475	Jan 08, 2030	U-1605			
		8318780	Jan 08, 2030	U-1606			
		8383150	Sep 22, 2026	DP U-1607			
		8383150	Sep 22, 2026	DP U-2361			
		8420674	Dec 18, 2027	DP U-1608			
		8592462	Apr 22, 2029	U-1609			
		8609701	Apr 22, 2029	U-1610			
		8648098	Jan 08, 2030	U-1611			
		8753679	Sep 22, 2026	DP U-1602			
		8754109	Jan 08, 2030	U-1612			
		8778947	Aug 30, 2033	U-1613			
PIRFENIDONE - ESBRIET							
N 208780	001	7566729	Apr 22, 2029	U-2077		NCE	Oct 15, 2019
		7566729	Apr 22, 2029	U-2078		ODE-77	Oct 15, 2021
		7635707	Apr 22, 2029	U-2072			
		7635707	Apr 22, 2029	U-2073			
		7635707	Apr 22, 2029	U-2074			
		7635707	Apr 22, 2029	U-2075			
		7635707	Apr 22, 2029	U-2076			
		7635707	Apr 22, 2029	U-2083			
		7767700	Dec 18, 2027	U-2080			
		7816383	Jan 08, 2030	U-2042			
		7816383	Jan 08, 2030	U-2050			
		7910610	Jan 08, 2030	U-2048			
		7910610	Jan 08, 2030	U-2049			
		8013002	Jan 08, 2030	U-2047			
		8013002	Jan 08, 2030	U-2082			
		8084475	Jan 08, 2030	U-2052			
		8084475	Jan 08, 2030	U-2054			
		8318780	Jan 08, 2030	U-2046			
		8318780	Jan 08, 2030	U-2081			
		8383150	Sep 22, 2026	DP U-2361			
		8420674	Dec 18, 2027	U-2079			
		8592462	Apr 22, 2029	U-2055			
		8592462	Apr 22, 2029	U-2056			
		8592462	Apr 22, 2029	U-2057			
		8592462	Apr 22, 2029	U-2058			
		8592462	Apr 22, 2029	U-2059			
		8592462	Apr 22, 2029	U-2060			
		8592462	Apr 22, 2029	U-2061			
		8592462	Apr 22, 2029	U-2062			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PIRFENIDONE - ESBRIET						
N 208780 001	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
	9561217	Jan 25, 2022	DP			
PIRFENIDONE - ESBRIET						
N 208780 002	7566729	Apr 22, 2029	U-2269		NCE	Oct 15, 2019
	7566729	Apr 22, 2029	U-2270		ODE-77	Oct 15, 2021
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2054			
	8084475	Jan 08, 2030	U-2268			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	Sep 22, 2026	DP U-2361			
	8420674	Dec 18, 2027	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
	9561217	Jan 25, 2022	DP			
PIRFENIDONE - ESBRIET						
N 208780 003	7566729	Apr 22, 2029	U-2077		NCE	Oct 15, 2019
	7566729	Apr 22, 2029	U-2078		ODE-77	Oct 15, 2021
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PIRFENIDONE - ESBRIET							
N 208780	003	7635707	Apr 22, 2029	U-2083			
		7767700	Dec 18, 2027	U-2080			
		7816383	Jan 08, 2030	U-2042			
		7816383	Jan 08, 2030	U-2050			
		7910610	Jan 08, 2030	U-2048			
		7910610	Jan 08, 2030	U-2049			
		8013002	Jan 08, 2030	U-2047			
		8013002	Jan 08, 2030	U-2082			
		8084475	Jan 08, 2030	U-2052			
		8084475	Jan 08, 2030	U-2054			
		8318780	Jan 08, 2030	U-2046			
		8318780	Jan 08, 2030	U-2081			
		8383150	Sep 22, 2026	DP U-2361			
		8420674	Dec 18, 2027	U-2079			
		8592462	Apr 22, 2029	U-2055			
		8592462	Apr 22, 2029	U-2056			
		8592462	Apr 22, 2029	U-2057			
		8592462	Apr 22, 2029	U-2058			
		8592462	Apr 22, 2029	U-2059			
		8592462	Apr 22, 2029	U-2060			
		8592462	Apr 22, 2029	U-2061			
		8592462	Apr 22, 2029	U-2062			
		8592462	Apr 22, 2029	U-2063			
		8609701	Apr 22, 2029	U-2064			
		8609701	Apr 22, 2029	U-2065			
		8609701	Apr 22, 2029	U-2066			
		8609701	Apr 22, 2029	U-2067			
		8609701	Apr 22, 2029	U-2068			
		8609701	Apr 22, 2029	U-2069			
		8609701	Apr 22, 2029	U-2070			
		8648098	Jan 08, 2030	U-2051			
		8648098	Jan 08, 2030	U-2052			
		8754109	Jan 08, 2030	U-2053			
		8778947	Aug 30, 2033	U-2044			
		8778947	Aug 30, 2033	U-2045			
		9561217	Jan 25, 2022	DP			
PITAVASTATIN CALCIUM - LIVALO							
N 022363	001	5856336	Dec 25, 2020	DS U-998			
		7022713	Feb 19, 2024	U-998			
		8557993	Feb 02, 2024	DP			
PITAVASTATIN CALCIUM - LIVALO							
N 022363	002	5856336	Dec 25, 2020	DS U-998			
		7022713	Feb 19, 2024	U-998			
		8557993	Feb 02, 2024	DP			
PITAVASTATIN CALCIUM - LIVALO							
N 022363	003	5856336	Dec 25, 2020	DS U-998			
		7022713	Feb 19, 2024	U-998			
		8557993	Feb 02, 2024	DS DP			
PITAVASTATIN MAGNESIUM - ZYPITAMAG							
N 208379	001	8829186	Jan 19, 2031	DS DP			
PITAVASTATIN MAGNESIUM - ZYPITAMAG							
N 208379	002	8829186	Jan 19, 2031	DS DP			
PITAVASTATIN MAGNESIUM - ZYPITAMAG							
N 208379	003	8829186	Jan 19, 2031	DS DP			
PLAZOMICIN SULFATE - ZEMDRI							
N 210303	001	8383596	Jun 02, 2031	DS U-2328		NCE	Jun 25, 2023
		8822424	Nov 21, 2028	DP		GAIN	Jun 25, 2028
		9266919	Nov 21, 2028	U-2328			
		9688711	Nov 21, 2028	DS U-2328			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PLECANATIDE - TRULANCE							
N 208745	001	10011637	Jun 05, 2034	DS		I-764	Jan 24, 2021
		7041786	Mar 25, 2023	DS		NCE	Jan 19, 2022
		7799897	Jun 09, 2022	DS			
		8637451	Mar 28, 2022	U-1964			
		9610321	Sep 15, 2031	U-1999			
		9610321	Sep 15, 2031	U-2230			
		9616097	Jul 02, 2032	DP			
		9919024	Sep 15, 2031	U-1999			
		9919024	Sep 15, 2031	U-2230			
		9925231	Sep 15, 2031	DP			
PLERIXAFOR - MOZOBIL							
N 022311	001	6987102	Jul 22, 2023	U-936			
		7897590	Jul 22, 2023	U-936			
POLIDOCANOL - VARITHENA							
N 205098	001	6572873	May 26, 2020	U-1461			
		6846412	Jul 19, 2022	DP			
		6942165	May 26, 2020	DP			
		7025290	May 26, 2020	DP U-1461			
		7357336	May 26, 2020	U-1461			
		7604185	May 26, 2020	DS DP U-1462			
		7731986	Nov 17, 2024	DS DP U-1463			
		7814943	Nov 19, 2027	DP U-1461			
		7842282	May 26, 2020	U-1461			
		7842283	May 26, 2020	DP			
		8122917	Sep 09, 2024	DP			
		8323677	May 26, 2020	DS			
		8734833	May 26, 2020	DS DP			
		9480652	May 12, 2032	DP			
POMALIDOMIDE - POMALYST							
N 204026	001	6315720	Oct 23, 2020	U-1361		ODE-43	Feb 08, 2020
		6561977	Oct 23, 2020	U-1361			
		6755784	Oct 23, 2020	U-1361			
		8198262	Jun 17, 2025	U-1360			
		8198262	Jun 17, 2025	U-2254			
		8315886	Oct 23, 2020	U-1361			
		8626531	Oct 23, 2020	U-1361			
		8673939	May 15, 2023	U-1360			
		8673939	May 15, 2023	U-2254			
		8735428	May 15, 2023	U-1360			
		8735428	May 15, 2023	U-2254			
		8828427	Jun 21, 2031	DS DP			
		9993467	May 19, 2030	DP			
POMALIDOMIDE - POMALYST							
N 204026	002	6315720	Oct 23, 2020	U-1361		ODE-43	Feb 08, 2020
		6561977	Oct 23, 2020	U-1361			
		6755784	Oct 23, 2020	U-1361			
		8198262	Jun 17, 2025	U-1360			
		8198262	Jun 17, 2025	U-2254			
		8315886	Oct 23, 2020	U-1361			
		8626531	Oct 23, 2020	U-1361			
		8673939	May 15, 2023	U-1360			
		8673939	May 15, 2023	U-2254			
		8735428	May 15, 2023	U-1360			
		8735428	May 15, 2023	U-2254			
		8828427	Jun 21, 2031	DS DP			
		9993467	May 19, 2030	DP			
POMALIDOMIDE - POMALYST							
N 204026	003	6315720	Oct 23, 2020	U-1361		ODE-43	Feb 08, 2020
		6561977	Oct 23, 2020	U-1361			
		6755784	Oct 23, 2020	U-1361			
		8198262	Jun 17, 2025	U-1360			
		8198262	Jun 17, 2025	U-2254			
		8315886	Oct 23, 2020	U-1361			
		8626531	Oct 23, 2020	U-1361			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
POMALIDOMIDE - POMALYST							
N 204026	003	8673939	May 15, 2023	U-1360			
		8673939	May 15, 2023	U-2254			
		8735428	May 15, 2023	U-1360			
		8735428	May 15, 2023	U-2254			
		8828427	Jun 21, 2031	DS DP			
		9993467	May 19, 2030	DP			
POMALIDOMIDE - POMALYST							
N 204026	004	6315720	Oct 23, 2020	U-1361		ODE-43	Feb 08, 2020
		6561977	Oct 23, 2020	U-1361			
		6755784	Oct 23, 2020	U-1361			
		8198262	Jun 17, 2025	U-1360			
		8198262	Jun 17, 2025	U-2254			
		8315886	Oct 23, 2020	U-1361			
		8626531	Oct 23, 2020	U-1361			
		8673939	May 15, 2023	U-1360			
		8673939	May 15, 2023	U-2254			
		8735428	May 15, 2023	U-1360			
		8735428	May 15, 2023	U-2254			
		8828427	Jun 21, 2031	DS DP			
		9993467	May 19, 2030	DP			
PONATINIB HYDROCHLORIDE - ICLUSIG							
N 203469	001	8114874	Dec 22, 2026	DS DP		ODE-35	Dec 14, 2019
		9029533	Dec 22, 2026	U-1283			
		9029533	Dec 22, 2026	U-1699			
		9029533	Dec 22, 2026	U-1700			
		9029533	Dec 22, 2026	U-1701			
		9029533	Dec 22, 2026	U-836			
		9493470	Dec 12, 2033	DS DP U-1700			
		9493470	Dec 12, 2033	DS DP U-1948			
PONATINIB HYDROCHLORIDE - ICLUSIG							
N 203469	002	8114874	Dec 22, 2026	DS DP		ODE-35	Dec 14, 2019
		9029533	Dec 22, 2026	U-1283			
		9029533	Dec 22, 2026	U-1699			
		9029533	Dec 22, 2026	U-1700			
		9029533	Dec 22, 2026	U-1701			
		9029533	Dec 22, 2026	U-836			
		9493470	Dec 12, 2033	DS DP U-1700			
		9493470	Dec 12, 2033	DS DP U-1948			
PONATINIB HYDROCHLORIDE - ICLUSIG							
N 203469	003	8114874	Dec 22, 2026	DS DP		ODE-35	Dec 14, 2019
		9029533	Dec 22, 2026	U-1283			
		9029533	Dec 22, 2026	U-1699			
		9029533	Dec 22, 2026	U-1700			
		9029533	Dec 22, 2026	U-1701			
		9029533	Dec 22, 2026	U-836			
		9493470	Dec 12, 2033	DS DP U-1700			
		9493470	Dec 12, 2033	DS DP U-1948			
POSACONAZOLE - NOXAFIL							
N 022003	001	5661151	Jul 19, 2019	DS DP U-760			
		8263600	Apr 01, 2022	DP			
POSACONAZOLE - NOXAFIL							
N 205053	001	5661151	Jul 19, 2019	DS DP U-1454			
POSACONAZOLE - NOXAFIL							
N 205596	001	10117951	Mar 13, 2029	DP			
		5661151	Jul 19, 2019	DS DP U-1454			
		8410077	Mar 13, 2029	DP			
		9023790	Jul 04, 2031	DP U-1698			
		9358297	Jun 24, 2031	DP U-1454			
		9493582	Feb 27, 2033	DP			
		9750822	Mar 13, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
POTASSIUM CHLORIDE - POTASSIUM CHLORIDE						
A 211067 001					CGT	Feb 25, 2019
POTASSIUM CHLORIDE - POTASSIUM CHLORIDE						
A 211067 002					CGT	Mar 06, 2019
PRALATREXATE - FOLOTYN						
N 022468 001	6028071	Jul 16, 2022	DS DP U-1004			
	7622470	May 31, 2025	U-1015			
	8299078	May 31, 2025	U-1004			
PRALATREXATE - FOLOTYN						
N 022468 002	6028071	Jul 16, 2022	DS DP U-1004			
	7622470	May 31, 2025	U-1015			
	8299078	May 31, 2025	U-1004			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 001	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 002	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 003	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 004	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 005	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 006	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 007	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRAMLINTIDE ACETATE - SYMLIN						
N 021332 001	5686411	Mar 16, 2019	DS DP U-638			
PRAMLINTIDE ACETATE - SYMLIN						
N 021332 002	5686411	Mar 16, 2019	DS DP U-638			
PRAMLINTIDE ACETATE - SYMLIN						
N 021332 003	5686411	Mar 16, 2019	DS DP U-638			
PRASTERONE - INTRAROSA						
N 208470 001	8268806	Mar 19, 2031	DP		NCE	Nov 16, 2021
	8629129	Aug 07, 2028	DP			
	8957054	Aug 07, 2028	U-1922			
PRASUGREL HYDROCHLORIDE - EFFIENT						
N 022307 001	8404703	Jan 02, 2023	U-1381		M-182	Jul 12, 2019
	8404703*PED	Jul 02, 2023			PED	Jan 12, 2020
	8569325	Jan 02, 2023	U-1381			
	8569325*PED	Jul 02, 2023				
PRASUGREL HYDROCHLORIDE - EFFIENT						
N 022307 002	8404703	Jan 02, 2023	U-1381		M-182	Jul 12, 2019
	8404703*PED	Jul 02, 2023			PED	Jan 12, 2020
	8569325	Jan 02, 2023	U-1381			
	8569325*PED	Jul 02, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PREDNISOLONE ACETATE - FLO-PRED							
N 022067	001	7799331	Oct 11, 2028	DP U-1068			
		7799331	Oct 11, 2028	DP U-139			
PREDNISOLONE ACETATE - FLO-PRED							
N 022067	002	7799331	Oct 11, 2028	DP U-1068			
		7799331	Oct 11, 2028	DP U-139			
PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT							
N 021959	001	6740341	Nov 24, 2019	DP			
PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT							
N 021959	002	6740341	Nov 24, 2019	DP			
PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT							
N 021959	003	6740341	Nov 24, 2019	DP			
PREDNISONE - RAYOS							
N 202020	001	6488960	Mar 14, 2020	DP U-1267			
		6677326	Mar 14, 2020	DP U-1268			
		8309124	Apr 23, 2024	U-1292			
		8394407	Apr 23, 2024	DP U-1362			
		9040085	Apr 23, 2024	U-1362			
		9186332	Apr 23, 2024	U-1362			
		9504699	Aug 03, 2027	U-1362			
PREDNISONE - RAYOS							
N 202020	002	6488960	Mar 14, 2020	DP U-1267			
		6677326	Mar 14, 2020	DP U-1268			
		8309124	Apr 23, 2024				
		8394407	Apr 23, 2024	DP U-1362			
		9040085	Apr 23, 2024	U-1362			
		9186332	Apr 23, 2024	U-1362			
		9504699	Aug 03, 2027	U-1362			
PREDNISONE - RAYOS							
N 202020	003	8168218	Jan 07, 2028	DP U-1269			
		8309124	Apr 23, 2024	U-1292			
		8394407	Apr 23, 2024	DP U-1362			
		9040085	Apr 23, 2024	U-1362			
		9186332	Apr 23, 2024	U-1362			
		9504699	Aug 03, 2027	U-1362			
PREGABALIN - LYRICA							
N 021446	001	6001876*PED	Jun 30, 2019			M-193	Dec 22, 2019
		6197819*PED	Jun 30, 2019			NPP	May 03, 2021
		RE41920*PED	Jun 30, 2019			PED	Jun 22, 2020
						PED	Nov 03, 2021
PREGABALIN - LYRICA							
N 021446	002	6001876*PED	Jun 30, 2019			M-193	Dec 22, 2019
		6197819*PED	Jun 30, 2019			NPP	May 03, 2021
		RE41920*PED	Jun 30, 2019			PED	Jun 22, 2020
						PED	Nov 03, 2021
PREGABALIN - LYRICA							
N 021446	003	6001876*PED	Jun 30, 2019			M-193	Dec 22, 2019
		6197819*PED	Jun 30, 2019			NPP	May 03, 2021
		RE41920*PED	Jun 30, 2019			PED	Jun 22, 2020
						PED	Nov 03, 2021
PREGABALIN - LYRICA							
N 021446	004	6001876*PED	Jun 30, 2019			M-193	Dec 22, 2019
		6197819*PED	Jun 30, 2019			NPP	May 03, 2021
		RE41920*PED	Jun 30, 2019			PED	Jun 22, 2020
						PED	Nov 03, 2021
PREGABALIN - LYRICA							
N 021446	005	6001876*PED	Jun 30, 2019			M-193	Dec 22, 2019
		6197819*PED	Jun 30, 2019			NPP	May 03, 2021

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PREGABALIN - LYRICA							
N 021446	005	RE41920*PED	Jun 30, 2019			PED	Jun 22, 2020
						PED	Nov 03, 2021
PREGABALIN - LYRICA							
N 021446	006	6001876*PED	Jun 30, 2019			M-193	Dec 22, 2019
		6197819*PED	Jun 30, 2019			NPP	May 03, 2021
		RE41920*PED	Jun 30, 2019			PED	Jun 22, 2020
						PED	Nov 03, 2021
PREGABALIN - LYRICA							
N 021446	007	6001876*PED	Jun 30, 2019			M-193	Dec 22, 2019
		6197819*PED	Jun 30, 2019			NPP	May 03, 2021
		RE41920*PED	Jun 30, 2019			PED	Jun 22, 2020
						PED	Nov 03, 2021
PREGABALIN - LYRICA							
N 021446	008	6001876*PED	Jun 30, 2019			M-193	Dec 22, 2019
		6197819*PED	Jun 30, 2019			NPP	May 03, 2021
		RE41920*PED	Jun 30, 2019			PED	Jun 22, 2020
						PED	Nov 03, 2021
PREGABALIN - LYRICA							
N 022488	001	6001876*PED	Jun 30, 2019			M-193	Dec 22, 2019
		6197819*PED	Jun 30, 2019			NPP	May 03, 2021
		RE41920*PED	Jun 30, 2019			PED	Jun 22, 2020
						PED	Nov 03, 2021
PREGABALIN - LYRICA CR							
N 209501	001	10022447	Nov 02, 2026	U-2136		NP	Oct 11, 2020
		10022447	Nov 02, 2026	U-2137		PED	Apr 11, 2021
		10022447*PED	May 02, 2027				
		6197819*PED	Jun 30, 2019				
		8945620	Nov 02, 2026	DP U-2136			
		8945620	Nov 02, 2026	DP U-2137			
		8945620*PED	May 02, 2027				
		9144559	Nov 02, 2026	DP			
		9144559*PED	May 02, 2027				
		RE41920*PED	Jun 30, 2019				
PREGABALIN - LYRICA CR							
N 209501	002	10022447	Nov 02, 2026	U-2136		NP	Oct 11, 2020
		10022447	Nov 02, 2026	U-2137		PED	Apr 11, 2021
		10022447*PED	May 02, 2027				
		6197819*PED	Jun 30, 2019				
		8945620	Nov 02, 2026	DP U-2136			
		8945620	Nov 02, 2026	DP U-2137			
		8945620*PED	May 02, 2027				
		9144559	Nov 02, 2026	DP			
		9144559*PED	May 02, 2027				
		RE41920*PED	Jun 30, 2019				
PREGABALIN - LYRICA CR							
N 209501	003	10022447	Nov 02, 2026	U-2136		NP	Oct 11, 2020
		10022447	Nov 02, 2026	U-2137		PED	Apr 11, 2021
		10022447*PED	May 02, 2027				
		6197819*PED	Jun 30, 2019				
		8945620	Nov 02, 2026	DP U-2136			
		8945620	Nov 02, 2026	DP U-2137			
		8945620*PED	May 02, 2027				
		9144559	Nov 02, 2026	DP			
		9144559*PED	May 02, 2027				
		RE41920*PED	Jun 30, 2019				
PROGESTERONE - ENDOMETRIN							
N 022057	001	7300664	Nov 17, 2019	U-856			
		7320800	Nov 17, 2019	U-856			
		7393543	Nov 17, 2019	DP U-880			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PROPOFOL - DIPRIVAN							
N 019627	002	8476010	Dec 01, 2024	DS DP			
		8476010*PED	Jun 01, 2025				
PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL							
N 021438	001	6500454	Oct 04, 2021	DP			
PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL							
N 021438	002	6500454	Oct 04, 2021	DP			
PROPRANOLOL HYDROCHLORIDE - HEMANGEOL							
N 205410	001	8338489	Oct 16, 2028	U-1496		ODE-62	Mar 14, 2021
PRUCALOPRIDE SUCCINATE - MOTEGRITY							
N 210166	001					NCE	Dec 14, 2023
PRUCALOPRIDE SUCCINATE - MOTEGRITY							
N 210166	002					NCE	Dec 14, 2023
QUAZEPAM - DORAL							
N 018708	001	7608616	Jun 03, 2028	U-1012			
QUAZEPAM - DORAL							
N 018708	003	7608616	Jun 03, 2028	U-1012			
RADIUM RA-223 DICHLORIDE - XOFIGO							
N 203971	001	6635234	Nov 17, 2022	U-2271			
RALTEGRAVIR POTASSIUM - ISENTRESS							
N 022145	001	7169780	Oct 03, 2023	DS DP		D-167	May 26, 2020
		7169780*PED	Apr 03, 2024			NPP	Nov 22, 2020
		7217713	Oct 21, 2022	U-257		PED	Nov 26, 2020
		7217713*PED	Apr 21, 2023			PED	May 22, 2021
		7435734	Oct 21, 2022	U-257			
		7435734	Oct 21, 2022	U-900			
		7435734*PED	Apr 21, 2023				
		7754731	Mar 11, 2029	DS DP U-257			
		7754731*PED	Sep 11, 2029				
RALTEGRAVIR POTASSIUM - ISENTRESS HD							
N 022145	002	7169780	Oct 03, 2023	DS DP		NPP	Nov 22, 2020
		7169780*PED	Apr 03, 2024			NS	May 26, 2020
		7217713	Oct 21, 2022	U-257		PED	Nov 26, 2020
		7217713*PED	Apr 21, 2023			PED	May 22, 2021
		7435734	Oct 21, 2022	U-257			
		7435734	Oct 21, 2022	U-900			
		7435734*PED	Apr 21, 2023				
		7754731	Mar 11, 2029	DS DP U-257			
		7754731*PED	Sep 11, 2029				
		9649311	Oct 21, 2030	DP			
		9649311*PED	Apr 21, 2031				
RALTEGRAVIR POTASSIUM - ISENTRESS							
N 203045	001	7169780	Oct 03, 2023	DS DP		NPP	Nov 22, 2020
		7169780*PED	Apr 03, 2024			PED	May 22, 2021
		7217713	Oct 21, 2022	U-257			
		7217713*PED	Apr 21, 2023				
		7435734	Oct 21, 2022	U-257			
		7435734*PED	Apr 21, 2023				
		7754731	Mar 11, 2029	DS DP U-257			
		7754731*PED	Sep 11, 2029				
RALTEGRAVIR POTASSIUM - ISENTRESS							
N 203045	002	7169780	Oct 03, 2023	DS DP		NPP	Nov 22, 2020
		7169780*PED	Apr 03, 2024			PED	May 22, 2021
		7217713	Oct 21, 2022	U-257			
		7217713*PED	Apr 21, 2023				
		7435734	Oct 21, 2022	U-257			
		7435734*PED	Apr 21, 2023				
		7754731	Mar 11, 2029	DS DP U-257			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RALTEGRAVIR POTASSIUM - ISENTRESS							
N 203045	002	7754731*PED	Sep 11, 2029				
RALTEGRAVIR POTASSIUM - ISENTRESS							
N 205786	001	7169780	Oct 03, 2023	DS DP		NPP	Nov 22, 2020
		7169780*PED	Apr 03, 2024			PED	May 22, 2021
		7217713	Oct 21, 2022	U-257			
		7217713*PED	Apr 21, 2023				
		7435734	Oct 21, 2022	U-257			
		7435734*PED	Apr 21, 2023				
		7754731	Mar 11, 2029	DS DP U-257			
		7754731*PED	Sep 11, 2029				
RAMELTEON - ROZEREM							
N 021782	001	10098866	Nov 16, 2021	DP U-2433			
		6034239	Jul 22, 2019	DS DP U-674			
RAMIPRIL - ALTACE							
N 019901	001	7368469	Aug 30, 2020	U-871			
RAMIPRIL - ALTACE							
N 019901	002	7368469	Aug 30, 2020	U-871			
RAMIPRIL - ALTACE							
N 019901	003	7368469	Aug 30, 2020	U-871			
RAMIPRIL - ALTACE							
N 019901	004	7368469	Aug 30, 2020	U-871			
RAMIPRIL - ALTACE							
N 022021	001	7368469	Aug 30, 2020	U-871			
RAMIPRIL - ALTACE							
N 022021	002	7368469	Aug 30, 2020	U-871			
RAMIPRIL - ALTACE							
N 022021	003	7368469	Aug 30, 2020	U-871			
RAMIPRIL - ALTACE							
N 022021	004	7368469	Aug 30, 2020	U-871			
RANOLAZINE - RANEXA							
N 021526	001	6303607	May 27, 2019	U-705			
		6369062	May 27, 2019	DP	Y		
		6479496	May 27, 2019	U-705			
		6503911	May 27, 2019	DP			
		6525057	May 27, 2019	U-705			
		6562826	May 27, 2019	U-705			
		6617328	May 27, 2019	DP			
		6620814	May 27, 2019	U-705			
		6852724	May 27, 2019	U-705			
		6864258	May 27, 2019	U-705			
RANOLAZINE - RANEXA							
N 021526	002	6303607	May 27, 2019	U-705			
		6369062	May 27, 2019	DP			
		6479496	May 27, 2019	U-705			
		6503911	May 27, 2019	DP			
		6525057	May 27, 2019	U-705			
		6562826	May 27, 2019	U-705			
		6617328	May 27, 2019	DP			
		6620814	May 27, 2019	U-705			
		6852724	May 27, 2019	U-705			
		6864258	May 27, 2019	U-705			
RASAGILINE MESYLATE - AZILECT							
N 021641	001	7572834	Dec 05, 2026	DP			
		7815942	Aug 27, 2027	DS DP U-219			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RASAGILINE MESYLATE - AZILECT							
N 021641	002	7572834	Dec 05, 2026	DP			
		7815942	Aug 27, 2027	DS DP U-219			
REGADENOSON - LEXISCAN							
N 022161	001	6403567	Apr 10, 2022	DS DP U-869		M-194	Jan 17, 2020
		6642210	Jun 22, 2019	DS DP U-869			
		7144872	Jun 22, 2019	DS DP U-116			
		7144872	Jun 22, 2019	DS DP U-869			
		7144872	Jun 22, 2019	DS DP U-870			
		7183264	Jun 22, 2019	DP U-116			
		7183264	Jun 22, 2019	DP U-869			
		7183264	Jun 22, 2019	DP U-870			
		7582617	Jun 22, 2019	U-1003			
		7655636	Jun 22, 2019	U-869			
		7655637	Jun 22, 2019	DS DP U-869			
		7683037	Jun 22, 2019	U-1042			
		8106029	Jun 22, 2019	U-1042			
		8106183	Feb 02, 2027	DS			
		8133879	Jun 22, 2019	DP			
		8183226	Jun 22, 2019	U-116			
		8470801	Jun 22, 2019	U-116			
		8536150	Jun 22, 2019	U-116			
		9045519	Jun 22, 2019	DP			
		9085601	Feb 02, 2027	DP			
		9289446	Jun 22, 2019	DP U-116			
REGORAFENIB - STIVARGA							
N 203085	001	7351834	Jun 28, 2022	DS		I-744	Apr 27, 2020
		8637553	Feb 16, 2031	DS DP		ODE-139	Apr 27, 2024
		8680124	Jun 02, 2030	U-1506		ODE-44	Feb 25, 2020
		9458107	Apr 08, 2031	DP			
		9957232	Jul 09, 2032	DS			
RETAPAMULIN - ALTABAX							
N 022055	001	7875630	Feb 14, 2027	DS			
		8207191	Aug 30, 2024	U-805			
		RE43390	Apr 12, 2021	DS DP U-805			
REVEFENACIN - YUPELRI							
N 210598	001	10106503	Mar 10, 2025	U-2440		NCE	Nov 09, 2023
		7288657	Dec 23, 2025	DS			
		7491736	Mar 10, 2025	U-2440			
		7521041	Mar 10, 2025	U-2440			
		7550595	Mar 10, 2025	DP			
		7585879	Mar 10, 2025	DS DP U-2440			
		7910608	Mar 10, 2025	DS DP			
		8034946	Mar 10, 2025	DP			
		8053448	Mar 10, 2025	U-2440			
		8273894	Mar 10, 2025	DP			
RIBAVIRIN - REBETOL							
N 021546	001	6790837	Apr 05, 2023	DP			
RIBOCICLIB SUCCINATE - KISQALI							
N 209092	001	8324225	Jun 17, 2028	DS DP		I-783	Jul 18, 2021
		8415355	Feb 19, 2031	DS DP		I-784	Jul 18, 2021
		8685980	May 25, 2030	DS DP		NCE	Mar 13, 2022
		8962630	Dec 09, 2029	U-1981			
		8962630	Dec 09, 2029	U-2355			
		8962630	Dec 09, 2029	U-2356			
		9193732	Nov 09, 2031	DS DP			
		9416136	Aug 20, 2029	U-1981			
		9416136	Aug 20, 2029	U-2355			
		9416136	Aug 20, 2029	U-2356			
		9868739	Nov 09, 2031	U-1981			
		9868739	Nov 09, 2031	U-2355			
		9868739	Nov 09, 2031	U-2356			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA						
N 203324 001					NP	Apr 15, 2019
					ODE-116	Apr 15, 2023
					ODE-121	Jul 15, 2023
RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA VISCOUS IN DEXTRAN 20%						
N 203324 002					NP	Apr 15, 2019
					ODE-116	Apr 15, 2023
					ODE-121	Jul 15, 2023
RIFAMYCIN - AEMCOLO						
N 210910 001	8263120	May 03, 2025	DP			
	8486446	May 03, 2025	DP			
	8529945	May 03, 2025	DP			
	8741948	May 03, 2025	DP	U-2448		
RIFAXIMIN - XIFAXAN						
N 021361 001	7045620	Jun 19, 2024	DS DP			
	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7928115	Jul 24, 2029		U-1121		
	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
	8518949	Feb 27, 2026	DP			
	8741904	Feb 27, 2026	DS	U-1526		
	8835452	Jun 19, 2024	DS DP			
	8853231	Jun 19, 2024	DP			
	9271968	Feb 27, 2026	DP			
RIFAXIMIN - XIFAXAN						
N 022554 001	6861053	Aug 11, 2019		U-1707		
	6861053	Aug 11, 2019		U-1708		
	7045620	Jun 19, 2024	DS			
	7452857	Aug 11, 2019		U-1707		
	7452857	Aug 11, 2019		U-1708		
	7605240	Aug 11, 2019		U-1707		
	7605240	Aug 11, 2019		U-1708		
	7612199	Jun 19, 2024	DS DP			
	7718608	Aug 11, 2019		U-1707		
	7718608	Aug 11, 2019		U-1708		
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7915275	Feb 23, 2025		U-1707		
	7915275	Feb 23, 2025		U-1708		
	7935799	Aug 11, 2019		U-1707		
	7935799	Aug 11, 2019		U-1708		
	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP	U-1707		
	8193196	Sep 02, 2027	DS DP	U-1708		
	8309569	Jul 18, 2029		U-1707		
	8309569	Jul 18, 2029		U-1708		
	8518949	Feb 27, 2026	DP			
	8642573	Oct 02, 2029		U-1481		
	8741904	Feb 27, 2026	DS	U-1526		
	8741904	Feb 27, 2026	DS	U-1707		
	8741904	Feb 27, 2026	DS	U-1708		
	8829017	Jul 24, 2029		U-1562		
	8835452	Jun 19, 2024	DS DP			
	8853231	Jun 19, 2024	DP			
	8946252	Jul 24, 2029		U-1481		
	8969398	Oct 02, 2029		U-1481		
	9271968	Feb 27, 2026	DP			
	9421195	Mar 10, 2030		U-1481		
	9629828	Jul 24, 2029		U-1994		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RILPIVIRINE HYDROCHLORIDE - EDURANT								
N 202022	001		6838464	Feb 26, 2021	DS DP		M-223	Feb 01, 2021
			7067522	Dec 20, 2019	DS DP			
			7125879	Apr 21, 2025	DS DP U-1153			
			7125879	Apr 21, 2025	DS DP U-1307			
			7125879	Apr 21, 2025	DS DP U-1740			
			7638522	Apr 14, 2023	DP			
			8080551	Apr 11, 2023	DS DP			
			8101629	Aug 09, 2022	DP			
RILUZOLE - TIGLUTIK KIT								
N 209080	001		8765150	Mar 12, 2029	DP U-2401			
RIOCIGUAT - ADEMPAS								
N 204819	001		6743798	Jul 16, 2019	DS DP		ODE-53	Oct 08, 2020
			7173037	Dec 04, 2026	DS DP			
RIOCIGUAT - ADEMPAS								
N 204819	002		6743798	Jul 16, 2019	DS DP		ODE-53	Oct 08, 2020
			7173037	Dec 04, 2026	DS DP			
RIOCIGUAT - ADEMPAS								
N 204819	003		6743798	Jul 16, 2019	DS DP		ODE-53	Oct 08, 2020
			7173037	Dec 04, 2026	DS DP			
RIOCIGUAT - ADEMPAS								
N 204819	004		6743798	Jul 16, 2019	DS DP		ODE-53	Oct 08, 2020
			7173037	Dec 04, 2026	DS DP			
RIOCIGUAT - ADEMPAS								
N 204819	005		6743798	Jul 16, 2019	DS DP		ODE-53	Oct 08, 2020
			7173037	Dec 04, 2026	DS DP			
RISEDRONATE SODIUM - ACTONEL								
N 020835	005		7192938	May 06, 2023	U-353			
			7718634	May 06, 2023	U-662			
RISEDRONATE SODIUM - ATELVIA								
N 022560	001		7645459	Jan 09, 2028	DP U-662			
			7645460	Jan 09, 2028	DP U-662			
			8246989	Jan 16, 2026	DP			
RISPERIDONE - RISPERDAL CONSTA								
N 021346	001		6667061	May 25, 2020	DP			
RISPERIDONE - RISPERDAL CONSTA								
N 021346	002		6667061	May 25, 2020	DP			
RISPERIDONE - RISPERDAL CONSTA								
N 021346	003		6667061	May 25, 2020	DP			
RISPERIDONE - PERSERIS KIT								
N 210655	001		10010612	Feb 13, 2028	DP		NP	Jul 27, 2021
			10058554	Sep 26, 2026	U-2363			
			9180197	Feb 13, 2028	DP			
			9186413	Feb 13, 2028	U-543			
			9597402	Sep 26, 2026	DP			
RISPERIDONE - PERSERIS KIT								
N 210655	002		10010612	Feb 13, 2028	DP		NP	Jul 27, 2021
			10058554	Sep 26, 2026	U-2363			
			9180197	Feb 13, 2028	DP			
			9186413	Feb 13, 2028	U-543			
			9597402	Sep 26, 2026	DP			
RITONAVIR - NORVIR								
N 020945	001		7141593	May 22, 2020	DP			
			7432294	May 22, 2020	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RITONAVIR - NORVIR						
N 022417 001	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP U-688			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
	8691878	Aug 25, 2024	U-688			
	8691878*PED	Feb 25, 2025				
RITONAVIR - NORVIR						
N 209512 001					ODE-184	Jun 07, 2024
RIVAROXABAN - XARELTO						
N 022406 001	7157456	Aug 28, 2024	DS DP U-1301		D-168	Oct 27, 2020
	7157456	Aug 28, 2024	DS DP U-1302			
	7585860	Dec 11, 2020	DS			
	7592339	Dec 11, 2020	U-1167			
	7592339	Dec 11, 2020	U-1200			
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1302			
	7592339	Dec 11, 2020	U-1303			
	7592339	Dec 11, 2020	U-2142			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-2142			
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
RIVAROXABAN - XARELTO						
N 022406 002	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	7585860	Dec 11, 2020	DS			
	7592339	Dec 11, 2020	U-1167			
	7592339	Dec 11, 2020	U-1200			
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1302			
	7592339	Dec 11, 2020	U-1303			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-1303			
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1956			
	9539218	Feb 17, 2034	U-1957			
RIVAROXABAN - XARELTO						
N 022406 003	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	7585860	Dec 11, 2020	DS			
	7592339	Dec 11, 2020	U-1167			
	7592339	Dec 11, 2020	U-1200			
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1302			
	7592339	Dec 11, 2020	U-1303			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIVAROXABAN - XARELTO							
N 022406	003	9539218	Feb 17, 2034	U-1955			
		9539218	Feb 17, 2034	U-1957			
RIVAROXABAN - XARELTO							
N 022406	004	7157456	Aug 28, 2024	DS DP			
		7585860	Dec 11, 2020	DS			
		7592339	Dec 11, 2020	U-2435			
		9415053	Nov 13, 2024	DP U-2435			
RIVASTIGMINE - EXELON							
N 022083	001	6316023	Jan 08, 2019	DP			
		6335031	Jan 08, 2019	DP			
RIVASTIGMINE - EXELON							
N 022083	002	6316023	Jan 08, 2019	DP			
		6335031	Jan 08, 2019	DP			
RIVASTIGMINE - EXELON							
N 022083	005	6316023	Jan 08, 2019	DP			
		6335031	Jan 08, 2019	DP			
ROFLUMILAST - DALIRESP							
N 022522	001	5712298	Jan 27, 2020	DS DP U-1115		D-171	Jan 23, 2021
		8431154	Feb 19, 2023	DP		M-208	Aug 31, 2020
		8536206	Mar 08, 2024	U-1115			
		8604064	Mar 08, 2024	U-1115			
		8618142	Mar 08, 2024	DP			
		9468598	Feb 19, 2023	DP			
ROFLUMILAST - DALIRESP							
N 022522	002	5712298	Jan 27, 2020	DS DP U-1115		NS	Jan 23, 2021
		8431154	Feb 19, 2023	DP			
		8536206	Mar 08, 2024	U-1115			
		8604064	Mar 08, 2024	U-1115			
		8618142	Mar 08, 2024	DP			
		9468598	Feb 19, 2023	DP			
ROLAPITANT HYDROCHLORIDE - VARUBI							
N 206500	001	7049320	Dec 08, 2023	DS DP U-1741		NCE	Sep 01, 2020
		7563801	Apr 04, 2027	DP			
		7981905	Apr 04, 2027	U-1741			
		8178550	Apr 04, 2027	DS DP			
		8361500	Oct 09, 2029	DP			
		8404702	Apr 04, 2027	U-1741			
		8470842	Jan 18, 2029	U-1741			
		8796299	Dec 17, 2022	U-1741			
ROLAPITANT HYDROCHLORIDE - VARUBI							
N 208399	001	7049320	Dec 08, 2023	DS DP U-1741		NCE	Sep 01, 2020
		7981905	Apr 04, 2027	U-1741			
		8178550	Apr 04, 2027	DS DP			
		8404702	Apr 04, 2027	U-1741			
		8470842	Jan 18, 2029	U-1741			
		8796299	Dec 17, 2022	U-1741			
		9101615	Jul 14, 2032	U-1741			
ROMIDEPSIN - ISTODAX							
N 022393	001	7608280	Aug 22, 2021	DS			
		7611724	Aug 22, 2021	DS			
ROPINIROLE HYDROCHLORIDE - REQUIP XL							
N 022008	001	7927624	Dec 02, 2021	DP U-20		M-203	Mar 23, 2020
		8303986	Apr 12, 2021	DP			
ROPINIROLE HYDROCHLORIDE - REQUIP XL							
N 022008	002	7927624	Dec 02, 2021	DP U-20		M-203	Mar 23, 2020
		8303986	Apr 12, 2021	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ROPINIROLE HYDROCHLORIDE - REQUIP XL							
N 022008	003	7927624	Dec 02, 2021	DP U-20		M-203	Mar 23, 2020
		8303986	Apr 12, 2021	DP			
ROPINIROLE HYDROCHLORIDE - REQUIP XL							
N 022008	004	7927624	Dec 02, 2021	DP U-20		M-203	Mar 23, 2020
		8303986	Apr 12, 2021	DP			
ROPINIROLE HYDROCHLORIDE - REQUIP XL							
N 022008	005	7927624	Dec 02, 2021	DP U-20		M-203	Mar 23, 2020
		8303986	Apr 12, 2021	DP			
ROPINIROLE HYDROCHLORIDE - REQUIP XL							
N 022008	006	7927624	Dec 02, 2021	DP U-20		M-203	Mar 23, 2020
		8303986	Apr 12, 2021	DP			
ROPIVACAINE HYDROCHLORIDE - NAROPIN							
N 020533	006	7828787	Oct 18, 2025	DP			
		7857802	Nov 28, 2026	DP			
		8118802	May 18, 2023	DP			
		8162915	May 23, 2024	DP			
ROPIVACAINE HYDROCHLORIDE - NAROPIN							
N 020533	007	7828787	Oct 18, 2025	DP			
		7857802	Nov 28, 2026	DP			
		8118802	May 18, 2023	DP			
		8162915	May 23, 2024	DP			
ROSIGLITAZONE MALEATE - AVANDIA							
N 021071	002	7358366	Apr 19, 2020	DS	Y		
		7358366*PED	Oct 19, 2020				
ROSIGLITAZONE MALEATE - AVANDIA							
N 021071	003	7358366	Apr 19, 2020	DS	Y		
		7358366*PED	Oct 19, 2020				
ROSIGLITAZONE MALEATE - AVANDIA							
N 021071	004	7358366	Apr 19, 2020	DS	Y		
		7358366*PED	Oct 19, 2020				
ROSUVASTATIN CALCIUM - CRESTOR							
N 021366	002	6316460	Aug 04, 2020	DP		ODE-118	May 27, 2023
		6858618	Dec 17, 2021	U-1032			
		6858618	Dec 17, 2021	U-1807			
		6858618	Dec 17, 2021	U-618			
		6858618*PED	Jun 17, 2022				
ROSUVASTATIN CALCIUM - CRESTOR							
N 021366	003	6316460	Aug 04, 2020	DP		ODE-118	May 27, 2023
		6858618	Dec 17, 2021	U-1032			
		6858618	Dec 17, 2021	U-1807			
		6858618	Dec 17, 2021	U-618			
		6858618*PED	Jun 17, 2022				
ROSUVASTATIN CALCIUM - CRESTOR							
N 021366	004	6316460	Aug 04, 2020	DP		I-732	May 27, 2019
		6858618	Dec 17, 2021	U-1032		ODE-118	May 27, 2023
		6858618	Dec 17, 2021	U-1807			
		6858618	Dec 17, 2021	U-618			
		6858618*PED	Jun 17, 2022				
ROSUVASTATIN CALCIUM - CRESTOR							
N 021366	005	6316460	Aug 04, 2020	DP		ODE-118	May 27, 2023
		6858618	Dec 17, 2021	U-618			
ROTIGOTINE - NEUPRO							
N 021829	001	10130589	Dec 22, 2030	DP			
		6699498	Nov 27, 2020	DP			
		6884434	Mar 30, 2021	DP			
		7413747	Mar 18, 2019	DP			
		8246979	Sep 01, 2027	DP U-1272			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ROTIGOTINE - NEUPRO						
N 021829 001	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
ROTIGOTINE - NEUPRO						
N 021829 002	10130589	Dec 22, 2030	DP			
	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
ROTIGOTINE - NEUPRO						
N 021829 003	10130589	Dec 22, 2030	DP			
	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
ROTIGOTINE - NEUPRO						
N 021829 004	10130589	Dec 22, 2030	DP			
	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
ROTIGOTINE - NEUPRO						
N 021829 005	10130589	Dec 22, 2030	DP			
	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
ROTIGOTINE - NEUPRO						
N 021829 006	10130589	Dec 22, 2030	DP			
	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 001	10130636	Aug 17, 2035	U-2012		I-772	Apr 06, 2021
	10130636	Aug 17, 2035	U-2101		NCE	Dec 19, 2021
	10130636	Aug 17, 2035	U-2273		ODE-126	Dec 19, 2023
	6495541	Jan 10, 2020	DS DP		ODE-168	Apr 06, 2025
	7351701	Jul 23, 2024	U-2012			
	7351701	Jul 23, 2024	U-2101			
	7351701	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2012			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 001	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	9045487	Feb 10, 2031	DS DP			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2101			
	9861638	Feb 10, 2031	U-2273			
	9987285	Aug 17, 2035	DP			
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 002	10130636	Aug 17, 2035	U-2012		I-772	Apr 06, 2021
	10130636	Aug 17, 2035	U-2101		NCE	Dec 19, 2021
	10130636	Aug 17, 2035	U-2273		ODE-126	Dec 19, 2023
	6495541	Jan 10, 2020	DS DP		ODE-168	Apr 06, 2025
	7351701	Jul 23, 2024	U-2012			
	7351701	Jul 23, 2024	U-2101			
	7351701	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	9045487	Feb 10, 2031	DS DP			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2101			
	9861638	Feb 10, 2031	U-2273			
	9987285	Aug 17, 2035	DP			
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 003	10130636	Aug 17, 2035	U-2012		I-772	Apr 06, 2021
	10130636	Aug 17, 2035	U-2101		NCE	Dec 19, 2021
	10130636	Aug 17, 2035	U-2273		ODE-126	Dec 19, 2023
	6495541	Jan 10, 2020	DS DP		ODE-168	Apr 06, 2025
	7351701	Jul 23, 2024	U-2012			
	7351701	Jul 23, 2024	U-2101			
	7351701	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	9045487	Feb 10, 2031	DS DP			
	9861638	Feb 10, 2031	U-2012			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUCAPARIB CAMSYLATE - RUBRACA							
N 209115	003	9861638	Feb 10, 2031	U-2101			
		9861638	Feb 10, 2031	U-2273			
		9987285	Aug 17, 2035	DP			
RUFINAMIDE - BANZEL							
N 021911	001	6740669	Nov 14, 2022	DS DP			
		6740669*PED	May 14, 2023				
		7750028*PED	Apr 19, 2019				
RUFINAMIDE - BANZEL							
N 021911	002	6740669	Nov 14, 2022	DS DP			
		6740669*PED	May 14, 2023				
		7750028*PED	Apr 19, 2019				
RUFINAMIDE - BANZEL							
N 021911	003	6740669	Nov 14, 2022	DS DP			
		6740669*PED	May 14, 2023				
		7750028*PED	Apr 19, 2019				
RUFINAMIDE - BANZEL							
N 201367	001	6740669	Nov 14, 2022	DS DP			
		6740669*PED	May 14, 2023				
		7750028*PED	Apr 19, 2019				
RUXOLITINIB PHOSPHATE - JAKAFI							
N 202192	001	7598257	Dec 24, 2027	DS DP U-1201		ODE-79	Dec 04, 2021
		7598257	Dec 24, 2027	DS DP U-1622			
		8415362	Dec 24, 2027	DS DP			
		8722693	Jun 12, 2028	DS DP			
		8822481	Jun 12, 2028	U-1573			
		8829013	Jun 12, 2028	U-1201			
		8829013	Jun 12, 2028	U-1622			
		9079912	Dec 12, 2026	U-1573			
		9079912	Dec 12, 2026	U-1721			
RUXOLITINIB PHOSPHATE - JAKAFI							
N 202192	002	7598257	Dec 24, 2027	DS DP U-1201		ODE-79	Dec 04, 2021
		7598257	Dec 24, 2027	DS DP U-1622			
		8415362	Dec 24, 2027	DS DP			
		8722693	Jun 12, 2028	DS DP			
		8822481	Jun 12, 2028	U-1573			
		8829013	Jun 12, 2028	U-1201			
		8829013	Jun 12, 2028	U-1622			
		9079912	Dec 12, 2026	U-1573			
		9079912	Dec 12, 2026	U-1721			
RUXOLITINIB PHOSPHATE - JAKAFI							
N 202192	003	7598257	Dec 24, 2027	DS DP U-1201		ODE-79	Dec 04, 2021
		7598257	Dec 24, 2027	DS DP U-1622			
		8415362	Dec 24, 2027	DS DP			
		8722693	Jun 12, 2028	DS DP			
		8822481	Jun 12, 2028	U-1573			
		8829013	Jun 12, 2028	U-1201			
		8829013	Jun 12, 2028	U-1622			
		9079912	Dec 12, 2026	U-1573			
		9079912	Dec 12, 2026	U-1721			
RUXOLITINIB PHOSPHATE - JAKAFI							
N 202192	004	7598257	Dec 24, 2027	DS DP U-1201		ODE-79	Dec 04, 2021
		7598257	Dec 24, 2027	DS DP U-1622			
		8415362	Dec 24, 2027	DS DP			
		8722693	Jun 12, 2028	DS DP			
		8822481	Jun 12, 2028	U-1573			
		8829013	Jun 12, 2028	U-1201			
		8829013	Jun 12, 2028	U-1622			
		9079912	Dec 12, 2026	U-1573			
		9079912	Dec 12, 2026	U-1721			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 005	7598257	Dec 24, 2027	DS DP U-1201		ODE-79	Dec 04, 2021
	7598257	Dec 24, 2027	DS DP U-1622			
	8415362	Dec 24, 2027	DS DP			
	8722693	Jun 12, 2028	DS DP			
	8822481	Jun 12, 2028	U-1573			
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
SACROSIDASE - SUCRAID						
N 020772 001	9255261	Feb 07, 2034	DS DP			
	9469847	Feb 07, 2034	DS DP			
	9849161	Feb 07, 2034	DS DP			
SACUBITRIL; VALSARTAN - ENTRESTO						
N 207620 001	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	8101659	Jan 14, 2023	DP			
	8404744	Jan 14, 2023	DP			
	8796331	Jan 14, 2023	U-1723			
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026	U-1723			
SACUBITRIL; VALSARTAN - ENTRESTO						
N 207620 002	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	8101659	Jan 14, 2023	DP			
	8404744	Jan 14, 2023	DP			
	8796331	Jan 14, 2023	U-1723			
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026	U-1723			
SACUBITRIL; VALSARTAN - ENTRESTO						
N 207620 003	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	8101659	Jan 14, 2023	DP			
	8404744	Jan 14, 2023	DP			
	8796331	Jan 14, 2023	U-1723			
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026	U-1723			
SAFINAMIDE MESYLATE - XADAGO						
N 207145 001	8076515	Dec 10, 2028	DS DP U-1993		NCE	Mar 21, 2022
	8278485	Jun 08, 2027	DS U-1993			
	8283380	Sep 01, 2027	U-1993			
SAFINAMIDE MESYLATE - XADAGO						
N 207145 002	8076515	Dec 10, 2028	DS DP U-1993		NCE	Mar 21, 2022
	8278485	Jun 08, 2027	DS U-1993			
	8283380	Sep 01, 2027	U-1993			
SAPROPTERIN DIHYDROCHLORIDE - KUVAN						
N 022181 001	7566462	Nov 16, 2025	DP			
	7566462*PED	May 16, 2026				
	7566714	Nov 17, 2024	U-989			
	7566714*PED	May 17, 2025				
	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	7727987	Nov 17, 2024	DP			
	7727987*PED	May 17, 2025				
	7947681	Nov 17, 2024	U-1156	Y		
	7947681*PED	May 17, 2025				
	8003126	Nov 16, 2025				
	8003126*PED	May 16, 2026				
	8067416	Nov 17, 2024	U-989			
	8067416*PED	May 17, 2025				
	8318745	Nov 17, 2024	DP			
	8318745*PED	May 17, 2025				
	9433624	Nov 17, 2024	U-1589			
	RE43797	Nov 17, 2024	U-1156			
	RE43797*PED	May 17, 2025				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SAPROPTERIN DIHYDROCHLORIDE - KUVAN						
N 022181 001	7566462	Nov 16, 2025	DP			
	7566462*PED	May 16, 2026				
	7566714	Nov 17, 2024	U-989			
	7566714*PED	May 17, 2025				
	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	7727987	Nov 17, 2024	DP			
	7727987*PED	May 17, 2025				
	7947681	Nov 17, 2024	U-1156	Y		
	7947681*PED	May 17, 2025				
	8003126	Nov 16, 2025				
	8003126*PED	May 16, 2026				
	8067416	Nov 17, 2024	U-989			
	8067416*PED	May 17, 2025				
	8318745	Nov 17, 2024	DP			
	8318745*PED	May 17, 2025				
	9433624	Nov 17, 2024	U-1589			
	RE43797	Nov 17, 2024	U-1156			
	RE43797*PED	May 17, 2025				
SAPROPTERIN DIHYDROCHLORIDE - KUVAN						
N 205065 001	7566714	Nov 17, 2024	U-1589			
	7566714*PED	May 17, 2025				
	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	8067416	Nov 17, 2024	U-1589			
	8067416*PED	May 17, 2025				
	9216178	Nov 01, 2032	DP			
	9433624	Nov 17, 2024	U-1589			
	RE43797	Nov 17, 2024	U-1590			
	RE43797*PED	May 17, 2025				
SAPROPTERIN DIHYDROCHLORIDE - KUVAN						
N 205065 002	7566714	Nov 17, 2024	U-1589			
	7566714*PED	May 17, 2025				
	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	8067416	Nov 17, 2024	U-1589			
	8067416*PED	May 17, 2025				
	9216178	Nov 01, 2032	DP			
	9433624	Nov 17, 2024	U-1589			
	RE43797	Nov 17, 2024	U-1590			
	RE43797*PED	May 17, 2025				
SAQUINAVIR - FORTOVASE						
N 020828 001	6352717	Nov 16, 2019				
SARECYCLINE HYDROCHLORIDE - SEYSARA						
N 209521 001	8318706	May 01, 2031	DS DP U-2405		NCE	Oct 01, 2023
	8513223	Dec 07, 2029	U-2406			
	9255068	Feb 09, 2033	DS DP U-2407			
	9255068	Feb 09, 2033	DS DP U-2408			
	9481639	Aug 10, 2028	U-2409			
SARECYCLINE HYDROCHLORIDE - SEYSARA						
N 209521 002	8318706	May 01, 2031	DS DP U-2405		NCE	Oct 01, 2023
	8513223	Dec 07, 2029	U-2406			
	9255068	Feb 09, 2033	DS DP U-2407			
	9255068	Feb 09, 2033	DS DP U-2408			
	9481639	Aug 10, 2028	U-2409			
SARECYCLINE HYDROCHLORIDE - SEYSARA						
N 209521 003	8318706	May 01, 2031	DS DP U-2405		NCE	Oct 01, 2023
	8513223	Dec 07, 2029	U-2406			
	9255068	Feb 09, 2033	DS DP U-2407			
	9255068	Feb 09, 2033	DS DP U-2408			
	9481639	Aug 10, 2028	U-2409			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA							
N 022350	001	7951400	Nov 30, 2028	DP		M-175	Apr 05, 2019
		RE44186	Jul 31, 2023	DS DP U-1837		M-198	Feb 27, 2020
		RE44186	Jul 31, 2023	DS DP U-995			
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA							
N 022350	002	7951400	Nov 30, 2028	DP		M-175	Apr 05, 2019
		RE44186	Jul 31, 2023	DS DP U-1837		M-198	Feb 27, 2020
		RE44186	Jul 31, 2023	DS DP U-995			
SECNIDAZOLE - SOLOSEC							
N 209363	001					NCE	Sep 15, 2022
						GAIN	Sep 15, 2027
SELEXIPAG - UPTRAVI							
N 207947	001	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
		8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
		9173881	Aug 12, 2029	U-1798			
		9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI							
N 207947	002	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
		8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
		9173881	Aug 12, 2029	U-1798			
		9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI							
N 207947	003	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
		8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
		9173881	Aug 12, 2029	U-1798			
		9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI							
N 207947	004	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
		8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
		9173881	Aug 12, 2029	U-1798			
		9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI							
N 207947	005	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
		8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
		9173881	Aug 12, 2029	U-1798			
		9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI							
N 207947	006	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
		8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
		9173881	Aug 12, 2029	U-1798			
		9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI							
N 207947	007	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
		8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
		9173881	Aug 12, 2029	U-1798			
		9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI							
N 207947	008	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
		8791122	Aug 01, 2030	DS DP		ODE-106	Dec 21, 2022
		9173881	Aug 12, 2029	U-1798			
		9284280	Jun 25, 2030	U-1831			
SEMAGLUTIDE - OZEMPIC							
N 209637	001	6899699	Jan 02, 2022	DP		NCE	Dec 05, 2022
		7762994	May 23, 2024	DP			
		8114833	Aug 13, 2025	DP			
		8129343	Jan 29, 2029	DS DP U-2202			
		8536122	Mar 20, 2026	DS DP U-2202			
		8579869	Jun 30, 2023	DP			
		8672898	Jan 02, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SEMAGLUTIDE - OZEMPIC								
N 209637	001		8684969	Oct 20, 2025	DP			
			8920383	Jul 17, 2026	DP			
			9108002	Jan 20, 2026	DP			
			9132239	Feb 01, 2032	DP			
			9457154	Sep 27, 2027	DP			
			9486588	Jan 02, 2022	DP			
			9616180	Jan 20, 2026	DP			
			9687611	Feb 27, 2027	DP			
			9775953	Jul 17, 2026	DP			
			9861757	Jan 20, 2026	DP			
			RE46363	Aug 03, 2026	DP			
SERTRALINE HYDROCHLORIDE - ZOLOFT								
N 020990	001		6727283	Oct 11, 2019	DP U-580			
			7067555	Oct 11, 2019	DP			
			7067555*PED	Apr 11, 2020				
SEVELAMER CARBONATE - RENVELA								
N 022127	001		7985418	Oct 27, 2025	DP		NPP	Nov 25, 2019
SEVELAMER CARBONATE - RENVELA								
N 022318	001		9095509	Dec 06, 2030	DP		NPP	Nov 25, 2019
SEVELAMER CARBONATE - RENVELA								
N 022318	002		9095509	Dec 06, 2030	DP		NPP	Nov 25, 2019
SEVELAMER HYDROCHLORIDE - RENAGEL								
N 021179	001		6733780	Oct 18, 2020	DP			
SEVELAMER HYDROCHLORIDE - RENAGEL								
N 021179	002		6733780	Oct 18, 2020	DP			
SILDENAFIL CITRATE - VIAGRA								
N 020895	001		6469012	Oct 22, 2019	U-155			
SILDENAFIL CITRATE - VIAGRA								
N 020895	002		6469012	Oct 22, 2019	U-155			
SILDENAFIL CITRATE - VIAGRA								
N 020895	003		6469012	Oct 22, 2019	U-155			
SIMEPREVIR SODIUM - OLYSIO								
N 205123	001		7671032	May 19, 2025	DS DP		M-171	Feb 26, 2019
			8148399	Sep 05, 2029	DS DP U-1467		M-179	May 20, 2019
			8349869	Jul 28, 2026	DS DP U-1467			
			8741926	Jul 28, 2026	DS U-1467			
			8754106	Jul 28, 2026	DS U-1467			
			9040562	Jul 28, 2026	DS DP U-1467			
			9353103	Jul 28, 2026	U-1467			
			9623022	Jul 28, 2026	U-1467			
			9856265	Jul 28, 2026	DS DP U-1467			
SIMVASTATIN - FLOLIPID								
N 206679	001		9597289	Feb 23, 2030	DP			
SIMVASTATIN - FLOLIPID								
N 206679	002		9597289	Feb 23, 2030	DP			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC								
N 202343	001		6699871	Jul 26, 2022	DS DP U-1188			
			6890898	Feb 02, 2019	U-1189			
			6890898	Feb 02, 2019	U-1190			
			6890898	Feb 02, 2019	U-1191			
			7078381	Feb 02, 2019	U-1188			
			7125873	Jul 26, 2022	DP U-1189			
			7125873	Jul 26, 2022	DP U-1190			
			7125873	Jul 26, 2022	DP U-1192			
			7125873	Jul 26, 2022	DP U-1193			
			7326708	Apr 11, 2026	DS DP U-1188			
			7459428	Feb 02, 2019	U-1189			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC							
N 202343	001	8168637	Jun 26, 2022	DP U-1188			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC							
N 202343	002	6699871	Jul 26, 2022	DS DP U-1188			
		6890898	Feb 02, 2019	U-1189			
		6890898	Feb 02, 2019	U-1190			
		6890898	Feb 02, 2019	U-1191			
		7078381	Feb 02, 2019	U-1188			
		7125873	Jul 26, 2022	DP U-1189			
		7125873	Jul 26, 2022	DP U-1190			
		7125873	Jul 26, 2022	DP U-1192			
		7125873	Jul 26, 2022	DP U-1193			
		7326708	Apr 11, 2026	DS DP U-1188			
		7459428	Feb 02, 2019	U-1189			
		8168637	Jun 26, 2022	DP U-1188			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC							
N 202343	003	6699871	Jul 26, 2022	DS DP U-1188			
		6890898	Feb 02, 2019	U-1189			
		6890898	Feb 02, 2019	U-1190			
		6890898	Feb 02, 2019	U-1191			
		7078381	Feb 02, 2019	U-1188			
		7125873	Jul 26, 2022	DP U-1189			
		7125873	Jul 26, 2022	DP U-1190			
		7125873	Jul 26, 2022	DP U-1192			
		7125873	Jul 26, 2022	DP U-1193			
		7326708	Apr 11, 2026	DS DP U-1188			
		7459428	Feb 02, 2019	U-1189			
		8168637	Jun 26, 2022	DP U-1188			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC							
N 202343	004	6699871	Jul 26, 2022	DS DP U-1188			
		6890898	Feb 02, 2019	U-1189			
		6890898	Feb 02, 2019	U-1190			
		6890898	Feb 02, 2019	U-1191			
		7078381	Feb 02, 2019	U-1188			
		7125873	Jul 26, 2022	DP U-1189			
		7125873	Jul 26, 2022	DP U-1190			
		7125873	Jul 26, 2022	DP U-1192			
		7125873	Jul 26, 2022	DP U-1193			
		7326708	Apr 11, 2026	DS DP U-1188			
		7459428	Feb 02, 2019	U-1189			
		8168637	Jun 26, 2022	DP U-1188			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC							
N 202343	005	6699871	Jul 26, 2022	DS DP U-1188			
		6890898	Feb 02, 2019	U-1189			
		6890898	Feb 02, 2019	U-1190			
		6890898	Feb 02, 2019	U-1191			
		7078381	Feb 02, 2019	U-1188			
		7125873	Jul 26, 2022	DP U-1189			
		7125873	Jul 26, 2022	DP U-1190			
		7125873	Jul 26, 2022	DP U-1192			
		7125873	Jul 26, 2022	DP U-1193			
		7326708	Apr 11, 2026	DS DP U-1188			
		7459428	Feb 02, 2019	U-1189			
		8168637	Jun 26, 2022	DP U-1188			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC							
N 202343	006	6699871	Jul 26, 2022	DS DP U-1188			
		6890898	Feb 02, 2019	U-1189			
		6890898	Feb 02, 2019	U-1190			
		6890898	Feb 02, 2019	U-1191			
		7078381	Feb 02, 2019	U-1188			
		7125873	Jul 26, 2022	DP U-1189			
		7125873	Jul 26, 2022	DP U-1190			
		7125873	Jul 26, 2022	DP U-1192			
		7125873	Jul 26, 2022	DP U-1193			
		7326708	Apr 11, 2026	DS DP U-1188			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC							
N 202343	006	7459428	Feb 02, 2019	U-1189			
		8168637	Jun 26, 2022	DP U-1188			
SINCALIDE - KINEVAC							
N 017697	001	6803046	Aug 16, 2022	DP			
SINECATECHINS - VEREGEN							
N 021902	001	5795911	Oct 31, 2020	U-172			
		7858662	Oct 02, 2026	DP U-172			
		9770406	Jul 12, 2025	DP U-172			
SIROLIMUS - RAPAMUNE							
N 021083	001					ODE-92	May 28, 2022
SIROLIMUS - RAPAMUNE							
N 021110	001					ODE-92	May 28, 2022
SIROLIMUS - RAPAMUNE							
N 021110	002					ODE-92	May 28, 2022
SIROLIMUS - RAPAMUNE							
N 021110	003					ODE-92	May 28, 2022
SIROLIMUS - RAPAMUNE							
N 021110	004					ODE-92	May 28, 2022
SITAGLIPTIN PHOSPHATE - JANUVIA							
N 021995	001	6699871	Jul 26, 2022	DS DP U-774			
		6890898	Feb 02, 2019	U-1997			
		7078381	Feb 02, 2019	U-1997			
		7125873	Jul 26, 2022	U-1036			
		7125873	Jul 26, 2022	U-1037			
		7125873	Jul 26, 2022	U-1038			
		7125873	Jul 26, 2022	U-775			
		7326708	Nov 24, 2026	DS DP U-802			
		7459428	Feb 02, 2019	U-1945			
SITAGLIPTIN PHOSPHATE - JANUVIA							
N 021995	002	6699871	Jul 26, 2022	DS DP U-774			
		6890898	Feb 02, 2019	U-1997			
		7078381	Feb 02, 2019	U-1997			
		7125873	Jul 26, 2022	U-1036			
		7125873	Jul 26, 2022	U-1037			
		7125873	Jul 26, 2022	U-1038			
		7125873	Jul 26, 2022	U-775			
		7326708	Nov 24, 2026	DS DP U-802			
		7459428	Feb 02, 2019	U-1945			
SITAGLIPTIN PHOSPHATE - JANUVIA							
N 021995	003	6699871	Jul 26, 2022	DS DP U-774			
		6890898	Feb 02, 2019	U-1997			
		7078381	Feb 02, 2019	U-1997			
		7125873	Jul 26, 2022	U-1036			
		7125873	Jul 26, 2022	U-1037			
		7125873	Jul 26, 2022	U-1038			
		7125873	Jul 26, 2022	U-775			
		7326708	Nov 24, 2026	DS DP U-802			
		7459428	Feb 02, 2019	U-1945			
SODIUM NITRITE - SODIUM NITRITE							
N 203922	001	8568793	Dec 24, 2031	DS DP			
SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE							
N 201444	001	8496973	Mar 29, 2031	DS DP U-1419			
		8568793	Dec 24, 2031	DS DP			
		9345724	Mar 29, 2031	DS DP U-2015			
		9585912	Mar 29, 2031	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SODIUM OXYBATE - XYREM						
N 021196 001	6780889	Jul 04, 2020	DP		NPP	Oct 26, 2021
	6780889*PED	Jan 04, 2021			PED	Apr 26, 2022
	7262219	Jul 04, 2020	DP			
	7262219*PED	Jan 04, 2021				
	7668730	Jun 16, 2024	U-1110			
	7668730*PED	Dec 16, 2024				
	7765106	Jun 16, 2024	U-1069			
	7765106*PED	Dec 16, 2024				
	7765107	Jun 16, 2024	U-1070			
	7765107*PED	Dec 16, 2024				
	7851506	Dec 22, 2019	U-1101			
	7851506	Dec 22, 2019	U-1102			
	7851506*PED	Jun 22, 2020				
	7895059	Dec 17, 2022	U-1110			
	7895059*PED	Jun 17, 2023				
	8263650	Dec 22, 2019	DP U-1101			
	8263650	Dec 22, 2019	DP U-1102			
	8263650*PED	Jun 22, 2020				
	8324275	Dec 22, 2019	U-1101			
	8324275	Dec 22, 2019	U-1102			
	8324275*PED	Jun 22, 2020				
	8457988	Dec 17, 2022	U-1110			
	8457988*PED	Jun 17, 2023				
	8589182	Dec 17, 2022	U-1110			
	8589182*PED	Jun 17, 2023				
	8731963	Dec 17, 2022	U-1110			
	8731963*PED	Jun 17, 2023				
	8772306	Mar 15, 2033	U-1532			
	8772306*PED	Sep 15, 2033				
	8859619	Dec 22, 2019	DP			
	8859619*PED	Jun 22, 2020				
	8952062	Dec 22, 2019	U-1101			
	8952062	Dec 22, 2019	U-1102			
	8952062*PED	Jun 22, 2020				
	9050302	Mar 15, 2033	U-1532			
	9050302*PED	Sep 15, 2033				
	9486426	Mar 15, 2033	U-1532			
	9486426*PED	Sep 15, 2033				
	9539330	Dec 22, 2019	DP			
	9539330*PED	Jun 22, 2020				
SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP						
N 021892 001	7687075	Jun 22, 2028	DS DP			
SODIUM THIOSULFATE - SODIUM THIOSULFATE						
N 203923 001	8496973	Mar 29, 2031	DS DP U-1419			
	9345724	Mar 29, 2031	DS DP U-2015			
	9585912	Mar 29, 2031	DS DP			
SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA						
N 207078 001	6332985	Mar 29, 2019	U-2312		NCE	May 18, 2023
	8802152	Apr 19, 2032	DS			
	8808750	Feb 10, 2032	U-2312			
	8877255	Oct 22, 2033	DS			
	9592253	Oct 14, 2035	DS U-2312			
	9844567	Feb 10, 2032	U-2312			
	9861658	Feb 10, 2032	U-2312			
SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA						
N 207078 002	6332985	Mar 29, 2019	U-2312		NCE	May 18, 2023
	8802152	Apr 19, 2032	DS			
	8808750	Feb 10, 2032	U-2312			
	8877255	Oct 22, 2033	DS			
	9592253	Oct 14, 2035	DS U-2312			
	9844567	Feb 10, 2032	U-2312			
	9861658	Feb 10, 2032	U-2312			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOFOSBUVIR - SOVALDI							
N 204671	001	7964580	Mar 26, 2029	DS DP U-1470		NPP	Apr 07, 2020
		8334270	Mar 21, 2028	DS DP U-1470		ODE-135	Apr 07, 2024
		8580765	Mar 21, 2028	DS DP U-1470			
		8618076	Dec 11, 2030	DS DP U-1470			
		8633309	Mar 26, 2029	DS DP U-1470			
		8889159	Mar 26, 2029	DP U-1470			
		9085573	Mar 21, 2028	DS DP U-1470			
		9284342	Sep 13, 2030	DS DP U-1470			
		9549941	Mar 26, 2029	U-1958			
SOFOSBUVIR; VELPATASVIR - EPCLUSA							
N 208341	001	10086011	Jan 30, 2034	U-1470		NCE	Jun 28, 2021
		7964580	Mar 26, 2029	DS DP U-1470		NPP	Aug 01, 2020
		8334270	Mar 21, 2028	DS DP U-1470			
		8575135	Nov 16, 2032	DS DP U-1470			
		8580765	Mar 21, 2028	DS DP U-1470			
		8618076	Dec 11, 2030	DS DP U-1470			
		8633309	Mar 26, 2029	DS DP U-1470			
		8735372	Mar 21, 2028	U-1470			
		8889159	Mar 26, 2029	DP U-1470			
		8921341	Nov 16, 2032	DS DP U-1470			
		8940718	Nov 16, 2032	DS DP U-1470			
		9085573	Mar 21, 2028	DS DP U-1470			
		9284342	Sep 13, 2030	DS DP U-1470			
		9757406	Jan 30, 2034	DP			
SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI							
N 209195	001	7964580	Mar 26, 2029	DS DP U-2039		NCE	Jul 18, 2022
		7964580	Mar 26, 2029	DS DP U-2040			
		8334270	Mar 21, 2028	DS DP U-2039			
		8334270	Mar 21, 2028	DS DP U-2040			
		8575135	Nov 05, 2033	DS DP U-2039			
		8575135	Nov 05, 2033	DS DP U-2040			
		8580765	Mar 21, 2028	DS DP U-2039			
		8580765	Mar 21, 2028	DS DP U-2040			
		8618076	Dec 11, 2030	DS DP U-2039			
		8618076	Dec 11, 2030	DS DP U-2040			
		8633309	Mar 26, 2029	DS DP U-2039			
		8633309	Mar 26, 2029	DS DP U-2040			
		8735372	Mar 21, 2028	DS DP U-2039			
		8735372	Mar 21, 2028	DS DP U-2040			
		8889159	Mar 26, 2029	DS DP U-2039			
		8889159	Mar 26, 2029	DS DP U-2040			
		8921341	Nov 16, 2032	DS DP U-2039			
		8921341	Nov 16, 2032	DS DP U-2040			
		8940718	Nov 16, 2032	DS DP U-2039			
		8940718	Nov 16, 2032	DS DP U-2040			
		9085573	Mar 21, 2028	DS DP U-2039			
		9085573	Mar 21, 2028	DS DP U-2040			
		9284342	Sep 13, 2030	DS DP U-2039			
		9284342	Sep 13, 2030	DS DP U-2040			
		9296782	Jul 17, 2034	DS DP			
		9585906	Mar 21, 2028	DS DP U-2039			
		9585906	Mar 21, 2028	DS DP U-2040			
		9868745	Nov 16, 2032	DS DP			
SOLIFENACIN SUCCINATE - VESICARE							
N 021518	001	6017927*PED	May 19, 2019				
SOLIFENACIN SUCCINATE - VESICARE							
N 021518	002	6017927*PED	May 19, 2019				
SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX							
N 021148	004	6004297	Jan 28, 2019	DP			
		6235004	Jan 28, 2019	DP			
		RE41956	Jan 21, 2021	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX							
N 021148	005	6004297	Jan 28, 2019	DP			
		6235004	Jan 28, 2019	DP			
		RE41956	Jan 21, 2021	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX							
N 021148	006	6004297	Jan 28, 2019	DP			
		6235004	Jan 28, 2019	DP			
		RE41956	Jan 21, 2021	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX							
N 021148	007	6004297	Jan 28, 2019	DP			
		RE41956	Jan 21, 2021	DP			
		RE43834	Jan 28, 2019	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO							
N 021148	008	6899699	Jan 02, 2022	DP			
		8672898	Jan 02, 2022	DP			
		8684969	Oct 20, 2025	DP			
		8920383	Jul 17, 2026	DP			
		9108002	Jan 20, 2026	DP			
		9132239	Feb 01, 2032	DP			
		9457154	Sep 27, 2027	DP			
		9486588	Jan 02, 2022	DP			
		9616180	Jan 20, 2026	DP			
		9687611	Feb 27, 2027	DP			
		9775953	Jul 17, 2026	DP			
		9861757	Jan 20, 2026	DP			
		RE46363	Aug 03, 2026	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO							
N 021148	009	6899699	Jan 02, 2022	DP			
		8672898	Jan 02, 2022	DP			
		8684969	Oct 20, 2025	DP			
		8920383	Jul 17, 2026	DP			
		9108002	Jan 20, 2026	DP			
		9132239	Feb 01, 2032	DP			
		9457154	Sep 27, 2027	DP			
		9486588	Jan 02, 2022	DP			
		9616180	Jan 20, 2026	DP			
		9687611	Feb 27, 2027	DP			
		9775953	Jul 17, 2026	DP			
		9861757	Jan 20, 2026	DP			
		RE46363	Aug 03, 2026	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO							
N 021148	010	6899699	Jan 02, 2022	DP			
		8672898	Jan 02, 2022	DP			
		8684969	Oct 20, 2025	DP			
		8920383	Jul 17, 2026	DP			
		9108002	Jan 20, 2026	DP			
		9132239	Feb 01, 2032	DP			
		9457154	Sep 27, 2027	DP			
		9486588	Jan 02, 2022	DP			
		9616180	Jan 20, 2026	DP			
		9687611	Feb 27, 2027	DP			
		9775953	Jul 17, 2026	DP			
		9861757	Jan 20, 2026	DP			
		RE46363	Aug 03, 2026	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO							
N 021148	011	6899699	Jan 02, 2022	DP			
		8672898	Jan 02, 2022	DP			
		8684969	Oct 20, 2025	DP			
		8920383	Jul 17, 2026	DP			
		9108002	Jan 20, 2026	DP			
		9132239	Feb 01, 2032	DP			
		9457154	Sep 27, 2027	DP			
		9486588	Jan 02, 2022	DP			
		9616180	Jan 20, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO							
N 021148	011	9687611	Feb 27, 2027	DP			
		9775953	Jul 17, 2026	DP			
		9861757	Jan 20, 2026	DP			
		RE46363	Aug 03, 2026	DP			
SONIDEGIB PHOSPHATE - ODOMZO							
N 205266	001	8063043	Sep 15, 2029	DS DP		NCE	Jul 24, 2020
		8178563	Feb 06, 2029	DS U-1722			
SORAFENIB TOSYLATE - NEXAVAR							
N 021923	001	7235576	Jan 12, 2020	DS DP		ODE-56	Nov 22, 2020
		7351834	Jan 12, 2020	DS			
		7897623	Jan 12, 2020	DP			
		8124630	Jan 12, 2020	U-1459			
		8618141	Feb 11, 2023	U-1480			
		8841330	Jan 12, 2020	U-1696			
		8877933	Dec 24, 2027	DS DP U-1624			
		9737488	Sep 10, 2028	DP U-1480			
		9737488	Sep 10, 2028	DP U-1696			
		9737488	Sep 10, 2028	DP U-2107			
SOTALOL HYDROCHLORIDE - SOTYLIZE							
N 205108	001	9724297	Aug 31, 2035	DP U-2096			
SPINOSAD - NATROBA							
N 022408	001	6063771	Jul 25, 2023	DP U-1670			
		6342482	Jun 22, 2019	DP U-1105			
		7030095	Jul 02, 2021	DP U-1105			
SPIRONOLACTONE - CAROSPIR							
N 209478	001	9757394	Oct 28, 2036	DP U-2109			
STAVUDINE - ZERIT XR							
N 021453	001	7135465	Feb 18, 2023	DP U-167			
STAVUDINE - ZERIT XR							
N 021453	002	7135465	Feb 18, 2023	DP U-167			
STAVUDINE - ZERIT XR							
N 021453	003	7135465	Feb 18, 2023	DP U-167			
STAVUDINE - ZERIT XR							
N 021453	004	7135465	Feb 18, 2023	DP U-167			
STIRIPENTOL - DIACOMIT							
N 206709	001					NCE	Aug 20, 2023
						ODE-198	Aug 20, 2025
STIRIPENTOL - DIACOMIT							
N 206709	002					NCE	Aug 20, 2023
						ODE-198	Aug 20, 2025
STIRIPENTOL - DIACOMIT							
N 207223	001					NCE	Aug 20, 2023
						ODE-198	Aug 20, 2025
STIRIPENTOL - DIACOMIT							
N 207223	002					NCE	Aug 20, 2023
						ODE-198	Aug 20, 2025
SUCROFERRIC OXYHYDROXIDE - VELPHORO							
N 205109	001	6174442	Dec 19, 2019	DS U-1468			
		9561251	Jan 23, 2030	DP U-1468			
SUFENTANIL CITRATE - DSUVIA							
N 209128	001	8202535	Oct 22, 2030	U-1351		NP	Nov 02, 2021
		8226978	Jan 05, 2027	DP U-1351			
		8231900	Jan 05, 2027	DP			
		8252328	Jan 05, 2027	DP			
		8252329	Jan 05, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SUFENTANIL CITRATE - DSUVIA							
N 209128	001	8535714	Jan 05, 2027	DP U-1351			
		8574189	Mar 16, 2030	DP			
		8778393	Jan 05, 2027	U-1351			
		8778394	Jan 05, 2027	U-1351			
		8865211	Jan 05, 2027	U-1351			
		8865743	Oct 22, 2030	U-1351			
		8945592	Jul 29, 2031	DP			
		9320710	Jan 05, 2027	U-1351			
		9744129	Jan 05, 2027	DP			
SUGAMMADEX SODIUM - BRIDION							
N 022225	001	6949527	Jan 27, 2021	U-1795		NCE	Dec 15, 2020
		7265099	Aug 07, 2020	U-1795			
		RE44733	Jan 27, 2021	DS DP U-1794			
SUGAMMADEX SODIUM - BRIDION							
N 022225	002	6949527	Jan 27, 2021	U-1795		NCE	Dec 15, 2020
		7265099	Aug 07, 2020	U-1795			
		RE44733	Jan 27, 2021	DS DP U-1794			
SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON							
N 203684	001	5686060	Nov 11, 2019	DS DP		I-728	Mar 31, 2019
						NCE	Oct 10, 2019
SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO							
N 022239	001	7776007	Nov 22, 2026	DP			
		7901385	Jul 31, 2026	DP			
		8118771	Aug 10, 2023	DP			
		8241243	Aug 10, 2023	DP			
		8241244	Nov 21, 2022	DP			
		8267903	Mar 18, 2023	DP			
		8287489	Dec 06, 2024	DP			
		8343130	Oct 18, 2022	DP			
		8491524	Nov 21, 2022	DP			
SUMATRIPTAN SUCCINATE - ALSUMA							
N 022377	001	7811254	Aug 26, 2027	DP U-1083			
SUMATRIPTAN SUCCINATE - ZECUITY							
N 202278	001	6745071	Feb 21, 2023	DP			
		7973058	Apr 12, 2027	U-1328			
		8155737	Apr 12, 2027	U-1328			
		8366600	Apr 21, 2029	U-1327			
		8470853	Apr 12, 2027	U-1328			
		8597272	Apr 12, 2027	DP			
		8983594	Nov 19, 2030	DP U-1328			
		9272137	Sep 07, 2027	DP			
		9327114	Oct 08, 2032	DP U-1328			
		9427578	Apr 12, 2027	DP U-1328			
SUMATRIPTAN SUCCINATE - ONZETRA XSAIL							
N 206099	001	10076614	Oct 20, 2034	DP			
		10076615	Jul 30, 2029	U-2010			
		10076615	Jul 30, 2029	U-2011			
		10076615	Jul 30, 2029	U-2404			
		10124132	Mar 06, 2027	DP U-1719			
		10124132	Mar 06, 2027	DP U-2010			
		10124132	Mar 06, 2027	DP U-2011			
		6715485	Mar 03, 2020	DP			
		7975690	Aug 18, 2025	DP U-1809			
		8047202	Jul 02, 2023	DP			
		8327844	Oct 03, 2023	U-1809			
		8550073	Oct 22, 2029	DP			
		8555877	Mar 03, 2020	DP			
		8590530	Sep 15, 2025	DP U-1809			
		8875704	Apr 07, 2028	DP U-1809			
		8899229	Aug 18, 2030	DP			
		8978647	Dec 06, 2030	DP			
		9108015	Sep 15, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SUMATRIPTAN SUCCINATE - ONZETRA XSAIL							
N 206099	001	9119932	Apr 23, 2024	DP			
		9649456	Oct 21, 2030	DP U-1719			
		9649456	Oct 21, 2030	DP U-2010			
		9649456	Oct 21, 2030	DP U-2011			
SUNITINIB MALATE - SUTENT							
N 021938	001	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
		6573293	Feb 15, 2021	DS DP U-2171			
		7125905	Feb 15, 2021	DS DP			
		7211600	Dec 22, 2020	U-883			
SUNITINIB MALATE - SUTENT							
N 021938	002	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
		6573293	Feb 15, 2021	DS DP U-2171			
		7125905	Feb 15, 2021	DS DP			
		7211600	Dec 22, 2020	U-883			
SUNITINIB MALATE - SUTENT							
N 021938	003	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
		6573293	Feb 15, 2021	DS DP U-2171			
		7125905	Feb 15, 2021	DS DP			
		7211600	Dec 22, 2020	U-883			
SUNITINIB MALATE - SUTENT							
N 021938	004	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
		6573293	Feb 15, 2021	DS DP U-2171			
		7125905	Feb 15, 2021	DS DP			
		7211600	Dec 22, 2020	U-883			
SUVOREXANT - BELSOMRA							
N 204569	001	10098892	May 29, 2033	DP		NCE	Aug 13, 2019
		7951797	Nov 20, 2029	DS DP U-620			
SUVOREXANT - BELSOMRA							
N 204569	002	10098892	May 29, 2033	DP		NCE	Aug 13, 2019
		7951797	Nov 20, 2029	DS DP U-620			
SUVOREXANT - BELSOMRA							
N 204569	003	10098892	May 29, 2033	DP		NCE	Aug 13, 2019
		7951797	Nov 20, 2029	DS DP U-620			
SUVOREXANT - BELSOMRA							
N 204569	004	10098892	May 29, 2033	DP		NCE	Aug 13, 2019
		7951797	Nov 20, 2029	DS DP U-620			
TACROLIMUS - ASTAGRAF XL							
N 204096	001	6440458	Mar 25, 2019	DP			
		6576259	Mar 25, 2019	DP U-1420			
		6884433	Mar 25, 2019	DP U-1420			
		8551522	Mar 25, 2019	DP			
TACROLIMUS - ASTAGRAF XL							
N 204096	002	6440458	Mar 25, 2019	DP			
		6576259	Mar 25, 2019	DP U-1420			
		6884433	Mar 25, 2019	DP U-1420			
		8551522	Mar 25, 2019	DP			
TACROLIMUS - ASTAGRAF XL							
N 204096	003	6440458	Mar 25, 2019	DP			
		6576259	Mar 25, 2019	DP U-1420			
		6884433	Mar 25, 2019	DP U-1420			
		8551522	Mar 25, 2019	DP			
TACROLIMUS - ENVARSUS XR							
N 206406	001	7994214	Aug 30, 2024	DP		ODE-94	Jul 10, 2022
		8486993	Aug 30, 2024	DP U-1752			
		8586084	Aug 30, 2024	U-1752			
		8591946	Aug 30, 2024	DP			
		8617599	Aug 30, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TACROLIMUS - ENVARSUS XR							
N 206406	001	8623410	Aug 30, 2024	DP			
		8623411	Aug 30, 2024	U-1752			
		8664239	May 30, 2028	U-1752			
		8685998	May 30, 2028	DP U-1752			
		8889185	Aug 30, 2024	U-1752			
		8889186	Aug 30, 2024	U-1752			
		9161907	Aug 30, 2024	DP U-1752			
		9549918	May 30, 2028	DP			
		9757362	Aug 30, 2024	DP			
		9763920	Aug 30, 2024	DP			
TACROLIMUS - ENVARSUS XR							
N 206406	002	7994214	Aug 30, 2024	DP		ODE-94	Jul 10, 2022
		8486993	Aug 30, 2024	DP U-1752			
		8586084	Aug 30, 2024	U-1752			
		8591946	Aug 30, 2024	DP			
		8617599	Aug 30, 2024	DP			
		8623410	Aug 30, 2024	DP			
		8623411	Aug 30, 2024	U-1752			
		8664239	May 30, 2028	U-1752			
		8685998	May 30, 2028	DP U-1752			
		8889185	Aug 30, 2024	U-1752			
		8889186	Aug 30, 2024	U-1752			
		9161907	Aug 30, 2024	DP U-1752			
		9549918	May 30, 2028	DP			
		9757362	Aug 30, 2024	DP			
		9763920	Aug 30, 2024	DP			
TACROLIMUS - ENVARSUS XR							
N 206406	003	7994214	Aug 30, 2024	DP		ODE-94	Jul 10, 2022
		8486993	Aug 30, 2024	DP U-1752			
		8586084	Aug 30, 2024	U-1752			
		8591946	Aug 30, 2024	DP			
		8617599	Aug 30, 2024	DP			
		8623410	Aug 30, 2024	DP			
		8623411	Aug 30, 2024	U-1752			
		8664239	May 30, 2028	U-1752			
		8685998	May 30, 2028	DP U-1752			
		8889185	Aug 30, 2024	U-1752			
		8889186	Aug 30, 2024	U-1752			
		9161907	Aug 30, 2024	DP U-1752			
		9549918	May 30, 2028	DP			
		9757362	Aug 30, 2024	DP			
		9763920	Aug 30, 2024	DP			
TADALAFIL - TADALAFIL							
A 090141	001					PC	Mar 26, 2019
TADALAFIL - TADALAFIL							
A 090141	002					PC	Mar 26, 2019
TADALAFIL - TADALAFIL							
A 090141	003					PC	Mar 26, 2019
TADALAFIL - TADALAFIL							
A 090141	004					PC	Mar 26, 2019
TADALAFIL - TADALAFIL							
A 200630	001					PC	Feb 05, 2019
TADALAFIL - CIALIS							
N 021368	001	6821975	Nov 19, 2020	DS DP U-1184	Y	M-219	Feb 15, 2021
		6821975	Nov 19, 2020	DS DP U-533	Y	PED	Aug 15, 2021
		6821975	Nov 19, 2020	DS DP U-614	Y		
		6821975*PED	May 19, 2021				
		6943166	Apr 26, 2020	U-1184			
		6943166	Apr 26, 2020	U-155			
		6943166	Apr 26, 2020	U-614			
		6943166*PED	Oct 26, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TADALAFIL - CIALIS						
N 021368 001	7182958	Apr 26, 2020	DP U-1184	Y		
	7182958	Apr 26, 2020	DP U-155	Y		
	7182958*PED	Oct 26, 2020				
TADALAFIL - CIALIS						
N 021368 002	6821975	Nov 19, 2020	DS DP U-533	Y	M-219	Feb 15, 2021
	6821975	Nov 19, 2020	DS DP U-614	Y	PED	Aug 15, 2021
	6821975*PED	May 19, 2021				
	6943166	Apr 26, 2020	U-155			
	6943166	Apr 26, 2020	U-614			
	6943166*PED	Oct 26, 2020				
	7182958	Apr 26, 2020	DP U-155	Y		
	7182958*PED	Oct 26, 2020				
TADALAFIL - CIALIS						
N 021368 003	6821975	Nov 19, 2020	DS DP U-533	Y	M-219	Feb 15, 2021
	6821975	Nov 19, 2020	DS DP U-614	Y	PED	Aug 15, 2021
	6821975*PED	May 19, 2021				
	6943166	Apr 26, 2020	U-614			
	6943166*PED	Oct 26, 2020				
	7182958	Apr 26, 2020	DP U-155	Y		
	7182958*PED	Oct 26, 2020				
TADALAFIL - CIALIS						
N 021368 004	6821975	Nov 19, 2020	DS DP U-533	Y	M-219	Feb 15, 2021
	6821975	Nov 19, 2020	DS DP U-614	Y	PED	Aug 15, 2021
	6821975*PED	May 19, 2021				
	6943166	Apr 26, 2020	U-155			
	6943166*PED	Oct 26, 2020				
	7182958	Apr 26, 2020	DP U-155	Y		
	7182958*PED	Oct 26, 2020				
TADALAFIL - ADCIRCA						
N 022332 001	6821975	Nov 19, 2020	DS DP	Y		
	6821975*PED	May 19, 2021				
	7182958	Apr 26, 2020	DP	Y		
	7182958*PED	Oct 26, 2020				
TAFENOQUINE SUCCINATE - ARAKODA						
N 210607 001					NCE	Jul 20, 2023
					NP	Aug 08, 2021
TAFENOQUINE SUCCINATE - KRINTAFEL						
N 210795 001					NCE	Jul 20, 2023
					ODE-201	Jul 20, 2025
TAFLUPROST - ZIOPTAN						
N 202514 001	5886035	Dec 18, 2022	DS DP U-778			
	9999593	May 28, 2029	DP			
TALAZOPARIB TOSYLATE - TALZENNA						
N 211651 001	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
TALAZOPARIB TOSYLATE - TALZENNA						
N 211651 002	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
TALC - STERITALC						
N 205555 001					ODE-143	May 01, 2024
					ODE-191	May 01, 2024
TALC - STERITALC						
N 205555 002					ODE-143	May 01, 2024
					ODE-191	May 01, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TALC - STERITALC							
N 205555	003					ODE-143	May 01, 2024
						ODE-191	May 01, 2024
TALIGLUCERASE ALFA - ELELYSO							
N 022458	001	8227230	Feb 24, 2024	DS DP			
		8741620	Feb 24, 2024	DS DP			
		8790641	Oct 18, 2025	U-1564			
		8790641	Oct 18, 2025	U-1574			
TAPENTADOL HYDROCHLORIDE - NUCYNTA							
N 022304	001	7994364	Jun 27, 2025	DS DP U-931			
		RE39593	Aug 05, 2022	DS DP U-931			
TAPENTADOL HYDROCHLORIDE - NUCYNTA							
N 022304	002	7994364	Jun 27, 2025	DS DP U-931			
		RE39593	Aug 05, 2022	DS DP U-931			
TAPENTADOL HYDROCHLORIDE - NUCYNTA							
N 022304	003	7994364	Jun 27, 2025	DS DP U-931			
		RE39593	Aug 05, 2022	DS DP U-931			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER							
N 200533	001	7994364	Jun 27, 2025	DS DP U-1178			
		7994364	Jun 27, 2025	DS DP U-1276			
		8075872	Nov 20, 2023	DP			
		8114383	Oct 10, 2024	DP	Y		
		8309060	Nov 20, 2023	DP U-1178			
		8309060	Nov 20, 2023	DP U-1276			
		8420056	Nov 20, 2023	DP			
		8536130	Sep 22, 2028	U-1276			
		RE39593	Aug 05, 2022	DS DP U-1178			
		RE39593	Aug 05, 2022	DS DP U-1276			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER							
N 200533	002	7994364	Jun 27, 2025	DS DP U-1178			
		7994364	Jun 27, 2025	DS DP U-1276			
		8075872	Nov 20, 2023	DP			
		8114383	Oct 10, 2024	DP	Y		
		8309060	Nov 20, 2023	DP U-1178			
		8309060	Nov 20, 2023	DP U-1276			
		8420056	Nov 20, 2023	DP			
		8536130	Sep 22, 2028	U-1276			
		RE39593	Aug 05, 2022	DS DP U-1178			
		RE39593	Aug 05, 2022	DS DP U-1276			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER							
N 200533	003	7994364	Jun 27, 2025	DS DP U-1178			
		7994364	Jun 27, 2025	DS DP U-1276			
		8075872	Nov 20, 2023	DP			
		8114383	Oct 10, 2024	DP	Y		
		8309060	Nov 20, 2023	DP U-1178			
		8309060	Nov 20, 2023	DP U-1276			
		8420056	Nov 20, 2023	DP			
		8536130	Sep 22, 2028	U-1276			
		RE39593	Aug 05, 2022	DS DP U-1178			
		RE39593	Aug 05, 2022	DS DP U-1276			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER							
N 200533	004	7994364	Jun 27, 2025	DS DP U-1178			
		7994364	Jun 27, 2025	DS DP U-1276			
		8075872	Nov 20, 2023	DP			
		8114383	Oct 10, 2024	DP	Y		
		8309060	Nov 20, 2023	DP U-1178			
		8309060	Nov 20, 2023	DP U-1276			
		8420056	Nov 20, 2023	DP			
		8536130	Sep 22, 2028	U-1276			
		RE39593	Aug 05, 2022	DS DP U-1178			
		RE39593	Aug 05, 2022	DS DP U-1276			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER							
N 200533	005	7994364	Jun 27, 2025	DS DP U-1178			
		7994364	Jun 27, 2025	DS DP U-1276			
		8075872	Nov 20, 2023	DP			
		8114383	Oct 10, 2024	DP	Y		
		8309060	Nov 20, 2023	DP U-1178			
		8309060	Nov 20, 2023	DP U-1276			
		8420056	Nov 20, 2023	DP			
		8536130	Sep 22, 2028	U-1276			
		RE39593	Aug 05, 2022	DS DP U-1178			
		RE39593	Aug 05, 2022	DS DP U-1276			
TAPENTADOL HYDROCHLORIDE - NUCYNTA							
N 203794	001	7994364	Jun 27, 2025	DS DP U-1289			
		RE39593	Aug 05, 2022	DS DP U-1289			
TASIMELTEON - HETLIOZ							
N 205677	001	10071977	Feb 12, 2035	DS DP		NCE	Jan 31, 2019
		10149829	Jan 25, 2033	U-2477		ODE-59	Jan 31, 2021
		5856529	Dec 09, 2022	DS DP U-2149			
		9060995	Jan 25, 2033	U-1710			
		9539234	Jan 25, 2033	U-1934			
		9549913	Jan 25, 2033	U-1486			
		9730910	May 17, 2034	U-2085			
		9855241	Jan 25, 2033	U-2149			
		RE46604	Jan 25, 2033	U-2147			
TAVABOROLE - KERYDIN							
N 204427	001	7582621	May 26, 2027	U-2016	Y	NCE	Jul 07, 2019
		7582621*PED	Nov 26, 2027				
		9549938	Feb 16, 2026	U-1951			
		9549938*PED	Aug 16, 2026				
		9566289	Feb 16, 2026	DP			
		9566289*PED	Aug 16, 2026				
		9566290	Feb 16, 2026	U-1970			
		9566290*PED	Aug 16, 2026				
		9572823	Feb 16, 2026	U-1970			
		9572823*PED	Aug 16, 2026				
TAZAROTENE - FABIOR							
N 202428	001	8808716	Feb 24, 2030	DP			
TECHNETIUM TC-99M SULFUR COLLOID KIT - AN-SULFUR COLLOID							
N 017858	001					ODE-29	Aug 13, 2019
TECHNETIUM TC-99M TEBOROXIME KIT - CARDIOTEC							
N 019928	001	6056941	Jul 28, 2019	DP			
TECHNETIUM TC-99M TETROFOSMIN KIT - MYOVIEW 30ML							
N 020372	002	9549999	Mar 10, 2030	DP			
TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT							
N 202207	001	6409990	May 12, 2020	DS		ODE-67	Jun 13, 2021
		9439985	Sep 27, 2033	DS DP			
TECOVIRIMAT - TPOXX							
N 208627	001	7737168	May 03, 2027	U-2346		NCE	Jul 13, 2023
		8039504	Jul 23, 2027	DP		ODE-200	Jul 13, 2025
		8124643	Jun 18, 2024	DS DP			
		8530509	Jun 18, 2024	DP			
		8802714	Jun 18, 2024	U-2346			
		9339466	Mar 23, 2031	DS DP			
TEDIZOLID PHOSPHATE - SIVEXTRO							
N 205435	001	7816379	Feb 23, 2028	DS DP U-282		NCE	Jun 20, 2019
		8420676	Feb 23, 2028	DS DP U-282		GAIN	Jun 20, 2024
		8426389	Dec 31, 2030	DS DP U-282			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TEDIZOLID PHOSPHATE - SIVEXTRO							
N 205436	001	7816379	Feb 23, 2028	DS DP U-282		NCE	Jun 20, 2019
		8420676	Feb 23, 2028	DS DP U-282		GAIN	Jun 20, 2024
		8426389	Dec 31, 2030	DS DP U-282			
TEDUGLUTIDE RECOMBINANT - GATTEX KIT							
N 203441	001	5789379	Apr 14, 2020	DS DP U-1320		ODE-37	Dec 21, 2019
		7056886	Sep 18, 2022	DP U-1320			
		7847061	Nov 01, 2025	U-1320			
		9060992	Nov 01, 2025	U-1320			
		9539310	Nov 01, 2025	U-1320			
		9545434	Nov 01, 2025	U-1320			
		9545435	Nov 01, 2025	U-1320			
		9555079	Nov 01, 2025	U-1320			
		9572867	Nov 01, 2025	U-1320			
		9592273	Nov 01, 2025	U-1320			
		9592274	Nov 01, 2025	U-1320			
		9968655	Nov 01, 2025	U-2308			
		9968656	Nov 01, 2025	U-2308			
		9968658	Nov 01, 2025	U-1320			
		9974835	Nov 01, 2025	U-1320			
		9974837	Nov 01, 2025	U-1320			
		9981014	Nov 01, 2025	U-1320			
		9981016	Nov 01, 2025	U-1320			
		9987334	Nov 01, 2025	U-1320			
		9987335	Nov 01, 2025	U-1320			
		9993528	Nov 01, 2025	U-1320			
TELAPREVIR - INCIVEK							
N 201917	001	7820671	Feb 25, 2025	DS DP			
		8431615	May 30, 2028	U-1398			
		8529882	Aug 31, 2021	U-1398			
TELAVANCIN HYDROCHLORIDE - VIBATIV							
N 022110	001	6635618	Sep 11, 2023	DS DP U-728			
		6858584	Aug 24, 2022	DP			
		6872701	Jun 05, 2021	DP			
		7008923	May 06, 2021	U-1005			
		7208471	May 01, 2021	DS DP			
		7351691	May 01, 2021	DS DP U-728			
		7531623	Jan 01, 2027	DS			
		7544364	May 01, 2021	DP			
		7700550	May 01, 2021	U-282			
		8101575	May 01, 2021	DP			
		8158580	May 01, 2021	DP			
TELAVANCIN HYDROCHLORIDE - VIBATIV							
N 022110	002	6635618	Sep 11, 2023	DS DP U-728			
		6858584	Aug 24, 2022	DP			
		6872701	Jun 05, 2021	DP			
		7008923	May 06, 2021	U-1005			
		7208471	May 01, 2021	DS DP			
		7351691	May 01, 2021	DS DP U-728			
		7531623	Jan 01, 2027	DS			
		7544364	May 01, 2021	DP			
		7700550	May 01, 2021	U-282			
		8101575	May 01, 2021	DP			
		8158580	May 01, 2021	DP			
TELBIVUDINE - TYZEKA							
N 022011	001	6395716	Aug 10, 2019	U-782			
		6444652	Aug 10, 2019	U-782			
		6566344	Aug 10, 2019	U-782			
		6569837	Oct 25, 2020	U-782			
		6569837	Oct 25, 2020	U-999			
		7589079	Sep 11, 2023	DS DP U-999			
		7795238	Aug 10, 2019	U-999			
		7858594	Sep 11, 2023	DS DP U-999			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TELBIVUDINE - TYZEKA							
N 022154	001	6395716	Aug 10, 2019	U-999			
		6444652	Aug 10, 2019	U-999			
		6566344	Aug 10, 2019	U-999			
		6569837	Oct 25, 2020	U-999			
		7795238	Aug 10, 2019	U-999			
		7858594	Sep 11, 2023	DS DP U-999			
TELMISARTAN - MICARDIS							
N 020850	001	6358986	Jan 10, 2020				
TELMISARTAN - MICARDIS							
N 020850	002	6358986	Jan 10, 2020				
		7998953	Jun 06, 2020	U-1177			
		8003679	Oct 06, 2022	U-1176			
TELMISARTAN - MICARDIS							
N 020850	003	6358986	Jan 10, 2020				
TELOTRISTAT ETIPRATE - XERMELO							
N 208794	001	7553840	Dec 11, 2027	DS		NCE	Feb 28, 2022
		7709493	Dec 11, 2027	DS U-1979		ODE-132	Feb 28, 2024
		7968559	Dec 11, 2027	U-1979			
		8193204	Feb 27, 2031	DS			
		8653094	Dec 19, 2028	U-1979			
TEMOZOLOMIDE - TEMODAR							
N 022277	001	6987108	Sep 08, 2023	DP			
		7786118	Feb 21, 2023	DP			
		8623868	Feb 21, 2023	DP			
TEMSIROLIMUS - TORISEL							
N 022088	001	5362718	Feb 15, 2019	DS DP	Y		
		5362718*PED	Aug 15, 2019				
		8026276	Jan 20, 2026	DP			
		8299116	Jul 25, 2023	DP			
		8455539	Jul 25, 2023	DP			
		8455539*PED	Jan 25, 2024				
		8722700	Jul 25, 2023	DP			
		8722700*PED	Jan 25, 2024				
		8791097	May 10, 2032	U-1550			
		8791097	May 10, 2032	U-1551			
		8791097*PED	Nov 10, 2032				
		RE44768	Feb 15, 2019	DS DP			
		RE44768*PED	Aug 15, 2019				
TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY							
N 208464	001	7390791	May 07, 2022	DS DP		NCE	Nov 05, 2020
		7803788	Feb 02, 2022	U-999		NP	Nov 11, 2019
		8754065	Aug 15, 2032	DS DP U-999			
		9296769	Aug 15, 2032	DS DP U-999			
TENOFOVIR DISOPROXIL FUMARATE - VIREAD							
N 021356	001					NPP	Dec 11, 2021
						PED	Jun 11, 2022
TENOFOVIR DISOPROXIL FUMARATE - VIREAD							
N 021356	002					NPP	Dec 11, 2021
						PED	Jun 11, 2022
TENOFOVIR DISOPROXIL FUMARATE - VIREAD							
N 021356	003					NPP	Dec 11, 2021
						PED	Jun 11, 2022
TENOFOVIR DISOPROXIL FUMARATE - VIREAD							
N 021356	004					NPP	Dec 11, 2021
						PED	Jun 11, 2022

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TENOFOVIR DISOPROXIL FUMARATE - VIREAD							
N 022577	001					NPP	Dec 11, 2021
						PED	Jun 11, 2022
TERIFLUNOMIDE - AUBAGIO							
N 202992	001	6794410	Sep 12, 2026	U-1285			
		8802735	Sep 14, 2030	DP			
		9186346	Feb 04, 2034	U-1786			
TERIFLUNOMIDE - AUBAGIO							
N 202992	002	6794410	Sep 12, 2026	U-1285			
		8802735	Sep 14, 2030	DP			
		9186346	Feb 04, 2034	U-1786			
TERIPARATIDE RECOMBINANT HUMAN - FORTEO							
N 021318	001	6977077	Aug 19, 2019	U-597			
		7163684	Aug 19, 2019	U-790			
		7351414	Aug 19, 2019	U-865			
		7517334	Mar 25, 2025	DP			
TERIPARATIDE RECOMBINANT HUMAN - FORTEO							
N 021318	002	6977077	Aug 19, 2019	U-982			
		6977077	Aug 19, 2019	U-994			
		7163684	Aug 19, 2019	U-983			
		7163684	Aug 19, 2019	U-994			
		7351414	Aug 19, 2019	U-984			
		7351414	Aug 19, 2019	U-994			
		7517334	Mar 25, 2025	DP			
TESAMORELIN ACETATE - EGRIFTA							
N 022505	001	5861379	May 26, 2020	DS DP U-1100			
		7144577	Jul 14, 2020	U-1100			
		7316997	Aug 14, 2023	U-1100			
		8314066	Aug 14, 2023	U-1100			
		8435945	Aug 14, 2023	U-1100			
TESAMORELIN ACETATE - EGRIFTA							
N 022505	002	5861379	May 26, 2020	DS DP U-1100			
		7144577	Jul 14, 2020	U-1100			
		7316997	Aug 14, 2023	U-1100			
		8314066	Aug 14, 2023	U-1100			
		8435945	Aug 14, 2023	U-1100			
TESTOSTERONE - TESTOSTERONE							
A 204268	001					PC	Apr 10, 2019
TESTOSTERONE - TESTODERM TTS							
N 020791	001	6348210	Nov 10, 2019	U-440			
TESTOSTERONE - ANDROGEL							
N 021015	001	6503894	Aug 30, 2020	U-490			
		9125816	Aug 30, 2020	U-490			
		9125816*PED	Mar 02, 2021				
		9132089	Aug 30, 2020	U-490			
		9132089*PED	Mar 02, 2021				
TESTOSTERONE - ANDROGEL							
N 021015	002	6503894	Aug 30, 2020	U-490			
		9125816	Aug 30, 2020	U-490			
		9125816*PED	Mar 02, 2021				
		9132089	Aug 30, 2020	U-490			
		9132089*PED	Mar 02, 2021				
TESTOSTERONE - ANDROGEL							
N 021015	003	6503894	Aug 30, 2020	U-490			
		9125816	Aug 30, 2020	U-490			
		9125816*PED	Mar 02, 2021				
		9132089	Aug 30, 2020	U-490			
		9132089*PED	Mar 02, 2021				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TESTOSTERONE - TESTIM							
N 021454	001	7320968	Jan 18, 2025	U-843			
		7608605	Apr 21, 2023	U-1009			
		7608606	Apr 21, 2023	U-1009			
		7608607	Apr 21, 2023	U-1009			
		7608608	Apr 21, 2023	U-1009			
		7608609	Apr 21, 2023	U-1009			
		7608610	Apr 21, 2023	U-1009			
		7935690	Apr 21, 2023	U-1009			
		8063029	Apr 21, 2023	U-843			
		8178518	Apr 21, 2023	DP			
TESTOSTERONE - STRIANT							
N 021543	001	6248358	Aug 23, 2019	U-527			
TESTOSTERONE - ANDROGEL							
N 022309	001	6503894	Aug 30, 2020	U-1103			
		6503894*PED	Mar 02, 2021				
		8466136	Oct 12, 2026	DP			
		8466137	Oct 12, 2026	U-1103			
		8466138	Oct 12, 2026	U-1103			
		8486925	Oct 12, 2026	DP			
		8729057	Oct 12, 2026	DP			
		8741881	Oct 12, 2026	U-1103			
		8754070	Oct 12, 2026	DP			
		8759329	Oct 12, 2026	DP			
		9125816	Aug 30, 2020	U-1103			
		9125816*PED	Mar 02, 2021				
		9132089	Aug 30, 2020	U-1103			
		9132089*PED	Mar 02, 2021				
TESTOSTERONE - ANDROGEL							
N 022309	002	6503894	Aug 30, 2020	U-1103			
		6503894*PED	Mar 02, 2021				
		8466136	Oct 12, 2026	DP			
		8466137	Oct 12, 2026	U-1103			
		8466138	Oct 12, 2026	U-1103			
		8486925	Oct 12, 2026	DP			
		8729057	Oct 12, 2026	DP			
		8741881	Oct 12, 2026	U-1103			
		8754070	Oct 12, 2026	DP			
		8759329	Oct 12, 2026	DP			
		9125816	Aug 30, 2020	U-1103			
		9125816*PED	Mar 02, 2021				
		9132089	Aug 30, 2020	U-1103			
		9132089*PED	Mar 02, 2021				
TESTOSTERONE - ANDROGEL							
N 022309	003	6503894	Aug 30, 2020	U-1103			
		6503894*PED	Mar 02, 2021				
		8466136	Oct 12, 2026	DP			
		8466137	Oct 12, 2026	U-1103			
		8466138	Oct 12, 2026	U-1103			
		8486925	Oct 12, 2026	DP			
		8729057	Oct 12, 2026	DP			
		8741881	Oct 12, 2026	U-1103			
		8754070	Oct 12, 2026	DP			
		8759329	Oct 12, 2026	DP			
		9125816	Aug 30, 2020	U-1103			
		9125816*PED	Mar 02, 2021				
		9132089	Aug 30, 2020	U-1103			
		9132089*PED	Mar 02, 2021				
TESTOSTERONE - AXIRON							
N 022504	001	8419307	Feb 26, 2027	U-1386			
		8435944	Sep 27, 2027	U-1390			
		8784878	Jul 13, 2023	DP U-1545			
		8807861	Feb 26, 2027	DP U-1563			
		8993520	Jun 02, 2026	U-1390			
		9180194	Jun 02, 2026	U-1390			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TESTOSTERONE - AXIRON						
N 022504 001	9289586	Feb 26, 2027	U-1390			
TESTOSTERONE - VOGELXO						
N 204399 002	8785426	Feb 11, 2034	DP U-1531			
	9295675	Feb 11, 2034	DP U-1531			
	9662340	Feb 11, 2034	DP U-1531			
TESTOSTERONE - VOGELXO						
N 204399 003	8785426	Feb 11, 2034	DP U-1531			
	9295675	Feb 11, 2034	DP U-1531			
	9662340	Feb 11, 2034	DP U-1531			
TESTOSTERONE - NATESTO						
N 205488 001	8574622	Feb 04, 2024	DP			
	8784869	Feb 04, 2024	DP			
	8784882	Feb 04, 2024	DP U-1557			
	8877230	Feb 04, 2024	U-1616			
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)						
N 209863 001	8021335	Oct 04, 2026	DP		NP	Sep 28, 2021
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9744302	Nov 19, 2035	DP			
	9950125	Sep 04, 2036	DP U-2418			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-2419			
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)						
N 209863 002	8021335	Oct 04, 2026	DP		NP	Sep 28, 2021
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9744302	Nov 19, 2035	DP			
	9950125	Sep 04, 2036	DP U-2418			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-2419			
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)						
N 209863 003	8021335	Oct 04, 2026	DP		NP	Sep 28, 2021
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9744302	Nov 19, 2035	DP			
	9950125	Sep 04, 2036	DP U-2418			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-2419			
TESTOSTERONE UNDECANOATE - AVEED						
N 022219 001	7718640	Mar 14, 2027	DP			
	8338395	Feb 27, 2026	U-1500			
THALIDOMIDE - THALOMID						
N 020785 001	6315720	Oct 23, 2020	U-442			
	6315720	Oct 23, 2020	U-731			
	6561977	Oct 23, 2020	U-371			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-733			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-732			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
THALIDOMIDE - THALOMID						
N 020785 001	7141018	Oct 23, 2020	U-733			
	7230012	Dec 09, 2023	DP			
	7959566	Oct 23, 2020	U-1155			
	8315886	Oct 23, 2020	U-1249			
	8626531	Oct 23, 2020	U-1465			
THALIDOMIDE - THALOMID						
N 020785 002	6315720	Oct 23, 2020	U-442			
	6315720	Oct 23, 2020	U-731			
	6561977	Oct 23, 2020	U-371			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-733			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-732			
	7141018	Oct 23, 2020	U-733			
	7230012	Dec 09, 2023	DP			
	7959566	Oct 23, 2020	U-1155			
	8315886	Oct 23, 2020	U-1249			
	8626531	Oct 23, 2020	U-1465			
THALIDOMIDE - THALOMID						
N 020785 003	6315720	Oct 23, 2020	U-442			
	6315720	Oct 23, 2020	U-731			
	6561977	Oct 23, 2020	U-371			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-733			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-732			
	7141018	Oct 23, 2020	U-733			
	7230012	Dec 09, 2023	DP			
	7959566	Oct 23, 2020	U-1155			
	8315886	Oct 23, 2020	U-1249			
	8626531	Oct 23, 2020	U-1465			
THALIDOMIDE - THALOMID						
N 020785 004	6315720	Oct 23, 2020	U-731			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-731			
	7959566	Oct 23, 2020	U-1155			
	8315886	Oct 23, 2020	U-1249			
	8626531	Oct 23, 2020	U-1465			
THIOTEPA - TEPADINA						
N 208264 001					I-747	Jan 26, 2020
					ODE-129	Jan 26, 2024
THIOTEPA - TEPADINA						
N 208264 002					I-747	Jan 26, 2020
					ODE-129	Jan 26, 2024
TICAGRELOR - BRILINTA						
N 022433 001	6525060	Dec 02, 2019	DS DP U-1171	Y		
	6525060	Dec 02, 2019	DS DP U-1860	Y		
	6525060	Dec 02, 2019	DS DP U-1862	Y		
	6525060	Dec 02, 2019	DS DP U-1863	Y		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TICAGRELOR - BRILINTA							
N 022433	001	7250419	Dec 02, 2019	DS DP U-1171			
		7250419	Dec 02, 2019	DS DP U-1860			
		7250419	Dec 02, 2019	DS DP U-1864			
		7250419	Dec 02, 2019	DS DP U-1865			
		7250419	Dec 02, 2019	DS DP U-1866			
		7250419	Dec 02, 2019	DS DP U-1867			
		7265124	Jul 09, 2021	DS DP U-1171			
		7265124	Jul 09, 2021	DS DP U-1860			
		7265124	Jul 09, 2021	DS DP U-1868			
		7265124	Jul 09, 2021	DS DP U-1869			
		8425934	Apr 17, 2030	DP			
		RE46276	Oct 30, 2024	DS DP U-1935			
		RE46276	Oct 30, 2024	DS DP U-1936			
		RE46276	Oct 30, 2024	DS DP U-1937			
		RE46276	Oct 30, 2024	DS DP U-1938			
TICAGRELOR - BRILINTA							
N 022433	002	6525060	Dec 02, 2019	DS DP U-1171	Y		
		6525060	Dec 02, 2019	DS DP U-1860	Y		
		6525060	Dec 02, 2019	DS DP U-1862	Y		
		6525060	Dec 02, 2019	DS DP U-1863	Y		
		7250419	Dec 02, 2019	DS DP U-1171			
		7250419	Dec 02, 2019	DS DP U-1860			
		7250419	Dec 02, 2019	DS DP U-1864			
		7250419	Dec 02, 2019	DS DP U-1865			
		7250419	Dec 02, 2019	DS DP U-1866			
		7250419	Dec 02, 2019	DS DP U-1867			
		7265124	Jul 09, 2021	DS DP U-1171			
		7265124	Jul 09, 2021	DS DP U-1860			
		7265124	Jul 09, 2021	DS DP U-1868			
		7265124	Jul 09, 2021	DS DP U-1869			
		8425934	Apr 17, 2030	DP			
		RE46276	Oct 30, 2024	DS DP U-1935			
		RE46276	Oct 30, 2024	DS DP U-1936			
		RE46276	Oct 30, 2024	DS DP U-1937			
		RE46276	Oct 30, 2024	DS DP U-1938			
TIGECYCLINE - TYGACIL							
N 021821	001	7879828	Feb 05, 2029	DP			
		8372995	Oct 08, 2030	DP			
		8975242	Oct 24, 2028	DP			
		9254328	Mar 13, 2026	DP			
		9694078	Mar 13, 2026	DP			
TIGECYCLINE - TIGECYCLINE							
N 211158	001	9855335	Apr 07, 2033	DP			
TIMOLOL MALEATE - TIMOLOL MALEATE							
N 020963	001	6174524	Mar 26, 2019	DP			
TIMOLOL MALEATE - TIMOLOL MALEATE							
N 020963	002	6174524	Mar 26, 2019	DP			
TIOTROPIUM BROMIDE - SPIRIVA							
N 021395	001	6777423	Sep 24, 2021	DS DP			
		6777423*PED	Mar 24, 2022				
		6908928	Sep 24, 2021	DS DP U-566			
		6908928	Sep 24, 2021	DS DP U-762			
		6908928*PED	Mar 24, 2022				
		7070800	Jan 22, 2022	DP U-566			
		7070800*PED	Jul 22, 2022				
		7309707	Sep 24, 2021	DS DP			
		7309707*PED	Mar 24, 2022				
		7642268	Sep 24, 2021	DS DP			
		7642268*PED	Mar 24, 2022				
		7694676	Mar 12, 2027	DP			
		7694676*PED	Sep 12, 2027				
		8022082	Jan 19, 2026	DP U-1186			
		8022082*PED	Jul 19, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIOTROPIUM BROMIDE - SPIRIVA							
N 021395	001	9010323	Apr 19, 2030	DP			
		RE38912	Oct 11, 2021	DP			
		RE38912*PED	Apr 11, 2022				
TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT							
N 021936	001	6846413*PED	Feb 28, 2019			NPP	Feb 15, 2020
		6977042*PED	Feb 28, 2019			PED	Aug 15, 2020
		6988496	Feb 23, 2020	DP			
		6988496*PED	Aug 23, 2020				
		7284474	Aug 26, 2024	DP			
		7284474*PED	Feb 26, 2025				
		7396341	Oct 10, 2026	DP			
		7396341*PED	Apr 10, 2027				
		7802568	Feb 26, 2019	DP			
		7802568*PED	Aug 26, 2019				
		7837235	Mar 13, 2028	DP			
		7837235*PED	Sep 13, 2028				
		7896264	May 26, 2025	DP			
		7896264*PED	Nov 26, 2025				
		7988001	Aug 04, 2021	DP			
		7988001*PED	Feb 04, 2022				
		8733341	Oct 16, 2030	DP			
		8733341*PED	Apr 16, 2031				
		9027967	Mar 31, 2027	DP			
		9027967*PED	Oct 01, 2027				
TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT							
N 021936	002	6846413*PED	Feb 28, 2019			NPP	Feb 15, 2020
		6977042*PED	Feb 28, 2019			PED	Aug 15, 2020
		6988496	Feb 23, 2020	DP			
		6988496*PED	Aug 23, 2020				
		7284474	Aug 26, 2024	DP			
		7284474*PED	Feb 26, 2025				
		7396341	Oct 10, 2026	DP			
		7396341*PED	Apr 10, 2027				
		7802568	Feb 26, 2019	DP			
		7802568*PED	Aug 26, 2019				
		7837235	Mar 13, 2028	DP			
		7837235*PED	Sep 13, 2028				
		7896264	May 26, 2025	DP			
		7896264*PED	Nov 26, 2025				
		7988001	Aug 04, 2021	DP			
		7988001*PED	Feb 04, 2022				
		8733341	Oct 16, 2030	DP			
		8733341*PED	Apr 16, 2031				
		9027967	Mar 31, 2027	DP			
		9027967*PED	Oct 01, 2027				
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF							
N 207981	001	6479500	Mar 16, 2020	U-1751		NCE	Sep 22, 2020
		9527833	Jun 17, 2034	DS DP			
		RE46284	Dec 16, 2026	U-1751			
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF							
N 207981	002	6479500	Mar 16, 2020	U-1751		NCE	Sep 22, 2020
		9527833	Jun 17, 2034	DS DP			
		RE46284	Dec 16, 2026	U-1751			
TIPRANAVIR - APTIVUS							
N 021814	001	5852195	Jun 22, 2019	DS			
		6147095	Oct 29, 2019	U-670			
TIPRANAVIR - APTIVUS							
N 022292	001	5852195	Jun 22, 2019	DS			
		6147095	Oct 29, 2019	U-670			
TIROFIBAN HYDROCHLORIDE - AGGRASTAT							
N 020912	001	6136794	Jan 29, 2019				
		6770660	May 01, 2023	U-1444			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIROFIBAN HYDROCHLORIDE - AGGRASTAT								
N 020912	001	6136794	Jan 29, 2019					
		6770660	May 01, 2023		U-1444			
TIROFIBAN HYDROCHLORIDE - AGGRASTAT								
N 020912	002	6136794	Jan 29, 2019		U-1898			
		6770660	May 01, 2023		U-1444			
TIROFIBAN HYDROCHLORIDE - AGGRASTAT								
N 020913	001	6136794	Jan 29, 2019					
		6770660	May 01, 2023		U-1444			
TIROFIBAN HYDROCHLORIDE - AGGRASTAT								
N 020913	002	6136794	Jan 29, 2019					
		6770660	May 01, 2023		U-1444			
TIROFIBAN HYDROCHLORIDE - AGGRASTAT								
N 020913	003	6136794	Jan 29, 2019					
		6770660	May 01, 2023		U-1444			
TOBRAMYCIN - TOBI PODHALER								
N 201688	001	7368102	Dec 19, 2022		DP U-909			
		7442388	May 10, 2020		DP			
		7516741	Jan 11, 2024		DP			
		7559325	Oct 27, 2025		DP			
		8069851	Sep 24, 2024		DP			
		8349294	May 10, 2020		DP			
		8715623	Dec 19, 2022		DP U-909			
TOBRAMYCIN - BETHKIS								
N 201820	001	6987094	Sep 22, 2022		DP			
		7696178	Sep 22, 2022		DP			
		7939502	Jun 14, 2022		U-1324			
TOFACITINIB CITRATE - XELJANZ								
N 203214	001	6956041	Dec 08, 2020		DP		I-761	Dec 14, 2020
		6965027	Mar 25, 2023	DS			I-780	May 30, 2021
		7091208	Dec 08, 2020		U-247			
		7265221	Dec 08, 2020	DS				
		7301023	May 23, 2022	DS				
		7842699	Dec 08, 2020		U-2322			
		RE41783	Dec 08, 2025	DS				
TOFACITINIB CITRATE - XELJANZ								
N 203214	002	6956041	Dec 08, 2020		DP		I-780	May 30, 2021
		6965027	Mar 25, 2023	DS				
		7265221	Dec 08, 2020	DS				
		7301023	May 23, 2022	DS				
		7842699	Dec 08, 2020		U-2322			
		RE41783	Dec 08, 2025	DS				
TOFACITINIB CITRATE - XELJANZ XR								
N 208246	001	6956041	Dec 08, 2020		DP		I-761	Dec 14, 2020
		6965027	Mar 25, 2023	DS				
		7091208	Dec 08, 2020		U-247			
		7265221	Dec 08, 2020	DS				
		7301023	May 23, 2022	DS				
		9937181	Mar 14, 2034		DP			
		RE41783	Dec 08, 2025	DS				
TOLTERODINE TARTRATE - DETROL LA								
N 021228	001	6630162	Nov 11, 2019		DP U-544			
		6770295	Aug 26, 2019		DP U-544			
		6911217	Nov 11, 2019		DP U-544			
		6911217*PED	May 11, 2020					
TOLTERODINE TARTRATE - DETROL LA								
N 021228	002	6630162	Nov 11, 2019		DP U-544			
		6770295	Aug 26, 2019		DP U-544			
		6911217	Nov 11, 2019		DP U-544			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOLTERODINE TARTRATE - DETROL LA							
N 021228	002	6911217*PED	May 11, 2020				
TOLVAPTAN - SAMSCA							
N 022275	001	5753677	May 19, 2020	U-978			
		8501730	Sep 01, 2026	DS			
TOLVAPTAN - SAMSCA							
N 022275	002	5753677	May 19, 2020	U-978			
		8501730	Sep 01, 2026	DS			
TOLVAPTAN - SAMSCA							
N 022275	003	5753677	May 19, 2020	U-978			
		8501730	Sep 01, 2026	DS			
TOLVAPTAN - JYNARQUE							
N 204441	001	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
		8501730	Sep 01, 2026	DS		ODE-178	Apr 23, 2025
TOLVAPTAN - JYNARQUE							
N 204441	002	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
		8501730	Sep 01, 2026	DS		ODE-178	Apr 23, 2025
TOLVAPTAN - JYNARQUE							
N 204441	003	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
		8501730	Sep 01, 2026	DS		ODE-178	Apr 23, 2025
TOLVAPTAN - JYNARQUE							
N 204441	004	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
		8501730	Sep 01, 2026	DS		ODE-178	Apr 23, 2025
TOLVAPTAN - JYNARQUE							
N 204441	005	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
		8501730	Sep 01, 2026	DS		ODE-178	Apr 23, 2025
TOPIRAMATE - TOPAMAX							
N 020844	001	7125560	Mar 01, 2019	U-766			
TOPIRAMATE - TOPAMAX							
N 020844	002	7125560	Mar 01, 2019	U-766			
TOPIRAMATE - TOPAMAX SPRINKLE							
N 020844	003	7125560	Mar 01, 2019	U-766			
TOPIRAMATE - TROKENDI XR							
N 201635	001	8298576	Apr 04, 2028	DP U-106			
		8298576	Apr 04, 2028	DP U-1992			
		8298580	Nov 16, 2027	DP U-106			
		8298580	Nov 16, 2027	DP U-1992			
		8663683	Nov 16, 2027	DP U-106			
		8663683	Nov 16, 2027	DP U-1992			
		8877248	Nov 16, 2027	DP U-106			
		8877248	Nov 16, 2027	DP U-1992			
		8889191	Nov 16, 2027	U-106			
		8889191	Nov 16, 2027	U-1992			
		8992989	Nov 16, 2027	DP U-1675			
		8992989	Nov 16, 2027	DP U-1992			
		9549940	Nov 16, 2027	DP U-1675			
		9549940	Nov 16, 2027	DP U-1992			
		9555004	Nov 16, 2027	DP U-1675			
		9555004	Nov 16, 2027	DP U-1992			
		9622983	Nov 16, 2027	DP U-1675			
		9622983	Nov 16, 2027	DP U-1992			
TOPIRAMATE - TROKENDI XR							
N 201635	002	8298576	Apr 04, 2028	DP U-106			
		8298576	Apr 04, 2028	DP U-1992			
		8298580	Nov 16, 2027	DP U-106			
		8298580	Nov 16, 2027	DP U-1992			
		8663683	Nov 16, 2027	DP U-106			
		8663683	Nov 16, 2027	DP U-1992			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOPIRAMATE - TROKENDI XR						
N 201635 002	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
TOPIRAMATE - TROKENDI XR						
N 201635 003	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
TOPIRAMATE - TROKENDI XR						
N 201635 004	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
TOPIRAMATE - QUDEXY XR						
N 205122 001	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 002	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 003	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOPIRAMATE - QUDEXY XR								
N 205122	003		9555005	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR								
N 205122	004		8652527	Mar 19, 2033	DP			
			8889190	Mar 19, 2033	DP			
			9101545	Mar 19, 2033	DP			
			9555005	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR								
N 205122	005		8652527	Mar 19, 2033	DP			
			8889190	Mar 19, 2033	DP			
			9101545	Mar 19, 2033	DP			
			9555005	Mar 19, 2033	DP			
TOPOTECAN HYDROCHLORIDE - HYCAMTIN								
N 020981	001		8158645	Dec 10, 2024	DP			
TOPOTECAN HYDROCHLORIDE - HYCAMTIN								
N 020981	002		8158645	Dec 10, 2024	DP			
TRABECTEDIN - YONDELIS								
N 207953	001		8895557	Jan 07, 2028	DP		M-232	Jun 29, 2021
			8895557*PED	Jul 07, 2028			NCE	Oct 23, 2020
							ODE-100	Oct 23, 2022
							PED	Apr 23, 2021
							PED	Dec 29, 2021
							PED	Apr 23, 2023
TRAMADOL HYDROCHLORIDE - ULTRAM								
N 020281	001		6339105	Oct 12, 2019	U-435			
TRAMADOL HYDROCHLORIDE - ULTRAM								
N 020281	002		6339105	Oct 12, 2019	U-435			
TRAMADOL HYDROCHLORIDE - RYZOLT								
N 021745	001		6607748	Jun 29, 2020	DP			
			7988998	Oct 27, 2023	DP			
TRAMADOL HYDROCHLORIDE - RYZOLT								
N 021745	002		6607748	Jun 29, 2020	DP			
			7988998	Oct 27, 2023	DP			
TRAMADOL HYDROCHLORIDE - RYZOLT								
N 021745	003		6607748	Jun 29, 2020	DP			
			7988998	Oct 27, 2023	DP			
TRAMADOL HYDROCHLORIDE - CONZIP								
N 022370	001		7858118	Apr 11, 2022	DP U-1104			
TRAMADOL HYDROCHLORIDE - CONZIP								
N 022370	002		7858118	Apr 11, 2022	DP U-1104			
TRAMADOL HYDROCHLORIDE - CONZIP								
N 022370	003		7858118	Apr 11, 2022	DP U-1104			
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST								
N 204114	001		7378423	May 29, 2027	DS DP		I-745	Jun 22, 2020
			8580304	Jan 28, 2032	DP		I-778	Apr 30, 2021
			8703781	Oct 15, 2030	DS DP U-1712		I-781	May 04, 2021
			8703781	Oct 15, 2030	DS DP U-2033		ODE-148	Jun 22, 2024
			8835443	Jun 10, 2025	U-1581		ODE-182	Apr 30, 2025
			8835443	Jun 10, 2025	U-1582		ODE-183	May 04, 2025
			8835443	Jun 10, 2025	U-2020		ODE-48	May 29, 2020
			8835443	Jun 10, 2025	U-2037		ODE-57	Jan 08, 2021
			8835443	Jun 10, 2025	U-2302			
			8835443	Jun 10, 2025	U-2305			
			8952018	Oct 15, 2030	U-2020			
			9155706	Jan 28, 2032	DP			
			9271941	Jan 28, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST							
N 204114	002	7378423	May 29, 2027	DS DP		I-745	Jun 22, 2020
		8580304	Jan 28, 2032	DP		I-778	Apr 30, 2021
		8703781	Oct 15, 2030	DS DP U-1712		I-781	May 04, 2021
		8703781	Oct 15, 2030	DS DP U-2033		ODE-148	Jun 22, 2024
		8835443	Jun 10, 2025	U-1581		ODE-182	Apr 30, 2025
		8835443	Jun 10, 2025	U-1582		ODE-183	May 04, 2025
		8835443	Jun 10, 2025	U-2020		ODE-48	May 29, 2020
		8835443	Jun 10, 2025	U-2037		ODE-57	Jan 08, 2021
		8835443	Jun 10, 2025	U-2302			
		8835443	Jun 10, 2025	U-2305			
		8952018	Oct 15, 2030	U-2020			
		9155706	Jan 28, 2032	DP			
		9271941	Jan 28, 2032	DP			
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST							
N 204114	003	7378423	May 29, 2027	DS DP		I-745	Jun 22, 2020
		8580304	Jan 28, 2032	DP		I-778	Apr 30, 2021
		8703781	Oct 15, 2030	DS DP U-1712		I-781	May 04, 2021
		8703781	Oct 15, 2030	DS DP U-2033		ODE-148	Jun 22, 2024
		8835443	Jun 10, 2025	U-1581		ODE-182	Apr 30, 2025
		8835443	Jun 10, 2025	U-1582		ODE-183	May 04, 2025
		8835443	Jun 10, 2025	U-2020		ODE-48	May 29, 2020
		8835443	Jun 10, 2025	U-2037		ODE-57	Jan 08, 2021
		8835443	Jun 10, 2025	U-2302			
		8835443	Jun 10, 2025	U-2305			
		8952018	Oct 15, 2030	U-2020			
		9155706	Jan 28, 2032	DP			
		9271941	Jan 28, 2032	DP			
TRANEXAMIC ACID - LYSTEDA							
N 022430	001	7947739	Mar 04, 2025	DP			
		8022106	Mar 04, 2025	U-1182			
		8273795	Mar 04, 2025	U-1182			
		8487005	Mar 04, 2025	DP U-1182			
		8791160	Mar 04, 2025	DP U-1182			
		8809394	Mar 04, 2025	DP U-1182			
		8957113	Mar 04, 2025	DP U-1182			
		9060939	Mar 04, 2025	DP			
TRAVOPROST - TRAVATAN Z							
N 021994	001	8268299	Oct 13, 2029	DP			
		8323630	Sep 20, 2027	DP			
		8388941	Sep 20, 2027	DP			
TRAVOPROST - IZBA							
N 204822	001	8178582	Oct 10, 2029	DP			
		8722735	Oct 10, 2029	DP			
		8754123	May 19, 2029	DP			
		9144561	Mar 13, 2029	DP			
TRAZODONE HYDROCHLORIDE - DESYREL							
N 018207	001	8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - DESYREL							
N 018207	002	8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - DESYREL							
N 018207	003	8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - DESYREL							
N 018207	004	8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - OLEPTRO							
N 022411	001	6607748	Jun 29, 2020	DP			
		7829120	Mar 27, 2027	DP U-796			
		8133893	Mar 13, 2029	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TRAZODONE HYDROCHLORIDE - OLEPTRO								
N 022411	002	6607748	Jun 29, 2020		DP			
		7829120	Mar 27, 2027		DP U-796			
		8133893	Mar 13, 2029	DS	DP			
TREPROSTINIL - REMODULIN								
N 021272	001	10076505	Dec 16, 2024		DP			
		7999007	Mar 29, 2029		DP U-1437			
		8653137	Sep 05, 2028		U-1437			
		8658694	Sep 05, 2028		U-1437			
		9199908	May 24, 2024		U-1771			
		9593066	Dec 15, 2028	DS				
		9604901	Dec 15, 2028	DS				
		9713599	Dec 16, 2024		U-2036			
TREPROSTINIL - REMODULIN								
N 021272	002	10076505	Dec 16, 2024		DP			
		7999007	Mar 29, 2029		DP U-1437			
		8653137	Sep 05, 2028		U-1437			
		8658694	Sep 05, 2028		U-1437			
		9199908	May 24, 2024		U-1771			
		9593066	Dec 15, 2028	DS				
		9604901	Dec 15, 2028	DS				
		9713599	Dec 16, 2024		U-2036			
TREPROSTINIL - REMODULIN								
N 021272	003	10076505	Dec 16, 2024		DP			
		7999007	Mar 29, 2029		DP U-1437			
		8653137	Sep 05, 2028		U-1437			
		8658694	Sep 05, 2028		U-1437			
		9199908	May 24, 2024		U-1771			
		9593066	Dec 15, 2028	DS				
		9604901	Dec 15, 2028	DS				
		9713599	Dec 16, 2024		U-2036			
TREPROSTINIL - REMODULIN								
N 021272	004	10076505	Dec 16, 2024		DP			
		7999007	Mar 29, 2029		DP U-1437			
		8653137	Sep 05, 2028		U-1437			
		8658694	Sep 05, 2028		U-1437			
		9199908	May 24, 2024		U-1771			
		9593066	Dec 15, 2028	DS				
		9604901	Dec 15, 2028	DS				
		9713599	Dec 16, 2024		U-2036			
TREPROSTINIL - TYVASO								
N 022387	001	8497393	Dec 15, 2028	DS		Y		
		9339507	Mar 10, 2028		DP			
		9358240	May 05, 2028		U-1849			
		9593066	Dec 15, 2028	DS				
		9604901	Dec 15, 2028	DS				
TREPROSTINIL - REMODULIN								
N 208276	001	10076505	Dec 16, 2024		DP			
		9593066	Dec 15, 2028	DS				
		9604901	Dec 15, 2028	DS				
		9713599	Dec 16, 2024		U-2036			
TREPROSTINIL - REMODULIN								
N 208276	002	10076505	Dec 16, 2024		DP			
		9593066	Dec 15, 2028	DS				
		9604901	Dec 15, 2028	DS				
		9713599	Dec 16, 2024		U-2036			
TREPROSTINIL - REMODULIN								
N 208276	003	10076505	Dec 16, 2024		DP			
		9593066	Dec 15, 2028	DS				
		9604901	Dec 15, 2028	DS				
		9713599	Dec 16, 2024		U-2036			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL - REMODULIN							
N 208276	004	10076505	Dec 16, 2024	DP			
		9593066	Dec 15, 2028	DS			
		9604901	Dec 15, 2028	DS			
		9713599	Dec 16, 2024	U-2036			
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496	001	7417070	Jul 30, 2026	DS		D-156	Jan 28, 2019
		7544713	Jul 14, 2024	U-1475		D-157	Jan 28, 2019
		8252839	May 24, 2024	DP			
		8349892	Jan 22, 2031	DP			
		8410169	Feb 13, 2030	DP			
		8747897	Oct 08, 2029	DP			
		9050311	May 24, 2024	DS DP			
		9278901	May 24, 2024	U-1475			
		9393203	Apr 27, 2026	DP U-1877			
		9422223	May 24, 2024	DP			
		9593066	Dec 15, 2028	DS			
		9604901	Dec 15, 2028	DS			
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496	002	7417070	Jul 30, 2026	DS		D-156	Jan 28, 2019
		7544713	Jul 14, 2024	U-1475		D-157	Jan 28, 2019
		8252839	May 24, 2024	DP			
		8349892	Jan 22, 2031	DP			
		8410169	Feb 13, 2030	DP			
		8497393	Dec 15, 2028	DS	Y		
		8747897	Oct 08, 2029	DP			
		9050311	May 24, 2024	DS DP			
		9278901	May 24, 2024	U-1475			
		9393203	Apr 27, 2026	DP U-1877			
		9422223	May 24, 2024	DP			
		9593066	Dec 15, 2028	DS			
		9604901	Dec 15, 2028	DS			
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496	003	7417070	Jul 30, 2026	DS		D-156	Jan 28, 2019
		7544713	Jul 14, 2024	U-1475		D-157	Jan 28, 2019
		8252839	May 24, 2024	DP			
		8349892	Jan 22, 2031	DP			
		8410169	Feb 13, 2030	DP			
		8497393	Dec 15, 2028	DS	Y		
		8747897	Oct 08, 2029	DP			
		9050311	May 24, 2024	DS DP			
		9278901	May 24, 2024	U-1475			
		9393203	Apr 27, 2026	DP U-1877			
		9422223	May 24, 2024	DP			
		9593066	Dec 15, 2028	DS			
		9604901	Dec 15, 2028	DS			
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496	004	7417070	Jul 30, 2026	DS		D-156	Jan 28, 2019
		7544713	Jul 14, 2024	U-1475		D-157	Jan 28, 2019
		8252839	May 24, 2024	DP			
		8349892	Jan 22, 2031	DP			
		8410169	Feb 13, 2030	DP			
		8497393	Dec 15, 2028	DS	Y		
		8747897	Oct 08, 2029	DP			
		9050311	May 24, 2024	DS DP			
		9278901	May 24, 2024	U-1475			
		9393203	Apr 27, 2026	DP U-1877			
		9422223	May 24, 2024	DP			
		9593066	Dec 15, 2028	DS			
		9604901	Dec 15, 2028	DS			
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496	005	7417070	Jul 30, 2026	DS		D-156	Jan 28, 2019
		7544713	Jul 14, 2024	U-1475		D-157	Jan 28, 2019
		8252839	May 24, 2024	DP			
		8349892	Jan 22, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496	005	8410169	Feb 13, 2030	DP			
		8747897	Oct 08, 2029	DP			
		9050311	May 24, 2024	DS DP			
		9278901	May 24, 2024	U-1475			
		9393203	Apr 27, 2026	DP U-1877			
		9422223	May 24, 2024	DP			
		9593066	Dec 15, 2028	DS			
		9604901	Dec 15, 2028	DS			
TRETINOIN - RENOVA							
N 021108	001	6531141	Mar 07, 2020				
TRETINOIN - ALTRENO							
N 209353	001					NDF	Aug 23, 2021
TRIAMCINOLONE ACETONIDE - TRIESENCE							
N 022048	001	6395294	Jan 13, 2020	DP U-846			
		8128960	Dec 17, 2029	DP			
		8211880	Mar 10, 2029	U-1257			
		8211880	Mar 10, 2029	U-1258			
TRIAMCINOLONE ACETONIDE - ZILRETTA							
N 208845	001	8828440	Aug 04, 2031	DP		NP	Oct 06, 2020
		9555048	Aug 04, 2031	U-2151			
TRIPTORELIN PAMOATE - TRIPTODUR KIT							
N 208956	001					NP	Jun 29, 2020
						ODE-149	Jun 29, 2024
TROSPIUM CHLORIDE - SANCTURA XR							
N 022103	001	7410978	Feb 01, 2025	DP	Y		
		7759359	Nov 04, 2024	U-1071	Y		
		7763635	Nov 04, 2024	U-1071	Y		
		7781448	Nov 04, 2024	U-1071	Y		
		7781449	Nov 04, 2024	U-1071	Y		
TRYPAN BLUE - VISIONBLUE							
N 021670	001	6367480	Oct 26, 2019	U-2321			
		6720314	May 07, 2019	U-2321			
TRYPAN BLUE - MEMBRANEBLUE							
N 022278	001	6372449	Nov 12, 2019	U-2379			
		6696430	May 07, 2019	U-2377			
ULIPRISTAL ACETATE - ELLA							
N 022474	001	8426392	Jun 12, 2030	U-1389			
		8512745	Jun 02, 2030	DP			
		8735380	Feb 20, 2029	DP			
		8962603	Jun 12, 2030	U-1657			
		9283233	Apr 13, 2030	U-1821			
UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA							
N 205382	001	7488827	Dec 18, 2027	DS DP		M-172	Feb 24, 2019
		7498440	Apr 27, 2025	DS DP			
		8113199	Oct 23, 2027	DP			
		8161968	Feb 05, 2028	DP			
		8183257	Jul 27, 2025	U-1476			
		8201556	Feb 05, 2029	DP			
		8309572	Apr 27, 2025	U-1476			
		8534281	Mar 08, 2030	DP			
		8746242	Oct 11, 2030	DP			
		9333310	Oct 02, 2027	DP			
UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA							
N 203975	001	7439393	May 21, 2025	DS DP U-1476			
		7488827	Dec 18, 2027	DS DP			
		7498440	Apr 27, 2025	DS DP			
		7776895	Sep 11, 2022	DP			
		8113199	Oct 23, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA							
N 203975	001	8161968	Feb 05, 2028	DP			
		8183257	Jul 27, 2025	U-1476			
		8309572	Apr 27, 2025	U-1476			
		8511304	Jun 14, 2027	DP U-1476			
		8534281	Mar 08, 2030	DP			
		8746242	Oct 11, 2030	DP			
		9333310	Oct 02, 2027	DP			
		9750726	Nov 29, 2030	DP			
		RE44874	Mar 23, 2023	DS DP U-1476			
UNOPROSTONE ISOPROPYL - RESCULA							
N 021214	001	6458836	Jul 09, 2021	U-1315			
		6458836	Jul 09, 2021	U-333			
URIDINE TRIACETATE - VISTOGARD							
N 208159	001	6258795	Jul 10, 2019	DP		NCE	Sep 04, 2020
		7776838	Aug 17, 2027	U-1791		ODE-104	Dec 11, 2022
URIDINE TRIACETATE - XURIDEN							
N 208169	001	6258795	Jul 10, 2019	DP		NCE	Sep 04, 2020
						ODE-98	Sep 04, 2022
VALBENAZINE TOSYLATE - INGREZZA							
N 209241	001	10065952	Oct 28, 2036	DS DP U-1995		NCE	Apr 11, 2022
		8039627	Oct 06, 2029	DS DP			
		8357697	Nov 08, 2027	U-1995			
VALBENAZINE TOSYLATE - INGREZZA							
N 209241	002	10065952	Oct 28, 2036	DS DP U-1995		NCE	Apr 11, 2022
		8039627	Oct 06, 2029	DS DP			
		8357697	Nov 08, 2027	U-1995			
VALGANCICLOVIR HYDROCHLORIDE - VALCYTE							
N 022257	001	8889109	Dec 11, 2027	DP			
		9642911	Dec 11, 2027	DP			
VANDETANIB - CAPRELSA							
N 022405	001	7173038	Aug 14, 2021	DS DP			
		8067427	Aug 08, 2028	DP			
		8642608	Feb 06, 2022	U-1490			
		RE42353	Jun 27, 2022	DS DP			
VANDETANIB - CAPRELSA							
N 022405	002	7173038	Aug 14, 2021	DS DP			
		8067427	Aug 08, 2028	DP			
		8642608	Feb 06, 2022	U-1490			
		RE42353	Jun 27, 2022	DS DP			
VARDENAFIL HYDROCHLORIDE - LEVITRA							
N 021400	001	8273876	Jul 23, 2027	U-1288			
		8841446	Jul 03, 2023	DP			
VARDENAFIL HYDROCHLORIDE - LEVITRA							
N 021400	002	8273876	Jul 23, 2027	U-1288			
		8841446	Jul 03, 2023	DP			
VARDENAFIL HYDROCHLORIDE - LEVITRA							
N 021400	003	8273876	Jul 23, 2027	U-1288			
		8841446	Jul 03, 2023	DP			
VARDENAFIL HYDROCHLORIDE - LEVITRA							
N 021400	004	8273876	Jul 23, 2027	U-1288			
		8841446	Jul 03, 2023	DP			
VARDENAFIL HYDROCHLORIDE - STAXYN							
N 200179	001	8613950	Dec 23, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VARENICLINE TARTRATE - CHANTIX						
N 021928 001	6410550	May 10, 2020	DS DP U-56		M-183	Aug 12, 2019
	6410550*PED	Nov 10, 2020			M-192	Dec 16, 2019
	6890927	May 06, 2022	DS DP U-56		PED	Feb 12, 2020
	6890927*PED	Nov 06, 2022			PED	Jun 16, 2020
	7265119	Aug 03, 2022	DS DP U-56			
	7265119*PED	Feb 03, 2023				
VARENICLINE TARTRATE - CHANTIX						
N 021928 002	6410550	May 10, 2020	DS DP U-56		M-183	Aug 12, 2019
	6410550*PED	Nov 10, 2020			M-192	Dec 16, 2019
	6890927	May 06, 2022	DS DP U-56		PED	Feb 12, 2020
	6890927*PED	Nov 06, 2022			PED	Jun 16, 2020
	7265119	Aug 03, 2022	DS DP U-56			
	7265119*PED	Feb 03, 2023				
VASOPRESSIN - VASOSTRICT						
N 204485 001	9375478	Jan 30, 2035	U-1857			
	9687526	Jan 30, 2035	U-1857			
	9744209	Jan 30, 2035	U-1857			
	9744239	Jan 30, 2035	U-1857			
	9750785	Jan 30, 2035	DP			
VASOPRESSIN - VASOSTRICT						
N 204485 002	9375478	Jan 30, 2035	U-1857			
	9687526	Jan 30, 2035	U-1857			
	9744209	Jan 30, 2035	U-1857			
	9744239	Jan 30, 2035	U-1857			
	9750785	Jan 30, 2035	DP			
	9937223	Jan 30, 2035	U-1857			
VEMURAFENIB - ZELBORAF						
N 202429 001	7504509	Oct 22, 2026	DS DP		I-757	Nov 06, 2020
	7863288	Jun 20, 2029	DS DP		M-184	Aug 31, 2019
	8143271	Jun 21, 2026	DS DP		ODE-158	Nov 06, 2024
	8470818	Aug 02, 2026	U-1418			
	8470818	Aug 02, 2026	U-2164			
	8741920	Jul 27, 2030	DS DP			
	9447089	Jun 06, 2032	DP			
VENETOCLAX - VENCLEXTA						
N 208573 001	8546399	Jun 27, 2031	DS DP		I-782	Jun 08, 2021
	9174982	May 26, 2030	U-2323		I-789	Nov 21, 2021
	9174982	May 26, 2030	U-2445		M-228	Jun 08, 2021
	9174982	May 26, 2030	U-2446		NCE	Apr 11, 2021
					ODE-114	Apr 11, 2023
					ODE-185	Jun 08, 2025
					ODE-211	Nov 21, 2025
VENETOCLAX - VENCLEXTA						
N 208573 002	8546399	Jun 27, 2031	DS DP		I-782	Jun 08, 2021
	9174982	May 26, 2030	U-2323		I-789	Nov 21, 2021
	9174982	May 26, 2030	U-2445		M-228	Jun 08, 2021
	9174982	May 26, 2030	U-2446		NCE	Apr 11, 2021
					ODE-114	Apr 11, 2023
					ODE-185	Jun 08, 2025
					ODE-211	Nov 21, 2025
VENETOCLAX - VENCLEXTA						
N 208573 003	8546399	Jun 27, 2031	DS DP		I-782	Jun 08, 2021
	9174982	May 26, 2030	U-2323		I-789	Nov 21, 2021
	9174982	May 26, 2030	U-2445		M-228	Jun 08, 2021
	9174982	May 26, 2030	U-2446		NCE	Apr 11, 2021
					ODE-114	Apr 11, 2023
					ODE-185	Jun 08, 2025
					ODE-211	Nov 21, 2025
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N 022567 001	5532241	Sep 29, 2019	DS DP			
	7834020	Jun 05, 2022	DS DP U-839			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VILAZODONE HYDROCHLORIDE - VIIBRYD							
N 022567	001	8193195	Jun 05, 2022	U-839			
		8236804	Jun 05, 2022	U-839			
		8673921	Jun 05, 2022	DS DP			
VILAZODONE HYDROCHLORIDE - VIIBRYD							
N 022567	002	5532241	Sep 29, 2019	DS DP			
		7834020	Jun 05, 2022	DS DP U-839			
		8193195	Jun 05, 2022	U-839			
		8236804	Jun 05, 2022	U-839			
		8673921	Jun 05, 2022	DS DP			
VILAZODONE HYDROCHLORIDE - VIIBRYD							
N 022567	003	5532241	Sep 29, 2019	DS DP			
		7834020	Jun 05, 2022	DS DP U-839			
		8193195	Jun 05, 2022	U-839			
		8236804	Jun 05, 2022	U-839			
		8673921	Jun 05, 2022	DS DP			
VINCRISTINE SULFATE - MARQIBO KIT							
N 202497	001	6723338	Mar 31, 2020	U-1271		ODE-28	Aug 09, 2019
		7247316	Sep 25, 2020	DP			
		7887836	Mar 31, 2020	U-1271			
VISMODEGIB - ERIVEDGE							
N 203388	001	7888364	Nov 11, 2028	DS DP			
		9278961	Dec 15, 2028	U-1825			
VORAPAXAR SULFATE - ZONTIVITY							
N 204886	001	7235567	Jun 13, 2021	DS DP		NCE	May 08, 2019
		7304078	Apr 06, 2024	DS DP U-1512			
		7713999	May 30, 2024	DS DP U-2291			
VORINOSTAT - ZOLINZA							
N 021991	001	7399787	Feb 09, 2025	U-892			
		7456219	Mar 11, 2027	DS			
		7652069	Mar 04, 2023	DP			
		7732490	Mar 04, 2023	U-892			
		7851509	Feb 21, 2024	DP U-892			
		8067472	Mar 04, 2023	U-892			
		8093295	May 16, 2026	DP			
		8101663	Mar 04, 2023	U-892			
		8450372	Mar 18, 2028	U-892			
VORTIOXETINE HYDROBROMIDE - TRINTELLIX							
N 204447	001	7144884	Jun 17, 2026	DS DP U-1439		M-227	May 02, 2021
		8476279	Oct 02, 2022	DP U-1439		M-234	Oct 19, 2021
		8722684	Jun 30, 2031	DS DP			
		8969355	Jun 15, 2027	U-1668			
		9125908	Jun 15, 2027	U-2309			
		9125909	Jun 15, 2027	U-2309			
		9125910	Jun 15, 2027	U-2309			
		9227946	Jun 15, 2027	U-1668			
		9278096	Mar 21, 2032	U-2436			
		9861630	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - TRINTELLIX							
N 204447	002	7144884	Jun 17, 2026	DS DP U-1439		M-227	May 02, 2021
		8476279	Oct 02, 2022	DP U-1439		M-234	Oct 19, 2021
		8722684	Jun 30, 2031	DS DP			
		8969355	Jun 15, 2027	U-1668			
		9125908	Jun 15, 2027	U-2309			
		9125909	Jun 15, 2027	U-2309			
		9125910	Jun 15, 2027	U-2309			
		9227946	Jun 15, 2027	U-1668			
		9278096	Mar 21, 2032	U-2436			
		9861630	Jun 15, 2027	U-1668			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VORTIOXETINE HYDROBROMIDE - TRINTELLIX							
N 204447	003	7144884	Jun 17, 2026	DS DP U-1439		M-227	May 02, 2021
		8476279	Oct 02, 2022	DP U-1439		M-234	Oct 19, 2021
		8722684	Jun 30, 2031	DS DP			
		8969355	Jun 15, 2027	U-1668			
		9125908	Jun 15, 2027	U-2309			
		9125909	Jun 15, 2027	U-2309			
		9125910	Jun 15, 2027	U-2309			
		9227946	Jun 15, 2027	U-1668			
		9278096	Mar 21, 2032	U-2436			
		9861630	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - TRINTELLIX							
N 204447	004	7144884	Jun 17, 2026	DS DP U-1439		M-227	May 02, 2021
		8476279	Oct 02, 2022	DP U-1439		M-234	Oct 19, 2021
		8722684	Jun 30, 2031	DS DP			
		8969355	Jun 15, 2027	U-1668			
		9125908	Jun 15, 2027	U-2309			
		9125909	Jun 15, 2027	U-2309			
		9125910	Jun 15, 2027	U-2309			
		9227946	Jun 15, 2027	U-1668			
		9278096	Mar 21, 2032	U-2436			
		9861630	Jun 15, 2027	U-1668			
ZICONOTIDE ACETATE - PRIALT							
N 021060	001	8653033	Oct 01, 2024	U-48			
		8653033	Oct 01, 2024	U-55			
		8765680	Oct 01, 2024	U-48			
		8765680	Oct 01, 2024	U-55			
		9707270	Oct 01, 2024	U-2084			
ZICONOTIDE ACETATE - PRIALT							
N 021060	002	8653033	Oct 01, 2024	U-48			
		8653033	Oct 01, 2024	U-55			
		8765680	Oct 01, 2024	U-48			
		8765680	Oct 01, 2024	U-55			
		9707270	Oct 01, 2024	U-2084			
ZICONOTIDE ACETATE - PRIALT							
N 021060	003	8653033	Oct 01, 2024	U-48			
		8653033	Oct 01, 2024	U-55			
		8765680	Oct 01, 2024	U-48			
		8765680	Oct 01, 2024	U-55			
		9707270	Oct 01, 2024	U-2084			
ZICONOTIDE ACETATE - PRIALT							
N 021060	004	8653033	Oct 01, 2024	U-48			
		8653033	Oct 01, 2024	U-55			
		8765680	Oct 01, 2024	U-48			
		8765680	Oct 01, 2024	U-55			
		9707270	Oct 01, 2024	U-2084			
ZIPRASIDONE HYDROCHLORIDE - GEODON							
N 020825	001	6150366	May 27, 2019	DP			
ZIPRASIDONE HYDROCHLORIDE - GEODON							
N 020825	002	6150366	May 27, 2019	DP			
ZIPRASIDONE HYDROCHLORIDE - GEODON							
N 020825	003	6150366	May 27, 2019	DP			
ZIPRASIDONE HYDROCHLORIDE - GEODON							
N 020825	004	6150366	May 27, 2019	DP			
ZIPRASIDONE HYDROCHLORIDE - GEODON							
N 021483	001	6150366	May 27, 2019	DP U-719			
		7175855	May 18, 2020	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZOLEDRONIC ACID - ZOMETA								
N	021223	002	8324189	May 29, 2025	U-1308			
			8324189	May 29, 2025	U-1309			
			8324189	May 29, 2025	U-53			
ZOLEDRONIC ACID - ZOMETA								
N	021223	003	7932241	Feb 05, 2028	DP			
			8324189	May 29, 2025	U-1308			
			8324189	May 29, 2025	U-1309			
			8324189	May 29, 2025	U-53			
ZOLEDRONIC ACID - RECLAST								
N	021817	001	7932241	Feb 05, 2028	DP			
			8052987	Oct 27, 2023	U-1199			
ZOLMITRIPTAN - ZOMIG								
N	021450	003	6750237	Nov 28, 2020	DP			
			6750237*PED	May 28, 2021				
			7220767	Nov 28, 2020	DP			
			7220767*PED	May 28, 2021				
ZOLMITRIPTAN - ZOMIG								
N	021450	004	6750237	Nov 28, 2020	DP			
			7220767	Nov 28, 2020	DP			
ZOLPIDEM TARTRATE - AMBIEN CR								
N	021774	001	6514531	Dec 01, 2019	DP			
ZOLPIDEM TARTRATE - AMBIEN CR								
N	021774	002	6514531	Dec 01, 2019	DP			
ZOLPIDEM TARTRATE - EDLUAR								
N	021997	001	6761910	Sep 24, 2019	DP U-674			
			8512747	Sep 24, 2019	U-674			
			9265720	Feb 25, 2031	U-674			
			9597281	Apr 06, 2027	U-674			
ZOLPIDEM TARTRATE - EDLUAR								
N	021997	002	6761910	Sep 24, 2019	DP U-674			
			8512747	Sep 24, 2019	U-674			
			9265720	Feb 25, 2031	U-674			
			9597281	Apr 06, 2027	U-674			
ZOLPIDEM TARTRATE - ZOLPIMIST								
N	022196	001	8236285	Aug 07, 2032	DS DP U-70			
ZOLPIDEM TARTRATE - INTERMEZZO								
N	022328	001	7658945	Apr 15, 2027	DP U-1194			
			7682628	Feb 16, 2025	U-1194			
			8242131	Aug 20, 2029	U-1266			
			8252809	Feb 16, 2025	DP			
ZOLPIDEM TARTRATE - INTERMEZZO								
N	022328	002	7658945	Apr 15, 2027	DP U-1194			
			7682628	Feb 16, 2025	U-1194			
			8242131	Aug 20, 2029	U-1266			
			8252809	Feb 16, 2025	DP			

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

PATENT AND EXCLUSIVITY TERMS

PATENT & EXCLUSIVITY ABBREVIATIONS

CGT	COMPETITIVE GENERIC THERAPY
D	NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES)
GAIN	GAIN EXCLUSIVITY
I	NEW INDICATION (SEE INDIVIDUAL REFERENCES)
M	MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES)
NC	NEW COMBINATION
NCE	NEW CHEMICAL ENTITY
NCE*	NEW CHEMICAL ENTITY (AN ENANTIOMER OF PREVIOUSLY APPROVED RACEMIC MIXTURE. SEE SECTION 505(U) OF THE FEDERAL FOOD AND DRUG COSMETIC ACT).
NDF	NEW DOSAGE FORM
NE	NEW ESTER OR SALT OF AN ACTIVE INGREDIENT
NP	NEW PRODUCT
NP*	NEW PRODUCT (MINT FLAVORED)
NPP	NEW PATIENT POPULATION
NR	NEW ROUTE
NS	NEW STRENGTH
ODE	ORPHAN DRUG EXCLUSIVITY (SEE INDIVIDUAL REFERENCES)
PC	PATENT CHALLENGE
PED	PEDIATRIC EXCLUSIVITY
RTO	RX TO OTC SWITCH OR OTC USE
RTO*	OTC USE FOR WOMEN AGES 15 AND 16
RTO**	OTC USE FOR WOMEN 14 AND BELOW
U	PATENT USE CODE (SEE INDIVIDUAL REFERENCES)
W	EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

EXCLUSIVITY DOSING SCHEDULE

D-1	ONCE A DAY APPLICATION
D-2	ONCE DAILY DOSING
D-3	SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE
D-4	SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE
D-5	TEN DAYS/ELEVEN DAYS DOSING SCHEDULE
D-6	SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE
D-7	BID DOSING
D-8	INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING
D-9	NARCOTIC OVERDOSE IN ADULTS
D-10	NARCOTIC OVERDOSE IN CHILDREN
D-11	POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN
D-12	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER
D-13	INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION
D-14	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
D-15	SINGLE DAILY DOSE OF 25MG/37.5MG
D-16	CONTINUOUS INTRAVENOUS INFUSION
D-17	400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS
D-18	LOWER RECOMMENDED STARTING DOSE GUIDELINES
D-19	BOLUS DOSING GUIDELINES
D-20	SINGLE 32MG DOSE
D-21	ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL
D-22	REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
D-23	INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
D-24	FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS
D-25	ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN

EXCLUSIVITY DOSING SCHEDULE

D-26	ONCE WEEKLY APPLICATION
D-27	BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY
D-28	USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300
D-29	INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS
D-30	5000 IU DOSE FOR PROPHYLAXIS AGAINST DEEP VEIN THROMBOSIS
D-31	CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID)
D-32	REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS
D-33	ONCE DAILY DOSING FOR PLAQUE PSORIASIS
D-34	EVERY FOUR MONTHS DOSAGE REGIMEN
D-35	FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS
D-36	FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY
D-37	DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID)
D-38	CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
D-39	CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM "..1/2 TO 1 HOUR BEFORE EATING" TO ".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING..."
D-40	ONCE-A-DAY DOSING REGIMEN
D-41	DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS
D-42	TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
D-43	INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD
D-44	IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED
D-45	ONCE DAILY DOSING FOR MAINTENANCE ONLY
D-46	NEW DOSING REGIMEN OF 80MG DAILY
D-47	PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
D-48	ADMINISTRATION OF CISATRACURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRACURIUM FOLLOWING INDUCTION WITH THIOPENTAL
D-49	PEDIATRIC DOSING GUIDELINES
D-50	INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS
D-51	OPTIONAL STARTING DOSE OF 40MG/DAY
D-52	ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY
D-53	USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE
D-54	USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS
D-55	ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)
D-56	ADDITION OF POSTPRANDIAL DOSING
D-57	3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER
D-58	CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION
D-59	REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY

EXCLUSIVITY DOSING SCHEDULE

D-60	ADDITION OF A POST-OPERATIVE DOSING REGIMEN
D-61	ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-62	ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-63	TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE
D-64	INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML
D-65	CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
D-66	DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
D-67	SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
D-68	CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS
D-69	SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS
D-70	80MG ONCE DAILY DOSING REGIMEN
D-71	EIGHT WEEK DOSING REGIMEN
D-72	INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON
D-73	ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-74	ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-75	INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE
D-76	FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
D-77	ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)
D-78	USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS
D-79	NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE
D-80	CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING
D-81	NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS
D-82	USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-83	750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)
D-84	ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS
D-85	LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
D-86	FOR USE IN SELECT EXTERNAL INSULIN PUMPS
D-87	ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
D-88	NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES
D-89	USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS
D-90	ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS
D-91	ALTERNATE INTERMITTENT DOSING REGIMEN

EXCLUSIVITY DOSING SCHEDULE

D-92	ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME
D-93	ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS
D-94	NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
D-95	BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE
D-96	ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS
D-97	PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFORE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE
D-98	DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE
D-99	ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS
D-100	750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS
D-101	ONCE DAILY IN CHRONIC IDIOPATHIC URTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
D-102	NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER
D-103	NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.
D-104	0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS
D-105	USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-106	FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA
D-107	PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
D-108	TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS
D-109	PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE
D-110	TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17
D-111	PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREATMENT OF ERECTILE DYSFUNCTION
D-112	PROVIDES FOR PEDIATRIC PUMP USE
D-113	ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN
D-114	NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS
D-115	STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
D-116	ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS
D-117	50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER
D-118	TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR
D-119	DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE
D-120	DOSING REGIMEN ADJUSTMENTS
D-121	CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION

EXCLUSIVITY DOSING SCHEDULE

D-122	USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
D-123	ALTERNATIVE DOSING REGIMEN DOSE OF 20 MG/METER SQUARE BY CONTINUOUS INTRAVENOUS INFUSION OVER 1 HOUR REPEATED DAILY FOR 5 DAYS
D-124	ONCE DAILY DOSING REGIMEN IN ADULT PATIENTS WITH LESS THAN THREE LOPINAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
D-125	EXTEND CURRENT DOSING REGIMEN TO 900MG (2-450MG TABLETS) ONCE A DAY WITHIN 10 DAYS OF TRANSPLANTATION UNTIL 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT PATIENTS AT HIGH RISK.
D-126	CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG
D-127	DOSING REGIMEN FOR ADULT PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND DECOMPENSATED LIVER DESEASE
D-128	SINGLE IV DOSE OF FOSAPREPITANT 150MG, DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID, FOR PREVENTION OF ACUTE & DELAYED NAUSEA & VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMO
D-129	800/100 MG DARUNAVIR/RITONAVIR, ONCE DAILY, IN TREATMENT-EXPERIENCED HIV-1 INFECTED PATIENTS WITH NO DARUNAVIR RESISTANCE ASSOCIATED SUBSTITUTIONS
D-130	DOSING RECOMMENDATIONS FOR TREATMENT OF HIV-1 INFECTION DURING PREGNANCY BASED ON DATA FROM STUDY AI424-182, A STUDY OF ATAZANAVIR/RITONAVIR IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE IN HIV INFECTED PREGNANT WOMEN
D-131	EVERY 6 TO 8 WEEKS FOR THE 120MG STRENGTH FOR PATIENTS WHO ARE CONTROLLED ON SOMATULINE DEPOT 60MG OR 90MG
D-132	45MG FOR 6 MONTH ADMINISTRATION
D-133	NEW EFFICACY DATA AND DOSING REGIMEN FOR PREGNANCY IN NORMAL OVULATORY WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION AS PART OF AN IVF OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLE
D-134	INCREASING MAXIMUM DOSING OF PATIENTS WITH SCHIZOPHRENIA TO 160 MG/DAY
D-135	UPDATE LABELING WITH ONCE DAILY DOSING IN HIV-1 INFECTED, TREATMENT-NAIVE PEDIATRIC PATIENTS 12 TO LESS THAN 18 YEARS OF AGE
D-136	ALTERNATE DOSING REGIMEN FOR UNCOMPLICATED URETHRAL OR ENDOCERVICAL INFECTION CAUSED BY CHLAMYDIA TRACHOMATIS, ADMINISTER 200 MG BY MOUTH ONCE-A-DAY FOR 7 DAYS
D-137	NEW LOWER DOSING REGIMEN FOR REVATIO IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS
D-138	80 MG DOSING REGIMEN FOR THE RISK REDUCTION OF REBLEEDING OF GASTRIC AND DUODENAL ULCERS IN THE FIRST 72 HOURS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS
D-139	ADDITIONAL INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE LABELING REGARDING THE ADMINISTRATION OF BRAVELLE AND MENOPUR IN THE SAME SYRINGE TO OVULATORY WOMEN AS PART OF AN ART CYCLE
D-140	REVISED DOSING SCHEDULE TO ADMINISTER AVANAFIL 15 MINUTES PRIOR TO SEXUAL ACTIVITY
D-141	DOSING INFORMATION IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA
D-142	DOSE MODIFICATION GUIDELINES FOR BORTEZOMIB WHEN GIVEN IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE
D-143	INITIATION OF VIMPAT THERAPY WITH A LOADING DOSE OF 200MG
D-144	LOWER LIMIT OF 15 MINUTES FOR THE INFUSION DURATION
D-145	UPDATES TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING TO REFLECT THE RESULTS OF TWO SHORT TERM STUDIES EVALUATING THE SAFETY AND EFFICACY OF INTUNIV IN CHILDREN AND ADOLESCENTS AGES 6 TO 17 WITH ADHD.
D-146	CHANGE IN TARGET DOSING TO 20MG TO 40MG ORALLY ONCE DAILY
D-147	ONCE DAILY DOSING IN PEDIATRIC PATIENTS 3 MONTHS OF AGE AND OLDER IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION
D-148	EXTENDED THE DURATION OF THE DOSING REGIMEN FROM 100 DAYS TO 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CMV DISEASE IN PEDIATRIC KIDNEY TRANSPLANT
D-149	DOSING INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH ITP

EXCLUSIVITY DOSING SCHEDULE

D-150 1600MG DAILY FOR PATIENTS ON ADJUNCTIVE THERAPY WHO DID NOT ACHIEVE A SATISFACTORY RESPONSE ON 1200MG DAILY DOSE

D-151 DOSING RECOMMENDATIONS FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS CO-INFECTED WITH HIV-1

D-152 DOSING RECOMMENDATIONS AS NECESSARY FOR FEVER AND PAIN FOR AGES 6MO TO LESS THAN 12 YEARS AND 12 TO 17 YEARS.

D-153 IN COMBINATION WITH RIBAVIRIN FOR 12 WEEKS, FOR THE TREATMENT OF GENOTYPE 1, CHRONIC HEPATITIS C TREATMENT EXPERIENCED PATIENTS WITH COMPENSATED CIRRHOSIS BASED UPON THE RESULTS OF THE SIRIUS STUDY

D-154 ADDITION OF A 1500MG-SINGLE-DOSE REGIMEN FOR THE TREATMENT OF ADULT PATIENTS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSI)

D-155 SINGLE IV DOSE OF FOSAPREPITANT 150MG DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID FOR PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY

D-156 DOSING INFORMATION ADDED TO THE LABELING PROVIDING INFORMATION ON TRANSITIONING FROM SUBCUTANEOUS OR INTRAVENOUS ROUTES OF ADMINISTRATION OF TREPROSTINIL

D-157 UPDATED INFORMATION ADDED TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING PROVIDING DOSAGE RECOMMENDATIONS FOR INTERRUPTIONS AND DISCONTINUATION OF THERAPY

D-158 REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE LIVER TRANSPLANT RECIPIENTS WITH GENOTYPE 1 HCV INFECTION

D-159 REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE LIVER TRANSPLANT RECIPIENTS WITH GENOTYPE 4 HCV INFECTION

D-160 REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE PATIENTS WITH DECOMPENSATED CIRRHOSIS WITH GENOTYPE 1 HCV INFECTION

D-161 DOSAGE RECOMMENDATIONS ADDED TO INCLUDE TREATMENT OF HCV GENOTYPE 3 SUBJECTS CO-INFECTED WITH HIV-1

D-162 DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION WITH COMPENSATED (CHILD-PUGH A) OR DECOMPENSATED (CHILD-PUGH B OR C) CIRRHOSIS AND TREATMENT OF CHRONIC HCV GENOTYPE 3 INFECTION IN SUBJECTS WITH DECOMPENSATED (CHILD-PUGH B OR C) CIRRHOSIS

D-163 DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1A INFECTION WITH COMPENSATED (CHILD-PUGH A) CIRRHOSIS AND GENOTYPE 1B WITH OR WITHOUT COMPENSATED (CHILD-PUGH A) CIRRHOSIS

D-164 UPDATES TO THE DOSAGE AND ADMINISTRATION, DOSE MODIFICATIONS SECTION OF THE LABELING

D-165 DOSING RECOMMENDATION ADDED TO THE LABELING FOR IMBRUVICA USE IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LEUKEMIA (SLL)

D-166 BROADEN INITIAL STARTING DOSE FOR BIPOLAR I DISORDER TO 5-10MG TWICE DAILY

D-167 ADDITION OF 1200 MG ONCE DAILY DOSING FOR TREATMENT-NAIVE PATIENTS OR PATIENTS WHO ARE VIROLOGICALLY SUPPRESSED ON AN INITIAL REGIMEN OF RALTEGRAVIR FILM-COATED TABLETS 400 MG TWICE DAILY

D-168 NEW DOSING REGIMEN OF 10 MG ONCE DAILY FOR THE REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR DVT AND/OR PE AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS

D-169 ONCE-DAILY DOSING FOR PATIENTS 5 YEARS OF AGE AND OLDER WHO HAVE UNDETECTABLE SERUM AND URINE SUCCINYLACETONE CONCENTRATIONS AFTER A MINIMUM OF 4 WEEKS ON A STABLE DOSAGE OF NITISINONE

D-170 TO ALLOW WITHDRAWAL THERAPY OF PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE WHO HAVE ACHIEVED A SUSTAINED MOLECULAR RESPONSE ON NILOTINIB THERAPY FOR A MINIMUM OF ONE YEAR PRIOR TO DISCONTINUATION

D-171 REVISED DOSING TO INCLUDE UP-TITRATION AS A STRATEGY TO IMPROVE TOLERABILITY AND THEREBY REDUCE TREATMENT DISCONTINUATION FOR ROFLUMILAST MAINTENANCE DOSAGE OF 500 MCG DAILY

D-172 ADDITION OF A ONCE WEEKLY DOSING REGIMEN FOR CARFILZOMIB IN COMBINATION WITH DEXAMETHASONE FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE

EXCLUSIVITY DOSING SCHEDULE

	RECEIVED ONE TO THREE LINES OF THERAPY
D-173	DOSING RECOMMENDATION FOR THE USE OF ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE FIXED DOSE COMBINATION IN HIV-1 INFECTED ADULT PATIENTS WITH END-STAGE-RENAL DISEASE WHO ARE RECEIVING CHRONIC HEMODIALYSIS

EXCLUSIVITY INDICATION

I-1	DYSMENORRHEA
I-2	CHOLANGIOPANCREATOGRAPHY
I-3	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-4	PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY)
I-5	HYSTEROSALPINGOGRAPHY
I-6	TREATMENT OF JUVENILE ARTHRITIS
I-7	BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN
I-8	ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY
I-9	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
I-10	PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY
I-11	RELIEF OF MILD TO MODERATE PAIN
I-12	TREATMENT OF CUTANEOUS CANDIDIASIS
I-13	URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI
I-14	SEBORRHEIC DERMATITIS
I-15	PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT
I-16	STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM
I-17	MANAGEMENT OF CONGESTIVE HEART FAILURE
I-18	ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
I-19	HERNIOGRAPHY
I-20	KNEE ARTHROGRAPHY
I-21	HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR
I-22	RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA
I-23	SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-24	TREATMENT OF RHEUMATOID ARTHRITIS
I-25	ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS
I-26	TREATMENT OF LIVER FLUKES
I-27	ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE
I-28	SELECTIVE ADULT VISCERAL ARTERIOGRAPHY
I-29	METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION
I-30	TREATMENT OF TINEA PEDIS
I-31	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES
I-32	PEDIATRIC MYELOGRAPHY
I-33	ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN

EXCLUSIVITY INDICATION

I-34	ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT
I-35	PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING
I-36	ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS
I-37	RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS
I-38	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER)
I-39	TREATMENT OF ACUTE MYOCARDIAL INFARCTION
I-40	PRIMARY NOCTURNAL ENURESIS
I-41	MIGRAINE HEADACHE PROPHYLAXIS
I-42	HERPES ZOSTER
I-43	HERPES SIMPLEX ENCEPHALITIS
I-44	MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY
I-45	ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS
I-46	USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING
I-47	TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE
I-48	PEDIATRIC ANGIOCARDIOGRAPHY
I-49	TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI
I-50	FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER
I-51	TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS
I-52	PEDIATRIC EXCRETORY UROGRAPHY
I-53	TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-54	RENAL CONCENTRATION CAPACITY TEST
I-55	HYPERTENSION
I-56	EROSIVE GASTROESOPHAGEAL REFLUX DISEASE
I-57	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER
I-58	INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS
I-59	ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE
I-60	SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE
I-61	FEMALE ANDROGENETIC ALOPECIA
I-62	PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-63	ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION
I-64	PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS
I-65	PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
I-66	UNCOMPLICATED GONORRHEA
I-67	TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER
I-68	CENTRAL PRECOCIOUS PUBERTY
I-69	SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY
I-70	USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER
I-71	VARICELLA INFECTIONS (CHICKENPOX)
I-72	PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE

	EXCLUSIVITY INDICATION
I-73	INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES
I-74	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-75	TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS
I-76	PREVENTION OF OSTEOPOROSIS
I-77	DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM
I-78	CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY
I-79	MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM
I-80	DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE
I-81	PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS
I-82	TREATMENT OF TRAVELERS' DIARRHEA
I-83	ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN
I-84	INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION
I-85	TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
I-86	TREATMENT OF SECONDARY CARNITINE DEFICIENCY
I-87	RENAL IMAGING AGENT FOR USE IN CHILDREN
I-88	MANAGEMENT OF ENDOMETRIOSIS
I-89	EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE
I-90	INTENSIVE CARE UNIT SEDATION
I-91	MONOTHERAPY USE FOR HYPERTENSION
I-92	ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE
I-93	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS
I-94	USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]
I-95	TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-96	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
I-97	ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT
I-98	TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY
I-99	PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER
I-100	TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY
I-101	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY
I-102	TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
I-103	PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA
I-104	TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATIENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
I-105	TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
I-106	TREATMENT OF ACROMEGALY
I-107	VAGINAL CANDIDIASIS
I-108	EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION
I-109	TYPHOID FEVER

EXCLUSIVITY INDICATION

I-110	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY
I-111	TREATMENT OF PAGET'S DISEASE OF BONE
I-112	MANAGEMENT OF MODERATE TO SEVERE PAIN
I-113	TREATMENT OF PROSTATITIS
I-114	USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE
I-115	USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK
I-116	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
I-117	TO SLOW THE PROGRESSION FO CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
I-118	PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY
I-119	TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
I-120	MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS
I-121	EXPANDED PATIENT POPULATION -- USE IN ICU PATIENTS
I-122	PSORIASIS OF THE SCALP
I-123	RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER
I-124	LEUKOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE
I-125	EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES
I-126	ADJUNCT TO THALLIUM- 201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY
I-127	TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS
I-128	IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...
I-129	TREATMENT OF ALCOHOL DEPENDENCE
I-130	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
I-131	PERIPHERAL ARTERIOGRAPHY
I-132	TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER
I-133	MANAGEMENT OF CHRONIC STABLE ANGINA
I-134	HEART FAILURE POST MYOCARDIAL INFARCTION
I-135	BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA
I-136	IDIOPATHIC CHRONIC URTICARIA
I-137	PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES
I-138	TREATMENT OF ACUTE RECURRENT GENITAL HERPES
I-139	PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN
I-140	PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE
I-141	TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL
I-142	LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION
I-143	EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-144	ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS
I-145	0.1MMOL/KG AS A SINGLE INTRAVENOUS BOLUS FOR MRI OF THE CNS IN CHILDREN
I-146	CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS

	EXCLUSIVITY INDICATION
I-147	PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS
I-148	TREATMENT OF ACUTE PNEUMOCYSTIS CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AaDO2) IS LESS THAN OR EQUAL TO 55 TORR
I-149	TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
I-150	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER
I-151	PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA
I-152	SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS
I-153	MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASSES SPINAL AND CEREBRAL ORIGIN]
I-154	PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE
I-155	TREATMENT OF ONYCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT
I-156	ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE
I-157	TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES
I-158	TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER
I-159	FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES
I-160	TREATMENT OF BACTERIAL CORNEAL ULCERS
I-161	TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY
I-162	FOR USE IN PATIENTS 6-11 YEARS OF AGE
I-163	TREATMENT OF PHOTOPHOBIA
I-164	CHRONIC BACTERIAL PROSTATITIS
I-165	MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
I-166	TREATMENT OF BULIMIA
I-167	COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS
I-168	MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS)
I-169	USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER
I-170	PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS
I-171	RELIEF OF SYMPTOMS OF THE COMMON COLD
I-172	TREATMENT OF INITIAL EPISODE OF GENITAL HERPES
I-173	PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY
I-174	PELVIC INFLAMMATORY DISEASE
I-175	TREATMENT OF TINEA CORPORIS AND TINEA CRURIS
I-176	TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
I-177	TX OF MODERATE ACNE VULGARIS IN FEMALES,GREATER OR EQUAL TO 15YRS OF AGE,WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY,DESIRE CONTRACEPTION,HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
I-178	TREATMENT OF ONYCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
I-179	NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE

EXCLUSIVITY INDICATION

I-180	TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
I-181	TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
I-182	TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
I-183	MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
I-184	TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG)
I-185	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-186	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
I-187	PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-188	TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
I-189	TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS
I-190	PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS
I-191	ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING
I-192	THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION
I-193	TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY
I-194	CONGESTIVE HEART FAILURE
I-195	FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER
I-196	ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-197	MAINTENANCE OF HEALING OF DUODENAL ULCER
I-198	FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER
I-199	MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYLUREA IN THE TREATMENT OF TYPE II DIABETES
I-200	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR
I-201	EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS
I-202	SECOND-LINE TREAMENT OF AIDS-RELATED KAPOSI'S SARCOMA
I-203	MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
I-204	USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-205	INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS
I-206	TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE
I-207	FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-208	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION
I-209	PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT)
I-210	TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS
I-211	FOR USE IN PEDIATRIC POPULATION
I-212	TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME
I-213	TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY

EXCLUSIVITY INDICATION

I-214	TREATMENT OF OSTEOPOROSIS
I-215	PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
I-216	FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-217	PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-218	USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)
I-219	USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET
I-220	TREATMENT OF EPISODIC- HEARTBURN, ACID INDIGESTION AND SOUR STOMACH
I-221	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY
I-222	PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
I-223	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
I-224	FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-225	USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS
I-226	FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN
I-227	SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESPHAGEAL REFLUX DISEASE (GERD)
I-228	PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL
I-229	PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
I-230	IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION
I-231	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
I-232	TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY
I-233	PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY
I-234	FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER
I-235	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER
I-236	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
I-237	MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
I-238	ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS
I-239	TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
I-240	MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS
I-241	USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL

	EXCLUSIVITY INDICATION
	NONSMALL CELL LUNG CANCER
I-242	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS
I-243	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS
I-244	REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER
I-245	TREATMENT OF ACUTE SINUSITIS
I-246	TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
I-247	USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG
I-248	INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM
I-249	TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY
I-250	PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C
I-251	TREATMENT OF GENERALIZED ANXIETY DISORDER
I-252	NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN
I-253	COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN
I-254	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)
I-255	PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)
I-256	USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY
I-257	TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMMATION
I-258	FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE
I-259	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-260	EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)
I-261	TREATMENT OF SOCIAL ANXIETY DISORDER
I-262	TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12
I-263	TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY
I-264	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION
I-265	TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER
I-266	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES
I-267	USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER - FOR CORTICOSTEROID-RESPONSIVE DERMATOSES
I-268	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE
I-269	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN
I-270	ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY
I-271	TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-272	TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING

	EXCLUSIVITY INDICATION
	GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY
I-273	ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-274	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
I-275	USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES
I-276	USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES
I-277	TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA
I-278	TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV)
I-279	TREATMENT OF POST-TRAUMATIC STRESS DISORDER
I-280	USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
I-281	INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-282	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
I-283	TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS
I-284	TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE
I-285	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER
I-286	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III
I-287	USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH
I-288	CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE
I-289	USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL
I-290	PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
I-291	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
I-292	TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-293	TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
I-294	TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS
I-295	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS
I-296	LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY
I-297	SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-298	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA
I-299	USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM
I-300	PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE
I-301	TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS
I-302	TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME

EXCLUSIVITY INDICATION

I-303	INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS
I-304	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV
I-305	TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
I-306	INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE
I-307	NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES
I-308	TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS
I-309	USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
I-310	REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES
I-311	ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS
I-312	FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
I-313	EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE
I-314	TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES
I-315	THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM,IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
I-316	TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID
I-317	PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER
I-318	FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
I-319	USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS
I-320	TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS)
I-321	JUVENILE RHEUMATOID ARTHRITIS
I-322	USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS
I-323	COLORECTAL CANCER
I-324	REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS
I-325	PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION
I-326	GENERALIZED ANXIETY DISORDER
I-327	SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER
I-328	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
I-329	UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-330	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYMPTOMS IN PATIENTS WITH GERD
I-331	TREATMENT OF MODERATE ACNE VULGARIS
I-332	EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN)
I-333	TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)
I-334	LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE

EXCLUSIVITY INDICATION

I-335	ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
I-336	EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS
I-337	PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME
I-338	MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA
I-339	TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS
I-340	ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5
I-341	BREAST CANCER COMBINATION THERAPY
I-342	USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-343	USE OF COREG FOR SEVERE HEART FAILURE
I-344	ACNE VULGARIS
I-345	TREATMENT OF POSTTRAUMATIC STRESS DISORDER
I-346	TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)
I-347	TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE
I-348	LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
I-349	ACUTE CORONARY SYNDROME
I-350	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
I-351	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
I-352	ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
I-353	TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
I-354	MANAGEMENT OF POST HERPETIC NEURALGIA
I-355	PREMENSTRUAL DYSPHORIC DISORDER
I-356	TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME
I-357	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-358	TREATMENT OF PANIC DISORDER
I-359	TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE
I-360	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE
I-361	TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY
I-362	TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-363	ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
I-364	TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
I-365	TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR
I-366	PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
I-367	COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS: METFORMIN, SULFONYLUREAS, REPAGLINIDE, OR THIAZOLIDINEDIONES

EXCLUSIVITY INDICATION

I-368	USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE
I-369	PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING
I-370	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY
I-371	HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
I-372	NOSOCOMIAL PNEUMONIA
I-373	TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
I-374	SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS
I-375	FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
I-376	TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML)
I-377	USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION
I-378	RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
I-379	USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION
I-380	TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR
I-381	TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER
I-382	FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION
I-383	TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
I-384	USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
I-385	MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD "INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML" TO STREPTOCOCCUS PNEUMONIAE
I-386	RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION
I-387	ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE
I-388	TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-389	SUPPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS
I-390	USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE, DIABETES, PERIPHERAL VESSEL DISEASE, STROKE HISTORY, OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH, REDUCE NONFATAL MI & STROKE.....
I-391	ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY
I-392	TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECURRENCE AFTER STEM CELL TRANSPLANT OR RESISTANCE TO INTERFERON ALPHA THERAPY. NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVEMENT IN DISEASE RELATED SX OR INCREASED SURVIVAL
I-393	CHRONIC BACTERIAL PROSTATITIS
I-394	USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES

EXCLUSIVITY INDICATION

I-395	TO IMPROVE PHYSICAL FUNCTION
I-396	EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION
I-397	EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY
I-398	IDIOPATHIC SHORT STATURE
I-399	TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSES, PERITONITIS AND PLEURAL SPACE INFECTIONS
I-400	USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER
I-401	LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA
I-402	DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS
I-403	USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESSIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE
I-404	MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
I-405	TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN
I-406	PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
I-407	IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION
I-408	STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE IDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP)
I-409	ESOPHAGEAL CANDIDIASIS
I-410	USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS
I-411	EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS
I-412	MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-413	ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-414	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
I-415	SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY
I-416	THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
I-417	USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
I-418	ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
I-419	MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-420	TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
I-421	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
I-422	INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
I-423	ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS

EXCLUSIVITY INDICATION

I-424	MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
I-425	ELOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER
I-426	TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
I-427	TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
I-428	FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED
I-429	FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER
I-430	FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS
I-431	NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS
I-432	TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE
I-433	TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)
I-434	PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA
I-435	CHRONIC IDIOPATHIC CONSTIPATION
I-436	FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
I-437	TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER
I-438	EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS
I-439	USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY
I-440	FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY
I-441	USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS
I-442	USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS
I-443	TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER
I-444	USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIVE ESOPHAGITIS
I-445	TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)
I-446	EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS
I-447	USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A)
I-448	TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE

EXCLUSIVITY INDICATION

I-449	TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER
I-450	TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT
I-451	MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN
I-452	EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
I-453	USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)
I-454	MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS
I-455	MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%)
I-456	TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR
I-457	TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS
I-458	USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)
I-459	NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN
I-460	TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER
I-461	USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED
I-462	LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE
I-463	TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION
I-464	TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME
I-465	PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER
I-466	FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS
I-467	USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES
I-468	USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUCE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFARCTION
I-469	RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER
I-470	DIABETIC PERIPHERAL NEUROPATHIC PAIN
I-471	INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE
I-472	USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE
I-473	USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER
I-474	TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECEIVING AN ERYTHROPOIETIN
I-475	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
I-476	TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS
I-477	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE

EXCLUSIVITY INDICATION

I-478	FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS
I-479	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOTAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES
I-480	PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE
I-481	INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
I-482	TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES
I-483	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
I-484	FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS
I-485	TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
I-486	ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI
I-487	INDICATED FOR THE RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER
I-488	MAINTENANCE THERAPY IN BIPOLAR I DISORDER
I-489	FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES
I-490	FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE
I-491	INFLUENZA PROPHYLAXIS
I-492	MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES
I-493	ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA
I-494	CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE
I-495	ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY
I-496	LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES
I-497	PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER
I-498	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
I-499	USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF PLATINUM-BASED THERAPY
I-500	FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
I-501	TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETENT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.
I-502	FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY
I-503	TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER
I-504	TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME
I-505	TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES

EXCLUSIVITY INDICATION

I-506	ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
I-507	ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
I-508	PREMENSTRUAL DYSPHONIC DISORDER
I-509	TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
I-510	ADULT DERMATOFIBROSARCOMA PROTUBERANS (DFSP)
I-511	ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP)
I-512	ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY
I-513	ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM)
I-514	ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL)
I-515	PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY
I-516	PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
I-517	TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS)
I-518	TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEOBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED
I-519	USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
I-520	USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL
I-521	TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY
I-522	TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.
I-523	USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE
I-524	GENERALIZED ANXIETY DISORDER (GAD)
I-525	USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS
I-526	TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS
I-527	ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
I-528	TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE
I-529	TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE
I-530	PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER
I-531	MAINTENANCE TREATMENT OF SCHIZOPHRENIA
I-532	TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES
I-533	ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)
I-534	EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECURRENCE OF VTE IN PATIENTS WITH CANCER
I-535	MANAGEMENT OF FIBROMYALGIA
I-536	FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME
I-537	LONG TERM TREATMENT OF PANIC DISORDER
I-538	SHORT TERM TREATMENT OF PANIC DISORDER

EXCLUSIVITY INDICATION

I-539 REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER

I-540 TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17

I-541 TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17

I-542 EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM "INOPERABLE" PATIENTS TO ALL PATIENTS

I-543 USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

I-544 ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY

I-545 ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER

I-546 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA

I-547 ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTHEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS

I-548 SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE

I-549 USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS

I-550 TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE

I-551 TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME

I-552 ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER

I-553 FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS

I-554 TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES

I-555 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS

I-556 PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY

I-557 USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD

I-558 MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERBATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

I-559 ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED

I-560 MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX

I-561 LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER

I-562 MAINTENANCE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS

I-563 ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SIEZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY

I-564 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

I-565 USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH)

I-566 MANAGEMENT OF FIBROMYALGIA

I-567 INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS

I-568 USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-

	EXCLUSIVITY INDICATION
	EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR
I-569	TREATMENT OF CHRONIC HEPATITIS B
I-570	TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE
I-571	NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQAUMOUS NON-SMALL CELL LUNG CANCER
I-572	TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.
I-573	TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDRICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET
I-574	MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION
I-575	MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA
I-576	ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA
I-577	SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
I-578	EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS
I-579	TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION
I-580	INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN
I-581	TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
I-582	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
I-583	ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTOINTESTINAL STROMAL TUMORS (GIST)
I-584	TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICOIDS FOR AT LEAST 12 MONTHS
I-585	TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS
I-586	COMMUNITY ACQUIRED BACTERIAL PNEUMONIA
I-587	ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION
I-588	ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION
I-589	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE
I-590	ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE)
I-591	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE
I-592	ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE)
I-593	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD)
I-594	INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS
I-595	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-596	USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
I-597	MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
I-598	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING
I-599	PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
I-600	FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS

EXCLUSIVITY INDICATION

I-601 MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY

I-602 TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE

I-603 GOUT FLARES

I-604 PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16 YEARS AT HIGH RISK

I-605 ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER

I-606 TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY

I-607 INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS

I-608 REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY

I-610 TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION

I-611 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY

I-612 MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS

I-613 MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE

I-614 SHORT TERM TREATMENT OF EROSIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER

I-615 MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE

I-616 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE

I-617 MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD)

I-618 ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

I-619 INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY

I-620 FOR USE IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER THAT OVEREXPRESSES THE HER2 RECEPTOR FOR WHOM HORMONAL THERAPY IS INDICATED

I-621 PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER)

I-622 ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS THIRTEEN YEARS OF AGE AND OLDER

I-623 TREATMENT OF SIGNS AND SYMPTOMS OF ADVANCED IDIOPATHIC PARKINSON'S DISEASE

I-624 MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY

I-625 PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY

I-626 RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER

I-627 TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE.

I-628 MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS

I-629 ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER

I-630 TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTIC INTERVENTION BUT

	EXCLUSIVITY INDICATION
	ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION.
I-631	PREVENTION OF RELAPSE TO OPIOID DEPENDENCE FOLLOWING OPIOID DETOXIFICATION
I-632	MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN
I-633	MAINTENANCE TREATMENT OF BIPOLAR I DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
I-634	TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY
I-635	ADJUNCTIVE TREATMENT WITH LONG-ACTING ORAL PSYCHOSTIMULANTS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
I-636	TREATMENT OF EXTERNAL GENITAL AND PERIANAL WARTS/CONDYLOMA ACUMINATA IN PATIENTS 12 YEARS OR OLDER
I-637	USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER
I-638	FOR PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC.
I-639	TREATMENT OF PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC DISEASE
I-640	MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
I-641	TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
I-642	TREATMENT OF ERECTILE DYSFUNCTION (ED) AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
I-643	REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION.
I-644	MONOTHERAPY IN PATIENTS 13 YEARS OF AGE AND OLDER WITH PARTIAL SEIZURES WHO ARE RECEIVING THERAPY WITH A SINGLE ANTIEPILEPTIC DRUG (AED)
I-645	MAINTENANCE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
I-646	SIGNS AND SYMPTOMS OF ADVANCED PARKINSON'S DISEASE (APD)
I-647	SIGNS AND SYMPTOMS OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
I-648	TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
I-649	TREATMENT OF PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY
I-650	TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC), NOT REQUIRING IMMEDIATE SURGERY
I-651	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH SPINAL CORD INJURY
I-652	MANAGEMENT OF POSTHERPETIC NEURALGIA
I-653	TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS
I-654	MAGNETIC RESONANCE ANGIOGRAPHY (MRA) TO EVALUATE ADULTS WITH KNOWN OR SUSPECTED RENAL OR AORTO-ILIO-FEMORAL OCCLUSIVE VASCULAR DISEASE
I-655	TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED HORMONE RECEPTOR-POSITIVE,HER2-NEGATIVE BREAST CANCER (ADVANCED HR+BC) IN COMBINATION WITH EXEMESTANE, AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE
I-656	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) IN ADULTS WHEN A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
I-657	PLAQUE PSORIASIS OF THE SCALP
I-658	FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH CARBOPLATIN, IN PATIENTS WHO ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION THERAPY
I-659	PLAQUE PSORIASIS OF THE BODY
I-660	TREATMENT OF DEEP VEIN THROMBOSIS
I-661	TREATMENT OF PULMONARY EMBOLISM
I-662	REDUCTION IN RISK FOR DEEP VEIN THROMBOSIS AND THE REDUCTION IN RISK FOR

EXCLUSIVITY INDICATION

PULMONARY EMBOLISM

I-663 IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

I-664 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY

I-665 TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS OF AGE AND OLDER WITH (NTDT)SYNDROMES AND WITH A (LIC) OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT (MG FE/G DW) AND SERUM FERRITIN GREATER THAN 300MCG/L

I-666 TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) IN COMBINATION WITH CHEMOTHERAPY

I-667 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE

I-668 PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT

I-669 SCINTIGRAPHIC ASSESSMENT OF SYMPATHETIC INNERVATION OF THE MYOCARDIUM BY MEASUREMENT OF THE HEART TO MEDIASTINUM (H/M) RATIO OF RADIOACTIVITY UPTAKE IN PATIENTS WITH NYHA CLASS II OR CLASS III HEART FAILURE AND LVEF LESS THAN 35%

I-670 TREATMENT OF OPIOID-INDUCED CONSTIPATION (OIC) IN ADULTS WITH CHRONIC, NON-CANCER PAIN

I-671 FIRSTLINE TREATMENT OF PATIENTS WITH METASTATIC NON- SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21(L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

I-672 USE IN PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB

I-673 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA/VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY SUSCEPTIBLE ISOLATES OF S. AUREUS (INCLUDING METHICILLIN-SUSCEPTIBLE AND RESISTANT ISOLATES) WHEN ALTERNATIVE TREATMENTS ARE NOT SUITABLE

I-674 TREATMENT OF PATIENTS WITH DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) AS MONOTHERAPY AND AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE

I-675 MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER

I-676 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS, IN COMBINATION WITH GEMCITABINE

I-677 TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DTC) THAT IS REFRACTORY TO RADIOACTIVE IODINE TREATMENT

I-678 TRAMETINIB, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

I-679 RISK REDUCTION OF REBLEEDING OF GASTRIC OR DUODENAL ULCERS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS

I-680 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

I-681 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) WHICH MAY LEAD TO PULMONARY EMBOLISM (PE), IN ADULT PATIENTS WHO HAVE UNDERGONE HIP OR KNEE REPLACEMENT

I-682 TREATMENT OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) IN PATIENTS WHO HAVE BEEN TREATED WITH A PARENTERAL ANTICOAGULANT FOR 5-10 DAYS

I-683 TO REDUCE THE RISK OF RECURRENCE OF DVT AND PE IN PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED

I-684 PREVENTION OF ACUTE NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING HIGHLY EMETOGENIC CANCER CHEMOTHERAPY IN PEDIATRIC PATIENTS AGED 1 MONTH TO LESS THAN 17 YEARS

I-685 EXPANDED INDICATION OF RASAGILINE AS AN ADD-ON THERAPY TO STABLE DOSES OF DOPAMINE AGONISTS IN THE TREATMENT OF EARLY PARKINSON'S DISEASE

I-686 INDICATED FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN PATIENTS WHO ARE PSEUDOPHAKIC OR ARE PHAKIC AND SCHEDULED FOR CATARACT SURGERY

EXCLUSIVITY INDICATION

I-687 GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY

I-688 GADAVIST IS INDICATED WITH MRI TO DETECT THE PRESENCE AND EXTENT OF MALIGNANT BREAST DISEASE

I-689 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION

I-690 INDICATED FOR THE TREATMENT OF DEEP VEIN THROMBOSIS (DVT)

I-691 INDICATED TO REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) FOLLOWING INITIAL THERAPY

I-692 INDICATED FOR MANAGEMENT OF OSTEOARTHRITIS PAIN.

I-693 TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)

I-694 TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY

I-695 REVISED INDICATION FOR BORTEZOMIB IN THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA

I-696 USE AS MONOTHERAPY IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGE 17 YEARS AND OLDER

I-697 FOR USE IN COMBINATION WITH SOFOSBUVIR FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 INFECTION

I-698 SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS

I-699 FOR TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA

I-700 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S DISORDER (6-18 YEARS)

I-701 FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, WELL-OR MODERATELY-DIFFERENTIATED, LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) TO IMPROVE PROGRESSION FREE SURVIVAL

I-702 FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA

I-703 MODERATE TO SEVERE BINGE EATING DISORDER (BED)

I-704 EXPANDED INDICATION TO INCLUDE PATIENTS WHO ARE VIROLOGICALLY-SUPPRESSED (HIV-1 RNA <50 COPIES/ML) ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS WITH NO HISTORY OF TREATMENT FAILURE IN ORDER TO REPLACE THEIR CURRENT REGIMEN

I-705 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO HAVE AN R117H MUTATION IN THE CFTR GENE

I-706 EXPANDED INDICATION FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

I-707 POMALYST, IN COMBINATION WITH DEXAMETHASONE, IS INDICATED FOR PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY

I-708 DAILY TREATMENT OF ASTHMA IN PATIENTS AGED 18 YEARS AND OLDER

I-709 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS

I-710 ADJUNCTIVE THERAPY FOR THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC (PG TC) SEIZURES IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE OR OLDER.

I-711 INCLUSION OF PEDIATRIC PATIENTS AGES 6 YRS AND OLDER FOR THE TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC ITP WHO HAVE HAD AN INSUFFICIENT RESPONSE TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR SPLENECTOMY.

I-712 EXPANDED INDICATION FOR USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE PRIOR LINES OF THERAPY

I-713 REVISIONS TO THE LABELING TO PERMIT THE USE OF ZUBSOLV AS INITIAL ("INDUCTION") TREATMENT OF OPIOID DEPENDENCE

I-714 EXTENDS THE 2011 APPROVAL OF BRILINTA FOR USE BEGINNING WITH ACS TO USE BEGINNING MORE REMOTE FROM MYOCARDIAL INFARCTION

I-715 FOR THE ADDITION OF THE INDICATION FOR MONOTHERAPY TREATMENT IN PARTIAL-ONSET SEIZURES IN ADULTS.

I-716 REVISED INDICATION TO INCLUDE LANGUAGE ABOUT THE BENEFITS OF USING LETAIRIS IN

	EXCLUSIVITY INDICATION
	COMBINATION WITH TADALAFIL TO REDUCE THE RISK OF DISEASE PROGRESSION AND HOSPITALIZATION FOR WORSENING PAH AND TO IMPROVE EXERCISE ABILITY, BASED ON THE AMBITION STUDY
I-717	EXPANDED INDICATION TO INCLUDE THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 4
I-718	EXPANDED INDICATION TO INCLUDE SUBJECTS INFECTED WITH CHRONIC HEPATITIS C, GENOTYPE 6 VIRUS INFECTION BASED UPON THE RESULTS OF THE ELECTRON- 2 STUDY
I-719	EXPANDED INDICATION TO INCLUDE THE TREATMENT OF SUBJECTS WITH GENOTYPE 5 CHRONIC HEPATITIS C VIRUS INFECTION BASED ON THE RESULTS FROM STUDY GS-US-337-119.
I-720	EXPANDED INDICATION TO INCLUDE TREATMENT OF GENOTYPE 4, CHRONIC HEPATITIS C VIRUS INFECTION BASED UPON THE RESULTS FROM STUDIES ION-4 AND GS-US-337-119.
I-721	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN.
I-722	REVISED INDICATION FOR USE IN COMBINATION WITH DEXAMETHASONE OR WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY.
I-723	AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE OR MORE LINES OF THERAPY
I-724	TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL DIFFERENTIATED, NON-FUNCTIONAL NEUROENDOCRINE TUMORS (NET) OF GI OR LUNG ORIGIN WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE
I-725	TREATMENT OF HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION THERAPY WITH PALBOCICLIB AND FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY.
I-726	EXPANSION OF THE PATIENT POPULATION TO INCLUDE PATIENTS WITH RECURRENCE OF HEPATITIS C VIRUS (HCV) GENOTYPE 1 OR 3 AFTER LIVER TRANSPLANTATION
I-727	EXPANSION OF THE INDICATION TO INCLUDE TREATMENT OF SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C VIRUS INFECTION, INCLUDING SUBJECTS WHO ARE CO-INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV-1) BASED ON THE RESULTS FROM THE ALLY-2 CLINICAL TRIAL
I-728	EXPANDED INDICATION FOR USE IN ULTRASONOGRAPHY OF THE LIVER FOR CHARACTERIZATION OF FOCAL LIVER LESIONS IN ADULT AND PEDIATRIC PATIENTS
I-729	PROVIDES FOR THE FRONTLINE INDICATION FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
I-730	NEW INDICATION FOR THE TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY
I-731	FOR USE IN MAGNETIC RESONANCE ANGIOGRAPHY IN ADULT AND PEDIATRIC PATIENTS (INCLUDING TERM NEONATES) TO EVALUATE KNOWN OR SUSPECTED SUPRA-AORTIC OR RENAL ARTERY DISEASE
I-732	TREATMENT OF PEDIATRIC PATIENTS 7 TO 17 YEARS OF AGE WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA TO REDUCE LDL-C, TOTAL C, NONHDL-C AND APOB AS AN ADJUNCT TO DIET, EITHER ALONE OR WITH OTHER LIPID-LOWERING TREATMENTS
I-733	USE OF CANAGLIFLOZIN FOR INITIAL THERAPY IN COMBINATION WITH METFORMIN
I-734	EXPANDED INDICATION FOR THE USE OF LENVIMA IN COMBINATION WITH EVEROLIMUS FOR THE TREATMENT OF PATIENTS WITH ADVANCED RCC FOLLOWING ONE PRIOR ANTI-ANGIOGENIC THERAPY.
I-735	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH CANAGLIFLOZIN AND METFORMIN IS APPROPRIATE
I-736	REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL)
I-737	REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL) WITH 17P DELETION
I-738	REVISIONS TO THE INDICATIONS AND USAGE SECTION WITH RESPECT TO COMPLICATED INTRA-ABDOMINAL INFECTIONS
I-739	TO REDUCE THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
I-740	EXPANDED INDICATION FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 YEARS AND OLDER TO INCLUDE THE G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, OR S549R MUTATION IN THE CFTR GENE

EXCLUSIVITY INDICATION

I-741 TREATMENT OF PATIENTS WITH MARGINAL ZONE LYMPHOMA (MZL) WHO REQUIRE SYSTEMIC THERAPY AND HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED THERAPY

I-742 TREATMENT OF NODAL MARGINAL ZONE LYMPHOMA

I-743 INFORMATION ADDED TO THE LABELING FOR THE ADDITION OF THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 4 (GT4) INFECTED PATIENTS WITH COMPENSATED CIRRHOSIS BASED ON RESULTS FROM STUDY M11-665

I-744 TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB

I-745 MEKINIST, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST.

I-746 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS

I-747 FOR REDUCING THE RISK OF GRAFT REJECTION WHEN USED WITH HIGH-DOSE BUSULFAN AND CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENEIC HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH CLASS 3 BETA-THALASSEMIA

I-748 TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS FIVE YEARS OF AGE AND OLDER

I-749 MONOTHERAPY FOR THE TREATMENT OF HORMONE RECEPTOR (HR) POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE, ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN NOT PREVIOUSLY TREATED WITH ENDOCRINE THERAPY

I-750 REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE

I-751 TREATMENT OF TARDIVE DYSKINESIA

I-752 CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY (CCTA) TO ASSIST DIAGNOSTIC EVALUATION OF PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE

I-753 TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY

I-754 TO REDUCE THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY WHEN USED FOR THE TREATMENT OF ADULTS WITH CARCINOID SYNDROME

I-755 ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC) FOLLOWING NEPHRECTOMY

I-756 EXPANDED THE APPROVED INDICATION BY REMOVING THE RESTRICTION FOR USE ONLY IN PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB

I-757 TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION

I-758 FOR USE WITH RILPIVIRINE AS A COMPLETE REGIMEN TO REPLACE THE CURRENT ARV REGIMEN IN VIROLOGICALLY SUPPRESSED PATIENTS ON A STABLE ARV REGIMEN FOR AT LEAST 6 MONTHS WITH NO HISTORY OF TX FAILURE OR KNOWN SUBSTITUTIONS ASSOC. WITH RESISTANCE TO EITHER ARV

I-759 TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+CML)

I-760 FOR THE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA

I-761 TREATMENT OF ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO METHOTREXATE OR OTHER NON-BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS

I-762 TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE METASTATIC BREAST CANCER WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT OR METASTATIC SETTING

I-763 TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON-RESISTANT EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

I-764 TREATMENT IN ADULT PATIENTS FOR IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C)

I-765 ABIRATERONE ACETATE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER

I-766 TREATMENT OF MINIMALLY TO MODERATELY THICK ACTINIC KERATOSIS OF THE UPPER

EXCLUSIVITY INDICATION

EXTREMITIES IN CONJUNCTION WITH A BLUE LIGHT PHOTODYNAMIC THERAPY ILLUMINATOR

I-767 TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON

I-768 IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER

I-769 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS

I-770 TREATMENT OF ACUTE OTITIS EXTERNA IN PATIENTS 6 MONTHS OF AGE AND OLDER DUE TO PSEUDOMONAS AERUGINOSA AND STAPHYLOCOCCUS AUREUS

I-771 REVISION OF THE INDICATION SECTION OF THE PACKAGE INSERT REGARDING AN INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA

I-772 FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY

I-773 FOR THE ADJUNCTIVE TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGE 2 YEARS AND OLDER WITH TUBEROUS SCLEROSIS COMPLEX (TSC)-ASSOCIATED PARTIAL-ONSET SEIZURES

I-774 TO ALLOW FOR FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS, AS DETECTED BY AN FDA APPROVED TEST

I-775 REVISED INDICATION FOR FIXED-DOSE COMBINATION OF FLUTICASONE FUROATE, UMECLIDINIUM, AND VILANTEROL TO TREAT AIRFLOW OBSTRUCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND TO REDUCE COPD EXACERBATIONS IN PTS WITH HISTORY OF EXACERBATIONS

I-776 FIRSTLINE MAINTENANCE TX IN PTS W/ DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE, SOMATIC BRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CA WHO ARE IN COMPLETE OR PARTIAL RESPONSE TO FIRSTLINE PLATINUM-BASED CHEMOTHERAPY

I-777 CO-ADMINISTRATION THERAPY OF MIRABEGRON WITH SOLIFENACIN SUCCINATE FOR TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY

I-778 DABRAFENIB IN COMBINATION WITH TRAMETINIB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION

I-779 USE OF TOLVAPTAN TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS AT RISK OF RAPIDLY PROGRESSING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)

I-780 TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC)

I-781 DABRAFENIB IN COMBINATION WITH TRAMETINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS

I-782 REVISIONS TO INDICATION FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

I-783 EXPANDED INDICATION TO INCLUDE RIBOCICLIB WITH AN AROMATASE INHIBITOR IN PRE/PERIMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE-BASED THERAPY

I-784 RIBOCICLIB WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY

I-785 TREATMENT OF PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE

I-786 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

I-787 FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)

I-788 NEW INDICATION FOR CANAGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND

EXCLUSIVITY INDICATION

	NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD)
I-789	VENETOCLAX IN COMBO WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
I-791	TREATMENT OF PEDIATRIC PATIENTS ONE YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY

EXCLUSIVITY MISCELLANEOUS

M-1	INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION
M-2	APPROVAL FOR ADDITION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE
M-3	ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN
M-4	CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD
M-5	INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION
M-6	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION
M-7	CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION
M-8	ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING
M-9	ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY
M-10	INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING
M-11	USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER
M-12	NEW LANGUAGE FOR PEDIATRIC USE
M-13	INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION
M-14	ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
M-15	LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
M-16	CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
M-17	INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
M-18	INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
M-19	INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER
M-20	LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME
M-21	COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR
M-22	CHANGE IN TIME TO ONSET OF ACTION
M-23	INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT
M-24	INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION
M-25	ADDITIONAL SAFETY AND PHARMACOKINETICS INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PACKAGE INSERT

EXCLUSIVITY MISCELLANEOUS

M-26	INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01
M-27	INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY
M-28	INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION
M-29	LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS
M-30	CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION
M-31	INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)
M-32	ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES
M-33	INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA
M-34	EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
M-35	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY
M-36	ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE
M-37	INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS
M-38	SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL
M-39	FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST
M-40	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS
M-41	REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED "THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENSITY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA"
M-42	ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION
M-43	INCLUSION OF RESULTS OF STUDY "PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION"
M-44	CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18
M-45	INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING, "EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY"
M-46	PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY
M-47	PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS
M-48	CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES
M-49	CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN
M-50	NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION
M-51	INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY

EXCLUSIVITY MISCELLANEOUS

M-52	INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
M-53	FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT
M-54	INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL
M-55	INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.
M-56	INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON "GEMINI" TRIAL
M-57	CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS
M-58	CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS
M-59	RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLESCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS
M-60	CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA
M-61	REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
M-62	CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES
M-63	DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY
M-64	CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS
M-65	ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS)
M-66	USE IN SPECIFIC POPULATIONS - PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER
M-67	INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS
M-68	DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL
M-69	RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY
M-70	PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY
M-71	REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
M-72	INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS
M-73	NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH - SECRETING PITUITARY ADENOMAS
M-74	REVISIONS TO CLINICAL STUDIES - CHILDREN AND ADOLESCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS
M-75	PROVISION FOR USE OF ARGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITTS)
M-76	REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA
M-77	USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS
M-78	CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING

EXCLUSIVITY MISCELLANEOUS

	WORSENING OF ANXIETY
M-79	LABELING REVISIONS RELATED TO SMOKING AND ERLOTINIB EXPOSURE
M-80	ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
M-81	ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOTOXICOSIS)
M-82	LABELING REVISIONS RELATED TO CLINICAL STUDIES
M-83	ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL
M-84	STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY
M-85	INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD
M-86	LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION
M-87	INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION
M-88	ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE
M-89	PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM
M-90	LABELING CHANGES BASED ON DATA FROM CLINICAL STUDIES NV20235 AND NV20236 STUDIES OF SEASONAL PROPHYLAXIS OF INFLUENZA IN IMMUNOCOMPROMISED PATIENTS AND CHILDREN AGES 1-12
M-91	UPDATED LABELING BASED UPON STUDY: A SINGLE-DOSE, SINGLE-BLIND, PLACEBO-AND MOXIFLOXACIN-CONTROLLED 2-PERIOD, RANDOMIZED, CROSSOVER, 3RD PERIOD SEQUENTIAL STUDY OF SIDE EFFECTS OF TEMSIROLIMUS ON CARDIAC REPOLARIZATION IN HEALTHY SUBJECTS
M-92	UPDATES TO THE PACKAGE INSERT BASED UPON THE TRIAL ENTITLED "A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS IN PATIENTS WITH ADVANCED MALIGNANCIES AND NORMAL AND IMPAIRED LIVER FUNCTION"
M-93	EXPANSION OF LABELING TO INCLUDE INFORMATION ON SAFETY AND EFFICACY OF CREON IN PATIENTS AGES 7 YEARS THROUGH 11 YEARS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CYSTIC FIBROSIS
M-94	INFO ADDED TO LABEL RELATED TO NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IC CHRONIC PHASE
M-95	INFORMATION FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN ADULT PATIENTS WITH DECOMPENSATED LIVER DISEASE BASED ON DATA FROM CLINICAL TRIAL GS-US-174-0108
M-96	UPDATED INFORMATION IN THE CLINICAL STUDIES SECTION RELATED TO THE LOSS AND RECOVERY OF BONE MINERAL DENSITY IN ADOLESCENT GIRLS DURING AND FOLLOWING THE USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION
M-97	LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES - NOT INDICATED FOR USE IN PEDIATRIC POPULATION
M-98	NEW INFORMATION FROM A STUDY WHICH EVALUATED THE SAFETY AND EFFICACY OF FAMVIR IN TREATING RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT BLACK/AFRICAN AMERICAN SUBJECTS.
M-99	ADDITION OF FINDINGS FROM A SINGLE PEDIATRIC CLINICAL TRIAL (P04292) OF NASONEX NASAL SPRAY IN THE TREATMENT OF NASAL POLYPS IN PATIENTS 6 TO <18 YEARS OF AGE TO THE PACKAGE INSERT.
M-100	INFORMATION ADDED TO LABEL BASED UPON COMPLETED CLINICAL TRIAL REPORTS
M-101	INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL
M-102	INFORMATION FROM PEDIATRIC STUDY REPORT ML16633, "INTRAVENOUS GRANISETRON (KYTRIL) IN THE PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING (PONV) IN PEDIATRIC SUBJECTS UNDERGOING TONSILLECTOMY OR ADENOTONSILLECTOMY."
M-103	SAFETY, EFFICACY AND PHARMACOKINETIC INFO FOR FASLODEX IN THE PEDIATRIC

EXCLUSIVITY MISCELLANEOUS

	POPULATION, SPECIFICALLY FOR GIRLS WITH PROGRESSIVE PRECOCIOUS PUBERTY ASSOCIATED WITH MCCUNE-ALBRIGHT SYNDROME ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING
M-104	INFORMATION ADDED TO DOSING AND ADMINISTRATION REGARDING A 26 WEEK STUDY
M-105	NEW LANGUAGE ADDED TO CLINICAL STUDIES REGARDING USE IN SMOKERS WITH CARDIOVASCULAR DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND USE ACCORDING TO AN ALTERNATIVE SET OF DIRECTIONS FOR SETTING A QUIT DATE
M-106	ADDITION OF THE T1-WEIGHTED GD-ENHANCED LESION EFFICACY VARIABLE IN THE CLINICAL STUDIES SECTION 14 OF THE PACKAGE INSERT
M-107	INFORMATION TO THE CLINICAL STUDIES SECTION OF THE LUPRON DEPOT-PED 1-MONTH BASED UPON THE PHASE 3/4 COMPLETED CLINICAL STUDY REPORT FOR STUDY M90-516 ENTITLED "STUDY OF LUPRON DEPOT IN THE TREATMENT OF CENTRAL PRECOCIOUS PUBERTY".
M-108	CHANGES ARE BASED ON RESULTS FROM STUDY CV181057
M-109	CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
M-110	CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
M-111	LABELING CHANGES BASED ON STUDY HW80-EW-GWCI ENTITLED A PLACEBO AND POSITIVE CONTROLLED STUDY OF THE ELECTROPHYSIOLOGICAL EFFECTS OF A SINGLE 10 MCG DOSE OF EXENATIDE ON THE 12 LEAD ELECTROCARDIOGRAM QT INTERVAL IN HEALTHY SUBJECTS
M-112	REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO ADD INFORMATION FROM A PEDIATRIC STUDY IN PATIENTS AGED 12 YEARS TO LESS THAN 18 YEARS OF AGE WITH RECURRENT HERPES LABIALIS
M-113	LABELING CHANGES BASED ON STUDY H80-US-GWCO ENTITLED A RANDOMIZED TRIAL COMPARING EXENATIDE WITH PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES ON INSULIN GLARGINE WITH OR WITHOUT ORAL ANTIHYPERGLYCEMIC MEDICATIONS
M-114	CHANGES IN SECTION 14 OF THE PACKAGE INSERT TO INCLUDE DATA FROM THE SWITCHMRK STUDIES (SWITCH OF SUPPRESSED SUBJECTS FROM LOPINAVIR/RITONAVIR TO RALTEGRAVIR)
M-115	REVISIONS TO THE PI BASED ON RESULTS FROM STUDY NN2211-1842, ENTITLED THE EFFECT OF INSULIN DETEMIR IN COMBINATION WITH LIRAGLUTIDE AND METFORMIN COMPARED TO LIRAGLUTIDE AND METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES
M-116	LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY 01-06-TL-OPIMET-008
M-117	ADDITION OF RESULTS OF PEDIATRIC TRIAL TO LABEL
M-118	LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.36
M-119	LABELING CHANGES REGARDING MISSED DOSES
M-120	CHANGES TO CLINICAL TRIALS DETAILING STUDY RESULTS
M-121	LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.43
M-122	LABELING CHANGES TO INCLUDE THE RESULTS OF THE PARAMOUNT TRIAL
M-123	UPDATED RESULTS OF OVERALL SURVIVAL FROM 'CONFIRM' STUDY
M-124	LONG TERM SAFETY AND EFFICACY DATA FROM STUDY CLDT600A2303 FOR SUBJECTS PREVIOUSLY ENROLLED IN THE ORIGINAL TWO YEAR GLOBE (NV-02B-007/CLDT600A2302) AND NV02B-015 STUDIES WHO CONTINUED TELBIVUDINE TREATMENT FOR UP TO 208 WEEKS
M-125	LABELING CHANGES TO INCLUDE LACK OF EFFICACY IN CHILDREN 6 MONTHS TO 4 YEARS OF AGE
M-126	UPDATES TO THE CLINICAL STUDIES SECTION 14, OF THE PACKAGE INSERT (PI), WITH THE RESULTS OF CLINICAL TRIAL P06086
M-127	REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO REFLECT THE RESULTS FROM CLINICAL STUDY C-10-004
M-128	CLINICAL TRIAL STUDY RESULTS
M-129	RESULTS OF A CLINICAL STUDY REPORT WHICH ASSESSES THE SAFETY AND EFFICACY IN CHILDREN AGES 6 TO 12 YEARS OF AGE
M-130	ADDITION OF INFORMATION ON LONG-TERM TREATMENT WITH VPRIV IN THE CLINICAL TRIALS SECTION OF THE PACKAGE INSERT
M-131	INFORMATION FROM STUDIES CONDUCTED IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED NON-DISSEMINATED DIFFUSED INTRINSIC BRAINSTEM GLIOMAS
M-132	REVISIONS TO THE CLINICAL TRIALS SECTION IN THE INOMAX LABEL TO REFLECT RESULTS

EXCLUSIVITY MISCELLANEOUS

FROM THE PEDIATRIC STUDY REPORTS

M-133 INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF SILDENAFIL TO BOSENTAN THERAPY

M-134 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED WITH SAXAGLIPTIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA ADDED TO THE LABELING

M-135 ADDITION OF INFORMATION TO THE CLINICAL STUDIES - RADIOGRAPHIC RESPONSE SECTION OF THE PACKAGE INSERT

M-136 ADDITIONAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING REGARDING POST-OPERATIVE NAUSEA AND VOMITING STUDIES IN PEDIATRIC PATIENTS

M-137 LABELING REVISIONS RESULTING FROM A MAINTENANCE TRIAL IN PEDIATRIC PATIENTS WITH IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER

M-138 INFORMATION ADDED TO THE 8.4 PEDIATRIC USE SECTION ON THE USE OF MEMANTINE IN CHILDREN AGES 6-12 YEARS WITH AUTISM SPECTRUM DISORDER

M-139 INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE PACKAGE INSERT REGARDING RETREATMENT WITH VELCADE FOR PATIENTS WITH MULTIPLE MYELOMA

M-140 INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING USE OF LATISSE IN PATIENTS WHO WERE POST-CHEMOTHERAPY OR HAD ALOPECIA AREATA, AND ADOLESCENTS WHO HAD HYPERTRICHOSIS WITH NO ASSOCIATED MEDICAL CONDITION

M-141 REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING TO INCORPORATE STUDY RESULTS FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER IN ADOLESCENTS (AGES 12-17)

M-142 ADDITIONS TO THE LABELING DESCRIBING RESULTS FROM STUDY H6P-MC-HDAY

M-143 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WITH CURRENT OR PAST HISTORY OF MAJOR DEPRESSIVE DISORDER

M-144 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WHO HAD BEEN PREVIOUSLY TREATED WITH VARENICLINE

M-145 ADDITION OF INFORMATION ABOUT LONG-TERM TREATMENT OF PULMONARY ARTERIAL HYPERTENSION TO THE CLINICAL STUDIES SECTION OF THE LABELING

M-146 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION ON INITIAL COMBINATION THERAPY WITH LINAGLIPTIN AND METFORMIN VS. LINAGLIPTIN MONOTHERAPY IN TREATMENT NAIVE PATIENTS

M-147 OTC USE FOR TEMPORARY RELIEF OF OCULAR SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES

M-148 LABELING CHANGES BASED ON STUDY H80-EW-GWDM

M-149 INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE MONOTHERAPY FOR ADHD

M-150 ADDITION OF THE RESULTS OF A CONTROLLED CLINICAL STUDY TREATING ADULT PATIENTS WITH SCHIZOPHRENIA EXPERIENCING AN ACUTE RELAPSE

M-151 REVISIONS TO THE LABELING BASED ON THE OUTCOMES OF PEDIATRIC STUDIES CONDUCTED TO ASSESS THE SAFETY AND EFFICACY OF XOPENEX IN SUBJECTS LESS THAN 6 YEARS OF AGE

M-152 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION OF THE LABELING REGARDING A SAFETY STUDY IN PEDIATRIC SUBJECTS AGES 6 MONTHS TO 4 YEARS OF AGE WITH AN ACTIVE HEAD LICE INFESTATION

M-153 ADDITION OF INFORMATION REGARDING THE INTRANASAL ABUSE POTENTIAL OF OXYCONTIN

M-154 UPDATE TO THE LABELING TO REFLECT THE RESULTS OF A LONG-TERM MAINTENANCE TREATMENT STUDY OF ADHD IN CHILDREN AND ADOLESCENTS AGES 6-17.

M-155 ADDITION OF CLINICAL FINDINGS FROM AN OBSERVATIONAL STUDY IN A PEDIATRIC AGE GROUP GREATER THAN 2 MONTHS TO 18 YEARS IN SECTION 8.4 PEDIATRIC USE OF THE PACKAGE INSERT

M-156 UPDATE TO THE LABELING WITH INFORMATION REGARDING A CLINICAL TRIAL IN CHILDREN LESS THAN 4 YEARS OF AGE.

M-157 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF DAPAGLIFLOZIN 10MG ONCE DAILY IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A BACKGROUND COMBINATION OF METFORMIN AND SULFONYLUREA

EXCLUSIVITY MISCELLANEOUS

M-158 UPDATES TO THE LABELING TO REFLECT SAFETY RESULTS FROM CLINICAL TRIALS IN SCHIZOPHRENIA ADOLESCENT PATIENTS AGED 12 TO 17 YEARS

M-159 ADDITION OF PED SAFETY INFORMATION DERIVED FROM A MAINTENANCE TREATMENT STUDY OF BIPOLAR 1 DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES IN PATIENTS (> THAN OR = TO 13 YRS OF AGE) TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY

M-160 UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND ACTIVE-CONTROLLED STUDY COMPARING EMPAGLIFLOZIN TO GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES AND INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN TREATMENT

M-161 UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND INSUFFICIENT GLYCEMIC CONTROL ON A MULTIPLE DAILY INJECTION INSULIN REGIMEN ALONE OR WITH METFORMIN

M-162 INCLUSION OF EFFICACY AND SAFETY DATA TO THE PRESCRIBING INFORMATION OF BYDUREON BASED ON STUDY GWDE

M-163 INFORMATION ADDED TO THE LABELING REGARDING PREVIOUSLY UNTREATED ALK-POSITIVE METASTATIC NON SMALL CELL LUNG CANCER (NSCLC)

M-164 REVISES THE CLINICAL TRIALS SECTION OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM STUDY E7273-G000-401 ENTITLED "PHASE IV RANDOMIZED STUDY OF TWO DOSE LEVELS OF TARGRETIN CAPSULES IN SUBJECTS WITH REFRACTORY CUTANEOUS T-CELL LYMPHOMA"

M-165 PROVIDES FOR UPDATES TO THE PEDIATRIC USE SECTION BASED ON THE PEDIATRIC STUDY REPORT ENTITLED, "A PHASE II PILOT TRIAL OF BORTEZOMIB IN COMBINATION WITH INTENSIVE RE-INDUCTION THERAPY IN CHILDREN WITH RELAPSED ACUTE LYMPHOBLASTIC LYMPHOMA (LL)"

M-166 UPDATE TO LABELING WITH WEEK 48 RESULTS FROM VIKING-4 IN ANTIRETROVIRAL THERAPY (ART) - EXPERIENCED INTEGRASE STRAND TRANSFER INHIBITOR (INSTI) - RESISTANT SUBJECTS

M-167 APPROVED FOR REVISIONS TO THE LABELING BASED ON THE CLINICAL STUDY ENTITLED "BRONCHOPULMONARY DYSPLASIA (BPD) IN PRETERM INFANTS REQUIRING MECHANICAL VENTILATION OR POSITIVE PRESSURE SUPPORT ON DAYS 5 TO 14 AFTER BIRTH".

M-168 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE RE-NOVATE AND RE-NOVATE LL STUDIES (PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM FOLLOWING HIP REPLACEMENT SURGERY)

M-169 UPDATES TO LABELING DESCRIBING RESPONSE TO A REPEAT COURSE OF PICATO GEL 0.015% ON THE FACE OR SCALP IF AN INCOMPLETE RESPONSE IS OBSERVED AT A FOLLOW-UP EXAMINATION.

M-170 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION REGARDING USE FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

M-171 UPDATES TO LABELING WITH RESULTS TO THE TIGER CLINICAL TRIAL

M-172 UPDATES TO THE CLINICAL TRIALS SECTION OF THE LABELING TO INCLUDE RESULTS OF STUDIES PERFORMED TO EVALUATE THE BENEFIT OF ADDING INCRUSE ELLIPTA TO PATIENTS WHO ARE ON BACKGROUND THERAPY WITH BREO ELLIPTA AND ADVAIR DISKUS

M-173 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING DESCRIBING THE EFFECTS OF STIOLTO RESPIMAT ON COPD PATIENTS

M-174 INFORMATION ADDED TO CLINICAL STUDIES SECTION OF THE LABELING REGARDING INITIAL COMBINATION THERAPY OF EMPAGLIFLOZIN WITH METFORMIN

M-175 INFORMATION ADDED TO THE LABELING DESCRIBING SAVOR, A PHASE IV TRIAL EVALUATING THE EFFECT OF SAXAGLIPTIN ON THE INCIDENCE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION OR ISCHAEMIC STROKE IN PATIENTS WITH TYPE 2 DIABETES

M-176 INFORMATION ADDED TO THE LABELING DESCRIBING TRIAL NN2211-3916, A TRIAL EVALUATING THE SAFETY AND EFFICACY OF LIRAGLUTIDE IN SUBJECTS WITH TYPE 2 DIABETES AND MODERATE RENAL IMPAIRMENT

M-177 INFORMATION ADDED TO THE LABELING DESCRIBING EXAMINE, A TRIAL EVALUATING CARDIOVASCULAR ISCHEMIC RISKS ASSOCIATED WITH ALOGLIPTIN USE IN PATIENTS WITH TYPE 2 DIABETES AT HIGH RISK OF ISCHEMIC CARDIOVASCULAR DISEASE

M-178 INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE OF REMISSION IN CROHN'S DISEASE IN PEDIATRIC PATIENTS

M-179 UPDATES TO THE PRODUCT LABELING WITH STUDY REPORTS FROM THE OPTIMIST-1 AND

EXCLUSIVITY MISCELLANEOUS

OPTIMIST-2 CLINICAL TRIALS

M-180 INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF MAINTENANCE TREATMENT IN PATIENTS WITH SCHIZOPHRENIA

M-181 UPDATE TO THE DOSAGE AND ADMINISTRATION, PATIENT SELECTION (2.1), SECTION OF THE PACKAGE INSERT TO INCLUDE THE USE OF AN FDA-APPROVED PLASMA TEST FOR THE IDENTIFICATION OF EGFR EXON 19 DELETION OR EXON 21 (L858R) SUBSTITUTION MUTATIONS

M-182 UPDATES TO THE PRODUCT LABELING BASED ON THE RESULTS OF STUDY H7T-MC-TADO TITLED, "A PHASE 3 DOUBLE-BLIND, RANDOMIZED, MULTICENTER, EFFICACY AND SAFETY STUDY OF PRASUGREL COMPARED TO PLACEBO IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE"

M-183 CHANGES TO THE DOSAGE AND ADMINISTRATION AND CLINICAL STUDIES SECTIONS OF THE LABELING TO SUPPORT THE REDUCE-TO-QUIT PARADIGM

M-184 UPDATES MADE TO THE LABELING TO INCLUDE INFORMATION FROM STUDY MO25743 ON THE ANTI-TUMOR ACTIVITY OF VEMURAFENIB IN THE TREATMENT OF PATIENTS WITH BRAF V600E MUTATION-POSITIVE MELANOMA WITH BRAIN METASTASES

M-185 UPDATES TO THE LABELING TO INCLUDE RESULTS OF A TRIAL TO EVALUATE THE SAFETY OF MOXIFLOXACIN IN PEDIATRIC PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS

M-186 UPDATES TO THE PRODUCT INFORMATION REGARDING MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS BASED UPON THE RESULTS FROM STUDY 331-10-232

M-187 ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING

M-188 PROVIDES FOR DATA SUPPORTING THE SAFETY AND EFFECTIVENESS FOR THE MAINTENANCE TREATMENT OF MODERATE TO SEVERE BINGE EATING DISORDER (BED)

M-189 LABELING DESCRIBING THE EXPECTED REDUCTION OF ABUSE OF SINGLE-ENTITY MORPHINE BY THE INTRANASAL ROUTE OF ADMINISTRATION DUE TO PHYSICOCHEMICAL PROPERTIES

M-190 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE LACK OF EFFICACY OF TARCEVA IN MAINTENANCE TREATMENT OF PATIENTS WITHOUT EGFR MUTATIONS

M-191 ADDITION OF DATA BASED ON PEDIATRIC STUDIES TO FULFILL THE POSTMARKETING REQUIREMENT 1857-2

M-192 PROVIDES FOR DATA EVALUATING THE NEUROPSYCHIATRIC SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN SUBJECTS WITH AND WITHOUT A HISTORY OF PSYCHIATRIC DISORDERS

M-193 INFORMATION ADDED TO THE LABELING REGARDING A 15-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED FLEXIBLE-DOSE SAFETY AND EFFICACY STUDY OF PREGABALIN IN ADOLESCENTS (12 THROUGH 17 YEARS OLD) WITH FIBROMYALGIA

M-194 INFORMATION ADDED TO THE LABELING REGARDING USE OF REGADENOSON ADMINISTRATION FOLLOWING AN INADEQUATE EXERCISE STRESS TEST AS COMPARED TO REGADENOSON ALONE

M-195 REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING REFLECTING LACK OF EFFICACY FOR IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17

M-196 REVISIONS TO THE PACKAGE INSERT BASED ON DATA FROM A RANDOMIZED, PLACEBO CONTROLLED, MULTICENTER STUDY OF INTRAVENOUS ACETAMINOPHEN FOR THE TREATMENT OF ACUTE PAIN IN PEDIATRIC PATIENTS TO FULFILL THE POST-MARKETING REQUIREMENT 1704-1

M-197 NEW CLINICAL DATA ADDED TO THE PRESCRIBING INFORMATION REGARDING CANAGLIFLOZIN ADD-ON COMBINATION THERAPY WITH METFORMIN AND A DIPEPTIDYL-PEPTIDASE-4 INHIBITOR

M-198 PACKAGE INSERT UPDATED WITH RESULTS FROM STUDY CV181168, A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE 3 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF SAXAGLIPTIN ADDED TO DAPAGLIFLOZIN AND METFORMIN

M-199 INFORMATION ADDED TO LABELING REGARDING THE TREATMENT OF PATIENTS WITH ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAD NOT RECEIVED PRIOR SYSTEMIC THERAPY FOR METASTATIC DISEASE.

M-200 CLINICAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING.

M-201 REVISIONS TO THE PACKAGE INSERT BASED ON DATA FROM AN OPEN LABEL, MULTI-CENTER STUDY OF CABAZITAXEL IN PEDIATRIC PATIENTS WITH REFRACTORY SOLID TUMORS INCLUDING TUMORS OF THE CENTRAL NERVOUS SYSTEM.

EXCLUSIVITY MISCELLANEOUS

M-202 INCLUSION OF DATA FROM THE SUMMIT STUDY FOR BREO ELLIPTA (FLUTICASONE FUROATE/VILANTEROL TRIFENATATE) INHALATION POWDER IN THE PACKAGE INSERT.

M-203 PROVIDES FOR REVISIONS TO THE PACKAGE INSERT TO REFLECT RESULTS OF TWO POSTMARKETING REQUIREMENT STUDIES ROP111662 AND ROP111569

M-204 CLINICAL INFORMATION ADDED TO THE PACKAGE INSERT REGARDING USE OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS AGES 10-17 WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)

M-205 INFORMATION ADDED TO THE LABELING REGARDING RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES ON PATIENTS WITH SEVERE RENAL IMPAIRMENT

M-206 INFORMATION ADDED TO LABELING REGARDING 48 WEEK EFFICACY, RESISTANCE AND SAFETY DATA ON VIROLOGICALLY SUPPRESSED HIV-1 INFECTED ADULTS SWITCHING FROM COMPLERA TO ODEFSEY

M-207 INFORMATION ADDED TO LABELING REGARDING 48 WEEK EFFICACY, RESISTANCE AND SAFETY DATA ON VIROLOGICALLY SUPPRESSED HIV-1 INFECTED ADULTS SWITCHING FROM ATRIPLA TO ODEFSEY

M-208 INFORMATION ADDED TO THE LABELING TO INCLUDE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS

M-209 INFORMATION ADDED TO THE LABELING REGARDING CABAZITAXEL AT 20 MG/M2 BASED ON THE RESULTS OF THE PROSELICA STUDY

M-210 INFORMATION ADDED TO LABELING TO SUPPORT THE USE OF SYMBICORT TO REDUCE EXACERBATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

M-211 PROVIDES FOR LABELING CHANGES REGARDING THE USE OF DAPTOMYCIN IN THE PEDIATRIC POPULATION FOR STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB) BASED ON RESULTS OF A TRIAL IN PEDIATRIC PATIENTS 1 TO 17 YEARS OF AGE

M-212 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A BACKGROUND COMBINATION OF METFORMIN AND EXENATIDE EXTENDED RELEASE

M-213 INFORMATION ADDED TO THE LABELING TO INCLUDE THE EFFICACY AND SAFETY OF CARIPRAZINE RELATIVE TO PLACEBO IN THE PREVENTION OF RELAPSE OF SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA

M-214 INFORMATION ADDED TO THE CLINICAL TRIALS SECTION OF THE LABELING REGARDING A POSTMARKETING SAFETY AND EFFICACY STUDY EVALUATING THE RISK OF SERIOUS ASTHMA-RELATED EVENTS

M-215 INFORMATION ADDED TO THE LABELING REGARDING THE COMPARISON OF PALIPERIDONE PALMITATE COMPARED WITH ORAL ANTIPSYCHOTIC TREATMENT IN DELAYING TIME TO TREATMENT FAILURE IN ADULTS WITH SCHIZOPHRENIA WHO HAVE BEEN INCARCERATED

M-216 UPDATE THE PRESCRIBING INFORMATION AND PATIENT LABELING WITH FINDINGS FROM STUDY RP103-08 CONDUCTED IN TREATMENT-NAIVE NEPHROPATHIC CYSTINOSIS PATIENTS TO EXPAND THE INDICATED POPULATION TO PATIENTS 1 YEAR AND OLDER

M-217 INCORPORATION OF THE LABELING REVISIONS PROVIDED FOR IN NDA 022253/S-039 AND NDA 022255/S-022 INTO THE LACOSAMIDE INJECTION LABELING

M-218 ADDITIONAL INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING A NEW CLINICAL TRIAL IN PATIENTS AGED 6 THROUGH 11 YEARS (TRIAL 4)

M-219 INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING A NEW CLINICAL TRIAL IN PATIENTS 7 TO 14 YEARS OF AGE WITH DUCHENNE MUSCULAR DYSTROPHY

M-220 ADDITIONAL INFORMATION ADDED TO THE LABELING FROM STUDY PC B308/13 REGARDING THE USE OF BLUE LIGHT CYSTOSCOPY WITH CYSVIEW AS AN ADJUNCT TO WHITE LIGHT CYSTOSCOPY

M-221 DRUG FACTS LABELING CHANGES UNDER THE DIRECTIONS HEADING TO REVISE THE STATED PREPARATION TIME OF A DRY SITE FROM 120 SECONDS SCRUBBING AND 90 SECONDS DRYING TO 30 SECONDS SCRUBBING AND 30 SECONDS DRYING

M-222 ADDITION OF DATA BASED ON THE ASSESSMENT OF SAFETY AND EFFICACY IN PEDIATRIC PATIENTS WITH MAJOR DEPRESSIVE DISORDER TO FULFILL POSTMARKETING STUDY REQUIREMENT 1229-1

M-223 INFORMATION ADDED TO SECTION 8.1 OF THE LABELING REGARDING PREGNANT PATIENTS WHO ARE ALREADY ON A STABLE RILPIVIRINE REGIMEN PRIOR TO PREGNANCY AND WHO ARE VIROLOGICALLY SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES/ML)

M-224 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF EXENATIDE EXTENDED RELEASE AS ADD-ON IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE

EXCLUSIVITY MISCELLANEOUS

	GLYCEMIC CONTROL ON BASAL INSULIN GLARGINE WITH OR WITHOUT METFORMIN
M-225	REVISIONS TO SECTION 8.4 OF THE PRESCRIBING INFORMATION TO INCLUDE A SAFETY AND EFFICACY STUDY IN PEDIATRIC PATIENTS AGES >=6 YEARS TO <18 YEARS WITH CHRONIC IDIOPATHIC CONSTIPATION
M-226	CHANGES TO THE LABELING BASED ON RESULTS FROM A CONTROLLED CLINICAL TRIAL IN PATIENTS WITH LATER-ONSET SPINAL MUSCULAR ATROPHY
M-227	ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING WITH THE SUBSECTION ENTITLED DIGIT SYMBOL SUBSTITUTION TEST IN MAJOR DEPRESSIVE DISORDER
M-228	INFORMATION ADDED TO THE PACKAGE INSERT REGARDING THE REVISION OF THE MONOTHERAPY INDICATION OF VENETOCLAX
M-229	REVISED LABELING TO INCORPORATE THE PEDIATRIC USE OF LOTEPREDNOL ETABONATE GEL IN PATIENTS FOR THE TREATMENT OF POSTOPERATIVE INFLAMMATION FOLLOWING OCULAR SURGERY
M-230	REVISIONS TO THE GLECAPREVIR/PIBRENTASVIR COMBINATION PRODUCT PRESCRIBING INFORMATION TO INCLUDE SAFETY AND EFFICACY DATA FROM THE HCV/HIV-1 COINFECTION STUDY M14-730 AND FROM THE LIVER AND RENAL TRANSPLANT STUDY M13-596
M-231	REVISIONS TO THE USE IN SPECIFIC POPULATIONS SECTION (SECTION 8.3) OF THE PACKAGE INSERT WITH THE RESULTS OF CLINICAL TRIAL WV25651, CONDUCTED TO EVALUATE THE EFFECT OF VALGANCYCLOVIR ON SPERMATOGENESIS AND TO FULFILL PMR 1670-3
M-232	INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES
M-233	INFORMATION ADDED TO THE LABELING TO DESCRIBE FIXED-DOSE COMBINATION OF TIOTROPIUM BROMIDE AND OLODATEROL TO INCLUDE REDUCTION OF COPD EXACERBATIONS
M-234	UPDATE TO THE PRESCRIBING INFORMATION FOR VORTIOXETINE ON TREATMENT-EMERGENT SEXUAL DYSFUNCTION COMPARING VORTIOXETINE AND SSRIS
M-235	INFORMATION ADDED TO SECTION 14 OF THE LABELING TO DESCRIBE STUDY LAP016A2307 TO FULFILL POSTMARKETING STUDY REQUIREMENT 1586-1

ORPHAN DRUG EXCLUSIVITY

ODE-1	TO REDUCE CHRONIC DROOLING IN PATIENTS AGED 3 - 16 WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING (E.G. CEREBRAL PALSY)
ODE-2	FOR TREATMENT OF NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
ODE-3	TO TREAT INFANTILE SPASMS
ODE-4	TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION
ODE-5	FOR SEQUENTIAL USE FOR THE TREATMENT OF CYANIDE POISONING THAT IS JUDGED TO BE LIFE-THREATENING
ODE-6	FOR THE MANAGEMENT OF POSTHERPETIC NEURALGIA
ODE-7	TO REDUCE THE RISK OF PRETERM BIRTH IN WOMEN WITH SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH
ODE-8	TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY
ODE-9	TREATMENT OF ASYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE
ODE-10	FOR USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER
ODE-11	TREATMENT OF PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE
ODE-12	TREATMENT OF PERIPHERAL T-CELL LYMPHOMA (PTCL) IN PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-13	TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA WITH THE BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-14	TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA IN ADULTS 18 YEARS OF AGE AND OLDER

ORPHAN DRUG EXCLUSIVITY

ODE-15	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) THAT IS ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA APPROVED TEST
ODE-16	TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO THALASSEMIA SYNDROMES WHEN CURRENT CHELATION THERAPY IS INADEQUATE
ODE-17	ADJUNCTIVE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME IN PATIENTS 2 YEARS OF AGE OR OLDER
ODE-18	ADJUNCTIVE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME INPATIENTS 2 YEARS OF AGE OR OLDER
ODE-19	TREATMENT OF PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS, INCLUDING PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
ODE-20	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE A G551D MUTATION IN THE CFTR GENE.
ODE-21	AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY
ODE-22	FOR THE CONTROL OF HYPERGLYCEMIA SECONDARY TO HYPERCORTISOLISM IN ADULT PATIENTS WITH ENDOGENOUS CUSHING'S SYNDROME WHO HAVE TYPE 2 DIABETES MELLITUS OR GLUCOSE INTOLERANCE AND HAVE FAILED SURGERY OR ARE NOT CANDIDATES FOR SURGERY
ODE-23	ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY
ODE-24	TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC) NOT REQUIRING IMMEDIATE SURGERY
ODE-25	MANAGEMENT OF POSTHERPETIC NEURALGIA IN ADULTS.
ODE-26	TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS
ODE-27	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
ODE-28	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE (PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES
ODE-29	LOCALIZATION OF LYMPH NODES DRAINING A PRIMARY TUMOR IN PATIENTS WITH MELANOMA WHEN USED WITH A HAND-HELD GAMMA COUNTER
ODE-30	TREATMENT OF ADULT PATIENTS WITH CHRONIC, ACCELERATED OR BLAST PHASE PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOGENOUS LEUKEMIA (CML) WITH RESISTANCE, OR INTOLERANCE TO PRIOR THERAPY
ODE-31	TREATMENT OF CORNEAL CYSTINE CRYSTAL ACCUMULATION IN PATIENTS WITH CYSTINOSIS
ODE-32	TREATMENT OF ADULT PATIENTS WITH CHRONIC OR ACCELERATED PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE AND/OR INTOLERANCE TO TWO OR MORE TYROSINE KINASE INHIBITORS (TKI)
ODE-33	TREATMENT OF PROGRESSIVE, METASTATIC MEDULLARY THYROID CANCER (MTC)
ODE-34	TREATMENT OF ADULT PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
ODE-35	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) THAT IS RESISTANT OR INTOLERANT TO PRIOR TYROSINE KINASE INHIBITOR THERAPY.
ODE-36	ADJUNCT TO A LOW-FAT DIET AND OTHER LIPID-LOWERING TREATMENTS, INCLUDING LDL APHERESIS WHERE AVAILABLE, TO REDUCE LDL-C, TC, APOLIPOPROTEIN B, & NON-HDL-C IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
ODE-37	TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME (SBS) WHO ARE DEPENDENT ON PARENTERAL SUPPORT
ODE-38	PART OF COMBINATION THERAPY IN ADULTS (GREATER THAN OR EQUAL TO 18 YEARS) WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS (MDR-TB)
ODE-39	TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS. & OLDER WITH NON-TRANSFUSION DEPENDENT THALASSEMIA (NTDT) SYNDROMES AND WITH A LIVER IRON CONCENTRATION OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT & SERUM FERRITIN GREATER THAN 300 MCG/L.
ODE-40	TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) IN COMBINATION WITH

ORPHAN DRUG EXCLUSIVITY

	CHEMOTHERAPY, APPROVED UNDER NDA #21588/S-037
ODE-41	ADJUNCT TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LDL-C, APOLIPOPROTEIN B (APO B), TOTAL CHOLESTEROL (TC), AND NON-HIGH DENSITY LIPOPROTEIN-CHOLESTEROL (NON-HDL-C) IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
ODE-42	USE AS A NITROGEN-BINDING ADJUNCTIVE THERAPY FOR CHRONIC MGMT OF ADULT AND PEDIATRIC PATIENTS AT LEAST 2 YRS WITH UREA CYCLE DISORDERS THAT CANNOT BE MANAGED BY DIETARY PROTEIN RESTRICTION AND/OR AMINO ACID SUPPLEMENTATION ALONE
ODE-43	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND BORTEZOMIB AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY.
ODE-44	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE.
ODE-45	MANAGEMENT OF NEPHROPATHIC CYSTINOSIS IN ADULTS AND CHILDREN AGES 6 YEARS AND OLDER.
ODE-46	IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS REGARDLESS OF THEIR POST-ICTUS NEUROLOGICAL CONDITION
ODE-47	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION AS DETECTED BY AN FDA APPROVED TEST.
ODE-48	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA APPROVED TEST
ODE-49	TREATMENT OF MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
ODE-50	FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST.
ODE-51	TOPICAL TREATMENT OF STAGE 1A AND 1B MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN-DIRECTED THERAPY
ODE-52	TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS AS FIRST-LINE TREATMENT, IN COMBINATION WITH GEMCITABINE.
ODE-53	TREATMENT OF ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) WHO GROUP 1, TO IMPROVE EXERCISE CAPACITY, WHO FUNCTIONAL CLASS AND TO DELAY CLINICAL WORSENING.
ODE-54	TX OF PAH TO DELAY DISEASE PROGRESSION. DISEASE PROGRESSION INCLUDED: DEATH, INITIATION OF IV OR SC PROSTANOIDS, OR CLINICAL WORSENING OF PAH (DECREASED 6-MINUTE WALK DISTANCE, WORSENED PAH SYMPTOMS AND NEED FOR ADDITIONAL PAH TREATMENT).
ODE-55	TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-56	TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DCT) THAT IS REFRACTORY TO RADIOACTIVE IODINE TREATMENT.
ODE-57	TRAMETINIB IN COMBO WITH DABRAFENIB FOR TX. OF PTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST. THIS INDICATION IS BASED ON THE DEMONSTRATION OF DURABLE RESPONSE RATE
ODE-58	DABRAFENIB IN COMBO WITH TRAMETINIB FOR TX. OF PTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST. THIS INDICATION IS BASED ON THE DEMONSTRATION OF DURABLE RESPONSE RATE
ODE-59	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER
ODE-60	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-61	TREATMENT OF NEUROGENIC SYMPTOMATIC ORTHOSTATIC HYPOTENSION IN PATIENTS WITH PRIMARY AUTONOMIC FAILURE, DOPAMINE-BETA-HYDROXYLASE DEFICIENCY, AND NONDIABETIC AUTONOMIC NEUROPATHY
ODE-62	TREATMENT OF PROLIFERATING INFANTILE HEMANGIOMA REQUIRING SYSTEMIC THERAPY.

ORPHAN DRUG EXCLUSIVITY

ODE-63	TREATMENT OF VISCERAL LEISHMANIASIS DUE TO LEISHMANIA DONOVANI; CUTANEOUS LEISHMANIASIS DUE TO LEISHMANIA BRAZILIENSIS, LEISHMANIA GUYANENSIS, AND LEISHMANIA PANAMENSIS; AND MUCOSAL LEISHMANIASIS DUE TO LEISHMANIA BRAZILIENSIS.
ODE-64	SELECTIVE HEPATIC INTRA-ARTERIAL USE FOR IMAGING TUMORS IN ADULTS WITH KNOWN HEPATOCELLULAR CARCINOMA (HCC)
ODE-65	TREATMENT OF PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AS PART OF A COMBINATION REGIMEN.
ODE-66	TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB.
ODE-67	GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY
ODE-68	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
ODE-69	TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK
ODE-70	RELAPSED CLL, IN COMBO. WITH RITUXIMAB, IN PATIENTS FOR WHOM RITUXIMAB ALONE WOULD BE CONSIDERED APPROPRIATE THERAPY DUE TO OTHER CO-MORBIDITIES; AND RELAPSED SLL IN PATIENTS WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES
ODE-71	RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA (FL) IN PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
ODE-72	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-73	LONG-TERM TREATMENT OF ADULT PATIENTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS (EMS), INTERMEDIATE METABOLIZERS (IMS), OR POOR METABOLIZERS (PMS) AS DETECTED BY AN FDA-CLEARED TEST.
ODE-74	TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
ODE-75	TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY.
ODE-76	TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE NOT RECEIVED AT LEAST 1 PRIOR THERAPY
ODE-77	TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
ODE-78	TREATMENT OF HYPERCALCEMIA IN ADULT PATIENTS WITH PRIMARY HYPERPARATHYROIDISM FOR WHOM PARATHYROIDECTOMY WOULD BE INDICATED ON THE BASIS OF SERUM CALCIUM LEVELS, BUT WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY.
ODE-79	TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
ODE-80	TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
ODE-81	TREATMENT OF PATIENTS WITH ACROMEGALY WHO HAVE HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION
ODE-82	TREATMENT OF PATIENTS WITH UNRESECTABLE,WELL- OR MODERATELY-DIFFERENTIATED LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS TO IMPROVE PROGRESSION-FREE SURVIVAL
ODE-83	USE OF AS MONOTHERAPY FOR PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA MUTATED (AS DETECTED BY AN FDA-APPROVED TEST) ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY
ODE-84	TREATMENT OF MOTOR FLUCTUATIONS IN PATIENTS WITH ADVANCED PARKINSON'S DISEASE
ODE-85	AS A REPLACEMENT SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) AND IN CASE OF DRUG POISONING WHEN CRRT IS USED TO REMOVE DIALYZABLE SUBSTANCES
ODE-86	TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA
ODE-87	TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER
ODE-88	FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE TREATMENT)
ODE-89	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR REGIMENS, INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT

ORPHAN DRUG EXCLUSIVITY

ODE-90	TREATMENT OF INVASIVE MUCORMYCOSIS IN PATIENTS 18 YEARS OF AGE AND OLDER
ODE-91	TREATMENT OF BILE ACID SYNTHESIS DISORDERS DUE TO SINGLE ENZYME DEFECTS
ODE-92	TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS (LAM)
ODE-93	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 12 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR F508DEL MUTATION IN THE CFTR GENE
ODE-94	PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY TRANSPLANT PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS
ODE-95	FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
ODE-96	TREATMENT OF PRIMARY HYPERKALEMIC PERIODIC PARALYSIS, PRIMARY HYPOKALEMIC PERIOD PARALYSIS, AND RELATED VARIANTS
ODE-97	TO EXPAND THE INDICATION TO PEDIATRIC PATIENTS 2-6 YEARS OF AGE WITH NEPHROPATHIC CYSTINOSIS
ODE-98	TREATMENT OF HEREDITARY OROTIC ACIDURIA
ODE-99	FOR USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, FOR THE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED FOLLOWING GEMCITABINE-BASED THERAPY
ODE-100	FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA OR LEIOMYOSARCOMA WHO RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN
ODE-101	FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATION, IN COMBINATION WITH VEMURAFENIB. COTELLIC IS NOT INDICATED FOR TREATMENT OF PATIENTS WITH WILD-TYPE BRAF MELANOMA
ODE-102	FOR TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), AS DETECTED BY AN FDA-APPROVED TEST, WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY
ODE-103	USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-104	EMERGENCY TX OF PTS FOLLOWING A FU OR CAPECITABINE OD, OR WHO EXHIBIT EARLY-ONSET, SEVERE OR LIFE-THREATENING TOXICITY AFFECTING THE CARDIAC SYSTEM OR CNS, AND/OR EARLY-ONSET, UNUSUALLY SEVERE AR W/IN 96 HRS FOLLOWING THE END OF FU OR CAPECITABINE ADMIN.
ODE-105	TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
ODE-106	FOR USE OF UPTRAVI (SELEXIPAG) TABLETS, 200, 400, 600, 800, 1000, 1200, 1400, AND 1600 MCG FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH, WHO GROUP I) TO REDUCE THE RISKS OF DISEASE PROGRESSION AND HOSPITALIZATION FOR PAH
ODE-107	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE RECEIVED A PRIOR ANTHRACYCLNE-CONTAINING REGIMEN
ODE-108	TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL-DIFFERENTIATED, NON-FUNCTIONAL, NEUROENDOCRINE TUMORS (NET) OF GASTROINTESTINAL (GI) OR LUNG ORIGIN, (EXCLUDING PANCREATIC) WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE
ODE-109	INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT 17P DELETION WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE THERAPY)
ODE-110	FOR HIGH-DOSE CONDITIONING TREATMENT PRIOR TO HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
ODE-111	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS ARE ROS-1 POSITIVE.
ODE-112	FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE (VOD), ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME (SOS), WITH RENAL OR PULMONARY DYSFUNCTION FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT).
ODE-113	FOR TREATMENT OF PEDIATRIC AND ADULT PATIENTS WITH ACQUIRED METHEMOGLOBINEMIA.
ODE-114	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR

ORPHAN DRUG EXCLUSIVITY

	THERAPY
ODE-115	TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY
ODE-116	TREATMENT OF PROGRESSIVE KERATOCONUS
ODE-117	FOR TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL)
ODE-118	AN ADJUNCT TO DIET TO REDUCE LDL-C, TOTAL-C, NONHDL-C AND APOB IN CHILDREN AND ADOLESCENTS 7 TO 17 YEARS OF AGE WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, EITHER ALONE OR WITH OTHER LIPID-LOWERING TREATMENTS (E.G., LDL APHERESIS)
ODE-119	TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA
ODE-120	FOR USE AFTER RADIOLABELING WITH GA 68, WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT AND PEDIATRIC PATIENTS.
ODE-121	TREATMENT OF CORNEAL ECTASIA FOLLOWING REFRACTIVE SURGERY
ODE-122	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
ODE-123	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6-11 YEAR OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE
ODE-124	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE FORMULATIONS, WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE, IN ADULTS WITH THE FOLLOWING SEIZURE TYPES: PARTIAL WITH COMPLEX SYMPTOMOLOGY, GENERALIZED CLONIC-TONIC, AND MIXED
ODE-125	INDICATED IN PEDIATRIC PATIENTS 10 YEARS AND OLDER FOR THE PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGES 3 AND 4 AND CKD STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
ODE-126	AS MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC) ASSOCIATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH TWO OR MORE CHEMOTHERAPIES
ODE-127	TREATMENT OF SPINAL MUSCULAR ATROPHY IN PEDIATRIC AND ADULT PATIENTS
ODE-128	TREATMENT OF PATIENTS WITH MARGINAL ZONE LYMPHOMA (MZL) WHO REQUIRE SYSTEMIC THERAPY AND HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED THERAPY
ODE-129	INDICATED FOR REDUCING THE RISK OF GRAFT REJECTION WHEN USED IN CONJUNCTION WITH HIGH-DOSE BUSULFAN & CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION FOR PEDS. PATIENTS WITH CLASS 3 BETA-THALASSEMIA
ODE-130	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS 5 YEARS OF AGE AND OLDER
ODE-131	TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
ODE-132	TREATMENT OF CARCINOID SYNDROME DIARRHEA IN COMBINATION WITH SOMATOSTATIN ANALOG (SSA) THERAPY IN ADULTS INADEQUATELY CONTROLLED BY SSA THERAPY
ODE-133	INDICATED FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
ODE-134	TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE
ODE-135	TREATMENT OF CHRONIC HCV GENOTYPE 2 OR 3 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER OR WEIGHING AT LEAST 35 KG WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-136	TREATMENT OF PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER OR WEIGHING AT LEAST 35 KG WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 4, 5, OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS
ODE-137	TREATMENT OF OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PERSISTENT OLIGOARTHRITIS, PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS-RELATED ARTHRITIS, OR UNDIFFERENTIATED ARTHRITIS) & POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN 0-16 YRS
ODE-138	TREATMENT OF PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AS A COMPONENT OF A COMBINATION CHEOMOTHERAPY MAINTENANCE REGIMEN
ODE-139	TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC OR LIVER CANCER) WHO

ORPHAN DRUG EXCLUSIVITY

	HAVE BEEN PREVIOUSLY TREATED WITH THE DRUG SORAFENIB.
ODE-140	TREATMENT OF ADULT PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), OR MAST CELL LEUKEMIA (MCL)
ODE-141	TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) THAT IS FLT3 MUTATION-POSITIVE AS DETECTED BY AN FDA APPROVED TEST, IN COMBINATION WITH STANDARD CYTARABINE AND DAUNORUBICIN INDUCTION AND CYTARABINE CONSOLIDATION
ODE-142	TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
ODE-143	TO DECREASE THE RECURRENCE OF PNEUMOTHORAX IN ADULTS
ODE-144	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
ODE-145	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST
ODE-146	OPTICAL IMAGING AGENT INDICATED IN PATIENTS WITH GLIOMA (SUSPECTED WORLD HEALTH ORGANIZATION GRADES III OR IV ON PREOPERATIVE IMAGING) AS AN ADJUNCT FOR THE VISUALIZATION OF MALIGNANT TISSUE DURING SURGERY
ODE-147	DABRAFENIB IN COMBINATION WITH TRAMETINIB, FOR THE TX. OF PTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-148	TRAMETINIB IN COMBINATION WITH DABRAFENIB, FOR THE TX. OF PTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-149	TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY
ODE-150	TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS 5 YEARS OF AGE AND OLDER.
ODE-151	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-152	TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD)
ODE-153	TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
ODE-154	FOR USE IN CHILDREN AGES 2 TO 12 YEARS OLD WITH CHAGAS DISEASE
ODE-155	TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
ODE-156	TREATMENT OF ADULTS WITH CARCINOID SYNDROME; WHEN USED, IT REDUCES THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY
ODE-157	FOR USE AS A NITROGEN-BINDING AGENT FOR CHRONIC MANAGEMENT OF PEDIATRIC PATIENTS >=2 MONTHS AND < 2 YEARS OF AGE WITH UREA CYCLE DISORDERS (UCDS) WHO CANNOT BE MANAGED BY DIETARY PROTEIN RESTRICTION AND/OR AMINO ACID SUPPLEMENTATION ALONE
ODE-158	TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION
ODE-159	FOR TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE, METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST, EXCLUDING PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
ODE-160	FOR TREATMENT OF SCURVY IN ADULT AND PEDIATRIC PATIENTS AGE 5 MONTHS AND OLDER FOR WHOM ORAL ADMINISTRATION IS NOT POSSIBLE, INSUFFICIENT OR CONTRAINDICATED
ODE-161	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) IN PEDIATRIC PATIENTS AGED 3 YRS AND OLDER WITH IDIOPATHIC OR CONGENITAL PAH TO IMPROVE PULMONARY VASCULAR RESISTANCE (PVR), WHICH IS EXPECTED TO RESULT IN AN IMPROVEMENT IN EXERCISE ABILITY
ODE-162	TREATMENT OF NEPHROPATHIC CYSTINOSIS IN PEDIATRIC PATIENTS 1 YEAR OF AGE TO LESS THAN 2 YEARS OF AGE
ODE-163	TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML)
ODE-164	TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+)

ORPHAN DRUG EXCLUSIVITY

	CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
ODE-165	PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) INFECTION AND DISEASE IN ADULT CMV-SEROPOSITIVE RECIPIENTS [R+] OF AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
ODE-166	TREATMENT OF SOMATOSTATIN RECEPTOR-POSITIVE GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) INCLUDING FOREGUT, MIDGUT, AND HINDGUT NEUROENDOCRINE TUMORS IN ADULTS
ODE-167	ARSENIC TRIOXIDE FOR USE IN COMBINATION WITH TRETINOIN FOR TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA (APL) WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
ODE-168	FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
ODE-169	FOR THE ADJUNCTIVE TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGED 2 YEARS AND OLDER WITH TUBEROUS SCLEROSIS COMPLEX (TSC)-ASSOCIATED PARTIAL-ONSET SEIZURES
ODE-170	FOR THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY (AGHD)
ODE-171	TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) IN CHRONIC PHASE
ODE-172	TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA WITH RESISTANCE OR INTOLERANCE TO PRIOR TYROSINE-KINASE INHIBITOR THERAPY
ODE-173	TREATMENT OF PATIENTS WITH CYSTIC FIBROSIS AGED 12 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR WHO HAVE AT LEAST ONE MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE RESPONSIVE TO TEZACAFTOR/IVACAFTOR
ODE-174	FOR THE TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
ODE-175	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-176	INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
ODE-177	TO REDUCE THE FREQUENCY OF PAINFUL CRISES AND TO REDUCE THE NEED FOR BLOOD TRANSFUSIONS IN PEDIATRIC PATIENTS, 2 YEARS OF AGE AND OLDER, WITH SICKLE CELL ANEMIA WITH RECURRENT MODERATE TO SEVERE PAINFUL CRISIS
ODE-178	INDICATED TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS AT RISK OF RAPIDLY PROGRESSING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
ODE-179	TREATMENT OF PATIENTS WITH CLL AND TREATMENT OF PATIENTS WITH INDOLENT B-CELL NHL THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN
ODE-180	MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
ODE-181	TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY
ODE-182	TRAMETINIB IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
ODE-183	TRAMETINIB AND DABRAFENIB IN COMBINATION, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS
ODE-184	INDICATED IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH HIV-1 INFECTION
ODE-185	INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

ORPHAN DRUG EXCLUSIVITY

	OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-186	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, OR S549R
ODE-187	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE AN R117H MUTATION IN THE CFTR GENE
ODE-188	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGES 2 TO LESS THAN 6 YEARS WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, AND R117H
ODE-189	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 2 YEARS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: 711+3A-G, E831X, 2789+5G-A, 3272-26A-G, AND 3849+10KBC-T
ODE-190	TX OF CF IN PTS 2 YRS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, R352Q, A455E, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, D1270N
ODE-191	TO DECREASE THE RECURRENCE OF MALIGNANT PLEURAL EFFUSIONS IN SYMPTOMATIC PATIENTS FOLLOWING MAXIMAL DRAINAGE OF THE PLEURAL EFFUSION
ODE-192	INDICATED TO INDUCE CONTROLLED CARDIAC SEPTAL INFRACTION TO IMPROVE EXERCISE CAPACITY IN ADULTS WITH SYMPTOMATIC HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY WHO ARE NOT CANDIDATES FOR SURGICAL MYECTOMY
ODE-193	INDICATED FOR THE TREATMENT OF ONCHOCERCIASIS DUE TO ONCHOCERCA VOLVULUS IN PATIENTS AGED 12 YEARS AND OLDER
ODE-194	ENCORAFENIB IS INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA-APPROVED TEST
ODE-195	FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 2 THROUGH 5 YEARS OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE
ODE-196	INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
ODE-197	INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS
ODE-198	INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER TAKING CLOBAZAM
ODE-199	THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 12 MONTHS AND OLDER WHO HAVE ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
ODE-200	INDICATED FOR THE TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG
ODE-201	INDICATED FOR THE RADICAL CURE (PREVENTION OF RELAPSE) OF PLASMODIUM VIVAX MALARIA IN PATIENTS AGED 16 YEARS AND OLDER WHO ARE RECEIVING APPROPRIATE ANTIMALARIAL THERAPY FOR ACUTE P. VIVAX INFECTION
ODE-202	INDICATED AS A SOURCE OF CALORIES AND FATTY ACIDS IN PEDIATRIC PATIENTS WITH PARENTERAL NUTRITION-ASSOCIATED CHOLESTASIS (PNAC)
ODE-203	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-204	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH IOBENGUANE SCAN POSITIVE, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC PHEOCHROMOCYTOMA OR PARAGANGLIOMA WHO REQUIRE SYSTEMIC ANTICANCER THERAPY
ODE-205	INDICATED FOR THE TREATMENT OF ADULTS WITH A CONFIRMED DIAGNOSIS OF FABRY DISEASE AND AN AMENABLE GALACTOSIDASE ALPHA GENE (GLA) VARIANT BASED ON IN VITRO ASSAY DATA
ODE-206	FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
ODE-207	TREATMENT OF STATUS EPILEPTICUS IN ADULTS
ODE-208	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC

ORPHAN DRUG EXCLUSIVITY

	LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) AFTER AT LEAST TWO PRIOR THERAPIES
ODE-209	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) AFTER AT LEAST TWO PRIOR SYSTEMIC THERAPIES
ODE-210	INDICATED IN COMBINATION WITH STANDARD IMMUNOSUPPRESSIVE THERAPY FOR THE FIRST-LINE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS AND OLDER WITH SEVERE APLASTIC ANEMIA
ODE-211	INDICATED IN COMBO WITH AZACITIDINE, OR DECITABINE, OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
ODE-212	INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS
ODE-213	INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
ODE-214	TX OF MAC LUNG DISEASE IN ADULTS WITH LIMITED OR NO ALTERNATIVE TX OPTIONS AS PART OF A COMBO ANTIBACTERIAL DRUG REGIMEN WHO DO NOT ACHIEVE NEGATIVE SPUTUM CULTURES AFTER A MINIMUM OF 6 CONSECUTIVE MONTHS OF A MULTIDRUG BACKGROUND REGIMEN THERAPY
ODE-215	INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT HAVE A NEUROTROPHIC RECEPTOR TYROSINE KINASE (NTRK) GENE FUSION WITHOUT A KNOWN ACQUIRED RESISTANCE MUTATION
ODE-216	INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) OR DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER
ODE-217	INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON CRIZOTINIB AND AT LEAST ONE OTHER ALK INHIBITOR FOR METASTATIC DIESASE
ODE-218	INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON ALECTINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC DISEASE
ODE-219	INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON CERITINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC DISEASE
ODE-220	INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT ARE METASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY
ODE-221	INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT HAVE NO SATISFACTORY ALTERNATIVE TREATMENTS OR THAT HAVE PROGRESSED FOLLOWING TREATMENT
ODE-222	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WHO HAVE RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH A FMS-LIKE TYROSINE KINASE 3 (FLT3) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-223	INDICATED FOR THE TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME (LEMS) IN ADULTS
ODE-224	INDICATED, IN COMBINATION WITH LOW-DOSE CYTARABINE, FOR THE TREATMENT OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULT PATIENTS WHO ARE >=75 YEARS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY

PATENT USE

U-1	PREVENTION OF PREGNANCY
U-2	TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA
U-3	TREATMENT OF HYPERTENSION
U-4	PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS
U-5	METHOD OF PRODUCING BRONCHODILATION

PATENT USE

U-6	METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS
U-7	INCREASING CARDIAC CONTRACTILITY
U-8	ACUTE MYOCARDIAL INFARCTION
U-9	CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT
U-10	DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALAMIC MALFUNCTIONS OR LESIONS IN HUMANS
U-11	TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS
U-12	METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION
U-13	A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT
U-14	ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES
U-15	METHOD OF LOWERING INTRAOCULAR PRESSURE
U-16	USE IN LUNG SCANNING PROCEDURES
U-17	TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS
U-18	METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS
U-19	TREATMENT OF INFLAMMATION
U-20	A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT
U-21	TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS
U-22	METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS
U-23	METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE
U-24	METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST
U-25	REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS
U-26	REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-27	DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-28	CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY
U-29	CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY
U-30	CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY
U-31	INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY
U-32	PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN
U-33	TREATING VIRAL INFECTIONS IN A MAMMAL
U-34	TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL
U-35	TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION
U-36	METHODS OF TREATING BACTERIAL ILLNESSES
U-37	METHOD OF TREATING GASTROINTESTINAL DISEASE
U-38	TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
U-39	ANGINA PECTORIS
U-40	METHOD OF TREATMENT OF BURNS
U-41	METHOD OF TREATING CARDIAC ARRHYTHMIAS
U-42	ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER
U-43	MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
U-44	RELIEF OF NAUSEA AND VOMITING
U-45	TREATMENT OF INFLAMMATION AND ANALGESIA

PATENT USE

U-46	TREATMENT OF PANIC DISORDER
U-47	STIMULATION OF THE RELEASE OF GROWTH HORMONE
U-48	ANALGESIA
U-49	SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA
U-50	USE IN TREATING INFLAMMATORY DERMATOSES
U-51	BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING
U-52	TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-53	HYPERCALCEMIA OF MALIGNANCY
U-54	REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS
U-55	TREATMENT OF PAIN
U-56	AID TO SMOKING CESSATION
U-57	OPHTHALMIC USE OF NORFLOXACIN
U-58	METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES
U-59	METHOD OF TREATING HYPERCHOLESTEROLEMIA
U-60	NASAL ADMINISTRATION OF BUTORPHANOL
U-61	CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD
U-62	CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY
U-63	ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE
U-64	TREATMENT OF VIRAL INFECTIONS
U-65	METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
U-66	TRIPHASIC REGIMEN
U-67	METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL
U-68	TREATMENT OF ACTINIC KERATOSIS
U-69	TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS
U-70	TREATMENT OF TRANSIENT INSOMNIA
U-71	METHOD OF TREATMENT OF HEART FAILURE
U-72	TREATMENT OF MIGRAINE
U-73	METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES
U-74	METHOD OF PROVIDING HYPNOTIC EFFECT
U-75	RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS
U-76	USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM
U-77	TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
U-78	ULCERATIVE COLITIS
U-79	SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD
U-80	METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
U-81	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS
U-82	TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE
U-83	TREATMENT OF SEIZURES
U-84	A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS
U-85	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-86	METHOD OF TREATING CERTAIN FORMS OF EPILEPSY
U-87	METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS
U-88	TREATMENT OF MODERATE PLAQUE PSORIASIS

PATENT USE

U-89	TREATMENT OR PROPHYLAXIS OF EMESIS
U-90	TREATMENT OF PSYCHOTIC DISORDERS
U-91	ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS
U-92	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY
U-93	USE AS AN ANTIHISTAMINE/DECONGESTANT
U-94	TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED
U-95	SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS
U-96	METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS
U-97	A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT
U-98	A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL
U-99	METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM
U-100	METHOD OF TREATING OCULAR INFLAMMATION
U-101	ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED
U-102	METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN
U-103	TREATMENT OF OCULAR HYPERTENSION
U-104	TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE
U-105	EMESIS
U-106	TREATMENT OF EPILEPSY
U-107	TREATMENT OF HYPERTENSION AND ANGINA PECTORIS
U-108	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS
U-109	ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE
U-110	USE AS A RETRIEVABLE PESSARY
U-111	DIABETES
U-112	CONTRACEPTION
U-113	METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE
U-114	USE FOR INHIBITING BONE RESORPTION
U-115	USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS
U-116	METHOD OF MYOCARDIAL IMAGING
U-117	TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES
U-118	METHOD OF LOWERING BLOOD SUGAR LEVEL
U-119	TREATMENT OF NASAL HYPERSECRETION
U-120	CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES
U-121	METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS
U-122	A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS
U-123	METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS
U-124	TREATMENT OF ACNE

PATENT USE

U-125	TREATMENT NEUROGENERATIVE DISEASES
U-126	TREATMENT OF GASTRITIS
U-127	METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE
U-128	METHOD FOR TREATMENT OF TUMORS
U-129	METHOD TO DESTROY OR IMPAIR TARGET CELLS
U-130	MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS
U-131	PHOTODAMAGED SKIN
U-132	INHIBITING HIV PROTEASE
U-133	MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET
U-134	TREATMENT OF ACNE VULGARIS
U-135	ANTITUMOR AGENT
U-136	PROCESS FOR WASTE NITROGEN REMOVAL
U-137	METHOD OF TREATING BACTERIAL VAGINOSIS
U-138	TREATMENT OF ALLERGIC RHINITIS
U-139	TREATMENT OF ALLERGIC REACTIONS
U-140	USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION
U-141	TREATMENT OF ULCERATIVE COLITIS
U-142	METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE
U-143	BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING
U-144	BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS
U-145	BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS
U-146	METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS
U-147	DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2
U-148	DEVICE FOR COLLECTING A BREATH SAMPLE
U-149	METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES
U-150	METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE
U-151	RELIEF OF SYMPTOMS OF THE COMMON COLD
U-152	METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER
U-153	TREATMENT OF INITIAL EPISODE GENITAL HERPES
U-154	METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER
U-155	TREATMENT OF ERECTILE DYSFUNCTION
U-156	METHOD OF PROVIDING ANESTHESIA
U-157	TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY
U-158	ANGINA
U-159	TREATMENT OF INTERSTITIAL CYSTITIS
U-160	TREATMENT OF BACTERIAL INFECTIOUS DISEASE
U-161	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT
U-162	METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA
U-163	METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS
U-164	METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-

PATENT USE

	DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS
U-165	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
U-166	TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER
U-167	METHOD FOR TREATING HIV-1 INFECTION
U-168	METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA
U-169	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING
U-170	METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT
U-171	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT
U-172	TREATMENT OF GENITAL WARTS
U-173	ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES
U-174	USE AS AN ANTIHISTAMINE AGENT
U-175	METHOD OF TREATING MALIGNANT TUMORS
U-176	METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES
U-177	FUNGICIDE
U-178	FACILITATED ADHERENCE OF AGENTS TO SKIN
U-179	ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT
U-180	TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-181	PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST
U-182	USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-183	TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION
U-184	TREATING ALLERGIC EYE DISEASES IN HUMANS
U-185	METHOD OF TREATING HYPERTENSION
U-186	METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT
U-187	THERAPEUTIC TREATMENT OF CALCIFIC TUMORS
U-188	TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER
U-189	ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
U-190	USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
U-191	METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN
U-192	USE IN TREATING ALLERGIC REACTIONS
U-193	PSORIASIS
U-194	TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE
U-195	METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOPE OR NITROGEN LABELED CARBON
U-196	TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS
U-197	USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER
U-198	TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA
U-199	METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN

PATENT USE

	ANTIMICROBIAL AGENT
U-200	METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-201	METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-202	METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS
U-203	TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
U-204	USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
U-205	METHOD FOR TREATING HEARTBURN
U-206	METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION
U-207	USE AS NASAL SPRAY
U-208	VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION
U-209	VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION
U-210	METHOD OF TREATING CONGESTIVE HEART FAILURE
U-211	USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-212	METHOD OF TREATMENT OF PARKINSON'S DISEASE
U-213	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA
U-214	USE AS A BLOOD GLUCOSE-LOWERING AGENT
U-215	TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
U-216	TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE
U-217	METHOD OF PRODUCING ANESTHESIA
U-218	METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
U-219	TREATMENT OF PARKINSON'S DISEASE
U-220	METHOD OF DIAGNOSIS
U-221	SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
U-222	METHOD OF TREATING PAGET'S DISEASE USING ACTONEL
U-223	TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
U-224	CONTROLLING INTRAOCULAR PRESSURE
U-225	METHOD FOR DELIVERY
U-226	METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
U-227	NASAL ADMINISTRATION
U-228	ASTHMA
U-229	CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
U-230	PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
U-231	USE IN PARKINSON'S DISEASE
U-232	METHOD OF TREATING MIGRAINE
U-233	DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-234	METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
U-235	METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE

PATENT USE

U-236	TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY
U-237	METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS
U-238	IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....
U-239	TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID
U-240	TREATMENT OF ACUTE MIGRAINE ATTACKS
U-241	FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-242	USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION
U-243	TOPICAL ADMINISTRATION
U-244	PLATELET AGGREGATION INHIBITORS
U-245	TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
U-246	PHOSPHATE BINDING
U-247	TREATMENT OF RHEUMATOID ARTHRITIS
U-248	TREATMENT OF HIV
U-249	METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE
U-250	TREATMENT OF HEPATITIS B INFECTION
U-251	USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES
U-252	METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE
U-253	ORAL TRANSMUCOSAL USE
U-254	USE OF AGGRASTAT IN COMBINATION WITH HEPARIN
U-255	IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
U-256	TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS
U-257	TREATMENT OF HIV INFECTION
U-258	TREATMENT OF NEURODEGENERATIVE DISEASES
U-259	TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE
U-260	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
U-261	TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE
U-262	TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE
U-263	METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN
U-264	METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN
U-265	USE AS LAXATIVE
U-266	RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS
U-267	PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE

PATENT USE

	FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE
U-268	ACROMEGALY
U-269	EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS
U-270	METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT
U-271	METHOD OF TREATING TUMORS
U-272	METHOD OF TREATING CARCINOMA
U-273	CUTANEOUS T-CELL LYMPHOMA
U-274	ZANAMIVIR FOR INHALATION
U-275	METHOD OF USE OF THE DRUG SUBSTANCE
U-276	METHOD OF USE OF LEVOBUPIVACAINE
U-277	NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)
U-278	METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT
U-279	METHOD OF USE OF THE APPROVED PRODUCT
U-280	TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE
U-281	ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS
U-282	METHOD OF TREATING BACTERIAL INFECTIONS
U-283	METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE
U-284	MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS
U-285	DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA
U-286	DEPRESSION
U-287	TREATMENT OR PREVENTION OF OSTEOPOROSIS
U-288	THERAPY OF INFLUENZA
U-289	TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP
U-290	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)
U-291	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN
U-292	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE
U-293	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID
U-294	TREATMENT OF HYPERPIGMENTARY DISORDERS
U-295	TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-296	TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY
U-297	PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS
U-298	METHOD OF COMBATING BACTERIA IN A PATIENT
U-299	TREATMENT OF ADENOMATOUS POLYPS
U-300	INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
U-301	USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES
U-302	TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS
U-303	METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS
U-304	A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION

PATENT USE

U-305	METHODS FOR USING THE DRUG PRODUCT
U-306	TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY
U-307	CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES,EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA
U-308	CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA
U-309	TREATING SJOEGREN SYNDROME
U-310	TREATMENT OF XEROSTOMIA
U-311	HORMONE REPLACEMENT
U-312	PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER
U-313	TREATMENT OF CONGESTIVE HEART FAILURE
U-314	METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY
U-315	METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT
U-316	METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER
U-317	METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE
U-318	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
U-319	TREATMENT OF MICROBIAL INFECTIONS
U-320	INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA
U-321	REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS
U-322	TREATMENT OF ALZHEIMER'S DEMENTIA
U-323	USE AS A BILE ACID SEQUESTRANT
U-324	METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE
U-325	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE
U-326	METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER
U-327	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE
U-328	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH
U-329	USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-330	TREATMENT OF NAUSEA AND VOMITING
U-331	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-332	TREATMENT OR PREVENTION OF BRONCHOSPASM
U-333	METHOD OF TREATING OCULAR HYPERTENSION
U-334	TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR
U-335	USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS
U-336	DIAGNOSTIC RADIOIMAGING
U-337	USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI
U-338	METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME
U-339	PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN

PATENT USE

U-340	THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN
U-341	METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER
U-342	METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER
U-343	REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION
U-344	METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR
U-345	RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION
U-346	METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMACOKINETICS OF A DRUG THAT IS METABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR
U-347	METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS
U-348	METHOD OF USE FOR INHIBITING HIV INFECTION
U-349	METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION
U-350	PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-351	INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIR
U-352	INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-353	PREVENTION AND TREATMENT OF OSTEOPOROSIS
U-354	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-355	METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING
U-356	DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.
U-357	USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE
U-358	DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER
U-359	METHOD OF USE OF VISICOL
U-360	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
U-361	MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY
U-362	USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS
U-363	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011
U-364	TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
U-365	METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION
U-366	METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION
U-367	TREATMENT OF CARDIOVASCULAR DISORDERS
U-368	HEARTBURN
U-369	METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE
U-370	INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS

PATENT USE

U-371	APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
U-372	METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...
U-373	GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-374	KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
U-375	METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C
U-376	TREATMENT OF INFLUENZA
U-377	METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS
U-378	METHOD FOR TREATING INCONTINENCE
U-379	METHOD OF TREATING ONYCHOMYCOSIS
U-380	COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS
U-381	TREATMENT OF HYPERPHOSPHATEMIA
U-382	METHOD OF STABILIZING PROSTAGLANDIN
U-383	METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION
U-384	TREATMENT OF CMV RETINITIS
U-385	TREATMENT OF PEPTIC ULCERS
U-386	TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA
U-387	TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS
U-388	SMOKING CESSATION AID APPLIED TO THE SKIN
U-389	SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS
U-390	METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)
U-391	USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER
U-392	TREATMENT OF PATIENTS FOR INFLAMMATION
U-393	MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT
U-394	METHOD OF USE OF ALPHAGAN
U-395	METHOD OF USE OF ALPHAGAN P
U-396	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION
U-397	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA
U-398	TREATMENT OF GENERALIZED ANXIETY DISORDER
U-399	IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS
U-400	USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS
U-401	USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS
U-402	TREATMENT OF ACTINIC KERATOSES
U-403	ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES

PATENT USE

U-404	TREATMENT OF ALLERGIC CONJUNCTIVITIS
U-405	FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS)
U-406	METHOD OF USE OF ATOVAQUONE AND PROGUANIL
U-407	METHOD OF TREATING OTOPATHY
U-408	FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION
U-409	METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE
U-410	METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-411	METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION
U-412	TREATMENT OF TYPE 2 DIABETES
U-413	USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS
U-414	A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-415	A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
U-416	A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
U-417	COMBINATION USE OF AD-4833 WITH A BIGUANIDE
U-418	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-419	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-420	METHOD OF TREATMENT OF TYPE II DIABETES
U-421	USE FOR SEDATION
U-422	METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-423	METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA
U-424	FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS
U-425	METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-426	PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION
U-427	METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS
U-428	METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE
U-429	METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS
U-430	METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER
U-431	POSTTRAUMATIC STRESS DISORDER
U-432	REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE
U-433	USE OF LEVOCARNITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS

PATENT USE

U-434	CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS
U-435	A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG
U-436	ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
U-437	METHOD OF USE EQUAL TO PROCESS OF PREPARATION
U-438	TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE
U-439	TREATMENT OF OBESITY
U-440	METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE
U-441	METHOD OF TREATING MS BY ADMINISTERING COPAXONE
U-442	METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURRENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
U-443	MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
U-444	TREATMENT OF MIGRAINE
U-445	USE AS AN ANTIMYCOTIC AGENT
U-446	TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
U-447	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-448	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-449	USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER
U-450	INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
U-451	TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
U-452	USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)
U-453	TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS
U-454	METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN
U-455	TREATMENT OF PULMONARY HYPERTENSION WITH UT-15
U-456	METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE
U-457	METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN
U-458	METHOD OF USE OF IMAGENT
U-459	TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
U-460	METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE
U-461	METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE
U-462	SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA
U-463	VENOGRAPHY
U-464	PERIPHERAL ARTERIOGRAPHY

PATENT USE

U-465	CT IMAGING OF THE HEAD
U-466	TREATMENT OF IRRITABLE BOWEL SYNDROME
U-467	USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION
U-468	METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS
U-469	TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE
U-470	THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION
U-471	METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
U-472	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES
U-473	TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
U-474	TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN
U-475	TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
U-476	METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
U-477	METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA
U-478	METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B
U-479	METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY
U-480	CONTRAST AGENT FOR MRI
U-481	DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY
U-482	METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....
U-483	METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND
U-484	METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION
U-485	METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
U-486	EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE
U-487	METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
U-488	METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA
U-489	EXPECTORANT
U-490	TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
U-491	METHOD OF DELIVERING A DRUG TO THE LUNG
U-492	METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID
U-493	TREATMENT OF TYPE 2 DIABETES MELLITUS
U-494	TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
U-495	PERITONEAL DIALYSIS SOLUTION

PATENT USE

U-496	METHOD FOR TREATING CHRONIC RENAL FAILURE
U-497	RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS
U-498	INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST
U-499	METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION
U-500	USE AS AN ANTIHYPERTENSIVE AGENT
U-501	TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
U-502	PITYRIASIS VERSICOLOR
U-503	GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR
U-504	TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS
U-505	ULTRASOUND CONTRAST AGENT
U-506	PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..
U-507	ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
U-508	METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS
U-509	TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
U-510	TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES
U-511	USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA
U-512	USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA
U-513	METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA
U-514	PREVENTION OF OVULATION IN A WOMAN
U-515	TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY
U-516	METHOD OF TREATING A PSYCHOTIC DISEASE
U-517	STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS
U-518	OBSESSIVE COMPULSIVE DISORDER
U-519	POST OPERATIVE NAUSEA AND VOMITING
U-520	PREMENOPAUSAL OSTEOPOROSIS
U-521	METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
U-522	TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA
U-523	METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL
U-524	METHOD OF TREATING DIARRHEA
U-525	METHOD OF TREATING PARASITIC INFECTIONS
U-526	METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION
U-527	METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE
U-528	PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
U-529	ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE
U-530	TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD

PATENT USE

	SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES
U-531	TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES
U-532	TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR
U-533	ERECTILE DYSFUNCTION
U-534	HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA
U-535	TREATMENT OF SOCIAL ANXIETY DISORDER
U-536	CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING
U-537	TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE
U-538	FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS
U-539	TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
U-540	TREATMENT OF FUNGAL INFECTIONS
U-541	METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1
U-542	METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION
U-543	TREATMENT OF SCHIZOPHRENIA
U-544	TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.
U-545	METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT
U-546	USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE
U-547	MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER
U-548	A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER
U-549	USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER
U-550	TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
U-551	METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID
U-552	TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION
U-553	MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS
U-554	TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS
U-555	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
U-556	USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING
U-557	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-558	INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)
U-559	METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL
U-560	METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM
U-561	COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS
U-562	TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S

PATENT USE

	SARCOMA
U-563	MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
U-564	TREATMENT OF HIV IN CONCOMITANT THERAPY
U-565	TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA
U-566	FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
U-567	METHOD OF TREATING INFERTILITY
U-568	METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION
U-569	METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED
U-570	METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG
U-571	TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA
U-572	INTENSIVE CARE UNIT SEDATION
U-573	TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
U-574	PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-575	LOTEMAX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.
U-576	ALREX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.
U-577	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN
U-578	TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.
U-579	TREATMENT OF EPILEPSY AND/OR MIGRAINE.
U-580	TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS
U-581	METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413
U-582	METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762
U-583	METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928
U-584	SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY
U-585	TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
U-586	AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH
U-587	USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION
U-588	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
U-589	METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A

PATENT USE

	METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966
U-590	METHOD FOR TREATMENT OF A RESPIRATORY DISORDER,E.G.,BRONCHOSPASM,COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955
U-591	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG
U-592	TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
U-593	TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
U-594	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
U-595	35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-596	TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
U-597	FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE
U-598	PROPHYLACTIC TREATMENT OF MIGRAINE
U-599	METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS
U-600	A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN
U-601	TREATMENT OF BIPOLAR DISORDER
U-602	SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS
U-603	METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION
U-604	METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION
U-605	TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MEHCHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS
U-606	USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER
U-607	CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.
U-608	USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA
U-609	USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA
U-610	ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.
U-611	METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER
U-612	TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
U-613	REDUCTION OF SERUM PHOSPHATE
U-614	TREATMENT OF SEXUAL DYSFUNCTION
U-615	ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
U-616	MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER
U-617	TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
U-618	USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR

PATENT USE

	TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.
U-619	TREATMENT OF MALIGNANT NEOPLASM
U-620	TREATMENT OF INSOMNIA
U-621	METHOD OF TREATING CANCER
U-622	TREATMENT OF VEGF MEDIATED OCULAR DISEASE.
U-623	SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
U-624	REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
U-625	ALLERGIC RHINITIS OR NASAL POLYPS
U-626	CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS
U-627	TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE
U-628	USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-629	METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE
U-630	TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN
U-631	TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN
U-632	METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING
U-633	METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR
U-634	METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL
U-635	TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS
U-636	TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS
U-637	TREATMENT OF DIABETES WITH AN AMYLIN AGONIST
U-638	TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN
U-639	TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE
U-640	USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGYLCEMIA
U-641	USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION
U-642	TREATMENT AND PREVENTION OF OSTEOPOROSIS
U-643	THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE
U-644	TREATMENT OF SEASONAL ALLERGIC RHINITIS
U-645	TREATMENT OF ASTHMA
U-646	METHOD OF TREATING OTITIS
U-647	TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
U-648	THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN
U-649	A METHOD FOR TREATING A TUMOR DISEASE
U-650	TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN

PATENT USE

	HSCT PATIENTS
U-651	TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)
U-652	TREATMENT OF CARDIAC ARRHYTHMIA
U-653	STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE
U-654	LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXENDIN OR ANALOG, SUCH AS EXENDIN-4
U-655	TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS
U-656	REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
U-657	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-658	TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER
U-659	TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN
U-660	TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE
U-661	TREATMENT OF SEIZURE DISORDER
U-662	TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-663	THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
U-664	TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION
U-665	METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
U-666	METHOD OF TREATING ADHD
U-667	MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE
U-668	LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS
U-669	INDICATION OF TYPE II DIABETES
U-670	TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.
U-671	PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4
U-672	TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER
U-673	METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML
U-674	METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET
U-675	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS
U-676	METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION
U-677	A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM
U-678	METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-679	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
U-680	A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM
U-681	TREATMENT OF PRIMARY IGF-1 DEFICIENCY
U-682	NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE
U-683	PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE
U-684	TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA

PATENT USE

	IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
U-685	EXPECTORANT AND COUGH SUPPRESSANT
U-686	EXPECTORANT AND NASAL DECONGESTANT
U-687	REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
U-688	TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
U-689	TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
U-690	TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-691	USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-692	USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
U-693	THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.
U-694	LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.
U-695	TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
U-696	TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
U-697	A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TREATMENT OF PRIMARY IGF-1 DEFICIENCY
U-698	METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH EUVOLEMIC HYPONATREMIA
U-699	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-700	TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-701	TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA
U-702	TOPICAL AEROSOL HAIR REGROWTH TREATMENT
U-703	TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB
U-704	METHOD OF ADMINISTERING INSULIN VIA INHALATION
U-705	TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE
U-706	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
U-707	ALLERGIC RHINITIS
U-708	TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
U-709	METHOD OF COMBATING BACTERIA IN A PATIENT
U-710	A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549
U-711	ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
U-712	A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA
U-713	TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE
U-714	TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM

PATENT USE

U-715	FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER
U-716	THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
U-717	METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT
U-718	TREATMENT OF FUNGAL INFECTIONS
U-719	TREATENT OF PSYCHOSIS
U-720	TREATMENT OF NEUROLEPTIC DISEASES
U-721	TREATMENT OF INFLUENZA
U-722	PROPHYLAXIS OF INFLUENZA
U-723	PROPHYLACTIC TREATMENT OF MIGRAINE
U-724	METHOD OF TREATING SEIZURES
U-725	ALLERGIC RHINITIS AND URTICARIA
U-726	ALLERGIC RHINITIS
U-727	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
U-728	METHOD FOR TREATING BACTERIAL INFECTION
U-729	TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-730	USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS
U-731	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
U-732	ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)
U-733	MAINTENANCE THERAPY FOR PREVENTION AND SUPPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE
U-734	FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS
U-735	METHOD OF TREATING CHRONIC IRON OVERLOAD
U-736	METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE
U-737	DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE
U-738	INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER
U-739	METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMMALIAN SUBJECT
U-740	FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS
U-741	COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER
U-742	TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.
U-743	ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA
U-744	TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS
U-745	TREATMENT OR PREVENTION OF EMESIS
U-746	PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT
U-747	PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
U-748	A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER
U-749	METHOD OF CONTRACEPTION
U-750	TREATMENT OF HIV-1 INFECTION IN ADULTS
U-751	ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA
U-752	SUNSCREEN

PATENT USE

U-753	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES
U-754	USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA
U-755	TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
U-756	ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
U-757	USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL
U-758	TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER
U-759	METHOD OF USE OF ADMINISTERING LEVOTHYROXINE
U-760	PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDIASIS
U-761	TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA
U-762	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-763	ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION
U-764	TREATMENT OF SCHIZOPHRENIA
U-765	METHOD OF TREATING ALLERGIC CONJUNCTIVITIS
U-766	TREATMENT OF SEIZURES
U-767	MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
U-768	A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID
U-769	REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-770	LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-771	METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELLITUS, IN A HUMAN PATIENT
U-772	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS
U-773	PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-774	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
U-775	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
U-776	TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.
U-777	DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-778	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-779	A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA
U-780	A METHOD FOR THE TREATMENT OF CANCER
U-781	FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY
U-782	TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE
U-783	DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER
U-784	TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)

PATENT USE

U-785	USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY
U-786	PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS
U-787	MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA
U-788	METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE
U-789	TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING
U-790	FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS
U-791	GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)
U-792	TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
U-793	FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
U-794	CLOSURE OF A CLINICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE
U-795	METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE
U-796	METHOD OF TREATING DEPRESSION
U-797	METHOD OF TREATING ANXIETY
U-798	TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID
U-799	METHOD FOR INHIBITING SEROTONIN UPTAKE
U-800	TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB
U-801	METHOD OF TREATING CANCER
U-802	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
U-803	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN
U-804	TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY
U-805	TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES
U-806	INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS
U-807	PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION
U-808	THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER
U-809	TREATMENT OF CHRONIC IDIOPATHIC URTICARIA
U-810	METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE
U-811	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA
U-812	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS
U-813	MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-814	TREATMENT OF SCHIZOPHRENIA
U-815	TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING

PATENT USE

U-816	DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER
U-817	NASAL ADMINISTRATION OF CYANOCOBALAMIN
U-818	TOPICAL TREATMENT OF ACNE VULGARIS
U-819	MANAGEMENT OF FIBROMYALGIA
U-820	IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER
U-821	METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.
U-822	USE IN LIPID MANAGEMENT
U-823	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE
U-824	METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1
U-825	USE FOR PREVENTION OF BREAST CANCER
U-826	RELIEF OF MODERATE TO SEVERE PAIN
U-827	USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES
U-828	PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
U-829	TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY
U-830	TREATMENT OF RELAPSED SMALL CELL LUNG CANCER
U-831	METHOD OF ADMINISTERING LANREOTIDE ACETATE
U-832	ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.
U-833	METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE
U-834	INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION
U-835	RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER
U-836	A METHOD FOR THE TREATMENT OF LEUKEMIAS
U-837	GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS
U-838	METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE
U-839	TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
U-840	TREATMENT FOR TYPE 2 DIABETES MELLITUS
U-841	INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER
U-842	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
U-843	METHOD FOR ADMINISTRATION OF TESTOSTERONE
U-844	PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS
U-845	TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES
U-846	USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE
U-847	ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
U-848	ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA

PATENT USE

U-849	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY
U-850	PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT
U-851	TREATMENT OF TYPE 2 DIABETES MELLITUS
U-852	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS
U-853	TREATMENT OR PREVENTION OF EMESIS
U-854	PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
U-855	METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION
U-856	SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
U-857	INHIBITION OF TRANSPLANT REJECTION
U-858	PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIVE ESOPHAGITIS
U-859	EROSIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD
U-860	FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION
U-861	RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
U-862	ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA
U-863	TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY
U-864	PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIVE ESOPHAGITIS
U-865	TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE
U-866	THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES
U-867	TREATMENT OF MIGRAINE
U-868	METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA
U-869	METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
U-870	METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION
U-871	METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH
U-872	TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
U-873	METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC)
U-874	METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME
U-875	FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER, IN COMBINATION WITH GEMCITABINE
U-876	TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
U-877	FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER
U-878	A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR
U-879	A METHOD OF TREATING OR PREVENTING ILEUS
U-880	ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED

PATENT USE

	REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
U-881	TREATMENT OF NON-SMALL CELL LUNG CANCER
U-882	MANAGEMENT OF FIBROMYALGIA (FM)
U-883	TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
U-884	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
U-885	TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
U-886	ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA
U-887	TREATMENT AND PREVENTION OF OSTEOPOROSIS
U-888	FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN
U-889	MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE)
U-890	REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
U-891	USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE
U-892	TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL)
U-893	CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE
U-894	TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER
U-895	TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
U-896	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER
U-897	METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT
U-898	USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME
U-899	USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
U-900	INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION
U-901	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
U-902	USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
U-903	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS
U-904	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
U-905	TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
U-906	PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS
U-907	FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER
U-908	PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS
U-909	TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA
U-910	TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY
U-911	METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE
U-912	SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
U-913	TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE,

PATENT USE

	URGENCY, AND FREQUENCY
U-914	METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER
U-915	TREATMENT OF MUSCULOSKELETAL CONDITIONS
U-916	TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER
U-917	TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
U-918	TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET
U-919	FOR THE TREATMENT OF DERMATITIS
U-920	STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS
U-921	TREATMENT OF ACNE VULGARIS
U-922	FOR THE TREATMENT OF FUNGAL INFECTIONS
U-923	METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION
U-924	TREATMENT OF MILD TO MODERATE INFECTION CAUSED BY SUSCEPTIBLE STRAINS
U-925	TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
U-926	MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)
U-927	METHOD FOR INCREASING TEAR PRODUCTION
U-928	TREATMENT OF BACTERIAL INFECTIOUS DISEASE
U-929	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI
U-930	TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
U-931	RELIEF OF MODERATE TO SEVERE ACUTE PAIN
U-932	PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI
U-933	FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-934	IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA
U-935	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER
U-936	USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA
U-937	TREATMENT OF PROSTATE CANCER
U-938	TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
U-939	TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
U-940	METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA
U-941	METHOD TO TREAT OVARIAN CANCER
U-942	METHOD TO TREAT MULTIPLE MYELOMA
U-943	GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER
U-944	TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
U-945	SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION

PATENT USE

U-946	TREATMENT OF BREAST CANCER
U-947	WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL GRADES OF EROSIVE ESOPHAGITIS
U-948	TREATMENT OF DIABETES MELLITUS
U-949	HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
U-950	MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
U-951	TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
U-952	USE AS AN ANALGESIC
U-953	METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION
U-954	CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA
U-955	PROPHYLACTIC TREATMENT OF MIGRAINE
U-956	TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE
U-957	A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE
U-958	METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION, DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR PT
U-959	METHOD OF TREATING CANCER, IV ADMIN, LYOPHILIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHILIZED IXABEPILONE WITH SOLVENT(DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML
U-960	METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT
U-961	METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE
U-962	SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
U-963	PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
U-964	ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
U-965	USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER
U-966	TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY)
U-967	A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC
U-968	A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-969	TREATMENT OF MIGRAINE
U-970	TOPICAL TREATMENT OF LICE INFESTATIONS
U-971	INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA
U-972	MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
U-973	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE
U-974	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
U-975	TREATMENT OF PULMONARY HYPERTENSION
U-976	IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES

PATENT USE

U-977	TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE
U-978	METHOD OF TREATING HYPONATREMIA
U-979	RELIEF OF MUSCLE SPASM
U-980	NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-981	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
U-982	A METHOD OF TREATING OSTEOPOROSIS
U-983	METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE
U-984	METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE
U-985	TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)
U-986	TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR
U-987	TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS
U-988	TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350
U-989	FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA
U-990	TREATMENT OF PROTOZOAL INFECTION
U-991	TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS
U-992	REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION
U-993	METHOD OF TREATING INFERTILITY
U-994	METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED
U-995	METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN
U-996	AN ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIX DYSLIPIDEMIA
U-997	TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS
U-998	ADJUNCITVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA
U-999	TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS
U-1000	ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS
U-1001	METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION
U-1002	METHOD OF TREATING INFLAMMATORY CONDITIONS
U-1003	A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW
U-1004	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
U-1005	METHOD OF TREATING A STAPHYLOCOCCAL INFECTION
U-1006	NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER)
U-1007	METHOD OF TREATING GOUT FLARES
U-1008	APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION
U-1009	METHOD FOR ADMINISTRATION OF TESTOSTERONE

PATENT USE

U-1010	TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION
U-1011	USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING
U-1012	METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION
U-1013	METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
U-1014	METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B(PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
U-1015	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
U-1016	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS
U-1017	A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
U-1018	TREATMENT OF PULMONARY HYPERTENSION BY INHALATION
U-1019	TREATMENT OF PULMONARY HYPERTENSION
U-1020	METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
U-1021	SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER
U-1022	FOR THE PREPARATION OF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION
U-1023	TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
U-1024	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP
U-1025	TREATING FREQUENT HEARTBURN
U-1026	A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.
U-1027	REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL
U-1028	A METHOD OF DISTRIBUTING SODIUM OXYBATE UNDER CONTROL OF A CENTRAL PHARMACY
U-1029	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
U-1030	IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
U-1031	IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
U-1032	USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS
U-1033	TOPICAL TREATMENT OF ACNE VULGARIS
U-1034	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
U-1035	NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-1036	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
U-1037	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST
U-1038	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST
U-1039	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN
U-1040	INHIBITION OF THROMBIN IN A PATIENT
U-1041	TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE
U-1042	METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART

PATENT USE

U-1043	MANAGEMENT OF MODERATE TO SEVERE PAIN
U-1044	TOPICAL TREATMENT OF SCALP PSORIASIS
U-1045	MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WTH PLATINUM-BASED CHEMOTHERAPY
U-1046	MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY
U-1047	TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC)
U-1048	WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES
U-1049	PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT
U-1050	USE OF METAXALONE FOR TREATMENT OF MUSCULOSKELETAL CONDITIONS
U-1051	TREATMENT OF OROPHARYNGEAL CANDIDIASIS
U-1052	RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
U-1053	RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
U-1054	ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS
U-1055	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE
U-1056	TREATMENT OF PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE
U-1057	TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE
U-1058	USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
U-1059	ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA
U-1060	ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS
U-1061	ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA
U-1062	ADMINISTRATION OF APPROVED PRODUCT FOR TREATMENT OF ALZHEIMER'S DISEASE
U-1063	TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
U-1064	TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
U-1065	METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
U-1066	METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMINISTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA
U-1067	TREATMENT OF CANCER
U-1068	TREATMENT OF ASTHMA
U-1069	A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION
U-1070	A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL PHARMACY THAT MAINTAINS A CENTRAL DATABASE
U-1071	METHOD OF TREATING BLADDER DSYFUNCTION WITH ONCE A DAY TROSPIUM SALT FORMULATION
U-1072	THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME
U-1073	USE FOR THE TREATMENT OF ASTHMA AND COPD
U-1074	USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT
U-1075	USE FOR THE TREATMENT OF ASTHMA
U-1076	REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING
U-1077	PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED

PATENT USE

	DISODIUM ADMINISTRATION
U-1078	TREATMENT OF ACNE
U-1079	REVLIMID (LENALIDOMIDE) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
U-1080	METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT
U-1081	LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1082	USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS
U-1083	ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES
U-1084	RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
U-1085	METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME
U-1086	TREATMENT OF AUTOIMMUNE DISEASE
U-1087	DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY
U-1088	RELIEF OF MUSCLE SPASM
U-1089	INHIBITION OF THROMBIN
U-1090	LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
U-1091	ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS 6 YEARS OF AGE OR OLDER WHO DO NOT HAVE CLINICALLY APPARENT ASTHMA
U-1092	TREATMENT OF BREAST CANCER
U-1093	TREATMENT OF PSEUDOBULBAR AFFECT
U-1094	MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN
U-1095	METHOD OF TREATING OCULAR INFLAMMATION
U-1096	TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER
U-1097	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE
U-1098	METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
U-1099	TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
U-1100	REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY
U-1101	METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
U-1102	METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY
U-1103	TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
U-1104	USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN
U-1105	TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER
U-1106	TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT
U-1107	TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT
U-1108	TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE
U-1109	TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) IN CONNECTION WITH A SPECIAL PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
U-1110	METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING A COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION
U-1111	NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

PATENT USE

U-1112	METHOD OF MR IMAGING OF A MAMMAL
U-1113	TREATMENT AND PROPHYLAXIS OF INFLUENZA
U-1114	TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA
U-1115	TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS
U-1116	METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS
U-1117	TREATMENT OF BREAST CANCER
U-1118	USE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
U-1119	CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING
U-1120	TO REDUCE GASTROINTESTINAL SIDE EFFECTS ADMINISTER WITH A MEAL; AS STARTING DOSE ADMINISTER ONCE DAILY WITH EVENING MEAL
U-1121	METHOD OF TREATING TRAVELERS' DIARRHEA
U-1122	TREATMENT OF SECONDARILY INFECTED TRAUMATIC SKIN LESIONS DUE TO S. AUREUS AND S. PYOGENES
U-1123	TREATMENT OF ALCOHOL DEPENDENCE
U-1124	PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION
U-1125	METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS
U-1126	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY CONTAINING DOCETAXEL
U-1127	TREATMENT OF PATENT DUCTUS ARTERIOSUS
U-1128	TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE
U-1129	TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1130	SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR A NIGHT WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1131	TREATMENT OF HYPERTRIGLYDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1132	TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1133	SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1134	TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1135	TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A) AND INCREASE OF HDL-C
U-1136	SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
U-1137	TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
U-1138	TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1139	REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1140	REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1141	REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1142	TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN

PATENT USE

U-1143 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR A T NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN

U-1144 REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN

U-1145 REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN

U-1146 REDUCTION IN TG WITH REDUCED FLUSHING BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1147 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C

U-1148 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C

U-1149 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN

U-1150 TRETMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, TG, LP(A), AND INCREASE OF HDL-C

U-1151 TREATMENT OF HYPERTRIGLYCDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, LP(A), AND INCREASE OF HDL-C

U-1152 CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION

U-1153 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION

U-1154 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB

U-1155 USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL)

U-1156 TO REDUCE BLOOD PHENYLALANINE (PHE) LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA (HPA)

U-1157 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES IN ADULTS AND CHILDREN 2 YEARS OF AGE AND OLDER AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER

U-1158 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER

U-1159 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES, SWELLING OF THE NASAL PASSAGES AND SINUS CONGESTION AND PRESSURE IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER

U-1160 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER AND 12 YEARS OF AGE AND OLDER

U-1161 FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER

U-1162 TREATMENT OF SEBORRHEIC DERMATITIS OF THE SCALP

U-1163 METHOD OF TREATING THROMBOSIS

U-1164 METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION

U-1165 USE FOR THE TREATMENT OF MULTIPLE MYELOMA

U-1166 A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS

U-1167 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)

U-1168 THE LONG TERM, ONCE-DAILY MAINTENANCE BRONCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA

U-1169 MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT

PATENT USE

	CANCER PAIN
U-1170	TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-1171	REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
U-1172	TO REDUCE ELEVATED TOTAL-C, APO B, AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE IN COMBINATION WITH A STATIN
U-1173	TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE
U-1174	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION, 0.9% SODIUM CHLORIDE INJECTION, OR FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO ADMINISTRATION
U-1175	REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
U-1176	TREATMENT OR PREVENTION OF STROKE
U-1177	REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
U-1178	RELIEF OF MODERATE TO SEVERE CHRONIC PAIN
U-1179	TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)
U-1180	TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS
U-1181	A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT
U-1182	TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING
U-1183	A METHOD FOR ADMINISTERING FOLLICLE STIMULATING HORMONE (FSH) FOR OVARIAN FOLLICLE OR TESTICULAR STIMULATION IN THE HUMAN
U-1184	TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA
U-1185	TREATMENT OF OPIOID-INDUCED CONSTIPATION
U-1186	ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE
U-1187	TREATMENT OF PATHOLOGICAL STATE BY ANTAGONIZING BRADYKININ RECEPTOR INCLUDING TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE)
U-1188	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE
U-1189	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN
U-1190	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN
U-1191	METHOD OF TX TYPE 2 DM IN PTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBO WITH AN AGENT ACTING ON AN ATP-DEPENDENT CHANNEL IN BETA CELLS SUCH AS A SULFYONYLUREA(INCL GLIPIZIDE, GLIMEPIRIIDE & GLYBURIDE)
U-1192	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A SULFONYLUREA (SUCH AS GLIPIZIDE, GLIMEPIRIDE AND GLYBURIDE)
U-1193	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A PPAR-GAMMA AGONIST (SUCH AS PIOGLITAZONE AND ROSIGLITAZONE)
U-1194	METHOD FOR TREATING INSOMNIA
U-1195	PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5, WHICH MAY RESULT IN RENAL OSTEODYSTROPHY, WHILE AVOIDING HYPERPHOSPHATEMIA
U-1196	RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS
U-1197	METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY
U-1198	RECTIV IS A NITRATE VASODILATOR INDICATED FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH CHRONIC ANAL FISSURE

PATENT USE

U-1199	TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
U-1200	REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
U-1201	FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
U-1202	METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME
U-1203	METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT
U-1204	TREATMENT OF UVEITIS
U-1205	TREATMENT OF MACULAR EDEMA
U-1206	DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX
U-1207	INFANT USE AGED 1 MONTH TO LESS THAN ONE YEAR, GERD AND EROSIVE ESOPHAGITIS
U-1208	TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
U-1209	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER
U-1210	USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)
U-1211	USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA
U-1212	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA AND TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
U-1213	TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN IMMUNOCOMPETENT PATIENTS 12 YEARS OF AGE AND OLDER
U-1214	METHOD FOR RELIEVING CONSTIPATION IN A HUMAN PATIENT THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MCG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1215	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
U-1216	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1217	METHOD OF INCREASING HAIR GROWTH
U-1218	METHOD OF STIMULATING HAIR GROWTH
U-1219	METHOD OF INCREASING THE NUMBER OF HAIRS
U-1220	TREATMENT OF RENAL CELL CARCINOMA
U-1221	TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION
U-1222	TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS
U-1223	METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE
U-1224	REDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE
U-1225	ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING PARTIAL LARGE OR SMALL BOWEL RESECTION SURGERY WITH PRIMARY ANASTOMOSIS
U-1226	A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT
U-1227	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
U-1228	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE ALONE OR IN COMBINATION WITH INSULIN
U-1229	TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS
U-1230	A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT
U-1231	TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS
U-1232	USE AS ANTICOAGULANT IN PTS W/ UNSTABLE ANGINA UNDERGOING PTCA; W/ PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR, AS ANTICOAGULANT IN PTS UNDERGOING PCI AND FOR PTS W/, OR AT RISK OF, HIT/HITTS UNDERGOING PCI.INTENDED FOR USE

PATENT USE

	W/ASPIRIN
U-1233	TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH FOOD
U-1234	FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA
U-1235	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION
U-1236	USE OF THALOMID (THALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1237	COMBO W/ OTHER ANTIRETROVIRALS FOR TX OF HIV-1 IN ANTIRETROVIRAL TX-EXPERIENCED PT 6 YEARS UP, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ANTIRETROVIRALS
U-1238	TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
U-1239	MAGNETIC RESONANCE IMAGING OF THE LIVER
U-1240	TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
U-1241	MANAGEMENT OF MODERATE TO SEVERE PAIN BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED
U-1242	PREVENTION OF RESPIRATORY DISTRESS (RDS) IN PREMATURE INFANTS
U-1243	WITH DRY HANDS, GENTLY REMOVE THE SUPRENZA (PHENTERMINE HYDROCHLORIDE ODT) TABLET FROM THE BOTTLE. IMMEDIATELY PLACE THE SUPRENZA TABLET ON TOP OF THE TONGUE WHERE IT WILL DISSOLVE, THEN SWALLOW WITH OR WITHOUT WATER
U-1244	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONLYUREA
U-1245	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE
U-1246	SINGLE DOSE ADMINISTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA
U-1247	MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS
U-1248	USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL MEDICATION ON THE SAME KNEE
U-1249	TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG
U-1250	TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
U-1251	A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT
U-1252	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE
U-1253	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY
U-1254	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN
U-1255	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
U-1256	TREATMENT OF SEBORRHEIC DERMATITIS
U-1257	TREATMENT OF OPHTHALMIC DISORDERS
U-1258	VISUALIZATION DURING VITRECTOMY PROCEDURES
U-1259	PROPHYLAXIS OF HIV-1 INFECTION
U-1260	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
U-1261	REDUCTION OF THE RISK OF HOSPITALIZATION FOR ATRIAL FIBRILLATION
U-1262	USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT

PATENT USE

U-1263	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS
U-1264	TREATMENT OF A RESPIRATORY DISEASE
U-1265	PATENTED METHOD OF USING REPAGLINIDE IN COMBINATION WITH METFORMIN AS INDICATED FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-1266	METHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA
U-1267	TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE
U-1268	TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE
U-1269	TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY, GASTROINTESTINAL, DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET
U-1270	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE)
U-1271	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE(PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES
U-1272	TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM
U-1273	TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM
U-1274	TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS
U-1275	TREATMENT OF CHRONIC HEPATITIS B IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-1276	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
U-1277	METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN
U-1278	METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS
U-1279	TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE
U-1280	USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS
U-1281	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL
U-1282	PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING
U-1283	A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA
U-1284	A METHOD OF TREATING A NEOPLASM
U-1285	TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS
U-1286	A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE
U-1287	METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
U-1288	TREATEMENT OF ERECTIILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET
U-1289	MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN
U-1290	TREATMENT OF LUNG CANCER
U-1291	TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE (15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
U-1292	TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET
U-1293	A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1294	METHOD OF TREATING GLAUCOMA IN A PATIENT
U-1295	A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION

PATENT USE

U-1296	USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION
U-1297	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION BY INHIBITING ENDOTHELIN RECEPTORS
U-1298	ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES
U-1299	TREATMENT OF PATIENTS WITH LEUKEMIA INCLUDING CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)
U-1300	TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)
U-1301	TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
U-1302	TREATMENT OF PULMONARY EMBOLISM (PE)
U-1303	REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM
U-1304	USE OF ONCE-A-DAY AMOXICILLIN PRODUCT TO TREAT TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES
U-1305	TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS, AND TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER, CO-ADMINISTERED WITH RITONAVIR (PREZISTA/RITONAVIR) AND WITH OTHER ANTIRETROVIRAL AGENTS
U-1306	TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
U-1307	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE ADULT PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY
U-1308	MULTIPLE MYELOMA
U-1309	BONE METASTASES
U-1310	FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
U-1311	METHOD OF TREATING CYSTIC FIBROSIS
U-1312	USE FOR THE TREATMENT OF HYPERGLYCEMIA
U-1313	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-1314	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
U-1315	THE LONG TERM TREATMENT OF PROPHYLACTIC MANAGEMENT OF OCULAR HYPERTENSION AND GLAUCOMA
U-1316	A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
U-1317	TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1318	TREATMENT OF HYPERCHOLESTEROLEMIA BY DECREASING THE AMOUNT OR ACTIVITY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1319	SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA
U-1320	TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT
U-1321	TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS
U-1322	METHOD OF REDUCING OCULAR HYPERTENSION
U-1323	REDUCING THE RISK OF STROKE
U-1324	MANAGEMENT OF CYSTIC FIBROSIS PATIENTS
U-1325	INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
U-1326	METHOD OF INDUCING CONTRACEPTION IN A FEMALE OF REPRODUCTIVE AGE WHO HAS NOT YET REACHED PREMENOPAUSE
U-1327	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION

PATENT USE

U-1328	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
U-1329	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER
U-1330	METHODS OF TREATING LIPID METABOLISM AND GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1331	METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1332	METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1333	METHODS OF LOWERING ELEVATED POST PRANDIAL BLOOD GLUCOSE LEVELS COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR
U-1334	METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1335	METHODS OF MODIFYING GLUCOSE METABOLISM AND TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND ONE OR MORE OTHER THERAPEUTIC AGENTS SUCH AS METFORMIN
U-1336	METHODS OF TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND METFORMIN
U-1337	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
U-1338	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
U-1339	METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1340	METHODS OF TREATING LIPID METABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1341	METHODS OF TREATING GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1342	METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1343	METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1344	METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN PREPARATION
U-1345	USE IN RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH A DOSAGE UNIT COMPRISING 24MICROG+/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1346	USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE
U-1347	TREATMENT OF A SKIN DISORDER
U-1348	TREATMENT OF OSTEOARTHRITIS
U-1349	TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS
U-1350	TREATMENT OF ANKYLOSING SPONDYLITIS
U-1351	TREATMENT OF ACUTE PAIN
U-1352	TREATMENT OF PRIMARY DYSMENORRHEA
U-1353	ADJUNCTIVE THERAPY TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LOW DENSITY LIPOPROTEIN-CHOLESTEROL, APOLIPOPROTEIN B, TOTAL CHOLESTEROL, AND NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN PTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

PATENT USE

U-1354	INHIBITION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION WITH FSH
U-1355	MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD
U-1356	TREATMENT OF NASAL SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER. TREATMENT OF NASAL SYMPTOMS ASSOCIATED W PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER
U-1357	TREATMENT OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHODS FOR TREATING A RESPIRATORY DISEASE IN A CHILD
U-1358	TREATMENT OF BACTERIAL INFECTIONS IN THE NASAL PASSAGE OF ADULT PATIENTS AND HEALTH CARE WORKERS WITH METHICILLIN RESISTANT S. AUREUS
U-1359	USE OF POMALIDOMIDE TO INHIBIT THE SECRETION OF PRO-INFLAMMATION CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA
U-1360	USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1361	USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE
U-1362	TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET
U-1363	A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING/STINGING FOLLOWING CORNEAL SURGERY
U-1364	MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
U-1365	PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT
U-1366	TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY TO ANOVULATORY INFERTILE WOMEN
U-1367	METHOD OF ADMINISTERING FSH FOR THE TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY IN ANOVULATORY INFERTILE WOMEN
U-1368	TREATMENT OF SOLID EXCRETORY SYSTEM TUMORS; ADVANCED RENAL CELL CARCINOMA (RCC), AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB
U-1369	TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE
U-1370	TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
U-1371	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE OR GLAUCOMA
U-1372	ADMINISTRATION WITHOUT FOOD FOR TREATMENT OF HIV-1 INFECTION
U-1373	METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS
U-1374	TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML)
U-1375	ADASUVE IS A TYPICAL ANTIPSYCHOTIC INDICATED FOR THE ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER IN ADULTS
U-1376	TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
U-1377	IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
U-1378	TREATMENT OF A NITROGEN METABOLISM DISORDER
U-1379	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
U-1380	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS WHEREIN THE PATIENT HAS CARDIOVASCULAR DISEASE
U-1381	USE OF PRASUGREL AND ASPIRIN IN PATIENTS REQUIRING THE REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS
U-1382	TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT
U-1383	DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE

PATENT USE

	DISORDER
U-1384	METHOD OF TREATING MULTIPLE SCLEROSIS
U-1385	METHOD OF TREATING AN AUTOIMMUNE DISEASE SELECTED FROM AUTOIMMUNE POLYARTHRITIS AND MULTIPLE SCLEROSIS BUT NOT TREATING PSORIATIC ARTHRITIS
U-1386	A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF
U-1387	REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1388	TREATMENT OF PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1389	ELLA IS A PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD
U-1390	A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF
U-1391	METHOD FOR TREATING OPIOID-INDUCED CONSTIPATION
U-1392	METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH OPIOID-INDUCED CONSTIPATION
U-1393	METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION
U-1394	METHOD FOR RELIEVING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING(I)24MICROG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1395	USE IN RELIEVING OR PREVENTING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION WITH A DOSAGE UNIT COMPRISING 24MICROG +/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1396	TREATMENT OF ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER IN COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE
U-1397	USE AS AN ANTISEPTIC FOR THE PREPARATION OF A PATIENT'S SKIN PRIOR TO SURGERY
U-1398	METHOD OF TREATING CHRONIC HEPATITIS C
U-1399	MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES
U-1400	FOR THE TREATMENT OF PRIMARY HYPERLIPIDEMIA, MIXED HYPERLIPIDEMIA OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1401	INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS
U-1402	FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)
U-1403	FIRST-LINE TREATMENT OF METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
U-1404	METHOD FOR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION BY OPENING CIC CHANNELS
U-1405	THERAPEUTIC TREATMENT OF BONE METASTASES
U-1406	TREATMENT OF MELANOMA
U-1407	TREATMENT OF NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH + CML)
U-1408	TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER
U-1409	TREATMENT OF HIV-1 BY ONCE DAILY ADMINISTRATION
U-1410	TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES
U-1411	THIS DRUG IS ADMINISTERED BY SUBLINGUAL ROUTE TO HUMANS FOR MAINTENANCE TREATMENT OF OPIOID DEPENDENCE

PATENT USE

U-1412	TREATMENT OF ATOPIC DERMATITIS
U-1413	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO INFUSION
U-1414	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL)
U-1415	TREATING A PATIENT HAVING A CONDITION SUSCEPTIBLE TO TREATMENT WITH METHYLPHENIDATE, SUCH AS ADHD, BY ADMINISTERING THE FORMULATION RECITED IN CLAIMS 1 OR 2
U-1416	USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES
U-1417	USE FOR TREATMENT OF HELICOBACTER INFECTIONS
U-1418	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAFV600E MUTATION AS DETECTED BY AN FDA APPROVED TEST
U-1419	TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE LIFE THREATENING
U-1420	METHOD OF ONCE A DAY ADMINISTRATION
U-1421	SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE
U-1422	METHOD OF TREATING PATIENTS NEEDING AN IRON SUPPLEMENT
U-1423	AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
U-1424	LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
U-1425	SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE
U-1426	USE FOR TREATMENT OF DIAPER DERMATITIS COMPLICATED BY CANDIDIASIS
U-1427	ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY
U-1428	TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
U-1429	TREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR
U-1430	TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL AND PERENNIAL ALLERGIC RHINITIS
U-1431	METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE
U-1432	METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX
U-1433	IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
U-1434	TREATMENT OF PANCREATIC CANCER
U-1435	COMBINATION USE OF TOPICAL DICLOFENAC ON THE KNEE AND ADMINISTRATION OF AN ORAL NSAID.
U-1436	USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL AGENT SELECTED FROM SUNSCREEN AND INSECT REPELLANT
U-1437	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION
U-1438	ZINGO INTRADERMAL INJECTION SYSTEM IS A DRUG DELIVERY SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION
U-1439	METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
U-1440	USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
U-1441	A METHOD OF TREATING OR REDUCING OCULAR PAIN AND BURNING/STINGING

PATENT USE

U-1442	SUBCUTANEOUS INJECTION OF METHOTREXATE
U-1443	ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS
U-1444	A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN INFUSION) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS
U-1445	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHERIN THE POLYSORBATE REPRESENTS 0.1 TO 1% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION
U-1446	METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING ADMINISTERING MACITENTAN IN COMBINATION WITH A COMPOUND HAVING PHOSPHODIESTERASE-5 INHIBITORY PROPERTIES
U-1447	TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA
U-1448	TREATING SEVERE HYPERTRIGLYCERIDEMIA
U-1449	METHOD OF ALLEVIATING A SKIN CONDITION
U-1450	TREATMENT OF ALLERGIC RHINITIS SYMPTOMS
U-1451	APPROVED INDICATIONS: APTIOM (ESLICARBAZEPINE ACETATE) IS INDICATED AS ADJUNCTIVE TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY. PATENT CLAIMS: IN A METHOD OF TREATING A SUBJECT AFFLICTED WITH EPILEPSY
U-1452	METHOD FOR CHRONIC WEIGHT MANAGEMENT
U-1453	A METHOD OF TREATING HYPOXIC RESPIRATORY FAILURE BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT
U-1454	PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS
U-1455	TREATMENT OF PERIANAL WARTS
U-1456	TREATMENT OF MANTLE CELL LYMPHOMA
U-1457	A METHOD OF PURGING A NITRIC OXIDE DELIVERY SYSTEM
U-1458	A METHOD OF REDUCING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1459	TREATMENT OF CARCINOMA OF THE THYROID
U-1460	TREATMENT OF HERPES LABIALIS
U-1461	A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE
U-1462	A METHOD OF USING A SCLEROSING AGENT FOR THE TREATMENT OF INCOMPETENT GREAT SAPHENOUS VEINS, ACCESSORY SAPHENOUS VEINS AND VISIBLE VARICOSITIES OF THE GREAT SAPHENOUS (GSV) SYSTEM ABOVE AND BELOW THE KNEE
U-1463	A METHOD OF INTRAVENOUS INJECTION USING ULTRASOUND GUIDANCE, ADMINISTERED VIA A SINGLE CANNULA INTO THE LUMEN OF THE TARGET INCOMPETENT TRUNK VEINS OR BY DIRECT INJECTION INTO VARICOSITIES
U-1464	TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION
U-1465	USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE
U-1466	RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
U-1467	METHOD OF TREATING HEPATITIS C
U-1468	CONTROL OF PHOSPHOROUS LEVELS IN PATIENTS
U-1469	USE OF PHOSLYRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS
U-1470	FOR THE TREATMENT OF HEPATITIS C
U-1471	A METHOD FOR TREATING CARDIOVASCULAR DISEASE COMPRISING ADMINISTERING A RECONSTITUTED LYOPHILIZED PHARMACEUTICAL COMPOSITION COMPRISING EPOPROSTENOL, ARGININE AND SODIUM HYDROXIDE.
U-1472	INTENSIVE CARE UNIT SEDATION, INCLUDING SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
U-1473	MANAGEMENT OF RISK OF DRONEDARONE/BETA-BLOCKER INTERACTION IN PATIENTS IN SINUS

PATENT USE

	RYTHM WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF
U-1474	A METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM A DISEASE TREATABLE WITH ROTIGOTINE, COMPRISING APPLYING THE CLAIMED TRANSDERMAL DELIVERY SYSTEM (TDS) TO THE SKIN OF THE PATIENT
U-1475	USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1).
U-1476	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.
U-1477	USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL PRESCRIPTION MEDICATION ON THE SAME KNEE
U-1478	METHOD OF REDUCING TG LEVELS IN PATIENT ON STATIN THERAPY SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
U-1479	INCREASE TEAR PRODUCTION TO TREAT PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).
U-1480	TREATMENT OF ADVANCED RENAL CELL CARCINOMA
U-1481	REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE
U-1482	DICLOFENAC POTASSIUM FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-1483	INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).
U-1484	COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND CHILDREN (6 YEARS OF AGE AND OLDER)
U-1485	TREATING A SUBJECT UNDERGOING ABDOMINAL SURGERY BY ADMINISTERING ALVIMOPAN TO ACCELERATE THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS
U-1486	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER
U-1487	METHOD OF INCREASING EYELASH GROWTH
U-1488	USE OF TOPICAL DICLOFENAC FOR TREATING PAIN
U-1489	USE OF TOPICAL DICLOFENAC ON A JOINT FOR TREATING OSTEOARTHRITIS
U-1490	FOR USE IN PATIENTS HAVING SYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER, WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE
U-1491	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
U-1492	TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
U-1493	METHOD FOR PREVENTING ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
U-1494	SUBLINGUAL OR BUCCAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE
U-1495	RISK REDUCTION OF REBLEEDING IN PTS FOLLOWING THERAPEUTIC ENDOSCOPY FOR ACUTE BLEEDING GASTRIC OR DUODENAL ULCERS IN ADULTS.
U-1496	METHOD TO TREAT HEMANGIOMA.
U-1497	NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
U-1498	METHOD OF TREATING PATIENTS WITH GASTRIC RETENTIVE DOSAGE FORM
U-1499	MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
U-1500	TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE; PRIMARY HYPOGONADISM (CONGENITAL OR ACQUIRED); HYPOGONADOTROPIC HYPOGONADISM (CONGENITAL OR ACQUIRED).
U-1501	PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM
U-1502	PROPHYLAXIS OF PULMONARY EMBOLISM
U-1503	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
U-1504	USE OF OTEZLA (APREMILAST) FOR INHIBITING PDE4
U-1505	USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS

PATENT USE

U-1506	TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST), INCLUDING BUT NOT LIMITED TO PATIENTS PREVIOUSLY TREATED WITH IMATINIB AND PATIENTS WITH GIST HAVING RESISTANCE TO A KIT TYROSINE KINASE INHIBITOR
U-1507	TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
U-1508	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED
U-1509	TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING A GASTRIC ACID REDUCER
U-1510	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATEMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED.
U-1511	TREATMENT OF HYPERTRIGLYCERIDEMIA
U-1512	REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS
U-1513	TREATMENT OF HIV-1 INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
U-1514	MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER BY BUCCAL OR SUBLINGUAL ADMINISTRATION OF FENTANYL
U-1515	METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULT PATIENTS.
U-1516	METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS.
U-1517	TREATMENT OF BACTERIAL INFECTIONS USING A TWO-DOSE REGIMEN OF DALBAVANCIN.
U-1518	MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN
U-1519	METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT WITH IRRITABLE BOWEL SYNDROME
U-1520	METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT
U-1521	MAINTENANCE TREATMENT OF OPIOID DEPENDENCE
U-1522	TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
U-1523	METHOD OF INDUCING TOPICAL ANESTHESIA IN THE EYE
U-1524	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
U-1525	METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
U-1526	THE TREATMENT OF PATIENTS WITH TRAVELERS' DIARRHEA (TD) OR THE REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE
U-1527	FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
U-1528	A METHOD OF LOWERING INTRAOCULAR PRESSURE
U-1529	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
U-1530	USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
U-1531	METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE
U-1532	METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED.
U-1533	PULMONARY ADMINISTRATION OF PARTICLES COMPRISING A DIKETOPIPERAZINE AND INSULIN.
U-1534	ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH A DIKETOPIPERAZINE.
U-1535	ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH MICROPARTICLES OF A DIKETOPIPERAZINE.
U-1536	ADMINISTRATION OF A COMPOSITION COMPRISING A DIKETOPIPERAZINE AND INSULIN.
U-1537	TREATMENT OF A PATIENT HAVING DIABETES MELLITUS WITH A PRANDIAL RAPID ACTING INSULIN.
U-1538	ADMINISTRATION OF FDKP MICROPARTICLES COMPRISING INSULIN.
U-1539	PULMONARY ADMINISTRATION OF AN INSULIN COMPOSITION COMPRISING FDKP AT THE BEGINNING OF A MEAL TO A PATIENT ALSO BEING TREATED WITH A LONG-ACTING INSULIN.
U-1540	BUTRANS IS A PARTIAL OPIOID AGONIST PRODUCT INDICATED FOR THE MANAGEMENT OF PAIN

PATENT USE

	SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
U-1541	TREATMENT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUT CANNOT BE CURATIVELY RESECTED.
U-1542	FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA
U-1543	TREATMENT OF A PATIENT BY ADMINISTERING THE FORMULATION RECITED IN CLAIM 1 OR CLAIM 23
U-1544	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL).
U-1545	A METHOD OF TRANSDERMALLY DELIVERING TESTOSTERONE
U-1546	FOR USE IN THE TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK.
U-1547	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA
U-1548	FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
U-1549	FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
U-1550	METHOD OF TREATING METASTATIC PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS.
U-1551	METHOD OF TREATING PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS, IN THE ABSENCE OF INTERFERON ALPHA.
U-1552	FOR HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE)
U-1553	TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
U-1554	FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD)
U-1555	MANAGEMENT OF MODERATE TO SEVERE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
U-1556	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
U-1557	A METHOD OF TESTOSTERONE REPLACEMENT THERAPY COMPRISING THE STEP OF NASALLY ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT AN EFFECTIVE AMOUNT OF TESTOSTERONE GEL FORMULATION.
U-1558	FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA
U-1559	INDICATED FOR THE ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 12 YEARS OF AGE AND OLDER
U-1560	A METHOD OF DISRUPTING LEUKOCYTE FUNCTION, INCLUDING AS AN INHIBITOR OF PI3KDELTA KINASE
U-1561	USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
U-1562	TREATMENT OF PATIENTS WITH HEPATIC ENCEPHALOPATHY (HE)
U-1563	A METHOD OF TRANSDERMAL ADMINISTRATION OF A PHYSIOLOGICALLY ACTIVE AGENT TO A SUBJECT.
U-1564	A METHOD OF TREATING GAUCHER'S DISEASE
U-1565	METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE
U-1566	METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER
U-1567	METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER
U-1568	METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL ADMINISTRATION IS

PATENT USE

	TEMPORARILY NOT FEASIBLE
U-1569	TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS
U-1570	TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE
U-1571	TREATMENT OF GAUCHER DISEASE TYPE 1
U-1572	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION.
U-1573	USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
U-1574	A METHOD OF CATALYZING THE HYDROLYSIS OF GLUCOCEREBROSIDE TO GLUCOSE AND CERAMIDE.
U-1575	PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
U-1576	TREATMENT OF LEUKEMIA
U-1577	CONTROL OF SERUM PHOSPHOROUS LEVELS
U-1578	TREATMENT OF ACUTE OTITIS MEDIA
U-1579	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
U-1580	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAD RECEIVED PRIOR DOCETAXEL CHEMOTHERAPY
U-1581	IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA.
U-1582	TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA
U-1583	FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
U-1584	USE OF NALTREXONE AND BUPROPION IN A LAYERED FORMULATION FOR CHRONIC WEIGHT MANAGEMENT FOR AFFECTING WEIGHT LOSS
U-1585	USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE
U-1586	FOR EFFECT ON BLOOD GLUCOSE PARAMETERS IN PATIENTS WITH INSULIN RESISTANCE
U-1587	SINGLE-DOSE INFILTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA.
U-1588	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).
U-1589	METHOD OF USE FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA
U-1590	KUVAN IS INDICATED TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA
U-1591	TREATMENT OF ASTHMA IN PATIENTS AGED 12 YEARS AND OLDER
U-1592	TO REDUCE SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
U-1593	MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA, AND REDUCTION OF EXACERBATIONS IN COPD PATIENTS.
U-1594	DILATION OF THE PUPIL
U-1595	USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIASIS
U-1596	LAMICTAL IS AN ANTIEPILEPTIC DRUG (AED) INDICATED FOR: EPILEPSY-ADJUNCTIVE THERAPY IN PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE: (1.1) PARTIAL SEIZURES PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
U-1597	TREATMENT OF DIABETIC MACULAR EDEMA
U-1598	METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE
U-1599	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADNUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
U-1600	DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
U-1601	DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
U-1602	METHOD OF ADMINISTERING PIRFENIDONE CAPSULES TO TREAT A FIBROTIC CONDITION

PATENT USE

U-1603	METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
U-1604	METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH A STRONG INHIBITOR OF CYP1A2
U-1605	METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING OR AVOIDING ANOTHER STRONG CYP1A2 INDUCER
U-1606	METHOD FOR ADMINISTERING PIRFENIDONE WHILE AVOIDING OR DISCONTINUING CONCOMITANT USE OF A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME INVOLVED IN PIRFENIDONE METABOLISM
U-1607	METHOD OF ADMINISTERING A DOSAGE FORM THAT INCLUDES A GRANULATE FORMULATION OF PIRFENIDONE TO TREAT A FIBROTIC CONDITION
U-1608	DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF A FIBROSIS CONDITION
U-1609	CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
U-1610	CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELVATED LIVER ENZYMES IN USE OF PIRFENIDONE
U-1611	METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING A STRONG CYP1A2 INDUCER
U-1612	METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY AVOIDING SMOKING OR BY AVOIDING ANOTHER STRONG CYP1A2 INDUCER
U-1613	DOSAGE MODIFICATION IN TREATMENT WITH PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH CIPROFLOXACIN
U-1614	USE OF TOPICAL DICLOFENAC SODIUM FOR TREATING PAIN
U-1615	FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL
U-1616	NASAL ADMINISTRATION OF A TESTOSTERONE GEL TO A PATIENT TO TREAT THE PATIENT FOR A CONDITION ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
U-1617	METHOD OF TREATING MEDULLARY THYROID CANCER
U-1618	A METHOD OF TREATING A PATIENT SUFFERING FROM A PAIN ASSOCIATED SLEEP DISTURBANCE COMPRISING ADMINISTERING A LIQUID COMPOSITION FORMULATED INSIDE A SOFT GEL CAPSULE, AS CLAIMED, TO THE PATIENT
U-1619	TREATMENT OF IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
U-1620	METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX, WITH A SUBSTANTIALLY NON-IMMUNOGENIC CARBOHYDRATE COMPONENT, IN ABOUT 15 MINUTES OR LESS.
U-1621	PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A COMPLEXING AGENT.
U-1622	FOR THE TREATMENT OF POLYCYTHEMIA VERA
U-1623	USE OF EXENATIDE MAY RESULT IN REDUCTION IN APPETITE.
U-1624	TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA.
U-1625	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6
U-1626	A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING
U-1627	TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS
U-1628	METHOD OF TREATING DISORDERS WITH AN ETIOLOGY COMPRISING OR ASSOCIATED WITH EXCESS GH-SECRETION
U-1629	METHOD OF TREATING ACROMEGALY
U-1630	TREATMENT IN COMBINATION WITH A CORTICOID SUCH AS PREDNISONE OF PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXEL
U-1631	TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
U-1632	TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
U-1633	USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
U-1634	TREATMENT OF BRCA MUTATED OVARIAN CANCER USING PARP INHIBITOR

PATENT USE

U-1635	USE OF RITONAVIR AS A POTENT CYP3A INHIBITOR TO INCREASE PLASMA DRUG CONCENTRATION OF PARITAPREVIR AND OVERALL DRUG EXPOSURE FOR TREATMENT OF HCV INFECTION
U-1636	USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
U-1637	TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
U-1638	TREATMENT OF HCV INFECTION USING PARITAPREVIR
U-1639	USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
U-1640	TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN BY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED
U-1641	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
U-1642	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN
U-1643	TREATING CUSHING'S SYNDROME
U-1644	TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN
U-1645	TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1646	TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1647	TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1648	TREATMENT OF PATIENTS WITH PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1649	TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
U-1650	TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA
U-1651	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
U-1652	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
U-1653	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN)
U-1654	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT INSULIN OR A SULFONYLUREA)
U-1655	A METHOD TO ACCELERATE THE TIME TO GASTROINTESTINAL RECOVERY BY ADMINISTERING ABOUT 12 MG OF ALVIMOPAN TO THE PATIENT FROM ABOUT 30 TO 60 MINUTES PRIOR TO SURGERY
U-1656	METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT
U-1657	METHOD FOR PROVIDING POST COITAL CONTRACEPTION TO A WOMAN BY ADMINISTERING ABOUT 30 MG OF ULIPRISTAL ACETATE WITHIN ABOUT 120 HOURS AFTER INTERCOURSE, WHEREIN THE WOMAN IS OVERWEIGHT HAVING A BMI OF 25 TO 29.99
U-1658	TREATMENT OF ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER IN COMBINATION WITH LETROZOLE AS INITIAL ENDOCRINE-BASED THERAPY FOR METASTATIC DISEASE IN POSTMENOPAUSAL WOMEN
U-1659	MANAGEMENT OF PAIN
U-1660	TREATMENT OF HIV-1 INFECTION IN ADULTS WITH NO DARUNAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
U-1661	RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS ALSO TAKING LOW DOSE ASPIRIN
U-1662	A METHOD OF TREATING OCULAR PAIN

PATENT USE

U-1663	TREATMENT OF HIV-1 INFECTION
U-1664	TREATMENT OF BACTERIAL VAGINOSIS WITH METRONIDAZOLE GEL
U-1665	METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING THE COMPOSITION OF CLAIM 1
U-1666	PALLIATIVE TREATMENT OF PROSTATE CANCER
U-1667	TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL ALLERGIC RHINITIS
U-1668	METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
U-1669	TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE
U-1670	NATROBA TOPICAL SUSPENSION IS A PEDICULICIDE INDICATED FOR THE TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS SIX (6) MONTHS OF AGE AND OLDER.
U-1671	TREATMENT OF OCULAR ITCHING ASSOCIATED WITH CONJUNCTIVITIS
U-1672	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION
U-1673	TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS
U-1674	DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
U-1675	USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
U-1676	METHODS FOR TREATING BACTERIAL INFECTIONS
U-1677	TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF)
U-1678	FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL
U-1679	TREATMENT OF ACUTE OTITIS EXTERNA
U-1680	TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
U-1681	TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
U-1682	TREATMENT OF BACTERIAL VAGINOSIS
U-1683	TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
U-1684	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
U-1685	DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
U-1686	A METHOD TO REDUCE WITHDRAWAL SYMPTOMS, INCLUDING NICOTINE CRAVING, ASSOCIATED WITH SMOKING CESSATION
U-1687	TREATMENT OF HCV INFECTION USING OMBITASVIR
U-1688	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
U-1689	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
U-1690	METHOD FOR REDUCTION OF SUBMENTAL FAT
U-1691	INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
U-1692	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
U-1693	METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS
U-1694	A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE
U-1695	METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER
U-1696	TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA
U-1697	PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A DIKETOPIPERAZINE.
U-1698	PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS
U-1699	A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA
U-1700	A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

PATENT USE

U-1701	A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN
U-1702	TREATMENT OF COPD
U-1703	TREATMENT OF RESPIRATORY COMPLAINTS
U-1704	USE FOR TREATMENT IN PATIENTS WITH DIABETES
U-1705	USE FOR TREATMENT IN PATIENTS WITH HYPERGLYCEMIA
U-1706	TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE WHEREIN THE COMBINED THERAPEUTIC EFFECT IS GREATER THAN THE ADDITIVE EFFECT OF ADMINISTERING EACH AGENT ALONE
U-1707	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF.
U-1708	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS.
U-1709	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).
U-1710	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH FLUVOXAMINE
U-1711	FOR THE TREATMENT OF PATIENTS WITH CLL, FL OR SLL
U-1712	MEKINIST IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA
U-1713	TAFINLAR IN COMBINATION WITH TRAMETINIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA
U-1714	TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
U-1715	P2Y12 PLATELET INHIBITOR FOR USE AS ADJUNCT TO PERCUTANEOUS CORONARY INTERVENTION TO REDUCE RISK OF VARIOUS DISEASES/CONDITIONS IN PATIENTS NOT TREATED WITH A P2Y12 PLATELET INHIBITOR AND NOT GIVEN A GLYCOPROTEIN IIB/IIIA INHIBITOR
U-1716	TREATMENT OF COUGH AND SYMPTOMS ASSOCIATED WITH UPPER RESPIRATORY ALLERGIES OR A COMMON COLD WITH CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE ORALLY ADMINISTERED EXTENDED RELEASE TABLETS
U-1717	METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE
U-1718	METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO HAVE THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE.
U-1719	ACUTE TREATMENT OF MIGRAINE
U-1720	METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA
U-1721	USE OF RUXOLITINIB (JAKAFI) FOR BLOCKING SIGNAL TRANSDUCTION OF JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2
U-1722	TREATMENT OF BASAL CELL CARCINOMA
U-1723	TREATMENT OF HEART FAILURE
U-1724	METHOD OF INHIBITING HEPATITIS C VIRUS
U-1725	METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY
U-1726	REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH CORONARY HEART DISEASE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1727	TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA
U-1728	REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH STABLE NYHA CLASS III HEART FAILURE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1729	REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT)
U-1730	REDUCE THE RISK OF RECURRENT PULMONARY EMBOLISM

PATENT USE

U-1731	TEMPORARY RELIEF OF MINOR ACHES AND PAINS
U-1732	TEMPORARY REDUCTION OF FEVER
U-1733	TREATMENT/PREVENTION OF CARDIOVASCULAR DISEASE
U-1734	USE OF FLIBANSERIN OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF TO TREAT HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)
U-1735	METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER WITH INTRAVENOUS IBUPROFEN SUCH THAT MEAN ARTERIAL BLOOD PRESSURE DOES NOT INCREASE THE DOSAGE INTERVAL
U-1736	TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
U-1737	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE BEING TREATED WITH FLUOXETINE
U-1738	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)
U-1739	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND -THE-CLOCK, LONG-TERM OPIOID TREATMENT, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
U-1740	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THEARPY
U-1741	PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY
U-1742	ROLAPITANT IS APPROVED FOR THE PREVENTION OF DELAYED NAUSEA AND VOMITING (I.E., EMESIS) ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY
U-1743	FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY
U-1744	PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
U-1745	FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA
U-1746	MONOTHERAPY OR ADJUNCTIVE THERAPY FOR TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY
U-1747	FOR CLAIMS 1-3,6-13,16-24 AND 26-32: METHOD OF TREATING ADHD
U-1748	FOR CLAIMS 1-4,6-14,16-24 AND 26-32: METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS
U-1749	ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
U-1750	TREATMENT OF SCHIZOPHRENIA AND/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE
U-1751	TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY
U-1752	PROPHYLAXIS OF ORGAN REJECTION
U-1753	TREATMENT OF HCV INFECTION USING DASABUVIR
U-1754	FOR THE TREATMENT OF PULMONARY HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL
U-1755	FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS
U-1756	METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF
U-1757	INHIBITION ON PI3K KINASE
U-1758	METHOD OF TREATING ALLERGIC REACTION VIA INJECTION
U-1759	METHOD OF REVERSING THE ANTICOAGULANT EFFECT OF DABIGATRAN USING IDARUCIZUMAB
U-1760	RISK-REDUCTION OF NSAID GASTRIC ULCER IN PATIENTS REQUIRING CHRONIC NSAID TREATMENT
U-1761	PLAQUE PSORIASIS
U-1762	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

PATENT USE

U-1763	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1764	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1765	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1766	TREATMENT OF HYPERKALEMIA
U-1767	USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 18 YEARS AND OLDER
U-1768	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN
U-1769	TREATEMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE
U-1770	TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA
U-1771	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION OR 0.9% SODIUM CHLORIDE INJECTION PRIOR TO ADMINISTRATION
U-1772	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
U-1773	LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-1774	USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE
U-1775	USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES INCLUDING PSORIASIS
U-1776	METHOD OF USING COBIMETINIB FOR THE TREATMENT OF MELANOMA
U-1777	TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY
U-1778	METHOD FOR TREATING MULTIPLE MYELOMA
U-1779	METHOD FOR TREATING MULTIPLE MYELOMA WITH ONE OR MORE OTHER THERAPEUTIC AGENTS
U-1780	METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA
U-1781	RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT
U-1782	FOR HEAD LICE INFESTATIONS
U-1783	METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM AS CLAIMED
U-1784	METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM TRIHYDRATE AS CLAIMED
U-1785	METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM FORMULATION AS CLAIMED
U-1786	TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHILE MANAGING THE RISK OF TERIFLUNOMIDE AND ROSUVASTATIN INTERACTION BY LIMITING THE ROSUVASTATIN DOSE TO NO MORE THAN 10MG AND/OR ADMINISTERING ABOUT HALF THE NORMAL DOSE
U-1787	TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY
U-1788	TREATMENT OF PATIENT HAVING DIABETES MELLITUS VIA ORAL INHALATION OF FDKP MICROPARTICLES COMPRISING INSULIN
U-1789	METHOD OF ADMINISTERING AN ETHANOL-FREE TAXANE LIQUID NANODISPERSION FORMULATION TO A SUBJECT COMBINING THE FORMULATION WITH AN AQUEOUS MEDIUM TO PROVIDE AN ETHANOL-FREE TAXANE DILUTED SOLUTION
U-1790	FOR USE IN TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR NON-HODGKIN'S LYMPHOMA
U-1791	EMERGENCY TREATMENT OF ADULT & PEDIATRIC PATIENTS FOLLOWING FLUOROURACIL OR CAPECITABINE OVERDOSE,OR WHO EXHIBIT EARLY-ONSET,SEVERE OR LIFE-THREATENING CARDIAC OR CNS TOXICITY OR UNUSUALLY SEVERE ADVERSE REACTIONS WITHIN 96 HOURS

PATENT USE

U-1792	TREATMENT OF OTIC INFECTION OR INFLAMMATION
U-1793	TREATMENT OF PEDIATRIC PATIENTS WITH OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT
U-1794	REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK
U-1795	REVERSAL OF NEUROMUSCULAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE
U-1796	TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA
U-1797	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG
U-1798	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN
U-1799	METHOD OF INCREASING GROWTH OF HAIR INCLUDING EYELASHES
U-1800	A METHOD OF TREATING OCULAR PAIN AND/OR ENHANCING OCULAR COMFORT
U-1801	REDUCTION OF SERUM URIC ACID LEVELS
U-1802	TREATMENT OF GOUT
U-1803	TREATMENT OF HYPERURICEMIA
U-1804	ACHIEVING A THERAPEUTIC BENEFIT IN A SUBJECT WITH GOUT
U-1805	USE OF DEXLANSOPRAZOLE IN PATIENTS TAKING CLOPIDOGREL WITHOUT MEANINGFUL CYP2C19 INTERACTIONS
U-1806	COADMINISTERING WITH ALLOPURINOL TO REDUCE SERUM URIC ACID (SUA) BELOW 4 MG/DL; BELOW 6MG/DL IN PATIENTS HAVING URIC ACID DEPOSITS; AND/OR BELOW 6MG/DL WITH SUA INTRADAY CHANGE MORE THAN 50% AND/OR ADVERSE EVENT RATE LESS THAN 15%
U-1807	TREATMENT OF PEDIATRIC PATIENTS 8 TO 17 YEARS OF AGE WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)
U-1808	USE OF NALTREXONE AND BUPROPION FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
U-1809	METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
U-1810	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
U-1811	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATIONS AFTER CONFIRMING THE PRESENCE OF BRAF V600E MUTATION
U-1812	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA
U-1813	TREATMENT OF PATIENTS INFECTED WITH HEPATITIS C VIRUS
U-1814	METHOD OF TREATING GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE
U-1815	TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
U-1816	TREATMENT OF A UREA CYCLE DISORDER
U-1817	PEDIATRIC USE AGES 1 MONTH TO 2 YEARS, GERD AND EROSIVE ESOPHAGITIS
U-1818	TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH LETROZOLE AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN, OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-1819	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
U-1820	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 3% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION
U-1821	METHOD FOR CONTRACEPTION TO A WOMAN COMPRISING ADMINISTERING TO THE WOMAN 30MG OF ULIPRISTAL ACETATE MORE THAN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
U-1822	TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER
U-1823	A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY COMPENSATING LONG-TERM SENSITIVITY DRIFT OF ELECTROCHEMICAL GAS SENSORS USED IN SYSTEMS FOR

PATENT USE

	DELIVERING THERAPEUTIC NITRIC OXIDE TO A PATIENT
U-1824	A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT
U-1825	METHOD OF USING VISMODEGIB TO TREAT CANCER IN A MAMMAL
U-1826	TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCICLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-1827	A METHOD OF PROVIDING A SUBJECT WITH THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET ACCORDING TO CLAIM 1
U-1828	INCREASING MEAN ARTERIAL BLOOD PRESSURE IN ADULT PATIENTS WITH HYPOTENSION ASSOCIATED WITH SEPTIC SHOCK
U-1829	EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS
U-1830	INDUCTION AND MAINTENANCE OF MYDRIASIS DURING INTRAOCULAR SURGERY
U-1831	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG
U-1832	IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
U-1833	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1834	TREATMENT OF POSTOPERATIVE INFLAMMATION AND PREVENTION OF OCULAR PAIN IN PATIENTS UNDERGOING CATARACT SURGERY
U-1835	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-1836	TREATMENT OF HEREDITARY TYROSINEMIA TYPE 1 (HT-1) IN COMBINATION WITH DIETARY RESTRICTION OF TYROSINE AND PHENYLALANINE
U-1837	METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN ALONE OR IN COMBINATION WITH INSULIN, METFORMIN, A THIAZOLIDINEDIONE, GLYBURIDE OR METFORMIN PLUS A SULFONYLUREA
U-1838	METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN
U-1839	COMPOSITION AND METHOD FOR PROVIDING A REDUCTION IN SIDE EFFECTS FOR HUMAN PATIENTS IN NEED OF ACETYLCYSTEINE THERAPY
U-1840	TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
U-1841	USE IN THE LONG-TERM, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-1842	METHOD OF TREATING EPILEPSY
U-1843	TREATMENT OF PSYCHOSIS
U-1844	TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS
U-1845	TREATMENT OF PSYCHOSIS OR A SYMPTOM THEREOF
U-1846	TREATMENT OF A NEURODEGENERATIVE DISEASE OR A SYMPTOM THEREOF
U-1847	METHOD OF TREATING A BACTERIAL INFECTION
U-1848	TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
U-1849	METHOD OF TREATING PULMONARY HYPERTENSION BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY INHALATION USING A DEVICE
U-1850	METHOD OF ADMINISTERING LEVETIRACETAM
U-1851	A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
U-1852	METHOD OF TREATING TYPE 2 DIABETES
U-1853	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A

PATENT USE

	SULFONYLUREA
U-1854	TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
U-1855	IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS
U-1856	TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE
U-1857	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
U-1858	TREATMENT OF PLAQUE PSORIASIS
U-1859	TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
U-1860	REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
U-1861	USE OF AN INHALER TO ADMINISTER DRY POWDER MEDICAMENT
U-1862	TREATMENT OF POST-MYOCARDIAL INFARCTION
U-1863	TREATMENT OF STROKE
U-1864	TREATMENT OF MYOCARDIAL INFARCTION
U-1865	TREATMENT OF THROMBOTIC STROKE
U-1866	TREATMENT OF STABLE AND UNSTABLE ANGINA
U-1867	METHOD OF INHIBITING PLATELET AGGREGATION
U-1868	TREATMENT OF ARTERIAL THROMBOTIC COMPLICATIONS SELECTED FROM THE GROUP CONSISTING OF UNSTABLE ANGINA, THROMBOTIC OR EMBOLIC STROKE, TRANSIENT ISCHAEMIC ATTACKS, PERIPHERAL VASCULAR DISEASE AND MYOCARDIAL INFARCTION
U-1869	TREATMENT OF AN ARTERIAL THROMBOTIC COMPLICATION IN A PATIENT WITH CORONARY ARTERY, CEREBROVASCULAR OR PERIPHERAL VASCULAR DISEASE
U-1870	ZINGO IS A POWDER INTRADERMAL SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION
U-1871	TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH STAGE 3 OR 4 CHRONIC KIDNEY DISEASE USING CONTROLLED RELEASE, ORAL 25-HYDROXYVITAMIN D
U-1872	USE OF SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN TREATING PATIENTS HAVING 25-HYDROXYVITAMIN D INSUFFICIENCY OR DEFICIENCY
U-1873	ADMINISTRATION OF 25-HYDROXYVITAMIN D3 BY CONTROLLED RELEASE
U-1874	TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING OMEPRAZOLE ACCORDING TO CLAIMS 1-8
U-1875	TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING S-OMEPRAZOLE TRIHYDRATE ACCORDING TO CLAIMS 1-3
U-1876	METHOD OF ANESTHETIZING AT LEAST A PORTION OF THE MAXILLARY DENTAL ARCH
U-1877	METHOD OF TREATING PULMONARY HYPERTENSION BY ORALLY ADMINISTERING A FORMULATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF TREPROSTINIL
U-1878	FOR OPIOID DEPENDENCE
U-1879	METHOD OF DIAGNOSING TUMORS USING POSITRON EMISSION TOMOGRAPHY
U-1880	TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
U-1881	IMPROVEMENT IN GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR
U-1882	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANALGESIC AND ANTIPYRETIC ACTIVITY
U-1883	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS (GIST)
U-1884	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1885	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER

PATENT USE

	THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1886	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1887	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1888	USE OF CONTROLLED RELEASE 25-HYDROXYVITAMIN D IN TREATING SECONDARY HYPERPARATHYROIDISM IN PATIENTS HAVING CHRONIC KIDNEY DISEASE
U-1889	TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
U-1890	OTC USE: ALLERGY SYMPTOM RELIEVER; TEMPORARILY RELIEVES THESE SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES; NASAL CONGESTION, RUNNY NOSE, SNEEZING, ITCHY NOSE, AND (ITCHY WATER EYES (AGES 12 AND UP))
U-1891	TREATMENT OR PREVENTION OF NAUSEA AND VOMITING
U-1892	METHOD OF TREATING LEFT VENTRICULAR DYSFUNCTION
U-1893	METHOD OF TREATING MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER IN PEDIATRIC PATIENTS
U-1894	COMBINATION TREATMENT WITH A GLITAZONE FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS
U-1895	METHOD OF TREATING PROSTATE CANCER
U-1896	SUPPLEMENT FOR VITAMIN B12 DEFICIENCIES
U-1897	METHOD OF TREATING ACS USING ANGIOPLASTY WITH AGGRASTAT (TIROFIBAN HYDROCHLORIDE)
U-1898	METHOD OF INHIBITING PLATELET AGGREGATION WITH AGGRASTAT (TIROFIBAN HYDROCHLORIDE)
U-1899	TREATMENT OF PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
U-1900	TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
U-1901	TREATMENT OF SCHIZOAFFECTIVE DISORDER AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS
U-1902	TREATMENT OR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE, CARDIOVASCULAR EVENTS, OR CEREBROVASCULAR EVENTS AND RISK-REDUCTION OF ASPIRIN-ASSOCIATED GASTRIC ULCERS
U-1903	USE OF NALOXONE HYDROCHLORIDE FOR EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION.
U-1904	(I)TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY; (II)RESTORING/INCREASING FUNCTIONAL DYSTROPHIN PROTEIN; OR (III) INDUCING SKIPPING; EACH OF (I)-(III) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-1905	METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, THE PATIENT HAVING A R117H MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE
U-1906	METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, SUCH AS A PATIENT HAVING A G551D MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE
U-1907	USE OF A DELIVERY DEVICE TO ADMINISTER A DOSE OF NALOXONE
U-1908	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND FORM I LUMACAFTOR
U-1909	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND LUMACAFTOR
U-1910	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING THE DOSAGE UNIT OF CLAIM 1 OF U.S. PATENT NO. 8,716,338
U-1911	METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS USING IVACAFTOR AND LUMACAFTOR
U-1912	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING A DOSAGE UNIT AS DEFINED IN CLAIM 1 OF U.S. PATENT NO.

PATENT USE

	9,192,606
U-1913	TREATMENT OF PEDIATRIC PATIENTS WITH BILATERAL OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT
U-1914	IN COMBINATION WITH RITUXIMAB, FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
U-1915	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND WHO ARE INELIGIBLE FOR METFORMIN THERAPY BY ADMINISTERING LINAGLIPTIN
U-1916	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY (CINV)
U-1917	TREATMENT OF EXOCRINE PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
U-1918	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-1919	RESTORING AN MRNA READING FRAME TO INDUCE DYSTROPHIN PROTEIN PRODUCTION IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-1920	USE OF EXTENDED RELEASE ORAL 25-HYDROXYVITAMIN D3 IN TREATING SECONDARY HYPERPARATHYROIDISM IN ADULT PATIENTS HAVING CHRONIC KIDNEY DISEASE STAGE 3 OR STAGE 4
U-1921	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE BY PROVIDING AN ABUSE-DETERRENT ORAL CONTROLLED RELEASE COMBINATION DRUG PRODUCT
U-1922	INTRAVAGINAL PRASTERONE (DEHYDROEPIANDROSTERONE) AT A DAILY DOSE OF 6.5MG FOR THE TREATMENT OF DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE
U-1923	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY BASAL INSULIN OR LIXISENATIDE BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
U-1924	KYPROLIS IS INDICATED IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
U-1925	USE OF AN AUTO INJECTOR TO ADMINISTER NALOXONE HCL
U-1926	METHOD OF TREATING, REDUCING THE INCIDENCE OF, OR PREVENTING AN ISCHEMIC EVENT IN A PATIENT UNDERGOING PCI BY ADMINISTERING INTRAVENOUSLY 30 UG/KG BOLUS BEFORE PCI AND CONTINUOUS INFUSION OF 4 UG/KG/MIN FOR AT LEAST 2 HOURS OR THE DURATION OF THE PCI
U-1927	TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
U-1928	RUBRACA IS INDICATED AS MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC) ASSOCIATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH TWO OR MORE CHEMOTHERAPIES.
U-1929	TREATMENT OF DIABETES MELLITUS WITH AN INHALED INSULIN TO IMPROVE GLYCEMIC CONTROL USING A DRY POWDER INHALATION SYSTEM COMPRISING AN INHALER, A CARTRIDGE AND A DRY POWDER MEDICAMENT COMPRISING INSULIN IN A SINGLE INHALATION
U-1930	METHOD OF AEROSOLIZING/DEAGGLOMERATING AN INSULIN DRY POWDER FOR USE IN TREATING DIABETES MELLITUS VIA ORAL INHALATION USING AN INHALER WITH A CARTRIDGE CONTAINING THE INSULIN DRY POWDER.
U-1931	PROPHYLAXIS OR TREATMENT OF VENOUS AND ARTERIAL THROMBOTIC DISEASE
U-1932	METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS.
U-1933	TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT SURGERY
U-1934	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CYP1A2 INHIBITOR
U-1935	REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION
U-1936	TREATMENT OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
U-1937	TREATMENT OF MYOCARDIAL INFARCTION IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A

PATENT USE

	HISTORY OF MYOCARDIAL INFARCTION
U-1938	TREATMENT OF STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
U-1939	ADMINISTRATION ONCE DAILY WITHIN TWO HOURS AFTER WAKING IN THE MORNING FOR IMPROVEMENT OF GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT
U-1940	IMPROVEMENT IN THE APPEARANCE OF MODERATE TO SEVERE CONVEXITY OR FULLNESS ASSOCIATED WITH SUBMENTAL FAT IN ADULTS BY MEANS OF REDUCING SUBMENTAL FAT VOLUME AS DESCRIBED IN THE APPROVED LABELING
U-1941	TREATMENT OF INFANTILE-ONSET SPINAL MUSCULAR ATROPHY
U-1942	TREATMENT OF SPINAL MUSCULAR ATROPHY BY INCREASING EXON-7 INCLUSION IN SMN2 MRNA
U-1943	TREATMENT OF SPINAL MUSCULAR ATROPHY
U-1944	TREATMENT OF SPINAL MUSCULAR ATROPHY BY INHIBITING AN SMN2 PRE-MRNA INTRONIC SPLICING SILENCER SITE
U-1945	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN.
U-1946	TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
U-1947	TREATMENT OF MARGINAL ZONE LYMPHOMA
U-1948	A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA
U-1949	FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
U-1950	TREATMENT OF PATIENTS WITH ADVANCED (METASTATIC) NON-SMALL CELL LUNG CANCER WHOSE DISEASE PROGRESSED DURING OR AFTER PLATINUM-BASED CHEMOTHERAPY
U-1951	TREATMENT OF ONYCHOMYCOSIS OF A TOENAIL
U-1952	FOR USE IN THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
U-1953	REDUCE THE RISK OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1954	TREATMENT OF DEEP VEIN THROMBOSIS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1955	TREATMENT OF PULMONARY EMBOLISM WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1956	FOLLOWING INITIAL 6 MONTHS TREATMENT FOR DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE), REDUCTION IN THE RISK OF RECURRENCE OF DVT AND OF PE WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1957	PROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM IN PATIENTS UNDERGOING KNEE OR HIP REPLACEMENT SURGERY, WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1958	FOR THE TREATMENT OF GENOTYPE 1, 2, 3 OR 4 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION AS A COMPONENT OF A COMBINATION ANTIVIRAL TREATMENT REGIMEN WITH RIBAVIRIN
U-1959	TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM
U-1960	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS
U-1961	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES (AGES 10 TO ADULT)
U-1962	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: MAINTENANCE MONOTHERAPY IN ADULTS
U-1963	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: AS ADJUNCTIVE TREATMENT TO LITHIUM OR VALPROATE IN ADULTS
U-1964	ELEVATION OF INTRACELLULAR CGMP RESULTING IN INCREASED INTESTINAL FLUID AND ACCELERATED TRANSIT
U-1965	FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL, WHEREIN THE WEIGHT RATIO OF AMBRISENTAN TO TADALAFIL IS ABOUT 1:2 TO ABOUT 1:3

PATENT USE

U-1966	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES IN PEDIATRIC PATIENTS AGE 10-17
U-1967	METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
U-1968	METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
U-1969	TOPICAL TREATMENT OF ONYCHOMYCOSIS OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
U-1970	TREATMENT OF ONYCHOMYCHOSIS OF A TOENAIL CAUSED BY TRICHOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES
U-1971	FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
U-1972	FOR THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
U-1973	METHOD OF TREATING CYSTIC FIBROSIS USING N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE AND 3-(6-(1-2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID
U-1974	TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH PARKINSON'S DISEASE PSYCHOSIS
U-1975	METHOD OF INCREASING EYELASH GROWTH WITH BIMATOPROST
U-1976	METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO HAVE INADEQUATE CONTROL WITH DAPAGLIFLOZIN
U-1977	METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO ARE ALREADY TREATED WITH DAPAGLIFLOZIN AND SAXAGLIPTIN
U-1978	TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT
U-1979	THE TREATMENT OF CARCINOID SYNDROME DIARRHEA IN COMBINATION WITH SOMATOSTATIN ANALOG (SSA) THERAPY IN ADULTS INADEQUATELY CONTROLLED BY SSA THERAPY
U-1980	A METHOD OF TREATING NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
U-1981	IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER-2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-1982	USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
U-1983	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
U-1984	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
U-1985	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
U-1986	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE, WHEREIN THOSE PATIENTS HAVE NOT RECEIVED PREVIOUS TREATMENT FOR MULTIPLE MYELOMA
U-1987	METHOD OF CONTROLLING GLYCEMIA IN DIABETICS BY ADMINISTERING AN INITIAL DOSE OF INSULIN-FDKP WITH A MEAL; DETERMINING BLOOD GLUCOSE LEVEL 1-2 HRS AFTER AND ADMINISTERING A SUPPLEMENTAL DOSE OF INSULIN-FDKP IF POSTPRANDIAL GLUCOSE LEVEL IS >140 MG/DL
U-1988	METHOD TO TREAT INFANTILE HEMANGIOMA
U-1989	INTRAVITREAL TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)
U-1990	INTRAVITREAL TREATMENT OF DIABETIC MACULAR EDEMA
U-1991	REDUCTION OF MORTALITY IN ACUTE MYOCARDIAL INFARCTION

PATENT USE

U-1992	USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
U-1993	ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING "OFF" EPISODES
U-1994	REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) IN ADULTS
U-1995	TREATMENT OF TARDIVE DYSKINESIA
U-1996	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-1997	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR A PPAR-GAMMA AGONIST AND/OR SULFONYLUREA AND/OR INSULIN
U-1998	TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-1999	CHRONIC IDIOPATHIC CONSTIPATION
U-2000	MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS
U-2001	USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER
U-2002	USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-2003	A METHOD OF POSITIONING AN INTRAUTERINE SYSTEM BY HOLDING AN INSERTER HANDLE WITH ONE HAND, ADVANCING THE INSERTER THROUGH THE CERVIX AND INTO THE UTERUS, AND RETRACTING A SLIDER ON THE HANDLE TO RELEASE THE INTRAUTERINE SYSTEM
U-2004	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH PARTIAL SEIZURES WITH COMPLEX SYMPTOMATOLOGY
U-2005	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH GENERALIZED TONIC-CLONIC SEIZURES
U-2006	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH MIXED SEIZURE PATTERNS THAT INCLUDE PARTIAL SEIZURES WITH COMPLEX SYMPTOMATOLOGY, GENERALIZED TONIC-CLONIC SEIZURES, OR OTHER PARTIAL OR GENERALIZED SEIZURES
U-2007	TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE FLT3 MUTATION-POSITIVE, IN COMBINATION WITH STANDARD CYTARABINE AND DAUNORUBICIN INDUCTION AND CYTARABINE CONSOLIDATION CHEMOTHERAPY
U-2008	TREATMENT OF ADULT PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), OR MAST CELL LEUKEMIA (MCL)
U-2009	METHOD OF TREATING POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE.
U-2010	ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
U-2011	TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
U-2012	A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUCAPARIB, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION
U-2013	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
U-2014	A METHOD OF TREATING SECONDARY HYPERPARATHYROIDISM (SHPT)
U-2015	SODIUM THIOSULFATE INJECTION IS INDICATED FOR SEQUENTIAL USE WITH SODIUM NITRITE FOR THE TREATMENT OF ACUTE CYANIDE POISONING
U-2016	TREATMENT FOR ONYCHOMYCOSIS THAT IS TINEA UNGUIUM
U-2017	TREATMENT OF OPIOID DEPENDENCE
U-2018	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF
U-2019	METHOD OF DELIVERING TO A PATIENT WITH DIABETES MELLITUS IN A SINGLE INHALATION, GREATER THAN 75% OF A DRY POWDER DOSE COMPRISING INSULIN AND FUMARYL DIKETOPIPERAZINE USING A HIGH RESISTANCE TO FLOW DRY POWDER INHALER.
U-2020	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST

PATENT USE

U-2021	METHOD OF ADMINISTERING LEVETIRACETAM UNDER FASTED CONDITIONS
U-2022	METHOD OF ADMINISTERING LEVETIRACETAM UNDER FED CONDITIONS
U-2023	A METHOD OF INCREASING THE BIOAVAILABILITY OF GUAIFENESIN IN A SOLUTION CONTAINING 54% TO 66% BY WEIGHT OF PROPYLENE GLYCOL AND GLYCEROL, WHEREIN THE METHOD INCREASES THE CMAX BY AT LEAST 1.5 AND/OR INCREASES THE AUC (0-INF) BY AT LEAST 1.4
U-2024	METHOD FOR TRANSDERMALLY DELIVERING A DRUG TO A USER IN NEED THEREOF
U-2025	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-2026	TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST.
U-2027	TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST.
U-2028	TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA IN ADULTS
U-2029	PREVENTING CONDITION CHARACTERIZED BY UNDESIRED THROMBOSIS
U-2030	PROPHYLAXIS OF VENOUS THROMBOSIS
U-2031	TAFINLAR IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
U-2032	TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST.
U-2033	MEKINIST IS INDICATED, AS A SINGLE AGENT OR IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS
U-2034	INHIBITING COAGULATION
U-2035	PROPHYLAXIS OF VENOUS THROMBOEMBOLISM
U-2036	A METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING PARENTERALLY ADMINISTERING A FORMULATION COMPRISING A) 0.1 TO 5% W/V OF TREPROSTINIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND B) A CITRATE BUFFER
U-2037	MEKINIST IS INDICATED, AS A SINGLE AGENT OR IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
U-2038	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
U-2039	TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
U-2040	TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
U-2041	TREATMENT OF PARTIAL-ONSET SEIZURES
U-2042	DISCONTINUING ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE AND THEN ADMINISTERING PIRFENIDONE
U-2043	EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED/AMPLIFIED BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASE THERAPY
U-2044	DOSE REDUCTION OF PIRFENIDONE BY ABOUT ONE HALF DURING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TWICE DAILY (1500 MG/DAY) TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER
U-2045	ADMINISTRATION OF PIRFENIDONE AND AVOIDING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER
U-2046	ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT USE OF A CYP1A2 INHIBITOR THAT IS A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME

PATENT USE

	SELECTED FROM CYP2C9, CYP2C19, AND CYP2D6
U-2047	ADMINISTERING PIRFENIDONE CONCURRENTLY WITH FLUVOXAMINE, THE PIRFENIDONE AT A DOSE OF ABOUT 801 MG/DAY TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
U-2048	ADMINISTERING PIRFENIDONE WHILE AVOIDING CO-ADMINISTRATION OF A STRONG CYP1A2 INHIBITOR TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE
U-2049	DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INHIBITOR TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE AND THEN ADMINISTERING PIRFENIDONE
U-2050	ADMINISTERING PIRFENIDONE WHILE AVOIDING CO-ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE
U-2051	DISCONTINUING SMOKING TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
U-2052	DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INDUCER TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
U-2053	ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2, INCLUDING CIGARETTE SMOKE, TO AVOID REDUCED PIRFENIDONE EFFICACY
U-2054	ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2 TO AVOID REDUCED PIRFENIDONE EFFICACY
U-2055	DOSING OF AT LEAST 1600 MG/DAY FOLLOWING GRADE 2 LIVER ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2056	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-1600 MG/DAY, FOLLOWING BY ADMINISTERING AT LEAST 1600 MG/DAY IN TREATMENT OF IPF
U-2057	DOSING 2403 MG/DAY PIRFENIDONE FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2058	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400MG/DAY DOSE, FOLLOWED BY ADMINISTERING 2403MG/DAY IN TREATMENT OF IPF
U-2059	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, FOLLOWED BY FULL DAILY DOSE IN TREATMENT OF IPF
U-2060	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, THEN AT LEAST 1600MG/DAY IN TREATMENT OF IPF
U-2061	DOSING OF AT LEAST 1600 MG/DAY FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2062	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-1600 MG/DAY DOSE, FOLLOWED BY ADMINISTERING AT LEAST 1600 MG/DAY DOSE IN TREATMENT OF IPF
U-2063	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY ADMINISTERING AT LEAST 1600 MG/DAY IN TREATMENT OF IPF
U-2064	DOSING AT LEAST 1602 MG/DAY FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION
U-2065	FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION
U-2066	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400 MG/DAY DOSE, FOLLOWED BY FULL DAILY DOSE
U-2067	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE, FOLLOWED BY ADMINISTERING AT LEAST 1602 MG/DAY
U-2068	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, FOLLOWED BY FULL DAILY DOSE

PATENT USE

U-2069 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING A SUB-1600 MG/DAY DOSE, FOLLOWED BY ADMINISTERING AT LEAST 1602 MG/DAY

U-2070 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, THEN SUB-1600 MG/DAY, THEN AT LEAST 1602 MG/DAY

U-2071 FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF

U-2072 FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF

U-2073 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY ADMINISTERING FULL DAILY DOSE IN TREATMENT OF IPF

U-2074 DOSING 1602 MG/DAY PIRFENIDONE FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF

U-2075 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS FOLLOWED BY ADMINISTERING 1602 MG/DAY IN TREATMENT OF IPF

U-2076 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING 801 MG/DAY FOLLOWED BY ADMINISTERING 1602 MG/DAY IN TREATMENT OF IPF

U-2077 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400 MG/DAY DOSE THEN FULL DAY DAILY DOSE IN TREATMENT OF IPF

U-2078 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN LIMITS, THEN SUB-2400MG/DAY DOSE, THEN FULL DAILY DOSE IN TREATMENT OF IPF

U-2079 PIRFENIDONE DOSE ESCALATION REGIMEN FOR TREATMENT OF FIBROSIS AS 801 MG/DAY FOR DAYS 1-7 OF THE REGIMEN, 1602 MG/DAY FOR DAYS 8-14 OF THE REGIMEN, AND 2403 MG/DAY FOR AT LEAST DAY 15 OF THE REGIMEN

U-2080 PIRFENIDONE DOSE ESCALATION REGIMEN FOR TREATMENT OF IPF AS 801 MG/DAY FOR DAYS 1-7 OF THE REGIMEN, 1602 MG/DAY FOR DAYS 8-14 OF THE REGIMEN, AND 2403 MG/DAY FOR AT LEAST DAY 15 OF THE REGIMEN

U-2081 DISCONTINUING USE OF A CYP1A2 INHIBITOR THAT IS A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME SELECTED FROM CYP2C9, CYP2C19, AND CYP2D6 AND THEN ADMINISTERING PIRFENIDONE

U-2082 MODIFYING PIRFENIDONE ADMINISTRATION FROM A DOSE OF ABOUT 2400 MG/DAY DOWNWARD BY ABOUT 1600 MG/DAY WHILE CO-ADMINISTERING FLUVOXAMINE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE

U-2083 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY 801 MG/DAY, DOSE, THEN 1602 MG/DAY IN TREATMENT OF IPF

U-2084 TREATMENT OF SEVERE CHRONIC PAIN VIA INTRATHECAL INFUSION OF ZICONOTIDE IN PATIENTS ALSO RECEIVING MORPHINE

U-2085 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH RIFAMPIN

U-2086 A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900

U-2087 TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION

U-2088 TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY

U-2089 TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY

PATENT USE

U-2090	FOR THE TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
U-2091	TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT NOT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE
U-2092	METHOD FOR CONFIRMING DOSE DELIVERY
U-2093	TREATMENT OF TYPE II SPINAL MUSCULAR ATROPHY
U-2094	TREATMENT OF TYPE III SPINAL MUSCULAR ATROPHY
U-2095	MITOSOL IS AN ANTIMETABOLITE INDICATED AS AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY. IT IS INTENDED FOR TOPICAL APPLICATION TO THE SITE OF GLAUCOMA FILTRATION SURGERY
U-2096	SOTYLIZE IS INDICATED FOR THE MAINTENANCE OF NORMAL SINUS RHYTHM [DELAY IN TIME TO RECURRENCE OF ATRIAL FIBRILLATION/ATRIAL FLUTTER (AFIB/AFL)] IN PATIENTS WITH SYMPTOMATIC AFIB/AFL WHO ARE CURRENTLY IN SINUS RHYTHM
U-2097	TREATMENT OF DMD IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-2098	INCREASING PRODUCTION OF FUNCTIONAL DYSTROPHIN PROTEIN IN DMD PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-2099	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING BRONCHITIS AND/OR EMPHYSEMA
U-2100	INDICATED FOR THE ONCE-DAILY TREATMENT OF ASTHMA IN PATIENTS 18 YEARS AND OLDER
U-2101	MAINTENANCE TREATMENT OF RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
U-2102	TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY BASED ON AN FDA-APPROVED COMPANION DIAGNOSTIC FOR LYNPARZA
U-2103	MAINTENANCE TREATMENT OF BRCA-MUTATED RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
U-2104	TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
U-2105	TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING IMMEDIATE RELEASE LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
U-2106	TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
U-2107	TREATMENT OF LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA REFRACTORY TO RADIOACTIVE IODINE TREATMENT
U-2108	TREATMENT OF HORMONE RECEPTOR POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN NOT PREVIOUSLY TREATED WITH ENDOCRINE THERAPY
U-2109	CAROSPIR IS INDICATED FOR TREATMENT OF NYHA CLASS III-IV HEART FAILURE AND REDUCED EJECTION FRACTION TO INCREASE SURVIVAL, MANAGE EDEMA, AND TO REDUCE THE NEED FOR HOSPITALIZATION FOR HEART FAILURE
U-2110	METHOD FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS WITH MODERATE RENAL IMPAIRMENT WHO ARE OBESE, OR OVERWEIGHT AND HAVE AT LEAST ONE WEIGHT RELATED COMORBID CONDITION
U-2111	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1-5 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1-5
U-2112	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 6 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 6
U-2113	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN

PATENT USE

	SECRETAGOGUE AS RECITED IN CLAIM 7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 7
U-2114	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 9 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 9
U-2115	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 10 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 10
U-2116	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 12 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 12
U-2117	ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 14-15 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 14-15
U-2118	ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 16-18 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 16-18
U-2119	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 19
U-2120	TREATMENT OF PATIENTS 18 YEARS OF AGE AND OLDER WITH COMPLICATED URINARY TRACT INFECTIONS CAUSED BY SUSCEPTIBLE MICROORGANISMS
U-2121	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES
U-2122	USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-2123	TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE
U-2124	TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
U-2125	THE TREATMENT OF AN INFLAMMATORY DISORDER OF THE RESPIRATORY TRACT BY ONCE-PER-DAY ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING FLUTICASONE FUROATE AND A LONG-ACTING BETA2 ADRENORECEPTOR AGONIST
U-2126	USE OF FLUTICASONE FUROATE FOR THE TREATMENT OF AN INFLAMMATORY OR ALLERGIC CONDITIONS, INCLUDING CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-2127	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
U-2128	METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA INHALATION
U-2129	METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION
U-2130	TREATMENT OF PARTIAL ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
U-2131	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH COMPARABLE EFFICACY, AND A REDUCTION IN SPECIFIED ADVERSE EVENTS, COMPARED TO BRIMONIDINE 0.2% TID
U-2132	IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY
U-2133	METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY
U-2134	THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ONCE-PER-DAY ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING FLUTICASONE FUROATE

PATENT USE

	AND A LONG-ACTING BETA2 ADRENORECEPTOR
U-2135	AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY AND PRIOR CHEMOTHERAPY IN THE METASTATIC SETTING
U-2136	TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
U-2137	TREATMENT OF POSTHERPETIC NEURALGIA
U-2138	TOPICAL TREATMENT OF ACTINIC KERATOSIS OF THE FACE OR SCALP USING MORE THAN ONE TREATMENT COURSE OF INGENOL MEBUTATE
U-2139	TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE
U-2140	METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
U-2141	TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6
U-2142	REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR RECURRENT DVT AND/OR AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS
U-2143	AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS, TO REDUCE THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS AND/OR PULMONARY EMBOLISM IN CERTAIN PATIENTS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS
U-2144	REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-2145	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-2146	IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR WITH A ROTATING DRIVE SLEEVE
U-2147	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ORALLY ADMINISTERING 20MG OF TASIMELTEON ONCE DAILY BEFORE BEDTIME
U-2148	A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY MEASURING AND DISPLAYING AN INDICATION OF THE CALCULATED DELIVERY CONCENTRATION OF NITIRIC OXIDE AS COMPARED TO THE DESIRED DELIVERY CONCENTRATION OF NITRIC OXIDE
U-2149	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON
U-2150	TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE
U-2151	METHOD OF TREATING PAIN OR INFLAMMATION WITH AN INJECTABLE CONTROLLED OR SUSTAINED RELEASE FORMULATION OF TRIAMCINOLONE ACETONIDE
U-2152	TREATMENT OF PAIN ASSOCIATED WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)
U-2153	REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2154	REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2155	REDUCING BODY WEIGHT IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2156	REDUCING HBA1C IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2157	TREATING TYPE 2 DIABETES MELLITUS BY STIMULATING INSULIN RELEASE
U-2158	DECREASING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY USING A SUSTAINED-RELEASE COMPOSITION
U-2159	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
U-2160	MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 5 MG OF MELOXICAM
U-2161	TREATMENT OF NAUSEA AND VOMITING, INCLUDING THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY OR MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
U-2162	FOR CLEANSING THE LARGE INTESTINE AS A PREPARATION FOR COLONOSCOPY
U-2163	TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER-2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCICLIB OR ABEMACICLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY

PATENT USE

U-2164	ZELBORAF IS INDICATED FOR THE TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION
U-2165	MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 10 MG OF MELOXICAM
U-2166	TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
U-2167	METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
U-2168	METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
U-2169	METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
U-2170	METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
U-2171	ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RCC FOLLOWING NEPHRECTOMY
U-2172	METHOD TO TREAT SEVERE ALLERGIC EMERGENCIES IN PATIENTS WEIGHING 7.5 TO 15 KG (16.5 TO 33 LBS)
U-2173	TREATING OPIOID DEPENDENCE BY ADMINISTERING BUPRENORPHINE
U-2174	TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE ONCE PER MONTH
U-2175	TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE ONCE MONTHLY
U-2176	TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE
U-2177	TREATING OPIOID ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE
U-2178	TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE COMPOSITION WITH 28 DAY DOSE DURATION
U-2179	IN SITU FORMATION OF SOLID BUPRENORPHINE COMPOSITION
U-2180	TREATING ADDICTION WITH 100 MG OR 300 MG DOSE OF BUPRENORPHINE
U-2181	TREATING OPIOID DEPENDENCY BY SUBCUTANEOUSLY ADMINISTERING BUPRENORPHINE
U-2182	IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS
U-2183	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 13
U-2184	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1, 13, AND 14
U-2185	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15 AND 27
U-2186	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15, 27, AND 28
U-2187	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29 AND 39
U-2188	ADJUNCT TO DIET AND EXECRISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29, 39, AND 40
U-2189	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41 AND 52
U-2190	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41, 52, AND 53
U-2191	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54 AND 64
U-2192	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2

PATENT USE

	DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54, 64, AND 65
U-2193	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66 AND 75
U-2194	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66, 75, AND 76
U-2195	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77 AND 87
U-2196	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77, 87, AND 88
U-2197	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89 AND 99
U-2198	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89, 99, AND 100
U-2199	TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA
U-2200	COMBINATION TREATMENT WITH INSULIN GLARGINE WITH OR WITHOUT METFORMIN FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS
U-2201	TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER
U-2202	OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-2203	A METHOD OF PROVIDING A SUBJECT WITH A THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET AS CLAIMED
U-2204	TREATING PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA (APL) WHO ARE REFRACTORY TO, OR HAVE RELAPSED FROM, RETINOID AND ANTHRACYCLINE CHEMOTHERAPY, AND WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
U-2205	TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED
U-2206	TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE
U-2207	TREATING ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE
U-2208	TREATING ADDICTION BY ONCE PER MONTH ADMINISTRATION OF BUPRENORPHINE
U-2209	TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE ONCE PER MONTH
U-2210	TREATING OPIOID ADDICTION BY 100 MG OR 300 MG DOSE BUPRENORPHINE
U-2211	TREATING OPIOID ADDICTION BY ADMINISTRATION OF BUPRENORPHINE
U-2212	REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2213	REDUCING HBA1C IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2214	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
U-2215	ERTUGLIFLOZIN IN COMBINATION WITH SITAGLIPTIN AND IN FURTHER COMBINATION WITH METFORMIN AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-2216	ERTUGLIFLOZIN AND SITAGLIPTIN IN COMBINATION AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-2217	TREATING HIGH OUTPUT SHOCK WITH ANGIOTENSIN II BY INCREASING MEAN ARTERIAL PRESSURE IN PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE
U-2218	MAINTAINING MEAN ARTERIAL PRESSURE OF ABOUT 65 MMHG OR HIGHER WITH ANGIOTENSIN II IN SHOCK PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE

PATENT USE

U-2219	TREATMENT OF CHRONIC SMALL LYMPHOCYTIC LEUKEMIA
U-2220	A METHOD FOR THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY BY MEASURING THE LEVEL OF GROWTH HORMONE AFTER ORAL ADMINISTRATION OF MACIMORELIN
U-2221	TREATING REFRACTORY HYPOTENSION WITH ABOUT 20 NG/KG/MIN ANGIOTENSIN II IN A PATIENT RECEIVING VASOPRESSOR
U-2222	RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS
U-2223	METHOD OF TREATING ANGINA PECTORIS
U-2224	TREATMENT OF DYSKINESIA AND INCREASING ON TIME WITHOUT TROUBLESOME DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
U-2225	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN PATIENTS WITH HEPATIC IMPAIRMENT
U-2226	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN PATIENTS WITH RENAL IMPAIRMENT
U-2227	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN GERIATRIC PATIENTS
U-2228	TREATMENT OF SMALL LYMPHOCYTIC LEUKEMIA
U-2229	IN COMBINATION WITH TRETINOIN, TREATING ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH NEWLY-DIAGNOSED LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA (APL) CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-A GENE EXPRESSION
U-2230	IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
U-2231	TREATING REFRACTORY HYPOTENSION WITH ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN ANGIOTENSIN II IN A PATIENT RECEIVING VASOPRESSOR
U-2232	TREATMENT OF PSORIATIC ARTHRITIS USING A DOSAGE TITRATION SCHEDULE
U-2233	TREATMENT OF PSORIATIC ARTHRITIS WITH APREMILAST USING A DOSAGE TITRATION SCHEDULE AND A SECOND ACTIVE AGENT
U-2234	USE OF IVACAFTOR FOR TREATING CYSTIC FIBROSIS IN A PATIENT WITH A MILD TO MODERATE CF PHENOTYPE WITH AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
U-2235	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER
U-2236	REDUCING THE RISK OF PRETERM BIRTH IN WOMEN WITH A SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH
U-2237	TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
U-2238	METHOD OF IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH DIABETES MELLITUS BY ADMINISTERING A MIXTURE OF INSULIN DEGLUDEC AND INSULIN ASPART DURING OR AROUND THE TIME OF THE LARGEST MEAL OF THE DAY
U-2239	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH A REDUCTION IN SPECIFIED ADVERSE EVENTS, COMPARED TO BRIMONIDINE 0.2% TID
U-2240	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH COMPARABLE EFFICACY TO BRIMONIDINE 0.2% TID
U-2241	TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
U-2242	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
U-2243	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
U-2244	A METHOD OF TREATING BACTERIAL INFECTIONS IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNENUMONIA (HABP/VABP) PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
U-2245	A METHOD OF TREATING A BACTERIAL INFECTION IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) PATIENTS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
U-2246	TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVING AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE

PATENT USE

U-2247	TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF PATIENTS WITH A MILD TO MODERATE CLINICAL PHENOTYPE OF CYSTIC FIBROSIS HAVING AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE
U-2248	TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR THE F508DEL MUTATION AND A SECOND MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR
U-2249	MANAGEMENT OF ACUTE PAIN SEVERE ENOUGH TO REQUIRE AN OPIOID ANALGESIC AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE
U-2250	DETECTION OF CARCINOMA IN THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY
U-2251	IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-2252	THE TREATMENT OF ACUTE OTITIS EXTERNA IN PATIENTS 6 MONTHS OF AGE AND OLDER DUE TO PSEUDOMONAS AERUGINOSA AND STAPHYLOCOCCUS AUREUS
U-2253	PROPHYLACTIC TREATMENT OF NAUSEA AND VOMITING, INCLUDING PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED CHEMOTHERAPY
U-2254	USE OF POMALIDOMIDE WITH DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR AND DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETING THE LAST THERAPY
U-2255	TREATING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND THE SUSTAINED RELEASE IS OVER AT LEAST 10 HOURS
U-2256	TREATING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND CMAX IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
U-2257	TREATING SHPT IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE SERUM PARATHYROID HORMONE LEVEL AND CHANGE IN SERUM CONCENTRATION OF CALCIFEDIOL IN DOSE INTERVAL IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
U-2258	TREATING SECONDARY HYPERPARATHYROIDISM IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND CMAX24HR/C24HR IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
U-2259	TREATING SECONDARY HYPERPARATHYROIDISM IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND TMAX IS INCREASED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
U-2260	METHOD OF REDUCING THE RISK OF PERIPROCEDURAL MYOCARDIAL INFARCTION, AND STENT THROMBOSIS IN A PATIENT UNDERGOING PCI BY ADMINISTERING INTRAVENOUSLY 30 UG/KG BOLUS BEFORE PCI AND THEN A CONTINUOUS INFUSION
U-2261	MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MILD TO MODERATE PAIN OR MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS
U-2262	MODIFIED DOSING REGIMEN FOR THE REDUCTION OF FEVER
U-2263	MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MODERATE TO SEVERE PAIN WITH ADJUNCTIVE OPIOID ANALGESICS
U-2264	METHODS OF TREATING PAIN, INFLAMMATION, FEVER, PATENT DUCTUS ARTERIOSIS WITH AQUEOUS COMPOSITION
U-2265	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HEC AND MEC IN ADULT AND PEDIATRIC PATIENTS
U-2266	METHODS OF MAKING AQUEOUS COMPOSITION AND TREATING PAIN, INFLAMMATION, FEVER, PATENT DUCTUS ARTERIOSIS WITH AQUEOUS COMPOSITION
U-2267	METHOD FOR RELIEVING THE PAIN ASSOCIATED WITH POST-HERPETIC NEURALGIA
U-2268	DISCONTINUING A STRONG CYP1A2 INDUCER TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
U-2269	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400MG/DAY DOSE THEN FULL DAILY DOSE IN TREATMENT OF IPF

PATENT USE

U-2270 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, THEN SUB-2400MG/DAY DOSE, THEN FULL DAILY DOSE IN TREATMENT OF IPF

U-2271 THERAPEUTIC TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER, SYMPTOMATIC BONE METASTASES AND NO KNOWN VISCERAL METASTATIC DISEASE

U-2272 TREATMENT OF NASAL POLYPS IN PATIENTS >=18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT

U-2273 A METHOD FOR TREATING EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION

U-2274 MAINTAINING SERUM 25-HYDROXYVITAMIN D AT A LEVEL OF AT LEAST 30 NG/ML WITH ORAL, SUSTAINED RELEASE 25-HYDROXYVITAMIN D

U-2275 TREATING CYSTIC FIBROSIS PATIENTS AGES 12 AND OLDER, WHO ARE HOMOZYGOUS FOR F508DEL OR HAVE AT LEAST 1 CFTR GENE MUTATION RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (<30% CRYSTALLINE) IVACAFTOR

U-2276 METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT AGE 6 OR OLDER HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR

U-2277 IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE

U-2278 IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE IN COMBINATION WITH METFORMIN

U-2279 IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE IN COMBINATION WITH METFORMIN AND A SECOND ORAL ANTIDIABETIC DRUG

U-2280 ADJUNCTIVE TREATMENT OF PATIENTS WITH TSC-ASSOCIATED PARTIAL-ONSET SEIZURES

U-2281 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2282 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 2 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 2

U-2283 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 3-7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 3-7

U-2284 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 8 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 8

U-2285 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 11 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 11

U-2286 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 14 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 14

U-2287 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 16-19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 16-19

U-2288 TREATMENT OF TYPE 2 DIABETES MELLITUS WITH EXENATIDE AS AN ADD-ON TO BASIL INSULIN OR BASAL INSULIN PLUS METFORMIN THERAPY

U-2289 TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21L858R MUTATIONS

PATENT USE

U-2290 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN

U-2291 REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION (MI) OR WITH PERIPHERAL ARTERIAL DISEASE (PAD)

U-2292 METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN

U-2293 USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY

U-2294 TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT

U-2295 TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER

U-2296 TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION

U-2297 IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES PATIENTS BY ADMINISTERING A STARTING DOSE OF 10 MCG FOR 14 DAYS AND INCREASING TO A MAINTENANCE DOSE OF 20 MCG ON DAY 15

U-2298 TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS

U-2299 TAFINLAR IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION

U-2300 USE IN COMBINATION WITH THE MUSCARINIC ANTAGONIST SOLIFENACIN SUCCINATE FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY

U-2301 USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMOTHERAPY

U-2302 MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION

U-2303 MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION

U-2304 MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION

U-2305 MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS

U-2306 ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM

U-2307 TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

U-2308 TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT

U-2309 USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION

U-2310 FOR CLEANSING OF THE COLON IN PREPARATION FOR COLONOSCOPY IN ADULTS

U-2311 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A XANTHINE OXIDASE INHIBITOR ALONE

U-2312 TREATMENT OF HYPERKALEMIA IN ADULTS

U-2313 METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, AND/OR NON-FATAL STROKE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND

PATENT USE

	ESTABLISHED CARDIOVASCULAR DISEASE BY ADMINISTERING LIRAGLUTIDE
U-2314	TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC LIVER DISEASE WHO IS SCHEDULED TO UNDERGO A PROCEDURE USING DOPTELET
U-2315	TREATMENT OF MULTIPLE SCLEROSIS IN THE PEDIATRIC PATIENT POPULATION WITH 0.25 MG FINGOLIMOD
U-2316	TREATMENT OF DYSPAREUNIA
U-2317	TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
U-2318	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR
U-2319	KYPROLIS IS INDICATED IN COMBINATION WITH DEXAMETHASONE OR WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
U-2320	KYPROLIS IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE OR MORE LINES OF THERAPY
U-2321	A METHOD OF APPLYING TRYPAN BLUE ONTO AN OUTER SURFACE OF THE ANTERIOR LENS CAPSULE TO FACILITATE REMOVAL OF THE LENS SUBSTANCE
U-2322	TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC)
U-2323	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-2324	FOR SECONDARY PREVENTION OF CARDIOVASCULAR AND CEREBROVASCULAR EVENTS IN PATIENTS AT RISK OF DEVELOPING ASPIRIN-ASSOCIATED GASTRIC ULCERS
U-2325	EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE 1), INCLUDING ANAPHYLAXIS; A METHOD OF TREATING ALLERGIC REACTION, ANAPHYLAXIS, ANAPHYLACTIC SHOCK, OR COMBINATION THEREOF BY AN INJECTION OF AT LEAST ONE DOSAGE OF THE INJECTABLE LIQUID PHARMACEUTICAL
U-2326	TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
U-2327	TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION
U-2328	METHOD OF USING PLAZOMICIN TO TREAT BACTERIAL INFECTIONS
U-2329	METHOD OF ADMINISTERING A LOCAL ANESTHETIC PRIOR TO PERFORMING A DIAGNOSTIC OR SURGICAL PROCEDURE ON A SUBJECT WITH HEPATIC OR RENAL IMPAIRMENT
U-2330	METHOD OF TREATING MELANOMA
U-2331	INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA
U-2332	INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA MEDIATED BY A B-RAF PROTEIN KINASE
U-2333	INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION
U-2334	TREATMENT OF MELANOMA WITH A BRAF MUTATION
U-2335	TREATMENT OF MELANOMA
U-2336	TREATMENT OF MELANOMA MEDIATED BY A B-RAF PROTEIN KINASE
U-2337	INDICATED IN COMBINATION WITH BINIMETINIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION
U-2338	MAINTAINING MEAN ARTERIAL PRESSURE OF ABOUT 65 MMHG OR ABOVE WITH ABOUT 1 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN HYPOTENSIVE PATIENTS TREATED WITH VASOPRESSIN OR A VASOPRESSIN ANALOGUE AND REDUCING VASOPRESSIN OR VASOPRESSIN ANALOGUE USE
U-2339	USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
U-2340	TREATMENT OF POSTOPERATIVE INFLAMMATION
U-2341	METHOD OF RECONSTITUTING A LYOPHILIZED LIPOSOMAL COMPOSITION FOR ADMINISTERING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-

PATENT USE

MRC)

U-2342 METHOD OF ADMINISTERING A RECONSTITUTED LIPOSOMAL COMPOSITION CONTAINING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)

U-2343 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR F508DEL AND A SECOND CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR

U-2344 TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC LIVER DISEASE WHO ARE SCHEDULED TO UNDERGO A PROCEDURE

U-2345 TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)

U-2346 TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG

U-2347 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN WITHOUT DOSE ADJUSTMENT

U-2348 A METHOD FOR PREVENTION OF PREGNANCY

U-2349 FOR ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 5 YEARS AND OLDER

U-2350 A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS ACUTE MYELOGENOUS LEUKEMIA (AML)

U-2351 TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 MUTATION

U-2352 TREATMENT OF HIV-1 INFECTION IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS

U-2353 TX OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENATES IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TX HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS

U-2354 COMBINATION WITH OTHER ANTIRETROVIRALS (ATV) FOR TREATMENT OF HIV-1 IN ATV TREATMENT-EXPERIENCED PATIENTS 2 YEARS AND OLDER WITH EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ATV

U-2355 IN COMBINATION WITH AN AROMATASE INHIBITOR FOR THE TREATMENT OF PRE/PERIMENOPAUSAL OR POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE-BASED THERAPY

U-2356 IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY

U-2357 METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

U-2358 TREATMENT OF PATIENTS WITH HORMONE RECEPTOR (HR)-NEGATIVE BREAST CANCER WITH DELETERIOUS OR SUSPECTED DELETERIOUS GBRCAM, HER2-NEGATIVE METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING

U-2359 TREATMENT OF PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER WHO SHOULD HAVE BEEN TREATED WITH PRIOR ENDOCRINE THERAPY OR BE CONSIDERED INAPPROPRIATE FOR ENDOCRINE THERAPY

U-2360 MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS

U-2361 METHOD OF ADMINISTERING A GRANULATE FORMULATION OF 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AS RECITED IN CLAIM 1, TO TREAT IDIOPATHIC PULMONARY FIBROSIS

U-2362 TREATMENT OF HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6

U-2363 ADMINISTRATION OF RISPERIDONE

U-2364 TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY

U-2365 TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO ARE

PATENT USE

	VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
U-2366	TREATMENT OF LIVER DISEASE THROUGH NUTRITION FOR PATIENTS UNDER THE AGE OF 12
U-2367	USE FOR PATIENTS WITH PARENTERAL NUTRITION ASSOCIATED CHOLESTASIS OR PARENTERAL NUTRITION ASSOCIATED LIVER DISEASE
U-2368	TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER
U-2369	FOR THE TREATMENT OF GENOTYPE 1, 4, 5 OR 6 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION
U-2370	FOR TREATMENT-NAIVE GENOTYPE 1 PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION FOR A DURATION OF 8-WEEKS
U-2371	THE TREATMENT OF FABRY PATIENTS
U-2372	A METHOD OF REDUCING LEFT VENTRICULAR MASS INDEX (LVMI) IN A FABRY PATIENT BY ADMINISTERING MIGALASTAT
U-2373	A METHOD OF REDUCING PODOCYTE GLOBOTRIAOSYLCERAMIDE (GL-3) IN A FABRY PATIENT BY ADMINISTERING MIGALASTAT
U-2374	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND IVACAFTOR
U-2375	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR FORM I AND IVACAFTOR
U-2376	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS AND LESS THAN ABOUT 30% CRYSTALLINE IVACAFTOR
U-2377	USE OF VITAL DYE FOR FACILITATING SURGICAL PROCEDURES FOR VITREO-RETINAL SURGERY
U-2378	TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS
U-2379	USE IN IDENTIFICATION OF INTRAOCULAR MEMBRANES TO FACILITATE REMOVAL DURING OPHTHALMIC SURGERY
U-2380	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN PATIENTS 18 YEARS OF AGE AND OLDER
U-2381	TREATMENT IN COMBINATION WITH A GNRH AGONIST OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
U-2382	TREATMENT IN COMBINATION WITH A GNRH AGONIST OF HIGH RISK NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
U-2383	METHOD OF CONTROLLING GLYCEMIA IN A DIABETIC PATIENT WITH DELAYED OR PROLONGED FOOD ABSORPBTION BY ADMINISTERING 50 TO 75% OF A PREDETERMINED DOSE OF INSULIN-FDKP AT MEALTIME, AND ADMINISTERING REMAINDER OF DOSE 30-120 MINUTES AFTER BEGINNING OF MEAL
U-2384	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 10
U-2385	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1,10 AND 11
U-2386	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12 AND 19
U-2387	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12, 19 AND 20
U-2388	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 21 AND 28
U-2389	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 21, 28, AND 29
U-2390	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 30 AND 41

PATENT USE

U-2391 ADJUNCT TO DIET AND EXCERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 30, 41, AND 42

U-2392 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 43 AND 50

U-2393 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 43, 50 AND 51

U-2394 FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY

U-2395 FOR THE TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY

U-2396 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFTOR AS RECITED IN CLAIM 1 OF US PATENT 8716338 AND IVACAFTOR

U-2397 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFTOR AND IVACAFTOR AS RECITED IN CLAIM 1 OF US PATENT 9192606

U-2398 TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER

U-2399 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 12 YEARS AND OLDER, WITH A F508DEL OR G551D CFTR GENE MUTATION AND A A455E, 2789+5G->A, OR 3849+10KBC->T MUTATION, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF U.S PATENT 10058546

U-2400 REDUCING ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION

U-2401 A METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS IN A PATIENT IN NEED OF SUCH TREATMENT, SAID METHOD COMPRISING ADMINISTERING TO SAID PATIENT AN EFFECTIVE AMOUNT OF A SUSPENSION ACCORDING TO CLAIM 1

U-2402 TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION

U-2403 TREATMENT OF PSORIASIS USING A DOSAGE TITRATION SCHEDULE

U-2404 METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY

U-2405 A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE

U-2406 A METHOD FOR TREATING A PATIENT 9 YEARS OF AGE AND OLDER SUFFERING FROM AN INFLAMMATORY SKIN DISORDER OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE

U-2407 A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT

U-2408 A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT

U-2409 A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING SARECYCLINE HYDROCHLORIDE IN 60 MG, 100 MG OR 150 MG EQUIVALENT DOSES

U-2410 TREATMENT OF ADULT PATIENTS FOR WHOM TREATMENT WITH BOTH AMLODIPINE FOR HYPERTENSION AND CELECOXIB FOR OSTEOARTHRITIS ARE APPROPRIATE

U-2411 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 12 YEARS OR OLDER WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE TABLET COMPRISING LUMACAFTOR AS RECITED IN CLAIM 1, 19, OR 21 OF U.S. PATENT NO. 10,076,513 AND IVACAFTOR

U-2412 FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL)

U-2413 FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL)

U-2414 TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS AS PART OF A

PATENT USE

	COMBINATION DRUG REGIMEN
U-2415	TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS AS PART OF A COMBINATION ANTIBACTERIAL DRUG REGIMEN
U-2416	TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS WITH CYSTIC FIBROSIS AS PART OF A COMBINATION DRUG REGIMEN
U-2417	TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN NON-CYSTIC FIBROSIS ADULTS AS PART OF A COMBINATION ANTIBACTERIAL DRUG REGIMEN
U-2418	METHOD OF ADMINISTERING TESTOSTERONE ENANTHATE SUBCUTANEOUSLY
U-2419	METHOD OF OPERATING AN INJECTION DEVICE
U-2420	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621
U-2421	USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2422	USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME WHO HAVE BEEN PREVIOUSLY TREATED WITH CLOBAZAM
U-2423	USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME WHO HAVE BEEN PREVIOUSLY TREATED WITH CLOBAZAM
U-2424	USE IN COMBINATION WITH CLOBAZAM FOR TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME
U-2425	USE FOR THE TREATMENT OF CONVULSIVE SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2426	USE FOR THE TREATMENT OF CONVULSIVE SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME
U-2427	USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2428	TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER
U-2429	TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
U-2430	TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS
U-2431	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS
U-2432	LONG-TERM, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-2433	METHOD OF TREATING A BIOLOGICAL RHYTHM DISORDER, SUCH AS INSOMNIA
U-2434	USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-2435	REDUCTION OF RISK OF MAJOR CARDIOVASCULAR EVENTS (CV DEATH, MI, AND STROKE) IN CHRONIC CAD OR PAD
U-2436	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT
U-2437	TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
U-2438	CARDIOVASCULAR OUTCOMES TRIAL OF LIRAGLUTIDE 1.8 MG IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE
U-2439	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
U-2440	FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-2441	REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
U-2442	USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
U-2443	USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH DRAVET SYNDROME

PATENT USE

U-2444	TREATMENT OF SUBJECTS HAVING BACTERIAL SKIN OR SKIN STRUCTURE INFECTION
U-2445	TREATMENT IN COMBINATION WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
U-2446	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-2447	TREATMENT OF SEVERE HYPERTRIGLYCERIDEMIA (500 MG/DL) IN ADULT PATIENTS AS AN ADJUNCT TO DIET
U-2448	TREATMENT OF TRAVELERS' DIARRHEA CAUSED BY NON-INVASIVE STRAINS OF ESCHERICHIA COLI IN ADULTS
U-2449	TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTION
U-2450	POSITRON EMISSION TOMOGRAPHY DIAGNOSTIC AGENT IN ADULTS WITH SUSPECTED PROSTATE CANCER RECURRENCE BASED ON ELEVATED BLOOD PROSTATE SPECIFIC ANTIGEN LEVELS FOLLOWING PRIOR TREATMENT
U-2451	TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
U-2452	COMBINATION WITH IMMUNOSUPPRESSIVE THERAPY FOR FIRST-LINE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS AND OLDER WITH SEVERE APLASTIC ANEMIA
U-2453	TREATMENT OF FUNGAL INFECTIONS, INCLUDING BLASTOMYCOSIS, HISTOPLASMOSIS, AND ASPERGILLOSIS
U-2454	USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
U-2455	USE IN COMBINATION WITH CLOBAZAM FOR TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME
U-2456	TREATMENT OF ACUTE MYELOID LEUKEMIA (AML)
U-2457	REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE MORE THAN 9 MONTHS AGO
U-2458	REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE 4-9 MONTHS AGO
U-2459	TREATMENT OF DYSKINESIA AND DECREASING OFF TIME IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
U-2460	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF CORONARY ARTERY BYPASS GRAFT IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2461	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF CARDIOVASCULAR BYPASS GRAFT AND VASCULATURE IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2462	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF VESSEL WITH ARTERIOVENOUS MALFORMATION IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2463	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION IN SURGICAL FLAPS IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2464	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF TRANSPLANTED ORGAN OR ATTACHED VESSEL IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2465	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF VESSEL GRAFT IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2466	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF DONOR ORGAN OR ATTACHED VESSEL IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2467	VISUALIZATION OF EXTRAHEPATIC BILIARY DUCT ATTACHED TO DONOR ORGAN IN PATIENTS 12 YEARS AND OLDER
U-2468	VISUALIZATION OF EXTRAHEPATIC BILIARY DUCT ATTACHED TO TRANSPLANTED ORGAN IN PATIENTS 12 YEARS AND OLDER
U-2469	METHOD OF TREATING CANCEROUS SOLID TUMORS

PATENT USE

U-2470	METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
U-2471	METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK FUSION GENE IN A PEDIATRIC PATIENT
U-2472	METHOD OF TREATING NEUROBLASTOMA, GLIOMA, THYROID, AND BREAST CANCER SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
U-2473	METHOD OF TREATING CMN, IFS, HGG, DIPGS, PTC, SOFT TISSUE SARCOMA, AND SPINDLE CELL SARCOMA SOLID TUMORS EXHIBITING AN NTRK GENE FUSION IN A PEDIATRIC PATIENT WITH AN ORAL SOLUTION
U-2474	METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION AFTER SURGICAL RESECTION
U-2475	METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION IN A PEDIATRIC PATIENT
U-2476	USE OF A DELIVERY DEVICE TO DELIVER A DOSE OF NALOXONE
U-2477	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS
U-2478	METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA PRIOR TO PERFORMING A PROCEDURE ON, THROUGH, OR ADJACENT TO THE MUCOUS MEMBRANES
U-2479	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES